﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Yan, T
   Seo, Y
   Kinsella, TJ
AF Yan, Tao
   Seo, Yuji
   Kinsella, Timothy J.
TI Differential Cellular Responses to Prolonged LDR-IR in MLH1-Proficient
   and MLH1-Deficient Colorectal Cancer HCT116 Cells
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DNA MISMATCH REPAIR; STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION;
   REPLICATION FIDELITY; S-PHASE; ARREST; GENES; RAD51; IRRADIATION;
   MECHANISMS
AB Purpose: MLH1 is a key DNA mismatch repair (MMR) protein involved in maintaining genomic stability by participating in the repair of endogenous and exogenous mispairs in the daughter strands during S phase. Exogenous mispairs can result following treatment with several classes of chemotherapeutic drugs, as well as with ionizing radiation. In this study, we investigated the role of the MLH1 protein in determining the cellular and molecular responses to prolonged low-dose rate ionizing radiation (LDR-IR), which is similar to the clinical use of cancer brachytherapy.
   Experimental Design: An isogenic pair of MMR+ (MLH1(+)) and MMR- (MLH1(-)) human colorectal cancer HCT116 cells was exposed to prolonged LDR-IR (1.3-17 cGy/h x 24-96 h). The clonogenic survival and gene mutation rates were examined. Cell cycle distribution was analyzed with flow cytometry. Changes in selected DNA damage repair proteins, DNA damage response proteins, and cell death marker proteins were examined with Western blotting.
   Results: MLH1(+) HCT116 cells showed greater radiosensitivity with enhanced expression of apoptotic and autophagic markers, a reduced HPRT gene mutation rate, and more pronounced cell cycle alterations (increased late-S population and a G(2)/M arrest) following LDR-IR compared with MLH1(-) HCT116 cells. Importantly, a progressive increase in MLH1 protein levels was found in MLH1(+) cells during prolonged LDR-IR, which was temporally correlated with a progressive decrease in Rad51 protein (involved in homologous recombination) levels.
   Conclusions: MLH1 status significantly affects cellular responses to prolonged LDR-IR. MLH1 may enhance cell radiosensitivity to prolonged LDR-IR through inhibition of homologous recombination (through inhibition of Rad51). (Clin Cancer Res 2009;15(22):6912-20)
C1 Univ Hosp Cleveland, Case Med Ctr, Dept Radiat Oncol, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   Univ Hosp Cleveland, Case Med Ctr, Case Integrat Canc Biol Program, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
RP Kinsella, TJ (corresponding author), SUNY Stony Brook, Ctr Canc, 3 Edmund Pellegrino Rd, Stony Brook, NY 11794 USA.
EM tkinsella@notes.cc.sunysb.edu
FU National Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U56 CA112963]; NASANational Aeronautics & Space
   Administration (NASA) [G1072]; DBJ; University Radiation Medicine
   foundations; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U56CA112963] Funding Source: NIH RePORTER
FX National Cancer Institute grant (U56 CA112963), NASA grant (G1072), and
   the DBJ and University Radiation Medicine foundations. The costs of
   publication of this article were defrayed in part by the payment of page
   charges. This article must therefore be hereby marked advertisement in
   accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
CR Berry SE, 2001, SEMIN RADIAT ONCOL, V11, P300, DOI 10.1053/S1053-4296(01)80067-9
   Brown KD, 2003, NAT GENET, V33, P80, DOI 10.1038/ng1052
   Cann KL, 2007, BIOCHEM CELL BIOL, V85, P663, DOI 10.1139/O07-135
   Cardis E, 2007, RADIAT RES, V167, P396, DOI 10.1667/RR0553.1
   Collis SJ, 2004, J BIOL CHEM, V279, P49624, DOI 10.1074/jbc.M409600200
   Daboussi F, 2002, CELL SIGNAL, V14, P969, DOI 10.1016/S0898-6568(02)00052-9
   DeWeese TL, 1998, P NATL ACAD SCI USA, V95, P11915, DOI 10.1073/pnas.95.20.11915
   Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332
   Fedier A, 2004, INT J ONCOL, V24, P1039
   Fink D, 1998, CLIN CANCER RES, V4, P1
   Fritzell JA, 1997, CANCER RES, V57, P5143
   Georgakilas AG, 2008, MOL BIOSYST, V4, P30, DOI 10.1039/b713178j
   Irving J A, 2001, Expert Rev Anticancer Ther, V1, P149, DOI 10.1586/14737140.1.1.149
   Jeggo PA, 2006, DNA REPAIR, V5, P1192, DOI 10.1016/j.dnarep.2006.05.011
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Karagiannis TC, 2004, CELL MOL LIFE SCI, V61, P2137, DOI 10.1007/s00018-004-4174-0
   Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6
   Kunkel TA, 2005, ANNU REV BIOCHEM, V74, P681, DOI 10.1146/annurev.biochem.74.082803.133243
   Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597
   Li GM, 2008, CELL RES, V18, P85, DOI 10.1038/cr.2007.115
   Marra G, 2005, ADV EXP MED BIOL, V570, P83
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   O'Brien V, 2006, CARCINOGENESIS, V27, P682, DOI 10.1093/carcin/bgi298
   Pors K, 2005, CURR TOP MED CHEM, V5, P1133, DOI 10.2174/156802605774370883
   Sahgal A, 2007, NAT CLIN PRACT UROL, V4, P658, DOI 10.1038/ncpuro0971
   Saintigny Y, 1999, ONCOGENE, V18, P3553, DOI 10.1038/sj.onc.1202941
   Siehler SY, 2009, DNA REPAIR, V8, P242, DOI 10.1016/j.dnarep.2008.10.011
   Snyder AR, 2004, CANCER METAST REV, V23, P259, DOI 10.1023/B:CANC.0000031765.17886.fa
   Surtees JA, 2004, CYTOGENET GENOME RES, V107, P146, DOI 10.1159/000080593
   Susse S, 2000, ONCOGENE, V19, P4500, DOI 10.1038/sj.onc.1203809
   Tamulevicius P, 2007, RADIAT RES, V167, P1, DOI 10.1667/RR0751.1
   Tomita M, 2008, J RADIAT RES, V49, P557, DOI 10.1269/jrr.08036
   Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x
   Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859
   Yan T, 2003, CLIN CANCER RES, V9, P2327
   Yan T, 2001, CANCER RES, V61, P8290
   Zeng M, 2000, CANCER RES, V60, P4889
   Zhang Y, 2008, DNA REPAIR, V7, P1835, DOI 10.1016/j.dnarep.2008.07.009
NR 38
TC 17
Z9 17
U1 0
U2 0
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD NOV 15
PY 2009
VL 15
IS 22
BP 6912
EP 6920
DI 10.1158/1078-0432.CCR-09-1698
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 520EJ
UT WOS:000271822600020
PM 19861440
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Malami, I
   Muhammad, A
   Abubakar, IB
   Etti, IC
   Waziri, PM
   Abubakar, RM
   Mshelia, HE
AF Malami, Ibrahim
   Muhammad, Aliyu
   Abubakar, Ibrahim B.
   Etti, Imaobong C.
   Waziri, Peter M.
   Abubakar, Ramadan M.
   Mshelia, Halilu E.
TI 5,6-dehydrokawain from the rhizome of Alpinia mutica Roxb. induced
   proangiogenic tumour-derived VEGF of HT-29 colorectal cancer
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE 5,6-dehydrokawain; VEGF; angiogenesis, HT-29 cells
ID ANGIOGENESIS; AUTOPHAGY
AB Vascular endothelial growth factor (VEGF) is a glycoprotein vital to the regulation of vascular endothelial cells proliferation, migration and angiogenesis. The expression of VEGF is required for the formation of new blood vessels critical in supplying oxygen and nutrition in the course of tumorigenesis. The present study investigated the effect of 5,6-dehydrokawain isolated from the rhizomes of Alpinia mutica on VEGF expression in vitro using HT-29 cell line. The results revealed that 5,6-dehydrokawain induced the expression of proangiogenic tumour-derived VEGF of HT-29 cells, which may explain the inability of 5,6-dehydrokawain in suppressing cancer cells proliferation.
   [GRAPHICS]
   .
C1 [Malami, Ibrahim; Mshelia, Halilu E.] Usmanu Danfodiyo Univ, Dept Pharmacognosy & Ethnopharm, Fac Pharmaceut Sci, Sokoto, Nigeria.
   [Muhammad, Aliyu] Ahmadu Bello Univ, Dept Biochem, Fac Life Sci, Zaria, Nigeria.
   [Abubakar, Ibrahim B.] Kebbi State Univ, Dept Biochem, Aliero, Nigeria.
   [Etti, Imaobong C.] Univ Uyo, Dept Pharmacol & Toxicol, Uyo, Nigeria.
   [Waziri, Peter M.] Kaduna State Univ, Dept Biochem, Kaduna, Nigeria.
   [Abubakar, Ramadan M.] Usmanu Danfodiyo Univ, Dept Pharmacol & Toxicol, Fac Pharmaceut Sci, Sokoto, Nigeria.
RP Malami, I (corresponding author), Usmanu Danfodiyo Univ, Dept Pharmacognosy & Ethnopharm, Fac Pharmaceut Sci, Sokoto, Nigeria.
EM Ibrahim.malami@udusok.edu.ng
RI Malami, Ibrahim/AAZ-3430-2021; Malami, Ibrahim/C-4513-2019; Abubakar,
   Ibrahim Babangida/X-5713-2019; Etti, Imaobong/AAE-4969-2022; Muhammad,
   Aliyu/AAC-6717-2019
OI Malami, Ibrahim/0000-0001-9271-6927; Malami,
   Ibrahim/0000-0001-9271-6927; Abubakar, Ibrahim
   Babangida/0000-0002-9359-8982; Muhammad, Aliyu/0000-0002-4167-7793
CR Ashton AW, 2004, CIRC RES, V95, P372, DOI 10.1161/01.RES.0000138300.41642.15
   Dharmaratne HRW, 2002, PHYTOCHEMISTRY, V59, P429
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   Fu ZP, 2015, ONCOTARGET, V6, P19469, DOI 10.18632/oncotarget.3625
   Jantan I, 2004, PHYTOTHER RES, V18, P1005, DOI 10.1002/ptr.1608
   Kumagai M, 2016, BIOSCI BIOTECH BIOCH, V80, P1425, DOI 10.1080/09168451.2016.1153959
   Liu ZB, 2017, J BIOMED RES, V31, P408, DOI 10.7555/JBR.31.20160160
   Malek NA, 2011, MOLECULES, V16, P583, DOI 10.3390/molecules16010583
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Sirat HM, 2013, NAT PROD RES, V27, P1468, DOI 10.1080/14786419.2012.718772
   Tanaka A, 2010, BIOORGAN MED CHEM, V18, P3133, DOI 10.1016/j.bmc.2010.03.034
   Teng C M, 1990, Chin J Physiol, V33, P41
   Xiao H, 2017, NAT PROD RES, V31, P2053, DOI 10.1080/14786419.2016.1269094
NR 13
TC 1
Z9 1
U1 1
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PD DEC 17
PY 2018
VL 32
IS 24
BP 2964
EP 2967
DI 10.1080/14786419.2017.1392954
PG 4
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HN0NE
UT WOS:000459884600017
PM 29052437
DA 2022-04-25
ER

PT J
AU Chen, LM
   Song, TJ
   Xiao, JH
   Huang, ZH
   Li, Y
   Lin, TY
AF Chen, Li-Min
   Song, Tian-Jiao
   Xiao, Jian-Hong
   Huang, Zheng-Hui
   Li, Yong
   Lin, Ting-Yan
TI Tripchlorolide induces autophagy in lung cancer cells by inhibiting the
   PI3K/AKT/mTOR pathway and improves cisplatin sensitivity in A549/DDP
   cells
SO ONCOTARGET
LA English
DT Article
DE tripchlorolide; autophagy; lung cancer; PI3K/AKT/mTOR; MDR1
ID COLORECTAL-CANCER; DOWN-REGULATION; APOPTOSIS; RESISTANCE; DEATH;
   KINASE; LIVER
AB Tripchlorolide (T4) has been shown to induce A549 lung cancer cell death predominantly by activating an autophagy pathway. However, the underlying mechanism remains unclear. Herein, we demonstrated that compared with T4 treatment alone, pretreatment with wortmannin (an inhibitor of phosphatidylinositol 3-kinase), perifosine (an inhibitor of AKT) or rapamycin (an inhibitor of mTOR) combined with a subsequent T4 treatment significantly impaired the cell viability of A549 and A549/DDP lung cancer cells. We found that either treatment scheme markedly reduced the activity of P13K and AKT. Expression of LC3II increased in parallel to the increase of the T4 concentration in both A549 and A549/DDP cells and was repressed by overexpression of AKT. The expression levels of PI3-K, PI3-P, AKT, TSC2, mTOR, p70S6K and 4E-BP1 were minimally affected by the wortmannin, perifosine, or rapamycin plus T4 treatments, but their phosphorylated products were greatly affected in A549 lung cancer cells and slightly affected in A549/DDP lung cancer cells. These results indicate that T4 induces autophagy in lung cancer cells by inhibiting the PI3K/AKT/mTOR signaling pathway. We further found that T4 decreased expression of MDR1 and improved cisplatin sensitivity of A549/DDP cells. Altogether, these results have meaningful implications for tumor therapy in the future.
C1 [Chen, Li-Min; Song, Tian-Jiao; Huang, Zheng-Hui; Li, Yong; Lin, Ting-Yan] Fujian Med Univ, Union Hosp, Dept Resp Med, Fuzhou 350001, Fujian, Peoples R China.
   [Chen, Li-Min; Song, Tian-Jiao] Fujian Med Univ, Union Hosp, Dept Geriatr, Fuzhou 350001, Fujian, Peoples R China.
   [Chen, Li-Min; Song, Tian-Jiao] Fujian Med Univ, Union Hosp, Fujian Inst Geriatr, Fuzhou 350001, Fujian, Peoples R China.
   [Xiao, Jian-Hong] Mindong Hosp Ningde City, Dept Resp Med, Fuan 355000, Fujian, Peoples R China.
RP Chen, LM; Lin, TY (corresponding author), Fujian Med Univ, Union Hosp, Dept Resp Med, Fuzhou 350001, Fujian, Peoples R China.; Chen, LM (corresponding author), Fujian Med Univ, Union Hosp, Dept Geriatr, Fuzhou 350001, Fujian, Peoples R China.; Chen, LM (corresponding author), Fujian Med Univ, Union Hosp, Fujian Inst Geriatr, Fuzhou 350001, Fujian, Peoples R China.
EM 13599438522@163.com; tingyanlin58@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472848]; Key Clinical Specialty Discipline
   Construction Program of Fujian and Nation, P.R.; Key Clinical Specialty
   Discipline Construction Program of Fujian and Nation, P.R. [2011J01176,
   2016J01454]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81472848) Key Clinical Specialty Discipline
   Construction Program of Fujian and Nation, P.R. and the Fujian
   Provincial Natural Science Foundation (grant number 2011J01176 and grant
   number 2016J01454).
CR CANUTO RA, 1993, CARCINOGENESIS, V14, P2581, DOI 10.1093/carcin/14.12.2581
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   Chen LM, 2012, INT J ONCOL, V40, P1066, DOI 10.3892/ijo.2011.1278
   Cho KH, 2014, ONCOL REP, V31, P248, DOI 10.3892/or.2013.2809
   Choi HS, 2013, TUBERC RESPIR DIS, V75, P9, DOI 10.4046/trd.2013.75.1.9
   Duan Zhen-Ling, 2007, Ai Zheng, V26, P258
   Emdad L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.995008
   Fang S, 2014, DRUG DES DEV THER, V8, P1595, DOI 10.2147/DDDT.S69690
   Ganesh S, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.29
   Gilligan D, 2007, LANCET, V369, P1929, DOI 10.1016/S0140-6736(07)60714-4
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Guan HT, 2016, TUMOR BIOL, V37, P12153, DOI 10.1007/s13277-016-5092-0
   HENELL F, 1987, EXP MOL PATHOL, V46, P1, DOI 10.1016/0014-4800(87)90026-8
   Kaewpiboon C, 2014, INT J ONCOL, V44, P1233, DOI 10.3892/ijo.2014.2297
   Lee KY, 2002, EXP MOL MED, V34, P462, DOI 10.1038/emm.2002.64
   Levin-Salomon V, 2014, APOPTOSIS, V19, P346, DOI 10.1007/s10495-013-0918-3
   Li JH, 2016, TUMOR BIOL, V37, P2387, DOI 10.1007/s13277-015-4017-7
   Liu FF, 2013, ONCOL LETT, V5, P1261, DOI 10.3892/ol.2013.1154
   Lou YJ, 2005, LEUKEMIA RES, V29, P99, DOI 10.1016/j.leukres.2004.05.014
   Melet A, 2008, ADV EXP MED BIOL, V615, P47, DOI 10.1007/978-1-4020-6554-5_4
   Meng Y, 2016, ONCOGENE, V35, P6359, DOI 10.1038/onc.2016.189
   Palmisano N. J., 2016, COLD SPRING HARB PRO, V2016
   Qi Chunsheng, 2014, Zhongguo Fei Ai Za Zhi, V17, P148, DOI 10.3779/j.issn.1009-3419.2014.02.14
   Roberts R, 2013, AUTOPHAGY, V9, P667, DOI 10.4161/auto.23877
   Veldhoen RA, 2013, ONCOGENE, V32, P736, DOI 10.1038/onc.2012.92
   Yu L, 2013, SEMIN CANCER BIOL, V23, P553, DOI 10.1016/j.semcancer.2013.08.008
   YUCEL T, 1989, EXP MOL PATHOL, V50, P38, DOI 10.1016/0014-4800(89)90055-5
   Zhang S, 2016, TOXICOL MECH METHOD, V26, P301, DOI 10.3109/15376516.2016.1172690
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zhou YT, 2013, ASIAN PAC J CANCER P, V14, P4635, DOI 10.7314/APJCP.2013.14.8.4635
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 31
TC 25
Z9 28
U1 2
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 8
PY 2017
VL 8
IS 38
BP 63911
EP 63922
DI 10.18632/oncotarget.19201
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FG4XE
UT WOS:000410284800091
PM 28969040
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ma, ZH
   Bao, XB
   Gu, JB
AF Ma, Zhao
   Bao, Xuebin
   Gu, Junbao
TI Furowanin A-induced autophagy alleviates apoptosis and promotes cell
   cycle arrest via inactivation STAT3/Mcl-1 axis in colorectal cancer
SO LIFE SCIENCES
LA English
DT Article
DE Furowanin A; Colorectal cancer; Autophagy; Apoptosis; Cell cycle arrest;
   STAT3
ID PROTECTIVE AUTOPHAGY; OVARIAN-CANCER; METASTASIS; KINASES; PATHWAY;
   GROWTH; DEATH; MCL-1; LIFE
AB Aim
   Furowanin A (Fur A) is a flavonoid isolated from Millettia pachycarpa Benth. Studies show its potent antineoplastic effects against leukemia cells. The aim of the present study was to determine the potential therapeutic effect of Fur A against colorectal cancer (CRC), and elucidate the underlying mechanism.
   Material and methods: Cell Counting Kit-8 (CCK-8) assay was used to determine cell, and TUNEL and Annexin-V/PI staining was used to detect apoptosis and the cell cycle distribution. The expression levels of specific proteins in the CRC cells were analyzed by Western blotting. A xenograft model was also established to evaluate the therapeutic effect of Fur A in vivo.
   Key findings: Fur A suppressed proliferation, blocked cell cycle progression, induced apoptosis and promoted autophagy in CRC cells. Interestingly, Fur A-induced autophagy functioned not only as a survival mechanism against apoptosis but also intensified the cell cycle arrest in CRC cells. In addition, Fur A mediated its effects via the inactivation of the STAT3/Mcl-1 axis.
   Significance: Fur A is a promising drug candidate for the treatment and prevention of CRC.
C1 [Ma, Zhao; Bao, Xuebin; Gu, Junbao] Zhengzhou Univ, Peoples Hosp Henan Prov, Peoples Hosp, Gastrointestinal Surg Dept, Zhengzhou, Henan, Peoples R China.
RP Bao, XB (corresponding author), 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China.
EM xuebinbaozz@126.com
FU Basic Frontier Project of Science and Technology Department in Henan
   Province [132300410367]
FX This study was supported by the Basic Frontier Project of Science and
   Technology Department in Henan Province (No. 132300410367).
CR Aarts M, 2013, CURR OPIN PHARMACOL, V13, P529, DOI 10.1016/j.coph.2013.03.012
   Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Cao JP, 2018, ANAT REC, V301, P786, DOI 10.1002/ar.23754
   Cao Z., 2017, CELL PHYSL BIOCH, V43
   Chai EZP, 2016, PHARMACOL THERAPEUT, V162, P86, DOI 10.1016/j.pharmthera.2015.10.004
   Dikic I, 2010, CANCER RES, V70, P3431, DOI 10.1158/0008-5472.CAN-09-4027
   Doherty J, 2018, NAT CELL BIOL, V20, P1110, DOI 10.1038/s41556-018-0201-5
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Granato M, 2015, CANCER LETT, V366, P191, DOI 10.1016/j.canlet.2015.07.006
   Han M, 2018, BIOMED PHARMACOTHER, V103, P272, DOI 10.1016/j.biopha.2018.04.014
   Ito C, 2006, PLANTA MED, V72, P424, DOI 10.1055/s-2005-916259
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jia LJ, 2018, LIFE SCI, V208, P123, DOI 10.1016/j.lfs.2018.07.027
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Li X., 2017, ANAT REC, V300
   Li ZP, 2016, AM J TRANSL RES, V8, P4628
   Liu KL, 2018, CANCER SCI, V109, P1369, DOI 10.1111/cas.13575
   Liu Y, 2017, APOPTOSIS, V22, P544, DOI 10.1007/s10495-016-1334-2
   Luo M, 2017, J CELL MOL MED, V21, P46, DOI 10.1111/jcmm.12937
   Lv XH, 2016, ANAT REC, V299, P741, DOI 10.1002/ar.23338
   Moon JY, 2016, MOLECULES, V21, DOI 10.3390/molecules21070914
   Radhakrishnan H, 2017, CANCER LETT, V403, P231, DOI 10.1016/j.canlet.2017.06.020
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607
   Salazar-Roa M, 2017, TRENDS CELL BIOL, V27, P69, DOI 10.1016/j.tcb.2016.08.009
   Su T, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00227
   Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503
   Tai WT, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.18
   Wang J, 2017, ACTA BIOCH BIOPH SIN, V49, P771, DOI 10.1093/abbs/gmx076
   Wang J, 2014, J BIOL CHEM, V289, P17163, DOI 10.1074/jbc.M114.558288
   Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0731-5
   Wingelhofer B, 2018, LEUKEMIA, V32, P1713, DOI 10.1038/s41375-018-0117-x
   Ye HY, 2014, AM J CHINESE MED, V42, P949, DOI 10.1142/S0192415X14500608
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4
   Yu RX, 2018, HUM CELL, V31, P50, DOI 10.1007/s13577-017-0188-4
   Zhang H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21766-3
   Zhang XY, 2018, INT J BIOCHEM CELL B, V95, P9, DOI 10.1016/j.biocel.2017.12.010
   Zhao YL, 2018, FOOD FUNCT, V9, P4548, DOI [10.1039/c8fo00850g, 10.1039/C8FO00850G]
   Zhu L, 2018, BIOMED PHARMACOTHER, V103, P708, DOI 10.1016/j.biopha.2018.04.090
   Zou MJ, 2015, MOL CARCINOGEN, V54, P1363, DOI 10.1002/mc.22212
NR 42
TC 6
Z9 7
U1 1
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD FEB 1
PY 2019
VL 218
BP 47
EP 57
DI 10.1016/j.lfs.2018.12.027
PG 11
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HH4WO
UT WOS:000455727100007
PM 30562490
DA 2022-04-25
ER

PT J
AU Zhu, HT
   Diao, S
   Lim, V
   Hu, LN
   Hu, JG
AF Zhu, Hongtao
   Diao, Shuai
   Lim, Vincent
   Hu, Lina
   Hu, Jianguo
TI FAM83D inhibits autophagy and promotes proliferation and invasion of
   ovarian cancer cells via PI3K/AKT/mTOR pathway
SO ACTA BIOCHIMICA ET BIOPHYSICA SINICA
LA English
DT Article
DE FAM83D; ovarian cancer; autophagy; mTOR
ID COLORECTAL-CANCER; SIGNALING PATHWAY; UP-REGULATION; MIGRATION;
   RESISTANCE; APOPTOSIS; MTOR
AB Ovarian cancer is one of the most lethal malignant tumors in women. The family with sequence similarity 83, member D (FAM83D) plays an important role in several cancers, but its function and underlying mechanism in ovarian cancer remain unknown. To investigate the role of FAM83D in ovarian cancer, the expression of FAM83D was determined by immunohistochemistry in tissue microarray slide. Cellular proliferation and invasion were detected by 5-Ethynyl-2-deoxyuridine assays and transwell invasion assays. The correlations between FAM83D and autophagy were detected by western blot analysis and confocal microscopy. Western blot analysis was used to identify the protein expression of FAM83D, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR) and Sequestosome 1 (P62). Tumorigenesis in nude mice was used to explore the function of FAM83D in vivo. We found high expression level of FAM83D in ovarian cancer tissues as compared to the normal ovarian tissues. Knockdown of FAM83D in SKOV3 cells enhanced autophagy and inhibited the proliferation and invasion in vitro, whereas ectopic expression of FAM83D in A2780 cells exerted an opposite effect. Mechanistically, overexpression of FAM83D activated the PI3K/AKT/mTOR pathway, and Torin1 could suppress FAM83D-induced cell proliferation and invasion. In vivo, overexpression FAM83D promoted tumor growth. Overall, FAM83D promoted ovarian cancer cell invasion and proliferation, while inhibited autophagy via the PI3K/AKT/mTOR signaling pathway. Our results suggest that FAM83D may be a candidate oncogene in ovarian cancer, which provides a fresh perspective of FAM83D in ovarian cancer.
C1 [Zhu, Hongtao; Diao, Shuai; Lim, Vincent; Hu, Lina; Hu, Jianguo] Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400016, Peoples R China.
RP Hu, LN; Hu, JG (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400016, Peoples R China.
EM 461374248@qq.com; cqhulina@126.com; angeljianguo@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81702557]
FX This work was supported by the grant from the National Natural Science
   Foundation of China (No. 81702557).
CR Au CWH, 2009, CANCER LETT, V281, P151, DOI 10.1016/j.canlet.2009.02.025
   Bai HM, 2015, ONCOTARGET, V6, P25520, DOI 10.18632/oncotarget.4550
   Cipriano R, 2013, ONCOTARGET, V4, P729, DOI 10.18632/oncotarget.1027
   CONSTANTINE NT, 1994, J VIROL METHODS, V47, P153, DOI 10.1016/0166-0934(94)90074-4
   Decollogne S, 2015, GYNECOL ONCOL, V138, P363, DOI 10.1016/j.ygyno.2015.06.018
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Feng LF, 2014, AUTOPHAGY, V10, P1442, DOI 10.4161/auto.29486
   Hu JG, 2017, AUTOPHAGY, V13, P333, DOI 10.1080/15548627.2016.1256520
   Hu JG, 2015, ONCOTARGET, V6, P12174, DOI 10.18632/oncotarget.3650
   Huang ML, 2017, ONCOTARGET, V8, P74479, DOI 10.18632/oncotarget.20157
   Jin ZS, 2014, MOL MED REP, V10, P3099, DOI 10.3892/mmr.2014.2664
   Ju JS, 2010, AUTOPHAGY, V6, P929, DOI 10.4161/auto.6.7.12785
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Lee SY, 2012, J CLIN INVEST, V122, P3211, DOI 10.1172/JCI60498
   Li J, 2014, INT J GYNECOL CANCER, V24, P437, DOI 10.1097/IGC.0000000000000065
   Liao WJ, 2015, ONCOTARGET, V6, P24132, DOI 10.18632/oncotarget.4432
   Meng Y, 2016, ONCOL REP, V36, P2463, DOI 10.3892/or.2016.5076
   Mu Y, 2017, BIOMED PHARMACOTHER, V90, P548, DOI 10.1016/j.biopha.2017.03.073
   Nasioudis D, 2016, GYNECOL ONCOL, V141, P128, DOI 10.1016/j.ygyno.2016.02.004
   Pang YX, 2014, FOOD CHEM TOXICOL, V69, P163, DOI 10.1016/j.fct.2014.04.010
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Perl A, 2018, EBIOMEDICINE, V36, P12, DOI 10.1016/j.ebiom.2018.09.033
   Ramakrishna M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009983
   Sauer G, 2005, MOL CELL PROTEOMICS, V4, P35, DOI 10.1074/mcp.M400158-MCP200
   Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577
   Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Varisli L, 2012, ONCOL LETT, V4, P1335, DOI 10.3892/ol.2012.925
   Wang D, 2015, BIOCHEM BIOPH RES CO, V458, P313, DOI 10.1016/j.bbrc.2015.01.108
   Wang ZR, 2013, ONCOTARGET, V4, P2476, DOI 10.18632/oncotarget.1581
   Yan LK, 2017, BIOMED PHARMACOTHER, V96, P974, DOI 10.1016/j.biopha.2017.11.138
   Zhan L, 2016, ONCOTARGET, V7, P83476, DOI 10.18632/oncotarget.13080
   Zi D, 2015, INT J MOL SCI, V16, P27228, DOI 10.3390/ijms161126018
NR 34
TC 14
Z9 17
U1 2
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1672-9145
EI 1745-7270
J9 ACTA BIOCH BIOPH SIN
JI Acta Biochim. Biophys. Sin.
PD MAY
PY 2019
VL 51
IS 5
BP 509
EP 516
DI 10.1093/abbs/gmz028
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA IA2ZA
UT WOS:000469431000007
PM 30939187
DA 2022-04-25
ER

PT J
AU Booth, L
   Cruickshanks, N
   Tavallai, S
   Roberts, JL
   Peery, M
   Poklepovic, A
   Dent, P
AF Booth, Laurence
   Cruickshanks, Nichola
   Tavallai, Seyedmehrad
   Roberts, Jane L.
   Peery, Matthew
   Poklepovic, Andrew
   Dent, Paul
TI Regulation of dimethyl-fumarate toxicity by proteasome inhibitors
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; NF-KAPPA-B;
   MITOCHONDRIAL DYSFUNCTION; CELLS; APOPTOSIS; CARFILZOMIB; ACID;
   GENERATION; BORTEZOMIB
AB The present studies examined the biology of the multiple sclerosis drug dimethyl-fumarate (DMF) or its in vivo breakdown product and active metabolite mono-methyl-fumarate (MMF), alone or in combination with proteasome inhibitors, in primary human glioblastoma (GBM) cells. MMF enhanced velcade and carfilzomib toxicity in multiple primary GBM isolates. Similar data were obtained in breast and colon cancer cells. MMF reduced the invasiveness of GBM cells, and enhanced the toxicity of ionizing radiation and temozolomide. MMF killed freshly isolated activated microglia which was associated with reduced IL-6, TGF and TNF production. The combination of MMF and the multiple sclerosis drug Gilenya further reduced both GBM and activated microglia viability and cytokine production. Over-expression of c-FLIP-s or BCL-XL protected GBM cells from MMF and velcade toxicity. MMF and velcade increased plasma membrane localization of CD95, and knock down of CD95 or FADD blocked the drug interaction. The drug combination inactivated AKT, ERK1/2 and mTOR. Molecular inhibition of AKT/ERK/mTOR signaling enhanced drug combination toxicity whereas molecular activation of these pathways suppressed killing. MMF and velcade increased the levels of autophagosomes and autolysosomes and knock down of ATG5 or Beclin1 protected cells. Inhibition of the eIF2/ATF4 arm or the IRE1/XBP1 arm of the ER stress response enhanced drug combination lethality. This was associated with greater production of reactive oxygen species and quenching of ROS suppressed cell killing.
C1 [Booth, Laurence; Cruickshanks, Nichola; Tavallai, Seyedmehrad; Roberts, Jane L.; Peery, Matthew; Dent, Paul] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA 23284 USA.
   [Poklepovic, Andrew] Virginia Commonwealth Univ, Richmond, VA USA.
RP Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA 23284 USA.
EM pdent@vcu.edu
FU PHS grants from the National Institutes of Health [R01-CA141704,
   R01-CA150214, R01-DK52825]; Department of DefenseUnited States
   Department of Defense [W81XWH-10-1-0009]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA150214] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01DK052825] Funding Source: NIH RePORTER
FX Support for the present study was funded from PHS grants from the
   National Institutes of Health [R01-CA141704, R01-CA150214, R01-DK52825];
   the Department of Defense [W81XWH-10-1-0009]. PD is the holder of the
   Universal Inc. Chair in Signal Transduction Research.
CR Bedford L, 2011, NAT REV DRUG DISCOV, V10, P29, DOI 10.1038/nrd3321
   Belge Katharina, 2014, F1000Prime Rep, V6, P4, DOI 10.12703/P6-4
   Booth L, 2014, CANCER BIOL THER, V15, P305, DOI 10.4161/cbt.27309
   Booth L, 2014, MOL PHARMACOL, V85, P408, DOI 10.1124/mol.113.090043
   Booth L, 2012, CANCER BIOL THER, V13, P224, DOI 10.4161/cbt.13.4.18877
   Dasmahapatra G, 2010, BLOOD, V115, P4478, DOI 10.1182/blood-2009-12-257261
   Field KM, 2014, ASIA-PAC J CLIN ONCO, V10, P153, DOI 10.1111/ajco.12076
   Foresti R, 2013, PHARMACOL RES, V76, P132, DOI 10.1016/j.phrs.2013.07.010
   Fribley A, 2004, MOL CELL BIOL, V24, P9695, DOI 10.1128/MCB.24.22.9695-9704.2004
   Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010
   Ghods Ali J, 2013, Surg Neurol Int, V4, P160, DOI 10.4103/2152-7806.123656
   Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287
   Juratli TA, 2013, PHARMACOL THERAPEUT, V139, P341, DOI 10.1016/j.pharmthera.2013.05.003
   Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0
   Kim I, 2008, NAT REV DRUG DISCOV, V7, P1013, DOI 10.1038/nrd2755
   Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood-2007-01-065888
   Li CY, 2010, J BIOL CHEM, V285, P16096, DOI 10.1074/jbc.M109.072694
   Li XN, 1997, NEUROSURGERY, V40, P1250, DOI 10.1097/00006123-199706000-00027
   Lin SX, 2011, ASN NEURO, V3, DOI 10.1042/AN20100033
   Ling YH, 2003, J BIOL CHEM, V278, P33714, DOI 10.1074/jbc.M302559200
   Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386
   Malhi H, 2011, J HEPATOL, V54, P795, DOI 10.1016/j.jhep.2010.11.005
   Martin-Perez R, 2012, APOPTOSIS, V17, P349, DOI 10.1007/s10495-011-0673-2
   Moharregh-Khiabani D, 2009, CURR NEUROPHARMACOL, V7, P60, DOI 10.2174/157015909787602788
   Peng HY, 2012, J BIOL CHEM, V287, P28017, DOI 10.1074/jbc.M112.383380
   Phillips JT, 2013, SEMIN NEUROL, V33, P56, DOI 10.1055/s-0033-1343796
   Qi YF, 2012, J BIOL CHEM, V287, P32236, DOI 10.1074/jbc.M112.362160
   Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132
   Schmidt MM, 2010, NEUROCHEM INT, V57, P460, DOI 10.1016/j.neuint.2010.01.006
   Senkal CE, 2010, FASEB J, V24, P296, DOI 10.1096/fj.09-135087
   Sureshbabu A, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00384
   Tsubaki M, 2013, EUR J CANCER, V49, P3708, DOI 10.1016/j.ejca.2013.07.010
   Van Nifterik KA, 2012, J NEURO-ONCOL, V107, P61, DOI 10.1007/s11060-011-0725-z
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang FM, 2011, BIOCHEM J, V433, P245, DOI 10.1042/BJ20101293
   Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764
   Wilms H, 2010, J NEUROINFLAMM, V19, P7
   Yacoub A, 2006, MOL PHARMACOL, V70, P589, DOI 10.1124/mol.106.025007
   Yang F, 2012, CANCER BIOL THER, V13, P349, DOI 10.4161/cbt.19239
   Yu CR, 2004, EXP CELL RES, V295, P555, DOI 10.1016/j.yexcr.2004.02.001
   Zangari M, 2011, EUR J HAEMATOL, V86, P484, DOI 10.1111/j.1600-0609.2011.01602.x
NR 41
TC 18
Z9 18
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PY 2014
VL 15
IS 12
BP 1646
EP 1657
DI 10.4161/15384047.2014.967992
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AZ7EP
UT WOS:000348382100009
PM 25482938
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Schmidt, LS
   Linehan, WM
AF Schmidt, Laura S.
   Linehan, W. Marston
TI FLCN: The causative gene for Birt-Hogg-Dube syndrome
SO GENE
LA English
DT Review
DE FLCN; Folliculin; FNIP1; FNIP2; Birt-Hogg-Dube syndrome; Kidney tumor;
   DENN domain; mTOR; AMPK; PGC1 alpha
ID RENAL-CELL CARCINOMA; TUMOR-SUPPRESSOR GENE; AMINO-ACID PERMEASE; NIHON
   RAT MODEL; SPONTANEOUS PNEUMOTHORAX; BHD GENE; PRIMARY CILIUM;
   INTRAGENIC DELETIONS; EMBRYONIC LETHALITY; COLORECTAL-CANCER
AB Germline mutations in the novel tumor suppressor gene FLCN are responsible for the autosomal dominant inherited disorder Birt-Hogg-Dube (BHD) syndrome that predisposes to fibrofolliculomas, lung cysts and spontaneous pneumothorax, and an increased risk for developing kidney tumors. Although the encoded protein, folliculin (FLCN), has no sequence homology to known functional domains, x-ray crystallographic studies have shown that the C-terminus of FLCN has structural similarity to DENN (differentially expressed in normal cells and neoplasia) domain proteins that act as guanine nucleotide exchange factors (GEFs) for small Rab GTPases. FLCN forms a complex with folliculin interacting proteins 1 and 2 (FNIP1, FNIP2) and with 5' AMP-activated protein kinase (AMPK). This review summarizes FLCN functional studies which support a role for FLCN in diverse metabolic pathways and cellular processes that include modulation of the mTOR pathway, regulation of PGC1 alpha a and mitochondrial biogenesis, cell-cell adhesion and RhoA signaling, control of TFE3/TFEB transcriptional activity, amino acid-dependent activation of mTORC1 on lysosomes through Rag GTPases, and regulation of autophagy. Ongoing research efforts are focused on clarifying the primary FLCN-associated pathway(s) that drives the development of fibrofolliculomas, lung cysts and kidney tumors in BHD patients carrying germline FLCN mutations.
C1 [Schmidt, Laura S.; Linehan, W. Marston] NCI, Urol Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA.
   [Schmidt, Laura S.] Leidos Biomed Res Inc, Basic Sci Program, Frederick Lab Canc Res, Frederick, MD 21702 USA.
RP Schmidt, LS; Linehan, WM (corresponding author), NCI, NIH, Bldg10 CRC 1W-5940,10 Ctr Dr, Bethesda, MD 20892 USA.
EM schmidtl@mail.nih.gov; wml@nih.gov
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [GM089820]; Intramural
   Research Program of the NIH, National Cancer Institute, Center for
   Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZIA BC011028, ZIA BC011043, ZO1BC011044-01]; Frederick
   National Laboratory for Cancer Research, NIH [HHSN261200800001E];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZICBC011044, ZIABC011043, Z01BC011043, ZIABC011028,
   Z01BC011028, ZIABC011038, ZIDBC011089] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of General Medical Sciences (NIGMS) [R01GM089820]
   Funding Source: NIH RePORTER
FX This review and the corresponding Gene Wiki article are written as part
   of the GeneWiki Review series-a series resulting from a collaboration
   between the journal GENE and the Gene Wiki Initiative. The Gene Wiki
   Initiative is supported by the National Institutes of Health (GM089820).
   Additional support for Gene Wiki Reviews is provided by Elsevier, the
   publisher of GENE. This work was supported by the Intramural Research
   Program of the NIH, National Cancer Institute (ZIA BC011028, ZIA
   BC011043, ZO1BC011044-01), Center for Cancer Research. This project has
   been funded in part with federal funds from the Frederick National
   Laboratory for Cancer Research, NIH, under Contract HHSN261200800001E.
   The content of this publication does not necessarily reflect the views
   or policies of the Department of Health and Human Services, nor does
   mention of trade names, commercial products or organizations imply
   endorsement by the US Government. The corresponding Gene Wiki entry for
   this review can be found here: http://en.wikipedia.org/wiki/Folliculin.
CR Argani P, 2015, SEMIN DIAGN PATHOL, V32, P103, DOI 10.1053/j.semdp.2015.02.003
   Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288
   Baba M, 2006, P NATL ACAD SCI USA, V103, P15552, DOI 10.1073/pnas.0603781103
   Baba M, 2012, BLOOD, V120, P1254, DOI 10.1182/blood-2012-02-410407
   Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003
   Bastola P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070030
   Benhammou JN, 2011, GENE CHROMOSOME CANC, V50, P466, DOI 10.1002/gcc.20872
   Benusiglio PR, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/s13023-014-0163-z
   Betschinger J, 2013, CELL, V153, P335, DOI 10.1016/j.cell.2013.03.012
   BINET O, 1986, ANN DERMATOL VENER, V113, P928
   BIRT AR, 1977, ARCH DERMATOL, V113, P1674, DOI 10.1001/archderm.113.12.1674
   Boehlke C, 2010, NAT CELL BIOL, V12, P1115, DOI 10.1038/ncb2117
   Bonsdorff TB, 2008, MAMM GENOME, V19, P121, DOI 10.1007/s00335-007-9088-3
   Cash TP, 2011, ONCOGENE, V30, P2534, DOI 10.1038/onc.2010.628
   Chen JD, 2015, KIDNEY INT, V88, P1057, DOI 10.1038/ki.2015.177
   Chen JD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003581
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chung JY, 1996, INT J DERMATOL, V35, P365, DOI 10.1111/j.1365-4362.1996.tb03642.x
   da Silva NF, 2003, J MED GENET, V40, P820
   Davis CF, 2014, CANCER CELL, V26, P319, DOI 10.1016/j.ccr.2014.07.014
   Ding YB, 2015, AM J MED GENET A, V167, P1125, DOI 10.1002/ajmg.a.36979
   Dunlop EA, 2014, AUTOPHAGY, V10, P1749, DOI 10.4161/auto.29640
   Esteban MA, 2006, J AM SOC NEPHROL, V17, P1801, DOI 10.1681/ASN.2006020181
   Furuya M, 2016, CLIN GENET, V90, P403, DOI 10.1111/cge.12807
   Furuya M, 2015, CANCER SCI, V106, P315, DOI 10.1111/cas.12601
   Gad S, 2007, BRIT J CANCER, V96, P336, DOI 10.1038/sj.bjc.6603492
   Gaur K, 2013, HUM MOL GENET, V22, P284, DOI 10.1093/hmg/dds428
   Gijezen LC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099071
   Goncharova EA, 2014, CELL REP, V7, P412, DOI 10.1016/j.celrep.2014.03.025
   Gupta N, 2013, FAM CANCER, V12, P387, DOI 10.1007/s10689-013-9660-9
   Hager M, 2010, CLIN EXP METASTAS, V27, P611, DOI 10.1007/s10585-010-9351-y
   Hartman TR, 2009, ONCOGENE, V28, P1594, DOI 10.1038/onc.2009.14
   Hartman TR, 2009, HUM MOL GENET, V18, P151, DOI 10.1093/hmg/ddn325
   Hasumi H, 2008, GENE, V415, P60, DOI 10.1016/j.gene.2008.02.022
   Hasumi H, 2017, HUM MOL GENET, V26, P354, DOI 10.1093/hmg/ddw392
   Hasumi H, 2015, P NATL ACAD SCI USA, V112, pE1624, DOI 10.1073/pnas.1419502112
   Hasumi H, 2012, JNCI-J NATL CANCER I, V104, P1750, DOI 10.1093/jnci/djs418
   Hasumi Y, 2014, HUM MOL GENET, V23, P5706, DOI 10.1093/hmg/ddu286
   Hasumi Y, 2009, P NATL ACAD SCI USA, V106, P18722, DOI 10.1073/pnas.0908853106
   Hong SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015793
   Hong SB, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-160
   Houweling AC, 2011, BRIT J CANCER, V105, P1912, DOI 10.1038/bjc.2011.463
   Hudon V, 2010, J MED GENET, V47, P182, DOI 10.1136/jmg.2009.072009
   Kenyon EJ, 2016, BMC DEV BIOL, V16, DOI 10.1186/s12861-016-0119-8
   Khabibullin D, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12107
   Khoo SK, 2003, CANCER RES, V63, P4583
   Khoo SK, 2002, J MED GENET, V39, P906, DOI 10.1136/jmg.39.12.906
   Khoo SK, 2001, ONCOGENE, V20, P5239, DOI 10.1038/sj.onc.1204703
   Kim S, 2013, CURR OPIN CELL BIOL, V25, P506, DOI 10.1016/j.ceb.2013.04.011
   Klomp JA, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-59
   Kluger N, 2010, BRIT J DERMATOL, V162, P527, DOI 10.1111/j.1365-2133.2009.09517.x
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Komori K, 2009, ONCOGENE, V28, P1142, DOI 10.1038/onc.2008.462
   Kunogi M, 2010, J MED GENET, V47, P281, DOI 10.1136/jmg.2009.070565
   Lancaster MA, 2011, NAT CELL BIOL, V13, P700, DOI 10.1038/ncb2259
   Laviolette LA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15866
   Laviolette LA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066775
   Leter EM, 2008, J INVEST DERMATOL, V128, P45, DOI 10.1038/sj.jid.5700959
   Lim DHK, 2010, HUM MUTAT, V31, pE1043, DOI 10.1002/humu.21130
   Lim TH, 2012, DNA REPAIR, V11, P259, DOI 10.1016/j.dnarep.2011.11.006
   Lingaas F, 2003, HUM MOL GENET, V12, P3043, DOI 10.1093/hmg/ddg336
   Liu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065869
   Luijten MNH, 2013, HUM MOL GENET, V22, P4383, DOI 10.1093/hmg/ddt288
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Medvetz DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047842
   Nagashima K, 2017, ONCOTARGET, V8, P9947, DOI 10.18632/oncotarget.14221
   Nagy A, 2004, INT J CANCER, V109, P472, DOI 10.1002/ijc.11694
   Nahorski MS, 2012, HUM MOL GENET, V21, P5268, DOI 10.1093/hmg/dds378
   Nahorski MS, 2011, HUM MUTAT, V32, P921, DOI 10.1002/humu.21519
   Nahorski MS, 2010, J MED GENET, V47, P385, DOI 10.1136/jmg.2009.073304
   Nakamura Mami, 2013, Hinyokika Kiyo, V59, P503
   Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6
   Nookala RK, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120071
   Okimoto K, 2004, P NATL ACAD SCI USA, V101, P2023, DOI 10.1073/pnas.0308071100
   Pacitto A, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150174
   Park H, 2012, IMMUNITY, V36, P769, DOI 10.1016/j.immuni.2012.02.019
   Pavlovich CP, 2002, AM J SURG PATHOL, V26, P1542, DOI 10.1097/00000478-200212000-00002
   Peli-Gulli MP, 2015, CELL REP, V13, P1, DOI 10.1016/j.celrep.2015.08.059
   Petit CS, 2013, J CELL BIOL, V202, P1107, DOI 10.1083/jcb.201307084
   Possik E, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004273
   Preston RS, 2011, ONCOGENE, V30, P1159, DOI 10.1038/onc.2010.497
   Raben N, 2016, ANNU REV CELL DEV BI, V32, P255, DOI 10.1146/annurev-cellbio-111315-125407
   Reyes NL, 2015, P NATL ACAD SCI USA, V112, P424, DOI 10.1073/pnas.1413021112
   Roberg KJ, 1997, GENETICS, V147, P1569
   Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790
   Rossing M, 2017, J HUM GENET, V62, P151, DOI 10.1038/jhg.2016.118
   ROTH JS, 1993, J AM ACAD DERMATOL, V29, P1055, DOI 10.1016/S0190-9622(08)82049-X
   Rubio-Texeira M, 2006, MOL BIOL CELL, V17, P3031, DOI 10.1091/mbc.E05-07-0669
   Schmidt LS, 2015, NAT REV UROL, V12, P558, DOI 10.1038/nrurol.2015.206
   Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842
   Schmidt LS, 2001, AM J HUM GENET, V69, P876, DOI 10.1086/323744
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Siggs OM, 2016, P NATL ACAD SCI USA, V113, pE3706, DOI 10.1073/pnas.1607592113
   Singh SR, 2006, ONCOGENE, V25, P5933, DOI 10.1038/sj.onc.1209593
   Starling GP, 2016, EMBO REP, V17, P823, DOI 10.15252/embr.201541382
   Takagi Y., 2008, ONCOGENE
   Togashi Y, 2006, ONCOGENE, V25, P2885, DOI 10.1038/sj.onc.1209317
   Toro JR, 2008, J MED GENET, V45, P321, DOI 10.1136/jmg.2007.054304
   Toro JR, 2007, AM J RESP CRIT CARE, V175, P1044, DOI 10.1164/rccm.200610-1483OC
   Toro JR, 1999, ARCH DERMATOL, V135, P1195, DOI 10.1001/archderm.135.10.1195
   Tsun ZY, 2013, MOL CELL, V52, P495, DOI 10.1016/j.molcel.2013.09.016
   van Slegtenhorst M, 2007, J BIOL CHEM, V282, P24583, DOI 10.1074/jbc.M700857200
   Vocke CD, 2005, J NATL CANCER I, V97, P931, DOI 10.1093/jnci/dji154
   Wada S, 2016, GENE DEV, V30, P2551, DOI 10.1101/gad.287953.116
   Wang L, 2010, FEBS LETT, V584, P39, DOI 10.1016/j.febslet.2009.11.033
   Warren MB, 2004, MODERN PATHOL, V17, P998, DOI 10.1038/modpathol.3800152
   Weirich G, 1998, J UROLOGY, V160, P335, DOI 10.1016/S0022-5347(01)62888-X
   Woodford MR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12037
   Wu MS, 2015, ONCOTARGET, V6, P32761, DOI 10.18632/oncotarget.5018
   Wu XD, 2011, P NATL ACAD SCI USA, V108, P18672, DOI 10.1073/pnas.1110415108
   Yan M, 2016, GENE DEV, V30, P1034, DOI 10.1101/gad.281410.116
   Yan M, 2014, J CLIN INVEST, V124, P2640, DOI 10.1172/JCI71749
   Yang Y, 2008, CANCER GENET CYTOGEN, V180, P100, DOI 10.1016/j.cancergencyto.2007.10.010
   Yoshimura S, 2010, J CELL BIOL, V191, P367, DOI 10.1083/jcb.201008051
   Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393
   Zhang Dapeng, 2012, Frontiers in Genetics, V3, P283, DOI 10.3389/fgene.2012.00283
   Zhong MM, 2016, J BIOL CHEM, V291, P11689, DOI 10.1074/jbc.M116.719997
NR 118
TC 59
Z9 60
U1 1
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JAN 15
PY 2018
VL 640
BP 28
EP 42
DI 10.1016/j.gene.2017.09.044
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FO1DE
UT WOS:000416496100005
PM 28970150
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Liu, WB
   Yu, XF
   Zhou, L
   Li, JG
   Li, M
   Li, W
   Gao, F
AF Liu, Wenbin
   Yu, Xinfang
   Zhou, Li
   Li, Jigang
   Li, Ming
   Li, Wei
   Gao, Feng
TI Sinomenine Inhibits Non-Small Cell Lung Cancer via Downregulation of
   Hexokinases II-Mediated Aerobic Glycolysis
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE sinomenine; non-small cell lung cancer; glycolysis; hexokinase 2
ID COLORECTAL-CANCER; CARCINOMA-CELLS; PROLIFERATION; MIGRATION;
   SUPPRESSION; AUTOPHAGY; INVASION; GROWTH
AB Background: Addiction to aerobic glycolysis is a common metabolic phenotype in human non-small cell lung cancer (NSCLC). The natural product Sinomenine (Sin) exhibits significant anti-tumor effects in various human cancers. However, the underlying mechanism remains elusive.
   Methods: The inhibitory effect of Sin on NSCLC cells was determined by MTS and soft agar assays. The glycolysis efficacy of NSCLC cells was examined by glucose uptake and lactate production. The activation of Akt signaling and the protein level of hexokinases II (HK2) were examined by immunoblot (IB), qRT-PCR, and immunohistochemical staining (IHC). The in vivo anti-tumor effect of Sin was validated by the xenograft mouse model.
   Results: We showed that HK2 is highly expressed in NSCLC tissues and cell lines. Depletion of HK2 suppressed cell viability, anchorage-independent colony formation, and xenograft tumor growth. Sinomenine exhibited a profound inhibitory effect on NSCLC cells by reducing HK2-mediated glycolysis both in vitro and in vivo. Ectopic overexpression of HK2 compromised these anti-tumor efficacies in sinomenine-treated NSCLC cells. Moreover, we revealed that sinomenine decreased Akt activity, which caused the down-regulation of HK2-mediated glycolysis. Knockdown of Akt reduced HK2 protein level and impaired glycolysis. In contrast, overexpression of constitutively activated Akt1 reversed this phenotype.
   Conclusion: This study suggests that targeting HK2-mediated aerobic glycolysis is required for sinomenine-mediated anti-tumor activity.
C1 [Liu, Wenbin; Li, Jigang] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Dept Pathol, Changsha 410006, Hunan, Peoples R China.
   [Yu, Xinfang] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA.
   [Zhou, Li] Cent South Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China.
   [Li, Ming] Hunan Univ Chinese Med, Sch Stomatol, Changsha 410208, Hunan, Peoples R China.
   [Li, Ming] Hunan Univ Chinese Med, Changsha Stomatol Hosp, Changsha 410004, Hunan, Peoples R China.
   [Li, Wei] Cent South Univ, Xiangya Hosp 3, Dept Radiol, Changsha 410013, Hunan, Peoples R China.
   [Gao, Feng] Cent South Univ, Xiangya Hosp 3, Dept Ultrasonog, Changsha 410013, Hunan, Peoples R China.
RP Li, W (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Radiol, Changsha 410013, Hunan, Peoples R China.; Gao, F (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Ultrasonog, Changsha 410013, Hunan, Peoples R China.
EM weililx@csu.edu.cn; gf0731@csu.edu.cn
OI li, wei/0000-0002-7267-6494
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81904262, 81972,837]; Natural Science
   Foundation of Hunan ProvinceNatural Science Foundation of Hunan Province
   [2018JJ3787, 2018JJ2604, 2019JJ50682]; Natural Science Foundation of
   Changsha Science and Technology Bureau [kq1701018]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81904262, 81972,837), the Natural Science Foundation of Hunan
   Province (2018JJ3787, 2018JJ2604, 2019JJ50682), and the Natural Science
   Foundation of Changsha Science and Technology Bureau (kq1701018).
CR Abbaszadeh Z, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144158
   Arbour KC, 2019, JAMA-J AM MED ASSOC, V322, P764, DOI 10.1001/jama.2019.11058
   Bianco A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194931
   Deng F, 2018, BIOMED PHARMACOTHER, V97, P1269, DOI 10.1016/j.biopha.2017.11.064
   Fu SB, 2018, ONCOL REP, V39, P1601, DOI 10.3892/or.2018.6228
   Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152
   Gao F, 2015, ONCOL REP, V33, P1533, DOI 10.3892/or.2015.3727
   Gao GL, 2019, ARTIF CELL NANOMED B, V47, P3839, DOI 10.1080/21691401.2019.1666861
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HE X, 2018, TECHNOL CANCER RES T, V17, DOI DOI 10.1177/1533034618770305
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183
   Jiang Y, 2018, INT J MOL SCI, V19, P3
   Katagiri M, 2017, HISTOL HISTOPATHOL, V32, P351, DOI 10.14670/HH-11-799
   Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07
   Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8
   Li W, 2018, J CELL MOL MED, V22, P6213, DOI 10.1111/jcmm.13908
   Li W, 2018, CANCER MED-US, V7, P208, DOI 10.1002/cam4.1269
   Li W, 2017, ONCOTARGET, V8, P32586, DOI 10.18632/oncotarget.15937
   Li W, 2016, EXP CELL RES, V349, P320, DOI 10.1016/j.yexcr.2016.11.002
   Liu HD, 2016, ONCOTARGET, V7, P56338, DOI 10.18632/oncotarget.10841
   Liu WB, 2019, INT J BIOL SCI, V15, P2497, DOI 10.7150/ijbs.37481
   Liu Y, 2019, ANTI-CANCER DRUG, V30, P983, DOI 10.1097/CAD.0000000000000834
   Londhe P, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00104
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Payen VL, 2016, CELL MOL LIFE SCI, V73, P1333, DOI 10.1007/s00018-015-2098-5
   Shi TG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1549-6
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song LQ, 2015, BIOCHEM BIOPH RES CO, V464, P705, DOI 10.1016/j.bbrc.2015.07.004
   Sun Z, 2018, DRUG DES DEV THER, V12, P2413, DOI 10.2147/DDDT.S155798
   Tun AM, 2019, FUTUR SCI OA, V5, DOI 10.2144/fsoa-2019-0081
   Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241
   Wolf A, 2011, J EXP MED, V208, P313, DOI 10.1084/jem.20101470
   Xu F, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.01.053
   Yu XF, 2019, ONCOGENE, V38, P7457, DOI 10.1038/s41388-019-0955-7
   Yuan HF, 2019, BASIC CLIN PHARMACOL, V125, P450, DOI 10.1111/bcpt.13285
   Zhang D, 2018, ONCOL REP, V40, P2886, DOI 10.3892/or.2018.6693
   Zhao B, 2017, BIOMED PHARMACOTHER, V96, P1036, DOI 10.1016/j.biopha.2017.11.123
   Zhong JT, 2017, ONCOTARGET, V8, P14133, DOI 10.18632/oncotarget.13044
   Zhou L, 2019, INT J BIOL SCI, V15, P826, DOI 10.7150/ijbs.31749
NR 43
TC 6
Z9 6
U1 2
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 3209
EP 3221
DI 10.2147/OTT.S243212
PG 13
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA LD5AQ
UT WOS:000526041900001
PM 32368080
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Tang, ZY
   Li, Y
   Tang, YT
   Ma, XD
   Tang, ZY
AF Tang, Zhong-Yuan
   Li, Yang
   Tang, Yu-Ting
   Ma, Xiao-Dong
   Tang, Ze-Yao
TI Anticancer activity of oleanolic acid and its derivatives: Recent
   advances in evidence, target profiling and mechanisms of action
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Oleanolic acid; Derivatives; Apoptotic pathways; Angiogenesis;
   Metastasis; Systematic-analysis review
ID NF-KAPPA-B; CELL-CYCLE ARREST; COLORECTAL-CANCER ANGIOGENESIS;
   HEPATOCELLULAR-CARCINOMA CELLS; FAMILY 1B10 AKR1B10; IN-VITRO;
   PROSTATE-CANCER; SAIKOSAPONIN-D; URSOLIC ACID; CDDO-ME
AB Oleanolic acid (OA, 3 13 - hydroxyoleanolic acid-12-en-28-oic acid) is a pentacyclic triterpenoid present in many plants. As a new framework for development of semi synthetic triterpenoids, OA is of great significance in the discovery of anticancer drugs. Some of these derivatives, such as CDDO (2-cyano-3,12-dioxooleana-1, 9 (11)dien-28-oic acid) have been verified in clinical trials, while other derivatives studied previously, such as SZC014, SZC015 and SZC017 (OA derivatives respectively), are also candidate drugs for cancer treatment. This paper reviews the preclinical studies, literature evidence, target analysis and anticancer mechanism of OA and its derivatives. The mechanism of action of its derivatives mainly includes anti-cancer cell proliferation, inducing tumor cell apoptosis, inducing autophagy, regulating cell cycle regulatory proteins, inhibiting vascular endothelial growth, anti angiogenesis, inhibiting tumor cell migration and invasion. In recent years, the molecular mechanism of OA and its derivatives has been elucidated. These effects seem to be mediated by the alterations in a variety of signaling pathways induced by OA and its derivatives. In conclusion, OA and its derivatives are considered as important candidate drugs for the treatment of cancer, indicating that OA and its derivatives have the potential to be used as anticancer drugs in practice.
C1 [Li, Yang; Tang, Yu-Ting; Ma, Xiao-Dong; Tang, Ze-Yao] Dalian Med Univ, Pharmacol Dept, 9 West Sect,South Rd Lvshun, Dalian 116044, Liaoning, Peoples R China.
   [Tang, Zhong-Yuan] Jilin Univ, Sch Stornatol, Dept Orthodont, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
RP Tang, ZY (corresponding author), Dalian Med Univ, Pharmacol Dept, 9 West Sect,South Rd Lvshun, Dalian 116044, Liaoning, Peoples R China.
EM tangzeyao411@dmu.edu.cn
CR Adamska A, 2019, MOLECULES, V24, DOI 10.3390/molecules24162958
   Akl MR, 2014, EUR J PHARMACOL, V740, P209, DOI 10.1016/j.ejphar.2014.07.011
   Bao YM, 2020, MOL PHARMACEUT, V17, P1343, DOI 10.1021/acs.molpharmaceut.0c00044
   Bian M., 2020, CHEMISTRY, V26
   Borella R, 2019, MOLECULES, V24, DOI 10.3390/molecules24224097
   Chakravarti B, 2012, J ETHNOPHARMACOL, V142, P72, DOI 10.1016/j.jep.2012.04.015
   Chang Q, 2013, NEOPLASIA, V15, P848, DOI 10.1593/neo.13706
   Chen D, 2020, ACS OMEGA, V5, P995, DOI 10.1021/acsomega.9b02261
   Chen X, 2016, PHYTOMEDICINE, V23, P1555, DOI 10.1016/j.phymed.2016.09.002
   Chen Z, 2019, J NAT PROD, V82, P3065, DOI 10.1021/acs.jnatprod.9b00659
   Cheng KG, 2015, EUR J MED CHEM, V89, P480, DOI 10.1016/j.ejmech.2014.10.066
   Cheng L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090848
   Chu R, 2010, INT J CANCER, V127, P1209, DOI 10.1002/ijc.25116
   Chung YT, 2012, MODERN PATHOL, V25, P758, DOI 10.1038/modpathol.2011.191
   Constantinou C, 2009, CURR CANCER DRUG TAR, V9, P717, DOI 10.2174/156800909789271512
   Deeb Dorrah, 2014, J Carcinog Mutagen, V5, P177
   Deeb D, 2013, MOLECULES, V18, P3250, DOI 10.3390/molecules18033250
   Deeb D, 2011, CARCINOGENESIS, V32, P757, DOI 10.1093/carcin/bgr030
   Duan LJ, 2019, ANTI-CANCER DRUG, V30, P812, DOI 10.1097/CAD.0000000000000777
   Nguyen DH, 2019, FITOTERAPIA, V137, DOI 10.1016/j.fitote.2019.104242
   Fan RC, 2020, J CANCER, V11, P1949, DOI 10.7150/jca.38847
   Farimani MM, 2015, PLANTA MED, V81, P1290, DOI 10.1055/s-0035-1546256
   Firempong CK, 2016, PHARMACOL RES, V110, P101, DOI 10.1016/j.phrs.2016.04.032
   Fontana G, 2019, BIOORG CHEM, V90, DOI 10.1016/j.bioorg.2019.103054
   Fotso WG, 2019, NAT PROD RES, V33, P3521, DOI 10.1080/14786419.2018.1486312
   Fujiwara Y, 2011, ONCOL REP, V26, P1533, DOI 10.3892/or.2011.1454
   Fukumura M, 2009, J NAT MED-TOKYO, V63, P181, DOI 10.1007/s11418-008-0311-7
   Ganbold M, 2010, J ETHNOPHARMACOL, V131, P396, DOI 10.1016/j.jep.2010.07.014
   Gao C, 2019, J BUON, V24, P1964
   Gao L, 2016, ONCOL REP, V35, P1101, DOI 10.3892/or.2015.4447
   Gao L, 2015, APOPTOSIS, V20, P1636, DOI 10.1007/s10495-015-1179-0
   Gao Xiaohua, 2011, Cancers (Basel), V3, P3353, DOI 10.3390/cancers3033353
   Gao XH, 2011, ANTICANCER RES, V31, P3673
   Ghosh N, 2010, PHARMACOL REP, V62, P233, DOI 10.1016/S1734-1140(10)70262-0
   Ghosh S, 2014, J INTEGR MED-JIM, V12, P102, DOI 10.1016/S2095-4964(14)60015-7
   Gibellini L, 2015, ONCOTARGET, V6, P25466, DOI 10.18632/oncotarget.4510
   Guo YF, 2017, BIOMED PHARMACOTHER, V85, P733, DOI 10.1016/j.biopha.2016.11.091
   Hosny S, 2021, NUTR CANCER, V73, P968, DOI 10.1080/01635581.2020.1776887
   Huang ZJ, 2012, ORG BIOMOL CHEM, V10, P3882, DOI 10.1039/c2ob25252j
   Husseinzadeh N, 2014, GYNECOL ONCOL, V133, P375, DOI 10.1016/j.ygyno.2014.02.017
   Janakiram NB, 2008, PHARM RES-DORDR, V25, P2151, DOI 10.1007/s11095-008-9582-7
   Jia LY, 2017, MOLECULES, V22, DOI 10.3390/molecules22101649
   Jo H, 2020, J GINSENG RES, V44, P96, DOI 10.1016/j.jgr.2018.09.003
   Kahnt M, 2019, STEROIDS, V149, DOI 10.1016/j.steroids.2019.05.014
   Kawahara KI, 2009, INT J MOL MED, V23, P615, DOI 10.3892/ijmm_00000172
   Kayouka M, 2020, CHEM-BIOL INTERACT, V315, DOI 10.1016/j.cbi.2019.108892
   Kesanakurti D, 2013, ONCOGENE, V32, P5144, DOI 10.1038/onc.2012.546
   Kim Gyeong-Ji, 2018, Oncotarget, V9, P26370, DOI 10.18632/oncotarget.25316
   Kim JD, 2014, BIOSCI BIOTECH BIOCH, V78, P279, DOI 10.1080/09168451.2014.893183
   Krajka-Kuzniak V, 2019, BIOORG CHEM, V93, DOI 10.1016/j.bioorg.2019.103326
   Krajka-Kuzniak V, 2019, CHEM-BIOL INTERACT, V311, DOI 10.1016/j.cbi.2019.108786
   Kuttan G, 2011, PHARM BIOL, V49, P995, DOI 10.3109/13880209.2011.559476
   Lee DH, 2018, MOL CELLS, V41, P771, DOI 10.14348/molcells.2018.0207
   Li DY, 2020, DRUG DELIV, V27, P191, DOI 10.1080/10717544.2019.1710622
   Li L, 2016, MOL MED REP, V13, P5276, DOI 10.3892/mmr.2016.5171
   Li L, 2015, INT J ONCOL, V47, P2247, DOI 10.3892/ijo.2015.3198
   Li XC, 2016, TUMOR BIOL, V37, P7599, DOI 10.1007/s13277-015-4655-9
   Li YY, 2019, GENE, V712, DOI 10.1016/j.gene.2019.143956
   Lin CC, 2011, J AGR FOOD CHEM, V59, P755, DOI 10.1021/jf103904b
   Lisiak N, 2014, CHEM-BIOL INTERACT, V208, P47, DOI 10.1016/j.cbi.2013.11.009
   Liu CL, 2018, PHYTOTHER RES, V32, P2299, DOI 10.1002/ptr.6172
   Liu HZ, 2013, ONCOL RES, V21, P247, DOI 10.3727/096504014X13946388748910
   Liu J, 2014, J NUTR BIOCHEM, V25, P1154, DOI 10.1016/j.jnutbio.2014.06.006
   Liu K, 2016, ONCOL REP, V35, P2328, DOI 10.3892/or.2016.4610
   Liu RY, 2014, EUR REV MED PHARMACO, V18, P2435
   Logashenko EB, 2011, CHEMBIOCHEM, V12, P784, DOI 10.1002/cbic.201000618
   Lucio KA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028596
   Ma H, 2017, NUTR CANCER, V69, P505, DOI 10.1080/01635581.2017.1285407
   Ma XB, 2015, INT IMMUNOPHARMACOL, V28, P399, DOI 10.1016/j.intimp.2015.06.020
   Mallavadhani UV, 2014, EUR J MED CHEM, V74, P398, DOI 10.1016/j.ejmech.2013.12.040
   Margheri F, 2005, INT J ONCOL, V27, P223
   Martin R, 2014, J MOL CELL CARDIOL, V72, P250, DOI 10.1016/j.yjmcc.2014.04.002
   Martin R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005975
   Matkowskyj KA, 2014, HUM PATHOL, V45, P834, DOI 10.1016/j.humpath.2013.12.002
   Mbaveng AT, 2020, PHYTOMEDICINE, V76, DOI 10.1016/j.phymed.2020.153261
   Mbaveng AT, 2018, PHYTOMEDICINE, V43, P78, DOI 10.1016/j.phymed.2018.03.035
   Medina-O'Donnell M, 2018, EUR J MED CHEM, V148, P325, DOI 10.1016/j.ejmech.2018.02.044
   Mencherini T, 2011, J NAT PROD, V74, P2116, DOI 10.1021/np200359v
   Meng YQ, 2021, J ASIAN NAT PROD RES, V23, P150, DOI 10.1080/10286020.2020.1717476
   Muhseen ZT, 2020, MOLECULES, V25, DOI 10.3390/molecules25010155
   Niu GP, 2018, ANTI-CANCER AGENT ME, V18, P583, DOI 10.2174/1871520617666171020124916
   Pattnaik B, 2016, BIOORG CHEM, V68, P152, DOI 10.1016/j.bioorg.2016.08.001
   Paz-Elizur T, 2008, CANCER LETT, V266, P60, DOI 10.1016/j.canlet.2008.02.032
   Pollier J, 2012, PHYTOCHEMISTRY, V77, P10, DOI 10.1016/j.phytochem.2011.12.022
   Potocnjak I, 2019, FOOD CHEM TOXICOL, V132, DOI 10.1016/j.fct.2019.110676
   Rui LX, 2016, TUMOR BIOL, V37, P5133, DOI 10.1007/s13277-015-4293-2
   Samarakoon S.R., 2017, BIOMED RES INT
   Shamsee ZR, 2019, MOL BIOL REP, V46, P381, DOI 10.1007/s11033-018-4482-3
   Shan Y, 2016, NUTR CANCER, V68, P280, DOI 10.1080/01635581.2016.1142587
   Shanmugam MK, 2014, CANCER LETT, V346, P206, DOI 10.1016/j.canlet.2014.01.016
   Castrejon-Jimenez NS, 2019, MOLECULES, V24, DOI 10.3390/molecules24193444
   Shen JF, 2010, INVEST OPHTH VIS SCI, V51, P35, DOI 10.1167/iovs.09-3544
   Shi Y, 2016, KOREAN J PHYSIOL PHA, V20, P237, DOI 10.4196/kjpp.2016.20.3.237
   Shopit A., MIR 421 UP REGULATIO
   Shyu MH, 2010, J AGR FOOD CHEM, V58, P6110, DOI 10.1021/jf100574j
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Sinha D, 2015, MOL CARCINOGEN, V54, P654, DOI 10.1002/mc.22136
   So JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107616
   Song XM, 2015, MOL MED REP, V12, P5494, DOI 10.3892/mmr.2015.4035
   Song YL, 2019, J CELL PHYSIOL, V234, P777, DOI 10.1002/jcp.26892
   Song YR, 2017, ONCOTARGET, V8, P67942, DOI 10.18632/oncotarget.18980
   Struh CM, 2012, PHYTOTHER RES, V26, P1507, DOI 10.1002/ptr.4604
   Subramaniya BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018695
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Sun B, 2016, INT IMMUNOPHARMACOL, V40, P400, DOI 10.1016/j.intimp.2016.09.026
   Takada K, 2010, PHYTOMEDICINE, V17, P1114, DOI 10.1016/j.phymed.2010.04.006
   Takemura M, 2011, J NAT PROD, V74, P1201, DOI 10.1021/np200118q
   Tsai SJ, 2008, J FOOD SCI, V73, pH174, DOI 10.1111/j.1750-3841.2008.00864.x
   Wang SS, 2020, BIOORG CHEM, V101, DOI 10.1016/j.bioorg.2020.104036
   Wang X, 2013, CARCINOGENESIS, V34, P1323, DOI 10.1093/carcin/bgt058
   Wang YY, 2015, DRUG DES DEV THER, V9, P993, DOI 10.2147/DDDT.S73493
   Wang YY, 2014, MOL CANCER, V13, DOI [10.1186/1476-4598-13-30, 10.1186/s12934-014-0151-y]
   Way TD, 2014, J AGR FOOD CHEM, V62, P875, DOI 10.1021/jf404243p
   Wei JT, 2013, J APPL TOXICOL, V33, P756, DOI 10.1002/jat.2725
   Wu JG, 2017, J ETHNOPHARMACOL, V203, P1, DOI 10.1016/j.jep.2017.03.013
   Wu PK, 2009, LIFE SCI, V85, P113, DOI 10.1016/j.lfs.2009.04.025
   Yang YT, 2018, TOXICOL APPL PHARM, V341, P98, DOI 10.1016/j.taap.2018.01.015
   Yu JP, 2014, J IMMUNOL, V193, P2574, DOI 10.4049/jimmunol.1400833
   Zhao Y, 2019, LIFE SCI, V231, DOI 10.1016/j.lfs.2019.116557
   Zhong D, 2016, BIOCHEM BIOPH RES CO, V474, P722, DOI 10.1016/j.bbrc.2016.05.017
   Zhou J., 2011, J OROFAC ORTHOP, V72
   Zhou L, 2020, J PHARMACOL EXP THER, V373, P149, DOI 10.1124/jpet.119.263434
   Zhou RP, 2011, J ORTHOP RES, V29, P846, DOI 10.1002/jor.21311
   Zhou WP, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.921606
   Zhu B, 2019, BIOCHEM PHARMACOL, V170, DOI 10.1016/j.bcp.2019.113642
   Zhu YY, 2015, MOL MED REP, V12, P5012, DOI 10.3892/mmr.2015.4033
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
   Zuo ZH, 2014, ONCOTARGET, V5, P7458, DOI 10.18632/oncotarget.2150
NR 128
TC 0
Z9 0
U1 22
U2 22
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2022
VL 145
AR 112397
DI 10.1016/j.biopha.2021.112397
EA NOV 2021
PG 21
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA XG8AZ
UT WOS:000724971900004
PM 34798468
OA gold
DA 2022-04-25
ER

PT J
AU Mahli, A
   Saugspier, M
   Koch, A
   Sommer, J
   Dietrich, P
   Lee, S
   Thasler, R
   Schulze-Luehrmann, J
   Luehrmann, A
   Thasler, WE
   Muller, M
   Bosserhoff, A
   Hellerbrand, C
AF Mahli, Abdo
   Saugspier, Michael
   Koch, Andreas
   Sommer, Judith
   Dietrich, Peter
   Lee, Seren
   Thasler, Reinhard
   Schulze-Luehrmann, Jan
   Luehrmann, Anja
   Thasler, Wolfgang Erwin
   Mueller, Martina
   Bosserhoff, Anja
   Hellerbrand, Claus
TI ERK activation and autophagy impairment are central mediators of
   irinotecan-induced steatohepatitis
SO GUT
LA English
DT Article
ID COLORECTAL LIVER METASTASES; CHEMOTHERAPY-ASSOCIATED HEPATOTOXICITY;
   HEPATOCELLULAR-CARCINOMA CELLS; SORAFENIB; CANCER; MITOCHONDRIA;
   CHLOROQUINE; RESISTANCE; THERAPY; STRESS
AB Objective Preoperative chemotherapy with irinotecan is associated with the development of steatohepatitis, which increases the risk of perioperative morbidity and mortality for liver surgery. The molecular mechanisms of this chemotherapeutic complication are widely unknown.
   Design Mechanisms of irinotecan-induced steatohepatitis were studied in primary human hepatocytes in vitro, in mice treated with irinotecan and in liver specimens from irinotecan-treated compared with control patients.
   Results Irinotecan dose-dependently induced lipid accumulation and pro-inflammatory gene expression in hepatocytes. This was accompanied by an impairment of mitochondrial function with reduced expression of carnitine palmitoyltransferase I and an induction of acylcoenzyme A oxidase-1 (ACOX1), oxidative stress and extracellular signal-regulated kinase (ERK) activation. ERK inhibition prevented irinotecan-induced pro-inflammatory gene expression but had only a slight effect on lipid accumulation. However, irinotecan also induced an impairment of the autophagic flux mediated by alkalisation of lysosomal pH. Re-acidification of lysosomal pH abolished irinotecan-induced autophagy impairment and lipid accumulation. Also in mice, irinotecan treatment induced hepatic ACOX1 expression, ERK phosphorylation and inflammation, as well as impairment of autophagy and significant steatosis. Furthermore, irinotecan-treated patients revealed higher hepatic ERK activity, expression of pro-inflammatory genes and markers indicative for a shift to peroxisomal fatty acid oxidation and an impaired autophagic flux. Pretreatment with the multityrosine kinase inhibitor sorafenib did not affect autophagy impairment and steatosis but significantly reduced ERK phosphorylation and inflammatory response in irinotecan-treated hepatocytes and murine livers.
   Conclusions Irinotecan induces hepatic steatosis via autophagy impairment and inflammation via ERK activation. Sorafenib appears as a novel therapeutic option for the prevention and treatment of irinotecan-induced inflammation.
C1 [Mahli, Abdo; Saugspier, Michael; Koch, Andreas; Sommer, Judith; Mueller, Martina; Hellerbrand, Claus] Univ Hosp Regensburg, Dept Internal Med 1, Regensburg, Germany.
   [Mahli, Abdo; Koch, Andreas; Sommer, Judith; Dietrich, Peter; Bosserhoff, Anja; Hellerbrand, Claus] Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, Emil Fischer Zentrum, Erlangen, Germany.
   [Lee, Seren; Thasler, Reinhard; Thasler, Wolfgang Erwin] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplantat Surg, Biobank Ob HTCR, Munich, Germany.
   [Schulze-Luehrmann, Jan; Luehrmann, Anja] Friedrich Alexander Univ FAU Erlangen Nurnberg, Univ Klinikum Erlangen, Klin Mikrobiol Immunol & Hyg, Mikrobiol Inst, Erlangen, Germany.
   [Bosserhoff, Anja] CCC Erlangen EMN, Comprehens Canc Ctr Erlangen, Erlangen, Germany.
RP Hellerbrand, C (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany.
EM claus.hellerbrand@fau.de
RI Mahli, Abdo/AAD-4744-2019
OI Mahli, Abdo/0000-0002-8333-7551; Bosserhoff, Anja/0000-0001-8147-394X;
   Lee, Serene/0000-0001-5231-0607
FU German Research Association (DFG)German Research Foundation (DFG) [FOR
   2127, Bo1573, He2458, KFO262]; Interdisciplinary Center for Clinical
   Research (IZKF) Erlangen [J55, D24]
FX This work was supported by grants from the German Research Association
   (DFG) to AB and CH (FOR 2127; Bo1573 and He2458) and CH (KFO262; He2458)
   and by the Interdisciplinary Center for Clinical Research (IZKF)
   Erlangen to PD (J55) and AB (D24).
CR Braunersreuther V, 2012, WORLD J GASTROENTERO, V18, P727, DOI 10.3748/wjg.v18.i8.727
   Chun YS, 2009, LANCET ONCOL, V10, P278, DOI 10.1016/S1470-2045(09)70064-6
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Ding WX, 2010, GASTROENTEROLOGY, V139, P1740, DOI 10.1053/j.gastro.2010.07.041
   Dong HQ, 2011, TRENDS ENDOCRIN MET, V22, P234, DOI 10.1016/j.tem.2011.02.003
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Ito S, 2007, ALCOHOL CLIN EXP RES, V31, p83S, DOI 10.1111/j.1530-0277.2006.00292.x
   Khan AZ, 2009, J HEPATO-BILIARY-PAN, V16, P137, DOI 10.1007/s00534-008-0016-z
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Lee SML, 2013, JOVE-J VIS EXP, DOI 10.3791/50615
   Lee SML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107567
   Li BH, 2017, TRANSL RES, V180, P103, DOI 10.1016/j.trsl.2016.08.006
   Mazard T, 2013, MOL CANCER THER, V12, P2121, DOI 10.1158/1535-7163.MCT-12-0966
   Messerer CL, 2004, CLIN CANCER RES, V10, P6638, DOI 10.1158/1078-0432.CCR-04-0221
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Morris-Stiff G, 2008, EJSO-EUR J SURG ONC, V34, P609, DOI 10.1016/j.ejso.2007.07.007
   Pessayre D, 2001, SEMIN LIVER DIS, V21, P57, DOI 10.1055/s-2001-12929
   Robinson SM, 2012, ANN SURG ONCOL, V19, P4287, DOI 10.1245/s10434-012-2438-8
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Tang TC, 2010, NEOPLASIA, V12, P928, DOI 10.1593/neo.10804
   Thasler Wolfgang E., 2003, Cell and Tissue Banking, V4, P49, DOI 10.1023/A:1026392429112
   Van Hootegem A, 2011, CASE REPORTS HEPATOL, V2011
   VARANASI U, 1994, P NATL ACAD SCI USA, V91, P3107, DOI 10.1073/pnas.91.8.3107
   Wang Z, 2015, NEOPLASMA, V62, P172, DOI 10.4149/neo_2015_022
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Wu DF, 2013, REDOX BIOL, V1, P552, DOI 10.1016/j.redox.2013.10.008
   Zhou SF, 2014, XENOBIOTICA, V44, P562, DOI 10.3109/00498254.2013.868061
   Zorzi D, 2007, BRIT J SURG, V94, P274, DOI 10.1002/bjs.5719
NR 29
TC 24
Z9 24
U1 1
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD APR
PY 2018
VL 67
IS 4
BP 746
EP +
DI 10.1136/gutjnl-2016-312485
PG 11
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA GB2SV
UT WOS:000428906300020
PM 28053052
DA 2022-04-25
ER

PT J
AU Ferraresi, A
   Phadngam, S
   Morani, F
   Galetto, A
   Alabiso, O
   Chiorino, G
   Isidoro, C
AF Ferraresi, Alessandra
   Phadngam, Suratchanee
   Morani, Federica
   Galetto, Alessandra
   Alabiso, Oscar
   Chiorino, Giovanna
   Isidoro, Ciro
TI Resveratrol inhibits IL-6-induced ovarian cancer cell migration through
   epigenetic up-regulation of autophagy
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE Resveratrol; ovarian cancer; autophagy; microRNA; cell migration
ID TUMOR-SUPPRESSOR GENE; EPITHELIAL-MESENCHYMAL TRANSITION; INDUCIBLE
   FACTOR-1-ALPHA EXPRESSION; EPHRIN-A1 MESSENGER-RNA; ARHI DIRAS3;
   IN-VITRO; MICRORNA-21 PROMOTES; COLORECTAL-CANCER; POOR-PROGNOSIS;
   INTERLEUKIN-6
AB Interleukin-6 (IL-6), a pro-inflammatory cytokine released by cancer-associated fibroblasts, has been linked to the invasive and metastatic behavior of ovarian cancer cells. Resveratrol is a naturally occurring polyphenol with the potential to inhibit cancer cell migration. Here we show that Resveratrol and IL-6 affect in an opposite manner the expression of RNA messengers and of microRNAs involved in cell locomotion and extracellular matrix remodeling associated with the invasive properties of ovarian cancer cells. Among the several potential candidates responsible for the anti-invasive effect promoted by Resveratrol, here we focused our attention on ARH-I (DIRAS3), that encodes a Ras homolog GTPase of 26-kDa. This protein is known to inhibit cell motility, and it has been shown to regulate autophagy by interacting with BECLIN 1. IL-6 down-regulated the expression of ARH-I and inhibited the formation of LC3-positive autophagic vacuoles, while promoting cell migration. On opposite, Resveratrol could counteract the IL-6 induction of cell migration in ovarian cancer cells through induction of autophagy in the cells at the migration front, which was paralleled by up-regulation of ARH-I and down-regulation of STAT3 expression. Spautin 1-mediated disruption of BECLIN 1-dependent autophagy abrogated the effects of Resveratrol, while promoting cell migration. The present data indicate that Resveratrol elicits its anti-tumor effect through epigenetic mechanisms and support its inclusion in the chemotherapy regimen for highly aggressive ovarian cancers. (C) 2016 Wiley Periodicals, Inc.
C1 [Ferraresi, Alessandra; Phadngam, Suratchanee; Morani, Federica; Isidoro, Ciro] Univ Piemonte Orientale, Dept Hlth Sci, Lab Mol Pathol & Nanobioimaging, Novara, Italy.
   [Galetto, Alessandra; Alabiso, Oscar] Univ Piemonte Orientale, Dept Translat Med, Unit Oncol, Novara, Italy.
   [Chiorino, Giovanna] Fdn Edo & Elvo Tempia, Canc Genom Lab, Biella, Italy.
RP Isidoro, C (corresponding author), Univ A Avogadro, Dipartimento Sci Salute, Via P Solaroli 17, I-28100 Novara, Italy.
RI Morani, Federica/D-2365-2018; Ferraresi, Alessandra/H-1518-2017;
   Isidoro, Ciro/J-6063-2016; Chiorino, Giovanna/K-5037-2016
OI Morani, Federica/0000-0002-4903-6878; Ferraresi,
   Alessandra/0000-0002-7192-9672; Isidoro, Ciro/0000-0002-5494-3034;
   Chiorino, Giovanna/0000-0002-9502-6400
FU Ministry of Education,Universities and Research (MIUR);ItalyMinistry of
   Education, Universities and Research (MIUR); Comoli,Ferrari C.SpA
FX A.F. and S.P. are PhD students supported by the Ministry of Education,
   Universities and Research (MIUR; Italy).The financial support of Comoli,
   Ferrari &C.SpA is fully acknowledged.The technical assistance for
   artwork by Roberto Serra is fully acknowledged.
CR Ataie-Kachoie P, 2015, AM J CANCER RES, V5, P575
   Aune G, 2011, GYNECOL ONCOL, V121, P402, DOI 10.1016/j.ygyno.2010.12.355
   Badgwell DB, 2012, ONCOGENE, V31, P68, DOI 10.1038/onc.2011.213
   Baez-Vega PM, 2016, ONCOTARGET, V7, P36321, DOI 10.18632/oncotarget.9216
   Bai HM, 2015, ONCOTARGET, V6, P25520, DOI 10.18632/oncotarget.4550
   BEREK JS, 1991, AM J OBSTET GYNECOL, V164, P1038, DOI 10.1016/0002-9378(91)90582-C
   Brown HM, 2014, HUM REPROD UPDATE, V20, P29, DOI 10.1093/humupd/dmt049
   Brun JL, 2012, ONCOL REP, V27, P1049, DOI 10.3892/or.2011.1608
   Castino R, 2011, J AGR FOOD CHEM, V59, P4264, DOI 10.1021/jf104917q
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chan JK, 2014, GYNECOL ONCOL, V132, P739, DOI 10.1016/j.ygyno.2014.01.034
   Chen CD, 2014, J PROTEOME RES, V13, P2818, DOI 10.1021/pr4012377
   Chung WM, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt247
   Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5
   Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794
   Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603
   Echevarria-Vargas IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097094
   Frojdo S, 2007, BIOCHEM J, V406, P511, DOI 10.1042/BJ20070236
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Giles KM, 2016, ONCOTARGET, V7, P31663, DOI 10.18632/oncotarget.9421
   Greco SA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-494
   Gwak H, 2015, MOL CARCINOGEN, V54, P1529, DOI 10.1002/mc.22227
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Jang M, 1999, DRUG EXP CLIN RES, V25, P65
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Katoh Y, 2006, INT J MOL MED, V18, P523
   Khan FH, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1642-x
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kumar J, 2014, BBA-REV CANCER, V1845, P117, DOI 10.1016/j.bbcan.2013.12.003
   Li JW, 2015, ONCOL REP, V33, P2829, DOI 10.3892/or.2015.3891
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Lo CW, 2011, CANCER RES, V71, P424, DOI 10.1158/0008-5472.CAN-10-1496
   Lou YH, 2011, CLIN INVEST MED, V34, pE281, DOI 10.25011/cim.v34i5.15671
   Lou YH, 2010, INT J MOL MED, V26, P819, DOI 10.3892/ijmm_00000530
   Lu Q, 2010, J PATHOL, V222, P119, DOI 10.1002/path.2755
   Lu Z, 2014, AUTOPHAGY, V10, P1071, DOI 10.4161/auto.28577
   Lu Z, 2013, CELL ADHES MIGR, V7, P232, DOI 10.4161/cam.23648
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Melhem A, 2009, CLIN CANCER RES, V15, P3196, DOI 10.1158/1078-0432.CCR-08-2131
   Morani Federica, 2014, Genes Cancer, V5, P226
   Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731
   Nishimoto A, 2005, CANCER RES, V65, P6701, DOI 10.1158/0008-5472.CAN-05-0130
   Obata NH, 1997, ANTICANCER RES, V17, P337
   Peracchio C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-22
   Pink RC, 2015, GYNECOL ONCOL, V137, P143, DOI 10.1016/j.ygyno.2014.12.042
   PLANTE M, 1994, CANCER, V73, P1882, DOI 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R
   Reed AEM, 2013, VIRCHOWS ARCH, V463, P535, DOI 10.1007/s00428-013-1468-3
   Salis O, 2016, TUMOR BIOL, V37, P3017, DOI 10.1007/s13277-015-4119-2
   SCAMBIA G, 1995, BRIT J CANCER, V71, P354, DOI 10.1038/bjc.1995.71
   Schmidt EM, 2012, FEBS J, V279, P1231, DOI 10.1111/j.1742-4658.2012.08515.x
   Schulze D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-144
   Selcuklu SD, 2009, BIOCHEM SOC T, V37, P918, DOI 10.1042/BST0370918
   Sengupta S, 2007, ONCOGENE, V26, P2894, DOI 10.1038/sj.onc.1210093
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Sodek KL, 2009, INT J CANCER, V124, P2060, DOI 10.1002/ijc.24188
   Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5
   Sorokin AV, 2013, ONCOGENE, V32, P3130, DOI 10.1038/onc.2012.327
   Syed V, 2005, ONCOGENE, V24, P8128, DOI 10.1038/sj.onc.1208959
   Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619
   Titone R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/343542
   Trincheri NF, 2008, CARCINOGENESIS, V29, P381, DOI 10.1093/carcin/bgm271
   Trincheri NF, 2007, CARCINOGENESIS, V28, P922, DOI 10.1093/carcin/bgl223
   Van Ginkel PR, 2007, CLIN CANCER RES, V13, P5162, DOI 10.1158/1078-0432.CCR-07-0347
   Venkatadri R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.6
   Wada H, 2014, INT J ONCOL, V45, P1051, DOI 10.3892/ijo.2014.2519
   Wang D, 2000, INT J ONCOL, V17, P1087
   Wang Y, 2012, CYTOKINE, V59, P228, DOI 10.1016/j.cyto.2012.04.020
   Washington MN, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.208
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Wyman SK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005311
   Xie Z, 2013, ONCOL LETT, V6, P795, DOI 10.3892/ol.2013.1432
   Xiong W, 2016, ONCOL LETT, V11, P484, DOI 10.3892/ol.2015.3888
   Yamamoto H, 2013, INT J ONCOL, V42, P549, DOI 10.3892/ijo.2012.1750
   Yu XB, 2016, GENE, V576, P339, DOI 10.1016/j.gene.2015.10.072
   Yu YH, 2006, METHOD ENZYMOL, V407, P455, DOI 10.1016/S0076-6879(05)07037-0
   Zhang W, 2013, ONCOL REP, V29, P637, DOI 10.3892/or.2012.2148
   Zhang Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep06248
NR 77
TC 59
Z9 63
U1 5
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD MAR
PY 2017
VL 56
IS 3
BP 1164
EP 1181
DI 10.1002/mc.22582
PG 18
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA EL4NM
UT WOS:000394597900033
PM 27787915
DA 2022-04-25
ER

PT J
AU Li, L
   Li, G
   Chen, MB
   Cai, RZ
AF Li, Liang
   Li, Gao
   Chen, Minbiao
   Cai, Renzhong
TI Astragaloside IV enhances the sensibility of lung adenocarcinoma cells
   to bevacizumab by inhibiting autophagy
SO DRUG DEVELOPMENT RESEARCH
LA English
DT Article; Early Access
DE apoptosis; astragaloside; autophagy; bevacizumab; proliferation
ID CISPLATIN CHEMOSENSITIVITY; ACTIVATION PROMOTES; COLORECTAL-CANCER;
   INDUCED APOPTOSIS; EXPRESSION; RESISTANCE; GLIOBLASTOMA; BCL-2;
   PROLIFERATION; CASPASE-3
AB Bevacizumab (BV) has an inhibitory effect on tumor growth including lung adenocarcinoma. However, its efficacy is greatly affected by drug resistance. Astragaloside IV (AST-IV) is effective in combination with other drugs is effective to treat cancer. This study aimed to investigate the effect of AST-IV on enhancing the sensibility of lung adenocarcinoma cells to BV. A549 cells were treated by different concentrations of BV and AST-IV. Cell viability, cell cycle, and apoptosis were detected by thiazolyl blue tetrazolium bromide (MTT) and flow cytometry, respectively. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting were performed to detect the expression levels of autophagy- and apoptosis-related proteins, protein kinase B (AKT), and mammalian target of rapamycin (mTOR). The results showed that BV or AST-IV could inhibit the viability and promote the apoptosis of A549 cells in a concentration-dependent manner. Moreover, BV or AST-IV inhibited Bcl-2 expression and increased the expressions of Bax and Cleaved caspase-3, and promoted apoptosis. BV and AST-IV in combination acted synergistically on viability and apoptosis of A549 cells. However, BV alone down-regulated P62 expression, LC3I/LC3II level, the number of cells arrested at S phase and the phosphorylation levels of AKT and mTOR, but upregulated the number of cells arrested at G0/G1 phase and Beclin1 expression, whereas AST-IV alone could reverse the effect of BV on autophagy-related proteins, the phosphorylation levels of AKT and mTOR. This paper demonstrates that AST-IV enhances the effect of BV on inhibiting proliferation and promoting apoptosis of lung adenocarcinoma cells through inhibiting autophagy pathway.
C1 [Li, Liang; Li, Gao; Chen, Minbiao; Cai, Renzhong] Hainan Gen Hosp, Dept Thorac Surg, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China.
RP Cai, RZ (corresponding author), Hainan Gen Hosp, Dept Thorac Surg, 19 Xiuhua Rd, Haikou 570311, Hainan, Peoples R China.
EM cairenzhong_crz@163.com
CR Bade BC, 2020, CLIN CHEST MED, V41, P1, DOI 10.1016/j.ccm.2019.10.001
   Cao ZJ, 2017, CELL PHYSIOL BIOCHEM, V43, P1803, DOI 10.1159/000484066
   Chen J, 2017, BIOMED PHARMACOTHER, V87, P118, DOI 10.1016/j.biopha.2016.12.093
   Chen Y, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109958
   Dolka I, 2016, RES VET SCI, V105, P124, DOI 10.1016/j.rvsc.2016.02.004
   Domagala A, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4126-y
   Du SX, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0468-8
   Gao ML, 2016, ACTA HISTOCHEM, V118, P63, DOI 10.1016/j.acthis.2015.11.002
   He CS, 2016, CELL PHYSIOL BIOCHEM, V40, P1221, DOI 10.1159/000453175
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Huang H, 2018, ONCOL LETT, V15, P1487, DOI 10.3892/ol.2017.7446
   Huo RC, 2016, MOL MED REP, V14, P3013, DOI 10.3892/mmr.2016.5648
   Jiang YF, 2018, BIOCHEM BIOPH RES CO, V506, P266, DOI 10.1016/j.bbrc.2018.10.089
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li W, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0805-4
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Lian X, 2018, BIOCHEM BIOPH RES CO, V496, P70, DOI 10.1016/j.bbrc.2017.12.168
   Liang J, 2015, ONCOTARGET, V6, P31479, DOI 10.18632/oncotarget.5491
   Lin HY, 2019, COLORECTAL DIS, V21, P123, DOI 10.1111/codi.14477
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Ma MJ, 2018, J THORAC DIS, V10, P5384, DOI 10.21037/jtd.2018.08.64
   Mathews ES, 2016, J NEUROSCI, V36, P7628, DOI 10.1523/JNEUROSCI.0726-16.2016
   Meher JG, 2018, ARTIF CELL NANOMED B, V46, pS344, DOI 10.1080/21691401.2018.1492933
   Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317
   Ming J, 2019, MOL CARCINOGEN, V58, P358, DOI 10.1002/mc.22933
   Muller-Greven G, 2017, CLIN CANCER RES, V23, P7059, DOI 10.1158/1078-0432.CCR-17-0249
   Nazim UMD, 2017, ONCOTARGET, V8, P100021, DOI 10.18632/oncotarget.21754
   Palladino G, 2016, ENDOCR-RELAT CANCER, V23, P699, DOI 10.1530/ERC-16-0063
   Ramezani S, 2019, CANCER BIOTHER RADIO, V34, P345, DOI 10.1089/cbr.2018.2651
   Rossi L, 2017, ONCOTARGET, V8, P12389, DOI 10.18632/oncotarget.13310
   Schlafli AM, 2016, ONCOTARGET, V7, P39544, DOI 10.18632/oncotarget.9647
   Shan YL, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1832-6
   Somers J, 2013, INT J BIOCHEM CELL B, V45, P1690, DOI 10.1016/j.biocel.2013.04.020
   Song P, 2017, CANCER MED-US, V6, P1154, DOI 10.1002/cam4.1047
   Tamura R, 2017, BRAIN TUMOR PATHOL, V34, P62, DOI 10.1007/s10014-017-0284-x
   Tian WG, 2018, DRUG DES DEV THER, V12, P3563, DOI 10.2147/DDDT.S163157
   Toyokawa G, 2018, ANN THORAC SURG, V105, P1655, DOI 10.1016/j.athoracsur.2018.01.037
   Wang L, 2020, FOOD SCI NUTR, V8, P6357, DOI 10.1002/fsn3.1751
   Wang Q, 2018, PHYTOMEDICINE, V39, P160, DOI 10.1016/j.phymed.2017.12.029
   Wu HB, 2017, AUTOPHAGY, V13, P1528, DOI 10.1080/15548627.2017.1336277
   Xie T, 2016, ONCOL RES, V24, P447, DOI 10.3727/096504016X14685034103590
   Xu HD, 2019, ADV EXP MED BIOL, V1206, P109, DOI 10.1007/978-981-15-0602-4_5
   Xu W, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01688-9
   Yang RF, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20176073, 10.1590/1414-431x20176073]
   Zhang S, 2017, ANTICANCER RES, V37, P464, DOI 10.21873/anticanres.11338
   Zhao Z, 2018, J CANCER, V9, P3407, DOI 10.7150/jca.24201
   Zheng YF, 2019, J CELL PHYSIOL, V234, P4277, DOI 10.1002/jcp.27196
   Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11
NR 50
TC 0
Z9 0
U1 5
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0272-4391
EI 1098-2299
J9 DRUG DEVELOP RES
JI Drug Dev. Res.
DI 10.1002/ddr.21878
EA SEP 2021
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UO4CI
UT WOS:000694642800001
PM 34499759
DA 2022-04-25
ER

PT J
AU Peng, ZH
   Yuan, L
   XuHong, JC
   Tian, H
   Zhang, Y
   Deng, J
   Qi, XW
AF Peng, Zaihui
   Yuan, Long
   XuHong, Juncheng
   Tian, Hao
   Zhang, Yi
   Deng, Jun
   Qi, Xiaowei
TI Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and
   photothermal ablation
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Review
DE Chirality; Nanomedicine; Biomaterials; Tumor therapy
ID QUANTUM DOTS; GOLD NANOPARTICLES; COLORECTAL-CANCER; BREAST-CANCER;
   SURFACE; PROTEIN; DIAGNOSIS; DESIGN; CYTOTOXICITY; BIOINTERFACE
AB Chirality is a fundamental characteristic of natural molecules and a crucial factor in the biochemical reactions of living cells and organisms. Recently, researchers have successfully introduced chiral molecules to the surfaces of nanomaterials, creating chiral nanomaterials that exhibit an upscaling of chiral behavior from the molecular scale to the nanoscale. These chiral nanomaterials can selectively induce autophagy, apoptosis, and photothermal ablation in tumor cells based on their chirality, making them promising for application in anti-tumor therapy. However, these interesting and important phenomena have hitherto received little attention. Accordingly, we herein present a review of recent research progress in the field of chiral nanomaterials for tumor therapy along with brief looks at the mechanistic details of their actions. Finally, the current challenges and future perspectives of chiral nanomaterials in terms of maximizing their potential in tumor therapy are discussed. Thus, this review provides a helpful introduction to the design of chiral nanomaterials and will hopefully highlight the importance of chirality in tumor therapy.
C1 [Peng, Zaihui; Yuan, Long; XuHong, Juncheng; Tian, Hao; Zhang, Yi; Qi, Xiaowei] Army Med Univ, Southwest Hosp, Dept Breast Surg, Chongqing 400038, Peoples R China.
   [Deng, Jun] Army Med Univ, Southwest Hosp, State Key Lab Trauma Burn & Combined Injury, Inst Burn Res, Chongqing 400038, Peoples R China.
RP Zhang, Y; Qi, XW (corresponding author), Army Med Univ, Southwest Hosp, Dept Breast Surg, Chongqing 400038, Peoples R China.; Deng, J (corresponding author), Army Med Univ, Southwest Hosp, State Key Lab Trauma Burn & Combined Injury, Inst Burn Res, Chongqing 400038, Peoples R China.
EM ZY53810@163.com; djun.123@163.com; qxw9908@foxmail.com
RI ; Qi, Xiaowei/O-1338-2018
OI Deng, Jun/0000-0002-9951-2393; Qi, Xiaowei/0000-0002-5876-4957
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [51703243]; Chongqing Basic Research
   and Frontier Exploration Project [cstc2018jcyjA0137]; Program of
   National Key Clinical Specialist Construction [413F1Z113]; Military
   Medical Staff Innovation Plan of Southwest Hospital [SWH2018BJLC-04];
   Army Medical University [XZ-2019-505-042]
FX This work was supported in National Natural Science Foundation of China
   (NSFC) (No. 51703243), Chongqing Basic Research and Frontier Exploration
   Project (No. cstc2018jcyjA0137), Program of National Key Clinical
   Specialist Construction (No. 413F1Z113), Military Medical Staff
   Innovation Plan of Southwest Hospital (No. SWH2018BJLC-04) and Army
   Medical University (No. XZ-2019-505-042).
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   ALLEN TD, 1976, IN VITRO CELL DEV B, V12, P837
   An FF, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00603-8
   Antaris AL, 2013, ACS NANO, V7, P3644, DOI 10.1021/nn4006472
   Bird GH, 2016, NAT CHEM BIOL, V12, P845, DOI [10.1038/NCHEMBIO.2153, 10.1038/nchembio.2153]
   Chang BS, 2015, SMALL, V11, P1097, DOI 10.1002/smll.201402038
   Chang GQ, 2018, NAT MATER, V17, P978, DOI 10.1038/s41563-018-0169-3
   Chattoraj S, 2014, J PHYS CHEM C, V118, P22339, DOI 10.1021/jp506745p
   Chen HY, 2020, ACTA BIOMATER, V112, P1, DOI 10.1016/j.actbio.2020.05.028
   Chen JH, 2021, ACS OMEGA, V6, P11240, DOI 10.1021/acsomega.1c00101
   Chen JS, 2010, J BIOL CHEM, V285, P25458, DOI 10.1074/jbc.M110.139345
   Chen Y, 2020, J NANOBIOTECHNOL, V18, DOI 10.1186/s12951-020-00660-z
   Coleman RE, 2012, NAT REV CLIN ONCOL, V9, P76, DOI 10.1038/nrclinonc.2011.198
   Deng J, 2017, ACTA BIOMATER, V53, P610, DOI 10.1016/j.actbio.2017.01.082
   Deng J, 2016, NANO RES, V9, P3683, DOI 10.1007/s12274-016-1239-y
   Deng J, 2016, SCI REP-UK, V6, DOI 10.1038/srep31595
   Deng J, 2016, LANGMUIR, V32, P5608, DOI 10.1021/acs.langmuir.6b01447
   Deng J, 2013, SCI CHINA CHEM, V56, P1533, DOI 10.1007/s11426-013-4972-z
   Deng S, 2019, CANCER-AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Ding FA, 2014, INT J NANOMED, V9, P4317, DOI 10.2147/IJN.S68685
   Djunic I, 2011, MED ONCOL, V28, P237, DOI 10.1007/s12032-010-9432-4
   Du XW, 2017, CHEMNANOMAT, V3, P17, DOI 10.1002/cnma.201600258
   Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991
   Folkers H, 2007, LIPOPHILICITY S
   Fukuda R, 2020, CARBON, V161, P718, DOI 10.1016/j.carbon.2020.02.002
   Gammon ST, 2003, BIOCONJUGATE CHEM, V14, P368, DOI 10.1021/bc0256291
   Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x
   Halawani EM, 2020, INT J NANOMED, V15, P1889, DOI 10.2147/IJN.S236182
   Hao CL, 2019, CHEM-EUR J, V25, P12235, DOI 10.1002/chem.201901721
   HII JTY, 1991, CLIN PHARMACOKINET, V21, P1, DOI 10.2165/00003088-199121010-00001
   Hu C, 2017, CHEM MATER, V29, P7658, DOI 10.1021/acs.chemmater.7b01982
   Huang YY, 2020, ANGEW CHEM INT EDIT, V59, P4406, DOI 10.1002/anie.201910615
   Ishigami T, 2015, ACS APPL MATER INTER, V7, P21065, DOI 10.1021/acsami.5b07198
   Jaque D, 2014, NANOSCALE, V6, P9494, DOI 10.1039/c4nr00708e
   Jiang Q, 2017, BIOMATERIALS, V143, P29, DOI 10.1016/j.biomaterials.2017.07.027
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Khojah SM, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5040038
   Kotcherlakota R, 2018, CURR TOP MED CHEM, V18, P2599, DOI 10.2174/1568026619666181224104838
   Lee HE, 2018, NATURE, V556, P360, DOI 10.1038/s41586-018-0034-1
   Li F, 2020, ANGEW CHEM INT EDIT, V59, P11087, DOI 10.1002/anie.202002904
   Li F, 2018, ANGEW CHEM INT EDIT, V57, P2377, DOI 10.1002/anie.201712453
   Li FJ, 2017, AUTOPHAGY, V13, P715, DOI 10.1080/15548627.2017.1280218
   Li YN, 2020, CHINESE CHEM LETT, V31, P3027, DOI 10.1016/j.cclet.2020.05.027
   Li YW, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201906311
   Li YY, 2011, ANGEW CHEM INT EDIT, V50, P5860, DOI 10.1002/anie.201008206
   Lim SY, 2015, CHEM SOC REV, V44, P362, DOI 10.1039/c4cs00269e
   Lin YC, 2017, KAOHSIUNG J MED SCI, V33, P215, DOI 10.1016/j.kjms.2017.01.004
   Liu GF, 2014, ANGEW CHEM INT EDIT, V53, P7789, DOI 10.1002/anie.201403249
   Liu J, 2015, J MATER CHEM B, V3, P6117, DOI 10.1039/c5tb00664c
   Liu J, 2014, CHEM-ASIAN J, V9, P275, DOI 10.1002/asia.201301010
   Liu J, 2013, NANOSCALE, V5, P11464, DOI 10.1039/c3nr02861e
   Mahmoudi M, 2016, NANO TODAY, V11, P817, DOI 10.1016/j.nantod.2016.10.005
   Marano F, 2011, ARCH TOXICOL, V85, P733, DOI 10.1007/s00204-010-0546-4
   Martin HL, 2014, BREAST CANCER-TARGET, V6, P1, DOI 10.2147/BCTT.S37638
   Martin S, 2017, AUTOPHAGY, V13, P1512, DOI 10.1080/15548627.2017.1332550
   Masteri-Farahani M, 2019, COLLOID SURFACE A, V569, P78, DOI 10.1016/j.colsurfa.2019.02.037
   Milton FP, 2016, NANOSCALE HORIZ, V1, P14, DOI 10.1039/c5nh00072f
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moloney MP, 2007, CHEM COMMUN, P3900, DOI 10.1039/b704636g
   Muller Jochen, 2013, Recent Results Cancer Res, V187, P221, DOI 10.1007/978-3-642-10853-2_7
   Nakashima T, 2009, J AM CHEM SOC, V131, P10342, DOI 10.1021/ja902800f
   Peynshaert K, 2014, CHEM REV, V114, P7581, DOI 10.1021/cr400372p
   Prost AC, 1998, INT J ONCOL, V13, P871
   Pu F, 2018, CHEM SOC REV, V47, P1285, DOI 10.1039/c7cs00673j
   Rosenberg RA, 2015, ANGEW CHEM INT EDIT, V54, P7295, DOI 10.1002/anie.201501678
   Ru Y, 2020, NANO TODAY, V34, DOI 10.1016/j.nantod.2020.100953
   Shaniba VS, 2019, BIOL TRACE ELEM RES, V192, P160, DOI 10.1007/s12011-019-1653-6
   Shibu ES, 2013, J PHOTOCH PHOTOBIO C, V15, P53, DOI 10.1016/j.jphotochemrev.2012.09.004
   Song L, 2012, ANAL CHEM, V84, P7330, DOI 10.1021/ac300437v
   SOUMERAI SB, 1987, AM J PUBLIC HEALTH, V77, P1518, DOI 10.2105/AJPH.77.12.1518
   Sun MZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06946-z
   Suzuki N, 2016, ACS NANO, V10, P1744, DOI 10.1021/acsnano.5b06369
   Tripathi I, 2018, ACS APPL MATER INTER, V10, P37886, DOI 10.1021/acsami.8b15618
   Vargesson N, 2015, BIRTH DEFECTS RES C, V105, P140, DOI 10.1002/bdrc.21096
   Vyas SP, 2000, ADV DRUG DELIVER REV, V43, P101, DOI 10.1016/S0169-409X(00)00067-3
   Wang X, 2011, ADV FUNCT MATER, V21, P3276, DOI 10.1002/adfm.201101032
   Wang XY, 2017, ACS NANO, V11, P4606, DOI 10.1021/acsnano.7b00200
   Wang Y, 2020, J MATER CHEM B, V8, P7921, DOI 10.1039/d0tb01223h
   Wei WJ, 2019, SMALL METHODS, V3, DOI 10.1002/smtd.201800365
   Xin Q, 2015, NANO LETT, V15, P6490, DOI 10.1021/acs.nanolett.5b01926
   Yang FF, 2019, J COLLOID INTERF SCI, V537, P422, DOI 10.1016/j.jcis.2018.11.057
   Yang X, 2013, CHEM COMMUN, V49, P2302, DOI 10.1039/c3cc00200d
   Yao J, 2012, LIFE SCI, V91, P186, DOI 10.1016/j.lfs.2012.06.034
   Yao X, 2013, BIOMATERIALS, V34, P9001, DOI 10.1016/j.biomaterials.2013.08.013
   Yeom J, 2020, ADV MATER, V32, DOI 10.1002/adma.201903878
   Yuan L, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0383-9
   Zada S, 2018, ARTIF CELL NANOMED B, V46, pS471, DOI 10.1080/21691401.2018.1499663
   Zeng XD, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800589
   Zhang H, 2018, ACS APPL MATER INTER, V10, P30680, DOI 10.1021/acsami.8b10594
   Zhang MX, 2012, CHEM SOC REV, V41, P1972, DOI 10.1039/c1cs15209b
   Zhao Y, 2016, ADV MATER, V28, P4877, DOI 10.1002/adma.201600369
   Zheng W, 2016, NANOMEDICINE-UK, V11, P1417, DOI 10.2217/nnm-2016-0040
   Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002
   Zhou ZR, 2017, ACTA PHARMACOL SIN, V38, P513, DOI 10.1038/aps.2016.136
NR 94
TC 3
Z9 2
U1 41
U2 74
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD JUL 22
PY 2021
VL 19
IS 1
AR 220
DI 10.1186/s12951-021-00965-7
PG 13
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA TR3DQ
UT WOS:000678849800001
PM 34294083
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Como, C
   Perego, P
AF Como, Cristina
   Perego, Paola
TI KiSS1 in regulation of metastasis and response to antitumor drugs
SO DRUG RESISTANCE UPDATES
LA English
DT Review
DE KiSS1; GPR54; Cancer; Metastasis; Drug response
ID RENAL-CELL CARCINOMA; BREAST-CANCER CELL; SUPPRESSOR GENE;
   TRANSCRIPTIONAL REGULATION; COLORECTAL-CANCER; KISSPEPTIN/GPR54 SYSTEM;
   EXPRESSION; RESISTANCE; GPR54; MELANOMA
AB Metastatic dissemination of tumor cells represents a major obstacle towards cancer cure. Tumor cells with metastatic capacity are often resistant to chemotherapy. Experimental efforts revealed that the metastatic cascade is a complex process that involves multiple positive and negative regulators. In this respect, several metastasis suppressor genes have been described. Here, we review the role of the metastasis suppressor KiSS1 in regulation of metastasis and in response to antitumor agents. Physiologically, KiSS1 plays a key role in the activation of the hypothalamic-pituitary-gonadal axis regulating puberty and reproductive functions. KiSS1derived peptides i.e., kisspeptins, signal through the G-protein coupled receptor GPR54. In cancer, KiSS1 signaling suppresses metastases and maintains dormancy of disseminated malignant cells, by interfering with cell migratory and invasive abilities. Besides, KiSS1 modulates glucose and lipid metabolism, by reprogramming energy production towards oxidative phosphorylation and beta-oxidation. Loss or reduced expression of KiSS1, in part through promoter hypermethylation, is related to the development of metastases in various cancer types, with some conflicting reports. The poorly understood role of KiSS1 in response to chemotherapeutic agents appears to be linked to stimulation of the intrinsic apoptotic pathway and inhibition of cell defense factors (e.g., glutathione S-transferase-pi) as well as autophagy modulation. Deciphering the molecular basis underlying regulation of the metastatic potential is crucial for the establishment of novel treatment strategies.
C1 [Como, Cristina; Perego, Paola] Fdn IRCCS Ist Nazl Tumori, Mol Pharmacol Unit, Dept Appl Res & Technol Dev, Via Amadeo 42,Via Venezian 1, I-20133 Milan, Italy.
RP Perego, P (corresponding author), Fdn IRCCS Ist Nazl Tumori, Mol Pharmacol Unit, Dept Appl Res & Technol Dev, Via Amadeo 42,Via Venezian 1, I-20133 Milan, Italy.
EM paola.perego@istitutotumori.mi.it
RI Perego, Paola/J-7647-2016; Corno, Cristina/J-2937-2018
OI Perego, Paola/0000-0003-2806-7269; Corno, Cristina/0000-0003-3529-0805
FU Fondazione CARIPLO-Regione LombardiaFondazione CariploRegione Lombardia
   [2016-1019]
FX This work was in part supported by a grant by Fondazione CARIPLO-Regione
   Lombardia to PP (grant 2016-1019).
CR Akkaya H, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21881
   Albers-Wolthers CHJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179156
   Altorki N. K., 2018, NAT REV CANC
   Arab K, 2011, CARCINOGENESIS, V32, P1467, DOI 10.1093/carcin/bgr138
   Asami T, 2013, J MED CHEM, V56, P8298, DOI 10.1021/jm401056w
   Asami T, 2012, BIOORG MED CHEM LETT, V22, P6328, DOI 10.1016/j.bmcl.2012.08.087
   Beck BH, 2010, EUR J CANCER, V46, P1283, DOI 10.1016/j.ejca.2010.02.023
   Blake A, 2017, SCI REP-UK, V7, DOI 10.1038/srep46525
   Cairns RA, 2011, COLD SH Q B, V76, P299, DOI 10.1101/sqb.2011.76.012856
   Cao F, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005296
   Castano JP, 2009, PEPTIDES, V30, P10, DOI 10.1016/j.peptides.2008.07.025
   Cebrian V, 2011, AM J PATHOL, V179, P540, DOI 10.1016/j.ajpath.2011.05.009
   Chaffer CL, 2016, CANCER METAST REV, V35, P645, DOI 10.1007/s10555-016-9648-7
   Chan YM, 2013, ADV EXP MED BIOL, V784, P89, DOI 10.1007/978-1-4614-6199-9_5
   Chen Y, 2018, MED SCI MONITOR, V24, P4128, DOI 10.12659/MSM.909138
   Cho SG, 2009, CANCER RES, V69, P7062, DOI 10.1158/0008-5472.CAN-09-0476
   Ciaramella Vincenza, 2018, Oncotarget, V9, P19273, DOI 10.18632/oncotarget.25018
   Clark AM, 2016, EXP BIOL MED, V241, P1639, DOI 10.1177/1535370216658144
   Clarke H, 2015, ENDOCRINOL METAB, V30, P124, DOI 10.3803/EnM.2015.30.2.124
   Colledge WH, 2009, TRENDS ENDOCRIN MET, V20, P115, DOI 10.1016/j.tem.2008.10.005
   Corno C, 2017, BIOCHEM PHARMACOL, V136, P40, DOI 10.1016/j.bcp.2017.04.002
   Cossa G, 2013, CURR PHARM DESIGN, V19, P883, DOI 10.2174/138161213804547187
   Cvetkovic D, 2013, ENDOCRINOLOGY, V154, P1999, DOI 10.1210/en.2012-2164
   d'Anglemont de Tassigny X, 2007, P NATL ACAD SCI USA, V104, P10714, DOI 10.1073/pnas.0704114104
   de Roux N, 2003, P NATL ACAD SCI USA, V100, P10972, DOI 10.1073/pnas.1834399100
   de Tassigny XD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176821
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Gahete MD, 2016, MOL CELL ENDOCRINOL, V438, P100, DOI 10.1016/j.mce.2016.07.039
   Gavrilovic IT, 2005, J NEURO-ONCOL, V75, P5, DOI 10.1007/s11060-004-8093-6
   Ghajar CM, 2015, NAT REV CANCER, V15, P238, DOI 10.1038/nrc3910
   Goertzen CG, 2016, CELL SIGNAL, V28, P165, DOI 10.1016/j.cellsig.2015.12.010
   Grundker C, 2015, BREAST CANCER RES TR, V152, P41, DOI 10.1007/s10549-015-3463-7
   Guzman S, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00437
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harihar S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084958
   Hori A, 2001, BIOCHEM BIOPH RES CO, V286, P958, DOI 10.1006/bbrc.2001.5470
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Ishikawa K, 2008, MITOCHONDRION, V8, P339, DOI 10.1016/j.mito.2008.07.006
   Jayasena CN, 2012, CLIN CHEM, V58, P1061, DOI 10.1373/clinchem.2011.177667
   Ji K, 2013, INT J MOL MED, V32, P747, DOI 10.3892/ijmm.2013.1472
   Jiffar T, 2011, ONCOGENE, V30, P3163, DOI 10.1038/onc.2011.39
   Kamarajugadda S, 2012, MOL CELL BIOL, V32, P1893, DOI 10.1128/MCB.06248-11
   Kaverina N, 2017, AUTOPHAGY, V13, P1905, DOI 10.1080/15548627.2017.1360466
   Kim JN, 2018, ANTICANCER RES, V38, P5791, DOI 10.21873/anticanres.12918
   Kolodziejski PA, 2018, PHYSIOL RES, V67, P45, DOI 10.33549/physiolres.933467
   Korch C, 2018, INT J CANCER, V142, P561, DOI 10.1002/ijc.31067
   Kotani M, 2001, J BIOL CHEM, V276, P34631, DOI 10.1074/jbc.M104847200
   Lam K, 2016, BBA-REV CANCER, V1866, P106, DOI 10.1016/j.bbcan.2016.07.001
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Lee JH, 1997, CANCER RES, V57, P2384
   Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731
   Li XN, 2018, FEBS OPEN BIO, V8, P1352, DOI 10.1002/2211-5463.12476
   Liberti MV, 2016, NAT CHEM BIOL, V12, P577, DOI 10.1038/nchembio.2133
   Liu GH, 2018, CELL PHYSIOL BIOCHEM, V48, P371, DOI 10.1159/000491767
   Liu W, 2014, CANCER RES, V74, P954, DOI 10.1158/0008-5472.CAN-13-1183
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Manley SJ, 2017, J MOL MED, V95, P951, DOI 10.1007/s00109-017-1552-2
   Marot D, 2007, ENDOCR-RELAT CANCER, V14, P691, DOI 10.1677/ERC-07-0012
   Martins I, 2012, AUTOPHAGY, V8, P413, DOI 10.4161/auto.19009
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Middleton JD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113333
   Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W
   Mitchell DC, 2007, ONCOGENE, V26, P1739, DOI 10.1038/sj.onc.1209963
   Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200
   Moya P, 2013, TUMOR BIOL, V34, P471, DOI 10.1007/s13277-012-0572-3
   Mueller JK, 2011, MOL CELL ENDOCRINOL, V342, P8, DOI 10.1016/j.mce.2011.04.025
   Naiditch JA, 2015, J SURG RES, V193, P279, DOI 10.1016/j.jss.2014.07.018
   Nash KT, 2007, JNCI-J NATL CANCER I, V99, P309, DOI 10.1093/jnci/djk053
   Navenot JM, 2005, CANCER RES, V65, P10450, DOI 10.1158/0008-5472.CAN-05-1757
   Niida A, 2006, BIOORG MED CHEM LETT, V16, P134, DOI 10.1016/j.bmcl.2005.09.054
   Ogawa H, 2015, MOL CLIN ONCOL, V3, P563, DOI 10.3892/mco.2015.490
   Ohtaki T, 2001, NATURE, V411, P613, DOI 10.1038/35079135
   Orsini MJ, 2007, J MED CHEM, V50, P462, DOI 10.1021/jm0609824
   Pamarthy S, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0811-3
   Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200
   Pineda R, 2010, PROG BRAIN RES, V181, P55, DOI 10.1016/S0079-6123(08)81005-9
   Popper HH, 2016, CANCER METAST REV, V35, P75, DOI 10.1007/s10555-016-9618-0
   Pruszynska-Oszmaek E, 2017, ENDOCRINE, V56, P54, DOI 10.1007/s12020-017-1248-y
   Roseweir AK, 2013, ADV EXP MED BIOL, V784, P159, DOI 10.1007/978-1-4614-6199-9_8
   Semaan SJ, 2013, INT J DEV NEUROSCI, V31, P452, DOI 10.1016/j.ijdevneu.2013.03.006
   Seminara SB, 2005, ENDOCRINOLOGY, V146, P1686, DOI 10.1210/en.2005-0070
   Seminara SB, 2003, NEW ENGL J MED, V349, P1614, DOI 10.1056/NEJMoa035322
   Shoji S, 2009, EUR UROL, V55, P441, DOI 10.1016/j.eururo.2008.02.048
   Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65
   Smith SC, 2009, NAT REV CANCER, V9, P253, DOI 10.1038/nrc2594
   Sun Y, 2013, ONCOL RES, V21, P261, DOI 10.3727/096504014X13946388748992
   Tan ZQ, 2016, MOL CANCER THER, V15, P774, DOI 10.1158/1535-7163.MCT-15-0621
   Tanaka A, 2018, EUR J PHARMACOL, V822, P138, DOI 10.1016/j.ejphar.2018.01.012
   Teoh ST, 2018, WIRES SYST BIOL MED, V10, DOI 10.1002/wsbm.1406
   Tomikawa J, 2012, P NATL ACAD SCI USA, V109, pE1294, DOI 10.1073/pnas.1114245109
   Topaloglu AK, 2012, NEW ENGL J MED, V366, P629, DOI 10.1056/NEJMoa1111184
   Trevisan CM, 2018, CELL PHYSIOL BIOCHEM, V49, P1259, DOI 10.1159/000493406
   Turajlic S, 2016, SCIENCE, V352, P169, DOI 10.1126/science.aaf2784
   Uno M, 2016, ANTICANCER RES, V36, P583
   Valiente M, 2018, TRENDS CANCER, V4, P176, DOI 10.1016/j.trecan.2018.01.003
   Wahab F, 2016, NAT REV UROL, V13, P21, DOI 10.1038/nrurol.2015.277
   Wang HH, 2012, AM J PATHOL, V180, P1170, DOI 10.1016/j.ajpath.2011.11.020
   Weidle UH, 2016, CANCER GENOM PROTEOM, V13, P1
   West A, 1998, GENOMICS, V54, P145, DOI 10.1006/geno.1998.5566
   Yan CY, 2018, CELL PHYSIOL BIOCHEM, V49, P2047, DOI 10.1159/000493715
   Yang JA, 2016, MOL CELL ENDOCRINOL, V437, P35, DOI 10.1016/j.mce.2016.08.008
   Yen C., 2001, J BIOL CHEM, V276, P1164
   Yun S, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00134
   Zhang H, 2012, UROLOGY, V80, P1298, DOI 10.1016/j.urology.2012.08.013
   Zhang YG, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0105725, 10.1371/journal.pone.0109159, 10.1371/journal.pone.0088491, 10.1371/journal.pone.0093458]
   Zuco V, 2015, BIOCHEM PHARMACOL, V94, P79, DOI 10.1016/j.bcp.2015.01.002
NR 107
TC 12
Z9 13
U1 0
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1368-7646
EI 1532-2084
J9 DRUG RESIST UPDATE
JI Drug Resist. Update
PD JAN
PY 2019
VL 42
BP 12
EP 21
DI 10.1016/j.drup.2019.02.001
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HW1PI
UT WOS:000466454400002
PM 30776659
DA 2022-04-25
ER

PT J
AU Xu, J
   Pan, YX
   Liu, YY
   Na, S
   Zhou, H
   Li, L
   Chen, FY
   Song, H
AF Xu, Jing
   Pan, Yunxia
   Liu, Yanyan
   Na, Sha
   Zhou, Hui
   Li, Lu
   Chen, Fengyuan
   Song, Hang
TI A review of anti-tumour effects of ginsenoside in gastrointestinal
   cancer
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Review
DE ginsenoside; gastrointestinal cancer; autophagy; apoptosis; natural
   product
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL TUMOR-GROWTH;
   GASTRIC-CANCER; INHIBITS PROLIFERATION; 20(S)-GINSENOSIDE RG3;
   ANTICANCER ACTIVITY; DOWN-REGULATION; RED GINSENG; COMPOUND K;
   CELL-DEATH
AB Objectives: Gastrointestinal cancer, one of the major causes of cancer-related deaths in the world, refers to malignant conditions of the gastrointestinal (GI) tract and other organs. Although conventional therapy has been successful to some extent in cancer treatment, drug resistance and cancer recurrence still limit the therapeutic efficacy. There is increasing evidence indicating that ginsenoside, as a kind of high nutritional value and widely used traditional Chinese medicine, could contribute to the promotion of treatment in GI cancer, which deserves further investigation.
   Key findings: Based on previous studies, the possible mechanisms mainly include regulation of autophagy, apoptosis, proliferation, migration and angiogenesis. However, no studies recently have conducted a more in-depth review of the anti-cancer effects of ginsenoside in GI cancer.
   Summary: Therefore, this review will summarise and analyse the latest developments in the anti-tumour effects of ginsenosides in GI cancer, thus may promote further research of the anti-tumour efficacy of ginsenoside.
C1 [Xu, Jing; Pan, Yunxia; Chen, Fengyuan; Song, Hang] Anhui Univ Chinese Med, Sch Integrated Tradit Chinese & Western Med, Hefei, Peoples R China.
   [Liu, Yanyan; Na, Sha; Zhou, Hui; Li, Lu; Song, Hang] Anhui Univ Chinese Med, Sch Integrated Tradit Chinese & Western Med, Dept Biochem & Mol Biol, Hefei, Peoples R China.
   [Liu, Yanyan; Na, Sha; Zhou, Hui; Li, Lu; Chen, Fengyuan; Song, Hang] Anhui Acad Chinese Med, Inst Integrat Med, Hefei, Peoples R China.
   [Liu, Yanyan; Na, Sha; Zhou, Hui; Li, Lu; Chen, Fengyuan; Song, Hang] Key Lab Chinese Med Formula Anhui Prov, Hefei, Peoples R China.
RP Chen, FY; Song, H (corresponding author), Anhui Univ Tradit Chinese Med, 1 Qianjiang Rd, Hefei, Peoples R China.
EM isobellachen@163.com
FU Project of High-Level Talents in Anhui University of Chinese Medicine
   [2019rcZD001, DT19200015]; Innovation Foundation for the Returned
   Overseas Chinese Scholars, Anhui ProvinceScientific Research Foundation
   for the Returned Overseas Chinese Scholars [2020LCX009]
FX This work was supported by the Project of High-Level Talents in Anhui
   University of Chinese Medicine (Project code: 2019rcZD001 and
   DT19200015) and the Innovation Foundation for the Returned Overseas
   Chinese Scholars, Anhui Province (Project code: 2020LCX009).
CR Aziz F, 2016, TOXICOL IN VITRO, V31, P158, DOI 10.1016/j.tiv.2015.09.025
   Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105
   Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234
   Cong ZY, 2020, PHARMACOLOGY, V105, P329, DOI 10.1159/000503821
   Dai GL, 2019, PHYTOMEDICINE, V56, P126, DOI 10.1016/j.phymed.2018.10.025
   Devassy JG, 2015, NUTR REV, V73, P155, DOI 10.1093/nutrit/nuu064
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Fleisher TA, 1997, ANN ALLERG ASTHMA IM, V78, P245, DOI 10.1016/S1081-1206(10)63176-6
   Gao JL, 2013, ONCOL REP, V30, P292, DOI 10.3892/or.2013.2438
   Gao YL, 2019, FOOD CHEM TOXICOL, V131, DOI 10.1016/j.fct.2019.110578
   Go GY, 2020, J GINSENG RES, V44, P435, DOI 10.1016/j.jgr.2019.01.007
   da Rocha IMG, 2019, J CACHEXIA SARCOPENI, V10, P445, DOI 10.1002/jcsm.12391
   Han QQ, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.202000187
   Han S, 2016, J ETHNOPHARMACOL, V194, P83, DOI 10.1016/j.jep.2016.08.039
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   Hiramoto S, 2018, INT J CLIN ONCOL, V23, P1090, DOI 10.1007/s10147-018-1317-0
   Hong C, 2019, THERANOSTICS, V9, P4437, DOI 10.7150/thno.34953
   Hong SZ, 2020, ONCOL REP, V44, P1333, DOI 10.3892/or.2020.7728
   Hong SH, 2020, J GINSENG RES, V44, P664, DOI 10.1016/j.jgr.2019.08.006
   Huang GX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12644-5
   Hwang JA, 2013, J NUTR BIOCHEM, V24, P1096, DOI 10.1016/j.jnutbio.2012.08.008
   Hwang JW, 2015, MOL MED REP, V11, P670, DOI 10.3892/mmr.2014.2704
   Jang HJ, 2014, J AGR FOOD CHEM, V62, P2830, DOI 10.1021/jf5000776
   Kang KA, 2013, INT J ONCOL, V43, P1907, DOI 10.3892/ijo.2013.2129
   Khan MSA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00569
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim MY, 2014, J GINSENG RES, V38, P251, DOI 10.1016/j.jgr.2014.06.003
   Kocaadam B, 2017, CRIT REV FOOD SCI, V57, P2889, DOI 10.1080/10408398.2015.1077195
   Phi LTH, 2019, IUBMB LIFE, V71, P601, DOI 10.1002/iub.1984
   Phi LTH, 2018, CANCER MED-US, V7, P5621, DOI 10.1002/cam4.1800
   Vinh LB, 2017, BIOORG MED CHEM LETT, V27, P5149, DOI 10.1016/j.bmcl.2017.10.058
   Lech G, 2016, WORLD J GASTROENTERO, V22, P1745, DOI 10.3748/wjg.v22.i5.1745
   Lee H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00130
   Lee IK, 2010, INT J MOL SCI, V11, P4916, DOI 10.3390/ijms11124916
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Li BQ, 2019, J CANCER RES THER, V15, P1642, DOI 10.4103/jcrt.JCRT_77_17
   Li CM, 2020, J ETHNOPHARMACOL, V248, DOI 10.1016/j.jep.2019.112323
   Li JL, 2019, EXP MOL PATHOL, V106, P131, DOI 10.1016/j.yexmp.2019.01.003
   Li W, 2019, J GINSENG RES, V43, P562, DOI 10.1016/j.jgr.2018.05.005
   Li WF, 2013, MOLECULES, V18, P3689, DOI 10.3390/molecules18043689
   Li Y, 2020, DIGEST DIS SCI, V65, P1364, DOI 10.1007/s10620-019-05856-4
   Lin Yan-Ping, 2016, Zhongguo Zhong Yao Za Zhi, V41, P4292, DOI 10.4268/cjcmm20162302
   Liu CY, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109543
   Liu GW, 2018, HUM CELL, V31, P189, DOI 10.1007/s13577-017-0189-3
   Liu HH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216759
   Liu JP, 2012, FOOD CHEM TOXICOL, V50, P3388, DOI 10.1016/j.fct.2012.07.004
   Liu TG, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1580427
   Liu W, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/2672648
   Liu YN, 2019, BIOCHEM PHARMACOL, V168, P285, DOI 10.1016/j.bcp.2019.07.008
   Lu S, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-019-2797-9
   Mao Q, 2014, PHYTOMEDICINE, V21, P515, DOI 10.1016/j.phymed.2013.10.013
   Pan LL, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/2417418
   Park EH, 2014, J GINSENG RES, V38, P22, DOI 10.1016/j.jgr.2013.11.007
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Qian Jun, 2016, Asian Pac J Cancer Prev, V17, P1817
   Qiu RN, 2019, BIOMED MICRODEVICES, V21, DOI 10.1007/s10544-019-0374-0
   Ren ZG, 2020, SMALL, V16, DOI 10.1002/smll.201905233
   Sabouri-Rad S, 2017, CURR PHARM DESIGN, V23, P1649, DOI 10.2174/1381612822666161021152322
   Shen H, 2018, J ETHNOPHARMACOL, V216, P47, DOI 10.1016/j.jep.2018.01.021
   Shi ZY, 2019, MOLECULES, V24, DOI 10.3390/molecules24132443
   Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273
   Song JM, 2015, J TRADIT CHIN MED, V35, P440, DOI 10.1016/S0254-6272(15)30122-9
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Sun MY, 2017, INT J MOL MED, V39, P507, DOI 10.3892/ijmm.2017.2857
   Sun YY, 2016, SCI CHINA LIFE SCI, V59, P292, DOI 10.1007/s11427-016-5007-8
   Tang YC, 2018, INT J ONCOL, V52, P127, DOI 10.3892/ijo.2017.4183
   Taniguchi H, 2016, CANCER SCI, V107, P1556, DOI 10.1111/cas.13069
   Wang L J, 2020, Zhonghua Yi Xue Za Zhi, V100, P2462, DOI 10.3760/cma.j.cn112137-202000123-00151
   Wang XD, 2020, EUR J PHARMACOL, V881, DOI 10.1016/j.ejphar.2020.173211
   Wang XD, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.01.050
   Wang XD, 2017, EUR J PHARMACOL, V798, P49, DOI 10.1016/j.ejphar.2016.12.027
   Wu C, 2020, ONCOTARGETS THER, V13, P10677, DOI 10.2147/OTT.S275327
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Yang WZ, 2014, PHYTOCHEMISTRY, V106, P7, DOI 10.1016/j.phytochem.2014.07.012
   Yang XL, 2017, BIOMED PHARMACOTHER, V96, P1240, DOI 10.1016/j.biopha.2017.11.092
   Yin SY, 2013, BIOL PHARM BULL, V36, P1002, DOI 10.1248/bpb.b13-00123
   Yue QX, 2008, CANCER SCI, V99, P1461, DOI 10.1111/j.1349-7006.2008.00824.x
   Zeng X, 2010, J CLIN PHARMACOL, V50, P285, DOI 10.1177/0091270009344334
   Zhang F, 2015, DRUG DES DEV THER, V9, P3969, DOI 10.2147/DDDT.S84527
   Zhao Xiang-Yu, 2020, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V36, P51, DOI 10.12047/j.cjap.5891.2020.011
   Zheng K, 2016, AUTOPHAGY, V12, P1593, DOI 10.1080/15548627.2016.1192751
   Zheng MM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8174345
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
   Zhou P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8030204
   Zhu H, 2021, J ETHNOPHARMACOL, V265, DOI 10.1016/j.jep.2020.113271
   Zhu YY, 2020, PHARMACOL RES, V155, DOI 10.1016/j.phrs.2020.104746
NR 87
TC 0
Z9 0
U1 16
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD OCT
PY 2021
VL 73
IS 10
BP 1292
EP 1301
DI 10.1093/jpp/rgab048
EA APR 2021
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UR2JX
UT WOS:000696581500002
PM 33836068
DA 2022-04-25
ER

PT J
AU Liu, ZQ
   Li, Q
   Zhao, X
   Cui, B
   Zhang, LB
   Wang, Q
AF Liu, Zhiqiang
   Li, Qiang
   Zhao, Xin
   Cui, Bin
   Zhang, Libo
   Wang, Qiang
TI MicroRNA-935 Inhibits Proliferation and Invasion of Osteosarcoma Cells
   by Directly Targeting High Mobility Group Box 1
SO ONCOLOGY RESEARCH
LA English
DT Article
DE MicroRNA-935; Osteosarcoma (OS); Proliferation; Invasion; High-mobility
   group box 1 (HMGB1)
ID TUMOR-SUPPRESSOR; HMGB1-MEDIATED AUTOPHAGY; COLORECTAL-CANCER; HMGB1
   EXPRESSION; CERVICAL-CANCER; POOR-PROGNOSIS; GASTRIC-CANCER; PROMOTES;
   MIGRATION; PROTEIN
AB Numerous studies have suggested that microRNAs (miRNAs) are dysregulated in osteosarcoma (OS), implicating miRNAs in OS initiation and progression. Therefore, knowledge of aberrantly expressed miRNAs in OS may provide novel mechanistic insights into the tumorigenesis and tumor development of OS and facilitate therapeutic methods for patients with this aggressive bone neoplasm. In this study, data obtained from reverse transcription quantitative polymerase chain reaction (RT-qPCR) revealed that miR-935 was significantly decreased in OS tissues and cell lines. Restoration expression of miR-935 obviously restricted proliferation and invasion of OS cells. In addition, high-mobility group box 1 (HMGB1) was predicted to be a putative target of miR-935. Subsequent dual-luciferase reporter assay, RT-qPCR, and Western blot analysis confirmed that miR-935 could directly target the 3'-untranslated region of HMGB1 and negatively regulated HMGB1 expression in OS cells. Furthermore, a significant negative association was found between miR-935 and HMGB1 mRNA expression in OS tissues. Rescue experiments showed that recovery of HMGB1 expression partially rescued miR-935-induced suppression of cell proliferation and invasion in OS. These results provide the first evidence for the suppressive roles of miR-935 in OS by directly targeting HMGB1, suggesting that miR-935 may be a potential candidate for the treatment of patients with this disease.
C1 [Liu, Zhiqiang; Li, Qiang; Cui, Bin; Zhang, Libo; Wang, Qiang] Daqing Long Nan Hosp, Dept Orthoped, Daqing, Heilongjiang, Peoples R China.
   [Zhao, Xin] Daqing Oilfield Gen Hosp, Dept Heart Noninvas Examinat, Daqing, Heilongjiang, Peoples R China.
RP Li, Q (corresponding author), Da Qing Long Nan Hosp, Dept Orthopaed, 35 Aiguo Rd, Daqing 163001, Heilongjiang, Peoples R China.
EM liqiang_orth@126.com
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bentwich I, 2005, NAT GENET, V37, P766, DOI 10.1038/ng1590
   Bianchi ME, 2005, CURR OPIN GENET DEV, V15, P496, DOI 10.1016/j.gde.2005.08.007
   Chen XX, 2017, AM J CANCER RES, V7, P2051
   Fagioli F, 2002, J CLIN ONCOL, V20, P2150, DOI 10.1200/JCO.2002.08.081
   Fei D, 2016, AM J CANCER RES, V6, P2859
   Gao D, 2017, J CELL BIOCHEM, V118, P3341, DOI 10.1002/jcb.25987
   Gelderblom H, 2011, EUR J CANCER, V47, P895, DOI 10.1016/j.ejca.2010.11.036
   Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16
   Guo SB, 2014, TUMOR BIOL, V35, P7025, DOI 10.1007/s13277-014-1965-2
   Hattinger CM, 2016, ONCOTARGET, V7, P61970, DOI 10.18632/oncotarget.11486
   He JL, 2016, ONCOL LETT, V11, P293, DOI 10.3892/ol.2015.3907
   Huang J, 2012, AUTOPHAGY, V8, P275, DOI 10.4161/auto.8.2.18940
   Jiang DQ, 2017, ONCOTARGET, V8, P4001, DOI 10.18632/oncotarget.13136
   Jiang R, 2017, AM J CANCER RES, V7, P88
   Kang R, 2017, CELL RES, V27, P916, DOI 10.1038/cr.2017.51
   Le F, 2017, EUR REV MED PHARMACO, V21, P5638, DOI 10.26355/eurrev_201712_14007
   Li XY, 2016, AM J CANCER RES, V6, P2869
   Lin Y, 2017, ONCOTARGET, V8
   Liu J, 2016, EXP THER MED, V12, P4135, DOI 10.3892/etm.2016.3880
   Liu K, 2017, CELL CYCLE, V16, P578, DOI 10.1080/15384101.2017.1288324
   Liu XR, 2017, ONCOL RES, V25, P427, DOI 10.3727/096504016X14747300207374
   Liu YJ, 2018, ONCOL REP, V39, P491, DOI 10.3892/or.2017.6142
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Meng QB, 2014, TUMOR BIOL, V35, P12265, DOI 10.1007/s13277-014-2535-3
   Ottaviani G, 2009, CANCER TREAT RES, V152, P15, DOI [10.1007/978-1-4419-0284-9_2, 10.1007/978-1-4419-0284-9_23]
   Ottaviani G, 2009, CANCER TREAT RES, V152, P3, DOI 10.1007/978-1-4419-0284-9_1
   Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6
   Ren XF, 2016, BRIT J BIOMED SCI, V73, P158, DOI 10.1080/09674845.2016.1220710
   SALGADO J, 1993, BIOCHIM BIOPHYS ACTA, V1145, P284, DOI 10.1016/0005-2736(93)90301-F
   Shrivastava S, 2016, MOL CANCER THER, V15, P471, DOI 10.1158/1535-7163.MCT-15-0581
   Ueda M, 2014, ANTICANCER RES, V34, P5357
   Ulloa L, 2006, CYTOKINE GROWTH F R, V17, P189, DOI 10.1016/j.cytogfr.2006.01.003
   Wang CY, 2017, ONCOL RES, V25, P559, DOI 10.3727/096504016X14759554689565
   Wang L, 2015, ONCOL REP, V34, P2969, DOI 10.3892/or.2015.4278
   Xu YR, 2015, TUMOR BIOL, V36, P9039, DOI 10.1007/s13277-015-3624-7
   Yan C, 2016, BIOCHEM BIOPH RES CO, V470, P68, DOI 10.1016/j.bbrc.2015.12.116
   Yang HY, 2017, ONCOL RES, V25, P1231, DOI 10.3727/096504017X14850134190255
   Yang M, 2016, BIOMED PHARMACOTHER, V79, P153, DOI 10.1016/j.biopha.2016.01.011
   Zhang J, 2014, INT J IMMUNOPATH PH, V27, P543, DOI 10.1177/039463201402700410
NR 40
TC 9
Z9 10
U1 0
U2 3
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2018
VL 26
IS 9
BP 1439
EP 1446
DI 10.3727/096504018X15189093975640
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GX3KP
UT WOS:000447623200015
PM 29471892
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Sainz, J
   Garcia-Verdejo, FJ
   Martinez-Bueno, M
   Kumar, A
   Sanchez-Maldonado, JM
   Diez-Villanueva, A
   Vodickova, L
   Vymetalkova, V
   Sanchez, VM
   Da Silva, MI
   Sampaio-Marques, B
   Brezina, S
   Butterbach, K
   ter Horst, R
   Hoffmeister, M
   Ludovico, P
   Jurado, M
   Li, Y
   Sanchez-Rovira, P
   Netea, MG
   Gsur, A
   Vodicka, P
   Moreno, V
   Hemminki, K
   Brenner, H
   Chang-Claude, J
   Forsti, A
AF Sainz, Juan
   Garcia-Verdejo, Francisco Jose
   Martinez-Bueno, Manuel
   Kumar, Abhishek
   Sanchez-Maldonado, Jose Manuel
   Diez-Villanueva, Anna
   Vodickova, Ludmila
   Vymetalkova, Veronika
   Martin Sanchez, Vicente
   Da Silva Filho, Miguel Inacio
   Sampaio-Marques, Belem
   Brezina, Stefanie
   Butterbach, Katja
   ter Horst, Rob
   Hoffmeister, Michael
   Ludovico, Paula
   Jurado, Manuel
   Li, Yang
   Sanchez-Rovira, Pedro
   Netea, Mihai G.
   Gsur, Andrea
   Vodicka, Pavel
   Moreno, Victor
   Hemminki, Kari
   Brenner, Hermann
   Chang-Claude, Jenny
   Foersti, Asta
TI Polymorphisms within Autophagy-Related Genes Influence the Risk of
   Developing Colorectal Cancer: A Meta-Analysis of Four Large Cohorts
SO CANCERS
LA English
DT Article
DE colorectal cancer; autophagy; genetic variants; susceptibility
AB Simple Summary
   We investigated the influence of autophagy-related variants in modulating colorectal cancer (CRC) risk through a meta-analysis of genome-wide association study (GWAS) data from four large European cohorts. We found that genetic variants within the DAPK2 and ATG5 loci were associated with CRC risk. This study also shed some light onto the functional mechanisms behind the observed associations and demonstrated the impact of DAPK2(rs11631973) and ATG5(rs546456) polymorphisms on the modulation of host immune responses, blood derived-cell counts and serum inflammatory protein levels, which might be involved in promoting cancer development. No effect of the DAPK2 and ATG5 polymorphisms on the autophagy flux was observed.
   The role of genetic variation in autophagy-related genes in modulating autophagy and cancer is poorly understood. Here, we comprehensively investigated the association of autophagy-related variants with colorectal cancer (CRC) risk and provide new insights about the molecular mechanisms underlying the associations. After meta-analysis of the genome-wide association study (GWAS) data from four independent European cohorts (8006 CRC cases and 7070 controls), two loci, DAPK2 (p = 2.19 x 10(-5)) and ATG5 (p = 6.28 x 10(-4)) were associated with the risk of CRC. Mechanistically, the DAPK2(rs11631973G) allele was associated with IL1 beta levels after the stimulation of peripheral blood mononuclear cells (PBMCs) with Staphylococcus aureus (p = 0.002), CD24 + CD38 + CD27 + IgM + B cell levels in blood (p = 0.0038) and serum levels of en-RAGE (p = 0.0068). ATG5(rs546456T) allele was associated with TNF alpha and IL1 beta levels after the stimulation of PBMCs with LPS (p = 0.0088 and p = 0.0076, respectively), CD14+CD16- cell levels in blood (p = 0.0068) and serum levels of CCL19 and cortisol (p = 0.0052 and p = 0.0074, respectively). Interestingly, no association with autophagy flux was observed. These results suggested an effect of the DAPK2 and ATG5 loci in the pathogenesis of CRC, likely through the modulation of host immune responses.
C1 [Sainz, Juan; Sanchez-Maldonado, Jose Manuel; Jurado, Manuel] Univ Granada, Andalusian Reg Govt, Ctr Genom & Oncol Res Pfizer, Genom Oncol Area,GENYO, Granada 18016, Spain.
   [Sainz, Juan; Sanchez-Maldonado, Jose Manuel; Jurado, Manuel] Virgen Nieves Univ Hosp, Hematol Dept, Granada 18012, Spain.
   [Sainz, Juan; Sanchez-Maldonado, Jose Manuel; Jurado, Manuel] Inst Invest Biosanataria IBs Granada, Granada 18012, Spain.
   [Sainz, Juan] Univ Granada, Dept Med, Granada 18016, Spain.
   [Garcia-Verdejo, Francisco Jose; Sanchez-Rovira, Pedro] Complejo Hosp Jaen, Dept Med Oncol, Jaen 23007, Spain.
   [Martinez-Bueno, Manuel] Univ Granada, Andalusian Reg Govt, Ctr Genom & Oncol Res Pfizer, Area Genom Med,GENYO, Granada 18016, Spain.
   [Kumar, Abhishek; Da Silva Filho, Miguel Inacio; Hemminki, Kari; Foersti, Asta] German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany.
   [Kumar, Abhishek] Int Technol Pk, Inst Bioinformat, Bangalore 560066, Karnataka, India.
   [Kumar, Abhishek] Manipal Acad Higher Educ MAHE, Manipal 576104, Karnataka, India.
   [Diez-Villanueva, Anna; Moreno, Victor] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Catalan Inst Oncol, Bellvitge Biomed Res Inst IDIBELL, Barcelona 08908, Spain.
   [Diez-Villanueva, Anna; Moreno, Victor] Univ Barcelona, Barcelona 08908, Spain.
   [Vodickova, Ludmila; Vymetalkova, Veronika; Vodicka, Pavel] Acad Sci Czech Republ, Inst Expt Med, Dept Mol Biol Canc, Prague 14200, Czech Republic.
   [Vodickova, Ludmila; Vymetalkova, Veronika; Vodicka, Pavel] Charles Univ Prague, Inst Biol & Med Genet, Med Fac 1, Prague 12800, Czech Republic.
   [Vodickova, Ludmila; Vymetalkova, Veronika; Vodicka, Pavel] Charles Univ Prague, Fac Med Pilsen, Biomed Ctr, Plzen 32300, Czech Republic.
   [Martin Sanchez, Vicente] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid 28029, Spain.
   [Martin Sanchez, Vicente] Univers Leon, Inst Biomed IBIOMED, Leon 24071, Spain.
   [Sampaio-Marques, Belem; Ludovico, Paula] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, P-4710057 Braga, Portugal.
   [Sampaio-Marques, Belem; Ludovico, Paula] ICVS 3BsPT Govt Associate Lab, Braga, Guimaraes, Portugal.
   [Brezina, Stefanie; Gsur, Andrea] Med Univ Vienna, Inst Canc Res, Dept Med 1, Borschkegasse 8a, A-1090 Vienna, Austria.
   [Butterbach, Katja; Brenner, Hermann] Heidelberg Univ, Network Aging Res, D-69115 Heidelberg, Germany.
   [ter Horst, Rob; Li, Yang; Netea, Mihai G.] Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Internal Med, NL-6525 GA Nijmegen, Netherlands.
   [ter Horst, Rob; Li, Yang; Netea, Mihai G.] Radboud Univ Nijmegen, Radboud Ctr Infect Dis, Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Hoffmeister, Michael] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Li, Yang] Helmholtz Ctr Infect Res HZI, Ctr Individualised Infect Med CiiM, D-30625 Hannover, Germany.
   [Li, Yang] Helmholtz Ctr Infect Res HZI, TWINCORE, D-30625 Hannover, Germany.
   [Li, Yang] Hannover Med Sch MHH, D-30625 Hannover, Germany.
   [Netea, Mihai G.] Univ Bonn, Life & Med Sci Inst LIMES, Dept Immunol & Metab, D-53115 Bonn, Germany.
   [Hemminki, Kari] German Canc Res Ctr, Div Canc Epidemiol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
   [Hemminki, Kari] Charles Univ Prague, Fac Med, Plzen 30605, Czech Republic.
   [Hemminki, Kari] Charles Univ Prague, Biomed Ctr Pilsen, Plzen 30605, Czech Republic.
   [Brenner, Hermann] Natl Ctr Tumour Dis NCT, German Canc Res Ctr DKFZ, Div Prevent Oncol, D-69120 Heidelberg, Germany.
   [Brenner, Hermann] German Canc Res Ctr, German Canc Consortium DKTK, D-69120 Heidelberg, Germany.
   [Chang-Claude, Jenny] German Canc Res Ctr, Div Canc Epidemiol, D-69120 Heidelberg, Germany.
   [Chang-Claude, Jenny] Univ Med Ctr Hamburg Eppendorf, Univ Canc Ctr, Genet Tumour Epidemiol Grp, D-20246 Hamburg, Germany.
   [Foersti, Asta] German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Div Pediat Neurooncol, D-69120 Heidelberg, Germany.
   [Foersti, Asta] Hopp Childrens Canc Ctr KiTZ, D-69120 Heidelberg, Germany.
RP Sainz, J (corresponding author), Univ Granada, Andalusian Reg Govt, Ctr Genom & Oncol Res Pfizer, Genom Oncol Area,GENYO, Granada 18016, Spain.; Sainz, J (corresponding author), Virgen Nieves Univ Hosp, Hematol Dept, Granada 18012, Spain.; Sainz, J (corresponding author), Inst Invest Biosanataria IBs Granada, Granada 18012, Spain.; Sainz, J (corresponding author), Univ Granada, Dept Med, Granada 18016, Spain.; Forsti, A (corresponding author), German Canc Res Ctr, Div Mol Genet Epidemiol, D-69120 Heidelberg, Germany.; Forsti, A (corresponding author), German Canc Consortium DKTK, German Canc Res Ctr DKFZ, Div Pediat Neurooncol, D-69120 Heidelberg, Germany.; Forsti, A (corresponding author), Hopp Childrens Canc Ctr KiTZ, D-69120 Heidelberg, Germany.
EM juan.sainz@genyo.es; francisco.garcia.verdejo.sspa@juntadeandalucia.es;
   manuel.martinez@genyo.es; abhishek@ibioinformatics.org;
   josemanuel.sanchez@genyo.es; adiez@iconcologia.net;
   ludmila.vodickova@iem.cas.cz; veronika.vymetalkova@iem.cas.cz;
   vicente.martin@unileon.es; m.daSilvaFilho@dkfz.de;
   mbmarques@med.uminho.pt; stefanie.brezina@meduniwien.ac.at;
   k.butterbach@dkfz.de; RterHorst@cemm.oeaw.ac.at; m.hoffmeister@dkfz.de;
   pludovico@med.uminho.pt; manuel.jurado.sspa@juntadeandalucia.es;
   Yang.Li@helmholtz-hzi.de; oncopsr@yahoo.es; mihai.netea@radboudumc.nl;
   andrea.gsur@meduniwien.ac.at; pavel.vodicka@iem.cas.cz;
   v.moreno@iconcologia.net; k.hemminki@dkfz-heidelberg.de;
   h.brenner@dkfz-heidelberg.de; j.chang-claude@dkfz.de;
   a.foersti@kitz-heidelberg.de
RI Hoffmeister, Michael/T-7187-2019; Martin, Vicente/A-1597-2008; Brenner,
   Hermann/B-4627-2017; Hoffmeister, Michael/AAB-2321-2022; Martin,
   Vicente/ABF-2276-2021; Brenner, Hermann/ABE-6383-2020; Vymetalkova,
   Veronika/H-3167-2014; Ludovico, Paula/B-4338-2011; Kumar,
   Abhishek/A-8727-2012; Sampaio-Marques, Belem/M-4758-2013
OI Hoffmeister, Michael/0000-0002-8307-3197; Martin,
   Vicente/0000-0003-0552-2804; Brenner, Hermann/0000-0002-6129-1572;
   Hoffmeister, Michael/0000-0002-8307-3197; Martin,
   Vicente/0000-0003-0552-2804; Brenner, Hermann/0000-0002-6129-1572;
   Martinez Bueno, Manuel/0000-0002-4333-4487; Sanchez Maldonado, Jose
   Manuel/0000-0002-4651-3675; Forsti, Asta/0000-0002-9857-4728; Li,
   Yang/0000-0003-4022-7341; Vymetalkova, Veronika/0000-0001-6870-6788;
   Gsur, Andrea/0000-0002-9795-1528; Ludovico, Paula/0000-0003-4130-7167;
   ter Horst, Rob/0000-0003-0576-5873; Kumar, Abhishek/0000-0003-4172-4059;
   Sampaio-Marques, Belem/0000-0001-6580-0971
FU Instituto de Salud Carlos III (Madrid, Spain)Instituto de Salud Carlos
   III [PI12/02688, PI17/02256]; Austrian Research Promotion Agency (FFG)
   BRIDGE grant [829675]; Herzfelder'sche Familienstiftung; GACRGrant
   Agency of the Czech Republic [18-09709S, 19-10543S, 20-03997S]; COST
   (European Cooperation in Science and Technology)European Cooperation in
   Science and Technology (COST) [CA17118]; Ramalingaswami Re-Retry Faculty
   Fellowship from the Department of Biotechnology (DBT), Government of
   India (GOI) [BT/RLF/Re-entry/38/2017]; Agency for Management of
   University and Research Grants (AGAUR) of the Catalan Government
   [2017SGR723]; Instituto de Salud Carlos IIIInstituto de Salud Carlos
   IIIEuropean Commission; FEDER funds-a way to build Europe [PI14-00613,
   PI17-00092]; Spanish Association Against Cancer (AECC) Scientific
   Foundation [GCTRA18022MORE]; European Union Horizon 2020 [856620]; 
   [ProgresQ28/1.LF];  [UNCE/MED/006]
FX This work was partially supported by grants from the Instituto de Salud
   Carlos III (Madrid, Spain; PI12/02688 and PI17/02256). CORSA was funded
   by the Austrian Research Promotion Agency (FFG) BRIDGE grant (no.
   829675, to Andrea Gsur), the "Herzfelder'sche Familienstiftung" (grant
   to Andrea Gsur). Czech Republic CCS was funded by GACR grants
   (18-09709S, 19-10543S and 20-03997S), ProgresQ28/1.LF and UNCE/MED/006
   grants. This article is based upon work from COST Action CA17118,
   supported by COST (European Cooperation in Science and Technology). A.K.
   is a recipient of a Ramalingaswami Re-Retry Faculty Fellowship (Grant;
   BT/RLF/Re-entry/38/2017) from the Department of Biotechnology (DBT),
   Government of India (GOI). V.M. received funding from the Agency for
   Management of University and Research Grants (AGAUR) of the Catalan
   Government grant 2017SGR723, the Instituto de Salud Carlos III,
   co-funded by FEDER funds-a way to build Europe-grants PI14-00613,
   PI17-00092 and the Spanish Association Against Cancer (AECC) Scientific
   Foundation grant GCTRA18022MORE. K.H. was supported by European Union
   Horizon 2020 grant No. 856620. We thank the CERCA Programme, Generalitat
   de Catalunya for institutional support.
CR Aguirre-Gamboa R, 2016, CELL REP, V17, P2474, DOI 10.1016/j.celrep.2016.10.053
   Ber Y, 2015, CELL DEATH DIFFER, V22, P465, DOI 10.1038/cdd.2014.177
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Butt J, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007861
   Coppola D, 2008, CANCER-AM CANCER SOC, V113, P2665, DOI 10.1002/cncr.23892
   Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Fernandez-Rozadilla C, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-55
   Furuta GT, 2005, AM J PHYSIOL-GASTR L, V289, pG890, DOI 10.1152/ajpgi.00015.2005
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Geering B, 2016, MOL CELL BIOL, V36, P132, DOI 10.1128/MCB.00515-15
   Geering B, 2014, J LEUKOCYTE BIOL, V95, P293, DOI 10.1189/jlb.0813462
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo F, 2020, CLIN GASTROENTEROL H, V18, P2742, DOI 10.1016/j.cgh.2020.04.077
   Hofer P, 2017, ONCOTARGET, V8, P98623, DOI 10.18632/oncotarget.21697
   Humbert M, 2014, J LEUKOCYTE BIOL, V95, P83, DOI 10.1189/jlb.1112608
   Huyghe JR, 2019, NAT GENET, V51, P76, DOI 10.1038/s41588-018-0286-6
   Iula L, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00269
   Lauzier A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47659-7
   Law PJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09775-w
   Li Y, 2016, CELL, V167, P1099, DOI 10.1016/j.cell.2016.10.017
   Ma YT, 2013, IMMUNITY, V39, P211, DOI 10.1016/j.immuni.2013.07.017
   Sanchez-Maldonado JM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61331-5
   Matsuzawa-Ishimoto Y, 2018, ANNU REV IMMUNOL, V36, P73, DOI 10.1146/annurev-immunol-042617-053253
   McLoed AG, 2016, CELL REP, V16, P120, DOI 10.1016/j.celrep.2016.05.085
   Moreno-Smith M, 2010, FUTURE ONCOL, V6, P1863, DOI [10.2217/fon.10.142, 10.2217/FON.10.142]
   Ngabire D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18092016
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Orru V, 2013, CELL, V155, P242, DOI 10.1016/j.cell.2013.08.041
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020
   Pliyev BK, 2012, APOPTOSIS, V17, P1050, DOI 10.1007/s10495-012-0738-x
   Punt CJA, 2009, NAT REV CLIN ONCOL, V6, P731, DOI 10.1038/nrclinonc.2009.168
   Rizzi M, 2007, J LEUKOCYTE BIOL, V81, P1599, DOI 10.1189/jlb.0606400
   Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009
   Schmit SL, 2019, JNCI-J NATL CANCER I, V111, P146, DOI 10.1093/jnci/djy099
   Schumacher FR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8138
   Shimabukuro-Vornhagen A, 2014, ONCOTARGET, V5, P4651, DOI 10.18632/oncotarget.1701
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Song MY, 2020, GASTROENTEROLOGY, V158, P322, DOI 10.1053/j.gastro.2019.06.048
   Swertz MA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S12-S12
   Wang LF, 2017, ONCOL LETT, V14, P6198, DOI 10.3892/ol.2017.6936
   Wang L, 2015, CANCER BIOL THER, V16, P383, DOI 10.1080/15384047.2014.1002331
   Weigl K, 2018, CLIN EPIDEMIOL, V10, P143, DOI 10.2147/CLEP.S145636
   Westra HJ, 2013, NAT GENET, V45, P1238, DOI 10.1038/ng.2756
   Wilkinson MD, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0009-6
   Wilkinson MD, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.18
   Xu ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1010-2
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Zeng CJ, 2016, GASTROENTEROLOGY, V150, P1633, DOI 10.1053/j.gastro.2016.02.076
   Zhang J, 2016, ONCOTARGET, V7, P26516, DOI 10.18632/oncotarget.8530
   Zhang X, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2030-2
NR 54
TC 1
Z9 1
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2021
VL 13
IS 6
AR 1258
DI 10.3390/cancers13061258
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RE7KV
UT WOS:000634329000001
PM 33809172
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, XL
   Zhou, JB
   Xia, CJ
   Min, H
   Lu, ZK
   Chen, ZR
AF Li, Xiao-Lan
   Zhou, Jianbiao
   Xia, Chen-Jing
   Min, Han
   Lu, Zhong-Kai
   Chen, Zhi-Rong
TI PRIMA-1(met) induces autophagy in colorectal cancer cells through
   upregulation of the mTOR/AMPK-ULK1-Vps34 signaling cascade
SO ONCOLOGY REPORTS
LA English
DT Article
DE p53-reactivation and induction of massive apoptosis-1(methylated);
   autophagy; oncotherapy; p53; colorectal cancer
AB p53-reactivation and induction of massive apoptosis-1, APR-017 methylated (PRIMA-1(met); APR246) targets mutant p53 to restore its wild-type structure and function. It was previously demonstrated that PRIMA-1(met) effectively inhibited the growth of colorectal cancer (CRC) cells in a p53-independent manner, and distinctly induced apoptosis by upregulating Noxa in p53-mutant cell lines. The present study including experiments of western blotting, acridine orange staining and transmission electron microscopy revealed that PRIMA-1(met) induced autophagy in CRC cells independently of p53 status. Importantly, PRIMA-1(met) not only promoted autophagic vesicle (AV) formation and AV-lysosome fusion, but also increased lysosomal degradation. Furthermore, Cell Counting Kit-8 assay, colony formation assay and small interfering RNA transfection were performed to investigate the underling mechanisms. The study indicated that activation of the mTOR/AMPK-ULK1-Vps34 autophagic signaling cascade was key for PRIMA-1(met)-induced autophagy. Additionally, autophagy served a crucial role in the inhibitory effect of PRIMA-1(met) in cells harboring wild-type p53, which was closely associated with the increased expression of Noxa. Taken together, the results determined the effect of PRIMA-1(met) on autophagy, and further revealed mechanistic insights into different CRC cell lines. It was concluded that PRIMA-1(met)-based therapy may be an effective strategy for CRC treatment.
C1 [Li, Xiao-Lan; Min, Han; Lu, Zhong-Kai; Chen, Zhi-Rong] Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Gastroenterol, 16 Baita St West, Suzhou 215001, Jiangsu, Peoples R China.
   [Zhou, Jianbiao] Natl Univ Singapore, Canc Sci Inst Singapore, Ctr Translat Med, Singapore 117599, Singapore.
   [Xia, Chen-Jing] Tradit Chinese Med Hosp Kunshan, Dept Gastroenterol, Suzhou 215300, Jiangsu, Peoples R China.
RP Chen, ZR (corresponding author), Nanjing Med Univ, Affiliated Suzhou Hosp, Dept Gastroenterol, 16 Baita St West, Suzhou 215001, Jiangsu, Peoples R China.
EM czr88188@163.com
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81603128]; Gusu Health Layer
   Training Program for Young Top Talent [GSWS2019059]; Science and
   Technology Project of Suzhou [SYSD2018136, SS201717]
FX The current study was supported by a grant from the National Natural
   Science Foundation of China (NSFC; grant no. 81603128), which funded the
   design of the study, experiments, data analysis and writingof the
   manuscript. The current study was also supported by the Gusu Health
   Layer Training Program for Young Top Talent (grant no. GSWS2019059) and
   the Science and Technology Project of Suzhou (grant nos. SYSD2018136 and
   SS201717), which contributed to completion of the experiments.
CR Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Huang KK, 2018, CANCER CELL, V33, P137, DOI 10.1016/j.ccell.2017.11.018
   Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kumar S, 2019, DEV CELL, V49, P130, DOI 10.1016/j.devcel.2019.01.027
   Kyaw M, 2016, MED J AUSTRALIA, V205, P450, DOI 10.5694/mja16.00957
   Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425
   Li XL, 2015, ONCOTARGET, V6, P36689, DOI 10.18632/oncotarget.5385
   Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lu T, 2016, ONCOTARGET, V7, P83017, DOI 10.18632/oncotarget.12940
   Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7
   Sobhani M, 2015, CANCER BIOL THER, V16, P799, DOI 10.1080/15384047.2015.1026482
   Takayama T, 2006, J GASTROENTEROL, V41, P185, DOI 10.1007/s00535-006-1801-6
   Tessoulin B, 2014, BLOOD, V124, P1626, DOI 10.1182/blood-2014-01-548800
   Wang JC, 2018, BBA-MOL CELL RES, V1865, P1105, DOI 10.1016/j.bbamcr.2018.05.007
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Yoshikawa N, 2016, ONCOL REP, V35, P2543, DOI 10.3892/or.2016.4653
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
NR 25
TC 2
Z9 2
U1 1
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2021
VL 45
IS 5
AR 86
DI 10.3892/or.2021.8037
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RJ5XB
UT WOS:000637674100001
PM 33846805
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Du, HL
   Chen, L
   Luo, FX
   Chen, XY
   Li, Y
   Cheng, QJ
AF Du, Hailei
   Chen, Ling
   Luo, Fangxiu
   Chen, Xueyu
   Li, Yong
   Cheng, Qijian
TI Beclin-1 expression is associated with prognosis in a Bcl-2-dependent
   manner in non-small cell lung cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE autophagy; Beclin-1; Bcl-2; prognosis; non-small cell lung cancer
ID COLORECTAL-CANCER; BCL-2; ADENOCARCINOMA; DISCOVERY; CARCINOMA
AB Beclin-1 and Bcl-2 expression abnormalities have been confirmed in different types of cancer. As important regulators of autophagy and apoptosis, respectively, these molecules serve a complex role in tumorigenesis. However, limited information is currently available regarding the association between Beclin-1 and Bcl-2 in (NSCLC). In the present study, the expression levels of Beclin-1 and Bcl-2 were detected in lung cancer tissues, and their prognostic significance was analyzed for NSCLC. A total of 120 patients with lung cancer who underwent surgical resection were included in the present study. Beclin-1 and Bcl-2 expression was assessed using immunohistochemistry and their associations with the overall survival (OS) in patients with NSCLC was examined. The expression rate of Beclin-1 was significantly lower in NSCLC tissues compared with that in adjacent tissues, whereas the expression rate of Bcl-2 was significantly higher in lung cancer tissues compared with that in adjacent tissues. Additionally, Beclin-1 and Bcl-2 protein expression was strongly associated (P<0.05) in NSCLC. Patients with NSCLC with low Beclin-1 expression were in more advanced stages, with more lymph node metastasis and more poorly differentiated tumors. Similarly, patients with NSCLC with high Bcl-2 expression were also in a more advanced stage and had more lymph node metastasis. Cox regression analysis revealed that the association between Bcl-2 expression and survival was not significant, while a multivariate analysis revealed that Beclin-1 expression was significantly associated with OS. Notably, Beclin-1 expression was significantly associated with OS only in patients with high Bcl-2 expression. In conclusion, the present data indicated that the autophagy activity is decreased in NSCLC. Beclin-1 expression was downregulated, while Bcl-2 expression was upregulated in NSCLC tissues compared with that in adjacent tissues. Additionally, these two proteins were associated with the occurrence and progression of NSCLC. Beclin-1 may be a promising prognostic marker for patients with NSCLC with high Bcl-2 expression. The present findings provided a more accurate prognostic assessment for patients with NSCLC. Furthermore, they may be used to actively follow-up and promptly treat patients with a poor prognosis, which may benefit a greater number of patients with NSCLC.
C1 [Du, Hailei; Chen, Xueyu] Shanghai Jiao Tong Univ, Ruijin Hosp, Dept Thorac Surg, Sch Med, Shanghai 200025, Peoples R China.
   [Chen, Ling; Li, Yong; Cheng, Qijian] Shanghai Jiao Tong Univ, Ruijin Hosp North, Sch Med, Dept Resp & Crit Care Med, Shanghai 201821, Peoples R China.
   [Luo, Fangxiu] Shanghai Jiao Tong Univ, Ruijin Hosp North, Sch Med, Dept Pathol, Shanghai 201821, Peoples R China.
RP Cheng, QJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Dept Resp & Crit Care Med, Ruijin Hosp North,Jiading New Town Ctr, Shanghai 201821, Peoples R China.
EM chengqijian@aliyun.com
FU project of the Shanghai Jiading District Health Committee [2017KY02]
FX The present study was partly supported by a grant from a project of the
   Shanghai Jiading District Health Committee (grant no. 2017KY02)
CR Baspinar S, 2014, PATHOL RES PRACT, V210, P412, DOI 10.1016/j.prp.2014.02.008
   Callagy GM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-153
   Cao MM, 2019, THORAC CANCER, V10, P3, DOI 10.1111/1759-7714.12916
   Chen LX, 2019, J CANCER, V10, P6207, DOI 10.7150/jca.37335
   Chen Y, 2017, MOL BIOSYST, V13, P991, DOI 10.1039/c6mb00653a
   Chi XX, 2018, J VET MED SCI, V80, P1348, DOI 10.1292/jvms.17-0001
   Cotzomi-Ortega I, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/4231591
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Goldstraw P, 2016, J THORAC ONCOL, V11, P39, DOI 10.1016/j.jtho.2015.09.009
   Guadagno E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164066
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hoy H, 2019, CRIT CARE NURS CLIN, V31, P303, DOI 10.1016/j.cnc.2019.05.002
   Huang Q, 2017, WORLD J GASTROENTERO, V23, P5018, DOI 10.3748/wjg.v23.i27.5018
   Jiang LC, 2014, BRAZ J MED BIOL RES, V47, P252, DOI 10.1590/1414-431X20133231
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liu XW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029670
   Mao YS, 2016, SURG ONCOL CLIN N AM, V25, P439, DOI 10.1016/j.soc.2016.02.001
   Nasim F, 2019, MED CLIN N AM, V103, P463, DOI 10.1016/j.mcna.2018.12.006
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Qiu XG, 2019, DNA CELL BIOL, V38, P85, DOI 10.1089/dna.2018.4318
   Rahman MA, 2016, BIOCHEM PHARMACOL, V117, P97, DOI 10.1016/j.bcp.2016.08.006
   Schenk RL, 2017, BIOCHEM BIOPH RES CO, V482, P459, DOI 10.1016/j.bbrc.2016.10.100
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Song SS, 2017, ONCOL LETT, V14, P7849, DOI 10.3892/ol.2017.7218
   Sun HY, 2019, J BUON, V24, P634
   Won KY, 2010, HUM PATHOL, V41, P107, DOI 10.1016/j.humpath.2009.07.006
   Xu HD, 2019, ADV EXP MED BIOL, V1206, P109, DOI 10.1007/978-981-15-0602-4_5
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Yu Y, 2018, MOL MED REP, V18, P2124, DOI 10.3892/mmr.2018.9209
   Zheng TL, 2018, ONCOTARGETS THER, V11, P4167, DOI 10.2147/OTT.S164987
NR 30
TC 3
Z9 3
U1 1
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD OCT
PY 2020
VL 20
IS 4
AR 9
DI 10.3892/ol.2020.11870
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NN6JV
UT WOS:000568893300072
PM 32802158
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Xia, Y
   Lei, Q
   Zhu, YX
   Ye, TH
   Wang, NY
   Li, GB
   Shi, XH
   Liu, YT
   Shao, B
   Yin, T
   Zhao, LF
   Wu, WS
   Song, XJ
   Xiong, Y
   Wei, YQ
   Yu, LT
AF Xia, Yong
   Lei, Qian
   Zhu, Yongxia
   Ye, Tinghong
   Wang, Ningyu
   Li, Guobo
   Shi, Xuanhong
   Liu, Yantong
   Shao, Bin
   Yin, Tao
   Zhao, Lifeng
   Wu, Wenshuang
   Song, Xuejiao
   Xiong, Ying
   Wei, Yuquan
   Yu, Luoting
TI SKLB316, a novel small-molecule inhibitor of cell-cycle progression,
   induces G2/M phase arrest and apoptosis in vitro and inhibits tumor
   growth in vivo
SO CANCER LETTERS
LA English
DT Article
DE SKLB316; Anti-cancer; Cell cycle arrest; Apoptosis; Drug discovery
ID BIOLOGICAL EVALUATION; EXPRESSION; AUTOPHAGY; DERIVATIVES; CHECKPOINT;
   STRATEGY; KINASES; PATHWAY; TARGETS; ROLES
AB Benzothiazole derivatives have received considerable attentions for their potencies in cancer therapy. In the present study, we reported that SKLB316, a novel synthesized benzothiazole derivative, exhibits activities to inhibit colorectal and pancreatic cancer in vitro and in vivo by inducing G2/M cell cycle arrest and apoptosis. In vitro, it exhibited significant anti-proliferative activities against human cancer cells derived from different histotypes including the colorectal cancer cell line HCT116 and pancreatic cancer cell line CFPAC-1. We chose these cell lines to study the possible anti-tumor mechanism because they are sensitive to SKLB316 treatment. Flow cytometry assays showed that SKLB316 could induce G2/M cell cycle arrest. Mechanistically, SKLB316 could decrease the activities of cdc2/cyclin B1 complex, including decreasing the synthesis of cyclin B1, cdc2 and cdc25c, while accumulating the levels of phosphorylated cdc2 (Tyr15) and checkpoint kinase 2. SKLB316 could also decrease the level of cyclin E and A2. Moreover, SKLB316 could induce cancer cell apoptosis, which was associated with activation of caspase 9, downregulation of Bcl-2 and upregulation of Bax. SKLB316 could also decrease the mitochondrial membrane potential and induce the generation of reactive oxygen species in cells. The results implied that SKLB316 may induce apoptosis via the mitochondria-mediated apoptotic pathway. Moreover, SKLB316 could suppress the growth of established colorectal and pancreatic cancer tumors in nude mice without causing obvious side effects. TUNEL assays confirmed that SKLB316 could also induce tumor cell apoptosis in vivo. Taken together, these findings demonstrate the potential value of SKLB316 as a novel anti-tumor drug candidate. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Xia, Yong; Lei, Qian; Zhu, Yongxia; Ye, Tinghong; Wang, Ningyu; Li, Guobo; Shi, Xuanhong; Liu, Yantong; Shao, Bin; Yin, Tao; Zhao, Lifeng; Wu, Wenshuang; Song, Xuejiao; Xiong, Ying; Wei, Yuquan; Yu, Luoting] Sichuan Univ, State Key Lab Biotherapy, Collaborat Innovat Ctr Biotherapy, West China Hosp,West China Med Sch, Chengdu 610041, Peoples R China.
   [Xiong, Ying] Third Mil Med Univ, Xinqiao Hosp, Dept Pharm, Chongqing 400037, Peoples R China.
RP Yu, LT (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Collaborat Innovat Ctr Biotherapy, West China Hosp,West China Med Sch, Chengdu 610041, Peoples R China.
EM yuluot@scu.edu.cn
OI Wang, Ning-Yu/0000-0003-3571-4903; Li, Guo-Bo/0000-0002-4915-6677
FU Shijiazhuang Pharmaceutical Group Co., Ltd [11H0684]
FX This work was financially supported by Shijiazhuang Pharmaceutical Group
   Co., Ltd (11H0684).
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Azmi AS, 2014, MOLECULAR DIAGNOSTICS AND TREATMENT OF PANCREATIC CANCER: SYSTEMS AND NETWORK BIOLOGY APPROACHES, P1
   Camidge DR, 2010, J THORAC ONCOL, V5, pS461, DOI 10.1097/01.JTO.0000391366.63882.30
   Cao D, 2013, EUR J MED CHEM, V62, P579, DOI 10.1016/j.ejmech.2013.01.007
   Cappella P, 2008, CYTOM PART A, V73A, P626, DOI 10.1002/cyto.a.20582
   Chen MC, 2013, CANCER LETT, V336, P370, DOI 10.1016/j.canlet.2013.03.028
   Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325
   Diaz-Moralli S, 2013, PHARMACOL THERAPEUT, V138, P255, DOI 10.1016/j.pharmthera.2013.01.011
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736
   Fletcher L, 2002, CANCER RES, V62, P241
   Fung TK, 2007, MOL BIOL CELL, V18, P1861, DOI 10.1091/mbc.E06-12-1092
   Gong D, 2010, MOL BIOL CELL, V21, P3149, DOI 10.1091/mbc.E10-05-0393
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hutchins JRA, 2004, CELL CYCLE, V3, P41
   Hutchinson I, 2001, J MED CHEM, V44, P1446, DOI 10.1021/jm001104n
   Jung KH, 2012, J CELL BIOCHEM, V113, P2167, DOI 10.1002/jcb.24090
   Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546
   Klein AP, 2013, NAT REV CANCER, V13, P66, DOI 10.1038/nrc3420
   Kok SHL, 2008, BIOORGAN MED CHEM, V16, P3626, DOI 10.1016/j.bmc.2008.02.005
   Li GB, 2013, J MOL GRAPH MODEL, V44, P278, DOI 10.1016/j.jmgm.2013.07.005
   Liu YY, 2013, EUR J PHARMACOL, V698, P95, DOI 10.1016/j.ejphar.2012.10.013
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747
   Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540
   Prystowsky M, 2013, SCI REP-UK, V3, DOI 10.1038/srep02640
   Schwartz GK, 2005, J CLIN ONCOL, V23, P9408, DOI 10.1200/JCO.2005.01.5594
   Shi XH, 2012, MOLECULES, V17, P3933, DOI 10.3390/molecules17043933
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siitonen T, 2005, LEUKEMIA RES, V29, P1335, DOI 10.1016/j.leukres.2005.04.018
   Stephenson JJ, 2014, LUNG CANCER, V83, P219, DOI 10.1016/j.lungcan.2013.11.020
   Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394
   Turner N., 2013, CANC RES S, V73
   Vidal-Laliena M, 2013, J BIOL CHEM, V288, P21096, DOI 10.1074/jbc.M113.458323
   Wang CC, 2012, WORLD J GASTROENTERO, V18, P25, DOI 10.3748/wjg.v18.i1.25
   Wang JC, 2014, SCI REP-UK, V4, DOI 10.1038/srep05006
   Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697
   Wang Z, 2011, BIOORG MED CHEM LETT, V21, P1097, DOI 10.1016/j.bmcl.2010.12.124
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Wu WS, 2013, CARCINOGENESIS, V34, P1636, DOI 10.1093/carcin/bgt087
   Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y
   Ye TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085887
   Yu XJ, 2012, CANCER LETT, V322, P185, DOI 10.1016/j.canlet.2012.03.004
   Zhang W, 2008, LEUKEMIA, V22, P808, DOI 10.1038/sj.leu.2405098
   Zhao BL, 2014, CANCER LETT, V347, P79, DOI 10.1016/j.canlet.2014.01.028
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
NR 46
TC 32
Z9 33
U1 4
U2 57
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD DEC 28
PY 2014
VL 355
IS 2
BP 297
EP 309
DI 10.1016/j.canlet.2014.09.042
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AS7IL
UT WOS:000344430000016
PM 25301449
DA 2022-04-25
ER

PT J
AU Zhuo, JW
   Wang, XY
AF Zhuo, Jingwei
   Wang, Xinying
TI Combination of targeting CD24 and inhibiting autophagy suppresses the
   proliferation and enhances the apoptosis of colorectal cancer cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE CD24; autophagy; proliferation; apoptosis; colorectal cancer
ID NF-KAPPA-B; SIGNALING PATHWAYS; ACTIVATION; CHEMOTHERAPY; EXPRESSION;
   CONTRIBUTES; PROGRESSION; SURVIVAL; THERAPY; DISEASE
AB CD24 can regulate angiogenesis, drug sensitivity and the progression of colorectal cancer (CRC). However, whether CD24 regulates autophagy and apoptosis in CRC cells remains to be fully elucidated. The present study investigated the functional role of the altered expression of CD24 in the autophagy and apoptosis of HCT116 and HT29 human CRC cells. The results revealed lower expression levels of CD24 in HCT116 cells but higher levels in HT29 cells. Inducing the overexpression or the knockdown of CD24 did not affect the viability or spontaneous apoptosis of HCT116 and HT29 cells, respectively. Induction of the overexpression of CD24 significantly decreased the relative expression levels of Beclin-1, autophagy-related (Atg)3 and Atg5, and the numbers of microtubule-associated protein-1 light chain-3 (LC3)-positive puncta, but increased the expression of p62 in HCT116 cells. By contrast, CD24 silencing increased the expression of Beclin-1, Atg3 and Atg5, and the numbers of LC3-positive puncta, but decreased the expression of p62 in HT29 cells. Treatment with 3-methyladenine, or the knockdown of Atg5 by specific small interfering RNA to attenuate autophagy significantly enhanced the viability of CD24-overexpressing HCT116 cells, but reduced the viability of CD24-silenced HT29 cells, relative to their controls. As a result, the attenuation of autophagy significantly decreased the frequency of apoptotic CD24-overexpressing HCT116 cells, but increased the percentages of apoptotic CD24-silenced HT29 cells. The overexpression of CD24 promoted the activation of nuclear factor (NF)-kappa Bp65, whereas CD24 silencing attenuated its activation in CRC cells. Inhibition of the activation of NF-kappa B enhanced the CD24 overexpression-induced decrease in autophagy, but attenuated the CD24 silencing-induced increase in autophagy in CRC cells. Therefore, CD24 inhibited the autophagy of CRC cells, and the combination of targeting CD24 and inhibiting autophagy promoted the apoptosis of CRC cells. Conceivably, these findings may aid in the design of novel therapies for the intervention of CRC.
C1 [Zhuo, Jingwei; Wang, Xinying] Southern Med Univ, Zhujiang Hosp, Dept Gastroenterol, 253 Ind Rd, Guangzhou 510280, Guangdong, Peoples R China.
   [Zhuo, Jingwei] Guangzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Guangzhou 510260, Guangdong, Peoples R China.
RP Wang, XY (corresponding author), Southern Med Univ, Zhujiang Hosp, Dept Gastroenterol, 253 Ind Rd, Guangzhou 510280, Guangdong, Peoples R China.
EM xinyingwang06@163.com
OI Wang, Xinyin/0000-0003-2956-0856
CR Ahmed MAH, 2010, INFLAMM BOWEL DIS, V16, P795, DOI 10.1002/ibd.21134
   Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chen N, 2009, BBA-MOL CELL RES, V1793, P1516, DOI 10.1016/j.bbamcr.2008.12.013
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Comb WC, 2011, ONCOGENE, V30, P1727, DOI 10.1038/onc.2010.553
   Copetti T, 2009, MOL CELL BIOL, V29, P2594, DOI 10.1128/MCB.01396-08
   Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364
   Djavaheri-Mergny M, 2007, CELL RES, V17, P576, DOI 10.1038/cr.2007.58
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Duex JE, 2017, CANCER RES, V77, P4858, DOI 10.1158/0008-5472.CAN-17-0367
   Eyvazi S, 2018, CURR CANCER DRUG TAR, V18, P328, DOI 10.2174/1570163814666170818125036
   Ghosh S, 2006, CANCER CELL, V10, P215, DOI 10.1016/j.ccr.2006.08.007
   Guo XL, 2012, CANCER LETT, V320, P171, DOI 10.1016/j.canlet.2012.03.002
   HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933
   Huett A, 2010, CURR OPIN GASTROEN, V26, P302, DOI 10.1097/MOG.0b013e32833ae2ed
   Ju JH, 2011, CARCINOGENESIS, V32, P1474, DOI 10.1093/carcin/bgr173
   Keeratichamroen S, 2011, INT J ONCOL, V39, P873, DOI 10.3892/ijo.2011.1088
   Kerr D, 2003, NAT REV CANCER, V3, P615, DOI 10.1038/nrc1147
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kristiansen G, 2004, J MOL HISTOL, V35, P255
   Kristiansen G, 2004, PROSTATE, V58, P183, DOI 10.1002/pros.10324
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Lee JH, 2009, ONCOL REP, V22, P1149, DOI 10.3892/or_00000548
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Lim SC, 2005, BIOMED PHARMACOTHER, V59, pS351, DOI 10.1016/S0753-3322(05)80076-9
   Lozy F, 2012, SEMIN CELL DEV BIOL, V23, P395, DOI 10.1016/j.semcdb.2012.01.005
   Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nivon M, 2009, AUTOPHAGY, V5, P766, DOI 10.4161/auto.8788
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Palta M, 2014, NAT REV CLIN ONCOL, V11, P182, DOI 10.1038/nrclinonc.2014.43
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Rikiishi Hidemi, 2012, Int J Cell Biol, V2012, P317645, DOI 10.1155/2012/317645
   Sagiv E, 2006, BIOMED PHARMACOTHER, V60, P280, DOI 10.1016/j.biopha.2006.06.006
   Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463
   Sagiv E, 2006, GASTROENTEROLOGY, V131, P630, DOI 10.1053/j.gastro.2006.04.028
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   Shapira S, 2011, GASTROENTEROLOGY, V140, P935, DOI 10.1053/j.gastro.2010.12.004
   Singh P, 2011, BIOCHEM BIOPH RES CO, V415, P181, DOI 10.1016/j.bbrc.2011.10.054
   Smith SC, 2006, CANCER RES, V66, P1917, DOI 10.1158/0008-5472.CAN-05-3855
   Su MF, 2013, J ONCOL, V2013, DOI 10.1155/2013/102735
   THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1
   Trocoli A, 2011, AM J CANCER RES, V1, P629
   Tschan MP, 2010, J INTERN MED, V268, P410, DOI 10.1111/j.1365-2796.2010.02266.x
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Wang JL, 2018, CLIN LAB, V64, P497, DOI 10.7754/Clin.Lab.2017.171012
   Wang WF, 2010, CANCER SCI, V101, P112, DOI 10.1111/j.1349-7006.2009.01370.x
   Wang XY, 2016, ONCOTARGET, V7, P55663, DOI 10.18632/oncotarget.10971
   Weichert W, 2005, CLIN CANCER RES, V11, P6574, DOI 10.1158/1078-0432.CCR-05-0606
   Whiteside ST, 1997, EMBO J, V16, P1413, DOI 10.1093/emboj/16.6.1413
   Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3
   Xiao GT, 2007, CYTOKINE GROWTH F R, V18, P233, DOI 10.1016/j.cytogfr.2007.04.006
   Yang SY, 2011, ANN SURG ONCOL, V18, pS239, DOI 10.1245/s10434-011-1789-x
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 62
TC 5
Z9 5
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2019
VL 20
IS 1
BP 539
EP 548
DI 10.3892/mmr.2019.10288
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA II0DR
UT WOS:000474876100057
PM 31180548
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Enkhbat, T
   Nishi, M
   Yoshikawa, K
   Jun, H
   Tokunaga, T
   Takasu, C
   Kashihara, H
   Ishikawa, D
   Tominaga, M
   Shimada, M
AF Enkhbat, Tumenjin
   Nishi, Masaaki
   Yoshikawa, Kozo
   Jun, Higashijima
   Tokunaga, Takuya
   Takasu, Chie
   Kashihara, Hideya
   Ishikawa, Daichi
   Tominaga, Masahide
   Shimada, Mitsuo
TI Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal
   Cancer Cells Through Nrf2 Activation and Autophagy
SO ANTICANCER RESEARCH
LA English
DT Article
DE EGCG; radiation; colorectal cancer; Nrf2; autophagy
ID GREEN TEA CATECHIN; GALLATE; MECHANISMS; APOPTOSIS; INDUCTION; ROLES;
   EGCG
AB Background/Aim: Epigallocatechin-3-gallate (EGCG) is a major polyphenolic component of green tea. EGCG plays a potential role in radio-sensitizing cancer cells. The combined effect of EGCG and radiation was investigated in a colorectal cancer cell line, focusing on nuclear factor (erythroid-derived 2)-like 2 (Nrf2) autophagy signalling. Materials and Methods: HCT-116 cells were treated with 12.5 ,uM EGCG for different periods of time, 2 Gy radiation, or both. Cell viability was determined with the WST-8 assay. The number of colonies was determined with the colony formation assay. mRNA expression of LC3 and caspase-9 was analyzed with quantitative real-time polymerase chain reaction. Results: Combination treatment with EGCG and radiation significantly decreased the growth of HCT-116 cells. The number of colonies was reduced to 34.2% compared to the control group. Immunofluorescence microscopy images showed that nuclear translocation of Nrf2 was significantly increased when cells were treated with the combination of EGCG and radiation compared to the control and single-treatment groups. Combined treatment with EGCG and radiation significantly induced LC3 and caspase-9 mRNA expression. Conclusion: EGCG increased the sensitivity of colorectal cancer cells to radiation by inhibiting cell proliferation and inducing Nrf2 nuclear translocation and autophagy.
C1 [Enkhbat, Tumenjin; Nishi, Masaaki; Yoshikawa, Kozo; Jun, Higashijima; Tokunaga, Takuya; Takasu, Chie; Kashihara, Hideya; Ishikawa, Daichi; Shimada, Mitsuo] Tokushima Univ, Inst Biomed Sci, Dept Surg, Grad Sch, Tokushima, Japan.
   [Tominaga, Masahide] Univ Tokushima, Dept Therapeut Radiol, Inst Biomed Sci, Grad Sch, Tokushima, Japan.
RP Shimada, M (corresponding author), Univ Tokushima, Inst Hlth Biosci, Dept Surg, Grad Sch, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
EM mitsuo.shimada@tokushima-u.ac.jp
OI Enkhbat, Tumenjin/0000-0002-9463-0622
CR Baatout S, 2005, INT J MOL MED, V15, P337
   Chen HHW, 2017, ONCOTARGET, V8, P62742, DOI 10.18632/oncotarget.18409
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549
   Haraldsdottir S, 2014, LAEKNABLADID, V100, P75, DOI 10.17992/lbl.2014.02.531
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Lee SLO, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6823471
   Masuda M, 2001, CLIN CANCER RES, V7, P4220
   Menegon S, 2016, TRENDS MOL MED, V22, P578, DOI 10.1016/j.molmed.2016.05.002
   Paschka AG, 1998, CANCER LETT, V130, P1, DOI 10.1016/S0304-3835(98)00084-6
   Saito Y, 2014, J GASTROENTEROL, V49, P692, DOI 10.1007/s00535-013-0799-9
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Suganuma M, 2011, CANCER SCI, V102, P317, DOI 10.1111/j.1349-7006.2010.01805.x
   Sun WX, 2017, FREE RADICAL BIO MED, V108, P840, DOI 10.1016/j.freeradbiomed.2017.04.365
   Tan XH, 2000, CANCER LETT, V158, P1, DOI 10.1016/S0304-3835(00)00445-6
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002
   Wang HN, 2018, CHEM-BIOL INTERACT, V281, P11, DOI 10.1016/j.cbi.2017.12.017
   Wubetu GY, 2016, J GASTROEN HEPATOL, V31, P256, DOI 10.1111/jgh.13069
   Yang CS, 2011, PHARMACOL RES, V64, P113, DOI 10.1016/j.phrs.2011.03.001
   Zhang G, 2012, CURR MOL MED, V12, P163, DOI 10.2174/156652412798889063
   Zhao HX, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150665
   Zhao HX, 2015, RADIOTHER ONCOL, V114, P351, DOI 10.1016/j.radonc.2015.02.014
NR 23
TC 26
Z9 27
U1 0
U2 14
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD NOV
PY 2018
VL 38
IS 11
BP 6247
EP 6252
DI 10.21873/anticanres.12980
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HA1KY
UT WOS:000449973000064
PM 30396944
OA Bronze
DA 2022-04-25
ER

PT J
AU Shi, DH
   Niu, PG
   Heng, XJ
   Chen, LJ
   Zhu, YT
   Zhou, JT
AF Shi, Daohua
   Niu, Peiguang
   Heng, Xiaojie
   Chen, Lijun
   Zhu, Yanting
   Zhou, Jintuo
TI Autophagy induced by cardamonin is associated with mTORC1 inhibition in
   SKOV3 cells
SO PHARMACOLOGICAL REPORTS
LA English
DT Article
DE Autophagy; Cardamonin; mTOR; Ovarian cancer; Raptor
ID NF-KAPPA-B; PI3K/AKT/MTOR SIGNALING PATHWAY; COLORECTAL-CARCINOMA
   HCT116; OVARIAN-CANCER; MULTIPLE-MYELOMA; DOWN-REGULATION; APOPTOSIS;
   CISPLATIN; ACTIVATION; ANTIPROLIFERATION
AB Background: The mammalian target of rapamycin (mTOR) integrates energy level to modulate cell proliferation and autophagy. Cardamonin exhibits anti-proliferative activity through inhibiting mTOR. In this study, the effect of cardamonin on autophagy and its mechanism on mTOR inhibition were investigated.
   Methods: Cell viability and proliferation were measured by MTT assay and BrdU incorporation, respectively. Cell apoptosis was assayed by flow cytometry and cell autophagy was detected by electron microscopy and GFP-LC3 fluorescence. The mechanism of cardamonin on mTORC1 inhibition was investigated by Raptor siRNA and Raptor over-expression.
   Results: The cell viability and proliferation were inhibited by cardamonin. The autophagosomes and the protein level of LC3-II were increased by cardamonin. Cell apoptosis and the levels of cleaved PARP and Caspase-3 were increased by cardamonin. Cardamonin inhibited the phosphorylation of mTOR and ribosome S6 protein kinase 1 (S6K1) as well as the protein level of regulatory associated protein of mTOR (Raptor). However, cardamonin had no effect on the component of mTORC2 and its downstream substrate Akt. The inhibitory effect of cardamonin on the phosphorylation of mTOR and S6K1 was eliminated by Raptor knockdown with siRNA, whereas this effect of cardamonin was stronger than that of rapamycin and AZD8055 in Raptor over-expression cells. Cell viability was inhibited by cardamonin in both Raptor knockdown and Raptor over-expression cells, which was consistent with the inhibitory effect of cardamonin on mTOR.
   Conclusion: These findings demonstrated that the autophagy induced by cardamonin was associated with mTORC1 inhibition through decreasing the protein level of Raptor in SKOV3 cells. (c) 2018 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.
C1 [Shi, Daohua; Niu, Peiguang; Heng, Xiaojie; Chen, Lijun; Zhu, Yanting; Zhou, Jintuo] Fujian Med Univ, Affiliated Hosp, Fujian Prov Matern & Childrens Hosp, Dept Pharm, Fuzhou, Fujian, Peoples R China.
RP Shi, DH (corresponding author), Fujian Med Univ, Affiliated Hosp, Fujian Prov Matern & Childrens Hosp, Dept Pharm, Fuzhou, Fujian, Peoples R China.
EM shidh@yeah.net
RI Daohua, Shi/C-3952-2011
OI Daohua, Shi/0000-0002-3383-5640
FU Natural Science Foundation of Fujian Province, ChinaNatural Science
   Foundation of Fujian Province [2015J01368, 2016J01492, 2017J01234];
   Innovative Medical Foundation of Fujian Provincial Health and Family
   Planning Commission, China [2016-CX-13]
FX This work was supported by the Natural Science Foundation of Fujian
   Province, China (grant numbers: 2015J01368, 2016J01492, 2017J01234) and
   Innovative Medical Foundation of Fujian Provincial Health and Family
   Planning Commission, China (grant number: 2016-CX-13).
CR Bahrami F, 2014, AM J CANCER RES, V4, P558
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Crazzolara R, 2009, AUTOPHAGY, V5, P727, DOI 10.4161/auto.5.5.8507
   Dennis MD, 2013, J BIOL CHEM, V288, P10, DOI 10.1074/jbc.M112.402461
   Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   El-Naga RN, 2014, TOXICOL APPL PHARM, V274, P87, DOI 10.1016/j.taap.2013.10.031
   Feng N, 2016, MOL MED REP, V13, P3243, DOI 10.3892/mmr.2016.4887
   Frey JW, 2014, CELL SIGNAL, V26, P313, DOI 10.1016/j.cellsig.2013.11.009
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Goncalves LM, 2014, J MED FOOD, V17, P633, DOI 10.1089/jmf.2013.0061
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Harder LM, 2014, AUTOPHAGY, V10, P339, DOI 10.4161/auto.26863
   Kim YJ, 2015, BIOORG MED CHEM LETT, V25, P2559, DOI 10.1016/j.bmcl.2015.04.054
   Ko H, 2011, J CELL BIOCHEM, V112, P2471, DOI 10.1002/jcb.23171
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Kumar S, 2015, J CELL BIOCHEM, V116, P985, DOI 10.1002/jcb.25053
   Lee DH, 2016, EUR J PHARMACOL, V784, P164, DOI 10.1016/j.ejphar.2016.05.025
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li YY, 2015, INT IMMUNOPHARMACOL, V25, P332, DOI 10.1016/j.intimp.2015.02.002
   Li YT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.407
   Liao Q, 2010, EUR J PHARMACOL, V641, P179, DOI 10.1016/j.ejphar.2010.05.024
   Lou M, 2016, BIOMED PHARMACOTHER, V84, P1, DOI 10.1016/j.biopha.2016.08.055
   Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770
   Mabuchi S, 2011, CLIN CANCER RES, V17, P4462, DOI 10.1158/1078-0432.CCR-10-2987
   Mabuchi S, 2009, CLIN CANCER RES, V15, P5404, DOI 10.1158/1078-0432.CCR-09-0365
   Matsumoto K, 2015, JPN J CLIN ONCOL, V45, P408, DOI 10.1093/jjco/hyv014
   Niu PG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127778
   Niu PG, 2018, ONCOL LETT, V15, P3991, DOI 10.3892/ol.2018.7743
   Prieto-Dominguez N, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00151
   Qin Y, 2012, LEUKEMIA RES, V36, P514, DOI 10.1016/j.leukres.2011.11.014
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shrivastava S, 2017, BIOFACTORS, V43, P152, DOI 10.1002/biof.1315
   Sini P, 2010, AUTOPHAGY, V6, P553, DOI 10.4161/auto.6.4.11671
   Tang Y, 2014, LIFE SCI, V99, P44, DOI 10.1016/j.lfs.2014.01.066
   Veverka V, 2008, ONCOGENE, V27, P585, DOI 10.1038/sj.onc.1210693
   Xu Dong-Wei, 2015, Asian Pac J Cancer Prev, V16, P2167
   Xue ZG, 2016, PLANTA MED, V82, P70, DOI 10.1055/s-0035-1557901
   Zhang DM, 2013, CARCINOGENESIS, V34, P1331, DOI 10.1093/carcin/bgt060
   Zhang SL, 2017, MOL IMMUNOL, V85, P214, DOI 10.1016/j.molimm.2017.02.020
   Zhang XJ, 2016, BIOMED PHARMACOTHER, V83, P1164, DOI 10.1016/j.biopha.2016.08.035
   Zheng Wei, 2010, Zhongguo Zhong Yao Za Zhi, V35, P2318
NR 42
TC 12
Z9 14
U1 0
U2 8
PU POLISH ACAD SCIENCES INST PHARMACOLOGY
PI KRAKOW
PA SMETNA 12, 31-343 KRAKOW, POLAND
SN 1734-1140
J9 PHARMACOL REP
JI Pharmacol. Rep.
PD OCT
PY 2018
VL 70
IS 5
BP 908
EP 916
DI 10.1016/j.pharep.2018.04.005
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GV2JK
UT WOS:000445914400012
DA 2022-04-25
ER

PT J
AU Xu, YC
   Huang, YS
   Pan, GF
   Li, ZX
   Lin, LW
   Chen, J
   Wu, JH
AF Xu, Yanchang
   Huang, Yisen
   Pan, Guofeng
   Li, Zhixiong
   Lin, Linwen
   Chen, Jian
   Wu, Jihuang
TI Expression of autophagy-related proteins is associated with the clinical
   outcome of patients with advanced gastric cancer receiving
   fluoropyrimidine/platinum chemotherapy
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Gastric cancer; autophagy; unc-51-like kinase 1; beclin 1; prognosis
ID SQUAMOUS-CELL CARCINOMA; HEDGEHOG SIGNALING PATHWAY; UNC-51-LIKE KINASE
   1; COLORECTAL-CANCER; INDUCED APOPTOSIS; POOR-PROGNOSIS; OVARIAN-CANCER;
   BECLIN-1; RESISTANCE; MTOR
AB The precise prediction of the clinical outcome of cancer patients is crucial for determining therapeutic options and providing optimal cancer care. Although targeted therapy is widely used in cancer treatment, chemotherapy remains the first-line treatment for patients with advanced gastric cancer. This study aimed to investigate the expression of autophagy-related proteins, unc-51-like kinase 1 (ULK1) and beclin 1 (BECN1), in advanced gastric cancer to clarify their clinical significance in the prognosis assessment of patients receiving fluoropyrimidine/platinum chemotherapy. The expression levels of ULK1 and BECN1 in gastric cancer tissues from 149 patients with TNM stages III and IV were measured by immunohistochemical staining. Both ULK1 and BECN1 were upregulated in gastric cancer. High expression of ULK1 and BECN1 were associated with older age and poor differentiation, respectively. In the univariate survival analysis, ULK1 and BECN1 expression were identified as predictors of poor prognosis. Only BECN1 expression was independently associated with poor prognosis in multivariate analysis. This association was significantly evident in cases who were older than 65 years, male, never smokers, drinkers, and those with poor differentiation or TNM stage III. Furthermore, the combined analysis revealed a significant cumulative effect on overall survival. Taken together, the expression levels of autophagy-related proteins could predict clinical benefit of fluoropyrimidine/platinum chemotherapy in patients with advanced gastric cancer.
C1 [Xu, Yanchang; Pan, Guofeng; Li, Zhixiong; Lin, Linwen; Chen, Jian; Wu, Jihuang] Fujian Med Univ, Hosp Putian City 1, Dept Gastrointestinal Surg, Putian, Fujian, Peoples R China.
   [Huang, Yisen] Fujian Med Univ, Hosp Quanzhou 1, Dept Gastroenterol, Putian, Fujian, Peoples R China.
RP Xu, YC (corresponding author), Fujian Med Univ, Hosp Putian City 1, Dept Gastrointestinal Surg, Putian, Fujian, Peoples R China.
EM cccxyc@163.com
FU Putian Science and Technology Agency, Fujian, China [2012 S01 (2)]
FX This study was supported by Research Fund of the Putian Science and
   Technology Agency, Fujian, China [grant No. 2012 S01 (2)].
CR Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi JH, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/179586
   Correa RJM, 2015, J OVARIAN RES, V8, DOI 10.1186/s13048-015-0182-y
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Geng QR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045968
   He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Huerta S, 2008, EXPERT REV MOL DIAGN, V8, P277, DOI 10.1586/14737159.8.3.277
   Jiang L, 2014, INT J CLIN EXP MED, V7, P1349
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jiang S, 2011, CANCER SCI, V102, P1568, DOI 10.1111/j.1349-7006.2011.01964.x
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518
   Kang KF, 2013, ONCOL LETT, V5, P1813, DOI 10.3892/ol.2013.1307
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Lee JH, 2010, INT J TISSUE REGEN, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0015394
   Li XS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-26
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu B, 2015, UROLOGY, V85, P1424, DOI 10.1016/j.urology.2015.03.006
   Mizushima N, 2010, CURR OPIN CELL BIOL, V22, P132, DOI 10.1016/j.ceb.2009.12.004
   Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Salih Barik A, 2009, Saudi J Gastroenterol, V15, P201, DOI 10.4103/1319-3767.54743
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tang H, 2015, EBIOMEDICINE, V2, P255, DOI 10.1016/j.ebiom.2015.01.008
   Tang J, 2012, BREAST CANCER RES TR, V134, P549, DOI 10.1007/s10549-012-2080-y
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Won KY, 2015, PATHOL RES PRACT, V211, P308, DOI 10.1016/j.prp.2014.11.005
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xu HT, 2013, INT J CLIN EXP PATHO, V6, P711
   Yu M, 2013, TUMOR BIOL, V34, P1071, DOI 10.1007/s13277-013-0648-8
   Yun M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117375
   Zeng X, 2015, AUTOPHAGY, V11, P355, DOI 10.4161/15548627.2014.994368
   Zhang XL, 2013, PATHOL RES PRACT, V209, P510, DOI 10.1016/j.prp.2013.06.005
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
NR 39
TC 0
Z9 0
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 3
BP 3735
EP 3742
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DO2FA
UT WOS:000377594100118
DA 2022-04-25
ER

PT J
AU Han, Y
   Zhou, SF
   Wang, XY
   Mao, EQ
   Huang, L
AF Han, Yi
   Zhou, Shaofei
   Wang, Xiaoyan
   Mao, Enqiang
   Huang, Liang
TI SNHG14 stimulates cell autophagy to facilitate cisplatin resistance of
   colorectal cancer by regulating miR-186/ATG14 axis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE CRC; SNHG14; miR-186; ATG14; Autophagy; Cisplatin resistance
ID LONG NONCODING RNA; PROLIFERATION; PROGRESSION; INVASION; PROMOTES
AB Colorectal cancer (CRC) is a malignant tumor with a high incidence and death rate in the world. Molecular interactions inside cells or tissues during tumor occurrence, development, and drug resistance are important for disease prevention and treatment. The long non-coding RNA SNHG14 has been proven to exert its oncogenic function in multiple cancers. However, there is no study regarding the role of SNHG14 in CRC research. In the present study, we applied RT-qPCR and western blot to determine the gene expression levels. MTT and TUNEL assays were used to detect cell proliferation and apoptosis rate. Cell migration and invasion abilities were determined by wound healing and transwell assays, respectively. StarBase was used to predict the potential binding sites and luciferase reporter assay was applied to confirm the direct interactions. Besides, we conducted a xenograft experiment to detect tumor growth rate in vivo. Our results showed that SNHG14 and ATG14 were both significantly higher in CRC tumor tissues than the normal ones, while miR-186 was decreased. The similar results were also observed in CRC cell lines. We confirmed that SNHG14 could directly interact with miR-186 and inhibited its expression. Meanwhile, miR-186 could directly bind ATG14 to inhibit its expression level. In vitro experiments showed that higher expression of SNHG14 led to higher cell proliferation, migration and invasion, while miR-186 significantly inhibited these tumor phenotypes. Furthermore, overexpression of ATG14 could strongly recover the CRC phenotypes attenuated by shSNHG14 or miR-186 mimics. Interestingly, we constructed cisplatin-resistant CRC cells and found that overexpression of ATG14 significantly enhanced the cell proliferation rate and inhibited cell apoptosis. Our research indicated that the novel axis of SNHG14/miR-186/ATG14 could play a vital role in regulating CRC cell progression. Moreover, this axis showed its clinical potential in regulating cisplatin resistance during CRC treatment.
C1 [Han, Yi; Wang, Xiaoyan; Huang, Liang] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Traumatol, 197 RuiJin Second Rd, Shanghai 200025, Peoples R China.
   [Zhou, Shaofei] Qingdao Municipal Hosp, Dept Gen Surg, Qingdao, Shandong, Peoples R China.
   [Mao, Enqiang] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Emergency, Shanghai, Peoples R China.
RP Huang, L (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Dept Traumatol, 197 RuiJin Second Rd, Shanghai 200025, Peoples R China.
EM liangh6522@126.com
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen Y, 2014, CELL PROLIFERAT, V47, P105, DOI 10.1111/cpr.12095
   Dong HY, 2018, INT J ONCOL, V53, P1013, DOI 10.3892/ijo.2018.4467
   Dueland S, 2015, ANN SURG, V261, P956, DOI 10.1097/SLA.0000000000000786
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Fang CY, 2017, CANCER LETT, V410, P50, DOI 10.1016/j.canlet.2017.09.012
   Gonzalez R, 2005, SURG ENDOSC, V19, P43, DOI 10.1007/s00464-003-8207-9
   Ji NN, 2019, PATHOL RES PRACT, V215, P668, DOI 10.1016/j.prp.2018.12.026
   Kramer N, 2013, MUTAT RES-REV MUTAT, V752, P10, DOI 10.1016/j.mrrev.2012.08.001
   Lambert JM, 2018, ANNU REV MED, V69, P191, DOI 10.1146/annurev-med-061516-121357
   Li B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0439-7
   Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042
   Li G, 2018, J CELL MOL MED, V22, P5565, DOI 10.1111/jcmm.13830
   Li JL, 2018, ARCH BIOCHEM BIOPHYS, V640, P53, DOI 10.1016/j.abb.2018.01.002
   Liao R, 2018, J GASTROINTEST SURG, V22, P1679, DOI 10.1007/s11605-018-3810-1
   Liu Z, 2018, J CELL BIOCHEM, V119, P6905, DOI 10.1002/jcb.26889
   Lu DF, 2018, CELL PHYSIOL BIOCHEM, V48, P2517, DOI 10.1159/000492690
   Ma T, 2018, CANCER LETT, V436, P129, DOI 10.1016/j.canlet.2018.08.010
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Riss T. L., 2016, CELL VIABILITY ASSAY
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Song H, 2017, J BUON, V22, P696
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Wild AT, 2017, VISC MED, V33, P54, DOI 10.1159/000454685
   Wu K, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.108995
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xie SD, 2019, EUR REV MED PHARMACO, V23, P2461, DOI 10.26355/eurrev_201903_17393
   Yang GD, 2014, BBA-GENE REGUL MECH, V1839, P1097, DOI 10.1016/j.bbagrm.2014.08.012
   Yin QQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180516
   Zhang JJ, 2019, J HIGH ENERGY PHYS, DOI 10.1007/JHEP02(2019)007
   Zhang XF, 2019, BIOCHEM BIOPH RES CO, V510, P508, DOI 10.1016/j.bbrc.2019.01.109
   Zhang Y, 2018, ONCOL LETT, V15, P6336, DOI 10.3892/ol.2018.8127
   Zhang Zhiqiang, 2019, Cell Physiol Biochem, V52, P553, DOI 10.33594/000000039
   Zhou JJ, 2017, MOL MED REP, V16, P4980, DOI 10.3892/mmr.2017.7162
NR 34
TC 20
Z9 20
U1 1
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2020
VL 121
AR 109580
DI 10.1016/j.biopha.2019.109580
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JT1GJ
UT WOS:000500746200044
PM 31704614
OA gold
DA 2022-04-25
ER

PT J
AU Zhao, GT
   Wang, YJ
   Yang, CQ
   Zhao, L
   Guo, LL
   Li, LM
   Wei, ZB
AF Zhao, Ganting
   Wang, Yanjing
   Yang, Changqing
   Zhao, Li
   Guo, Lili
   Li, Lingmin
   Wei, Zibai
TI Interplay Between Autophagy and Apoptosis in Lycorine
   Hydrochloride-Induced Cytotoxicity of HCT116 Cells
SO NATURAL PRODUCT COMMUNICATIONS
LA English
DT Article
DE lycorine hydrochloride; apoptosis; autophagy; colorectal cancer;
   interplay
ID CANCER
AB The aim of this study was to investigate the antitumor effect of lycorine hydrochloride (LH) and discuss the correlation between LH-induced apoptosis and autophagy in the human colorectal cancer cell line HCT116. Here the results by the Cell Counting Kit-8 and colony formation assays showed that LH concentration-dependently decreased cell viability and colony formation in HCT116 cells, suggesting inhibition of cell proliferation by LH. By flow cytometry, LH was found to increase apoptotic rate in HCT116 cells. Mechanistically, Western blot results revealed that LH increased the expression of the protein of Bax and Caspase-3, and decreased Bcl-2 proteins expression. Moreover, the reverse transcriptase quantitative polymerase chain reaction and Western blot analysis also showed that LH increased the expression of Beclin-1 and LC3B-II/LC3B-I ratio, indicating that autophagy was induced by LH. LH induced autophagy via downregulating phospho-mammalian target of rapamycin and upregulating phospho-AMPK (5 ' adenosine monophosphate-activated protein kinase). Furthermore, to understand the role of LH-induced autophagy and its association with apoptosis, cells were analyzed after Beclin-1 small interfering RNA transfection. The results indicated that the proapoptotic ability of LH was increased by inhibition of autophagy. In conclusion, the present investigation suggested that LH induced apoptosis and autophagy in HCT116 cells via the mitochondrial and AMPK/mTOR pathways. The suppression of autophagy promoted LH-induced apoptosis by modulating Beclin-1 and Bcl-2.
C1 [Zhao, Ganting; Yang, Changqing; Zhao, Li; Guo, Lili; Wei, Zibai] Changzhi Med Coll, Heping Hosp, Dept Gastroenterol & Hepatol, 100 South Yanan Rd, Changzhi 046000, Peoples R China.
   [Wang, Yanjing] Capital Med Univ, Beijing Anzhen Hosp, Dept Ultrasound, Beijing, Peoples R China.
   [Li, Lingmin] Shanxi Med Univ, Dept Pathol, Taiyuan, Shanxi, Peoples R China.
RP Wei, ZB (corresponding author), Changzhi Med Coll, Heping Hosp, Dept Gastroenterol & Hepatol, 100 South Yanan Rd, Changzhi 046000, Peoples R China.
EM 15914308560@163.com
CR Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Cerella C, 2014, BIOTECHNOL ADV, V32, P1111, DOI 10.1016/j.biotechadv.2014.03.006
   Cimmino A, 2017, CHIRALITY, V29, P486, DOI 10.1002/chir.22719
   Cui YQ, 2018, BIOCHEM BIOPH RES CO, V497, P916, DOI 10.1016/j.bbrc.2017.12.144
   Ji YB, 2017, SAUDI PHARM J, V25, P633, DOI 10.1016/j.jsps.2017.04.036
   Jiang HB, 2010, BIOCHEM BIOPH RES CO, V395, P471, DOI 10.1016/j.bbrc.2010.04.030
   Lamoral-Theys D, 2009, J MED CHEM, V52, P6244, DOI 10.1021/jm901031h
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li JZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23975
   Ludmir EB, 2017, CANCER-AM CANCER SOC, V123, P1497, DOI 10.1002/cncr.30600
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nair JJ, 2014, NAT PROD COMMUN, V9, P1193
   Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Wang CS, 2017, BIOCHEM BIOPH RES CO, V483, P197, DOI 10.1016/j.bbrc.2016.12.168
   Wang Q, 2018, TOXICOL LETT, V289, P28, DOI 10.1016/j.toxlet.2018.03.002
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Ying XX, 2017, SCI CHINA LIFE SCI, V60, P417, DOI 10.1007/s11427-016-0368-y
   Yu HY, 2017, MOL CANCER THER, V16, P2711, DOI 10.1158/1535-7163.MCT-17-0498
   Zeng H, 2017, MED SCI MONITOR, V23, P2035, DOI 10.12659/MSM.900742
   Zerillo JA, 2017, JAMA ONCOL, V3, P686, DOI 10.1001/jamaoncol.2017.0417
   Zhang XY, 2018, APPL MICROBIOL BIOT, V102, P6503, DOI 10.1007/s00253-018-9069-3
NR 22
TC 1
Z9 1
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1934-578X
EI 1555-9475
J9 NAT PROD COMMUN
JI Nat. Prod. Commun.
PD JUL
PY 2019
VL 14
IS 7
DI 10.1177/1934578X19862100
PG 7
WC Chemistry, Medicinal; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Food Science & Technology
GA IM5OZ
UT WOS:000478044500023
OA hybrid
DA 2022-04-25
ER

PT J
AU Wang, YH
   Feng, L
   Piao, BK
   Zhang, PT
AF Wang, Yaohan
   Feng, Li
   Piao, Bingkui
   Zhang, Peitong
TI Review on Research about Traditional Chinese Medicine in Cancer Stem
   Cell
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Review
ID BUFALIN-INDUCED APOPTOSIS; ACUTE MYELOID-LEUKEMIA; TZE HUANG SUPPRESSES;
   COLORECTAL-CANCER; PROLIFERATION; AUTOPHAGY; ACTIVATION; MECHANISMS;
   STAT3; MODEL
AB Cancer stem cells (CSCs) are small subpopulations of neoplastic cells within a tumor, which have self-renewal and differentiation abilities and could generate new tumors with few cells. Researches have showed that CSCs are considered the most likely reason for cancer recurrence and metastasis. Accumulating evidences have showed that traditional Chinese medicine (TCM) has significant effect on CSCs. It could inhibit the proliferation, self-renew, and multidifferentiation of CSCs. We aimed to summarize the theories of CSCs in TCM, the inhibitory effect, and the pathway on CSCs of TCM. This review will provide potential new strategies and alternative perspectives for CSCs treatments and basic research into complementary and alternative medicine.
C1 [Wang, Yaohan; Piao, Bingkui; Zhang, Peitong] China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, 5 Beixiange, Beijing 100053, Peoples R China.
   [Feng, Li] Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Tradit Chinese Med Dept, Beijing 100021, Peoples R China.
   [Feng, Li] Peking Union Med Coll, Beijing 100021, Peoples R China.
RP Piao, BK; Zhang, PT (corresponding author), China Acad Chinese Med Sci, Guanganmen Hosp, Dept Oncol, 5 Beixiange, Beijing 100053, Peoples R China.; Feng, L (corresponding author), Chinese Acad Med Sci, Canc Hosp, Natl Canc Ctr, Tradit Chinese Med Dept, Beijing 100021, Peoples R China.; Feng, L (corresponding author), Peking Union Med Coll, Beijing 100021, Peoples R China.
EM fengli663@126.com; piaobingkui123@163.com; drzhangpeitong@hotmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81173450]
FX This work was supported by National Natural Science Foundation of China
   (no. 81173450).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Almanaa TN, 2013, J CANCER, V4, P536, DOI 10.7150/jca.6477
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Cabrera MC, 2015, WORLD J STEM CELLS, V7, P27, DOI 10.4252/wjsc.v7.i1.27
   Cao ZY, 2010, FUJIAN J TRADIT CHIN, V3, P18
   Chang YW, 2015, CELL PHYSIOL BIOCHEM, V36, P1186, DOI 10.1159/000430289
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Eaves CJ, 2008, NATURE, V456, P581, DOI 10.1038/456581a
   Efferth T, 2012, PLANTA MED, V78, P935, DOI 10.1055/s-0031-1298540
   Fan Q. Y., 2013, HU NAN U TRADITIONAL, V5
   Fessler E, 2013, CANCER LETT, V341, P97, DOI 10.1016/j.canlet.2012.10.015
   Girouard SD, 2011, LAB INVEST, V91, P647, DOI 10.1038/labinvest.2011.50
   Guo W, 2006, PEDIATR RES, V59, p59R, DOI 10.1203/01.pdr.0000203592.04530.06
   Han KQ, 2007, WORLD J GASTROENTERO, V13, P3374, DOI 10.3748/wjg.v13.i24.3374
   Han S, 2016, BIOCHEM BIOPH RES CO, V469, P1153, DOI 10.1016/j.bbrc.2015.12.066
   Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Jordan CT, 2004, CURR OPIN CELL BIOL, V16, P708, DOI 10.1016/j.ceb.2004.09.002
   Kan SF, 2007, J CELL BIOCHEM, V101, P44, DOI 10.1002/jcb.21036
   Karamboulas C, 2013, BBA-GEN SUBJECTS, V1830, P2481, DOI 10.1016/j.bbagen.2012.11.008
   Kaushik G, 2014, AM J SURG, V208, P995, DOI 10.1016/j.amjsurg.2014.09.014
   Kumazoe M, 2017, J BIOL CHEM, V292, P10813, DOI 10.1074/jbc.M116.772111
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li D, 2009, ANTI-CANCER DRUG, V20, P59, DOI 10.1097/CAD.0b013e3283160fd6
   Li J., 2013, BENG BU MEDCINE, V5
   Li SH, 2013, MOL CELL BIOCHEM, V373, P217, DOI 10.1007/s11010-012-1493-6
   Li YY, 2010, CLIN CANCER RES, V16, P2580, DOI 10.1158/1078-0432.CCR-09-2937
   Lin L, 2011, BRIT J CANCER, V105, P212, DOI 10.1038/bjc.2011.200
   Lin LC, 2012, J AGR FOOD CHEM, V60, P7031, DOI 10.1021/jf301981n
   Liu J. M., 2013, J NEW CHINESE MED, V43, P192
   Liu JM, 2008, ADV THER, V25, P389, DOI 10.1007/s12325-008-0050-x
   Liu P. Y., 2003, J HUNAN COLL TRADITI, V23, P29
   [卢小路 Lu Xiaolu], 2015, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V31, P139
   Luo Y. Y., 2014, NANJING U TRADITIONA
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6
   Pathak S, 2002, ANTICANCER RES, V22, P1353
   Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379
   Qi F, 2016, ONCOL REP, V35, P511, DOI 10.3892/or.2015.4378
   Rahman M, 2011, NEUROSURGERY, V68, P531, DOI 10.1227/NEU.0b013e3181ff9eb5
   Ravikumar B, 2004, NAT GENET, V36, P585, DOI 10.1038/ng1362
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Shankar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016530
   Shen A, 2013, ONCOL REP, V30, P1701, DOI 10.3892/or.2013.2609
   Shen AL, 2012, ONCOL REP, V28, P2125, DOI 10.3892/or.2012.2067
   Shi M. P., 2003, CHINESE J INTEGRATED, V23, P142
   [史玉荣 Shi Yurong], 2015, [中药药理与临床, Pharmacology and Clinics of Chinese Materia Medica], V31, P133
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Srivastava Rakesh K, 2011, Front Biosci (Elite Ed), V3, P515, DOI 10.2741/e266
   Sun GD, 2016, ONCOL LETT, V11, P3875, DOI 10.3892/ol.2016.4431
   Sun X., 2012, STUDY MCF 7CELL ENRI
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   Mai TT, 2012, CANCER LETT, V321, P144, DOI 10.1016/j.canlet.2012.01.045
   Tung SL, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.25
   Tysnes BB, 2007, BBA-REV CANCER, V1775, P283, DOI 10.1016/j.bbcan.2007.01.001
   Wang S., 2012, ACTA U TRADITIONS ME, V26, P77
   Wang WL, 2013, ANTICANCER RES, V33, P4279
   Wang Y., 2016, LIAONING J TRADITION, V5, p[1024, 1120]
   Wang YH, 2017, INT J NANOMED, V12, P1369, DOI 10.2147/IJN.S124276
   Watabe M, 1998, ONCOGENE, V16, P779, DOI 10.1038/sj.onc.1201592
   Wei LH, 2014, MOL MED REP, V9, P261, DOI 10.3892/mmr.2013.1760
   Wu WB, 2012, INT J NANOMED, V7, P3487, DOI [10.2147/IJN.S32620, 10.2147/IJN.S34702]
   Xiao D. S., 2007, ZHEJIANG J TRADITION, V42, P669
   Xu DD, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0521-7
   Xu Wei, 2011, Cancers (Basel), V3, P2274, DOI 10.3390/cancers3022274
   Xu WR, 2011, J TRADIT CHIN MED, V31, P158, DOI 10.1016/S0254-6272(11)60032-0
   Xu Z. W., 2009, J YUNNAN U TRADITION, P14
   Yang D., 2015, CHINA ACAD CHINESE M
   Yang D., 2015, CHINA CANC, V24, P234
   [杨栋 Yang Dong], 2015, [中医杂志, Journal of Traditional Chinese Medicine], V56, P1140
   Yang J, 2016, TUMOR BIOL, V37, P13871, DOI 10.1007/s13277-016-5152-5
   Yang Y., 2010, PHARM CLIN CHINESE M, V26, P39
   Yang ZG, 2006, CHEM BIODIVERS, V3, P187, DOI 10.1002/cbdv.200690022
   Ye M., 2016, CHINA MED HERALD, V13, P80
   Yeh JY, 2003, PROSTATE, V54, P112, DOI 10.1002/pros.10172
   Zhang J., 2004, CHIN ARCH TRADIT CHI, V23, P1198, DOI [10.3969/j.issn.1673-7717.2004.07.023, DOI 10.3969/J.ISSN.1673-7717.2004.07.023]
   Zhang J, 2015, ONCOL REP, V34, P2375, DOI 10.3892/or.2015.4213
   Zhang S. Q., 2014, FUJIAN UN TRADITINAL
   Zhang W. T., 2012, STUDY EFFECT 5 KINDS
   Zhang Y., 2009, CHINA ACAD CHINESE M, V4
   Zhang Y. R., 2014, BEIJING U CHINESE TR
   Zheng J., 2011, CELLULAR MOL BIOL CA, P150
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
   Zhou QM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136694
   Zhuang QC, 2012, INT J ONCOL, V40, P1569, DOI 10.3892/ijo.2012.1326
   颜兵, 2012, [中国中医药信息杂志, Chinese Journal of Information on Traditional Chinese Medicine], V19, P93
NR 92
TC 2
Z9 2
U1 0
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2017
VL 2017
AR 4505194
DI 10.1155/2017/4505194
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA FI7AT
UT WOS:000412148700001
PM 29234398
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhou, Z
   Mo, SB
   Dai, WX
   Ying, Z
   Zhang, L
   Xiang, WA
   Han, LY
   Wang, ZM
   Li, QG
   Wang, RJ
   Cai, GX
AF Zhou, Zheng
   Mo, Shaobo
   Dai, Weixing
   Ying, Zhen
   Zhang, Long
   Xiang, Wengiang
   Han, Lingyu
   Wang, Zhimin
   Li, Qingguo
   Wang, Renjie
   Cai, Guoxiang
TI Development and Validation of an Autophagy Score Signature for the
   Prediction of Post-operative Survival in Colorectal Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; early relapse; autophagy; signature; nomogram
ID EARLY RELAPSE; GENE SIGNATURE; STAGES II; STATISTICS; POLYMORPHISMS
AB Background: Survival rates for Colorectal cancer (CRC) patients who experienced early relapse have usually been relatively low. Our study aims at developing an autophagy signature that could help to detect early relapse cases in CRC.
   Methods: Propensity score matching analysis was carried out between patients from the early relapse group and the long-term survival group from GSE39582. For both groups, respectively, global autophagy expression changes were then analyzed to identify the differentially expressed prognostic autophagy related genes by conducting Linear Models for Microarray data method analysis. Then, the multi-gene signature was validated in TCGA and Fudan University Shanghai Cancer Center (FUSCC) cohorts. Time-dependent ROC were used to test the efficiency of this signature feature in predicting the prognosis of CRC patients.
   Results: 5 autophagy genes were finally identified to build an early relapse classifier. With specific risk score formula, patients were classified into low- or high-risk group. Time-dependent ROC analyses proved its prognostic accuracy, with AUC 0.841 and 0.803 at 1 and 3 years, respectively. Then, we validated its prognostic value in two external validation series (GSE17538 and GSE33113) and proved that the result is indeed significant irrespective of datasets in two external independent validation cohorts (TCGA and FUSCC cohorts). A nomogram was constructed to guide individualized treatment of patients with CRC.
   Conclusions: The identification of robust autophagy-related features can effectively classify CRC patients into groups with low and high risk of early relapse. This signature may be used to help select high-risk CRC patients who require more aggressive treatment interventions.
C1 [Zhou, Zheng; Mo, Shaobo; Dai, Weixing; Ying, Zhen; Zhang, Long; Xiang, Wengiang; Han, Lingyu; Li, Qingguo; Wang, Renjie; Cai, Guoxiang] Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China.
   [Zhou, Zheng; Mo, Shaobo; Dai, Weixing; Ying, Zhen; Xiang, Wengiang; Han, Lingyu; Li, Qingguo; Wang, Renjie; Cai, Guoxiang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
   [Zhang, Long] Fudan Univ, Dept Canc Inst, Shanghai Canc Ctr, Shanghai, Peoples R China.
   [Wang, Zhimin] Shanghai Ind Technol Inst, Shanghai MOST Key Lab Hlth & Dis Genom, Chinese Natl Human Genome Ctr, Shanghai, Peoples R China.
RP Li, QG; Wang, RJ; Cai, GX (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Colorectal Surg, Shanghai, Peoples R China.; Li, QG; Wang, RJ; Cai, GX (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.
EM oncosurgeonli@sohu.com; wangbladejay@sina.com; gxcaifuscc@163.com
FU National Key R&D Program of China [2016YFC0905300, 2016YFC0905301];
   Science and Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [16401970502];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572351]; Shanghai Shenkang Program
   [SHDC12014206]; development fund for Shanghai talents [2017120]; FDUROP
   (Fudan's Undergraduate Research Opportunities Program) [18097]
FX The present study was supported by the National Key R&D Program of China
   (Nos. 2016YFC0905300 and 2016YFC0905301), the Grant of Science and
   Technology Commission of Shanghai Municipality (No. 16401970502), the
   Grant of National Natural Science Foundation of China (No. 81572351),
   Shanghai Shenkang Program (No. SHDC12014206), the development fund for
   Shanghai talents (No. 2017120), and FDUROP (Fudan's Undergraduate
   Research Opportunities Program) (No. 18097).
CR Bathe OF, 2014, GENES-BASEL, V5, P536, DOI 10.3390/genes5030536
   Catto JWF, 2010, EUR UROL, V57, P398, DOI 10.1016/j.eururo.2009.10.029
   Chen DT, 2011, JNCI-J NATL CANCER I, V103, P1859, DOI 10.1093/jnci/djr420
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Dai WX, 2018, MOL ONCOL, V12, P463, DOI 10.1002/1878-0261.12175
   Hu XQ, 2013, ASIAN PAC J CANCER P, V14, P6673, DOI 10.7314/APJCP.2013.14.11.6673
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Hwang CC, 2011, ANN SURG ONCOL, V18, P139, DOI 10.1245/s10434-010-1209-7
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Lee HJ, 2015, CELL DEATH DIFFER, V22, P86, DOI 10.1038/cdd.2014.116
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Lu CY, 2011, BRIT J CANCER, V104, P1178, DOI 10.1038/bjc.2011.40
   Mo SB, 2019, CARCINOGENESIS, V40, P861, DOI 10.1093/carcin/bgz031
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Roh SA, 2016, J CANCER RES CLIN, V142, P1705, DOI 10.1007/s00432-016-2177-5
   Saka E, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4266-5
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan IB, 2011, NAT REV CLIN ONCOL, V8, P131, DOI 10.1038/nrclinonc.2010.229
   Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Yang IP, 2012, CARCINOGENESIS, V33, P1522, DOI 10.1093/carcin/bgs166
   Zhang J, 2016, ONCOTARGET, V7, P26516, DOI 10.18632/oncotarget.8530
   Zhang Y, 2015, CANCER LETT, V356, P978, DOI 10.1016/j.canlet.2014.11.013
NR 27
TC 36
Z9 37
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 9
PY 2019
VL 9
AR 878
DI 10.3389/fonc.2019.00878
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IW4SX
UT WOS:000484971100001
PM 31552190
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ito, C
   Matsui, T
   Takano, M
   Wu, TS
   Itoigawa, M
AF Ito, Chihiro
   Matsui, Takuya
   Takano, Makiko
   Wu, Tian-Shung
   Itoigawa, Masataka
TI Anti-cell proliferation effect of naphthoquinone dimers isolated from
   Plumbago zeylanica
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE Plumbago zeylanica; Plumbaginaceae; naphthoquinones; cell proliferation;
   cell cycle
ID CANCER CELLS; APOPTOSIS; AUTOPHAGY; CONSTITUENTS; PATHWAYS; ARREST;
   CYCLE
AB Study of the chemical constituents of the roots of Plumbago zeylanica L. collected in Taiwan led to the isolation and identification of a new naphthoquinone dimer, plumzeylanone (1), along with eight known compounds (2-9). Nine naphthoquinones isolated from this plant were assayed for cell growth inhibition activity using NALM-6 (human B cell precursor leukaemia), A549 (human lung adenocarcinoma), Colo205 (human colorectal adenocarcinoma) and KB (human epidermoid carcinoma). Plumzeylanone (1), a novel plumbagin dimer, suppressed cell proliferation in only NALM-6 cells (IC50 3.98M). However, maritinone (9) showed strong inhibition of cell growth in all cell lines tested (0.12<IC50<9.06M). This compound appeared to affect the cell cycle.
   [GRAPHICS]
   .
C1 [Ito, Chihiro; Matsui, Takuya; Takano, Makiko] Meijo Univ, Fac Pharm, Tempaku, Japan.
   [Matsui, Takuya] Aichi Med Univ, Dept Physiol, Nagakute, Aichi, Japan.
   [Wu, Tian-Shung] Natl Cheng Kung Univ, Dept Chem, Tainan, Taiwan.
   [Itoigawa, Masataka] Tokai Gakuen Univ, Sch Sport & Hlth Sci, Miyoshi, Japan.
RP Matsui, T (corresponding author), Meijo Univ, Fac Pharm, Tempaku, Japan.; Matsui, T (corresponding author), Aichi Med Univ, Dept Physiol, Nagakute, Aichi, Japan.
EM tmatsui@aichi-med-u.ac.jp
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K08353]
FX This work was supported by JSPS KAKENHI [grant number 17K08353].
CR Bae KJ, 2016, BIOCHEM BIOPH RES CO, V473, P272, DOI 10.1016/j.bbrc.2016.03.092
   BINDER RG, 1989, PHYTOCHEMISTRY, V28, P2799, DOI 10.1016/S0031-9422(00)98092-0
   Bringmann G, 1999, PHYTOCHEMISTRY, V51, P693, DOI 10.1016/S0031-9422(99)00080-1
   Demma J, 2009, TOXICOL IN VITRO, V23, P266, DOI 10.1016/j.tiv.2008.12.007
   Feng S, 2016, NAT PROD RES, P1
   Gu JQ, 2004, J NAT PROD, V67, P1156, DOI 10.1021/np040027m
   GUNAHERATH GMKB, 1983, PHYTOCHEMISTRY, V22, P1245, DOI 10.1016/0031-9422(83)80232-5
   Kawamura F, 2010, BIOL PHARM BULL, V33, P881, DOI 10.1248/bpb.33.881
   Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001
   Maruo S, 2013, ORG LETT, V15, P1556, DOI 10.1021/ol400335s
   Mishra BB, 2013, NAT PROD RES, V27, P480, DOI 10.1080/14786419.2012.696254
   Pan ST, 2015, DRUG DES DEV THER, V9, P1601, DOI 10.2147/DDDT.S76057
   Qiu JX, 2015, DRUG DES DEV THER, V9, P349, DOI 10.2147/DDDT.S71677
   Reshma RS, 2016, PHARMACOL RES, V105, P134, DOI 10.1016/j.phrs.2016.01.012
   SANKARAM AVB, 1979, TETRAHEDRON, V35, P1777, DOI 10.1016/0040-4020(79)88008-4
   Sunil C, 2012, FOOD CHEM TOXICOL, V50, P4356, DOI 10.1016/j.fct.2012.08.046
   Wang F, 2015, DRUG DES DEV THER, V9, P537, DOI 10.2147/DDDT.S73689
   Xue YL, 2016, ONCOL LETT, V12, P1095, DOI 10.3892/ol.2016.4725
NR 18
TC 2
Z9 3
U1 1
U2 15
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478-6419
EI 1478-6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PY 2018
VL 32
IS 18
BP 2127
EP 2132
DI 10.1080/14786419.2017.1366476
PG 6
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA GP7EW
UT WOS:000441057100001
PM 28823173
DA 2022-04-25
ER

PT J
AU Vania, L
   Morris, G
   Ferreira, E
   Weiss, SFT
AF Vania, Leila
   Morris, Gavin
   Ferreira, Eloise
   Weiss, Stefan F. T.
TI Knock-down of LRP/LR influences signalling pathways in late-stage
   colorectal carcinoma cells
SO BMC CANCER
LA English
DT Article
DE Colorectal cancer; Small interfering RNAs; Apoptosis; 37 kDa/67 kDa
   laminin receptor; LRP/LR; Telomerase; Proteomics; Therapeutics
AB Background The 37 kDa/67 kDa laminin receptor (LRP/LR) is involved in several tumourigenic-promoting processes including cellular viability maintenance and apoptotic evasion. Thus, the aim of this study was to assess the molecular mechanism of LRP/LR on apoptotic pathways in late stage (DLD-1) colorectal cancer cells upon siRNA-mediated down-regulation of LRP/LR. Methods siRNAs were used to down-regulate the expression of LRP/LR in DLD-1 cells which was assessed using western blotting and qPCR. To evaluate the mechanistic role of LRP/LR, proteomic analysis of pathways involved in proliferation and apoptosis were investigated. The data from the study was analysed using a one-way ANOVA, followed by a two-tailed student's t-test with a confidence interval of 95%. Results Here we show that knock-down of LRP/LR led to significant changes in the proteome of DLD-1 cells, exposing new roles of the protein. Moreover, analysis showed that LRP/LR may alter components of the MAPK, p53-apoptotic and autophagic signalling pathways to aid colorectal cancer cells in continuous growth and survival. Knock-down of LRP/LR also resulted in significant decreases in telomerase activity and telomerase-related proteins in the DLD-1 cells. Conclusions These findings show that LRP/LR is critically implicated in apoptosis and cell viability maintenance and suggest that siRNA-mediated knock-down of LRP/LR may be a possible therapeutic strategy for the treatment of colorectal cancer.
C1 [Vania, Leila; Morris, Gavin; Ferreira, Eloise; Weiss, Stefan F. T.] Univ Witwatersrand, Sch Mol & Cell Biol, Private Bag 3, ZA-2050 Johannesburg, South Africa.
RP Weiss, SFT (corresponding author), Univ Witwatersrand, Sch Mol & Cell Biol, Private Bag 3, ZA-2050 Johannesburg, South Africa.
EM stefan.weiss@wits.ac.za
FU National Research Foundation (NRF), the Republic of South Africa (RSA)
   [99061, 92745, 109298]; South African Medical Research Council (MRC)
   under the Wits Common Epithelial Cancer Research Centre (CECRC) grant;
   Cancer Association of South Africa (CANSA)
FX This work is based upon research supported by the National Research
   Foundation (NRF), the Republic of South Africa (RSA). Grant Numbers
   99061, 92745 and 109298. Any opinions, findings and conclusions or
   recommendations expressed in this material are those of the author(s),
   and therefore, the National Research Foundation does not accept any
   liability in this regard thereto. Financial support was received from
   the South African Medical Research Council (MRC) under the Wits Common
   Epithelial Cancer Research Centre (CECRC) grant. Any opinions, findings
   and conclusions or recommendations expressed in this material are those
   of the author(s), and therefore, the MRC does not accept any liability
   in this regard thereto. Financial support was further received from the
   Cancer Association of South Africa (CANSA). Any opinions, findings and
   conclusions or recommendations expressed in this material are those of
   the author(s), and therefore, CANSA does not accept any liability in
   this regard thereto.
CR BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chetty CJ, 2017, EXP CELL RES, V360, P264, DOI 10.1016/j.yexcr.2017.09.016
   Choi CH, 2015, PATHOBIOLOGY, V82, P203, DOI 10.1159/000434726
   Choi JK, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040010
   Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dias BD, 2014, SCI REP-UK, V4, DOI 10.1038/srep05556
   DiGiacomo V, 2016, BIOL REV, V91, P288, DOI 10.1111/brv.12170
   Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863
   Jovanovic K, 2015, EXPERT OPIN THER PAT, V25, P567, DOI 10.1517/13543776.2015.1014802
   Khusal R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058888
   Kinoshita K, 1998, BIOCHEM BIOPH RES CO, V253, P277, DOI 10.1006/bbrc.1998.9699
   Lee J, 2008, ONCOGENE, V27, P3754, DOI 10.1038/sj.onc.1211037
   Ludwig C, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178126
   Maciejowski J, 2017, NAT REV MOL CELL BIO, V18, P175, DOI 10.1038/nrm.2016.171
   Maida Y, 2002, ONCOGENE, V21, P4071, DOI 10.1038/sj.onc.1205509
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Modugno M, 2002, ONCOGENE, V21, P7478, DOI 10.1038/sj.onc.1205957
   Naidoo K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141618
   Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955
   Nelson J, 2008, BIOSCIENCE REP, V28, P33, DOI 10.1042/BSR20070004
   O'Donohue MF, 2010, J CELL BIOL, V190, P853, DOI 10.1083/jcb.201005117
   Olive PL, 2009, AGING-US, V1, P154, DOI 10.18632/aging.100025
   Omar A, 2012, J MOL BIOL, V419, P102, DOI 10.1016/j.jmb.2012.02.035
   Otgaar TC, 2017, ONCOTARGET, V8, P86646, DOI 10.18632/oncotarget.21278
   Poggesi M, 2013, MADAME CURIE BIOSCIE
   Rahman R, 2005, ONCOGENE, V24, P1320, DOI 10.1038/sj.onc.1208232
   Rebelo TM, 2018, EXP CELL RES, V368, P1, DOI 10.1016/j.yexcr.2018.04.003
   Rebelo TM, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2953-2
   Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337
   Shay JW, 2005, CARCINOGENESIS, V26, P867, DOI 10.1093/carcin/bgh296
   Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049
   Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000
   Sun L, 2014, CANCER SCI, V105, P651, DOI 10.1111/cas.12414
   Sundquist T., 2006, CELL NOTES, V16, P18
   Thepparit C, 2004, J VIROL, V78, P12647, DOI 10.1128/JVI.78.22.12647-12656.2004
   Vania L, 2019, EXPERT OPIN THER PAT, V29, P987, DOI 10.1080/13543776.2019.1693543
   Vania L, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4531-2
   Vania L, 2016, MOL MED, V22, P664, DOI 10.2119/molmed.2016.00169
   Venticinque L, 2012, J PROTEOME RES, V11, P4863, DOI 10.1021/pr300307h
   Venticinque L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015895
   Wen AY, 2010, J IMMUNOL, V185, P6413, DOI 10.4049/jimmunol.1001829
   WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C
   Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890
   Yoon H, 2015, J HISTOCHEM CYTOCHEM, V63, P114, DOI 10.1369/0022155414561498
   Yoshida R, 1999, ANTICANCER RES, V19, P2167
   Yuan XT, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133338
NR 48
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 9
PY 2021
VL 21
IS 1
AR 392
DI 10.1186/s12885-021-08081-3
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RL6UN
UT WOS:000639105700010
PM 33836696
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhu, QY
   Meng, YX
   Li, SW
   Xin, JY
   Du, ML
   Wang, ML
   Cheng, G
AF Zhu, Qiuyuan
   Meng, Yixuan
   Li, Shuwei
   Xin, Junyi
   Du, Mulong
   Wang, Meilin
   Cheng, Gong
TI Association of genetic variants in autophagy-lysosome pathway genes with
   susceptibility and survival to prostate cancer
SO GENE
LA English
DT Article
DE SLC11A1; Single nucleotide polymorphism; Risk; Prognosis
ID ACTIVE SURVEILLANCE; RISK; SLC11A1; POLYMORPHISMS; BIOMARKERS;
   TRANSPORT; MANGANESE; DISEASE
AB Background: Previous studies have indicated the connections between autophagy-lysosome pathway genes dysfunction and prostate cancer, but few studies have investigated whether single nucleotide polymorphisms (SNPs) in autophagy-lysosome pathway genes are implicated in prostate cancer risk and survival.
   Materials and methods: Logistic regression analysis and stepwise Cox regression analysis were conducted in 4,662 cases and 3,114 controls from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. The false positive rate probability (FPRP) method was applied to correct for multiple comparisons. Gene-based analysis was calculated by versatile gene-based association study approach.
   Results: We found that SLC11A1 rs7573065 significantly increased the risk of prostate cancer [adjusted odds ratio (OR) = 1.24, 95% confidence interval (CI) = 1.06-1.46, P = 7.02 x 10(-3), FPRP = 0.082]. Furthermore, rs7573065 was confirmed as the independent predicator of overall survival (OS) for prostate cancer patients [Hazard ratio (HR) = 1.30, 95% CI = 1.01-1.66, P = 0.041]. The significant association between SLC11A1 and prostate cancer risk was calculated by gene-based analysis (P = 0.030). We also observed that the mRNA of SLC11A1 in prostate tumor tissues was significantly over-expressed than that in normal tissues.
   Conclusion: This study suggested that rs7573065 in SLC11A1 was associated with an increased risk and poor OS of prostate cancer. Our findings may provide evidence for genetic variants in autophagy-lysosome pathway as the risk and prognostic biomarkers for prostate cancer.
C1 [Zhu, Qiuyuan; Cheng, Gong] Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Peoples R China.
   [Zhu, Qiuyuan; Meng, Yixuan; Li, Shuwei; Xin, Junyi; Wang, Meilin] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Genet Toxicol,Key Lab Modern Toxicol,Minist, Nanjing, Peoples R China.
   [Du, Mulong] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, Nanjing, Peoples R China.
RP Cheng, G (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Urol, Nanjing, Peoples R China.
EM gcheng@njmu.edu.cn
CR Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580-019-0185-4
   Blessing AM, 2017, AUTOPHAGY, V13, P506, DOI 10.1080/15548627.2016.1268300
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cao DL, 2020, CANCER MED-US, V9, P9462, DOI 10.1002/cam4.3538
   Chistiakov DA, 2018, SEMIN CANCER BIOL, V52, P9, DOI 10.1016/j.semcancer.2018.01.012
   Cucchiara V, 2018, EUR UROL, V73, P572, DOI 10.1016/j.eururo.2017.10.036
   Culp MB, 2020, EUR UROL, V77, P38, DOI 10.1016/j.eururo.2019.08.005
   Cuzick J, 2014, LANCET ONCOL, V15, pE484, DOI 10.1016/S1470-2045(14)70211-6
   de la Rosa J, 2017, NAT GENET, V49, P730, DOI 10.1038/ng.3817
   Farrow JM, 2014, NAT REV UROL, V11, P508, DOI 10.1038/nrurol.2014.196
   Fenton JJ, 2018, JAMA-J AM MED ASSOC, V319, P1914, DOI 10.1001/jama.2018.3712
   Forbes JR, 2003, BLOOD, V102, P1884, DOI 10.1182/blood-2003-02-0425
   Forbes JR, 2001, TRENDS MICROBIOL, V9, P397, DOI 10.1016/S0966-842X(01)02098-4
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   GAO X, 1995, CANCER RES, V55, P1002
   Gohagan JK, 2015, REV RECENT CLIN TRIA, V10, P173, DOI 10.2174/1574887110666150730123004
   Hu DX, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02323-x
   Huang CY, 2015, SCI REP-UK, V5, DOI 10.1038/srep14045
   Islami F, 2014, EUR UROL, V66, P1054, DOI 10.1016/j.eururo.2014.08.059
   Jabado N, 2000, J EXP MED, V192, P1237, DOI 10.1084/jem.192.9.1237
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Klotz L, 2014, CURR OPIN UROL, V24, P270, DOI 10.1097/MOU.0000000000000055
   Leongamornlert DA, 2019, EUR UROL, V76, P329, DOI 10.1016/j.eururo.2019.01.050
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li WQ, 2018, EUR UROL, V74, P710, DOI 10.1016/j.eururo.2018.06.021
   Liu JZ, 2010, AM J HUM GENET, V87, P139, DOI 10.1016/j.ajhg.2010.06.009
   Loeb S, 2015, EUR UROL, V67, P619, DOI 10.1016/j.eururo.2014.10.010
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Pernar CH, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a030361
   Romero-Gomez M, 2004, GUT, V53, P446, DOI 10.1136/gut.2003.028274
   Schumacher FR, 2018, NAT GENET, V50, P928, DOI 10.1038/s41588-018-0142-8
   Shui IM, 2014, EUR UROL, V65, P1069, DOI 10.1016/j.eururo.2013.12.058
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Tan J, 2018, INT J CANCER, V143, P80, DOI 10.1002/ijc.31288
   Tangen CM, 2016, J CLIN ONCOL, V34, P4338, DOI 10.1200/JCO.2016.68.1965
   Tryka KA, 2014, NUCLEIC ACIDS RES, V42, pD975, DOI 10.1093/nar/gkt1211
   Wacholder S, 2004, J NATL CANCER I, V96, P434, DOI 10.1093/jnci/djh075
   Yang JHM, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-59
   Yang L, 2016, J CLIN ONCOL, V34, P4231, DOI 10.1200/JCO.2016.68.4837
   Yeager M, 2007, NAT GENET, V39, P645, DOI 10.1038/ng2022
   Yu L, 2018, ONCOL LETT, V15, P9413, DOI 10.3892/ol.2018.8504
   Zaahl MG, 2005, CANCER GENET CYTOGEN, V159, P48, DOI 10.1016/j.cancergencyto.2004.09.017
   Zaahl MG, 2004, BLOOD CELL MOL DIS, V33, P45, DOI 10.1016/j.bcmd.2004.04.003
   Zaahl MG, 2006, INT J COLORECTAL DIS, V21, P402, DOI 10.1007/s00384-005-0019-z
   Zhu XY, 2012, EUR UROL, V61, P652, DOI 10.1016/j.eururo.2011.11.029
NR 46
TC 0
Z9 0
U1 9
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD JAN 15
PY 2022
VL 808
AR 145953
DI 10.1016/j.gene.2021.145953
EA OCT 2021
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA WG2VH
UT WOS:000706854800001
PM 34500048
DA 2022-04-25
ER

PT J
AU Zhang, HS
   Xu, G
   Wu, SH
   Gong, L
   Zhou, YY
   Li, XM
AF Zhang, Haosheng
   Xu, Gang
   Wu, Shihai
   Gong, Long
   Zhou, Yayan
   Li, Xianming
TI THE MECHANISM OF CAIX IN TUMOR THERAPY AND ITS INFLUENCE ON PATIENT
   PROGNOSIS
SO ACTA MEDICA MEDITERRANEA
LA English
DT Article
DE Carbonic anhydrase IX (CAIX); PH; radiosensitivity; chemotherapy
   sensitivity
ID CARBONIC-ANHYDRASE IX; CARCINOMA-CELL LINE; ENHANCES RADIOSENSITIVITY;
   CANCER-THERAPY; AUTOPHAGY; HYPOXIA; ACIDITY; TARGET
AB The carbonic anhydrase IX (CAIX) family (originally named MN/G250) is a type of zinc-containing metalloenzyme family of cell surface transmembrane protein v. Many studies worldwide have demonstrated that CAIX is a protease that rapidly converts CO2 and H2O into H+ and HCO3-. its main mechanism in cells is to act as a "proton pump" in similar cells to maintain the weak alkalinity and extracelltdar acidic microenvironment of tumour cells. The positive expression of CAIX protein can be detected in trimly tumours such as nasopharyngeal carcinoma, cervical cancer, breast cancer, rectal cancer and gastric cancer, and is related to the occurrence and development of the tumour as well as the therapeutic effect and prognosis of patients. Therefore, the mechanism of CAIX in rumour cells is described in this paper, and the relationship between the expression of CAIX in cells and tumour treatment and prognosis is also discussed.
C1 [Zhang, Haosheng; Xu, Gang; Wu, Shihai; Gong, Long; Zhou, Yayan; Li, Xianming] Southern Univ Sci & Technol, Affiliated Hosp 1, Clin Med Coll 2, Dept Radiat Oncol,Shenzhen Peoples Hosp,Jinan Uni, Shenzhen 518020, Guangdong, Peoples R China.
RP Li, XM (corresponding author), Southern Univ Sci & Technol, Affiliated Hosp 1, Clin Med Coll 2, Dept Radiat Oncol,Shenzhen Peoples Hosp,Jinan Uni, Shenzhen 518020, Guangdong, Peoples R China.
EM lxm1828@hotmail.com
CR Andersen CJ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060764
   Aspatwar A, 2018, J ENZYM INHIB MED CH, V33, P1064, DOI 10.1080/14756366.2018.1482285
   Chen Xinwei, 2016, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V30, P42
   Chen YH, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0304-1
   Denoyer D, 2015, METALLOMICS, V7, P1459, DOI 10.1039/c5mt00149h
   Huber V, 2017, SEMIN CANCER BIOL, V43, P74, DOI 10.1016/j.semcancer.2017.03.001
   Huizing FJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54824-5
   Hussein EM, 2019, BMC CHEM, V13, DOI 10.1186/s13065-019-0603-x
   Jan YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0698-5
   Jiang LJ, 2017, ONCOTARGETS THER, V10, P4701, DOI 10.2147/OTT.S144756
   Khoshinani HM, 2016, CANCER INVEST, V34, P536, DOI 10.1080/07357907.2016.1245317
   Kim BR, 2012, CELL SIGNAL, V24, P1406, DOI 10.1016/j.cellsig.2012.03.002
   Kim SR, 2016, INT J RADIAT BIOL, V92, P502, DOI 10.1080/09553002.2016.1206222
   Kopecka J, 2016, ONCOTARGET, V7, P85861, DOI 10.18632/oncotarget.13040
   Lacroix R, 2018, CANCER IMMUNOL IMMUN, V67, P1331, DOI 10.1007/s00262-018-2195-z
   Lai E, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101926
   Lee CT, 2014, ANTIOXID REDOX SIGN, V21, P313, DOI 10.1089/ars.2013.5759
   Luo YT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11500-6
   McDonald PC, 2019, GASTROENTEROLOGY, V157, P823, DOI 10.1053/j.gastro.2019.05.004
   Najy AJ, 2016, AM J PHYSIOL-CELL PH, V310, pC293, DOI 10.1152/ajpcell.00043.2015
   Pastorek J, 2015, SEMIN CANCER BIOL, V31, P52, DOI 10.1016/j.semcancer.2014.08.002
   Pellegrini P, 2016, ONCOTARGET, V7, P35703, DOI 10.18632/oncotarget.9601
   Pilon-Thomas S, 2016, CANCER RES, V76, P1381, DOI 10.1158/0008-5472.CAN-15-1743
   Rabiee S, 2019, J CELL PHYSIOL, V234, P12061, DOI 10.1002/jcp.27876
   Ren JL, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0708-x
   Rzepakowska A, 2019, EUR ARCH OTO-RHINO-L, V276, P1
   Salaroglio IC, 2018, MOL CANCER THER, V17, P2598, DOI 10.1158/1535-7163.MCT-18-0533
   Song JR, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.68
   Suresh PK, 2017, ACTA CYTOL, V61, P199, DOI 10.1159/000471916
   Takacova M, 2013, ONCOL LETT, V5, P191, DOI 10.3892/ol.2012.1001
   Tang M, 2020, ARTIF CELL NANOMED B, V48, P159, DOI 10.1080/21691401.2019.1699822
   Taylor MA, 2018, APOPTOSIS, V23, P563, DOI 10.1007/s10495-018-1480-9
   Tsai MM, 2014, WORLD J GASTROENTERO, V20, P13791, DOI 10.3748/wjg.v20.i38.13791
   von Neubeck B, 2018, INT J CANCER, V143, P2065, DOI 10.1002/ijc.31607
   Wachters JE, 2013, LARYNGOSCOPE, V123, P2154, DOI 10.1002/lary.23831
   Waheed A, 2017, GENE, V623, P33, DOI 10.1016/j.gene.2017.04.027
   Wang F, 2018, CELL PHYSIOL BIOCHEM, V45, P54, DOI 10.1159/000486222
   Wang W, 2016, EUR REV MED PHARMACO, V20, P92
   Wang YS, 2014, ACTA OTO-LARYNGOL, V134, P105, DOI 10.3109/00016489.2013.844365
   Ward C, 2018, METABOLITES, V8, DOI 10.3390/metabo8010013
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Xin Y, 2017, J CANCER RES CLIN, V143, P2147, DOI 10.1007/s00432-017-2487-2
   Xu H, 2018, COMPR PHYSIOL, V8, P555, DOI 10.1002/cphy.c170027
   Zhou H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19069-0
NR 45
TC 0
Z9 0
U1 3
U2 4
PU CARBONE EDITORE
PI PALERMO
PA VIA QUINTINO SELLA, 68, PALERMO, 90139, ITALY
SN 0393-6384
EI 2283-9720
J9 ACTA MEDICA MEDITERR
JI Acta Medica Mediterr.
PY 2020
VL 36
IS 6
BP 3661
EP 3667
DI 10.19193/0393-6384_2020_6_580
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA PE6WK
UT WOS:000598504300079
DA 2022-04-25
ER

PT J
AU Huang, YY
   Du, J
   Mi, Y
   Li, TY
   Gong, Y
   Ouyang, HS
   Hou, Y
AF Huang, Yongye
   Du, Juan
   Mi, Yan
   Li, Tianye
   Gong, Ying
   Ouyang, Hongsheng
   Hou, Yue
TI Long Non-coding RNAs Contribute to the Inhibition of Proliferation and
   EMT by Pterostilbene in Human Breast Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE pterostilbene; lncRNAs; cancer; autophagy; epithelial-to-mesenchymal
   transition
ID EPITHELIAL-MESENCHYMAL TRANSITION; ENDOPLASMIC-RETICULUM STRESS;
   COLORECTAL-CANCER; E-CADHERIN; CELLS; AUTOPHAGY; PROMOTES; METASTASIS;
   LNCRNA; MICROENVIRONMENT
AB Background: There is increasing evidence that long non-coding RNAs (lncRNAs) are involved in the process of carcinogenesis and treatment using chemotherapy. Pterostilbene, a phytochemical agent with natural antioxidant and anti-inflammatory properties, has been shown to modulate oncogenic processes in many cancers. However, there has been limited research on the association between pterostilbene and the expression of lncRNAs.
   Methods: MCF7 breast cancer cells were treated with various concentrations of pterostilbene and their gene expression profile was analyzed by quantitative real-time PCR, Western blotting and immunofluorescence.
   Results: Treatment with pterostilbene inhibited cell proliferation and epithelial-to-mesenchymal transition (EMT), and increased cell apoptosis, autophagy and ER stress. The Akt/mTOR pathway was downregulated, but p38 MAPK/Erk signaling was activated in cells following treatment with pterostilbene. Pterostilbene increased the expression of the lncRNAs MEG3, TUG1, H19, and DICER1-AS1 whereas the expression of LINC01121, PTTG3P, and HOTAIR declined. Knockdown of lncRNA H19 resulted in a reduction of the cell invasion, with the cells becoming more sensitive to pterostilbene therapy.
   Conclusions: These results suggest that efficient optimum disruption of lncRNA expression might possibly improve the anti-tumor effects of phytochemical agents, thus serving as a potential therapy for breast cancer.
C1 [Huang, Yongye; Du, Juan; Mi, Yan; Li, Tianye; Gong, Ying; Hou, Yue] Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Liaoning, Peoples R China.
   [Ouyang, Hongsheng] Jilin Univ, Coll Anim Sci, Jilin Prov Key Lab Anim Embryo Engn, Changchun, Jilin, Peoples R China.
RP Hou, Y (corresponding author), Northeastern Univ, Coll Life & Hlth Sci, Shenyang, Liaoning, Peoples R China.; Ouyang, HS (corresponding author), Jilin Univ, Coll Anim Sci, Jilin Prov Key Lab Anim Embryo Engn, Changchun, Jilin, Peoples R China.
EM ouyh@jlu.edu.cn; houyue@mail.neu.edu.cn
OI Huang, Yongye/0000-0002-9083-250X
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81502582, 81473330, U1603125]; Program for
   JLU Science and Technology Innovative Research Team [2017TD-28];
   Fundamental Research Funds for the Central Universities of
   ChinaFundamental Research Funds for the Central Universities
   [N162004003]; Fundamental Research Funds for the Central
   UniversitiesFundamental Research Funds for the Central Universities
FX This work was supported by the National Natural Science Foundation of
   China (No. 81502582, No. 81473330 and U1603125). This work was also
   financially supported by the Program for JLU Science and Technology
   Innovative Research Team (2017TD-28), Fundamental Research Funds for the
   Central Universities of China (N162004003), and Fundamental Research
   Funds for the Central Universities.
CR Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   Barber AG, 2015, CANCER MED-US, V4, P1258, DOI 10.1002/cam4.463
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Chen RJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010287
   Chen RJ, 2010, MOL NUTR FOOD RES, V54, P1819, DOI 10.1002/mnfr.201000067
   Chen RB, 2017, NUCLEIC ACIDS RES, V45, P9947, DOI 10.1093/nar/gkx600
   Cheng JC, 2010, MOL ENDOCRINOL, V24, P1569, DOI 10.1210/me.2010-0034
   Chunharojrith P, 2015, MOL CELL ENDOCRINOL, V416, P27, DOI 10.1016/j.mce.2015.08.018
   Daniel M, 2018, J CELL BIOCHEM, V119, P3326, DOI 10.1002/jcb.26495
   Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006
   Ding DY, 2018, MOL CELLS, V41, P423, DOI 10.14348/molcells.2018.2258
   Ding WX, 2007, AM J PATHOL, V171, P513, DOI 10.2353/ajpath.2007.070188
   Frith Martin C, 2006, RNA Biol, V3, P40
   Galehdar Z, 2010, J NEUROSCI, V30, P16938, DOI 10.1523/JNEUROSCI.1598-10.2010
   Grille SJ, 2003, CANCER RES, V63, P2172
   Gu ZH, 2018, BIOMED PHARMACOTHER, V104, P110, DOI 10.1016/j.biopha.2018.04.193
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Han JG, 2018, TOXICOL APPL PHARM, V359, P55, DOI 10.1016/j.taap.2018.09.018
   Hougee S, 2005, PLANTA MED, V71, P387, DOI 10.1055/s-2005-864130
   Huang JL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0841-x
   Hung CM, 2017, J AGR FOOD CHEM, V65, P11179, DOI 10.1021/acs.jafc.7b02358
   Jia LW, 2018, ONCOTARGETS THER, V11, P313, DOI 10.2147/OTT.S154339
   Jing GJ, 2012, EXP DIABETES RES, DOI 10.1155/2012/589589
   Li H, 2018, EXP THER MED, V16, P779, DOI 10.3892/etm.2018.6216
   Li LX, 2018, CELL PHYSIOL BIOCHEM, V48, P1723, DOI 10.1159/000492300
   Liu S, 2018, J CELL BIOCHEM, V119, P9694, DOI 10.1002/jcb.27284
   Lu L, 2016, CANCER MED-US, V5, P3544, DOI 10.1002/cam4.946
   Mak KK, 2013, MOL NUTR FOOD RES, V57, P1123, DOI 10.1002/mnfr.201200549
   Mathiyalagan R, 2017, NANOMEDICINE-UK, V12, P1091, DOI 10.2217/nnm-2017-0070
   Pan L, 2018, ONCOTARGET, V9, P1915, DOI 10.18632/oncotarget.23019
   Papandreou I, 2015, EXP CELL RES, V339, P147, DOI 10.1016/j.yexcr.2015.10.014
   Qian YG, 2018, CELL PHYSIOL BIOCHEM, V47, P1007, DOI 10.1159/000490167
   Qian YY, 2018, BIOMED PHARMACOTHER, V101, P852, DOI 10.1016/j.biopha.2018.03.022
   Rashid HO, 2015, AUTOPHAGY, V11, P1956, DOI 10.1080/15548627.2015.1091141
   Ren G, 2018, BIOCHEM BIOPH RES CO, V498, P640, DOI 10.1016/j.bbrc.2018.03.035
   Singh JC, 2017, ONCOLOGIST, V22, P139, DOI 10.1634/theoncologist.2016-0268
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Wang HJ, 2018, BIOMED PHARMACOTHER, V106, P1607, DOI 10.1016/j.biopha.2018.07.131
   Wu KF, 2017, EXP CELL RES, V350, P312, DOI 10.1016/j.yexcr.2016.12.003
   Xing F, 2016, CANCER RES, V76, P4970, DOI 10.1158/0008-5472.CAN-15-3541
   Yoshimura H, 2018, FRONT BIOSCI-LANDMRK, V23, P614, DOI 10.2741/4608
   Zhang H, 2016, BIOCHEM BIOPH RES CO, V478, P845, DOI 10.1016/j.bbrc.2016.08.035
   Zhang QQ, 2018, J CELL BIOCHEM, V119, P4447, DOI 10.1002/jcb.26537
   Zhou W, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aak9557
NR 45
TC 26
Z9 26
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD DEC 18
PY 2018
VL 8
AR 629
DI 10.3389/fonc.2018.00629
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HE7WO
UT WOS:000453651800003
PM 30619763
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Yan, ZL
   Ohuchida, K
   Fei, S
   Zheng, B
   Guan, WY
   Feng, HM
   Kibe, S
   Ando, Y
   Koikawa, K
   Abe, T
   Iwamoto, C
   Shindo, K
   Moriyama, T
   Nakata, K
   Miyasaka, Y
   Ohtsuka, T
   Mizumoto, K
   Hashizume, M
   Nakamura, M
AF Yan, Zilong
   Ohuchida, Kenoki
   Fei, Shuang
   Zheng, Biao
   Guan, Weiyu
   Feng, Haimin
   Kibe, Shin
   Ando, Yohei
   Koikawa, Kazuhiro
   Abe, Toshiya
   Iwamoto, Chika
   Shindo, Koji
   Moriyama, Taiki
   Nakata, Kohei
   Miyasaka, Yoshihiro
   Ohtsuka, Takao
   Mizumoto, Kazuhiro
   Hashizume, Makoto
   Nakamura, Masafumi
TI Inhibition of ERK1/2 in cancer-associated pancreatic stellate cells
   suppresses cancer-stromal interaction and metastasis
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE ERK1/2; Pancreatic cancer; Cancer-stromal interaction; Pancreatic
   stellate cell; Cellular senescence
ID SENESCENCE; PATHWAY; GROWTH; TUMORS; DESMOPLASIA; PROGRESSION;
   AUTOPHAGY; MODELS
AB BackgroundExtracellular signal-regulated kinases (ERKs) have been related to multiple cancers, including breast cancer, hepatocellular cancer, lung cancer and colorectal cancer. ERK1/2 inhibitor can suppress growth of KRAS-mutant pancreatic tumors by targeting cancer cell. However, no studies have shown the expression of ERK1/2 on pancreatic stromal and its effect on pancreatic cancer-stromal interaction.MethodsImmunohistochemistry and western blotting were performed to detect the expression of p-ERK1/2 in pancreatic tissues and cells. Cell viability assay was used to study IC50 of ERK inhibitor on pancreatic cancer cells (PCCs) and primary cancer-associated pancreatic stellate cells (PSCs). Transwell migration, invasion, cell viability assay, senescence -galactosidase staining were performed to determine the effect of ERK inhibitor on PCCs and PSCs in vitro and in vivo. The expression of key factors involved in autophagy and epithelial-to-mesenchymal transition (EMT) process were evaluated by western blotting. The expression of key factors related to cell invasiveness and malignancy were confirmed by qRT-PCR. Co-transplantation of PCC Organoid and PSC using a splenic xenograft mouse model was used to evaluated combined treatment of ERK inhibitor and autophagy inhibitor.ResultsImmunohistochemical staining in pancreatic tumor samples and transgenetic mice detected p-ERK1/2 expression in both cancer cells and stromal cells. In pancreatic tissues, p-ERK1/2 was strongly expressed in cancer-associated PSCs compared with cancer cells and normal PSCs. PSCs were also significantly more sensitive to ERK1/2 inhibitor treatment. Inhibition of ERK1/2 suppressed EMT transition in HMPCCs, upregulated cellular senescence markers, activated autophagy in cancer-associated PSCs; and suppressed cancer-stromal interaction, which enhanced invasiveness and viability of cancer cells. We also found that chloroquine, an autophagy inhibitor, suppressed ERK inhibition-induced autophagy and promoted PSC cellular senescence, leading to significantly decreased cell proliferation. The combination of an ERK inhibitor and autophagy inhibitor suppressed liver metastasis in a splenic pancreatic cancer organoid xenograft mouse model.ConclusionsThese data indicate that inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.
C1 [Yan, Zilong; Ohuchida, Kenoki; Fei, Shuang; Zheng, Biao; Guan, Weiyu; Feng, Haimin; Kibe, Shin; Ando, Yohei; Koikawa, Kazuhiro; Abe, Toshiya; Shindo, Koji; Moriyama, Taiki; Nakata, Kohei; Miyasaka, Yoshihiro; Ohtsuka, Takao; Nakamura, Masafumi] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
   [Ohuchida, Kenoki; Iwamoto, Chika; Hashizume, Makoto] Kyushu Univ, Grad Sch Med Sci, Dept Adv Med Initiat, Fukuoka, Fukuoka, Japan.
   [Zheng, Biao] Shenzhen Univ, Gen Hosp, Dept Gen Surg, Shenzhen, Peoples R China.
   [Mizumoto, Kazuhiro] Kyushu Univ Hosp, Canc Ctr, Fukuoka, Fukuoka, Japan.
RP Ohuchida, K; Nakamura, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
EM kenoki@surg1.med.kyushu-u.ac.jp; mnaka@surg1.med.kyushu-u.ac.jp
RI Abe, Toshiya/AAT-2579-2021
OI Koikawa, Kazuhiro/0000-0002-3208-9447
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [26108010,
   26293305, 15 K10185, 25713050, 16 K15621, 16 K10601, 16 K10600,
   16H05417, 15 K15498, 15H04933, 16H05418, 17H04284, 17 K19602, 17 K19605]
FX This work was supported by JSPS KAKENHI (Grant numbers: 26108010,
   26293305, 15 K10185, 25713050, 16 K15621, 16 K10601, 16 K10600,
   16H05417, 15 K15498, 15H04933, 16H05418, 17H04284, 17 K19602 and 17
   K19605).
CR Ai X, 2013, CANCER BIOL THER, V14, P1059, DOI 10.4161/cbt.26427
   Apte MV, 1998, GUT
   Apte MV, 1999, GUT
   Bachem MG, 2005, GASTROENTEROLOGY
   Bachem MG, 1998, GASTROENTEROLOGY
   Bartholomeusz C, 2008, CANC RES
   Bartholomeusz C, 2012, ONCOLOGIST
   Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021
   Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438
   Capparelli C, 2012, CELL CYCLE
   Cerami E, 2012, CANC DISCOV
   Chadha KS, 2006, ANN SURG ONCOL
   Chijiiwa Y, 2016, INT J ONCOL, V48, P1688, DOI 10.3892/ijo.2016.3389
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Conciatori F, 2018, J EXP CLIN CANC RES, P1
   Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071
   Endo S, 2017, GASTROENTEROLOGY, V152, P1492, DOI 10.1053/j.gastro.2017.01.010
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garcia-Prat L, 2016, NATURE
   Gleisner AL, 2007, CANCER-AM CANCER SOC, V110, P2484, DOI 10.1002/cncr.23074
   Hayes TK, 2016, CANCER CELL, V29, P75, DOI 10.1016/j.ccell.2015.11.011
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Howlader N, 2016, SEER CANC STAT REV 1
   Huang L, 2015, NAT MED
   Ikenaga N, 2010, GASTROENTEROLOGY, V139, P1041, DOI 10.1053/j.gastro.2010.05.084
   Javle MM, 2007, ANN SURG ONCOL
   Kang HT, 2011, PLOS ONE
   Kikuta K, 2010, BIOCHEM BIOPH RES CO, V403, P380, DOI 10.1016/j.bbrc.2010.11.040
   Koikawa K, 2018, CANC LETT
   Kozono S, 2013, CANCER RES, V73, P2345, DOI 10.1158/0008-5472.CAN-12-3180
   Lee SH, 2018, CELL
   Mahadevan D, 2007, MOL CANCER THER, V6, P1186, DOI 10.1158/1535-7163.MCT-06-0686
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001
   Minchinton AI, 2006, NAT REV CANC
   Mirzayans R, 2012, BIOCHEM RES INT, V2012, DOI 10.1155/2012/951574
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070
   Neesse A, 2011, GUT
   Ng KH, 2017, EMBEDDED COURTS: JUDICIAL DECISION-MAKING IN CHINA, P1
   Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464
   Pandol S, 2009, CLIN GASTROENTEROL H
   Principe DR, 2017, ONCOGENE, V36, P4336, DOI 10.1038/onc.2016.500
   Rayess H, 2012, INT J CANC
   Stewart B., 2014, WORLD CANC REPORT 20
   Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916
   Virtakoivu R, 2015, CANC RES
   Wang L, 2005, CANC CELL
   Wang T, 2017, MOL CANC RES
   Whatcott CJ, 2015, CLIN CANCER RES, V21, P3561, DOI 10.1158/1078-0432.CCR-14-1051
   White E., 2016, COLD SPRING HARB PER
   Yan ZL, 2019, J CANCER RES CLIN, V145, P1147, DOI 10.1007/s00432-019-02860-z
   Yoshida M, 2016, CALPAIN INHIBITOR CA, V107
   Yu Y, 2011, ANTICANCER RES, V31, P1147
   Zheng B, 2016, MOL CARCINOGEN, V55, P1560, DOI 10.1002/mc.22409
NR 54
TC 25
Z9 27
U1 5
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD MAY 27
PY 2019
VL 38
AR 221
DI 10.1186/s13046-019-1226-8
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IA2MM
UT WOS:000469395500001
PM 31133044
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lenis-Rojas, OA
   Cabral, R
   Carvalho, B
   Friaes, S
   Roma-Rodrigues, C
   Fernandez, JAA
   Vila, SF
   Sanchez, L
   Gomes, CSB
   Fernandes, AR
   Royo, B
AF Lenis-Rojas, Oscar A.
   Cabral, Rui
   Carvalho, Beatriz
   Friaes, Sofia
   Roma-Rodrigues, Catarina
   Fernandez, Jhonathan A. A.
   Vila, Sabela F.
   Sanchez, Laura
   Gomes, Clara S. B.
   Fernandes, Alexandra R.
   Royo, Beatriz
TI Triazole-Based Half-Sandwich Ruthenium(II) Compounds: From In Vitro
   Antiproliferative Potential to In Vivo Toxicity Evaluation
SO INORGANIC CHEMISTRY
LA English
DT Article
ID CYTOTOXIC RUTHENIUM(II); ANTICANCER DRUGS; CROSS-RESISTANCE; CANCER
   CELLS; COMPLEXES; APOPTOSIS; INVASION; BINDING; DETERMINANTS; MODULATION
AB A new series of half-sandwich ruthenium(II) compounds [(eta(6)-arene)Ru(L)Cl][CF3SO3] bearing 1,2,3-triazole ligands (arene = p-cymene, L = L1 (1); arene = p-cymene, L = L2 (2); arene = benzene, L = L1 (3); arene = benzene, L2 (4); L1 = 2-[1-(p-tolyl)-1H-1,2,3-triazol-4-yl]pyridine and L2 = 1,1'-di-p-tolyl-1H,1'H-4,4'-bi(1,2,3-triazole) have been synthesized and fully characterized by H-1 and C-13 NMR and IR spectroscopy, mass spectrometry, and elemental analysis. The molecular structures of 1, 2, and 4 have been determined by single-crystal X-ray diffraction. The cytotoxic activity of 1-4 was evaluated using the MTS assay against human tumor cells, namely ovarian carcinoma (A2780), colorectal carcinoma (HCT116), and colorectal carcinoma resistant to doxorubicin (HCT116dox), and against normal primary fibroblasts. Whereas compounds 2 and 4 showed no cytotoxic activity toward tumor cell lines, compounds 1 and 3 were active in A2780, while showing no antiproliferative effect in human normal dermal fibroblasts at the IC50 concentrations of the A2780 cell line. Exposure of ovarian carcinoma cells to IC50 concentrations of compound 1 or 3 led to an accumulation of reactive oxygen species and an increase of apoptotic and autophagic cells. While compound 3 displayed low levels of angiogenesis induction, compound 1 showed an ability to induce cell cycle delay and to interfere with cell migration. When the in vivo toxicity studies using zebrafish and chicken embryos are considered, compounds 1 and 3, which were not lethal, are promising candidates as anticancer agents against ovarian cancer due to their good cytotoxic activity in tumor cells and their low toxicity both in vitro and in vivo.
C1 [Cabral, Rui; Carvalho, Beatriz; Roma-Rodrigues, Catarina; Fernandes, Alexandra R.] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Ciencias Vida, UCIBIO, P-2829516 Caparica, Portugal.
   [Lenis-Rojas, Oscar A.; Friaes, Sofia; Royo, Beatriz] Univ Nova Lisboa, ITQB NOVA, Inst Tecnol Quim & Biol Antonio Xavier, P-2780157 Oeiras, Portugal.
   [Fernandez, Jhonathan A. A.] Univ Estadual Campinas, UNICAMP, Sch Med Sci, Lab Zebrafish,Dept Med Genet & Genom Med, BR-13083887 Campinas, SP, Brazil.
   [Fernandez, Jhonathan A. A.; Vila, Sabela F.; Sanchez, Laura] Univ Santiago de Compostela, Fac Vet, Dept Zool Genet & Antropol Fis, Lugo 27002, Spain.
   [Sanchez, Laura] Hlth Res Inst Santiago de Compostela IDIS, Preclin Anim Models Grp, La Coruna, Spain.
   [Gomes, Clara S. B.] Univ NOVA Lisboa, Fac Ciencias & Tecnol, Dept Quim, LAQV REQUIMTE UCIBIO, P-2829516 Caparica, Portugal.
RP Fernandes, AR (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Ciencias Vida, UCIBIO, P-2829516 Caparica, Portugal.; Lenis-Rojas, OA; Royo, B (corresponding author), Univ Nova Lisboa, ITQB NOVA, Inst Tecnol Quim & Biol Antonio Xavier, P-2780157 Oeiras, Portugal.
EM oscar.rojas@itqb.unl.pt; ma.fernandes@fct.unl.pt; broyo@itqb.unl.pt
RI Gomes, Clara S. B./H-7759-2012; Rojas, Oscar/ABE-2206-2021;
   Roma-Rodrigues, Catarina/S-6144-2016; Roma-Rodrigues,
   Catarina/AAT-5658-2021; Sanchez Pinon, Laura/L-2411-2014; Fernandes,
   Alexandra/C-7465-2011
OI Gomes, Clara S. B./0000-0003-3672-0045; Rojas,
   Oscar/0000-0002-5914-5787; Roma-Rodrigues, Catarina/0000-0002-8676-6562;
   Roma-Rodrigues, Catarina/0000-0002-8676-6562; Sanchez Pinon,
   Laura/0000-0001-7927-5303; Fernandes, Alexandra/0000-0003-2054-4438
FU Fundacao da Ciencia e a Tecnologia, FCT [UIDB/04612/2020,
   UIDP/04612/2020]; Applied Molecular Biosciences Unit-UCIBIO - FCT
   [UIDP/04378/2020, UIDB/04378/2020]; Coordenacao de Aperfeicoamento de
   Pessoal de Nivel SuperiorBrasil (CAPES)Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES); program CAPES/PRINT
   [88887.470075/2019-00]; Applied Molecular Biosciences Unit-UCIBIO
   [UIDP/04378/2020, UIDB/04378/2020, UIDB/50006/2020, UIDP/50006/2020];
   FCT-MCTESPortuguese Foundation for Science and TechnologyEuropean
   Commission [RECI/BBB-BEP/0124/2012];  [022162]
FX We are grateful to the Fundacao da Ciencia e a Tecnologia, FCT, fo rthe
   project MOSTMICRO-ITQB NOVA with references UIDB/04612/2020 and
   UIDP/04612/2020. The NMR spectrometers at CERMAX are integrated in the
   national NMR Network and partially supported through project 022162. We
   also thank the Analytic Services of ITQB and C. Almeida for elemental
   analysis and HRMS spectrometry. O.A.L.-R. acknowledges FCT,
   POPH-Programa Operacional Potencial Humano, and FSE (European Social
   Fund) for the CEEC 2017 Initiative. Also, this work was supported by the
   Applied Molecular Biosciences Unit-UCIBIO which is financed by national
   funds from FCT (UIDP/04378/2020 and UIDB/04378/2020). J.A.A.F.
   acknowledges Coordenacao de Aperfeicoamento de Pessoal de Niv ' el
   SuperiorBrasil (CAPES) and the program CAPES/PRINT Proc.
   88887.470075/2019-00. C.S.B.G. acknowledges the Associate Laboratory for
   Green Chemistry-LAQV, the Applied Molecular Biosciences Unit-UCIBIO
   (UIDB/50006/2020, UIDP/50006/2020, UIDB/04378/2020, UIDP/04378/2020),
   and Xray infrastructure financed by FCT-MCTES through project
   RECI/BBB-BEP/0124/2012.
CR Abbas Z., 2018, NEOPLASMA, V1, P139, DOI [DOI 10.5772/INTECHOPEN.76558, 10.5772/intechopen.76558]
   Adhireksan Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4462
   Aird RE, 2002, BRIT J CANCER, V86, P1652, DOI 10.1038/sj.bjc.6600290
   Almeida J, 2019, J INORG BIOCHEM, V199, DOI 10.1016/j.jinorgbio.2019.110789
   Ang WH, 2006, INORG CHEM, V45, P9006, DOI 10.1021/ic061008y
   [Anonymous], 2010, OFFICIAL J EUROPEAN, VL276, P33
   [Anonymous], EUR J ORG CHEM
   Berndsen RH, 2017, SCI REP-UK, V7, DOI 10.1038/srep43005
   Betanzos-Lara S, 2009, CHEM COMMUN, P6622, DOI 10.1039/b914153g
   Bugarcic T, 2008, INORG CHEM, V47, P11470, DOI 10.1021/ic801361m
   Burla MC, 2015, J APPL CRYSTALLOGR, V48, P306, DOI 10.1107/S1600576715001132
   Chen HM, 2003, J AM CHEM SOC, V125, P173, DOI 10.1021/ja027719m
   Chen SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174136
   Chen YJ, 2015, DALTON T, V44, P7347, DOI 10.1039/c5dt00939a
   Choroba K, 2019, DALTON T, V48, P13081, DOI 10.1039/c9dt02894c
   Chow MJ, 2016, CHEM SCI, V7, P4117, DOI 10.1039/c6sc00268d
   Chow MJ, 2016, MOL PHARMACEUT, V13, P2543, DOI 10.1021/acs.molpharmaceut.6b00348
   Costa MS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72420-w
   Coverdale JPC, 2019, INORGANICS, V7, DOI 10.3390/inorganics7030031
   Das K, 2018, NEW J CHEM, V42, P9126, DOI 10.1039/c8nj01033a
   de Vicente JC, 2006, J ORAL PATHOL MED, V35, P140
   Elie BT, 2018, J BIOL INORG CHEM, V23, P399, DOI 10.1007/s00775-018-1546-8
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Finney D.J., 1952, PROBIT ANAL
   Fozard J. R., 1980, EUR J PHARMACOL, V65, P379
   Gao LX, 2020, ADV EXP MED BIOL, V1260, P1, DOI 10.1007/978-3-030-42667-5_1
   Ghosh S, 2019, BIOORG CHEM, V88, DOI 10.1016/j.bioorg.2019.102925
   Groom CR, 2016, ACTA CRYSTALLOGR B, V72, P171, DOI 10.1107/S2052520616003954
   Gunnarsson L, 2008, ENVIRON SCI TECHNOL, V42, P5807, DOI 10.1021/es8005173
   Han BJ, 2015, TRANSIT METAL CHEM, V40, P153, DOI 10.1007/s11243-014-9901-2
   Hayward RL, 2005, CANCER CHEMOTH PHARM, V55, P577, DOI 10.1007/s00280-004-0932-9
   Hohloch S, 2015, DALTON T, V44, P686, DOI 10.1039/c4dt02879a
   Hohloch S, 2013, ORGANOMETALLICS, V32, P7376, DOI 10.1021/om4009185
   Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111
   Hubschle CB, 2011, J APPL CRYSTALLOGR, V44, P1281, DOI 10.1107/S0021889811043202
   Hulkower Keren I, 2011, Pharmaceutics, V3, P107, DOI 10.3390/pharmaceutics3010107
   Krause L, 2015, J APPL CRYSTALLOGR, V48, P3, DOI 10.1107/S1600576714022985
   Lai SH, 2016, RSC ADV, V6, P63143, DOI 10.1039/c6ra11391e
   Lenis-Rojas OA, 2016, DALTON T, V45, P19127, DOI 10.1039/c6dt03591d
   Lenis-Rojas OA, 2021, INORG CHEM, V60, P2914, DOI 10.1021/acs.inorgchem.0c02768
   Lenis-Rojas OA, 2018, INORG CHEM, V57, P13150, DOI 10.1021/acs.inorgchem.8b01270
   Lenis-Rojas OA, 2017, INORG CHEM, V56, P7127, DOI 10.1021/acs.inorgchem.7b00790
   Lokman NA, 2012, INT J MOL SCI, V13, P9959, DOI 10.3390/ijms13089959
   Loreto C, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/616149
   Ma Z, 2016, DALTON T, V45, P5339, DOI 10.1039/c5dt02744f
   McCollum CW, 2011, BIRTH DEFECTS RES C, V93, P67, DOI 10.1002/bdrc.20210
   Morris RE, 2001, J MED CHEM, V44, P3616, DOI 10.1021/jm010051m
   Ndagi U, 2017, DRUG DES DEV THER, V11, P599, DOI 10.2147/DDDT.S119488
   Olivares CI, 2016, CHEMOSPHERE, V148, P361, DOI 10.1016/j.chemosphere.2016.01.050
   Pedrosa P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29870-0
   Perrin D.D., 1980, PURIFICATION LAB CHE, P65
   Prager GW, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2017-000285
   Raposo LR, 2017, VET COMP ONCOL, V15, P952, DOI 10.1111/vco.12235
   Reigosa-Chamorro F, 2021, INORG CHEM, V60, P3939, DOI 10.1021/acs.inorgchem.0c03763
   Riedl CA, 2018, DALTON T, V47, P4625, DOI 10.1039/c8dt00449h
   Riedl CA, 2017, INORG CHEM, V56, P528, DOI 10.1021/acs.inorgchem.6b02430
   Roma-Rodrigues C, 2019, INT J NANOMED, V14, P6843, DOI 10.2147/IJN.S215711
   Roma-Rodrigues C, 2016, INT J NANOMED, V11, P2633, DOI 10.2147/IJN.S108661
   Romero-Canelon I, 2013, J MED CHEM, V56, P1291, DOI 10.1021/jm3017442
   Rono CK, 2019, ORGANOMETALLICS, V38, P3197, DOI 10.1021/acs.organomet.9b00440
   Scattergood PA, 2016, INORG CHEM, V55, P7787, DOI 10.1021/acs.inorgchem.6b00782
   Scolaro C, 2005, J MED CHEM, V48, P4161, DOI 10.1021/jm050015d
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Silva SLR, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47539-0
   Simovic AR, 2019, COORDIN CHEM REV, V398, DOI 10.1016/j.ccr.2019.07.008
   Sivandzade F, 2019, BIO-PROTOCOL, V9, DOI 10.21769/BioProtoc.3128
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Truong L, 2011, METHODS MOL BIOL, V691, P271, DOI 10.1007/978-1-60761-849-2_16
   van Genderen HO, 2008, BBA-MOL CELL RES, V1783, P953, DOI 10.1016/j.bbamcr.2008.01.030
   Wang XJ, 2019, BMC PHARMACOL TOXICO, V20, DOI 10.1186/s40360-018-0284-4
   Westerfield M., 2000, ZEBRAFISH BOOK GUIDE
   Wu Q, 2014, METALLOMICS, V6, P2204, DOI 10.1039/c4mt00158c
NR 73
TC 1
Z9 1
U1 5
U2 14
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0020-1669
EI 1520-510X
J9 INORG CHEM
JI Inorg. Chem.
PD JUN 7
PY 2021
VL 60
IS 11
BP 8011
EP 8026
DI 10.1021/acs.inorgchem.1c00527
EA MAY 2021
PG 16
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA SR8OY
UT WOS:000661306200043
PM 33973771
DA 2022-04-25
ER

PT J
AU Zhang, H
   Yi, JK
   Huang, H
   Park, S
   Park, S
   Kwon, W
   Kim, E
   Jang, S
   Kim, SY
   Choi, SK
   Kim, SH
   Liu, KD
   Dong, ZG
   Ryoo, ZY
   Kim, MO
AF Zhang, Haibo
   Yi, Jun-Koo
   Huang, Hai
   Park, Song
   Park, Sijun
   Kwon, Wookbong
   Kim, Eungyung
   Jang, Soyoung
   Kim, Si-Yong
   Choi, Seong-Kyoon
   Kim, Sung-Hyun
   Liu, Kangdong
   Dong, Zigang
   Ryoo, Zae Young
   Kim, Myoung Ok
TI Rhein Suppresses Colorectal Cancer Cell Growth by Inhibiting the mTOR
   Pathway In Vitro and In Vivo
SO CANCERS
LA English
DT Article
DE Rhein; colorectal cancer; mTOR; xenograft
ID SHOCK FACTOR-1 HSF1; S-PHASE ARREST; HEAT-SHOCK; DOWN-REGULATION;
   POOR-PROGNOSIS; EXPRESSION; INITIATION; DEGRADATION; RECURRENCE;
   AUTOPHAGY
AB Simple Summary
   Colorectal cancer (CRC) is the fourth most common cancer and the second most common cause of cancer-related deaths globally. Rhein is a natural anthraquinone extract from rhubarb, which exhibits potent anticancer activity in various cancers. In this study, we show that rhein significantly inhibited the growth, migration, and invasion of CRC cells by directly binding to mTOR and inhibiting the mTOR signaling pathway. Rhein promotes mTOR degradation through the ubiquitin-proteasome pathway. In addition, rhein significantly suppressed tumor growth in a xenograft mouse model without obvious toxicity. Our results indicate that rhein is a promising anticancer agent that may be useful for the prevention and treatment of CRC.
   Colorectal cancer (CRC) is one of the leading causes of mortality and morbidity in the world. Rhein has demonstrated therapeutic effects in various cancer models. However, its effects and underlying mechanisms of action in CRC remain poorly understood. We investigated the potential anticancer activity and underlying mechanisms of rhein in CRC in vitro and in vivo. Cell viability and anchorage-independent colony formation assays were performed to examine the antigrowth effects of rhein on CRC cells. Wound-healing and Transwell assays were conducted to assess cell migration and invasion capacity. Cell cycle and apoptosis were investigated by flow cytometry and verified by immunoblotting. A tissue microarray was used to detect mTOR expression in CRC patient tissues. Gene overexpression and knockdown were done to analyze the function of mTOR in CRC. The anticancer effect of rhein in vivo was assessed in a CRC xenograft mouse model. The results show that rhein significantly inhibited CRC cell growth by inducing S-phase cell cycle arrest and apoptosis. Rhein inhibited CRC cell migration and invasion through the epithelial-mesenchymal transition (EMT) process. mTOR was highly expressed in CRC cancer tissues and cells. Overexpression of mTOR promoted cell growth, migration, and invasion, whereas mTOR knockdown diminished these phenomena in CRC cells in vitro. In addition, rhein directly targeted mTOR and inhibited the mTOR signaling pathway in CRC cells. Rhein promoted mTOR degradation through the ubiquitin-proteasome pathway. Intraperitoneal administration of rhein inhibited HCT116 xenograft tumor growth through the mTOR pathway. In conclusion, rhein exerts anticancer activity in vitro and in vivo by targeting mTOR and inhibiting the mTOR signaling pathway in CRC. Our results indicate that rhein is a potent anticancer agent that may be useful for the prevention and treatment of CRC.
C1 [Zhang, Haibo; Huang, Hai; Kim, Eungyung; Kim, Myoung Ok] Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, ITRD, Sangju 37224, South Korea.
   [Yi, Jun-Koo] Gyeongbuk Livestock Res Inst, Yeongju 36052, South Korea.
   [Park, Song; Choi, Seong-Kyoon] DGIST, Core Prot Resources Ctr, Daegu 41566, South Korea.
   [Park, Song] DGIST, Dept Brain & Cognit Sci, Daegu 41566, South Korea.
   [Park, Sijun; Jang, Soyoung; Kim, Si-Yong; Ryoo, Zae Young] Kyungpook Natl Univ, BK21 FOUR KNU Creat Bioresearch, Sch Life Sci, Daegu 41566, South Korea.
   [Kwon, Wookbong; Choi, Seong-Kyoon] DGIST, Div Biotechnol, Daegu 41566, South Korea.
   [Kim, Sung-Hyun] Korea Polytech Coll, Dept Biomed Anal, Chungnam 34134, South Korea.
   [Liu, Kangdong; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou 450008, Peoples R China.
RP Kim, MO (corresponding author), Kyungpook Natl Univ, Dept Anim Sci & Biotechnol, ITRD, Sangju 37224, South Korea.; Ryoo, ZY (corresponding author), Kyungpook Natl Univ, BK21 FOUR KNU Creat Bioresearch, Sch Life Sci, Daegu 41566, South Korea.
EM 2018326925@knu.ac.kr; 79lee38@korea.kr; huanghai@knu.ac.kr;
   stemsj@knu.ac.kr; cristaling@dgist.ac.kr; bongdaling@dgist.ac.kr;
   kge99777@knu.ac.kr; jangsy@knu.ac.kr; kim_si-yong@knu.ac.kr;
   cskbest@dgist.ac.kr; shkim92@kopo.ac.kr; kdliu@zzu.edu.cn;
   zgdong@hi.umm.edu; jaewoong64@knu.ac.kr; ok4325@knu.ac.kr
OI Park, Song/0000-0001-6217-2017; Park, Sijun/0000-0002-8791-8249; Yi,
   JunKoo/0000-0003-2593-6529; Liu, Kangdong/0000-0002-4425-5625; Kwon,
   Wookbong/0000-0002-0655-6531
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of EducationNational Research Foundation of
   Korea [2020R1I1A2075315, 2020R1A4A1018280]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (2020R1I1A2075315 and 2020R1A4A1018280).
CR Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715
   Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Bu TC, 2020, J CELL PHYSIOL, V235, P3309, DOI 10.1002/jcp.29218
   Cao YJ, 2017, CHIN MED-UK, V12, DOI 10.1186/s13020-017-0158-5
   Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x
   Chou SD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039679
   Conciatori F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082453
   Dai WG, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0755-3
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Echalier A, 2010, BBA-PROTEINS PROTEOM, V1804, P511, DOI 10.1016/j.bbapap.2009.10.002
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Garner KM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-206
   Kim SY, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030595
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593
   Leal P, 2013, ARCH PATHOL LAB MED, V137, P552, DOI 10.5858/arpa.2012-0032-OA
   Lee JH, 2003, J ETHNOPHARMACOL, V84, P5, DOI 10.1016/S0378-8741(02)00222-2
   Li SH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08345-8
   Li XL, 2018, ONCOTARGETS THER, V11, P8977, DOI 10.2147/OTT.S187315
   Lin YJ, 2009, ANTI-CANCER DRUG, V20, P65, DOI 10.1097/CAD.0b013e3283182913
   Liu GX, 2020, AM J CHINESE MED, V48, P47, DOI 10.1142/S0192415X20500032
   Manfredi S, 2001, BRIT J SURG, V88, P1221, DOI 10.1046/j.0007-1323.2001.01861.x
   Mayhew DL, 2011, J PHYSIOL-LONDON, V589, P3023, DOI 10.1113/jphysiol.2010.202432
   Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031
   Pandurangan AK, 2018, ARCH MED SCI, V14, P1281, DOI 10.5114/aoms.2018.76935
   Ponnurangam S, 2013, MOL CANCER THER, V12, P598, DOI 10.1158/1535-7163.MCT-12-0907
   Ren BY, 2019, BIOL PHARM BULL, V42, P568, DOI 10.1248/bpb.b18-00431
   Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Seim J, 2003, CELL PROLIFERAT, V36, P321, DOI 10.1046/j.1365-2184.2003.00288.x
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Song MQ, 2019, CANCERS, V11, DOI 10.3390/cancers11121964
   Steeg PS, 2016, NAT REV CANCER, V16, P201, DOI 10.1038/nrc.2016.25
   Teklemichael AA, 2020, MALARIA J, V19, DOI 10.1186/s12936-020-03273-x
   Thomford NE, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061578
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Tu Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep43790
   Vilella-Bach M, 1999, J BIOL CHEM, V274, P4266, DOI 10.1074/jbc.274.7.4266
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang HN, 2020, CANCER GENE THER, V27, P448, DOI 10.1038/s41417-019-0117-7
   Willis SD, 2020, MOL BIOL CELL, V31, P1015, DOI 10.1091/mbc.E19-11-0622
   Xie XD, 2018, NAT CELL BIOL, V20, P320, DOI 10.1038/s41556-017-0033-8
   Xie XM, 2019, CANCER LETT, V442, P126, DOI 10.1016/j.canlet.2018.10.016
   Xu Y, 2016, MOL NEUROBIOL, V53, P706, DOI 10.1007/s12035-014-9028-7
   Xu ZH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0590-5
   Yang LH, 2019, CANCER MANAG RES, V11, P1167, DOI 10.2147/CMAR.S171517
   Yeung KT, 2017, MOL ONCOL, V11, P28, DOI 10.1002/1878-0261.12017
   You LT, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041060
   You SP, 2018, MOL MED REP, V17, P4203, DOI 10.3892/mmr.2018.8444
   Young PE, 2014, J CANCER, V5, P262, DOI 10.7150/jca.7988
   Yuan XF, 2018, EXP THER MED, V16, P5350, DOI 10.3892/etm.2018.6855
   Zhao R, 2020, BRIT J PHARMACOL, V177, P2303, DOI 10.1111/bph.14981
   Zhou YX, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/578107
   Zhuang Y, 2019, ONCOTARGETS THER, V12, P5281, DOI 10.2147/OTT.S206833
   Zou ZL, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00396-1
NR 57
TC 2
Z9 2
U1 7
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2021
VL 13
IS 9
AR 2176
DI 10.3390/cancers13092176
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SB3PB
UT WOS:000649909600001
PM 33946531
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Dan, XL
   Liu, WL
   Wong, JH
   Ng, TB
AF Dan, Xiuli
   Liu, Wenlong
   Wong, Jack H.
   Ng, Tzi B.
TI A Ribonuclease Isolated from Wild Ganoderma Lucidum Suppressed Autophagy
   and Triggered Apoptosis in Colorectal Cancer Cells
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Ganoderma lucidum; ribonucleases; colorectal cancer cells; apoptosis;
   autophagy
ID FRESH FRUITING BODIES; CHINA BLACK BEANS; ANTIPROLIFERATIVE ACTIVITY;
   INHIBITORY-ACTIVITY; CONCANAVALIN-A; MUSHROOM; THERAPY; PURIFICATION;
   EXPRESSION; INDUCTION
AB The mushroom Ganoderma lucidum (G. lucidum) has been consumed in China as a medicine for promoting health and longevity for thousands of years. Due to its paramount and multiple pharmaceutical effects, G. lucidum has received considerable attention from researchers and its chemical constituents as well as their respective functions were gradually unveiled by using modern research methods. Herein, we reported the isolation of a protein (Ganoderma lucidum ribonuclease, GLR) with anti colorectal cancer activities from G. lucidum. This protein is a 17.4-kDa RNA degrading enzyme (ribonuclease) and was purified by using liquid chromatography procedures. GLR manifested potent anti proliferative and anti colony formation activities on HT29 and HCT116 colorectal cancer cells by inducing cell cycle arrest in G1 phase through the regulation of cyclin D1 and P53 expression. GLR was demonstrated to induce cell apoptosis in HCT116 cells by activating unfolded protein response and caspase-9 regulated pathways. Besides, the ability to undergo autophagy which is a stress adaption mechanism to cope with metabolic crisis was significantly suppressed by GLR treatment in HCT116 cells. The activation of apoptosis in GLR-treated HT29 cells was, however, independent of caspase-9 and the suppression of autophagy was also relatively minor. Thus the apoptosis of HT29 cells triggered by GLR was much milder than that in HCT116 cells. Our findings show that the RNase from G. lucidum may be one of the bioactive components that contribute to the anti-colorectal cancer activity of G. lucidum.
C1 [Dan, Xiuli; Wong, Jack H.; Ng, Tzi B.] Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Liu, Wenlong] Chinese Acad Sci, Shenzhen Inst Adv Technol, Shenzhen Key Lab Marine Biomed Mat, Shenzhen, Peoples R China.
RP Wong, JH; Ng, TB (corresponding author), Chinese Univ Hong Kong, Fac Med, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
EM b111590@mailserv.cuhk.edu.hk; b021770@mailserv.cuhk.edu.hk
OI Liu, Wenlong/0000-0003-2988-7963; WONG, Jack/0000-0002-9732-986X
FU award of Health and Medical Research Fund from Food and Health Bureau,
   Hong Kong [12131221]
FX We gratefully acknowledge the award of Health and Medical Research Fund
   (research grant number: 12131221) from Food and Health Bureau, Hong
   Kong. Special Administration Region Government.
CR ALLGOOD VE, 1990, J BIOL CHEM, V265, P12424
   APHANASENKO GA, 1979, FEBS LETT, V97, P77, DOI 10.1016/0014-5793(79)80056-3
   Arber N, 1997, CANCER RES, V57, P1569
   Ardelt W, 2009, EUR J PHARMACOL, V625, P181, DOI 10.1016/j.ejphar.2009.06.067
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Chen HS, 2004, BIOORGAN MED CHEM, V12, P5595, DOI 10.1016/j.bmc.2004.08.003
   Cheng SJ, 2015, INTEGR CANCER THER, V14, P249, DOI 10.1177/1534735414568721
   Cuervo AM, 2005, AUTOPHAGY, V1, P131, DOI 10.4161/auto.1.3.2017
   Dan XL, 2016, BBA-MOL CELL RES, V1863, P2201, DOI 10.1016/j.bbamcr.2016.05.019
   Dan XL, 2015, J AGR FOOD CHEM, V63, P3903, DOI 10.1021/acs.jafc.5b00106
   Fang EF, 2011, BBA-REV CANCER, V1815, P65, DOI 10.1016/j.bbcan.2010.09.001
   Fiorini C, 2015, BBA-MOL CELL RES, V1853, P549, DOI 10.1016/j.bbamcr.2014.12.016
   Gardner BM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013169
   Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024
   GREEN PJ, 1994, ANNU REV PLANT PHYS, V45, P421, DOI 10.1146/annurev.pp.45.060194.002225
   Guan GP, 2007, BBA-GEN SUBJECTS, V1770, P1593, DOI 10.1016/j.bbagen.2007.07.014
   Huie CW, 2004, J CHROMATOGR B, V812, P241, DOI 10.1016/j.jchromb.2004.08.038
   Kobayashi H, 2003, BIOSCI BIOTECH BIOCH, V67, P2307, DOI 10.1271/bbb.67.2307
   Lee I, 2008, EXPERT OPIN BIOL TH, V8, P813, DOI 10.1517/14712598.8.6.813 
   Lei HY, 2007, AUTOPHAGY, V3, P402, DOI 10.4161/auto.4280
   Lei HY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-10
   Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8
   Liang ZE, 2015, MOL MED REP, V12, P7629, DOI 10.3892/mmr.2015.4345
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Makarov AA, 2003, FEBS LETT, V540, P15, DOI 10.1016/S0014-5793(03)00225-4
   Newton DL, 1997, PROTEIN ENG, V10, P463, DOI 10.1093/protein/10.4.463
   Ngai PHK, 2003, PEPTIDES, V24, P639, DOI 10.1016/S0196-9781(03)00136-0
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Piccoli R, 1999, P NATL ACAD SCI USA, V96, P7768, DOI 10.1073/pnas.96.14.7768
   Podzimek T, 2011, PLANT SCI, V180, P343, DOI 10.1016/j.plantsci.2010.10.006
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Ruan WM, 2015, PHYTOTHER RES, V29, P1744, DOI 10.1002/ptr.5426
   Russell R, 2006, PHYTOCHEMISTRY, V67, P1985, DOI 10.1016/j.phytochem.2006.07.004
   Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009
   Shevchenko A, 2006, NAT PROTOC, V1, P2856, DOI 10.1038/nprot.2006.468
   Wang HX, 2006, APPL MICROBIOL BIOT, V72, P912, DOI 10.1007/s00253-006-0385-7
   Wang HX, 2004, BIOCHEM BIOPH RES CO, V324, P855, DOI 10.1016/j.bbrc.2004.09.132
   Wang HX, 2004, BIOCHEM BIOPH RES CO, V314, P519, DOI 10.1016/j.bbrc.2003.12.139
   Wang HX, 2003, BIOCHEM BIOPH RES CO, V312, P965, DOI 10.1016/j.bbrc.2003.10.201
   Weng CJ, 2010, CLIN EXP METASTAS, V27, P361, DOI 10.1007/s10585-010-9334-z
   Yang Y, 2004, INT J BIOCHEM CELL B, V36, P223, DOI 10.1016/S1357-2725(03)00215-2
   Zhang RY, 2010, BIOCHEM GENET, V48, P658, DOI 10.1007/s10528-010-9347-y
   Zhang R, 2015, J BASIC MICROB, V55, P269, DOI 10.1002/jobm.201300876
   Zhao S, 2010, J MICROBIOL BIOTECHN, V20, P693, DOI 10.4014/jmb.0911.11022
NR 45
TC 18
Z9 18
U1 1
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUL 25
PY 2016
VL 7
AR 217
DI 10.3389/fphar.2010.00217
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DR7QI
UT WOS:000380094400001
PM 27504094
DA 2022-04-25
ER

PT J
AU Yan, C
   Luo, L
   Guo, CY
   Goto, S
   Urata, Y
   Shao, JH
   Li, TS
AF Yan, Chen
   Luo, Lan
   Guo, Chang-Ying
   Goto, Shinji
   Urata, Yoshishige
   Shao, Jiang-Hua
   Li, Tao-Sheng
TI Doxorubicin-induced mitophagy contributes to drug resistance in cancer
   stem cells from HCT8 human colorectal cancer cells
SO CANCER LETTERS
LA English
DT Article
DE Cancer stem cells; Drug resistance; Mitophagy; BNIP3L; Autophagy
ID STEM/PROGENITOR CELLS; INITIATING CELLS; AUTOPHAGY; APOPTOSIS; THERAPY;
   MITOCHONDRIA; CHEMOTHERAPY; INHIBITION; DISCOVERY; PATHWAY
AB Cancer stem cells (CSCs) are known to be drug resistant. Mitophagy selectively degrades unnecessary or damaged mitochondria by autophagy during cellular stress. To investigate the potential role of mitophagy in drug resistance in CSCs, we purified CD133(+)/CD44(+) CSCs from HCT8 human colorectal cancer cells and then exposed to doxorubicin (DXR). Compared with parental cells, CSCs were more resistant to DXR treatment. Although DXR treatment enhanced autophagy levels in both cell types, the inhibition of autophagy by ATG7 silencing significantly increased the toxicity of DXR only in parental cells, not in CSCs. Interestingly, the level of mitochondria(superoxide was detected to be significantly lower in CSCs than in parental cells after DXR treatment. Furthermore, the mitophagy level and expression of BNIP3L, a mitophagy regulator, were significantly higher in CSCs than in parental cells after DXR treatment. Silencing BNIP3L significantly halted mitophagy and enhanced the sensitivity to DXR in CSCs. Our data suggested that mitophagy, but not non-selective autophagy, likely contributes to drug resistance in CSCs isolated from HCT8 cells. Further studies in other cancer cell lines will be needed to confirm our findings. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Yan, Chen; Luo, Lan; Guo, Chang-Ying; Goto, Shinji; Urata, Yoshishige; Li, Tao-Sheng] Nagasaki Univ, Grad Sch Biomed Sci, Dept Stem Cell Biol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
   [Guo, Chang-Ying] Jiangxi Canc Hosp, Dept Thorac Surg, Nanchang 330029, Jiangxi, Peoples R China.
   [Shao, Jiang-Hua] Nanchang Univ, Dept Gen Surg, Affiliated Hosp 2, Nanchang 330006, Jiangxi, Peoples R China.
RP Li, TS (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Stem Cell Biol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.
EM litaoshe@nagasaki-u.ac.jp
RI chang-ying, guo/F-2770-2018
OI Li, Tao-Sheng/0000-0002-7653-8873; Luo, Lan/0000-0001-7549-9852
FU Ministry of Education, Science, Sports, Culture and Technology,
   JapanMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT) [26293279]; Collaborative Research Program of the
   Atomic-bomb Disease Institute of Nagasaki University
FX This study was supported in part by a Grant-in-Aid from the Ministry of
   Education, Science, Sports, Culture and Technology, Japan (NO.
   26293279), and the Collaborative Research Program of the Atomic-bomb
   Disease Institute of Nagasaki University. The funder played no role in
   the study design, the data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ali H, 2014, BIOCHEM BIOPH RES CO, V452, P548, DOI 10.1016/j.bbrc.2014.08.112
   Ashley N, 2009, BIOCHEM BIOPH RES CO, V378, P450, DOI 10.1016/j.bbrc.2008.11.059
   De Angelis ML, 2016, STEM CELL TRANSL MED, V5, P511, DOI 10.5966/sctm.2015-0214
   Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428
   Gao F, 2015, HUM MOL GENET, V24, P2528, DOI 10.1093/hmg/ddv017
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Haraguchi N, 2008, ANN SURG ONCOL, V15, P2927, DOI 10.1245/s10434-008-0074-0
   Harper ME, 2002, FASEB J, V16, P1550, DOI 10.1096/fj.02-0541com
   He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145
   Hirota Y, 2015, AUTOPHAGY, V11, P332, DOI 10.1080/15548627.2015.1023047
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Lamb R, 2014, ONCOTARGET, V5, P11029, DOI 10.18632/oncotarget.2789
   Li X, 2016, ONCOGENE, V35, P4881, DOI 10.1038/onc.2016.20
   Liu L, 2014, CELL RES, V24, P787, DOI 10.1038/cr.2014.75
   Lu HQ, 2013, AUTOPHAGY, V9, P1720, DOI 10.4161/auto.26550
   Luanpitpong S, 2012, BIOCHEM PHARMACOL, V83, P1643, DOI 10.1016/j.bcp.2012.03.010
   Maes H, 2014, MITOCHONDRION, V19, P58, DOI 10.1016/j.mito.2014.07.003
   McLelland GL, 2014, EMBO J, V33, P282, DOI 10.1002/embj.201385902
   Ney PA, 2015, BBA-MOL CELL RES, V1853, P2775, DOI 10.1016/j.bbamcr.2015.02.022
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Sandoval H, 2008, NATURE, V454, P232, DOI 10.1038/nature07006
   Shen YA, 2015, CELL CYCLE, V14, P86, DOI 10.4161/15384101.2014.974419
   Tourneur L, 2010, TRENDS IMMUNOL, V31, P260, DOI 10.1016/j.it.2010.05.005
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Vlashi E, 2015, FREE RADICAL BIO MED, V79, P264, DOI 10.1016/j.freeradbiomed.2014.10.732
   Vyas S, 2016, CELL, V166, P555, DOI 10.1016/j.cell.2016.07.002
   Yadav N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.305
   Yan C, 2016, ONCOTARGET, V7, P45112, DOI 10.18632/oncotarget.8972
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Yenigun VB, 2013, INT J MOL MED, V31, P1477, DOI 10.3892/ijmm.2013.1342
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Zhang S, 2012, NAT MED, V18, P1639, DOI 10.1038/nm.2919
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
NR 37
TC 74
Z9 78
U1 3
U2 35
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 1
PY 2017
VL 388
BP 34
EP 42
DI 10.1016/j.canlet.2016.11.018
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EN4EC
UT WOS:000395959800004
PM 27913197
DA 2022-04-25
ER

PT J
AU Xia, XJ
   Wang, X
   Cheng, Z
   Qin, WH
   Lei, LC
   Jiang, JQ
   Hu, JH
AF Xia, Xiaojing
   Wang, Xin
   Cheng, Zhe
   Qin, Wanhai
   Lei, Liancheng
   Jiang, Jinqing
   Hu, Jianhe
TI The role of pyroptosis in cancer: pro-cancer or pro-"host"?
SO CELL DEATH & DISEASE
LA English
DT Review
ID CELL-DEATH PATHWAYS; GASDERMIN-D; INFLAMMASOME ACTIVATION; LUNG-CANCER;
   HEPATOCELLULAR-CARCINOMA; MOLECULAR-MECHANISMS; INDUCE PYROPTOSIS;
   COLORECTAL-CANCER; AIM2 EXPRESSION; CASPASE 1
AB Programmed cell death (PCD) refers to the way in which cells die depending on specific genes encoding signals or activities. Apoptosis, autophagy, and pyroptosis are all mechanisms of PCD. Among these mechanisms, pyroptosis is mediated by the gasdermin family, accompanied by inflammatory and immune responses. The relationship between pyroptosis and cancer is complex, and the effects of pyroptosis on cancer vary in different tissues and genetic backgrounds. On one hand, pyroptosis can inhibit the occurrence and development of tumors; on the other hand, as a type of proinflammatory death, pyroptosis can form a suitable microenvironment for tumor cell growth and thus promote tumor growth. In addition, the induction of tumor pyroptosis is also considered a potential cancer treatment strategy. Studies have shown that DFNA5 (nonsyndromic hearing impairment protein 5)/GSDME (Gasdermin-E) mRNA methylation results in lower expression levels of DFNA5/GSDME in most tumor cells than in normal cells, making it difficult to activate the pyroptosis in most tumor cells. During the treatment of malignant tumors, appropriate chemotherapeutic drugs can be selected according to the expression levels of DFNA5/GSDME, which can be upregulated in tumor cells, thereby increasing the sensitivity to chemotherapeutic drugs and reducing drug resistance. Therefore, induced pyroptosis may play a predominant role in the treatment of cancer. Here, we review the latest research on the anti- and protumor effects of pyroptosis and its potential applications in cancer treatment.
C1 [Xia, Xiaojing; Cheng, Zhe; Jiang, Jinqing; Hu, Jianhe] Henan Inst Sci & Technol, Coll Anim Sci & Vet Med, Xinxiang, Henan, Peoples R China.
   [Wang, Xin] Linyi Univ, Coll Agr & Forestry Sci, Linyi, Shandong, Peoples R China.
   [Qin, Wanhai] Univ Amsterdam, Amsterdam UMC, Ctr Expt & Mol Med, Amsterdam Infect & Immun, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Lei, Liancheng] Jilin Univ, Coll Vet Med, Changchun, Jilin, Peoples R China.
RP Xia, XJ (corresponding author), Henan Inst Sci & Technol, Coll Anim Sci & Vet Med, Xinxiang, Henan, Peoples R China.
EM quik500@163.com
RI qin, wanhai/M-1773-2019; Xia, Xiaojing/O-7934-2018; Qin,
   Wanhai/R-8266-2016
OI qin, wanhai/0000-0002-7776-5007; Xia, Xiaojing/0000-0001-7717-8411; Qin,
   Wanhai/0000-0002-7776-5007
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31702263]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2017M622346]
FX This review was funded by the National Natural Science Foundation of
   China (no. 31702263) and the China Postdoctoral Science Foundation (no.
   2017M622346).
CR Agard NJ, 2010, MOL CELL PROTEOMICS, V9, P880, DOI 10.1074/mcp.M900528-MCP200
   Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Akino K, 2007, CANCER SCI, V98, P88, DOI 10.1111/j.1349-7006.2006.00351.x
   Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Bergsbaken T, 2007, PLOS PATHOG, V3, P1570, DOI 10.1371/journal.ppat.0030161
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Boise LH, 2001, TRENDS MICROBIOL, V9, P64, DOI 10.1016/S0966-842X(00)01937-5
   Burgener SS, 2019, CELL REP, V27, P3646, DOI 10.1016/j.celrep.2019.05.065
   Carl-Mcgrath S, 2008, PATHOLOGY, V40, P13, DOI 10.1080/00313020701716250
   Chen C, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.532
   Chen LP, 2019, CHEM BIOL DRUG DES, V94, P1368, DOI 10.1111/cbdd.13514
   Chen LP, 2019, APOPTOSIS, V24, P74, DOI 10.1007/s10495-018-1499-y
   Chen X, 2016, CELL RES, V26, P1007, DOI 10.1038/cr.2016.100
   Chen YF, 2018, EUR REV MED PHARMACO, V22, P8186, DOI 10.26355/eurrev_201812_16511
   Chien H, 2012, J VIROL, V86, P10961, DOI 10.1128/JVI.01275-12
   Chu Q, 2016, ONCOTARGET, V7, P84658, DOI 10.18632/oncotarget.12384
   Colunga AG, 2010, GENE THER, V17, P315, DOI 10.1038/gt.2009.126
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Crawford ED, 2011, ANNU REV BIOCHEM, V80, P1055, DOI 10.1146/annurev-biochem-061809-121639
   Croes L, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0479-y
   Cui JJ, 2019, MOL CANCER RES, V17, P1316, DOI 10.1158/1541-7786.MCR-18-0910
   Derangere V, 2014, CELL DEATH DIFFER, V21, P1914, DOI 10.1038/cdd.2014.117
   Dihlmann S, 2014, INT J CANCER, V135, P2387, DOI 10.1002/ijc.28891
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Doitsh G, 2014, NATURE, V505, P509, DOI 10.1038/nature12940
   Draganov D, 2015, SCI REP-UK, V5, DOI 10.1038/srep16222
   Drexler SK, 2013, CANCER J, V19, P468, DOI 10.1097/PPO.0000000000000004
   Dunn JH, 2012, CANCER LETT, V314, P24, DOI 10.1016/j.canlet.2011.10.001
   Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012
   Elion DL, 2018, CANCER RES, V78, P6183, DOI 10.1158/0008-5472.CAN-18-0730
   Falcon T, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2864120
   Feng SY, 2018, J MOL BIOL, V430, P3068, DOI 10.1016/j.jmb.2018.07.002
   Fink SL, 2005, INFECT IMMUN, V73, P1907, DOI 10.1128/IAI.73.4.1907-1916.2005
   Fink SL, 2006, CELL MICROBIOL, V8, P1812, DOI 10.1111/j.1462-5822.2006.00751.x
   Flood B, 2019, ONCOGENE, V38, P2658, DOI 10.1038/s41388-018-0613-5
   Freeman L, 2017, J EXP MED, V214, P1351, DOI 10.1084/jem.20150237
   Fujikane T, 2010, BREAST CANCER RES TR, V122, P699, DOI 10.1007/s10549-009-0600-1
   Fulda S, 2015, SEMIN CANCER BIOL, V31, P84, DOI 10.1016/j.semcancer.2014.05.002
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Gao JW, 2018, ONCOL REP, V40, P1971, DOI 10.3892/or.2018.6634
   Gao WQ, 2016, P NATL ACAD SCI USA, V113, pE4857, DOI 10.1073/pnas.1601700113
   Grottke C, 2000, INT J CANCER, V88, P535, DOI 10.1002/1097-0215(20001115)88:4<535::AID-IJC4>3.3.CO;2-M
   He LM, 2017, CELL MOL LIFE SCI, V74, P2395, DOI 10.1007/s00018-017-2477-1
   Hergueta-Redondo M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090099
   Hersh D, 1999, P NATL ACAD SCI USA, V96, P2396, DOI 10.1073/pnas.96.5.2396
   Hilbi H, 1997, INFECT IMMUN, V65, P5165, DOI 10.1128/IAI.65.12.5165-5170.1997
   Hoseini Z, 2018, J CELL PHYSIOL, V233, P2116, DOI 10.1002/jcp.25930
   Hu B, 2016, SCIENCE, V354, P765, DOI 10.1126/science.aaf7532
   Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108
   Ibrahim J, 2019, CANCER MED-US, V8, P2133, DOI 10.1002/cam4.2103
   Janowski AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00370
   Jiang ZF, 2017, ONCOL RES, V25, P1009, DOI 10.3727/096504016X14813859905646
   Jiao Y, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5912194
   Johnson DC, 2018, NAT MED, V24, P1151, DOI 10.1038/s41591-018-0082-y
   Joosten LAB, 2013, SEMIN IMMUNOL, V25, P416, DOI 10.1016/j.smim.2013.10.018
   Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287
   Kambara H, 2018, CELL REP, V22, P2924, DOI 10.1016/j.celrep.2018.02.067
   Kang SJ, 2000, J CELL BIOL, V149, P613, DOI 10.1083/jcb.149.3.613
   Karki R, 2019, NAT REV CANCER, V19, P197, DOI 10.1038/s41568-019-0123-y
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Kim MS, 2008, ONCOGENE, V27, P3624, DOI 10.1038/sj.onc.1211021
   Kim MS, 2008, BIOCHEM BIOPH RES CO, V370, P38, DOI 10.1016/j.bbrc.2008.03.026
   Kolb R, 2014, PROTEIN CELL, V5, P12, DOI 10.1007/s13238-013-0001-4
   Komiyama H, 2010, GENES GENET SYST, V85, P75, DOI 10.1266/ggs.85.75
   Lage H, 2001, FEBS LETT, V494, P54, DOI 10.1016/S0014-5793(01)02304-3
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Lee BL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21998-3
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Lu HJ, 2018, CLIN CANCER RES, V24, P6066, DOI 10.1158/1078-0432.CCR-18-1478
   Ma XM, 2016, ONCOTARGET, V7, P36185, DOI 10.18632/oncotarget.9154
   Ma YS, 2018, ONCOL REP, V40, P2648, DOI 10.3892/or.2018.6694
   Man SM, 2017, IMMUNOL REV, V277, P61, DOI 10.1111/imr.12534
   Man SM, 2014, P NATL ACAD SCI USA, V111, P7403, DOI 10.1073/pnas.1402911111
   Mariathasan S, 2005, J EXP MED, V202, P1043, DOI 10.1084/jem.20050977
   Martirosyan A, 2013, FUTURE MICROBIOL, V8, P147, DOI [10.2217/FMB.12.140, 10.2217/fmb.12.140]
   Masuda Yoshiko, 2006, J Hum Genet, V51, P652, DOI 10.1007/s10038-006-0004-6
   Melotti A, 2014, EMBO MOL MED, V6, P1263, DOI 10.15252/emmm.201404084
   Miao EA, 2010, NAT IMMUNOL, V11, P1136, DOI 10.1038/ni.1960
   Miguchi M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166422
   Monack DM, 1996, P NATL ACAD SCI USA, V93, P9833, DOI 10.1073/pnas.93.18.9833
   Nadatani Y, 2016, CELL MOL GASTROENTER, V2, P439, DOI 10.1016/j.jcmgh.2016.03.006
   Nagarajan K, 2019, TRANSL ONCOL, V12, P925, DOI 10.1016/j.tranon.2019.04.010
   Okondo MC, 2017, NAT CHEM BIOL, V13, P46, DOI [10.1038/NCHEMBIO.2229, 10.1038/nchembio.2229]
   Orita H, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-3424
   Orning P, 2018, SCIENCE, V362, P1064, DOI 10.1126/science.aau2818
   Pizato N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20422-0
   Qiu SQ, 2017, CELL DEATH DIFFER, V24, P588, DOI 10.1038/cdd.2017.24
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Ruhl S, 2018, SCIENCE, V362, P956, DOI 10.1126/science.aar7607
   Saeki N, 2000, MAMM GENOME, V11, P718, DOI 10.1007/s003350010138
   Saeki N, 2009, GENE CHROMOSOME CANC, V48, P261, DOI 10.1002/gcc.20636
   Sarhan J, 2018, P NATL ACAD SCI USA, V115, pE10888, DOI 10.1073/pnas.1809548115
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shi JJ, 2014, NATURE, V514, P187, DOI 10.1038/nature13683
   [石瑛 Shi Ying], 2019, [中国肿瘤生物治疗杂志, Chinese Journal of Cancer Biotherapy], V26, P146
   So D, 2018, ONCOGENE, V37, P5191, DOI 10.1038/s41388-018-0339-4
   Song Jinyan, 2013, Wei Sheng Yan Jiu, V42, P273
   Tabraue C, 2019, INT J RADIAT ONCOL, V104, P913, DOI 10.1016/j.ijrobp.2019.03.028
   Thi HTH, 2017, J CANCER PREV, V22, P62, DOI 10.15430/JCP.2017.22.2.62
   Thompson DA, 1998, EUR J BIOCHEM, V252, P169, DOI 10.1046/j.1432-1327.1998.2520169.x
   Timmer JC, 2007, CELL DEATH DIFFER, V14, P66, DOI 10.1038/sj.cdd.4402059
   Van Opdenbosch N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4209
   Wang CJ, 2013, MOL BIOL REP, V40, P6525, DOI 10.1007/s11033-013-2581-8
   Wang FJ, 2018, INT J BIOL SCI, V14, P406, DOI 10.7150/ijbs.23542
   Wang L, 2019, CANCER LETT, V450, P22, DOI 10.1016/j.canlet.2019.02.014
   Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5
   Wang WJ, 2018, J DIGEST DIS, V19, P74, DOI 10.1111/1751-2980.12576
   Wang Y., 2015, CHIN J IMMUNOL, V31
   Wang YB, 2018, BIOCHEM BIOPH RES CO, V495, P1418, DOI 10.1016/j.bbrc.2017.11.156
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Watabe E, 2001, JPN J CANCER RES, V92, P140, DOI 10.1111/j.1349-7006.2001.tb01076.x
   Wei Q, 2019, ONCOL RES, V27, P827, DOI 10.3727/096504018X15462920753012
   Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126
   [魏智民(综述) Wei Zhimin], 2018, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V45, P1117
   Williams TM, 2015, J IMMUNOL, V194, P3369, DOI 10.4049/jimmunol.1402098
   Wu MJ, 2019, EBIOMEDICINE, V41, P244, DOI 10.1016/j.ebiom.2019.02.012
   Xi GM, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105713
   Yu JH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1441-4
   Yu PA, 2019, ACTA PHARMACOL SIN, V40, P1237, DOI 10.1038/s41401-019-0222-z
   Yu XL, 2017, SCI CHINA LIFE SCI, V60, P1291, DOI 10.1007/s11427-017-9142-2
   Yue E, 2019, PHYTOMEDICINE, V56, P286, DOI 10.1016/j.phymed.2018.09.223
   Zaki MH, 2011, TRENDS IMMUNOL, V32, P171, DOI 10.1016/j.it.2011.02.002
   Zhang CC, 2019, APOPTOSIS, V24, P312, DOI 10.1007/s10495-019-01515-1
   Zhang HF, 2018, LIFE SCI, V207, P296, DOI 10.1016/j.lfs.2018.06.015
   Zhao Z.L., 2017, PRACT J CANC, V32, P358
   Zhou B, 2018, CELL RES, V28, P1171, DOI 10.1038/s41422-018-0090-y
   Zhou CB, 2019, BBA-REV CANCER, V1872, P1, DOI 10.1016/j.bbcan.2019.05.001
   ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0
NR 131
TC 166
Z9 178
U1 16
U2 44
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 9
PY 2019
VL 10
AR 650
DI 10.1038/s41419-019-1883-8
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JK6RN
UT WOS:000494969700009
PM 31501419
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Xu, LJ
   Qiao, YQ
   Zheng, Q
AF Xu, Lijun
   Qiao, Yuqi
   Zheng, Qing
TI Identification of an autophagy-related gene expression signature for
   colorectal cancer
SO ALL LIFE
LA English
DT Article
DE Autophagy; colorectal cancer; prognostic signature; survival analysis;
   TCGA
AB Autophagy, a major lysosomal degradation process, has been implicated in the pathogenesis of colorectal cancer (CRC). However, it still remains unclear what role all the autophagy-related genes (ARGs) play in CRC prognosis. A univariate Cox analysis was conducted to select ARGs related with overall survival (OS) for CRC cohort of the TCGA database. A multivariate Cox analysis was used to develop an ARGs expression signature, whose risk score stratified CRC patients into two groups. The OS time between the above two groups was estimated using the Kaplan-Meier curve and log-rank test. In order to evaluate the predictive performance of this expression signature and other clinicopathological parameters for CRC prognosis, the area under the curve (AUC) was calculated. Nine out of 20 OS-related ARGs were finally incorporated into this ARGs expression signature, whose risk score stratified CRC patients into either high-risk or low-risk group. The OS time of patients in low-risk group was higher than that in high-risk group and the difference was statistically significant (P < 0.001). The AUC for this risk score was higher than other clinicopathological parameters, including TNM stage. This study presents an ARGs expression signature, which outperforms other clinicopathological parameters in predicting CRC prognosis.
C1 [Xu, Lijun; Qiao, Yuqi; Zheng, Qing] Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Minist Hlth,Inflammatory Bowel Dis Res Ctr, Shanghai Inst Digest Dis,Renji Hosp,Sch Med,Key L, 160 Pu Jian Ave, Shanghai 200127, Peoples R China.
RP Qiao, YQ; Zheng, Q (corresponding author), Shanghai Jiao Tong Univ, Div Gastroenterol & Hepatol, Minist Hlth,Inflammatory Bowel Dis Res Ctr, Shanghai Inst Digest Dis,Renji Hosp,Sch Med,Key L, 160 Pu Jian Ave, Shanghai 200127, Peoples R China.
EM qiaoyuqi@renji.com; qingzheng124@126.com
CR Abu N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.564648
   Ait-Aissa K, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01107-3
   Al Bandar MH, 2017, ONCOL REP, V37, P2553, DOI 10.3892/or.2017.5531
   Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388
   An YY, 2018, J CANCER, V9, P4058, DOI 10.7150/jca.25587
   Bagherniya M, 2018, AGEING RES REV, V47, P183, DOI 10.1016/j.arr.2018.08.004
   Chowdhury S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069132
   Conroy MJ, 2020, ADV EXP MED BIOL, V1231, P1, DOI 10.1007/978-3-030-36667-4_1
   Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Fang YY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.602574
   Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236
   Huang Z, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819894179
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002711
   Li J, 2014, WORLD J GASTROENTERO, V20, P5104, DOI 10.3748/wjg.v20.i17.5104
   Li MJ, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0208-8
   Li T, 2020, AGING DIS, V11, P967, DOI 10.14336/AD.2019.0901
   Li XL, 2015, WORLD J GASTROENTERO, V21, P84, DOI 10.3748/wjg.v21.i1.84
   Maloverjan A, 2010, EXP CELL RES, V316, P627, DOI 10.1016/j.yexcr.2009.10.018
   Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417
   Mo SB, 2019, CARCINOGENESIS, V40, P861, DOI 10.1093/carcin/bgz031
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Packer M, 2020, CARDIOVASC DIABETOL, V19, DOI 10.1186/s12933-020-01041-4
   Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002
   Shi FY, 2018, SEMIN CANCER BIOL, V50, P124, DOI 10.1016/j.semcancer.2017.09.009
   Steinmann S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2122-z
   Su QH, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0336-9
   Wang SS, 2019, ONCOTARGETS THER, V12, P3695, DOI 10.2147/OTT.S197676
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   Xie JM, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180480
   Xu JL, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.621428
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhao YG, 2019, CURR OPIN CELL BIOL, V61, P117, DOI 10.1016/j.ceb.2019.08.003
   Zhou XH, 2020, BMC ENDOCR DISORD, V20, DOI 10.1186/s12902-020-00647-9
NR 35
TC 1
Z9 1
U1 2
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2689-5293
EI 2689-5307
J9 ALL LIFE
JI All Life
PD JAN 1
PY 2021
VL 14
IS 1
BP 91
EP 101
DI 10.1080/26895293.2021.1872716
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA PZ7ZI
UT WOS:000612960700001
OA gold
DA 2022-04-25
ER

PT J
AU Fontana, R
   Ranieri, M
   La Mantia, G
   Vivo, M
AF Fontana, Rosa
   Ranieri, Michela
   La Mantia, Girolama
   Vivo, Maria
TI Dual Role of the Alternative Reading Frame ARF Protein in Cancer
SO BIOMOLECULES
LA English
DT Review
DE tumor suppression; autophagy; anoikis; CDKN2a; ARF locus;
   chemoresistance; FAK sumoylation; actin cytoskeleton
ID TUMOR-SUPPRESSOR PROTEIN; N-TERMINAL POLYUBIQUITINATION; P53-INDEPENDENT
   FUNCTIONS; NUCLEOLAR LOCALIZATION; PHYSICAL INTERACTION; MITOCHONDRIAL
   FORM; GERMLINE MUTATION; OXIDATIVE STRESS; INK4A/ARF LOCUS; STABILIZES
   P53
AB The CDKN2a/ARF locus expresses two partially overlapping transcripts that encode two distinct proteins, namely p14ARF (p19Arf in mouse) and p16INK4a, which present no sequence identity. Initial data obtained in mice showed that both proteins are potent tumor suppressors. In line with a tumor-suppressive role, ARF-deficient mice develop lymphomas, sarcomas, and adenocarcinomas, with a median survival rate of one year of age. In humans, the importance of ARF inactivation in cancer is less clear whereas a more obvious role has been documented for p16INK4a. Indeed, many alterations in human tumors result in the elimination of the entire locus, while the majority of point mutations affect p16INK4a. Nevertheless, specific mutations of p14ARF have been described in different types of human cancers such as colorectal and gastric carcinomas, melanoma and glioblastoma. The activity of the tumor suppressor ARF has been shown to rely on both p53-dependent and independent functions. However, novel data collected in the last years has challenged the traditional and established role of this protein as a tumor suppressor. In particular, tumors retaining ARF expression evolve to metastatic and invasive phenotypes and in humans are associated with a poor prognosis. In this review, the recent evidence and the molecular mechanisms of a novel role played by ARF will be presented and discussed, both in pathological and physiological contexts.
C1 [Fontana, Rosa] Univ Calif San Diego, Moores Canc Ctr, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Ranieri, Michela] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, Div Hematol & Med Oncol, New York, NY 10016 USA.
   [La Mantia, Girolama; Vivo, Maria] Univ Naples Federico II, Dept Biol, I-80126 Naples, Italy.
RP Vivo, M (corresponding author), Univ Naples Federico II, Dept Biol, I-80126 Naples, Italy.
EM rofontana@ucsd.edu; Michela.Ranieri@nyulangone.org; lamantia@unina.it;
   maria.vivo@unina.it
RI Fontana, Rosa/AAD-7852-2019; Vivo, Maria/S-3390-2017
OI Fontana, Rosa/0000-0003-0445-6016; Vivo, Maria/0000-0003-2458-4226;
   Ranieri, Michela/0000-0002-3833-3594
FU University of Naples Federico II [GLAMANTIA 2018]
FX This research received funding from Grant GLAMANTIA 2018 assigned to GLM
   from University of Naples Federico II.
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07
   Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Bartolini D, 2018, TRANSL RES, V193, P54, DOI 10.1016/j.trsl.2017.11.007
   Berggren P, 2003, CLIN CANCER RES, V9, P235
   Berkovich E, 2003, CELL CYCLE, V2, P127, DOI 10.4161/cc.2.2.293
   Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004
   Bieging-Rolett KT, 2016, ONCOGENE, V35, P4414, DOI 10.1038/onc.2015.490
   Bleicher M, 2012, BEILSTEIN J NANOTECH, V3, P556, DOI 10.3762/bjnano.3.64
   Bocci F., 2018, BIORXIV, DOI [10.1101/390237, DOI 10.1101/390237]
   Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500
   Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964
   Britigan EMC, 2014, MOL BIOL CELL, V25, P2761, DOI 10.1091/mbc.E14-05-0966
   Budina-Kolomets A, 2013, AUTOPHAGY, V9, P1553, DOI 10.4161/auto.25831
   Calabro V, 2004, MOL CELL BIOL, V24, P8529, DOI 10.1128/MCB.24.19.8529-8540.2004
   Chen DL, 2010, NATURE, V464, P624, DOI 10.1038/nature08820
   Chen JD, 1996, MOL CELL BIOL, V16, P2445
   Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851
   Chen XY, 2007, MOL CELL, V26, P843, DOI 10.1016/j.molcel.2007.05.022
   Chen ZB, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000053
   Cheng K, 2007, ONCOGENE, V26, P7391, DOI 10.1038/sj.onc.1210549
   Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348
   Churchman ML, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002157
   Clark PA, 2002, ONCOGENE, V21, P4498, DOI 10.1038/sj.onc.1205558
   Collado M, 2010, CANCER CELL, V17, P317, DOI 10.1016/j.ccr.2010.03.015
   Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378
   Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005
   Damalas A, 2011, INT J CANCER, V128, P1989, DOI 10.1002/ijc.25510
   de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434
   del Arroyo AG, 2005, ADV EXP MED BIOL, V570, P227
   den Besten W, 2006, ISR MED ASSOC J, V8, P249
   Deyrieux AF, 2007, J CELL SCI, V120, P125, DOI 10.1242/jcs.03317
   Di Costanzo A, 2011, J CELL PHYSIOL, V226, P2189, DOI 10.1002/jcp.22553
   Di Costanzo A, 2009, CELL CYCLE, V8, P1185, DOI 10.4161/cc.8.8.8202
   di Martino O, 2016, GENES CELLS, V21, P648, DOI 10.1111/gtc.12373
   di Tommaso A, 2009, EXP CELL RES, V315, P1326, DOI 10.1016/j.yexcr.2009.01.010
   Esteller M, 2000, CANCER RES, V60, P129
   Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303
   Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200
   Ferru A, 2006, BRIT J CANCER, V95, P1670, DOI 10.1038/sj.bjc.6603479
   Fontana R, 2018, CANCERS, V10, DOI 10.3390/cancers10070221
   Fontana R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25496-4
   Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gardie B, 1998, BLOOD, V91, P1016, DOI 10.1182/blood.V91.3.1016.1016_1016_1020
   Grenier K, 2014, J BIOL CHEM, V289, P29519, DOI 10.1074/jbc.M114.607150
   Gromley A, 2009, P NATL ACAD SCI USA, V106, P6285, DOI 10.1073/pnas.0902310106
   Guarino AM, 2018, GENES-BASEL, V9, DOI 10.3390/genes9100513
   Gwangwa MV, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0088-y
   Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151
   Haindl M, 2008, EMBO REP, V9, P273, DOI 10.1038/embor.2008.3
   Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Herkert B, 2010, J CELL BIOL, V188, P905, DOI 10.1083/jcb.200908103
   Hewitt C, 2002, HUM MOL GENET, V11, P1273, DOI 10.1093/hmg/11.11.1273
   Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4
   Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22
   Horvat A, 2018, ONCOGENE, V37, P5054, DOI 10.1038/s41388-018-0343-8
   Humbey O, 2008, CANCER RES, V68, P9608, DOI 10.1158/0008-5472.CAN-08-2263
   Ip YC, 2007, MOL CARCINOGEN, V46, P225, DOI 10.1002/mc.20270
   Iqbal N, 2014, CELL CYCLE, V13, P792, DOI 10.4161/cc.27725
   Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3
   Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Kadandale P, 2010, AUTOPHAGY, V6, P1194, DOI 10.4161/auto.6.8.13476
   Kamijo T, 1999, CANCER RES, V59, P2217
   Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292
   Konishi N, 2002, AM J PATHOL, V160, P1207, DOI 10.1016/S0002-9440(10)62547-3
   Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005
   Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002
   Kotsinas A, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00236
   Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0
   Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138
   Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930
   Kuo ML, 2004, CELL CYCLE, V3, P1367, DOI 10.4161/cc.3.11.1244
   Kuo ML, 2004, GENE DEV, V18, P1862, DOI 10.1101/gad.1213904
   Lee YK, 2003, CLIN LAB HAEMATOL, V25, P233, DOI 10.1046/j.1365-2257.2003.00520.x
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Li CL, 2013, P NATL ACAD SCI USA, V110, pE1112, DOI 10.1073/pnas.1302184110
   Li TW, 2006, J BIOL CHEM, V281, P36221, DOI 10.1074/jbc.M608236200
   Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506
   Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3
   Luchinat E, 2018, FEBS J, V285, P832, DOI 10.1111/febs.14373
   Maggi LB, 2014, BBA-MOL BASIS DIS, V1842, P831, DOI 10.1016/j.bbadis.2014.01.016
   Magi Shigeyuki, 2017, Current Opinion in Systems Biology, V2, P39, DOI 10.1016/j.coisb.2017.02.008
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   McKeller RN, 2002, P NATL ACAD SCI USA, V99, P3848, DOI 10.1073/pnas.052484199
   Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Mowers EE, 2016, AUTOPHAGY, V12, P1679, DOI 10.1080/15548627.2016.1203487
   Muniz VP, 2011, MOL CANCER RES, V9, P867, DOI 10.1158/1541-7786.MCR-10-0475
   Nakamura M, 2001, CANCER RES, V61, P6335
   Natale F, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0226-9
   Natale F, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15760
   Owczarek TB, 2017, CANCER RES, V77, P1035, DOI 10.1158/0008-5472.CAN-16-2621
   Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511
   Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870
   Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pickles S, 2018, CURR BIOL, V28, pR170, DOI 10.1016/j.cub.2018.01.004
   Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200
   Pollice A, 2007, ONCOGENE, V26, P5154, DOI 10.1038/sj.onc.1210313
   Pollice A, 2004, J BIOL CHEM, V279, P6345, DOI 10.1074/jbc.M310957200
   Pollice A, 2008, FEBS LETT, V582, P3257, DOI 10.1016/j.febslet.2008.09.026
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   QUELLE DE, 1995, CELL, V83, P993
   Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55
   Ranieri M, 2018, GENE, V645, P34, DOI 10.1016/j.gene.2017.12.018
   Reef S, 2007, ONCOGENE, V26, P6677, DOI 10.1038/sj.onc.1210485
   Reef S, 2006, AUTOPHAGY, V2, P328, DOI 10.4161/auto.3107
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629
   Rizos H, 2001, J BIOL CHEM, V276, P41424, DOI 10.1074/jbc.M105299200
   Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728
   Rodway H, 2004, ONCOGENE, V23, P6186, DOI 10.1038/sj.onc.1207854
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155
   Rutter JL, 2003, ONCOGENE, V22, P4444, DOI 10.1038/sj.onc.1206564
   Sanchez-Aguilera A, 2002, BLOOD, V99, P1411, DOI 10.1182/blood.V99.4.1411
   Sandilands E, 2012, NAT CELL BIOL, V14, P51, DOI 10.1038/ncb2386
   Saporita AJ, 2007, CURR MED CHEM, V14, P1815
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Sfakianos JP, 2015, EUR UROL, V68, P970, DOI 10.1016/j.eururo.2015.07.039
   Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021
   Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5
   Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9
   Sherr CJ, 2005, COLD SH Q B, V70, P129, DOI 10.1101/sqb.2005.70.004
   Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954
   Sherr CJ, 2012, WIRES DEV BIOL, V1, P731, DOI 10.1002/wdev.40
   Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984
   Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312
   Silva J, 2001, ONCOGENE, V20, P4586, DOI 10.1038/sj.onc.1204617
   Silva RLA, 2005, EMBO J, V24, P2803, DOI 10.1038/sj.emboj.7600751
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Su XH, 2009, EMBO J, V28, P1904, DOI 10.1038/emboj.2009.151
   Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1
   Tago K, 2005, P NATL ACAD SCI USA, V102, P7689, DOI 10.1073/pnas.0502978102
   Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937
   Tompkins VS, 2007, J BIOL CHEM, V282, P1322, DOI 10.1074/jbc.M609612200
   Troiano A, 2015, J CELL PHYSIOL, V230, P2067, DOI 10.1002/jcp.24934
   Tsujimoto H, 2002, PATHOL RES PRACT, V198, P785, DOI 10.1078/0344-0338-00337
   Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795
   Vivo M, 2017, ONCOGENE, V36, P4913, DOI 10.1038/onc.2017.104
   Vivo M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117252
   Vivo M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053631
   Vivo M, 2009, CELL CYCLE, V8, P3545, DOI 10.4161/cc.8.21.9954
   Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501
   Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000
   Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991
   Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Xie YQ, 2016, ONCOTARGET, V7, P47609, DOI 10.18632/oncotarget.10251
   Xie YQ, 2014, MOL ONCOL, V8, P1355, DOI 10.1016/j.molonc.2014.05.006
   Xirodimas DP, 2002, FEBS LETT, V528, P207, DOI 10.1016/S0014-5793(02)03310-0
   Yang A, 2014, AUTOPHAGY, V10, P1683, DOI 10.4161/auto.29961
   Zhang Q, 2015, NAT IMMUNOL, V16, P458, DOI 10.1038/ni.3130
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
   Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
   Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100
NR 162
TC 23
Z9 24
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD MAR 4
PY 2019
VL 9
IS 3
AR 87
DI 10.3390/biom9030087
PG 21
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HT2TM
UT WOS:000464416200001
PM 30836703
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhou, J
   Zhang, L
   Wang, M
   Zhou, L
   Feng, XP
   Yu, LL
   Lan, J
   Gao, W
   Zhang, CD
   Bu, YQ
   Huang, CH
   Zhang, HY
   Lei, YL
AF Zhou, Jing
   Zhang, Lu
   Wang, Meng
   Zhou, Li
   Feng, Xuping
   Yu, Linli
   Lan, Jiang
   Gao, Wei
   Zhang, Chundong
   Bu, Youquan
   Huang, Canhua
   Zhang, Haiyuan
   Lei, Yunlong
TI CPX Targeting DJ-1 Triggers ROS-induced Cell Death and Protective
   Autophagy in Colorectal Cancer
SO THERANOSTICS
LA English
DT Article
DE Ciclopirox olamine; DJ-1; mitochondria; ROS; Autophagy
ID OXIDATIVE STRESS; DRUG-RESISTANCE; STAGE-II; CICLOPIROX; EXPRESSION;
   REGULATOR; CHEMOTHERAPY; ANTIOXIDANTS; ACTIVATION; GENES
AB Rationale: Colorectal cancer (CRC) is one of the most common cancers worldwide. Ciclopirox olamine (CPX) has recently been identified to be a promising anticancer candidate; however, novel activities and detailed mechanisms remain to be uncovered.
   Methods: The cytotoxic potential of CPX towards CRC cells was examined in vitro and in vivo. The global gene expression pattern, ROS levels, mitochondrial function, autophagy, apoptosis, etc. were determined between control and CPX-treated CRC cells.
   Results: We found that CPX inhibited CRC growth by inhibiting proliferation and inducing apoptosis both in vitro and in vivo. The anti-cancer effects of CPX involved the downregulation of DJ-1, and overexpression of DJ-1 could reverse the cytotoxic effect of CPX on CRC cells. The loss of DJ-1 resulted in mitochondrial dysfunction and ROS accumulation, thus leading to CRC growth inhibition. The cytoprotective autophagy was provoked simultaneously, and blocking autophagy pharmacologically or genetically could further enhance the anti-cancer efficacy of CPX.
   Conclusion: Our study demonstrates that DJ-1 loss-induced ROS accumulation plays a pivotal role in CPX-mediated CRC inhibition, providing a further understanding for CRC treatment via modulating compensatory protective autophagy.
C1 [Zhou, Jing; Yu, Linli; Zhang, Chundong; Bu, Youquan; Lei, Yunlong] Chongqing Med Univ, Mol Med & Canc Res Ctr, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Meng; Zhou, Li; Feng, Xuping; Lan, Jiang; Gao, Wei; Huang, Canhua] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Meng; Zhou, Li; Feng, Xuping; Lan, Jiang; Gao, Wei; Huang, Canhua] Sichuan Univ, Canc Ctr, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Meng; Zhou, Li; Feng, Xuping; Lan, Jiang; Gao, Wei; Huang, Canhua] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Sichuan, Peoples R China.
   [Zhou, Jing; Zhang, Lu; Wang, Meng; Zhou, Li; Feng, Xuping; Lan, Jiang; Gao, Wei; Huang, Canhua] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Sichuan, Peoples R China.
   [Zhang, Haiyuan] Hainan Med Univ, Key Lab Trop Dis & Translat Med, Minist Educ, Haikou, Hainan, Peoples R China.
   [Zhang, Haiyuan] Hainan Med Univ, Dept Neurol, Affiliated Hosp 1, Haikou, Hainan, Peoples R China.
RP Zhang, HY (corresponding author), Hainan Med Univ, Key Lab Trop Dis & Translat Med, Minist Educ, Haikou, Hainan, Peoples R China.; Zhang, HY (corresponding author), Hainan Med Univ, Dept Neurol, Affiliated Hosp 1, Haikou, Hainan, Peoples R China.; Lei, YL (corresponding author), Chongqing Med Univ, Dept Biochem & Mol Biol, Chongqing 400016, Peoples R China.; Lei, YL (corresponding author), Chongqing Med Univ, Mol Med & Canc Res Ctr, Chongqing 400016, Peoples R China.
EM hyzhang_88@163.com; leiyunlong@cqmu.edu.cn
OI Lei, Yunlong/0000-0002-7918-0221
FU Chinese NSFCNational Natural Science Foundation of China (NSFC)
   [81660499, 81872014, 81401951]; Chongqing Natural Science
   FoundationNatural Science Foundation of Chongqing [cstc2016jcyjA0227];
   Scientific and Technological Research Program of Chongqing Municipal
   Education Commission [KJQN201800429]
FX This work was supported by grants from Chinese NSFC (81660499, 81872014,
   and 81401951), Chongqing Natural Science Foundation (cstc2016jcyjA0227),
   and Scientific and Technological Research Program of Chongqing Municipal
   Education Commission (Grant No. KJQN201800429).
CR ALPERMANN HG, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1328
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Auberger P, 2017, BLOOD, V129, P547, DOI 10.1182/blood-2016-07-692707
   Bardia A, 2010, SEMIN ONCOL, V37, P39, DOI 10.1053/j.seminoncol.2009.12.005
   Bernier KM, 2018, ANTIVIR RES, V156, P102, DOI 10.1016/j.antiviral.2018.06.010
   Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cao J, 2015, BIOCHEM PHARMACOL, V93, P241, DOI 10.1016/j.bcp.2014.11.012
   Chan JYH, 2015, PHARMACOL THERAPEUT, V156, P69, DOI 10.1016/j.pharmthera.2015.09.005
   Clement PMJ, 2002, INT J CANCER, V100, P491, DOI 10.1002/ijc.10515
   Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103
   Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597
   Davidson B, 2008, HUM PATHOL, V39, P87, DOI 10.1016/j.humpath.2007.05.014
   Eberhard Y, 2009, BLOOD, V114, P3064, DOI 10.1182/blood-2009-03-209965
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Hering R, 2004, HUM MUTAT, V24, P321, DOI 10.1002/humu.20089
   Hod Y, 2004, J CELL BIOCHEM, V92, P1221, DOI 10.1002/jcb.20159
   Im JY, 2010, NEUROSCI RES, V67, P203, DOI 10.1016/j.neures.2010.04.002
   Irrcher I, 2010, HUM MOL GENET, V19, P3734, DOI 10.1093/hmg/ddq288
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   JUE SG, 1985, DRUGS, V29, P330, DOI 10.2165/00003495-198529040-00002
   Junn E, 2005, P NATL ACAD SCI USA, V102, P9691, DOI 10.1073/pnas.0409635102
   Kang JA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10200-5
   KELLNER HM, 1981, ARZNEIMITTEL-FORSCH, V31-2, P1337
   Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Korting HC, 1997, MYCOSES, V40, P243, DOI 10.1111/j.1439-0507.1997.tb00227.x
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Lin XM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00954
   Linden T, 2003, FASEB J, V17, P761, DOI 10.1096/fj.02-0586fje
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Maes H, 2013, TRENDS MOL MED, V19, P428, DOI 10.1016/j.molmed.2013.04.005
   Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC
   Memin E, 2014, CANCER RES, V74, P552, DOI 10.1158/0008-5472.CAN-13-0474
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   MIHAILIDOU C, 2017, ANN ONCOL S11, V28
   Mihailidou Chrysovalantou, 2018, Oncotarget, V9, P10360, DOI 10.18632/oncotarget.23164
   Minden MD, 2014, AM J HEMATOL, V89, P363, DOI 10.1002/ajh.23640
   Niewerth M, 2003, ANTIMICROB AGENTS CH, V47, P1805, DOI 10.1128/AAC.47.6.1805-1817.2003
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   Shen Tao, 2017, Genes Cancer, V8, P505, DOI 10.18632/genesandcancer.135
   Shen T, 2016, CURR PHARM DESIGN, V22, P4443, DOI 10.2174/1381612822666160530151209
   Shi SY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8415
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Subissi A, 2010, DRUGS, V70, P2133, DOI 10.2165/11538110-000000000-00000
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Thomas KJ, 2011, HUM MOL GENET, V20, P40, DOI 10.1093/hmg/ddq430
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Wang K., 2017, IEEE T SMART GRID, VPP, P1
   Weir SJ, 2019, THE JOURNAL OF PHARM
   Wu JR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161509
   Xie N, 2016, AUTOPHAGY, V12, P1507, DOI 10.1080/15548627.2016.1191857
   Yang J, 2017, CANCER RES, V77, P4626, DOI [10.1158/0008-5472.can-16-0826, 10.1158/0008-5472.CAN-16-0826]
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhou HY, 2014, ONCOTARGET, V5, P10140, DOI 10.18632/oncotarget.2471
   Zhou HY, 2010, INT J CANCER, V127, P2467, DOI 10.1002/ijc.25255
   Zhou J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0883-4
   Zhou WB, 2005, J BIOL CHEM, V280, P43150, DOI 10.1074/jbc.M507124200
   Zhu H, 2014, FREE RADICAL BIO MED, V71, P121, DOI 10.1016/j.freeradbiomed.2014.03.026
NR 63
TC 33
Z9 33
U1 7
U2 18
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2019
VL 9
IS 19
BP 5577
EP 5594
DI 10.7150/thno.34663
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IR7DF
UT WOS:000481600100011
PM 31534504
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Son, HJ
   Jo, YS
   Kim, MS
   Yoo, NJ
   Lee, SH
AF Son, Hyun Ji
   Jo, Yun Sol
   Kim, Min Sung
   Yoo, Nam Jin
   Lee, Sug Hyung
TI DAB2IP with tumor-inhibiting activities exhibits frameshift mutations in
   gastrointestinal cancers
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE DAB2; DAB2IP; Tumor suppressor gene; Frameshift mutation; GI cancer;
   Microsatellite instability
ID ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; PROSTATE-CANCER;
   DOWN-REGULATION; MICROSATELLITE INSTABILITY; UROTHELIAL CARCINOMA;
   EXPRESSION; HETEROGENEITY; DOC-2/DAB2; AUTOPHAGY
AB A scaffold protein DAB2 and its interaction partner DAB2IP have putative tumor suppressor gene (TSG) functions. Previous studies identified that both DAB2 and DAB2IP genes were inactivated by promoter hypermethylation in human cancers, but their mutational alterations in cancers remain largely unknown. The aim of our study was to find whether DAB2 and DAB2IP were mutated in gastric (GCs) and colorectal cancers (CRCs) by DNA sequencing. Both DAB2 and DAB2IP have mononucleotide repeats in their coding sequence that could be mutation targets in high microsatellite instability (MSI-H) cancers. We analyzed GC and CRC tissues and found that 8 of 34 GCs (23.5%) and 15 of 79 CRCs (20.0%) with MSI-H harbored DAB2IP frameshift mutations. DAB2 frameshift mutations were found in 2 of 79 CRCs (2.5%) with MSI-H. These mutations were not detected in microsatellite stable (MSS) cancers. We also found intratumoral heterogeneity (ITH) of DAB2IP frameshift mutations in 7 of 16 CRCs (43.8%). Loss of DAB2IP protein expression was found in approximately 20% of GCs and CRCs irrespective of MSI and DAB2IP frameshift mutation status. Our study shows that the TSG DAB2IP harbored frameshift mutations and ITH as well as expression loss. Together these tumor alterations might play a role in tumorigenesis of GC and CRC with MSI-H by down-regulating the tumor-inhibiting activities of DAB2IP.
C1 [Son, Hyun Ji; Jo, Yun Sol; Kim, Min Sung; Yoo, Nam Jin; Lee, Sug Hyung] Catholic Univ Korea, Dept Pathol, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.
RP Lee, SH (corresponding author), Catholic Univ Korea, Dept Pathol, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.
EM suhulee@catholic.ac.kr
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [2012R1A5A2047939]
FX This study was supported by grants from National Research Foundation of
   Korea (2012R1A5A2047939).
CR Akiyama Y, 2003, MOL CELL BIOL, V23, P8429, DOI 10.1128/MCB.23.23.8429-8439.2003
   Bellazzo A, 2017, CELL DEATH DIFFER, V24, P15, DOI 10.1038/cdd.2016.134
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458
   Finkielstein CV, 2016, BIOESSAYS, V38, pS45, DOI 10.1002/bies.201670907
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228
   Jiang Y, 2009, ONCOGENE, V28, P2999, DOI 10.1038/onc.2009.157
   Jou YC, 2016, VIRCHOWS ARCH, V468, P733, DOI 10.1007/s00428-016-1924-y
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Karam JA, 2007, CLIN CANCER RES, V13, P4400, DOI 10.1158/1078-0432.CCR-07-0287
   Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim MS, 2015, PATHOLOGY, V47, P598, DOI 10.1097/PAT.0000000000000305
   Kim TM, 2014, J PATHOL, V233, P425, DOI 10.1002/path.4380
   Kleeff J, 2002, DIS COLON RECTUM, V45, P1242, DOI 10.1007/s10350-004-6399-2
   Kong ZL, 2010, CANCER RES, V70, P2829, DOI 10.1158/0008-5472.CAN-09-2919
   Li C, 2015, AM J MED SCI, V349, P425, DOI 10.1097/MAJ.0000000000000436
   Liu L, 2016, ONCOTARGET, V7, P3766, DOI 10.18632/oncotarget.6501
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769
   Murphy KM, 2006, J MOL DIAGN, V8, P305, DOI 10.2353/jmoldx.2006.050092
   Oh HR, 2015, PATHOLOGY, V47, P101, DOI 10.1097/PAT.0000000000000212
   Tong JH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-253
   Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Yu L, 2012, NEOPLASIA, V14, P1203, DOI 10.1593/neo.121310
   Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x
   Zhou J, 2001, J BIOL CHEM, V276, P27793, DOI 10.1074/jbc.M102803200
NR 30
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD DEC
PY 2018
VL 214
IS 12
BP 2075
EP 2080
DI 10.1016/j.prp.2018.10.005
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA HG0YQ
UT WOS:000454675600023
PM 30477644
DA 2022-04-25
ER

PT J
AU Wang, XK
   Lan, ZX
   He, J
   Lai, QH
   Yao, X
   Li, QY
   Liu, YF
   Lai, HS
   Gu, CC
   Yan, Q
   Fang, YX
   Zhang, Y
   Li, AM
   Liu, SD
AF Wang, Xinke
   Lan, Zhixian
   He, Juan
   Lai, Qiuhua
   Yao, Xiang
   Li, Qingyuan
   Liu, Yongfeng
   Lai, Huasheng
   Gu, Chuncai
   Yan, Qun
   Fang, Yuxin
   Zhang, Yue
   Li, Aimin
   Liu, Side
TI LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by
   sponging miR-26a-5p in colorectal cancer cells
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Colorectal cancer; SNHG6; ULK1-induced autophagy; Chemoresistance; ceRNA
ID COMPETING ENDOGENOUS RNA; LONG NONCODING RNA; SIGNALING PATHWAY;
   EXPRESSION; PROLIFERATION; PROGRESSION; MECHANISMS; UPF1; EMT
AB Background Chemotherapy resistance is one of the main causes of recurrence in colorectal cancer (CRC) patients and leads to poor prognosis. Long noncoding RNAs (lncRNAs) have been reported to regulate chemoresistance. We aimed to determine the role of the lncRNA small nucleolar RNA host gene 6 (SNHG6) in CRC cell chemoresistance. Methods Cell drug sensitivity tests and flow cytometry were performed to analyze CRC cell chemoresistance. Animal models were used to determine chemoresistance in vivo, and micro RNA (miRNA) binding sites were detected by dual-luciferase reporter assays. Bioinformatics analysis was performed to predict miRNAs binding to SNHG6 and target genes of miR-26a-5p. SNHG6/miR-26a-5p/ULK1 axis and autophagy-related proteins were detected by qRT-PCR and western blotting. Furthermore, immunofluorescence was employed to confirm the presence of autophagosomes. Results SNHG6 enhanced CRC cell resistance to 5-fluorouracil (5-FU), promoted autophagy, inhibited 5-FU-induced apoptosis, and increased 5-FU resistance in vivo. Bioinformatics analysis showed that miR-26a-5p might bind to SNHG6 and target ULK1, and dual-luciferase reporter assays confirmed this activity. qRT-PCR and western blotting showed that SNHG6 was able to negatively regulate miR-26a-5p but correlated positively with ULK1. Conclusion SNHG6 may promote chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in CRC cells.
C1 [Wang, Xinke; Lan, Zhixian; He, Juan; Lai, Qiuhua; Yao, Xiang; Li, Qingyuan; Liu, Yongfeng; Lai, Huasheng; Gu, Chuncai; Yan, Qun; Fang, Yuxin; Zhang, Yue; Li, Aimin; Liu, Side] Southern Med Univ, Guangdong Prov Key Lab Gastroenterol, Dept Gastroenterol, Nanfang Hosp, 1838 Guangzhou Ave North, Guangzhou, Guangdong, Peoples R China.
RP Li, AM; Liu, SD (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Gastroenterol, Dept Gastroenterol, Nanfang Hosp, 1838 Guangzhou Ave North, Guangzhou, Guangdong, Peoples R China.
EM Lam0725@163.com; Liuside2011@163.com
FU China Postdoctoral Science FoundationChina Postdoctoral Science
   Foundation [2018M643130]; Medical Scientific Research Foundation of
   Guangdong Province, China [A2019538]; Guangdong gastrointestinal disease
   research center [2017B020209003]; Special Scientific Research Fund of
   Public Welfare Profession of National Health and Family Planning
   Commission [201502026]
FX This research was funded by China Postdoctoral Science Foundation, Grant
   Number 2018M643130; Medical Scientific Research Foundation of Guangdong
   Province, China, Grant Number A2019538; Guangdong gastrointestinal
   disease research center, Grant Number 2017B020209003; the Special
   Scientific Research Fund of Public Welfare Profession of National Health
   and Family Planning Commission, Grant Number 201502026.
CR Antonioli M, 2017, TRENDS BIOCHEM SCI, V42, P28, DOI 10.1016/j.tibs.2016.09.008
   Bester AC, 2018, CELL, V173, P649, DOI 10.1016/j.cell.2018.03.052
   Cao C, 2017, ONCOGENE, V36, P1112, DOI 10.1038/onc.2016.278
   Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012
   Chang L, 2016, CANCER LETT, V383, P183, DOI 10.1016/j.canlet.2016.09.034
   Ebert MPA, 2012, NEW ENGL J MED, V366, P44, DOI 10.1056/NEJMoa1009473
   Fitzmaurice C, 2018, JAMA ONCOL, V4, P1553, DOI 10.1001/jamaoncol.2018.2706
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Hurley JH, 2017, ANNU REV BIOCHEM, V86, P225, DOI 10.1146/annurev-biochem-061516-044820
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Lee S, 2016, CELL, V164, P69, DOI 10.1016/j.cell.2015.12.017
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li Y, 2018, LIFE SCI, V208, P295, DOI 10.1016/j.lfs.2018.07.032
   Li ZM, 2018, CELL PHYSIOL BIOCHEM, V49, P463, DOI 10.1159/000492986
   Liang R, 2018, BIOMED PHARMACOTHER, V107, P1434, DOI 10.1016/j.biopha.2018.08.099
   Lin MG, 2016, CURR OPIN CELL BIOL, V39, P61, DOI 10.1016/j.ceb.2016.02.010
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722
   Papinski D, 2016, J MOL BIOL, V428, P1725, DOI 10.1016/j.jmb.2016.03.030
   Russell RC, 2013, NAT CELL BIOL, V15, P741, DOI 10.1038/ncb2757
   Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang CY, 2019, J CELL BIOCHEM, V120, P357, DOI 10.1002/jcb.27387
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang P, 2019, NUCLEIC ACIDS RES, V47, pD121, DOI 10.1093/nar/gky1144
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Wang YJ, 2019, BOSNIAN J BASIC MED, V19, P155, DOI 10.17305/bjbms.2019.3935
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Yan K, 2017, CELL PHYSIOL BIOCHEM, V42, P999, DOI 10.1159/000478682
   Yu G, 2014, MOL CANCER THER, V13, P3086, DOI 10.1158/1535-7163.MCT-14-0245
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang L, 2018, J MED CHEM, V61, P6491, DOI 10.1021/acs.jmedchem.7b01684
   Zhao Y, 2016, NUCLEIC ACIDS RES, V44, pD203, DOI 10.1093/nar/gkv1252
   Zhu X, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0794-1
   Zhu YK, 2018, ONCOTARGETS THER, V11, P5743, DOI 10.2147/OTT.S170246
   Zou WP, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad7118
NR 45
TC 47
Z9 49
U1 1
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD SEP 9
PY 2019
VL 19
IS 1
AR 234
DI 10.1186/s12935-019-0951-6
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IW4MU
UT WOS:000484955100003
PM 31516391
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lin, SC
   Yang, LH
   Yao, YL
   Xu, LY
   Xiang, YQ
   Zhao, HY
   Wang, LX
   Zuo, ZG
   Huang, XY
   Zhao, CG
AF Lin, Shichong
   Yang, Lehe
   Yao, Yulei
   Xu, Lingyuan
   Xiang, Youqun
   Zhao, Haiyang
   Wang, Liangxing
   Zuo, Zhigui
   Huang, Xiaoying
   Zhao, Chengguang
TI Flubendazole demonstrates valid antitumor effects by inhibiting STAT3
   and activating autophagy
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Article
DE Flubendazole; Colorectal cancer; STAT3; Autophagy; Apoptosis
ID CANCER; RESISTANCE; OVERCOMES
AB BackgroundSignal transducer and activator of transcription 3 (STAT3) is an oncogene, which upregulates in approximately 70% of human cancers. Autophagy is an evolutionarily conserved process which maintains cellular homeostasis and eliminates damaged cellular components. Moreover, the STAT3 signaling pathway, which may be triggered by cancer cells, has been implicated in the autophagic process.MethodsIn this study, we found that the anthelmintic flubendazole exerts potent antitumor activity in three human colorectal cancer (CRC) cell lines and in the nude mouse model. The inhibition of cell proliferation in vitro by flubendazole was evaluated using a clonogenic assay and the MTT assay. Western blot analysis, flow cytometry analysis, siRNA growth experiment and cytoplasmic and nuclear protein extraction were used to investigate the mechanisms of inhibiting STAT3 signaling and activation of autophagy induced by flubendazole. Additionally, the expression of STAT3 and mTOR was analyzed in paired colorectal cancer and normal tissues collected from clinical patients.ResultsFlubendazole blocked the IL6-induced nuclear translocation of STAT3, which led to inhibition of the transcription of STAT3 target genes, such as MCL1, VEGF and BIRC5. In addition, flubendazole also reduced the expression of P-mTOR, P62, BCL2, and upregulated Beclin1 and LC3-I/II, which are major autophagy-related genes. These processes induced potent cell apoptosis in CRC cells. In addition, flubendazole displayed a synergistic effect with the chemotherapeutic agent 5-fluorouracil in the treatment of CRC.ConclusionsTaken together, these results indicate that flubendazole exerts antitumor activities by blocking STAT3 signaling and inevitably affects the autophagy pathway. Flubendazole maybe a novel anticancer drug and offers a distinctive therapeutic strategy in neoadjuvant chemotherapy of CRC.
C1 [Lin, Shichong; Yang, Lehe; Yao, Yulei; Xu, Lingyuan; Zhao, Chengguang] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China.
   [Lin, Shichong; Yang, Lehe; Yao, Yulei; Xu, Lingyuan; Xiang, Youqun; Wang, Liangxing; Zuo, Zhigui; Huang, Xiaoying] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
   [Zhao, Haiyang] Wenzhou Univ, Inst Life Sci, Wenzhou 325035, Zhejiang, Peoples R China.
RP Zhao, CG (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China.; Zuo, ZG; Huang, XY (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
EM zuozg007@126.com; zjwzhxy@126.com; zhaochengguang@wmu.edu.cn
RI Zhao, Chengguang/AAK-2981-2021
FU Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [LY17H160055]; Medical Scientific
   Research Fund of Zhejiang Province [2019322308]; Wenzhou science and
   technology project [Y20170280]
FX This work was financially supported by the Zhejiang Provincial Natural
   Science Foundation of China (LY17H160055), Medical Scientific Research
   Fund of Zhejiang Province (2019322308) and Wenzhou science and
   technology project (Y20170280).
CR Beebe JD, 2018, PHARMACOL THERAPEUT, V191, P74, DOI 10.1016/j.pharmthera.2018.06.006
   Canova Kristyna, 2017, Acta Medica (Hradec Kralove), V60, P5, DOI 10.14712/18059694.2017.44
   Chauhan S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9620
   Fu SL, 2019, CANCER LETT, V448, P11, DOI 10.1016/j.canlet.2019.01.026
   Huang Z, 2018, THERANOSTICS, V8, P4995, DOI 10.7150/thno.26627
   Huynh J, 2019, NAT REV CANCER, V19, P82, DOI 10.1038/s41568-018-0090-8
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Keklikoglou I, 2019, NAT CELL BIOL, V21, P190, DOI 10.1038/s41556-018-0256-3
   Kim YJ, 2018, CANCER LETT, V412, P118, DOI 10.1016/j.canlet.2017.10.020
   Kuo WY, 2017, THERANOSTICS, V7, P647, DOI 10.7150/thno.16827
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388-018-0340-y
   Oh E, 2018, INT J CANCER, V143, P1978, DOI 10.1002/ijc.31585
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Spagnuolo PA, 2010, BLOOD, V115, P4824, DOI 10.1182/blood-2009-09-243055
   Wei J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1072-8
   Wei N, 2019, ONCOGENE, V38, P1676, DOI 10.1038/s41388-018-0547-y
   Wolf AMD, 2018, CA-CANCER J CLIN, V68, P250, DOI 10.3322/caac.21457
   Yang LH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1015-9
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Zhang T, 2017, ONCOGENE, V36, P6627, DOI 10.1038/onc.2017.270
   Zhao CG, 2016, TRENDS PHARMACOL SCI, V37, P47, DOI 10.1016/j.tips.2015.10.001
   Zheng HL, 2019, MOL CARCINOGEN, V58, P565, DOI 10.1002/mc.22951
   Zheng K, 2019, THERANOSTICS, V9, P104, DOI 10.7150/thno.30308
   Zhu H, 2018, THERANOSTICS, V8, P676, DOI 10.7150/thno.21463
NR 27
TC 23
Z9 24
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD JUL 8
PY 2019
VL 38
AR 293
DI 10.1186/s13046-019-1303-z
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IJ1SX
UT WOS:000475679700002
PM 31287013
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, MH
   Zhao, G
   Zhang, D
   An, WX
   Lai, HL
   Li, XF
   Cao, SS
   Lin, XK
AF Liu, Minghua
   Zhao, Ge
   Zhang, Dan
   An, Weixiao
   Lai, Honglin
   Li, Xiaofang
   Cao, Shousong
   Lin, Xiukun
TI Active fraction of clove induces apoptosis via PI3K/Akt/mTOR-mediated
   autophagy in human colorectal cancer HCT-116 cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE clove; apoptosis; autophagy; coloretal cancer; phosphoinositide
   3-kinase; Akt; mechanistic target of rapamycin pathway
ID SYZYGIUM-AROMATICUM L.; OLEANOLIC ACID; EUGENIA-CARYOPHYLLATA; ESSENTIAL
   OIL; IN-VITRO; INHIBITION; INDUCTION; PATHWAYS; CYCLE; SUPPRESSION
AB Previous studies by our group have demonstrated that extract of clove exhibits potent anticancer effects in vitro and in vivo. In the present study, the effect of an extracted and isolated active fraction of clove (AFC) on induction of cellular apoptosis in human colorectal cancer HCT-116 cells was investigated by morphological observation, flow cytometry, and western blotting analysis. The results revealed that AFC induced apoptosis of HCT-116 cells. AFC also induced autophagy, demonstrated by increased punctuate microtubule-associated protein 1A/1B-light chain 3 (LC3) staining, and LC3-II and Beclin-1 protein expression levels. Furthermore, the autophagy inhibitors 3-MA and baflomycin A1 potentiated the pro-apoptotic activity of AFC in HCT-116 cells. AFC also inhibited the phosphorylation of the phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin signaling pathway. The present study may improve the existing understanding of the anticancer mechanisms of clove and provide a scientific rationale for AFC to be further developed as a promising novel anticancer agent for the treatment of colorectal cancer.
C1 [Liu, Minghua; Zhao, Ge; Zhang, Dan; An, Weixiao; Lai, Honglin; Li, Xiaofang; Cao, Shousong; Lin, Xiukun] Southwest Med Univ, Sch Pharm, Dept Pharmacol, 319 Zhongshan Rd, Luzhou 646000, Sichuan, Peoples R China.
RP Cao, SS; Lin, XK (corresponding author), Southwest Med Univ, Sch Pharm, Dept Pharmacol, 319 Zhongshan Rd, Luzhou 646000, Sichuan, Peoples R China.
EM shousongc@gmail.com; linxiukun@yahoo.com
OI Lin, Xiukun/0000-0002-0306-4953
FU National innovative drug development projects of China
   [014ZX-09102043-001]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81302906,
   81273550, 41306157]; Distinguished Professor Research Startup Funding
   from Southwest Medical University; Sichuan Sci. and Tech Dept., China
   [2017SZ0201, 17GJHZ0074]
FX The present study was supported by grants from the National innovative
   drug development projects of China (grant no. 014ZX-09102043-001),
   National Natural Science Foundation of China (grant nos. 81302906,
   81273550 and 41306157), and the Distinguished Professor Research Startup
   Funding (SC and XKL) from Southwest Medical University. This study was
   also supported in part by the grants from Sichuan Sci. and Tech Dept.,
   China (grant nos. 2017SZ0201 and 17GJHZ0074).
CR Abd El Azim M, 2014, J MICROBIAL BIOCH TE, V007, pS8
   Aboubakr HA, 2016, J FOOD PROTECT, V79, P1001, DOI 10.4315/0362-028X.JFP-15-593
   Al-Daghri NM, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-202
   Al-Sharif I, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-600
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950
   Apel A, 2009, INT J CANCER, V125, P991, DOI 10.1002/ijc.24500
   Banerjee S, 2006, CARCINOGENESIS, V27, P1645, DOI 10.1093/carcin/bgi372
   Brouquet A, 2013, NAT REV GASTRO HEPAT, V10, P266, DOI 10.1038/nrgastro.2013.53
   Chen X, 2017, ONCOL REP, V38, P1051, DOI 10.3892/or.2017.5747
   Cheng Y, 2014, BIOMED REP, V2, P188, DOI 10.3892/br.2013.211
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Gerl R, 2005, CARCINOGENESIS, V26, P263, DOI 10.1093/carcin/bgh283
   Ghosh R, 2005, J BIOL CHEM, V280, P5812, DOI 10.1074/jbc.M411429200
   Gulcin I, 2004, FOOD CHEM, V87, P393, DOI 10.1016/j.foodchem.2003.12.008
   Han XS, 2017, PHARM BIOL, V55, P1619, DOI 10.1080/13880209.2017.1314513
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Klionsky DJ, 2011, AUTOPHAGY, V7, P1273, DOI 10.4161/auto.7.11.17661
   Kubatka P, 2017, J CELL MOL MED, V21, P2837, DOI 10.1111/jcmm.13197
   Kuipers EJ, 2013, NAT REV CLIN ONCOL, V10, P130, DOI 10.1038/nrclinonc.2013.12
   Li HM, 2013, ONCOL LETT, V6, P885, DOI 10.3892/ol.2013.1497
   Li JP, 2015, DRUG DES DEV THER, V9, P1627, DOI 10.2147/DDDT.S75378
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu HZ, 2013, ONCOL RES, V21, P247, DOI 10.3727/096504014X13946388748910
   Liu J, 2014, ONCOL REP, V32, P567, DOI 10.3892/or.2014.3239
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Nagelkerke A, 2015, SEMIN CANCER BIOL, V31, P99, DOI 10.1016/j.semcancer.2014.06.001
   Periyasamy-Thandavan S, 2008, KIDNEY INT, V74, P631, DOI 10.1038/ki.2008.214
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Pourgholami MH, 1999, J ETHNOPHARMACOL, V64, P167, DOI 10.1016/S0378-8741(98)00121-4
   Povsic TJ, 2003, J BIOL CHEM, V278, P51334, DOI 10.1074/jbc.M309968200
   Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schmoll HJ, 2014, NAT REV CLIN ONCOL, V11, P79, DOI 10.1038/nrclinonc.2013.254
   Shanmugam MK, 2014, CANCER LETT, V346, P206, DOI 10.1016/j.canlet.2014.01.016
   Shao XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35482
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Slamenova D, 2009, MUTAT RES-GEN TOX EN, V677, P46, DOI 10.1016/j.mrgentox.2009.05.016
   Tanko Y, 2008, AFR J TRADIT COMPLEM, V5, P209
   Wei JT, 2013, J APPL TOXICOL, V33, P756, DOI 10.1002/jat.2725
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wlodkowic D, 2011, METHOD CELL BIOL, V103, P55, DOI 10.1016/B978-0-12-385493-3.00004-8
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   Yang SJ, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-12
   Yi JL, 2015, INT J CLIN EXP PATHO, V8, P1116
   Zarzynska JM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/710345
   Zhirnov OP, 2007, APOPTOSIS, V12, P1419, DOI 10.1007/s10495-007-0071-y
NR 54
TC 18
Z9 19
U1 3
U2 31
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD SEP
PY 2018
VL 53
IS 3
BP 1363
EP 1373
DI 10.3892/ijo.2018.4465
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GP1NO
UT WOS:000440583100039
PM 30015913
OA Bronze
DA 2022-04-25
ER

PT J
AU Itahana, Y
   Itahana, K
AF Itahana, Yoko
   Itahana, Koji
TI Emerging Roles of Mitochondrial p53 and ARF
SO CURRENT DRUG TARGETS
LA English
DT Review
DE ARF; apoptosis; autophagy; mitochondria; mitochondrial localization;
   mitochondrial metabolism; p53; tumor suppressor
ID DNA-BINDING DOMAIN; COLORECTAL-CANCER CELLS; BASE EXCISION-REPAIR;
   TUMOR-SUPPRESSOR P53; NUCLEOLAR LOCALIZATION; P53-DEPENDENT APOPTOSIS;
   FUNCTIONAL INTERACTIONS; INDUCE APOPTOSIS; ACTIVATES P53; PROTEIN
AB After mitochondria colonized eukaryotic cells more than a billion years ago, they acquired numerous functions over the course of evolution, such as those involved in controlling apoptosis, autophagy, and cellular metabolism together with host cells. The major tumor suppressors, p53 and ARF in the nucleus also participate in such crosstalk between host cells and mitochondria by activating p53 target genes involved in varied mitochondrial functions. However, recent evidence suggests that p53 and ARF can also directly localize to mitochondria and contribute to this cross talk to maintain tissue homeostasis for the prevention of various diseases. Here, we discuss the functions of mitochondrial p53 and ARF via interactions with mitochondrial proteins as well as the mechanism of the localization of p53 and ARF to mitochondria. Because mitochondrial dysregulation is involved in the development of several disease types, such as cancer, neurodegenerative diseases, and age-related diseases, understanding the roles of p53 and ARF in mitochondria may facilitate the development of novel mitochondrial-specific drug targets against such diseases.
C1 [Itahana, Yoko; Itahana, Koji] Duke NUS Grad Med Sch Singapore, Canc & Stem Cell Biol Program, Singapore 169857, Singapore.
RP Itahana, K (corresponding author), Duke NUS Grad Med Sch Singapore, Canc & Stem Cell Biol Program, Rm 07-18,Level 7,8 Coll Rd, Singapore 169857, Singapore.
EM koji.itahana@duke-nus.edu.sg
RI Itahana, Koji/J-5505-2013
OI Itahana, Koji/0000-0002-7241-2894
FU NMRC IRG grant [NMRC/1303/2011]; St. Baldrick's Foundation International
   Beneficiary grant; Duke-National University of Singapore core grant
FX We acknowledge the funding from NMRC IRG grant (NMRC/1303/2011), St.
   Baldrick's Foundation International Beneficiary grant, and Duke-National
   University of Singapore core grant.
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819
   Assaily W, 2011, MOL CELL, V44, P491, DOI 10.1016/j.molcel.2011.08.038
   Bakhanashvili M, 2009, AIDS, V23, P779, DOI 10.1097/QAD.0b013e328329c74e
   Balaburski GM, 2010, TRENDS CELL BIOL, V20, P363, DOI 10.1016/j.tcb.2010.02.007
   Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004
   CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0
   Chen DX, 2006, CANCER RES, V66, P3485, DOI 10.1158/0008-5472.CAN-05-4103
   Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297
   Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   de Souza-Pinto NC, 2004, ONCOGENE, V23, P6559, DOI 10.1038/sj.onc.1207874
   Deng XM, 2006, MOL CELL BIOL, V26, P4421, DOI 10.1128/MCB.01647-05
   Dhar SK, 2009, J BIOL CHEM, V284, P16409, DOI 10.1074/jbc.M109.005736
   Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809
   Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587
   HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170
   Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107
   Humbey O, 2008, CANCER RES, V68, P9608, DOI 10.1158/0008-5472.CAN-08-2263
   Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111
   Ide T, 2009, MOL CELL, V36, P379, DOI 10.1016/j.molcel.2009.09.031
   Irvine M, 2010, CELL CYCLE, V9, P829, DOI 10.4161/cc.9.4.10785
   Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10
   Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3
   Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002
   Itahana K, 2008, CELL CYCLE, V7, P3641, DOI 10.4161/cc.7.23.7105
   Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06
   Johnson TM, 2008, P NATL ACAD SCI USA, V105, P1215, DOI 10.1073/pnas.0706764105
   Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292
   Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3
   Kim SH, 2003, P NATL ACAD SCI USA, V100, P211, DOI 10.1073/pnas.0135557100
   Korgaonkar C, 2005, MOL CELL BIOL, V25, P1258, DOI 10.1128/MCB.25.4.1258-1271.2005
   Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154
   Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560
   Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nithipongvanitch R, 2007, J HISTOCHEM CYTOCHEM, V55, P629, DOI 10.1369/jhc.6A7146.2007
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870
   Park BS, 2005, APOPTOSIS, V10, P193, DOI 10.1007/s10495-005-6074-7
   Park JY, 2009, CIRC RES, V105, P705, DOI 10.1161/CIRCRESAHA.109.205310
   Pietsch EC, 2008, J BIOL CHEM, V283, P21294, DOI 10.1074/jbc.M710539200
   Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200
   Pimkina JS, 2011, CANCER BIOL THER, V12, P503, DOI 10.4161/cbt.12.6.15976
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   Reef S, 2007, ONCOGENE, V26, P6677, DOI 10.1038/sj.onc.1210485
   Reef S, 2008, AUTOPHAGY, V4, P866, DOI 10.4161/auto.6691
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Rizos H, 2000, ONCOGENE, V19, P2978, DOI 10.1038/sj.onc.1203629
   Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Saleem A, 2009, PHYSIOL GENOMICS, V37, P58, DOI 10.1152/physiolgenomics.90346.2008
   Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954
   Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965
   Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001
   Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Sykes SM, 2009, J BIOL CHEM, V284, P20197, DOI 10.1074/jbc.M109.026096
   Szklarczyk R, 2007, P NATL ACAD SCI USA, V104, P12807, DOI 10.1073/pnas.0703238104
   Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200
   Ueda Y, 2008, FEBS LETT, V582, P1459, DOI 10.1016/j.febslet.2008.03.032
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000
   Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991
   Wong TS, 2009, NUCLEIC ACIDS RES, V37, P568, DOI 10.1093/nar/gkn974
   Yamaguchi H, 2009, J BIOL CHEM, V284, P11171, DOI 10.1074/jbc.M809268200
   Yoshida Y, 2003, CANCER RES, V63, P3729
   Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4
   Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2
   Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424
NR 83
TC 3
Z9 4
U1 3
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD DEC
PY 2012
VL 13
IS 13
BP 1633
EP 1640
DI 10.2174/138945012803529992
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 027YE
UT WOS:000310389200007
PM 22998186
DA 2022-04-25
ER

PT J
AU Galadari, S
   Rahman, A
   Pallichankandy, S
   Thayyullathil, F
AF Galadari, Sehamuddin
   Rahman, Anees
   Pallichankandy, Siraj
   Thayyullathil, Faisal
TI Tumor suppressive functions of ceramide: evidence and mechanisms
SO APOPTOSIS
LA English
DT Article
DE Ceramide; Apoptosis; Autophagy; Senescence; Tumor suppression; Molecular
   targets
ID ACTIVATED PROTEIN-KINASE; DAUNORUBICIN-INDUCED APOPTOSIS; CHRONIC
   MYELOID-LEUKEMIA; COLORECTAL-CANCER CELLS; CYTOCHROME-C RELEASE;
   LONGEVITY ASSURANCE GENE-1; ENDOTHELIAL GROWTH-FACTOR; ANALOG LCL29.
   EVIDENCE; RETICULUM ER STRESS; ACID SPHINGOMYELINASE
AB Studies over the past two decades have identified ceramide as a multifunctional central molecule in the sphingolipid biosynthetic pathway. Given its diverse tumor suppressive activities, molecular understanding of ceramide action will produce fundamental insights into processes that limit tumorigenesis and may identify key molecular targets for therapeutic intervention. Ceramide can be activated by a diverse array of stresses such as heat shock, genotoxic damage, oxidative stress and anticancer drugs. Ceramide triggers a variety of tumor suppressive and anti-proliferative cellular programs such as apoptosis, autophagy, senescence, and necroptosis by activating or repressing key effector molecules. Defects in ceramide generation and metabolism in cancer contribute to tumor cell survival and resistance to chemotherapy. The potent and versatile anticancer activity profile of ceramide has motivated drug development efforts to (re-)activate ceramide in established tumors. This review focuses on our current understanding of the tumor suppressive functions of ceramide and highlights the potential downstream targets of ceramide which are involved in its tumor suppressive action.
C1 [Galadari, Sehamuddin; Rahman, Anees; Pallichankandy, Siraj; Thayyullathil, Faisal] UAE Univ, Coll Med & Hlth Sci, Dept Biochem, Cell Signaling Lab, Abu Dhabi, U Arab Emirates.
   [Galadari, Sehamuddin] Al Jalila Fdn Res Ctr, Dubai, U Arab Emirates.
RP Galadari, S (corresponding author), UAE Univ, Coll Med & Hlth Sci, Dept Biochem, Cell Signaling Lab, POB 17666, Abu Dhabi, U Arab Emirates.
EM sehamuddin@uaeu.ac.ae
RI Galadari, Sehamuddin/AAK-6039-2020
FU UAE University-National Research Foundation [31M097]; Terry Fox
   Foundation for Cancer Research [21M093]; Sheikh Hamdan Award for Medical
   Sciences [MRG-60/2011-2012]; Al Jalila Foundation for Medical Education
   and Research
FX This work was financially supported by grants from the UAE
   University-National Research Foundation (31M097), Terry Fox Foundation
   for Cancer Research (21M093), The Sheikh Hamdan Award for Medical
   Sciences (MRG-60/2011-2012). SG is supported by the Al Jalila Foundation
   for Medical Education and Research.
CR Abousalham A, 1997, J BIOL CHEM, V272, P1069, DOI 10.1074/jbc.272.2.1069
   Albi E, 2006, J CELL PHYSIOL, V206, P189, DOI 10.1002/jcp.20448
   Alesse E, 1998, CELL DEATH DIFFER, V5, P381, DOI 10.1038/sj.cdd.4400358
   Ali M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.451
   Alphonse G, 2004, ONCOGENE, V23, P2703, DOI 10.1038/sj.onc.1207357
   Alphonse G, 2002, INT J RADIAT BIOL, V78, P821, DOI 10.1080/09553000210153943
   Ardestani Shidrokh, 2013, J Mol Signal, V8, P12, DOI 10.1186/1750-2187-8-12
   Asakuma J, 2003, CANCER RES, V63, P1365
   Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305
   Bansode RR, 2011, INT J BIOL SCI, V7, P629, DOI 10.7150/ijbs.7.629
   Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200
   Bareford MD, 2012, CANCER BIOL THER, V13, P793, DOI 10.4161/cbt.20562
   Basnakian AG, 2005, AM J PHYSIOL-RENAL, V288, pF308, DOI 10.1152/ajprenal.00204.2004
   Basu S, 1998, J BIOL CHEM, V273, P30419, DOI 10.1074/jbc.273.46.30419
   Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101
   Bhutia SK, 2011, AUTOPHAGY, V7, P1076, DOI 10.4161/auto.7.9.16163
   Birbes H, 2005, BIOCHEM J, V386, P445, DOI 10.1042/BJ20041627
   Birbes H, 2002, ADV ENZYME REGUL, V42, P113, DOI 10.1016/S0065-2571(01)00026-7
   Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com
   Biswal SS, 2000, TOXICOLOGY, V154, P45, DOI 10.1016/S0300-483X(00)00296-1
   Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927
   Blazquez C, 2008, CANCER RES, V68, P1945, DOI 10.1158/0008-5472.CAN-07-5176
   Bocci G, 2012, NEOPLASIA, V14, P833, DOI 10.1593/neo.12772
   BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8
   Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200
   Bourbon NA, 2002, J BIOL CHEM, V277, P3286, DOI 10.1074/jbc.M110541200
   Bradshaw CD, 1996, BIOCHEM MOL BIOL INT, V40, P709
   Cabot MC, 1999, CANCER RES, V59, P880
   Canals D, 2012, J BIOL CHEM, V287, P10145, DOI 10.1074/jbc.M111.306456
   Canals D, 2010, J BIOL CHEM, V285, P32476, DOI 10.1074/jbc.M110.141028
   Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400
   Casson L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054525
   Chalfant CE, 2001, J BIOL CHEM, V276, P44848, DOI 10.1074/jbc.M106291200
   Charles AG, 2001, CANCER CHEMOTH PHARM, V47, P444, DOI 10.1007/s002800000265
   Chauvier D, 2002, INT J ONCOL, V20, P855
   Chen BA, 2011, HEMATOLOGY, V16, P24, DOI 10.1179/102453311X12902908411797
   Chen CL, 2008, BLOOD, V111, P4365, DOI 10.1182/blood-2007-08-106336
   Chen JYF, 2010, LIFE SCI, V87, P350, DOI 10.1016/j.lfs.2010.06.017
   Chen LM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103033
   Chen MB, 2013, CELL SIGNAL, V25, P1993, DOI 10.1016/j.cellsig.2013.05.026
   Chiu WH, 2014, CANCER LETT, V349, P144, DOI 10.1016/j.canlet.2014.04.005
   Chow SE, 2014, APOPTOSIS, V19, P527, DOI 10.1007/s10495-013-0945-0
   Cianchi F, 2010, J PHARMACOL EXP THER, V334, P710, DOI 10.1124/jpet.110.167270
   Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296
   Clarke CJ, 2011, J BIOL CHEM, V286, P21565, DOI 10.1074/jbc.M110.193375
   Colell A, 2007, CELL, V129, P983, DOI 10.1016/j.cell.2007.03.045
   Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828
   Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910
   Czubowicz K, 2014, MOL NEUROBIOL, V50, P26, DOI 10.1007/s12035-013-8606-4
   Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084
   Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729
   Dbaibo GS, 2007, HAEMATOLOGICA, V92, P753, DOI 10.3324/haematol.10968
   Dbaibo GS, 1998, J CLIN INVEST, V102, P329, DOI 10.1172/JCI1180
   DBAIBO GS, 1993, J BIOL CHEM, V268, P17762
   DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347
   De Simone C, 2011, MOL NUTR FOOD RES, V55, P229, DOI 10.1002/mnfr.201000074
   Debret R, 2008, BBA-MOL CELL RES, V1783, P1718, DOI 10.1016/j.bbamcr.2008.06.001
   Deroyer C, 2014, AUTOPHAGY, V10, P1229, DOI 10.4161/auto.28777
   Dhule SS, 2014, MOL PHARMACEUT, V11, P417, DOI 10.1021/mp400366r
   Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567
   DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174
   Dumitru CA, 2006, ONCOGENE, V25, P5612, DOI 10.1038/sj.onc.1209568
   Dumitru CA, 2009, J MOL MED, V87, P1123, DOI 10.1007/s00109-009-0514-8
   Edsall LC, 1997, J NEUROSCI, V17, P6952
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Elliott BE, 2005, BREAST CANCER RES, V7, pR365, DOI 10.1186/bcr1006
   Elojeimy S, 2007, MOL THER, V15, P1259, DOI 10.1038/sj.mt.6300167
   Erdreich-Epstein A, 2005, BLOOD, V105, P4353, DOI 10.1182/blood-2004-08-3098
   Erdreich-Epstein A, 2002, J BIOL CHEM, V277, P49531, DOI 10.1074/jbc.M209962200
   Flamigni F, 1997, BIOCHEM J, V324, P783, DOI 10.1042/bj3240783
   Flowers M, 2012, BREAST CANCER RES TR, V133, P447, DOI 10.1007/s10549-011-1768-8
   Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627
   Galadari S, 1998, BIOCHEMISTRY-US, V37, P11232, DOI 10.1021/bi980911+
   Galadari S, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-98
   Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171
   Garzotto M, 1998, CANCER RES, V58, P2260
   Gencer EB, 2011, ANN HEMATOL, V90, P1265, DOI 10.1007/s00277-011-1212-5
   Gill JS, 1997, CANCER LETT, V119, P169, DOI 10.1016/S0304-3835(97)00272-3
   Giovannetti E, 2010, NUCLEOS NUCLEOT NUCL, V29, P419, DOI 10.1080/15257771003730193
   Giussani P, 2012, CANCER INVEST, V30, P27, DOI 10.3109/07357907.2011.629379
   Gong L, 2014, CANCER CHEMOTH PHARM, V73, P69, DOI 10.1007/s00280-013-2318-3
   Gong T, 2012, BIOCHEM BIOPH RES CO, V427, P461, DOI 10.1016/j.bbrc.2012.08.068
   Gopalan A, 2012, MOL NUTR FOOD RES, V56, P1803, DOI 10.1002/mnfr.201200350
   GOTO F, 1993, LAB INVEST, V69, P508
   Gouaze V, 2005, CANCER RES, V65, P3861, DOI 10.1158/0008-5472.CAN-04-2329
   Gouaze-Andersson V, 2011, PROSTATE, V71, P1064, DOI 10.1002/pros.21321
   Guillermet-Guibert J, 2009, MOL CANCER THER, V8, P809, DOI 10.1158/1535-7163.MCT-08-1096
   Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Harley CB, 2008, NAT REV CANCER, V8, P167, DOI 10.1038/nrc2275
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hearps AC, 2002, APOPTOSIS, V7, P387, DOI 10.1023/A:1020034906200
   Heinrich M, 1999, EMBO J, V18, P5252, DOI 10.1093/emboj/18.19.5252
   Heinrich M, 2004, CELL DEATH DIFFER, V11, P550, DOI 10.1038/sj.cdd.4401382
   Hetz CA, 2002, J CELL SCI, V115, P4671, DOI 10.1242/jcs.00153
   Hoe KK, 2014, NAT REV DRUG DISCOV, V13, P217, DOI 10.1038/nrd4236
   Hu W, 2005, MOL BIOL CELL, V16, P1555, DOI 10.1091/mbc.E04-07-0594
   Huang H, 2011, DNA CELL BIOL, V30, P407, DOI 10.1089/dna.2010.1122
   Huang WC, 2011, FASEB J, V25, P3661, DOI 10.1096/fj.10-180190
   Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959
   Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7
   Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x
   Ji C, 2010, ONCOGENE, V29, P6557, DOI 10.1038/onc.2010.379
   Ji C, 2012, BIOCHEM BIOPH RES CO, V421, P462, DOI 10.1016/j.bbrc.2012.04.012
   Jiang LL, 2011, BIOCHEM BIOPH RES CO, V405, P314, DOI 10.1016/j.bbrc.2011.01.036
   Jiang YJ, 2013, EXP DERMATOL, V22, P113, DOI 10.1111/exd.12079
   Jiang YX, 2011, CANCER BIOL THER, V12, P574, DOI 10.4161/cbt.12.7.15971
   Jin JF, 2009, J LIPID RES, V50, P2389, DOI 10.1194/jlr.M900119-JLR200
   Jin YJ, 2006, J BIOL CHEM, V281, P39033, DOI 10.1074/jbc.M605097200
   Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146
   Kashkar H, 2005, J BIOL CHEM, V280, P20804, DOI 10.1074/jbc.M410869200
   Kawase M, 2002, BBA-MOL CELL BIOL L, V1584, P104, DOI 10.1016/S1388-1981(02)00301-3
   Kim HJ, 2008, CANCER LETT, V260, P88, DOI 10.1016/j.canlet.2007.10.030
   Kim HJ, 2001, FEBS LETT, V505, P264, DOI 10.1016/S0014-5793(01)02836-8
   Kim NH, 2007, J CELL BIOCHEM, V102, P1160, DOI 10.1002/jcb.21344
   Kim SW, 2010, J TOXICOL ENV HEAL A, V73, P1465, DOI 10.1080/15287394.2010.511553
   Kim SS, 2002, ONCOGENE, V21, P2020, DOI 10.1038/sj.onc.1205037
   Kim WH, 2000, BIOCHEM CELL BIOL, V78, P127, DOI 10.1139/bcb-78-2-127
   Kimura K, 1999, CANCER RES, V59, P1606
   Kimura K, 2003, CELL DEATH DIFFER, V10, P240, DOI 10.1038/sj.cdd.4401145
   Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335
   Kizhakkayil J, 2012, FREE RADICAL BIO MED, V52, P1854, DOI 10.1016/j.freeradbiomed.2012.02.026
   Kolesnick R, 2003, ONCOGENE, V22, P5897, DOI 10.1038/sj.onc.1206702
   Kondo T, 2000, J BIOL CHEM, V275, P7668, DOI 10.1074/jbc.275.11.7668
   Koomoa DLT, 2008, CANCER RES, V68, P9825, DOI 10.1158/0008-5472.CAN-08-1865
   Koybasi S, 2004, J BIOL CHEM, V279, P44311, DOI 10.1074/jbc.M406920200
   Krasnov GS, 2013, EXPERT OPIN THER TAR, V17, P681, DOI 10.1517/14728222.2013.775253
   Kurinna SM, 2004, CANCER RES, V64, P7852, DOI 10.1158/0008-5472.CAN-04-1552
   Kurita-Ochiai T, 2003, J IMMUNOL, V171, P3576, DOI 10.4049/jimmunol.171.7.3576
   Lacour S, 2004, CANCER RES, V64, P3593, DOI 10.1158/0008-5472.CAN-03-2787
   Laethem RM, 1998, BLOOD, V91, P4350, DOI 10.1182/blood.V91.11.4350.411k27_4350_4360
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Lee JY, 1996, J BIOL CHEM, V271, P13169, DOI 10.1074/jbc.271.22.13169
   Lee JY, 2000, EXP CELL RES, V261, P303, DOI 10.1006/excr.2000.5028
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Li J, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-40
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Li T, 2012, TOXICOL SCI, V128, P147, DOI 10.1093/toxsci/kfs141
   Lin CF, 2007, J CELL SCI, V120, P2935, DOI 10.1242/jcs.03473
   Lin IL, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-1
   Litvak DA, 2003, J GASTROINTEST SURG, V7, P140, DOI 10.1016/S1091-255X(02)00126-9
   Liu X, 2010, BLOOD, V116, P4192, DOI 10.1182/blood-2010-02-271080
   Liu YY, 2011, CANCER RES, V71, P2276, DOI 10.1158/0008-5472.CAN-10-3107
   Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   MacKichan ML, 1999, J BIOL CHEM, V274, P1767, DOI 10.1074/jbc.274.3.1767
   Maggio SC, 2004, CANCER RES, V64, P2590, DOI 10.1158/0008-5472.CAN-03-2631
   Mahdy AEM, 2009, MOL THER, V17, P430, DOI 10.1038/mt.2008.281
   Mandil R, 2001, CANCER RES, V61, P4612
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Marchesini N, 2004, J BIOL CHEM, V279, P25101, DOI 10.1074/jbc.M313662200
   Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200
   Mehta S, 2000, CANCER CHEMOTH PHARM, V46, P85, DOI 10.1007/s002800000140
   Mengubas K, 1999, EXP CELL RES, V249, P116, DOI 10.1006/excr.1999.4474
   Mesicek J, 2010, CELL SIGNAL, V22, P1300, DOI 10.1016/j.cellsig.2010.04.006
   Meyers-Needham M, 2012, MOL CANCER THER, V11, P1092, DOI 10.1158/1535-7163.MCT-11-0705
   Min JX, 2007, MOL CANCER RES, V5, P801, DOI 10.1158/1541-7786.MCR-07-0100
   Modrak DE, 2009, MOL CANCER RES, V7, P890, DOI 10.1158/1541-7786.MCR-08-0457
   Mondal S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-239
   Morad SAF, 2013, BIOCHEM PHARMACOL, V85, P1057, DOI 10.1016/j.bcp.2013.01.015
   Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398
   Morales A, 2007, ONCOGENE, V26, P905, DOI 10.1038/sj.onc.1209834
   Morales MC, 2007, FREE RADICAL RES, V41, P591, DOI 10.1080/10715760701218558
   Moussavi M, 2006, CARCINOGENESIS, V27, P1636, DOI 10.1093/carcin/bgi371
   Mullen TD, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.230870
   Navarro P, 2000, GROWTH HORM IGF RES, V10, P256, DOI 10.1054/ghir.2000.0165
   Nica AF, 2008, CELL CYCLE, V7, P3362, DOI 10.4161/cc.7.21.6894
   Noda S, 2001, J NEURO-ONCOL, V52, P11, DOI 10.1023/A:1010624823158
   Novgorodov SA, 2005, J BIOL CHEM, V280, P16096, DOI 10.1074/jbc.M411707200
   O'Donnell PH, 2002, LEUKEMIA, V16, P902, DOI 10.1038/sj.leu.2402485
   OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305
   Ogretmen B, 2001, J BIOL CHEM, V276, P32506, DOI 10.1074/jbc.M101350200
   Ogretmen B, 2001, J BIOL CHEM, V276, P24901, DOI 10.1074/jbc.M100314200
   Park JY, 2011, ARCH TOXICOL, V85, P1057, DOI 10.1007/s00204-011-0645-x
   Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623
   Park MA, 2010, CANCER RES, V70, P6313, DOI 10.1158/0008-5472.CAN-10-0999
   Paschall AV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-24
   Pattingre S, 2009, J BIOL CHEM, V284, P2719, DOI 10.1074/jbc.M805920200
   Patwardhan GA, 2014, BBA-MOL CELL BIOL L, V1841, P1571, DOI 10.1016/j.bbalip.2014.08.017
   Pelled D, 2002, J BIOL CHEM, V277, P1957, DOI 10.1074/jbc.M104677200
   Perry DM, 2012, J LIPID RES, V53, P1513, DOI 10.1194/jlr.M025395
   Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078
   Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1
   Pfeilschifter J, 1998, KIDNEY INT, V54, pS34, DOI 10.1046/j.1523-1755.1998.06707.x
   Phillips DC, 2007, CELL DEATH DIFFER, V14, P1780, DOI 10.1038/sj.cdd.4402198
   Pruschy M, 1999, BRIT J CANCER, V80, P693, DOI 10.1038/sj.bjc.6690411
   Qin LS, 2013, MOL BIOL REP, V40, P5645, DOI 10.1007/s11033-013-2666-4
   Rana Ajay, 2013, Genes Cancer, V4, P334, DOI 10.1177/1947601913485415
   RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Realini N, 2013, SCI REP-UK, V3, DOI 10.1038/srep01035
   Reyes JG, 1996, J BIOL CHEM, V271, P21375, DOI 10.1074/jbc.271.35.21375
   Rubio S, 2010, MOL CARCINOGEN, V49, P32, DOI 10.1002/mc.20574
   Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296
   Ruvolo PP, 2001, LEUKEMIA, V15, P515, DOI 10.1038/sj.leu.2402090
   Ryland LK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084648
   Saddoughi SA, 2013, ADV CANCER RES, V117, P37, DOI 10.1016/B978-0-12-394274-6.00002-9
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Salh B, 2002, J LEUKOCYTE BIOL, V72, P790
   Salinas M, 2000, MOL CELL NEUROSCI, V15, P156, DOI 10.1006/mcne.1999.0813
   Sanchez AM, 2007, APOPTOSIS, V12, P2013, DOI 10.1007/s10495-007-0119-z
   Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7
   Sawada N, 2000, CELL DEATH DIFFER, V7, P761, DOI 10.1038/sj.cdd.4400711
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Scarlatti F, 2003, FASEB J, V17, P2339, DOI 10.1096/fj.03-0292fje
   Schaefer JT, 2000, J PEDIATR SURG, V35, P473, DOI 10.1016/S0022-3468(00)90217-3
   Schiffmann S, 2010, BIOCHEM PHARMACOL, V80, P1632, DOI 10.1016/j.bcp.2010.08.012
   Schiffmann S, 2009, CARCINOGENESIS, V30, P745, DOI 10.1093/carcin/bgp061
   Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330
   Senkal CE, 2007, MOL CANCER THER, V6, P712, DOI 10.1158/1535-7163.MCT-06-0558
   Senkal CE, 2011, J BIOL CHEM, V286, P42446, DOI 10.1074/jbc.M111.287383
   Senkal CE, 2010, FASEB J, V24, P296, DOI 10.1096/fj.09-135087
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Separovic D, 2011, INT J ONCOL, V38, P521, DOI 10.3892/ijo.2010.863
   Separovic D, 2009, BRIT J CANCER, V100, P626, DOI 10.1038/sj.bjc.6604896
   Separovic D, 2011, J LIPIDS, V2011, DOI 10.1155/2011/713867
   Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200
   Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029
   Singh IN, 2001, BIOCHEMISTRY-US, V40, P11227, DOI 10.1021/bi010787l
   Siskind LJ, 2006, MITOCHONDRION, V6, P118, DOI 10.1016/j.mito.2006.03.002
   Siskind LJ, 2010, J BIOL CHEM, V285, P11818, DOI 10.1074/jbc.M109.078121
   Smyth MJ, 1996, BIOCHEM J, V316, P25, DOI 10.1042/bj3160025
   Struckhoff AP, 2010, INT J ONCOL, V37, P21, DOI 10.3892/ijo_00000649
   Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146
   Sundararaj KP, 2004, J BIOL CHEM, V279, P6152, DOI 10.1074/jbc.M310549200
   Tan XH, 2002, LIFE SCI, V70, P2023, DOI 10.1016/S0024-3205(01)01543-0
   Taniguchi M, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.416552
   Thayyullathil F, 2014, FEBS OPEN BIO, V4, P763, DOI 10.1016/j.fob.2014.08.005
   Thayyullathil F, 2011, BIOCHEM BIOPH RES CO, V411, P1, DOI 10.1016/j.bbrc.2011.05.156
   Thayyullathil F, 2011, J CELL BIOCHEM, V112, P1138, DOI 10.1002/jcb.23033
   Thon L, 2005, FASEB J, V19, P1945, DOI 10.1096/fj.05-3726com
   Tran MA, 2008, CLIN CANCER RES, V14, P3571, DOI 10.1158/1078-0432.CCR-07-4881
   Turnbull KJ, 1999, LEUKEMIA, V13, P1056, DOI 10.1038/sj.leu.2401438
   Ulrich S, 2007, BIOCHEM PHARMACOL, V74, P281, DOI 10.1016/j.bcp.2007.04.001
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Venable ME, 1996, J BIOL CHEM, V271, P24800, DOI 10.1074/jbc.271.40.24800
   Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701
   Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0
   Voelkel-Johnson C, 2005, MOL CANCER THER, V4, P1320, DOI 10.1158/1535-7163.MCT-05-0086
   Voigt S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-74
   von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   Wang HT, 2002, MOL CANCER THER, V1, P719
   Wang M, 2014, NUTR CANCER, V66, P435, DOI 10.1080/01635581.2013.878738
   White-Gilbertson S, 2009, ONCOGENE, V28, P1132, DOI 10.1038/onc.2008.468
   Whitman SP, 1997, J BIOL CHEM, V272, P23481, DOI 10.1074/jbc.272.38.23481
   Widau RC, 2010, J BIOL CHEM, V285, P13827, DOI 10.1074/jbc.M109.085076
   Wiesner DA, 1996, J NEUROCHEM, V66, P1418
   WOLFF RA, 1994, J BIOL CHEM, V269, P19605
   Won JS, 2006, FREE RADICAL BIO MED, V40, P1875, DOI 10.1016/j.freeradbiomed.2006.01.035
   Xin MG, 2006, J BIOL CHEM, V281, P18859, DOI 10.1074/jbc.M512543200
   Yabu T, 2005, BLOOD, V106, P125, DOI 10.1182/blood-2004-09-3679
   Yabu T, 2015, CELL DEATH DIFFER, V22, P258, DOI 10.1038/cdd.2014.128
   Yabu T, 2008, J BIOL CHEM, V283, P29971, DOI 10.1074/jbc.M805402200
   Yang L, 2015, EXP CELL RES, V332, P47, DOI 10.1016/j.yexcr.2014.12.017
   Yang YL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054736, 10.1371/journal.pone.0067755, 10.1371/journal.pone.0055384]
   Yao J, 2013, INT J MOL SCI, V14, P10355, DOI 10.3390/ijms140510355
   Yazama H, 2014, INT J CLIN ONCOL
   Yin XL, 2009, CELL PHYSIOL BIOCHEM, V24, P219, DOI 10.1159/000233248
   Yip KW, 2008, ONCOGENE, V27, P6398, DOI 10.1038/onc.2008.307
   Yoon G, 2002, J NEURO-ONCOL, V60, P135, DOI 10.1023/A:1020604705831
   Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278
   Young MM, 2012, J BIOL CHEM, V287, P12455, DOI 10.1074/jbc.M111.309104
   Yu T, 2010, CANCER CHEMOTH PHARM, V66, P999, DOI 10.1007/s00280-010-1374-1
   Yun SH, 2012, CLIN CANCER RES, V18, P5934, DOI 10.1158/1078-0432.CCR-12-0655
   Zeidan YH, 2008, FASEB J, V22, P183, DOI 10.1096/fj.07-8967com
   Zhang JD, 1996, P NATL ACAD SCI USA, V93, P5325, DOI 10.1073/pnas.93.11.5325
   Zhang SH, 2012, MED ONCOL, V29, P2251, DOI 10.1007/s12032-011-0023-9
   Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X
   Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093
   Zhu QY, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2010.96
   Zhu Q, 2012, BBA-MOL CELL BIOL L, V1821, P1453, DOI 10.1016/j.bbalip.2012.08.005
   Zhu WY, 2014, INT J MOL SCI, V15, P3336, DOI 10.3390/ijms15023336
   Zhu XF, 2003, CANCER LETT, V193, P149, DOI 10.1016/S0304-3835(03)00050-8
   Zhu XH, 2014, BIOCHEM BIOPH RES CO, V452, P72, DOI 10.1016/j.bbrc.2014.08.065
NR 275
TC 63
Z9 68
U1 3
U2 30
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD MAY
PY 2015
VL 20
IS 5
SI SI
BP 689
EP 711
DI 10.1007/s10495-015-1109-1
PG 23
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CE5VY
UT WOS:000351905000010
PM 25702155
DA 2022-04-25
ER

PT J
AU Jamali, L
   Sadeghi, H
   Ghasemi, MR
   Mohseni, R
   Nazemalhosseini-Mojarad, E
   Yassaee, VR
   Larki, P
   Zali, MR
   Mirfakhraie, R
AF Jamali, Leila
   Sadeghi, Hossein
   Ghasemi, Mohammad-Reza
   Mohseni, Roohollah
   Nazemalhosseini-Mojarad, Ehsan
   Yassaee, Vahid Reza
   Larki, Pegah
   Zali, Mohammad Reza
   Mirfakhraie, Reza
TI Autophagy ATG16L1 rs2241880 impacts the colorectal cancer risk: A
   case-control study
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE ATG5; autophagy; colorectal cancer (CRC); single-nucleotide polymorphism
   (SNP)
ID POLYMORPHISM
AB Background Despite many efforts to discover the important role of the autophagy process in the pathogenesis of colorectal cancer (CRC), the exact involved molecular mechanism still remains to be elucidated. Recently, a limited number of studies have been employed to discover the impact of autophagy genes' variants on the development and progression of CRC. Here, we evaluated the association between two single-nucleotide polymorphisms (SNPs) in the main components of the autophagy genes, ATG16L1 rs2241880, and ATG5 rs1475270, and the CRC risk in an Iranian population. Methods During this investigation, a total of 369 subjects, including 179 CRC patients and 190 non-cancer controls have been genotyped using Tetra-primer amplification refractory mutation system-polymerase chain reaction (TP-ARMS-PCR) method. Result The results demonstrated that the T allele of the ATG16L1 rs2241880 was significantly associated with the increased risk of CRC in the studied population (OR 1.64, 95% CI: 1.21-2.22, p = 0.0015). Moreover, ATG16L1 rs2241880 TT genotype increased the susceptibility to CRC (OR 3.31, 95% CI: 1.64-6.69, p = 0.0008). Furthermore, a significant association was observed under the recessive and dominant inheritance models (p = 0.0015 and p = 0.017, respectively). No statistically significant differences were found in the ATG5 rs1475270 alleles and genotypes between the cases and controls. Conclusion The results of the present study may be helpful concerning the risk stratification in CRC patients based on the genotyping approach of autophagy pathways and emphasize the need for further investigations among different populations and ethnicities to refine our conclusions.
C1 [Jamali, Leila; Ghasemi, Mohammad-Reza; Mirfakhraie, Reza] Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Koodakyar St,Velenjak Ave,Chamran Highway, Tehran 193954719, Iran.
   [Sadeghi, Hossein; Yassaee, Vahid Reza; Larki, Pegah] Shahid Beheshti Univ Med Sci, Genom Res Ctr, Yeman St,Chamran Highway, Tehran, Iran.
   [Mohseni, Roohollah] Shahrekord Univ Med Sci, Clin Biochem Res Ctr, Basic Hlth Sci Inst, Shahrekord, Iran.
   [Nazemalhosseini-Mojarad, Ehsan; Zali, Mohammad Reza] Shahid Beheshti Univ Med Sci, Gastroenterol & Liver Dis Res Ctr, Res Inst Gastroenterol & Liver Dis, Dept Gastrointestinal Canc, Tehran, Iran.
   [Mirfakhraie, Reza] Shahid Beheshti Univ Med Sci, Hematopoiet Stem Cell Res Ctr, Tehran, Iran.
RP Mirfakhraie, R (corresponding author), Shahid Beheshti Univ Med Sci, Sch Med, Dept Med Genet, Koodakyar St,Velenjak Ave,Chamran Highway, Tehran 193954719, Iran.; Sadeghi, H (corresponding author), Shahid Beheshti Univ Med Sci, Genom Res Ctr, Yeman St,Chamran Highway, Tehran, Iran.
EM Hsadeqi86@gmail.com; reza_mirfakhraie@yahoo.com
OI Mirfakhraie, Reza/0000-0003-1709-8975; Ghasemi,
   Mohammad-Reza/0000-0002-3183-5495
FU Genomic Research Center, Shahid Beheshti University of Medical Sciences
FX Y The authors would like to thank the "Genomic Research Center, Shahid
   Beheshti University of Medical Sciences" for financial support
CR Al-Ali R, 2017, GENE REP, V7, P74, DOI 10.1016/j.genrep.2017.02.001
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Budak Diler Songul, 2018, Asian Pac J Cancer Prev, V19, P2625, DOI 10.22034/APJCP.2018.19.9.2625
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Burada F, 2016, PATHOL ONCOL RES, V22, P317, DOI 10.1007/s12253-015-0006-9
   Cao H, 2016, INT J CLIN EXP PATHO, V9, P8586
   Collins A., 2012, OPEN BIOINFORM J, V6, P55, DOI [10.2174/1875036201206010055, DOI 10.2174/1875036201206010055]
   Dolatkhah R, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2342-9
   Fernandez-Mateos J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07270-0
   Gaaib JN, 2011, TIKRIT J PURE SCI, V16, P9
   Gandomani HS, 2017, BIOMED RES THER, V4, P1656, DOI 10.15419/bmrat.v4i10.372
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guerrero-Martinez JA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20217-3
   Guo LY, 2014, NUCLEIC ACIDS RES, V42, pD1033, DOI 10.1093/nar/gkt1167
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5
   Klionsky DJ, 2014, NAT STRUCT MOL BIOL, V21, P336, DOI 10.1038/nsmb.2787
   Lesurf R, 2016, NUCLEIC ACIDS RES, V44, pD126, DOI 10.1093/nar/gkv1203
   Li MY, 2018, CHIN J CANCER, V37, DOI 10.1186/s40880-018-0268-1
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Migliore L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/792362
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Nissar S., 2021, GENETIC POLYMORPHISM, P1
   Pourhoseingholi MA, 2012, WORLD J GASTRO ONCOL, V4, P68, DOI 10.4251/wjgo.v4.i4.68
   Sameer AS, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00114
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Vargas AJ, 2012, NUTR CLIN PRACT, V27, P613, DOI 10.1177/0884533612454885
   Ward LD, 2016, NUCLEIC ACIDS RES, V44, pD877, DOI 10.1093/nar/gkv1340
   Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033
   White KAM, 2016, CANCER MED-US, V5, P3336, DOI 10.1002/cam4.929
   Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295
   Yu JH, 2019, MOL CELL BIOCHEM, V457, P191, DOI 10.1007/s11010-019-03523-w
   Zhang HF, 2009, HUM GENET, V125, P627, DOI 10.1007/s00439-009-0660-7
NR 38
TC 0
Z9 0
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PD JAN
PY 2022
VL 36
IS 1
AR e24169
DI 10.1002/jcla.24169
EA DEC 2021
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA YH0NC
UT WOS:000729173200001
PM 34894411
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kageyama, S
   Ii, H
   Taniguchi, K
   Kubota, S
   Yoshida, T
   Isono, T
   Chano, T
   Yoshiya, T
   Ito, K
   Yoshiki, T
   Kawauchi, A
   Nakata, S
AF Kageyama, Susumu
   Ii, Hiromi
   Taniguchi, Keiko
   Kubota, Shigehisa
   Yoshida, Tetsuya
   Isono, Takahiro
   Chano, Tokuhiro
   Yoshiya, Taku
   Ito, Kosei
   Yoshiki, Tatsuhiro
   Kawauchi, Akihiro
   Nakata, Susumu
TI Mechanisms of Tumor Growth Inhibition by Depletion of
   gamma-Glutamylcyclotransferase (GGCT): A Novel Molecular Target for
   Anticancer Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE GGCT; C7orf24; cancer; cellular senescence; autophagy
ID CANCER-CELL-PROLIFERATION; HUMAN C7ORF24 GENE; GLUTAMYL
   CYCLOTRANSFERASE; IDENTIFICATION; EXPRESSION; KNOCKDOWN; APOPTOSIS;
   BIOMARKER; SYSTEM; ENZYME
AB gamma-Glutamylcyclotransferase (GGCT), which is one of the major enzymes involved in glutathione metabolism, is upregulated in a wide range of cancers-glioma, breast, lung, esophageal, gastric, colorectal, urinary bladder, prostate, cervical, ovarian cancers and osteosarcoma-and promotes cancer progression; its depletion leads to the suppression of proliferation, invasion, and migration of cancer cells. It has been demonstrated that the suppression or inhibition of GGCT has an antitumor effect in cancer-bearing xenograft mice. Based on these observations, GGCT is now recognized as a promising therapeutic target in various cancers. This review summarizes recent advances on the mechanisms of the antitumor activity of GGCT inhibition.
C1 [Kageyama, Susumu; Kubota, Shigehisa; Yoshida, Tetsuya; Yoshiki, Tatsuhiro; Kawauchi, Akihiro] Shiga Univ Med Sci, Dept Urol, Otsu, Shiga 5202192, Japan.
   [Ii, Hiromi; Taniguchi, Keiko; Yoshiki, Tatsuhiro; Nakata, Susumu] Kyoto Pharmaceut Univ, Dept Clin Oncol, Kyoto 6078414, Japan.
   [Isono, Takahiro] Shiga Univ Med Sci, Cent Res Lab, Otsu, Shiga 5202192, Japan.
   [Chano, Tokuhiro] Shiga Univ Med Sci, Dept Clin Lab Med, Otsu, Shiga 5202192, Japan.
   [Yoshiya, Taku] Peptide Inst Inc, Osaka 5670085, Japan.
   [Ito, Kosei] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, Nagasaki 8528588, Japan.
RP Nakata, S (corresponding author), Kyoto Pharmaceut Univ, Dept Clin Oncol, Kyoto 6078414, Japan.
EM kageyama@belle.shiga-med.ac.jp; iihiromi@mb.kyoto-phu.ac.jp;
   kd16006@poppy.kyoto-phu.ac.jp; kubota@belle.shiga-med.ac.jp;
   yoshida9@belle.shiga-med.ac.jp; isono@belle.shiga-med.ac.jp;
   chano@belle.shiga-med.ac.jp; t.yoshiya@peptide.co.jp;
   itok@nagasaki-u.ac.jp; yoshiki@mb.kyoto-phu.ac.jp;
   kawauchi@belle.shiga-med.ac.jp; snakata@mb.kyoto-phu.ac.jp
RI Chano, Tokuhiro/F-5816-2018
OI Chano, Tokuhiro/0000-0002-9959-1183; Kageyama,
   Susumu/0000-0001-7150-647X
FU JSPS KAKENHI by the Ministry of Education, Culture, Sports, Science and
   Technology [17K11131, 18K09192, 16K08722, 26461436]
FX This research was funded by JSPS KAKENHI Grant Numbers 17K11131,
   18K09192, 16K08722, and 26461436 by the Ministry of Education, Culture,
   Sports, Science and Technology-Supported Program for the Strategic
   Research Foundation at Private Universities 2015-2019.
CR Amano T, 2012, J HISTOCHEM CYTOCHEM, V60, P76, DOI 10.1369/0022155411428468
   Azumi K, 2009, MOL MED REP, V2, P385, DOI 10.3892/mmr_00000110
   Dong J, 2016, ANTI-CANCER DRUG, V27, P1011, DOI 10.1097/CAD.0000000000000407
   Gromov P, 2010, J PROTEOME RES, V9, P3941, DOI 10.1021/pr100160u
   Hama S, 2012, CANCER GENE THER, V19, P553, DOI 10.1038/cgt.2012.31
   Ii H, 2018, CHEMMEDCHEM, V13, P155, DOI 10.1002/cmdc.201700660
   Ii H, 2016, CHEM PHARM BULL, V64, P785, DOI 10.1248/cpb.c16-00167
   Kageyama S, 2004, CLIN CHEM, V50, P857, DOI 10.1373/clinchem.2003.027425
   Kageyama S, 2007, PROTEOM CLIN APPL, V1, P192, DOI 10.1002/prca.200600468
   Kageyama S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/345219
   Li YL, 2018, GYNECOL ONCOL, V149, P163, DOI 10.1016/j.ygyno.2018.01.023
   Lin ZF, 2015, CANCER BIOTHER RADIO, V30, P211, DOI 10.1089/cbr.2014.1807
   Liu YL, 2014, ADV CANCER RES, V122, P69, DOI 10.1016/B978-0-12-420117-0.00002-5
   Masuda Y, 2006, BIOCHEM BIOPH RES CO, V346, P454, DOI 10.1016/j.bbrc.2006.05.161
   Matsumura K, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2779-y
   MEISTER A, 1974, ANN INTERN MED, V81, P247, DOI 10.7326/0003-4819-81-2-247
   Nakamura YK, 2012, LIFE SCI, V90, P116, DOI 10.1016/j.lfs.2011.10.016
   Oakley AJ, 2008, J BIOL CHEM, V283, P22031, DOI 10.1074/jbc.M803623200
   Oda K, 2009, J HISTOCHEM CYTOCHEM, V57, P1121, DOI 10.1369/jhc.2009.953976
   Ohno Y, 2013, J BIOCHEM, V154, P355, DOI 10.1093/jb/mvt063
   Ohno Y, 2011, FEBS J, V278, P4088, DOI 10.1111/j.1742-4658.2011.08314.x
   ORLOWSKI M, 1970, P NATL ACAD SCI USA, V67, P1248, DOI 10.1073/pnas.67.3.1248
   Ran R, 2015, J PHARM SCI-US, V104, P476, DOI 10.1002/jps.24163
   Shen SH, 2016, BIOCHEM BIOPH RES CO, V471, P616, DOI 10.1016/j.bbrc.2016.01.165
   Takemura K, 2014, HUM PATHOL, V45, P331, DOI 10.1016/j.humpath.2013.09.009
   Taniguchi K, 2018, AM J CANCER RES, V8, P650
   Taniguchi K, 2018, BIOCHEM BIOPH RES CO, V496, P218, DOI 10.1016/j.bbrc.2018.01.029
   Uejima D, 2011, ANTICANCER RES, V31, P1297
   Xu L, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-275
   Yoshiya T, 2017, J PEPT SCI, V23, P618, DOI 10.1002/psc.2984
   Yoshiya T, 2015, ORG BIOMOL CHEM, V13, P3182, DOI 10.1039/c5ob00086f
   Yoshiya T, 2013, CHEMBIOCHEM, V14, P2110, DOI 10.1002/cbic.201300481
   Zhang WJ, 2016, BMC BIOCHEM, V17, DOI 10.1186/s12858-016-0075-8
   Zhang Y, 2017, INT J CLIN EXP PATHO, V10, P2589
NR 34
TC 17
Z9 18
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUL
PY 2018
VL 19
IS 7
AR 2054
DI 10.3390/ijms19072054
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GR6UX
UT WOS:000442807400233
PM 30011933
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhao, HG
   Zhou, SL
   Lin, YY
   Wang, H
   Dai, HF
   Huang, FY
AF Zhao, Huan-Ge
   Zhou, Song-Lin
   Lin, Ying-Ying
   Wang, Hua
   Dai, Hao-Fu
   Huang, Feng-Ying
TI Autophagy plays a protective role against apoptosis induced by
   toxicarioside N via the Akt/mTOR pathway in human gastric cancer
   SGC-7901 cells
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE Toxicarioside N; Autophagy; Apoptosis; SGC-7901 cells; Akt; mTOR
ID CARDIAC-GLYCOSIDES; COLORECTAL-CANCER; MODULATION; DISCOVERY; INDUCTION;
   GROWTH; AGENTS; KINASE; TARGET
AB Toxicarioside N (Tox N), a natural product extract from Antiaris toxicaria, has been reported to induce apoptosis in human gastric cancer cells. However, the mechanism and actual role of autophagy in Tox N-induced apoptosis of human gastric cancer cells remains poorly understood. In the current study, we demonstrated that Tox N could induce autophagy by inhibiting the Akt/mTOR signaling pathway in SGC-7901 cells. Moreover, we found that the inhibition of autophagy by 3-methyladenine, an autophagy inhibitor, enhanced Tox N-induced apoptotic cell death. However, the stimulation of autophagy by rapamycin, an autophagy activator, remarkably suppressed Tox N-induced apoptosis, suggesting that autophagy plays a protective role in Tox N-induced apoptosis. Thus, the results from this study suggested that Tox N combination with an autophagy inhibitor might be a promising strategy to enhance the anticancer activity of Tox N for the treatment of human gastric cancer.
C1 [Zhao, Huan-Ge; Zhou, Song-Lin; Lin, Ying-Ying; Wang, Hua; Huang, Feng-Ying] Minist Educ, Hainan Med Coll, Key Lab Trop Dis & Translat Med, Haikou 571199, Hainan, Peoples R China.
   [Zhao, Huan-Ge; Zhou, Song-Lin; Lin, Ying-Ying; Wang, Hua; Huang, Feng-Ying] Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou 571199, Hainan, Peoples R China.
   [Dai, Hao-Fu] Chinese Acad Trop Agr Sci, Inst Trop Biosci, Haikou 571199, Hainan, Peoples R China.
   [Dai, Hao-Fu] Chinese Acad Trop Agr Sci, Inst Biotechnol, Haikou 571199, Hainan, Peoples R China.
RP Huang, FY (corresponding author), Minist Educ, Hainan Med Coll, Key Lab Trop Dis & Translat Med, Haikou 571199, Hainan, Peoples R China.; Huang, FY (corresponding author), Hainan Med Coll, Hainan Prov Key Lab Trop Med, Haikou 571199, Hainan, Peoples R China.; Dai, HF (corresponding author), Chinese Acad Trop Agr Sci, Inst Trop Biosci, Haikou 571199, Hainan, Peoples R China.; Dai, HF (corresponding author), Chinese Acad Trop Agr Sci, Inst Biotechnol, Haikou 571199, Hainan, Peoples R China.
EM daihaofu@itbb.org.cn; fyhuang16@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81560484, 81460557]; Hainan province natural
   science foundation of China [817147]
FX The authors acknowledge the financial support provided by The National
   Natural Science Foundation of China, Project Nos 81560484 and 81460557,
   Hainan province natural science foundation of China, Project No. 817147.
CR Brothers KM, 2018, EXP EYE RES, V168, P12, DOI 10.1016/j.exer.2017.12.010
   Chang YT, 2011, EUR J CLIN INVEST, V41, P84, DOI 10.1111/j.1365-2362.2010.02383.x
   Charalampakis N, 2018, CANCER MED-US, V7, P123, DOI 10.1002/cam4.1274
   Cho KH, 2014, ONCOL REP, V31, P248, DOI 10.3892/or.2013.2809
   Cragg GM, 2016, MED PRIN PRACT, V25, P41, DOI 10.1159/000443404
   Dou QH, 2016, CANCER RES, V76, P4457, DOI 10.1158/0008-5472.CAN-15-2887
   Foukakis T, 2007, ACTA ONCOL, V46, P277, DOI 10.1080/02841860701218634
   Fulda S, 2015, ONCOGENE, V34, P5105, DOI 10.1038/onc.2014.458
   Huang FY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050351
   Huang YH, 2017, ONCOTARGET, V8, P52783, DOI 10.18632/oncotarget.17189
   Lee HW, 2014, BMB REP, V47, P697, DOI 10.5483/BMBRep.2014.47.12.069
   Levin-Salomon V, 2014, APOPTOSIS, V19, P346, DOI 10.1007/s10495-013-0918-3
   Li X, 2013, ACTA PHARMACOL SIN, V34, P612, DOI 10.1038/aps.2013.23
   Liu C, 2017, WORLD J GASTROENTERO, V23, P1964, DOI 10.3748/wjg.v23.i11.1964
   Newman RA, 2008, MOL INTERV, V8, P36, DOI 10.1124/mi.8.1.8
   Prassas I, 2008, NAT REV DRUG DISCOV, V7, P926, DOI 10.1038/nrd2682
   Prassas I, 2011, MOL CANCER THER, V10, P2083, DOI 10.1158/1535-7163.MCT-11-0421
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shi LS, 2010, J NAT PROD, V73, P1214, DOI 10.1021/np9005212
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Tanida I, 2010, METHODS MOL BIOL, V648, P193, DOI 10.1007/978-1-60761-756-3_13
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3
   Vitale I, 2015, INT J DEV BIOL, V59, P95, DOI 10.1387/ijdb.150082iv
   Zhang Y, 2015, DRUG DES DEV THER, V9, P2001, DOI 10.2147/DDDT.S77071
   Zhao HG, 2018, ARCH PHARM RES, V41, P71, DOI 10.1007/s12272-017-0956-4
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zou N, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2017-4
   Zuo WJ, 2013, PHYTOCHEM LETT, V6, P1, DOI 10.1016/j.phytol.2012.10.001
NR 29
TC 7
Z9 9
U1 3
U2 9
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD OCT
PY 2018
VL 41
IS 10
BP 986
EP 994
DI 10.1007/s12272-018-1049-8
PG 9
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GU3NF
UT WOS:000445185100005
PM 29992400
DA 2022-04-25
ER

PT J
AU Thongchot, S
   Ferraresi, A
   Vidoni, C
   Loilome, W
   Yongvanit, P
   Namwat, N
   Isidoro, C
AF Thongchot, Suyanee
   Ferraresi, Alessandra
   Vidoni, Chiara
   Loilome, Watcharin
   Yongvanit, Puangrat
   Namwat, Nisana
   Isidoro, Ciro
TI Resveratrol interrupts the pro-invasive communication between cancer
   associated fibroblasts and cholangiocarcinoma cells
SO CANCER LETTERS
LA English
DT Article
DE Autophagy; Desmoplastic stroma; Nutraceuticals; Cancer therapy;
   Cytokines; Cholangiocarcinoma; Cancer associated fibroblasts;
   Resveratrol; Tumor invasion; Cadherins
ID EPITHELIAL-MESENCHYMAL TRANSITION; FLUKE OPISTHORCHIS-VIVERRINI;
   COLORECTAL-CANCER; MIGRATION; AUTOPHAGY; PROGRESSION; ACTIVATION;
   EXPRESSION; PROMOTE; GROWTH
AB Cholangiocarcinoma (CCA), the cancer arising from the epithelial cells of bile ducts, is a prototype of inflammatory-driven cancer. Cytokines released by cancer associated fibroblasts (CAFs) play a pivotal role in CCA progression, driving the epigenetic Epithelial-to-Mesenchymal transition and the growth and metastasization of CCA cells. Consistently, the conditioned medium from CCA-derived CAFs further stimulated the secretion of IL-6, and to a lesser extent of IL-8, by CCA cells. CCA has a poor prognosis, because of late diagnosis and of high resistance to radio- and chemo-therapy of CCA cells. Targeting the CAFs and their secretion could be an alternative option. We found that while IL-6 indeed promoted the cell migration of invasive CCA cells, the nutraceutical Resveratrol strongly counteracted this effect both in CCA cells and in immortalized cholangiocytes. More importantly, here we show that Resveratrol has the potential to abrogate the secretion of IL-6 by CAFs. While the conditioned medium from CAFs strongly induced IL-6 mediated motility of CCA cells, the conditioned medium from CAFs pre-treated with Resveratrol completely halted cancer cell motility and reverted the N-to E-cadherin switch in migrating cells. This effect was associated with stimulation of autophagy in the cancer cells. This is the first demonstration that CAFs secretory products directly affect the regulation of autophagy and consequently the behavior of CCA cells, and that a nutraceutical may revert the malignant phenotype of cancer cells by acting on CAFs metabolism and secretion.
C1 [Thongchot, Suyanee; Ferraresi, Alessandra; Vidoni, Chiara; Isidoro, Ciro] Univ Piemonte Orientale, Dept Hlth Sci, Lab Mol Pathol, I-28100 Novara, Italy.
   [Thongchot, Suyanee; Loilome, Watcharin; Namwat, Nisana] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Fac Med, Dept Biochem, Khon Kaen 40002, Thailand.
   [Yongvanit, Puangrat] Khon Kaen Univ, Cholangiocarcinoma Res Inst, Khon Kaen 40002, Thailand.
RP Isidoro, C (corresponding author), Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy.
EM ciro.isidoro@med.uniupo.it
RI Ferraresi, Alessandra/H-1518-2017; Isidoro, Ciro/J-6063-2016; Loilome,
   Watcharin/AAW-6203-2021
OI Ferraresi, Alessandra/0000-0002-7192-9672; Isidoro,
   Ciro/0000-0002-5494-3034; 
FU Khon Kaen University (Thailand); University del Piemonte Orientale "A.
   Avogadro" (Italy); Thailand Research Fund through the Royal Golden
   Jubilee PhD ProgramThailand Research Fund (TRF) [PHD/0048/2557];
   Mid-Career Grant of Thailand Research Fund (Thailand) [RSA5980012]
FX This work was supported by Khon Kaen University (Thailand), University
   del Piemonte Orientale "A. Avogadro" (Italy), the Thailand Research Fund
   through the Royal Golden Jubilee PhD Program (Grant No. PHD/0048/2557)
   to ST and NN, and a grant from a Mid-Career Grant (RSA5980012) of
   Thailand Research Fund (Thailand) to NN. The fluorescence imaging
   facility in the CI's laboratory was donated by Comoli, Ferrari & SpA
   (Novara, Italy). Thanks are due to Rocco Bettua (Thermo Fisher
   Scientific, Monza, Italy) for kind assistance in videoclip filming with
   EVOS FL Auto 2 Imaging System.
CR Araki K, 2011, BRIT J CANCER, V105, P1885, DOI 10.1038/bjc.2011.452
   Barbato DL, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/917698
   Ben-Menachem T, 2007, EUR J GASTROEN HEPAT, V19, P615, DOI 10.1097/MEG.0b013e328224b935
   Berman AY, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0038-6
   Butsri S, 2017, ONCOL LETT, V13, P4540, DOI 10.3892/ol.2017.5951
   Cadamuro M, 2018, BBA-MOL BASIS DIS, V1864, P1435, DOI 10.1016/j.bbadis.2017.07.028
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chan CC, 2011, MOL NUTR FOOD RES, V55, P1841, DOI 10.1002/mnfr.201100374
   Chiarugi P, 2016, CANCER LETT, V380, P272, DOI 10.1016/j.canlet.2015.10.027
   Chuaysri C, 2009, ONCOL REP, V21, P957, DOI 10.3892/or_00000309
   Claperon A, 2013, HEPATOLOGY, V58, P2001, DOI 10.1002/hep.26585
   Comito G, 2014, ONCOGENE, V33, P2423, DOI 10.1038/onc.2013.191
   Dominguez C, 2017, SEMIN CANCER BIOL, V47, P177, DOI 10.1016/j.semcancer.2017.08.002
   Farooqi AA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030652
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P2681, DOI 10.1002/mc.22711
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P1164, DOI 10.1002/mc.22582
   Frampton G, 2012, GUT, V61, P268, DOI 10.1136/gutjnl-2011-300643
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gescher AJ, 2003, CANCER EPIDEM BIOMAR, V12, P953
   Ghanim H, 2010, J CLIN ENDOCR METAB, V95, pE1, DOI 10.1210/jc.2010-0482
   Gharaee-Kermani M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158357
   Godichaud S, 2000, HEPATOLOGY, V31, P922, DOI 10.1053/he.2000.5848
   Govaere O, 2017, ONCOGENE, V36, P6605, DOI 10.1038/onc.2017.260
   Harbaum L, 2011, HISTOPATHOLOGY, V59, P225, DOI 10.1111/j.1365-2559.2011.03694.x
   Heits N, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2360-8
   Honjo S, 2005, INT J CANCER, V117, P854, DOI 10.1002/ijc.21146
   Howells LM, 2011, CANCER PREV RES, V4, P1419, DOI 10.1158/1940-6207.CAPR-11-0148
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Jiang ZD, 2017, ANN NY ACAD SCI, V1403, P59, DOI 10.1111/nyas.13466
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Ko JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122589
   Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144
   Kulkarni SS, 2015, BBA-MOL BASIS DIS, V1852, P1114, DOI 10.1016/j.bbadis.2014.10.005
   Kuzet SE, 2016, CELL TISSUE RES, V365, P607, DOI 10.1007/s00441-016-2467-x
   Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185
   Leyva-Illades Dinorah, 2012, Transl Gastrointest Cancer, V1, P71
   Liu LZ, 2018, J SURG ONCOL, V117, P1531, DOI 10.1002/jso.25027
   Lustri AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183932
   Maemura K, 2014, J HEPATO-BIL-PAN SCI, V21, P754, DOI 10.1002/jhbp.126
   MAIRIANG E, 1992, J GASTROEN HEPATOL, V7, P17, DOI 10.1111/j.1440-1746.1992.tb00928.x
   Martinez-Outschoorn UE, 2014, CANCER CELL, V26, P5, DOI 10.1016/j.ccr.2014.06.021
   Massani M, 2013, ONCOL REP, V30, P1143, DOI 10.3892/or.2013.2568
   McLean L, 2006, LIVER INT, V26, P1047, DOI 10.1111/j.1478-3231.2006.01350.x
   Mertens JC, 2013, CANCER RES, V73, P897, DOI 10.1158/0008-5472.CAN-12-2130
   Morandi A, 2016, TRENDS CANCER, V2, P736, DOI 10.1016/j.trecan.2016.11.001
   Pal M, 2018, EXP CELL RES, V368, P137, DOI 10.1016/j.yexcr.2018.04.014
   Pistore C, 2017, ONCOGENE, V36, P5551, DOI 10.1038/onc.2017.159
   Pitozzi V, 2013, J GERONTOL A-BIOL, V68, P371, DOI 10.1093/gerona/gls183
   Raffaghello L, 2015, ONCOTARGET, V6, P2589, DOI 10.18632/oncotarget.2661
   Rizvi S, 2018, NAT REV CLIN ONCOL, V15, P95, DOI 10.1038/nrclinonc.2017.157
   Rizvi S, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013
   Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902
   Singh CK, 2015, BBA-MOL BASIS DIS, V1852, P1178, DOI 10.1016/j.bbadis.2014.11.004
   Sirica AE, 2012, NAT REV GASTRO HEPAT, V9, P44, DOI 10.1038/nrgastro.2011.222
   Sripa B, 2007, PLOS MED, V4, P1148, DOI 10.1371/journal.pmed.0040201
   Sripa B, 2012, TRENDS PARASITOL, V28, P395, DOI 10.1016/j.pt.2012.07.006
   Sripa B, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001654
   Sripa B, 2009, HEPATOLOGY, V50, P1273, DOI 10.1002/hep.23134
   Surapaitoon A, 2017, PARASITOL INT, V66, P889, DOI 10.1016/j.parint.2016.10.009
   Takano M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2949-y
   Talcaishi M., 2016, PLOS ONE, V11
   Techasen A, 2014, TUMOR BIOL, V35, P8645, DOI 10.1007/s13277-014-2087-6
   Techasen A, 2012, ASIAN PAC J CANCER P, V13, P115, DOI 10.7314/APJCP.2012.13.KKSuppl.115
   Thanee Malinee, 2015, Asian Pac J Cancer Prev, V16, P3043
   Thuwajit C, 2018, MED RES REV, V38, P1235, DOI 10.1002/med.21473
   Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130
   Worzfeld T, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00024
   Yongvanit P, 2014, J HEPATO-BIL-PAN SCI, V21, P309, DOI 10.1002/jhbp.63
   Yongvanit P, 2012, PARASITOL INT, V61, P130, DOI 10.1016/j.parint.2011.06.011
   Yothaisong S, 2013, TUMOR BIOL, V34, P3637, DOI 10.1007/s13277-013-0945-2
   Zahedi HS, 2013, INT J PREVENTIVE MED, V4, pS8
   Zhang XF, 2017, HUM PATHOL, V65, P92, DOI 10.1016/j.humpath.2017.04.014
NR 72
TC 36
Z9 39
U1 7
U2 24
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 430
BP 160
EP 171
DI 10.1016/j.canlet.2018.05.031
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GL1ZG
UT WOS:000436912200015
PM 29802929
DA 2022-04-25
ER

PT J
AU Li, R
   Hao, YY
   Wang, QH
   Meng, Y
   Wu, KH
   Liu, CQ
   Xu, LJ
   Liu, ZG
   Zhao, L
AF Li, Rui
   Hao, Yanyu
   Wang, Qiuhan
   Meng, Yuan
   Wu, Kunhe
   Liu, Chaoqun
   Xu, Lijun
   Liu, Ziguang
   Zhao, Liang
TI ECHS1, an interacting protein of LASP1, induces sphingolipid-metabolism
   imbalance to promote colorectal cancer progression by regulating
   ceramide glycosylation
SO CELL DEATH & DISEASE
LA English
DT Article
ID INHIBITS CELL-PROLIFERATION; SH3 PROTEIN-1; 1 EXPRESSION; METASTASIS;
   MIGRATION; LIM; ATTENUATION; PROTEASOME; RESISTANCE; AUTOPHAGY
AB Sphingolipid metabolic dysregulation has increasingly been considered to be a drug-resistance mechanism for a variety of tumors. In this study, through an LC-MS assay, LIM and SH3 protein 1 (LASP1) was identified as a sphingolipid-metabolism-involved protein, and short-chain enoyl-CoA hydratase (ECHS1) was identified as a new LASP1-interacting protein through a protein assay in colorectal cancer (CRC). Gain- and loss-of-function analyses demonstrated the stimulatory role played by ECHS1 in CRC cell proliferation, migration, and invasion in vitro and in vivo. Mechanistic studies of the underlying tumor-supportive oncometabolism indicate that ECHS1 enables altering ceramide (Cer) metabolism that increases glycosphingolipid synthesis (HexCer) by promoting UDP-glucose ceramide glycosyltransferase (UGCG). Further analysis showed that ECHS1 promotes CRC progression and drug resistance by releasing reactive oxygen species (ROS) and interfering mitochondrial membrane potential via the PI3K/Akt/mTOR-dependent signaling pathway. Meanwhile, the phenomenon of promoting the survival and drug resistance of CRC cells caused by ECHS1 could be reversed by Eliglustat, a specific inhibitor of UCCG, in vitro and in vivo. IHC assay showed that ECHS1 was overexpressed in CRC tissues, which was related to the differentiation and poor prognosis of CRC patients. This study provides new insight into the mechanism by which phospholipids promote drug resistance in CRC and identifies potential targets for future therapies.
C1 [Li, Rui; Liu, Ziguang; Zhao, Liang] Southern Med Univ, Shunde Hosp, Dept Pathol, Peoples Hosp Shunde 1, Foshan, Peoples R China.
   [Li, Rui; Hao, Yanyu; Wang, Qiuhan; Liu, Chaoqun; Xu, Lijun; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.
   [Li, Rui; Hao, Yanyu; Wang, Qiuhan; Liu, Chaoqun; Xu, Lijun; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Peoples R China.
   [Meng, Yuan] Second Peoples Hosp Longgang Dist, Dept Pathol, Shenzhen, Peoples R China.
   [Wu, Kunhe] Guangdong Women & Children Hosp, Dept Pathol, Guangzhou 511442, Guangdong, Peoples R China.
RP Zhao, L (corresponding author), Southern Med Univ, Shunde Hosp, Dept Pathol, Peoples Hosp Shunde 1, Foshan, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Peoples R China.
EM liangsmu@foxmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972813, 81902946]; China Postdoctoral
   Science FoundationChina Postdoctoral Science Foundation [F119280111];
   Guangdong Basic and Applied Basic Research Foundation [2019A1515010974]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81972813, 81902946), China Postdoctoral Science Foundation
   (F119280111), and Guangdong Basic and Applied Basic Research Foundation
   (2019A1515010974).
CR Checchetto V, 2018, BIOCHEM BIOPH RES CO, V500, P51, DOI 10.1016/j.bbrc.2017.06.095
   Chen Q, 2020, J CELL MOL MED, V24, P1626, DOI 10.1111/jcmm.14854
   De Rosa M, 2015, ONCOL REP, V34, P1087, DOI 10.3892/or.2015.4108
   Dunn WB, 2011, NAT PROTOC, V6, P1060, DOI 10.1038/nprot.2011.335
   Grune T, 2011, FREE RADICAL BIO MED, V51, P1355, DOI 10.1016/j.freeradbiomed.2011.06.015
   Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545
   Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016
   Hu LL, 2016, INT J ONCOL, V49, P2217, DOI 10.3892/ijo.2016.3719
   Huang H, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4714-x
   Huang H, 2016, SCI REP-UK, V6, DOI 10.1038/srep34684
   Ichikawa S, 1996, P NATL ACAD SCI USA, V93, P4638, DOI 10.1073/pnas.93.10.4638
   Jesko H, 2019, MOL NEUROBIOL, V56, P3501, DOI 10.1007/s12035-018-1286-3
   KANAZAWA M, 1993, ENZYME PROTEIN, V47, P9, DOI 10.1159/000468650
   Kopecka J, 2020, DRUG RESIST UPDATE, V49, DOI 10.1016/j.drup.2019.100670
   Kozovska Z, 2014, BIOMED PHARMACOTHER, V68, P911, DOI 10.1016/j.biopha.2014.10.019
   Liu YY, 2013, ADV CANCER RES, V117, P59, DOI 10.1016/B978-0-12-394274-6.00003-0
   Madigan JP, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111860
   Morozov AV, 2017, CELL STRESS CHAPERON, V22, P687, DOI 10.1007/s12192-017-0792-y
   Niu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26112
   Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531
   Pattingre S, 2009, AUTOPHAGY, V5, P558, DOI 10.4161/auto.5.4.8390
   Qu YY, 2020, CANCER RES, V80, P319, DOI 10.1158/0008-5472.CAN-19-1023
   Sharpe AJ, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7060046
   Tang RX, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-163
   Vykoukal J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17645-z
   Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485
   Wang H, 2013, EUR J CANCER, V49, P3924, DOI 10.1016/j.ejca.2013.07.149
   Wang W, 2016, ONCOTARGET, V7, P68674, DOI 10.18632/oncotarget.11919
   Xiao CX, 2013, CANCER LETT, V330, P67, DOI 10.1016/j.canlet.2012.11.030
   Xie JP, 2014, MOL CLIN ONCOL, V2, P1081, DOI 10.3892/mco.2014.340
   Xu LJ, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0244-8
   Zhang YK, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00489-5
   Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739
   Zhao QM, 2015, MOL MED REP, V12, P470, DOI 10.3892/mmr.2015.3418
   Zhu XS, 2014, CELL MOL BIOL LETT, V19, P576, DOI 10.2478/s11658-014-0213-5
   Zhu XS, 2013, CRIT REV EUKAR GENE, V23, P275, DOI 10.1615/CritRevEukaryotGeneExpr.2013007531
NR 36
TC 0
Z9 0
U1 4
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT 6
PY 2021
VL 12
IS 10
AR 911
DI 10.1038/s41419-021-04213-6
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA WD2RV
UT WOS:000704795500002
PM 34615856
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yen, JH
   Huang, ST
   Huang, HS
   Fong, YC
   Wu, YY
   Chiang, JH
   Su, YC
AF Yen, Jia-Hau
   Huang, Sheng-Teng
   Huang, Hung-Sen
   Fong, Yi-Chin
   Wu, Yi-Ying
   Chiang, Jen-Huai
   Su, Yuan-Chih
TI HGK-sestrin 2 signaling-mediated autophagy contributes to antitumor
   efficacy of Tanshinone IIA in human osteosarcoma cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID PROGNOSTIC-SIGNIFICANCE; PI3K/AKT/MTOR PATHWAY; COLORECTAL-CANCER;
   CERVICAL-CANCER; TUMOR-GROWTH; IN-VITRO; EXPRESSION; APOPTOSIS;
   INHIBITION; KINASE
AB Tanshinone IIA (TIIA) is a diterpenoid naphthoquinone isolated from the herb Salvia miltiorrhiza with antitumor effects manifested at multiple levels that are mechanistically obscure. In our previous studies, we illustrated that TIIA treatment triggered apoptosis in human osteosarcoma 143B cells both in vitro and in vivo, accompanied with mitochondrial dysfunction. Importantly, the overall survival rate of patients with osteosarcoma who were randomly recruited to S. miltiorrhiza treatment was significantly higher than those without. Pursuing this observation, we evaluated the potential effect of TIIA on autophagy induction in osteosarcoma both in vivo and in vitro. We discovered that TIIA inhibited osteosarcoma cell survival through class I PI3K and Akt signaling pathways. In contrast, expression of class III PI3K required in the early stages of autophagosome generation was predominantly enhanced by TIIA treatment. Our study indicated that treatment of TIIA effectively induced autophagy in human osteosarcoma cells, which contributed to the blockade of anchorage-independent growth of osteosarcoma cells and ameliorated tumor progression in NOD/SCID mice. We demonstrated that TIIA-mediated autophagy occurred in a sestrin 2 (SESN2)-dependent but not Beclin 1-dependent manner. In addition, we defined the activation of HGK (MAP4K4 or mitogenactivated protein kinase kinase kinase kinase)/SAPK/JNK1/Jun kinase pathways in upregulating transcription of SESN2, in which TIIA triggered HGK/JNK1-dependent Jun activation and led to increased Jun recruitment to AP-1-binding site in the SESN2 promoter region. Our results offer novel mechanistic insight into how TIIA inhibits osteosarcoma growth and suggest TIIA as a promising therapeutic agent for the treatment of cancer.
C1 [Yen, Jia-Hau; Huang, Sheng-Teng; Huang, Hung-Sen] China Med Univ Hosp, Res Canc Ctr Tradit Chinese Med, Dept Med Res, Taichung, Taiwan.
   [Huang, Sheng-Teng] China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan.
   [Huang, Sheng-Teng] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Fong, Yi-Chin] China Med Univ Hosp, Dept Orthopaed & Traumatol, Taichung, Taiwan.
   [Fong, Yi-Chin] China Med Univ, Coll Hlth Care, Dept Sports Med, Taichung, Taiwan.
   [Fong, Yi-Chin] China Med Univ, Beigang Hosp, Dept Surg, Yunlin, Taiwan.
   [Wu, Yi-Ying] China Med Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.
   [Chiang, Jen-Huai; Su, Yuan-Chih] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Chiang, Jen-Huai; Su, Yuan-Chih] China Med Univ, Sch Chinese Med, Grad Inst Integrated Med, Taichung, Taiwan.
RP Huang, ST (corresponding author), China Med Univ Hosp, Res Canc Ctr Tradit Chinese Med, Dept Med Res, Taichung, Taiwan.; Huang, ST (corresponding author), China Med Univ Hosp, Dept Chinese Med, Taichung, Taiwan.; Huang, ST (corresponding author), China Med Univ, Sch Chinese Med, Taichung, Taiwan.
EM sheng.teng@yahoo.com
FU Ministry of Science and TechnologyMinistry of Education, Culture,
   Sports, Science and Technology, Japan (MEXT) [MOST 106-2320-B-039-022];
   National Research Institute of Chinese Medicine, Ministry of Health and
   Welfare [MOHW106-NRICM-C-104-000002]; Health and welfare surcharge of
   tobacco products, China Medical University Hospital Cancer Research
   Center of Excellence [MOHW107-TDU-B-212-114024]; China Medical
   University Hospital [DMR-107-003, DMR-107-006]; China Medical University
   under the Aim for Top University Plan of the Ministry of Education,
   Taiwan [CHM106-7, CHM106-8]; Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   [MOHW107-TDU-B-212-123004]; China Medical University Hospital, Academia
   Sinica Stroke Biosignature Project [BM10701010021]; MOST Clinical Trial
   Consortium for Stroke [MOST 106-2321-B-039-005]; Tseng-Lien Lin
   Foundation, Taichung, Taiwan; Katsuzo and Kiyo Aoshima Memorial Funds,
   Japan
FX This work was supported and funded by Ministry of Science and Technology
   with MOST 106-2320-B-039-022, National Research Institute of Chinese
   Medicine, Ministry of Health and Welfare (MOHW106-NRICM-C-104-000002),
   Health and welfare surcharge of tobacco products, China Medical
   University Hospital Cancer Research Center of Excellence
   (MOHW107-TDU-B-212-114024) China Medical University Hospital
   (DMR-107-003 and DMR-107-006), and China Medical University under the
   Aim for Top University Plan of the Ministry of Education, Taiwan
   (CHM106-7 and CHM106-8). This study was also supported in part by the
   Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence (MOHW107-TDU-B-212-123004), China Medical University
   Hospital, Academia Sinica Stroke Biosignature Project (BM10701010021),
   MOST Clinical Trial Consortium for Stroke (MOST 106-2321-B-039-005)",
   Tseng-Lien Lin Foundation, Taichung, Taiwan, and Katsuzo and Kiyo
   Aoshima Memorial Funds, Japan. We are thankful to Dr. Gregory J Tsay for
   his kind help with collection of human tissue specimen and James Waddell
   for the critical reading and revision of our manuscript.
CR Bae SH, 2013, CELL METAB, V17, P73, DOI 10.1016/j.cmet.2012.12.002
   Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877
   Chang CC, 2014, PHYTOMEDICINE, V21, P207, DOI 10.1016/j.phymed.2013.09.012
   Chen S, 2014, CARCINOGENESIS, V35, P613, DOI 10.1093/carcin/bgt371
   Cirstea D, 2010, MOL CANCER THER, V9, P963, DOI 10.1158/1535-7163.MCT-09-0763
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   D'Amelio M, 2009, CELL CYCLE, V8, P1467
   Dong YZ, 2011, NAT PROD REP, V28, P529, DOI 10.1039/c0np00035c
   Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001
   Fu JJ, 2007, EUR J PHARMACOL, V568, P213, DOI 10.1016/j.ejphar.2007.04.031
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Guntur KVP, 2010, J BIOL CHEM, V285, P6595, DOI 10.1074/jbc.M109.068502
   Hao JM, 2010, J PATHOL, V220, P475, DOI 10.1002/path.2668
   Huang ST, 2017, SCI REP-UK, V7, DOI 10.1038/srep40382
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Li GB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117440
   Li XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043918
   Liang JJ, 2008, CLIN CANCER RES, V14, P7043, DOI 10.1158/1078-0432.CCR-08-0381
   Liu AW, 2011, CLIN CANCER RES, V17, P710, DOI 10.1158/1078-0432.CCR-10-0331
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Loftus JC., 2013, J SIGNAL TRANSDUCT, V2013, P956580, DOI [10.1155/2013/956580, DOI 10.1155/2013/956580]
   Messerschmitt PJ, 2008, CLIN ORTHOP RELAT R, V466, P2168, DOI 10.1007/s11999-008-0338-9
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Morgan TM, 2009, CURR CANCER DRUG TAR, V9, P237, DOI 10.2174/156800909787580999
   Munagala R, 2015, CANCER LETT, V356, P536, DOI 10.1016/j.canlet.2014.09.037
   Qiu MH, 2012, PATHOL RES PRACT, V208, P541, DOI 10.1016/j.prp.2012.06.001
   Savage Sharon A., 2011, Sarcoma, V2011, P548151, DOI 10.1155/2011/548151
   Slomovitz BM, 2012, CLIN CANCER RES, V18, P5856, DOI 10.1158/1078-0432.CCR-12-0662
   Su CC, 2014, ANTICANCER RES, V34, P7097
   Tanida I, 2011, ANTIOXID REDOX SIGN, V14, P2201, DOI 10.1089/ars.2010.3482
   Thorpe LM, 2015, NAT REV CANCER, V15, P7, DOI 10.1038/nrc3860
   Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86
   Wang XJ, 2005, INT J CANCER, V116, P799, DOI 10.1002/ijc.20880
   Weydert CJ, 2010, NAT PROTOC, V5, P51, DOI 10.1038/nprot.2009.197
   Wright JH, 2003, MOL CELL BIOL, V23, P2068, DOI 10.1128/MCB.23.6.2068-2082.2003
   Xiao XX, 2012, GYNECOL ONCOL, V127, P249, DOI 10.1016/j.ygyno.2012.06.032
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118
   Zhang Y, 2012, INT J MOL SCI, V13, P13621, DOI 10.3390/ijms131013621
   Zheng LY, 2013, CLIN CANCER RES, V19, P5372, DOI 10.1158/1078-0432.CCR-13-0203
   Zhou LL, 2008, LIFE SCI, V83, P394, DOI 10.1016/j.lfs.2008.07.011
   Zhou LM, 2005, J CLIN PHARMACOL, V45, P1345, DOI 10.1177/0091270005282630
   Zhu J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050099
   Zulato E, 2014, BRIT J CANCER, V111, P25, DOI 10.1038/bjc.2014.274
NR 44
TC 26
Z9 28
U1 2
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP 26
PY 2018
VL 9
AR 1003
DI 10.1038/s41419-018-1016-9
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GV6YY
UT WOS:000446268400001
PM 30258193
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kitazawa, S
   Nishizawa, S
   Nakagawa, H
   Funata, M
   Nishimura, K
   Soga, T
   Hara, T
AF Kitazawa, Satoshi
   Nishizawa, Satoru
   Nakagawa, Hideyuki
   Funata, Masaaki
   Nishimura, Kazuho
   Soga, Tomoyoshi
   Hara, Takahito
TI Cancer with low cathepsin D levels is susceptible to vacuolar
   (H+)-ATPase inhibition
SO CANCER SCIENCE
LA English
DT Article
DE Cathepsin D; colorectal cancer; patient selection marker; V-ATPase;
   vulnerability
ID H+-ATPASE; TRANSFER-RNA; AMINO-ACIDS; CELL-LINE; ASPARTIC PROTEASE;
   BREAST-CANCER; PROTON PUMP; APOPTOSIS; ACTIVATION; MTORC1
AB Vacuolar (H+)-ATPases (V-ATPases) have important roles in the supply of nutrients to tumors by mediating autophagy and the endocytic uptake of extracellular fluids. Accordingly, V-ATPases are attractive therapeutic targets for cancer. However, the clinical use of V-ATPase inhibitors as anticancer drugs has not been realized, possibly owing to their high toxicity in humans. Inhibition of V-ATPase may be an appropriate strategy in highly susceptible cancers. In this study, we explored markers of V-ATPase inhibitor sensitivity. V-ATPase inhibitors led to pH impairment in acidic intracellular compartments, suppression of macropinocytosis, and decreased intracellular amino acid levels. The sensitivity of cells to V-ATPase inhibitors was correlated with low cathepsin D expression, and cancer cells showed increased sensitivity to V-ATPase inhibitors after pretreatment with a cathepsin D inhibitor and siRNA targeting the cathepsin D gene (CTSD). In addition, V-ATPase inhibitor treatment led to the induction of the amino acid starvation response, upregulation of endoplasmic reticulum stress markers, and suppression of mammalian target of rapamycin (mTOR) signaling in cells expressing low levels of cathepsin D. Some colorectal cancer patients showed the downregulation of cathepsin D in tumor tissues compared with matched normal tissues. These findings indicate that V-ATPase inhibitors are promising therapeutic options for cancers with downregulated cathepsin D.
C1 [Kitazawa, Satoshi; Nishizawa, Satoru; Nishimura, Kazuho; Hara, Takahito] Takeda Pharmaceut Co Ltd, Oncol Drug Discovery Unit, Div Pharmaceut Res, Fujisawa, Kanagawa 2518555, Japan.
   [Nakagawa, Hideyuki; Funata, Masaaki] Takeda Pharmaceut Co Ltd, Biomol Res Labs, Fujisawa, Kanagawa, Japan.
   [Soga, Tomoyoshi] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.
RP Hara, T (corresponding author), Takeda Pharmaceut Co Ltd, Oncol Drug Discovery Unit, Div Pharmaceut Res, Fujisawa, Kanagawa 2518555, Japan.
EM takahito.hara@takeda.com
RI Soga, Tomoyoshi/B-8105-2014
OI Soga, Tomoyoshi/0000-0001-9502-2509
FU Takeda Pharmaceutical Company Limited, JapanTakeda Pharmaceutical
   Company Ltd; Japan Agency for Medical Research and DevelopmentJapan
   Agency for Medical Research and Development (AMED); Yamagata prefectural
   government; City of Tsuruoka
FX Takeda Pharmaceutical Company Limited, Japan; Japan Agency for Medical
   Research and Development; Yamagata prefectural government; City of
   Tsuruoka.
CR Benes P, 2008, CRIT REV ONCOL HEMAT, V68, P12, DOI 10.1016/j.critrevonc.2008.02.008
   Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x
   Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9
   Fais S, 2007, CANCER RES, V67, P10627, DOI 10.1158/0008-5472.CAN-07-1805
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Guha S, 2008, INDIAN J BIOCHEM BIO, V45, P75
   Hah YS, 2012, CANCER LETT, V323, P208, DOI 10.1016/j.canlet.2012.04.012
   Han KY, 2015, MOL MED REP, V11, P3866, DOI 10.3892/mmr.2015.3158
   Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211
   Kirana Chandra, 2012, Int J Proteomics, V2012, P245819, DOI 10.1155/2012/245819
   Koltai T, 2016, ONCOTARGETS THER, V9, P6343, DOI 10.2147/OTT.S115438
   Lee JC, 2005, CARCINOGENESIS, V26, P1716, DOI 10.1093/carcin/bgi133
   Liaudet-Coopman E, 2006, CANCER LETT, V237, P167, DOI 10.1016/j.canlet.2005.06.007
   Maxson ME, 2014, J CELL SCI, V127, P4987, DOI 10.1242/jcs.158550
   Mijaljica D, 2011, AUTOPHAGY, V7, P666, DOI 10.4161/auto.7.6.15812
   Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Murakami T, 2001, INT J CANCER, V93, P869, DOI 10.1002/ijc.1418
   Nakashima S, 2003, J BIOCHEM, V134, P359, DOI 10.1093/jb/mvg153
   Neefjes J, 2004, NAT REV DRUG DISCOV, V3, P58, DOI 10.1038/nrd1282
   Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729
   Ohta T, 1998, J PATHOL, V185, P324, DOI 10.1002/(SICI)1096-9896(199807)185:3<324::AID-PATH72>3.0.CO;2-9
   Oliveira CSF, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.157
   Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017
   Roberg K, 2002, AM J PATHOL, V161, P89, DOI 10.1016/S0002-9440(10)64160-0
   Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535
   Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024
   Schestkowa O, 2007, J CELL BIOCHEM, V101, P1558, DOI 10.1002/jcb.21269
   Schneider LS, 2015, CANCER RES, V75, P2863, DOI 10.1158/0008-5472.CAN-14-2097
   Sennoune SR, 2012, CURR PROTEIN PEPT SC, V13, P152
   Sevlever D, 2008, BIOCHEMISTRY-US, V47, P9678, DOI 10.1021/bi800699v
   Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200
   Stankiewicz M, 1996, INT J PARASITOL, V26, P445, DOI 10.1016/0020-7519(96)00003-3
   Stransky L, 2016, PHYSIOL REV, V96, P1071, DOI 10.1152/physrev.00035.2015
   TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504
   Theodoropoulos GE, 1997, J SURG ONCOL, V65, P242, DOI 10.1002/(SICI)1096-9098(199708)65:4<242::AID-JSO4>3.0.CO;2-5
   Torigoe T, 2002, J BIOL CHEM, V277, P36534, DOI 10.1074/jbc.M202605200
   Vandewynckel YP, 2013, ANTICANCER RES, V33, P4683
   WEK RC, 1989, P NATL ACAD SCI USA, V86, P4579, DOI 10.1073/pnas.86.12.4579
   WEK SA, 1995, MOL CELL BIOL, V15, P4497
   Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yumoto R, 2012, DRUG METAB PHARMACOK, V27, P336, DOI 10.2133/dmpk.DMPK-11-RG-127
   Zaidi N, 2008, BIOCHEM BIOPH RES CO, V376, P5, DOI 10.1016/j.bbrc.2008.08.099
   Zhao Y, 2013, MED CHEM RES, V22, P2505, DOI 10.1007/s00044-012-0245-1
   Zoncu R, 2011, SCIENCE, V334, P678, DOI 10.1126/science.1207056
NR 48
TC 9
Z9 10
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD JUN
PY 2017
VL 108
IS 6
BP 1185
EP 1193
DI 10.1111/cas.13240
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EY5LZ
UT WOS:000404020000011
PM 28317223
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Wang, ZH
   Wang, JH
   Wang, KQ
   Zhou, Y
   Wang, J
AF Wang, Z-H
   Wang, J-H
   Wang, K-Q
   Zhou, Y.
   Wang, J.
TI LncRNA FEZF1-AS1 promoted chemoresistance, autophagy and epithelial-
   mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis
   in prostate cancer
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE FEZF1-AS1; Chemoresistance; Autophagy; EMT; Prostate cancer
ID CELL-PROLIFERATION; COLORECTAL-CANCER; METASTASIS; RNA; EXPRESSION;
   PACLITAXEL; RESISTANCE; MIGRATION; INVASION; MIRNA
AB OBJECTIVE: Accumulating evidence determined that lncRNA plays important roles in the development and occurrence of cancers. Prostate cancer is the second most common type of cancer and one of the top five cancers for the cause of male death in the world. Therefore, this study was to explore the regulatory mechanism of lncRNA in chemoresistance of PC. MATERIALS AND METHODS: qRT-PCR was used to detect the mRNA expression of FEZF1AS1, miR-25- 3p and ITGB8. Western blot was applied to measure the protein expression of ITGB8 E- cadherin, N-cadherin, Vimentin, LC3I, LC3II, ATG5 and Beclin-1. In addition, CCK-8 assay was used to assess cell proliferation of transfected cells. Luciferase reporter assay and RIP assay were used to determine the relationship among FEZF1-AS1, miR-25-3p and ITGB8. RESULTS: In this study, the expression of FEZF1-AS1 and ITGB8 was upregulated, whereas the expression of miR-25-3p was downregulated in PC tumor tissues and PC/PTX cells. Luciferase reporter assay and RIP assay determined that miR-25-3p was a target of FEZF1-AS1 and ITGB8 was a target mRNA of miR-25-3p. Interestingly, knockdown of FEZF1-AS1 could inhibit cell viability and EMT and promoted cell autophagy in PC/PTX cells, but inhibition of miR25-3p or promotion of ITGB8 could reverse the effects of si-FEZF1-AS1 on PC/PTX cells. CONCLUSIONS: In this study, we found that lncRNA FEZF1-AS1 promoted chemoresistance, autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25- 3p/ ITGB8 axis in PC, providing a new regulatory mechanism of PC and a novel therapeutic target.
C1 [Wang, Z-H; Wang, J-H; Wang, J.] Sichuan Univ, West China Hosp, Dept Urol, Chengdu, Peoples R China.
   [Wang, K-Q] Daguan Hosp Jinjiang Dist, Dept Urol, Chengdu, Peoples R China.
   [Zhou, Y.] Peoples Hosp Kaizhou Dist, Dept Urol, Chongqing, Peoples R China.
RP Wang, J (corresponding author), Sichuan Univ, West China Hosp, Dept Urol, Chengdu, Peoples R China.
EM hjxwoq@163.com
CR Al-Batran SE, 2007, J CLIN ONCOL, V25, P729, DOI 10.1200/JCO.2006.09.4896
   Aoyama Y, 2017, BIOCHEM BIOPH RES CO, V486, P551, DOI 10.1016/j.bbrc.2017.03.084
   Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383
   Chen HY, 2015, INT J CLIN EXP PATHO, V8, P12718
   Chen N, 2016, ONCOTARGET, V7, P11271, DOI 10.18632/oncotarget.7168
   Cochetti G, 2016, ONCOTARGETS THER, V9, P7545, DOI 10.2147/OTT.S119027
   Cui YJ, 2018, ONCOL REP, V39, P1649, DOI 10.3892/or.2018.6259
   Esfandiar A, 2017, SCIENCE, V358, P511, DOI 10.1126/science.aan5275
   Garcia-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108
   Goldsmith J, 2014, METHOD ENZYMOL, V542, P25, DOI 10.1016/B978-0-12-416618-9.00002-9
   Guo JB, 2019, J CELL BIOCHEM, V120, P17975, DOI 10.1002/jcb.29064
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   Hong L, 2013, CURR DRUG TARGETS, V14, P1118, DOI 10.2174/13894501113149990183
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang L, 2017, AM J CANCER RES, V7, P1996
   Ivanovic RF, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0516-0
   Jia JG, 2019, J CELL MOL MED, V23, P656, DOI 10.1111/jcmm.13970
   Keating B, 2014, AM J TRANSPLANT, V14, P223
   Kumar V, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01764-7
   Lanzi C, 2001, PROSTATE, V48, P254, DOI 10.1002/pros.1105
   LaPointe VLS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082035
   Li J, 2016, ONCOL RES, V23, P205, DOI 10.3727/096504016X14549667334007
   Li L, 2015, ONCOTARGET, V6, P14179, DOI 10.18632/oncotarget.3651
   Liu JH, 2014, ASIAN PAC J CANCER P, V15, P2971, DOI 10.7314/APJCP.2014.15.7.2971
   Liu YN, 2017, PROCEEDINGS OF THE 2017 INTERNATIONAL CONFERENCE ON WIRELESS COMMUNICATIONS, NETWORKING AND APPLICATIONS (WCNA2017), P16, DOI 10.1145/3180496.3180601
   Malik R, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-983
   Mertens-Walker I, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1164-6
   Muluhngwi P, 2015, ENDOCR-RELAT CANCER, V22, pR279, DOI 10.1530/ERC-15-0355
   NW, 2006, CANCER EPIDEM BIOMAR, V15, pED01
   Prensner JR, 2014, NEOPLASIA, V16, P900, DOI 10.1016/j.neo.2014.09.001
   Reddy KB, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0185-1
   Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100
   Safavy A, 1999, J MED CHEM, V42, P4919, DOI 10.1021/jm990355x
   Schaefer A, 2010, EXP MOL MED, V42, P749, DOI 10.3858/emm.2010.42.11.076
   Shen CJ, 2017, J DRUG TARGET, V25, P637, DOI 10.1080/1061186X.2017.1307379
   Shi XL, 2020, INT J CANCER, V146, P475, DOI 10.1002/ijc.32422
   Si XX, 2016, ONCOTARGET, V7, P81452, DOI 10.18632/oncotarget.13263
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Wang H, 2017, ONCOTARGET, V9, P7501
   Wang WW, 2015, INT J CLIN EXP MED, V8, P3063
   Wang ZW, 2010, DRUG RESIST UPDATE, V13, P109, DOI 10.1016/j.drup.2010.07.001
   Weaver BA, 2014, MOL BIOL CELL, V25, P2677, DOI 10.1091/mbc.E14-04-0916
   Wu Jin-Bo, 2017, Zhongguo Ying Yong Sheng Li Xue Za Zhi, V33, P146, DOI 10.12047/j.cjap.5449.2017.037
   Wu XL, 2017, MOL MED REP, V16, P4293, DOI 10.3892/mmr.2017.7103
   Xu ZG, 2012, ANAT REC, V295, P1446, DOI 10.1002/ar.22521
   Xue D, 2018, J CELL MOL MED, V22, P3223, DOI 10.1111/jcmm.13604
   Ye S, 2014, CELL BIOCHEM BIOPHYS, V70, P1849, DOI 10.1007/s12013-014-0142-y
   Zhang PF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09482-6
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhou CW, 2018, ONCOL RES, V26, P1335, DOI 10.3727/096504018X15188367859402
   Zhu LF, 2019, EUR REV MED PHARMACO, V23, P5122, DOI 10.26355/eurrev_201906_18176
   Zhu MJ, 2014, FEBS J, V281, P3766, DOI 10.1111/febs.12902
NR 54
TC 11
Z9 12
U1 1
U2 4
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 5
BP 2281
EP 2293
DI 10.26355/eurrev_202003_20493
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KY2JG
UT WOS:000522397800014
PM 32196579
DA 2022-04-25
ER

PT J
AU Liu, Y
   Peng, XL
   Li, H
   Jiao, WH
   Peng, X
   Shao, JR
   Xu, YL
   Wang, R
   Wang, W
   Kong, DX
AF Liu, Yao
   Peng, Xiaolin
   Li, Hui
   Jiao, Wenhui
   Peng, Xin
   Shao, Jingrong
   Xu, Yanglu
   Wang, Ran
   Wang, Wei
   Kong, Dexin
TI STAT3 Inhibitor Napabucasin Inhibits Tumor Growth and Cooperates with
   Proteasome Inhibition in Human Ovarian Cancer Cells
SO RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
LA English
DT Article
DE Ovarian cancer; STAT3; Napabucasin; proteasome inhibitor; G2; M phase
   arrest; autophagy
ID COLORECTAL-CANCER; PROSTATE-CANCER; EXPRESSION; INVASION; STRATEGIES;
   THERAPIES; APOPTOSIS; PROMOTES; PROTEIN; OBESITY
AB Background: Ovarian cancer is a disease with the highest mortality in gynecologic malignancies. Activation of STAT3 pathway is well known to be associated with tumor progression and metastasis in a number of cancers, including ovarian cancer. Therefore, STAT3 may be an ideal target for ovarian cancer treatment. Objective: The present study aims to determine the antitumor activity of STAT3 inhibitor Napabucasin as a single agent or in combination with proteasome inhibitor MG-132 in ovarian cancer cells. Methods: MTT was performed to determine the anti-proliferative effect of Napabucasin on ovarian cancer SKOV-3 cells. The involved anti-tumor mechanism was explored by flow cytometry, qRTPCR and western blot. MDC staining and tandem mRFP-GFP-LC3 fluorescence microscopy were used to analyze the autophagy-inducing capability of Napabucasin with or without MG-132. The combinational anticancer effect of Napabucasin and MG-132 was evaluated according to Chou and Talalay's method (1984). Results: Napabucasin showed obvious tumor-inhibitory effects against SKOV-3 cells. Treatment by Napabucasin arrested cell cycle progression in G2/M phase. Mechanistically, elevated expression of p21 may contribute to the blockade of the cell cycle. Moreover, we demonstrated that Napabucasin induced autophagy in SKOV-3 cells by using various assays, including MDC staining, autophagic flux examination, and detection of the autophagy markers. In addition, a combination of Napabucaisin with MG-132 exhibited a significant synergistic anti-proliferative effect, probably by inducing apoptosis through a mitochondria-dependent pathway. The two compounds induced pro-survival autophagies, and co-treatment with autophagy inhibiter might further enhance their antitumor effects. Conclusion: Napabucasin alone or in combination with MG-132 might be promising treatment strategy for ovarian cancer patients.
C1 [Liu, Yao; Peng, Xiaolin; Li, Hui; Jiao, Wenhui; Peng, Xin; Shao, Jingrong; Xu, Yanglu; Wang, Ran; Kong, Dexin] Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
   [Liu, Yao; Peng, Xiaolin; Wang, Wei] Tianjin First Cent Hosp, Inst Otolaryngol Tianjin, Dept Otorhinolaryngol Head & Neck Surg, Key Lab Auditory Speech & Balance Med, Tianjin 300192, Peoples R China.
   [Kong, Dexin] Tianyuan Univ, Tianjin Tianshi Coll, Sch Med, Tianjin 301700, Peoples R China.
RP Wang, R; Wang, W; Kong, DX (corresponding author), Tianjin Med Univ, Sch Pharm, Tianjin Key Lab Technol Enabling Dev Clin Therape, Tianjin 300070, Peoples R China.
EM wangran@tmu.edu.cn; wwei1106@hotmail.com; kongdexin@tmu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81673464, 81373441, 81971698]; Tianjin for
   New Drug Development, China [17ZXXYSY00050]
FX The work was supported by a grant from the National Natural Science
   Foundation of China (Grant Nos. 81673464, 81373441 and 81971698) and the
   grant for Major Project of Tianjin for New Drug Development, China
   (Grant No. 17ZXXYSY00050) .
CR Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284
   Aleskandarany MA, 2016, BREAST CANCER RES TR, V156, P9, DOI 10.1007/s10549-016-3709-z
   Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923
   Banerjee S, 2013, CLIN CANCER RES, V19, P961, DOI 10.1158/1078-0432.CCR-12-2243
   Beyreis M, 2019, CANCERS, V11, DOI 10.3390/cancers11030276
   Bi SL, 2019, EUR J PHARMACOL, V855, P252, DOI 10.1016/j.ejphar.2019.05.020
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004
   Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Crawford LJ, 2011, J CELL COMMUN SIGNAL, V5, P101, DOI 10.1007/s12079-011-0121-7
   Deng JH, 2012, CANCER CELL, V21, P642, DOI 10.1016/j.ccr.2012.03.039
   Fagard Remi, 2013, JAKSTAT, V2, pe22882, DOI 10.4161/jkst.22882
   Fan Y, 2008, WORLD J GASTROENTERO, V14, P428, DOI 10.3748/wjg.14.428
   Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945
   Grunewald T, 2017, BEST PRACT RES CL OB, V41, P139, DOI 10.1016/j.bpobgyn.2016.12.001
   Hubbard JM, 2017, DRUGS, V77, P1091, DOI 10.1007/s40265-017-0759-4
   Jia ZH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183622
   Kane RC, 2006, CLIN CANCER RES, V12, P2955, DOI 10.1158/1078-0432.CCR-06-0170
   Kaplan GS, 2017, FREE RADICAL BIO MED, V103, P1, DOI 10.1016/j.freeradbiomed.2016.12.007
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Kawazoe A, 2020, CLIN CANCER RES, V26, P5887, DOI 10.1158/1078-0432.CCR-20-1803
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Li HY, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12719
   Li X, 2020, CANCER LETT, V491, P146, DOI 10.1016/j.canlet.2020.07.032
   Liu XN, 2019, MED SCI MONITOR, V25, P8905, DOI 10.12659/MSM.918384
   MacDonagh L, 2018, CANCER LETT, V428, P117, DOI 10.1016/j.canlet.2018.04.008
   Martine C, 2010, Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer, Patent No. [US20100311774, 20100311774]
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Priceman SJ, 2013, P NATL ACAD SCI USA, V110, P13079, DOI 10.1073/pnas.1311557110
   Saini U, 2017, ONCOGENE, V36, P168, DOI 10.1038/onc.2016.197
   Samer A, 2005, Methods for assessing cisplatin resistance, disease progression, and treatment efficacy in ovarian cancer, Patent No. [US20050176669, 20050176669]
   Santoni M, 2015, EXPERT OPIN INV DRUG, V24, P809, DOI 10.1517/13543784.2015.1020370
   Schmidtova S, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01458-7
   Schroeder A, 2014, CANCER RES, V74, P1227, DOI 10.1158/0008-5472.CAN-13-0594
   Sebti S, 2014, Platinum compounds that inhibit constitutive STAT3 signaling and induce cell cycle arrest and apoptosis of malignant cells, Patent No. [US20140303134, 20140303134]
   Soave CL, 2017, CANCER METAST REV, V36, P717, DOI 10.1007/s10555-017-9705-x
   Stark George R, 2004, Methods Mol Biol, V280, P51
   Teicher BA, 2015, BIOCHEM PHARMACOL, V96, P1, DOI 10.1016/j.bcp.2015.04.008
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071
   Wang ZM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01450
   Wu TY, 2017, MOL CANCER THER, V16, P717, DOI 10.1158/1535-7163.MCT-16-0553
   Wu WY, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-506
   Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zarei S, 2019, BRATISL MED J, V120, P468, DOI 10.4149/BLL_2019_075
   Zhang YM, 2016, CANCER MED-US, V5, P1251, DOI 10.1002/cam4.675
   Zhou J, 2017, STAT3 inhibitor, Patent No. [US20170152260, 20170152260]
   Zhou QX, 2016, INT J BIOL SCI, V12, P631, DOI 10.7150/ijbs.14878
NR 49
TC 1
Z9 1
U1 7
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-8928
EI 2212-3970
J9 RECENT PAT ANTI-CANC
JI Recent Patents Anti-Canc. Drug Discov.
PY 2021
VL 16
IS 3
BP 350
EP 362
DI 10.2174/1574892816666210224155403
PG 13
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA US8MP
UT WOS:000697680100004
PM 33655847
DA 2022-04-25
ER

PT J
AU Signorile, ML
   Grossi, V
   Di Franco, S
   Forte, G
   Disciglio, V
   Fasano, C
   Sanese, P
   De Marco, K
   Susca, FC
   Mangiapane, LR
   Nicotra, A
   Di Carlo, G
   Dituri, F
   Giannelli, G
   Ingravallo, G
   Canettieri, G
   Stassi, G
   Simone, C
AF Signorile, Martina Lepore
   Grossi, Valentina
   Di Franco, Simone
   Forte, Giovanna
   Disciglio, Vittoria
   Fasano, Candida
   Sanese, Paola
   De Marco, Katia
   Susca, Francesco Claudio
   Mangiapane, Laura Rosa
   Nicotra, Annalisa
   Di Carlo, Gabriella
   Dituri, Francesco
   Giannelli, Gianluigi
   Ingravallo, Giuseppe
   Canettieri, Gianluca
   Stassi, Giorgio
   Simone, Cristiano
TI Pharmacological targeting of the novel beta-catenin chromatin-associated
   kinase p38 alpha in colorectal cancer stem cell tumorspheres and
   organoids
SO CELL DEATH & DISEASE
LA English
DT Article
ID P38 MAPK; IN-VITRO; INHIBITORS; PATHWAY; GROWTH; DEATH; PHOSPHORYLATION;
   MUTATIONS; MECHANISM; AUTOPHAGY
AB The prognosis of locally advanced colorectal cancer (CRC) is currently unsatisfactory. This is mainly due to drug resistance, recurrence, and subsequent metastatic dissemination, which are sustained by the cancer stem cell (CSC) population. The main driver of the CSC gene expression program is Wnt signaling, and previous reports indicate that Wnt3a can activate p38 MAPK. Besides, p38 was shown to feed into the canonical Wnt/beta -catenin pathway. Here we show that patient-derived locally advanced CRC stem cells (CRC-SCs) are characterized by increased expression of p38 alpha and are "addicted" to its kinase activity. Of note, we found that stage III CRC patients with high p38 alpha levels display reduced disease-free and progression-free survival. Extensive molecular analysis in patient-derived CRC-SC tumorspheres and APC(Min/+) mice intestinal organoids revealed that p38 alpha acts as a beta -catenin chromatin-associated kinase required for the regulation of a signaling platform involved in tumor proliferation, metastatic dissemination, and chemoresistance in these CRC model systems. In particular, the p38 alpha kinase inhibitor ralimetinib, which has already entered clinical trials, promoted sensitization of patient-derived CRC-SCs to chemotherapeutic agents commonly used for CRC treatment and showed a synthetic lethality effect when used in combination with the MEK1 inhibitor trametinib. Taken together, these results suggest that p38 alpha may be targeted in CSCs to devise new personalized CRC treatment strategies.
C1 [Signorile, Martina Lepore; Grossi, Valentina; Forte, Giovanna; Disciglio, Vittoria; Fasano, Candida; Sanese, Paola; De Marco, Katia; Simone, Cristiano] IRCCS S Bellis Res Hosp, Natl Inst Gastroenterol, Med Genet, I-70013 Castellana Grotte, BA, Italy.
   [Di Franco, Simone; Mangiapane, Laura Rosa; Nicotra, Annalisa; Stassi, Giorgio] Univ Palermo, Dept Surg & Oncol Sci, Cellular & Mol Pathophysiol Lab, I-90127 Palermo, Italy.
   [Susca, Francesco Claudio; Simone, Cristiano] Univ Bari Aldo Moro, Med Genet, Dept Biomed Sci & Human Oncol DIMO, I-70124 Bari, Italy.
   [Di Carlo, Gabriella; Ingravallo, Giuseppe] Univ Bari Aldo Moro, Operating Unit Pathol Anat, Dept Emergency & Organ Transplantat, I-70124 Bari, Italy.
   [Dituri, Francesco; Giannelli, Gianluigi] IRCCS S de Bellis Res Hosp, Natl Inst Gastroenterol, Personalized Med, I-70013 Castellana Grotte, BA, Italy.
   [Canettieri, Gianluca] Sapienza Univ Rome, Dept Mol Med, I-00161 Rome, Italy.
RP Grossi, V; Simone, C (corresponding author), IRCCS S Bellis Res Hosp, Natl Inst Gastroenterol, Med Genet, I-70013 Castellana Grotte, BA, Italy.
EM grossi.labsimone@gmail.com; cristianosimone73@gmail.com
RI Fasano, Candida/K-3372-2018; Stassi, Giorgio/AAC-1175-2022; Grossi,
   Valentina/K-9821-2016; SIMONE, Cristiano/K-3452-2018
OI Grossi, Valentina/0000-0003-3843-1618; SIMONE,
   Cristiano/0000-0002-2628-7658; CANETTIERI, Gianluca/0000-0001-6694-2613;
   Mangiapane, Laura Rosa/0000-0003-4186-0157
FU Italian Ministry of HealthMinistry of Health, Italy [SG-2019-12371540];
   PRIN-Research Projects of National Relevance (PRIN 2017) from the
   Italian MIUR [2017WNKSLrLS4]; AIRCFondazione AIRC per la ricerca sul
   cancro [IG-23794]
FX This work was supported by the Italian Ministry of Health 'Ricerca
   Corrente 2018-2020; 2019-2021' to C.S. and 'Starting Grant'
   SG-2019-12371540 to P.S., PRIN-Research Projects of National Relevance
   (PRIN 2017, no. 2017WNKSLrLS4) from the Italian MIUR to C.S. and G.S.,
   AIRC IG-23794 2020-2024 to C.S.
CR Alepuz PM, 2003, EMBO J, V22, P2433, DOI 10.1093/emboj/cdg243
   Alten R, 2013, Z RHEUMATOL, V72, P867, DOI 10.1007/s00393-013-1139-4
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Buhler S, 2014, EXPERT OPIN THER PAT, V24, P535, DOI 10.1517/13543776.2014.894977
   Cammareri P, 2008, METHOD CELL BIOL, V86, P311, DOI 10.1016/S0091-679X(08)00014-9
   Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0036784, 10.1371/journal.pone.0050456, 10.1371/journal.pone.0045763, 10.1371/journal.pone.0049275]
   Chiacchiera F, 2009, CELL DEATH DIFFER, V16, P1203, DOI 10.1038/cdd.2009.36
   Chiacchiera F, 2012, CANCER LETT, V324, P98, DOI 10.1016/j.canlet.2012.05.006
   Cicenas J, 2018, CANCERS, V10, DOI 10.3390/cancers10030063
   Cidado J, 2016, ONCOTARGET, V7, P6281, DOI 10.18632/oncotarget.7057
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Feitelson MA, 2015, SEMIN CANCER BIOL, V35, pS25, DOI 10.1016/j.semcancer.2015.02.006
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Germani A, 2014, CANCER LETT, V344, P110, DOI 10.1016/j.canlet.2013.10.035
   Grossi V, 2014, WORLD J GASTROENTERO, V20, P9744, DOI 10.3748/wjg.v20.i29.9744
   Grossi V, 2012, CANCER BIOL THER, V13, P1471, DOI 10.4161/cbt.22254
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267
   Hornik K, 2012, WIRES COMPUT STAT, V4, P394, DOI 10.1002/wics.1212
   Joosten SPJ, 2017, GASTROENTEROLOGY, V153, P1040, DOI 10.1053/j.gastro.2017.07.008
   Kassambara A., 2020, DRAWING SURVIVAL CUR DRAWING SURVIVAL CUR DRAWING SURVIVAL CUR DRAWING SURVIVAL CUR
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Lee MR, 2005, CURR MED CHEM, V12, P2979, DOI 10.2174/092986705774462914
   Li CL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000013239
   Lieu C, 2019, J CLIN ONCOL, V37, P1436, DOI 10.1200/JCO.19.00281
   Lin SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049605
   Madia Federica, 2012, Cells, V1, P535, DOI 10.3390/cells1030535
   Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Nakatani Y, 2003, METHOD ENZYMOL, V370, P430
   Paldino E, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/859871
   Patnaik A, 2016, CLIN CANCER RES, V22, P1095, DOI 10.1158/1078-0432.CCR-15-1718
   Roy Sanchita, 2012, J Mol Signal, V7, P11, DOI 10.1186/1750-2187-7-11
   Roy S, 2018, J ORAL PATHOL MED, V47, P492, DOI 10.1111/jop.12707
   Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852
   Scott LJ, 2013, DRUGS, V73, P857, DOI 10.1007/s40265-013-0065-8
   Sheth Ketan R, 2005, Clin Colon Rectal Surg, V18, P215, DOI 10.1055/s-2005-916282
   Simone C, 2004, NAT GENET, V36, P738, DOI 10.1038/ng1378
   Simone C, 2007, AUTOPHAGY, V3, P468, DOI 10.4161/auto.4319
   Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273
   Stuart SA, 2015, MOL CELL PROTEOMICS, V14, P1599, DOI 10.1074/mcp.M114.047233
   Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597
   Suzui M, 2002, CANCER LETT, V183, P31, DOI 10.1016/S0304-3835(02)00114-3
   Szarynska M, 2017, ONCOL LETT, V14, P7653, DOI 10.3892/ol.2017.7261
   Therneau, 2021, PACKAGE SURVIVAL ANA
   Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Trempolec N, 2013, CELL, V152, P656, DOI [10.1016/j.cell.2013.01.029, 10.1016/j.cell.2013.01.047]
   Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5
   Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607
NR 53
TC 1
Z9 1
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR 25
PY 2021
VL 12
IS 4
AR 316
DI 10.1038/s41419-021-03572-4
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA RG0EE
UT WOS:000635208800001
PM 33767160
OA Green Published, gold
DA 2022-04-25
ER

PT S
AU Wechman, SL
   Pradhan, AK
   DeSalle, R
   Das, SK
   Emdad, L
   Sarkar, D
   Fisher, PB
AF Wechman, Stephen L.
   Pradhan, Anjan K.
   DeSalle, Rob
   Das, Swadesh K.
   Emdad, Luni
   Sarkar, Devanand
   Fisher, Paul B.
BE Tew, KD
   Fisher, PB
TI New Insights Into Beclin-1: Evolution and Pan-Malignancy Inhibitor
   Activity
SO ADVANCES IN CANCER RESEARCH, VOL 137
SE Advances in Cancer Research
LA English
DT Review; Book Chapter
ID DIFFERENTIATION-ASSOCIATED GENE; AUTOPHAGY-RELATED PROTEIN;
   BREAST-CANCER CELLS; MELANOMA-DIFFERENTIATION; TUMOR-SUPPRESSOR;
   REGULATES AUTOPHAGY; COLORECTAL-CANCER; PROGNOSTIC-SIGNIFICANCE;
   SELECTIVE APOPTOSIS; CYTOTOXIC AUTOPHAGY
AB Autophagy is a functionally conserved self-degradation process that facilitates the survival of eukaryotic life via the management of cellular bioenergetics and maintenance of the fidelity of genomic DNA. The first known autophagy inducer was Beclin-1. Beclin-1 is expressed in multicellular eukaryotes ranging throughout plants to animals, comprising a nonmonophyllic group, as shown in this report via aggressive BLAST searches. In humans, Beclin-1 is a haploinsuffient tumor suppressor as biallelic deletions have not been observed in patient tumors clinically. Therefore, Beclin-1 fails the Knudson hypothesis, implicating expression of at least one Beclin-1 allele is essential for cancer cell survival. However, Beclin-1 is frequently monoallelically deleted in advanced human cancers and the expression of two Beclin-1 allelles is associated with greater anticancer effects. Overall, experimental evidence suggests that Beclin-1 inhibits tumor formation, angiogenesis, and metastasis alone and in cooperation with the tumor suppressive molecules UVRAG, Bif-1, Ambra1, and MDA-7/IL-24 via diverse mechanisms of action. Conversely, Beclin-1 is upregulated in cancer stem cells (CSCs), portending a role in cancer recurrence, and highlighting this molecule as an intriguing molecular target for the treatment of CSCs. Many aspects of Beclin-1's biological effects remain to be studied. The consequences of these BLAST searches on the molecular evolution of Beclin-1, and the eukaryotic branches of the tree of life, are discussed here in greater detail with future inquiry focused upon protist taxa. Also in this review, the effects of Beclin-1 on tumor suppression and cancer malignancy are discussed. Beclin-1 holds significant promise for the development of novel targeted cancer therapeutics and is anticipated to lead to a many advances in our understanding of eukaryotic evolution, multicellularity, and even the treatment of CSCs in the coming decades.
C1 [Wechman, Stephen L.; Pradhan, Anjan K.; Das, Swadesh K.; Emdad, Luni; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, Richmond, VA 23284 USA.
   [Das, Swadesh K.; Emdad, Luni; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, VCU Inst Mol Med, Sch Med, Richmond, VA 23284 USA.
   [Das, Swadesh K.; Emdad, Luni; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA.
   [DeSalle, Rob] Amer Museum Nat Hist, Sackler Inst Comparat Genom, New York, NY 10024 USA.
RP Fisher, PB (corresponding author), Virginia Commonwealth Univ, VCU Inst Mol Med, Sch Med, Richmond, VA 23284 USA.; Fisher, PB (corresponding author), Virginia Commonwealth Univ, VCU Massey Canc Ctr, Sch Med, Richmond, VA 23284 USA.
EM paul.fisher@vcuhealth.org
RI Pradhan, Anjan K/O-2555-2014
FU NCI NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA168517, R01 CA097318, P30 CA016059] Funding Source: Medline; NIGMS NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [K12 GM093857] Funding Source: Medline;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA168517] Funding Source: NIH RePORTER
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Bernhard EJ, 2000, CANCER RES, V60, P6597
   Bhoopathi P, 2016, CANCER RES, V76, P3572, DOI 10.1158/0008-5472.CAN-15-2959
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bhutia SK, 2010, CANCER RES, V70, P3667, DOI 10.1158/0008-5472.CAN-09-3647
   Bonner JA, 2000, J CLIN ONCOL, V18, p47S
   Bristol ML, 2012, AUTOPHAGY, V8, P739, DOI 10.4161/auto.19313
   Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802
   Cai-McRae X, 2015, ONCOGENE, V34, P2968, DOI 10.1038/onc.2014.244
   Cao JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077922
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Chada S, 2006, CANCER GENE THER, V13, P490, DOI 10.1038/sj.cgt.7700915
   Chakradeo S, 2015, MOL PHARMACOL, V87, P803, DOI 10.1124/mol.114.095273
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   CLIBY W, 1993, CANCER RES, V53, P2393
   Copetti T, 2009, AUTOPHAGY, V5, P858, DOI 10.4161/auto.8822
   Coppola D, 2011, PANCREAS, V40, P433, DOI 10.1097/MPA.0b013e318205eb03
   Cuddeback SM, 2001, J BIOL CHEM, V276, P20559, DOI 10.1074/jbc.M101527200
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Cui L, 2016, ONCOL REP, V35, P3639, DOI 10.3892/or.2016.4752
   Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019
   Das SK, 2010, P NATL ACAD SCI USA, V107, P11948, DOI 10.1073/pnas.0914143107
   Dash R, 2010, CYTOKINE GROWTH F R, V21, P381, DOI 10.1016/j.cytogfr.2010.08.004
   De Amicis F, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0403-4
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   ECCLES DM, 1992, ONCOGENE, V7, P2069
   Emdad L, 2007, MOL CANCER THER, V6, P2985, DOI 10.1158/1535-7163.MCT-07-0399
   Emdad L, 2009, CANCER BIOL THER, V8, P402, DOI 10.4161/cbt.8.5.7581
   Emdad L, 2007, J CELL PHYSIOL, V210, P549, DOI 10.1002/jcp.20906
   Fimia GM, 2013, ONCOGENE, V32, P3311, DOI 10.1038/onc.2012.455
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Finka A, 2013, CELL STRESS CHAPERON, V18, P591, DOI 10.1007/s12192-013-0413-3
   Fisher PB, 2007, TOXICOL APPL PHARM, V224, P300, DOI 10.1016/j.taap.2006.11.021
   Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008-5472.CAN-05-3127
   Fisher PB, 2003, CANCER BIOL THER, V2, pS23
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Fujiwara N, 2016, J BIOL CHEM, V291, P10858, DOI 10.1074/jbc.M115.704908
   Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542
   FUTREAL PA, 1992, CANCER RES, V52, P2624
   Gallop JL, 2006, EMBO J, V25, P2898, DOI 10.1038/sj.emboj.7601174
   Gao P, 2008, CANCER RES, V68, P3890, DOI 10.1158/0008-5472.CAN-08-0156
   GAO X, 1995, CANCER RES, V55, P1002
   Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014
   Gawriluk TR, 2014, P NATL ACAD SCI USA, V111, pE4194, DOI 10.1073/pnas.1409323111
   Gewirtz DA, 2014, RADIAT RES, V182, P363, DOI 10.1667/RR13774.1
   Giles NM, 2003, FEBS LETT, V535, P179, DOI 10.1016/S0014-5793(02)03890-5
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090151
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Gupta P, 2006, CANCER RES, V66, P8182, DOI 10.1158/0008-5472.CAN-06-0577
   Han J, 2013, J BIOL CHEM, V288, P20315, DOI 10.1074/jbc.M113.461350
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043
   He WS, 2012, ONCOL RES, V20, P251, DOI 10.3727/096504013X13589503483012
   Ho J, 2009, J PROTEOME RES, V8, P583, DOI 10.1021/pr8007368
   Huang JJ, 2010, AUTOPHAGY, V6, P777, DOI 10.4161/auto.6.6.12784
   Huang XH, 2014, SCI WORLD J, DOI 10.1155/2014/954849
   Huettenbrenner S, 2003, MUTAT RES-REV MUTAT, V543, P235, DOI 10.1016/S1383-5742(02)00110-2
   Jiang Hongping, 1993, Molecular and Cellular Differentiation, V1, P285
   Jiang HP, 1995, ONCOGENE, V11, P2477
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim MS, 2008, APMIS, V116, P939, DOI 10.1111/j.1600-0463.2008.01091.x
   Kim Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0114370
   Klein SR, 2015, ONCOGENE, V34, P5295, DOI 10.1038/onc.2014.452
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Ko YH, 2013, PANCREAS, V42, P829, DOI 10.1097/MPA.0b013e318279d0dc
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   le Sage C, 2007, EMBO J, V26, P3699, DOI 10.1038/sj.emboj.7601790
   Lebedeva IV, 2005, MOL THER, V11, P4, DOI 10.1016/j.ymthe.2004.08.012
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee SJ, 2011, AUTOPHAGY, V7, P829, DOI 10.4161/auto.7.8.15598
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li XS, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-26
   Li XQ, 2010, AUTOPHAGY, V6, P1066, DOI 10.4161/auto.6.8.13366
   Li YM, 2012, AM J MED SCI, V343, P155, DOI 10.1097/MAJ.0b013e31821f978d
   Li ZD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-98
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liang XH, 2001, CANCER RES, V61, P3443
   Lin HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060516
   Liu J, 2016, ADV CANCER RES, V130, P1, DOI 10.1016/bs.acr.2016.01.005
   Ma K, 2016, ONCOL REP, V36, P1807, DOI 10.3892/or.2016.5003
   Maddison DR, 2019, MESQUITE MODULAR SYS
   Martin M, 2016, CLIN TRANSL ONCOL, V18, P825, DOI 10.1007/s12094-015-1445-1
   Masuda M, 2006, EMBO J, V25, P2889, DOI 10.1038/sj.emboj.7601176
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Miracco C, 2007, INT J ONCOL, V30, P429
   Miracco C, 2010, HUM PATHOL, V41, P503, DOI 10.1016/j.humpath.2009.09.004
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mohan CD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153155
   Moreau K, 2010, CURR OPIN CELL BIOL, V22, P206, DOI 10.1016/j.ceb.2009.12.002
   Morran DC, 2014, GUT, V63, P1481, DOI 10.1136/gutjnl-2013-306202
   Mowers EE, 2017, ONCOGENE, V36, P1619, DOI 10.1038/onc.2016.333
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Nishikawa T, 2004, MOL THER, V9, P818, DOI 10.1016/j.ymthe.2004.03.014
   Noble CG, 2008, J BIOL CHEM, V283, P26274, DOI 10.1074/jbc.M804723200
   Park JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100819
   Peter BJ, 2004, SCIENCE, V303, P495, DOI 10.1126/science.1092586
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378
   Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227
   Pradhan AK, 2017, CANCER RES, V77, P949, DOI 10.1158/0008-5472.CAN-16-1731
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Radwan SM, 2016, CANCER BIOMARK, V16, P619, DOI 10.3233/CBM-160603
   Ramesh R, 2003, CANCER RES, V63, P5105
   Ren J, 2015, J MOL CELL CARDIOL, V84, P223, DOI 10.1016/j.yjmcc.2015.03.001
   Riley BE, 2010, J CELL BIOL, V191, P537, DOI 10.1083/jcb.201005012
   Rosenfeld JA, 2012, MOL PHYLOGENET EVOL, V63, P342, DOI 10.1016/j.ympev.2012.01.003
   Runkle KB, 2012, CANCER BIOL THER, V13, P956, DOI 10.4161/cbt.20951
   RUSSELL SEH, 1990, ONCOGENE, V5, P1581
   SAITO H, 1993, CANCER RES, V53, P3382
   Sarkar D, 2002, P NATL ACAD SCI USA, V99, P10054, DOI 10.1073/pnas.152327199
   Sauane M, 2008, P NATL ACAD SCI USA, V105, P9763, DOI 10.1073/pnas.0804089105
   Shin JY, 2012, J RADIAT RES, V53, P506, DOI 10.1093/jrr/rrs005
   Singh S. P., 2010, Progressive Agriculture, V10, P8
   Su ZZ, 2003, ONCOGENE, V22, P1164, DOI 10.1038/sj.onc.1206062
   Su ZZ, 2005, ONCOGENE, V24, P7552, DOI 10.1038/sj.onc.1208911
   Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400
   Sun W, 2016, MATH PROBL ENG, V2016, DOI 10.1155/2016/9748378
   Sun Y, 2010, J INSECT SCI, V10, P1, DOI DOI 10.1016/J.CANLET.2010.02.001
   Sun Y, 2011, ASIAN PAC J CANCER P, V12, P1269
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Tan Q, 2016, NEOPLASIA, V18, P347, DOI 10.1016/j.neo.2016.04.003
   Tan XJ, 2015, CELL, V160, P145, DOI 10.1016/j.cell.2014.12.006
   Tong AW, 2005, MOL THER, V11, P160, DOI 10.1016/j.ymthe.2004.09.021
   Valente G, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/462658
   Wang BL, 2010, BIOMED MATER, V5, DOI 10.1088/1748-6041/5/4/044102
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001
   Wei YJ, 2013, CELL, V154, P1269, DOI 10.1016/j.cell.2013.08.015
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wilson Eden N., 2011, Hormones & Cancer, V2, P272, DOI 10.1007/s12672-011-0081-7
   Wirawan E, 2012, AUTOPHAGY, V8, P6, DOI 10.4161/auto.8.1.16645
   Xu F, 2017, SCI REP-UK, V7, DOI 10.1038/srep45385
   Yacoub A, 2003, CLIN CANCER RES, V9, P3272
   Yamaguchi H, 2008, J BIOL CHEM, V283, P19112, DOI 10.1074/jbc.M709882200
   Yang W, 2013, EXP CELL RES, V319, P122, DOI 10.1016/j.yexcr.2012.11.014
   Yin XC, 2011, AUTOPHAGY, V7, P1242, DOI 10.4161/auto.7.10.16507
   Ying HC, 2015, ONCOL LETT, V9, P1759, DOI 10.3892/ol.2015.2950
   Zhang CZ, 2010, INT J ONCOL, V37, P1621, DOI 10.3892/ijo_00000816
   Zhang DY, 2016, AUTOPHAGY, V12, P1447, DOI 10.1080/15548627.2016.1185576
   Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3
   Zhao Z, 2012, DEV CELL, V22, P1001, DOI 10.1016/j.devcel.2011.12.027
   Zhou YY, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20140141
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
NR 154
TC 11
Z9 12
U1 3
U2 8
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-230X
BN 978-0-12-815123-5
J9 ADV CANCER RES
JI Adv.Cancer Res.
PY 2018
VL 137
BP 77
EP 114
DI 10.1016/bs.acr.2017.11.002
PG 38
WC Oncology
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA BK3UY
UT WOS:000435593400004
PM 29405978
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Ko, H
   Kim, YJ
   Amor, EC
   Lee, JW
   Kim, HC
   Kim, HJ
   Yang, HO
AF Ko, Hyeonseok
   Kim, Young-Joo
   Amor, Evangeline C.
   Lee, Jong Wha
   Kim, Han-Cheon
   Kim, Hee Ju
   Yang, Hyun Ok
TI Induction of Autophagy by Dimethyl Cardamonin Is Associated With
   Proliferative Arrest in Human Colorectal Carcinoma HCT116 and LOVO Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE DIMETHYL CARDAMONIN; AUTOPHAGY; G(2)/M CELL CYCLE ARREST; HCT116; LOVO
ID MALIGNANT GLIOMA-CELLS; SYZYGIUM-SAMARANGENSE; UP-REGULATION; APOPTOSIS;
   DEATH; CYTOTOXICITY; INHIBITION; FLAVONOIDS; ROLES
AB Dimethyl cardamonin (2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone; DMC) is a naturally occurring chalcone, and it is the major compound isolated from the leaves of Syzygium samarangense (Blume) Merr. & L. M. Perry (Myrtaceae). Experiments were conducted to determine the effects of DMC on cell proliferation, cell-cycle distribution, and programmed cell death in cultures of human colorectal carcinoma HCT116 and LOVO cells. Results showed that DMC inhibited HCT116 and LOVO cell proliferation and induced G(2)/M cell cycle arrest, which was associated with the conversion of microtubule associated protein light chain 3 (LC3)-I-LC3-II, an autophagosome marker, and the incorporation of monodansylcadaverine (MDC), a marker for the acidic compartment of autolysosomes or acidic vesicular organelles. The treatment of HCT116 and LOVO cells using a combination of DMC with an autophagy inhibitor, such as 3-methyladenine (3-MA), beclin 1 siRNA, or atg5 siRNA, suppressed the effect of DMC-mediated anti-proliferation. These results imply that DMC can suppress colorectal carcinoma HCT116 and LOVO cell proliferation through a G(2)/M phase cell-cycle delay, and can induce autophagy, the hallmark of Type II programmed cell death (PCD). Taken together, our results suggest that DMC may be an effective chemotherapeutic agent for HCT116 and LOVO colorectal carcinoma cells. J. Cell. Biochem. 112:2471-2479, 2011. (C) 2011 Wiley-Liss, Inc.
C1 [Ko, Hyeonseok; Kim, Young-Joo; Kim, Han-Cheon; Kim, Hee Ju; Yang, Hyun Ok] Korea Inst Sci & Technol, Nat Prod Res Ctr, Kangnung 210340, Gangwon Do, South Korea.
   [Amor, Evangeline C.; Lee, Jong Wha] Univ Philippines, Inst Chem, Coll Sci, Quezon City 1101, Philippines.
RP Yang, HO (corresponding author), Korea Inst Sci & Technol, Nat Prod Res Ctr, 290 Daejeon Dong, Kangnung 210340, Gangwon Do, South Korea.
EM hoyang@kist.re.kr
FU Korea Institute of Science and Technology, KoreaKorea Institute of
   Science & Technology (KIST) [2Z03401]
FX Grant sponsor: Korea Institute of Science and Technology, Korea; Grant
   number: 2Z03401.
CR Backer JM, 2008, BIOCHEM J, V410, P1, DOI 10.1042/BJ20071427
   Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595
   Chattopadhyay D, 1998, FITOTERAPIA, V69, P365
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Elliott A, 2008, TOXICOL APPL PHARM, V232, P169, DOI 10.1016/j.taap.2008.06.017
   Gafner S, 1996, PLANTA MED, V62, P67, DOI 10.1055/s-2006-957804
   Ghayur MN, 2006, PHYTOTHER RES, V20, P49, DOI 10.1002/ptr.1801
   Hansen K, 2007, J NEUROCHEM, V103, P259, DOI 10.1111/j.1471-4159.2007.04753.x
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2005, ONCOGENE, V24, P980, DOI 10.1038/sj.onc.1208095
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim YJ, 2008, BIOL PHARM BULL, V31, P826, DOI 10.1248/bpb.31.826
   Ko H, 2007, CELLS TISSUES ORGANS, V185, P66, DOI 10.1159/000101305
   Komata T, 2004, J NEURO-ONCOL, V68, P101, DOI 10.1023/B:NEON.0000027739.33842.6c
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kuo YC, 2004, PLANTA MED, V70, P1237, DOI 10.1055/s-2004-835859
   Lee HM, 2010, BIOMOL THER, V18, P262, DOI 10.4062/biomolther.2010.18.3.262
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li DD, 2009, CANCER BIOL THER, V8, P739, DOI 10.4161/cbt.8.8.7917
   Li N, 2008, J AGR FOOD CHEM, V56, P3876, DOI 10.1021/jf073520n
   Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Resurreccion-Magno MHC, 2005, PHYTOTHER RES, V19, P246, DOI 10.1002/ptr.1658
   Scarlatti F, 2004, J BIOL CHEM, V279, P18384, DOI 10.1074/jbc.M313561200
   Shin S, 2005, EMBO J, V24, P3532, DOI 10.1038/sj.emboj.7600827
   SRIVASTAVA R, 1995, PHYTOCHEMISTRY, V38, P687, DOI 10.1016/0031-9422(94)00739-G
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Wang M, 2008, J BIOL CHEM, V283, P18678, DOI 10.1074/jbc.M801855200
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
NR 34
TC 43
Z9 45
U1 1
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2011
VL 112
IS 9
BP 2471
EP 2479
DI 10.1002/jcb.23171
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 818QN
UT WOS:000294769500030
PM 21538483
DA 2022-04-25
ER

PT J
AU Zheng, YS
   Tan, KL
   Huang, HP
AF Zheng, Yansheng
   Tan, Kanglian
   Huang, Haipeng
TI RETRACTED: Long noncoding RNA HAGLROS regulates apoptosis and autophagy
   in colorectal cancer cells via sponging miR-100 to target ATG5
   expression (Retracted article. See vol. 122, 2021)
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article; Retracted Publication
DE apoptosis; autophagy; colorectal cancer; HOXD antisense
   growth-associated long noncoding RNA; long noncoding RNA; microRNA-100
ID CETUXIMAB RESISTANCE; POOR-PROGNOSIS; METASTASIS; ONCOGENE; PATHWAY;
   GENES
AB The aim of this study was to explore the relationship between the expression of HOXD antisense growth-associated long noncoding RNA (HAGLROS) and prognosis of patients with colorectal cancer (CRC), as well as the roles and regulatory mechanism of HAGLROS in CRC development. The HAGLROS expression in CRC tissues and cells was detected. The correlation between HAGLROS expression and survival time of CRC patients was investigated. Moreover, HAGLROS was overexpressed and suppressed in HCT-116 cells, followed by detection of cell viability, apoptosis, and the expression of apoptosis-related proteins and autophagy markers. Furthermore, the association between HAGLROS and miR-100 and the potential targets of miR-100 were investigated. Besides, the regulatory relationship between HAGLROS and PI3K/AKT/mTOR pathway was elucidated. The results showed that HAGLROS was highly expressed in CRC tissues and cells. Highly expression of HAGLROS correlated with a shorter survival time of CRC patients. Moreover, knockdown of HAGLROS in HCT-116 cells induced apoptosis by increasing the expression of Bax/Bcl-2 ratio, cleaved-caspase-3, and cleaved-caspase-9, and inhibited autophagy by decreasing the expression of LC3II/LC3I and Beclin-1 and increasing P62 expression. Furthermore, HAGLROS negatively regulated the expression of miR-100, and HAGLROS controlled HCT-116 cell apoptosis and autophagy through negatively regulation of miR-100. Autophagy related 5 (ATG5) was verified as a functional target of miR-100 and miR-100 regulated HCT-116 cell apoptosis and autophagy through targeting ATG5. Besides, HAGLROS overexpression activated phosphatidylinositol-3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. In conclusion, a highly expression of HAGLROS correlated with shorter survival time of CRC patients. Downregulation of HAGLROS may induce apoptosis and inhibit autophagy in CRC cells by regulation of miR-100/ATG5 axis and PI3K/AKT/mTOR pathway.
C1 [Zheng, Yansheng; Tan, Kanglian; Huang, Haipeng] Tradit Chinese Med Hosp Guangdong Prov, Dept Gastrointestinal Surg, 111 Dade Rd, Guangzhou 510000, Guangdong, Peoples R China.
RP Zheng, YS (corresponding author), Tradit Chinese Med Hosp Guangdong Prov, Dept Gastrointestinal Surg, 111 Dade Rd, Guangzhou 510000, Guangdong, Peoples R China.
EM yanshengzhang26@163.com
OI Zheng, Yansheng/0000-0002-2785-7923
CR Aherne ST, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1327-5
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bahrami A, 2018, J CELL BIOCHEM, V119, P2460, DOI 10.1002/jcb.25950
   Chen JF, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0756-y
   Chen P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0775-5
   Cho DH, 2012, ANTICANCER RES, V32, P4091
   Christensen LL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096767
   de Groen FLM, 2014, GENE CHROMOSOME CANC, V53, P339, DOI 10.1002/gcc.22144
   Dey BK, 2014, TRANSCR-AUSTIN, V5, DOI 10.4161/21541272.2014.944014
   Dikaiakos P, 2015, CANCER BIOMARK, V15, P157, DOI 10.3233/CBM-140449
   Fan XJ, 2016, ONCOL REP, V36, P3559, DOI 10.3892/or.2016.5138
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Fujino Y, 2017, CANCER SCI, V108, P390, DOI 10.1111/cas.13152
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Iguchi T, 2015, ANTICANCER RES, V35, P1385
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Jiao CJ, 2016, ONCOL REP, V36, P2960, DOI 10.3892/or.2016.5121
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kang MR, 2009, J PATHOL, V217, P702, DOI 10.1002/path.2509
   Kim TW, 2018, CANCER LETT, V417, P89, DOI 10.1016/j.canlet.2017.12.033
   Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078-0432.CCR-14-1374
   Li W, 2016, EUR REV MED PHARMACO, V20, P4874
   Lu M, 2017, J CANCER RES CLIN, V143, P71, DOI 10.1007/s00432-016-2252-y
   Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266
   Peng H, 2014, ONCOL REP, V31, P2055, DOI 10.3892/or.2014.3075
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Qi P, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0524-4
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sirnes S, 2012, INT J CANCER, V131, P570, DOI 10.1002/ijc.26392
   Slattery ML, 2017, GENE CHROMOSOME CANC, V56, P769, DOI 10.1002/gcc.22481
   Slattery ML, 2017, MODERN PATHOL, V30, P1152, DOI 10.1038/modpathol.2017.38
   Smolle M, 2014, INT J MOL SCI, V15, P13993, DOI 10.3390/ijms150813993
   Thomas H, 2017, NAT REV GASTRO HEPAT, V14, P691, DOI 10.1038/nrgastro.2017.156
   Wang HY, 2014, INT J MED SCI, V11, P841, DOI 10.7150/ijms.8128
   Won SJ, 2015, J CELL PHYSIOL, V230, P930, DOI 10.1002/jcp.24825
   Xue Y, 2015, MUTAGENESIS, V30, P303, DOI 10.1093/mutage/geu076
   Yang L, 2016, ONCOL LETT, V12, P3771, DOI 10.3892/ol.2016.5213
   Yang XD, 2015, AM J CANCER RES, V5, P545
   Zhang XF, 2018, ONCOTARGET, V9, P3519, DOI 10.18632/oncotarget.23336
NR 40
TC 43
Z9 44
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAR
PY 2019
VL 120
IS 3
BP 3922
EP 3933
DI 10.1002/jcb.27676
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HL1LP
UT WOS:000458459600125
PM 30430634
OA hybrid
DA 2022-04-25
ER

PT J
AU Yu, Y
   Yu, XF
   Ma, JX
   Tong, YL
   Yao, JF
AF Yu, Yang
   Yu, Xiaofeng
   Ma, Jianxia
   Tong, Yili
   Yao, Jianfeng
TI Effects of NVP-BEZ235 on the proliferation, migration, apoptosis and
   autophagy in HT-29 human colorectal adenocarcinoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE NVP-BEZ235; cis-diamminedichloroplatinum; HT-29; colorectal
   adenocarcinoma; PI3K/mTOR
ID PI3K/MTOR INHIBITOR NVP-BEZ235; SIGNALING PATHWAY; CANCER CELLS;
   STEM-CELLS; IN-VITRO; 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR;
   MTOR INHIBITION; COMBINATION; CISPLATIN
AB The phosphoinositide 3 kinase (PI3K)/Akt/ mammalian target of the rapamycin (mTOR) pathway plays a significant role in colorectal adenocarcinoma. NVP-BEZ235 (dactolisib) is a novel dual inhibitor of PI3K/mTOR. The effects of NVP-BEZ235 in human colorectal adenocarcinoma are still unclear. In the present study, we aimed to explore the proliferation, migration, apoptosis and autophagy in HT-29 human colorectal adenocarcinoma cells. HT-29 human colorectal adenocarcinoma cells were treated with NVP-BEZ235 (0, 0.001, 0.01, 0.1,1 and 3 mu M) for 24 and 48 h, respectively. Cells were also treated with NVP-BEZ235 (0.1 mu M), DDP (100, 300 and 1,000 mu M), and NVP-BEZ235 (0.1 mu M) combined with DDP (100, 300 and 1,000 mu M) respectively, and cultured for 24 h after treatment. MTT assay was utilized to evaluate the effects of NVP-BEZ235 alone or NVP-BEZ235 combined with cis-diammin.edichloroplatinum (DDP) on proliferation of HT-29 cells. Cell wound-scratch assay was used detect cell migration. In addition, expression of microtubule-associated proteins 1A/1B light chain 3B (MAP1LC3B and LC3B) in HT-29 cells was detected by immunofluorescence at 48 h after NVP-BEZ235 (1 mu M) treatment. Expression of proteins involved in cell cycle and proliferation (p-Akt, p-mTOR and cyclin Dl), apoptosis (cleaved caspase-3), and autophagy (cleaved LC3B and Beclin-1) were detected by western blot analysis. NVP-BEZ235 inhibited the proliferation and migration of HT-29 human colorectal adenocarcinoma cells. NVP-BEZ235 decreased protein expression of p-Akt, p-mTOR and cyclin Dl, and increased protein expression of cleaved caspase-3, cleaved LC3B and Beclin-1 as the concentrations and the incubation time of NVP-BEZ235 increased. In addition, NVP-BEZ235 and DDP had synergic effects in inhibiting cell proliferation and migration. The expression of protein involved in apoptosis (cleaved caspase-3) was higher in drug combination group compared to the NVP-BEZ235 single treatment group. NVP-BEZ235 inhibited the proliferation and migration, and induced apoptosis and autophagy of HT -29 human colorectal adenocarcinoma cells.
C1 [Yu, Yang; Yu, Xiaofeng; Ma, Jianxia; Tong, Yili; Yao, Jianfeng] Fudan Univ, Hua Dong Hosp, Dept Gastroenterol, 221 West Yanan Rd, Shanghai 200040, Peoples R China.
RP Yao, JF (corresponding author), Fudan Univ, Hua Dong Hosp, Dept Gastroenterol, 221 West Yanan Rd, Shanghai 200040, Peoples R China.
EM yaojianfeng037@hotmail.com
CR Apps MG, 2015, ENDOCR-RELAT CANCER, V22, pR219, DOI 10.1530/ERC-15-0237
   Cakir E, 2011, APMIS, V119, P574, DOI 10.1111/j.1600-0463.2011.02778.x
   Chen JZ, 2015, CLIN EXP PHARMACOL P, V42, P1317, DOI 10.1111/1440-1681.12493
   Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107
   Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108
   Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l
   Dubrovska A, 2010, CLIN CANCER RES, V16, P5692, DOI 10.1158/1078-0432.CCR-10-1601
   Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106
   Hernlund E, 2012, EUR J CANCER, V48, P396, DOI 10.1016/j.ejca.2011.11.013
   Horie R, 2016, INT J ONCOL, V48, P37, DOI 10.3892/ijo.2015.3227
   Ji YH, 2015, CLIN LAB, V61, P1043, DOI 10.7754/Clin.Lab.2015.150144
   Jin ZJ, 2004, ACTA PHARMACOL SIN, V25, P146
   Kanai R, 2011, CLIN CANCER RES, V17, P3686, DOI 10.1158/1078-0432.CCR-10-3142
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Li Chun-hong, 2008, Zhonghua Zhong Liu Za Zhi, V30, P418
   Li CT, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0213-1
   Lin SJ, 2015, ONCOTARGET, V6, P39329, DOI 10.18632/oncotarget.5744
   Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160
   Meyer G, 2013, CURR PHARM DESIGN, V19, P6912, DOI 10.2174/138161281939131127122510
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Ojeda L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023414
   Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Pruefer FG, 2008, J CHEMOTHERAPY, V20, P348, DOI 10.1179/joc.2008.20.3.348
   Rafalski VA, 2011, PROG NEUROBIOL, V93, P182, DOI 10.1016/j.pneurobio.2010.10.007
   Sacco A, 2010, ONCOTARGET, V1, P578
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shen Y, 2011, EXP THER MED, V2, P1171, DOI 10.3892/etm.2011.330
   Shimura T, 2016, ONCOTARGET, V7, P3559, DOI 10.18632/oncotarget.6518
   Sui HY, 2015, DRUG DES DEV THER, V9, P3183, DOI 10.2147/DDDT.S82035
   Sui L, 2008, LEARN MEMORY, V15, P762, DOI 10.1101/lm.1067808
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Wang GH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055298
   Wang WJ, 2013, ACTA PHARMACOL SIN, V34, P681, DOI 10.1038/aps.2013.22
   Wani ZA, 2016, FOOD CHEM TOXICOL, V87, P1, DOI 10.1016/j.fct.2015.11.016
   Weng YJ, 2011, J HUAZHONG U SCI-MED, V31, P550, DOI 10.1007/s11596-011-0488-y
   Wyatt LA, 2014, J COMP NEUROL, V522, P2741, DOI 10.1002/cne.23580
   Zou MJ, 2015, MOL CARCINOGEN, V54, P1363, DOI 10.1002/mc.22212
NR 38
TC 17
Z9 21
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2016
VL 49
IS 1
BP 285
EP 293
DI 10.3892/ijo.2016.3507
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DO2WD
UT WOS:000377640800026
PM 27176231
OA Bronze
DA 2022-04-25
ER

PT J
AU Lin, Y
   Stevens, C
   Hrstka, R
   Harrison, B
   Fourtouna, A
   Pathuri, S
   Vojtesek, B
   Hupp, T
AF Lin, Yao
   Stevens, Craig
   Hrstka, Roman
   Harrison, Ben
   Fourtouna, Argyro
   Pathuri, Suresh
   Vojtesek, Borek
   Hupp, Ted
TI An alternative transcript from the death-associated protein kinase 1
   locus encoding a small protein selectively mediates membrane blebbing
SO FEBS JOURNAL
LA English
DT Article
ID TUMOR-SUPPRESSOR DAPK; KINASE; STRESS; FIBERS; DOMAIN
AB Death-associated protein kinase 1 (DAPK-1) is a multidomain protein kinase with diverse roles in autophagic, apoptotic and survival pathways. Bioinformatic screens were used to identify a small internal mRNA from the DAPK-1 locus (named s-DAPK-1). This encodes a 295 amino acid polypeptide encompassing part of the ankyrin-repeat domain, the P-loop motifs, part of the cytoskeletal binding domain of DAPK-1, and a unique C-terminal 'tail' extension not present in DAPK-1. Expression of s-DAPK-1 mRNA was detected in a panel of normal human tissues as well as primary colorectal cancers, indicating that its expression occurs in vivo. s-DAPK-1 gene transfection into cells produces two protein products: one with a denatured mass of 44 kDa, and a smaller product of 40 kDa. Double alanine mutation of the C-terminal tail extension of s-DAPK-1 (Gly296/Arg297) prevented production of the 40 kDa fragment, suggesting that the smaller product is generated by in vivo proteolytic processing. The s-DAPK-1 gene cannot substitute for full-length DAPK-1 in an mitogen-activated protein kinase kinase/extracellular signal-regulated kinase-dependent apoptotic transfection assay. However, the transfection of s-DAPK-1 was able to mimic full-length DAPK-1 in the induction of membrane blebbing. The 44 kDa protease-resistant mutant s-DAPK-1G296A/R297A had very low activity in membrane blebbing, whereas the 40 kDa s-DAPK-1 Delta tail protein exhibited the highest levels of membrane blebbing. Deletion of the tail extension of s-DAPK-1 increased its half-life, shifted the equilibrium of the protein from cytoskeletal to soluble cytosolic pools, and altered green fluorescent protein-tagged s-DAPK-1 protein localization as observed by confocal microscopy. These data highlight the existence of an alternative product of the DAPK-1 locus, and suggest that proteolytic removal of the C-terminal tail of s-DAPK-1 is required to stimulate maximally its membrane-blebbing function.
C1 [Lin, Yao; Stevens, Craig; Harrison, Ben; Fourtouna, Argyro; Pathuri, Suresh; Hupp, Ted] Univ Edinburgh, Inst Genet & Mol Med, Cell Signaling Unit, CRUK p53 Signal Transduct Grp, Edinburgh EH4 2XR, Midlothian, Scotland.
   [Hrstka, Roman; Vojtesek, Borek] Masaryk Mem Canc Inst, Brno, Czech Republic.
RP Hupp, T (corresponding author), Univ Edinburgh, Inst Genet & Mol Med, Cell Signaling Unit, CRUK p53 Signal Transduct Grp, Edinburgh EH4 2XR, Midlothian, Scotland.
EM ted.hupp@ed.ac.uk
RI Hrstka, Roman/AAM-4430-2020
OI Hrstka, Roman/0000-0002-6139-2664; Harrison,
   Benjamin/0000-0002-6078-5060; , yao/0000-0002-0493-0155
FU Cancer Research UKCancer Research UK Funding Source: Medline
CR Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386
   Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615
   Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085
   Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   HARRISON B, 2008, IN PRESS J BIOL CHEM
   Houle F, 2007, J CELL SCI, V120, P3666, DOI 10.1242/jcs.003251
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   Jin YJ, 2002, J BIOL CHEM, V277, P46980, DOI 10.1074/jbc.M208585200
   Kuo JC, 2006, J CELL BIOL, V172, P619, DOI 10.1083/jcb.200505138
   Kuo JC, 2003, J CELL SCI, V116, P4777, DOI 10.1242/jcs.00794
   Li JN, 2006, BIOCHEMISTRY-US, V45, P15168, DOI 10.1021/bi062188q
   Lin Y, 2007, J BIOL CHEM, V282, P16792, DOI 10.1074/jbc.M611559200
   Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500
   Stevens C, 2007, J BIOL CHEM, V282, P13791, DOI 10.1074/jbc.M605649200
   Torgerson RR, 1998, J CELL SCI, V111, P2911
   Wang WJ, 2007, MOL CELL, V27, P701, DOI 10.1016/j.molcel.2007.06.037
NR 19
TC 4
Z9 6
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD MAY
PY 2008
VL 275
IS 10
BP 2574
EP 2584
DI 10.1111/j.1742-4658.2008.06404.x
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 292SF
UT WOS:000255285700020
PM 18422656
OA Bronze
DA 2022-04-25
ER

PT J
AU Kim, ER
   Kim, KM
   Lee, JY
   Joo, M
   Kim, S
   Noh, JH
   Ward, SM
   Koh, SD
   Rhee, PL
AF Kim, Eun Ran
   Kim, Kyoung Mee
   Lee, Ji Yeon
   Joo, Mee
   Kim, Sung
   Noh, Jae Hyung
   Ward, Sean M.
   Koh, Sang Don
   Rhee, Poong-Lyul
TI The clue of Interstitial Cell of Cajalopathy (ICCpathy) in human
   diabetic gastropathy The ultrastructural and electrical clues of
   ICCpathy in human diabetic gastropathy
SO EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE Diabetic gastropathy; Ultrastructure; Electrophysiology; Slow waves;
   Interstitial Cells of Cajal (ICC)
ID NITRIC-OXIDE SYNTHASE; MYENTERIC PLEXUS; CAJAL; EXPRESSION;
   PATHOPHYSIOLOGY; DEFICIENCY; PACEMAKERS; MUSCLE; COLON; GUT
AB Recent studies of diabetic animal models suggest an important role of ICC in the pathogenesis of gastropathy. The aim of this study was to characterize the ultrastructural features of ICC and record the electrical properties in the stomach of patients with type 2 DM. Gastric specimens were obtained from 13 diabetic patients and 6 control subjects with gastric cancer that underwent gastrectomy. All specimens were taken from disease-free areas. The samples were processed for both electron microscopic and electrophysiologic examination. The characteristic ultrastructural changes of the ICC were observed in both the nucleus and cytoplasm in patients with type 2 DM. Wrinkling of the nuclear envelope and changes in the cytoplasm such as dilatation of the endoplasmic reticulum, an increase of autophagic vacuoles, were more frequently observed in the diabetic patients. Apoptosis characterized by nuclear karyorrhexis or pyknosis was observed only in the diabetic patients. Slow waves were recorded in the circular muscle of stomach. In diabetic patients, the mean resting membrane. potential was higher and amplitude was lower than controls. These changes of electrical activities of slow waves were accompanied with ultrastructural changes of ICC, particularly the characteristic nuclear changes. In human diabetic patients, the characteristic ultrastructural changes of ICC such as preapoptosis, accompanied with electrical dysrhythmia of slow waves, were observed. These results show several evidence converging to support that degeneration of the ICC may be associated with the pathogenesis of diabetic gastropathy. (C) 2010 Elsevier GmbH. All rights reserved.
C1 [Rhee, Poong-Lyul] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Gastroenterol,Dept Med, Seoul 135710, South Korea.
   [Kim, Kyoung Mee] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea.
   [Lee, Ji Yeon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Biomed Res Inst, Seoul 135710, South Korea.
   [Joo, Mee] Inje Univ, Sch Med, Ilsan Paik Hosp, Dept Pathol, Gyeonggi Do, South Korea.
   [Kim, Sung; Noh, Jae Hyung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea.
   [Ward, Sean M.; Koh, Sang Don] Univ Nevada, Sch Med, Dept Physiol & Cell Biol, Reno, NV 89557 USA.
RP Rhee, PL (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Gastroenterol,Dept Med, 50 Irwon Dong, Seoul 135710, South Korea.
EM plrhee@skku.edu
RI Kim, Eun Ran/AAD-8003-2022; Kim, Sung/G-4114-2014
OI Kim, Eun Ran/0000-0002-0495-2565; Rhee, Poong-Lyul/0000-0003-0495-5296
FU Samsung Biomedical Research InstituteSamsung [SBRI C-A8-226-1]; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Diabetes & Digestive & Kidney Diseases
   (NIDDK) [R01DK057236, P01DK041315, R01DK045713] Funding Source: NIH
   RePORTER
FX This work was supported by Samsung Biomedical Research Institute grant
   (SBRI C-A8-226-1).
CR Camborova P, 2003, PHYSIOL RES, V52, P275
   Faussone-Pellegrini MS, 1999, MICROSC RES TECHNIQ, V47, P248, DOI 10.1002/(SICI)1097-0029(19991115)47:4<248::AID-JEMT4>3.0.CO;2-W
   FAUSSONEPELLEGRINI MS, 1989, J SUBMICR CYTOL PATH, V21, P439
   Hudson NPH, 2006, ACTA PHYSIOL, V187, P391, DOI 10.1111/j.1748-1716.2006.01589.x
   Iwasaki H, 2006, J GASTROENTEROL, V41, P1076, DOI 10.1007/s00535-006-1909-8
   Koch KL, 1999, DIGEST DIS SCI, V44, P1061, DOI 10.1023/A:1026647417465
   Komuro T, 1999, MICROSC RES TECHNIQ, V47, P267, DOI 10.1002/(SICI)1097-0029(19991115)47:4<267::AID-JEMT5>3.0.CO;2-O
   Miller SM, 2008, NEUROGASTROENT MOTIL, V20, P349, DOI 10.1111/j.1365-2982.2007.01040.x
   Mitsui R, 2003, ANAT EMBRYOL, V206, P453, DOI 10.1007/s00429-003-0323-8
   Nakahara M, 2002, J GASTROEN HEPATOL, V17, P666, DOI 10.1046/j.1440-1746.2002.02756.x
   Negreanu LM, 2008, WORLD J GASTROENTERO, V14, P6285, DOI 10.3748/wjg.14.6285
   Ordog T, 2008, NEUROGASTROENT MOTIL, V20, P8, DOI 10.1111/j.1365-2982.2007.01056.x
   Ordog T, 2000, DIABETES, V49, P1731, DOI 10.2337/diabetes.49.10.1731
   Pasricha PJ, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-21
   RATHMANN W, 1991, DIABETES CARE, V14, P1086, DOI 10.2337/diacare.14.11.1086
   Sanders KM, 1996, GASTROENTEROLOGY, V111, P492, DOI 10.1053/gast.1996.v111.pm8690216
   Sanders KM, 2006, ANNU REV PHYSIOL, V68, P307, DOI 10.1146/annurev.physiol.68.040504.094718
   Sanders KM, 2004, NEUROGASTROENT MOTIL, V16, P100, DOI 10.1111/j.1743-3150.2004.00483.x
   Takahashi T, 1997, GASTROENTEROLOGY, V113, P1535, DOI 10.1053/gast.1997.v113.pm9352855
   Thomsen L, 1998, NAT MED, V4, P848, DOI 10.1038/nm0798-848
   Tong WD, 2004, INT J COLORECTAL DIS, V19, P467, DOI 10.1007/s00384-003-0577-x
   Vanderwinden JM, 1999, MICROSC RES TECHNIQ, V47, P344, DOI 10.1002/(SICI)1097-0029(19991201)47:5<344::AID-JEMT6>3.0.CO;2-1
   Vittal H, 2007, NAT CLIN PRACT GASTR, V4, P336, DOI 10.1038/ncpgasthep0838
   Ward SM, 2001, AM J PHYSIOL-GASTR L, V281, pG602, DOI 10.1152/ajpgi.2001.281.3.G602
   Wrzos HF, 1997, DIGEST DIS SCI, V42, P2106, DOI 10.1023/A:1018830820537
   Yamamoto T, 2008, J GASTROEN HEPATOL, V23, P660, DOI 10.1111/j.1440-1746.2008.05326.x
NR 26
TC 6
Z9 6
U1 0
U2 7
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0940-2993
EI 1618-1433
J9 EXP TOXICOL PATHOL
JI Exp. Toxicol. Pathol.
PD JUL
PY 2012
VL 64
IS 5
BP 521
EP 526
DI 10.1016/j.etp.2010.11.008
PG 6
WC Pathology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Toxicology
GA 948OU
UT WOS:000304513300019
PM 21185163
DA 2022-04-25
ER

PT J
AU Park, E
   Park, MH
   Na, HS
   Chung, J
AF Park, Eunjoo
   Park, Mi Hee
   Na, Hee Sam
   Chung, Jin
TI Xylitol induces cell death in lung cancer A549 cells by autophagy
SO BIOTECHNOLOGY LETTERS
LA English
DT Article
DE Anti-cancer agent; Autophagy; Cancer; Lung cancer; Xylitol
ID PORPHYROMONAS-GINGIVALIS; ULCERATIVE-COLITIS; COLORECTAL-CANCER;
   THERAPY; INFLAMMATION
AB Xylitol is a widely used anti-caries agent that has anti-inflammatory effects. We have evaluated the potential of xylitol in cancer treatment. It's effects on cell proliferation and cytotoxicity were measured by MTT assay and LDH assay. Cell morphology and autophagy were examined by immunostaining and immunoblotting. Xylitol inhibited cell proliferation in a dose-dependent manner in these cancer cells: A549, Caki, NCI-H23, HCT-15, HL-60, K562, and SK MEL-2. The IC50 of xylitol in human gingival fibroblast cells was higher than in cancer cells, indicating that it is more specific for cancer cells. Moreover, xylitol induced autophagy in A549 cells that was inhibited by 3-methyladenine, an autophagy inhibitor. These results indicate that xylitol has potential in therapy against lung cancer by inhibiting cell proliferation and inducing autophagy of A549 cells.
C1 [Park, Eunjoo; Park, Mi Hee; Na, Hee Sam; Chung, Jin] Pusan Natl Univ, Sch Dent, Dept Oral Microbiol, Yangsan Si 626870, Gyeongsangnam D, South Korea.
RP Chung, J (corresponding author), Pusan Natl Univ, Sch Dent, Dept Oral Microbiol, Yangsan Si 626870, Gyeongsangnam D, South Korea.
EM jchung@pusan.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government
   (MEST)Ministry of Education, Science and Technology, Republic of
   KoreaNational Research Foundation of KoreaKorean Government
   [2012R1A2A2A01015470]
FX A National Research Foundation of Korea (NRF) Grant funded by the Korea
   government (MEST; No. 2012R1A2A2A01015470) supported this research.
CR Brown ER, 2008, ANN ONCOL, V19, P1340, DOI 10.1093/annonc/mdn054
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Eaden J, 2000, ALIMENT PHARM THERAP, V14, P145
   Fu L, 2009, CANCER RES, V69, P8967, DOI 10.1158/0008-5472.CAN-09-2190
   Han SJ, 2005, CLIN DIAGN LAB IMMUN, V12, P1285, DOI 10.1128/CDLI.12.11.1285-1291.2005
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Lynch Heather, 2003, J Calif Dent Assoc, V31, P205
   Moody GA, 1996, EUR J GASTROEN HEPAT, V8, P1179, DOI 10.1097/00042737-199612000-00009
   Park E, 2014, J PERIODONTOL, V85, pE212, DOI 10.1902/jop.2014.130455
   Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006
NR 15
TC 11
Z9 12
U1 3
U2 17
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-5492
EI 1573-6776
J9 BIOTECHNOL LETT
JI Biotechnol. Lett.
PD MAY
PY 2015
VL 37
IS 5
BP 983
EP 990
DI 10.1007/s10529-014-1757-1
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA CF6BP
UT WOS:000352641700004
PM 25650339
DA 2022-04-25
ER

PT J
AU Akter, M
   Ullah, AKMA
   Banik, S
   Sikder, MT
   Hosokawa, T
   Saito, T
   Kurasaki, M
AF Akter, Mahmuda
   Atique Ullah, A. K. M.
   Banik, Subrata
   Sikder, Md. Tajuddin
   Hosokawa, Toshiyuki
   Saito, Takeshi
   Kurasaki, Masaaki
TI Green Synthesized Silver Nanoparticles-Mediated Cytotoxic Effect in
   Colorectal Cancer Cells: NF-kappa B Signal Induced Apoptosis Through
   Autophagy
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Apoptosis; Autophagy; Brassica silver nanoparticles; NF&#954; B; Caco-2
   cells
ID OXIDATIVE STRESS; ACTIVATION; TOXICITY; DEATH; MTOR
AB Green synthesized silver nanoparticles (Ag-NPs) have demonstrated promising effects, including cytotoxicity and anticancer potential, in different cell lines. Therefore, in our previous study, Ag-NPs were synthesized from the reduction of AgNO3 using Brassica rapa var. japonica (Bj) leaf extract as a reducing and stabilizing agent. The synthesized Ag-NPs were spherical in shape, with a size range of 15-30 nm. They had phase-centered cubic structure with strong growth inhibition potential against some bacteria. In continuation with our previous study, in the present study, we aimed to investigate the autophagy-regulated cytotoxic effect of Ag-NPs against human epithelial colorectal adenocarcinoma cells (Caco-2 cells). We found that the Bj leaf aqueous extract facilitated Brassica silver nanoparticles (Brassica Ag-NPs)-induced NF-kappa B mediated autophagy in Caco-2 cells. Results showed that Ag-NPs reduced cell viability of Caco-2 cells by inducing oxidative stress and DNA damage. Therefore, to understand the mechanism underlying the death-promoting activity of Ag-NPs in Caco-2 cells, western blotting was performed. Western blot analysis showed decreased expression of NF kappa B and increased expression of I kappa B, which is a sign of autophagy initiation. In addition, autophagosome formation was accelerated by the activity of p53 and light chain 3 (LC3) II. In addition, inhibition of Akt and mTOR also played a pivotal role in autophagy formation. Finally, excessive expansion of autophagy promoted apoptosis, which subsequently resulted in necrosis. These findings support a novel cell death-promoting function of autophagy by Ag-NPs in Caco-2 cells.
C1 [Akter, Mahmuda; Kurasaki, Masaaki] Hokkaido Univ, Grp Environm Adaptat Sci, Fac Environm Earth Sci, Kita Ku, Kita 10,Nishi 5, Sapporo, Hokkaido 0600810, Japan.
   [Atique Ullah, A. K. M.] Bangladesh Atom Energy Commiss, Nanosci & Technol Res Lab, Chem Div, Atom Energy Ctr, Dhaka 1000, Bangladesh.
   [Banik, Subrata; Kurasaki, Masaaki] Hokkaido Univ, Grad Sch Environm Sci, Sapporo, Hokkaido 0600810, Japan.
   [Sikder, Md. Tajuddin] Jahangirnagar Univ, Dept Publ Hlth & Informat, Dhaka 1342, Bangladesh.
   [Hosokawa, Toshiyuki] Hokkaido Univ, Inst Adv Higher Educ, Res Div Higher Educ, Sapporo, Hokkaido 0600817, Japan.
   [Saito, Takeshi] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan.
RP Kurasaki, M (corresponding author), Hokkaido Univ, Grp Environm Adaptat Sci, Fac Environm Earth Sci, Kita Ku, Kita 10,Nishi 5, Sapporo, Hokkaido 0600810, Japan.; Kurasaki, M (corresponding author), Hokkaido Univ, Grad Sch Environm Sci, Sapporo, Hokkaido 0600810, Japan.
EM kura@ees.hokuda.ac.jp
RI KURASAKI, Masaaki/B-8207-2012
OI KURASAKI, Masaaki/0000-0003-2125-095X; Sikder, Dr. Md.
   Tajuddin/0000-0002-5717-2263
CR Acharya D, 2021, BIOL TRACE ELEM RES, V199, P1812, DOI 10.1007/s12011-020-02304-7
   Akter M, 2018, J INORG ORGANOMET P, V28, P1483, DOI 10.1007/s10904-018-0818-7
   Akter M, 2018, J ADV RES, V9, P1, DOI 10.1016/j.jare.2017.10.008
   Bagur H, 2020, J CLUST SCI, V31, P1241, DOI 10.1007/s10876-019-01731-4
   Beer C, 2012, TOXICOL LETT, V208, P286, DOI 10.1016/j.toxlet.2011.11.002
   Buttacavoli Miriam, 2018, Oncotarget, V9, P9685, DOI 10.18632/oncotarget.23859
   Chan Francis Ka-Ming, 2013, Methods Mol Biol, V979, P65, DOI 10.1007/978-1-62703-290-2_7
   Criollo A, 2012, CELL CYCLE, V11, P194, DOI 10.4161/cc.11.1.18669
   Djavaheri-Mergny M, 2004, FEBS LETT, V578, P111, DOI 10.1016/j.febslet.2004.10.082
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398
   Ghosh S, 2006, CANCER CELL, V10, P215, DOI 10.1016/j.ccr.2006.08.007
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Hulkoti NI, 2014, COLLOID SURFACE B, V121, P474, DOI 10.1016/j.colsurfb.2014.05.027
   Ishida AE, 2004, ENDOCRINOLOGY, V145, P2014, DOI [10.1210/en.2003-1199, DOI 10.1210/EN.2003-1199]
   Kahzad N, 2020, BIOL TRACE ELEM RES, V198, P359, DOI 10.1007/s12011-020-02055-5
   Kanmani P, 2013, CARBOHYD POLYM, V97, P421, DOI 10.1016/j.carbpol.2013.04.048
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Kim S, 2009, TOXICOL IN VITRO, V23, P1076, DOI 10.1016/j.tiv.2009.06.001
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Moshfegh A, 2019, MICRO NANO LETT, V14, P581, DOI 10.1049/mnl.2018.5260
   Ong C, 2013, CURR MED CHEM, V20, P772
   Park EJ, 2010, TOXICOL IN VITRO, V24, P872, DOI 10.1016/j.tiv.2009.12.001
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Perez-Herrero E, 2015, EUR J PHARM BIOPHARM, V93, P52, DOI 10.1016/j.ejpb.2015.03.018
   Rahman MM, 2018, CHEMOSPHERE, V196, P453, DOI 10.1016/j.chemosphere.2017.12.149
   Rajawat YS, 2008, HORM-INT J ENDOCRINO, V7, P46, DOI 10.14310/horm.2002.1111037
   Roy R, 2014, TOXICOL LETT, V227, P29, DOI 10.1016/j.toxlet.2014.02.024
   Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379
   Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948
   Salehzadeh A, 2019, IET NANOBIOTECHNOL, V13, P766, DOI 10.1049/iet-nbt.2018.5364
   Satapathy SR, 2013, NANOMEDICINE-UK, V8, P1307, DOI [10.2217/NNM.12.176, 10.2217/nnm.12.176]
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Schlottmann S, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725854
   Somu P, 2019, J MOL LIQ, V291, DOI 10.1016/j.molliq.2019.111303
   Tang JJ, 2015, CANCER LETT, V363, P101, DOI 10.1016/j.canlet.2015.04.014
   Urso ML, 2003, TOXICOLOGY, V189, P41, DOI 10.1016/S0300-483X(03)00151-3
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Zou MJ, 2012, CELL SIGNAL, V24, P1722, DOI 10.1016/j.cellsig.2012.04.009
NR 44
TC 3
Z9 3
U1 3
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163-4984
EI 1559-0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD SEP
PY 2021
VL 199
IS 9
BP 3272
EP 3286
DI 10.1007/s12011-020-02463-7
EA NOV 2020
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA TE2TW
UT WOS:000592136600001
PM 33236292
DA 2022-04-25
ER

PT J
AU Bai, S
   Tian, B
   Li, A
   Yao, Q
   Zhang, G
   Li, F
AF Bai, S.
   Tian, B.
   Li, A.
   Yao, Q.
   Zhang, G.
   Li, F.
TI MicroRNA-125b promotes tumor growth and suppresses apoptosis by
   targeting DRAM2 in retinoblastoma
SO EYE
LA English
DT Article
ID RETINAL DYSTROPHY; CANCER; IDENTIFICATION; PROLIFERATION; EXPRESSION;
   AUTOPHAGY; MUTATIONS; CELLS
AB Purpose It is known that microRNAs (miRNAs) are a class of small, noncoding RNAs that act as key regulators in various physiological and pathological processes. However, the regulatory mechanisms involving miRNAs in retinoblastoma (RB) remain largely unknown. The miRNA miR-125b is dysregulated in various human cancers such as breast cancer, human hepatocellular carcinoma, ovarian cancer, and colorectal cancer. However, the significance of miR-125b in RB has not been sufficiently investigated. Our objective was to explore the role of the miR-125b in RB.
   Methods In this study, we measured miR-125b levels using real-time polymerase chain reaction in human RB cell lines, including HXO-Rb44, Y79, SO-RB50, and the normal human retinal pigment epithelial cell line ARPE-19; a total of 38 pairs of primary RB tissues and adjacent noncancerous tissues were also measured. In addition, overexpression of miR-125b in RB cell lines was performed to determine the role of miR-125b in RB.
   Results We found that miR-125b is significantly upregulated in RB, and closely associated with tumor cell proliferation and apoptosis. In addition, overexpression of miR-125b apparently promotes RB cell proliferation and migration in vitro. Gain-of-function in vitro experiments further showed that the miR-125b mimic significantly suppressed RB cell apoptosis. A subsequent dual-luciferase reporter assay identified the suppressor gene DRAM2 as direct target of miR-125b.
   Conclusions Our data collectively demonstrate that miR-125b is a suppressor gene miRNA that can promote RB cell proliferation and migration by downregulating the suppressor gene DRAM2, indicating that miR-125b may represent a new potential diagnostic and therapeutic target for RB treatment.
C1 [Bai, S.; Tian, B.; Yao, Q.; Zhang, G.; Li, F.] Xi An Jiao Tong Univ, Guangren Hosp, Xian Hosp 4, Dept Ophthalmol, Xian, Peoples R China.
   [Li, A.] Jilin Univ, Hosp 1, Dept Ophthalmol, Xinmin St 71, Changchun 130021, Jilin Province, Peoples R China.
RP Li, A (corresponding author), Jilin Univ, Hosp 1, Dept Ophthalmol, Xinmin St 71, Changchun 130021, Jilin Province, Peoples R China.
EM aipengli4@163.com
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81302198]
FX We are grateful to all the patients and individuals in the study who
   made this work possible. We thank the clinicians and hospital staff who
   contributed to data collection for this study. This study was funded by
   the National Natural Science Foundation (No. 81302198). All procedures
   performed in studies involving human participants were in accordance
   with the ethical standards of the institutional and/or national research
   committee, and with the 1964 Helsinki declaration and its later
   amendments, or comparable ethical standards. Informed consent was
   obtained from all individual participants included in the study.
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990
   Cotter TG, 2009, NAT REV CANCER, V9, P501, DOI 10.1038/nrc2663
   Dalgard CL, 2009, INVEST OPHTH VIS SCI, V50, P4542, DOI 10.1167/iovs.09-3520
   Dimaras H, 2012, LANCET, V379, P1436, DOI 10.1016/S0140-6736(11)61137-9
   Du TT, 2007, CELL RES, V17, P661, DOI 10.1038/cr.2007.67
   El-Asrag ME, 2015, AM J HUM GENET, V96, P948, DOI 10.1016/j.ajhg.2015.04.006
   Feng SP, 2011, NUCLEIC ACIDS RES, V39, P6669, DOI 10.1093/nar/gkr232
   Gu Wen-Li, 2015, Shanghai Kou Qiang Yi Xue, V24, P71
   Houston Samuel K, 2011, Int Ophthalmol Clin, V51, P77, DOI 10.1097/IIO.0b013e3182010f29
   Jo DH, 2011, J PEDIAT HEMATOL ONC, V33, P529, DOI 10.1097/MPH.0b013e318228280a
   Kivela T, 2009, BRIT J OPHTHALMOL, V93, P1129, DOI 10.1136/bjo.2008.150292
   Li Q, 2015, ADV DIFFER EQU-NY, DOI 10.1186/s13662-015-0377-y
   Marlhens F, 1998, EUR J HUM GENET, V6, P527, DOI 10.1038/sj.ejhg.5200205
   Park SM, 2009, BIOCHEM BIOPH RES CO, V390, P1340, DOI 10.1016/j.bbrc.2009.10.149
   Peracchio C, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-22
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270
   To KH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-69
   Tolosa L, 2015, METHODS MOL BIOL, V1250, P333, DOI 10.1007/978-1-4939-2074-7_26
   Wang TY, 2015, MOL MED REP, V12, P2849, DOI 10.3892/mmr.2015.3769
   Xu PZ, 2003, CURR BIOL, V13, P790, DOI 10.1016/S0960-9822(03)00250-1
   Xu XF, 2015, ONCOL REP, V33, P2789, DOI 10.3892/or.2015.3900
   Zhang L, 2013, CANCER LETT, V332, P94, DOI 10.1016/j.canlet.2013.01.023
   Zhang Y, 2013, NEOPLASMA, V60, P247, DOI 10.4149/neo_2013_033
   Zhao JJ, 2009, CHILD NERV SYST, V25, P13, DOI 10.1007/s00381-008-0701-x
NR 30
TC 40
Z9 40
U1 2
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2016
VL 30
IS 12
BP 1630
EP 1638
DI 10.1038/eye.2016.189
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EL1AP
UT WOS:000394353200015
PM 27518550
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Jin, X
   Dai, L
   Ma, YL
   Wang, JY
   Liu, Z
AF Jin, Xiao
   Dai, Lu
   Ma, Yilan
   Wang, Jiayan
   Liu, Zheng
TI Implications of HIF-1 alpha in the tumorigenesis and progression of
   pancreatic cancer
SO CANCER CELL INTERNATIONAL
LA English
DT Review
DE Hypoxia; HIF-1 alpha; Pancreatic cancer; Tumorigenesis; Progression;
   Review
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; EPITHELIAL-MESENCHYMAL TRANSITION;
   FACTOR-I; UP-REGULATION; GEMCITABINE RESISTANCE; GLUCOSE-METABOLISM;
   COLORECTAL-CANCER; INDUCED AUTOPHAGY; TUMOR-GROWTH; EXPRESSION
AB Pancreatic cancer is one of the leading causes of cancer-related deaths worldwide and is characterized by highly hypoxic tumor microenvironment. Hypoxia-inducible factor-1 alpha (HIF-1 alpha) is a major regulator of cellular response to changes in oxygen concentration, supporting the adaptation of tumor cells to hypoxia in an oxygen-deficient tumor microenvironment. Numerous studies revealed the central role of HIF-1 alpha in the carcinogenesis and progression of pancreatic cancer. This article reviewed the molecular mechanisms of how HIF-1 alpha regulated tumorigenesis and progression of pancreatic cancer and suggested that targeting HIF-1 alpha and its signaling pathways could be promising therapeutics for pancreatic cancer.
C1 [Jin, Xiao; Dai, Lu; Ma, Yilan; Wang, Jiayan; Liu, Zheng] Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
RP Liu, Z (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, 121 Jiangjiayuan Rd, Nanjing 210011, Jiangsu, Peoples R China.
EM liuzheng117@126.com
CR Arora S, 2013, J BIOL CHEM, V288, P21197, DOI 10.1074/jbc.M113.484576
   Azoitei N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-015-0490-2
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Carlessi R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02838-2
   Chaika NV, 2012, P NATL ACAD SCI USA, V109, P13787, DOI 10.1073/pnas.1203339109
   Chand S, 2016, INT J BIOL SCI, V12, P273, DOI 10.7150/ijbs.14951
   Chen H, 2014, BIOORGAN MED CHEM, V22, P1496, DOI 10.1016/j.bmc.2013.10.018
   Chen S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0986-x
   Chen S, 2016, CANCER LETT, V383, P73, DOI 10.1016/j.canlet.2016.09.027
   Cheng K, 2010, J CLIN INVEST, V120, P2171, DOI 10.1172/JCI35846
   Cheng ZX, 2014, ONCOL REP, V31, P1891, DOI 10.3892/or.2014.3022
   Chiorean EG, 2015, DRUG DES DEV THER, V9, P3529, DOI 10.2147/DDDT.S60328
   Cho IR, 2015, INT J ONCOL, V46, P2076, DOI 10.3892/ijo.2015.2922
   Dai ZJ, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-28
   Dauer P, 2017, PANCREATOLOGY, V17, P7, DOI 10.1016/j.pan.2016.12.010
   de Andrade LF, 2018, SCIENCE, V359, P1537, DOI 10.1126/science.aao0505
   Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1
   Dewhirst MW, 2009, RADIAT RES, V172, P653, DOI 10.1667/RR1926.1
   Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899
   Ganapathy-Kanniappan S, 2018, CRIT REV BIOCHEM MOL, V53, P667, DOI 10.1080/10409238.2018.1556578
   Ganji PN, 2013, ANGIOGENESIS, V16, P903, DOI 10.1007/s10456-013-9364-7
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Hashimoto O, 2011, PATHOBIOLOGY, V78, P181, DOI 10.1159/000325538
   He GD, 2014, ASIA PAC J CLIN NUTR, V23, P174, DOI 10.6133/apjcn.2014.23.1.14
   He XD, 2016, CANCER BIOL THER, V17, P188, DOI 10.1080/15384047.2016.1139228
   Heinis M, 2012, FASEB J, V26, P2734, DOI 10.1096/fj.11-199224
   Huang CB, 2018, GASTROENTEROLOGY, V154, P675, DOI 10.1053/j.gastro.2017.09.039
   Ito E, 2010, BIOCHEM BIOPH RES CO, V393, P222, DOI 10.1016/j.bbrc.2010.01.105
   Jia XH, 2012, CELL TRANSPLANT, V21, P1269, DOI 10.3727/096368911X627408
   Jiang Y, 2015, NUTR CANCER, V67, P1314, DOI 10.1080/01635581.2015.1085584
   Katagiri Tomohiro, 2018, Oncotarget, V9, P10525, DOI 10.18632/oncotarget.24156
   Koong AC, 2000, INT J RADIAT ONCOL, V48, P919, DOI 10.1016/S0360-3016(00)00803-8
   Kourtidis A, 2017, EXP CELL RES, V358, P78, DOI 10.1016/j.yexcr.2017.04.006
   Lang SA, 2007, CLIN CANCER RES, V13, P6459, DOI 10.1158/1078-0432.CCR-07-1104
   Lee BL, 2008, CARCINOGENESIS, V29, P44, DOI 10.1093/carcin/bgm232
   Lee KE, 2018, CELL REP, V23, P3457, DOI 10.1016/j.celrep.2018.05.071
   Li FH, 2013, BMC SYST BIOL, V7, DOI 10.1186/1752-0509-7-S2-S12
   Li N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060799
   Li W, 2018, COMPUT STRUCT BIOTEC, V16, P479, DOI 10.1016/j.csbj.2018.10.006
   Li X, 2016, ONCOTARGET, V7, P6000, DOI 10.18632/oncotarget.6830
   Li XQ, 2019, CELL DEATH DIFFER, V26, P382, DOI 10.1038/s41418-018-0207-3
   Liu ML, 2019, THERANOSTICS, V9, P4795, DOI 10.7150/thno.30988
   Liu Y, 2017, ONCOTARGET, V8, P77474, DOI 10.18632/oncotarget.20535
   Lu YB, 2017, BIOL OPEN, V6, P252, DOI 10.1242/bio.021774
   Lu YB, 2015, MOL MED REP, V11, P3666, DOI 10.3892/mmr.2015.3144
   Luo GT, 2018, EXP CELL RES, V369, P120, DOI 10.1016/j.yexcr.2018.05.013
   Lv CQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087868
   Mace TA, 2013, J SURG RES, V184, P855, DOI 10.1016/j.jss.2013.04.061
   Maeda K, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071025
   Malakar P, 2019, CANCER RES, V79, P2480, DOI 10.1158/0008-5472.CAN-18-1432
   Milanovic D, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-42
   Miyake K, 2012, EXP CELL RES, V318, P1554, DOI 10.1016/j.yexcr.2012.03.013
   Nagaraju GP, 2019, INT J CANCER, V145, P1529, DOI 10.1002/ijc.32227
   Nagaraju GP, 2015, CANCER LETT, V357, P557, DOI 10.1016/j.canlet.2014.12.007
   Niu F, 2015, J CELL PHYSIOL, V230, P2212, DOI 10.1002/jcp.24949
   Olbryt M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105104
   Ou ZL, 2019, RNA BIOL, V16, P1592, DOI 10.1080/15476286.2019.1649585
   Ou ZL, 2019, J CELL PHYSIOL, V234, P15407, DOI 10.1002/jcp.28188
   Pang YJ, 2017, INT J CANCER, V140, P1781, DOI 10.1002/ijc.30599
   Pereira T, 2006, CELL CYCLE, V5, P2720, DOI 10.4161/cc.5.23.3536
   Rachdi L, 2012, DIABETES, V61, P409, DOI 10.2337/db11-0765
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Reeves E, 2017, IMMUNOLOGY, V150, P16, DOI 10.1111/imm.12675
   Robey RW, 2007, CANCER METAST REV, V26, P39, DOI 10.1007/s10555-007-9042-6
   Roman CL, 2019, PEPTIDES, V117, DOI 10.1016/j.peptides.2019.05.002
   Ryu YL, 2014, CANCER LETT, V353, P68, DOI 10.1016/j.canlet.2014.07.001
   Sankar KS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222424
   Schwartz DL, 2010, MOL CANCER THER, V9, P2057, DOI 10.1158/1535-7163.MCT-09-0768
   Seo JH, 2013, CANCER LETT, V338, P271, DOI 10.1016/j.canlet.2013.04.002
   Shah SR, 2011, DEV BIOL, V349, P342, DOI 10.1016/j.ydbio.2010.10.033
   Shan T, 2013, CURR MOL MED, V13, P1023, DOI 10.2174/15665240113139990055
   Shen YH, 2019, ONCOTARGETS THER, V12, P5003, DOI 10.2147/OTT.S207560
   Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004
   Sibenaller ZA, 2014, FREE RADICAL BIO MED, V69, P357, DOI 10.1016/j.freeradbiomed.2014.02.002
   Soggia A, 2014, DIABETOLOGIA, V57, P2348, DOI 10.1007/s00125-014-3365-y
   Spivak-Kroizman TR, 2013, CANCER RES, V73, P3235, DOI 10.1158/0008-5472.CAN-11-1433
   Sun SZ, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.110014
   Takahashi K, 2018, ONCOGENE, V37, P2757, DOI 10.1038/s41388-018-0144-0
   Tang LR, 2018, ONCOTARGETS THER, V11, P8507, DOI 10.2147/OTT.S187615
   Tirpe AA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20246140
   Tung KH, 2013, CANCER LETT, V331, P58, DOI 10.1016/j.canlet.2012.12.001
   Van de Velde S, 2011, P NATL ACAD SCI USA, V108, P16876, DOI 10.1073/pnas.1114228108
   Vikram A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3451528
   Wang F, 2018, CLIN CANCER RES, V24, P3176, DOI 10.1158/1078-0432.CCR-17-3435
   Wang J, 2019, CANCER BIOL MED, V16, P100, DOI 10.20892/j.issn.2095-3941.2018.0304
   Wen ZD, 2016, EUR J PHARMACOL, V771, P93, DOI 10.1016/j.ejphar.2015.12.020
   Wilkes JG, 2018, CLIN EXP METASTAS, V35, P37, DOI 10.1007/s10585-018-9876-z
   Wu DL, 2015, NATURE, V524, P303, DOI 10.1038/nature14883
   Xiang JF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0367-6
   Yasui H, 2010, CANCER RES, V70, P6427, DOI 10.1158/0008-5472.CAN-10-1350
   Ye LY, 2014, PANCREATOLOGY, V14, P391, DOI 10.1016/j.pan.2014.06.008
   Zhang H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092824
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang WQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0334-2
   Zhao QY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1182-9
   Zhao TS, 2020, THERANOSTICS, V10, P4088, DOI 10.7150/thno.42416
   Zhao TS, 2015, ONCOTARGET, V6, P2250, DOI 10.18632/oncotarget.2948
   Zhou PT, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0624-9
   Zhu GH, 2013, DIGEST DIS SCI, V58, P3503, DOI 10.1007/s10620-013-2841-4
   Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298
   Zhu HT, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-119
   Zhu SK, 2011, MOL CARCINOGEN, V50, P770, DOI 10.1002/mc.20678
   Zhu S, 2018, J PATHOL, V245, P349, DOI 10.1002/path.5089
NR 103
TC 25
Z9 25
U1 2
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD JUN 24
PY 2020
VL 20
IS 1
AR 273
DI 10.1186/s12935-020-01370-0
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MS0ER
UT WOS:000553960800008
PM 32587480
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Bostad, M
   Olsen, CE
   Peng, Q
   Berg, K
   Hogset, A
   Selbo, PK
AF Bostad, Monica
   Olsen, Cathrine Elisabeth
   Peng, Qian
   Berg, Kristian
   Hogset, Anders
   Selbo, Pal Kristian
TI Light-controlled endosomal escape of the novel CD133-targeting
   immunotoxin AC133-saporin by photochemical internalization - A minimally
   invasive cancer stem cell-targeting strategy
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Controlled drug delivery; Photochemical internalization; Endosomal
   escape; Targeting; CD133; Immunotoxin; Cancer stem cells; Photodynamic
   therapy; Cancer therapy; Autophagy
ID PHOTODYNAMIC THERAPY; COLORECTAL-CANCER; CD133 EXPRESSION;
   DRUG-DELIVERY; OVARIAN-CANCER; BREAST-CANCER; TUMOR-GROWTH; AUTOPHAGY;
   MARKER; APOPTOSIS
AB The cancer stem cell (CSC) marker CD133 is an attractive target to improve antitumor therapy. We have used photochemical internalization (PCI) for the endosomal escape of the novel CD133-targeting immunotoxin AC133-saporin (PCIAC133-saporin). PCI employs an endocytic vesicle-localizing photosensitizer, which generates reactive oxygen species upon light-activation causing a rupture of the vesicle membranes and endosomal escape of entrapped drugs. Here we show that AC133-saporin co-localizes with the PCI-photosensitizer TPCS2a, which upon light exposure induces cytosolic release of AC133-saporin. PCI of picomolar levels of AC133-saporin in colorectal adenocarcinoma WiDr cells blocked cell proliferation and induced 100% inhibition of cell viability and colony forming ability at the highest light doses, whereas no cytotoxicity was obtained in the absence of light. Efficient PCI-based CD133-targeting was in addition demonstrated in the stem-cell-like, triple negative breast cancer cell line MDA-MB-231 and in the aggressive malignant melanoma cell line FEMX-1, whereas no enhanced targeting was obtained in the CD133-negative breast cancer cell line MCF-7. PCIAC133-saporin induced mainly necrosis and a minimal apoptotic response based on assessing cleavage of caspase-3 and PARP, and the TUNEL assay. PCIAC133-saporin resulted in S phase arrest and reduced LC3-II conversion compared to control treatments. Notably, co-treatment with Bafilomycin A1 and PCIAC133-saporin blocked LC3-II conversion, indicating a termination of the autophagic flux in WiDr cells. For the first time, we demonstrate laser-controlled targeting of CD133 in vivo. After only one systemic injection of AC133-saporin and TPCS2a, a strong anti-tumor response was observed after PCIAC133-saporin. The present PCI-based endosomal escape technology represents a minimally invasive strategy for spatio-temporal, light-controlled targeting of CD133+ cells in localized primary tumors or metastasis. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Bostad, Monica; Olsen, Cathrine Elisabeth; Berg, Kristian; Selbo, Pal Kristian] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, N-0424 Oslo, Norway.
   [Bostad, Monica; Olsen, Cathrine Elisabeth; Hogset, Anders; Selbo, Pal Kristian] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Canc Stem Cell Innovat Ctr SFI CAST, N-0424 Oslo, Norway.
   [Peng, Qian] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Pathol, N-0424 Oslo, Norway.
   [Hogset, Anders] PCI Biotech AS, Lysaker, Norway.
RP Selbo, PK (corresponding author), Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Dept Radiat Biol, Postboks 4953 Nydalen, N-0424 Oslo, Norway.
EM selbo@rr-research.no
RI Selbo, Pål Kristian/B-4638-2009
OI Selbo, Pål Kristian/0000-0002-5310-057X; Berg,
   Kristian/0000-0002-7816-7543
FU Norwegian Research Council (SFI-CAST)Research Council of Norway;
   Norwegian Radium Hospital Research Foundation [FU0803]; Norwegian Cancer
   SocietyNorwegian Cancer Society [3327285]
FX This work was supported by grants from the Norwegian Research Council
   (SFI-CAST), the Norwegian Radium Hospital Research Foundation (FU0803)
   and the Norwegian Cancer Society (3327285). We thank Mette Forsund at
   the Department of Pathology for skilful technical assistance with the
   IHC preparation and staining and Idun Dale Rein at the Flow Cytometry
   Core Facility for excellent technical assistance with the live/dead and
   TUNEL assay.
CR Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Aomatsu N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045865
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   BERG K, 1990, INT J RADIAT BIOL, V58, P475, DOI 10.1080/09553009014551821
   Berg K, 2007, CURR PHARM BIOTECHNO, V8, P362, DOI 10.2174/138920107783018354
   Berg K, 2010, METHODS MOL BIOL, V635, P133, DOI 10.1007/978-1-60761-697-9_10
   Berstad M.B., 2015, ONCOGENE
   Bostad M, 2014, MOL PHARMACEUT, V11, P2764, DOI 10.1021/mp500129t
   Bostad M, 2013, J CONTROL RELEASE, V168, P317, DOI 10.1016/j.jconrel.2013.03.023
   Chen HY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056878
   Curley MD, 2009, STEM CELLS, V27, P2875, DOI 10.1002/stem.236
   Dewaele M, 2011, J CELL MOL MED, V15, P1402, DOI 10.1111/j.1582-4934.2010.01118.x
   Dittfeld C, 2009, RADIOTHER ONCOL, V92, P353, DOI 10.1016/j.radonc.2009.06.034
   Galizia G, 2012, ARCH SURG-CHICAGO, V147, P18, DOI 10.1001/archsurg.2011.795
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Hogset A, 2004, ADV DRUG DELIVER REV, V56, P95, DOI 10.1016/j.addr.2003.08.016
   Horst D, 2008, BRIT J CANCER, V99, P1285, DOI 10.1038/sj.bjc.6604664
   Irollo E, 2013, AM J TRANSL RES, V5, P563
   Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820
   Kojima M, 2008, CANCER SCI, V99, P1578, DOI 10.1111/j.1349-7006.2008.00849.x
   Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85
   Lomonaco SL, 2009, INT J CANCER, V125, P717, DOI 10.1002/ijc.24402
   Lund K, 2014, MABS-AUSTIN, V6, P1038, DOI 10.4161/mabs.28207
   Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016
   Noodt BB, 1996, BRIT J CANCER, V74, P22, DOI 10.1038/bjc.1996.310
   Noodt BB, 1999, BRIT J CANCER, V79, P72, DOI 10.1038/sj.bjc.6690014
   Norum OJ, 2009, PHOTOCHEM PHOTOBIOL, V85, P740, DOI 10.1111/j.1751-1097.2008.00477.x
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Oleinick NL, 2002, PHOTOCH PHOTOBIO SCI, V1, P1, DOI 10.1039/b108586g
   Polito L, 2013, TOXINS, V5, P1698, DOI 10.3390/toxins5101698
   Rappa G, 2008, STEM CELLS, V26, P3008, DOI 10.1634/stemcells.2008-0601
   Reiners JJ, 2010, AUTOPHAGY, V6, P7, DOI 10.4161/auto.6.1.10220
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Selbo PK, 2006, J PHARMACOL EXP THER, V319, P604, DOI 10.1124/jpet.106.109165
   Selbo PK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006691
   Selbo PK, 2012, J CONTROL RELEASE, V159, P197, DOI 10.1016/j.jconrel.2012.02.003
   Selbo PK, 2010, J CONTROL RELEASE, V148, P2, DOI 10.1016/j.jconrel.2010.06.008
   Selbo PK, 2000, INT J CANCER, V87, P853, DOI 10.1002/1097-0215(20000915)87:6<853::AID-IJC15>3.0.CO;2-0
   Selbo PK, 2001, INT J CANCER, V92, P761, DOI 10.1002/1097-0215(20010601)92:5<761::AID-IJC1238>3.0.CO;2-4
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Skubitz APN, 2013, GYNECOL ONCOL, V130, P579, DOI 10.1016/j.ygyno.2013.05.027
   Stirpe F, 2004, TOXICON, V44, P371, DOI 10.1016/j.toxicon.2004.05.004
   Stratford EW, 2013, BBA-GEN SUBJECTS, V1830, P4235, DOI 10.1016/j.bbagen.2013.04.033
   Swaminathan SK, 2013, J CONTROL RELEASE, V171, P280, DOI 10.1016/j.jconrel.2013.07.014
   Swaminathan SK, 2010, J IMMUNOL METHODS, V361, P110, DOI 10.1016/j.jim.2010.07.007
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Waldron NN, 2011, MOL CANCER THER, V10, P1829, DOI 10.1158/1535-7163.MCT-11-0206
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Weyergang A, 2011, LASER SURG MED, V43, P721, DOI 10.1002/lsm.21084
   Woodhams J, 2010, J CONTROL RELEASE, V142, P347, DOI 10.1016/j.jconrel.2009.11.017
   YAMAIZUMI M, 1978, CELL, V15, P245, DOI 10.1016/0092-8674(78)90099-5
   Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012
   Yip WL, 2007, MOL PHARM, V4, P241, DOI 10.1021/mp060105u
NR 54
TC 53
Z9 56
U1 0
U2 69
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY 28
PY 2015
VL 206
BP 37
EP 48
DI 10.1016/j.jconrel.2015.03.008
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA CG5UM
UT WOS:000353361400004
PM 25758331
DA 2022-04-25
ER

PT J
AU Cheng, TC
   Tu, SH
   Chen, LC
   Chen, MY
   Chen, WY
   Lin, YK
   Ho, CT
   Lin, SY
   Wu, CH
   Ho, YS
AF Cheng, Tzu-Chun
   Tu, Shih-Hsin
   Chen, Li-Ching
   Chen, Ming-Yao
   Chen, Wen-Ye
   Lin, Yen-Kuang
   Ho, Chi-Tang
   Lin, Shyr-Yi
   Wu, Chih-Hsiung
   Ho, Yuan-Soon
TI Down-regulation of alpha-L-fucosidase 1 expression confers inferior
   survival for triple-negative breast cancer patients by modulating the
   glycosylation status of the tumor cell surface
SO ONCOTARGET
LA English
DT Article
DE alpha-L-fucosidase; triple-negative breast cancer; overall survival
   rate; glycosylation; metastasis
ID FOCAL ADHESION KINASE; L-FUCOSE MOIETIES; SIALYL-LEWIS-X;
   HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; CYCLE ARREST; SIGNALING
   PATHWAY; IN-VITRO; LINES; AUTOPHAGY
AB alpha-L-fucosidase 1 (FUCA1) is a lysosomal enzyme that catalyzes the hydrolytic cleavage of the terminal fucose residue in breast cancer cells. FUCA1 mRNA levels were detected by real-time PCR, and there was a greater than 139-fold increase in FUCA1 mRNA expression in breast tumor samples compared with normal breast tissue samples (*P = 0.005, n = 236). Higher FUCA1 mRNA expression was preferentially detected in early-stage tumors (stage 0 to 2) compared with advanced-stage tumors (stage 3 to 4) (stage 0-1 versus stage 3, *P = 0.015; stage 0-1 versus stage 4, *P = 0.024). FUCA1 protein levels were higher in advanced-stage tumors concomitant with decreased fucosylated Lewis-x antigen expression, as evidenced using the immunohistochemical staining H-score method (*P < 0.001). Statistical analysis revealed that lower FUCA1 levels significantly predicted an inferior overall survival rate among triple-negative breast cancer (TNBC) patients compared with non-TNBC patients (*P = 0.009). Two stable FUCA1 siRNA knock-down MDA-MB-231 cell lines were established, and the results suggest that transient FUCA inhibition creates a selective pressure that triggers the metastasis of primary tumor cells, as detected by wound healing and invasion assays (*P < 0.01). The results suggest that FUCA1 may be a potential prognostic molecular target for clinical use, especially in TNBC patients.
C1 [Cheng, Tzu-Chun; Ho, Yuan-Soon] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
   [Tu, Shih-Hsin; Wu, Chih-Hsiung] Taipei Med Univ, Coll Med, Sch Med, Dept Surg, Taipei, Taiwan.
   [Chen, Li-Ching; Chen, Ming-Yao] Taipei Med Univ, Shuang Ho Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan.
   [Chen, Li-Ching] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Chen, Wen-Ye; Ho, Yuan-Soon] Taipei Med Univ, Coll Med Sci & Technol, Sch Med Lab Sci & Biotechnol, Taipei, Taiwan.
   [Lin, Yen-Kuang] Taipei Med Univ, Biol Stat & Res Consultat Ctr, Taipei, Taiwan.
   [Ho, Chi-Tang] Rutgers State Univ, Dept Food Sci, New Brunswick, NJ 08903 USA.
   [Lin, Shyr-Yi] Taipei Med Univ, Coll Med, Sch Med, Dept Gen Med, Taipei, Taiwan.
   [Wu, Chih-Hsiung] Taipei Med Univ, Shuang Ho Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan.
   [Ho, Yuan-Soon] Taipei Med Univ Hosp, Dept Lab Med, Taipei, Taiwan.
   [Ho, Yuan-Soon] Taipei Med Univ, Ctr Comprehens Canc, Taipei, Taiwan.
RP Ho, YS (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
EM chwu@tmu.edu.tw; hoyuansn@tmu.edu.tw
OI Tu, Shih-Hsin/0000-0002-4106-8146
FU Health and Welfare Surcharge on tobacco products
   [MOHW104-TDU-B-212-124-001]; Ministry of Science and TechnologyMinistry
   of Education, Culture, Sports, Science and Technology, Japan (MEXT)
   [MOST 103-2320-B-038-045-MY3]
FX This study was supported by the Health and Welfare Surcharge on tobacco
   products (MOHW104-TDU-B-212-124-001) and by the Ministry of Science and
   Technology (MOST 103-2320-B-038-045-MY3).
CR Abdelkarim M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023334
   Ayude D, 2003, DIS MARKERS, V19, P267
   Ayukawa T, 2012, P NATL ACAD SCI USA, V109, P15318, DOI 10.1073/pnas.1202369109
   BACUS SS, 1993, CANCER RES, V53, P5251
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Chen LC, 2012, BREAST CANCER RES TR, V134, P989, DOI 10.1007/s10549-012-1986-8
   Chen RJ, 2000, TOXICOL APPL PHARM, V169, P132, DOI 10.1006/taap.2000.9062
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Chou YH, 2007, FOOD CHEM TOXICOL, V45, P1356, DOI 10.1016/j.fct.2007.01.012
   Clarke K, 2000, CLIN CANCER RES, V6, P3621
   delaCadena M, 1996, INT J ONCOL, V9, P747
   Fujita T, 2011, JPN J CLIN ONCOL, V41, P394, DOI 10.1093/jjco/hyq190
   GIARDINA MG, 1992, CANCER, V70, P1044, DOI 10.1002/1097-0142(19920901)70:5<1044::AID-CNCR2820700506>3.0.CO;2-U
   Greene F.L., 2002, AJCC CANC STAGING HD
   Ho YS, 2001, INT J CANCER, V91, P393, DOI 10.1002/1097-0215(200002)9999:9999&lt;::AID-IJC1070&gt;3.0.CO;2-#
   Huang C, 2007, CANCER GENET CYTOGEN, V175, P19, DOI 10.1016/j.cancergencyto.2007.01.003
   Julien S, 2011, CANCER RES, V71, P7683, DOI 10.1158/0008-5472.CAN-11-1139
   Kaklamani Virginia G, 2003, Clin Breast Cancer, V4 Suppl 1, pS26, DOI 10.3816/CBC.2003.s.012
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Koh YW, 2013, AM J CLIN PATHOL, V139, P746, DOI 10.1309/AJCP2E6QNDIDPTTC
   LASFARGUES EY, 1978, J NATL CANCER I, V61, P967
   Lee CH, 2011, BREAST CANCER RES TR, V129, P331, DOI 10.1007/s10549-010-1209-0
   Lee CH, 2010, JNCI-J NATL CANCER I, V102, P1322, DOI 10.1093/jnci/djq300
   Lee WS, 2003, INT J CANCER, V106, P125, DOI 10.1002/ijc.11194
   Lien YC, 2011, ANN SURG ONCOL, V18, P2671, DOI 10.1245/s10434-011-1598-2
   Listinsky JJ, 2011, AM J TRANSL RES, V3, P292
   Liu JJ, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-154
   Liu TW, 2009, P NATL ACAD SCI USA, V106, P14581, DOI 10.1073/pnas.0903286106
   Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108
   Madjd Z, 2005, BREAST CANCER RES, V7, pR780, DOI 10.1186/bcr1305
   Martinez J, 2011, P NATL ACAD SCI USA, V108, P17396, DOI 10.1073/pnas.1113421108
   Milde-Langosch K, 2014, BREAST CANCER RES TR, V145, P295, DOI 10.1007/s10549-014-2949-z
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Paglin S, 2001, CANCER RES, V61, P439
   Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029
   Robles E, 2006, NAT NEUROSCI, V9, P1274, DOI 10.1038/nn1762
   RUSSO J, 1976, J NATL CANCER I, V56, P279, DOI 10.1093/jnci/56.2.279
   Sturla L, 2003, J BIOL CHEM, V278, P26727, DOI 10.1074/jbc.M304068200
   Sun Y, 2009, POSTGRAD MED J, V85, P134, DOI 10.1136/pgmj.2008.072629
   TAKAHASHI H, 1994, HEPATOLOGY, V19, P1414, DOI 10.1002/hep.1840190615
   Tappel A, 2005, MED HYPOTHESES, V64, P288, DOI 10.1016/j.mehy.2004.07.025
   TRAGANOS F, 1994, METHOD CELL BIOL, V41, P185
   Wu YH, 2011, BREAST CANCER RES TR, V127, P397, DOI 10.1007/s10549-010-1013-x
   Yuan K, 2008, PATHOL ONCOL RES, V14, P145, DOI 10.1007/s12253-008-9036-x
   Yuan K, 2008, INT J ONCOL, V32, P797
   Zhou SM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0544-9
NR 48
TC 23
Z9 24
U1 3
U2 16
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 28
PY 2015
VL 6
IS 25
BP 21283
EP 21300
DI 10.18632/oncotarget.4238
PG 18
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CQ9XO
UT WOS:000360969200046
PM 26204487
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Lu, C
   Zhou, DT
   Wang, Q
   Liu, WL
   Yu, FL
   Wu, F
   Chen, C
AF Lu, Can
   Zhou, Danting
   Wang, Qiang
   Liu, Wenliang
   Yu, Fenglei
   Wu, Fang
   Chen, Chen
TI Crosstalk of MicroRNAs and Oxidative Stress in the Pathogenesis of
   Cancer
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; AUTOPHAGIC CELL-DEATH;
   PANCREATIC-CANCER; COLORECTAL-CANCER; GASTRIC-CANCER; INHIBITS
   PROLIFERATION; DOWN-REGULATION; MITOCHONDRIAL METABOLISM; NRF2
   ACTIVATION
AB Oxidative stress refers to an imbalance between reactive oxygen species (ROS) generation and body's capability to detoxify the reactive mediators or to fix the relating damage. MicroRNAs are considered to be important mediators that play essential roles in the regulation of diverse aspects of carcinogenesis. Growing studies have demonstrated that the ROS can regulate microRNA biogenesis and expression mainly through modulating biogenesis course, transcription factors, and epigenetic changes. On the other hand, microRNAs may in turn modulate the redox signaling pathways, altering their integrity, stability, and functionality, thus contributing to the pathogenesis of multiple diseases. Both ROS and microRNAs have been identified to be important regulators and potential therapeutic targets in cancers. However, the information about the interplay between oxidative stress and microRNA regulation is still limited. The present review is aimed at summarizing the current understanding of molecular crosstalk between microRNAs and the generation of ROS in the pathogenesis of cancer.
C1 [Lu, Can] Cent South Univ, Xiangya Hosp, Ctr Stomatol, Changsha 410008, Peoples R China.
   [Zhou, Danting; Wang, Qiang; Liu, Wenliang; Yu, Fenglei; Chen, Chen] Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha 410011, Hunan, Peoples R China.
   [Wu, Fang] Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China.
RP Chen, C (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha 410011, Hunan, Peoples R China.; Wu, F (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Oncol, Changsha 410011, Hunan, Peoples R China.
EM 494801611@qq.com; 16748191@qq.com; rummer925@163.com;
   liuwenliang@csu.edu.cn; dajiubei925@163.com; wufang4461@csu.edu.cn;
   chenchen1981412@hotmail.com
RI chen, chen/M-6561-2017
OI chen, chen/0000-0003-4569-6032
FU China National Natural Science FoundationNational Natural Science
   Foundation of China (NSFC) [81000905, 81902351, 81972638]; Hunan
   Provincial Key Area RD Program [2019SK2253]; Hunan Provincial Natural
   Science FoundationNatural Science Foundation of Hunan Province
   [14JJ4014, 2019JJ50953]; CSCO Cancer Research Foundation
   [CSCO-Y-young2019-034, CSCO-2019Roche-073]
FX This study was funded by the China National Natural Science Foundation
   (No. 81000905, No. 81902351, and No. 81972638), the Hunan Provincial Key
   Area R&D Program (No. 2019SK2253), the Hunan Provincial Natural Science
   Foundation (No. 14JJ4014 and No. 2019JJ50953), and the CSCO Cancer
   Research Foundation (CSCO-Y-young2019-034 and CSCO-2019Roche-073).
CR Ahir M, 2016, BIOMATERIALS, V76, P115, DOI 10.1016/j.biomaterials.2015.10.044
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Ayers D, 2015, J NUCLEIC ACIDS, V2015, DOI 10.1155/2015/143636
   Bakirtzi K, 2011, GASTROENTEROLOGY, V141, P1749, DOI 10.1053/j.gastro.2011.07.038
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012
   Binker-Cosen MJ, 2017, BIOCHEM BIOPH RES CO, V484, P152, DOI 10.1016/j.bbrc.2017.01.051
   Blick C, 2015, BRIT J CANCER, V113, P634, DOI 10.1038/bjc.2015.203
   Braun CJ, 2008, CANCER RES, V68, P10094, DOI 10.1158/0008-5472.CAN-08-1569
   Burchard J, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.58
   Camps C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-28
   Carrer M, 2012, P NATL ACAD SCI USA, V109, P15330, DOI 10.1073/pnas.1207605109
   Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015
   Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chao JL, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5025610
   Chen D, 2015, ONCOTARGET, V6, P32701, DOI 10.18632/oncotarget.4702
   Chen YF, 2019, REDOX BIOL, V22, DOI 10.1016/j.redox.2019.101140
   Chen Z, 2010, ONCOGENE, V29, P4362, DOI 10.1038/onc.2010.193
   Cheng XH, 2013, FREE RADICAL BIO MED, V64, P4, DOI 10.1016/j.freeradbiomed.2013.07.025
   Cross CE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/257090
   Cui YJ, 2016, ONCOL RES, V23, P275, DOI 10.3727/096504016X14562725373798
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495
   Eastlack SC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0851-8
   el Azzouzi H, 2015, TRENDS ENDOCRIN MET, V26, P502, DOI 10.1016/j.tem.2015.06.008
   El Banna N, 2019, REDOX BIOL, V26, DOI 10.1016/j.redox.2019.101290
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Esposti DD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16226-3
   Faller M, 2007, NAT STRUCT MOL BIOL, V14, P23, DOI 10.1038/nsmb1182
   Fan S, 2019, CANCER RES, V79, P1069, DOI 10.1158/0008-5472.CAN-18-2505
   Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345
   Fiori ME, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0080-x
   Fuschi P, 2017, AGING-US, V9, P2559, DOI 10.18632/aging.101341
   Gandhy SU, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-564
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7
   Gu SY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06061-x
   Guo WT, 2019, CELL MOL LIFE SCI, V76, P1697, DOI 10.1007/s00018-019-03020-9
   Guo YM, 2015, EXP CELL RES, V337, P103, DOI 10.1016/j.yexcr.2015.06.021
   Han Y, 2019, ONCOGENE, V38, P7089, DOI 10.1038/s41388-019-0949-5
   Hatley ME, 2010, CANCER CELL, V18, P282, DOI 10.1016/j.ccr.2010.08.013
   He C, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0603-1
   He F, 2015, INT J MOL SCI, V16, P27770, DOI 10.3390/ijms161126059
   He Jun, 2016, Curr Pharmacol Rep, V2, P82
   He J, 2014, ENVIRON HEALTH PERSP, V122, P255, DOI 10.1289/ehp.1307545
   Hong J, 2017, ONCOTARGET, V8, P70967, DOI 10.18632/oncotarget.20235
   Hu HY, 2013, ACTA PHARMACOL SIN, V34, P157, DOI 10.1038/aps.2012.161
   Iqbal MA, 2019, MOL ASPECTS MED, V70, P3, DOI 10.1016/j.mam.2018.07.003
   Irlam-Jones JJ, 2016, BRIT J CANCER, V115, P571, DOI 10.1038/bjc.2016.218
   Itoh K, 2010, ANTIOXID REDOX SIGN, V13, P1665, DOI 10.1089/ars.2010.3222
   Jajoo S, 2013, ANTIOXID REDOX SIGN, V19, P1863, DOI 10.1089/ars.2012.4820
   Janssen AML, 2000, CLIN CANCER RES, V6, P3183
   Jeon YJ, 2015, P NATL ACAD SCI USA, V112, pE3355, DOI 10.1073/pnas.1504630112
   Jia YY, 2016, ONCOTARGET, V7, P35257, DOI 10.18632/oncotarget.9135
   Jin FF, 2019, CANCER LETT, V440, P211, DOI 10.1016/j.canlet.2018.10.025
   Kai AKL, 2016, HEPATOLOGY, V64, P473, DOI 10.1002/hep.28577
   Kao YY, 2019, CANCER LETT, V456, P40, DOI 10.1016/j.canlet.2019.04.028
   Karihtala P, 2019, ONCOLOGY-BASEL, V96, P164, DOI 10.1159/000494274
   Kim B, 2014, CLIN EXP MED, V14, P331, DOI 10.1007/s10238-013-0243-8
   Kim JH, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.219
   Kim J, 2017, FREE RADICAL BIO MED, V104, P185, DOI 10.1016/j.freeradbiomed.2017.01.010
   Kong DJ, 2008, STEM CELLS, V26, P1425, DOI 10.1634/stemcells.2007-1076
   Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101
   Kong YY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1854-0
   Kuosmanen SM, 2018, NUCLEIC ACIDS RES, V46, P1124, DOI 10.1093/nar/gkx1155
   Lan J, 2018, CANCER LETT, V418, P250, DOI 10.1016/j.canlet.2018.01.010
   Lee JH, 2013, PHARMACOL THERAPEUT, V137, P153, DOI 10.1016/j.pharmthera.2012.09.008
   Lei W, 2016, SCI REP-UK, V6, DOI 10.1038/srep32174
   Leisegang MS, 2018, ANTIOXID REDOX SIGN, V29, P793, DOI 10.1089/ars.2017.7276
   Li BW, 2017, MOL THER-NUCL ACIDS, V9, P294, DOI 10.1016/j.omtn.2017.10.008
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li JW, 2014, FEBS LETT, V588, P3491, DOI 10.1016/j.febslet.2014.08.008
   Li SC, 2012, MOL MED REP, V5, P949, DOI 10.3892/mmr.2012.779
   Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014
   Lin JM, 2017, ONCOTARGET, V8, P17328, DOI 10.18632/oncotarget.14461
   Liu L, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.20
   Liu YD, 2019, INT J CANCER, V144, P3056, DOI 10.1002/ijc.32060
   Lou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.27
   Luo MY, 2018, CELL DEATH DIFFER, V25, P1457, DOI 10.1038/s41418-017-0053-8
   Madhyastha R, 2014, BIOCHEM BIOPH RES CO, V451, P615, DOI 10.1016/j.bbrc.2014.08.035
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Melnik BC, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0377-9
   Meng XQ, 2013, GASTROENTEROLOGY, V145, P426, DOI 10.1053/j.gastro.2013.04.004
   Mohammad J, 2019, APOPTOSIS, V24, P730, DOI 10.1007/s10495-019-01553-9
   Mori MA, 2012, CELL METAB, V16, P336, DOI 10.1016/j.cmet.2012.07.017
   Muys BR, 2019, CANCER RES, V79, P3294, DOI 10.1158/0008-5472.CAN-19-0490
   Nakamura T, 2019, BBA-GEN SUBJECTS, V1863, P1398, DOI 10.1016/j.bbagen.2019.06.010
   Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022
   Niu Y, 2018, ONCOGENE, V37, P1743, DOI 10.1038/s41388-017-0082-2
   Orang AV, 2019, MOL METAB, V23, P98, DOI 10.1016/j.molmet.2019.01.014
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Pant K, 2017, REDOX BIOL, V12, P340, DOI 10.1016/j.redox.2017.03.006
   Parvez S, 2018, CHEM REV, V118, P8798, DOI 10.1021/acs.chemrev.7b00698
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Patel GK, 2017, BRIT J CANCER, V116, P609, DOI 10.1038/bjc.2017.18
   Petrelli A, 2014, HEPATOLOGY, V59, P228, DOI 10.1002/hep.26616
   Pogue AI, 2009, J INORG BIOCHEM, V103, P1591, DOI 10.1016/j.jinorgbio.2009.05.012
   Prasad S, 2017, CANCER LETT, V387, P95, DOI 10.1016/j.canlet.2016.03.042
   Pulkkinen KH, 2011, FREE RADICAL BIO MED, V51, P2124, DOI 10.1016/j.freeradbiomed.2011.09.014
   Rezatabar S, 2019, J CELL PHYSIOL, V234, P14951, DOI 10.1002/jcp.28334
   Rowlands DJ, 2011, HYPERTENSION, V57, P833, DOI 10.1161/HYPERTENSIONAHA.110.162198
   Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803
   Saikolappan S, 2019, CANCER LETT, V452, P132, DOI 10.1016/j.canlet.2019.03.020
   Sampath D, 2012, BLOOD, V119, P1162, DOI 10.1182/blood-2011-05-351510
   Seok JK, 2014, NUCLEIC ACIDS RES, V42, P8062, DOI 10.1093/nar/gku515
   Shang YY, 2017, EXP CELL RES, V360, P243, DOI 10.1016/j.yexcr.2017.09.014
   Shi CZ, 2016, GUT, V65, P1470, DOI 10.1136/gutjnl-2014-308455
   Singh A, 2013, J CLIN INVEST, V123, P2921, DOI 10.1172/JCI66353
   Singh B, 2013, CARCINOGENESIS, V34, P1165, DOI 10.1093/carcin/bgt026
   Singh R, 2015, SCI REP-UK, V5, DOI 10.1038/srep17454
   Sun J, 2019, ONCOGENE, V38, P564, DOI 10.1038/s41388-018-0459-x
   Tagscherer KE, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0321-6
   Taguchi K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00085
   Tong LY, 2015, CANCER LETT, V367, P18, DOI 10.1016/j.canlet.2015.07.008
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Tu HL, 2014, CURR PHARM DESIGN, V20, P1917, DOI 10.2174/13816128113199990547
   Ungvari Z, 2013, J GERONTOL A-BIOL, V68, P877, DOI 10.1093/gerona/gls242
   Ungvari Z, 2010, AM J PHYSIOL-HEART C, V299, pH18, DOI 10.1152/ajpheart.00260.2010
   Upadhyay P, 2019, BIOMATER SCI-UK, V7, P4325, DOI 10.1039/c9bm00912d
   Venkataraman S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010748
   Wang HP, 2014, NAT IMMUNOL, V15, P393, DOI 10.1038/ni.2846
   Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006
   Wang K, 2019, TRENDS BIOCHEM SCI, V44, P401, DOI 10.1016/j.tibs.2019.01.001
   Wang P, 2015, ONCOTARGET, V6, P21148, DOI 10.18632/oncotarget.4125
   Wang Q, 2014, J BIOL CHEM, V289, P5654, DOI 10.1074/jbc.M113.526152
   Wang T, 2017, ONCOGENE, V36, P3240, DOI 10.1038/onc.2016.468
   Wei J, 2014, FREE RADICAL BIO MED, V67, P91, DOI 10.1016/j.freeradbiomed.2013.10.811
   Wilczynska A, 2015, CELL DEATH DIFFER, V22, P22, DOI 10.1038/cdd.2014.112
   Wong CCL, 2014, HEPATOLOGY, V60, P1645, DOI 10.1002/hep.27320
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Wu SJ, 2019, CANCER MED-US, V8, P2252, DOI 10.1002/cam4.2101
   Xiao FJ, 2019, BIOCHEM BIOPH RES CO, V515, P448, DOI 10.1016/j.bbrc.2019.05.147
   Xiao YT, 2015, CELL CYCLE, V14, P1548, DOI 10.1080/15384101.2015.1026491
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Xu Q, 2015, ONCOGENE, V34, P5482, DOI 10.1038/onc.2015.6
   Xu Z, 2018, MOL THER-NUCL ACIDS, V13, P64, DOI 10.1016/j.omtn.2018.08.009
   Xue D, 2016, ONCOTARGET, V7, P78804, DOI [10.18632/oncotarget.12972, 10.18632/oncotarget.12860]
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
   Yan KW, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1734-7
   Yang HP, 2011, GASTROENTEROLOGY, V141, P378, DOI 10.1053/j.gastro.2011.03.044
   Yang MH, 2011, BREAST CANCER RES TR, V129, P983, DOI 10.1007/s10549-011-1604-1
   Yang SB, 2018, EXP CELL RES, V370, P31, DOI 10.1016/j.yexcr.2018.06.001
   Yang WS, 2016, TRENDS CELL BIOL, V26, P165, DOI 10.1016/j.tcb.2015.10.014
   Ye MX, 2015, CANCER LETT, V357, P196, DOI 10.1016/j.canlet.2014.11.028
   Yeh YM, 2013, INT J CANCER, V133, P867, DOI 10.1002/ijc.28086
   Yin Y, 2018, ONCOL REP, V40, P3479, DOI 10.3892/or.2018.6772
   You BR, 2017, MOL CARCINOGEN, V56, P2566, DOI 10.1002/mc.22701
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yuan P, 2017, CANCER RES, V77, P100, DOI 10.1158/0008-5472.CAN-16-1898
   Yue H, 2019, EXP THER MED, V17, P2359, DOI 10.3892/etm.2019.7213
   Yue ZJ, 2017, LEUKEMIA RES, V60, P115, DOI 10.1016/j.leukres.2017.07.003
   Zhang BL, 2019, CANCER LETT, V459, P50, DOI 10.1016/j.canlet.2019.05.042
   Zhang HF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.180
   Zhang KX, 2018, MOL CARCINOGEN, V57, P1566, DOI 10.1002/mc.22878
   Zhang L, 2013, CANCER LETT, V331, P230, DOI 10.1016/j.canlet.2013.01.003
   Zhang XM, 2012, CANCER RES, V72, P4707, DOI 10.1158/0008-5472.CAN-12-0639
   Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003
   Zhu S, 2016, MOL CANCER THER, V15, P2209, DOI 10.1158/1535-7163.MCT-15-0877
   2019, CELLS-BASEL, V8, DOI DOI 10.3390/CELLS8080874
NR 159
TC 15
Z9 15
U1 5
U2 9
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD APR 28
PY 2020
VL 2020
AR 2415324
DI 10.1155/2020/2415324
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LN9WY
UT WOS:000533282500002
PM 32411322
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Mi, YJ
   Geng, GJ
   Zou, ZZ
   Gao, J
   Luo, XY
   Liu, Y
   Li, N
   Li, CL
   Chen, YQ
   Yu, XY
   Jiang, J
AF Mi, Yan-jun
   Geng, Guo-jun
   Zou, Zheng-zhi
   Gao, Jing
   Luo, Xian-yang
   Liu, Yu
   Li, Ning
   Li, Chun-lei
   Chen, Yu-qiang
   Yu, Xiu-yi
   Jiang, Jie
TI Dihydroartemisinin Inhibits Glucose Uptake and Cooperates with
   Glycolysis Inhibitor to Induce Apoptosis in Non-Small Cell Lung
   Carcinoma Cells
SO PLOS ONE
LA English
DT Article
ID COLORECTAL-CANCER CELLS; MAMMALIAN TARGET; METABOLISM; EXPRESSION; MTOR;
   RESISTANCE; AUTOPHAGY; GROWTH
AB Despite recent advances in the therapy of non-small cell lung cancer (NSCLC), the chemotherapy efficacy against NSCLC is still unsatisfactory. Previous studies show the herbal antimalarial drug dihydroartemisinin (DHA) displays cytotoxic to multiple human tumors. Here, we showed that DHA decreased cell viability and colony formation, induced apoptosis in A549 and PC-9 cells. Additionally, we first revealed DHA inhibited glucose uptake in NSCLC cells. Moreover, glycolytic metabolism was attenuated by DHA, including inhibition of ATP and lactate production. Consequently, we demonstrated that the phosphorylated forms of both S6 ribosomal protein and mechanistic target of rapamycin (mTOR), and GLUT1 levels were abrogated by DHA treatment in NSCLC cells. Furthermore, the upregulation of mTOR activation by high expressed Rheb increased the level of glycolytic metabolism and cell viability inhibited by DHA. These results suggested that DHA-suppressed glycolytic metabolism might be associated with mTOR activation and GLUT1 expression. Besides, we showed GLUT1 overexpression significantly attenuated DHA-triggered NSCLC cells apoptosis. Notably, DHA synergized with 2-Deoxy-D-glucose (2DG, a glycolysis inhibitor) to reduce cell viability and increase cell apoptosis in A549 and PC-9 cells. However, the combination of the two compounds displayed minimal toxicity to WI-38 cells, a normal lung fibroblast cell line. More importantly, 2DG synergistically potentiated DHA-induced activation of caspase-9, -8 and -3, as well as the levels of both cytochrome c and AIF of cytoplasm. However, 2DG failed to increase the reactive oxygen species (ROS) levels elicited by DHA. Overall, the data shown above indicated DHA plus 2DG induced apoptosis was involved in both extrinsic and intrinsic apoptosis pathways in NSCLC cells.
C1 [Mi, Yan-jun; Geng, Guo-jun; Liu, Yu; Li, Ning; Li, Chun-lei; Yu, Xiu-yi; Jiang, Jie] Xiamen Univ, Affiliated Hosp 1, Dept Thorac Surg, Xiamen, Peoples R China.
   [Mi, Yan-jun; Chen, Yu-qiang] Xiamen Univ, Chenggong Hosp, Dept Med Oncol, Xiamen, Peoples R China.
   [Zou, Zheng-zhi] S China Normal Univ, Coll Biophoton, MOE Key Lab Laser Life Sci, Guangzhou, Guangdong, Peoples R China.
   [Zou, Zheng-zhi] S China Normal Univ, Coll Biophoton, Inst Laser Life Sci, Guangzhou, Guangdong, Peoples R China.
   [Gao, Jing; Luo, Xian-yang] Xiamen Univ, Affiliated Hosp 1, Dept Head & Neck Surg, Xiamen, Peoples R China.
RP Yu, XY (corresponding author), Xiamen Univ, Affiliated Hosp 1, Dept Thorac Surg, Xiamen, Peoples R China.
EM Xiuyiyu@126.com; Jiejiangfy@163.com
FU Postdoctoral Science Foundation of ChinaChina Postdoctoral Science
   Foundation [2014M561853]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81402187];
   South China Normal University Science Fund for Young Scholars [670325];
   Fujian Provincial Department of Science Technology [2014D020]; Fujian
   Provincial Department of Health [wzhw201304, wst201214]
FX This study was supported by grants from the Postdoctoral Science
   Foundation of China (No. 2014M561853 to YJM), the National Natural
   Science Foundation of China (No. 81402187 to ZZZ), the South China
   Normal University Science Fund for Young Scholars (No. 670325 to ZZZ),
   the Fujian Provincial Department of Science & Technology (No. 2014D020
   to JJ) and Fujian Provincial Department of Health (wzhw201304,
   wst201214). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ariffin AB, 2014, CANCER RES, V74, P2655, DOI 10.1158/0008-5472.CAN-13-3696
   Ben Sahra I, 2010, AUTOPHAGY, V6, P670, DOI 10.4161/auto.6.5.12434
   Buller CL, 2008, AM J PHYSIOL-CELL PH, V295, pC836, DOI 10.1152/ajpcell.00554.2007
   Cai Y, 2014, J OBSTET GYNAECOL RE, V40, P1925, DOI 10.1111/jog.12447
   Chen H, 2010, J CANCER RES CLIN, V136, P897, DOI 10.1007/s00432-009-0731-0
   Chen TS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059827
   Cheng SC, 2014, SCIENCE, V345, P1579, DOI 10.1126/science.1250684
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Cornu M, 2013, CURR OPIN GENET DEV, V23, P53, DOI 10.1016/j.gde.2012.12.005
   Disbrow GL, 2005, CANCER RES, V65, P10854, DOI 10.1158/0008-5472.CAN-05-1216
   Dodson M, 2013, AUTOPHAGY, V9, P1996, DOI 10.4161/auto.26094
   El Mjiyad N, 2011, ONCOGENE, V30, P253, DOI 10.1038/onc.2010.466
   Feng X, 2014, BIOCHEM BIOPH RES CO, V444, P376, DOI 10.1016/j.bbrc.2014.01.053
   Handrick R, 2010, MOL CANCER THER, V9, P2497, DOI 10.1158/1535-7163.MCT-10-0051
   He Q, 2010, CANCER BIOL THER, V9, P819, DOI 10.4161/cbt.9.10.11552
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Kim SM, 2013, MOL CANCER THER, V12, P2145, DOI 10.1158/1535-7163.MCT-12-1188
   Kong R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037222
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li X, 2006, INT J MOL SCI, V7, P59, DOI 10.3390/i7020059
   Liu T, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.493
   Lou YF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097719
   Lu M, 2014, TUMOR BIOL, V35, P5307, DOI 10.1007/s13277-014-1691-9
   Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123
   Odaka Y, 2014, CARCINOGENESIS, V35, P192, DOI 10.1093/carcin/bgt277
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Rashmi R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092948
   Shackelford DB, 2013, CANCER CELL, V23, P143, DOI 10.1016/j.ccr.2012.12.008
   Takanaga H, 2010, FASEB J, V24, P2849, DOI 10.1096/fj.09-146472
   Vuyyuri SB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067081
   Wang QL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017234
   Wang SJ, 2011, CANCER CHEMOTH PHARM, V68, P1421, DOI 10.1007/s00280-011-1643-7
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wu GS, 2013, PHARMACOL REP, V65, P453, DOI 10.1016/S1734-1140(13)71021-1
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Zhang CZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039870
   Zhang SQ, 2014, ONCOL LETT, V7, P1375, DOI 10.3892/ol.2014.1918
   Zhang T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080544
   Zhao CB, 2014, APOPTOSIS, V19, P668, DOI 10.1007/s10495-013-0953-0
   Zhao YG, 2012, J IMMUNOL, V189, P4417, DOI 10.4049/jimmunol.1200919
   Zhou HJ, 2010, CANCER CHEMOTH PHARM, V66, P21, DOI 10.1007/s00280-009-1129-z
   Zhu H, 2014, FREE RADICAL BIO MED, V71, P121, DOI 10.1016/j.freeradbiomed.2014.03.026
   Zou ZZ, 2012, AUTOPHAGY, V8, P1798, DOI 10.4161/auto.22110
NR 43
TC 40
Z9 43
U1 1
U2 34
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 23
PY 2015
VL 10
IS 3
AR e0120426
DI 10.1371/journal.pone.0120426
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE6ZS
UT WOS:000351987300142
PM 25799586
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Giuliano, S
   Pages, G
AF Giuliano, Sandy
   Pages, Gilles
TI Mechanisms of resistance to anti-angiogenesis therapies
SO BIOCHIMIE
LA English
DT Review
DE Anti-angiogenesis; Resistance; Targeted therapies; Predictive markers;
   Autophagy
ID ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; TYROSINE KINASE
   INHIBITOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; BEVACIZUMAB PLUS
   IRINOTECAN; MARROW-DERIVED CELLS; CANCER STEM-CELLS; PHASE-II TRIAL;
   BREAST-CANCER; TUMOR ANGIOGENESIS
AB Angiogenesis, the formation of new blood vessels from preexisting ones, provides oxygen and nutrients to actively proliferating tumor cells. Hence, it represents a critical aspect of tumor progression and metastasis. Because inhibition of angiogenesis represents a major approach to cancer treatment, the development of inhibitors of angiogenesis is a major challenge. The first FDA approved anti-angiogenic drug bevacizumab, a humanized monoclonal antibody directed against the Vascular Endothelial Growth Factor (VEGF), has been approved for the treatment of metastatic colorectal, lung, breast, and kidney cancers. The encouraging results have lead to the development, in the past few years, of other agents targeting angiogenic pathways as potent anti-cancer drugs and a number of them have been approved for metastatic breast, lung, kidney, and central nervous system cancers. Despite a statistically significant increase in progression free survival, which has accelerated FDA approval, no major benefit to overall survival was described and patients inevitably relapsed due to acquired resistance. However, while progression free survival was increased by only a few months for the majority of the patients, some clearly benefited from the treatment with a real increase in life span. The objective of this review is to present an overview of the different treatments targeting angiogenesis, their efficacy and the mechanisms of resistance that have been identified in different cancer types. It is essential to understand how resistance (primary or acquired over time) develops and how it may be overcome. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Giuliano, Sandy; Pages, Gilles] Univ Nice Sophia Antipolis, IRCAN, CNRS, U7284,INSERM,U1081, F-06189 Nice, France.
RP Pages, G (corresponding author), Univ Nice Sophia Antipolis, IRCAN, CNRS, U7284,INSERM,U1081, 33 Ave Valombrose, F-06189 Nice, France.
EM gpages@unice.fr
RI Pages, Gilles/N-7135-2017; Giuliano, Sandy/U-2498-2019
FU Institut National pour la Sante et la Recherche Medicale
   (INSERM)Institut National de la Sante et de la Recherche Medicale
   (Inserm); Centre National de la Recherche Scientifique (CNRS)Centre
   National de la Recherche Scientifique (CNRS); National Institute of
   Cancer (INCA)Institut National du Cancer (INCA) France; Association for
   Cancer Research (ARC); Fondation de FranceFondation de France; Fondation
   pour la Recherche Medicale (FRM)Fondation pour la Recherche Medicale;
   Association pour la Recherche sur les Tumeurs du Rein (ARTuR); ROCHE
   FranceRoche Holding
FX This work was supported by the Institut National pour la Sante et la
   Recherche Medicale (INSERM) and the Centre National de la Recherche
   Scientifique (CNRS). This work was supported by the National Institute
   of Cancer (INCA), the Association for Cancer Research (ARC), the
   Fondation de France, the Fondation pour la Recherche Medicale (FRM), the
   "Association pour la Recherche sur les Tumeurs du Rein (ARTuR)" and
   ROCHE France. We thank Dr M Christiane Brahimi-Horn for editorial
   assistance.
CR Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Aghi M, 2005, MOL THER, V12, P994, DOI 10.1016/j.ymthe.2005.07.693
   Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855
   Allen E, 2011, CLIN CANCER RES, V17, P5299, DOI 10.1158/1078-0432.CCR-10-2847
   Almog N, 2010, CANCER LETT, V294, P139, DOI 10.1016/j.canlet.2010.03.004
   Ansell SM, 2011, LANCET ONCOL, V12, P361, DOI 10.1016/S1470-2045(11)70062-6
   Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Bates DO, 2002, CANCER RES, V62, P4123
   Baumann KH, 2012, ANN ONCOL, V23, P2265, DOI 10.1093/annonc/mds003
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Calvani M, 2006, BLOOD, V107, P2705, DOI 10.1182/blood-2005-09-3541
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Cascone T, 2011, J CLIN INVEST, V121, P1313, DOI 10.1172/JCI42405
   Catena R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-320
   Cheng WL, 2011, ANN ONCOL, V22, P2267, DOI 10.1093/annonc/mdq739
   Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109
   Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004
   de Gramont A, 2012, LANCET ONCOL, V13, P1225, DOI 10.1016/S1470-2045(12)70509-0
   de Groot J, 2012, ONCOTARGET, V3, P1036
   de Oliveira RL, 2011, MOL ASPECTS MED, V32, P71, DOI 10.1016/j.mam.2011.04.001
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140-6736(07)61904-7
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Escudier B, 2010, J CLIN ONCOL, V28, P2144, DOI 10.1200/JCO.2009.26.7849
   Escudier B, 2009, J CLIN ONCOL, V27, P4068, DOI 10.1200/JCO.2008.20.5476
   Favaro E, 2008, APMIS, V116, P648, DOI 10.1111/j.1600-0463.2008.01025.x
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Gerber HP, 2005, CANCER RES, V65, P671
   Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397
   Gotink KJ, 2011, CLIN CANCER RES, V17, P7337, DOI 10.1158/1078-0432.CCR-11-1667
   Grepin R, 2012, ONCOGENE, V31, P1683, DOI 10.1038/onc.2011.360
   GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915
   Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036
   Hammers HJ, 2010, MOL CANCER THER, V9, P1525, DOI 10.1158/1535-7163.MCT-09-1106
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Harris S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035231
   Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092-8674(02)00754-7
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Indelicato M, 2010, J CELL PHYSIOL, V223, P359, DOI 10.1002/jcp.22041
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368
   Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kim Y.J., 2012, INT J CANC
   Konings IRHM, 2009, CURR CANCER DRUG TAR, V9, P439, DOI 10.2174/156800909788166556
   Kopp HG, 2006, J CLIN INVEST, V116, P3277, DOI 10.1172/JCI29314
   Kreisl TN, 2009, J CLIN ONCOL, V27, P740, DOI 10.1200/JCO.2008.16.3055
   Lacal PM, 2005, INT J ONCOL, V27, P1625
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001
   Ledermann JA, 2011, J CLIN ONCOL, V29, P3798, DOI 10.1200/JCO.2010.33.5208
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194
   Machiels JPH, 2010, J CLIN ONCOL, V28, P21, DOI 10.1200/JCO.2009.23.8584
   Mackay HJ, 2010, GYNECOL ONCOL, V116, P163, DOI 10.1016/j.ygyno.2009.08.012
   MacKenzie MJ, 2011, ANN ONCOL, V22, P145, DOI 10.1093/annonc/mdq320
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Matei D, 2011, J CLIN ONCOL, V29, P69, DOI 10.1200/JCO.2009.26.7856
   Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109
   Mendel DB, 2003, CLIN CANCER RES, V9, P327
   Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165
   Miles D, 2011, J CLIN ONCOL, V29, P83, DOI 10.1200/JCO.2010.30.2794
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Moccia F., 2012, CURR VASC PHARM
   Montero AJ, 2012, CURR ONCOL REP, V14, P1, DOI 10.1007/s11912-011-0202-z
   Moserle L, 2009, CURR MOL MED, V9, P935, DOI 10.2174/156652409789712800
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   Motzer RJ, 2006, J CLIN ONCOL, V24, P5601, DOI 10.1200/JCO.2006.08.5415
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Nagengast WB, 2011, CANCER RES, V71, P143, DOI 10.1158/0008-5472.CAN-10-1088
   Naumov GN, 2003, BREAST CANCER RES TR, V82, P199, DOI 10.1023/B:BREA.0000004377.12288.3c
   Norden-Zfoni A, 2007, CLIN CANCER RES, V13, P2643, DOI 10.1158/1078-0432.CCR-06-0919
   Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200
   OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Patel Purvi, 2012, Front Endocrinol (Lausanne), V3, P125, DOI 10.3389/fendo.2012.00125
   Perren TJ, 2011, NEW ENGL J MED, V365, P2484, DOI 10.1056/NEJMoa1103799
   Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234
   Prior JO, 2009, J CLIN ONCOL, V27, P439, DOI 10.1200/JCO.2008.17.2742
   Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925
   Rajantie I, 2004, BLOOD, V104, P2084, DOI 10.1182/blood-2004-01-0336
   Rak J, 2000, CANCER RES, V60, P490
   Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51
   Raymond E, 2011, NEW ENGL J MED, V364, P501, DOI 10.1056/NEJMoa1003825
   Relf M, 1997, CANCER RES, V57, P963
   Rini BI, 2011, JNCI-J NATL CANCER I, V103, P763, DOI 10.1093/jnci/djr128
   Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884
   Schneider BP, 2008, J CLIN ONCOL, V26, P4672, DOI 10.1200/JCO.2008.16.1612
   Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240
   Seto T, 2006, LUNG CANCER-J IASLC, V53, P91, DOI 10.1016/j.lungcan.2006.02.009
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Shojaei F, 2012, CANCER LETT, V320, P48, DOI 10.1016/j.canlet.2012.01.026
   Shojaei F, 2009, P NATL ACAD SCI USA, V106, P6742, DOI 10.1073/pnas.0902280106
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   Smith I, 2011, BREAST CANCER RES TR, V130, P133, DOI 10.1007/s10549-011-1695-8
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Sosa MS, 2013, ADV EXP MED BIOL, V734, P73, DOI 10.1007/978-1-4614-1445-2_5
   Sosa MS, 2011, CLIN CANCER RES, V17, P5850, DOI 10.1158/1078-0432.CCR-10-2574
   Sullivan R, 2007, CANCER METAST REV, V26, P319, DOI 10.1007/s10555-007-9062-2
   Taylor M, 2012, CANCER DISCOV, V2, P434, DOI 10.1158/2159-8290.CD-11-0171
   Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337
   van den Beucken T, 2006, CANCER BIOL THER, V5, P749, DOI 10.4161/cbt.5.7.2972
   Vandercappellen J, 2008, CANCER LETT, V267, P226, DOI 10.1016/j.canlet.2008.04.050
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Varney ML, 2006, AM J CLIN PATHOL, V125, P209, DOI 10.1309/VPL5R.JR7F1D6V03
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Willett CG, 2005, J CLIN ONCOL, V23, P8136, DOI 10.1200/JCO.2005.02.5635
   Williamson SK, 2010, J CLIN ONCOL, V28, P3330, DOI 10.1200/JCO.2009.25.6834
   Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011
   Woolard J, 2009, MICROCIRCULATION, V16, P572, DOI 10.1080/10739680902997333
   Xia GB, 2006, J UROLOGY, V175, P1245, DOI 10.1016/S0022-5347(05)00736-6
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   Yeung David T., 2012, Critical Reviews in Oncogenesis, V17, P17
   Yu K, 2010, CANCER RES, V70, P621, DOI 10.1158/0008-5472.CAN-09-2340
   Zhong H, 2000, CANCER RES, V60, P1541
   Zuniga RM, 2009, J NEURO-ONCOL, V91, P329, DOI 10.1007/s11060-008-9718-y
NR 133
TC 92
Z9 96
U1 0
U2 68
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0300-9084
EI 1638-6183
J9 BIOCHIMIE
JI Biochimie
PD JUN
PY 2013
VL 95
IS 6
BP 1110
EP 1119
DI 10.1016/j.biochi.2013.03.002
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 152QO
UT WOS:000319546400004
PM 23507428
DA 2022-04-25
ER

PT J
AU Sachdeva, UM
   Thompson, CB
AF Sachdeva, Uma M.
   Thompson, Craig B.
TI Diurnal rhythms of autophagy - Implications for cell biology and human
   disease
SO AUTOPHAGY
LA English
DT Review
DE autophagy; diurnal; circadian; fasting; metabolic cycle; insulin;
   glucagon
ID GLUCAGON-INDUCED AUTOPHAGY; CIRCADIAN GENE-EXPRESSION; LIFE-SPAN
   EXTENSION; RAT-LIVER; VISUAL CELLS; AEROBIC GLYCOLYSIS;
   PERIPHERAL-TISSUES; COLORECTAL-CANCER; TERM STARVATION; METABOLIC CYCLE
AB Autophagy is a key mechanism for cell survival under conditions of nutrient limitation. On the organismal level, autophagy is essential for survival of lower eukaryotes during extended periods of starvation, and it is induced in mammals during short-term starvation. As a consequence of the induction of autophagy during short periods of fasting, animals experience diurnal rhythms of autophagy in concert with their circadian cycle. Autophagy has also been identified as a component of the metabolic cycle of yeast, an ultradian rhythm that bears many similarities to the circadian rhythm of plants, flies and mammals. The circadian clock, which is present in almost all mammalian cell types studied to date, temporally regulates expression of multiple genes, gating cell processes such as nutrient uptake, glycolysis and proliferation, to particular times of day. Whether the circadian clock directly regulates autophagy in mammalian cells, or whether autophagy may play a role in the cycling of mammalian cell clocks is not yet clear. Nevertheless, the relationship between circadian cycles and autophagy is an intriguing area for future study and has implications for multiple human diseases, including aging, neurodegeneration and cancer.
C1 [Sachdeva, Uma M.; Thompson, Craig B.] Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA.
RP Thompson, CB (corresponding author), Univ Penn, Sch Med, Dept Canc Biol, Abramson Family Canc Res Inst, 1600 Penn Tower,3400 Spruce St, Philadelphia, PA 19104 USA.
EM craig@mail.med.upenn.edu
CR Alessi DR, 1998, BBA-MOL CELL BIOL L, V1436, P151, DOI 10.1016/S0005-2760(98)00133-7
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   AMHERDT M, 1974, J CLIN INVEST, V54, P188, DOI 10.1172/JCI107742
   ARSTILA AU, 1968, AM J PATHOL, V53, P687
   Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344
   Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X
   Barata JT, 2004, J EXP MED, V200, P659, DOI 10.1084/jem.20040789
   Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje
   Bentley J, 2003, J BIOL CHEM, V278, P39337, DOI 10.1074/jbc.M305689200
   BERGAMINI E, 1994, AM J PHYSIOL, V266, pG118, DOI 10.1152/ajpgi.1994.266.1.G118
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Buzzai M, 2005, ONCOGENE, V24, P4165, DOI 10.1038/sj.onc.1208622
   Cataldo AM, 1996, J NEUROSCI, V16, P186
   Chen Z, 2007, SCIENCE, V316, P1916, DOI 10.1126/science.1140958
   Cure H, 2002, J CLIN ONCOL, V20, P1175, DOI 10.1200/JCO.20.5.1175
   Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500
   DETER RL, 1971, J CELL BIOL, V48, P473, DOI 10.1083/jcb.48.3.473
   DETER RL, 1975, EXP CELL RES, V94, P122, DOI 10.1016/0014-4827(75)90538-8
   DETER RL, 1975, EXP CELL RES, V94, P127, DOI 10.1016/0014-4827(75)90539-X
   DETER RL, 1967, J CELL BIOL, V35, pC11, DOI 10.1083/jcb.35.2.C11
   DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437
   DEWAAL EJ, 1986, CELL TISSUE RES, V243, P641, DOI 10.1007/BF00218073
   Edinger AL, 2003, DEV CELL, V5, P571, DOI 10.1016/S1534-5807(03)00291-0
   Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904
   Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270
   Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3
   Gery S, 2006, MOL CELL, V22, P375, DOI 10.1016/j.molcel.2006.03.038
   Gery S, 2005, BLOOD, V106, P2827, DOI 10.1182/blood-2005-01-0358
   Giacchetti S, 2006, J CLIN ONCOL, V24, P3562, DOI 10.1200/JCO.2006.06.1440
   Harper DG, 2005, AM J GERIAT PSYCHIAT, V13, P359, DOI 10.1176/appi.ajgp.13.5.359
   HUTSON NJ, 1982, J BIOL CHEM, V257, P9548
   Ishioka K, 2005, VET J, V169, P85, DOI 10.1016/j.tvjl.2004.01.003
   Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989
   Kalamidas SA, 2000, HISTOL HISTOPATHOL, V15, P1011, DOI 10.14670/HH-15.1011
   Kamada Y, 2003, CURR TOP MICROBIOL, V279, P73
   Keegan KP, 2007, PLOS COMPUT BIOL, V3, P2087, DOI 10.1371/journal.pcbi.0030208
   Ko CH, 2006, HUM MOL GENET, V15, pR271, DOI 10.1093/hmg/ddl207
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lakowski B, 1998, P NATL ACAD SCI USA, V95, P13091, DOI 10.1073/pnas.95.22.13091
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lum JJ, 2005, NAT REV MOL CELL BIO, V6, P439, DOI 10.1038/nrm1660
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   McDonald MJ, 2001, CELL, V107, P567, DOI 10.1016/S0092-8674(01)00545-1
   Melendez A, 2003, SCIENCE, V301, P1387, DOI 10.1126/science.1087782
   Merl V, 2004, METABOLISM, V53, P1449, DOI 10.1016/j.metabol.2004.06.012
   Misset JL, 2000, SEMIN ONCOL, V27, P78
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Moreira PI, 2007, AUTOPHAGY, V3, P614, DOI 10.4161/auto.4872
   MORTIMORE GE, 1983, P NATL ACAD SCI-BIOL, V80, P2179, DOI 10.1073/pnas.80.8.2179
   MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0
   MULLER OM, 1985, SCAND J GASTROENTERO, V20, P12
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Otto GP, 2004, J BIOL CHEM, V279, P15621, DOI 10.1074/jbc.M311139200
   Otto GP, 2003, J BIOL CHEM, V278, P17636, DOI 10.1074/jbc.M212467200
   Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   PFEIFER U, 1978, J CELL BIOL, V78, P152, DOI 10.1083/jcb.78.1.152
   PFEIFER U, 1977, ACTA BIOL MED GER, V36, P1691
   PFEIFER U, 1981, J MOL CELL CARDIOL, V13, P37, DOI 10.1016/0022-2828(81)90227-3
   PFEIFER U, 1977, VIRCHOWS ARCH B, V24, P109
   PFEIFER U, 1973, VIRCHOWS ARCH B, V12, P195
   PFEIFER U, 1972, VIRCHOWS ARCH B, V10, P1
   PFEIFER U, 1975, J CELL BIOL, V64, P608, DOI 10.1083/jcb.64.3.608
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   REME C, 1985, J COMP PHYSIOL A, V156, P669, DOI 10.1007/BF00619116
   REME CE, 1977, A GRAEF ARCH KLIN EX, V203, P261, DOI 10.1007/BF00409832
   REME CE, 1977, INVEST OPHTH VIS SCI, V16, P807
   Reme CE, 1999, INVEST OPHTH VIS SCI, V40, P2398
   REME CE, 1977, INVEST OPHTH VIS SCI, V16, P815
   Schernhammer ES, 2001, J NATL CANCER I, V93, P1563, DOI 10.1093/jnci/93.20.1563
   Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   SCHIAFFINO S, 1972, J CELL BIOL, V52, P41, DOI 10.1083/jcb.52.1.41
   SCHWORER CM, 1979, P NATL ACAD SCI USA, V76, P3169, DOI 10.1073/pnas.76.7.3169
   TATE B, 1992, P NATL ACAD SCI USA, V89, P7090, DOI 10.1073/pnas.89.15.7090
   TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E
   Tu BP, 2007, P NATL ACAD SCI USA, V104, P16886, DOI 10.1073/pnas.0708365104
   Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499
   Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001
   Yu WH, 2005, J CELL BIOL, V171, P87, DOI 10.1083/jcb.200505082
   Yue ZY, 2003, P NATL ACAD SCI USA, V100, P15077, DOI 10.1073/pnas.2436255100
NR 84
TC 41
Z9 43
U1 1
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JUL 1
PY 2008
VL 4
IS 5
BP 581
EP 589
DI 10.4161/auto.6141
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 325NW
UT WOS:000257596600007
PM 18437053
OA Bronze
DA 2022-04-25
ER

PT J
AU Kutikhin, AG
AF Kutikhin, Anton G.
TI Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology
SO HUMAN IMMUNOLOGY
LA English
DT Article
DE NOD1/CARD4; NOD2/CARD15; Single nucleotide polymorphisms; Cancer;
   Inflammation
ID INFLAMMATORY-BOWEL-DISEASE; TOLL-LIKE RECEPTORS; INTESTINAL
   EPITHELIAL-CELLS; NON-HODGKIN-LYMPHOMA; FACTOR-KAPPA-B; NOD2 3020INSC
   MUTATION; INNATE IMMUNE-RESPONSE; CROHNS-DISEASE; COLORECTAL-CANCER;
   NUCLEOTIDE-BINDING
AB NOD1/CARD4 and NOD2/CARD15 are members of Nod-like receptor family. They are located in cytosol, bind bacterial and viral ligands and play a key role in realization of innate and adaptive immune response, apoptosis, autophagy, and reactive oxygen species generation. Polymorphisms in NOD1/CARD4 and NOD2/CARD15 genes may shift balance between pro- and anti-inflammatory cytokines, modulating the risk of infection, chronic inflammation and cancer. NOD1/CARD4 and NOD2/CARD15 gene polymorphisms may be associated with altered risk of gastric, colorectal, breast, ovarian, prostate, testicular, lung, laryngeal, liver, gallbladder, biliary tract, pancreatic, small bowel, kidney, urinary bladder cancer, skin cancer, nonthyroid endocrine tumors, lymphoma and leukemia. The short list of such polymorphisms perspective for oncogenomic investigations may include rs2006847, rs2066845, rs2066844, rs2066842, ND(1)+32656, rs2075820 whereas rs104895493, rs104895476, rs104895475, rs104895474, rs104895473, rs104895472, rs104895462, rs104895461, rs104895460, rs104895438, rs5743291, rs5743260, rs2076756, rs2066843, Pro371Thr, Ala794Pro, Gln908His, rs72551113, rs72551107, rs6958571, rs2907749, rs2907748, rs2075822, rs2075819, rs2075818 may be added to the extended list. Reasons of discrepancies between different studies include confounding host genetic, bacterial, or environmental factors modulating penetrance of variant allele and affecting risk of condition increasing cancer risk, different bacterial impact in aetiology of such conditions, differences in sample size, clinicopathological characteristics, diagnostics, stratification, genotyping methods, and chance. (C) 2011 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.
C1 [Kutikhin, Anton G.] Kemerovo State Med Acad, Dept Epidemiol, Kemerovo, Russia.
   [Kutikhin, Anton G.] Kemerovo State Med Acad, Cent Res Lab, Kemerovo, Russia.
RP Kutikhin, AG (corresponding author), Kemerovo State Med Acad, Dept Epidemiol, Kemerovo, Russia.
EM antonkutikhin@gmail.com
RI Kutikhin, Anton/B-9397-2012; Kutikhin, Anton G/H-6439-2017
OI Kutikhin, Anton/0000-0001-8679-4857; Kutikhin, Anton
   G/0000-0001-8679-4857
CR Alhopuro P, 2004, CANCER RES, V64, P7245, DOI 10.1158/0008-5472.CAN-04-2364
   Andruilli A, 2004, GASTROENTEROLOGY, V126, P625, DOI 10.1053/j.gastro.2003.12.027
   Angeletti S, 2009, HUM IMMUNOL, V70, P729, DOI 10.1016/j.humimm.2009.04.026
   Arnott IDR, 2004, GENES IMMUN, V5, P417, DOI 10.1038/sj.gene.6364111
   Ashton KA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-382
   Austin CM, 2008, J INFECT DIS, V197, P1713, DOI 10.1086/588384
   Barnich N, 2005, J CELL BIOL, V170, P21, DOI 10.1083/jcb.200502153
   Bene J, 2006, WORLD J GASTROENTERO, V12, P5550, DOI 10.3748/wjg.v12.i34.5550
   Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   Boffetta P, 2009, INT J CANCER, V124, P2697, DOI 10.1002/ijc.24261
   Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019
   Buning C, 2005, WORLD J GASTROENTERO, V11, P407
   Buhner S, 2006, GUT, V55, P342, DOI 10.1136/gut.2005.065557
   Buning C, 2004, ALIMENT PHARM THER, V19, P1073, DOI 10.1111/j.1365-2036.2004.01967.x
   Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
   Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239
   Csongei V, 2010, WORLD J GASTROENTERO, V16, P176, DOI 10.3748/wjg.v16.i2.176
   Debniak T, 2005, EUR J CANCER PREV, V14, P143, DOI 10.1097/00008469-200504000-00010
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Ennas MG, 2008, HEMATOL ONCOL, V26, P98, DOI 10.1002/hon.843
   Faustin B, 2007, MOL CELL, V25, P713, DOI 10.1016/j.molcel.2007.01.032
   Ferreira AC, 2005, INFLAMM BOWEL DIS, V11, P331, DOI 10.1097/01.MIB.0000158153.71579.b4
   Ferwerda B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006870
   Ferwerda G, 2007, J LEUKOCYTE BIOL, V82, P1011, DOI 10.1189/jlb.0307147
   Ferwerda G, 2005, PLOS PATHOG, V1, P279, DOI 10.1371/journal.ppat.0010034
   Forrest MS, 2006, BRIT J HAEMATOL, V134, P180, DOI 10.1111/j.1365-2141.2006.06141.x
   Freire P, 2010, INT J COLORECTAL DIS, V25, P1211, DOI 10.1007/s00384-010-1028-0
   Gaj P, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-81
   Gazouli M, 2004, EUR J GASTROEN HEPAT, V16, P1177, DOI 10.1097/00042737-200411000-00016
   Gazouli M, 2005, WORLD J GASTROENTERO, V11, P681, DOI 10.3748/wjg.v11.i5.681
   Gazouli M, 2010, WORLD J GASTROENTERO, V16, P1753, DOI 10.3748/wjg.v16.i14.1753
   Gearry RB, 2007, INFLAMM BOWEL DIS, V13, P1220, DOI 10.1002/ibd.20190
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Gutierrez O, 2002, J BIOL CHEM, V277, P41701, DOI 10.1074/jbc.M206473200
   Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088
   Hasegawa M, 2006, J BIOL CHEM, V281, P29054, DOI 10.1074/jbc.M602638200
   Hehlio T, 2003, GUT, V52, P558, DOI 10.1136/gut.52.4.558
   Hemminki K, 2009, ANN ONCOL, V20, P574, DOI 10.1093/annonc/mdn595
   Hisamatsu T, 2003, GASTROENTEROLOGY, V124, P993, DOI 10.1053/gast.2003.50153
   Hnatyszyn A, 2010, EXP MOL PATHOL, V88, P388, DOI 10.1016/j.yexmp.2010.03.003
   Hofner P, 2007, HELICOBACTER, V12, P124, DOI 10.1111/j.1523-5378.2007.00481.x
   Huebner Claudia, 2009, BMC Res Notes, V2, P52, DOI 10.1186/1756-0500-2-52
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Huzarski T, 2005, BREAST CANCER RES TR, V89, P91, DOI 10.1007/s10549-004-1250-y
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Inohara N, 2001, ONCOGENE, V20, P6473, DOI 10.1038/sj.onc.1204787
   Irmejs Arvids, 2006, Hered Cancer Clin Pract, V4, P48, DOI 10.1186/1897-4287-4-1-48
   Ismair MG, 2006, CAN J PHYSIOL PHARM, V84, P1313, DOI 10.1139/Y06-076
   Janiszewska Hanna, 2006, Hered Cancer Clin Pract, V4, P15, DOI 10.1186/1897-4287-4-1-15
   Ji J, 2009, ANN ONCOL, V20, P1121, DOI 10.1093/annonc/mdn767
   Kanazawa N, 2005, BLOOD, V105, P1195, DOI 10.1182/blood-2004-07-2972
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   Kara B, 2010, CLIN EXP MED, V10, P107, DOI 10.1007/s10238-009-0077-6
   Kim JG, 2004, INFECT IMMUN, V72, P1487, DOI 10.1128/IAI.72.3.1487-1495.2004
   Kinlen L, 2004, ONCOGENE, V23, P6341, DOI 10.1038/sj.onc.1207898
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Kocazeybek B, 2003, J MED MICROBIOL, V52, P721, DOI 10.1099/jmm.0.04845-0
   Kufer TA, 2008, CELL MICROBIOL, V10, P477, DOI 10.1111/j.1462-5822.2007.01062.x
   Kumar H, 2009, BIOCHEM J, V420, P1, DOI 10.1042/BJ20090272
   Kurzawski G, 2004, CANCER RES, V64, P1604, DOI 10.1158/0008-5472.CAN-03-3791
   Kutikhin AG, 2011, HUM IMMUNOL, V72, P193, DOI 10.1016/j.humimm.2010.11.003
   Lakatos PL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-54
   Lakatos PL, 2005, WORLD J GASTROENTERO, V11, P1489
   Lamba V, 2003, J PHARMACOL EXP THER, V307, P906, DOI 10.1124/jpet.103.054866
   Lappalainen M, 2008, INFLAMM BOWEL DIS, V14, P1118, DOI 10.1002/ibd.20431
   Lesage S, 2002, AM J HUM GENET, V70, P845, DOI 10.1086/339432
   Leung E, 2005, IMMUNOL CELL BIOL, V83, P498, DOI 10.1111/j.1440-1711.2005.01362.x
   Lipinski S, 2009, J CELL SCI, V122, P3522, DOI 10.1242/jcs.050690
   Lubinski J, 2005, HERED CANCER CLIN PR, V3, P59, DOI 10.1186/1897-4287-3-2-59
   Magnowski P, 2008, GINEKOL POL, V79, P544
   Marina-Garcia N, 2008, J IMMUNOL, V180, P4050, DOI 10.4049/jimmunol.180.6.4050
   McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135
   Medici V, 2006, EUR J HUM GENET, V14, P459, DOI 10.1038/sj.ejhg.5201576
   Mockelmann N, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-79
   Molnar T, 2007, DIGEST LIVER DIS, V39, P1064, DOI 10.1016/j.dld.2007.09.003
   Munkholm P, 2003, ALIMENT PHARM THER, V18, P1, DOI 10.1046/j.1365-2036.18.s2.2.x
   Nagya Z, 2005, ANN NY ACAD SCI, V1051, P45, DOI 10.1196/annals.1361.045
   Nej Katarzyna, 2004, Hered Cancer Clin Pract, V2, P149, DOI 10.1186/1897-4287-2-3-149
   Netea MG, 2005, NETH J MED, V63, P305
   Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   Opitz B, 2006, J IMMUNOL, V176, P484, DOI 10.4049/jimmunol.176.1.484
   Opitz B, 2004, J BIOL CHEM, V279, P36426, DOI 10.1074/jbc.M403861200
   Papaconstantinou L, 2005, INT J CANCER, V114, P433, DOI 10.1002/ijc.20747
   Radlmayr M, 2002, GASTROENTEROLOGY, V122, P2091, DOI 10.1053/gast.2002.34020
   Ratner AJ, 2007, CELL MICROBIOL, V9, P1343, DOI 10.1111/j.1462-5822.2006.00878.x
   Rigoli L, 2010, ANTICANCER RES, V30, P513
   Roberts RL, 2006, CANCER RES, V66, P2532, DOI 10.1158/0008-5472.CAN-05-4165
   Rosenstiel P, 2006, CELL MICROBIOL, V8, P1188, DOI 10.1111/j.1462-5822.2006.00701.x
   Rothman N, 2006, LANCET ONCOL, V7, P27, DOI 10.1016/S1470-2045(05)70434-4
   Sabbah A, 2009, NAT IMMUNOL, V10, P1073, DOI 10.1038/ni.1782
   Shaw MH, 2009, NAT IMMUNOL, V10, P1267, DOI 10.1038/ni.1816
   Shaw PJ, 2010, EUR J IMMUNOL, V40, P624, DOI 10.1002/eji.200940211
   Shebl FM, 2010, JAIDS-J ACQ IMM DEF, V55, P375, DOI 10.1097/QAI.0b013e3181eef4f7
   Shiels MS, 2011, CANCER EPIDEM BIOMAR, V20, P672, DOI 10.1158/1055-9965.EPI-10-1166
   Skibola CF, 2010, AM J EPIDEMIOL, V171, P267, DOI 10.1093/aje/kwp383
   Sterka D, 2006, J NEUROIMMUNOL, V179, P65, DOI 10.1016/j.jneuroim.2006.06.009
   Suchy J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-112
   Sugimura K, 2003, AM J HUM GENET, V72, P509, DOI 10.1086/367848
   Szeliga J, 2008, MED SCI MONITOR, V14, pCR480
   Tanabe T, 2006, BBA-MOL BASIS DIS, V1762, P794, DOI 10.1016/j.bbadis.2006.07.006
   Thomas KH, 2006, AM J PHYSIOL-LUNG C, V291, pL386, DOI 10.1152/ajplung.00193.2005
   Tian Y, 2010, INT J COLORECTAL DIS, V25, P161, DOI 10.1007/s00384-009-0809-9
   Tierney MJ, 2001, J BIOL CHEM, V276, P13675, DOI 10.1074/jbc.M010627200
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Travassos LH, 2005, J BIOL CHEM, V280, P36714, DOI 10.1074/jbc.M501649200
   Ture-Ozdemir F, 2008, ANTICANCER RES, V28, P3697
   Tuupanen S, 2007, INT J CANCER, V121, P76, DOI 10.1002/ijc.22651
   Uehara A, 2007, MOL IMMUNOL, V44, P3100, DOI 10.1016/j.molimm.2007.02.007
   Verma R, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-82
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
   Vind I, 2005, DIGESTION, V72, P156, DOI 10.1159/000088371
   von Roon AC, 2007, DIS COLON RECTUM, V50, P839, DOI 10.1007/s10350-006-0848-z
   Voss E, 2006, J BIOL CHEM, V281, P2005, DOI 10.1074/jbc.M511044200
   Wehkamp J, 2004, GUT, V53, P1658, DOI 10.1136/gut.2003.032805
   Welter-Stahl L, 2006, CELL MICROBIOL, V8, P1047, DOI 10.1111/j.1462-5822.2006.00686.x
   Wex T, 2008, ANTICANCER RES, V28, P757
   Wu CY, 2011, CANCER-AM CANCER SOC, V117, P618, DOI 10.1002/cncr.25616
   Yazdanyar S, 2010, J INTERN MED, V267, P228, DOI 10.1111/j.1365-2796.2009.02137.x
   Zilbauer M, 2007, CELL MICROBIOL, V9, P2404, DOI 10.1111/j.1462-5822.2007.00969.x
   ZYSOW BR, 1995, ARTERIOSCL THROM VAS, V15, P58, DOI 10.1161/01.ATV.15.1.58
NR 125
TC 54
Z9 55
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0198-8859
EI 1879-1166
J9 HUM IMMUNOL
JI Hum. Immunol.
PD OCT
PY 2011
VL 72
IS 10
BP 955
EP 968
DI 10.1016/j.humimm.2011.06.003
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 833QX
UT WOS:000295901100030
PM 21745515
DA 2022-04-25
ER

PT J
AU Chang, TC
   Wei, PL
   Makondi, PT
   Chen, WT
   Huang, CY
   Chang, YJ
AF Chang, Tung-Cheng
   Wei, Po-Li
   Makondi, Precious Takondwa
   Chen, Wei-Ting
   Huang, Chien-Yu
   Chang, Yu-Jia
TI Bromelain inhibits the ability of colorectal cancer cells to proliferate
   via activation of ROS production and autophagy
SO PLOS ONE
LA English
DT Article
ID INDUCED CYTOKINE PRODUCTION; INDUCED APOPTOSIS; OXIDATIVE STRESS;
   STATISTICS; PATHWAY; LC3; EXPRESSION; AIF
AB Advanced colorectal cancer (CRC) survival rates are still low despite advances in cytotoxic and targeted therapies. The development of new effective or alternative therapies is therefore urgently needed. Bromelain, an extract of pineapple, was shown to have anticancer effects, but its mechanisms in CRC have not been fully explored. Therefore, the roles of bromelain in CRC progression were investigated using different CRC cell lines, a zebrafish model, and a xenograft mouse model. The anticancer mechanisms were explored by assessing the role of bromelain in inducing reactive oxygen species (ROS), superoxide, autophagosomes, and lysosomes. The role of bromelain in the induction of apoptosis was also assessed. It was found that bromelain inhibited CRC cell growth in cell lines and tumor growth in the zebrafish and xenograft mouse models. It also induced high levels of ROS and superoxide, plus autophagosome and lysosome formation. High levels of apoptosis were also induced, which were associated with elevated amounts of apoptotic proteins like apoptotic induction factor, Endo G, and caspases-3, -8, and -9 according to a qPCR analysis. In a Western blot analysis, increases in levels of ATG5/12, beclin, p62, and LC3 conversion rates were found after bromelain treatment. Levels of cleaved caspase-3, caspase-8, caspase-9, and poly(ADP ribose) polymerase (PARP)-1 increased after bromelain exposure. This study explored the role of bromelain in CRC while giving insights into its mechanisms of action. This compound can offer a cheap alternative to current therapies.
C1 [Chang, Tung-Cheng; Wei, Po-Li; Makondi, Precious Takondwa; Chen, Wei-Ting; Chang, Yu-Jia] Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.
   [Chang, Tung-Cheng; Wei, Po-Li; Huang, Chien-Yu] Taipei Med Univ, Coll Med, Dept Surg, Taipei, Taiwan.
   [Chang, Tung-Cheng; Huang, Chien-Yu] Taipei Med Univ, Shuang Ho Hosp, Div Gen Surg, Dept Surg, New Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Taipei Med Univ Hosp, Dept Surg, Div Colorectal Surg, Taipei, Taiwan.
   [Wei, Po-Li; Chang, Yu-Jia] Taipei Med Univ, Taipei Med Univ Hosp, Canc Res Ctr, Taipei, Taiwan.
   [Wei, Po-Li; Chang, Yu-Jia] Taipei Med Univ, Taipei Med Univ Hosp, Dept Med Res, Translat Lab, Taipei, Taiwan.
   [Wei, Po-Li] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan.
   [Makondi, Precious Takondwa; Chang, Yu-Jia] Taipei Med Univ, Int PhD Program Med, Taipei, Taiwan.
RP Chang, YJ (corresponding author), Taipei Med Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan.; Huang, CY (corresponding author), Taipei Med Univ, Coll Med, Dept Surg, Taipei, Taiwan.; Huang, CY (corresponding author), Taipei Med Univ, Shuang Ho Hosp, Div Gen Surg, Dept Surg, New Taipei, Taiwan.; Chang, YJ (corresponding author), Taipei Med Univ, Taipei Med Univ Hosp, Canc Res Ctr, Taipei, Taiwan.; Chang, YJ (corresponding author), Taipei Med Univ, Taipei Med Univ Hosp, Dept Med Res, Translat Lab, Taipei, Taiwan.; Chang, YJ (corresponding author), Taipei Med Univ, Int PhD Program Med, Taipei, Taiwan.
EM cyh@tmu.edu.tw; r5424012@tmu.edu.tw
FU Taipei Medical University; Shuang Ho Hospital [105TMU-SHH-19]; Shuang Ho
   Hospital, Taipei Medical University [105TMU-SHH-19]
FX This work was supported by a grant form Taipei Medical University and
   Shuang Ho Hospital (105TMU-SHH-19). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.; This study was supported by a grant from
   Taipei Medical University and Shuang Ho Hospital, Taipei Medical
   University (105TMU-SHH-19).
CR Amini A, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0092-7
   Baez R, 2007, PLANTA MED, V73, P1377, DOI 10.1055/s-2007-990221
   Bhui K, 2012, MOL CARCINOGEN, V51, P231, DOI 10.1002/mc.20769
   Bhui K, 2009, CANCER LETT, V282, P167, DOI 10.1016/j.canlet.2009.03.003
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Brien S, 2004, EVID-BASED COMPL ALT, V1, P251, DOI 10.1093/ecam/neh035
   Cadwell K, 2018, J CELL BIOL, V217, P813, DOI 10.1083/jcb.201706157
   Castell JV, 1997, AM J PHYSIOL-GASTR L, V273, pG139, DOI 10.1152/ajpgi.1997.273.1.G139
   Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17
   Chobotova K, 2010, CANCER LETT, V290, P148, DOI 10.1016/j.canlet.2009.08.001
   Davalli P, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2389523
   Novaes LCD, 2016, BIOTECHNOL PROGR, V32, P5, DOI 10.1002/btpr.2190
   Dhandayuthapani S, 2012, J MED FOOD, V15, P344, DOI 10.1089/jmf.2011.0145
   Dolman NJ, 2013, AUTOPHAGY, V9, P1653, DOI 10.4161/auto.24001
   FELTON GE, 1980, MED HYPOTHESES, V6, P1123, DOI 10.1016/0306-9877(80)90134-6
   Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312
   GERARD G, 1972, AGRESSOLOGIE, V13, P261
   Glaser D, 2006, PLATELETS, V17, P37, DOI 10.1080/09537100500197489
   Goldstein N, 1975, Hawaii Med J, V34, P91
   GUM JR, 1992, AM J RESP CELL MOL, V7, P557, DOI 10.1165/ajrcmb/7.6.557
   Hou RCW, 2006, J AGR FOOD CHEM, V54, P2193, DOI 10.1021/jf052390k
   Huang JR, 2008, IMMUNOL INVEST, V37, P263, DOI 10.1080/08820130802083622
   Joza N, 2009, ANN NY ACAD SCI, V1171, P2, DOI 10.1111/j.1749-6632.2009.04681.x
   Juhasz B, 2008, AM J PHYSIOL-HEART C, V294, pH1365, DOI 10.1152/ajpheart.01005.2007
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kalra N, 2008, TOXICOL APPL PHARM, V226, P30, DOI 10.1016/j.taap.2007.08.012
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kuo LJ, 2013, J SURG RES, V185, P264, DOI 10.1016/j.jss.2013.05.020
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li DY, 2017, EUR REV MED PHARMACO, V21, P5548, DOI 10.26355/eurrev_201712_13991
   Liang HH, 2013, TUMOR BIOL, V34, P3209, DOI 10.1007/s13277-013-0891-z
   Liu KC, 2011, INT J ONCOL, V38, P787, DOI 10.3892/ijo.2010.894
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Matsuda K, 2008, SCAND J GASTROENTERO, V43, P25, DOI 10.1080/00365520701579795
   Maurer HR, 2001, CELL MOL LIFE SCI, V58, P1234, DOI 10.1007/PL00000936
   McNicol Archibald, 2008, Cardiovascular & Hematological Disorders - Drug Targets, V8, P99, DOI 10.2174/187152908784533739
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   MORITA AH, 1979, ARCH INT PHARMACOD T, V239, P340
   Park S, 2014, AUTOPHAGY, V10, P1906, DOI 10.4161/auto.32177
   Pavan Rajendra, 2012, Biotechnol Res Int, V2012, P976203, DOI 10.1155/2012/976203
   Qi Rong, 2006, Int J Biomed Sci, V2, P211
   Rathnavelu V, 2016, BIOMED REP, V5, P283, DOI 10.3892/br.2016.720
   Romano B, 2014, MOL NUTR FOOD RES, V58, P457, DOI 10.1002/mnfr.201300345
   Rosenberg L, 2015, Ann Burns Fire Disasters, V28, P264
   Satyanarayana A, 2009, ONCOGENE, V28, P2925, DOI 10.1038/onc.2009.170
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   TAUSSIG SJ, 1985, PLANTA MED, V51, P538, DOI 10.1055/s-2007-969596
   TAUSSIG SJ, 1975, HIROSHIMA J MED SCI, V24, P185
   Twayana KS, 2018, LIFE SCI, V205, P73, DOI 10.1016/j.lfs.2018.05.002
   Tysnes BB, 2001, NEOPLASIA, V3, P469, DOI 10.1038/sj.neo.7900196
   VanKlinken BJW, 1996, GLYCOCONJUGATE J, V13, P757, DOI 10.1007/BF00702340
   Wurzer B, 2015, ELIFE, V4, DOI 10.7554/eLife.08941
   Yang J, 2017, ONCOTARGET, V8, P23492, DOI 10.18632/oncotarget.15626
   Yonezawa S, 2011, PATHOL INT, V61, P697, DOI 10.1111/j.1440-1827.2011.02734.x
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 59
TC 21
Z9 21
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 18
PY 2019
VL 14
IS 1
AR e0210274
DI 10.1371/journal.pone.0210274
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HH8XI
UT WOS:000456017000008
PM 30657763
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Zhou, JB
   Kang, Y
   Chen, L
   Wang, H
   Liu, JQ
   Zeng, S
   Yu, LS
AF Zhou, Jiabei
   Kang, Yu
   Chen, Lu
   Wang, Hua
   Liu, Junqing
   Zeng, Su
   Yu, Lushan
TI The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE platinum-based anticancer drugs; transporter; apoptosis; autophagy; DNA
   repair; resistance
ID OVARIAN-CANCER CELLS; COPPER TRANSPORTER CTR1; ORGANIC CATION
   TRANSPORTERS; OVERCOMES CISPLATIN RESISTANCE; LUNG ADENOCARCINOMA CELLS;
   COLORECTAL-CANCER; GASTRIC-CANCER; CHEMOTHERAPY RESISTANCE; CELLULAR
   ACCUMULATION; BLADDER-CANCER
AB Platinum-based anticancer drugs, including cisplatin, carboplatin, oxaliplatin, nedaplatin, and lobaplatin, are heavily applied in chemotherapy regimens. However, the intrinsic or acquired resistance severely limit the clinical application of platinum-based treatment. The underlying mechanisms are incredibly complicated. Multiple transporters participate in the active transport of platinum-based antitumor agents, and the altered expression level, localization, or activity may severely decrease the cellular platinum accumulation. Detoxification components, which are commonly increasing in resistant tumor cells, can efficiently bind to platinum agents and prevent the formation of platinum-DNA adducts, but the adducts production is the determinant step for the cytotoxicity of platinum-based antitumor agents. Even if adequate adducts have formed, tumor cells still manage to survive through increased DNA repair processes or elevated apoptosis threshold. In addition, autophagy has a profound influence on platinum resistance. This review summarizes the critical participators of platinum resistance mechanisms mentioned above and highlights the most potential therapeutic targets or predicted markers. With a deeper understanding of the underlying resistance mechanisms, new solutions would be produced to extend the clinical application of platinum-based antitumor agents largely.
C1 [Zhou, Jiabei; Kang, Yu; Chen, Lu; Zeng, Su; Yu, Lushan] Zhejiang Univ, Coll Pharmaceut Sci, Inst Drug Metab & Pharmaceut Anal, Hangzhou, Peoples R China.
   [Wang, Hua] Canc Hosp Zhejiang Prov, Dept Urol, Hangzhou, Peoples R China.
   [Liu, Junqing] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China.
RP Yu, LS (corresponding author), Zhejiang Univ, Coll Pharmaceut Sci, Inst Drug Metab & Pharmaceut Anal, Hangzhou, Peoples R China.
EM yuls@zju.edu.cn
RI Kang, Yu/L-2912-2013
OI Kang, Yu/0000-0002-0999-8802
FU Leading Talent of "Ten Thousand Plan" - National High-Level Talents
   Special Support Plan; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81773805,
   81703616]
FX This work was supported by the Leading Talent of "Ten Thousand Plan" -
   National High-Level Talents Special Support Plan and the grants from
   National Natural Science Foundation of China (81773805 and 81703616)
CR Aguilar Andrea, 2016, Nat Rev Nephrol, V12, P581, DOI 10.1038/nrneph.2016.122
   Ahmed AA, 2010, J PATHOL, V221, P49, DOI 10.1002/path.2696
   Ahmed EM, 2018, CELL ONCOL, V41, P319, DOI 10.1007/s13402-018-0374-8
   Ai ZH, 2016, CANCER LETT, V373, P36, DOI 10.1016/j.canlet.2016.01.009
   Akerfeldt MC, 2017, J BIOL INORG CHEM, V22, P765, DOI 10.1007/s00775-017-1467-y
   Akkari L, 2016, CELL RES, V26, P867, DOI 10.1038/cr.2016.82
   Al-Eisawi Z, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-78
   Al-Minawi AZ, 2009, NUCLEIC ACIDS RES, V37, P6400, DOI 10.1093/nar/gkp705
   Aoyama K, 2013, INT J MOL SCI, V14, P21021, DOI 10.3390/ijms141021021
   Arora S, 2010, DNA REPAIR, V9, P745, DOI 10.1016/j.dnarep.2010.03.010
   Bai LC, 2014, ANNU REV MED, V65, P139, DOI 10.1146/annurev-med-010713-141310
   Bao LJ, 2017, MOL CARCINOGEN, V56, P1543, DOI 10.1002/mc.22615
   Basu S, 2016, CELL CYCLE, V15, P2557, DOI 10.1080/15384101.2016.1215390
   Belli C, 2018, CANCER TREAT REV, V65, P22, DOI 10.1016/j.ctrv.2018.02.004
   Benard A, 2014, APOPTOSIS, V19, P1769, DOI 10.1007/s10495-014-1042-8
   Beretta GL, 2010, BIOCHEM PHARMACOL, V79, P1108, DOI 10.1016/j.bcp.2009.12.002
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Blair BG, 2011, MOL PHARMACOL, V79, P157, DOI 10.1124/mol.110.068411
   Blair BG, 2009, CLIN CANCER RES, V15, P4312, DOI 10.1158/1078-0432.CCR-09-0311
   Boal AK, 2009, J AM CHEM SOC, V131, P14196, DOI 10.1021/ja906363t
   Bompiani KM, 2016, METALLOMICS, V8, P951, DOI 10.1039/c6mt00076b
   Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295
   Brozovic A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076397
   Brozovic A, 2010, CRIT REV TOXICOL, V40, P347, DOI 10.3109/10408441003601836
   Bruno PM, 2017, NAT MED, V23, P461, DOI 10.1038/nm.4291
   Burger H, 2010, BRIT J PHARMACOL, V159, P898, DOI 10.1111/j.1476-5381.2009.00569.x
   Buss I, 2018, METALLOMICS, V10, P414, DOI 10.1039/c7mt00334j
   Byun SS, 2005, BJU INT, V95, P1086, DOI 10.1111/j.1464-410X.2005.05472.x
   Cadoni E, 2017, J INORG BIOCHEM, V173, P126, DOI 10.1016/j.jinorgbio.2017.05.004
   Chaney SG, 2005, CRIT REV ONCOL HEMAT, V53, P3, DOI 10.1016/j.critrevonc.2004.08.008
   Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866
   Chapman TM, 2015, BIOORG MED CHEM LETT, V25, P4097, DOI 10.1016/j.bmcl.2015.08.031
   Chen Helen H. W., 2010, Metal-Based Drugs, P430939, DOI 10.1155/2010/430939
   Chen JL, 2017, CANCER CHEMOTH PHARM, V79, P369, DOI 10.1007/s00280-016-3225-1
   Chen X, 2015, INT J ONCOL, V47, P1603, DOI 10.3892/ijo.2015.3143
   Chen XS, 2016, SCI REP-UK, V6, DOI 10.1038/srep19455
   Chen Y, 2018, AM J PHYSIOL-CELL PH, V315, pC225, DOI 10.1152/ajpcell.00283.2017
   Cheng CY, 2018, INT J BIOL MACROMOL, V107, P2620, DOI 10.1016/j.ijbiomac.2017.10.154
   Chisholm CL, 2016, ONCOTARGET, V7, P84439, DOI 10.18632/oncotarget.12992
   Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083
   Cruz-Bermudez A, 2019, FREE RADICAL BIO MED, V135, P167, DOI 10.1016/j.freeradbiomed.2019.03.009
   Dai Chen-Xin, 2009, BMC Cancer, V9, P418, DOI 10.1186/1471-2407-9-418
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Danford AJ, 2005, P NATL ACAD SCI USA, V102, P12311, DOI 10.1073/pnas.0506025102
   Dann RB, 2012, GYNECOL ONCOL, V125, P677, DOI 10.1016/j.ygyno.2012.03.006
   DIJT FJ, 1988, CANCER RES, V48, P6058
   Drayton RM, 2014, CLIN CANCER RES, V20, P1990, DOI 10.1158/1078-0432.CCR-13-2805
   Duan CM, 2016, AM J PHYSIOL-CELL PH, V310, pC260, DOI 10.1152/ajpcell.00315.2015
   Estrela JM, 2006, CRIT REV CL LAB SCI, V43, P143, DOI 10.1080/10408360500523878
   Faivre S, 2003, BIOCHEM PHARMACOL, V66, P225, DOI 10.1016/S0006-2952(03)00260-0
   Fang TT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08102-z
   Fang Z, 2017, CANCER MED-US, V6, P2897, DOI 10.1002/cam4.1253
   Foulkes WD, 2013, J PATHOL, V230, P347, DOI 10.1002/path.4205
   Fu Q, 2016, ONCOL REP, V36, P3682, DOI 10.3892/or.2016.5195
   Fu SQ, 2012, MOL CANCER THER, V11, P1221, DOI 10.1158/1535-7163.MCT-11-0864
   Fujiwara N, 2015, CANCER RES, V75, P3890, DOI 10.1158/0008-5472.CAN-15-0257
   Fukuda T, 2015, GYNECOL ONCOL, V137, P538, DOI 10.1016/j.ygyno.2015.03.053
   Gadhikar MA, 2013, MOL CANCER THER, V12, P1860, DOI 10.1158/1535-7163.MCT-13-0157
   Gao H, 2019, CHEM-BIOL INTERACT, V297, P130, DOI 10.1016/j.cbi.2018.11.008
   Gao J, 2019, CHEM-BIOL INTERACT, V297, P50, DOI 10.1016/j.cbi.2018.10.014
   Gao ZJ, 2018, MED SCI MONITOR, V24, P1104, DOI 10.12659/MSM.906107
   GATELY DP, 1993, BRIT J CANCER, V67, P1171, DOI 10.1038/bjc.1993.221
   Gillet LCJ, 2006, CHEM REV, V106, P253, DOI 10.1021/cr040483f
   Golan T, 2014, BRIT J CANCER, V111, P1132, DOI 10.1038/bjc.2014.418
   Gong TX, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1543-2
   Goodspeed A, 2019, EUR UROL, V75, P242, DOI 10.1016/j.eururo.2018.10.040
   Graf N, 2011, CHEMBIOCHEM, V12, P1115, DOI 10.1002/cbic.201000724
   Guillemette S, 2015, GENE DEV, V29, P489, DOI 10.1101/gad.256214.114
   Gupta A, 2009, FUTURE MED CHEM, V1, P1125, DOI 10.4155/FMC.09.84
   Habel N, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.405
   Hall MD, 2008, ANNU REV PHARMACOL, V48, P495, DOI 10.1146/annurev.pharmtox.48.080907.180426
   Hernandez-Luna MA, 2013, LEUKEMIA LYMPHOMA, V54, P1048, DOI 10.3109/10428194.2012.733874
   Hernandez-Valencia J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10091148
   Hervouet E, 2007, BIOCHIMIE, V89, P1080, DOI 10.1016/j.biochi.2007.03.010
   Holzer AK, 2006, CANCER RES, V66, P10944, DOI 10.1158/0008-5472.CAN-06-1710
   Holzer AK, 2006, MOL PHARMACOL, V70, P1390, DOI 10.1124/mol.106.022624
   Howell SB, 2010, MOL PHARMACOL, V77, P887, DOI 10.1124/mol.109.063172
   Huang CP, 2014, METALLOMICS, V6, P654, DOI 10.1039/c3mt00331k
   Huang FX, 2019, INT J ONCOL, V54, P339, DOI 10.3892/ijo.2018.4614
   Huang HJ, 2018, INT J ONCOL, V53, P2769, DOI 10.3892/ijo.2018.4593
   Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691
   Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399
   Ishida S, 2010, CANCER CELL, V17, P574, DOI 10.1016/j.ccr.2010.04.011
   ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116
   Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146
   Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n
   JEDLITSCHKY G, 1994, CANCER RES, V54, P4833
   Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115
   Jiang LG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124994
   Jung YW, 2007, CHEM REV, V107, P1387, DOI 10.1021/cr068207j
   Kalayda GV, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-175
   Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P1, DOI 10.1016/s0027-5107(01)00142-7
   Keppler D, 2011, HANDB EXP PHARMACOL, V201, P299, DOI 10.1007/978-3-642-14541-4_8
   Kim ES, 2014, LUNG CANCER, V85, P88, DOI 10.1016/j.lungcan.2014.04.005
   Kim EA, 2017, INT J ONCOL, V50, P984, DOI 10.3892/ijo.2017.3851
   Kim M, 2017, AUTOPHAGY, V13, P149, DOI 10.1080/15548627.2016.1239676
   Kim R, 2002, CANCER CHEMOTH PHARM, V50, P343, DOI 10.1007/s00280-002-0522-7
   Kimura T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030336
   Kong LR, 2015, MOL CANCER THER, V14, P1750, DOI 10.1158/1535-7163.MCT-15-0062
   Krizkova S, 2010, INT J MOL SCI, V11, P4826, DOI 10.3390/ijms11124826
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259
   Kuwahara A, 2009, INT J MED SCI, V6, P305
   Lee JH, 2015, J CONTROL RELEASE, V215, P82, DOI 10.1016/j.jconrel.2015.07.015
   Lehmann J, 2017, CELL MOL LIFE SCI, V74, P2081, DOI 10.1007/s00018-017-2455-7
   Li BW, 2017, CANCER LETT, V410, P212, DOI 10.1016/j.canlet.2017.09.035
   Li HC, 2007, J CELL BIOCHEM, V101, P805, DOI 10.1002/jcb.21159
   Li QD, 2000, ANTICANCER RES, V20, P645
   Li XC, 2016, AM J PHYSIOL-LUNG C, V310, P1299, DOI 10.1152/ajplung.00189.2015
   Li YL, 2016, BIOMED PHARMACOTHER, V83, P1239, DOI 10.1016/j.biopha.2016.08.053
   Li YF, 2017, INT J PHARMACOL, V13, P1, DOI 10.3923/ijp.2017.1.10
   Li YF, 2017, CANCER-AM CANCER SOC, V123, P420, DOI 10.1002/cncr.30328
   Liang LL, 2018, BASIC CLIN PHARMACOL, V123, P692, DOI 10.1111/bcpt.13090
   Liu CW, 2017, MOL CANCER THER, V16, P1421, DOI 10.1158/1535-7163.MCT-16-0567-T
   Liu JG, 2018, ONCOL REP, V39, P1631, DOI 10.3892/or.2018.6268
   Liu WJ, 2017, CANCER LETT, V394, P65, DOI 10.1016/j.canlet.2017.02.025
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Liu Y, 2017, CANCER GENE THER, V24, P208, DOI 10.1038/cgt.2017.6
   Liu Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14088-3
   Liu YQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf3124
   Liu YC, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv934
   Ma BB, 2017, BBA-MOL CELL RES, V1864, P1393, DOI 10.1016/j.bbamcr.2017.05.008
   Ma LW, 2015, INT J ONCOL, V47, P1890, DOI 10.3892/ijo.2015.3176
   Ma MZ, 2015, CANCER LETT, V368, P88, DOI 10.1016/j.canlet.2015.07.031
   MacDonagh L, 2016, CANCER LETT, V372, P147, DOI [10.1016/j.canlet.2016,01.012, 10.1016/j.canlet.2016.01.012]
   Marchenko ND, 2007, CELL CYCLE, V6, P1718, DOI 10.4161/cc.6.14.4503
   Martens-de Kemp SR, 2017, MOL CANCER THER, V16, P540, DOI 10.1158/1535-7163.MCT-16-0457
   Martinez-Balibrea E, 2009, INT J CANCER, V124, P2905, DOI 10.1002/ijc.24273
   Martinez-Rivera M, 2012, BIOCHEM PHARMACOL, V83, P1049, DOI 10.1016/j.bcp.2011.12.026
   Masters JRW, 1996, EUR J CANCER, V32A, P1248, DOI 10.1016/0959-8049(96)00033-0
   MCKEAGE MJ, 1995, DRUG SAFETY, V13, P228, DOI 10.2165/00002018-199513040-00003
   Meng YX, 2018, CANCER LETT, V428, P104, DOI 10.1016/j.canlet.2018.04.029
   Miow QH, 2015, ONCOGENE, V34, P1899, DOI 10.1038/onc.2014.136
   Mizushima N, 2007, ANNU REV NUTR, V27, P19, DOI 10.1146/annurev.nutr.27.061406.093749
   Muggia F, 2014, ANTICANCER RES, V34, P551
   Myint K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130727
   Nagao A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020238
   Naik PP, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12411
   Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980
   Ohrvik H, 2016, J BIOL CHEM, V291, P13905, DOI 10.1074/jbc.M116.731281
   Oien DB, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00970
   Osada R, 2007, HUM PATHOL, V38, P1310, DOI 10.1016/j.humpath.2007.02.010
   Ozcan MF, 2013, UROL ONCOL-SEMIN ORI, V31, P1709, DOI 10.1016/j.urolonc.2012.06.014
   Pan CY, 2019, J CLIN INVEST, V129, P2431, DOI 10.1172/JCI124550
   Pan HZ, 2013, EMBO MOL MED, V5, P327, DOI 10.1002/emmm.201201999
   Pan JJ, 2016, CANCER LETT, V382, P64, DOI 10.1016/j.canlet.2016.08.015
   Pan Y, 2013, ONCOGENE, V32, P2756, DOI 10.1038/onc.2012.294
   Pannuru P, 2014, CELL SIGNAL, V26, P2193, DOI 10.1016/j.cellsig.2014.06.014
   Pawlus MR, 2013, CELL SIGNAL, V25, P1895, DOI 10.1016/j.cellsig.2013.05.018
   Pekarik V, 2013, CURR MED CHEM, V20, P534
   Peng PJ, 2017, THER ADV MED ONCOL, V9, P68, DOI 10.1177/1758834016675099
   Perland E, 2017, TRENDS PHARMACOL SCI, V38, P305, DOI 10.1016/j.tips.2016.11.008
   Qin X, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1604-0
   Ramadoss S, 2017, ONCOGENE, V36, P6508, DOI 10.1038/onc.2017.331
   Cirilo PDR, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3721-7
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Rocha CRR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.101
   Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038
   Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007
   Safaei R, 2008, MOL PHARMACOL, V73, P461, DOI 10.1124/mol.107.040980
   Safaei R, 2012, J INORG BIOCHEM, V110, P8, DOI 10.1016/j.jinorgbio.2012.02.016
   Samimi G, 2004, MOL PHARMACOL, V66, P25, DOI 10.1124/mol.66.1.25
   Sawant A, 2015, DNA REPAIR, V35, P126, DOI 10.1016/j.dnarep.2015.10.003
   Schrock MS, 2017, ONCOGENE, V36, P2215, DOI 10.1038/onc.2016.389
   Shi L, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3132-9
   Shteingauz A, 2015, CANCER RES, V75, P3946, DOI 10.1158/0008-5472.CAN-15-0037
   Somasagara RR, 2017, ONCOGENE, V36, P6680, DOI 10.1038/onc.2017.279
   Somers J, 2015, GENE DEV, V29, P1891, DOI 10.1101/gad.261867.115
   Song IS, 2004, MOL CANCER THER, V3, P1543
   Song LQ, 2014, J CELL BIOCHEM, V115, P1234, DOI 10.1002/jcb.24665
   Soni S, 2017, ACTA ONCOL, V56, P503, DOI 10.1080/0284186X.2017.1301680
   Soyano AE, 2018, CLIN COLORECTAL CANC, V17, pE647, DOI 10.1016/j.clcc.2018.06.006
   Spada F, 2016, NEUROENDOCRINOLOGY, V103, P806, DOI 10.1159/000444087
   Sprowl JA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10880
   Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
   Sui CG, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0488-y
   Sullivan I, 2014, CANCER LETT, V353, P160, DOI 10.1016/j.canlet.2014.07.023
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Sun J, 2019, ONCOGENE, V38, P564, DOI 10.1038/s41388-018-0459-x
   Sun J, 2017, CELL CYCLE, V16, P2100, DOI 10.1080/15384101.2017.1361071
   Sun Y, 2016, INT J ONCOL, V48, P225, DOI 10.3892/ijo.2015.3256
   Surowiak P, 2006, CLIN CANCER RES, V12, P7149, DOI 10.1158/1078-0432.CCR-06-0564
   Takekuma M, 2018, CANCER SCI, V109, P1602, DOI 10.1111/cas.13577
   Tan SF, 2016, INT J MOL MED, V37, P1030, DOI 10.3892/ijmm.2016.2492
   Taniguchi K, 1996, CANCER RES, V56, P4124
   Tao LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep38408
   Tariba B, 2015, CANCER CHEMOTH PHARM, V75, P813, DOI 10.1007/s00280-015-2702-2
   Ushijima R, 2007, ANTICANCER RES, V27, P4351
   Van den Berghe PVE, 2007, BIOCHEM J, V407, P49, DOI 10.1042/BJ20070705
   van Jaarsveld MTM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0464-4
   Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472
   Wang J, 2016, AUTOPHAGY, V12, P1791, DOI 10.1080/15548627.2016.1203483
   Wang N, 2019, EBIOMEDICINE, V47, P65, DOI 10.1016/j.ebiom.2019.08.057
   Wang SF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113389
   Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009
   Wang XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125402
   Wang XR, 2016, INT J MOL MED, V37, P1636, DOI 10.3892/ijmm.2016.2569
   Wang ZG, 2019, DALTON T, V48, P2536, DOI 10.1039/c8dt03923b
   Wang ZQ, 2019, INT J ONCOL, V54, P1071, DOI 10.3892/ijo.2019.4690
   Wanzel I, 2016, NAT CHEM BIOL, V12, P22, DOI [10.1038/nchembio.1965, 10.1038/NCHEMBIO.1965]
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Woynarowski JM, 2000, MOL PHARMACOL, V58, P920, DOI 10.1124/mol.58.5.920
   Wu B, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.251
   Wu XC, 2016, SCI REP-UK, V6, DOI 10.1038/srep19000
   Wynne P, 2007, BRIT J CANCER, V97, P927, DOI 10.1038/sj.bjc.6603973
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xiao F, 2018, CANCER CHEMOTH PHARM, V81, P935, DOI 10.1007/s00280-018-3548-1
   Xiao M, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-017-0321-8
   Xie XL, 2017, MOL CANCER RES, V15, P328, DOI 10.1158/1541-7786.MCR-16-0257-T
   Xu W, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.517
   Xu YJ, 2018, INT J ONCOL, V53, P1055, DOI 10.3892/ijo.2018.4476
   Yamamoto M, 1999, ONCOLOGY-BASEL, V56, P332, DOI 10.1159/000011988
   Yamasaki M, 2011, BRIT J CANCER, V104, P707, DOI 10.1038/sj.bjc.6606071
   Yaneff A, 2019, CURR MED CHEM, V26, P1270, DOI 10.2174/0929867325666171229133259
   Yang G, 2019, INT J ONCOL, V54, P177, DOI 10.3892/ijo.2018.4613
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Yang LW, 2018, MOL CARCINOGEN, V57, P419, DOI 10.1002/mc.22765
   Yokoo S, 2007, BIOCHEM PHARMACOL, V74, P477, DOI 10.1016/j.bcp.2007.03.004
   Yonezawa A, 2006, J PHARMACOL EXP THER, V319, P879, DOI 10.1124/jpet.106.110346
   Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020
   Zarogoulidis P, 2015, CELL SIGNAL, V27, P1576, DOI 10.1016/j.cellsig.2015.04.009
   Zhang L, 2017, NEOPLASIA, V19, P908, DOI 10.1016/j.neo.2017.08.008
   Zhang Q, 2016, INT J CANCER, V139, P2827, DOI 10.1002/ijc.30396
   Zhang XW, 2015, BIOCHEM BIOPH RES CO, V462, P227, DOI 10.1016/j.bbrc.2015.04.121
   Zhang YJ, 2016, INT J BIOL SCI, V12, P1437, DOI 10.7150/ijbs.16529
   Zhang YH, 2010, CANCER LETT, V291, P76, DOI 10.1016/j.canlet.2009.10.003
   Zhao L, 2015, FREE RADICAL BIO MED, V82, P29, DOI 10.1016/j.freeradbiomed.2015.01.014
   Zhao Q, 2016, ONCOL RES, V23, P129, DOI 10.3727/096504015X14500513118029
   Zhao X, 2018, CANCER SCI, V109, P3068, DOI 10.1111/cas.13764
   Zhao Y, 2018, INT J ONCOL, V53, P644, DOI 10.3892/ijo.2018.4409
   Zhen Y, 2017, ONCOGENE, V36, P275, DOI 10.1038/onc.2016.201
   Zheng DT, 2017, MOL CARCINOGEN, V56, P2234, DOI 10.1002/mc.22676
   Zheng PM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0528-y
   Zheng ZG, 2016, SCI REP-UK, V6, DOI 10.1038/srep26093
   Zhong LZ, 2018, ONCOTARGETS THER, V11, P5509, DOI 10.2147/OTT.S168391
   Zhou B, 2016, INT J ONCOL, V48, P2087, DOI 10.3892/ijo.2016.3442
   Zhou FF, 2017, ADV DRUG DELIVER REV, V116, P21, DOI 10.1016/j.addr.2016.06.004
   Zhou P, 2016, INT J ONCOL, V48, P1737, DOI 10.3892/ijo.2016.3392
   Zhou W, 2018, ONCOGENE, V37, P3981, DOI 10.1038/s41388-018-0238-8
   Zhu QY, 2019, EPIGENETICS-US, V14, P791, DOI 10.1080/15592294.2019.1615354
   Zhu XF, 2017, INT J ONCOL, V50, P835, DOI 10.3892/ijo.2017.3873
   Zhu ZL, 2018, J NEUROCHEM, V144, P93, DOI 10.1111/jnc.14250
   Zimmermann T, 2010, INTERDISCIP SCI, V2, P98, DOI 10.1007/s12539-010-0094-x
NR 246
TC 69
Z9 70
U1 42
U2 78
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 20
PY 2020
VL 11
AR 343
DI 10.3389/fphar.2020.00343
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KZ7TK
UT WOS:000523461800001
PM 32265714
OA gold, Green Published
HC Y
HP N
DA 2022-04-25
ER

PT J
AU An, X
   Sarmiento, C
   Tan, T
   Zhu, H
AF An, Xin
   Sarmiento, Cesar
   Tan, Tao
   Zhu, Hua
TI Regulation of multidrug resistance by microRNAs in anti-cancer therapy
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Review
DE Multidrug resistance; miRNA; Cancer; Therapy; Autophagy; Redox
   Homeostasis
ID GLUTATHIONE-S-TRANSFERASE; BREAST-CANCER CELLS; HUMAN
   HEPATOCELLULAR-CARCINOMA; P53 PROTEIN EXPRESSION; DRUG-RESISTANCE;
   GASTRIC-CANCER; DOWN-REGULATION; COLORECTAL-CANCER; MDR1/P-GLYCOPROTEIN
   EXPRESSION; CISPLATIN RESISTANCE
AB Multidrug resistance (MDR) remains a major clinical obstacle to successful cancer treatment. Although diverse mechanisms of MDR have been well elucidated, such as dysregulation of drugs transporters, defects of apoptosis and autophagy machinery, alterations of drug metabolism and drug targets, disrupti on of redox homeostasis, the exact mechanisms of MDR in a specific cancer patient and the cross-talk among these different mechanisms and how they are regulated are poorly understood. MicroRNAs (miRNAs) are a new class of small noncoding RNAs that could control the global activity of the cell by post-transcriptionally regulating a large variety of target genes and proteins expression. Accumulating evidence shows that miRNAs play a key regulatory role in MDR through modulating various drug resistant mechanisms mentioned above, thereby holding much promise for developing novel and more effective individualized therapies for cancer treatment. This review summarizes the various MDR mechanisms and mainly focuses on the role of miRNAs in regulating MDR in cancer treatment. (C) 2017 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [An, Xin] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.
   [An, Xin; Sarmiento, Cesar; Tan, Tao; Zhu, Hua] Ohio State Univ, Dept Surg, Davis Heart & Lung Res Inst, Wexner Med Ctr, Columbus, OH 43210 USA.
RP Tan, T; Zhu, H (corresponding author), Ohio State Univ, Dept Surg, Davis Heart & Lung Res Inst, Wexner Med Ctr, Columbus, OH 43210 USA.
EM Tao.Tan@osumc.edu; Hua.Zhu@osumc.edu
OI Zhu, Hua/0000-0001-7136-7326
FU U.S. National Institute of HealthUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA [R01 HL124122,
   AR067766]; American Heart AssociationAmerican Heart Association
   [12SDG12070174]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81401155]; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung
   & Blood Institute (NHLBI) [R01HL124122] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS) [R01AR067766] Funding Source:
   NIH RePORTER
FX The Zhu's laboratory is supported by U.S. National Institute of Health
   Grants R01 HL124122, AR067766 and American Heart Association Grant
   12SDG12070174. The Tan's laboratory is supported by the National Natural
   Science Foundation of China (Grant No. 81401155).
CR Acharya A, 2010, OXID MED CELL LONGEV, V3, P23, DOI 10.4161/oxim.3.1.10095
   Allen KA, 1998, CANCER CYTOPATHOL, V84, P324, DOI 10.1002/(SICI)1097-0142(19981225)84:6<324::AID-CNCR2>3.0.CO;2-5
   Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Assaraf YG, 2003, J BIOL CHEM, V278, P6680, DOI 10.1074/jbc.M209186200
   Backos DS, 2012, BIOCHEM PHARMACOL, V83, P1005, DOI 10.1016/j.bcp.2011.11.016
   Baguley BC, 2010, METHODS MOL BIOL, V596, P1, DOI 10.1007/978-1-60761-416-6_1
   Bao LL, 2012, AM J PATHOL, V180, P2490, DOI 10.1016/j.ajpath.2012.02.024
   Beeghly A, 2006, GYNECOL ONCOL, V100, P330, DOI 10.1016/j.ygyno.2005.08.035
   Bentires-Alj M, 2003, ONCOGENE, V22, P90, DOI 10.1038/sj.onc.1206056
   Bhutia YD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053436
   Blower PE, 2008, MOL CANCER THER, V7, P1, DOI 10.1158/1535-7163.MCT-07-0573
   Boni V, 2010, MOL CANCER THER, V9, P2265, DOI 10.1158/1535-7163.MCT-10-0061
   Chakraborty S, 2014, FEBS LETT, V588, P549, DOI 10.1016/j.febslet.2013.11.040
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023
   Chen F, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031645, 10.1371/journal.pone.0039197]
   Chen L, 2014, EXP THER MED, V8, P527, DOI 10.3892/etm.2014.1752
   Chen M, 2014, INT J MOL MED, V34, P276, DOI 10.3892/ijmm.2014.1772
   Chen S, 2015, DRUG DES DEV THER, V9, P5225, DOI 10.2147/DDDT.S87526
   Chen SN, 2016, TUMOR BIOL, V37, P2321, DOI 10.1007/s13277-015-3800-9
   Chen ZL, 2013, CELL SIGNAL, V25, P2693, DOI 10.1016/j.cellsig.2013.08.032
   Chiyomaru T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058929
   Choi YM, 2012, INT J ONCOL, V41, P331, DOI 10.3892/ijo.2012.1418
   Cittelly DM, 2010, CARCINOGENESIS, V31, P2049, DOI 10.1093/carcin/bgq192
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Crommentuyn KML, 1998, CANCER TREAT REV, V24, P345, DOI 10.1016/S0305-7372(98)90057-3
   DOLE M, 1994, CANCER RES, V54, P3253
   Dong J, 2011, ARCH MED RES, V42, P8, DOI 10.1016/j.arcmed.2011.01.006
   Drayton RM, 2014, CLIN CANCER RES, V20, P1990, DOI 10.1158/1078-0432.CCR-13-2805
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fan CD, 2014, ONCOTARGET, V5, P2853, DOI 10.18632/oncotarget.1854
   Fan YN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108514
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x
   Feng R, 2015, INT J CLIN EXP PATHO, V8, P6107
   FOJO A, 1987, CANCER-AM CANCER SOC, V60, P2075, DOI 10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F
   Fojo T, 2007, DRUG RESIST UPDATE, V10, P59, DOI 10.1016/j.drup.2007.02.002
   Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797
   Fujita Y, 2008, BIOCHEM BIOPH RES CO, V377, P114, DOI 10.1016/j.bbrc.2008.09.086
   Ganapathi RN, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00089
   Ge J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067589
   Geng M, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-198
   Ghadimi MP, 2012, MOL CANCER THER, V11, P1758, DOI 10.1158/1535-7163.MCT-12-0015
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002
   Gong J, 2012, CANCER TREAT REV, V38, P226, DOI 10.1016/j.ctrv.2011.06.005
   Gottesman MM, 2006, FEBS LETT, V580, P998, DOI 10.1016/j.febslet.2005.12.060
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Hamada S, 2014, CELL SIGNAL, V26, P179, DOI 10.1016/j.cellsig.2013.11.003
   He HF, 2016, MOL MED REP, V13, P1923, DOI 10.3892/mmr.2015.4727
   Hennigan RF, 2013, ONCOGENE, V32, P1135, DOI 10.1038/onc.2012.135
   Henson ES, 2006, CELL SIGNAL, V18, P2089, DOI 10.1016/j.cellsig.2006.05.015
   Hirota T, 2012, LUNG CANCER, V77, P16, DOI 10.1016/j.lungcan.2011.12.018
   Huang NN, 2015, CANCER BIOL THER, V16, P941, DOI 10.1080/15384047.2015.1040963
   Huang SX, 2014, TOXICOL LETT, V226, P277, DOI 10.1016/j.toxlet.2014.02.017
   Huang WC, 2009, J FORMOS MED ASSOC, V108, P180, DOI 10.1016/S0929-6646(09)60051-6
   Iida K, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-21
   Jardim BV, 2013, ONCOL REP, V30, P1119, DOI 10.3892/or.2013.2540
   Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714
   Jiao XY, 2013, BREAST CANCER RES TR, V139, P717, DOI 10.1007/s10549-013-2607-x
   Kap EJ, 2014, PHARMACOGENET GENOM, V24, P340, DOI 10.1097/FPC.0000000000000059
   KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Kivisto KT, 1995, BRIT J CLIN PHARMACO, V40, P523, DOI 10.1111/j.1365-2125.1995.tb05796.x
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Kumar A, 2015, FUTURE MED CHEM, V7, P1535, DOI 10.4155/fmc.15.88
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li J, 2011, MOL CELL BIOCHEM, V357, P31, DOI 10.1007/s11010-011-0872-8
   Li WQ, 2010, MED SCI MONITOR, V16, pHY27
   Li X, 2015, CURR PROTEIN PEPT SC, V16, P301, DOI 10.2174/138920371604150429153309
   Li X, 2011, BIOCHEM PHARMACOL, V81, P783, DOI 10.1016/j.bcp.2010.12.018
   Li ZM, 2010, GYNECOL ONCOL, V119, P125, DOI 10.1016/j.ygyno.2010.06.004
   Liang LH, 2011, ACTA PHARMACOL SIN, V32, P1311, DOI 10.1038/aps.2011.103
   Liang S, 2016, ACTA BIOCH BIOPH SIN, V48, P174, DOI 10.1093/abbs/gmv127
   Liang ZX, 2010, BIOCHEM PHARMACOL, V79, P817, DOI 10.1016/j.bcp.2009.10.017
   Lin CJF, 2008, BIOCHEM BIOPH RES CO, V375, P315, DOI 10.1016/j.bbrc.2008.07.154
   Liu W, 2015, J CELL MOL MED, V19, P1949, DOI 10.1111/jcmm.12570
   Liu Y.T., 2016, ONCOTARGET
   Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma MT, 2013, CANCER LETT, V339, P107, DOI 10.1016/j.canlet.2013.07.016
   Maftouh M, 2014, NUCLEOS NUCLEOT NUCL, V33, P384, DOI 10.1080/15257770.2014.891741
   Mao QC, 2005, AAPS J, V7, pE118, DOI 10.1208/aapsj070112
   Martinez VG, 2008, BRIT J CANCER, V98, P564, DOI 10.1038/sj.bjc.6604195
   Marullo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081162
   Mendell JT, 2012, CELL, V148, P1172, DOI 10.1016/j.cell.2012.02.005
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Mikhed Y, 2015, REDOX BIOL, V5, P275, DOI 10.1016/j.redox.2015.05.008
   Milicevic Z, 2014, EXCLI J, V13, P691
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Mu WJ, 2015, CELL RES, V25, P477, DOI 10.1038/cr.2015.23
   Munoz JL, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.60
   Mwinyi J, 2014, CANCER CHEMOTH PHARM, V73, P1181, DOI 10.1007/s00280-014-2453-5
   Nakamura J, 2010, INT J ONCOL, V37, P845, DOI 10.3892/ijo_00000735
   Nitiss JL, 2009, NAT REV CANCER, V9, P338, DOI 10.1038/nrc2607
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Oshika Y, 1998, MODERN PATHOL, V11, P1059
   Ouyang YB, 2015, ANTIOXID REDOX SIGN, V22, P187, DOI 10.1089/ars.2013.5757
   Paillas S, 2012, AUTOPHAGY, V8, P1098, DOI 10.4161/auto.20268
   Pan BZ, 2015, ONCOTARGET, V6, P32805, DOI 10.18632/oncotarget.5352
   Pan YZ, 2015, GENET MOL RES, V14, P5621, DOI 10.4238/2015.May.25.14
   Pan YZ, 2013, DRUG METAB DISPOS, V41, P1744, DOI 10.1124/dmd.113.052092
   Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163
   Patterson LH, 2002, CURR PHARM DESIGN, V8, P1335, DOI 10.2174/1381612023394502
   Penna E, 2015, J INVEST DERMATOL, V135, P960, DOI 10.1038/jid.2014.479
   Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0
   Piecuch A, 2014, CELL MOL BIOL LETT, V19, P1, DOI 10.2478/s11658-013-0111-2
   Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515
   Pompella A, 2007, CURR OPIN PHARMACOL, V7, P360, DOI 10.1016/j.coph.2007.04.004
   Qu J, 2015, J CELL PHYSIOL, V230, P535, DOI 10.1002/jcp.24366
   Quintavalle C, 2013, ONCOGENE, V32, P4001, DOI 10.1038/onc.2012.410
   Ramsay EE, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00181
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109
   Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852
   Rutnam ZJ, 2013, MATRIX BIOL, V32, P74, DOI 10.1016/j.matbio.2012.11.003
   Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2
   Schnekenburger M, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00170
   Shang Y, 2014, ONCOGENE, V33, P3267, DOI 10.1038/onc.2013.297
   Shang YL, 2016, ONCOTARGET, V7, P538, DOI 10.18632/oncotarget.6374
   Singh S, 2015, CANCER CHEMOTH PHARM, V75, P1, DOI 10.1007/s00280-014-2566-x
   Sodani K, 2012, CHIN J CANCER, V31, P58, DOI 10.5732/cjc.011.10329
   Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621
   Stanton MJ, 2013, CANCER RES, V73, P160, DOI 10.1158/0008-5472.CAN-11-3635
   Sumbul AT, 2014, TUMOR BIOL, V35, P12713, DOI 10.1007/s13277-014-2596-3
   Sun CY, 2013, JNCI-J NATL CANCER I, V105, P1750, DOI 10.1093/jnci/djt302
   Sun YL, 2012, ANTI-CANCER DRUG, V23, P865, DOI 10.1097/CAD.0b013e328354a196
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takagi S, 2008, J BIOL CHEM, V283, P9674, DOI 10.1074/jbc.M709382200
   Tiwari AK, 2011, CURR PHARM BIOTECHNO, V12, P570
   To KKW, 2008, MOL CELL BIOL, V28, P5147, DOI 10.1128/MCB.00331-08
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Traverso N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/972913
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   Turrini E, 2012, PHARMACOGENET GENOM, V22, P198, DOI 10.1097/FPC.0b013e328350012b
   Turzanski J, 2000, EUR J CANCER, V36, P270, DOI 10.1016/S0959-8049(99)00286-5
   Ubeyli E. D., 2010, COMPUTATIONAL INTELL, V37, P233, DOI DOI 10.1371/J0URNAL.P0NE.0038706
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P6982, DOI 10.1073/pnas.1002472107
   Vassal G, 1998, BIOCHIMIE, V80, P271, DOI 10.1016/S0300-9084(98)80009-6
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Verdoodt B, 2013, INT J ONCOL, V43, P307, DOI 10.3892/ijo.2013.1915
   Wang DS, 2014, ONCOTARGET, V5, P4529, DOI 10.18632/oncotarget.2102
   Wang F, 2013, BIOCHEM BIOPH RES CO, V434, P688, DOI 10.1016/j.bbrc.2013.04.010
   Wang F, 2013, FEBS LETT, V587, P488, DOI 10.1016/j.febslet.2013.01.016
   Wang J, 2015, DRUG DEVELOP RES, V76, P368, DOI 10.1002/ddr.21275
   Wang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125473
   Wang YS, 2012, ASIAN PAC J CANCER P, V13, P255, DOI 10.7314/APJCP.2012.13.1.255
   Wen J, 2015, BREAST CANCER RES TR, V149, P619, DOI 10.1007/s10549-015-3283-9
   Wilson TR, 2006, ANN ONCOL, V17, pX315, DOI 10.1093/annonc/mdl280
   Wilson TR, 2009, CURR CANCER DRUG TAR, V9, P307, DOI 10.2174/156800909788166547
   Wu DD, 2016, TUMOR BIOL, V37, P10499, DOI 10.1007/s13277-016-4944-y
   Wu K, 2016, CANCER LETT, V371, P125, DOI 10.1016/j.canlet.2015.11.031
   Wu Q, 2014, ONCOTARGET, V5, P11552, DOI 10.18632/oncotarget.2594
   Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501
   Xiao J, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-35
   Xu K, 2013, MOL CARCINOGEN, V52, P70, DOI 10.1002/mc.21832
   Xu RD, 2016, ONCOL REP, V35, P1757, DOI 10.3892/or.2015.4497
   Xu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082062
   Yang GW, 2013, DISCRETE DYN NAT SOC, V2013, DOI 10.1155/2013/507828
   Yang MF, 2014, ANTI-CANCER AGENT ME, V14, P884, DOI 10.2174/1871520614666140528161318
   Yang SM, 2013, TOXICOLOGY, V306, P162, DOI 10.1016/j.tox.2013.02.014
   Yang T, 2013, EXP BIOL MED, V238, P1024, DOI 10.1177/1535370213497321
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Ying HC, 2015, ONCOL LETT, V9, P1759, DOI 10.3892/ol.2015.2950
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Yu L, 2014, CANCER LETT, V355, P34, DOI 10.1016/j.canlet.2014.09.020
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yu Y, 2012, AUTOPHAGY, V8, P853, DOI 10.4161/auto.20053
   Zeng LP, 2016, J CELL MOL MED, V20, P559, DOI 10.1111/jcmm.12760
   Zhang XL, 2012, LUNG CANCER, V77, P488, DOI 10.1016/j.lungcan.2012.05.107
   Zhang Y, 2014, BIOCHEM PHARMACOL, V87, P562, DOI 10.1016/j.bcp.2013.12.004
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
   Zhao J, 2016, GENE, V576, P828, DOI 10.1016/j.gene.2015.11.013
   Zhao XH, 2010, LEUKEMIA RES, V34, P1078, DOI 10.1016/j.leukres.2009.10.002
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zhu J, 2014, FRONT GENET, V5, DOI [10.3389/fgene.2014.00149, 10.3389/fgene.2014.00187]
   Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3
   Zhu W, 2012, MED ONCOL, V29, P384, DOI 10.1007/s12032-010-9797-4
NR 183
TC 112
Z9 120
U1 3
U2 41
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD JAN
PY 2017
VL 7
IS 1
BP 38
EP 51
DI 10.1016/j.apsb.2016.09.002
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EO1FB
UT WOS:000396442700006
PM 28119807
OA Green Published, gold
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Ha, TK
   Her, NG
   Lee, MG
   Ryu, BK
   Lee, JH
   Han, J
   Jeong, SI
   Kang, MJ
   Kim, NH
   Kim, HJ
   Chi, SG
AF Ha, Tae-Kyu
   Her, Nam-Gu
   Lee, Min-Goo
   Ryu, Byung-Kyu
   Lee, Jin-Hee
   Han, Jikhyon
   Jeong, Seong-In
   Kang, Min-Ju
   Kim, Nam-Hoon
   Kim, Hyo-Jong
   Chi, Sung-Gil
TI Caveolin-1 Increases Aerobic Glycolysis in Colorectal Cancers by
   Stimulating HMGA1-Mediated GLUT3 Transcription
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; GENE; METASTASIS; EXPRESSION; PROSTATE
AB Caveolin-1 (CAV1) acts as a growth suppressor in various human malignancies, but its expression is elevated in many advanced cancers, suggesting the oncogenic switch of its role during tumor progression. To understand the molecular basis for the growth-promoting function of CAV1, we characterized its expression status, differential roles for tumor growth, and effect on glucose metabolism in colorectal cancers. Abnormal elevation of CAV1 was detected in a substantial fraction of primary tumors and cell lines and tightly correlated with promoter CpG sites hypomethylation. Depletion of elevated CAV1 led to AMPK activation followed by a p53-dependent G(1) cell-cycle arrest and autophagy, suggesting that elevated CAV1 may contribute to ATP generation. Furthermore, CAV1 depletion downregulated glucose uptake, lactate accumulation, and intracellular ATP level, supporting that aerobic glycolysis is enhanced by CAV1. Consistently, CAV1 was shown to stimulate GLUT3 transcription via an HMGA1-binding site within the GLUT3 promoter. HMGA1 was found to interact with and activate the GLUT3 promoter and CAV1 increased the HMGA1 activity by enhancing its nuclear localization. Ectopic expression of HMGA1 increased glucose uptake, whereas its knockdown caused AMPK activation. In addition, GLUT3 expression was strongly induced by cotransfection of CAV1 and HMGA1, and its overexpression was observed predominantly in tumors harboring high levels of CAV1 and HMGA1. Together, these data show that elevated CAV1 upregulates glucose uptake and ATP production through HMGA1-mediated GLUT3 transcription, suggesting that CAV1 may render tumor cells growth advantages by enhancing aerobic glycolysis. Cancer Res; 72(16); 4097-109. (C) 2012 AACR.
C1 [Ha, Tae-Kyu; Her, Nam-Gu; Lee, Min-Goo; Ryu, Byung-Kyu; Lee, Jin-Hee; Han, Jikhyon; Jeong, Seong-In; Kang, Min-Ju; Chi, Sung-Gil] Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.
   [Kim, Hyo-Jong] Kyung Hee Univ, Dept Internal Med, Sch Med, Seoul, South Korea.
   [Kim, Nam-Hoon] Inje Univ, Dept Internal Med, Ilsan Paik Hosp, Coll Med, Goyang, South Korea.
RP Chi, SG (corresponding author), Korea Univ, Sch Life Sci & Biotechnol, Seoul 136701, South Korea.
EM chi6302@korea.ac.kr
RI Her, Nam-Gu/AGY-5470-2022; Kang, Min-Ju/AAY-8706-2021; Han,
   Jikhyon/L-7891-2014
OI Han, Jikhyon/0000-0002-7767-3305; KANG, MIN-JU/0000-0001-5040-1388
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [2009-0078864, 2009-0087099]; National Cancer Center, Republic of
   Korea [0820070]
FX This work was supported in part by grants from National Research
   Foundation of Korea (2009-0078864 and 2009-0087099) and the National
   Cancer Center (0820070), Republic of Korea.
CR Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Byun DS, 2003, CANCER RES, V63, P7068
   Capozza F, 2003, AM J PATHOL, V162, P2029, DOI 10.1016/S0002-9440(10)64335-0
   Chae KS, 2011, ONCOGENE, V30, P1213, DOI 10.1038/onc.2010.498
   Detterbeck FC, 2004, CHEST, V126, P1656, DOI 10.1378/chest.126.5.1656
   Eng CH, 2011, ONCOGENE, V30, P4687, DOI 10.1038/onc.2011.220
   Fernandez MA, 2006, SCIENCE, V313, P1628, DOI 10.1126/science.1130773
   Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271
   Gustavsson J, 1999, FASEB J, V13, P1961, DOI 10.1096/fasebj.13.14.1961
   Hardie DG, 2011, AM J CLIN NUTR, V93, p891S, DOI 10.3945/ajcn.110.001925
   Hayashi K, 2001, CANCER RES, V61, P2361
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381
   Lopez-Lazaro M, 2007, INT J CANCER, V120, P1378, DOI 10.1002/ijc.22493
   Medina RA, 2002, BIOL RES, V35, P9, DOI 10.4067/S0716-97602002000100004
   Mori Y, 2006, GASTROENTEROLOGY, V131, P797, DOI 10.1053/j.gastro.2006.06.006
   Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Resar LMS, 2010, CANCER RES, V70, P436, DOI 10.1158/0008-5472.CAN-09-1212
   Shatz M, 2008, INT J RADIAT BIOL, V84, P177, DOI 10.1080/09553000701745293
   Simpson IA, 2008, AM J PHYSIOL-ENDOC M, V295, pE242, DOI 10.1152/ajpendo.90388.2008
   Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856
   Tahir SA, 2001, CANCER RES, V61, P3882
   Timme TL, 2000, ONCOGENE, V19, P3256, DOI 10.1038/sj.onc.1203654
   Van den Eynden GG, 2006, BREAST CANCER RES TR, V95, P219, DOI 10.1007/s10549-005-9002-1
   Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004
   Yang G, 1998, CLIN CANCER RES, V4, P1873
NR 29
TC 81
Z9 82
U1 2
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD AUG 15
PY 2012
VL 72
IS 16
BP 4097
EP 4109
DI 10.1158/0008-5472.CAN-12-0448
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 993SY
UT WOS:000307881100022
PM 22706202
DA 2022-04-25
ER

PT J
AU Guo, ZX
   Zhou, C
   Zhong, X
   Shi, JX
   Wu, ZH
   Tang, KW
   Wang, ZN
   Song, YX
AF Guo, Zhexu
   Zhou, Cen
   Zhong, Xi
   Shi, Jinxin
   Wu, Zhonghua
   Tang, Kaiwen
   Wang, Zhenning
   Song, Yongxi
TI The long noncoding RNA CTA-941F9.9 is frequently downregulated and may
   serve as a biomarker for carcinogenesis in colorectal cancer
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE biomarker; carcinogenesis; colorectal cancer; 9; long noncoding RNAs
ID POOR-PROGNOSIS; CELL-PROLIFERATION; EXPRESSION; AUTOPHAGY; PROMOTES;
   CCAT1; LC3; INHIBITION; INVASION
AB Background Long noncoding RNAs (lncRNAs) participate in the carcinogenesis of many different cancers. This study aimed to detect expression of lncRNA CTA-941F9.9 in colorectal cancer tissues compared with matched nontumorous adjacent tissues (NATs). Moreover, we investigated whether this molecule is able to influence carcinogenesis in colorectal cancer (CRC). Methods Colorectal cancer tissues and NATs from two cohorts of patients were examined. Quantitative PCR was performed to quantify levels of CTA-941F9.9 expression in these samples. The association between CTA-941F9.9 expression and clinicopathological features, including receiver operating characteristic (ROC) curves, was also analyzed to evaluate the diagnostic value of CTA-941F9.9 in CRC. Potential effects of lncRNA CTA-941F9.9 on CRC cells were assessed via autophagy, transwell assay, CCK8 assays, and flow cytometry. Results Our experimental results showed lncRNA CTA-941F9.9 to be significantly downregulated in CRC tissues in both cohorts, with areas under the ROC curve (AUC) of 0.802 and 0.876. However, no significant correlations between CTA-941F9.9 expression levels and clinicopathological characteristics or patient outcomes were observed. We also found that CTA-941F9.9 promotes autophagy in CRC cell lines but no significant function of CTA-941F9.9 in regulating cancer cell proliferation or migration. Conclusions LncRNA CTA-941F9.9 is frequently downregulated in CRC compared with NATs and might play an important role in CRC carcinogenesis.
C1 [Guo, Zhexu; Zhou, Cen; Zhong, Xi; Shi, Jinxin; Wu, Zhonghua; Tang, Kaiwen; Wang, Zhenning; Song, Yongxi] China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
RP Wang, ZN; Song, YX (corresponding author), China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, 155 North Nanjing St, Shenyang 110001, Liaoning, Peoples R China.
EM josieon826@sina.cn; songyongxi840309@126.com
RI wang, zhen ning/E-1878-2011
OI wang, zhen ning/0000-0003-0557-3097; Song, Yongxi/0000-0002-5736-9453
FU Natural Science Foundation of Liaoning ProvinceNatural Science
   Foundation of Liaoning Province [20180550582]; National Nature Science
   Foundation-Outstanding Youth Foundation Training Project of China
   Medical University [YQ20160001]; Project of Science and Technology of
   Shenyang [18-014-4-07]
FX This work was supported by Natural Science Foundation of Liaoning
   Province (No. 20180550582), National Nature Science
   Foundation-Outstanding Youth Foundation Training Project of China
   Medical University (YQ20160001), and Project of Science and Technology
   of Shenyang (18-014-4-07).
CR Booth RA, 2007, CANCER LETT, V249, P87, DOI 10.1016/j.canlet.2006.12.021
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   DiStefano JK, 2018, METHODS MOL BIOL, V1706, P91, DOI 10.1007/978-1-4939-7471-9_6
   Dong L, 2015, INT J CANCER, V137, P1128, DOI 10.1002/ijc.29484
   Fu ZQ, 2017, BIOCHEM BIOPH RES CO, V492, P480, DOI 10.1016/j.bbrc.2017.08.070
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Hardcastle JD, 1996, LANCET, V348, P1472, DOI 10.1016/S0140-6736(96)03386-7
   Huang L, 2019, J CELL PHYSIOL, V234, P7032, DOI 10.1002/jcp.27456
   Ito H, 2005, INT J ONCOL, V26, P1401
   Kam Y, 2014, CANCER LETT, V352, P90, DOI 10.1016/j.canlet.2013.02.014
   Kronborg O, 1996, LANCET, V348, P1467, DOI 10.1016/S0140-6736(96)03430-7
   Li L, 2015, ONCOTARGET, V6, P14179, DOI 10.18632/oncotarget.3651
   Li LX, 2018, CELL PHYSIOL BIOCHEM, V48, P1723, DOI 10.1159/000492300
   Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Liu Shi-Ping, 2013, Cancer Biology Medicine, V10, P138, DOI 10.7497/j.issn.2095-3941.2013.03.003
   Liu T, 2016, ONCOTARGETS THER, V9, P1437, DOI 10.2147/OTT.S98268
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901
   Muers M, 2011, NAT REV GENET, V12, DOI 10.1038/nrg3088
   Peng SP, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8273648
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Qi P, 2015, MOL CARCINOGEN, V54, P742, DOI 10.1002/mc.22137
   Qiu MT, 2013, TUMOR BIOL, V34, P613, DOI 10.1007/s13277-013-0658-6
   Sana J, 2012, ONCOLOGY-BASEL, V82, P114, DOI 10.1159/000336479
   Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457
   Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Wang FB, 2014, ONCOTARGET, V5, P11091, DOI 10.18632/oncotarget.2691
   Wang JW, 2017, ONCOL LETT, V13, P3508, DOI 10.3892/ol.2017.5893
   Wang L, 2015, BIOCHEM BIOPH RES CO, V456, P459, DOI 10.1016/j.bbrc.2014.11.106
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   Wu CL, 2018, CANCER MANAG RES, V10, P5261, DOI 10.2147/CMAR.S174066
   Xiao JA, 2011, INT J CARDIOL, V148, P110, DOI 10.1016/j.ijcard.2011.01.029
   Xin XR, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0843-8
   Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x
   Yin DD, 2015, TUMOR BIOL, V36, P4851, DOI 10.1007/s13277-015-3139-2
   Zhang XF, 2015, INT J CLIN EXP PATHO, V8, P9440
   Zheng Q, 2015, CLIN TRANSL ONCOL, V17, P640, DOI 10.1007/s12094-015-1290-2
   Zhu Hua-Qiang, 2015, Asian Pac J Cancer Prev, V16, P5181
NR 43
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PD NOV
PY 2019
VL 33
IS 9
AR e22986
DI 10.1002/jcla.22986
EA JUL 2019
PG 11
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA JR2OL
UT WOS:000479450200001
PM 31343781
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Nahimana, A
   Attinger, A
   Aubry, D
   Greaney, P
   Ireson, C
   Thougaard, AV
   Tjornelund, J
   Dawson, KM
   Dupuis, M
   Duchosal, MA
AF Nahimana, Aimable
   Attinger, Antoine
   Aubry, Dominique
   Greaney, Peter
   Ireson, Christopher
   Thougaard, Annemette V.
   Tjornelund, Jette
   Dawson, Keith M.
   Dupuis, Marc
   Duchosal, Michel A.
TI The NAD biosynthesis inhibitor APO866 has potent antitumor activity
   against hematologic malignancies
SO BLOOD
LA English
DT Article
ID NICOTINAMIDE ADENINE-DINUCLEOTIDE; MAMMALIAN-CELLS; COLORECTAL-CANCER;
   DNA-DAMAGE; DEPLETION; APOPTOSIS; FK866; AUTOPHAGY; DEATH; CASCADE
AB APO866 inhibits nicotinamide phosphoribosyltransferase (NMPRTase), a key enzyme involved in nicotinamide adenine dinucleotide (NAD) biosynthesis from the natural precursor nicotinamide. Intracellular NAD is essential for cell survival, and NAD depletion resulting from APO866 treatment elicits tumor cell death. Here, we determine the in vitro and in vivo sensitivities of hematologic cancer cells to APO866 using a panel of cell lines (n = 45) and primary cells (n = 32). Most cancer cells (acute myeloid leukemia [AML], acute lymphoblastic leukemia [ALL], mantle cell lymphoma [MCL], chronic lymphocytic leukemia [CLL], and T-cell lymphoma), but not normal hematopoietic progenitor cells, were sensitive to low concentrations of APO866 as measured in cytotoxicity and clonogenic assays. Treatment with APO866 decreased intracellular NAD and adenosine triphosphate (ATP) at 24 hours and 48 to 72 hours, respectively. The NAD depletion led to cell death. At 96 hours, APO866-mediated cell death occurred in a caspase-independent mode, and was associated with mitochondrial dysfunction and autophagy. Further, in vivo administration of APO866 as a single agent prevented and abrogated tumor growth in animal models of human AML, lymphoblastic lymphoma, and leukemia without significant toxicity to the animals. The results support the potential of APO866 for treating hematologic malignancies. (Blood. 2009; 113:3276-3286)
C1 [Nahimana, Aimable; Aubry, Dominique; Duchosal, Michel A.] Univ Lausanne Hosp, Serv Hematol, Lausanne, Switzerland.
   [Attinger, Antoine; Greaney, Peter; Ireson, Christopher; Dawson, Keith M.; Dupuis, Marc] TopoTarget Switzerland, Lausanne, Switzerland.
   [Thougaard, Annemette V.; Tjornelund, Jette] TopoTarget Denmark, Copenhagen, Denmark.
RP Duchosal, MA (corresponding author), Univ Hosp Lausanne CHUV, Serv Hematol, 46 Rue Bugnon, CH-1011 Lausanne, Switzerland.
EM michel.duchosal@chuv.ch
OI Thougaard, Annemette Vinding/0000-0001-5407-2315
FU Swiss Federal Office for Professional Education and Technology [8368.2
   LSPP-LS]
FX This work was supported by a contract (no. 8368.2 LSPP-LS) from the
   innovation promotion agency at the Swiss Federal Office for Professional
   Education and Technology.
CR Alano CC, 2004, J BIOL CHEM, V279, P18895, DOI 10.1074/jbc.M313329200
   ALVAREZGONZALEZ R, 1986, BIOCHEM BIOPH RES CO, V138, P1051, DOI 10.1016/S0006-291X(86)80388-6
   Basso K, 1999, AM J PATHOL, V155, P1479, DOI 10.1016/S0002-9440(10)65463-6
   Billington RA, 2008, AUTOPHAGY, V4, P385, DOI 10.4161/auto.5635
   Billington RA, 2008, J BIOL CHEM, V283, P6367, DOI 10.1074/jbc.M706204200
   Busso N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002267
   Dick JE, 1997, STEM CELLS, V15, P199, DOI 10.1002/stem.5530150826
   Drevs J, 2003, ANTICANCER RES, V23, P4853
   Du LN, 2003, J BIOL CHEM, V278, P18426, DOI 10.1074/jbc.M301295200
   Greaney P, 2006, LEUKEMIA RES, V30, P415, DOI 10.1016/j.leukres.2005.08.006
   Hasmann M, 2003, CANCER RES, V63, P7436
   Heller B, 1997, ADV EXP MED BIOL, V426, P329
   Holen K, 2008, INVEST NEW DRUG, V26, P45, DOI 10.1007/s10637-007-9083-2
   Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1
   JACOBSON MK, 1986, BIOCHEMISTRY-US, V25, P5929, DOI 10.1021/bi00368a014
   Khan JA, 2006, NAT STRUCT MOL BIOL, V13, P582, DOI 10.1038/nsmb1105
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Komatsu N, 2000, J BIOCHEM-TOKYO, V128, P463, DOI 10.1093/oxfordjournals.jbchem.a022775
   Martin DS, 1997, ONCOL RES, V9, P1
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Muruganandham M, 2005, CLIN CANCER RES, V11, P3503, DOI 10.1158/1078-0432.CCR-04-1399
   Pogrebniak A, 2006, EUR J MED RES, V11, P313
   Rongvaux A, 2008, J IMMUNOL, V181, P4685, DOI 10.4049/jimmunol.181.7.4685
   van Beijnum JR, 2002, INT J CANCER, V101, P118, DOI 10.1002/ijc.10584
   Wosikowski K, 2002, CANCER RES, V62, P1057
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Ziegler M, 2000, EUR J BIOCHEM, V267, P1550, DOI 10.1046/j.1432-1327.2000.01187.x
NR 28
TC 147
Z9 152
U1 4
U2 18
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD APR 2
PY 2009
VL 113
IS 14
BP 3276
EP 3286
DI 10.1182/blood-2008-08-173369
PG 11
WC Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology
GA 428LH
UT WOS:000264848900021
PM 19196867
DA 2022-04-25
ER

PT J
AU Cazzanelli, G
   Pereira, F
   Alves, S
   Francisco, R
   Azevedo, L
   Carvalho, PD
   Almeida, A
   Corte-Real, M
   Oliveira, MJ
   Lucas, C
   Sousa, MJ
   Preto, A
AF Cazzanelli, Giulia
   Pereira, Flavia
   Alves, Sara
   Francisco, Rita
   Azevedo, Luisa
   Carvalho, Patricia Dias
   Almeida, Ana
   Corte-Real, Manuela
   Oliveira, Maria Jose
   Lucas, Candida
   Sousa, Maria Joao
   Preto, Ana
TI The Yeast Saccharomyces cerevisiae as a Model for Understanding RAS
   Proteins and Their Role in Human Tumorigenesis
SO CELLS
LA English
DT Review
DE RAS proteins; S. cerevisiae; model; homologues; colorectal cancer;
   autophagy; KRAS
ID GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; ANCHORAGE-INDEPENDENT GROWTH;
   ADENYLATE-CYCLASE PATHWAY; PROGRAMMED CELL-DEATH; GENOME-WIDE SCREEN;
   CDC25 GENE-PRODUCT; K-RAS; H-RAS; CYCLIC-AMP
AB The exploitation of the yeast Saccharomyces cerevisiae as a biological model for the investigation of complex molecular processes conserved in multicellular organisms, such as humans, has allowed fundamental biological discoveries. When comparing yeast and human proteins, it is clear that both amino acid sequences and protein functions are often very well conserved. One example of the high degree of conservation between human and yeast proteins is highlighted by the members of the RAS family. Indeed, the study of the signaling pathways regulated by RAS in yeast cells led to the discovery of properties that were often found interchangeable with RAS proto-oncogenes in human pathways, and vice versa. In this work, we performed an updated critical literature review on human and yeast RAS pathways, specifically highlighting the similarities and differences between them. Moreover, we emphasized the contribution of studying yeast RAS pathways for the understanding of human RAS and how this model organism can contribute to unveil the roles of RAS oncoproteins in the regulation of mechanisms important in the tumorigenic process, like autophagy.
C1 [Cazzanelli, Giulia; Pereira, Flavia; Alves, Sara; Francisco, Rita; Azevedo, Luisa; Carvalho, Patricia Dias; Almeida, Ana; Corte-Real, Manuela; Lucas, Candida; Sousa, Maria Joao; Preto, Ana] Univ Minho, Dept Biol, CBMA Ctr Mol & Environm Biol, Campus Gualtar, P-4710057 Braga, Portugal.
   [Pereira, Flavia; Alves, Sara; Azevedo, Luisa; Carvalho, Patricia Dias; Oliveira, Maria Jose] Univ Porto, Inst Invest & Inovacao Saude, Rua Alfredo Allen 208, P-4200135 Porto, Portugal.
   [Pereira, Flavia; Oliveira, Maria Jose] INEB Inst Biomed Engn, New Therapies Grp, P-4200135 Porto, Portugal.
   [Alves, Sara; Azevedo, Luisa; Carvalho, Patricia Dias] Univ Porto, IPATIMUP Inst Mol Pathol & Immunol, Rua Julio Amaral de Carvalho 45, P-4200135 Porto, Portugal.
   [Azevedo, Luisa] Univ Porto, Dept Biol, Fac Sci, Rua Campo Alegre S-N, P-4169007 Porto, Portugal.
RP Sousa, MJ; Preto, A (corresponding author), Univ Minho, Dept Biol, CBMA Ctr Mol & Environm Biol, Campus Gualtar, P-4710057 Braga, Portugal.
EM giulia.cazzanelli88@gmail.com; flaviabrandao.fcbp@gmail.com;
   sara.csa@gmail.com; rita.francisco.28@gmail.com; lazevedo@ipatimup.pt;
   pat.dcarvalho@gmail.com; anafmalmeida@gmail.com;
   mcortereal@bio.uminho.pt; mariajo@ineb.up.pt; clucas@bio.uminho.pt;
   mjsousa@bio.uminho.pt; apreto@bio.uminho.pt
RI Preto, Ana/H-8112-2012; Almeida, Ana/AAB-8709-2020; Corte-Real,
   Manuela/B-6328-2013; Alves, Sara/U-5006-2019; Sousa, Maria
   João/H-8775-2013; Oliveira, Maria Jose/K-3275-2013; Azevedo,
   Luisa/J-4051-2013; Lucas, Candida/A-3663-2010
OI Preto, Ana/0000-0002-7302-0630; Almeida, Ana/0000-0001-6663-6851;
   Corte-Real, Manuela/0000-0002-1423-1331; Sousa, Maria
   João/0000-0001-9424-4150; Oliveira, Maria Jose/0000-0002-0724-0272;
   Francisco, Rita/0000-0002-4398-3401; Azevedo, Luisa/0000-0002-3157-7342;
   Alves, Sara/0000-0003-0404-5954; Lucas, Candida/0000-0001-8605-4525;
   Dias Carvalho, Patricia/0000-0002-8110-8157
FU national funds through the FCT I. P [UID/BIA/04050/2013
   (POCI-01-0145-FEDER-007569)]; ERDF through the COMPETE2020-Programa
   Operacional Competitividade e Internacionalizacao (POCI); Portuguese
   Foundation for Science and Technology (FCT)Portuguese Foundation for
   Science and Technology [UID/BIO/04469/2013]; COMPETE
   [POCI-01-0145-FEDER-006684]; FCT fellowships: Sara Alves [FCT
   SFRH/BD/64695/2009]; Marie Curie Initial Training NetworkEuropean
   Commission [PITN-GA-2012-317297]
FX This work was supported by the strategic program UID/BIA/04050/2013
   (POCI-01-0145-FEDER-007569) funded by national funds through the FCT I.
   P. and by the ERDF through the COMPETE2020-Programa Operacional
   Competitividade e Internacionalizacao (POCI). It was also supported by
   the Portuguese Foundation for Science and Technology (FCT) under the
   scope of the strategic funding of the UID/BIO/04469/2013 unit and
   COMPETE 2020 (POCI-01-0145-FEDER-006684) and FCT fellowships: Sara Alves
   (FCT SFRH/BD/64695/2009). This work was also the Marie Curie Initial
   Training Network: PITN-GA-2012-317297 (GC PhD Grant).
CR Abankwa D, 2010, P NATL ACAD SCI USA, V107, P1130, DOI 10.1073/pnas.0903907107
   Agudo-Ibanez L, 2017, METHODS MOL BIOL, V1487, P151, DOI 10.1007/978-1-4939-6424-6_11
   Ahearn IM, 2011, MOL CELL, V41, P173, DOI 10.1016/j.molcel.2011.01.001
   Alves S, 2015, ONCOTARGET, V6, P30787, DOI 10.18632/oncotarget.5021
   Aouida M, 2004, CANCER RES, V64, P1102, DOI 10.1158/0008-5472.CAN-03-2729
   Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000
   Arozarena Imanol, 2011, Genes Cancer, V2, P182, DOI 10.1177/1947601911409213
   Arrington AK, 2012, INT J MOL SCI, V13, P12153, DOI 10.3390/ijms131012153
   Ashery U, 2006, CELL MOL NEUROBIOL, V26, P471, DOI 10.1007/s10571-006-9059-3
   Azevedo L, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-266
   BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4
   Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388
   BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0
   Belotti F, 2012, BBA-MOL CELL RES, V1823, P1208, DOI 10.1016/j.bbamcr.2012.04.016
   Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003
   Bhagatji P, 2010, BIOPHYS J, V99, P3327, DOI 10.1016/j.bpj.2010.10.001
   Birrell GW, 2001, P NATL ACAD SCI USA, V98, P12608, DOI 10.1073/pnas.231366398
   Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241
   Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012
   Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1
   Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358
   BOTSTEIN D, 1988, SCIENCE, V240, P1439, DOI 10.1126/science.3287619
   Botstein D, 2011, GENETICS, V189, P695, DOI 10.1534/genetics.111.130765
   BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0
   BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   BREVIARIO D, 1986, P NATL ACAD SCI USA, V83, P4152, DOI 10.1073/pnas.83.12.4152
   BREVIARIO D, 1988, EMBO J, V7, P1805, DOI 10.1002/j.1460-2075.1988.tb03012.x
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X
   BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6
   BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X
   Broggi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079274
   Busti S, 2010, SENSORS-BASEL, V10, P6195, DOI 10.3390/s100606195
   CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7
   Carmona-Gutierrez D, 2010, CELL DEATH DIFFER, V17, P763, DOI 10.1038/cdd.2009.219
   Carneiro J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064674
   Carozzi AJ, 2002, J BIOL CHEM, V277, P17944, DOI 10.1074/jbc.M110879200
   CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323
   Cazzanelli G., 2017, THESIS
   Cebollero E, 2009, BBA-MOL CELL RES, V1793, P1413, DOI 10.1016/j.bbamcr.2009.01.008
   Chang FM, 2003, INT J ONCOL, V22, P469
   Chen M, 2012, ALTERNATIVE PREMRNA, P603
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Chen YQ, 2011, J CELL SCI, V124, P161, DOI 10.1242/jcs.064576
   Cheng CM, 2011, CELL CYCLE, V10, P1180, DOI 10.4161/cc.10.8.15259
   Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174
   Chiu VK, 2002, NAT CELL BIOL, V4, P343, DOI 10.1038/ncb783
   Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8
   CLARK SG, 1985, MOL CELL BIOL, V5, P2746, DOI 10.1128/MCB.5.10.2746
   Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365
   Conrad M, 2014, FEMS MICROBIOL REV, V38, P254, DOI 10.1111/1574-6976.12065
   Coutinho I, 2011, EXP CELL RES, V317, P1147, DOI 10.1016/j.yexcr.2011.02.007
   Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111
   Cox AD, 2002, CANCER BIOL THER, V1, P599, DOI 10.4161/cbt.306
   Cox Adrienne D, 2010, Small GTPases, V1, P2
   Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905
   DEFEOJONES D, 1983, NATURE, V306, P707, DOI 10.1038/306707a0
   DEFEOJONES D, 1985, SCIENCE, V228, P179, DOI 10.1126/science.3883495
   DHAR R, 1984, NUCLEIC ACIDS RES, V12, P3611, DOI 10.1093/nar/12.8.3611
   Di Como CJ, 1998, ONCOGENE, V16, P2527
   Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0
   Downward J, 1997, CURR BIOL, V7, pR258, DOI 10.1016/S0960-9822(06)00116-3
   Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377
   Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113
   Efferth T, 2012, CURR MED CHEM, V19, P5735, DOI 10.2174/092986712803988884
   Elad-Sfadia G, 2004, J BIOL CHEM, V279, P34922, DOI 10.1074/jbc.M312697200
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Engel SR, 2014, G3-GENES GENOM GENET, V4, P389, DOI 10.1534/g3.113.008995
   Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076
   FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2
   FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455
   Fields S, 2005, SCIENCE, V307, P1885, DOI 10.1126/science.1108872
   FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6
   FRAENKEL DG, 1985, P NATL ACAD SCI USA, V82, P4740, DOI 10.1073/pnas.82.14.4740
   FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x
   FRANCOIS J, 1984, EUR J BIOCHEM, V145, P187, DOI 10.1111/j.1432-1033.1984.tb08539.x
   Frohlich KU, 2007, SEMIN CANCER BIOL, V17, P112, DOI 10.1016/j.semcancer.2006.11.006
   Fruhmann G, 2017, MECH AGEING DEV, V161, P288, DOI 10.1016/j.mad.2016.05.002
   FUJIYAMA A, 1991, J BIOL CHEM, V266, P17926
   FUJIYAMA A, 1986, P NATL ACAD SCI USA, V83, P1266, DOI 10.1073/pnas.83.5.1266
   FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x
   FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Gancedo JM, 2008, FEMS MICROBIOL REV, V32, P673, DOI 10.1111/j.1574-6976.2008.00117.x
   Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046
   Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935
   GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026
   GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989
   Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546
   GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665
   Gourlay CW, 2006, MOL CELL BIOL, V26, P6487, DOI 10.1128/MCB.00117-06
   Gourlay CW, 2006, MOL MICROBIOL, V62, P1515, DOI 10.1111/j.1365-2958.2006.05486.x
   Gourlay CW, 2005, J CELL SCI, V118, P2119, DOI 10.1242/jcs.02337
   Guaragnella N, 2014, FEMS YEAST RES, V14, P2, DOI 10.1111/1567-1364.12094
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0
   HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O
   HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8
   HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x
   HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x
   Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105
   HARTWELL LH, 1977, J CELL BIOL, V75, P422, DOI 10.1083/jcb.75.2.422
   HARVEY JJ, 1964, NATURE, V204, P1104, DOI 10.1038/2041104b0
   Hayashi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007655
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Heinicke S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000766
   Herrmann C, 2003, CURR OPIN STRUC BIOL, V13, P122, DOI 10.1016/S0959-440X(02)00007-6
   Ho J, 2001, MOL BIOL CELL, V12, P1541, DOI 10.1091/mbc.12.6.1541
   HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089
   Hu JD, 2001, ONCOGENE, V20, P4235, DOI 10.1038/sj.onc.1204585
   HUBLER L, 1993, MOL CELL BIOL, V13, P6274, DOI 10.1128/MCB.13.10.6274
   Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026
   Ihle N., 2012, THESIS
   Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649
   Jacinto E, 2008, BIOCHEM J, V410, P19, DOI 10.1042/BJ20071518
   Jiang XJ, 2002, MOL BIOL CELL, V13, P1522, DOI 10.1091/mbc.01-11-0552
   JOHNSTON GC, 1979, J BACTERIOL, V137, P1
   Joneson T, 1999, MOL CELL BIOL, V19, P5892
   Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189
   Kang JS, 1996, MOL CELL BIOL, V16, P3370
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   KATAOKA T, 1984, CELL, V37, P437, DOI 10.1016/0092-8674(84)90374-X
   KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6
   Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100
   Kearse M, 2012, BIOINFORMATICS, V28, P1647, DOI 10.1093/bioinformatics/bts199
   Kido M, 2002, J BIOL CHEM, V277, P3117, DOI 10.1074/jbc.M109526200
   KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483
   Kim JH, 2011, AUTOPHAGY, V7, P1187, DOI 10.4161/auto.7.10.16643
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   KIRSTEN W. H., 1966, NAT CANCER INST MONOGR, V22, P369
   Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013
   Kroemer G, 2005, NAT REV CANCER, V5, P886, DOI 10.1038/nrc1738
   Lambert JM, 2002, NAT CELL BIOL, V4, P621, DOI 10.1038/ncb833
   Lastauskiene E, 2014, BIOTECHNOL APPL BIOC, V61, P3, DOI 10.1002/bab.1183
   Laurent JM, 2016, BRIEF FUNCT GENOMICS, V15, P155, DOI 10.1093/bfgp/elv041
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2007, NAT REV IMMUNOL, V7, P767, DOI 10.1038/nri2161
   Levy R, 2010, MOL CANCER THER, V9, P2208, DOI 10.1158/1535-7163.MCT-10-0262
   Liu XL, 2011, AM J CLIN PATHOL, V135, P245, DOI 10.1309/AJCP7FO2VAXIVSTP
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Longo VD, 2012, SUBCELL BIOCHEM, V57, P101, DOI 10.1007/978-94-007-2561-4_5
   LOPEZBOADO YS, 1987, ARCH MICROBIOL, V147, P231, DOI 10.1007/BF00463480
   LORD PG, 1983, J CELL SCI, V59, P183
   Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186
   Ludovico P, 2001, MICROBIOL-SGM, V147, P3335, DOI 10.1099/00221287-147-12-3335
   Madeo F, 1999, J CELL BIOL, V145, P757, DOI 10.1083/jcb.145.4.757
   Mager WH, 2005, TRENDS PHARMACOL SCI, V26, P265, DOI 10.1016/j.tips.2005.03.004
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Majumdar S, 2017, FEBS J, V284, P4358, DOI 10.1111/febs.14314
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Markowska AI, 2010, J EXP MED, V207, P1981, DOI 10.1084/jem.20090121
   MARSHALL MS, 1987, MOL CELL BIOL, V7, P2309, DOI 10.1128/MCB.7.7.2309
   MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x
   Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x
   Massey A, 2004, INT J BIOCHEM CELL B, V36, P2420, DOI 10.1016/j.biocel.2004.04.010
   Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   MATSUMOTO K, 1982, P NATL ACAD SCI-BIOL, V79, P2355, DOI 10.1073/pnas.79.7.2355
   MATSUMOTO K, 1983, CELL, V32, P417, DOI 10.1016/0092-8674(83)90461-0
   MATSUMOTO K, 1983, EXP CELL RES, V146, P151, DOI 10.1016/0014-4827(83)90333-6
   Matuo R, 2012, CANCER CHEMOTH PHARM, V70, P491, DOI 10.1007/s00280-012-1937-4
   Mayo MW, 2000, BBA-REV CANCER, V1470, pM55, DOI 10.1016/S0304-419X(00)00002-0
   MBONYI K, 1990, MOL CELL BIOL, V10, P4518, DOI 10.1128/MCB.10.9.4518
   McDonald CM, 2009, GENETICS, V181, P511, DOI 10.1534/genetics.108.098434
   Meijer AJ, 2011, CURR BIOL, V21, pR227, DOI 10.1016/j.cub.2011.02.007
   Menacho-Marquez M, 2007, CLIN TRANSL ONCOL, V9, P221, DOI 10.1007/s12094-007-0043-2
   MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906
   Mitchison JM, 1971, BIOL CELL CYCLE
   Mitsui K, 2005, FEBS LETT, V579, P723, DOI 10.1016/j.febslet.2004.12.051
   Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0
   Mizunuma M, 2013, J BIOL CHEM, V288, P10558, DOI 10.1074/jbc.M112.402214
   Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594
   Mokdad-Gargouri R, 2001, NUCLEIC ACIDS RES, V29, P1222, DOI 10.1093/nar/29.5.1222
   Mollapour M, 2006, BIOCHEM J, V395, P73, DOI 10.1042/BJ20051765
   MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0
   MULLER G, 1987, Z NATURFORSCH C, V42, P1291
   Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976
   Narasimhan ML, 2001, MOL CELL, V8, P921, DOI 10.1016/S1097-2765(01)00365-3
   Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857
   NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357
   NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931
   Nitiss J.L., 2007, YEAST TOOL CANC RES, P433
   Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963
   Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111
   Oliveira C, 2007, ONCOGENE, V26, P158, DOI 10.1038/sj.onc.1209758
   ORITZ CH, 1983, J BACTERIOL, V153, P644, DOI 10.1128/JB.153.2.644-651.1983
   Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439
   Outeiro TF, 2004, J MOL NEUROSCI, V23, P49, DOI 10.1385/JMN:23:1-2:049
   PAPAGEORGE AG, 1984, MOL CELL BIOL, V4, P23, DOI 10.1128/MCB.4.1.23
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950
   Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431
   Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0
   PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N
   Pereira C, 2012, FEBS J, V279, P697, DOI 10.1111/j.1742-4658.2012.08477.x
   Phillips AJ, 2006, P NATL ACAD SCI USA, V103, P726, DOI 10.1073/pnas.0506405103
   POHLIG G, 1985, J BIOL CHEM, V260, P3818
   POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4
   Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091
   Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050
   Prior IA, 2012, SEMIN CELL DEV BIOL, V23, P145, DOI 10.1016/j.semcdb.2011.09.002
   Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6
   Pruitt K, 2000, J BIOL CHEM, V275, P40916, DOI 10.1074/jbc.M006682200
   Rajalingam K, 2007, BBA-MOL CELL RES, V1773, P1177, DOI 10.1016/j.bbamcr.2007.01.012
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rebollo A, 1999, ONCOGENE, V18, P4930, DOI 10.1038/sj.onc.1202875
   Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014
   Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9
   RITTENHOUSE J, 1987, J BIOL CHEM, V262, P10114
   Robert V, 2000, CARCINOGENESIS, V21, P563, DOI 10.1093/carcin/21.4.563
   ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648
   RODEL G, 1985, J BACTERIOL, V161, P7
   Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474
   Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093
   Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q
   Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067
   Saif MW, 2010, EXPERT OPIN INV DRUG, V19, P357, DOI 10.1517/13543781003593962
   Samuels Y, 2004, CELL CYCLE, V3, P1221, DOI 10.4161/cc.3.10.1164
   Santos J, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/161986
   Santos J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037090
   Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518
   SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238
   SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235
   SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539
   Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333
   Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0
   Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067
   Scheid MP, 2001, J MAMMARY GLAND BIOL, V6, P83, DOI 10.1023/A:1009520616247
   SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0
   Schmidt A, 2002, GENE DEV, V16, P1587, DOI 10.1101/gad.1003302
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012
   SEGAL M, 1992, J BIOL CHEM, V267, P22747
   Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953
   Shalom-Feuerstein R, 2005, CANCER RES, V65, P7292, DOI 10.1158/0008-5472.CAN-05-0775
   Shalom-Feuerstein R, 2008, CANCER RES, V68, P6608, DOI 10.1158/0008-5472.CAN-08-1117
   Sherman F, 2002, METHOD ENZYMOL, V350, P3, DOI 10.1016/S0076-6879(02)50954-X
   Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2
   SHIH TY, 1979, VIROLOGY, V96, P64, DOI 10.1016/0042-6822(79)90173-9
   SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0
   Silva RD, 2005, MOL MICROBIOL, V58, P824, DOI 10.1111/j.1365-2958.2005.04868.x
   Simon JA, 2004, NAT REV CANCER, V4, P481, DOI 10.1038/nrc1372
   Smith G, 2010, BRIT J CANCER, V102, P693, DOI 10.1038/sj.bjc.6605534
   Sobering AK, 2003, MOL CELL BIOL, V23, P4983, DOI 10.1128/MCB.23.14.4983-4990.2003
   Song S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045835
   Sorkin A, 2000, CURR BIOL, V10, P1395, DOI 10.1016/S0960-9822(00)00785-5
   SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609
   Stephan JS, 2009, P NATL ACAD SCI USA, V106, P17049, DOI 10.1073/pnas.0903316106
   Sulciner DJ, 1996, MOL CELL BIOL, V16, P7115
   SUN JY, 1994, J BIOL CHEM, V269, P18638
   Tamanoi Fuyuhiko, 2011, Genes Cancer, V2, P210, DOI 10.1177/1947601911407322
   Tan Y, 1999, J BIOL CHEM, V274, P34859, DOI 10.1074/jbc.274.49.34859
   TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0
   TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785
   Tatchell T., 1993, SIGNAL TRANSDUCTION, P147
   TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0
   Tenreiro S, 2017, CURR OPIN GENET DEV, V44, P74, DOI 10.1016/j.gde.2017.01.013
   THEVELEIN JM, 1992, ANTON LEEUW INT J G, V62, P109, DOI 10.1007/BF00584466
   Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x
   THEVELEIN JM, 1994, YEAST, V10, P1753, DOI 10.1002/yea.320101308
   Tisi R, 2014, METHODS MOL BIOL, V1120, P359, DOI 10.1007/978-1-62703-791-4_23
   Toda T, 1986, Princess Takamatsu Symp, V17, P253
   TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371
   TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6
   TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8
   TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0
   Torgler CN, 1997, CELL DEATH DIFFER, V4, P263, DOI 10.1038/sj.cdd.4400239
   TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624
   Tsuchida T, 2000, CANCER GENE THER, V7, P373, DOI 10.1038/sj.cgt.7700136
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   UNO I, 1983, J BIOL CHEM, V258, P867
   UNO I, 1985, J CELL BIOL, V100, P1854, DOI 10.1083/jcb.100.6.1854
   Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020
   VANONI M, 1983, J BACTERIOL, V156, P1282, DOI 10.1128/JB.156.3.1282-1291.1983
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Wang Y, 2001, EXP LUNG RES, V27, P255, DOI 10.1080/019021401300054028
   WEI W, 1992, P NATL ACAD SCI USA, V89, P7100, DOI 10.1073/pnas.89.15.7100
   Weinberger M, 2005, J CELL SCI, V118, P3543, DOI 10.1242/jcs.02477
   Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660
   Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459
   WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074
   Willingham S, 2003, SCIENCE, V302, P1769, DOI 10.1126/science.1090389
   Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901
   WITTINGHOFER A, 1993, CIBA F SYMP, V176, P6
   Wittinghofer A, 2014, RAS SUPERFAMILY SMAL, V1
   Wright ME, 2000, FEBS LETT, V481, P13, DOI 10.1016/S0014-5793(00)01962-1
   Wu KL, 2013, J GASTROENTEROL, V48, P350, DOI 10.1007/s00535-012-0663-3
   Wu SY, 2011, NEOPLASIA, V13, P1171, DOI 10.1593/neo.11888
   XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9
   Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9
   Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052
   YANG JJ, 1995, ONCOGENE, V10, P1291
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Yorimitsu T, 2007, MOL BIOL CELL, V18, P4180, DOI 10.1091/mbc.E07-05-0485
   Yousef AF, 2008, INT J CANCER, V122, P942, DOI 10.1002/ijc.23174
   Zabrocki P, 2005, FEBS J, V272, P1386, DOI 10.1111/j.1742-4658.2005.04571.x
   Zaman S, 2008, ANNU REV GENET, V42, P27, DOI 10.1146/annurev.genet.41.110306.130206
   Zeitouni D, 2016, CANCERS, V8, DOI 10.3390/cancers8040045
   Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597
   Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092
NR 310
TC 11
Z9 12
U1 2
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD FEB
PY 2018
VL 7
IS 2
AR 14
DI 10.3390/cells7020014
PG 35
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FZ3US
UT WOS:000427516700005
PM 29463063
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Zhen, YF
   Li, ST
   Zhu, YR
   Wang, XD
   Zhou, XZ
   Zhu, LQ
AF Zhen, Yun-fang
   Li, Song-tao
   Zhu, Yun-rong
   Wang, Xiao-dong
   Zhou, Xiao-zhong
   Zhu, Lun-qing
TI Identification of DNA-PKcs as a primary resistance factor of salinomycin
   in osteosarcoma cells
SO ONCOTARGET
LA English
DT Article
DE osteosarcoma (OS); salinomycin; DNA-PKcs; microRNA-101; autophagy
ID DEPENDENT PROTEIN-KINASE; COLORECTAL-CANCER CELLS; INDUCED APOPTOSIS;
   INHIBITOR; ACTIVATION; PATHWAY; PROLIFERATION; TARGET; REPAIR;
   TRANSCRIPTION
AB Malignant osteosarcoma (OS) is still a deadly disease for many affected patients. The search for the novel anti-OS agent is extremely urgent and important. Our previous study has proposed that salinomycin is a novel anti-OS agent. Here we characterized DNA-dependent protein kinase catalytic subunit (DNA-PKcs) as a primary salinomycin resistance factor in OS cells. DNA-PKcs inhibitors (NU7026, NU7441 and LY294002) or DNA-PKcs shRNA knockdown dramatically potentiated salinomycin-induced death and apoptosis of OS cells (U2OS and MG-63 lines). Further, forced-expression of microRNA-101 ("miR-101") downregulated DNA-PKcs and augmented salinomycin's cytotoxicity against OS cells. Reversely, over-expression of DNA-PKcs in OS cells inhibited salinomycin's lethality. For the mechanism study, we show that DNA-PKcs is required for salinomycin-induced pro-survival autophagy activation. DNA-PKcs inhibition (by NU7441), shRNA knockdown or miR-101 expression inhibited salinomycin-induced Beclin-1 expression and autophagy induction. Meanwhile, knockdown of Beclin-1 by shRNA significantly sensitized salinomycin-induced OS cell lethality. In vivo, salinomycin administration suppressed U2OS xenograft tumor growth in severe combined immuno-deficient (SCID) mice, and its anti-tumor activity was dramatically potentiated with co-administration of the DNA-PKcs inhibitor NU7026. Together, these results suggest that DNA-PKcs could be a primary resistance factor of salinomycin in OS cells. DNA-PKcs inhibition or silence may thus significantly increase salinomycin's sensitivity in OS cells.
C1 [Zhen, Yun-fang; Wang, Xiao-dong; Zhu, Lun-qing] Soochow Univ, Childrens Hosp, Ctr Diag & Treatment Childrens Bone Dis, Suzhou, Peoples R China.
   [Li, Song-tao; Zhou, Xiao-zhong] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou, Peoples R China.
   [Zhu, Yun-rong] Southeast Univ, Affiliated Jiangyin Hosp, Coll Med, Dept Orthoped, Jiangyin, Peoples R China.
RP Wang, XD; Zhu, LQ (corresponding author), Soochow Univ, Childrens Hosp, Ctr Diag & Treatment Childrens Bone Dis, Suzhou, Peoples R China.; Zhou, XZ (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou, Peoples R China.
EM xiaodongwangsz@163.com; zhouxiaozhongorth@163.com;
   zhulunqingszgk@163.com
FU nature science foundation of ChinaNational Natural Science Foundation of
   China (NSFC) [81171712, 81402475]; Natural Science Foundation of Jiangsu
   ProvinceNatural Science Foundation of Jiangsu Province [BK20151213];
   Innovation Project of JiangSu Province [201423]
FX The study was supported by the nature science foundation of China
   (81171712 and 81402475). Grants from Natural Science Foundation of
   Jiangsu Province (BK20151213) and Innovation Project of JiangSu Province
   (201423).
CR Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085
   Bjork-Eriksson T, 1999, INT J RADIAT ONCOL, V45, P1005, DOI 10.1016/S0360-3016(99)00268-0
   Booth L, 2014, CANCER BIOL THER, V15, P305, DOI 10.4161/cbt.27309
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x
   Chen MB, 2016, ONCOTARGET, V7, P17047, DOI 10.18632/oncotarget.7742
   Chen MB, 2015, BIOCHEM BIOPH RES CO, V463, P954, DOI 10.1016/j.bbrc.2015.06.041
   Chiang CW, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-35
   Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332
   Davidson D, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00005
   Dejmek J, 2009, MOL CANCER RES, V7, P581, DOI 10.1158/1541-7786.MCR-08-0049
   Deriano L, 2005, BLOOD, V105, P4776, DOI 10.1182/blood-2004-07-2888
   Ding HY, 2015, BIOCHEM BIOPH RES CO, V460, P157, DOI 10.1016/j.bbrc.2015.02.161
   Eriksson A, 2002, ANTICANCER RES, V22, P1787
   Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442
   Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Fuchs D, 2009, BIOCHEM BIOPH RES CO, V390, P743, DOI 10.1016/j.bbrc.2009.10.042
   Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6
   Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838
   Klose J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095970
   Leahy JJJ, 2004, BIOORG MED CHEM LETT, V14, P6083, DOI 10.1016/j.bmcl.2004.09.060
   Li Y., 2013, ADV DIFF EQU, V2013, P2, DOI DOI 10.1016/J.SCS.2013.10.002
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515
   Munck JM, 2012, MOL CANCER THER, V11, P1789, DOI 10.1158/1535-7163.MCT-11-0535
   Nishida Y, 2014, BBA-GENE REGUL MECH, V1839, P265, DOI 10.1016/j.bbagrm.2014.02.004
   Nutley BP, 2005, BRIT J CANCER, V93, P1011, DOI 10.1038/sj.bjc.6602823
   Qin LS, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0174-1
   Qu YQ, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-52
   Riccioni R, 2010, BLOOD CELL MOL DIS, V45, P86, DOI 10.1016/j.bcmd.2010.03.008
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Toulany M, 2008, MOL CANCER THER, V7, P1772, DOI 10.1158/1535-7163.MCT-07-2200
   Tu Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-172
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wu L, 2015, BIOCHEM BIOPH RES CO, V466, P547, DOI 10.1016/j.bbrc.2015.09.068
   Xu Y, 2014, BIOCHEM BIOPH RES CO, V453, P362, DOI 10.1016/j.bbrc.2014.09.088
   Xu ZL, 2015, SCI REP-UK, V5, DOI 10.1038/srep12276
   Yan D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011397
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Zhang Y, 2007, CANCER LETT, V250, P63, DOI 10.1016/j.canlet.2006.09.021
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
   Zheng B, 2016, SCI REP-UK, V6, DOI 10.1038/srep29415
   Zhou J, 2013, TOXICOL LETT, V222, P139, DOI 10.1016/j.toxlet.2013.07.022
   Zhou S, 2013, CURR MED CHEM, V20, P4095
   Zhu LQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084175
   Zhu Y., 2016, ONCOTARGET
   Zhu YR, 2015, CANCER BIOL THER, V16, P602, DOI 10.1080/15384047.2015.1017155
   Zhu YR, 2014, BIOCHEM BIOPH RES CO, V451, P112, DOI 10.1016/j.bbrc.2014.07.077
NR 52
TC 27
Z9 28
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 29
PY 2016
VL 7
IS 48
BP 79403
EP 79413
DI 10.18632/oncotarget.12712
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE5HH
UT WOS:000389636000097
PM 27765904
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Anestakis, D
   Petanidis, S
   Kalyvas, S
   Nday, CM
   Tsave, O
   Kioseoglou, E
   Salifoglou, A
AF Anestakis, Doxakis
   Petanidis, Savvas
   Kalyvas, Spyridon
   Nday, Christiane M.
   Tsave, Olga
   Kioseoglou, Efrosini
   Salifoglou, Athanasios
TI Mechanisms and Applications of Interleukins in Cancer Immunotherapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE interleukins; cancer immunotherapy; immunoediting; immunosurveilance;
   microRNA; cancer stem cells; tumor microenvironment (TME); inflammation;
   DNA methylation; epithelial-mesenchymal transition (EMT); autophagy
ID EPITHELIAL-MESENCHYMAL TRANSITION; REGULATORY T-CELLS;
   COLORECTAL-CANCER; TUMOR MICROENVIRONMENT; IMMUNE MICROENVIRONMENT;
   COMBINATION THERAPY; GENE-THERAPY; CYTOKINES; PROMOTES; GROWTH
AB Over the past years, advances in cancer immunotherapy have resulted in innovative and novel approaches in molecular cancer diagnostics and cancer therapeutic procedures. However, due to tumor heterogeneity and inter-tumoral discrepancy in tumor immunity, the clinical benefits are quite restricted. The goal of this review is to evaluate the major cytokines-interleukins involved in cancer immunotherapy and project their basic biochemical and clinical applications. Emphasis will be given to new cytokines in pre-clinical development, and potential directions for future investigation using cytokines. Furthermore, current interleukin-based approaches and clinical trial data from combination cancer immunotherapies will also be discussed. It appears that continuously increasing comprehension of cytokine-induced effects, cancer stemness, immunoediting, immune-surveillance as well as understanding of molecular interactions emerging in the tumor microenvironment and involving microRNAs, autophagy, epithelial-mesenchymal transition (EMT), inflammation, and DNA methylation processes may hold much promise in improving anti-tumor immunity. To this end, the emerging in-depth knowledge supports further studies on optimal synergistic combinations and additional adjuvant therapies to realize the full potential of cytokines as immunotherapeutic agents.
C1 [Anestakis, Doxakis] Aristotle Univ Thessaloniki, Sch Med, Lab Gen Biol, Thessaloniki 54124, Greece.
   [Anestakis, Doxakis] Aristotle Univ Thessaloniki, Sch Med, Lab Forens Med & Toxicol, Thessaloniki 54124, Greece.
   [Petanidis, Savvas; Nday, Christiane M.; Tsave, Olga; Kioseoglou, Efrosini] Aristotle Univ Thessaloniki, Dept Chem Engn, Thessaloniki 54124, Greece.
   [Kalyvas, Spyridon] Gen Hosp Halkidiki, Dept Internal Med, Poligiros 63100, Greece.
RP Salifoglou, A (corresponding author), Aristotle Univ Thessaloniki, Dept Chem Engn, Thessaloniki 54124, Greece.
EM anestaki@auth.gr; spetanid@auth.gr; roskal@otenet.gr;
   christiane.nday@yahoo.com; tsaveolga@gmail.com;
   efi.kioseoglou@gmail.com; salif@auth.gr
RI petanidis, savvas/P-5637-2018; Petanidis, Savvas/AAC-3082-2022
OI Anestakis, Doxakis/0000-0001-8004-7666
FU Research Committee of Aristotle University of Thessaloniki, Greece
FX This work was supported by funding from the Research Committee of
   Aristotle University of Thessaloniki, Greece.
CR Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050
   Amedei A, 2013, RECENT PAT ANTI-CANC, V8, P126
   Baek S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-178
   Bai FL, 2014, CANCER BIOL THER, V15, P1226, DOI 10.4161/cbt.29686
   Baird AM, 2011, EUR J CANCER, V47, P1908, DOI 10.1016/j.ejca.2011.04.012
   Banchereau J, 2012, NAT IMMUNOL, V13, P925, DOI 10.1038/ni.2406
   Bhatia A, 2014, EXPERT REV CLIN IMMU, V10, P41, DOI 10.1586/1744666X.2014.865519
   Brocker Chad, 2010, Human Genomics, V5, P30
   Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Chae WJ, 2011, BIOCHEM BIOPH RES CO, V414, P31, DOI 10.1016/j.bbrc.2011.09.016
   Chang PC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088556
   Christian DA, 2012, IMMUNOTHERAPY-UK, V4, P425, DOI [10.2217/IMT.12.26, 10.2217/imt.12.26]
   Denies S, 2014, J CONTROL RELEASE, V187, P175, DOI 10.1016/j.jconrel.2014.05.045
   Desai S, 2013, CELL SIGNAL, V25, P1780, DOI 10.1016/j.cellsig.2013.05.025
   Drexler SK, 2013, CANCER J, V19, P468, DOI 10.1097/PPO.0000000000000004
   Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803
   Duque GA, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00491
   Gadina M, 2003, CURR OPIN INFECT DIS, V16, P211, DOI 10.1097/00001432-200306000-00005
   Gasche JA, 2011, INT J CANCER, V129, P1053, DOI 10.1002/ijc.25764
   Girardin A, 2013, INT J CANCER, V132, P1842, DOI 10.1002/ijc.27855
   Gross E, 2013, CANCER J, V19, P483, DOI 10.1097/PPO.0000000000000005
   Guo LY, 2012, TRENDS IMMUNOL, V33, P598, DOI 10.1016/j.it.2012.07.006
   Hall BM, 2011, CURR OPIN IMMUNOL, V23, P641, DOI 10.1016/j.coi.2011.07.012
   Hayata K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053131
   He H, 2012, INT J MOL MED, V30, P599, DOI 10.3892/ijmm.2012.1027
   Heikamp EB, 2012, SEMIN IMMUNOL, V24, P414, DOI 10.1016/j.smim.2012.12.003
   Hodge LS, 2012, BLOOD, V120, P3774, DOI 10.1182/blood-2012-03-419440
   Hurwitz AA, 2012, CANCER IMMUNOL IMMUN, V61, P289, DOI 10.1007/s00262-011-1181-5
   Introna M, 2013, IMMUNOL LETT, V155, P27, DOI 10.1016/j.imlet.2013.09.017
   Jasinski-Bergner S, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju257
   Jauch D, 2011, GUT, V60, P1678, DOI 10.1136/gutjnl-2011-300612
   Ji XY, 2013, INT J CLIN EXP PATHO, V6, P1481
   Kared H, 2014, CURR OPIN IMMUNOL, V29, P79, DOI 10.1016/j.coi.2014.05.003
   Kim JS, 2013, MOL CELLS, V35, P17, DOI 10.1007/s10059-013-2154-7
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Krishnamurthy S, 2014, STEM CELLS, V32, P2845, DOI 10.1002/stem.1793
   Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010
   Li J, 2012, J BIOL CHEM, V287, P35484, DOI 10.1074/jbc.M112.367532
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Liang XY, 2012, CANCER RES, V72, P2791, DOI 10.1158/0008-5472.CAN-12-0320
   Ma J., 2014, MOL CANCER, V26, P13
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P5637, DOI 10.1002/cncr.25488
   Mao Y, 2014, J INTERN MED, V276, P154, DOI 10.1111/joim.12229
   Matsushita H, 2012, NATURE, V482, P400, DOI 10.1038/nature10755
   Miao JW, 2014, INT J ONCOL, V45, P165, DOI 10.3892/ijo.2014.2422
   Newman RG, 2014, BLOOD, V123, P3045, DOI 10.1182/blood-2013-08-520775
   Ngiow SF, 2013, TRENDS IMMUNOL, V34, P548, DOI 10.1016/j.it.2013.07.004
   O'Sullivan T, 2014, CELL REP, V7, P989, DOI 10.1016/j.celrep.2014.03.073
   O'Sullivan T, 2012, J EXP MED, V209, P1869, DOI 10.1084/jem.20112738
   Oleinika K, 2013, CLIN EXP IMMUNOL, V171, P36, DOI 10.1111/j.1365-2249.2012.04657.x
   Pappu R, 2011, IMMUNOLOGY, V134, P8, DOI 10.1111/j.1365-2567.2011.03465.x
   Park JS, 2013, CELL ONCOL, V36, P493, DOI 10.1007/s13402-013-0154-4
   PARK SJ, 2013, ASIAN WOMEN, V29, P1
   Patel SAA, 2014, BRIT J CANCER, V111, P2287, DOI 10.1038/bjc.2014.540
   Petanidis S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073616
   Pollari S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037361
   Qian XS, 2013, J IMMUNOL, V190, P5894, DOI 10.4049/jimmunol.1203141
   Ramstead AG, 2012, J INTERF CYTOK RES, V32, P563, DOI 10.1089/jir.2012.0073
   Ranganathan Kannan, 2014, J Oral Maxillofac Pathol, V18, P229, DOI 10.4103/0973-029X.140762
   Rui LX, 2011, NAT IMMUNOL, V12, P933, DOI 10.1038/ni.2094
   Rutz S, 2011, CURR OPIN IMMUNOL, V23, P605, DOI 10.1016/j.coi.2011.07.018
   Sahoo A, 2010, INT REV IMMUNOL, V29, P77, DOI 10.3109/08830180903349651
   Sato Shingo, 2014, Clin Calcium, V24, P1209, DOI CliCa140812091215
   Shale M, 2013, IMMUNOL REV, V252, P164, DOI 10.1111/imr.12039
   Steinestel K, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-17
   Stewart TJ, 2011, CANCER METAST REV, V30, P125, DOI 10.1007/s10555-011-9280-5
   Tayal V, 2008, EUR J PHARMACOL, V579, P1, DOI 10.1016/j.ejphar.2007.10.049
   Tekpli X, 2013, CANCER IMMUNOL IMMUN, V62, P337, DOI 10.1007/s00262-012-1340-3
   Tsai HC, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/267971
   van Wolfswinkel JC, 2010, J CELL SCI, V123, P1825, DOI 10.1242/jcs.061713
   Vegran F, 2014, NAT IMMUNOL, V15, P758, DOI 10.1038/ni.2925
   Volonte A, 2014, J IMMUNOL, V192, P523, DOI 10.4049/jimmunol.1301342
   Voronov E, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00114
   Wheeler V S, 1996, Semin Oncol Nurs, V12, P106, DOI 10.1016/S0749-2081(96)80005-2
   Xiang T, 2015, ONCOGENE, V34, P165, DOI 10.1038/onc.2013.537
   Xie GZ, 2012, INT J ONCOL, V40, P1171, DOI 10.3892/ijo.2011.1275
   Xu B, 2014, INT J CLIN EXP PATHO, V7, P3620
   Xu SL, 2013, CANCER LETT, V335, P421, DOI 10.1016/j.canlet.2013.02.055
   Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271
   Yang B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/623759
   Yang C, 2010, CANCER GENE THER, V17, P109, DOI 10.1038/cgt.2009.57
   Yeung YT, 2013, BRIT J PHARMACOL, V168, P591, DOI 10.1111/bph.12008
   Yoshimoto T, 2009, IMMUNOTHERAPY-UK, V1, P825, DOI 10.2217/IMT.09.46
   Yuan LJ, 2013, TUMOR BIOL, V34, P3027, DOI 10.1007/s13277-013-0867-z
   Zarogoulidis P, 2014, J CANCER, V5, P765, DOI 10.7150/jca.10471
   Zhang X, 2013, CURR CANCER DRUG TAR, V13, P92, DOI 10.2174/156800913804486665
   Zhao N, 2013, J GENE MED, V15, P366, DOI 10.1002/jgm.2739
NR 87
TC 47
Z9 50
U1 1
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2015
VL 16
IS 1
BP 1691
EP 1710
DI 10.3390/ijms16011691
PG 20
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AZ7MN
UT WOS:000348403100096
PM 25590298
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Wei, YJ
   Li, CH
   Zhang, Y
   He, HL
   Zilang, GZ
   Hao, XH
   Liu, HL
   Wang, HL
   Tian, W
AF Wei, Yanjie
   Li, Chenhao
   Zhang, Yuan
   He, Hailan
   Zhang, Guozhi
   Hao, Xiaohui
   Liu, Heliang
   Wang, Hongli
   Tian, Wei
TI Hydroxycamptothecin mediates antiproliferative effects through apoptosis
   and autophagy in A549 cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE lung cancer; non-small cell lung cancer; autophagy; apoptosis; autophagy
   inhibitor; hydroxycamptothecin
ID COLORECTAL-CANCER; KINASE; BAX; ACTIVATION; 10-HYDROXYCAMPTOTHECIN;
   RESISTANCE; INHIBITORS; PROTEIN; TARGET; ROLES
AB Hydroxycamptothecin (HCPT) represents a new generation of anticancer drugs, with almost no side effects when used for the treatment of a number of types of cancer. Autophagy is becoming recognized as an important biological mechanism in human cancer, including lung cancer. However, the involvement of autophagy in the antiproliferative effects of HCPT on lung cancer remains unclear. In the present study, A549 cells, an accepted model of non-small cell lung cancer (NSCLC) cells, were employed. It was demonstrated that HCPT was able to suppress proliferation and induce apoptosis and autophagy in A549 cells. The molecular mechanism underlying HCPT-induced cell death was attributed to apoptosis and autophagy. Furthermore, it was demonstrated that an autophagy inhibitor, 3-methyladenine, accelerated HCPT-induced cell death in A549 cells. The results of the present study may lead to a deeper understanding of the molecular mechanism by which HCPT regulates NSCLC A549 cells. These results highlight the potential use of autophagy inhibitors in combination with traditional chemotherapy drugs for the treatment of lung cancer.
C1 [Wei, Yanjie; Zhang, Yuan; He, Hailan; Hao, Xiaohui; Liu, Heliang; Wang, Hongli; Tian, Wei] North China Univ Sci & Technol, Med Res Ctr, 57 Jianshenan Rd, Tangshan 063000, Hebei, Peoples R China.
   [Li, Chenhao] Cangzhou Cent Hosp, Dept Oncol, Cangzhou 061000, Hebei, Peoples R China.
   [Zhang, Guozhi] North China Univ Sci & Technol, Affiliated Hosp, Dept Gen Surg, Tarigshan 063000, Hebei, Peoples R China.
   [Wang, Hongli] North China Univ Sci & Technol, Publ Hlth Sch, 57 Jianshenan Rd, Tarigshan 063000, Hebei, Peoples R China.
RP Tian, W (corresponding author), North China Univ Sci & Technol, Med Res Ctr, 57 Jianshenan Rd, Tangshan 063000, Hebei, Peoples R China.; Wang, HL (corresponding author), North China Univ Sci & Technol, Publ Hlth Sch, 57 Jianshenan Rd, Tarigshan 063000, Hebei, Peoples R China.
EM tsruoshui@163.com; twhzm@aliyun.com
FU North China University of Science and Technology Research [201610081026,
   X2016026]; Key Projects of Science and Technology Research in Hebei
   Province [ZD2017063]; Tangshan International Technological Cooperation
   Projects [14160201B]
FX The present study was supported by the North China University of Science
   and Technology Research (grant no. 201610081026), the Key Projects of
   Science and Technology Research in Hebei Province (grant no. ZD2017063),
   the North China University of Science and Technology Research (grant no.
   X2016026) and the Tangshan International Technological Cooperation
   Projects (grant no. 14160201B).
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bailly C, 2003, CRIT REV ONCOL HEMAT, V45, P91, DOI 10.1016/S1040-8428(02)00090-2
   Bian ZH, 2015, MOL MED REP, V11, P3188, DOI 10.3892/mmr.2014.3108
   Chen XP, 2014, MOL BIOL REP, V41, P1247, DOI 10.1007/s11033-013-2969-5
   Cheng YX, 2016, EUR J GYNAECOL ONCOL, V37, P238
   Cheng YX, 2015, BIOMED PHARMACOTHER, V75, P67, DOI 10.1016/j.biopha.2015.08.034
   Cui Q, 2007, BIOL PHARM BULL, V30, P859, DOI 10.1248/bpb.30.859
   Desai SD, 2013, J BIOL CHEM, V288, P2388, DOI 10.1074/jbc.M112.403832
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034
   Eskelinen EL, 2002, TRAFFIC, V3, P878, DOI 10.1034/j.1600-0854.2002.31204.x
   Fu T, 2016, ACTA PHARMACOL SIN, V37, P505, DOI 10.1038/aps.2015.148
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Guo B, 2003, NATURE, V423, P456, DOI 10.1038/nature01627
   Hamedani FS, 2014, LEUKEMIA RES, V38, P503, DOI 10.1016/j.leukres.2013.12.027
   Iwamaru A, 2007, ONCOGENE, V26, P1840, DOI 10.1038/sj.onc.1209992
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu ZY, 2017, AM J CANCER RES, V7, P574
   Liu Z, 2015, J CELL BIOCHEM, V116, P1341, DOI 10.1002/jcb.25091
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nie F, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0162-y
   Pan XH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056679
   Ravikumar B, 2006, HUM MOL GENET, V15, P1209, DOI 10.1093/hmg/ddl036
   Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tallman Martin S, 2005, Hematology Am Soc Hematol Educ Program, P143
   Urasaki Y, 2000, CANCER RES, V60, P6577
   Vilgelm AE, 2015, CANCER RES, V75, P181, DOI 10.1158/0008-5472.CAN-14-2405
   Weckman A, 2015, ENDOCR-RELAT CANCER, V22, pR205, DOI 10.1530/ERC-15-0042
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Yan JG, 2010, AUTOPHAGY, V6, P67, DOI 10.4161/auto.6.1.10437
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yuan YF, 2015, J GENET GENOMICS, V42, P1, DOI 10.1016/j.jgg.2014.12.001
   Zhang G, 2011, CANCER SCI, V102, P1216, DOI 10.1111/j.1349-7006.2011.01930.x
   Zhang H, 2015, TRENDS CELL BIOL, V25, P376, DOI 10.1016/j.tcb.2015.03.001
   Zhang RW, 1998, CANCER CHEMOTH PHARM, V41, P257, DOI 10.1007/s002800050738
   Zhu MC, 2015, CANCER SCI, V106, P833, DOI 10.1111/cas.12689
NR 49
TC 8
Z9 9
U1 2
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD MAY
PY 2018
VL 15
IS 5
BP 6322
EP 6328
DI 10.3892/ol.2018.8107
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GF3DN
UT WOS:000431825900031
PM 29616109
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Ha, HA
   Chiang, JH
   Tsai, FJ
   Bau, DT
   Juan, YN
   Lo, YH
   Hour, MJ
   Yang, JS
AF Ha, Hai-Anh
   Chiang, Jo-Hua
   Tsai, Fuu-Jen
   Bau, Da-Tian
   Juan, Yu-Ning
   Lo, Yu-Hsiang
   Hour, Mann-Jen
   Yang, Jai-Sing
TI Novel quinazolinone MJ-33 induces AKT/mTOR-mediated autophagy-associated
   apoptosis in 5FU-resistant colorectal cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE MJ-33; colorectal cancer; fluorouracil-resistant HT-29 cells; autophagy;
   apoptosis
ID ENDOPLASMIC-RETICULUM STRESS; NF-KAPPA-B; THYMIDYLATE SYNTHASE; 1ST-LINE
   TREATMENT; DRUG-RESISTANCE; IN-VITRO; INHIBITION; PATHWAY; ANGIOGENESIS;
   FLUOROURACIL
AB Novel quinazolinone compounds have been studied in the field of drug discovery for a long time. Among their broad range of pharmacological effects, certain compounds effectively inhibit cancer cell proliferation. MJ-33 is a quinazolinone derivative with proposed anticancer activities that was synthesized in our laboratory. The present study aimed to evaluate the anticancer activity of MJ-33 in fluorouracil (5FU)-resistant colorectal cancer cells (HT-29/5FUR) and to investigate the underlying molecular mechanisms. The cell viability assay results indicated that HT-29/5FUR cell viability was inhibited by MJ-33 treatment in a concentration-dependent manner compared with the control group. The cellular morphological alterations observed following MJ-33 treatment indicated the occurrence of apoptosis and autophagy, as well as inhibition of cell proliferation in a time-dependent manner compared with the control group. The acridine orange, LysoTracker Red and LC3-green fluorescent protein staining results indicated that MJ-33 treatment significantly induced autophagy compared with the control group. The DAPI/TUNEL dual staining results demonstrated increased nuclear fragmentation and condensation following MJ-33 treatment compared with the control group. The Annexin V apoptosis assay and image cytometry analysis results demonstrated a significant increase in apoptotic cells following MJ-33 treatment compared with the control group. The western blotting results demonstrated markedly decreased Bcl-2, phosphorylated (p)-BAD, pro-caspase-9 and pro-caspase-3 expression levels, and notably increased cytochrome c and apoptotic peptidase activating factor 1 expression levels following MJ-33 treatment compared with the control group. Moreover, the expression levels of autophagy-related proteins, including autophagy related (ATG)-5, ATG-7, ATG-12, ATG-16, p62 and LC3-II, were increased following MJ-33 treatment compared with the control group. Furthermore, MJ-33-treated HT-29/5FUR cells displayed decreased expression levels of p-AKT and p-mTOR compared with control cells. The results suggested that MJ-33-induced apoptosis was mediated by AKT signaling, and subsequently modulated via the mitochondria-dependent signaling pathway. Therefore, the results suggested that suppression of AKT/mTOR activity triggered autophagy in the HT-29/5FUR cell line. In summary, the results indicated that MJ-33 inhibited HT-29/5FUR cell viability, and induced apoptosis and autophagy via the AKT/mTOR signaling pathway. The present study may provide novel insight into the anticancer effects and mechanisms underlying MJ-33 in 5FU-resistant colorectal cancer cells.
C1 [Ha, Hai-Anh; Hour, Mann-Jen] China Med Univ, Sch Pharm, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.
   [Ha, Hai-Anh] Duy Tan Univ, Fac Pharm, Da Nang 550000, Vietnam.
   [Chiang, Jo-Hua] Chung Jen Jr Coll Nursing Hlth Sci & Management, Dept Nursing, Chiayi 62241, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ, China Med Univ Hosp, Dept Med Res, Human Genet Ctr, Taichung 40447, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ, China Med Univ Hosp, Dept Med Genet, Taichung 40447, Taiwan.
   [Tsai, Fuu-Jen] China Med Univ, Sch Chinese Med, Taichung 40402, Taiwan.
   [Bau, Da-Tian] China Med Univ, Grad Inst Biomed Sci, Taichung 40402, Taiwan.
   [Bau, Da-Tian] China Med Univ, China Med Univ Hosp, Terry Fox Canc Res Lab, Taichung 40447, Taiwan.
   [Bau, Da-Tian] Asia Univ, Dept Bioinformat & Med Engn, Taichung 41354, Taiwan.
   [Juan, Yu-Ning; Lo, Yu-Hsiang; Yang, Jai-Sing] China Med Univ, China Med Univ Hosp, Dept Med Res, 2 Yude Rd, Taichung 40447, Taiwan.
RP Hour, MJ (corresponding author), China Med Univ, Sch Pharm, 91 Hsueh Shih Rd, Taichung 40402, Taiwan.; Yang, JS (corresponding author), China Med Univ, China Med Univ Hosp, Dept Med Res, 2 Yude Rd, Taichung 40447, Taiwan.
EM mjhou@mail.cmu.edu.tw; jaisingyang@gmail.com
RI HA, HAI-ANH/AAR-1652-2021; Ha, Hai-Anh/AAD-3454-2022
OI Ha, Hai-Anh/0000-0002-4252-2128
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 109-2320-B-039-041]; China Medical University
   Hospital [DMR-108-106]
FX The present study was supported by the Ministry of Science and
   Technology, Taiwan (grant no. MOST 109-2320-B-039-041) and China Medical
   University Hospital (grant no. DMR-108-106).
CR Alam MM, 2016, APOPTOSIS, V21, P1191, DOI 10.1007/s10495-016-1277-7
   Araghi M, 2019, INT J CANCER, V144, P2992, DOI 10.1002/ijc.32055
   Beberok A, 2018, INT J ONCOL, V52, P1727, DOI 10.3892/ijo.2018.4310
   Benepal TS, 2005, ANTI-CANCER DRUG, V16, P1, DOI 10.1097/00001813-200501000-00001
   Chang CH, 2017, INT J ONCOL, V50, P873, DOI 10.3892/ijo.2017.3866
   Chen KT, 2011, INT J ONCOL, V39, P611, DOI 10.3892/ijo.2011.1071
   Denton D, 2019, CELL DEATH DIFFER, V26, P605, DOI 10.1038/s41418-018-0252-y
   Dohle W, 2018, J MED CHEM, V61, P1031, DOI 10.1021/acs.jmedchem.7b01474
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Gelles JD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.332
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   He LF, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0128-8
   Hour MJ, 2012, INT J ONCOL, V41, P1513, DOI 10.3892/ijo.2012.1560
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Huang TY, 2020, J FOOD BIOCHEM, V44, DOI 10.1111/jfbc.13122
   Hussain A, 2016, MOL CARCINOGEN, V55, P2135, DOI 10.1002/mc.22457
   Hussain A, 2016, CANCER LETT, V374, P250, DOI 10.1016/j.canlet.2016.02.030
   Ito S, 2007, INT J ONCOL, V31, P261
   JACKMAN AL, 1994, ADV EXP MED BIOL, V370, P185
   Kawaguchi T, 2011, INT J ONCOL, V38, P643, DOI 10.3892/ijo.2010.882
   Kawi K, 2002, GENE CHROMOSOME CANC, V34, P1, DOI 10.1002/gcc.10003
   Khan Maliha, 2014, ISRN Oncol, V2014, P931858, DOI 10.1155/2014/931858
   Kumar S, 2014, TOXICOL REP, V1, P1013, DOI 10.1016/j.toxrep.2014.07.018
   Lee CF, 2018, BIOMEDICINE-TAIWAN, V8, P13, DOI 10.1051/bmdcn/2018080315
   Lee HP, 2019, J FUNCT FOODS, V52, P537, DOI 10.1016/j.jff.2018.11.040
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Lin CC, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12902
   Liu T, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00408
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Liu XY, 2016, CELL MOL NEUROBIOL, V36, P1197, DOI 10.1007/s10571-015-0318-z
   Lu CC, 2019, INT J ONCOL, V54, P1271, DOI 10.3892/ijo.2019.4704
   Lu CC, 2014, BBA-GEN SUBJECTS, V1840, P2310, DOI 10.1016/j.bbagen.2014.02.022
   Maiuthed A, 2018, CANCERS, V10, DOI 10.3390/cancers10100373
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005
   Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597
   Nitulescu GM, 2016, INT J ONCOL, V48, P869, DOI 10.3892/ijo.2015.3306
   O'Donnell JS, 2018, SEMIN CANCER BIOL, V48, P91, DOI 10.1016/j.semcancer.2017.04.015
   Pan P, 2018, SURG ONCOL CLIN N AM, V27, P243, DOI 10.1016/j.soc.2017.11.002
   Pardini B, 2011, BRIT J CLIN PHARMACO, V72, P162, DOI 10.1111/j.1365-2125.2010.03892.x
   Pivot X, 2001, ANN ONCOL, V12, P1595, DOI 10.1023/A:1013185402896
   Plasencia C, 2004, INVEST NEW DRUG, V22, P399, DOI 10.1023/B:DRUG.0000036682.99818.71
   Qiu Tingting, 2015, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V31, P328
   Rahman MU, 2017, SYNTHETIC COMMUN, V47, P379, DOI 10.1080/00397911.2016.1269926
   Rajitha B, 2016, CANCER LETT, V373, P227, DOI 10.1016/j.canlet.2016.01.052
   Ravanan P, 2017, LIFE SCI, V188, P53, DOI 10.1016/j.lfs.2017.08.029
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Sever ON., 2017, J ONCOL SCI, V3, P37
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Wang W, 2003, BRIT J CANCER, V88, P624, DOI 10.1038/sj.bjc.6600753
   West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6
   Xia XJ, 2018, J CELL BIOCHEM, V119, P4009, DOI 10.1002/jcb.26559
   Xu J, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20160447
   Yang JS, 2017, BIOMEDICINE-TAIWAN, V7, DOI 10.1051/bmdcn/2017070201
   Yang JS, 2010, J PHARMACOL EXP THER, V334, P477, DOI 10.1124/jpet.109.165415
   Zhang JH, 2000, CELL RES, V10, P205, DOI 10.1038/sj.cr.7290049
   Zhang YM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008242
   Zhao Enpeng, 2012, Hepatology, V55, P1632, DOI 10.1002/hep.25619
   Zhao HW, 2016, ONCOL RES, V23, P237, DOI 10.3727/096504016X14562725373671
   Zheng XG, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0883-8
NR 62
TC 11
Z9 11
U1 2
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD FEB
PY 2021
VL 45
IS 2
BP 680
EP 692
DI 10.3892/or.2020.7882
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PR2HV
UT WOS:000607063300024
PM 33416156
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Zhou, WJ
   Fang, C
   Zhang, LW
   Wang, Q
   Li, D
   Zhu, DX
AF Zhou, Wenjie
   Fang, Cheng
   Zhang, Liwen
   Wang, Qi
   Li, Dong
   Zhu, Danxia
TI Thioredoxin domain-containing protein 9 (TXNDC9) contributes to
   oxaliplatin resistance through regulation of autophagy-apoptosis in
   colorectal adenocarcinoma
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE TXNDC9; Oxaliplatin resistance; Autophagy; Apoptosis; Nrf2 pathway
ID TRANSCRIPTION FACTOR NRF2; PATHWAY; CANCER; STRESS; ACTIVATION;
   MECHANISMS; PACLITAXEL; PATTERNS; CELLS
AB Colorectal cancer (CRC) is the third most commonly malignancy worldwide. The incidence of CRC is on the rise and leads to indisputable society burden due to the high cost of cancer treatments. Resistance to oxaliplatin-chemotherapy is the major cause for treatment failure and CRC-related death. In this study, we anticipated that TXNDC9 might demonstrate a protective role in oxaliplatin-resistant CRC cells. TXNDC9 was found significantly upregulated when treated with oxaliplatin. Manipulation of TXNDC9 expression largely affected the oxaliplatin-induced cell death. Moreover, TXNDC9 regulates autophagy and apoptosis in response to oxaliplatin treatment in HT29 cells via the Nrf2 pathway. Taken together, our findings explore the biological role of TXNDC9 in oxaliplatin resistance in CRC cells and may identify a novel therapeutic target to counteract drug resistance to oxaliplatin in CRC. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Zhou, Wenjie; Fang, Cheng; Zhang, Liwen; Wang, Qi; Li, Dong; Zhu, Danxia] Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou 213003, Jiangsu, Peoples R China.
RP Zhou, WJ; Zhu, DX (corresponding author), Soochow Univ, Dept Oncol, Affiliated Hosp 3, Changzhou 213003, Jiangsu, Peoples R China.
EM Wenjie_czyy@163.com; Danxia_czyy@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81770212]
FX This research was supported by grants from the National Natural Science
   Foundation of China (No.81770212).
CR Ajabnoor GMA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.139
   Bao LJ, 2014, INT J CLIN EXP PATHO, V7, P1502
   Bartolini D, 2018, TRANSL RES, V193, P54, DOI 10.1016/j.trsl.2017.11.007
   Cai JJ, 2018, CELL REP, V25, P1708, DOI 10.1016/j.celrep.2018.10.040
   Cazanave SC, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.968065
   Chen DW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1150-4
   Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Feng TT, 2020, ONCOGENE, V39, P356, DOI 10.1038/s41388-019-0991-3
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kroemer G, 2010, CURR OPIN CELL BIOL, V22, P121, DOI 10.1016/j.ceb.2010.02.003
   Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139
   Liska D, 2017, ANN SURG ONCOL, V24, P1093, DOI 10.1245/s10434-016-5643-z
   Lu AG, 2012, CANCER INVEST, V30, P721, DOI 10.3109/07357907.2012.732160
   Lv HM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1543-z
   Mizushima N, 2011, COLD SH Q B, V76, P397, DOI 10.1101/sqb.2011.76.011023
   Mizushima N, 2010, FEBS LETT, V584, P1279, DOI 10.1016/j.febslet.2010.02.053
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Piya S, 2016, BLOOD, V128, P1260, DOI 10.1182/blood-2016-01-692244
   Qiao SX, 2013, AUTOPHAGY, V9, P2087, DOI 10.4161/auto.26506
   Rosen A.W., 2016, UGESKR LAEGE, V178
   Shen WT, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.137
   Siegel RL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw322
   Slocum SL, 2011, ARCH TOXICOL, V85, P273, DOI 10.1007/s00204-011-0675-4
   Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278
   Tebay LE, 2015, FREE RADICAL BIO MED, V88, P108, DOI 10.1016/j.freeradbiomed.2015.06.021
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Zeng X, 2015, AUTOPHAGY, V11, P355, DOI 10.4161/15548627.2014.994368
   Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931
   Zhang Yue, 2015, Zhonghua Liu Xing Bing Xue Za Zhi, V36, P709
   Zhen ZJ, 2017, CANCER SCI, V108, P1485, DOI 10.1111/cas.13279
NR 38
TC 4
Z9 5
U1 2
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 9
PY 2020
VL 524
IS 3
BP 582
EP 588
DI 10.1016/j.bbrc.2020.01.092
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA LE5WX
UT WOS:000526792800009
PM 32029274
DA 2022-04-25
ER

PT J
AU Feng, JB
   Zhang, Y
   Ren, X
   Li, D
   Fu, HJ
   Liu, CH
   Zhou, W
   Liu, Q
   Liu, Q
   Wu, MH
AF Feng, Jianbo
   Zhang, Yan
   Ren, Xing
   Li, Di
   Fu, Haijuan
   Liu, Changhong
   Zhou, Wen
   Liu, Qing
   Liu, Qiang
   Wu, Minghua
TI Leucine-rich repeat containing 4 act as an autophagy inhibitor that
   restores sensitivity of glioblastoma to temozolomide
SO ONCOGENE
LA English
DT Article
ID COLORECTAL-CANCER; GLIOMA-CELLS; BETA-TRCP; RESISTANCE; MTOR;
   CHEMORESISTANCE; PROLIFERATION; EXPRESSION; APOPTOSIS; CYTOKINE
AB Temozolomide (TMZ) insensitivity and resistance are major causes of treatment failure and poor prognosis for GBM patients. Here, we identify LRRC4 as a novel autophagy inhibitor that restores the sensitivity of GBMs to TMZ. LRRC4 was associated with the DEPTOR/mTOR complex, and this interaction resulted in autophagy inhibition. Further investigation demonstrated that the PDZ binding domain of LRRC4 binds to the PDZ domain of DEPTOR. This binding decreases the half-life of DEPTOR via ubiquitination, thus inhibiting GBM cell autophagy and increasing the TMZ treatment response of GBM. Combined LRRC4 expression and TMZ treatment prolonged the survival of mice with tumour xenografts. Furthermore, the levels of LRRC4, DEPTOR and autophagy are clinically relevant for GBM, indicating that LRRC4 is likely to have significant potential as a therapeutic marker and target for TMZ treatment in glioma patients.
C1 [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Wu, Minghua] Cent South Univ, Hunan Prov Tumor Hosp, Changsha 410006, Hunan, Peoples R China.
   [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Wu, Minghua] Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410006, Hunan, Peoples R China.
   [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Changsha 410078, Hunan, Peoples R China.
   [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Hunan, Peoples R China.
   [Feng, Jianbo; Zhang, Yan; Ren, Xing; Li, Di; Fu, Haijuan; Liu, Changhong; Zhou, Wen; Wu, Minghua] Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China.
   [Liu, Changhong] Shandong Univ, Hosp 2, Inst Med Sci, Jinan 250033, Shandong, Peoples R China.
   [Liu, Qing] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Liu, Qiang] Cent South Univ, Xiangya Hosp 3, Changsha 410013, Hunan, Peoples R China.
RP Wu, MH (corresponding author), Cent South Univ, Hunan Prov Tumor Hosp, Changsha 410006, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Xiangya Med Sch, Affiliated Tumor Hosp, Changsha 410006, Hunan, Peoples R China.; Wu, MH (corresponding author), Cent South Univ, Canc Res Inst, Sch Basic Med Sci, Changsha 410078, Hunan, Peoples R China.; Wu, MH (corresponding author), Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410078, Hunan, Peoples R China.; Wu, MH (corresponding author), Minist Hlth, Key Lab Carcinogenesis, Changsha 410078, Hunan, Peoples R China.
EM wuminghua554@aliyun.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81874150]; Graduate Student Research
   Innovation Project in Hunan Province [2019zzts084]
FX This works was supported by the National Natural Science Foundation of
   China (Grant No. 81874150) and Graduate Student Research Innovation
   Project in Hunan Province (2019zzts084).
CR Catena V, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0484-y
   Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985
   Cosin-Roger J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00213-3
   Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005
   Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006
   Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Hombach-Klonisch S, 2018, PHARMACOL THERAPEUT, V184, P13, DOI 10.1016/j.pharmthera.2017.10.017
   Hori YS, 2015, J NEURO-ONCOL, V122, P11, DOI 10.1007/s11060-014-1686-9
   Huang J, 2011, ANTIOXID REDOX SIGN, V14, P2215, DOI 10.1089/ars.2010.3554
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487
   Kim S, 2006, NAT NEUROSCI, V9, P1294, DOI 10.1038/nn1763
   Li PY, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01748
   Li PY, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-266
   Masui K, 2012, NEUROPATH APPL NEURO, V38, P271, DOI 10.1111/j.1365-2990.2011.01238.x
   Menzies FM, 2017, NEURON, V93, P1015, DOI 10.1016/j.neuron.2017.01.022
   Minghua W, 2010, J CELL BIOCHEM, V103, P245
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Murat A, 2008, J CLIN ONCOL, V26, P3015, DOI 10.1200/JCO.2007.15.7164
   Nanegrungsunk D, 2015, NEUROL RES, V37, P167, DOI 10.1179/1743132814Y.0000000423
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Soto F, 2018, ELIFE, V7, DOI 10.7554/eLife.30388
   Um SM, 2018, CELL REP, V23, P3839, DOI 10.1016/j.celrep.2018.05.087
   Wang JR, 2002, PROG BIOCHEM BIOPHYS, V29, P233
   Wang QD, 2018, CANCER RES, V78, P3163, DOI 10.1158/0008-5472.CAN-17-3107
   Wang ZY, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0355-1
   Wang ZW, 2012, NEOPLASIA, V14, P368, DOI 10.1593/neo.12542
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wick W, 2014, CANCER DISCOV, V4, P1120, DOI 10.1158/2159-8290.CD-14-0918
   Woo J, 2009, NAT NEUROSCI, V12, P428, DOI 10.1038/nn.2279
   Wu MH, 2008, J CELL PHYSIOL, V214, P65, DOI 10.1002/jcp.21163
   Wu MH, 2006, MOL BIOL CELL, V17, P3534, DOI 10.1091/mbc.E05-11-1082
   Xu G, 2015, J NEUROSCI, V35, P7153, DOI 10.1523/JNEUROSCI.4726-14.2015
   Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5
   Yang ZNJ, 2011, CANCER BIOL THER, V11, P169, DOI 10.4161/cbt.11.2.14663
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041
   Zanotto-Filho A, 2015, CANCER LETT, V358, P220, DOI 10.1016/j.canlet.2014.12.044
   Zhang W, 2008, GENES BRAIN BEHAV, V7, P385, DOI 10.1111/j.1601-183X.2007.00361.x
   Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029
   Zhou WC, 2017, CELL STEM CELL, V21, P591, DOI 10.1016/j.stem.2017.10.002
NR 48
TC 4
Z9 4
U1 3
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUN
PY 2020
VL 39
IS 23
BP 4551
EP 4566
DI 10.1038/s41388-020-1312-6
EA MAY 2020
PG 16
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA LU5ZF
UT WOS:000530617200002
PM 32372061
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Shu, CW
   Weng, JR
   Chang, HW
   Liu, PF
   Chen, JJ
   Peng, CC
   Huang, JW
   Lin, WY
   Yen, CY
AF Shu, Chih-Wen
   Weng, Jing-Ru
   Chang, Hsueh-Wei
   Liu, Pei-Feng
   Chen, Jih-Jung
   Peng, Chien-Chi
   Huang, Jia-Wen
   Lin, Wei-Yu
   Yen, Ching-Yu
TI Tribulus terrestris fruit extract inhibits autophagic flux to diminish
   cell proliferation and metastatic characteristics of oral cancer cells
SO ENVIRONMENTAL TOXICOLOGY
LA English
DT Article
DE ATG4B; autophagy; oral cancer; plant extract
AB Elevated autophagy is highly associated with cancer development and progression. Fruit extracts of several plants inhibit activity of autophagy-related protease ATG4B and autophagy activity in colorectal cancer cells. However, the effects of these plant extracts in oral cancer cells remain unclear. In this study, we found that the extracted Tribulus terrestris fruit (TT-(fr)) and Xanthium strumarium fruit had inhibitory effects on autophagy inhibition in both SAS and TW2.6 oral cancer cells. Moreover, the fruit extracts had differential effects on cell proliferation of oral cancer cells. In addition, the fruit extracts hampered cell migration and invasion of oral cancer cells, particularly in TT-(fr) extracts. Our results indicated that TT-(fr) extracts consistently inhibited autophagic flux, cell growth and metastatic characteristics of oral cancer cells, suggesting TT-(fr) might contain function ingredient to suppress oral cancer cells.
C1 [Shu, Chih-Wen; Peng, Chien-Chi] Natl Sun Yat Sen Univ, Inst Biopharmaceut Sci, Kaohsiung, Taiwan.
   [Shu, Chih-Wen; Liu, Pei-Feng] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung, Taiwan.
   [Shu, Chih-Wen; Chang, Hsueh-Wei; Liu, Pei-Feng] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung, Taiwan.
   [Weng, Jing-Ru] Natl Sun Yat Sen Univ, Dept Marine Biotechnol & Resources, Kaohsiung, Taiwan.
   [Chang, Hsueh-Wei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Canc Ctr, Kaohsiung, Taiwan.
   [Liu, Pei-Feng] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung, Taiwan.
   [Chen, Jih-Jung] Natl Yang Ming Chiao Tung Univ, Fac Pharm, Sch Pharmaceut Sci, Taipei, Taiwan.
   [Huang, Jia-Wen; Yen, Ching-Yu] Chi Mei Med Ctr, Oral & Maxillofacial Surg Sect, Tainan, Taiwan.
   [Lin, Wei-Yu] Kinmen Hosp, Dept Pharm, Kinmen, Taiwan.
   [Yen, Ching-Yu] Taipei Med Univ, Dept Dent, Taipei, Taiwan.
RP Yen, CY (corresponding author), Chi Mei Med Ctr, Oral & Maxillofacial Surg Sect, Tainan, Taiwan.
EM ycysmc@gmail.com
OI Liu, Pei-Feng/0000-0002-7849-8940; Shu, Chih-Wen/0000-0002-7774-0002
FU Ministry of Science and Technology [MOST107-2314-B384-005, MOST
   108-2320-B-075B-003, MOST 108-2320-B-110-008-MY3]
FX This work was supported by the Ministry of Science and Technology
   (MOST107-2314-B384-005, MOST 108-2320-B-075B-003, and MOST
   108-2320-B-110-008-MY3).
CR Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Chang HW, 2019, TOXINS, V11, DOI 10.3390/toxins11060313
   Cheng JS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00474
   Chude CI, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061279
   Fu YY, 2019, CANCERS, V11, DOI 10.3390/cancers11050649
   Goan YG, 2019, CANCERS, V11, DOI 10.3390/cancers11081117
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Huang NC, 2017, PEERJ, V5, DOI 10.7717/peerj.3448
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Li H, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2046-z
   Li W, 2017, ONCOL REP, V37, P3459, DOI 10.3892/or.2017.5637
   Liu PF, 2019, CANCERS, V11, DOI 10.3390/cancers11121854
   Liu PF, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120478
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Liu PF, 2017, CELL PHYSIOL BIOCHEM, V44, P728, DOI 10.1159/000485286
   Liu PF, 2015, J INVEST DERMATOL, V135, P2714, DOI 10.1038/jid.2015.254
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mocholi E, 2018, CELL REP, V24, P1136, DOI 10.1016/j.celrep.2018.06.065
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Sheu SJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213932
   Stefanescu R, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050752
   Toshima T, 2014, J GASTROENTEROL, V49, P907, DOI 10.1007/s00535-013-0835-9
   Wang J, 2018, ONCOTARGETS THER, V11, P7777, DOI 10.2147/OTT.S159095
   Wang WK, 2016, ENVIRON TOXICOL, V31, P77, DOI 10.1002/tox.22023
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Wu HM, 2015, SCI REP-UK, V5, DOI 10.1038/srep12291
   Yang XY, 2018, INT J ONCOL, V53, P215, DOI 10.3892/ijo.2018.4376
   Yoshii SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091865
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhao GM, 2016, ONCOL REP, V35, P1065, DOI 10.3892/or.2015.4413
   Zhu WY, 2017, CHEM CENT J, V11, DOI 10.1186/s13065-017-0289-x
NR 34
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1520-4081
EI 1522-7278
J9 ENVIRON TOXICOL
JI Environ. Toxicol.
PD JUN
PY 2021
VL 36
IS 6
BP 1173
EP 1180
DI 10.1002/tox.23116
EA MAR 2021
PG 8
WC Environmental Sciences; Toxicology; Water Resources
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology; Toxicology; Water Resources
GA RO8CH
UT WOS:000626936100001
PM 33751830
DA 2022-04-25
ER

PT J
AU Lin, CM
   Chen, HH
   Lin, CA
   Wu, HC
   Sheu, JJC
   Chen, HJ
AF Lin, Chung-Ming
   Chen, Hsin-Han
   Lin, Chun-An
   Wu, Hui-Chung
   Sheu, Jim Jinn-Chyuan
   Chen, Hui-Jye
TI Apigenin-induced lysosomal degradation of beta-catenin in Wnt/beta
   catenin signaling
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COLORECTAL-CANCER; PRODEATH AUTOPHAGY; CELL-LINE; STEM; INHIBITION; LC3;
   CHEMOTHERAPY; EXPRESSION; DISCOVERY; PORCUPINE
AB The bioflavonoid apigenin has been shown to possess cancer-preventive and anti-cancer activities. In a drug screening, we found that apigenin can inhibit Wnt/beta-catenin signaling, a pathway that participates in pivotal biological functions, which dis-regulation results in various human diseases including cancers. However, the underlying mechanism of apigenin in this pathway and its link to anti-cancer activities remain largely unknown. Here we showed that apigenin reduced the amount of total, cytoplasmic, and nuclear beta-catenin, leading to the suppression in the beta-catenin/TCF-mediated transcriptional activity, the expression of Wnt target genes, and cell proliferation of Wnt-stimulated P19 cells and Wnt-driven colorectal cancer cells. Western blotting and immunofluorescent staining analyses further revealed that apigenin could induce autophagy-mediated down-regulation of beta-catenin in treated cells. Treatment with autophagy inhibitors wortmannin and chloroquine compromised this effect, substantiating the involvement of autophagy-lysosomal system on the degradation of beta-catenin during Wnt signaling through inhibition of the AKT/mTOR signaling pathway. Our data not only pointed out a route for the inhibition of canonical Wnt signaling through the induction of autophagy-lysosomal degradation of key player beta-catenin, but also suggested that apigenin or other treatments which can initiate this degradation event are potentially used for the therapy of Wnt-related diseases including cancers.
C1 [Lin, Chung-Ming; Wu, Hui-Chung] Ming Chuan Univ, Dept Biotechnol, Taoyuan 33348, Taiwan.
   [Chen, Hsin-Han] China Med Univ Hosp, Div Plast & Reconstruct Surg, Dept Surg, Taichung 40402, Taiwan.
   [Lin, Chun-An; Chen, Hui-Jye] China Med Univ, Grad Inst Basic Med Sci, Taichung 40402, Taiwan.
   [Sheu, Jim Jinn-Chyuan] Natl Sun Yat Sen Univ, Inst Biomed Sci, Kaohsiung 80424, Taiwan.
   [Chen, Hui-Jye] Asia Univ, Dept Nursing, Taichung 40354, Taiwan.
   [Chen, Hui-Jye] China Med Univ, Grad Inst Biomed Sci, Taichung 40402, Taiwan.
RP Chen, HJ (corresponding author), China Med Univ, Grad Inst Basic Med Sci, Taichung 40402, Taiwan.; Chen, HJ (corresponding author), Asia Univ, Dept Nursing, Taichung 40354, Taiwan.; Chen, HJ (corresponding author), China Med Univ, Grad Inst Biomed Sci, Taichung 40402, Taiwan.
EM huijyechen@mail.cmu.edu.tw
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [104-2314-B039-027]; China Medical UniversityChina
   Medical University [CMU103-S-08]; Research Center for Tumor Medical
   Science, China Medical University, Taiwan [CMU104-S-05]
FX This paper was sponsored by grants from the Ministry of Science and
   Technology, Taiwan (MOST 104-2314-B039-027), China Medical University
   (CMU103-S-08), and partially from the Research Center for Tumor Medical
   Science, China Medical University, Taiwan (CMU104-S-05) to H.J.C. We
   thank the Medical Research Core Facilities Center, Office of Research &
   Development at China Medical University, Taichung, Taiwan, R.O.C. for
   all the help with the flow cytometry.
CR Abu-Baker A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.342
   Arvelo F, 2015, ECANCERMEDICALSCIENC, V9, DOI 10.3332/ecancer.2015.520
   Ayadi M, 2015, ONCOTARGET, V6, P18518, DOI 10.18632/oncotarget.3934
   Bao RY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048670
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cao BY, 2014, SCI REP-UK, V4, DOI 10.1038/srep05749
   Chen HB, 2016, ONCOTARGET, V7, P78747, DOI 10.18632/oncotarget.12288
   Chen HJ, 2006, GENE DEV, V20, P1933, DOI 10.1101/gad.1411206
   Chen HJ, 2012, BIOCHEM PHARMACOL, V84, P1143, DOI 10.1016/j.bcp.2012.08.011
   CHEN TR, 1987, CANCER GENET CYTOGEN, V27, P125, DOI 10.1016/0165-4608(87)90267-6
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   de Haan CAM, 2010, AUTOPHAGY, V6, P994, DOI 10.4161/auto.6.7.13309
   Duraiswamy AJ, 2015, J MED CHEM, V58, P5889, DOI 10.1021/acs.jmedchem.5b00507
   El-Bahrawy M, 2004, INT J EXP PATHOL, V85, P65, DOI 10.1111/j.0959-9673.2004.0371.x
   Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872
   Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gulbake A, 2016, WORLD J GASTROENTERO, V22, P582, DOI 10.3748/wjg.v22.i2.582
   Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Holland JD, 2013, CURR OPIN CELL BIOL, V25, P254, DOI 10.1016/j.ceb.2013.01.004
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ihara Y, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006361
   Johnson JL, 2011, J MED FOOD, V14, P325, DOI 10.1089/jmf.2010.0310
   Joshi RK, 2014, ASIAN PAC J CANCER P, V15, P397, DOI 10.7314/APJCP.2014.15.1.397
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim E, 2013, NUTR RES, V33, P983, DOI 10.1016/j.nutres.2013.07.018
   Lee HJ, 2015, J BIOL CHEM, V290, P30596, DOI 10.1074/jbc.M115.673202
   Lefort EC, 2013, MOL NUTR FOOD RES, V57, P126, DOI 10.1002/mnfr.201200424
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mansouri A, 2014, J TISSUE ENG REGEN M
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025
   Negraes P. D., 2012, CURR PROTOC STEM CE, V2
   Ong CW, 2010, MODERN PATHOL, V23, P450, DOI 10.1038/modpathol.2009.181
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pascolo S, 2016, EUR J PHARMACOL, V771, P139, DOI 10.1016/j.ejphar.2015.12.017
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Saiki Y, 2009, ANN SURG ONCOL, V16, P2638, DOI 10.1245/s10434-009-0567-5
   Sarkar FH, 2004, MUTAT RES-FUND MOL M, V555, P53, DOI 10.1016/j.mrfmmm.2004.04.015
   Schlafli AM, 2015, EUR J HISTOCHEM, V59, P137, DOI 10.4081/ejh.2015.2481
   Schneider JL, 2014, CURR OPIN GENET DEV, V26, P16, DOI 10.1016/j.gde.2014.04.003
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Shukla S, 2007, CANCER RES, V67, P6925, DOI 10.1158/0008-5472.CAN-07-0717
   Shukla S, 2010, PHARM RES-DORDR, V27, P962, DOI 10.1007/s11095-010-0089-7
   Singh A.K., 2016, CRIT REV FOOD SCI NU
   Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199
   Srivastava JK, 2010, MOL MED REP, V3, P895, DOI 10.3892/mmr.2010.377
   Stracci F, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00210
   Takagaki N, 2005, INT J ONCOL, V26, P185
   Tanida I, 2010, METHODS MOL BIOL, V648, P193, DOI 10.1007/978-1-60761-756-3_13
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Lopez PJT, 2014, CLIN MED INSIGHTS-GA, V7, P33, DOI 10.4137/CGast.S14039
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031
   van der Heyden MAG, 2003, CARDIOVASC RES, V58, P292, DOI 10.1016/S0008-6363(02)00771-X
   Vilchez V, 2016, WORLD J GASTROENTERO, V22, P823, DOI 10.3748/wjg.v22.i2.823
   Yang K, 2016, LAB INVEST, V96, P116, DOI 10.1038/labinvest.2015.144
   Yang YP, 2013, ACTA PHARMACOL SIN, V34, P625, DOI 10.1038/aps.2013.5
NR 63
TC 28
Z9 28
U1 2
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 23
PY 2017
VL 7
AR 372
DI 10.1038/s41598-017-00409-z
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EP0SM
UT WOS:000397097000002
PM 28337019
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Shen, MY
   Lin, L
AF Shen, Mingyang
   Lin, Lin
TI Functional variants of autophagy-related genes are associated with the
   development of hepatocellular carcinoma
SO LIFE SCIENCES
LA English
DT Article
DE Hepatocellular carcinoma; Genetic; Autophagy; Expression quantitative
   trait loci
ID COLORECTAL-CANCER; THR300ALA VARIANT; BREAST-CANCER; TARGET GENES;
   POLYMORPHISMS; EXPRESSION; ATG10; PROLIFERATION; SURVIVAL; RISK
AB Aims: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and accounts for substantial morbidity and mortality. Autophagy plays an essential role in the development and progression of HCC. This study aims to evaluate whether genetic variants in autophagy-related genes (ATGs) affect the development of HCC.
   Materials and methods: We conducted a case-control study with 986 HCC cases and 1000 healthy controls to analyze 14 functional variants of five ATGs (ATG3, ATG5, ATG10, ATG12 and ATG16L1) among a Chinese population.
   Key findings: We found ATG5 rs17067724 (G vs A: OR=0.80; 95% CI=0.65-0.98; P=0.031), ATG10 rs1864183 (G vs A: OR=1.29; 95% CI=1.07-1.57; P=0.009), ATG10 rs10514231 (C vs T: OR=1.41; 95% CI=1.15-1.73; P=0.001), ATG12 rs26537 (C vs T: OR=1.16; 95% CI=1.02-1.33; P=0.030), and ATG16L1 rs4663402 (T vs A: OR=1.28; 95% CI=1.01-1.63; P=0.044) were significantly associated with HCC risk. Specifically, ATG10 rs10514231 kept significant association even adjusted for Bonferroni correction (P=0.001x14=0.014). Bioinformatics analyses showed that allele C of ATG10 rs10514231 was significantly correlated with higher expression of ATG10 gene in both HCC tissues and normal liver tissues. Dual-luciferase reporter assay presented that cell lines transfected with vectors containing the risk allele C of rs10514231 showed higher relative luciferase activity compared to that containing the allele T.
   Significance: These results suggested that ATG10 rs10514231 might contribute to an allele-specific effect on the expression of host gene ATG10 and explain a fraction of HCC genetic susceptibility. Our study would benefit the construction of early warning model, early prevention, screening, even therapeutic target of HCC.
C1 [Shen, Mingyang; Lin, Lin] China Med Univ, Affiliated Hosp 4, Dept Gen Surg, Shenyang 110032, Liaoning, Peoples R China.
RP Lin, L (corresponding author), 4 Chongshandong Rd, Shenyang 110032, Liaoning, Peoples R China.
EM linlin_sy@aliyun.com
CR Berger MD, 2017, EUR J CANCER, V77, P13, DOI 10.1016/j.ejca.2017.02.020
   Cao QH, 2016, AM J TRANSL RES, V8, P3831
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Fan Q, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0673-y
   Fernandez-Mateos J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07270-0
   Fujioka Y, 2010, J BIOL CHEM, V285, P1508, DOI 10.1074/jbc.M109.053520
   Gong J, 2018, NUCLEIC ACIDS RES, V46, pD971, DOI 10.1093/nar/gkx861
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Guo XY, 2018, AM J HUM GENET, V102, P890, DOI 10.1016/j.ajhg.2018.03.016
   Hanada T, 2005, AUTOPHAGY, V1, P110, DOI 10.4161/auto.1.2.1858
   Hong SB, 2012, ACTA CRYSTALLOGR D, V68, P1409, DOI 10.1107/S0907444912034166
   Jo YK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052705
   Kim H., 2017, INT J MOL SCI, V18
   Kunanopparat A, 2016, WORLD J GASTROENTERO, V22, P8361, DOI 10.3748/wjg.v22.i37.8361
   Li J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0329-z
   Li MS, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-96
   Li N, 2019, IMMUNOL INVEST, V48, P378, DOI 10.1080/08820139.2019.1567532
   Li QX, 2017, AUTOPHAGY, V13, P1053, DOI 10.1080/15548627.2017.1308997
   Liu BL, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0343-7
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   Mak Lung-Yi, 2018, Am Soc Clin Oncol Educ Book, V38, P262, DOI 10.1200/EDBK_200939
   McGlynn KA, 2015, CLIN LIVER DIS, V19, P223, DOI 10.1016/j.cld.2015.01.001
   Nikseresht M., 2018, J CELL BIOCHEM
   Nooraei Marzieh Shams, 2018, Iranian Biomedical Journal, V22, P15, DOI 10.22034/ibj.22.1.15
   Plantinga TS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094086
   Qin ZZ, 2013, GENE, V527, P491, DOI 10.1016/j.gene.2013.06.067
   Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song XY, 2018, MOL CARCINOGEN, V57, P1030, DOI 10.1002/mc.22823
   Tan J, 2018, INT J CANCER, V143, P80, DOI 10.1002/ijc.31288
   Wang Shiming, 2017, Yichuan, V39, P250, DOI 10.16288/j.yczz.16-294
   Ward LD, 2016, NUCLEIC ACIDS RES, V44, pD877, DOI 10.1093/nar/gkv1340
   Wei HM, 2019, INT IMMUNOPHARMACOL, V73, P72, DOI 10.1016/j.intimp.2019.04.049
   Wu SY, 2018, HEPATOLOGY, V68, P141, DOI 10.1002/hep.29781
   Xie KP, 2016, INT J CANCER, V139, P1564, DOI 10.1002/ijc.30205
   Yamaguchi M, 2012, STRUCTURE, V20, P1244, DOI 10.1016/j.str.2012.04.018
   Yuan JP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18165-5
   Zhang K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0344-0
   Zhao ZZ, 2018, CANCER LETT, V421, P73, DOI 10.1016/j.canlet.2018.02.024
NR 40
TC 11
Z9 11
U1 1
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD OCT 15
PY 2019
VL 235
AR 116675
DI 10.1016/j.lfs.2019.116675
PG 6
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA JG8RS
UT WOS:000492345900002
PM 31340167
DA 2022-04-25
ER

PT J
AU Ginet, V
   Puyal, J
   Rummel, C
   Aubry, D
   Breton, C
   Cloux, AJ
   Majjigapu, SR
   Sordat, B
   Vogel, P
   Bruzzone, S
   Nencioni, A
   Duchosal, MA
   Nahimana, A
AF Ginet, Vanessa
   Puyal, Julien
   Rummel, Coralie
   Aubry, Dominique
   Breton, Caroline
   Cloux, Anne-Julie
   Majjigapu, Somi R.
   Sordat, Bernard
   Vogel, Pierre
   Bruzzone, Santina
   Nencioni, Alessio
   Duchosal, Michel A.
   Nahimana, Aimable
TI A critical role of autophagy in antileukemia/lymphoma effects of APO866,
   an inhibitor of NAD biosynthesis
SO AUTOPHAGY
LA English
DT Article
DE NAD; ATG; CATALASE; ROS; autophagy; APO866; lymphoma; leukemia; therapy
ID ADENINE-DINUCLEOTIDE BIOSYNTHESIS; MULTIPLE-MYELOMA CELLS; NICOTINAMIDE
   PHOSPHORIBOSYLTRANSFERASE; CASPASE-ACTIVATION; COLORECTAL-CANCER;
   LEUKEMIA-CELLS; DEATH; FK866; APOPTOSIS; DEGRADATION
AB APO866, an inhibitor of NAD biosynthesis, exhibits potent antitumor properties in various malignancies. Recently, it has been shown that APO866 induces apoptosis and autophagy in human hematological cancer cells, but the role of autophagy in APO866-induced cell death remains unclear. Here, we report studies on the molecular mechanisms underlying APO866-induced cell death with emphasis on autophagy. Treatment of leukemia and lymphoma cells with APO866 induced both autophagy, as evidenced by an increase in autophagosome formation and in SQSTM1/p62 degradation, but also increased caspase activation as revealed by CASP3/caspase 3 cleavage. As an underlying mechanism, APO866-mediated autophagy was found to deplete CAT/catalase, a reactive oxygen species (ROS) scavenger, thus promoting ROS production and cell death. Inhibition of autophagy by ATG5 or ATG7 silencing prevented CAT degradation, ROS production, caspase activation, and APO866-induced cell death. Finally, supplementation with exogenous CAT also abolished APO866 cytotoxic activity. Altogether, our results indicated that autophagy is essential for APO866 cytotoxic activity on cells from hematological malignancies and also indicate an autophagy-dependent CAT degradation, a novel mechanism for APO866-mediated cell killing. Autophagy-modulating approaches could be a new way to enhance the antitumor activity of APO866 and related agents.
C1 [Ginet, Vanessa; Puyal, Julien; Rummel, Coralie] Univ Lausanne, Dept Fundamental Neurosci, Fac Biol & Med, Lausanne, Switzerland.
   [Aubry, Dominique; Breton, Caroline; Cloux, Anne-Julie; Duchosal, Michel A.; Nahimana, Aimable] Univ Lausanne Hosp, Serv & Cent Lab Hematol, Lausanne, Switzerland.
   [Majjigapu, Somi R.; Sordat, Bernard; Vogel, Pierre] Swiss Fed Inst Technol EPFL, Lab Glycochem & Asymmetr Synth, Lausanne, Switzerland.
   [Bruzzone, Santina] Univ Genoa, Sect Biochem, Dept Expt Med, Genoa, Italy.
   [Nencioni, Alessio] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy.
RP Nahimana, A (corresponding author), Univ Lausanne Hosp, Serv & Cent Lab Hematol, Lausanne, Switzerland.
EM aimable.nahimana@chuv.ch
RI Puyal, Julien P/G-4210-2018; Bruzzone, Santina/A-4264-2015; Nencioni,
   Alessio/K-3692-2018
OI Puyal, Julien P/0000-0002-8140-7026; Bruzzone,
   Santina/0000-0003-2034-3716; NENCIONI, ALESSIO/0000-0001-5068-8884
FU Faculty of Biology and Medicine of the University of Lausanne; Fondation
   Dr Henri Dubois-Ferriere Dinu Lipatti; Swiss National Science
   FoundationSwiss National Science Foundation (SNSF)European Commission;
   AIRCFondazione AIRC per la ricerca sul cancro; FP7 project PANACREAS
FX We thank TopoTarget for kindly providing us with clinical grade APO866.
   We also thank Peter GH Clarke for critical reading of the manuscript.
   This work was supported by a grant from the Faculty of Biology and
   Medicine of the University of Lausanne (A Nahimana, J Puyal), the
   Fondation Dr Henri Dubois-Ferriere Dinu Lipatti (A Nahimana), the Swiss
   National Science Foundation (J Puyal), the AIRC (A Nencioni), and the
   FP7 project PANACREAS (A Nahimana, A Nencioni, MA Duchosal).
CR Berger F, 2005, J BIOL CHEM, V280, P36334, DOI 10.1074/jbc.M508660200
   Berta T, 2008, MOL CELL NEUROSCI, V37, P196, DOI 10.1016/j.mcn.2007.09.007
   Billington RA, 2008, AUTOPHAGY, V4, P385, DOI 10.4161/auto.5635
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bruzzone S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007897
   Cea M, 2013, AUTOPHAGY, V9, P410, DOI 10.4161/auto.22866
   Cea M, 2012, BLOOD, V120, P3519, DOI 10.1182/blood-2012-03-416776
   Cerna D, 2012, J BIOL CHEM, V287, P22408, DOI 10.1074/jbc.M112.357301
   Chen SY, 2011, AUTOPHAGY, V7, P217, DOI 10.4161/auto.7.2.14212
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Chen YQ, 2008, AUTOPHAGY, V4, P246, DOI 10.4161/auto.5432
   Clarke PGH, 2012, AUTOPHAGY, V8, P867, DOI 10.4161/auto.20380
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Creagh EM, 2003, IMMUNOL REV, V193, P10, DOI 10.1034/j.1600-065X.2003.00048.x
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Grishchuk Y, 2011, AUTOPHAGY, V7, P1115, DOI 10.4161/auto.7.10.16608
   Hasmann M, 2003, CANCER RES, V63, P7436
   Holen K, 2008, INVEST NEW DRUG, V26, P45, DOI 10.1007/s10637-007-9083-2
   Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1
   Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kubota C, 2010, J BIOL CHEM, V285, P667, DOI 10.1074/jbc.M109.053058
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Lenardo MJ, 2009, METHOD ENZYMOL, V453, P17, DOI 10.1016/S0076-6879(08)04002-0
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Martin DS, 1997, ONCOL RES, V9, P1
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Muruganandham M, 2005, CLIN CANCER RES, V11, P3503, DOI 10.1158/1078-0432.CCR-04-1399
   Nahimana A, 2009, BLOOD, V113, P3276, DOI 10.1182/blood-2008-08-173369
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Okumura S, 2012, J THORAC ONCOL, V7, P49, DOI 10.1097/JTO.0b013e318233d686
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Perrin V, 2007, MOL THER, V15, P903, DOI 10.1038/mt.sj.6300141
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Revollo JR, 2007, CURR OPIN GASTROEN, V23, P164, DOI 10.1097/MOG.0b013e32801b3c8f
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Seo G, 2011, FREE RADICAL RES, V45, P389, DOI 10.3109/10715762.2010.535530
   Shimizu S, 2010, ONCOGENE, V29, P2070, DOI 10.1038/onc.2009.487
   Thakur BK, 2013, INT J CANCER, V132, P766, DOI 10.1002/ijc.27726
   Thakur BK, 2012, BIOCHEM BIOPH RES CO, V424, P371, DOI 10.1016/j.bbrc.2012.06.075
   Travelli C, 2011, J PHARMACOL EXP THER, V338, P829, DOI 10.1124/jpet.111.184630
   van Beijnum JR, 2002, INT J CANCER, V101, P118, DOI 10.1002/ijc.10584
   Wang ZB, 2005, CELL BIOL INT, V29, P489, DOI 10.1016/j.cellbi.2005.04.001
   Yu L, 2006, P NATL ACAD SCI USA, V103, P4952, DOI 10.1073/pnas.0511288103
   Zhang LY, 2012, EUR J PHARMACOL, V674, P163, DOI 10.1016/j.ejphar.2011.11.017
   Zoppoli G, 2010, EXP HEMATOL, V38, P979, DOI 10.1016/j.exphem.2010.07.013
NR 47
TC 21
Z9 22
U1 0
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD APR 1
PY 2014
VL 10
IS 4
BP 603
EP 617
DI 10.4161/auto.27722
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AG6SD
UT WOS:000335547800006
PM 24487122
OA Green Submitted, Green Accepted, Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Wang, QX
   Lv, L
   Ye, DR
   Sun, YH
   Pan, XX
   Bhandari, A
   Zhang, XH
   Wang, OC
   Liu, HG
AF Wang, Qing-Xuan
   Lv, Lin
   Ye, Dan-Rong
   Sun, Yi-Han
   Pan, Xin-Xin
   Bhandari, Adheesh
   Zhang, Xiao-Hua
   Wang, Ou-Chen
   Liu, Hai-Guang
TI Downregulation of CD44v6 Enhances Chemosensitivity by Promoting
   Apoptosis and Inhibiting Autophagy in Colorectal Cancer HT29 Cells
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE colorectal cancer; CD44v6; chemosensitivity; knockdown
ID PROGNOSTIC IMPACT; POOR-PROGNOSIS; EXPRESSION; STATISTICS; METASTASIS
AB Background. Chemotherapy resistance reduces the effectiveness of chemotherapeutic drugs greatly, resulting in treatment failure. Therefore, exploring chemoresistance-related genes and the corresponding mechanism is extremely important. The central role of CD44v6 in colorectal cancer has been previously reported. However, the effects of CD44v6 gene knockdown on the chemosensitivity of colorectal cancer cells are not conclusive. Material and Methods. A stable CD44v6 knockdown cell model in HT29 cells (HT29-KD) was established via lentiviral transduction. A quantitative real-time polymerase chain reaction (PCR) was carried out to confirm the knockdown efficiency. The chemosensitivity of cells to 5-fluorouracil (5-FU) was determined by a cell counting kit (CCK)-8 assay. Cell apoptosis and the cell cycle were assessed by flow cytometry. Results. The CD44v6 knockdown cell model was successfully constructed by using lentiviral transduction. Upon treatment with 5-FU, the inhibitory rate for cell activity of HT29-KD cells was significantly higher than that of the control group (HT29-NC). CD44v6 gene knockdown did not significantly affect HT-29 cell proliferation, according to the CCK-8 assay and cell cycle analysis. The cell apoptosis assay revealed that CD44v6 gene knockdown promoted HT-29 cell apoptosis. Without 5-FU treatment, there was no significant difference in terms of the relative expression level of the autophagy-related gene BECN1 between the two groups. However, with 5-FU treatment, the relative expression level of BECN1 in HT29-KD cells was much lower than that in HT29-NC cells. Conclusion. Our study confirms that CD44v6 gene knockdown can enhance chemosensitivity in HT29 cells by promoting apoptosis and inhibiting autophagy, thus affirming the effects of CD44v6 on the chemosensitivity of colorectal cancer.
C1 [Wang, Qing-Xuan; Ye, Dan-Rong; Sun, Yi-Han; Pan, Xin-Xin; Bhandari, Adheesh; Zhang, Xiao-Hua; Wang, Ou-Chen; Liu, Hai-Guang] Wenzhou Med Univ, Affiliated Hosp 1, Dept Thyroid & Breast Surg, Wenzhou 325000, Zhejiang, Peoples R China.
   [Lv, Lin] Zhejiang Univ, Jinhua Hosp, Jinhua Municipal Cent Hosp, Dept Oncol, Jinhua, Zhejiang, Peoples R China.
RP Liu, HG (corresponding author), Wenzhou Med Univ, Affiliated Hosp 1, Dept Thyroid & Breast Surg, Wenzhou 325000, Zhejiang, Peoples R China.
EM liuhgwzmc@yahoo.com
RI Bhandari, Adheesh/L-4023-2018
OI Bhandari, Adheesh/0000-0002-0406-2685
FU Science Foundation of the Health Bureau of Wenzhou City of Zhejiang,
   China [Y20140173]; Scientific Research Incubator Project of The First
   Affiliated Hospital of Wenzhou Medical University [FHY2014013]; 2016
   annual CSCO Cancer Research Fund from Merck Serono [Y-MX2016-070];
   Wenzhou Science and Technology Planning Project [2017Y0336]
FX This work was supported by the Science Foundation of the Health Bureau
   of Wenzhou City of Zhejiang, China (Y20140173), Scientific Research
   Incubator Project of The First Affiliated Hospital of Wenzhou Medical
   University (No. FHY2014013), the 2016 annual CSCO Cancer Research Fund
   from Merck Serono (Y-MX2016-070), and the Wenzhou Science and Technology
   Planning Project (2017Y0336).
CR Bellerby R, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00145
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Ji FH, 2014, ONCOL LETT, V7, P1284, DOI 10.3892/ol.2014.1824
   Kodama H, 2017, BRIT J CANCER, V116, P186, DOI 10.1038/bjc.2016.401
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Loh TJ, 2015, ONCOL REP, V34, P1231, DOI 10.3892/or.2015.4110
   Lv L, 2016, TUMOR BIOL, V37, P8811, DOI 10.1007/s13277-015-4755-6
   Maida M, 2017, EXPERT REV ANTICANC, V17, P1131, DOI 10.1080/14737140.2017.1392243
   Saito S, 2013, ONCOL REP, V29, P1570, DOI 10.3892/or.2013.2273
   Senbanjo LT, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00018
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Snyder EL, 2009, LAB INVEST, V89, P857, DOI 10.1038/labinvest.2009.54
   Tjhay F, 2015, CANCER SCI, V106, P1421, DOI 10.1111/cas.12765
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   van der Stok EP, 2017, NAT REV CLIN ONCOL, V14, P297, DOI 10.1038/nrclinonc.2016.199
   Verma M, 2015, CA-CANCER J CLIN, V65, P496, DOI 10.3322/caac.21295
   Vogel A, 2017, CANCER TREAT REV, V59, P54, DOI 10.1016/j.ctrv.2017.04.007
   Wang JL, 2017, ONCOTARGET, V8, P12866, DOI 10.18632/oncotarget.14163
   Wang LL, 2015, INT J CLIN EXP PATHO, V8, P14283
   Wang Z, 2016, ONCOTARGET, V7, P55409, DOI 10.18632/oncotarget.10580
   Xu YY, 2017, ONCOTARGET, V8, P45848, DOI 10.18632/oncotarget.17435
   Zhi XC, 2015, INT J NANOMED, V10, P2775, DOI 10.2147/IJN.S72263
   Zlobec I, 2009, HISTOPATHOLOGY, V55, P564, DOI 10.1111/j.1365-2559.2009.03421.x
NR 24
TC 2
Z9 3
U1 0
U2 1
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD JUL-AUG
PY 2019
VL 49
IS 4
BP 481
EP 487
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA JW6KP
UT WOS:000503158800008
PM 31471337
DA 2022-04-25
ER

PT J
AU Sajithlal, GB
   Hamed, HA
   Cruickshanks, N
   Booth, L
   Tavallai, S
   Syed, J
   Grant, S
   Poklepovic, A
   Dent, P
AF Sajithlal, Gangadharan B.
   Hamed, Hossein A.
   Cruickshanks, Nichola
   Booth, Laurence
   Tavallai, Seyedmehrad
   Syed, Jahangir
   Grant, Steven
   Poklepovic, Andrew
   Dent, Paul
TI Sorafenib/Regorafenib and Phosphatidyl Inositol 3 Kinase/Thymoma Viral
   Proto-Oncogene Inhibition Interact to Kill Tumor Cells
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; PI3K INHIBITORS; CANCER-CELLS; SOLID
   TUMORS; SORAFENIB; KINASE; CARCINOMA; APOPTOSIS; COMBINATION; AUTOPHAGY
AB The present studies were undertaken to determine whether the multikinase inhibitors sorafenib/regorafenib cooperated with clinically relevant, phosphatidyl inositol 3 kinase (PI3K)-thymoma viral proto-oncogene (AKT) inhibitors to kill tumor cells. In liver, colorectal, lung, breast, kidney, and brain cancer cells, at clinically achievable doses, sorafenib/regorafenib and the PI3K inhibitor acetic acid (1S, 4E, 10R, 11R, 13S, 14R)-[4-diallylaminomethylene-6-hydroxy-1-methoxymethyl-10,13-dimethyl-3,7,17-trioxo-1,3,4, 7,10,11,12,13,14,15,16,17-dodecahydro-2-oxa-cyclopenta[a]phenanthren-11-yl ester (PX-866) cooperated in a greater than additive fashion to kill tumor cells. Cells lacking phosphatase and tensin homolog were as sensitive to the drug combination as cells expressing the protein. Similar data were obtained using the AKT inhibitors perifosine and 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl-1,2,4-triazolo[3,4-f][1,6]naphthyridin-3(2H)-one hydrochloride (MK2206). PX-866 treatment abolished AKT/glycogen synthase kinase 3 (GSK3) phosphorylation, and cell killing correlated with reduced activity of AKT and mammalian target of rapamycin (mTOR). Expression of activated AKT and to a lesser extent activated mTOR reduced drug combination lethality. Expression of B-cell lymphoma-extra large or dominant negative caspase 9, but not cellular FLICE (FADD-like IL-1b-converting enzyme)-inhibitory protein short, protected cells from the drug combination. Treatment of cells with PX-866 increased protein levels of p62, lysosome-associated membrane protein 2 (LAMP2), and microtubule-associated protein light chain (LC) 3 and LC3II that correlated with a large increase in LC3-green fluorescent protein (GFP) vesicle numbers. Exposure of PX-866 treated cells to sorafenib reduced p62 and LAMP2 levels, decreased the ratio of LC3 to LC3II, and reduced LC3-GFP vesicle levels. Knockdown of Beclin1 or autophagy-related 5 suppressed drug toxicity by similar to 40%. In vivo, sorafenib and PX-866 or regorafenib and MK2206 cooperated to suppress the growth of established HuH7 and HCT116 tumors, respectively. Collectively our data demonstrate that the combination of sorafenib family kinase inhibitors with inhibitors of the PI3K/AKT pathway kills tumor cells in vitro and in vivo.
C1 [Sajithlal, Gangadharan B.; Hamed, Hossein A.; Cruickshanks, Nichola; Booth, Laurence; Tavallai, Seyedmehrad; Syed, Jahangir; Dent, Paul] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA.
   [Grant, Steven; Poklepovic, Andrew] Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA.
RP Dent, P (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, Massey Canc Ctr, 401 Coll St,Box 980035, Richmond, VA 23298 USA.
EM pdent@vcu.edu
FU National Institutes of Health National Cancer InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01-CA141704, R01-CA150214];
   National Institutes of Health National Institute of Diabetes and
   Digestive and Kidney DiseasesUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK52825];
   Department of DefenseUnited States Department of Defense
   [W81XWH-10-1-0009]; Universal Inc. Professorship in Signal Transduction
   Research; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA141703, R01CA150214] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK052825] Funding Source: NIH
   RePORTER
FX This work was funded from PHS grants from the National Institutes of
   Health National Cancer Institute [Grants R01-CA141704 and R01-CA150214];
   the National Institutes of Health National Institute of Diabetes and
   Digestive and Kidney Diseases [Grant R01-DK52825]; and the Department of
   Defense [W81XWH-10-1-0009]. P. D. is the holder of the Universal Inc.
   Professorship in Signal Transduction Research. The authors have no
   conflicts of interest to report.
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Bareford MD, 2011, CANCER RES, V71, P4955, DOI 10.1158/0008-5472.CAN-11-0898
   Caron RW, 2005, MOL CANCER THER, V4, P257
   Carr BI, 2013, J CELL PHYSIOL, V228, P292, DOI 10.1002/jcp.24148
   Cho DC, 2012, CANCER-AM CANCER SOC, V118, P6055, DOI 10.1002/cncr.27668
   Cruickshanks N, 2012, MOL PHARMACOL, V82, P1217, DOI 10.1124/mol.112.081539
   Elser C, 2007, J CLIN ONCOL, V25, P3766, DOI 10.1200/JCO.2006.10.2871
   Fulda S, 2013, MITOCHONDRION, V13, P195, DOI 10.1016/j.mito.2012.05.001
   Gollob JA, 2006, SEMIN ONCOL, V33, P392, DOI 10.1053/j.seminoncol.2006.04.002
   Gores GJ, 2012, GENE DEV, V26, P305, DOI 10.1101/gad.186189.111
   Gwak HS, 2011, INT J CANCER, V128, P787, DOI 10.1002/ijc.25394
   Hafsi S, 2012, INT J ONCOL, V40, P639, DOI 10.3892/ijo.2011.1312
   Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714
   Ibrahim N, 2012, ONCOL REP, V27, P1303, DOI 10.3892/or.2012.1675
   Ihle NT, 2009, CANCER RES, V69, P143, DOI 10.1158/0008-5472.CAN-07-6656
   Kim SH, 2008, CANCER RES, V68, P2062, DOI 10.1158/0008-5472.CAN-07-6278
   Locatelli SL, 2013, LEUKEMIA, V27, P1677, DOI 10.1038/leu.2013.28
   Matsuda Y, 2011, MED MOL MORPHOL, V44, P183, DOI 10.1007/s00795-011-0558-z
   Park MA, 2008, CANCER BIOL THER, V7, P1648, DOI 10.4161/cbt.7.10.6623
   Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200
   Rahmani M, 2007, MOL CELL BIOL, V27, P5499, DOI 10.1128/MCB.01080-06
   Rahmani M, 2013, CANCER RES, V73, P1340, DOI 10.1158/0008-5472.CAN-12-1365
   Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Roulin D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-90
   Sancho-Martinez I, 2009, CELL CYCLE, V8, P838, DOI 10.4161/cc.8.6.7906
   Sheridan C, 2008, J BIOL CHEM, V283, P22128, DOI 10.1074/jbc.M800271200
   Sun H, 2012, ANTICANCER AGENTS ME
   Yacoub A, 2010, MOL PHARMACOL, V77, P298, DOI 10.1124/mol.109.061820
   Zhang G, 2008, CLIN CANCER RES, V14, P5385, DOI 10.1158/1078-0432.CCR-08-0469
NR 30
TC 25
Z9 26
U1 0
U2 19
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD OCT
PY 2013
VL 84
IS 4
BP 562
EP 571
DI 10.1124/mol.113.088005
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 216YN
UT WOS:000324322900008
PM 23877009
OA Green Published
DA 2022-04-25
ER

PT J
AU Wang, M
   Han, D
   Yuan, ZM
   Hu, HQ
   Zhao, ZX
   Yang, RK
   Jin, YH
   Zou, CX
   Chen, YG
   Wang, GY
   Gao, X
   Wang, XS
AF Wang, Meng
   Han, Dong
   Yuan, Ziming
   Hu, Hanqing
   Zhao, Zhixun
   Yang, Runkun
   Jin, Yinghu
   Zou, Chaoxia
   Chen, Yinggang
   Wang, Guiyu
   Gao, Xu
   Wang, Xishan
TI Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by
   promoting SIRT1-mediated autophagy
SO CELL DEATH & DISEASE
LA English
DT Article
ID IN-VITRO; SIRT1; METASTASIS; CELLS; INHIBITION; EXPRESSION; CETUXIMAB
AB Chemotherapy failure is the major cause of recurrence and poor prognosis in colorectal cancer (CRC) patients. The role of the differentially expressed IncRNAs in 5-Fluorouracil chemoresistance has not fully explained. Here, we observed IncRNA H19 was associated with the 5-Fu resistance in CRC. Quantitative analysis indicated that H19 was significantly increased in recurrent CRC patient samples. Kaplan-Meier survival analysis indicated that high H19 expression in CRC tissues was significantly associated with poor recurrent free survival. Our functional studies demonstrated that H19 promoted colorectal cells 5-Fu resistance. Mechanistically, H19 triggered autophagy via SIRT1 to induce cancer chemoresistance. Furthermore, bioinformatics analysis showed that miR-194-5p could directly bind to H19, suggesting H19 might work as a ceRNA to sponge miR-194-5p, which was confirmed by Dual-luciferase reporter assay and Immunoprecipitation assay. Extensively, our study also showed that SIRT1 is the novel direct target of miR-194-5p in CRC cells. Taken together, our study suggests that H19 mediates 5-Fu resistance in CRC via SIRT1 mediated autophagy. Our finding provides a novel mechanistic role of H19 in CRC chemoresistance, suggesting that H19 may function as a marker for prediction of chemotherapeutic response to 5-Fu.
C1 [Wang, Meng; Yuan, Ziming; Hu, Hanqing; Zhao, Zhixun; Yang, Runkun; Jin, Yinghu; Chen, Yinggang; Wang, Guiyu; Wang, Xishan] Harbin Med Univ, Dept Colorectal Surg, Affiliated Hosp 2, Harbin 150081, Heilongjiang, Peoples R China.
   [Han, Dong; Zou, Chaoxia; Gao, Xu] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150081, Heilongjiang, Peoples R China.
   [Wang, Xishan] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, Dept Colorectal Surg, Beijing 100000, Peoples R China.
RP Wang, XS (corresponding author), Harbin Med Univ, Dept Colorectal Surg, Affiliated Hosp 2, Harbin 150081, Heilongjiang, Peoples R China.; Gao, X (corresponding author), Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150081, Heilongjiang, Peoples R China.
EM gaoxu_671227@163.com; wxshan1208@126.com
RI jin, yinghu/AAI-5725-2020; gao, xu/U-4765-2019
FU National Key Research and Development Program of the Ministry of Science
   and Technology of China [2016YFC0905303]; CAMS Innovation Fund for
   Medical Sciences (CIFMS) [2016-I2M-1-001]; Beijing Science and
   Technology Program [D17110002617004]; Heilongjiang Health and Family
   Planning Commission Research project [2017064]; Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81501998]; Postdoctoral Foundation of Heilongjiang Province
   [LBH-Q15079]; Innovation Talent Training Plan for Ordinary Colleges and
   Universities of Heilongjiang Province [UNPYSCT-2017072]
FX This study was partly supported by National Key Research and Development
   Program of the Ministry of Science and Technology of China
   (2016YFC0905303), CAMS Innovation Fund for Medical Sciences (CIFMS)
   (2016-I2M-1-001), Beijing Science and Technology Program
   (D17110002617004), Heilongjiang Health and Family Planning Commission
   Research project (2017064), Natural Science Foundation of China
   (81501998), the Postdoctoral Foundation of Heilongjiang Province
   (LBH-Q15079), the Innovation Talent Training Plan for Ordinary Colleges
   and Universities of Heilongjiang Province (UNPYSCT-2017072).
CR Baek SH, 2017, MOL CELL, V65, P781, DOI 10.1016/j.molcel.2016.12.027
   Berteaux N, 2005, J BIOL CHEM, V280, P29625, DOI 10.1074/jbc.M504033200
   Dell'Aversana C, 2017, LEUKEMIA, V31, P2315, DOI 10.1038/leu.2017.64
   Engemann S, 2000, HUM MOL GENET, V9, P2691, DOI 10.1093/hmg/9.18.2691
   Fanale D, 2016, ADV EXP MED BIOL, V937, P207, DOI 10.1007/978-3-319-42059-2_11
   Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Han D, 2016, ONCOTARGET, V7, P22159, DOI 10.18632/oncotarget.8063
   Han D, 2015, CANCER LETT, V361, P13, DOI 10.1016/j.canlet.2015.03.002
   Hu HQ, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171428
   Jandura A, 2017, TRENDS GENET, V33, P665, DOI 10.1016/j.tig.2017.08.002
   Jiang PF, 2016, ONCOTARGETS THER, V9, P3501, DOI 10.2147/OTT.S96278
   Kemp Michael G, 2017, J Cell Death, V9, p1179670716685085, DOI 10.1177/1179670716685085
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Liang WC, 2015, ONCOTARGET, V6, P22513, DOI 10.18632/oncotarget.4154
   Lin CR, 2018, TRENDS CELL BIOL, V28, P287, DOI 10.1016/j.tcb.2017.11.008
   Lin J, 2018, ONCOGENE, V37, P2432, DOI 10.1038/s41388-018-0146-y
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033
   Marquez-Jurado S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02787-4
   Miao JL, 2018, CELL PHYSIOL BIOCHEM, V45, P1966, DOI 10.1159/000487973
   Morel E, 2017, ANNU REV PHARMACOL, V57, P375, DOI 10.1146/annurev-pharmtox-010716-104936
   Ohtsuka M, 2016, EBIOMEDICINE, V13, P113, DOI 10.1016/j.ebiom.2016.10.026
   Oon CE, 2015, EUR J PHARMACOL, V757, P59, DOI 10.1016/j.ejphar.2015.03.064
   Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641
   Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004
   Schiedel Matthias, 2018, Med Res Rev, V38, P147, DOI 10.1002/med.21436
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8
   Sun LN, 2017, CANCER LETT, V409, P104, DOI 10.1016/j.canlet.2017.09.001
   Vennin C, 2017, CANCER LETT, V385, P198, DOI 10.1016/j.canlet.2016.10.023
   Wang Q, 2017, ONCOTARGET, V8, P2558, DOI 10.18632/oncotarget.13708
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xiong XD, 2016, DRUG RESIST UPDATE, V26, P28, DOI 10.1016/j.drup.2016.04.001
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang CL, 2017, CANCER LETT, V396, P66, DOI 10.1016/j.canlet.2017.03.018
   Zhang J, 2017, AUTOPHAGY, V13, P1004, DOI 10.1080/15548627.2017.1312041
   Zhang L, 2013, CARCINOGENESIS, V34, P577, DOI 10.1093/carcin/bgs381
   Zhang YL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7589813
NR 42
TC 82
Z9 85
U1 4
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 19
PY 2018
VL 9
AR 1149
DI 10.1038/s41419-018-1187-4
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA HA8TC
UT WOS:000450565200006
PM 30451820
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Dai, HT
   Liu, CM
   Liu, YH
   Zhang, Z
   Peng, CW
   Wang, ZY
   Zheng, J
   Li, CL
   Yu, WM
   Cheng, F
AF Dai, Haitao
   Liu, Changmao
   Liu, Yuanhua
   Zhang, Zhong
   Peng, Changwei
   Wang, Zhongyu
   Zheng, Jiang
   Li, Chenglong
   Yu, Weimin
   Cheng, Fan
TI Research on mechanism of miR-130a in regulating autophagy of bladder
   cancer cells through CYLD
SO JOURNAL OF BUON
LA English
DT Article
DE miR-130a; CYLD; bladder cancer cells; autophagy
ID COLORECTAL-CANCER; PROLIFERATION; MIGRATION; INVASION; MICRORNA-130A
AB Purpose: The study aimed to explore the regulatory mechanism of micro ribonucleic acid (miR)-130a in the autophagy of bladder cancer cells through cylindromatosis (CYLD).
   Methods: Human bladder cancer T24 cell line was used as the objects of the study. After miR-130a was knocked down using small-interfering RNA (siRNA) in T24 cell line, the changes in expressions of miR-130a and CYLD in each group were detected via quantitative reverse transcription-polymerase chain reaction (qRT-PCR). The cell proliferation in each group was detected using cell counting kit-8 (CCK8) assay and flow cytometry. The changes in mRNA and protein levels of microtubule-associated protein 1 light chain 3 (LC3) and Beclin1 were determined using qRT-PCR and Western blotting. The autolysosomes were detected through acridine orange (AO)/ethidium staining bromide (ER) staining. Moreover, CYLD was knocked down using siRNA, and then the changes in mRNA expressions of miR-130a, LC3 and Beclin1 in each group were detected through qRT-PCR.
   Results: After interference in miR-130a with siRNA, miR-130a-siRNA group had a significantly lower mRNA expression of miR-130a compared with NC-siRNA group and a significantly higher mRNA expression of CYLD (p<0.05), obviously inhibited cell proliferation (p<0.05), and decreased significantly mRNA and protein expressions of LC3 showing Beclin1 (p<0.05), and an evidently smaller number of autolysosomes. After knockdown of CYLD using siRNA, the mRNA expression of miR-130a had no significant changes (p>0.05), while the mRNA expressions of LC3 and Beclin1 declined significantly in CYLD-siRNA group compared with those in NC-siRNA group (p<0.05).
   Conclusion: MiR-130 can promote the autophagy of bladder cancer cells through regulating CYLD, thus facilitating the proliferation of tumor cells.
C1 [Dai, Haitao; Liu, Changmao; Liu, Yuanhua; Zhang, Zhong; Peng, Changwei; Wang, Zhongyu; Zheng, Jiang] Yangtze Univ, Affiliated Hosp 1, Peoples Hosp Jingzhou 1, Dept Urol, Jingzhou 434000, Hubei, Peoples R China.
   [Dai, Haitao; Li, Chenglong; Yu, Weimin; Cheng, Fan] Wuhan Univ, Hubei Gen Hosp, Renmin Hosp, Dept Urol, 238 Jiefang Rd,99 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China.
RP Cheng, F (corresponding author), Wuhan Univ, Hubei Gen Hosp, Renmin Hosp, Dept Urol, 238 Jiefang Rd,99 Zhangzhidong Rd, Wuhan 430060, Hubei, Peoples R China.
EM jiha77@126.com
CR Acunzo M, 2012, ONCOGENE, V31, P634, DOI 10.1038/onc.2011.260
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bauckman KA, 2016, AUTOPHAGY, V12, P850, DOI 10.1080/15548627.2016.1160176
   Chen L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085771
   Chen WZ, 2017, MOL MED REP, V16, P5241, DOI 10.3892/mmr.2017.7257
   Hunstig F, 2016, J CANCER RES CLIN, V142, P845, DOI 10.1007/s00432-015-2079-y
   Jiang H, 2015, ONCOL REP, V34, P1153, DOI 10.3892/or.2015.4099
   Kong PZ, 2016, ONCOTARGET, V7, P55601, DOI 10.18632/oncotarget.10876
   Li BK, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0230-2
   Liu L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055532
   Liu S, 2015, ONCOL REP, V33, P1372, DOI 10.3892/or.2014.3693
   Navarro M, 2017, WORLD J GASTROENTERO, V23, P3632, DOI 10.3748/wjg.v23.i20.3632
   Ozpolat B, 2015, CANCER MANAG RES, V7, P291, DOI 10.2147/CMAR.S34859
   Pan YQ, 2015, INT J CLIN EXP PATHO, V8, P384
   Sun L, 2015, PLOS ONE, V10, DOI [10.1371/journal.pone.0117695, 10.1371/journal.pone.0143820]
   Yang G, 2010, INT J BIOL SCI, V6, P1
   Yang JM, 2003, MOL CANCER RES, V1, P420
   Yang Ling-Yun, 2012, Sichuan Da Xue Xue Bao Yi Xue Ban, V43, P60
   Zhang Y, 2014, INT J MOL SCI, V15, P19330, DOI 10.3390/ijms151119330
   Zhao YG, 2015, J BIOL CHEM, V290, P22076, DOI 10.1074/jbc.M115.658096
   Zheng YZ, 2015, MOL CLIN ONCOL, V3, P713, DOI 10.3892/mco.2015.511
   Zhu X, 2015, CANCER GENE THER, V22, P573, DOI 10.1038/cgt.2015.50
NR 22
TC 1
Z9 1
U1 2
U2 3
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD MAY-JUN
PY 2020
VL 25
IS 3
BP 1636
EP 1642
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MM0PH
UT WOS:000549861700021
PM 32862616
DA 2022-04-25
ER

PT J
AU Jiso, A
   Demuth, P
   Bachowsky, M
   Haas, M
   Seiwert, N
   Heylmann, D
   Rasenberger, B
   Christmann, M
   Dietrich, L
   Brunner, T
   Riyanti
   Schaberle, TF
   Plubrukarn, A
   Fahrer, J
AF Jiso, Apisada
   Demuth, Philipp
   Bachowsky, Madeleine
   Haas, Manuel
   Seiwert, Nina
   Heylmann, Daniel
   Rasenberger, Birgit
   Christmann, Markus
   Dietrich, Lea
   Brunner, Thomas
   Riyanti
   Schaeberle, Till F.
   Plubrukarn, Anuchit
   Fahrer, Joerg
TI Natural Merosesquiterpenes Activate the DNA Damage Response via DNA
   Strand Break Formation and Trigger Apoptotic Cell Death in p53-Wild-Type
   and Mutant Colorectal Cancer
SO CANCERS
LA English
DT Article
DE colorectal cancer; chemotherapy; tumor suppressor p53; apoptosis;
   natural compounds; DNA damage
ID MARINE SPONGE METABOLITES; LIPOIC ACID; P53 MUTATIONS; ILIMAQUINONE;
   ETHYLSMENOQUINONE; SMENOSPONGINE; AMINOQUINONE; DERIVATIVES; EXPRESSION;
   AUTOPHAGY
AB Simple Summary Bowel cancer is a serious disease, which affects many people worldwide. Unfortunately, the disease is often diagnosed in an advanced stage, which impairs the chance of survival. Furthermore, resistance to therapy occurs frequently. Thus, novel therapeutic approaches are required to improve cancer therapy. Here, we studied whether merosesquiterpenes might be useful for cancer treatment. These compounds occur in marine sponges and were isolated by our group. We were able to identify three compounds with potent cytotoxic activity in different cell lines established from human large bowel cancer. Our experiments provided evidence that the compounds cause DNA damage and trigger cell death, so-called mitochondrial apoptosis, which was attested in cancer cells with expression of wild-type and mutated p53 tumor suppressor. Finally, we show that merosesquiterpenes also kill intestinal tumor organoids, an ex vivo model of large bowel cancer. Colorectal cancer (CRC) is a frequently occurring malignant disease with still low survival rates, highlighting the need for novel therapeutics. Merosesquiterpenes are secondary metabolites from marine sponges, which might be useful as antitumor agents. To address this issue, we made use of a compound library comprising 11 isolated merosesquiterpenes. The most cytotoxic compounds were smenospongine > ilimaquinone approximate to dactylospontriol, as shown in different human CRC cell lines. Alkaline Comet assays and gamma H2AX immunofluorescence microscopy demonstrated DNA strand break formation in CRC cells. Western blot analysis revealed an activation of the DNA damage response with CHK1 phosphorylation, stabilization of p53 and p21, which occurred both in CRC cells with p53 knockout and in p53-mutated CRC cells. This resulted in cell cycle arrest followed by a strong increase in the subG1 population, indicative of apoptosis, and typical morphological alterations. In consistency, cell death measurements showed apoptosis following exposure to merosesquiterpenes. Gene expression studies and analysis of caspase cleavage revealed mitochondrial apoptosis via BAX, BIM, and caspase-9 as the main cell death pathway. Interestingly, the compounds were equally effective in p53-wild-type and p53-mutant CRC cells. Finally, the cytotoxic activity of the merosesquiterpenes was corroborated in intestinal tumor organoids, emphasizing their potential for CRC chemotherapy.
C1 [Jiso, Apisada; Demuth, Philipp; Bachowsky, Madeleine; Haas, Manuel; Seiwert, Nina; Fahrer, Joerg] Tech Univ Kaiserslautern, Div Food Chem & Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany.
   [Jiso, Apisada; Plubrukarn, Anuchit] Prince Songkla Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Hat Yai 90112, Songkhla, Thailand.
   [Heylmann, Daniel; Fahrer, Joerg] Justus Liebig Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany.
   [Rasenberger, Birgit; Christmann, Markus] Univ Med Ctr Mainz, Inst Toxicol, D-55131 Mainz, Germany.
   [Dietrich, Lea; Brunner, Thomas] Univ Konstanz, Dept Biol, Biochem Pharmacol, D-78464 Constance, Germany.
   [Riyanti; Schaeberle, Till F.] Justus Liebig Univ Giessen, Inst Insect Biotechnol, D-35392 Giessen, Germany.
   [Riyanti] Jenderal Soedirman Univ, Fac Fisheries & Marine Sci, Purwokerto 53122, Indonesia.
   [Schaeberle, Till F.] Fraunhofer Inst Mol Biol & Appl Ecol IME, Branch Bioresources, D-35392 Giessen, Germany.
RP Fahrer, J (corresponding author), Tech Univ Kaiserslautern, Div Food Chem & Toxicol, Dept Chem, D-67663 Kaiserslautern, Germany.; Fahrer, J (corresponding author), Justus Liebig Univ Giessen, Rudolf Buchheim Inst Pharmacol, D-35392 Giessen, Germany.
EM jiso.apisada@gmail.com; pdemuth@rhrk.uni-kl.de; madele.bach@online.de;
   manhaas@rhrk.uni-kl.de; seiwert@rhrk.uni-kl.de;
   Daniel.Heylmann@pharma.med.uni-giessen.de; rasebi00@uni-mainz.de;
   mchristm@uni-mainz.de; lea.dietrich@uni-konstanz.de;
   thomas.brunner@uni-konstanz.de; Riyanti@bio.uni-giessen.de;
   Till.F.Schaeberle@agrar.uni-giessen.de; anuchit.pl@psu.ac.th;
   fahrer@chemie.uni-kl.de
OI Christmann, Markus/0000-0002-9672-231X; Jiso,
   Apisada/0000-0002-4297-7819; Heylmann, Daniel/0000-0002-8335-2313;
   Schaberle, Till/0000-0001-9947-8079; Seiwert, Nina/0000-0003-2169-3670;
   Dietrich, Lea/0000-0002-5931-7964
FU Wilhelm Sander Foundation [2016.039.2]; Royal Golden Jubilee PhD
   ProgramThailand Research Fund (TRF) [PHD/0094/2556]; German Federal
   Ministry of Education and Research (BMBF)Federal Ministry of Education &
   Research (BMBF) [01DP17037]; Indonesia Endowment Fund for Education
   (LPDP) [20160222305487]
FX This research was partially supported by Wilhelm Sander Foundation,
   Grant Number 2016.039.2 (to J.F.). A.J. was supported by a grant from
   the Royal Golden Jubilee PhD Program (PHD/0094/2556). T.F.S. and A.P.
   were supported by the German Federal Ministry of Education and Research
   (BMBF) Grant Number 01DP17037. R. received a PhD fellowship from the
   Indonesia Endowment Fund for Education (LPDP), Grant Number
   20160222305487.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Balansa W, 2019, MAR DRUGS, V17, DOI 10.3390/md17030158
   Bode KJ, 2019, BIOTECHNIQUES, V67, P23, DOI 10.2144/btn-2019-0023
   CARTE B, 1985, J ORG CHEM, V50, P2785, DOI 10.1021/jo00215a039
   Do MT, 2014, FOOD CHEM TOXICOL, V71, P51, DOI 10.1016/j.fct.2014.06.001
   Dorsam B, 2018, P NATL ACAD SCI USA, V115, pE4061, DOI 10.1073/pnas.1712345115
   Dorsam B, 2016, CANCER LETT, V371, P12, DOI 10.1016/j.canlet.2015.11.019
   Dorsam B, 2015, ARCH TOXICOL, V89, P1829, DOI 10.1007/s00204-014-1434-0
   Dorsam B, 2015, ARCH TOXICOL, V89, P797, DOI 10.1007/s00204-014-1281-z
   Fahrer J, 2014, DNA REPAIR, V18, P31, DOI 10.1016/j.dnarep.2014.03.002
   Fahrer J, 2013, BIOCONJUGATE CHEM, V24, P595, DOI 10.1021/bc300563c
   Goder A, 2015, CARCINOGENESIS, V36, P817, DOI 10.1093/carcin/bgv070
   Jiso A, 2021, SCI PHARM, V89, DOI 10.3390/scipharm89020026
   Jiso A, 2020, J NAT PROD, V83, P532, DOI 10.1021/acs.jnatprod.9b00886
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   KAZLAUSKAS R, 1978, AUST J CHEM, V31, P2685, DOI 10.1071/CH9782685
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   KONDRACKI ML, 1989, TETRAHEDRON, V45, P1995, DOI 10.1016/S0040-4020(01)80062-4
   KONDRACKI ML, 1987, TETRAHEDRON LETT, V28, P5815, DOI 10.1016/S0040-4039(01)81061-3
   Kong D, 2008, MAR DRUGS, V6, P480, DOI 10.3390/md20080023
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   KUSHLAN DM, 1989, TETRAHEDRON, V45, P3307, DOI 10.1016/S0040-4020(01)81009-7
   Kwak CH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176021
   Lee HY, 2015, MAR DRUGS, V13, P543, DOI 10.3390/md13010543
   Lin CW, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090296
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Lu PH, 2007, EUR J PHARMACOL, V556, P45, DOI 10.1016/j.ejphar.2006.10.061
   LUIBRAND RT, 1979, TETRAHEDRON, V35, P609, DOI 10.1016/0040-4020(79)87004-0
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Mauri G, 2020, ANN ONCOL, V31, P1135, DOI 10.1016/j.annonc.2020.05.027
   Maximo P, 2016, MAR DRUGS, V14, DOI 10.3390/md14080139
   Mimmler M, 2016, NUCLEIC ACIDS RES, V44, P10259, DOI 10.1093/nar/gkw791
   Murphy N, 2019, MOL ASPECTS MED, V69, P2, DOI 10.1016/j.mam.2019.06.005
   Neitzel C, 2020, CANCERS, V12, DOI 10.3390/cancers12071731
   Neitzel C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080794
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Park S, 2014, MAR DRUGS, V12, P3231, DOI 10.3390/md12063231
   Ripani P, 2020, ONCOGENE, V39, P2345, DOI 10.1038/s41388-019-1142-6
   RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555
   RODRIGUEZ J, 1992, TETRAHEDRON, V48, P6667, DOI 10.1016/S0040-4020(01)80012-0
   Ross D, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101950
   Seiwert N, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02950-8
   Seiwert N, 2020, BBA-REV CANCER, V1873, DOI 10.1016/j.bbcan.2019.188334
   Seiwert N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.418
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Sionov RV, 2015, ONCOTARGET, V6, P23058, DOI 10.18632/oncotarget.5492
   Son H, 2019, MAR DRUGS, V17, DOI 10.3390/md17030171
   Strzeszewska-Potyrala A, 2021, CANCERS, V13, DOI 10.3390/cancers13092115
   Tang J, 2018, CANCER MED-US, V7, P3965, DOI 10.1002/cam4.1640
   van Stuijvenberg J, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2019.115279
   VENKATESWARLU Y, 1991, J ORG CHEM, V56, P6271, DOI 10.1021/jo00022a011
   Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yang Y, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01612
   Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226
NR 55
TC 1
Z9 1
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2021
VL 13
IS 13
AR 3282
DI 10.3390/cancers13133282
PG 25
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TF9VY
UT WOS:000671063800001
PM 34209047
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huang, YH
   Zhou, J
   Luo, SL
   Wang, Y
   He, JT
   Luo, P
   Chen, ZL
   Liu, T
   Tan, X
   Ou, JJ
   Miao, HM
   Liang, HJ
   Shi, CM
AF Huang, Yinghui
   Zhou, Jie
   Luo, Shenglin
   Wang, Yang
   He, Jintao
   Luo, Peng
   Chen, Zelin
   Liu, Tao
   Tan, Xu
   Ou, Juanjuan
   Miao, Hongming
   Liang, Houjie
   Shi, Chunmeng
TI Identification of a fluorescent small-molecule enhancer for therapeutic
   autophagy in colorectal cancer by targeting mitochondrial protein
   translocase TIM44
SO GUT
LA English
DT Article
ID HEPTAMETHINE DYE; DRUG-DELIVERY; IR-780 DYE; NANOPARTICLES;
   ACCUMULATION; METFORMIN; PROGRESSION; RISK; GENE
AB Objective As the modulation of autophagic processes can be therapeutically beneficial to cancer treatment, the identification of novel autophagic enhancers is highly anticipated. However, current autophagy-inducing anticancer agents exert undesired side effects owing to their non-specific biodistribution in off-target tissues. This study aims to develop a multifunctional agent to integrate cancer targeting, imaging and therapy and to investigate its mechanism.
   Design A series of mitochondria-targeting near-infrared (NIR) fluorophores were synthesised, screened and identified for their autophagy-enhancing activity. The optical properties and biological effects were tested both in vitro and in vivo. The underlying mechanism was investigated using inhibitors, small interfering RNA (siRNA), RNA sequencing, mass spectrometry and human samples.
   Results We have screened and identified a new NIR autophagy-enhancer, IR-58, which exhibits significant tumour-selective killing effects. IR-58 preferentially accumulates in the mitochondria of colorectal cancer (CRC) cells and xenografts, a process that is glycolysis-dependent and organic anion transporter polypeptide-dependent. IR-58 kills tumour cells and induces apoptosis via inducing excessive autophagy, which is mediated through the reactive oxygen species (ROS)-Akt-mammalian target of rapamycin (mTOR) pathway. RNA sequencing, mass spectrometry and siRNA interference studies demonstrate that translocase of inner mitochondrial membrane 44 (TIM44)-superoxide dismutase 2 (SOD2) pathway inhibition is responsible for the excessive ROS, autophagy and apoptosis induced by IR-58. TIM44 expression correlates positively with CRC development and poor prognosis in patients.
   Conclusions A novel NIR small-molecule autophagy-enhancer, IR-58, with mitochondria-targeted imaging and therapy capabilities was developed for CRC treatment. Additionally, TIM44 was identified for the first time as a potential oncogene, which plays an important role in autophagy through the TIM44-SOD2-ROS-mTOR pathway.
C1 [Huang, Yinghui; Luo, Shenglin; Wang, Yang; He, Jintao; Luo, Peng; Chen, Zelin; Liu, Tao; Tan, Xu; Shi, Chunmeng] Third Mil Med Univ, Coll Prevent Med, Chongqing Engn Res Ctr Nanomed,Inst Combined Inju, State Key Lab Trauma Burns & Combined Injury, Chongqing 400038, Peoples R China.
   [Zhou, Jie; Ou, Juanjuan; Miao, Hongming; Liang, Houjie] Third Mil Med Univ, Southwest Hosp, Southwest Canc Ctr, Dept Oncol, Chongqing, Peoples R China.
RP Shi, CM (corresponding author), Third Mil Med Univ, Coll Prevent Med, Chongqing Engn Res Ctr Nanomed,Inst Combined Inju, State Key Lab Trauma Burns & Combined Injury, Chongqing 400038, Peoples R China.
EM shicm@sina.com
RI Sung, Joseph J. Y./R-3203-2018; miao, hongming/AAV-8561-2020; Chen,
   Zhiwei/B-7793-2019
OI Sung, Joseph J. Y./0000-0003-3125-5199; Chen,
   Zhiwei/0000-0002-4511-2888; Shi, Chunmeng/0000-0002-8264-738X; Huang,
   Yinghui/0000-0002-9263-1111; Luo, Peng/0000-0002-9668-4771
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81130026, 81372727]; State Key Basic
   Research Development Program [2012CB518103]; Ministry of Education
   [NCET-11-0869]
FX This work was supported by the National Natural Science Foundation of
   China (Grant No. 81130026 and 81372727), State Key Basic Research
   Development Program (2012CB518103), Program of New Century Excellent
   Talents in University (NCET-11-0869) from the Ministry of Education.
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Boni L, 2015, SURG ENDOSC, V29, P2046, DOI 10.1007/s00464-014-3895-x
   Chauhan S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9620
   Chen HP, 2013, GUT, V62, P606, DOI 10.1136/gutjnl-2011-301708
   Chen ZY, 2012, THERANOSTICS, V2, P238, DOI 10.7150/thno.3509
   Chong HS, 2009, CHEM COMMUN, P3011, DOI 10.1039/b823000e
   Chouchani ET, 2014, NATURE, V515, P431, DOI 10.1038/nature13909
   DeCensi A, 2010, CANCER PREV RES, V3, P1451, DOI 10.1158/1940-6207.CAPR-10-0157
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006
   Huang YH, 2016, CANCER LETT, V373, P57, DOI 10.1016/j.canlet.2016.01.034
   Kim K, 2010, J CONTROL RELEASE, V146, P219, DOI 10.1016/j.jconrel.2010.04.004
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kobayashi H, 2010, LANCET ONCOL, V11, P589, DOI 10.1016/S1470-2045(10)70009-7
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Miao HM, 2014, CELL REP, V7, P223, DOI 10.1016/j.celrep.2014.02.047
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8
   Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016
   Ozdemir V, 2006, NAT BIOTECHNOL, V24, P942, DOI 10.1038/nbt0806-942
   Pene F, 2009, CRIT CARE MED, V37, pS50, DOI 10.1097/CCM.0b013e3181921349
   Preston TC, 2009, J PHYS CHEM C, V113, P14236, DOI 10.1021/jp903284h
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shi CM, 2010, LANCET ONCOL, V11, P815, DOI 10.1016/S1470-2045(10)70196-0
   Shoji-Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tan X, 2012, BIOMATERIALS, V33, P2230, DOI 10.1016/j.biomaterials.2011.11.081
   Teng ACT, 2015, P NATL ACAD SCI USA, V112, P7165, DOI 10.1073/pnas.1508815112
   Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86
   Wang X, 2008, CA-CANCER J CLIN, V58, P97, DOI 10.3322/CA.2007.0003
   Wang Y, 2014, BIOMATERIALS, V35, P4116, DOI 10.1016/j.biomaterials.2014.01.061
   Wang Y, 2015, ADV MATER, V27, P2627, DOI 10.1002/adma.201405926
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Yue CX, 2013, BIOMATERIALS, V34, P6853, DOI 10.1016/j.biomaterials.2013.05.071
   Zhang C, 2010, BIOMATERIALS, V31, P9535, DOI 10.1016/j.biomaterials.2010.08.059
   Zhang C, 2010, BIOMATERIALS, V31, P6612, DOI 10.1016/j.biomaterials.2010.05.007
   Zhang EL, 2014, BIOMATERIALS, V35, P771, DOI 10.1016/j.biomaterials.2013.10.033
   Zhang F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6775
   Zhang JW, 2015, NAT CELL BIOL, V17, P1259, DOI 10.1038/ncb3230
   Zhang YL, 2006, J AM SOC NEPHROL, V17, P1090, DOI 10.1681/ASN.2005111148
NR 41
TC 24
Z9 25
U1 6
U2 30
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD FEB
PY 2018
VL 67
IS 2
BP 307
EP 319
DI 10.1136/gutjnl-2016-311909
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA FS2JN
UT WOS:000419604800018
PM 27849558
DA 2022-04-25
ER

PT J
AU Li, ZJ
   Li, YS
   Zhou, X
   Dai, PY
   Li, CM
AF Li, Zhaojian
   Li, Yansen
   Zhou, Xin
   Dai, Pengyuan
   Li, Chunmei
TI Autophagy involved in the activation of the Nrf2-antioxidant system in
   testes of heat-exposed mice
SO JOURNAL OF THERMAL BIOLOGY
LA English
DT Article
DE Heat exposure; Nrf2; p62; Autophagy; Testis; Mice
ID TRANSCRIPTION FACTOR NRF2; CUL3-BASED E3 LIGASE; OXIDATIVE STRESS;
   ANTIOXIDANT RESPONSE; APOPTOSIS; KEAP1; CANCER; GROWTH; P62; PATHWAY
AB Hyperthermia causes oxidative stress in testes, which triggers antioxidant signals including autophagy and nuclear factor erythroid 2-related factor 2 (Nrf2). However, their relationship in testes under oxidative stress is unclear. In this study, we conducted testes injection for autophagy alteration and heat exposure to reveal the interaction between autophagy and the Nrf2-antioxidant system. Male mice were injected once with normal saline as control (Cont group), autophagy inhibitor 3-methyladenine (3-MA group) or autophagy inducer rapaihycin (Rapa group). Then, each group was divided into two parts: one received a 2-h 42 degrees C heat treatment for eight days (HT groups), and the other was kept thermal neutral (NT groups). Heat-exposed mice showed significantly increased rectal, scrotal surface and body surface temperatures. Histology of the testes revealed many vacuoles inserted in the seminiferous tubules in the HT Cont group and two 3-MA groups. Ultrastructural changes in germ cells revealed autophagosomes in two 3-MA groups. Immunohistochemical detection of Nrf2 and p62/SQSTM1 proteins showed prominent expression in Leydig cells. Heat exposure increased Nrf2 protein and mRNA levels. 3-MA and Rapa testes injection also resulted in Nrf2 cytoplasm accumulation. Massive conversion of LC3 (microtubule-associated protein light chain 3)1 to LC3II was detected in two 3-MA groups, accompanied by decreased ATG5 (autophagy related gene 5) mRNA levels in the HT 3-MA group. These results indicated autophagy alteration triggered the Nrf2 signaling pathway with consequences such that the autophagy inducer protected the testes and the autophagy inhibitor enhanced the detrimental effects caused by heat exposure.
C1 [Li, Zhaojian; Li, Yansen; Zhou, Xin; Dai, Pengyuan; Li, Chunmei] Nanjing Agr Univ, Coll Anim Sci & Technol, Nanjing 210095, Jiangsu, Peoples R China.
RP Li, CM (corresponding author), Nanjing Agr Univ, Coll Anim Sci & Technol, Nanjing 210095, Jiangsu, Peoples R China.
EM chunmeili@njau.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31402116, 31272485]; National Key Research
   and Development Program of China [2016YFD0500505]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 31402116 and 31272485) and the National Key Research and
   Development Program of China (2016YFD0500505).
CR Copple IM, 2008, TOXICOLOGY, V246, P24, DOI 10.1016/j.tox.2007.10.029
   Copple IM, 2010, J BIOL CHEM, V285, P16782, DOI 10.1074/jbc.M109.096545
   Coto-Montes A, 2012, MOL CELL ENDOCRINOL, V361, P12, DOI 10.1016/j.mce.2012.04.009
   Cui WP, 2013, AM J PHYSIOL-ENDOC M, V304, pE87, DOI 10.1152/ajpendo.00430.2012
   Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Fan GW, 2016, J CELL MOL MED, V20, P1908, DOI 10.1111/jcmm.12883
   Fan WL, 2010, AUTOPHAGY, V6, P614, DOI 10.4161/auto.6.5.12189
   Fu QL, 2017, ENVIRON POLLUT, V227, P314, DOI 10.1016/j.envpol.2017.04.078
   Gordon CJ, 2012, J THERM BIOL, V37, P654, DOI 10.1016/j.jtherbio.2012.08.004
   Haider SG, 2004, INT REV CYTOL, V233, P181, DOI 10.1016/S0074-7696(04)33005-6
   Hansen PJ, 2009, PHILOS T R SOC B, V364, P3341, DOI 10.1098/rstb.2009.0131
   Harikai N, 2004, PHYSIOL BEHAV, V83, P373, DOI 10.1016/j.physbeh.2004.06.019
   Huang KQ, 2016, TUMOR BIOL, V37, P9625, DOI 10.1007/s13277-015-4689-z
   Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067
   Ivell R, 2007, REPROD BIOL ENDOCRIN, V5, DOI 10.1186/1477-7827-5-15
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Ko J. H., 2017, ONCOTARGET
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lau A, 2013, MOL CELL BIOL, V33, P2436, DOI 10.1128/MCB.01748-12
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li Y, 2015, J ANIM SCI, V93, P3421, DOI 10.2527/jas.2015-8910
   Li YS, 2014, ACTA HISTOCHEM, V116, P883, DOI 10.1016/j.acthis.2014.02.008
   Li YS, 2013, REPROD BIOL ENDOCRIN, V11, DOI 10.1186/1477-7827-11-23
   Lin SY, 2012, SCIENCE, V336, P477, DOI 10.1126/science.1217032
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Moscat J, 2009, CELL, V137, P1001, DOI 10.1016/j.cell.2009.05.023
   Munkelwitz R, 1998, J UROLOGY, V160, P1329, DOI 10.1016/S0022-5347(01)62528-X
   Oberley TD, 2008, J HISTOCHEM CYTOCHEM, V56, P615, DOI 10.1369/jhc.2008.950873
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Paul C, 2008, REPRODUCTION, V136, P73, DOI 10.1530/REP-08-0036
   Paul C, 2009, BIOL REPROD, V80, P913, DOI 10.1095/biolreprod.108.071779
   Sciarretta S, 2012, AUTOPHAGY, V8, P1252, DOI 10.4161/auto.20670
   Shin D, 2017, REDOX BIOL, V13, P219, DOI 10.1016/j.redox.2017.05.025
   Shiraishi K, 2010, WORLD J UROL, V28, P359, DOI 10.1007/s00345-009-0462-5
   Song BS, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.111.097949
   Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278
   Wang HN, 2014, CELL RES, V24, P852, DOI 10.1038/cr.2014.70
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xi GM, 2016, BIOMED PHARMACOTHER, V84, P1610, DOI 10.1016/j.biopha.2016.10.063
   YAMAUCHI C, 1981, LAB ANIM SCI, V31, P251
   Yin YZ, 1997, J ANDROL, V18, P159
   Yu J, 2011, FUNCT INTEGR GENOMIC, V11, P203, DOI 10.1007/s10142-010-0198-8
   Yue J., 2015, BIOCHEM BIOPH RES CO, V469, P665
   Zhang MQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041412
   Zhang YH, 2015, TOXICOL REP, V2, P664, DOI 10.1016/j.toxrep.2015.04.007
   Zou X, 2012, J NUTR BIOCHEM, V23, P994, DOI 10.1016/j.jnutbio.2011.05.006
NR 50
TC 12
Z9 12
U1 2
U2 19
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4565
J9 J THERM BIOL
JI J. Therm. Biol.
PD JAN
PY 2018
VL 71
BP 142
EP 152
DI 10.1016/j.jtherbio.2017.11.006
PG 11
WC Biology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Zoology
GA FU1VK
UT WOS:000423637400018
PM 29301683
DA 2022-04-25
ER

PT J
AU Otterpohl, KL
   Gould, KA
AF Otterpohl, Karla L.
   Gould, Karen A.
TI Evaluation of Rint1 as a modifier of intestinal tumorigenesis and cancer
   risk
SO PLOS ONE
LA English
DT Article
ID GOLGI-ER RETROGRADE; RAD50-INTERACTING PROTEIN; COMPLEX; ZW10;
   LOCALIZATION; TRAFFICKING; BREAST; LOCUS; MOM5
AB The Rad50 Interacting Protein 1 (Rint1) influences cellular homeostasis through maintenance of endoplasmic reticulum, Golgi and centrosome integrity and regulation of vesicle transport, autophagy and the G(2)/M checkpoint. Rint1 has been postulated to function as a tumor suppressor as well as an oncogene, with its role depending perhaps upon the precise cellular and/or experimental context. In humans, heterozygosity for germline missense variants in RINT1 have, in some studies, been associated with increased risk of both breast and Lynch syndrome type cancers. However, it is not known if these germline variants represent loss of function alleles or gain of function alleles. Based upon these findings, as well as our initial consideration of Rint1 as a potential candidate for Mom5, a genetic modifier of intestinal tumorigenesis in Apc(Min/+) mice, we sought to explicitly examine the impact of Rint1 on tumorigenesis in Apc(Min/+) mice. However, heterozygosity for a knockout of Rint1 had no impact on tumorigenesis in Rint1(+/-); Apc(Min/+) mice. Likewise, we found no evidence to suggest that the remaining Rint1 allele was lost somatically in intestinal tumors in Apc(Min/+) mice. Interestingly, in contrast to what has been observed in Rint1(+/-) mice on a mixed genetic background, Rint1(+/-) mice on a pure C57BL/6J background did not show spontaneous tumor development. We also evaluated colorectal cancer data available in the COSMIC and ONCOMINE databases and found that RINT1 overexpression, as well as the presence of somatic missense mutations in RINT1 were associated with colorectal cancer development. In vitro evaluation of two missense variants in RINT1 suggested that such variants do have the potential to impact RINT1 function.
C1 [Otterpohl, Karla L.; Gould, Karen A.] Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.
   [Otterpohl, Karla L.] Sanford Res, Childrens Hlth Res Ctr, Sioux Falls, SD USA.
RP Gould, KA (corresponding author), Univ Nebraska Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.
EM kagould@unmc.edu
FU NCRRUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Center for Research
   Resources (NCRR) [5P20RR016469, RR018788]; National Institute for
   General Medical Science (NIGMS) [8P20GM103427, P20GM103471]
FX The University of Nebraska DNA Sequencing Core receives partial support
   from the NCRR (5P20RR016469, RR018788) and the National Institute for
   General Medical Science (NIGMS) (8P20GM103427, P20GM103471). The
   author(s) received no other specific funding for this work.
CR Arasaki K, 2007, BIOCHEM BIOPH RES CO, V359, P811, DOI 10.1016/j.bbrc.2007.05.188
   Arasaki K, 2006, MOL BIOL CELL, V17, P2780, DOI 10.1091/mbc.E05-10-0973
   Arasaki K, 2013, MOL BIOL CELL, V24, P2907, DOI 10.1091/mbc.E13-01-0014
   DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8
   Grigaravicius P, 2016, CELL DEATH DIFFER, V23, P454, DOI 10.1038/cdd.2015.113
   Haines DC, 2001, TOXICOL PATHOL, V29, P653, DOI 10.1080/019262301753385988
   He SS, 2014, AUTOPHAGY, V10, P180, DOI 10.4161/auto.26917
   He SS, 2013, NAT CELL BIOL, V15, P1206, DOI 10.1038/ncb2848
   Hirose H, 2004, EMBO J, V23, P1267, DOI 10.1038/sj.emboj.7600135
   Kong LJ, 2006, MOL CELL, V22, P63, DOI 10.1016/j.molcel.2006.02.016
   Li N, 2016, BREAST CANCER RES TR, V159, P385, DOI 10.1007/s10549-016-3944-3
   Lin XQ, 2007, MOL CELL BIOL, V27, P4905, DOI 10.1128/MCB.02396-06
   Oikarinen SI, 2009, CARCINOGENESIS, V30, P1591, DOI 10.1093/carcin/bgp159
   Otterpohl KL, 2015, MAMM GENOME, V26, P235, DOI 10.1007/s00335-015-9567-x
   Park DJ, 2014, CANCER DISCOV, V4, P804, DOI 10.1158/2159-8290.CD-14-0212
   Quayle SN, 2012, NEURO-ONCOLOGY, V14, P1325, DOI 10.1093/neuonc/nos246
   Xiao J, 2001, J BIOL CHEM, V276, P6105, DOI 10.1074/jbc.M008893200
NR 17
TC 4
Z9 4
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2017
VL 12
IS 3
AR e0172247
DI 10.1371/journal.pone.0172247
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN5OE
UT WOS:000396054300009
PM 28264000
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Kitahara, T
   Haraguchi, N
   Takahashi, H
   Nishimura, J
   Hata, T
   Takemasa, I
   Mizushima, T
   Yamamoto, H
   Doki, Y
   Mori, M
AF Kitahara, Tomohiro
   Haraguchi, Naotsugu
   Takahashi, Hidekazu
   Nishimura, Junichi
   Hata, Taishi
   Takemasa, Ichiro
   Mizushima, Tsunekazu
   Yamamoto, Hirofumi
   Doki, Yuichiro
   Mori, Masaki
TI Identification and Characterization of CD107a as a Marker of Low
   Reactive Oxygen Species in Chemoresistant Cells in Colorectal Cancer
SO ANNALS OF SURGICAL ONCOLOGY
LA English
DT Article
ID STEM-CELLS; OXIDATIVE STRESS; OXALIPLATIN; APOPTOSIS; THERAPY;
   DIFFERENTIATION; CYTOTOXICITY; EXPRESSION; CARCINOMA; AUTOPHAGY
AB Background. Reactive oxygen species (ROS) generated by chemoradiotherapy lead to cancer cell death. Although ROS regulation mechanisms play important roles in chemoradioresistance, few markers exist that indicated intracellular ROS status. This study aimed to identify novel cell surface markers that represented intracellular ROS status to characterize cells with low ROS (ROSlow) in colorectal cancer (CRC).
   Methods. We used ROS indicators and an antibody array with 242 cell surface antibodies to identify markers of ROSlow cells. After validation, we performed immunohistochemical analyses and chemosensitivity assays. We used small interfering RNA to assess the effect of silencing the identified markers. We tested cell differentiation assays with spheroid cell assays.
   Results. CD107a was identified as a common marker of ROSlow cells in several CRC cell lines and clinical specimens. CD107a(+)/ROSlow cells were enriched in HT29 and DLD1 cultures after treatments with oxaliplatin, 5-fluorouracil, and the irinotecan metabolite SN38. CD107a silencing improved chemosensitivity by increasing ROS production. Immunohistochemistry showed enhanced CD107a surface expression on cells that formed immature cell clusters and on cells located in the invasive fronts of cancer foci. CD107a expression was also enhanced on specimens from patients with poorly differentiated adenocarcinoma who had received neoadjuvant chemotherapy. Cell surface CD107a expression was enhanced on cells that formed colonospheres, but expression diminished during cell differentiation.
   Conclusions. CD107a was identified as a novel marker of ROSlow cells in CRC. CD107a expression was closely related to chemoresistance and the immature cell phenotype. Anti-CD107a treatments represent a novel approach for targeting chemoresistant cells in CRC.
C1 [Kitahara, Tomohiro; Haraguchi, Naotsugu; Takahashi, Hidekazu; Nishimura, Junichi; Hata, Taishi; Takemasa, Ichiro; Mizushima, Tsunekazu; Yamamoto, Hirofumi; Doki, Yuichiro; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan.
RP Haraguchi, N (corresponding author), Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan.
EM nharaguchi@gesurg.med.osaka-u.ac.jp
FU Pharma-Link between Academia and Shionogi (FLASH)
FX Supported in part by the Foundation of the Pharma-Link between Academia
   and Shionogi (FLASH), an initiative between Osaka University and
   Shionogi & Co .Ltd.
CR Agarwal AK, 2015, J CANCER RES CLIN, V141, P1563, DOI 10.1007/s00432-015-1917-2
   AUGERON C, 1984, CANCER RES, V44, P3961
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   DONALDSON KL, 1994, INT J CANCER, V57, P847, DOI 10.1002/ijc.2910570614
   Eskelinen Eeva-Liisa, 2006, Molecular Aspects of Medicine, V27, P495, DOI 10.1016/j.mam.2006.08.005
   Haraguchi N, 2008, ANN SURG ONCOL, V15, P2927, DOI 10.1245/s10434-008-0074-0
   Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550
   Hosokawa K, 2007, BIOCHEM BIOPH RES CO, V363, P578, DOI 10.1016/j.bbrc.2007.09.014
   HSIANG YH, 1989, CANCER RES, V49, P5077
   Huang AF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-115
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Jensen SS, 2013, INT J CLIN EXP PATHO, V6, P1294
   Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838
   Kim HM, 2012, ANN SURG ONCOL, V19, pS539, DOI 10.1245/s10434-011-2040-5
   Krzewski K, 2013, BLOOD, V121, P4672, DOI 10.1182/blood-2012-08-453738
   Kunzli BM, 2002, CANCER, V9, P228
   Li X, 2015, CANCER LETT, V357, P219, DOI 10.1016/j.canlet.2014.11.026
   Moore KA, 2006, SCIENCE, V311, P1880, DOI 10.1126/science.1110542
   Naka K, 2008, ANTIOXID REDOX SIGN, V10, P1883, DOI 10.1089/ars.2008.2114
   Okumura H, 2014, SURG TODAY, V44, P421, DOI 10.1007/s00595-013-0580-y
   Ozben T, 2007, J PHARM SCI-US, V96, P2181, DOI 10.1002/jps.20874
   REISHER SR, 1993, P NATL ACAD SCI USA, V90, P5757, DOI 10.1073/pnas.90.12.5757
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Song IS, 2015, GASTROENTEROLOGY, V149, P1006, DOI 10.1053/j.gastro.2015.06.007
   Sukhai MA, 2013, J CLIN INVEST, V123, P315, DOI 10.1172/JCI64180
   SUSSMAN NL, 1989, AM J PHYSIOL, V257, pG14, DOI 10.1152/ajpgi.1989.257.1.G14
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Tang JQ, 2012, CANCER INVEST, V30, P380, DOI 10.3109/07357907.2012.666692
   Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063
   Uehara K, 2016, SURG TODAY, V46, P161, DOI 10.1007/s00595-015-1218-z
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Wei B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039069
   Xing YY, 2015, APOPTOSIS, V20, P83, DOI 10.1007/s10495-014-1044-6
NR 36
TC 5
Z9 5
U1 0
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1068-9265
EI 1534-4681
J9 ANN SURG ONCOL
JI Ann. Surg. Oncol.
PD APR
PY 2017
VL 24
IS 4
BP 1110
EP 1119
DI 10.1245/s10434-016-5671-8
PG 10
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA EQ4LC
UT WOS:000398047600040
PM 27834032
DA 2022-04-25
ER

PT J
AU Coni, S
   Serrao, SM
   Yurtsever, ZN
   Di Magno, L
   Bordone, R
   Bertani, C
   Licursi, V
   Ianniello, Z
   Infante, P
   Moretti, M
   Petroni, M
   Guerrieri, F
   Fatica, A
   Macone, A
   De Smaele, E
   Di Marcotullio, L
   Giannini, G
   Maroder, M
   Agostinelli, E
   Canettieri, G
AF Coni, Sonia
   Serrao, Silvia Maria
   Yurtsever, Zuleyha Nihan
   Di Magno, Laura
   Bordone, Rosa
   Bertani, Camilla
   Licursi, Valerio
   Ianniello, Zaira
   Infante, Paola
   Moretti, Marta
   Petroni, Marialaura
   Guerrieri, Francesca
   Fatica, Alessandro
   Macone, Alberto
   De Smaele, Enrico
   Di Marcotullio, Lucia
   Giannini, Giuseppe
   Maroder, Marella
   Agostinelli, Enzo
   Canettieri, Gianluca
TI Blockade of EIF5A hypusination limits colorectal cancer growth by
   inhibiting MYC elongation
SO CELL DEATH & DISEASE
LA English
DT Article
ID TARGETING ORNITHINE-DECARBOXYLASE; TRANSLATION FACTOR EIF5A; C-MYC;
   GENOMIC TARGETS; CELL-GROWTH; EXPRESSION; INITIATION; PROMOTES;
   IDENTIFICATION; REQUIREMENT
AB Eukaryotic Translation Initiation Factor 5A (EIF5A) is a translation factor regulated by hypusination, a unique posttranslational modification catalyzed by deoxyhypusine synthetase (DHPS) and deoxyhypusine hydroxylase (DOHH) starting from the polyamine spermidine. Emerging data are showing that hypusinated EIF5A regulates key cellular processes such as autophagy, senescence, polyamine homeostasis, energy metabolism, and plays a role in cancer. However, the effects of EIF5A inhibition in preclinical cancer models, the mechanism of action, and specific translational targets are still poorly understood. We show here that hypusinated EIF5A promotes growth of colorectal cancer (CRC) cells by directly regulating MYC biosynthesis at specific pausing motifs. Inhibition of EIF5A hypusination with the DHPS inhibitor GC7 or through lentiviral-mediated knockdown of DHPS or EIF5A reduces the growth of various CRC cells. Multiplex gene expression analysis reveals that inhibition of hypusination impairs the expression of transcripts regulated by MYC, suggesting the involvement of this oncogene in the observed effect. Indeed, we demonstrate that EIF5A regulates MYC elongation without affecting its mRNA content or protein stability, by alleviating ribosome stalling at five distinct pausing motifs in MYC CDS. Of note, we show that blockade of the hypusination axis elicits a remarkable growth inhibitory effect in preclinical models of CRC and significantly reduces the size of polyps in APC(Min/+) mice, a model of human familial adenomatous polyposis (FAP). Together, these data illustrate an unprecedented mechanism, whereby the tumor-promoting properties of hypusinated EIF5A are linked to its ability to regulate MYC elongation and provide a rationale for the use of DHPS/EIF5A inhibitors in CRC therapy.
C1 [Coni, Sonia; Serrao, Silvia Maria; Di Magno, Laura; Bordone, Rosa; Bertani, Camilla; Petroni, Marialaura; Di Marcotullio, Lucia; Giannini, Giuseppe; Maroder, Marella; Canettieri, Gianluca] Sapienza Univ Rome, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.
   [Yurtsever, Zuleyha Nihan; Macone, Alberto] Sapienza Univ Rome, Dept Biochem Sci A Rossi Fanelli, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Licursi, Valerio; Ianniello, Zaira; Fatica, Alessandro] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Infante, Paola] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Viale Regina Elena 291, I-00161 Rome, Italy.
   [Moretti, Marta; De Smaele, Enrico] Sapienza Univ Rome, Dept Expt Med, Viale Regina Elena 324, I-00161 Rome, Italy.
   [Guerrieri, Francesca] Canc Res Ctr Lyon CRCL, UMR Inserm U1052, CNRS 5286, Lyon, France.
   [Di Marcotullio, Lucia; Canettieri, Gianluca] Sapienza Univ Rome, Ist Pasteur, Fdn Cenci Bolognetti, Viale Regina Elena 291, I-00161 Rome, Italy.
   [Agostinelli, Enzo; Canettieri, Gianluca] Int Polyamines Fdn ONLUS, Via Forte Tiburtino 98, I-00159 Rome, Italy.
   [Agostinelli, Enzo] Sapienza Univ Rome, Policlin Umberto I, Dept Sense Organs, Viale Policlin 155, I-00161 Rome, Italy.
RP Canettieri, G (corresponding author), Sapienza Univ Rome, Dept Mol Med, Viale Regina Elena 291, I-00161 Rome, Italy.; Canettieri, G (corresponding author), Sapienza Univ Rome, Ist Pasteur, Fdn Cenci Bolognetti, Viale Regina Elena 291, I-00161 Rome, Italy.; Canettieri, G (corresponding author), Int Polyamines Fdn ONLUS, Via Forte Tiburtino 98, I-00159 Rome, Italy.
EM gianluca.canettieri@uniroma1.it
RI petroni, marialaura/AAB-8637-2019; guerrieri, francesca/G-3908-2013; De
   Smaele, Enrico/C-1124-2013; Giannini, Giuseppe/B-5672-2013
OI petroni, marialaura/0000-0002-6021-1657; De Smaele,
   Enrico/0000-0003-4524-4423; DI MARCOTULLIO, LUCIA/0000-0003-0274-7178;
   Guerrieri, Francesca/0000-0002-2021-4394; Fatica,
   Alessandro/0000-0002-0743-7905; CANETTIERI,
   Gianluca/0000-0001-6694-2613; Giannini, Giuseppe/0000-0003-0299-4056;
   Infante, Paola/0000-0003-0682-3916
FU AIRCFondazione AIRC per la ricerca sul cancro [IG 17575, IG 20801];
   Istituto Pasteur - Fondazione Cenci-BolognettiIstituto Pasteur Italia
   Fondazione Cenci Bolognetti; Italian MIUR (Ministero dell'Istruzione,
   dell'Universita e della Ricerca), Dipartimenti di Eccellenza
   [L.232/2016]; SAPIENZA University; International Polyamines
   Foundation-ONLUS-ETS; AFM-Telethon grant [21025]; Fondazione "Enrico ed
   Enrica Sovena"; Istituto Pasteur (Fondazione Cenci-Bolognetti)Istituto
   Pasteur Italia Fondazione Cenci Bolognetti
FX We are grateful to Dr Raghu Mimira (Indianapolis, USA) for sharing the
   Hypusine antibody, Drs Sergio Nasi and Barbara Illi (lBPM-CNR, Rome,
   Italy) for MYC Mouse plasmid, and Dr. Debora Salerno and Ms. Martina
   Schito for technical assistance. The studies reported herein were
   financially supported by the following grants: AIRC IG 17575, IG 20801;
   Istituto Pasteur - Fondazione Cenci-Bolognetti; Italian MIUR (Ministero
   dell'Istruzione, dell'Universita e della Ricerca), Dipartimenti di
   Eccellenza -L.232/2016; SAPIENZA University; "International Polyamines
   Foundation-ONLUS-ETS"; AFM-Telethon grant #21025; Fondazione "Enrico ed
   Enrica Sovena" (scholarship to Z.N.Y. for supporting her PhD); S.C., L.
   Di Magno, and S.M.S. were supported by fellowships from Istituto Pasteur
   (Fondazione Cenci-Bolognetti).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Antonucci L, 2019, INT J ONCOL, V54, P505, DOI 10.3892/ijo.2018.4638
   Arnold CN, 2005, CANCER-AM CANCER SOC, V104, P2035, DOI 10.1002/cncr.21462
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bandino A, 2014, CELL ONCOL, V37, P387, DOI 10.1007/s13402-014-0201-9
   BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804
   Bugide S, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0228-x
   Capalbo C, 2019, CANCERS, V11, DOI 10.3390/cancers11020147
   Casero RA, 2018, NAT REV CANCER, V18, P681, DOI 10.1038/s41568-018-0050-3
   Coni S, 2017, SCI REP-UK, V7, DOI 10.1038/srep44079
   D'Amico D, 2015, DEV CELL, V35, P21, DOI 10.1016/j.devcel.2015.09.008
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   Dever TE, 2018, J BIOL CHEM, V293, P18719, DOI 10.1074/jbc.TM118.003338
   Di Magno L, 2020, CELL REP, V30, P1735, DOI 10.1016/j.celrep.2020.01.024
   Di Magno L, 2016, ONCOTARGET, V7, P9539, DOI 10.18632/oncotarget.7070
   Di Magno L, 2014, CELL CYCLE, V13, P3404, DOI 10.4161/15384101.2014.952973
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003
   Fernandez-Montes A, 2020, CLIN COLORECTAL CANC, V19, P165, DOI 10.1016/j.clcc.2020.04.003
   Fujimura K, 2018, CANCER RES, V78, P1444, DOI 10.1158/0008-5472.CAN-17-2873
   Gerner EW, 2018, J BIOL CHEM, V293, P18770, DOI 10.1074/jbc.TM118.003343
   Gutierrez E, 2013, MOL CELL, V51, P35, DOI 10.1016/j.molcel.2013.04.021
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Landau G, 2010, J BIOL CHEM, V285, P12474, DOI 10.1074/jbc.M110.106419
   Liu L, 2009, MOL BIOL CELL, V20, P4885, DOI 10.1091/mbc.E09-07-0550
   Liu S, 2019, CELL, V176, P491, DOI 10.1016/j.cell.2018.11.038
   LoGiudice Nicole, 2018, Med Sci (Basel), V6, DOI 10.3390/medsci6010012
   Lubas M, 2018, EMBO REP, V19, DOI 10.15252/embr.201846072
   Manjunath H, 2019, CELL REP, V29, P3134, DOI 10.1016/j.celrep.2019.10.129
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Martella M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134583
   Mathews MB, 2015, BBA-GENE REGUL MECH, V1849, P836, DOI 10.1016/j.bbagrm.2015.05.002
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Mustachio LM, 2019, AM J CANCER RES, V9, P1830
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nilsson JA, 2005, CANCER CELL, V7, P433, DOI 10.1016/j.ccr.2005.03.036
   Park MH, 2006, J BIOCHEM, V139, P161, DOI 10.1093/jb/mvj034
   Park MH, 2018, J BIOL CHEM, V293, P18710, DOI 10.1074/jbc.TM118.003341
   Pelechano V, 2017, NUCLEIC ACIDS RES, V45, P7326, DOI 10.1093/nar/gkx479
   Richart L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10153
   Rounbehler RJ, 2009, CANCER RES, V69, P547, DOI 10.1158/0008-5472.CAN-08-2968
   Schuller AP, 2017, MOL CELL, V66, P194, DOI 10.1016/j.molcel.2017.03.003
   SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108
   Tunca B, 2013, J CANCER RES CLIN, V139, P691, DOI 10.1007/s00432-013-1372-x
   Turpaev KT, 2018, BIOCHEMISTRY-MOSCOW+, V83, P863, DOI 10.1134/S0006297918080011
   Wiegering A, 2015, CANCER DISCOV, V5, P768, DOI 10.1158/2159-8290.CD-14-1040
   Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69
   Zhang HL, 2019, MOL CELL, V76, P110, DOI 10.1016/j.molcel.2019.08.005
   Zhang J, 2018, BIOMED PHARMACOTHER, V100, P168, DOI 10.1016/j.biopha.2018.02.016
NR 50
TC 9
Z9 9
U1 1
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD DEC 10
PY 2020
VL 11
IS 12
AR 1045
DI 10.1038/s41419-020-03174-6
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA PD3ZQ
UT WOS:000597627300001
PM 33303756
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, YX
   Lv, CS
   Dong, Y
   Yang, QK
AF Zhang, Yixiang
   Lv, Changsheng
   Dong, Yan
   Yang, Qingkai
TI Aspirin-targeted PD-L1 in lung cancer growth inhibition
SO THORACIC CANCER
LA English
DT Article
DE Aspirin; growth; lung cancer; PD-L1; TAZ
ID COLORECTAL-CANCER; ANTIPLATELET THERAPY; DIAGNOSIS; SURVIVAL;
   EXPRESSION; AUTOPHAGY; RISK
AB Background Aspirin is a classic anti-inflammatory drug and its anticancer effect has been previously explored in many types of cancer including colorectal cancer therapy. Programmed cell death-ligand 1 (PD-L1) is widely expressed in tumor cells and displays an inhibitory role in antitumor immunity. This study aimed to clarify the role of PD-L1 in aspirin-suppressed lung cancer.
   Methods The inhibitory effect of aspirin on lung cancer cell proliferation was assessed using an MTT cell viability assay. The role of aspirin in the modulation of PD-L1 expression was analyzed by western blot or RT-PCR assays. In lung cancer cells, the influence of aspirin on PD-L1 promoter activity was detected using a luciferase reporter assay. The interaction of TAZ with PD-L1 promoter in the cells, with or without aspirin administration, was tested via chromatin immunoprecipitation (ChIP) analysis. The function of PD-L1 in aspirin-mediated growth inhibition of lung cancer was examined using a cell viability assay.
   Results Following treatment with aspirin, lung cancer cell growth was markedly suppressed. Aspirin was able to markedly decrease the expression of PD-L1 at the mRNA and protein levels in lung cancer cells. For the mechanism study, we found that the promoter of PD-L1 was inactivated by aspirin via TAZ transcriptional coactivator in the cells. With regard to the functional investigation, aspirin was capable of resisting cell proliferation and PD-L1 overexpression abolished aspirin-depressed cell proliferation in lung cancer.
   Conclusions Aspirin suppressed the growth of lung cancer cells via targeting the TAZ/PD-L1 axis.
C1 [Zhang, Yixiang; Lv, Changsheng] Dalian Med Univ, Dept Thorac Surg, Affiliated Hosp 1, Dalian, Peoples R China.
   [Dong, Yan] Dalian Med Univ, Dept Oncol, Affiliated Hosp 1, Dalian 116000, Peoples R China.
   [Yang, Qingkai] Dalian Med Univ, Dept Canc Stem Cell, Dalian 116044, Peoples R China.
RP Dong, Y (corresponding author), Dalian Med Univ, Dept Oncol, Affiliated Hosp 1, Dalian 116000, Peoples R China.; Yang, QK (corresponding author), Dalian Med Univ, Dept Canc Stem Cell, Dalian 116044, Peoples R China.
EM dongyan100@aliyun.com; dalianmed@163.com
RI Yang, Qingkai/D-1566-2011
OI Yang, Qingkai/0000-0001-6628-5393
FU Funding of natural science foundation of Liaoning province, china
   [20180550106] Funding Source: Medline
CR Benamouzig R, 2010, GUT, V59, P622, DOI 10.1136/gut.2008.175406
   Cai GF, 2004, CELL IMMUNOL, V230, P89, DOI 10.1016/j.cellimm.2004.09.004
   Cao DL, 2019, CANCER RES, V79, P2604, DOI 10.1158/0008-5472.CAN-18-3842
   Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112
   Choi BH, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.91
   Clark CA, 2016, CANCER RES, V76, P6964, DOI 10.1158/0008-5472.CAN-16-0258
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Downer MK, 2017, EUR UROL, V72, P821, DOI 10.1016/j.eururo.2017.01.044
   Feng J, 2017, ONCOGENE, V36, P5829, DOI 10.1038/onc.2017.188
   Fujita Y, 2015, MOL THER, V23, P717, DOI 10.1038/mt.2015.10
   Galipeau PC, 2007, PLOS MED, V4, P342, DOI 10.1371/jourmal.pmed.0040067
   Hersey P, 2013, CLIN CANCER RES, V19, P514, DOI 10.1158/1078-0432.CCR-12-3312
   Huo XF, 2018, GUT, V67, P606, DOI 10.1136/gutjnl-2016-313584
   Li PW, 2015, GUT, V64, P1419, DOI 10.1136/gutjnl-2014-308260
   Lim SO, 2016, CANCER CELL, V30, P925, DOI 10.1016/j.ccell.2016.10.010
   Marshall SF, 2005, JNCI-J NATL CANCER I, V97, P805, DOI 10.1093/jnci/dji140
   McCowan C, 2013, EUR J CANCER, V49, P1049, DOI 10.1016/j.ejca.2012.10.024
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Ritprajak P, 2015, ORAL ONCOL, V51, P221, DOI 10.1016/j.oraloncology.2014.11.014
   Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8
   Sitia G, 2013, J HEPATOL, V59, P1135, DOI 10.1016/j.jhep.2013.05.040
   Sitia G, 2012, P NATL ACAD SCI USA, V109, pE2165, DOI 10.1073/pnas.1209182109
   Trabert B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt431
   Wang SJ, 2018, ONCOGENE, V37, P4164, DOI 10.1038/s41388-018-0252-x
NR 24
TC 4
Z9 4
U1 6
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1759-7706
EI 1759-7714
J9 THORAC CANCER
JI Thorac. Cancer
PD JUN
PY 2020
VL 11
IS 6
BP 1587
EP 1593
DI 10.1111/1759-7714.13433
PG 7
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA LS9CP
UT WOS:000536676900025
PM 32297484
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, J
   Shen, LM
   Li, X
   Song, WT
   Liu, Y
   Huang, L
AF Zhang, Jing
   Shen, Limei
   Li, Xiang
   Song, Wantong
   Liu, Yun
   Huang, Leaf
TI Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an
   Antitumor Response through Synergistic Immunogenic Cell Death for
   Microsatellite-Stable Colorectal Cancer
SO ACS NANO
LA English
DT Article
DE quercetin; alantolactone; immunogenic cell death; micelle; tumor
   microenvironment
ID GEMCITABINE MONOPHOSPHATE; POLYMERIC MICELLES; IMMUNOTHERAPY;
   NANOPARTICLES; CHEMOTHERAPY; APOPTOSIS; AUTOPHAGY; MECHANISMS;
   CISPLATIN; SYNTHASE
AB Microsatellite-stable colorectal cancer (CRC) is known to be resistant to immunotherapy. The combination of quercetin (Q) and alantolactone (A) was found to induce synergistic immunogenic cell death (ICD) at a molar ratio of 1:4 (Q:A). To achieve ratiometric loading and delivery, the micellar delivery of Q and A (QA-M) was developed with high entrapment efficiency and drug loading at an optimal ratio. QA-M achieved prolonged blood circulation and increased tumor accumulation for both drugs. More importantly, QA-M retained the desired drug ratio (molar ratio of Q to A = 1:4) in tumors at 2 and 4 h after intravenous injection for synergistic immunotherapy. Tumor growth was significantly inhibited in murine orthotopic CRC by the treatment of QA-M compared to PBS and the combination of free drugs (p < 0.005). The combination of nanotherapy stimulated the host immune response to induce long-term tumor destruction and induced memory tumor surveillance with a 1.3-fold increase in survival median time compared to PBS (p < 0.0001) and a combination of free drugs (p < 0.0005). The synergistic therapeutic effect induced by codelivery of Q and A is capable of reactivating antitumor immunity by inducing ICD, causing cell toxicity and modulating the immune-suppressive tumor microenvironment. Such a combination of Q and A with synergistic effects entrapped in a simple and safe nanodelivery system may provide the potential for scale-up manufacturing and clinical applications as immunotherapeutic agents for CRC.
C1 [Zhang, Jing; Shen, Limei; Song, Wantong; Liu, Yun; Huang, Leaf] Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
   [Zhang, Jing; Li, Xiang] Jiangxi Univ Tradit Chinese Med, Key Lab Modern Preparat TCM, Minist Educ, Nanchang 330004, Jiangxi, Peoples R China.
   [Song, Wantong] Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, Changchun 130022, Jilin, Peoples R China.
RP Huang, L (corresponding author), Univ N Carolina, Eshelman Sch Pharm, Div Pharmacoengn & Mol Pharmaceut, Chapel Hill, NC 27599 USA.
EM leafh@email.unc.edu
RI Li, Xiang/R-9392-2019; Li, Xiang/ABC-6376-2020
OI Li, Xiang/0000-0003-1526-6103; Liu, Yun/0000-0002-6763-496X; Huang,
   Leaf/0000-0002-9421-8283
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA198999]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81560575, 81760639, 81603054]; Jiangxi Province Outstanding Young
   Talents Program [20162BCB23034, 20171BCB23097]; Young Jinggang Scholar
   of Jiangxi Province [[2018]82, [2018]42]; "1050" Talents Program
   [[2018]82, [2018]42]; Jiangxi BaiQianWan Talents Program [2017082];
   Natural Science Fund of Jiangxi Province [20171BAB215066,
   20171ACB21074]; Fund for FirstRate Discipline of Chinese Materia Medica
   [JXSYLXKZHYA0055, JXSYLXK-ZHYA0056, JXSYLXK-ZHYA0019]; China
   Postdoctoral Science FoundationChina Postdoctoral Science Foundation
   [2016M602084]
FX The work was supported by NIH grant CA198999 (LB.), the National Natural
   Science Foundation of China (Nos. 81560575, 81760639, 81603054), the
   Jiangxi Province Outstanding Young Talents Program (20162BCB23034,
   20171BCB23097), Young Jinggang Scholar of Jiangxi Province and "1050"
   Talents Program ([2018]82 and [2018]42, Jing Zhang), Jiangxi BaiQianWan
   Talents Program (2017082, Xiang Li), the Natural Science Fund of Jiangxi
   Province (20171BAB215066, 20171ACB21074), the Fund for FirstRate
   Discipline of Chinese Materia Medica (JXSYLXKZHYA0055, JXSYLXK-ZHYA0056,
   JXSYLXK-ZHYA0019), and a project funded by the China Postdoctoral
   Science Foundation (2016M602084).
CR Ahn J, 2008, BIOCHEM BIOPH RES CO, V373, P545, DOI 10.1016/j.bbrc.2008.06.077
   Alev M, 2018, J CONTROL RELEASE, V285, P67, DOI 10.1016/j.jconrel.2018.07.007
   American Cancer Society, 2019, CANC FACTS FIG 2019, P9
   Birendra KC, 2017, AM J HEMATOL-ONCOL, V13, P4
   Cascao R, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00069
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chun J, 2015, CANCER LETT, V357, P393, DOI 10.1016/j.canlet.2014.11.049
   Chun J, 2012, INT IMMUNOPHARMACOL, V14, P375, DOI 10.1016/j.intimp.2012.08.011
   Crawford J, 2004, CANCER-AM CANCER SOC, V100, P228, DOI 10.1002/cncr.11882
   Duan HF, 2018, CELL PHYSIOL BIOCHEM, V47, P441, DOI 10.1159/000489979
   Egert S, 2008, J NUTR, V138, P1615, DOI 10.1093/jn/138.9.1615
   Feng JH, 2018, BIOCHEM BIOPH RES CO, V498, P132, DOI 10.1016/j.bbrc.2018.02.044
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703
   Gilabert-Oriol R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102922
   Goodwin TJ, 2017, VACCINE, V35, P2550, DOI 10.1016/j.vaccine.2017.03.067
   Gubin MM, 2015, SCIENCE, V350, P158, DOI 10.1126/science.aad4140
   Han JH, 2017, SCI REP-UK, V7, DOI 10.1038/srep46652
   Hodge JW, 2013, INT J CANCER, V133, P624, DOI 10.1002/ijc.28070
   Hou L, 2011, CARBOHYD POLYM, V86, P1157, DOI 10.1016/j.carbpol.2011.06.008
   Jin Y, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-017-2340-y
   Kawano M, 2016, ONCOL LETT, V11, P2169, DOI 10.3892/ol.2016.4175
   Khan M, 2012, IUBMB LIFE, V64, P783, DOI 10.1002/iub.1068
   Kim J, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.16
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kono K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.207
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Le Page C, 2000, Rev Immunogenet, V2, P374
   Lee TJ, 2006, CANCER LETT, V240, P234, DOI 10.1016/j.canlet.2005.09.013
   Li TT, 2014, WORLD J GASTROENTERO, V20, P17699, DOI 10.3748/wjg.v20.i47.17699
   Li Y, 2016, NUTRIENTS, V8, P167, DOI DOI 10.3390/NU8030167
   Liu Q, 2018, ACS NANO, V12, P7812, DOI 10.1021/acsnano.8b01890
   Liu Y, 2017, APOPTOSIS, V22, P544, DOI 10.1007/s10495-016-1334-2
   Lu JQ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01651-9
   Marin-Acevedo JA, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0552-6
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   McKeown E, 2014, J CANCER, V5, P31, DOI 10.7150/jca.7987
   Mi Y, 2011, BIOMATERIALS, V32, P4058, DOI 10.1016/j.biomaterials.2011.02.022
   Miao L, 2014, ADV FUNCT MATER, V24, P6601, DOI 10.1002/adfm.201401076
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258
   Pan QB, 2019, RSC ADV, V9, P15042, DOI 10.1039/c9ra01381d
   Pandey G, 2018, ACS APPL MATER INTER, V10, P16964, DOI 10.1021/acsami.7b18699
   Parveen S, 2011, EUR J PHARMACOL, V670, P372, DOI 10.1016/j.ejphar.2011.09.023
   Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024
   Rasul A, 2013, SCI WORLD J, DOI 10.1155/2013/248532
   Rivera AR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157251
   Rockenbach L, 2013, UROL ONCOL-SEMIN ORI, V31, P1204, DOI 10.1016/j.urolonc.2011.10.009
   Sage PT, 2018, J IMMUNOL, V200, P2592, DOI 10.4049/jimmunol.1701231
   Sakaguchi S, 2010, NAT REV IMMUNOL, V10, P490, DOI 10.1038/nri2785
   Sezgin Z, 2006, EUR J PHARM BIOPHARM, V64, P261, DOI 10.1016/j.ejpb.2006.06.003
   Showalter A, 2017, CYTOKINE, V97, P123, DOI 10.1016/j.cyto.2017.05.024
   Song WT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04605-x
   Sun XR, 2019, INT J NANOMED, V14, P2115, DOI 10.2147/IJN.S193783
   Suryadevara CM, 2016, CLIN CANCER RES, V22, P5164, DOI 10.1158/1078-0432.CCR-16-1666
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Varela-Garcia A, 2018, INT J PHARMACEUT, V552, P39, DOI 10.1016/j.ijpharm.2018.09.053
   Wang DZ, 2013, ANNU REV MED, V64, P131, DOI 10.1146/annurev-med-112211-154330
   Wang N, 2018, J CELL PHYSIOL, V233, P2434, DOI 10.1002/jcp.26118
   Wang SF, 2011, DRUG CHEM TOXICOL, V34, P61, DOI 10.3109/01480545.2010.494664
   Wang X, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0563-8
   Ward AB, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1400-z
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   Wellenstein MD, 2018, IMMUNITY, V48, P399, DOI 10.1016/j.immuni.2018.03.004
   Wu CJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1477459
   Xu JY, 2013, CANCER RES, V73, P2782, DOI 10.1158/0008-5472.CAN-12-3981
   Yesudhas D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00334
   Zhang J, 2018, MOLECULES, V23, DOI 10.3390/molecules23112906
   Zhang J, 2014, J CONTROL RELEASE, V182, P90, DOI 10.1016/j.jconrel.2014.03.016
   Zhang T, 2017, DRUG DEV IND PHARM, V43, P1827, DOI 10.1080/03639045.2017.1349784
   Zhang Y, 2013, MOL THER, V21, P1559, DOI 10.1038/mt.2013.120
   Zhao P, 2015, J BIOCHEM MOL TOXIC, V29, P199, DOI 10.1002/jbt.21685
   Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397
NR 73
TC 38
Z9 43
U1 18
U2 130
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD NOV
PY 2019
VL 13
IS 11
BP 12511
EP 12524
DI 10.1021/acsnano.9b02875
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA JS9WN
UT WOS:000500650000027
PM 31664821
DA 2022-04-25
ER

PT J
AU Choroba, K
   Machura, B
   Raposo, LR
   Malecki, JG
   Kula, S
   Pajak, M
   Erfurt, K
   Maroh, AM
   Fernandes, AR
AF Choroba, Katarzyna
   Machura, Barbara
   Raposo, Luis R.
   Malecki, Jan G.
   Kula, Slawomir
   Pajak, Michal
   Erfurt, Karol
   Maroh, Anna M.
   Fernandes, Alexandra R.
TI Platinum(ii) complexes showing high cytotoxicity toward A2780 ovarian
   carcinoma cells
SO DALTON TRANSACTIONS
LA English
DT Article
ID PREFERRED HORIZONTAL DISPLACEMENTS; AROMATIC-AROMATIC INTERACTIONS;
   ANTICANCER ACTIVITY; METAL-COMPLEXES; DNA-BINDING; METALLOINTERCALATION
   REAGENTS; RUTHENIUM(II) COMPLEXES; LUMINESCENCE PROPERTIES; BIOLOGICAL
   EVALUATION; COPPER(II) COMPLEXES
AB 2,6-Bis(thiazol-2-yl)pyridines functionalized with 9-anthryl (L-1), 9-phenanthryl (L-2), and 1-pyrenyl (L-3) groups were used for the preparation of [Pt(L-n)Cl]CF3SO3 (1-3). The constitution of the Pt(ii) complexes was determined by H-1 and C-13 NMR spectroscopy, HR-MS spectrometry, elemental analysis and X-ray analysis (for (1)). The electrochemical and photophysical properties of [Pt(L-n)Cl]CF3SO3 were compared with the behaviour of the Pt(ii) complexes with aryl-substituted 2,2 ':6 ',2 ''-terpyridine ligands. What is noteworthy is that the coordination ability of dtpy toward the Pt(ii) centre was investigated for the first time. All complexes were tested in vitro by MTS assay on four tumor cell lines, A2780 (ovarian carcinoma), HTC116 (colon rectal carcinoma), MCF7 (breast adenocarcinoma), and PC3 (prostate carcinoma) and on normal primary fibroblasts. Compounds (1-3) showed a dose dependent antiproliferative effect in the A2780 cell line with (3) > (2) > (1) and this loss of A2780 cell viability was due to a combination of an apoptotic cell death mechanism via mitochondria and autophagic cell death. Exposure to IC50 concentration of (2) induced an increase in the number of apoptotic nuclei and a depolarization of the mitochondrial membrane which is consistent with the induction of apoptosis while exposure to IC50 concentration of (3) showed an increase in the apoptotic nuclei with a slight hyperpolarization of the mitochondrial membrane that might indicate an initial step of apoptosis induction. The complexes (2) and (3) induce an increase in the production of intracellular ROS which is associated with the trigger of the apoptotic pathways. The ROS production was augmented by the presence of oxidants and correlated with an increase of oxygen radicals. The IC50 of (2) and (3) (4.4 mu M and 2.9 mu M, respectively) was similar to the IC50 of cisplatin (3.4 mu M) in the A2780 cell line, which together with their low cytotoxicity in normal fibroblasts, demonstrates their potential for further studies.
C1 [Choroba, Katarzyna; Machura, Barbara; Malecki, Jan G.; Kula, Slawomir; Pajak, Michal; Maroh, Anna M.] Univ Silesia, Inst Chem, Szkolna 9, PL-10006 Katowice, Poland.
   [Raposo, Luis R.; Fernandes, Alexandra R.] Univ Nova Lisboa, UCIBIO, Dept Ciencias Vida, Fac Ciencias & Tecnol, Campus Caparica, P-2829516 Caparica, Portugal.
   [Erfurt, Karol] Silesian Tech Univ, Dept Chem Organ Technol & Petrochem, Krzywoustego 4, PL-44100 Gliwice, Poland.
RP Maroh, AM (corresponding author), Univ Silesia, Inst Chem, Szkolna 9, PL-10006 Katowice, Poland.; Fernandes, AR (corresponding author), Univ Nova Lisboa, UCIBIO, Dept Ciencias Vida, Fac Ciencias & Tecnol, Campus Caparica, P-2829516 Caparica, Portugal.
EM anna.maron@us.edu.pl; ma.fernandes@fct.unl.pt
RI Raposo, Luís/AAX-1610-2021; Raposo, Luís R/T-3754-2017; Fernandes,
   Alexandra R/C-7465-2011; Malecki, Jan Grzegorz/M-4022-2017
OI Raposo, Luís/0000-0002-8637-346X; Raposo, Luís R/0000-0002-8637-346X;
   Fernandes, Alexandra R/0000-0003-2054-4438; Choroba,
   Katarzyna/0000-0003-0168-5753; Machura, Barbara/0000-0001-7688-6491;
   Kula, Slawomir/0000-0003-4520-1570; Maron, Anna
   Maria/0000-0001-8245-5532; Malecki, Jan Grzegorz/0000-0001-5571-3196
FU National Science Centre of Poland under grant MINIATURA 1
   [2017/01/X/ST5/00026]; Applied Molecular Biosciences Unit-UCIBIO -
   FCT/MCTES [UID/Multi/04378/2019];  [PTDC/CVT/EPI/6685/2014]
FX This work was supported by the National Science Centre of Poland under
   grant MINIATURA 1 (2017/01/X/ST5/00026) and the Applied Molecular
   Biosciences Unit-UCIBIO which is financed by national funds from
   FCT/MCTES (UID/Multi/04378/2019). LR acknowledges project
   PTDC/CVT/EPI/6685/2014.
CR Altintop MD, 2018, MOLECULES, V23, DOI 10.3390/molecules23061318
   ANNIBALE G, 1995, POLYHEDRON, V14, P451, DOI 10.1016/0277-5387(94)00408-7
   [Anonymous], 2014, CRYSALISRED VERSION1
   Banerjee S, 2013, CHEM COMMUN, V49, P8522, DOI 10.1039/c3cc44962a
   Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i
   Bligh SWA, 2003, DALTON T, P184, DOI 10.1039/b208790a
   Boulikas T, 2009, EXPERT OPIN INV DRUG, V18, P1197, DOI 10.1517/13543780903114168
   Branowska D, 2010, BIOORGAN MED CHEM, V18, P3551, DOI 10.1016/j.bmc.2010.03.058
   Buchner R, 1999, J CHEM SOC DALTON, P711, DOI 10.1039/a807914e
   Buchner R, 1997, INORG CHEM, V36, P3952, DOI 10.1021/ic961068b
   Cao Q, 2017, INORG CHEM FRONT, V4, P10, DOI 10.1039/c6qi00300a
   Chia YY, 2014, DALTON T, V43, P13159, DOI 10.1039/c4dt01098a
   Choy H, 2008, CLIN CANCER RES, V14, P1633, DOI 10.1158/1078-0432.CCR-07-2176
   Clark ML, 2008, INORG CHEM, V47, P9410, DOI 10.1021/ic8009354
   Constable EC, 2007, DALTON T, P4323, DOI 10.1039/b709557k
   Cummings SD, 2009, COORDIN CHEM REV, V253, P1495, DOI 10.1016/j.ccr.2008.12.009
   Czerwinska K, 2017, DALTON T, V46, P9591, DOI 10.1039/c7dt01244f
   Das K, 2018, NEW J CHEM, V42, P9126, DOI 10.1039/c8nj01033a
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   de Santana TI, 2018, EUR J MED CHEM, V144, P874, DOI 10.1016/j.ejmech.2017.12.040
   Deibel N, 2014, INORG CHEM, V53, P1021, DOI 10.1021/ic4024713
   Desiraju R., 1999, WEAK HYDROGEN BOND S
   Dolomanov OV, 2009, J APPL CRYSTALLOGR, V42, P339, DOI 10.1107/S0021889808042726
   Fanelli M, 2016, COORDIN CHEM REV, V310, P41, DOI 10.1016/j.ccr.2015.11.004
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fuertes MA, 2003, CHEM REV, V103, P645, DOI 10.1021/cr020010d
   Gama S, 2016, J INORG BIOCHEM, V160, P275, DOI 10.1016/j.jinorgbio.2016.04.002
   Giovannini C, 2002, FEBS LETT, V523, P200, DOI 10.1016/S0014-5793(02)02972-1
   Gomha SM, 2018, J HETEROCYCLIC CHEM, V55, P995, DOI 10.1002/jhet.3131
   Guo FQ, 2006, J PHYS CHEM B, V110, P15029, DOI 10.1021/jp062770o
   Harriman A, 1999, PHYS CHEM CHEM PHYS, V1, P4203, DOI 10.1039/a904390j
   Helal MHM, 2013, EUR J MED CHEM, V65, P517, DOI 10.1016/j.ejmech.2013.04.005
   Heng WY, 2007, ORGANOMETALLICS, V26, P6760, DOI 10.1021/om700716p
   HOWEGRANT M, 1976, BIOCHEMISTRY-US, V15, P4339, DOI 10.1021/bi00664a031
   Hsiao CH, 2019, EXP THER MED, V17, P4213, DOI 10.3892/etm.2019.7419
   Huff GS, 2016, INORG CHEM, V55, P12238, DOI 10.1021/acs.inorgchem.6b01959
   Huo JQ, 2011, DALTON T, V40, P7534, DOI 10.1039/c1dt10465a
   Icsel C, 2015, J INORG BIOCHEM, V152, P38, DOI 10.1016/j.jinorgbio.2015.08.026
   JENNETTE KW, 1974, P NATL ACAD SCI USA, V71, P3839, DOI 10.1073/pnas.71.10.3839
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   KELLAND LR, 1993, CANCER RES, V53, P2581
   Kharat AN, 2011, POLYHEDRON, V30, P1134, DOI 10.1016/j.poly.2011.01.024
   Klemens T, 2017, DALTON T, V46, P9605, DOI 10.1039/c7dt01948c
   Kruszynski R, 2016, CRYST GROWTH DES, V16, P587, DOI 10.1021/acs.cgd.5b00852
   Lentijo S, 2010, INORG CHEM, V49, P9169, DOI 10.1021/ic1003319
   Li DD, 2009, DALTON T, P3574, DOI 10.1039/b823472h
   Li GY, 2013, J INORG BIOCHEM, V119, P43, DOI 10.1016/j.jinorgbio.2012.09.019
   Li LY, 2013, DALTON T, V42, P11576, DOI 10.1039/c3dt50395j
   Li MJ, 2014, DALTON T, V43, P2789, DOI 10.1039/c3dt52978a
   Lo YC, 2009, J INORG BIOCHEM, V103, P1082, DOI 10.1016/j.jinorgbio.2009.05.006
   Lowe G, 1999, J MED CHEM, V42, P3167, DOI 10.1021/jm991053y
   Ma Z, 2016, DALTON T, V45, P5339, DOI 10.1039/c5dt02744f
   Makovi J. M., 2018, MEDCHEMCOMM, V9, P831
   Maron A, 2018, DALTON T, V47, P6444, DOI 10.1039/c8dt00558c
   Mauro C., 2007, ANTI-CANCER AGENT ME, V7, P111
   Michalec JF, 2000, INORG CHEM, V39, P2708, DOI 10.1021/ic000304m
   Michalec JF, 2001, INORG CHEM, V40, P2193, DOI 10.1021/ic0013126
   Nguyen MH, 2013, ORGANOMETALLICS, V32, P1620, DOI 10.1021/om300904b
   Mohammad H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130385
   Ninkovic DB, 2014, PHYS CHEM CHEM PHYS, V16, P11173, DOI 10.1039/c3cp54474e
   Ninkovic DB, 2013, CHEMPHYSCHEM, V14, P237, DOI 10.1002/cphc.201200607
   Ninkovic DB, 2011, CHEMPHYSCHEM, V12, P3511, DOI 10.1002/cphc.201100777
   Nowotnik DP, 2009, ADV DRUG DELIVER REV, V61, P1214, DOI 10.1016/j.addr.2009.06.004
   Okuniewski A, 2015, POLYHEDRON, V90, P47, DOI 10.1016/j.poly.2015.01.035
   Ou ZZ, 2017, J INORG BIOCHEM, V166, P126, DOI 10.1016/j.jinorgbio.2016.11.012
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Perl A, 2004, TRENDS IMMUNOL, V25, P360, DOI 10.1016/j.it.2004.05.001
   Raja FA, 2012, ANN ONCOL, V23, P118, DOI 10.1093/annonc/mds315
   Sahin Z, 2018, BIOORGAN MED CHEM, V26, P1986, DOI 10.1016/j.bmc.2018.02.048
   Santosh R, 2018, CHEMISTRYSELECT, V3, P3892, DOI 10.1002/slct.201800222
   Sarkar A, 2018, J PHOTOCH PHOTOBIO A, V361, P86, DOI 10.1016/j.jphotochem.2018.04.045
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Silva TFS, 2014, CHEM-ASIAN J, V9, P1132, DOI 10.1002/asia.201301331
   Silva TFS, 2013, EUR J INORG CHEM, V2013, P3651, DOI 10.1002/ejic.201300197
   Silva TFS, 2012, DALTON T, V41, P12888, DOI 10.1039/c2dt11577h
   Song YL, 2013, ASIAN J CHEM, V25, P1849, DOI 10.14233/ajchem.2013.13185
   Spackman MA, 2002, CRYSTENGCOMM, V4, P378, DOI 10.1039/b203191b
   Spackman MA, 2009, CRYSTENGCOMM, V11, P19, DOI 10.1039/b818330a
   Stafford VS, 2015, DALTON T, V44, P3686, DOI 10.1039/c4dt02910k
   Stathopoulos GP, 2011, CANCER CHEMOTH PHARM, V68, P945, DOI 10.1007/s00280-011-1572-5
   Stathopoulos GP, 2005, ONCOL REP, V13, P589
   Suntharalingam K, 2009, INORG CHEM, V48, P9427, DOI 10.1021/ic901319n
   Sutradhar M, 2019, J INORG BIOCHEM, V190, P31, DOI 10.1016/j.jinorgbio.2018.09.018
   Svahn N, 2018, CHEM-EUR J, V24, P14654, DOI 10.1002/chem.201802547
   Todd JA, 2005, INORG CHEM, V44, P6401, DOI 10.1021/ic050265k
   Wade AM, 1998, J NUTR BIOCHEM, V9, P308, DOI 10.1016/S0955-2863(98)00022-9
   Wang BL, 2015, J INORG BIOCHEM, V142, P118, DOI 10.1016/j.jinorgbio.2014.10.003
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wang JH, 2005, SYNLETT, P1251, DOI 10.1055/s-2005-868481
   Wang L, 2018, APPL ORGANOMET CHEM, V32, DOI 10.1002/aoc.4311
   Wang XY, 2008, DALTON T, P1521, DOI 10.1039/b715903j
   Wei CY, 2013, INT J BIOL MACROMOL, V57, P1, DOI 10.1016/j.ijbiomac.2013.02.010
   Wheate NJ, 2010, DALTON T, V39, P8113, DOI 10.1039/c0dt00292e
   Wilson MH, 2005, DALTON T, P2754, DOI 10.1039/b508127k
   Wolff S.K., 2012, CRYSTALEXPLORER 3 1
   Woodhouse SL, 2005, DALTON T, P2827, DOI 10.1039/b508340k
   Yang QZ, 2002, INORG CHEM, V41, P5653, DOI 10.1021/ic025580a
   Yu HJ, 2017, DYES PIGMENTS, V136, P416, DOI 10.1016/j.dyepig.2016.08.059
   Zaki YH, 2018, CHEM CENT J, V12, DOI 10.1186/s13065-018-0439-9
   Zhang JJ, 2015, J ORGANOMET CHEM, V782, P37, DOI 10.1016/j.jorganchem.2014.10.041
NR 101
TC 14
Z9 14
U1 2
U2 17
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-9226
EI 1477-9234
J9 DALTON T
JI Dalton Trans.
PD SEP 14
PY 2019
VL 48
IS 34
BP 13081
EP 13093
DI 10.1039/c9dt02894c
PG 13
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA IU4YS
UT WOS:000483593600029
PM 31411239
DA 2022-04-25
ER

PT J
AU Liu, WT
   Lo, YL
   Hsu, C
   Wu, YT
   Liao, ZX
   Wu, WJ
   Chen, YJ
   Kao, C
   Chiu, CC
   Wang, LF
AF Liu, Wangta
   Lo, Yu-Lun
   Hsu, Chin
   Wu, Yi-Ting
   Liao, Zi-Xian
   Wu, Wen-Jeng
   Chen, Yi-Jou
   Kao, Chieh
   Chiu, Chien-Chih
   Wang, Li-Fang
TI CS-PEI/Beclin-siRNA Downregulate Multidrug Resistance Proteins and
   Increase Paclitaxel Therapeutic Efficacy against NSCLC
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID CELL LUNG-CANCER; BREAST-CANCER; CO-DELIVERY; DRUG-RESISTANCE;
   CHONDROITIN SULFATE; COLORECTAL-CANCER; DNA-DAMAGE; AUTOPHAGY;
   INHIBITION; NANOPARTICLES
AB Paclitaxel (PTX) is a widely used chemotherapy drug; however, frequent use causes multidrug resistance (MDR), which limits the utility of PTX against advanced non-small-cell lung cancer (NSCLC). PTX-resistant subline (NCI-H23-TXR) was established in vitro by exposing NCI-H23 cells to gradually increased concentrations of PTX in culture medium. Distinct Beclin expression of autophagy level was observed between resistant NCI-H23-TXR and parental NCI-H23 cells. Beclin-small interfering RNA (siRNA) was selected to restore sensitivity of PTX against NCI-H23-TXR. Chondroitin sulfate-polyethylenimine (CS-PEI) was constructed for delivery and protection of Beclin-siRNA. To delineate the underlying molecular mechanism of Beclin knockdown, we analyzed different MDR expression proteins of two cells using western blot, and the corresponding genes were confirmed by real-time PCR. Compared with NCI-H23, NCI-H23-TXR had higher expression levels in P-glycoprotein (P-gp) and multidrug resistance protein 7 (ABCC10). Knockdown of Beclin simultaneously inhibited P-gp and ABCC10, and renewed the sensitivity of PTX against NCI-H23-TXR. Research on zebrafish embryos revealed that tumor sizes decreased in NCI-H23 tumor xenografts but remained intact in NCI-H23-TXR tumor xenografts as zebrafish were treated with 1 mu g/mL PTX. In contrast, the tumor sizes decreased in NCI-H23-TXR tumor xenografts with zebrafish pre-transfected with CS-PEI/Beclin-siRNA followed by the same treatment of PTX. The role of autophagy was associated with MDR development. This study paves the way for a new avenue of PTX in MDR-related lung cancer therapy using CS-PEI as a gene delivery carrier.
C1 [Liu, Wangta; Chiu, Chien-Chih] Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
   [Lo, Yu-Lun; Wu, Yi-Ting; Wang, Li-Fang] Kaohsiung Med Univ, Coll Life Sci, Dept Med & Appl Chem, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
   [Lo, Yu-Lun; Hsu, Chin] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Physiol, Kaohsiung 807, Taiwan.
   [Hsu, Chin; Wu, Wen-Jeng; Chiu, Chien-Chih; Wang, Li-Fang] Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.
   [Liao, Zi-Xian; Wang, Li-Fang] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 804, Taiwan.
   [Wu, Wen-Jeng] Kaohsiung Med Univ, Coll Med, Sch Med, Dept Urol, Kaohsiung 807, Taiwan.
   [Chen, Yi-Jou] Chang Guan Univ, Sch Med, Taoyuan 33302, Taiwan.
   [Kao, Chieh] I Shou Univ, Sch Med Int Students, Kaohsiung 82445, Taiwan.
RP Chiu, CC (corresponding author), Kaohsiung Med Univ, Coll Life Sci, Dept Biotechnol, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.; Wang, LF (corresponding author), Kaohsiung Med Univ, Coll Life Sci, Dept Med & Appl Chem, 100,Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM cchiu@kmu.edu.tw; lfwang@kmu.edu.tw
OI Lo, Yu-Lun/0000-0002-6384-3051
FU Ministry of Science and Technology of TaiwanMinistry of Science and
   Technology, Taiwan [MOST104-2314-B-037-006-MY3, MOST
   106-2320-B-037-004-MY3]; Kaohsiung Medical University [KMU-DK108013];
   NSYSU-KMU Joint Research Project [NSYSUKMU 107-P026]
FX We are grateful for the financial support from the Ministry of Science
   and Technology of Taiwan (grants MOST104-2314-B-037-006-MY3 and MOST
   106-2320-B-037-004-MY3). This study was also supported by Kaohsiung
   Medical University under grant KMU-DK108013 and by the NSYSU-KMU Joint
   Research Project under grant NSYSUKMU 107-P026. NCI-H23 and NCI-H23-TXR
   cell lines were gifted from Dr. N.Y. Shih of the NHRI of Taiwan. We
   appreciate the experimental support of a CLSM and a TEM provided by the
   Center for Research Resources and Development of Kaohsiung Medical
   University.
CR BROWER M, 1986, CANCER RES, V46, P798
   Castedo M, 2002, CELL DEATH DIFFER, V9, P99, DOI 10.1038/sj.cdd.4400978
   Chakraborty C, 2009, CURR DRUG METAB, V10, P116, DOI 10.2174/138920009787522197
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060
   Chiu CC, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1970-x
   Czarny P, 2015, INT J MOL SCI, V16, P2641, DOI 10.3390/ijms16022641
   Delvecchio C, 2011, ASSAY DRUG DEV TECHN, V9, P354, DOI 10.1089/adt.2010.0346
   Dower CM, 2017, CANCER RES, V77, P646, DOI 10.1158/0008-5472.CAN-15-3458
   Eum KH, 2011, MOL CELLS, V31, P231, DOI 10.1007/s10059-011-0034-6
   Feng Q, 2014, BIOMATERIALS, V35, P5028, DOI 10.1016/j.biomaterials.2014.03.012
   Georgiadis MS, 1997, CLIN CANCER RES, V3, P449
   Gu JJ, 2015, BIOMATERIALS, V45, P99, DOI 10.1016/j.biomaterials.2014.12.030
   Hamilton L, 2016, ZEBRAFISH, V13, P523, DOI 10.1089/zeb.2016.1339
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hung AC, 2016, CANCER LETT, V371, P251, DOI 10.1016/j.canlet.2015.11.035
   Kim YD, 2015, NANOMEDICINE-UK, V10, P1165, DOI [10.2217/NNM.14.214, 10.2217/nnm.14.214]
   Liang B, 2016, BIOMED PHARMACOTHER, V82, P98, DOI 10.1016/j.biopha.2016.04.054
   Lin C, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0080883, 10.1371/journal.pone.0056499, 10.1371/journal.pone.0065734, 10.1371/journal.pone.0070187]
   Lin CM, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/10/105101
   Liu CX, 2009, J CONTROL RELEASE, V140, P277, DOI 10.1016/j.jconrel.2009.08.013
   Lo YL, 2015, NANOSCALE, V7, P8554, DOI 10.1039/c5nr01404b
   Lo YL, 2013, MOL PHARMACEUT, V10, P664, DOI 10.1021/mp300432s
   Ma ZS, 2003, PHARM RES-DORDR, V20, P1812, DOI 10.1023/B:PHAM.0000003379.76417.3e
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mollberg NM, 2012, CANCER BIOL THER, V13, P694, DOI 10.4161/cbt.20087
   Nascimento AV, 2017, ACTA BIOMATER, V47, P71, DOI 10.1016/j.actbio.2016.09.045
   Oguri T, 2008, MOL CANCER THER, V7, P1150, DOI 10.1158/1535-7163.MCT-07-2088
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Peng X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.297
   Saiyin W, 2014, MOL PHARMACEUT, V11, P1662, DOI 10.1021/mp5000423
   Shen JA, 2012, BIOMATERIALS, V33, P8613, DOI 10.1016/j.biomaterials.2012.08.007
   Shimomura M, 2012, INT J ONCOL, V40, P995, DOI 10.3892/ijo.2011.1297
   Shubayev VI, 2009, ADV DRUG DELIVER REV, V61, P467, DOI 10.1016/j.addr.2009.03.007
   Singhal SS, 2007, INT J ONCOL, V30, P717
   Song XZ, 2017, REDOX BIOL, V11, P219, DOI 10.1016/j.redox.2016.12.015
   Sun WL, 2015, NEOPLASMA, V62, P199, DOI 10.4149/neo_2015_025
   Tang S, 2015, BIOMATERIALS, V48, P1, DOI 10.1016/j.biomaterials.2015.01.049
   Tat Jennifer, 2013, Drug Discov Today Technol, V10, pe83, DOI 10.1016/j.ddtec.2012.04.006
   Ungaro F, 2003, J PHARMACEUT BIOMED, V31, P143, DOI 10.1016/S0731-7085(02)00571-X
   Wang GD, 2017, INT J NANOMED, V12, P6661, DOI 10.2147/IJN.S141592
   Wang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069038
   Wang L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.328
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wu SH, 2015, HUM PATHOL, V46, P1752, DOI 10.1016/j.humpath.2015.07.016
   Yeh JJ, 2003, RESPIRATION, V70, P32, DOI 10.1159/000068411
   Yin TJ, 2015, BIOMATERIALS, V61, P10, DOI 10.1016/j.biomaterials.2015.05.022
   Yu HJ, 2014, MACROMOL BIOSCI, V14, P100, DOI 10.1002/mabi.201300282
NR 49
TC 12
Z9 12
U1 1
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD SEP 6
PY 2019
VL 17
BP 477
EP 490
DI 10.1016/j.omtn.2019.06.017
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA JA6XF
UT WOS:000487984400043
PM 31336235
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chen, ZH
   Wang, C
   Dong, H
   Wang, X
   Gao, F
   Zhang, S
   Zhang, XL
AF Chen, Zhihang
   Wang, Chun
   Dong, Hao
   Wang, Xing
   Gao, Feng
   Zhang, Sen
   Zhang, Xiaolong
TI Aspirin has a better effect on PIK3CA mutant colorectal cancer cells by
   PI3K/Akt/Raptor pathway
SO MOLECULAR MEDICINE
LA English
DT Article
DE Colorectal cancer; Aspirin; PI3K; Akt; raptor pathway; PIK3CA mutated
ID A-INDUCED APOPTOSIS; PRIMARY PREVENTION; MTOR; MUTATIONS;
   PHOSPHORYLATION; AUTOPHAGY; DISEASE; GENE; LC3
AB Background Aspirin, as a non-steroidal anti-inflammatory drug, can improve the survival rate of patients with colorectal cancer, while aspirin is effective in patients with PIK3CA mutant colorectal cancer (CRC). However, the mechanism of aspirin in the treatment of PIK3CA mutated CRC patients remains unclear. Methods In this study, immunohistochemistry was used to detect the expression levels of PI3K and Raptor in colorectal cancer patients with PIK3CA mutation and PIK3CA wild-type patients. To demonstrate that aspirin has a better effect on the CRC of PIK3CA mutations in association with the PI3K/Akt/Raptor pathway, we used aspirin to treat PIK3CA mutant CRC cells (HCT-116 and RKO). Subsequently, the CCK8 assay and flow cytometry assay were used to detect the apoptosis of PIK3CA mutant CRC cells before and after aspirin use. Western blot was used to detect the changes of PI3K/Akt/Raptor-associated protein, autophagy protein microtubule associated protein 1 light chain 3 alpha (MAP1LC3A, LC3), beclin 1 (BECN1) and apoptosis protein BCL2-associated X protein/ BCL2 apoptosis regulator (Bax/Bcl2), Caspase 3 after treatment of CRC cells with PIK3CA mutation by aspirin. Results Phosphoinositide-3-kinase (PI3K) and regulatory associated protein of MTOR complex 1 (Raptor) protein expression levels were higher in PIK3CA-mutant patients than in IK3CA wild-type patients. The expression of Bax/Bcl2 increased after treatment indicates that aspirin can induce apoptosis of PIK3CA-mutant CRC cells. The expression level of MAP1LC3 (LC3) in cells increases with the concentration of aspirin demonstrates that aspirin can induce autophagy in CRC cells. After 48 h of treatment with aspirin, the phosphorylation of eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1) and ribosomal protein S6 kinase B1 (S6K1) was reduced, cell proliferation has been inhibited. After treatment with aspirin, as phosphorylation of PI3K and Protein kinase B (PKB, Akt) was decreased, Raptor expression was also decreased. Conclusion Aspirin can regulate the proliferation, apoptosis and autophagy of CRC cells through the PI3K/Akt/Raptor pathway, affecting PIK3CA-mutant CRC.
C1 [Chen, Zhihang; Dong, Hao; Wang, Xing; Gao, Feng; Zhang, Sen; Zhang, Xiaolong] Guangxi Med Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, Nanning 530021, Peoples R China.
   [Wang, Chun] Wuhan Univ, Dept Gastroenterol, Zhongnan Hosp, Wuhan 430000, Peoples R China.
RP Zhang, XL (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Colorectal & Anal Surg, Nanning 530021, Peoples R China.
EM 1368913114@qq.com
FU Guangxi Natural Science Foundation ProgramNational Natural Science
   Foundation of Guangxi Province [2015GXNSFAA139185]
FX This work has been financially supported by Guangxi Natural Science
   Foundation Program (2015GXNSFAA139185).
CR Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792
   Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577
   Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016
   Din FVN, 2010, GUT, V59, P1670, DOI 10.1136/gut.2009.203000
   Domingo E, 2013, J CLIN ONCOL, V31, P4297, DOI 10.1200/JCO.2013.50.0322
   Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142
   Hayakawa J, 2000, CANCER RES, V60, P5988
   KOSEKI T, 1995, FEBS LETT, V376, P247, DOI 10.1016/0014-5793(95)01290-7
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Levesque H, 2000, REV MED INTERNE, V21, p8S, DOI 10.1016/S0248-8663(00)88720-2
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402
   Mayer IA, 2016, ANNU REV MED, V67, P11, DOI 10.1146/annurev-med-062913-051343
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   O'Keefe SJD, 2016, NAT REV GASTRO HEPAT, V13, P691, DOI 10.1038/nrgastro.2016.165
   Patrignani P, 2016, J AM COLL CARDIOL, V68, P967, DOI 10.1016/j.jacc.2016.05.083
   Raber I, 2019, LANCET, V393, P2155, DOI 10.1016/S0140-6736(19)30541-0
   Saltzman A, 1998, EXP CELL RES, V242, P244, DOI 10.1006/excr.1998.4096
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Sonenberg N, 1998, CURR OPIN CELL BIOL, V10, P268, DOI 10.1016/S0955-0674(98)80150-6
   Su Y, 2019, J CANCER RES CLIN, V145, P573, DOI 10.1007/s00432-018-2808-0
   Wang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0776-6
   Weidberg H, 2011, DEV CELL, V20, P444, DOI 10.1016/j.devcel.2011.02.006
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Yurgelun MB, 2017, J CLIN ONCOL, V35, P1086, DOI 10.1200/JCO.2016.71.0012
   Zumwalt TJ, 2017, CANCER PREV RES, V10, P208, DOI 10.1158/1940-6207.CAPR-16-0175
NR 33
TC 8
Z9 9
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD JAN 30
PY 2020
VL 26
IS 1
AR 14
DI 10.1186/s10020-020-0139-5
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA KU9WD
UT WOS:000520074100001
PM 32000660
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Gibault, F
   Corvaisier, M
   Bailly, F
   Huet, G
   Melnyk, P
   Cotelle, P
AF Gibault, Floriane
   Corvaisier, Matthieu
   Bailly, Fabrice
   Huet, Guillemette
   Melnyk, Patricia
   Cotelle, Philippe
TI Non-Photoinduced Biological Properties of Verteporfin
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Hippo pathway; YAP/TEAD complex; non-photoinduced therapy; oncogene;
   autophagy; proteotoxicity
ID PROTEIN-PROTEIN INTERACTION; HIPPO SIGNALING PATHWAY; YAP-TEAD;
   PHOTOSENSITIZER VERTEPORFIN; THERAPEUTIC TARGET; CELL-PROLIFERATION;
   ANTITUMOR-ACTIVITY; CANCER-CELLS; ACTIVATION; IDENTIFICATION
AB Background: Verteporfin is a porphyrinic photosensitizer clinically used for the photodynamic treatment of age-related macular degeneration. It has been identified almost simultaneously as a YAP/TEAD and an autophagosome inhibitor. Over the last few years, YAP (TAZ), the downstream effectors of the Hippo pathway, have emerged as promising anticancer targets, as shown by several experimental lines of evidence, showing the overproduction of YAP in several cancers. However, YAP was also found to be closely connected to autophagy, mitochondria and reactive oxygen/nitrogen species. We herein, review the recent studies where VP was used without photoactivation as a YAP/TEAD inhibitor or protein oligomerization promoter, focusing on its effects on the YAP/TEAD gene targets and other biomarkers related to autophagy. Results: Since the identification of VP as YAP/TEAD inhibitor, several in vitro and in vivo studies have revealed the new potential of this molecule in different cancers, where YAP is overexpressed. However, detailed structural information about its interaction with YAP is still lacking. Concomitantly, VP was identified as autophagosome inhibitor by promoting oligomerization of p62. Moreover, VP proves to be tumor-selective proteotoxic (by oligomerization of p62, STAT3) in colorectal cancer. Knowledge on the biological properties of the only YAP inhibitor available to date is vital for its pharmacological use on cellular and animal models. Conclusion: VP is a multi-target drug interacting with several proteins implicated in major cellular processes. Although this does not impact its clinical use, VP does not seem to be the ideal drug for pharmacological inhibitions of YAP/TEAD.
C1 [Gibault, Floriane; Bailly, Fabrice; Melnyk, Patricia; Cotelle, Philippe] Univ Lille, INSERM, Jean Pierre Aubert Res Ctr, Onco & NeuroChem Team,UMR S 1172, F-59000 Lille, France.
   [Corvaisier, Matthieu; Huet, Guillemette] Univ Lille, INSERM, Mucins Epithelial Differenciat & Carcinogenesis, Jean Pierre Aubert Res Ctr,UMR S 1172, F-59000 Lille, France.
RP Cotelle, P (corresponding author), Fac Sci Pharmaceut & Biol, 3 Rue Prof Laguesse,BP 83, F-59006 Lille, France.
EM phi-lippe.cotelle@inserm.fr
RI Cotelle, Philippe/AAX-3905-2020
OI bailly, fabrice/0000-0001-9681-9309
CR AVELINE BM, 1995, J PHOTOCH PHOTOBIO B, V30, P161, DOI 10.1016/1011-1344(95)07174-Z
   Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693
   Basu D, 2014, MOL CANCER THER, V13, P1457, DOI 10.1158/1535-7163.MCT-13-0918
   Belzacq AS, 2001, CANCER RES, V61, P1260
   Benham-Pyle BW, 2015, SCIENCE, V348, P1024, DOI 10.1126/science.aaa4559
   Brodowska K, 2014, EXP EYE RES, V124, P67, DOI 10.1016/j.exer.2014.04.011
   Cebola I, 2015, NAT CELL BIOL, V17, P615, DOI 10.1038/ncb3160
   Chen WS, 2015, BIOCHEM BIOPH RES CO, V466, P221, DOI 10.1016/j.bbrc.2015.09.012
   Chiou JF, 2010, FREE RADICAL RES, V44, P155, DOI 10.3109/10715760903380458
   Ciamporcero E, 2016, ONCOGENE, V35, P1541, DOI 10.1038/onc.2015.219
   Donohue E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114964
   Donohue E, 2013, J CANCER, V4, P585, DOI 10.7150/jca.7030
   Donohue E, 2011, J BIOL CHEM, V286, P7290, DOI 10.1074/jbc.M110.139915
   Feng XD, 2014, CANCER CELL, V25, P831, DOI 10.1016/j.ccr.2014.04.016
   Fernandez JM, 1997, J PHOTOCH PHOTOBIO B, V37, P131, DOI 10.1016/S1011-1344(96)07349-6
   Gaffney CJ, 2012, GENE, V509, P215, DOI 10.1016/j.gene.2012.08.025
   Garcia-Rendueles MER, 2015, CANCER DISCOV, V5, P1178, DOI 10.1158/2159-8290.CD-15-0330
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   Hau JC, 2013, CHEMBIOCHEM, V14, P1218, DOI 10.1002/cbic.201300163
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Imajo M, 2015, NAT CELL BIOL, V17, P7, DOI 10.1038/ncb3084
   Jiang N, 2015, ONCOGENE, V34, P2764, DOI 10.1038/onc.2014.206
   Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010
   Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161
   KEENE JP, 1986, PHOTOCHEM PHOTOBIOL, V43, P117, DOI 10.1111/j.1751-1097.1986.tb09501.x
   Kimura TE, 2016, J MOL CELL CARDIOL, V90, P1, DOI 10.1016/j.yjmcc.2015.11.024
   Kong DL, 2015, J DRUG TARGET, V23, P125, DOI 10.3109/1061186X.2014.983522
   Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711
   Lamar JM, 2012, P NATL ACAD SCI USA, V109, pE2441, DOI 10.1073/pnas.1212021109
   Liang N, 2014, J EXP MED, V211, P2249, DOI 10.1084/jem.20140341
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Ma YL, 2015, INT J CANCER, V137, P2275, DOI 10.1002/ijc.29073
   Mannaerts I, 2015, J HEPATOL, V63, P679, DOI 10.1016/j.jhep.2015.04.011
   Mellish K. J., 2001, EXPERT OPIN PHARMACO, V2, P351
   Mesrouze Y, 2014, CHEMBIOCHEM, V15, P537, DOI 10.1002/cbic.201300715
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Nagaraj R, 2012, GENE DEV, V26, P2027, DOI 10.1101/gad.183061.111
   Nguyen LT, 2015, CANCER CELL, V27, P797, DOI 10.1016/j.ccell.2015.05.005
   Oku Y, 2015, FEBS OPEN BIO, V5, P542, DOI 10.1016/j.fob.2015.06.007
   Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151
   PANGKA VS, 1986, J ORG CHEM, V51, P1094, DOI 10.1021/jo00357a029
   Peng TI, 2005, ANN NY ACAD SCI, V1042, P419, DOI 10.1196/annals.1338.035
   Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033
   Pobbati AV, 2015, STRUCTURE, V23, P2076, DOI 10.1016/j.str.2015.09.009
   Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004
   Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006
   Richter A M, 1996, J Clin Laser Med Surg, V14, P335
   RICHTER AM, 1990, J PHOTOCH PHOTOBIO B, V5, P231, DOI 10.1016/1011-1344(90)80008-L
   RICHTER AM, 1991, BRIT J CANCER, V63, P87, DOI 10.1038/bjc.1991.18
   RICHTER AM, 1990, PHOTOCHEM PHOTOBIOL, V52, P495, DOI 10.1111/j.1751-1097.1990.tb01791.x
   RICHTER AM, 1987, J NATL CANCER I, V79, P1327
   RICHTER AM, 1992, BIOCHEM PHARMACOL, V43, P2349, DOI 10.1016/0006-2952(92)90313-8
   Santucci M, 2015, J MED CHEM, V58, P4857, DOI 10.1021/jm501615v
   Slemmons KK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140781
   Song QH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120790
   Song SM, 2015, CLIN CANCER RES, V21, P2580, DOI 10.1158/1078-0432.CCR-14-2191
   Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569
   Sorrentino G, 2014, NAT CELL BIOL, V16, P357, DOI 10.1038/ncb2936
   Taccioli C, 2015, ONCOTARGET, V6, P38854, DOI 10.18632/oncotarget.5749
   Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854
   Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009
   Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504
   Yu FX, 2014, CANCER CELL, V25, P822, DOI 10.1016/j.ccr.2014.04.017
   Zhang HB, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac5418
   Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408
   Zhou Z, 2015, FASEB J, V29, P724, DOI 10.1096/fj.14-262980
   Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617
NR 67
TC 56
Z9 61
U1 2
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2016
VL 23
IS 11
BP 1171
EP 1184
DI 10.2174/0929867323666160316125048
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DJ8YZ
UT WOS:000374501900006
PM 26980565
DA 2022-04-25
ER

PT J
AU Cadena-Cruz, JE
   Guaman-Ortiz, LM
   Romero-Benavides, JC
   Bailon-Moscoso, N
   Murillo-Sotomayor, KE
   Ortiz-Guaman, NV
   Heredia-Moya, J
AF Cadena-Cruz, Jose Eduardo
   Guaman-Ortiz, Luis M.
   Romero-Benavides, Juan Carlos
   Bailon-Moscoso, Natalia
   Murillo-Sotomayor, Kevin E.
   Ortiz-Guaman, Nadia V.
   Heredia-Moya, Jorge
TI Synthesis of 4,4
   '-(arylmethylene)bis(3-methyl-1-phenyl-1H-pyrazol-5-ols) and evaluation
   of their antioxidant and anticancer activities
SO BMC CHEMISTRY
LA English
DT Article
DE 4; 4MODIFIER LETTER PRIME-(arylmethylene)bis(1H-pyrazol-5-ols);
   Antioxidant; Apoptosis; Autophagy
ID SOLID ACID CATALYST; EFFICIENT; DERIVATIVES; APOPTOSIS; EDARAVONE;
   REGULATORS; AUTOPHAGY; PYRAZOLE; DFT
AB Background Pyrazoles have attracted particular attention due to the diverse biological activities associated with this heterocyclic system, and some have been shown to be cytotoxic to several human cell lines. Several drugs currently on the market have this heterocycle as the key structural motif, and some have been approved for the treatment of different types of cancer. Results 4,4MODIFIER LETTER PRIME-(Arylmethylene)bis(1H-pyrazol-5-ols) derivatives 3a-q were synthetized by a three components reaction of 3-methyl-1-phenyl-5-pyrazolone (1) with various benzaldehydes 2 catalyzed by sodium acetate at room temperature. The structures of all synthesized compounds were characterized by physicochemical properties and spectral means (IR and NMR) and were evaluated for their radical scavenging activity by DPPH assay and tested in vitro on colorectal RKO carcinoma cells in order to determine their cytotoxic properties. All 4,4MODIFIER LETTER PRIME-(arylmethylene)bis(1H-pyrazol-5-ols) derivatives 3a-q were synthetized in high to excellent yield, and pure products were isolated by simple filtration. All compounds have good radical scavenging activity, and half of them are more active than ascorbic acid used as standard. Conclusion Several derivatives proved to be cytotoxic in the RKO cell line. In particular, compound 3i proved to be a very potent scavenger with an IC50 of 6.2 +/- 0.6 mu M and exhibited an IC50 of 9.9 +/- 1.1 mu M against RKO cell. Autophagy proteins were activated as a survival mechanism, whereas the predominant pathway of death was p53-mediated apoptosis.
C1 [Cadena-Cruz, Jose Eduardo] Univ Cent Ecuador, Fac Ciencias Quim, Quito, Ecuador.
   [Guaman-Ortiz, Luis M.; Bailon-Moscoso, Natalia; Murillo-Sotomayor, Kevin E.; Ortiz-Guaman, Nadia V.] Univ Tecn Particular Loja, Dept Ciencias Salud, San Cayetano Alto S-N, Loja 1101608, Ecuador.
   [Romero-Benavides, Juan Carlos] Univ Tecn Particular Loja, Dept Quim & Ciencias Exactas, San Cayetano Alto S-N, Loja 1101608, Ecuador.
   [Heredia-Moya, Jorge] Univ UTE, Fac Ciencias Salud Eugenio Espejo, Ctr Invest Biomed CENBIO, Quito 170527, Ecuador.
RP Heredia-Moya, J (corresponding author), Univ UTE, Fac Ciencias Salud Eugenio Espejo, Ctr Invest Biomed CENBIO, Quito 170527, Ecuador.
EM jorgeh.heredia@ute.edu.ec
RI ; Romero Benavides, Juan Carlos/Q-9855-2018
OI Heredia-Moya, Jorge/0000-0001-7620-9140; Cadena Cruz, Jose
   Eduardo/0000-0001-9023-7674; Romero Benavides, Juan
   Carlos/0000-0003-1660-1217
FU Corporacion Ecuatoriana para el Desarrollo de la Investigacion y la
   Academia (CEDIA) [CEPRA XI-2017-10]; Universidad Tecnica Particular de
   Loja (UTPL) [PROY_INV_QUI_2017_2222]; Universidad UTE; Universidad
   Central del Ecuador
FX This work was supported by Corporacion Ecuatoriana para el Desarrollo de
   la Investigacion y la Academia (CEDIA), (CEPRA XI-2017-10), Universidad
   Tecnica Particular de Loja (UTPL), (PROY_INV_QUI_2017_2222), Universidad
   UTE, and Universidad Central del Ecuador.
CR Aghayan Z, 2017, J APPL CHEM-USSR, V11, P31, DOI [10.1007/s40092-014-0072-8, DOI 10.1007/S40092-014-0072-8]
   Bailly C, 2020, BIOORGAN MED CHEM, V28, DOI 10.1016/j.bmc.2020.115463
   Bhavanarushi S, 2014, MED CHEM RES, V23, P158, DOI 10.1007/s00044-013-0623-3
   Borges RS, 2012, INT J MOL SCI, V13, P7594, DOI 10.3390/ijms13067594
   Collavin L, 2010, CELL DEATH DIFFER, V17, P901, DOI 10.1038/cdd.2010.35
   Das Gupta A, 2014, GREEN CHEM LETT REV, V7, P404, DOI 10.1080/17518253.2014.970236
   Du LW, 2017, BIOMED PHARMACOTHER, V95, P447, DOI 10.1016/j.biopha.2017.08.119
   Farooqui M, 2018, CHEM BIOL INTERFACE, V8, P255
   Foti M, 1996, J AGR FOOD CHEM, V44, P497, DOI 10.1021/jf950378u
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Giansanti V, 2011, APOPTOSIS, V16, P321, DOI 10.1007/s10495-011-0589-x
   Gomtsyan A, 2012, CHEM HETEROCYCL COM+, V48, P7, DOI 10.1007/s10593-012-0960-z
   Grigalius I, 2017, MOLECULES, V22, DOI 10.3390/molecules22122169
   Guaman-Ortiz LM, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/1565306
   Guaman-Ortiz LM, 2021, NAT PROD RES, V35, P3151, DOI 10.1080/14786419.2019.1690485
   Halim KNM, 2021, J HETEROCYCLIC CHEM, V58, P636, DOI 10.1002/jhet.4204
   Halim KNM, 2020, SYNTHETIC COMMUN, V50, P1159, DOI 10.1080/00397911.2020.1720739
   Hamama WS, 2001, SYNTHETIC COMMUN, V31, P1335, DOI 10.1081/SCC-100104042
   Haque ME, 2003, BBA-GEN SUBJECTS, V1619, P39, DOI 10.1016/S0304-4165(02)00440-3
   Hasaninejed A, 2013, ACS SUSTAIN CHEM ENG, V1, P679, DOI 10.1021/sc400081c
   Higashi Yukihito, 2006, Recent Pat Cardiovasc Drug Discov, V1, P85
   Kauthale SS, 2016, MOL DIVERS, V20, P763, DOI 10.1007/s11030-016-9673-z
   Keshavarz M, 2016, CATAL LETT, V146, P353, DOI 10.1007/s10562-015-1668-3
   Khan K, 2015, MONATSH CHEM, V146, P1587, DOI 10.1007/s00706-015-1424-9
   Kuarm BS, 2012, SYNTHETIC COMMUN, V42, P2382, DOI 10.1080/00397911.2011.557516
   Les F, 2015, FOOD FUNCT, V6, P2049, DOI [10.1039/C5FO00426H, 10.1039/c5fo00426h]
   Li XL, 1998, J HETEROCYCLIC CHEM, V35, P129, DOI 10.1002/jhet.5570350124
   Mahajan PS, 2017, J HETEROCYCLIC CHEM, V54, P1109, DOI 10.1002/jhet.2681
   Markovic V, 2011, BIOORG CHEM, V39, P18, DOI 10.1016/j.bioorg.2010.10.003
   Mohamed MS, 2018, BIOORGAN MED CHEM, V26, P623, DOI 10.1016/j.bmc.2017.12.026
   Moosavi-Zare AR, 2016, RES CHEM INTERMEDIAT, V42, P4759, DOI 10.1007/s11164-015-2317-6
   Murias M, 2005, BIOCHEM PHARMACOL, V69, P903, DOI 10.1016/j.bcp.2004.12.001
   Naim MJ, 2016, J PHARM BIOALLIED SC, V8, P2, DOI 10.4103/0975-7406.171694
   Niknam K, 2013, MONATSH CHEM, V144, P987, DOI 10.1007/s00706-012-0910-6
   Noruzian F, 2019, SYNTHETIC COMMUN, V49, P2717, DOI 10.1080/00397911.2019.1643483
   Pandey A., 2011, INT J CHEM TECH RES, V3, P178
   Phatangare KR, 2012, SYNTHETIC COMMUN, V42, P1349, DOI 10.1080/00397911.2010.539759
   Polkam N, 2016, BIOORG MED CHEM LETT, V26, P2562, DOI 10.1016/j.bmcl.2016.03.024
   Queiroz AN, 2010, J COMPUT THEOR NANOS, V7, P153, DOI 10.1166/jctn.2010.1339
   Ramadan SK, 2021, J HETEROCYCLIC CHEM, V58, P290, DOI 10.1002/jhet.4168
   Ramadan SK, 2020, J IRAN CHEM SOC, V17, P1575, DOI 10.1007/s13738-020-01880-8
   Rezaei F, 2020, CHEMISTRYSELECT, V5, P1760, DOI 10.1002/slct.201904831
   Saito T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08829-3
   Sobhani S, 2012, SYNTHETIC COMMUN, V42, P2245, DOI 10.1080/00397911.2011.555589
   Sobhani S, 2009, J ORGANOMET CHEM, V694, P3027, DOI 10.1016/j.jorganchem.2009.05.004
   Wang LF, 2003, BIOORG MED CHEM LETT, V13, P3789, DOI 10.1016/j.bmcl.2003.07.016
   Wright JS, 2001, J AM CHEM SOC, V123, P1173, DOI 10.1021/ja002455u
   Yamamoto I, 2019, FRONT BIOSCI-LANDMRK, V24, P1241, DOI 10.2741/4777
   Yang XH, 2012, CHINESE J CHEM, V30, P670, DOI 10.1002/cjoc.201280009
   Zheng LW, 2010, BIOORG MED CHEM LETT, V20, P4766, DOI 10.1016/j.bmcl.2010.06.121
   Zolfigol MA, 2015, RSC ADV, V5, P71942, DOI 10.1039/c5ra14001c
NR 51
TC 2
Z9 2
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2661-801X
J9 BMC CHEM
JI BMC Chem.
PD JUN 3
PY 2021
VL 15
IS 1
AR 38
DI 10.1186/s13065-021-00765-y
PG 12
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA SM6XY
UT WOS:000657746900001
PM 34082794
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Maiese, K
AF Maiese, Kenneth
TI WISP1: Clinical Insights for a Proliferative and Restorative Member of
   the CCN Family
SO CURRENT NEUROVASCULAR RESEARCH
LA English
DT Article
DE Akt; Alzheimer's; amyloid; apoptosis; autophagy; beta-catenin; bone;
   cancer; cardiac; caspase; CCN4; erythropoietin; fibrosis; forkhead
   transcription factor; FoxO3a; liver; lung; metastases; miRNA; mTOR;
   PRAS40; pulmonary; sirtuin; SIRT1; stem cell; WISP1; Wnt
ID WNT1-INDUCIBLE SIGNALING PROTEIN-1; WNT/BETA-CATENIN PATHWAY; FOCAL
   CEREBRAL-ISCHEMIA; HUMAN COLORECTAL-CANCER; TISSUE GROWTH-FACTOR;
   BETA-CATENIN; OXIDATIVE STRESS; CELL-SURVIVAL; WNT PATHWAY; STEM-CELLS
AB As a proliferative and restorative entity, Wnt1 inducible signaling pathway protein 1 (WISP1) is emerging as a novel target for a number of therapeutic strategies that are relevant for disorders such as traumatic injury, neurodegeneration, musculoskeletal disorders, cardiovascular disease, pulmonary compromise, and control of tumor growth as well as distant metastases. WISP1, a target of the wingless pathway Wnt1, oversees cellular mechanisms that include apoptosis, autophagy, cellular migration, stem cell proliferation, angiogenesis, immune cell modulation, and tumorigenesis. The signal transduction pathways of WISP1 are broad and involve phosphoinositide 3-kinase (PI 3-K), protein kinase B (Akt), mitogen activated protein (MAP) kinase, c-Jun N-terminal kinase (JNK), caspases, forkhead transcription factors, sirtuins, c-myc, glycogen synthase kinase -3 beta (GSK-3 beta), beta-catenin, miRNAs, and the mechanistic target of rapamaycin (mTOR). Ultimately, these signal transduction pathways of WISP1 can result in varied and sometimes unpredictable outcomes especially for cell survival, tissue repair, and tumorigenesis that demand increased insight into the critical role WISP1 holds for cellular biology and clinical medicine.
EM wntin75@yahoo.com
FU American Diabetes AssociationAmerican Diabetes Association; American
   Heart Association [National)American Heart Association; Bugher
   Foundation AwardAmerican Heart Association; Janssen Neuroscience
   AwardJohnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc; LEARN
   Foundation Award; NIH NIEHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Environmental Health Sciences (NIEHS); NIH NIAUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute on Aging (NIA); NIH NINDSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Neurological Disorders & Stroke (NINDS);
   NIH ARRAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Neurological Disorders & Stroke (NINDS) [R01NS053946] Funding Source:
   NIH RePORTER
FX This research was supported by the following grants to Kenneth Maiese:
   American Diabetes Association, American Heart Association [National),
   Bugher Foundation Award, Janssen Neuroscience Award, LEARN Foundation
   Award, NIH NIEHS, NIH NIA, NIH NINDS, and NIH ARRA.
CR Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   Aly H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066131
   Arunachalam G, 2014, BRIT J PHARMACOL, V171, P523, DOI 10.1111/bph.12496
   Bagul PK, 2013, CURR PHARM DESIGN, V19, P5663, DOI 10.2174/13816128113199990372
   Balaiya S, 2012, INVEST OPHTH VIS SCI, V53, P4315, DOI 10.1167/iovs.11-9259
   Balan V, 2008, J BIOL CHEM, V283, P27810, DOI 10.1074/jbc.M804681200
   Banerjee KK, 2012, CELL REP, V2, P1485, DOI 10.1016/j.celrep.2012.11.013
   Barbieri F, 2014, DRUG DISCOV TODAY, V19, P458, DOI 10.1016/j.drudis.2013.10.015
   Bayod S, 2014, BRAIN RES, V1543, P38, DOI 10.1016/j.brainres.2013.10.048
   Bayrakdar ET, 2014, FREE RADICAL RES, V48, P146, DOI 10.3109/10715762.2013.857018
   Bayrakdar E. Turunc, 2014, CELL BIOCH FUNCT
   Berschneider B, 2014, INT J BIOCHEM CELL B, V53, P432, DOI 10.1016/j.biocel.2014.06.011
   Berschneider B, 2011, INT J BIOCHEM CELL B, V43, P306, DOI 10.1016/j.biocel.2010.11.013
   Berwick DC, 2014, J MOL CELL BIOL, V6, P3, DOI 10.1093/jmcb/mjt037
   Berwick DC, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00082
   Blundell J, 2008, NEUROBIOL LEARN MEM, V90, P28, DOI 10.1016/j.nlm.2007.12.004
   Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987
   Borrell-Pages M, 2014, J CELL MOL MED, V18, P314, DOI 10.1111/jcmm.12190
   Cai Zhiyou, 2013, J Biochem Pharmacol Res, V1, P84
   Canto C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022
   Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107
   Case N, 2008, J BIOL CHEM, V283, P29196, DOI 10.1074/jbc.M801907200
   Case N, 2010, J ORTHOP RES, V28, P1531, DOI 10.1002/jor.21156
   Castilho RM, 2009, CELL STEM CELL, V5, P279, DOI 10.1016/j.stem.2009.06.017
   Chang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055291
   Chen A, 2013, MOL MED REP, V8, P1011, DOI 10.3892/mmr.2013.1628
   Chen CJ, 2014, MOL CELL BIOCHEM, V386, P167, DOI 10.1007/s11010-013-1855-8
   Chen JR, 2010, J BONE MINER RES
   Chong ZZ, 2007, BRIT J PHARMACOL, V150, P839, DOI 10.1038/sj.bjp.0707161
   Chong ZZ, 2007, CURR NEUROVASC RES, V4, P194
   Chong ZZ, 2007, CELL SIGNAL, V19, P1150, DOI 10.1016/j.cellsig.2006.12.009
   Chong ZZ, 2007, INT J MOL MED, V19, P263
   Chong ZZ, 2006, CURR NEUROVASC RES, V3, P107, DOI 10.2174/156720206776875830
   Chong ZZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045456
   Chong ZZ, 2012, PROG NEUROBIOL, V99, P128, DOI 10.1016/j.pneurobio.2012.08.001
   Chong ZZ, 2012, EXPERT OPIN THER TAR, V16, P167, DOI 10.1517/14728222.2012.648926
   Chong ZZ, 2012, FUTUR CARDIOL, V8, P89, DOI [10.2217/fca.11.76, 10.2217/FCA.11.76]
   Chong ZZ, 2011, CURR NEUROVASC RES, V8, P103
   Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P153, DOI 10.4161/oxim.3.2.11758
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P271, DOI 10.2174/156720205774322584
   Chong ZZ, 2005, CURR NEUROVASC RES, V2, P197, DOI 10.2174/1567202054368317
   Chong ZZ, 2005, BRAIN RES REV, V49, P1, DOI 10.1016/j.brainresrev.2004.11.005
   Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004
   Chong ZZ, 2004, J CEREBR BLOOD F MET, V24, P728, DOI 10.1097/01.WCB.0000122746.72175.0E
   Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161
   Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528
   Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F
   Chonga ZZ, 2004, EXP CELL RES, V296, P196, DOI 10.1016/j.yexcr.2004.01.021
   Cui JJ, 2012, CURR PHARM DESIGN, V18, P2464, DOI 10.2174/13816128112092464
   Davies SR, 2007, ANN SURG ONCOL, V14, P1909, DOI 10.1245/s10434-007-9376-x
   Davies SR, 2010, INT J ONCOL, V36, P1129, DOI 10.3892/ijo_00000595
   Desnoyers L, 2001, J BIOL CHEM, V276, P47599, DOI 10.1074/jbc.M108339200
   Dong SZ, 2007, BLOOD, V110, P360, DOI 10.1182/blood-2006-12-065615
   Doubravska L, 2008, APOPTOSIS, V13, P573, DOI 10.1007/s10495-008-0191-z
   Du J, 2014, AM J PHYSIOL-CELL PH, V306, pC28, DOI 10.1152/ajpcell.00066.2013
   Duan WZ, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00036
   Chamorro ME, 2013, BBA-MOL CELL RES, V1833, P1960, DOI 10.1016/j.bbamcr.2013.04.006
   Francois A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0139-x
   French DM, 2004, AM J PATHOL, V165, P855, DOI 10.1016/S0002-9440(10)63348-2
   Fu WG, 2013, J SURG RES, V183, P876, DOI 10.1016/j.jss.2013.01.044
   Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874
   Garwood CJ, 2014, NEUROPATHOL APPL NEU
   Gezginci-Oktayoglu S, 2014, ACTA HISTOCHEM, V116, P32, DOI 10.1016/j.acthis.2013.04.016
   Gonzalez-Fernandez C., 2013, J NEUROTRAUMA
   Gubern C, 2014, NEUROSCIENCE, V268, P48, DOI 10.1016/j.neuroscience.2014.02.051
   Halperin-Sheinfeld M, 2012, AGING-US, V4, P436, DOI 10.18632/aging.100468
   He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511
   Heise RL, 2011, J BIOL CHEM, V286, P17435, DOI 10.1074/jbc.M110.137273
   Heo J, 2013, BIOCHEM BIOPH RES CO, V434, P235, DOI 10.1016/j.bbrc.2013.02.109
   Hong EH, 2010, J BIOL CHEM, V285, P1283, DOI 10.1074/jbc.M109.058628
   Hong YK, 2012, BIOCHEM BIOPH RES CO, V419, P49, DOI 10.1016/j.bbrc.2012.01.122
   Hou JL, 2011, CURR NEUROVASC RES, V8, P220, DOI 10.2174/156720211796558069
   Hou JL, 2010, MOL CELL ENDOCRINOL, V321, P194, DOI 10.1016/j.mce.2010.02.037
   Hou JL, 2010, CURR NEUROVASC RES, V7, P95, DOI 10.2174/156720210791184899
   Hwang SK, 2011, BMB REP, V44, P506, DOI 10.5483/BMBRep.2011.44.8.506
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jang SY, 2012, J BIOL CHEM, V287, P19304, DOI 10.1074/jbc.M112.363747
   Ji YF, 2013, GLIA, V61, P1959, DOI 10.1002/glia.22566
   Jian YC, 2014, CLIN LAB, V60, P29, DOI 10.7754/Clin.Lab.2013.121035
   Jiang T, 2014, PHARMACOL RES, V81, P54, DOI 10.1016/j.phrs.2014.02.008
   Jiang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102342
   Jung DW, 2014, ACS CHEM BIOL, V9, P80, DOI 10.1021/cb400754f
   Kanbay M, 2007, ADV THER, V24, P346, DOI 10.1007/BF02849903
   Kang J, 2014, CARDIOVASC RES
   Kaushal N, 2011, ANTIOXID REDOX SIGN, V14, P1403, DOI 10.1089/ars.2010.3323
   Kelly KR, 2012, INT J CANCER, V131, P2693, DOI 10.1002/ijc.27579
   Khor TO, 2006, INT J COLORECTAL DIS, V21, P291, DOI 10.1007/s00384-005-0002-8
   Kilic U, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090428
   Klinke DJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003409
   Knight JRP, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130130
   Knoblich K, 2014, CELL MOL LIFE SCI, V71, P1305, DOI 10.1007/s00018-013-1444-8
   Knobloch Jurgen, 2011, Curr Mol Pharmacol, V4, P26
   Konigshoff M, 2009, J CLIN INVEST, V119, P772, DOI 10.1172/JCI33950
   Koh PO, 2013, NEUROSCI LETT, V555, P7, DOI 10.1016/j.neulet.2013.09.001
   Kohan-Ghadr HR, 2012, REPROD FERT DEVELOP, V24, P588, DOI 10.1071/RD11162
   Kozako T, 2012, INT J CANCER, V131, P2044, DOI 10.1002/ijc.27481
   Kwon MS, 2014, NEUROL RES, V36, P215, DOI 10.1179/1743132813Y.0000000284
   L'Episcopo F, 2011, NEUROBIOL DIS, V41, P508, DOI 10.1016/j.nbd.2010.10.023
   L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259-11.2012
   L'Episcopo F, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-49
   Lahoti TS, 2012, CURR NEUROVASC RES, V9, P282
   Lai CS, 2012, J AGR FOOD CHEM, V60, P1094, DOI 10.1021/jf204862d
   Lee G, 2010, GASTROENTEROLOGY, V139, P869, DOI 10.1053/j.gastro.2010.05.037
   Lee SJ, 2014, GLIA, V62, P639, DOI 10.1002/glia.22631
   Li F, 2006, HISTOL HISTOPATHOL, V21, P103, DOI 10.14670/HH-21.103
   Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758
   Li JG, 2014, INT J MOL SCI, V15, P5928, DOI 10.3390/ijms15045928
   Li QH, 2012, ARCH GERONTOL GERIAT, V55, P749, DOI 10.1016/j.archger.2012.06.013
   Li S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078541
   Liguori C., 2014, J NEUROL NEUROSURG P
   Lim JH, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/171383
   Lin FW, 2013, CELL BIOCHEM FUNCT, V31, P166, DOI 10.1002/cbf.2871
   Liu H, 2013, MOL CELLS, V36, P112, DOI 10.1007/s10059-013-0012-2
   Liu JQ, 2012, J DERMATOL SCI, V65, P38, DOI 10.1016/j.jdermsci.2011.09.012
   Liu J, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-71
   Liu QP, 2013, ANTIOXID REDOX SIGN, V18, P1141, DOI 10.1089/ars.2012.4583
   Liu XN, 2014, MOL CANCER THER, V13, P596, DOI 10.1158/1535-7163.MCT-13-0579
   Loilome W, 2014, TUMOUR BIOL J INT SO
   Lough D, 2013, PLAST RECONSTR SURG, V132, P1159, DOI 10.1097/PRS.0b013e3182a48af6
   Ma T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012845
   Macsai CE, 2012, BONE, V50, P1081, DOI 10.1016/j.bone.2012.02.013
   Mahajan SG, 2012, THROMB HAEMOSTASIS, V108, P148, DOI 10.1160/TH11-11-0756
   Maier-Hein K. H., 2014, ANN MED, VS1552-5260, P1
   Maiese K, 2011, ROM J MORPHOL EMBRYO, V52, P1173
   Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90
   Maiese K., 2014, CURR NEUROVASC RES
   Maiese K., 2014, NEURAL REG RES, V9
   Maiese K., 2012, CURR NEUROVASC RES, V9, P1
   Maiese K, 2008, TRENDS MOL MED, V14, P219, DOI 10.1016/j.molmed.2008.03.002
   Maiese K, 2008, BIOMED PHARMACOTHER, V62, P218, DOI 10.1016/j.biopha.2008.01.009
   Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004
   Maiese K, 2013, INDIAN J MED RES, V137, P243
   Maiese K, 2013, TRENDS MOL MED, V19, P51, DOI 10.1016/j.molmed.2012.11.001
   Maiese K, 2013, EXPERT OPIN DRUG DIS, V8, P35, DOI 10.1517/17460441.2013.736485
   Maiese K, 2012, INT J MOL SCI, V13, P13830, DOI 10.3390/ijms131113830
   Maiese K, 2012, EXPERT OPIN THER TAR, V16, P1203, DOI 10.1517/14728222.2012.719499
   Maiese K, 2009, OXID MED CELL LONGEV, V2, P279, DOI 10.4161/oxim.2.5.9990
   Maiese K, 2009, MED RES REV, V29, P395, DOI 10.1002/med.20139
   Mao WK, 2008, J MOL CELL CARDIOL, V45, P250, DOI 10.1016/j.yjmcc.2008.05.010
   Marchand A, 2011, AGING CELL, V10, P220, DOI 10.1111/j.1474-9726.2010.00661.x
   Marchetti B, 2013, EUR J NEUROSCI, V37, P1550, DOI 10.1111/ejn.12166
   Marchetti B, 2013, TRENDS MOL MED, V19, P144, DOI 10.1016/j.molmed.2012.12.001
   Uranga RM, 2013, J BIOL CHEM, V288, P19773, DOI 10.1074/jbc.M113.457622
   de Morentin PBM, 2014, CURR MOL MED, V14, P3, DOI 10.2174/1566524013666131118103706
   Maurice T, 2013, J PSYCHOPHARMACOL, V27, P1044, DOI 10.1177/0269881113494939
   Mehrjerdi FZ, 2013, BRAIN RES, V1526, P94, DOI 10.1016/j.brainres.2013.06.018
   Meng XF, 2013, J NEUROL SCI, V332, P4, DOI 10.1016/j.jns.2013.05.029
   Mercer KE, 2014, CANCER PREV RES, V7, P675, DOI 10.1158/1940-6207.CAPR-13-0444-T
   Nagai Y, 2011, ANTICANCER RES, V31, P991
   Nakazawa Y, 2013, J NEPHROL, V26, P527, DOI 10.5301/jn.5000178
   Neasta J, 2014, J NEUROCHEM, V130, P172, DOI 10.1111/jnc.12725
   Ng F, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00186
   Noseda R, 2013, J NEUROSCI, V33, P15295, DOI 10.1523/JNEUROSCI.2408-13.2013
   Ono M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071709
   Ono M, 2011, J BONE MINER RES, V26, P193, DOI 10.1002/jbmr.205
   Ortiz-Masia D, 2014, MUCOSAL IMMUNOL, V7, P929, DOI 10.1038/mi.2013.108
   Pandey S, 2013, MOL BIOL REP, V40, P6011, DOI 10.1007/s11033-013-2710-4
   Pang WJ, 2013, EXP CELL RES, V319, P670, DOI 10.1016/j.yexcr.2012.12.025
   Parsons RG, 2006, J NEUROSCI, V26, P12977, DOI 10.1523/JNEUROSCI.4209-06.2006
   Pasmant E, 2010, J NEUROPATH EXP NEUR, V69, P60, DOI 10.1097/NEN.0b013e3181c79bff
   PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x
   Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717
   Pilar-Cuellar F, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/537265
   Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840
   Price RM, 2004, J AM COLL SURGEONS, V199, P411, DOI 10.1016/j.jamcollsurg.2004.04.023
   Puthanveetil P, 2013, CARDIOVASC RES, V97, P393, DOI 10.1093/cvr/cvs426
   Qi XF, 2013, EXP MOL PATHOL, V95, P242, DOI 10.1016/j.yexmp.2013.08.003
   Ramalingam M, 2014, J RECEPTOR SIGN 0124
   Reddy VS, 2011, J CELL PHYSIOL, V226, P3303, DOI 10.1002/jcp.22676
   Rong Z, 2013, NEUROSCIENCE, V255, P292, DOI 10.1016/j.neuroscience.2013.09.030
   Saidak Z, 2014, J ENDOCRINOL
   Sansone L, 2013, J CELL PHYSIOL, V228, P1754, DOI 10.1002/jcp.24334
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Schluesener JK, 2014, IET SYST BIOL, V8, P169, DOI 10.1049/iet-syb.2013.0047
   Schneider S, 2014, EUR ARCH OTO-RHINO-L, V271, P1999, DOI 10.1007/s00405-013-2740-5
   Bilbao PS, 2013, BBA-GEN SUBJECTS, V1830, P4456, DOI 10.1016/j.bbagen.2013.05.034
   Shah N., 2014, CELL BIOCH FUNCT
   Shahani N, 2014, J BIOL CHEM, V289, P5799, DOI 10.1074/jbc.M113.532713
   Shang YC, 2013, CURR NEUROVASC RES, V10, P29
   Shang YC, 2012, CURR NEUROVASC RES, V9, P239
   Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440
   Shang YC, 2011, CURR NEUROVASC RES, V8, P270
   Shang YC, 2010, CELL SIGNAL, V22, P1317, DOI 10.1016/j.cellsig.2010.04.009
   Shang YC, 2009, CURR NEUROVASC RES, V6, P20, DOI 10.2174/156720209787466064
   Shao H, 2011, ONCOGENE, V30, P4316, DOI 10.1038/onc.2011.142
   Shao SY, 2013, DNA CELL BIOL, V32, P41, DOI 10.1089/dna.2012.1874
   Shi J, 2012, ACTA PHARMACOL SIN, V33, P888, DOI 10.1038/aps.2012.73
   Soon LL, 2003, J BIOL CHEM, V278, P11465, DOI 10.1074/jbc.M210945200
   Sowers LP, 2013, MOL PSYCHIATR, V18, P1077, DOI 10.1038/mp.2013.71
   Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902
   Su LN, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-378
   Svirshchevskaya EV, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-176
   Tanaka S, 2003, HEPATOLOGY, V37, P1122, DOI 10.1053/jhep.2003.50187
   Tanaka S, 2001, ONCOGENE, V20, P5525, DOI 10.1038/sj.onc.1204723
   Tang QL, 2011, J OBSTET GYNAECOL RE, V37, P606, DOI 10.1111/j.1447-0756.2011.01631.x
   Tang Z, 2014, J PROTEOME RES, V13, P2433, DOI 10.1021/pr500192g
   Tank J, 2014, J MOL CELL CARDIOL, V66, P141, DOI 10.1016/j.yjmcc.2013.11.004
   Tanno M, 2010, J BIOL CHEM, V285, P8375, DOI 10.1074/jbc.M109.090266
   Tao GZ, 2013, J BIOL CHEM, V288, P17214, DOI 10.1074/jbc.M112.445965
   Thorfve A, 2014, ACTA BIOMATER, V10, P1451, DOI 10.1016/j.actbio.2013.12.012
   Trinh DL, 2013, BLOOD, V121, P3666, DOI 10.1182/blood-2013-01-479865
   Turkcu UO, 2014, GENE, V536, P129, DOI 10.1016/j.gene.2013.11.055
   Uzdensky AB, 2013, CURR CANCER DRUG TAR, V13, P843
   van den Bosch MH, 2014, CELL SIGNAL, V26, P951, DOI 10.1016/j.cellsig.2014.01.021
   Venkatachalam K, 2009, J BIOL CHEM, V284, P14414, DOI 10.1074/jbc.M809757200
   Venkatesan B, 2010, CELL SIGNAL, V22, P809, DOI 10.1016/j.cellsig.2010.01.005
   Wang C, 2014, MOL NEUROBIOL, V49, P120, DOI 10.1007/s12035-013-8505-8
   Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347
   Wang GB, 2014, MOL CELL BIOCHEM, V385, P125, DOI 10.1007/s11010-013-1821-5
   Wang HY, 2009, J MOL MED, V87, P435, DOI 10.1007/s00109-009-0445-4
   Wang JG, 2014, INT J MOL MED, V33, P441, DOI 10.3892/ijmm.2013.1587
   Wang S, 2012, CURR NEUROVASC RES, V9, P89
   Wang SH, 2013, CURR NEUROVASC RES, V10, P54, DOI 10.2174/156720213804805945
   Wang SH, 2012, CURR NEUROVASC RES, V9, P20, DOI 10.2174/156720212799297137
   Wang WR, 2013, APOPTOSIS, V18, P689, DOI 10.1007/s10495-013-0833-7
   Wang Y., 2014, CNS NEUROSCI THER
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Wei L, 2013, J MOL NEUROSCI, V49, P105, DOI 10.1007/s12031-012-9900-8
   Wu Y, 2007, EUR J PHARMACOL, V564, P47, DOI 10.1016/j.ejphar.2007.02.020
   Xie D, 2001, CANCER RES, V61, P8917
   Xie R, 2013, J NEUROCHEM, V127, P723, DOI 10.1111/jnc.12342
   Xing YX, 2012, BRAIN RES, V1482, P71, DOI 10.1016/j.brainres.2012.08.057
   Xiong X, 2014, NEUROBIOL DIS
   Xu DW, 2014, J MOL NEUROSCI, V52, P410, DOI 10.1007/s12031-013-0191-5
   Xu LF, 2000, GENE DEV, V14, P585
   Xue ZF, 2014, EUR J PHARMACOL, V741, P195, DOI 10.1016/j.ejphar.2014.08.006
   Yamada Y, 2009, HYPERTENS RES, V32, P325, DOI 10.1038/hr.2009.23
   Yang CS, 2011, STEM CELLS, V29, P1528, DOI 10.1002/stem.717
   Yang H, 2014, RESTOR NEUROL NEUROS
   Yang MJ, 2013, INT IMMUNOPHARMACOL, V17, P350, DOI 10.1016/j.intimp.2013.06.011
   Yang YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/351895
   Yang Y, 2013, CIRCULATION, V128, P2232, DOI 10.1161/CIRCULATIONAHA.113.002480
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065309
   Yang ZH, 2014, CANCER GENE THER, V21, P74, DOI 10.1038/cgt.2013.86
   Yeger H, 2007, J CELL COMMUN SIGNAL, V1, P159, DOI 10.1007/s12079-008-0022-6
   You H, 2014, CURR NEUROVASC RES
   You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110
   Zara S, 2013, GERONTOLOGY, V59, P250, DOI 10.1159/000346445
   Zemans RL, 2013, AM J PHYSIOL-LUNG C, V304, pL415, DOI 10.1152/ajplung.00180.2012
   Zhang J, 2013, BIOFACTORS OXFORD EN
   Zhang JG, 2013, PANCREATOLOGY, V13, P140, DOI 10.1016/j.pan.2013.01.001
   Zheng WP, 2013, EUR J MED CHEM, V59, P132, DOI 10.1016/j.ejmech.2012.11.014
   Zhou W, 2014, NEUROIMMUNOMODULAT, V21, P183, DOI 10.1159/000356517
   Zhu ZY, 2013, J NEUROSCI, V33, P13138, DOI 10.1523/JNEUROSCI.4790-12.2013
NR 244
TC 39
Z9 39
U1 1
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1567-2026
EI 1875-5739
J9 CURR NEUROVASC RES
JI Curr. Neurovasc. Res.
PY 2014
VL 11
IS 4
BP 378
EP 389
DI 10.2174/1567202611666140912115107
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AS2DM
UT WOS:000344089700011
PM 25219658
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Huang, LN
   Wang, WN
   Hu, ZT
   Guan, CH
   Li, WZ
   Jiang, XM
AF Huang, Lining
   Wang, Weina
   Hu, Zengtao
   Guan, Canghai
   Li, Wenzhi
   Jiang, Xingming
TI Hypoxia and lncRNAs in gastrointestinal cancers
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE Hypoxia; LncRNA; Gastrointestinal cancer; Regulation; Functions
ID COMPETING ENDOGENOUS RNA; GASTRIC-CANCER; COLORECTAL-CANCER; NONCODING
   RNAS; MESSENGER-RNAS; TUMOR; METASTASIS; CELLS; CONTRIBUTES; AUTOPHAGY
AB Objectives: Hypoxia is a hallmark of the tumor microenvironment, and hypoxia regions are frequently found in gastrointestinal cancers, which are associated with worse patients' survival and therapy resistance. However, the potential mechanisms of hypoxic tumor microenvironment still need to be further elucidated, especially about the roles of long non-coding RNAs (lncRNAs) in hypoxic tumor regions. In recent years, a great mount of independent research showed that many lncRNAs were modulated by hypoxia, and these lncRNAs were named as "hypoxia-regulated lncRNAs". In this review, the recent developments in the expression, regulation and functions of hypoxia-regulated lncRNAs in gastrointestinal cancers were summarized.
   Materials and methods: In this review, we summarized and figured out recent studies concerning the expression and biological mechanisms of hypoxia-regulated lncRNAs in gastrointestinal cancers. The related studies were obtained through a systematic search of PubMed, Embase and Cochrane Library.
   Results: Hypoxia-regulated lncRNAs have various roles in the regulation of metabolism, autophagy, invasion and metastasis in the hypoxic microenvironment. More importantly, hypoxic-regulated lncRNAs have a variety of potential mechanisms in gastrointestinal tumors, including epigenetic, lncRNA-miRNA interaction, lncRNA-protein interactions.
   Conclusions: Hypoxia-regulated lncRNAs will undoubtedly be developed as targets and promote the progress in ideal therapies for gastrointestinal cancer patients.
C1 [Huang, Lining; Hu, Zengtao; Guan, Canghai; Jiang, Xingming] Harbin Med Univ, Affiliated Hosp 2, Dept HPB Surg, 246 Xuefu Ro, Harbin 150086, Peoples R China.
   [Wang, Weina; Li, Wenzhi] Harbin Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 246 Xuefu Ro, Harbin 150086, Peoples R China.
RP Jiang, XM (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept HPB Surg, 246 Xuefu Ro, Harbin 150086, Peoples R China.; Li, WZ (corresponding author), Harbin Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 246 Xuefu Ro, Harbin 150086, Peoples R China.
EM liwz2nd@163.com; jiangxingming@hrbmu.edu.cn
RI Jiang, Xingming/ABA-1971-2021
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81602088]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2017M621305];
   Heilongjiang Postdoctoral Science Foundation [LBH-Z16096]; Health and
   Family Planning Commission Research Project of Heilongjiang Province
   [2016-049]; HMU College Students' Innovation and Entrepreneurship
   Training Program [201810226105]; Innovative Science Foundation of Harbin
   Medical University [2016LCZX09]
FX This work was supported by grants from National Natural Science
   Foundation of China [grant numbers 81602088], China Postdoctoral Science
   Foundation [grant numbers 2017M621305], Heilongjiang Postdoctoral
   Science Foundation [grant numbers LBH-Z16096], Health and Family
   Planning Commission Research Project of Heilongjiang Province [grant
   numbers 2016-049], HMU College Students' Innovation and Entrepreneurship
   Training Program [grant numbers 201810226105] and Innovative Science
   Foundation of Harbin Medical University [grant numbers 2016LCZX09].
CR Backes C, 2016, ANAL CHEM, V88, P2088, DOI 10.1021/acs.analchem.5b03376
   Cai Q, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.160247
   Cai Q, 2016, AM J TRANSL RES, V8, P4068
   Camuzi D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040300
   Chee NT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0968-4
   Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0
   Chen FB, 2019, INT J ONCOL, V54, P1183, DOI 10.3892/ijo.2019.4707
   Chen JL, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919838958
   Chen LL, 2016, TRENDS BIOCHEM SCI, V41, P761, DOI 10.1016/j.tibs.2016.07.003
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen WM, 2015, DIGEST DIS SCI, V60, P1655, DOI 10.1007/s10620-015-3524-0
   Choudhry H, 2016, MOL ASPECTS MED, V47-48, P35, DOI 10.1016/j.mam.2016.01.003
   Daniel SK, 2019, CLIN TRANSL MED, V8, DOI 10.1186/s40169-019-0226-9
   Deng SJ, 2018, ONCOGENE, V37, P5811, DOI 10.1038/s41388-018-0382-1
   DiStefano Johanna K, 2017, Noncoding RNA Res, V2, P129, DOI 10.1016/j.ncrna.2017.11.001
   Dong HY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0931-9
   Dong HY, 2018, J CELL MOL MED, V22, P4935, DOI 10.1111/jcmm.13758
   Engreitz JM, 2016, NAT REV MOL CELL BIO, V17, P756, DOI 10.1038/nrm.2016.126
   Han Y, 2019, MED SCI MONITOR, V25, P2009, DOI 10.12659/MSM.915179
   He ZY, 2019, J CELL PHYSIOL, V234, P6769, DOI 10.1002/jcp.27424
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Huang T, 2017, BIOMED PHARMACOTHER, V88, P302, DOI 10.1016/j.biopha.2017.01.049
   Infanger DW, 2013, ANNU REV BIOMED ENG, V15, P29, DOI 10.1146/annurev-bioeng-071811-150028
   Iyer AK, 2013, ADV DRUG DELIVER REV, V65, P1784, DOI 10.1016/j.addr.2013.07.012
   Jiang CY, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0545-z
   Jiang XG, 2019, CIRCULATION, V139, P502, DOI 10.1161/CIRCULATIONAHA.118.036157
   LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330
   Li HM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0576-5
   Li J, 2018, AM J TRANSL RES, V10, P1022
   Li JL, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12381
   Li X, 2016, ONCOTARGET, V7, P6000, DOI 10.18632/oncotarget.6830
   Li YS, 2019, TRENDS BIOCHEM SCI, V44, P659, DOI 10.1016/j.tibs.2019.03.009
   Liu L, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00420
   Liu XQ, 2018, CANCER SCI, V109, P988, DOI 10.1111/cas.13519
   Lou Y, 2019, J CELL MOL MED, V23, P1873, DOI 10.1111/jcmm.14088
   Ma BB, 2019, DNA RES, V26, P105, DOI 10.1093/dnares/dsy042
   Ma MZ, 2015, MOL CARCINOGEN, V54, P1397, DOI 10.1002/mc.22215
   Macharia LW, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00125
   McCarty G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119837
   Nishizawa Y, 2018, INT J ONCOL, V52, P453, DOI 10.3892/ijo.2017.4218
   Ou ZL, 2019, J CELL PHYSIOL, V234, P15407, DOI 10.1002/jcp.28188
   Pan XH, 2019, THERANOSTICS, V9, P1794, DOI 10.7150/thno.31841
   Sadiku P, 2019, EMBO REP, V20, DOI 10.15252/embr.201847388
   Sanchez-Mejias A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0129-1
   Semenza GL, 2019, ANNU REV PHARMACOL, V59, P379, DOI 10.1146/annurev-pharmtox-010818-021637
   Shen YM, 2017, EXP CELL RES, V358, P188, DOI 10.1016/j.yexcr.2017.06.016
   Shih JW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15874
   Strowitzki MJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050384
   Sun YW, 2014, BRIT J CANCER, V111, P2131, DOI 10.1038/bjc.2014.520
   Takahashi K, 2014, J CELL SCI, V127, P1585, DOI 10.1242/jcs.141069
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang HF, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12600
   Wang R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0916-8
   Wang TH, 2016, ONCOTARGET, V7, P43588, DOI 10.18632/oncotarget.9635
   Wang YF, 2014, NEOPLASIA, V16, P1094, DOI 10.1016/j.neo.2014.10.008
   Wels J, 2008, GENE DEV, V22, P559, DOI 10.1101/gad.1636908
   Wernberg JA, 2014, SURG CLIN N AM, V94, P343, DOI 10.1016/j.suc.2014.01.009
   Wohlrab C, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00574
   Wu FX, 2019, ONCOTARGETS THER, V12, P657, DOI 10.2147/OTT.S175521
   Xiang LS, 2019, ADV CANCER RES, V141, P175, DOI 10.1016/bs.acr.2018.11.001
   Xu LL, 2016, AM J PHYSIOL-CELL PH, V310, pC903, DOI 10.1152/ajpcell.00309.2015
   Xu YXX, 2018, CELL PHYSIOL BIOCHEM, V49, P1403, DOI 10.1159/000493445
   Yang F, 2013, MOL CELL, V49, P1083, DOI 10.1016/j.molcel.2013.01.010
   Yang Y, 2018, BIOCHEM BIOPH RES CO, V497, P1003, DOI 10.1016/j.bbrc.2018.02.141
   Yang Z, 2015, INT J CLIN EXP MED, V8, P19954
   Yang ZC, 2018, EXP CELL RES, V368, P194, DOI 10.1016/j.yexcr.2018.04.030
   Yao Jie, 2015, Onco Targets Ther, V8, P3467, DOI 10.2147/OTT.S81393
   Zhang J, 2019, CLIN TRANSL ONCOL, V21, P1142, DOI 10.1007/s12094-019-02035-9
   Zhang LG, 2017, AM J CANCER RES, V7, P2536
   Zhang PF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09482-6
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhao XL, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00200
   Zhou C, 2017, ONCOGENE, V36, P3878, DOI 10.1038/onc.2017.14
   Zhou H, 2012, EXP CELL RES, V318, P1685, DOI 10.1016/j.yexcr.2012.04.019
NR 75
TC 9
Z9 10
U1 0
U2 3
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2019
VL 215
IS 12
AR 152687
DI 10.1016/j.prp.2019.152687
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA KK1BP
UT WOS:000512485400003
PM 31640897
DA 2022-04-25
ER

PT J
AU Bathula, C
   Roma-Rodrigues, C
   Chauhan, J
   Fernandes, AR
   Sen, S
AF Bathula, Chandramohan
   Roma-Rodrigues, Catarina
   Chauhan, Jyoti
   Fernandes, Alexandra R.
   Sen, Subhabrata
TI Synthesis of tetrahydro-1H-indolo[2,3-b]-pyrrolo[3,2-c] quinolones via
   intramolecular oxidative ring rearrangement of
   tetrahydro-beta-bcarbolines and their biological evaluation
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID OXINDOLE ALKALOIDS; COBALT COMPLEXES; IN-VIVO; APOPTOSIS; CANCER;
   CHLORINATION; COMMUNESINS; CYCLIZATION; NOMOFUNGIN; LIGANDS
AB A simple oxidative ring rearrangement of diversely substituted 1-(2-amminoaryl)-tetrahydro-b-carbolines has been developed to generate architecturally interesting tetrahydro-1H-indolo[2,3-b]pyrrolo[3,2-c] quinolones. This unique transformation involves four reaction centers (aniline, C1-carboline and C-2/C-3 of indole) and utilizes tert-butylhypochlorite as the reagent. The generic nature of the reaction was demonstrated by the synthesis of a wide variety of analogs 9a-j. A putative reaction mechanism was proposed. Cytotoxicity screening of these compounds against three human cancer cells (A2780 ovarian and HCT116 colorectal carcinoma cell lines and A549 lung adenocarcinoma cell line) revealed selective inhibition of proliferation of the A2780 human ovarian carcinoma cell line by one of the molecules 9a with an IC50 of 14 mu M. No cytotoxic activity was observed in human normal fibroblasts for concentrations up to 100 mM. Compound 9a induced hyperpolarization of the mitochondrial membrane potential of the A2780 cell line leading to an increase of reactive oxygen species (ROS) that trigger cell death via apoptosis. Interestingly, compound 9a was also able to induce cell death via autophagy. Compounds that induce apoptosis and autophagy, thus leading to cancer cells' death, are good candidates for cancer therapy.
C1 [Bathula, Chandramohan; Chauhan, Jyoti; Sen, Subhabrata] Shiv Nadar Univ, Sch Nat Sci, Dept Chem, Gautambudh Nagar 201314, Uttar Pradesh, India.
   [Roma-Rodrigues, Catarina; Fernandes, Alexandra R.] Univ Nova Lisboa, Dept Ciencias Vida, UCIBIO, Fac Ciencias & Tecnol, Caparica, Portugal.
RP Sen, S (corresponding author), Shiv Nadar Univ, Sch Nat Sci, Dept Chem, Gautambudh Nagar 201314, Uttar Pradesh, India.; Fernandes, AR (corresponding author), Univ Nova Lisboa, Dept Ciencias Vida, UCIBIO, Fac Ciencias & Tecnol, Caparica, Portugal.
EM ma.fernandes@fct.unl.pt; subhabrata.sen@snu.edu.in
RI chauhan, jyoti/O-5069-2017; Roma-Rodrigues, Catarina/S-6144-2016;
   Roma-Rodrigues, Catarina/AAT-5658-2021; Fernandes, Alexandra
   R/C-7465-2011
OI Roma-Rodrigues, Catarina/0000-0002-8676-6562; Roma-Rodrigues,
   Catarina/0000-0002-8676-6562; Fernandes, Alexandra
   R/0000-0003-2054-4438; Sen, Subhabrata/0000-0002-4608-5498
FU Shiv Nadar University; national funds from FCT/MEC
   [UID/Multi/04378/2013]; ERDF under the PT Partnership Agreement
   [POCI-01-0145-FEDER-007728]
FX This work was supported by Shiv Nadar University and The Unidade de
   Ciencias Biomoleculares Aplicadas - UCIBIO which is financed by national
   funds from FCT/MEC (UID/Multi/04378/2013) and co-financed by the ERDF
   under the PT2020 Partnership Agreement (POCI-01-0145-FEDER-007728).
CR Bischler A., 1893, CHEM BER-RECL, V26, P1903
   Boal BW, 2009, ORG LETT, V11, P3458, DOI 10.1021/ol901383j
   Circu ML, 2010, FREE RADICAL BIO MED, V48, P749, DOI 10.1016/j.freeradbiomed.2009.12.022
   Crawley SL, 2003, ORG LETT, V5, P3169, DOI 10.1021/ol034407v
   Cui CB, 1996, J ANTIBIOT, V49, P832, DOI 10.7164/antibiotics.49.832
   DIDEBERG O, 1977, ACTA CRYSTALLOGR B, V33, P1796, DOI 10.1107/S0567740877007080
   EARLEY WG, 1988, TETRAHEDRON LETT, V29, P3785, DOI 10.1016/S0040-4039(00)82114-0
   GRIGG R, 1984, J CHEM SOC CHEM COMM, P182, DOI 10.1039/c39840000182
   Hati S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32213
   Huang FQ, 2016, ORG LETT, V18, P684, DOI 10.1021/acs.orglett.5b03649
   Ito M, 2001, J AM CHEM SOC, V123, P8003, DOI 10.1021/ja010935v
   Jadulco R, 2004, J NAT PROD, V67, P78, DOI 10.1021/np030271y
   Jiang L, 2015, RSC ADV, V5, P9204, DOI 10.1039/c4ra14092c
   JONES K, 1992, J CHEM SOC CHEM COMM, P1767, DOI 10.1039/c39920001767
   Lenis-Rojas OA, 2016, DALTON T, V45, P19127, DOI 10.1039/c6dt03591d
   Lenis-Rojas OA, 2017, INORG CHEM, V56, P7127, DOI 10.1021/acs.inorgchem.7b00790
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Ma D., 2011, ANGEW CHEM, V123, P12214
   Madin A, 1999, ANGEW CHEM INT EDIT, V38, P2934
   Mahmudov KT, 2014, J ORGANOMET CHEM, V760, P67, DOI 10.1016/j.jorganchem.2013.12.019
   Marti C, 2003, EUR J ORG CHEM, V2003, P2209, DOI 10.1002/ejoc.200300050
   May JA, 2003, TETRAHEDRON LETT, V44, P1203, DOI 10.1016/S0040-4039(02)02790-9
   NUMATA A, 1993, TETRAHEDRON LETT, V34, P2355, DOI 10.1016/S0040-4039(00)77612-X
   Per A., 2004, TRENDS IMMUNOL, V25, P360
   Perry SW, 2011, BIOTECHNIQUES, V50, P98, DOI 10.2144/000113610
   Ratnayake AS, 2001, J ORG CHEM, V66, P8717, DOI 10.1021/jo010335e
   RATNAYAKE AS, 2003, J ORG CHEM, V68, P1640
   SAKAI S, 1975, TETRAHEDRON LETT, P715
   Saxon J.E., 1983, HETEROCYCLIC COMPO 4, V25, P85
   Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1
   Schammel AW, 2010, TETRAHEDRON, V66, P4687, DOI 10.1016/j.tet.2010.02.050
   Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723
   Shimizu S, 2014, INT J MOL SCI, V15, P3145, DOI 10.3390/ijms15023145
   Shimojo H., 2013, SYNTHESIS-STUTTGART, P2155
   Silva Ana, 2013, Drug Metabolism and Drug Interactions, V28, P167, DOI 10.1515/dmdi-2013-0015
   Silva TFS, 2014, CHEM-ASIAN J, V9, P1132, DOI 10.1002/asia.201301331
   Silva TFS, 2013, EUR J INORG CHEM, V2013, P3651, DOI 10.1002/ejic.201300197
   Silva TFS, 2012, DALTON T, V41, P12888, DOI 10.1039/c2dt11577h
   Suski JM, 2012, METHODS MOL BIOL, V810, P183, DOI 10.1007/978-1-61779-382-0_12
   Takeda Y., 2013, SYNTHESIS-STUTTGART, P1029
   van Henegouwen W. G. B. Beyersbergen, 1999, ANGEW CHEM INT EDIT, V38, P2214
   van Henegouwen WGB, 2000, J ORG CHEM, V65, P8317, DOI 10.1021/jo001119t
   Verbitski SM, 2002, J ORG CHEM, V67, P7124, DOI 10.1021/jo026012f
   Wang ZT, 2012, J AM CHEM SOC, V134, P4258, DOI 10.1021/ja210361z
   Wu Danli, 2011, J Vis Exp, DOI 10.3791/3357
   Yu P, 1997, TETRAHEDRON LETT, V38, P8799, DOI 10.1016/S0040-4039(97)10420-8
   Zhang XB, 1999, ARCH PATHOL LAB MED, V123, P921
   Zuo ZW, 2011, ANGEW CHEM INT EDIT, V50, P12008, DOI 10.1002/anie.201106205
NR 48
TC 1
Z9 1
U1 0
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD APR 21
PY 2018
VL 42
IS 8
BP 6538
EP 6547
DI 10.1039/c7nj04616b
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA GE1SJ
UT WOS:000430996700099
DA 2022-04-25
ER

PT J
AU Tu, CE
   Hu, Y
   Zhou, PR
   Guo, XX
   Gu, CC
   Zhang, YL
   Li, AM
   Liu, SD
AF Tu, Cheng-e
   Hu, Ying
   Zhou, Peirong
   Guo, Xuxue
   Gu, Chuncai
   Zhang, Yali
   Li, Aimin
   Liu, Side
TI Lactate and TGF-beta antagonistically regulate inflammasome activation
   in the tumor microenvironment
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE autophagy; inflammasome; lactate; reactive oxygen species; transforming
   growth factor&#8208; &#946
ID COLORECTAL-CANCER; TRANSCRIPTION; POLARIZATION; MACROPHAGES; GROWTH;
   CELLS
AB The tumor microenvironment significantly affects tumor progression, and tumor cells can also remodel the tumor microenvironment through complex interaction. Inflammasomes are innate immune system receptors/sensors that regulate an inflammatory response mainly mediated by the nucleotide-binding oligomerization domain-like receptors in macrophages, which can also influence the formation, progression and therapeutic response of cancer. However, the effects of tumor-derived factors in the microenvironment on inflammasomes have rarely been reported. In this study, we found that lactate, as the main metabolite of tumor cells could specifically activate the nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain-containing protein 3 inflammasome through increasing the level of reactive oxygen species (ROS) in THP-1-derived macrophages. Furthermore, we showed that transforming growth factor-beta (TGF-beta), a cytokine accumulated in the tumor microenvironment, could be induced by lactate treatment in tumor cells, and in turn inhibit inflammasome activation induced by lactate and other canonical ligands in macrophages. In addition, TGF-beta might induce autophagy of macrophages in a SMAD-dependent manner, leading to ROS clearance and eventually inhibiting the activation of inflammasomes. Collectively, these results indicated that in the tumor microenvironment, tumor-derived lactate could act as a danger signal alerting innate immunity, but nevertheless tumor cells produced more TGF-beta to avoid immune surveillance.
C1 [Tu, Cheng-e; Hu, Ying; Zhou, Peirong; Guo, Xuxue; Gu, Chuncai; Zhang, Yali; Li, Aimin; Liu, Side] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China.
RP Zhang, YL; Li, AM; Liu, SD (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangdong Prov Key Lab Gastroenterol, Guangzhou, Peoples R China.
EM zyl41531@.163.com; Lam0725@163.com; liuside2011@163.com
FU Guangdong gastrointestinal disease research center [2017B020209003];
   Natural Science Foundation of Guangdong ProvinceNational Natural Science
   Foundation of Guangdong Province [2020A1515011283]
FX Guangdong gastrointestinal disease research center, Grant/Award Number:
   2017B020209003; Natural Science Foundation of Guangdong Province,
   Grant/Award Number: 2020A1515011283
CR Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011
   Brooks GA, 2018, CELL METAB, V27, P757, DOI 10.1016/j.cmet.2018.03.008
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Dupaul-Chicoine J, 2015, IMMUNITY, V43, P751, DOI 10.1016/j.immuni.2015.08.013
   Feng J, 2017, ONCOGENE, V36, P5829, DOI 10.1038/onc.2017.188
   Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384
   Hahm KB, 2000, J CLIN INVEST, V105, P1057, DOI 10.1172/JCI8337
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Ivashkiv LB, 2020, NAT REV IMMUNOL, V20, P85, DOI 10.1038/s41577-019-0259-8
   Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401
   Koelwyn GJ, 2017, NAT REV CANCER, V17, P620, DOI 10.1038/nrc.2017.78
   Li XR, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0701-y
   Moossavi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0900-3
   Rajamaki K, 2013, J BIOL CHEM, V288, P13410, DOI 10.1074/jbc.M112.426254
   Rathinam VAK, 2016, CELL, V165, P792, DOI 10.1016/j.cell.2016.03.046
   Regateiro FS, 2011, EUR J IMMUNOL, V41, P2955, DOI 10.1002/eji.201141512
   Samuvel DJ, 2009, J IMMUNOL, V182, P2476, DOI 10.4049/jimmunol.0802059
   Schmid SA, 2007, EXP CELL RES, V313, P2531, DOI 10.1016/j.yexcr.2007.05.016
   Wilson JE, 2015, NAT MED, V21, P906, DOI 10.1038/nm.3908
   Worthington JJ, 2015, IMMUNITY, V42, P903, DOI 10.1016/j.immuni.2015.04.012
   Yoshida Y, 2014, IMMUNITY, V40, P187, DOI 10.1016/j.immuni.2013.11.022
   Zhou L, 2008, NATURE, V453, P236, DOI 10.1038/nature06878
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 28
TC 2
Z9 2
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2021
VL 236
IS 6
BP 4528
EP 4537
DI 10.1002/jcp.30169
EA NOV 2020
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA RA5YF
UT WOS:000591564600001
PM 33230810
DA 2022-04-25
ER

PT J
AU Pathania, AS
   Challagundla, KB
AF Pathania, Anup S.
   Challagundla, Kishore B.
TI Exosomal Long Non-coding RNAs: Emerging Players in the Tumor
   Microenvironment
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Review
ID CELL-DERIVED EXOSOMES; EXTRACELLULAR VESICLES; COLORECTAL-CANCER;
   LNCRNA; PROMOTE; INVASION; PROGRESSION; EXPRESSION; MICRORNAS; AUTOPHAGY
AB Recent advances in exosome biology have uncovered a significant role of exosomes in cancer and make them a determining factor in intercellular communication. Exosomes are types of extracellular vesicles that are involved in the communication between cells by exchanging various signaling molecules between the surrounding cells. Among various signaling molecules, long non-coding RNAs (lncRNAs), a type of non-coding RNA having a size of more than 200 nt in length and lacking protein-coding potential, have emerged as crucial regulators of intercellular communication. Tumor-derived exosomes containing various lncRNAs, known as exosomal lncRNAs, reprogram the microenvironment by regulating numerous cellular functions, including the regulation of gene transcription that favors cancer growth and progression, thus significantly determining the biological effects of exosomes. In addition, deregulated expression of lncRNAs is found in various human cancers and serves as a diagnostic biomarker to predict cancer type. The present review discusses the role of exosomal lncRNAs in the crosstalk between tumor cells and the surrounding cells of the microenvironment. Furthermore, we also discuss the involvement of exosomal lncRNAs within the tumor microenvironment in favoring tumor growth, metabolic reprogramming of tumor cells, and tumor-supportive autophagy. Therefore, lncRNAs can be used as a therapeutic target in the treatment of various human cancers.
C1 [Pathania, Anup S.; Challagundla, Kishore B.] Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.
   [Pathania, Anup S.; Challagundla, Kishore B.] Univ Nebraska Med Ctr, Fred & Pamela Buffet Canc Ctr, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.
   [Challagundla, Kishore B.] Univ Nebraska Med Ctr, Childrens Hlth Res Inst, Omaha, NE 68198 USA.
RP Challagundla, KB (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.; Challagundla, KB (corresponding author), Univ Nebraska Med Ctr, Fred & Pamela Buffet Canc Ctr, 985870 Nebraska Med Ctr, Omaha, NE 68198 USA.
EM kishore.challagundla@unmc.edu
RI Challagundla, Kishore B./H-8189-2019
OI Challagundla, Kishore B./0000-0001-8654-7717
FU NIH/National Cancer Institute (NCI)United States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [1K22CA197074]; Buffet Pilot & Pediatric Cancer
   Research Grants at the University of Nebraska Medical Center (UNMC)
   [LB506]; Leukemia Research Foundation [LB506]; Department of
   Biochemistry & Molecular Biology start-up grants
FX K.B.C.'s laboratory is supported in whole or part by NIH/National Cancer
   Institute (NCI) grant 1K22CA197074; Buffet Pilot & Pediatric Cancer
   Research Grants at the University of Nebraska Medical Center (UNMC),
   LB506 (Nebraska Department of Health and Human Services) and Leukemia
   Research Foundation, LB506 (Nebraska Department of Health and Human
   Services); and the Department of Biochemistry & Molecular Biology
   start-up grants. The authors would like to thank Jeffrey Patterson,
   University of Nebraska Medical Center (Omaha, NE, USA), for editorial
   assistance. Figures were prepared using EazyDraw and BioRender tools.
CR Abbastabar M, 2020, EXCLI J, V19, P301, DOI 10.17179/excli2019-1683
   Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2
   [Anonymous], 2019, NAT MED, V25, P1321, DOI 10.1038/s41591-019-0580-6
   Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9
   Bae Susan, 2018, Genes Cancer, V9, P87, DOI 10.18632/genesandcancer.172
   Bang C, 2012, INT J BIOCHEM CELL B, V44, P2060, DOI 10.1016/j.biocel.2012.08.007
   Beckedorff FC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003705
   Bellin G, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020166
   Cai ZJ, 2012, J IMMUNOL, V188, P5954, DOI 10.4049/jimmunol.1103466
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Castellano JJ, 2020, CANCERS, V12, DOI 10.3390/cancers12030734
   Challagundla KB, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv135
   Chen CH, 2020, J CLIN INVEST, V130, P404, DOI 10.1172/JCI130892
   Chen DY, 2017, ONCOL REP, V38, P2182, DOI 10.3892/or.2017.5919
   Chen D, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00739
   Chen F, 2019, NAT CELL BIOL, V21, P498, DOI 10.1038/s41556-019-0299-0
   Chen MS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210003
   Chen Y, 2020, MOL THER-NUCL ACIDS, V19, P1237, DOI 10.1016/j.omtn.2019.11.031
   Cheng CF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113447
   Cho SW, 2018, CELL, V173, P1398, DOI 10.1016/j.cell.2018.03.068
   Collins FS, 2004, NATURE, V431, P931, DOI 10.1038/nature03001
   Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x
   Cui C, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0239-2
   Cui XY, 2019, ONCOTARGETS THER, V12, P10827, DOI 10.2147/OTT.S224881
   Deng X, 2020, INT J CANCER, V146, P1700, DOI 10.1002/ijc.32608
   Deng ZB, 2009, DIABETES, V58, P2498, DOI 10.2337/db09-0216
   DeWaal D, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02733-4
   Ding L, 2018, CARCINOGENESIS, V39, P397, DOI 10.1093/carcin/bgy006
   Dong HY, 2018, INT J ONCOL, V53, P1013, DOI 10.3892/ijo.2018.4467
   Feng TB, 2019, GENE, V710, P258, DOI 10.1016/j.gene.2019.06.004
   Feng WL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1049-4
   Ferrone S, 2007, SURG ONCOL CLIN N AM, V16, P755, DOI 10.1016/j.soc.2007.08.004
   Filippov-Levy N, 2018, GYNECOL ONCOL, V148, P559, DOI 10.1016/j.ygyno.2018.01.004
   Fletcher JI, 2016, DRUG RESIST UPDATE, V26, P1, DOI 10.1016/j.drup.2016.03.001
   Fruhbeis C, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00182
   Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917
   Goldenring JR, 2015, CURR OPIN CELL BIOL, V35, P117, DOI 10.1016/j.ceb.2015.04.018
   Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755
   Hannafon BN, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0753-x
   Harada T, 2017, CANCER SCI, V108, P42, DOI 10.1111/cas.13109
   Harris KA, 2018, MICROBIOL SPECTR, V6, DOI 10.1128/microbiolspec.RWR-0005-2017
   Hess C, 1999, J IMMUNOL, V163, P4564
   HOLME PA, 1994, THROMB HAEMOSTASIS, V72, P666
   Hu HY, 2019, INT J BIOL MACROMOL, V132, P470, DOI 10.1016/j.ijbiomac.2019.03.221
   Hu QS, 2019, NAT IMMUNOL, V20, P835, DOI 10.1038/s41590-019-0400-7
   Hu TR, 2019, CELL CYCLE, V18, P3085, DOI 10.1080/15384101.2019.1669380
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Huotari J, 2011, EMBO J, V30, P3481, DOI 10.1038/emboj.2011.286
   Isin M, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00168
   Jin JJ, 2018, P NATL ACAD SCI USA, V115, pE9802, DOI 10.1073/pnas.1801471115
   Johannes L, 2008, CELL, V135, P1175, DOI 10.1016/j.cell.2008.12.009
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99
   Keller S, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-86
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kim DH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0295-2
   Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512
   Kowal J, 2016, P NATL ACAD SCI USA, V113, pE968, DOI 10.1073/pnas.1521230113
   Kumari S, 2010, CELL RES, V20, P256, DOI 10.1038/cr.2010.19
   Latos PA, 2012, SCIENCE, V338, P1469, DOI 10.1126/science.1228110
   Lee JT, 1999, NAT GENET, V21, P400, DOI 10.1038/7734
   Lee YS, 2009, GENE DEV, V23, P2639, DOI 10.1101/gad.1837609
   Li XB, 2006, J CELL MOL MED, V10, P364, DOI 10.1111/j.1582-4934.2006.tb00405.x
   Li X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102958
   Li Y, 2020, APPL BIOCHEM BIOTECH, V191, P1084, DOI 10.1007/s12010-020-03244-7
   Liang YR, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01206-5
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liu QQ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163884
   Lu Chang, 2017, Yichuan, V39, P1054, DOI 10.16288/j.yczz.17-120
   Lu RZ, 2018, CANCER BIOMARK, V22, P249, DOI 10.3233/CBM-170874
   Lu YH, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7461727
   Lugini L, 2012, J IMMUNOL, V189, P2833, DOI 10.4049/jimmunol.1101988
   Ma J, 2017, ONCOTARGET, V8, P86410, DOI 10.18632/oncotarget.21195
   Ma R, 2020, EUR REV MED PHARMACO, V24, P2601, DOI 10.26355/eurrev_202003_20529
   Ma Y, 2019, ONCOL LETT, V18, P2212, DOI 10.3892/ol.2019.10551
   Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018
   Martins TS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198820
   Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007
   Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005
   Mirzaei R, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1478647
   Ni C, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0129-7
   Ortega-Molina A, 2013, TRENDS ENDOCRIN MET, V24, P184, DOI 10.1016/j.tem.2012.11.002
   Panning Barbara, 2008, Journal of Biology (London), V7, P301, DOI 10.1186/jbiol95
   Papa S, 2019, ONCOGENE, V38, P2223, DOI 10.1038/s41388-018-0582-8
   Pasquinelli AE, 2002, ANNU REV CELL DEV BI, V18, P495, DOI 10.1146/annurev.cellbio.18.012502.105832
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Pavlaki I, 2018, EMBO J, V37, DOI 10.15252/embj.201798219
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Pfeffer SR, 2009, FEBS LETT, V583, P3811, DOI 10.1016/j.febslet.2009.10.075
   Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x
   Piper RC, 2007, ANNU REV CELL DEV BI, V23, P519, DOI 10.1146/annurev.cellbio.23.090506.123319
   Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4
   Saha S, 2002, NAT BIOTECHNOL, V20, P508, DOI 10.1038/nbt0502-508
   Segura E, 2005, BLOOD CELL MOL DIS, V35, P89, DOI 10.1016/j.bcmd.2005.05.003
   Sheff DR, 1999, J CELL BIOL, V145, P123, DOI 10.1083/jcb.145.1.123
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI [10.1586/epr.09.17, 10.1586/EPR.09.17]
   Sinha MS, 2018, ACTA NEUROPATHOL, V136, P41, DOI 10.1007/s00401-018-1868-1
   Sinkala M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0666-1
   Skokos D, 2001, J IMMUNOL, V166, P868, DOI 10.4049/jimmunol.166.2.868
   Song YB, 2020, EUR J PHARMACOL, V872, DOI 10.1016/j.ejphar.2020.172977
   Song YH, 2017, ADV EXP MED BIOL, V998, P187, DOI 10.1007/978-981-10-4397-0_13
   Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901
   Spector DL, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a000646
   St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Taguchi T, 2013, J BIOCHEM, V153, P505, DOI 10.1093/jb/mvt034
   Takahashi K, 2014, MOL CANCER RES, V12, P1377, DOI 10.1158/1541-7786.MCR-13-0636
   Takahashi K, 2014, J CELL SCI, V127, P1585, DOI 10.1242/jcs.141069
   Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309
   Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855
   Till P, 2018, APPL MICROBIOL BIOT, V102, P7319, DOI 10.1007/s00253-018-9187-y
   Tong YS, 2020, MOL THER-ONCOLYTICS, V18, P1, DOI 10.1016/j.omto.2020.05.014
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Wahlgren J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049723
   Wang HLV, 2017, ADV EXP MED BIOL, V1008, P133, DOI 10.1007/978-981-10-5203-3_5
   Wang XH, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12395
   Wang XX, 2020, J CELL PHYSIOL, V235, P6896, DOI 10.1002/jcp.29585
   Wang YL, 2019, BREAST, V46, P64, DOI 10.1016/j.breast.2019.05.003
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Watnick RS, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006676
   Wei SB, 2017, ONCOL REP, V38, P1902, DOI 10.3892/or.2017.5840
   West JA, 2014, MOL CELL, V55, P791, DOI 10.1016/j.molcel.2014.07.012
   Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271
   Wieckowski EU, 2009, J IMMUNOL, V183, P3720, DOI 10.4049/jimmunol.0900970
   Wortzel I, 2019, DEV CELL, V49, P347, DOI 10.1016/j.devcel.2019.04.011
   Wu DJ, 2017, ONCOL REP, V38, P1525, DOI 10.3892/or.2017.5806
   Wu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2426-z
   Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200
   Xia SL, 2016, NEURO-ONCOLOGY, V18, P507, DOI 10.1093/neuonc/nov171
   Xu HX, 2019, CLIN CANCER RES, V25, P1923, DOI 10.1158/1078-0432.CCR-18-2363
   Xu JC, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01562-6
   Xu R, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0665-3
   Xue M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0714-8
   Yang CJ, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/842849
   Yang Y, 2018, CELL RES, V28, P862, DOI 10.1038/s41422-018-0060-4
   Yi KN, 2019, FRONT BIOSCI-LANDMRK, V24, P777, DOI 10.2741/4750
   Yin K, 2019, BIOMARK RES, V7, DOI 10.1186/s40364-019-0159-x
   Yin Z, 2020, J CELL MOL MED, V24, P5028, DOI 10.1111/jcmm.15125
   Yoshii S, 2019, CANCER SCI, V110, P2396, DOI 10.1111/cas.14084
   Zaborowski MP, 2015, BIOSCIENCE, V65, P783, DOI 10.1093/biosci/biv084
   Zeng R, 2019, AM J TRANSL RES, V11, P7441
   Zhang L, 2019, BBA-REV CANCER, V1871, P455, DOI 10.1016/j.bbcan.2019.04.004
   Zhang Q, 2019, EMBO J, V38, DOI 10.15252/embj.2018100041
   Zhang ZR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1139-6
   Zhao W, 2019, AGING-US, V11, P9581, DOI 10.18632/aging.102406
   Zheng R, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0880-3
   Zheng ZQ, 2019, MED SCI MONITOR, V25, P2211, DOI 10.12659/MSM.915419
   Zhou LY, 2019, CURR GENE THER, V19, P172, DOI 10.2174/1566523219666190719100526
NR 152
TC 13
Z9 14
U1 5
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD MAR 5
PY 2021
VL 23
BP 1371
EP 1383
DI 10.1016/j.omtn.2020.09.039
EA MAR 2021
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA RB1FJ
UT WOS:000631861800011
PM 33738133
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Saxena, M
   Yeretssian, G
AF Saxena, Mansi
   Yeretssian, Garabet
TI NOD-like receptors: master regulators of inflammation and cancer
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE apoptosis; autophagy; colorectal cancer; innate immunity; intestinal
   inflammation; inflammasome; nod-like receptors; nodosome
ID NF-KAPPA-B; TOLL-LIKE-RECEPTOR; CASPASE RECRUITMENT DOMAIN; GENOME-WIDE
   ASSOCIATION; NLRP3 INFLAMMASOME; NALP3 INFLAMMASOME; MURAMYL DIPEPTIDE;
   CELL-DEATH; PROTEIN-KINASE; CUTTING EDGE
AB Cytosolic NOD-like receptors (NLRs) have been associated with human diseases including infections, cancer, and autoimmune and inflammatory disorders. These innate immune pattern recognition molecules are essential for controlling inflammatory mechanisms through induction of cytokines, chemokines, and anti-microbial genes. Upon activation, some NLRs form multi-protein complexes called inflammasomes, while others orchestrate caspase-independent nuclear factor kappa B (NE-kappa B) and mitogen activated protein kinase (MARK) signaling. Moreover, NLRs and their downstream signaling components engage in an intricate crosstalk with cell death and autophagy pathways, both critical processes for cancer development. Recently, increasing evidence has extended the concept that chronic inflammation caused by abberant NLR signaling is a powerful driver of carcinogenesis, where it abets genetic mutations, tumor growth, and progression. In this review, we explore the rapidly expanding area of research regarding the expression and functions of NLRs in different types of cancers. Furthermore, we particularly focus on how maintaining tissue homeostasis and regulating tissue repair may provide a logical platform for understanding the liaisons between the NLR-driven inflammatory responses and cancer. Finally, we outline novel therapeutic approaches that target NLR signaling and speculate how these could be developed as potential pharmaceutical alternatives for cancer treatment.
C1 [Saxena, Mansi; Yeretssian, Garabet] Icahn Sch Med Mt Sinai, Inst Immunol, Dept Med, New York, NY 10029 USA.
   [Yeretssian, Garabet] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA.
RP Yeretssian, G (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, Clin Immunol Immunol Inst, Dept Med, 1425 Madison Ave,12-20E, New York, NY 10029 USA.
EM garabet.yeretssian@mssm.edu
OI Saxena, Mansi/0000-0001-5482-3158; Saleh, Maya/0000-0003-1538-9146
FU Helmsley Foundation
FX We thank all the Yeretssian lab members for the insightful and critical
   reading of the manuscript. This work was supported by the Helmsley
   Foundation.
CR Abbott DW, 2007, MOL CELL BIOL, V27, P6012, DOI 10.1128/MCB.00270-07
   Abbott DW, 2004, CURR BIOL, V14, P2217, DOI 10.1016/j.cub.2004.12.032
   Abdul-Sater AA, 2010, J BIOL CHEM, V285, P41637, DOI 10.1074/jbc.M110.137885
   Agostini L, 2004, IMMUNITY, V20, P319, DOI 10.1016/S1074-7613(04)00046-9
   Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012
   Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026
   Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005
   Arthur JC, 2007, J IMMUNOL, V179, P6291, DOI 10.4049/jimmunol.179.9.6291
   Arthur JC, 2010, J IMMUNOL, V185, P4515, DOI 10.4049/jimmunol.1002227
   Ayna G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040069
   Bai LC, 2014, PHARMACOL THERAPEUT, V144, P82, DOI 10.1016/j.pharmthera.2014.05.007
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bauernfeind F, 2011, J IMMUNOL, V187, P613, DOI 10.4049/jimmunol.1100613
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955
   Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014
   Bertrand MJM, 2009, IMMUNITY, V30, P789, DOI 10.1016/j.immuni.2009.04.011
   Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164
   Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711
   Borghini S, 2011, ARTHRITIS RHEUM-US, V63, P830, DOI 10.1002/art.30170
   Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999
   Bruey JM, 2007, CELL, V129, P45, DOI 10.1016/j.cell.2007.01.045
   Busca A, 2012, J BIOL CHEM, V287, P15118, DOI 10.1074/jbc.M111.312660
   Busca A, 2009, CURR GENOMICS, V10, P306, DOI 10.2174/138920209788920967
   Cassel SL, 2008, P NATL ACAD SCI USA, V105, P9035, DOI 10.1073/pnas.0803933105
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
   Chen GY, 2011, J IMMUNOL, V186, P7187, DOI 10.4049/jimmunol.1100412
   Chen GY, 2008, CANCER RES, V68, P10060, DOI 10.1158/0008-5472.CAN-08-2061
   Chin AI, 2002, NATURE, V416, P190, DOI 10.1038/416190a
   Chow MT, 2012, CANCER RES, V72, P5721, DOI 10.1158/0008-5472.CAN-12-0509
   Chretien AS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00122
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Correia JD, 2007, CELL DEATH DIFFER, V14, P830, DOI 10.1038/sj.cdd.4402070
   Correia JD, 2006, P NATL ACAD SCI USA, V103, P1840, DOI 10.1073/pnas.0509228103
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236
   Craven RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007446
   Damgaard RB, 2013, EMBO MOL MED, V5, P1278, DOI 10.1002/emmm.201303090
   Damgaard RB, 2012, MOL CELL, V46, P746, DOI 10.1016/j.molcel.2012.04.014
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   de Martel C, 2009, CRIT REV ONCOL HEMAT, V70, P183, DOI 10.1016/j.critrevonc.2008.07.021
   Diez E, 2003, NAT GENET, V33, P55, DOI 10.1038/ng1065
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Dostert C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006510
   Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012
   Easwaran H, 2014, MOL CELL, V54, P716, DOI 10.1016/j.molcel.2014.05.015
   Eickhoff J, 2004, J BIOL CHEM, V279, P9642, DOI 10.1074/jbc.M312893200
   Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939
   Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022
   Ershler WB, 2000, ANNU REV MED, V51, P245, DOI 10.1146/annurev.med.51.1.245
   Faustin B, 2009, P NATL ACAD SCI USA, V106, P3935, DOI 10.1073/pnas.0809414106
   Franchi L, 2012, NAT IMMUNOL, V13, P449, DOI 10.1038/ni.2263
   Franchi L, 2012, NAT IMMUNOL, V13, P325, DOI 10.1038/ni.2231
   Fujimura T, 2011, J DERMATOL SCI, V62, P107, DOI 10.1016/j.jdermsci.2011.02.002
   Fukazawa A, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000228
   Galluzzi L, 2012, EMBO REP, V13, P322, DOI 10.1038/embor.2012.19
   Garaude J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002868
   Ghonime MG, 2014, J IMMUNOL, V192, P3881, DOI 10.4049/jimmunol.1301974
   Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200
   Girardin SE, 2003, J BIOL CHEM, V278, P41702, DOI 10.1074/jbc.M307198200
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Gombault A, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00414
   Goubau D, 2013, IMMUNITY, V38, P855, DOI 10.1016/j.immuni.2013.05.007
   Grenier JM, 2002, FEBS LETT, V530, P73, DOI 10.1016/S0014-5793(02)03416-6
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Guarda G, 2011, J IMMUNOL, V186, P2529, DOI 10.4049/jimmunol.1002720
   Gurung P, 2014, J IMMUNOL, V192, P1835, DOI 10.4049/jimmunol.1302839
   Gurung P, 2012, J BIOL CHEM, V287, P34474, DOI 10.1074/jbc.M112.401406
   Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889
   Hager KM, 2014, CARCINOGENESIS, V35, P740, DOI 10.1093/carcin/bgt487
   Halle A, 2008, NAT IMMUNOL, V9, P857, DOI 10.1038/ni.1636
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen JD, 2011, DEV COMP IMMUNOL, V35, P886, DOI 10.1016/j.dci.2011.01.008
   Hardison SE, 2012, NAT IMMUNOL, V13, P817, DOI 10.1038/ni.2369
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962
   Hawkins CJ, 1996, P NATL ACAD SCI USA, V93, P13786, DOI 10.1073/pnas.93.24.13786
   Hnatyszyn A, 2010, EXP MOL PATHOL, V88, P388, DOI 10.1016/j.yexmp.2010.03.003
   Hoffman HM, 2001, NAT GENET, V29, P301, DOI 10.1038/ng756
   Homer CR, 2012, J BIOL CHEM, V287, P25565, DOI 10.1074/jbc.M111.326835
   Homer CR, 2010, GASTROENTEROLOGY, V139, P1630, DOI 10.1053/j.gastro.2010.07.006
   Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631
   Hu B, 2011, CELL CYCLE, V10, P1936, DOI 10.4161/cc.10.12.16008
   Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108
   Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Huzarski T, 2005, BREAST CANCER RES TR, V89, P91, DOI 10.1007/s10549-004-1250-y
   Inohara N, 2000, J BIOL CHEM, V275, P27823
   Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560
   Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296
   Itzkowitz S, 2003, J CLIN GASTROENTEROL, V36, pS70, DOI 10.1097/00004836-200305001-00012
   Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Janowski AM, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00370
   Jeru I, 2008, P NATL ACAD SCI USA, V105, P1614, DOI 10.1073/pnas.0708616105
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Juliana C, 2012, J BIOL CHEM, V287, P36617, DOI 10.1074/jbc.M112.407130
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kanneganti TD, 2006, NATURE, V440, P233, DOI 10.1038/nature04517
   Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008
   Kanneganti TD, 2006, J BIOL CHEM, V281, P36560, DOI 10.1074/jbc.M607594200
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   Keestra AM, 2013, NATURE, V496, P233, DOI 10.1038/nature12025
   Kelly PN, 2011, CELL DEATH DIFFER, V18, P1414, DOI 10.1038/cdd.2011.17
   Khasawneh J, 2009, P NATL ACAD SCI USA, V106, P3354, DOI 10.1073/pnas.0802864106
   Kingsbury SR, 2011, J INFLAMM RES, V4, P39, DOI 10.2147/JIR.S11330
   Krieg A, 2009, P NATL ACAD SCI USA, V106, P14524, DOI 10.1073/pnas.0907131106
   Kufer TA, 2008, CELL MICROBIOL, V10, P477, DOI 10.1111/j.1462-5822.2007.01062.x
   Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006
   Kutikhin AG, 2011, HUM IMMUNOL, V72, P955, DOI 10.1016/j.humimm.2011.06.003
   Labbe K, 2011, IMMUNITY, V35, P897, DOI 10.1016/j.immuni.2011.10.016
   Lamkanfi M, 2012, ANNU REV CELL DEV BI, V28, P137, DOI 10.1146/annurev-cellbio-101011-155745
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lee GS, 2012, NATURE, V492, P123, DOI 10.1038/nature11588
   Lee J, 2009, J BIOL CHEM, V284, P23818, DOI 10.1074/jbc.M109.033670
   Lei Y, 2013, AUTOPHAGY, V9, P432, DOI 10.4161/auto.23026
   Lei Y, 2012, IMMUNITY, V36, P933, DOI 10.1016/j.immuni.2012.03.025
   Lener MR, 2006, BREAST CANCER RES TR, V95, P141, DOI 10.1007/s10549-005-9057-z
   Lich JD, 2007, J IMMUNOL, V178, P1256, DOI 10.4049/jimmunol.178.3.1256
   Lightfield KL, 2008, NAT IMMUNOL, V9, P1171, DOI 10.1038/ni.1646
   Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563
   Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114
   Macaluso F, 2007, EXP DERMATOL, V16, P692, DOI 10.1111/j.1600-0625.2007.00589.x
   Magalhaes JG, 2011, EUR J IMMUNOL, V41, P1445, DOI 10.1002/eji.201040827
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997
   Marina-Garcia N, 2009, J IMMUNOL, V182, P4321, DOI 10.4049/jimmunol.0802197
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Maruyama K, 2000, ONCOLOGY-BASEL, V59, P302, DOI 10.1159/000012187
   McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968
   McNeela EA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001191
   Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195
   Millrud CR, 2013, ACTA OTO-LARYNGOL, V133, P1333, DOI 10.3109/00016489.2013.831476
   Moore CB, 2008, NATURE, V451, P573, DOI 10.1038/nature06501
   MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722
   Muniz LR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00310
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Murakami T, 2012, P NATL ACAD SCI USA, V109, P11282, DOI 10.1073/pnas.1117765109
   Nachbur U, 2012, NATURE, V488, pE4, DOI 10.1038/nature11366
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakamura N, 2014, NATURE, V509, P240, DOI 10.1038/nature13133
   Nassiri M, 2013, ASIAN PAC J CANCER P, V14, P5609, DOI 10.7314/APJCP.2013.14.10.5609
   Navas TA, 1999, J BIOL CHEM, V274, P33684, DOI 10.1074/jbc.274.47.33684
   Nembrini C, 2009, J BIOL CHEM, V284, P19183, DOI 10.1074/jbc.M109.006353
   Netea MG, 2009, BLOOD, V113, P2324, DOI 10.1182/blood-2008-03-146720
   Nickerson K, 2001, J BIOL CHEM, V276, P19089, DOI 10.1074/jbc.M101295200
   Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89
   Nitta Y, 2000, ONCOL RES, V12, P25
   Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108
   Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200
   Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   Park JH, 2007, J IMMUNOL, V178, P2380, DOI 10.4049/jimmunol.178.4.2380
   Pastorelli L, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00280
   Philpott DJ, 2014, NAT REV IMMUNOL, V14, P9, DOI 10.1038/nri3565
   Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105
   Rajan JV, 2010, FEBS LETT, V584, P4627, DOI 10.1016/j.febslet.2010.10.036
   Rathinam VAK, 2012, CELL, V150, P606, DOI 10.1016/j.cell.2012.07.007
   Ratsimandresy RA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00440
   Reardon C, 2009, IMMUNITY, V30, P755, DOI 10.1016/j.immuni.2009.06.005
   Rebsamen M, 2011, CELL DEATH DIFFER, V18, P1387, DOI 10.1038/cdd.2011.64
   Reuter BK, 2004, EUR J IMMUNOL, V34, P2347, DOI 10.1002/eji.200425351
   Rigoli L, 2010, ANTICANCER RES, V30, P513
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Rossol M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2339
   Sadasivam S, 2005, ONCOGENE, V24, P627, DOI 10.1038/sj.onc.1208201
   Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199
   Salinger Andrew P, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4985
   Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866
   Saxena M, 2011, J IMMUNOL, V187, P5865, DOI 10.4049/jimmunol.1100115
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584
   Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Siegmund B, 2010, IMMUNITY, V32, P300, DOI 10.1016/j.immuni.2010.03.010
   Soares F, 2013, INNATE IMMUN-LONDON, V19, P438, DOI 10.1177/1753425912467383
   Sorbara MT, 2013, IMMUNITY, V39, P858, DOI 10.1016/j.immuni.2013.10.013
   Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307
   Subramanian N, 2013, CELL, V153, P348, DOI 10.1016/j.cell.2013.02.054
   Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004
   Suzuki Y, 2001, J BIOL CHEM, V276, P27058, DOI 10.1074/jbc.M102415200
   Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008
   Tanaka T, 2003, CANCER SCI, V94, P965, DOI 10.1111/j.1349-7006.2003.tb01386.x
   Tao MF, 2009, CURR BIOL, V19, P1255, DOI 10.1016/j.cub.2009.06.038
   Tattoli I, 2008, EMBO REP, V9, P293, DOI 10.1038/sj.embor.7401161
   Terme M, 2012, CANCER RES, V72, P2757, DOI 10.1158/0008-5472.CAN-11-3379
   Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993
   Thomas PG, 2009, IMMUNITY, V30, P566, DOI 10.1016/j.immuni.2009.02.006
   Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1
   Tigno-Aranjuez JT, 2010, GENE DEV, V24, P2666, DOI 10.1101/gad.1964410
   Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005
   Tokunaga F, 2012, ENDOCR J, V59, P641, DOI 10.1507/endocrj.EJ12-0148
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Ungerback J, 2012, CARCINOGENESIS, V33, P2126, DOI 10.1093/carcin/bgs256
   Verma D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034977
   Verma D, 2012, PIGM CELL MELANOMA R, V25, P506, DOI 10.1111/j.1755-148X.2012.01008.x
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
   Villani AC, 2009, NAT GENET, V41, P71, DOI 10.1038/ng.285
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174
   Vladimer GI, 2012, IMMUNITY, V37, P96, DOI 10.1016/j.immuni.2012.07.006
   Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200
   Watanabe T, 2008, J CLIN INVEST, V118, P545, DOI [10.1172/JC133145, 10.1172/JCI33145]
   Watanabe T, 2010, J CLIN INVEST, V120, P1645, DOI 10.1172/JCI39481
   Wei Q, 2014, LAB INVEST, V94, P52, DOI 10.1038/labinvest.2013.126
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Williams KL, 2005, J BIOL CHEM, V280, P39914, DOI 10.1074/jbc.M502820200
   Windheim M, 2007, BIOCHEM J, V404, P179, DOI 10.1042/BJ20061704
   Wright EK, 2003, CURR BIOL, V13, P27, DOI 10.1016/S0960-9822(02)01359-3
   Xia XJ, 2011, IMMUNITY, V34, P843, DOI 10.1016/j.immuni.2011.02.022
   Yamada Y, 2007, CANCER SCI, V98, P6, DOI 10.1111/j.1349-7006.2006.00348.x
   Yanagawa H, 2000, LUNG CANCER, V27, P67, DOI 10.1016/S0169-5002(99)00090-2
   Yang YB, 2007, J BIOL CHEM, V282, P36223, DOI 10.1074/jbc.M703079200
   Yeretssian G, 2012, IMMUNOL RES, V54, P25, DOI 10.1007/s12026-012-8317-3
   Yeretssian G, 2012, NATURE, V488, pE6, DOI 10.1038/nature11367
   Yeretssian G, 2011, NATURE, V474, P96, DOI 10.1038/nature09982
   Yeretssian G, 2008, CYTOKINE, V43, P380, DOI 10.1016/j.cyto.2008.07.015
   Yomade O, 2013, ANN HEMATOL, V92, P1071, DOI 10.1007/s00277-013-1734-0
   YOO YC, 1994, VACCINE, V12, P175
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022
   Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003
   Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
   Zhong ZY, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2608
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zitvogel L, 2012, NAT IMMUNOL, V13, P343, DOI 10.1038/ni.2224
NR 241
TC 130
Z9 133
U1 2
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JUL 14
PY 2014
VL 5
AR 327
DI 10.3389/fimmu.2014.00327
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA CH9SZ
UT WOS:000354377900001
PM 25071785
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shi, CH
   Wu, J
   Fu, M
   Zhang, BH
   Wang, J
   Yang, X
   Chi, YP
AF Shi, Conghong
   Wu, Jing
   Fu, Min
   Zhang, Baohong
   Wang, Juan
   Yang, Xi
   Chi, Yunpeng
TI Ambra1 modulates starvation-induced autophagy through AMPK signaling
   pathway in cardiomyocytes
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Autophagy; Ambra1; Cardiomyocytes
ID COLORECTAL-CANCER CELLS; REGULATES AUTOPHAGY; APOPTOSIS; MTOR;
   CLEARANCE; RADICALS; DISEASE; INJURY; HEALTH
AB Recent research has revealed a role for Ambra1, an autophagy-related gene-related (ATG) protein, in the autophagic pro-survival response, and Ambra1 has been shown to regulate Beclin1 and Beclin1-dependent autophagy in embryonic stem cells and cancer cells. However, whether Ambra1 plays an important role in the autophagy pathway in cardiomyocytes is unknown. In this study, we hypothesized that Ambra1 is an important regulator of autophagy and apoptosis in cardiomyocytes. To test this hypothesis, we confirmed autophagic activity in serum-starved cardiomyocytes by assessing endogenous microtubule-associated protein 1 light chain 3 (LC3) localization, the presence of autophagosomes and LC3 protein levels. Cell apoptosis and viability were measured by annexin-V and PI staining and MTT assays. We determined that serum deprivation-induced autophagy was associated with Ambra1 upregulation in cardiomyocytes. When Ambra1 expression was reduced by siRNA, the cardiomyocytes were more sensitive to staurosporine-induced apoptosis. In addition, co-immunoprecipitation of Ambra1 and Beclin1 demonstrated that Ambra1 and Beclin1 interact in serum-starved or rapamycin-treated cardiomyocytes, suggesting that Ambra1 regulates autophagy in cardiomyocytes by interacting with Beclin1. Finally, we determined that starvation stress-induced activation of Ambra1 contributes to the attenuation of adaptive AMP-activated protein kinase (AMPK) signaling. In conclusion, Ambra1 is a crucial regulator of autophagy and apoptosis through AMPK signaling pathway in cardiomyocytes that maintains the balance between autophagy and apoptosis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Chi, Yunpeng] Capital Univ Med Sci, Beijing Anzhen Hosp, Beijing 100029, Peoples R China.
   [Shi, Conghong; Fu, Min; Zhang, Baohong; Wang, Juan] Baotou Fourth Hosp, Baoutou, Inner Mongolia, Peoples R China.
   [Wu, Jing] Inner Mongolia Med Univ, Affiliated Hosp, Image Sect, Hohhot, Inner Mongolia, Peoples R China.
   [Yang, Xi] Inner Mongolia Med Univ, Teaching & Res Sect Human Anat & Histol, Hohhot, Inner Mongolia, Peoples R China.
RP Chi, YP (corresponding author), Capital Univ Med Sci, Beijing Anzhen Hosp, Beijing 100029, Peoples R China.
EM ypchiaz@163.com
CR Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609
   Boya P, 2008, BIOCHEM SOC T, V36, P813, DOI 10.1042/BST0360813
   Cheng TO, 1999, HOSP MED, V60, P456
   Dutta D, 2013, AUTOPHAGY, V9, P328, DOI 10.4161/auto.22971
   Fan YJ, 2013, CHIN J CANCER, V32, P121, DOI 10.5732/cjc.012.10106
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Fimia GM, 2011, AUTOPHAGY, V7, P115, DOI 10.4161/auto.7.1.14071
   GOLDHABER JI, 1992, HYPERTENSION, V20, P118, DOI 10.1161/01.HYP.20.1.118
   Gu W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090151
   Harhaji-Trajkovic L, 2009, J CELL MOL MED, V13, P3644, DOI 10.1111/j.1582-4934.2009.00663.x
   HESS ML, 1979, J SURG RES, V26, P175, DOI 10.1016/0022-4804(79)90097-0
   Holt SV, 2011, TOXICOL PATHOL, V39, P516, DOI 10.1177/0192623310396903
   Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537
   JEROUDI MO, 1994, AM J CARDIOL, V73, pB2, DOI 10.1016/0002-9149(94)90257-7
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kundu M, 2008, BLOOD, V112, P1493, DOI 10.1182/blood-2008-02-137398
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2009, METHOD ENZYMOL, V452, P13, DOI 10.1016/S0076-6879(08)03602-1
   Pagliarini V, 2012, CELL DEATH DIFFER, V19, P1495, DOI 10.1038/cdd.2012.27
   Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143
   Reiter RJ, 2003, CARDIOVASC RES, V58, P10, DOI 10.1016/S0008-6363(02)00827-1
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Sakoda H, 2002, AM J PHYSIOL-ENDOC M, V282, pE1239, DOI 10.1152/ajpendo.00455.2001
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Singh R, 2009, J CLIN INVEST, V119, P3329, DOI 10.1172/JCI39228
   Srinivas V, 2009, CELLS TISSUES ORGANS, V189, P88, DOI 10.1159/000151428
   Strappazzon F, 2011, EMBO J, V30, P1195, DOI 10.1038/emboj.2011.49
   Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016
   Tsujimoto Y, 2005, CELL DEATH DIFFER, V12, P1528, DOI 10.1038/sj.cdd.4401777
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
NR 35
TC 10
Z9 10
U1 1
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 26
PY 2014
VL 452
IS 3
BP 308
EP 314
DI 10.1016/j.bbrc.2014.08.017
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AQ7UE
UT WOS:000343023900002
PM 25117440
DA 2022-04-25
ER

PT J
AU Zhang, SH
   Zhou, L
   Zhang, MD
   Wang, YH
   Wang, MQ
   Du, JC
   Gu, WW
   Kui, FG
   Li, JH
   Geng, SN
   Du, GJ
AF Zhang, Shuhui
   Zhou, Lin
   Zhang, Mengdi
   Wang, Yuehua
   Wang, Mengqi
   Du, Jincheng
   Gu, Wenwen
   Kui, Fuguang
   Li, Jiahuan
   Geng, Shengnan
   Du, Gangjun
TI Berberine Maintains the Neutrophil N1 Phenotype to Reverse Cancer Cell
   Resistance to Doxorubicin
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE berberine; doxorubicin; neutrophil phenotype; carcinogenesis;
   chemotherapeutic resistance
ID BREAST-CANCER; PERITONEAL CARCINOMATOSIS; SYSTEMIC CHEMOTHERAPY;
   COLORECTAL-CANCER; APOPTOSIS; CYCLOPHOSPHAMIDE; MICROENVIRONMENT;
   COMBINATION; AUTOPHAGY; THERAPY
AB This study explores the contributions of neutrophils to chemotherapeutic resistance and berberine-regulated cancer cell sensitivity to doxorubicin (DOX). In vitro experiments, continuous DOX treatment led to the shift of HL-60 cells to N2 neutrophils and thus induced chemotherapeutic resistance. The combination treatment with DOX and 2 mu M berberine resulted in the differentiation of HL-60 cells toward N1 and therefore stimulated HL-60 cell immune clearance. Berberine increased reactive oxygen species (ROS) and decreased autophagy and therefore induced apoptosis in HL-60-N2 cells with morphological changes, but had no effect on cell viability in HL-60-N1 cells. The neutrophil-regulating efficacy of berberine was confirmed in the urethane-induced lung carcinogenic model and H22 liver cancer allograft model. Furthermore, we found that DOX-derived neutrophils had high levels of CD133 and CD309 surface expression, which prevented both chemotherapeutic sensitivity and immune rejection by self-expression of PD-L1 and surface expression of PD-1 receptor on T cells, whereas berberine could downregulate CD133 and CD309 surface expression. Finally, berberine-relevant targets and pathways were evaluated. This study first suggests an important role of berberine in regulating neutrophil phenotypes to maintain cancer cell sensitivity to DOX.
C1 [Zhang, Shuhui; Zhou, Lin; Zhang, Mengdi; Wang, Yuehua; Wang, Mengqi; Du, Jincheng; Gu, Wenwen; Kui, Fuguang; Li, Jiahuan; Du, Gangjun] Henan Univ, Pharmaceut Coll, Inst Pharm, Kaifeng, Peoples R China.
   [Geng, Shengnan; Du, Gangjun] Zhengzhou Univ Ind Technol, Sch Pharm & Chem Engn, Xinzheng, Peoples R China.
   [Du, Jincheng] Hunan Univ Chinese Med, Chinese Med Sch, Changsha, Peoples R China.
RP Li, JH; Du, GJ (corresponding author), Henan Univ, Pharmaceut Coll, Inst Pharm, Kaifeng, Peoples R China.; Geng, SN; Du, GJ (corresponding author), Zhengzhou Univ Ind Technol, Sch Pharm & Chem Engn, Xinzheng, Peoples R China.
EM jiahuan1020@126.com; 1017172540@qq.com; 10200029@vip.henu.edu.cn
FU Natural Science Foundation of Henan Province [182300410310];
   Postgraduate Education Reform Project of Henan Province [hnyjs2015kc24];
   Postgraduate Education Innovation and Quality Improvement Project of
   Henan University [SYL18060136, SYL18060137, SYL19060140, SYL19060139]
FX Natural Science Foundation of Henan Province (No. 182300410310).
   Postgraduate Education Reform Project of Henan Province (No.
   hnyjs2015kc24). Postgraduate Education Innovation and Quality
   Improvement Project of Henan University (No. SYL18060136, SYL18060137,
   SYL19060140 and SYL19060139).
CR Almzaiel AJ, 2013, LIFE SCI, V93, P125, DOI 10.1016/j.lfs.2013.06.003
   Amini MA, 2019, JNCI-J NATL CANCER I, V111, P399, DOI 10.1093/jnci/djy131
   Nicolas-Avila JA, 2017, IMMUNITY, V46, P15, DOI 10.1016/j.immuni.2016.12.012
   Berns K, 2017, CANCER CELL, V31, P169, DOI 10.1016/j.ccell.2017.01.013
   Bohm S, 2016, CLIN CANCER RES, V22, P3025, DOI 10.1158/1078-0432.CCR-15-2657
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   Chen GR, 2017, INT IMMUNOPHARMACOL, V46, P87, DOI 10.1016/j.intimp.2017.02.025
   Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307
   Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282
   Daniels BP, 2017, CELL, V169, P301, DOI 10.1016/j.cell.2017.03.011
   Du GJ, 2013, INT IMMUNOPHARMACOL, V17, P245, DOI 10.1016/j.intimp.2013.06.018
   Du GJ, 2010, INT IMMUNOPHARMACOL, V10, P819, DOI 10.1016/j.intimp.2010.04.018
   Eruslanov EB, 2014, J CLIN INVEST, V124, P5466, DOI 10.1172/JCI77053
   Fillmore CM, 2015, NATURE, V520, P239, DOI 10.1038/nature14122
   Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017
   Garg AD, 2017, CELL DEATH DIFFER, V24, P832, DOI 10.1038/cdd.2017.15
   Grenader T, 2016, BRIT J CANCER, V114, P612, DOI 10.1038/bjc.2016.23
   Guo ZZ, 2017, J ETHNOPHARMACOL, V196, P29, DOI 10.1016/j.jep.2016.12.010
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hou D, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.471
   Hunter KA, 2018, MOL DIAGN THER, V22, P1, DOI 10.1007/s40291-017-0308-6
   Kaewkangsadan V, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/4757405
   Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026
   Kong XJ, 2017, NATURE, V550, P270, DOI 10.1038/nature24037
   Kono K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.207
   Kuijpers AM, 2014, ANN ONCOL, V25, P864, DOI 10.1093/annonc/mdu031
   Li J, 2015, MOL MED REP, V12, P4572, DOI 10.3892/mmr.2015.3926
   Li YJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0173-6
   Li ZB, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1838-y
   Liu LX, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143438
   Ma XF, 2016, TOXICOL LETT, V240, P130, DOI 10.1016/j.toxlet.2015.10.021
   Matei D, 2019, NEW ENGL J MED, V380, P2317, DOI 10.1056/NEJMoa1813181
   Pan X, 2016, EXP THER MED, V12, P2161, DOI 10.3892/etm.2016.3611
   Pan Y, 2017, J CANCER, V8, P1679, DOI 10.7150/jca.19106
   Pan Y, 2017, INT J BIOL SCI, V13, P794, DOI 10.7150/ijbs.18969
   Patel S, 2018, NAT IMMUNOL, V19, P1236, DOI 10.1038/s41590-018-0229-5
   Pollyea DA, 2018, J LEUKOCYTE BIOL, V104, P641, DOI 10.1002/JLB.5AB1017-419RR
   Ponzetta A, 2019, CELL, V178, P346, DOI 10.1016/j.cell.2019.05.047
   Riffelmacher T, 2017, IMMUNITY, V47, P466, DOI 10.1016/j.immuni.2017.08.005
   Rincon E, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4957-6
   Royer B, 2016, J CLIN ONCOL, V34, P2125, DOI 10.1200/JCO.2015.63.1929
   Sagiv JY, 2015, CELL REP, V10, P562, DOI 10.1016/j.celrep.2014.12.039
   Su ZX, 2019, YONSEI MED J, V60, P22, DOI 10.3349/ymj.2019.60.1.22
   Tap WD, 2016, LANCET, V388, P488, DOI 10.1016/S0140-6736(16)30587-6
   Thomas A, 2018, J CLIN ONCOL, V36, P1594, DOI 10.1200/JCO.2017.76.6915
   Uderhardt S, 2019, CELL, V177, P541, DOI 10.1016/j.cell.2019.02.028
   Veglia F, 2019, NATURE, V569, P73, DOI 10.1038/s41586-019-1118-2
   Verwaal VJ, 2003, J CLIN ONCOL, V21, P3737, DOI 10.1200/JCO.2003.04.187
   Wculek SK, 2015, NATURE, V528, P413, DOI 10.1038/nature16140
   Wojtaszek JL, 2019, CELL, V178, P152, DOI 10.1016/j.cell.2019.05.028
   Yang L, 2019, ANIM SCI J, V90, P1229, DOI 10.1111/asj.13255
   Yaseen R, 2017, J NEGAT RESULTS BIOM, V16, DOI 10.1186/s12952-017-0067-2
   Younes A, 2014, LANCET ONCOL, V15, P1019, DOI 10.1016/S1470-2045(14)70311-0
   Zhao YW, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12393
   Zhu XX, 2017, ONCOTARGET, V8, P97671, DOI 10.18632/oncotarget.18311
   Zou K, 2017, ACTA PHARMACOL SIN, V38, P157, DOI 10.1038/aps.2016.125
NR 56
TC 10
Z9 11
U1 3
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 29
PY 2020
VL 10
AR 1658
DI 10.3389/fphar.2019.01658
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KM7BY
UT WOS:000514296000001
PM 32063859
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wang, KS
   Chan, CK
   Hidayat, AFA
   Wong, YH
   Kadir, HA
AF Wang, Kar Suen
   Chan, Chim Kei
   Hidayat, Ahmad Fadhlurrahman Ahmad
   Wong, Yau Hsiung
   Kadir, Habsah Abdul
TI Clinacanthus nutans induced reactive oxygen species-dependent apoptosis
   and autophagy in HCT116 human colorectal cancer cells
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Apoptosis; autophagy; Clinacanthus nutans; colorectal cancer; reactive
   oxygen species
ID LUPEOL INHIBITS PROLIFERATION; OXIDATIVE STRESS; DEATH; ROS; GENERATION;
   NECROSIS; LC3
AB Background: Clinacanthus nutans (Burm.f.) Lindau is a medicinal herb that is conventionally used for the treatment of skin rashes, insect bites, snake bites, diabetes, and cancer. Objective: Our study aims to investigate the apoptosis- and autophagy-inducing effects of C. nutans in HCT116 human colorectal cancer cells. Materials and Methods: Cytotoxicity of ethanol extract, hexane, ethyl acetate, and aqueous fractions of C. nutans against various cancer cell lines was determined via MTT assay. Apoptosis assays including annexin V, mito-ID, and Hoechst 33342/propidium iodide staining were carried out. The level of intracellular reactive oxidative species was determined using flow cytometry. Western blot analysis was carried out to assess the protein expression in C. nutans ethyl acetate fraction (CNEAF)-treated HCT116 cells. Results: CNEAF was found to exert the strongest cytotoxic effect against HCT116 cells (IC50 =48.81 1.44 mg/mL). CNEAF-induced apoptosis was evidenced by nuclear morphological alterations, phosphatidylserine externalization, dissipation of mitochondrial membrane potential, and elevation of intracellular reactive oxygen species (ROS) level. Dissipation of mitochondrial membrane potential was attributed to the upregulation of Bax and Bak accompanied by downregulation of Bcl-2 and Bcl-xL, leading to caspase-3, -9, -8, and -10 activation. Interestingly, an upregulation of death receptor 5 was detected, suggesting involvement of intrinsic and extrinsic pathways. In addition, the occurrence of autophagy by CNEAF was supported by LC-3 accumulation and p62 degradation. The reduction of intracellular ROS level by N-acetylcysteine showed that the apoptosis and autophagy induced by CNEAF is ROS dependent. Conclusions: CNEAF induced ROS-dependent apoptosis and autophagy on HCT116 cells. Abbreviations used: CNEAF: Clinacanthus nutans ethyl acetate fraction; ROS: Reactive oxygen species; PS: Phosphatidylserine; NAC:N-Acetyl Cysteine; Bax: Bcl-2-associated X; Bcl-2: B-cell lymphoma 2; DR-5: Death receptor 5 Bak: Bcl-2-antagonist/killer 1; Bcl-xL: B-cell lymphoma-extra large.
C1 [Wang, Kar Suen; Chan, Chim Kei; Hidayat, Ahmad Fadhlurrahman Ahmad; Kadir, Habsah Abdul] Univ Malaya, Inst Biol Sci, Fac Sci, Kuala Lumpur 50603, Malaysia.
   [Wong, Yau Hsiung] Taylors Univ Lakeside Campus, Sch Liberal Art & Sci, Dept Math & Comp Sci, Subang Jaya, Selangor Darul, Malaysia.
RP Kadir, HA (corresponding author), Univ Malaya, Inst Biol Sci, Fac Sci, Kuala Lumpur 50603, Malaysia.
EM habsah@um.edu.my
RI Hsiung, Wong Yau/AAC-7291-2022
OI Hsiung, Wong Yau/0000-0001-8050-1064
CR Alam A., 2016, CLINACANTHUS NUTANS, V9, P402, DOI DOI 10.1016/j.apjtm.2016.03.011
   Arullappan S, 2014, TROP J PHARM RES, V13, P1455, DOI 10.4314/tjpr.v13i9.11
   Ashkenazi A, 2008, CYTOKINE GROWTH F R, V19, P325, DOI 10.1016/j.cytogfr.2008.04.001
   Awad AB, 2007, PHYTOMEDICINE, V14, P747, DOI 10.1016/j.phymed.2007.01.003
   Awan A.J., 2014, INT J PHARM PHARM SC, V10, P44
   Baskar AA, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-24
   Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002
   Bold RJ, 1997, SURG ONCOL, V6, P133, DOI 10.1016/S0960-7404(97)00015-7
   Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891-5849(97)00007-5
   Bursch W, 2000, ANN NY ACAD SCI, V926, P1, DOI 10.1111/j.1749-6632.2000.tb05594.x
   Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234
   Chen Y, 2008, CELL DEATH DIFFER, V15, P171, DOI 10.1038/sj.cdd.4402233
   Duan P, 2016, TOXICOLOGY, V341, P28, DOI 10.1016/j.tox.2016.01.004
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   Edlich F, 2016, CELL DEATH BIOL DIS, P69, DOI 10.1007/978-1-4939-3612-0_4
   Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fong SY, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1348-x
   Fulda S, 2015, SEMIN CELL DEV BIOL, V39, P20, DOI 10.1016/j.semcdb.2015.01.006
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Li L, 2012, FREE RADICAL BIO MED, V53, P1399, DOI 10.1016/j.freeradbiomed.2012.07.011
   Liu Y, 2016, CYTOTECHNOLOGY, V68, P123, DOI 10.1007/s10616-014-9763-7
   Liu Y, 2015, N-S ARCH PHARMACOL, V388, P295, DOI 10.1007/s00210-014-1071-4
   Lu YP, 2016, EUR J PHARMACOL, V771, P130, DOI 10.1016/j.ejphar.2015.12.026
   Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012
   Paglin S, 2001, CANCER RES, V61, P439
   Park KW, 2014, INT J ONCOL, V44, P1309, DOI 10.3892/ijo.2014.2281
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Pongmuangmul S, 2016, ASIAN PAC J TROP BIO, V6, P192, DOI 10.1016/j.apjtb.2015.12.014
   Rauth S, 2016, MOL CELL BIOCHEM, V417, P97, DOI 10.1007/s11010-016-2717-y
   Sakdarat S, 2009, BIOORGAN MED CHEM, V17, P1857, DOI 10.1016/j.bmc.2009.01.059
   Saleem M, 2009, CARCINOGENESIS, V30, P808, DOI 10.1093/carcin/bgp044
   Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304
   Tan ML, 2009, PHARM RES-DORDR, V26, P1547, DOI 10.1007/s11095-009-9895-1
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tarapore RS, 2013, MOL NUTR FOOD RES, V57, P1950, DOI 10.1002/mnfr.201300155
   Temraz S, 2014, CRIT REV ONCOL HEMAT, V89, P217, DOI 10.1016/j.critrevonc.2013.08.015
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x
   Tuntiwachwuttikul P, 2004, CHEM PHARM BULL, V52, P27, DOI 10.1248/cpb.52.27
   von Holtz RL, 1998, NUTR CANCER, V32, P8, DOI 10.1080/01635589809514709
   Wei MC, 2000, GENE DEV, V14, P2060
   Yahaya R., 2015, INT J PHARMACOGN PHY, V7, P1244
   Yian ShimSiang, 2013, International Journal of Integrative Biology, V14, P7
   Yong YK, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/462751
NR 50
TC 5
Z9 6
U1 1
U2 11
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0973-1296
EI 0976-4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD JAN-MAR
PY 2019
VL 15
IS 60
BP 87
EP 97
DI 10.4103/pm.pm_299_17
PG 11
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HI7BR
UT WOS:000456610600013
DA 2022-04-25
ER

PT J
AU Podralska, M
   Ciesielska, S
   Kluiver, J
   van den Berg, A
   Dzikiewicz-Krawczyk, A
   Slezak-Prochazka, I
AF Podralska, Marta
   Ciesielska, Sylwia
   Kluiver, Joost
   van den Berg, Anke
   Dzikiewicz-Krawczyk, Agnieszka
   Slezak-Prochazka, Izabella
TI Non-Coding RNAs in Cancer Radiosensitivity: MicroRNAs and lncRNAs as
   Regulators of Radiation-Induced Signaling Pathways
SO CANCERS
LA English
DT Review
DE non-coding RNA; miRNA; lncRNA; circRNA; radiation response; radiotherapy
ID CELL LUNG-CANCER; NASOPHARYNGEAL CARCINOMA RADIORESISTANCE; HUMAN
   COLORECTAL-CANCER; STRAND BREAK REPAIR; DNA-DAMAGE RESPONSE; ENHANCES
   RADIOSENSITIVITY; PROSTATE-CANCER; IONIZING-RADIATION; DOWN-REGULATION;
   GASTRIC-CANCER
AB Radiotherapy is a cancer treatment that applies high doses of ionizing radiation to induce cell death, mainly by triggering DNA double-strand breaks. The outcome of radiotherapy greatly depends on radiosensitivity of cancer cells, which is determined by multiple proteins and cellular processes. In this review, we summarize current knowledge on the role of microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), in determining the response to radiation. Non-coding RNAs modulate ionizing radiation response by targeting key signaling pathways, including DNA damage repair, apoptosis, glycolysis, cell cycle arrest, and autophagy. Additionally, we indicate miRNAs and lncRNAs that upon overexpression or inhibition alter cellular radiosensitivity. Current data indicate the potential of using specific non-coding RNAs as modulators of cellular radiosensitivity to improve outcome of radiotherapy.
C1 [Podralska, Marta; Dzikiewicz-Krawczyk, Agnieszka] Polish Acad Sci, Inst Human Genet, PL-60479 Poznan, Poland.
   [Ciesielska, Sylwia] Silesian Tech Univ, Dept Syst Biol & Engn, Fac Automat Control Elect & Comp Sci, PL-44100 Gliwice, Poland.
   [Kluiver, Joost; van den Berg, Anke] Univ Groningen, Univ Med Ctr, Dept Pathol & Med Biol, NL-9700 RB Groningen, Netherlands.
   [Slezak-Prochazka, Izabella] Silesian Tech Univ, Ctr Biotechnol, PL-44100 Gliwice, Poland.
RP Dzikiewicz-Krawczyk, A (corresponding author), Polish Acad Sci, Inst Human Genet, PL-60479 Poznan, Poland.; Slezak-Prochazka, I (corresponding author), Silesian Tech Univ, Ctr Biotechnol, PL-44100 Gliwice, Poland.
EM marta.podralska@igcz.poznan.pl; sylwia.ciesielska@polsl.pl;
   j.l.kluiver@umcg.nl; a.van.den.berg01@umcg.nl;
   marta.podralska@igcz.poznan.pl; izabella.slezak-prochazka@polsl.pl
RI Kluiver, Joost/G-6406-2014; van den Berg, Anke/H-1718-2011;
   Slezak-Prochazka, Izabella/F-7674-2019
OI Kluiver, Joost/0000-0001-7650-2937; Podralska,
   Marta/0000-0001-9720-7881; van den Berg, Anke/0000-0002-8894-2638;
   Slezak-Prochazka, Izabella/0000-0002-0707-2213; Ciesielska,
   Sylwia/0000-0002-1051-0632; Dzikiewicz-Krawczyk,
   Agnieszka/0000-0001-7633-2114
FU National Science Centre, PolandNational Science Centre, Poland
   [2017/27/B/NZ1/00877, 2015/19/B/ST7/02984, 2015/19/D/NZ1/03443]
FX This research was funded by the National Science Centre, Poland, grants
   number 2017/27/B/NZ1/00877 to AD-K and MP, 2015/19/B/ST7/02984 to SC and
   2015/19/D/NZ1/03443 to IS-P.
CR Baek D., 2008, NATURE, V455, P1710, DOI [10.1038/nature10908, DOI 10.1038/NATURE10908]
   Bekker-Jensen S, 2010, DNA REPAIR, V9, P1219, DOI 10.1016/j.dnarep.2010.09.010
   Borras-Fresneda M, 2016, SCI REP-UK, V6, DOI 10.1038/srep27043
   Cao K, 2017, ONCOTARGET, V8, P83660, DOI 10.18632/oncotarget.19014
   Chaudhary R, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1410
   Chaudhry MA, 2013, J RADIAT RES, V54, P808, DOI 10.1093/jrr/rrt014
   Chaudhry MA, 2010, DNA CELL BIOL, V29, P553, DOI 10.1089/dna.2009.0978
   Chen CX, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431X20187080, 10.1590/1414-431x20187080]
   Chen GH, 2020, MOL THER-NUCL ACIDS, V19, P961, DOI 10.1016/j.omtn.2019.12.031
   Chen H, 2020, CANCER LETT, V483, P114, DOI 10.1016/j.canlet.2020.01.037
   Chen LJ, 2019, J CELL BIOCHEM, V120, P6178, DOI 10.1002/jcb.27905
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271
   Chen X, 2018, CANCER MED-US, V7, P3834, DOI 10.1002/cam4.1527
   Cortez MA, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.47
   Davis AJ, 2013, TRANSL CANCER RES, V2, P130, DOI 10.3978/j.issn.2218-676X.2013.04.02
   Deng XB, 2013, J NEURO-ONCOL, V114, P263, DOI 10.1007/s11060-013-1179-2
   Dou QR, 2019, EUR J PHARMACOL, V852, P134, DOI 10.1016/j.ejphar.2019.03.002
   Duan WM, 2013, J RADIAT RES, V54, P611, DOI 10.1093/jrr/rrs136
   Duan XM, 2019, KAOHSIUNG J MED SCI, V35, P659, DOI 10.1002/kjm2.12108
   El Bezawy R, 2017, CANCER LETT, V395, P53, DOI 10.1016/j.canlet.2017.02.033
   El-Sahli S, 2019, CANCERS, V11, DOI 10.3390/cancers11070904
   Fadaka A., 2017, J ONCOL SCI, V3, P45
   Fan L, 2018, INT J MOL MED, V42, P2247, DOI 10.3892/ijmm.2018.3778
   Fan LY, 2020, AM J CANCER RES, V10, P314
   Fang SS, 2018, NUCLEIC ACIDS RES, V46, pD308, DOI 10.1093/nar/gkx1107
   Fu XD, 2014, NATL SCI REV, V1, P190, DOI 10.1093/nsr/nwu008
   Fu Y, 2016, CROAT MED J, V57, P457, DOI 10.3325/cmj.2016.57.457
   Gasparini P, 2014, P NATL ACAD SCI USA, V111, P4536, DOI 10.1073/pnas.1402604111
   Ghiam AF, 2017, ONCOTARGET, V8, P4668, DOI 10.18632/oncotarget.13576
   Gou CX, 2020, BRIT J RADIOL, V93, DOI 10.1259/bjr.20190154
   Gu H, 2016, CANCER MED-US, V5, P1174, DOI 10.1002/cam4.664
   Gu ZM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0392-4
   Guan YC, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01169-z
   Guo P, 2014, EXP CELL RES, V320, P200, DOI 10.1016/j.yexcr.2013.10.020
   Guo XG, 2019, J CELL PHYSIOL, V234, P3478, DOI 10.1002/jcp.26828
   Han DM, 2018, ONCOTARGET, V9, P2395, DOI 10.18632/oncotarget.23416
   He JP, 2017, CELL CYCLE, V16, P1943, DOI 10.1080/15384101.2017.1367070
   He X, 2018, ONCOL REP, V39, P977, DOI 10.3892/or.2017.6156
   He Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0265-y
   Hu JL, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0028-8
   Hu LL, 2016, INT J ONCOL, V49, P2217, DOI 10.3892/ijo.2016.3719
   Hu XG, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181038
   Hu ZQ, 2019, INT J CLIN EXP PATHO, V12, P229
   Huang YJ, 2018, J CANCER RES THER, V14, P111, DOI 10.4103/jcrt.JCRT_682_17
   Indovina P, 2015, ONCOTARGET, V6, P17873, DOI 10.18632/oncotarget.4286
   Jackstadt R, 2020, ANNU REV CANC BIOL, V4, P177, DOI 10.1146/annurev-cancerbio-030419-033628
   Jiang HJ, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0802-3
   Jiang P, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-100
   Jiang YH, 2016, TUMOR BIOL, V37, P3957, DOI 10.1007/s13277-015-4234-0
   Jin C, 2016, TUMOR BIOL, V37, P4025, DOI 10.1007/s13277-015-4227-z
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   Kakarougkas A, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130685
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Knezevic D, 2004, CELL CYCLE, V3, P729
   Kwon JE, 2013, APOPTOSIS, V18, P896, DOI 10.1007/s10495-013-0841-7
   Lai Y, 2018, CELL BIOL INT, V42, P227, DOI 10.1002/cbin.10890
   Lal A, 2009, NAT STRUCT MOL BIOL, V16, P492, DOI 10.1038/nsmb.1589
   Lan FM, 2020, J NEUROSURG, V132, P1456, DOI 10.3171/2018.12.JNS181798
   Lee HC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.116
   Li G, 2016, INT J RADIAT ONCOL, V96, pE168, DOI 10.1016/j.ijrobp.2016.06.1013
   Li G, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2755-6
   Li G, 2014, CANCER SCI, V105, P1560, DOI 10.1111/cas.12555
   Li G, 2013, EUR J CANCER, V49, P2596, DOI 10.1016/j.ejca.2013.03.001
   Li J, 2015, TUMOR BIOL, V36, P3611, DOI 10.1007/s13277-014-2998-2
   Li L, 2018, ONCOL RES, V26, P547, DOI 10.3727/096504017X15016337254605
   Li ZJ, 2017, J ORAL PATHOL MED, V46, P583, DOI 10.1111/jop.12538
   Liang LP, 2014, INT J RADIAT ONCOL, V88, P955, DOI 10.1016/j.ijrobp.2013.12.036
   Liang ZX, 2013, PHARM RES-DORDR, V30, P1008, DOI 10.1007/s11095-012-0936-9
   Lin JG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1214-z
   Liu G, 2016, ONCOL LETT, V11, P2903, DOI 10.3892/ol.2016.4316
   Liu HY, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0532-2
   Liu J, 2016, J BIOCHEM, V160, P195, DOI 10.1093/jb/mvw025
   Liu Y, 2018, BIOMED PHARMACOTHER, V105, P1232, DOI 10.1016/j.biopha.2018.06.087
   Liu YX, 2013, DNA REPAIR, V12, P741, DOI 10.1016/j.dnarep.2013.06.002
   Liu YQ, 2020, RSC ADV, V10, P1711, DOI 10.1039/c9ra08525d
   Liu ZL, 2013, MOL CELL BIOCHEM, V372, P35, DOI 10.1007/s11010-012-1443-3
   Lu HJ, 2018, LIFE SCI, V199, P167, DOI 10.1016/j.lfs.2018.02.016
   Lu HZ, 2016, TUMOR BIOL, V37, P1683, DOI 10.1007/s13277-015-3946-5
   Lu YY, 2016, TUMOR BIOL, V37, P11733, DOI 10.1007/s13277-015-4773-4
   Lv Q, 2017, CANCER BIOL THER, V18, P142, DOI 10.1080/15384047.2017.1281497
   Ma WH, 2015, ONCOTARGET, V6, P15984, DOI 10.18632/oncotarget.3762
   Maier P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010102
   Mansour WY, 2013, RADIOTHER ONCOL, V106, P147, DOI 10.1016/j.radonc.2012.10.020
   Mao AH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27346
   Marbaniang Casterland, 2018, Asian Pac J Cancer Prev, V19, P2377
   Meng CD, 2018, ONCOL LETT, V15, P1435, DOI 10.3892/ol.2017.7452
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Metheetrairut C, 2017, ONCOGENE, V36, P512, DOI 10.1038/onc.2016.222
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Navarro F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132767
   Neijenhuis S, 2013, DNA REPAIR, V12, P394, DOI 10.1016/j.dnarep.2013.02.003
   Ng WL, 2010, DNA REPAIR, V9, P1170, DOI 10.1016/j.dnarep.2010.08.007
   Pawlik TM, 2004, INT J RADIAT ONCOL, V59, P928, DOI 10.1016/j.ijrobp.2004.03.005
   Pedroza-Torres A, 2018, ONCOL REP, V39, P1532, DOI 10.3892/or.2018.6219
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Qu CJ, 2012, CELL CYCLE, V11, P785, DOI 10.4161/cc.11.4.19228
   Ray P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32979
   Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002
   Rossi Marianna Nicoletta, 2014, Int J Cell Biol, V2014, P473857, DOI 10.1155/2014/473857
   Rothenberg C, 2010, HUM MOL GENET, V19, P3219, DOI 10.1093/hmg/ddq231
   Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673
   Sharma K, 2014, INT J MOL SCI, V15, P10034, DOI 10.3390/ijms150610034
   Shen YM, 2017, EXP CELL RES, V358, P188, DOI 10.1016/j.yexcr.2017.06.016
   Shi R, 2020, ONCOTARGETS THER, V13, P3025, DOI 10.2147/OTT.S237559
   Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017
   Sladky V, 2017, J CELL SCI, V130, P3779, DOI 10.1242/jcs.203448
   Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454
   Song W, 2019, CELL CYCLE, V18, P3177, DOI 10.1080/15384101.2019.1671089
   Su HF, 2019, ONCOL REP, V41, P599, DOI 10.3892/or.2018.6799
   Su HF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0977-7
   Sun DY, 2018, BIOL RES, V51, DOI 10.1186/s40659-018-0203-6
   Sun HF, 2016, MOL MED REP, V14, P3285, DOI 10.3892/mmr.2016.5656
   Sun QQ, 2015, MOL MED REP, V11, P3330, DOI 10.3892/mmr.2015.3221
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Tam SY, 2017, RADIAT ONCOL, V12, DOI 10.1186/s13014-017-0795-y
   Tang YT, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0285-3
   Thapar R, 2018, MOLECULES, V23, DOI 10.3390/molecules23112789
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Ummanni R, 2008, FEBS J, V275, P5703, DOI 10.1111/j.1742-4658.2008.06697.x
   Vahabi M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1119-x
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Villanova L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040958
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang BY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1996-0
   Wang F, 2019, J CELL PHYSIOL, V234, P13182, DOI 10.1002/jcp.27989
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wang J, 2016, RADIAT RES, V186, P292, DOI 10.1667/RR14428.1
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang MJ, 2017, CELL PHYSIOL BIOCHEM, V44, P2017, DOI 10.1159/000485907
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang XX, 2018, CELL CYCLE, V17, P439, DOI 10.1080/15384101.2018.1442625
   Wang YM, 2011, MOL CANCER RES, V9, P1100, DOI 10.1158/1541-7786.MCR-11-0007
   Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y
   Wang YJ, 2017, ONCOTARGET, V8, P70156, DOI 10.18632/oncotarget.19596
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   Williams JR, 2008, INT J RADIAT BIOL, V84, P253, DOI 10.1080/09553000801953342
   Wright WD, 2018, J BIOL CHEM, V293, P10524, DOI 10.1074/jbc.TM118.000372
   Wu CL, 2018, CANCER MANAG RES, V10, P5261, DOI 10.2147/CMAR.S174066
   Wu DP, 2017, CELL PHYSIOL BIOCHEM, V42, P2453, DOI 10.1159/000480209
   Wu SY, 2013, STRAHLENTHER ONKOL, V189, P675, DOI 10.1007/s00066-013-0347-9
   Wu SJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-017-0639-5
   Wu SY, 2014, J BUON, V19, P137
   Xiao SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108810
   Xie CY, 2020, J CELL MOL MED, V24, P747, DOI 10.1111/jcmm.14784
   Xu CG, 2016, EUR REV MED PHARMACO, V20, P1501
   Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724
   Xue Q, 2013, WORLD J GASTROENTERO, V19, P9307, DOI 10.3748/wjg.v19.i48.9307
   Yan D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011397
   Yang BL, 2020, CANCER BIOTHER RADIO, V35, P241, DOI 10.1089/cbr.2019.3220
   Yang CX, 2016, ONCOL LETT, V12, P4983, DOI 10.3892/ol.2016.5340
   Yang F, 2015, EUR REV MED PHARMACO, V19, P4507
   Yang PX, 2017, J GASTROEN HEPATOL, V32, P837, DOI 10.1111/jgh.13606
   Yang QS, 2017, J CELL BIOCHEM, V118, P2625, DOI 10.1002/jcb.25829
   Yang W, 2012, EXP CELL RES, V318, P944, DOI 10.1016/j.yexcr.2012.02.010
   Yang XD, 2018, ONCOL REP, V40, P1554, DOI 10.3892/or.2018.6573
   Yang Y, 2015, TUMOR BIOL, V36, P4079, DOI 10.1007/s13277-015-3496-x
   Yang Y, 2019, J CANCER RES THER, V15, P272, DOI 10.4103/jcrt.JCRT_421_18
   Yi HQ, 2013, FEBS LETT, V587, P436, DOI 10.1016/j.febslet.2012.12.027
   Yin H, 2018, CELL PHYSIOL BIOCHEM, V46, P471, DOI 10.1159/000488615
   Yu D, 2018, PEERJ, V6, DOI 10.7717/peerj.5011
   Yu L, 2017, J CANCER, V8, P3430, DOI 10.7150/jca.21125
   Yu ZW, 2020, CELL CYCLE, V19, P300, DOI 10.1080/15384101.2019.1708016
   Yue X, 2019, MOL THER, V27, P1939, DOI 10.1016/j.ymthe.2019.07.011
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang CZ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-367
   Zhang CZ, 2011, INT J RADIAT ONCOL, V80, P240, DOI 10.1016/j.ijrobp.2010.12.049
   Zhang HF, 2019, CLIN CANCER RES, V25, P1989, DOI 10.1158/1078-0432.CCR-18-0773
   Zhang HF, 2015, ONCOTARGET, V6, P6218, DOI 10.18632/oncotarget.3358
   Zhang J, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181599
   Zhang M, 2018, ONCOL RES, V26, P1245, DOI 10.3727/096504017X14944585873668
   Zhang N, 2019, MOL THER-NUCL ACIDS, V18, P871, DOI 10.1016/j.omtn.2019.09.033
   Zhang Q, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170327
   Zhang X, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0133-8
   Zhang XL, 2015, ONCOL REP, V34, P1557, DOI 10.3892/or.2015.4078
   Zhang YH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027893
   Zhang YQ, 2015, INT J RADIAT ONCOL, V92, P1132, DOI 10.1016/j.ijrobp.2015.04.007
   Zheng L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0592-z
   Zhou JD, 2015, CANCER BIOL THER, V16, P846, DOI 10.1080/15384047.2015.1030545
   Zhou JY, 2017, ONCOTARGET, V8, P40994, DOI 10.18632/oncotarget.17343
   Zhou L, 2003, FRONT BIOSCI-LANDMRK, V8, pD9, DOI 10.2741/927
   Zhou LL, 2015, HEMATOLOGY, V20, P343, DOI 10.1179/1607845414Y.0000000201
   Zhou YX, 2015, MELANOMA RES, V25, P119, DOI 10.1097/CMR.0000000000000140
   Zou YM, 2018, EUR J CELL BIOL, V97, P369, DOI 10.1016/j.ejcb.2018.04.005
NR 184
TC 18
Z9 21
U1 14
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUN
PY 2020
VL 12
IS 6
AR 1662
DI 10.3390/cancers12061662
PG 27
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MT4SS
UT WOS:000554963000001
PM 32585857
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Kim, EK
   Jang, M
   Song, MJ
   Kim, D
   Kim, Y
   Jang, HH
AF Kim, Eun-Kyung
   Jang, MinGyeong
   Song, Min-Jeong
   Kim, Dongwoo
   Kim, Yosup
   Jang, Ho Hee
TI Redox-Mediated Mechanism of Chemoresistance in Cancer Cells
SO ANTIOXIDANTS
LA English
DT Review
DE reactive oxygen species; antioxidant proteins; chemoresistance;
   oxaliplatin; 5-Fluorouracil
ID ENDOPLASMIC-RETICULUM-STRESS; EPITHELIAL-MESENCHYMAL TRANSITION;
   MANGANESE SUPEROXIDE-DISMUTASE; OXYGEN SPECIES ROS; NADPH OXIDASE 2;
   DRUG-RESISTANCE; COLORECTAL-CANCER; 5-FLUOROURACIL RESISTANCE;
   PANCREATIC-CANCER; OXIDATIVE STRESS
AB Cellular reactive oxygen species (ROS) status is stabilized by a balance of ROS generation and elimination called redox homeostasis. ROS is increased by activation of endoplasmic reticulum stress, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase family members and adenosine triphosphate (ATP) synthesis of mitochondria. Increased ROS is detoxified by superoxide dismutase, catalase, and peroxiredoxins. ROS has a role as a secondary messenger in signal transduction. Cancer cells induce fluctuations of redox homeostasis by variation of ROS regulated machinery, leading to increased tumorigenesis and chemoresistance. Redox-mediated mechanisms of chemoresistance include endoplasmic reticulum stress-mediated autophagy, increased cell cycle progression, and increased conversion to metastasis or cancer stem-like cells. This review discusses changes of the redox state in tumorigenesis and redox-mediated mechanisms involved in tolerance to chemotherapeutic drugs in cancer.
C1 [Kim, Eun-Kyung; Jang, MinGyeong; Song, Min-Jeong; Jang, Ho Hee] Gachon Univ, Coll Med, Dept Biochem, Incheon 21999, South Korea.
   [Kim, Dongwoo; Kim, Yosup; Jang, Ho Hee] Gachon Univ, Dept Hlth Sci & Technol, GAIHST, Incheon 21999, South Korea.
RP Jang, HH (corresponding author), Gachon Univ, Coll Med, Dept Biochem, Incheon 21999, South Korea.; Jang, HH (corresponding author), Gachon Univ, Dept Hlth Sci & Technol, GAIHST, Incheon 21999, South Korea.
EM ekkim@gachon.ac.kr; apnea4001@naver.com; neptune6nrg@hanmail.net;
   cd0575@naver.com; youandkys@naver.com; hhjang@gachon.ac.kr
OI Jang, Ho Hee/0000-0003-0314-8230
FU National Research Foundation of Korea (NRF) - Korea governmentNational
   Research Foundation of Korea [NRF-2017R1D1A1B03035550]; National
   Research Foundation of Korea (NRF)National Research Foundation of Korea;
   Center for Women In Science, Engineering and Technology (WISET) -
   Ministry of Science, ICT & Future Planning of Korea (MSIP) under the
   Program for Returners into RD
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (NRF-2017R1D1A1B03035550) to
   E.-K.K., and by the National Research Foundation of Korea (NRF) and the
   Center for Women In Science, Engineering and Technology (WISET) Grant
   funded by the Ministry of Science, ICT & Future Planning of Korea (MSIP)
   under the Program for Returners into R&D to M.J.
CR Akhdar H, 2009, EUR J CANCER, V45, P2219, DOI 10.1016/j.ejca.2009.05.017
   Alimbetov D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061690
   Ameziane-El-Hassani R, 2016, NAT REV ENDOCRINOL, V12, P485, DOI 10.1038/nrendo.2016.64
   Araki K, 2013, J CELL BIOL, V202, P861, DOI 10.1083/jcb.201303027
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Bahar E, 2019, CANCERS, V11, DOI 10.3390/cancers11030338
   Bai XP, 2016, DRUG METAB REV, V48, P541, DOI 10.1080/03602532.2016.1197239
   Begicevic RR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112362
   Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046
   Brufsky AM, 2014, BREAST CANCER-BASIC, V8, P109, DOI 10.4137/BCBCR.S9453
   Bruno PM, 2017, NAT MED, V23, P461, DOI 10.1038/nm.4291
   Burhans WC, 2009, FREE RADICAL BIO MED, V47, P1282, DOI 10.1016/j.freeradbiomed.2009.05.026
   Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460
   Canta A, 2015, TOXICS, V3, P198, DOI 10.3390/toxics3020198
   Chan JY, 2008, CANCER BIOL THER, V7, P1305, DOI 10.4161/cbt.7.8.6302
   Che MX, 2016, DRUG DISCOV TODAY, V21, P143, DOI 10.1016/j.drudis.2015.10.001
   Cheng CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.204
   Chian S, 2014, ASIAN PAC J CANCER P, V15, P2911, DOI 10.7314/APJCP.2014.15.6.2911
   Choi MH, 2005, NATURE, V435, P347, DOI 10.1038/nature03587
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Cui Q, 2018, DRUG RESIST UPDATE, V41, P1, DOI 10.1016/j.drup.2018.11.001
   Das CK, 2018, NEOPLASIA, V20, P263, DOI 10.1016/j.neo.2018.01.001
   Dayem Ahmed Abdal, 2010, Cancers (Basel), V2, P859, DOI 10.3390/cancers2020859
   Del Vecchio CA, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001945
   Delgado M, 2014, AUTOPHAGY, V10, P168, DOI 10.4161/auto.26759
   Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991
   Deshpande SS, 2002, HUM EXP TOXICOL, V21, P63, DOI 10.1191/0960327102ht211oa
   Dhar A., 2010, Experimental Oncology, V32, P2
   Dhar SK, 2012, FREE RADICAL BIO MED, V52, P2209, DOI 10.1016/j.freeradbiomed.2012.03.009
   Dharmaraja AT, 2017, J MED CHEM, V60, P3221, DOI 10.1021/acs.jmedchem.6b01243
   Ding ZB, 2011, CLIN CANCER RES, V17, P6229, DOI 10.1158/1078-0432.CCR-11-0816
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Du HL, 2012, ONCOL REP, V27, P143, DOI 10.3892/or.2011.1464
   Dufey E, 2014, AM J PHYSIOL-CELL PH, V307, pC582, DOI 10.1152/ajpcell.00258.2014
   El Khoury F, 2016, INT J ONCOL, V49, P2558, DOI 10.3892/ijo.2016.3725
   Enyedi B, 2010, ANTIOXID REDOX SIGN, V13, P721, DOI 10.1089/ars.2009.2880
   Fisher AB, 2009, ANTIOXID REDOX SIGN, V11, P1349, DOI 10.1089/ARS.2008.2378
   Fisher AB, 2011, ANTIOXID REDOX SIGN, V15, P831, DOI 10.1089/ars.2010.3412
   Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959
   Fujimoto E, 2005, ONCOGENE, V24, P3684, DOI 10.1038/sj.onc.1208430
   Fukai T, 2002, CARDIOVASC RES, V55, P239, DOI 10.1016/S0008-6363(02)00328-0
   Fulton DJR, 2009, ANTIOXID REDOX SIGN, V11, P2443, DOI [10.1089/ars.2009.2587, 10.1089/ARS.2009.2587]
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Ganan-Gomez I, 2013, FREE RADICAL BIO MED, V65, P750, DOI 10.1016/j.freeradbiomed.2013.06.041
   Garrido-Laguna I, 2015, NAT REV CLIN ONCOL, V12, P319, DOI 10.1038/nrclinonc.2015.53
   Gines A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123830
   Giudice A, 2019, ONCOTARGETS THER, V12, P4937, DOI 10.2147/OTT.S183192
   Giudice A, 2010, METHODS MOL BIOL, V647, P37, DOI 10.1007/978-1-60761-738-9_3
   Glasauer A, 2014, J CLIN INVEST, V124, P117, DOI 10.1172/JCI71714
   Glorieux C, 2017, BIOL CHEM, V398, P1095, DOI 10.1515/hsz-2017-0131
   Glorieux C, 2015, FREE RADICAL BIO MED, V87, P84, DOI 10.1016/j.freeradbiomed.2015.06.017
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Grasso C, 2017, CRIT REV ONCOL HEMAT, V114, P139, DOI 10.1016/j.critrevonc.2017.03.026
   Grespi F, 2010, CELL DEATH DIFFER, V17, P1672, DOI 10.1038/cdd.2010.97
   Grewal GK, 2017, MOLECULES, V22, DOI 10.3390/molecules22030365
   Guo XX, 2008, ANTICANCER RES, V28, P9
   Harada K, 2014, INT J ONCOL, V44, P1302, DOI 10.3892/ijo.2014.2270
   Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06
   Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008
   He L, 2017, CELL PHYSIOL BIOCHEM, V44, P532, DOI 10.1159/000485089
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Hempel N, 2014, REDOX BIOL, V2, P245, DOI 10.1016/j.redox.2014.01.005
   Hempel N, 2011, ANTI-CANCER AGENT ME, V11, P191, DOI 10.2174/187152011795255911
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Holl M, 2016, MOL CARCINOGEN, V55, P27, DOI 10.1002/mc.22255
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Hsu HH, 2018, J CELL PHYSIOL, V233, P5458, DOI 10.1002/jcp.26406
   Hu XF, 2013, ASIAN PAC J CANCER P, V14, P5231, DOI 10.7314/APJCP.2013.14.9.5231
   Huang Z, 2016, INT J CANCER, V139, P23, DOI 10.1002/ijc.29990
   Hwang IT, 2007, BIOCHEM BIOPH RES CO, V359, P304, DOI 10.1016/j.bbrc.2007.05.088
   Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111
   Hwang TS, 2007, EJSO-EUR J SURG ONC, V33, P474, DOI 10.1016/j.ejso.2006.10.024
   Imanishi Y, 2001, J CLIN INVEST, V107, P1093, DOI 10.1172/JCI10523
   Izumiya M, 2012, ANTICANCER RES, V32, P3847
   Jiang JW, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.36
   Jiao L, 2016, TUMOR BIOL, V37, P8413, DOI 10.1007/s13277-015-4736-9
   Jung I, 2011, FEBS LETT, V585, P1973, DOI 10.1016/j.febslet.2011.05.033
   Kaehler C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050134
   Kang KA, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.149
   Kang KA, 2018, REDOX BIOL, V17, P224, DOI 10.1016/j.redox.2018.04.020
   Kang KA, 2016, ONCOTARGET, V7, P40594, DOI 10.18632/oncotarget.9745
   Kelley MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106485
   Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151
   Kim JK, 2016, ENVIRON TOXICOL PHAR, V44, P128, DOI 10.1016/j.etap.2016.05.005
   Kim Y, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8060169
   Knoops B, 2011, ANTIOXID REDOX SIGN, V15, P817, DOI 10.1089/ars.2010.3584
   Kojima H, 2017, INT J ONCOL, V51, P49, DOI 10.3892/ijo.2017.4001
   Kuramitsu Y, 2010, ANTICANCER RES, V30, P3367
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Laurindo FRM, 2014, ANTIOXID REDOX SIGN, V20, P2755, DOI 10.1089/ars.2013.5605
   Lee DJ, 2013, CANCER RES, V73, P4744, DOI 10.1158/0008-5472.CAN-12-4226
   Li MH, 2004, ORAL ONCOL, V40, P63, DOI 10.1016/S1368-8375(03)00136-2
   Liao X, 2019, HEPATOL INT, V13, P440, DOI 10.1007/s12072-019-09960-5
   Lin L, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1362-2
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu QB, 2018, REDOX BIOL, V14, P656, DOI 10.1016/j.redox.2017.11.012
   Ma X, 2017, AUTOPHAGY, V13, P592, DOI 10.1080/15548627.2016.1269988
   Madden E, 2019, BIOL CELL, V111, P1, DOI 10.1111/boc.201800050
   Malhotra JD, 2007, ANTIOXID REDOX SIGN, V9, P2277, DOI 10.1089/ars.2007.1782
   Marin JJG, 2019, CANCERS, V11, DOI 10.3390/cancers11030407
   Marlein CR, 2017, BLOOD, V130, P1649, DOI 10.1182/blood-2017-03-772939
   Martinez-Balibrea E, 2015, MOL CANCER THER, V14, P1767, DOI 10.1158/1535-7163.MCT-14-0636
   MASON COLE V., 1966, INVEST OPHTHALMOL, V5, P601
   Maziere C, 2011, ATHEROSCLEROSIS, V218, P308, DOI 10.1016/j.atherosclerosis.2011.06.034
   Menon SG, 2007, ONCOGENE, V26, P1101, DOI 10.1038/sj.onc.1209895
   Miyata Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102214
   Miyoshi S, 2018, ANTICANCER RES, V38, P6163, DOI 10.21873/anticanres.12969
   Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023
   Nicolussi A, 2017, MOL CLIN ONCOL, V6, P139, DOI 10.3892/mco.2017.1129
   Nobel S, 2001, EUR J BIOCHEM, V268, P4113, DOI 10.1046/j.1432-1327.2001.02359.x
   Nordzieke DE, 2018, ANTIOXIDANTS-BASEL, V7, DOI 10.3390/antiox7110168
   Oakes SA, 2017, AM J PHYSIOL-CELL PH, V312, pC93, DOI 10.1152/ajpcell.00266.2016
   OBERLEY LW, 1979, CANCER RES, V39, P1141
   Oliva CR, 2016, J BIOL CHEM, V291, P24188, DOI 10.1074/jbc.M116.749978
   Papa L, 2014, J BIOL CHEM, V289, P5412, DOI 10.1074/jbc.C113.526475
   Park YH, 2016, ONCOGENE, V35, P3503, DOI 10.1038/onc.2015.411
   Plasencia C, 2006, INT J ONCOL, V29, P225
   Porporato PE, 2016, CELL MOL LIFE SCI, V73, P1349, DOI 10.1007/s00018-015-2100-2
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155
   Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574
   Qin M, 2015, P NATL ACAD SCI USA, V112, P11241, DOI 10.1073/pnas.1503909112
   Rainis T, 2007, DIGEST DIS SCI, V52, P526, DOI 10.1007/s10620-006-9177-2
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   Robinson SM, 2013, J HEPATOL, V59, P318, DOI 10.1016/j.jhep.2013.04.014
   Rushworth Stuart A, 2011, Cancers (Basel), V3, P1605, DOI 10.3390/cancers3021605
   Sakamaki T, 2006, MOL CELL BIOL, V26, P5449, DOI 10.1128/MCB.02074-05
   Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0
   Sander CS, 2003, BRIT J DERMATOL, V148, P913, DOI 10.1046/j.1365-2133.2003.05303.x
   Sauer H, 2001, CELL PHYSIOL BIOCHEM, V11, P173, DOI 10.1159/000047804
   Scherz-Shouval R, 2007, AUTOPHAGY, V3, P371, DOI 10.4161/auto.4214
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Shanmugasundaram K, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01106-1
   Sharapov MG, 2019, BIOCHEMISTRY-MOSCOW+, V84, P79, DOI 10.1134/S0006297919020019
   Shen Y, 2015, EXP CELL RES, V334, P207, DOI 10.1016/j.yexcr.2015.04.010
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Shi L, 2015, CELL PHYSIOL BIOCHEM, V35, P2333, DOI 10.1159/000374036
   Shi Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051076
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Shin YK, 2005, CANCER RES, V65, P3162, DOI 10.1158/0008-5472.CAN-04-3300
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Skonieczna M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9420539
   Song SL, 2018, J CELL PHYSIOL, V233, P3867, DOI 10.1002/jcp.26137
   Stamatakos M, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-111
   Sun L, 2017, J CANCER, V8, P2802, DOI 10.7150/jca.19142
   Tazehkand AP, 2018, BIOMED PHARMACOTHER, V103, P755, DOI 10.1016/j.biopha.2018.04.105
   Terzioglu G, 2018, CELL J, V20, P312, DOI 10.22074/cellj.2018.5309
   Tickner J, 2011, FREE RADICAL BIO MED, V51, P763, DOI 10.1016/j.freeradbiomed.2011.05.027
   Tischner D, 2012, APOPTOSIS, V17, P1197, DOI 10.1007/s10495-012-0756-8
   Vara D, 2018, ANTIOXID REDOX SIGN, V28, P110, DOI 10.1089/ars.2016.6869
   Vasiliou Vasilis, 2009, Human Genomics, V3, P281
   Vishnoi K, 2016, TUMOR BIOL, V37, P13137, DOI 10.1007/s13277-016-5143-6
   Wang J, 2016, ONCOL LETT, V12, P1355, DOI 10.3892/ol.2016.4757
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Wang P, 2015, WORLD J GASTROENTERO, V21, P6271, DOI 10.3748/wjg.v21.i20.6271
   Wang P, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0012-z
   Wang WB, 2014, WORLD J GASTROENTERO, V20, P15682, DOI 10.3748/wjg.v20.i42.15682
   Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970
   Weng MS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0728-0
   Weyemi U, 2013, ANTI-CANCER AGENT ME, V13, P502
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2
   Woo J, 2014, P NATL ACAD SCI USA, V111, P863, DOI 10.1073/pnas.1318207111
   XU BH, 1994, INT J CANCER, V58, P686, DOI 10.1002/ijc.2910580512
   Xu HD, 2005, BIOCHEM BIOPH RES CO, V328, P618, DOI 10.1016/j.bbrc.2005.01.015
   Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038
   Yang D, 2013, ONCOL RES, V21, P51, DOI 10.3727/096504013X13793555706768
   Yang HT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0909-x
   Yang Y, 2019, CANCER MANAG RES, V11, P5133, DOI 10.2147/CMAR.S203656
   Yao CW, 2017, BIOMOL THER, V25, P315, DOI 10.4062/biomolther.2016.069
   Yasui M, 2006, CLIN CANCER RES, V12, P4720, DOI 10.1158/1078-0432.CCR-05-1213
   Yen HC, 2011, FREE RADICAL RES, V45, P707, DOI 10.3109/10715762.2011.572969
   Yin X, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0637-7
   Zhang C, 2017, ONCOL REP, V37, P2942, DOI 10.3892/or.2017.5539
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang WJ, 2012, BIOCHEM BIOPH RES CO, V417, P679, DOI 10.1016/j.bbrc.2011.11.142
   Zhang XZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10938
   Zhang Y, 2018, CANCER SCI, V109, P94, DOI 10.1111/cas.13425
   Zhang Z, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.005
   Zou ZZ, 2017, APOPTOSIS, V22, P1321, DOI 10.1007/s10495-017-1424-9
NR 179
TC 42
Z9 45
U1 5
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD OCT
PY 2019
VL 8
IS 10
AR 471
DI 10.3390/antiox8100471
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA JT1LQ
UT WOS:000500759900054
PM 31658599
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Jiang, LH
   Zhang, HD
   Tang, JH
AF Jiang, Lin-hong
   Zhang, He-da
   Tang, Jin-hai
TI MiR-30a: A Novel Biomarker and Potential Therapeutic Target for Cancer
SO JOURNAL OF ONCOLOGY
LA English
DT Review
ID EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ALTERED MICRORNA
   EXPRESSION; WNT/BETA-CATENIN PATHWAY; DOWN-REGULATION;
   COLORECTAL-CANCER; MATRIX METALLOPROTEINASES; SIGNALING PATHWAY;
   POOR-PROGNOSIS; TUMOR-GROWTH
AB MicroRNAs (miRNAs) are small, highly conserved noncoding RNAs molecules, consisting of 18-25 nucleotides that regulate gene expression by binding to complementary binding sites within the 3' untranslated region (3'UTR) of target mRNAs. MiRNAs have been involved in regulating gene expression and diverse physiological and pathological processes. Several studies have reported that miR-30a, situated on chromosome 6q.13, is produced by an intronic transcriptional unit. Moreover, miR-30a has demonstrated its role in biological processes, including inhibiting proliferation and metastasis in many tumors, autophagy in chronic myelogenous leukemia, and regulating TGF-b1-induced epithelial-mesenchymal transition. However, based on the pathogenetic relationship between miR-30a and cancer in tumorigenesis, we believe that miR-30a may serve as tumor promising biomarker. Moreover, it would offer a therapeutic target for the treatment of cancer.
C1 [Jiang, Lin-hong] Xuzhou Med Univ, Dept Oncol, Xuzhou, Jiangsu, Peoples R China.
   [Jiang, Lin-hong] Xuzhou Infect Dis Hosp, Xuzhou, Jiangsu, Peoples R China.
   [Zhang, He-da] Southeast Univ, Sch Med, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China.
   [Tang, Jin-hai] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China.
RP Tang, JH (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Jiangsu, Peoples R China.
EM jhtang@njmu.edu.cn
FU National Key Research and Development Program of China [2016YFC0905900];
   Natural Science Foundation of Jiangsu ProvinceNatural Science Foundation
   of Jiangsu Province [BK20151579]
FX This research was supported by the National Key Research and Development
   Program of China (no. 2016YFC0905900) and Natural Science Foundation of
   Jiangsu Province (no. BK20151579).
CR Banyard J, 2015, CONNECT TISSUE RES, V56, P403, DOI 10.3109/03008207.2015.1060970
   Baraniskin A, 2012, CARCINOGENESIS, V33, P732, DOI 10.1093/carcin/bgs020
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Botrugno OA, 2004, MOL CELL, V15, P499, DOI 10.1016/j.molcel.2004.07.009
   Canzio D, 2014, TRENDS CELL BIOL, V24, P377, DOI 10.1016/j.tcb.2014.01.002
   Chang CW, 2016, ONCOTARGET, V7, P16462, DOI 10.18632/oncotarget.7656
   Cheng CW, 2012, BREAST CANCER RES TR, V134, P1081, DOI 10.1007/s10549-012-2034-4
   Cheng YX, 2015, BIOMED PHARMACOTHER, V75, P67, DOI 10.1016/j.biopha.2015.08.034
   Chitnis MM, 2008, CLIN CANCER RES, V14, P6364, DOI 10.1158/1078-0432.CCR-07-4879
   Demirkan B, 2013, J CLIN MED, V2, P264, DOI 10.3390/jcm2040264
   Duran GE, 2015, MOL CANCER THER, V14, P193, DOI 10.1158/1535-7163.MCT-14-0155
   Franzetti GA, 2013, ONCOGENE, V32, P3915, DOI 10.1038/onc.2012.403
   Fu J, 2014, BIOCHEM BIOPH RES CO, V445, P314, DOI 10.1016/j.bbrc.2014.01.174
   Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011
   Huang Q, 2014, BIOCHEM BIOPH RES CO, V453, P160, DOI 10.1016/j.bbrc.2014.09.076
   Igci YZ, 2015, GENET TEST MOL BIOMA, V19, P418, DOI 10.1089/gtmb.2015.0062
   Jia ZF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055008
   Jiang D, 2016, TUMOR BIOL, V37, P5933, DOI 10.1007/s13277-015-4454-3
   Kim Y, 2010, J BIOL CHEM, V285, P25957, DOI 10.1074/jbc.M109.095950
   Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218
   Lee CH, 2013, INT J MOL SCI, V14, P11560, DOI 10.3390/ijms140611560
   Lee JH, 2015, ONCOTARGET, V6, P6386, DOI 10.18632/oncotarget.3443
   Li CY, 2016, MED SCI MONITOR, V22, P4509, DOI 10.12659/MSM.898415
   Li WF, 2016, TUMOR BIOL, V37, P5885, DOI 10.1007/s13277-015-4456-1
   Li WT, 2016, INT J ONCOL, V48, P1155, DOI 10.3892/ijo.2016.3319
   Liao HZ, 2015, ONCOTARGET, V6, P8914, DOI 10.18632/oncotarget.3563
   Liu KM, 2015, EUR J CELL BIOL, V94, P22, DOI 10.1016/j.ejcb.2014.10.006
   Liu M, 2015, CANCER RES, V75, P4593, DOI 10.1158/0008-5472.CAN-14-3735
   Liu ZY, 2014, FEBS LETT, V588, P3089, DOI 10.1016/j.febslet.2014.06.037
   Liu ZF, 2014, J CELL MOL MED, V18, P610, DOI 10.1111/jcmm.12209
   Lu N, 2015, TUMOR BIOL, V36, P3843, DOI 10.1007/s13277-014-3026-2
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mallini P, 2014, CANCER TREAT REV, V40, P341, DOI 10.1016/j.ctrv.2013.09.008
   Mathew LK, 2014, CANCER DISCOV, V4, P53, DOI 10.1158/2159-8290.CD-13-0291
   Ouzounova M, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-139
   Park D, 2016, MOL CELLS, V39, P299, DOI 10.14348/molcells.2016.2242
   Qi FF, 2015, CLIN CANCER RES, V21, P3071, DOI 10.1158/1078-0432.CCR-14-2785
   Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Sestito R, 2016, ONCOTARGET, V7, P4009, DOI 10.18632/oncotarget.6546
   Shi ZD, 2012, J NEUROIMMUNE PHARM, V7, P892, DOI 10.1007/s11481-012-9354-3
   Song MX, 2014, PROTEIN CELL, V5, P851, DOI 10.1007/s13238-014-0093-5
   Sousa JF, 2016, GUT, V65, P914, DOI 10.1136/gutjnl-2014-308759
   Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228
   Tang RX, 2015, MED SCI MONITOR, V21, P2514, DOI 10.12659/MSM.894372
   Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tseng CW, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-99
   Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400
   Wach S, 2013, BRIT J CANCER, V109, P714, DOI 10.1038/bjc.2013.313
   Wang HY, 2014, EXP BIOL MED, V239, P891, DOI 10.1177/1535370214532758
   Wang LL, 2016, EUR REV MED PHARMACO, V20, P1733
   Wang TR, 2015, ONCOL LETT, V9, P967, DOI 10.3892/ol.2014.2723
   Wang W, 2014, EJSO-EUR J SURG ONC, V40, P1586, DOI 10.1016/j.ejso.2013.11.008
   Wang X, 2013, CANCER LETT, V331, P211, DOI 10.1016/j.canlet.2013.01.005
   Wang Y, 2014, INT J ONCOL, V44, P1904, DOI 10.3892/ijo.2014.2359
   Wang ZY, 2015, BIOCHEM BIOPH RES CO, V465, P374, DOI 10.1016/j.bbrc.2015.08.007
   Wei W, 2016, CELL PHYSIOL BIOCHEM, V39, P1165, DOI 10.1159/000447823
   Wen JL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115622
   Wen XP, 2015, CELL MOL BIOL, V61, P78
   Xiong J., 2016, BIOCH BIOPHYSICAL RE
   Xu CG, 2016, EUR REV MED PHARMACO, V20, P1501
   Xu XJ, 2017, J MOL MED, V95, P861, DOI 10.1007/s00109-017-1539-z
   Yang LY, 2012, ONCOL REP, V28, P592, DOI 10.3892/or.2012.1823
   Yuan YC, 2016, ACTA BIOCH BIOPH SIN, V48, P220, DOI 10.1093/abbs/gmv139
   Zhang C, 2016, BJU INT, V118, P578, DOI 10.1111/bju.13407
   Zhang HD, 2015, TUMOR BIOL, V36, P1355, DOI 10.1007/s13277-015-3199-3
   Zhang LJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-124
   Zhang N, 2014, ONCOGENE, V33, P3119, DOI 10.1038/onc.2013.286
   Zhang PY, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0325-1
   Zhang Q, 2015, MOL CELL BIOL, V35, P988, DOI 10.1128/MCB.01242-14
   Zheng B, 2015, BIOCHEM BIOPH RES CO, V459, P234, DOI 10.1016/j.bbrc.2015.02.084
   Zhong M, 2013, CELL PHYSIOL BIOCHEM, V31, P209, DOI 10.1159/000343362
   Zhu ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106049
   Zhu H, 2009, AUTOPHAGY, V5, P816, DOI 10.4161/auto.9064
   Zou ZY, 2016, BIOCHEM J, V473, P2131, DOI 10.1042/BCJ20160177
   Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437
NR 77
TC 35
Z9 35
U1 1
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-8450
EI 1687-8469
J9 J ONCOL
JI J. Oncol.
PY 2018
VL 2018
AR 5167829
DI 10.1155/2018/5167829
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GQ8CL
UT WOS:000441977800001
PM 30158978
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Skalka, N
   Caspi, M
   Lahav-Ariel, L
   Loh, YP
   Hirschberg, K
   Rosin-Arbesfeld, R
AF Skalka, N.
   Caspi, M.
   Lahav-Ariel, L.
   Loh, Y. P.
   Hirschberg, K.
   Rosin-Arbesfeld, R.
TI Carboxypeptidase E (CPE) inhibits the secretion and activity of Wnt3a
SO ONCOGENE
LA English
DT Article
ID CELL-PROLIFERATION; COLORECTAL-CANCER; PATHWAY; STRESS; NEUROPROTECTION;
   EXPRESSION; ENDOCRINE; AUTOPHAGY; SURVIVAL; NEURONS
AB The Wnt pathway has essential roles in cell proliferation, cell fate determination and tumorigenesis by regulating the expression of a wide range of target genes. As a core signaling cascade, the canonical Wnt pathway is regulated at different levels by numerous proteins. We have previously shown that carboxypeptidase E (CPE) is a novel regulator of the canonical Wnt signaling pathway. Here, we show that CPE and the Wnt3a ligand are co-secreted from cells. We show that although the C'-terminal Lys residue of Wnt3a is critical for its activity and is important for the effect of CPE on the Wnt pathway, CPE does not execute its effect by removing this Wnt3a residue. Interestingly, CPE through its N'-terminal sequence, forms aggregates with Wnt3a and possible endoplasmic reticulum (ER) stress leading to its loss of function. Together, our current results provide a mechanistic insight into the way CPE regulates the canonical Wnt signaling pathway.
C1 [Skalka, N.; Caspi, M.; Lahav-Ariel, L.; Rosin-Arbesfeld, R.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.
   [Loh, Y. P.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Sect Cellular Neurobiol, Program Dev Neurosci, NIH, Bethesda, MD USA.
   [Hirschberg, K.] Tel Aviv Univ, Sackler Sch Med, Dept Pathol, Tel Aviv, Israel.
RP Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.
EM arina@post.tau.ac.il
FU Rising Tide Foundation for Clinical Cancer Research; Gateway for Cancer
   Research Foundation; Israel Science FoundationIsrael Science Foundation
   [20120016]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &
   HUMAN DEVELOPMENTUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy
   Shriver National Institute of Child Health & Human Development (NICHD)
   [ZIAHD000056] Funding Source: NIH RePORTER
FX This work was supported by Rising Tide Foundation for Clinical Cancer
   Research, by the Gateway for Cancer Research Foundation and by the
   Israel Science Foundation (Grant no. 20120016).
CR Bar F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102347
   Cawley NX, 2012, ENDOCR REV, V33, P216, DOI 10.1210/er.2011-1039
   Cheng Y, 2014, NEUROSCI BULL, V30, P692, DOI 10.1007/s12264-013-1430-z
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7
   Du C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033830
   FRICKER LD, 1983, J BIOL CHEM, V258, P950
   He P, 2004, HUM PATHOL, V35, P1196, DOI 10.1016/j.humpath.2004.06.014
   Horing E, 2012, ACTA NEUROPATHOL, V124, P83, DOI 10.1007/s00401-011-0940-x
   Holzer T, 2012, FEBS LETT, V586, P1638, DOI 10.1016/j.febslet.2012.04.035
   Kim HJ, 2014, MOL CELLS, V37, P685, DOI 10.14348/molcells.2014.0179
   Kunz M, 2004, DEV BIOL, V273, P390, DOI 10.1016/j.ydbio.2004.06.015
   Li XH, 2015, INFLAMM RES, V64, P1, DOI 10.1007/s00011-014-0772-y
   Liang XH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-412
   Liu AA, 2014, TUMOR BIOL, V35, P12459, DOI 10.1007/s13277-014-2564-y
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Moeller C, 2003, DEVELOPMENT, V130, P5103, DOI 10.1242/dev.00686
   Murthy SRK, 2013, ENDOCRINOLOGY, V154, P3284, DOI 10.1210/en.2013-1118
   Murthy SRK, 2013, CANCER LETT, V341, P204, DOI 10.1016/j.canlet.2013.08.011
   NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135
   Park JJ, 2008, MOL ENDOCRINOL, V22, P989, DOI 10.1210/me.2007-0473
   Polakis P, 2000, GENE DEV, V14, P1837
   Qian YM, 1999, J BIOL CHEM, V274, P11582, DOI 10.1074/jbc.274.17.11582
   Qin XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112996
   RAWLINGS ND, 1995, METHOD ENZYMOL, V248, P183
   Reznik SE, 2001, CELL MOL LIFE SCI, V58, P1790, DOI 10.1007/PL00000819
   Rhinn M, 2005, DEVELOPMENT, V132, P1261, DOI 10.1242/dev.01685
   Selvaraj P, 2015, MOL CELL NEUROSCI, V68, P222, DOI 10.1016/j.mcn.2015.08.005
   Sharma K, 2016, BIOCHEM PHARMACOL, V103, P17, DOI 10.1016/j.bcp.2015.12.018
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Skalka N, 2013, ONCOGENE, V32, P2836, DOI 10.1038/onc.2012.308
   Thouennon E, 2015, J NEUROCHEM, V134, P463, DOI 10.1111/jnc.13152
   Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981
   Wallkamm V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109428
   Wang L, 2009, J BONE MINER RES, V24, P265, DOI 10.1359/JBMR.081014
   Willert K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007864
   Zhang JT, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147218
   Zhou K, 2013, TUMOR BIOL, V34, P3691, DOI 10.1007/s13277-013-0952-3
NR 38
TC 6
Z9 6
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD DEC 15
PY 2016
VL 35
IS 50
BP 6416
EP 6428
DI 10.1038/onc.2016.173
PG 13
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA EF3TP
UT WOS:000390247600006
PM 27375026
OA Bronze
DA 2022-04-25
ER

PT J
AU Berger, MD
   Yamauchi, S
   Cao, S
   Hanna, DL
   Sunakawa, Y
   Schirripa, M
   Matsusaka, S
   Yang, DY
   Groshen, S
   Zhang, W
   Ning, Y
   Okazaki, S
   Miyamoto, Y
   Suenaga, M
   Lonardi, S
   Cremolini, C
   Falcone, A
   Heinemann, V
   Loupakis, F
   Stintzing, S
   Lenz, HJ
AF Berger, Martin D.
   Yamauchi, Shinichi
   Cao, Shu
   Hanna, Diana L.
   Sunakawa, Yu
   Schirripa, Marta
   Matsusaka, Satoshi
   Yang, Dongyun
   Groshen, Susan
   Zhang, Wu
   Ning, Yan
   Okazaki, Satoshi
   Miyamoto, Yuji
   Suenaga, Mitsukuni
   Lonardi, Sara
   Cremolini, Chiara
   Falcone, Alfredo
   Heinemann, Volker
   Loupakis, Fotios
   Stintzing, Sebastian
   Lenz, Heinz-Josef
TI Autophagy-related polymorphisms predict hypertension in patients with
   metastatic colorectal cancer treated with FOLFIRI and bevacizumab:
   Results from TRIBE and FIRE-3 trials
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Autophagy; Hypertension; Colorectal cancer; Single-nucleotide
   polymorphism; Bevacizumab-associated toxicity; FOLFIRI/bevacizumab
ID PLUS BEVACIZUMAB; INHIBITION; STRESS; PROGRESSION; SENESCENCE; APOPTOSIS
AB Purpose: The most frequent bevacizumab-related side-effects are hypertension, proteinuria, bleeding and thromboembolism. To date, there is no biomarker that predicts anti-VEGF-associated toxicity. As autophagy inhibits angiogenesis, we hypothesised that single-nucleotide polymorphisms (SNPs) within autophagy-related genes may predict bevacizumab-mediated toxicity in patients with metastatic colorectal cancer (mCRC).
   Patients and methods: Patients with mCRC treated with first-line FOLFIRI and bevacizumab in two phase III randomised trials, namely the TRIBE trial (n = 219, discovery cohort) and the FIRE-3 trial (n = 234, validation cohort) were included in this study. Patients receiving treatment with FOLFIRI and cetuximab (FIRE-3, n = 204) served as a negative control. 12 SNPs in eight autophagy-related genes (ATG3/5/8/13, beclin 1, FIP200, unc-51-like kinase 1, UVRAG) were analysed by PCR-based direct sequencing.
   Results: The FIP200 rs1129660 variant showed significant associations with hypertension in the TRIBE cohort. Patients harbouring any G allele of the FIP200 rs1129660 SNP showed a significantly lower rate of grade 2-3 hypertension compared with the A/A genotype (3% versus 15%, odds ratio [OR] 0.17; 95% confidence interval [CI], 0.02-0.73; P = 0.009). Similarly, G allele carriers of the FIP200 rs1129660 SNP were less likely to develop grade 2-3 hypertension than patients with an A/A genotype in the FIRE-3 validation cohort (9% versus 20%, OR 0.43; 95% CI, 0.14-1.11; P =0.077), whereas this association could not be observed in the control cohort (12% versus 9%, OR 1.40; 95% CI, 0.45-4.04; P = 0.60).
   Conclusion: This is the first report demonstrating that polymorphisms in the autophagy-related FIP200 gene may predict hypertension in patients with mCRC treated with FOLFIRI and bevacizumab. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Berger, Martin D.; Yamauchi, Shinichi; Hanna, Diana L.; Sunakawa, Yu; Schirripa, Marta; Matsusaka, Satoshi; Zhang, Wu; Ning, Yan; Okazaki, Satoshi; Miyamoto, Yuji; Suenaga, Mitsukuni; Lenz, Heinz-Josef] Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Keck Sch Med, 1441 Eastlake Ave, Los Angeles, CA 90033 USA.
   [Cao, Shu; Yang, Dongyun; Groshen, Susan; Lenz, Heinz-Josef] Univ Southern Calif, Dept Prevent Med, Norris Comprehens Canc Ctr, Keck Sch Med, 1441 Eastlake Ave, Los Angeles, CA 90033 USA.
   [Heinemann, Volker; Stintzing, Sebastian] Univ Munich LMU, Dept Med Oncol, Marchioninistr 15, D-81377 Munich, Germany.
   [Heinemann, Volker; Stintzing, Sebastian] Univ Munich LMU, Ctr Comprehens Canc, Marchioninistr 15, D-81377 Munich, Germany.
   [Schirripa, Marta; Lonardi, Sara; Loupakis, Fotios] IRCCS, Oncol Med 1, Ist Oncol Veneto, Via Gattamelata 64, I-35128 Padua, Italy.
   [Cremolini, Chiara; Falcone, Alfredo] Azienda Osped Univ Pisana, Ist Toscano Tumori, UO Oncol Med, Via Roma 67, I-56126 Pisa, Italy.
RP Lenz, HJ (corresponding author), Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Keck Sch Med, 1441 Eastlake Ave, Los Angeles, CA 90033 USA.
EM lenz@med.usc.edu
RI Lonardi, Sara/F-4228-2014; Berger, Martin D./AAR-4415-2021; Cremolini,
   Chiara/AAC-1889-2019; Loupakis, Fotios/I-7243-2012; Yang,
   Dongyun/M-2579-2019; Schirripa, Marta/F-3688-2017; Berger, Martin
   D./AAS-1238-2021; Stintzing, Sebastian/I-4538-2016
OI Lonardi, Sara/0000-0002-7593-8138; Loupakis, Fotios/0000-0001-9651-0395;
   Yang, Dongyun/0000-0003-0736-4977; Schirripa, Marta/0000-0001-8316-4411;
   Berger, Martin D./0000-0001-9224-7104; Stintzing,
   Sebastian/0000-0002-3297-5801; Falcone, Alfredo/0000-0001-5840-2529;
   CREMOLINI, CHIARA/0000-0002-0520-4841; Miyamoto,
   Yuji/0000-0003-3948-5044
FU Swiss Cancer League [BIL KLS-3334-02-2014]; Werner and Hedy
   Berger-Janser Foundation for Cancer Research; National Cancer
   InstituteUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [P30CA014089]; Gloria Borges WunderGlo Project; Dhont Family Foundation;
   Japan Society for the Promotion of ScienceMinistry of Education,
   Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for
   the Promotion of Science [S2606]; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [P30CA014089] Funding Source:
   NIH RePORTER
FX Martin D. Berger received a grant from the Swiss Cancer League (BIL
   KLS-3334-02-2014) and the Werner and Hedy Berger-Janser Foundation for
   Cancer Research. This work was partly supported by the National Cancer
   Institute (grant number P30CA014089), the Gloria Borges WunderGlo
   Project and the Dhont Family Foundation. Y. Miyamoto received a grant
   from the Japan Society for the Promotion of Science (S2606).
CR Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Berger MD, 2016, EXPERT OPIN DRUG SAF, V15, P799, DOI 10.1517/14740338.2016.1167186
   Cai J, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-306
   Chao YM, 2013, HYPERTENSION, V61, P1270, DOI 10.1161/HYPERTENSIONAHA.111.00469
   Chen F, 2014, CELL PHYSIOL BIOCHEM, V33, P1058, DOI 10.1159/000358676
   De Meyer GRY, 2015, CIRC RES, V116, P468, DOI 10.1161/CIRCRESAHA.116.303804
   Du JH, 2012, AM J PHYSIOL-CELL PH, V302, pC383, DOI 10.1152/ajpcell.00164.2011
   Epstein JA, 2010, NEW ENGL J MED, V363, P1638, DOI 10.1056/NEJMra1003941
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Gan BY, 2006, J CELL BIOL, V175, P121, DOI 10.1083/jcb.200604129
   Ganley IG, 2009, J BIOL CHEM, V284, P12297, DOI 10.1074/jbc.M900573200
   Grothey A, 2008, J CLIN ONCOL, V26, P5326, DOI 10.1200/JCO.2008.16.3212
   Guo FX, 2014, ANN BIOMED ENG, V42, P1978, DOI 10.1007/s10439-014-1033-5
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Heinze G, 2006, STAT MED, V25, P4216, DOI 10.1002/sim.2687
   Kaizuka T, 2016, MOL CELL BIOL, V36, P585, DOI 10.1128/MCB.01005-15
   Kelekar A, 2005, ANN NY ACAD SCI, V1066, P259, DOI 10.1196/annals.1363.015
   Kumar S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.399
   Lambrechts D, 2014, ANGIOGENESIS, V17, P685, DOI 10.1007/s10456-014-9424-7
   Liang J, 2015, ONCOTARGET, V6, P31479, DOI 10.18632/oncotarget.5491
   Long L, 2013, CIRC RES, V112, P1159, DOI 10.1161/CIRCRESAHA.111.300483
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454
   Mei Y, 2015, BBA-MOL BASIS DIS, V1852, P243, DOI 10.1016/j.bbadis.2014.05.005
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352
   Ouseph MM, 2015, BLOOD, V126, P1224, DOI 10.1182/blood-2014-09-598722
   Ramakrishnan S, 2007, AUTOPHAGY, V3, P512
   Schneider BP, 2014, BRIT J CANCER, V111, P1241, DOI 10.1038/bjc.2014.430
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shan HY, 2014, APMIS, V122, P985, DOI 10.1111/apm.12242
   Wang ZV, 2010, J BIOL CHEM, V285, P8509, DOI 10.1074/jbc.R109.025023
   Wong R, 2011, ANN ONCOL, V22, P2042, DOI 10.1093/annonc/mdq714
   Wu SM, 2006, CELL, V127, P1137, DOI 10.1016/j.cell.2006.10.028
NR 37
TC 15
Z9 15
U1 2
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD MAY
PY 2017
VL 77
BP 13
EP 20
DI 10.1016/j.ejca.2017.02.020
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EV7BS
UT WOS:000401929900003
PM 28347919
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Lin, YM
   Chen, CI
   Hsiang, YP
   Hsu, YC
   Cheng, KC
   Chien, PH
   Pan, HL
   Lu, CC
   Chen, YJ
AF Lin, Yueh-Ming
   Chen, Chih-I
   Hsiang, Yi-Ping
   Hsu, Yung-Chia
   Cheng, Kung-Chuan
   Chien, Pei-Hsuan
   Pan, Hsiao-Lin
   Lu, Chien-Chang
   Chen, Yun-Ju
TI Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells
   through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE CRC; chrysin; chemotherapy; autophagy; ROS
ID FLAVONOID CHRYSIN; CROSS-TALK; RESISTANCE; OXALIPLATIN; EXPRESSION;
   BIOMARKERS; MICRORNAS; TOXICITY
AB Chemotherapeutic 5-fluorouracil (5-FU) combined with oxaliplatin is often used as the standard treatment for colorectal cancer (CRC). The disturbing side effects and drug resistance commonly observed in chemotherapy motivate us to develop alternative optimal therapeutic options for CRC treatment. Chrysin, a natural and biologically active flavonoid abundant in propolis, is reported to have antitumor effects on a few CRCs. However, whether and how chrysin achieves similar effectiveness to the 5-FU combination is not clear. In this study, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), western blotting, fluorescence microscopy, and reactive oxygen species (ROS) production were assayed. We found that chrysin exhibited similar inhibition of cell viability as the 5-FU combination in a panel of human CRC cells. Furthermore, the results showed that chrysin significantly increased the levels of LC3-II, an autophagy-related marker, in CRC cells, which was not observed with the 5-FU combination. More importantly, blockage of autophagy induction restored chrysin-attenuated CRC cell viability. Further mechanistic analysis revealed that chrysin, not the 5-FU combination, induced ROS generation, and in turn, inhibited the phosphorylation of protein kinase B (Akt) and mammalian target of rapamycin (mTOR). Collectively, these results imply that chrysin may be a potential replacement for the 5-FU and oxaliplatin combination to achieve antitumor activity through autophagy for CRC treatment in the future.
C1 [Lin, Yueh-Ming; Cheng, Kung-Chuan; Lu, Chien-Chang] Kaohsiung Chang Gung Mem Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung 833, Taiwan.
   [Lin, Yueh-Ming; Cheng, Kung-Chuan; Lu, Chien-Chang] Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan.
   [Chen, Chih-I] E Da Hosp, Dept Surg, Div Colon & Rectal Surg, Kaohsiung 824, Taiwan.
   [Chen, Chih-I; Chen, Yun-Ju] I Shou Univ, Sch Med Int Students, Kaohsiung 824, Taiwan.
   [Hsiang, Yi-Ping] E Da Hosp, Dept Pharm, Kaohsiung 824, Taiwan.
   [Hsu, Yung-Chia; Chen, Yun-Ju] E Da Canc Hosp, Dept Pharm, Kaohsiung 824, Taiwan.
   [Chien, Pei-Hsuan; Pan, Hsiao-Lin; Chen, Yun-Ju] E Da Hosp, Dept Med Res, Kaohsiung 824, Taiwan.
RP Lu, CC (corresponding author), Kaohsiung Chang Gung Mem Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung 833, Taiwan.; Lu, CC (corresponding author), Chang Gung Univ, Coll Med, Kaohsiung 833, Taiwan.; Chen, YJ (corresponding author), I Shou Univ, Sch Med Int Students, Kaohsiung 824, Taiwan.; Chen, YJ (corresponding author), E Da Canc Hosp, Dept Pharm, Kaohsiung 824, Taiwan.; Chen, YJ (corresponding author), E Da Hosp, Dept Med Res, Kaohsiung 824, Taiwan.
EM porta2005@gmail.com; jimmyee0901@gmail.com; ed108228@edah.org.tw;
   ed108840@edah.org.tw; topguncheng@gmail.com; peihsuan68@gmail.com;
   dkiyh@yahoo.com.tw; doctor.lu@msa.hinet.net; yjchen0326@isu.edu.tw
OI Chen, Chih-I/0000-0002-5311-6889
FU Ministry of Science and Technology, R.O.C. [MOST 105-2320-B-214-005];
   E-Da Hospital [EDPJ104070, EDPJ105083]
FX This work was supported by grants from the Ministry of Science and
   Technology, R.O.C. (MOST 105-2320-B-214-005), and E-Da Hospital
   (EDPJ104070 and EDPJ105083).
CR Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   Basu A, 2016, J CARDIOVASC PHARM, V68, P89, DOI 10.1097/FJC.0000000000000380
   CLARKE PGH, 1990, ANAT EMBRYOL, V181, P195, DOI 10.1007/bf00174615
   Coppede F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Feng XJ, 2014, BIOCHEM PHARMACOL, V89, P503, DOI 10.1016/j.bcp.2014.03.016
   Field KM, 2008, J ONCOL PRACT, V4, P271, DOI 10.1200/JOP.0852002
   Fu BB, 2007, MOL CANCER THER, V6, P220, DOI 10.1158/1535-7163.MCT-06-0526
   Goldman B, 2003, J NATL CANCER I, V95, P255, DOI 10.1093/jnci/95.4.255
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Jiang YQ, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/8519169
   Kandemir FM, 2017, SCI PHARM, V85, DOI 10.3390/scipharm85010004
   Kim KY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051088
   Koosha S, 2016, INT J MED SCI, V13, P374, DOI 10.7150/ijms.14485
   Kuropatnicki AK, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/964149
   Lee CS, 2014, WORLD J GASTROENTERO, V20, P3751, DOI 10.3748/wjg.v20.i14.3751
   Liao CL, 2014, J AGR FOOD CHEM, V62, P10458, DOI 10.1021/jf501234b
   Lin SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071412
   Lirdprapamongkol K, 2013, ONCOL REP, V30, P2357, DOI 10.3892/or.2013.2667
   Mohammadi A, 2016, BIOMED PHARMACOTHER, V84, P705, DOI 10.1016/j.biopha.2016.09.099
   Prochilo T, 2012, CURR DRUG SAF, V7, P179, DOI 10.2174/157488612802715672
   Puccini A, 2017, BBA-REV CANCER, V1868, P439, DOI 10.1016/j.bbcan.2017.09.003
   Ryu S, 2017, J CELL PHYSIOL, V232, P3786, DOI 10.1002/jcp.25861
   Sak Katrin, 2014, Pharmacogn Rev, V8, P122, DOI 10.4103/0973-7847.134247
   Salimi A, 2017, CANCER INVEST, V35, P174, DOI 10.1080/07357907.2016.1276187
   Sharom FJ, 2008, PHARMACOGENOMICS, V9, P105, DOI 10.2217/14622416.9.1.105
   Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x
   Shin S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/568671
   Sun LP, 2012, J AGR FOOD CHEM, V60, P11748, DOI 10.1021/jf303261r
   Swart C, 2016, EUR J CELL BIOL, V95, P598, DOI 10.1016/j.ejcb.2016.10.005
   Temraz S, 2014, CRIT REV ONCOL HEMAT, V89, P217, DOI 10.1016/j.critrevonc.2013.08.015
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Walle T, 2001, BRIT J CLIN PHARMACO, V51, P143, DOI 10.1111/j.1365-2125.2001.01317.x
   Woo KJ, 2005, FEBS LETT, V579, P705, DOI 10.1016/j.febslet.2004.12.048
   Xie T, 2016, CELL PHYSIOL BIOCHEM, V40, P62, DOI 10.1159/000452525
   Xu D, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0514-4
   Zeinali M, 2017, BIOMED PHARMACOTHER, V92, P998, DOI 10.1016/j.biopha.2017.06.003
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1
NR 39
TC 18
Z9 18
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JUN
PY 2018
VL 19
IS 6
AR 1763
DI 10.3390/ijms19061763
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GK8UZ
UT WOS:000436506600218
PM 29899208
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Tian, Y
   Gong, GY
   Ma, LL
   Wang, ZQ
   Song, D
   Fang, MY
AF Tian, Ye
   Gong, Guan-Yu
   Ma, Liang-Liang
   Wang, Zhuo-Qun
   Song, Dan
   Fang, Mei-Yun
TI Anti-cancer effects of Polyphyllin I: An update in 5 years
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Review
DE Traditional medicine; Polyphyllin I; Cancer; Inflammation
ID D INDUCES APOPTOSIS; BREAST-CANCER CELLS; HUMAN GLIOMA-CELLS;
   PARIS-POLYPHYLLA; CYCLE ARREST; COLORECTAL-CANCER; GROWTH-INHIBITION;
   SIGNALING PATHWAY; STEROIDAL SAPONIN; PHASE ARREST
AB Chong-lou, the rhizome of Paris polyphylla, has been used in herbal regimes to treat parotitis, mastitis and certain malignant tumors for thousands of years in traditional medicine. Polyphyllin I (PPI) is the main bioactive component in Paris polyphylla. Recent studies of PPI in various types of cancers have shown that PPI may exert a broad spectrum of anti-tumor effects, including inducing cell cycle arrest, inducing cell apoptosis, inducing autophagy, anti-angiogenesis, sensitizing tumors to chemotherapy, and participating in the modulation of inflammatory and immune response. Along with the growing research interest in PPI as well as accumulation of experimental evidences, this review periodically summarized the recent advances in regard to PPI's anti-tumor propensities in various cancers and the underlying mechanisms for future prospective research.
C1 [Tian, Ye] Xian Med Univ, Dept Nephrol & Endocrinol, Affiliated Hosp 2, Xian 710038, Peoples R China.
   [Gong, Guan-Yu] Dalian Univ, Inst Translat Med, Affiliated Zhongshan Hosp, Dalian 116001, Peoples R China.
   [Ma, Liang-Liang] Dalian Med Univ, Dept Hematol, Affiliated Hosp 1, Dalian 116021, Peoples R China.
   [Wang, Zhuo-Qun] Cent Hosp Zibo, Dept Oncol, Zibo 255036, Peoples R China.
   [Song, Dan] Dalian Med Univ, Dept Oncol, Affiliated Hosp 1, Dalian 116021, Peoples R China.
   [Fang, Mei-Yun] Dalian Univ, Dept Hematol, Affiliated Zhongshan Hosp, 6 Jiefang St, Dalian 116001, Peoples R China.
RP Fang, MY (corresponding author), Dalian Univ, Dept Hematol, Affiliated Zhongshan Hosp, 6 Jiefang St, Dalian 116001, Peoples R China.
EM 646603350@qq.com; dlfangmeiyun@sina.com
RI Gong, Guanyu/ABA-1935-2021
OI Gong, Guanyu/0000-0002-5791-0916
CR Al Sawah E, 2015, J CANCER RES CLIN, V141, P237, DOI 10.1007/s00432-014-1797-x
   Ballweg R, 2018, BIOPHYS J, V115, P2250, DOI 10.1016/j.bpj.2018.10.025
   Chan JYW, 2011, J ETHNOPHARMACOL, V137, P64, DOI 10.1016/j.jep.2011.04.021
   Chang JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07194-9
   Chen HJ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123055
   Chen JR, 2016, INT J ONCOL, V48, P2063, DOI 10.3892/ijo.2016.3423
   Chen MS, 2019, ARCH ORAL BIOL, V98, P75, DOI 10.1016/j.archoralbio.2018.10.027
   Chen XX, 2017, FOOD CHEM TOXICOL, V107, P248, DOI 10.1016/j.fct.2017.07.012
   Cheung JYN, 2005, CANCER LETT, V217, P203, DOI 10.1016/j.canlet.2004.06.042
   Cui DR, 2016, CELL DIV, V11, DOI 10.1186/s13008-016-0022-5
   Cui Q, 2018, DRUG RESIST UPDATE, V41, P1, DOI 10.1016/j.drup.2018.11.001
   Dasiram JD, 2017, BIOMED PHARMACOTHER, V86, P373, DOI 10.1016/j.biopha.2016.12.034
   Deng SJ, 2015, FOOD CHEM TOXICOL, V75, P173, DOI 10.1016/j.fct.2014.11.019
   Deng SJ, 1999, CARBOHYD RES, V317, P53, DOI 10.1016/S0008-6215(99)00066-X
   Ding XY, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0671-3
   Dong RZ, 2018, BIOCHEM BIOPH RES CO, V497, P1129, DOI 10.1016/j.bbrc.2018.02.193
   Franklin RA, 2000, LEUKEMIA, V14, P2019, DOI 10.1038/sj.leu.2401967
   Gao CL, 2018, ONCOL LETT, V15, P2815, DOI 10.3892/ol.2017.7691
   Gao MH, 2012, ARCH TOXICOL, V86, P741, DOI 10.1007/s00204-012-0808-4
   Gu LH, 2013, J TRADIT CHIN MED, V33, P325, DOI 10.1016/S0254-6272(13)60174-0
   Hervouet Eric, 2013, Cells, V2, P545, DOI 10.3390/cells2030545
   Hseu YC, 2011, J ETHNOPHARMACOL, V134, P111, DOI 10.1016/j.jep.2010.11.058
   Hsui CM, 2013, INT J ONCOL, V43, P338, DOI 10.3892/ijo.2013.1942
   Hu J., 2010, MOD ONCOL MED, V18, P1886
   Hu W.Y., 2015, PROPRIETARY CHIN MED, V37, P1582
   Hustedt N, 2017, NAT CELL BIOL, V19, P1, DOI 10.1038/ncb3452
   Kang YJ, 2011, J NAT PROD, V74, P701, DOI 10.1021/np1007735
   Kong MJ, 2010, ACTA BIOCH BIOPH SIN, V42, P827, DOI 10.1093/abbs/gmq091
   Kumar I, 2009, BRIT J SURG, V96, P1484, DOI 10.1002/bjs.6778
   Lee MS, 2005, CANCER BIOL THER, V4, P1248, DOI 10.4161/cbt.4.11.2136
   Li B, 2001, CARBOHYD RES, V331, P1, DOI 10.1016/S0008-6215(01)00014-3
   Li GB, 2017, ONCOTARGET, V8, P10359, DOI 10.18632/oncotarget.14413
   Li LM, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0388-x
   Li Yuxiu, 2016, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V32, P625
   Liang Y, 2016, EUR J HAEMATOL, V97, P371, DOI 10.1111/ejh.12741
   Lin JG, 2018, BIOMED PHARMACOTHER, V98, P433, DOI 10.1016/j.biopha.2017.12.058
   Liu CQ, 2015, INT J CLIN EXP MED, V8, P16571
   Liu JT, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0721-9
   Liu JX, 2017, ACTA BIOCH BIOPH SIN, V49, P479, DOI 10.1093/abbs/gmx033
   Liu J, 2016, BIOORG MED CHEM LETT, V26, P4970, DOI 10.1016/j.bmcl.2016.09.005
   Liu XW, 2018, INT J ONCOL, V53, P1279, DOI 10.3892/ijo.2018.4464
   Long J.W., 2014, CHIN J DERMATOVENERO, V2, P128
   Lou W, 2017, BIOL PHARM BULL, V40, P1306, DOI 10.1248/bpb.b17-00271
   Ma DD, 2009, J INT MED RES, V37, P631, DOI 10.1177/147323000903700305
   Ma JJ, 2018, IRAN J BASIC MED SCI, V21, P717, DOI 10.22038/IJBMS.2018.23897.5995
   Mitomo S, 2016, RES VET SCI, V107, P147, DOI 10.1016/j.rvsc.2016.06.007
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Moroishi T, 2016, CELL, V167, P1525, DOI 10.1016/j.cell.2016.11.005
   Nahata, 2017, INT J CLIN PHARM TOX, V6, P250, DOI DOI 10.19070/2167-910x-1700042
   Negi JS, 2014, ANTI-CANCER AGENT ME, V14, P833, DOI 10.2174/1871520614666140611101040
   Ong RCY, 2008, CANCER LETT, V261, P158, DOI 10.1016/j.canlet.2007.11.005
   Pan P., 2015, NANO RES, V8, P1
   Pare MF, 2017, BBA-MOL CELL RES, V1864, P708, DOI 10.1016/j.bbamcr.2016.12.015
   Patil Shankargouda, 2015, J Int Oral Health, V7, pi
   Pharmacopoeia Commission of PRC, 2001, PHARMACOPOEIA COMMIS, P243
   Redza-Dutordoir M, 2016, BBA-MOL CELL RES, V1863, P2977, DOI 10.1016/j.bbamcr.2016.09.012
   Ruan YS, 2015, MOL MED REP, V12, P5796, DOI 10.3892/mmr.2015.4148
   Shi LL, 2016, BIOCONJUGATE CHEM, V27, P2943, DOI 10.1021/acs.bioconjchem.6b00643
   Shi YM, 2015, PHYTOMEDICINE, V22, P1139, DOI 10.1016/j.phymed.2015.08.014
   Siu FM, 2008, PROTEOMICS, V8, P3105, DOI 10.1002/pmic.200700829
   Sun QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098866
   Sun YF, 2016, AM J CANCER RES, V6, P114
   Teng W.J., 2015, SHI J J, V4, P808
   Tian Y, 2019, CHEM-BIOL INTERACT, V311, DOI 10.1016/j.cbi.2019.108793
   Um HD, 2016, ONCOTARGET, V7, P5193, DOI 10.18632/oncotarget.6405
   Wahl DR, 2017, ADV DRUG DELIVER REV, V109, P74, DOI 10.1016/j.addr.2015.11.007
   Wang K, 2018, J INT MED RES, V46, P675, DOI 10.1177/0300060517734460
   Wang Q, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02091
   Wu HW, 2016, ONCOL LETT, V12, P3614, DOI 10.3892/ol.2016.5048
   Wu LN, 2014, J PHARM PHARMACOL, V66, P713, DOI 10.1111/jphp.12188
   Xiang S, 2017, BIOCHIM BIOPHYS ACTA, V1862, P589, DOI DOI 10.1016/J.BBAGEN.2017.12.001
   Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0902-5
   Yang CH, 2016, INT IMMUNOPHARMACOL, V36, P17, DOI 10.1016/j.intimp.2016.04.011
   Yang Q, 2018, TOXICOL APPL PHARM, V356, P1, DOI 10.1016/j.taap.2018.07.031
   Yu F.L., 2018, EUR J DRUG METAB PH, V3, P1
   Yu Q, 2014, J MED FOOD, V17, P1036, DOI 10.1089/jmf.2013.2957
   Zhang JX, 2015, J CONTROL RELEASE, V213, pE51, DOI 10.1016/j.jconrel.2015.05.083
   Zhang TG, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00753
   Zhang YF, 2018, J PHARMACOL SCI, V137, P305, DOI 10.1016/j.jphs.2018.07.008
   Zhu T., 2018, INFLAMMATION, V18, P1
   Zhu X, 2018, ANTI-CANCER AGENT ME, V18, P875, DOI 10.2174/1871520618666180108095148
   Zhuo ZJ, 2018, ONCOL LETT, V15, P2097, DOI 10.3892/ol.2017.7575
   Zong W, 2016, ONCOL RES, V24, P17, DOI 10.3727/096504016X14570992647203
NR 83
TC 11
Z9 13
U1 12
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD JAN 25
PY 2020
VL 316
AR 108936
DI 10.1016/j.cbi.2019.108936
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA KN4NM
UT WOS:000514815400024
PM 31870841
DA 2022-04-25
ER

PT J
AU Cheng, L
   Han, T
   Zhang, ZY
   Yi, PJ
   Zhang, CH
   Zhang, SF
   Peng, WJ
AF Cheng, Lin
   Han, Tong
   Zhang, Zheyu
   Yi, Pengji
   Zhang, Chunhu
   Zhang, Sifang
   Peng, Weijun
TI Identification and Validation of Six Autophagy-related Long Non-coding
   RNAs as Prognostic Signature in Colorectal Cancer
SO INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
LA English
DT Article
DE Autophagy; colorectal cancer; long non-coding RNA; prognostic signature
ID MTOR PATHWAY; VEGF; P53; ACTIVATION; THERAPY; DISEASE; HEALTH; UCA1;
   DRAM
AB Colorectal cancer (CRC) is a commonly occurring tumour with poor prognosis. Autophagy-related long non-coding RNAs (lncRNAs) have received much attention as biomarkers for cancer prognosis and diagnosis. However, few studies have focused on their prognostic predictive value specifically in CRC. This research aimed to construct a robust autophagy-related lncRNA prognostic signature for CRC. Autophagy-related lncRNAs from The Cancer Genome Atlas database were screened using univariate Cox, LASSO, and multivariate Cox regression analyses, and the resulting key lncRNAs were used to establish a prognostic risk score model. Furthermore, quantitative real-time polymerase chain reaction (qRT-PCR) analysis was performed to detect the expression of several lncRNAs in cancer tissues from CRC patients and in normal tissues adjacent to the cancer tissues. A prognostic signature comprising lncRNAs AC125603.2, LINC00909, AC016876.1, MIR210HG, AC009237.14, and LINC01063 was identified in patients with CRC. A graphical nomogram based on the autophagy-related lncRNA signature was developed to predict CRC patients' 1-, 3-, and 5-year survival. Overall survival in patients with low risk scores was significantly better than in those with high risk scores (P < 0.0001); a similar result was obtained in an internal validation sample. The nomogram was shown to be suitable for clinical use and gave correct predictions. The 1- and 3-year values of the area under the receiver operating characteristic curve were 0.797 and 0.771 in the model sample, and 0.656 and 0.642 in the internal validation sample, respectively. The C-index values for the verification samples and training samples were 0.756 (95% CI = 0.668-0.762) and 0.715 (95% CI = 0.683-0.829), respectively. Gene set enrichment analysis showed that the six autophagy-related lncRNAs were greatly enriched in CRC-related signalling pathways, including p53 and VEGF signalling. The qRT-PCR results showed that the expression of lncRNAs in CRC was higher than that in adjacent tissues, consistent with the expression trends of lncRNAs in the CRC data set. In summary, we established a signature of six autophagy-related lncRNAs that could effectively guide clinical prediction of prognosis in patients with CRC. This lncRNA signature has significant clinical implications for improving the prediction of outcomes and, with further prospective validation, could be used to guide tailored therapy for CRC patients.
C1 [Cheng, Lin; Zhang, Zheyu; Yi, Pengji; Zhang, Sifang; Peng, Weijun] Cent South Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Med, Changsha 410011, Hunan, Peoples R China.
   [Han, Tong] Cent South Univ, Xiangya Hosp 2, Dept Gen Surg, 139 Middle Renmin Rd, Changsha 410011, Hunan, Peoples R China.
   [Zhang, Chunhu] Cent South Univ, Xiangya Hosp, Dept Integrated Tradit Chinese & Western Med, Changsha 410008, Hunan, Peoples R China.
RP Zhang, SF; Peng, WJ (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Integrated Tradit Chinese & Western Med, Changsha 410011, Hunan, Peoples R China.
EM sifangzhang2005@csu.edu.cn; pengweijun87@csu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81273722]; Hunan Provincial Natural Science
   Foundation of ChinaNatural Science Foundation of Hunan Province
   [2018JJ2595]; Research projects of traditional Chinese medicine of Hunan
   Province [2020012]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81273722),Hunan Provincial Natural Science Foundation of
   China (No. 2018JJ2595), and Research projects of traditional Chinese
   medicine of Hunan Province (No. 2020012).
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Bhattacharya R, 2017, BRIT J CANCER, V117, P848, DOI 10.1038/bjc.2017.238
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Cross B, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.228981
   Fang YW, 2016, GENOM PROTEOM BIOINF, V14, P42, DOI 10.1016/j.gpb.2015.09.006
   Gao ZY, 2018, MOL NEUROBIOL, V55, P1988, DOI 10.1007/s12035-017-0426-5
   Guan YS, 2016, ANTI-CANCER DRUG, V27, P811, DOI 10.1097/CAD.0000000000000397
   Han Y, 2014, PATHOLOGY, V46, P396, DOI 10.1097/PAT.0000000000000125
   Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282
   Hsu P, 2017, BBA-MOL CELL BIOL L, V1862, P114, DOI 10.1016/j.bbalip.2016.08.003
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Jarroux J, 2017, ADV EXP MED BIOL, V17, P1008
   Nguyen JT, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao5838
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kondo Y, 2017, CANCER SCI, V108, P1927, DOI 10.1111/cas.13342
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kulasingam V, 2008, NAT CLIN PRACT ONCOL, V5, P588, DOI 10.1038/ncponc1187
   Lane DP, 2005, COLD SH Q B, V70, P489, DOI 10.1101/sqb.2005.70.049
   Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723
   Li ZK, 2014, CANCER SCI, V105, P951, DOI 10.1111/cas.12461
   Luan FK, 2019, FEBS OPEN BIO, V9, P653, DOI 10.1002/2211-5463.12601
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Mishra SK, 2018, AUTOPHAGY, V14, P862, DOI 10.1080/15548627.2017.1393129
   Mrschtik M, 2016, AUTOPHAGY, V12, P603, DOI 10.1080/15548627.2015.1137412
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nannini M, 2009, CANCER TREAT REV, V35, P201, DOI 10.1016/j.ctrv.2008.10.006
   Naruse T, 2011, ANTICANCER RES, V31, P4429
   Pappa KI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142229
   Rosner M, 2008, MUTAT RES-REV MUTAT, V659, P284, DOI 10.1016/j.mrrev.2008.06.001
   Ruan GX, 2012, EMBO J, V31, P1692, DOI 10.1038/emboj.2012.21
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Schirripa M, 2016, CANCER J, V22, P156, DOI 10.1097/PPO.0000000000000190
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Song J, 2014, J ORTHOP RES, V32, P1628, DOI 10.1002/jor.22718
   Sood AK, 2012, J CLIN ONCOL, V30, P345, DOI 10.1200/JCO.2011.38.8413
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Yan BA, 2010, J CELL BIOCHEM, V111, P1114, DOI 10.1002/jcb.22797
   Yang L, 2016, MOL BIOSYST, V12, P2605, DOI 10.1039/c6mb00114a
   Yu IS, 2018, CAN J GASTROENTEROL, V2018, DOI 10.1155/2018/9450754
   Zhang YM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008242
   Zhao YG, 2019, CURR OPIN CELL BIOL, V61, P117, DOI 10.1016/j.ceb.2019.08.003
   Zheng R, 2014, J BUON, V19, P336
NR 44
TC 8
Z9 8
U1 1
U2 14
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449-1907
J9 INT J MED SCI
JI Int. J. Med. Sci.
PY 2021
VL 18
IS 1
BP 88
EP 98
DI 10.7150/ijms.49449
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA OP2JW
UT WOS:000587910700010
PM 33390777
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Shu, YH
   Yuan, HH
   Xu, MT
   Hong, YT
   Gao, CC
   Wu, ZP
   Han, HT
   Sun, X
   Gao, RL
   Yang, SF
   Li, SX
   Tian, JK
   Zhang, JB
AF Shu, Yu-han
   Yuan, Hua-hua
   Xu, Meng-ting
   Hong, Ye-ting
   Gao, Cheng-cheng
   Wu, Zhi-pan
   Han, Hao-te
   Sun, Xin
   Gao, Rui-lan
   Yang, Si-fu
   Li, Shou-xin
   Tian, Jing-kui
   Zhang, Jian-bin
TI A novel Diels-Alder adduct of mulberry leaves exerts anticancer effect
   through autophagy-mediated cell death
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE Guangsangon E; autophagy; ER stress; respiratory cancer
ID COLORECTAL-CANCER; OXIDATIVE STRESS; APOPTOSIS; ACTIVATION; INJURY
AB Guangsangon E (GSE) is a novel Diels-Alder adduct isolated from leaves ofMorus albaL, a traditional Chinese medicine widely applied in respiratory diseases. It is reported that GSE has cytotoxic effect on cancer cells. In our research, we investigated its anticancer effect on respiratory cancer and revealed that GSE induces autophagy and apoptosis in lung and nasopharyngeal cancer cells. We first observed that GSE inhibits cell proliferation and induces apoptosis in A549 and CNE1 cells. Meanwhile, the upregulation of autophagosome marker LC3 and increased formation of GFP-LC3 puncta demonstrates the induction of autophagy in GSE-treated cells. Moreover, GSE increases the autophagy flux by enhancing lysosomal activity and the fusion of autophagosomes and lysosomes. Next, we investigated that endoplasmic reticulum (ER) stress is involved in autophagy induction by GSE. GSE activates the ER stress through reactive oxygen species (ROS) accumulation, which can be blocked by ROS scavenger NAC. Finally, inhibition of autophagy attenuates GSE-caused cell death, termed as "autophagy-mediated cell death." Taken together, we revealed the molecular mechanism of GSE against respiratory cancer, which demonstrates great potential of GSE in the treatment of representative cancer.
C1 [Shu, Yu-han; Yuan, Hua-hua; Xu, Meng-ting; Gao, Cheng-cheng; Wu, Zhi-pan; Han, Hao-te; Li, Shou-xin; Tian, Jing-kui] Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Hangzhou 310058, Peoples R China.
   [Shu, Yu-han; Zhang, Jian-bin] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Clin Res Inst, Peoples Hosp, Hangzhou 310014, Peoples R China.
   [Hong, Ye-ting] Hangzhou Med Coll, Hangzhou 310053, Peoples R China.
   [Sun, Xin; Yang, Si-fu] Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Dept Oncol, Peoples Hosp, Hangzhou 310014, Peoples R China.
   [Gao, Rui-lan] Zhejiang Chinese Med Univ, Dept Hematol, Affiliated Hosp 1, Hangzhou 310006, Peoples R China.
   [Li, Shou-xin; Tian, Jing-kui] Zhejiang Univ, Zhejiang Malaysia Joint Res Ctr Tradit Med, Key Lab Biomed Engn, Minist Educ, Hangzhou 310058, Peoples R China.
RP Tian, JK (corresponding author), Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Hangzhou 310058, Peoples R China.; Zhang, JB (corresponding author), Hangzhou Med Coll, Zhejiang Prov Peoples Hosp, Clin Res Inst, Peoples Hosp, Hangzhou 310014, Peoples R China.; Tian, JK (corresponding author), Zhejiang Univ, Zhejiang Malaysia Joint Res Ctr Tradit Med, Key Lab Biomed Engn, Minist Educ, Hangzhou 310058, Peoples R China.
EM tjk@zju.edu.cn; zhangjianbin@hmc.edu.cn
FU National Science and Technology Major Project of China [2019ZX09301004];
   Zhejiang Provincial Science and Technology Planning Project
   [2016C04005]; Zhejiang Provincial Outstanding Talent Project of Ten
   Thousand Talents Program; Zhejiang Provincial Qianjiang Talents Program;
   Zhejiang Provincial Natural Science FoundationNatural Science Foundation
   of Zhejiang Province [LR18H160002]; Traditional Chinese Medicine
   Scientific Research Fund Project of Zhejiang Province [2018ZB010];
   Zhejiang Provincial Program in Medicine and Health Sciences and
   Technology [2018253645, 2018KY223]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [81703907]
FX This work was supported by the National Science and Technology Major
   Project of China (2019ZX09301004), Zhejiang Provincial Science and
   Technology Planning Project (2016C04005) to JKT; Zhejiang Provincial
   Outstanding Talent Project of Ten Thousand Talents Program, Zhejiang
   Provincial Qianjiang Talents Program, Zhejiang Provincial Natural
   Science Foundation (LR18H160002), Traditional Chinese Medicine
   Scientific Research Fund Project of Zhejiang Province (2018ZB010),
   Zhejiang Provincial Program in Medicine and Health Sciences and
   Technology (2018253645) to JBZ; National Natural Science Foundation of
   China (81703907) to XS; Zhejiang Provincial Program in Medicine and
   Health Sciences and Technology (2018KY223) to SFY.
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cao SS, 2014, ANTIOXID REDOX SIGN, V21, P396, DOI 10.1089/ars.2014.5851
   Chaabane W, 2013, ARCH IMMUNOL THER EX, V61, P43, DOI 10.1007/s00005-012-0205-y
   Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49
   Cho SW, 2017, AM J CANCER RES, V7, P518
   Dang SP, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0245-4
   Denton D, 2012, CELL DEATH DIFFER, V19, P87, DOI 10.1038/cdd.2011.146
   Denton D, 2009, CURR BIOL, V19, P1741, DOI 10.1016/j.cub.2009.08.042
   Fandy TE, 2014, CLIN CANCER RES, V20, P1249, DOI 10.1158/1078-0432.CCR-13-1453
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0
   Gorzalczany Y, 2011, CANCER LETT, V310, P207, DOI 10.1016/j.canlet.2011.07.002
   Gu Y, 2017, MOL MED REP, V16, P8130, DOI 10.3892/mmr.2017.7646
   Guo F, 2018, INT IMMUNOPHARMACOL, V58, P80, DOI 10.1016/j.intimp.2018.03.015
   Henschke CI, 2016, AM J ROENTGENOL, V207, P1176, DOI 10.2214/AJR.16.16043
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183
   Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lee JG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048532
   Lee JC, 2008, BIOCHEM BIOPH RES CO, V372, P236, DOI 10.1016/j.bbrc.2008.05.023
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Maheswari U, 2018, APOPTOSIS, V23, P210, DOI 10.1007/s10495-018-1449-8
   Min TR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092244
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mori K, 2015, P JPN ACAD B-PHYS, V91, P469, DOI 10.2183/pjab.91.469
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Nihira K, 2014, J PATHOL, V234, P277, DOI 10.1002/path.4354
   Onorati AV, 2018, CANCER-AM CANCER SOC, V124, P3307, DOI 10.1002/cncr.31335
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Platania M, 2011, TARGET ONCOL, V6, P181, DOI 10.1007/s11523-011-0185-6
   Remark R, 2015, AM J RESP CRIT CARE, V191, P377, DOI 10.1164/rccm.201409-1671PP
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Shuang E, 2017, J CLIN BIOCHEM NUTR, V61, P47, DOI 10.3164/jcbn.16-94
   Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014
   Sun X, 2019, MED RES REV, V39, P2172, DOI 10.1002/med.21580
   Syah YM, 2000, FITOTERAPIA, V71, P630, DOI 10.1016/S0367-326X(00)00221-5
   Tang ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep26241
   Ureshino RP, 2014, ANTIOXID REDOX SIGN, V21, P123, DOI 10.1089/ars.2013.5777
   Wei H, 2016, COGENT CHEM, V2, DOI 10.1080/23312009.2016.1212320
   Yang Y, 2014, J ASIAN NAT PROD RES, V16, P690, DOI 10.1080/10286020.2014.923405
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu JS, 2018, BIOORG CHEM, V76, P28, DOI 10.1016/j.bioorg.2017.10.015
   Zhang MT, 2016, AM J CANCER RES, V6, P187
NR 45
TC 5
Z9 5
U1 6
U2 21
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD MAY
PY 2021
VL 42
IS 5
BP 780
EP 790
DI 10.1038/s41401-020-0492-5
EA AUG 2020
PG 11
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA RQ2FF
UT WOS:000560981000001
PM 32814819
DA 2022-04-25
ER

PT J
AU Tang, B
   Wang, K
   Jia, YP
   Zhu, P
   Fang, Y
   Zhang, ZJ
   Mao, XH
   Li, Q
   Zeng, DZ
AF Tang, Bin
   Wang, Kun
   Jia, Yin-ping
   Zhu, Pan
   Fang, Yao
   Zhang, Zhu-jun
   Mao, Xu-hu
   Li, Qian
   Zeng, Dong-zhu
TI Fusobacterium nucleatum-Induced Impairment of Autophagic Flux Enhances
   the Expression of Proinflammatory Cytokines via ROS in Caco-2 Cells
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-CELLS; VACUOLATING CYTOTOXIN; COLORECTAL-CANCER;
   INFLAMMATION; GENERATION; INFECTION; PATHWAY; DISEASE; MECHANISMS;
   MICROBIOTA
AB Fusobacterium nucleatum (F. nucleatum) plays a critical role in gastrointestinal inflammation. However, the exact mechanism by which F. nucleatum contributes to inflammation is unclear. In the present study, it was revealed that F. nucleatum could induce the production of proinflammatory cytokines (IL- 8, IL- 1 beta and TNF-alpha) and reactive oxygen species (ROS) in Caco-2 colorectal) adenocarcinoma cells. Furthermore, ROS scavengers (NAC or Tiron) could decrease the production of proinflammatory cytokines during F. nucleatum infection. In addition, we observed that autophagy is impaired in Caco-2 cells after F. nucleatum infection. The production of proinflammatory cytokines and ROS induced by F. nucleatum was enhanced with either autophagy pharmacologic inhibitors (3-methyladenine, bafilomycin A1) or RNA interference in essential autophagy genes (ATG5 or ATG12) in Caco-2 cells. Taken together, these results indicate that F. nucleatum-induced impairment of autophagic flux enhances the expression of proinflammatory cytokines via ROS in Caco-2 Cells.
C1 [Tang, Bin; Wang, Kun; Jia, Yin-ping; Zhu, Pan; Fang, Yao; Zhang, Zhu-jun; Mao, Xu-hu; Li, Qian] Third Mil Med Univ, Southwest Hosp, Dept Clin Microbiol & Immunol, Chongqing, Peoples R China.
   [Tang, Bin; Wang, Kun; Jia, Yin-ping; Zhu, Pan; Fang, Yao; Zhang, Zhu-jun; Mao, Xu-hu; Li, Qian] Third Mil Med Univ, Coll Med Lab Sci, Chongqing, Peoples R China.
   [Zeng, Dong-zhu] Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing, Peoples R China.
   [Zeng, Dong-zhu] Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Chongqing, Peoples R China.
   [Tang, Bin] Emei Sanat PLA Rocket Force, Emeishan, Peoples R China.
RP Li, Q (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Clin Microbiol & Immunol, Chongqing, Peoples R China.; Li, Q (corresponding author), Third Mil Med Univ, Coll Med Lab Sci, Chongqing, Peoples R China.; Zeng, DZ (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Gen Surg, Chongqing, Peoples R China.; Zeng, DZ (corresponding author), Third Mil Med Univ, Southwest Hosp, Ctr Minimal Invas Gastrointestinal Surg, Chongqing, Peoples R China.
EM liqianjane@163.com; zdz1140@163.com
RI bin, tang/AAK-9399-2020
OI bin, tang/0000-0002-1762-3883
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81301482, 81501796]; project of
   medical science and technology for training youth scholars of PLA
   [14QNP054]
FX This work was supported by a grant from National Natural Science
   Foundation of China (NSFC, 81301482 and 81501796), and the project of
   medical science and technology for training youth scholars of PLA
   (14QNP054).; This work was supported by Grant Nos. 81301482 (for B.T.)
   and 81501796 (for Q.L.) from National Natural Science Foundation of
   China (NSFC,), and the project of medical science and technology for
   training youth scholars of PLA (14QNP054) (for B.T.).
CR Amano A, 2006, J BIOCHEM, V140, P161, DOI 10.1093/jb/mvj162
   Bashir A, 2015, TUMOR BIOL, DOI [10.1007/a13277-015-4724-0, DOI 10.1007/A13277-015-4724-0]
   Choudhury S, 2015, FREE RADICAL RES, V49, P1371, DOI 10.3109/10715762.2015.1075016
   Cremer TJ, 2009, AUTOPHAGY, V5, P125, DOI 10.4161/auto.5.1.7305
   Deretic V, 2009, CELL HOST MICROBE, V5, P527, DOI 10.1016/j.chom.2009.05.016
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   FALKLER WA, 1982, J PERIODONTOL, V53, P762, DOI 10.1902/jop.1982.53.12.762
   Flanagan L, 2014, EUR J CLIN MICROBIOL, V33, P1381, DOI 10.1007/s10096-014-2081-3
   Fubini B, 2003, FREE RADICAL BIO MED, V34, P1507, DOI 10.1016/S0891-5849(03)00149-7
   HSU CY, 1995, ACTA CYTOL, V39, P114
   Huang J, 2014, NAT REV MICROBIOL, V12, P101, DOI 10.1038/nrmicro3160
   Kayath CA, 2010, MICROBES INFECT, V12, P956, DOI 10.1016/j.micinf.2010.06.006
   Kim M, 2010, CELL HOST MICROBE, V8, P20, DOI 10.1016/j.chom.2010.06.006
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Leavy O, 2014, NAT REV IMMUNOL, V14, P357, DOI 10.1038/nri3685
   Leung A, 2015, EXPERT REV GASTROENT, V9, P651, DOI 10.1586/17474124.2015.1001745
   Liu P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085280
   Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090
   Marcato LG, 2008, ORAL MICROBIOL IMMUN, V23, P353, DOI 10.1111/j.1399-302X.2008.00432.x
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Pi J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140935
   Py BF, 2007, AUTOPHAGY, V3, P117, DOI 10.4161/auto.3618
   Raju D, 2012, GASTROENTEROLOGY, V142, P1160, DOI 10.1053/j.gastro.2012.01.043
   Rasul A, 2013, MOLECULES, V18, P1418, DOI 10.3390/molecules18021418
   Ray Katrina, 2011, Nat Rev Gastroenterol Hepatol, V8, P662, DOI 10.1038/nrgastro.2011.208
   ROVIN BH, 1990, KIDNEY INT, V37, P1509, DOI 10.1038/ki.1990.142
   Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007
   Shin DM, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001230
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Strauss J, 2011, INFLAMM BOWEL DIS, V17, P1971, DOI 10.1002/ibd.21606
   Tang B, 2015, AUTOPHAGY, V11, P344, DOI 10.1080/15548627.2015.1023682
   Tang B, 2012, AUTOPHAGY, V8, P1045, DOI 10.4161/auto.20159
   Terebiznik MR, 2009, AUTOPHAGY, V5, P370, DOI 10.4161/auto.5.3.7663
   Underwood MA, 2014, PREV MED, V65, P133, DOI 10.1016/j.ypmed.2014.05.010
NR 35
TC 26
Z9 27
U1 5
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 9
PY 2016
VL 11
IS 11
AR e0165701
DI 10.1371/journal.pone.0165701
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EB9OG
UT WOS:000387724300055
PM 27828984
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Benigno, SJ
   Oyong, G
   Licayan, JJ
   Sumayao, R
AF Benigno, Sol Joaquin
   Oyong, Glenn
   Licayan, Josafat John
   Sumayao, Rodolfo, Jr.
TI Antidesma bunius aqueous crude extract promotes cell death via
   modulation of redox-sensitive and autophagy-associated genes in HCT 116
   human-derived colorectal cancer cells
SO ARCHIVES OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Antidesma bunius; colorectal cancer; oxidative stress; antioxidants;
   autophagy; mitochondria
ID ANTIOXIDANT ACTIVITIES
AB Antidesma bunius fruit was previously shown to exhibit antioxidant properties, but its anticancer activities remain underexplored. We hypothesized that the phytochemicals in this fruit can influence mitochondrial integrity and can modulate stress-responsive genes in cancer cells. The present study investigated the effects of A. bunius fruit aqueous crude extract (A. bunius ACE) on the viability, redox status, and mitochondrial transmembrane potential (MTP) using a colorectal cancer cell line, HCT 116. The expression of key genes associated with oxidative stress and autophagy was also determined. Treatment of cells with A. bunius ACE resulted in a similar to 27% reduction in viability, coupled with a marked decrease in oxidative stress index by similar to 59%. This was accompanied by the upregulation of NRF2 and NRF2-dependent genes. MTP increased similar to 3-fold in response to A. bunius ACE. The expression of BECLIN1, ATG5, and LC3 genes also increased. Our results indicate that the phytochemicals in A. bunius fruits enhance mitochondrial integrity and modulate the expression of stress-responsive genes, which may be responsible for the mitigation of oxidative stress in cancer cells. These alterations may be involved in the cascade of events leading to cancer cell death effected by A. bunius.
C1 [Benigno, Sol Joaquin; Licayan, Josafat John; Sumayao, Rodolfo, Jr.] De La Salle Univ, Chem Dept, 2401 Taft Ave, Manila 0922, Philippines.
   [Oyong, Glenn] De La Salle Univ, Ctr Nat Sci & Ecol Res CENSER, 2401 Taft Ave, Manila 0922, Philippines.
RP Sumayao, R (corresponding author), De La Salle Univ, Chem Dept, 2401 Taft Ave, Manila 0922, Philippines.
EM rodolfo.sumayao@dlsu.edu.ph
RI Oyong, Glenn/A-6142-2019
OI Oyong, Glenn/0000-0001-8224-9034
FU De La Salle University Research Fellowship Program
FX This study was supported by the De La Salle University Research
   Fellowship Program.
CR Bakar A, 2016, EVID-BASED COMPL ALT, V2016
   Barcelo J. M., 2016, PHILIPPINE E OURNAL, V6, P32
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Butkhup Luchai, 2011, Journal of Fruit and Ornamental Plant Research, V19, P85
   Cadenas Enrique, 2004, Molecular Aspects of Medicine, V25, P17, DOI 10.1016/j.mam.2004.02.005
   Cuadrado A, 2019, NAT REV DRUG DISCOV, V18, P295, DOI 10.1038/s41573-018-0008-x
   Dhanani T, 2017, ARAB J CHEM, V10, pS1193, DOI 10.1016/j.arabjc.2013.02.015
   Drozdz P, 2017, PLANT FOOD HUM NUTR, V72, P360, DOI 10.1007/s11130-017-0640-3
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Gaya A, 2015, CUREUS, V7, P1
   Ghasemzadeh A, 2010, MOLECULES, V15, P4324, DOI 10.3390/molecules15064324
   Ibrahim TA, 2019, PAK J PHARM SCI, V32, P153
   Jakubowski W, 2000, CELL BIOL INT, V24, P757, DOI 10.1006/cbir.2000.0556
   Jeong SM, 2004, J AGR FOOD CHEM, V52, P3389, DOI 10.1021/jf049899k
   Jorjong S, 2015, FOOD CHEM, V181, P248, DOI 10.1016/j.foodchem.2015.02.093
   Kang Kyoung Ah, 2019, Exp Mol Med, V51, P1, DOI 10.1038/s12276-019-0238-y
   Lee B, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2645465
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005
   MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6
   Panceri CP, 2013, FOOD RES INT, V54, P1343, DOI 10.1016/j.foodres.2013.10.016
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Recuenco M. C., 2016, PHILIPP J SCI, V145, P275
   Satti J, 2009, DOSE-RESPONSE, V7, P208, DOI 10.2203/dose-response.08-010.Satti
   Shahidi F, 2016, MOLECULES, V21, DOI 10.3390/molecules21091216
   Shaimaa G, 2016, NAT PROD CHEM RES, V4
   Shariful Islam M., 2018, J ANAL PHARM RES, V7, P602, DOI [10.15406/japlr.2018.07.00289, DOI 10.15406/JAPLR.2018.07.00289]
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Sumayao R, 2016, J PHYSIOL-LONDON, V594, P3353, DOI 10.1113/JP271858
   Vara-Perez M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050493
   Xie Xianhe, 2017, Asian Pac J Cancer Prev, V18, P479
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zuo Q, 2018, J CELL BIOCHEM, V119, P9573, DOI 10.1002/jcb.27275
NR 34
TC 0
Z9 0
U1 1
U2 2
PU INST BIOLOSKA ISTRAZIVANJA SINISA STANKOVIC
PI BEOGRAD
PA 29 NOVEMBRA 142, BEOGRAD, 11060, SERBIA
SN 0354-4664
EI 1821-4339
J9 ARCH BIOL SCI
JI Arch. Biol. Sci.
PY 2020
VL 72
IS 3
BP 433
EP 443
DI 10.2298/ABS200703037B
PG 11
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA OJ4NI
UT WOS:000583939900014
OA gold
DA 2022-04-25
ER

PT J
AU Brunel, A
   Begaud, G
   Auger, C
   Durand, S
   Battu, S
   Bessette, B
   Verdier, M
AF Brunel, Aude
   Begaud, Gaelle
   Auger, Clement
   Durand, Stephanie
   Battu, Serge
   Bessette, Barbara
   Verdier, Mireille
TI Autophagy and Extracellular Vesicles, Connected to rabGTPase Family,
   Support Aggressiveness in Cancer Stem Cells
SO CELLS
LA English
DT Review
DE rab family; autophagy; extracellular vesicles; cancer stem cells
ID GLIOMA-INITIATING CELLS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER;
   COLORECTAL-CANCER; MULTIVESICULAR BODIES; DYNAMIC EQUILIBRIUM;
   ENDOTHELIAL-CELLS; EXOSOME SECRETION; PROGENITOR CELLS; PROSTATE-CANCER
AB Even though cancers have been widely studied and real advances in therapeutic care have been made in the last few decades, relapses are still frequently observed, often due to therapeutic resistance. Cancer Stem Cells (CSCs) are, in part, responsible for this resistance. They are able to survive harsh conditions such as hypoxia or nutrient deprivation. Autophagy and Extracellular Vesicles (EVs) secretion are cellular processes that help CSC survival. Autophagy is a recycling process and EVs secretion is essential for cell-to-cell communication. Their roles in stemness maintenance have been well described. A common pathway involved in these processes is vesicular trafficking, and subsequently, regulation by Rab GTPases. In this review, we analyze the role played by Rab GTPases in stemness status, either directly or through their regulation of autophagy and EVs secretion.
C1 [Brunel, Aude; Begaud, Gaelle; Auger, Clement; Durand, Stephanie; Battu, Serge; Bessette, Barbara; Verdier, Mireille] Univ Limoges, Fac Med, GEIST Inst, EA 3842,CAPTuR, 2 Rue Dr Marcland, F-87025 Limoges, France.
RP Verdier, M (corresponding author), Univ Limoges, Fac Med, GEIST Inst, EA 3842,CAPTuR, 2 Rue Dr Marcland, F-87025 Limoges, France.
EM aude.brunel@unilim.fr; gaelle.begaud@unilim.fr; clement.auger@unilim.fr;
   stephanie.durand@unilim.fr; serge.battu@unilim.fr;
   barbara.bessette@unilim.fr; mireille.verdier@unilim.fr
OI Bessette, Barbara/0000-0001-6673-3694; DURAND,
   Stephanie/0000-0003-2434-9429; Auger, Clement/0000-0001-5260-535X;
   Begaud, Gaelle/0000-0003-4771-8979; VERDIER,
   Mireille/0000-0002-8162-4856
FU La Ligue contre le cancer, comite de la Haute-Vienne
FX This research was funded by La Ligue contre le cancer, comite de la
   Haute-Vienne.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Balbi C, 2017, STEM CELL TRANSL MED, V6, P1340, DOI 10.1002/sctm.16-0297
   Baulch JE, 2016, P NATL ACAD SCI USA, V113, P4836, DOI 10.1073/pnas.1521668113
   Biserova K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030621
   Blanc Lionel, 2018, Small GTPases, V9, P95, DOI 10.1080/21541248.2016.1264352
   Bobrie A, 2012, CANCER RES, V72, P4920, DOI 10.1158/0008-5472.CAN-12-0925
   Bogard N, 2007, DEVELOPMENT, V134, P3413, DOI 10.1242/dev.008466
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Chang C, 2017, GENE, V605, P99, DOI 10.1016/j.gene.2016.12.030
   Chano Tokuhiro, 2018, Oncotarget, V9, P9852, DOI 10.18632/oncotarget.23955
   Che N, 2021, J CELL MOL MED, V25, P2110, DOI 10.1111/jcmm.16169
   Cheng WC, 2019, INT J CANCER, V145, P2209, DOI 10.1002/ijc.32338
   Cho SH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0915-0
   Choi DS, 2014, STEM CELLS, V32, P2309, DOI 10.1002/stem.1746
   Choi SA, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01645-6
   Chua CEL, 2014, FEBS LETT, V588, P3186, DOI 10.1016/j.febslet.2014.06.060
   Chung YC, 2016, EUR J CLIN INVEST, V46, P1002, DOI 10.1111/eci.12683
   Chung YC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-587
   Ciechomska IA, 2016, SCI REP-UK, V6, DOI 10.1038/srep38723
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Das S, 2015, DEVELOPMENT, V142, P2147, DOI 10.1242/dev.121046
   de Jong OG, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18396
   Ding XM, 2019, AUTOPHAGY, V15, P1774, DOI 10.1080/15548627.2019.1596478
   Dirkse A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09853-z
   Dong WW, 2012, WORLD J GASTROENTERO, V18, P1806, DOI 10.3748/wjg.v18.i15.1806
   Duijvesz D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082589
   Feng FX, 2017, ONCOL LETT, V14, P2947, DOI 10.3892/ol.2017.6542
   Feng FX, 2016, ONCOTARGET, V7, P63342, DOI 10.18632/oncotarget.11454
   Figueroa J, 2017, CANCER RES, V77, P5808, DOI 10.1158/0008-5472.CAN-16-2524
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Gao XG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1348-z
   Garcia-Prat L, 2016, NATURE, V529, P37, DOI 10.1038/nature16187
   Geng DH, 2016, TUMOR BIOL, V37, P7713, DOI 10.1007/s13277-015-4606-5
   Gernapudi R, 2015, BREAST CANCER RES TR, V150, P685, DOI 10.1007/s10549-015-3326-2
   Gomez-Puerto MC, 2016, STEM CELLS, V34, P1651, DOI 10.1002/stem.2347
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gray JL, 2020, ANGEW CHEM INT EDIT, V59, P6342, DOI 10.1002/anie.201900585
   Han D, 2016, ONCOTARGET, V7, P22159, DOI 10.18632/oncotarget.8063
   Han YY, 2018, INT J ONCOL, V52, P1057, DOI 10.3892/ijo.2018.4270
   Hao CC, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619866097
   Heebkaew N, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4378710
   Hill E, 2000, EMBO J, V19, P5711, DOI 10.1093/emboj/19.21.5711
   Hirota Y, 2009, CELL MOL LIFE SCI, V66, P2913, DOI 10.1007/s00018-009-0080-9
   Hsu C, 2010, J CELL BIOL, V189, P223, DOI 10.1083/jcb.200911018
   Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x
   Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9
   Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Ishiguro K, 2020, HEPATOL COMMUN, V4, P298, DOI 10.1002/hep4.1462
   Itoh T, 2008, MOL BIOL CELL, V19, P2916, DOI 10.1091/mbc.E07-12-1231
   Jawhari S, 2017, CARCINOGENESIS, V38, P592, DOI 10.1093/carcin/bgx029
   Jawhari S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.318
   Johnson JL, 2016, J BIOL CHEM, V291, P25965, DOI 10.1074/jbc.M116.741884
   Katsuda T., 2014, STEM CELL RENEWAL CE, P171
   Ke Y, 2020, INT J BIOL SCI, V16, P777, DOI 10.7150/ijbs.40305
   Keller S, 2007, KIDNEY INT, V72, P1095, DOI 10.1038/sj.ki.5002486
   Kim JK, 2014, MOL BIOL REP, V41, P5903, DOI 10.1007/s11033-014-3465-2
   Koh HM, 2019, THORAC CANCER, V10, P143, DOI 10.1111/1759-7714.12919
   Kong XJ, 2018, BIOCHEM BIOPH RES CO, V501, P486, DOI 10.1016/j.bbrc.2018.05.018
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kuc N, 2018, BIOCHEM PHARMACOL, V156, P458, DOI 10.1016/j.bcp.2018.09.017
   Kumar D, 2015, ONCOTARGET, V6, P3280, DOI 10.18632/oncotarget.2462
   Langemeyer L, 2018, TRENDS CELL BIOL, V28, P957, DOI 10.1016/j.tcb.2018.06.007
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lee KS, 2019, BIOCHEM BIOPH RES CO, V512, P511, DOI 10.1016/j.bbrc.2019.03.072
   Lei X, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01488-9
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0949-7
   Li X, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01272-2
   Li ZH, 2018, ONCOGENE, V37, P3822, DOI 10.1038/s41388-018-0237-9
   Lin MC, 2018, INT J CANCER, V143, P1440, DOI 10.1002/ijc.31523
   Liu J, 2017, ONCOTARGET, V8, P75272, DOI 10.18632/oncotarget.20775
   Liu L, 2020, EXP CELL RES, V391, DOI 10.1016/j.yexcr.2020.111956
   Liu X, 2020, J CELL MOL MED, V24, P3346, DOI 10.1111/jcmm.15008
   Luo ML, 2015, CELL REP, V11, P111, DOI 10.1016/j.celrep.2015.03.002
   Luo ML, 2014, CANCER RES, V74, P3603, DOI 10.1158/0008-5472.CAN-13-2785
   Lyu ZS, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102677
   Machida T, 2015, INT J MOL SCI, V16, P21294, DOI 10.3390/ijms160921294
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Zoppino FCM, 2010, TRAFFIC, V11, P1246, DOI 10.1111/j.1600-0854.2010.01086.x
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9
   Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487
   Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
   Mitra S, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00888-8
   Miyoshi N, 2021, REGEN THER, V17, P13, DOI 10.1016/j.reth.2021.01.002
   Munafo DB, 2002, TRAFFIC, V3, P472, DOI 10.1034/j.1600-0854.2002.30704.x
   Nabissi M, 2015, INT J CANCER, V137, P1855, DOI 10.1002/ijc.29573
   Naik PP, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12411
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231
   Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000
   Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327
   Peng DY, 2018, LEUKEMIA, V32, P1180, DOI 10.1038/s41375-018-0015-2
   Pfeffer SR, 2010, NAT CELL BIOL, V12, P3, DOI 10.1038/ncb0110-3
   Pinet S, 2016, ONCOTARGET, V7, P50349, DOI 10.18632/oncotarget.10387
   Pouyafar A, 2019, CELL TISSUE RES, V376, P377, DOI 10.1007/s00441-019-02998-9
   Qin WY, 2016, CLIN CANCER RES, V22, P4517, DOI 10.1158/1078-0432.CCR-16-0135
   Qin XY, 2017, DRUG DISCOV TODAY, V22, P1139, DOI 10.1016/j.drudis.2017.03.012
   Ramteke A, 2015, MOL CARCINOGEN, V54, P554, DOI 10.1002/mc.22124
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Riazifar M, 2019, ACS NANO, V13, P6670, DOI 10.1021/acsnano.9b01004
   Rothe K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030461
   Rustighi A, 2014, EMBO MOL MED, V6, P99, DOI 10.1002/emmm.201302909
   Sakamori R, 2012, J CLIN INVEST, V122, P1052, DOI 10.1172/JCI60282
   Samanta D, 2016, CANCER RES, V76, P4430, DOI 10.1158/0008-5472.CAN-16-0530
   Savina A, 2005, TRAFFIC, V6, P131, DOI 10.1111/j.1600-0854.2004.00257.x
   Seto S, 2011, TRAFFIC, V12, P407, DOI 10.1111/j.1600-0854.2011.01165.x
   Sharif T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0997-8
   Sharif T, 2017, AUTOPHAGY, V13, P264, DOI 10.1080/15548627.2016.1260808
   Shen M, 2019, CANCER RES, V79, P3608, DOI 10.1158/0008-5472.CAN-18-4055
   Shi CB, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0303-3
   Singh SK, 2003, CANCER RES, V63, P5821
   Song YJ, 2013, CANCER LETT, V339, P70, DOI 10.1016/j.canlet.2013.07.021
   Spiegel J, 2014, ANGEW CHEM INT EDIT, V53, P2498, DOI 10.1002/anie.201308568
   Stroupe C, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00129
   Sugimachi K, 2015, BRIT J CANCER, V112, P532, DOI 10.1038/bjc.2014.621
   Sun R, 2016, BIOMATERIALS, V103, P44, DOI 10.1016/j.biomaterials.2016.06.038
   Sun X, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-018-1097-5
   Sun Z, 2020, CELL MOL NEUROBIOL, V40, P767, DOI 10.1007/s10571-019-00771-8
   Szatmari Z, 2014, AUTOPHAGY, V10, P1154, DOI 10.4161/auto.29395
   Takeda M, 2019, CANCER RES, V79, P1426, DOI 10.1158/0008-5472.CAN-18-2192
   Tanaka C, 2012, BIOCHEM BIOPH RES CO, V419, P368, DOI 10.1016/j.bbrc.2012.02.030
   Tao ZN, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0957-3
   Tra T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027485
   Tian HJ, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00375
   Tsai CH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5804
   Tudela JG, 2015, J CELL SCI, V128, P3068, DOI 10.1242/jcs.170092
   Tzeng HT, 2017, CLIN CANCER RES, V23, P2335, DOI 10.1158/1078-0432.CCR-16-1520
   Wang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032086
   Wang C, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287-019-1528-y
   Wang HJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089782
   Wang J, 2013, P NATL ACAD SCI USA, V110, P9800, DOI 10.1073/pnas.1302337110
   Wang ML, 2020, THORAC CANCER, V11, P379, DOI 10.1111/1759-7714.13278
   Wang QQ, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0372-2
   Wang Z, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1129-8
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wolf J, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3576
   Worst TS, 2017, INT J ONCOL, V50, P920, DOI 10.3892/ijo.2017.3872
   Xue F, 2016, CANCER LETT, V371, P38, DOI 10.1016/j.canlet.2015.11.022
   Xue HY, 2018, ARCH BIOCHEM BIOPHYS, V637, P48, DOI 10.1016/j.abb.2017.11.011
   Yagi Y, 2017, NEUROSCI LETT, V636, P48, DOI 10.1016/j.neulet.2016.10.042
   Yamashita T, 2013, PHARMAZIE, V68, P969, DOI 10.1691/ph.2013.3599
   Yan T, 2014, J CANCER, V5, P572, DOI 10.7150/jca.8865
   Yang LW, 2018, MOL CARCINOGEN, V57, P419, DOI 10.1002/mc.22765
   Yang L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0990-6
   Yang MC, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0449-3
   Yang SW, 2016, ONCOTARGET, V7, P39279, DOI 10.18632/oncotarget.9827
   You Y, 2019, CANCER MED-US, V8, P656, DOI 10.1002/cam4.1975
   Yue W, 2013, AUTOPHAGY, V9, P714, DOI 10.4161/auto.23997
   Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055
   Zhang HY, 2020, HUM CELL, V33, P140, DOI 10.1007/s13577-019-00295-9
   Zhang L, 2020, PATHOL ONCOL RES, V26, P301, DOI 10.1007/s12253-018-0463-z
   Zhao B, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9290728
   Zhao ZX, 2019, CANCER MANAG RES, V11, P5737, DOI 10.2147/CMAR.S197634
   Zheng Y, 2013, EXP CELL RES, V319, P1706, DOI 10.1016/j.yexcr.2012.10.006
   Zhou F, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007020
   Zhu JL, 2019, CANCERS, V11, DOI 10.3390/cancers11030349
   Zhu JL, 2019, ONCOGENE, V38, P3301, DOI 10.1038/s41388-018-0664-7
   Zhuang Wen-Zhuo, 2011, Chin J Cancer, V30, P712, DOI 10.5732/cjc.011.10234
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
   Zhuang WZ, 2011, INT J CANCER, V129, P2720, DOI 10.1002/ijc.25975
   Zou C, 2019, EXP CELL RES, V378, P139, DOI 10.1016/j.yexcr.2019.02.025
NR 162
TC 3
Z9 3
U1 2
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUN
PY 2021
VL 10
IS 6
AR 1330
DI 10.3390/cells10061330
PG 18
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA SY0NH
UT WOS:000665591400001
PM 34072080
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Schaaf, MBE
   Keulers, TG
   Vooijs, MA
   Rouschop, KMA
AF Schaaf, Marco B. E.
   Keulers, Tom G.
   Vooijs, Marc A.
   Rouschop, Kasper M. A.
TI LC3/GABARAP family proteins: autophagy-(un) related functions
SO FASEB JOURNAL
LA English
DT Article
DE cancer; ATG7; Atg8 orthologues; autophagosome
ID RECEPTOR-ASSOCIATED PROTEIN; GABA(A) RECEPTOR; AUTOPHAGOSOME BIOGENESIS;
   SKELETAL-MUSCLE; MEMBRANE-FUSION; ANTIBACTERIAL AUTOPHAGY; REGULATES
   AUTOPHAGY; GLYCOGEN-METABOLISM; COLORECTAL-CANCER; PLASMA-MEMBRANE
AB From yeast to mammals, autophagy is an important mechanism for sustaining cellular homeostasis through facilitating the degradation and recycling of aged and cytotoxic components. During autophagy, cargo is captured in double-membraned vesicles, the autophagosomes, and degraded through lysosomal fusion. In yeast, autophagy initiation, cargo recognition, cargo engulfment, and vesicle closure is Atg8 dependent. In higher eukaryotes, Atg8 has evolved into the LC3/GABARAP protein family, consisting of 7 family proteins [LC3A(2 splice variants), LC3B, LC3C, GABARAP, GABARAPL1, and GABARAPL2]. LC3B, the most studied family protein, is associated with autophagosome development and maturation and is used to monitor autophagic activity. Given the high homology, the other LC3/GABARAP family proteins are often presumed to fulfill similar functions. Nevertheless, substantial evidence shows that the LC3/GABARAP family proteins are unique in function and important in autophagy-independent mechanisms. In this review, we discuss the current knowledge and functions of the LC3/GABARAP family proteins. We focus on processing of the individual family proteins and their role in autophagy initiation, cargo recognition, vesicle closure, and trafficking, a complex and tightly regulated process that requires selective presentation and recruitment of these family proteins. In addition, functions unrelated to autophagy of the LC3/GABARAP protein family members are discussed.-Schaaf, M. B. E., Keulers, T. G, Vooijs, M. A., Rouschop, K. M. A. LC3/GABARAP family proteins: autophagy-(un) related functions.
C1 [Schaaf, Marco B. E.; Keulers, Tom G.; Vooijs, Marc A.; Rouschop, Kasper M. A.] Maastricht Univ, Med Ctr, Dept Radiat Oncol, Maastro Lab,GROW Sch Oncol & Dev Biol, Maastricht, Netherlands.
RP Rouschop, KMA (corresponding author), Maastricht Univ, Med Ctr, Univ Singel 50,Room 3-318, NL-6200 MD Maastricht, Netherlands.
EM kasper.rouschop@maastrichtuniversity.nl
RI Vooijs, Marc/K-3522-2019
OI Rouschop, Kasper/0000-0002-4208-5415
FU Dutch Cancer Society (KWF)KWF Kankerbestrijding [UM 2012-5506,
   2015-7735]; Worldwide Cancer Research Award [16-0265]; European Research
   Council under the European Union's Seventh Framework Programme (FP)/ERC
   GrantEuropean Research Council (ERC) [617060]
FX The authors apologize to researchers whose work could not be included
   due to the extensive field of autophagy. This work was supported by the
   Dutch Cancer Society (KWF) Grants UM 2012-5506 and 2015-7735 (to K.R.),
   Worldwide Cancer Research Award 16-0265 (to K.R.), and European Research
   Council under the European Union's Seventh Framework Programme (FP)
   2007-2013/ERC Grant Agreement 617060 (to M.V.).
CR Alam J, 2010, REGUL PEPTIDES, V159, P78, DOI 10.1016/j.regpep.2009.09.002
   Alemu EA, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.378109
   Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bai H, 2012, ONCOGENE, V31, P4397, DOI 10.1038/onc.2011.613
   Behrends C, 2010, NATURE, V466, P68, DOI 10.1038/nature09204
   Betin VMS, 2009, J CELL SCI, V122, P2554, DOI 10.1242/jcs.046250
   Boyer-Guittaut M, 2014, AUTOPHAGY, V10, P986, DOI 10.4161/auto.28390
   Burman C, 2010, FEBS LETT, V584, P1302, DOI 10.1016/j.febslet.2010.01.011
   Cali T, 2008, BIOCHEM BIOPH RES CO, V371, P405, DOI 10.1016/j.bbrc.2008.04.098
   Cemma M, 2016, AUTOPHAGY, V12, P1440, DOI 10.1080/15548627.2016.1191724
   Chanturiya A, 2000, J MEMBRANE BIOL, V176, P67, DOI 10.1007/s002320001076
   Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024
   Chen CG, 2011, J BIOL CHEM, V286, P15106, DOI 10.1074/jbc.M111.230896
   Chen DD, 2012, MOL CELL, V45, P629, DOI 10.1016/j.molcel.2011.12.036
   Chen ZW, 2007, J NEUROSCI, V27, P6655, DOI 10.1523/JNEUROSCI.0919-07.2007
   Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108
   Choi S, 2014, BIOCHEM BIOPH RES CO, V443, P56, DOI 10.1016/j.bbrc.2013.11.044
   Clausen TH, 2010, AUTOPHAGY, V6, P330, DOI 10.4161/auto.6.3.11226
   Comes F, 2007, CELL DEATH DIFFER, V14, P693, DOI 10.1038/sj.cdd.4402076
   Cook JL, 2008, CIRC RES, V102, P1539, DOI 10.1161/CIRCRESAHA.108.176594
   Cowey CL, 2009, CURR ONCOL REP, V11, P94, DOI 10.1007/s11912-009-0015-5
   Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X
   Dupont N, 2009, CELL HOST MICROBE, V6, P137, DOI 10.1016/j.chom.2009.07.005
   Fader CM, 2009, CELL DEATH DIFFER, V16, P70, DOI 10.1038/cdd.2008.168
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Genau HM, 2015, MOL CELL, V57, P995, DOI 10.1016/j.molcel.2014.12.040
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Giatromanolaki A, 2015, LUNG CANCER, V90, P98, DOI 10.1016/j.lungcan.2015.07.008
   Huang J, 2009, P NATL ACAD SCI USA, V106, P6226, DOI 10.1073/pnas.0811045106
   Huang R, 2015, MOL CELL, V57, P456, DOI 10.1016/j.molcel.2014.12.013
   Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114
   Ishihara N, 2001, MOL BIOL CELL, V12, P3690, DOI 10.1091/mbc.12.11.3690
   Jacob TC, 2005, J NEUROSCI, V25, P10469, DOI 10.1523/JNEUROSCI.2267-05.2005
   Jacob TC, 2008, NAT REV NEUROSCI, V9, P331, DOI 10.1038/nrn2370
   Jager S, 2004, J CELL SCI, V117, P4837, DOI 10.1242/jcs.01370
   Jensen D, 2011, J CELL SCI, V124, P1, DOI 10.1242/jcs.069773
   Jiang SX, 2011, BIOCHEM BIOPH RES CO, V413, P420, DOI 10.1016/j.bbrc.2011.08.106
   Jiang SX, 2010, J BIOL CHEM, V285, P34960, DOI 10.1074/jbc.M110.150839
   Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131
   Kang YA, 2012, MOL CELL BIOL, V32, P226, DOI 10.1128/MCB.06166-11
   Kaufmann A, 2014, CELL, V156, P469, DOI 10.1016/j.cell.2013.12.022
   Keulers TG, 2015, RADIOTHER ONCOL, V116, P417, DOI 10.1016/j.radonc.2015.06.023
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Kittler JT, 2001, MOL CELL NEUROSCI, V18, P13, DOI 10.1006/mcne.2001.1005
   Klebig C, 2005, CANCER RES, V65, P394
   Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594
   Kneussel M, 1999, J NEUROSCI, V19, P9289, DOI 10.1523/jneurosci.19-21-09289.1999
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Labonte D, 2014, EUR J CELL BIOL, V93, P338, DOI 10.1016/j.ejcb.2014.07.007
   Lainez S, 2010, FASEB J, V24, P1958, DOI 10.1096/fj.09-151472
   Lamb CA, 2013, NAT REV MOL CELL BIO, V14, P759, DOI 10.1038/nrm3696
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Legesse-Miller A, 1998, J BIOL CHEM, V273, P3105, DOI 10.1074/jbc.273.5.3105
   Leil TA, 2004, J NEUROSCI, V24, P11429, DOI 10.1523/JNEUROSCI.3355-04.2004
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li DD, 2009, ONCOGENE, V28, P886, DOI 10.1038/onc.2008.441
   Liu HY, 2009, J BIOL CHEM, V284, P31484, DOI 10.1074/jbc.M109.033936
   Liu L, 2012, NAT CELL BIOL, V14, P177, DOI 10.1038/ncb2422
   Lu KF, 2014, CELL, V158, P549, DOI 10.1016/j.cell.2014.05.048
   Lystad AH, 2014, EMBO REP, V15, P557, DOI 10.1002/embr.201338003
   Ma D, 2011, EMBO J, V30, P4642, DOI 10.1038/emboj.2011.322
   Malicdan MCV, 2012, BRAIN PATHOL, V22, P82, DOI 10.1111/j.1750-3639.2011.00543.x
   Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001
   Mandell MA, 2014, AUTOPHAGY, V10, P2387, DOI 10.4161/15548627.2014.984278
   Mansuy V, 2004, BIOCHEM BIOPH RES CO, V325, P639, DOI 10.1016/j.bbrc.2004.10.072
   Martinez J, 2016, NATURE, V533, P115, DOI 10.1038/nature17950
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   Martinez J, 2011, P NATL ACAD SCI USA, V108, P17396, DOI 10.1073/pnas.1113421108
   Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160
   McEwan DG, 2015, MOL CELL, V57, P39, DOI 10.1016/j.molcel.2014.11.006
   McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105
   Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Mohrluder J, 2007, FEBS J, V274, P5543, DOI 10.1111/j.1742-4658.2007.06073.x
   Monastyrska I, 2009, BIOL REV, V84, P431, DOI 10.1111/j.1469-185X.2009.00082.x
   Mostowy S, 2011, J BIOL CHEM, V286, P26987, DOI 10.1074/jbc.M111.223610
   Nakajima K, 2012, NEURON, V76, P945, DOI 10.1016/j.neuron.2012.10.012
   Nath S, 2014, NAT CELL BIOL, V16, P415, DOI 10.1038/ncb2940
   Novak I, 2010, EMBO REP, V11, P45, DOI 10.1038/embor.2009.256
   O'Sullivan GA, 2005, EUR J NEUROSCI, V22, P2644, DOI 10.1111/j.1460-9568.2005.04448.x
   Otomo C, 2013, NAT STRUCT MOL BIOL, V20, P59, DOI 10.1038/nsmb.2431
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pankiv S, 2010, J CELL BIOL, V188, P253, DOI 10.1083/jcb.200907015
   Polager S, 2008, ONCOGENE, V27, P4860, DOI 10.1038/onc.2008.117
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Romao S, 2013, J CELL BIOL, V203, P757, DOI 10.1083/jcb.201308173
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Rouschop KMA, 2009, RADIOTHER ONCOL, V92, P411, DOI 10.1016/j.radonc.2009.06.029
   Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494
   Salah FS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.93
   Sanchez AMJ, 2012, J CELL BIOCHEM, V113, P695, DOI 10.1002/jcb.23399
   Sanchez-Wandelmer J, 2015, J CELL SCI, V128, P185, DOI 10.1242/jcs.158758
   Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421
   Schaaf MBE, 2013, RADIOTHER ONCOL, V108, P529, DOI 10.1016/j.radonc.2013.06.015
   Sengupta A, 2009, J BIOL CHEM, V284, P28319, DOI 10.1074/jbc.M109.024406
   Seo YK, 2011, CELL METAB, V13, P367, DOI 10.1016/j.cmet.2011.03.005
   Settembre C, 2013, NAT CELL BIOL, V15, P647, DOI 10.1038/ncb2718
   Shabb JB, 2001, CHEM REV, V101, P2381, DOI 10.1021/cr000236l
   Shang LB, 2011, P NATL ACAD SCI USA, V108, P4788, DOI 10.1073/pnas.1100844108
   Shpilka T, 2012, J CELL SCI, V125, P2343, DOI 10.1242/jcs.093757
   Shvets E, 2011, AUTOPHAGY, V7, P683, DOI 10.4161/auto.7.7.15279
   Sou Y, 2006, J BIOL CHEM, V281, P3017, DOI 10.1074/jbc.M505888200
   Stadel D, 2015, MOL CELL, V60, P89, DOI 10.1016/j.molcel.2015.09.010
   Sugawara K, 2004, GENES CELLS, V9, P611, DOI 10.1111/j.1356-9597.2004.00750.x
   Sun T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-161
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Thielmann Y, 2009, PROTEINS, V77, P637, DOI 10.1002/prot.22477
   Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744
   Tumbarello DA, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1005174
   Verlhac P, 2015, AUTOPHAGY, V11, P965, DOI 10.1080/15548627.2015.1046672
   Verlhac P, 2015, CELL HOST MICROBE, V17, P515, DOI 10.1016/j.chom.2015.02.008
   Vernier-Magnin S, 2005, BBA-GENE STRUCT EXPR, V1731, P23, DOI 10.1016/j.bbaexp.2005.05.002
   von Muhlinen N, 2012, MOL CELL, V48, P329, DOI 10.1016/j.molcel.2012.08.024
   Wang H, 2015, BRIT J NUTR, V114, P519, DOI 10.1017/S0007114515002172
   Weidberg H, 2011, DEV CELL, V20, P444, DOI 10.1016/j.devcel.2011.02.006
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263
   Wild P, 2014, J CELL SCI, V127, P3, DOI 10.1242/jcs.140426
   Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405
   Wilkinson DS, 2015, MOL CELL, V57, P55, DOI 10.1016/j.molcel.2014.11.019
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Xie ZP, 2008, MOL BIOL CELL, V19, P3290, DOI 10.1091/mbc.E07-12-1292
   Xu P, 2011, GENE DEV, V25, P310, DOI 10.1101/gad.1984311
   Zhang YQ, 2011, CELL PHYSIOL BIOCHEM, V27, P503, DOI 10.1159/000329952
   Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345
NR 130
TC 271
Z9 301
U1 12
U2 56
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD DEC
PY 2016
VL 30
IS 12
BP 3961
EP 3978
DI 10.1096/fj.201600698R
PG 18
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA EC5UG
UT WOS:000388201500005
PM 27601442
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Renga, G
   Oikonomou, V
   Stincardini, C
   Pariano, M
   Borghi, M
   Costantini, C
   Bartoli, A
   Garaci, E
   Goldstein, AL
   Romani, L
AF Renga, Giorgia
   Oikonomou, Vasilis
   Stincardini, Claudia
   Pariano, Marilena
   Borghi, Monica
   Costantini, Claudio
   Bartoli, Andrea
   Garaci, Enrico
   Goldstein, Allan L.
   Romani, Luigina
TI Thymosin 4 limits inflammation through autophagy
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE Autophagy; chronic granulomatous disease; inflammation; thymosin 4
ID CHRONIC GRANULOMATOUS-DISEASE; INTEGRIN-LINKED KINASE; LC3-ASSOCIATED
   PHAGOCYTOSIS; ASPERGILLUS-FUMIGATUS; COLORECTAL-CARCINOMA; IFN-GAMMA;
   REPAIR; INFLAMMASOMES; IMMUNITY; ACTIN
AB Introduction: Thymosin 4 (T4) is a thymic hormone with multiple and different intracellular and extracellular activities affecting wound healing, inflammation, fibrosis and tissue regeneration. As the failure to resolve inflammation leads to uncontrolled inflammatory pathology which underlies many chronic diseases, the endogenous pathway through which T4 may promote inflammation resolution becomes of great interest. In this review, we discuss data highlighting the efficacy of T4 in resolving inflammation by restoring autophagy.Areas covered: The authors provide an overview of the T4's anti-inflammatory properties in several pathologies and provide preliminary evidence on the ability of T4 to resolve inflammation via the promotion of non-canonical autophagy associated with the activation of the DAP kinase anti-inflammatory function.Expert opinion: Based on its multitasking activity in various animal studies, including tissue repair and prevention of chronic inflammation, T4 may represent a potential, novel treatment for inflammatory diseases associated with defective autophagy.
C1 [Renga, Giorgia; Oikonomou, Vasilis; Stincardini, Claudia; Pariano, Marilena; Borghi, Monica; Costantini, Claudio; Bartoli, Andrea; Romani, Luigina] Univ Perugia, Dept Expt Med, I-06132 Perugia, Italy.
   [Garaci, Enrico] Univ San Raffaele, Rome, Italy.
   [Garaci, Enrico] IRCCS San Raffaele, Rome, Italy.
   [Goldstein, Allan L.] George Washington Univ, Sch Med & Hlth Sci, Dept Biochem & Mol Med, Washington, DC 20052 USA.
RP Renga, G (corresponding author), Univ Perugia, Dept Expt Med, I-06132 Perugia, Italy.
EM rengagiorgia@gmail.com
RI Oikonomou, Vasileios/ABC-7703-2021; Romani, Luigina/O-9987-2018; GARACI,
   ENRICO/AAB-3349-2021
OI Oikonomou, Vasileios/0000-0002-7553-0159; Renga,
   Giorgia/0000-0002-9762-6493; pariano, marilena/0000-0002-9896-171X;
   Romani, Luigina/0000-0002-1356-525X; Borghi, Monica/0000-0002-6337-5999;
   Costantini, Claudio/0000-0002-1433-7830
FU European Research CouncilEuropean Research Council (ERC)European
   Commission [ERC-2011-AdG-293714]
FX This study was supported by the European Research Council
   (ERC-2011-AdG-293714 to LR). The data contained in this paper were
   presented at the 5th International Symposium on Thymosins in Health and
   Disease, Washington DC, USA, November 15-17, 2017.
CR Akoumianaki T, 2016, CELL HOST MICROBE, V19, P79, DOI 10.1016/j.chom.2015.12.002
   Badamchian M, 2003, INT IMMUNOPHARMACOL, V3, P1225, DOI 10.1016/S1567-5769(03)00024-9
   Ballweber E, 2002, J MOL BIOL, V315, P613, DOI 10.1006/jmbi.2001.5281
   Bock-Marquette I, 2004, NATURE, V432, P466, DOI 10.1038/nature03000
   Cha HJ, 2003, J NATL CANCER I, V95, P1674, DOI 10.1093/jnci/djg100
   Chiriaco M, 2016, PEDIAT ALLERG IMM-UK, V27, P242, DOI 10.1111/pai.12527
   de Luca A, 2014, P NATL ACAD SCI USA, V111, P3526, DOI 10.1073/pnas.1322831111
   Ehrlich HP, 2010, ANN NY ACAD SCI, V1194, P118, DOI 10.1111/j.1749-6632.2010.05483.x
   Evans MA, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3081
   Gade P, 2012, P NATL ACAD SCI USA, V109, P10316, DOI 10.1073/pnas.1119273109
   GOLDSTEI.AL, 1966, P NATL ACAD SCI USA, V56, P1010, DOI 10.1073/pnas.56.3.1010
   Goldstein AL, 2005, TRENDS MOL MED, V11, P421, DOI 10.1016/j.molmed.2005.07.004
   Goldstein AL, 2015, EXPERT OPIN BIOL TH, V15, pS139, DOI 10.1517/14712598.2015.1011617
   Harris J, 2011, J BIOL CHEM, V286, P9587, DOI 10.1074/jbc.M110.202911
   Holland SM, 2013, HEMATOL ONCOL CLIN N, V27, P89, DOI 10.1016/j.hoc.2012.11.002
   Huang HC, 2007, ONCOGENE, V26, P2781, DOI 10.1038/sj.onc.1210078
   Kroemer G, 2015, J CLIN INVEST, V125, P1, DOI 10.1172/JCI78652
   Kumar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026912
   Kyrmizi I, 2013, J IMMUNOL, V191, P1287, DOI 10.4049/jimmunol.1300132
   Levine B, 2015, J CLIN INVEST, V125, P14, DOI 10.1172/JCI73938
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Liu T., 2017, SIGNAL TRANSDUCT TAR, P2
   Lv XX, 2017, J ASIAN NAT PROD RES, V19, P101, DOI 10.1080/10286020.2017.1279151
   Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528
   Marks ED, 2016, VITAM HORM, V102, P227, DOI 10.1016/bs.vh.2016.04.010
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   MUTCHNICK MG, 1988, CLIN IMMUNOL IMMUNOP, V47, P84, DOI 10.1016/0090-1229(88)90147-X
   Nair S, 2013, INT J MOL SCI, V14, P13858, DOI 10.3390/ijms140713858
   Nakav S, 2012, AM J RESP CELL MOL, V46, P313, DOI 10.1165/rcmb.2011-0181OC
   Oikonomou V, 2016, CELL HOST MICROBE, V20, P744, DOI 10.1016/j.chom.2016.10.012
   Aguilera MO, 2012, AUTOPHAGY, V8, P1590, DOI 10.4161/auto.21459
   Philp D, 2004, MECH AGEING DEV, V125, P113, DOI 10.1016/j.mad.2003.11.005
   Piludu M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119642
   Qiu P, 2011, FASEB J, V25, P1815, DOI 10.1096/fj.10-167940
   SAFER D, 1991, J BIOL CHEM, V266, P4029
   Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009
   Shaw SY, 2013, ACS CHEM BIOL, V8, P2724, DOI 10.1021/cb400352d
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Sosne G, 2005, INVEST OPHTH VIS SCI, V46, P2388, DOI 10.1167/iovs.04-1368
   Sosne G, 2016, VITAM HORM, V102, P277, DOI 10.1016/bs.vh.2016.04.012
   Sosne G, 2007, EXP EYE RES, V84, P663, DOI 10.1016/j.exer.2006.12.004
   Sprenkeler EGG, 2016, CELL MICROBIOL, V18, P1208, DOI 10.1111/cmi.12616
   Sumpter R, 2010, SEMIN CELL DEV BIOL, V21, P699, DOI 10.1016/j.semcdb.2010.04.003
   Takahama M, 2018, IMMUNOL REV, V281, P62, DOI 10.1111/imr.12613
   Wang WS, 2004, ONCOGENE, V23, P6666, DOI 10.1038/sj.onc.1207888
   Wei CY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042586
   Young JD, 1999, NAT MED, V5, P1424
   Zheng XY, 2017, WORLD J GASTROENTERO, V23, P242, DOI 10.3748/wjg.v23.i2.242
   Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051
NR 49
TC 12
Z9 12
U1 0
U2 6
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PY 2018
VL 18
SU 1
BP 171
EP 175
DI 10.1080/14712598.2018.1473854
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA GP1QR
UT WOS:000440592000025
PM 30063848
DA 2022-04-25
ER

PT J
AU Zhang, H
   Wei, PT
   Lv, WW
   Han, XT
   Yang, JH
   Qin, SF
AF Zhang, Han
   Wei, Pengtao
   Lv, Wenwei
   Han, Xingtao
   Yang, Jinhui
   Qin, Shuaifeng
TI Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell
   renal cell carcinoma progression
SO CELL AND BIOSCIENCE
LA English
DT Article
DE Ubiquitination; PTEN; WWP2; USP11
ID PROMOTES; CANCER; GROWTH; PHOSPHORYLATION; METASTASIS; EXPRESSION;
   AUTOPHAGY; INVASION; PROTEIN; CERNA
AB Background: Increasing evidence has indicated that long noncoding RNAs (lncRNAs) are crucial regulators affecting the progression of human cancers. Recently, lncRNA downregulated in liver cancer stem cells (lnc-DILC) was identified to function as a tumor suppressor inhibiting the tumorigenesis and metastasis in liver cancer and colorectal cancer. However, to date, little is known about the functional roles of lnc-DILC in modulating malignant phenotypes of clear cell renal cell carcinoma (ccRCC) cells.
   Methods: lnc-DILC expression in human ccRCC tissues was detected by qRT-PCR. Overexpression and knockdown experiments were carried out to determine the effects of lnc-DILC on ccRCC cell proliferation, migration and invasion. To reveal the underlying mechanisms of lnc-DILC functions in ccRCC cells. RNA immunoprecipitation, RNA pull-down, in vivo ubiquitination, co-immunoprecipitation and western blot assays were performed.
   Results: Here, we identified that lnc-DILC levels were dramatically downregulated in ccRCC tissues. Loss of lncDILC expression was correlated with larger tumor size, advanced tumor grade and lymph node metastasis, and also predicted worse prognosis in patients with ccRCC. Functionally, knockdown and overexpression experiments demonstrated that lnc-DILC inhibited cell proliferation, migration and invasion in ccRCC cells. Mechanistic investigation revealed that lnc-DILC bound to tumor suppressor PTEN and suppressed its degradation. lnc-DILC repressed the PTEN ubiquitination through blocking the interaction between PTEN and E3 ubiquitin ligase WWP2 and recruiting the deubiquitinase USP11 to PTEN. Moreover, we demonstrated that PTEN-AKT signaling was crucial for lnc-DILC-mediated suppressive effects.
   Conclusions: In summary, our research revealed a novel mechanism by which lnc-DILC regulates PTEN stability via WWP2 and USP11, and shed light on potential therapeutic strategies by the restoration of lnc-DILC expression in patients with ccRCC.
C1 [Zhang, Han; Wei, Pengtao; Lv, Wenwei; Han, Xingtao; Yang, Jinhui; Qin, Shuaifeng] Luoyang Cent Hosp, Urol Dept, 288 Zhongzhou Rd, Luoyang 471000, Henan, Peoples R China.
RP Zhang, H (corresponding author), Luoyang Cent Hosp, Urol Dept, 288 Zhongzhou Rd, Luoyang 471000, Henan, Peoples R China.
EM zhanghanlyh@163.com
FU Clinical study on anatomic adrenalectomy through abdomen pathway Grant
   [1301070A-5]
FX The research was supported by Clinical study on anatomic adrenalectomy
   through abdomen pathway Grant (No: 1301070A-5).
CR Bawa-Khalfe T, 2017, ONCOTARGET, V8, P17651, DOI 10.18632/oncotarget.13283
   Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634
   Cao Q, 2019, J CANCER, V10, P2501, DOI 10.7150/jca.29285
   Chen B, 2018, CANCER BIOMARK, V22, P359, DOI 10.3233/CBM-170979
   Deng TG, 2018, P NATL ACAD SCI USA, V115, P4678, DOI 10.1073/pnas.1714938115
   Dushukyan N, 2017, CELL REP, V21, P1883, DOI 10.1016/j.celrep.2017.10.074
   Fan CB, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00357
   Garcia DA, 2018, MOL CANCER RES, V16, P1172, DOI 10.1158/1541-7786.MCR-17-0723
   Gu LQ, 2018, GENE, V666, P18, DOI 10.1016/j.gene.2018.03.100
   Gul A, 2019, CANCER-AM CANCER SOC, V125, P2935, DOI 10.1002/cncr.32144
   Hu Guoku, 2018, Oncotarget, V9, P18648, DOI 10.18632/oncotarget.24307
   Hu XW, 2014, CANCER CELL, V26, P344, DOI 10.1016/j.ccr.2014.07.009
   Jia ZM, 2019, GENE, V685, P222, DOI 10.1016/j.gene.2018.11.072
   Kim H, 2015, CELL REP, V13, P495, DOI 10.1016/j.celrep.2015.09.010
   Kotecha RR, 2019, NAT REV CLIN ONCOL, V16, P621, DOI 10.1038/s41571-019-0209-1
   Lai YJ, 2017, MOL CELL BIOCHEM, V432, P179, DOI 10.1007/s11010-017-3008-y
   Lan Y, 2018, NUCLEIC ACIDS RES, V46, P5809, DOI 10.1093/nar/gky214
   Li GQ, 2014, CANCER CELL, V25, P455, DOI 10.1016/j.ccr.2014.02.007
   Li HC, 2018, J BIOL CHEM, V293, P8886, DOI 10.1074/jbc.RA117.001060
   Li JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0681-0
   Li XW, 2019, J CELL MOL MED, V23, P2920, DOI 10.1111/jcmm.14200
   Liang C, 2019, GENE, V694, P102, DOI 10.1016/j.gene.2018.12.086
   Linehan WM, 2019, NAT REV UROL, V16, P539, DOI 10.1038/s41585-019-0211-5
   Liu GH, 2017, AM J CANCER RES, V7, P2515
   Liu SW, 2013, UROL ONCOL-SEMIN ORI, V31, P938, DOI 10.1016/j.urolonc.2011.07.006
   Longacre M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050759
   Luo JW, 2019, BIOCHEM BIOPH RES CO, V514, P140, DOI 10.1016/j.bbrc.2019.04.050
   Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Mai HM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1213-0
   Milella M, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00024
   Miranda-Castro R, 2019, ANAL BIOANAL CHEM, V411, P4265, DOI 10.1007/s00216-019-01607-6
   Mongelli A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00369
   Park MK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08481-x
   Puvvula PK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112615
   Qu L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12692
   Ren Y, 2019, ONCOTARGETS THER, V12, P2563, DOI 10.2147/OTT.S190239
   Renganathan A, 2017, ADV EXP MED BIOL, V1008, P199, DOI 10.1007/978-981-10-5203-3_7
   Song KF, 2019, AM J CANCER RES, V9, P300
   Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020
   Su K, 2018, AM J CANCER RES, V8, P1176
   Wang QY, 2019, CANCER LETT, V451, P68, DOI 10.1016/j.canlet.2019.02.041
   Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019
   Xie CR, 2017, MOL THER-NUCL ACIDS, V9, P440, DOI 10.1016/j.omtn.2017.10.018
   Zeng S, 2018, CANCER LETT, V412, P179, DOI 10.1016/j.canlet.2017.10.026
   Zhai W, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0998-y
   Zhang H, 2019, CELL PROLIFERAT, V27
   Zhang S, 2018, LAB INVEST, V98, P883, DOI 10.1038/s41374-018-0050-7
   Zheng TL, 2018, AM J CANCER RES, V8, P1801
NR 49
TC 15
Z9 16
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2045-3701
J9 CELL BIOSCI
JI Cell Biosci.
PD OCT 2
PY 2019
VL 9
IS 1
AR 81
DI 10.1186/s13578-019-0345-4
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA JF2GA
UT WOS:000491202700001
PM 31592114
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lin, GG
   Andrejeva, G
   Te Fong, ACW
   Hill, DK
   Orton, MR
   Parkes, HG
   Koh, DM
   Robinson, SP
   Leach, MO
   Eykyn, TR
   Chung, YL
AF Lin, Gigin
   Andrejeva, Gabriela
   Te Fong, Anne-Christine Wong
   Hill, Deborah K.
   Orton, Matthew R.
   Parkes, Harry G.
   Koh, Dow-Mu
   Robinson, Simon P.
   Leach, Martin O.
   Eykyn, Thomas R.
   Chung, Yuen-Li
TI Reduced Warburg Effect in Cancer Cells Undergoing Autophagy:
   Steady-State H-1-MRS and Real-Time Hyperpolarized C-13-MRS Studies
SO PLOS ONE
LA English
DT Article
ID TUMOR RESPONSE; BREAST; PYRUVATE; LACTATE; INHIBITOR; INDUCTION;
   PROSTATE; RECOVERY; SURVIVAL; BRAIN
AB Autophagy is a highly regulated, energy dependent cellular process where proteins, organelles and cytoplasm are sequestered in autophagosomes and digested to sustain cellular homeostasis. We hypothesized that during autophagy induced in cancer cells by i) starvation through serum and amino acid deprivation or ii) treatment with PI-103, a class I PI3K/mTOR inhibitor, glycolytic metabolism would be affected, reducing flux to lactate, and that this effect may be reversible. We probed metabolism during autophagy in colorectal HT29 and HCT116 Bax knock-out cells using hyperpolarized C-13-magnetic resonance spectroscopy (MRS) and steady-state H-1-MRS. 24 hr PI103-treatment or starvation caused significant reduction in the apparent forward rate constant (k(PL)) for pyruvate to lactate exchange compared with controls in HT29 (100 mu M PI-103: 82%, p = 0.05) and HCT116 Bax-ko cells (10 mu M PI-103: 53%, p = 0.05; 20 mu M PI-103: 42%, p<0.0001; starvation: 52%, p<0.001), associated with reduced lactate excretion and intracellular lactate in all cases, and unchanged lactate dehydrogenase (LDH) activity and increased NAD+/NADH ratio following PI103 treatment or decreased LDH activity and unchanged NAD+/NADH ratio following starvation. After 48 hr recovery from PI103 treatment, k(PL) remained below control levels in HT29 cells (74%, p = 0.02), and increased above treated values, but remained below 24 hr vehicle-treated control levels in HCT116 Bax-ko cells (65%, p = 0.004) both were accompanied by sustained reduction in lactate excretion, recovery of NAD+/NADH ratio and intracellular lactate. Following recovery from starvation, k(PL) was significantly higher than 24 hr vehicle-treated controls (140%, p = 0.05), associated with increased LDH activity and total cellular NAD(H). Changes in k(PL) and cellular and excreted lactate provided measureable indicators of the major metabolic processes accompanying starvation-and drug-induced autophagy. The changes are reversible, returning towards and exceeding control values on cellular recovery, which potentially identifies resistance. k(PL) (hyperpolarized C-13-MRS) and lactate (H-1-MRS) provide useful biomarkers for the autophagic process, enabling non-invasive monitoring of the Warburg effect.
C1 [Lin, Gigin; Andrejeva, Gabriela; Te Fong, Anne-Christine Wong; Hill, Deborah K.; Orton, Matthew R.; Parkes, Harry G.; Koh, Dow-Mu; Robinson, Simon P.; Leach, Martin O.; Eykyn, Thomas R.; Chung, Yuen-Li] Canc Res UK, Sutton, Surrey, England.
   [Lin, Gigin; Andrejeva, Gabriela; Te Fong, Anne-Christine Wong; Hill, Deborah K.; Orton, Matthew R.; Parkes, Harry G.; Koh, Dow-Mu; Robinson, Simon P.; Leach, Martin O.; Eykyn, Thomas R.; Chung, Yuen-Li] Inst Canc Res, Div Radiotherapy & Imaging, EPSRC Canc Imaging Ctr, Sutton, Surrey, England.
   [Lin, Gigin; Andrejeva, Gabriela; Te Fong, Anne-Christine Wong; Hill, Deborah K.; Orton, Matthew R.; Parkes, Harry G.; Koh, Dow-Mu; Robinson, Simon P.; Leach, Martin O.; Eykyn, Thomas R.; Chung, Yuen-Li] Royal Marsden Hosp, Sutton, Surrey, England.
   [Lin, Gigin] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Dept Med Imaging & Intervent, Taoyuan, Taiwan.
   [Eykyn, Thomas R.] St Thomas Hosp, Rayne Inst, Kings Coll London, Div Imaging Sci & Biomed Engn, London SE1 7EH, England.
RP Leach, MO (corresponding author), Canc Res UK, Sutton, Surrey, England.
EM Martin.Leach@icr.ac.uk; ylichung@icr.ac.uk
RI Chung, Yuen-Li/K-2269-2019; leach, martin o/C-2248-2008; Parkes, Harold
   G/I-7412-2012; Lin, Gigin/A-2676-2017; Eykyn, Thomas/J-3284-2016
OI Chung, Yuen-Li/0000-0003-0807-1658; leach, martin o/0000-0002-0756-5368;
   Lin, Gigin/0000-0001-7246-1058; Eykyn, Thomas/0000-0003-1768-3808;
   Robinson, Simon/0000-0003-4101-7274; Andrejeva,
   Gabriela/0000-0002-3508-7682; Parkes, Harold/0000-0003-4981-864X; Hill,
   Deborah/0000-0002-6441-5489; Koh, Dow-Mu/0000-0001-7654-8011
FU Cancer Research UKCancer Research UK; EPSRC Cancer Imaging CentreUK
   Research & Innovation (UKRI)Engineering & Physical Sciences Research
   Council (EPSRC); MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC); Department of Health (England) [C1060/A10334]; NHS;
   Chang Gung Medical Foundation (Taiwan) [CMRPG370443, CMRPG3B1922];
   Cancer Research UKCancer Research UK [16464] Funding Source:
   researchfish; Engineering and Physical Sciences Research CouncilUK
   Research & Innovation (UKRI)Engineering & Physical Sciences Research
   Council (EPSRC) [EP/H046526/1, GR/S23612/01] Funding Source:
   researchfish; Medical Research CouncilUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC)European Commission [1100738]
   Funding Source: researchfish; National Institute for Health
   ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10162]
   Funding Source: researchfish; EPSRCUK Research & Innovation
   (UKRI)Engineering & Physical Sciences Research Council (EPSRC)
   [EP/H046526/1] Funding Source: UKRI
FX The authors acknowledge the support received from the Cancer Research UK
   and EPSRC Cancer Imaging Centre in association with the MRC and
   Department of Health (England) grant C1060/A10334, also NHS funding to
   the NIHR Biomedical Research Centre, MRC-funded studentship, also Chang
   Gung Medical Foundation (Taiwan) grants CMRPG370443 and CMRPG3B1922. MOL
   is an NIHR Senior Investigator. The authors also thank Alice Warley at
   the King's College London Centre for Ultrastructural Imaging (CUI) for
   assistance with electron microscopy. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503
   Bohndiek SE, 2010, MOL CANCER THER, V9, P3278, DOI 10.1158/1535-7163.MCT-10-0706
   Christensen CE, 2013, J BIOL CHEM, DOI [10.1074/jbc.M113.498626, DOI 10.1074/JBC.M113.498626.32.SANTIDRIAN]
   Crowley LC, 2011, AM J HEMATOL, V86, P38, DOI 10.1002/ajh.21914
   Day SE, 2007, NAT MED, V13, P1382, DOI 10.1038/nm1650
   Day SE, 2011, MAGN RESON MED, V65, P557, DOI 10.1002/mrm.22698
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Golman K, 2006, CANCER RES, V66, P10855, DOI 10.1158/0008-5472.CAN-06-2564
   Han J, 2008, J BIOL CHEM, V283, P19665, DOI 10.1074/jbc.M710169200
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harris T, 2009, P NATL ACAD SCI USA, V106, P18131, DOI 10.1073/pnas.0909049106
   Hill DK, 2013, NMR BIOMED, V26, P1321, DOI 10.1002/nbm.2957
   Hill DK, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0071996, 10.1371/journal.pone.0074627]
   HOURI JJ, 1995, BIOCHEM J, V309, P521, DOI 10.1042/bj3090521
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   Kwock L, 2006, LANCET ONCOL, V7, P859, DOI 10.1016/S1470-2045(06)70905-6
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lodi A, 2013, NMR BIOMED, V26, P299, DOI 10.1002/nbm.2848
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Nedelsky NB, 2008, BBA-MOL BASIS DIS, V1782, P691, DOI 10.1016/j.bbadis.2008.10.002
   Nishida K, 2009, CELL DEATH DIFFER, V16, P31, DOI 10.1038/cdd.2008.163
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Park I, 2011, J MAGN RESON IMAGING, V33, P1284, DOI 10.1002/jmri.22563
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264
   Sitter B, 2002, NMR BIOMED, V15, P327, DOI 10.1002/nbm.775
   Tyagi RK, 1996, MAGN RESON MED, V35, P194, DOI 10.1002/mrm.1910350210
   Ward CS, 2010, CANCER RES, V70, P1296, DOI 10.1158/0008-5472.CAN-09-2251
   WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514
   Witney TH, 2011, J BIOL CHEM, V286, P24572, DOI 10.1074/jbc.M111.237727
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
NR 36
TC 14
Z9 14
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 25
PY 2014
VL 9
IS 3
AR e92645
DI 10.1371/journal.pone.0092645
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AE0SD
UT WOS:000333675600059
PM 24667972
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Cioccoloni, G
   Soteriou, C
   Websdale, A
   Wallis, L
   Zulyniak, MA
   Thorne, JL
AF Cioccoloni, Giorgia
   Soteriou, Chrysa
   Websdale, Alex
   Wallis, Lewis
   Zulyniak, Michael A.
   Thorne, James L.
TI Phytosterols and phytostanols and the hallmarks of cancer in model
   organisms: A systematic review and meta-analysis
SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION
LA English
DT Review
DE Phytosterol; phytostanol; cancer; neoplasm; cancer hallmarks; molecular
   mechanism
ID BETA-SITOSTEROL GLUCOSIDE; CELL PROLIFERATION; TUMOR-FORMATION;
   BREAST-CANCER; IN-VITRO; GROWTH; RISK; APOPTOSIS; AUTOPHAGY; MICE
AB Phytosterols and phytostanols are natural products present in vegetable oils, nuts, and seeds, or added to consumer food products whose intake is inversely associated with incidence and prognosis of several cancers. Randomized cancer prevention trials in humans are unfeasible due to time and cost yet the cellular processes and signaling cascades that underpin anti-cancer effects of these phytochemicals have been explored extensively in vitro and in preclinical in vivo models. Here we have performed an original systematic review, meta-analysis, and qualitative interpretation of literature published up to June 2020. MEDLINE, Scopus, and hand-searching identified 408 unique records that were screened leading to 32 original articles that had investigated the effects of phytosterols or phytostanols on cancer biology in preclinical models. Data was extracted from 22 publications for meta-analysis. Phytosterols were most commonly studied and found to reduce primary and metastatic tumor burden in all cancer sites evaluated. Expression of pAKT, and markers of metastasis (alkaline phosphatase, matrix metalloproteases, epithelial to mesenchymal transcription factors, lung and brain colonization), angiogenesis (vascular endothelial growth factor, CD31), and proliferation (Ki67, proliferating cell nuclear antigen) were consistently reduced by phytosterol treatment in breast and colorectal cancer. Very high dose treatment (equivalent to 0.2-1 g/kg body weight not easily achievable through diet or supplementation in humans) was associated with adverse events including poor gut health and intestinal adenoma development. Phytosterols and phytostanols are already clinically recommended for cardiovascular disease risk reduction, and represent promising anti-cancer agents that could be delivered in clinic and to the general population at low cost, with a well understood safety profile, and now with a robust understanding of mechanism-of-action.
C1 [Cioccoloni, Giorgia; Soteriou, Chrysa; Websdale, Alex; Wallis, Lewis; Zulyniak, Michael A.; Thorne, James L.] Univ Leeds, Food Sci & Nutr, Leeds LS2 9JT, W Yorkshire, England.
RP Thorne, JL (corresponding author), Univ Leeds, Food Sci & Nutr, Leeds LS2 9JT, W Yorkshire, England.
EM j.l.thorne@leeds.ac.uk
OI Websdale, Alex/0000-0002-6147-933X; Soteriou,
   Chrysa/0000-0002-2808-1215; Zulyniak, Michael/0000-0003-4944-5521;
   Wallis, Lewis/0000-0001-5800-3245; Cioccoloni,
   Giorgia/0000-0003-0102-9182; Thorne, James/0000-0002-3037-8528
FU Breast Cancer Action [3T57/9R17-02]; University of Leeds
FX GC is supported by a research grant from Breast Cancer Action
   (3T57/9R17-02). CS and AW are supported by doctoral scholarships from
   the University of Leeds.
CR Ali H, 2015, DRUG DES DEV THER, V9, P2793, DOI 10.2147/DDDT.S83514
   Alrawi SJ, 2006, ANTICANCER RES, V26, P107
   An MJ, 2009, CANCER LETT, V279, P93, DOI 10.1016/j.canlet.2009.01.026
   [Anonymous], 2020, Br J Pharmacol, V177, P2179, DOI 10.1111/bph.15053
   [Anonymous], 2018, BRIT J PHARMACOL, V175, P2711, DOI 10.1111/bph.14206
   [Anonymous], 2018, BRIT J PHARMACOL, V175, P2710, DOI 10.1111/bph.14208
   [Anonymous], 2018, BRIT J PHARMACOL, V175, P2709, DOI 10.1111/bph.14207
   [Anonymous], 2014, REV MAN REVMAN COMP
   [Anonymous], 2013, TREAT GUIDEL MED LET, V11, pe1
   Awad AB, 2001, EUR J CANCER PREV, V10, P507, DOI 10.1097/00008469-200112000-00005
   Bae H, 2020, MAR DRUGS, V18, DOI 10.3390/md18050261
   Baek AE, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00910-z
   Baskar AA, 2010, BMC COMPLEM ALTERN M, V10, DOI 10.1186/1472-6882-10-24
   Borenstein JT, 2009, 2009 IEEE/NIH LIFE SCIENCE SYSTEMS AND APPLICATIONS WORKSHOP, P21, DOI 10.1109/LISSA.2009.4906699
   Cao ZQ, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01525
   De Stefani E, 2000, NUTR CANCER, V37, P140, DOI 10.1207/S15327914NC372_4
   Couder-Garcia BD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01341
   DESCHNER EE, 1982, J CANCER RES CLIN, V103, P49, DOI 10.1007/BF00410305
   Dilly SJ, 2017, CANCER LETT, V393, P16, DOI 10.1016/j.canlet.2017.01.042
   Dolai N, 2016, NAT PROD RES, V30, P482, DOI 10.1080/14786419.2015.1023201
   Fakih O, 2018, BIOCHIMIE, V153, P150, DOI 10.1016/j.biochi.2018.04.028
   Han B, 2018, J AGR FOOD CHEM, V66, P6031, DOI 10.1021/acs.jafc.8b01387
   Han SF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31337
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He SS, 2019, ENDOCR-RELAT CANCER, V26, P659, DOI 10.1530/ERC-18-0572
   Higgins JPT, 2019, COCHRANE HDB SYSTEMA
   Huang J, 2017, BRIT J NUTR, V117, P839, DOI 10.1017/S0007114517000617
   Hutchinson SA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133241
   Imanaka H, 2008, BIOL PHARM BULL, V31, P400, DOI 10.1248/bpb.31.400
   Iyer D., 2012, ASIAN PAC J TROP DIS, V2, pS849
   Jackson D, 2017, RES SYNTH METHODS, V8, P290, DOI 10.1002/jrsm.1240
   JANEZIC SA, 1992, FOOD CHEM TOXICOL, V30, P611, DOI 10.1016/0278-6915(92)90195-Q
   Jiang L, 2019, J ONCOL, V2019, DOI 10.1155/2019/7479518
   Jiang P, 2019, J PHARMACEUT BIOMED, V174, P718, DOI 10.1016/j.jpba.2019.06.048
   Ju YH, 2004, J NUTR, V134, P1145, DOI 10.1093/jn/134.5.1145
   Kangsamaksin T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189628
   Kazlowska K, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/493869
   Llaverias G, 2013, J NUTR BIOCHEM, V24, P39, DOI 10.1016/j.jnutbio.2012.01.007
   Ma H, 2019, APOPTOSIS, V24, P168, DOI 10.1007/s10495-018-1500-9
   Mao ZF, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2018.12.032
   Marttinen M, 2014, NUTR CANCER, V66, P259, DOI 10.1080/01635581.2014.865244
   Marttinen M, 2013, J NUTR BIOCHEM, V24, P343, DOI 10.1016/j.jnutbio.2012.07.002
   McCann SE, 2003, J NUTR, V133, P1937, DOI 10.1093/jn/133.6.1937
   Mendilaharsu M, 1998, LUNG CANCER-J IASLC, V21, P37, DOI 10.1016/S0169-5002(98)00044-0
   Moreau RA, 2018, PROG LIPID RES, V70, P35, DOI 10.1016/j.plipres.2018.04.001
   Nguedia MY, 2020, ENVIRON TOXICOL, V35, P1125, DOI 10.1002/tox.22948
   Peter EL, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-019-1265-4
   Phillips KM, 2005, J AGR FOOD CHEM, V53, P9436, DOI 10.1021/jf051505h
   Quilliot D, 2001, EUR J CANCER PREV, V10, P237, DOI 10.1097/00008469-200106000-00006
   Revathidevi S, 2019, SEMIN CANCER BIOL, V59, P80, DOI 10.1016/j.semcancer.2019.06.002
   Rohatgi A., 2019, WEBPLOTDIGITIZER V4
   Segala G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01948-9
   Sharmila R, 2017, INDIAN J CLIN BIOCHE, V32, P142, DOI 10.1007/s12291-016-0583-8
   Sharmila R, 2017, PHARMACOGN MAG, V13, P95, DOI 10.4103/0973-1296.197634
   Shin EJ, 2018, BIOCHEM PHARMACOL, V152, P60, DOI 10.1016/j.bcp.2018.03.010
   Sofi MS, 2018, 3 BIOTECH, V8, DOI 10.1007/s13205-018-1395-8
   Sundstrom T, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0712-8
   Thorne J. L., 2020, PROSPERO INT PROSPEC
   Vesterinen HM, 2014, J NEUROSCI METH, V221, P92, DOI 10.1016/j.jneumeth.2013.09.010
   Wang XC, 2017, ONCOL REP, V37, P3046, DOI 10.3892/or.2017.5508
   WCRF/AICR, 2018, CONTINUOUS UPDATE PR
   Yaacob NS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126426
   Yang RN, 2019, FOODS, V8, DOI 10.3390/foods8080334
   Zhao CK, 2015, LIFE SCI, V137, P37, DOI 10.1016/j.lfs.2015.07.019
NR 65
TC 7
Z9 7
U1 1
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1040-8398
EI 1549-7852
J9 CRIT REV FOOD SCI
JI Crit. Rev. Food Sci. Nutr.
PD MAR 9
PY 2022
VL 62
IS 5
BP 1145
EP 1165
DI 10.1080/10408398.2020.1835820
EA NOV 2020
PG 21
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA YX0KC
UT WOS:000592301100001
PM 33238719
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Bobbili, MR
   Mader, RM
   Grillari, J
   Dellago, H
AF Bobbili, Madhusudhan Reddy
   Mader, Robert M.
   Grillari, Johannes
   Dellago, Hanna
TI OncomiR-17-5p: alarm signal in cancer?
SO ONCOTARGET
LA English
DT Review
DE miRNA; miR-17-5p; biomarker; cancer
ID TUMOR-SUPPRESSOR GENE; MIR-17-92 CLUSTER; MICRORNA EXPRESSION;
   CELL-PROLIFERATION; HEPATOCELLULAR-CARCINOMA; NONCODING RNAS;
   GASTRIC-CANCER; MOLECULAR MARKERS; MYELOID-LEUKEMIA; MATURE MIR-17-5P
AB Soon after microRNAs entered the stage as novel regulators of gene expression, they were found to regulate -and to be regulated by- the development, progression and aggressiveness of virtually all human types of cancer. Therefore, miRNAs in general harbor a huge potential as diagnostic and prognostic markers as well as potential therapeutic targets in cancer.
   The miR-17-92 cluster was found to be overexpressed in many human cancers and to promote unrestrained cell growth, and has therefore been termed onco-miR-1. In addition, its expression is often dysregulated in many other diseases. MiR-17-5p, its most prominent member, is an essential regulator of fundamental cellular processes like proliferation, autophagy and apoptosis, and its deficiency is neonatally lethal in the mouse. Many cancer types are associated with elevated miR-17-5p expression, and the degree of overexpression might correlate with cancer aggressiveness and responsiveness to chemotherapeutics - suggesting miR-17-5p to be an alarm signal. Liver, gastric or colorectal cancers are examples where miR-17-5p has been observed exclusively as an oncogene, while, in other cancer types, like breast, prostate and lung cancer, the role of miR-17-5p is not as clear-cut, and it might also act as tumor-suppressor.
   However, in all cancer types studied so far, miR-17-5p has been found at elevated levels in the circulation. In this review, we therefore recapitulate the current state of knowledge about miR-17-5p in the context of cancer, and suggest that elevated miR-17-5p levels in the plasma might be a sensitive and early alarm signal for cancer ('alarmiR'), albeit not a specific alarm for a specific type of tumor.
C1 [Bobbili, Madhusudhan Reddy; Grillari, Johannes] BOKU Univ Nat Resources & Life Sci, Dept Biotechnol, Vienna, Austria.
   [Grillari, Johannes; Dellago, Hanna] BOKU Univ Nat Resources & Life Sci, Dept Biotechnol, Christian Doppler Lab Biotechnol Skin Aging, Vienna, Austria.
   [Mader, Robert M.] Med Univ Vienna, Comprehens Canc Ctr, Dept Med 1, Vienna, Austria.
   [Grillari, Johannes] Evercyte GmbH, Vienna, Austria.
   [Dellago, Hanna] TAmiRNA GmbH, Vienna, Austria.
RP Grillari, J (corresponding author), BOKU Univ Nat Resources & Life Sci, Dept Biotechnol, Vienna, Austria.
EM johannes.grillari@boku.ac.at
RI Grillari, Johannes/B-2967-2011
OI Grillari, Johannes/0000-0001-5474-6332; Mader,
   Robert/0000-0003-3017-8240
FU BioToP 'Biomolecular technology of proteins' PhD Programme; Austrian
   Science Funds (FWF) ProjectAustrian Science Fund (FWF) [W1224];
   Christian Doppler Society; Austrian Federal Ministry of Economy, Family
   and Youth; National Foundation for Research, Technology and Development;
   FP7 EU project Frailomic; FP7 EU project Sybil
FX This work was funded by the BioToP 'Biomolecular technology of proteins'
   PhD Programme, Austrian Science Funds (FWF) Project W1224, and the
   Christian Doppler Society. The financial support by the Austrian Federal
   Ministry of Economy, Family and Youth, the National Foundation for
   Research, Technology and Development as well as the FP7 EU projects
   Frailomic and Sybil are also gratefully acknowledged.
CR Ahadi A, 2016, SCI REP-UK, V6, DOI 10.1038/srep24922
   AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891
   Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905
   Bertoli G, 2015, THERANOSTICS, V5, P1122, DOI 10.7150/thno.11543
   Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085
   Brodersen P, 2009, NAT REV MOL CELL BIO, V10, P141, DOI 10.1038/nrm2619
   Calvano CMC, 2014, TUMOR BIOL, V35, P7733, DOI 10.1007/s13277-014-2025-7
   Carraro G, 2009, DEV BIOL, V333, P238, DOI 10.1016/j.ydbio.2009.06.020
   Chatterjee A, 2015, CELL SIGNAL, V27, P189, DOI 10.1016/j.cellsig.2014.11.023
   Chatterjee A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095716
   Chen CL, 2015, BIOMATERIALS, V44, P71, DOI 10.1016/j.biomaterials.2014.12.023
   Chen L, 2012, J INVEST SURG, V25, P156, DOI 10.3109/08941939.2011.618523
   Chen Q, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0353-2
   Chen XJ, 2015, ONCOTARGET, V6, P37553, DOI 10.18632/oncotarget.6065
   Chi SW, 2012, NAT STRUCT MOL BIOL, V19, P321, DOI 10.1038/nsmb.2230
   Cloonan N, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-8-r127
   Concepcion CP, 2012, CANCER J, V18, P262, DOI 10.1097/PPO.0b013e318258b60a
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Dang CV, 1999, MOL CELL BIOL, V19, P1
   De Summa S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.30
   Dellago H, 2017, GERONTOLOGY, V63, P20, DOI 10.1159/000447773
   Dereani S, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/s13045-014-0079-z
   Dews M, 2010, CANCER RES, V70, P8233, DOI 10.1158/0008-5472.CAN-10-2412
   Dhar S, 2015, ONCOTARGET, V6, P27214, DOI 10.18632/oncotarget.4877
   Diaz R, 2008, GENE CHROMOSOME CANC, V47, P794, DOI 10.1002/gcc.20580
   Du WW, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.305
   Eichelser C, 2013, CLIN CHEM, V59, P1489, DOI 10.1373/clinchem.2013.205161
   Fan MY, 2014, BREAST CANCER RES TR, V146, P487, DOI 10.1007/s10549-014-3040-5
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Firatligil B, 2013, J BUON, V18, P437
   Gandhy SU, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-564
   Gao X, 2012, LEUKEMIA RES, V36, P1505, DOI 10.1016/j.leukres.2012.08.021
   Gao Y, 2014, BIOCHEM BIOPH RES CO, V444, P230, DOI 10.1016/j.bbrc.2014.01.061
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Gong AY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-492
   Gu JN, 2016, CANCER LETT, V380, P434, DOI 10.1016/j.canlet.2016.06.016
   Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250
   He M, 2013, CELL DEATH DIFFER, V20, P408, DOI 10.1038/cdd.2012.130
   He S, 2010, CELL MOL LIFE SCI, V67, P2069, DOI 10.1007/s00018-010-0340-8
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   Jadhav V, 2014, J BIOTECHNOL, V175, P38, DOI 10.1016/j.jbiotec.2014.01.032
   Jia J, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.43
   Jin YY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142574
   Johnson SC, 2013, NATURE, V493, P338, DOI 10.1038/nature11861
   Kara M, 2015, GENE, V567, P81, DOI 10.1016/j.gene.2015.04.065
   Karami F, 2016, CHEM BIOL DRUG DES, V87, P317, DOI 10.1111/cbdd.12671
   Kaya KD, 2011, NUCLEIC ACIDS RES, V39, pD170, DOI 10.1093/nar/gkq1256
   Knudsen KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140503
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016-2365
   Komatsu S, 2014, IN VIVO, V28, P293
   Komatsu S, 2013, ANTICANCER RES, V33, P271
   Lal A, 2009, MOL CELL, V35, P610, DOI 10.1016/j.molcel.2009.08.020
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Lehmann TP, 2015, MOL MED REP, V12, P4692, DOI 10.3892/mmr.2015.4002
   Leidinger P, 2016, ONCOTARGET, V7, P4611, DOI 10.18632/oncotarget.6566
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li Haoran, 2014, Oncoscience, V1, P531
   Li HR, 2012, ONCOTARGET, V3, P1653
   Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4
   Li YL, 2016, ONCOTARGET, V7, P26926, DOI 10.18632/oncotarget.8731
   Li YL, 2014, ONCOTARGET, V5, P7986, DOI 10.18632/oncotarget.2474
   Li YL, 2014, CANCER CELL, V26, P262, DOI 10.1016/j.ccr.2014.06.014
   Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105
   Liang Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-166
   Liao XH, 2017, ONCOTARGET, V8, P15763, DOI 10.18632/oncotarget.15000
   Liao XH, 2014, FEBS J, V281, P927, DOI 10.1111/febs.12658
   Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315
   Lin S, 2012, MOL CELLS, V33, P277, DOI 10.1007/s10059-012-2252-y
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   Luo HS, 2012, BIOCHEM J, V442, P311, DOI 10.1042/BJ20111517
   Ma YL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2276
   Matsubara H, 2007, ONCOGENE, V26, P6099, DOI 10.1038/sj.onc.1210425
   Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125
   Monzo M, 2008, CELL RES, V18, P823, DOI 10.1038/cr.2008.81
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   Mraz M, 2009, LEUKEMIA, V23, P1159, DOI 10.1038/leu.2008.377
   Mraz M, 2009, LEUKEMIA LYMPHOMA, V50, P506, DOI 10.1080/10428190902763517
   Musilova K, 2015, LEUKEMIA, V29, P1004, DOI 10.1038/leu.2014.351
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Pentheroudakis G, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-57
   Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013
   Qu YJ, 2016, ONCOTARGET, V7, P33286, DOI 10.18632/oncotarget.8946
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Roa W, 2010, CLIN INVEST MED, V33, pE124
   Roa WH, 2012, CLIN INVEST MED, V35, pE271, DOI 10.25011/cim.v35i5.18700
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Schwentner R, 2017, ONCOTARGET, V8, P10980, DOI 10.18632/oncotarget.14091
   Shan SW, 2013, J CELL SCI, V126, P1517, DOI 10.1242/jcs.122895
   Shan SW, 2009, NAT CELL BIOL, V11, P1031, DOI 10.1038/ncb1917
   Stefani G, 2008, NAT REV MOL CELL BIO, V9, P219, DOI 10.1038/nrm2347
   Stiefel F, 2015, PHARM BIOPROCESS, V3, P227, DOI 10.4155/PBP.14.65
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Totary-Jain H, 2013, J BIOL CHEM, V288, P6034, DOI 10.1074/jbc.M112.416446
   Trompeter HI, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016138
   Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang M, 2013, EUR J CANCER, V49, P2010, DOI 10.1016/j.ejca.2012.12.017
   Wang M, 2012, MOL MED REP, V5, P1514, DOI 10.3892/mmr.2012.828
   Wang Q, 2008, P NATL ACAD SCI USA, V105, P2889, DOI 10.1073/pnas.0800178105
   Wang W, 2016, ONCOL REP, V35, P1473, DOI 10.3892/or.2016.4542
   Weilner S, 2013, EXP GERONTOL, V48, P626, DOI 10.1016/j.exger.2012.11.017
   Wu Q, 2014, FEBS LETT, V588, P2055, DOI 10.1016/j.febslet.2014.04.036
   Xiang J, 2010, CURR GENOMICS, V11, P129, DOI 10.2174/138920210790886853
   Xu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014356
   Yan HL, 2009, EMBO J, V28, P2719, DOI 10.1038/emboj.2009.214
   Yang F, 2010, HEPATOLOGY, V51, P1614, DOI 10.1002/hep.23566
   Yang LQ, 2016, CANCER MED-US, V5, P2022, DOI 10.1002/cam4.760
   Yang XL, 2013, NUCLEIC ACIDS RES, V41, P9688, DOI 10.1093/nar/gkt680
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Yu CG, 2013, MOL NUTR FOOD RES, V57, P1825, DOI 10.1002/mnfr.201200810
   Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003
   Zekri ARN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154130
   Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69
   Zeng QH, 2014, CHINESE J CANCER RES, V26, P711, DOI 10.3978/j.issn.1000-9604.2014.12.03
   Zeng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046367
   Zhang L, 2016, ONCOTARGET, V7, P30876, DOI 10.18632/oncotarget.9021
   Zhao J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1713-z
   Zheng JJ, 2013, HEPATO-GASTROENTEROL, V60, P549, DOI 10.5754/hge12754
   Zhou H, 2010, J MOL MED, V88, P709, DOI 10.1007/s00109-010-0617-2
   Zhu HQ, 2015, CARCINOGENESIS, V36, P1213, DOI 10.1093/carcin/bgv112
NR 126
TC 34
Z9 36
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 19
PY 2017
VL 8
IS 41
BP 71206
EP 71222
DI 10.18632/oncotarget.19331
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH4TA
UT WOS:000411153300163
PM 29050357
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhen, HC
   Li, GX
   Zhao, PF
   Zhang, Y
   Wang, J
   Yu, JX
   Cao, BW
AF Zhen, Hongchao
   Li, Guangxin
   Zhao, Pengfei
   Zhang, Ying
   Wang, Jing
   Yu, Junxian
   Cao, Bangwei
TI Raltitrexed Enhances the Antitumor Effect of Apatinib in Human
   Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE raltitrexed; apatinib; antitumor; ESCC; Akt; Erk
ID ENDOTHELIAL GROWTH-FACTOR; SALVAGE TREATMENT; CANCER-CELL; PHASE-III;
   INHIBITOR; APOPTOSIS; CARDIOTOXICITY; PROLIFERATION; CHEMOTHERAPY;
   EFFICACY
AB Objective: Apatinib has been proved effective in the treatment of advanced gastric cancer and a variety of solid tumors. Raltitrexed is emerging as a promising alternative for treating advanced colorectal cancer in China. This work aims to study the combinatory antitumor effect of apatinib and raltitrexed on human esophageal squamous carcinoma cells (ESCC).
   Materials and Methods: Two VEGFR-2-positive human ESCC lines, KYSE-30 and TE-1, were treated with apatinib or raltitrexed, or both, then the cell proliferation rate was measured by MTS assay; cell migration and invasion were studied by transwell assays; cell apoptosis rate was determined by flow cytometry; cellular autophagy level affected was analyzed by Western blot analysis; finally, quantitative polymerase chain reaction (qPCR) was used to monitor transcription and Western blot was performed to check phosphorylation of apoptotic proteins after treatment.
   Results: Both apatinib and raltitrexed significantly inhibited KYSE-30 and TE-1 cell proliferation in a dose-dependent manner. Treatment with both drugs showed enhanced inhibitory effects on cell proliferation, migration, and invasiveness compared with apatinib monotherapy. Apoptosis percentages in both cell lines were also remarkably increased by the combined treatment. Moreover, the combination of apatinib and raltitrexed down-regulated mRNA level of the anti-apoptotic protein Bcl-2, while up-regulated pro-apoptotic protein PARP, Bax, and caspase-3 transcription. Western blot analysis showed that phosphorylation levels of Erk, Akt, and invasiveness-associated protein matrix metalloproteinases-9 (MMP-9) were decreased in the combination group.
   Conclusion: Taken together, these results indicate that raltitrexed enhances the antitumor effects of apatinib on human ESCC cells by down-regulating phosphorylation of Akt and Erk, implying a combination of raltitrexed and apatinib might be an effective option for treating esophageal squamous cell carcinoma patients.
C1 [Zhen, Hongchao; Zhao, Pengfei; Zhang, Ying; Wang, Jing; Cao, Bangwei] Capital Med Univ, Beijing Friendship Hosp, Ctr Canc, 95 Yong An Rd, Beijing 100050, Peoples R China.
   [Li, Guangxin] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Radiat Oncol, Beijing 102218, Peoples R China.
   [Yu, Junxian] Capital Med Univ, Beijing Friendship Hosp, Dept Pharm, Beijing 100050, Peoples R China.
RP Cao, BW (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Ctr Canc, 95 Yong An Rd, Beijing 100050, Peoples R China.
EM oncology@ccmu.edu.cn
FU Research Foundation of Beijing Friendship Hospital, Capital Medical
   University [yyqdkt2017-19]; Digestive Medical Coordinated Development
   Center of Beijing Hospitals Authority [XXT01]; Beijing key clinical
   specialist project funding (2018-2020); pilot project of clinical
   collaboration with traditional Chinese medicine and western medicine in
   major refractory disease-esophageal cancer [2019-ZX-005]
FX This work was supported by Grants from the Research Foundation of
   Beijing Friendship Hospital, Capital Medical University
   (No.yyqdkt2017-19); the Digestive Medical Coordinated Development Center
   of Beijing Hospitals Authority (to Bangwei Cao, No. XXT01); the Beijing
   key clinical specialist project funding (2018-2020); the pilot project
   of clinical collaboration with traditional Chinese medicine and western
   medicine in major refractory disease-esophageal cancer (to Bangwei Cao,
   No. 2019-ZX-005).
CR Adlung L, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20167258
   Asati V, 2016, EUR J MED CHEM, V109, P314, DOI 10.1016/j.ejmech.2016.01.012
   Barillari G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124526
   Candido S, 2016, BBA-MOL CELL RES, V1863, P438, DOI 10.1016/j.bbamcr.2015.08.010
   Ding WX, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0752-y
   Ewald F, 2015, J CANCER, V6, P1195, DOI 10.7150/jca.12452
   Frezzetti D, 2016, J CELL PHYSIOL, V231, P1514, DOI 10.1002/jcp.25243
   Gou MM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22302-z
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hu LJ, 2019, ONCOL LETT, V17, P1609, DOI 10.3892/ol.2018.9803
   Hu XC, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-820
   JACKMAN AL, 1995, EUR J CANCER, V31A, P1277, DOI 10.1016/0959-8049(95)00166-G
   Kelly C, 2013, EUR J CANCER, V49, P2303, DOI 10.1016/j.ejca.2013.03.004
   Kosmas C, 2008, J CANCER RES CLIN, V134, P75, DOI 10.1007/s00432-007-0250-9
   Li F, 2017, ONCOTARGET, V8, P64471, DOI 10.18632/oncotarget.16293
   Li HX, 2016, MED SCI MONITOR, V22, DOI 10.12659/MSM.899950
   Li JQ, 2017, ONCOTARGETS THER, V10, P3965, DOI 10.2147/OTT.S132756
   Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995
   Liang LJ, 2018, ONCOTARGETS THER, V11, P5821, DOI 10.2147/OTT.S174429
   Lieto E, 2008, ANN SURG ONCOL, V15, P69, DOI 10.1245/s10434-007-9596-0
   Luz Caio Cesar Floriano, 2018, Asian Pac J Cancer Prev, V19, P171
   Ma YJ, 2020, BIOSCI BIOTECH BIOCH, V84, P743, DOI 10.1080/09168451.2019.1709789
   McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001
   Pan WT, 2015, SCI REP-UK, V5, DOI 10.1038/srep11833
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Planting A, 2005, EUR J CANCER, V41, P93, DOI 10.1016/j.ejca.2004.09.022
   Qiu HF, 2018, CELL CYCLE, V17, P1235, DOI 10.1080/15384101.2018.1471315
   Reni M, 2006, BRIT J CANCER, V94, P785, DOI 10.1038/sj.bjc.6603026
   Saif MW, 2009, EXPERT OPIN DRUG SAF, V8, P191, DOI [10.1517/14740330902733961, 10.1517/14740330902733961 ]
   Song ZB, 2017, ONCOTARGETS THER, V10, P1821, DOI 10.2147/OTT.S113435
   Tian S, 2011, CANCER SCI, V102, P1374, DOI 10.1111/j.1349-7006.2011.01939.x
   van Meerbeeck JP, 2005, J CLIN ONCOL, V23, P6881, DOI 10.1200/JCO.20005.14.589
   Wei L, 2020, ONCOTARGETS THER, V13, P2459, DOI 10.2147/OTT.S238348
   Wu J, 2018, ONCOTARGETS THER, V11, P2685, DOI 10.2147/OTT.S157129
   Wu J, 2018, BIOMED PHARMACOTHER, V100, P176, DOI 10.1016/j.biopha.2018.01.140
   Xu WW, 2015, ONCOTARGET, V6, P1790, DOI 10.18632/oncotarget.2781
   Xue S, 2014, MOL MED REP, V10, P1927, DOI 10.3892/mmr.2014.2438
   Yamazaki T, 2020, NAT IMMUNOL, V21, P1160, DOI 10.1038/s41590-020-0751-0
   Yang L, 2017, INT J ONCOL, V51, P378, DOI 10.3892/ijo.2017.4015
   Yang LG, 2018, ONCOTARGETS THER, V11, P5333, DOI 10.2147/OTT.S175507
   Yang YS, 2017, ONCOTARGET, V8, P43397, DOI 10.18632/oncotarget.14762
   Yu WC, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009704
   Zhao HW, 2016, ONCOL RES, V23, P237, DOI 10.3727/096504016X14562725373671
NR 43
TC 0
Z9 0
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2020
VL 13
BP 12325
EP 12339
DI 10.2147/OTT.S276125
PG 15
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA PB9HH
UT WOS:000596622800005
PM 33293826
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, RG
   Deng, H
   Liu, XH
   Chen, ZY
   Wan, SS
   Wang, L
AF Li, Ren-Gui
   Deng, Huan
   Liu, Xiu-Heng
   Chen, Zhi-yuan
   Wan, Shan-shan
   Wang, Lei
TI Histone Methyltransferase G9a Promotes the Development of Renal Cancer
   through Epigenetic Silencing of Tumor Suppressor Gene SPINK5
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID PROTEIN EXPRESSION; COLORECTAL-CANCER; DNA METHYLATION; PROLIFERATION;
   METASTASIS; INHIBITOR; AUTOPHAGY; INVASION; PATHWAY; TARGET
AB Background. Renal cell carcinoma (RCC) accounts for approximately 2-3% of malignant tumors in adults, while clear cell renal cell carcinoma accounts for 70-85% of kidney cancer cases, with an increasing incidence worldwide. G9a is the second histone methyltransferase found in mammals, catalyzing lysine and histone methylation. It regulates gene transcription by catalyzing histone methylation and interacting with transcription factors to alter the tightness of histone-DNA binding. The main purpose of this study is to explore the role and mechanism of G9a in renal cell carcinoma. Methods. Firstly, we investigated the expression of G9a in 80 clinical tissues and four cell lines. Then, we explored the effect of G9a-specific inhibitor UNC0638 on proliferation, apoptosis, migration, and invasion of two renal cancer cell lines (786-O, SN12C). In order to study the specific mechanism, G9a knocking down renal cancer cell line was constructed by lentivirus. Finally, we identified the downstream target genes of G9a using ChIP experiments and rescue experiments. Results. The results showed that the specific G9a inhibitor UNC0638 significantly inhibited the proliferation, migration, and invasion of kidney cancer in vivo and in vitro; similar results were obtained after knocking down G9a. Meanwhile, we demonstrated that SPINK5 was one of the downstream target genes of G9a through ChIP assay and proved that G9a downregulate the expression of SPINK5 by methylation of H3K9me2. Therefore, targeting G9a might be a new approach to the treatment of kidney cancer. Conclusion. G9a was upregulated in renal cancer and could promote the development of renal cancer in vitro and in vivo. Furthermore, we identified SPINK5 as one of the downstream target genes of G9a. Therefore, targeting G9a might be a new treatment for kidney cancer.
C1 [Li, Ren-Gui; Liu, Xiu-Heng; Chen, Zhi-yuan; Wang, Lei] Wuhan Univ, Dept Urol, Renmin Hosp, Wuhan, Peoples R China.
   [Li, Ren-Gui; Deng, Huan] Chongqing Univ, Canc Hosp, Chongqing, Peoples R China.
   [Deng, Huan] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan, Peoples R China.
   [Wan, Shan-shan] Wuhan Univ, Dept Ophthalmol, Renmin Hosp, Wuhan, Peoples R China.
RP Wang, L (corresponding author), Wuhan Univ, Dept Urol, Renmin Hosp, Wuhan, Peoples R China.; Wan, SS (corresponding author), Wuhan Univ, Dept Ophthalmol, Renmin Hosp, Wuhan, Peoples R China.
EM 2012302180010@whu.edu.cn; huangdeng@whu.edu.cn; drliuxh@126.com;
   176023442@qq.com; ophwss@whu.edu.cn; drwanglei@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81972408, 82000639]; Application and Basic
   Research Project of Wuhan City [2018060401011321]; Innovation Project of
   Medical School of Wuhan University [TFZZ2018017]
FX We thank Dr. Huan Deng for the assistance in statistical analysis. This
   study was supported by the National Natural Science Foundation of China
   (No. 81972408, No. 82000639), Application and Basic Research Project of
   Wuhan City (No. 2018060401011321), and Innovation Project of Medical
   School of Wuhan University (TFZZ2018017).
CR Bai K, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002493
   Bittencourt D, 2012, P NATL ACAD SCI USA, V109, P19673, DOI 10.1073/pnas.1211803109
   Casciello F, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00487
   Chang CC, 2015, CANCER RES, V75, P2375, DOI 10.1158/0008-5472.CAN-14-3076
   Chavanas S, 2000, NAT GENET, V25, P141, DOI 10.1038/75977
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13
   Deng H, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109477
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Flavin R, 2014, CLIN CANCER RES, V20, P4904, DOI 10.1158/1078-0432.CCR-13-1341
   Hua KT, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-189
   Ida S, 2015, MOL CANCER RES, V13, P1130, DOI 10.1158/1541-7786.MCR-14-0581
   Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377
   Liu SL, 2015, ONCOTARGET, V6, P6887, DOI 10.18632/oncotarget.3159
   Liu XR, 2018, MOL MED REP, V17, P2239, DOI 10.3892/mmr.2017.8190
   Mayr C, 2018, HUM PATHOL, V72, P117, DOI 10.1016/j.humpath.2017.11.003
   McCroskey Z, 2017, ANN DIAGN PATHOL, V29, P32, DOI 10.1016/j.anndiagpath.2017.04.011
   Patard JJ, 2011, EUR UROL, V60, P684, DOI 10.1016/j.eururo.2011.06.017
   Pei JJ, 2016, AUTOPHAGY, V12, P1738, DOI 10.1080/15548627.2016.1196318
   Purcell DJ, 2012, J CELL BIOCHEM, V113, P2406, DOI 10.1002/jcb.24114
   Rao VK, 2016, NUCLEIC ACIDS RES, V44, P8129, DOI 10.1093/nar/gkw483
   Shankar SR, 2013, EPIGENETICS-US, V8, P16, DOI 10.4161/epi.23331
   Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Staunton JE, 2001, P NATL ACAD SCI USA, V98, P10787, DOI 10.1073/pnas.191368598
   Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/nchembio.599, 10.1038/NCHEMBIO.599]
   Wang Q, 2019, CANCER MED-US, V8, P2360, DOI 10.1002/cam4.2078
   Wei L, 2017, J HEPATOL, V67, P758, DOI 10.1016/j.jhep.2017.05.015
   Wong CM, 2016, HEPATOLOGY, V63, P474, DOI 10.1002/hep.28304
   Yuan Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.191
   Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y
   Zhang J, 2018, THERANOSTICS, V8, P2884, DOI 10.7150/thno.23824
   Zhang J, 2015, ONCOTARGET, V6, P2917, DOI 10.18632/oncotarget.2784
   Zhang T, 2016, CELL REP, V15, P77, DOI 10.1016/j.celrep.2016.03.007
   Zhang X, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10810
NR 38
TC 1
Z9 1
U1 7
U2 8
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD JUL 14
PY 2021
VL 2021
AR 6650781
DI 10.1155/2021/6650781
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA TT7LV
UT WOS:000680527100004
PM 34336110
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wu, CS
   Wu, SY
   Chen, HC
   Chu, CA
   Tang, HH
   Liu, HS
   Hong, YR
   Huang, CYF
   Huang, GC
   Su, CL
AF Wu, Chi-Shivan
   Wu, Shan-Ying
   Chen, Hsin-Chih
   Chu, Chien-An
   Tang, Han-Hsuan
   Liu, Hsiao-Sheng
   Hong, Yi-Ren
   Huang, Chi-Ying F.
   Huang, Guan-Cheng
   Su, Chun-Li
TI Curcumin functions as a MEK inhibitor to induce a synthetic lethal
   effect on KRAS mutant colorectal cancer cells receiving targeted drug
   regorafenib
SO JOURNAL OF NUTRITIONAL BIOCHEMISTRY
LA English
DT Article
DE Curcumin; Regorafenib; Synthetic lethality; Chemosensitivity; MEK
   inhibition; FDA-approved anticancer drugs
ID NF-KAPPA-B; GENE-EXPRESSION; MOLECULAR-MECHANISMS; RAS; APOPTOSIS;
   AURORA; CHEMOSENSITIVITY; SUPPRESSION; ACTIVATION; PATHWAY
AB Curcumin, a major yellow pigment and spice in turmeric and curry, has been demonstrated to have an anticancer effect in human clinical trials. Mutation of KRAS has been shown in 35%-45% of colorectal cancer, and regorafenib has been approved by the US FDA to treat patients with colorectal cancer. Synthetic lethality is a type of genetic interaction between two genes such that simultaneous perturbations of the two genes result in cell death or a dramatic decrease of cell viability, while a perturbation of either gene alone is not lethal. Here, we reveal that curcumin significantly enhanced the growth inhibition of regorafenib in human colorectal cancer HCT 116 cells (KRAS mutant) to a greater extent than in human colorectal cancer HT-29 cells (KRAS wild-type), producing an additive or synergistic effect in HCT 116 cells and causing an antagonistic effect in HT-29 cells. Flow cytometric analysis showed that the addition of curcumin elevated apoptosis and greatly increased autophagy in HCT 116 cells but not in HT-29 cells. Mechanistically, curcumin behaved like MEK-specific inhibitor (U0126) to enhance regorafenib-induced growth inhibition, apoptosis and autophagy in HCT 116 cells. Our data suggest that curcumin may target one more gene other than mutant KRAS to enhance regorafenib-induced growth inhibition (synthetic lethality) in colorectal cancer HCT 116 cells, indicating a possible role of curcumin in regorafenib-treated KRAS mutant colorectal cancer. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Wu, Chi-Shivan; Wu, Shan-Ying; Chen, Hsin-Chih; Su, Chun-Li] Natl Taiwan Normal Univ, Dept Human Dev & Family Studies, Taipei 106, Taiwan.
   [Wu, Shan-Ying; Tang, Han-Hsuan; Su, Chun-Li] Natl Taiwan Normal Univ, Sch Life Sci, Grad Program Nutr Sci, 162,Sec 1,He Ping East Rd, Taipei 106, Taiwan.
   [Chu, Chien-An; Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan.
   [Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Ctr Infect Dis, Tainan 701, Taiwan.
   [Liu, Hsiao-Sheng] Natl Cheng Kung Univ, Coll Med, Signaling Res Ctr, Tainan 701, Taiwan.
   [Hong, Yi-Ren] Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung 807, Taiwan.
   [Hong, Yi-Ren; Huang, Chi-Ying F.] Kaohsiung Med Univ, Dept Biochem, Coll Med, Kaohsiung 807, Taiwan.
   [Huang, Chi-Ying F.] Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Linong St, Taipei 112, Taiwan.
   [Huang, Guan-Cheng] Yuans Gen Hosp, Dept Internal Med, Div Hematooncol, 162 Cheng Kung 1st Rd, Kaohsiung 802, Taiwan.
RP Su, CL (corresponding author), Natl Taiwan Normal Univ, Sch Life Sci, Grad Program Nutr Sci, 162,Sec 1,He Ping East Rd, Taipei 106, Taiwan.; Huang, CYF (corresponding author), Natl Yang Ming Univ, Inst Biopharmaceut Sci, 155,Sec 2,Linong St, Taipei 112, Taiwan.; Huang, GC (corresponding author), Yuans Gen Hosp, Dept Internal Med, Div Hematooncol, 162 Cheng Kung 1st Rd, Kaohsiung 802, Taiwan.
EM cyhuang5@ym.edu.tw; guanchenghuang@yahoo.com.tw; chunlisu@ntnu.edu.tw
RI Huang, Chi-Ying/AAG-7672-2022; Huang, Chi-Ying/AFL-7729-2022
OI Huang, Chi-Ying/0000-0003-4898-4937; Huang,
   Chi-Ying/0000-0003-4898-4937; Tang, Han-Hsuan/0000-0002-9034-3597; Wu,
   Shan-Ying/0000-0003-2380-5760; Liu, Hsiao-Sheng/0000-0003-0576-7203;
   Hong, Yi-Ren/0000-0001-5470-6090
FU National Science Council, TaiwanMinistry of Science and Technology,
   Taiwan [101-2313-B-003-002-MY3]; Ministry of Science and Technology,
   TaiwanMinistry of Science and Technology, Taiwan [MOST
   104-2320-B-003-007, 105-2320-B-003-003, 106-2320-B-003-006-MY3];
   National Taiwan Normal University, Taiwan [10502, 10602]; Yuan's General
   Hospital [RG15-003, YGH 17-002]
FX This work was supported by grants from the National Science Council,
   Taiwan (101-2313-B-003-002-MY3); the Ministry of Science and Technology,
   Taiwan (MOST 104-2320-B-003-007, 105-2320-B-003-003 and
   106-2320-B-003-006-MY3); National Taiwan Normal University, Taiwan
   (10502 and 10602); and Yuan's General Hospital (RG15-003 and YGH
   17-002).
CR Bahrami A, 2018, J CELL PHYSIOL, V233, P2058, DOI 10.1002/jcp.25890
   Caputo E, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0216-z
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36
   Davis SL, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00120
   Deng Y, 2016, ANTICANCER RES, V36, P5639, DOI 10.21873/anticanres.11147
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992
   GALANG CK, 1994, ONCOGENE, V9, P2913
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Gewirtz DA, 2014, CANCER RES, V74, P647, DOI 10.1158/0008-5472.CAN-13-2966
   Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689
   Huang XF, 2008, BLOOD, V111, P2854, DOI 10.1182/blood-2007-07-099325
   Ke CS, 2014, J NUTR BIOCHEM, V25, P526, DOI 10.1016/j.jnutbio.2014.01.003
   Khan G, 2014, CANCER MANAG RES, V6, P93, DOI 10.2147/CMAR.S52217
   Knickelbein K, 2015, GENES DIS, V2, P4, DOI 10.1016/j.gendis.2014.10.002
   Kunnumakkara AB, 2017, BRIT J PHARMACOL, V174, P1325, DOI 10.1111/bph.13621
   Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033
   Lee JC, 2005, CARCINOGENESIS, V26, P1716, DOI 10.1093/carcin/bgi133
   LIU HS, 1989, P NATL ACAD SCI USA, V86, P9951, DOI 10.1073/pnas.86.24.9951
   LIU HS, 1992, CANCER RES, V52, P983
   Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344
   Magne N, 2003, BRIT J CANCER, V89, P585, DOI 10.1038/sj.bjc.6601131
   McLornan DP, 2014, NEW ENGL J MED, V371, P1725, DOI 10.1056/NEJMra1407390
   Megchelenbrink W, 2015, P NATL ACAD SCI USA, V112, P12217, DOI 10.1073/pnas.1508573112
   Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Seca AML, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010263
   Sini P, 2016, MOL CANCER THER, V15, P2388, DOI 10.1158/1535-7163.MCT-16-0066
   Srihari S, 2015, BIOL DIRECT, V10, DOI 10.1186/s13062-015-0086-1
   Su CL, 2017, EUR J MED CHEM, V132, P90, DOI 10.1016/j.ejmech.2017.03.034
   Sui XB, 2014, SCI REP-UK, V4, DOI 10.1038/srep04694
   Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
   Temraz S, 2015, INT J MOL SCI, V16, P22976, DOI 10.3390/ijms160922976
   Thompson Jordan M., 2015, Yale Journal of Biology and Medicine, V88, P145
   Waddell T, 2013, LANCET, V381, P273, DOI 10.1016/S0140-6736(12)62006-6
   Wang YT, 2014, INT J FOOD SCI NUTR, V65, P368, DOI 10.3109/09637486.2013.871694
   Yan YY, 2015, ONCOTARGETS THER, V8, P2949, DOI 10.2147/OTT.S79145
   Zhou Y Y, 1984, Zhongguo Yao Li Xue Bao, V5, P217
   Ziemke EK, 2016, CLIN CANCER RES, V22, P405, DOI 10.1158/1078-0432.CCR-15-0829
   Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008
NR 42
TC 9
Z9 9
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0955-2863
EI 1873-4847
J9 J NUTR BIOCHEM
JI J. Nutr. Biochem.
PD DEC
PY 2019
VL 74
AR 108227
DI 10.1016/j.jnutbio.2019.108227
PG 13
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA JY4GN
UT WOS:000504375400005
PM 31675556
DA 2022-04-25
ER

PT J
AU Liang, JX
   Ning, Z
   Gao, W
   Ling, J
   Wang, AM
   Luo, HF
   Liang, Y
   Yan, Q
   Wang, ZY
AF Liang, Jin-Xiao
   Ning, Zhen
   Gao, Wei
   Ling, Jun
   Wang, A-Man
   Luo, Hai-Feng
   Liang, Yong
   Yan, Qiu
   Wang, Zhong-Yu
TI Ubiquitin-specific protease 22-induced autophagy is correlated with poor
   prognosis of pancreatic cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE autophagy; LC3; pancreatic cancer; prognosis; ubiquitin-specific
   protease 22
ID COLORECTAL-CANCER; THERAPY FAILURE; CELL-DEATH; INHIBITION; EXPRESSION;
   USP22; TRANSCRIPTION; CHEMOTHERAPY; GEMCITABINE; PROGRESSION
AB Ubiquitin-specific protease 22 (USP22) is a component of the transcription regulatory histone acetylation complex SAGA, which broadly regulates gene transcription and correlates with cancer progression, metastasis and prognosis. Autophagy is a cell pathway with dual functions that promotes cell survival or death. However, it is not known whether USP22 can regulate autophagy in pancreatic cancer. In the present study, we first identified that USP22 was overexpressed in a large number of pancreatic cancer patient samples, concomitant with the increased expression of LC3, a marker of autophagy. Statistical analysis revealed that the increase in USP22 and autophagy was positively correlated with poor prognosis of pancreatic cancer patients. Further investigation using a human pancreatic cancer cell (Panc-1) identified that the overexpression of USP22 increased the processing of LC3 into the active form LC3-II and the number of autophagosomes, thus leading to enhanced autophagy. Activation of ERK1/2 kinase rather than AKT1 by USP22 was found to be one of the mechanisms promoting LC3 processing. USP22-induced autophagy was also found to enhance cell proliferation and resistance to starvation and chemotherapeutic drugs in Panc-1 cells, therefore expressing an overall effect that promotes cell survival. Collectively, the present study demonstrated a new function of USP22 that induces autophagy, thus leading to the poor prognosis of pancreatic cancer.
C1 [Liang, Jin-Xiao] Zhejiang Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China.
   [Ning, Zhen; Wang, A-Man; Luo, Hai-Feng; Wang, Zhong-Yu] Dalian Med Univ, Affiliated Hosp 1, Dalian 116011, Liaoning, Peoples R China.
   [Gao, Wei; Yan, Qiu] Dalian Med Univ, Dept Biochem & Mol Biol, Dalian 116011, Liaoning, Peoples R China.
   [Ling, Jun] Commonwealth Med Coll, Dept Basic Sci, Scranton, PA 18509 USA.
   [Liang, Yong] Taizhou Univ, Sch Med, Dept Clin Med, Taizhou 318000, Zhejiang, Peoples R China.
RP Wang, ZY (corresponding author), Dalian Med Univ, Affiliated Hosp 1, 222 Zhongshan Rd, Dalian 116011, Liaoning, Peoples R China.
EM yanqiudalian@gmail.com; wangzhongyudl@gmail.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [30870719]; Dalian Municipal Science and
   Technology Foundation [2011E15SF114]
FX This study was supported by grants from the National Natural Science
   Foundation of China (no. 30870719), and the Dalian Municipal Science and
   Technology Foundation (no. 2011E15SF114).
CR Atanassov BS, 2009, MOL CELL, V35, P352, DOI 10.1016/j.molcel.2009.06.015
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Cherra SJ, 2010, J CELL BIOL, V190, P533, DOI 10.1083/jcb.201002108
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Debnath J, 2005, AUTOPHAGY, V1, P66, DOI 10.4161/auto.1.2.1738
   Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36
   Egner J.R., 2010, JAMA-J AM MED ASSOC, V304, P1726, DOI [DOI 10.1001/JAMA.2010.1525, 10.1001/jama.2010.1525]
   Fujii S, 2008, CANCER SCI, V99, P1813, DOI 10.1111/j.1349-7006.2008.00893.x
   Gillett CE, 2006, METH MOLEC MED, V120, P191
   Glinsky GV, 2008, J CLIN ONCOL, V26, P2846, DOI 10.1200/JCO.2008.17.0266
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011
   Gukovskaya AS, 2004, PANCREATOLOGY, V4, P567, DOI 10.1159/000082182
   Jiang HB, 2010, BIOCHEM BIOPH RES CO, V395, P471, DOI 10.1016/j.bbrc.2010.04.030
   Lee HJ, 2006, GENE EXPR PATTERNS, V6, P277, DOI 10.1016/j.modgep.2005.07.007
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Ling SB, 2012, CELL MOL BIOL S, V58
   Liu FF, 2013, ONCOL LETT, V5, P1261, DOI 10.3892/ol.2013.1154
   Liu YL, 2010, J GASTROEN HEPATOL, V25, P1800, DOI 10.1111/j.1440-1746.2010.06352.x
   Liu YL, 2011, J SURG ONCOL, V103, P283, DOI 10.1002/jso.21802
   Lv L, 2011, MOL CELL BIOCHEM, V346, P11, DOI 10.1007/s11010-010-0585-4
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092
   Ning J, 2012, EUR J HISTOCHEM, V56, P289, DOI 10.4081/ejh.2012.e46
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Pardo R, 2010, PANCREATOLOGY, V10, P19, DOI 10.1159/000264680
   Pattingre S, 2003, J BIOL CHEM, V278, P16667, DOI 10.1074/jbc.M210998200
   Rausch V, 2012, J PATHOL, V227, P325, DOI 10.1002/path.3994
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Tung WL, 2011, PROSTATE, V71, P675, DOI 10.1002/pros.21283
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Yang DD, 2011, CELL BIOCHEM BIOPHYS, V61, P703, DOI 10.1007/s12013-011-9229-x
   Yang SH, 2011, AUTOPHAGY, V7, P912, DOI 10.4161/auto.7.8.15762
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Zhang XY, 2008, MOL CELL, V29, P102, DOI 10.1016/j.molcel.2007.12.015
   Zhang YX, 2011, J CANCER RES CLIN, V137, P1245, DOI 10.1007/s00432-011-0998-9
   Zhao Y, 2008, MOL CELL, V29, P92, DOI 10.1016/j.molcel.2007.12.011
NR 38
TC 30
Z9 32
U1 1
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD DEC
PY 2014
VL 32
IS 6
BP 2726
EP 2734
DI 10.3892/or.2014.3508
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AT4JE
UT WOS:000344904900055
PM 25241857
OA Bronze
DA 2022-04-25
ER

PT J
AU Shan, CY
   Hui, WQ
   Li, HW
   Wang, Z
   Guo, CL
   Peng, RK
   Gu, J
   Chen, YC
   Ouyang, Q
AF Shan, Changyu
   Hui, Wenqi
   Li, Hongwei
   Wang, Zheng
   Guo, Chunling
   Peng, Ruikun
   Gu, Jing
   Chen, Yingchun
   Ouyang, Qin
TI Discovery of Novel Autophagy Inhibitors and Their Sensitization
   Abilities for Vincristine-Resistant Esophageal Cancer Cell Line
   Eca109/VCR
SO CHEMMEDCHEM
LA English
DT Article
DE autophagy inhibitors; drug-resistant cancer cell lines; molecular
   docking
ID COLORECTAL-CANCER; RECURRENCE; HYDROXYCHLOROQUINE; COMBINATION;
   DISSECTION; ACTIVATION; PROGNOSIS; PROTEIN; POTENT; TRIAL
AB Resistance phenomena, especially acquired drug resistance, have been severely hampering the application of chemotherapeutics during cancer chemotherapy. Autophagy plays a role in maintaining the survival of cancer cells and might mediate resistance to chemotherapy drugs. Herein, a new series of 5-amino-2-ether-benzamide derivatives were synthesized and evaluated as autophagy inhibitors. Selected from 14 synthesized compounds as lead autophagy inhibitor, N-(cyclohexylmethyl)-5-(((cyclohexylmethyl)amino)methyl)-2-((4-(trifluoromethyl)benzyl)oxy)benzamide (4 d) showed the most obvious effect of LC3B protein conversion. Further, its autophagy inhibition, evaluated by using transmission electron microscopy and confocal microscopy, showed that the fusion of autophagosomes and lysosomes in the final stage of autophagic flux was suppressed. We also found that 4 d could enhance the chemosensitivity of vincristine in vincristine-resistant esophageal cancer cell line Eca109/VCR in a synergistic, associative manner. Moreover, a computational study showed that 4 d might bind with p62-zz to inhibit autophagy. We also found 4 d to be relatively less cytotoxic to normal cells versus cancer cells than the reported p62-zz inhibitor.
C1 [Shan, Changyu; Hui, Wenqi; Li, Hongwei; Guo, Chunling; Peng, Ruikun; Gu, Jing; Chen, Yingchun; Ouyang, Qin] Third Mil Med Univ, Dept Pharmaceut Chem, Chongqing 400038, Peoples R China.
   [Hui, Wenqi] Xian Fifth Hosp, Dept Pharm, Xian 710082, Shanxi, Peoples R China.
   [Wang, Zheng] Sichuan Univ Sci & Engn, Coll Chem & Environm Engn, Zigong 643000, Sichuan, Peoples R China.
RP Ouyang, Q (corresponding author), Third Mil Med Univ, Dept Pharmaceut Chem, Chongqing 400038, Peoples R China.
EM ouyangq@tmmu.edu.cn
FU National Key R&D program of China [2018YFA0507900]; Chongqing Young Top
   Talents Training Plan
FX We are grateful for the financial support from the National Key R&D
   program of China (2018YFA0507900) and Chongqing Young Top Talents
   Training Plan.
CR Adler DG, 2017, GASTROINTEST ENDOSC, V86, P560, DOI 10.1016/j.gie.2017.02.029
   Aksenov AV, 2015, J MED CHEM, V58, P2206, DOI 10.1021/jm501518y
   Campbell GR, 2011, J BIOL CHEM, V286, P18890, DOI 10.1074/jbc.M110.206110
   Cha-Molstad H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00085-7
   CHOU TC, 1983, TRENDS PHARMACOL SCI, V4, P450, DOI 10.1016/0165-6147(83)90490-X
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Das LM, 2019, AUTOPHAGY, V15, P813, DOI 10.1080/15548627.2019.1569298
   Dinda B, 2019, EUR J MED CHEM, V169, P185, DOI 10.1016/j.ejmech.2019.03.009
   Grasso S, 2016, EUR J MED CHEM, V122, P611, DOI 10.1016/j.ejmech.2016.06.043
   Guo QX, 2018, J MED CHEM, V61, P881, DOI 10.1021/acs.jmedchem.7b01402
   Haenisch S, 2012, EPIGENOMICS-UK, V4, P369, DOI [10.2217/EPI.12.39, 10.2217/epi.12.39]
   He CC, 2012, NATURE, V481, P511, DOI 10.1038/nature10758
   He SY, 2018, J MED CHEM, V61, P4656, DOI 10.1021/acs.jmedchem.7b01019
   Hong L, 2015, EXPERT REV GASTROENT, V9, P887, DOI 10.1586/17474124.2015.1041507
   Jain AN, 2000, J COMPUT AID MOL DES, V14, P199, DOI 10.1023/A:1008100132405
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Joo JY, 2015, ORAL ONCOL, V51, P164, DOI 10.1016/j.oraloncology.2014.11.004
   Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451
   Kimura T, 2013, CANCER RES, V73, P3, DOI 10.1158/0008-5472.CAN-12-2464
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723
   Koren I, 2012, SCIENCE, V338, P889, DOI 10.1126/science.1230577
   Kumar A, 2019, EUR J MED CHEM, V176, P268, DOI 10.1016/j.ejmech.2019.05.027
   Li K, 2019, BIOL PSYCHIAT, V85, P214, DOI 10.1016/j.biopsych.2018.07.026
   Liu XC, 2016, ONCOTARGET, V7, P53515, DOI 10.18632/oncotarget.10650
   Liu YM, 2017, EXP CELL RES, V358, P335, DOI 10.1016/j.yexcr.2017.07.008
   Lou F, 2013, J THORAC CARDIOV SUR, V145, P75, DOI 10.1016/j.jtcvs.2012.09.030
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Matthews H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173303
   Miyata H, 2009, CANCER, V115, P3324, DOI 10.1002/cncr.24390
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Ouyang L, 2018, J MED CHEM, V61, P2776, DOI 10.1021/acs.jmedchem.7b01575
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6
   Rangwala R, 2014, AUTOPHAGY, V10, P1391, DOI 10.4161/auto.29119
   Rosenfeldt MT, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001306
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Sato H, 2016, J GASTROENTEROL, V51, P465, DOI 10.1007/s00535-015-1122-8
   Settembre C, 2013, NAT REV MOL CELL BIO, V14, P283, DOI 10.1038/nrm3565
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sun X, 2018, CELL ONCOL, V41, P651, DOI 10.1007/s13402-018-0399-z
   Teramachi J, 2016, LEUKEMIA, V30, P390, DOI 10.1038/leu.2015.229
   van Roozendaal LM, 2016, BREAST CANCER RES TR, V156, P465, DOI 10.1007/s10549-016-3757-4
   Vogl DT, 2014, AUTOPHAGY, V10, P1380, DOI 10.4161/auto.29264
   Vu CB, 2017, J MED CHEM, V60, P458, DOI 10.1021/acs.jmedchem.6b01539
   Wang T, 2015, J MED CHEM, V58, P3025, DOI 10.1021/jm501586m
   Wang ZH, 2013, CARCINOGENESIS, V34, P128, DOI 10.1093/carcin/bgs295
   Zhang Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02251-3
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
   Zhu Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1900-y
NR 50
TC 3
Z9 3
U1 0
U2 5
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD JUN 4
PY 2020
VL 15
IS 11
BP 970
EP 981
DI 10.1002/cmdc.202000004
EA APR 2020
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA LU1NK
UT WOS:000527323000001
PM 32207878
DA 2022-04-25
ER

PT J
AU Zhang, J
   Yang, ZZ
   Dong, J
AF Zhang, Jing
   Yang, Zuozhang
   Dong, Jian
TI P62: An emerging oncotarget for osteolytic metastasis
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Review
DE P62/SQSTM1; Bone metastasis; Cancer; Osteoclasts; Autophagy
ID TRANSCRIPTION FACTOR NRF2; TUMOR-ASSOCIATED ANTIGENS; PAGETS-DISEASE;
   OXIDATIVE STRESS; PROTEIN P62; DNA VACCINE; SELECTIVE AUTOPHAGY;
   COLORECTAL-CANCER; BREAST-CANCER; CELL-DEATH
AB Bone metastasis occurs in the majority of late-stage tumors with poor prognosis. It is mainly classified as osteoblastic metastasis and osteolytic metastasis. The pathogenesis of osteolytic metastasis is a "vicious cycle" between tumor cells and bone cells (primarily the osteoclasts), which is mediated by secretory factors. The P62 adapter protein is a versatile multitasker between tumor cells and bone cells. The overexpression of P62 has been detected among a variety of tumors, playing positive roles in both tumorigenesis and metastasis. Moreover, P62 is an important modulator of the osteoclastogenesis pathway. Therefore, the ability of P62 to modulate tumors and osteoclasts suggests that it may be a feasible oncotarget for bone metastasis, especially for osteolytic metastasis. Recent research has shown that a P62 DNA vaccine triggered effective anti-tumor, anti-metastatic and anti-osteoporotic activities. Growing lines of evidence point to P62 as an emerging oncotarget for osteolytic metastasis. In this review, we outline the different roles of P62 in tumor cells and osteoclasts, focusing on the P62-related signaling pathway in key steps of osteolytic metastasis, including tumorigenesis, metastasis and osteoclastogenesis. Finally, we discuss the newest observations on P62 as an oncotarget for osteolytic metastasis treatment. (C) 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license.
C1 [Zhang, Jing; Yang, Zuozhang; Dong, Jian] Kunming Med Univ, Tumor Hosp Yunnan Prov, Bone & Soft Tissue Tumors Res Ctr Yunnan Prov, Affiliated Hosp 3,Dept Orthopaed, Kunming 650118, Yunnan, Peoples R China.
   [Dong, Jian] Stem Cell Therapy Tech Clin Transformat & Basic R, Kunming 650118, Yunnan, Peoples R China.
RP Dong, J (corresponding author), Kunming Med Univ, Tumor Hosp Yunnan Prov, Bone & Soft Tissue Tumors Res Ctr Yunnan Prov, Affiliated Hosp 3,Dept Orthopaed, Kunming 650118, Yunnan, Peoples R China.
EM nmlimit@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81302343/H1624]; Joint Special Funds for the
   Department of Science and Technology of Yunnan Province - Kunming
   Medical University [2014FB0 592014FB067]
FX This research was supported in part by Grants (no. 81302343/H1624) from
   the National Natural Science Foundation of China, a Grant (no. 2014FB0
   592014FB067) from the Joint Special Funds for the Department of Science
   and Technology of Yunnan Province - Kunming Medical University.
CR Bloy N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1026531
   Boyce BF, 2013, J BONE MINER RES, V28, P711, DOI 10.1002/jbmr.1885
   Cejka D, 2010, ARTHRITIS RHEUM-US, V62, P2294, DOI 10.1002/art.27504
   Cerda C, 2014, ADV EXP MED BIOL, V824, P5, DOI 10.1007/978-3-319-07320-0_2
   Chang MA, 2014, J CELL BIOCHEM, V115, P2188, DOI 10.1002/jcb.24897
   Chang MA, 2014, PROSTATE, V74, P149, DOI 10.1002/pros.22737
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi J, 2013, HISTOPATHOLOGY, V62, P275, DOI 10.1111/his.12002
   Colunga A, 2014, GENE THER, V21, P371, DOI 10.1038/gt.2014.6
   Demchenko YN, 2010, ONCOTARGET, V1, P59, DOI 10.18632/oncotarget.109
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Duran A, 2004, DEV CELL, V6, P303, DOI 10.1016/S1534-5807(03)00403-9
   Duran A, 2008, CANCER CELL, V13, P343, DOI 10.1016/j.ccr.2008.02.001
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Ellis RA, 2014, J INVEST DERMATOL, V134, P1476, DOI 10.1038/jid.2013.497
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140-6736(10)62344-6
   Gabai V, 2014, ONCOTARGET, V5, P12803, DOI 10.18632/oncotarget.2516
   Gabai VL, 2014, INT REV IMMUNOL, V33, P375, DOI 10.3109/08830185.2014.954699
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Giatromanolaki A., 2014, UROL ONCOL, V32, pe11, DOI DOI 10.1016/J.UR0L0NC.2013.04.003
   Green DR, 2014, CELL, V157, P65, DOI 10.1016/j.cell.2014.02.049
   Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304
   Hiruma Y, 2009, BLOOD, V113, P4894, DOI 10.1182/blood-2008-08-173948
   Hocking LJ, 2012, J BONE MINER RES, V27, P1439, DOI 10.1002/jbmr.1668
   Hua F, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8951
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003
   Inoue D, 2012, CANCER SCI, V103, P760, DOI 10.1111/j.1349-7006.2012.02216.x
   Islam A., 2014, P INT C INF EL VIS I, P1
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jang JH, 2015, CLIN EXP METASTAS, V32, P677, DOI 10.1007/s10585-015-9736-z
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Jin MY, 2013, CELL, V152, P368, DOI 10.1016/j.cell.2013.01.004
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Kim JY, 2014, TUMORI, V100, pE118, DOI 10.1700/1636.17924
   Kim YS, 2014, YONSEI MED J, V55, P1484, DOI 10.3349/ymj.2014.55.6.1484
   Kitamura H, 2006, HISTOPATHOLOGY, V48, P157, DOI 10.1111/j.1365-2559.2005.02313.x
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Kuo WL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090171
   Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731
   Leidal AM, 2014, GENE DEV, V28, P1137, DOI 10.1101/gad.244681.114
   Li LJ, 2013, CANCER CELL, V24, P738, DOI 10.1016/j.ccr.2013.10.025
   Li RF, 2014, J HISTOCHEM CYTOCHEM, V62, P879, DOI 10.1369/0022155414551367
   Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006
   Lotz MK, 2011, NAT REV RHEUMATOL, V7, P579, DOI 10.1038/nrrheum.2011.109
   Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222
   Maroni P, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.465
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Matsumoto G, 2011, MOL CELL, V44, P279, DOI 10.1016/j.molcel.2011.07.039
   Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812
   McCarthy N, 2014, NAT REV CANCER, V14, P74, DOI 10.1038/nrc3673
   McManus Stephen, 2012, J Mol Signal, V7, P1, DOI 10.1186/1750-2187-7-1
   Milan E, 2015, AUTOPHAGY, V11, P1161, DOI 10.1080/15548627.2015.1052928
   Mortensen M, 2011, J EXP MED, V208, P455, DOI 10.1084/jem.20101145
   Moscat J, 2012, TRENDS BIOCHEM SCI, V37, P230, DOI 10.1016/j.tibs.2012.02.008
   Moscat J, 2011, CELL, V147, P724, DOI 10.1016/j.cell.2011.10.021
   Najat D, 2009, J BONE MINER RES, V24, P632, DOI 10.1359/JBMR.081204
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Nihira K, 2014, CANCER SCI, V105, P568, DOI 10.1111/cas.12396
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Owen Helen C, 2015, Intensive Care Med Exp, V3, P52, DOI 10.1186/s40635-015-0052-3
   Park JM, 2013, CANCER BIOL THER, V14, P100, DOI 10.4161/cbt.22954
   Peng YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074407
   Qian Hong-liu, 2003, Zhonghua Bing Li Xue Za Zhi, V32, P329
   Qiang L, 2014, P NATL ACAD SCI USA, V111, P9241, DOI 10.1073/pnas.1322913111
   Rahim Agus Hadian, 2015, Acta Inform Med, V23, P228, DOI 10.5455/aim.2015.23.228-232
   Rea SL, 2013, ENDOCR REV, V34, P501, DOI 10.1210/er.2012-1034
   Ren F, 2014, MOL CELL BIOCHEM, V385, P95, DOI 10.1007/s11010-013-1818-0
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Rolland P, 2007, ENDOCR-RELAT CANCER, V14, P73, DOI 10.1677/erc.1.01312
   Roodman GD, 2012, CANCER METAST REV, V31, P569, DOI 10.1007/s10555-012-9372-x
   Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865
   Sabbieti MG, 2015, ONCOTARGET, V6, P3590, DOI 10.18632/oncotarget.2884
   Sanchez C.P., 2007, BMC PEDIATR, V22, P954
   Sanchez P, 1998, MOL CELL BIOL, V18, P3069, DOI 10.1128/MCB.18.5.3069
   Shen CC, 2013, INT J MOL MED, V32, P448, DOI 10.3892/ijmm.2013.1399
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Singer FR, 2015, NAT REV ENDOCRINOL, V11, P662, DOI 10.1038/nrendo.2015.138
   Song CJ, 2014, CYTOTHERAPY, V16, P1361, DOI 10.1016/j.jcyt.2014.04.006
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Sundaram K, 2011, ENDOCRINOLOGY, V152, P4180, DOI 10.1210/en.2011-1225
   Thompson HGR, 2003, ONCOGENE, V22, P2322, DOI 10.1038/sj.onc.1206325
   Valencia T, 2014, CANCER CELL, V26, P121, DOI 10.1016/j.ccr.2014.05.004
   Venanzi F, 2013, ONCOTARGET, V4, P1829, DOI 10.18632/oncotarget.1397
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Wei HJ, 2014, GENE DEV, V28, P1204, DOI 10.1101/gad.237354.113
   Wright T, 2013, BONE, V52, P699, DOI 10.1016/j.bone.2012.10.023
   Xu JK, 2009, CYTOKINE GROWTH F R, V20, P7, DOI 10.1016/j.cytogfr.2008.11.007
   Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019
   Zhang J, 2013, INT J BIOCHEM CELL B, V45, P745, DOI 10.1016/j.biocel.2012.11.001
   Zhou SL, 2015, DIS ESOPHAGUS, V28, P371, DOI 10.1111/dote.12206
   Zhou SL, 2014, DIS ESOPHAGUS, V27, P790, DOI 10.1111/dote.12145
NR 95
TC 21
Z9 24
U1 1
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212-1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD MAR
PY 2016
VL 5
IS 1
BP 30
EP 37
DI 10.1016/j.jbo.2016.01.003
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DO3UY
UT WOS:000377708900005
PM 26998424
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Gupta, SC
   Kismali, G
   Aggarwal, BB
AF Gupta, Subash C.
   Kismali, Gorkem
   Aggarwal, Bharat B.
TI Curcumin, a component of turmeric: From farm to pharmacy
SO BIOFACTORS
LA English
DT Review
DE autophagy; cancer stem cells; curcumin; microRNA
ID CANCER STEM-CELLS; ADVANCED PANCREATIC-CANCER; EPITHELIAL
   OVARIAN-CANCER; LUNG ADENOCARCINOMA CELLS; I CLINICAL-TRIAL;
   COLORECTAL-CANCER; BRAIN-TUMORS; ORAL BIOAVAILABILITY; MIR-21
   EXPRESSION; MOLECULAR TARGETS
AB Curcumin, an active polyphenol of the golden spice turmeric, is a highly pleiotropic molecule with the potential to modulate the biological activity of a number of signaling molecules. Traditionally, this polyphenol has been used in Asian countries to treat such human ailments as acne, psoriasis, dermatitis, and rash. Recent studies have indicated that curcumin can target newly identified signaling pathways including those associated with microRNA, cancer stem cells, and autophagy. Extensive research from preclinical and clinical studies has delineated the molecular basis for the pharmaceutical uses of this polyphenol against cancer, pulmonary diseases, neurological diseases, liver diseases, metabolic diseases, autoimmune diseases, cardiovascular diseases, and numerous other chronic diseases. Multiple studies have indicated the safety and efficacy of curcumin in numerous animals including rodents, monkeys, horses, rabbits, and cats and have provided a solid basis for evaluating its safety and efficacy in humans. To date, more than 65 human clinical trials of curcumin, which included more than 1000 patients, have been completed, and as many as 35 clinical trials are underway. Curcumin is now used as a supplement in several countries including the United States, India, Japan, Korea, Thailand, China, Turkey, South Africa, Nepal, and Pakistan. In this review, we provide evidence for the pharmaceutical uses of curcumin for various diseases. (c) 2013 BioFactors, 39(1):213, 2013
C1 [Gupta, Subash C.; Kismali, Gorkem; Aggarwal, Bharat B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
RP Aggarwal, BB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Cytokine Res Lab, Houston, TX 77030 USA.
EM aggarwal@mdanderson.org
RI Gupta, Subash/AAF-2563-2019; Aggarwal, Bharat B/G-3388-2013
OI Gupta, Subash/0000-0002-0418-1940; 
CR Aggarwal BB, 2009, TRENDS PHARMACOL SCI, V30, P85, DOI 10.1016/j.tips.2008.11.002
   Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Ali S, 2012, CANCER LETT, V319, P173, DOI 10.1016/j.canlet.2012.01.013
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Antony B, 2008, INDIAN J PHARM SCI, V70, P445, DOI 10.4103/0250-474X.44591
   Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Appiah-Opong R, 2007, TOXICOLOGY, V235, P83, DOI 10.1016/j.tox.2007.03.007
   Asawanonda P, 2010, PHOTOMED LASER SURG, V28, P679, DOI 10.1089/pho.2009.2637
   Bao B, 2012, CANCER RES, V72, P335, DOI 10.1158/0008-5472.CAN-11-2182
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931
   Bergmann L, 1997, BLOOD, V90, P1217, DOI 10.1182/blood.V90.3.1217.1217_1217_1225
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Cao J, 2006, TOXICOL SCI, V91, P476, DOI 10.1093/toxsci/kfj153
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098
   Chatterjee SJ, 2011, CANCER BIOL THER, V11, P216, DOI 10.4161/cbt.11.2.13798
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Clutterbuck AL, 2009, ANN NY ACAD SCI, V1171, P428, DOI 10.1111/j.1749-6632.2009.04687.x
   Colitti M, 2012, VET IMMUNOL IMMUNOP, V147, P136, DOI 10.1016/j.vetimm.2012.04.001
   Cuomo J, 2011, J NAT PROD, V74, P664, DOI 10.1021/np1007262
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Deshpande SS, 1997, CANCER LETT, V118, P79, DOI 10.1016/S0304-3835(97)00238-3
   Deshpande SS, 1998, CANCER LETT, V123, P35, DOI 10.1016/S0304-3835(97)00400-X
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Dillhoff M, 2008, J GASTROINTEST SURG, V12, P2171, DOI 10.1007/s11605-008-0584-x
   Durgaprasad S, 2005, INDIAN J MED RES, V122, P315
   Epelbaum R, 2010, NUTR CANCER, V62, P1137, DOI 10.1080/01635581.2010.513802
   Epstein J, 2010, BRIT J NUTR, V103, P1545, DOI 10.1017/S0007114509993667
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Fong D, 2010, CANCER LETT, V293, P65, DOI 10.1016/j.canlet.2009.12.018
   Fong MY, 2010, HISTOL HISTOPATHOL, V25, P113, DOI 10.14670/HH-25.113
   Franck T, 2008, PHYSIOL RES, V57, P577, DOI 10.33549/physiolres.931086
   Gao SM, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-27
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Gota VS, 2010, J AGR FOOD CHEM, V58, P2095, DOI 10.1021/jf9024807
   GOVINDARAJAN VS, 1980, CRC CR REV FOOD SCI, V12, P199, DOI 10.1080/10408398009527278
   Gupta S. C., 2012, MOL NUTR FOOD RES, DOI [10.0002/mnfr.201100741, DOI 10.0002/MNFR.201100741]
   Gupta S. C., 2012, AAPS J, DOI [10.1208/s12248-12012-1943212248, DOI 10.1208/S12248-12012-1943212248]
   Gupta SC, 2012, ANTIOXID REDOX SIGN, V16, P1295, DOI 10.1089/ars.2011.4414
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Gupta SC, 2011, NAT PROD REP, V28, P1937, DOI 10.1039/c1np00051a
   Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008
   He QX, 2008, FEBS J, V275, P5725, DOI 10.1111/j.1742-4658.2008.06699.x
   He ZY, 2011, CANCER INVEST, V29, P208, DOI 10.3109/07357907.2010.550592
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Hippert MM, 2006, CANCER RES, V66, P9349, DOI 10.1158/0008-5472.CAN-06-1597
   Hu XX, 2009, GYNECOL ONCOL, V114, P457, DOI 10.1016/j.ygyno.2009.05.022
   Huang WP, 2002, CELL STRUCT FUNCT, V27, P409, DOI 10.1247/csf.27.409
   Huang WT, 2008, EUR J PHARMACOL, V593, P105, DOI 10.1016/j.ejphar.2008.07.017
   Ide H, 2010, PROSTATE, V70, P1127, DOI 10.1002/pros.21147
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Ischenko I, 2008, CURR MED CHEM, V15, P3171, DOI 10.2174/092986708786848541
   Jia YL, 2009, J ASIAN NAT PROD RES, V11, P918, DOI 10.1080/10286020903264077
   Jiao Y, 2009, BLOOD, V113, P462, DOI 10.1182/blood-2008-05-155952
   Kakarala M, 2010, BREAST CANCER RES TR, V122, P777, DOI 10.1007/s10549-009-0612-x
   Kanai M, 2011, CANCER CHEMOTH PHARM, V68, P157, DOI 10.1007/s00280-010-1470-2
   Kannappan R, 2011, MOL NEUROBIOL, V44, P142, DOI 10.1007/s12035-011-8168-2
   Kanwar SS, 2011, PHARM RES-DORDR, V28, P827, DOI 10.1007/s11095-010-0336-y
   Khan MA, 2012, MOL CANCER THER, V11, P1873, DOI 10.1158/1535-7163.MCT-12-0141
   Kim JH, 2012, MOL NUTR FOOD RES, V56, P454, DOI 10.1002/mnfr.201100270
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kim JS, 2010, CURR EYE RES, V35, P274, DOI 10.3109/02713680903528345
   Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Lahiff C, 2011, INFLAMM BOWEL DIS, V17, P2585, DOI [10.1002/ibd.21710, 10.1002/ibd.21712, 10.1002/ibd.21765]
   Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394
   Lee YJ, 2011, KOREAN J PHYSIOL PHA, V15, P1, DOI 10.4196/kjpp.2011.15.1.1
   Leray V, 2011, BRIT J NUTR, V106, pS198, DOI 10.1017/S0007114511002492
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li S, 2011, CROPS, V2, P28
   Lim KJ, 2011, CANCER BIOL THER, V11, P464, DOI 10.4161/cbt.11.5.14410
   Lin JK, 2007, ADV EXP MED BIOL, V595, P227
   Lin L, 2011, BRIT J CANCER, V105, P212, DOI 10.1038/bjc.2011.200
   Liu SL, 2005, BREAST CANCER RES, V7, P86, DOI 10.1186/bcr1021
   Ma D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028780
   Mahfouz MM, 2011, INT J VITAM NUTR RES, V81, P378, DOI 10.1024/0300-9831/a000084
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Mutsuga M, 2012, J VET MED SCI, V74, P51, DOI 10.1292/jvms.11-0307
   Nautiyal Jyoti, 2011, J Mol Signal, V6, P7, DOI 10.1186/1750-2187-6-7
   Nishiyama T, 2005, J AGR FOOD CHEM, V53, P959, DOI 10.1021/jf0483873
   Noda T, 2002, TRENDS CELL BIOL, V12, P231, DOI 10.1016/S0962-8924(02)02278-X
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308
   Oetari S, 1996, BIOCHEM PHARMACOL, V51, P39, DOI 10.1016/0006-2952(95)02113-2
   Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522
   Oppenheimer A., 1937, LANCET, V229, P619, DOI [10.1016/S0140-6736(00)98193-5, DOI 10.1016/S0140-6736(00)98193-5, 10.1016/s0140-6736(00)98193-5]
   Padhye S, 2009, PHARM RES-DORDR, V26, P2438, DOI 10.1007/s11095-009-9955-6
   Padhye S, 2009, PHARM RES-DORDR, V26, P1874, DOI 10.1007/s11095-009-9900-8
   Paterson EL, 2008, THESCIENTIFICWORLDJO, V8, P901, DOI 10.1100/tsw.2008.115
   Pelletier J., 1815, J PHARM, V1, P289
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Qian HR, 2011, EUR J PHARM SCI, V43, P125, DOI 10.1016/j.ejps.2011.04.002
   Rai Balwant, 2010, J Oral Sci, V52, P251
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Sakariassen PO, 2007, NEOPLASIA, V9, P882, DOI 10.1593/neo.07658
   Sasaki H, 2011, BIOL PHARM BULL, V34, P660, DOI 10.1248/bpb.34.660
   Schaefers MM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032813
   Schatton T, 2008, NATURE, V451, P345, DOI 10.1038/nature06489
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Singh S, 2007, CELL, V130, P765, DOI 10.1016/j.cell.2007.08.024
   Singh SK, 2003, CANCER RES, V63, P5821
   Son MJ, 2009, CELL STEM CELL, V4, P440, DOI 10.1016/j.stem.2009.03.003
   Soubani O, 2012, CARCINOGENESIS, V33, P1563, DOI 10.1093/carcin/bgs189
   Sreenivasan S, 2012, CURR EYE RES, V37, P421, DOI 10.3109/02713683.2011.647224
   SRIVASTAVA R, 1986, ARZNEIMITTEL-FORSCH, V36-1, P715
   Subramaniam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030590
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Suryanarayana P, 2005, INVEST OPHTH VIS SCI, V46, P2092, DOI 10.1167/iovs.04-1304
   Teiten MH, 2011, INT J ONCOL, V38, P603, DOI 10.3892/ijo.2011.905
   Tetzlaff MT, 2007, ENDOCR PATHOL, V18, P163, DOI 10.1007/s12022-007-0023-7
   Thapliyal R, 2001, FOOD CHEM TOXICOL, V39, P541, DOI 10.1016/S0278-6915(00)00165-4
   Usharani P, 2008, DRUGS R&D, V9, P243, DOI 10.2165/00126839-200809040-00004
   Yamauchi Y, 2012, PHYTOTHER RES, V26, P1779, DOI 10.1002/ptr.4645
   Yang J, 2010, MED ONCOL, V27, P1114, DOI 10.1007/s12032-009-9344-3
   Yang ZF, 2008, CANCER CELL, V13, P153, DOI 10.1016/j.ccr.2008.01.013
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   Yu YJ, 2009, TRANSL ONCOL, V2, P321, DOI 10.1593/tlo.09193
   Zhang J, 2010, ONCOL REP, V24, P1217, DOI 10.3892/or_00000975
   Zhang J, 2010, BIOCHEM BIOPH RES CO, V399, P1, DOI 10.1016/j.bbrc.2010.07.013
   Zhang Yan, 2010, Zhonghua Xin Xue Guan Bing Za Zhi, V38, P369
   Zhang Y, 2007, ACTA PHARMACOL SIN, V28, P1343, DOI 10.1111/j.1745-7254.2007.00679.x
   Zhu Z, 2009, ACTA BIOCH BIOPH SIN, V41, P407, DOI 10.1093/abbs/gmp023
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 128
TC 247
Z9 258
U1 3
U2 136
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-6433
EI 1872-8081
J9 BIOFACTORS
JI Biofactors
PD JAN-FEB
PY 2013
VL 39
IS 1
SI SI
BP 2
EP 13
DI 10.1002/biof.1079
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 093RX
UT WOS:000315210600002
PM 23339055
DA 2022-04-25
ER

PT J
AU Itahana, Y
   Itahana, K
AF Itahana, Yoko
   Itahana, Koji
TI Emerging Roles of p53 Family Members in Glucose Metabolism
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE p53; p63; p73; p53 mutant; glucose metabolism; glycolysis; mitochondria;
   autophagy; diabetes; cancer
ID TUMOR-SUPPRESSOR P53; PENTOSE-PHOSPHATE PATHWAY; PANCREATIC BETA-CELLS;
   MITOCHONDRIAL-DNA DEPLETION; COLORECTAL-CANCER CELLS; BASE
   EXCISION-REPAIR; LI-FRAUMENI-SYNDROME; FATTY LIVER-DISEASE; WILD-TYPE
   P53; MUTANT P53
AB Glucose is the key source for most organisms to provide energy, as well as the key source for metabolites to generate building blocks in cells. The deregulation of glucose homeostasis occurs in various diseases, including the enhanced aerobic glycolysis that is observed in cancers, and insulin resistance in diabetes. Although p53 is thought to suppress tumorigenesis primarily by inducing cell cycle arrest, apoptosis, and senescence in response to stress, the non-canonical functions of p53 in cellular energy homeostasis and metabolism are also emerging as critical factors for tumor suppression. Increasing evidence suggests that p53 plays a significant role in regulating glucose homeostasis. Furthermore, the p53 family members p63 and p73, as well as gain-of-function p53 mutants, are also involved in glucose metabolism. Indeed, how this protein family regulates cellular energy levels is complicated and difficult to disentangle. This review discusses the roles of the p53 family in multiple metabolic processes, such as glycolysis, gluconeogenesis, aerobic respiration, and autophagy. We also discuss how the dysregulation of the p53 family in these processes leads to diseases such as cancer and diabetes. Elucidating the complexities of the p53 family members in glucose homeostasis will improve our understanding of these diseases.
C1 [Itahana, Yoko; Itahana, Koji] Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore.
RP Itahana, K (corresponding author), Duke NUS Med Sch, Canc & Stem Cell Biol Program, 8 Coll Rd, Singapore 169857, Singapore.
EM yoko.itahana@duke-nus.edu.sg; koji.itahana@duke-nus.edu.sg
FU Duke-NUS Signature Programme Block Grant; Singapore Ministry of Health's
   National Medical Research CouncilNational Medical Research Council,
   Singapore [NMRC/OFIRG/15nov049/2016]; Singapore Ministry of Education
   Academic Research FundMinistry of Education, Singapore
   [MOE2013-T2-2-123, MOE2017-T2-1-081]
FX We thank Angela Andersen, Life Science Editors for editorial assistance.
   We acknowledge the funding supports from Duke-NUS Signature Programme
   Block Grant, the Singapore Ministry of Health's National Medical
   Research Council grants (NMRC/OFIRG/15nov049/2016 to K.I.) and Singapore
   Ministry of Education Academic Research Fund Tier 2 grants
   (MOE2013-T2-2-123 and MOE2017-T2-1-081 to K.I.).
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Armata HL, 2010, MOL CELL BIOL, V30, P5787, DOI 10.1128/MCB.00347-10
   Bakhanashvili M, 2009, AIDS, V23, P779, DOI 10.1097/QAD.0b013e328329c74e
   Belgardt BF, 2015, NAT MED, V21, P619, DOI 10.1038/nm.3862
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bensaad K, 2009, EMBO J, V28, P3015, DOI 10.1038/emboj.2009.242
   Bogazzi F, 2013, ENDOCRINOLOGY, V154, P4226, DOI 10.1210/en.2013-1220
   Boidot R, 2012, CANCER RES, V72, P939, DOI 10.1158/0008-5472.CAN-11-2474
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Candi E, 2017, BIOCHEM BIOPH RES CO, V482, P440, DOI 10.1016/j.bbrc.2016.10.094
   Carvajal LA, 2013, EMBO REP, V14, P414, DOI 10.1038/embor.2013.25
   Chen DX, 2006, CANCER RES, V66, P3485, DOI 10.1158/0008-5472.CAN-05-4103
   Cheng Y, 2008, BIOCHEM BIOPH RES CO, V376, P483, DOI 10.1016/j.bbrc.2008.09.018
   Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001
   Chillemi G, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a028308
   CLAUS TH, 1984, BIOCHEM BIOPH RES CO, V122, P529, DOI 10.1016/S0006-291X(84)80065-0
   Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   D'Alessandro A, 2014, ONCOTARGET, V5, P7722, DOI 10.18632/oncotarget.2300
   D'Alessandro A, 2013, J PROTEOME RES, V12, P4207, DOI 10.1021/pr4005508
   de Souza-Pinto NC, 2004, ONCOGENE, V23, P6559, DOI 10.1038/sj.onc.1207874
   Derdak Z, 2013, J HEPATOL, V58, P785, DOI 10.1016/j.jhep.2012.11.042
   Derdak Z, 2011, J HEPATOL, V54, P164, DOI 10.1016/j.jhep.2010.08.007
   Du WJ, 2013, NAT CELL BIOL, V15, P991, DOI 10.1038/ncb2789
   Du YL, 2009, AUTOPHAGY, V5, P663, DOI 10.4161/auto.5.5.8377
   Fei PW, 2004, CANCER CELL, V6, P597, DOI 10.1016/j.ccr.2004.10.012
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   Franck D, 2013, ENDOCR RES, V38, P139, DOI 10.3109/07435800.2012.735735
   Franklin DA, 2016, SCI REP-UK, V6, DOI 10.1038/srep38067
   Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112
   Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017
   Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001
   Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33
   Giacobbe A, 2013, CELL CYCLE, V12, P1395, DOI 10.4161/cc.24478
   Goh AM, 2011, J PATHOL, V223, P116, DOI 10.1002/path.2784
   Goldstein I, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-9
   Harrison B, 2008, J BIOL CHEM, V283, P9999, DOI 10.1074/jbc.M706040200
   He GF, 2014, MOL CELL BIOL, V34, P148, DOI 10.1128/MCB.00670-13
   Hinault C, 2011, DIABETES, V60, P1210, DOI 10.2337/db09-1379
   Hoshino A, 2014, P NATL ACAD SCI USA, V111, P3116, DOI 10.1073/pnas.1318951111
   Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107
   Huang YP, 2012, CELL CYCLE, V11, P3810, DOI 10.4161/cc.22022
   Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111
   Ibrahim MM, 1998, BBA-MOL CELL RES, V1403, P254, DOI 10.1016/S0167-4889(98)00066-4
   Irvine M, 2010, CELL CYCLE, V9, P829, DOI 10.4161/cc.9.4.10785
   Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002
   Itahana K, 2010, CELL CYCLE, V9, P864
   Itahana K, 2008, CELL CYCLE, V7, P3641, DOI 10.4161/cc.7.23.7105
   Itahana Y, 2015, ONCOGENE, V34, P1799, DOI 10.1038/onc.2014.119
   Itahana Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep28112
   Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012
   Jiang P, 2013, CELL CYCLE, V12, P3720, DOI 10.4161/cc.27267
   Jiang P, 2013, NATURE, V493, P689, DOI 10.1038/nature11776
   Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1
   Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724
   Kawauchi K, 2008, BIOCHEM BIOPH RES CO, V372, P137, DOI 10.1016/j.bbrc.2008.05.021
   Kim HR, 2013, BIOCHEM BIOPH RES CO, V437, P225, DOI 10.1016/j.bbrc.2013.06.043
   Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185
   Kim WH, 2005, CELL SIGNAL, V17, P1516, DOI 10.1016/j.cellsig.2005.03.020
   Kitamura N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016060
   Kon N, 2012, J BIOL CHEM, V287, P5102, DOI 10.1074/jbc.M111.322867
   Kondoh H, 2005, CANCER RES, V65, P177
   Kulawiec Mariola, 2009, J Carcinog, V8, P8, DOI 10.4103/1477-3163.50893
   Kung CP, 2016, J ENDOCRINOL, V231, pR61, DOI 10.1530/JOE-16-0324
   Kung CP, 2016, CELL REP, V14, P2413, DOI 10.1016/j.celrep.2016.02.037
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004
   Lee CW, 2012, CANCER RES, V72, P4394, DOI 10.1158/0008-5472.CAN-12-0429
   Lee IH, 2012, SCIENCE, V336, P225, DOI 10.1126/science.1218395
   Leonardi R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011107
   Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086
   Li H, 2009, J BIOL CHEM, V284, P1748, DOI 10.1074/jbc.M807821200
   Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026
   Li XM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11740
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lovis P, 2008, DIABETES, V57, P2728, DOI 10.2337/db07-1252
   Ma WZ, 2007, J BIOENERG BIOMEMBR, V39, P243, DOI 10.1007/s10863-007-9083-0
   Macheda ML, 2005, J CELL PHYSIOL, V202, P654, DOI 10.1002/jcp.20166
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202
   Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256
   Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Minamino T, 2009, NAT MED, V15, P1082, DOI 10.1038/nm.2014
   Mirzayans R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050928
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Mor I, 2011, COLD SH Q B, V76, P211, DOI 10.1101/sqb.2011.76.010868
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Moyers JS, 1996, J BIOL CHEM, V271, P23111, DOI 10.1074/jbc.271.38.23111
   Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026
   Napoli M, 2017, BRIT J CANCER, V116, P149, DOI 10.1038/bjc.2016.384
   Nemajerova A, 2018, CELL DEATH DIFFER, V25, P144, DOI 10.1038/cdd.2017.178
   Nithipongvanitch R, 2007, J HISTOCHEM CYTOCHEM, V55, P629, DOI 10.1369/jhc.6A7146.2007
   Okamura S, 1999, ONCOL RES, V11, P281
   Okoshi R, 2008, J BIOL CHEM, V283, P3979, DOI 10.1074/jbc.M705232200
   Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004
   Park JY, 2009, CIRC RES, V105, P705, DOI 10.1161/CIRCRESAHA.109.205310
   Park KJ, 2009, BIOCHEM BIOPH RES CO, V382, P726, DOI 10.1016/j.bbrc.2009.03.095
   Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200
   Prokesch A, 2017, FASEB J, V31, P732, DOI 10.1096/fj.201600845R
   Ratovitski EA, 2015, CURR PHARM BIOTECHNO, V16, P832, DOI 10.2174/1389201016666150619114344
   Ratovitski EA, 2013, CURR GENOMICS, V14, P441, DOI 10.2174/13892029113146660011
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Rodriguez OC, 2012, CELL CYCLE, V11, P4436, DOI 10.4161/cc.22778
   Ros S, 2017, ONCOGENE, V36, P3287, DOI 10.1038/onc.2016.477
   Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112
   Ruiz-Lozano P, 1999, CELL GROWTH DIFFER, V10, P295
   Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Secchiero P, 2013, ACTA DIABETOL, V50, P899, DOI 10.1007/s00592-013-0476-8
   Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044
   Shestov AA, 2014, ELIFE, V3, DOI 10.7554/eLife.03342
   Shimizu I, 2013, CELL METAB, V18, P491, DOI 10.1016/j.cmet.2013.09.001
   Shimizu I, 2012, CELL METAB, V15, P51, DOI 10.1016/j.cmet.2011.12.006
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Spitsina E V, 2007, Mol Biol (Mosk), V41, P989
   Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965
   Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tavana O, 2010, DIABETES, V59, P135, DOI 10.2337/db09-0792
   Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730
   Tong XM, 2009, P NATL ACAD SCI USA, V106, P21660, DOI 10.1073/pnas.0911316106
   Tornovsky-Babeay S, 2014, CELL METAB, V19, P109, DOI 10.1016/j.cmet.2013.11.007
   Uversky VN, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111874
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012
   Venkatanarayan A, 2016, CELL CYCLE, V15, P164, DOI 10.1080/15384101.2015.1121333
   Venkatanarayan A, 2015, NATURE, V517, P626, DOI 10.1038/nature13910
   Viticchie G, 2015, P NATL ACAD SCI USA, V112, P11577, DOI 10.1073/pnas.1508871112
   Voet D., 2004, BIOCHEMISTRY
   Wang SJ, 2013, CELL CYCLE, V12, P753, DOI 10.4161/cc.23597
   Wang XW, 2013, J MOL CELL BIOL, V5, P147, DOI 10.1093/jmcb/mjs064
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O., 1925, J CANCER RES CLIN, V9, P148, DOI [10.1158/jcr.1925.148, DOI 10.1158/JCR.1925.148]
   Webster NJG, 1996, CANCER RES, V56, P2781
   Wong TS, 2009, NUCLEIC ACIDS RES, V37, P568, DOI 10.1093/nar/gkn974
   Yahagi N, 2004, J BIOL CHEM, V279, P20571, DOI 10.1074/jbc.M400884200
   Yahagi N, 2003, J BIOL CHEM, V278, P25395, DOI 10.1074/jbc.M302364200
   Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   Yeo SY, 2016, ELIFE, V5, DOI 10.7554/eLife.07101
   Yoshida Y, 2003, CANCER RES, V63, P3729
   Yuan HP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015726
   Zhang C, 2014, ONCOTARGET, V5, P5535, DOI 10.18632/oncotarget.2137
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935
   Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang XM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.85
   Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024
   Zhou S, 2003, MUTAGENESIS, V18, P287, DOI 10.1093/mutage/18.3.287
   Zhou YD, 2012, HUM MOL GENET, V21, P196, DOI 10.1093/hmg/ddr454
NR 169
TC 57
Z9 59
U1 3
U2 31
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2018
VL 19
IS 3
AR 776
DI 10.3390/ijms19030776
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GA4OO
UT WOS:000428309800133
PM 29518025
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Dezelak, M
   Repnik, K
   Koder, S
   Ferkolj, I
   Potocnik, U
AF Dezelak, Matjaz
   Repnik, Katja
   Koder, Silvo
   Ferkolj, Ivan
   Potocnik, Uros
TI A Prospective Pharmacogenomic Study of Crohn's Disease Patients during
   Routine Therapy with Anti-TNF- Drug Adalimumab: Contribution of ATG5,
   NFKB1, and CRP Genes to Pharmacodynamic Variability
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; INFLIXIMAB
   THERAPY; CLINICAL-RESPONSE; ASSOCIATION ANALYSIS; COLORECTAL-CANCER;
   PREDICT RESPONSE; AUTOPHAGY; POLYMORPHISMS
AB Crohn's disease is often treated with the anti-tumor necrosis factor- drug adalimumab. However, about 20%-40% of patients do not display adequate therapeutic response. We prospectively evaluated, during a routine therapy of Crohn's disease patients, the candidate autophagy-related genes ATG12 and ATG5 and the inflammation-related genes NFKB1, NFKBIA, and CRP as potential predictors of adalimumab treatment response (pharmacodynamics). The associations of haplotypes and SNPs in these genes with response to drug therapy, biochemical parameters, and body mass were determined at baseline and after 4, 12, 20, and 30 weeks of therapy. Association analysis showed that haplotypes defined with the SNPs rs9373839 and rs510432 in ATG5 gene were significantly associated with positive response to therapy (p<0.002). In addition, allele C and genotypes CC and CT of the rs1130864 in the CRP gene were positively associated with therapeutic response (p<0.002). To the best of our knowledge, this is the first report that supports the association of SNPs in ATG5 and CRP genes with response to adalimumab therapy in Crohn's disease. Further study of these biological pathways in larger and independent clinical samples is warranted as novel streams of research on precision medicine and diagnostics for Crohn's disease.
C1 [Dezelak, Matjaz; Repnik, Katja; Potocnik, Uros] Univ Maribor, Fac Med, Ctr Human Mol Genet & Pharmacogen, Taborska Ulica 8, SLO-2000 Maribor, Slovenia.
   [Repnik, Katja; Potocnik, Uros] Univ Maribor, Lab Biochem Mol Biol & Genom, Fac Chem & Chem Engn, SLO-2000 Maribor, Slovenia.
   [Koder, Silvo] Univ Med Ctr Maribor, Maribor, Slovenia.
   [Ferkolj, Ivan] Univ Med Ctr Ljubljana, Ljubljana, Slovenia.
RP Potocnik, U (corresponding author), Univ Maribor, Fac Med, Ctr Human Mol Genet & Pharmacogen, Taborska Ulica 8, SLO-2000 Maribor, Slovenia.
EM uros.potocnik@um.si
RI Dezelak, Matjaz/H-3935-2011
OI Dezelak, Matjaz/0000-0002-9298-4582
FU Slovenian Research AgencySlovenian Research Agency - Slovenia [P3-0067]
FX The authors thank Alojz Tapajner for technical support in statistical
   analysis. This study was financially supported by Slovenian Research
   Agency (grant P3-0067).
CR Andersen V, 2011, WORLD J GASTROENTERO, V17, P197, DOI 10.3748/wjg.v17.i2.197
   Baert F, 2010, GASTROENTEROLOGY, V138, P463, DOI 10.1053/j.gastro.2009.09.056
   Bank S, 2014, PHARMACOGENOMICS J, V14, P526, DOI 10.1038/tpj.2014.19
   Bank S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098815
   Barreiro-de Acosta M, 2010, REV ESP ENFERM DIG, V102, P591, DOI 10.4321/s1130-01082010001000005
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Chen DF, 2013, NEUROSCI LETT, V538, P49, DOI 10.1016/j.neulet.2013.01.044
   Colombel JF, 2007, GASTROENTEROLOGY, V132, P52, DOI 10.1053/j.gastro.2006.11.041
   Correia CT, 2010, PHARMACOGENOMICS J, V10, P418, DOI 10.1038/tpj.2009.63
   Delgado MA, 2008, EMBO J, V27, P1110, DOI 10.1038/emboj.2008.31
   Dideberg V, 2006, PHARMACOGENET GENOM, V16, P727, DOI 10.1097/01.fpc.0000230117.26581.a4
   Djavaheri-Mergny M, 2006, J BIOL CHEM, V281, P30373, DOI 10.1074/jbc.M602097200
   Dubinsky MC, 2010, INFLAMM BOWEL DIS, V16, P1357, DOI 10.1002/ibd.21174
   Duerr RH, 2000, AM J HUM GENET, V66, P1857, DOI 10.1086/302947
   European Medicines Agency, 2014, HUM AD
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Fujita N, 2008, MOL BIOL CELL, V19, P2092, DOI 10.1091/mbc.E07-12-1257
   Gutierrez A, 2014, GUT, V63, P272, DOI 10.1136/gutjnl-2012-303557
   Hanauer SB, 2006, GASTROENTEROLOGY, V130, P323, DOI 10.1053/j.gastro.2005.11.030
   Henderson P, 2015, INFLAMM BOWEL DIS, V21, P596, DOI 10.1097/MIB.0000000000000296
   Hlavaty T, 2005, ALIMENT PHARM THER, V22, P613, DOI 10.1111/j.1365-2036.2005.02635.x
   Hlavaty T, 2006, INFLAMM BOWEL DIS, V12, P199, DOI 10.1097/01.MIB.0000217768.75519.32
   Hsieh YC, 2009, TRENDS MOL MED, V15, P129, DOI 10.1016/j.molmed.2009.01.002
   Hu M, 2010, AM J CARDIOL, V106, P1588, DOI 10.1016/j.amjcard.2010.07.044
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Jurgens M, 2011, CLIN GASTROENTEROL H, V9, P421, DOI 10.1016/j.cgh.2011.02.008
   Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129
   Klein W, 2004, INT J COLORECTAL DIS, V19, P153, DOI 10.1007/s00384-003-0531-y
   Koder S, 2015, PHARMACOGENOMICS, V16, P191, DOI 10.2217/pgs.14.172
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Liu JF, 2009, GENET EPIDEMIOL, V33, P217, DOI 10.1002/gepi.20372
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marquez RT, 2012, AM J CANCER RES, V2, P214
   Martin LJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033454
   Mayes MD, 2014, AM J HUM GENET, V94, P47, DOI 10.1016/j.ajhg.2013.12.002
   Mugnier B, 2003, ARTHRITIS RHEUM, V48, P1849, DOI 10.1002/art.11168
   Nedjic J, 2008, NATURE, V455, P396, DOI 10.1038/nature07208
   Nichita C, 2010, DIGESTION, V81, P78, DOI 10.1159/000253855
   Nimptsch K, 2015, INT J CANCER, V136, P1181, DOI 10.1002/ijc.29086
   Peyrin-Biroulet L, 2012, GUT, V61, P78, DOI 10.1136/gutjnl-2011-300370
   Pierdominici M, 2012, FASEB J, V26, P1400, DOI 10.1096/fj.11-194175
   Prieto-Perez R, 2013, PHARMACOGENOMICS J, V13, P297, DOI 10.1038/tpj.2012.53
   Reinisch W, 2012, ALIMENT PHARM THER, V35, P568, DOI 10.1111/j.1365-2036.2011.04987.x
   Rhodes B, 2011, NAT REV RHEUMATOL, V7, P283, DOI 10.1038/nrrheum.2011.37
   Roberts RL, 2012, J GASTROEN HEPATOL, V27, P1546, DOI 10.1111/j.1440-1746.2012.07220.x
   Sandborn WJ, 2007, GUT, V56, P1232, DOI 10.1136/gut.2006.106781
   Sandborn WJ, 2007, ANN INTERN MED, V146, P829, DOI 10.7326/0003-4819-146-12-200706190-00159
   Schiotis R, 2014, RHEUMATOL INT, V34, P793, DOI 10.1007/s00296-013-2913-y
   Seufert BL, 2012, THESIS U WASHINGTON
   Seufert BL, 2013, CARCINOGENESIS, V34, P79, DOI 10.1093/carcin/bgs296
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Singh P, 2014, MOL BIOL REP, V41, P5851, DOI 10.1007/s11033-014-3459-0
   Slattery ML, 2014, INT J MOL EPIDEMIOL, V5, P100
   Sobolewska A, 2016, DIGEST DIS SCI, V61, P542, DOI 10.1007/s10620-015-3894-3
   Tersigni R, 2010, UPDATES SURG SER, P143, DOI 10.1007/978-88-470-1472-5_14
   Thompson D, 1999, STRUCTURE, V7, P169, DOI 10.1016/S0969-2126(99)80023-9
   Toedter GP, 2009, AM J GASTROENTEROL, V104, P2768, DOI 10.1038/ajg.2009.454
   VanDeventer SJH, 1997, GUT, V40, P443, DOI 10.1136/gut.40.4.443
   Vermeire S, 2006, GUT, V55, P426, DOI 10.1136/gut.2005.069476
   Zahir F, 2015, CELL MOL BIOL LETT, V20, P418, DOI 10.1515/cmble-2015-0012
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zhang H, 2014, GASTROENTEROLOGY, V146, pS876
   Zhou XJ, 2012, AUTOPHAGY, V8, P1286, DOI 10.4161/auto.21212
NR 63
TC 16
Z9 17
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD MAY
PY 2016
VL 20
IS 5
BP 296
EP 309
DI 10.1089/omi.2016.0005
PG 14
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA DN0SA
UT WOS:000376773300005
PM 27096233
DA 2022-04-25
ER

PT J
AU Baek, SH
   Jang, YK
AF Baek, Seung-Heon
   Jang, Yeun-Kyu
TI AMBRA1 Negatively Regulates the Function of ALDH1B1, a Cancer Stem Cell
   Marker, by Controlling Its Ubiquitination
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colorectal cancer stem cell; E3 ubiquitin ligase; substrate receptor;
   noncanonical ubiquitination
ID AUTOPHAGY; PARKIN
AB Activating molecule in Beclin-1-regulated autophagy (AMBRA1), a negative regulator of tumorigenesis, is a substrate receptor of the ubiquitin conjugation system. ALDH1B1, an aldehyde dehydrogenase, is a cancer stem cell (CSC) marker that is required for carcinogenesis via upregulation of the beta-catenin pathway. Although accumulating evidence suggests a role for ubiquitination in the regulation of CSC markers, the ubiquitination-mediated regulation of ALDH1B1 has not been unraveled. While proteome analysis has suggested that AMBRA1 and ALDH1B1 can interact, their interaction has not been validated. Here, we show that AMBRA1 is a negative regulator of ALDH1B1. The expression of ALDH1B1-regulated genes, including PTEN, CTNNB1 (beta-catenin), and CSC-related beta-catenin target genes, is inversely regulated by AMBRA1, suggesting a negative regulatory role of AMBRA1 in the expression of ALDH1B1-regulated genes. We found that the K27- and K33-linked ubiquitination of ALDH1B1 is mediated via the cooperation of AMBRA1 with other E3 ligases, such as TRAF6. Importantly, ubiquitination site mapping revealed that K506, K511, and K515 are important for the K27-linked ubiquitination of ALDH1B1, while K33-linked ubiquitination occurs at K506. A ubiquitination-defective mutant of ALDH1B1 increased the self-association ability of ALDH1B1, suggesting a negative correlation between the ubiquitination and self-association of ALDH1B1. Together, our findings indicate that ALDH1B1 is negatively regulated by AMBRA1-mediated noncanonical ubiquitination.
C1 [Baek, Seung-Heon; Jang, Yeun-Kyu] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Syst Biol, Seoul 03722, South Korea.
   [Baek, Seung-Heon; Jang, Yeun-Kyu] Yonsei Univ, BK21 Yonsei Educ & Res Ctr Biosyst, Seoul 03722, South Korea.
RP Jang, YK (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Syst Biol, Seoul 03722, South Korea.; Jang, YK (corresponding author), Yonsei Univ, BK21 Yonsei Educ & Res Ctr Biosyst, Seoul 03722, South Korea.
EM baeksh9505@naver.com; ykjang@yonsei.ac.kr
OI Baek, SeungHeon/0000-0003-1793-1576
FU National Research Foundation of Korea (NRF) - Korean government
   (MSIT)National Research Foundation of Korea [2019R1A2C1009907]; Brain
   Korea 21 (BK21) FOUR program
FX This work was supported in part by a National Research Foundation of
   Korea (NRF) grant funded by the Korean government (MSIT) (No.
   2019R1A2C1009907). In addition, S.H.B. and Y.K.J. were supported in part
   by the Brain Korea 21 (BK21) FOUR program.
CR Ahmed A., 2018, SOHAG MED J, V22, P109, DOI [10.21608/smj.2018.31537, DOI 10.21608/SMJ.2018.31537]
   Antonioli M, 2014, DEV CELL, V31, P734, DOI 10.1016/j.devcel.2014.11.013
   Applegate CC, 2015, WORLD J GASTRO ONCOL, V7, P184, DOI 10.4251/wjgo.v7.i10.184
   Chaikovsky AC, 2021, NATURE, V592, P794, DOI 10.1038/s41586-021-03474-7
   Chen SH, 2018, EMBO J, V37, DOI 10.15252/embj.201797508
   Chen Y, 2011, BIOCHEM BIOPH RES CO, V405, P173, DOI 10.1016/j.bbrc.2011.01.002
   Cianfanelli V, 2015, J CELL SCI, V128, P2003, DOI 10.1242/jcs.168153
   Cianfanelli V, 2015, NAT CELL BIOL, V17, P20, DOI 10.1038/ncb3072
   Ciccone V., 2020, CANC DRUG RESIST, V3, P26, DOI [DOI 10.20517/CDR.2019.70, 10.20517/CDR.2019.70]
   Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304
   Crabb DW, 1995, ALCOHOL CLIN EXP RES, V19, P1414, DOI 10.1111/j.1530-0277.1995.tb01000.x
   Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060
   Di Rita A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05722-3
   Fimia GM, 2007, NATURE, V447, P1121, DOI 10.1038/nature05925
   Gan, 2020, STEMEDICINE, V1, pE37, DOI [DOI 10.37175/STEMEDICINE.V1I3.37, 10.37175/stemedicine.v1i3.37]
   Lutfullah G, 2011, PROTEIN PEPTIDE LETT, V18, P41, DOI 10.2174/092986611794328645
   Maiani E, 2021, NATURE, V592, P799, DOI 10.1038/s41586-021-03422-5
   Matsumoto A, 2017, BRIT J CANCER, V117, P1537, DOI 10.1038/bjc.2017.304
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Nazio F, 2013, NAT CELL BIOL, V15, P406, DOI 10.1038/ncb2708
   Road, 2020, ALL T RETINOIC ACID, DOI [10.1101/2020.11.05.369322, DOI 10.1101/2020.11.05.369322]
   Simoneschi D, 2021, NATURE, V592, P789, DOI 10.1038/s41586-021-03445-y
   Singh S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121648
   Skobo T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099210
   Strappazzon F, 2015, CELL DEATH DIFFER, V22, P419, DOI 10.1038/cdd.2014.139
   Uversky VN, 2010, BBA-PROTEINS PROTEOM, V1804, P1231, DOI 10.1016/j.bbapap.2010.01.017
   Van Humbeeck C, 2011, J NEUROSCI, V31, P10249, DOI 10.1523/JNEUROSCI.1917-11.2011
   Vasiliou, 2014, FREE RADICAL BIO MED, V1, P89, DOI [10.1016/j.freeradbiomed.2012.11.010.Aldehyde, DOI 10.1016/J.FREERADBIOMED.2012.11.010.ALDEHYDE]
   Wang X, 2020, LIFE SCI, V262, DOI 10.1016/j.lfs.2020.118544
   Wang X, 2018, ONCOTARGET, V9, P2502, DOI 10.18632/oncotarget.23506
   Zhou QQ, 2022, J LEUKOCYTE BIOL, V111, P223, DOI 10.1002/JLB.4RU0620-397RR
   Zucchelli S, 2010, HUM MOL GENET, V19, P3759, DOI 10.1093/hmg/ddq290
NR 32
TC 0
Z9 0
U1 6
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 21
AR 12079
DI 10.3390/ijms222112079
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WZ9KP
UT WOS:000720278700001
PM 34769507
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Khan, MZI
   Law, HKW
AF Khan, Md Zahirul Islam
   Law, Helen Ka Wai
TI Cancer Susceptibility Candidate 9 (CASC9) Promotes Colorectal Cancer
   Carcinogenesis via mTOR-Dependent Autophagy and Epithelial-Mesenchymal
   Transition Pathways
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Article
DE cancer susceptibility candidate 9; long non-coding RNA; colorectal
   cancer; autophagy; epithelial-mesenchymal transition
ID LONG NONCODING RNA; PROLIFERATION; PROGRESSION; CELLS; CONTRIBUTES;
   METASTASIS; INHIBITION; ACTIVATION; APOPTOSIS; GROWTH
AB Background Colorectal cancer (CRC) is the third most common cancer worldwide. Many recent studies have demonstrated that different long non-coding RNAs (lncRNAs) are involved in the initiation, advancement, and metastasis of many cancers including CRC. Cancer susceptibility candidate 9 (CASC9) is an lncRNA that has been reported in many cancers, but its role in CRC is poorly understood. In this study, we aimed to examine the expression of CASC9 in CRC cell lines and to determine the mechanism of action of CASC9 in CRC carcinogenesis. Methods The expression of CASC9 in CRC tissues was compared with normal samples from publicly available datasets in The Cancer Genome Atlas (TCGA) and The Encyclopedia of RNA Interactomes (ENCORI). CASC9 expression was further verified in four CRC cell lines (DLD1, HT-29, SW480, and HCT-116) and normal colorectal cell line (CCD-112CoN) by real-time quantitative polymerase chain reaction (RT-qPCR). After gene silencing in HCT-116 and SW480, Cell Counting Kit-8 assay, clonogenic assay, and wound healing assay were performed to evaluate cell proliferation, viability, and migration index of cells. Western blotting was used to explore the key pathways involved. Results CASC9 was significantly upregulated as analyzed from both public datasets TCGA and ENCORI where its overexpression was associated with poor survival of CRC patients. Similarly, CASC9 was significantly overexpressed in the CRC cell lines compared with normal cells studied. The silencing of CASC9 in HCT-116 and SW480 attenuated cell proliferation and migration significantly. Furthermore, pathways investigations showed that silencing of CASC9 significantly induced autophagy, promoted AMP-activated protein kinase (AMPK) phosphorylation, inhibited mTOR and AKT signaling pathways, and altered epithelial-mesenchymal transition (EMT) marker protein expression. Conclusion We demonstrated that silencing of CASC9 contributes to the reduced CRC cell proliferation and migration by regulating autophagy and AKT/mTOR/EMT signaling. Therefore, CASC9 plays an important role in carcinogenesis, and its expression may act as a prognostic biomarker and a potential therapeutic target of CRC management.
C1 [Khan, Md Zahirul Islam; Law, Helen Ka Wai] Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Hong Kong, Peoples R China.
RP Law, HKW (corresponding author), Hong Kong Polytech Univ, Fac Hlth & Social Sci, Dept Hlth Technol & Informat, Hong Kong, Peoples R China.
EM hthelen@polyu.edu.hk
OI Islam Khan, Md Zahirul/0000-0001-7048-2613
FU Internal Institutional Research Fund from The Hong Kong Polytechnic
   University [P0031318-UAHS]; Hong Kong Polytechnic UniversityHong Kong
   Polytechnic University; Departmental Seeding Fund from The Hong Kong
   Polytechnic University [P0031318-UAHS]
FX This project was partially supported by the research grant to HL
   including Departmental Seeding Fund and Internal Institutional Research
   Fund (P0031318-UAHS) and Postgraduate studentship from The Hong Kong
   Polytechnic University for MI.
CR Araghi M, 2019, INT J CANCER, V144, P2992, DOI 10.1002/ijc.32055
   Bin J, 2021, J CELL PHYSIOL, V236, P523, DOI 10.1002/jcp.29880
   Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen C, 2020, AGING-US, V12, P11685, DOI 10.18632/aging.103334
   Chen YH, 2020, CANCER MED-US, V9, P1830, DOI 10.1002/cam4.2839
   Cohen-Kaplan V, 2016, P NATL ACAD SCI USA, V113, pE7490, DOI 10.1073/pnas.1615455113
   Cui ZH, 2019, ONCOTARGETS THER, V12, P11531, DOI 10.2147/OTT.S229104
   Ding YS, 2020, CANCER MANAG RES, V12, P1281, DOI 10.2147/CMAR.S234620
   Esmaeili M, 2020, GENE, V753, DOI 10.1016/j.gene.2020.144796
   Fang J, 2020, PATHOL ONCOL RES, V26, P475, DOI 10.1007/s12253-019-00703-3
   Galamb O, 2019, WORLD J GASTROENTERO, V25, P5026, DOI 10.3748/wjg.v25.i34.5026
   Gao L, 2019, INT J ONCOL, V54, P1651, DOI 10.3892/ijo.2019.4758
   Huo WQ, 2020, NEPHRON, V144, P388, DOI 10.1159/000507828
   Jiang PD, 2015, METHODS, V75, P13, DOI 10.1016/j.ymeth.2014.11.021
   Jin YX, 2019, ONCOTARGETS THER, V12, P9017, DOI 10.2147/OTT.S226078
   Kessler T, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00124
   Khan MZI, 2019, FRONT GENET, V9, DOI 10.3389/fgene.2018.00750
   Khan M, 2015, INT J BIOL SCI, V11, P1100, DOI 10.7150/ijbs.11595
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Lin CP, 2017, ANNU REV CANC BIOL, V1, P163, DOI 10.1146/annurev-cancerbio-050216-034443
   Liu WJ, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0031-z
   Liu X, 2020, DRUG DELIV, V27, P323, DOI 10.1080/10717544.2020.1716882
   Luo KL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1263-3
   Marchese FP, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1348-2
   Mathiassen SG, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00051
   Mitra S., 2018, CANC NONCODING RNAS, P151, DOI [10.1016/b978-0-12-811022-5.00009-7, DOI 10.1016/B978-0-12-811022-5.00009-7]
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Noguchi M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2724-5
   Pan K, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2633-7
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Pavel M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05388-x
   Peng Y, 2020, CANCER METAST REV, V39, P825, DOI 10.1007/s10555-020-09910-w
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Qi FF, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110329
   Qian P, 2020, J GENET, V99, DOI 10.1007/s12041-020-01203-z
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Sharma U, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100774
   Song FL, 2019, J CELL PHYSIOL, V234, P7420, DOI 10.1002/jcp.27500
   Sparber P, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0487-6
   Tam SY, 2020, CANCERS, V12, DOI 10.3390/cancers12010224
   Tam SY, 2019, BIOCHEM BIOPH RES CO, V517, P193, DOI 10.1016/j.bbrc.2019.07.043
   Terracciano L.M, 2019, REFERENCE MODULE BIO
   Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181
   van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0
   Vellai T, 2008, AUTOPHAGY, V4, P507, DOI 10.4161/auto.5670
   Wang LL, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919874651
   Wang RC, 2010, FEBS LETT, V584, P1417, DOI 10.1016/j.febslet.2010.01.009
   Wang X, 2020, ARCH BIOCHEM BIOPHYS, V689, DOI 10.1016/j.abb.2020.108469
   Wang Y, 2019, ADV EXP MED BIOL, V1206, P67, DOI 10.1007/978-981-15-0602-4_3
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007
   Yan B, 2014, TUMOR BIOL, V35, P11329, DOI 10.1007/s13277-014-2465-0
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x
   Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8
   Zampetaki A, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01201
   Zeng YL, 2019, WORLD J GASTROENTERO, V25, P6902, DOI 10.3748/wjg.v25.i48.6902
   Zhai HY, 2013, CLIN COLORECTAL CANC, V12, P261, DOI 10.1016/j.clcc.2013.06.003
   Zhang J, 2019, BIOCHEM BIOPH RES CO, V515, P644, DOI 10.1016/j.bbrc.2019.05.080
   Zhang XZ, 2020, CANCERS, V12, DOI 10.3390/cancers12051245
   Zhang Y, 2020, ARTIF CELL NANOMED B, V48, P60, DOI 10.1080/21691401.2019.1699809
   Zhao WG, 2020, ONCOTARGETS THER, V13, P6027, DOI 10.2147/OTT.S249973
   Zheng Hai-yang, 2012, Cancer Biology Medicine, V9, P105, DOI 10.3969/j.issn.2095-3941.2012.02.004
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhu JJ, 2013, SCI CHINA LIFE SCI, V56, P876, DOI 10.1007/s11427-013-4553-6
NR 71
TC 4
Z9 4
U1 3
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD MAY 4
PY 2021
VL 8
AR 627022
DI 10.3389/fmolb.2021.627022
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SD2SC
UT WOS:000651219600001
PM 34017854
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Amin, A
   Bajbouj, K
   Koch, A
   Gandesiri, M
   Schneider-Stock, R
AF Amin, Amr
   Bajbouj, Khuloud
   Koch, Adrian
   Gandesiri, Muktheshwar
   Schneider-Stock, Regine
TI Defective Autophagosome Formation in p53-Null Colorectal Cancer
   Reinforces Crocin-Induced Apoptosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE autophagy; autophagosome; apoptosis; crocin; colorectal cancer; p53
ID CELL-DEATH; MONITORING AUTOPHAGY; P53; SAFFRON; INDUCTION; P21;
   CONTRIBUTES; CORDYCEPIN; MUTATION; THERAPY
AB Crocin, a bioactive molecule of saffron, inhibited proliferation of both HCT116 wild-type and HCT116 p53-/- cell lines at a concentration of 10 mM. Flow cytometric analysis of cell cycle distribution revealed that there was an accumulation of HCT116 wild-type cells in G1 (55.9%, 56.1%) compared to the control (30.4%) after 24 and 48 h of crocin treatment, respectively. However, crocin induced only mild G2 arrest in HCT116 p53-/- after 24 h. Crocin induced inefficient autophagy in HCT116 p53-/- cells, where crocin induced the formation of LC3-II, which was combined with a decrease in the protein levels of Beclin 1 and Atg7 and no clear p62 degradation. Autophagosome formation was not detected in HCT116 p53-/- after crocin treatment predicting a nonfunctional autophagosome formation. There was a significant increase of p62 after treating the cells with Bafilomycin A1 (Baf) and crocin compared to crocin exposure alone. Annexin V staining showed that Baf-pretreatment enhanced the induction of apoptosis in HCT116 wild-type cells. Baf-exposed HCT116 p53-/- cells did not, however, show any enhancement
C1 [Amin, Amr; Bajbouj, Khuloud] United Arab Emirates Univ, Coll Sci, Dept Biol, Al Ain 15551, U Arab Emirates.
   [Amin, Amr] Cairo Univ, Fac Sci, Dept Zool, Cairo 12613, Egypt.
   [Bajbouj, Khuloud] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
   [Koch, Adrian; Gandesiri, Muktheshwar; Schneider-Stock, Regine] Univ Erlangen Nurnberg, Inst Pathol, D-91054 Erlangen, Germany.
RP Amin, A (corresponding author), United Arab Emirates Univ, Coll Sci, Dept Biol, Al Ain 15551, U Arab Emirates.
EM a.amin@uaeu.ac.ae; khuloud@hotmail.de; adrian.koch@uk-erlangen.de;
   mukthi_14@yahoo.com; regine.schneider-stock@uk-erlangen.de
RI Amin, Amr/I-2137-2019
OI Amin, Amr/0000-0001-8888-1102
FU Emirates Foundation [2009-079]; National Research Foundation [U-IRCA
   2012-21832]; UPAR; Terry Fox Foundation
FX This study was funded by Emirates Foundation Grant (No. 2009-079) and in
   part by National Research Foundation Grant (No. U-IRCA 2012-21832), UPAR
   2013 and the Terry Fox Foundation 2013 for Amr Amin. We also thank Ala'a
   Al-Hrout at UAE and Moustafa Abdalla at MSU for their technical
   assistance formatting the figures.
CR Abdullaev FI, 2002, EXP BIOL MED, V227, P20, DOI 10.1177/153537020222700104
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amelio I, 2011, BIOCHEM BIOPH RES CO, V414, P277, DOI 10.1016/j.bbrc.2011.09.080
   Amin A, 2011, HEPATOLOGY, V54, P857, DOI 10.1002/hep.24433
   Aung H H, 2007, Exp Oncol, V29, P175
   Bajbouj K, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-69
   Boyle P, 2000, BRIT MED J, V321, P805, DOI 10.1136/bmj.321.7264.805
   Choi S, 2011, TOXICOL APPL PHARM, V257, P165, DOI 10.1016/j.taap.2011.08.030
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   Goussetis DJ, 2010, J BIOL CHEM, V285, P29989, DOI 10.1074/jbc.M109.090530
   Hemmati PG, 2008, ONCOGENE, V27, P6707, DOI 10.1038/onc.2008.193
   Herman-Antosiewicz A, 2006, CANCER RES, V66, P5828, DOI 10.1158/0008-5472.CAN-06-0139
   Hoekstra E, 2012, BBA-REV CANCER, V1826, P179, DOI 10.1016/j.bbcan.2012.04.001
   Iacopetta B, 2003, HUM MUTAT, V21, P271, DOI 10.1002/humu.10175
   Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Kanzawa T, 2003, CANCER RES, V63, P2103
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kong DJ, 2012, BIOMED PHARMACOTHER, V66, P271, DOI 10.1016/j.biopha.2011.12.002
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Liang JY, 2007, NAT CELL BIOL, V9, P218, DOI 10.1038/ncb1537
   Longo L, 2008, MOL CANCER THER, V7, P2476, DOI 10.1158/1535-7163.MCT-08-0361
   Lopez I, 2012, GENE, V499, P81, DOI 10.1016/j.gene.2012.02.011
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Melnyk J. P., 2010, Food Research International, V43, P1981, DOI 10.1016/j.foodres.2010.07.033
   Nyiraneza C, 2011, HUM PATHOL, V42, P1897, DOI 10.1016/j.humpath.2010.06.021
   Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Rubinsztein DC, 2009, AUTOPHAGY, V5, P585, DOI 10.4161/auto.5.5.8823
   Ryan KM, 2011, EUR J CANCER, V47, P44, DOI 10.1016/j.ejca.2010.10.020
   Shin SW, 2012, BBA-MOL CELL RES, V1823, P451, DOI 10.1016/j.bbamcr.2011.10.014
   Tavakkol-Afshari J, 2008, FOOD CHEM TOXICOL, V46, P3443, DOI 10.1016/j.fct.2008.08.018
   WALDMAN T, 1995, CANCER RES, V55, P5187
   Wang SY, 2011, INT J BIOCHEM CELL B, V43, P1263, DOI 10.1016/j.biocel.2011.05.010
   Wong SHK, 2008, AM J PHYSIOL-CELL PH, V294, pC1342, DOI 10.1152/ajpcell.00061.2008
   Wu WC, 2007, CANCER CHEMOTH PHARM, V60, P103, DOI 10.1007/s00280-006-0354-y
   Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016
   Xu Y, 2006, J BIOL CHEM, V281, P19179, DOI 10.1074/jbc.M513377200
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Zhong LLD, 2012, COMPLEMENT THER MED, V20, P240, DOI 10.1016/j.ctim.2012.02.004
NR 48
TC 50
Z9 52
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2015
VL 16
IS 1
BP 1544
EP 1561
DI 10.3390/ijms16011544
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AZ7MN
UT WOS:000348403100087
PM 25584615
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhang, P
   Holowatyj, AN
   Roy, T
   Pronovost, SM
   Marchetti, M
   Liu, HB
   Ulrich, CM
   Edgar, BA
AF Zhang, Peng
   Holowatyj, Andreana N.
   Roy, Taylor
   Pronovost, Stephen M.
   Marchetti, Marco
   Liu, Hanbin
   Ulrich, Cornelia M.
   Edgar, Bruce A.
TI An SH3PX1-Dependent Endocytosis-Autophagy Network Restrains Intestinal
   Stem Cell Proliferation by Counteracting EGFR-ERK Signaling
SO DEVELOPMENTAL CELL
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; SORTING NEXIN; MICROSATELLITE INSTABILITY;
   DROSOPHILA; TRAFFICKING; MAINTENANCE; RECEPTOR; MIDGUT; REGENERATION;
   DEGRADATION
AB The effect of intracellular vesicle trafficking on stem-cell behavior is largely unexplored. We screened the Drosophila sorting nexins (SNXs) and discovered that one, SH3PX1, profoundly affects gut homeostasis and lifespan. SH3PX1 restrains intestinal stem cell (ISC) division through an endocytosis-autophagy network that includes Dynamin, Rab5, Rab7, Atg1, 5, 6, 7, 8a, 9, 12, 16, and Syx17. Blockages in this network stabilize ligand-activated EGFRs, recycling them via Rab11-dependent endosomes to the plasma membrane. This hyperactivated ERK, calcium signaling, and ER stress, autonomously stimulating ISC proliferation. The excess divisions induced epithelial stress, Yki activity, and Upd3 and Rhomboid production in enterocytes, catalyzing feedforward ISC hyperplasia. Similarly, blocking autophagy increased ERK activity in human cells. Many endocytosis-autophagy genes are mutated in cancers, most notably those enriched in microsatellite instable-high and KRAS-wild-type colorectal cancers. Disruptions in endocytosis and autophagy may provide an alternative route to RAS-ERK activation, resulting in EGFR-dependent cancers.
C1 [Zhang, Peng; Holowatyj, Andreana N.; Roy, Taylor; Pronovost, Stephen M.; Marchetti, Marco; Liu, Hanbin; Ulrich, Cornelia M.; Edgar, Bruce A.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [Zhang, Peng; Roy, Taylor; Pronovost, Stephen M.; Marchetti, Marco; Liu, Hanbin; Edgar, Bruce A.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
   [Holowatyj, Andreana N.; Ulrich, Cornelia M.] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT 84112 USA.
   [Ulrich, Cornelia M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.
RP Edgar, BA (corresponding author), Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.; Edgar, BA (corresponding author), Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
EM bruce.edgar@hci.utah.edu
FU Huntsman Cancer Foundation; National Institutes of HealthUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USA [R01 GM124434, P30 CA042014, U01 CA206110, R01 CA189184, R01
   CA211705]; NIH/National Human Genome Research InstituteUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Human Genome Research Institute (NHGRI) [T32
   HG008962]; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [U01CA206110, R01CA189184, R01CA211705,
   P30CA042014, R01CA207371] Funding Source: NIH RePORTER; NATIONAL HUMAN
   GENOME RESEARCH INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Human
   Genome Research Institute (NHGRI) [T32HG008962] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [R01GM124434] Funding Source: NIH RePORTER
FX We thank X. Lin, H. Kn ae velsrud, A. Rodal, D. Strutt, U. Banerjee, N.
   Perrimon, H. Jasper, J. Dixon, and X. Yang for fly stocks and
   antibodies. This work was supported by the Huntsman Cancer Foundation
   (to B.A.E. and C.M.U.) and grants from the National Institutes of Health
   (R01 GM124434 to B.A.E.; P30 CA042014 to B.A.E. and C.M.U.; U01
   CA206110, R01 CA189184, and R01 CA211705 to C.M.U.). A.N.H. was
   supported by the NIH/National Human Genome Research Institute (T32
   HG008962).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Antonacopoulou AG, 2008, HISTOPATHOLOGY, V53, P698, DOI 10.1111/j.1365-2559.2008.03165.x
   Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Bardin AJ, 2010, DEVELOPMENT, V137, P705, DOI 10.1242/dev.039404
   Bel S, 2017, SCIENCE, V357, P1047, DOI 10.1126/science.aal4677
   Buchon N, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-152
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987
   Choi EJ, 2018, PATHOL ONCOL RES, V24, P827, DOI 10.1007/s12253-017-0297-0
   Choi JH, 2004, J CELL SCI, V117, P4209, DOI 10.1242/jcs.01233
   Cullen PJ, 2008, NAT REV MOL CELL BIO, V9, P574, DOI 10.1038/nrm2427
   Deng HS, 2015, NATURE, V528, P212, DOI 10.1038/nature16170
   Deniaud A, 2008, ONCOGENE, V27, P285, DOI 10.1038/sj.onc.1210638
   EDGAR BA, 1989, CELL, V57, P177, DOI 10.1016/0092-8674(89)90183-9
   Ganley IG, 2011, MOL CELL, V42, P731, DOI 10.1016/j.molcel.2011.04.024
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Giannakis M, 2016, CELL REP, V17, P1206, DOI 10.1016/j.celrep.2016.10.009
   Guichard A, 2014, NAT REV MICROBIOL, V12, P624, DOI 10.1038/nrmicro3325
   Hay JC, 2007, EMBO REP, V8, P236, DOI 10.1038/sj.embor.7400921
   Hubin EA, 2017, ELIFE, V6, DOI 10.7554/eLife.22520
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jiang HQ, 2011, EXP CELL RES, V317, P2780, DOI 10.1016/j.yexcr.2011.07.020
   Jiang HQ, 2011, CELL STEM CELL, V8, P84, DOI 10.1016/j.stem.2010.11.026
   Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014
   Jin YH, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005634
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Kitamoto T, 2001, J NEUROBIOL, V47, P81, DOI 10.1002/neu.1018
   Knaevelsrud H, 2013, J CELL BIOL, V202, P331, DOI 10.1083/jcb.201205129
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liang J, 2017, NATURE, V548, P588, DOI 10.1038/nature23678
   Matsuzawa-Ishimoto Y, 2017, J EXP MED, V214, P3687, DOI 10.1084/jem.20170558
   Micchelli CA, 2006, NATURE, V439, P475, DOI 10.1038/nature04371
   Miguel-Aliaga I, 2018, GENETICS, V210, P357, DOI 10.1534/genetics.118.300224
   Mulakkal NC, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/273473
   Nagy P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23065-3
   Nagy P, 2016, DIS MODEL MECH, V9, P501, DOI 10.1242/dmm.023416
   Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082
   Ohlstein B, 2006, NATURE, V439, P470, DOI 10.1038/nature04333
   Patel PH, 2015, NAT CELL BIOL, V17, P1182, DOI 10.1038/ncb3214
   Pesic M, 2016, CURR OPIN CELL BIOL, V43, P55, DOI 10.1016/j.ceb.2016.07.010
   Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078
   Rodal AA, 2011, J CELL BIOL, V193, P201, DOI 10.1083/jcb.201009052
   Ryoo HD, 2007, EMBO J, V26, P242, DOI 10.1038/sj.emboj.7601477
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Shaw RL, 2010, DEVELOPMENT, V137, P4147, DOI 10.1242/dev.052506
   Shukla S, 2014, J BIOL CHEM, V289, P22306, DOI 10.1074/jbc.M114.567032
   Sigismund S, 2008, DEV CELL, V15, P209, DOI 10.1016/j.devcel.2008.06.012
   Singh SR, 2016, NATURE, V538, P109, DOI 10.1038/nature19788
   Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883
   Spalluto C, 2013, FEBS OPEN BIO, V3, P334, DOI 10.1016/j.fob.2013.08.002
   Strutt H, 2011, DEV CELL, V20, P511, DOI 10.1016/j.devcel.2011.03.018
   Teasdale RD, 2012, BIOCHEM J, V441, P39, DOI 10.1042/BJ20111226
   Tooze SA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018358
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Vessoni AT, 2012, STEM CELLS DEV, V21, P513, DOI 10.1089/scd.2011.0526
   Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086
   Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237
   Vodovar N, 2005, P NATL ACAD SCI USA, V102, P11414, DOI 10.1073/pnas.0502240102
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wen JK, 2017, ELIFE, V6, DOI 10.7554/eLife.29338
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Worby CA, 2001, J BIOL CHEM, V276, P41782, DOI 10.1074/jbc.M107080200
   Xiang JY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15125
   Zeng XK, 2015, CELL REP, V10, P1226, DOI 10.1016/j.celrep.2015.01.051
   Zhang P, 2017, DEV CELL, V43, P603, DOI 10.1016/j.devcel.2017.10.033
   Zhang P, 2011, CELL RES, V21, P1677, DOI 10.1038/cr.2011.167
   2013, NAT CELL BIOL, V15, P1067, DOI DOI 10.1038/NCB2804
   2002, J BIOL CHEM, V277, P4915, DOI DOI 10.1074/JBC.M206316200
   2002, J BIOL CHEM, V277, P1013
   2009, J PATHOL, V217, P702, DOI DOI 10.1002/PATH.2509
   2013, J CELL BIOL, V201, P531, DOI DOI 10.1083/JCB.201211160
   2015, NAT CELL BIOL, V17, P1062, DOI DOI 10.1038/NCB3206
   2013, DEV CELL, V27, P489, DOI DOI 10.1016/J.DEVCEL.2013.10.017
NR 76
TC 31
Z9 32
U1 2
U2 20
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1534-5807
EI 1878-1551
J9 DEV CELL
JI Dev. Cell
PD MAY 20
PY 2019
VL 49
IS 4
BP 574
EP +
DI 10.1016/j.devcel.2019.03.029
PG 21
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA HY7HE
UT WOS:000468303700010
PM 31006650
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Coronel-Hernandez, J
   Salgado-Garcia, R
   Cantu-De Leon, D
   Jacobo-Herrera, N
   Millan-Catalan, O
   Delgado-Waldo, I
   Campos-Parra, AD
   Rodriguez-Morales, M
   Delgado-Buenrostro, NL
   Perez-Plasencia, C
AF Coronel-Hernandez, Jossimar
   Salgado-Garcia, Rebeca
   Cantu-De Leon, David
   Jacobo-Herrera, Nadia
   Millan-Catalan, Oliver
   Delgado-Waldo, Izamary
   Campos-Parra, Alma D.
   Rodriguez-Morales, Miguel
   Delgado-Buenrostro, Norma L.
   Perez-Plasencia, Carlos
TI Combination of Metformin, Sodium Oxamate and Doxorubicin Induces
   Apoptosis and Autophagy in Colorectal Cancer Cells via Downregulation
   HIF-1 alpha
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE HIF-1 alpha; autophagy; ULK1; mir-26a; AKT; proliferation
ID NEGATIVE BREAST-CANCER; HYPOXIA; INHIBITION; EXPRESSION; MIR-26A; AKT;
   PROLIFERATION; INVOLVEMENT; DEPRIVATION; PANITUMUMAB
AB Colorectal cancer (CRC) is the third leading cause of cancer-related death worldwide in both sexes. Current therapies include surgery, chemotherapy, and targeted therapy; however, prolonged exposure to chemical agents induces toxicity in patients and drug resistance. So, we implemented a therapeutic strategy based on the combination of doxorubicin, metformin, and sodium oxamate called triple therapy (Tt). We found that Tt significantly reduced proliferation by inhibiting the mTOR/AKT pathway and promoted apoptosis and autophagy in CRC derived cells compared with doxorubicin. Several autophagy genes were assessed by western blot; ULK1, ATG4, and LC3 II were overexpressed by Tt. Interestingly, ULK1 was the only one autophagy-related protein gradually overexpressed during Tt administration. Thus, we assumed that there was a post-transcriptional mechanism mediating by microRNAs that regulate UKL1 expression during autophagy activation. Through bioinformatics approaches, we ascertained that ULK1 could be targeted by mir-26a, which is overexpressed in advanced stages of CRC. In vitro experiments revealed that overexpression of mir-26a decreased significantly ULK1, mRNA, and protein expression. Contrariwise, the Tt recovered ULK1 expression by mir-26a decrease. Due to triple therapy repressed mir-26a expression, we hypothesized this drug combination could be involved in mir-26a transcription regulation. Consequently, we analyzed the mir-26a promoter sequence and found two HIF-1 alpha transcription factor recognition sites. We developed two different HIF-1 alpha stabilization models. Both showed mir-26a overexpression and ULK1 reduction in hypoxic conditions. Immunoprecipitation experiments were performed and HIF-1 alpha enrichment was observed in mir-26a promoter. Surprisingly, Tt diminished HIF-1 alpha detection and restored ULK1 mRNA expression. These results reveal an important regulation mechanism controlled by the signaling that activates HIF-1 alpha and that in turn regulates mir-26a transcription.
C1 [Coronel-Hernandez, Jossimar; Perez-Plasencia, Carlos] UNAM, FES Iztacala, Unidad Biomed, Lab Genom Func, Tlalnepantla, Mexico.
   [Coronel-Hernandez, Jossimar; Salgado-Garcia, Rebeca; Cantu-De Leon, David; Millan-Catalan, Oliver; Delgado-Waldo, Izamary; Campos-Parra, Alma D.; Rodriguez-Morales, Miguel; Perez-Plasencia, Carlos] Inst Nacl Cancerol, Lab Genomica, Tlalpan, Mexico.
   [Jacobo-Herrera, Nadia] INCMNSZ, Unidad Bioquimca, Tlalpan, Mexico.
   [Delgado-Buenrostro, Norma L.] UNAM, FES IZTACALA, Lab Toxicol, Unidad Biomed, Tlalnepantla, Mexico.
RP Perez-Plasencia, C (corresponding author), UNAM, FES Iztacala, Unidad Biomed, Lab Genom Func, Tlalnepantla, Mexico.; Perez-Plasencia, C (corresponding author), Inst Nacl Cancerol, Lab Genomica, Tlalpan, Mexico.
EM carlos.pplas@gmail.com
RI Rodriguez, Miguel/AGY-0751-2022; Jacobo-Herrera, Nadia/AGG-8009-2022
OI Rodriguez, Miguel/0000-0002-4302-1069; Jacobo-Herrera,
   Nadia/0000-0002-1026-3774; Delgado-Waldo, Izamary/0000-0002-3688-9775
FU CONACYTConsejo Nacional de Ciencia y Tecnologia (CONACyT) [402278];
   COMECYT [2019ND0005-11]; UNAMUniversidad Nacional Autonoma de Mexico
   [PAPIIT-IN231420]
FX JC-H is a doctoral student from Programa de Doctorado en Ciencias
   Biomedicas, Universidad Nacional Autonoma de Mexico (UNAM) and received
   fellowship 402278 from CONACYT and 2019ND0005-11 from COMECYT. This
   study was supported by UNAM PAPIIT-IN231420 research funds granted to
   CP-P.
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Al-Haidari A, 2018, CANCER LETT, V421, P145, DOI 10.1016/j.canlet.2018.02.026
   Babichev Y, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0814-z
   Basho RK, 2017, JAMA ONCOL, V3, P509, DOI 10.1001/jamaoncol.2016.5281
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Cabello P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081298
   Castellano L, 2017, NUCLEIC ACIDS RES, V45, P4401, DOI 10.1093/nar/gkx022
   Chakraborty PK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14634
   Chaube B, 2015, ONCOTARGET, V6, P37281, DOI 10.18632/oncotarget.6134
   Chen B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-443
   Chen C, 2018, ANTI-CANCER DRUG, V29, P1, DOI 10.1097/CAD.0000000000000572
   Chen Yong, 2012, Sci Rep, V2, P808, DOI 10.1038/srep00808
   Clotaire DZJ, 2016, BIOCHEM BIOPH RES CO, V472, P194, DOI 10.1016/j.bbrc.2016.02.093
   Coronel-Hernandez J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0802-5
   Diab DL., 2009, GASTROENTEROLOGY, V6, P1249, DOI [10.1016/j.cgh.2008.07.016.Cytokeratin, DOI 10.1016/J.CGH.2008.07.016.CYTOKERATIN]
   Ding JQ, 2018, ACTA BIOCH BIOPH SIN, V50, P597, DOI 10.1093/abbs/gmy040
   Doktorova H, 2015, BIOMED PAP, V159, P166, DOI 10.5507/bp.2015.025
   Emami F, 2019, MOL PHARMACEUT, V16, P1184, DOI 10.1021/acs.molpharmaceut.8b01157
   Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59
   Figueroa-Gonzalez G, 2016, J CANCER, V7, P1632, DOI 10.7150/jca.13123
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Garcia-Castillo V, 2017, J CANCER, V8, P178, DOI 10.7150/jca.16387
   Gee HE, 2014, ANTIOXID REDOX SIGN, V21, P1220, DOI 10.1089/ars.2013.5639
   Graham CN, 2016, CLIN THER, V38, P1376, DOI 10.1016/j.clinthera.2016.03.023
   Jin FF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.461
   Kim JH, 2015, WORLD J GASTROENTERO, V21, P5158, DOI 10.3748/wjg.v21.i17.5158
   Kim SH, 2016, BIOCHEM BIOPH RES CO, V473, P607, DOI 10.1016/j.bbrc.2016.03.132
   Kishton RJ, 2015, CANCER J, V21, P62, DOI 10.1097/PPO.0000000000000099
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Lan B, 2017, FRONT BIOSCI-LANDMRK, V22, P248, DOI 10.2741/4484
   Lee CS, 2017, EUR J MED CHEM, V142, P416, DOI 10.1016/j.ejmech.2017.08.063
   Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260
   Li HP, 2017, NEUROSCI LETT, V650, P89, DOI 10.1016/j.neulet.2017.02.075
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li M, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15028193
   Li MM, 2015, APOPTOSIS, V20, P769, DOI 10.1007/s10495-015-1110-8
   Liu T, 2019, CANCER BIOL THER, V20, P989, DOI 10.1080/15384047.2019.1591674
   Liu WW, 2017, BRIT J CANCER, V117, P1139, DOI 10.1038/bjc.2017.293
   Lopez-Urrutia E, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317695945
   Loscalzo J, 2010, J CLIN INVEST, V120, P3815, DOI 10.1172/JCI45105
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60
   Mkrtchian S, 2017, EXP CELL RES, V352, P412, DOI 10.1016/j.yexcr.2017.02.027
   Muilenburg D, 2014, ANTICANCER RES, V34, P631
   Muramatsu H, 2019, ONCOL REP, V42, P224, DOI 10.3892/or.2019.7171
   Nallamshetty S, 2013, FREE RADICAL BIO MED, V64, P20, DOI 10.1016/j.freeradbiomed.2013.05.022
   Nie Y, 2011, INT J BIOL SCI, V7, P762, DOI 10.7150/ijbs.7.762
   Pang JJ, 2019, BBA-MOL BASIS DIS, V1865, P1627, DOI 10.1016/j.bbadis.2019.03.015
   Peng H, 2020, ACTA BIOCH BIOPH SIN, V52, P665, DOI 10.1093/abbs/gmaa041
   Price T, 2016, EUR J CANCER, V68, P51, DOI 10.1016/j.ejca.2016.08.010
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Qu F, 2016, ONCOL LETT, V11, P1592, DOI 10.3892/ol.2015.4073
   Ran M, 2018, REPROD DOMEST ANIM, V53, P864, DOI 10.1111/rda.13177
   Shen WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086871
   Song HS, 2018, PHYTOMEDICINE, V40, P37, DOI 10.1016/j.phymed.2017.12.030
   Soni M, 2018, MOL CANCER RES, V16, P1348, DOI 10.1158/1541-7786.MCR-17-0634
   Suhaimi NAM, 2017, MOL CANCER THER, V16, P2035, DOI 10.1158/1535-7163.MCT-16-0793
   Thorburn A, 2008, APOPTOSIS, V13, P1, DOI 10.1007/s10495-007-0154-9
   Tormo E, 2015, J CELL BIOCHEM, V116, P2061, DOI 10.1002/jcb.25162
   Valvona CJ, 2016, BRAIN PATHOL, V26, P3, DOI 10.1111/bpa.12299
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Wang F, 2016, MOL MED REP, V13, P4671, DOI 10.3892/mmr.2016.5143
   Wang H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.138
   Wang YQ, 2019, SPECTROCHIM ACTA A, V220, DOI 10.1016/j.saa.2019.05.010
   Wang Y, 2017, ARCH PHARM RES, V40, P69, DOI 10.1007/s12272-016-0763-3
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wu H, 2012, CELL SIGNAL, V24, P2179, DOI 10.1016/j.cellsig.2012.07.001
   Young A, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101339
   Zhai XM, 2013, ONCOL REP, V30, P2983, DOI 10.3892/or.2013.2735
   Zhang JQ, 2012, GASTROENTEROLOGY, V143, P246, DOI 10.1053/j.gastro.2012.03.045
   Zhao KC, 2019, EUR J PHARMACOL, V854, P298, DOI 10.1016/j.ejphar.2019.03.034
   Zhao Z, 2015, CANCER LETT, V358, P17, DOI 10.1016/j.canlet.2014.11.046
   Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928
   Zheng LL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20561-4
   Zhu J, 2018, CELL PHYSIOL BIOCHEM, V51, P113, DOI 10.1159/000495168
   Zhu X, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0794-1
NR 78
TC 4
Z9 4
U1 4
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 26
PY 2021
VL 11
AR 594200
DI 10.3389/fonc.2021.594200
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SO6MK
UT WOS:000659084500001
PM 34123772
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Shen, CY
   Yang, C
   Xia, B
   You, ML
AF Shen, Chongyang
   Yang, Chuan
   Xia, Bing
   You, Mingliang
TI Long non-coding RNAs: Emerging regulators for chemo/immunotherapy
   resistance in cancer stem cells
SO CANCER LETTERS
LA English
DT Article
DE lncRNA; CSCs; Chemo/immunotherapy; Chemoresistance; Cancer immunotherapy
   resistance
ID EPITHELIAL-MESENCHYMAL TRANSITION; PREDICTS POOR-PROGNOSIS; HLA-G
   EXPRESSION; LUNG-CANCER; COLORECTAL-CANCER; PROSTATE-CANCER; PROMOTES;
   AUTOPHAGY; HOTAIR; CHEMOSENSITIVITY
AB Cancer stem cells (CSCs) are a small subpopulation of tumor cells critical for tumor development. Their unique abilities, such as self-renewal, have resulted in tumor resistance to various cancer treatments, including traditional chemotherapy and latest immunotherapy. CSCs-targeting therapy is a promising treatment to overcome the therapeutic resistances to different tumors. However, despite their significance, the regulatory mechanism generating therapy-resistant CSCs is still obscure. Long non-coding RNAs (lncRNAs) are key regulators in various biological processes, including cell proliferation, apoptosis, migration, and invasion. Recent studies have revealed that lncRNAs play an important role in the therapeutic resistance of CSCs. Here we summarize the latest studies on the regulatory role of lncRNAs in sustaining the stemness of CSCs, and discuss the associated mechanisms behind these behavior changes in CSCs-related chemo- and immune-resistance. Future research implications are also discussed, shedding light on the potential CSCs-targeted strategies to break through the resistance of current therapies.
C1 [Shen, Chongyang] Chengdu Univ Tradit Chinese Med, Basic Med Sch, Chengdu 611137, Peoples R China.
   [Shen, Chongyang] Anhui Univ Chinese Med, Key Lab Xinan Med, Minist Educ, Hefei 230038, Anhui, Peoples R China.
   [Yang, Chuan] Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, Clin Res Ctr Resp Dis, Chengdu 610041, Peoples R China.
   [Yang, Chuan] Sichuan Univ, Frontiers Sci Ctr Dis Related Mol Network, Lab Pulm Immunol & Inflammat, Chengdu 610041, Peoples R China.
   [Xia, Bing] Hangzhou Canc Hosp, Dept Radiat Oncol, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310002, Peoples R China.
   [You, Mingliang] Hangzhou Canc Hosp, Hangzhou Canc Inst, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310002, Peoples R China.
RP You, ML (corresponding author), Hangzhou Canc Hosp, Hangzhou Canc Inst, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310002, Peoples R China.
EM youml@zjhealth.org
OI Yang, Chuan/0000-0003-0725-7207
FU Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research
   of Zhejiang Province [2020E10021]; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [81603478];
   Key research program of science technology department of Sichuan
   province [2019YFS0317, 2020YFQ004]; Sichuan Youth Science and Technology
   Innovation Research Team of Experimental Formulology [2020JDTD0022];
   Sichuan National (International) High-end Talents Introduction Project
   [SYZ202069]
FX This work was supported by Key Laboratory of Clinical Cancer
   Pharmacology and Toxicology Research of Zhejiang Province (2020E10021),
   National Natural Science Foundation of China (81603478), Key research
   program of science technology department of Sichuan province
   (2019YFS0317,2020YFQ004), Sichuan Youth Science and Technology
   Innovation Research Team of Experimental Formulology (2020JDTD0022),
   Sichuan National (International) High-end Talents Introduction Project
   in 2020 (SYZ202069). We thank LetPub (www.letpub.com) for its linguistic
   assistance during the preparation of this manuscript.
CR Abdolmaleki F, 2020, GENOMICS, V112, P677, DOI 10.1016/j.ygeno.2019.04.020
   Barbato L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080926
   Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383
   Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012
   Chen X, 2019, CLIN CANCER RES, V25, P1389, DOI 10.1158/1078-0432.CCR-18-1656
   Chen ZZ, 2018, J BIOL CHEM, V293, P7982, DOI 10.1074/jbc.RA117.001321
   Colak S, 2014, FEBS J, V281, P4779, DOI 10.1111/febs.13023
   D'Angelo Edoardo, 2018, Noncoding RNA Res, V3, P174, DOI 10.1016/j.ncrna.2018.08.002
   Ding K, 2018, BIOCHEM BIOPH RES CO, V502, P194, DOI 10.1016/j.bbrc.2018.05.143
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Esfandi F, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104383
   Farooqi AA, 2020, CELL MOL BIOL, V66, P215, DOI 10.14715/cmb/2020.66.3.35
   Fu T, 2021, GASTRIC CANCER, V24, P45, DOI 10.1007/s10120-020-01096-y
   Gao JJ, 2017, NAT MED, V23, P551, DOI 10.1038/nm.4308
   Han DF, 2019, J CANCER, V10, P6738, DOI 10.7150/jca.35770
   Hardy SD, 2017, ONCOTARGET, V8, P103302, DOI 10.18632/oncotarget.21871
   Hatano Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071446
   Hou ZH, 2020, AM J PHYSIOL-CELL PH, V318, pC649, DOI 10.1152/ajpcell.00510.2018
   Hu QS, 2019, NAT IMMUNOL, V20, P835, DOI 10.1038/s41590-019-0400-7
   Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112
   Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108
   Ji J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0528-7
   Jiang P, 2018, J CELL PHYSIOL, V233, P4852, DOI 10.1002/jcp.26288
   Jiao PF, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109164
   Jun BH, 2020, CANCERS, V12, DOI 10.3390/cancers12092553
   Kim SS, 2018, NUCLEIC ACIDS RES, V46, P1424, DOI 10.1093/nar/gkx1221
   Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Lee SP, 2020, CANCERS, V12, DOI 10.3390/cancers12051073
   Li H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00615
   Li X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102958
   Li ZX, 2020, FUNCT INTEGR GENOMIC, V20, P17, DOI 10.1007/s10142-019-00696-x
   Libring S, 2020, CANCERS, V12, DOI 10.3390/cancers12051270
   Lin ZY, 2018, MOL THER, V26, P1494, DOI 10.1016/j.ymthe.2018.04.002
   Liu F, 2020, CANCER MED-US, V9, P1079, DOI 10.1002/cam4.2746
   Liu J, 2019, IMMUNITY, V50, P600, DOI 10.1016/j.immuni.2019.01.021
   Liu KS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01162-0
   Liu Y, 2015, TOXICOL APPL PHARM, V282, P9, DOI 10.1016/j.taap.2014.10.022
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Maccalli C, 2015, CANCER IMMUNOL IMMUN, V64, P91, DOI 10.1007/s00262-014-1592-1
   Mazor G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1477-5
   Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307
   Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771
   Qiu H, 2015, CELL MOL LIFE SCI, V72, P3411, DOI 10.1007/s00018-015-1920-4
   Qu L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12692
   Reifenberger G, 2017, NAT REV CLIN ONCOL, V14, P434, DOI 10.1038/nrclinonc.2016.204
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2
   Saez PJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah7107
   Salama EA, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01459
   Saleh R, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040149
   Shang WC, 2019, CANCER IMMUNOL RES, V7, P813, DOI 10.1158/2326-6066.CIR-18-0443
   Shin VY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1513-5
   Shinde A, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0204-5
   Shinde A, 2019, CANCER RES, V79, P1831, DOI 10.1158/0008-5472.CAN-18-2636
   Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151
   Song BT, 2015, BIOCHEM BIOPH RES CO, V464, P807, DOI 10.1016/j.bbrc.2015.07.040
   Stem J, 2019, REGEN MED, V14, P331, DOI 10.2217/rme-2018-0146
   Sun B, 2021, CELL ONCOL, V44, P179, DOI 10.1007/s13402-020-00560-2
   Sun J, 2014, INT J MOL SCI, V15, P20434, DOI 10.3390/ijms151120434
   Sun JB, 2016, INT J ONCOL, V49, P943, DOI 10.3892/ijo.2016.3589
   Sun W, 2017, ONCOL REP, V38, P3347, DOI 10.3892/or.2017.6056
   Sznarkowska A, 2020, CANCERS, V12, DOI 10.3390/cancers12051155
   Tang YY, 2017, ONCOTARGET, V8, P39001, DOI 10.18632/oncotarget.16545
   Uzunalli Gozde, 2019, Oncotarget, V10, P6334, DOI 10.18632/oncotarget.27274
   Wang JH, 2019, MOL CELL BIOCHEM, V454, P67, DOI 10.1007/s11010-018-3453-2
   Wang LJ, 2014, INT J ONCOL, V44, P2041, DOI 10.3892/ijo.2014.2363
   Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456
   Wang S, 2016, CELL REPROGRAM, V18, P319, DOI 10.1089/cell.2016.0001
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019
   Wei SQ, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419859699
   Wu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2426-z
   Wu MJ, 2020, PEERJ, V8, DOI 10.7717/peerj.8961
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xia H, 2018, EUR REV MED PHARMACO, V22, P1020, DOI 10.26355/eurrev_201802_14384
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xu S, 2016, ONCOL REP, V36, P10, DOI 10.3892/or.2016.4791
   Yang C, 2019, GENE, V687, P73, DOI 10.1016/j.gene.2018.10.087
   Yang C, 2019, J LEUKOCYTE BIOL, V105, P63, DOI 10.1002/JLB.1RU0518-197RR
   Yang Y, 2018, HUM CELL, V31, P232, DOI 10.1007/s13577-018-0206-1
   Yang YH, 2018, ONCOTARGETS THER, V11, P3649, DOI 10.2147/OTT.S165290
   Ye YB, 2018, J CELL BIOCHEM, V119, P2951, DOI 10.1002/jcb.26509
   Yin DH, 2020, ONCOTARGETS THER, V13, P7111, DOI 10.2147/OTT.S243542
   You J, 2014, INDIAN J CANCER, V51, P77, DOI 10.4103/0019-509X.154055
   Yu XF, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3731-5
   Yuan ZN, 2019, J CELL PHYSIOL, V234, P23111, DOI 10.1002/jcp.28874
   Zhang DX, 2018, SEMIN CANCER BIOL, V52, P94, DOI 10.1016/j.semcancer.2018.05.001
   Zhang GX, 2019, J CELL PHYSIOL, V234, P13097, DOI 10.1002/jcp.27980
   Zhang H, 2016, HEPATOLOGY, V64, P1033, DOI 10.1002/hep.28698
   Zhang PH, 2019, MED MOL MORPHOL, V52, P114, DOI 10.1007/s00795-018-0209-8
   Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0
   Zhang W, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13239
   Zhang YQ, 2020, BREAST CANCER-TOKYO, V27, P573, DOI 10.1007/s12282-020-01048-5
   Zhang Y, 2019, MOL THER-NUCL ACIDS, V17, P362, DOI 10.1016/j.omtn.2019.05.030
   Zhang YF, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117280
   Zhao LN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1886-5
   Zhao YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1375-9
   Zhou QF, 2018, J CANCER, V9, P2436, DOI 10.7150/jca.24796
   Zhu MZ, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2577-6
NR 100
TC 9
Z9 11
U1 6
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 1
PY 2021
VL 500
BP 244
EP 252
DI 10.1016/j.canlet.2020.11.010
EA JAN 2021
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PR4II
UT WOS:000607200800023
PM 33242560
DA 2022-04-25
ER

PT J
AU Mastorci, K
   Montico, B
   Fae, DA
   Sigalotti, L
   Ponzoni, M
   Inghirami, G
   Dolcetti, R
   Dal Col, J
AF Mastorci, Katy
   Montico, Barbara
   Fae, Damiana A.
   Sigalotti, Luca
   Ponzoni, Maurilio
   Inghirami, Giorgio
   Dolcetti, Riccardo
   Dal Col, Jessica
TI Phospholipid scramblase 1 as a critical node at the crossroad between
   autophagy and apoptosis in mantle cell lymphoma
SO ONCOTARGET
LA English
DT Article
DE mantle cell lymphoma; phospholipid scramblase 1; autophagy; apoptosis;
   interferon-alpha
ID COLORECTAL-CANCER; CYCLIN D1; GENE-EXPRESSION; MOLECULAR-BASIS; RETINOIC
   ACID; RESISTANCE; BORTEZOMIB; INHIBITION; EFFICACY; REVEALS
AB Mantle cell lymphoma (MCL) is an aggressive haematological malignancy in which the response to therapy can be limited by aberrantly activated molecular and cellular pathways, among which autophagy was recently listed. Our study shows that the 9-cis-retinoic acid (RA)/Interferon(IFN)-beta combination induces protective autophagy in MCL cell lines and primary cultures reducing the extent of drug-induced apoptosis. The treatment significantly up-regulates phospholipid scramblase 1 (PLSCR1), a protein which bi-directionally flips lipids across membranes. In particular, RA/IFN-beta combination concomitantly increases PLSCR1 transcription and controls PLSCR1 protein levels via lysosomal degradation. Herein we describe a new function for PLSCR1 as negative regulator of autophagy. Indeed, PLSCR1 overexpression reduced MCL cell susceptibility to autophagy induced by RA/IFN-beta, serum deprivation or mTOR pharmacological inhibition. Moreover, PLSCR1 can bind the ATG12/ATG5 complex preventing ATG16L1 recruitment and its full activation, as indicated by co-immunoprecipitation experiments. The combination of doxorubicin or bortezomib with RA/IFN-beta strengthened PLSCR1 up-regulation and enhanced apoptosis, as a likely consequence of the blockade of RA/IFN-beta-induced autophagy. Immunohistochemical analysis of 32 MCL biopsies revealed heterogeneous expression of PLSCR1 and suggests its possible implication in the response to anticancer therapies, especially to drugs promoting protective autophagy.
C1 [Mastorci, Katy; Montico, Barbara; Fae, Damiana A.; Sigalotti, Luca; Dolcetti, Riccardo; Dal Col, Jessica] IRCCS Natl Canc Inst, Dept Translat Res, Canc Bioimmunotherapy Unit, Ctr Riferimento Oncol, Aviano, PN, Italy.
   [Ponzoni, Maurilio] Univ Vita Salute San Raffaele, Pathol Unit, Milan, Italy.
   [Ponzoni, Maurilio] Ist Sci San Raffaele, Unit Lymphoid Malignancies, Milan, Italy.
   [Inghirami, Giorgio] Univ Turin, Dept Pathol, Turin, Italy.
   [Inghirami, Giorgio] Univ Turin, CeRMS, Turin, Italy.
   [Dolcetti, Riccardo] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
RP Dal Col, J (corresponding author), IRCCS Natl Canc Inst, Dept Translat Res, Canc Bioimmunotherapy Unit, Ctr Riferimento Oncol, Aviano, PN, Italy.
EM jdalcol@cro.it
RI Dolcetti, Riccardo/O-3832-2015; Montico, Barbara/AAB-8942-2020; Dal Col,
   Jessica/ABD-9479-2020; Sigalotti, Luca/AAC-2926-2020; , Dal Col
   Jessica/AAC-4852-2020
OI Dolcetti, Riccardo/0000-0003-1625-9853; Montico,
   Barbara/0000-0001-6783-2969; Dal Col, Jessica/0000-0002-0042-2161;
   Sigalotti, Luca/0000-0002-1436-2358; 
FU Italian Association for Cancer ResearchFondazione AIRC per la ricerca
   sul cancro [MFAG 11729, 14257]; "CRO Intramural Bench to Bedside" Grant;
   Italian Foundation for Cancer ResearchFondazione AIRC per la ricerca sul
   cancro
FX This study was supported by: Italian Association for Cancer Research (My
   First Grant MFAG 11729 to JDC, and contract 14257 to RD), "CRO
   Intramural Bench to Bedside" Grant 2012 (to RD). KM was supported by an
   Italian Foundation for Cancer Research fellowship.
CR Alinari L, 2012, AUTOPHAGY, V8, P416, DOI 10.4161/auto.19050
   Avivi I, 2015, CLIN CANCER RES, V21, P3853, DOI 10.1158/1078-0432.CCR-15-0488
   Bertoni F, 2004, BRIT J HAEMATOL, V124, P130, DOI 10.1046/j.1365-2141.2003.04761.x
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   BOSCH F, 1994, BLOOD, V84, P2726
   Campo E, 2015, BLOOD, V125, P48, DOI 10.1182/blood-2014-05-521898
   Chen CY, 2014, CHEM BIOL DRUG DES, V84, P36, DOI 10.1111/cbdd.12347
   Cheng Y, 2011, CANCER RES, V71, P2654, DOI 10.1158/0008-5472.CAN-10-2889
   Coiffier B, 2009, LEUKEMIA LYMPHOMA, V50, P1916, DOI 10.3109/10428190903207548
   Cui W, 2012, HEPATOB PANCREAT DIS, V11, P393, DOI 10.1016/S1499-3872(12)60197-0
   Dal Col J, 2008, BLOOD, V111, P5142, DOI 10.1182/blood-2007-07-103481
   Dal Col J, 2012, CANCER RES, V72, P1825, DOI 10.1158/0008-5472.CAN-11-2505
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665
   Furtado M, 2015, BRIT J HAEMATOL, V168, P55, DOI 10.1111/bjh.13101
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Guidoboni M, 2005, CANCER RES, V65, P587
   Hess G, 2015, EXP HEMATOL ONCOL, V4, DOI 10.1186/s40164-015-0006-1
   Huett A, 2009, J IMMUNOL, V182, P4917, DOI 10.4049/jimmunol.0803050
   Jaffe, 2008, HEMATOL-AM SOC HEMAT, P523, DOI DOI 10.1182/ASHEDUCATI0N-2009.1.523
   Jares P, 2012, J CLIN INVEST, V122, P3416, DOI 10.1172/JCI61272
   Kao C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.468
   Klier M, 2008, LEUKEMIA, V22, P2097, DOI 10.1038/leu.2008.213
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kodigepalli KM, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-32
   Kuo YB, 2011, MOL MED, V17, P41, DOI 10.2119/molmed.2010.00115
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martin P, 2009, J CLIN ONCOL, V27, P1209, DOI 10.1200/JCO.2008.19.6121
   Martin S, 2015, BIOCHEM PHARMACOL, V93, P290, DOI 10.1016/j.bcp.2014.12.003
   Niewerth D, 2015, DRUG RESIST UPDATE, V18, P18, DOI 10.1016/j.drup.2014.12.001
   Njue A, 2015, CL LYMPH MYELOM LEUK, V15, P1, DOI 10.1016/j.clml.2014.03.006
   Orchard J, 2003, BLOOD, V101, P4975, DOI 10.1182/blood-2002-06-1864
   Rajawat Y, 2010, AUTOPHAGY, V6, P1224, DOI 10.4161/auto.6.8.13793
   Rizzatti EG, 2005, BRIT J HAEMATOL, V130, P516, DOI 10.1111/j.1365-2141.2005.05630.x
   Robak T, 2015, NEW ENGL J MED, V372, P944, DOI 10.1056/NEJMoa1412096
   Rosich L, 2012, CLIN CANCER RES, V18, P5278, DOI 10.1158/1078-0432.CCR-12-0351
   Rudelius M, 2006, BLOOD, V108, P1668, DOI 10.1182/blood-2006-04-015586
   Sahu SK, 2007, ARCH BIOCHEM BIOPHYS, V462, P103, DOI 10.1016/j.abb.2007.04.002
   Schmeisser H, 2014, J INTERF CYTOK RES, V34, P71, DOI 10.1089/jir.2013.0128
   Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708
   Sun WL, 2015, NEOPLASMA, V62, P199, DOI 10.4149/neo_2015_025
   Vignon M, 2013, DRUG AGING, V30, P979, DOI 10.1007/s40266-013-0129-1
   Xiao Y, 2015, NEOPLASMA, V62, P391, DOI 10.4149/neo_2015_047
   Yang ZL, 2015, CLIN RES HEPATOL GAS, V39, P98, DOI 10.1016/j.clinre.2014.06.014
   Zeng X, 2015, AUTOPHAGY, V11, P355, DOI 10.4161/15548627.2014.994368
   Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630
   Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599
NR 49
TC 13
Z9 14
U1 2
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 5
PY 2016
VL 7
IS 27
BP 41913
EP 41928
DI 10.18632/oncotarget.9630
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DS7DI
UT WOS:000380942600075
PM 27248824
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, J
   Song, QQ
   Wu, MN
   Zheng, WJ
AF Zhang, Jie
   Song, Qianqian
   Wu, Mengna
   Zheng, Wenjie
TI The Emerging Roles of Exosomes in the Chemoresistance of Hepatocellular
   Carcinoma
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Hepatocellular carcinoma; chemoresistance; exosome; tumor
   microenvironment; epithelial-mesenchymal transition; cancer stem cell
ID TO-MESENCHYMAL TRANSITION; BINDING CASSETTE TRANSPORTER;
   MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; STEM-CELLS; P-GLYCOPROTEIN;
   CANCER CELLS; TUMOR MICROENVIRONMENT; POTENTIAL BIOMARKERS;
   COLORECTAL-CANCER
AB Hepatocellular carcinoma (HCC) is a common gastrointestinal malignancy with a leading incidence of cancer-related mortality worldwide. Despite the progress of treatment options, there remains low efficacy for patients with intermediate-advanced HCC, due to tumor metastasis, recurrence and chemoresistance. Increasing evidence suggests that exosomes in the tumor microenvironment (TME), along with other extracellular vesicles (EVs) and cytokines, contribute to the drug chemosensitivity of cancer cells. Exosomes, the intercellular communicators in various biological activities, have shown to play important roles in HCC progression. This review summarizes the underlying associations between exosomes and chemoresistance of HCC cells. The exosomes derived from distinct cell types mediate the drug resistance by regulating drug efflux, epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) properties, autophagic phenotypes, as well as the immune response. In summary, TME-related exosomes can be a potential target to reverse chemoresistance and a candidate biomarker of drug efficacy in HCC patients.
C1 [Zhang, Jie] Nantong Univ, Dept Chemotherapy, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
   [Zhang, Jie; Wu, Mengna; Zheng, Wenjie] Nantong Univ, Res Ctr Clin Med, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
   [Song, Qianqian] Wake Forest Sch Med, Dept Radiol, One Med Ctr Blvd, Winston Salem, NC 27157 USA.
RP Zheng, WJ (corresponding author), Nantong Univ, Res Ctr Clin Med, Affiliated Hosp, 20 Xisi Rd, Nantong 226001, Jiangsu, Peoples R China.
EM zwj007008009@163.com
OI Zheng, Wenjie/0000-0001-5987-5272; zheng, wenjie/0000-0002-3073-4596
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81702419]; Jiangsu Graduate innovation [KYCX17_1934];
   Nan-tong Health and Family Planning Commission [WQ2016083]
FX This study has been supported by grants from the National Natural
   Science Foundation (81702419), Jiangsu Graduate innovation
   (KYCX17_1934), and Nan-tong Health and Family Planning Commission
   (WQ2016083).
CR Abdul-Ghani R, 2006, ONCOGENE, V25, P1743, DOI 10.1038/sj.onc.1209201
   Alzahrani FA, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8058979
   Aung T, 2011, P NATL ACAD SCI USA, V108, P15336, DOI 10.1073/pnas.1102855108
   Bang C, 2012, INT J BIOCHEM CELL B, V44, P2060, DOI 10.1016/j.biocel.2012.08.007
   Barancik M, 2006, EUR J PHARM SCI, V29, P426, DOI 10.1016/j.ejps.2006.08.006
   Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76
   Bimonte S, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8352684
   BUSCHER HP, 1990, KLIN WOCHENSCHR, V68, P443, DOI 10.1007/BF01648895
   Chen L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0534-9
   Chen R, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-018-0315-1
   Chen X, 2009, ONCOL REP, V22, P73, DOI 10.3892/or_00000408
   Chen ZL, 2016, CANCER LETT, V370, P153, DOI 10.1016/j.canlet.2015.10.010
   Cheng YT, 2016, PHARMACOL RES, V114, P128, DOI 10.1016/j.phrs.2016.10.022
   Cheng ZJ, 2019, MOL CARCINOGEN, V58, P1389, DOI 10.1002/mc.23022
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x
   Couri T, 2019, HEPATOL INT, V13, P125, DOI 10.1007/s12072-018-9919-1
   Cui GH, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0150-2
   El-Awady Raafat, 2016, Front Pharmacol, V7, P535, DOI 10.3389/fphar.2016.00535
   Espelt MV, 2019, WORLD J HEPATOL, V11, P344, DOI 10.4254/wjh.v11.i4.344
   Ferguson SW, 2016, J CONTROL RELEASE, V228, P179, DOI 10.1016/j.jconrel.2016.02.037
   Fernandes C, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01230
   Findlay VJ, 2014, MOL CANCER THER, V13, P2713, DOI 10.1158/1535-7163.MCT-14-0207
   Finn R S, 2012, Minerva Gastroenterol Dietol, V58, P25
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Fornari F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141448
   Fu QH, 2018, ONCOGENE, V37, P6105, DOI 10.1038/s41388-018-0391-0
   Fu X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0677-7
   Gangoda L, 2015, PROTEOMICS, V15, P260, DOI 10.1002/pmic.201400234
   Gramantieri Laura, 2018, Oncotarget, V9, P35085, DOI 10.18632/oncotarget.26202
   Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P72, DOI 10.1016/j.semcdb.2015.02.009
   Guan DX, 2015, HEPATOLOGY, V62, P1791, DOI 10.1002/hep.28117
   Guescini M, 2010, J NEURAL TRANSM, V117, P1, DOI 10.1007/s00702-009-0288-8
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Han QF, 2019, CANCER LETT, V457, P47, DOI 10.1016/j.canlet.2019.04.035
   Haraguchi N, 2010, J CLIN INVEST, V120, P3326, DOI 10.1172/JCI42550
   He M, 2015, CARCINOGENESIS, V36, P1008, DOI 10.1093/carcin/bgv081
   Hoffmann K, 2011, ANTICANCER RES, V31, P3883
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Hou YC, 2018, AM J TRANSL RES, V10, P1648
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006
   Jia HY, 2018, AM J TRANSL RES, V10, P101
   Jiang WQ, 1997, CLIN CANCER RES, V3, P395
   Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341
   Kamil F, 2018, J GASTROINTEST ONCOL, V9, P180, DOI 10.21037/jgo.2017.06.09
   Kamiyama N, 2006, ANTICANCER RES, V26, P885
   Karaosmanoglu O, 2018, CELL ONCOL, V41, P439, DOI 10.1007/s13402-018-0384-6
   Kato A, 2001, J SURG ONCOL, V78, P110, DOI 10.1002/jso.1129
   Kim SM, 2017, J CONTROL RELEASE, V266, P8, DOI 10.1016/j.jconrel.2017.09.013
   Kogure T, 2011, HEPATOLOGY, V54, P1237, DOI 10.1002/hep.24504
   Kriajevska M, 1998, J BIOL CHEM, V273, P9852, DOI 10.1074/jbc.273.16.9852
   Lange N, 2019, DIGEST DIS SCI, V64, P903, DOI 10.1007/s10620-019-05515-8
   Lee Hsin-Yi, 2018, Oncotarget, V9, P13193, DOI 10.18632/oncotarget.24149
   Li BG, 2018, LIFE SCI, V197, P122, DOI 10.1016/j.lfs.2018.02.006
   Li CF, 2016, ONCOTARGET, V7, P17021, DOI 10.18632/oncotarget.7740
   Li G, 2015, CLIN TRANSL ONCOL, V17, P684, DOI 10.1007/s12094-015-1294-y
   Li GP, 2007, J HUAZHONG U SCI-MED, V27, P173, DOI 10.1007/s11596-007-0217-8
   Li HD, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0429-z
   Li I, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0975-5
   Li JQ, 2018, ONCOTARGETS THER, V11, P5885, DOI 10.2147/OTT.S179509
   Li RK, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0948-8
   Liang GF, 2018, INT J NANOMED, V13, P585, DOI 10.2147/IJN.S154458
   Lin ML, 2018, FEBS J, V285, P3835, DOI 10.1111/febs.14635
   Liu DX, 2019, ONCOL LETT, V17, P323, DOI 10.3892/ol.2018.9584
   Liu JT, 2019, HEPATOLOGY, V70, P241, DOI 10.1002/hep.30607
   Liu L, 2017, ONCOTARGET, V8, P57707, DOI 10.18632/oncotarget.17202
   Liu WF, 2017, ONCOTARGETS THER, V10, P3843, DOI 10.2147/OTT.S140062
   Lou GH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0220-7
   Lv MM, 2014, TUMOR BIOL, V35, P10773, DOI 10.1007/s13277-014-2377-z
   Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811
   Maas SLN, 2017, TRENDS CELL BIOL, V27, P172, DOI 10.1016/j.tcb.2016.11.003
   Mani SKK, 2018, GENES-BASEL, V9, DOI 10.3390/genes9030137
   Martinez VG, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1362530
   Matsuura Y, 2019, DIGEST DIS SCI, V64, P792, DOI 10.1007/s10620-018-5380-1
   Meena AS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061524
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Mittelbrunn M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1285
   Munson Phillip, 2015, Medicines (Basel), V2, P310
   Neumuller RA, 2009, GENE DEV, V23, P2675, DOI 10.1101/gad.1850809
   Nies AT, 2001, INT J CANCER, V94, P492, DOI 10.1002/ijc.1498
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Overbye A, 2015, ONCOTARGET, V6, P30357, DOI 10.18632/oncotarget.4851
   Pascucci L, 2014, J CONTROL RELEASE, V192, P262, DOI 10.1016/j.jconrel.2014.07.042
   Personeni N, 2019, J HEPATOCELL CARCINO, V6, P31, DOI 10.2147/JHC.S168953
   Qu Z, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0430-z
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Raji GR, 2017, CELL SIGNAL, V38, P146, DOI 10.1016/j.cellsig.2017.07.005
   Saari H, 2015, J CONTROL RELEASE, V220, P727, DOI 10.1016/j.jconrel.2015.09.031
   Saha T, 2012, AUTOPHAGY, V8, P1643, DOI 10.4161/auto.21654
   Sasaki R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061406
   Schneider A, 2013, CELL TISSUE RES, V352, P33, DOI 10.1007/s00441-012-1428-2
   Schutte K, 2009, DIGEST DIS, V27, P80, DOI 10.1159/000218339
   Sell S, 2016, CURR DRUG TARGETS, V17, P1103, DOI 10.2174/1389450116666150907102717
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Shan JJ, 2012, HEPATOLOGY, V56, P1004, DOI 10.1002/hep.25745
   Shi M, 2018, J CELL BIOCHEM, V119, P4711, DOI 10.1002/jcb.26650
   Shi SB, 2018, TRANSL ONCOL, V11, P250, DOI 10.1016/j.tranon.2018.01.001
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI [10.1586/epr.09.17, 10.1586/EPR.09.17]
   Sipos F, 2012, WORLD J GASTROENTERO, V18, P601, DOI 10.3748/wjg.v18.i7.601
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Sohn W, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.68
   Soini Y, 1996, J CLIN PATHOL, V49, P470, DOI 10.1136/jcp.49.6.470
   Song K, 2015, ONCOTARGET, V6, P40822, DOI 10.18632/oncotarget.5812
   Song Y, 2017, ONCOTARGET, V8, P21650, DOI 10.18632/oncotarget.15521
   Sousa D, 2015, TRENDS MOL MED, V21, P595, DOI 10.1016/j.molmed.2015.08.002
   Srivastava A, 2016, J BIOMED NANOTECHNOL, V12, P1159, DOI 10.1166/jbn.2016.2205
   Sugimachi K, 2015, BRIT J CANCER, V112, P532, DOI 10.1038/bjc.2014.621
   Sun L, 2018, J CANCER, V9, P2631, DOI 10.7150/jca.24978
   Sun ZG, 2010, TUMORI J, V96, P90, DOI 10.1177/030089161009600115
   Takahashi K, 2014, MOL CANCER RES, V12, P1377, DOI 10.1158/1541-7786.MCR-13-0636
   Takahashi K, 2014, FEBS OPEN BIO, V4, P458, DOI 10.1016/j.fob.2014.04.007
   Tato-Costa J, 2016, CLIN COLORECTAL CANC, V15, P170, DOI 10.1016/j.clcc.2015.09.003
   Tian XP, 2019, THERANOSTICS, V9, P1965, DOI 10.7150/thno.30958
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Tsang WP, 2007, ONCOGENE, V26, P4877, DOI 10.1038/sj.onc.1210266
   Tsoumas D, 2018, CANCER GENOM PROTEOM, V15, P127, DOI 10.21873/cgp.20071
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125
   Wakamatsu T, 2007, INT J ONCOL, V31, P1465
   Wang F, 2018, HEPATOLOGY, V67, P940, DOI 10.1002/hep.29586
   Wang J, 2017, NANOSCALE, V9, P15598, DOI 10.1039/c7nr04425a
   Wang J, 2017, J CONTROL RELEASE, V268, P147, DOI 10.1016/j.jconrel.2017.10.020
   Wang JH, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00533
   Wang NZ, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758835918816287
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071
   Wang S, 2017, ONCOL LETT, V14, P8122, DOI 10.3892/ol.2017.7257
   Wang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0180-7
   Xiang QF, 2015, LIVER INT, V35, P1010, DOI 10.1111/liv.12524
   Xu H, 2018, CANCER EPIDEM BIOMAR, V27, P710, DOI [10.1158/1055-9965.epi-17-0770, 10.1158/1055-9965.EPI-17-0770]
   Xu H, 2018, CLIN CHEM LAB MED, V56, P479, DOI 10.1515/cclm-2017-0327
   Xu LC, 2017, ONCOTARGET, V8, P56168, DOI 10.18632/oncotarget.17040
   Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9
   Xu X, 2018, J CANCER, V9, P3557, DOI 10.7150/jca.26350
   Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044
   Ye CG, 2013, HEPATOL RES, V43, P289, DOI 10.1111/j.1872-034X.2012.01067.x
   Ye LS, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0451-6
   Yoo Young Dong, 2015, J Anal Sci Technol, V6, P28
   Younes R, 2018, J HEPATOL, V68, P326, DOI 10.1016/j.jhep.2017.10.006
   Yu LX, 2019, ONCOL REP, V41, P257, DOI 10.3892/or.2018.6829
   Zhang HG, 2011, CLIN CANCER RES, V17, P959, DOI 10.1158/1078-0432.CCR-10-1489
   Zhang J, 2017, BIOCHEM BIOPH RES CO, V491, P469, DOI 10.1016/j.bbrc.2017.07.041
   Zhang QY, 2019, J CELL BIOCHEM, V120, P14885, DOI 10.1002/jcb.28750
   Zhang Y, 2018, MED SCI MONITOR, V24, P2735, DOI 10.12659/MSM.907514
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
   Zhou J, 2001, BIOCHEM BIOPH RES CO, V280, P1237, DOI 10.1006/bbrc.2001.4268
   Zhou Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0965-2
NR 150
TC 8
Z9 8
U1 6
U2 14
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2021
VL 28
IS 1
BP 93
EP 109
DI 10.2174/0929867327666200130103206
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA QC1RB
UT WOS:000614610300007
PM 32000636
DA 2022-04-25
ER

PT J
AU Qu, JS
   Luo, MY
   Zhang, JW
   Han, F
   Hou, NN
   Pan, RY
   Sun, XD
AF Qu, Junsheng
   Luo, Moyi
   Zhang, Jingwen
   Han, Fang
   Hou, Ningning
   Pan, Ruiyan
   Sun, Xiaodong
TI A paradoxical role for sestrin 2 protein in tumor suppression and
   tumorigenesis
SO CANCER CELL INTERNATIONAL
LA English
DT Review
DE Sestrin 2; Cancer; Tumor suppressor; Tumorigenesis
ID ENDOPLASMIC-RETICULUM STRESS; SIGNALING PATHWAY; DRUG-RESISTANCE;
   UP-REGULATION; CANCER; MTOR; INDUCTION; APOPTOSIS; AUTOPHAGY; EXPRESSION
AB Sestrin 2, a highly conserved stress-induced protein, participates in the pathological processes of metabolic and age-related diseases. This p53-inducible protein also regulates cell growth and metabolism, which is closely related to malignant tumorigenesis. Sestrin 2 was reported to regulate various cellular processes, such as tumor cell proliferation, invasion and metastasis, apoptosis, anoikis resistance, and drug resistance. Although sestrin 2 is associated with colorectal, lung, liver, and other cancers, sestrin 2 expression varies among different types of cancer, and the effects and mechanisms of action of this protein are also different. Sestrin 2 was considered a tumor suppressor gene in most studies, whereas conflicting reports considered sestrin 2 an oncogene. Thus, this review aims to examine the literature regarding sestrin 2 in various cancers, summarize its roles in suppression and tumorigenesis, discuss potential mechanisms in the regulation of cancer, and provide a basis for follow-up research and potential cancer treatment development.
C1 [Qu, Junsheng; Zhang, Jingwen; Hou, Ningning; Sun, Xiaodong] Weifang Med Univ, Affiliated Hosp, Dept Endocrinol & Metab, 2428 Yuhe Rd, Weifang 261031, Shandong, Peoples R China.
   [Luo, Moyi] Weifang Med Univ, Sch Clin Med, Weifang, Peoples R China.
   [Luo, Moyi; Zhang, Jingwen; Sun, Xiaodong] Weifang Med Univ, Affiliated Hosp, Clin Res Ctr, Weifang, Peoples R China.
   [Han, Fang] Weifang Med Univ, Affiliated Hosp, Dept Pathol, Weifang, Peoples R China.
   [Pan, Ruiyan] Weifang Med Univ, Sch Pharm, Weifang, Peoples R China.
RP Sun, XD (corresponding author), Weifang Med Univ, Affiliated Hosp, Dept Endocrinol & Metab, 2428 Yuhe Rd, Weifang 261031, Shandong, Peoples R China.; Pan, RY (corresponding author), Weifang Med Univ, Sch Pharm, Weifang, Peoples R China.
EM panry@wfmc.edu.cn; xiaodong.sun@wfmc.edu.cn
RI Sun, Xiaodong/Q-8284-2018
OI Sun, Xiaodong/0000-0001-7775-2823; Han, Fang/0000-0002-8743-8763; Zhang,
   Jingwen/0000-0002-6064-1374; Hou, Ningning/0000-0002-3813-8465
FU Natural Science Foundation of Shandong ProvinceNatural Science
   Foundation of Shandong Province [ZR2019BH036, ZR2020MH106]; Science and
   Technology Development Project of Weifang [2018YX058]; PhD Foundation of
   Weifang Medical University [20217-03]
FX This work was supported by the Natural Science Foundation of Shandong
   Province (ZR2019BH036, ZR2020MH106), the Science and Technology
   Development Project of Weifang (2018YX058), the PhD Foundation of
   Weifang Medical University and the public domestic visiting program of
   Weifang Medical University (20217-03).
CR Ambrosio S, 2017, ONCOGENE, V36, P6701, DOI 10.1038/onc.2017.267
   Ayachi O, 2019, CELL ONCOL, V42, P319, DOI 10.1007/s13402-019-00427-1
   Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519
   Ben-Sahra I, 2013, CELL DEATH DIFFER, V20, P611, DOI 10.1038/cdd.2012.157
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bruning A, 2013, MOL ONCOL, V7, P1012, DOI 10.1016/j.molonc.2013.07.010
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877
   Byun JK, 2017, CELL REP, V20, P586, DOI 10.1016/j.celrep.2017.06.066
   Chae HS, 2020, J PERS MED, V10, DOI 10.3390/jpm10030109
   Chen KB, 2016, AM J TRANSL RES, V8, P1903
   Chen MJ, 2021, J CELL PHYSIOL, V236, P392, DOI 10.1002/jcp.29867
   Chen SS, 2017, DIAGN PATHOL, V12, DOI 10.1186/s13000-016-0591-2
   Chen XP, 2011, MED ONCOL, V28, P1288, DOI 10.1007/s12032-010-9617-x
   Chen Z, 2020, DRUG TODAY, V56, P469, DOI 10.1358/dot.2020.56.7.3112071
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Dai JM, 2018, CANCER MED-US, V7, P5691, DOI 10.1002/cam4.1826
   Dai XF, 2020, CANCERS, V12, DOI 10.3390/cancers12113360
   Di Zazzo E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040839
   Ding BX, 2015, CELL CYCLE, V14, P3231, DOI 10.1080/15384101.2015.1084447
   Ding L, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092791
   Pham DV, 2020, CANCERS, V12, DOI 10.3390/cancers12030613
   Ershaid N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12370-8
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Fu H, 2018, IRAN J BASIC MED SCI, V21, P621, DOI 10.22038/IJBMS.2018.18283.4923
   Gambardella V, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102015
   Guha D, 2019, APOPTOSIS, V24, P958, DOI 10.1007/s10495-019-01573-5
   Guo YY, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.580407
   Han X, 2020, BIOCHEM BIOPH RES CO, V525, P895, DOI 10.1016/j.bbrc.2020.03.032
   Hoekstra HJ, 2016, ANN SURG ONCOL, V23, P2131, DOI 10.1245/s10434-016-5194-3
   Hu HJ, 2015, DNA CELL BIOL, V34, P296, DOI 10.1089/dna.2014.2627
   Hua XH, 2018, CANCER LETT, V436, P38, DOI 10.1016/j.canlet.2018.08.013
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Jayaraj P, 2018, BRIT J OPHTHALMOL, V102, P848, DOI 10.1136/bjophthalmol-2017-311283
   Jie MM, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01160-2
   Jin HR, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1548-7
   Kim Guen Tae, 2013, J Cancer Prev, V18, P264
   Kim H, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10025
   Kim H, 2019, TOXICOL APPL PHARM, V374, P77, DOI 10.1016/j.taap.2019.04.025
   Kozak J, 2019, MOL CELL BIOCHEM, V459, P21, DOI 10.1007/s11010-019-03547-2
   Kumar A, 2018, FEBS J, V285, P1326, DOI 10.1111/febs.14406
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Liang YG, 2016, AUTOPHAGY, V12, P1229, DOI 10.1080/15548627.2016.1179403
   Lin Liang-Ting, 2018, Oncotarget, V9, P16028, DOI 10.18632/oncotarget.24678
   Lippert TH, 2008, ARZNEIMITTELFORSCH, V58, P261, DOI 10.1055/s-0031-1296504
   Liu YC, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20204986
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6
   Lu S, 2019, BIOMED PHARMACOTHER, V111, P142, DOI 10.1016/j.biopha.2018.12.043
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0991-5
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mody K, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0601-1
   Mohamed E, 2017, CANCER IMMUNOL IMMUN, V66, P1069, DOI 10.1007/s00262-017-2019-6
   Mossmann D, 2018, NAT REV CANCER, V18, P744, DOI 10.1038/s41568-018-0074-8
   Murugan AK, 2019, SEMIN CANCER BIOL, V59, P92, DOI 10.1016/j.semcancer.2019.07.003
   Oura K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218362
   Pasha M, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3296294
   Perez-Ramirez C, 2015, PHARMACOGENOMICS, V16, P1843, DOI 10.2217/pgs.15.122
   Populo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Qi WC, 2020, ONCOL REP, V43, P839, DOI 10.3892/or.2020.7484
   Ren D, 2021, REDOX BIOL, V38, DOI 10.1016/j.redox.2020.101824
   Reyes-Farias M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133177
   Ro SH, 2016, ELIFE, V5, DOI 10.7554/eLife.12204
   Sanli T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032035
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Saveljeva S, 2016, ONCOTARGET, V7, P12254, DOI 10.18632/oncotarget.7601
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Seo K, 2017, ARCH PHARM RES, V40, P231, DOI 10.1007/s12272-016-0878-6
   Seo K, 2016, FREE RADICAL BIO MED, V101, P511, DOI 10.1016/j.freeradbiomed.2016.11.014
   Seoane J, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022277
   Shen MH, 2021, CANCER RES, V81, P1014, DOI 10.1158/0008-5472.CAN-20-1876
   Shin J, 2020, CANCERS, V12, DOI 10.3390/cancers12092515
   Sisinni L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040857
   Sun XD, 2020, DIABETES, V69, P1292, DOI 10.2337/db19-0991
   Wang LX, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02797
   Wang N, 2011, BRIT J PHARMACOL, V164, P731, DOI 10.1111/j.1476-5381.2011.01349.x
   Wang XJ, 2017, ONCOTARGET, V8, P90132, DOI 10.18632/oncotarget.21487
   Wei JL, 2017, ONCOTARGET, V8, P49318, DOI 10.18632/oncotarget.17595
   Wei JL, 2015, ONCOL REP, V33, P1349, DOI 10.3892/or.2014.3701
   Wolfson RL, 2016, SCIENCE, V351, P43, DOI 10.1126/science.aab2674
   Won DH, 2019, J CLIN BIOCHEM NUTR, V64, P97, DOI 10.3164/jcbn.18-63
   Xia J, 2019, J BIOPHOTONICS, V12, DOI 10.1002/jbio.201800046
   Xiao T, 2019, LIFE SCI, V218, P132, DOI 10.1016/j.lfs.2018.12.043
   Xu H, 2021, ONCOGENE, V40, P1555, DOI 10.1038/s41388-020-01587-3
   Xu H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124033
   Yang XZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0874-1
   Yang Y, 2021, J PHARMACOL SCI, V145, P175, DOI 10.1016/j.jphs.2020.11.012
   Zhang L, 2018, MOLECULES, V23, DOI 10.3390/molecules23030565
   Zhang XY, 2013, CELL SIGNAL, V25, P150, DOI 10.1016/j.cellsig.2012.09.004
   Zhao BZ, 2014, J BIOL CHEM, V289, P35806, DOI 10.1074/jbc.M114.595397
   Zhou L, 2020, INT J BIOL SCI, V16, P309, DOI 10.7150/ijbs.37162
   Zhu GN, 2020, J INVEST DERMATOL, V140, P666, DOI 10.1016/j.jid.2019.07.720
NR 94
TC 1
Z9 1
U1 3
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD NOV 16
PY 2021
VL 21
IS 1
AR 606
DI 10.1186/s12935-021-02317-9
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WY5NK
UT WOS:000719325200001
PM 34784907
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chow, MJ
   Alfiean, M
   Pastorin, G
   Gaiddon, C
   Ang, WH
AF Chow, Mun Juinn
   Alfiean, Mohammad
   Pastorin, Giorgia
   Gaiddon, Christian
   Ang, Wee Han
TI Apoptosis-independent organoruthenium anticancer complexes that overcome
   multidrug resistance: self-assembly and phenotypic screening strategies
SO CHEMICAL SCIENCE
LA English
DT Article
ID CELL-DEATH; DRUG DISCOVERY; TUMOR RESISTANCE; CANCER-CELLS; AUTOPHAGY;
   INDUCERS; STRESS
AB Multidrug resistance is a major impediment to chemotherapy and limits the efficacies of conventional anticancer drugs. A strategy to bypass multidrug resistance is to develop new drug candidates capable of inducing apoptosis-independent programmed cell death. However, cellular pathways implicated in alternative programmed cell death are not well-elucidated and multifactorial, making a target-based discovery approach a challenge. Here, we show that a coordination-directed three-component assembly and phenotypic screening strategy could be employed as a viable alternative for the identification of apoptosis-independent organoruthenium anticancer agents. Through an on-plate synthesis and screening of 195 organoruthenium complexes against apoptosis-sensitive and -resistant cancers, we identified two apoptosis-independent hits. Subsequent validation of the two hits showed a lack of induction of apoptotic biomarkers, a caspase-independent activity and an equal efficacy in both apoptosis-sensitive and -resistant colorectal cancers. This validated their apoptosis-independent modes-of-action, paving the way as potential candidates for the treatment of highly-refractory cancer phenotypes.
C1 [Chow, Mun Juinn; Ang, Wee Han] Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.
   [Alfiean, Mohammad] Nanyang Polytech, Sch Chem & Life Sci, Singapore, Singapore.
   [Pastorin, Giorgia] Natl Univ Singapore, Dept Pharm, 3 Sci Dr 3, Singapore 117543, Singapore.
   [Pastorin, Giorgia; Ang, Wee Han] NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore.
   [Gaiddon, Christian] Univ Strasbourg, Strasbourg, France.
   [Gaiddon, Christian] INSERM, U1113, 3 Ave Moliere, F-67200 Strasbourg, France.
RP Chow, MJ; Ang, WH (corresponding author), Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.; Ang, WH (corresponding author), NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore.
EM a0037979@u.nus.edu; chmawh@nus.edu.sg
RI Ang, Wee Han/L-2249-2013; Chow, Mun Juinn/D-8847-2016; Gaiddon,
   Christian/F-7321-2012; Chow, Mun Juinn/N-3882-2019
OI Ang, Wee Han/0000-0003-2027-356X; Chow, Mun Juinn/0000-0002-0812-9226;
   Gaiddon, Christian/0000-0003-4315-3851; Chow, Mun
   Juinn/0000-0002-0812-9226; Pastorin, Giorgia/0000-0002-2568-0626
FU Ministry of Education; National University of SingaporeNational
   University of Singapore [R143-000-680-114]; Ligue contre le CancerLigue
   nationale contre le cancer; COSTEuropean Cooperation in Science and
   Technology (COST) [CM1105]; Accociation pour la Recherche contre le
   Cancer (ARC)
FX The authors gratefully acknowledge financial support from Ministry of
   Education and the National University of Singapore (R143-000-680-114)
   and Ligue contre le Cancer, COST CM1105, Accociation pour la Recherche
   contre le Cancer (ARC). The authors also thank Associate Professor
   Han-ming Shen (NUS) for providing the HCT116 and HCT116
   p53<SUP>-/-</SUP> cell lines and CMMAC for performing elemental analysis
   and ICP-OES experiments.
CR Chow MJ, 2016, CHEM SCI, V7, P4117, DOI 10.1039/c6sc00268d
   Chow MJ, 2016, MOL PHARMACEUT, V13, P2543, DOI 10.1021/acs.molpharmaceut.6b00348
   Chow MJ, 2014, J MED CHEM, V57, P6043, DOI 10.1021/jm500455p
   Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3
   Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Guo WJ, 2013, AUTOPHAGY, V9, P996, DOI 10.4161/auto.24407
   Hervouet Eric, 2013, Cells, V2, P545, DOI 10.3390/cells2030545
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Kornienko A, 2013, J MED CHEM, V56, P4823, DOI 10.1021/jm400136m
   Krakstad C, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-135
   Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kumbhar AA, 2013, CHEM COMMUN, V49, P2460, DOI 10.1039/c3cc38927h
   Librizzi M, 2012, CHEM RES TOXICOL, V25, P2608, DOI 10.1021/tx300376h
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Marzano C, 2006, J MED CHEM, V49, P7317, DOI 10.1021/jm0601248
   Moffat JG, 2014, NAT REV DRUG DISCOV, V13, P588, DOI 10.1038/nrd4366
   O'Gorman DM, 2001, LEUKEMIA, V15, P21, DOI 10.1038/sj.leu.2401998
   Paul I, 2014, WORLD J CLIN ONCOL, V5, P588, DOI 10.5306/wjco.v5.i4.588
   Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515
   Robinson MW, 2012, J MED CHEM, V55, P1940, DOI 10.1021/jm201006x
   Sams-Dodd F, 2005, DRUG DISCOV TODAY, V10, P139, DOI 10.1016/S1359-6446(04)03316-1
   Shaw AT, 2011, P NATL ACAD SCI USA, V108, P8773, DOI 10.1073/pnas.1105941108
   Siewert B, 2016, CHEM-EUR J, V22, P10960, DOI 10.1002/chem.201600927
   Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454
   Soldevila-Barreda JJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7582
   Suntharalingam K, 2015, J AM CHEM SOC, V137, P2967, DOI 10.1021/ja511978y
   Swinney DC, 2013, CLIN PHARMACOL THER, V93, P299, DOI 10.1038/clpt.2012.236
   Tardito S, 2011, J AM CHEM SOC, V133, P6235, DOI 10.1021/ja109413c
   Tardito S, 2009, J BIOL CHEM, V284, P24306, DOI 10.1074/jbc.M109.026583
   Tian SH, 2011, CHEM COMMUN, V47, P9318, DOI 10.1039/c1cc11820j
   Trejo-Solis C, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-156
   Violette S, 2002, INT J CANCER, V98, P498, DOI 10.1002/ijc.10146
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wasik AM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.106
   Weiwer M, 2012, BIOORG MED CHEM LETT, V22, P1822, DOI 10.1016/j.bmcl.2011.09.047
   Williams R, 2013, EXPERT OPIN INV DRUG, V22, P1627, DOI 10.1517/13543784.2013.847088
   Yuan J, 2015, METALLOMICS, V7, P896, DOI 10.1039/c5mt00010f
NR 39
TC 30
Z9 29
U1 0
U2 19
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2041-6520
EI 2041-6539
J9 CHEM SCI
JI Chem. Sci.
PD MAY 1
PY 2017
VL 8
IS 5
BP 3641
EP 3649
DI 10.1039/c7sc00497d
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA ET8MH
UT WOS:000400553000041
PM 30155208
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Guo, KB
   Feng, YQ
   Zheng, XE
   Sun, LT
   Wasan, HS
   Ruan, SM
   Shen, MH
AF Guo, Kaibo
   Feng, Yuqian
   Zheng, Xueer
   Sun, Leitao
   Wasan, Harpreet S.
   Ruan, Shanming
   Shen, Minhe
TI Resveratrol and Its Analogs: Potent Agents to Reverse
   Epithelial-to-Mesenchymal Transition in Tumors
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE epithelial-to-mesenchymal transition; metastasis; chemoresistance;
   cancer cell stemness; resveratrol
ID SIGNALING PATHWAY; COLORECTAL-CANCER; GASTRIC-CANCER; NADPH OXIDASE;
   UP-REGULATION; EMT; INHIBITION; RESISTANCE; AUTOPHAGY; CELLS
AB Epithelial-to-mesenchymal transition (EMT), a complicated program through which polarized epithelial cells acquire motile mesothelial traits, is regulated by tumor microenvironment. EMT is involved in tumor progression, invasion and metastasis via reconstructing the cytoskeleton and degrading the tumor basement membrane. Accumulating evidence shows that resveratrol, as a non-flavonoid polyphenol, can reverse EMT and inhibit invasion and migration of human tumors via diverse mechanisms and signaling pathways. In the present review, we will summarize the detailed mechanisms and pathways by which resveratrol and its analogs (e.g. Triacetyl resveratrol, 3,5,4'-Trimethoxystilbene) might regulate the EMT process in cancer cells to better understand their potential as novel anti-tumor agents. Resveratrol can also reverse chemoresistance via EMT inhibition and improvement of the antiproliferative effects of conventional treatments. Therefore, resveratrol and its analogs have the potential to become novel adjunctive agents to inhibit cancer metastasis, which might be partly related to their blocking of the EMT process.
C1 [Guo, Kaibo; Feng, Yuqian; Zheng, Xueer; Sun, Leitao; Ruan, Shanming; Shen, Minhe] Zhejiang Chinese Med Univ, First Clin Med Coll, Hangzhou, Peoples R China.
   [Sun, Leitao; Ruan, Shanming; Shen, Minhe] Zhejiang Chinese Med Univ, Dept Med Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China.
   [Wasan, Harpreet S.] Imperial Coll Healthcare NHS Trust, Dept Canc Med, Hammersmith Hosp, London, England.
RP Ruan, SM; Shen, MH (corresponding author), Zhejiang Chinese Med Univ, First Clin Med Coll, Hangzhou, Peoples R China.; Ruan, SM; Shen, MH (corresponding author), Zhejiang Chinese Med Univ, Dept Med Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China.
EM shanmingruan@zcmu.edu.cn; shenminhe@zcmu.edu.cn
RI Ruan, Shanming/S-3999-2018; Guo, Kaibo/AAT-7116-2021
OI Ruan, Shanming/0000-0003-1061-5255; Guo, Kaibo/0000-0002-6348-9785
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81573902]; Zhejiang provincial TCM
   scientific research fund project [2019ZQ015]; China Postdoctoral Science
   FoundationChina Postdoctoral Science Foundation [2017M612040,
   2018T110610]; Top ten thousand talents program of Zhejiang Province
   [2019-97]; Zhejiang Provincial Project for the key discipline of
   Traditional Chinese Medicine [2017-XKA09]; Science and technology
   innovation activity plan and new seedling of college students in
   Zhejiang Province [2019R410001]
FX National Natural Science Foundation of China (81573902); Zhejiang
   provincial TCM scientific research fund project (2019ZQ015); China
   Postdoctoral Science Foundation (2017M612040; 2018T110610); Top ten
   thousand talents program of Zhejiang Province (SR, no.2019-97,
   http://www.zjzzgz.gov.cn/); Zhejiang Provincial Project for the key
   discipline of Traditional Chinese Medicine (YG, no,2017-XKA09,
   http://www.zjwjw.gov.cn/); Science and technology innovation activity
   plan and new seedling of college students in Zhejiang Province
   (2019R410001).
CR Almale L, 2019, STEM CELLS, V37, P1108, DOI 10.1002/stem.3038
   Aragon E, 2019, GENE DEV, V33, P1506, DOI 10.1101/gad.330837.119
   Babaei G, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110909
   Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003
   Baribeau S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086987
   Borretzen A, 2019, J PATHOL CLIN RES, V5, P272, DOI 10.1002/cjp2.142
   Breuss JM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071523
   Broertjes J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209563
   Buhrmann C, 2020, MOLECULES, V25, DOI 10.3390/molecules25184292
   Buhrmann C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030704
   Buhrmann C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070888
   Buhrmann C, 2015, BIOCHEM PHARMACOL, V98, P51, DOI 10.1016/j.bcp.2015.08.105
   Cao L, 2016, INT J ONCOL, V49, P735, DOI 10.3892/ijo.2016.3559
   Chen CY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092729
   Chen H, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07367-2
   Chen KY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219317
   Chen LY, 2021, EXP CELL RES, V398, DOI 10.1016/j.yexcr.2020.112414
   Chen MC, 2012, INNATE IMMUN-LONDON, V18, P685, DOI 10.1177/1753425912436589
   Chen PC, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.625943
   Chen WJ, 2019, ONCOTARGETS THER, V12, P3099, DOI 10.2147/OTT.S202129
   Chen XM, 2021, FOOD FUNCT, V12, P2075, DOI [10.1039/d0fo03076g, 10.1039/D0FO03076G]
   Cho KH, 2019, ARCH PHARM RES, V42, P519, DOI 10.1007/s12272-019-01149-6
   Choi MJ, 2015, ONCOGENE, V34, P3402, DOI 10.1038/onc.2014.270
   Cilibrasi C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169854
   Coban B, 2021, BRIT J CANCER, V124, P49, DOI 10.1038/s41416-020-01150-7
   Cumin C, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11010062
   Dantas RCM, 2021, APPL IMMUNOHISTO M M, V29, P335, DOI 10.1097/PAI.0000000000000866
   Fernandes GMD, 2021, AM J TRANSL RES, V13, P143
   Deng ZH, 2020, CURR CANCER DRUG TAR, V20, P306, DOI 10.2174/1568009620666200101094736
   Dermani FK, 2017, J CELL BIOCHEM, V118, P1547, DOI 10.1002/jcb.25816
   Di Matteo S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81172-0
   Duan HX, 2021, ACTA PHARM SIN B, V11, P55, DOI 10.1016/j.apsb.2020.09.016
   Dudas J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020428
   Fan PJ, 2020, CELL BIOCHEM FUNCT, V38, P38, DOI 10.1002/cbf.3447
   Ferraresi A, 2017, MOL CARCINOGEN, V56, P1164, DOI 10.1002/mc.22582
   da Costa DCF, 2020, MOLECULES, V25, DOI 10.3390/molecules25040893
   Fu JS, 2019, INT J ONCOL, V54, P1306, DOI 10.3892/ijo.2019.4700
   Fukuda S, 2016, SCI REP-UK, V6, DOI 10.1038/srep20209
   Gao Q, 2015, ONCOL LETT, V9, P2381, DOI 10.3892/ol.2015.2988
   Gonzalez-Gonzalez L, 2019, ONCOLOGY-BASEL, V97, P373, DOI 10.1159/000501802
   Gooding AJ, 2020, MOL CANCER RES, V18, P1257, DOI 10.1158/1541-7786.MCR-20-0067
   Groves I, 2020, PHILOS T R SOC B, V375, DOI 10.1098/rstb.2019.0660
   Guimaraes VSN, 2020, J MOL HISTOL, V51, P675, DOI 10.1007/s10735-020-09913-5
   Guo Q, 2020, AGING-US, V12, P80, DOI 10.18632/aging.102598
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Hartman ZC, 2013, CANCER RES, V73, P3470, DOI 10.1158/0008-5472.CAN-12-4524-T
   Hayakawa Y, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121995
   He Y, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4862
   Howells LM, 2011, CANCER PREV RES, V4, P1419, DOI 10.1158/1940-6207.CAPR-11-0148
   Hsieh TC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051760
   Hu FW, 2012, MOL NUTR FOOD RES, V56, P1247, DOI 10.1002/mnfr.201200150
   Huang CY, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111046
   Huang XB, 2020, MOL MED REP, V22, P551, DOI 10.3892/mmr.2020.11097
   Jang YG, 2019, J STEROID BIOCHEM, V192, DOI 10.1016/j.jsbmb.2019.105406
   Ji Q, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1119-y
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Jia CC, 2020, INT J BIOL SCI, V16, P2542, DOI 10.7150/ijbs.45446
   Jiang ZD, 2017, ANN NY ACAD SCI, V1403, P59, DOI 10.1111/nyas.13466
   Jin W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010217
   Jin XX, 2019, CANCER MED-US, V8, P1246, DOI 10.1002/cam4.1993
   Kaszak I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207624
   Khusbu FY, 2020, INT J BIOCHEM CELL B, V118, DOI 10.1016/j.biocel.2019.105644
   Kim JY, 2020, EXP MOL MED, V52, P1152, DOI 10.1038/s12276-020-0474-1
   Kim SE, 2018, NUTR CANCER, V70, P125, DOI 10.1080/01635581.2018.1397708
   Kim SH, 2016, ARCH PHARM RES, V39, P240, DOI 10.1007/s12272-015-0666-8
   Kokkorakis N, 2020, WORLD J STEM CELLS, V12, P1553, DOI 10.4252/wjsc.v12.i12.1553
   Kou XJ, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090927
   Kudo-Saito C, 2021, CANCERS, V13, DOI 10.3390/cancers13030554
   Kyuno D, 2021, BBA-BIOMEMBRANES, V1863, DOI 10.1016/j.bbamem.2020.183503
   Lambert AW, 2021, NAT REV CANCER, V21, P325, DOI 10.1038/s41568-021-00332-6
   Li B, 2019, ONCOL LETT, V18, P4651, DOI 10.3892/ol.2019.10847
   Li B, 2020, J MED CHEM, V63, P12707, DOI 10.1021/acs.jmedchem.0c01059
   Li CW, 2016, CANCER RES, V76, P1451, DOI 10.1158/0008-5472.CAN-15-1941
   Li JP, 2014, MOL MED REP, V10, P1717, DOI 10.3892/mmr.2014.2417
   Li JT, 2021, PHARMACOL THERAPEUT, V223, DOI 10.1016/j.pharmthera.2021.107800
   Li L, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.562823
   Li W, 2016, ONCOL REP, V35, P1718, DOI 10.3892/or.2015.4504
   Li W, 2013, CURR MED CHEM, V20, P4185
   Li ZL, 2021, ONCOTARGETS THER, V14, P503, DOI 10.2147/OTT.S294378
   Liang X, 2019, CANCER MANAG RES, V11, P8923, DOI 10.2147/CMAR.S222708
   Lin WH, 2021, ONCOGENE, V40, P791, DOI 10.1038/s41388-020-01566-8
   Lin YT, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929-020-00632-3
   Liu MY, 2021, GASTROENTEROLOGY, V160, P1771, DOI 10.1053/j.gastro.2020.12.077
   Liu X, 2020, J ZHEJIANG UNIV-SC B, V21, P218, DOI 10.1631/jzus.B1900468
   Lopez-Grueso MJ, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101737
   Luo YF, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.622074
   Mao L, 2020, JAMA NEUROL, V77, P683, DOI 10.1001/jamaneurol.2020.1127
   Menicacci B, 2017, J GERONTOL A-BIOL, V72, P1187, DOI 10.1093/gerona/glw336
   Mirzaei S, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.111077
   Moshiri A, 2017, BBA-GENE REGUL MECH, V1860, P291, DOI 10.1016/j.bbagrm.2017.01.001
   Nabih HK, 2020, ARCH BIOCHEM BIOPHYS, V686, DOI 10.1016/j.abb.2020.108326
   Nejad AE, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01719-5
   Novikov NM, 2021, BRIT J CANCER, V124, P102, DOI 10.1038/s41416-020-01149-0
   Nunes S, 2018, NUTR RES REV, V31, P85, DOI 10.1017/S095442241700021X
   Osada AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217451
   Palomera-Avalos V, 2017, MOL NEUROBIOL, V54, P1661, DOI 10.1007/s12035-016-9770-0
   Paolillo M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194947
   Pastushenko I, 2021, NATURE, V589, P448, DOI 10.1038/s41586-020-03046-1
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Pei DQ, 2019, NAT CELL BIOL, V21, P44, DOI 10.1038/s41556-018-0195-z
   Pezzuto JM, 2019, BIOMOL THER, V27, P1, DOI 10.4062/biomolther.2018.176
   Popat R, 2013, BRIT J HAEMATOL, V160, P714, DOI 10.1111/bjh.12154
   Qin T, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01038
   Qiu YS, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa440
   Rahman MH, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.619024
   Rasheduzzaman M, 2018, LIFE SCI, V208, P208, DOI 10.1016/j.lfs.2018.07.035
   Rauf A, 2018, CRIT REV FOOD SCI, V58, P1428, DOI 10.1080/10408398.2016.1263597
   Reutovich MY, 2019, EJSO-EUR J SURG ONC, V45, P2405, DOI 10.1016/j.ejso.2019.07.030
   Richard V, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100909
   Rodriguez-Aznar E, 2019, CANCERS, V11, DOI 10.3390/cancers11081136
   Roshan MK, 2019, BIOCHIMIE, V165, P229, DOI 10.1016/j.biochi.2019.08.003
   Samec M, 2021, CANCERS, V13, DOI 10.3390/cancers13010130
   Shankar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016530
   Shen YA, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/590393
   Sheng X, 2021, RECENT PAT ANTI-CANC, V16, P54, DOI 10.2174/1574892816666210201120324
   Shi XP, 2013, INT J MOL SCI, V14, P15655, DOI 10.3390/ijms140815655
   Shi YN, 2017, ANN NY ACAD SCI, V1403, P38, DOI 10.1111/nyas.13426
   Shome R, 2021, CELL ONCOL, V44, P405, DOI 10.1007/s13402-020-00576-8
   Song Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/1321973
   Stemmler MP, 2019, NAT CELL BIOL, V21, P102, DOI 10.1038/s41556-018-0196-y
   Su J, 2020, NATURE, V577, P566, DOI 10.1038/s41586-019-1897-5
   Sun HL, 2019, ONCOTARGETS THER, V12, P10227, DOI 10.2147/OTT.S226580
   Sun LN, 2013, JNCI-J NATL CANCER I, V105, P887, DOI 10.1093/jnci/djt118
   Sun T, 2021, MOL CANCER RES, V19, P429, DOI 10.1158/1541-7786.MCR-20-0557
   Sun XD, 2020, CANCER MED-US, V9, P8685, DOI 10.1002/cam4.3510
   Sun Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24061131
   Sun YM, 2015, MOL MED REP, V11, P1975, DOI 10.3892/mmr.2014.2913
   Sun YY, 2018, MOL CARCINOGEN, V57, P752, DOI 10.1002/mc.22797
   Tan YY, 2020, BMC COMPLEMENT MED, V20, DOI 10.1186/s12906-020-03177-y
   Tang XL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00396-9
   Tao YK, 2021, NANOMEDICINE-UK, V16, DOI 10.2217/nnm-2020-0096
   Teixeira FCOB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.559554
   Thomas SK, 2020, EBIOMEDICINE, V53, DOI 10.1016/j.ebiom.2020.102662
   Thongchot S, 2018, CANCER LETT, V430, P160, DOI 10.1016/j.canlet.2018.05.031
   Tian JH, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112128
   Torregrosa-Munumer R, 2021, EUR J NUTR, V60, P2683, DOI 10.1007/s00394-020-02457-0
   Touchefeu Y, 2019, GASTRIC CANCER, V22, P577, DOI 10.1007/s10120-018-0885-z
   Tsai JH, 2013, TOXICOL APPL PHARM, V272, P746, DOI 10.1016/j.taap.2013.07.019
   Vadlamudi Y, 2020, CURR CANCER DRUG TAR, V20, P654, DOI 10.2174/1568009620666200621153831
   Vaquero J, 2020, CURR OPIN GASTROEN, V36, P63, DOI 10.1097/MOG.0000000000000609
   Vergara D, 2017, MOL BIOSYST, V13, P1131, DOI 10.1039/c7mb00128b
   Vergara D, 2011, CANCER LETT, V310, P1, DOI 10.1016/j.canlet.2011.04.009
   Wang HY, 2013, TOXICOLOGY, V303, P139, DOI 10.1016/j.tox.2012.09.017
   Wang XY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01840-x
   Wen FC, 2014, CARCINOGENESIS, V35, P1481, DOI 10.1093/carcin/bgu009
   Wu JR, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0149-8
   Xiao Y, 2020, CELL TRANSPLANT, V29, DOI 10.1177/0963689720929987
   Xie BW, 2019, CANCER LETT, V443, P56, DOI 10.1016/j.canlet.2018.11.019
   Fan X, 2021, INT J CANCER, V148, P3060, DOI 10.1002/ijc.33494
   Xu JH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0487-8
   Xu QH, 2020, ANTI-CANCER AGENT ME, V20, P1105, DOI 10.2174/1871520620666200402080034
   Yang MT, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/3296192
   Yang XX, 2020, ONCOTARGETS THER, V13, P4665, DOI 10.2147/OTT.S245681
   Yang ZY, 2019, EXP THER MED, V17, P1569, DOI 10.3892/etm.2018.7142
   Saglam ASY, 2021, MOL BIOL REP, V48, P475, DOI 10.1007/s11033-020-06078-y
   Yin L, 2020, HUM CELL, V33, P652, DOI 10.1007/s13577-020-00339-5
   Yu YH, 2013, ONCOGENE, V32, P431, DOI 10.1038/onc.2012.74
   Yuan L, 2019, MOL MED REP, V20, P2783, DOI 10.3892/mmr.2019.10528
   Zhang JX, 2018, FREE RADICAL RES, V52, P1432, DOI 10.1080/10715762.2018.1500020
   Zhang MN, 2019, CANCER LETT, V459, P168, DOI 10.1016/j.canlet.2019.05.039
   Zhang Q, 2021, J INFLAMM RES, V14, P217, DOI 10.2147/JIR.S287242
   Zhu WZ, 2012, NUTR CANCER, V64, P393, DOI 10.1080/01635581.2012.654926
   Zimmermann RC, 2020, CANCER METAST REV, V39, P755, DOI 10.1007/s10555-020-09871-0
NR 163
TC 4
Z9 4
U1 7
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 16
PY 2021
VL 11
AR 644134
DI 10.3389/fonc.2021.644134
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RV0PR
UT WOS:000645540300001
PM 33937049
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chan, YT
   Cheung, F
   Zhang, C
   Fu, BW
   Tan, HY
   Norimoto, H
   Wang, N
   Feng, YB
AF Chan, Yau-Tuen
   Cheung, Fan
   Zhang, Cheng
   Fu, Bowen
   Tan, Hor-Yue
   Norimoto, Hisayoshi
   Wang, Ning
   Feng, Yibin
TI Ancient Chinese Medicine Herbal Formula Huanglian Jiedu Decoction as a
   Neoadjuvant Treatment of Chemotherapy by Improving Diarrhea and Tumor
   Response
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Huanglian Jiedu decoction; chemotherapy-induced diarrhea;
   5-fluorouracil; irinotecan; tumor response
ID GASTROINTESTINAL TOXICITY; IRINOTECAN; CANCER; 5-FLUOROURACIL;
   REGENERATION; AUTOPHAGY; MODULATOR; INJURY; RATS
AB Background
   Diarrhea is a major gastrointestinal complication in cancer patients receiving chemotherapy. Prognosis and treatment of chemotherapy-induced diarrhea (CID) remain unsatisfactory. This study aims to explore the potential of an ancient Chinese Medicine herbal formula Huanglian Jiedu Decoction (HLJDD) as an adjuvant treatment on CID.
   Method
   HLJDD extract was prepared by GMP manufacturing standard with quality and stability being checked. 5-fluorouracil (5-Fu) and irinotecan (CPT-11)-induced diarrhea model in mice was established and pre-, co- and post-treatment of HLJDD was implemented. Mechanism of action was explored by detecting related protein expression. In addition, the effect of HLJDD on diarrhea and tumor response induced by clinical regimens FOLFOX and FOLFIRI was measured in murine orthotopic colorectal cancer model.
   Results
   HLJDD exhibited consistency in quality and stability after 24-month storage. Pre-treatment of HLJDD, but not co-treatment or post-treatment, could significantly improve the diarrhea score, body weight loss and intestinal damage in 5-Fu- and CPT-11-treated mice. Pre-treatment of HLJDD reduced cell apoptosis in the intestine of chemotherapy-treated mice, and promoted renewal of intestinal cell wall. CD44 was predicted as the potential target of HLJDD-containing compounds in CID. HLJDD pre-treatment induced presentation of CD44-postive cells in the intestine of chemotherapy-treated mice, and initiated expression of stemness-associated genes. Transcriptional products of the downstream Wnt signaling of CD44 were elevated. Furthermore, pre-treatment of HLJDD could significantly improve the tumor response of clinical chemotherapy regimens FOLFOX and FOLFIRI in orthotopic colorectal cancer, and reduce diarrhea and intestinal damage. Conclusion: Our study suggests the potential of HLJDD as a neoadjuvant treatment of chemotherapy by reducing diarrhea and improving tumor response.
C1 [Chan, Yau-Tuen; Cheung, Fan; Zhang, Cheng; Fu, Bowen; Tan, Hor-Yue; Wang, Ning; Feng, Yibin] Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China.
   [Norimoto, Hisayoshi] PuraPharm Int HK Ltd, Shatin, Hong Kong, Peoples R China.
RP Feng, YB (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Sch Chinese Med, Pokfulam, Hong Kong, Peoples R China.
EM yfeng@hku.hk
FU Research Grant Council, HKSARHong Kong Research Grants Council [RGC GRF
   17152116]; Commissioner for Innovation Technology, HKSAR [ITS/091/16FX];
   Health and Medical Research Fund (HMRF) [15162961, 16172751]
FX This study was supported by Research Grant Council, HKSAR (Project code:
   RGC GRF 17152116), Commissioner for Innovation Technology, HKSAR
   (Project code: ITS/091/16FX), and Health and Medical Research Fund
   (HMRF, project code: 15162961 and 16172751).
CR Andreyev J, 2014, LANCET ONCOL, V15, pE447, DOI 10.1016/S1470-2045(14)70006-3
   Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132
   Chen MY, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.02380
   Chen X, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004520.pub7
   Conti JA, 1996, J CLIN ONCOL, V14, P709, DOI 10.1200/JCO.1996.14.3.709
   Dekaney CM, 2009, AM J PHYSIOL-GASTR L, V297, pG461, DOI 10.1152/ajpgi.90446.2008
   Di Fiore F, 2009, BEST PRACT RES CL GA, V23, P113, DOI 10.1016/j.bpg.2008.11.016
   Gou H, 2016, HUM EXP TOXICOL, V35, P1243, DOI 10.1177/0960327115627686
   Hu YH, 2013, J ETHNOPHARMACOL, V150, P1137, DOI 10.1016/j.jep.2013.10.038
   Joosten SPJ, 2017, GASTROENTEROLOGY, V153, P1040, DOI 10.1053/j.gastro.2017.07.008
   Kojouharov BM, 2014, ONCOTARGET, V5, P802, DOI 10.18632/oncotarget.1773
   Kummar S, 2011, CLIN COLORECTAL CANC, V10, P85, DOI 10.1016/j.clcc.2011.03.003
   Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270
   Lee CS, 2014, WORLD J GASTROENTERO, V20, P3751, DOI 10.3748/wjg.v20.i14.3751
   Lenfers BHM, 1999, ANN ONCOL, V10, P1251, DOI 10.1023/A:1008390308416
   Levine B, 2019, CELL, V176, P11, DOI 10.1016/j.cell.2018.09.048
   Li HL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00455
   Mishra AP, 2018, MOL DIAGN THER, V22, P281, DOI 10.1007/s40291-018-0329-9
   Mitchell EP, 2006, SEMIN ONCOL, V33, P106, DOI 10.1053/j.seminoncol.2005.12.001
   Mok TSK, 2007, ANN ONCOL, V18, P768, DOI 10.1093/annonc/mdl465
   Pearson JS, 2013, NATURE, V501, P247, DOI 10.1038/nature12524
   Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
   Robinson SM, 2013, BRIT J CANCER, V109, P2396, DOI 10.1038/bjc.2013.604
   Robinson SM, 2013, J HEPATOL, V59, P318, DOI 10.1016/j.jhep.2013.04.014
   Sakai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054788
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Stein Alexander, 2010, Ther Adv Med Oncol, V2, P51, DOI 10.1177/1758834009355164
   Stringer Andrea M, 2007, J Support Oncol, V5, P259
   Su J, 2016, MOL CARCINOGEN, V55, P1962, DOI 10.1002/mc.22443
   Tang ZM, 2019, ANGEW CHEM INT EDIT, V58, P946, DOI 10.1002/anie.201805664
   Tarricone R, 2016, CRIT REV ONCOL HEMAT, V99, P37, DOI 10.1016/j.critrevonc.2015.12.012
   Tseng William, 2007, J Vis Exp, P484, DOI 10.3791/484
   Wang N, 2015, J ETHNOPHARMACOL, V164, P309, DOI 10.1016/j.jep.2015.02.025
   Wang PR, 2013, J ETHNOPHARMACOL, V149, P270, DOI 10.1016/j.jep.2013.06.035
   Watanabe-Fukuda Y, 2009, J GASTROENTEROL, V44, P380, DOI 10.1007/s00535-009-0005-2
   Wei DD, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00458
   Xue HY, 2007, CLIN CANCER RES, V13, P7146, DOI 10.1158/1078-0432.CCR-07-0823
   Zhan YS, 2014, J DIGEST DIS, V15, P425, DOI 10.1111/1751-2980.12157
   Zhang J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0864-6
   Zhang Q, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00165
   Zhang XJ, 2014, PHYTOMEDICINE, V21, P615, DOI 10.1016/j.phymed.2013.11.004
NR 41
TC 9
Z9 9
U1 5
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAR 10
PY 2020
VL 11
AR 252
DI 10.3389/fphar.2020.00252
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA LC8QQ
UT WOS:000525597800001
PM 32210825
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zeng, KX
   Chen, XX
   Xu, M
   Liu, XX
   Hu, XX
   Xu, T
   Sun, HL
   Pan, YQ
   He, BS
   Wang, SK
AF Zeng, Kaixuan
   Chen, Xiaoxiang
   Xu, Mu
   Liu, Xiangxiang
   Hu, Xiuxiu
   Xu, Tao
   Sun, Huiling
   Pan, Yuqin
   He, Bangshun
   Wang, Shukui
TI CircHIPK3 promotes colorectal cancer growth and metastasis by sponging
   miR-7
SO CELL DEATH & DISEASE
LA English
DT Article
ID CIRCULAR RNA; EXPRESSION; MICRORNA-7; ABUNDANT; AUTOPHAGY; MIGRATION;
   REVEALS; GLUCOSE; CELLS
AB Mounting evidences indicate that circular RNAs (circRNAs) have a vital role in human diseases, especially cancers. More recently, circHIPK3, a particularly abundant circRNA, was proposed to be involved in tumorigenesis. However, its role in colorectal cancer (CRC) has not been explored. In this study, we found circHIPK3 was significantly upregulated in CRC tissues and cell lines, at least in part, due to c-Myb overexpression and positively correlated with metastasis and advanced clinical stage. Moreover, Cox multivariate survival analysis showed that high-level expression of circHIPK3 was an independent prognostic factor of poor overall survival (OS) in CRC (hazard ratio [HR] - 2.75, 95% confidence interval [CI] 1.74-6.51, p = 0.009). Functionally, knockdown of circHIPK3 markedly inhibited CRC cells proliferation, migration, invasion, and induced apoptosis in vitro and suppressed CRC growth and metastasis in vivo. Mechanistically, by using biotinylated-circHIPK3 probe to perform RNA pull-down assay in CRC cells, we identified miR7 was the only one microRNA that was abundantly pulled down by circHIPK3 in both HCT116 and HT29 cells and these interactions were also confirmed by biotinylated miR-7 pull-down and dual-luciferase reporter assays. Overexpression of miR-7 mimicked the effect of circHIPK3 knockdown on CRC cells proliferation, migration, invasion, and apoptosis. Furthermore, ectopic expression of circHIPK3 effectively reversed miR-7-induced attenuation of malignant phenotypes of CRC cells by increasing the expression levels of miR-7 targeting proto-oncogenes (FAK, IGF1R, EGFR, YY1). Remarkably, the combination of circHIPK3 silencing and miR-7 overexpression gave a better effect on tumor suppression both in vitro and in vivo than did circHIPK3 knockdown or miR-7 overexpression alone. Taken together, our data indicate that circHIPK3 may have considerable potential as a prognostic biomarker in CRC, and support the notion that therapeutic targeting of the c-Myb/circHIPK3/miR-7 axis may be a promising treatment approach for CRC patients.
C1 [Zeng, Kaixuan; Chen, Xiaoxiang; Xu, Mu; Liu, Xiangxiang; Hu, Xiuxiu; Xu, Tao; Sun, Huiling; Pan, Yuqin; He, Bangshun; Wang, Shukui] Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Jiangsu, Peoples R China.
   [Zeng, Kaixuan; Chen, Xiaoxiang; Wang, Shukui] Southeast Univ, Sch Med, Nanjing 210009, Peoples R China.
RP Wang, SK (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Gen Clin Res Ctr, Nanjing 210006, Jiangsu, Peoples R China.; Wang, SK (corresponding author), Southeast Univ, Sch Med, Nanjing 210009, Peoples R China.
EM sk_wang@njmu.edu.cn
FU National Nature Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81472027, 81501820]; Key Project of Science
   and Technology Development of Nanjing Medicine [ZDX16005]
FX This project was supported by grants from the National Nature Science
   Foundation of China (Nos. 81472027, 81501820) to S.W. and Y.P.; Key
   Project of Science and Technology Development of Nanjing Medicine
   (ZDX16005). Innovation team of Jiangsu provincial health-strengthening
   engineering by science and education to S.W.
CR Bhere D, 2018, NEURO-ONCOLOGY, V20, P215, DOI 10.1093/neuonc/nox138
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen J, 2017, CANCER LETT, V388, P208, DOI 10.1016/j.canlet.2016.12.006
   Chen L, 2017, ONCOGENE, V36, P4551, DOI 10.1038/onc.2017.89
   Cui YX, 2017, BRIT J CANCER, V117, P89, DOI 10.1038/bjc.2017.156
   Dienstmann Rodrigo, 2017, Nat Rev Cancer, V17, P268, DOI 10.1038/nrc.2017.24
   Fu LY, 2017, ONCOTARGET, V8, P43878, DOI 10.18632/oncotarget.16709
   Gu DN, 2017, CANCER LETT, V400, P69, DOI 10.1016/j.canlet.2017.04.020
   Gu DN, 2015, EXPERT OPIN THER TAR, V19, P415, DOI 10.1517/14728222.2014.988708
   Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883
   Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Kabir TD, 2018, HEPATOLOGY, V67, P216, DOI 10.1002/hep.29478
   Kristensen LS, 2018, ONCOGENE, V37, P555, DOI 10.1038/onc.2017.361
   Lee YH, 2016, J DENT RES, V95, P430, DOI 10.1177/0022034515622139
   Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581
   Liang DM, 2014, GENE DEV, V28, P2233, DOI 10.1101/gad.251926.114
   Liu YC, 2016, NUCLEIC ACIDS RES, V44, pD209, DOI 10.1093/nar/gkv940
   Malaterre J, 2016, ONCOGENE, V35, P2475, DOI 10.1038/onc.2015.305
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Pekarcikova L, 2016, CELL SIGNAL, V28, P924, DOI [10.1016/j.cellsig2016.04.007, 10.1016/j.cellsig.2016.04.007]
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078
   Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439
   Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027
   Shan K, 2017, CIRCULATION, V136, P1629, DOI 10.1161/CIRCULATIONAHA.117.029004
   Sun Y, 2017, CIRC RES, V121, P628, DOI 10.1161/CIRCRESAHA.117.311441
   Suto T, 2015, CARCINOGENESIS, V36, P338, DOI 10.1093/carcin/bgu242
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Wang K, 2016, EUR HEART J, V37, P2602, DOI 10.1093/eurheartj/ehv713
   Wei XF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.541
   Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541
   Yu CY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01216-w
   Zeng KX, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1185582
   Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001
   Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215
   Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919
   Zhu JL, 2017, TRANSL ONCOL, V10, P271, DOI 10.1016/j.tranon.2016.12.006
NR 42
TC 379
Z9 393
U1 13
U2 80
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR 16
PY 2018
VL 9
AR 417
DI 10.1038/s41419-018-0454-8
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA FZ7BY
UT WOS:000427755700005
PM 29549306
OA gold, Green Published
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Chen, XR
   Zhang, L
   Ding, SP
   Lei, QF
   Fang, WJ
AF Chen, Xuerui
   Zhang, Li
   Ding, Shiping
   Lei, Qunfang
   Fang, Wenjun
TI Cisplatin combination drugs induce autophagy in HeLa cells and interact
   with HSA via electrostatic binding affinity
SO RSC ADVANCES
LA English
DT Article
ID COLORECTAL-CANCER CELLS; HUMAN SERUM-ALBUMIN; INDUCED APOPTOSIS; SILVER
   NANOPARTICLES; ANTITUMOR-ACTIVITY; IN-VITRO; INHIBITION; DEATH;
   CYTOTOXICITY; PATHWAY
AB Cisplatin, as a significant chemotherapeutic drug for the treatment of cancers, was combined with rapamycin (RAPA), an autophagy inducer, or 3-methyladenine (3-MA), an autophagy inhibitor, and these cisplatin combination drugs were tested with HeLa cells to explore their specific effects on autophagy by cell viability assay, mitochondria membrane potential (MMP) determination, transmission electron microscopic (TEM) observation, dansylcadaverine (MDC) staining, and western blotting analysis. Results revealed that cisplatin combination drugs enhanced formation of autophagosomes, and morphological and biochemical markers of autophagy in HeLa cells can be clearly determined with the formation of enlarged acidic vesicles and conversion of light chain 3 (LC3) protein. Cisplatin combination drugs induce stronger effects on autophagy than either of the components does. Combination drug-induced autophagy inhibits the growth of HeLa cell in a dose-dependent manner and subsequently sensitizes the cells to apoptosis and cell death. Furthermore, interactions between cisplatin combination drugs and human serum albumin (HSA) were investigated under fluorescence, synchronous fluorescence, and circular dichroism analysis. Results suggest that cisplatin combination drugs can bind to HSA and induce conformation and microenvironmental changes of HSA via electrostatic binding affinity. These investigations can provide useful and fundamental information, which could be used in cytotoxic chemotherapy to dramatically increase efficacy in pharmaceutical and biotechnology fields.
C1 [Chen, Xuerui; Zhang, Li; Lei, Qunfang; Fang, Wenjun] Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
   [Ding, Shiping] Zhejiang Univ, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.
RP Lei, QF; Fang, WJ (corresponding author), Zhejiang Univ, Dept Chem, Hangzhou 310027, Zhejiang, Peoples R China.
EM qflei@zju.edu.cn; fwjun@zju.edu.cn
OI Chen, Xuerui/0000-0003-2945-6311
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [21473157]
FX This work was supported by the National Natural Science Foundation of
   China (No. 21473157).
CR Abd-Alla MH, 2016, AGR ECOSYST ENVIRON, V218, P163, DOI 10.1016/j.agee.2015.11.022
   Bae-Jump VL, 2009, CANCER-AM CANCER SOC, V115, P3887, DOI 10.1002/cncr.24431
   Barraud M, 2016, ONCOTARGET, V7, P53783, DOI 10.18632/oncotarget.10776
   Bergmann A, 2007, CELL, V131, P1032, DOI 10.1016/j.cell.2007.11.027
   Bjorklund M, 2011, CANCER CHEMOTH PHARM, V68, P1459, DOI 10.1007/s00280-011-1640-x
   Bolattin MB, 2016, J MOL RECOGNIT, V29, P308, DOI 10.1002/jmr.2532
   Campone M, 2009, BRIT J CANCER, V100, P315, DOI 10.1038/sj.bjc.6604851
   Chennoufi R, 2015, CHEM COMMUN, V51, P14881, DOI 10.1039/c5cc05970d
   Choi AR, 2016, ANTICANCER RES, V36, P1641
   Chou TC, 2007, PHARMACOL REV, V59, P124
   Claerhout S, 2010, INT J CANCER, V127, P2790, DOI 10.1002/ijc.25300
   Dong XZ, 2015, ANTI-CANCER DRUG, V26, P331, DOI 10.1097/CAD.0000000000000193
   Fazi B, 2008, AUTOPHAGY, V4, P435, DOI 10.4161/auto.5669
   Fuertes MA, 2003, CHEM REV, V103, P645, DOI 10.1021/cr020010d
   Gao J, 2015, TOXICOLOGY, V337, P21, DOI 10.1016/j.tox.2015.08.011
   Gu J, 2016, INT IMMUNOPHARMACOL, V32, P1, DOI 10.1016/j.intimp.2016.01.002
   Guo ST, 2014, ACS NANO, V8, P4996, DOI 10.1021/nn5010815
   Guo YQ, 2015, MOL MED REP, V12, P3681, DOI 10.3892/mmr.2015.3860
   Ha SW, 2014, ACS NANO, V8, P5898, DOI 10.1021/nn5009879
   Han L, 2012, WSPOLCZESNA ONKOL, V16, P512, DOI 10.5114/wo.2012.32483
   Hartman ML, 2010, J THORAC CARDIOV SUR, V139, P1233, DOI 10.1016/j.jtcvs.2009.06.027
   Jiang K, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-551
   Kabir MZ, 2016, J PHOTOCH PHOTOBIO B, V160, P229, DOI 10.1016/j.jphotobiol.2016.04.005
   Kim JH, 2013, BIOCHEM BIOPH RES CO, V441, P655, DOI 10.1016/j.bbrc.2013.10.095
   Kim WK, 2016, J NAT PROD, V79, P1097, DOI 10.1021/acs.jnatprod.6b00006
   Kong LJ, 2015, J PHARM INNOV, V10, P13, DOI 10.1007/s12247-014-9199-9
   Lee YH, 2014, BIOMATERIALS, V35, P4706, DOI 10.1016/j.biomaterials.2014.02.021
   Li H, 2017, ACTA PHARMACOL SIN, V38, P252, DOI 10.1038/aps.2016.101
   Li RB, 2014, ACS NANO, V8, P10280, DOI 10.1021/nn505002w
   Li YY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09288
   Liu MP, 2016, SCI REP-UK, V6, DOI 10.1038/srep34245
   Ly JD, 2003, APOPTOSIS, V8, P115, DOI 10.1023/A:1022945107762
   Manov I, 2011, FEBS J, V278, P3494, DOI 10.1111/j.1742-4658.2011.08271.x
   Martin MD, 2015, ACS CHEM BIOL, V10, P1099, DOI 10.1021/cb501013w
   Obakan P, 2015, TURK J BIOL, V39, P712, DOI 10.3906/biy-1501-18
   Oshiro S, 2014, ACS CHEM BIOL, V9, P1052, DOI 10.1021/cb400946m
   Pawlik A, 2016, EUR J NUTR, V55, P1165, DOI 10.1007/s00394-015-0930-1
   Peynshaert K, 2014, CHEM REV, V114, P7581, DOI 10.1021/cr400372p
   Plimack ER, 2015, EUR UROL, V68, P959, DOI 10.1016/j.eururo.2015.07.009
   Shi SM, 2016, ONCOL REP, V35, P2606, DOI 10.3892/or.2016.4680
   Shigematsu H, 2010, INT J CANCER, V126, P2716, DOI 10.1002/ijc.24990
   Sun TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043442
   Tsai JP, 2015, ONCOTARGET, V6, P28851, DOI 10.18632/oncotarget.4767
   Wang WG, 2011, CANCER BIOL THER, V12, P229, DOI 10.4161/cbt.12.3.17033
   Zajkowicz A, 2015, CELL SIGNAL, V27, P1677, DOI 10.1016/j.cellsig.2015.05.005
   Zhang RJ, 2015, MOL MED REP, V12, P1727, DOI 10.3892/mmr.2015.3588
   Zhang SS, 2016, COLLOID SURFACE A, V495, P30, DOI 10.1016/j.colsurfa.2016.01.051
   Zhang SS, 2015, LANGMUIR, V31, P12161, DOI 10.1021/acs.langmuir.5b01430
   Zhang ZC, 2015, ONCOL LETT, V10, P2941, DOI 10.3892/ol.2015.3692
   Zhao S, 2012, INT J MOL MED, V30, P939, DOI 10.3892/ijmm.2012.1066
NR 50
TC 5
Z9 6
U1 1
U2 23
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2017
VL 7
IS 36
BP 22270
EP 22279
DI 10.1039/c7ra00056a
PG 10
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA ET3DO
UT WOS:000400157700031
OA gold
DA 2022-04-25
ER

PT J
AU Li, XH
   Ma, L
   Huang, K
   Wei, YL
   Long, SD
   Liu, QY
   Zhang, DQ
   Wu, SY
   Wang, WR
   Yang, G
   Zhou, HG
   Yang, C
AF Li, Xiaohe
   Ma, Ling
   Huang, Kai
   Wei, Yuli
   Long, Shida
   Liu, Qinyi
   Zhang, Deqiang
   Wu, Shuyang
   Wang, Wenrui
   Yang, Guang
   Zhou, Honggang
   Yang, Cheng
TI Regorafenib-Attenuated, Bleomycin-Induced Pulmonary Fibrosis by
   Inhibiting the TGF-beta 1 Signaling Pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE pulmonary fibrosis; regorafenib; myofibroblasts; TGF-&#946; 1 signaling
   pathway
AB Idiopathic pulmonary fibrosis (IPF) is a fatal and age-related pulmonary disease. Nintedanib is a receptor tyrosine kinase inhibitor, and one of the only two listed drugs against IPF. Regorafenib is a novel, orally active, multi-kinase inhibitor that has similar targets to nintedanib and is applied to treat colorectal cancer and gastrointestinal stromal tumors in patients. In this study, we first identified that regorafenib could alleviate bleomycin-induced pulmonary fibrosis in mice. The in vivo experiments indicated that regorafenib suppresses collagen accumulation and myofibroblast activation. Further in vitro mechanism studies showed that regorafenib inhibits the activation and migration of myofibroblasts and extracellular matrix production, mainly through suppressing the transforming growth factor (TGF)-beta 1/Smad and non-Smad signaling pathways. In vitro studies have also indicated that regorafenib could augment autophagy in myofibroblasts by suppressing TGF-beta 1/mTOR (mechanistic target of rapamycin) signaling, and could promote apoptosis in myofibroblasts. In conclusion, regorafenib attenuates bleomycin-induced pulmonary fibrosis by suppressing the TGF-beta 1 signaling pathway.
C1 [Li, Xiaohe; Ma, Ling; Huang, Kai; Wei, Yuli; Long, Shida; Liu, Qinyi; Zhang, Deqiang; Wu, Shuyang; Wang, Wenrui; Yang, Guang; Zhou, Honggang; Yang, Cheng] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin 300353, Peoples R China.
   [Li, Xiaohe; Ma, Ling; Huang, Kai; Wei, Yuli; Long, Shida; Liu, Qinyi; Zhang, Deqiang; Wu, Shuyang; Wang, Wenrui; Yang, Guang; Zhou, Honggang; Yang, Cheng] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300353, Peoples R China.
   [Li, Xiaohe; Ma, Ling; Zhou, Honggang; Yang, Cheng] Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin 300457, Peoples R China.
RP Yang, G; Zhou, HG; Yang, C (corresponding author), Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin 300353, Peoples R China.; Yang, G; Zhou, HG; Yang, C (corresponding author), Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300353, Peoples R China.; Zhou, HG; Yang, C (corresponding author), Tianjin Int Joint Acad Biomed, Tianjin Key Lab Mol Drug Res, Tianjin 300457, Peoples R China.
EM lixiaohe908@163.com; mal930602@163.com; kaihuang0819@163.com;
   weiyuli2021@126.com; starlongsd@163.com; jiukn365@126.com;
   13345278851@163.com; shuyang_wu@163.com; wwr15641208039@163.com;
   Guang.yang@nankai.edu.cn; honggang.zhou@nankai.edu.cn;
   cheng.yang@nankai.edu.cn
OI Liu, Qinyi/0000-0001-5439-7849
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [82072660, 82070060, 82000073]
FX This study was supported by The National Natural Science Foundation of
   China (grants 82072660, 82070060, 82000073).
CR Arai H, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101912
   Aschner Y, 2016, AM J RESP CELL MOL, V54, P647, DOI 10.1165/rcmb.2015-0391TR
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Ettrich Thomas J, 2018, Recent Results Cancer Res, V211, P45, DOI 10.1007/978-3-319-91442-8_3
   Fernandez Isis E, 2012, Proc Am Thorac Soc, V9, P111, DOI 10.1513/pats.201203-023AW
   Frangogiannis NG, 2020, J EXP MED, V217, DOI 10.1084/jem.20190103
   Ghavami S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.36
   Gilhodes JC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170561
   Goss CH, 2004, AM J RESP CRIT CARE, V169, P816, DOI 10.1164/rccm.200306-779OC
   Gupta SS, 2016, ONCOTARGET, V7, P78516, DOI 10.18632/oncotarget.12392
   Horowitz Jeffrey C, 2006, Treat Respir Med, V5, P325, DOI 10.2165/00151829-200605050-00004
   Jiang DH, 2004, J CLIN INVEST, V114, P291, DOI 10.1172/JCI200416861
   Jiang JW, 2020, AUTOPHAGY, V16, P106, DOI 10.1080/15548627.2019.1598752
   Karimi-Shah BA, 2015, NEW ENGL J MED, V372, P1189, DOI 10.1056/NEJMp1500526
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kolb M, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1022-1
   KUHN C, 1991, AM J PATHOL, V138, P1257
   Lederer DJ, 2018, NEW ENGL J MED, V378, P1811, DOI 10.1056/NEJMra1705751
   Martinez FJ, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.74
   Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Mi S, 2011, J IMMUNOL, V187, P3003, DOI 10.4049/jimmunol.1004081
   Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6
   Molkentin JD, 2017, CIRCULATION, V136, P549, DOI 10.1161/CIRCULATIONAHA.116.026238
   Ning W, 2004, P NATL ACAD SCI USA, V101, P14895, DOI 10.1073/pnas.0401168101
   Park JS, 2014, BMC PULM MED, V14, DOI 10.1186/1471-2466-14-168
   Patel AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041394
   Richeldi L, 2017, LANCET, V389, P1941, DOI 10.1016/S0140-6736(17)30866-8
   Sgalla G, 2016, RESPIROLOGY, V21, P427, DOI 10.1111/resp.12683
   Upagupta C, 2018, EUR RESPIR REV, V27, DOI 10.1183/16000617.0033-2018
   Wang K, 2018, AUTOPHAGY, V14, P269, DOI 10.1080/15548627.2017.1409405
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wolters PJ, 2014, ANNU REV PATHOL-MECH, V9, P157, DOI 10.1146/annurev-pathol-012513-104706
   Woodcock HV, 2019, NAT COMMUN, V10, DOI [10.1038/s41467-018-07858-8, 10.1038/s41467-020-18621-3]
   Xaubet A, 2003, AM J RESP CRIT CARE, V168, P431, DOI 10.1164/rccm.200210-1165OC
   Zhang HY, 1999, AM J RESP CELL MOL, V21, P658, DOI 10.1165/ajrcmb.21.6.3720
NR 35
TC 3
Z9 3
U1 6
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2021
VL 22
IS 4
AR 1985
DI 10.3390/ijms22041985
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA QP4GS
UT WOS:000623795300001
PM 33671452
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, B
   Huang, QL
   Wei, GH
AF Li, Bo
   Huang, Qilai
   Wei, Gong-Hong
TI The Role of HOX Transcription Factors in Cancer Predisposition and
   Progression
SO CANCERS
LA English
DT Review
DE HOX; cancer susceptibility; risk SNP; coding mutation; regulatory SNP;
   mechanism
ID LONG NONCODING RNA; GENETIC SUSCEPTIBILITY LOCI; GENOME-WIDE
   ASSOCIATION; PROSTATE-CANCER; BREAST-CANCER; COLORECTAL-CANCER; GERMLINE
   MUTATION; OVARIAN-CANCER; MALIGNANT PROGRESSION; EPIGENETIC REGULATION
AB Homeobox (HOX) transcription factors, encoded by a subset of homeodomain superfamily genes, play pivotal roles in many aspects of cellular physiology, embryonic development, and tissue homeostasis. Findings over the past decade have revealed that mutations in HOX genes can lead to increased cancer predisposition, and HOX genes might mediate the effect of many other cancer susceptibility factors by recognizing or executing altered genetic information. Remarkably, several lines of evidence highlight the interplays between HOX transcription factors and cancer risk loci discovered by genome-wide association studies, thereby gaining molecular and biological insight into cancer etiology. In addition, deregulated HOX gene expression impacts various aspects of cancer progression, including tumor angiogenesis, cell autophagy, proliferation, apoptosis, tumor cell migration, and metabolism. In this review, we will discuss the fundamental roles of HOX genes in cancer susceptibility and progression, highlighting multiple molecular mechanisms of HOX involved gene misregulation, as well as their potential implications in clinical practice.
C1 [Li, Bo; Huang, Qilai] Shandong Univ, Sch Life Sci, Shandong Prov Key Lab Anim Cell & Dev Biol, Qingdao 266237, Shandong, Peoples R China.
   [Wei, Gong-Hong] Univ Oulu, Bioctr Oulu, Fac Biochem & Mol Med, SF-90220 Oulu, Finland.
RP Huang, QL (corresponding author), Shandong Univ, Sch Life Sci, Shandong Prov Key Lab Anim Cell & Dev Biol, Qingdao 266237, Shandong, Peoples R China.; Wei, GH (corresponding author), Univ Oulu, Bioctr Oulu, Fac Biochem & Mol Med, SF-90220 Oulu, Finland.
EM libo1051@163.com; qlhuang@sdu.edu.cn; gonghong.wei@oulu.fi
RI ; Huang, Qilai/B-4725-2015
OI Wei, Gong-Hong/0000-0001-6546-9334; Huang, Qilai/0000-0002-4252-3980
FU Shandong Provincial Natural Science Foundation, ChinaNatural Science
   Foundation of Shandong Province [ZR2016CM50]; Academy of FinlandAcademy
   of Finland; Finnish Cancer Foundation; Jane and Aatos Erkkos Foundation
FX This work was supported by the grants Shandong Provincial Natural
   Science Foundation, China, ZR2016CM50, the Academy of Finland, the
   Finnish Cancer Foundation, and the Jane and Aatos Erkkos Foundation.
CR Abdel-Wahab O, 2012, CANCER CELL, V22, P180, DOI 10.1016/j.ccr.2012.06.032
   Akbari MR, 2013, CANCER EPIDEMIOL, V37, P424, DOI 10.1016/j.canep.2013.03.003
   Al Olama AA, 2013, HUM MOL GENET, V22, P408, DOI 10.1093/hmg/dds425
   Alanee S, 2012, NEW ENGL J MED, V367, P480, DOI 10.1056/NEJMc1205138
   Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603
   Bach C, 2010, BLOOD, V115, P2910, DOI 10.1182/blood-2009-04-216606
   Beebe-Dimmer JL, 2015, CANCER EPIDEM BIOMAR, V24, P1366, DOI 10.1158/1055-9965.EPI-15-0247
   Bejar R, 2011, NEW ENGL J MED, V364, P2496, DOI 10.1056/NEJMoa1013343
   Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024
   Bjornsson JM, 2001, BLOOD, V98, P3301, DOI 10.1182/blood.V98.12.3301
   Botezatu L, 2016, EXP HEMATOL, V44, P713, DOI 10.1016/j.exphem.2016.05.004
   Brechka H, 2017, GENES DIS, V4, P75, DOI 10.1016/j.gendis.2017.01.003
   Brennan P, 2011, LANCET ONCOL, V12, P399, DOI 10.1016/S1470-2045(10)70126-1
   Brock A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007048
   Brunetti L, 2018, CANCER CELL, V34, P499, DOI 10.1016/j.ccell.2018.08.005
   Care A, 2001, CANCER RES, V61, P6532
   Chandrasekaran G, 2017, SCI REP-UK, V7, DOI 10.1038/srep43830
   Chen D, 2015, TRENDS GENET, V31, P41, DOI 10.1016/j.tig.2014.10.005
   Chen HT, 2018, PROSTATE, V78, P186, DOI 10.1002/pros.23453
   Chen HX, 2007, CANCER RES, V67, P8007, DOI 10.1158/0008-5472.CAN-07-1405
   Chen HX, 2004, MOL CELL BIOL, V24, P924, DOI 10.1128/MCB.24.2.924-935.2004
   Chen LN, 2014, PROSTATE, V74, P714, DOI 10.1002/pros.22790
   Chen LS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089508
   Chen RQ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00594
   Chen YQ, 2019, GENE, V689, P18, DOI 10.1016/j.gene.2018.11.081
   Chen Y, 2008, BLOOD, V111, P1217, DOI 10.1182/blood-2007-07-104133
   Cheng JZ, 2018, CANCER BIOMARK, V23, P107, DOI 10.3233/CBM-181459
   Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848
   Courtnay R, 2015, MOL BIOL REP, V42, P841, DOI 10.1007/s11033-015-3858-x
   Crowther-Swanepoel D, 2010, SEMIN CANCER BIOL, V20, P363, DOI 10.1016/j.semcancer.2010.08.006
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   de Bock CE, 2018, CANCER DISCOV, V8, P616, DOI 10.1158/2159-8290.CD-17-0583
   Deplancke B, 2016, CELL, V166, P538, DOI 10.1016/j.cell.2016.07.012
   Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005
   Edwards S, 2005, BRIT J CANCER, V92, P376, DOI 10.1038/sj.bjc.6602261
   Eeles RA, 2013, NAT GENET, V45, P385, DOI 10.1038/ng.2560
   Ewing CM, 2012, NEW ENGL J MED, V366, P141, DOI 10.1056/NEJMoa1110000
   FitzGerald LM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18217-w
   Frank SA, 2004, NAT REV GENET, V5, P764, DOI 10.1038/nrg1450
   Fujiki K, 2008, GASTROENTEROLOGY, V135, P907, DOI 10.1053/j.gastro.2008.06.034
   Gabriely G, 2011, AUTOPHAGY, V7, P1384, DOI 10.4161/auto.7.11.17371
   Gao P, 2018, CELL, V174, P576, DOI 10.1016/j.cell.2018.06.003
   Gao P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061239
   Garcia-Closas M, 2008, CLIN CANCER RES, V14, P8000, DOI 10.1158/1078-0432.CCR-08-0975
   Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534
   Goode LL, 2010, NAT GENET, V42, P874, DOI 10.1038/ng.668
   Gough SM, 2014, CANCER DISCOV, V4, P564, DOI 10.1158/2159-8290.CD-13-0419
   Gough SM, 2011, BLOOD, V118, P6247, DOI 10.1182/blood-2011-07-328880
   Guo LY, 2017, ONCOTARGET, V8, P103410, DOI 10.18632/oncotarget.21902
   Guo XG, 2019, J CELL PHYSIOL, V234, P3478, DOI 10.1002/jcp.26828
   Hahn WC, 1999, NAT MED, V5, P1164, DOI 10.1038/13495
   Han Y, 2015, HUM MOL GENET, V24, P5603, DOI 10.1093/hmg/ddv269
   Hatanaka Y, 2019, PROSTATE, V79, DOI 10.1002/pros.23761
   Hayano T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164233
   Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107
   Heinonen H, 2015, INT J CANCER, V137, P2374, DOI 10.1002/ijc.29616
   Heubach J, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0371-8
   Hoffmann TJ, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004930
   Horton SJ, 2005, CANCER RES, V65, P9245, DOI 10.1158/0008-5472.CAN-05-1691
   Hsu K, 2003, CANCER CELL, V4, P81, DOI 10.1016/S1535-6108(03)00192-2
   Hua JT, 2018, CELL, V174, P564, DOI 10.1016/j.cell.2018.06.014
   Huan HB, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0559-4
   Huang HP, 2016, INT J MOL MED, V37, P669, DOI 10.3892/ijmm.2016.2480
   Huang QL, 2014, NAT GENET, V46, P126, DOI 10.1038/ng.2862
   Jiang Y, 2015, ONCOGENE, V34, P6079, DOI 10.1038/onc.2015.53
   Jogi A, 2012, UPSALA J MED SCI, V117, P217, DOI 10.3109/03009734.2012.659294
   Johng D, 2019, PROSTATE, V79, P414, DOI 10.1002/pros.23747
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Jung C, 2005, BRIT J CANCER, V92, P2233, DOI 10.1038/sj.bjc.6602631
   Karlsson A, 2014, CLIN CANCER RES, V20, P6127, DOI 10.1158/1078-0432.CCR-14-1087
   Karlsson R, 2014, EUR UROL, V65, P169, DOI 10.1016/j.eururo.2012.07.027
   Kelemen LE, 2015, NAT GENET, V47, P888, DOI 10.1038/ng.3336
   Khandanpour C, 2012, BLOOD, V120, P4006, DOI 10.1182/blood-2011-02-334722
   Khandanpour C, 2010, BLOOD, V115, P2462, DOI 10.1182/blood-2009-08-239822
   Kim JC, 2016, CANCER RES, V76, P6424, DOI 10.1158/0008-5472.CAN-16-1571
   Kote-Jarai Z, 2015, ANN ONCOL, V26, P756, DOI 10.1093/annonc/mdv004
   Krishnaraju K, 1997, BLOOD, V90, P1840, DOI 10.1182/blood.V90.5.1840
   Kron KJ, 2017, NAT GENET, V49, P1336, DOI 10.1038/ng.3930
   Lai CK, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.86
   Lawrenson K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9234
   Li J, 2019, J CELL BIOCHEM, V120, P7056, DOI 10.1002/jcb.27975
   Li LL, 2018, CLIN CHIM ACTA, V487, P197, DOI 10.1016/j.cca.2018.10.002
   Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Lin XL, 2013, PROSTATE, V73, P169, DOI 10.1002/pros.22552
   Lin YH, 2009, BLOOD, V114, P651, DOI 10.1182/blood-2009-03-209395
   Liu S, 2015, CANCER RES, V75, P709, DOI 10.1158/0008-5472.CAN-14-3100
   Liu WJ, 2016, MOL MED REP, V13, P4221, DOI 10.3892/mmr.2016.5086
   Liu YW, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.150
   Lu R, 2016, CANCER CELL, V30, P92, DOI 10.1016/j.ccell.2016.05.008
   Luo ZF, 2019, CANCERS, V11, DOI 10.3390/cancers11030323
   Luo ZF, 2017, CELL REP, V21, P1411, DOI 10.1016/j.celrep.2017.10.048
   Lynch HT, 2013, HUM GENET, V132, P1, DOI 10.1007/s00439-012-1226-7
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Mann RS, 2009, CURR TOP DEV BIOL, V88, P63, DOI 10.1016/S0070-2153(09)88003-4
   Mao L, 2011, CANCER RES, V71, P4314, DOI 10.1158/0008-5472.CAN-11-0051
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Mayle A, 2015, BLOOD, V125, P629, DOI 10.1182/blood-2014-08-594648
   McCormack MP, 2013, BLOOD, V122, P2093, DOI 10.1182/blood-2012-09-458570
   Miao J, 2007, P NATL ACAD SCI USA, V104, P17093, DOI 10.1073/pnas.0707938104
   Mohr S, 2017, CANCER CELL, V31, P549, DOI 10.1016/j.ccell.2017.03.001
   Moon SM, 2012, J BIOL CHEM, V287, P35678, DOI 10.1074/jbc.M112.361675
   Muntean AG, 2012, ANNU REV PATHOL-MECH, V7, P283, DOI 10.1146/annurev-pathol-011811-132434
   Nagel S, 2007, BLOOD, V109, P3015, DOI 10.1182/blood-2006-08-044347
   Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020
   Ordonez-Moran P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001
   Palakurthy RK, 2009, MOL CELL, V36, P219, DOI 10.1016/j.molcel.2009.10.009
   Pawlowska E, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112317
   Peters U, 2013, GASTROENTEROLOGY, V144, P799, DOI 10.1053/j.gastro.2012.12.020
   Pfaltzgraff ER, 2019, CANCERS, V11, DOI 10.3390/cancers11030313
   Pfeifer GP, 2009, SEMIN CANCER BIOL, V19, P181, DOI 10.1016/j.semcancer.2009.02.008
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Pilie PG, 2017, CANCER-AM CANCER SOC, V123, P3925, DOI 10.1002/cncr.30817
   Prokunina-Olsson L, 2010, CANCER EPIDEM BIOMAR, V19, P1349, DOI 10.1158/1055-9965.EPI-09-1181
   Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906
   Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125
   Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103
   Rhoads Kim, 2005, Lymphatic Research and Biology, V3, P240, DOI 10.1089/lrb.2005.3.240
   Richards EJ, 2015, ONCOTARGET, V6, P34745, DOI 10.18632/oncotarget.5784
   Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039
   Schubeler D, 2015, NATURE, V517, P321, DOI 10.1038/nature14192
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Sherborne AL, 2011, HAEMATOL-HEMATOL J, V96, P1049, DOI 10.3324/haematol.2011.040121
   Shields BJ, 2019, LEUKEMIA, V33, P1868, DOI 10.1038/s41375-018-0361-0
   Shui IM, 2014, EUR UROL, V65, P1069, DOI 10.1016/j.eururo.2013.12.058
   Sibin MK, 2017, J MOL NEUROSCI, V61, P144, DOI 10.1007/s12031-016-0855-z
   Sipeky C, 2018, CLIN CANCER RES, V24, P6265, DOI 10.1158/1078-0432.CCR-18-0444
   Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017
   Spisak S, 2015, NAT MED, V21, P1357, DOI 10.1038/nm.3975
   Steger J, 2015, LEUKEMIA, V29, P901, DOI 10.1038/leu.2014.287
   Stiegelbauer V, 2017, CLIN CANCER RES, V23, P5255, DOI 10.1158/1078-0432.CCR-17-0023
   Storebjerg TM, 2016, BJU INT, V118, P646, DOI 10.1111/bju.13416
   Storti P, 2011, LEUKEMIA, V25, P527, DOI 10.1038/leu.2010.270
   Strathdee G, 2006, LEUKEMIA, V20, P1326, DOI 10.1038/sj.leu.2404254
   Strathdee G, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004222
   Su JZ, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1492-3
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Sun M, 2016, CANCER RES, V76, P6299, DOI 10.1158/0008-5472.CAN-16-0356
   Sun YQ, 2018, CANCER CELL, V34, P643, DOI 10.1016/j.ccell.2018.08.018
   Svoboda LK, 2014, EPIGENETICS-US, V9, P1613, DOI 10.4161/15592294.2014.988048
   Takeda A, 2006, CANCER RES, V66, P6628, DOI 10.1158/0008-5472.CAN-06-0458
   Taminiau A, 2016, NUCLEIC ACIDS RES, V44, P7331, DOI 10.1093/nar/gkw606
   Tan SH, 2015, CANCER CELL, V28, P683, DOI 10.1016/j.ccell.2015.11.004
   Tan YT, 2016, LEUKEMIA, V30, P1609, DOI 10.1038/leu.2016.15
   Tanwar PS, 2013, CARCINOGENESIS, V34, P893, DOI 10.1093/carcin/bgs405
   Teschendorff AE, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0233-4
   Thim VV, 2005, HUM MUTAT, V25, P384, DOI 10.1002/humu.20155
   Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679
   Tong N, 2014, MUTAT RES-FUND MOL M, V759, P16, DOI 10.1016/j.mrfmmm.2013.11.004
   Tsai KW, 2016, SCI REP-UK, V6, DOI 10.1038/srep28176
   Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796
   Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608
   Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966
   Wang LM, 2016, ONCOTARGET, V7, P45302, DOI 10.18632/oncotarget.9605
   Wang YS, 2019, FASEB J, V33, P3901, DOI 10.1096/fj.201801099RR
   Wang ZF, 2019, ONCOL REP, V41, P1122, DOI 10.3892/or.2018.6874
   Wang Z, 2007, CLIN CANCER RES, V13, P6327, DOI 10.1158/1078-0432.CCR-07-0310
   Weiss FU, 2009, GASTROENTEROLOGY, V137, P2136, DOI 10.1053/j.gastro.2009.08.065
   Wermuth PJ, 2005, BLOOD, V105, P1222, DOI 10.1182/blood-2004-03-0802
   White E, 2015, CLIN CANCER RES, V21, P5037, DOI 10.1158/1078-0432.CCR-15-0490
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   Whitington T, 2016, NAT GENET, V48, P387, DOI 10.1038/ng.3523
   Williams TM, 2005, DEV BIOL, V277, P457, DOI 10.1016/j.ydbio.2004.10.004
   Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169
   Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470
   Xia JH, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1516451
   Xu HM, 2016, CANCER CELL, V30, P863, DOI 10.1016/j.ccell.2016.10.019
   Xuan F, 2016, NEURO-ONCOLOGY, V18, P819, DOI 10.1093/neuonc/nov281
   Xylinas E, 2016, BIOMOLECULES, V6, DOI 10.3390/biom6030037
   Yan TD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02601-1
   Yoshida HY, 2006, CANCER RES, V66, P889, DOI 10.1158/0008-5472.CAN-05-2828
   Zhang EB, 2017, NUCLEIC ACIDS RES, V45, P3086, DOI 10.1093/nar/gkw1247
   Zhang H, 2018, GENE DEV, V32, P341, DOI 10.1101/gad.311639.118
   Zhang JG, 2019, MOL CARCINOGEN, V58, P633, DOI 10.1002/mc.22955
   Zhang XJ, 2014, CARCINOGENESIS, V35, P2062, DOI 10.1093/carcin/bgu103
   Zhang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05856-2
   Zhou L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03914-5
   Zhu QQ, 2017, J CELL MOL MED, V21, P2184, DOI 10.1111/jcmm.13142
NR 179
TC 59
Z9 59
U1 4
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2019
VL 11
IS 4
AR 528
DI 10.3390/cancers11040528
PG 25
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HY0BE
UT WOS:000467773400096
PM 31013831
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Flanigan, PM
   Aghi, MK
AF Flanigan, Patrick M.
   Aghi, Manish K.
TI Adaptation to antiangiogenic therapy in neurological tumors
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE Resistance; Adaptive; Glioblastoma; Bevacizumab; Pericytes; Bone marrow;
   Autophagy
ID ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; ANTI-ANGIOGENIC THERAPY;
   CELL-SURVIVAL; COLORECTAL-CANCER; PROGENITOR CELLS; BLOOD-VESSELS;
   GLIOMA GROWTH; STEM-CELLS; PDGF-B
AB Because tumors require a vascular supply for their survival and growth, angiogenesis is considered an important therapeutic target in most human cancers including cancer of the central nervous system. Antiangiogenic therapy has focused on inhibitors of the vascular endothelial growth factor (VEGF) signaling pathway. VEGF pathway-targeted drugs have shown therapeutic efficacy in several CNS tumors and have been tried most frequently in glioblastoma. These therapies, however, have been less effective than anticipated as some patients do not respond to therapy and some receive only modest benefit. Underlying this suboptimal response are multiple mechanisms of drug resistance involving changes in both tumor cells and their microenvironment. In this review, we discuss the multiple proposed mechanisms by which neurological tumors evolve to become resistant to antiangiogenic therapies. A better understanding of these mechanisms, their context, and their interplay will likely facilitate improvements in pharmacological strategies for the targeted treatment of neurological tumors.
C1 [Flanigan, Patrick M.] Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA.
   [Aghi, Manish K.] Univ Calif San Francisco, Dept Neurol Surg, Calif Ctr Pituitary Disorders, San Francisco, CA 94143 USA.
RP Aghi, MK (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Calif Ctr Pituitary Disorders, San Francisco, CA 94143 USA.
EM aghim@neurosurg.ucsf.edu
OI Flanigan, Patrick/0000-0002-3611-8575
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [1 R01 NS079697]; NATIONAL INSTITUTE OF
   NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Neurological Disorders & Stroke (NINDS) [R01NS079697]
   Funding Source: NIH RePORTER
FX This work was supported by funding to M.K.A.'s laboratory from the NIH
   (1 R01 NS079697).
CR Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549
   Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Aghi M, 2006, CANCER RES, V66, P9054, DOI 10.1158/0008-5472.CAN-05-3759
   Akino T, 2009, AM J PATHOL, V175, P2657, DOI 10.2353/ajpath.2009.090202
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003
   Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005
   Barlow KD, 2013, CANCER MICROENVIRON, V6, P1, DOI 10.1007/s12307-012-0102-2
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Bello L, 2004, CANC TREAT, V117, P263
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bergers G, 2005, NEURO-ONCOLOGY, V7, P452, DOI 10.1215/S1152851705000232
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165
   Boer JC, 2014, CRIT REV ONCOL HEMAT, V92, P38, DOI 10.1016/j.critrevonc.2014.05.001
   Bottsford-Miller JN, 2012, J CLIN ONCOL, V30, P4026, DOI 10.1200/JCO.2012.41.9242
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Cea Valentina, 2012, J Signal Transduct, V2012, P483040, DOI 10.1155/2012/483040
   Chamberlain MC, 2011, CLIN MED INSIGHTS-ON, V5, P117, DOI 10.4137/CMO.S7232
   Cheng L, 2013, CELL, V153, P139, DOI 10.1016/j.cell.2013.02.021
   Chow LQM, 2007, J CLIN ONCOL, V25, P884, DOI 10.1200/JCO.2006.06.3602
   de Bouard S, 2007, NEURO-ONCOLOGY, V9, P412, DOI 10.1215/15228517-2007-024
   de Groot JF, 2011, J CLIN ONCOL, V29, P2689, DOI 10.1200/JCO.2010.34.1636
   de Groot JF, 2010, NEURO-ONCOLOGY, V12, P233, DOI 10.1093/neuonc/nop027
   Deng YM, 2014, MOL CLIN ONCOL, V2, P116, DOI 10.3892/mco.2013.190
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Eckerich C, 2007, INT J CANCER, V121, P276, DOI 10.1002/ijc.22679
   Eklund L, 2006, EXP CELL RES, V312, P630, DOI 10.1016/j.yexcr.2005.09.002
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.521
   Folberg R, 2004, APMIS, V112, P508, DOI 10.1111/j.1600-0463.2004.apm11207-0810.x
   Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540
   Galanis E, 2013, CLIN CANCER RES, V19, P4816, DOI 10.1158/1078-0432.CCR-13-0708
   Gu GZ, 2014, BIOMATERIALS, V35, P8215, DOI 10.1016/j.biomaterials.2014.06.022
   Guo KT, 2012, ANTICANCER RES, V32, P4971
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Herbst RS, 2009, J CLIN ONCOL, V27, P3557, DOI 10.1200/JCO.2008.19.6683
   Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Jahangiri A, 2012, BBA-REV CANCER, V1825, P86, DOI 10.1016/j.bbcan.2011.10.004
   Jain RK, 2003, J CLIN INVEST, V112, P1134, DOI 10.1172/JCI200320087
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Karcher S, 2006, INT J CANCER, V118, P2182, DOI 10.1002/ijc.21648
   Kaur B, 2005, NEURO-ONCOLOGY, V7, P134, DOI 10.1215/S1152851704001115
   KOBAYASHI N, 1980, J NEUROSURG, V53, P808, DOI 10.3171/jns.1980.53.6.0808
   Koutsimpelas D, 2007, OTOL NEUROTOL, V28, P1094, DOI 10.1097/MAO.0b013e31814b2787
   Kreisl TN, 2013, J NEURO-ONCOL, V111, P41, DOI 10.1007/s11060-012-0988-z
   Lakka Sajani S, 2008, Expert Rev Neurother, V8, P1457, DOI 10.1586/14737175.8.10.1457
   Lau D, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14519
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Li YQ, 2011, P NATL ACAD SCI USA, V108, P9951, DOI 10.1073/pnas.1016912108
   Lu Kan V, 2013, CNS Oncol, V2, P49
   Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037
   Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Mantovani A, 2004, EUR J CANCER, V40, P1660, DOI 10.1016/j.ejca.2004.03.016
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Moens S, 2014, CYTOKINE GROWTH F R, V25, P473, DOI 10.1016/j.cytogfr.2014.07.009
   Norden AD, 2009, J NEURO-ONCOL, V92, P149, DOI 10.1007/s11060-008-9745-8
   Nunes FP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059941
   Patan S, 2004, CANC TREAT, V117, P3
   Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Raizer JJ, 2010, NEURO-ONCOLOGY, V12, P95, DOI 10.1093/neuonc/nop015
   Reardon David A, 2014, Clin Adv Hematol Oncol, V12, P293
   Reardon DA, 2011, J NATL COMPR CANC NE, V9, P414, DOI 10.6004/jnccn.2011.0038
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Rigamonti N, 2014, CELL REP, V8, P696, DOI 10.1016/j.celrep.2014.06.059
   Rosen Lee S, 2002, Cancer Control, V9, P36
   Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102
   Rundhaug JE, 2005, J CELL MOL MED, V9, P267, DOI 10.1111/j.1582-4934.2005.tb00355.x
   Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Shen J, 2013, BRIT J CANCER, V109, P164, DOI 10.1038/bjc.2013.306
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Snuderl M, 2011, CANCER CELL, V20, P810, DOI 10.1016/j.ccr.2011.11.005
   Soda Y, 2013, J MOL MED, V91, P439, DOI 10.1007/s00109-013-1019-z
   Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108
   Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385
   Song N, 2009, CANCER RES, V69, P6057, DOI 10.1158/0008-5472.CAN-08-2007
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Tchaicha JH, 2011, CANCER RES, V71, P6371, DOI 10.1158/0008-5472.CAN-11-0991
   Valter MM, 1999, INT J DEV NEUROSCI, V17, P565, DOI 10.1016/S0736-5748(99)00048-9
   van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Welti JC, 2012, ANGIOGENESIS, V15, P623, DOI 10.1007/s10456-012-9291-z
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
   Xu T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-252
   Yung WKA, 2010, NEURO-ONCOLOGY, V12, P1061, DOI 10.1093/neuonc/noq072
   Zagzag D, 2000, LAB INVEST, V80, P837, DOI 10.1038/labinvest.3780088
   Zustovich F, 2013, ANTICANCER RES, V33, P3487
NR 103
TC 1
Z9 1
U1 0
U2 13
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD AUG
PY 2015
VL 72
IS 16
BP 3069
EP 3082
DI 10.1007/s00018-015-1916-0
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CN0EX
UT WOS:000358088000005
PM 25943307
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Stramucci, L
   Pranteda, A
   Stravato, A
   Amoreo, CA
   Pennetti, A
   Diodoro, MG
   Bartolazzi, A
   Milella, M
   Bossi, G
AF Stramucci, Lorenzo
   Pranteda, Angelina
   Stravato, Arianna
   Amoreo, Carla Azzurra
   Pennetti, Annarita
   Diodoro, Maria Grazia
   Bartolazzi, Armando
   Milella, Michele
   Bossi, Gianluca
TI MKK3 sustains cell proliferation and survival through p38DELTA MAPK
   activation in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID P38 MAPK; TUMOR-SUPPRESSOR; PROTEIN-KINASES; BREAST-CANCER; IN-VITRO;
   P38-DELTA; P38-ALPHA; ISOFORMS; IDENTIFICATION; INHIBITION
AB Colorectal cancer (CRC) is one of the most common malignant tumors worldwide and understanding its underlying molecular mechanisms is crucial for the development of therapeutic strategies. The mitogen-activated protein kinase-kinase 3 (MKK3) is a specific activator of p38 MAP kinases (p38 MAPKs), which contributes to the regulation of several cellular functions, such as proliferation, differentiation, apoptosis as well as response to drugs. At present, the exact MKK3/p38 MAPK pathway contribution in cancer is heavily debated because of its pleiotropic function. In this work, we retrospectively explored the prognostic and pathobiologic relevance of MKK3 in a cohort of CRC patients and assessed MKK3 molecular functions in a panel of CRC lines and colonocytes primary cultures. We found increased MKK3 levels in late-stage CRC patients which correlated with shorter overall survival. Herein, we report that the MKK3 targeting by inducible RNA interference univocally exerts antitumor effects in CRC lines but not in primary colonocytes. While MKK3 depletion per se affects growth and survival by induction of sustained autophagy and death in some CRC lines, it potentiates response to chemotherapeutic drug 5-fluorouracil (5-FU) in all of the tested CRC lines in vitro. Here, we demonstrate for the first time that in CRC the MKK3 specifically activates p38delta MAPK isoform to sustain prosurvival signaling and that such effect is exacerbated upon 5-FU challenge. Indeed, p38delta MAPK silencing recapitulates MKK3 depletion effects in CRC cells in vitro and in vivo. Overall, our data identified a molecular mechanism through which MKK3 supports proliferation and survival signaling in CRC, further supporting MKK3 as a novel and extremely attractive therapeutic target for the development of promising strategies for the management of CRC patients.
C1 [Stramucci, Lorenzo; Pranteda, Angelina; Stravato, Arianna; Bossi, Gianluca] IRCCS Regina Elena NCI, Lab Med Phys & Expert Syst, Dept Diagnost Res & Technol Innovat, I-00144 Rome, Italy.
   [Stramucci, Lorenzo; Pranteda, Angelina; Stravato, Arianna; Bossi, Gianluca] IRCCS Regina Elena NCI, Oncogen & Epigenet Unit, Dept Diagnost Res & Technol Innovat, I-00144 Rome, Italy.
   [Amoreo, Carla Azzurra; Pennetti, Annarita; Diodoro, Maria Grazia] IRCCS Regina Elena NCI, Dept Pathol, I-00144 Rome, Italy.
   [Bartolazzi, Armando] St Andrea Hosp, Pathol Res Lab, I-00189 Rome, Italy.
   [Milella, Michele] IRCCS Regina Elena NCI, Med Oncol 1, I-00144 Rome, Italy.
   [Milella, Michele] Univ Verona, Dept Med, Oncol Sect, Sch Med,Verona Univ Hosp Trust, I-37134 Verona, Italy.
RP Bossi, G (corresponding author), IRCCS Regina Elena NCI, Lab Med Phys & Expert Syst, Dept Diagnost Res & Technol Innovat, I-00144 Rome, Italy.; Bossi, G (corresponding author), IRCCS Regina Elena NCI, Oncogen & Epigenet Unit, Dept Diagnost Res & Technol Innovat, I-00144 Rome, Italy.
EM gianluca.bossi@ifo.gov.it
RI Milella, Michele/ABH-8606-2020; Bossi, Gianluca/B-9394-2017; Bossi,
   Gianluca/ABH-6846-2020
OI Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063
FU AIRCFondazione AIRC per la ricerca sul cancro [IG 2016-ID. 18449];
   "Alice triangi" Pezcoller-Foundation fellowship; Italian Ministry of
   HealthMinistry of Health, Italy
FX The research leading to these results has received funding from AIRC
   under IG 2016-ID. 18449 project-P.I. Bossi Gianluca. LS was supported by
   "Alice triangi" Pezcoller-Foundation fellowship. B.G. was supported by 5
   x 1000 funds from Italian Ministry of Health (years 2011, 2012 and
   2016). Results published here are in part based upon data generated by
   the TCGA Research Network: http://cancergenome.nih.gov/.
CR Adams M, 2016, BIOORG MED CHEM LETT, V26, P1086, DOI 10.1016/j.bmcl.2015.11.054
   Anaya J, 2016, PEERJ COMPUT SCI, DOI 10.7717/peerj-cs.67
   Baldari S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.591
   Benson AB, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bertero L, 2018, VIRCHOWS ARCH, V472, P519, DOI 10.1007/s00428-017-2276-y
   Bossi G, 2016, AGING-US, V8, P1
   Boyle DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103091
   Bracht K, 2010, BRIT J CANCER, V103, P340, DOI 10.1038/sj.bjc.6605780
   Brancho D, 2003, GENE DEV, V17, P1969, DOI 10.1101/gad.1107303
   Chen JH, 2007, ACS CHEM BIOL, V2, P329, DOI 10.1021/cb700025j
   Corre I, 2017, ONCOTARGET, V8, P55684, DOI 10.18632/oncotarget.18264
   Cuenda A, 2017, TRENDS BIOCHEM SCI, V42, P431, DOI 10.1016/j.tibs.2017.02.008
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   De Nicola GF, 2013, NAT STRUCT MOL BIOL, V20, P1182, DOI 10.1038/nsmb.2668
   del Reino P, 2014, CANCER RES, V74, P6150, DOI 10.1158/0008-5472.CAN-14-0870
   DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144
   Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006
   Escos A, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00031
   Galan-Moya EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028406
   Germani A, 2014, CANCER LETT, V344, P110, DOI 10.1016/j.canlet.2013.10.035
   Giafis N, 2006, CANCER RES, V66, P6763, DOI 10.1158/0008-5472.CAN-05-3699
   Guma M, 2012, ARTHRITIS RHEUM-US, V64, P2887, DOI 10.1002/art.34489
   Gurtner A, 2010, J BIOL CHEM, V285, P14160, DOI 10.1074/jbc.M109.094813
   Hall Michael J, 2018, Am Soc Clin Oncol Educ Book, V38, P220, DOI 10.1200/EDBK_200961
   Han JH, 1997, FEBS LETT, V403, P19, DOI 10.1016/S0014-5793(97)00021-5
   Huth HW, 2016, CELL SIGNAL, V28, P1283, DOI 10.1016/j.cellsig.2016.05.009
   Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1
   Kuma Y, 2005, J BIOL CHEM, V280, P19472, DOI 10.1074/jbc.M414221200
   Kwong J, 2013, MOL CELL BIOL, V33, P3780, DOI 10.1128/MCB.00784-13
   Liu JL, 2018, J CELL BIOCHEM, V119, P8472, DOI 10.1002/jcb.27073
   Loesch M, 2010, J BIOL CHEM, V285, P15149, DOI 10.1074/jbc.M110.105429
   MacNeil AJ, 2014, CANCER RES, V74, P162, DOI 10.1158/0008-5472.CAN-13-1310
   Mittelstadt PR, 2005, CELL CYCLE, V4, P1189, DOI 10.4161/cc.4.9.2043
   Patnaik A, 2016, CLIN CANCER RES, V22, P1095, DOI 10.1158/1078-0432.CCR-15-1718
   Remy G, 2010, CELL SIGNAL, V22, P660, DOI 10.1016/j.cellsig.2009.11.020
   Steelman LS, 2016, CURR PHARM DESIGN, V22, P2358, DOI 10.2174/1381612822666160304151011
   Stramucci L, 2018, CANCERS, V10, DOI 10.3390/cancers10050131
   Svensson C, 2011, BIOCHEM BIOPH RES CO, V406, P488, DOI 10.1016/j.bbrc.2011.02.083
   Tsai MS, 2012, MOL CANCER THER, V11, P561, DOI 10.1158/1535-7163.MCT-11-0684
   Yoshida T, 2002, J CLIN MICROBIOL, V40, P105, DOI 10.1128/JCM.40.1.105-110.2002
   Zhang CL, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216671
   Zou X, 2017, CANCER LETT, V384, P19, DOI 10.1016/j.canlet.2016.10.008
NR 43
TC 14
Z9 14
U1 1
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 6
PY 2019
VL 10
AR 842
DI 10.1038/s41419-019-2083-2
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA JP0OF
UT WOS:000497970800002
PM 31695024
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, J
   Chu, DK
   Kawamura, T
   Tanaka, K
   He, SX
AF Zhang, Juan
   Chu, Dake
   Kawamura, Takuji
   Tanaka, Kiyohito
   He, Shuixiang
TI GRIM-19 repressed hypoxia-induced invasion and EMT of colorectal cancer
   by repressing autophagy through inactivation of STAT3/HIF-1 signaling
   axis
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE colorectal cancer; epithelial-mesenchymal transition; GRIM-19; invasion;
   STAT3; HIF-1 signaling
ID EPITHELIAL-MESENCHYMAL TRANSITION; DOWN-REGULATION; CELL-DEATH;
   EXPRESSION; STAT3; PROLIFERATION; SWITCH
AB Hypoxia leads to cancer progression and promotes the metastatic potential of cancer cells. Thereby, the aim of the present study was to investigate the detailed effects of gene associated with retinoid-interferon-induced mortality-19 (GRIM-19) in colorectal cancer (CRC) cell lines under hypoxia conditions and explore the potential molecular mechanisms. Here, we observed that GRIM-19 expression was downregulated in several CRC cell lines as well as in HCT116 and Caco-2 cells under a hypoxic microenvironment. Additionally, the introduction of GRIM-19 obviously suppressed cell invasive ability and epithelial-mesenchymal transition (EMT) through modulating EMT markers as reflected by the upregulation of E-cadherin along with the downregulation of vimentin and N-cadherin under hypoxic conditions. Moreover, the addition of GRIM-19 repressed hypoxia-induced autophagy through modulating autophagy associated proteins as reflected by the downregulation of LC3-II/LC3-I ratio and Beclin-1 expression, as well as the increased of p62 expression. Interestingly, overexpression of GRIM-19 markedly ameliorated the accumulation of HIF-1 triggered by hypoxia accompanied by an inhibition of vascular endothelial growth factor (VEGF) production and phospho-signal transducer and activator of transcription 3(p-STAT3) expression. Further data demonstrated that GRIM-19 have a negative feedback effect on the expression of HIF-1. Mechanistically, re-expression of HIF-1 completely reversed the inhibitory effects of GRIM-19 on hypoxia-induced invasion and EMT. Taken all data together, our findings established that GRIM-19 suppresses hypoxia-triggered invasion and EMT by inhibiting hypoxia-induced autophagy through inactivation HIF-1/STAT3 signaling pathway, indicating that GRIM-19 may serve as a potential predictive factor and therapeutic target for CRC treatment.
C1 [Zhang, Juan; Chu, Dake; He, Shuixiang] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gastroenterol, Yan Tower West Rd 277, Xian 710061, Shaanxi, Peoples R China.
   [Kawamura, Takuji; Tanaka, Kiyohito] Kyoto Second Red Cross Hosp, Dept Gastroenterol, Kyoto 6028026, Japan.
RP He, SX (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gastroenterol, Yan Tower West Rd 277, Xian 710061, Shaanxi, Peoples R China.; Tanaka, K (corresponding author), Kyoto Second Red Cross Hosp, Dept Gastroenterol, Kyoto 6028026, Japan.
EM seijin7705@gmail.com; dyyyjxk@mail.xjtu.edu.cn
RI Kawamura, Takuji/AAT-4380-2020
OI Kawamura, Takuji/0000-0002-1155-3116
FU Xi'an Science and Technology Planning Project [201805094YX2SF28]
FX This research was supported by Xi'an Science and Technology Planning
   Project (201805094YX2SF28).
CR Aziz MH, 2010, ONCOGENE, V29, P3100, DOI 10.1038/onc.2010.63
   Bao B, 2012, BBA-REV CANCER, V1826, P272, DOI 10.1016/j.bbcan.2012.04.008
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216
   Chen HJ, 2015, J BUON, V20, P438
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Hao M, 2015, HUM PATHOL, V46, P1815, DOI 10.1016/j.humpath.2015.07.020
   Indelicato M, 2010, J CELL PHYSIOL, V223, P359, DOI 10.1002/jcp.22041
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Liu MH, 2018, INT J ONCOL, V53, P1363, DOI 10.3892/ijo.2018.4465
   Liu Q, 2013, CARCINOGENESIS, V34, P1728, DOI 10.1093/carcin/bgt125
   Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135
   Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019
   Pang L, 2017, JPN J CLIN ONCOL, V47, P795, DOI 10.1093/jjco/hyx090
   Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Wang XW, 2018, J CELL BIOCHEM, V119, P1819, DOI 10.1002/jcb.26342
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu N, 2017, BIOMED PHARMACOTHER, V95, P1169, DOI 10.1016/j.biopha.2017.09.055
   Xiong Z, 2016, CARCINOGENESIS, V37, P1079, DOI 10.1093/carcin/bgw089
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Yue X, 2016, TUMOR BIOL, V37, P9789, DOI 10.1007/s13277-016-4877-5
   Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhu HT, 2014, ONCOL REP, V32, P935, DOI 10.3892/or.2014.3298
NR 28
TC 21
Z9 23
U1 1
U2 30
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD AUG
PY 2019
VL 234
IS 8
BP 12800
EP 12808
DI 10.1002/jcp.27914
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA HX2SA
UT WOS:000467240800058
PM 30537081
DA 2022-04-25
ER

PT J
AU Jin, KT
   Lu, ZB
   Lv, JQ
   Zhang, JG
AF Jin, Ke-Tao
   Lu, Ze-Bei
   Lv, Jie-Qing
   Zhang, Jun-Gang
TI The role of long non-coding RNAs in mediating chemoresistance by
   modulating autophagy in cancer
SO RNA BIOLOGY
LA English
DT Review
DE Cancer; LncRNAs; metastasis; chemoresistance; autophagy
ID EPITHELIAL-MESENCHYMAL TRANSITION; GASTRIC-CANCER; COLORECTAL-CANCER;
   MULTIDRUG-RESISTANCE; DOWN-REGULATION; OVARIAN-CANCER;
   CISPLATIN-RESISTANCE; CELL-PROLIFERATION; BLADDER-CANCER; UP-REGULATION
AB Cancer is a complex process in which protein-coding and non-coding genes play essential roles. Long noncoding RNAs (lncRNAs), as a subclass of noncoding genes, are implicated in various cancer processes including growth, proliferation, metastasis, and angiogenesis. Due to presence in body fluids such as blood and urine, lncRNAs have become novel biomarkers in cancer detection, diagnosis, progression, and therapy response. Remarkably, increasing evidence has verified that lncRNAs play essential roles in chemoresistance by targeting different signalling pathways. Autophagy, a highly conserved process in response to environmental stresses such as starvation and hypoxia, plays a paradoxical role in inducing resistance or sensitivity to chemotherapy agents. In this regard, we reviewed chemoresistance, the role of lncRNAs in cancer, and the role of lncRNAs in chemoresistance by modulating autophagy.
C1 [Jin, Ke-Tao; Lv, Jie-Qing] Zhejiang Univ, Shaoxing Peoples Hosp, Dept Colorectal Surg, Sch Med, Shaoxing, Zhejiang, Peoples R China.
   [Lu, Ze-Bei; Zhang, Jun-Gang] Hangzhou Med Coll, Key Lab Tumor Mol Diag & Individualized Med Zheji, Zhejiang Prov Peoples Hosp, Peoples Hosp, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Jun-Gang] Hangzhou Med Coll, Hepatobiliary & Pancreat Surg, Zhejiang Prov Peoples Hosp, Peoples Hosp, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
RP Zhang, JG (corresponding author), Hangzhou Med Coll, Hepatobiliary & Pancreat Surg, Zhejiang Prov Peoples Hosp, Peoples Hosp, 158 Shangtang Rd, Hangzhou 310014, Zhejiang, Peoples R China.
EM zjg2sy1@163.com
FU Zhejiang Provincial Science and Technology Projects [LGF18H160041,
   LGD19H160001]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81772537, 81374014,
   81502482]; Zhejiang Provincial Research Projects of Medical and Healthy
   Industries [2017KY193, 2017KY210]
FX This work was supported by the [Zhejiang Provincial Science and
   Technology Projects] under Grant [Nos. LGF18H160041 to LJQ, LGD19H160001
   to JKT]; [National Natural Science Foundation of China] under Grant
   [Nos. 81772537 to JKT; 81374014 to JKT; 81502482 to JGZ]; and [Zhejiang
   Provincial Research Projects of Medical and Healthy Industries] under
   Grant [Nos. 2017KY193 and 2017KY210 to JGZ].
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Aghaei M, 2019, J CELL PHYSIOL, V234, P16768, DOI 10.1002/jcp.28345
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   An JH, 2017, ONCOTARGETS THER, V10, P5377, DOI 10.2147/OTT.S147586
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   Augustine CK, 2009, CLIN CANCER RES, V15, P502, DOI 10.1158/1078-0432.CCR-08-1916
   Aydinlik S, 2017, BBA-GEN SUBJECTS, V1861, P49, DOI 10.1016/j.bbagen.2016.11.013
   Azmi AS, 2009, J CELL PHYSIOL, V218, P13, DOI 10.1002/jcp.21567
   Balas Maggie M, 2018, Noncoding RNA Res, V3, P108, DOI 10.1016/j.ncrna.2018.03.001
   Bento CF, 2016, ANNU REV BIOCHEM, V85, P685, DOI 10.1146/annurev-biochem-060815-014556
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Botti G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092279
   Cai Q, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1016-0
   Cai T, 2018, CANCER MED-US, V7, P1404, DOI 10.1002/cam4.1384
   Catalano M, 2015, MOL ONCOL, V9, P1612, DOI 10.1016/j.molonc.2015.04.016
   Chen L., 2018, CURRENT UNDERSTANDIN
   Cho S, 2011, P NATL ACAD SCI USA, V108, P20778, DOI 10.1073/pnas.1019452108
   Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Damia G, 2019, CANCERS, V11, DOI 10.3390/cancers11010119
   De Angelis PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-20
   De Angelis PM, 2004, INT J ONCOL, V24, P1279
   De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4
   Dimberg LY, 2013, ONCOGENE, V32, P1341, DOI 10.1038/onc.2012.164
   Drablos F, 2004, DNA REPAIR, V3, P1389, DOI 10.1016/j.dnarep.2004.05.004
   Fan Y, 2014, FEBS J, V281, P1750, DOI 10.1111/febs.12737
   Fang ZX, 2018, BIOMED PHARMACOTHER, V101, P536, DOI 10.1016/j.biopha.2018.02.130
   Feng SQ, 2018, NEOPLASMA, V65, P925, DOI 10.4149/neo_2018_180125N55
   Fernandes JCR, 2019, NON-CODING RNA, V5, DOI 10.3390/ncrna5010017
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   FUTREAL PA, 1992, CANCER RES, V52, P2624
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Gao HL, 2018, ONCOTARGETS THER, V11, P8001, DOI 10.2147/OTT.S172379
   GAO X, 1995, CANCER RES, V55, P1002
   Gao ZQ, 2018, BIOMED PHARMACOTHER, V97, P809, DOI 10.1016/j.biopha.2017.10.157
   Ge J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110293
   Gong FC, 2019, EUR J PHARMACOL, V853, P345, DOI 10.1016/j.ejphar.2019.04.022
   Goradel NH, 2019, J CELL PHYSIOL, V234, P1099, DOI 10.1002/jcp.27051
   Goradel NH, 2018, J CELL PHYSIOL, V233, P2902, DOI 10.1002/jcp.26029
   Goradel NH, 2017, TOXICOL APPL PHARM, V335, P56, DOI 10.1016/j.taap.2017.09.022
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Gu Y, 2015, FUTURE ONCOL, V11, P2427, DOI 10.2217/fon.15.175
   Guo BQ, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2790-3
   Hamada S, 2012, J CELL PHYSIOL, V227, P729, DOI 10.1002/jcp.22781
   Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342
   Horsey AJ, 2016, BIOCHEM SOC T, V44, P824, DOI 10.1042/BST20160014
   Hou YX, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.53
   Hu Shaopu, 2018, Oncotarget, V9, P13911, DOI 10.18632/oncotarget.23744
   Hu YR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0743-3
   Huang FX, 2019, INT J ONCOL, V54, P339, DOI 10.3892/ijo.2018.4614
   Huang JK, 2017, J CELL BIOCHEM, V118, P4821, DOI 10.1002/jcb.26153
   Huang PD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36231-4
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178
   Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192
   Ji JL, 2019, CANCER MANAG RES, V11, P2729, DOI 10.2147/CMAR.S189052
   Jia J, 2016, ONCOTARGET, V7, P37868, DOI 10.18632/oncotarget.9350
   Jiang CM, 2018, BIOMED PHARMACOTHER, V97, P844, DOI 10.1016/j.biopha.2017.10.146
   Jiang MC, 2019, AM J CANCER RES, V9, P1354
   Jo Y, 2018, THERANOSTICS, V8, P5259, DOI 10.7150/thno.29098
   Kim AY, 2015, TOX RESEARCH, V31, P151, DOI 10.5487/TR.2015.31.2.151
   Kim MS, 2008, HUM PATHOL, V39, P1059, DOI 10.1016/j.humpath.2007.11.013
   Kim MS, 2011, APMIS, V119, P802, DOI 10.1111/j.1600-0463.2011.02812.x
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015
   Lakshmanan I, 2017, CLIN CANCER RES, V23, P3906, DOI 10.1158/1078-0432.CCR-16-2530
   Lee SH, 2014, BRIT J CANCER, V111, P2122, DOI 10.1038/bjc.2014.528
   Lee YJ, 2012, INT J MED SCI, V9, P881, DOI 10.7150/ijms.5011
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li B, 2019, CANCER CHEMOTH PHARM, V84, P187, DOI 10.1007/s00280-019-03873-8
   Li HY, 2015, ONCOTARGET, V6, P27847, DOI 10.18632/oncotarget.4443
   Li JR, 2013, TOXICOL LETT, V220, P267, DOI 10.1016/j.toxlet.2013.04.021
   Li J, 2016, ONCOL RES, V23, P205, DOI 10.3727/096504016X14549667334007
   Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419
   Li WT, 2011, ASIAN PAC J CANCER P, V12, P2575
   Li YX, 2018, BIOMED PHARMACOTHER, V108, P1775, DOI 10.1016/j.biopha.2018.09.181
   Li YC, 2019, ONCOTARGETS THER, V12, P2649, DOI 10.2147/OTT.S188054
   Li ZX, 2018, CANCER MANAG RES, V10, P6757, DOI 10.2147/CMAR.S169406
   Liao YW, 2017, J CELL BIOCHEM, V118, P1889, DOI 10.1002/jcb.25910
   Lin CI, 2010, MOL CANCER RES, V8, P1217, DOI 10.1158/1541-7786.MCR-10-0162
   Liu MJ, 2018, CANCER SCI, V109, P3055, DOI 10.1111/cas.13746
   Liu Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4273290
   Liu ZC, 2019, DNA CELL BIOL, V38, P1366, DOI 10.1089/dna.2019.4882
   Long XR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1329-2
   Lu DF, 2018, CELL PHYSIOL BIOCHEM, V48, P2517, DOI 10.1159/000492690
   Lu H, 2019, BIOMED RES INT, V2019, P10
   Lu ZP, 2016, ONCOTARGET, V7, P241, DOI 10.18632/oncotarget.6280
   Luo T, 2016, AUTOPHAGY, V12, P1355, DOI 10.1080/15548627.2015.1034405
   Lv MX, 2017, BBA-MOL CELL RES, V1864, P1887, DOI 10.1016/j.bbamcr.2017.08.001
   Ma BB, 2017, BBA-MOL CELL RES, V1864, P1393, DOI 10.1016/j.bbamcr.2017.05.008
   Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604
   Mandinova A, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001366
   Mao QC, 2015, AAPS J, V17, P65, DOI 10.1208/s12248-014-9668-6
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   MEIJER C, 1992, CANCER RES, V52, P6885
   Mizushima N, 2002, CELL STRUCT FUNCT, V27, P421, DOI 10.1247/csf.27.421
   Munoz M, 2007, IUBMB LIFE, V59, P752, DOI 10.1080/15216540701736285
   Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Nunes T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124036
   Ozes AR, 2016, ONCOGENE, V35, P5350, DOI 10.1038/onc.2016.75
   Pagotto A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.327
   Pilie PG, 2019, NAT REV CLIN ONCOL, V16, P81, DOI 10.1038/s41571-018-0114-z
   Qi X, 2019, MOL THER-NUCL ACIDS, V17, P804, DOI 10.1016/j.omtn.2019.06.010
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Quail DF, 2016, SCIENCE, V352, DOI 10.1126/science.aad3018
   Ravikumar B, 2010, PHYSIOL REV, V90, P1383, DOI 10.1152/physrev.00030.2009
   Rebucci M, 2013, BIOCHEM PHARMACOL, V85, P1219, DOI 10.1016/j.bcp.2013.02.017
   Ren KM, 2017, CANCER CHEMOTH PHARM, V80, P243, DOI 10.1007/s00280-017-3356-z
   Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Sauna ZE, 2007, J BIOENERG BIOMEMBR, V39, P481, DOI 10.1007/s10863-007-9115-9
   Schafer A, 2012, NEURO-ONCOLOGY, V14, P1452, DOI 10.1093/neuonc/nos270
   Schmidt K, 2016, CELL REP, V15, P2025, DOI 10.1016/j.celrep.2016.04.018
   Senthebane DA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071586
   Shang AQ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1394-6
   Smith BN, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020017
   Solomon VR, 2009, EUR J PHARMACOL, V625, P220, DOI 10.1016/j.ejphar.2009.06.063
   Su J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.83
   Sun MY, 2017, BIOTECHNOL LETT, V39, P1477, DOI 10.1007/s10529-017-2392-4
   Sun W, 2017, ONCOL REP, V38, P3347, DOI 10.3892/or.2017.6056
   Sun Y, 2016, INT J ONCOL, V48, P225, DOI 10.3892/ijo.2015.3256
   Tan Q, 2017, CANCER CHEMOTH PHARM, V79, P959, DOI 10.1007/s00280-017-3298-5
   Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479
   Tang Q, 2018, CELL PHYSIOL BIOCHEM, V47, P893, DOI 10.1159/000490131
   Taylor MA, 2018, APOPTOSIS, V23, P563, DOI 10.1007/s10495-018-1480-9
   Tripathi MK, 2018, DRUG DISCOV TODAY, V23, P1635, DOI 10.1016/j.drudis.2018.04.010
   Tsou SH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116747
   Wang J., 2019, PEER PEER NETW APPL, V12, P1
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Wang M, 2019, J CANCER, V10, P4603, DOI 10.7150/jca.32065
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang MJ, 2017, ONCOTARGET, V8, P33713, DOI 10.18632/oncotarget.16735
   Wang P, 2017, ONCOTARGET, V8, P84086, DOI 10.18632/oncotarget.20475
   Wang Q, 2017, BIOMED PHARMACOTHER, V91, P906, DOI 10.1016/j.biopha.2017.05.014
   Wang TH, 2015, ONCOTARGET, V6, P23342, DOI 10.18632/oncotarget.4344
   Wang X-H, 2017, TUMOR BIOL, V39, P1
   Wang XY, 2021, ENVIRON TECHNOL, V42, P2021, DOI 10.1080/09593330.2019.1687588
   Wang Xuan, 2019, Cancer Drug Resist, V2, P141, DOI 10.20517/cdr.2019.10
   Wang ZG, 2017, ONCOTARGET, V8, P31465, DOI 10.18632/oncotarget.16356
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011
   Westhoff MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083128
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wojtkowiak JW, 2011, MOL PHARMACEUT, V8, P2032, DOI 10.1021/mp200292c
   Wu HJ, 2019, CANCER MED-US, V8, P2484, DOI 10.1002/cam4.1809
   Wu X, 2018, BIOMED PHARMACOTHER, V99, P832, DOI 10.1016/j.biopha.2018.01.130
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xiao Y, 2017, ONCOTARGET, V8, P83171, DOI 10.18632/oncotarget.20487
   Xiao ZG, 2018, CELL PHYSIOL BIOCHEM, V46, P1275, DOI 10.1159/000489110
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xue X, 2012, CHIN J CANCER, V31, P100, DOI 10.5732/cjc.011.10326
   Yan J, 2016, TUMOR BIOL, V37, P16345, DOI 10.1007/s13277-016-5448-5
   Yang BY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0722-8
   Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x
   Yang WW, 2019, J CELL PHYSIOL, V234, P23571, DOI 10.1002/jcp.28926
   Yao J, 2017, J CANCER RES CLIN, V143, P419, DOI 10.1007/s00432-016-2302-5
   Yarmishyn AA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00145
   Yin Jiye, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P927, DOI 10.3969/j.issn.1672-7347.2011.10.002
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yu X, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12506
   Yu X, 2017, J CELL MOL MED, V21, P410, DOI 10.1111/jcmm.12956
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang CY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317701311
   Zhang N, 2016, EUR REV MED PHARMACO, V20, P2271
   Zhang SY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0793-5
   Zhang XF, 2019, BIOCHEM BIOPH RES CO, V510, P508, DOI 10.1016/j.bbrc.2019.01.109
   Zhang Y, 2017, ONCOGENE, V36, P5473, DOI 10.1038/onc.2017.152
   Zhang YF, 2016, J MED BIOCHEM, V35, P137, DOI 10.1515/jomb-2015-0016
   Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3
   Zhao GD, 2019, EXP THER MED, V18, P199, DOI 10.3892/etm.2019.7526
   Zhao JH, 2016, PHARMACOL THERAPEUT, V160, P145, DOI 10.1016/j.pharmthera.2016.02.008
   Zhao J, 2018, ONCOGENE, V37, P4094, DOI 10.1038/s41388-018-0250-z
   Zheng A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1315-8
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
   Zhou Q, 2018, CLIN CHIM ACTA, V482, P1, DOI 10.1016/j.cca.2018.03.016
   Zhu DY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00350
   Zhu J, 2018, CELL PHYSIOL BIOCHEM, V51, P113, DOI 10.1159/000495168
   Zhu JL, 2017, MOL THER-NUCL ACIDS, V7, P299, DOI 10.1016/j.omtn.2017.04.012
   Zhu KX, 2012, ONCOL REP, V27, P1027, DOI 10.3892/or.2012.1633
   Zhu KP, 2017, ONCOTARGET, V8, P71881, DOI 10.18632/oncotarget.17985
NR 190
TC 12
Z9 12
U1 3
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1547-6286
EI 1555-8584
J9 RNA BIOL
JI RNA Biol.
PD DEC 1
PY 2020
VL 17
IS 12
BP 1727
EP 1740
DI 10.1080/15476286.2020.1737787
EA MAR 2020
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA OY4PW
UT WOS:000519901500001
PM 32129701
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Yin, X
   Zhang, N
   Di, W
AF Yin, Xia
   Zhang, Ning
   Di, Wen
TI Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells
   by Protein Phosphatase 2A
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
DE Protein phosphatase 2A; Cisplatin; Apoptosis; Protective autophagy;
   Ovarian cancer
ID PPP2R1B GENE; SUBUNIT INTERACTION; COLORECTAL CANCERS; CISPLATIN
   THERAPY; P38 MAPK; PP2A; MUTATIONS; DEPHOSPHORYLATION; PHOSPHORYLATION;
   SUPPRESSION
AB Objective: Protein phosphatase 2A (PP2A) is a target for cisplatin, which is a widely used platinum drug to treat various cancer, including ovarian cancer. However, to date, the exact role of PP2A in chemoresistance to cisplatin-centered ovarian cancer therapy is not clear.
   Methods and Materials: To analyze the function of PP2A in cisplatin-resistant ovarian cancer cells, we derived A2780/cisplatin (CDDP), which is resistant to cisplatin, from A2780 cell line. Western blotting was used to detect the expression of PP2A, autophagy, and apoptosis markers.
   Results: The expression of PP2A catalytic subunit, (PP2Ac) was reduced in A2780/CDDP as well as in cisplatin-resistant patients' tissues compared with A2780 and cisplatin-sensitive patients. In the A2780 cells, cisplatin induced both apoptosis and autophagy. Interestingly, however, the autophagy inhibitor 3-methyladenine increased the cell death induced by diamindichloridoplatin (DDP), which suggested the protective function of autophagy in DDP-induced cell death. Knocking down of PP2A promoted autophagy but suppressed DDP-induced apoptosis and cell death. In contrast, overexpression of PP2Ac or reinduction of the activity of PP2A by FTY720 decreased autophagy but increased cell death induced by DDP. Our experiments demonstrated that apoptosis suppressed by the knocking down of PP2Ac can be reversed by the administration of 3-methyladenine. The elevated accumulation of microtubule-associated protein 1 light chain 3-II and the decline of the autophagy substrate p62 were also observed in PP2Ac-small interfering RNA transfected cells. However, overexpression of PP2Ac suppressed the accumulation of microtubule-associated protein 1 light chain 3-II and restored p62.
   Conclusions: Taken together, our results showed that protective autophagy regulated by PP2Ac is at least part of the mechanism to how certain ovarian cancers are resistant to cisplatin. Prospective studies are necessary to determine the detailed mechanism of how PP2Ac regulates autophagy in chemoresistant patients.
C1 [Yin, Xia; Zhang, Ning; Di, Wen] Shanghai Jiao Tong Univ, Renji Hosp, Dept Obstet & Gynecol, Sch Med, Shanghai 200127, Peoples R China.
RP Di, W (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Dept Obstet & Gynecol, Sch Med, Peoples Republic China E mail diwen163 163 com T, Shanghai 200127, Peoples R China.
EM diwen163@163.com
RI ZHANG, NING/C-8105-2015
OI Zhang, Ning/0000-0001-6306-4819
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81072137]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81072137).
CR Borst P, 2008, CELL CYCLE, V7, P1353, DOI 10.4161/cc.7.10.5930
   Calin GA, 2000, ONCOGENE, V19, P1191, DOI 10.1038/sj.onc.1203389
   De Wulf P, 2009, CURR OPIN CELL BIOL, V21, P806, DOI 10.1016/j.ceb.2009.08.003
   Feng JJ, 2009, MOL CELL BIOL, V29, P5696, DOI 10.1128/MCB.00191-09
   Grethe S, 2006, CELL SIGNAL, V18, P531, DOI 10.1016/j.cellsig.2005.05.023
   Heikkinen PT, 2010, J BIOL CHEM, V285, P3740, DOI 10.1074/jbc.M109.042978
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI 10.3322/caac.20073
   Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044
   Li SP, 2003, CANCER RES, V63, P3473
   Liu QH, 2004, AM J PHYSIOL-HEART C, V286, pH2204, DOI 10.1152/ajpheart.01050.2003
   McConechy MK, 2011, J PATHOL, V223, P567, DOI 10.1002/path.2848
   OZOLS RF, 1985, SEMIN ONCOL, V12, P21
   Ozols RF, 2006, GYNECOL ONCOL, V103, P1, DOI 10.1016/j.ygyno.2006.06.026
   Purev E, 2006, J CELL PHYSIOL, V206, P495, DOI 10.1002/jcp.20490
   Ruediger R, 2001, ONCOGENE, V20, P1892, DOI 10.1038/sj.onc.1204279
   Ruediger R, 2001, ONCOGENE, V20, P10, DOI 10.1038/sj.onc.1204059
   Sablina AA, 2010, CANCER RES, V70, P10474, DOI 10.1158/0008-5472.CAN-10-2855
   Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006
   Shih IM, 2011, AM J PATHOL, V178, P1442, DOI 10.1016/j.ajpath.2011.01.009
   SLEDGE GW, 1988, J CLIN ONCOL, V6, P1811, DOI 10.1200/JCO.1988.6.12.1811
   Takagi Y, 2000, GUT, V47, P268, DOI 10.1136/gut.47.2.268
   Tamaki M, 2004, ONCOL REP, V11, P655
   Wang JY, 2012, J CELL BIOCHEM, V113, P1733, DOI 10.1002/jcb.24043
   Wang SS, 1998, SCIENCE, V282, P284, DOI 10.1126/science.282.5387.284
   Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200
NR 25
TC 19
Z9 21
U1 0
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD MAY
PY 2013
VL 23
IS 4
BP 630
EP 641
DI 10.1097/IGC.0b013e3182892cee
PG 12
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA 132MB
UT WOS:000318071300009
PM 23518861
DA 2022-04-25
ER

PT J
AU Li, H
   Meng, XX
   Zhang, L
   Zhang, BJ
   Liu, XY
   Fu, WW
   Tan, HS
   Lao, YZ
   Xu, HX
AF Li, Hui
   Meng, Xiao-xiao
   Zhang, Li
   Zhang, Bao-jun
   Liu, Xin-yu
   Fu, Wen-wei
   Tan, Hong-sheng
   Lao, Yuan-zhi
   Xu, Hong-xi
TI Oblongifolin C and guttiferone K extracted from Garcinia yunnanensis
   fruit synergistically induce apoptosis in human colorectal cancer cells
   in vitro
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE Garcinia yunnanensis Hu; oblongifolin C; guttiferone K; colorectal
   cancer; HCT116 cells; apoptosis; autophagy; ROS; JNK
ID DRUG-COMBINATION; AUTOPHAGY; COMPOUND; BENZOPHENONES; STRESS; DEATH
AB Oblongifolin C (OC) and guttiferone K (GUTK) are two anticancer compounds extracted from Garcinia yunnanensis Hu, but they act by different mechanisms. In this study we investigated whether a combination of OC and GUTK (1:1 molar ratio) could produce synergistic anticancer effects against human colorectal cancer cells in vitro. For comparison, we also examined the anticancer efficacy of ethanol extracts from G yunnanensis fruit, which contain OC and GUTK up to 5%. Compared to OC and GUTK alone, the combination of OC and GUTK as well as the ethanol extracts more potently inhibited the cancer cell growth with IC50 values of 3.4 mu mol/L and 3.85 mu g/mL, respectively. Furthermore, OC and GUTK displayed synergistic inhibition on HCT116 cells: co-treatment with OC and GUTK induced more prominent apoptosis than treatment with either drug alone. Moreover, the combination of OC and GUTK markedly increased cleavage of casapse-3 and PARP, and enhanced cellular ROS production and increased JNK protein phosphorylation. In addition, the combination of OC and GUTK exerted stronger effects under nutrient-deprived conditions than in complete medium, suggesting that autophagy played an essential role in regulating OC- and GUTK-mediated cell death. OC and GUTK are the main components that contribute to the anticancer activity of G yunnanensis and the compounds have apoptosis-inducing effects in HCT116 cells in vitro.
C1 [Li, Hui; Meng, Xiao-xiao; Zhang, Li; Zhang, Bao-jun; Liu, Xin-yu; Fu, Wen-wei; Tan, Hong-sheng; Lao, Yuan-zhi; Xu, Hong-xi] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.
   [Li, Hui; Meng, Xiao-xiao; Zhang, Li; Zhang, Bao-jun; Liu, Xin-yu; Fu, Wen-wei; Tan, Hong-sheng; Lao, Yuan-zhi; Xu, Hong-xi] Shanghai Coll TCM New Drug Discovery, Engn Res Ctr, Shanghai 201203, Peoples R China.
RP Lao, YZ; Xu, HX (corresponding author), Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.; Lao, YZ; Xu, HX (corresponding author), Shanghai Coll TCM New Drug Discovery, Engn Res Ctr, Shanghai 201203, Peoples R China.
EM laurence_ylao@163.com; xuhongxi88@gmail.com
RI Fu, Wenwei/AAD-6756-2020; Zhang, Li/AAD-5917-2020; tan,
   Hongsheng/AAD-5830-2020; Xu, Hongxi/AAC-2799-2020; , Yuanzhi/D-3936-2015
OI Xu, Hongxi/0000-0001-6238-4511; , Yuanzhi/0000-0002-7803-4484
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81173485, 81273403]; Natural Science
   Foundation of ShanghaiNatural Science Foundation of Shanghai
   [14ZR1441300]
FX This work was supported by the National Natural Science Foundation of
   China (No 81173485 and 81273403) and the Natural Science Foundation of
   Shanghai (No 14ZR1441300).
CR Anholeti MC, 2015, AN ACAD BRAS CIENC, V87, P289, DOI 10.1590/0001-3765201520140564
   [Anonymous], 2004, GUID IND BOT DRUG PR
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Date AA, 2016, DRUG DISCOV TODAY, V21, P333, DOI 10.1016/j.drudis.2015.10.019
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Farooqi AA, 2014, MAR DRUGS, V12, P5408, DOI 10.3390/md12115408
   Feng C, 2012, INT J CANCER, V131, P1445, DOI 10.1002/ijc.27365
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Goldar Samira, 2015, Asian Pac J Cancer Prev, V16, P2129
   Guo XQ, 2015, CHEM-BIOL INTERACT, V235, P27, DOI 10.1016/j.cbi.2015.04.009
   Kan WLT, 2013, INT J CANCER, V132, P707, DOI 10.1002/ijc.27694
   Kim GT, 2014, INT J MOL MED, V33, P863, DOI 10.3892/ijmm.2014.1658
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Liu EY, 2012, J CELL SCI, V125, P2349, DOI 10.1242/jcs.093708
   Nash KM, 2015, INTEGR MED INSIGHTS, V10, P1, DOI 10.4137/IMI.S25054
   Ouyang L, 2012, CELL PROLIFERAT, V45, P487, DOI 10.1111/j.1365-2184.2012.00845.x
   Ovadje P, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/751348
   Romano B, 2014, PHYTOMEDICINE, V21, P631, DOI 10.1016/j.phymed.2013.11.006
   van Beek TA, 2009, J CHROMATOGR A, V1216, P2002, DOI 10.1016/j.chroma.2009.01.013
   Wang XY, 2015, SCI REP-UK, V5, DOI 10.1038/srep10293
   Wu M, 2015, PHYTOMEDICINE, V22, P902, DOI 10.1016/j.phymed.2015.06.008
   Wu SB, 2014, NAT PROD REP, V31, P1158, DOI 10.1039/c4np00027g
   Wu Z. Y., 1991, FLORA OF YUNNAN
   Xu G, 2008, J AGR FOOD CHEM, V56, P11144, DOI 10.1021/jf802690g
NR 26
TC 14
Z9 14
U1 3
U2 19
PU ACTA PHARMACOLOGICA SINICA
PI SHANGHAI
PA 294 TAI-YUAN RD, SHANGHAI, 200031, PEOPLES R CHINA
SN 1671-4083
EI 1745-7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD FEB
PY 2017
VL 38
IS 2
BP 252
EP 263
DI 10.1038/aps.2016.101
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA EJ2AY
UT WOS:000393013400010
PM 27840412
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Liu, J
   Ren, YJ
   Hou, YL
   Zhang, CQ
   Wang, B
   Li, XR
   Sun, R
   Liu, J
AF Liu, Jing
   Ren, Yanjun
   Hou, Yinglong
   Zhang, Caiqing
   Wang, Bei
   Li, Xiaorui
   Sun, Rong
   Liu, Ju
TI Dihydroartemisinin Induces Endothelial Cell Autophagy through
   Suppression of the Akt/mTOR Pathway
SO JOURNAL OF CANCER
LA English
DT Article
DE Dihydroartemisinin; Autophagy; HUVEC; Akt; MTOR
ID COLORECTAL-CANCER CELLS; SIGNALING PATHWAYS; MAMMALIAN TARGET;
   ANGIOGENESIS; INHIBITION; APOPTOSIS; PHOSPHORYLATION; PROLIFERATION;
   ARTESUNATE; INDUCTION
AB Aims: Dihydroartemisinin (DHA), a derivative of artemisinin, suppresses angiogenesis by regulating endothelial cell phenotypes. In this study, we investigated the effect of DHA on endothelial cell autophagy and the underlying mechanisms.
   Methods: Human umbilical vein endothelial cells (HUVECs) were treated with DHA. Formation of autophagosomes in HUVECs was observed by fluorescence microscope after pcDNA3.1-green fluorescent protein (GFP)-microtubule-associated protein 1 light chain 3 (LC3) plasmids transfection. Dichlorofluorescein diacetate (DCFH-DA) staining was used to detect intracellular reactive oxygen species (ROS). Western blot was performed to detect the protein levels of LC3, p62, beclin 1, autophagy-related protein (Atg) 5, p-Akt (protein kinase B), p-mTOR (mammalian target of rapamycin), p-4E-BP1 (eukaryotic translation initiation factor 4E-binding protein 1), and p-p70S6K (p70 ribosomal S6 kinase).
   Results: DHA increased LC3-II and the number of fluorescent GFP-LC3 puncta in HUVECs. Silencing ATG5 by siRNA interference attenuated DHA-induced LC3-II elevation. DHA enhanced ROS production, but pretreatment with antioxidant N-acety-l-cysteine (NAC) failed to reduce DHA-induced autophagy in HUVECs. Pretreatment with PD98059, SP600125 and SB203580, the inhibitors of ERK, JNK, and p38 MAPK, did not reverse autophagy in DHA-treated HUVECs. DHA significantly reduced phosphorylation of Akt, mTOR, p70S6K, 4E-BP1 in HUVECs. Rapamycin, an mTOR antagonist, compromised DHA-induced autophagy.
   Conclusion: DHA induces autophagy in HUVECs by inhibition of the Akt/mTOR pathway
C1 [Liu, Jing; Liu, Ju] Shandong First Med Univ, Hosp 1, Shandong Prov Qianfoshan Hosp, Lab Microvasc Med,Med Res Ctr, Jinan, Shandong, Peoples R China.
   [Ren, Yanjun] Shandong First Med Univ, Hosp 1, Shandong Prov Qianfoshan Hosp, Dept Orthopaed, Jinan, Shandong, Peoples R China.
   [Hou, Yinglong] Shandong First Med Univ, Hosp 1, Shandong Prov Qianfoshan Hosp, Dept Cardiol, Jinan, Shandong, Peoples R China.
   [Zhang, Caiqing] Shandong First Med Univ, Hosp 1, Shandong Prov Qianfoshan Hosp, Dept Resp Med, Jinan, Shandong, Peoples R China.
   [Wang, Bei] Shandong First Med Univ, Hosp 1, Shandong Prov Qianfoshan Hosp, Dept Ultrasound, Jinan, Shandong, Peoples R China.
   [Li, Xiaorui] Shandong First Med Univ & Shandong Acad Med Sci, Grad Sch, Jinan, Shandong, Peoples R China.
   [Sun, Rong] Shandong Univ, Adv Med Res Inst, Jinan, Shandong, Peoples R China.
   [Sun, Rong] Shandong Univ, Hosp 2, Jinan, Shandong, Peoples R China.
RP Liu, J (corresponding author), Shandong First Med Univ, Hosp 1, Shandong Prov Qianfoshan Hosp, Med Res Ctr, 16766 Jingshi Rd, Jinan 250014, Shandong, Peoples R China.
EM ju.liu@sdu.edu.cn
RI Liu, Ju/Q-6319-2016
OI Liu, Ju/0000-0001-9932-2613
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81700319]; Traditional Chinese Medicine
   Research Projects of Shandong Province [2015-285]; National Fundamental
   Research Program of China [2009CB522802]; Shandong Taishan Scholarship;
   Science and Technology Development Plan of Shandong Province
   [2016GSF121037]
FX This work was supported by grants from National Natural Science
   Foundation of China (81700319), the Traditional Chinese Medicine
   Research Projects of Shandong Province (no. 2015-285), the National
   Fundamental Research Program of China (2009CB522802), the Shandong
   Taishan Scholarship (R.S and J.L) and the Science and Technology
   Development Plan of Shandong Province (2016GSF121037).
CR Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI 10.1089/ARS.2008.2270
   Chen HH, 2003, PHARMACOL RES, V48, P231, DOI 10.1016/S1043-6618(03)00107-5
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   D'Alessandro S, 2011, BIOCHEM PHARMACOL, V82, P476, DOI 10.1016/j.bcp.2011.06.002
   DiPietro LA, 2016, J LEUKOCYTE BIOL, V100, P979, DOI 10.1189/jlb.4MR0316-102R
   Dong FY, 2016, ONCOL LETT, V12, P4699, DOI 10.3892/ol.2016.5223
   Dong FY, 2015, INT J MOL MED, V35, P1381, DOI 10.3892/ijmm.2015.2140
   Dong FY, 2014, CANCER BIOL THER, V15, P1479, DOI 10.4161/15384047.2014.955728
   Dong WD, 2018, STEM CELLS, V36, P1863, DOI 10.1002/stem.2904
   Edwards SR, 2007, J BIOL CHEM, V282, P13395, DOI 10.1074/jbc.M700498200
   Feng FB, 2018, BIOMED PHARMACOTHER, V102, P1209, DOI 10.1016/j.biopha.2018.03.142
   Feng X, 2014, BIOCHEM BIOPH RES CO, V444, P376, DOI 10.1016/j.bbrc.2014.01.053
   Guo L, 2014, EXP THER MED, V8, P1707, DOI 10.3892/etm.2014.1997
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Jia G, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-8
   Jiang LB, 2016, SCI REP-UK, V6, DOI 10.1038/srep38979
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Kuang M, 2018, CELL PHYSIOL BIOCHEM, V47, P475, DOI 10.1159/000489982
   Lampada A, 2017, CELL DEATH DIFFER, V24, P1045, DOI 10.1038/cdd.2017.41
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Lu M, 2014, TUMOR BIOL, V35, P5307, DOI 10.1007/s13277-014-1691-9
   Lu QL, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002529
   Martina JA, 2012, AUTOPHAGY, V8, P903, DOI 10.4161/auto.19653
   Mi YJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120426
   Moriyama M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.4
   Odaka Y, 2014, CARCINOGENESIS, V35, P192, DOI 10.1093/carcin/bgt277
   Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Virgin HW, 2009, NAT IMMUNOL, V10, P461, DOI 10.1038/ni.1726
   Wahl O, 2011, CURR MED CHEM, V18, P3136, DOI 10.2174/092986711796391570
   Wang ZW, 2015, SEMIN CANCER BIOL, V35, pS224, DOI 10.1016/j.semcancer.2015.01.001
   Wei TS, 2017, INT J MOL MED, V40, P972, DOI 10.3892/ijmm.2017.3085
   Xu CC, 2016, EUR J MED CHEM, V107, P192, DOI 10.1016/j.ejmech.2015.11.003
   Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33
   Yang WJ, 2005, J BIOL CHEM, V280, P9330, DOI 10.1074/jbc.M413394200
   Ying Z, 2016, AUTOPHAGY, V12, P707, DOI 10.1080/15548627.2016.1151596
   Zhang ZL, 2016, FREE RADICAL BIO MED, V101, P272, DOI 10.1016/j.freeradbiomed.2016.10.498
NR 40
TC 22
Z9 22
U1 4
U2 13
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2019
VL 10
IS 24
BP 6057
EP 6064
DI 10.7150/jca.33704
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JE7YF
UT WOS:000490906300017
PM 31762815
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bagherian, A
   Roudi, B
   Masoudian, N
   Mirzaei, H
AF Bagherian, Ali
   Roudi, Bostan
   Masoudian, Nahid
   Mirzaei, Hamed
TI Anti-glioblastoma effects of nanomicelle-curcumin plus erlotinib
SO FOOD & FUNCTION
LA English
DT Article
ID KAPPA-B; CELL-PROLIFERATION; COLORECTAL-CANCER; DOWN-REGULATION;
   LUNG-CANCER; CYCLIN D1; IN-VITRO; GROWTH; EGFR; ANGIOGENESIS
AB Glioblastoma (GBM), one of the most significant brain neoplasms, is characterized by high metastasis and recurrence. Crossing the blood-brain barrier is one of the main therapeutic obstacles, seriously hampering therapeutic agents entering the brain. This research investigated the co-delivery of erlotinib and curcumin via nanomicelles for enhancing anti-GBM treatment in vitro. For this purpose, curcumin and nanomicelle-curcumin (50 mu M) were investigated alone and also with erlotinib (50 mu M) in U87 glioblastoma cells. The cell viability of U87 cells after exposure to curcumin/nanomicelle curcumin/erlotinib and their combinations was measured by CCK-8 assay. The expression of the Wnt signaling-related genes was measured by qRT-PCR assay. The altered expression of NF-kB and proteins associated with angiogenesis, apoptosis, and autophagy were investigated by western blot assay. Compared with the control, all treatments reduced the viability of U87 glioblastoma cells. Furthermore, the level of proteins related to angiogenesis and Wnt pathway-associated genes in the nanomicelle-curcumin + erlotinib group were significantly decreased compared to the curcumin, erlotinib, and control groups. Each treatment regulated autophagy and apoptosis-associated proteins. Total phospho-NF-kappa B (p65) and total NF-kappa B (p65) declined in each treatment at the protein levels. Overall, nanomicelle-curcumin alone or combined with erlotinib showed anti-GBM activity in the U87 cell line by regulating the signaling pathways in GBM pathogenesis and thus may be a promising nanodrug candidate for application in the field of GBM therapy.
C1 [Bagherian, Ali; Roudi, Bostan; Masoudian, Nahid] Islamic Azad Univ, Damghan Branch, Dept Biol, Fac Sci, Damghan, Iran.
   [Mirzaei, Hamed] Kashan Univ Med Sci, Inst Basic Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran.
   [Mirzaei, Hamed] Kashan Univ Med Sci, Student Res Comm, Kashan, Iran.
RP Masoudian, N (corresponding author), Islamic Azad Univ, Damghan Branch, Dept Biol, Fac Sci, Damghan, Iran.; Mirzaei, H (corresponding author), Kashan Univ Med Sci, Inst Basic Sci, Res Ctr Biochem & Nutr Metab Dis, Kashan, Iran.; Mirzaei, H (corresponding author), Kashan Univ Med Sci, Student Res Comm, Kashan, Iran.
EM nahidmasoudian@yahoo.com; h.mirzaei2002@gmail.com
OI mirzaei, hamed/0000-0002-9399-8281
FU Islamic Azad University, Damghan Branch, Damghan, IranIslamic Azad
   University
FX This study was a part of thesis that was supported from Islamic Azad
   University, Damghan Branch, Damghan, Iran.
CR Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167
   Bae MK, 2006, ONCOL REP, V15, P1557
   Bagherian A, 2020, J MOL NEUROSCI, V70, P1471, DOI 10.1007/s12031-020-01639-z
   Bayet-Robert M, 2010, CANCER BIOL THER, V9, P8, DOI 10.4161/cbt.9.1.10392
   Binion DG, 2008, GUT, V57, P1509, DOI 10.1136/gut.2008.152496
   Chen YH, 2018, EXP THER MED, V15, P2922, DOI 10.3892/etm.2018.5783
   Deng Y, 2016, ANTICANCER RES, V36, P5639, DOI 10.21873/anticanres.11147
   Dhandapani KM, 2007, J NEUROCHEM, V102, P522, DOI 10.1111/j.1471-4159.2007.04633.x
   Eimer S, 2011, CANCER BIOL THER, V11, P1017, DOI 10.4161/cbt.11.12.15693
   El-Azab M, 2011, EUR J PHARMACOL, V652, P7, DOI 10.1016/j.ejphar.2010.11.008
   Eskilsson E, 2018, NEURO-ONCOLOGY, V20, P743, DOI 10.1093/neuonc/nox191
   Ferreira LC, 2015, ANTI-CANCER AGENT ME, V15, P1285, DOI 10.2174/1871520615666150520093644
   Gallardo M, 2016, INT J ONCOL, V49, P1019, DOI 10.3892/ijo.2016.3598
   Ganjali S, 2014, SCI WORLD J, DOI 10.1155/2014/898361
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Halatsch M.-E., 2014, TUMORS CENTRAL NERVO
   Hesari A, 2019, INT J CANCER, V144, P1215, DOI 10.1002/ijc.31947
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Karmakar S, 2007, NEUROCHEM RES, V32, P2103, DOI 10.1007/s11064-007-9376-z
   Karpel-Massler G, 2009, MOL CANCER RES, V7, P1000, DOI 10.1158/1541-7786.MCR-08-0479
   Keller S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061295
   Kim JY, 2012, ARCH ORAL BIOL, V57, P1018, DOI 10.1016/j.archoralbio.2012.04.005
   Kim SY, 2005, BIOCHEM BIOPH RES CO, V337, P510, DOI 10.1016/j.bbrc.2005.09.079
   Koprowski S, 2015, J SURG RES, V198, P434, DOI 10.1016/j.jss.2015.03.029
   Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002/ijc.24593
   Lainey E, 2013, ONCOGENE, V32, P4331, DOI 10.1038/onc.2012.469
   Leo JE, 2019, BIOMOL THER, V27, P484, DOI 10.4062/biomolther.2019.107
   Li L, 2015, ONCOGENE, V34, P129, DOI 10.1038/onc.2013.534
   Li L, 2007, MOL CANCER THER, V6, P1276, DOI 10.1158/1535-7163.MCT-06-0556
   Lichtor T., 2013, EVOLUTION MOL BIOL B, P37
   Liu XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1235-7
   Liu XJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0338-2
   Luthra PM, 2016, EUR J MED CHEM, V109, P23, DOI 10.1016/j.ejmech.2015.11.049
   Mardani R, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153082
   Mortezaee K, 2019, J CELL PHYSIOL, V234, P12537, DOI 10.1002/jcp.28122
   Mukhopadhyay A, 2002, ONCOGENE, V21, P8852, DOI 10.1038/sj.onc.1206048
   Mulvihill JJE, 2020, NANOMEDICINE-UK, V15, P205, DOI 10.2217/nnm-2019-0367
   Nduom EK, 2016, NEURO-ONCOLOGY, V18, P195, DOI 10.1093/neuonc/nov172
   Noch EK, 2018, WORLD NEUROSURG, V116, P505, DOI 10.1016/j.wneu.2018.04.022
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pradhan N, 2015, J MOL MED, V93, P1095, DOI 10.1007/s00109-015-1277-z
   Saadeh FS, 2018, INT J BIOL MARKER, V33, P22, DOI 10.5301/ijbm.5000301
   Sandur SK, 2009, INT J RADIAT ONCOL, V75, P534, DOI 10.1016/j.ijrobp.2009.06.034
   Shabaninejad Z, 2020, EUR J MED CHEM, V188, DOI 10.1016/j.ejmech.2020.112040
   Shafabakhsh R, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104353
   Shi Z, 2007, CANCER RES, V67, P11012, DOI 10.1158/0008-5472.CAN-07-2686
   Shi Z, 2009, ONCOL REP, V21, P483, DOI 10.3892/or_00000248
   Sordillo LA, 2015, ANTICANCER RES, V35, P6373
   Soubannier V, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020029
   Tan AC, 2020, CA-CANCER J CLIN, V70, P299, DOI 10.3322/caac.21613
   Timotheadou Eleni, 2011, Chemother Res Pract, V2011, P878912, DOI 10.1155/2011/878912
   Vivanco I, 2012, CANCER DISCOV, V2, P458, DOI 10.1158/2159-8290.CD-11-0284
   Wang G, 2017, ONCOL REP, V37, P657, DOI 10.3892/or.2016.5309
   Wang YS, 2012, THER ADV MED ONCOL, V4, P19, DOI 10.1177/1758834011427927
   Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1
   Westover D, 2018, ANN ONCOL, V29, pI10, DOI 10.1093/annonc/mdx703
   Wieser F, 2007, FERTIL STERIL, V88, pS204, DOI 10.1016/j.fertnstert.2007.07.700
   Wong SC, 2021, NUTRIENTS, V13, DOI 10.3390/nu13030950
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Zhou T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107876
   Zhuang WZ, 2012, CANCER SCI, V103, P684, DOI 10.1111/j.1349-7006.2011.02198.x
NR 61
TC 2
Z9 2
U1 9
U2 9
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042-6496
EI 2042-650X
J9 FOOD FUNCT
JI Food Funct.
PD NOV 1
PY 2021
VL 12
IS 21
BP 10926
EP 10937
DI 10.1039/d1fo01611c
EA OCT 2021
PG 12
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA WP8NF
UT WOS:000707177900001
PM 34647945
DA 2022-04-25
ER

PT J
AU Miranda-Goncalves, V
   Cardoso-Carneiro, D
   Valbom, I
   Cury, FP
   Silva, VA
   Granja, S
   Reis, RM
   Baltazar, F
   Martinho, O
AF Miranda-Goncalves, Vera
   Cardoso-Carneiro, Diana
   Valbom, Ines
   Cury, Fernanda Paula
   Silva, Viviane Aline
   Granja, Sara
   Reis, Rui M.
   Baltazar, Fatima
   Martinho, Olga
TI Metabolic alterations underlying Bevacizumab therapy in glioblastoma
   cells
SO ONCOTARGET
LA English
DT Article
DE anti-angiogenic therapy; Bevacizumab; glioblastoma; glycolytic
   metabolism
ID ANTI-ANGIOGENIC THERAPY; ENDOTHELIAL GROWTH-FACTOR; COLORECTAL-CANCER
   CELLS; PHASE-II TRIAL; IN-VIVO; ANTIANGIOGENIC THERAPY; ADJUVANT
   TEMOZOLOMIDE; GLYCOLYTIC PHENOTYPE; RADIATION-THERAPY; INDUCED AUTOPHAGY
AB Anti-VEGF therapy with Bevacizumab is approved for glioblastoma treatment, however, it is known that tumors acquired resistance and eventually became even more aggressive and infiltrative after treatment. In the present study we aimed to unravel the potential cellular mechanisms of resistance to Bevacizumab in glioblastoma in vitro models.
   Using a panel of glioblastoma cell lines we found that Bevacizumab is able to block the secreted VEGF by the tumor cells and be internalized to the cytoplasm, inducing cytotoxicity in vitro. We further found that Bevacizumab increases the expression of hypoxic HIF-1 alpha and CAIX) and glycolytic markers GLUT1 and MCT1), leading to higher glucose uptake and lactate production. Furthermore, we showed that part of the consumed glucose by the tumor cells can be stored as glycogen, hampering cell dead following Bevacizumab treatment. Importantly, we found that this change on the glycolytic metabolism occurs independently of hypoxia and before mitochondrial impairment or autophagy induction. Finally, the combination of Bevacizumab with glucose uptake inhibitors decreased in vivo tumor growth and angiogenesis and shift the expression of glycolytic proteins.
   In conclusion, we reported that Bevacizumab is able to increase the glucose metabolism on cancer cells by abrogating autocrine VEGF in vitro. Define the effects of anti-angiogenic drugs at the cellular level can allow us to discover ways to revert acquired resistance to this therapeutic approaches in the future.
C1 [Miranda-Goncalves, Vera; Cardoso-Carneiro, Diana; Valbom, Ines; Granja, Sara; Reis, Rui M.; Baltazar, Fatima; Martinho, Olga] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Campus Gualtar, Braga, Portugal.
   [Miranda-Goncalves, Vera; Cardoso-Carneiro, Diana; Valbom, Ines; Granja, Sara; Reis, Rui M.; Baltazar, Fatima; Martinho, Olga] ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.
   [Cury, Fernanda Paula; Silva, Viviane Aline; Reis, Rui M.; Martinho, Olga] Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil.
RP Martinho, O (corresponding author), Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Campus Gualtar, Braga, Portugal.; Martinho, O (corresponding author), ICVS 3Bs PT Govt Associate Lab, Braga, Portugal.; Martinho, O (corresponding author), Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil.
EM olgamartinho@med.uminho.pt
RI Granja, Sara/AAE-7136-2021; Martinho, Olga/B-9695-2009; Reis, Rui
   Manuel/B-1744-2018; Sara, Granja C/T-6442-2018; Silva, Viviane A
   O/O-1772-2015; F, Baltazar/A-8720-2010; Reis, Rui Manuel/AAD-6470-2020
OI Granja, Sara/0000-0001-8717-6751; Martinho, Olga/0000-0002-3221-0403;
   Reis, Rui Manuel/0000-0002-9639-7940; Sara, Granja
   C/0000-0001-8717-6751; F, Baltazar/0000-0002-1770-4544; Reis, Rui
   Manuel/0000-0002-9639-7940; Silva, Viviane A O/0000-0001-5919-5242;
   Miranda-Goncalves, Vera/0000-0002-4231-5532
FU Northern Portugal Regional Operational Programme (NORTE), under the
   Portugal, through the European Regional Development Fund (FEDER)
   [NORTE-01-0145-FEDER-000013]; Competitiveness Factors Operational
   Programme (COMPETE); Foundation for Science and Technology
   (FCT)Portuguese Foundation for Science and TechnologyEuropean Commission
   [POCI-01-0145-FEDER-007038]; Brazilian MCTI/CNPq [73/2013]; Fundacao
   para a Ciencia e Tecnologia (FCT), PortugalPortuguese Foundation for
   Science and Technology [SFRH/BD/51997/2012]; FAPESP fellowshipFundacao
   de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2014/03684-0];
   BEPE - Bolsa Estagio de Pesquisa no Exterior [2015/02691-6]; FCT,
   PortugalPortuguese Foundation for Science and TechnologyEuropean
   Commission [SFRH/BPD/108351/2015]
FX This study was partially developed under the scope of the project
   NORTE-01-0145-FEDER-000013, supported by the Northern Portugal Regional
   Operational Programme (NORTE 2020), under the Portugal 2020 Partnership
   Agreement, through the European Regional Development Fund (FEDER), and
   through the Competitiveness Factors Operational Programme (COMPETE), by
   Portuguese funds, through the Foundation for Science and Technology
   (FCT), under the scope of the project POCI-01-0145-FEDER-007038, and by
   Brazilian MCTI/CNPq No 73/2013. VMG was recipient from a PhD fellowship
   (SFRH/BD/51997/2012) from Fundacao para a Ciencia e Tecnologia (FCT),
   Portugal. FC was recipient of a master FAPESP fellowship (no
   2014/03684-0) and "BEPE - Bolsa Estagio de Pesquisa no Exterior" (no
   2015/02691-6). OM is recipient of a post-doc fellowship
   (SFRH/BPD/108351/2015) from FCT, Portugal.
CR Agnihotri S, 2013, ARCH IMMUNOL THER EX, V61, P25, DOI 10.1007/s00005-012-0203-0
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Curtarello M, 2015, CANCER RES, V75, P120, DOI 10.1158/0008-5472.CAN-13-2037
   De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83
   Delay M, 2012, CLIN CANCER RES, V18, P2930, DOI 10.1158/1078-0432.CCR-11-2390
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Fack F, 2015, ACTA NEUROPATHOL, V129, P115, DOI 10.1007/s00401-014-1352-5
   Favaro E, 2012, CELL METAB, V16, P751, DOI 10.1016/j.cmet.2012.10.017
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Gentzler RD, 2013, CURR TREAT OPTION ON, V14, P595, DOI 10.1007/s11864-013-0255-3
   Gil-Gil MJ, 2013, CLIN MED INSIGHTS-ON, V7, P123, DOI 10.4137/CMO.S8503
   Gila MJ, 2012, ANTI-CANCER DRUG, V23, P659, DOI 10.1097/CAD.0b013e3283534d3e
   Granja S, 2015, CURR DRUG METAB, V16, P221, DOI 10.2174/1389200216666150602145145
   Guan H, 2005, CLIN CANCER RES, V11, P2008, DOI 10.1158/1078-0432.CCR-04-0777
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hartwich J, 2013, J PEDIATR SURG, V48, P39, DOI 10.1016/j.jpedsurg.2012.10.016
   Hasan MR, 2011, INT J CANCER, V129, P2115, DOI 10.1002/ijc.26179
   Hasselbalch B, 2010, NEURO-ONCOLOGY, V12, P508, DOI 10.1093/neuonc/nop063
   Hattingen E, 2011, NEURO-ONCOLOGY, V13, P1349, DOI 10.1093/neuonc/nor132
   Hong X, 2007, J EXP THER ONCOL, V6, P219
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175
   Jurgensmeier JM, 2014, CLIN CANCER RES, V20, P4425, DOI 10.1158/1078-0432.CCR-13-0753
   Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108
   Kramer I, 2007, J CLIN PHARM THER, V32, P1, DOI 10.1111/j.1365-2710.2007.00800.x
   Kumar K, 2013, J MOL MED, V91, P749, DOI 10.1007/s00109-013-0996-2
   Lai A, 2011, J CLIN ONCOL, V29, P142, DOI 10.1200/JCO.2010.30.2729
   Liang J, 2015, ONCOTARGET, V6, P31479, DOI 10.18632/oncotarget.5491
   Marchiq I, 2016, J MOL MED, V94, P155, DOI 10.1007/s00109-015-1307-x
   Martinho O, 2017, THERANOSTICS, V7, P717, DOI 10.7150/thno.17154
   Martinho O, 2013, TRANSL ONCOL, V6, P187, DOI 10.1593/tlo.12400
   McIntyre A, 2015, EMBO MOL MED, V7, P368, DOI 10.15252/emmm.201404271
   McIntyre A, 2012, CLIN CANCER RES, V18, P3100, DOI 10.1158/1078-0432.CCR-11-1877
   Mehta Shaveta, 2011, Journal of the National Cancer Institute Monographs, P71, DOI 10.1093/jncimonographs/lgr027
   Miranda-Goncalves V, 2016, ONCOTARGET, V7, P46335, DOI 10.18632/oncotarget.10114
   Miranda-Goncalves V, 2013, NEURO-ONCOLOGY, V15, P172, DOI 10.1093/neuonc/nos298
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087
   Perera RM, 2007, NEOPLASIA, V9, P1099, DOI 10.1593/neo.07721
   Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274
   Reardon DA, 2011, J NEURO-ONCOL, V103, P371, DOI 10.1007/s11060-010-0403-6
   Sathornsumetee S, 2008, J CLIN ONCOL, V26, P271, DOI 10.1200/JCO.2007.13.3652
   Sathornsumetee S, 2010, NEURO-ONCOLOGY, V12, P1300, DOI 10.1093/neuonc/noq099
   Silva-Oliveira RJ, 2016, CELL ONCOL, V39, P253, DOI 10.1007/s13402-016-0270-z
   Soda Y, 2013, J MOL MED, V91, P439, DOI 10.1007/s00109-013-1019-z
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Tanaka S, 2013, NAT REV CLIN ONCOL, V10, P14, DOI 10.1038/nrclinonc.2012.204
   Weller M, 2014, LANCET ONCOL, V15, pE395, DOI 10.1016/S1470-2045(14)70011-7
   Weller M, 2013, LANCET ONCOL, V14, pE370, DOI 10.1016/S1470-2045(13)70168-2
   Xu J, 2013, MOL CANCER THER, V12, P717, DOI 10.1158/1535-7163.MCT-12-1016-T
   Yang LJ, 2014, CANCER INVEST, V32, P31, DOI 10.3109/07357907.2013.861474
   Yopp AC, 2011, ANN SURG ONCOL, V18, P2192, DOI 10.1245/s10434-011-1570-1
NR 52
TC 12
Z9 12
U1 1
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 28
PY 2017
VL 8
IS 61
BP 103657
EP 103670
DI 10.18632/oncotarget.21761
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1TY
UT WOS:000419562500074
PM 29262591
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Hernandez-Borrero, LJ
   Zhang, SL
   Lulla, A
   Dicker, DT
   El-Deiry, WS
AF Hernandez-Borrero, Liz J.
   Zhang, Shengliang
   Lulla, Amriti
   Dicker, David T.
   El-Deiry, Wafik S.
TI CB002, a novel p53 tumor suppressor pathway-restoring small molecule
   induces tumor cell death through the pro-apoptotic protein NOXA
SO CELL CYCLE
LA English
DT Article
DE apoptosis; autophagy; mutant p53 degradation; NOXA; p53 pathway
   restoration; ubiquitin proteasome system
ID MUTANT P53; CANCER-CELLS; OPPORTUNITIES; RESTORATION; ACTIVATION;
   AUTOPHAGY; GAIN; ATG5; DRUG; P73
AB P53 tumor suppressor gene mutations occur in the majority of human cancers and contribute to tumor development, progression and therapy resistance. Direct functional restoration of p53 as a transcription factor has been difficult to achieve in the clinic. We performed a functional screen using a bioluminescence-based transcriptional read-out to identify small molecules that restore the p53 pathway in mutant p53-bearing cancer cells. We identified CB002, as a candidate that restores p53 function in mutant p53-expressing colorectal cancer cells and without toxicity to normal human fibroblasts. Cells exposed to CB002 show increased expression of endogenous p53 target genes NOXA, DR5, and p21 and cell death which occurs by 16hours, as measured by cleaved caspases or PARP. Stable knockdown of NOXA completely abrogates PARP cleavage and reduces sub-G1 content, implicating NOXA as the key mediator of cell death induction by CB002. Moreover, CB002 decreases the stability of mutant p53 in RXF393 cancer cells and an exogenously expressed R175H p53 mutant in HCT116 p53-null cells. R175H p53 expression was rescued by addition of proteasome inhibitor MG132 to CB002, suggesting a role for ubiquitin-mediated degradation of the mutant protein. In summary, CB002, a p53 pathway-restoring compound that targets mutant p53 for degradation and induces tumor cell death through NOXA, may be further developed as a cancer therapeutic.
C1 Fox Chase Canc Ctr, Dept Med Oncol, Lab Translat Oncol & Expt Canc Therapeut, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
   Fox Chase Canc Ctr, Mol Therapeut Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.
RP El-Deiry, WS (corresponding author), 333 Cottman Ave,P2035, Philadelphia, PA 19111 USA.
EM wafik.eldeiry@gmail.com
RI Lulla, Amriti R./AAI-4167-2020; El-Deiry, Wafik/AAJ-6080-2020
OI El-Deiry, Wafik/0000-0002-9577-8266
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [N01-CN43302-WA-17, N01-CN43302- WA-27,
   R01 CA176289]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA176289] Funding Source: NIH
   RePORTER
FX This work was supported by NIH grants N01-CN43302-WA-17, N01-CN43302-
   WA-27, and R01 CA176289 (W.S.E-D.). W.S.E-D. is an American Cancer
   Society (ACS) Research Professor.
CR Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105
   Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282
   DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42
   Garufi A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.217
   Hong B, 2014, CANCER RES, V74, P1153, DOI 10.1158/0008-5472.CAN-13-0955
   Hong B, 2014, CURR DRUG TARGETS, V15, P80, DOI 10.2174/1389450114666140106101412
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71
   Liu YL, 2014, ONCOTARGET, V5, P11237
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038
   Oshima Y, 2007, CANCER BIOL THER, V6, P1058, DOI 10.4161/cbt.6.7.4320
   Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114
   Parrales A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00288
   Pyo JO, 2005, J BIOL CHEM, V280, P20722, DOI 10.1074/jbc.M413934200
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
   Yu X, 2010, CANCER CELL, V21, P614
   Zhang SL, 2015, CANCER RES, V75, P3842, DOI 10.1158/0008-5472.CAN-13-1079
NR 24
TC 7
Z9 8
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PY 2018
VL 17
IS 5
BP 557
EP 567
DI 10.1080/15384101.2017.1346762
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GE0VN
UT WOS:000430934900005
PM 28749203
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Podolski-Renic, A
   Bosze, S
   Dinic, J
   Kocsis, L
   Hudecz, F
   Csampai, A
   Pesic, M
AF Podolski-Renic, Ana
   Bosze, Szilvia
   Dinic, Jelena
   Kocsis, Laszlo
   Hudecz, Ferenc
   Csampai, Antal
   Pesic, Milica
TI Ferrocene-cinchona hybrids with triazolyl-chalcone linkers act as
   pro-oxidants and sensitize human cancer cell lines to paclitaxel
SO METALLOMICS
LA English
DT Article
ID COLLATERAL SENSITIVITY; IN-VITRO; ANTIPROLIFERATIVE ACTIVITY; AUTOPHAGY;
   SUPEROXIDE; BREAST
AB Recently, we demonstrated that ferrocene-containing compounds with a cinchona moiety displayed marked anticancer activity. Here we report on the effects of the most promising isomers encompassing quinine-(compounds 4 and 5) and quinidine-epimers (compounds 6 and 7)-synthesized using improved methods providing controlled diastereoselectivity-in three different human multidrug resistant (MDR) cancer cell lines and their sensitive counterparts (non-small cell lung carcinoma NCI-H460/R/NCI-H460, colorectal carcinoma DLD1-TxR/DLD1 and glioblastoma U87-TxR/U87). We observed that the presence of the MDR phenotype did not diminish the activity of the compounds suggesting that ferrocene quinine-and quinidine-epimers are not substrates for P-glycoprotein, which has been indicated as a major mechanism of MDR in the cell lines used. Considering that metal-based anticancer agents mainly act by increasing ROS production, we investigated the potential of ferrocene-quinidine epimers to generate ROS. We found that 6 and 7 more readily increased ROS production and induced mitochondrial damage in MDR cancer cells. According to cell death analysis, 6 and 7 were more active against MDR cancer cells showing collateral sensitivity. In addition, our data suggest that these compounds could act as inhibitors of autophagy. Importantly, simultaneous treatments of 6 and 7 with paclitaxel (PTX) increased the sensitivity of MDR cancer cells to PTX. In conclusion, the ferrocene-quinidine epimers, besides being selective towards MDR cancer cells, could also possess potential to overcome PTX resistance.
C1 [Podolski-Renic, Ana; Dinic, Jelena; Pesic, Milica] Univ Belgrade, Dept Neurobiol, Inst Biol Res Sinisa Stankovic IBISS, Belgrade, Serbia.
   [Bosze, Szilvia; Hudecz, Ferenc] Eotvos Lorand Univ, MTA ELTE Res Grp Peptide Chem, Budapest, Hungary.
   [Kocsis, Laszlo; Hudecz, Ferenc] Eotvos Lorand Univ, Dept Organ Chem, Budapest, Hungary.
   [Csampai, Antal] Eotvos Lorand Univ, Dept Inorgan Chem, Budapest, Hungary.
RP Pesic, M (corresponding author), Univ Belgrade, Dept Neurobiol, Inst Biol Res Sinisa Stankovic IBISS, Belgrade, Serbia.
EM camala@ibiss.bg.ac.rs
RI Kocsis, László/AAB-3683-2019; Bosze, Szilvia/X-1368-2019; Pešić,
   Milica/I-4727-2019
OI Kocsis, László/0000-0002-0277-5374; Bosze, Szilvia/0000-0001-9555-699X;
   Pešić, Milica/0000-0002-9045-8239; Podolski-Renic,
   Ana/0000-0001-7412-3685; Dinic, Jelena/0000-0003-3371-2381
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia [III41031]; Hungarian National Research FundOrszagos
   Tudomanyos Kutatasi Alapprogramok (OTKA) [OTKA K104385]
FX This research was supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia (Grant No. III41031)
   and by a grant from the Hungarian National Research Fund (OTKA K104385).
   This work was performed within the framework of COST Actions CM1106
   (Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells)
   and CM1407 (Challenging organic syntheses inspired by nature from
   natural products chemistry to drug discovery).
CR Arambula JF, 2016, CHEM SCI, V7, P1245, DOI 10.1039/c5sc03519h
   Baraniak D, 2011, BIOORG MED CHEM LETT, V21, P723, DOI 10.1016/j.bmcl.2010.11.127
   Braga SS, 2013, ORGANOMETALLICS, V32, P5626, DOI 10.1021/om400446y
   Choi YM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135083
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Ci Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.506
   Ferle-Vidovic A, 2000, CANCER BIOTHER RADIO, V15, P617, DOI 10.1089/cbr.2000.15.617
   Garg Tarun K., 2004, BMC Pharmacology, V4, P6, DOI 10.1186/1471-2210-4-6
   Gasser G, 2011, J MED CHEM, V54, P3, DOI 10.1021/jm100020w
   Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231
   Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X
   Hall MD, 2009, TRENDS PHARMACOL SCI, V30, P546, DOI 10.1016/j.tips.2009.07.003
   Jaouen G, 2015, CHEM SOC REV, V44, P8802, DOI 10.1039/c5cs00486a
   Jourd'heuil D, 2001, J BIOL CHEM, V276, P28799, DOI 10.1074/jbc.M102341200
   Kachalaki S, 2016, EUR J PHARM SCI, V89, P20, DOI 10.1016/j.ejps.2016.03.025
   Karolyi BI, 2012, MOLECULES, V17, P2316, DOI 10.3390/molecules17032316
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kim JR, 2005, CANCER DETECT PREV, V29, P570, DOI 10.1016/j.cdp.2005.07.005
   Kocsis L, 2016, BIOORG MED CHEM LETT, V26, P946, DOI 10.1016/j.bmcl.2015.12.059
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krzyanowski D, 2014, FREE RADICAL BIO MED, V76, P47, DOI 10.1016/j.freeradbiomed.2014.07.020
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635
   Merenlender-Wagner A, 2015, MOL PSYCHIATR, V20, P126, DOI 10.1038/mp.2013.174
   Mizushima N, 2006, AUTOPHAGY, V2, P302, DOI 10.4161/auto.2945
   Mooney A, 2012, J MED CHEM, V55, P5455, DOI 10.1021/jm3004027
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Ornelas C, 2011, NEW J CHEM, V35, P1973, DOI 10.1039/c1nj20172g
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Pesic M, 2006, J CHEMOTHERAPY, V18, P66, DOI 10.1179/joc.2006.18.1.66
   Plazuk D, 2009, J MED CHEM, V52, P4964, DOI 10.1021/jm900297x
   Pluchino KM, 2012, DRUG RESIST UPDATE, V15, P98, DOI 10.1016/j.drup.2012.03.002
   Podolski-Renic A, 2011, BIOMED PHARMACOTHER, V65, P345, DOI 10.1016/j.biopha.2011.04.015
   Poillet-Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Skiera I, 2015, CHEM BIOL DRUG DES, V86, P911, DOI 10.1111/cbdd.12523
   Stankovic T, 2015, CANCER CHEMOTH PHARM, V76, P555, DOI 10.1007/s00280-015-2821-9
   Taylor CW, 1997, BREAST CANCER RES TR, V42, P7, DOI 10.1023/A:1005716214718
   Todd RC, 2009, METALLOMICS, V1, P280, DOI 10.1039/b907567d
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zhang YB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.77
   Zhao HT, 2003, FREE RADICAL BIO MED, V34, P1359, DOI 10.1016/S0891-5849(03)00142-4
NR 42
TC 22
Z9 22
U1 0
U2 15
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1756-5901
EI 1756-591X
J9 METALLOMICS
JI Metallomics
PD AUG 1
PY 2017
VL 9
IS 8
BP 1132
EP 1141
DI 10.1039/c7mt00183e
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA FH2TV
UT WOS:000410996000011
PM 28737782
DA 2022-04-25
ER

PT J
AU Fricker, M
   O'Prey, J
   Tolkovsky, AM
   Ryan, KM
AF Fricker, M.
   O'Prey, J.
   Tolkovsky, A. M.
   Ryan, K. M.
TI Phosphorylation of Puma modulates its apoptotic function by regulating
   protein stability
SO CELL DEATH & DISEASE
LA English
DT Article
DE Puma; phosphorylation; protein stability
ID COLORECTAL-CANCER CELLS; BH3-ONLY PROTEINS; BCL-2 FAMILY; DEPENDENT
   APOPTOSIS; INDUCE APOPTOSIS; DEATH; BAX; P53; AUTOPHAGY; BINDING
AB Puma is a potent BH3-only protein that antagonises anti-apoptotic Bcl-2 proteins, promotes Bax/Bak activation and has an essential role in multiple apoptotic models. Puma expression is normally kept very low, but can be induced by several transcription factors including p53, p73, E2F1 and FOXO3a, whereby it can induce an apoptotic response. As Puma can to bind and inactivate all anti-apoptotic members of the Bcl-2 family, its activity must be tightly controlled. We report here, for the first time, evidence that Puma is subject to post-translational control through phosphorylation. We show that Puma is phosphorylated at multiple sites, with the major site of phosphorylation being serine 10. Replacing serine 10 with alanine causes reduced Puma turnover and enhanced cell death. Interestingly, Puma turnover occurs through the proteasome, and substitution of serine 10 causes elevated Puma levels independently of macroautophagy, Bcl-2 family member binding, caspase activity and apoptotic death. We conclude, therefore, that phosphorylation of Puma at serine 10 promotes Puma turnover, represses Puma's cell death potential and promotes cell survival. Owing to the highly pro-apoptotic nature of Puma, these studies highlight an important additional regulatory step in the determination of cellular life or death. Cell Death and Disease (2010) 1, e59; doi:10.1038/cddis.2010.38; published online 29 July 2010
C1 [Fricker, M.; O'Prey, J.; Ryan, K. M.] Beatson Inst Canc Res, Tumour Cell Death Lab, Glasgow G61 1BD, Lanark, Scotland.
   [Fricker, M.; Tolkovsky, A. M.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England.
   [Tolkovsky, A. M.] Univ Cambridge, Cambridge Ctr Brain Repair, Cambridge CB2 OPY, England.
RP Ryan, KM (corresponding author), Beatson Inst Canc Res, Tumour Cell Death Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.
EM mf309@cam.ac.uk; k.ryan@beatson.gla.ac.uk
RI FRICKER, MICHAEL/ABE-2316-2021
OI Fricker, Michael/0000-0002-8587-1774; Ryan, Kevin M./0000-0002-1059-9681
FU Cancer Research UKCancer Research UK; Association for International
   Cancer Research; Wellcome TrustWellcome TrustEuropean Commission; BBSRC
   (University of Cambridge)UK Research & Innovation (UKRI)Biotechnology
   and Biological Sciences Research Council (BBSRC)University of Cambridge;
   Cancer Research UK (Beatson Institute)Cancer Research UK
FX We thank Noboru Mizushima, Craig Thompson, Andy Villunger, Stanley
   Korsmeyer, Bert Vogelstein and Karen Vousden for reagents and members of
   the Tumour Cell Death Laboratory for critical reading of the paper. Work
   in the Tumour Cell Death Laboratory is supported by Cancer Research UK
   and the Association for International Cancer Research. Work in the
   Tolkovsky Laboratory was supported by the Wellcome Trust. MF was the
   recipient of a BBSRC research studentship (University of Cambridge) and
   was supported by Cancer Research UK as a post-doctoral fellow (Beatson
   Institute).
CR Bell HS, 2007, J CLIN INVEST, V117, P1008, DOI 10.1172/JCI28920
   Bell LA, 2006, ONCOGENE, V25, P5656, DOI 10.1038/sj.onc.1209580
   Callus BA, 2008, J MOL BIOL, V384, P313, DOI 10.1016/j.jmb.2008.09.041
   Cartron PF, 2004, MOL CELL, V16, P807, DOI 10.1016/j.molcel.2004.10.028
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723
   Giam M, 2008, ONCOGENE, V27, pS128, DOI 10.1038/onc.2009.50
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798
   Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200
   Kim H, 2006, NAT CELL BIOL, V8, P1348, DOI 10.1038/ncb1499
   Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100
   Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7
   Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39
   Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200
   Ming L, 2006, J BIOL CHEM, V281, P16034, DOI 10.1074/jbc.M513587200
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   O'Prey J, 2010, CELL CYCLE, V9, P947, DOI 10.4161/cc.9.5.10872
   O'Prey J, 2009, CELL CYCLE, V8, P2260, DOI 10.4161/cc.8.14.9050
   Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6
   Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200
   van Delft MF, 2006, CELL RES, V16, P203, DOI 10.1038/sj.cr.7310028
   Verma S, 2001, J BIOL CHEM, V276, P4671, DOI 10.1074/jbc.M008983200
   Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   Yee KS, 2008, APOPTOSIS, V13, P87, DOI 10.1007/s10495-007-0140-2
   You H, 2006, J EXP MED, V203, P1657, DOI 10.1084/jem.20060353
   Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1
   Yu J, 2008, ONCOGENE, V27, pS71, DOI 10.1038/onc.2009.45
   Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
   Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200
NR 35
TC 49
Z9 50
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2010
VL 1
AR e59
DI 10.1038/cddis.2010.38
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 665VP
UT WOS:000283064100007
PM 21364664
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhou, CF
   Yi, CH
   Yi, YX
   Qin, WY
   Yan, YN
   Dong, XY
   Zhang, XW
   Huang, Y
   Zhang, R
   Wei, J
   Ali, DW
   Michalak, M
   Chen, XZ
   Tang, JF
AF Zhou, Cefan
   Yi, Changhua
   Yi, Yongxiang
   Qin, Wenying
   Yan, Yanan
   Dong, Xueying
   Zhang, Xuewen
   Huang, Yuan
   Zhang, Rui
   Wei, Jie
   Ali, Declan William
   Michalak, Marek
   Chen, Xing-Zhen
   Tang, Jingfeng
TI LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via
   activating Wnt/beta-catenin and autophagy pathway through modulating the
   miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes
SO MOLECULAR CANCER
LA English
DT Article
DE PVT1; Gemcitabine resistance; Autophagy; miR-619-5p; Wnt/beta-catenin
ID NONCODING RNA PVT1; COLORECTAL-CANCER; INDUCED APOPTOSIS; BREAST-CANCER;
   CHEMORESISTANCE; AXIS; DEGRADATION; PROGRESSION; EXPRESSION; COMPLEX
AB Background: Pancreatic cancer is one of the most lethal malignancies and has an extremely poor diagnosis and prognosis. The development of resistance to gemcitabine is still a major challenge. The long noncoding RNA PVT1 was reported to be involved in carcinogenesis and chemoresistance; however, the mechanism by which PVT1 regulates the sensitivity of pancreatic cancer to gemcitabine remains poorly understood.
   Methods: The viability of pancreatic cancer cells was assessed by MTT assay in vitro and xenograft tumor formation assay in vivo. The expression levels of PVT1 and miR-619-5p were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Western blotting analysis and qRT-PCR were performed to assess the protein and mRNA levels of Pygo2 and ATG14, respectively. Autophagy was explored via autophagic flux detection under confocal microscopy and autophagic vacuole investigation under transmission electron microscopy (TEM). The functional role and mechanism of PVT1 were further investigated by gain- and loss-of-function assays in vitro.
   Results: In the present study, we demonstrated that PVT1 was up-regulated in gemcitabine-resistant pancreatic cancer cell lines. Gain- and loss-of-function assays revealed that PVT1 impaired sensitivity to gemcitabine in vitro and in vivo. We further found that PVT1 up-regulated the expression of both Pygo2 and ATG14 and thus regulated Wnt/beta-catenin signaling and autophagic activity to overcome gemcitabine resistance through sponging miR-619-5p. Moreover, we discovered three TCF/LEF binding elements (TBEs) in the promoter region of PVT1, and activation of Wnt/beta-catenin signaling mediated by the up-regulation of Pygo2 increased PVT1 expression by direct binding to the TBE region. Furthermore, PVT1 was discovered to interact with ATG14, thus promoting assembly of the autophagy specific complex I (PtdIns3K-C1) and ATG14-dependent class III PtdIns3K activity.
   Conclusions: These data indicate that PVT1 plays a critical role in the sensitivity of pancreatic cancer to gemcitabine and highlight its potential as a valuable target for pancreatic cancer therapy.
C1 [Zhou, Cefan; Qin, Wenying; Yan, Yanan; Dong, Xueying; Zhang, Xuewen; Huang, Yuan; Zhang, Rui; Tang, Jingfeng] Hubei Univ Technol, Natl 111 Ctr Cellular Regulat & Mol Pharmaceut, Key Lab Fermentat Engn, Minist Educ, 28 NanLi Rd, Wuhan 430068, Hubei, Peoples R China.
   [Yi, Changhua; Yi, Yongxiang; Wei, Jie] Southeast Univ, Nanjing Clin Med Ctr Infect Dis, Affiliated Hosp 2, Hosp Nanjing 2, Nanjing, Peoples R China.
   [Ali, Declan William] Univ Alberta, Dept Biol Sci, Edmonton, AB, Canada.
   [Michalak, Marek] Univ Alberta, Dept Biochem, Edmonton, AB, Canada.
   [Chen, Xing-Zhen] Univ Alberta, Fac Med & Dent, Dept Physiol, Membrane Prot Dis Res Grp, Edmonton, AB, Canada.
RP Tang, JF (corresponding author), Hubei Univ Technol, Natl 111 Ctr Cellular Regulat & Mol Pharmaceut, Key Lab Fermentat Engn, Minist Educ, 28 NanLi Rd, Wuhan 430068, Hubei, Peoples R China.
EM Jingfeng_hut@163.com
OI Zhou, Cefan/0000-0003-0680-3843
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31701228, 31871420, 31871176]; Wuhan Science
   and Technology Project [2019020701011475]
FX This work was supported by the National Natural Science Foundation of
   China (31701228 to C.F.Z., 31871420 to J.F.T., 31871176 to X.Z.C.),
   Wuhan Science and Technology Project (2019020701011475 to J.F.T).
CR Chen ZL, 2020, MOL THER-NUCL ACIDS, V19, P1434, DOI 10.1016/j.omtn.2020.01.030
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Du PZ, 2019, J ONCOL, V2019, DOI 10.1155/2019/9325407
   Ferrarelli LK, 2017, SCIENCE, V356, P1346, DOI [10.1126/science.356.6345.1346-r, DOI 10.1126/SCIENCE.356.6345.1346-R]
   Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001
   Frankel LB, 2017, AUTOPHAGY, V13, P3, DOI 10.1080/15548627.2016.1222992
   Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082
   Ghosal S, 2013, STEM CELLS DEV, V22, P2240, DOI 10.1089/scd.2013.0014
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   He J, 2015, AUTOPHAGY, V11, P373, DOI 10.1080/15548627.2015.1009781
   Hosokawa N, 2009, MOL BIOL CELL, V20, P1981, DOI 10.1091/mbc.E08-12-1248
   Huang MG, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay7522
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Keihani S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aay2670
   Kim J, 2013, CELL, V152, P290, DOI 10.1016/j.cell.2012.12.016
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kugimiya N, 2015, J CELL MOL MED, V19, P1569, DOI 10.1111/jcmm.12531
   Larson-Casey JL, 2016, IMMUNITY, V44, P582, DOI 10.1016/j.immuni.2016.01.001
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0439-7
   Liu CG, 2018, P NATL ACAD SCI USA, V115, P13075, DOI 10.1073/pnas.1809681115
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Munschauer M, 2018, NATURE, V563, DOI 10.1038/s41586-018-0584-2
   Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489
   Nager M, 2018, AUTOPHAGY, V14, P619, DOI 10.1080/15548627.2017.1423439
   Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0
   Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Ping GF, 2018, AM J TRANSL RES, V10, P138
   Rothenberg M L, 1996, Oncology (Williston Park), V10, P18
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20
   Uppada SB, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0848-3
   Wan L, 2016, MOL CANCER THER, V15, P1082, DOI 10.1158/1535-7163.MCT-15-0707
   Wickstrom M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9904
   Wu CM, 2018, CELL DEATH DIFFER, V25, P1855, DOI 10.1038/s41418-018-0138-z
   Wu FQ, 2016, J HEPATOL, V65, P314, DOI 10.1016/j.jhep.2016.04.019
   Yamada T, 2000, CANCER RES, V60, P4761
   You L, 2011, BIOCHEM BIOPH RES CO, V407, P1, DOI 10.1016/j.bbrc.2011.02.027
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zeng FR, 2020, ONCOGENE, V39, P293, DOI 10.1038/s41388-019-0984-2
   Zhang A, 2015, CELL REP, V13, P209, DOI 10.1016/j.celrep.2015.08.069
   Zhang DY, 2016, AUTOPHAGY, V12, P1447, DOI 10.1080/15548627.2016.1185576
   Zhang J, 2019, CANCER RES, V79, P3714, DOI 10.1158/0008-5472.CAN-18-3928
   Zhang XW, 2015, BIOCHEM BIOPH RES CO, V462, P227, DOI 10.1016/j.bbrc.2015.04.121
   Zhang YF, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117280
   Zhang ZM, 2016, ONCOGENE, V35, P4787, DOI 10.1038/onc.2016.10
   Zhou C, 2019, AUTOPHAGY, V7, P1, DOI DOI 10.1080/15548627.2019.1687212.PUBMED
   Zhou CF, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0422-7
   Zhou CF, 2017, ONCOTARGET, V8, P101309, DOI 10.18632/oncotarget.21087
   Zhou CF, 2017, ONCOTARGET, V8, P27915, DOI 10.18632/oncotarget.15843
   Zhou CF, 2016, ONCOTARGET, V7, P54488, DOI 10.18632/oncotarget.10239
   Zhou CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep31789
   Zhuang JL, 2017, THERANOSTICS, V7, P3053, DOI 10.7150/thno.19542
NR 56
TC 68
Z9 69
U1 12
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 29
PY 2020
VL 19
IS 1
AR 118
DI 10.1186/s12943-020-01237-y
PG 24
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA MX1FJ
UT WOS:000557472000001
PM 32727463
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ren, BJ
   Zhou, ZW
   Zhu, DJ
   Ju, YL
   Wu, JH
   Ouyang, MZ
   Chen, XW
   Zhou, SF
AF Ren, Bao-Jun
   Zhou, Zhi-Wei
   Zhu, Da-Jian
   Ju, Yong-Le
   Wu, Jin-Hao
   Ouyang, Man-Zhao
   Chen, Xiao-Wu
   Zhou, Shu-Feng
TI Alisertib Induces Cell Cycle Arrest, Apoptosis, Autophagy and Suppresses
   EMT in HT29 and Caco-2 Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE alisertib; colorectal cancer; cell cycle; programmed cell death; EMT
ID TO-MESENCHYMAL TRANSITION; INVESTIGATIONAL AURORA KINASE; SIGNALING
   PATHWAYS; CANCER; INHIBITOR; PHOSPHORYLATION; PROTEIN; DEATH;
   PI3K/AKT/MTOR; CHEMOTHERAPY
AB Colorectal cancer (CRC) is one of the most common malignancies worldwide with substantial mortality and morbidity. Alisertib (ALS) is a selective Aurora kinase A (AURKA) inhibitor with unclear effect and molecular interactome on CRC. This study aimed to evaluate the molecular interactome and anticancer effect of ALS and explore the underlying mechanisms in HT29 and Caco-2 cells. ALS markedly arrested cells in G2/M phase in both cell lines, accompanied by remarkable alterations in the expression level of key cell cycle regulators. ALS induced apoptosis in HT29 and Caco-2 cells through mitochondrial and death receptor pathways. ALS also induced autophagy in HT29 and Caco-2 cells, with the suppression of phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), but activation of 5 1 AMP-activated protein kinase (AMPK) signaling pathways. There was a differential modulating effect of ALS on p38 MAPK signaling pathway in both cell lines. Moreover, induction or inhibition of autophagy modulated basal and ALS-induced apoptosis in both cell lines. ALS potently suppressed epithelial to mesenchymal transition (EMT) in HT29 and Caco-2 cells. Collectively, it suggests that induction of cell cycle arrest, promotion of apoptosis and autophagy, and suppression of EMT involving mitochondrial, death receptor, PI3K/Akt/mTOR, p38 MAPK, and AMPK signaling pathways contribute to the cancer cell killing effect of ALS on CRC cells.
C1 [Ren, Bao-Jun; Zhu, Da-Jian; Ju, Yong-Le; Wu, Jin-Hao; Ouyang, Man-Zhao; Chen, Xiao-Wu] Southern Med Univ, Shunde Peoples Hosp 1, Dept Gastrointestinal Surg, Guangzhou 528300, Guangdong, Peoples R China.
   [Ren, Bao-Jun; Zhou, Zhi-Wei; Zhou, Shu-Feng] Univ S Florida, Coll Med, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA.
RP Chen, XW (corresponding author), Southern Med Univ, Shunde Peoples Hosp 1, Dept Gastrointestinal Surg, Guangzhou 528300, Guangdong, Peoples R China.; Zhou, SF (corresponding author), Univ S Florida, Coll Med, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA.
EM rbjsdyy@outlook.com; zzhou1@health.usf.edu; zdjsdyy@outlook.com;
   jylsdyy@outlook.com; wjhsdyy@outlook.com; oymzsdyy@outlook.com;
   cxwsdyy@outlook.com; szhou@health.usf.edu
RI Ouyang, Manzhao/U-2758-2017; Zhou, Shu-Feng/E-3166-2013
OI Zhou, Shu-Feng/0000-0002-5542-6119
FU College of Pharmacy, University of South Florida, Tampa, Florida, USA
FX The authors appreciate the financial support from the Startup Fund of
   the College of Pharmacy, University of South Florida, Tampa, Florida
   33612, USA. Zhi-Wei Zhou is a holder of a postdoctoral scholarship from
   the College of Pharmacy, University of South Florida, Tampa, Florida
   33612, USA.
CR Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508
   Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11
   American Cancer Society, 2013, CANC FACTS FIG
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Baba Y, 2009, NEOPLASIA, V11, P418, DOI 10.1593/neo.09154
   Bolanos-Garcia VM, 2005, INT J BIOCHEM CELL B, V37, P1572, DOI 10.1016/j.biocel.2005.02.021
   Boss DS, 2009, ONCOLOGIST, V14, P780, DOI 10.1634/theoncologist.2009-0019
   Cammareri P, 2010, CANCER RES, V70, P4655, DOI 10.1158/0008-5472.CAN-09-3953
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06
   CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3
   Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200
   Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005
   D'Assoro AB, 2014, ONCOGENE, V33, P599, DOI 10.1038/onc.2012.628
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Ding YH, 2015, DRUG DES DEV THER, V9, P425, DOI 10.2147/DDDT.S74062
   Dotan E, 2012, BRIT J CANCER, V106, P748, DOI 10.1038/bjc.2011.587
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179
   Gorgun G, 2010, BLOOD, V115, P5202, DOI 10.1182/blood-2009-12-259523
   Goos JACM, 2013, BRIT J CANCER, V109, P2445, DOI 10.1038/bjc.2013.608
   Harel M, 2015, MOL CELL PROTEOMICS, V14, P1127, DOI 10.1074/mcp.M114.043364
   Heerboth S, 2015, CLIN TRANSL MED, V4, DOI 10.1186/s40169-015-0048-3
   Heras-Sandoval D, 2014, CELL SIGNAL, V26, P2694, DOI 10.1016/j.cellsig.2014.08.019
   Hong X, 2014, CANCER CHEMOTH PHARM, V73, P983, DOI 10.1007/s00280-014-2430-z
   Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401
   HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178
   Li JP, 2015, DRUG DES DEV THER, V9, P1627, DOI 10.2147/DDDT.S75378
   Lombardi L, 2010, CANCER TREAT REV, V36, pS34, DOI 10.1016/S0305-7372(10)70018-9
   Lozy F, 2012, SEMIN CELL DEV BIOL, V23, P395, DOI 10.1016/j.semcdb.2012.01.005
   Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046
   Macurek L, 2009, CANCER RES, V69, P4555, DOI 10.1158/0008-5472.CAN-09-0142
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Mester J, 2013, AM J MED GENET C, V163C, P114, DOI 10.1002/ajmg.c.31364
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nauseef JT, 2011, NAT REV UROL, V8, P428, DOI 10.1038/nrurol.2011.85
   Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096
   Niu NK, 2015, DRUG DES DEV THER, V9, P1555, DOI 10.2147/DDDT.S74197
   Polette M, 2007, CELLS TISSUES ORGANS, V185, P61, DOI 10.1159/000101304
   Sehdev V, 2012, MOL CANCER THER, V11, P763, DOI 10.1158/1535-7163.MCT-11-0623
   Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219
   Siegel R., 2014, CANC J CLIN, V64
   Tang GM, 2008, HUM MOL GENET, V17, P1540, DOI 10.1093/hmg/ddn042
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Troiani T, 2012, EXPERT OPIN INV DRUG, V21, P949, DOI 10.1517/13543784.2012.689287
   Tyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165
   Wang F, 2015, DRUG DES DEV THER, V9, P575, DOI 10.2147/DDDT.S75221
   Yuan CX, 2015, DRUG DES DEV THER, V9, P487, DOI 10.2147/DDDT.S74127
   Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011
   Zhou N, 2013, CLIN CANCER RES, V19, P1717, DOI 10.1158/1078-0432.CCR-12-2383
   Zhou ZW, 2015, DRUG DES DEV THER, V9, P1511, DOI 10.2147/DDDT.S75976
NR 61
TC 27
Z9 28
U1 1
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2016
VL 17
IS 1
AR 41
DI 10.3390/ijms17010041
PG 34
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA DK0DW
UT WOS:000374583800039
PM 26729093
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Kordestani, N
   Rudbari, HA
   Fernandes, AR
   Raposo, LR
   Luz, A
   Baptista, PV
   Bruno, G
   Scopelliti, R
   Fateminia, Z
   Micale, N
   Tumanov, N
   Wouters, J
   Kajani, AA
   Bordbar, AK
AF Kordestani, Nazanin
   Rudbari, Hadi Amiri
   Fernandes, Alexandra R.
   Raposo, Luis R.
   Luz, Andre
   Baptista, Pedro, V
   Bruno, Giuseppe
   Scopelliti, Rosario
   Fateminia, Zohreh
   Micale, Nicola
   Tumanov, Nikolay
   Wouters, Johan
   Kajani, Abolghasem Abbasi
   Bordbar, Abdol-Khalegh
TI Copper(ii) complexes with tridentate halogen-substituted Schiff base
   ligands: synthesis, crystal structures and investigating the effect of
   halogenation, leaving groups and ligand flexibility on antiproliferative
   activities
SO DALTON TRANSACTIONS
LA English
DT Article
ID CU(II) COMPLEXES; CELL APOPTOSIS; DNA-BINDING; CYTOTOXICITY;
   SALICYLALDEHYDE; SPECTROSCOPY
AB To investigate the effect of different halogen substituents and leaving groups and the flexibility of ligands on the anticancer activity of copper complexes, sixteen copper(ii) complexes with eight different tridentate Schiff-base ligands containing pyridine and 3,5-halogen-substituted phenol moieties were synthesized and characterized by spectroscopic methods. Four of these complexes were also characterized by X-ray crystallography. The cytotoxicity of the complexes was determined in three different tumor cell lines (i.e. the A2780 ovarian, HCT116 colorectal and MCF7 breast cancer cell line) and in a normal primary fibroblast cell line. Complexes were demonstrated to induce a higher loss of cell viability in the ovarian carcinoma cell line (A2780) with respect to the other two tumor cell lines, and therefore the biological mechanisms underlying this loss of viability were further investigated. Complexes with ligand L-1 (containing a 2-pycolylamine-type motif) were more cytotoxic than complexes with L-2 (containing a 2-(2-pyridyl)ethylamine-type motif). The loss of cell viability in A2780 tumor cells was observed in the order Cu(Cl-2-L-1)NO3 > Cu(Cl-2-L-1)Cl > Cu(Br-2-L-1)Cl > Cu(BrCl-L-1)Cl. All complexes were able to induce reactive oxygen species (ROS) that could be related to the loss of cell viability. Complexes Cu(BrCl-L-1)Cl and Cu(Cl-2-L-1)NO3 were able to promote A2780 cell apoptosis and autophagy and for complex Cu(BrCl-L-1)Cl the increase in apoptosis was due to the intrinsic pathway. Cu(Cl-2-L-1)Cl and Cu(Br-2-L-1)Cl complexes lead to cellular detachment allowing to correlate with the results of loss of cell viability. Despite the ability of the Cu(BrCl-L-1)Cl complex to induce programmed cell death in A2780 cells, its therapeutic window turned out to be low making the Cu(Cl-2-L-1)NO3 complex the most promising candidate for additional biological applications.
C1 [Kordestani, Nazanin; Rudbari, Hadi Amiri; Fateminia, Zohreh; Bordbar, Abdol-Khalegh] Univ Isfahan, Dept Chem, Esfahan 8171673111, Iran.
   [Fernandes, Alexandra R.; Raposo, Luis R.; Luz, Andre; Baptista, Pedro, V] Univ Nova Lisboa, Fac Ciencias & Tecnol, UCIBIO, Dept Ciencias Vida, P-2829516 Caparica, Portugal.
   [Bruno, Giuseppe; Micale, Nicola] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno Alcontres 31, I-98166 Messina, Italy.
   [Scopelliti, Rosario] Ecole Polytech Fed Lausanne EPFL, Inst Sci Ingn Chim, CH-1015 Lausanne, Switzerland.
   [Tumanov, Nikolay; Wouters, Johan] Univ Namur, Dept Chem, Namur Inst Struct Matter, B-5000 Namur, Belgium.
   [Kajani, Abolghasem Abbasi] Isfahan Univ Med Sci, Appl Physiol Res Ctr, Cardiovasc Res Inst, Esfahan 8174673461, Iran.
   [Bordbar, Abdol-Khalegh] Univ Calif Berkeley, Calif Inst Quantitat Biosci QB3, Berkeley, CA 94720 USA.
RP Rudbari, HA (corresponding author), Univ Isfahan, Dept Chem, Esfahan 8171673111, Iran.; Fernandes, AR (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, UCIBIO, Dept Ciencias Vida, P-2829516 Caparica, Portugal.
EM hamiri1358@gmail.com; ma.fernandes@fct.unl.pt
RI Raposo, Luís/AAX-1610-2021; Kordestani, Nazanin/AAP-9585-2021; Raposo,
   Luís R/T-3754-2017; rudbari, Hadi Amiri/G-8030-2011; Fernandes,
   Alexandra/C-7465-2011; Baptista, Pedro/A-1237-2009
OI Raposo, Luís/0000-0002-8637-346X; Kordestani,
   Nazanin/0000-0001-5108-920X; Raposo, Luís R/0000-0002-8637-346X;
   rudbari, Hadi Amiri/0000-0002-3020-8596; Scopelliti,
   Rosario/0000-0001-8161-8715; Luz, Andre/0000-0001-7764-9033; MICALE,
   Nicola/0000-0002-9294-6033; Fernandes, Alexandra/0000-0003-2054-4438;
   Baptista, Pedro/0000-0001-5255-7095
FU Research Council of the University of Isfahan; national funds from
   FCT/MCTESPortuguese Foundation for Science and Technology
   [UIDB/04378/2020]
FX The authors are grateful to the Research Council of the University of
   Isfahan for financial support of this work. This work was supported by
   the Applied Molecular Biosciences Unit-UCIBIO which is financed by
   national funds from FCT/MCTES (UIDB/04378/2020).
CR Ainscough EW, 1999, J INORG BIOCHEM, V77, P125, DOI 10.1016/S0162-0134(99)00131-2
   Ali SMH, 2014, DALTON T, V43, P1449, DOI 10.1039/c3dt52297k
   An Y, 2006, J INORG BIOCHEM, V100, P1586, DOI 10.1016/j.jinorgbio.2006.05.002
   Angeles-Boza AM, 2004, INORG CHEM, V43, P8510, DOI 10.1021/ic049091h
   [Anonymous], 2018, CRYSALIS PRO RIGAKU
   Aryaeifar M, 2018, POLYHEDRON, V155, P114, DOI 10.1016/j.poly.2018.08.023
   BLESSING RH, 1995, ACTA CRYSTALLOGR A, V51, P33, DOI 10.1107/S0108767394005726
   Chen D, 2008, EXPERT OPIN THER TAR, V12, P739, DOI 10.1517/14728222.12.6.739 
   Choroba K, 2019, DALTON T, V48, P12656, DOI 10.1039/c9dt01922g
   Czerwinska K, 2017, DALTON T, V46, P9591, DOI 10.1039/c7dt01244f
   Daniel KG, 2005, BREAST CANCER RES, V7, pR897, DOI 10.1186/bcr1322
   Daniel KG, 2004, BIOCHEM PHARMACOL, V67, P1139, DOI 10.1016/j.bcp.2003.10.031
   Dehkhodaei M, 2017, INORG CHIM ACTA, V466, P48, DOI 10.1016/j.ica.2017.05.035
   Dhar S, 2003, INORG CHEM, V42, P2483, DOI 10.1021/ic026241k
   Dhar S, 2003, J AM CHEM SOC, V125, P12118, DOI 10.1021/ja036681q
   Diaz-Torres R, 2011, DALTON T, V40, P10742, DOI 10.1039/c1dt11000d
   Duisenberg AJM, 2003, J APPL CRYSTALLOGR, V36, P220, DOI 10.1107/S0021889802022628
   EICHHORN GL, 1968, J AM CHEM SOC, V90, P7323, DOI 10.1021/ja01028a024
   da Silva JLF, 2017, CRYSTENGCOMM, V19, P2802, DOI 10.1039/c7ce00362e
   Fialho L, 2021, INT J POLYM MATER PO, V70, P90, DOI 10.1080/00914037.2019.1695205
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Frezza M, 2007, LETT DRUG DES DISCOV, V4, P311, DOI 10.2174/157018007780867799
   Frezza M, 2009, INORG CHEM, V48, P5928, DOI 10.1021/ic900276g
   Galanski M, 2003, CURR PHARM DESIGN, V9, P2078, DOI 10.2174/1381612033454180
   Gama S, 2011, J INORG BIOCHEM, V105, P637, DOI 10.1016/j.jinorgbio.2011.01.013
   Gielen M., 2005, METALLOTHERAPEUTIC D
   Giovannini C, 2002, FEBS LETT, V523, P200, DOI 10.1016/S0014-5793(02)02972-1
   Hardegger LA, 2011, ANGEW CHEM INT EDIT, V50, P314, DOI 10.1002/anie.201006781
   Hindo SS, 2009, EUR J MED CHEM, V44, P4353, DOI 10.1016/j.ejmech.2009.05.019
   Kannappan R, 2005, INORG CHIM ACTA, V358, P383, DOI 10.1016/j.ica.2004.09.003
   Kazemi Z, 2017, EUR J MED CHEM, V135, P230, DOI 10.1016/j.ejmech.2017.04.053
   Kelland L, 2007, EXPERT OPIN INV DRUG, V16, P1009, DOI 10.1517/13543784.16.7.1009
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373
   Knight KRG, 2005, J CLIN ONCOL, V23, P8588, DOI 10.1200/JCO.2004.00.5355
   Kordestani N, 2021, APPL ORGANOMET CHEM, V35, DOI 10.1002/aoc.6079
   Kordestani N, 2020, ACS COMB SCI, V22, P89, DOI 10.1021/acscombsci.9b00202
   Kumar RS, 2008, J INORG BIOCHEM, V102, P234, DOI 10.1016/j.jinorgbio.2007.08.005
   Lakshmipraba J, 2015, J BIOMOL STRUCT DYN, V33, P877, DOI 10.1080/07391102.2014.918523
   Lee WY, 2012, METALLOMICS, V4, P188, DOI 10.1039/c1mt00147g
   Lee WY, 2010, METALLOMICS, V2, P694, DOI 10.1039/c0mt00016g
   Lu Y., 2010, PHYS CHEM, V18, P4543
   Ma Z, 2016, DALTON T, V45, P5339, DOI 10.1039/c5dt02744f
   Maheswari PU, 2006, J AM CHEM SOC, V128, P710, DOI 10.1021/ja056970+
   Maron A, 2018, DALTON T, V47, P6444, DOI 10.1039/c8dt00558c
   Meng T, 2016, MEDCHEMCOMM, V7, P1802, DOI 10.1039/c6md00201c
   Mukherjee A, 2014, ACCOUNTS CHEM RES, V47, P2514, DOI 10.1021/ar5001555
   Mukherjee S, 2010, INORG CHIM ACTA, V363, P2752, DOI 10.1016/j.ica.2010.04.026
   Parisini E, 2011, CHEM SOC REV, V40, P2267, DOI 10.1039/c0cs00177e
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Rajendiran V, 2007, INORG CHEM, V46, P8208, DOI 10.1021/ic700755p
   Riley KE, 2011, CRYST GROWTH DES, V11, P4272, DOI 10.1021/cg200882f
   Santini C, 2014, CHEM REV, V114, P815, DOI 10.1021/cr400135x
   Shakya R, 2006, INORG CHEM, V45, P6263, DOI 10.1021/ic060106g
   Shakya R, 2006, DALTON T, P2517, DOI 10.1039/b514190g
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Spek AL, 2009, ACTA CRYSTALLOGR D, V65, P148, DOI 10.1107/S090744490804362X
   Strober W., 2001, CURR PROTOC IMMUNOL, V21
   Sun YX, 2007, J COORD CHEM, V60, P2607, DOI 10.1080/00958970701286441
   Sutradhar M, 2019, J INORG BIOCHEM, V200, DOI 10.1016/j.jinorgbio.2019.110811
   Svahn N, 2018, CHEM-EUR J, V24, P14654, DOI 10.1002/chem.201802547
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wang HX, 2012, ACTA CRYSTALLOGR E, V68, pM540, DOI 10.1107/S1600536812013359
   Zhang HR, 2015, MEDCHEMCOMM, V6, P2224, DOI 10.1039/c5md00406c
   Zhang SC, 2004, EUR J INORG CHEM, P4028, DOI 10.1002/ejic.200400357
NR 65
TC 8
Z9 7
U1 1
U2 8
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1477-9226
EI 1477-9234
J9 DALTON T
JI Dalton Trans.
PD MAR 21
PY 2021
VL 50
IS 11
BP 3990
EP 4007
DI 10.1039/d0dt03962d
PG 18
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA RA7LQ
UT WOS:000631597500026
PM 33650599
DA 2022-04-25
ER

PT J
AU Kapuy, O
   Makk-Merczel, K
   Szarka, A
AF Kapuy, Orsolya
   Makk-Merczel, Kinga
   Szarka, Andras
TI Therapeutic Approach of KRAS Mutant Tumours by the Combination of
   Pharmacologic Ascorbate and Chloroquine
SO BIOMOLECULES
LA English
DT Article
DE cancer; Warburg effect; mutant KRAS; PKM2; GLUT1; autophagy;
   chloroquine; ascorbate; systems biology
ID COLORECTAL-CANCER CELLS; AEROBIC GLYCOLYSIS; UP-REGULATION; METABOLISM;
   PKM2; AUTOPHAGY; DYNAMICS; PROMOTES; MTORC1; ACCUMULATION
AB The Warburg effect has been considered a potential therapeutic target to fight against cancer progression. In KRAS mutant cells, PKM2 (pyruvate kinase isozyme M2) is hyper-activated, and it induces GLUT1 expression; therefore, KRAS has been closely involved in the initiation of Warburg metabolism. Although mTOR (mammalian target of rapamycin), a well-known inhibitor of autophagy-dependent survival in physiological conditions, is also activated in KRAS mutants, many recent studies have revealed that autophagy becomes hyper-active in KRAS mutant cancer cells. In the present study, a mathematical model was built containing the main elements of the regulatory network in KRAS mutant cancer cells to explore the further possible therapeutic strategies. Our dynamical analysis suggests that the downregulation of KRAS, mTOR and autophagy are crucial in anti-cancer therapy. PKM2 has been assumed to be the key switch in the stress response mechanism. We predicted that the addition of both pharmacologic ascorbate and chloroquine is able to block both KRAS and mTOR pathways: in this case, no GLUT1 expression is observed, meanwhile autophagy, essential for KRAS mutant cancer cells, is blocked. Corresponding to our system biological analysis, this combined pharmacologic ascorbate and chloroquine treatment in KRAS mutant cancers might be a therapeutic approach in anti-cancer therapies.
C1 [Kapuy, Orsolya; Szarka, Andras] Semmelweis Univ, Inst Biochem & Mol Biol, Dept Mol Biol, H-1428 Budapest, Hungary.
   [Makk-Merczel, Kinga; Szarka, Andras] Budapest Univ Technol & Econ, Dept Appl Biotechnol & Food Sci, Lab Biochem & Mol Biol, H-1111 Budapest, Hungary.
   [Makk-Merczel, Kinga; Szarka, Andras] Budapest Univ Technol & Econ, Fac Chem Technol & Biotechnol, Biotechnol Model Lab, Szent Gellert Ter 4, H-1111 Budapest, Hungary.
RP Szarka, A (corresponding author), Semmelweis Univ, Inst Biochem & Mol Biol, Dept Mol Biol, H-1428 Budapest, Hungary.; Szarka, A (corresponding author), Budapest Univ Technol & Econ, Dept Appl Biotechnol & Food Sci, Lab Biochem & Mol Biol, H-1111 Budapest, Hungary.; Szarka, A (corresponding author), Budapest Univ Technol & Econ, Fac Chem Technol & Biotechnol, Biotechnol Model Lab, Szent Gellert Ter 4, H-1111 Budapest, Hungary.
EM kapuy.orsolya@med.semmelweis-univ.hu; makkmerczel@mail.bme.hu;
   szarka.andras@vbk.bme.hu
OI Szarka, Andras/0000-0001-6594-254X
FU National Research, Development and Innovation Fund of Hungary [K 123752,
   129593, FK 134267, 2018-1.2.1-NKP-2018-00005]
FX This work was financially supported by the National Research,
   Development and Innovation Fund of Hungary under Grant K 123752 and
   129593, FK 134267, 2018-1.2.1-NKP-2018-00005 and by the
   BME-Biotechnology FIKP grant.
CR Abdel-Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511
   Aguilera O, 2016, ONCOTARGET, V7, P47954, DOI 10.18632/oncotarget.10087
   Astanin S, 2009, J THEOR BIOL, V258, P578, DOI 10.1016/j.jtbi.2009.01.034
   Bhattacharya B, 2016, BRIT J PHARMACOL, V173, P970, DOI 10.1111/bph.13422
   Birsoy K, 2014, NATURE, V508, P108, DOI 10.1038/nature13110
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Cai Y, 2018, ONCOL LETT, V15, P1143, DOI 10.3892/ol.2017.7415
   Carmona-Fontaine C, 2013, P NATL ACAD SCI USA, V110, P19402, DOI 10.1073/pnas.1311939110
   CHANCE B, 1952, SCIENCE, V116, P200, DOI 10.1126/science.116.3008.200
   CHANCE B, 1959, SCIENCE, V129, P700, DOI 10.1126/science.129.3350.700
   Colombo SL, 2010, P NATL ACAD SCI USA, V107, P18868, DOI 10.1073/pnas.1012362107
   Dey Prasanta, 2019, Cell Physiol Biochem, V52, P1535, DOI 10.33594/000000107
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904
   Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X
   Gao SM, 2019, J CELL BIOCHEM, V120, P1193, DOI 10.1002/jcb.26915
   GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   He CL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21524
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Holczer M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/319589
   Iovanna JL, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00226
   Iwamoto M, 2014, J NUCL MED, V55, P2038, DOI 10.2967/jnumed.114.142927
   Kaplan D., UNDERSTANDING NONLIN
   Kapuy O, 2009, PROG BIOPHYS MOL BIO, V100, P47, DOI 10.1016/j.pbiomolbio.2009.06.004
   Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909
   Kelloff G, 2005, CLIN CANCER RES, V11, P2785, DOI 10.1158/1078-0432.CCR-04-2626
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Komatsu N, 2015, ONCOGENE, V34, P5607, DOI 10.1038/onc.2015.16
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Luo WB, 2012, TRENDS ENDOCRIN MET, V23, P560, DOI 10.1016/j.tem.2012.06.010
   Martin SP, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01605-y
   NOVAK B, 1993, J CELL SCI, V106, P1153
   O'Brien C, 2019, METAB ENG, V56, P154, DOI 10.1016/j.ymben.2019.08.005
   Onodera Y, 2014, J CLIN INVEST, V124, P367, DOI 10.1172/JCI63146
   Piffoux M, 2021, BRIT J CANCER, V124, P333, DOI 10.1038/s41416-020-01039-5
   Potter M, 2016, BIOCHEM SOC T, V44, P1499, DOI 10.1042/BST20160094
   Schuster S, 2015, BIOCHEM SOC T, V43, P1187, DOI 10.1042/BST20150153
   Segel I.H., ENZYME KINETICS BEHA
   Serna-Blasco R, 2019, SEMIN CANCER BIOL, V54, P80, DOI 10.1016/j.semcancer.2018.01.016
   Shamsi M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27303-6
   Strogatz S. H, 1994, NONLINEAR DYNAMICS C
   Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108
   Szarka A, 2021, ANTIOXID REDOX SIGN, V34, P831, DOI 10.1089/ars.2019.7897
   Tyson JJ, 2002, BIOESSAYS, V24, P1095, DOI 10.1002/bies.10191
   Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6
   Tyson JJ, 2001, NAT REV MOL CELL BIO, V2, P908, DOI 10.1038/35103078
   Tyson JJ, 2011, NAT REV CANCER, V11, P523, DOI 10.1038/nrc3081
   Unterlass JE, 2019, EXPERT REV MOL MED, V21, DOI 10.1017/erm.2019.4
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   Warburg O., 1928, UBER KATALYTISCHEN W, P501
   WARBURG OTTO, 1926, KLIN WOCHENSCHR, V5, P829, DOI 10.1007/BF01726240
   WEINHOUSE S, 1956, SCIENCE, V124, P267, DOI 10.1126/science.124.3215.267
   Xie Jianling, 2016, F1000Res, V5, DOI 10.12688/f1000research.9207.1
   Xu YQ, 2012, J BIOL CHEM, V287, P26409, DOI 10.1074/jbc.M112.352229
   Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182
   Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159
NR 64
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD MAY
PY 2021
VL 11
IS 5
AR 652
DI 10.3390/biom11050652
PG 20
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SG5BD
UT WOS:000653454100001
PM 33925206
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Maddalena, F
   Sisinni, L
   Lettini, G
   Condelli, V
   Matassa, DS
   Piscazzi, A
   Amoroso, MR
   La Torre, G
   Esposito, F
   Landriscina, M
AF Maddalena, Francesca
   Sisinni, Lorenza
   Lettini, Giacomo
   Condelli, Valentina
   Matassa, Danilo Swann
   Piscazzi, Annamaria
   Amoroso, Maria Rosaria
   La Torre, Giuseppe
   Esposito, Franca
   Landriscina, Matteo
TI Resistance to paclitxel in breast carcinoma cells requires a quality
   control of mitochondrial antiapoptotic proteins by TRAP1
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE TRAP1; Paclitaxel; Apoptosis; ER stress; Drug resistance; Breast
   carcinoma
ID HUMAN COLORECTAL-CANCER; ENDOPLASMIC-RETICULUM-STRESS; CHAPERONE TRAP1;
   ER CHAPERONE; GRP78; APOPTOSIS; SORCIN; ACTIVATION; BIOMARKERS;
   AUTOPHAGY
AB TRAP1 is a mitochondrial antiapoptotic protein up-regulated in several human malignancies. However, recent evidences suggest that TRAP1 is also localized in the endoplasmic reticulum (ER) where it is involved in ER stress protection and protein quality control of tumor cells. Based on the mechanistic link between ER stress, protection from apoptosis and drug resistance, we questioned whether these novel roles of TRAP1 are relevant for its antiapoptotic function. Here, we show for the first time that: i) TRAP1 expression is increased in about 50% of human breast carcinomas (BC), and ii) the ER stress protecting activity of TRAP1 is conserved in human tumors since TRAP1 is co-upregulated with the ER stress marker, BiP/Grp78. Notably, ER-associated TRAP1 modulates mitochondrial apoptosis by exerting a quality control on 18 kDa Sorcin, a TRAP1 mitochondrial client protein involved in TRAP1 cytoprotective pathway. Furthermore, this TRAP1 function is relevant in favoring resistance to paclitaxel, a microtubule stabilizing/ER stress inducer agent widely used in BC therapy. Indeed, the transfection of a TRAP1 deletion mutant, whose localization is restricted to the ER, in shTRAP1 cells enhances the expression of mitochondrial Sorcin and protects from apoptosis induced by ER stress agents and paclitaxel. Furthermore, BC cells adapted to paclitaxel or ER stress inducers share common resistance mechanisms: both cell models exhibit cross-resistance to single agents and the inhibition of TRAP1 by siRNAs or gamitrinib, a mitochondria-directed HSP90 family inhibitor, in paclitaxel-resistant cells rescues the sensitivity to paclitaxel. These results support the hypothesis that ER-associated TRAP1 is responsible for an extramitochondrial control of apoptosis and, therefore, an interference of ER stress adaptation through TRAP1 inhibition outside of mitochondria may be considered a further compartment-specific molecular approach to rescue drug-resistance. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Maddalena, Francesca; Sisinni, Lorenza; Lettini, Giacomo; Condelli, Valentina] Referral Canc Ctr Basilicata, IRCCS, Lab Preclin & Translat Res, Rionero In Vulture, PZ, Italy.
   [Matassa, Danilo Swann; Amoroso, Maria Rosaria; Esposito, Franca] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Naples, Italy.
   [Piscazzi, Annamaria; Landriscina, Matteo] Univ Foggia, Dept Med & Surg Sci, Clin Oncol Unit, I-71100 Foggia, Italy.
   [La Torre, Giuseppe] Referral Canc Ctr Basilicata, IRCCS, Unit Gen Surg, Rionero In Vulture, PZ, Italy.
RP Landriscina, M (corresponding author), Univ Foggia, Dipartimento Sci Med & Chirurg, Viale Pinto 1, I-71100 Foggia, Italy.
EM franca.esposito@unina.it; m.landriscina@unifg.it
RI Matassa, Danilo Swann/K-1596-2016; La Torre, Giuseppe/AAI-6866-2020;
   Lettini, Giacomo/K-5391-2018; MADDALENA, FRANCESCA/J-9983-2016;
   Condelli, Valentina/K-1426-2016; Sisinni, Lorenza/K-7543-2016;
   Landriscina, Matteo/K-1092-2016; Esposito, Franca/K-2024-2016
OI Matassa, Danilo Swann/0000-0002-4259-9221; La Torre,
   Giuseppe/0000-0002-1233-2040; MADDALENA, FRANCESCA/0000-0003-4859-885X;
   Condelli, Valentina/0000-0003-4552-2980; Sisinni,
   Lorenza/0000-0002-8159-8109; Esposito, Franca/0000-0001-9340-6875;
   Landriscina, Matteo/0000-0003-0591-9799; Amoroso, Maria
   Rosaria/0000-0002-8982-0616
FU Associazione Italiana per la Ricerca sul Cancro (AIRC)Fondazione AIRC
   per la ricerca sul cancro [IG13128]; Italian Ministry of HealthMinistry
   of Health, Italy [GR-2010-2310057, E66110000220001]
FX Our special thanks to Professor John Credico for proofreading the
   manuscript and suggesting stylistic improvements. This work was
   supported by grants from the Associazione Italiana per la Ricerca sul
   Cancro (AIRC, IG13128) to M.L. and F.E. and from the Italian Ministry of
   Health (Giovani Ricercatori GR-2010-2310057 E66110000220001) to FM.
CR Altieri DC, 2011, ONCOTARGET, V2, P347
   Amoroso MR, 2012, CELL DEATH DIFFER, V19, P592, DOI 10.1038/cdd.2011.128
   Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320
   Badiola N, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.31
   Barone C, 2007, BRIT J CANCER, V96, P21, DOI 10.1038/sj.bjc.6603496
   Boengler K, 2010, BASIC RES CARDIOL, V105, P771, DOI 10.1007/s00395-010-0124-1
   Chae YC, 2012, CANCER CELL, V22, P331, DOI 10.1016/j.ccr.2012.07.015
   Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269
   Costantino E, 2009, CANCER LETT, V279, P39, DOI 10.1016/j.canlet.2009.01.018
   del Alamo M, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001100
   Fang WY, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-32
   Gorman AM, 2012, PHARMACOL THERAPEUT, V134, P306, DOI 10.1016/j.pharmthera.2012.02.003
   Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Kang BH, 2009, ONCOGENE, V28, P3681, DOI 10.1038/onc.2009.227
   Kang BH, 2007, CELL, V131, P257, DOI 10.1016/j.cell.2007.08.028
   Kang BH, 2009, J CLIN INVEST, V119, P454, DOI 10.1172/JCI37613
   Landriscina M, 2010, CANCER RES, V70, P6577, DOI 10.1158/0008-5472.CAN-10-1256
   Landriscina M, 2010, GYNECOL ONCOL, V117, P177, DOI 10.1016/j.ygyno.2009.10.078
   Leav I, 2010, AM J PATHOL, V176, P393, DOI 10.2353/ajpath.2010.090521
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Lee E, 2006, CANCER RES, V66, P7849, DOI 10.1158/0008-5472.CAN-06-1660
   Liao PC, 2008, J CELL BIOCHEM, V104, P1509, DOI 10.1002/jcb.21730
   Liu YF, 2011, CELL RES, V21, P867, DOI 10.1038/cr.2011.75
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Maddalena F, 2011, CANCER RES, V71, P7659, DOI 10.1158/0008-5472.CAN-11-2172
   Matassa DS, 2012, AM J CANCER RES, V2, P235
   Mhaidat NM, 2009, ANTI-CANCER DRUG, V20, P601, DOI 10.1097/CAD.0b013e32832e3120
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Murray S, 2012, CANCER TREAT REV, V38, P890, DOI 10.1016/j.ctrv.2012.02.011
   Ozcan L, 2012, ANNU REV MED, V63, P317, DOI 10.1146/annurev-med-043010-144749
   Rodriguez D, 2011, BBA-MOL CELL RES, V1813, P564, DOI 10.1016/j.bbamcr.2010.11.012
   Scriven P, 2009, BRIT J CANCER, V101, P1692, DOI 10.1038/sj.bjc.6605365
   Siegelin MD, 2011, J CLIN INVEST, V121, P1349, DOI 10.1172/JCI44855
   Suarez J, 2013, AM J PHYSIOL-CELL PH, V304, pC248, DOI 10.1152/ajpcell.00039.2012
   Takemoto K, 2011, NEUROCHEM INT, V58, P880, DOI 10.1016/j.neuint.2011.02.015
   Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795
   Wang J, 2009, J CELL MOL MED, V13, P3888, DOI 10.1111/j.1582-4934.2009.00873.x
   Zhang LH, 2010, J CELL BIOCHEM, V110, P1299, DOI 10.1002/jcb.22679
   Zheng BB, 2012, J PHYSIOL BIOCHEM, V68, P281, DOI 10.1007/s13105-011-0140-0
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 41
TC 57
Z9 62
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD OCT
PY 2013
VL 7
IS 5
BP 895
EP 906
DI 10.1016/j.molonc.2013.04.009
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 234TW
UT WOS:000325668200004
PM 23735188
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Cai, H
   Scott, E
   Kholghi, A
   Andreadi, C
   Rufini, A
   Karmokar, A
   Britton, RG
   Horner-Glister, E
   Greaves, P
   Jawad, D
   James, M
   Howells, L
   Ognibene, T
   Malfatti, M
   Goldring, C
   Kitteringham, N
   Walsh, J
   Viskaduraki, M
   West, K
   Miller, A
   Hemingway, D
   Steward, WP
   Gescher, AJ
   Brown, K
AF Cai, Hong
   Scott, Edwina
   Kholghi, Abeer
   Andreadi, Catherine
   Rufini, Alessandro
   Karmokar, Ankur
   Britton, Robert G.
   Horner-Glister, Emma
   Greaves, Peter
   Jawad, Dhafer
   James, Mark
   Howells, Lynne
   Ognibene, Ted
   Malfatti, Michael
   Goldring, Christopher
   Kitteringham, Neil
   Walsh, Joanne
   Viskaduraki, Maria
   West, Kevin
   Miller, Andrew
   Hemingway, David
   Steward, William P.
   Gescher, Andreas J.
   Brown, Karen
TI Cancer chemoprevention: Evidence of a nonlinear dose response for the
   protective effects of resveratrol in humans and mice
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID ACCELERATOR MASS-SPECTROMETRY; PROSTATE-CANCER; BETA-CAROTENE;
   COLORECTAL-CANCER; AGENT RESVERATROL; CLINICAL-TRIAL; APC(MIN/+);
   SUPPLEMENTATION; MECHANISMS; MOUSE
AB Resveratrol is widely promoted as a potential cancer chemopreventive agent, but a lack of information on the optimal dose prohibits rationally designed trials to assess efficacy. To challenge the assumption that "more is better," we compared the pharmacokinetics and activity of a dietary dose with an intake 200 times higher. The dose-response relationship for concentrations generated and the metabolite profile of [C-14]-resveratrol in colorectal tissue of cancer patients helped us to define clinically achievable levels. In Apc(Min) mice (a model of colorectal carcinogenesis) that received a high-fat diet, the low resveratrol dose suppressed intestinal adenoma development more potently than did the higher dose. Efficacy correlated with activation of adenosine monophosphate-activated protein kinase (AMPK) and increased expression of the senescence marker p21. Nonlinear dose responses were observed for AMPK and mechanistic target of rapamycin (mTOR) signaling in mouse adenoma cells, culminating in autophagy and senescence. In human colorectal tissues exposed to low dietary concentrations of resveratrol ex vivo, we measured enhanced AMPK phosphorylation and autophagy. The expression of the cytoprotective NAD(P) H dehydrogenase, quinone 1 (NQO1) enzyme was also increased in tissues from cancer patients participating in our [C-14]-resveratrol trial. These findings warrant a revision of developmental strategies for diet-derived agents designed to achieve cancer chemoprevention.
C1 [Cai, Hong; Scott, Edwina; Kholghi, Abeer; Andreadi, Catherine; Rufini, Alessandro; Karmokar, Ankur; Britton, Robert G.; Horner-Glister, Emma; Greaves, Peter; Jawad, Dhafer; James, Mark; Howells, Lynne; Steward, William P.; Gescher, Andreas J.; Brown, Karen] Univ Leicester, Dept Canc Studies, Canc Chemoprevent Grp, Leicester LE2 7LX, Leics, England.
   [Ognibene, Ted; Malfatti, Michael] Lawrence Livermore Natl Lab, Livermore, CA 94551 USA.
   [Goldring, Christopher; Kitteringham, Neil; Walsh, Joanne] Univ Liverpool, Dept Pharmacol & Therapeut, MRC, Ctr Drug Safety Sci, Liverpool L69 3GE, Merseyside, England.
   [Viskaduraki, Maria] Univ Leicester, Bioinformat & Biostat Support Hub, Leicester LE1 9HN, Leics, England.
   [West, Kevin; Miller, Andrew; Hemingway, David] Univ Hosp Leicester NHS Trust, Leicester LE1 5WW, Leics, England.
RP Brown, K (corresponding author), Univ Leicester, Dept Canc Studies, Canc Chemoprevent Grp, Leicester LE2 7LX, Leics, England.
EM kb20@le.ac.uk
OI Brown, Karen/0000-0002-5217-1501; Walsh, Joanne/0000-0002-5109-2019
FU Cancer Research UKCancer Research UK [C325/A13101]; Libyan government
   through Benghazi University; NIH National Centre for Research Resources,
   Biomedical Technology ProgramUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [P41RR13461]; Cancer
   Research UKCancer Research UK [13101] Funding Source: researchfish;
   NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Center for Research Resources (NCRR) [P41RR013461] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of General Medical Sciences (NIGMS)
   [P41GM103483] Funding Source: NIH RePORTER
FX This work was supported by Cancer Research UK (C325/A13101) with
   assistance from the Leicester Experimental Cancer Medicine Centre
   (C325/A15575, Cancer Research UK/UK Department of Health). A. Kholghi
   was funded by a studentship from the Libyan government through Benghazi
   University. AMS analysis was performed at the Research Resource for
   Biomedical AMS Laboratory, operated at LLNL, and supported by the NIH
   National Centre for Research Resources, Biomedical Technology Program
   grant #P41RR13461.
CR Aleksandrova K, 2011, CANCER PREV RES, V4, P1873, DOI 10.1158/1940-6207.CAPR-11-0218
   Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Bernstein L, 1999, J NATL CANCER I, V91, P1654, DOI 10.1093/jnci/91.19.1654
   Bhatt JK, 2012, NUTR RES, V32, P537, DOI 10.1016/j.nutres.2012.06.003
   Boocock DJ, 2007, J CHROMATOGR B, V848, P182, DOI 10.1016/j.jchromb.2006.10.017
   Brasnyo P, 2011, BRIT J NUTR, V106, P383, DOI 10.1017/S0007114511000316
   Brown K, 2005, METHOD ENZYMOL, V402, P423, DOI 10.1016/S0076-6879(05)02014-8
   Brown K, 2006, MASS SPECTROM REV, V25, P127, DOI 10.1002/mas.20059
   Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364
   Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)82148-6
   Christensen MJ, 2014, CANCER PREV RES, V7, P781, DOI 10.1158/1940-6207.CAPR-14-0197
   Cuzick J, 2007, JNCI-J NATL CANCER I, V99, P272, DOI 10.1093/jnci/djk049
   Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5
   Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104
   Day SD, 2013, CYTOKINE, V64, P454, DOI 10.1016/j.cyto.2013.04.031
   De Giovanni C, 2004, INT J CANCER, V109, P200, DOI 10.1002/ijc.11690
   Gescher AJ, 2003, CANCER EPIDEM BIOMAR, V12, P953
   Gledhill JR, 2007, P NATL ACAD SCI USA, V104, P13632, DOI 10.1073/pnas.0706290104
   Goodman GE, 2003, CANCER EPIDEM BIOMAR, V12, P518
   Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327
   Hawley SA, 2010, CELL METAB, V11, P554, DOI 10.1016/j.cmet.2010.04.001
   Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221
   Hershman D, 2002, J CLIN ONCOL, V20, P9, DOI 10.1200/JCO.20.1.9
   Ju TC, 2014, BBA-MOL BASIS DIS, V1842, P1668, DOI 10.1016/j.bbadis.2014.06.012
   Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Koehl GE, 2010, ONCOGENE, V29, P1553, DOI 10.1038/onc.2009.435
   Kristal AR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt456
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Larsson SC, 2005, JNCI-J NATL CANCER I, V97, P1679, DOI 10.1093/jnci/dji375
   LUONGO C, 1994, CANCER RES, V54, P5947
   Marshall JR, 1999, J NATL CANCER I, V91, P2068, DOI 10.1093/jnci/91.24.2068
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Park SJ, 2012, CELL, V148, P421, DOI 10.1016/j.cell.2012.01.017
   Patel KR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005870
   Patel KR, 2011, ANN NY ACAD SCI, V1215, P161, DOI 10.1111/j.1749-6632.2010.05853.x
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Patterson SL, 2013, CLIN CHEM, V59, P94, DOI 10.1373/clinchem.2012.185389
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773
   Perkins S, 2002, CANCER EPIDEM BIOMAR, V11, P535
   Pezzuto JM, 2008, PHARM BIOL, V46, P443, DOI 10.1080/13880200802116610
   Poulsen MM, 2013, DIABETES, V62, P1186, DOI 10.2337/db12-0975
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Ristow M, 2014, NAT MED, V20, P709, DOI 10.1038/nm.3624
   Sale S, 2005, INT J CANCER, V115, P194, DOI 10.1002/ijc.20884
   Sansom OJ, 2001, CANCER RES, V61, P7060
   Scott E, 2012, MOL NUTR FOOD RES, V56, P7, DOI 10.1002/mnfr.201100400
   Scott EN, 2009, CANCER PREV RES, V2, P525, DOI 10.1158/1940-6207.CAPR-08-0223
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   STOCCHI V, 1985, ANAL BIOCHEM, V146, P118, DOI 10.1016/0003-2697(85)90405-1
   Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002
   Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x
   Wang QL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017234
   Winzell MS, 2004, DIABETES, V53, pS215, DOI 10.2337/diabetes.53.suppl_3.S215
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   Yoshino J, 2012, CELL METAB, V16, P658, DOI 10.1016/j.cmet.2012.09.015
   Young ARJ, 2010, CURR OPIN CELL BIOL, V22, P234, DOI 10.1016/j.ceb.2009.12.005
   Zheng JB, 2000, BRIT J PHARMACOL, V130, P1115, DOI 10.1038/sj.bjp.0703397
   Ziegler CC, 2004, J NUTR, V134, P5, DOI 10.1093/jn/134.1.5
   Zmijewski JW, 2010, J BIOL CHEM, V285, P33154, DOI 10.1074/jbc.M110.143685
NR 63
TC 100
Z9 100
U1 2
U2 63
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUL 29
PY 2015
VL 7
IS 298
AR 298ra117
DI 10.1126/scitranslmed.aaa7619
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CN9AZ
UT WOS:000358739300003
PM 26223300
OA Green Submitted, Green Accepted
DA 2022-04-25
ER

PT J
AU Chen, PH
   Liu, AJ
   Ho, KH
   Chiu, YT
   Lin, ZHA
   Lee, YT
   Shih, CM
   Chen, KC
AF Chen, Peng-Hsu
   Liu, Ann-Jeng
   Ho, Kuo-Hao
   Chiu, Ya-Ting
   Lin, Zhe-Harn Anne
   Lee, Yi-Ting
   Shih, Chwen-Ming
   Chen, Ku-Chung
TI microRNA-199a/b-5p enhance imatinib efficacy via repressing WNT2
   signaling-mediated protective autophagy in imatinib-resistant chronic
   myeloid leukemia cells
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Imatinib resistance; Autophagy; miR-199a-5p; miR-199b-5p; WNT2; Chronic
   myeloid leukemia (CML)
ID BCR-ABL; LUNG-CANCER; COLORECTAL-CANCER; CML; PATHWAY; INHIBITION;
   DEGRADATION; ACTIVATION; PROTEIN; GENES
AB Imatinib (IM) is a first-line therapeutic drug for chronic myeloid leukemia (CML), a hematological disease. Mutations in the BCR-ABL domain increase formation of IM resistance in CML. However, not all patients are BCR-ABL domain-mutant dependent. Investigating non-mutant mechanisms in the development of acquired IM resistance is a critical issue. We explored the mechanisms which influence IM efficacy and resistance in CML. Higher protective autophagy was identified in IM-resistant K562 (K562R) cells. Inhibition of autophagy by the inhibitors, chloroquine and 3-methyladenine, enhanced IM's efficacy in K562R cells. In addition, microRNA (miR)-199a/b-5p were downregulated in K562R cells compared to parent cells. Overexpression of miR-199a/b-5p reduced autophagy and induced cell apoptosis, resulting in enhanced IM's efficacy in K562R cells. Moreover, expression levels of the Wingless-type MMTV integration site family member 2 (WNT2), a positive regulator of autophagy, were significantly higher in K562R cells, and it was validated as a direct target gene of miR-199a/b5p. Overexpressions of miR-199a/b-5p inhibited WNT2 downstream signaling. Furthermore, overexpression and knockdown of WNT2 influenced autophagy formation and CML drug sensitivity to IM. Overexpression of WNT2 could also reverse miR-199a/b-5p-enhanced IM efficacy in K562R cells. These results emphasized that miR-199a/b-5p inhibited autophagy via repressing WNT2 signaling and might provide novel therapeutic strategies for future IM-resistant CML therapy and drug development.
C1 [Chen, Peng-Hsu; Ho, Kuo-Hao; Chiu, Ya-Ting; Lee, Yi-Ting; Shih, Chwen-Ming; Chen, Ku-Chung] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan.
   [Chen, Peng-Hsu; Ho, Kuo-Hao; Chiu, Ya-Ting; Lee, Yi-Ting; Shih, Chwen-Ming; Chen, Ku-Chung] Taipei Med Univ, Sch Med, Dept Biochem & Mol Cell Biol, Coll Med, Taipei, Taiwan.
   [Liu, Ann-Jeng] Taipei City Hosp, Dept Neurosurg, Ren Ai Branch, Taipei, Taiwan.
   [Lin, Zhe-Harn Anne] Taipei Med Univ, Sch Med, Coll Med, Taipei, Taiwan.
RP Shih, CM; Chen, KC (corresponding author), Taipei Med Univ, Dept Biochem & Mol Cell Biol, 250 Wu Hsing St, Taipei 11031, Taiwan.
EM cmshih@tmu.edu.tw; kuchung@tmu.edu.tw
OI Chiu, wendy/0000-0002-7438-3556
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 106-2320-B-038-051-MY3]; Taipei City Government
   [105XDAA00013]; Taipei City Hospital Ren-Ai Branch [TPCH-106-020];
   Taipei Medical University [106-1200-008-110]
FX This work was supported by the Ministry of Science and Technology,
   Taiwan contract grant no.: MOST 106-2320-B-038-051-MY3
   [https://www.most.gov.tw/] (to Ku-Chung Chen); Taipei City Government
   contract grant no.: 105XDAA00013 [http://english.gov.taipei/] (to
   Ann-Jeng Liu); Taipei City Hospital Ren-Ai Branch contract grant no.:
   TPCH-106-020 [http://tcgwww.taipei.gov.tw] (to Ann-Jeng Liu); and Taipei
   Medical University contract grant no.: 106-1200-008-110
   [http://www.tmu.edu.tw] (to Chwen-Ming Shih). The funders had no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmadi A, 2017, GENE, V620, P15, DOI 10.1016/j.gene.2017.03.032
   Aloisi A, 2006, BLOOD, V107, P1591, DOI 10.1182/blood-2005-05-2123
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Buchdunger E, 1996, CANCER RES, V56, P100
   Can G, 2011, HEMATOLOGY, V16, P95, DOI 10.1179/102453311X12902908412039
   Cao L, 2016, BIOMED PHARMACOTHER, V78, P30, DOI 10.1016/j.biopha.2015.12.029
   Correa S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-303
   Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097
   DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0
   Dharmapuri G, 2015, LEUKEMIA RES, V39, P696, DOI 10.1016/j.leukres.2015.02.013
   Di Stefano C, 2016, ONCOL REP, V35, P614, DOI 10.3892/or.2015.4456
   Elzinga BM, 2013, AM J HEMATOL, V88, P455, DOI 10.1002/ajh.23428
   Fernandes Q, 2017, BLOOD REV, V31, P129, DOI 10.1016/j.blre.2016.11.003
   Goussetis DJ, 2012, BLOOD, V120, P3555, DOI 10.1182/blood-2012-01-402578
   Helgason GV, 2011, BLOOD, V118, P2035, DOI 10.1182/blood-2011-01-330621
   Hochhaus A, 2002, LEUKEMIA, V16, P2190, DOI 10.1038/sj.leu.2402741
   Hofmann WK, 2003, BLOOD, V102, P659, DOI 10.1182/blood-2002-06-1756
   Huang CB, 2015, AM J CANCER RES, V5, P1032
   Jiang H, 2014, AM J CANCER RES, V4, P537
   Joshi D, 2014, GENE, V542, P109, DOI 10.1016/j.gene.2014.03.049
   Jung YS, 2015, ONCOTARGET, V6, P37257, DOI 10.18632/oncotarget.6133
   Kamitsuji Y, 2008, CELL DEATH DIFFER, V15, P1712, DOI 10.1038/cdd.2008.107
   Katoh M, 2001, INT J ONCOL, V19, P1003
   Koshizuka K, 2017, CANCER SCI, V108, P1681, DOI 10.1111/cas.13298
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Petherick KJ, 2013, EMBO J, V32, P1903, DOI 10.1038/emboj.2013.123
   Polakova KM, 2011, MOL CANCER, V10, P41, DOI DOI 10.1186/1476-4598-10-41
   Rokah OH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035501
   Salomoni P, 2009, AUTOPHAGY, V5, P1050, DOI 10.4161/auto.5.7.9509
   San Jose-Eneriz E, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-69
   Seca H, 2013, CURR DRUG TARGETS, V14, P1135, DOI 10.2174/13894501113149990185
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Tsubaki M, 2017, ONCOTARGET, V8, P38717, DOI 10.18632/oncotarget.16314
   Wang LS, 2015, BLOOD, V125, P1302, DOI 10.1182/blood-2014-06-581926
   Wei Y, 2006, ANN HEMATOL, V85, P841, DOI 10.1007/s00277-006-0171-8
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Zhan YY, 2017, ONCOTARGET, V8, P67169, DOI 10.18632/oncotarget.18052
   Zhang B, 2013, BLOOD, V121, P1824, DOI 10.1182/blood-2012-02-412890
NR 41
TC 18
Z9 21
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD AUG 1
PY 2018
VL 291
BP 144
EP 151
DI 10.1016/j.cbi.2018.06.006
PG 8
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA GM6UH
UT WOS:000438310700018
PM 29890129
DA 2022-04-25
ER

PT J
AU Tran, PHL
   Wang, T
   Yin, W
   Tran, TTD
   Nguyen, TNG
   Lee, BJ
   Duan, W
AF Tran, Phuong H. L.
   Wang, Tao
   Yin, Wang
   Tran, Thao T. D.
   Nguyen, Tuong N. G.
   Lee, Beom-Jin
   Duan, Wei
TI Aspirin-loaded nanoexosomes as cancer therapeutics
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE Exosome; Aspirin; Breast cancer; Colorectal cancer; Cancer stem cell
ID STEM-CELLS; TARGETED DELIVERY; EXOSOMES; CARRIERS; APTAMER; ACID;
   DOXORUBICIN; STABILITY; AUTOPHAGY
AB The long history of discovery and recently encouraging studies of the anti-cancer effect of aspirin promise a closer step to widely used aspirin-based medication in cancer therapy. To resolve the poor water-solubility of aspirin and low encapsulation efficiency of exosomes for further developing a new delivery of aspirin as anticancer treatment, our nanoamorphous exosomal delivery platform was established. In this study, the anti-tumour effects of nanoamorphous aspirin-loaded exosomes with exosomes derived from breast and colorectal cancer cells, were comprehensively studied using both in vitro and in vivo models. These exosomes displayed enhanced cellular uptake via both clathrin-dependent and -independent endocytosis pathways, and significantly improved cytotoxicity of aspirin to breast and colorectal cancer cells, accompanied by the enhanced apoptosis and autophagy. Remarkably, this nanoamorphous exosomal platform endowed aspirin with the unprecedented cancer stem cell eradication capacity. Further animal study demonstrated that this developed exosomal system was able to efficiently deliver aspirin to in vivo tumours. The active targeting of these exosomes to tumour was further improved by conjugating an aptamer specifically targeting EpCAM protein. Hence, this nanoamorphous structured exosome system effectively transformed aspirin into a potential cancer stem cell killer with distinguished properties for clinical translation.
C1 [Tran, Phuong H. L.; Yin, Wang; Nguyen, Tuong N. G.; Duan, Wei] Deakin Univ, Sch Med, Waurn Ponds, Vic 3216, Australia.
   [Tran, Phuong H. L.; Yin, Wang; Nguyen, Tuong N. G.; Duan, Wei] Deakin Univ, Ctr Mol & Med Res, Waurn Ponds, Vic 3216, Australia.
   [Wang, Tao] Zhengzhou Univ, Sch Nursing, Zhengzhou 450001, Henan, Peoples R China.
   [Wang, Tao] Murdoch Univ, Ctr Comparat Genom, Perth, WA 6150, Australia.
   [Tran, Thao T. D.] Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City, Vietnam.
   [Tran, Thao T. D.] Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City, Vietnam.
   [Lee, Beom-Jin] Ajou Univ, Coll Pharm, Suwon 16499, South Korea.
RP Tran, PHL; Duan, W (corresponding author), Deakin Univ, Sch Med, Waurn Ponds, Vic 3216, Australia.; Tran, PHL; Duan, W (corresponding author), Deakin Univ, Ctr Mol & Med Res, Waurn Ponds, Vic 3216, Australia.
EM phuong.tran1@deakin.edu.au; wei.duan@deakin.edu.au
RI Tran, Thao/A-5591-2011
OI Tran, Thao/0000-0003-2885-5134; Wang, Tao/0000-0002-9623-8800
FU Australian Research Council's Discovery Early Career Researcher
   AwardAustralian Research Council [DE160100900]
FX Dr. Phuong Ha Lien Tran is the recipient of Australian Research
   Council's Discovery Early Career Researcher Award (project number
   DE160100900).
CR Akuma P, 2019, FRONT SUSTAIN FOOD S, V3, DOI 10.3389/fsufs.2019.00023
   Alberts D.B., 1994, MOL BIOL CELL
   AlShamaileh H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05859-z
   Altman Raul, 2004, Thromb J, V2, P1, DOI 10.1186/1477-9560-2-1
   BAKAR SK, 1983, J PHARM SCI, V72, P1024, DOI 10.1002/jps.2600720914
   Banizs AB, 2014, INT J NANOMED, V9, P4223, DOI 10.2147/IJN.S64267
   Bashir AIJ, 2019, INT J ONCOL, V54, P1256, DOI 10.3892/ijo.2019.4701
   Batrakova EV, 2015, J CONTROL RELEASE, V219, P396, DOI 10.1016/j.jconrel.2015.07.030
   Batrakova EV, 2010, J CONTROL RELEASE, V143, P290, DOI 10.1016/j.jconrel.2010.01.004
   Chazotte B., 2011, COLD SPRING HARB PRO, V2011, P5571, DOI DOI 10.1101/PDB.PR0T5571
   Chen LJ, 2015, NANOSCALE, V7, P14080, DOI 10.1039/c5nr03527a
   Dong XT, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671-017-1980-5
   Dovizio M, 2012, PHARMACEUTICALS-BASE, V5, P1346, DOI 10.3390/ph5121346
   Dutta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097580
   Edgar JR, 2016, BMC BIOL, V14, DOI 10.1186/s12915-016-0268-z
   ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436
   Elwood PC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152402
   Fan YJ, 2013, CHIN J CANCER, V32, P121, DOI 10.5732/cjc.012.10106
   Gilligan KE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061122
   Gomari H, 2018, ONCOTARGETS THER, V11, P5753, DOI 10.2147/OTT.S173110
   Ha D, 2016, ACTA PHARM SIN B, V6, P287, DOI 10.1016/j.apsb.2016.02.001
   Hancock BC, 2000, PHARM RES-DORDR, V17, P397, DOI 10.1023/A:1007516718048
   Hood JL, 2016, NANOMEDICINE-UK, V11, P1745, DOI 10.2217/nnm-2016-0102
   Jiang XC, 2017, INT J PHARMACEUT, V521, P167, DOI 10.1016/j.ijpharm.2017.02.038
   Lai CP, 2014, ACS NANO, V8, P483, DOI 10.1021/nn404945r
   Larcher LM, 2019, MOLECULES, V24, DOI 10.3390/molecules24132489
   LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619
   Lee J.-K., 2014, PLOS ONE, V8
   Li JL, 2016, INT J PHARMACEUT, V512, P262, DOI 10.1016/j.ijpharm.2016.08.037
   Lichtenberger LM, 2017, CANCER PREV RES, V10, P142, DOI 10.1158/1940-6207.CAPR-16-0241
   Lin JE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031686
   Liu L, 2017, CELL PHYSIOL BIOCHEM, V43, P52, DOI 10.1159/000480317
   Luan X, 2017, ACTA PHARMACOL SIN, V38, P754, DOI 10.1038/aps.2017.12
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Meldolesi J, 2018, CURR BIOL, V28, pR435, DOI 10.1016/j.cub.2018.01.059
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Pitto-Barry A, 2014, POLYM CHEM-UK, V5, P3291, DOI 10.1039/c4py00039k
   Shanmuganathan M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01159
   Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3
   Shigdar S, 2013, CANCER LETT, V330, P84, DOI 10.1016/j.canlet.2012.11.032
   Shigdar S, 2011, CANCER SCI, V102, P991, DOI 10.1111/j.1349-7006.2011.01897.x
   Shiozawa Y, 2013, PHARMACOL THERAPEUT, V138, P285, DOI 10.1016/j.pharmthera.2013.01.014
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301
   Tran PHL, 2019, INT J PHARMACEUT, V566, P697, DOI 10.1016/j.ijpharm.2019.06.028
   Voelker M., 2012, Inflammopharmacology, V20, P225, DOI 10.1007/s10787-011-0099-z
   Wang BY, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-016-0463-4
   Wang JH, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00533
   Wang T, 2019, HUM GENE THER METHOD, V30, P1, DOI 10.1089/hgtb.2018.237
   Wang T, 2019, BIOTECHNOL ADV, V37, P28, DOI 10.1016/j.biotechadv.2018.11.001
   Wang T, 2017, CANCER LETT, V387, P77, DOI 10.1016/j.canlet.2016.03.045
   Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176
   Wang T, 2015, THERANOSTICS, V5, P1456, DOI 10.7150/thno.11692
   Whiteside TL, 2018, EXPERT REV MOL DIAGN, V18, P1029, DOI 10.1080/14737159.2018.1544494
   Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316
   Xiang DX, 2017, THERANOSTICS, V7, P4071, DOI 10.7150/thno.20168
   Zhang XW, 2014, EUR J PHARM SCI, V62, P301, DOI 10.1016/j.ejps.2014.06.008
   Zhao QQ, 2016, ONCOL LETT, V12, P2804, DOI 10.3892/ol.2016.5017
   Zhuang XY, 2011, MOL THER, V19, P1769, DOI 10.1038/mt.2011.164
   Zou T, 2013, FASEB J, V27
NR 60
TC 30
Z9 32
U1 5
U2 33
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-5173
EI 1873-3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD DEC 15
PY 2019
VL 572
AR 118786
DI 10.1016/j.ijpharm.2019.118786
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JS4WU
UT WOS:000500308000044
PM 31669214
DA 2022-04-25
ER

PT J
AU Cao, H
   Li, ZL
   Zhou, D
   Wan, LD
   Yu, D
   Zhang, J
   Xu, EP
   Zhang, DD
   Lai, MD
AF Cao, Hui
   Li, Zhenli
   Zhou, Dan
   Wan, Ledong
   Yu, Dan
   Zhang, Jing
   Xu, Enping
   Zhang, Dandan
   Lai, Maode
TI ATG16L1 rs2241880 polymorphism predicts unfavorable clinical outcomes
   for colorectal cancer patients in the Chinese population
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ATG16L1; SNP; rs2241880; colorectal cancer; survival
ID GENOME-WIDE ASSOCIATION; CROHNS-DISEASE; SUSCEPTIBILITY LOCI; JAPANESE
   POPULATION; AUTOPHAGY; CYTOKINES; VARIANTS; T300A; PATHOGENESIS;
   DEGRADATION
AB Numerous studies have shown that the single-nucleotide polymorphism (SNP) rs2241880 (Thr300Ala) of autophagy related 16-like 1 (ATG16L1) is strongly associated with development of Crohn's disease, which represents a risk factor for colorectal cancer (CRC). To date, the role of ATG16L1 rs2241880 polymorphism in CRC remains unclear. In this study, we aim to determine if the rs2241880 SNP is correlated with the risk of developing CRC and to investigate the prognostic value of this SNP in patients with CRC in the Chinese population. No significant association was found between the ATG16L1 genotypes and clinicopathological parameters. We observed that ATG16L1 rs2241880 was not associated with the risk of CRC. However, compared to those with AA and AG genotypes, CRC patients carrying the GG genotype at ATG16L1 showed a marginal trend to be diagnosed with CRC at younger age (recessive model) (P=0.067). Besides, overall median follow-up time was significantly decreased in patients with the GG genotype (recessive model) (P=0.027). Kaplan-Meier survival analysis exhibited that patients carrying the GG genotype of rs2241880 had worse overall survival than those with the AA and AG genotype (P<0.001). In multivariate analyses, rs2241880 GG genotype was revealed as an independent prognostic marker for overall survival (HR=4.70, P<0.001). These results suggest that GG genotype of rs2241880 may predict unfavorable outcome of patients with colorectal cancer. Further investigations are required to explore the role and mechanism of the polymorphism rs2241880 at ATG16L1 in colorectal cancer.
C1 [Cao, Hui; Li, Zhenli; Zhou, Dan; Wan, Ledong; Yu, Dan; Zhang, Jing; Xu, Enping; Zhang, Dandan; Lai, Maode] Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China.
   [Cao, Hui; Li, Zhenli; Zhou, Dan; Wan, Ledong; Yu, Dan; Zhang, Jing; Xu, Enping; Zhang, Dandan; Lai, Maode] Key Lab Dis Prote Zhejiang Prov, Hangzhou 310058, Zhejiang, Peoples R China.
   [Zhou, Dan] Zhejiang Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Hangzhou 310058, Zhejiang, Peoples R China.
RP Lai, MD (corresponding author), Zhejiang Univ, Sch Med, Dept Pathol, Hangzhou 310058, Zhejiang, Peoples R China.
EM lmp@zju.edu.cn
RI wan, ledong/J-8445-2017
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81101640/81572716]; 111 projectMinistry of
   Education, China - 111 Project [B13026]
FX This work was funded by National Natural Science Foundation of China
   (81101640/81572716) and the 111 project (B13026).
CR Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Burada F, 2016, PATHOL ONCOL RES, V22, P317, DOI 10.1007/s12253-015-0006-9
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Cardon LR, 2006, SCIENCE, V314, P1403, DOI 10.1126/science.1136668
   Chen WQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0042-6
   Chen ZY, 2015, INT J CANCER, V136, P584, DOI 10.1002/ijc.29017
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Douroudis K, 2011, HUM IMMUNOL, V72, P613, DOI 10.1016/j.humimm.2011.03.009
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Glas J, 2008, AM J GASTROENTEROL, V103, P682, DOI 10.1111/j.1572-0241.2007.01694.x
   Grimm WA, 2016, GUT, V65, P456, DOI 10.1136/gutjnl-2014-308735
   Gudmundsson J, 2009, NAT GENET, V41, P460, DOI 10.1038/ng.339
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Hirano A, 2013, INFLAMM BOWEL DIS, V19, P526, DOI 10.1097/MIB.0b013e31828075e7
   Hong SN, 2016, GUT, V65, P788, DOI 10.1136/gutjnl-2014-308617
   Huijbers A, 2012, ENDOCR-RELAT CANCER, V19, pL15, DOI 10.1530/ERC-11-0302
   Kenific CM, 2010, CURR OPIN CELL BIOL, V22, P241, DOI 10.1016/j.ceb.2009.10.008
   Kuballa P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003391
   Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf
   Marchiando AM, 2013, CELL HOST MICROBE, V14, P216, DOI 10.1016/j.chom.2013.07.013
   Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044
   Ngoh EN, 2015, GENES IMMUN, V16, P452, DOI 10.1038/gene.2015.30
   Nicoli ER, 2014, ROM J MORPHOL EMBRYO, V55, P57
   Plantinga TS, 2011, GUT, V60, P1229, DOI 10.1136/gut.2010.228908
   Prescott NJ, 2007, GASTROENTEROLOGY, V132, P1665, DOI 10.1053/j.gastro.2007.03.034
   Puleston DJ, 2014, IMMUNOLOGY, V141, P1, DOI 10.1111/imm.12165
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131
   Sadabad MS, 2015, GUT, V64, P1546, DOI 10.1136/gutjnl-2014-307289
   Salem M, 2015, AUTOPHAGY, V11, P585, DOI 10.1080/15548627.2015.1017187
   Seruga B, 2008, NAT REV CANCER, V8, P887, DOI 10.1038/nrc2507
   Sorbara MT, 2013, IMMUNITY, V39, P858, DOI 10.1016/j.immuni.2013.10.013
   Symington JW, 2015, MUCOSAL IMMUNOL, V8, P1388, DOI 10.1038/mi.2015.7
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Usategui-Martin R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128984
   WEEDON DD, 1973, NEW ENGL J MED, V289, P1099, DOI 10.1056/NEJM197311222892101
   Yamazaki K, 2013, GASTROENTEROLOGY, V144, P781, DOI 10.1053/j.gastro.2012.12.021
   Yang SK, 2014, GUT, V63, P80, DOI 10.1136/gutjnl-2013-305193
NR 43
TC 2
Z9 2
U1 2
U2 9
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 8
BP 8586
EP 8595
PG 10
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EA5IR
UT WOS:000386653400098
DA 2022-04-25
ER

PT J
AU Silva, DF
   Vidal, FCB
   Santos, D
   Costa, MCP
   Morgado-Diaz, JA
   Nascimento, MDSB
   de Moura, RS
AF Silva, Dulcelena Ferreira
   Branco Vidal, Flavia Castello
   Santos, Debora
   Pires Costa, Maria Celia
   Morgado-Diaz, Jose Andres
   Soares Brandao Nascimento, Maria do Desterro
   de Moura, Roberto Soares
TI Cytotoxic effects of Euterpe oleracea Mart. in malignant cell lines
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE Anticancer; Euterpe oleracea mart.; MC Gamma-7; Phytochemicals;
   Chemopreventive
ID BREAST-CANCER CELLS; AUTOPHAGOSOME FORMATION; ACAI; INDUCTION;
   APOPTOSIS; RAT; ANTHOCYANINS; PREVENTION; STRESS; FRUIT
AB Background: Euterpe oleracea Mart., a plant from the Amazon region, is commonly known as acai or jucara; it has high nutritional value and elevated levels of lipids, proteins, and minerals. Acai is an abundant and much consumed fruit by the Amazon local population, and studies have demonstrated that it is rich in phytochemicals with antioxidant, anti-inflammatory, and anticancer activities. Therefore, the aim of this study was to test this plant for anticancer activity in different human malignant cell lines.
   Methods: Cell lines derived from breast and colorectal adenocarcinomas were treated with 10, 20, and 40 mu g/mL of bark, seed, and total acai fruit hydroalcoholic extracts for 24 and 48 h. After treatment, cell viability was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, and cell morphological features were observed by light and transmission electron microscopy. The type of cell death was also evaluated. The data were analyzed statistically by one-way analysis of variance (ANOVA), followed by Dunnett's or Tukey's post hoc tests, as appropriate.
   Results: We observed that of all the cell lines tested, MCF-7 was the only line that responded to acai treatment. The extracts caused significant reduction (p < 0.01) in cell viability and altered cell morphological features by inducing the appearance of autophagic vacuoles, as observed by transmission electron microscopy. Furthermore, increased expression of LC3BII, a protein marker of autophagosome formation, was observed by western blotting. Caspase Glo (TM) assays and morphologic observations by DAPI nuclear staining and transmission electron microscopy did not indicate any apoptotic events.
   Conclusions: The present study demonstrated that acai possesses antitumorigenic potential in the MCF-7 cell line. Further studies are needed to identify the compound (s) responsible for this cytotoxic activity and the molecular target in the cell. This discovery of the anticancer potential of acai may help in the development of chemopreventive drugs and may have therapeutic effects in the treatment of breast cancer.
C1 [Silva, Dulcelena Ferreira; Branco Vidal, Flavia Castello] Univ Fed Maranhao, Dept Morphol, BR-65020140 Sao Luis, Maranhao, Brazil.
   [Branco Vidal, Flavia Castello; Soares Brandao Nascimento, Maria do Desterro] Univ Fed Maranhao, Tumors & DNA Bank Maranhao, BR-65020140 Sao Luis, Maranhao, Brazil.
   [Santos, Debora; Pires Costa, Maria Celia] Univ Estadual Maranhao, Dept Biol & Chem, Maranhao, Brazil.
   [Morgado-Diaz, Jose Andres] Natl Canc Inst, Struct Biol Lab, Div Cell Biol, Rio De Janeiro, Brazil.
   [Soares Brandao Nascimento, Maria do Desterro] Univ Fed Maranhao, Dept Pathol, BR-65020140 Sao Luis, Maranhao, Brazil.
   [de Moura, Roberto Soares] Univ Estado Rio De Janeiro, Dept Pharmacol, Lab Pharmacol & Psychobiol, Rio De Janeiro, Brazil.
RP Vidal, FCB (corresponding author), Univ Fed Maranhao, Dept Morphol, Rua Coelho Neto 311, BR-65020140 Sao Luis, Maranhao, Brazil.
EM flavidal@hotmail.com
RI Morgado-Diaz, Jose A./A-9649-2010; Santos, Débora S./P-9188-2014; Vidal,
   Flavia/AAX-6843-2021; do Desterro Soares Brandão Nascimento,
   Maria/S-7024-2019
OI Santos, Débora S./0000-0003-0659-4711; Vidal,
   Flavia/0000-0002-4721-6824; do Desterro Soares Brandão Nascimento,
   Maria/0000-0003-2783-362X
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq),
   Ministerio da Saude, Brasil; Fundacao de Amparo a Pesquisa e ao
   Desenvolvimento Cientifico e Tecnologico do Estado do Maranhao (FAPEMA)
FX This study was supported by grants from the Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq), Ministerio da Saude,
   Brasil, and Fundacao de Amparo a Pesquisa e ao Desenvolvimento
   Cientifico e Tecnologico do Estado do Maranhao (FAPEMA). We are grateful
   to Dr. Marcelo for the preparation of acai extracts and Simone Fernandes
   for sample processing for TEM observations.
CR Ainsworth EA, 2007, NAT PROTOC, V2, P875, DOI 10.1038/nprot.2007.102
   Ait-Mohamed O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024537
   Apostolou A, 2013, FOOD CHEM T IN PRESS
   Bode AM, 2009, NAT REV CANCER, V9, P508, DOI 10.1038/nrc2646
   Branca F, 2003, P NUTR SOC, V62, P877, DOI 10.1079/PNS2003309
   Charalambous C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-238
   da Costa CA, 2012, N-S ARCH PHARMACOL, V385, P1199, DOI 10.1007/s00210-012-0798-z
   De Albuquerque-Xavier AC, 2012, INT J ONCOL, V40, P1267, DOI 10.3892/ijo.2012.1329
   de Moura RS, 2012, PHYTOMEDICINE, V19, P262, DOI 10.1016/j.phymed.2011.11.004
   de Souza MO, 2012, NUTR RES, V32, P976, DOI 10.1016/j.nutres.2012.10.001
   Del Pozo-Insfran D, 2006, J AGR FOOD CHEM, V54, P1222, DOI 10.1021/jf052132n
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fragoso MF, 2013, FOOD CHEM TOXICOL, V58, P68, DOI 10.1016/j.fct.2013.04.011
   Gavilan E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.95
   Harun FB, 2012, SCI WORLD J, DOI 10.1100/2012/439479
   Heinrich M, 2011, PHYTOCHEM LETT, V4, P10, DOI 10.1016/j.phytol.2010.11.005
   Huang HC, 2010, J AGR FOOD CHEM, V58, P8699, DOI 10.1021/jf101003v
   Lee KW, 2011, NAT REV CANCER, V11, P211, DOI 10.1038/nrc3017
   Lichtenthaler R, 2005, INT J FOOD SCI NUTR, V56, P53, DOI 10.1080/09637480500082082
   Mertens-Talcott SU, 2008, J AGR FOOD CHEM, V56, P7796, DOI 10.1021/jf8007037
   Ministerio da Saude I: Estimativa, 2012, ESTIMATIVA 2012 INCI, P118
   Mulabagal V, 2012, PHARM BIOL, V50, P1289, DOI 10.3109/13880209.2012.674141
   Neida S, 2007, ARCH LATINOAM NUTR, V57, P94
   Pietrocola F, 2012, CELL CYCLE, V11, P3851, DOI 10.4161/cc.22027
   Poulose SM, 2012, J AGR FOOD CHEM, V60, P1084, DOI 10.1021/jf203989k
   Prabhakaran P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00134
   Rocha APM, 2007, VASC PHARMACOL, V46, P97, DOI 10.1016/j.vph.2006.08.411
   Schauss AG, 2006, J AGR FOOD CHEM, V54, P8604, DOI 10.1021/jf0609779
   Singh M, 2013, LIFE SCI, V93, P7, DOI 10.1016/j.lfs.2013.02.001
   Stoner GD, 2009, CANCER PREV RES, V2, P187, DOI 10.1158/1940-6207.CAPR-08-0226
   Tsuyuki S, 2012, J BIOCHEM MOL TOXIC, V26, P445, DOI 10.1002/jbt.21443
   Usui T, 2006, ENDOCR J, V53, P7, DOI 10.1507/endocrj.53.7
NR 32
TC 29
Z9 32
U1 1
U2 37
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD MAY 29
PY 2014
VL 14
AR 175
DI 10.1186/1472-6882-14-175
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA AI4UR
UT WOS:000336860800001
PM 24886139
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Moghadasi, M
   Alivand, M
   Fardi, M
   Moghadam, KS
   Solali, S
AF Moghadasi, Maryam
   Alivand, Mohammadreza
   Fardi, Masoumeh
   Moghadam, Kobra Shojaei
   Solali, Saeed
TI Emerging molecular functions of microRNA-124: Cancer pathology and
   therapeutic implications
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE microRNA; Cancer; Drug; Target therapy; Leukemia
ID EPITHELIAL-MESENCHYMAL TRANSITION; INHIBITS CELL-PROLIFERATION;
   WNT/BETA-CATENIN PATHWAY; NONCODING RNA; DOWN-REGULATION;
   MULTIDRUG-RESISTANCE; COLORECTAL-CANCER; ESOPHAGEAL CANCER; INDUCED
   APOPTOSIS; BRAIN METASTASIS
AB MicroRNAs are characterized as small, single-stranded, non-coding RNA molecules that bind to their target mRNA to prevent protein synthesis. MicroRNAs regulate various normal processes; however, they are aberrantly regulated in many cancers. They control the expression of various genes, including cancer-related genes. This causes microRNAs to be considered as a good target for further investigations for designing novel therapeutic strategies.
   Since miR124 is known for some time already, it has a tumor-suppressing role in various cancers. Numerous studies indicate its definite roles in malignant processes such as epithelial-to-mesenchymal transition, cell cycle arrest, metastasis, cancer stem cell formation and induction of apoptosis. However, some studies have indicated a dual role for miR-124 in oncogenic processes like autophagy and multi-drug resistance. In this article, we will review recent researches on the biological functions and clinical implications of miR-124. Subsequently, we will discuss future perspectives in terms of the roles of this miRNA in cancers.
C1 [Moghadasi, Maryam] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Moghadasi, Maryam; Fardi, Masoumeh; Moghadam, Kobra Shojaei] Tabriz Univ Med Sci, IRC, Tabriz, Iran.
   [Alivand, Mohammadreza] Tabriz Univ Med Sci, Dept Med Genet, Tabriz, Iran.
   [Solali, Saeed] Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.
   [Solali, Saeed] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Div Hematol & Transfus Med, Tabriz, Iran.
RP Solali, S (corresponding author), Tabriz Univ Med Sci, Fac Med, Dept Immunol, Div Hematol & Transfus Med, Tabriz, Iran.
EM ssolali@gmail.com
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034
   Awasthi R, 2018, DRUG DELIV TRANSL RE, V8, P97, DOI 10.1007/s13346-017-0440-1
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Cai QQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40733
   Cai WL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0746-0
   Chen SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128472
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Du XX, 2017, TOXICOL LETT, V280, P195, DOI 10.1016/j.toxlet.2017.08.082
   Fardi M., 2018, GENES DIS
   Fardi M, 2019, J CELL PHYSIOL, V234, P14783, DOI 10.1002/jcp.28277
   Feng TB, 2016, ONCOTARGET, V7, P16205, DOI 10.18632/oncotarget.7578
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   FOJO A, 1987, CANCER-AM CANCER SOC, V60, P2075, DOI 10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F
   Friedman HS, 2000, CLIN CANCER RES, V6, P2585
   Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002
   Gong X, 2016, AM J TRANSL RES, V8, P2127
   Gu H, 2016, CANCER MED-US, V5, P1174, DOI 10.1002/cam4.664
   Hashemi Mohammad, 2018, Oncotarget, V9, P24857, DOI 10.18632/oncotarget.25324
   He B., 2018, J CELL BIOCH
   Hong L, 2013, CURR DRUG TARGETS, V14, P1118, DOI 10.2174/13894501113149990183
   Hu FY, 2016, J HUAZHONG U SCI-MED, V36, P839, DOI 10.1007/s11596-016-1672-x
   Hu SL, 2019, J BUON, V24, P805
   Huang J, 2018, J CELL BIOCHEM, V119, P3853, DOI 10.1002/jcb.26464
   Huang TT, 2018, ONCOGENE, V37, P1159, DOI 10.1038/s41388-017-0029-7
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Jia H, 2019, PATHOL RES PRACT, V215, P697, DOI 10.1016/j.prp.2018.12.039
   Jun JH, 2016, INVEST OPHTH VIS SCI, V57, P12, DOI 10.1167/iovs.15-17111
   Kang QM, 2017, ONCOTARGET, V8, P24314, DOI 10.18632/oncotarget.15149
   Kim JC, 2018, CANCER METAST REV, V37, P5, DOI 10.1007/s10555-017-9712-y
   Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002
   la Cour JM, 2003, AM J PATHOL, V163, P81, DOI 10.1016/S0002-9440(10)63632-2
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li JP, 2013, MOL CELL BIOCHEM, V380, P277, DOI 10.1007/s11010-013-1682-y
   Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008
   Li SL, 2017, EUR REV MED PHARMACO, V21, P3389
   Li ZL, 2016, INT J CLIN PHARM TH, V54, P603, DOI 10.5414/CP202551
   Liang YN, 2017, J STEROID BIOCHEM, V172, P62, DOI 10.1016/j.jsbmb.2017.05.014
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Long QZ, 2015, TUMOR BIOL, V36, P7017, DOI 10.1007/s13277-015-3369-3
   Luna JI, 2017, EXPERT OPIN BIOL TH, V17, P313, DOI 10.1080/14712598.2017.1271874
   Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289
   Lv ZH, 2013, MOL MED REP, V8, P345, DOI 10.3892/mmr.2013.1561
   Ma J, 2018, EXP CELL RES, V366, P103, DOI 10.1016/j.yexcr.2018.02.037
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Marisetty AL, 2017, NEURO-ONCOLOGY, V19, P514, DOI 10.1093/neuonc/now232
   Murugan AK, 2016, J CELL PHYSIOL, V231, P1424, DOI 10.1002/jcp.25269
   Peng XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-186
   Perron MP, 2008, FRONT BIOSCI-LANDMRK, V13, P2537, DOI 10.2741/2865
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Schouten M, 2015, SCI REP-UK, V5, DOI 10.1038/srep12448
   Shao QL, 2015, INT J CLIN EXP PATHO, V8, P14465
   Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425
   Shin JH, 2014, AGR WATER MANAGE, V135, P9, DOI 10.1016/j.agwat.2013.12.009
   Tang DX, 2019, J CELL PHYSIOL, V234, P20816, DOI 10.1002/jcp.28687
   Tu HF, 2013, CURR OPIN OTOLARYNGO, V21, P104, DOI 10.1097/MOO.0b013e32835e1d6e
   Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267
   Wang MJ, 2017, CELL PHYSIOL BIOCHEM, V44, P2017, DOI 10.1159/000485907
   Wang XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep36796
   Wang YB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2862-4
   Weiner J.A., 2018, INT J MOL SCI, V19
   Wen XY, 2014, J VIROL, V88, P6906, DOI 10.1128/JVI.00023-14
   Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Wu YJ, 2012, J NEURO-ONCOL, V110, P27, DOI 10.1007/s11060-012-0942-0
   Wu YJ, 2017, ANTICANCER RES, V37, P4029, DOI 10.21873/anticanres.11788
   Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030
   Xie YK, 2012, J NEURO-ONCOL, V110, P179, DOI 10.1007/s11060-012-0961-x
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-276
   Yu B, 2018, MOL MED REP, V17, P6736, DOI 10.3892/mmr.2018.8637
   Yuan L, 2017, ONCOL LETT, V14, P7311, DOI 10.3892/ol.2017.7157
   Zang RK, 2018, EUR REV MED PHARMACO, V22, P4532, DOI 10.26355/eurrev_201807_15508
   Zhang HW, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-84
   Zhang L, 2018, ONCOL LETT, V15, P984, DOI 10.3892/ol.2017.7358
   Zhang N, 2016, MOL PHARMACEUT, V13, P2466, DOI 10.1021/acs.molpharmaceut.6b00211
   Zhang TH, 2017, ONCOL REP, V37, P2087, DOI 10.3892/or.2017.5445
   Zhao Y, 2017, ONCOTARGET, V8, P25005, DOI 10.18632/oncotarget.15334
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
   Zhou LQ, 2016, CELL PHYSIOL BIOCHEM, V38, P1785, DOI 10.1159/000443117
NR 80
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2020
VL 216
IS 3
AR 152827
DI 10.1016/j.prp.2020.152827
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA KW1QS
UT WOS:000520946600001
PM 31983567
DA 2022-04-25
ER

PT J
AU Ahmadi, M
   Amiri, S
   Pecic, S
   Machaj, F
   Rosik, J
   Los, MJ
   Alizadeh, J
   Mahdian, R
   Rosa, SCD
   Schaafsma, D
   Shojaei, S
   Madrakian, T
   Zeki, AA
   Ghavami, S
AF Ahmadi, Mazaher
   Amiri, Shayan
   Pecic, Stevan
   Machaj, Filip
   Rosik, Jakub
   Los, Marek J.
   Alizadeh, Javad
   Mahdian, Reza
   Rosa, Simone C. da Silva
   Schaafsma, Dedmer
   Shojaei, Shahla
   Madrakian, Tayyebeh
   Zeki, Amir A.
   Ghavami, Saeid
TI Pleiotropic effects of statins: A focus on cancer
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Review
DE Mevalonate cascade; Prenylation; Apoptosis; Cancer therapy; Autophagy;
   Chemotherapy
ID HMG-COA REDUCTASE; LOVASTATIN-INDUCED APOPTOSIS; COENZYME-A REDUCTASE;
   ENDOTHELIAL-CELL MIGRATION; DRUG-DRUG INTERACTIONS; IN-VITRO; MEVALONATE
   PATHWAY; GROWTH-FACTOR; LUNG-CANCER; COLORECTAL-CANCER
AB The statin drugs (`statins') potently inhibit hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by competitively blocking the active site of the enzyme. Statins decrease de novo cholesterol biosynthesis and thereby reduce plasma cholesterol levels. Statins exhibit "pleiotropic" properties that are independent of their lipidlowering effects. For example, preclinical evidence suggests that statins inhibit tumor growth and induce apoptosis in specific cancer cell types. Furthermore, statins show chemo-sensitizing effects by impairing Ras family GTPase signaling. However, whether statins have clinically meaningful anti-cancer effects remains an area of active investigation. Both preclinical and clinical studies on the potential mechanisms of action of statins in several cancers have been reviewed in the literature. Considering the contradictory data on their efficacy, we present an up-to-date summary of the pleiotropic effects of statins in cancer therapy and review their impact on different malignancies. We also discuss the synergistic anti-cancer effects of statins when combined with other more conventional anti-cancer drugs to highlight areas of potential therapeutic development.
C1 [Ahmadi, Mazaher; Madrakian, Tayyebeh] Bu Ali Sina Univ, Fac Chem, Dept Analyt Chem, Hamadan, Hamadan, Iran.
   [Amiri, Shayan] St Boniface Gen Hosp, Div Neurodegenerat Disorders, Albrechtsen Res Ctr, R4046-351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.
   [Amiri, Shayan] Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada.
   [Pecic, Stevan] Calif State Univ Fullerton, Dept Chem & Biochem, Fullerton, CA 92634 USA.
   [Machaj, Filip; Rosik, Jakub; Alizadeh, Javad; Rosa, Simone C. da Silva; Ghavami, Saeid] Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
   [Machaj, Filip; Rosik, Jakub] Pomeranian Med Univ, Dept Pathol, Szczecin, Poland.
   [Los, Marek J.] Silesian Tech Univ, Biotechnol Ctr, Gliwice, Poland.
   [Alizadeh, Javad] Univ Manitoba, Children Hosp Res Inst Manitoba, Biol Breathing Theme, Winnipeg, MB, Canada.
   [Mahdian, Reza] Pasteur Inst Iran, Biotechnol Res Ctr, Mol Med Dept, Tehran, Iran.
   [Schaafsma, Dedmer] Sci Impact, Winnipeg, MB, Canada.
   [Zeki, Amir A.] Univ Calif Davis, UC Davis Lung Ctr, Davis Sch Med, Div Pulm Crit Care & Sleep Med, Davis, CA 95616 USA.
   [Ghavami, Saeid] Shiraz Univ Med Sci, Hlth Policy Res Ctr, Inst Hlth, Shiraz, Iran.
   [Ghavami, Saeid] Univ Manitoba, Res Inst Oncol & Hematol, Canc Care Manitoba, Winnipeg, MB, Canada.
   [Shojaei, Shahla] Univ Manitoba, Coll Pharm, Rady Fac Hlth Sci, Winnipeg, MB, Canada.
   [Zeki, Amir A.] Vet Affairs Med Ctr, Mather, CA USA.
RP Ghavami, S (corresponding author), Univ Manitoba, Max Rady Coll Med, Rady Fac Hlth Sci, Dept Human Anat & Cell Sci, Winnipeg, MB, Canada.
EM saeid.ghavami@umanitoba.ca
RI Pecic, Stevan/E-3578-2018; Madrakian, Tayyebeh/C-2780-2018; Ahmadi,
   Mazaher/C-2568-2018; Rosik, Jakub/P-6960-2018
OI Pecic, Stevan/0000-0002-3706-8768; Madrakian,
   Tayyebeh/0000-0002-6876-7633; Ahmadi, Mazaher/0000-0001-9969-170X;
   Rosik, Jakub/0000-0001-7377-4566; da Silva Rosa, Simone
   C./0000-0002-3732-3781
FU NIEHS NIH HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Environmental
   Health Sciences (NIEHS) [P30 ES023513] Funding Source: Medline
CR Abdel-Rahman O, 2019, CLIN TRANSL ONCOL, V21, P810, DOI 10.1007/s12094-018-1992-3
   Adnane J, 1998, MOL CELL BIOL, V18, P6962, DOI 10.1128/MCB.18.12.6962
   Agarwal B, 1999, CLIN CANCER RES, V5, P2223
   Ahmadi Y, 2018, BIOMED PHARMACOTHER, V108, P1856, DOI 10.1016/j.biopha.2018.09.122
   Alfaqih MA, 2017, NAT REV UROL, V14, P107, DOI 10.1038/nrurol.2016.199
   Alizadeh J., 2018, J VIS EXP, V141
   Alizadeh J, 2017, SCI REP-UK, V7, DOI 10.1038/srep44841
   Allott EH, 2016, CANCER EPIDEM BIOMAR, V25, P670, DOI 10.1158/1055-9965.EPI-15-0631
   Altwairgi AK, 2015, ONCOL REP, V33, P1019, DOI 10.3892/or.2015.3741
   Amerongen GPV, 2003, ARTERIOSCL THROM VAS, V23, P211, DOI 10.1161/01.ATV.0000054198.68894.88
   Antoszczak M, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172784
   Asakage M, 2004, ANTI-CANCER DRUG, V15, P625, DOI 10.1097/01.cad.0000131680.83518.91
   Bahrami A, 2018, PHARMACOL RES, V135, P230, DOI 10.1016/j.phrs.2018.08.014
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1
   Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/fmc.11.121, 10.4155/FMC.11.121]
   Bardou M, 2010, GUT, V59, P1572, DOI 10.1136/gut.2009.190900
   Baron JA, 2010, CANCER PREV RES, V3, P573, DOI 10.1158/1940-6207.CAPR-10-0050
   Barone E, 2014, BIOCHEM PHARMACOL, V88, P605, DOI 10.1016/j.bcp.2013.10.030
   Bedi O, 2016, N-S ARCH PHARMACOL, V389, P695, DOI 10.1007/s00210-016-1252-4
   Bischoff H, 1997, ATHEROSCLEROSIS, V135, P119, DOI 10.1016/S0021-9150(97)00188-3
   Biselli-Chicote PM, 2019, ORAL ONCOL, V90, P109, DOI 10.1016/j.oraloncology.2019.01.025
   Bjarnadottir O, 2013, BREAST CANCER RES TR, V138, P499, DOI 10.1007/s10549-013-2473-6
   Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557
   Bocci G, 2005, BRIT J CANCER, V93, P319, DOI 10.1038/sj.bjc.6602720
   Bourgier C, 2019, INT J RADIAT ONCOL, V104, P365, DOI 10.1016/j.ijrobp.2019.02.024
   Bouterfa HL, 2000, ANTICANCER RES, V20, P2761
   Brown M, 2012, BRIT J CANCER, V106, P1689, DOI 10.1038/bjc.2012.138
   Cafforio P, 2005, CARCINOGENESIS, V26, P883, DOI 10.1093/carcin/bgi036
   Cai AP, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002113
   Calabro A, 2008, ANTI-CANCER DRUG, V19, P705, DOI 10.1097/CAD.0b013e328304ae19
   Campbell MJ, 2006, CANCER RES, V66, P8707, DOI 10.1158/0008-5472.CAN-05-4061
   CASEY PJ, 1995, BIOCHEM SOC T, V23, P161, DOI 10.1042/bst0230161
   Cemeus C, 2008, J NEURO-ONCOL, V90, P9, DOI 10.1007/s11060-008-9627-0
   Chan KKW, 2003, CLIN CANCER RES, V9, P10
   Chen JB, 2013, J MED CHEM, V56, P3645, DOI 10.1021/jm400179b
   Chen MJ, 2018, J CELL PHYSIOL, V233, P4618, DOI 10.1002/jcp.26156
   Cimbora-Zovko T, 2010, CANCER LETT, V295, P182, DOI 10.1016/j.canlet.2010.02.025
   Cimino M, 2007, NEUROSCIENTIST, V13, P208, DOI 10.1177/1073858406297121
   Clendening JW, 2010, BLOOD, V115, P4787, DOI 10.1182/blood-2009-07-230508
   Clutterbuck RD, 1998, BRIT J HAEMATOL, V102, P522, DOI 10.1046/j.1365-2141.1998.00783.x
   Coimbra M, 2010, J CONTROL RELEASE, V148, P303, DOI 10.1016/j.jconrel.2010.09.011
   Collisson EA, 2003, MOL CANCER THER, V2, P941
   Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200
   Cox Adrienne D., 1992, Current Opinion in Cell Biology, V4, P1008, DOI 10.1016/0955-0674(92)90133-W
   Crick DC, 1998, J NEUROCHEM, V70, P2397
   Davignon J, 2004, CIRCULATION, V109, P39, DOI 10.1161/01.CIR.0000131517.20177.5a
   Davignon J, 2005, VASC HEALTH RISK MAN, V1, P29, DOI 10.2147/vhrm.1.1.29.58937
   Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139
   DER CJ, 1991, CANCER CELL-MON REV, V3, P331
   Dimitroulakos J, 1999, BLOOD, V93, P1308, DOI 10.1182/blood.V93.4.1308.404k08_1308_1318
   Dimitroulakos J, 2002, NEOPLASIA, V4, P337, DOI 10.1038/sj.neo.7900247
   Ding JJ, 2019, EUR J PHARMACOL, V857, DOI 10.1016/j.ejphar.2019.172425
   DuBroff R, 2015, WORLD J CARDIOL, V7, P404, DOI 10.4330/wjc.v7.i7.404
   Dworacka M, 2018, DIABETES RES CLIN PR, V143, P245, DOI 10.1016/j.diabres.2018.07.023
   Emami A, 2019, EUR J PHARMACOL, V862, DOI 10.1016/j.ejphar.2019.172616
   Emberson JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029849
   Emelyanova L, 2019, ESC HEART FAIL, V6, P1027, DOI 10.1002/ehf2.12509
   Fan ZQ, 2016, ONCOL REP, V36, P1016, DOI 10.3892/or.2016.4897
   Fang ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062823
   Farina HG, 2002, CLIN EXP METASTAS, V19, P551, DOI 10.1023/A:1020355621043
   Farooqi MAM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209486
   Feldt M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0486-0
   Feleszko W, 2002, INT J CANCER, V100, P111, DOI 10.1002/ijc.10440
   Feleszko W, 1999, INT J CANCER, V81, P560, DOI 10.1002/(SICI)1097-0215(19990517)81:4<560::AID-IJC10>3.0.CO;2-7
   Forouzanfar F, 2018, PHARMACOL RES, V134, P134, DOI 10.1016/j.phrs.2018.06.020
   Frick M, 2003, ATHEROSCLEROSIS, V170, P229, DOI 10.1016/S0021-9150(03)00299-5
   Fritz G, 2005, INT J ONCOL, V27, P1401
   Fromigue O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fu CH, 2019, EUR J PHARMACOL, V856, DOI 10.1016/j.ejphar.2019.05.029
   Gaist D, 2014, CANCER EPIDEMIOL, V38, P722, DOI 10.1016/j.canep.2014.09.010
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Garwood ER, 2010, BREAST CANCER RES TR, V119, P137, DOI 10.1007/s10549-009-0507-x
   Gbelcova H, 2008, INT J CANCER, V122, P1214, DOI 10.1002/ijc.23242
   Ghavami S, 2012, AM J PHYSIOL-LUNG C, V302, pL420, DOI 10.1152/ajplung.00312.2011
   Ghavami S, 2010, BBA-MOL CELL RES, V1803, P452, DOI 10.1016/j.bbamcr.2009.12.005
   Ghosh-Choudhury N, 2010, CELL SIGNAL, V22, P749, DOI 10.1016/j.cellsig.2009.12.010
   Gizzo S, 2015, CURR DRUG TARGETS, V16, P1142, DOI 10.2174/1389450116666150330113239
   Gliemroth J, 2003, NEUROSURG REV, V26, P117, DOI 10.1007/s10143-003-0258-9
   Glynn SA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-9
   Gnad R, 2000, MOL PHARMACOL, V58, P1389, DOI 10.1124/mol.58.6.1389
   Gniadecki R, 2004, BIOCHEM BIOPH RES CO, V320, P165, DOI 10.1016/j.bbrc.2004.05.145
   Goard CA, 2014, BREAST CANCER RES TR, V143, P301, DOI 10.1007/s10549-013-2800-y
   Estanislau IMG, 2015, BRIT J CLIN PHARMACO, V79, P877, DOI 10.1111/bcp.12564
   Gordon JA, 2016, PROSTATE CANCER P D, V19, P21, DOI 10.1038/pcan.2015.37
   Goss GD, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0836-6
   Gotto AM, 2010, EXPERT REV CARDIOVAS, V8, P1079, DOI 10.1586/ERC.10.82
   Gupta VK, 2018, CANCER LETT, V439, P101, DOI 10.1016/j.canlet.2018.09.028
   Hagenbuch B, 2004, PFLUG ARCH EUR J PHY, V447, P653, DOI 10.1007/s00424-003-1168-y
   Hamelin BA, 1998, TRENDS PHARMACOL SCI, V19, P26, DOI 10.1016/S0165-6147(97)01147-4
   Han JY, 2011, LUNG CANCER, V74, P293, DOI 10.1016/j.lungcan.2011.02.021
   Han JY, 2011, CLIN CANCER RES, V17, P1553, DOI 10.1158/1078-0432.CCR-10-2525
   Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015
   Hatanaka T, 2000, CLIN PHARMACOKINET, V39, P397, DOI 10.2165/00003088-200039060-00002
   Haukka J, 2010, INT J CANCER, V126, P279, DOI 10.1002/ijc.24536
   Helbig Grzegorz, 2004, Wiad Lek, V57, P462
   Helbig L, 2011, J BIOL CHEM, V286, P12991, DOI 10.1074/jbc.M110.190645
   Hentosh P, 2001, MOL CARCINOGEN, V32, P154, DOI 10.1002/mc.1074
   Herrero-Martin G, 2008, FEBS LETT, V582, P2589, DOI 10.1016/j.febslet.2008.06.034
   Higgins MJ, 2012, BREAST CANCER RES TR, V131, P915, DOI 10.1007/s10549-011-1858-7
   Hindler K, 2006, ONCOLOGIST, V11, P306, DOI 10.1634/theoncologist.11-3-306
   Holstein SA, 2001, MOL CANCER THER, V1, P141
   Horiguchi A, 2004, CLIN CANCER RES, V10, P8648, DOI 10.1158/1078-0432.CCR-04-1568
   Howe K, 2011, XENOBIOTICA, V41, P519, DOI 10.3109/00498254.2011.569773
   Hu M, 2014, EXPERT OPIN DRUG MET, V10, P51, DOI 10.1517/17425255.2014.851667
   Hu TJ, 2020, ANTI-CANCER DRUG, V31, P377, DOI 10.1097/CAD.0000000000000885
   Huang BZ, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw275
   Hybiak J, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172762
   Iannelli F, 2018, RECENT PAT ANTI-CANC, V13, P184, DOI 10.2174/1574892812666171129141211
   Inano H, 1997, CARCINOGENESIS, V18, P1723, DOI 10.1093/carcin/18.9.1723
   Infante E, 2011, J LEUKOCYTE BIOL, V89, P577, DOI 10.1189/jlb.0810441
   Istvan E, 2003, ATHEROSCLEROSIS SUPP, V4, P3, DOI 10.1016/S1567-5688(03)00003-5
   Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344
   Jacobs EJ, 2011, CANCER RES, V71, P1763, DOI 10.1158/0008-5472.CAN-10-2953
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901
   Janicko M, 2016, WORLD J GASTROENTERO, V22, P6201, DOI 10.3748/wjg.v22.i27.6201
   Jemal A, 2017, J NATL CANC I, V109
   Jiang P, 2014, BRIT J CANCER, V111, P1562, DOI 10.1038/bjc.2014.431
   Jin HY, 2019, THERANOSTICS, V9, P265, DOI 10.7150/thno.27246
   Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048
   Jouve JL, 2019, J HEPATOL, V71, P516, DOI 10.1016/j.jhep.2019.04.021
   Kang S, 2009, ONCOL REP, V21, P1317, DOI 10.3892/or_00000357
   Kato S, 2010, J CELL MOL MED, V14, P1180, DOI 10.1111/j.1582-4934.2009.00771.x
   Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456
   KEYOMARSI K, 1991, CANCER RES, V51, P3602
   Khanzada UK, 2006, ONCOGENE, V25, P877, DOI 10.1038/sj.onc.1209117
   Kim ST, 2014, EUR J CANCER, V50, P2822, DOI 10.1016/j.ejca.2014.08.005
   Kochuparambil ST, 2011, J PHARMACOL EXP THER, V336, P496, DOI 10.1124/jpet.110.174870
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Koohestanimobarhan S, 2019, J CELL BIOCHEM, V120, P2515, DOI 10.1002/jcb.27544
   Kostapanos Michael S, 2009, J Cardiometab Syndr, V4, pE4, DOI 10.1111/j.1559-4572.2008.00052.x
   Kostapanos MS, 2010, AM J CARDIOVASC DRUG, V10, P11, DOI 10.2165/13168600-000000000-00000
   Kubatka P, 2014, CRIT REV ONCOL HEMAT, V92, P296, DOI 10.1016/j.critrevonc.2014.08.002
   Kubatka P, 2013, EUR J CANCER PREV, V22, P352, DOI 10.1097/CEJ.0b013e32835b385d
   Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510
   Kusama T, 2001, CANCER RES, V61, P4885
   Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093
   Larner J, 1998, AM J CLIN ONCOL-CANC, V21, P579, DOI 10.1097/00000421-199812000-00010
   Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069
   Lee J, 2006, BIOCHEM BIOPH RES CO, V339, P748, DOI 10.1016/j.bbrc.2005.11.075
   Lee J, 2011, JNCI-J NATL CANCER I, V103, P674, DOI 10.1093/jnci/djr070
   Lee JE, 2011, CANCER PREV RES, V4, P1808, DOI 10.1158/1940-6207.CAPR-11-0113
   Lee MH, 2007, STEM CELLS, V25, P1654, DOI 10.1634/stemcells.2006-0753
   Li M, 2020, EXP THER MED, V19, P2861, DOI 10.3892/etm.2020.8569
   Liang YW, 2013, INT J MOL SCI, V14, P5806, DOI 10.3390/ijms14035806
   Liao JK, 2005, CURR OPIN LIPIDOL, V16, P624, DOI 10.1097/01.mol.0000191913.16321.60
   Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748
   Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421
   Liberto M, 2002, ONCOGENE, V21, P1590, DOI 10.1038/sj.onc.1205242
   Likus W, 2016, DRUG RESIST UPDATE, V25, P13, DOI 10.1016/j.drup.2016.02.001
   Lin YC, 2008, CANCER RES, V68, P2375, DOI 10.1158/0008-5472.CAN-07-5807
   Ling Q, 2016, PROG NEURO-PSYCHOPH, V66, P80, DOI 10.1016/j.pnpbp.2015.11.013
   Liu H, 2013, NEOPLASMA, V60, P240, DOI 10.4149/neo_2013_032
   Liu Q, 2020, ONCOTARGETS THER, V13, P2057, DOI 10.2147/OTT.S237693
   Liu WH, 2018, CLIN EXP HYPERTENS, V40, P224, DOI 10.1080/10641963.2017.1313849
   Livney YD, 2013, ADV DRUG DELIVER REV, V65, P1716, DOI 10.1016/j.addr.2013.08.006
   Longo J, 2020, PROSTATE CANCER P D, V23, P630, DOI 10.1038/s41391-020-0221-7
   Mace AG, 2013, DIS COLON RECTUM, V56, P1217, DOI 10.1097/DCR.0b013e3182a4b236
   Maksimova E, 2008, LUNG, V186, P45, DOI 10.1007/s00408-007-9053-7
   MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808
   Marcelli M, 1998, CANCER RES, V58, P76
   Marlatt KL, 2019, J ADOLESC YOUNG ADUL, V8, P442, DOI 10.1089/jayao.2017.0075
   Martirosyan A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-103
   Matusewicz L, 2015, TUMOR BIOL, V36, P4889, DOI 10.1007/s13277-015-3551-7
   Mehta N, 1998, CLIN EXP METASTAS, V16, P587, DOI 10.1023/A:1006548902592
   Mei ZB, 2017, INT J CANCER, V140, P1068, DOI 10.1002/ijc.30526
   Menter DG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028813
   Mihaylova B, 2012, LANCET, V380, P581, DOI 10.1016/S0140-6736(12)60367-5
   Miller T, 2011, DIGEST LIVER DIS, V43, P395, DOI 10.1016/j.dld.2011.01.010
   Misra J, 2016, STEM CELLS, V34, P756, DOI 10.1002/stem.2255
   Misra S, 2005, J BIOL CHEM, V280, P20310, DOI 10.1074/jbc.M500737200
   Mohammad S, 2019, CURR VASC PHARMACOL, V17, P239, DOI 10.2174/1570161116666180723120608
   Mohammadkhani N, 2019, EUR J PHARMACOL, V863, DOI 10.1016/j.ejphar.2019.172704
   Mollazadeh H, 2018, PHARMACOL RES, V137, P150, DOI 10.1016/j.phrs.2018.10.006
   Muck AO, 2004, Z KARDIOL, V93, P398, DOI 10.1007/s00392-004-0081-5
   Mullen PJ, 2016, NAT REV CANCER, V16, P718, DOI 10.1038/nrc.2016.76
   Muniz FWMG, 2018, CLIN ORAL INVEST, V22, P671, DOI 10.1007/s00784-018-2354-9
   Narisawa T, 1996, TOHOKU J EXP MED, V180, P131, DOI 10.1620/tjem.180.131
   Nayan M, 2017, CANCER TREAT REV, V52, P105, DOI 10.1016/j.ctrv.2016.11.009
   Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735
   Nubel T, 2004, CARCINOGENESIS, V25, P1335, DOI 10.1093/carcin/bgh133
   Oda H, 1999, KIDNEY INT, V56, pS2, DOI 10.1046/j.1523-1755.1999.07101.x
   Oesterle A, 2017, CIRC RES, V120, P229, DOI 10.1161/CIRCRESAHA.116.308537
   Osmak M, 2012, CANCER LETT, V324, P1, DOI 10.1016/j.canlet.2012.04.011
   Peng P, 2017, BIOCHEM BIOPH RES CO, V489, P293, DOI 10.1016/j.bbrc.2017.05.147
   Raghu VK, 2018, BIOCHEM BIOPH RES CO, V495, P659, DOI 10.1016/j.bbrc.2017.11.065
   Ramkumar S, 2016, ACTA CARDIOL SIN, V32, P631, DOI 10.6515/ACS20160611A
   Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797
   REED SI, 1994, J CELL SCI, P69
   Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5
   Riganti C, 2005, CANCER RES, V65, P516
   Riganti C, 2008, MINI-REV MED CHEM, V8, P609, DOI 10.2174/138955708784534436
   Rikitake Y, 2005, CIRC RES, V97, P1232, DOI 10.1161/01.RES.0000196564.18314.23
   Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/NCHEM.2479, 10.1038/nchem.2479]
   Roth BD, 2002, PROGR MED CHEM, V40, P1, DOI 10.1016/S0079-6468(08)70080-8
   ROTH BD, 1990, J MED CHEM, V33, P21, DOI 10.1021/jm00163a005
   Roudier E, 2006, MOL CANCER THER, V5, P2706, DOI 10.1158/1535-7163.MCT-06-0352
   Rozados VR, 2005, J EXP CLIN CANC RES, V24, P55
   Sacks D, 2018, J VASC INTERV RADIOL, V29, P441, DOI [10.1016/j.jvir.2017.11.026, 10.1177/1747493018778713]
   Schaafsma D, 2008, CELL SIGNAL, V20, P1705, DOI 10.1016/j.cellsig.2008.04.012
   Schaafsma D, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-113
   Schaafsma D, 2011, AM J RESP CELL MOL, V44, P394, DOI 10.1165/rcmb.2010-0052OC
   Schointuch MN, 2014, GYNECOL ONCOL, V134, P346, DOI 10.1016/j.ygyno.2014.05.015
   Sheikholeslami K, 2019, CANCERS, V11, DOI 10.3390/cancers11070994
   Shellman YG, 2005, MELANOMA RES, V15, P83, DOI 10.1097/00008390-200504000-00001
   Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B
   Shojaei S, 2020, FEBS J, V287, P1005, DOI 10.1111/febs.15069
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sikorski JA, 2007, COMPREHENSIVE MED CH, VII, P459
   Singh B.M., 2004, STATINS PRIMARY PREV, P53
   Sivaprasad U, 2006, MOL CANCER THER, V5, P2310, DOI 10.1158/1535-7163.MCT-06-0175
   Song X, 2014, BBA-MOL CELL RES, V1843, P894, DOI 10.1016/j.bbamcr.2014.02.002
   STOKKER GE, 1985, J MED CHEM, V28, P347, DOI 10.1021/jm00381a014
   Student S, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172783
   Su XL, 2016, AM J KIDNEY DIS, V67, P881, DOI 10.1053/j.ajkd.2016.01.016
   Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743
   Takeda N, 2006, AM J RESP CELL MOL, V35, P722, DOI 10.1165/rcmb.2006-0034OC
   Tardoski S, 2015, SCI REP-UK, V5, DOI 10.1038/srep16354
   Tate R, 2017, INT J ONCOL, V51, P1851, DOI 10.3892/ijo.2017.4158
   Taylor F, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004816.pub5
   Thibault A, 1996, CLIN CANCER RES, V2, P483
   Thurnher M, 2012, CLIN CANCER RES, V18, P3524, DOI 10.1158/1078-0432.CCR-12-0489
   Transon C, 1996, EUR J CLIN PHARMACOL, V50, P209, DOI 10.1007/s002280050094
   Tu YS, 2011, EUR J PHARMACOL, V670, P356, DOI 10.1016/j.ejphar.2011.09.031
   Vinayak S, 2013, BREAST CANCER RES TR, V142, P389, DOI 10.1007/s10549-013-2739-z
   Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7
   Vincent L, 2002, ARTERIOSCL THROM VAS, V22, P623, DOI 10.1161/01.ATV.0000012283.15789.67
   Vinogradova Y, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-409
   Vosper J, 2015, ONCOTARGET, V6, P2889, DOI 10.18632/oncotarget.3068
   Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964
   Wang AG, 2016, BRIT J CANCER, V115, P129, DOI 10.1038/bjc.2016.149
   Wang CY, 2008, TRENDS MOL MED, V14, P37, DOI 10.1016/j.molmed.2007.11.004
   Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x
   WANG RW, 1991, ARCH BIOCHEM BIOPHYS, V290, P355, DOI 10.1016/0003-9861(91)90551-S
   Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041
   Wei TT, 2016, EBIOMEDICINE, V10, P124, DOI 10.1016/j.ebiom.2016.07.019
   Weis M, 2002, CIRCULATION, V105, P739, DOI 10.1161/hc0602.103393
   Wolfe AR, 2015, BREAST CANCER RES TR, V154, P495, DOI 10.1007/s10549-015-3645-3
   Xia Z, 2001, LEUKEMIA, V15, P1398, DOI 10.1038/sj.leu.2402196
   Xue J, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172541
   Yeganeh B, 2014, PHARMACOL THERAPEUT, V143, P87, DOI 10.1016/j.pharmthera.2014.02.007
   Yu O, 2014, J CLIN ONCOL, V32, P5, DOI 10.1200/JCO.2013.49.4757
   Yu XF, 2012, ONCOL RES, V20, P351, DOI 10.3727/096504013X13657689382897
   Zeki AA, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12352
   Zeki AA, 2009, AM J RESP CRIT CARE, V180, P731, DOI 10.1164/rccm.200901-0018OC
   Zhao JR, 2014, CURR NEUROPHARMACOL, V12, P564, DOI 10.2174/1570159X12666140923210929
   Zhao XM, 2015, J BONE ONCOL, V4, P98, DOI 10.1016/j.jbo.2015.08.001
   Zheng X, 2010, CANCER PREV RES, V3, P114, DOI 10.1158/1940-6207.CAPR-09-0059
   Zhitomirsky B, 2016, DRUG RESIST UPDATE, V24, P23, DOI 10.1016/j.drup.2015.11.004
   Zhong WB, 2003, ENDOCRINOLOGY, V144, P3852, DOI 10.1210/en.2003-0098
   Zhou Q, 2010, CIRC J, V74, P818, DOI 10.1253/circj.CJ-10-0110
   Zhu Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.103
NR 252
TC 27
Z9 28
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD DEC 1
PY 2020
VL 1866
IS 12
AR 165968
DI 10.1016/j.bbadis.2020.165968
PG 17
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA OU7QZ
UT WOS:000591721000034
PM 32927022
OA Bronze
DA 2022-04-25
ER

PT J
AU Chen, HY
   He, LJ
   Li, SQ
   Zhang, YJ
   Huang, JH
   Qin, HX
   Wang, JL
   Li, QY
   Yang, DL
AF Chen, He-ying
   He, Liu-jun
   Li, Shi-qiang
   Zhang, Ya-jun
   Huang, Jiu-hong
   Qin, Hong-xia
   Wang, Juan-li
   Li, Qian-yin
   Yang, Dong-lin
TI A Derivate of Benzimidazole-Isoquinolinone Induces SKP2 Transcriptional
   Inhibition to Exert Anti-Tumor Activity in Glioblastoma Cells
SO MOLECULES
LA English
DT Article
DE compound-7g; glioblastoma; SKP2; E2F-1; cell cycle; autophagic flux
ID CANCER; AUTOPHAGY; TARGET; DEGRADATION; EXPRESSION; CYCLE
AB We have previously shown that compound-7g inhibits colorectal cancer cell proliferation and survival by inducing cell cycle arrest and PI3K/AKT/mTOR pathway blockage. However, whether it has the ability to exert antitumor activity in other cancer cells and what is the exact molecular mechanism for its antiproliferation effect remained to be determined. In the present study, compound-7g exhibited strong activity in suppressing proliferation and growth of glioblastoma cells. The inhibitor selectively downregulated F-box protein SKP2 expression and upregulated cell cycle inhibitor p27, and then resulted in G1 cell cycle arrest. Mechanism analysis revealed that compound-7g also provokes the down-regulation of E2F-1, which acts as a transcriptional factor of SKP2. Further results indicated that compound-7g induced an increase of LC3B-II and p62, which causes a suppression of fusion between autophagosome and lysosome. Moreover, compound-7g mediated autophagic flux blockage promoted accumulation of ubiquitinated proteins and then led to endoplasmic reticulum stress. Our study thus demonstrated that pharmacological inactivation of E2F-1-SKP2-p27 axis is a promising target for restricting cancer progression.
C1 [Chen, He-ying; Li, Qian-yin] Chongqing Med Univ, Coll Lab Med, Div Mol Nephrol, Chongqing 400016, Peoples R China.
   [Chen, He-ying; Li, Qian-yin] Chongqing Med Univ, Coll Lab Med, Creat Training Ctr Undergraduates, Minist Educ,Key Lab Lab Med Diagnost, Chongqing 400016, Peoples R China.
   [Chen, He-ying; He, Liu-jun; Li, Shi-qiang; Zhang, Ya-jun; Huang, Jiu-hong; Qin, Hong-xia; Wang, Juan-li; Yang, Dong-lin] Chongqing Univ Arts & Sci, Chongqing Engn Lab Targeted & Innovat Therapeut, Chongqing Key Lab Kinase Modulators Innovat Med, IATTI, 319 Honghe Ave, Chongqing 402160, Peoples R China.
   [Chen, He-ying] Chongqing Med Univ, Undergrad Class 2016 Entry Coll Lab Med, Chongqing 400016, Peoples R China.
RP Li, QY (corresponding author), Chongqing Med Univ, Coll Lab Med, Div Mol Nephrol, Chongqing 400016, Peoples R China.; Li, QY (corresponding author), Chongqing Med Univ, Coll Lab Med, Creat Training Ctr Undergraduates, Minist Educ,Key Lab Lab Med Diagnost, Chongqing 400016, Peoples R China.; Yang, DL (corresponding author), Chongqing Univ Arts & Sci, Chongqing Engn Lab Targeted & Innovat Therapeut, Chongqing Key Lab Kinase Modulators Innovat Med, IATTI, 319 Honghe Ave, Chongqing 402160, Peoples R China.
EM liqianyin@cqmu.edu.cn; dlyang09@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802549]; Chongqing Research Program of
   Basic Research and Frontier Technology [cstc2016jcyjA0534,
   cstc2018jcyjAX0219]; Chongqing Education commission Project of China
   [KJQN201801304, KJZH17129, KJ1711284, KJ1711287, KJ1601123]; Scientific
   Research Foundation of the Chongqing University of Arts and Sciences
   [R2015BX03, 2017RBX11, 2017ZBX05, 2017ZBX07, 2017ZBX08, 2017ZBX10]
FX This research was funded by National Natural Science Foundation of China
   (81802549), Chongqing Research Program of Basic Research and Frontier
   Technology (cstc2016jcyjA0534 and cstc2018jcyjAX0219), Chongqing
   Education commission Project of China (KJQN201801304, KJZH17129,
   KJ1711284, KJ1711287 and KJ1601123) and the Scientific Research
   Foundation of the Chongqing University of Arts and Sciences (R2015BX03,
   2017RBX11, 2017ZBX05, 2017ZBX07, 2017ZBX08 and 2017ZBX10).
CR Chan CH, 2014, CELL CYCLE, V13, P679, DOI 10.4161/cc.27853
   Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347
   Hao ZL, 2015, FRONT BIOSCI-LANDMRK, V20, P474, DOI 10.2741/4320
   He LJ, 2018, BIOORGAN MED CHEM, V26, P3899, DOI 10.1016/j.bmc.2018.06.010
   Huenga DY, 2017, J NUTR BIOCHEM, V41, P109, DOI 10.1016/j.jnutbio.2016.12.008
   Jung D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20531-w
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Kurland JF, 2004, CANCER CELL, V5, P305, DOI 10.1016/S1535-6108(04)00091-1
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Lee Y, 2016, CURR MED CHEM, V23, P2363, DOI 10.2174/0929867323666160510122624
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Liu KP, 2018, J MOL CELL BIOL, V10, P205, DOI 10.1093/jmcb/mjy012
   Liu YY, 2016, J NEURO-ONCOL, V128, P217, DOI 10.1007/s11060-016-2107-z
   Lu WF, 2015, ONCOTARGET, V6, P771, DOI 10.18632/oncotarget.2718
   Lu ZL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4463
   Luo J, 2015, TUMOR BIOL, V36, P5119, DOI 10.1007/s13277-015-3164-1
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Reichert M, 2007, CANCER RES, V67, P4149, DOI 10.1158/0008-5472.CAN-06-4484
   Salon C, 2007, ONCOGENE, V26, P6927, DOI 10.1038/sj.onc.1210499
   Sathornsumetee S, 2007, CANCER-AM CANCER SOC, V110, P13, DOI 10.1002/cncr.22741
   Shin HJR, 2016, NATURE, V534, P553, DOI 10.1038/nature18014
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Wang HB, 2010, CELL CYCLE, V9, P1021, DOI 10.4161/cc.9.5.10916
   Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700
   Wei Z, 2013, CELL SIGNAL, V25, P931, DOI 10.1016/j.cellsig.2013.01.011
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Wu HB, 2017, BIOCHEM BIOPH RES CO, V484, P304, DOI 10.1016/j.bbrc.2017.01.108
   Yang CC, 2015, BREAST CANCER-BASIC, V9, P13, DOI 10.4137/BCBCR.S30101
   Yeh CT, 2010, HEPATOLOGY, V52, P1922, DOI 10.1002/hep.23898
   Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286
NR 30
TC 8
Z9 8
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2019
VL 24
IS 15
AR 2722
DI 10.3390/molecules24152722
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA IS9AP
UT WOS:000482441100045
PM 31357480
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Huang, DQ
   Qiu, SW
   Ge, RG
   He, L
   Li, M
   Li, Y
   Peng, Y
AF Huang, Daquan
   Qiu, Shuwei
   Ge, Ruiguang
   He, Lei
   Li, Mei
   Li, Yi
   Peng, Ying
TI miR-340 suppresses glioblastoma multiforme
SO ONCOTARGET
LA English
DT Article
DE glioblastoma multiforme; miR-340; ROCK1; biomarker
ID GLIOMA-CELLS; COLORECTAL-CANCER; MALIGNANT GLIOMAS; INITIATING CELLS;
   STRUCTURAL BASIS; BRAIN-TUMORS; BONE-MARROW; STEM-CELLS;
   DIFFERENTIATION; INHIBITION
AB Deregulation of microRNAs (miRs) contributes to tumorigenesis. Down-regulation of miR-340 is observed in multiple types of cancers. However, the biological function of miR-340 in glioblastoma multiforme (GBM) remains largely unknown. In the present study, we demonstrated that expression of miR-340 was downregulated in both glioma cell lines and tissues. Survival of GBM patients with high levels of miR-340 was significantly extended in comparison to patients expressing low miR-340 levels. Biological functional experiments showed that the restoration of miR-340 dramatically inhibited glioma cell proliferation, induced cell-cycle arrest and apoptosis, suppressed cell motility and promoted autophagy and terminal differentiation. Mechanistic studies disclosed that, miR-340 over-expression suppressed several oncogenes including p-AKT, EZH2, EGFR, BMI1 and XIAP. Furthermore, ROCK1 was validated as a direct functional target miR-340 and silencing of ROCK1 phenocopied the anti-tumor effect of mR-340. Our findings indicate an important role of miR-340 as a glioma killer, and suggest a potential prognosis biomarker and therapeutic target for GBM.
C1 [Huang, Daquan; Qiu, Shuwei; He, Lei; Li, Mei; Li, Yi; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.
   [Huang, Daquan; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510275, Guangdong, Peoples R China.
   [Ge, Ruiguang] Sun Yat Sen Univ, Coll Life Sci, Minist Educ, Key Lab Gene Engn, Guangzhou 510275, Guangdong, Peoples R China.
   [Ge, Ruiguang] Sun Yat Sen Univ, Coll Life Sci, State Key Lab Biocontrol, Guangzhou 510275, Guangdong, Peoples R China.
RP Peng, Y (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510275, Guangdong, Peoples R China.
EM docpengy123@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272197, 81402065]; Culture program for Key
   project of National Natural Science Foundation of China of Sun Yat-Sen
   University [10ykjc26]; International Collaboration Program of
   Universities in Guangdong province [2012gjhz001]; Science & Technique
   Plan fund of Guangdong Province [2013B021800098]; Key Laboratory of
   Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher
   Education Institutes, Sun-Yat-Sen University [KLB09001]; Key Laboratory
   of Malignant Tumor Molecular Mechanism and Translational Medicine of
   Guangzhou Bureau of Science and Information Technology [[2013]163]
FX This work was supported by National Natural Science Foundation of China
   (No. 81272197 to Y. Peng and No. 81402065 to S. Qiu) and Culture program
   for Key project of National Natural Science Foundation of China of Sun
   Yat-Sen University (No. 10ykjc26 to Y. Peng), International
   Collaboration Program of Universities in Guangdong province
   (2012gjhz001) to Y. Peng, and the Science & Technique Plan fund of
   Guangdong Province (2013B021800098) to M. Li, Grant KLB09001 from the
   Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of
   Guangdong Higher Education Institutes, Sun-Yat-Sen University and Grant
   [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and
   Translational Medicine of Guangzhou Bureau of Science and Information
   Technology.
CR Abdouh M, 2009, J NEUROSCI, V29, P8884, DOI 10.1523/JNEUROSCI.0968-09.2009
   Babae N, 2014, ONCOTARGET, V5, P6687, DOI 10.18632/oncotarget.2235
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032
   Campos B, 2010, CLIN CANCER RES, V16, P2715, DOI 10.1158/1078-0432.CCR-09-1800
   Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(01)00272-0
   Das S, 2013, ONCOGENE, V32, P2927, DOI 10.1038/onc.2012.311
   Dong H, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-163
   Dontula Ranadheer, 2013, Genes Cancer, V4, P285, DOI 10.1177/1947601913500141
   Du Y, 2010, DIFFERENTIATION, V79, P84, DOI 10.1016/j.diff.2009.10.003
   Fernandez S, 2014, ONCOGENE, V0
   Frankel LB, 2011, EMBO J, V30, P4628, DOI 10.1038/emboj.2011.331
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629
   Guerau-de-Arellano M, 2011, BRAIN, V134, P3575, DOI 10.1093/brain/awr262
   Gurkar AU, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3189
   Hosono Y, 2012, EMBO J, V31, P481, DOI 10.1038/emboj.2011.416
   Huang X, 2013, EMBO J, V32, P2204, DOI 10.1038/emboj.2013.133
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Karsy Michael, 2012, Genes Cancer, V3, P3, DOI 10.1177/1947601912448068
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502
   Li Y, 2007, P NATL ACAD SCI USA, V104, P13438, DOI 10.1073/pnas.0701990104
   Liu X, 2014, J MOL HISTOL, V45, P707, DOI 10.1007/s10735-014-9594-z
   Lock FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008190
   Naumann U, 2007, GENE THER, V14, P147, DOI 10.1038/sj.gt.3302845
   Oellers P, 2009, GLIA, V57, P499, DOI 10.1002/glia.20777
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349
   Qiu SW, 2013, BBA-MOL BASIS DIS, V1832, P1697, DOI 10.1016/j.bbadis.2013.05.015
   Qiu SW, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-10
   Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6
   Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128
   Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008
   Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6
   Sun Y, 2012, ONCOL REP, V28, P1346, DOI 10.3892/or.2012.1958
   Suva ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Swartling FJ, 2015, CELL TISSUE RES, V359, P225, DOI 10.1007/s00441-014-2046-y
   Takeyama H, 2014, MOL CANCER THER, V13, P976, DOI 10.1158/1535-7163.MCT-13-0571
   Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069
   Vigil D, 2012, CANCER RES, V72, P5338, DOI 10.1158/0008-5472.CAN-11-2373
   Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860
   Xu XT, 2012, HEPATO-GASTROENTEROL, V59, P2523, DOI 10.5754/hge12147
   Zhang H, 2010, ONCOGENE, V29, P937, DOI 10.1038/onc.2009.406
   Zhang X, 2013, CURR MED CHEM, V20, P1974, DOI 10.2174/0929867311320150004
   Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033
   Zhuang WZ, 2011, INT J CANCER, V129, P2720, DOI 10.1002/ijc.25975
NR 49
TC 67
Z9 71
U1 2
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 20
PY 2015
VL 6
IS 11
BP 9257
EP 9270
DI 10.18632/oncotarget.3288
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CN9NB
UT WOS:000358774600058
PM 25831237
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU He, F
   Zhang, C
   Chen, XL
   Luo, J
   Tie, HT
   Li, Q
   Wu, QC
AF He, Feng
   Zhang, Cheng
   Chen, Xiaolong
   Luo, Jun
   Tie, Hongtao
   Li, Qiang
   Wu, Qingchen
TI FBXL20 promotes cell proliferation and metastasis through activating
   Wnt/beta-catenin signaling pathway in esophageal cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE FBXL20; esophageal cancer; Wnt/beta-catenin; cell cycle arrest;
   proliferation; migration
ID UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; GROWTH; FBXW7; FBW7
AB Previous studies have demonstrated that FBXL20 can promote tumor progression in human colorectal adenocarcinoma. Additionally, FBXL20, acts as a checkpoint of p53, controls autophagy and receptor degradation. These studies suggest that FBXL20 is involved in several cancer progression. However, the role of FBXL20 in esophageal cancer remains unknown. The present study demonstrated that the expression of FBXL20 in esophageal cancer tissue was significantly higher than its expression in adjacent tissues. In vitro studies, silencing FBXL20 expression by lentiviral vector shRNA induced G0/G1 cell cycle arrest, and inhibited the proliferation, migration and invasion ability of esophageal cancer cells through Wnt/beta-catenin signaling pathway. In addition, FBXL20 silencing could increase the apoptosis of esophageal cancer cells. In summary, this study demonstrated that FBXL20 was an oncogenic gene, which could promote proliferation, migration, invasion, and G0/G1 cell cycle arrest via activating Wnt/beta-catenin signaling pathway and induce apoptosis in esophageal cancer. Therefore, FBXL20 might serve as a potential tumor marker and therapeutic target for esophageal cancer.
C1 [He, Feng; Zhang, Cheng; Chen, Xiaolong; Luo, Jun; Tie, Hongtao; Li, Qiang; Wu, Qingchen] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China.
   [He, Feng; Chen, Xiaolong] Chongqing Med Univ, Affiliated Hosp 1, Chongqing Key Lab Mol Oncol & Epigenet, Chongqing 400016, Peoples R China.
RP Wu, QC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM qcwucq@163.com
RI Tie, Hongtao/X-7863-2019
OI Tie, Hongtao/0000-0003-1058-6407
FU Key Scientific Research Project of Chongqing Municipal Bureau of Health
   [2012-1-015]
FX The present study was supported by grant from the Key Scientific
   Research Project of Chongqing Municipal Bureau of Health (grant No.
   2012-1-015).
CR Bengoechea-Alonso MT, 2010, ONCOGENE, V29, P5322, DOI 10.1038/onc.2010.278
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Cheng YB, 2012, CANCER METAST REV, V31, P75, DOI 10.1007/s10555-011-9330-z
   EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gu ZD, 2005, AM J GASTROENTEROL, V100, P1835, DOI 10.1111/j.1572-0241.2005.50018.x
   Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317
   Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879
   Jin JP, 2004, GENE DEV, V18, P2573, DOI 10.1101/gad.1255304
   Jung P, 2008, P NATL ACAD SCI USA, V105, P15046, DOI 10.1073/pnas.0801773105
   Lepage C, 2008, AM J GASTROENTEROL, V103, P2694, DOI 10.1111/j.1572-0241.2008.02191.x
   Li SJ, 2016, AM J TRANSL RES, V8, P597
   Mir R, 2016, ONCOGENE, V35, P1679, DOI 10.1038/onc.2015.232
   Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881
   Ougolkov AV, 2002, GASTROENTEROLOGY, V122, P60, DOI 10.1053/gast.2002.30306
   Peter C., 2003, NEW ENGL J MED, V249, P2241
   Polette M, 2004, CRIT REV ONCOL HEMAT, V49, P179, DOI 10.1016/j.critrevonc.2003.10.008
   SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2
   Tian XR, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/567305
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Vinnedge LMP, 2015, ONCOGENE, V34, P2325, DOI 10.1038/onc.2014.173
   Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290
   Wu PX, 2015, EXP MOL PATHOL, V98, P360, DOI 10.1016/j.yexmp.2015.03.015
   Xiao J, 2015, GENE DEV, V29, P184, DOI 10.1101/gad.252528.114
   Zhang YW, 2013, WORLD J GASTROENTERO, V19, P5598, DOI 10.3748/wjg.v19.i34.5598
   Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429
   Zhu JJ, 2014, ONCOL LETT, V7, P2185, DOI 10.3892/ol.2014.2031
   Zhu JJ, 2012, ONCOL REP, V28, P2290, DOI 10.3892/or.2012.2065
   Zhu JR, 2016, SCI REP-UK, V6, DOI 10.1038/srep21549
NR 29
TC 1
Z9 2
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2017
VL 10
IS 5
BP 7796
EP 7805
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EW1ZA
UT WOS:000402294200047
DA 2022-04-25
ER

PT J
AU Spanou, E
   Kalisperati, P
   Pateras, IS
   Papalampros, A
   Barbouti, A
   Tzioufas, AG
   Kotsinas, A
   Sougioultzis, S
AF Spanou, Evagelia
   Kalisperati, Polyxeni
   Pateras, Ioannis S.
   Papalampros, Alexandros
   Barbouti, Alexandra
   Tzioufas, Athanasios G.
   Kotsinas, Athanassios
   Sougioultzis, Stavros
TI Genetic Variability as a Regulator of TLR4 and NOD Signaling in Response
   to Bacterial Driven DNA Damage Response (DDR) and Inflammation: Focus on
   the Gastrointestinal (GI) Tract
SO FRONTIERS IN GENETICS
LA English
DT Review
DE toll-like receptors (TLRs); nod-like receptors (NLRs); DNA damage
   response (DDR); single nucleotide polymorphism (SNP); mutation;
   inflammation and tumorigenesis
ID TOLL-LIKE RECEPTORS; HELICOBACTER-PYLORI; GASTRIC-CANCER;
   COLORECTAL-CANCER; INNATE IMMUNITY; GENOMIC INSTABILITY; 3020INSC
   MUTATION; CROHNS-DISEASE; LUNG-CANCER; POLYMORPHISMS
AB The fundamental role of human Toll-like receptors (TLRs) and NOD-like receptors (NLRs), the two most studied pathogen recognition receptors (PRRs), is the protection against pathogens and excessive tissue injury. Recent evidence supports the association between TLR/NLR gene mutations and susceptibility to inflammatory, autoimmune, and malignant diseases. PRRs also interfere with several cellular processes, such as cell growth, apoptosis, cell proliferation, differentiation, autophagy, angiogenesis, cell motility and migration, and DNA repair mechanisms. We briefly review the impact of TLR4 and NOD1/NOD2 and their genetic variability in the process of inflammation, tumorigenesis and DNA repair, focusing in the gastrointestinal tract. We also review the available data on new therapeutic strategies utilizing TLR/NLR agonists and antagonists for cancer, allergic diseases, viral infections and vaccine development against both infectious diseases and cancer.
C1 [Spanou, Evagelia; Kalisperati, Polyxeni; Sougioultzis, Stavros] Univ Athens, Laikon Gen Hosp, Gastroenterol Div, Dept Pathophysiol, Athens, Greece.
   [Pateras, Ioannis S.; Kotsinas, Athanassios] Univ Athens, Dept Histol & Embryol, Athens, Greece.
   [Papalampros, Alexandros] Univ Athens, Laikon Gen Hosp, Dept Surg 1, Athens, Greece.
   [Barbouti, Alexandra] Univ Ioannina, Dept Anat Histol Embryol, Ioannina, Greece.
   [Tzioufas, Athanasios G.] Univ Athens, Laikon Gen Hosp, Dept Pathophysiol, Athens, Greece.
RP Kotsinas, A (corresponding author), Univ Athens, Dept Histol & Embryol, Athens, Greece.
EM akotsin@med.uoa.gr
RI TZIOUFAS, ATHANASIOS G/A-1690-2008
OI BARBOUTI, ALEXANDRA/0000-0001-6730-359X
FU NKUA SARG [12128, 8916]
FX This work was supported by NKUA SARG grants 12128, 8916.
CR Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013
   Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485
   Goto Y, 2008, MOL CANCER THER, V7, P3642, DOI 10.1158/1535-7163.MCT-08-0582
   Gunther C, 2015, J CLIN INVEST, V125, P413, DOI 10.1172/JCI78001
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   Harberts E, 2013, J INVEST DERMATOL, V133, P296, DOI 10.1038/jid.2012.288
   Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203
   Hnatyszyn A, 2010, EXP MOL PATHOL, V88, P388, DOI 10.1016/j.yexmp.2010.03.003
   Hofner P, 2007, HELICOBACTER, V12, P124, DOI 10.1111/j.1523-5378.2007.00481.x
   Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026
   Huang LN, 2014, GENE, V537, P46, DOI 10.1016/j.gene.2013.12.030
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Hysi P, 2005, HUM MOL GENET, V14, P935, DOI 10.1093/hmg/ddi087
   Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Jang TJ, 2010, PATHOL RES PRACT, V206, P34, DOI 10.1016/j.prp.2009.07.019
   Janssens S, 2003, CLIN MICROBIOL REV, V16, P637, DOI 10.1128/CMR.16.4.637-646.2003
   Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589
   Kawai T, 2011, IMMUNITY, V34, P637, DOI 10.1016/j.immuni.2011.05.006
   Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863
   Keestra AM, 2013, NATURE, V496, P233, DOI 10.1038/nature12025
   Kim J, 2013, CANCER RES TREAT, V45, P313, DOI 10.4143/crt.2013.45.4.313
   Kim S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6236
   Kim YK, 2016, YONSEI MED J, V57, P5, DOI 10.3349/ymj.2016.57.1.5
   Koberlin MS, 2016, CURR OPIN CELL BIOL, V39, P28, DOI 10.1016/j.ceb.2016.01.010
   Kupcinskas J, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-112
   Kurzawski G, 2004, CANCER RES, V64, P1604, DOI 10.1158/0008-5472.CAN-03-3791
   Kutikhin AG, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00343
   Kutikhin AG, 2011, HUM IMMUNOL, V72, P1095, DOI 10.1016/j.humimm.2011.07.307
   Lener MR, 2006, BREAST CANCER RES TR, V95, P141, DOI 10.1007/s10549-005-9057-z
   Licandro G, 2013, EUR J IMMUNOL, V43, P2126, DOI 10.1002/eji.201242918
   Liu J, 2011, ALLERGY, V66, P1020, DOI 10.1111/j.1398-9995.2011.02573.x
   Liu JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089340
   Lowe EL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013027
   Magalhaes JG, 2011, EUR J IMMUNOL, V41, P1445, DOI 10.1002/eji.201040827
   Maisonneuve C, 2014, P NATL ACAD SCI USA, V111, P12294, DOI 10.1073/pnas.1400478111
   Manolakis AC, 2010, HELICOBACTER, V15, P481, DOI 10.1111/j.1523-5378.2010.00785.x
   Mayerle J, 2013, JAMA-J AM MED ASSOC, V309, P1912, DOI 10.1001/jama.2013.4350
   McGovern DPB, 2005, HUM MOL GENET, V14, P1245, DOI 10.1093/hmg/ddi135
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Menendez D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001360
   Mitchell JA, 2007, J ENDOCRINOL, V193, P323, DOI 10.1677/JOE-07-0067
   Moura SB, 2008, MICROBES INFECT, V10, P1477, DOI 10.1016/j.micinf.2008.08.009
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   Nihon-Yanagi Y, 2012, CANCER IMMUNOL IMMUN, V61, P71, DOI 10.1007/s00262-011-1085-4
   O'Neill LAJ, 2006, CURR OPIN IMMUNOL, V18, P3, DOI 10.1016/j.coi.2005.11.012
   Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591
   Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114
   Opal SM, 2013, JAMA-J AM MED ASSOC, V309, P1154, DOI 10.1001/jama.2013.2194
   Orr N, 2008, ADV GENET, V62, P1, DOI 10.1016/S0065-2660(08)00601-9
   Pateras IS, 2015, PHARMACOL THERAPEUT, V154, P36, DOI 10.1016/j.pharmthera.2015.06.011
   Philpott DJ, 2014, NAT REV IMMUNOL, V14, P9, DOI 10.1038/nri3565
   Pimentel-Nunes P, 2013, DIGEST LIVER DIS, V45, P63, DOI 10.1016/j.dld.2012.08.006
   Qadri Q, 2014, IMMUNOL INVEST, V43, P324, DOI 10.3109/08820139.2013.854378
   Rodier F, 2007, NUCLEIC ACIDS RES, V35, P7475, DOI 10.1093/nar/gkm744
   Romagne F, 2007, DRUG DISCOV TODAY, V12, P80, DOI 10.1016/j.drudis.2006.11.007
   Rossignol Daniel P, 2005, Curr Opin Investig Drugs, V6, P496
   Santini D, 2008, CLIN EXP IMMUNOL, V154, P360, DOI 10.1111/j.1365-2249.2008.03776.x
   Sato K, 2012, J BIOL CHEM, V287, P25163, DOI 10.1074/jbc.M111.338426
   Savva A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00387
   Saxena M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00327
   Semlali A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146333
   Sheng WY, 2015, ARCH MED SCI, V11, P699, DOI 10.5114/aoms.2015.53288
   Solier S, 2014, CELL MOL LIFE SCI, V71, P2289, DOI 10.1007/s00018-013-1555-2
   Souliotis VL, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1081-3
   Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x
   Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788
   Tseng FC, 2006, HELICOBACTER, V11, P425, DOI 10.1111/j.1523-5378.2006.00433.x
   Uehori J, 2003, INFECT IMMUN, V71, P4238, DOI 10.1128/IAI.71.8.4238-4249.2003
   Vacchelli E, 2012, ONCOIMMUNOLOGY, V1, P894, DOI 10.4161/onci.20931
   Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795
   Viala J, 2004, NAT IMMUNOL, V5, P1166, DOI 10.1038/ni1131
   Wang EL, 2010, BRIT J CANCER, V102, P908, DOI 10.1038/sj.bjc.6605558
   Wang H, 2006, MOL CANCER THER, V5, P1585, DOI 10.1158/1535-7163.MCT-06-0094
   Wang P, 2012, WORLD J GASTROENTERO, V18, P2112, DOI 10.3748/wjg.v18.i17.2112
   Wang ZY, 2013, HEPATOLOGY, V57, P1869, DOI 10.1002/hep.26234
   Wu YW, 2015, ACTA PHARMACOL SIN, V36, P1395, DOI 10.1038/aps.2015.91
   Yang HA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-92
   Zhong Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00333
NR 80
TC 6
Z9 7
U1 0
U2 16
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015,
   SWITZERLAND
SN 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD MAY 29
PY 2017
VL 8
AR 65
DI 10.3389/fgene.2017.00065
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EW7ZN
UT WOS:000402737700001
PM 28611823
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Phang, JM
   Donald, SP
   Pandhare, J
   Liu, YM
AF Phang, James M.
   Donald, Steven P.
   Pandhare, Jui
   Liu, Yongmin
TI The metabolism of proline, a stress substrate, modulates carcinogenic
   pathways
SO AMINO ACIDS
LA English
DT Article; Proceedings Paper
CT 2nd International Symposium on Proline Metabolism in Health and Disease
CY SEP 10-11, 2007
CL Frederick, MD
DE proline oxidase; proline dehydrogenase; mTOR; PPAR gamma; apoptosis;
   bioenergetics
ID ACTIVATED-RECEPTOR-GAMMA; MATRIX METALLOPROTEINASES; COLORECTAL-CANCER;
   PPAR-GAMMA; OXIDASE; GENE; APOPTOSIS; COLLAGEN; OXYGEN; INTERCONVERSIONS
AB The resurgence of interest in tumor metabolism has led investigators to emphasize the metabolism of proline as a "stress substrate" and to suggest this pathway as a potential anti-tumor target. Proline oxidase, a.k.a. proline dehydrogenase (POX/PRODH), catalyzes the first step in proline degradation and uses proline to generate ATP for survival or reactive oxygen species for programmed cell death. POX/PRODH is induced by p53 under genotoxic stress and initiates apoptosis by both mitochondrial and death receptor pathways. Furthermore, POX/PRODH is induced by PPAR gamma and its pharmacologic ligands, the thiazolidinediones. The anti-tumor effects of PPAR gamma may be critically dependent on POX/PRODH. In addition, it is upregulated by nutrient stress through the mTOR pathway to maintain ATP levels. We propose that proline is made available as a stress substrate by the degradation of collagen in the microenvironmental extracellular matrix by matrix metalloproteinases. In a manner analogous to autophagy, this proline-dependent process for bioenergetics from collagen in extracellular matrix can be designated "ecophagy".
C1 [Phang, James M.; Donald, Steven P.; Pandhare, Jui] NCI, Ctr Canc Res, Comparat Carcinogenesis Lab, Frederick, MD 21702 USA.
   [Liu, Yongmin] NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21702 USA.
RP Phang, JM (corresponding author), NCI, Ctr Canc Res, Comparat Carcinogenesis Lab, Bldg 538,Room 115, Frederick, MD 21702 USA.
EM phang@mail.ncifcrf.gov
OI Pandhare, Jui/0000-0002-0356-064X
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [ZIABC010743, Z01BC010746, Z01BC010744] Funding Source:
   NIH RePORTER; Intramural NIH HHSUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA Funding Source:
   Medline; NCI NIH HHSUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [N01-CO-12400] Funding Source: Medline
CR ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041
   ADAMS E, 1960, J BIOL CHEM, V235, P3499
   Adams E, 1970, Int Rev Connect Tissue Res, V5, P1
   Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje
   Campbell HD, 1997, HUM GENET, V101, P69, DOI 10.1007/s004390050589
   Carter C, 2006, NATURWISSENSCHAFTEN, V93, P72, DOI 10.1007/s00114-005-0062-1
   COOPER SK, 2008, J BIOL CHEM IN PRESS
   Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9
   DIXIT SN, 1977, EUR J BIOCHEM, V81, P599, DOI 10.1111/j.1432-1033.1977.tb11987.x
   Donald SP, 2001, CANCER RES, V61, P1810
   EGGLESTON LV, 1974, BIOCHEM J, V138, P425, DOI 10.1042/bj1380425
   Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710
   FRIES W, 1994, DIGESTION, V55, P229, DOI 10.1159/000201152
   Gade G, 2002, COMP BIOCHEM PHYS B, V132, P117, DOI 10.1016/S1096-4959(01)00541-3
   Gogos JA, 1999, NAT GENET, V21, P434, DOI 10.1038/7777
   GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199
   Govindarajan R, 2007, J CLIN ONCOL, V25, P1476, DOI 10.1200/JCO.2006.07.2777
   HAGEDORN CH, 1986, ARCH BIOCHEM BIOPHYS, V248, P166, DOI 10.1016/0003-9861(86)90413-3
   HAGEDORN CH, 1983, ARCH BIOCHEM BIOPHYS, V225, P95, DOI 10.1016/0003-9861(83)90010-3
   Han S, 2007, ANTI-CANCER DRUG, V18, P237, DOI 10.1097/CAD.0b013e328011e67d
   Hechtman P, 2001, METABOLIC MOL BASES, P1839
   Hu CAA, 2007, MOL CELL BIOCHEM, V295, P85, DOI 10.1007/s11010-006-9276-6
   Hu Chien-An A., 2001, Proceedings of the American Association for Cancer Research Annual Meeting, V42, P225
   Kim KY, 2007, MOL PHARMACOL, V72, P674, DOI 10.1124/mol.107.035584
   Laconi E, 2007, BIOESSAYS, V29, P738, DOI 10.1002/bies.20606
   Li MY, 2006, CRIT REV CL LAB SCI, V43, P183, DOI 10.1080/10408360600552587
   LIEDTKE AJ, 1992, CIRC RES, V71, P689, DOI 10.1161/01.RES.71.3.689
   Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564
   Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083
   Lu KP, 2003, BIOESSAYS, V25, P174, DOI 10.1002/bies.10223
   Lupi A, 2006, J MED GENET, V43, DOI 10.1136/jmg.2006.043315
   Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915
   MARIAN B, 1985, CARCINOGENESIS, V6, P501, DOI 10.1093/carcin/6.4.501
   Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200
   Mazurek S, 2001, ONCOGENE, V20, P6891, DOI 10.1038/sj.onc.1204792
   McAlpine CA, 2006, INT J CANCER, V119, P2339, DOI 10.1002/ijc.22115
   MERRILL MJ, 1989, J BIOL CHEM, V264, P9352
   Micheu S, 2000, AMINO ACIDS, V18, P157, DOI 10.1007/s007260050014
   Natali A, 2006, DIABETOLOGIA, V49, P434, DOI 10.1007/s00125-006-0141-7
   Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125
   PAN JG, 2007, SCI STKE, pPE14, DOI DOI 10.1126/STKE.3812007PE14
   Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200
   PANDHARE J, 2008, SIGNIFICANCE P UNPUB
   PANDHARE J, 2007, P AM ASSOC CANC RES, V48, P4501
   Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418
   PHANG JM, 1980, BIOCHEM BIOPH RES CO, V93, P462, DOI 10.1016/0006-291X(80)91100-6
   PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   REDDY GK, 1989, BONE, V10, P439, DOI 10.1016/8756-3282(89)90076-8
   Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889
   Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513
   SCHWARTZ LM, 1993, P NATL ACAD SCI USA, V90, P980, DOI 10.1073/pnas.90.3.980
   Scriver C.R., 2001, METABOLIC MOL BASIS, P1821
   SEMENIUK C, 2007, WETLANDS ECOL CONSER, V1, P1
   Stallings-Mann M, 2007, CELLS TISSUES ORGANS, V185, P104, DOI 10.1159/000101310
   Straus DS, 2007, TRENDS IMMUNOL, V28, P551, DOI 10.1016/j.it.2007.09.003
   SURAZYNSKI A, 2007, INT J CANC      1112
   VALLE D, 1979, J CLIN INVEST, V64, P1365, DOI 10.1172/JCI109593
   van Wijk Jeroen P H, 2005, Curr Atheroscler Rep, V7, P369
   Wagenaar-Miller RA, 2004, CANCER METAST REV, V23, P119, DOI 10.1023/A:1025819214508
   WANG X, 1994, CANCER RES, V54, P4726
   Warburg O, 1930, UEBER STOFFWECHSEL T
   White TA, 2007, J BIOL CHEM, V282, P14316, DOI 10.1074/jbc.M700912200
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
NR 64
TC 177
Z9 186
U1 6
U2 34
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0939-4451
EI 1438-2199
J9 AMINO ACIDS
JI Amino Acids
PD NOV
PY 2008
VL 35
IS 4
BP 681
EP 690
DI 10.1007/s00726-008-0063-4
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology
GA 355NE
UT WOS:000259714800006
PM 18401543
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Zhao, HB
   Xu, XG
   Lei, SZ
   Shao, DY
   Jiang, CM
   Shi, JL
   Zhang, YW
   Liu, L
   Lei, SZ
   Sun, H
   Huang, QS
AF Zhao, Haobin
   Xu, Xiaoguang
   Lei, Shuzhen
   Shao, Dongyan
   Jiang, Chunmei
   Shi, Junling
   Zhang, Yawen
   Liu, Li
   Lei, Shuzhen
   Sun, Hui
   Huang, Qingsheng
TI Iturin A-like lipopeptides from Bacillus subtilis trigger apoptosis,
   paraptosis, and autophagy in Caco-2 cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE anticancer; apoptosis; autophagy; endoplasmic reticulum stress; iturin;
   lipopeptide; paraptosis
ID CANCER-CELLS; ER STRESS; CA2+ OVERLOAD; SURFACTIN; ACTIVATION;
   INDUCTION; MEMBRANE; PATHWAY; INVOLVEMENT; DYSFUNCTION
AB This study revealed that iturin A-like lipopeptides produced by Bacillus subtillis induced both paraptosis and apoptosis in heterogeneous human epithelial colorectal adenocarcinoma (Caco-2) cells. Autophagy was simultaneously induced in Caco-2 cells treated with iturin A-like lipopeptides at the early stage and inhibited at the later stage. A western blot analysis showed that the lipopeptides induced apoptosis in Caco-2 cells via a mitochondrial-dependent pathway, as indicated by upregulated expression of the apoptotic genes bax and bad and downregulated expression of the antiapoptotic gene bcl-2. The induction of paraptosis in Caco-2 cells was indicated by the occurrence of many cytoplasmic vacuoles accompanied by endoplasmic reticulum (ER) dilatation and mitochondrial swelling and dysfunction. ER stress also occurred with significant increases in reactive oxygen species and Ca2+ levels in cells. Autophagy was detected by a transmission electron microscopy analysis and by upregulated expression of LC3-II and downregulated expression of LC3-I. The inhibition of autophagy at the later stage was shown by upregulated expression of p62. This study revealed the capability of iturin A-like B. subtilis lipopeptides to simultaneously execute antitumor potential via multiple pathways.
C1 [Zhao, Haobin; Xu, Xiaoguang; Lei, Shuzhen; Shao, Dongyan; Jiang, Chunmei; Shi, Junling; Zhang, Yawen; Liu, Li; Lei, Shuzhen; Sun, Hui; Huang, Qingsheng] Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, 127 Youyi West Rd, Xian 710072, Shaanxi, Peoples R China.
   [Sun, Hui] Guilin Tourism Univ, Sch Hospitality Management, Guilin, Peoples R China.
RP Shi, JL (corresponding author), Northwestern Polytech Univ, Sch Life Sci, Key Lab Space Biosci & Biotechnol, 127 Youyi West Rd, Xian 710072, Shaanxi, Peoples R China.
EM sjlshi2004@nwpu.edu.cn
OI Shi, Junling/0000-0002-4643-1792; Xu, Xiaoguang/0000-0001-9754-9857
FU Shaanxi Postdoctoral Science Foundation; Seed Foundation of Innovation
   and Creation for Graduate Students in Northwestern Polytechnical
   University [zz2017242]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [1701722,
   31471718]; Key research and development plan of Shaanxi Province
   [2017ZDXL-NY-0304]; Modern Agricultural Industry Technology System
   [CARS-30]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2017M613211]
FX Shaanxi Postdoctoral Science Foundation, Seed Foundation of Innovation
   and Creation for Graduate Students in Northwestern Polytechnical
   University, Grant/Award Number: zz2017242; National Natural Science
   Foundation of China, Grant/Award Numbers: 1701722, 31471718; Key
   research and development plan of Shaanxi Province, Grant/Award Number:
   2017ZDXL-NY-0304; Modern Agricultural Industry Technology System,
   Grant/Award Number: CARS-30; China Postdoctoral Science Foundation,
   Grant/Award Number: 2017M613211
CR Almutary A, 2016, INT J TOXICOL, V35, P454, DOI 10.1177/1091581816648906
   Bardo S, 2006, TRENDS PHARMACOL SCI, V27, P78, DOI 10.1016/j.tips.2005.12.008
   Borutaite V, 2007, J BIOL CHEM, V282, P31124, DOI 10.1074/jbc.M700322200
   Cao XH, 2010, CHEM-BIOL INTERACT, V183, P357, DOI 10.1016/j.cbi.2009.11.027
   Coutte F, 2015, BIOTECHNOL J, V10, P1216, DOI 10.1002/biot.201400541
   Crowley Lisa C, 2016, Cold Spring Harb Protoc, V2016, DOI 10.1101/pdb.prot087221
   Dey G, 2015, SCI REP-UK, V5, DOI 10.1038/srep10316
   Dey G, 2015, DRUG DISCOV TODAY, V20, P136, DOI 10.1016/j.drudis.2014.09.006
   Engstrom PF, 2012, J NATL COMPR CANC NE, V10, P574, DOI 10.6004/jnccn.2012.0058
   Gandin V, 2012, J CELL MOL MED, V16, P142, DOI 10.1111/j.1582-4934.2011.01292.x
   Hajare SN, 2013, BIOCHIMIE, V95, P1722, DOI 10.1016/j.biochi.2013.05.015
   He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910
   Hong B, 2014, CURR DRUG TARGETS, V15, P80, DOI 10.2174/1389450114666140106101412
   Huang XQ, 2006, INT J PEPT RES THER, V12, P373, DOI 10.1007/s10989-006-9041-4
   Ines M, 2015, PEPTIDES, V71, P100, DOI 10.1016/j.peptides.2015.07.006
   Jaferian S, 2016, BIOMED PHARMACOTHER, V84, P780, DOI 10.1016/j.biopha.2016.10.004
   Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144
   Kim SY, 2007, FEBS LETT, V581, P865, DOI 10.1016/j.febslet.2007.01.059
   Korsnes MS, 2011, TOXICOL IN VITRO, V25, P1764, DOI 10.1016/j.tiv.2011.09.005
   Korytowski W, 2011, J BIOL CHEM, V286, P26334, DOI 10.1074/jbc.M110.188516
   Kurosu T, 2010, APOPTOSIS, V15, P608, DOI 10.1007/s10495-010-0457-0
   Lee D, 2016, PHARMACOL THERAPEUT, V162, P120, DOI 10.1016/j.pharmthera.2016.01.003
   Lemasters JJ, 2009, BBA-BIOENERGETICS, V1787, P1395, DOI 10.1016/j.bbabio.2009.06.009
   Lin PY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1611-9
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, DOI 10.1038/nrd.2016.53
   Murphy RC, 2001, FEBS LETT, V497, P73, DOI 10.1016/S0014-5793(01)02440-1
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ostroumova OS, 2010, LANGMUIR, V26, P15092, DOI 10.1021/la102691y
   Park EJ, 2014, TOXICOL LETT, V230, P69, DOI 10.1016/j.toxlet.2014.07.027
   Park SY, 2013, TOXICOL APPL PHARM, V268, P68, DOI 10.1016/j.taap.2013.01.017
   Pathak KV, 2014, 3 BIOTECH, V4, P283, DOI 10.1007/s13205-013-0151-3
   Prosperini A, 2013, TOXICOL LETT, V222, P36, DOI 10.1016/j.toxlet.2013.07.009
   Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008
   Sun QR, 2010, J CELL PHYSIOL, V222, P421, DOI 10.1002/jcp.21982
   Wang WB, 2012, J CELL PHYSIOL, V227, P2196, DOI 10.1002/jcp.22956
   Wieldraaijer T, 2017, EJSO-EUR J SURG ONC, V43, P118, DOI 10.1016/j.ejso.2016.08.011
   Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905
   Xin J, 2013, CANCER LETT, V336, P260, DOI 10.1016/j.canlet.2013.03.019
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   Xu WJ, 2017, MOLECULES, V22, DOI 10.3390/molecules22030467
   Yin HP, 2013, ANTI-CANCER DRUG, V24, P587, DOI 10.1097/CAD.0b013e3283611395
   Yoon MJ, 2012, CANCER LETT, V324, P197, DOI 10.1016/j.canlet.2012.05.018
   Yoon MJ, 2010, FREE RADICAL BIO MED, V48, P713, DOI 10.1016/j.freeradbiomed.2009.12.016
   Yumnam S, 2016, J CELL PHYSIOL, V231, P1261, DOI 10.1002/jcp.25222
   Zhang LA, 2010, FEBS LETT, V584, P4646, DOI 10.1016/j.febslet.2010.10.038
   Zhao HB, 2018, AMB EXPRESS, V8, DOI 10.1186/s13568-018-0606-3
   Zhao HB, 2017, APPL MICROBIOL BIOT, V101, P5951, DOI 10.1007/s00253-017-8396-0
   Zhao X, 2015, INT J BIOCHEM CELL B, V65, P155, DOI 10.1016/j.biocel.2015.06.005
   Zhou H, 2015, ONCOTARGET, V6, P26599, DOI 10.18632/oncotarget.5613
NR 49
TC 26
Z9 29
U1 2
U2 82
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2019
VL 234
IS 5
BP 6414
EP 6427
DI 10.1002/jcp.27377
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA HK7AQ
UT WOS:000458138600092
PM 30238995
DA 2022-04-25
ER

PT J
AU Payen, VL
   Zampieri, LX
   Porporato, PE
   Sonveaux, P
AF Payen, Valery L.
   Zampieri, Luca X.
   Porporato, Paolo E.
   Sonveaux, Pierre
TI Pro- and antitumor effects of mitochondrial reactive oxygen species
SO CANCER AND METASTASIS REVIEWS
LA English
DT Review
DE Cancer; Mitochondria; Mitochondrial reactive oxygen species (mtROS);
   Antioxidants; Pro-oxidants; mitoQ
ID DNA G10398A POLYMORPHISM; COLORECTAL-CANCER CELLS; PYRUVATE-KINASE M2;
   OXIDATIVE STRESS; BREAST-CANCER; COMPLEX-III; PROSTATE-CANCER;
   SUPEROXIDE/HYDROGEN PEROXIDE; ALLOSTERIC REGULATION; ANTIOXIDANT
   VITAMINS
AB In cancer, mitochondrial functions are commonly altered. Directly involved in metabolic reprogramming, mitochondrial plasticity confers to cancer cells a high degree of adaptability to a wide range of stresses and to the harsh tumor microenvironment. Lack of nutrients or oxygen caused by altered perfusion, metabolic needs of proliferating cells, co-option of the microenvironment, control of the immune system, cell migration and metastasis, and evasion of exogenous stress (e.g., chemotherapy) are all, at least in part, influenced by mitochondria. Mitochondria are undoubtedly one of the key contributors to cancer development and progression. Understanding their protumoral (dys)functions may pave the way to therapeutic strategies capable of turning them into innocent entities. Here, we will focus on the production and detoxification of mitochondrial reactive oxygen species (mtROS), on their impact on tumorigenesis (genetic, prosurvival, and microenvironmental effects and their involvement in autophagy), and on tumor metastasis. We will also summarize the latest therapeutic approaches involving mtROS.
C1 [Payen, Valery L.; Zampieri, Luca X.; Sonveaux, Pierre] Univ Catholique Louvain UCLouvain, IREC, Pole Pharmacol, Ave Hippocrate 57,Box B1-57-04, B-1200 Brussels, Belgium.
   [Payen, Valery L.] UCLouvain, Pole Pediat, IREC, Brussels, Belgium.
   [Payen, Valery L.] UCLouvain, Louvain Drug Res Inst, Brussels, Belgium.
   [Porporato, Paolo E.] Univ Torino, Dept Mol Biotechnol & Hlth Sci, Mol Biotechnol Ctr, Turin, Italy.
RP Sonveaux, P (corresponding author), Univ Catholique Louvain UCLouvain, IREC, Pole Pharmacol, Ave Hippocrate 57,Box B1-57-04, B-1200 Brussels, Belgium.
EM pierre.sonveaux@uclouvain.be
FU European Union's Horizon 2020 research and innovation program under the
   Marie Skodowska-Curie grant [642623 RADIATE, 722605 TRANSMIT]; Belgian
   Fonds National de la Recherche Scientifique (F.R.S.-FNRS)Fonds de la
   Recherche Scientifique - FNRS; Belgian Televie; Fondation Louvain;
   Italian Ministry for University and Research (MIUR, Rita Levi-Montalcini
   program for young researchers 2014)Ministry of Education, Universities
   and Research (MIUR); Marie Skodowska-Curie grant [722605 TRANSMIT]
FX Works at authors' labs are supported by European Union's Horizon 2020
   research and innovation program under the Marie Skodowska-Curie grant
   agreement No. 642623 RADIATE and No. 722605 TRANSMIT, the Belgian Fonds
   National de la Recherche Scientifique (F.R.S.-FNRS), the Belgian Televie
   and the Fondation Louvain (all to PS), and the Italian Ministry for
   University and Research (MIUR, Rita Levi-Montalcini program for young
   researchers 2014) to PEP. PS is a F.R.S.-FNRS Senior Research Associate.
   LXZ is a PhD Fellow of Marie Skodowska-Curie grant No. 722605 TRANSMIT.
CR Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013
   Alexeyev M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012641
   Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485
   Arnold RS, 2009, PROSTATE, V69, P1, DOI 10.1002/pros.20854
   Assi M, 2017, AM J PHYSIOL-REG I, V313, pR646, DOI 10.1152/ajpregu.00247.2017
   Assi M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9579868
   Bairati I, 2005, J CLIN ONCOL, V23, P5805, DOI 10.1200/JCO.2005.05.514
   Basit F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.133
   Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
   Bell EL, 2007, J CELL BIOL, V177, P1029, DOI 10.1083/jcb.200609074
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bonner MY, 2014, FUTURE MED CHEM, V6, P1413, DOI [10.4155/FMC.14.86, 10.4155/fmc.14.86]
   Brunelle JK, 2005, CELL METAB, V1, P409, DOI 10.1016/j.cmet.2005.05.002
   Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428
   Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189
   Chakrabortty S, 2017, J AM CHEM SOC, V139, P2512, DOI 10.1021/jacs.6b13399
   Chandel NS, 2014, NEW ENGL J MED, V371, P177, DOI 10.1056/NEJMcibr1405701
   Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715
   Chang J, 2014, BIOCHEM BIOPH RES CO, V455, P290, DOI 10.1016/j.bbrc.2014.11.005
   Checchetto V, 2018, BIOCHEM BIOPH RES CO, V500, P51, DOI 10.1016/j.bbrc.2017.06.095
   Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Cheriyath V, 2018, BRIT J CANCER, V119, P52, DOI 10.1038/s41416-018-0137-3
   Chung WJ, 2005, J NEUROSCI, V25, P7101, DOI 10.1523/JNEUROSCI.5258-04.2005
   Comito G, 2011, FREE RADICAL BIO MED, V51, P893, DOI 10.1016/j.freeradbiomed.2011.05.042
   Corbet C, 2017, NAT REV CANCER, V17, P577, DOI 10.1038/nrc.2017.77
   Corbet C, 2016, CELL METAB, V24, P311, DOI 10.1016/j.cmet.2016.07.003
   Cramer SL, 2017, NAT MED, V23, P120, DOI 10.1038/nm.4232
   Darvishi K, 2007, CANCER LETT, V249, P249, DOI 10.1016/j.canlet.2006.09.005
   Dasgupta S, 2008, CANCER RES, V68, P700, DOI 10.1158/0008-5472.CAN-07-5532
   De Haes W, 2014, P NATL ACAD SCI USA, V111, pE2501, DOI 10.1073/pnas.1321776111
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   De Saedeleer CJ, 2014, ONCOGENE, V33, P4060, DOI 10.1038/onc.2013.454
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   Di Marcantonio D, 2018, CLIN CANCER RES, V24, P608, DOI 10.1158/1078-0432.CCR-17-2684
   Dikalova AE, 2010, CIRC RES, V107, P106, DOI 10.1161/CIRCRESAHA.109.214601
   Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923
   Ebner S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027192
   Esparza-Molto PB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00053
   Ferraro D, 2006, ONCOGENE, V25, P3689, DOI 10.1038/sj.onc.1209409
   Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004
   Gasparre G, 2008, HUM MOL GENET, V17, P986, DOI 10.1093/hmg/ddm371
   Gasparre G, 2011, CANCER RES, V71, P6220, DOI 10.1158/0008-5472.CAN-11-1042
   Gasparre G, 2011, BBA-BIOENERGETICS, V1807, P633, DOI 10.1016/j.bbabio.2010.08.006
   Gaude E, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-10
   Girnun GD, 2012, SEMIN CELL DEV BIOL, V23, P381, DOI 10.1016/j.semcdb.2012.01.007
   Goncalves RLS, 2016, FREE RADICAL BIO MED, V91, P247, DOI 10.1016/j.freeradbiomed.2015.12.020
   Govindarajan B, 2007, J CLIN INVEST, V117, P719, DOI 10.1172/JCI30102
   Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20
   Griguer CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061035
   Guo RR, 2016, SMALL, V12, P4541, DOI 10.1002/smll.201601094
   Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Hammerova J, 2012, BIOL CHEM, V393, P647, DOI 10.1515/hsz-2011-0279
   He XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061677
   Hercberg S, 2004, ARCH INTERN MED, V164, P2335, DOI 10.1001/archinte.164.21.2335
   Hou XS, 2018, BIOMATER SCI-UK, V6, DOI 10.1039/c8bm00673c
   Imhoff BR, 2009, BIOCHEM J, V424, P491, DOI 10.1042/BJ20091286
   Ishikawa K, 2008, FEBS LETT, V582, P3525, DOI 10.1016/j.febslet.2008.09.024
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jacobs C, 2015, ONCOLOGIST, V20, P210, DOI 10.1634/theoncologist.2014-0381
   Jin H, 2014, BBA-MOL BASIS DIS, V1842, P1282, DOI 10.1016/j.bbadis.2013.09.007
   Jung HS, 2017, J AM CHEM SOC, V139, P9972, DOI 10.1021/jacs.7b04263
   Jung HS, 2015, J AM CHEM SOC, V137, P3017, DOI 10.1021/ja5122809
   Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5
   Justus CR, 2015, INT J MOL SCI, V16, P11055, DOI 10.3390/ijms160511055
   Kamarajugadda S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.20
   Kang KA, 2012, TUMOR BIOL, V33, P403, DOI 10.1007/s13277-012-0322-6
   Karnati S, 2013, HISTOCHEM CELL BIOL, V140, P105, DOI 10.1007/s00418-013-1099-4
   Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183
   Khacho M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4550
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   Kong H, 2018, J BIOL CHEM, V293, P7499, DOI 10.1074/jbc.TM117.000257
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Lawenda BD, 2008, JNCI-J NATL CANCER I, V100, P773, DOI 10.1093/jnci/djn148
   Le Gal K, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aad3740
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039
   Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515
   Lu X, 2010, J BIOL CHEM, V285, P9317, DOI 10.1074/jbc.C110.104448
   Luo C, 2016, NATURE, V537, P422, DOI 10.1038/nature19347
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Maddocks ODK, 2013, NATURE, V493, P542, DOI 10.1038/nature11743
   Malinska D, 2010, FEBS LETT, V584, P2043, DOI 10.1016/j.febslet.2010.01.013
   Mansfield KD, 2005, CELL METAB, V1, P393, DOI 10.1016/j.cmet.2005.05.003
   Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]
   Masson N, 2012, EMBO REP, V13, P251, DOI 10.1038/embor.2012.9
   Mayr JA, 2008, CLIN CANCER RES, V14, P2270, DOI 10.1158/1078-0432.CCR-07-4131
   Moeller BJ, 2007, CANCER METAST REV, V26, P241, DOI 10.1007/s10555-007-9056-0
   Molognoni F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081937
   MORAIS R, 1994, CANCER RES, V54, P3889
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Muller FL, 2004, J BIOL CHEM, V279, P49064, DOI 10.1074/jbc.M407715200
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Nazarewicz RR, 2013, AM J PHYSIOL-HEART C, V305, pH1131, DOI 10.1152/ajpheart.00063.2013
   Nazarewicz RR, 2013, ANTIOXID REDOX SIGN, V19, P344, DOI 10.1089/ars.2013.5185
   Oliva CR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024665
   Oliva CR, 2010, J BIOL CHEM, V285, P39759, DOI 10.1074/jbc.M110.147504
   Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498
   Ozben T, 2015, CURR TOP MED CHEM, V15, P170, DOI 10.2174/1568026615666141209160918
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726
   Poillet-Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043
   Quinlan CL, 2014, J BIOL CHEM, V289, P8312, DOI 10.1074/jbc.M113.545301
   Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688
   Riemann A, 2016, ADV EXP MED BIOL, V876, P215, DOI 10.1007/978-1-4939-3023-4_27
   Riemann A, 2014, PFLUG ARCH EUR J PHY, V466, P2127, DOI 10.1007/s00424-014-1458-6
   Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001
   Ruas JL, 2012, CELL, V151, P1319, DOI 10.1016/j.cell.2012.10.050
   Sabharwal SS, 2014, NAT REV CANCER, V14, P709, DOI 10.1038/nrc3803
   Sanita P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-154
   Santacatterina F, 2016, ONCOTARGET, V7, P490, DOI 10.18632/oncotarget.6357
   Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   SEMENZA GL, 1994, J BIOL CHEM, V269, P23757
   Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005
   Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025
   Shaw AT, 2011, P NATL ACAD SCI USA, V108, P8773, DOI 10.1073/pnas.1105941108
   Singh RK, 2014, SCI REP-UK, V4, DOI 10.1038/srep06571
   Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1
   Sonkusre P, 2017, J NANOBIOTECHNOL, V15, DOI 10.1186/s12951-017-0276-3
   Sreevalsan S, 2013, CURR COLORECT CANC R, V9, P350, DOI 10.1007/s11888-013-0190-5
   St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024
   Stacpoole PW, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx071
   Stolik S, 2000, J PHOTOCH PHOTOBIO B, V57, P90, DOI 10.1016/S1011-1344(00)00082-8
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Tallini G, 1998, VIRCHOWS ARCH, V433, P5, DOI 10.1007/s004280050209
   Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003
   Thorpe GW, 2013, MOL BIOL CELL, V24, P2876, DOI 10.1091/mbc.E13-01-0052
   Titova E, 2018, CELL CYCLE, V17, P1797, DOI 10.1080/15384101.2018.1496748
   Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Verrax F, 2005, FREE RADICAL RES, V39, P649, DOI 10.1080/10715760500097906
   Verrax J, 2004, APOPTOSIS, V9, P223, DOI 10.1023/B:APPT.0000018804.26026.1a
   Verrax J, 2006, BIOCHEM PHARMACOL, V72, P671, DOI 10.1016/j.bcp.2006.05.025
   Wang BB, 2018, HEPATOLOGY, V67, P623, DOI 10.1002/hep.29518
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004
   Wen JF, 2018, ONCOGENE, V37, P3549, DOI 10.1038/s41388-018-0208-1
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9
   Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859
   Yu TC, 2017, YONSEI MED J, V58, P489, DOI 10.3349/ymj.2017.58.3.489
   ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367
   Zarse K, 2012, CELL METAB, V15, P451, DOI 10.1016/j.cmet.2012.02.013
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang W, 2012, NAT CELL BIOL, V14, P276, DOI 10.1038/ncb2432
   Zhao XL, 2018, CHEM-BIOL INTERACT, V290, P57, DOI 10.1016/j.cbi.2018.05.011
NR 154
TC 21
Z9 22
U1 2
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-7659
EI 1573-7233
J9 CANCER METAST REV
JI Cancer Metastasis Rev.
PD JUN
PY 2019
VL 38
IS 1-2
BP 189
EP 203
DI 10.1007/s10555-019-09789-2
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IJ1TK
UT WOS:000475681100018
PM 30820778
DA 2022-04-25
ER

PT J
AU Fumet, JD
   Limagne, E
   Thibaudin, M
   Ghiringhelli, F
AF Fumet, Jean-David
   Limagne, Emeric
   Thibaudin, Marion
   Ghiringhelli, Francois
TI Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A
   Double-Edged Sword of Chemotherapy
SO CANCERS
LA English
DT Review
DE cancer; chemotherapy; immunotherapy; immunogenic cell death;
   immunosuppression
ID REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; SUPPRESSOR-CELLS;
   COLORECTAL-CANCER; APOPTOTIC CELLS; CYCLOPHOSPHAMIDE; CALRETICULIN;
   AUTOPHAGY; EFFICACY; TARGETS
AB Simple Summary The aim of this review is to detailed immunological effects of chemotherapies focusing on 2 main effects: immunogenic cell death and depletion of suppressive cells. It provides a strong rational for combination of chemotherapy and immunotherapy. Chemotherapy is initially used to kill proliferative cells. In the current area of emerging immunotherapy, chemotherapies have shown their ability to modulate the tumor micro environment and immune response. We focus here on two main effects: first, immunogenic cell death, defined as a form of regulated cell death (RCD) that is sufficient to activate an adaptive immune response in immunocompetent hosts; and second, the depletion of suppressive cells, known to play a major role in immune escape and resistance to immunotherapy. In this review, we present a review of different classically used chemotherapies focusing on this double effect on immunity. These immunological effects of chemotherapy could be exploited to promote efficacy of immunotherapy. Broadening our understanding will make it possible to provide rationales for the combination of chemoimmunotherapy in early clinical trials.
C1 [Fumet, Jean-David; Ghiringhelli, Francois] Ctr GF Leclerc, Dept Med Oncol, F-21000 Dijon, France.
   [Fumet, Jean-David; Limagne, Emeric; Thibaudin, Marion; Ghiringhelli, Francois] Ctr GF Leclerc, Platform Transfer Canc Biol, F-21000 Dijon, France.
   [Fumet, Jean-David; Limagne, Emeric; Thibaudin, Marion; Ghiringhelli, Francois] Univ Burgundy Franche Compte, F-21000 Dijon, France.
   [Fumet, Jean-David; Limagne, Emeric; Thibaudin, Marion; Ghiringhelli, Francois] UMR INSERM 1231 Lipides Nutr Canc, F-21000 Dijon, France.
RP Fumet, JD (corresponding author), Ctr GF Leclerc, Dept Med Oncol, F-21000 Dijon, France.; Fumet, JD (corresponding author), Ctr GF Leclerc, Platform Transfer Canc Biol, F-21000 Dijon, France.; Fumet, JD (corresponding author), Univ Burgundy Franche Compte, F-21000 Dijon, France.; Fumet, JD (corresponding author), UMR INSERM 1231 Lipides Nutr Canc, F-21000 Dijon, France.
EM jd.fumet@gmail.com; elimagne@cgfl.fr; mthibaudin@cgfl.fr;
   fghiringhelli@cgfl.fr
OI Thibaudin, Marion/0000-0002-1046-5982; ghiringhelli,
   francois/0000-0002-5465-8305; Emeric, Limagne/0000-0002-1098-8441
CR Alizadeh D, 2014, CANCER RES, V74, P104, DOI 10.1158/0008-5472.CAN-13-1545
   Anestakis D, 2020, MOL IMMUNOL, V118, P99, DOI 10.1016/j.molimm.2019.11.008
   Annels NE, 2014, CANCER IMMUNOL IMMUN, V63, P175, DOI 10.1007/s00262-013-1502-y
   Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937
   Aranda F, 2015, ONCOGENE, V34, P3053, DOI 10.1038/onc.2014.234
   Banissi C, 2009, CANCER IMMUNOL IMMUN, V58, P1627, DOI 10.1007/s00262-009-0671-1
   Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643
   Bruchard M, 2014, B CANCER, V101, P605, DOI 10.1684/bdc.2014.1936
   Bugaut H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065181
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   Chen C, 2015, J INT MED RES, V43, P180, DOI 10.1177/0300060514561504
   Conte A, 2017, CELL DEATH DIFFER, V24, P1948, DOI 10.1038/cdd.2017.117
   Cottone L, 2015, INT J CANCER, V136, P1381, DOI 10.1002/ijc.29125
   Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Dosset M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433981
   Duan QQ, 2020, TRENDS CANCER, V6, P605, DOI 10.1016/j.trecan.2020.02.022
   Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296
   Eriksson E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1037-z
   Fares Charlene M, 2019, Am Soc Clin Oncol Educ Book, V39, P147, DOI 10.1200/EDBK_240837
   Fumet JD, 2018, BRIT J CANCER, V119, P950, DOI 10.1038/s41416-018-0220-9
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Geary SM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067904
   Germano G, 2013, CANCER CELL, V23, P249, DOI 10.1016/j.ccr.2013.01.008
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8
   Ghiringhelli F, 2020, J CLIN ONCOL, V38
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Giglio P, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1466765
   Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518
   Hato SV, 2014, CLIN CANCER RES, V20, P2831, DOI 10.1158/1078-0432.CCR-13-3141
   Hodge JW, 2013, INT J CANCER, V133, P624, DOI 10.1002/ijc.28070
   Horn L, 2018, NEW ENGL J MED, V379, P2220, DOI 10.1056/NEJMoa1809064
   Huang J, 2015, AGEING RES REV, V24, P3, DOI 10.1016/j.arr.2014.10.004
   Huang X, 2016, IMMUNOL RES, V64, P160, DOI 10.1007/s12026-015-8734-1
   Kanterman J, 2014, CANCER RES, V74, P6022, DOI 10.1158/0008-5472.CAN-14-0657
   Keyvani-Ghamsari S, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317698354
   Kim NR, 2019, CANCER MED-US, V8, P276, DOI 10.1002/cam4.1878
   Ko EC, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918768240
   Kodumudi KN, 2010, CLIN CANCER RES, V16, P4583, DOI 10.1158/1078-0432.CCR-10-0733
   Krysko O, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.156
   Lau TS, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-1232
   Le HK, 2009, INT IMMUNOPHARMACOL, V9, P900, DOI 10.1016/j.intimp.2009.03.015
   Li JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/286170
   Liechtenstein T, 2014, ONCOTARGET, V5, P7843, DOI 10.18632/oncotarget.2279
   Limagne E, 2019, CANCER IMMUNOL RES, V7, P1958, DOI 10.1158/2326-6066.CIR-19-0228
   Limagne E, 2016, CANCER RES, V76, P5241, DOI 10.1158/0008-5472.CAN-15-3164
   Liu WM, 2010, BRIT J CANCER, V102, P115, DOI 10.1038/sj.bjc.6605465
   Maeda K, 2011, ANTICANCER RES, V31, P4569
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295
   Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Minute L, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000325
   Nakahara T, 2010, BLOOD, V115, P4384, DOI 10.1182/blood-2009-11-251231
   Novosiadly R, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-4549
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Petty AJ, 2017, IMMUNOTHERAPY-UK, V9, P289, DOI 10.2217/imt-2016-0135
   Pfannenstiel LW, 2010, CELL IMMUNOL, V263, P79, DOI 10.1016/j.cellimm.2010.03.001
   Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024
   Ridolfi L, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-135
   Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714
   Roselli M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27025
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Schaer DA, 2019, CLIN CANCER RES, V25, P7175, DOI 10.1158/1078-0432.CCR-19-0433
   Schiavoni G, 2011, CANCER RES, V71, P768, DOI 10.1158/0008-5472.CAN-10-2788
   Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615
   Sevko A, 2013, J CANCER, V4, P3, DOI 10.7150/jca.5047
   Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708
   Sistigu A, 2011, SEMIN IMMUNOPATHOL, V33, P369, DOI 10.1007/s00281-011-0245-0
   Stojanovska V, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4650695
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Vacchelli E, 2015, SCIENCE, V350, P972, DOI 10.1126/science.aad0779
   Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237
   Vanpouille-Box C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15618
   Vicari AP, 2009, CANCER IMMUNOL IMMUN, V58, P615, DOI 10.1007/s00262-008-0586-2
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690
   Volk-Draper L, 2014, CANCER RES, V74, P5421, DOI 10.1158/0008-5472.CAN-14-0067
   Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4
   Wan S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032542
   Wang J, 2016, ONCOTARGET, V7, P19312, DOI 10.18632/oncotarget.8344
   Yamamura Y, 2015, INT J CLIN ONCOL, V20, P386, DOI 10.1007/s10147-014-0719-x
   Yanai H, 2009, NATURE, V462, P99, DOI 10.1038/nature08512
   Yin HB, 2017, ONCOTARGET, V8, P71642, DOI 10.18632/oncotarget.17796
   Zhang L, 2008, CLIN IMMUNOL, V129, P219, DOI 10.1016/j.clim.2008.07.013
   Zhao J, 2010, CANCER RES, V70, P4850, DOI 10.1158/0008-5472.CAN-10-0283
NR 88
TC 16
Z9 16
U1 4
U2 16
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD SEP
PY 2020
VL 12
IS 9
AR 2637
DI 10.3390/cancers12092637
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OE0RC
UT WOS:000580248000001
PM 32947882
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Tejeda-Munoz, N
   Albrecht, LV
   Bui, MH
   De Robertis, EM
AF Tejeda-Munoz, Nydia
   Albrecht, Lauren V.
   Bui, Maggie H.
   De Robertis, Edward M.
TI Wnt canonical pathway activates macropinocytosis and lysosomal
   degradation of extracellular proteins
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE macropinocytosis; arginine methylation; ESCRT; adenomatous polyposis
   coli; Wnt-STOP
ID COLI APC PROTEIN; ARGININE METHYLATION; LRP6; MECHANISMS; CANCER;
   SEQUESTRATION; PINOCYTOSIS; ENDOCYTOSIS; LOCALIZES; CELLS
AB 6 Canonical Wnt signaling is emerging as a major regulator of endocytosis. Wnt treatment markedly increased the endocytosis and degradation in lysosomes of BSA. In this study, we report that in addition to receptor-mediated endocytosis, Wnt also triggers the intake of large amounts of extracellular fluid by macropinocytosis, a nonreceptor-mediated actin-driven process. Macropinocytosis induction is rapid and independent of protein synthesis. In the presence of Wnt, large amounts of nutrient-rich packages such as proteins and glycoproteins were channeled into lysosomes after fusing with smaller receptor-mediated vesicles containing glycogen synthase kinase 3 (GSK3) and protein arginine ethyltransferase 1 (PRMT1), an enzyme required for canonical Wnt signaling. Addition of Wnt3a, as well as overexpression of Disheveled (Dvl), Frizzled (Fz8), or dominant-negative Axin induced endocytosis. Depletion of the tumor suppressors adenomatous polyposis coli (APC) or Axin dramatically increased macropinocytosis, defined by incorporation of the high molecular weight marker tetramethylrhodamine (TMR)-dextran and its blockage by the Na+/H+ exchanger ethylisopropyl amiloride (EIPA). Macropinocytosis was blocked by dominant-negative vacuolar protein sorting 4 (Vps4), indicating that the Wnt pathway is dependent on multivesicular body formation, a process called microautophagy. SW480 colorectal cancer cells displayed constitutive macropinocytosis and increased extracellular protein degradation in lysosomes, which were suppressed by restoring full-length APC. Accumulation of the transcriptional activator beta-catenin in the nucleus of SW480 cells was inhibited by methyltransferase inhibition, EIPA, or the diuretic amiloride. The results indicate that Wnt signaling switches metabolism toward nutrient acquisition by engulfment of extracellular fluids and suggest possible treatments for Wnt-driven cancer progression.
C1 [Tejeda-Munoz, Nydia; Albrecht, Lauren V.; Bui, Maggie H.; De Robertis, Edward M.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.
   [Tejeda-Munoz, Nydia; Albrecht, Lauren V.; Bui, Maggie H.; De Robertis, Edward M.] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.
RP De Robertis, EM (corresponding author), Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.; De Robertis, EM (corresponding author), Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA.
EM ederobertis@mednet.ucla.edu
RI Munoz, Nydia Tejeda/ABF-3038-2020
OI Munoz, Nydia Tejeda/0000-0001-8314-412X; Albrecht,
   Lauren/0000-0002-3147-8010; De Robertis, Edward/0000-0002-7843-1869
FU University of California Institute for Mexico; University of California
   Institute for United States (UC MEXUS); Consejo Nacional de Ciencia y
   Tecnologia (CONACYT)Consejo Nacional de Ciencia y Tecnologia (CONACyT)
   [FE-17-65]; NIHUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [NIH F32 GM123622];
   UCLA Clinical and Translational Institute undergraduate fellowship [CTSI
   UL1TR000124]; Norman Sprague Endowment for Molecular Oncology; Howard
   Hughes Medical InstituteHoward Hughes Medical Institute; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of General Medical Sciences (NIGMS) [F32GM123622] Funding
   Source: NIH RePORTER
FX We thank Dr. M. Faux and the Ludwig Institute for SW480APC cells; Drs.
   S. Sokol, M. Bienz, R. Moon, and F. Costantini for plasmid constructs;
   Drs. K. Saito-Diaz and E. Lee for advice on APC siRNA; and Y. Moriyama,
   Y. Ding, S. Rundle, A. Dsouza, and G. Colozza for comments on the
   manuscript. N.T.-M. was supported by a joint University of California
   Institute for Mexico and the United States (UC MEXUS) and Consejo
   Nacional de Ciencia y Tecnologia (CONACYT) postdoctoral fellowship
   (FE-17-65); L.V.A. was supported by an NIH postdoctoral fellowship (NIH
   F32 GM123622); and M.H.B. was supported by a UCLA Clinical and
   Translational Institute undergraduate fellowship (CTSI UL1TR000124).
   This work was supported by the Norman Sprague Endowment for Molecular
   Oncology and the Howard Hughes Medical Institute, of which E.M.D.R. is
   an investigator.
CR Acebron SP, 2016, TRENDS CELL BIOL, V26, P956, DOI 10.1016/j.tcb.2016.07.009
   Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014
   Albrecht LV, 2019, P NATL ACAD SCI USA, V116, P2987, DOI 10.1073/pnas.1820161116
   Albrecht LV, 2018, P NATL ACAD SCI USA, V115, pE5317, DOI 10.1073/pnas.1804091115
   Albrecht LV, 2015, J CELL BIOL, V208, P597, DOI 10.1083/jcb.201406020
   Arena E. T., 2017, WILEY INTERDISCIP RE, V6, p[260, 2017]
   BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687
   Bedford MT, 2009, MOL CELL, V33, P1, DOI 10.1016/j.molcel.2008.12.013
   Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065
   Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227
   Blitzer JT, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-28
   Bloomfield G, 2016, J CELL SCI, V129, P2697, DOI 10.1242/jcs.176149
   Buckley CM, 2017, FEBS J, V284, P3778, DOI 10.1111/febs.14115
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Capelluto DGS, 2002, NATURE, V419, P726, DOI 10.1038/nature01056
   CHAPMANANDRESEN C, 1955, EXP CELL RES, P52
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Commisso C, 2014, NAT PROTOC, V9, P182, DOI 10.1038/nprot.2014.004
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Condon ND, 2018, J CELL BIOL, V217, P3873, DOI 10.1083/jcb.201804137
   Crosignani V, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.11.116023
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   Doherty GJ, 2009, ANNU REV BIOCHEM, V78, P857, DOI 10.1146/annurev.biochem.78.081307.110540
   Faux MC, 2004, J CELL SCI, V117, P427, DOI 10.1242/jcs.00862
   HAIGLER HT, 1979, J CELL BIOL, V83, P82, DOI 10.1083/jcb.83.1.82
   Itoh K, 1998, MECH DEVELOP, V74, P145, DOI 10.1016/S0925-4773(98)00076-8
   Katsuno Y, 2018, J BIOL CHEM, V293, P13059, DOI 10.1074/jbc.RA118.002027
   Kim H, 2015, CELL REP, V11, P1151, DOI 10.1016/j.celrep.2015.04.048
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914
   Koch S, 2015, CELL, V163, P1225, DOI 10.1016/j.cell.2015.10.029
   LEIBOVITZ A, 1976, CANCER RES, V36, P4562
   LEWIS WARREN H., 1937, AMER JOUR CANCER, V29, P666
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marques PE, 2017, CELL, V169, P766, DOI 10.1016/j.cell.2017.04.031
   Matsuda H, 2010, STEM CELLS, V28, P2073, DOI 10.1002/stem.529
   MCKANNA JA, 1979, P NATL ACAD SCI USA, V76, P5689, DOI 10.1073/pnas.76.11.5689
   Metcalfe C, 2010, J CELL SCI, V123, P1588, DOI 10.1242/jcs.067546
   Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165
   Nelson S, 2013, J CELL SCI, V126, P873, DOI 10.1242/jcs.100479
   Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Palm W, 2017, P NATL ACAD SCI USA, V114, pE8628, DOI 10.1073/pnas.1712726114
   Palm W, 2017, NATURE, V546, P234, DOI 10.1038/nature22379
   Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Recouvreux MV, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00261
   Redelman-Sidi G, 2018, CANCER RES, V78, P4658, DOI 10.1158/0008-5472.CAN-17-3199
   Reilein A, 2005, NAT CELL BIOL, V7, P463, DOI 10.1038/ncb1248
   Sahu R, 2011, DEV CELL, V20, P131, DOI 10.1016/j.devcel.2010.12.003
   Saito-Diaz K, 2018, DEV CELL, V44, P566, DOI 10.1016/j.devcel.2018.02.013
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Sokol SY, 1996, CURR BIOL, V6, P1456, DOI 10.1016/S0960-9822(96)00750-6
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Thompson CB, 2014, EMBO J, V33, P1420, DOI 10.15252/embj.201488785
   Vinyoles M, 2014, MOL CELL, V53, P444, DOI 10.1016/j.molcel.2013.12.010
   WEST MA, 1989, J CELL BIOL, V109, P2731, DOI 10.1083/jcb.109.6.2731
   Xu J, 2013, MOL CELL, V51, P5, DOI 10.1016/j.molcel.2013.05.004
   Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003
   Yang H, 2017, BIOORG MED CHEM LETT, V27, P4635, DOI 10.1016/j.bmcl.2017.09.016
   Yoshida S, 2018, CELL MOL LIFE SCI, V75, P1227, DOI 10.1007/s00018-017-2710-y
   Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4
   Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540
NR 66
TC 26
Z9 26
U1 2
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 21
PY 2019
VL 116
IS 21
BP 10402
EP 10411
DI 10.1073/pnas.1903506116
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HY8PY
UT WOS:000468403400039
PM 31061124
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Bigelsen, S
AF Bigelsen, Stephen
TI Evidence-based complementary treatment of pancreatic cancer: a review of
   adjunct therapies including paricalcitol, hydroxychloroquine,
   intravenous vitamin C, statins, metformin, curcumin, and aspirin
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Review
DE vitamin D; autophagy; stroma; T cells; integrative medicine;
   supplements; stellate cell
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; NF-KAPPA-B; PHASE-II TRIAL;
   ASCORBIC-ACID; PHARMACOLOGICAL ASCORBATE; COLORECTAL-CANCER;
   DOWN-REGULATION; BREAST-CANCER; DOUBLE-BLIND; THERAPEUTIC APPLICATIONS
AB Despite new and exciting research and renewed optimism about future therapy, current statistics of survival from pancreatic cancer remains dismal. Patients seeking alternative or complementary treatments should be warned to avoid the hype and instead look to real science. A variety of relatively safe and inexpensive treatment options that have shown success in preclinical models and/or retrospective studies are currently available. Patients require their physicians to provide therapeutic guidance and assistance in obtaining and administrating these various therapies. Paricalcitol, an analog of vitamin D, has been shown by researchers at the Salk Institute for Biological Studies to break though the protective stroma surrounding tumor cells. Hydroxychloroquine has been shown to inhibit autophagy, a process by which dying cells recycle injured organelles and internal toxins to generate needed energy for survival and reproduction. Intravenous vitamin C creates a toxic accumulation of hydrogen peroxide within cancer cells, hastening their death. Metformin inhibits mitochondrial oxidative metabolism utilized by cancer stem cells. Statins inhibit not only cholesterol but also other factors in the same pathway that affect cancer cell growth, protein synthesis, and cell cycle progression. A novel formulation of curcumin may prevent resistance to chemotherapy and inhibit pancreatic cancer cell proliferation. Aspirin therapy has been shown to prevent pancreatic cancer and may be useful to prevent recurrence. These therapies are all currently available and are reviewed in this paper with emphasis on the most recent laboratory research and clinical studies.
C1 [Bigelsen, Stephen] Rutgers New Jersey Med Sch, Dept Allergy Asthma & Immunol, Newark, NJ USA.
RP Bigelsen, S (corresponding author), Rutgers New Jersey Med Sch, Dept Allergy Asthma & Immunol, 57 Melrose Rd, Mt Lakes, NJ 07046 USA.
EM snrbig@optonline.net
OI Bigelsen, Stephen/0000-0003-2429-9177
CR Aguilera O, 2016, ONCOTARGET, V7, P47954, DOI 10.18632/oncotarget.10087
   Ai GQ, 2016, TUMOR BIOL, V37, P1727, DOI 10.1007/s13277-015-3959-0
   Ali S, 2010, CANCER RES, V70, P3606, DOI 10.1158/0008-5472.CAN-09-4598
   Ambe CM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151632
   Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Anderson KE, 2002, J NATL CANCER I, V94, P1168, DOI 10.1093/jnci/94.15.1168
   Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-12
   Apte MV, 2012, J GASTROEN HEPATOL, V27, P69, DOI 10.1111/j.1440-1746.2011.07000.x
   Archibugi L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13430-z
   Arlt A, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.35
   Arlt A, 2003, ONCOGENE, V22, P3243, DOI 10.1038/sj.onc.1206390
   Audo I, 2003, INVEST OPHTH VIS SCI, V44, P4192, DOI 10.1167/iovs.02-1198
   Bao B, 2012, CANCER PREV RES, V5, P355, DOI 10.1158/1940-6207.CAPR-11-0299
   Bathaie SZ, 2017, CURR MOL PHARMACOL, V10, P77, DOI 10.2174/1874467209666160112123205
   Bimonte Sabrina, 2017, Recenti Progressi in Medicina, V108, P282, DOI 10.1701/2715.27715
   Bimonte S, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070433
   Bimonte S, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/8352684
   Bimonte S, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0016-y
   Bimonte S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/810423
   Bonuccelli G, 2017, ONCOTARGET, V8, P20667, DOI 10.18632/oncotarget.15400
   Borazanci EH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.TPS511
   CAMERON E, 1978, P NATL ACAD SCI USA, V75, P4538, DOI 10.1073/pnas.75.9.4538
   CAMERON E, 1974, CHEM-BIOL INTERACT, V9, P285, DOI 10.1016/0009-2797(74)90019-2
   Chaiteerakij R, 2016, J CLIN ONCOL, V34, P1898, DOI 10.1200/JCO.2015.63.3511
   Chakraborti CK, 2011, INDIAN J PHARMACOL, V43, P113, DOI 10.4103/0253-7613.77335
   Chan AT, 2005, JAMA-J AM MED ASSOC, V294, P914, DOI 10.1001/jama.294.8.914
   Chan AT, 2017, JAMA-J AM MED ASSOC, V302, P649
   Cheema A, 2016, J CLIN ONCOL, V34
   Chen P, 2012, ANTI-CANCER DRUG, V23, P437, DOI 10.1097/CAD.0b013e32834fd01f
   Chen P, 2011, FREE RADICAL BIO MED, V51, P681, DOI 10.1016/j.freeradbiomed.2011.05.031
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Churilla TM, 2011, BMJ OPEN, V1, DOI 10.1136/bmjopen-2011-000397
   Churilla TM, 2012, NUTR CANCER, V64, P521, DOI 10.1080/01635581.2012.661515
   Cifarelli V, 2015, DIABETES, V64, P1632, DOI 10.2337/db14-1132
   Collet JP, 1999, BRIT J CANCER, V81, P62, DOI 10.1038/sj.bjc.6690651
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   CREAGAN ET, 1979, NEW ENGL J MED, V301, P687, DOI 10.1056/NEJM197909273011303
   Cullen JJ, 2010, AUTOPHAGY, V6, P421, DOI 10.4161/auto.6.3.11527
   Currie CJ, 2009, DIABETOLOGIA, V52, P1766, DOI 10.1007/s00125-009-1440-6
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Diaz Osterman CJ, 2015, J NAT SCI, V1, pe124
   Doskey CM, 2016, REDOX BIOL, V10, P274, DOI 10.1016/j.redox.2016.10.010
   Du J, 2016, FREE RADICAL BIO MED, V100, pS121, DOI 10.1016/j.freeradbiomed.2016.10.312
   Du JA, 2010, CLIN CANCER RES, V16, P509, DOI 10.1158/1078-0432.CCR-09-1713
   Duan WX, 2017, CANCER LETT, V385, P225, DOI 10.1016/j.canlet.2016.10.019
   E JY, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3288
   Elwood PC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152402
   Espey MG, 2011, FREE RADICAL BIO MED, V50, P1610, DOI 10.1016/j.freeradbiomed.2011.03.007
   Ferrucci LM, 2010, ASIAN PAC J CANCER P, V11, P1621
   Fromberg A, 2011, CANCER CHEMOTH PHARM, V67, P1157, DOI 10.1007/s00280-010-1418-6
   Fujioka S, 2012, ANTICANCER RES, V32, P4813
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Glienke W, 2010, CANCER INVEST, V28, P166, DOI 10.3109/07357900903287006
   Goldstein MR, 2008, CURR ONCOL, V15, P76
   Gonzalez-Perez A, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-28
   Graumlich JF, 1997, PHARMACEUT RES, V14, P1133, DOI 10.1023/A:1012186203165
   Gupta SC, 2013, MOL NUTR FOOD RES, V57, P1510, DOI 10.1002/mnfr.201100741
   Hardaway CM, 2012, MOL MED REP, V5, P1449, DOI 10.3892/mmr.2012.857
   Harris HR, 2014, EUR J CANCER, V50, P1223, DOI 10.1016/j.ejca.2014.02.013
   Harris RE, 2003, CANCER RES, V63, P6096
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hoffer LJ, 2008, ANN ONCOL, V19, P1969, DOI 10.1093/annonc/mdn377
   Holmes MD, 2010, J CLIN ONCOL, V28, P1467, DOI 10.1200/JCO.2009.22.7918
   Hong JY, 2014, CANCER CHEMOTH PHARM, V73, P125, DOI 10.1007/s00280-013-2328-1
   Hong TS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4118
   Huang BZ, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw275
   Incio J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141392
   Jacobs EJ, 2005, JNCI-J NATL CANCER I, V97, P975, DOI 10.1093/jnci/dji173
   Jeon CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121783
   Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240
   Kalkunte Satyan, 2005, Angiogenesis, V8, P349
   Kanai M, 2014, WORLD J GASTROENTERO, V20, P9384, DOI 10.3748/wjg.v20.i28.9384
   Kanai M, 2013, CANCER CHEMOTH PHARM, V71, P1521, DOI 10.1007/s00280-013-2151-8
   Kanai M, 2012, CANCER CHEMOTH PHARM, V69, P65, DOI 10.1007/s00280-011-1673-1
   Kanai M, 2011, CANCER CHEMOTH PHARM, V68, P157, DOI 10.1007/s00280-010-1470-2
   Kasum CM, 2003, CANCER EPIDEM BIOMAR, V12, P534
   Khurana V, 2007, PANCREAS, V34, P260, DOI 10.1097/MPA.0b013e318030e963
   Kisfalvi K, 2013, PANCREAS, V42, P781, DOI 10.1097/MPA.0b013e31827aec40
   Klingelhoeffer C, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-61
   Kordes S, 2015, LANCET ONCOL, V16, P839, DOI 10.1016/S1470-2045(15)00027-3
   Kunnumakkara AB, 2008, CLIN CANCER RES, V14, P2128, DOI 10.1158/1078-0432.CCR-07-4722
   Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Lee HS, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003607
   Leung LSB, 2015, AM J OPHTHALMOL, V160, P799, DOI 10.1016/j.ajo.2015.07.012
   Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704
   Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013
   Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605
   Li Y, 2011, CANCER CHEMOTH PHARM, V68, P603, DOI 10.1007/s00280-010-1515-6
   Li YW, 2015, PANCREAS, V44, P1, DOI 10.1097/MPA.0000000000000257
   Liao J, 2013, MOL CARCINOGEN, V52, P739, DOI 10.1002/mc.21916
   Lin ZY, 2010, BIOMED PHARMACOTHER, V64, P348, DOI 10.1016/j.biopha.2009.06.005
   Mahipal A, 2006, CANCER EPIDEM BIOMAR, V15, P1785, DOI 10.1158/1055-9965.EPI-05-0674
   Marmor MF, 2016, OPHTHALMOLOGY, V123, P1386, DOI 10.1016/j.ophtha.2016.01.058
   Marshall SF, 2005, JNCI-J NATL CANCER I, V97, P805, DOI 10.1093/jnci/dji140
   Matsubara S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03230
   Miller-Ocuin JL, 2017, ANN SURG ONCOL, V24, pS6
   Mitrugno A, 2017, AM J PHYSIOL-CELL PH, V312, pC176, DOI 10.1152/ajpcell.00196.2016
   MOERTEL CG, 1985, NEW ENGL J MED, V312, P137, DOI 10.1056/NEJM198501173120301
   Mohammed A, 2013, TRANSL ONCOL, V6, P649, DOI 10.1593/tlo.13556
   Monti DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029794
   Moon DC, 2016, YONSEI MED J, V57, P1124, DOI 10.3349/ymj.2016.57.5.1124
   Nechuta S, 2011, CANCER EPIDEM BIOMAR, V20, P262, DOI 10.1158/1055-9965.EPI-10-1072
   Nielsen SF, 2012, NEW ENGL J MED, V367, P1792, DOI 10.1056/NEJMoa1201735
   ODwyer PJ, 2015, AM SOC CLIN ONC ANN
   Osterman CJD, 2016, PANCREAS, V45, P101, DOI 10.1097/MPA.0000000000000411
   Padayatty SJ, 2004, ANN INTERN MED, V140, P533, DOI 10.7326/0003-4819-140-7-200404060-00010
   Park W, 2013, CANCER PREV RES, V6, P387, DOI 10.1158/1940-6207.CAPR-12-0410
   Pathi SS, 2011, NUTR CANCER, V63, P1133, DOI 10.1080/01635581.2011.605984
   Peng Lin-ji, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P264
   Perera RM, 2015, CANCER DISCOV, V5, P1247, DOI 10.1158/2159-8290.CD-15-0671
   Perkins S, 2002, CANCER EPIDEM BIOMAR, V11, P535
   Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2
   Prizment AE, 2010, CANCER EPIDEM BIOMAR, V19, P435, DOI 10.1158/1055-9965.EPI-09-0976
   Reni M, 2016, CLIN CANCER RES, V22, P1076, DOI 10.1158/1078-0432.CCR-15-1722
   Risch HA, 2017, CANCER EPIDEM BIOMAR, V26, P68, DOI 10.1158/1055-9965.EPI-16-0508
   Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Sadeghi N, 2012, CLIN CANCER RES, V18, P2905, DOI 10.1158/1078-0432.CCR-11-2994
   Sahu RP, 2009, BRIT J CANCER, V100, P1425, DOI 10.1038/sj.bjc.6605039
   Salinas CA, 2010, AM J EPIDEMIOL, V172, P578, DOI 10.1093/aje/kwq175
   Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015
   Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633
   Sasaki H, 2011, BIOL PHARM BULL, V34, P660, DOI 10.1248/bpb.34.660
   Schneider MB, 2001, GASTROENTEROLOGY, V120, P1263, DOI 10.1053/gast.2001.23258
   Schwartz GG, 2008, CANCER BIOL THER, V7, P430, DOI 10.4161/cbt.7.3.5418
   Schwartz GG, 2005, CLIN CANCER RES, V11, P8680, DOI 10.1158/1078-0432.CCR-05-1237
   Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007
   Singletary K, 1996, CANCER LETT, V103, P137, DOI 10.1016/0304-3835(96)04224-3
   Skinner HG, 2006, CANCER EPIDEM BIOMAR, V15, P1688, DOI 10.1158/1055-9965.EPI-06-0206
   Sprague SM, 2003, KIDNEY INT, V63, P1483, DOI 10.1046/j.1523-1755.2003.00878.x
   Streicher SA, 2014, CANCER EPIDEM BIOMAR, V23, P1254, DOI 10.1158/1055-9965.EPI-13-1284
   Sun XD, 2013, ONCOL REP, V29, P2401, DOI 10.3892/or.2013.2385
   Sunagawa Y, 2015, J NUTR SCI VITAMINOL, V61, P37, DOI 10.3177/jnsv.61.37
   Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X
   Takemura Y, 2010, BIOCHEM BIOPH RES CO, V394, P249, DOI 10.1016/j.bbrc.2010.02.012
   Tan XL, 2007, PHARMACOGENET GENOM, V17, P639, DOI 10.1097/FPC.0b013e3280d5121c
   Tan XL, 2011, CANCER PREV RES, V4, P1835, DOI 10.1158/1940-6207.CAPR-11-0146
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Ushida J, 2000, JPN J CANCER RES, V91, P893, DOI 10.1111/j.1349-7006.2000.tb01031.x
   Uwagawa T, 2015, SURG TODAY, V45, P1481, DOI 10.1007/s00595-015-1129-z
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
   Verrax J, 2009, FREE RADICAL BIO MED, V47, P32, DOI 10.1016/j.freeradbiomed.2009.02.016
   Villarino N, 2017, ONCOTARGET, V8, P53154, DOI 10.18632/oncotarget.18587
   Viswanathan AN, 2008, CANCER RES, V68, P2507, DOI 10.1158/0008-5472.CAN-07-6257
   Welsh JL, 2013, CANCER CHEMOTH PHARM, V71, P765, DOI 10.1007/s00280-013-2070-8
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wolpin BM, 2012, CANCER EPIDEM BIOMAR, V21, P82, DOI 10.1158/1055-9965.EPI-11-0836
   Wu BU, 2015, AM J GASTROENTEROL, V110, P1233, DOI 10.1038/ajg.2015.217
   Yang L, 2011, J BIOMED RES, V25, P246, DOI 10.1016/S1674-8301(11)60033-X
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yoshida K, 2017, CARCINOGENESIS, V38, P1036, DOI 10.1093/carcin/bgx065
   Youns M, 2013, J CELL BIOCHEM, V114, P2654, DOI 10.1002/jcb.24612
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
NR 158
TC 19
Z9 19
U1 2
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2018
VL 10
BP 2003
EP 2018
DI 10.2147/CMAR.S161824
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GM9JT
UT WOS:000438564400003
PM 30034255
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Sutradhar, M
   Alegria, ECBA
   Ferretti, F
   Raposo, LR
   da Silva, MFCG
   Baptista, PV
   Fernandes, AR
   Pombeiro, AJL
AF Sutradhar, Manas
   Alegria, Elisabete C. B. A.
   Ferretti, Francesco
   Raposo, Luis R.
   Guedes da Silva, M. Fatima C.
   Baptista, Pedro, V
   Fernandes, Alexandra R.
   Pombeiro, Armando J. L.
TI Antiproliferative activity of heterometallic sodium and
   potassium-dioxidovanadium(V) polymers
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Dioxidovanadium(V); Aroylhydrazone; X-ray structure; Antiproliferative
   agent
ID X-RAY-STRUCTURE; COPPER(II) COMPLEXES; IN-VIVO; COORDINATION CHEMISTRY;
   CATALYST PRECURSORS; VANADIUM COMPOUNDS; CRYSTAL-STRUCTURE; CU(II)
   COMPLEXES; DNA-BINDING; CANCER
AB The syntheses of the heterometallic sodium and potassium-dioxidovanadium 2D polymers, [NaVO2(1 kappa NOO';2 kappa O ''-L)(H2O)](n), (1) and [KVO2(1 kappa NOO';2 kappa O';3 kappa O ''-L)(EtOH)](n) (2) (where the kappa notation indicates the coordinating atoms of the polydentate ligand L) derived from (3,5-di-tert-butyl-2-hydroxybenzylidene)-2-hydroxybenzohydrazide (H2L) are reported. The polymers were characterized by IR, NMR, elemental analysis and single crystal X-ray diffraction analysis. The antiproliferative potential of 1 and 2 was examined towards four human cancer cell lines (ovarian carcinoma, A2780, colorectal carcinoma, HCT116, prostate carcinoma, PC3 and breast adenocarcinoma, MCF-7cell lines) and normal human fibroblasts. Complex 1 and 2 showed the highest cytotoxic activity against A2780 cell line (IC50 8.2 and 11.3 mu M, respectively) with 1 > 2 and an IC50 in the same range as cisplatin (IC50 3.4 mu M; obtained in the same experimental conditions) but, interestingly, with no cytotoxicity to healthy human fibroblasts for concentrations up to 75 mu M. This high cytotoxicity of 1 in ovarian cancer cells and its low cytotoxicity in healthy cells demonstrates its potential for further biological studies. Our results suggest that both complexes induce ovarian carcinoma cell death via apoptosis and autophagy, but autophagy is the main biological cause of the reduction of viability observed and that ROS (reactive oxygen species) may play an important role in triggering cell death.
C1 [Sutradhar, Manas; Alegria, Elisabete C. B. A.; Ferretti, Francesco; Guedes da Silva, M. Fatima C.; Fernandes, Alexandra R.; Pombeiro, Armando J. L.] Univ Lisbon, Ctr Quim Estrutural, Inst Super Tecn, Av Rovisco Pais, P-1049001 Lisbon, Portugal.
   [Alegria, Elisabete C. B. A.] Inst Politecn Lisboa, Inst Super Engn Lisboa, Chem Engn Dept, R Conselheiro Emidio Navarro 1, P-1959007 Lisbon, Portugal.
   [Raposo, Luis R.; Baptista, Pedro, V; Fernandes, Alexandra R.] Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Ciencias Vida, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.
RP Sutradhar, M; Fernandes, AR (corresponding author), Univ Lisbon, Ctr Quim Estrutural, Inst Super Tecn, Av Rovisco Pais, P-1049001 Lisbon, Portugal.; Fernandes, AR (corresponding author), Univ Nova Lisboa, Fac Ciencias & Tecnol, Dept Ciencias Vida, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.
EM manas@tecnico.ulisboa.pt; ma.fernandes@fct.unl.pt
RI da Silva, M. Fátima C Guedes/H-8274-2012; Pombeiro, Armando
   JL/I-5945-2012; Raposo, Luís/AAX-1610-2021; Alegria,
   Elisabete/E-9945-2012; Fernandes, Alexandra R/C-7465-2011; Raposo, Luís
   R/T-3754-2017; da Silva, Maria de Fatima Guedes/P-3458-2019; Sutradhar,
   Manas/M-4089-2013; Baptista, Pedro/A-1237-2009
OI da Silva, M. Fátima C Guedes/0000-0003-4836-2409; Pombeiro, Armando
   JL/0000-0001-8323-888X; Raposo, Luís/0000-0002-8637-346X; Alegria,
   Elisabete/0000-0003-4060-1057; Fernandes, Alexandra
   R/0000-0003-2054-4438; Raposo, Luís R/0000-0002-8637-346X; da Silva,
   Maria de Fatima Guedes/0000-0003-4836-2409; Sutradhar,
   Manas/0000-0003-3349-9154; Baptista, Pedro/0000-0001-5255-7095
FU Fundacao para a Ciencia e a Tecnologia (FCT), PortugalPortuguese
   Foundation for Science and Technology [PTDC/QEQ-ERQ/1648/2014,
   UID/QUI/00100/2019]; FCTPortuguese Foundation for Science and
   TechnologyEuropean Commission [DL/57/2017, IST-ID/102/2018]; IST
   [DL/57/2017, IST-ID/102/2018]; Applied Molecular Biosciences Unit -
   UCIBIO - national funds from FCT/MCTES [UID/Multi/04378/2019]
FX The authors gratefully acknowledge the Fundacao para a Ciencia e a
   Tecnologia (FCT), Portugal, and its projects PTDC/QEQ-ERQ/1648/2014 and
   UID/QUI/00100/2019. M.S. acknowledges the FCT and IST for a working
   contract "DL/57/2017" (Contract no. IST-ID/102/2018). This work was also
   supported by the Applied Molecular Biosciences Unit - UCIBIO which is
   financed by national funds from FCT/MCTES (UID/Multi/04378/2019).
   Authors are thankful to the Portuguese NMR Network (IST-UL Centre) for
   access to the NMR facility and the IST Node of the Portuguese Network of
   mass -spectrometry for the ESI-MS measurements.
CR ADDISON AW, 1984, J CHEM SOC DALTON, P1349, DOI 10.1039/dt9840001349
   Bishayee A, 2010, CANCER LETT, V294, P1, DOI 10.1016/j.canlet.2010.01.030
   Bruker, 2012, APEX2
   Chi ZX, 2012, Z ANORG ALLG CHEM, V638, P1523, DOI 10.1002/zaac.201200097
   Chimmalagi GH, 2018, APPL ORGANOMET CHEM, V32, DOI 10.1002/aoc.4337
   Correia I, 2015, J INORG BIOCHEM, V147, P134, DOI 10.1016/j.jinorgbio.2015.02.021
   Correia I, 2014, J INORG BIOCHEM, V141, P83, DOI 10.1016/j.jinorgbio.2014.07.019
   Crans DC, 2013, INORG CHEM, V52, P12262, DOI 10.1021/ic4007873
   Czerwinska K, 2017, DALTON T, V46, P9591, DOI 10.1039/c7dt01244f
   Das K, 2019, J COORD CHEM, V72, P920, DOI 10.1080/00958972.2019.1597973
   Domingues N, 2014, J INORG BIOCHEM, V131, P115, DOI 10.1016/j.jinorgbio.2013.11.005
   Dong YH, 2000, J INORG BIOCHEM, V78, P321, DOI 10.1016/S0162-0134(00)00060-X
   Etcheverry SB, 2008, J BIOL INORG CHEM, V13, P435, DOI 10.1007/s00775-007-0332-9
   Evangelou AM, 2002, CRIT REV ONCOL HEMAT, V42, P249, DOI 10.1016/S1040-8428(01)00221-9
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Fernandes AR, 2017, J CONTROL RELEASE, V245, P52, DOI 10.1016/j.jconrel.2016.11.021
   Hosseini MJ, 2013, METALLOMICS, V5, P152, DOI 10.1039/c2mt20198d
   Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373
   Kioseoglou E, 2015, COORDIN CHEM REV, V301, P87, DOI 10.1016/j.ccr.2015.03.010
   Kowalski S, 2017, ONCOTARGET, V8, P60324, DOI 10.18632/oncotarget.19454
   KUSTIN K, 2007, ACS SYM SER, V974
   Lee SY, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/3537471
   Lenis-Rojas OA, 2018, INORG CHEM, V57, P13150, DOI 10.1021/acs.inorgchem.8b01270
   Li YQ, 2017, RSC ADV, V7, P41527, DOI 10.1039/c7ra05504h
   Luis DV, 2014, J BIOL INORG CHEM, V19, P787, DOI 10.1007/s00775-014-1110-0
   Maron A, 2018, DALTON T, V47, P6444, DOI 10.1039/c8dt00558c
   Mendes R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11491-8
   Messerschmidt A, 1996, P NATL ACAD SCI USA, V93, P392, DOI 10.1073/pnas.93.1.392
   Noblia P, 2004, EUR J INORG CHEM, P322, DOI 10.1022/ejic.200300421
   NOVOTNY L, 2014, J CANC RES UPDATES, P00097, DOI DOI 10.6000/1929-2279.2014.03.02.3
   Pessoa JC, 2015, COORDIN CHEM REV, V301, P24, DOI 10.1016/j.ccr.2014.12.002
   Ray RS, 2007, INT J CANCER, V120, P13, DOI 10.1002/ijc.22277
   Rehder D., 2008, BIOINORGANIC VANADIU
   Rehder D, 2013, DALTON T, V42, P11749, DOI 10.1039/c3dt50457c
   Rehder D, 2012, FUTURE MED CHEM, V4, P1823, DOI [10.4155/FMC.12.103, 10.4155/fmc.12.103]
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Silva TFS, 2014, CHEM-ASIAN J, V9, P1132, DOI 10.1002/asia.201301331
   Silva TFS, 2013, EUR J INORG CHEM, V2013, P3651, DOI 10.1002/ejic.201300197
   Soriano-Agueda LA, 2016, COMPUT THEOR CHEM, V1077, P99, DOI 10.1016/j.comptc.2015.11.002
   Sutradhar M, 2007, INORG CHEM, V46, P5069, DOI 10.1021/ic062242r
   Sutradhar M, 2006, INORG CHEM, V45, P5150, DOI 10.1021/ic051120g
   Sutradhar M, 2017, J INORG BIOCHEM, V175, P267, DOI 10.1016/j.jinorgbio.2017.07.034
   Sutradhar M, 2016, CHEMCATCHEM, V8, P2254, DOI 10.1002/cctc.201600316
   Sutradhar M, 2016, J INORG BIOCHEM, V155, P17, DOI 10.1016/j.jinorgbio.2015.11.010
   Sutradhar M, 2015, COORDIN CHEM REV, V301, P200, DOI 10.1016/j.ccr.2015.01.020
   Sutradhar M, 2015, EUR J INORG CHEM, P3959, DOI 10.1002/ejic.201500440
   Sutradhar M, 2015, APPL CATAL A-GEN, V493, P50, DOI 10.1016/j.apcata.2015.01.005
   Sutradhar M, 2014, COORDIN CHEM REV, V265, P89, DOI 10.1016/j.ccr.2014.01.007
   Sutradhar M, 2013, DALTON T, V42, P11791, DOI 10.1039/c3dt50584g
   Sutradhar M, 2012, INORG CHEM, V51, P11229, DOI 10.1021/ic3017062
   Sutradhar M, 2012, J MOL STRUCT, V1020, P148, DOI 10.1016/j.molstruc.2012.04.007
   Sutradhar M, 2011, INORG CHIM ACTA, V368, P13, DOI 10.1016/j.ica.2010.12.018
   Thompson KH, 2001, COORDIN CHEM REV, V219, P1033, DOI 10.1016/S0010-8545(01)00395-2
   Tracey A.S., 1998, ACS SYM SER, V711, P2, DOI [DOI 10.1021/BK-1998-0711.CH001, 10.1021/bk-1998-0711.ch001]
   Willsky GR, 2011, COORDIN CHEM REV, V255, P2258, DOI 10.1016/j.ccr.2011.06.015
   Zhao YB, 2010, J INORG BIOCHEM, V104, P371, DOI 10.1016/j.jinorgbio.2009.11.007
NR 56
TC 10
Z9 10
U1 1
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD NOV
PY 2019
VL 200
AR 110811
DI 10.1016/j.jinorgbio.2019.110811
PG 7
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JA8YB
UT WOS:000488136100006
PM 31493756
DA 2022-04-25
ER

PT J
AU Aftab, O
   Fryknas, M
   Zhang, XN
   De Milito, A
   Hammerling, U
   Linder, S
   Larsson, R
   Gustafsson, MG
AF Aftab, Obaid
   Fryknas, Marten
   Zhang, Xiaonan
   De Milito, Angelo
   Hammerling, Ulf
   Linder, Stig
   Larsson, Rolf
   Gustafsson, Mats G.
TI Label-free detection and dynamic monitoring of drug-induced
   intracellular vesicle formation enabled using a 2-dimensional matched
   filter
SO AUTOPHAGY
LA English
DT Article
DE phase-contrast microscopy; automated microscopy; vesicle detection;
   autophagy; image processing
ID LINEAGE CONSTRUCTION; CHEMICAL MODULATORS; AUTOPHAGY; ASSAY; INHIBITORS;
   PATHWAY; CELLS; LC3
AB Analysis of vesicle formation and degradation is a central issue in autophagy research and microscopy imaging is revolutionizing the study of such dynamic events inside living cells. A limiting factor is the need for labeling techniques that are labor intensive, expensive, and not always completely reliable. To enable label-free analyses we introduced a generic computational algorithm, the label-free vesicle detector (LFVD), which relies on a matched filter designed to identify circular vesicles within cells using only phase-contrast microscopy images. First, the usefulness of the LFVD is illustrated by presenting successful detections of autophagy modulating drugs found by analyzing the human colorectal carcinoma cell line HCT116 exposed to each substance among 1266 pharmacologically active compounds. Some top hits were characterized with respect to their activity as autophagy modulators using independent in vitro labeling of acidic organelles, detection of LC3-II protein, and analysis of the autophagic flux. Selected detection results for 2 additional cell lines (DLD1 and RKO) demonstrate the generality of the method. In a second experiment, label-free monitoring of dose-dependent vesicle formation kinetics is demonstrated by recorded detection of vesicles over time at different drug concentrations. In conclusion, label-free detection and dynamic monitoring of vesicle formation during autophagy is enabled using the LFVD approach introduced.
C1 [Aftab, Obaid; Fryknas, Marten; Hammerling, Ulf; Larsson, Rolf; Gustafsson, Mats G.] Uppsala Univ, Dept Med Sci, Univ Hosp, Uppsala, Sweden.
   [Zhang, Xiaonan; De Milito, Angelo; Linder, Stig] Karolinska Inst, Dept Oncol Pathol, Canc Ctr Karolinska, Stockholm, Sweden.
RP Gustafsson, MG (corresponding author), Uppsala Univ, Dept Med Sci, Univ Hosp, Uppsala, Sweden.
EM Mats.Gustafsson@medsci.uu.se
OI De Milito, Angelo/0000-0003-2591-2914
FU Higher Education Commission of PakistanHigher Education Commission of
   Pakistan; SSF framework project "Tools for diagnosis and drug discovery
   in cancer"; Association for International Cancer Research; Worldwide
   Cancer Research [11-0522] Funding Source: researchfish
FX This work was supported by the Higher Education Commission of Pakistan
   (OA), by the SSF framework project "Tools for diagnosis and drug
   discovery in cancer" (MF). ADM is supported by a grant from the
   Association for International Cancer Research. We thank the anonymous
   reviewers for their valuable suggestions for improvements to the paper.
CR Al-Kofahi O, 2006, CELL CYCLE, V5, P327, DOI 10.4161/cc.5.3.2426
   Asraf DE, 2003, J ACOUST SOC AM, V113, P2732, DOI 10.1121/1.1566976
   Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124
   Bao ZR, 2006, P NATL ACAD SCI USA, V103, P2707, DOI 10.1073/pnas.0511111103
   Eng KE, 2010, AUTOPHAGY, V6, P634, DOI 10.4161/auto.6.5.12112
   Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500
   Fraz MM, 2012, COMPUT METH PROG BIO, V108, P407, DOI 10.1016/j.cmpb.2012.03.009
   GARTH LM, 1994, P IEEE, V82, P1061, DOI 10.1109/5.293163
   Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1
   Gustafsson MG, 1998, DETECTION SPATIO TEM, P227
   Huang J, 2012, AUTOPHAGY, V8, P275, DOI 10.4161/auto.8.2.18940
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   LARSSON R, 1992, INT J CANCER, V50, P177, DOI 10.1002/ijc.2910500204
   Li K, 2008, MED IMAGE ANAL, V12, P546, DOI 10.1016/j.media.2008.06.001
   Li Q, 2012, EXPERT SYST APPL, V39, P7600, DOI 10.1016/j.eswa.2011.12.046
   Lindhagen E, 2008, NAT PROTOC, V3, P1364, DOI 10.1038/nprot.2008.114
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Murphy D., 2001, PHASE CONTRAST MICRO, P97
   Muzzey D, 2009, ANNU REV CELL DEV BI, V25, P301, DOI 10.1146/annurev.cellbio.042308.113408
   O'Toole JM, 2010, IET SIGNAL PROCESS, V4, P428, DOI 10.1049/iet-spr.2009.0104
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Park SJ, 2012, FEBS LETT, V586, P4303, DOI 10.1016/j.febslet.2012.10.035
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shen HM, 2012, EXP CELL RES, V318, P1304, DOI 10.1016/j.yexcr.2012.02.006
   Shu CW, 2011, J BIOMOL SCREEN, V16, P174, DOI 10.1177/1087057110392996
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Xia XC, 2010, J BONE MINER RES, V25, P2479, DOI 10.1002/jbmr.160
   Zhang LH, 2007, P NATL ACAD SCI USA, V104, P19023, DOI 10.1073/pnas.0709695104
NR 32
TC 6
Z9 6
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD JAN 1
PY 2014
VL 10
IS 1
BP 57
EP 69
DI 10.4161/auto.26678
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 277IO
UT WOS:000328812400006
PM 24169509
OA Green Published, Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Han, ST
   Zhu, LY
   Zhu, YR
   Meng, Y
   Li, JQ
   Song, P
   Yousafzai, NA
   Feng, LF
   Chen, MQ
   Wang, YM
   Jin, HCA
   Wang, X
AF Han, Shuting
   Zhu, Liyuan
   Zhu, Yiran
   Meng, Yuan
   Li, Jiaqiu
   Song, Ping
   Yousafzai, Neelum Aziz
   Feng, Lifeng
   Chen, Miaoqin
   Wang, Yanmei
   Jin, Hongchuan
   Wang, Xian
TI Targeting ATF4-dependent pro-survival autophagy to synergize
   glutaminolysis inhibition
SO THERANOSTICS
LA English
DT Article
DE Glutaminolysis inhibition; ATF4; DDIT4; N-6-methyladenosine; metabolic
   synthetic lethality
ID AMINO-ACID; METABOLISM; GLUTAMINASE; STRESS; CANCER; ASPARAGINE;
   PATHWAY; GROWTH; MTOR; PROLIFERATION
AB As glutamine plays a central role in cancer metabolism, inhibition of glutaminolysis has become an ideal anticancer therapeutic target. However, glutaminolysis inhibition leads to activation of autophagy, which compromises its antitumor effect. Hence, we investigated the mechanism underlying glutaminolysis inhibition-induced pro-survival autophagy.
   Methods: High-throughput sequencing was performed on colorectal cancer (CRC) cells before and after glutaminolysis inhibition to identify differentially expressed genes. Activating transcription factor 4 (ATF4) pathway enrichment in glutaminolysis inhibited cells was identified through gene set enrichment analysis. ATF4 expression was assessed by quantitative real-time PCR (qRT-PCR) and western blotting. The function of ATF4 on mechanistic target of rapamycin (mTOR) regulation was assessed by western blotting. Luciferase reporter assays and chromatin immunoprecipitation were used to confirm the regulation of DNA damage inducible transcript 4 (DDIT4) by ATF4. mRNA half-life assays, RNA immunoprecipitation, qRT-PCR and western blotting were performed to determine the relationship between FTO alpha-ketoglutarate dependent dioxygenase (FTO), YTH N-6-methyladenosine RNA binding protein 2 (YTHDF2), and ATF4. ATF4 regulation of pro-survival autophagy was measured by tandem monomeric red fluorescent protein-green fluorescent protein fluorescence microscopy. Finally, the synergistic effect of autophagy and glutaminolysis inhibition was analyzed in an azoxymethane/dextran sodium sulfate mouse model.
   Results: The ATF4 pathway was activated in CRC cells upon glutaminolysis inhibition. Functionally, ATF4 transcriptionally upregulated DDIT4 to suppress mTOR, which induced pro-survival autophagy during glutaminolysis inhibition. Interestingly, glutaminolysis inhibition promoted ATF4 mRNA expression by abrogating N-6-methyladenosine (m(6)A) modification and YTHDF2-mediated RNA decay. Finally, inhibition of ATF4-induced autophagy enhanced the antitumor efficacy of glutaminolysis inhibition.
   Conclusion: Glutaminolysis inhibition upregulated ATF4 expression in an m(6)A-dependent manner to activate pro-survival autophagy through transcriptional activation of the mTOR inhibitor DDIT4. Targeting ATF4-induced autophagy is a new strategy to synergize glutaminolysis-targeting therapies for cancer treatment.
C1 [Han, Shuting; Li, Jiaqiu; Song, Ping; Wang, Yanmei; Wang, Xian] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Med Sch, Hangzhou, Peoples R China.
   [Zhu, Liyuan; Zhu, Yiran; Meng, Yuan; Feng, Lifeng; Chen, Miaoqin; Jin, Hongchuan] Zhejiang Univ, Med Sch, Sir Run Run Shaw Hosp, Lab Canc Biol,Canc Ctr,Key Lab Biotherapy, Hangzhou, Peoples R China.
   [Yousafzai, Neelum Aziz] Univ Poonch Rawalakot, Dept Allied Hlth Sci, Rawalakot, Ajk, Pakistan.
RP Jin, HCA (corresponding author), Zhejiang Univ, Lab Canc Biol, Canc Ctr, Hangzhou 310016, Peoples R China.; Wang, X (corresponding author), Sir Run Run Shaw Hosp, Dept Med Oncol, Hangzhou 310016, Peoples R China.
EM jinhc@zju.edu.cn; wangx118@zju.edu.cn
FU national natural science foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC: 32070650, 82073035, 81772944]; Natural
   science foundation of ZhejiangNatural Science Foundation of Zhejiang
   Province [ZJNSF: LZ18H160001]
FX This work was supported by grants from national natural science
   foundation of China (NSFC: 32070650; 82073035 and 81772944 to WX and JH)
   and Natural science foundation of Zhejiang (ZJNSF: LZ18H160001 to FL) .
   We thank members of our laboratories for their suggestions.
CR Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859
   B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Bar-Peled L, 2014, TRENDS CELL BIOL, V24, P400, DOI 10.1016/j.tcb.2014.03.003
   BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bravard A, 2011, DIABETES, V60, P258, DOI 10.2337/db10-0281
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804
   Chan DLH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007047.pub2
   Chen R, 2014, J CELL BIOL, V206, P173, DOI 10.1083/jcb.201403009
   Dai DJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0129-x
   Das CK, 2020, SEMIN CANCER BIOL, V66, P59, DOI 10.1016/j.semcancer.2019.08.020
   Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626
   EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Feng LF, 2017, THERANOSTICS, V7, P1890, DOI 10.7150/thno.19135
   Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001
   Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870
   Guan BJ, 2014, J BIOL CHEM, V289, P12593, DOI 10.1074/jbc.M113.543215
   Guo JY, 2013, AUTOPHAGY, V9, P1636, DOI 10.4161/auto.26123
   Gwinn DM, 2018, CANCER CELL, V33, P91, DOI 10.1016/j.ccell.2017.12.003
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Huang Y, 2015, NUCLEIC ACIDS RES, V43, P373, DOI 10.1093/nar/gku1276
   Jacque N, 2015, BLOOD, V126, P1346, DOI 10.1182/blood-2015-01-621870
   Jewell JL, 2015, SCIENCE, V347, P194, DOI 10.1126/science.1259472
   Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522
   Li JQ, 2018, MOL THER, V26, P1828, DOI 10.1016/j.ymthe.2018.04.014
   Li JQ, 2017, ONCOTARGET, V8, P42664, DOI 10.18632/oncotarget.16844
   Martinelli E, 2013, EXPERT OPIN EMERG DR, V18, P25, DOI 10.1517/14728214.2013.749856
   Niu Y, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1004-4
   Oki S, 2018, EMBO REP, V19, DOI 10.15252/embr.201846255
   Pavlova NN, 2018, CELL METAB, V27, P428, DOI 10.1016/j.cmet.2017.12.006
   Ries RJ, 2019, NATURE, V571, P424, DOI 10.1038/s41586-019-1374-1
   ROBERTS E, 1956, CANCER RES, V16, P970
   Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Seo JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep37594
   Song P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01244-z
   Stalnecker CA, 2015, P NATL ACAD SCI USA, V112, P394, DOI 10.1073/pnas.1414056112
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Villar VH, 2015, AUTOPHAGY, V11, P1198, DOI 10.1080/15548627.2015.1053680
   Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009
   Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730
   WINDMUELLER HG, 1974, J BIOL CHEM, V249, P5070
   Xu DD, 2020, J NUTR, V150, P1022, DOI 10.1093/jn/nxz309
   Yang LF, 2017, ANNU REV BIOMED ENG, V19, P163, DOI 10.1146/annurev-bioeng-071516-044546
   Yang LX, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0059-4
   Yang S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10669-0
   Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81
   Yuan LQ, 2016, AM J TRANSL RES, V8, P4265
   Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015
   Zhang J, 2017, EMBO J, V36, P1302, DOI 10.15252/embj.201696151
   Zhao S, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1504-6
   Zhou J, 2018, MOL CELL, V69, P636, DOI 10.1016/j.molcel.2018.01.019
   Zhou Y, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw104
   Zhu LY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1585-2
NR 59
TC 2
Z9 2
U1 6
U2 8
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2021
VL 11
IS 17
BP 8464
EP 8479
DI 10.7150/thno.60028
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA TR0IP
UT WOS:000678657400005
PM 34373753
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wu, JY
   Qin, J
   Li, L
   Zhang, KD
   Chen, YS
   Li, Y
   Jin, T
   Xu, JM
AF Wu, Jun-yi
   Qin, Jun
   Li, Lei
   Zhang, Kun-dong
   Chen, Yi-sheng
   Li, Yang
   Jin, Tao
   Xu, Jun-ming
TI Roles of the Immune/Methylation/Autophagy Landscape on Single-Cell
   Genotypes and Stroke Risk in Breast Cancer Microenvironment
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID LONG-TERM SURVIVAL; CONDITIONAL SURVIVAL; MULTIINSTITUTIONAL ANALYSIS;
   TUMOR MICROENVIRONMENT; COLORECTAL-CANCER; GENE-EXPRESSION; IMMUNE
   CELLS; RESECTION; PROGNOSIS; MORTALITY
AB This study sought to perform integrative analysis of the immune/methylation/autophagy landscape on breast cancer prognosis and single-cell genotypes. Breast Cancer Recurrence Risk Score (BCRRS) and Breast Cancer Prognostic Risk Score (BCPRS) were determined based on 6 prognostic IMAAGs obtained from the TCGA-BRCA cohort. BCRRS and BCPRS, respectively, were used to construct a risk prediction model of overall survival and progression-free survival. Predictive capacity of the model was evaluated using clinical data. Analysis showed that BCRRS is associated with a high risk of stroke. In addition, PPI and drug-ceRNA networks based on differences in BCPRS were constructed. Single cells were genotyped through integrated scRNA-seq of the TNBC samples based on clustering results of BCPRS-related genes. The findings of this study show the potential regulatory effects of IMAAGs on breast cancer tumor microenvironment. High AUCs of 0.856 and 0.842 were obtained for the OS and PFS prognostic models, respectively. scRNA-seq analysis showed high expression levels of adipocytes and adipose tissue macrophages (ATMs) in high BCPRS clusters. Moreover, analysis of ligand-receptor interactions and potential regulatory mechanisms were performed. The LINC00276&MALAT1/miR-206/FZD4-Wnt7b pathway was also identified which may be useful in future research on targets against breast cancer metastasis and recurrence. Neural network-based deep learning models using BCPRS-related genes showed that these genes can be used to map the tumor microenvironment. In summary, analysis of IMAAGs, BCPRS, and BCRRS provides information on the breast cancer microenvironment at both the macro- and microlevels and provides a basis for development of personalized treatment therapy.
C1 [Wu, Jun-yi; Qin, Jun; Li, Lei; Zhang, Kun-dong; Chen, Yi-sheng; Li, Yang; Jin, Tao; Xu, Jun-ming] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200080, Peoples R China.
RP Jin, T; Xu, JM (corresponding author), Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Gen Surg, Sch Med, Shanghai 200080, Peoples R China.
EM empiric_taojin@163.com; 1640423@tongji.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [8197032698]
FX We appreciate the valuable bioinformatics analysis support received from
   Dr. Xueran Kang (Contact Email: otokang@sjtu.edu.cn;1131303222@qq.com)
   over the years. This work was supported by grants from the National
   Natural Science Foundation of China (8197032698).
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Aponte-Lopez A, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/2584243
   Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y
   Bieniasz-Krzywiec P, 2019, CELL METAB, V30, P917, DOI 10.1016/j.cmet.2019.07.015
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Borgen E, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1049-0
   Buettner S, 2016, HPB, V18, P510, DOI 10.1016/j.hpb.2016.04.001
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Cai DL, 2017, J CANCER, V8, P2915, DOI 10.7150/jca.20314
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016
   Chen QJ, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00093
   Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1033-z
   Cheong H, 2015, ARCH PHARM RES, V38, P358, DOI 10.1007/s12272-015-0562-2
   Chou CH, 2018, NUCLEIC ACIDS RES, V46, pD296, DOI 10.1093/nar/gkx1067
   Cserni G, 2018, VIRCHOWS ARCH, V472, P697, DOI 10.1007/s00428-018-2301-9
   Cucchetti A, 2012, CLIN CANCER RES, V18, P4397, DOI 10.1158/1078-0432.CCR-11-2663
   da Rocha EL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03214-y
   Deng XL, 2018, CURR OPIN GENET DEV, V48, P1, DOI 10.1016/j.gde.2017.10.005
   Dennison JB, 2016, CLIN CANCER RES, V22, P5068, DOI 10.1158/1078-0432.CCR-16-0171
   Efremova M, 2020, NAT PROTOC, V15, P1484, DOI 10.1038/s41596-020-0292-x
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724
   Fukusumi T, 2018, CLIN CANCER RES, V24, P619, DOI 10.1158/1078-0432.CCR-17-1366
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gill BJ, 2014, P NATL ACAD SCI USA, V111, P12550, DOI 10.1073/pnas.1405839111
   Gnjatic S, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0243-4
   Goeman JJ, 2010, BIOMETRICAL J, V52, P70, DOI 10.1002/bimj.200900028
   Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
   He XF, 2021, CANCER GENE THER, V28, P188, DOI 10.1038/s41417-020-00208-1
   Hesser CR, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006995
   Honscheid P, 2014, INT J RADIAT BIOL, V90, P628, DOI 10.3109/09553002.2014.907932
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang YQ, 2016, J CLIN ONCOL, V34, P2157, DOI 10.1200/JCO.2015.65.9128
   Iasonos A, 2008, J CLIN ONCOL, V26, P1364, DOI 10.1200/JCO.2007.12.9791
   Jang JE, 2017, CELL REP, V20, P558, DOI 10.1016/j.celrep.2017.06.062
   Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344
   Jiang GM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0944-z
   Jin XS, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12612
   Kamarudin AN, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0332-6
   Kang XR, 2021, J CANCER, V12, P4148, DOI 10.7150/jca.58076
   Karaayvaz M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06052-0
   Katoh M, 2007, STEM CELL REV, V3, P30, DOI 10.1007/s12015-007-0006-6
   Kramer AA, 2007, CRIT CARE MED, V35, P2052, DOI 10.1097/01.CCM.0000275267.64078.B0
   Lall S, 2018, J COMPUT BIOL, V25, P1365, DOI 10.1089/cmb.2018.0027
   Latenstein AEJ, 2020, ANN SURG ONCOL, V27, P2516, DOI 10.1245/s10434-020-08235-w
   Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019
   Lee MH, 2012, ONCOGENE, V31, P116, DOI 10.1038/onc.2011.217
   Li B, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00333
   Lin QG, 2020, AGING-US, V12, P1366, DOI 10.18632/aging.102687
   Liu SP, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110098
   Lu S., 2014, PLOS ONE, V9
   Mayo SC, 2012, CANCER-AM CANCER SOC, V118, P2674, DOI 10.1002/cncr.26553
   Melville J., UMAP UNIFORM MANIFOL
   Mertz D, 2020, TISSUE ENG REGEN MED, V17, P773, DOI 10.1007/s13770-020-00299-9
   Miyoshi N, 2018, SURG TODAY, V48, P709, DOI 10.1007/s00595-018-1644-9
   Mori M, 2019, ONCOLOGIST, V24, pE943, DOI 10.1634/theoncologist.2018-0643
   Nathan H, 2010, J AM COLL SURGEONS, V210, P755, DOI 10.1016/j.jamcollsurg.2009.12.041
   Nie XB, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01341
   Nikas JB, 2020, ACS OMEGA, V5, P481, DOI 10.1021/acsomega.9b02995
   Niu R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/851320
   Odle TG, 2017, RADIOL TECHNOL, V88, p401M
   Pages F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X
   Pinello N, 2018, CANCER BIOL MED, V15, P323, DOI 10.20892/j.issn.2095-3941.2018.0365
   Qiu XJ, 2017, NAT METHODS, V14, P979, DOI [10.1038/nmeth.4402, 10.1038/NMETH.4402]
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Schaum N, 2018, NATURE, V562, P367, DOI 10.1038/s41586-018-0590-4
   Shen X, 2019, BIOCHEM BIOPH RES CO, V509, P448, DOI 10.1016/j.bbrc.2018.12.074
   Shibutani M, 2018, IN VIVO, V32, P151, DOI 10.21873/invivo.11218
   Siebert S, 2019, SCIENCE, V365, P341, DOI 10.1126/science.aav9314
   Spolverato G, 2015, JAMA SURG, V150, P538, DOI 10.1001/jamasurg.2015.0219
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suo HD, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7575862
   Tanay A, 2017, NATURE, V541, P331, DOI 10.1038/nature21350
   Tang FC, 2009, NAT METHODS, V6, P377, DOI [10.1038/NMETH.1315, 10.1038/nmeth.1315]
   Thewes B, 2017, J CLIN ONCOL, V35, P3275, DOI 10.1200/JCO.2017.72.8212
   Tong JY, 2018, CELL RES, V28, P253, DOI 10.1038/cr.2018.7
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Vickers AJ, 2008, BMC MED INFORM DECIS, V8, DOI 10.1186/1472-6947-8-53
   Wang J., 2015, BMC CANCER, V15
   Wang N, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav0198
   Wang SQ, 2020, MOL CELL PROBE, V51, DOI 10.1016/j.mcp.2020.101540
   Wang SH, 2016, ONCOTARGET, V7, P37857, DOI [10.18632/oncotarget.9347, 10.18632/oncotarget.9350]
   Wang TY, 2018, CELL METAB, V27, P1357, DOI 10.1016/j.cmet.2018.04.018
   Wang TT, 2017, GUT, V66, P1900, DOI 10.1136/gutjnl-2016-313075
   Wang Y, 2020, AGING-US, V12, P24033, DOI 10.18632/aging.104095
   Wang Y, 2018, CANCER IMMUNOL IMMUN, V67, P435, DOI 10.1007/s00262-017-2094-8
   Wang ZT, 2016, CELL SIGNAL, V28, P506, DOI 10.1016/j.cellsig.2016.02.006
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
   Winslow S, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0530-2
   Wu HY, 2020, CELL CYCLE, V19, P39, DOI 10.1080/15384101.2019.1691787
   Xu C, 2013, CANCER RES, V73, P3181, DOI 10.1158/0008-5472.CAN-12-4403
   Yang GR, 2020, NEURON, V107, P1048, DOI 10.1016/j.neuron.2020.09.005
   Yeo EJ, 2014, CANCER RES, V74, P2962, DOI 10.1158/0008-5472.CAN-13-2421
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Yu W, 2010, DIGEST DIS SCI, V55, P3171, DOI 10.1007/s10620-010-1138-0
   Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0
   Zhang CY, 2020, CELL METAB, V31, P148, DOI 10.1016/j.cmet.2019.10.013
   Zhang SC, 2019, CANCER SCI, V110, P1564, DOI 10.1111/cas.13996
   Zhang XX, 2019, NUCLEIC ACIDS RES, V47, pD721, DOI 10.1093/nar/gky900
   Zhang Y, 2017, CANCER CELL, V32, P377, DOI 10.1016/j.ccell.2017.08.004
NR 104
TC 7
Z9 7
U1 6
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 20
PY 2021
VL 2021
AR 5633514
DI 10.1155/2021/5633514
PG 32
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA UJ2SM
UT WOS:000691141700002
PM 34457116
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lee, JH
   Yoon, YM
   Han, YS
   Yun, CW
   Lee, SH
AF Lee, Jun Hee
   Yoon, Yeo Min
   Han, Yong-Seok
   Yun, Chul Won
   Lee, Sang Hun
TI Melatonin Promotes Apoptosis of Oxaliplatin-resistant Colorectal Cancer
   Cells Through Inhibition of Cellular Prion Protein
SO ANTICANCER RESEARCH
LA English
DT Article
DE Colorectal cancer cells; cellular prion protein; melatonin; oxaliplatin;
   drug resistance
ID OXIDATIVE STRESS; ANTIOXIDANT; PROGRESSION; AUTOPHAGY; AXIS
AB Background/Aim: Drug resistance restricts the efficacy of chemotherapy in colorectal cancer. However, the detailed molecular mechanism of drug resistance in colorectal cancer cells remains unclear. Materials and Methods: The level of cellular prion protein (PrPC) in oxaliplatin-resistant colorectal cancer (SNU-C5/Oxal-R) cells was assessed. Results: PrPC level in SNU-C5/Oxal-R cells was significantly increased compared to that in wildtype (SNU-C5) cells. Superoxide dismutase and catalase activities were higher in SNU-C5/Oxal-R cells than in SNU-C5 cells. Treatment of SNU-C5/Oxal-R cells with oxaliplatin and melatonin reduced PrPC expression, while suppressing antioxidant enzyme activity and increasing superoxide anion generation. In SNU-C5/Oxal-R cells, endoplasmic reticulum stress and apoptosis were significantly increased following co-treatment with oxaliplatin and melatonin compared to treatment with oxaliplatin alone. Conclusion: Co-treatment with oxaliplatin and melatonin increased endoplasmic reticulum stress in and apoptosis of SNU-C5/Oxal-R cells through inhibition of PrPC, suggesting that PrPC could be a key molecule in oxaliplatin resistance of colorectal cancer cells.
C1 [Lee, Jun Hee] Univ Alabama Birmingham, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL USA.
   [Yoon, Yeo Min; Han, Yong-Seok; Yun, Chul Won; Lee, Sang Hun] Soonchunhyang Univ, Seoul Hosp, Med Sci Res Inst, Seoul, South Korea.
   [Lee, Sang Hun] Soonchunhyang Univ, Dept Med Biosci, Asan, South Korea.
RP Lee, SH (corresponding author), Soonchunhyang Univ, Seoul Hosp, Soonchunhyang Med Sci Res Inst, 59 Daesagwan Ro 657 Hannam Dong, Seoul 140887, South Korea.
EM jhlee0407@sch.ac.kr
RI lee, sang hun/Q-4650-2019
OI lee, sang hun/0000-0002-9005-5966
FU National Research Foundation grant - Korean governmentNational Research
   Foundation of Korea [NRF-2016R1D1A3B01007727, NRF-2017M3A9B4032528]
FX This work was supported by the National Research Foundation grant funded
   by the Korean government (grant number NRF-2016R1D1A3B01007727,
   NRF-2017M3A9B4032528). The funding agencies had no role in formulating
   the study design, data collection or analysis, the decision to publish,
   or preparation of the manuscript.
CR Bejarano I, 2009, J PINEAL RES, V46, P392, DOI 10.1111/j.1600-079X.2009.00675.x
   Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505
   Brown DR, 2002, J NEUROSCI RES, V67, P211, DOI 10.1002/jnr.10118
   Buldak RJ, 2015, MOL MED REP, V12, P2275, DOI 10.3892/mmr.2015.3599
   Castle AR, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00019
   Chieng CKL, 2015, TUMOR BIOL, V36, P8107, DOI 10.1007/s13277-015-3530-z
   Doeppner TR, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.365
   Fernandez A, 2015, J PINEAL RES, V59, P292, DOI 10.1111/jpi.12264
   Garcia JJ, 2014, J PINEAL RES, V56, P225, DOI 10.1111/jpi.12128
   Han YS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.310
   Hinton C, 2013, CURR CANCER DRUG TAR, V13, P895
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hong Y, 2014, J PINEAL RES, V56, P264, DOI 10.1111/jpi.12119
   Jan JE, 2009, J PINEAL RES, V46, P1, DOI 10.1111/j.1600-079X.2008.00628.x
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Klamt F, 2001, FREE RADICAL BIO MED, V30, P1137
   Lee JH, 2017, ONCOGENE, V36, P6555, DOI 10.1038/onc.2017.263
   Lee JH, 2018, BIOMOL THER, V26, P1
   Lee JH, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12385
   Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x
   Li Y, 2017, ONCOTARGET, V8, P39896, DOI 10.18632/oncotarget.16379
   Liang JJ, 2012, PRION, V6, DOI 10.4161/pri.22511
   Luo GH, 2017, ONCOTARGET, V8, P71630, DOI 10.18632/oncotarget.17795
   Martin-Lanneree S, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00055
   Reiter RJ, 2016, J PINEAL RES, V61, P253, DOI 10.1111/jpi.12360
   Reiter RJ, 2009, BIOL REPROD, V81, P445, DOI 10.1095/biolreprod.108.075655
   Shi FS, 2016, J MOL NEUROSCI, V59, P48, DOI 10.1007/s12031-016-0733-8
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Wang JS, 2013, J PINEAL RES, V54, P406, DOI 10.1111/jpi.12035
   Wang QW, 2012, ONCOL REP, V28, P2029, DOI 10.3892/or.2012.2025
   Wei JY, 2015, J PINEAL RES, V58, P429, DOI 10.1111/jpi.12226
   Yoon YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep39838
NR 32
TC 21
Z9 22
U1 1
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD APR
PY 2018
VL 38
IS 4
BP 1993
EP 2000
DI 10.21873/anticanres.12437
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GB1GA
UT WOS:000428798000015
PM 29599315
OA Bronze
DA 2022-04-25
ER

PT J
AU Chen, L
   Liao, FY
   Jiang, ZY
   Zhang, C
   Wang, ZW
   Luo, P
   Jiang, QZ
   Wu, J
   Wang, Q
   Luo, M
   Li, XR
   Leng, Y
   Ma, L
   Shen, GF
   Chen, ZL
   Wang, Y
   Tan, X
   Gan, YB
   Liu, DQ
   Liu, YS
   Shi, CM
AF Chen, Long
   Liao, Fengying
   Jiang, Zhongyong
   Zhang, Chi
   Wang, Ziwen
   Luo, Peng
   Jiang, Qingzhi
   Wu, Jie
   Wang, Qing
   Luo, Min
   Li, Xueru
   Leng, Yu
   Ma, Le
   Shen, Gufang
   Chen, Zelin
   Wang, Yu
   Tan, Xu
   Gan, Yibo
   Liu, Dengqun
   Liu, Yunsheng
   Shi, Chunmeng
TI Metformin mitigates gastrointestinal radiotoxicity and radiosensitises
   P53 mutation colorectal tumours via optimising autophagy
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID IONIZING-RADIATION; DNA METHYLATION; OXIDATIVE STRESS; BOWEL TOXICITY;
   CANCER; IRRADIATION; APOPTOSIS; KINASE; INJURY; RADIOTHERAPY
AB Background and Purpose There is an urgent but unmet need for mitigating radiation-induced intestinal toxicity while radio sensitising tumours for abdominal radiotherapy. We aimed to investigate the effects of metformin on radiation-induced intestinal toxicity and radiosensitivity of colorectal tumours. Experimental Approach Acute and chronic histological injuries of the intestine from mice were used to assess radioprotection and IEC-6 cell line was used to investigate the mechanisms in vitro. The fractionated abdominal radiation model of HCT116 and HT29 tumour grafts was used to determine the effects on colorectal cancer. Key Results Metformin alleviated radiation-induced acute and chronic intestinal toxicity by optimising mitophagy which was AMPK-dependent. In addition, our data indicated that metformin increased the radiosensitivity of colorectal tumours with P53 mutation both in vitro and in vivo. Conclusion and Implications Metformin may be a radiotherapy adjuvant agent for colorectal cancers especially those carrying P53 mutation. Our findings provide a new strategy for further precise clinical trials for metformin on radiotherapy.
C1 [Chen, Long; Liao, Fengying; Jiang, Zhongyong; Zhang, Chi; Wang, Ziwen; Luo, Peng; Jiang, Qingzhi; Wu, Jie; Wang, Qing; Luo, Min; Ma, Le; Shen, Gufang; Chen, Zelin; Wang, Yu; Tan, Xu; Gan, Yibo; Liu, Dengqun; Liu, Yunsheng; Shi, Chunmeng] Third Mil Med Univ, Army Med Univ, Inst Rocket Force Med, State Key Lab Trauma Burns & Combined Injury, Chongqing, Peoples R China.
   [Jiang, Qingzhi; Wang, Qing] Southwest Med Univ, Inst Clin Med, Luzhou, Peoples R China.
   [Luo, Min] Guizhou Med Univ, Minist Educ, Key Lab Environm Pollut Monitoring & Dis Control, Dept Toxicol, Guiyang, Peoples R China.
   [Li, Xueru; Leng, Yu] Chongqing Med Univ, Gener Hosp, Dept Ophthalmol, Chongqing, Peoples R China.
RP Shi, CM (corresponding author), Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Rocket Force Med, Chongqing 400038, Peoples R China.
EM shicm@tmmu.edu.cn
RI Wang, Ziwen/AAG-9607-2021
OI Shi, Chunmeng/0000-0002-8264-738X; chen, long/0000-0001-5907-6374
FU National Key Research and Development Program [2016YFC1000805];
   University Innovation Team Building Program of Chongqing
   [CXTDG201602020];  [AWS17J007];  [2018-JCJQ-ZQ-001]
FX This work was supported by the National Key Research and Development
   Program (2016YFC1000805), University Innovation Team Building Program of
   Chongqing (CXTDG201602020) and Intramural Research Project Grants
   (AWS17J007 and 2018-JCJQ-ZQ-001).
CR Abu el Maaty MA, 2017, MOL CARCINOGEN, V56, P2486, DOI 10.1002/mc.22696
   Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS1, DOI 10.1111/bph.14747
   Alexander SPH, 2018, BRIT J PHARMACOL, V175, P407, DOI 10.1111/bph.14112
   [Anonymous], 2010, EXP PHYSIOL, V95, P842, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]
   Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Banerjee S, 2016, FREE RADICAL BIO MED, V99, P296, DOI 10.1016/j.freeradbiomed.2016.08.022
   Bauer PV, 2018, CELL METAB, V27, P101, DOI 10.1016/j.cmet.2017.09.019
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Chaurasia M, 2019, AUTOPHAGY, V15, P1391, DOI 10.1080/15548627.2019.1582973
   Ciorba MA, 2012, GUT, V61, P829, DOI 10.1136/gutjnl-2011-300367
   Cordani M, 2017, BBA-REV CANCER, V1867, P19, DOI 10.1016/j.bbcan.2016.11.003
   Cordani M, 2016, MOL ONCOL, V10, P1008, DOI 10.1016/j.molonc.2016.04.001
   Coyle C, 2016, ANN ONCOL, V27, P2184, DOI 10.1093/annonc/mdw410
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   Cuyas E, 2018, ONCOGENE, V37, P963, DOI 10.1038/onc.2017.367
   de Mey S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01073
   De Ruysscher D, 2019, NAT REV DIS PRIMERS, V5, DOI 10.1038/s41572-019-0064-5
   Ferreira MR, 2014, LANCET ONCOL, V15, pE139, DOI 10.1016/S1470-2045(13)70504-7
   Fransson P, 2007, ACTA ONCOL, V46, P517, DOI 10.1080/02841860601113596
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Greenhill C, 2018, NAT REV ENDOCRINOL, V15, P2, DOI 10.1038/s41574-018-0133-y
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Hauer-Jensen M, 2014, NAT REV GASTRO HEPAT, V11, P470, DOI 10.1038/nrgastro.2014.46
   He L, 2015, CELL METAB, V21, P159, DOI 10.1016/j.cmet.2015.01.003
   Hu LL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/9460462
   Huang YH, 2018, GUT, V67, P307, DOI 10.1136/gutjnl-2016-311909
   Kam WWY, 2013, FREE RADICAL BIO MED, V65, P607, DOI 10.1016/j.freeradbiomed.2013.07.024
   Lamark T, 2017, ESSAYS BIOCHEM, V61, P609, DOI 10.1042/EBC20170035
   Larson-Casey JL, 2016, IMMUNITY, V44, P582, DOI 10.1016/j.immuni.2016.01.001
   Liu XN, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7161592
   Massat NJ, 2013, J MED SCREEN, V20, P125, DOI 10.1177/0969141313501292
   McGrath JC, 2015, BRIT J PHARMACOL, V172, P3189, DOI 10.1111/bph.12955
   Meng FQ, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/5063239
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Miousse IR, 2017, INT J RADIAT BIOL, V93, P457, DOI 10.1080/09553002.2017.1287454
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Muaddi H, 2013, RADIOTHER ONCOL, V108, P446, DOI 10.1016/j.radonc.2013.06.014
   O'Rourke Kevin P, 2016, Bio Protoc, V6
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Qaseem A, 2017, ANN INTERN MED, V166, P279, DOI 10.7326/M16-1860
   Riehl TE, 2019, GUT, V68, P1003, DOI 10.1136/gutjnl-2018-316226
   Sabit Hussein, 2018, Asian Pac J Cancer Prev, V19, P2991
   Sanli T, 2014, CANCER BIOL THER, V15, P156, DOI 10.4161/cbt.26726
   Sanli T, 2010, INT J RADIAT ONCOL, V78, P221, DOI 10.1016/j.ijrobp.2010.03.005
   SHER ME, 1990, AM J GASTROENTEROL, V85, P121
   Singh A, 2016, ACS CHEM BIOL, V11, P3214, DOI 10.1021/acschembio.6b00651
   Szumiel I, 2015, INT J RADIAT BIOL, V91, P1, DOI 10.3109/09553002.2014.934929
   Taneja N, 2001, ONCOGENE, V20, P167, DOI 10.1038/sj.onc.1204054
   Tchelebi Leila, 2014, Subcell Biochem, V85, P133, DOI 10.1007/978-94-017-9211-0_8
   Nguyen TD, 2019, BLOOD, V133, P168, DOI 10.1182/blood-2018-02-833475
   Turinetto V, 2015, NUCLEIC ACIDS RES, V43, P2489, DOI 10.1093/nar/gkv061
   Vancura A, 2018, TRENDS PHARMACOL SCI, V39, P867, DOI 10.1016/j.tips.2018.07.006
   Vial G, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00294
   Wang J, 2017, RADIAT RES, V188, P105, DOI 10.1667/RR14708.1
   Wang ZW, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10386-8
   Wei L, 2016, J CLIN INVEST, V126, P4076, DOI 10.1172/JCI88410
   Xu GS, 2015, FREE RADICAL BIO MED, V87, P15, DOI 10.1016/j.freeradbiomed.2015.05.045
   Yamamori T, 2012, FREE RADICAL BIO MED, V53, P260, DOI 10.1016/j.freeradbiomed.2012.04.033
   Zannella VE, 2013, CLIN CANCER RES, V19, P6741, DOI 10.1158/1078-0432.CCR-13-1787
   Zhang Y, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12542
   Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505
NR 65
TC 4
Z9 4
U1 9
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD SEP
PY 2020
VL 177
IS 17
BP 3991
EP 4006
DI 10.1111/bph.15149
EA JUL 2020
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NB5UP
UT WOS:000546356500001
PM 32472692
OA Bronze, Green Published
DA 2022-04-25
ER

PT J
AU Jung, HJ
   Kang, JH
   Choi, S
   Son, YK
   Lee, KR
   Seong, JK
   Kim, SY
   Oh, SH
AF Jung, Hyun Jin
   Kang, Ju-Hee
   Choi, Seungho
   Son, Youn Kyoung
   Lee, Kang Ro
   Seong, Je Kyung
   Kim, Sun Yeou
   Oh, Seung Hyun
TI Pharbitis Nil (PN) induces apoptosis and autophagy in lung cancer cells
   and autophagy inhibition enhances PN-induced apoptosis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Pharbitis Nil; Apoptosis; Autophagy; STAT3; ERK1/2
ID PROKINETIC AGENT; OSTEOSARCOMA CELLS; COLORECTAL-CANCER;
   NATURAL-PRODUCTS; GENE-EXPRESSION; INDUCTION; STAT3; ACTIVATION;
   DA-9701; PATHWAY
AB Ethnopharmacological relevance: Pharbitis Nil (PN) is used as a main component of the existing drug, DA-9701, which was developed to treat functional dyspepsia (FD) in Korea. PN extracts isolated from its seeds have been reported to have anticancer effects.
   Aim of the study: The purpose of this study was to investigate the underlying mechanism of the chemotherapeutic effects of PN in lung cancer cells.
   Materials and methods: We performed MTT assays, colony formation assays, flow cytometry assays, Western blot analysis, reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence analysis, and cell counting assays to study the molecular mechanism of chemotherapeutic effects of PN in lung cancer cells.
   Results: Our results indicate that PN induced autophagy as well as apoptosis. PN inhibited cell proliferation and survival by inducing apoptosis in several lung cancer cell lines. PN-treated cells also exhibited induction of autophagy, as evidenced by increased protein expression levels and punctuate patterns of LC3 II. Moreover, activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2), which plays an important role in autophagy activation, was shown to be related with PN-induced autophagy. Interestingly, pharmacological blockade of autophagy activation with wortmannin and inhibition of ERK1/2 phosphorylation by U0126 markedly enhanced PN-induced apoptosis and reduced cell viability, suggesting that autophagy induced by PN may have a cytoprotective effect by suppressing apoptosis. PN- induced apoptosis was regulated by signal transducer and activator of transcription 3 (STAT3) deactivation. Moreover, decrease of STAT3 activation in PN-treated cells was associated with reduced survivin expression, further demonstrating that PN-induced apoptosis was regulated by STAT3 deactivation.
   Conclusion: We believe that PN, which is already proven to treat human patients with FD, might be a potential anticancer drug for human lung cancer. In addition, our data suggest that the combination of PN treatment with an autophagy inhibitor or traditional anticancer agents may be an effective anticancer therapy.
C1 [Jung, Hyun Jin; Seong, Je Kyung] Seoul Natl Univ, Coll Vet Med, Korea Mouse Phenotyping Ctr, Seoul 08826, South Korea.
   [Kang, Ju-Hee; Kim, Sun Yeou; Oh, Seung Hyun] Gachon Univ, Coll Pharm, 191 Hambangmoe Ro, Incheon 21936, South Korea.
   [Choi, Seungho] Seoul Natl Univ, Coll Vet Med, Seoul 08826, South Korea.
   [Son, Youn Kyoung] Natl Inst Biol Resources, Biol & Genet Resources Assessment Div, Incheon 22689, South Korea.
   [Lee, Kang Ro] Sungkyunkwan Univ, Sch Pharm, Nat Prod Lab, Suwon 1641916, South Korea.
RP Oh, SH (corresponding author), Gachon Univ, Coll Pharm, 191 Hambangmoe Ro, Incheon 21936, South Korea.
EM eyeball@hanmail.net
RI Oh, Seung/AAN-6744-2021
OI Seong, Je Kyung/0000-0003-1177-6958
FU National Institute of Biological Resources (NIBR) - Ministry of
   Environment (MOE) of the Republic of Korea [NIBR201725201]; National
   Research Foundation of Korea (NRF) - Ministry of Science, ICT & Future
   Planning [2012M3A9D1054622]
FX This work was supported by a grant from the National Institute of
   Biological Resources (NIBR), funded by the Ministry of Environment (MOE)
   of the Republic of Korea (NIBR201725201).; This research was supported
   by the National Research Foundation of Korea (NRF) funded by the
   Ministry of Science, ICT & Future Planning (No. 2012M3A9D1054622)
CR Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Choi CH, 2010, MOL PHARMACOL, V78, P114, DOI 10.1124/mol.110.063495
   Choi S, 2009, MOL CELLS, V27, P307, DOI 10.1007/s10059-009-0039-6
   Corcelle E, 2007, AUTOPHAGY, V3, P57, DOI 10.4161/auto.3424
   Ellington AA, 2006, CARCINOGENESIS, V27, P298, DOI 10.1093/carcin/bgi214
   Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752
   Guo SH, 2016, J DRUG TARGET, V24, P934, DOI 10.3109/1061186X.2016.1157882
   Itakura E, 2011, J CELL BIOL, V192, P17, DOI 10.1083/jcb.201009067
   Ju JH, 2011, J ETHNOPHARMACOL, V133, P126, DOI 10.1016/j.jep.2010.09.021
   Kang JH, 2015, J ETHNOPHARMACOL, V173, P303, DOI 10.1016/j.jep.2015.07.030
   Kang TS, 2017, CANCER LETT, V396, P76, DOI 10.1016/j.canlet.2017.03.016
   Kim HJ, 2013, INT J ONCOL, V42, P1985, DOI 10.3892/ijo.2013.1884
   Kim KH, 2014, J AGR FOOD CHEM, V62, P7746, DOI 10.1021/jf501470k
   Klabunde CN, 2007, ANN EPIDEMIOL, V17, P584, DOI 10.1016/j.annepidem.2007.03.011
   Ko SG, 2004, BIOL PHARM BULL, V27, P1604, DOI 10.1248/bpb.27.1604
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Lang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129196
   Lee J.I., 2013, 2013 IEEE INT C IEEE, P1, DOI [10.1109/tencon.2013.6718487, DOI 10.1109/TENCON.2013.6718487, DOI 10.1007/S12282-013-0442-X#]
   Lee SP, 2017, J NEUROGASTROENTEROL, V23, P109, DOI 10.5056/jnm16003
   Lee TH, 2008, PHYTOMEDICINE, V15, P836, DOI 10.1016/j.phymed.2008.02.019
   Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a
   Li X, 2011, TOXICOL APPL PHARM, V251, P146, DOI 10.1016/j.taap.2010.12.007
   Mann J, 2002, NAT REV CANCER, V2, P143, DOI 10.1038/nrc723
   Martinez-Lopez N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3799
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Peng X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.297
   Prick T, 2006, BIOCHEM J, V394, P153, DOI 10.1042/BJ20051243
   Qin BB, 2015, SCI REP-UK, V5, DOI 10.1038/srep15701
   Reddy L, 2003, PHARMACOL THERAPEUT, V99, P1, DOI 10.1016/S0163-7258(03)00042-1
   Shen SS, 2012, MOL CELL, V48, P667, DOI 10.1016/j.molcel.2012.09.013
   Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996
   Sridharan Savitha, 2011, Cancers (Basel), V3, P2630, DOI 10.3390/cancers3022630
   Wang YY, 2013, TOXICOL IN VITRO, V27, P1928, DOI 10.1016/j.tiv.2013.06.001
   Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971
   You LK, 2015, ONCOTARGET, V6, P40268, DOI 10.18632/oncotarget.5592
   You LK, 2015, AUTOPHAGY, V11, P729, DOI 10.1080/15548627.2015.1017192
   Yuan G, 2014, J BIOL CHEM, V289, P10607, DOI 10.1074/jbc.M113.528760
   Zeng YJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030312, 10.1371/journal.pone.0043478]
   Zhang J, 2013, ONCOL LETT, V5, P756, DOI 10.3892/ol.2013.1132
   Zhou J, 2013, CELL RES, V23, P508, DOI 10.1038/cr.2013.11
NR 43
TC 14
Z9 14
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD SEP 17
PY 2017
VL 208
BP 253
EP 263
DI 10.1016/j.jep.2017.07.020
PG 11
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA FI8MC
UT WOS:000412255700026
PM 28729229
DA 2022-04-25
ER

PT J
AU Kobayashi, T
   Ishida, M
   Miki, H
   Matsumi, Y
   Fukui, T
   Hamada, M
   Tsuta, K
   Sekimoto, M
AF Kobayashi, Toshinori
   Ishida, Mitsuaki
   Miki, Hisanori
   Matsumi, Yuki
   Fukui, Toshiro
   Hamada, Madoka
   Tsuta, Koji
   Sekimoto, Mitsugu
TI p62 is a useful predictive marker for tumour regression after
   chemoradiation therapy in patients with advanced rectal cancer: an
   immunohistochemical study
SO COLORECTAL DISEASE
LA English
DT Article
DE advanced rectal cancer; autophagy; chemoradiation therapy; p62; tumour
   regression grade
ID PROGNOSTIC-SIGNIFICANCE; EXPRESSION; RADIOTHERAPY; PROTEIN; WATCH
AB Aim: This study aimed to evaluate the relationship between p62 expression status and tumour regression grade in advanced rectal cancer.
   Methods: We enrolled 47 consecutive patients with advanced rectal cancer who underwent chemoradiation therapy (CRT) before surgery. p62 expression in the biopsy specimens was immunohistochemically evaluated, and p62 expression score (staining intensity x positive tumour cells, %) was calculated (range 0-300). The relationship between p62 expression score and CRT effect was analysed.
   Results: The staining intensity was +2 and +3 in 29 and 18 patients, respectively. The median proportion of positive neoplastic cells was 87.8%, and that of the p62 expression score was 200. Stronger staining intensity and a higher proportion of p62-positive neoplastic cells were significantly associated with CRT non-effectiveness (P = 0.0002 and P = 0.0116, respectively), and a higher p62 expression score was significantly associated with CRT non-effectiveness (P < 0.0001). The optimal cut-off value for predicting the CRT effect was 240.
   Conclusions: A higher p62 expression score was significantly associated with less CRT effectiveness in patients with advanced rectal cancer. Analysis of p62 expression score using biopsy specimens is a useful and easily assessable prediction marker for CRT effect and might help select patients who can undergo a 'watch-and-wait' strategy after CRT.
C1 [Kobayashi, Toshinori; Miki, Hisanori; Matsumi, Yuki; Hamada, Madoka; Sekimoto, Mitsugu] Kansai Med Univ, Dept Surg, Osaka, Japan.
   [Ishida, Mitsuaki; Tsuta, Koji] Kansai Med Univ, Dept Pathol, Osaka, Japan.
   [Ishida, Mitsuaki; Tsuta, Koji] Kansai Med Univ, Clin Lab, Osaka, Japan.
   [Fukui, Toshiro] Kansai Med Univ, Div Gastroenterol & Hepatol, Dept Internal Med 3, Osaka, Japan.
RP Ishida, M (corresponding author), Kansai Med Univ, Dept Pathol, 2-5-1,Shinmachi, Hirakata, Osaka 5731010, Japan.
EM ishidamt@hirakata.kmu.ac.jp
RI Hamada, Madoka/AFG-8058-2022
OI Fukui, Toshiro/0000-0003-1131-4067; Kobayashi,
   Toshinori/0000-0001-8042-5073
FU Kansai Medical University
FX This study was partially supported by the research grant D2 from the
   Kansai Medical University (to TK). The paper has not been in a podium or
   poster meeting presentation.
CR Arai A, 2017, AM J CANCER RES, V7, P881
   Dayde D, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030573
   Dreyer SB, 2017, ANN SURG ONCOL, V24, P1295, DOI 10.1245/s10434-016-5684-3
   Dworak O, 1997, INT J COLORECTAL DIS, V12, P19, DOI 10.1007/s003840050072
   Fluss R, 2005, BIOMETRICAL J, V47, P458, DOI 10.1002/bimj.200410135
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Habr-Gama A, 2004, ANN SURG, V240, P711, DOI 10.1097/01.sla.0000141194.27992.32
   Hupkens BJP, 2017, DIS COLON RECTUM, V60, P1032, DOI 10.1097/DCR.0000000000000862
   Hur H, 2016, DIS COLON RECTUM, V59, P1174, DOI 10.1097/DCR.0000000000000711
   Inomata M, 2016, MOL CLIN ONCOL, V4, P510, DOI 10.3892/mco.2016.767
   Iwadate R, 2015, AM J PATHOL, V185, P2523, DOI 10.1016/j.ajpath.2015.05.008
   Kosumi K, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1284720
   Lei C, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018791
   Li XF, 2016, WORLD J GASTROENTERO, V22, P8576, DOI 10.3748/wjg.v22.i38.8576
   Liu JL, 2014, BRIT J CANCER, V111, P944, DOI 10.1038/bjc.2014.355
   Nakayama S, 2017, CANCER MED-US, V6, P1264, DOI 10.1002/cam4.1093
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Rodel C, 2005, J CLIN ONCOL, V23, P8688, DOI 10.1200/JCO.2005.02.1329
   Rogov V, 2014, MOL CELL, V53, P167, DOI 10.1016/j.molcel.2013.12.014
   Saito T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12030
   Su YX, 2005, CLIN IMMUNOL, V116, P118, DOI 10.1016/j.clim.2005.04.004
   van der Sande ME, 2021, ANN SURG, V274, pE541, DOI 10.1097/SLA.0000000000003718
   van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X
   Wang Z, 2020, THORAC CANCER, V11, P130, DOI 10.1111/1759-7714.13252
   Zhao MF, 2015, HUM PATHOL, V46, P843, DOI 10.1016/j.humpath.2015.02.009
NR 25
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8910
EI 1463-1318
J9 COLORECTAL DIS
JI Colorectal Dis.
PD MAY
PY 2021
VL 23
IS 5
BP 1083
EP 1090
DI 10.1111/codi.15486
EA JAN 2021
PG 8
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA RZ5NR
UT WOS:000606007100001
PM 33316131
DA 2022-04-25
ER

PT J
AU Sun, B
   Xu, Y
   Liu, ZY
   Meng, WX
   Yang, H
AF Sun, B.
   Xu, Y.
   Liu, Z-Y
   Meng, W-X
   Yang, H.
TI Autophagy assuages myocardial infarction through Nrf2 signaling
   activation-mediated reactive oxygen species clear
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Autophagy; Nrf2; Apoptosis; CytC; ROS; Myocardial infarction
ID OXIDATIVE STRESS; CARDIOVASCULAR-DISEASE; REPERFUSION INJURY; PRIMARY
   PREVENTION; COLORECTAL-CANCER; ASPIRIN; RATS; PROTECTS
AB OBJECTIVE: The activation of autophagy was shown to shrink infarct size and mitigate cardiac dysfunction caused by myocardial infarction (MI). However, the underlying mechanisms remain largely unknown. As excessive generation of reactive oxygen species (ROS) deteriorates MI process and Nrf2 signaling exerts an antioxidant role, we explored whether autophagy assuaged MI through Nrf2 signaling activation-mediated ROS clear.
   MATERIALS AND METHODS: MI models were induced by ligation of the left descending coronary artery (LAD) in C57BL/6J mice or Nrf2 knockout mice (Nrf2-KO). Rapamycin and 3-methyladenine (3-MA) were used to activate and repress autophagy in MI mice, respectively. Aspirin, a cardioprotective drug was given to MI mice to evaluate its effects on autophagy.
   RESULTS: Compared with the MI group, rapamycin treatment remarkably decreased the infarct size, cell apoptosis and blood troponin I level, accompanied by the reduced redox potential (Eh), ROS, malondialdehyde (MDA) and cytochrome C levels, and the increased reduced glutathione (GSH) level. Also, rapamycin treatment increased the expressions of bcl-2, bcl-xL, HSP70, and HSP90. In addition, rapamycin treatment promoted the nuclear accumulation of Nrf2 protein. However, Nrf2 downregulation significantly impaired the effects of rapamycin on the reductions of infarct size, cell apoptosis, troponin I and ROS levels. Similarly, to rapamycin roles, aspirin treatment also remarkably reduced infarct size, cell apoptosis and troponin I in mice with MI surgery, as well as increased the expression level of LC3II/LC3I.
   CONCLUSIONS: This study demonstrated that autophagy enhancement contributed to the improvement of MI through Nrf2 signaling activation-mediated ROS clear.
C1 [Sun, B.; Meng, W-X; Yang, H.] Harbin Med Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China.
   [Xu, Y.] Harbin Med Univ, Editorial Board Journal, Harbin, Heilongjiang, Peoples R China.
   [Liu, Z-Y] Harbin Med Univ, Affiliated Hosp 1, Cent Lab Hematol & Oncol, Harbin, Heilongjiang, Peoples R China.
RP Yang, H (corresponding author), Harbin Med Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, Harbin, Heilongjiang, Peoples R China.
EM redrosefive@163.com
CR Aisa Z, 2017, EUR REV MED PHARMACO, V21, P3705
   [Anonymous], 2002, Methods Enzymol, V355, P1
   Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577
   Cho JS, 2015, J KOREAN MED SCI, V30, P903, DOI 10.3346/jkms.2015.30.7.903
   Dehmer SP, 2016, ANN INTERN MED, V164, P777, DOI 10.7326/M15-2129
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fisher CD, 2007, DRUG METAB DISPOS, V35, P995, DOI 10.1124/dmd.106.014340
   Florczyk Urszula, 2010, Postepy Biochem, V56, P147
   Gonzalez-Montero J, 2018, WORLD J CARDIOL, V10, P74, DOI 10.4330/wjc.v10.i9.74
   Grunwell JR, 2015, FRONT PEDIATR, V3, DOI 10.3389/fped.2015.00046
   Harris Craig, 2012, Methods Mol Biol, V889, P325, DOI 10.1007/978-1-61779-867-2_21
   Hausenloy DJ, 2013, J CLIN INVEST, V123, P92, DOI 10.1172/JCI62874
   Hori M, 2009, CARDIOVASC RES, V81, P457, DOI 10.1093/cvr/cvn335
   Huang ZJ, 2018, EUR J PHARMACOL, V823, P58, DOI 10.1016/j.ejphar.2018.01.031
   Kirchberger I, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2124-4
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Lin C, 2016, J PHARM PHARMACOL, V68, P941, DOI 10.1111/jphp.12567
   Liu ZH, 2017, AM J PHYSIOL-HEART C, V312, pH422, DOI 10.1152/ajpheart.00249.2016
   McCormick J, 2012, J CELL MOL MED, V16, P386, DOI 10.1111/j.1582-4934.2011.01323.x
   McDonald H, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13699
   Sable A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21866-0
   Sciarretta S, 2018, ANNU REV PHYSIOL, V80, P1, DOI 10.1146/annurev-physiol-021317-121427
   Shi XM, 2014, INT J CLIN EXP MED, V7, P5310
   Sun LJ, 2012, EXP THER MED, V4, P811, DOI 10.3892/etm.2012.674
   von Knethen A, 1999, J IMMUNOL, V163, P2858
   Wang S, 2018, EUR REV MED PHARMACO, V22, P8990, DOI 10.26355/eurrev_201812_16670
   Wang Y, 2018, BIOCHEM BIOPH RES CO, V503, P3219, DOI 10.1016/j.bbrc.2018.08.129
   Waypa GB, 2002, CIRC RES, V91, P719, DOI 10.1161/01.RES.0000036751.04896.F1
   Wei P, 2015, INT J CLIN EXP PATHO, V8, P9836
   Wu XQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112891
   Xiao JH, 2018, J CELL BIOCHEM, V119, DOI 10.1002/jcb.26878
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Zhang JL, 2009, CHINESE MED J-PEKING, V122, P2372, DOI 10.3760/cma.j.issn.0366-6999.2009.19.033
   Zhao QX, 2018, INT J MOL MED, V41, P3243, DOI 10.3892/ijmm.2018.3552
   Zhao ZS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7212
   Zhu HH, 2018, CELL PHYSIOL BIOCHEM, V49, P2138, DOI 10.1159/000493817
NR 36
TC 2
Z9 2
U1 0
U2 3
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PY 2020
VL 24
IS 13
BP 7381
EP 7390
DI 10.26355/eurrev_202007_21906
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MN9OX
UT WOS:000551170100021
PM 32706077
DA 2022-04-25
ER

PT J
AU Liu, Q
   Zhu, DC
   Hao, BZ
   Zhang, ZW
   Tian, YJ
AF Liu, Qing
   Zhu, Dongchuan
   Hao, Baozhen
   Zhang, Zhiwei
   Tian, Yongjie
TI Luteolin promotes the sensitivity of cisplatin in ovarian cancer by
   decreasing PRPA1-medicated autophagy
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Ovarian cancer; Luteolin; Cisplatin; Autophagy; Chemosensitivity
ID PARP1 INHIBITORS; CELLS; APOPTOSIS; STRESS; ROLES
AB Luteolin (LUT) is a flavone universally presented in plants. It shows an anti-carcinogenic effect in different cancers and could increase the sensitivity of cisplatin in colorectal cancer cell lines through Nrf2 pathway. However, the effect of luteolin on the sensitivity to ovarian cancer cells has not been studied. In this study, luteolin was found to suppress autophagy with reduced expression of LC3-II, but enhanced the inhibition of cell vitality and promoted apoptosis induced by cisplatin, leading to restoration of the sensitivity to cisplatin in ovarian cancer cells through CCK-8, flow cytometry and immunofluorescent assays. Although cisplatin elevated the PARP1 for cell survival, the cisplatin-induced expression of PARP1 was inhibited by luteolin a dose- and time-dependent manner through Q-PCR and WB assays. Further, PARP1 siRNA could further improve the LUT-induced inhibition of cell vitality and restore the sensitivity to cisplatin with reduced LC3-II levels. Our present work demonstrate that LUT can suppresses autophagy but enhance apoptosis induced by cisplatin and promote the sensitivity to cisplatin through suppressing the expression of RARP1 in ovarian cancer.
C1 [Liu, Qing; Tian, Yongjie] Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, Jinan, Shandong, Peoples R China.
   [Liu, Qing; Zhang, Zhiwei] Shandong Univ, Shandong Prov Qianfoshan Hosp, Dept Obstet & Gynecol, Jinan, Shandong, Peoples R China.
   [Zhu, Dongchuan] First Peoples Hosp Jinan, Dept Urol, Jinan, Shandong, Peoples R China.
   [Hao, Baozhen] Shandong Matern & Child Hlth Care Hosp, Dept Gynecol, Jinan, Shandong, Peoples R China.
RP Tian, YJ (corresponding author), Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, Jinan, Shandong, Peoples R China.
EM tianyongjie@sdu.edu.cn
FU Key Research and Development Program of Shandong Province
   [2015GSF118140]; Natural Science Foundation of Shandong ProvinceNatural
   Science Foundation of Shandong Province [ZR2014HM108]
FX This work was supported by Key Research and Development Program of
   Shandong Province (2015GSF118140) and Natural Science Foundation of
   Shandong Province (ZR2014HM108).
CR Beck C, 2014, EXP CELL RES, V329, P18, DOI 10.1016/j.yexcr.2014.07.003
   Booth LA, 2014, CELL SIGNAL, V26, P549, DOI 10.1016/j.cellsig.2013.11.028
   Bravo-San Pedro JM, 2017, CIRC RES, V120, P1812, DOI 10.1161/CIRCRESAHA.117.311082
   Chakrabarti M, 2016, APOPTOSIS, V21, P312, DOI 10.1007/s10495-015-1198-x
   Deng L, 2017, ONCOL LETT, V13, P1370, DOI 10.3892/ol.2017.5597
   Dia VP, 2017, J CELL PHYSIOL, V232, P391, DOI 10.1002/jcp.25436
   Guo YF, 2017, ONCOTARGET, V8, P28481, DOI 10.18632/oncotarget.16092
   Hou XY, 2015, MOL CELLS, V38, P396, DOI 10.14348/molcells.2015.2183
   Ji YBA, 2010, CURR OPIN GENET DEV, V20, P512, DOI 10.1016/j.gde.2010.06.001
   Kwon Do Youn, 2017, Obstet Gynecol Sci, V60, P115, DOI 10.5468/ogs.2017.60.1.115
   Lluesma SM, 2016, BIOMEDICINES, V4, DOI 10.3390/biomedicines4020010
   Lu DF, 2012, J AGR FOOD CHEM, V60, P8411, DOI 10.1021/jf3022817
   Malyuchenko NV, 2015, ACTA NATURAE, V7, P27, DOI 10.32607/20758251-2015-7-3-27-37
   Mangerich A, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/321653
   Muller S., 2017, AUTOIMMUN REV, V29, P30139
   Park SH, 2013, FOOD CHEM TOXICOL, V56, P100, DOI 10.1016/j.fct.2013.02.022
   Peng MH, 2017, ANTIVIR RES, V143, P176, DOI 10.1016/j.antiviral.2017.03.026
   Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812
   Samuel P, 2016, EXPERT REV ANTICANC, V16, P57, DOI 10.1586/14737140.2016.1121107
   Schiewer MJ, 2014, MOL CANCER RES, V12, P1069, DOI 10.1158/1541-7786.MCR-13-0672
   Singh SS, 2014, CURR TOP MED CHEM, V14, P2020, DOI 10.2174/1568026614666140929152123
   Sui XB, 2014, CANCER LETT, V344, P174, DOI 10.1016/j.canlet.2013.11.019
   Tomao F, 2017, EXPERT OPIN PHARMACO, V18, P1443, DOI 10.1080/14656566.2017.1328055
   Verdoodt F, 2017, MATURITAS, V100, P1, DOI 10.1016/j.maturitas.2017.03.001
   Wang Q, 2017, CANCER CHEMOTH PHARM, V79, P1031, DOI 10.1007/s00280-017-3299-4
   Yan MM, 2016, MOL MED REP, V14, P1986, DOI 10.3892/mmr.2016.5517
NR 26
TC 17
Z9 18
U1 6
U2 15
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2018
VL 64
IS 6
BP 17
EP 22
DI 10.14715/cmb/2018.64.6.4
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HD3SN
UT WOS:000452439600001
PM 29808795
OA Bronze
DA 2022-04-25
ER

PT J
AU Hu, M
   Yu, ZM
   Mei, PY
   Li, JX
   Luo, D
   Zhang, HM
   Zhou, MF
   Liang, FX
   Chen, R
AF Hu, Man
   Yu, Zhaomin
   Mei, Peiyuan
   Li, Jinxiao
   Luo, Dan
   Zhang, Haiming
   Zhou, Minfeng
   Liang, Fengxia
   Chen, Rui
TI Lycorine Induces autophagy-associated apoptosis by targeting MEK2 and
   enhances vemurafenib activity in colorectal cancer
SO AGING-US
LA English
DT Article
DE apoptosis; colorectal cancer; lycorine; vemurafenib
ID MAP KINASE; BRAF; MELANOMA; SURVIVAL; CELLS; COBIMETINIB; EVOLUTION;
   PROMOTES; PATHWAY; BCL-2
AB Lycorine is a powerful anti-cancer agent against various cancer cell lines with minor side effects. However, the detailed mechanisms of its effects in colorectal cancer (CRC) remain unclear. In this study, we investigated the function and mechanism of lycorine against CRC both in vitro and in vivo. Molecular docking modeling was used to identify potential inhibitory targets of lycorine in CRC. Cell viability was measured using the Cell Counting Kit-8 assay, and apoptosis was measured using flow cytometry. Autophagosomes were examined using transmission electron microscopy and confocal microscopy. HCT116-derived xenografts were constructed to analyze the effect of lycorine in CRC in vivo. Using the CDOCKER algorithm, we determined that lycorine has four interactions with the conserved domain of mitogen-activated protein kinase kinase 2 (MEK2). This prediction was further confirmed by the degradation of phosphorylated MEK2 and its downstream targets after lycorine treatment, and MEK2 overexpression abolished lycorine-induced autophagy-associated apoptosis. Additionally, we revealed that the combination of vemurafenib and lycorine had better effects in CRC models in vitro and in vivo than monotherapy. Our findings identified lycorine as an effective MEK2 inhibitor and suggested that the combination of lycorine and vemurafenib could be used to treat CRC.
C1 [Hu, Man; Yu, Zhaomin; Li, Jinxiao; Chen, Rui] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan, Peoples R China.
   [Mei, Peiyuan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Thorac Surg, Wuhan, Peoples R China.
   [Luo, Dan] Wuhan First Hosp, Dept Resp Med, Wuhan, Peoples R China.
   [Zhang, Haiming] Huazhong Univ Sci & Technol, Cent Hosp Wuhan, Tongji Med Coll, Dept Oncol,Integrated Tradit Chinese & Western Me, Wuhan, Peoples R China.
   [Zhou, Minfeng; Liang, Fengxia] Hubei Prov Hosp Tradit Chinese Med, Dept Acupuncture, Wuhan, Peoples R China.
RP Chen, R (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Integrated Tradit Chinese & Western Med, Wuhan, Peoples R China.
EM unioncr@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81774401, 81574065]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81774401, 81574065).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Arur S, 2009, P NATL ACAD SCI USA, V106, P4776, DOI 10.1073/pnas.0812285106
   Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148
   Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Britten CD, 2013, CANCER CHEMOTH PHARM, V71, P1395, DOI 10.1007/s00280-013-2121-1
   Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799
   Cao ZF, 2013, TOXICOL LETT, V218, P174, DOI 10.1016/j.toxlet.2013.01.018
   Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Cui Q, 2007, J PHARMACOL SCI, V105, P317, DOI 10.1254/jphs.FP0070336
   Dasari R, 2014, BIOORG MED CHEM LETT, V24, P923, DOI 10.1016/j.bmcl.2013.12.073
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Deng S, 2019, CANCER-AM CANCER SOC, V125, P1228, DOI 10.1002/cncr.31978
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286
   Erickson JA, 2004, J MED CHEM, V47, P45, DOI 10.1021/jm030209y
   Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Grosdidier A, 2011, NUCLEIC ACIDS RES, V39, pW270, DOI 10.1093/nar/gkr366
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7
   Klionsky DJ, 2008, AUTOPHAGY, V4, P740, DOI 10.4161/auto.6398
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Lee CS, 2019, P NATL ACAD SCI USA, V116, P4508, DOI 10.1073/pnas.1817494116
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Lin SR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071412
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)02124-9
   Mandal R, 2016, ONCOGENE, V35, P2547, DOI 10.1038/onc.2015.329
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Menzies AM, 2012, DRUG DES DEV THER, V6, P391, DOI 10.2147/DDDT.S38998
   Miller KD, 2016, CA-CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Olson JM, 2004, TRENDS MOL MED, V10, P125, DOI 10.1016/j.molmed.2004.01.007
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Ribas A, 2014, LANCET ONCOL, V15, P954, DOI 10.1016/S1470-2045(14)70301-8
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Roy M, 2018, BIOMED PHARMACOTHER, V107, P615, DOI 10.1016/j.biopha.2018.07.147
   Roy M, 2016, THERANOSTICS, V6, P2209, DOI 10.7150/thno.15584
   Shen J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0785-4
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
   Sun YF, 2018, BIOCHEM BIOPH RES CO, V495, P911, DOI 10.1016/j.bbrc.2017.11.032
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   von Kriegsheim A, 2009, NAT CELL BIOL, V11, P1458, DOI 10.1038/ncb1994
   Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
   Wu S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00881
   Ye YC, 2011, J PHARMACOL SCI, V117, P160, DOI 10.1254/jphs.11105FP
   Ying XX, 2017, SCI CHINA LIFE SCI, V60, P417, DOI 10.1007/s11427-016-0368-y
   Yu HY, 2017, MOL CANCER THER, V16, P2711, DOI 10.1158/1535-7163.MCT-17-0498
   Zeng H, 2017, MED SCI MONITOR, V23, P2035, DOI 10.12659/MSM.900742
   Zhang PH, 2017, AUTOPHAGY, V13, P1093, DOI 10.1080/15548627.2017.1319039
NR 60
TC 9
Z9 10
U1 1
U2 15
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JAN 15
PY 2020
VL 12
IS 1
BP 138
EP 155
DI 10.18632/aging.102606
PG 18
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA KC5QX
UT WOS:000507233100010
PM 31901897
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Maranhao, SS
   Moura, AF
   Oliveira, ACA
   Lima, DJB
   Barros-Nepomuceno, FWA
   Paier, CRK
   Pinheiro, AC
   Nogueira, TCM
   de Souza, MVN
   Pessoa, C
AF Maranhao, Sarah Sant'Anna
   Moura, Andrea Felinto
   Aragao Oliveira, Augusto Cesar
   Barbosa Lima, Daisy Jereissati
   Araujo Barros-Nepomuceno, Francisco Washington
   Koscky Paier, Carlos Roberto
   Pinheiro, Alessandra Campbell
   Mendonca Nogueira, Thais Cristina
   Nora de Souza, Marcus Vinicius
   Pessoa, Claudia
TI Synthesis of PJOV56, a new quinoxalinyl-hydrazone derivative able to
   induce autophagy and apoptosis in colorectal cancer cells, and related
   compounds
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Quinoxalines; Cytotoxicity; HCT-116 cells; Cell cycle arrest
ID BIOLOGICAL EVALUATION; IN-VITRO; ANTIPROLIFERATIVE ACTIVITY; PHASE-I;
   INHIBITION; POTENT
AB Quinoxaline derivatives are reported as antineoplastic agents against a variety of human cancer cell lines, with some compounds being submitted to clinical trials. In this work, we report the synthesis, characterization and cytotoxicity potential of a new series of quinoxalinyl-hydrazones. The most cytotoxic compound was (E)-2-[2-(2-pyridin-2-ylmethylene)hydrazinyl] quinoxaline (PJOV56) that presented a time-dependent effect against HCT116 cells. After 48 h of incubation, PJOV56 was able to induce autophagy and apoptosis of HCT-116 cells, mediated by upregulation of Beclin 1, upregulation of LC3A/B II and activation of caspase 7. Apoptosis was induced along with G0/G1 cell cycle arrest at the highest concentration of PJOV56 (6.0 mu M). Thus, PJOV56 showed a dose-dependent mode of action related to induction of autophagy and apoptosis in HCT-116 cells.
C1 [Maranhao, Sarah Sant'Anna; Moura, Andrea Felinto; Aragao Oliveira, Augusto Cesar; Barbosa Lima, Daisy Jereissati; Araujo Barros-Nepomuceno, Francisco Washington; Koscky Paier, Carlos Roberto; Pessoa, Claudia] Univ Fed Ceara, Ctr Res & Drug Dev, Lab Expt Oncol, Rua Coronel Nunes Melo 1000, BR-60430275 Fortaleza, Ceara, Brazil.
   [Araujo Barros-Nepomuceno, Francisco Washington] Univ Int Integrat Afro Brazilian Lusophony, Inst Hlth Sci, CE 060,Km 51, BR-62785000 Acarape, Ceara, Brazil.
   [Pinheiro, Alessandra Campbell; Mendonca Nogueira, Thais Cristina; Nora de Souza, Marcus Vinicius] Fundacao Oswaldo Cruz, Inst Technol Drugs Farmanguinhos, BR-21041250 Rio De Janeiro, RJ, Brazil.
   [Nora de Souza, Marcus Vinicius] Univ Fed Rio de Janeiro, Inst Chem, Dept Organ Chem, CP 68563, BR-21945970 Rio De Janeiro, RJ, Brazil.
RP Pessoa, C (corresponding author), Univ Fed Ceara, Ctr Res & Drug Dev, Lab Expt Oncol, Rua Coronel Nunes Melo 1000, BR-60430275 Fortaleza, Ceara, Brazil.
EM cpessoa@ufc.br
RI pinheiro, alessandra/AAA-3523-2022; de Souza, Marcus/W-5002-2019;
   Barros-Nepomuceno, Francisco Washington Araujo/B-3111-2018; Koscky
   Paier, Carlos Roberto/M-9072-2017
OI Barros-Nepomuceno, Francisco Washington Araujo/0000-0001-9932-028X;
   Koscky Paier, Carlos Roberto/0000-0001-5255-4644; Pessoa,
   Claudia/0000-0002-4344-4336
FU CAPESCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES); CNPqConselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPQ); FAPERJFundacao Carlos Chagas Filho de Amparo a
   Pesquisa do Estado do Rio De Janeiro (FAPERJ); FUNCAPFundacao Cearense
   de Apoio ao Desenvolvimento Cientifico e Tecnologico (FUNCAP); Fiocruz
FX We thank federal and state Brazilian research agencies CAPES, CNPq,
   FAPERJ and FUNCAP for funding. We also thank Fiocruz for funding and
   provisioning the necessary equipment and infrastructure for chemical
   synthesis and structural characterization of quinoxalinylhydrazones. The
   authors also thank the National Cancer Institute (Bethesda, MD, USA) for
   the donation of the tumor cell lines used in this study.
CR Ajani OO, 2014, EUR J MED CHEM, V85, P688, DOI 10.1016/j.ejmech.2014.08.034
   Ancizu S, 2009, MOLECULES
   Cohen EEW, 2007, INT J RAD ONCOL BIOL
   Covens A, 2006, GYNECOL ONCOL, V100, P586, DOI 10.1016/j.ygyno.2005.09.032
   Dawson S, 2007, NAT PROD REP, V24, P109, DOI 10.1039/b516347c
   Desplat V, 2010, J ENZYM INHIB MED CH, V25, P204, DOI 10.3109/14756360903169881
   Diana P, 2008, J MED CHEM, V51, P2387, DOI 10.1021/jm070834t
   Ding Z, 2001, CLIN CANC RES
   Ferreira MDL, 2010, SCI WORLD J
   Foster BJ, 1985, INVEST NEW DRUGS
   Gali-Muhtasib HU, 2005, CANCER CHEMOTH PHARM, V55, P369, DOI 10.1007/s00280-004-0907-x
   Harakeh S, 2004, CHEM-BIOL INTERACT, V148, P101, DOI 10.1016/j.cbi.2004.05.002
   Hattori K, 2016, ORG BIOMOL CHEM, V14, P2090, DOI 10.1039/c5ob02505b
   Husain A., 2011, J PHARM RES, V4, P924
   Kakodkar NC, 2011, PEDIAT BLOOD CANC
   Kim WK, 2016, J NAT PROD
   Kong DH, 2005, CANCER RES, V65, P9047, DOI 10.1158/0008-5472.CAN-05-1235
   Lipinski CA, 2001, ADV DRUG DELIV REV
   Loch-Neckel G, 2015, EUR J MED CHEM, V90, P93, DOI 10.1016/j.ejmech.2014.11.014
   Magalhaes LG, 2018, ACAD BRAS CIENC
   Maluf FC, 2006, INT J GYNECOL CANC
   Modica-Napolitano JS, 2015, INT J MOL SCI
   Mosmann TT, 1983, J IMMUNOL METHODS
   Noolvi MN, 2011, EUR J MED CHEM, V46, P2327, DOI 10.1016/j.ejmech.2011.03.015
   Ozpolat B, 2015, CANCER MANAG RES, V7, P291, DOI 10.2147/CMAR.S34859
   Parrino B, 2015, EUR J MED CHEM, V94, P367, DOI 10.1016/j.ejmech.2015.03.009
   Parrino B, 2015, EUR J MED CHEM, V94, P149, DOI 10.1016/j.ejmech.2015.03.005
   Pedro JM, 2015, AUTOPHAGY
   Pereira JA, 2015, EUR J MED CHEM, V97, P664, DOI 10.1016/j.ejmech.2014.06.058
   Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448
   Pucci B, 2000, NEOPLASIA
   Qi J, 2018, EUR J MED CHEM
   Reiners Jr JJ, 2009, J PHARM EXP THER
   Rodrigues FAR, 2014, BIOORG MED CHEM LETT, V24, P934, DOI 10.1016/j.bmcl.2013.12.074
   Stock W, 2008, INVEST NEW DRUG, V26, P331, DOI 10.1007/s10637-008-9129-0
   Tristan-Manzano M, 2015, CURR MED CHEM, V22, P3075, DOI 10.2174/0929867322666150812144104
   Undevia SD, 2008, EUR J CANCER, V44, P1684, DOI 10.1016/j.ejca.2008.05.018
   Vicente E, 2010, BIOORG MED CHEM LETT
   Watanabe K, 2009, CURR OPIN CHEM BIOL, V13, P189, DOI 10.1016/j.cbpa.2009.02.012
   Werner J, 2016, VISC MED, V32, P156, DOI 10.1159/000447070
   Wu P, 2011, EUR J MED CHEM, V46, P5540, DOI 10.1016/j.ejmech.2011.09.015
   Yang ZJ, 2011, MOL CANC THER
   Zhao Y, 2020, J SCI FOOD AGR, V100, P897, DOI 10.1002/jsfa.10049
   Zhou C, 2017, ONCOTARGET
NR 44
TC 8
Z9 8
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JAN 15
PY 2020
VL 30
IS 2
AR 126851
DI 10.1016/j.bmcl.2019.126851
PG 8
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy; Chemistry
GA JZ1OE
UT WOS:000504873300051
PM 31836446
DA 2022-04-25
ER

PT J
AU Zhu, YY
   Liu, WW
   Chen, SG
   Xu, FX
   Zhang, LX
   Hayashi, T
   Mizuno, K
   Hattori, S
   Fujisaki, H
   Ikejima, T
AF Zhu, Yingying
   Liu, Weiwei
   Chen, Shuaigao
   Xu, Fanxing
   Zhang, Luxin
   Hayashi, Toshihiko
   Mizuno, Kazunori
   Hattori, Shunji
   Fujisaki, Hitomi
   Ikejima, Takashi
TI Collagen type 1 enhances cell growth and insulin biosynthesis in rat
   pancreatic cells
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
DE type 1 diabetes mellitus; collagen I; IGF-1R; autophagy; beta-catenin
ID FACTOR-I; COLORECTAL-CANCER; AUTOPHAGY; MATRIX; PROLIFERATION;
   SECRETION; PATHWAY; SYSTEM; ISLETS
AB Type I collagen (collagen I) is the most abundant component of the extracellular matrix (ECM) in the pancreas. We previously reported that collagen I-coated culture dishes enhanced proliferation of rat pancreatic beta cell line, INS-1 cells, via up-regulation of beta-catenin nuclear translocation. In this study, we further investigated the effects of collagen I on insulin production of INS-1 cells. The results indicate that insulin synthesis as well as cell proliferation is increased in the INS-1 cells cultured on the dishes coated with collagen I. Up-regulation of insulin-like growth factor 1 receptor (IGF-1 R) on the INS-1 cells cultured on the collagen-coated dishes is involved in up-regulation of cell proliferation and increase of insulin biosynthesis; however, up-regulation of insulin secretion in the INS-1 cells on collagen I-coated dishes was further enhanced by inhibition of IGF-1R. Autophagy of INS-1 cells on collagen I-coated dishes was repressed via IGF-1R upregulation, and inhibition of a utophagy with 3MA further enhanced cell proliferation and insulin biosynthesis but did not affect insulin secretion. E-cadherin/beta-catenin adherent junction complexes are stabilized by autophagy. That is, autophagy negatively regulates the nuclear translocation of beta-catenin that leads to insulin biosynthesis and cell proliferation. In conclusion, IGF-1R/downregulation of autophagy/nuclear translocation of beta-catenin is involved in collagen I-induced INS-1 cell proliferation and insulin synthesis.
C1 [Zhu, Yingying; Liu, Weiwei; Chen, Shuaigao; Xu, Fanxing; Zhang, Luxin; Hayashi, Toshihiko; Ikejima, Takashi] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang, Liaoning, Peoples R China.
   [Hayashi, Toshihiko] Kogakuin Univ, Sch Adv Engn, Dept Chem & Life Sci, Tokyo, Japan.
   [Hayashi, Toshihiko; Mizuno, Kazunori; Hattori, Shunji; Fujisaki, Hitomi] Nippi Res Inst Biomatrix, Toride, Ibaraki, Japan.
   [Ikejima, Takashi] Key Lab Computat Chem Based Nat Antitumor Drug Re, Shenyang, Liaoning, Peoples R China.
RP Ikejima, T (corresponding author), Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang, Liaoning, Peoples R China.; Ikejima, T (corresponding author), Key Lab Computat Chem Based Nat Antitumor Drug Re, Shenyang, Liaoning, Peoples R China.
EM ikejimat@vip.sina.com
OI Mizuno, Kazunori/0000-0003-3354-6264
CR Llacua LA, 2018, DIABETOLOGIA, V61, P1261, DOI 10.1007/s00125-017-4524-8
   Aragona M, 2013, CELL, V154, P1047, DOI 10.1016/j.cell.2013.07.042
   Baarsma HA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025450
   Belfiore A, 2018, CELL ADHES MIGR, V12, P305, DOI 10.1080/19336918.2018.1445953
   Bonnans C, 2014, NAT REV MOL CELL BIO, V15, P786, DOI 10.1038/nrm3904
   Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756
   Cevenini A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082411
   Chang CK, 2003, DIABETOLOGIA, V46, P595, DOI 10.1007/s00125-003-1109-5
   Chen YQ, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118286
   Chen ZF, 2011, AUTOPHAGY, V7, P12, DOI 10.4161/auto.7.1.13607
   Cheng JYC, 2011, TISSUE ENG PART B-RE, V17, P235, DOI [10.1089/ten.teb.2011.0004, 10.1089/ten.TEB.2011.0004]
   Chik CL, 1997, ENDOCRINOLOGY, V138, P2033, DOI 10.1210/en.138.5.2033
   Colella B, 2019, CELL SIGNAL, V53, P357, DOI 10.1016/j.cellsig.2018.10.017
   Degtyarev M, 2008, J CELL BIOL, V183, P101, DOI 10.1083/jcb.200801099
   Denysenko T, 2016, CANCER GENOM PROTEOM, V13, P31
   Ercin M, 2018, BBA-MOL CELL RES, V1865, P1934, DOI 10.1016/j.bbamcr.2018.09.010
   Fujimoto K, 2009, DIABETES OBES METAB, V11, P30, DOI 10.1111/j.1463-1326.2009.01121.x
   Grassi G, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.249
   Hald J, 2012, DIABETOLOGIA, V55, P154, DOI 10.1007/s00125-011-2295-1
   Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012
   Hilling D, 2009, TRANSPL P, V41, P326, DOI 10.1016/j.transproceed.2008.10.065
   Hu QC, 2012, ASN NEURO, V4, P253, DOI 10.1042/AN20120009
   Hubbell JA, 2003, CURR OPIN BIOTECH, V14, P551, DOI 10.1016/j.copbio.2003.09.004
   Kaido T, 2004, J BIOL CHEM, V279, P53762, DOI 10.1074/jbc.M411202200
   Kharat A, 2019, LIFE SCI, V216, P287, DOI 10.1016/j.lfs.2018.11.028
   Kim IG, 2018, CANCER SCI, V109, P3519, DOI 10.1111/cas.13791
   Krishnamurthy M, 2011, ENDOCRINOLOGY, V152, P424, DOI 10.1210/en.2010-0877
   Lal NK, 2020, CELL HOST MICROBE, V28, P558, DOI 10.1016/j.chom.2020.07.010
   Lee KY, 2020, EXP MOL MED, V52, P1948, DOI 10.1038/s12276-020-00533-3
   Lee YH, 2019, MOL METAB, V27, pS92, DOI 10.1016/j.molmet.2019.06.014
   Li XY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174083
   Liu JYP, 2015, INT J NANOMED, V10, P3519, DOI 10.2147/IJN.S80502
   Liu XL, 2019, MOL CELL BIOCHEM, V450, P1, DOI 10.1007/s11010-018-3368-y
   Llacua LA, 2018, ISLETS, V10, P60, DOI 10.1080/19382014.2017.1420449
   Llacua LA, 2018, J TISSUE ENG REGEN M, V12, P460
   LOMEDICO P, 1979, CELL, V18, P545, DOI 10.1016/0092-8674(79)90071-0
   Malaguarnera R, 2015, ONCOTARGET, V6, P16084, DOI 10.18632/oncotarget.3177
   Mano JF, 2007, J R SOC INTERFACE, V4, P999, DOI 10.1098/rsif.2007.0220
   MONTESANO R, 1983, J CELL BIOL, V97, P935, DOI 10.1083/jcb.97.3.935
   Nagata N, 2001, CELL TRANSPLANT, V10, P447
   Nowosad A, 2020, NAT CELL BIOL, V22, P1076, DOI 10.1038/s41556-020-0554-4
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Ommati MM, 2020, ECOTOX ENVIRON SAFE, V204, DOI 10.1016/j.ecoenv.2020.110973
   OTONKOSKI T, 1988, DIABETES, V37, P1678, DOI 10.2337/diabetes.37.12.1678
   Rosado-Olivieri EA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09404-6
   Rosenzweig SA, 2010, BIOCHEM PHARMACOL, V80, P1115, DOI 10.1016/j.bcp.2010.06.013
   Sabatini PV, 2019, MOL METAB, V21, P1, DOI 10.1016/j.molmet.2018.12.007
   Shih HP, 2016, CELL REP, V14, P169, DOI 10.1016/j.celrep.2015.12.027
   Shiono S, 2006, EJSO-EUR J SURG ONC, V32, P308, DOI 10.1016/j.ejso.2005.12.003
   Sipos F, 2017, WORLD J GASTROENTERO, V23, P8109, DOI 10.3748/wjg.v23.i46.8109
   SMITH FE, 1991, P NATL ACAD SCI USA, V88, P6152, DOI 10.1073/pnas.88.14.6152
   Su VYF, 2019, STEM CELLS, V37, P1516, DOI 10.1002/stem.3093
   Subramani R, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0061-7
   Tian FM, 2018, J ORTHOP RES, V36, P576, DOI 10.1002/jor.23767
   Tiano JP, 2012, NAT REV ENDOCRINOL, V8, P342, DOI 10.1038/nrendo.2011.242
   Vella V, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118522
   Wang R, 2001, J ENDOCRINOL, V171, P309, DOI 10.1677/joe.0.1710309
   Wang XW, 2020, AM J PHYSIOL-ENDOC M, V319, pE734, DOI 10.1152/ajpendo.00071.2020
   Wijshake T, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020478118
   Xiao D, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00034
   Yang J, 2019, CONNECT TISSUE RES, V60, P463, DOI 10.1080/03008207.2019.1593393
   Yoshida T, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9091970
   Zhang QY, 2015, BIOMED PHARMACOTHER, V73, P12, DOI 10.1016/j.biopha.2015.05.004
   Zhou YT, 2015, DIS MODEL MECH, V8, P1625, DOI 10.1242/dmm.021857
   Zhu Y, 2020, COMPUTER VISION ECCV, P1, DOI 10.1080/03008207.2020.1845321
NR 65
TC 1
Z9 1
U1 10
U2 10
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND
SN 0952-5041
EI 1479-6813
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD OCT
PY 2021
VL 67
IS 3
BP 135
EP 148
DI 10.1530/JME-21-0032
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA UN1DE
UT WOS:000693761100007
PM 34370695
DA 2022-04-25
ER

PT J
AU Zhu, ZL
   Du, SS
   Ding, FX
   Guo, SS
   Ying, GG
   Yan, Z
AF Zhu, Zhongling
   Du, Shuangshuang
   Ding, Fengxia
   Guo, Shanshan
   Ying, Guoguang
   Yan, Zhao
TI Ursolic acid attenuates temozolomide resistance in glioblastoma cells by
   downregulating O-6-methylguanine-DNA methyltransferase (MGMT) expression
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Ursolic acid; temozolomide; glioblastoma; O-6-methylguanine-DNA
   methyltransferase; senescence
ID COLORECTAL-CANCER CELLS; HIGH-GRADE GLIOMAS; MALIGNANT GLIOMA; OLEANOLIC
   ACID; PHASE-II; IN-VITRO; APOPTOSIS; AUTOPHAGY; PATHWAY; PROLIFERATION
AB The DNA-alkylating agent temozolomide (TMZ) is an effective chemotherapeutic agent against malignant glioma, including glioblastoma multiforme (GBM). However, the clinical efficacy of TMZ is limited in many patients because of O-6-methylguanine-DNA methyltransferase (MGMT)-driven resistance. Thus, new strategies to overcome TMZ resistance are urgently needed. Ursolic acid (UA) is a naturally derived pentacyclic triterpene acid that exerts broad anticancer effects, and shows capability to cross the blood-brain barrier. In this study, we evaluated the possible synergistic effect of TMZ and UA in resistant GBM cell lines. The results showed that UA prevented the proliferation of resistant GBM cells in a concentration-dependent manner. Compared with TMZ or UA treatment alone, the combination treatment of TMZ and UA synergistically enhanced cytotoxicity and senescence in TMZ-resistant GBM cells. This effect was correlated with the downregulation of MGMT. Moreover, experimental results with an in vivo mouse xenograft model showed that the combination treatment of UA and TMZ reduced tumor volumes by depleting MGMT. Therefore, UA as both a monotherapy and a resensitizer, might be a candidate agent for patients with refractory malignant gliomas.
C1 [Zhu, Zhongling; Du, Shuangshuang; Ding, Fengxia; Guo, Shanshan; Yan, Zhao] Tianjin Med Univ Canc Inst & Hosp, Dept Clin Pharmacol, Tianjin 300060, Peoples R China.
   [Zhu, Zhongling; Du, Shuangshuang; Ding, Fengxia; Guo, Shanshan; Ying, Guoguang; Yan, Zhao] Natl Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
   [Ying, Guoguang] Tianjin Med Univ Canc Inst & Hosp, Dept Tumor Cell Biol, Tianjin 300060, Peoples R China.
RP Ying, GG; Yan, Z (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Natl Clin Res Ctr Canc, Huan Hu Xi Rd, Tianjin 300060, Peoples R China.
EM yingguoguang163@163.com; yanzhaopaper@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81402481]; Tianjin Municipal Health Bureau
   fund [2014KZ085]; Doctoral Foundation of Tianjin Medical University
   Cancer Institute and Hospital [B1312]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81402481), Tianjin Municipal Health Bureau fund
   (No. 2014KZ085) and Doctoral Foundation of Tianjin Medical University
   Cancer Institute and Hospital (No. B1312).
CR Balmaceda C, 2008, CANCER-AM CANCER SOC, V112, P1139, DOI 10.1002/cncr.23167
   Batich KA, 2014, EXPERT OPIN PHARMACO, V15, P2047, DOI 10.1517/14656566.2014.947266
   Chen CM, 2015, INT J MOL MED, V36, P1244, DOI 10.3892/ijmm.2015.2332
   Chen QH, 2011, ANAL BIOANAL CHEM, V399, P2877, DOI 10.1007/s00216-011-4651-x
   Filippi-Chiela EC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042522
   Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707
   Goder A, 2015, CARCINOGENESIS, V36, P817, DOI 10.1093/carcin/bgv070
   Grogan PT, 2014, INVEST NEW DRUG, V32, P604, DOI 10.1007/s10637-014-0084-7
   Jiang G, 2014, MOL BIOL REP, V41, P6659, DOI 10.1007/s11033-014-3549-z
   Jiang G, 2011, BIOCHEM BIOPH RES CO, V406, P311, DOI 10.1016/j.bbrc.2011.02.042
   Kaina B, 2010, CELL MOL LIFE SCI, V67, P3663, DOI 10.1007/s00018-010-0491-7
   Knizhnik AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055665
   Kohsaka S, 2012, MOL CANCER THER, V11, P1289, DOI 10.1158/1535-7163.MCT-11-0801
   Lin CJ, 2012, FREE RADICAL BIO MED, V52, P377, DOI 10.1016/j.freeradbiomed.2011.10.487
   Liu J, 1995, J ETHNOPHARMACOL, V49, P57, DOI 10.1016/0378-8741(95)90032-2
   Meng Y, 2015, AM J CHINESE MED, V43, P1471, DOI 10.1142/S0192415X15500834
   Messaoudi K, 2015, DRUG DISCOV TODAY, V20, P899, DOI 10.1016/j.drudis.2015.02.011
   Pathak AK, 2007, MOL CANCER RES, V5, P943, DOI 10.1158/1541-7786.MCR-06-0348
   Prasad S, 2011, J BIOL CHEM, V286, P5546, DOI 10.1074/jbc.M110.183699
   Quinn JA, 2009, J CLIN ONCOL, V27, P1262, DOI 10.1200/JCO.2008.18.8417
   Ryu CH, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/987495
   Shan JZ, 2011, CHIN J INTEGR MED, V17, P607, DOI 10.1007/s11655-011-0815-y
   Shanmugam MK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032476
   Shen D, 2015, ONCOL REP, V34, P2715, DOI 10.3892/or.2015.4232
   Theeler BJ, 2011, CURR TREAT OPTION NE, V13, P386, DOI 10.1007/s11940-011-0130-0
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Yang L, 2010, CANCER LETT, V298, P128, DOI 10.1016/j.canlet.2010.06.010
   Zhang Jihong, 2012, Curr Mol Pharmacol, V5, P102
   Zhang YX, 2010, J CELL BIOCHEM, V109, P764, DOI 10.1002/jcb.22455
   Zheng MZ, 2008, MOL CANCER THER, V7, P3842, DOI 10.1158/1535-7163.MCT-08-0516
NR 31
TC 20
Z9 20
U1 1
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2016
VL 8
IS 7
BP 3299
EP 3308
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA DT7DM
UT WOS:000381647300044
PM 27508051
DA 2022-04-25
ER

PT J
AU El-Far, AH
   Sroga, G
   Al Jaouni, SK
   Mousa, SA
AF El-Far, Ali H.
   Sroga, Grazyna
   Al Jaouni, Soad K.
   Mousa, Shaker A.
TI Role and Mechanisms of RAGE-Ligand Complexes and RAGE-Inhibitors in
   Cancer Progression
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE RAGE-ligands; AGEs; HMGB1; S100s; RAGE-inhibitors; carcinogenesis
ID GLYCATION END-PRODUCTS; GROUP BOX 1; HUMAN NASOPHARYNGEAL CARCINOMA;
   PROMOTES CELL-PROLIFERATION; COLORECTAL-CANCER; EXTRACELLULAR S100A4;
   HEPATOCELLULAR-CARCINOMA; REGULATES AUTOPHAGY; MALIGNANT PHENOTYPE;
   CYTOPLASMIC DOMAIN
AB Interactions of the receptor for advanced glycation end product (RAGE) and its ligands in the context of their role in diabetes mellitus, inflammation, and carcinogenesis have been extensively investigated. This review focuses on the role of RAGE-ligands and anti-RAGE drugs capable of controlling cancer progression. Different studies have demonstrated interaction of RAGE with a diverse range of acidic (negatively charged) ligands such as advanced glycation end products (AGEs), high-mobility group box1 (HMGB1), and S100s, and their importance to cancer progression. Some RAGE-ligands displayed effects on anti- and pro-apoptotic proteins through upregulation of the phosphatidylinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR), mitogen-activated protein kinases (MAPKs), matrix metalloproteinases (MMPs), vascular endothelial growth factor (VEGF), and nuclear factor kappa B (NF-kappa B) pathways, while downregulating p53 in cancer progression. In addition, RAGE may undergo ligand-driven multimodal dimerization or oligomerization mediated through self-association of some of its subunits. We conclude our review by proposing possible future lines of study that could result in control of cancer progression through RAGE inhibition.
C1 [El-Far, Ali H.] Damanhour Univ, Fac Vet Med, Dept Biochem, Damanhour 22511, Damanhour, Egypt.
   [Sroga, Grazyna] Rensselaer Polytech Inst, NY RPI, Troy, NY 12180 USA.
   [Al Jaouni, Soad K.] King Abdulaziz Univ, Fac Med, Dept Hematol Pediat Oncol, Prophet Med Applicat, Jeddah 21589, Saudi Arabia.
   [Mousa, Shaker A.] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA.
RP Mousa, SA (corresponding author), Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY 12144 USA.
EM ali.elfar@damanhour.edu.eg; srogag@rpi.edu; saljaouni@kau.edu.sa;
   shaker.mousa@acphs.edu
RI El-Far, Prof Dr/Ali H./L-7946-2017; Mousa, Shaker A/A-7151-2017
OI El-Far, Prof Dr/Ali H./0000-0001-9721-4360; Mousa, Shaker
   A/0000-0002-9294-015X
CR Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545
   Ahmed N, 2005, DIABETES RES CLIN PR, V67, P3, DOI 10.1016/j.diabres.2004.09.004
   Arumugam T, 2006, J NATL CANCER I, V98, P1806, DOI 10.1093/jnci/djj498
   Arumugam T, 2012, CLIN CANCER RES, V18, P4356, DOI 10.1158/1078-0432.CCR-12-0221
   Bao JM, 2015, AM J CANCER RES, V5, P1741
   Bresnick AR, 2015, NAT REV CANCER, V15, P96, DOI 10.1038/nrc3893
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Chandimali N, 2018, ANTICANCER RES, V38, P3967, DOI 10.21873/anticanres.12683
   Chen BQ, 2017, BIOMED PHARMACOTHER, V92, P468, DOI 10.1016/j.biopha.2017.05.111
   Chen Chuan-gui, 2012, Zhonghua Zhong Liu Za Zhi, V34, P566, DOI 10.3760/cma.j.issn.0253-3766.2012.08.002
   Chen HB, 2014, MOL CELL ENDOCRINOL, V395, P69, DOI 10.1016/j.mce.2014.07.021
   Chen QY, 2018, MOL PHARMACOL, V94, P784, DOI 10.1124/mol.118.112268
   Chen RC, 2014, MOL CELL BIOCHEM, V390, P271, DOI 10.1007/s11010-014-1978-6
   Chen YM, 2016, TUMOR BIOL, V37, P4399, DOI 10.1007/s13277-015-4049-z
   Choi YR, 2003, CANCER RES, V63, P2188
   Dahlmann M, 2014, ONCOTARGET, V5, P3220, DOI 10.18632/oncotarget.1908
   Dakhel S, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.7
   De Ponti A, 2015, CANCER LETT, V369, P396, DOI 10.1016/j.canlet.2015.09.005
   Deng RY, 2017, ONCOTARGET, V8, P104216, DOI 10.18632/oncotarget.22185
   Deng RY, 2017, BBA-GEN SUBJECTS, V1861, P1065, DOI 10.1016/j.bbagen.2017.02.024
   Dhumale SS, 2015, IUBMB LIFE, V67, P361, DOI 10.1002/iub.1379
   Ding QX, 2005, BBA-MOL CELL RES, V1746, P18, DOI 10.1016/j.bbamcr.2005.08.006
   El-Far Ali H, 2016, Curr Drug Discov Technol, V13, P123
   El-Far AHAM, 2018, ONCOL LETT, V15, P4627, DOI 10.3892/ol.2018.7902
   Emberley ED, 2004, BREAST CANCER RES, V6, P153, DOI 10.1186/bcr816
   Esumi S, 2018, BIOL PHARM BULL, V41, P1727, DOI 10.1248/bpb.b18-00392
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Fallon MT, 2013, BRIT J ANAESTH, V111, P105, DOI 10.1093/bja/aet208
   Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2
   Flohr AM, 2001, ANTICANCER RES, V21, P3881
   Fuentes MK, 2007, DIS COLON RECTUM, V50, P1230, DOI 10.1007/s10350-006-0850-5
   Furtek SL, 2016, ACS CHEM BIOL, V11, P308, DOI 10.1021/acschembio.5b00945
   Gao H, 2018, CANCER LETT, V439, P91, DOI 10.1016/j.canlet.2018.07.034
   Gong W, 2013, ONCOL REP, V30, P1249, DOI 10.3892/or.2013.2595
   Grotterod I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-241
   Haase-Kohn C, 2014, BIOCHEM BIOPH RES CO, V446, P143, DOI 10.1016/j.bbrc.2014.02.126
   Haase-Kohn C, 2011, BIOCHEM BIOPH RES CO, V413, P494, DOI 10.1016/j.bbrc.2011.08.132
   He M, 2011, EMBO REP, V12, P358, DOI 10.1038/embor.2011.28
   Hermani A, 2005, EXP CELL RES, V312, P184, DOI 10.1016/j.yexcr.2005.10.013
   Herwig N, 2016, BIOCHEM BIOPH RES CO, V477, P963, DOI 10.1016/j.bbrc.2016.07.009
   Herwig N, 2016, J CELL MOL MED, V20, P825, DOI 10.1111/jcmm.12808
   Huang EH, 2004, J AM COLL SURGEONS, V199, pS18
   Huang ML, 2018, INT J ONCOL, V53, P1481, DOI 10.3892/ijo.2018.4502
   Huang ZC, 2015, SCI REP-UK, V5, DOI 10.1038/srep12807
   Hudson BI, 2008, FASEB J, V22, P1572, DOI 10.1096/fj.07-9909com
   Hudson BI, 2018, ANNU REV MED, V69, P349, DOI 10.1146/annurev-med-041316-085215
   Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200
   Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919
   Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394
   Iizuka K, 2008, ENDOCR J, V55, P617, DOI 10.1507/endocrj.K07E-110
   Inada M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216358
   Iotzova-Weiss G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120971
   Ishibashi Y, 2013, HORM METAB RES, V45, P387, DOI 10.1055/s-0032-1331204
   Iwamura M, 2016, EXP DERMATOL, V25, P235, DOI 10.1111/exd.12899
   Jikuzono T, 2013, INT J ONCOL, V42, P1858, DOI 10.3892/ijo.2013.1879
   Jin QE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019375
   Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631
   Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681
   Kim JY, 2008, INT J ONCOL, V33, P493, DOI 10.3892/ijo_00000032
   KO' SY, 2017, ONCOL LETT, V13, P3328, DOI 10.3892/ol.2017.5809
   Ko SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110542
   Korwar AM, 2012, BIOCHEM BIOPH RES CO, V419, P490, DOI 10.1016/j.bbrc.2012.02.039
   Kuniyasu H, 2003, INT J CANCER, V104, P722, DOI 10.1002/ijc.11016
   Lan JQ, 2019, CANCER RES, V79, P146, DOI 10.1158/0008-5472.CAN-18-0014
   Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810
   Leclerc E, 2007, J BIOL CHEM, V282, P31317, DOI 10.1074/jbc.M703951200
   Lee YM, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/210604
   Li AC, 2017, MOL CARCINOGEN, V56, P972, DOI 10.1002/mc.22563
   Li YM, 2017, MOL CELL BIOCHEM, V431, P1, DOI 10.1007/s11010-017-2968-2
   Li YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035016
   Lim JH, 2014, ANTICANCER RES, V34, P4087
   Lin J, 2004, J BIOL CHEM, V279, P34071, DOI 10.1074/jbc.M405419200
   Lin J, 2001, J BIOL CHEM, V276, P35037, DOI 10.1074/jbc.M104379200
   Lin J, 2010, J BIOL CHEM, V285, P27487, DOI 10.1074/jbc.M110.155382
   Lin LG, 2012, J CANCER RES CLIN, V138, P11, DOI 10.1007/s00432-011-1067-0
   Liu QQ, 2019, ONCOL REP, V42, P817, DOI 10.3892/or.2019.7176
   Liu YY, 2017, ONCOL LETT, V14, P525, DOI 10.3892/ol.2017.6198
   Lopez-Diez R, 2013, GENOME BIOL EVOL, V5, P2420, DOI 10.1093/gbe/evt188
   Mardente S, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/512027
   Mardente S, 2012, ONCOL REP, V28, P2285, DOI 10.3892/or.2012.2058
   Matou-Nasri S, 2017, BBA-MOL BASIS DIS, V1863, P2808, DOI 10.1016/j.bbadis.2017.07.011
   Matsuoka H, 2012, ANTICANCER RES, V32, P1805
   Medapati MR, 2015, THYROID, V25, P514, DOI 10.1089/thy.2014.0257
   Mercado-Pimentel ME, 2015, FEBS LETT, V589, P2388, DOI 10.1016/j.febslet.2015.07.010
   Mizumoto S, 2012, J BIOL CHEM, V287, P18985, DOI 10.1074/jbc.M111.313437
   Mook ORF, 2004, BBA-REV CANCER, V1705, P69, DOI 10.1016/j.bbcan.2004.09.006
   Munesue S, 2013, FOOD FUNCT, V4, P1835, DOI 10.1039/c2fo30359k
   Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161
   Onyeagucha BC, 2013, EXP CELL RES, V319, P2081, DOI 10.1016/j.yexcr.2013.05.009
   Pang XA, 2017, ONCOL REP, V37, P831, DOI 10.3892/or.2016.5317
   Park IH, 2004, ARCH PHARM RES, V27, P615, DOI 10.1007/BF02980159
   Pellegrini L, 2017, ONCOTARGET, V8, P22649, DOI 10.18632/oncotarget.15152
   Peng T, 2015, MOL MED REP, V12, P7531, DOI 10.3892/mmr.2015.4402
   Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4
   Peyroux J, 2006, PATHOL BIOL, V54, P405, DOI 10.1016/j.patbio.2006.07.006
   Pusterla T, 2013, HEPATOLOGY, V58, P363, DOI 10.1002/hep.26395
   Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y
   Ranganathan Kannan, 2014, J Oral Maxillofac Pathol, V18, P229, DOI 10.4103/0973-029X.140762
   Reed JC, 1998, BBA-BIOENERGETICS, V1366, P127, DOI 10.1016/S0005-2728(98)00108-X
   Riuzzi F, 2007, AM J PATHOL, V171, P947, DOI 10.2353/ajpath.2007.070049
   Rohatgi RA, 2015, ONCOGENE, V34, P5352, DOI 10.1038/onc.2014.454
   Rohatgi RA, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1030539
   SAARIALHOKERE UK, 1992, J CLIN INVEST, V90, P1952, DOI 10.1172/JCI116073
   Sajadimajd S, 2018, CURR CANCER DRUG TAR, V18, P538, DOI 10.2174/1568009617666171002144228
   Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200
   Sasahira T, 2008, CANCER SCI, V99, P1806, DOI 10.1111/j.1349-7006.2008.00894.x
   Sasahira T, 2011, ONCOL REV, V5, P49, DOI 10.1007/s12156-010-0065-9
   Satyamoorthy K, 2000, CELL GROWTH DIFFER, V11, P467
   Sharaf H, 2015, BBA-MOL BASIS DIS, V1852, P429, DOI 10.1016/j.bbadis.2014.12.009
   Sharma S, 2016, CELL TISSUE RES, V365, P357, DOI 10.1007/s00441-016-2389-7
   Sheikh MS, 2003, CELL CYCLE, V2, P550, DOI 10.4161/cc.2.6.566
   Shubbar E, 2012, BREAST CANCER RES TR, V134, P71, DOI 10.1007/s10549-011-1920-5
   Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005
   Smolarczyk R, 2012, POSTEP HIG MED DOSW, V66, P913, DOI 10.5604/17322693.1021108
   Song TY, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4824371
   Su ZL, 2015, IMMUNOBIOLOGY, V220, P539, DOI 10.1016/j.imbio.2014.12.009
   Taccioli C, 2009, GASTROENTEROLOGY, V136, P953, DOI 10.1053/j.gastro.2008.11.039
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Takada M, 2004, HEPATO-GASTROENTEROL, V51, P928
   Takeuchi A, 2013, CANCER SCI, V104, P740, DOI 10.1111/cas.12133
   Takino J, 2012, WORLD J GASTROENTERO, V18, P1781, DOI 10.3748/wjg.v18.i15.1781
   Tan B, 2018, BIOCHEM BIOPH RES CO, V495, P78, DOI 10.1016/j.bbrc.2017.10.071
   Tang CH, 2012, CANCER LETT, V322, P98, DOI 10.1016/j.canlet.2012.02.014
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang Q, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/713859
   Thomas SJ, 2015, BRIT J CANCER, V113, P365, DOI 10.1038/bjc.2015.233
   Tian T, 2017, ONCOTARGET, V8, P24964, DOI 10.18632/oncotarget.15329
   Tong XM, 2009, P NATL ACAD SCI USA, V106, P21660, DOI 10.1073/pnas.0911316106
   Torres I, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068434, 10.1371/journal.pone.0072480]
   Voigtlaender M, 2019, HAMOSTASEOLOGIE, V39, P67, DOI 10.1055/s-0039-1677796
   Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729
   Wan SG, 2011, INT J CANCER, V129, P331, DOI 10.1002/ijc.25688
   Wang CH, 2012, CANCER BIOL THER, V13, P727, DOI 10.4161/cbt.20555
   Wang HY, 2014, INT J MED SCI, V11, P841, DOI 10.7150/ijms.8128
   Wang X, 2015, IN VITRO CELL DEV-AN, V51, P204, DOI 10.1007/s11626-014-9823-5
   Win MTT, 2012, EXP DIABETES RES, DOI 10.1155/2012/894605
   Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535-7163.MCT-17-0646
   Wu R, 2015, EXP CELL RES, V334, P228, DOI 10.1016/j.yexcr.2015.04.008
   Wu TS, 2015, ONCOGENE, V34, P1207, DOI 10.1038/onc.2014.43
   Wu XJ, 2013, MOL CELL BIOCHEM, V380, P249, DOI 10.1007/s11010-013-1680-0
   Xu X, 2014, SCAND J IMMUNOL, V79, P386, DOI 10.1111/sji.12174
   Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0
   Yan W, 2012, HEPATOLOGY, V55, P1863, DOI 10.1002/hep.25572
   Yang T, 2017, STEM CELLS, V35, P325, DOI 10.1002/stem.2472
   Yaser AM, 2012, INT J MOL SCI, V13, P5982, DOI 10.3390/ijms13055982
   Yin CG, 2013, BREAST CANCER RES TR, V142, P297, DOI 10.1007/s10549-013-2737-1
   Zhang F, 2011, J SURG RES, V171, P871, DOI 10.1016/j.jss.2010.04.027
   Zhang JL, 2018, INT J ONCOL, V53, P659, DOI 10.3892/ijo.2018.4420
   Zhang QB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2883-z
   Zhang QY, 2015, ONCOL REP, V33, P1630, DOI 10.3892/or.2015.3782
   Zhu LY, 2015, CANCER LETT, V357, P527, DOI 10.1016/j.canlet.2014.12.012
   Zhu WD, 2016, TUMOR BIOL, V37, P12241, DOI 10.1007/s13277-016-5096-9
   Zill H, 2001, BIOCHEM BIOPH RES CO, V288, P1108, DOI 10.1006/bbrc.2001.5901
NR 153
TC 14
Z9 15
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2020
VL 21
IS 10
DI 10.3390/ijms21103613
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LW7GO
UT WOS:000539312100209
PM 32443845
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lu, WC
   Saha, A
   Yan, WP
   Garrison, K
   Lamb, C
   Pandey, R
   Irani, S
   Lodi, A
   Lu, XY
   Tiziani, S
   Zhang, YJ
   Georgiou, G
   DiGiovanni, J
   Stone, E
AF Lu, Wei-Cheng
   Saha, Achinto
   Yan, Wupeng
   Garrison, Kendra
   Lamb, Candice
   Pandey, Renu
   Irani, Seema
   Lodi, Alessia
   Lu, Xiyuan
   Tiziani, Stefano
   Zhang, Yan Jessie
   Georgiou, George
   DiGiovanni, John
   Stone, Everett
TI Enzyme-mediated depletion of serum L-Met abrogates prostate cancer
   growth via multiple mechanisms without evidence of systemic toxicity
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE prostate cancer; L-methionine depletion; hMGL
ID DIETARY METHIONINE RESTRICTION; VIRUS 40-TRANSFORMED HUMAN;
   CYSTATHIONINE-GAMMA-LYASE; RECOMBINANT METHIONINASE; DNA
   METHYLTRANSFERASE; COLORECTAL-CANCER; CELL-CYCLE; IN-VITRO; INHIBITION;
   TUMORS
AB Extensive studies in prostate cancer and other malignancies have revealed that L-methionine (L-Met) and its metabolites play a critical role in tumorigenesis. Preclinical and clinical studies have demonstrated that systemic restriction of serum L-Met, either via partial dietary restriction or with bacterial L-Met-degrading enzymes exerts potent antitumor effects. However, administration of bacterial L-Met-degrading enzymes has not proven practical for human therapy because of problems with immunogenicity. As the human genome does not encode L-Met-degrading enzymes, we engineered the human cystathionine-gamma-lyase (hMGL-4.0) to catalyze the selective degradation of L-Met. At therapeutically relevant dosing, hMGL-4.0 reduces serum L-Met levels to >75% for >72 h and significantly inhibits the growth of multiple prostate cancer allografts/xenografts without weight loss or toxicity. We demonstrate that in vitro, hMGL-4.0 causes tumor cell death, associated with increased reactive oxygen species, S-adenosyl-methionine depletion, global hypomethylation, induction of autophagy, and robust poly(ADP-ribose) polymerase (PARP) cleavage indicative of DNA damage and apoptosis.
C1 [Lu, Wei-Cheng; Garrison, Kendra; Lamb, Candice; Irani, Seema; Georgiou, George] Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.
   [Saha, Achinto; DiGiovanni, John] Univ Texas Austin, Div Pharmacol & Toxicol, Dell Pediat Res Inst, Austin, TX 78712 USA.
   [Yan, Wupeng; Zhang, Yan Jessie; Georgiou, George; Stone, Everett] Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.
   [Pandey, Renu; Lodi, Alessia; Lu, Xiyuan; Tiziani, Stefano] Univ Texas Austin, Dept Nutr Sci, Austin, TX 78712 USA.
   [Zhang, Yan Jessie; Georgiou, George] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA.
   [Georgiou, George; DiGiovanni, John; Stone, Everett] Univ Texas Dell Med Sch, Dept Oncol, LiveSTRONG Canc Inst, Austin, TX 78712 USA.
RP Georgiou, G (corresponding author), Univ Texas Austin, Dept Chem Engn, Austin, TX 78712 USA.; DiGiovanni, J (corresponding author), Univ Texas Austin, Div Pharmacol & Toxicol, Dell Pediat Res Inst, Austin, TX 78712 USA.; Georgiou, G; Stone, E (corresponding author), Univ Texas Austin, Dept Mol Biosci, Austin, TX 78712 USA.; Georgiou, G (corresponding author), Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA.; Georgiou, G; DiGiovanni, J; Stone, E (corresponding author), Univ Texas Dell Med Sch, Dept Oncol, LiveSTRONG Canc Inst, Austin, TX 78712 USA.
EM gg@che.utexas.edu; john.digiovanni@austin.utexas.edu;
   stonesci@utexas.edu
OI Pandey, Renu/0000-0003-1892-2495
FU College of Natural Sciences at The University of Texas at Austin; Office
   of the Executive Vice President and Provost at The University of Texas
   at Austin; Institute for Cellular and Molecular Biology at The
   University of Texas at Austin; US Department of EnergyUnited States
   Department of Energy (DOE) [DE-AC02-06CH11357]; National Institutes of
   HealthUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [R01 GM104896, GM125882, CA154754,
   CA189623]; Cancer Prevention and Research Institute of Texas [RP180590];
   Welch FoundationThe Welch Foundation [F-1778]
FX Instrumentation and technical assistance for this work were provided by
   the Macromolecular Crystallography Facility, with financial support from
   the College of Natural Sciences, the Office of the Executive Vice
   President and Provost, and the Institute for Cellular and Molecular
   Biology at The University of Texas at Austin. We acknowledge the support
   of the Advanced Light Source and the Advanced Photon Source (operated
   for the US Department of Energy Office of Science by Argonne National
   Laboratory and supported by the US Department of Energy under Contract
   DE-AC02-06CH11357) for X-ray crystallographic data collection. This work
   was supported by grants funded by the National Institutes of Health R01
   GM104896 and GM125882 (to Y.J.Z.), CA154754 (to G.G. and E.S.), and
   CA189623 (to J.D., G.G., and E.S.); the Cancer Prevention and Research
   Institute of Texas RP180590 (to E.S. and J.D.); and the Welch Foundation
   F-1778 (to Y.J.Z.).
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Afonine P., 2005, CCP4 NEWSLETTER, V42
   Aki T, 2012, J NEURO-ONCOL, V109, P115, DOI 10.1007/s11060-012-0873-9
   ASHE H, 1974, BIOCHEM BIOPH RES CO, V57, P417, DOI 10.1016/0006-291X(74)90947-4
   AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0
   BACKLUND PS, 1981, J BIOL CHEM, V256, P1533
   BACKLUND PS, 1982, J BIOL CHEM, V257, P4196
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   BREILLOUT F, 1990, J NATL CANCER I, V82, P1628, DOI 10.1093/jnci/82.20.1628
   Caballero F, 2010, J BIOL CHEM, V285, P18528, DOI 10.1074/jbc.M109.099333
   Cacan E, 2013, J MOL EVOL, V76, P4, DOI 10.1007/s00239-013-9540-9
   Casero RA, 2018, NAT REV CANCER, V18, P681, DOI 10.1038/s41568-018-0050-3
   Chaturvedi S, 2018, BIOCHEM PHARMACOL, V154, P170, DOI 10.1016/j.bcp.2018.05.003
   Cole MF, 2011, CURR OPIN CHEM BIOL, V15, P399, DOI 10.1016/j.cbpa.2011.03.005
   Cole MF, 2011, J MOL EVOL, V72, P193, DOI 10.1007/s00239-010-9415-2
   Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   Desjobert C, 2015, EPIGENETICS-US, V10, P82, DOI 10.1080/15592294.2014.995542
   Dieterle F, 2006, ANAL CHEM, V78, P4281, DOI 10.1021/ac051632c
   Durando X, 2008, NUTR CANCER, V60, P23, DOI 10.1080/01635580701525877
   Durando X, 2010, ONCOLOGY-BASEL, V78, P205, DOI 10.1159/000313700
   Eipel C, 2010, WORLD J GASTROENTERO, V16, P6046, DOI 10.3748/wjg.v16.i48.6046
   Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Epner DE, 2002, NUTR CANCER, V42, P158, DOI 10.1207/S15327914NC422_2
   Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200
   Fialova B, 2016, ONCOL REP, V36, P2365, DOI 10.3892/or.2016.5000
   Forney LA, 2017, OBESITY, V25, P730, DOI 10.1002/oby.21806
   Galldiks N, 2010, J NEURO-ONCOL, V96, P231, DOI 10.1007/s11060-009-9953-x
   Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3
   Gay F, 2017, CANCER MED-US, V6, P1437, DOI 10.1002/cam4.1086
   GOSEKI N, 1995, JPN J CANCER RES, V86, P484, DOI 10.1111/j.1349-7006.1995.tb03082.x
   HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133, DOI 10.1073/pnas.71.4.1133
   Headd JJ, 2012, ACTA CRYSTALLOGR D, V68, P381, DOI 10.1107/S0907444911047834
   Hendrikx JJMA, 2017, ONCOLOGIST, V22, P1212, DOI 10.1634/theoncologist.2017-0167
   HOFFMAN RM, 1976, P NATL ACAD SCI USA, V73, P1523, DOI 10.1073/pnas.73.5.1523
   HOFFMAN RM, 1980, P NATL ACAD SCI-BIOL, V77, P7306, DOI 10.1073/pnas.77.12.7306
   HOFFMAN RM, 1979, P NATL ACAD SCI USA, V76, P1313, DOI 10.1073/pnas.76.3.1313
   Hu J, 2009, INT J CANCER, V124, P1700, DOI 10.1002/ijc.24104
   Igarashi K, 2018, CANCER LETT, V417, P168, DOI 10.1016/j.canlet.2017.12.028
   Jeon H, 2016, ONCOTARGET, V7, P67223, DOI 10.18632/oncotarget.11615
   Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   Kaste SC, 2017, J NUCL MED, V58, P419, DOI 10.2967/jnumed.116.178640
   Kawaguchi K, 2017, ONCOTARGET, V8, P85516, DOI 10.18632/oncotarget.20231
   Kleiner HE, 2002, CARCINOGENESIS, V23, P1667, DOI 10.1093/carcin/23.10.1667
   Kokkinakis DM, 2001, CANCER RES, V61, P4017
   KREIS W, 1978, CANCER RES, V38, P2259
   KREIS W, 1980, CANCER RES, V40, P634
   KREIS W, 1979, CANCER TREAT REP, V63, P1069
   Kwon HM, 2017, ONCOTARGET, V8, P89005, DOI 10.18632/oncotarget.21642
   Lodi A, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0024-z
   Lu XY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03108-x
   MEGOSH L, 1995, CANCER RES, V55, P4205
   Miousse IR, 2018, CARCINOGENESIS, V39, P1117, DOI 10.1093/carcin/bgy085
   Murakami T, 2017, ONCOTARGET, V8, P35630, DOI 10.18632/oncotarget.15823
   Okuda S, 2008, NUCLEIC ACIDS RES, V36, pW423, DOI 10.1093/nar/gkn282
   Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X
   Palanichamy K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00257
   Poirson-Bichat F, 2000, CLIN CANCER RES, V6, P643
   Qian XJ, 2015, ONCOTARGET, V6, P5134, DOI 10.18632/oncotarget.3016
   READ RJ, 1988, J APPL CRYSTALLOGR, V21, P490, DOI 10.1107/S002188988800562X
   Roder C, 2015, DRUGS R&D, V15, P13, DOI 10.1007/s40268-015-0083-y
   Saha A, 2016, ONCOTARGET, V7, P25194, DOI 10.18632/oncotarget.7535
   Saha A, 2014, CANCER PREV RES, V7, P627, DOI 10.1158/1940-6207.CAPR-13-0420
   Saha A, 2010, CANCER PREV RES, V3, P953, DOI 10.1158/1940-6207.CAPR-09-0247
   Schneider KM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020308
   Sinha R, 2014, PROSTATE, V74, P1663, DOI 10.1002/pros.22884
   STERN PH, 1984, J CELL PHYSIOL, V119, P29, DOI 10.1002/jcp.1041190106
   STERN PH, 1983, J CELL PHYSIOL, V117, P9, DOI 10.1002/jcp.1041170103
   STERN PH, 1984, IN VITRO CELL DEV B, V20, P663
   Stone E, 2012, ACS CHEM BIOL, V7, P1822, DOI 10.1021/cb300335j
   Strekalova E, 2015, CLIN CANCER RES, V21, P2780, DOI 10.1158/1078-0432.CCR-14-2792
   Sumner LW, 2007, METABOLOMICS, V3, P211, DOI 10.1007/s11306-007-0082-2
   Sun QX, 2009, J BIOL CHEM, V284, P3076, DOI 10.1074/jbc.M805459200
   Tan YY, 1999, CLIN CANCER RES, V5, P2157
   Tang BNT, 2008, RADIOTHER ONCOL, V89, P270, DOI 10.1016/j.radonc.2008.07.029
   TENEYCK LF, 1973, ACTA CRYSTALLOGR A, VA 29, P183, DOI 10.1107/S0567739473000458
   Thivat E, 2009, ANTICANCER RES, V29, P5235
   Thomas T, 2003, J CELL MOL MED, V7, P113, DOI 10.1111/j.1582-4934.2003.tb00210.x
   Tiziani S, 2008, ANAL BIOCHEM, V377, P16, DOI 10.1016/j.ab.2008.01.037
   Toth G, 2005, J UROLOGY, V173, P66, DOI 10.1097/01.ju.0000148326.71981.44
   Vitale G, 2017, MOL ONCOL, V11, P1007, DOI 10.1002/1878-0261.12070
   Wang ZX, 2019, NAT MED, V25, P825, DOI 10.1038/s41591-019-0423-5
   Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749
   Wishart DS, 2007, NUCLEIC ACIDS RES, V35, pD521, DOI 10.1093/nar/gkl923
   Xiong H, 2009, J CELL MOL MED, V13, P3668, DOI 10.1111/j.1582-4934.2009.00661.x
   Yan WP, 2017, BIOCHEMISTRY-US, V56, P876, DOI 10.1021/acs.biochem.6b01172
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang ZJ, 2004, CLIN CANCER RES, V10, P2131, DOI 10.1158/1078-0432.CCR-03-0068
   Ye JZ, 2018, WORLD J GASTROENTERO, V24, P2468, DOI 10.3748/wjg.v24.i23.2468
   Zhang YJ, 2009, INT J COLORECTAL DIS, V24, P629, DOI 10.1007/s00384-009-0664-8
NR 91
TC 11
Z9 12
U1 1
U2 3
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
EI 1091-6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 9
PY 2020
VL 117
IS 23
BP 13000
EP 13011
DI 10.1073/pnas.1917362117
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MG3PN
UT WOS:000545946100009
PM 32434918
OA hybrid, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Pileczki, V
   Pop, L
   Braicu, C
   Budisan, L
   Morar, GB
   Monroig-Bosque, PD
   Sandulescu, RV
   Berindan-Neagoe, I
AF Pileczki, Valentina
   Pop, Laura
   Braicu, Cornelia
   Budisan, Livia
   Morar, Gabriela Bolba
   Monroig-Bosque, Paloma del C.
   Sandulescu, Robert V.
   Berindan-Neagoe, Ioana
TI Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in
   triple-negative breast cancer cells
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE apoptosis; double gene silencing; mut-p53; TNF; TNBC
ID NECROSIS-FACTOR-ALPHA; NF-KAPPA-B; COLORECTAL-CANCER; TRAIL; THERAPY;
   INFLAMMATION; COMBINATION; ACTIVATION; EXPRESSION; RECEPTOR
AB Apoptosis is the major downregulated pathway in cancer. Simultaneous inhibition using specific small interfering RNA (siRNA) of two key player genes, p53 and TNF, is an interesting and feasible strategy when it comes to investigating various molecular pathways and biological processes in triple-negative breast cancer (TNBC), which is one of the most aggressive and therapeutically unresponsive forms of breast cancers. Our present research focuses on evaluating the impact of double p53-siRNA and TNF-siRNA knockdown at a cellular level, and also evaluating cell proliferation, apoptosis, induction of autophagy, and gene expression by using reverse transcription polymerase chain reaction array approaches. Simultaneous inhibition of p53 and TNF in Hs578T TNBC human cell line revealed a panel of up-and downregulated genes involved in apoptosis. Furthermore, the effects of double gene knockdown were validated in a second TNBC cell line, MDA-MB-231, by using reverse transcription polymerase chain reaction TaqMan assay. All our findings help in understanding the functional mechanisms of extrinsic apoptosis, cell signaling pathways, and the mechanisms involved in tumor cell survival, growth, and death in TNBC.
C1 [Pileczki, Valentina; Pop, Laura; Braicu, Cornelia; Budisan, Livia; Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, 23 Gh Marinescu St, Cluj Napoca 400337, Romania.
   [Pileczki, Valentina; Sandulescu, Robert V.] Iuliu Hatieganu Univ Med & Pharm, Dept Analyt Chem, Fac Pharm, Cluj Napoca, Romania.
   [Morar, Gabriela Bolba] Oncol Inst Prof Dr Ion Chiricuta, Dept Senol, Cluj Napoca, Romania.
   [Monroig-Bosque, Paloma del C.] Univ Puerto Rico, Sch Med, San Juan, PR 00936 USA.
   [Berindan-Neagoe, Ioana] Iuliu Hatieganu Univ Med & Pharm, MedFuture Res Ctr Adv Med, Cluj Napoca, Romania.
   [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom & Expt Pathol, Cluj Napoca, Romania.
RP Berindan-Neagoe, I (corresponding author), Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom Biomed & Translat Med, 23 Gh Marinescu St, Cluj Napoca 400337, Romania.
EM ioananeagoe29@gmail.com
RI Săndulescu, Robert/C-4953-2011; Berindan-Neagoe, Ioana/AAH-9854-2019;
   Pop, Laura/AAY-8349-2020; Pileczki, Valentina/ABB-6273-2020
OI Pop, Laura/0000-0002-5806-0220; 
FU "Iuliu Hatieganu" University of Medicine and Pharmacy, The Research
   Center for Functional Genomics, Biomedicine and Translational Medicine,
   Cluj-Napoca, Romania [1492/4/28.01.2014]; POSCCE [709/2010]
FX Valentina Pileczki's work was partially financed by "Iuliu Hatieganu"
   University of Medicine and Pharmacy, The Research Center for Functional
   Genomics, Biomedicine and Translational Medicine, Cluj-Napoca, Romania,
   internal grant no: 1492/4/28.01.2014.; This work was financed by the
   POSCCE 709/2010 grant with the title, "Clinical and economical impact of
   proteom and transcriptom molecular profiling in neoadjuvant therapy of
   triple negative breast cancer (BREASTIMPACT)".
CR Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284
   Alkim C, 2009, DIGEST DIS SCI, V54, P1979, DOI 10.1007/s10620-008-0554-x
   Anders C, 2008, ONCOLOGY-NY, V22, P1233
   Arnedos M, 2012, THER ADV MED ONCOL, V4, P195, DOI 10.1177/1758834012444711
   Braicu C, 2013, MOL CELL BIOCHEM, V381, P61, DOI 10.1007/s11010-013-1688-5
   Buchsbaum DJ, 2003, CLIN CANCER RES, V9, P3731
   Cai W, 2008, BIOCHEM INSIGHTS, V1, P5
   Choi J, 2007, J KOREAN MED SCI, V22, pS17, DOI 10.3346/jkms.2007.22.S.S17
   Cooks T, 2014, MOL CELL, V56, P611, DOI 10.1016/j.molcel.2014.11.018
   Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022
   Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013
   Fakhr E, 2016, CANCER GENE THER, V23, P73, DOI 10.1038/cgt.2016.4
   Fox JL, 2015, CANCER RES, V75, P1345, DOI 10.1158/0008-5472.CAN-14-1340
   Fu QS, 2016, MOL CELL, V61, P602, DOI 10.1016/j.molcel.2016.01.009
   Garimella SV, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3645
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   Hellwig CT, 2012, MOL CANCER THER, V11, P3, DOI 10.1158/1535-7163.MCT-11-0434
   Keane MM, 2000, BREAST CANCER RES TR, V64, P211, DOI 10.1023/A:1006458407515
   Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172
   Lamy L, 2013, CANCER CELL, V23, P435, DOI 10.1016/j.ccr.2013.02.017
   Li HH, 2015, SCI REP-UK, V5, DOI 10.1038/srep10244
   Mitsuhashi J, 2005, PATHOL INT, V55, P113, DOI 10.1111/j.1440-1827.2005.01802.x
   Ozbayer C, 2015, INFLAMM RES, V64, P775, DOI 10.1007/s00011-015-0859-0
   Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1
   Pastor DM, 2010, DIS COLON RECTUM, V53, P257, DOI 10.1007/DCR.0b013e3181c522c7
   Peddi PF, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/217185
   Pileczki V, 2013, INT J MOL SCI, V14, P411, DOI 10.3390/ijms14010411
   Rahman M, 2009, ADV CANCER RES, V103, P43, DOI 10.1016/S0065-230X(09)03003-6
   Rahman M, 2009, BREAST CANCER RES TR, V113, P217, DOI 10.1007/s10549-008-9924-5
   Ramachandran PV, 2012, ASIAN PAC J CANCER P, V13, P2445, DOI 10.7314/APJCP.2012.13.6.2445
   Schneider G, 2010, ONCOGENE, V29, P2795, DOI 10.1038/onc.2010.46
   Tatsumi Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.568
   Varfolomeev E, 2016, CYTOKINE
   Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517
   Wang YD, 2016, ONCOL LETT, V11, P984, DOI 10.3892/ol.2015.4003
   Weisz L, 2007, CANCER RES, V67, P2396, DOI 10.1158/0008-5472.CAN-06-2425
   Yerbes R, 2011, CLIN TRANSL ONCOL, V13, P839, DOI 10.1007/s12094-011-0744-4
   Yu MX, 2013, CANCER RES, V73, P4061, DOI 10.1158/0008-5472.CAN-12-3946
   Yu ZR, 2012, J MAMMARY GLAND BIOL, V17, P59, DOI 10.1007/s10911-012-9246-4
NR 39
TC 7
Z9 7
U1 0
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2016
VL 9
BP 6921
EP 6933
DI 10.2147/OTT.S110719
PG 13
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA EB7ZJ
UT WOS:000387610000001
PM 27956838
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Yang, ZL
   Ghoorun, RA
   Fan, XJ
   Wu, PH
   Bai, Y
   Li, JZ
   Chen, H
   Wang, L
   Wang, JP
AF Yang, Zuli
   Ghoorun, Roshan Ara
   Fan, Xinjuan
   Wu, Peihuang
   Bai, Yang
   Li, Jizheng
   Chen, Hao
   Wang, Lei
   Wang, Jianping
TI High expression of Beclin-1 predicts favorable prognosis for patients
   with colorectal cancer
SO CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
LA English
DT Article
ID AUTOPHAGY; PANITUMUMAB; EFFICACY; PROTEIN; GROWTH; GENE; KRAS
AB Purpose: Beclin-1 is an autophagy gene. It promotes the formation of the autophagic vesicle as well as plays an essential role in guarding the cells against chromosomal instability. Overexpression of Beclin-1 has been reported to predict a favorable survival in various cancers. However, little is known about its prognostic significance in colorectal cancer.
   Methods and materials: A total of three hundred and sixty-three (363) colorectal tissues from colorectal cancer (CRC) patients were collected. Tissue micro-arrays and immunohistochemistry were used to investigate the expression and prognostic significance of Beclin-1 in CRC. The associations among Beclin-1 expression, clinicopathological parameters and prognosis were evaluated.
   Results: Bectin-1 had a higher expression in CRC tissues than in normal tissues. A high expression of Beclin-1 was positively correlated with gender (P=0.027), histological grade (P=0.003), pM status (P=0.003) and clinical stage (P=0.024). Patients with a high Beclin-1 expression, when compared to those with a lower expression had both a better overall survival (OS, P=0.006) and disease-free survival (DFS. P=0.008). In the pT3 subgroup, Beclin-1 was also found to be a good prognostic indicator (P < 0.05). Multivariate analysis showed a high expression of Bectin-1 was indeed a positive independent prognostic factor of OS and DES for CRC patients (P < 0.05).
   Conclusion: Our results demonstrated that a high expression of Beaclin-1 correlated with a better overall survival and disease-free survival, thus serving as a favorable independent prognostic marker in CRC. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Yang, Zuli; Ghoorun, Roshan Ara; Bai, Yang; Li, Jizheng; Chen, Hao] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Gastrointestinal Surg, Guangdong Gastrointestinal & Anal Hosp, Guangzhou 510655, Guangdong, Peoples R China.
   [Fan, Xinjuan; Wu, Peihuang] Sun Yat Sen Univ, Gastrointestinal Inst, Guangzhou 510655, Guangdong, Peoples R China.
   [Wang, Lei; Wang, Jianping] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colon & Rectum Surg, Guangdong Gastrointestinal & Anal Hosp, Guangzhou 510655, Guangdong, Peoples R China.
RP Wang, JP (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colon & Rectum Surg, Guangdong Gastrointestinal & Anal Hosp, 26 Yuancun Erheng Rd, Guangzhou 510655, Guangdong, Peoples R China.
EM wangjply01@sohu.com
FU Natural Science Fund Committee of Guangdong Province, China
   [10251008901000008]
FX This study was supported by the grant from Natural Science Fund
   Committee of Guangdong Province, China (No. 10251008901000008).
CR Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Baynes RD, 2009, AM J THER, V16, P554, DOI 10.1097/MJT.0b013e318199fa17
   Birgisson H, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-438
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Chifenti Barbara, 2013, Clin Exp Reprod Med, V40, P33, DOI 10.5653/cerm.2013.40.1.33
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8
   Fan XJ, 2012, BRIT J CANCER, V106, P1735, DOI 10.1038/bjc.2012.82
   Geng QR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045968
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Huang L, 2013, PATHOL ONCOL RES, V19, P771, DOI 10.1007/s12253-013-9642-0
   Kelley RK, 2011, J NATL COMPR CANC NE, V9, P1293, DOI 10.6004/jnccn.2011.0105
   Kim HS, 2011, PATHOL RES PRACT, V207, P247, DOI 10.1016/j.prp.2011.02.007
   Koneri K, 2007, ANTICANCER RES, V27, P1453
   Lao VV, 2013, TRANSL ONCOL, V6, P458, DOI 10.1593/tlo.13238
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Lin HX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060516
   Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4
   Roesly HB, 2012, AM J PHYSIOL-GASTR L, V302, pG864, DOI 10.1152/ajpgi.00340.2011
   Tsuchihara K, 2009, CANCER LETT, V278, P130, DOI 10.1016/j.canlet.2008.09.040
   Wan XB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031989
   Xia P, 2013, TUMOR BIOL, V34, P3303, DOI 10.1007/s13277-013-1049-8
   Yang XQ, 2011, ASIAN PAC J CANCER P, V12, P1251
   Zlobec I, 2007, BRIT J CANCER, V96, P793, DOI 10.1038/sj.bjc.6603619
NR 28
TC 34
Z9 38
U1 0
U2 7
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 2210-7401
EI 2210-741X
J9 CLIN RES HEPATOL GAS
JI Clin. Res. Hepatol. Gastroenterol.
PD FEB
PY 2015
VL 39
IS 1
BP 98
EP 106
DI 10.1016/j.clinre.2014.06.014
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA CB3SV
UT WOS:000349549800014
PM 25130795
DA 2022-04-25
ER

PT J
AU Li, LD
   Sun, HF
   Liu, XX
   Gao, SP
   Jiang, HL
   Hu, X
   Jin, W
AF Li, Liang-Dong
   Sun, He-Fen
   Liu, Xue-Xiao
   Gao, Shui-Ping
   Jiang, Hong-Lin
   Hu, Xin
   Jin, Wei
TI Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation,
   Metastasis by Mediating Mitochondrial Metabolism
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; COMPLEX-I; TARGET;
   GENES; TUMORIGENESIS; ACTIVATION; AUTOPHAGY; MOTILITY; PATHWAY
AB Despite advances in basic and clinical research, metastasis remains the leading cause of death in breast cancer patients. Genetic abnormalities in mitochondria, including mutations affecting complex I and oxidative phosphorylation, are found in breast cancers and might facilitate metastasis. Genes encoding complex I components have significant breast cancer prognostic value. In this study, we used quantitative proteomic analyses to compare a highly metastatic cancer cell line and a parental breast cancer cell line; and observed that NDUFB9, an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (complex I), was down-regulated in highly metastatic breast cancer cells. Furthermore, we demonstrated that loss of NDUFB9 promotes MDA-MB-231 cells proliferation, migration, and invasion because of elevated levels of mtROS, disturbance of the NAD(+)/NADH balance, and depletion of mtDNA. We also showed that, the Akt/mTOR/p70S6K signaling pathway and EMT might be involved in this mechanism. Thus, our findings contribute novel data to support the hypothesis that misregulation of mitochondrial complex I NADH dehydrogenase activity can profoundly enhance the aggressiveness of human breast cancer cells, suggesting that complex I deficiency is a potential and important biomarker for further basic research or clinical application.
C1 [Li, Liang-Dong; Sun, He-Fen; Gao, Shui-Ping; Jiang, Hong-Lin; Hu, Xin; Jin, Wei] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai 200030, Peoples R China.
   [Li, Liang-Dong; Sun, He-Fen; Gao, Shui-Ping; Jiang, Hong-Lin; Jin, Wei] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200030, Peoples R China.
   [Liu, Xue-Xiao] Lishui Cent Hosp, Dept Radiotherapy, Lishui 323000, Zhejiang, Peoples R China.
RP Jin, W (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, Shanghai 200030, Peoples R China.
EM weijin7207@126.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81272923]; Program for New Century Excellent
   Talents in UniversityProgram for New Century Excellent Talents in
   University (NCET) [NCET-12-0127]
FX This work was supported by National Natural Science Foundation of China
   (81272923), Program for New Century Excellent Talents in University
   (NCET-12-0127) http://www.nsfc.gov.cn/publish/portal1/. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bhat TA, 2015, DRUG DISCOV TODAY, V20, P635, DOI 10.1016/j.drudis.2015.03.001
   Brieger K, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13659
   Cannito S, 2010, ANTIOXID REDOX SIGN, V12, P1383, DOI 10.1089/ars.2009.2737
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Cheon H, 2010, ONCOL REP, V23, P779, DOI 10.3892/or_00000698
   Cichon MA, 2014, ONCOTARGET, V5, P2827, DOI 10.18632/oncotarget.1940
   Cui HH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-110
   Dong LF, 2014, PROG MOL BIOL TRANSL, V127, P211, DOI 10.1016/B978-0-12-394625-6.00008-8
   Fiorini C, 2015, BBA-MOL CELL RES, V1853, P549, DOI 10.1016/j.bbamcr.2014.12.016
   Gu JZ, 1996, GENOMICS, V35, P6, DOI 10.1006/geno.1996.0316
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Haack TB, 2012, J MED GENET, V49, P83, DOI 10.1136/jmedgenet-2011-100577
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Imanishi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023401
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jiang HL, 2015, ONCOTARGET, V2015
   Lamouille S, 2012, J CELL SCI, V125, P1259, DOI 10.1242/jcs.095299
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039
   Li XY, 2014, ONCOTARGET, V5, P788, DOI 10.18632/oncotarget.1772
   Lin HC, 2013, J PROTEOME RES, V12, P3423, DOI 10.1021/pr400273z
   Lin X, 1999, HUM HERED, V49, P75, DOI 10.1159/000022848
   Moro L, 2009, CELL DEATH DIFFER, V16, P571, DOI 10.1038/cdd.2008.178
   Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043
   Porporato PE, 2011, FRONT PHARMACOL, V2, DOI 10.3389/fphar.2011.00049
   Ren W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096816
   Santidrian AF, 2014, DNA REPAIR, V23, P79, DOI 10.1016/j.dnarep.2014.08.006
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264
   Schroder K, 2014, ANTIOXID REDOX SIGN, V20, P2043, DOI 10.1089/ars.2013.5633
   Sun H, 2013, ANTI-CANCER AGENT ME, V13, P1048, DOI 10.2174/18715206113139990130
   Tan AS, 2014, BBA-GEN SUBJECTS, V1840, P1454, DOI 10.1016/j.bbagen.2013.10.016
   Tochhawng L, 2013, MITOCHONDRION, V13, P246, DOI 10.1016/j.mito.2012.08.002
   Ushio-Fukai M, 2008, CANCER LETT, V266, P37, DOI 10.1016/j.canlet.2008.02.044
   van Horssen R, 2013, CELL MOL LIFE SCI, V70, P2175, DOI 10.1007/s00018-012-1249-1
   WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X
   Wang F, 2015, DRUG DES DEV THER, V9, P537, DOI 10.2147/DDDT.S73689
   Wang L, 2008, CANCER EPIDEM BIOMAR, V17, P3558, DOI 10.1158/1055-9965.EPI-08-0434
   Yang J, 2013, NEOPLASMA, V60, P364, DOI 10.4149/neo_2013_048
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Yu M, 2013, TRANSL RES, V161, P165, DOI 10.1016/j.trsl.2012.10.011
   Zhou W, 2015, CANCER LETT, V360, P68, DOI 10.1016/j.canlet.2015.02.004
NR 42
TC 36
Z9 40
U1 4
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 7
PY 2015
VL 10
IS 12
AR e0144441
DI 10.1371/journal.pone.0144441
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CZ1YS
UT WOS:000366902700122
PM 26641458
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Zhou, Y
   Sha, ZH
   Yang, Y
   Wu, SM
   Chen, H
AF Zhou, Yun
   Sha, Zhenghong
   Yang, Yong
   Wu, Shuimei
   Chen, Hong
TI lncRNA NEAT1 regulates gastric carcinoma cell proliferation, invasion
   and apoptosis via the miR-500a-3p/XBP-1 axis
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE long non-coding RNA nuclear paraspeckle assembly transcript 1;
   microRNA-500A; X-box binding protein-1; proliferation; invasion;
   apoptosis
ID ENDOPLASMIC-RETICULUM STRESS; CANCER STATISTICS; EXPRESSION;
   IRE1-ALPHA/XBP-1; CLASSIFICATION; ACTIVATION; PROGNOSIS; XBP-1
AB Gastric cancer is a serious malignant tumor. Despite progression in gastric cancer research in recent years, the specific molecular mechanism underlying the pathogenesis of the disease is not completely understood. Long non-coding RNA (lncRNA) nuclear paraspeckle assembly transcript 1 (NEAT1) affects the proliferation and metastasis of multiple types of tumor cells in colorectal cancer and breast cancer but its specific role in gastric cancer requires further investigation. The aim of the present study was to analyze the role of NEAT1 in gastric cancer. The expression of endoplasmic reticulum stress marker proteins and apoptosis-related proteins in gastric cancer tissue and cell lines was analyzed using western blotting. The targeting relationship of NEAT1 and miR-500a-3p was analyzed using dual-luciferase reporter assay. Cell proliferation was analyzed using CCK8 assay and colony formation assay while cell invasion was detected using Transwell assay. Cell apoptosis was analyzed using TUNEL staining and LC3 expression through immunofluorescent staining (IF). The results showed that lncRNA NEAT1-overexpression gastric cancer cells were established to determine its effects on cell proliferation, invasion, apoptosis, autophagy and endoplasmic reticulum stress. Subsequently, microRNA (miR)-500a was overexpressed in lncRNA NEAT1-overexpression cells. Compared with the vector group, lncRNA NEAT1 overexpression significantly inhibited gastric cancer cell proliferation and invasion, but significantly promoted cell apoptosis. Furthermore, the results indicated that lncRNA NEAT1 targeted and downregulated the expression of miR-500a-3p, and miR-500a-3p targeted X-box binding protein-1 (XBP-1) mRNA. lncRNA NEAT1 overexpression-mediated inhibition of gastric cancer cell proliferation and invasion was significantly reversed by miR-500a-3p overexpression. Furthermore, compared with the vector group, the expression levels of endoplasmic reticulum stress-related proteins (XBP-1S/XBP-1U ratio and 78-kDa glucose-regulated protein) and apoptosis-related proteins (Bax and cleaved-caspase-3) were significantly upregulated by lncRNA NEAT1 overexpression; however, miR-500a-3p overexpression reversed lncRNA NEAT1 overexpression-mediated effects on protein expression. The present study demonstrated that lncRNA NEAT1 inhibited gastric cancer cell proliferation and invasion, and promoted apoptosis by regulating the miR-500a-3p/XBP-1 axis.
C1 [Zhou, Yun; Chen, Hong] Southeast Univ, Med Coll, Zhongda Hosp, Dept Gastroenterol, 87 Dingjiaqiao Rd, Nanjing 210000, Jiangsu, Peoples R China.
   [Sha, Zhenghong] Wuhu 1 Peoples Hosp, Dept Gen Surg, Wuhu 241000, Anhui, Peoples R China.
   [Yang, Yong; Wu, Shuimei] Wuhu 1 Peoples Hosp, Dept Gastroenterol, Wuhu 241000, Anhui, Peoples R China.
RP Chen, H (corresponding author), Southeast Univ, Med Coll, Zhongda Hosp, Dept Gastroenterol, 87 Dingjiaqiao Rd, Nanjing 210000, Jiangsu, Peoples R China.
EM zkw201912@126.com
CR Bao LL, 2018, CELL PHYSIOL BIOCHEM, V47, P2046, DOI 10.1159/000491472
   Barez SR, 2020, J CELL COMMUN SIGNAL, V14, P403, DOI 10.1007/s12079-020-00562-7
   Bertuccio P, 2009, INT J CANCER, V125, P666, DOI 10.1002/ijc.24290
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chern YJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1687-x
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Davies MPA, 2008, INT J CANCER, V123, P85, DOI 10.1002/ijc.23479
   Ding Li-Hua, 2004, Acta Genetica Sinica, V31, P380
   Duplan E, 2013, J CELL SCI, V126, P2124, DOI 10.1242/jcs.127340
   Guo YT, 2017, BIOMED PHARMACOTHER, V91, P13, DOI 10.1016/j.biopha.2017.04.018
   Hsu HT, 2018, CLIN CHIM ACTA, V479, P66, DOI 10.1016/j.cca.2018.01.001
   Hsu SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102518
   Hu H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03083
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Larsen AC, 2016, ACTA OPHTHALMOL, V94, P1, DOI 10.1111/aos.13100
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Li RT, 2017, CANCER LETT, V386, P123, DOI 10.1016/j.canlet.2016.10.032
   Liao XH, 2018, NEOPLASMA, V65, P673, DOI 10.4149/neo_2018_170516N355
   Liu ZY, 2018, MOL MED REP, V18, P2689, DOI 10.3892/mmr.2018.9259
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez J, 2015, BRIT J CANCER, V112, P957, DOI 10.1038/bjc.2015.85
   Mohamed E, 2017, CANCER IMMUNOL IMMUN, V66, P1069, DOI 10.1007/s00262-017-2019-6
   Mowers EE, 2018, FEBS J, V285, P1751, DOI 10.1111/febs.14388
   Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649
   Rona KA, 2017, J SURG ONCOL, V115, P371, DOI 10.1002/jso.24533
   Saito Y, 2019, NATURE, V569, P275, DOI 10.1038/s41586-019-1126-2
   Sepulveda D, 2018, RHEUMATOLOGY, V57, P1021, DOI 10.1093/rheumatology/key021
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Travis WD, 2013, J CLIN ONCOL, V31, P992, DOI 10.1200/JCO.2012.46.9270
   Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007
   Wang M, 2013, EUR J CANCER, V49, P2010, DOI 10.1016/j.ejca.2012.12.017
   Yu HG, 2008, INT J CANCER, V122, P433, DOI 10.1002/ijc.23049
   Zhang L, 2015, ONCOTARGET, V6, P2483, DOI 10.18632/oncotarget.2800
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7
   Zhao YF, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170837
   Zhu XM, 2012, INT J BIOCHEM CELL B, V44, P1097, DOI 10.1016/j.biocel.2012.03.018
NR 37
TC 1
Z9 1
U1 3
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUL
PY 2021
VL 24
IS 1
AR 503
DI 10.3892/mmr.2021.12142
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA SF2DS
UT WOS:000652572300001
PM 33982777
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Quintana, M
   Bilbao, A
   Comas-Barcelo, J
   Bujons, J
   Triola, G
AF Quintana, Mireia
   Bilbao, Ana
   Comas-Barcelo, Julia
   Bujons, Jordi
   Triola, Gemma
TI Identification of benzo[cd]indol-2(1H)-ones as novel Atg4B inhibitors
   via a structure-based virtual screening and a novel AlphaScreen assay
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Atg4B; LC3; Autophagy; AlphaScreen
ID CYSTEINE PROTEASE ENZYME; PARTICLE MESH EWALD; CRYSTAL-STRUCTURE;
   ACCURATE DOCKING; SMALL MOLECULES; CANCER-CELLS; AUTOPHAGY; DISCOVERY;
   DESIGN; GLIDE
AB Targeting autophagy is a promising therapeutic strategy for cancer treatment. As a result, the identification of novel autophagy inhibitors is an emerging field of research. Herein, we report the development of a novel AlphaScreen HTS assay that combined with a MS-based assay and a structure-based high-throughput virtual screening have enabled the identification of benzo[cd]indol-2(1H)-one as a novel scaffold that targets Atg4B. Thus, an initial screening campaign led to the identification of NSC126353 and NSC611216 bearing a chlorohydrin moiety. Structural-activity relationship analysis of the initial hits provided an optimized lead, compound 33, bearing a 7-aminobenzo[cd]indol-2-[1H]-one scaffold and a propyl group replacing the chlorine. Inhibition of autophagy was also investigated in cells by measuring LC3-II and p62 protein levels. Moreover, the synergistic effect of 33 combined with oxaliplatin resulted in an enhanced cell death in the human colorectal adenocarcinoma cell line HT-29. We are convinced that the developed AlphaScreen and MS-based assays can be key tools enabling the high-throughput identification of novel Atg4B inhibitors. Moreover, the aminobenzo[cd]indol-2-[1H]-one scaffold represents a novel chemotype for the further development of small molecule inhibitors of Atg4B. (C) 2019 Elsevier Masson SAS. All rights reserved.
C1 [Quintana, Mireia; Bilbao, Ana; Comas-Barcelo, Julia; Bujons, Jordi; Triola, Gemma] IQAC CSIC, Dept Biol Chem, Inst Adv Chem Catalonia, Barcelona, Spain.
RP Triola, G (corresponding author), IQAC CSIC, Dept Biol Chem, Inst Adv Chem Catalonia, Barcelona, Spain.
EM gemma.triola@iqac.csic.es
RI Triola, Gemma/E-2235-2017; Quintana, Mireia/AAD-6864-2020; Bujons,
   Jordi/AAA-9283-2020
OI Triola, Gemma/0000-0003-4177-8989; Bujons, Jordi/0000-0003-2944-2905
FU Ministerio de Economia and CompetitividadSpanish Government
   [CTQ2013-44334-P]; FPI fellowshipSpanish Government [BES-2014-070026]
FX We would like to thank Karel Hernandez and Roman Bonet for his support
   in the expression and purification of recombinant proteins and Kristina
   Lang for her help in the preparation of N-(His)<INF>6</INF>-LC3B-L123C.
   We are grateful to the Ministerio de Economia and Competitividad for
   supporting this work with a research grant CTQ2013-44334-P) and FPI
   fellowship to A.B.G (BES-2014-070026).
CR Acker M.G., 2014, PERSPECT SCI, V1, P56, DOI DOI 10.1016/J.PISC.2013.12.001
   Akin David L., 2014, AIAA Space 2014 Conference and Exposition
   Aldrich C, 2017, J MED CHEM, V60, P2165, DOI 10.1021/acs.jmedchem.7b00229
   Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562
   Baell JB, 2010, J MED CHEM, V53, P2719, DOI 10.1021/jm901137j
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bortnik S, 2016, ONCOTARGET, V7, P66970, DOI 10.18632/oncotarget.11408
   Bosc D, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29900-x
   Bowers K. J., 2006, P ACM IEEE C SUP SC0, P43
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   CHINI M, 1990, TETRAHEDRON LETT, V31, P4661, DOI 10.1016/S0040-4039(00)97701-3
   Cleenewerck M, 2016, EUR J MED CHEM, V123, P631, DOI 10.1016/j.ejmech.2016.07.073
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117
   EVANS DJ, 1985, J CHEM PHYS, V83, P4069, DOI 10.1063/1.449071
   Fleming A, 2011, NAT CHEM BIOL, V7, P9, DOI 10.1038/NCHEMBIO.500
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fu Y., 2018, AUTOPHAGY, P1
   Girouard S, 2005, J AM CHEM SOC, V127, P559, DOI 10.1021/ja045742x
   Glickman JF, 2002, J BIOMOL SCREEN, V7, P3, DOI 10.1177/108705710200700102
   Gryshchenko AA, 2015, J ENZYM INHIB MED CH, V30, P126, DOI 10.3109/14756366.2014.895718
   Halgren TA, 2004, J MED CHEM, V47, P1750, DOI 10.1021/jm030644s
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   He SY, 2018, J MED CHEM, V61, P4656, DOI 10.1021/acs.jmedchem.7b01019
   HSIANG YH, 1989, MOL PHARMACOL, V36, P371
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P384, DOI 10.1038/nrclinonc.2011.82
   Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263
   Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356
   Krautler V, 2001, J COMPUT CHEM, V22, P501, DOI 10.1002/1096-987X(20010415)22:5<501::AID-JCC1021>3.0.CO;2-V
   Kumanomidou T, 2006, J MOL BIOL, V355, P612, DOI 10.1016/j.jmb.2005.11.018
   KURASAWA Y, 1983, CHEM PHARM BULL, V31, P3897
   Kurdi A, 2017, BIOCHEM PHARMACOL, V138, P150, DOI 10.1016/j.bcp.2017.06.119
   Li J., 2018, POLYM B, V2, P1, DOI DOI 10.1109/TVCG.2018.2882449
   Li M, 2012, AUTOPHAGY, V8, P401, DOI 10.4161/auto.18777
   Li M, 2011, J BIOL CHEM, V286, P7327, DOI 10.1074/jbc.M110.199059
   Liu JJ, 2003, BIOORG MED CHEM LETT, V13, P2465, DOI 10.1016/S0960-894X(03)00488-8
   Liu PF, 2018, THERANOSTICS, V8, P830, DOI 10.7150/thno.22012
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200
   MARTYNA GJ, 1992, J CHEM PHYS, V97, P2635, DOI 10.1063/1.463940
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Metcalf DJ, 2012, EXP NEUROL, V238, P22, DOI 10.1016/j.expneurol.2010.11.003
   Nakatogawa H, 2012, AUTOPHAGY, V8, P177, DOI 10.4161/auto.8.2.18373
   Nguyen TG, 2014, ASSAY DRUG DEV TECHN, V12, P176, DOI 10.1089/adt.2013.561
   Olsson MHM, 2011, J CHEM THEORY COMPUT, V7, P525, DOI 10.1021/ct100578z
   Pagadala Nataraj S, 2017, Biophys Rev, V9, P91, DOI 10.1007/s12551-016-0247-1
   Pasquier B, 2015, J MED CHEM, V58, P376, DOI 10.1021/jm5013352
   Pieper U, 2011, NUCLEIC ACIDS RES, V39, pD465, DOI 10.1093/nar/gkq1091
   Qiu ZX, 2016, ACS MED CHEM LETT, V7, P802, DOI 10.1021/acsmedchemlett.6b00208
   RIDEOUT D, 1993, J CELL BIOCHEM, V51, P446, DOI 10.1002/jcb.2400510410
   Robke L, 2017, ANGEW CHEM INT EDIT, V56, P8153, DOI 10.1002/anie.201703738
   Rothe K., 2014, BLOOD
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Satoo K, 2009, EMBO J, V28, P1341, DOI 10.1038/emboj.2009.80
   Schrodinger, 2016, REL 2016 4 PRIM
   Schrodinger, 2016, REL 2016 4 PROT PREP
   Schrodinger, 2016, REL 2016 4 MAESTR DE
   Schrodinger, 2016, REL 2016 4 GLID
   Schrodinger, 2016, REL 2016 4 MAESTR
   Schrodinger, 2016, REL 2016 4
   Schrodinger, 2016, REL 2016 4 VIRT SCRE
   Schrodinger, 2016, REL 2016 4 LIGPREP
   Schrodinger, 2016, IND FIT DOCK PROT 20
   Schrodinger, 2016, REL 2016 4 DESM MIL
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shaaban MA, 2009, J CHEM RES, P574, DOI 10.3184/030823409X12510409044803
   Shu CW, 2011, J BIOMOL SCREEN, V16, P174, DOI 10.1177/1087057110392996
   Shu CW, 2010, AUTOPHAGY, V6, P936, DOI 10.4161/auto.6.7.13075
   Sugawara K, 2005, J BIOL CHEM, V280, P40058, DOI 10.1074/jbc.M509158200
   Tanida I, 2004, J BIOL CHEM, V279, P36268, DOI 10.1074/jbc.M401461200
   Tariq S, 2018, EUR J MED CHEM, V143, P542, DOI 10.1016/j.ejmech.2017.11.064
   Triola G, 2015, TETRAHEDRON, V71, P387, DOI 10.1016/j.tet.2014.10.057
   TUCKERMAN M, 1992, J CHEM PHYS, V97, P1990, DOI 10.1063/1.463137
   VARNEY MD, 1992, J MED CHEM, V35, P663, DOI 10.1021/jm00082a006
   Vezenkov L, 2015, BIOORGAN MED CHEM, V23, P3237, DOI 10.1016/j.bmc.2015.04.064
   Wang T, 2015, J MED CHEM, V58, P3025, DOI 10.1021/jm501586m
   Wang Z, 2016, PHYS CHEM CHEM PHYS, V18, P12964, DOI 10.1039/c6cp01555g
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Wu G, 2003, J BIOMOL SCREEN, V8, P694, DOI 10.1177/1087057103260050
   WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xu DQ, 2017, SLAS DISCOV, V22, P338, DOI 10.1177/1087057116639202
   Xue XQ, 2016, J MED CHEM, V59, P1565, DOI 10.1021/acs.jmedchem.5b01511
   Yu ZQ, 2012, AUTOPHAGY, V8, P883, DOI 10.4161/auto.19652
   Zhang C, 2017, J CHEM INF MODEL, V57, P355, DOI 10.1021/acs.jcim.6b00551
NR 91
TC 7
Z9 7
U1 1
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD SEP 15
PY 2019
VL 178
BP 648
EP 666
DI 10.1016/j.ejmech.2019.05.086
PG 19
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA IQ3PR
UT WOS:000480664100047
PM 31226656
DA 2022-04-25
ER

PT J
AU He, LW
   Han, JJ
   Li, BW
   Huang, L
   Ma, K
   Chen, Q
   Liu, XZ
   Bao, L
   Liu, HW
AF He, Luwei
   Han, Junjie
   Li, Baowei
   Huang, Li
   Ma, Ke
   Chen, Quan
   Liu, Xinzhong
   Bao, Li
   Liu, Hongwei
TI Identification of a new cyathane diterpene that induces mitochondrial
   and autophagy-dependent apoptosis and shows a potent in vivo
   anti-colorectal cancer activity
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Fungal diterpene; Cyathin Q; Apoptosis; Autophagy; ATG5 cleavage; ROS
ID BAX-INDEPENDENT APOPTOSIS; DRUG-RESISTANCE; CELL-DEATH; BCL-2; FAMILY;
   ATG5; P53; INHIBITION; ALCOHOLS
AB Diterpenes has been reported to possess multiple bioactivities consisting of anti-microbial and anti-inflammatory properties. This study reveals a new cyathane-type diterpene (cyathin Q) from the culture of the fungus Cyathus africanus by bioactivity-guided separation. The structure of cyathin Q was determined based on spectroscopic measurements (NMR and MS). The bioactivity evaluation shows that cyathin Q has a strong anticancer activity against HCT116 cells and Bax-deficient HCT116 in vitro and in vivo. This compound induced hallmarks of apoptotic events in HCT116 cells, including caspase activation, cytochrome c release, poly (ADP-ribose) polymerase (PARP) cleavage, and depolarization of the mitochondrial inner transmembrane potential. This process is accompanied with the increased mitochondrial ROS, down-regulation of Bcl-2 protein, and up-regulation of Bim protein. We also observed the cleavage of autophagy-related protein ATG5 in cyathin Q-induced apoptosis. Taken together, our study identified a new fungal diterpene that exhibited anticancer activity via induction of mitochondria and autophagy-dependent apoptosis in HCT116 cells. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [He, Luwei; Han, Junjie; Ma, Ke; Liu, Xinzhong; Bao, Li; Liu, Hongwei] Chinese Acad Sci, Inst Microbiol, State Key Lab Mycol, Beijing 100101, Peoples R China.
   [Li, Baowei; Huang, Li; Chen, Quan] Chinese Acad Sci, Inst Zool, State Key Lab Biomembrane & Membrane Biotechnol, Beijing 100101, Peoples R China.
RP Liu, HW (corresponding author), Chinese Acad Sci, Inst Microbiol, State Key Lab Mycol, Beijing 100101, Peoples R China.
EM liuhw@im.ac.cn
RI Liu, Xingzhong/B-6280-2015
OI Liu, Xingzhong/0000-0002-3224-8604; Ma, Ke/0000-0002-9716-6968
FU National Nature Science FoundationNational Natural Science Foundation of
   China (NSFC) [21472233]; Ministry of Science and Technology of
   ChinaMinistry of Science and Technology, China [2014CB138304]
FX Financial supports of the National Nature Science Foundation (21472233)
   and the Ministry of Science and Technology of China (2014CB138304) are
   acknowledged. Dr. Jinwei Ren (State Key Laboratory of Mycology,
   Institute of Microbiology, Chinese Academy of Sciences) is appreciated
   for their help in measuring the NMR data. We also thank Mrs. Jing Wang
   (State Key Laboratory of Biomembrane and Membrane Biotechnology,
   Institute of Zoology, Chinese Academy of Sciences) for operating the
   flow cytometer.
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099
   Bhattacharya AK, 2015, EUR J MED CHEM, V94, P1, DOI 10.1016/j.ejmech.2015.02.054
   Chandrika BB, 2010, BIOCHEM PHARMACOL, V79, P1589, DOI 10.1016/j.bcp.2010.01.032
   Codogno P, 2006, NAT CELL BIOL, V8, P1045, DOI 10.1038/ncb1006-1045
   De Silva DD, 2013, FUNGAL DIVERS, V62, P1, DOI 10.1007/s13225-013-0265-2
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Frelek J, 1999, TETRAHEDRON-ASYMMETR, V10, P1507, DOI 10.1016/S0957-4166(99)00115-9
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Genestier AL, 2005, J CLIN INVEST, V115, P3117, DOI 10.1172/JCI22684
   GERARDS M, 1990, TETRAHEDRON-ASYMMETR, V1, P221, DOI 10.1016/S0957-4166(00)86328-4
   Goodsell DS, 2002, ONCOLOGIST, V7, P259, DOI 10.1634/theoncologist.7-3-259
   Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Han JJ, 2013, FITOTERAPIA, V84, P22, DOI 10.1016/j.fitote.2012.10.001
   Haupt S, 2003, J CELL SCI, V116, P4077, DOI 10.1242/jcs.00739
   Kamo T, 2004, BIOSCI BIOTECH BIOCH, V68, P1362, DOI 10.1271/bbb.68.1362
   Kasibhatla S, 2003, MOL CANCER THER, V2, P573
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Krzyczkowski Wojciech, 2008, Biotechnologia (Poznan), P146
   Luo S, 2007, CELL DEATH DIFFER, V14, P1247, DOI 10.1038/sj.cdd.4402149
   Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002
   Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6
   McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Olmo F, 2015, EUR J MED CHEM, V89, P683, DOI 10.1016/j.ejmech.2014.11.004
   Orrenius S, 2013, ANNU REV PHARMACOL, V53, P275, DOI 10.1146/annurev-pharmtox-011112-140210
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Shen JW, 2009, J BASIC MICROB, V49, P242, DOI 10.1002/jobm.200800102
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Simmonds P C, 2000, BMJ, V321, P531
   Tang HY, 2015, CURR MED CHEM, V22, P2375, DOI 10.2174/0929867322666150521091333
   Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x
   Vogelaar I, 2006, CANCER-AM CANCER SOC, V107, P1624, DOI 10.1002/cncr.22115
   Wilson TR, 2009, ONCOGENE, V28, P63, DOI 10.1038/onc.2008.366
   Wright DL, 2000, ORG PREP PROCED INT, V32, P307, DOI 10.1080/00304940009355934
   Young RM, 2015, EUR J MED CHEM, V93, P373, DOI 10.1016/j.ejmech.2015.02.011
   Yousefi S, 2007, CRIT REV ONCOL HEMAT, V63, P241, DOI 10.1016/j.critrevonc.2007.06.005
   Yousefi S, 2006, NAT CELL BIOL, V8, P1124, DOI 10.1038/ncb1482
NR 40
TC 23
Z9 26
U1 5
U2 43
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD MAR 23
PY 2016
VL 111
BP 183
EP 192
DI 10.1016/j.ejmech.2016.01.056
PG 10
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DG1PY
UT WOS:000371841200015
PM 26871659
DA 2022-04-25
ER

PT J
AU Cao, HX
   Miao, CF
   Sang, LN
   Huang, YM
   Zhang, R
   Sun, L
   Jiang, ZX
AF Cao, Hai-xia
   Miao, Chao-feng
   Sang, Li-na
   Huang, Yu-min
   Zhang, Ran
   Sun, Ling
   Jiang, Zhong-xing
TI Circ_0009910 promotes imatinib resistance through ULK1-induced autophagy
   by sponging miR-34a-5p in chronic myeloid leukemia
SO LIFE SCIENCES
LA English
DT Article
DE CML; Circ_0009910; MiR-34a-5p; Autophagy; ULK1
ID BREAST-CANCER CELLS; COLORECTAL-CANCER; PROLIFERATION; METASTASIS;
   SENSITIVITY; ACTIVATION; APOPTOSIS; THERAPY; TARGET; GROWTH
AB Background: The occurrence in drug resistance of chronic myeloid leukemia (CML) was accompanied by autophagy activation. Abnormal circular RNAs (circRNAs) participated in this progression. This study attempted to investigate the potential role of circ_0009910 in imatinib resistance of CML cells.
   Methods: The expression of circ_0009910 and miR-34a-5p was measured by quantitative real-time polymerase chain reaction (qRT-PCR). The characterization of circ_0009910 was investigated using oligo (dT)18 primers, Actinomycin D and RNase R. Cell viability (IC50 value) and apoptosis were assessed by Cell Counting Kit-8 (CCK8) assay and flow cytometry assay, respectively. The relative protein expression was quantified by western blot. The relationship among miR-34a-5p, circ_0009910 and ULK1 was predicted by online bioinformatics tool, and verified by dual-luciferase reporter assay and RNA immunoprecipitation (RIP).
   Results: The expression of circ_0009910 was up-regulated in the serum of imatinib-resistance CML patients and K562/R cells, and associated with unfavorable clinicopathologic features. Circ_0009910 in K562 and K562/R cells was mainly localized in the cytoplasm. Circ_0009910 knockdown inhibited cell proliferation and autophagy, but induced apoptosis in K562/R cells. Circ_0009910 targeted miR-34a-5p to regulate ULK1. MiR-34a-5p depression rescued the effects of circ_0009910 knockdown on apoptosis and autophagy in K562/R cells.
   Conclusion: Circ_0009910 accelerated imatinib-resistance in CML cells by modulating ULK1-induced autophagy via targeting miR-34a-5p, providing a potential target in imatinib resistance of CML.
C1 [Cao, Hai-xia; Sang, Li-na; Huang, Yu-min; Zhang, Ran; Sun, Ling; Jiang, Zhong-xing] Zhengzhou Univ, Dept Hematol, Affiliated Hosp 1, 1 Jianshedong Rd, Zhengzhou 450052, Henan, Peoples R China.
   [Miao, Chao-feng] Zhengzhou Univ, Dept Vasc Surg, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China.
RP Jiang, ZX (corresponding author), Zhengzhou Univ, Dept Hematol, Affiliated Hosp 1, 1 Jianshedong Rd, Zhengzhou 450052, Henan, Peoples R China.
EM liangwei16037@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81800104]
FX This work was approved by National Natural Science Foundation of China
   (81800104).
CR Alers S, 2011, AUTOPHAGY, V7, P1424, DOI 10.4161/auto.7.12.18027
   Bach M, 2011, BIOCHEM J, V440, P283, DOI 10.1042/BJ20101894
   Bonizzato A, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.81
   Carella A M, 2012, Leuk Suppl, V1, pS49, DOI 10.1038/leusup.2012.25
   Carella AM, 2018, HAEMATOLOGICA, V103, P928, DOI 10.3324/haematol.2017.182022
   Chakraborty S, 2014, FEBS LETT, V588, P549, DOI 10.1016/j.febslet.2013.11.040
   Chan EY, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.284pe51
   Chen F, 2012, J BIOCHEM MOL TOXIC, V26, P79, DOI 10.1002/jbt.20412
   Chen PH, 2018, CHEM-BIOL INTERACT, V291, P144, DOI 10.1016/j.cbi.2018.06.006
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Chopra P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014305
   Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565
   Dhakal P, 2018, FUTURE ONCOL, V14, P177, DOI 10.2217/fon-2017-0334
   Dykes IM, 2017, GENOM PROTEOM BIOINF, V15, P177, DOI 10.1016/j.gpb.2016.12.005
   Ebbesen KK, 2017, RNA BIOL, V14, P1035, DOI 10.1080/15476286.2016.1271524
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348
   Goldman JM, 2010, J CLIN ONCOL, V28, P1888, DOI 10.1200/JCO.2009.26.7757
   Gupta S, 2020, FEBS LETT, V594, P227, DOI 10.1002/1873-3468.13615
   Han SH, 2019, AUTOPHAGY, V15, P2076, DOI 10.1080/15548627.2019.1596492
   He W, 2016, INT J ONCOL, V48, P1710, DOI 10.3892/ijo.2016.3382
   Jabbour E, 2018, AM J HEMATOL, V93, P442, DOI 10.1002/ajh.25011
   Li AL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0527-8
   Li CJ, 2018, BIOL OPEN, V7, DOI 10.1242/bio.033290
   Li MS, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9681863
   Liu H, 2019, BIOCHEM BIOPH RES CO, V519, P227, DOI 10.1016/j.bbrc.2019.08.162
   Liu JH, 2018, BIOCHEM BIOPH RES CO, V504, P660, DOI 10.1016/j.bbrc.2018.08.154
   Liu J, 2016, ONCOL LETT, V12, P2065, DOI 10.3892/ol.2016.4831
   Liu M, 2018, EUR REV MED PHARMACO, V22, P8248, DOI 10.26355/eurrev_201812_16519
   Maroni P, 2017, CARCINOGENESIS, V38, P492, DOI 10.1093/carcin/bgx027
   Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839
   Ping Lei, 2019, Oncol Res, DOI 10.3727/096504018X15412701483326
   Ping L, 2019, BLOOD CELL MOL DIS, V75, P41, DOI 10.1016/j.bcmd.2018.12.006
   Pu YG, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3002-x
   Salomoni P, 2009, AUTOPHAGY, V5, P1050, DOI 10.4161/auto.5.7.9509
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Wang CY, 2018, MED SCI MONITOR, V24, P7043, DOI 10.12659/MSM.912092
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Weisberg E, 2014, ARCH TOXICOL, V88, P2233, DOI 10.1007/s00204-014-1385-5
   Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030
   Yu Y, 2012, LEUKEMIA, V26, P1752, DOI 10.1038/leu.2012.65
   Yuan DM, 2019, EUR REV MED PHARMACO, V23, P9251, DOI 10.26355/eurrev_201911_19417
   Zhang GW, 2018, BIOMED PHARMACOTHER, V97, P736, DOI 10.1016/j.biopha.2017.10.163
   Zhang Y, 2014, INT J BIOCHEM CELL B, V54, P338, DOI 10.1016/j.biocel.2013.10.009
   Zhou J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5967-8
NR 46
TC 21
Z9 22
U1 2
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD FEB 15
PY 2020
VL 243
AR 117255
DI 10.1016/j.lfs.2020.117255
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KK8OR
UT WOS:000512996200014
PM 31923418
DA 2022-04-25
ER

PT J
AU Li, GW
   Chen, T
   Zhu, YX
   Xiao, XY
   Bu, JY
   Huang, ZW
AF Li, Guowei
   Chen, Tao
   Zhu, Yingxian
   Xiao, Xiaoyu
   Bu, Juyuan
   Huang, Zongwen
TI MiR-103 alleviates autophagy and apoptosis by regulating SOX2 in
   LPS-injured PC12 cells and SCI rats
SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE Apoptosis; Autophagy; MAPK/ERK and JAK/STAT -pathway; MiR-103; SOX2;
   Spinal cord injury
ID SPINAL-CORD-INJURY; NEURAL STEM-CELLS; SIGNALING PATHWAYS;
   COLORECTAL-CANCER; PANCREATIC-CANCER; MICRORNAS; EXPRESSION; KINASE;
   ROLES; STAT3
AB Objective(s): Recent studies revealed that microRNAs (miRNAs) may play crucial roles in the responses and pathologic processes of spinal cord injury (SCI). This study aimed to investigate the effect and the molecular basis of miR-103 on LPS-induced injuries in PC12 cells in vitro and SCI rats in vivo.
   Materials and Methods: PC12 cells were exposed to LPS to induce cell injuries to mimic the in vitro model of SCI. The expression of miR-103 and SOX2 in PC12 cells were altered by transient transfections. Cell viability and apoptotic cell rate were measured by CCK-8 assay and flow cytometry assay. Furthermore, Western blot analysis was performed to detect the expression levels of apoptosis-and autophagy-related proteins, MAPK/ERK pathway- and JAK/STAT pathway-related proteins. In addition, we also assessed the effect of miR-103 agomir on SCI rats.
   Results: LPS exposure induced cell injuries in PC12 cells. miR-103 overexpression significantly increased cell viability, reduced cell apoptosis and autophagy, and opposite results were observed in miR-103 inhibition. miR-103 attenuated LPS-induced injuries by indirect upregulation of SOX2. SOX2 overexpression protected PC12 cells against LPS-induced injuries, while SOX2 inhibition expedited LPS-induced cell injuries. Furthermore, miR-103 overexpression inhibited MAPK/ERK pathway and JAK/STAT pathway through upregulation of SOX2. We also found that miR-103 agomir inhibited cell apoptosis and autophagy in SCI rats.
   Conclusion: This study demonstrates that miR-103 may represent a protective effect against cell apoptosis and autophagy in LPS-injured PC12 cells and SCI rats by upregulation of SOX2 expression.
C1 [Li, Guowei; Chen, Tao; Huang, Zongwen] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Spine Surg, Zhuhai 519000, Guangdong, Peoples R China.
   [Zhu, Yingxian; Xiao, Xiaoyu] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Anaesthesiol, Zhuhai 519000, Guangdong, Peoples R China.
   [Bu, Juyuan] Sun Yat Sen Univ, Affiliated Hosp 5, Dept Gastroenterol Surg, Zhuhai 519000, Guangdong, Peoples R China.
RP Huang, ZW (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 5, Dept Spine Surg, Zhuhai 519000, Guangdong, Peoples R China.
EM zwhuang0031@126.com
FU Zhuhai Science and Technology Program [20161027E030050, 20171009E030027]
FX This work was supported by Zhuhai Science and Technology Program (No.
   20161027E030050 and 20171009E030027).
CR Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004
   Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67
   Chen HY, 2012, CANCER RES, V72, P3631, DOI 10.1158/0008-5472.CAN-12-0667
   Chen S, 2014, CARCINOGENESIS, V35, P613, DOI 10.1093/carcin/bgt371
   Collins CS, 2006, P NATL ACAD SCI USA, V103, P3775, DOI 10.1073/pnas.0600040103
   Ding DF, 2012, INT ORTHOP, V36, P1087, DOI 10.1007/s00264-011-1368-6
   Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gao X, 2017, MOL ONCOL, V11, P628, DOI 10.1002/1878-0261.12055
   Genovese T, 2008, J PHARMACOL EXP THER, V325, P100, DOI 10.1124/jpet.107.131060
   GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0
   Guo XJ, 2013, J MOL NEUROSCI, V50, P453, DOI 10.1007/s12031-013-9955-1
   Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008
   Hong Z, 2014, BMB REP, V47, P500, DOI 10.5483/BMBRep.2014.47.9.212
   Hu JZ, 2013, J NEUROTRAUM, V30, P1349, DOI 10.1089/neu.2012.2748
   Hutchison ER, 2009, NEUROMOL MED, V11, P153, DOI 10.1007/s12017-009-8086-x
   Jee MK, 2012, HUM GENE THER, V23, P508, DOI 10.1089/hum.2011.121
   Jiang JX, 2015, CANCER LETT, V356, P962, DOI 10.1016/j.canlet.2014.11.007
   Kim NH, 2007, IMMUNOLOGY, V122, P607, DOI 10.1111/j.1365-2567.2007.02679.x
   Krichevsky Anna M, 2007, ScientificWorldJournal, V7, P155
   Lee BB, 2014, SPINAL CORD, V52, P110, DOI 10.1038/sc.2012.158
   Li GX, 2011, J CELL BIOCHEM, V112, P1318, DOI 10.1002/jcb.23045
   Li MH, 2015, BIOL CHEM, V396, P235, DOI 10.1515/hsz-2014-0241
   Li R, 2017, BIOMED PHARMACOTHER, V92, P952, DOI 10.1016/j.biopha.2017.05.122
   Li Z, 2015, ONCOTARGET, V6, P13914, DOI 10.18632/oncotarget.4227
   Liebscher T, 2005, ANN NEUROL, V58, P706, DOI 10.1002/ana.20627
   Liu NK, 2009, EXP NEUROL, V219, P424, DOI 10.1016/j.expneurol.2009.06.015
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Miyagi S, 2008, FEBS LETT, V582, P2811, DOI 10.1016/j.febslet.2008.07.011
   Moncini S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020038
   Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702
   Nakanishi K, 2010, SPINAL CORD, V48, P192, DOI 10.1038/sc.2009.89
   Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171
   Nieto-Diaz M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00053
   Ning B, 2014, INT J BIOL SCI, V10, P997, DOI 10.7150/ijbs.9058
   Park JK, 2016, J CELL BIOL, V215, P667, DOI 10.1083/jcb.201604032
   Parra P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013005
   Peng H, 2015, INVEST OPHTH VIS SCI, V56, P2069
   Pevny LH, 2010, INT J BIOCHEM CELL B, V42, P421, DOI 10.1016/j.biocel.2009.08.018
   Thoennissen NH, 2009, CANCER RES, V69, P5876, DOI 10.1158/0008-5472.CAN-09-0536
   Trajkovski M, 2011, NATURE, V474, P649, DOI 10.1038/nature10112
   Tsuda M, 2011, BRAIN, V134, P1127, DOI 10.1093/brain/awr025
   Xie HM, 2009, DIABETES, V58, P1050, DOI 10.2337/db08-1299
   Xu Z, 2006, LIFE SCI, V79, P1895, DOI 10.1016/j.lfs.2006.06.023
   Yamauchi K, 2006, J NEUROCHEM, V96, P1060, DOI 10.1111/j.1471-4159.2005.03559.x
   Yunta M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034534
   Zhang HY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-130
   Zhou Y, 2014, CELL MOL NEUROBIOL, V34, P1151, DOI 10.1007/s10571-014-0090-5
NR 48
TC 19
Z9 22
U1 0
U2 11
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 -
   445, MASHHAD, 00000, IRAN
SN 2008-3866
EI 2008-3874
J9 IRAN J BASIC MED SCI
JI Iran. J. Basic Med. Sci.
PD MAR
PY 2018
VL 21
IS 3
BP 292
EP 300
DI 10.22038/ijbms.2018.25980.6392
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GB0EO
UT WOS:000428718100009
PM 29511496
DA 2022-04-25
ER

PT J
AU Menconi, A
   Marzo, T
   Massai, L
   Pratesi, A
   Severi, M
   Petroni, G
   Antonuzzo, L
   Messori, L
   Pillozzi, S
   Cirri, D
AF Menconi, Alessio
   Marzo, Tiziano
   Massai, Lara
   Pratesi, Alessandro
   Severi, Mirko
   Petroni, Giulia
   Antonuzzo, Lorenzo
   Messori, Luigi
   Pillozzi, Serena
   Cirri, Damiano
TI Anticancer effects against colorectal cancer models of
   chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles
SO BIOMETALS
LA English
DT Article
DE PLGA&#8211; PEG nanoparticles; Auranofin; Anticancer complexes;
   Colorectal cancer
AB Chloro(triethylphosphine)gold(I), (Et3PAuCl hereafter), is an Auranofin (AF)-related compound showing very similar biological and pharmacological properties. Like AF, Et3PAuCl exhibits potent antiproliferative properties in vitro toward a variety of cancer cell lines and is a promising anticancer drug candidate. We wondered whether Et3PAuCl encapsulation might lead to an improved pharmacological profile also considering the likely reduction of unwanted side-reactions that are responsible for adverse effects and for drug inactivation. Et3PAuCl was encapsulated in biocompatible PLGA-PEG nanoparticles (NPs) and the new formulation evaluated in colorectal HCT-116 cancer cells in comparison to the free gold complex. Notably, encapsulated Et3PAuCl (nano-Et3PAuCl hereafter) mostly retains the cellular properties of the free gold complex and elicits even greater cytotoxic effects in colorectal cancer (CRC) cells, mediated by apoptosis and autophagy. Moreover, a remarkable inhibition of two crucial signaling pathways, i.e. ERK and AKT, by nano-Et3PAuCl, was clearly documented. The implications of these findings are discussed.
C1 [Menconi, Alessio; Petroni, Giulia; Pillozzi, Serena] Univ Florence, Dept Expt & Clin Med, Viale GB Morgagni 50, I-50134 Florence, Italy.
   [Marzo, Tiziano] Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy.
   [Massai, Lara; Severi, Mirko; Messori, Luigi] Univ Florence, Dept Chem Schiff, Lab Met Med MetMed, Via Lastruccia 3, I-50019 Sesto Fiorentino, Italy.
   [Pratesi, Alessandro; Cirri, Damiano] Univ Pisa, Dept Chem & Ind Chem DCCI, Via G Moruzzi 13, I-56124 Pisa, Italy.
   [Antonuzzo, Lorenzo] Azienda Osped Univ Careggi, SC Oncol Med 1, Florence, Italy.
   [Pillozzi, Serena] DIVAL Toscana SRL, Via Madonna del Piano 6, I-50019 Sesto Fiorentino, Italy.
RP Pillozzi, S (corresponding author), Univ Florence, Dept Expt & Clin Med, Viale GB Morgagni 50, I-50134 Florence, Italy.; Marzo, T (corresponding author), Univ Pisa, Dept Pharm, Via Bonanno Pisano 6, I-56126 Pisa, Italy.; Cirri, D (corresponding author), Univ Pisa, Dept Chem & Ind Chem DCCI, Via G Moruzzi 13, I-56124 Pisa, Italy.
EM tiziano.marzo@unipi.it; serena.pillozzi@unifi.it;
   damiano.cirri@dcci.unipi.it
RI Pratesi, Alessandro/AAB-4169-2019; Severi, Mirko/J-2508-2012
OI Pratesi, Alessandro/0000-0002-9553-9943; Severi,
   Mirko/0000-0003-1511-6762; MARZO, TIZIANO/0000-0002-2567-3637; messori,
   luigi/0000-0002-9490-8014; Antonuzzo, Lorenzo/0000-0003-3349-5604;
   MASSAI, LARA/0000-0003-0765-1802
FU AIRC (Associazione Italiana per la Ricerca sul Cancro)Fondazione AIRC
   per la ricerca sul cancro [22294, 23852]; AIRC (Associazione Italiana
   per la Ricerca sul Cancro)Fondazione AIRC per la ricerca sul cancro;
   ECRF (Ente Cassa di Risparmio di Firenze) [AIRCECRF19650]; Beneficentia
   Stiftung (Vaduz) [BEN2019/48, BEN2020/34]; University of Pisa under the
   ``PRA-Progetti di Ricerca di Ateneo'' Institutional Research Grants
   [PRA_2020_58]
FX D.C. gratefully acknowledges AIRC (Associazione Italiana per la Ricerca
   sul Cancro) for the financial support (one-year Fellowship for
   Italy-Project Code: 22294 and 2-year fellowship for Italy-Project Code:
   23852). L.M. and A.P. gratefully acknowledge AIRC (Associazione Italiana
   per la Ricerca sul Cancro) and ECRF (Ente Cassa di Risparmio di Firenze)
   for the financial support (AIRCECRF19650). Authors thank CSGI
   (Department of Chemistry, University of Florence) for DLS experiments.
   T.M. and A.P. thank University of Pisa (Rating Ateneo 2019 and 2020).
   T.M. and A.P. thank Beneficentia Stiftung (Vaduz) for supporting
   projects BEN2019/48 and BEN2020/34, respectively. This work is also
   supported by the University of Pisa under the ``PRA-Progetti di Ricerca
   di Ateneo'' Institutional Research Grants-Project no. PRA_2020_58
   ``Agenti innovative e nanosistemi per target molecolari nell'ambito
   dell'oncologia di precisione'' to TM.
CR Afshari M, 2014, J MICROENCAPSUL, V31, P239, DOI 10.3109/02652048.2013.834991
   Anari E, 2016, ARTIF CELL NANOMED B, V44, P1410, DOI 10.3109/21691401.2015.1029633
   BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5
   Chen WJ, 2014, JOVE-J VIS EXP, DOI 10.3791/51639
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Cirri D, 2017, DALTON T, V46, DOI 10.1039/c6dt03867k
   Comfort KK, 2011, ACS NANO, V5, P10000, DOI 10.1021/nn203785a
   Fan C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.132
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   Lei H, 2018, ONCOL REP, V40, P3447, DOI 10.3892/or.2018.6740
   Li H, 2016, ONCOTARGET, V7, P3548, DOI 10.18632/oncotarget.6516
   Magherini Francesca, 2018, Oncotarget, V9, P28042, DOI 10.18632/oncotarget.25556
   Marzo T, 2019, ACS MED CHEM LETT, V10, P656, DOI 10.1021/acsmedchemlett.9b00007
   Marzo T, 2018, CHEMMEDCHEM, V13, P2448, DOI 10.1002/cmdc.201800498
   Marzo T, 2017, ACS MED CHEM LETT, V8, P997, DOI 10.1021/acsmedchemlett.7b00162
   Merlino A, 2017, CHEM-EUR J, V23, P6942, DOI 10.1002/chem.201605801
   Micale N, 2014, J INORG BIOCHEM, V141, P79, DOI 10.1016/j.jinorgbio.2014.08.001
   MIRABELLI CK, 1985, CANCER RES, V45, P32
   Park H, 2008, SMALL, V4, P192, DOI 10.1002/smll.200700807
   Pillozzi S, 2018, BRIT J CANCER, V118, P200, DOI 10.1038/bjc.2017.392
   Poursharifi M, 2019, INORGANICS, V7, DOI 10.3390/inorganics7010002
   Pratesi A, 2018, INORG CHEM, V57, P10507, DOI 10.1021/acs.inorgchem.8b02177
   Pratesi A, 2014, J INORG BIOCHEM, V136, P161, DOI 10.1016/j.jinorgbio.2014.01.009
   Roder C, 2015, DRUGS R&D, V15, P13, DOI 10.1007/s40268-015-0083-y
   Scalcon V, 2018, FREE RADICAL BIO MED, V127, P62, DOI 10.1016/j.freeradbiomed.2018.03.043
   SUTTON BM, 1972, J MED CHEM, V15, P1095, DOI 10.1021/jm00281a001
   Tian J, 2017, J MATER CHEM B, V5, P6049, DOI [10.1039/C7TB01370A, 10.1039/c7tb01370a]
   Tolbatov I, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00812
   Zoppi C, 2020, DALTON T, V49, P5906, DOI 10.1039/d0dt00283f
NR 29
TC 1
Z9 1
U1 3
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0966-0844
EI 1572-8773
J9 BIOMETALS
JI Biometals
PD AUG
PY 2021
VL 34
IS 4
BP 867
EP 879
DI 10.1007/s10534-021-00313-0
EA APR 2021
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA TP7AD
UT WOS:000644752700001
PM 33907910
OA hybrid, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Zhang, XQ
   Zhao, H
AF Zhang, Xueqin
   Zhao, Hu
TI Deoxyelephantopin Suppresses Invasion and Migration of Colorectal Cancer
   Cells Through Matrix Metalloproteinase-13
SO INTERNATIONAL JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Deoxyelephantopin; colorectal cancer cells; proliferation; metastasis;
   matrix metalloproteinase-13
ID ELEPHANTOPUS-SCABER; OSTEOSARCOMA CELLS; IN-VITRO; METASTASIS;
   APOPTOSIS; EXPRESSION; GROWTH; MMP13; AUTOPHAGY; PATHWAYS
AB Background and Objective: Deoxyelephantopin (DET), the major constituent of Elephantopus scaber, has been shown to have anti-inflammatory effect in vitro. However, there is no direct evidence that DET can inhibit colorectal cancer cells migration and invasion. The anticancer activity of DET was evaluated by a MTT assay. Materials and Methods: Cell apoptosis were detected by Annexin V/PI staining. Cell invasion and transwell migration assays were used to observe the effect of DET on cells invasion and migration. Results: In the present study, data showed that DET treatment reduced colorectal cancer (CRC) cells migration and invasion and DET treatment decreased the protein levels of matrix metalloproteinase-13 (MMP-13). This is the first paper suggested DET-reduced MMP-13 expression can inhibit CRC invasion and migration. Conclusion: Therefore, the present study provides evidence that the DET reduced MMP-13 expression, leading to decrease the migration and invasion of CRC cells. This study provides a mechanistic insight into the inhibiting CRC functions of DET.
C1 [Zhang, Xueqin; Zhao, Hu] First Peoples Hosp Qujing, Dept Gastroenterol, Qujing, Yunnan, Peoples R China.
RP Zhang, XQ (corresponding author), First Peoples Hosp Qujing, Dept Gastroenterol, Qujing, Yunnan, Peoples R China.
CR Al Bandar MH, 2017, ONCOL REP, V37, P2553, DOI 10.3892/or.2017.5531
   Bersini S, 2014, DRUG DISCOV TODAY, V19, P735, DOI 10.1016/j.drudis.2013.12.006
   Chan CK, 2016, MOLECULES, V21, DOI 10.3390/molecules21030385
   Chen N, 2017, ONCOTARGET, V8, P32356, DOI 10.18632/oncotarget.16020
   Chen RX, 2014, INT J CLIN EXP PATHO, V7, P2527
   Deng BY, 2015, CELL PHYSIOL BIOCHEM, V37, P2434, DOI 10.1159/000438596
   Fan L, 2015, MOL MED REP, V11, P705, DOI 10.3892/mmr.2014.2728
   Farha AK, 2015, NAT PROD RES, V29, P2341, DOI 10.1080/14786419.2015.1012165
   Farha AK, 2014, CELL BIOL TOXICOL, V30, P331, DOI 10.1007/s10565-014-9288-z
   Huang CC, 2010, BRIT J PHARMACOL, V159, P856, DOI 10.1111/j.1476-5381.2009.00581.x
   Huang RH, 2017, CELL PHYSIOL BIOCHEM, V41, P1851, DOI 10.1159/000471933
   Jin D, 2015, ONCOTARGET, V6, P33523, DOI 10.18632/oncotarget.5590
   Leake Isobel, 2013, Nat Rev Gastroenterol Hepatol, V10, P260, DOI 10.1038/nrgastro.2013.58
   Li Y, 2013, GASTROENTEROLOGY, V144, P179, DOI 10.1053/j.gastro.2012.09.042
   Liu WJ, 2016, MOL MED REP, V13, P4221, DOI 10.3892/mmr.2016.5086
   Mehmood T, 2017, MOLECULES, V22, DOI 10.3390/molecules22061013
   Moss LAS, 2012, AM J PATHOL, V181, P1895, DOI 10.1016/j.ajpath.2012.08.044
   Nian JY, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2016.66
   Ou BC, 2016, ONCOTARGET, V7, P47637, DOI 10.18632/oncotarget.10256
   Shiau JY, 2017, ONCOTARGET, V8, P56942, DOI 10.18632/oncotarget.18183
   Su MX, 2011, BIOCHEM BIOPH RES CO, V411, P342, DOI 10.1016/j.bbrc.2011.06.144
   Tan MY, 2013, CELL PHYSIOL BIOCHEM, V32, P542, DOI 10.1159/000354458
   Vermeer NCA, 2017, CANCER TREAT REV, V54, P87, DOI 10.1016/j.ctrv.2017.02.002
   Wei W, 2016, CELL PHYSIOL BIOCHEM, V39, P1165, DOI 10.1159/000447823
   Wu MH, 2012, J CELL PHYSIOL, V227, P3016, DOI 10.1002/jcp.23043
   Xu LY, 2015, CELL PHYSIOL BIOCHEM, V36, P509, DOI 10.1159/000430116
   Yang B, 2012, SCAND J CLIN LAB INV, V72, P501, DOI 10.3109/00365513.2012.699638
   Zhang NN, 2016, CELL PHYSIOL BIOCHEM, V40, P1559, DOI 10.1159/000453206
   Zhu GW, 2016, CELL PHYSIOL BIOCHEM, V39, P1665, DOI 10.1159/000447868
   Zou JL, 2017, CELL PHYSIOL BIOCHEM, V42, P1812, DOI 10.1159/000479537
NR 30
TC 1
Z9 1
U1 0
U2 1
PU ASIAN NETWORK SCIENTIFIC INFORMATION-ANSINET
PI FAISALABAD
PA 308-LASANI TOWN, SARGODHA RD, FAISALABAD, 38090, PAKISTAN
SN 1811-7775
EI 1812-5700
J9 INT J PHARMACOL
JI Int. J. Pharmacol.
PY 2018
VL 14
IS 6
BP 751
EP 757
DI 10.3923/ijp.2018.751.757
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GN3LW
UT WOS:000438908200001
DA 2022-04-25
ER

PT J
AU Han, YD
   Tan, Y
   Zhao, YY
   Zhang, YC
   He, XJ
   Yu, L
   Jiang, HP
   Lu, HJ
   Tian, HY
AF Han, Yudong
   Tan, Ye
   Zhao, Yuanyuan
   Zhang, Yongchun
   He, Xinjia
   Yu, Li
   Jiang, Haiping
   Lu, Haijun
   Tian, Haiying
TI TRIM23 overexpression is a poor prognostic factor and contributes to
   carcinogenesis in colorectal cancer
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE cell cycle; colorectal cancer; P53; proliferation; TRIM23
ID PROTEINS; P53; AUTOPHAGY
AB The tripartite motif (TRIM) family proteins play a great role in carcinogenesis. However, the expression pattern, prognostic value and biological functions of tripartite motif containing 23 (TRIM23) in colorectal cancer (CRC) are poorly understood. Here, we found that TRIM23 is up-regulated and associated with tumour size, lymph node metastasis, American Joint Committee on Cancer (AJCC) stage and poor prognosis in CRC. Multivariate Cox regression analyses revealed that TRIM23 overexpression could be identified as an independent prognostic factor for CRC. TRIM23 could promote the proliferation of CRC cell in vitro and in vivo; additionally, TRIM23 depletion induced G1-phase arrest. Gene set enrichment analysis (GSEA) revealed that P53 and cell cycle signalling pathway-related genes were enriched in patients with high TRIM23 expression levels. We show in this study that TRIM23 physically binds to P53 and enhances the ubiquitination of P53, thereby promoting tumour proliferation. Thus, our data indicated that TRIM23 acts as an oncogene in colorectal carcinogenesis and may provide a novel therapeutic target for CRC management.
C1 [Han, Yudong] Qingdao Univ, Dept Thorac Surg, Affiliated Hosp, Qingdao, Peoples R China.
   [Tan, Ye; Zhao, Yuanyuan; Zhang, Yongchun; He, Xinjia; Yu, Li; Jiang, Haiping; Lu, Haijun; Tian, Haiying] Qingdao Univ, Dept Radiat Oncol, Affiliated Hosp, 16 Jiangsu Rd, Qingdao 266000, Peoples R China.
RP Lu, HJ; Tian, HY (corresponding author), Qingdao Univ, Dept Radiat Oncol, Affiliated Hosp, 16 Jiangsu Rd, Qingdao 266000, Peoples R China.
EM lhj82920608@163.com; tianhaiying123@126.com
CR Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bao CY, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa8441
   Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cambiaghi V, 2012, ADV EXP MED BIOL, V770, P77
   Crawford LJ, 2018, J CELL COMMUN SIGNAL, V12, P21, DOI 10.1007/s12079-017-0423-5
   Eymin B, 2010, CELL ADHES MIGR, V4, P114, DOI 10.4161/cam.4.1.10977
   Gushchina LV, 2018, PHARMACOL THERAPEUT, V185, P12, DOI 10.1016/j.pharmthera.2017.10.020
   Han YD, 2017, ONCOTARGET, V8, P22730, DOI 10.18632/oncotarget.15188
   Hatakeyama S, 2017, TRENDS BIOCHEM SCI, V42, P297, DOI 10.1016/j.tibs.2017.01.002
   Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139
   Liang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1143-x
   Micale L, 2012, ADV EXP MED BIOL, V770, P11
   Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140
   Seton-Rogers S, 2015, NAT REV CANCER, V15, P318, DOI 10.1038/nrc3962
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Sparrer KMJ, 2017, NAT MICROBIOL, V2, P1543, DOI 10.1038/s41564-017-0017-2
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takayama K, 2018, ONCOGENE, V37, P2165, DOI 10.1038/s41388-017-0095-x
   Valletti A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071776
   Venuto S, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050510
   Vieler M, 2018, CANCERS, V10, DOI 10.3390/cancers10090288
   Vunjak M, 2019, CURR BIOL, V29, pR42, DOI 10.1016/j.cub.2018.11.026
   Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087
   Watanabe M, 2015, ELIFE, V4, DOI 10.7554/eLife.05615
   Wei WS, 2018, CANCER LETT, V435, P10, DOI 10.1016/j.canlet.2018.07.036
   Yao YY, 2018, PATHOL RES PRACT, V214, P2062, DOI 10.1016/j.prp.2018.10.010
   Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09
   Zhang P, 2015, ONCOGENE, V34, P5729, DOI 10.1038/onc.2015.21
   Zhang XQ, 2016, EUR J GYNAECOL ONCOL, V37, P30
   Zhang Y, 2018, INT J ONCOL, V53, P620, DOI 10.3892/ijo.2018.4408
   Zhou ZC, 2014, GASTROENTEROLOGY, V147, P1043, DOI 10.1053/j.gastro.2014.07.021
NR 34
TC 13
Z9 13
U1 2
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD MAY
PY 2020
VL 24
IS 10
BP 5491
EP 5500
DI 10.1111/jcmm.15203
EA MAR 2020
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA LL3FK
UT WOS:000522311200001
PM 32227572
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Maniam, S
   Maniam, S
AF Maniam, Subashani
   Maniam, Sandra
TI Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE programmed cell death; apoptosis; autophagy; breast cancer; small
   molecule
ID TYROSINE KINASE INHIBITOR; LEUCINE-ZIPPER KINASE; 2 HUMAN HOMOLOGS;
   DNA-REPAIR; IN-VITRO; SURVIVIN SUPPRESSANT; GOLD NANOPARTICLES;
   OXIDATIVE STRESS; WILD-TYPE; AUTOPHAGY
AB Targeted chemotherapy has become the forefront for cancer treatment in recent years. The selective and specific features allow more effective treatment with reduced side effects. Most targeted therapies, which include small molecules, act on specific molecular targets that are altered in tumour cells, mainly in cancers such as breast, lung, colorectal, lymphoma and leukaemia. With the recent exponential progress in drug development, programmed cell death, which includes apoptosis and autophagy, has become a promising therapeutic target. The research in identifying effective small molecules that target compensatory mechanisms in tumour cells alleviates the emergence of drug resistance. Due to the heterogenous nature of breast cancer, various attempts were made to overcome chemoresistance. Amongst breast cancers, triple negative breast cancer (TNBC) is of particular interest due to its heterogeneous nature in response to chemotherapy. TNBC represents approximately 15% of all breast tumours, however, and still has a poor prognosis. Unlike other breast tumours, signature targets lack for TNBCs, causing high morbidity and mortality. This review highlights several small molecules with promising preclinical data that target autophagy and apoptosis to induce cell death in TNBC cells.
C1 [Maniam, Subashani] RMIT Univ, Sch Sci, STEM Coll, Melbourne, Vic 3001, Australia.
   [Maniam, Sandra] Univ Putra Malaysia, Dept Human Anat, Fac Med & Hlth Sci, Serdang 43400, Malaysia.
RP Maniam, S (corresponding author), RMIT Univ, Sch Sci, STEM Coll, Melbourne, Vic 3001, Australia.; Maniam, S (corresponding author), Univ Putra Malaysia, Dept Human Anat, Fac Med & Hlth Sci, Serdang 43400, Malaysia.
EM subashani.maniam@rmit.edu.au; sandra@upm.edu.my
RI Maniam, Subashani/AAB-4651-2020
OI Maniam, Subashani/0000-0002-0272-864X; Maniam,
   Sandra/0000-0001-5335-6666
FU Universiti Putra Malaysia [GP/2018/9616500]; RMIT ECDF scheme
FX This research was funded by RMIT ECDF scheme and Universiti Putra
   Malaysia, grant number GP/2018/9616500.
CR Abdel-Fatah TMA, 2013, ANN ONCOL, V24, P2801, DOI 10.1093/annonc/mdt277
   Adams CJ, 2019, FRONT MOL BIOSCI, V6, DOI 10.3389/fmolb.2019.00011
   Aggarwal V, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110735
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Akman M, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-020-01824-3
   Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Anderson KE, 2017, ACS CHEM BIOL, V12, P2522, DOI 10.1021/acschembio.7b00711
   Anido J, 2003, CLIN CANCER RES, V9, P1274
   Arihara Y, 2017, ONCOTARGET, V8, P65889, DOI 10.18632/oncotarget.19508
   Barbieri I, 2013, BRIEF FUNCT GENOMICS, V12, P219, DOI 10.1093/bfgp/elt007
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Cao C, 2017, ONCOGENE, V36, P133, DOI 10.1038/onc.2016.186
   Cao CY, 2018, INT J CANCER, V143, P1388, DOI 10.1002/ijc.31419
   Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788
   Carew JS, 2011, J BIOL CHEM, V286, P6602, DOI 10.1074/jbc.M110.151324
   Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]
   CASTELLINO SM, 1995, BRIT J CANCER, V71, P1181, DOI 10.1038/bjc.1995.230
   Chang CH, 2019, AUTOPHAGY, V15, P1376, DOI 10.1080/15548627.2019.1582951
   Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53
   Chen CH, 2018, CLIN CANCER RES, V24, P1176, DOI 10.1158/1078-0432.CCR-17-2066
   Chen HX, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00909
   Chen K, 2016, TUMOR BIOL, V37, P10539, DOI 10.1007/s13277-016-4929-x
   Chen ZK, 2017, THERANOSTICS, V7, DOI 10.7150/thno.17555
   Cheng SM, 2015, BRIT J PHARMACOL, V172, P214, DOI 10.1111/bph.12935
   Chestukhin A, 2003, P NATL ACAD SCI USA, V100, P4574, DOI 10.1073/pnas.0730733100
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Chollat-Namy M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1950-1
   Connor EE, 2005, SMALL, V1, P325, DOI 10.1002/smll.200400093
   Dassonneville L, 1999, BIOCHEM PHARMACOL, V58, P1307, DOI 10.1016/S0006-2952(99)00221-X
   Deng LJ, 2020, J LEUKOCYTE BIOL, V108, P493, DOI 10.1002/JLB.3MR0320-444R
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503
   Dyczynski M, 2018, CANCER LETT, V435, P32, DOI 10.1016/j.canlet.2018.07.028
   Eck W, 2008, ACS NANO, V2, P2263, DOI 10.1021/nn800429d
   Egan DF, 2015, MOL CELL, V59, P285, DOI 10.1016/j.molcel.2015.05.031
   Ehsanian R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-13
   Engstrom W, 2015, CARCINOGENESIS, V36, pS38, DOI 10.1093/carcin/bgv030
   Farina A, 2004, MOL CELL BIOL, V24, P9059, DOI 10.1128/MCB.24.20.9059-9069.2004
   Ferrara R, 2018, EXPERT REV ANTICANC, V18, P161, DOI 10.1080/14737140.2018.1419870
   Franco R, 2008, CANCER LETT, V266, P6, DOI 10.1016/j.canlet.2008.02.026
   Fu LL, 2016, SCI REP-UK, V6, DOI 10.1038/s41598-016-0007-2
   Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784
   Go A, 2020, EUR J MED CHEM, V204, DOI 10.1016/j.ejmech.2020.112635
   Gornati D, 1997, ANTI-CANCER DRUG, V8, P509, DOI 10.1097/00001813-199706000-00014
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   Guo YZ, 2018, EUR J MED CHEM, V143, P402, DOI 10.1016/j.ejmech.2017.11.065
   Haynes B, 2016, NANOMED-NANOTECHNOL, V12, P745, DOI 10.1016/j.nano.2015.10.010
   Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960
   Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100
   Hu H, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03083
   Huang MB, 2021, CANCER LETT, V504, P125, DOI 10.1016/j.canlet.2021.02.009
   Jain K, 2013, AM J CANCER RES, V3, P251
   JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0
   Jia L, 2016, ONCOGENE, V35, P2040, DOI 10.1038/onc.2015.263
   Jorgensen I, 2017, NAT REV IMMUNOL, V17, P151, DOI 10.1038/nri.2016.147
   Jung S, 2020, EXP MOL MED, V52, P921, DOI 10.1038/s12276-020-0455-4
   Kalle AM, 2010, BIOCHEM BIOPH RES CO, V401, P13, DOI 10.1016/j.bbrc.2010.08.118
   Kallifatidis G, 2011, MOL THER, V19, P188, DOI 10.1038/mt.2010.216
   Karginova O, 2019, MOL CANCER THER, V18, P873, DOI 10.1158/1535-7163.MCT-18-0667
   KERR JFR, 1965, J PATHOL BACTERIOL, V90, P419, DOI 10.1002/path.1700900210
   Khalifa SAM, 2019, MAR DRUGS, V17, DOI 10.3390/md17090491
   Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   KOKEN MHM, 1992, GENOMICS, V12, P447, DOI 10.1016/0888-7543(92)90433-S
   KOKEN MHM, 1991, P NATL ACAD SCI USA, V88, P8865, DOI 10.1073/pnas.88.20.8865
   Kondo Y, 2014, J BIOCHEM, V156, P249, DOI 10.1093/jb/mvu054
   Kozyreva VK, 2016, MOL CANCER THER, V15, P1809, DOI 10.1158/1535-7163.MCT-15-0688
   LaFargue CJ, 2019, LANCET ONCOL, V20, pE15, DOI 10.1016/S1470-2045(18)30786-1
   Law BYK, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00388
   Lee J, 2012, BIOCHEM J, V441, P523, DOI 10.1042/BJ20111451
   Lee YR, 2013, BMB REP, V46, P201, DOI 10.5483/BMBRep.2013.46.4.160
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li XL, 2018, SPRINGERBRIEF MATH, P1, DOI [10.1007/978-3-319-89617-5_1, 10.1109/ICDCS.2018.00011]
   Lin ZY, 2014, FREE RADICAL BIO MED, V72, P296, DOI 10.1016/j.freeradbiomed.2014.04.004
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Liu JC, 2014, EMBO MOL MED, V6, P1542, DOI 10.15252/emmm.201404402
   Liu R, 2016, ACTA PHARMACOL SIN, V37, P285, DOI 10.1038/aps.2015.123
   Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110
   Liu Y, 2020, EUR J MED CHEM, V204, DOI 10.1016/j.ejmech.2020.112505
   Liu ZQ, 2017, J MED CHEM, V60, P4533, DOI 10.1021/acs.jmedchem.6b01761
   Luo MH, 2004, ANTICANCER RES, V24, P2127
   Lyons TG, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0682-x
   MacKenzie SH, 2012, ADV EXP MED BIOL, V747, P55, DOI 10.1007/978-1-4614-3229-6_4
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Marie SKN, 2008, INT J CANCER, V122, P807, DOI 10.1002/ijc.23189
   Marra A, 2020, NPJ BREAST CANCER, V6, DOI 10.1038/s41523-020-00197-2
   Mathiassen SG, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00051
   Maurais AJ, 2019, CURR OPIN CHEM BIOL, V50, P29, DOI 10.1016/j.cbpa.2019.02.010
   McKenna S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82215-2
   Moasser MM, 2001, CANCER RES, V61, P7184
   Moulder SL, 2001, CANCER RES, V61, P8887
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Nakahara T, 2007, CANCER RES, V67, P8014, DOI 10.1158/0008-5472.CAN-07-1343
   Nakano I, 2008, J NEUROSCI RES, V86, P48, DOI 10.1002/jnr.21471
   Nedeljkovic M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090957
   New J, 2017, CANCER RES, V77, P6679, DOI 10.1158/0008-5472.CAN-17-1077
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Nyfeler B, 2016, AUTOPHAGY, V12, P1206, DOI 10.1080/15548627.2016.1170265
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Ofori S, 2019, ACS OMEGA, V4, P12584, DOI 10.1021/acsomega.9b01106
   Okamoto K, 2012, BBA-GEN SUBJECTS, V1820, P595, DOI 10.1016/j.bbagen.2011.08.001
   Ong CC, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0564-5
   Ouyang L, 2017, J MED CHEM, V60, P9990, DOI 10.1021/acs.jmedchem.7b00275
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002
   Pennati M, 2015, INT J CANCER, V136, P299, DOI 10.1002/ijc.28993
   Pickard MR, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2350
   Preet R, 2012, INT J CANCER, V130, P1660, DOI 10.1002/ijc.26158
   PROUD CG, 1994, MOL BIOL REP, V19, P161, DOI 10.1007/BF00986958
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Qin JJ, 2016, ONCOTARGET, V7, P32566, DOI 10.18632/oncotarget.8873
   Rashmi KC, 2019, CHEM-BIOL INTERACT, V299, P120, DOI 10.1016/j.cbi.2018.12.005
   Rauch A, 2014, BBA-REV CANCER, V1845, P202, DOI 10.1016/j.bbcan.2014.01.003
   Ren HY, 2020, J MED CHEM, V63, P14609, DOI 10.1021/acs.jmedchem.0c00873
   Ren XS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087660
   Robke L, 2018, CHEM SCI, V9, P3014, DOI 10.1039/c7sc05040b
   Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413
   Roth S, 2019, CELL MOL LIFE SCI, V76, P2761, DOI 10.1007/s00018-019-03112-6
   Rozeboom B, 2019, AM J CANCER RES, V9, P2821
   Rozengurt E, 2014, MOL CANCER THER, V13, P2477, DOI 10.1158/1535-7163.MCT-14-0330
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Sanders MA, 2013, MOL CANCER THER, V12, P373, DOI 10.1158/1535-7163.MCT-12-0793
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Schlutermann D, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2017.11.021
   Sharma P, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02437
   Shoji-Kawata S, 2013, NATURE, V494, P201, DOI 10.1038/nature11866
   Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200
   Song XJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep20864
   Sun DJ, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12402
   Sun HY, 2007, J AM CHEM SOC, V129, P15279, DOI 10.1021/ja074725f
   Tekedereli I, 2013, MOL THER-NUCL ACIDS, V2, DOI 10.1038/mtna.2013.45
   Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007
   Vequaud E, 2015, ONCOTARGET, V6, P13476, DOI 10.18632/oncotarget.3638
   Vogel RI, 2015, ONCOTARGET, V6, P4159, DOI 10.18632/oncotarget.2904
   Voutsadakis IA, 2013, MOL BIOL REP, V40, P2019, DOI 10.1007/s11033-012-2261-0
   Wang J, 2012, INT J ONCOL, V41, P1101, DOI 10.3892/ijo.2012.1534
   Wang L, 2015, CANCER CELL, V28, P240, DOI 10.1016/j.ccell.2015.07.005
   Wang MH, 2017, BIOCHEM BIOPH RES CO, V489, P103, DOI 10.1016/j.bbrc.2017.05.097
   Wang W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9051176
   Wang XM, 2017, CANCERS, V9, DOI 10.3390/cancers9120162
   Wang Y, 2015, ADV MATER, V27, P2627, DOI 10.1002/adma.201405926
   Werfel TA, 2018, CANCER RES, V78, P1845, DOI 10.1158/0008-5472.CAN-17-2388
   White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941
   WILLIAMS JR, 1974, NATURE, V252, P754, DOI 10.1038/252754a0
   Xiao T, 2016, ACTA PHARM SIN B, V6, P557, DOI 10.1016/j.apsb.2016.04.002
   Xu JM, 2010, CANCER RES, V70, P6566, DOI 10.1158/0008-5472.CAN-10-0942
   Xu T, 2021, EUR J MED CHEM, V219, DOI 10.1016/j.ejmech.2021.113424
   Yamanaka K, 2011, INT J ONCOL, V39, P569, DOI 10.3892/ijo.2011.1077
   Yang D, 2012, BREAST CANCER RES TR, V133, P189, DOI 10.1007/s10549-011-1752-3
   Yang F, 2018, LIFE SCI, V213, P149, DOI 10.1016/j.lfs.2018.10.034
   Yang J, 2011, MOL CANCER THER, V10, P658, DOI 10.1158/1535-7163.MCT-10-0643
   Ye FG, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.574813
   York B, 2010, J BIOL CHEM, V285, P38743, DOI 10.1074/jbc.R110.193367
   Young CD, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0656-2
   Yuan X, 2017, ONCOTARGET, V8, P21626, DOI 10.18632/oncotarget.15451
   Zhang L, 2017, CHEM SCI, V8, P2687, DOI 10.1039/c6sc05368h
   Zhang L, 2015, MOL BIOSYST, V11, P2860, DOI 10.1039/c5mb00466g
   Zhang NG, 2014, J BIOMOL SCREEN, V19, P878, DOI 10.1177/1087057114520972
   Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482
   Zhao QY, 2019, CHEM COMMUN, V55, P369, DOI 10.1039/c8cc07813k
   Zhou DH, 2017, BIOORGAN MED CHEM, V25, P2995, DOI 10.1016/j.bmc.2017.03.048
   Zhu HC, 2015, CELL STRESS CHAPERON, V20, P217, DOI 10.1007/s12192-014-0545-0
NR 168
TC 0
Z9 0
U1 8
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2021
VL 22
IS 18
AR 9722
DI 10.3390/ijms22189722
PG 34
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA UV9ZP
UT WOS:000699827900001
PM 34575883
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhong, Y
   Long, T
   Gu, CS
   Tang, JY
   Gao, LF
   Zhu, JX
   Hu, ZY
   Wang, X
   Ma, YD
   Ding, YQ
   Li, ZG
   Wang, XY
AF Zhong, Yan
   Long, Ting
   Gu, Chuan-Sha
   Tang, Jing-Yi
   Gao, Ling-Fang
   Zhu, Jia-Xian
   Hu, Zhi-Yan
   Wang, Xia
   Ma, Yi-Dan
   Ding, Yan-Qing
   Li, Zu-Guo
   Wang, Xiao-Yan
TI MYH9-dependent polarization of ATG9B promotes colorectal cancer
   metastasis by accelerating focal adhesion assembly
SO CELL DEATH AND DIFFERENTIATION
LA English
DT Article
ID AUTOPHAGY; MEMBRANE
AB Tumour metastasis is a major reason accounting for the poor prognosis of colorectal cancer (CRC), and the discovery of targets in the primary tumours that can predict the risk of CRC metastasis is now urgently needed. In this study, we identified autophagy-related protein 9B (ATG9B) as a key potential target gene for CRC metastasis. High expression of ATG9B in tumour significantly increased the risk of metastasis and poor prognosis of CRC. Mechanistically, we further find that ATG9B promoted CRC invasion mainly through autophagy-independent manner. MYH9 is the pivotal interacting protein for ATG9B functioning, which directly binds to cytoplasmic peptide segments aa368-411 of ATG9B by its head domain. Furthermore, the combination of ATG9B and MYH9 enhance the stability of each other by decreasing their binding to E3 ubiquitin ligase STUB1, therefore preventing them from ubiquitin-mediated degradation, which further amplified the effect of ATG9B and MYH9 in CRC cells. During CRC cell invasion, ATG9B is transported to the cell edge with the assistance of MYH9 and accelerates focal adhesion (FA) assembly through mediating the interaction of endocytosed integrin beta 1 and Talin-1, which facilitated to integrin beta 1 activation. Clinically, upregulated expression of ATG9B in human CRC tissue is always accompanied with highly elevated expression of MYH9 and associated with advanced CRC stage and poor prognosis. Taken together, this study highlighted the important role of ATG9B in CRC metastasis by promoting focal adhesion assembly, and ATG9B together with MYH9 can provide a pair of potential therapeutic targets for preventing CRC progression.
C1 [Zhong, Yan; Long, Ting; Gao, Ling-Fang; Zhu, Jia-Xian; Li, Zu-Guo] Southern Med Univ, Shenzhen Hosp, Dept Pathol, Shenzhen, Guangdong, Peoples R China.
   [Zhong, Yan; Gu, Chuan-Sha; Tang, Jing-Yi; Gao, Ling-Fang; Zhu, Jia-Xian; Hu, Zhi-Yan; Wang, Xia; Ma, Yi-Dan; Ding, Yan-Qing; Wang, Xiao-Yan] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Guangdong, Peoples R China.
   [Gu, Chuan-Sha; Tang, Jing-Yi; Hu, Zhi-Yan; Wang, Xia; Ma, Yi-Dan; Ding, Yan-Qing; Li, Zu-Guo; Wang, Xiao-Yan] Key Lab Mol Tumour Pathol Guangdong Prov, Guangzhou, Guangdong, Peoples R China.
   [Hu, Zhi-Yan; Ding, Yan-Qing; Wang, Xiao-Yan] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China.
RP Li, ZG; Wang, XY (corresponding author), Southern Med Univ, Shenzhen Hosp, Dept Pathol, Shenzhen, Guangdong, Peoples R China.; Ding, YQ; Wang, XY (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Guangdong, Peoples R China.; Ding, YQ; Li, ZG; Wang, XY (corresponding author), Key Lab Mol Tumour Pathol Guangdong Prov, Guangzhou, Guangdong, Peoples R China.; Ding, YQ; Wang, XY (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Guangdong, Peoples R China.
EM dyqgz@126.com; lizg@smu.edu.cn; wangxiaoyan639@163.com
OI Li, Zuguo/0000-0001-9229-1973
FU National Natural Science Foundation of China (NSFC)National Natural
   Science Foundation of China (NSFC) [81201664, 81672437, 81974441]
FX This research was partly supported by grants from the National Natural
   Science Foundation of China (NSFC) (Nos. 81201664, 81672437, 81974441).
CR Chan EYW, 2009, MOL CELL BIOL, V29, P157, DOI 10.1128/MCB.01082-08
   Chen TT, 2019, CANCER MED-US, V8, P4404, DOI 10.1002/cam4.2351
   Chorev DS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4758
   Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552
   Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Hamidi Hellyeh, 2018, Nat Rev Cancer, V18, P533, DOI 10.1038/s41568-018-0038-z
   Hu ZY, 2016, ONCOTARGET, V7, P11733, DOI 10.18632/oncotarget.7367
   Katheder NS, 2017, NATURE, V541, P417, DOI 10.1038/nature20815
   Klionsky DJ, 2021, AUTOPHAGY, V17, P1, DOI 10.1080/15548627.2020.1797280
   Li FP, 2018, J CANCER, V9, P3839, DOI 10.7150/jca.25469
   Liao Q, 2017, BRIT J CANCER, V117, P563, DOI 10.1038/bjc.2017.193
   Libanje F, 2019, EMBO J, V38, DOI 10.15252/embj.201899299
   Ma Z, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20171082
   Malinin NL, 2012, CURR OPIN HEMATOL, V19, P206, DOI 10.1097/MOH.0b013e3283523df0
   Militello RD, 2011, CURR MOL MED, V11, P197
   Mygind KJ, 2018, J CELL SCI, V131, DOI 10.1242/jcs.205393
   Nader GPF, 2016, NAT CELL BIOL, V18, P491, DOI 10.1038/ncb3333
   Samarelli AV, 2020, J CELL SCI, V133, DOI 10.1242/jcs.243683
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Tang HW, 2011, EMBO J, V30, P636, DOI 10.1038/emboj.2010.338
   Ungermann C, 2018, AUTOPHAGY, V14, P1456, DOI 10.1080/15548627.2018.1477382
   Wang N, 2017, THERANOSTICS, V7, P2325, DOI 10.7150/thno.18225
   Webber JL, 2010, EMBO J, V29, P27, DOI 10.1038/emboj.2009.321
   Yamamoto H, 2012, J CELL BIOL, V198, P219, DOI 10.1083/jcb.201202061
   Yang MH, 2015, BBA-MOL BASIS DIS, V1852, P166, DOI 10.1016/j.bbadis.2014.11.013
   Zhang XM, 2016, GENE, V590, P285, DOI 10.1016/j.gene.2016.05.036
   Zhao CX, 2021, ACTA PHARMACOL SIN, V42, P179, DOI 10.1038/s41401-020-0441-3
NR 28
TC 2
Z9 2
U1 11
U2 13
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1350-9047
EI 1476-5403
J9 CELL DEATH DIFFER
JI Cell Death Differ.
PD DEC
PY 2021
VL 28
IS 12
BP 3251
EP 3269
DI 10.1038/s41418-021-00813-z
EA JUN 2021
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA XE9TM
UT WOS:000661843600002
PM 34131310
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Lin, XT
   Zheng, XB
   Fan, DJ
   Yao, QQ
   Hu, JC
   Lian, L
   Wu, XJ
   Lan, P
   He, XS
AF Lin, Xu-tao
   Zheng, Xiao-bin
   Fan, De-jun
   Yao, Qiu-qiong
   Hu, Jian-cong
   Lian, Lei
   Wu, Xiao-jian
   Lan, Ping
   He, Xiao-sheng
TI MicroRNA-143 Targets ATG2B to Inhibit Autophagy and Increase
   Inflammatory Responses in Crohn's Disease
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE autophagy; ATG2B; miR-143; Crohn's disease; inflammatory responses
ID GENOME-WIDE ASSOCIATION; TANDEM 3' UTRS; FACTOR-KAPPA-B; ALTERNATIVE
   POLYADENYLATION; SUSCEPTIBILITY LOCI; COLORECTAL-CANCER;
   ESCHERICHIA-COLI; EPITHELIAL-CELLS; DENDRITIC CELLS; BOWEL-DISEASE
AB Background: Dysfunctional autophagy is recognized as a contributing factor in many chronic inflammatory diseases, including Crohn's disease (CD). Genetic analyses have found that microRNA (miRNA) levels are altered in the intestinal tissues of CD patients.
   Methods: The Sequencing Alternative Poly-Adenylation Sites (SAPAS) method was used to compare the 3' end of the total mRNA sequence of 3 surgical specimens of CD patients (including inflamed tissues and corresponding noninflamed tissues in each case). The levels of autophagy-related 2B (ATG2B), LC3, and miR-143 were compared between inflamed tissues and noninflamed tissues using immunoblot and quantitative reverse transcription polymerase chain reaction. Luciferase assays were used to verify the interactions between miR-143 and ATG2B. Autophagy was measured by immunoblot analyses of LC3 and transmission electron microscopy. Inflammatory cytokines and I kappa B alpha were analyzed to evaluate the effect of miR-143 on inflammatory response.
   Results: The tandem repeat 3'-UTR of ATG2B was longer in inflamed tissues than in corresponding noninflamed tissues and contained an miR-143 target site. miR-143 expression was elevated, whereas ATG2B and LC3-II were downregulated in inflamed tissues. The direct interaction between miR-143 and ATG2B was verified by a 3'-UTR dual-luciferase reporter assay. Constitutive expression of miR-143 or depletion of ATG2B in cultured intestinal epithelial cells inhibited autophagy, reduced I kappa B alpha levels, and increased inflammatory responses.
   Conclusions: miR-143 may induce bowel inflammation by regulating ATG2B and autophagy, suggesting that miR-143 might play a critical role in the development of CD. Therefore, miR-143 could be a promising novel target for gene therapy in CD patients.
C1 [Lin, Xu-tao; Fan, De-jun] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Dept Gastrointestinal Endoscopy, Guangzhou, Guangdong, Peoples R China.
   [Lin, Xu-tao; Zheng, Xiao-bin; Fan, De-jun; Yao, Qiu-qiong; Hu, Jian-cong; Lian, Lei; Wu, Xiao-jian; Lan, Ping; He, Xiao-sheng] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Dept Colorectal Surg, Guangzhou, Guangdong, Peoples R China.
   [Lin, Xu-tao; Zheng, Xiao-bin; Fan, De-jun; Yao, Qiu-qiong; Hu, Jian-cong; Lian, Lei; Wu, Xiao-jian; Lan, Ping; He, Xiao-sheng] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Inst Gastroenterol, Guangdong Prov Key Lab Colorectal & Pelv Floor Di, Guangzhou, Guangdong, Peoples R China.
RP Wu, XJ; Lan, P; He, XS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, 26 Yuancun Erheng Rd, Guangzhou 510655, Guangdong, Peoples R China.
EM sumswxj@126.com; sumslp@163.com; hexsheng@mail.sysu.edu.cn
CR Arroyo DS, 2014, INT IMMUNOPHARMACOL, V18, P55, DOI 10.1016/j.intimp.2013.11.001
   Awan MUF, 2014, APPL MICROBIOL BIOT, V98, P5319, DOI 10.1007/s00253-014-5721-8
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Brain O, 2013, IMMUNITY, V39, P521, DOI 10.1016/j.immuni.2013.08.035
   Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762
   Cadwell K, 2010, GASTROENTEROLOGY, V139, P1448, DOI 10.1053/j.gastro.2010.09.023
   Chen Y, 2013, BIOCHEM BIOPH RES CO, V438, P133, DOI 10.1016/j.bbrc.2013.07.040
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Denton D, 2015, IMMUNOL CELL BIOL, V93, P35, DOI 10.1038/icb.2014.85
   Di Giammartino DC, 2011, MOL CELL, V43, P853, DOI 10.1016/j.molcel.2011.08.017
   El-Khider F, 2016, DIGEST DIS, V34, P27, DOI 10.1159/000442921
   Elliott TR, 2015, J GASTROEN HEPATOL, V30, P1265, DOI 10.1111/jgh.12955
   Fasseu M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013160
   Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110
   Fujishima Y, 2011, ARCH BIOCHEM BIOPHYS, V506, P223, DOI 10.1016/j.abb.2010.12.009
   Ghorpade DS, 2013, J BIOL CHEM, V288, P33037, DOI 10.1074/jbc.M113.492496
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hollenbach E, 2005, J BIOL CHEM, V280, P14981, DOI 10.1074/jbc.M500966200
   Holtta V, 2008, INFLAMM BOWEL DIS, V14, P1175, DOI 10.1002/ibd.20475
   Homer CR, 2010, GASTROENTEROLOGY, V139, P1630, DOI 10.1053/j.gastro.2010.07.006
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Jones SA, 2013, IMMUNOL CELL BIOL, V91, P250, DOI 10.1038/icb.2012.82
   Liu CD, 2015, INFLAMM BOWEL DIS, V21, P1918, DOI 10.1097/MIB.0000000000000439
   Lu CM, 2014, GASTROENTEROLOGY, V146, P188, DOI 10.1053/j.gastro.2013.09.006
   Massey DCO, 2007, AUTOPHAGY, V3, P649, DOI 10.4161/auto.5075
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Plantinga TS, 2011, GUT, V60, P1229, DOI 10.1136/gut.2010.228908
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Sadabad MS, 2015, GUT, V64, P1546, DOI 10.1136/gutjnl-2014-307289
   Salem M, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.47
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Strober W, 2011, MUCOSAL IMMUNOL, V4, P484, DOI 10.1038/mi.2011.29
   Sun MZ, 2014, MOL MED REP, V9, P1597, DOI 10.3892/mmr.2014.2003
   Sun Y, 2012, J MOL CELL BIOL, V4, P352, DOI 10.1093/jmcb/mjs041
   Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158
   Tian P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048997
   Torres J, 2017, LANCET, V389, P1741, DOI 10.1016/S0140-6736(16)31711-1
   Warner N, 2014, J BIOL CHEM, V289, P28213, DOI 10.1074/jbc.M114.574756
   Xi C, 2016, INFLAMM RES, V65, P325, DOI 10.1007/s00011-016-0919-0
   Yu C, 2011, FITOTERAPIA, V82, P709, DOI 10.1016/j.fitote.2011.02.011
   Yuan RX, 2015, CLIN EXP METASTAS, V32, P169, DOI 10.1007/s10585-015-9700-y
   Zhai ZL, 2014, AUTOPHAGY, V10, P468, DOI 10.4161/auto.27553
NR 48
TC 25
Z9 29
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD APR
PY 2018
VL 24
IS 4
BP 781
EP 791
DI 10.1093/ibd/izx075
PG 11
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA GA7VO
UT WOS:000428546400012
PM 29562274
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhang, WJ
   Peng, C
   Shen, X
   Yuan, YM
   Zhang, W
   Yang, CJ
   Yao, MC
AF Zhang, Weijia
   Peng, Chang
   Shen, Xue
   Yuan, Yuemei
   Zhang, Wei
   Yang, Chunjuan
   Yao, Meicun
TI A Bioactive Compound from Sanguisorba officinalis L. Inhibits Cell
   Proliferation and Induces Cell Death in
   5-Fluorouracil-Sensitive/Resistant Colorectal Cancer Cells
SO MOLECULES
LA English
DT Article
DE colorectal cancer; AGE; apoptosis; autophagy; Wnt/beta-catenin signaling
   pathway
ID CHEMICAL-CONSTITUENTS; APOPTOSIS; CHEMOTHERAPY; TRANSITION; PATHWAY;
   PLANTS
AB Colorectal cancer (CRC) is one of the most common cancer in the world. The first line chemotherapeutic agent, 5-fluorouracil (5-FU), plays a predominant role in the clinical treatment of CRC. However, with the wide use of 5-FU, more and more CRC patients have been obtaining drug resistance to 5-FU, which leads to a large amount of treatment failures. One of the effective strategies to overcome this obstacle is to find bioactive natural products from traditional medicine. In our previous work, Sanguisorba officinalis L. was found to exert a strong anti-proliferative activity against 5-FU-senstive/resistant CRC cells. Therefore, several compounds were isolated from this herb and screened for their anti-CRC effects to find promising compounds. Among them, a triterpenoid compound named 3 beta-[(alpha-l-arabinopyranosyl) oxy]-urs-12,18(19)-dien-28-oic acid beta-d-glucopyranosyl ester (AGE), showed strong activity against both 5-FU-senstive and resistant CRC cells. In order to further study the mechanism of AGE on CRC cells, flow cytometer analysis, mitochondrial membrane potential (MMP) measurement, Western blotting, and RT-PCR assays were performed. Results demonstrated that AGE induced cell death by apoptosis pathway and autophagy, and inhibited cell proliferation via cell cycle arrest in G0-G1 phase mediated by Wnt signaling pathway. Therefore, AGE may be a potential bioactive compound for CRC treatment in clinic.
C1 [Zhang, Weijia; Shen, Xue] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Peoples R China.
   [Peng, Chang; Yao, Meicun] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen 518107, Peoples R China.
   [Yuan, Yuemei] Sun Yat Sen Univ, Sch Ecol, 6 Ming Yuan, Guangzhou 510006, Peoples R China.
   [Zhang, Wei] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Taipa, Macau, Peoples R China.
   [Yang, Chunjuan] Harbin Med Univ, Coll Pharm, Dept Pharmaceut Anal & Analyt Chem, Harbin 150081, Peoples R China.
RP Yao, MC (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen 518107, Peoples R China.; Yang, CJ (corresponding author), Harbin Med Univ, Coll Pharm, Dept Pharmaceut Anal & Analyt Chem, Harbin 150081, Peoples R China.
EM zhangwj66@mail2.sysu.edu.cn; pengch56@mail2.sysu.edu.cn;
   shenx27@mail2.sysu.edu.cn; yuanym@mail.sysu.edu.cn; wzhang@must.edu.mo;
   chunjuanyang@hrbmu.edu.cn; lssymc@mail.sysu.edu.cn
OI Yao, Meicun/0000-0002-4372-6528; Peng, Chang/0000-0003-0462-0373
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973552, 81573551]
FX This work was supported by National Natural Science Foundation of China
   (No. 81973552 and No. 81573551).
CR Ahn VE, 2011, DEV CELL, V21, P862, DOI 10.1016/j.devcel.2011.09.003
   Albayrak G, 2018, HUM EXP TOXICOL, V37, P953, DOI 10.1177/0960327117747025
   Bai C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.576547
   Bai CF, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01646
   Benarba B, 2018, BIOMED PHARMACOTHER, V107, P408, DOI 10.1016/j.biopha.2018.08.006
   Blanchard JM, 2000, BIOCHEM PHARMACOL, V60, P1179, DOI 10.1016/S0006-2952(00)00384-1
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Chikazawa N, 2010, ANTICANCER RES, V30, P2041
   Dai J, 2016, EUR REV MED PHARMACO, V20, P4230
   Ewen ME, 2004, TRENDS MOL MED, V10, P158, DOI 10.1016/j.molmed.2004.02.005
   Hong ZC, 2021, INT J BIOL SCI, V17, P942, DOI 10.7150/ijbs.57164
   Huang XM, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109142
   Jang E, 2018, AM J CHINESE MED, V46, P299, DOI 10.1142/S0192415X18500155
   Katoh M, 2017, INT J MOL MED, V40, P587, DOI 10.3892/ijmm.2017.3071
   Kukcinaviciute E, 2018, J CELL BIOCHEM, V119, P5913, DOI 10.1002/jcb.26783
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li W, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0244-y
   Liu MP, 2016, SCI REP-UK, V6, DOI 10.1038/srep34245
   McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436
   Munoz-Pinedo C, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.246
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Nikoletopoulou V, 2013, BBA-MOL CELL RES, V1833, P3448, DOI 10.1016/j.bbamcr.2013.06.001
   Panda M, 2019, MOL BIOL REP, V46, P5645, DOI 10.1007/s11033-019-04958-6
   Pawlaczyk-Graja I, 2016, INT J BIOL MACROMOL, V93, P1019, DOI 10.1016/j.ijbiomac.2016.09.082
   Qi L, 2020, ARCH BIOCHEM BIOPHYS, V695, DOI 10.1016/j.abb.2020.108644
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x
   Ren H, 2019, PHYTOTHER RES, V33, P1570, DOI 10.1002/ptr.6347
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Su XD, 2018, BIOORG MED CHEM LETT, V28, P2210, DOI 10.1016/j.bmcl.2018.04.033
   Suwala Abigail Kora, 2018, Oncotarget, V9, P22703, DOI 10.18632/oncotarget.25210
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Wang L, 2015, PHYTOMEDICINE, V22, P1079, DOI 10.1016/j.phymed.2015.08.009
   Wu CC, 2018, MOLECULES, V23, DOI 10.3390/molecules23112980
   Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P11312, DOI 10.1073/pnas.1203015109
   Zhao JL, 2020, ONCOL REP, V44, P768, DOI 10.3892/or.2020.7617
   Zhao JL, 2017, INT J ONCOL, V50, P613, DOI 10.3892/ijo.2017.3843
   Zhao ZF, 2017, AM J CHINESE MED, V45, P199, DOI 10.1142/S0192415X17500136
NR 39
TC 1
Z9 1
U1 5
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUL
PY 2021
VL 26
IS 13
AR 3843
DI 10.3390/molecules26133843
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TF8BW
UT WOS:000670941800001
PM 34202548
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Xu, CF
   Liu, ZL
   Xiao, JW
AF Xu, Chengfei
   Liu, Ziling
   Xiao, Jiangwei
TI Ferroptosis: A Double-Edged Sword in Gastrointestinal Disease
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE ferroptosis; ischemia/reperfusion injury; inflammatory bowel disease;
   gastric cancer; colorectal cancer
ID ERASTIN-INDUCED FERROPTOSIS; MUTANT COLORECTAL-CANCER; CELL-DEATH;
   GASTRIC-CANCER; INTESTINAL ISCHEMIA; LIPID-PEROXIDATION; OXIDATIVE
   STRESS; COENZYME Q(10); IN-VITRO; IRON
AB Ferroptosis is a novel form of regulated cell death (RCD) that is typically accompanied by iron accumulation and lipid peroxidation. In contrast to apoptosis, autophagy, and necroptosis, ferroptosis has unique biological processes and pathophysiological characteristics. Since it was first proposed in 2012, ferroptosis has attracted attention worldwide. Ferroptosis is involved in the progression of multiple diseases and could be a novel therapeutic target in the future. Recently, tremendous progress has been made regarding ferroptosis and gastrointestinal diseases, including intestinal ischemia/reperfusion (I/R) injury, inflammatory bowel disease (IBD), gastric cancer (GC), and colorectal cancer (CRC). In this review, we summarize the recent progress on ferroptosis and its interaction with gastrointestinal diseases. Understanding the role of ferroptosis in gastrointestinal disease pathogenesis could provide novel therapeutic targets for clinical treatment.
C1 [Xu, Chengfei; Liu, Ziling; Xiao, Jiangwei] Chengdu Med Coll, Dept Gastrointestinal Surg, Chengdu 610500, Peoples R China.
RP Xiao, JW (corresponding author), Chengdu Med Coll, Dept Gastrointestinal Surg, Chengdu 610500, Peoples R China.
EM cos119@163.com; nsmc2007@163.com; xiaojiangwei@126.com
FU National Natural Science Foundation of the P.R. of ChinaNational Natural
   Science Foundation of China (NSFC) [81070378, 81270561]; Sichuan
   Outstanding Youth Fund Project Grant [2015JQ0060]
FX This study was financially supported by the National Natural Science
   Foundation of the P.R. of China (No. 81070378 and No. 81270561); Sichuan
   Outstanding Youth Fund Project Grant (No. 2015JQ0060).
CR Ahmed I, 2018, BIOMED OPT EXPRESS, V9, P4184, DOI 10.1364/BOE.9.004184
   Akbari G, 2020, J PHYSIOL BIOCHEM, V76, P525, DOI 10.1007/s13105-020-00772-y
   Alim I, 2019, CELL, V177, P1262, DOI 10.1016/j.cell.2019.03.032
   ALjohani AM, 2017, TRENDS ENDOCRIN MET, V28, P831, DOI 10.1016/j.tem.2017.10.003
   Alvarez SW, 2017, NATURE, V551, P639, DOI 10.1038/nature24637
   Andrews NC, 2007, ANNU REV PHYSIOL, V69, P69, DOI 10.1146/annurev.physiol.69.031905.164337
   Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064
   Balogh N, 2002, ACTA VET HUNG, V50, P343, DOI 10.1556/AVet.50.2002.3.10
   Beal MF, 2003, BIOFACTORS, V18, P153
   Bersuker K, 2019, NATURE, V575, P688, DOI 10.1038/s41586-019-1705-2
   Bogdan AR, 2016, TRENDS BIOCHEM SCI, V41, P274, DOI 10.1016/j.tibs.2015.11.012
   Bornschein J, 2010, DIGEST DIS SCI, V55, P3124, DOI 10.1007/s10620-010-1351-x
   Bosl MR, 1997, P NATL ACAD SCI USA, V94, P5531, DOI 10.1073/pnas.94.11.5531
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Butner JD, 2015, IEEE ENG MED BIO, P1444, DOI 10.1109/EMBC.2015.7318641
   Cai HJ, 2021, BOSNIAN J BASIC MED, V21, P569, DOI 10.17305/bjbms.2020.5617
   Carrier JC, 2006, INT J COLORECTAL DIS, V21, P381, DOI 10.1007/s00384-005-0011-7
   Chapkin RS, 2020, DIGEST DIS SCI, V65, P840, DOI 10.1007/s10620-020-06106-8
   Chaudhary N, 2021, INT J CANCER, V149, P1495, DOI 10.1002/ijc.33711
   Chen B., 2020, RES SQ, DOI [10.21203/rs.3.rs-111305/v1, DOI 10.21203/RS.3.RS-111305/V1]
   Chen DL, 2017, MOL CELL, V68, P224, DOI 10.1016/j.molcel.2017.09.009
   Chen L, 2020, BIOCHEM BIOPH RES CO, V526, P293, DOI 10.1016/j.bbrc.2020.03.079
   Chen MS, 2017, ONCOTARGET, V8, P114588, DOI 10.18632/oncotarget.23055
   Chen P, 2020, THERANOSTICS, V10, P5107, DOI 10.7150/thno.44705
   Chen X, 2021, CELL DEATH DIFFER, V28, P2843, DOI 10.1038/s41418-021-00859-z
   Chen X, 2021, AUTOPHAGY, V17, P2054, DOI 10.1080/15548627.2020.1810918
   Chen Y, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109384
   Chen YR, 2020, IMMUNOL LETT, V225, P9, DOI 10.1016/j.imlet.2020.06.005
   Chiba Mitsuro, 2019, Perm J, V23, P18, DOI 10.7812/TPP/18-107
   Choy KJ, 2003, FREE RADICAL BIO MED, V35, P300, DOI 10.1016/S0891-5849(03)00304-6
   Conrad M, 2019, NAT CHEM BIOL, V15, P1137, DOI 10.1038/s41589-019-0408-1
   Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5
   D'Herde K, 2017, NAT CHEM BIOL, V13, P4, DOI 10.1038/nchembio.2261
   Deng F, 2021, GUT MICROBES, V13, DOI 10.1080/19490976.2021.1902719
   Ding RR, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00220
   Divine JG, 2018, CURR SPORT MED REP, V17, P151, DOI 10.1249/JSR.0000000000000485
   Dixon SJ, 2015, ACS CHEM BIOL, V10, P1604, DOI 10.1021/acschembio.5b00245
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Doll S, 2019, NATURE, V575, P693, DOI 10.1038/s41586-019-1707-0
   Doll S, 2017, NAT CHEM BIOL, V13, P91, DOI [10.1038/NCHEMBIO.2239, 10.1038/nchembio.2239]
   Gao ZW, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110092
   Geng RX, 2015, EXPERT OPIN PHARMACO, V16, P117, DOI 10.1517/14656566.2015.981526
   Grabherr F, 2019, Z GASTROENTEROL, V57, pV04, DOI DOI 10.1055/S-0039-1691856
   Green DR, 2018, CELL, V172, P389, DOI 10.1016/j.cell.2018.01.003
   Guan ZH, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20201807
   Gunther C, 2013, GUT, V62, P1062, DOI 10.1136/gutjnl-2011-301364
   Guo C, 2021, AM J CANCER RES, V11, P3039
   Hagele S, 2009, BIOCHEM J, V417, P235, DOI 10.1042/BJ20081353
   Hao SH, 2017, NEOPLASIA, V19, P1022, DOI 10.1016/j.neo.2017.10.005
   Hong ZC, 2021, INT J BIOL SCI, V17, P942, DOI 10.7150/ijbs.57164
   Hu YP, 2018, PHARMACOL RES, V137, P56, DOI 10.1016/j.phrs.2018.09.016
   Huo JY, 2021, EPIGENOMICS-UK, V13, P875, DOI 10.2217/epi-2020-0411
   Ingold I, 2018, CELL, V172, P409, DOI 10.1016/j.cell.2017.11.048
   ISHII T, 1981, J BIOL CHEM, V256, P2387
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Jiang XT, 2021, J ONCOL, V2021, DOI 10.1155/2021/6635526
   Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/NCHEMBIO.2238, 10.1038/nchembio.2238]
   Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020
   Karmi O, 2021, FREE RADICAL BIO MED, V176, P92, DOI 10.1016/j.freeradbiomed.2021.09.013
   Kim SW, 1999, J ANIM SCI, V77, P2510
   Kobayashi Y, 2019, J GASTROEN HEPATOL, V34, P1703, DOI 10.1111/jgh.14642
   LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859
   Lee JY, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10030184
   Lee JY, 2020, P NATL ACAD SCI USA, V117, P32433, DOI 10.1073/pnas.2006828117
   Li C, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01168-0
   Li Y, 2019, CELL DEATH DIFFER, V26, P2284, DOI 10.1038/s41418-019-0299-4
   Li YS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.508
   Liu G, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0254368
   Liu J, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20904-2
   Liu Y, 2021, ACTA PHARM SIN B, V11, P1513, DOI 10.1016/j.apsb.2021.05.006
   Lorenz K, 2009, NAT MED, V15, P75, DOI 10.1038/nm.1893
   Luo MY, 2018, CELL DEATH DIFFER, V25, P1457, DOI 10.1038/s41418-017-0053-8
   Magtanong L, 2019, CELL CHEM BIOL, V26, P420, DOI 10.1016/j.chembiol.2018.11.016
   Maiorino M, 2018, ANTIOXID REDOX SIGN, V29, P61, DOI 10.1089/ars.2017.7115
   Malfa GA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112723
   Mao C, 2021, NATURE, V593, P586, DOI 10.1038/s41586-021-03539-7
   Mao SH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.681338
   Mayr L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15646-6
   McCarthy S, 2004, TOXICOL APPL PHARM, V201, P21, DOI 10.1016/j.taap.2004.04.019
   Miao L, 2014, CANCER IMMUNOL IMMUN, V63, P699, DOI 10.1007/s00262-014-1550-y
   Millar AD, 2000, ALIMENT PHARM THERAP, V14, P1163
   Minaiyan M, 2012, INT J PREVENTIVE MED, V3, pS162
   MINOTTI G, 1987, CHEM PHYS LIPIDS, V44, P191, DOI 10.1016/0009-3084(87)90050-8
   Miotto G, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101328
   MOHR D, 1992, BIOCHIM BIOPHYS ACTA, V1126, P247, DOI 10.1016/0005-2760(92)90237-P
   Ni HW, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02394-7
   Nie JH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.654076
   Niu Y, 2019, LIFE SCI, V237, DOI 10.1016/j.lfs.2019.116893
   Park MW, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101947
   Park S, 2018, ANIM CELLS SYST, V22, P334, DOI 10.1080/19768354.2018.1512521
   Pithadia AB, 2011, PHARMACOL REP, V63, P629, DOI 10.1016/S1734-1140(11)70575-8
   Qi X, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.692426
   Qiu YM, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104919
   Rahman MS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105161
   Richard D, 2008, PHARMACOL RES, V57, P451, DOI 10.1016/j.phrs.2008.05.002
   Rizzello F, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051033
   Schomburg L, 2009, BBA-GEN SUBJECTS, V1790, P1453, DOI 10.1016/j.bbagen.2009.03.015
   Shao YF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.711776
   Shimura T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87283-y
   Shojaie L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249682
   Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035
   Stefanutti G, 2008, CRIT CARE MED, V36, P1564, DOI 10.1097/CCM.0b013e3181709e9f
   Stewart OA, 2020, GUT MICROBES, V11, P1220, DOI 10.1080/19490976.2020.1762520
   Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371
   Sun YW, 2020, MOL MED REP, V22, P2826, DOI 10.3892/mmr.2020.11376
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Thimmappa R, 2014, ANNU REV PLANT BIOL, V65, P225, DOI 10.1146/annurev-arplant-050312-120229
   Ursini F, 2020, FREE RADICAL BIO MED, V152, P175, DOI 10.1016/j.freeradbiomed.2020.02.027
   Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3
   Wang C, 2020, AGING-US, V12, P15374, DOI 10.18632/aging.103598
   Wang J, 2021, IUBMB LIFE, V73, P1180, DOI 10.1002/iub.2525
   Wang JB, 2020, NAT PROD COMMUN, V15, DOI 10.1177/1934578X20982779
   Wang LY, 2020, CELL DEATH DIFFER, V27, P662, DOI 10.1038/s41418-019-0380-z
   Wang SJ, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118356
   Wang ZY, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101343
   Wei GF, 2018, EUR J MED CHEM, V157, P759, DOI 10.1016/j.ejmech.2018.08.036
   Wei RR, 2021, INT J BIOL SCI, V17, P2703, DOI 10.7150/ijbs.59404
   Wen SH, 2017, J CELL MOL MED, V21, P432, DOI 10.1111/jcmm.12987
   Winterbourn CC, 1995, TOXICOL LETT, V82-3, P969, DOI 10.1016/0378-4274(95)03532-X
   Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174
   Xia Y, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03194-2
   Xian ZY, 2020, NEOPLASMA, V67, P1063, DOI 10.4149/neo_2020_191024N1084
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu MY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2299-1
   Xu S, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03559-1
   Xu XT, 2020, EUR J PHARM SCI, V152, DOI 10.1016/j.ejps.2020.105450
   Xu ZY, 2018, PHYTOMEDICINE, V51, P58, DOI 10.1016/j.phymed.2018.05.012
   Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859
   Yang C, 2021, PEERJ, V9, DOI 10.7717/peerj.11745
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yang YY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01689-8
   Ye SZ, 2021, J CELL MOL MED, V25, P3300, DOI 10.1111/jcmm.16400
   Yoshizato K, 2016, P JPN ACAD B-PHYS, V92, P77, DOI 10.2183/pjab.92.77
   Yu YY, 2020, BLOOD, V136, P726, DOI 10.1182/blood.2019002907
   Yuan Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.614778
   Zhang HY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01168-8
   Zhang L, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1675613
   Zhang YJ, 2018, EXP THER MED, V16, P2931, DOI 10.3892/etm.2018.6562
   Zhang ZL, 2020, AUTOPHAGY, V16, P1482, DOI 10.1080/15548627.2019.1687985
   Zhao LY, 2021, GASTRIC CANCER, V24, P642, DOI 10.1007/s10120-021-01159-8
NR 141
TC 0
Z9 0
U1 20
U2 20
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2021
VL 22
IS 22
AR 12403
DI 10.3390/ijms222212403
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XE7WG
UT WOS:000723593100001
PM 34830285
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Ren, LQ
   Li, Q
   Zhang, Y
AF Ren, Li-Qun
   Li, Qi
   Zhang, Yang
TI Luteolin Suppresses the Proliferation of Gastric Cancer Cells and Acts
   in Synergy with Oxaliplatin
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID COLORECTAL-CANCER; IN-VITRO; CISPLATIN; APOPTOSIS; INHIBITION;
   EXPRESSION; AUTOPHAGY; MICE
AB Objective. Gastric cancer, one of the most common malignant tumors worldwide, arises from the gastric mucosal epithelium and severely affects patient health and quality of life. Luteolin (LUT) is a flavonoid found in vegetables and fruits with diverse functions. A large number of studies have confirmed that LUT has an antitumor effect. Therefore, this study is aimed at verifying whether LUT can exert antitumor effects in synergy with oxaliplatin (OXA). As such, we examined the effects of LUT, OXA, and their coadministration in a gastric adenocarcinoma cell line (SGC-7901). We used the MTT assay to quantify the proliferation of SGC-7901 cells, flow cytometry to detect the cell cycle and apoptosis, ELISA to detect the expression of cell-cycle-related proteins, and western blot to detect the expression of related apoptotic factors. The results of this study show that the combination of LUT and OXA inhibited SGC-7901 cell proliferation and induced apoptosis by altering cell-cycle proportions. In addition, the combination also activated Cyt c/caspase signaling in SGC-7901 cells. In summary, LUT synergy with OXA inhibited the proliferation of gastric cancer cells in vitro. The present study also elucidated the mechanism by which LUT potentiated the sensitivity of SGC-7901 cells to OXA through the Cyt c/caspase pathway.
C1 [Ren, Li-Qun; Li, Qi; Zhang, Yang] Jilin Univ, Sch Pharmaceut Sci, Dept Expt Pharmacol & Toxicol, Changchun, Jilin, Peoples R China.
   [Li, Qi] Jinzhou Med Univ, Dept Pathol, Affiliated Hosp 3, Jinzhou, Liaoning, Peoples R China.
RP Zhang, Y (corresponding author), Jilin Univ, Sch Pharmaceut Sci, Dept Expt Pharmacol & Toxicol, Changchun, Jilin, Peoples R China.
EM renlq630210@163.com; 1758365335@qq.com; 807525580@qq.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81773934]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81773934).
CR Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005
   Alvarez S, 2003, BIOCHEM BIOPH RES CO, V305, P771, DOI 10.1016/S0006-291X(03)00818-0
   Azevedo MI, 2013, MOL PAIN, V9, DOI 10.1186/1744-8069-9-53
   Chen G, 2018, INT J MOL MED, V42, P3073, DOI 10.3892/ijmm.2018.3915
   Choi YJ, 2016, KOREAN J INTERN MED, V31, P1042, DOI 10.3904/kjim.2016.147
   Cinci L, 2017, Z NATURFORSCH C, V72, P219, DOI 10.1515/znc-2016-0194
   Dammeyer P, 2014, ACTA OTO-LARYNGOL, V134, P448, DOI 10.3109/00016489.2013.879740
   Das S, 2012, J MOL CELL CARDIOL, V52, P448, DOI 10.1016/j.yjmcc.2011.09.007
   Domitrovic R, 2013, TOXICOLOGY, V310, P115, DOI 10.1016/j.tox.2013.05.015
   Forcello NP, 2015, J ONCOL PHARM PRACT, V21, P148, DOI 10.1177/1078155213520262
   George VC, 2017, J NUTR BIOCHEM, V45, P1, DOI 10.1016/j.jnutbio.2016.11.007
   Haghi-Aminjan H, 2018, EXPERT OPIN DRUG MET, V14, P937, DOI 10.1080/17425255.2018.1513492
   Helmerick EC, 2014, VET COMP ONCOL, V12, P299, DOI 10.1111/vco.12013
   Huang LM, 2019, ONCOL LETT, V17, P3842, DOI 10.3892/ol.2019.10052
   Jeong S, 2019, CANCERS, V11, DOI 10.3390/cancers11060781
   Kim MS, 2012, NUTRITION, V28, P1044, DOI 10.1016/j.nut.2011.12.003
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Kweekel DM, 2005, CANCER TREAT REV, V31, P90, DOI 10.1016/j.ctrv.2004.12.006
   Li H, 2018, INTEGR CANCER THER, V17, P511, DOI 10.1177/1534735417696702
   Liu HY, 2015, INT J CLIN EXP PATHO, V8, P15128
   Lu XY, 2017, ONCOL LETT, V14, P1993, DOI 10.3892/ol.2017.6380
   Nabavi SF, 2015, BRAIN RES BULL, V119, P1, DOI 10.1016/j.brainresbull.2015.09.002
   Pandurangan AK, 2014, ASIAN PAC J CANCER P, V15, P5501, DOI 10.7314/APJCP.2014.15.14.5501
   Ryu S, 2019, J CELL PHYSIOL, V234, P9504, DOI 10.1002/jcp.27638
   Shi RX, 2007, MOL CANCER THER, V6, P1338, DOI 10.1158/1535-7163.MCT-06-0638
   Strong VE, 2015, J SURG ONCOL, V112, P31, DOI 10.1002/jso.23940
   Suh YS, 2015, SURG CLIN N AM, V95, P1053, DOI 10.1016/j.suc.2015.05.012
   Van Cutsem E, 2006, J CLIN ONCOL, V24, P4991, DOI 10.1200/JCO.2006.06.8429
   Wang YH, 2015, IRAN J PHARM RES, V14, P531
   Wei F, 2017, INT J ONCOL, V51, P1383, DOI 10.3892/ijo.2017.4134
   Wei J, 2016, WORLD J GASTROENTERO, V22, P7478, DOI 10.3748/wjg.v22.i33.7478
   Yakirevich E, 2013, GASTROENTEROL CLIN N, V42, P261, DOI 10.1016/j.gtc.2013.01.004
   Yang C, 2012, ONCOL REP, V28, P1006, DOI 10.3892/or.2012.1868
   Zhang BL, 2015, INT J CLIN EXP MED, V8, P15190
   Zhang F, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20187843, 10.1590/1414-431x20187843]
NR 35
TC 9
Z9 10
U1 2
U2 15
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD FEB 22
PY 2020
VL 2020
AR 9396512
DI 10.1155/2020/9396512
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA KS9JB
UT WOS:000518623200002
PM 32149146
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Jabir, NR
   Islam, MT
   Tabrez, S
   Shakil, S
   Zaidi, SK
   Khan, FR
   Araujo, LD
   de Meneses, AAPM
   Santos, JVD
   Melo-Cavalcante, AAD
AF Jabir, Nasimudeen R.
   Islam, Muhammad Torequl
   Tabrez, Shams
   Shakil, Shazi
   Zaidi, Syed Kashif
   Khan, Fayaz Rahman
   Araujo, Lidiane da Silva
   Melo de Meneses, Ag-Anne Pereira
   de Oliveira Santos, Jose Victor
   de Carvalho Melo-Cavalcante, Ana Amelia
TI An insight towards anticancer potential of major coffee constituents
SO BIOFACTORS
LA English
DT Review
DE antioxidants; autophagy; cancer; coffee; genotoxicity
ID ACID PHENETHYL ESTER; POLYCYCLIC AROMATIC AGENTS; CANCER-CELLS;
   COMPONENTS KAHWEOL; COLORECTAL-CANCER; FERULIC ACID; QUINACRINE MUSTARD;
   SIGNALING PATHWAY; TUMOR INITIATION; DNA-DAMAGE
AB Cancer is a complex disease that transforms a normal cell into a malignant cell by disturbing different molecular mechanisms. Lately, plant-derived bioactive products have gained prominent attention to serve as anti-cancer agents. These natural anti-neoplastic agents are believed to act as alternatives for the synthetic drugs or could be used to enhance the prospect of other drugs in reducing their dose, thus limiting their possible toxic effects. They could also counterbalance the other anti-cancer drug-induced adverse effects. Among natural plant-derived products, coffee has been reported for its significant anti-carcinogenic effects in the scientific literature. This article aims to highlight the anti-cancer potential of different coffee components viz. caffeic acid, chlorogenic acids, caffeine (1,3,7-trimethylxanthine), cafestol, ferulic acid, and kahweol together in a single article. Based on our article, it is quite clear that these bioactive components have important therapeutic potentials against cancerous cells. However, the lack of clinical data negates their use in humans. Therefore, more research is recommended to achieve the desired pharmaceutical value. We also implore assessing their safety and possible adverse effects prior to their progress into clinical trials. (c) 2018 BioFactors, 44(4):315-326, 2018
C1 [Jabir, Nasimudeen R.; Tabrez, Shams] King Abdulaziz Univ, King Fahd Med Res Ctr, POB 80216, Jeddah 21589, Saudi Arabia.
   [Islam, Muhammad Torequl] Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City 700000, Vietnam.
   [Islam, Muhammad Torequl] Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City 700000, Vietnam.
   [Shakil, Shazi] King Abdulaziz Univ, Ctr Innovat Personalized Med, Jeddah, Saudi Arabia.
   [Shakil, Shazi] King Abdulaziz Univ, Fac Appl Med Sci, Dept Med Lab Technol, Jeddah, Saudi Arabia.
   [Shakil, Shazi; Zaidi, Syed Kashif] King Abdulaziz Univ, Ctr Excellence Genom Med Res, Jeddah, Saudi Arabia.
   [Khan, Fayaz Rahman] King Abdulaziz Univ, Fac Appl Med Sci, Dept Phys Therapy, Jeddah, Saudi Arabia.
   [Araujo, Lidiane da Silva; Melo de Meneses, Ag-Anne Pereira; de Oliveira Santos, Jose Victor; de Carvalho Melo-Cavalcante, Ana Amelia] Univ Fed Piaui, Postgrad Program Pharmaceut Sci, Teresina, Brazil.
RP Tabrez, S (corresponding author), King Abdulaziz Univ, King Fahd Med Res Ctr, POB 80216, Jeddah 21589, Saudi Arabia.; Islam, MT (corresponding author), Ton Duc Thang Univ, Dept Management Sci & Technol Dev, Ho Chi Minh City 700000, Vietnam.; Islam, MT (corresponding author), Ton Duc Thang Univ, Fac Pharm, Ho Chi Minh City 700000, Vietnam.
EM muhammad.torequl.islam@tdt.edu.vn; shamstabrez1@gmail.com
RI Shakil, Shazi/K-4132-2015; Zaidi, Syed Kashif M/A-6160-2013; Shakil,
   Shazi/AAA-1449-2022; Tabrez, Shams/H-9476-2012; Khan, Fayaz
   R/O-1281-2015; Tabrez, Shams/H-7315-2019; Zaidi, Syed
   Kashif/AAA-3924-2022; Rehumathbeevi, Jabir Nasimudeen/H-9483-2012;
   Islam, Muhammad/Q-9563-2017
OI Shakil, Shazi/0000-0003-4075-9153; Zaidi, Syed Kashif
   M/0000-0003-2391-414X; Shakil, Shazi/0000-0003-4075-9153; Tabrez,
   Shams/0000-0003-4550-415X; Khan, Fayaz R/0000-0003-2512-4563; Tabrez,
   Shams/0000-0003-4550-415X; Zaidi, Syed Kashif/0000-0003-2391-414X;
   Rehumathbeevi, Jabir Nasimudeen/0000-0001-8548-7986; de Oliveira Santos,
   Jose Victor/0000-0002-9811-641X; Islam, Muhammad/0000-0003-0034-8202;
   Pereira Melo de Menezes, Ag-Anne/0000-0003-2830-990X
CR Aleksandrova K, 2015, AM J CLIN NUTR, V102, P1498, DOI 10.3945/ajcn.115.116095
   Anbazhagan AN, 2016, AM J PHYSIOL-CELL PH, V310, pC612, DOI 10.1152/ajpcell.00123.2015
   Anese M, 2003, J AGR FOOD CHEM, V51, P942, DOI 10.1021/jf025859+
   Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Bravi F, 2009, AM J OBSTET GYNECOL, V200, P130, DOI 10.1016/j.ajog.2008.10.032
   Bruning A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00047
   Bruunsgaard H, 2006, DAN MED BULL, V53, P285
   Burdan F., 2015, COFFEE HLTH DIS PREV, P823
   Camouse MM, 2005, EXPERT REV ANTICANC, V5, P1061, DOI 10.1586/14737140.5.6.1061
   Cardenas C, 2014, BIOCHEM BIOPH RES CO, V447, P452, DOI 10.1016/j.bbrc.2014.04.026
   Cardenas C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023407
   Carrillo JA, 2000, THER DRUG MONIT, V22, P409, DOI 10.1097/00007691-200008000-00008
   Cavaliere V, 2009, TRANSL ONCOL, V2, P46, DOI 10.1593/tlo.08202
   Chae JI, 2014, PHYTOTHER RES, V28, P1879, DOI 10.1002/ptr.5217
   Chauhan P.S., 2011, J APPL PHARM SCI, V1, P67
   Chen JC, 2015, TZU CHI MED J, V27, P74, DOI 10.1016/j.tcmj.2015.03.002
   Chiang EPI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099631
   Choi DW, 2015, BIOMOL THER, V23, P128, DOI 10.4062/biomolther.2014.133
   Choi MJ, 2011, CHEM-BIOL INTERACT, V190, P102, DOI 10.1016/j.cbi.2011.02.013
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cuesta-Gragera A, 2015, EUR J PHARM SCI, V73, P57, DOI 10.1016/j.ejps.2015.03.018
   Dai JZ, 2017, CELL PHYSIOL BIOCHEM, V43, P247, DOI 10.1159/000480367
   dos Santos MD, 2006, BIOL PHARM BULL, V29, P2236, DOI 10.1248/bpb.29.2236
   de Mejia EG, 2014, TRENDS ENDOCRIN MET, V25, P489, DOI 10.1016/j.tem.2014.07.003
   Ding WX, 2014, HEPATOLOGY, V59, P1235, DOI 10.1002/hep.26736
   Dixit A, 2016, INDIAN J CLIN BIOCHE, V31, P125, DOI 10.1007/s12291-016-0561-1
   Dodurga Y, 2016, TUMOR BIOL, V37, P1933, DOI 10.1007/s13277-015-3984-z
   dos Santos JS, 2013, J BURN CARE RES, V34, P682, DOI 10.1097/BCR.0b013e3182839b1c
   Eini H, 2015, BIOCHEM PHARMACOL, V98, P110, DOI 10.1016/j.bcp.2015.08.092
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Carrasco-Legleu CE, 2006, WORLD J GASTROENTERO, V12, P6779, DOI 10.3748/wjg.v12.i42.6779
   Fahrioglu U, 2016, GENE, V576, P476, DOI 10.1016/j.gene.2015.10.061
   Feng D, 2013, EXP CELL RES, V319, P1697, DOI 10.1016/j.yexcr.2013.03.034
   Ferk F, 2014, MOL NUTR FOOD RES, V58, P229, DOI 10.1002/mnfr.201300154
   Firat U, 2015, EUR REV MED PHARMACO, V19, P1907
   Fukuma Y, 2015, BIOFACTORS, V41, P222, DOI 10.1002/biof.1218
   Galeone C, 2010, CANCER CAUSE CONTROL, V21, P1949, DOI 10.1007/s10552-010-9623-5
   Gasscht F, 2015, GENES NUTR, V10, DOI 10.1007/s12263-015-0501-3
   Genkinger J. M., 2015, COFFEE HLTH DIS PREV, P367
   GLOBOCAN, 2012, GLOB CANC FACTS FIG
   Godos J, 2014, INT J FOOD SCI NUTR, V65, P925, DOI 10.3109/09637486.2014.940287
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gressner O., 2010, OPEN C P J, V1
   Gu XS, 2012, EXPERT REV MOL MED, V14, DOI 10.1017/S1462399411002110
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   Hatzi VI, 2015, MUTAT RES-GEN TOX EN, V793, P71, DOI 10.1016/j.mrgentox.2015.08.002
   Higgins LG, 2008, TOXICOL APPL PHARM, V226, P328, DOI 10.1016/j.taap.2007.09.018
   Hosoi T, 2014, NEUROSCI LETT, V569, P23, DOI 10.1016/j.neulet.2014.03.053
   Hsu T, 2016, J GERIATR ONCOL, V7, P390, DOI 10.1016/j.jgo.2016.07.013
   Huber WW, 2004, ENVIRON MOL MUTAGEN, V44, P265, DOI 10.1002/em.20052
   Huber WW, 2003, MUTAT RES-FUND MOL M, V522, P57, DOI 10.1016/S0027-5107(02)00264-6
   Huber WW, 2002, ARCH TOXICOL, V76, P209, DOI 10.1007/s00204-002-0322-1
   Huo RC, 2016, MOL MED REP, V14, P3013, DOI 10.3892/mmr.2016.5648
   Hussain T, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7432797
   Jabir NR, 2018, SEMIN CANCER BIOL, V49, P56, DOI 10.1016/j.semcancer.2017.06.005
   Jabir NR, 2018, ANTI-CANCER AGENT ME, V18, P6, DOI 10.2174/1871520616666160520112839
   Jabir NR, 2012, INT J NANOMED, V7, P4391, DOI 10.2147/IJN.S33838
   Jaganathan SK, 2012, SCI WORLD J, DOI 10.1100/2012/372345
   Je YJ, 2009, INT J CANCER, V124, P1662, DOI 10.1002/ijc.24124
   Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017
   Kapuscinski J, 2002, BIOCHEM PHARMACOL, V63, P625, DOI 10.1016/S0006-2952(01)00904-2
   Kaur Gurpreet, 2015, Biotechnol Rep (Amst), V6, P64, DOI 10.1016/j.btre.2015.01.005
   Kim HG, 2006, TOXICOL APPL PHARM, V217, P332, DOI 10.1016/j.taap.2006.09.013
   Kim HG, 2012, FOOD CHEM, V133, P1521, DOI 10.1016/j.foodchem.2012.02.043
   Kim HG, 2009, TOXICOL LETT, V187, P28, DOI 10.1016/j.toxlet.2009.01.022
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim JY, 2004, CANCER LETT, V213, P147, DOI 10.1016/j.canlet.2004.04.002
   Kim JY, 2004, FEBS LETT, V569, P321, DOI 10.1016/j.febslet.2004.05.070
   Kotowski U, 2015, STRAHLENTHER ONKOL, V191, P511, DOI 10.1007/s00066-014-0807-x
   Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009
   Kronschlager M, 2014, EXP EYE RES, V127, P179, DOI 10.1016/j.exer.2014.07.023
   Kudugunti SK, 2010, CHEM-BIOL INTERACT, V188, P1, DOI 10.1016/j.cbi.2010.05.018
   Lee KA, 2012, J BIOMED SCI, V19, DOI [10.1186/1423-0127-19-60, 10.6117/kmeps.2012.19.3.001]
   Lee Y, 2010, EUR J PHARMACOL, V643, P21, DOI 10.1016/j.ejphar.2010.06.016
   Li RR, 2014, J BIOMED RES, V28, P423, DOI 10.7555/JBR.28.20120109
   Li Y, 2015, BRAZ J MED BIOL RES, V48, P502, DOI 10.1590/1414-431X20143729
   Lin HP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031286, 10.1371/journal.pone.0035240]
   Liu JB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147056
   Luo KW, 2014, J NUTR BIOCHEM, V25, P395, DOI 10.1016/j.jnutbio.2013.11.013
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathew TS, 2014, BIOCHEM BIOPH RES CO, V453, P411, DOI 10.1016/j.bbrc.2014.09.094
   Michaluart P, 1999, CANCER RES, V59, P2347
   Migliori M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117530
   Mileo AM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6475624
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moretti L, 2007, DRUG RESIST UPDATE, V10, P135, DOI 10.1016/j.drup.2007.05.001
   Moschetta M, 2014, BRIT J PHARMACOL, V171, P3801, DOI 10.1111/bph.12749
   Islam MT, 2018, CURR DRUG METAB, V19, P544, DOI 10.2174/1389200219666180302154551
   Nair S, 2008, BRIT J CANCER, V99, P2070, DOI 10.1038/sj.bjc.6604703
   Naso LG, 2014, J INORG BIOCHEM, V135, P86, DOI 10.1016/j.jinorgbio.2014.02.013
   Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090
   Neuwirthova J., 2017, KLIN ONKOL, V30, P106, DOI [10.14735/amko2017106, DOI 10.14735/AMKO2017106]
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Nikitina D, 2015, J NUTRIGENET NUTRIGE, V8, P174, DOI 10.1159/000439110
   Norat T, 2014, CANCER TREAT RES, V159, P35, DOI 10.1007/978-3-642-38007-5_3
   O'Neill CE, 2016, PSYCHONEUROENDOCRINO, V67, P40, DOI 10.1016/j.psyneuen.2016.01.030
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Oh JH, 2009, APOPTOSIS, V14, P1378, DOI 10.1007/s10495-009-0407-x
   Park GH, 2017, BIOMOL THER, V25, P337, DOI 10.4062/biomolther.2016.114
   Perveen A, 2015, ADV EXP MED BIOL, V822, P37, DOI 10.1007/978-3-319-08927-0_7
   Piosik J, 2003, MUTAT RES-FUND MOL M, V530, P47, DOI 10.1016/S0027-5107(03)00136-2
   Poillet-Perez L, 2015, REDOX BIOL, V4, P184, DOI 10.1016/j.redox.2014.12.003
   Poleszak E, 2016, PHARMACOL REP, V68, P56, DOI 10.1016/j.pharep.2015.06.138
   Preedy, 2015, COFFEE HLTH DIS PREV, P119
   Qian MJ, 2017, CLIN TRANSL MED, V6, DOI 10.1186/s40169-017-0154-5
   Rajesh E, 2015, J PHARM BIOALLIED SC, V7, pS181, DOI 10.4103/0975-7406.155895
   Sabisz M, 2008, CURR PHARM BIOTECHNO, V9, P325, DOI 10.2174/138920108785161497
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Schilter B, 1996, CARCINOGENESIS, V17, P2377, DOI 10.1093/carcin/17.11.2377
   Shacter E, 2002, ONCOLOGY-NY, V16, P217
   Shen T, 2010, BIOL PHARM BULL, V33, P1159, DOI 10.1248/bpb.33.1159
   Shirley KL, 2003, NEUROPSYCHOPHARMACOL, V28, P961, DOI 10.1038/sj.npp.1300123
   Sinha R, 2012, AM J CLIN NUTR, V96, P374, DOI 10.3945/ajcn.111.031328
   Sinha RA, 2014, HEPATOLOGY, V59, P1366, DOI 10.1002/hep.26667
   Tabrez S, 2013, J ENVIRON SCI HEAL C, V31, P67, DOI 10.1080/10590501.2013.763577
   Tseng TH, 2014, J BIOMED SCI, V21, DOI 10.1186/1423-0127-21-61
   Um HJ, 2011, J PINEAL RES, V50, P359, DOI 10.1111/j.1600-079X.2010.00851.x
   Um HJ, 2010, CHEM-BIOL INTERACT, V186, P36, DOI 10.1016/j.cbi.2010.04.013
   van Cruchten STJ, 2010, J NUTR BIOCHEM, V21, P757, DOI 10.1016/j.jnutbio.2009.05.001
   Wang JS, 2016, MOL MED REP, V14, P4063, DOI 10.3892/mmr.2016.5743
   Wang Q, 2015, INT IMMUNOPHARMACOL, V25, P340, DOI 10.1016/j.intimp.2015.02.012
   Wang S, 2012, BIOCHEM BIOPH RES CO, V421, P567, DOI 10.1016/j.bbrc.2012.04.046
   Wang T, 2014, NEUROPHARMACOLOGY, V86, P203, DOI 10.1016/j.neuropharm.2014.06.029
   Wilson KM, 2011, JNCI-J NATL CANCER I, V103, P876, DOI 10.1093/jnci/djr151
   Woo SM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.472
   Woziwodzka A, 2011, BIOORG CHEM, V39, P10, DOI 10.1016/j.bioorg.2010.11.001
   Wu J, 2011, CANCER LETT, V308, P43, DOI 10.1016/j.canlet.2011.04.012
   Xu F, 2015, NEUROIMAGE, V110, P39, DOI 10.1016/j.neuroimage.2015.01.046
   Xu JG, 2012, J AGR FOOD CHEM, V60, P11625, DOI 10.1021/jf303771s
   Xu L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.322
   Yang GW, 2015, INT J MOL SCI, V16, P24011, DOI 10.3390/ijms161024011
   Yang WS, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/518183
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Yu SH, 2011, PLANTA MED, V77, P907, DOI 10.1055/s-0030-1250682
   Zhang JJ, 2015, J ORGANOMET CHEM, V782, P37, DOI 10.1016/j.jorganchem.2014.10.041
   Zhang XH, 2010, JNCI-J NATL CANCER I, V102, P771, DOI 10.1093/jnci/djq107
   Zhao Y, 2014, J ETHNOPHARMACOL, V156, P147, DOI 10.1016/j.jep.2014.08.043
NR 141
TC 6
Z9 6
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-6433
EI 1872-8081
J9 BIOFACTORS
JI Biofactors
PD JUL-AUG
PY 2018
VL 44
IS 4
BP 315
EP 326
DI 10.1002/biof.1437
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA GR0LF
UT WOS:000442207300001
DA 2022-04-25
ER

PT J
AU Li, G
   Yang, TQ
   Chen, YL
   Bao, JP
   Wu, D
   Hu, XH
   Feng, CX
   Xu, LX
   Li, M
   Li, G
   Jin, MF
   Xu, YY
   Zhang, R
   Qian, GH
   Pan, J
AF Li, Gen
   Yang, Tianquan
   Chen, Yanling
   Bao, Jianping
   Wu, Di
   Hu, Xiaohan
   Feng, Chenxi
   Xu, Lixiao
   Li, Mei
   Li, Gang
   Jin, Meifang
   Xu, Yunyun
   Zhang, Rui
   Qian, Guanghui
   Pan, Jian
TI USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of
   CyclinD1
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE glioblastoma multiforme; USP5; CyclinD1; deubiquitination; cell cycle
ID CELL LUNG-CANCER; COLORECTAL-CANCER; UBIQUITIN; INHIBITION; DEGRADATION;
   PROGRESSION; PATHWAY; TUMORIGENESIS; RESISTANCE; INVASION
AB Glioblastoma multiforme (GBM) is one of the most malignant primary tumors in humans. Despite standard therapeutic strategy with tumor resection combined with radiochemotherapy, the prognosis remains disappointed. Recently, deubiquitinating enzymes (DUBs) has been reported as potential cancer therapy targets due to their multifunctions involved in the regulation of tumorigenesis, cell cycle, apoptosis, and autophagy. In this study, we found that knockdown of ubiquitin specific protease (USP5), a family member of DUB, could significantly suppress GBM cell line U251 and DBTRG-05MG proliferation and colony formation by inducing cell cycle G1/S arrest, which was correlated with downregulation of CyclinD1 protein level. CyclinD1 had been reported to play a critical role in the tumorigenesis and development of GBM via regulating cell cycle transition. Overexpression of USP5 could significantly extend the half-life of CyclinD1, while knockdown of USP5 decreased the protein level of CyclinD1, which could be restored by proteasome inhibitor MG-132. Indeed, USP5 was found to directly interact with CyclinD1, and decrease its K48-linked polyubiquitination level. Furthermore, knockdown of USP5 in U251 cells remarkably inhibited tumor growth in vivo. Taken together, these findings demonstrate that USP5 plays a critical role in tumorigenesis and progression of GBM by stabilizing CyclinD1 protein. Targeting USP5 could be a potential therapeutic strategy for GBM.
C1 [Li, Gen; Wu, Di; Hu, Xiaohan; Feng, Chenxi; Xu, Lixiao; Li, Mei; Li, Gang; Jin, Meifang; Xu, Yunyun; Qian, Guanghui; Pan, Jian] Soochow Univ, Inst Pediat Res, Childrens Hosp, Suzhou, Peoples R China.
   [Li, Gen] Soochow Univ, Coll Pharmaceut Sci, Lab Mol Neuropathol, Suzhou, Peoples R China.
   [Yang, Tianquan] Soochow Univ, Dept Neurosurg, Childrens Hosp, Suzhou, Peoples R China.
   [Chen, Yanling] Soochow Univ, Sch Basic Med & Biol Sci, Suzhou, Peoples R China.
   [Bao, Jianping] Soochow Univ, Dept Neonatol, Childrens Hosp, Suzhou, Peoples R China.
   [Zhang, Rui] Soochow Univ, Clin Pediat Sch, Suzhou, Peoples R China.
RP Qian, GH; Pan, J (corresponding author), Soochow Univ, Inst Pediat Res, Childrens Hosp, Suzhou, Peoples R China.
EM ghqian@suda.edu.cn; panjian2008@163.com
FU National Natural Science FoundationNational Natural Science Foundation
   of China (NSFC) [81702737, 81902972, 82072767, 81770145, 81971477,
   81701596]; Natural Science Foundation of Jiangsu ProvinceNatural Science
   Foundation of Jiangsu Province [BK20191175]; Jiangsu Provincial Medical
   Young Talents [QNRC2016756]; Applied Foundational Research of Medical
   and Health Care of Suzhou City [SYS2019086]; Suzhou Health Talent
   Training Project [GSWS2020048]; project of Soochow Science and
   Technology Plan [SYS201761]
FX This work was supported by the grants from the National Natural Science
   Foundation (81702737, 81902972, 82072767, 81770145, 81971477, 81701596),
   Natural Science Foundation of Jiangsu Province BK20191175, Jiangsu
   Provincial Medical Young Talents (QNRC2016756), the Applied Foundational
   Research of Medical and Health Care of Suzhou City (SYS2019086), Suzhou
   Health Talent Training Project (YX, GSWS2020048), the project of Soochow
   Science and Technology Plan (XH, SYS201761).
CR AnsariLari MA, 1996, GENOME RES, V6, P314, DOI 10.1101/gr.6.4.314
   Cao MN, 2014, BBA-GEN SUBJECTS, V1840, P2004, DOI 10.1016/j.bbagen.2014.02.006
   Carlsson SK, 2014, EMBO MOL MED, V6, P1359, DOI 10.15252/emmm.201302627
   Chang CJ, 2009, BIOCHEM BIOPH RES CO, V380, P236, DOI 10.1016/j.bbrc.2009.01.040
   Chang H, 2018, CELL MOL NEUROBIOL, V38, P421, DOI 10.1007/s10571-017-0485-1
   Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014
   Cheung BB, 2021, ONCOGENE, V40, P2367, DOI 10.1038/s41388-021-01712-w
   Chuang SJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21476-w
   Clague MJ, 2013, PHYSIOL REV, V93, P1289, DOI 10.1152/physrev.00002.2013
   Davis MI, 2016, J BIOL CHEM, V291, P24628, DOI 10.1074/jbc.M116.738567
   Du YH, 2019, AGING-US, V11, P9778, DOI 10.18632/aging.102425
   Gadotti VM, 2018, MOL BRAIN, V11, DOI 10.1186/s13041-018-0405-4
   Guo P, 2013, BIOCHEM BIOPH RES CO, V441, P186, DOI 10.1016/j.bbrc.2013.10.034
   Harrigan JA, 2018, NAT REV DRUG DISCOV, V17, P57, DOI 10.1038/nrd.2017.152
   Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960
   Issaenko OA, 2012, CELL CYCLE, V11, P1804, DOI 10.4161/cc.20174
   Joksimovic SL, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao4425
   Kaistha BP, 2017, ONCOTARGET, V8, P66215, DOI 10.18632/oncotarget.19882
   Kategaya L, 2017, NATURE, V550, P534, DOI 10.1038/nature24006
   Kim SY, 2018, INT J ONCOL, V52, P1705, DOI 10.3892/ijo.2018.4302
   Kitamura H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031209
   Lee KY, 2010, J BIOL CHEM, V285, P10362, DOI 10.1074/jbc.M109.092544
   Li XY, 2017, BIOCHEM BIOPH RES CO, V492, P48, DOI 10.1016/j.bbrc.2017.08.040
   Lian J, 2020, J CANCER, V11, P6802, DOI 10.7150/jca.48536
   Ling XM, 2017, FEBS LETT, V591, P875, DOI 10.1002/1873-3468.12580
   Liu J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01947-w
   Liu QX, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aar2824
   Liu Y, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600350
   Ma XJ, 2018, AM J CANCER RES, V8, P2284
   Magiera K, 2017, CELL CHEM BIOL, V24, P458, DOI 10.1016/j.chembiol.2017.03.002
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Meng J, 2019, THERANOSTICS, V9, P573, DOI 10.7150/thno.27654
   Mevissen TET, 2017, ANNU REV BIOCHEM, V86, P159, DOI 10.1146/annurev-biochem-061516-044916
   Mollaoglu G, 2017, CANCER CELL, V31, P270, DOI 10.1016/j.ccell.2016.12.005
   Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090
   Nakajima S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084899
   Okada K, 2013, BIOORG MED CHEM LETT, V23, P4328, DOI 10.1016/j.bmcl.2013.05.093
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P1, DOI 10.1093/neuonc/nou223
   Pal A, 2014, CANCER RES, V74, P4955, DOI 10.1158/0008-5472.CAN-14-1211
   Panner A, 2010, CANCER RES, V70, P5046, DOI 10.1158/0008-5472.CAN-09-3979
   Qian GH, 2016, BIOCHEM BIOPH RES CO, V474, P491, DOI 10.1016/j.bbrc.2016.04.135
   Rape M, 2018, NAT REV MOL CELL BIO, V19, P59, DOI 10.1038/nrm.2017.83
   Reardon DA, 2017, SEMIN IMMUNOPATHOL, V39, P225, DOI 10.1007/s00281-016-0616-7
   Rehman SAA, 2016, MOL CELL, V63, P146, DOI 10.1016/j.molcel.2016.05.009
   Rowinsky EK, 2020, INVEST NEW DRUG, V38, P1448, DOI 10.1007/s10637-020-00915-4
   Santoni M, 2013, CURR PROTEIN PEPT SC, V14, P133, DOI 10.2174/1389203711314020005
   Siebzehnrubl FA, 2013, EMBO MOL MED, V5, P1196, DOI 10.1002/emmm.201302827
   Stemkowski P, 2017, CELL REP, V18, P2289, DOI 10.1016/j.celrep.2017.02.050
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Sun HL, 2020, MOL CELL, V80, P633, DOI 10.1016/j.molcel.2020.10.026
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451
   Vashistha V, 2020, BIOCHEM BIOPHYS REP, V24, DOI 10.1016/j.bbrep.2020.100846
   Wang JL, 2010, STEM CELLS, V28, P17, DOI 10.1002/stem.261
   Wang SY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.450
   Wang X, 2015, CHEM BIOL DRUG DES, V86, P1036, DOI 10.1111/cbdd.12571
   Weisberg EL, 2017, NAT CHEM BIOL, V13, P1207, DOI [10.1038/nchembio.2486, 10.1038/NCHEMBIO.2486]
   Weller M, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.17
   WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032
   Wu HC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4214
   Wu LT, 2020, J CELL BIOCHEM, V121, P642, DOI 10.1002/jcb.29309
   Xia Q, 2020, ONCOGENE, V39, P5902, DOI 10.1038/s41388-020-01400-1
   Xie X, 2018, J CELL SCI, V131, DOI 10.1242/jcs.210856
   Xu X, 2019, THERANOSTICS, V9, P4208, DOI 10.7150/thno.33803
   Xue SD, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00668
   Yan FJ, 2017, HEPATOLOGY, V65, P1492, DOI 10.1002/hep.28971
   Young MJ, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0522-0
   Yuan JH, 2021, MOL CARCINOGEN, V60, P265, DOI 10.1002/mc.23290
NR 68
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 16
PY 2021
VL 12
DI 10.3389/fphar.2021.720307
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UM6UN
UT WOS:000693465700001
PM 34483932
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Santos, P
   Almeida, F
AF Santos, Patrick
   Almeida, Fausto
TI Role of Exosomal miRNAs and the Tumor Microenvironment in Drug
   Resistance
SO CELLS
LA English
DT Review
DE exosomal miRNAs; chemoresistance; therapy resistance; extracellular
   vesicles
ID EPITHELIAL-MESENCHYMAL TRANSITION; PANCREATIC-CANCER CELLS; STEM-CELLS;
   CISPLATIN RESISTANCE; COLORECTAL-CANCER; PROSTATE-CANCER;
   P-GLYCOPROTEIN; LIGAND 2; AUTOPHAGY; HETEROGENEITY
AB Tumor microenvironment (TME) is composed of different cellular populations, such as stromal, immune, endothelial, and cancer stem cells. TME represents a key factor for tumor heterogeneity maintenance, tumor progression, and drug resistance. The transport of molecules via extracellular vesicles emerged as a key messenger in intercellular communication in the TME. Exosomes are small double-layered lipid extracellular vesicles that can carry a variety of molecules, including proteins, lipids, and nucleic acids. Exosomal miRNA released by cancer cells can mediate phenotypical changes in the cells of TME to promote tumor growth and therapy resistance, for example, fibroblast- and macrophages-induced differentiation. Cancer stem cells can transfer and enhance drug resistance in neighboring sensitive cancer cells by releasing exosomal miRNAs that target antiapoptotic and immune-suppressive pathways. Exosomes induce drug resistance by carrying ABC transporters, which export chemotherapeutic agents out of the recipient cells, thereby reducing the drug concentration to suboptimal levels. Exosome biogenesis inhibitors represent a promising adjunct therapeutic approach in cancer therapy to avoid the acquisition of a resistant phenotype. In conclusion, exosomal miRNAs play a crucial role in the TME to confer drug resistance and survivability to tumor cells, and we also highlight the need for further investigations in this promising field.
C1 [Santos, Patrick; Almeida, Fausto] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, 3900 Bandeirantes Ave, BR-14049900 Sao Paulo, SP, Brazil.
RP Almeida, F (corresponding author), Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Biochem & Immunol, 3900 Bandeirantes Ave, BR-14049900 Sao Paulo, SP, Brazil.
EM patricksantos@usp.br; fbralmeida@usp.br
RI dos Santos, Patrick Wellington da Silva/M-5709-2019; Almeida,
   Fausto/N-6540-2013
OI dos Santos, Patrick Wellington da Silva/0000-0001-5722-023X; Almeida,
   Fausto/0000-0002-3782-3698
FU Fundacao de Amparo a Pesquisa do Estado de Sao PauloFundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP) [2016/03322-7]; Fundacao de
   Apoio ao Ensino, Pesquisa e Assistencia do Hospital das Clinicas da
   Faculdade de Medicina de Ribeirao Preto da Universidade de Sao Paulo;
   CNPq (Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico)Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPQ) [420670/2018-1]; CAPES (Coordenacao de
   Aperfeicoamento de Nivel Superior)Coordenacao de Aperfeicoamento de
   Pessoal de Nivel Superior (CAPES)
FX This research was funded by Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (2016/03322-7); Fundacao de Apoio ao Ensino, Pesquisa e
   Assistencia do Hospital das Clinicas da Faculdade de Medicina de
   Ribeirao Preto da Universidade de Sao Paulo; CNPq (Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico - 420670/2018-1); and CAPES
   (Coordenacao de Aperfeicoamento de Nivel Superior).
CR Ahmed F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00173
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4
   Azmi AS, 2013, CANCER METAST REV, V32, P623, DOI 10.1007/s10555-013-9441-9
   Bach DH, 2017, INT J CANCER, V141, P220, DOI 10.1002/ijc.30669
   Bae Susan, 2018, Genes Cancer, V9, P87, DOI 10.18632/genesandcancer.172
   Bayraktar R, 2018, CANCER METAST REV, V37, P33, DOI 10.1007/s10555-017-9724-7
   Begicevic RR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112362
   Bigagli E, 2019, CANCER GENOM PROTEOM, V16, P163, DOI 10.21873/cgp.20122
   Binenbaum Y, 2018, CANCER RES, V78, P5287, DOI 10.1158/0008-5472.CAN-18-0124
   Cavalcante LD, 2014, EUR J PHARMACOL, V741, P8, DOI [10.1010/j.ejphar.2014.07.041, 10.1016/j.ejphar.2014.07.041]
   Chang JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004766
   Chen JL, 2017, J CELL MOL MED, V21, P3679, DOI 10.1111/jcmm.13278
   Chen X, 2018, CANCER LETT, V435, P80, DOI 10.1016/j.canlet.2018.08.001
   Chen X, 2017, ONCOL REP, V38, P522, DOI 10.3892/or.2017.5697
   Chen Yi, 2019, Jishengchong Yu Yixue Kunchong Xuebao, V26, P1, DOI 10.3969/j.issn.1005-0507.2019.01.001
   Colak S, 2014, FEBS J, V281, P4779, DOI 10.1111/febs.13023
   Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w
   Corcoran C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050999
   Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166
   Datta A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26411-7
   Datta A, 2017, CANCER LETT, V408, P73, DOI 10.1016/j.canlet.2017.08.020
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Dutta S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097580
   Faict S, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0139-7
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0
   Fang Y, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.111543
   Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2
   Folkerts H, 2019, MED RES REV, V39, P517, DOI 10.1002/med.21531
   Fu X, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0677-7
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Gangoda L, 2015, PROTEOMICS, V15, P260, DOI 10.1002/pmic.201400234
   Gavert N, 2008, TRENDS MOL MED, V14, P199, DOI 10.1016/j.molmed.2008.03.004
   Gewirtz DA, 2013, AUTOPHAGY, V9, P1263, DOI 10.4161/auto.25233
   Greening DW, 2015, SEMIN CELL DEV BIOL, V40, P60, DOI 10.1016/j.semcdb.2015.02.008
   Guo H, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1051-3
   Guo S, 2018, INT J BIOL SCI, V14, P2083, DOI 10.7150/ijbs.25720
   Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z
   Han L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0980-8
   Han ML, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2250-5
   Hannafon Bethany N, 2015, Stem Cell Investig, V2, P11, DOI 10.3978/j.issn.2306-9759.2015.05.02
   Hardin H, 2018, LAB INVEST, V98, P1133, DOI 10.1038/s41374-018-0065-0
   Hessvik NP, 2018, CELL MOL LIFE SCI, V75, P193, DOI 10.1007/s00018-017-2595-9
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hsieh CH, 2018, NEOPLASIA, V20, P775, DOI 10.1016/j.neo.2018.06.004
   Hsu HH, 2019, CANCERS, V11, DOI 10.3390/cancers11101576
   Huang F, 2018, WORLD J GASTROENTERO, V24, P4643, DOI 10.3748/wjg.v24.i41.4643
   Huang LM, 2019, CELL SIGNAL, V63, DOI 10.1016/j.cellsig.2019.109385
   Huang T, 2019, INT J BIOL SCI, V15, P1, DOI 10.7150/ijbs.27796
   Huang Z, 2018, INT J BIOL SCI, V14, P2094, DOI 10.7150/ijbs.28288
   Im EJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09387-4
   Janiszewska M, 2020, ONCOGENE, V39, P2031, DOI 10.1038/s41388-019-1127-5
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Januchowski R, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0278-z
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kanlikilicer P, 2018, EBIOMEDICINE, V38, P100, DOI 10.1016/j.ebiom.2018.11.004
   Kim WT, 2017, BMB REP, V50, P285, DOI 10.5483/BMBRep.2017.50.6.039
   Koch R, 2016, CLIN CANCER RES, V22, P395, DOI 10.1158/1078-0432.CCR-15-0577
   Kosgodage US, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051007
   La Shu S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31323-7
   Lai SC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1442-2
   Li DB, 2020, CANCER SCI, V111, P47, DOI 10.1111/cas.14230
   Li I, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0975-5
   Li Q, 2013, SCI REP-UK, V3, DOI 10.1038/srep02038
   Li XJ, 2017, CELL PHYSIOL BIOCHEM, V44, P1741, DOI 10.1159/000485780
   Lin F, 2020, INT J ONCOL, V56, P151, DOI 10.3892/ijo.2019.4933
   Lindoso Rafael Soares, 2017, Stem Cell Investig, V4, P75, DOI 10.21037/sci.2017.08.08
   Liu DX, 2019, ONCOL LETT, V17, P323, DOI 10.3892/ol.2018.9584
   Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7
   Lv MM, 2014, TUMOR BIOL, V35, P10773, DOI 10.1007/s13277-014-2377-z
   Ma YZ, 2019, INT J NANOMED, V14, P8121, DOI 10.2147/IJN.S221383
   Ma ZJ, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287-019-1149-5
   Maacha S, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0965-7
   Mansoori B, 2017, ADV PHARM BULL, V7, P339, DOI 10.15171/apb.2017.041
   Mashouri L, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0991-5
   Milman N, 2019, DRUG RESIST UPDATE, V45, P1, DOI 10.1016/j.drup.2019.07.003
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Netea-Maier RT, 2018, CANCER LETT, V413, P102, DOI 10.1016/j.canlet.2017.10.037
   Nikolaou M, 2018, CLIN EXP METASTAS, V35, P309, DOI 10.1007/s10585-018-9903-0
   Panigrahi GK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22068-4
   Park JE, 2019, ONCOGENE, V38, P5158, DOI 10.1038/s41388-019-0782-x
   Patel GK, 2017, BRIT J CANCER, V116, P609, DOI 10.1038/bjc.2017.18
   Qin XB, 2017, INT J NANOMED, V12, P3721, DOI 10.2147/IJN.S131516
   Qin X, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1604-0
   Qu Y, 2017, J CELL MOL MED, V21, P2491, DOI 10.1111/jcmm.13170
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353
   Ringuette Goulet C, 2018, MOL CANCER RES, V16, P1196, DOI [10.1158/1541-7786.MCR-17-0784, DOI 10.1158/1541-7786.MCR-17-0784]
   Sanchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540
   Santos JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19339-5
   Sawa-Wejksza K, 2018, ARCH IMMUNOL THER EX, V66, P97, DOI 10.1007/s00005-017-0480-8
   Seo HA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010029
   Sharma A, 2017, NANOMEDICINE-UK, V12, P2137, DOI 10.2217/nnm-2017-0184
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Soekmadji C, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/454837
   Sousa D, 2020, CANCERS, V12, DOI 10.3390/cancers12010200
   Steinbichler TB, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0970-x
   Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180
   Sullivan R, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00194
   Sun JY, 2019, MOL MED REP, V20, P323, DOI 10.3892/mmr.2019.10237
   Sun ZP, 2017, ONCOTARGET, V8, P93839, DOI 10.18632/oncotarget.21288
   Tang TT, 2018, FASEB J, V32, P6965, DOI 10.1096/fj.201801013R
   Togo Shinsaku, 2013, Cancers (Basel), V5, P149, DOI 10.3390/cancers5010149
   Tomasetti M, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.153
   Tomono T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200015
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1
   Vessoni AT, 2020, ONCOGENE, V39, P2055, DOI 10.1038/s41388-019-1128-4
   Wang B, 2019, CURR DRUG METAB, V20, P804, DOI 10.2174/1389200220666190819151946
   Wang D, 2020, CANCER LETT, V474, P36, DOI 10.1016/j.canlet.2020.01.005
   Wang JH, 2017, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00533
   Wang M, 2019, INT J ONCOL, V54, P326, DOI 10.3892/ijo.2018.4601
   Wang XF, 2018, CANCER RES, V78, P4586, DOI 10.1158/0008-5472.CAN-17-3841
   Webber JP, 2015, ONCOGENE, V34, P319, DOI 10.1038/onc.2013.560
   Wu HJ, 2020, ONCOGENE, V39, P2539, DOI 10.1038/s41388-020-1162-2
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Xiao DY, 2016, CANCER LETT, V376, P318, DOI 10.1016/j.canlet.2016.03.050
   Xu JS, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/4837370
   Xu J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215210
   Xu R, 2018, NAT REV CLIN ONCOL, V15, P617, DOI 10.1038/s41571-018-0036-9
   Xu Y, 2019, J CELL PHYSIOL, V234, P21380, DOI 10.1002/jcp.28747
   Yang FM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0718-4
   Yang ZY, 2020, CELL ONCOL, V43, P123, DOI 10.1007/s13402-019-00476-6
   Yano K, 2018, BIOL PHARM BULL, V41, P11, DOI 10.1248/bpb.b17-00725
   Yeon JH, 2018, ACTA BIOMATER, V76, P146, DOI 10.1016/j.actbio.2018.07.001
   Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150
   Yin JX, 2019, EBIOMEDICINE, V42, P238, DOI 10.1016/j.ebiom.2019.03.016
   Yuwen DL, 2019, CANCER EPIDEM BIOMAR, V28, P163, DOI 10.1158/1055-9965.EPI-18-0569
   Zeng AL, 2018, CANCER LETT, V436, P10, DOI 10.1016/j.canlet.2018.08.004
   Zhang FF, 2014, EUR J PHARMACOL, V738, P83, DOI 10.1016/j.ejphar.2014.05.026
   Zhang HY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01168-8
   Zhang J, 2010, PROG MOL BIOL TRANSL, V95, P31, DOI 10.1016/B978-0-12-385071-3.00003-4
   Zhang XN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0959-5
   Zhang Y, 2018, BIOCHEM BIOPH RES CO, V507, P457, DOI 10.1016/j.bbrc.2018.11.061
   Zheng PM, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0528-y
   Zhou Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0965-2
   Zhu XL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1095-1
NR 138
TC 29
Z9 31
U1 4
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUN
PY 2020
VL 9
IS 6
AR 1450
DI 10.3390/cells9061450
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA MN3QW
UT WOS:000550760100001
PM 32545155
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Galluzzi, L
   Morselli, E
   Kepp, O
   Vitale, I
   Pinti, M
   Kroemer, G
AF Galluzzi, Lorenzo
   Morselli, Eugenia
   Kepp, Oliver
   Vitale, Ilio
   Pinti, Marcello
   Kroemer, Guido
TI Mitochondrial Liaisons of p53
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID TUMOR-SUPPRESSOR P53; WILD-TYPE P53; ADENINE-NUCLEOTIDE TRANSLOCATOR;
   APOPTOSIS-INDUCING FACTOR; TRANSITION PORE COMPLEX; PROGRAMMED
   CELL-DEATH; DNA-BINDING DOMAIN; STRESS-INDUCED APOPTOSIS;
   COLORECTAL-CANCER CELLS; BCL-2 PROTEIN FAMILY
AB Mitochondria play a central role in cell survival and cell death. While producing the bulk of intracellular ATP, mitochondrial respiration represents the most prominent source of harmful reactive oxygen species. Mitochondria participate in many anabolic pathways, including cholesterol and nucleotide biosynthesis, yet also control multiple biochemical cascades that contribute to the programmed demise of cells. The tumor suppressor protein p53 is best known for its ability to orchestrate a transcriptional response to stress that can have multiple outcomes, including cell cycle arrest and cell death. p53-mediated tumor suppression, however, also involves transcription-independent mechanisms. Cytoplasmic p53 can physically interact with members of the BCL-2 protein family, thereby promoting mitochondrial membrane permeabilization. Moreover, extranuclear p53 can suppress autophagy, a major prosurvival mechanism that is activated in response to multiple stress conditions. Thirty years have passed since its discovery, and p53 has been ascribed with an ever-increasing number of functions. For instance, p53 has turned out to influence the cell's redox status, by transactivating either anti- or pro-oxidant factors, and to regulate the metabolic switch between glycolysis and aerobic respiration. In this review, we will analyze the mechanisms by which p53 affects the balance between the vital and lethal functions of mitochondria. Antioxid. Redox Signal. 15, 1691-1714.
C1 [Galluzzi, Lorenzo; Morselli, Eugenia; Kepp, Oliver; Vitale, Ilio; Kroemer, Guido] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France.
   [Pinti, Marcello] Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, Modena, Italy.
   [Kroemer, Guido] Ctr Rech Cordeliers, Paris, France.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, Paris, France.
   [Kroemer, Guido] Univ Paris 05, Paris, France.
   [Galluzzi, Lorenzo; Morselli, Eugenia; Kepp, Oliver; Vitale, Ilio] Univ Paris 11, Villejuif, France.
RP Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1, F-94805 Paris, France.
EM kroemer@orange.fr
RI Kroemer, Guido/AAY-9859-2020; Pinti, Marcello/C-9351-2015; Kepp,
   Oliver/N-2763-2017; Galluzzi, Lorenzo/K-2709-2012; Galluzzi,
   Lorenzo/AAG-6294-2019; Galluzzi, Lorenzo/AAH-3286-2021; Galluzzi,
   Lorenzo/AAG-6432-2019; Vitale, Ilio/M-3960-2017; KROEMER,
   Guido/B-4263-2013
OI Pinti, Marcello/0000-0001-9118-1262; Kepp, Oliver/0000-0002-6081-9558;
   Galluzzi, Lorenzo/0000-0003-2257-8500; Vitale, Ilio/0000-0002-5918-1841;
   KROEMER, Guido/0000-0002-9334-4405
FU Ligue Nationale contre le Cancer (Equipe labellisee)Ligue nationale
   contre le cancer; Agence Nationale pour la RechercheFrench National
   Research Agency (ANR); European CommissionEuropean CommissionEuropean
   Commission Joint Research Centre; Fondation pour la Recherche
   MedicaleFondation pour la Recherche Medicale; Institut National du
   CancerInstitut National du Cancer (INCA) France; Canceropole
   Ile-de-FranceRegion Ile-de-France; European UnionEuropean Commission;
   ApopTrain; INSERMInstitut National de la Sante et de la Recherche
   Medicale (Inserm)European Commission
FX G. K. is supported by the Ligue Nationale contre le Cancer (Equipe
   labellisee), Agence Nationale pour la Recherche, European Commission
   (Apo-Sys, ChemoRes, ApopTrain, Active p53), Fondation pour la Recherche
   Medicale, Institut National du Cancer, and Canceropole Ile-de-France.
   L.G. is supported by the Apo-Sys consortium of the European Union. E. M.
   is funded by a Ph.D. student grant from ApopTrain. O.K. receives a
   postdoctoral fellowship from INSERM.
CR Abida WM, 2008, CANCER RES, V68, P352, DOI 10.1158/0008-5472.CAN-07-2069
   AbouElela S, 1997, CANCER LETT, V117, P23, DOI 10.1016/S0304-3835(97)00196-1
   Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0
   AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500
   Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303
   ALTMANN R, 1890, ELEMENTARORGANISMEN, P145
   Araki N, 2000, ELECTROPHORESIS, V21, P1880, DOI 10.1002/(SICI)1522-2683(20000501)21:9<1880::AID-ELPS1880>3.3.CO;2-0
   Arima Y, 2005, J BIOL CHEM, V280, P19166, DOI 10.1074/jbc.M410691200
   Bauer DE, 2004, FASEB J, V18, P1303, DOI 10.1096/fj.03-1001fje
   Belzacq AS, 2003, CANCER RES, V63, P541
   Benda C., 1898, ARCH ANAT PHYSL, V73, P393
   Bensaad K, 2007, TRENDS CELL BIOL, V17, P286, DOI 10.1016/j.tcb.2007.04.004
   Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036
   Bishop AJR, 2003, CANCER RES, V63, P5335
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905
   Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005
   Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003
   BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0
   Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609
   Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569
   Budanov AV, 2002, ONCOGENE, V21, P6017, DOI 10.1038/sj.onc.1205877
   Buettner VL, 1997, MUTAT RES-FUND MOL M, V379, P13, DOI 10.1016/S0027-5107(97)00078-X
   Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808
   Burr KLA, 2005, ONCOGENE, V24, P4315, DOI 10.1038/sj.onc.1208604
   CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0
   Cande C, 2004, CELL DEATH DIFFER, V11, P591, DOI 10.1038/sj.cdd.4401400
   Cano CE, 2009, CANCER RES, V69, P219, DOI 10.1158/0008-5472.CAN-08-2320
   CHANG C, 1979, J VIROL, V31, P463, DOI 10.1128/JVI.31.2.463-471.1979
   Chatoo W, 2009, J NEUROSCI, V29, P529, DOI 10.1523/JNEUROSCI.5303-08.2009
   Chen DX, 2006, CANCER RES, V66, P3485, DOI 10.1158/0008-5472.CAN-05-4103
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Clemens MJ, 2004, ONCOGENE, V23, P3180, DOI 10.1038/sj.onc.1207544
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874
   CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404
   Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Criollo A, 2009, CELL CYCLE, V8, P2319, DOI 10.4161/cc.8.15.9153
   DEFROMENTEL CC, 1987, INT J CANCER, V39, P185, DOI 10.1002/ijc.2910390211
   DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420
   DEPPERT W, 1987, MOL CELL BIOL, V7, P4453, DOI 10.1128/MCB.7.12.4453
   Ding HF, 1998, J BIOL CHEM, V273, P28378, DOI 10.1074/jbc.273.43.28378
   Donald SP, 2001, CANCER RES, V61, P1810
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105
   Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101
   Ekert PG, 2005, CURR OPIN CELL BIOL, V17, P626, DOI 10.1016/j.ceb.2005.09.001
   ELIYAHU D, 1985, NATURE, V316, P158, DOI 10.1038/316158a0
   ERNSTER L, 1981, J CELL BIOL, V91, pS227, DOI 10.1083/jcb.91.3.227s
   Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004
   Faraonio R, 2006, J BIOL CHEM, V281, P39776, DOI 10.1074/jbc.M605707200
   Farre JC, 2008, DEV CELL, V14, P365, DOI 10.1016/j.devcel.2007.12.011
   Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363
   Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9
   Frade JM, 1997, BIOESSAYS, V19, P827, DOI 10.1002/bies.950190913
   Frank S, 2003, BIOCHEM BIOPH RES CO, V304, P481, DOI 10.1016/S0006-291X(03)00620-X
   Gabaldon T, 2004, BBA-BIOENERGETICS, V1659, P212, DOI 10.1016/j.bbabio.2004.07.011
   Gabaldon T, 2007, PLOS COMPUT BIOL, V3, P2209, DOI 10.1371/journal.pcbi.0030219
   Galluzzi L, 2008, ONCOGENE, V27, P4633, DOI 10.1038/onc.2008.114
   Galluzzi L, 2008, CELL DEATH DIFFER, V15, P1113, DOI 10.1038/cdd.2008.28
   Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148
   Galluzzi L, 2008, CURR MOL MED, V8, P78
   Galluzzi L, 2010, MOL ASPECTS MED, V31, P1, DOI 10.1016/j.mam.2009.08.002
   Galluzzi L, 2010, CELL CYCLE, V9, P250, DOI 10.4161/cc.9.2.10493
   Galluzzi L, 2009, CELL HOST MICROBE, V5, P107, DOI 10.1016/j.chom.2009.01.002
   Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587
   Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459
   Gray MW, 1999, SCIENCE, V283, P1476, DOI 10.1126/science.283.5407.1476
   Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871
   Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Harms KL, 2006, CELL DEATH DIFFER, V13, P890, DOI 10.1038/sj.cdd.4401904
   Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397
   Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615
   Harrison B, 2008, J BIOL CHEM, V283, P9999, DOI 10.1074/jbc.M706040200
   HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170
   Heyne K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-54
   Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200
   Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2
   Ibrahim MM, 1998, BBA-MOL CELL RES, V1403, P254, DOI 10.1016/S0167-4889(98)00066-4
   Ichikawa W, 2006, CANCER CHEMOTH PHARM, V58, P794, DOI 10.1007/s00280-006-0217-6
   Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003
   ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0
   Iwakuma T, 2003, MOL CANCER RES, V1, P993
   Iyer JP, 2009, EXPERT OPIN THER TAR, V13, P849, DOI 10.1517/14728220903018932
   Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000
   Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946
   JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0
   Jiang P, 2006, MOL CELL BIOL, V26, P9071, DOI 10.1128/MCB.01025-06
   Johnson TM, 2005, NAT GENET, V37, P145, DOI 10.1038/ng1498
   Kawauchi K, 2008, NAT CELL BIOL, V10, P611, DOI 10.1038/ncb1724
   KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879
   Kondoh H, 2005, CANCER RES, V65, P177
   Koonin EV, 2002, CELL DEATH DIFFER, V9, P394, DOI 10.1038/sj.cdd.4400991
   KRESS M, 1979, J VIROL, V31, P472, DOI 10.1128/JVI.31.2.472-483.1979
   Kroemer G, 2005, CELL DEATH DIFFER, V12, P1463, DOI 10.1038/sj.cdd.4401724
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Kruse JP, 2009, J BIOL CHEM, V284, P3250, DOI 10.1074/jbc.M805658200
   Kulawiec Mariola, 2009, J Carcinog, V8, P8, DOI 10.4103/1477-3163.50893
   LANE DP, 1984, NATURE, V312, P596, DOI 10.1038/312596a0
   LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0
   Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351
   Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x
   Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524
   Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925
   Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004
   Lee JH, 2010, ONCOGENE, V29, P1431, DOI 10.1038/onc.2009.438
   Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737
   Li MY, 2003, SCIENCE, V302, P1972, DOI 10.1126/science.1091362
   Liang SH, 1999, J BIOL CHEM, V274, P32699, DOI 10.1074/jbc.274.46.32699
   LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9
   Liu G, 2002, ONCOGENE, V21, P7195, DOI 10.1038/sj.onc.1205862
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Liu ZH, 2005, CANCER RES, V65, P1647, DOI 10.1158/0008-5472.CAN-04-1754
   Lomonosova E, 2008, ONCOGENE, V27, pS2, DOI 10.1038/onc.2009.39
   Lyakhov IG, 2008, NUCLEIC ACIDS RES, V36, P3828, DOI 10.1093/nar/gkn189
   Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003
   MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599
   Maiuri MC, 2009, CELL DEATH DIFFER, V16, P87, DOI 10.1038/cdd.2008.131
   Maiuri MC, 2007, AUTOPHAGY, V3, P374, DOI 10.4161/auto.4237
   Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001
   Maiuri MC, 2009, CELL CYCLE, V8, P1571, DOI 10.4161/cc.8.10.8498
   Mankoff DA, 2007, CLIN CANCER RES, V13, P3460, DOI 10.1158/1078-0432.CCR-07-0074
   Marchenko ND, 2007, CELL CYCLE, V6, P1718, DOI 10.4161/cc.6.14.4503
   Marchenko ND, 2007, EMBO J, V26, P923, DOI 10.1038/sj.emboj.7601560
   Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202
   Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912
   Marshall KR, 2005, J BIOL CHEM, V280, P30735, DOI 10.1074/jbc.M414018200
   Martoriati A, 2005, ONCOGENE, V24, P1461, DOI 10.1038/sj.onc.1208256
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261
   Mathupala SP, 2009, SEMIN CANCER BIOL, V19, P17, DOI 10.1016/j.semcancer.2008.11.006
   Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776
   MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Matsuda K, 2002, CANCER RES, V62, P2883
   MELERO JA, 1979, VIROLOGY, V93, P466, DOI 10.1016/0042-6822(79)90250-2
   Michal G., 1999, BIOCH PATHWAYS ATLAS, P277
   Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195
   Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311
   Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9
   MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0
   MIYASHITA T, 1994, ONCOGENE, V9, P1799
   Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008
   Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601
   Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007
   Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527
   Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895
   Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751
   Morselli E, 2008, CELL RES, V18, P708, DOI 10.1038/cr.2008.77
   Morselli E, 2009, AGING-US, V1, P961, DOI 10.18632/aging.100110
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narkar VA, 2008, CELL, V134, P405, DOI 10.1016/j.cell.2008.06.051
   Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526
   Nowak J, 2009, MOL BIOL CELL, V20, P870, DOI 10.1091/mbc.E08-07-0671
   O'Connor JC, 2008, INVEST OPHTH VIS SCI, V49, P4237, DOI 10.1167/iovs.08-1963
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8
   Okamura S, 1999, ONCOL RES, V11, P281
   Okar DO, 2001, TRENDS BIOCHEM SCI, V26, P30, DOI 10.1016/S0968-0004(00)01699-6
   Olovnikov IA, 2009, SEMIN CANCER BIOL, V19, P32, DOI 10.1016/j.semcancer.2008.11.005
   Olsson A, 2007, CELL DEATH DIFFER, V14, P1561, DOI 10.1038/sj.cdd.4402196
   OROURKE RW, 1990, ONCOGENE, V5, P1829
   Pani G, 2009, INT J BIOCHEM CELL B, V41, P1002, DOI 10.1016/j.biocel.2008.10.011
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x
   Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5
   Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386
   Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6
   Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079
   Pietrzak M, 2008, BIOL CHEM, V389, P383, DOI 10.1515/BC.2008.039
   Pietsch EC, 2008, J BIOL CHEM, V283, P21294, DOI 10.1074/jbc.M710539200
   Pimkina J, 2009, J BIOL CHEM, V284, P2803, DOI 10.1074/jbc.M804705200
   Pohl U, 1999, CELL PHYSIOL BIOCHEM, V9, P29, DOI 10.1159/000016300
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Ponnamperuma RM, 2009, J PATHOL, V219, P263, DOI 10.1002/path.2600
   Porte S, 2009, J BIOL CHEM, V284, P17194, DOI 10.1074/jbc.M109.001800
   Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047
   Prats AC, 2002, PROG NUCLEIC ACID RE, V72, P367, DOI 10.1016/S0079-6603(02)72075-8
   Ravikumar Brinda, 2008, V445, P195, DOI 10.1007/978-1-59745-157-4_13
   Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623
   Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014
   Reichert AS, 2004, TRENDS GENET, V20, P555, DOI 10.1016/j.tig.2004.08.012
   Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395
   Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200
   Robles AI, 2001, CANCER RES, V61, P6660
   Rohaly G, 2005, CELL, V122, P21, DOI 10.1016/j.cell.2005.04.032
   Rong Y, 2008, ANNU REV PHYSIOL, V70, P73, DOI 10.1146/annurev.physiol.70.021507.105852
   Rosenbluth JM, 2009, AUTOPHAGY, V5, P114, DOI 10.4161/auto.5.1.7294
   ROTTER V, 1980, J VIROL, V36, P547, DOI 10.1128/JVI.36.2.547-555.1980
   Rubinsztein DC, 2007, NAT REV DRUG DISCOV, V6, P304, DOI 10.1038/nrd2272
   Ruiz-Lozano P, 1999, CELL GROWTH DIFFER, V10, P295
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Sansome C, 2001, FEBS LETT, V488, P110, DOI 10.1016/S0014-5793(00)02368-1
   Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866
   Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788
   Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x
   SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727
   Song G, 2009, CURR CANCER DRUG TAR, V9, P871, DOI 10.2174/156800909789760302
   Sot B, 2007, J BIOL CHEM, V282, P29193, DOI 10.1074/jbc.M705544200
   Soussi T, 2007, ONCOGENE, V26, P2145, DOI 10.1038/sj.onc.1210280
   Soussi T, 2005, BRIT J SURG, V92, P1331, DOI 10.1002/bjs.5177
   Stambolsky P, 2006, CELL DEATH DIFFER, V13, P2140, DOI 10.1038/sj.cdd.4401965
   Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660
   Sugars KL, 2001, NUCLEIC ACIDS RES, V29, P4530, DOI 10.1093/nar/29.22.4530
   Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061
   Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tasdemir E, 2008, CELL CYCLE, V7, P3006, DOI 10.4161/cc.7.19.6702
   Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730
   Tasdemir E, 2007, CELL CYCLE, V6, P2263, DOI 10.4161/cc.6.18.4681
   Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121
   Tolkovsky AM, 2009, BBA-MOL CELL RES, V1793, P1508, DOI 10.1016/j.bbamcr.2009.03.002
   Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200
   Trinei M, 2002, ONCOGENE, V21, P3872, DOI 10.1038/sj.onc.1205513
   Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780
   Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461
   Vaseva AV, 2009, CELL CYCLE, V8, P1711, DOI 10.4161/cc.8.11.8596
   Vaseva AV, 2009, BBA-BIOENERGETICS, V1787, P414, DOI 10.1016/j.bbabio.2008.10.005
   Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274
   Verrier F, 2004, ONCOGENE, V23, P8049, DOI 10.1038/sj.onc.1208001
   Voet D., 1995, BIOCHEMISTRY
   Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675
   Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147
   Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang T, 2005, J BIOL CHEM, V280, P4374, DOI 10.1074/jbc.M408708200
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   WARBURG O, 1930, METABOLISM TUMORS, P327
   WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570
   Williams A, 2008, NAT CHEM BIOL, V4, P295, DOI 10.1038/nchembio.79
   Willis SN, 2005, CURR OPIN CELL BIOL, V17, P617, DOI 10.1016/j.ceb.2005.10.001
   Wolff S, 2008, CELL RES, V18, P733, DOI 10.1038/cr.2008.62
   Wong TS, 2009, NUCLEIC ACIDS RES, V37, P6765, DOI 10.1093/nar/gkp750
   Wu M, 2004, ONCOGENE, V23, P6815, DOI 10.1038/sj.onc.1207909
   Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200
   Yakovlev AG, 2004, J BIOL CHEM, V279, P28367, DOI 10.1074/jbc.M313526200
   Yao HJ, 2008, J BIOL CHEM, V283, P20060, DOI 10.1074/jbc.M802940200
   Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28
   Yin X, 2003, J CELL PHYSIOL, V196, P474, DOI 10.1002/jcp.10329
   Yoon KA, 2004, J HUM GENET, V49, P134, DOI 10.1007/s10038-003-0122-3
   Yoshida Y, 2003, CANCER RES, V63, P3729
   Yu L, 2008, AUTOPHAGY, V4, P567, DOI 10.4161/auto.5902
   Yu X, 2006, CANCER RES, V66, P4795, DOI 10.1158/0008-5472.CAN-05-4579
   Zalckvar E, 2009, AUTOPHAGY, V5, P720, DOI 10.4161/auto.5.5.8625
   Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246
   Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533
   ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367
   ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661
   Zamzami N, 2000, ONCOGENE, V19, P6342, DOI 10.1038/sj.onc.1204030
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
   Zhang J, 2009, METHOD ENZYMOL, V452, P227, DOI 10.1016/S0076-6879(08)03615-X
   Zhang Y, 2004, J BIOL CHEM, V279, P42545, DOI 10.1074/jbc.M314213200
   Zhao YF, 2005, CANCER RES, V65, P3745, DOI 10.1158/0008-5472.CAN-04-3835
   ZIEMER MA, 1982, J BIOL CHEM, V257, P1176
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 275
TC 55
Z9 56
U1 1
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD SEP
PY 2011
VL 15
IS 6
BP 1691
EP 1714
DI 10.1089/ars.2010.3504
PG 24
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 803JA
UT WOS:000293576400014
PM 20712408
DA 2022-04-25
ER

PT J
AU Chen, TQ
   Yang, PY
   Jia, YJ
AF Chen, Tianqi
   Yang, Peiying
   Jia, Yingjie
TI Molecular mechanisms of astragaloside-IV in cancer therapy (Review)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Review
DE astragaloside IV; epithelial-mesenchymal transformation; cancer;
   molecular mechanisms; chemosensitivity
ID EPITHELIAL-MESENCHYMAL TRANSITION; ENHANCES CISPLATIN CHEMOSENSITIVITY;
   LUNG-CANCER; DOWN-REGULATION; COLORECTAL-CANCER; MULTIDRUG-RESISTANCE;
   INHIBITS PROGRESSION; CELL-PROLIFERATION; SIGNALING PATHWAYS;
   TUMOR-SUPPRESSOR
AB Radix Astragali (RA) is widely used in traditional Chinese medicine (TCM), and astragaloside IV (AS-IV) is the most critical component of RA. Previous studies have demonstrated that AS-IV exerts effects on the myocardium, nervous system and endocrine system, among others. In the present review article, data from studies conducted over the past 20 years were collated, which have evaluated the effects of AS-IV on tumors. The mechanisms of action of AS-IV on malignant cells both in vivo and in vitro were summarized and it was demonstrated that AS-IV plays a vital role, particularly in inhibiting tumor growth and metastasis, promoting the apoptosis of tumor cells, enhancing immune function and preventing drug resistance. Moreover, AS-IV controls several epithelial-mesenchymal transformation (EMT)-related and autophagy-related pathways, such as the phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT), Wnt/beta-catenin, mitogen-activated protein kinase (MAPK)/extracellular regulated protein kinase (ERK) and transforming growth factor-beta (TGF-beta)/SMAD signaling pathways, which are commonly affected in the majority of tumors. The present review provides new perspectives on the functions of AS-IV and its role as an adjuvant treatment in cancer chemotherapy.
C1 [Chen, Tianqi; Yang, Peiying; Jia, Yingjie] Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Oncol, 88 Changling Rd, Tianjin 300380, Peoples R China.
RP Jia, YJ (corresponding author), Tianjin Univ Tradit Chinese Med, Teaching Hosp 1, Dept Oncol, 88 Changling Rd, Tianjin 300380, Peoples R China.
EM bchen@casit.com.cn
FU Tianjin Science & Technology Plan Projects [17ZXMFSY00190]; Tianjin
   Traditional Chinese Medicine Research Project, Tianjin health and family
   planning commission [2017003]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81403220]
FX The present study was supported by Tianjin Science & Technology Plan
   Projects (no. 17ZXMFSY00190), the Tianjin Traditional Chinese Medicine
   Research Project, Tianjin health and family planning commission (no.
   2017003) and the National Natural Science Foundation of China (no.
   81403220).
CR An XC, 2019, MOD DIG INTERVENT, V12, P1399
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Asati V, 2016, EUR J MED CHEM, V109, P314, DOI 10.1016/j.ejmech.2016.01.012
   Avila MA, 2006, ONCOGENE, V25, P3866, DOI 10.1038/sj.onc.1209550
   Bagci EZ, 2006, BIOPHYS J, V90, P1546, DOI 10.1529/biophysj.105.068122
   Bhoday J, 2018, COLORECTAL DIS, V20, P97, DOI 10.1111/codi.14088
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0
   Buldak RJ, 2014, POL J PATHOL, V65, P167, DOI 10.5114/PJP.2014.45779
   Cameron BD, 2019, STEM CELLS, V37, P1629, DOI 10.1002/stem.3081
   Cao LP, 2010, MOD J INTEGR TRADIT, V7, P798
   Cao Y, 2015, SHANXI MED J, V6, P656
   Cave A, 2009, CURR OPIN PHARMACOL, V9, P208, DOI 10.1016/j.coph.2008.10.001
   Chang Laughter, 2019, Chinese Journal of Gerontology, V39, P3282
   Che YF, 2012, AM J PATHOL, V180, P1798, DOI 10.1016/j.ajpath.2012.01.016
   Chen JR, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.607576
   Cheng XD, 2014, INT IMMUNOPHARMACOL, V23, P304, DOI 10.1016/j.intimp.2014.08.027
   Choi YH, 2014, CURR PHARM DESIGN, V20, P793, DOI 10.2174/138161282005140214165212
   Cui X, 2020, ENVIRON TOXICOL PHAR, V78, DOI 10.1016/j.etap.2020.103397
   Dai PC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697555
   Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239
   Di Cintio F, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.603647
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Du XL, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-24
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Farhood B, 2019, J CELL PHYSIOL, V234, P8509, DOI 10.1002/jcp.27782
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   Fleischer B, 2006, INT J ONCOL, V28, P25
   Flem-Karlsen K, 2018, TRENDS CANCER, V4, P401, DOI 10.1016/j.trecan.2018.03.010
   Giovannini C, 2013, ONCOTARGET, V4, P1618, DOI 10.18632/oncotarget.1221
   Giovannini C, 2009, J HEPATOL, V50, P969, DOI 10.1016/j.jhep.2008.12.032
   Goradel NH, 2019, J CELL PHYSIOL, V234, P5683, DOI 10.1002/jcp.27411
   Gui DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039824
   Hajitou A, 2001, CANCER RES, V61, P3450
   Han JM, 2020, BIOSCI BIOTECH BIOCH, V84, P1345, DOI 10.1080/09168451.2020.1737502
   He CS, 2016, CELL PHYSIOL BIOCHEM, V40, P1221, DOI 10.1159/000453175
   Hong CS, 2016, CELL REP, V14, P1590, DOI 10.1016/j.celrep.2016.01.057
   Hu TZ, 2017, PHARMACOL REP, V69, P1159, DOI 10.1016/j.pharep.2017.07.001
   Iachettini S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1065-0
   Jia LW, 2019, ONCOL RES, V27, P503, DOI 10.3727/096504018X15344989701565
   Jiang K, 2017, INT IMMUNOPHARMACOL, V42, P195, DOI 10.1016/j.intimp.2016.10.001
   Jiang XY, 2017, INT IMMUNOPHARMACOL, V48, P135, DOI 10.1016/j.intimp.2017.05.004
   Jung Y, 2016, CHIN J INTEGR MED, V22, P225, DOI 10.1007/s11655-015-2324-x
   Karmakar S, 2006, NEUROSCI LETT, V407, P53, DOI 10.1016/j.neulet.2006.08.013
   Keshavarz-Pakseresht Behta, 2017, Gastroenterol Hepatol Bed Bench, V10, P29
   Kitamura K, 2014, MOL CANCER THER, V13, P444, DOI 10.1158/1535-7163.MCT-13-0448
   Krishnamoorthy V, 2020, GENOMICS, V112, P3703, DOI 10.1016/j.ygeno.2020.04.027
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Li B, 2017, BIOCHEM BIOPH RES CO, V491, P98, DOI 10.1016/j.bbrc.2017.07.052
   Li XX, 2014, MOLECULES, V19, P18850, DOI 10.3390/molecules191118850
   Li YL, 2018, BIOMED PHARMACOTHER, V99, P134, DOI 10.1016/j.biopha.2017.12.108
   Li Y, 2016, INT J BIOL SCI, V12, P1022, DOI 10.7150/ijbs.15438
   Li YJ, 2017, CHIN J CANCER, V52, DOI 10.1186/s40880-017-0219-2
   Li Y, 2017, INT IMMUNOPHARMACOL, V49, P38, DOI 10.1016/j.intimp.2017.05.017
   Lin AF, 2017, NAT CELL BIOL, V19, P238, DOI 10.1038/ncb3473
   Lin J, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172490
   Lin L., 2011, ANTITUMOR EFFECT ASI
   Lin YC, 2019, ANTICANCER RES, V39, P3231, DOI 10.21873/anticanres.13464
   Ling V, 2003, GENOMICS, V82, P365, DOI 10.1016/S0888-7543(03)00126-5
   Liu TieGang, 2020, Chinese Journal of Gerontology, V40, P863
   Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58
   Liu YY, 2015, DNA CELL BIOL, V34, P429, DOI 10.1089/dna.2014.2629
   Liu YY, 2013, ADV CANCER RES, V117, P59, DOI 10.1016/B978-0-12-394274-6.00003-0
   Lou Huiquan, 2006, Pathophysiology, V13, P103, DOI 10.1016/j.pathophys.2006.02.004
   Lou YM, 2019, J ETHNOPHARMACOL, V228, P82, DOI 10.1016/j.jep.2018.09.026
   Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023
   Morrison DK, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011254
   Nickl-Jockschat T, 2007, INT J ONCOL, V30, P499
   Ogata Yutaka, 2001, Kurume Medical Journal, V48, P211
   Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019
   Qi HY, 2010, INT J ONCOL, V36, P725, DOI 10.3892/ijo_00000548
   Qin CD, 2017, ONCOL REP, V37, P1725, DOI 10.3892/or.2017.5389
   Ren S, 2013, J TRADIT CHIN MED, V33, P413, DOI 10.1016/S0254-6272(13)60189-2
   Rizzo D, 2016, EXPERT OPIN DRUG MET, V12, P1397, DOI 10.1080/17425255.2016.1214710
   Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Shang JL, 2021, ACTA PHARMACOL SIN, V42, P120, DOI 10.1038/s41401-020-0442-2
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Su CC, 2009, MOL MED REP, V2, P107, DOI 10.3892/mmr_00000070
   Su CM, 2020, IN VIVO, V34, P631, DOI 10.21873/invivo.11817
   Sun P, 2019, FRONT BIOSCI-LANDMRK, V24, P597, DOI 10.2741/4738
   Tanaka N, 2015, CLIN CANCER RES, V21, P4831, DOI 10.1158/1078-0432.CCR-15-0279
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   [田彦璋 Tian Yanzhang], 2018, [中华肝胆外科杂志, Chinese Journal of Hepatobiliary Surgery], V24, P555
   Trepat X, 2012, COMPR PHYSIOL, V2, P2369, DOI 10.1002/cphy.c110012
   Wang JY, 2020, ADV CLIN EXP MED, V29, P873, DOI 10.17219/acem/117685
   Wang L, 2014, INT J CANCER, V134, P2764, DOI 10.1002/ijc.28474
   Wang PP, 2017, MOL MED REP, V16, P2761, DOI 10.3892/mmr.2017.6924
   Wang PP, 2014, MOL MED REP, V9, P2131, DOI 10.3892/mmr.2014.2074
   Wang SX, 2018, BIOMED PHARMACOTHER, V102, P1037, DOI 10.1016/j.biopha.2018.03.127
   Wang ZF, 2017, WORLD J GASTROENTERO, V23, P8512, DOI 10.3748/wjg.v23.i48.8512
   Wang ZY, 2015, ONCOTARGET, V6, P37135, DOI 10.18632/oncotarget.5789
   Wu J., 2016, INT J SYST SCI-OPER, V3, P138, DOI DOI 10.1080/23302674.2015.1068880
   Wu QN, 2018, CANCER LETT, V412, P243, DOI 10.1016/j.canlet.2017.10.007
   Xia CL, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00218-9
   Xie T, 2016, ONCOL RES, V24, P447, DOI 10.3727/096504016X14685034103590
   Xu F, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0878-0
   Xu WJ, 2014, J PHARMACOL EXP THER, V350, P552, DOI 10.1124/jpet.114.214205
   Yan XH, 2015, CANCER CELL, V28, P529, DOI 10.1016/j.ccell.2015.09.006
   Yang JY, 2016, CHIN TRADITIONAL PAT, V8, P1818
   Ye Q, 2017, CELL PHYSIOL BIOCHEM, V43, P1617, DOI 10.1159/000482025
   Ying G., 2018, INT J LAB MED, V19, P2341
   Yu SY, 2007, J ETHNOPHARMACOL, V110, P352, DOI 10.1016/j.jep.2006.09.024
   Yuan JH, 2014, CANCER CELL, V25, P666, DOI 10.1016/j.ccr.2014.03.010
   Zhang AL, 2014, J CANCER RES CLIN, V140, P1883, DOI 10.1007/s00432-014-1744-x
   Zhang CZ, 2018, PHYTOTHER RES, V32, P1364, DOI 10.1002/ptr.6070
   Zhang GY, 2016, J ETHNOPHARMACOL, V180, P104, DOI 10.1016/j.jep.2016.01.031
   Zhang L, 2019, ONCOL REP, V41, P2975, DOI 10.3892/or.2019.7062
   Zhao J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044938
   Zhao Y, 2019, DERMATOL THER, V32, DOI 10.1111/dth.12849
   Zheng YF, 2019, J CELL PHYSIOL, V234, P4277, DOI 10.1002/jcp.27196
   Zhou K, 2016, EFFECTS ASTRAGALOSID
   Zhou L, 2012, ONCOL REP, V28, P874, DOI 10.3892/or.2012.1880
   Zhu JH, 2018, PHYTOTHER RES, V32, P1289, DOI 10.1002/ptr.6057
   Zohrabian VM, 2009, ANTICANCER RES, V29, P119
NR 114
TC 1
Z9 1
U1 10
U2 34
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2021
VL 47
IS 3
AR 13
DI 10.3892/ijmm.2021.4846
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA PY4XK
UT WOS:000612048900001
PM 33448320
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Ham, J
   Lee, S
   Lee, H
   Jeong, D
   Park, S
   Kim, SJ
AF Ham, Juyeon
   Lee, Seungyeon
   Lee, Hyunkyung
   Jeong, Dawoon
   Park, Sungbin
   Kim, Sun Jung
TI Genome-Wide Methylation Analysis Identifies NOX4 and KDM5A as Key
   Regulators in Inhibiting Breast Cancer Cell Proliferation by Ginsenoside
   Rg3
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Breast Cancer; Ginsenoside Rg3; KDM5A; Methylation; NOX4
ID EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEPATOCARCINOMA CELLS; HUMAN
   COLORECTAL-CANCER; DNA METHYLATION; LUNG-CANCER; TUMOR PROGRESSION;
   SIGNALING PATHWAY; OVARIAN-CANCER; EXPRESSION; AUTOPHAGY
AB Ginsenoside Rg3 is a key metabolite of ginseng and is known to inhibit cancer cell growth. However, the epigenetics of CpG methylation and its regulatory mechanism have yet to be determined. Genome-wide methylation analysis of MCF-7 breast cancer cells treated with Rg3 was performed to identify epigenetically regulated genes and pathways. The effect of Rg3 on apoptosis and cell proliferation was examined by a colony formation assay and a dye-based cell proliferation assay. The association between methylation and gene expression was monitored by RT-PCR and Western blot analysis. Genome-wide methylation analysis identified the "cell morphology"-related pathway as the top network. Rg3 induced late stage apoptosis but inhibited cell proliferation up to 60%. Hypermethylated TRMT1L, PSMC6 and NOX4 were downregulated by Rg3, while hypomethylated ST3GAL4, RNLS and KDM5A were upregulated. In accordance, downregulation of NOX4 by siRNA abrogated the cell growth effect of Rg3, while the effect was opposite for KDM5A. Notably, breast cancer patients with a higher expression of NOX4 and KDM5A showed poor and good prognosis of survival, respectively. In conclusion, Rg3 deregulated tumor-related genes through alteration of the epigenetic methylation level leading to growth inhibition of cancer cells.
C1 [Ham, Juyeon; Lee, Seungyeon; Lee, Hyunkyung; Jeong, Dawoon; Park, Sungbin; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
RP Kim, SJ (corresponding author), Dongguk Univ, Dept Life Sci, 32 Dongguk Ro, Ilsan 10326, Goyang, South Korea.
EM sun-jungk@dongguk.edu
RI kim, sun jung/T-1013-2019
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science, and TechnologyMinistry of Education, Science and Technology,
   Republic of KoreaNational Research Foundation of Korea [2016R1D
   1A1B01009235]
FX This study was supported by the Basic Science Research Program (2016R1D
   1A1B01009235) through the National Research Foundation of Korea (NRF),
   funded by the Ministry of Education, Science, and Technology.
CR Akers SN, 2014, GYNECOL ONCOL, V132, P462, DOI 10.1016/j.ygyno.2013.12.024
   Altenberger C, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0568-5
   Breig O, 2017, ONCOTARGET, V8, P7839, DOI 10.18632/oncotarget.13975
   Cheong JH, 2015, BIOL PHARM BULL, V38, P102, DOI 10.1248/bpb.b14-00603
   Choi KT, 2008, ACTA PHARMACOL SIN, V29, P1109, DOI 10.1111/j.1745-7254.2008.00869.x
   Ehrhardt GRA, 2005, J EXP MED, V202, P783, DOI 10.1084/jem.20050879
   Gomes C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066737
   Hiraga R, 2013, ANTICANCER RES, V33, P4431
   Hu H, 2016, MOL PSYCHIATR, V21, P133, DOI 10.1038/mp.2014.193
   Hur K, 2014, GUT, V63, P635, DOI 10.1136/gutjnl-2012-304219
   Keung MH, 2016, J GINSENG RES, V40, P151, DOI 10.1016/j.jgr.2015.07.002
   Lee SY, 2009, BIOSCI BIOTECH BIOCH, V73, P811, DOI 10.1271/bbb.80637
   Lee SM, 2016, METHODSX, V3, P1, DOI 10.1016/j.mex.2015.11.008
   Li J, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00499-16
   Li W, 2015, SCI REP-UK, V5, DOI 10.1038/srep16506
   Li Y, 2016, MOL MED REP, V14, P2222, DOI 10.3892/mmr.2016.5475
   Liao LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027361
   Lin XL, 2017, ONCOTARGET, V8, P33586, DOI 10.18632/oncotarget.16829
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Oshimo Y, 2003, INT J ONCOL, V23, P1663
   Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008
   Park SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129931
   Prieto-Garcia E, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-0980-8
   Quan K, 2015, SCI REP-UK, V5, DOI 10.1038/srep08598
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Shan X, 2015, INT J ONCOL, V47, P701, DOI 10.3892/ijo.2015.3057
   SHARRARD RM, 1992, BRIT J CANCER, V65, P667, DOI 10.1038/bjc.1992.142
   Shetty PJ, 2011, J CANCER RES CLIN, V137, P339, DOI 10.1007/s00432-010-0890-z
   Stawski R, 2013, BRAIN TUMOR PATHOL, V30, P160, DOI 10.1007/s10014-012-0117-x
   Sun HY, 2016, ANTICANCER RES, V36, P4647, DOI 10.21873/anticanres.11015
   Tang QQ, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0282-6
   Teng SY, 2017, MOL MED REP, V15, P2029, DOI 10.3892/mmr.2017.6255
   Tian LL, 2016, ONCOTARGET, V7, P1619, DOI 10.18632/oncotarget.6451
   Vauti F, 2007, GENE, V389, P174, DOI 10.1016/j.gene.2006.11.004
   Wang Xing-tao, 2016, Journal of Traffic and Transportation Engineering, V16, P1
   Xie QP, 2017, BIOMED PHARMACOTHER, V85, P16, DOI 10.1016/j.biopha.2016.11.096
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yoo HS, 2017, ONCOL REP, V37, P3287, DOI 10.3892/or.2017.5590
   Yuan ZG, 2017, BIOMED PHARMACOTHER, V89, P227, DOI 10.1016/j.biopha.2017.02.038
   Zheng X, 2017, BIOMED PHARMACOTHER, V85, P620, DOI 10.1016/j.biopha.2016.11.072
NR 40
TC 20
Z9 22
U1 1
U2 13
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192-415X
EI 1793-6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2018
VL 46
IS 6
BP 1333
EP 1355
DI 10.1142/S0192415X18500702
PG 23
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA GW2US
UT WOS:000446743100010
PM 30149757
DA 2022-04-25
ER

PT J
AU Iratni, R
   Ayoub, MA
AF Iratni, Rabah
   Ayoub, Mohammed Akli
TI Sildenafil in Combination Therapy against Cancer: A Literature Review
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Sildenafil; drug repurposing; PDE-5 inhibitor; cancer; combination
   therapy; cancer therapy
ID PDE5 INHIBITORS; MULTIDRUG-RESISTANCE; ERECTILE DYSFUNCTION;
   COLORECTAL-CANCER; PROSTATE-CANCER; PLUS SILDENAFIL; IN-VITRO;
   CHEMOTHERAPY; DOXORUBICIN; CISPLATIN
AB The concepts of drug repurposing and Sildenafil or blue pill are tightly linked over the years. Indeed, in addition to its initial clinical application as an anti-hypertensive drug in the pulmonary system, Sildenafil is also known for its beneficial effects in erectile dysfunction. Moreover, evidence has been accumulated to support its value in anti-cancer therapy, either alone or in combination with other clinically efficient chemotherapy drugs. In this review, we focused on the old and recent in vitro and in vivo studies demonstrating the cellular and molecular rationale for the application of Sildenafil in combination therapy in various types of cancer. We emphasized on the different molecular targets as well as the different signaling pathways involved in cancer cells. The pro-apoptotic effect of Sildenafil through nitric oxide (NO)/ phosphodiesterase type 5 (PDE5)-dependent manner seems to be one of the most common mechanisms. However, the activation of autophagy, as well as the modulation of the anti-tumor immunity, constitutes the other pathways triggered by Sildenafil. Overall, the studies converged to reveal the complexity of the anti-cancer potential of Sildenafil. Thus, through our review, we aimed to present an updated and simplified picture of such repurposing of Sildenafil in the field of oncology.
C1 [Iratni, Rabah; Ayoub, Mohammed Akli] United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Al Ain, U Arab Emirates.
RP Iratni, R; Ayoub, MA (corresponding author), United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Al Ain, U Arab Emirates.
EM R_iratni@uaeu.ac.ae; mayoub@uaeu.ac.ae
FU Al Jalila FoundationAl Jalila Foundation (AJF) [AJF2018007-21S02]
FX The paper has been financially supported by Al Jalila Foundation grant
   (AJF2018007-21S02).
CR Adjei Alex A, 2004, Clin Lung Cancer, V5 Suppl 2, pS51
   Ali BH, 2011, BASIC CLIN PHARMACOL, V109, P300, DOI 10.1111/j.1742-7843.2011.00724.x
   Ashburn TT, 2004, NAT REV DRUG DISCOV, V3, P673, DOI 10.1038/nrd1468
   Booth L, 2019, J CELL PHYSIOL, V234, P4874, DOI 10.1002/jcp.27276
   Booth L, 2017, CANCER BIOL THER, V18, P705, DOI 10.1080/15384047.2017.1362511
   Booth L, 2017, ONCOTARGET, V8, P13464, DOI 10.18632/oncotarget.14562
   Booth L, 2017, ONCOTARGET, V8, P1449, DOI 10.18632/oncotarget.13640
   Booth L, 2014, MOL CANCER THER, V13, P2384, DOI 10.1158/1535-7163.MCT-14-0172
   Booth L, 2014, MOL PHARMACOL, V85, P408, DOI 10.1124/mol.113.090043
   Chatterjee K, 2010, CARDIOLOGY, V115, P155, DOI 10.1159/000265166
   Chen JJ, 2012, CANCER SCI, V103, P1531, DOI 10.1111/j.1349-7006.2012.02328.x
   Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729
   Das A, 2016, ONCOTARGET, V7, P4399, DOI 10.18632/oncotarget.6749
   Das A, 2015, PHARMACOL THERAPEUT, V147, P12, DOI 10.1016/j.pharmthera.2014.10.003
   Das A, 2010, P NATL ACAD SCI USA, V107, P18202, DOI 10.1073/pnas.1006965107
   de Melo-Diogo D, 2014, EUR J PHARM BIOPHARM, V88, P718, DOI 10.1016/j.ejpb.2014.09.013
   Dent P, 2020, J CELL PHYSIOL, V235, P6862, DOI 10.1002/jcp.29580
   Dhayade S, 2016, CELL REP, V14, P2599, DOI 10.1016/j.celrep.2016.02.028
   Di X, 2010, BREAST CANCER RES TR, V124, P349, DOI 10.1007/s10549-010-0765-7
   Ding PR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019329
   Domankevich V, 2019, CANCER IMMUNOL IMMUN, V68, P1949, DOI 10.1007/s00262-019-02418-5
   Domvri K, 2017, J CANCER, V8, P3648, DOI 10.7150/jca.21783
   El-Naa Mona Mohamed, 2016, Drug Des Devel Ther, V10, P3661
   Fisher PW, 2005, CIRCULATION, V111, P1601, DOI 10.1161/01.CIR.0000160359.49478.C2
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Ghofrani HA, 2006, NAT REV DRUG DISCOV, V5, P689, DOI 10.1038/nrd2030
   Greish K, 2018, J DRUG TARGET, V26, P610, DOI 10.1080/1061186X.2017.1405427
   Islam BN, 2017, CANCER PREV RES, V10, P377, DOI 10.1158/1940-6207.CAPR-17-0015
   Jourdan JP, 2020, J PHARM PHARMACOL, V72, P1145, DOI 10.1111/jphp.13273
   Kaaijk Patricia, 2003, Expert Rev Anticancer Ther, V3, P79, DOI 10.1586/14737140.3.1.79
   Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200
   Keats T, 2018, ANTI-CANCER AGENT ME, V18, P367, DOI 10.2174/1871520617666171103100959
   Kelly SA, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43086
   Kosier J H, 1999, Urol Nurs, V19, P158
   Kouvelas D, 2009, CURR PHARM DESIGN, V15, P3464, DOI 10.2174/138161209789206971
   Krishnappa P, 2019, INT J IMPOT RES, V31, P65, DOI 10.1038/s41443-018-0099-2
   Langedijk J, 2015, DRUG DISCOV TODAY, V20, P1027, DOI 10.1016/j.drudis.2015.05.001
   Langtry HD, 1999, DRUGS, V57, P967, DOI 10.2165/00003495-199957060-00015
   Lee KW, 2009, TOXICOLOGY, V257, P137, DOI 10.1016/j.tox.2008.12.017
   Lin F, 2013, EUR J CANCER, V49, P2059, DOI 10.1016/j.ejca.2012.12.028
   Loeb S, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx086
   Loeb S, 2015, JAMA-J AM MED ASSOC, V313, P2449, DOI 10.1001/jama.2015.6604
   Mei XL, 2015, AM J CANCER RES, V5, P3311
   Morales A, 1998, INT J IMPOT RES, V10, P69, DOI 10.1038/sj.ijir.3900354
   Morgan S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070117
   Naylor S., 2014, DRUG DISCOV WORLD, P50
   Nowicki TS, 2018, CANCER J, V24, P47, DOI 10.1097/PPO.0000000000000303
   Pantziarka P, 2018, ECANCERMEDICALSCIENC, V12, DOI 10.3332/ecancer.2018.824
   Park JH, 2014, ONCOL REP, V31, P2365, DOI 10.3892/or.2014.3071
   Poklepovic Andrew, 2018, Cardiooncology, V4, DOI 10.1186/s40959-018-0033-2
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Roberts JL, 2017, ONCOTARGET, V8, P99451, DOI 10.18632/oncotarget.19807
   Roberts JL, 2014, CANCER BIOL THER, V15, P758, DOI 10.4161/cbt.28553
   Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8
   Sastry J, 2005, PEDIATR HEMAT ONCOL, V22, P441, DOI 10.1080/08880010590964381
   Shi Z, 2011, CANCER RES, V71, P3735, DOI 10.1158/0008-5472.CAN-11-0375
   Shi Z, 2011, CANCER RES, V71, P3029, DOI 10.1158/0008-5472.CAN-10-3820
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI [10.3322/caac.21254, 10.3322/caac.21208, 10.1001/jamaoto.2014.2530, 10.1136/bmj.g1502]
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Taskin MI, 2015, GYNECOL ENDOCRINOL, V31, P272, DOI 10.3109/09513590.2014.984679
   Tavallai M, 2015, J CELL PHYSIOL, V230, P2281, DOI 10.1002/jcp.24961
   Volarevic V, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0518-9
   Wang L, 1998, CIRC RES, V83, P516, DOI 10.1161/01.RES.83.5.516
   Webb T, 2015, CANCER BIOL THER, V16, P1660, DOI 10.1080/15384047.2015.1099769
   World Health Organization, 2014, WORLD HLTH STAT 2014
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yi HQ, 2016, CRIT REV ONCOL HEMAT, V100, P137, DOI 10.1016/j.critrevonc.2016.02.006
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
NR 68
TC 3
Z9 3
U1 2
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2021
VL 28
IS 11
BP 2248
EP 2259
DI 10.2174/0929867327666200730165338
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA RY0BS
UT WOS:000647580600010
PM 32744956
DA 2022-04-25
ER

PT J
AU Cui, JQ
   Wei, CM
   Deng, LL
   Kuang, XY
   Zhang, ZT
   Pierides, C
   Chi, JX
   Wang, L
AF Cui, Jiaqi
   Wei, Chunmei
   Deng, Linli
   Kuang, Xingyi
   Zhang, Zengtie
   Pierides, Chryso
   Chi, Jianxiang
   Wang, Li
TI MicroRNA-143 increases cell apoptosis in myelodysplastic syndrome
   through the Fas/FasL pathway both in vitro and in vivo
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE microRNA-143; myelodysplastic syndrome; cell apoptosis; lentivirus;
   xenograft
ID COLORECTAL-CANCER; TUMOR-SUPPRESSOR; INHIBITS GROWTH; GASTRIC-CANCER;
   EXPRESSION; LEUKEMIA; PROLIFERATION; DYSREGULATION; CHEMOTHERAPY;
   AUTOPHAGY
AB Whilst the role of microRNA-143 (miR-143) in myelodysplastic syndrome (MDS) remains unclear, abnormally expressed microRNA-143 has been detected in many types of cancer tissues. In this study, we describe a cohort study for the verification of miR-143 expression, as well as the investigation of the molecular mechanisms of miR-143 in MDS/acute myeloid leukaemia (AML). In a series of experiments, miR-143 recombinant lentiviral vectors transformed into SKM-1 cells were either overexpressed or knocked down, and the results illustrated that the overexpression of miR-143 inhibited SKM-1 cell growth, arrested the SKM-1 cells in the G0/G1 phase, interfered with cell proliferation and induced cell apoptosis via the Fas/FasL pathway. Conversely, miR-143 knockdown induced a decrease in the apoptosis and promoted the proliferation of SKM-1 cells. Moreover, miR-143 was shown to suppress MLLT3/AF9 expression by binding to its 3'-UTR. Taken together, the findings of this study indicate that miR-143 may be a critical regulator of MDS/AML cell carcinogenesis, acting as a potent antitumour molecular target for the diagnosis or treatment of cancers associated with the abnormal expression of MLLT3/AF9, hence facilitating the development of potential therapeutics against MDS/AML.
C1 [Cui, Jiaqi; Wei, Chunmei; Deng, Linli; Wang, Li] Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
   [Zhang, Zengtie] Xi An Jiao Tong Univ, Hlth Sci Ctr, Dept Pathol, Xian 710061, Shaanxi, Peoples R China.
   [Pierides, Chryso; Chi, Jianxiang] Karaiskakio Fdn, Ctr Study Haematol Malignancies, CY-2032 Nicosia, Cyprus.
RP Wang, L (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Hematol, 1 Youyi Rd, Chongqing 400016, Peoples R China.
EM liwangls@yahoo.com
RI WEI, chunmei/AGX-9143-2022
FU Chongqing Education Commission Foundation [KJ1702017]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [30971277, 81250034]
FX This study was supported by the Chongqing Education Commission
   Foundation (KJ1702017) and the National Natural Science Foundation of
   China (grant nos. 30971277 and 81250034).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019
   Chen JH, 2016, EXP THER MED, V12, P3749, DOI 10.3892/etm.2016.3847
   Chen XY, 2017, AUTOPHAGY, V13, P955, DOI 10.1080/15548627.2017.1287652
   de Witte T, 2017, BLOOD, V129, P1753, DOI 10.1182/blood-2016-06-724500
   Dong PX, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0617-y
   Du FJ, 2015, BIOMED PHARMACOTHER, V74, P169, DOI 10.1016/j.biopha.2015.08.005
   Guerenne L, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0235-8
   He BF, 2016, ONCOL LETT, V12, P5023, DOI 10.3892/ol.2016.5363
   Hu YB, 2017, BIOCHEM BIOPH RES CO, V490, P317, DOI 10.1016/j.bbrc.2017.06.042
   Kuang XY, 2016, HEMATOLOGY, V21, P593, DOI 10.1080/10245332.2016.1193962
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li JB, 2016, EXP THER MED, V12, P676, DOI 10.3892/etm.2016.3429
   Li WH, 2016, BIOMED PHARMACOTHER, V80, P8, DOI 10.1016/j.biopha.2016.03.001
   Liu ZY, 2016, BIOMED PHARMACOTHER, V83, P1032, DOI 10.1016/j.biopha.2016.08.023
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mallik A, 2014, SCIENTOMETRICS, V98, P2011, DOI 10.1007/s11192-013-1128-z
   Merkerova MD, 2011, EUR J HUM GENET, V19, P313, DOI 10.1038/ejhg.2010.209
   Ozdogan H, 2017, LEUKEMIA RES, V63, P62, DOI 10.1016/j.leukres.2017.10.006
   Pellagatti A, 2015, EUR J HAEMATOL, V95, P3, DOI 10.1111/ejh.12515
   Pramanik D, 2011, MOL CANCER THER, V10, P1470, DOI 10.1158/1535-7163.MCT-11-0152
   Proetzel G, 2010, MOUSE MODELS DRUG DI
   Rodriguez M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0726-4
   Shen JZ, 2014, ONCOL REP, V31, P2035, DOI 10.3892/or.2014.3078
   Simmer F, 2015, ONCOTARGET, V6, P22996, DOI 10.18632/oncotarget.4035
   Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37
   Vogel T, 2009, GENE EXPR PATTERNS, V9, P83, DOI 10.1016/j.gep.2008.10.004
   Votavova H, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-1
   Wang F, 2017, ONCOTARGET, V8, P28711, DOI 10.18632/oncotarget.15646
   Wang L, 2014, HEMATOLOGY, V19, P225, DOI 10.1179/1607845413Y.0000000127
   Wu LY, 2011, J CANCER RES CLIN, V137, P1563, DOI 10.1007/s00432-011-1020-2
   Yu B, 2017, MINERVA MED, V108, P13, DOI 10.23736/S0026-4806.16.04651-6
   Zhang H, 2017, ONCOTARGET, V8, P61687, DOI 10.18632/oncotarget.18671
   Zhang T, 2012, LEUKEMIA LYMPHOMA, V53, P2033, DOI 10.3109/10428194.2012.678005
   Zhou JH, 2015, CYTOKINE, V71, P89, DOI 10.1016/j.cyto.2014.09.003
   Zhou P, 2015, AM J CANCER RES, V5, P2056
NR 36
TC 6
Z9 6
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2018
VL 53
IS 5
BP 2191
EP 2199
DI 10.3892/ijo.2018.4534
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GX4LG
UT WOS:000447703300031
PM 30132510
OA Bronze
DA 2022-04-25
ER

PT J
AU Song, MQ
   Yoon, G
   Choi, JS
   Kim, E
   Liu, XJ
   Oh, H
   Chae, JI
   Lee, MH
   Shim, JH
AF Song, Mengqiu
   Yoon, Goo
   Choi, Joon-Seok
   Kim, Eunae
   Liu, Xuejiao
   Oh, Ha-Na
   Chae, Jung-Il
   Lee, Mee-Hyun
   Shim, Jung-Hyun
TI Janus kinase 2 inhibition by Licochalcone B suppresses esophageal
   squamous cell carcinoma growth
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE esophageal squamous cell carcinoma; JAK2 inhibitor; Licochalcone B
ID IN-VITRO; COLORECTAL-CANCER; CYCLE PROGRESSION; JAK INHIBITOR;
   APOPTOSIS; AZD1480; SURVIVAL; STAT3; AUTOPHAGY; ACCURACY
AB Esophageal cancer (EC) is one of the leading causes to cancer death in the worldwide and major population of EC is esophageal squamous cell carcinoma (ESCC). Still, ESCC-targeted therapy has not been covered yet. In the present study we have identified that Licochalcone B (Lico B) inhibited the ESCC growth by directly blocking the Janus kinase (JAK) 2 activity and its downstream signaling pathway. Lico B suppressed KYSE450 and KYSE510 ESCC cell growth, arrested cell cycle at G2/M phase and induced apoptosis. Direct target of Lico B was identified by kinase assay and verified with in vitro and ex vivo binding. Computational docking model predicted for Lico B interaction to ATP-binding pocket of JAK2. Furthermore, treatment of JAK2 clinical medicine AZD1480 to ESCC cells showed similar tendency with Lico B. Thus, JAK2 downstream signaling proteins phosphorylation of STAT3 at Y705 and S727 as well as STAT3 target protein Mcl-1 expression was decreased with treatment of Lico B. Our results suggest that Lico B inhibits ESCC cell growth, arrests cell cycle and induces apoptosis, revealing the underlying mechanism involved in JAK2/STAT3 signaling pathways after Lico B treatment. It might provide potential role of Lico B in the treatment of ESCC.
C1 [Song, Mengqiu; Liu, Xuejiao; Lee, Mee-Hyun] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou, Peoples R China.
   [Song, Mengqiu; Liu, Xuejiao; Lee, Mee-Hyun] China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.
   [Yoon, Goo; Oh, Ha-Na; Shim, Jung-Hyun] Mokpo Natl Univ, Coll Pharm, Dept Pharm, Muan Gun 58554, Jeonnam, South Korea.
   [Choi, Joon-Seok] Daegu Catholic Univ, Coll Pharm, Gyongsan, South Korea.
   [Kim, Eunae] Chosun Univ, Coll Pharm, Gwangju, South Korea.
   [Chae, Jung-Il] Jeonbuk Natl Univ, BK21 Plus, Sch Dent, Dept Dent Pharmacol, Jeonju, South Korea.
   [Lee, Mee-Hyun] Dongshin Univ, Coll Korean Med, 85 Geonjae Ro, Naju Si 58245, Jeollanam Do, South Korea.
RP Lee, MH (corresponding author), China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.; Shim, JH (corresponding author), Mokpo Natl Univ, Coll Pharm, Dept Pharm, Muan Gun 58554, Jeonnam, South Korea.; Lee, MH (corresponding author), Dongshin Univ, Coll Korean Med, 85 Geonjae Ro, Naju Si 58245, Jeollanam Do, South Korea.
EM mhlee@hci-cn.org; s1004jh@gmail.com
OI Shim, Jung-Hyun/0000-0002-4062-4016; Lee, Mee-Hyun/0000-0002-1216-0218
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC81972839] Funding Source: Medline; Basic
   Science Research program through the NRF Funded by the Ministry of
   Education [2019R1A2C1005899] Funding Source: Medline
CR Abraham M. J., 2015, GROMACS USER MANUAL
   Avalle L, 2017, CYTOKINE, V98, P42, DOI 10.1016/j.cyto.2017.03.018
   Bak EJ, 2016, CLIN NUTR, V35, P414, DOI 10.1016/j.clnu.2015.03.005
   Bose P, 2017, BLOOD, V130, P115, DOI 10.1182/blood-2017-04-742288
   Carrington EM, 2017, CELL DEATH DIFFER, V24, P878, DOI 10.1038/cdd.2017.30
   Couto JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046869
   Du HZ, 2018, EUR J PHARM SCI, V123, P546, DOI 10.1016/j.ejps.2018.08.018
   Fang JM, 2015, ONCOL REP, V33, P494, DOI 10.3892/or.2014.3609
   Furusawa JI, 2009, INT IMMUNOPHARMACOL, V9, P499, DOI 10.1016/j.intimp.2009.01.031
   Groner B, 2017, MOL CELL ENDOCRINOL, V451, P1, DOI 10.1016/j.mce.2017.05.033
   Jang SH, 2016, MOL CELLS, V39, P699, DOI 10.14348/molcells.2016.0149
   Kallifatidis G, 2016, SEMIN CANCER BIOL, V40-41, P160, DOI 10.1016/j.semcancer.2016.06.003
   Kang TH, 2017, PHYTOTHER RES, V31, P1858, DOI 10.1002/ptr.5928
   Kashyap MK, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0790-4
   Ko Eun-Yi, 2015, J Cancer Prev, V20, P223, DOI 10.15430/JCP.2015.20.4.223
   Lee JH, 2013, CLIN CANCER RES, V19, P6777, DOI 10.1158/1078-0432.CCR-13-1110
   Li N, 2015, J FUNCT FOODS, V19, P563, DOI 10.1016/j.jff.2015.09.045
   Liang LJ, 2018, ONCOTARGETS THER, V11, P5821, DOI 10.2147/OTT.S174429
   Lu WJ, 2018, FOOD FUNCT, V9, P4500, DOI 10.1039/c8fo00728d
   Maier JA, 2015, J CHEM THEORY COMPUT, V11, P3696, DOI 10.1021/acs.jctc.5b00255
   Matsuda S, 2016, ANN THORAC CARDIOVAS, V22, P275, DOI 10.5761/atcs.ra.16-00111
   Meyerovich K, 2017, DIABETES, V66, P2446, DOI 10.2337/db16-1252
   Nowakowska Z, 2007, EUR J MED CHEM, V42, P125, DOI 10.1016/j.ejmech.2006.09.019
   Oh HN, 2018, J CELL BIOCHEM, V119, P10118, DOI 10.1002/jcb.27349
   Oh H, 2016, INT J ONCOL, V48, P1749, DOI 10.3892/ijo.2016.3365
   Schiller GJ, 2018, J ADOLESC YOUNG ADUL, V7, P546, DOI 10.1089/jayao.2018.0041
   Seo JH, 2019, J CELL PHYSIOL, V234, P1780, DOI 10.1002/jcp.27050
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48
   Sprenger KG, 2015, J PHYS CHEM B, V119, P5882, DOI 10.1021/acs.jpcb.5b00689
   Sun ZL, 2013, ASIAN PAC J CANCER P, V14, P4823, DOI 10.7314/APJCP.2013.14.8.4823
   Tao YL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32734-2
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang SW, 2014, ONCOL REP, V32, P1991, DOI 10.3892/or.2014.3477
   Wang ZT, 2013, ARCH PHARM RES, V36, P1432, DOI 10.1007/s12272-013-0222-3
   Wu XX, 2018, ONCOL LETT, V16, P2949, DOI 10.3892/ol.2018.9045
   Xie KN, 2018, CANCER MANAG RES, V10, P3657, DOI 10.2147/CMAR.S165168
   Xu YF, 2015, INT J GYNECOL CANCER, V25, P1557, DOI 10.1097/IGC.0000000000000550
   Yan S, 2013, ONCOTARGET, V4, P433, DOI 10.18632/oncotarget.930
   Yang YW, 2019, CELL BIOL INT, V43, P117, DOI 10.1002/cbin.11055
   Yu H, 2014, NAT REV CANCER, V14, P736, DOI 10.1038/nrc3818
   Yu LN, 2016, RECENT PAT ANTI-CANC, V11, P444, DOI 10.2174/1574892811666160906091405
   Yu X, 2018, ONCOTARGETS THER, V11, P1833, DOI 10.2147/OTT.S155716
   Yuan X, 2014, FOOD CHEM TOXICOL, V65, P242, DOI 10.1016/j.fct.2013.12.030
   Zhao H, 2014, BASIC CLIN PHARMACOL, V115, P527, DOI 10.1111/bcpt.12273
   Zhou LH, 2017, ONCOTARGET, V8, P79305, DOI 10.18632/oncotarget.17954
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
NR 47
TC 9
Z9 9
U1 2
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-418X
EI 1099-1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD AUG
PY 2020
VL 34
IS 8
BP 2032
EP 2043
DI 10.1002/ptr.6661
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MV8PF
UT WOS:000556612000021
PM 32144852
DA 2022-04-25
ER

PT S
AU Maji, S
   Panda, S
   Samal, SK
   Shriwas, O
   Rath, R
   Pellecchia, M
   Emdad, L
   Das, SK
   Fisher, PB
   Dash, R
AF Maji, Santanu
   Panda, Sanjay
   Samal, Sabindra K.
   Shriwas, Omprakash
   Rath, Rachna
   Pellecchia, Maurizio
   Emdad, Luni
   Das, Swadesh K.
   Fisher, Paul B.
   Dash, Rupesh
BE Tew, KD
   Fisher, PB
TI Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer
SO ADVANCES IN CANCER RESEARCH, VOL 137
SE Advances in Cancer Research
LA English
DT Review; Book Chapter
ID FATTY-ACID SYNTHASE; CELL LUNG-CANCER; PHASE-II TRIAL; ADVANCED
   BREAST-CANCER; HUMAN NONSMALL CELL; STEM-LIKE CELLS;
   MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; OVARIAN-CANCER; COLORECTAL-CANCER
AB Cancer is a daunting global problem confronting the world's population. The most frequent therapeutic approaches include surgery, chemotherapy, radiotherapy, and more recently immunotherapy. In the case of chemotherapy, patients ultimately develop resistance to both single and multiple chemotherapeutic agents, which can culminate in metastatic disease which is a major cause of patient death from solid tumors. Chemoresistance, a primary cause of treatment failure, is attributed to multiple factors including decreased drug accumulation, reduced drug-target interactions, increased populations of cancer stem cells, enhanced autophagy activity, and reduced apoptosis in cancer cells. Reprogramming tumor cells to undergo drug-induced apoptosis provides a promising and powerful strategy for treating resistant and recurrent neoplastic diseases. This can be achieved by downregulating dysregulated antiapoptotic factors or activation of proapoptotic factors in tumor cells. A major target of dysregulation in cancer cells that can occur during chemoresistance involves altered expression of Bcl-2 family members. Bcl-2 antiapoptotic molecules (Bcl-2, Bcl-xL, and Mcl-1) are frequently upregulated in acquired chemoresistant cancer cells, which block drug-induced apoptosis. We presently overview the potential role of Bcl-2 antiapoptotic proteins in the development of cancer chemoresistance and overview the clinical approaches that use Bcl-2 inhibitors to restore cell death in chemoresistant and recurrent tumors.
C1 [Maji, Santanu; Samal, Sabindra K.; Shriwas, Omprakash; Dash, Rupesh] Inst Life Sci, Bhubaneswar, Odisha, India.
   [Maji, Santanu; Samal, Sabindra K.; Shriwas, Omprakash] Manipal Univ, Manipal, Karnataka, India.
   [Panda, Sanjay] HCG Panda Canc Ctr, Cuttack, Odisha, India.
   [Panda, Sanjay] Acharya Harihar Reg Canc Ctr, Cuttack, Odisha, India.
   [Rath, Rachna] Sriram Chandra Bhanj Dent Coll & Hosp, Cuttack, Odisha, India.
   [Pellecchia, Maurizio] Univ Calif Riverside, Riverside, CA 92521 USA.
   [Emdad, Luni; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, Richmond, VA USA.
   [Emdad, Luni; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA USA.
   [Emdad, Luni; Das, Swadesh K.; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA USA.
RP Dash, R (corresponding author), Inst Life Sci, Bhubaneswar, Odisha, India.
EM rupesh.dash@gmail.com
RI Pellecchia, Maurizio/Y-7072-2018
OI SAMAL, SABINDRA KUMAR/0000-0003-4785-1032
FU NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R01CA168517] Funding Source: NIH RePORTER; NCI NIH
   HHSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01
   CA168517] Funding Source: Medline
CR Abdullah LN, 2013, CLIN TRANSL MED, V2, DOI 10.1186/2001-1326-2-3
   Adhikari S, 2008, ANTI-CANCER AGENT ME, V8, P351, DOI 10.2174/187152008784220366
   Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9
   Azuma Y, 2015, J SURG ONCOL, V112, P231, DOI 10.1002/jso.23975
   Bae J, 2000, J BIOL CHEM, V275, P25255, DOI 10.1074/jbc.M909826199
   BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2
   Balaji SA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155013
   Barile E, 2017, ACS CHEM BIOL, V12, P444, DOI 10.1021/acschembio.6b00962
   Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075
   Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393
   Bose D, 2011, BRIT J CANCER, V105, P1759, DOI 10.1038/bjc.2011.449
   Brotin E, 2010, INT J CANCER, V126, P885, DOI 10.1002/ijc.24787
   Cacan E, 2017, CELL BIOL INT, V41, P328, DOI 10.1002/cbin.10729
   Cai BL, 2011, ORAL ONCOL, V47, P1134, DOI 10.1016/j.oraloncology.2011.08.005
   Calabrese CR, 2004, J NATL CANCER I, V96, P56, DOI 10.1093/jnci/djh005
   Campbell KJ, 2010, BLOOD, V116, P3197, DOI 10.1182/blood-2010-04-281071
   CAMPOS L, 1993, BLOOD, V81, P3091
   Cao XH, 2007, CANCER CHEMOTH PHARM, V59, P495, DOI 10.1007/s00280-006-0291-9
   Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529
   Chen BH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317715155
   Chen D., 2017, CELL STEM CELL, V20, pe6
   Chen HC, 2017, APPL POWER ELECT CO, P1, DOI 10.1109/APEC.2017.7930605
   Chen WT, 2017, J OVARIAN RES, V10, DOI 10.1186/s13048-016-0301-4
   Chiang YC, 2013, ENDOCR-RELAT CANCER, V20, P213, DOI 10.1530/ERC-12-0117
   Choi BY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1776-2
   Choi BH, 2011, CURR OPIN PHARMACOL, V11, P354, DOI 10.1016/j.coph.2011.04.013
   Choudhary GS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.525
   Coloff JL, 2011, CANCER RES, V71, P5204, DOI 10.1158/0008-5472.CAN-10-4531
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   Croce CM, 2017, ADV CANCER RES, V135, pIX, DOI 10.1016/S0065-230X(17)30034-9
   Dai Y, 2017, ONCOTARGET, V8, P1354, DOI 10.18632/oncotarget.13817
   Dalvi MP, 2017, CELL REP, V19, P1669, DOI 10.1016/j.celrep.2017.04.077
   Danial NN, 2007, CLIN CANCER RES, V13, P7254, DOI 10.1158/1078-0432.CCR-07-1598
   Dash R, 2011, P NATL ACAD SCI USA, V108, P8785, DOI 10.1073/pnas.1100769108
   Dash R, 2010, CANCER RES, V70, P5034, DOI 10.1158/0008-5472.CAN-10-0563
   de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9
   Deng JL, 2016, ONCOTARGET, V7, P55771, DOI 10.18632/oncotarget.9908
   Deng X, 2001, J Natl Cancer Inst Monogr, P30
   Doles J, 2010, P NATL ACAD SCI USA, V107, P20786, DOI 10.1073/pnas.1011409107
   Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039
   du Bois A, 2003, JNCI-J NATL CANCER I, V95, P1320, DOI 10.1093/jnci/djg036
   Elkholi Rana, 2011, Genes Cancer, V2, P523, DOI 10.1177/1947601911417177
   Evers B, 2008, CLIN CANCER RES, V14, P3916, DOI 10.1158/1078-0432.CCR-07-4953
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI 10.2217/FON.10.11
   FREI E, 1965, BLOOD-J HEMATOL, V26, P642, DOI 10.1182/blood.V26.5.642.642
   Fujita Y, 2015, MOL THER, V23, P717, DOI 10.1038/mt.2015.10
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Gao CH, 2016, ONCOL LETT, V12, P1051, DOI 10.3892/ol.2016.4738
   Gao W, 2017, CANCER MED-US, V6, P439, DOI 10.1002/cam4.982
   Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577
   Garza-Trevino EN, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0163-7
   Geng M, 2013, INT J CLIN EXP PATHO, V6, P2554
   Ghuwalewala S, 2016, STEM CELL RES, V16, P405, DOI 10.1016/j.scr.2016.02.028
   GILMAN A, 1963, AM J SURG, V105, P574, DOI 10.1016/0002-9610(63)90232-0
   Go RS, 1999, J CLIN ONCOL, V17, P409, DOI 10.1200/JCO.1999.17.1.409
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320
   Grover R, 1996, EUR J SURG ONCOL, V22, P347, DOI 10.1016/S0748-7983(96)90176-6
   Gu XT, 2016, EUR J PHARMACOL, V792, P7, DOI 10.1016/j.ejphar.2016.10.024
   Guo W, 2006, PEDIATR RES, V59, p59R, DOI 10.1203/01.pdr.0000203592.04530.06
   Habata S, 2016, INT J ONCOL, V49, P402, DOI 10.3892/ijo.2016.3494
   Ham SY, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.47
   Han WD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018691
   He XD, 2016, CANCER BIOL THER, V17, P188, DOI 10.1080/15384047.2016.1139228
   Hermine O, 1996, BLOOD, V87, P265, DOI 10.1182/blood.V87.1.265.bloodjournal871265
   HITCHINGS GEORGE H., 1954, ANN NEW YORK ACAD SCI, V60, P195
   Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P1516, DOI 10.1002/cncr.25599
   Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625
   Hulleman E, 2009, BLOOD, V113, P2014, DOI 10.1182/blood-2008-05-157842
   Iqbal Nida, 2014, Chemother Res Pract, V2014, P357027, DOI 10.1155/2014/357027
   Jeon YJ, 2015, P NATL ACAD SCI USA, V112, pE3355, DOI 10.1073/pnas.1504630112
   Jiang H, 2009, J GASTROINTEST SURG, V13, P1831, DOI 10.1007/s11605-009-0964-x
   JOENSUU H, 1994, AM J PATHOL, V145, P1191
   JOHNSON IS, 1963, CANCER RES, V23, P1390
   Kang MH, 2009, CLIN CANCER RES, V15, P1126, DOI 10.1158/1078-0432.CCR-08-0144
   KERBEL RS, 1994, J CELL BIOCHEM, V56, P37, DOI 10.1002/jcb.240560108
   Kim DW, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-28
   Kim JH, 2009, FEBS LETT, V583, P2758, DOI 10.1016/j.febslet.2009.08.006
   KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x
   KISH J, 1982, CANCER TREAT REP, V66, P471
   Klaassen U, 1997, Oncology (Williston Park), V11, P38
   Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006
   Kucuk O, 2000, AM J CLIN ONCOL-CANC, V23, P371, DOI 10.1097/00000421-200008000-00012
   Kumar Bhavna, 2015, Genes Cancer, V6, P169
   Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392
   Lestini BJ, 2009, CANCER BIOL THER, V8, P1587, DOI 10.4161/cbt.8.16.8964
   Li HY, 2013, CELL BIOCHEM FUNCT, V31, P427, DOI 10.1002/cbf.2917
   LI MC, 1958, NEW ENGL J MED, V259, P66, DOI 10.1056/NEJM195807102590204
   Liao MM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-44
   Lin KH, 2016, SCI REP-UK, V6, DOI 10.1038/srep27696
   Linde N, 2016, ADV CANCER RES, V132, P45, DOI 10.1016/bs.acr.2016.07.002
   LINN SC, 1995, EUR J CANCER, V31A, P1291, DOI 10.1016/0959-8049(95)00278-Q
   Liu C, 2014, MOL CELL BIOCHEM, V393, P265, DOI 10.1007/s11010-014-2069-4
   Liu HL, 2008, MOL CANCER THER, V7, P263, DOI 10.1158/1535-7163.MCT-07-0445
   Liu J, 2016, ADV CANCER RES, V130, P1, DOI 10.1016/bs.acr.2016.01.005
   Liu MX, 2014, ONCOTARGET, V5, P944, DOI 10.18632/oncotarget.1458
   Liu T, 2010, MOL CELL BIOCHEM, V340, P265, DOI 10.1007/s11010-010-0426-5
   Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131
   Liu YY, 2016, TUMOR BIOL, V37, P12231, DOI 10.1007/s13277-016-5066-2
   Mahon FX, 2003, BLOOD, V101, P2368, DOI 10.1182/blood.V101.6.2368
   Maji S, 2015, ONCOTARGET, V6, P16623, DOI 10.18632/oncotarget.3932
   Mayer MJ, 2015, PROSTATE CANCER P D, V18, P303, DOI 10.1038/pcan.2015.35
   McBrayer SK, 2012, BLOOD, V119, P4686, DOI 10.1182/blood-2011-09-377846
   MCDONNELL TJ, 1992, CANCER RES, V52, P6940
   MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0
   McIntosh K, 2016, EXPERT OPIN DRUG MET, V12, P633, DOI 10.1080/17425255.2016.1179280
   Menendez JA, 2005, MED HYPOTHESES, V64, P997, DOI 10.1016/j.mehy.2004.09.027
   Menendez JA, 2004, BREAST CANCER RES TR, V84, P183, DOI 10.1023/B:BREA.0000018409.59448.60
   Meynet O, 2012, LEUKEMIA, V26, P1145, DOI 10.1038/leu.2011.327
   Michels J, 2014, BIOCHEM PHARMACOL, V92, P55, DOI 10.1016/j.bcp.2014.07.029
   MIYASHITA T, 1993, BLOOD, V81, P151
   Moitra K, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/635745
   Morales AA, 2005, INT J CANCER, V113, P730, DOI 10.1002/ijc.20614
   Morgan RJ, 2000, GYNECOL ONCOL, V77, P433, DOI 10.1006/gyno.2000.5793
   Munoz-Pinedo C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.123
   Naik E, 2007, J CELL BIOL, V176, P415, DOI 10.1083/jcb.200608070
   Ni J, 2014, CURR CANCER DRUG TAR, V14, P225, DOI 10.2174/1568009614666140328152459
   Nishioka T, 2014, BRIT J CANCER, V110, P1785, DOI 10.1038/bjc.2014.78
   Oh William K, 2005, Clin Prostate Cancer, V4, P61, DOI 10.3816/CGC.2005.n.014
   Okamoto K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077623
   Olsson A, 2007, BRIT J CANCER, V97, P769, DOI 10.1038/sj.bjc.6603951
   Osaki S, 2016, SCI REP-UK, V6, DOI 10.1038/srep28953
   Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609
   Park IC, 1997, ANTICANCER RES, V17, P4619
   Placzek WJ, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.18
   Quinn BA, 2011, EXPERT OPIN INV DRUG, V20, P1397, DOI 10.1517/13543784.2011.609167
   Rahman M, 2015, METABOLITES, V5, P571, DOI 10.3390/metabo5040571
   Ronnekleiv-Kelly SM, 2017, CANCER TREAT REV, V55, P200, DOI 10.1016/j.ctrv.2017.03.008
   Rosell R, 2002, ANN ONCOL, V13, P1539, DOI 10.1093/annonc/mdf332
   ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0
   Sabnis NG, 2017, MOL CANCER RES, V15, P128, DOI 10.1158/1541-7786.MCR-16-0270-T
   Saha S, 2016, CANCER RES, V76, P2000, DOI 10.1158/0008-5472.CAN-15-1360
   Sakamoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145985
   Saleem A, 2012, PROSTATE, V72, P1374, DOI 10.1002/pros.22487
   Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372
   Schneider J, 2001, BREAST CANCER RES, V3, P183, DOI 10.1186/bcr293
   Schoenlein PV, 2009, AUTOPHAGY, V5, P400, DOI 10.4161/auto.5.3.7784
   Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646
   Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Shintani Y, 2011, ANN THORAC SURG, V92, P1794, DOI 10.1016/j.athoracsur.2011.07.032
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Sieghart W, 2006, J HEPATOL, V44, P151, DOI 10.1016/j.jhep.2005.09.010
   SKIPPER HE, 1954, CANCER RES, V14, P294
   Skubisz Monika M, 2012, ISRN Obstet Gynecol, V2012, P637094, DOI 10.5402/2012/637094
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96
   Stacy AE, 2013, MOL PHARMACOL, V84, P655, DOI 10.1124/mol.113.088609
   Stanton MJ, 2013, CANCER RES, V73, P160, DOI 10.1158/0008-5472.CAN-11-3635
   Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188
   Strik H, 1999, J NEUROL NEUROSUR PS, V67, P763, DOI 10.1136/jnnp.67.6.763
   Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350
   Sun YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055576
   Tabuchi Y, 2009, INT J ONCOL, V34, P313, DOI 10.3892/ijo_00000153
   Talukdar S, 2016, ADV CANCER RES, V131, P159, DOI 10.1016/bs.acr.2016.04.003
   Tao LL, 2015, CANCER BIOTHER RADIO, V30, P100, DOI 10.1089/cbr.2014.1797
   Thomas S, 2013, EXPERT OPIN THER TAR, V17, P61, DOI 10.1517/14728222.2013.733001
   Toge M, 2015, INT J ONCOL, V46, P1844, DOI 10.3892/ijo.2015.2861
   Triller N, 2006, LUNG CANCER, V54, P235, DOI 10.1016/j.lungcan.2006.06.019
   Varin E, 2010, CARCINOGENESIS, V31, P984, DOI 10.1093/carcin/bgq026
   Vazquez-Martin A, 2007, ONCOL REP, V18, P973
   Viana LD, 2016, HEAD NECK-J SCI SPEC, V38, pE970, DOI 10.1002/hed.24137
   Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411
   Vogler M, 2012, CELL DEATH DIFFER, V19, P67, DOI 10.1038/cdd.2011.158
   Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310
   Wang L., 2017, FRONT PLANT SCI, V8, P1, DOI DOI 10.1186/s40529-017-0163-0
   Wang L, 2012, MOL CANCER THER, V11, P2401, DOI 10.1158/1535-7163.MCT-12-0448
   Wasserheit C, 1996, J CLIN ONCOL, V14, P1993, DOI 10.1200/JCO.1996.14.7.1993
   Williams J, 2005, GYNECOL ONCOL, V96, P287, DOI 10.1016/j.ygyno.2004.10.026
   Wu Chung-Pu, 2008, Curr Mol Pharmacol, V1, P93
   Xie K, 2010, P NATL ACAD SCI USA, V107, P20792, DOI 10.1073/pnas.1011412107
   Yamaguchi R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024102
   Yang JL, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1690896
   Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954
   Yang S, 2005, MOL CANCER THER, V4, P1923, DOI 10.1158/1535-7163.MCT-05-0229
   Yang Xiao-kui, 2002, Ai Zheng, V21, P1288
   Yang Youyun, 2011, Int J Biochem Mol Biol, V2, P89
   Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304
   Youle RJ, 2008, NATURE REV, V9, P4759
   Zalcberg J, 2000, PROSTATE CANCER P D, V3, P66, DOI 10.1038/sj.pcan.4500394
   Zarogoulidis P, 2015, CELL SIGNAL, V27, P1576, DOI 10.1016/j.cellsig.2015.04.009
   Zhang N, 2010, AUTOPHAGY, V6, P1157, DOI 10.4161/auto.6.8.13614
   Zhang Y, 2012, ONCOGENE, V31, P1055, DOI 10.1038/onc.2011.290
   Zhang Y, 2017, CANCER RES, V77, P3082, DOI 10.1158/0008-5472.CAN-16-1633
   Zhao LD, 2015, ONCOTARGET, V6, P44538, DOI 10.18632/oncotarget.6253
   Zhao Q, 2015, AM J CANCER RES, V5, P1692
   Zhao YB, 2013, SCI REP-UK, V3, DOI 10.1038/srep03120
   Zhao Y, 2009, BIOCHEM BIOPH RES CO, V390, P642, DOI 10.1016/j.bbrc.2009.10.020
   Zhao YH, 2011, CANCER RES, V71, P4585, DOI 10.1158/0008-5472.CAN-11-0127
   Zhou JJ, 2014, INT J ONCOL, V44, P2034, DOI 10.3892/ijo.2014.2347
   Zhou M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-33
   Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630
NR 200
TC 81
Z9 83
U1 4
U2 22
PU ELSEVIER ACADEMIC PRESS INC
PI SAN DIEGO
PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0065-230X
EI 2162-5557
BN 978-0-12-815123-5
J9 ADV CANCER RES
JI Adv.Cancer Res.
PY 2018
VL 137
BP 37
EP 75
DI 10.1016/bs.acr.2017.11.001
PG 39
WC Oncology
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA BK3UY
UT WOS:000435593400003
PM 29405977
DA 2022-04-25
ER

PT J
AU Wu, HL
   Hao, AX
   Cui, HH
   Wu, WB
   Yang, HR
   Hu, BH
   Li, P
AF Wu, Hanli
   Hao, Aixia
   Cui, Honghong
   Wu, Wenbin
   Yang, Huanrong
   Hu, Baohong
   Li, Peng
TI TRAF6 expression is associated with poorer prognosis and high recurrence
   in urothelial bladder cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE TNF receptor-associated factor 6; recurrence; prognosis; metastasis;
   urothelial bladder cancer
ID KAPPA-B; COLORECTAL-CANCER; GROWTH-FACTOR; UBIQUITINATION; ACTIVATION;
   CARCINOMA; CHOLANGIOCARCINOMA; PROGRESSION; AUTOPHAGY; TBL1XR1
AB The aim of the present study was to investigate the clinical significance of TNF receptor-associated factor 6 (TRAF6) expression in urothelial bladder cancer. TRAF6 expression was detected by immunohistochemistry in 126 samples of patients with urothelial bladder cancer. The association between clinicopathological factors and TRAF6 expression was analyzed by chi(2) test. The association between TRAF6 expression, overall survival rate and the recurrence-free survival rate was evaluated in univariate analysis with Kaplan-Meier test and in multivariate analysis with Cox-regression model. In the cohort tested, the rate of high TRAF6 expression was 61.9% (78/126). TRAF6 expression was demonstrated to be significantly associated with positive metastasis (P=0.001) with chi(2) test. Furthermore, TRAF6 expression was demonstrated to be associated with overall survival rate (P=0.016) and recurrence-free survival rate (P=0.016). With Cox-regression model, it was indicate that TRAF6 high expression was an independent predictive factor of poor prognosis (P=0.037) and high recurrence (P=0.011). High TRAF6 expression may predict unfavorable prognosis and high recurrence in urothelial bladder cancer, indicating that TRAF6 may be a potential and promising therapeutic target in urothelial bladder cancer.
C1 [Wu, Hanli; Hao, Aixia; Cui, Honghong; Wu, Wenbin; Yang, Huanrong] Yidu Cent Hosp Weifang, Dept Nephrol, Weifang 262500, Shandong, Peoples R China.
   [Hu, Baohong] Shandong Univ, East Dist Shandong Prov Hosp, Jinan 250014, Shandong, Peoples R China.
   [Hu, Baohong; Li, Peng] Qingdao Univ, Yantai Yuhuangding Hosp, Dept Med Oncol, 20 Yuhuangding East Rd, Yantai 264000, Shandong, Peoples R China.
RP Hu, BH; Li, P (corresponding author), Qingdao Univ, Yantai Yuhuangding Hosp, Dept Med Oncol, 20 Yuhuangding East Rd, Yantai 264000, Shandong, Peoples R China.
EM khan2017@126.com; lipengyuhuangding@163.com
FU Science and Technology Project of Yantai City [2015WS018, 2016WS006];
   Youth Research Initiation Foundation of Yuhuangding Hospital [201511];
   Shandong Province Medical Science and Technology development project
   [2016WS0706]
FX The present study was supported by Science and Technology Project of
   Yantai City (grant nos. 2015WS018 and 2016WS006), Youth Research
   Initiation Foundation of Yuhuangding Hospital (grant no. 201511) and
   Shandong Province Medical Science and Technology development project
   (grant no. 2016WS0706).
CR Babjuk M, 2011, EUR UROL, V59, P997, DOI 10.1016/j.eururo.2011.03.017
   Black PC, 2006, J CLIN ONCOL, V24, P5528, DOI 10.1200/JCO.2006.08.0895
   Chan ECY, 2015, J PROTEOME RES, V14, P587, DOI 10.1021/pr500966h
   Chaudhry SI, 2013, ONCOGENE, V32, P747, DOI 10.1038/onc.2012.91
   Chen H, 2006, ONCOGENE, V25, P6520, DOI 10.1038/sj.onc.1209653
   Cheng LA, 2011, HUM PATHOL, V42, P455, DOI 10.1016/j.humpath.2010.07.007
   Chiu HW, 2015, CANCER LETT, V365, P229, DOI 10.1016/j.canlet.2015.05.025
   Choi YB, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004458
   Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4
   Dy GW, 2017, EUR UROL, V71, P437, DOI 10.1016/j.eururo.2016.10.008
   Gogalic S, 2015, ANALYST, V140, P724, DOI 10.1039/c4an01432d
   Hemdan T, 2014, BRIT J CANCER, V111, P1180, DOI 10.1038/bjc.2014.427
   Jiang XM, 2015, INT J CANCER, V136, P854, DOI 10.1002/ijc.29041
   La Vecchia C, 2010, ANN ONCOL, V21, P1323, DOI 10.1093/annonc/mdp530
   Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200
   Lin YY, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju012
   Liu HD, 2017, SURG ONCOL, V26, P13, DOI 10.1016/j.suronc.2016.12.003
   Liu HD, 2017, SCI REP-UK, V7, DOI 10.1038/srep44275
   Liu H, 2012, J CANCER RES CLIN, V138, P1853, DOI 10.1007/s00432-012-1255-6
   Liu J, 2015, ONCOTARGET, V6, P29129, DOI 10.18632/oncotarget.4895
   Mitra AP, 2009, CANCER METAST REV, V28, P317, DOI 10.1007/s10555-009-9196-5
   Pickart CM, 2001, MOL CELL, V8, P499, DOI 10.1016/S1097-2765(01)00347-1
   Rong YF, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0260-9
   Sanli O, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.22
   Shaid S, 2013, CELL DEATH DIFFER, V20, P21, DOI 10.1038/cdd.2012.72
   Solomon JP, 2015, ADV ANAT PATHOL, V22, P102, DOI 10.1097/PAP.0000000000000050
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang KZQ, 2010, J CELL BIOCHEM, V110, P763, DOI 10.1002/jcb.22589
   Wang ML, 2012, CANCER RES, V72, P6173, DOI 10.1158/0008-5472.CAN-12-0688
   Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697
   Xu YF, 2014, BIOCHEM BIOPH RES CO, V446, P54, DOI 10.1016/j.bbrc.2014.02.050
   Xu YF, 2017, ONCOTARGET, V8, P4888, DOI 10.18632/oncotarget.13982
   Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065
   Yang XQ, 2014, WORLD J GASTROENTERO, V20, P4076, DOI 10.3748/wjg.v20.i14.4076
NR 34
TC 6
Z9 6
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2017
VL 14
IS 2
BP 2432
EP 2438
DI 10.3892/ol.2017.6427
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FE0IS
UT WOS:000407904600173
PM 28781679
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Berdowska, I
   Matusiewicz, M
   Fecka, I
AF Berdowska, Izabela
   Matusiewicz, Malgorzata
   Fecka, Izabela
TI Punicalagin in Cancer Prevention-Via Signaling Pathways Targeting
SO NUTRIENTS
LA English
DT Review
DE punicalagin; pomegranate; ellagitannins; breast cancer; cervical cancer;
   ovarian cancer; colorectal cancer; thyroid cancer; apoptosis; autophagy
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; ELLAGIC ACID;
   CELL-LINE; POMEGRANATE JUICE; DRUG-RESISTANCE; OVARIAN-CANCER; ANNEXIN
   A1; BECLIN 1; EXPRESSION
AB The extract of pomegranate (Punica granatum) has been applied in medicine since ancient times due to its broad-spectrum health-beneficial properties. It is a rich source of hydrolyzable tannins and anthocyanins, exhibiting strong antioxidative, anti-inflammatory, and antineoplastic properties. Anticancer activities of pomegranate with reference to modulated signaling pathways in various cancer diseases have been recently reviewed. However, less is known about punicalagin (Pug), a prevailing compound in pomegranate, seemingly responsible for its most beneficial properties. In this review, the newest data derived from recent scientific reports addressing Pug impact on neoplastic cells are summarized and discussed. Its attenuating effect on signaling circuits promoting cancer growth and invasion is depicted. The Pug-induced redirection of signal-transduction pathways from survival and proliferation into cell-cycle arrest, apoptosis, senescence, and autophagy (thus compromising neoplastic progression) is delineated. Considerations presented in this review are based mainly on data obtained from in vitro cell line models and concern the influence of Pug on human cervical, ovarian, breast, lung, thyroid, colorectal, central nervous system, bone, as well as other cancer types.
C1 [Berdowska, Izabela; Matusiewicz, Malgorzata] Wroclaw Med Univ, Dept Med Biochem, Chalubinskiego 10, PL-50368 Wroclaw, Poland.
   [Fecka, Izabela] Wroclaw Med Univ, Dept Pharmacognosy & Herbal Med, Borowska 211A, PL-50556 Wroclaw, Poland.
RP Berdowska, I; Matusiewicz, M (corresponding author), Wroclaw Med Univ, Dept Med Biochem, Chalubinskiego 10, PL-50368 Wroclaw, Poland.
EM izabela.berdowska@umed.wroc.pl; malgorzata.matusiewicz@umed.wroc.pl;
   izabela.fecka@umed.wroc.pl
RI Berdowska, Izabela/AAZ-4016-2021; Fecka, Izabela/AAS-8974-2021
OI Fecka, Izabela/0000-0002-1139-4581; Berdowska,
   Izabela/0000-0002-0275-4522; Matusiewicz, Malgorzata/0000-0003-4624-0109
CR Adams LS, 2006, J AGR FOOD CHEM, V54, P980, DOI 10.1021/jf052005r
   Al-Harbi SA, 2021, FRONT NUTR, V8, DOI 10.3389/fnut.2021.647582
   Alzahrani AM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115465
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Gimenez-Bastida JA, 2020, FOOD CHEM TOXICOL, V139, DOI 10.1016/j.fct.2020.111260
   Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034
   Babaei G, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110909
   Beltran D, 2018, INT J SYST EVOL MICR, V68, P1707, DOI 10.1099/ijsem.0.002735
   Berkoz M, 2020, GEN PHYSIOL BIOPHYS, V39, P557, DOI 10.4149/gpb_2020024
   Bialonska D, 2009, J AGR FOOD CHEM, V57, P8344, DOI 10.1021/jf901931b
   Bian Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020684
   Buzun K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115804
   Cai MB, 2014, INT J MOL SCI, V15, P5292, DOI 10.3390/ijms15045292
   Chen CX, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10142
   Chen YM, 2016, TUMOR BIOL, V37, P10861, DOI 10.1007/s13277-016-4909-1
   Cheng F, 2021, ONCOTARGETS THER, V14, P3199, DOI 10.2147/OTT.S305595
   Cheng X, 2018, BIOMED PHARMACOTHER, V103, P490, DOI 10.1016/j.biopha.2018.04.074
   Cheng X, 2016, RSC ADV, V6, P68485, DOI 10.1039/c6ra13431a
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Danesi F, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090958
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   El-Wetidy MS, 2021, CELL STRESS CHAPERON, V26, P473, DOI 10.1007/s12192-020-01189-8
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fang L, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22771
   Fecka I, 2020, IND CROP PROD, V158, DOI 10.1016/j.indcrop.2020.112971
   Fu ZQ, 2020, CLIN CHIM ACTA, V504, P36, DOI 10.1016/j.cca.2020.01.022
   Ganesan T, 2020, NUTRIENTS, V12, DOI 10.3390/nu12082430
   Garcia-Villalba R, 2019, J AGR FOOD CHEM, V67, P11099, DOI 10.1021/acs.jafc.9b04435
   Ge SS, 2021, J ETHNOPHARMACOL, V271, DOI 10.1016/j.jep.2021.113877
   Gonzalez-Sarrias A, 2015, FOOD FUNCT, V6, P1460, DOI [10.1039/C5FO00120J, 10.1039/c5fo00120j]
   Gonzalez-Sarrias A, 2014, EUR J NUTR, V53, P853, DOI 10.1007/s00394-013-0589-4
   Gu HF, 2020, CRIT REV FOOD SCI, V60, P810, DOI 10.1080/10408398.2018.1551778
   Guo XH, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050452
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang J, 2015, INT J ONCOL, V47, P840, DOI 10.3892/ijo.2015.3084
   Huang T, 2020, MOL MED REP, V22, P2386, DOI 10.3892/mmr.2020.11304
   Huang X, 2010, J CLIN NEUROSCI, V17, P1515, DOI 10.1016/j.jocn.2010.03.051
   Khan H, 2020, CRIT REV FOOD SCI, V60, P2790, DOI 10.1080/10408398.2019.1661827
   Khan H, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2019.04.007
   Khwairakpam AD, 2018, PHARMACOL RES, V133, P53, DOI 10.1016/j.phrs.2018.04.021
   Kim YY, 2021, FASEB J, V35, DOI 10.1096/fj.202002007R
   Lalle G, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10020355
   Larrosa M, 2006, J NUTR BIOCHEM, V17, P611, DOI 10.1016/j.jnutbio.2005.09.004
   Lecona E, 2008, MOL CELL BIOL, V28, P4665, DOI 10.1128/MCB.00650-07
   Li JL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-49
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lou YH, 2017, ONCOTARGET, V8, P69983, DOI 10.18632/oncotarget.19545
   McMellen A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124272
   Miyata Y, 2019, MOLECULES, V24, DOI 10.3390/molecules24010193
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moghanibashi M, 2012, GENE, V500, P124, DOI 10.1016/j.gene.2012.03.038
   Pham NM, 2019, EUR J CLIN NUTR, V73, P647, DOI 10.1038/s41430-018-0218-7
   Nielsen M, 1999, LEUKEMIA, V13, P735, DOI 10.1038/sj.leu.2401415
   Norden E, 2019, CARCINOGENESIS, V40, P93, DOI 10.1093/carcin/bgy158
   Nunez-Sanchez MA, 2014, MOL NUTR FOOD RES, V58, P1199, DOI 10.1002/mnfr.201300931
   Oelrichs Peter B., 1994, Natural Toxins, V2, P144, DOI 10.1002/nt.2620020311
   Palma-Duran SA, 2017, CRIT REV FOOD SCI, V57, P975, DOI 10.1080/10408398.2014.973932
   Pan L, 2020, J RECEPT SIG TRANSD, V40, P173, DOI 10.1080/10799893.2020.1719152
   Patton KT, 2005, HISTOPATHOLOGY, V47, P597, DOI 10.1111/j.1365-2559.2005.02300.x
   Pirzadeh M, 2021, CRIT REV FOOD SCI, V61, P982, DOI 10.1080/10408398.2020.1749825
   Piwowarski JP, 2017, DRUG METAB DISPOS, V45, P657, DOI 10.1124/dmd.117.075200
   Puar YR, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030082
   Qiu DM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-327
   Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039
   Rahman MA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.639628
   Ramachandran I, 2012, ONCOGENE, V31, P2725, DOI 10.1038/onc.2011.455
   Ramesh V, 2020, TRENDS CANCER, V6, P942, DOI 10.1016/j.trecan.2020.06.005
   Romo-Vaquero M, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201800958
   Roth U, 2010, PROTEOMICS, V10, P194, DOI 10.1002/pmic.200900614
   Roxanis I, 2013, J CLIN PATHOL, V66, P517, DOI 10.1136/jclinpath-2012-201348
   SATOMI H, 1993, BIOL PHARM BULL, V16, P787, DOI 10.1248/bpb.16.787
   Sechi S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030933
   Seeram NP, 2006, J NUTR, V136, P2481, DOI 10.1093/jn/136.10.2481
   Seeram NP, 2005, J NUTR BIOCHEM, V16, P360, DOI 10.1016/j.jnutbio.2005.01.006
   Selma MV, 2018, CLIN NUTR, V37, P897, DOI 10.1016/j.clnu.2017.03.012
   Selma MV, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01521
   Senga SS, 2021, OPEN BIOL, V11, DOI 10.1098/rsob.200358
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Sharma P, 2017, MOLECULES, V22, DOI 10.3390/molecules22010177
   Shen MX, 2017, EUR REV MED PHARMACO, V21, P3038
   Shen Y, 2008, AUTOPHAGY, V4, P1067, DOI 10.4161/auto.6827
   Shirode AB, 2015, INT J NANOMED, V10, P475, DOI 10.2147/IJN.S65145
   Suo AL, 2012, MED ONCOL, V29, P1827, DOI 10.1007/s12032-011-0013-y
   Tang JM, 2016, INT J GYNECOL CANCER, V26, P1557, DOI 10.1097/IGC.0000000000000805
   Tang JM, 2017, MOL MED REP, V16, P1439, DOI 10.3892/mmr.2017.6687
   Tang S, 2017, ONCOTARGET, V8, P105155, DOI 10.18632/oncotarget.21927
   Teeuwssen M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8101658
   Tegowski M, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6020066
   Tilborghs S, 2017, CRIT REV ONCOL HEMAT, V120, P141, DOI 10.1016/j.critrevonc.2017.11.001
   Tokuda E, 2014, CANCER RES, V74, P3054, DOI 10.1158/0008-5472.CAN-13-2441
   Tomas-Barberan FA, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201500901
   Totiger TM, 2019, MOL CANCER THER, V18, P301, DOI 10.1158/1535-7163.MCT-18-0464
   Viuda-Martos M, 2010, COMPR REV FOOD SCI F, V9, P635, DOI 10.1111/j.1541-4337.2010.00131.x
   Voon DC, 2017, MOL ONCOL, V11, P878, DOI 10.1002/1878-0261.12082
   Nguyen VHL, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0596-z
   Wang SG, 2013, ACTA PHARMACOL SIN, V34, P1411, DOI 10.1038/aps.2013.98
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Yamagata K, 2019, CURR PHARM DESIGN, V25, P2443, DOI 10.2174/1381612825666190722100504
   Yang HY, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2686340
   Yang M, 2018, J CANCER, V9, P1277, DOI 10.7150/jca.22005
   Yao X, 2017, NUTR RES, V47, P63, DOI 10.1016/j.nutres.2017.09.001
   Yoshida T, 2010, INT J MOL SCI, V11, P79, DOI 10.3390/ijms11010079
   Yu S, 2018, ANTI-CANCER AGENT ME, V18, P1680, DOI 10.2174/1871520618666180830110700
   Yun CW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010179
   Zada S, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188565
   Zahin M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/467465
   Zeng ZL, 2012, CLIN CANCER RES, V18, P4059, DOI 10.1158/1078-0432.CCR-11-3156
   Zhang L, 2020, SAUDI J BIOL SCI, V27, P1100, DOI 10.1016/j.sjbs.2020.02.015
   Zhang ZC, 2009, J HUAZHONG U SCI-MED, V29, P737, DOI 10.1007/s11596-009-0613-3
   Zhao WH, 2018, MOL CARCINOGEN, V57, P193, DOI 10.1002/mc.22746
NR 112
TC 0
Z9 0
U1 4
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD AUG
PY 2021
VL 13
IS 8
AR 2733
DI 10.3390/nu13082733
PG 20
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA UH8WN
UT WOS:000690203700001
PM 34444893
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Dai, W
   Liu, XH
AF Dai, Wei
   Liu, Xinghui
TI Circular RNA 0004904 promotes autophagy and regulates the fused in
   sarcoma/vascular endothelial growth factor axis in preeclampsia
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE circular RNA 0004904; microRNA-570; invasion; autophagy; VEGF
ID COLORECTAL-CANCER; GASTRIC-CANCER; CIRCRNA; PATHOGENESIS; INVASION;
   PROGRESSION; METASTASIS; INHIBITION; PREDICTION; PLACENTAS
AB Circular (circ)RNA has been demonstrated to serve crucial roles in cell proliferation, differentiation and autophagy. However, to date, the function and mechanism of action of circRNA in preeclampsia have not been reported. The present study aimed to analyze the roles of circRNA-0004904 in preeclampsia and to clarify its underlying pathogenic mechanism. The expression levels of circ-0004904, microRNA (miR)-570 and autophagy-related 12 (ATG12) were detected by reverse transcription-quantitative (RT-q)PCR. In addition, the protein levels of ATG12, vascular endothelial growth factor (VEGF) and fused in sarcoma (FUS) were determined by western blot assay. The distribution of mRFP-GFP-LC3 in HTR8 and JEG3 cells was analyzed by confocal microscopy. Fluorescence in situ hybridization assay was utilized to identify the colocalization of circ-0004904 and miR-570. Cell proliferation was determined by 5-ethynyl-2 '-deoxyuridine assay, and invasion was evaluated by Matrigel invasion assay. The results of the present study demonstrated that the expression levels of circ-0004904 were elevated in the placental tissues and plasma samples of patients with preeclampsia compared with those in the control group samples. Ectopic expression of circ-0004904 promoted autophagy, but inhibited migration and proliferation of HTR8 cells compared with those in the negative control group. Silencing of circ-0004904 inhibited autophagy, and induced migration and proliferation in JEG3 cells compared with those in the negative control group. In addition, circ-0004904 regulated the levels of ATG12 via interaction with miR-570. Furthermore, circ-0004904 regulated the FUS/VEGF axis in HTR8 and JEG3 cells. In conclusion, circ-0004904 was abnormally expressed in the plasma and placental tissues of patients with preeclampsia. In addition, circ-0004904 was involved in the regulation of proliferation, invasion and autophagy in HTR8 and JEG3 cells. Thus, circ-0004904 may be used as a potential diagnostic biomarker and therapeutic target for preeclampsia.
C1 [Dai, Wei; Liu, Xinghui] Sichuan Univ, Dept Obstet, West China Hosp, 1416 Sect 1,Chenglong Ave, Chengdu 610041, Sichuan, Peoples R China.
RP Liu, XH (corresponding author), Sichuan Univ, Dept Obstet, West China Hosp, 1416 Sect 1,Chenglong Ave, Chengdu 610041, Sichuan, Peoples R China.
EM xinghuiliu@163.com
CR [Anonymous], 2019, Obstet Gynecol, V133, P1, DOI 10.1097/AOG.0000000000003018
   Bai SH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70484-2
   Bakrania BA, 2022, AM J OBSTET GYNECOL, V226, pS973, DOI 10.1016/j.ajog.2020.10.025
   Bao X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0620-z
   Bian LJ, 2018, BIOCHEM BIOPH RES CO, V505, P346, DOI 10.1016/j.bbrc.2018.09.073
   Chen DS, 2018, CELL CYCLE, V17, P2080, DOI 10.1080/15384101.2018.1515553
   Chen ZH, 2014, AM J PHYSIOL-LUNG C, V306, pL1016, DOI 10.1152/ajplung.00268.2013
   Chilumula K, 2021, J ULTRASOUND, V24, P303, DOI 10.1007/s40477-020-00524-0
   Cornelius DC, 2020, EBIOMEDICINE, V57, DOI 10.1016/j.ebiom.2020.102864
   D'Ambra E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215477
   Dai J, 2020, EUR REV MED PHARMACO, V24, P7963, DOI 10.26355/eurrev_202008_22479
   Deepthi K, 2020, GENE, V762, DOI 10.1016/j.gene.2020.145040
   Deng WG, 2007, CANCER RES, V67, P709, DOI 10.1158/0008-5472.CAN-06-3463
   Ding CY, 2020, CANCER LETT, V479, P1, DOI 10.1016/j.canlet.2020.03.002
   Dyess NF, 2021, J PEDIATR-US, V228, P11, DOI 10.1016/j.jpeds.2020.08.015
   Gao L, 2015, J HYPERTENS, V33, P106, DOI 10.1097/HJH.0000000000000366
   Garikipati VNS, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11777-7
   Gong G, 2020, CELL CYCLE, V19, P2139, DOI 10.1080/15384101.2020.1792636
   Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270
   Hu XP, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0482-3
   Jia YH, 2020, FASEB J, V34, P13224, DOI 10.1096/fj.202000253RR
   Jiang M, 2018, CELL PHYSIOL BIOCHEM, V46, P2576, DOI 10.1159/000489685
   Lin L, 2021, IMMUNOL LETT, V230, P27, DOI 10.1016/j.imlet.2020.12.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Murrow L, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2015.1039191
   Nakashima A, 2020, AUTOPHAGY, V16, P1771, DOI 10.1080/15548627.2019.1707494
   Oh SY, 2008, REPROD SCI, V15, P912, DOI 10.1177/1933719108319159
   Ou YH, 2019, TAIWAN J OBSTET GYNE, V58, P769, DOI 10.1016/j.tjog.2019.09.007
   Panda AC, 2018, METHODS MOL BIOL, V1724, P43, DOI 10.1007/978-1-4939-7562-4_4
   Reddy M, 2021, AM J OBSTET GYNECOL, V224, DOI 10.1016/j.ajog.2020.08.019
   Saghafi N, 2018, INT J REPROD BIOMED, V16, P1, DOI 10.29252/ijrm.16.1.1
   Sahay AS, 2018, MOL CELL BIOCHEM, V438, P141, DOI 10.1007/s11010-017-3121-y
   Shang AQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01235-0
   Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629
   Wang YJ, 2019, BOSNIAN J BASIC MED, V19, P155, DOI 10.17305/bjbms.2019.3935
   Wang Z, 2020, CANCER MANAG RES, V12, P6947, DOI 10.2147/CMAR.S254250
   Wu YP, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00892
   Xia LQ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07395-y
   Xiao GH, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23252
   Xin Y, 2020, BURNS TRAUMA, V8, DOI 10.1093/burnst/tkaa025
   Xu YY, 2020, CANCER COMMUN, V40, P484, DOI 10.1002/cac2.12075
   Yildiz DA, 2017, CELL MOL BIOL, V63, P51, DOI 10.14715/cmb/2017.63.12.12
   Zhang HD, 2018, BIOMED PHARMACOTHER, V107, P1342, DOI 10.1016/j.biopha.2018.08.030
   Zhang J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0719-3
   Zhao HQ, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102813
   Zhao YS, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01390-w
NR 46
TC 2
Z9 2
U1 2
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JUN
PY 2021
VL 47
IS 6
AR 111
DI 10.3892/ijmm.2021.4944
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA RX7FR
UT WOS:000647386000001
PM 33907824
DA 2022-04-25
ER

PT J
AU Zhang, L
   Cheng, X
   Xu, SC
   Bao, JD
   Yu, HX
AF Zhang, Li
   Cheng, Xian
   Xu, Shichen
   Bao, Jiandong
   Yu, Huixin
TI Curcumin induces endoplasmic reticulum stress-associated apoptosis in
   human papillary thyroid carcinoma BCPAP cells via disruption of
   intracellular calcium homeostasis
SO MEDICINE
LA English
DT Article
DE apoptosis; curcumin; endoplasmic reticulum stress; human papillary
   thyroid carcinoma; intracellular calcium homeostasis
ID UNFOLDED PROTEIN RESPONSE; ER STRESS; COLORECTAL-CANCER; MITOCHONDRIA;
   INHIBITION; ACTIVATION; PREVENTION; ONCOGENES; AUTOPHAGY; TUMORS
AB Background: Thyroid cancer is the most common endocrine tumor. Our previous studies have demonstrated that curcumin can induce apoptosis in human papillary thyroid carcinoma BCPAP cells. However, the underlined mechanism has not been clearly elucidated. Endoplasmic reticulum (ER) is a major organelle for synthesis, maturation, and folding proteins as well as a large store for Ca2+. Overcoming chronically activated ER stress by triggering pro-apoptotic pathways of the unfolded protein response (UPR) is a novel strategy for cancer therapeutics. Our study aimed to uncover the ER stress pathway involved in the apoptosis caused by curcumin.
   Methods: BCPAP cells were treated with different doses of curcumin (12.5-50 mu M). Annexin V/PI double staining was used to determine cell apoptosis. Rhod-2/AM calcium fluorescence probe assay was performed to measure the calcium level of endoplasmic reticulum. Western blot was used to examine the expression of ER stress marker C/EBP homologous protein 10 (CHOP) and glucose-regulated protein 78 (GRP78). X-box binding protein1 (XBP-1) spliced form was examined by reverse transcriptase-polymerase chain reaction (RT-PCR).
   Results: Curcumin significantly inhibited anchorage-independent cell growth and induced apoptosis in BCPAP cells. Curcumin induced ER stress and UPR responses in a dose-and time-dependent manner, and the chemical chaperone 4-phenylbutyrate (4-PBA) partially reversed the antigrowth activity of curcumin. Moreover, curcumin significantly increased inositol-requiring enzyme 1 alpha (IRE1 alpha) phosphorylation and XBP-1 mRNA splicing to induce a subsets of ER chaperones. Increased cleavage of activating transcription factor 6 (ATF6), which enhances expression of its downstream target CHOP was also observed. Furthermore, curcumin induced intracellular Ca2+ influx through inhibition of the sarco-endoplasmic reticulum ATPase 2A (SERCA2) pump. The increased cytosolic Ca2+ then bound to calmodulin to activate calcium/calmodulin-dependent protein kinase II (CaMKII) signaling, leading to mitochondrial apoptosis pathway activation. Ca2+ chelator BAPTA partially reversed curcumin-induced ER stress and growth suppression, confirming the possible involvement of calcium homeostasis disruption in this response.
   Conclusions: Curcumin inhibits thyroid cancer cell growth, at least partially, through ER stress-associated apoptosis. Our observations provoked that ER stress activation may be a promising therapeutic target for thyroid cancer treatment.
C1 [Zhang, Li; Cheng, Xian; Xu, Shichen; Bao, Jiandong; Yu, Huixin] Jiangsu Inst Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Key Lab Nucl Med, 20 Qianrong Rd, Wuxi 214063, Jiangsu, Peoples R China.
RP Zhang, L (corresponding author), Jiangsu Inst Nucl Med, Jiangsu Key Lab Mol Nucl Med, Minist Hlth, Key Lab Nucl Med, 20 Qianrong Rd, Wuxi 214063, Jiangsu, Peoples R China.
EM zhangli@jsinm.org
FU Science and Research Foundation of Health Bureau of Jiangsu Province
   [H2017032]; National Natural Science Foundation of ChinaNational Natural
   Science Foundation of China (NSFC) [81602352, 81673436]; Natural Science
   Foundation of Jiangsu ProvinceNatural Science Foundation of Jiangsu
   Province [BK20171145, BK20151119]; Wuxi Municipal Commission of Health
   and Family Planning [Q201608]
FX This study was funded by the Science and Research Foundation of Health
   Bureau of Jiangsu Province (No. H2017032), the grants from the National
   Natural Science Foundation of China (Nos. 81602352 and 81673436), the
   Natural Science Foundation of Jiangsu Province (BK20171145 and
   BK20151119), and Wuxi Municipal Commission of Health and Family Planning
   (Q201608).
CR Basile V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053664
   Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823
   Bilmen JG, 2001, EUR J BIOCHEM, V268, P6318, DOI 10.1046/j.0014-2956.2001.02589.x
   Bittremieux M, 2016, BBA-MOL CELL RES, V1863, P1364, DOI 10.1016/j.bbamcr.2016.01.002
   Bowen NJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-71
   Carneiro RM, 2015, CANCER TREAT REV, V41, P690, DOI 10.1016/j.ctrv.2015.06.002
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098
   Chung FY, 2006, AM J SURG PATHOL, V30, P969, DOI 10.1097/00000478-200608000-00006
   EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X
   Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002
   Grande E, 2012, J THROID RES, V2012, DOI 10.1155/2012/847108
   Griffith LC, 2004, J NEUROSCI, V24, P8394, DOI 10.1523/JNEUROSCI.3604-04.2004
   Heger M, 2014, PHARMACOL REV, V66, P222, DOI 10.1124/pr.110.004044
   Hoyer-Hansen M, 2007, CELL DEATH DIFFER, V14, P1576, DOI 10.1038/sj.cdd.4402200
   Kim SM, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1982-6
   La Rovere RML, 2016, CELL CALCIUM, V60, P74, DOI 10.1016/j.ceca.2016.04.005
   LEMOINE NR, 1988, CANCER RES, V48, P4459
   Li W, 2014, CELL DEATH DIS, V5, pe1025
   Mahdi AA, 2016, INDIAN J CLIN BIOCHE, V31, P127, DOI 10.1007/s12291-015-0502-4
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Pierro C, 2014, J CELL SCI, V127, P1607, DOI 10.1242/jcs.141408
   Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027
   Rizzuto R, 2012, NAT REV MOL CELL BIO, V13, P566, DOI 10.1038/nrm3412
   Rodriguez D, 2011, BBA-MOL CELL RES, V1813, P564, DOI 10.1016/j.bbamcr.2010.11.012
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Schuck S, 2009, J CELL BIOL, V187, P525, DOI 10.1083/jcb.200907074
   Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728
   Stewart TA, 2015, BBA-BIOMEMBRANES, V1848, P2502, DOI 10.1016/j.bbamem.2014.08.016
   TANIGAWA N, 1982, CANCER RES, V42, P2159
   Timmins JM, 2009, J CLIN INVEST, V119, P2925, DOI 10.1172/JCI38857
   Urra H, 2013, BBA-MOL CELL RES, V1833, P3507, DOI 10.1016/j.bbamcr.2013.07.024
   Wang LL, 2016, J LIPID RES, V57, P1243, DOI 10.1194/jlr.M067397
   Wang WA, 2014, BBA-MOL CELL RES, V1843, P2143, DOI 10.1016/j.bbamcr.2014.01.012
   WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1
   Wu HT, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7239
   Xu L, 2016, PEST MANAG SCI, V72, P1710, DOI 10.1002/ps.4198
   Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7
   Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200
   Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000
   Zhang L, 2007, EUR J PHARMACOL, V564, P18, DOI 10.1016/j.ejphar.2007.01.089
   Zhang L, 2016, EXP CELL RES, V341, P157, DOI 10.1016/j.yexcr.2016.01.006
   Zhang L, 2016, FOOD FUNCT, V7, P315, DOI [10.1039/c5fo00681c, 10.1039/C5FO00681C]
   Zhang LX, 2016, RSC ADV, V6, P52905, DOI 10.1039/c6ra01515h
   Zheng M, 2013, INT IMMUNOPHARMACOL, V15, P517, DOI 10.1016/j.intimp.2013.02.002
NR 46
TC 34
Z9 35
U1 2
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN
PY 2018
VL 97
IS 24
AR e11095
DI 10.1097/MD.0000000000011095
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GN9RP
UT WOS:000439545200054
PM 29901626
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Wang, J
   Shao, L
   Wang, CZ
   Zhou, HH
   Yuan, CS
   Huang, WH
AF Wang, Jin
   Shao, Li
   Wang, Chong-Zhi
   Zhou, Hong-Hao
   Yuan, Chun-Su
   Huang, Wei-Hua
TI Synergetic Inhibition of Human Colorectal Cancer Cells by Combining
   Polyyne-Enriched Fraction from Oplopanax elatus and Irinotecan
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID QUANTITATIVE-ANALYSIS; CASPASES; CONSTITUENTS; FALCARINDIOL; CISPLATIN;
   AUTOPHAGY; HORRIDUS; DRUGS; LUNG
AB Although irinotecan is an important anticancer drug for treating colorectal cancer, its dose-dependent side effects limited its clinical application. Thus, it's important to develop low-toxic candidates to enhance the efficacy of irinotecan. Polyynes from genus Oplopanax were reported to possess potential anticancer effects on colorectal cancer. Hereby, we evaluated the synergetic inhibition of human colorectal cancer cells by combining polyyne-enriched fraction from Oplopanax elatus (the dichloromethane fraction of Oplopanax elatus, OED) and irinotecan. The results showed that 5 mu g/ml of OED combined with 40 mu M of irinotecan possessed significant synergetic inhibition on SW-480 cells with a combination index (CI) of 0.56. Besides, the percentage of apoptotic cells was significantly increased from 69.57% (40 mu M of irinotecan) or 72.7% (5 mu g/ml of OED) to 95.6% after treatment of OED combined with irinotecan (OCI), suggesting OED and irinotecan possess the synergistic apoptotic effect (P < 0.01). Furthermore, Caspase-3 was significantly activated in OCI group (P < 0.05). Besides, the percentage of apoptotic cells of OED or/and irinotecan significantly decreased after inhibition of caspase-3. These data indicated that OED could enhance antiproliferative effects of irinotecan on colorectal cancer cells, which was related with induction of apoptosis and regulations of activity of caspase-3.
C1 [Wang, Jin; Zhou, Hong-Hao; Huang, Wei-Hua] Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China.
   [Wang, Jin; Zhou, Hong-Hao; Huang, Wei-Hua] Cent S Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.
   [Shao, Li] Hunan Univ Chinese Med, Sch Pharm, Dept Pharmacognosy, Changsha, Hunan, Peoples R China.
   [Wang, Chong-Zhi; Yuan, Chun-Su; Huang, Wei-Hua] Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA.
RP Huang, WH (corresponding author), Cent S Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha 410008, Hunan, Peoples R China.
EM endeavor34852@aliyun.com
RI Wang, Chong-Zhi/B-8337-2014
OI Wang, Chong-Zhi/0000-0002-0950-2109; Huang, Wei-Hua/0000-0003-4167-8304
FU National Natural Scientific Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31400306]; Hunan Provincial Natural Science
   Foundation of ChinaNatural Science Foundation of Hunan Province
   [2015JJ3156]; China Postdoctoral Science FoundationChina Postdoctoral
   Science Foundation [2015M570692]; fundamental research funds for the
   central universities of Central South University [1681-7608040003]
FX This work was supported by the National Natural Scientific Foundation of
   China (31400306), Hunan Provincial Natural Science Foundation of China
   (2015JJ3156), China Postdoctoral Science Foundation (2015M570692) and
   the fundamental research funds for the central universities of Central
   South University (1681-7608040003).
CR Aitini Enrico, 2012, Cancer Manag Res, V4, P99, DOI 10.2147/CMAR.S29267
   Allan LA, 2009, FEBS J, V276, P6063, DOI 10.1111/j.1742-4658.2009.07330.x
   Bastos Diogo Assed, 2010, Ther Adv Med Oncol, V2, P261, DOI 10.1177/1758834010367905
   Cassidy S, 2017, NAT REV DRUG DISCOV, V16, P525, DOI 10.1038/nrd.2017.59
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Creagh EM, 2001, BIOCHEM SOC T, V29, P696, DOI 10.1042/BST0290696
   D'Amelio M, 2010, CELL DEATH DIFFER, V17, P1104, DOI 10.1038/cdd.2009.180
   Du GJ, 2012, J PHARM PHARMACOL, V64, P727, DOI 10.1111/j.2042-7158.2012.01463.x
   Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234
   Goto K, 2016, LANCET ONCOL, V17, P1147, DOI 10.1016/S1470-2045(16)30104-8
   Huang WH, 2014, CHEM BIODIVERS, V11, P181, DOI 10.1002/cbdv.201200306
   Huang WH, 2010, J PHARMACEUT BIOMED, V53, P906, DOI 10.1016/j.jpba.2010.06.021
   Huang YF, 2017, ONCOTARGET, V8, P40264, DOI 10.18632/oncotarget.16828
   Jin HR, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.122
   Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270
   Mukhopadhyay S, 2014, APOPTOSIS, V19, P555, DOI 10.1007/s10495-014-0967-2
   Nautiyal Jyoti, 2011, J Mol Signal, V6, P7, DOI 10.1186/1750-2187-6-7
   Nicholson DW, 2003, SCIENCE, V299, P214, DOI 10.1126/science.1081274
   Peinert Stefan, 2010, Ther Adv Med Oncol, V2, P161, DOI 10.1177/1758834010365061
   Qiao X, 2017, MOLECULES, V22, DOI 10.3390/molecules22101593
   Rejhova A, 2018, EUR J MED CHEM, V144, P582, DOI 10.1016/j.ejmech.2017.12.039
   Semalty A, 2012, SCHWEIZ Z GANZHEITSM, V24, P155, DOI 10.1159/000339011
   Shikov AN, 2014, CHIN J NAT MEDICINES, V12, P721, DOI 10.1016/S1875-5364(14)60111-4
   Smyth EC, 2015, J CLIN ONCOL, V33, P2409, DOI 10.1200/JCO.2014.59.7088
   Sun S, 2010, J ETHNOPHARMACOL, V132, P280, DOI 10.1016/j.jep.2010.08.026
   Sun W, 2016, CHIN J NAT MEDICINES, V14, P714, DOI 10.1016/S1875-5364(16)30085-1
   Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056
   Wu DM, 2017, ONCOTARGET, V8
   Yang MC, 2010, J NAT PROD, V73, P801, DOI 10.1021/np900628j
   Yu ML, 2014, MOL MED REP, V9, P249, DOI 10.3892/mmr.2013.1762
NR 33
TC 5
Z9 5
U1 0
U2 15
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PD APR 3
PY 2019
VL 71
IS 3
BP 472
EP 482
DI 10.1080/01635581.2018.1516788
PG 11
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA HU9KZ
UT WOS:000465614600013
PM 30372160
DA 2022-04-25
ER

PT J
AU Scaioli, E
   Biondi, R
   Liverani, E
   Sartini, A
   Troiano, A
   Fuccio, L
   Muratori, R
   Lombardi, G
   Onorini, D
   Dal Monte, P
   Donati, M
   Belluzzi, A
AF Scaioli, Eleonora
   Biondi, Roberta
   Liverani, Elisa
   Sartini, Alessandro
   Troiano, Antonella
   Fuccio, Lorenzo
   Muratori, Rosangela
   Lombardi, Giulia
   Onorini, Delia
   Dal Monte, Paola
   Donati, Manuela
   Belluzzi, Andrea
TI Simkania negevensis in Crohn's Disease
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE Simkania negevensis; Crohn's disease; Infective hypothesis
ID CHLAMYDIA-PNEUMONIAE; INFECTION; PREVALENCE; AUTOPHAGY; WATER; IGG
AB Background Simkania negevensis is an obligate intracellular Gram-negative bacterium ( family Simkaniaceae, order Chlamydiales) that has been isolated from domestic and mains water supplies, is able to infect human macrophages, and can induce an inflammatory response in the host.
   Methods From June to December 2016, in a single-center observational study, colonic Crohn's disease patients and controls (subjects undergoing screening for colorectal cancer) underwent blood tests to identify serum-specific immunoglobulin G (IgG) and immunoglobulin A (IgA) to S. negevensis and a colonoscopy with biopsies for detection of S. negevensis DNA by polymerase chain reaction (PCR).
   Results Forty-three Crohn's disease patients and 18 controls were enrolled. Crohn's disease patients had higher prevalence of IgA antibodies to S. negevensis compared with controls (20.9% versus 0%, p = 0.04). Simkaniaceae negevensis DNA was detected in 34.9% and 5.6% of intestinal biopsies in Crohn's disease patients and controls, respectively (p = 0.02). All Crohn's disease patients with PCR-positive biopsies for S. negevensis were IgG seropositive, with specific IgA in 60% of them (p < 0.001). Immunosuppressive therapies, extraintestinal manifestations, or disease activity did not influence the presence of S. negevensis in the Crohn's disease population.
   Conclusions We identified S. negevensis in Crohn's disease patients by demonstrating the presence of S. negevensis mucosal DNA and seropositivity to the bacterium. These results could support the presence of an acute or persistent S. negevensis infection and suggest a possible role in the pathogenesis of Crohn's disease.
C1 [Scaioli, Eleonora; Liverani, Elisa; Sartini, Alessandro; Troiano, Antonella; Fuccio, Lorenzo; Muratori, Rosangela; Belluzzi, Andrea] Univ Bologna, Gastroenterol Unit, Dept Med & Surg Sci, St Orsola Malpighi Hosp, Via Massarenti 9, I-40138 Bologna, Italy.
   [Biondi, Roberta; Lombardi, Giulia; Onorini, Delia; Dal Monte, Paola; Donati, Manuela] Univ Bologna, St Orsola Malpighi Hosp, Microbiol Unit, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy.
RP Belluzzi, A (corresponding author), Univ Bologna, Gastroenterol Unit, Dept Med & Surg Sci, St Orsola Malpighi Hosp, Via Massarenti 9, I-40138 Bologna, Italy.
EM elescaio@gmail.com; roberta.biondi5@unibo.it; elisa.liverani@yahoo.it;
   ale.sartini@gmail.com; a.t.26101989@gmail.com; lorenzofuccio@gmail.com;
   rosangela.muratori@aosp.bo.it; giulia.lombardi@aosp.bo.it;
   delia.onorini@studio.unibo.it; paola.dalmonte@unibo.it;
   manuela.donati@unibo.it; andrea.belluzzi@aosp.bo.it
RI Sartini, Alessandro/AAN-3396-2020; Fuccio, Lorenzo/A-2557-2010
OI Sartini, Alessandro/0000-0003-1573-6451; Fuccio,
   Lorenzo/0000-0001-8618-2447; DAL MONTE, PAOLA/0000-0003-2326-7464
CR BEST WR, 1976, GASTROENTEROLOGY, V70, P439
   Buisson A, 2016, INFLAMM BOWEL DIS, V22, P2943, DOI 10.1097/MIB.0000000000000946
   Casson N, 2006, INT J ANTIMICROB AG, V27, P541, DOI 10.1016/j.ijantimicag.2006.03.009
   Chen WX, 2002, J GASTROEN HEPATOL, V17, P987, DOI 10.1046/j.1440-1746.2002.02793.x
   Daperno M, 2004, GASTROINTEST ENDOSC, V60, P505, DOI 10.1016/S0016-5107(04)01878-4
   Donati M, 2015, J APPL MICROBIOL, V118, P1076, DOI 10.1111/jam.12761
   Donati M, 2013, NEW MICROBIOL, V36, P303
   Donati M, 2013, NEW MICROBIOL, V36, P85
   Fasoli L, 2008, SCAND J INFECT DIS, V40, P269, DOI 10.1080/00365540701642146
   Friedman MG, 1999, EPIDEMIOL INFECT, V122, P117, DOI 10.1017/S095026889800185X
   FUKUSHI H, 1988, J CLIN MICROBIOL, V26, P675, DOI 10.1128/JCM.26.4.675-680.1988
   Gordon SB, 2002, BRIT MED BULL, V61, P45, DOI 10.1093/bmb/61.1.45
   Herweg JA, 2016, FEBS J, V283, P608, DOI 10.1111/febs.13609
   Homer CR, 2010, GASTROENTEROLOGY, V139, P1630, DOI 10.1053/j.gastro.2010.07.006
   Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107
   Kahane S, 1998, J INFECT DIS, V177, P1425, DOI 10.1086/517830
   Kahane S, 2004, APPL ENVIRON MICROB, V70, P3346, DOI 10.1128/AEM.70.6.3346-3351.2004
   KAHANE S, 1993, FEMS MICROBIOL LETT, V109, P329, DOI 10.1111/j.1574-6968.1993.tb06189.x
   Kahane S, 2001, APPL ENVIRON MICROB, V67, P4789, DOI 10.1128/AEM.67.10.4789-4795.2001
   Kahane Simona, 2007, J Infect, V55, pe13, DOI 10.1016/j.jinf.2007.03.002
   Kahane S, 2008, FEMS IMMUNOL MED MIC, V52, P219, DOI 10.1111/j.1574-695X.2007.00361.x
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Lieberman D, 2002, EUR J CLIN MICROBIOL, V21, P307, DOI 10.1007/s10096-002-0703-7
   Liverani E, 2014, WORLD J GASTROENTERO, V20, P13060, DOI 10.3748/wjg.v20.i36.13060
   Muller S, 2006, EUR J GASTROEN HEPAT, V18, P889, DOI 10.1097/00042737-200608000-00015
   Petersen BT, 2011, GASTROINTEST ENDOSC, V73, P1075, DOI 10.1016/j.gie.2011.03.1183
   Petrich A, 2002, CHLAM INF P 10 INT S
   Vouga M, 2017, CRIT REV MICROBIOL, V43, P62, DOI 10.3109/1040841X.2016.1165650
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
NR 29
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD NOV
PY 2019
VL 64
IS 11
BP 3284
EP 3290
DI 10.1007/s10620-019-05632-4
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA JL4EL
UT WOS:000495483700034
PM 31041636
DA 2022-04-25
ER

PT J
AU Tian, F
   Wang, JH
   Zhang, ZH
   Yang, J
AF Tian, Feng
   Wang, Junhu
   Zhang, Zhanhua
   Yang, Jie
TI LncRNA SNHG7/miR-34a-5p/SYVN1 axis plays a vital role in proliferation,
   apoptosis and autophagy in osteoarthritis
SO BIOLOGICAL RESEARCH
LA English
DT Article
DE Osteoarthritis; SNHG7; miR-34a-5p; SYVN1; Cell growth; Autophagy
ID COLORECTAL-CANCER; DOWN-REGULATION; NONCODING RNAS; SNHG7 PROMOTES;
   PROGRESSION; CHONDROCYTE; EXPRESSION; CARTILAGE; CELLS; METASTASIS
AB Background Osteoarthritis (OA) is one of the most common rheumatic diseases of which clinical symptoms includes swelling, synovitis and inflammatory pain, affect patients' daily life. It was reported that non-coding RNAs play vital roles in OA. However, the regulation mechanism of ncRNA in OA pathogenesis has not been fully elucidated. Methods The expression of SNHG7, miR-34a-5p and SYVN1 was detected using qRT-PCR in tissues, serum and cells. The protein expression of SYVN1, PCNA, cleavage-caspase 3, beclin1 and LC3 were measured using western blot. The RNA immunoprecipitation (RIP), RNA pulldown, and luciferase reporter assays were used to verify the relationship between SNHG7, miR-34a-5p and SYVN1. The MTT and flow cytometry assay was performed to detected cell proliferation and cell apoptosis respectively. Results In this study, SNHG7 and SYVN1 expression were down-regulated, but miR-34a-5p was up-regulated in OA tissues and IL-1 beta treated cells compared with normal tissues and chondrocyte. Functional investigation revealed that up-regulated SNHG7 or down-regulated miR-34a-5p could promote cell proliferation and inhibit cell apoptosis and autophagy in OA cells. More than that, RIP, pulldown and luciferase reporter assay was applied to determine that miR-34a-5p was a target miRNA of SNHG7 and SYVN1 was a target mRNA of miR-34-5p. Rescue experiments showed that overexpression of miR-34a reversed high expression of SNHG7-mediated suppression of apoptosis and autophagy as well as promotion of proliferation, while its knockdown inhibited cell apoptosis and autophagy and promoted cell proliferation which could be impaired by silencing SYVN1. In addition, SNHG7 regulated SYVN1 through sponging miR-34a-5p. Conclusion SNHG7 sponged miR-34a-5p to affect cell proliferation, apoptosis and autophagy through targeting SYVN1 which provides a novel sight into the pathogenesis of OA.
C1 [Tian, Feng; Wang, Junhu; Yang, Jie] Xi An Jiao Tong Univ, Honghui Hosp, Dept Foot & Ankle Surg, 555 East Youyi Rd, Xian 710054, Shaanxi, Peoples R China.
   [Zhang, Zhanhua] Xi An Jiao Tong Univ, Honghui Hosp, Dept Internal Med, Xian, Shaanxi, Peoples R China.
RP Yang, J (corresponding author), Xi An Jiao Tong Univ, Honghui Hosp, Dept Foot & Ankle Surg, 555 East Youyi Rd, Xian 710054, Shaanxi, Peoples R China.
EM kcbgpf@163.com
FU Xi'an health and family planning commission [J20161008]; National
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81200076]
FX This work was supported by Xi'an health and family planning commission.
   (Grant No. J20161008) and National Natural Science Foundation of China
   (Grant No. 81200076).
CR Abouheif MM, 2010, RHEUMATOLOGY, V49, P2054, DOI 10.1093/rheumatology/keq247
   Alajez NM, 2011, CANCER RES, V71, P2381, DOI 10.1158/0008-5472.CAN-10-2754
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Chafik A, 2018, INT J MOL BIOL OPEN, V3, P8
   Chen L, 2019, ONCOL LETT, V18, P4726, DOI 10.3892/ol.2019.10782
   Ding J, 2018, ONCOGENE, V37, P5037, DOI 10.1038/s41388-018-0175-6
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Fu M, 2015, OSTEOARTHR CARTILAGE, V23, P423, DOI 10.1016/j.joca.2014.12.001
   Gao J, 2015, ONCOGENE, V34, P4142, DOI 10.1038/onc.2014.348
   Ge FX, 2017, ONCOL REP, V37, P2490, DOI 10.3892/or.2017.5475
   Jia DF, 2018, ONCOL RES, V26, P753, DOI 10.3727/096504017X15024946480113
   Li Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0632-2
   Liang TT, 2018, FASEB J, V32, P377, DOI 10.1096/fj.201700560RR
   Liu Q, 2016, MOL THER, V24, P1726, DOI 10.1038/mt.2016.151
   Marques-Rocha JL, 2015, FASEB J, V29, P3595, DOI 10.1096/fj.14-260323
   Masahiko K, 2010, ARTHRITIS RHEUM, V52, P128
   Michael JWP, 2010, DTSCH ARZTEBL INT, V107, P152, DOI 10.3238/arztebl.2010.0152
   Ren J, 2018, BIOCHEM BIOPH RES CO, V496, P712, DOI 10.1016/j.bbrc.2018.01.109
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   She KL, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12406
   Shen HJ, 2018, ACTA BIOCH BIOPH SIN, V50, P191, DOI 10.1093/abbs/gmx141
   Song P, 2016, GENE, V592, P8, DOI 10.1016/j.gene.2016.07.055
   Tili E, 2011, J NUCLEIC ACIDS, V2011, DOI 10.4061/2011/102431
   Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108
   Vanderford NL, 2010, ISLETS, V2, P334, DOI 10.4161/isl.2.5.13095
   Wang CJ, 2017, INT J MED SCI, V14, P213, DOI 10.7150/ijms.17469
   Wang MW, 2017, EUR REV MED PHARMACO, V21, P4613
   Wang W, 2017, SCI REP-UK, V7, DOI 10.1038/srep41639
   Xu J, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0195-x
   Xu TX, 2016, EUR REV MED PHARMACO, V20, P399
   Yang B, 2018, J CELL BIOCHEM, V119, P7959, DOI 10.1002/jcb.26600
   Yang GG, 2005, GENE, V363, P166, DOI 10.1016/j.gene.2005.08.006
   Yang S, 2015, SCI REP-UK, V5, DOI 10.1038/srep14036
   Zhang G, 2016, DNA CELL BIOL, V35, P691, DOI 10.1089/dna.2016.3397
   Zhang HM, 2014, BIOTECHNOL BIOFUELS, V7, DOI 10.1186/1754-6834-7-3
   Zhao HE, 2013, ONCOL REP, V29, P1027, DOI 10.3892/or.2013.2234
NR 37
TC 32
Z9 33
U1 5
U2 9
PU SOC BIOLGIA CHILE
PI SANTIAGO
PA CASILLA 16164, SANTIAGO 9, CHILE
SN 0716-9760
EI 0717-6287
J9 BIOL RES
JI Biol. Res.
PD FEB 17
PY 2020
VL 53
IS 1
AR 9
DI 10.1186/s40659-020-00275-6
PG 11
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA KN0OV
UT WOS:000514539300001
PM 32066502
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Jiang, ZY
   Liu, JB
   Chen, BA
   Mani, R
   Pugazhendhi, A
   Shanmuganathan, R
   Jacob, JA
AF Jiang, Ziyu
   Liu, Jingbing
   Chen, Baoan
   Mani, Rajesh
   Pugazhendhi, Arivalagan
   Shanmuganathan, Rajasree
   Jacob, Joe Antony
TI Cytotoxic effects of a sesquiterpene beta-elemene on THP-1 leukemia
   cells is mediated via crosstalk between beclin-1 mediated autophagy and
   caspase-dependent apoptosis
SO PROCESS BIOCHEMISTRY
LA English
DT Article
DE beta-elemene; Leukemia; Cytotoxicity; mRNA; Expressions; Crosstalk
ID COLORECTAL-CANCER; IN-VIVO; EXPRESSION; MECHANISM; LIFE; PCR
AB beta- elemene extracted from Curcuma zedoaria rhizome (commonly known as white turmeric) is an effective anticancer agent. There are limited reports on the use of this agent against THP-1 cells employing a mechanistic study. Therefore, as a foremost aim of the present study, the cytotoxic effect of elemene and its mechanism will be elucidated. For this aim, the method adopted was to treat THP-1 cells in a dose- and time- dependent manner with elemene and the cytotoxicity to be evaluated. The mRNA expressions of a set of autophagy and apoptosis related genes will be analyzed by quantitative PCR. The findings indicate that the IC50 values for 24, 48, 72 and 96 h of treated THP-1 cells were 64.71, 42.19, 25.29 and 20.21 mu g/mL respectively. The expressions of autophagy related genes such as Beclin-1, LC3II, ATG-5 and XBP-1 were upregulated. The expressions of anti-apoptotic Bcl2 was upregulated, whereas, the expression of pro-apoptotic Box was downregulated. Interestingly, the expressions of Caspase-3 and Caspase-8 were upregulated. To summarize, autophagy might have occurred in endoplasmic reticulum and there might be a crosstalk with apoptosis which could be the rationale behind the cytotoxic effects of elemene on THP-1 cells. Therefore, beta- elemene could be a potential therapeutic agent for leukemia.
C1 [Jiang, Ziyu; Chen, Baoan; Jacob, Joe Antony] Southeast Univ, Sch Med, Zhongda Hosp, Dept Hematol & Oncol, Nanjing 210009, Jiangsu, Peoples R China.
   [Jiang, Ziyu; Liu, Jingbing] Nanjing Univ Chinese Med, Dept Oncol, Affiliated Hosp Integrated Tradit Chinese & Weste, Nanjing, Jiangsu, Peoples R China.
   [Mani, Rajesh] Jawaharlal Nehru Univ, Mol & Cell Biol Lab, Sch Biotechnol, New Delhi, India.
   [Pugazhendhi, Arivalagan] Ton Duc Thang Univ, Fac Environm & Labour Safety, Innovat Green Prod Synth & Renewable Environm Dev, Ho Chi Minh City, Vietnam.
   [Shanmuganathan, Rajasree] Duy Tan Univ, Inst Res & Dev, Da Nang 550000, Vietnam.
RP Chen, BA (corresponding author), Southeast Univ, Sch Med, Zhongda Hosp, Dept Hematol & Oncol, Nanjing 210009, Jiangsu, Peoples R China.
EM cba8888@hotmail.com
RI Pugazhendhi, Arivalagan/F-5411-2018; Shanmuganathan,
   Rajasree/AAU-5295-2020
OI Pugazhendhi, Arivalagan/0000-0002-9529-3306; Mani,
   Rajesh/0000-0001-8649-0212
FU National natural science foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81973525]; Jiangsu Branch of China Academy
   of Chinese Medical Sciences [Y201803]
FX This work was supported by the National natural science foundation of
   China (Grant No. 81973525), Jiangsu Branch of China Academy of Chinese
   Medical Sciences (Grant No. Y201803, Nanjing 210028, China).
CR Adan A, 2016, CURR PHARM BIOTECHNO, V17, P1213, DOI 10.2174/1389201017666160808160513
   Aranjani JM, 2013, AM J CHINESE MED, V41, P145, DOI 10.1142/S0192415X13500110
   Badadani M., 2012, ISRN CELL BIOL, V2012, P1, DOI [10.5402/2012/927064, DOI 10.5402/2012/927064]
   Barth S, 2010, J PATHOL, V221, P117, DOI 10.1002/path.2694
   Bialik S, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215152
   Bishop E, 2018, CANCER CHEMOTH PHARM, V82, P913, DOI 10.1007/s00280-018-3669-6
   Bosshart H, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.08.53
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Cai B, 2018, ONCOL LETT, V16, P6019, DOI 10.3892/ol.2018.9401
   Chanput W, 2014, INT IMMUNOPHARMACOL, V23, P37, DOI 10.1016/j.intimp.2014.08.002
   Chung Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1229-y
   Codogno P, 2006, NAT CELL BIOL, V8, P1045, DOI 10.1038/ncb1006-1045
   Decuypere Jean-Paul, 2012, Cells, V1, P284, DOI 10.3390/cells1030284
   Deepak SA, 2007, CURR GENOMICS, V8, P234
   El-Khattouti Abdelouahid, 2013, J Cell Death, V6, P37, DOI 10.4137/JCD.S11034
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688
   Ge J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110293
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Guo W, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.276
   Han Y, 2014, ASIAN PAC J CANCER P, V15, P4583, DOI 10.7314/APJCP.2014.15.11.4583
   Hou W, 2010, AUTOPHAGY, V6, P891, DOI 10.4161/auto.6.7.13038
   Hu TL, 2018, BIOMED PHARMACOTHER, V106, P1557, DOI 10.1016/j.biopha.2018.07.124
   Jacob JA, 2017, CLIN CHIM ACTA, V468, P85, DOI 10.1016/j.cca.2017.01.028
   Janji B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00887
   Jiang DD, 2015, SEMIN CANCER BIOL, V33, P48, DOI 10.1016/j.semcancer.2015.04.010
   Jiang ZY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00105
   Kabeer FA, 2017, INTEGR MED RES, V6, P190, DOI 10.1016/j.imr.2017.03.004
   Kelaini S, 2017, AUTOPHAGY: CANCER, OTHER PATHOLOGIES, INFLAMMATION, IMMUNITY, INFECTION, AND AGING, VOL 11, P259, DOI 10.1016/B978-0-12-805420-8.00013-5
   Kishino A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02960-1
   Lakshmi S, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/253962
   Li M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030332
   Li QQ, 2010, J PHARM PHARMACOL, V62, P1018, DOI 10.1111/j.2042-7158.2010.01135.x
   Li X, 2005, CELL MOL LIFE SCI, V62, P894, DOI 10.1007/s00018-005-5027-1
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma K, 2016, ONCOL REP, V36, P1807, DOI 10.3892/or.2016.5003
   Manoto SL, 2017, MOLECULES, V22, DOI 10.3390/molecules22050791
   Margariti A, 2013, J BIOL CHEM, V288, P859, DOI 10.1074/jbc.M112.412783
   McKnight Nicole C, 2013, Curr Pathobiol Rep, V1, P231
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Onyegeme-Okerenta B., 2018, J CANC TREATMENT RES, V6, P44
   Pan Z, 2018, RSC ADV, V8, P38910, DOI 10.1039/c8ra06566g
   Piccolo M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43411-3
   Pistritto G, 2016, AGING-US, V8, P603, DOI 10.18632/aging.100934
   Rao Xiayu, 2013, Biostat Bioinforma Biomath, V3, P71
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   Su M., 2013, J ONCOLOGY, V2013, P14
   Tsapras P, 2017, CELL DEATH DIFFER, V24, P1369, DOI 10.1038/cdd.2017.43
   Yao YQ, 2008, CANCER LETT, V264, P127, DOI 10.1016/j.canlet.2008.01.049
   Ye X, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02334
   Yu XM, 2017, BIOCHEM BIOPH RES CO, V490, P514, DOI 10.1016/j.bbrc.2017.06.071
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zhang C, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00029
NR 53
TC 5
Z9 5
U1 4
U2 11
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1359-5113
EI 1873-3298
J9 PROCESS BIOCHEM
JI Process Biochem.
PD DEC
PY 2019
VL 87
BP 174
EP 178
DI 10.1016/j.procbio.2019.09.006
PG 5
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Engineering
GA JZ4WV
UT WOS:000505103600023
DA 2022-04-25
ER

PT J
AU Cirone, M
   Lotti, LV
   Granato, M
   Di Renzo, L
   Biunno, I
   Cattaneo, M
   Verginelli, F
   Vespa, S
   Davies, D
   Wells, V
   Mariani-Costantini, R
   Mallucci, L
AF Cirone, Mara
   Lotti, Lavinia Vittoria
   Granato, Marisa
   Di Renzo, Livia
   Biunno, Ida
   Cattaneo, Monica
   Verginelli, Fabio
   Vespa, Simone
   Davies, Derek
   Wells, Valerie
   Mariani-Costantini, Renato
   Mallucci, Livio
TI Sourcing the immune system to induce immunogenic cell death in
   Kras-colorectal cancer cells
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
ID GALACTOSIDE-BINDING PROTEIN; CALRETICULIN EXPOSURE; ER STRESS; BETA-GBP;
   AUTOPHAGY; PATHWAY; PI3K
AB BACKGROUND: Current approaches aimed at inducing immunogenic cell death (ICD) to incite an immune response against cancer neoantigens are based on the use of chemotherapeutics and other agents. Results are hampered by issues of efficacy, combinatorial approaches, dosing and toxicity. Here, we adopted a strategy based on the use of an immunomolecule that overcomes pharmachemical limitations.
   METHODS: Cytofluorometry, electron microscopy, RT-PCR, western blotting, apotome immunofluorescence, MLR and xenografts.
   RESULTS: We report that an ICD process can be activated without the use of pharmacological compounds. We show that in Krasmut/TP53-mut colorectal cancer cells the 15 kDa beta GBP cytokine, a T cell effector with onco-suppressor properties and a potential role in cancer immunosurveillance, induces key canonical events required for ICD induction. We document ER stress, autophagy that extends from cancer cells to the corresponding xenograft tumours, CRT cell surface shifting, ATP release and evidence of dendritic cell activation, a process required for priming cytotoxic T cells into a specific anticancer immunogenic response.
   CONCLUSIONS: Our findings provide experimental evidence for a rationale to explore a strategy based on the use of an immunomolecule that as a single agent couples oncosuppression with the activation of procedures necessary for the induction of long term response to cancer.
C1 [Cirone, Mara; Lotti, Lavinia Vittoria; Granato, Marisa; Di Renzo, Livia] Univ Roma La Sapienza, Dipartimento Med Sperimentale, Viale Regina Elena 324, I-0061 Rome, Italy.
   [Biunno, Ida; Cattaneo, Monica] CNR, Ist Ric Genet & Biomed, Via Fantoli 15-16, I-20138 Milan, Italy.
   [Verginelli, Fabio] Univ G dAnnunzio, Dipartimento Farm, Via Vestini 1, I-66100 Chieti, Italy.
   [Vespa, Simone; Mariani-Costantini, Renato] Univ G DAnnunzio, Dipartimento Sci Med Orali & Biotechnol, Unita Patol Gen, Via Luigi Polacchi 11, I-66100 Chieti, Italy.
   [Vespa, Simone; Mariani-Costantini, Renato] Univ G DAnnunzio, Ctr Ateneo Ric Invecchiamento & Malattie Correlat, Via Luigi Polacchi 11, I-66100 Chieti, Italy.
   [Davies, Derek] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England.
   [Wells, Valerie] NYU London, 6 Bedford Sq, London WC1B 3RA, England.
   [Mallucci, Livio] Kings Coll London, Sch Canc & Pharmaceut Sci, Fac Life Sci & Med, Guys Campus, London SE1 1UL, England.
   [Cattaneo, Monica] MultiMedica, Via Fantoli 16-15, I-20138 Milan, Italy.
RP Mallucci, L (corresponding author), Kings Coll London, Sch Canc & Pharmaceut Sci, Fac Life Sci & Med, Guys Campus, London SE1 1UL, England.
EM livio.mallucci@kcl.ac.uk
RI Granato, Marisa/K-6203-2014
OI Vespa, Simone/0000-0001-6146-9302; , IDA_2/0000-0002-1068-4763;
   /0000-0002-1866-5866; , Marisa/0000-0002-2758-5120; VERGINELLI,
   Fabio/0000-0002-8636-2517; Mariani-Costantini,
   Renato/0000-0002-4440-1848
FU King's College London; Universita' di Roma La Sapienza; G.d'Annunzio
   University Chieti
FX The work was supported by internal funding from King's College London,
   Universita' di Roma La Sapienza, and the G.d'Annunzio University Chieti.
CR Blaser C, 1998, EUR J IMMUNOL, V28, P2311, DOI 10.1002/(SICI)1521-4141(199808)28:08<2311::AID-IMMU2311>3.0.CO;2-G
   Cattaneo M, 2011, PLOS, V6, P172
   Dudek AM, 2013, CYTOKINE GROWTH F R, V24, P319, DOI 10.1016/j.cytogfr.2013.01.005
   Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Mallucci L, 2014, DRUG DISCOV TODAY, V19, P383, DOI 10.1016/j.drudis.2013.11.018
   Mallucci L, 2012, MOL CANCER THER, V11, P1884, DOI 10.1158/1535-7163.MCT-11-1041-T
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Pol J, 2015, ONCOIMMUNOLOGY, V4
   Ravatn R, 2005, CANCER RES, V65, P1631, DOI 10.1158/0008-5472.CAN-04-1970
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Shimodaira Y, 2014, BIOCHEM BIOPH RES CO, V445, P524, DOI 10.1016/j.bbrc.2014.02.054
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wells V, 1999, EUR J CANCER, V35, P978, DOI 10.1016/S0959-8049(99)00020-9
   Wells V, 2007, ONCOGENE, V26, P7709, DOI 10.1038/sj.onc.1210580
   WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G
   Wells V, 2009, BREAST CANCER RES, V11, P1
   Yatim N, 2017, NAT REV IMMUNOL, V17, P262, DOI 10.1038/nri.2017.9
   Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0
NR 29
TC 2
Z9 2
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 29
PY 2019
VL 121
IS 9
BP 768
EP 775
DI 10.1038/s41416-019-0561-z
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JI6GB
UT WOS:000493564700006
PM 31558803
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Liu, KS
   Guo, YM
   Zheng, K
   Zou, C
   Wu, HX
   Wang, SX
   Ou, L
   Wang, YF
   Huang, BW
   Wang, X
AF Liu, Kaisheng
   Guo, Yaomin
   Zheng, Kai
   Zou, Chang
   Wu, Haixiong
   Wang, Shaoxiang
   Ou, Ling
   Wang, Yifei
   Huang, Bowan
   Wang, Xiao
TI Identification of the circRNA-miRNA-mRNA regulatory network of Hsp90
   inhibitor-induced cell death in colorectal cancer by integrated analysis
SO GENE
LA English
DT Article
DE Colorectal cancer; SNX-2112; Cell death; mRNA; miRNA; circRNA
ID APOPTOSIS; AUTOPHAGY
AB Colorectal cancer (CRC) is a global disease with high incidence and mortality rate. Hsp90 inhibitors induce cell death in various cancers, including CRC. However, the underlying mechanisms need to be clarified further. In this study, Caco-2 cells were treated with 0.25 mu M SNX-2112, an Hsp90 inhibitor, for 48 h; subsequently, whole-transcriptome sequencing was performed. At the mRNA level in SNX-2112-treated Caco-2 cells, 1588 genes were upregulated, and 433 genes were downregulated. Six genes were found to be associated with necroptosis and apoptosis, and these 6 upregulated genes were validated by RT-qPCR. Hundred and six miRNAs were upregulated, and 48 miRNAs were downregulated in SNX-2112-treated Caco-2 cells. Eleven downregulated miRNAs were found to interact with the 6 upregulated genes. Moreover, 676 circRNAs were upregulated, and 291 circRNAs were downregulated in SNX-2112-treated Caco-2 cells. Among them, 126 circRNAs were found to be the target of the 11 downregulated miRNAs. The circRNA-miRNA-mRNA regulatory network of Hsp90 inhibitor-induced cell death in colorectal cancer was constructed. This regulatory network extends the underlying mechanism of Hsp90 and improves our understanding of Hsp90 inhibitors as potential targeted therapeutic agents.
C1 [Liu, Kaisheng; Guo, Yaomin; Zou, Chang; Wu, Haixiong; Ou, Ling; Wang, Xiao] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Southern Univ Sci & Technol,Affiliated Hosp 1, Shenzhen 518020, Guangdong, Peoples R China.
   [Zheng, Kai; Wang, Shaoxiang] Shenzhen Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Shenzhen 518060, Guangdong, Peoples R China.
   [Wang, Yifei] Jinan Univ, Coll Life Sci & Technol, Inst Biomed, Guangzhou 510632, Guangdong, Peoples R China.
   [Huang, Bowan] Cent Peoples Hosp Zhanjiang, Dept Anesthesiol, Zhanjiang 524000, Guangdong, Peoples R China.
RP Wang, X (corresponding author), Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Southern Univ Sci & Technol,Affiliated Hosp 1, Shenzhen 518020, Guangdong, Peoples R China.; Huang, BW (corresponding author), Cent Peoples Hosp Zhanjiang, Dept Anesthesiol, Zhanjiang 524000, Guangdong, Peoples R China.
EM bowanhuang@126.com; wangxiao0719@163.com
RI Zheng, Kai/AAT-8994-2021; Zou, Chang/AAS-3356-2021
OI Zheng, Kai/0000-0001-9275-1239; Zou, Chang/0000-0002-2003-7834; Wang,
   Xiao/0000-0001-8824-6280; Liu, Kaisheng/0000-0002-4755-0523
FU Cultivating Fund Project of Shenzhen People's Hospital [SYKYPY201928];
   Science and Technology Foundation of Shenzhen [JCYJ20180301170047864,
   GJHZ20180928171802117]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [81802749]
FX This research was funded by the Cultivating Fund Project of Shenzhen
   People's Hospital (SYKYPY201928), the Science and Technology Foundation
   of Shenzhen (JCYJ20180301170047864, GJHZ20180928171802117), and the
   National Natural Science Foundation of China (No. 81802749).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Calderwood SK, 2016, ADV CANCER RES, V129, P89, DOI 10.1016/bs.acr.2015.08.002
   Chen B, 2005, GENOMICS, V86, P627, DOI 10.1016/j.ygeno.2005.08.012
   Condelli V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060532
   Goetz MP, 2003, ANN ONCOL, V14, P1169, DOI 10.1093/annonc/mdg316
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hance MW, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.389015
   Jhaveri K, 2012, BBA-MOL CELL RES, V1823, P742, DOI 10.1016/j.bbamcr.2011.10.008
   Karanikas M, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.04.13
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Koren E, 2016, DRUG RESIST UPDATE, V28, P1, DOI 10.1016/j.drup.2016.06.006
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Liu KS, 2012, INT J ONCOL, V41, P2276, DOI 10.3892/ijo.2012.1670
   Liu KS, 2012, CANCER LETT, V318, P180, DOI 10.1016/j.canlet.2011.12.015
   Lorusso D, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12618
   Messaoudi S, 2008, ANTI-CANCER AGENT ME, V8, P761, DOI 10.2174/187152008785914824
   Mosinska P, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00126
   Neckers L, 2002, TRENDS MOL MED, V8, pS55, DOI 10.1016/S1471-4914(02)02316-X
   Pertea M, 2015, NAT BIOTECHNOL, V33, P290, DOI 10.1038/nbt.3122
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Shirjang S, 2019, FREE RADICAL BIO MED, V139, P1, DOI 10.1016/j.freeradbiomed.2019.05.017
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Xu PZ, 2004, TRENDS GENET, V20, P617, DOI 10.1016/j.tig.2004.09.010
   Yuan Y, 2018, J NEURO-ONCOL, V137, P493, DOI 10.1007/s11060-018-2757-0
   Yuno A, 2018, METHODS MOL BIOL, V1709, P423, DOI 10.1007/978-1-4939-7477-1_29
   Zhang XO, 2016, GENOME RES, V26, P1277, DOI 10.1101/gr.202895.115
   Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001
NR 30
TC 7
Z9 7
U1 1
U2 40
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD FEB 15
PY 2020
VL 727
AR 144232
DI 10.1016/j.gene.2019.144232
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KE7QS
UT WOS:000508746800001
PM 31715300
DA 2022-04-25
ER

PT J
AU Yassin, AM
   El-Deeb, NM
   Elsaid, FG
   Shati, AA
   Cioca, G
   Tit, DM
   Bungau, S
   Popa, A
   Hafez, EE
AF Yassin, Abdelrahman Mohamed
   El-Deeb, Nehal Mohamed
   Elsaid, Fahmy Gad
   Shati, Ali Abdullah
   Cioca, Gabriela
   Tit, Delia Mirela
   Bungau, Simona
   Popa, Amorin
   Hafez, Elsayed Elsayed
TI Lectin from Pisum fulvum Seeds as in vitro Anticancer and Apoptotic Gene
   Regulator
SO REVISTA DE CHIMIE
LA English
DT Article
DE lectin; Pisum fulvum; Fabaceae; cancer cell lines; antioxidant;
   anticancer
ID CONCANAVALIN-A; PURIFICATION; CELLS; POPULATION; AUTOPHAGY; ANTITUMOR;
   THERAPY; OBESITY
AB The lectins are non-immune origin carbohydrate-binding proteins. Plant's lectins are distributed in many species of medicinal plants, family Fabaceae. In this study the safety usage pattern of wild Pisum fulvum lectin was evaluated on different mammalian noncancerous cell types and the anticancer activity was examined on different cancer human cell lines: colorectal adenocarcinoma (Caco-2), hepatocellular carcinoma (HepG2), breast cancer cells (MCF7) and laryngeal carcinoma (Hep-2 cells). Moreover, both morphological and molecular evidence of apoptosis have been detected using both acridine orange/ethidium bromide (AO/EB) stain and RT-qPCR. The results revealed that IC50 of the wild lectin on the noncancerous cells ranged from 19.7 to 2.4 mu g protein/mL. In addition, lectin was more potent against HepG2 cells than the other used cells, with inhibition percentages ranged from 68.45 to 90.98 and with cancer cell selectivity index ranged 3.5 to 28.14. The treatment showed 67.6% inhibition of BrdU incorporation in the proliferated hepatocellular carcinoma cells. Furthermore, HepG2-lectin treated cells showed obvious nuclear condensation after 48 h of treatment with ability to down-regulate the expression of BCL2 and BAX and to up-regulate the expression of Ikab gene. The results obtained in this research work clearly indicated the Pisum fulvum lectin could be a promising potential anticancer agent.
C1 [Yassin, Abdelrahman Mohamed; El-Deeb, Nehal Mohamed] City Sci Res & Technol Applicat, Genet Engn & Biotechnol Res Inst, Biopharmacet Prod Res Dept, Alexandria 21934, Egypt.
   [Elsaid, Fahmy Gad; Shati, Ali Abdullah] King Khalid Univ, RCAMS, Box 9004, Abha 61413, Saudi Arabia.
   [Elsaid, Fahmy Gad; Shati, Ali Abdullah] King Khalid Univ, Sci Coll, Biol Dept, Abha 61321, Saudi Arabia.
   [Elsaid, Fahmy Gad] Mansoura Univ, Fac Sci, Zool Dept, Mansoura 35516, Egypt.
   [Cioca, Gabriela] Lucian Blaga Univ Sibiu, Fac Med, 10 Victoriei Blvd, Sibiu 550024, Romania.
   [Tit, Delia Mirela; Bungau, Simona; Popa, Amorin] Univ Oradea, Fac Med & Pharm, Oradea 410028, Romania.
   [Hafez, Elsayed Elsayed] City Sci Res & Technol Applicat, ALCRI, Dept Plant Protect & Biomol Diag, Alexandria 21934, Egypt.
RP Cioca, G (corresponding author), Lucian Blaga Univ Sibiu, Fac Med, 10 Victoriei Blvd, Sibiu 550024, Romania.; Popa, A (corresponding author), Univ Oradea, Fac Med & Pharm, Oradea 410028, Romania.
EM gabriela.cioca@ulbsibiu.ro; popa_amorin@yahoo.com
RI hafez, elsayed/ABG-2456-2021; Bungau, Simona Gabriela/C-1831-2015; Tit,
   Delia Mirela/AAT-5032-2020; Cioca, Gabriela/B-5504-2012
OI hafez, elsayed/0000-0003-4044-5103; Bungau, Simona
   Gabriela/0000-0003-3236-1292; Tit, Delia Mirela/0000-0002-0296-6592;
   Cioca, Gabriela/0000-0003-1165-1389; Yassin,
   Abdelrahman/0000-0001-6780-1521; Shati, Ali/0000-0003-1800-7238
CR Abdullaev FI, 1997, ARCH LATINOAM NUTR, V47, P195
   AL-SOHAIMY A, 2007, AUST J BASIC APPL SC, V1, P213
   Borenfreund E., 1985, J TISS CULT METHODS, V9, P7, DOI DOI 10.1007/BF01666038
   Cagliari R, 2018, INT J BIOL MACROMOL, V119, P811, DOI 10.1016/j.ijbiomac.2018.07.156
   Chang CP, 2007, HEPATOLOGY, V45, P286, DOI 10.1002/hep.21509
   Cheung AHK, 2009, PHYTOMEDICINE, V16, P594, DOI 10.1016/j.phymed.2008.12.016
   Coligan J, 1995, CURRENT PROTOCOLS IM
   Faheina-Martins GV, 2012, TOXICOL IN VITRO, V26, P1161, DOI 10.1016/j.tiv.2012.06.017
   Fang EF, 2010, J AGR FOOD CHEM, V58, P2221, DOI 10.1021/jf903964u
   Fodor K, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4147320
   Gabius HJ, 2002, BBA-GEN SUBJECTS, V1572, P165, DOI 10.1016/S0304-4165(02)00306-9
   Guja C, 2016, DIABETES RES CLIN PR, V120, pS101
   Guja C, 2016, INT C INTERD MANAG D, P255
   Guja C, 2015, INTERDISCIPLINARY APPROACHES IN DIABETIC CHRONIC KIDNEY DISEASE, P230
   HAFEZ E. E., 2015, ASIAN ACAD RES J MUL, V2, P28
   Hussein S, 2001, DIABETOLOGIA, V44, pA138
   Islam F, 2018, INT J BIOL MACROMOL, V117, P1050, DOI 10.1016/j.ijbiomac.2018.06.021
   Kuramoto T, 2005, J BIOCHEM, V137, P41, DOI 10.1093/jb/mvi005
   Lannoo N, 2010, BBA-GEN SUBJECTS, V1800, P190, DOI 10.1016/j.bbagen.2009.07.021
   Lei HY, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-10
   Lin P, 2008, ACTA BIOCH BIOPH SIN, V40, P1029, DOI 10.1111/j.1745-7270.2008.00488.x
   LITTLEFIELD JW, 1960, J BIOL CHEM, V235, P1129
   Liu B, 2009, ARCH BIOCHEM BIOPHYS, V482, P1, DOI 10.1016/j.abb.2008.12.003
   Liu JJ, 2011, CANCER LETT, V300, P105, DOI 10.1016/j.canlet.2010.10.001
   LORD JM, 1987, PLANT PHYSIOL, V85, P1, DOI 10.1104/pp.85.1.1
   Michishita E, 1999, J BIOCHEM-TOKYO, V126, P1052
   MODY R, 1995, J PHARMACOL TOX MET, V33, P1, DOI 10.1016/1056-8719(94)00052-6
   Mota M, 2016, J DIABETES, V8, P336, DOI 10.1111/1753-0407.12297
   Naeem A, 2007, PROTEIN J, V26, P403, DOI 10.1007/s10930-007-9080-5
   Nishimura R, 2002, NATURE, V420, P426, DOI 10.1038/nature01231
   Pauly D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035360
   Popa S, 2016, J ENDOCRINOL INVEST, V39, P1045, DOI 10.1007/s40618-016-0470-4
   Pryme IF, 2001, EUR J GASTROEN HEPAT, V13, P1041, DOI 10.1097/00042737-200109000-00007
   REIS L., 2014, BMC P, V8, pP265, DOI [10,1186/1753-6561-8-S4-P265, DOI 10.1186/1753-6561-8-S4-P265, 10.1186/1753-6561-8-S4-P265]
   Roman G, 2015, ACTA ENDOCRINOL-BUCH, V11, P64, DOI 10.4183/aeb.2015.64
   Sabova L, 2010, PHYTOTHER RES, V24, P365, DOI 10.1002/ptr.2947
   SHARON N., 2008, GLYCOBIOLOGY, V14, p53R
   Singh M, 2013, ELSEV INSIGHT, P1, DOI 10.1016/B978-0-12-397935-3.00001-3
   Singh P, 2013, FRONT PLANT SCI, V4, DOI 10.3389/fpls.2013.00124
   Subramanyam S, 2008, PLANT PHYSIOL, V147, P1412, DOI 10.1104/pp.108.116145
   Atul TA, 2007, BBA-GEN SUBJECTS, V1770, P1404, DOI 10.1016/j.bbagen.2007.05.009
   Tsivileva OM, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1154, DOI 10.1134/S0006297908100131
   TUZZO S, 2018, STUDIES NATURAL PROD, P1
   Van Damme EJM, 2008, ADV BOT RES, V48, P107, DOI 10.1016/S0065-2296(08)00403-5
   Vasta GR, 2004, CURR OPIN STRUC BIOL, V14, P617, DOI 10.1016/j.sbi.2004.09.008
   Wang Y, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.79
   Yassin AM, 2016, APPL BIOCHEM BIOTECH, V180, P623, DOI 10.1007/s12010-016-2120-x
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
NR 48
TC 2
Z9 2
U1 0
U2 2
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R-77131, ROMANIA
SN 0034-7752
J9 REV CHIM-BUCHAREST
JI Rev. Chim.
PD APR
PY 2019
VL 70
IS 4
BP 1490
EP 1495
PG 6
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering
GA IA2JK
UT WOS:000469387200080
DA 2022-04-25
ER

PT J
AU Manne, NDPK
   Lima, M
   Enos, RT
   Wehner, P
   Carson, JA
   Blough, E
AF Manne, Nandini D. P. K.
   Lima, M.
   Enos, R. T.
   Wehner, P.
   Carson, J. A.
   Blough, Eric
TI Altered cardiac muscle mTOR regulation during the progression of cancer
   cachexia in the Apc(Min/+) mouse
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE cachexia; Apc(Min/+); heart; Akt; AMPK; mTOR
ID PROTEIN-SYNTHESIS; SKELETAL-MUSCLE; AMPK ACTIVITY; CELL-DEATH;
   INTERLEUKIN-6; ATROPHY; MICE; PHOSPHORYLATION; TUMORIGENESIS; ACTIVATION
AB Cancer cachexia is a muscle wasting condition that occurs in response to a malignant growth in the body. The mechanisms regulating cardiac muscle mass with cachexia are not well understood. Using the Apc(Min/+) mouse model of colorectal cancer, we investigated how cachexia affects the regulation of 5'-adenosine monophosphate-activated protein kinase (AMPK), protein kinase B (Akt) and mammalian target of rapamycin (mTOR) signaling in the heart. Compared to age-matched C57BL/6 (BL6) mice, Apc(Min/+) body mass and heart mass were lower at 12 (11+/-5 and 8+/-3%, respectively) and 20 weeks (26+/-3 and 6+/-4%, respectively) of age (P<0.05). Diminished heart mass in the 20-week-old Apc(Min/+) mice coincided with a decreased rate of myofibrillar protein synthesis and increased AMPK alpha phosphorylation. Cachexia decreased mTOR phosphorylation and the phosphorylation of the mTOR substrates, S6 ribosomal protein and 4EBP1 independent of Akt activation. These changes in mTOR-related protein signaling were accompanied by modest increases in the amount of Beclin1 but not protein ubiquitination or cardio-myocyte apoptosis. Taken together, these data suggest that loss of cardiac mass during cachexia progression in the Apc(Min/+) mouse is associated with an Akt-independent suppression of anabolic signaling and evidence of increased autophagy.
C1 [Manne, Nandini D. P. K.; Blough, Eric] Marshall Univ, Ctr Diagnost Nanosyst, Huntington, WV 25755 USA.
   [Manne, Nandini D. P. K.; Blough, Eric] Marshall Univ, Dept Pharmacol Physiol & Toxicol, Huntington, WV 25755 USA.
   [Wehner, P.; Blough, Eric] Marshall Univ, Joan C Edwards Sch Med, Dept Cardiol, Huntington, WV 25755 USA.
   Marshall Univ, Sch Pharm, Dept Pharmaceut Sci & Res, Huntington, WV 25755 USA.
   [Lima, M.; Enos, R. T.; Carson, J. A.] Univ S Carolina, Appl Physiol Div Exercise Sci, Integrated Muscle Biol Lab, Columbia, SC 29208 USA.
RP Blough, E (corresponding author), Marshall Univ, Ctr Diagnost Nanosyst, Dept Pharmaceut Sci & Res, Room 241N,Robert C Byrd Biotechnol Sci Ctr Bldg,1, Huntington, WV 25755 USA.
EM blough@marshall.edu
RI Manne, Nandini Durga Prasanna Kumar/ABD-5834-2021; Enos,
   Reilly/AFO-4814-2022; Carson, James/Q-5693-2019
OI Manne, Nandini Durga Prasanna Kumar/0000-0001-9159-0090; Enos,
   Reilly/0000-0001-5571-4586; Carson, James/0000-0003-3733-8796; Lima,
   Maria/0000-0002-0289-3477
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [RO1CA121249]; DOEUnited States
   Department of Energy (DOE) [DE-PS02-09ER-01]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA121249] Funding Source: NIH RePORTER
FX This study was supported from NIH grant RO1CA121249 (to J.A.C), DOE
   grant (DE-PS02-09ER-01 to E.R.B). The authors would like to thank John
   W. Baynes and Suichi Sato for their technical input related to the heart
   protein synthesis measurements.
CR Argiles JM, 2005, NUTRITION, V21, P977, DOI 10.1016/j.nut.2005.02.003
   Baltgalvis KA, 2008, AM J PHYSIOL-REG I, V294, pR393, DOI 10.1152/ajpregu.00716.2007
   BURCH GE, 1968, DIS CHEST, V54, P403, DOI 10.1378/chest.54.5.403
   Carson JA, 2010, EXERC SPORT SCI REV, V38, P168, DOI 10.1097/JES.0b013e3181f44f11
   Chan AYM, 2005, CAN J PHYSIOL PHARM, V83, P24, DOI 10.1139/Y04-107
   Cosper PF, 2011, CANCER RES, V71, P1710, DOI 10.1158/0008-5472.CAN-10-3145
   Costelli P, 2001, BRIT J CANCER, V84, P946, DOI 10.1054/bjoc.2001.1696
   Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123
   Fujita J, 1996, INT J CANCER, V68, P637, DOI 10.1002/(SICI)1097-0215(19961127)68:5<637::AID-IJC14>3.0.CO;2-Z
   Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200
   Kandarian SC, 2006, MUSCLE NERVE, V33, P155, DOI 10.1002/mus.20442
   Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188
   Labianca R, 2010, TUMORI, V96, P889, DOI 10.1177/548.6506
   Latronico MVG, 2004, ANN NY ACAD SCI, V1015, P250, DOI 10.1196/annals.1302.021
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Lima M, 2013, J APPL PHYSIOL, V114, P824, DOI 10.1152/japplphysiol.01141.2012
   MANDEL ID, 1992, J ORAL PATHOL MED, V21, P209, DOI 10.1111/j.1600-0714.1992.tb00103.x
   Martin DE, 2005, CURR OPIN CELL BIOL, V17, P158, DOI 10.1016/j.ceb.2005.02.008
   McClellan JL, 2012, CYTOKINE, V57, P113, DOI 10.1016/j.cyto.2011.09.027
   MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H
   Schiaffino S, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-4
   STRASSMANN G, 1993, J IMMUNOL, V150, P2341
   van Hall G, 2008, J CLIN ENDOCR METAB, V93, P2851, DOI 10.1210/jc.2007-2223
   Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006
   White JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024650
   White JP, 2011, AM J PHYSIOL-REG I, V300, pR201, DOI 10.1152/ajpregu.00300.2010
   Wysong A, 2011, AM J PATHOL, V178, P1059, DOI 10.1016/j.ajpath.2010.12.009
   YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5
   Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3
   Zhang HC, 2007, AM J PHYSIOL-HEART C, V292, pH2408, DOI 10.1152/ajpheart.01150.2006
NR 30
TC 36
Z9 36
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUN
PY 2013
VL 42
IS 6
BP 2134
EP 2140
DI 10.3892/ijo.2013.1893
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 151WI
UT WOS:000319490700033
PM 23589074
OA Green Submitted, Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Kawada, K
   Toda, K
   Sakai, Y
AF Kawada, Kenji
   Toda, Kosuke
   Sakai, Yoshiharu
TI Targeting metabolic reprogramming in KRAS-driven cancers
SO INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
DE KRAS; Cancer metabolism; Reprograming; Glycolysis; Glutaminolysis
ID AMINO-ACID TRANSPORTERS; F-18-FLUORODEOXYGLUCOSE ACCUMULATION;
   GLUTAMINE-METABOLISM; MAMMALIAN-CELLS; MUTATIONS; AUTOPHAGY;
   HYDROXYCHLOROQUINE; ADAPTATION; PATHWAY; TUMORS
AB Mutations of KRAS are found in a variety of human malignancies, including in pancreatic cancer, colorectal cancer, and non-small cell lung cancer at high frequency. To date, no effective treatments that target mutant variants of KRAS have been introduced into clinical practice. In recent years, a number of studies have shown that the oncogene KRAS plays a critical role in controlling cancer metabolism by orchestrating multiple metabolic changes. One of the metabolic hallmarks of malignant tumor cells is their dependency on aerobic glycolysis, known as the Warburg effect. The role of KRAS signaling in the regulation of aerobic glycolysis has been reported in several types of cancer. KRAS-driven cancers are characterized by altered metabolic pathways involving enhanced nutrients uptake, enhanced glycolysis, enhanced glutaminolysis, and elevated synthesis of fatty acids and nucleotides. However, Just how mutated KRAS can coordinate the metabolic shift to promote tumor growth and whether specific metabolic pathways are essential for the tumorigenesis of KRAS-driven cancers are questions which remain to be answered. In this context, the aim of this review is to summarize current data on KRAS-related metabolic alterations in cancer cells. Given that cancer cells rely on changes in metabolism to support their growth and survival, the targeting of metabolic processes may be a potential strategy for treating KRAS-driven cancers.
C1 [Kawada, Kenji; Toda, Kosuke; Sakai, Yoshiharu] Kyoto Univ, Grad Sch Med, Dept Surg, Sakyo Ku, 54 Shogoin Kawara Cho, Kyoto 6068507, Japan.
RP Kawada, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Surg, Sakyo Ku, 54 Shogoin Kawara Cho, Kyoto 6068507, Japan.
EM kkawada@kuhp.kyoto-u.ac.jp
CR Aguilera O, 2016, ONCOTARGET, V7, P47954, DOI 10.18632/oncotarget.10087
   Balasubramanian MN, 2013, AM J PHYSIOL-ENDOC M, V304, pE789, DOI 10.1152/ajpendo.00015.2013
   Bhutia YD, 2016, BBA-MOL CELL RES, V1863, P2531, DOI 10.1016/j.bbamcr.2015.12.017
   Bhutia YD, 2015, CANCER RES, V75, P1782, DOI 10.1158/0008-5472.CAN-14-3745
   Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004
   Caicedo C, 2014, EUR J NUCL MED MOL I, V41, P2058, DOI 10.1007/s00259-014-2833-4
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Chen SW, 2014, CLIN NUCL MED, V39, P685, DOI 10.1097/RLU.0000000000000481
   Cohen R, 2015, ONCOTARGET, V6, P16832, DOI 10.18632/oncotarget.4160
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Csibi A, 2014, CURR BIOL, V24, P2274, DOI 10.1016/j.cub.2014.08.007
   Davidson SM, 2016, CELL METAB, V23, P517, DOI 10.1016/j.cmet.2016.01.007
   DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358
   Dufour E, 2012, PANCREAS, V41, P940, DOI 10.1097/MPA.0b013e318247d903
   EAGLE H, 1955, SCIENCE, V122, P501, DOI 10.1126/science.122.3168.501
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005
   Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145
   Gouw AM, 2017, P NATL ACAD SCI USA, V114, P4300, DOI 10.1073/pnas.1617709114
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo JY, 2013, GENE DEV, V27, P1447, DOI 10.1101/gad.219642.113
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Hettmer S, 2015, ELIFE, V4, DOI 10.7554/eLife.09436
   Ikeuchi H, 2012, BIOORGAN MED CHEM, V20, P5915, DOI 10.1016/j.bmc.2012.07.047
   Iwamoto M, 2014, J NUCL MED, V55, P2038, DOI 10.2967/jnumed.114.142927
   Jadvar H, 2009, J NUCL MED, V50, P1820, DOI 10.2967/jnumed.108.054098
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Kamphorst JJ, 2013, P NATL ACAD SCI USA, V110, P8882, DOI 10.1073/pnas.1307237110
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Kawada K, 2016, WORLD J RADIOL, V8, P880, DOI 10.4329/wjr.v8.i11.880
   Kawada K, 2015, J NUCL MED, V56, P1322, DOI 10.2967/jnumed.115.160614
   Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909
   Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363
   Kimmelman AC, 2015, CLIN CANCER RES, V21, P1828, DOI 10.1158/1078-0432.CCR-14-2425
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   KOVACEVIC Z, 1972, CANCER RES, V32, P326
   Krall AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11457
   Lee JH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002236
   Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600
   Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171
   Mayers JR, 2014, NAT MED, V20, P1193, DOI 10.1038/nm.3686
   Miles KA, 2014, J NUCL MED, V55, P386, DOI 10.2967/jnumed.113.120485
   Miyo M, 2016, SCI REP-UK, V6, DOI 10.1038/srep38415
   Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009
   Palm W, 2015, CELL, V162, P259, DOI 10.1016/j.cell.2015.06.017
   Patra KC, 2013, CANCER CELL, V24, P213, DOI 10.1016/j.ccr.2013.06.014
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Ratnikov BI, 2017, ONCOGENE, V36, P147, DOI 10.1038/onc.2016.198
   Richards NGJ, 2006, ANNU REV BIOCHEM, V75, P629, DOI 10.1146/annurev.biochem.75.103004.142520
   Rosenfeld MR, 2014, AUTOPHAGY, V10, P1359, DOI 10.4161/auto.28984
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040
   Toda K, 2016, NEOPLASIA, V18, P654, DOI 10.1016/j.neo.2016.09.004
   Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Wang YP, 2016, MOL CELL, V64, P673, DOI 10.1016/j.molcel.2016.09.028
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wong CC, 2016, GASTROENTEROLOGY, V151, P945, DOI 10.1053/j.gastro.2016.07.011
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhang J, 2014, MOL CELL, V56, P205, DOI 10.1016/j.molcel.2014.08.018
   Zhou BY, 2016, SEMIN CELL DEV BIOL, V58, P60, DOI 10.1016/j.semcdb.2016.07.012
NR 75
TC 71
Z9 73
U1 2
U2 30
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1341-9625
EI 1437-7772
J9 INT J CLIN ONCOL
JI Int. J. Clin. Oncol.
PD AUG
PY 2017
VL 22
IS 4
BP 651
EP 659
DI 10.1007/s10147-017-1156-4
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FC2ST
UT WOS:000406689300007
PM 28647837
DA 2022-04-25
ER

PT J
AU Queiroz, KCS
   Milani, R
   Ruela-de-Sousa, RR
   Fuhler, GM
   Justo, GZ
   Zambuzzi, WF
   Duran, N
   Diks, SH
   Spek, CA
   Ferreira, CV
   Peppelenbosch, MP
AF Queiroz, Karla C. S.
   Milani, Renato
   Ruela-de-Sousa, Roberta R.
   Fuhler, Gwenny M.
   Justo, Giselle Z.
   Zambuzzi, Willian F.
   Duran, Nelson
   Diks, Sander H.
   Spek, C. Arnold
   Ferreira, Carmen V.
   Peppelenbosch, Maikel P.
TI Violacein Induces Death of Resistant Leukaemia Cells via Kinome
   Reprogramming, Endoplasmic Reticulum Stress and Golgi Apparatus Collapse
SO PLOS ONE
LA English
DT Article
ID CHROMOBACTERIUM-VIOLACEUM; COLORECTAL-CANCER; SIGNAL-TRANSDUCTION;
   PROTEIN-KINASE; DAP-KINASE; APOPTOSIS; MECHANISM; CALPAIN; INHIBITION;
   EXPRESSION
AB It is now generally recognised that different modes of programmed cell death (PCD) are intimately linked to the cancerous process. However, the mechanism of PCD involved in cancer chemoprevention is much less clear and may be different between types of chemopreventive agents and tumour cell types involved. Therefore, from a pharmacological view, it is crucial during the earlier steps of drug development to define the cellular specificity of the candidate as well as its capacity to bypass dysfunctional tumoral signalling pathways providing insensitivity to death stimuli. Studying the cytotoxic effects of violacein, an antibiotic dihydro-indolone synthesised by an Amazon river Chromobacterium, we observed that death induced in CD34(+)/c-Kit(+)/P-glycoprotein(+)/MRP1(+) TF1 leukaemia progenitor cells is not mediated by apoptosis and/or autophagy, since biomarkers of both types of cell death were not significantly affected by this compound. To clarify the working mechanism of violacein, we performed kinome profiling using peptide arrays to yield comprehensive descriptions of cellular kinase activities. Pro-death activity of violacein is actually carried out by inhibition of calpain and DAPK1 and activation of PKA, AKT and PDK, followed by structural changes caused by endoplasmic reticulum stress and Golgi apparatus collapse, leading to cellular demise. Our results demonstrate that violacein induces kinome reprogramming, overcoming death signaling dysfunctions of intrinsically resistant human leukaemia cells.
C1 [Fuhler, Gwenny M.; Peppelenbosch, Maikel P.] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
   [Queiroz, Karla C. S.; Ruela-de-Sousa, Roberta R.; Spek, C. Arnold] Univ Amsterdam, Acad Med Ctr, Ctr Expt & Mol Med, NL-1105 AZ Amsterdam, Netherlands.
   [Queiroz, Karla C. S.; Milani, Renato; Ruela-de-Sousa, Roberta R.; Ferreira, Carmen V.] Univ Estadual Campinas, Brazil UNICAMP, Dept Biochem, Inst Biol, Sao Paulo, Brazil.
   [Justo, Giselle Z.] Fed Univ Sao Paulo UNIFESP, Dept Biochem, Sao Paulo, Brazil.
   [Justo, Giselle Z.] Fed Univ Sao Paulo UNIFESP, Dept Cell Biol, Sao Paulo, Brazil.
   [Zambuzzi, Willian F.] Univ Grande Rio UNIGRANRIO, Heath Sci Sch, Multidisciplinary Lab Dent Res, Rio De Janeiro, Brazil.
   [Zambuzzi, Willian F.] Natl Inst Metrol Qual & Technol Inmetro, Biotechnol Lab, Bioengn Sect, Rio De Janeiro, Brazil.
   [Duran, Nelson] Univ Campinas UNICAMP, Inst Chem, Biol Chem Lab, Rio De Janeiro, Brazil.
   [Diks, Sander H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Oncol, Beatrix Childrens Hosp, Groningen, Netherlands.
RP Peppelenbosch, MP (corresponding author), Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
EM M.Peppelenbosch@erasmusmc.nl
RI Fuhler, Gwenny/AAC-7122-2019; Milani, Renato/G-1037-2010; Inomat,
   Inct/H-9989-2013; Spek, Arnold/AAC-5866-2019; Zambuzzi,
   Willian/ABD-8339-2020; Peppelenbosch, Maikel P./U-5304-2019; Ruela de
   Sousa, Roberta/C-6825-2012; Queiroz, Karla/L-6438-2014; Zambuzzi,
   Willian Fernando/F-9519-2012
OI Fuhler, Gwenny/0000-0001-9221-4855; Milani, Renato/0000-0002-6902-6589;
   Spek, Arnold/0000-0002-2149-4068; Ruela de Sousa,
   Roberta/0000-0002-3762-2247; Zambuzzi, Willian
   Fernando/0000-0002-4149-5965; Duran, Nelson/0000-0001-8372-5143;
   Peppelenbosch, Maikel/0000-0001-9112-6028
FU TopInstitute pharma (The Netherlands)Netherlands Government; Fundacao de
   Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPq)Conselho Nacional de
   Desenvolvimento Cientifico e Tecnologico (CNPQ); Dutch Cancer SocietyKWF
   Kankerbestrijding [EMCR 2010-4737]
FX This work was supported by grants from TopInstitute pharma (The
   Netherlands), Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   (FAPESP) and Conselho Nacional de Desenvolvimento Cientifico e
   Tecnologico (CNPq). CVF was supported by a research fellowship from
   CNPq. GMF was supported by the Dutch Cancer Society (grant EMCR
   2010-4737). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR BAILLY JD, 1995, LEUKEMIA, V9, P799
   Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292
   Bromberg N, 2010, CHEM-BIOL INTERACT, V186, P43, DOI 10.1016/j.cbi.2010.04.016
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Carragher NO, 2002, INT J BIOCHEM CELL B, V34, P1539, DOI 10.1016/S1357-2725(02)00069-9
   Dessaux Y, 2004, REV MED INTERNE, V25, P659, DOI 10.1016/j.revmed.2004.03.012
   DIEDEREN JHB, 1992, CELL TISSUE RES, V268, P117, DOI 10.1007/BF00338060
   Duprez L, 2009, MICROBES INFECT, V11, P1050, DOI 10.1016/j.micinf.2009.08.013
   Ferreira CV, 2004, BLOOD, V104, P1459, DOI 10.1182/blood-2004-02-0594
   Fuhler GM, 2010, EXP CELL RES, V316, P1816, DOI 10.1016/j.yexcr.2010.03.013
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Gozuacik D, 2008, CELL DEATH DIFFER, V15, P1875, DOI 10.1038/cdd.2008.121
   Hedrick SM, 2010, IMMUNOL REV, V236, P41, DOI 10.1111/j.1600-065X.2010.00918.x
   Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Kiakos K, 2007, MOL CANCER THER, V6, P2708, DOI 10.1158/1535-7163.MCT-07-0294
   Kodach LL, 2007, GASTROENTEROLOGY, V132, pA23
   Kodach LL, 2006, CARCINOGENESIS, V27, P508, DOI 10.1093/carcin/bgi307
   Lowenberg M, 2005, EUR J GASTROEN HEPAT, V17, pA65
   Michie AM, 2010, FEBS J, V277, P74, DOI 10.1111/j.1742-4658.2009.07414.x
   Milani R, 2010, J CELL BIOCHEM, V109, P957, DOI 10.1002/jcb.22479
   Parikh K, 2010, CANCER RES, V70, P2575, DOI 10.1158/0008-5472.CAN-09-3989
   Queiroz KCS, 2010, ONCOGENE, V29, P6314, DOI 10.1038/onc.2010.375
   Reed JC, 2000, SEMIN HEMATOL, V37, P9, DOI 10.1016/S0037-1963(00)90055-6
   Rettori D, 1998, WORLD J MICROB BIOT, V14, P685, DOI 10.1023/A:1008809504504
   RIVEROS R, 1989, BRAZ J MED BIOL RES, V22, P569
   Ruela-de-Sousa RR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.18
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200
   Sorimachi H, 2010, EXP ANIM TOKYO, V59, P549, DOI 10.1538/expanim.59.549
   Sun Y, 2009, POSTGRAD MED J, V85, P134, DOI 10.1136/pgmj.2008.072629
   TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X
   Tuynman JB, 2004, CRIT REV ONCOL HEMAT, V52, P81, DOI 10.1016/j.critrevonc.2004.08.004
   Tuynman JB, 2008, CANCER RES, V68, P1213, DOI 10.1158/0008-5472.CAN-07-5172
   West NJ, 2009, CANCER EPIDEM BIOMAR, V18, P1680, DOI 10.1158/1055-9965.EPI-09-0006
   Wlodkowic D, 2009, LEUKEMIA RES, V33, P1440, DOI 10.1016/j.leukres.2009.05.025
   Xu LJ, 2006, J BIOL CHEM, V281, P35567, DOI 10.1074/jbc.M607702200
NR 37
TC 34
Z9 34
U1 2
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2012
VL 7
IS 10
AR e45362
DI 10.1371/journal.pone.0045362
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 020KP
UT WOS:000309807700009
PM 23071514
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Kim, MJ
   Huang, YJ
   Park, JI
AF Kim, Moon Jong
   Huang, Yuanjian
   Park, Jae-Il
TI Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and
   Evolving Views
SO CANCERS
LA English
DT Review
DE Wnt signaling; &#946; -catenin; cancer; gastrointestinal cancers;
   therapeutic targeting of Wnt signaling; &#946; -catenin paradox;
   molecular targeting
ID SMALL-MOLECULE INHIBITOR; BETA-CATENIN DEGRADATION; WNT/BETA-CATENIN;
   COLORECTAL-CANCER; STEM-CELLS; PHASE-I; AUTOPHAGY INHIBITION; TANKYRASE
   INHIBITOR; FRIZZLED HOMOLOGS; BREAST-CANCER
AB Simple Summary
   Therapeutic targeting of Wnt has long been suggested for gastrointestinal (GI) cancer treatment because deregulation of Wnt signaling is associated with GI cancers. However, therapeutic targeting of Wnt is still challenging because of the pleiotropic roles of Wnt signaling in the human body. Thus, targeting strategies of Wnt signaling are continuously evolving. The current flows of targeting Wnt signaling for cancer treatment are focused on increasing the specificity of drugs and combinatory treatment with other cancer drugs that minimize side effects and increase efficacy. Additionally, increased knowledge about the beta-catenin paradox has expanded the cases that can be treated with Wnt targeting therapy, not strictly considering Wnt upstream and downstream mutations. Here, we discuss these evolving views of targeting Wnt signaling and describe examples of current clinical trials.
   Wnt signaling governs tissue development, homeostasis, and regeneration. However, aberrant activation of Wnt promotes tumorigenesis. Despite the ongoing efforts to manipulate Wnt signaling, therapeutic targeting of Wnt signaling remains challenging. In this review, we provide an overview of current clinical trials to target Wnt signaling, with a major focus on gastrointestinal cancers. In addition, we discuss the caveats and alternative strategies for therapeutically targeting Wnt signaling for cancer treatment.
C1 [Kim, Moon Jong; Huang, Yuanjian; Park, Jae-Il] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.
   [Park, Jae-Il] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Park, Jae-Il] Hlth Sci Ctr, Houston, TX 77030 USA.
   [Park, Jae-Il] Univ Texas MD Anderson Canc Ctr, Program Genet & Epigenet, Houston, TX 77030 USA.
RP Park, JI (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.; Park, JI (corresponding author), Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Park, JI (corresponding author), Hlth Sci Ctr, Houston, TX 77030 USA.; Park, JI (corresponding author), Univ Texas MD Anderson Canc Ctr, Program Genet & Epigenet, Houston, TX 77030 USA.
EM mkim312@mdanderson.org; yhuang14@mdanderson.org; jaeil@mdanderson.org
RI park, jaeil/AAS-5894-2021; Kim, Moon Jong/AAK-7406-2021
OI Kim, Moon Jong/0000-0002-7876-4639; PARK, JAE-IL/0000-0002-0737-2654
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [2R01 CA193297];
   Department of Defense Peer Reviewed Cancer Research ProgramUnited States
   Department of Defense [CA140572]; Specialized Program of Research
   Excellence (SPORE) grant in endometrial cancer [P50 CA83639]; ROSI Seed
   Award [00057597]; Institutional Research Grant (MD Anderson); 
   [RP140563];  [RP200315]
FX This work was supported by grants to the Cancer Prevention and Research
   Institute of Texas (RP140563 and RP200315 to J.-I.P.), the National
   Institutes of Health (2R01 CA193297 to J.-I.P.), the Department of
   Defense Peer Reviewed Cancer Research Program (CA140572 to J.-I.P.), an
   Institutional Research Grant (MD Anderson to J.-I.P.), a Specialized
   Program of Research Excellence (SPORE) grant in endometrial cancer (P50
   CA83639), and an ROSI Seed Award (00057597 to M.J.K.).
CR Agostino M, 2017, J BIOL CHEM, V292, P11218, DOI 10.1074/jbc.M117.786269
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Arora SP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3551
   Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Bendell J, 2016, EUR J CANCER, V69, pS29, DOI 10.1016/S0959-8049(16)32668-5
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Bossard C, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.PANCA19-A02
   Bossard C, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e15185
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0
   Bu QX, 2017, J BIOL CHEM, V292, P16055, DOI 10.1074/jbc.M117.791756
   Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816
   Burock S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e14536
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007
   Cha SW, 2008, DEVELOPMENT, V135, P3719, DOI 10.1242/dev.029025
   Chen CY, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0089305, 10.1371/journal.pone.0105414, 10.1371/journal.pone.0104899]
   Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677
   Chen W, 2016, MOL MED REP, V13, P3466, DOI 10.3892/mmr.2016.4986
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Davis SL, 2020, INVEST NEW DRUG, V38, P821, DOI 10.1007/s10637-019-00824-1
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   de la Roche M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1680
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008-5472.CAN-10-0148
   Diamond JR, 2020, BREAST CANCER RES TR, V184, P53, DOI 10.1007/s10549-020-05817-w
   Dotan E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.369
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   Eads JR, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e15603
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   El-Khoueiry AB, 2013, J CLIN ONC ABSTR, V31, P2501, DOI DOI 10.1200/jco.2013.31.15_suppl.2501
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Feng M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau5240
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07
   Fiedler M, 2011, P NATL ACAD SCI USA, V108, P1937, DOI 10.1073/pnas.1017063108
   Fischer MM, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700090
   Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008-5472.CAN-18-2095
   Flanagan DJ, 2017, DIS MODEL MECH, V10, P971, DOI 10.1242/dmm.029876
   Flanagan DJ, 2015, STEM CELL REP, V4, P759, DOI 10.1016/j.stemcr.2015.03.003
   Fodde R, 2010, J PATHOL, V221, P239, DOI 10.1002/path.2718
   Fujii N, 2007, CANCER RES, V67, P573, DOI 10.1158/0008-5472.CAN-06-2726
   Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199
   Gay DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08586-3
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017
   Gong X, 2016, MOL CANCER THER, V15, P1580, DOI 10.1158/1535-7163.MCT-16-0114
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Grandy D, 2009, J BIOL CHEM, V284, P16256, DOI 10.1074/jbc.M109.009647
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839
   Hikasa H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.185280
   Hikasa H, 2010, DEV CELL, V19, P521, DOI 10.1016/j.devcel.2010.09.005
   Hong TS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4118
   Horst D, 2012, CANCER RES, V72, P1547, DOI 10.1158/0008-5472.CAN-11-3222
   Hou PP, 2019, GENE DEV, V33, P1361, DOI 10.1101/gad.326314.119
   Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hwang SY, 2016, CELL REP, V16, P28, DOI 10.1016/j.celrep.2016.05.071
   Inglis DJ, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3910
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003
   Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674
   Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Jansson M, 2001, J CELL SCI, V114, P2043
   Ji L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12143-3
   Ji L, 2017, GENE DEV, V31, P904, DOI 10.1101/gad.300053.117
   Jimeno A, 2017, CLIN CANCER RES, V23, P7490, DOI 10.1158/1078-0432.CCR-17-2157
   Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028
   Jung YS, 2021, HEPATOLOGY, V73, P776, DOI 10.1002/hep.31305
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6
   Jung YS, 2018, NAT CELL BIOL, V20, P1421, DOI 10.1038/s41556-018-0219-8
   Jung YS, 2015, ONCOTARGET, V6, P37257, DOI 10.18632/oncotarget.6133
   Junttila MR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7433
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Khalaf AM, 2018, J HEPATOCELL CARCINO, V5, P61, DOI 10.2147/JHC.S156701
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1
   Kim MJ, 2018, DEV CELL, V44, P582, DOI 10.1016/j.devcel.2018.02.010
   Kishida S, 1999, MOL CELL BIOL, V19, P4414
   Ko AH, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e15721
   Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308
   Kuhl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562
   Lee Y, 2017, ONCOTARGET, V8, P41091, DOI 10.18632/oncotarget.17056
   Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Liang CJ, 2019, CELL REP, V28, P1511, DOI 10.1016/j.celrep.2019.07.023
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu L, 2018, CANCER RES, V78, P1958, DOI 10.1158/0008-5472.CAN-17-2683
   Loaiza-Bonilla A, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3614
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lopez-Rios J, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-19
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mahmoudi T, 2009, EMBO J, V28, P3329, DOI 10.1038/emboj.2009.285
   Malinauskas T, 2011, NAT STRUCT MOL BIOL, V18, P886, DOI 10.1038/nsmb.2081
   Martins-Neves SR, 2018, CANCER LETT, V414, P1, DOI 10.1016/j.canlet.2017.11.004
   Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586
   Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104
   Molenaar RJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014961
   Moverare-Skrtic S, 2019, FASEB J, V33, P11163, DOI 10.1096/fj.201900707R
   Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Mzoughi S, 2017, NAT GENET, V49, P1354, DOI 10.1038/ng.3922
   Nagle PW, 2018, SEMIN CANCER BIOL, V53, P258, DOI 10.1016/j.semcancer.2018.06.005
   Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008-5472.CAN-10-3978
   PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978
   Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037
   Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Pintova S, 2019, CANCER CHEMOTH PHARM, V84, P591, DOI 10.1007/s00280-019-03886-3
   Prossomariti A, 2020, CELL MOL GASTROENTER, V10, P491, DOI 10.1016/j.jcmgh.2020.04.007
   Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868
   Rios-Esteves J, 2014, J BIOL CHEM, V289, P17009, DOI 10.1074/jbc.M114.561209
   Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352
   Russell JO, 2018, ANNU REV PATHOL-MECH, V13, P351, DOI 10.1146/annurev-pathol-020117-044010
   Ryan DP, 2016, ANN ONCOL, V27, P108
   Safholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200
   Safholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711
   Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014
   Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Scarborough HA, 2017, CLIN CANCER RES, V23, P1531, DOI 10.1158/1078-0432.CCR-16-1179
   Schepers A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007989
   Schutgens F, 2020, ANNU REV PATHOL-MECH, V15, P211, DOI 10.1146/annurev-pathmechdis-012419-032611
   Seino T, 2018, CELL STEM CELL, V22, P454, DOI 10.1016/j.stem.2017.12.009
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shan JF, 2005, BIOCHEMISTRY-US, V44, P15495, DOI 10.1021/bi0512602
   Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8
   Shi RY, 2013, CANCER-AM CANCER SOC, V119, P993, DOI 10.1002/cncr.27788
   Shi Y, 2014, ACTA OTO-LARYNGOL, V134, P753, DOI 10.3109/00016489.2014.894251
   Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081
   Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306
   Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507
   Simonetta KR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09358-9
   Simons M, 2008, ANNU REV GENET, V42, P517, DOI 10.1146/annurev.genet.42.110807.091432
   Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219
   Suciu RM, 2018, ACS MED CHEM LETT, V9, P563, DOI 10.1021/acsmedchemlett.8b00191
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249
   Tam BY, 2020, CANCER LETT, V473, P186, DOI 10.1016/j.canlet.2019.09.009
   Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tian W, 2012, BIOCHEMISTRY-US, V51, P724, DOI 10.1021/bi201428h
   Tomar VS, 2020, CELL BIOL TOXICOL, V36, P273, DOI 10.1007/s10565-019-09502-7
   vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X
   Vermorken J, 2019, ANN ONCOL, V30, P36
   Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774
   Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610
   Waaler J, 2012, CANCER RES, V72, P2822, DOI 10.1158/0008-5472.CAN-11-3336
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1
   Xavier CP, 2014, CELL SIGNAL, V26, P94, DOI 10.1016/j.cellsig.2013.09.016
   Xu WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037624
   Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075
   Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010
   Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020
   Yu J, 2014, DEV CELL, V29, P277, DOI 10.1016/j.devcel.2014.03.016
   Zhang XJ, 2016, J BIOL CHEM, V291, P2435, DOI 10.1074/jbc.M115.677807
   Zhang XJ, 2012, CELL, V149, P1565, DOI 10.1016/j.cell.2012.04.039
   Zhang YN, 2009, NAT CHEM BIOL, V5, P217, DOI 10.1038/nchembio.152
   Zhong Z, 2019, ONCOGENE, V38, P6662, DOI 10.1038/s41388-019-0908-1
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 185
TC 5
Z9 5
U1 5
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD DEC
PY 2020
VL 12
IS 12
AR 3638
DI 10.3390/cancers12123638
PG 27
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PJ5VP
UT WOS:000601835300001
PM 33291655
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, SH
   Joshi, K
   Denning, MF
   Zhang, JW
AF Liu, Shanhui
   Joshi, Kanak
   Denning, Mitchell F.
   Zhang, Jiwang
TI RIPK3 signaling and its role in the pathogenesis of cancers
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Review
DE RIPK3 signaling; MLKL necroptosis; MLKL-independent signaling; Cancer
   pathogenesis
ID MIXED LINEAGE KINASE; NF-KAPPA-B; DOMAIN-LIKE PROTEIN;
   RECEPTOR-INTERACTING PROTEIN; NECROPTOSIS ADAPTER RIPK3;
   SHIKONIN-INDUCED NECROPTOSIS; INDUCED CELL-DEATH; PROGRAMMED NECROSIS;
   NUCLEAR TRANSLOCATION; PROGNOSTIC BIOMARKER
AB RIPK3 (receptor-interacting protein kinase 3) is a serine/threonine-protein kinase. As a key component of necrosomes, RIPK3 is an essential mediator of inflammatory factors (such as TNF alpha-tumor necrosis factor alpha) and infection-induced necroptosis, a programmed necrosis. In addition, RIPK3 signaling is also involved in the regulation of apoptosis, cytokine/chemokine production, mitochondrial metabolism, autophagy, and cell proliferation by interacting with and/or phosphorylating the critical regulators of the corresponding signaling pathways. Similar to apoptosis, RIPK3-signaling-mediated necroptosis is inactivated in most types of cancers, suggesting RIPK3 might play a critical suppressive role in the pathogenesis of cancers. However, in some inflammatory types of cancers, such as pancreatic cancers and colorectal cancers, RIPK3 signaling might promote cancer development by stimulating proliferation signaling in tumor cells and inducing an immunosuppressive response in the tumor environment. In this review, we summarize recent research progress in the regulators of RIPK3 signaling, and discuss the function of this pathway in the regulation of mixed lineage kinase domain-like (MLKL)-mediated necroptosis and MLKL-independent cellular behaviors. In addition, we deliberate the potential roles of RIPK3 signaling in the pathogenesis of different types of cancers and discuss the potential strategies for targeting this pathway in cancer therapy.
C1 [Liu, Shanhui; Joshi, Kanak; Denning, Mitchell F.; Zhang, Jiwang] Loyola Univ Med Ctr, Dept Canc Biol, Inst Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
   [Zhang, Jiwang] Loyola Univ Med Ctr, Dept Pathol, Maywood, IL 60153 USA.
   [Zhang, Jiwang] Loyola Univ Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA.
RP Zhang, JW (corresponding author), Loyola Univ Med Ctr, Dept Canc Biol, Inst Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.; Zhang, JW (corresponding author), Loyola Univ Med Ctr, Dept Pathol, Maywood, IL 60153 USA.; Zhang, JW (corresponding author), Loyola Univ Med Ctr, Dept Radiat Oncol, Maywood, IL 60153 USA.
EM jzhang@luc.edu
OI shanhui, liu/0000-0001-9254-5339
FU NIH through Loyola University Chicago [R01 HL133560-01, R01
   CA223194-01]; Loyola program development funds
FX This work was supported by NIH Grants R01 HL133560-01 and R01
   CA223194-01 through Loyola University Chicago, as well as Loyola program
   development funds to Jiwang Zhang.
CR Aaes TL, 2016, CELL REP, V15, P274, DOI 10.1016/j.celrep.2016.03.037
   Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413
   Ahmed N, 2011, NAT IMMUNOL, V12, P1176, DOI 10.1038/ni.2157
   Al-Moujahed A, 2019, STEM CELL RES, V35, DOI 10.1016/j.scr.2019.101387
   Alvarez-Diaz S, 2021, CELL DEATH DIFFER, V28, P1466, DOI 10.1038/s41418-020-00673-z
   Alvarez-Diaz S, 2016, IMMUNITY, V45, P513, DOI 10.1016/j.immuni.2016.07.016
   Ando Y, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228015
   Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014
   Besse A, 2007, J BIOL CHEM, V282, P3918, DOI 10.1074/jbc.M608867200
   Bozec D, 2016, ONCOTARGET, V7, P46384, DOI 10.18632/oncotarget.10135
   Brumatti G, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3099
   Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883
   Chan FKM, 2003, J BIOL CHEM, V278, P51613, DOI 10.1074/jbc.M305633200
   Chan FKM, 2015, ANNU REV IMMUNOL, V33, P79, DOI 10.1146/annurev-immunol-032414-112248
   Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115
   Chen WZ, 2013, J BIOL CHEM, V288, P16247, DOI 10.1074/jbc.M112.435545
   Chen X, 2014, CELL RES, V24, P105, DOI 10.1038/cr.2013.171
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Choi ME, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128834
   Choi SW, 2018, MOL CELL, V70, P920, DOI 10.1016/j.molcel.2018.05.016
   Ci TY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc3013
   Colbert LE, 2013, CANCER-AM CANCER SOC, V119, P3148, DOI 10.1002/cncr.28144
   Colijn S, 2020, CELL DEATH DIFFER, V27, P618, DOI 10.1038/s41418-019-0376-8
   Conev NV, 2019, CLIN INVEST MED, V42, pE31, DOI 10.25011/cim.v42i1.32390
   Conos SA, 2017, P NATL ACAD SCI USA, V114, pE961, DOI 10.1073/pnas.1613305114
   Daniels BP, 2019, IMMUNITY, V50, P64, DOI 10.1016/j.immuni.2018.11.017
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Degterev A, 2019, P NATL ACAD SCI USA, V116, P9714, DOI 10.1073/pnas.1901179116
   Ding Y, 2019, CANCER LETT, V467, P58, DOI 10.1016/j.canlet.2019.09.007
   Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026
   Dowling JP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08584-5
   Draber P, 2015, CELL REP, V13, P2258, DOI 10.1016/j.celrep.2015.11.009
   Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026
   Eigenbrod T, 2008, J IMMUNOL, V181, P8194, DOI 10.4049/jimmunol.181.12.8194
   Elton L, 2015, IMMUNOL REV, V266, P208, DOI 10.1111/imr.12307
   Emmerich CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002187
   Fan YH, 2010, J BIOL CHEM, V285, P5347, DOI 10.1074/jbc.M109.076976
   Feng SS, 2007, CELL SIGNAL, V19, P2056, DOI 10.1016/j.cellsig.2007.05.016
   Feng X, 2015, NEOPLASMA, V62, P592, DOI 10.4149/neo_2015_071
   Feoktistova M, 2015, FEBS J, V282, P19, DOI 10.1111/febs.13120
   Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011
   Fukasawa M, 2006, J HUM GENET, V51, P368, DOI 10.1007/s10038-005-0355-4
   Gerges S, 2016, CANCER LETT, V375, P127, DOI 10.1016/j.canlet.2016.02.040
   Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816
   Geserick P, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.240
   Gong YT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1029-8
   Gupta K, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102320
   Han WD, 2009, APOPTOSIS, V14, P674, DOI 10.1007/s10495-009-0334-x
   Hanna-Addams S, 2020, P NATL ACAD SCI USA, V117, P1962, DOI 10.1073/pnas.1917112117
   He L, 2013, ONCOTARGETS THER, V6, P1539, DOI [10.2147/OTT.SS2805, 10.2147/OTT.S52805]
   He SJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0626-6
   He SD, 2009, CELL, V137, P1100, DOI 10.1016/j.cell.2009.05.021
   Hockendorf U, 2016, CANCER CELL, V30, P75, DOI 10.1016/j.ccell.2016.06.002
   Hu D, 2019, J CELL MOL MED, V23, P5317, DOI 10.1111/jcmm.14408
   Huang CY, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.149
   Huang Z, 2015, CELL HOST MICROBE, V17, P229, DOI 10.1016/j.chom.2015.01.002
   Humphries F, 2015, CELL DEATH DIFFER, V22, P225, DOI 10.1038/cdd.2014.126
   Ingram JP, 2019, J IMMUNOL, V203, P1348, DOI 10.4049/jimmunol.1900216
   Jayakumar A, 2019, CANCER RES, V79, P1587, DOI 10.1158/0008-5472.CAN-18-2153
   Jensen S, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aax8295
   Jouan-Lanhouet S, 2012, CELL DEATH DIFFER, V19, P2003, DOI 10.1038/cdd.2012.90
   Kaiser WJ, 2013, J BIOL CHEM, V288, P31268, DOI 10.1074/jbc.M113.462341
   Kaiser WJ, 2005, J IMMUNOL, V174, P4942, DOI 10.4049/jimmunol.174.8.4942
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kang T, 2018, BIOMATERIALS, V164, P80, DOI 10.1016/j.biomaterials.2018.02.033
   Kang YJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9371
   Kasof GM, 2000, FEBS LETT, V473, P285, DOI 10.1016/S0014-5793(00)01473-3
   Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1223-7
   Kitur K, 2016, CELL REP, V16, P2219, DOI 10.1016/j.celrep.2016.07.039
   Komander D, 2009, EMBO REP, V10, P466, DOI 10.1038/embor.2009.55
   Kono H, 2010, J IMMUNOL, V184, P4470, DOI 10.4049/jimmunol.0902485
   Koo GB, 2015, CELL RES, V25, P707, DOI 10.1038/cr.2015.56
   Krysko DV, 2003, J MORPHOL, V258, P336, DOI 10.1002/jmor.10161
   Kuriakose T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag2045
   Lalaoui N, 2020, NATURE, V577, P103, DOI 10.1038/s41586-019-1828-5
   Lalaoui N, 2016, CANCER CELL, V29, P145, DOI 10.1016/j.ccell.2016.01.006
   Laurien L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15466-8
   Lawlor KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7282
   Lee SB, 2019, NAT CELL BIOL, V21, P940, DOI 10.1038/s41556-019-0356-8
   Lee SY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2146-4
   Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019
   Li L, 2018, GYNECOL OBSTET INVES, V83, P259, DOI 10.1159/000487434
   Li X, 2017, TECHNOL CANCER RES T, V16, P428, DOI 10.1177/1533034616655909
   Liang L, 2013, CELL SIGNAL, V25, P247, DOI 10.1016/j.cellsig.2012.09.003
   Liccardi G, 2019, MOL CELL, V73, P413, DOI 10.1016/j.molcel.2018.11.010
   Lin CC, 2020, CELL DEATH DIFFER, V27, P2234, DOI 10.1038/s41418-020-0499-y
   Lin J, 2016, NATURE, V540, P124, DOI 10.1038/nature20558
   Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514
   Linkermann A, 2014, NEW ENGL J MED, V370, P455, DOI 10.1056/NEJMra1310050
   Liu TC, 2019, ONCOTARGETS THER, V12, P2605, DOI 10.2147/OTT.S200740
   Liu XJ, 2016, ONCOTARGET, V7, P22219, DOI 10.18632/oncotarget.7924
   Liu ZY, 2019, THERANOSTICS, V9, P3659, DOI 10.7150/thno.32126
   Liu ZY, 2015, AM J CANCER RES, V5, P3174
   Liu ZJ, 2021, IMMUNITY, V54, P247, DOI 10.1016/j.immuni.2020.11.020
   Lu B, 2017, ACTA PHARMACOL SIN, V38, P1543, DOI 10.1038/aps.2017.112
   Lu L, 2011, EUR J PHARMACOL, V658, P242, DOI 10.1016/j.ejphar.2011.02.043
   Mabe NW, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108341
   Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105
   Mao RF, 2011, CELL SIGNAL, V23, P222, DOI 10.1016/j.cellsig.2010.09.006
   Markowitsch SD, 2021, CANCERS, V13, DOI 10.3390/cancers13040882
   Matias D, 2017, CELL ONCOL, V40, P247, DOI 10.1007/s13402-017-0320-1
   McCormick KD, 2016, CARCINOGENESIS, V37, P522, DOI 10.1093/carcin/bgw032
   McKee CM, 2020, J LEUKOCYTE BIOL, V108, P937, DOI 10.1002/JLB.3MR0720-513R
   McQuade T, 2013, BIOCHEM J, V456, P409, DOI 10.1042/BJ20130860
   Mei PC, 2021, CELL DEATH DIFFER, V28, P2888, DOI 10.1038/s41418-021-00790-3
   Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   Moriwaki K, 2017, CELL REP, V18, P2441, DOI 10.1016/j.celrep.2017.02.015
   Moriwaki K, 2016, J IMMUNOL, V196, P407, DOI 10.4049/jimmunol.1501662
   Moriwaki K, 2015, J IMMUNOL, V194, P1938, DOI 10.4049/jimmunol.1402167
   Moriwaki K, 2014, IMMUNITY, V41, P567, DOI 10.1016/j.immuni.2014.09.016
   Moriwaki K, 2013, GENE DEV, V27, P1640, DOI 10.1101/gad.223321.113
   Muendlein HI, 2020, CELL REP, V30, P699, DOI 10.1016/j.celrep.2019.12.073
   Mulay SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10274
   Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018
   Murphy JM, 2015, F1000RES, V4, P1297, DOI DOI 10.12688/F1000RESEARCH.7046.1
   Najafov A, 2019, MOL CELL, V75, P457, DOI 10.1016/j.molcel.2019.05.022
   Najafov A, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005756
   Najafov A, 2017, TRENDS CANCER, V3, P294, DOI 10.1016/j.trecan.2017.03.002
   Najjar M, 2016, IMMUNITY, V45, P46, DOI 10.1016/j.immuni.2016.06.007
   Newton K, 2016, NATURE, V540, P129, DOI 10.1038/nature20559
   Nugues AL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.347
   O'Donnell MA, 2007, CURR BIOL, V17, P418, DOI 10.1016/j.cub.2007.01.027
   Ofengeim D, 2015, CELL REP, V10, P1836, DOI 10.1016/j.celrep.2015.02.051
   Onizawa M, 2015, NAT IMMUNOL, V16, P618, DOI 10.1038/ni.3172
   Orozco SL, 2019, CELL REP, V28, P2275, DOI 10.1016/j.celrep.2019.07.077
   Park JH, 2019, CANCER LETT, V444, P94, DOI 10.1016/j.canlet.2018.12.006
   Pasparakis M, 2015, NATURE, V517, P311, DOI 10.1038/nature14191
   Patel S, 2020, CELL DEATH DIFFER, V27, P161, DOI 10.1038/s41418-019-0347-0
   Peltzer N, 2018, NATURE, V557, P112, DOI 10.1038/s41586-018-0064-8
   Peltzer N, 2016, TRENDS CELL BIOL, V26, P445, DOI 10.1016/j.tcb.2016.01.006
   Peltzer N, 2014, CELL REP, V9, P153, DOI 10.1016/j.celrep.2014.08.066
   Rebsamen M, 2009, EMBO REP, V10, P916, DOI 10.1038/embor.2009.109
   Reiley WW, 2007, J EXP MED, V204, P1475, DOI 10.1084/jem.20062694
   Ren JM, 2017, CELL MOL IMMUNOL, V14, P639, DOI 10.1038/cmi.2017.31
   Rickard JA, 2014, CELL, V157, P1175, DOI 10.1016/j.cell.2014.04.019
   Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122
   Rodriguez DA, 2016, CELL DEATH DIFFER, V23, P76, DOI 10.1038/cdd.2015.70
   Roedig J, 2021, EMBO REP, V22, DOI 10.15252/embr.202050163
   Ruan JY, 2015, INT J CLIN EXP PATHO, V8, P15035
   Sato Y, 2015, NAT STRUCT MOL BIOL, V22, P222, DOI 10.1038/nsmb.2970
   Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423
   Schenk B, 2015, ONCOGENE, V34, P5796, DOI 10.1038/onc.2015.35
   Schmidt SV, 2015, ONCOTARGET, V6, P8635, DOI 10.18632/oncotarget.3249
   Seehawer M, 2018, NATURE, V562, P69, DOI 10.1038/s41586-018-0519-y
   Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403
   Seo J, 2016, NAT CELL BIOL, V18, P291, DOI 10.1038/ncb3314
   Shahsavari Zahra, 2015, Asian Pac J Cancer Prev, V16, P7261
   Shlomovitz I, 2017, IMMUNOL CELL BIOL, V95, P166, DOI 10.1038/icb.2016.124
   Silke J, 2015, NAT IMMUNOL, V16, P689, DOI [10.1038/ni.3206, 10.1038/ni0815-889b]
   Snyder AG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aaw2004
   Sreenivasan K, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107652
   Steinhart L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.320
   Steinwascher S, 2015, CANCER LETT, V366, P32, DOI 10.1016/j.canlet.2015.05.020
   Stoll G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1299302
   Strilic B, 2016, NATURE, V536, P215, DOI 10.1038/nature19076
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Sun XQ, 2002, J BIOL CHEM, V277, P9505, DOI 10.1074/jbc.M109488200
   Sun XQ, 1999, J BIOL CHEM, V274, P16871, DOI 10.1074/jbc.274.24.16871
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577-019-0165-0
   Takizawa H, 2017, CELL STEM CELL, V21, P225, DOI 10.1016/j.stem.2017.06.013
   Tan YF, 2021, CLIN CANCER RES, V27, P1200, DOI 10.1158/1078-0432.CCR-18-3683
   Tang Y, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12033-8
   Tao PF, 2020, NATURE, V577, P109, DOI 10.1038/s41586-019-1830-y
   Tenev T, 2011, MOL CELL, V43, P689, DOI 10.1016/j.molcel.2011.08.005
   Thijssen R, 2020, CELL DEATH DIFFER, V27, P2531, DOI 10.1038/s41418-020-0576-2
   Thonsri U, 2020, ANTICANCER RES, V40, P5115, DOI 10.21873/anticanres.14515
   Torii S, 2020, AUTOPHAGY, V16, P1532, DOI 10.1080/15548627.2020.1776476
   Torii S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15577-2
   Tortola L, 2016, CELL REP, V16, P3414, DOI 10.1016/j.celrep.2016.08.072
   Upton JW, 2008, J BIOL CHEM, V283, P16966, DOI 10.1074/jbc.C800051200
   Vanden Berghe T, 2017, ONCOTARGET, V8, P1, DOI 10.18632/oncotarget.13926
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200
   Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037
   Vucur M, 2013, CELL REP, V4, P776, DOI 10.1016/j.celrep.2013.07.035
   Wallach D, 2011, TRENDS IMMUNOL, V32, P505, DOI 10.1016/j.it.2011.07.004
   Wang FF, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00861
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Wang KJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01720
   Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036
   Wang LL, 2020, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00393
   Wang W, 2018, CANCER CELL, V34, P757, DOI 10.1016/j.ccell.2018.10.006
   Wang XQ, 2014, NAT IMMUNOL, V15, P1126, DOI 10.1038/ni.3015
   Wang X, 2014, P NATL ACAD SCI USA, V111, P15438, DOI 10.1073/pnas.1412767111
   Wang YW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1423-5
   Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030
   Weber K, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-017-0007-1
   Wegner KW, 2017, TRENDS PHARMACOL SCI, V38, P202, DOI 10.1016/j.tips.2016.12.005
   Weinlich R, 2017, NAT REV MOL CELL BIO, V18, P127, DOI 10.1038/nrm.2016.149
   Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794
   Wu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052706
   Wu L, 2020, CANCER IMMUNOL RES, V8, P710, DOI 10.1158/2326-6066.CIR-19-0261
   Wu WX, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107547
   Wu XR, 2012, MOL CELL PROTEOMICS, V11, P1640, DOI 10.1074/mcp.M112.019091
   Xie T, 2013, CELL REP, V5, P70, DOI 10.1016/j.celrep.2013.08.044
   Xie YD, 2020, J CLIN INVEST, V130, P2111, DOI 10.1172/JCI133264
   Xin J, 2017, LEUKEMIA, V31, P1154, DOI 10.1038/leu.2016.287
   Xin JP, 2017, HAEMATOLOGICA, V102, P295, DOI 10.3324/haematol.2016.151514
   Yang CK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.483
   Yang YH, 2004, J BIOL CHEM, V279, P38820, DOI 10.1074/jbc.M401663200
   Yang ZH, 2020, MOL CELL, V80, P296, DOI 10.1016/j.molcel.2020.09.004
   Yang ZT, 2018, NAT CELL BIOL, V20, P186, DOI 10.1038/s41556-017-0022-y
   Yatim N, 2015, SCIENCE, V350, P328, DOI 10.1126/science.aad0395
   Yoon S, 2016, CELL DEATH DIFFER, V23, P253, DOI 10.1038/cdd.2015.92
   Yu PW, 1999, CURR BIOL, V9, P539, DOI 10.1016/S0960-9822(99)80239-5
   Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200
   Zhai ET, 2016, TUMOR BIOL, V37, P13679, DOI 10.1007/s13277-016-5229-1
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhang T, 2016, NAT MED, V22, P175, DOI 10.1038/nm.4017
   Zhang YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14329
   Zhao QL, 2015, INT J CANCER, V137, P1446, DOI 10.1002/ijc.29483
   Zheng LX, 2006, MOL CELL BIOL, V26, P3505, DOI 10.1128/MCB.26.9.3505-3513.2006
   Zhou MX, 2021, J CROHNS COLITIS, V15, P99, DOI 10.1093/ecco-jcc/jjaa131
   Zhou ZJ, 2017, CANCER LETT, V390, P77, DOI 10.1016/j.canlet.2017.01.004
NR 216
TC 0
Z9 0
U1 6
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2021
VL 78
IS 23
BP 7199
EP 7217
DI 10.1007/s00018-021-03947-y
EA OCT 2021
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA XE9QL
UT WOS:000707516100001
PM 34654937
DA 2022-04-25
ER

PT J
AU Park, SY
   Park, C
   Park, SH
   Hong, SH
   Kim, GY
   Hong, SH
   Choi, YH
AF Park, Seon Young
   Park, Cheol
   Park, Shin-Hyung
   Hong, Su-Hyun
   Kim, Gi-Young
   Hong, Sang Hoon
   Choi, Yung-Hyun
TI Induction of apoptosis by ethanol extract of Evodia rutaecarpa in HeLa
   human cervical cancer cells via activation of AMP-activated protein
   kinase
SO BioScience Trends
LA English
DT Article
DE Evodia rutaecarpa; cervical cancer; apoptosis; caspase; AMPK
ID COLORECTAL-CANCER; UPSTREAM KINASE; TUMOR-CELLS; GROWTH; MITOCHONDRIA;
   METFORMIN; AUTOPHAGY; PATHWAYS; STRESS; EXPRESSION
AB The fruit of Evodia rutaecarpa (Juss.) Benth has been used widely in traditional medicine therapy. Although it has been shown to possess many pharmacological activities, the molecular mechanisms of its anti-cancer activity have not been clearly elucidated. In the present study, we investigated the pro-apoptotic effects of an ethanol extract isolated from immature fruits of E. rutaecarpa (EEER) in HeLa human cervical cancer cells. EEER treatment decreased the cell viability of HeLa cells in a concentration-dependent manner, which was related to apoptotic cell death resulting from apoptotic body formation, DNA fragmentation, and an increased population of annexin V+-positive cells. EEER treatment significantly suppressed anti-apoptotic Bcl-2 expression, leading to subsequent loss of mitochondrial membrane potential (MMP), while it did not change expression levels of death receptor (DR)-related proteins. EEER treatment increased activity of caspase-3 and-9 but not caspase-8, and pretreatment of a caspase-3 inhibitor markedly attenuated EEER-induced apoptosis. Furthermore, EEER activated the AMP-activated protein kinase (AMPK) signaling pathway; however, inhibition of AMPK markedly abrogated EEER-induced apoptosis. Overall, the results suggest that the apoptotic activity of EEER may be associated with a caspase-dependent cascade through activation of the intrinsic signaling pathway connected with AMPK activation. E. rutaecarpa could be a prospective clinical application to treat human cervical cancer.
C1 [Park, Seon Young; Hong, Sang Hoon] Dong Eui Univ, Coll Korean Med, Dept Internal Med, Busan 47227, South Korea.
   [Park, Cheol] Dong Eui Univ, Coll Nat Sci & Human Ecol, Dept Mol Biol, Busan, South Korea.
   [Park, Shin-Hyung] Dong Eui Univ, Coll Korean Med, Dept Pathol, Busan, South Korea.
   [Hong, Su-Hyun; Choi, Yung-Hyun] Dong Eui Univ, Coll Korean Med, Dept Biochem, Busan 47227, South Korea.
   [Kim, Gi-Young] Jeju Natl Univ, Sch Marine Biomed Sci, Dept Marine Life Sci, Jeju, South Korea.
   [Choi, Yung-Hyun] Dong Eui Univ, Antiaging Res Ctr, Busan, South Korea.
RP Hong, SH (corresponding author), Dong Eui Univ, Coll Korean Med, Dept Internal Med, Busan 47227, South Korea.; Choi, YH (corresponding author), Dong Eui Univ, Coll Korean Med, Dept Biochem, Busan 47227, South Korea.
EM shhong@deu.ac.kr; choiyh@deu.ac.kr
RI Park, Shin-Hyung/U-9406-2017
OI Park, Shin-Hyung/0000-0002-4792-3393
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT and Future Planning
   [2014R1A1A1008460, 2015R1A2A2A01004633]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT and Future Planning (2014R1A1A1008460 and
   2015R1A2A2A01004633).
CR Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Chen HY, 2015, APOPTOSIS, V20, P821, DOI 10.1007/s10495-015-1111-7
   Chen TC, 2016, PHYTOMEDICINE, V23, P68, DOI 10.1016/j.phymed.2015.12.003
   Chiang PC, 2010, BIOCHEM PHARMACOL, V79, P162, DOI 10.1016/j.bcp.2009.08.022
   Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517
   Eom DW, 2015, BMB REP, V48, P461, DOI 10.5483/BMBRep.2015.48.8.216
   Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149
   Figarola JL, 2015, J BIOL CHEM, V290, P30321, DOI 10.1074/jbc.M115.686352
   Groenendijk FH, 2015, INT J CANCER, V136, P1434, DOI 10.1002/ijc.29113
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304
   Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009
   Hensley P, 2013, BIOL CHEM, V394, P831, DOI 10.1515/hsz-2013-0128
   Huang J, 2015, ONCOL REP, V34, P3203, DOI 10.3892/or.2015.4309
   Hwang JT, 2004, CARCINOGENESIS, V25, P2497, DOI 10.1093/carcin/bgh253
   Jeon SM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.81
   Jiang JL, 2009, MOLECULES, V14, P1852, DOI 10.3390/molecules14051852
   Jimbo A, 2003, EXP CELL RES, V283, P156, DOI 10.1016/S0014-4827(02)00033-2
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Kim D, 2014, J ETHNOPHARMACOL, V151, P1072, DOI 10.1016/j.jep.2013.12.006
   Ko HC, 2007, EUR J PHARMACOL, V555, P211, DOI 10.1016/j.ejphar.2006.10.002
   Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Li YL, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0726-4
   Lin L, 2016, MOL MED REP, V14, P2832, DOI 10.3892/mmr.2016.5575
   Liu AJ, 2013, CHEM-BIOL INTERACT, V205, P20, DOI 10.1016/j.cbi.2013.06.004
   Modica-Napolitano JS, 2015, INT J MOL SCI, V16, P17394, DOI 10.3390/ijms160817394
   Monteverde T, 2015, FEBS J, V282, P4658, DOI 10.1111/febs.13534
   Okada H, 2004, NAT REV CANCER, V4, P592, DOI 10.1038/nrc1412
   Oronsky BT, 2014, ANTI-CANCER AGENT ME, V14, P1187, DOI 10.2174/1871520614666140804224637
   Papandreou I, 2008, CELL DEATH DIFFER, V15, P1572, DOI 10.1038/cdd.2008.84
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Ralph SJ, 2010, MOL ASPECTS MED, V31, P29, DOI 10.1016/j.mam.2009.12.006
   Ralph SJ, 2009, MOL NUTR FOOD RES, V53, P9, DOI 10.1002/mnfr.200800044
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007
   Sid B, 2013, BIOCHEM PHARMACOL, V86, P200, DOI 10.1016/j.bcp.2013.05.007
   Solaini G, 2011, BBA-BIOENERGETICS, V1807, P534, DOI 10.1016/j.bbabio.2010.09.003
   Sui H, 2016, J CELL BIOCHEM, V117, P1471, DOI 10.1002/jcb.25451
   Sui XB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097781
   Tan MX, 2012, ADV MATER RES-SWITZ, V396-398, P52, DOI 10.4028/www.scientific.net/AMR.396-398.52
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031
   Xu ZX, 2007, CELL DEATH DIFFER, V14, P1948, DOI 10.1038/sj.cdd.4402207
   You MK, 2016, NUTR RES PRACT, V10, P139, DOI 10.4162/nrp.2016.10.2.139
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008-5472.CAN-06-1500
   Zhao LC, 2015, INT J MOL SCI, V16, P27411, DOI 10.3390/ijms161126031
   Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029
NR 49
TC 8
Z9 9
U1 1
U2 7
PU IRCA-BSSA
PI TOKYO
PA PEARL CITY KOISHIKAWA 603, 2-4-5 KASUGA, BUNKYO-KU, TOKYO, 112-0003,
   JAPAN
SN 1881-7815
EI 1881-7823
J9 BIOSCI TRENDS
JI BioSci. Trends
PD DEC
PY 2016
VL 10
IS 6
BP 467
EP 476
DI 10.5582/bst.2016.01170
PG 10
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA EI9FS
UT WOS:000392813900006
PM 27890875
OA Bronze
DA 2022-04-25
ER

PT J
AU Kuan, YD
   Lee, CH
AF Kuan, Yu-Diao
   Lee, Che-Hsin
TI Salmonella overcomes tumor immune tolerance by inhibition of tumor
   indoleamine 2, 3-dioxygenase 1 expression
SO ONCOTARGET
LA English
DT Article
DE salmonella; tumor-targeting; indoleamine 2; 3-dioxygenase 1; immune
   tolerance
ID TYPHIMURIUM A1-R; COLORECTAL-CANCER; TARGETED THERAPY; STEM-LIKE;
   2,3-DIOXYGENASE; AUTOPHAGY; BACTERIAL; CELLS; METASTASIS; EFFICACY
AB Over the past decades, Salmonella has been proven capable of inhibiting tumor growth. It can specifically target tumors and due to its facultative anaerobic property, can be more penetrative than other drug therapies. However, the molecular mechanism by which Salmonella inhibits tumor growth is still incompletely known. The antitumor therapeutic effect mediated by Salmonella is associated with an inflammatory immune response at the tumor site and a T cell-dependent immune response. Many tumors have been proven to have a high expression of indoleamine 2, 3-dioxygenase 1 (IDO), which is a rate-limiting enzyme that catalyzes tryptophan to kynurenine, thus causing immune tolerance within the tumor microenvironment. With decreased expression of IDO, increased immune response can be observed, which might be helpful when developing cancer immunotherapy. The expression of IDO was decreased after tumor cells were infected with Salmonella. In addition, Western blot analysis showed that the expression levels of phospho-protein kinase B (P-AKT), phospho-mammalian targets of rapamycin (P-mTOR), and phospho-p70 ribosomal s6 kinase (P-p70s6K) in tumor cells were decreased after Salmonella infection. In conclusion, our results indicate that Salmonella inhibits IDO expression and plays a crucial role in anti-tumor therapy, which might be a promising strategy combined with other cancer treatments.
C1 [Kuan, Yu-Diao; Lee, Che-Hsin] China Med Univ, Grad Inst Basic Med Sci, Sch Med, Taichung, Taiwan.
   [Lee, Che-Hsin] China Med Univ, Sch Med, Dept Microbiol, Taichung, Taiwan.
RP Lee, CH (corresponding author), China Med Univ, Grad Inst Basic Med Sci, Sch Med, Taichung, Taiwan.; Lee, CH (corresponding author), China Med Univ, Sch Med, Dept Microbiol, Taichung, Taiwan.
EM chlee@mail.cmu.edu.tw
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 104-2320-B-039-042-MY3]
FX This work was supported by grants from the Ministry of Science and
   Technology, Taiwan (MOST 104-2320-B-039-042-MY3).
CR Brandacher G, 2006, CLIN CANCER RES, V12, P1144, DOI 10.1158/1078-0432.CCR-05-1966
   Brunschwig A, 1939, ANN SURG, V109, P108, DOI 10.1097/00000658-193901000-00010
   Budak G, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.00730
   Cao J, 2015, INT IMMUNOPHARMACOL, V26, P212, DOI 10.1016/j.intimp.2015.03.028
   Chang WW, 2014, INT J MOL SCI, V15, P14546, DOI 10.3390/ijms150814546
   Chang WW, 2013, TOXINS, V5, P2353, DOI 10.3390/toxins5122353
   Chang WW, 2013, INT J CANCER, V133, P1926, DOI 10.1002/ijc.28155
   Chang WW, 2012, EXP BIOL MED, V237, P1189, DOI 10.1258/ebm.2012.012063
   Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015
   Dalotto-Moreno T, 2013, CANCER RES, V73, P1107, DOI 10.1158/0008-5472.CAN-12-2418
   Fallarino F, 2012, EUR J IMMUNOL, V42, P1932, DOI 10.1002/eji.201242572
   Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073
   Flavell RA, 2010, NAT REV IMMUNOL, V10, P554, DOI 10.1038/nri2808
   Forbes NS, 2010, NAT REV CANCER, V10, P784, DOI 10.1038/nrc2934
   Hayashi K, 2009, J CELL BIOCHEM, V106, P992, DOI 10.1002/jcb.22078
   Hiroshima Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120358
   Hiroshima Y, 2014, ONCOTARGET, V5, P12346, DOI 10.18632/oncotarget.2641
   Hiroshima Y, 2014, J CELL BIOCHEM, V115, P1254, DOI 10.1002/jcb.24769
   Hiroshima Y, 2013, CELL CYCLE, V12, P2774, DOI 10.4161/cc.25872
   Hix LM, 2013, J BIOL CHEM, V288, P11676, DOI 10.1074/jbc.M112.441402
   Hou DY, 2007, CANCER RES, V67, P792, DOI 10.1158/0008-5472.CAN-06-2925
   Kawai K, 2013, CANCER SCI, V104, P22, DOI 10.1111/cas.12075
   Kimura H, 2010, CELL PROLIFERAT, V43, P41, DOI 10.1111/j.1365-2184.2009.00652.x
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Lee CH, 2014, GENE THER, V21, P309, DOI 10.1038/gt.2013.86
   Lee CH, 2005, MOL THER, V11, P707, DOI 10.1016/j.ymthe.2005.01.008
   Lee CH, 2008, INT J CANCER, V122, P930, DOI 10.1002/ijc.23047
   Lee CH, 2014, INT J MOL SCI, V15, P10334, DOI 10.3390/ijms150610334
   Lee CH, 2012, APPL MICROBIOL BIOT, V93, P517, DOI 10.1007/s00253-011-3695-3
   Lee CH, 2011, APPL MICROBIOL BIOT, V90, P1381, DOI 10.1007/s00253-011-3180-z
   Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205
   Lu B, 2008, CELL DEATH DIFFER, V15, P70, DOI 10.1038/sj.cdd.4402274
   Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041
   Matsumoto Y, 2015, ONCOTARGET, V6, P11369, DOI 10.18632/oncotarget.3607
   Metz R, 2012, ONCOIMMUNOLOGY, V1, P1460, DOI 10.4161/onci.21716
   Miwa S, 2014, ONCOTARGET, V5, P12849, DOI 10.18632/oncotarget.2561
   Miwa S, 2014, ONCOTARGET, V5, P7119, DOI 10.18632/oncotarget.2226
   MOSE JR, 1964, CANCER RES, V24, P212
   Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196
   Munn DH, 2006, CURR OPIN IMMUNOL, V18, P220, DOI 10.1016/j.coi.2006.01.002
   NAUTS H C, 1953, Acta Med Scand Suppl, V276, P1
   Pan ST, 2015, DRUG DES DEV THER, V9, P1601, DOI 10.2147/DDDT.S76057
   Pattingre S, 2006, CANCER RES, V66, P2885, DOI 10.1158/0008-5472.CAN-05-4412
   Pawelek JM, 1997, CANCER RES, V57, P4537
   Saccheri F, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000739
   Shiau AL, 2014, ENVIRON TOXICOL, V29, P363, DOI 10.1002/tox.21763
   Tattoli I, 2012, BIOL OPEN, V1, P1215, DOI 10.1242/bio.20122840
   Thornlow DN, 2015, BIOTECHNOL BIOENG, V112, P2397, DOI 10.1002/bit.25645
   Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.20.1.142
   Wang WK, 2014, POLYMERS-BASEL, V6, P1119, DOI [10.3390/polym6041119, 10.3390/polym6030755]
   Wang WK, 2015, AM J CANCER RES, V5, P2222
   Yam C, 2010, J SURG RES, V164, P248, DOI 10.1016/j.jss.2009.02.023
   Yan J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024705
   Yano S, 2014, CELL CYCLE, V13, P3958, DOI 10.4161/15384101.2014.964115
   Zhang Y, 2015, ONCOTARGET, V6, P2615, DOI 10.18632/oncotarget.2811
   Zhao M, 2005, P NATL ACAD SCI USA, V102, P755, DOI 10.1073/pnas.0408422102
   Zhao M, 2007, P NATL ACAD SCI USA, V104, P10170, DOI 10.1073/pnas.0703867104
   Zhao M, 2006, CANCER RES, V66, P7647, DOI 10.1158/0008-5472.CAN-06-0716
NR 58
TC 26
Z9 28
U1 0
U2 9
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 5
PY 2016
VL 7
IS 1
BP 374
EP 385
DI 10.18632/oncotarget.6258
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5GI
UT WOS:000369950300030
PM 26517244
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Mendez-Blanco, C
   Fondevila, F
   Fernandez-Palanca, P
   Garcia-Palomo, A
   van Pelt, J
   Verslype, C
   Gonzalez-Gallego, J
   Mauriz, JL
AF Mendez-Blanco, Carolina
   Fondevila, Flavia
   Fernandez-Palanca, Paula
   Garcia-Palomo, Andres
   van Pelt, Jos
   Verslype, Chris
   Gonzalez-Gallego, Javier
   Mauriz, Jose L.
TI Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter
   Methylation Contribute to Acquired Sorafenib Resistance in Human
   Hepatocarcinoma Cells
SO CANCERS
LA English
DT Article
DE BNIP3; hepatocarcinoma; HIF; hypoxia; resistance; sorafenib
ID HEPATOCELLULAR-CARCINOMA CELLS; COLORECTAL-CANCER; UP-REGULATION;
   PROTECTIVE AUTOPHAGY; EXPRESSION; APOPTOSIS; GENE; MECHANISMS;
   5-AZA-2'-DEOXYCYTIDINE; CHEMORESISTANCE
AB Despite sorafenib effectiveness against advanced hepatocarcinoma (HCC), long-term exposure to antiangiogenic drugs leads to hypoxic microenvironment, a key contributor to chemoresistance acquisition. We aimed to study the role of hypoxia in the development of sorafenib resistance in a human HCC in vitro model employing the HCC line HepG2 and two variants with acquired sorafenib resistance, HepG2S1 and HepG2S3, and CoCl2 as hypoximimetic. Resistant cells exhibited a faster proliferative rate and hypoxia adaptive mechanisms, linked to the increased protein levels and nuclear translocation of hypoxia-inducible factors (HIFs). HIF-1 alpha and HIF-2 alpha overexpression was detected even under normoxia through a deregulation of its degradation mechanisms. Proapoptotic markers expression and subG1 population decreased significantly in HepG2S1 and HepG2S3, suggesting evasion of sorafenib-mediated cell death. HIF-1 alpha and HIF-2 alpha knockdown diminished resistant cells viability, relating HIFs overexpression with its prosurvival ability. Additionally, epigenetic silencing of Bcl-2 interacting protein 3 (BNIP3) was observed in sorafenib resistant cells under hypoxia. Demethylation of BNIP3 promoter, but not histone acetylation, restored BNIP3 expression, driving resistant cells' death. Altogether, our results highlight the involvement of HIFs overexpression and BNIP3 methylation-dependent knockdown in the development of sorafenib resistance in HCC. Targeting both prosurvival mechanisms could overcome chemoresistance and improve future therapeutic approaches.
C1 [Mendez-Blanco, Carolina; Fondevila, Flavia; Fernandez-Palanca, Paula; Gonzalez-Gallego, Javier; Mauriz, Jose L.] Univ Leon, Inst Biomed IBIOMED, Campus Vegazana S-N, E-24071 Leon, Spain.
   [Mendez-Blanco, Carolina; Fondevila, Flavia; Fernandez-Palanca, Paula; Gonzalez-Gallego, Javier; Mauriz, Jose L.] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Av Monforte de Lemos 5, Madrid 28029, Spain.
   [Garcia-Palomo, Andres] Complejo Asistencial Univ Leon, Serv Oncol, Calle Altos de Nava S-N, Leon 24001, Spain.
   [van Pelt, Jos; Verslype, Chris] Katholieke Univ Leuven, Dept Oncol, Lab Clin Digest Oncol, B-3000 Leuven, Belgium.
   [van Pelt, Jos; Verslype, Chris] Univ Hosp Leuven, B-3000 Leuven, Belgium.
   [van Pelt, Jos; Verslype, Chris] Leuven Canc Inst LKI, B-3000 Leuven, Belgium.
RP Mauriz, JL (corresponding author), Univ Leon, Inst Biomed IBIOMED, Campus Vegazana S-N, E-24071 Leon, Spain.; Mauriz, JL (corresponding author), Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Av Monforte de Lemos 5, Madrid 28029, Spain.
EM cmenb@unileon.es; ffonp@unileon.es; pferp@unileon.es; dfijmg@unileon.es;
   jos.vanpelt@kuleuven.be; chris.verslype@uzleuven.be; jgonga@unileon.es;
   jl.mauriz@unileon.es
RI Fernández-Palanca, Paula/AAH-1161-2019; Mauriz, Jose L/G-9970-2014;
   Pena, Flavia Fondevila/S-2788-2018; Blanco, Carolina
   Méndez/AAR-9136-2021; Blanco, Carolina Méndez/L-2569-2017;
   Gonzalez-Gallego, Javier/D-8219-2012
OI Fernández-Palanca, Paula/0000-0001-9765-9562; Mauriz, Jose
   L/0000-0003-3160-8599; Pena, Flavia Fondevila/0000-0003-2881-704X;
   Blanco, Carolina Méndez/0000-0001-6378-2554; Blanco, Carolina
   Méndez/0000-0001-6378-2554; Gonzalez-Gallego,
   Javier/0000-0002-4386-9342; van Pelt, Jos/0000-0001-6903-4338; Verslype,
   Chris/0000-0003-3857-466X
FU Instituto de Salud Carlos III, SpainInstituto de Salud Carlos III;
   Asociacion Espanola Contra el Cancer (AECC)-Junta Provincial de Leon;
   Ministry of Education of SpainSpanish Government [FPU16/05277,
   FPU17/01995]
FX CIBERehd is funded by Instituto de Salud Carlos III, Spain. C.M.B. is
   supported by the Asociacion Espanola Contra el Cancer (AECC)-Junta
   Provincial de Leon. F.F. and P.F.P. by the Ministry of Education of
   Spain (FPU16/05277 and FPU17/01995 grants).
CR Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1
   Alqahtani A, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55090526
   An HJ, 2011, MOL CELLS, V31, P579, DOI 10.1007/s10059-011-0065-z
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Bielecka ZF, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0197-8
   Chen J, 2015, CANCER LETT, V367, P1, DOI 10.1016/j.canlet.2015.06.019
   Chen YN, 2017, J GENE MED, V19, DOI 10.1002/jgm.2998
   Crespo I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050407
   Crespo I, 2010, J PINEAL RES, V49, P193, DOI 10.1111/j.1600-079X.2010.00787.x
   De Angelis PM, 2004, INT J ONCOL, V24, P1279
   Deng Q, 2012, CHEMOTHERAPY, V58, P445, DOI 10.1159/000345916
   Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642
   Fernando J, 2012, J CELL PHYSIOL, V227, P1319, DOI 10.1002/jcp.22843
   Hajigholami S, 2018, IRAN J PHARM RES, V17, P1
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   He M, 2019, MOL ONCOL, V13, P403, DOI 10.1002/1878-0261.12419
   Hikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836
   Huang SH, 2019, ONCOL REP, V41, P1759, DOI 10.3892/or.2018.6929
   Ishiguro M, 2007, ANN SURG ONCOL, V14, P1752, DOI 10.1245/s10434-006-9285-4
   Jagannathan M, 2012, J CELL SCI, V125, P133, DOI 10.1242/jcs.089938
   Jiang WJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28010-y
   Ju C, 2016, J MOL MED, V94, P613, DOI 10.1007/s00109-016-1408-1
   Krutilina R, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3693
   Li JQ, 2017, ACTA PHARMACOL SIN, V38, P1642, DOI 10.1038/aps.2017.79
   Li SN, 2017, BRIT J CANCER, V117, P1518, DOI 10.1038/bjc.2017.323
   Li XF, 2012, BIOCHEM BIOPH RES CO, V418, P531, DOI 10.1016/j.bbrc.2012.01.060
   Li Y, 2017, ONCOTARGET, V8, P63208, DOI 10.18632/oncotarget.18736
   Liang YJ, 2013, HEPATOLOGY, V57, P1847, DOI 10.1002/hep.26224
   Liu FY, 2011, CANCER RES, V71, P6807, DOI 10.1158/0008-5472.CAN-11-1575
   Liu F, 2015, ONCOL LETT, V10, P778, DOI 10.3892/ol.2015.3315
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Liu LP, 2012, CLIN CANCER RES, V18, P5662, DOI 10.1158/1078-0432.CCR-12-0552
   Long Q, 2019, BIOCHEM BIOPH RES CO, V513, P642, DOI 10.1016/j.bbrc.2019.03.109
   Ma L, 2014, CANCER LETT, V355, P96, DOI 10.1016/j.canlet.2014.09.011
   Mendez-Blanco C, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0159-1
   Mian OY, 2016, PROSTATE, V76, P199, DOI 10.1002/pros.23111
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Niu LL, 2017, BBA-REV CANCER, V1868, P564, DOI 10.1016/j.bbcan.2017.10.002
   Prieto-Dominguez N, 2017, ONCOTARGET, V8, P91402, DOI 10.18632/oncotarget.20592
   Prieto-Dominguez N, 2016, J PINEAL RES, V61, P396, DOI 10.1111/jpi.12358
   Qiu YX, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0200-8
   Rodriguez-Hernandez MA, 2019, J CELL PHYSIOL, V234, P692, DOI 10.1002/jcp.26855
   Saint-Martin A, 2019, CANCERS, V11, DOI 10.3390/cancers11060755
   Schiller I, 2003, J VET DIAGN INVEST, V15, P585, DOI 10.1177/104063870301500614
   Shao YX, 2019, INT J ONCOL, V54, P348, DOI 10.3892/ijo.2018.4603
   Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024
   Tak E, 2011, J HEPATOL, V54, P328, DOI 10.1016/j.jhep.2010.06.045
   Tang H, 2007, ANTI-CANCER DRUG, V18, P633, DOI 10.1097/CAD.0b013e3280200428
   Valdez BC, 2010, LEUKEMIA RES, V34, P364, DOI 10.1016/j.leukres.2009.08.014
   van Malenstein H, 2013, CANCER LETT, V329, P74, DOI 10.1016/j.canlet.2012.10.021
   van Oosterwijk JG, 2018, J CLIN INVEST, V128, P369, DOI 10.1172/JCI91893
   Vasagiri N, 2014, MOL BIOL REP, V41, P7705, DOI 10.1007/s11033-014-3664-x
   Wang JZ, 2011, J HEPATOL, V55, P359, DOI 10.1016/j.jhep.2010.10.043
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Wu FQ, 2016, J HEPATOL, V65, P314, DOI 10.1016/j.jhep.2016.04.019
   Xiong XX, 2017, MOL PHARMACOL, V92, P246, DOI 10.1124/mol.116.107706
   Xu HT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115565
   Yang F, 2014, TECHNOL CANCER RES T, V13, P77, DOI 10.7785/tcrt.2012.500364
   Yeh CC, 2015, MOL CELL PROTEOMICS, V14, P1527, DOI 10.1074/mcp.M114.046417
   You A, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0253-6
   Zhai B, 2014, MOL CANCER THER, V13, P1589, DOI 10.1158/1535-7163.MCT-13-1043
   Zhao CX, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0419-4
   Zhao DL, 2014, CELL SIGNAL, V26, P1030, DOI 10.1016/j.cellsig.2014.01.026
   Zhou TY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30483
   Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5
   Ziogas IA, 2017, WORLD J CLIN ONCOL, V8, P203, DOI 10.5306/wjco.v8.i3.203
NR 66
TC 13
Z9 15
U1 5
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD DEC
PY 2019
VL 11
IS 12
AR 1984
DI 10.3390/cancers11121984
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KC7VZ
UT WOS:000507382100161
PM 31835431
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU D'Alessandro, R
   Refolo, MG
   Lippolis, C
   Giannuzzi, G
   Carella, N
   Messa, C
   Cavallini, A
   Carr, BI
AF D'Alessandro, Rosalba
   Refolo, Maria G.
   Lippolis, Catia
   Giannuzzi, Grazia
   Carella, Nicola
   Messa, Caterina
   Cavallini, Aldo
   Carr, Brian I.
TI Antagonism of Sorafenib and Regorafenib actions by platelet factors in
   hepatocellular carcinoma cell lines
SO BMC CANCER
LA English
DT Article
DE Regorefenib; Platelets; HCC; Apoptosis; Growth; Invasion
ID CANCER-CELLS; MULTIDRUG-RESISTANCE; RAF/MEK/ERK PATHWAY;
   COLORECTAL-CANCER; ANTICANCER DRUGS; HEPATOMA-CELLS; THROMBOCYTOSIS;
   RECEPTOR; GROWTH; ANGIOGENESIS
AB Background: Platelets are frequently altered in hepatocellular carcinoma (HCC) patients. Platelet lysates (hPL) can enhance HCC cell growth and decrease apoptosis. The aims were to evaluate whether hPL can modulate the actions of Sorafenib or Regorafenib, two clinical HCC multikinase antagonists.
   Methods: Several human HCC cell lines were grown in the presence and absence of Sorafenib or Regorafenib, with or without hPL. Growth was measured by MTT assay, apoptosis was assessed by Annexin V and by western blot, and autophagy and MAPK growth signaling were also measured by western blot, and migration and invasion were measured by standard in vitro assays.
   Results: Both Sorafenib and Regorafenib-mediated inhibition of cell growth, migration and invasion were all antagonized by hPL. Drug-mediated apoptosis and decrease in phospho-ERK levels were both blocked by hPL, which also increased anti-apoptotic phospho-STAT, Bax and Bcl-xL levels. Preliminary data, obtained with epidermal growth factor (EGF) and insulin-like growth factor-I (IGF-I), included in hPL, revealed that these factors were able to antagonized Sorafenib in a proliferation assay, in particular when used in combination.
   Conclusions: Platelet factors can antagonize Sorafenib or Regorafenib-mediated growth inhibition and apoptosis in HCC cells. The modulation of platelet activity or numbers has the potential to enhance multikinase drug actions.
C1 [D'Alessandro, Rosalba; Refolo, Maria G.; Lippolis, Catia; Carella, Nicola; Messa, Caterina; Cavallini, Aldo; Carr, Brian I.] IRCCS Saverio de Bellis, Natl Inst Digest Dis, Lab Biochem, I-70013 Castellana Grotte, BA, Italy.
   [Giannuzzi, Grazia] S Maria degli Angeli Hosp, Transfus Med Ctr, I-70017 Putignano, BA, Italy.
RP Carr, BI (corresponding author), IRCCS Saverio de Bellis, Natl Inst Digest Dis, Lab Biochem, Via Turi 27, I-70013 Castellana Grotte, BA, Italy.
EM brianicarr@hotmail.com
RI D'Alessandro, Rosalba/J-2351-2018
OI Carr, Brian/0000-0002-6111-5077
FU NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [CA82723]; Ministry of Health of
   ItalyMinistry of Health, Italy; NATIONAL CANCER INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [R01CA082723] Funding Source:
   NIH RePORTER
FX This research was supported in part by NIH grant CA82723 (BIC) and by
   Ministry of Health of Italy. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of
   either NIH or Italian Ministry of Health.
CR Atzori F, 2009, TARGET ONCOL, V4, P255, DOI 10.1007/s11523-009-0123-z
   Bambace NM, 2011, J THROMB HAEMOST, V9, P237, DOI 10.1111/j.1538-7836.2010.04131.x
   Borsig L, 2008, EXPERT REV ANTICANC, V8, P1247, DOI 10.1586/14737140.8.8.1247
   Buergy D, 2012, INT J CANCER, V130, P2747, DOI 10.1002/ijc.27441
   Carr BI, 2013, LIV M P BOST MA US A
   Carr BI, 2014, EUR J GASTROEN HEPAT, V26, P101, DOI 10.1097/MEG.0b013e3283644c49
   Carr BI, 2013, DIGEST DIS SCI, V58, P1790, DOI 10.1007/s10620-012-2527-3
   Carr BI, 2013, J CELL PHYSIOL, V228, P292, DOI 10.1002/jcp.24148
   D'Alessandro R, 2013, CANCER CHEMOTH PHARM, V72, P869, DOI 10.1007/s00280-013-2269-8
   Dai Y, 2007, CANCER RES, V67, P2908, DOI 10.1158/0008-5472.CAN-07-0082
   Dashevsky O, 2009, INT J CANCER, V124, P1773, DOI 10.1002/ijc.24016
   Demers M, 2012, ONCOIMMUNOLOGY, V1, P100, DOI 10.4161/onci.1.1.17962
   Demers M, 2011, CANCER RES, V71, P1540, DOI 10.1158/0008-5472.CAN-10-2038
   Ezzoukhry Z, 2012, INT J CANCER, V131, P2961, DOI 10.1002/ijc.27604
   Galmiche A, 2010, MOL CANCER RES, V8, P1116, DOI 10.1158/1541-7786.MCR-10-0029
   Goubran HA, 2013, EUR J INTERN MED, V24, P393, DOI 10.1016/j.ejim.2013.01.017
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Hikita H, 2010, HEPATOLOGY, V52, P1310, DOI 10.1002/hep.23836
   Hwang SJ, 2004, WORLD J GASTROENTERO, V10, P2472, DOI 10.3748/wjg.v10.i17.2472
   Jalving M, 2010, EUR J CANCER, V46, P2369, DOI 10.1016/j.ejca.2010.06.012
   Kina S, 2013, EUR J PHARMACOL, V699, P227, DOI 10.1016/j.ejphar.2012.11.014
   Labelle M, 2011, CANCER CELL, V20, P576, DOI 10.1016/j.ccr.2011.09.009
   Leslie M, 2010, SCIENCE, V328, P562, DOI 10.1126/science.328.5978.562
   LEVIN J, 1964, ARCH INTERN MED, V114, P497, DOI 10.1001/archinte.1964.03860100079008
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Liu Y, 2011, CANCER PREV RES, V4, P1296, DOI 10.1158/1940-6207.CAPR-10-0317
   Louandre C, 2013, INT J CANCER, V133, P1732, DOI 10.1002/ijc.28159
   Nishihara R, 2013, JAMA-J AM MED ASSOC, V309, P2563, DOI 10.1001/jama.2013.6599
   Peer D, 2004, CANCER RES, V64, P7562, DOI 10.1158/0008-5472.CAN-03-4046
   Sasaki K, 2012, WORLD J SURG, V36, P192, DOI 10.1007/s00268-011-1329-7
   Shen K, 2012, J CELL BIOCHEM, V113, P2086, DOI 10.1002/jcb.24080
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Sitia G, 2013, J HEPATOL, V4
   Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697
   Stone RL, 2012, NEW ENGL J MED, V366, P610, DOI 10.1056/NEJMoa1110352
   Trousseau A, 1885, CLIN MED HOTEL DIEU, V3, P654
   Wan Shaogui, 2013, J Gastrointest Cancer, V44, P293, DOI 10.1007/s12029-013-9491-9
   Wang HY, 2014, PLATELETS, V25, P382, DOI 10.3109/09537104.2013.827782
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Yu DF, 2013, EXP THER MED, V5, P1351, DOI 10.3892/etm.2013.1003
   Zhou T, 2012, TUMOR BIOL, V33, P1299, DOI 10.1007/s13277-012-0377-4
NR 41
TC 27
Z9 27
U1 0
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 21
PY 2014
VL 14
AR 351
DI 10.1186/1471-2407-14-351
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI4CX
UT WOS:000336814300001
PM 24885890
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Palethorpe, HM
   Tomita, Y
   Smith, E
   Pei, JV
   Townsend, AR
   Price, TJ
   Young, JP
   Yool, AJ
   Hardingham, JE
AF Palethorpe, Helen M.
   Tomita, Yoko
   Smith, Eric
   Pei, Jinxin V.
   Townsend, Amanda R.
   Price, Timothy J.
   Young, Joanne P.
   Yool, Andrea J.
   Hardingham, Jennifer E.
TI The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell
   Migration and Tubulogenesis and Induces Apoptosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE angiogenesis; aquaporin-1 (AQP1); bacopaside II; endothelial cell
   migration
ID METASTATIC COLORECTAL-CANCER; TUMOR ANGIOGENESIS; BEVACIZUMAB; THERAPY;
   CAPECITABINE; OXALIPLATIN; COMBINATION; AUTOPHAGY; MONNIERA; PLANT
AB Expression of aquaporin-1 (AQP1) in endothelial cells is critical for their migration and angiogenesis in cancer. We tested the AQP1 inhibitor, bacopaside II, derived from medicinal plant Bacopa monnieri, on endothelial cell migration and tube-formation in vitro using mouse endothelial cell lines (2H11 and 3B11) and human umbilical vein endothelial cells (HUVEC). The effect of bacopaside II on viability, apoptosis, migration and tubulogenesis was assessed by a proliferation assay, annexin-V/propidium iodide flow cytometry, the scratch wound assay and endothelial tube-formation, respectively. Cell viability was reduced significantly for 2H11 at 15 mu M (p = 0.037), 3B11 at 12.5 mu M (p = 0.017) and HUVEC at 10 mu M (p < 0.0001). At 15 mu M, the reduced viability was accompanied by an increase in apoptosis of 38%, 50% and 32% for 2H11, 3B11 and HUVEC, respectively. Bacopaside II at >= 10 mu M significantly reduced migration of 2H11 (p = 0.0002) and 3B11 (p = 0.034). HUVECs were most sensitive with a significant reduction at 7.5 mu M (p = 0.037). Tube-formation was reduced with a 15 mu M dose for all cell lines and 10 mu M for 3B11 (p < 0.0001). These results suggest that bacopaside II is a potential anti-angiogenic agent.
C1 [Palethorpe, Helen M.; Tomita, Yoko; Smith, Eric; Young, Joanne P.; Hardingham, Jennifer E.] Queen Elizabeth Hosp, Basil Hetzel Inst, Mol Oncol, Woodville South, SA 5011, Australia.
   [Tomita, Yoko; Smith, Eric; Pei, Jinxin V.; Townsend, Amanda R.; Price, Timothy J.; Young, Joanne P.; Yool, Andrea J.; Hardingham, Jennifer E.] Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5005, Australia.
   [Townsend, Amanda R.; Price, Timothy J.] Queen Elizabeth Hosp, Med Oncol, Woodville South, SA 5011, Australia.
RP Hardingham, JE (corresponding author), Queen Elizabeth Hosp, Basil Hetzel Inst, Mol Oncol, Woodville South, SA 5011, Australia.; Hardingham, JE (corresponding author), Univ Adelaide, Adelaide Med Sch, Adelaide, SA 5005, Australia.
EM helen.palethorpe@adelaide.edu.au; yoko.tomita@sa.gov.au;
   eric.smith@adelaide.edu.au; jinxin.pei@adelaide.edu.au;
   amanda.townsend@sa.gov.au; timothy.price@sa.gov.au;
   joanne.young@adelaide.edu.au; andrea.yool@adelaide.edu.au;
   jenny.hardingham@sa.gov.au
RI Palethorpe, Helen Marie/AAC-4219-2022; Smith, Eric/ABG-7104-2020; Smith,
   Eric/Y-1350-2019; Yool, Andrea/AAK-9907-2020
OI Palethorpe, Helen Marie/0000-0003-3803-5113; Smith,
   Eric/0000-0003-2958-3492; Yool, Andrea/0000-0003-1283-585X; Tomita,
   Yoko/0000-0001-7934-2203; Hardingham, Jennifer/0000-0001-8277-1199
FU Australian Research CouncilAustralian Research Council [ARC
   DP160104641]; Hospital Research Foundation
FX This study was partly funded by grants from the Australian Research
   Council to Andrea J. Yool and Jennifer E. Hardingham (ARC DP160104641)
   and from the Hospital Research Foundation to Amanda R. Townsend,
   Jennifer E. Hardingham and Timothy J. Price.
CR Abdollahi A, 2010, DRUG RESIST UPDATE, V13, P16, DOI 10.1016/j.drup.2009.12.001
   AGRE P, 1995, TRANSFUS CLIN BIOL, V2, P303, DOI 10.1016/S1246-7820(05)80096-5
   Bruhn MA, 2014, INT J CANCER, V135, P731, DOI 10.1002/ijc.28698
   Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
   Dorward HS, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0310-6
   Folkman J, 2003, CANCER BIOL THER, V2, pS127
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304
   Monzani E, 2007, CURR DRUG TARGETS, V8, P1132, DOI 10.2174/138945007782151342
   Nguyen TMB, 2007, BLOOD, V109, P4793, DOI 10.1182/blood-2006-11-059352
   Ohta T, 2008, BIOSCI BIOTECH BIOCH, V72, P2436, DOI 10.1271/bbb.80169
   Papadopoulos MC, 2008, PFLUG ARCH EUR J PHY, V456, P693, DOI 10.1007/s00424-007-0357-5
   Pei JXV, 2016, MOL PHARMACOL, V90, P496, DOI 10.1124/mol.116.105882
   Rajabi M., 2017, BIOMEDICINES, V21, P5
   Ramakrishnan S, 2007, AUTOPHAGY, V3, P512
   Russo A, 2005, PHYTOMEDICINE, V12, P305, DOI 10.1016/j.phymed.2003.12.008
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Singh R, 2015, XENOBIOTICA, V45, P741, DOI 10.3109/00498254.2015.1017752
   SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418
   Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
   Tomida C, 2017, J MED INVESTIG, V64, P262, DOI 10.2152/jmi.64.262
   Tomita Y., 2017, INT J MOL SCI, P18
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y
NR 26
TC 19
Z9 21
U1 0
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2018
VL 19
IS 3
AR 653
DI 10.3390/ijms19030653
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA GA4OO
UT WOS:000428309800010
PM 29495367
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Jahangiri, L
   Ishola, T
   Pucci, P
   Trigg, RM
   Pereira, J
   Williams, JA
   Cavanagh, ML
   Gkoutos, GV
   Tsaprouni, L
   Turner, SD
AF Jahangiri, Leila
   Ishola, Tala
   Pucci, Perla
   Trigg, Ricky M.
   Pereira, Joao
   Williams, John A.
   Cavanagh, Megan L.
   Gkoutos, Georgios V.
   Tsaprouni, Loukia
   Turner, Suzanne D.
TI The Role of Autophagy and lncRNAs in the Maintenance of Cancer Stem
   Cells
SO CANCERS
LA English
DT Review
DE cancer stem cells (CSCs); tumour microenvironment; solid cancers;
   haematological malignancies; autophagy; LncRNAs
ID LONG NONCODING RNA; ACUTE MYELOID-LEUKEMIA; SIDE POPULATION CELLS;
   PANCREATIC-CANCER; COLORECTAL-CANCER; INITIATING CELLS; HYPOXIC STRESS;
   SELF-RENEWAL; OF-ORIGIN; C-MYC
AB Simple Summary
   Cancer stem cells (CSCs) represent a distinct cancer subpopulation that can influence the tumour microenvironment, in addition to cancer progression and relapse. A multitude of factors including CSC properties, long noncoding RNAs (lncRNAs), and autophagy play pivotal roles in maintaining CSCs. We discuss the methods of detection of CSCs and how our knowledge of regulatory and cellular processes, and their interaction with the microenvironment, may lead to more effective targeting of these cells. Autophagy and lncRNAs can regulate several cellular functions, thereby promoting stemness factors and CSC properties, hence understanding this triangle and its associated signalling networks can lead to enhanced therapy response, while paving the way for the development of novel therapeutic approaches.
   Cancer stem cells (CSCs) possess properties such as self-renewal, resistance to apoptotic cues, quiescence, and DNA-damage repair capacity. Moreover, CSCs strongly influence the tumour microenvironment (TME) and may account for cancer progression, recurrence, and relapse. CSCs represent a distinct subpopulation in tumours and the detection, characterisation, and understanding of the regulatory landscape and cellular processes that govern their maintenance may pave the way to improving prognosis, selective targeted therapy, and therapy outcomes. In this review, we have discussed the characteristics of CSCs identified in various cancer types and the role of autophagy and long noncoding RNAs (lncRNAs) in maintaining the homeostasis of CSCs. Further, we have discussed methods to detect CSCs and strategies for treatment and relapse, taking into account the requirement to inhibit CSC growth and survival within the complex backdrop of cellular processes, microenvironmental interactions, and regulatory networks associated with cancer. Finally, we critique the computationally reinforced triangle of factors inclusive of CSC properties, the process of autophagy, and lncRNA and their associated networks with respect to hypoxia, epithelial-to-mesenchymal transition (EMT), and signalling pathways.
C1 [Jahangiri, Leila; Ishola, Tala; Cavanagh, Megan L.; Tsaprouni, Loukia] Birmingham City Univ, Dept Life Sci, Birmingham B15 3TN, W Midlands, England.
   [Jahangiri, Leila; Pucci, Perla; Trigg, Ricky M.; Turner, Suzanne D.] Univ Cambridge, Dept Pathol, Div Cellular & Mol Pathol, Cambridge CB2 0QQ, England.
   [Trigg, Ricky M.] GlaxoSmithKline, Dept Funct Genom, Stevenage SG1 2NY, Herts, England.
   [Pereira, Joao] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [Williams, John A.; Gkoutos, Georgios V.] Univ Hosp Birmingham NHS Fdn Trust, Inst Translat Med, Birmingham B15 2TH, W Midlands, England.
   [Williams, John A.; Gkoutos, Georgios V.] Univ Birmingham, Coll Med & Dent Sci, Inst Canc & Genom Sci, Birmingham B15 2SY, W Midlands, England.
   [Gkoutos, Georgios V.] Med Res Council Harwell Inst, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England.
   [Gkoutos, Georgios V.] Univ Birmingham, MRC Hlth Data Res Midlands, Birmingham B15 2TT, W Midlands, England.
   [Gkoutos, Georgios V.] NIHR Expt Canc Med Ctr, Birmingham B15 2TT, W Midlands, England.
   [Gkoutos, Georgios V.] NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham B15 2TT, W Midlands, England.
   [Gkoutos, Georgios V.] NIHR Biomed Res Ctr, Birmingham B15 2TT, W Midlands, England.
   [Turner, Suzanne D.] Masaryk Univ, Cent European Inst Technol CEITEC, Brno 62500, Czech Republic.
RP Jahangiri, L (corresponding author), Birmingham City Univ, Dept Life Sci, Birmingham B15 3TN, W Midlands, England.; Jahangiri, L (corresponding author), Univ Cambridge, Dept Pathol, Div Cellular & Mol Pathol, Cambridge CB2 0QQ, England.; Gkoutos, GV (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Inst Translat Med, Birmingham B15 2TH, W Midlands, England.; Gkoutos, GV (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Inst Canc & Genom Sci, Birmingham B15 2SY, W Midlands, England.; Gkoutos, GV (corresponding author), Med Res Council Harwell Inst, Mammalian Genet Unit, Didcot OX11 0RD, Oxon, England.; Gkoutos, GV (corresponding author), Univ Birmingham, MRC Hlth Data Res Midlands, Birmingham B15 2TT, W Midlands, England.; Gkoutos, GV (corresponding author), NIHR Expt Canc Med Ctr, Birmingham B15 2TT, W Midlands, England.; Gkoutos, GV (corresponding author), NIHR Surg Reconstruct & Microbiol Res Ctr, Birmingham B15 2TT, W Midlands, England.; Gkoutos, GV (corresponding author), NIHR Biomed Res Ctr, Birmingham B15 2TT, W Midlands, England.
EM leila.jahangiri@bcu.ac.uk; tala.ishola@bcu.ac.uk; pp504@cam.ac.uk;
   ricky.m.trigg@gsk.com; jtavaresdasilvapereira@mgh.harvard.edu;
   megan.cavanagh@mail.bcu.ac.uk; g.gkoutos@bham.ac.uk;
   loukia.tsaprouni@bcu.ac.uk; sdt36@cam.ac.uk
RI Turner, Suzanne Dawn/K-4405-2013
OI Turner, Suzanne Dawn/0000-0002-8439-4507; Tsaprouni,
   Loukia/0000-0002-4740-3099; Williams, John/0000-0002-0357-5454;
   Jahangiri, Leila/0000-0003-0235-8447; Pereira, Joao/0000-0002-5587-7593;
   Ishola, Dr. Tala/0000-0002-3067-0553; Pucci, Perla/0000-0003-1264-3487
FU NIHR Birmingham ECMC; NIHR Birmingham SRMRCUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC); Nanocommons Horizon 2020-EU
   [731032]; NIHR Birmingham Biomedical Research Centre; MRC HDR UKUK
   Research & Innovation (UKRI)Medical Research Council UK (MRC)
   [HDRUK/CFC/01]; UK Research and Innovation, Department of Health and
   Social Care (England)
FX G.V.G. acknowledges support from the NIHR Birmingham ECMC, NIHR
   Birmingham SRMRC, Nanocommons Horizon 2020-EU (731032), the NIHR
   Birmingham Biomedical Research Centre, and the MRC HDR UK
   (HDRUK/CFC/01), an initiative funded by UK Research and Innovation,
   Department of Health and Social Care (England) and the devolved
   administrations, and leading medical research charities. The views
   expressed in this publication are those of the authors and not
   necessarily those of the NHS, the National Institute for Health
   Research, the Medical Research Council, or the Department of Health.
CR Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Allan Alison L, 2006, Breast Dis, V26, P87
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Baquero P, 2019, LEUKEMIA, V33, P981, DOI 10.1038/s41375-018-0252-4
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Barzilay R, 2009, STEM CELLS, V27, P2509, DOI 10.1002/stem.172
   Basu-Roy U, 2012, ONCOGENE, V31, P2270, DOI 10.1038/onc.2011.405
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Bellmunt J, 2017, ANN ONCOL, V28, P2481, DOI 10.1093/annonc/mdx400
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bradshaw A, 2016, FRONT SURG, V3, DOI 10.3389/fsurg.2016.00021
   Bruttel VS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00360
   Castro-Oropeza R, 2018, CELL ONCOL, V41, P585, DOI 10.1007/s13402-018-0406-4
   Chaterjee M, 2011, BONE MARROW RES, DOI 10.1155/2011/362938
   Cheray M, 2017, J CELL MOL MED, V21, P244, DOI 10.1111/jcmm.12960
   Chery Jessica, 2016, Postdoc J, V4, P35
   Chi KN, 2017, LANCET ONCOL, V18, P473, DOI 10.1016/S1470-2045(17)30168-7
   Cho RW, 2008, CURR OPIN GENET DEV, V18, P48, DOI 10.1016/j.gde.2008.01.017
   Clark PA, 2012, NEOPLASIA, V14, P420, DOI 10.1596/neo.12432
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Conigliaro A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0426-x
   Courtois S, 2021, GASTRIC CANCER, V24, P133, DOI 10.1007/s10120-020-01118-9
   Crea F, 2016, EPIGENOMICS-UK, V8, P721, DOI 10.2217/epi.16.6
   Crea F, 2014, CANCER METAST REV, V33, P1, DOI 10.1007/s10555-013-9455-3
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Dai DJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0129-x
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   DETER RL, 1967, J CELL BIOL, V33, P437, DOI 10.1083/jcb.33.2.437
   Dick JE, 2005, ANN NY ACAD SCI, V1044, P1, DOI 10.1196/annals.1349.001
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Eades G, 2014, WORLD J CLIN ONCOL, V5, P134, DOI 10.5306/wjco.v5.i2.134
   Esclatine A, 2009, CURR TOP MICROBIOL, V335, P33, DOI 10.1007/978-3-642-00302-8_2
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Flynn Alyssa La Belle, 2019, J Cancer Metastasis Treat, V5, DOI 10.20517/2394-4722.2019.13
   Forde S, 2021, BRIT J HAEMATOL, V192, P354, DOI 10.1111/bjh.17043
   Fu YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102535
   Fu ZQ, 2017, CANCER LETT, V410, P68, DOI 10.1016/j.canlet.2017.09.019
   Fulda Simone, 2010, Int J Cell Biol, V2010, P214074, DOI 10.1155/2010/214074
   Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111
   Galoczova M, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0078-0
   Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504
   Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gong TX, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1543-2
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Han ML, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1145-5
   Hanekamp D, 2017, INT J HEMATOL, V105, P549, DOI 10.1007/s12185-017-2221-5
   Hasmim M, 2017, J IMMUNOL, V198, P1423, DOI 10.4049/jimmunol.1600981
   Held NM, 2015, BIOESSAYS, V37, P867, DOI 10.1002/bies.201500013
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Herreros-Pomares A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1898-1
   Huang RL, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108685
   Huang RL, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01500-8
   Huntly BJP, 2005, NAT REV CANCER, V5, P311, DOI 10.1038/nrc1592
   Islam F, 2015, CRIT REV ONCOL HEMAT, V96, P9, DOI 10.1016/j.critrevonc.2015.04.007
   Iversen PL, 2003, CLIN CANCER RES, V9, P2510
   Jang JE, 2017, AUTOPHAGY, V13, P761, DOI 10.1080/15548627.2016.1278328
   Jiao F, 2015, INT J MOL SCI, V16, P6677, DOI 10.3390/ijms16046677
   Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849
   Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546
   Kiyono K, 2009, CANCER RES, V69, P8844, DOI 10.1158/0008-5472.CAN-08-4401
   Klionsky DJ, 2007, AUTOPHAGY, V3, P181, DOI 10.4161/auto.3678
   L SC, 2007, J BIOL CHEM, V282, P20534, DOI DOI doi:10.1074/jbc.M611782200
   LaBarbera DV, 2012, EXPERT OPIN DRUG DIS, V7, P819, DOI 10.1517/17460441.2012.708334
   Lavalou P, 2019, RNA, V25, P897, DOI 10.1261/rna.069484.118
   Lecerf C, 2019, CELL MOL LIFE SCI, V76, P4673, DOI 10.1007/s00018-019-03240-z
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li HY, 2015, ONCOTARGET, V6, P27847, DOI 10.18632/oncotarget.4443
   Li HY, 2017, MOL CARCINOGEN, V56, P3, DOI 10.1002/mc.22338
   Li LQ, 2018, EUR REV MED PHARMACO, V22, P3402, DOI 10.26355/eurrev_201806_15162
   Li L, 2016, ONCOTARGET, V7, P83828, DOI 10.18632/oncotarget.13912
   Li XC, 2014, INT J ONCOL, V45, P1507, DOI 10.3892/ijo.2014.2544
   Liang XH, 2017, MOL THER, V25, P2075, DOI 10.1016/j.ymthe.2017.06.002
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Liu CC, 2019, INT J CANCER, V145, P2144, DOI 10.1002/ijc.32301
   Liu K, 2017, MOL CELL, V68, P281, DOI 10.1016/j.molcel.2017.09.022
   Liu L, 2013, CELL REP, V4, P189, DOI 10.1016/j.celrep.2013.05.043
   Lleonart ME, 2018, ANTIOXID REDOX SIGN, V28, P1066, DOI 10.1089/ars.2017.7223
   Losuwannarak N, 2019, CANCERS, V11, DOI 10.3390/cancers11122032
   Mandhair HK, 2020, WORLD J STEM CELLS, V12, P303, DOI 10.4252/wjsc.v12.i5.303
   Mari Muriel, 2011, F1000 Biol Rep, V3, P25, DOI 10.3410/B3-25
   Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1784, DOI 10.4161/cc.10.11.15674
   Masciale V, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01394
   Maurizi G, 2018, ONCOGENE, V37, P4626, DOI 10.1038/s41388-018-0292-2
   Maycotte P, 2015, MOL CANCER RES, V13, P651, DOI 10.1158/1541-7786.MCR-14-0487
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Mele L, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102043
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Monastyrska I, 2009, BIOL REV, V84, P431, DOI 10.1111/j.1469-185X.2009.00082.x
   Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562
   Moreira MP, 2018, EXP CELL RES, V363, P283, DOI 10.1016/j.yexcr.2018.01.018
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Murase M, 2009, BRIT J CANCER, V101, P1425, DOI 10.1038/sj.bjc.6605330
   Nakuluri K, 2019, J CELL PHYSIOL, V234, P6503, DOI 10.1002/jcp.27387
   Nazio F, 2019, CELL DEATH DIFFER, V26, P690, DOI 10.1038/s41418-019-0292-y
   Nguyen LV, 2012, NAT REV CANCER, V12, P133, DOI 10.1038/nrc3184
   Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733
   Ogawa T, 2017, ONCOTARGET, V8, P112550, DOI 10.18632/oncotarget.22545
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Panda S, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2004204
   Peiris-Pages M, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0712-6
   Peixoto J, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.033464
   Peng QH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0644-8
   Pennisi E, 2012, SCIENCE, V337, P1159, DOI 10.1126/science.337.6099.1159
   Peperstraete E, 2020, CANCERS, V12, DOI 10.3390/cancers12071730
   Piao LZ, 2018, HUM PATHOL, V80, P152, DOI 10.1016/j.humpath.2018.05.021
   Pickles S, 2018, CURR BIOL, V28, pR170, DOI 10.1016/j.cub.2018.01.004
   Pinero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Ponjavic J, 2007, GENOME RES, V17, P556, DOI 10.1101/gr.6036807
   Praharaj PP, 2021, CANCER LETT, V498, P217, DOI 10.1016/j.canlet.2020.10.036
   Pucci P, 2020, EPIGENOMICS-UK, V12, P1123, DOI 10.2217/epi-2019-0316
   Pucci P, 2018, TRENDS PHARMACOL SCI, V39, P695, DOI 10.1016/j.tips.2018.05.002
   Qiu GC, 2019, INT J ONCOL, V55, P45, DOI 10.3892/ijo.2019.4798
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   Qureshi-Baig K, 2020, AUTOPHAGY, V16, P1436, DOI 10.1080/15548627.2019.1687213
   Rahman MA, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00283
   Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Roberts R, 2013, ESSAYS BIOCHEM, V55, P17, DOI [10.1042/BSE0550017, 10.1042/bse0550017]
   Roobol MJ, 2010, EUR UROL, V58, P475, DOI 10.1016/j.eururo.2010.06.039
   Russell RC, 2014, CELL RES, V24, P42, DOI 10.1038/cr.2013.166
   Rycaj K, 2015, CANCER RES, V75, P4003, DOI 10.1158/0008-5472.CAN-15-0798
   Sasaki Norihiko, 2018, Oncotarget, V9, P34719, DOI 10.18632/oncotarget.26176
   Sekhon HS, 2008, LUNG CANCER, V60, P347, DOI 10.1016/j.lungcan.2007.10.028
   Semenza GL, 2016, MOL ASPECTS MED, V47-48, P15, DOI 10.1016/j.mam.2015.09.004
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen XL, 2018, NUCLEIC ACIDS RES, V46, P1584, DOI 10.1093/nar/gkx1239
   Shi J, 2017, ONCOTARGET, V8, P27582, DOI 10.18632/oncotarget.15175
   Shima H, 2018, BREAST CANCER RES TR, V170, P507, DOI 10.1007/s10549-018-4793-z
   Shiozawa Y, 2016, ONCOTARGET, V7, P41217, DOI 10.18632/oncotarget.9251
   Siebenthall KT, 2019, EBIOMEDICINE, V41, P427, DOI 10.1016/j.ebiom.2019.01.063
   Silvestri G, 2020, BLOOD CANCER DISCOV, V1, P48, DOI [10.1158/2643-3249.BCD-19-0039, 10.1158/0008-5472.BCD-19-0039]
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020
   Sreepadmanabh M, 2018, BIOTECHNOL ADV, V36, P1094, DOI 10.1016/j.biotechadv.2018.03.009
   Sun L, 2018, J CANCER, V9, P2631, DOI 10.7150/jca.24978
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI 10.1093/nar/gky1131
   Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013
   Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13
   Tang KH, 2013, CANCER RES, V73, P2322, DOI 10.1158/0008-5472.CAN-12-2991
   Taniguchi H, 2016, CANCER SCI, V107, P1556, DOI 10.1111/cas.13069
   Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331
   Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187
   Terry S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103044
   Terry S, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1271858
   Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920
   Tong WW, 2018, INT J ONCOL, V53, P469, DOI 10.3892/ijo.2018.4417
   Tooze SA, 2010, NAT CELL BIOL, V12, P831, DOI 10.1038/ncb0910-831
   Vallette FM, 2019, BIOCHEM PHARMACOL, V162, P169, DOI 10.1016/j.bcp.2018.11.004
   van Doeselaar S, 2018, CURR TOP DEV BIOL, V127, P49, DOI 10.1016/bs.ctdb.2017.10.003
   Vidovic D, 2020, CELL DEATH DIFFER, V27, P363, DOI 10.1038/s41418-019-0362-1
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang CH, 2015, BBA-MOL BASIS DIS, V1852, P188, DOI 10.1016/j.bbadis.2014.07.028
   Wang HH, 2017, AM J TRANSL RES, V9, P4785
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Wang LH, 2016, ELIFE, V5, DOI 10.7554/eLife.14620
   Wang SS, 2015, ONCOTARGETS THER, V8, P2973, DOI 10.2147/OTT.S91863
   Wang WT, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0748-z
   Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019
   Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003
   Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501
   Wu Guanming, 2014, F1000Res, V3, P146, DOI 10.12688/f1000research.4431.1
   Wu JY, 2019, J HEPATOL, V70, P918, DOI 10.1016/j.jhep.2018.12.015
   Xie Q, 2015, NAT NEUROSCI, V18, P501, DOI 10.1038/nn.3960
   Xu X, 2015, CANCER LETT, V369, P50, DOI 10.1016/j.canlet.2015.08.018
   Xu XB, 2015, J BIOL CHEM, V290, P16653, DOI 10.1074/jbc.M115.636944
   Xu Z, 2020, PHARMACOL RES, V152, DOI 10.1016/j.phrs.2020.104628
   Xue ZF, 2012, J CELL BIOCHEM, V113, P302, DOI 10.1002/jcb.23356
   Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024
   Yan C, 2018, ANTICANCER RES, V38, P617, DOI 10.21873/anticanres.12266
   Yan C, 2017, CANCER LETT, V388, P34, DOI 10.1016/j.canlet.2016.11.018
   Yan CF, 2020, MOL MED REP, V22, P1295, DOI 10.3892/mmr.2020.11205
   Yan HW, 2018, CANCER LETT, V421, P121, DOI 10.1016/j.canlet.2018.01.027
   Yang M, 2011, CANCER SCI, V102, P1774, DOI 10.1111/j.1349-7006.2011.02028.x
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yang ZT, 2018, HUM PATHOL, V81, P148, DOI 10.1016/j.humpath.2018.07.001
   Yap TA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003854
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan N, 2015, HAEMATOLOGICA, V100, P345, DOI 10.3324/haematol.2014.113324
   Zaarour RF, 2021, CANCERS, V13, DOI 10.3390/cancers13030533
   Zhan YH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1143-7
   Zhang B, 2018, NAT MED, V24, P450, DOI 10.1038/nm.4499
   Zhang B, 2018, BIOCHEM BIOPH RES CO, V503, P1342, DOI 10.1016/j.bbrc.2018.07.046
   Zheng A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1315-8
   Zheng QD, 2018, J CELL MOL MED, V22, P3246, DOI 10.1111/jcmm.13606
   Zhou J, 2015, AUTOPHAGY, V11, P1259, DOI 10.1080/15548627.2015.1056970
   Zhu HT, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-119
   Zhu ZP, 2020, INT J MED SCI, V17, P2040, DOI 10.7150/ijms.46774
   Zhu ZJ, 2020, AGING-US, V12, P20523, DOI 10.18632/aging.103911
NR 198
TC 3
Z9 3
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2021
VL 13
IS 6
AR 1239
DI 10.3390/cancers13061239
PG 31
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RE8BN
UT WOS:000634372400001
PM 33799834
OA Green Published, Green Accepted, gold
DA 2022-04-25
ER

PT J
AU Xiao, YZ
   Sun, LQ
   Fu, YM
   Huang, Y
   Zhou, RR
   Hu, XW
   Zhou, PC
   Quan, J
   Li, N
   Fan, XG
AF Xiao, Yinzong
   Sun, Lunquan
   Fu, Yongming
   Huang, Yan
   Zhou, Rongrong
   Hu, Xingwang
   Zhou, Pengcheng
   Quan, Jun
   Li, Ning
   Fan, Xue-Gong
TI High mobility group box 1 promotes sorafenib resistance in HepG2 cells
   and in vivo
SO BMC CANCER
LA English
DT Article
DE HCC; HMGB1; Sorafenib resistance; Mitochondria
ID HEPATOCELLULAR-CARCINOMA; HMGB1-MEDIATED AUTOPHAGY; REGULATES AUTOPHAGY;
   CANCER CELLS; LIVER-CANCER; HMGB1; APOPTOSIS; OSTEOSARCOMA; EXPRESSION;
   INVASION
AB Background: Primary liver cancer is a lethal malignancy with a high mortality worldwide. Currently, sorafenib is the most effective molecular-targeted drug against hepatocellular carcinoma (HCC). However, the sorafenib resistance rate is high. The molecular mechanism of this resistance has not been fully elucidated. High mobility group box 1 (HMGB1) is a multifaceted protein that plays a key role in the proliferation, apoptosis, metastasis and angiogenesis of HCC cells. In addition, HMGB1 has been suggested to contribute to chemotherapy resistance in tumours, including lung cancer, osteosarcoma, neuroblastoma, leukaemia, and colorectal cancer. This study investigated the association between HMGB1 and sorafenib resistance in HCC.
   Methods: HepG2 cells with HMGB1 knockdown or overexpression were generated. The efficacy of sorafenib in these cells was tested using flow cytometry and a cell counting assay. The subcellular localization of HMGB1 in HepG2 cells following sorafenib treatment was measured by western blotting and confocal microscopy. A murine subcutaneous HCC model was generated to examine the association between HMGB1 and the sensitivity of sorafenib treatment.
   Results: The HMGB1 knockdown cells exhibited a significantly higher apoptotic level and lower cell viability than the normal HMGB1 expressing cells following the sorafenib treatment. In addition, the cell viability observed in the HMGB1 overexpressing cells was higher than that observed in the control cells following the sorafenib intervention. Sorafenib had a better tumour inhibition effect in the HMGB1 knockdown group in vivo. The amount of mitochondrial HMGB1 decreased, while the amount of cytosolic HMGB1 increased following the exposure to sorafenib. Altogether, HMGB1 translocated from the mitochondria to the cytoplasm outside the mitochondria following the exposure of HepG2 cells to sorafenib.
   Conclusions: A novel potential role of HMGB1 in the regulation of sorafenib therapy resistance in HCC was observed. The knockdown of HMGB1 restores sensitivity to sorafenib and enhances HepG2 cell death, while HMGB1 overexpression blunts these effects. The translocation of HMGB1 from the mitochondria to the cytosol following sorafenib treatment provides new insight into sorafenib resistance in HCC.
C1 [Xiao, Yinzong; Fu, Yongming; Huang, Yan; Zhou, Rongrong; Hu, Xingwang; Zhou, Pengcheng; Quan, Jun; Fan, Xue-Gong] Cent S Univ, Dept Infect Dis, Hunan Key Lab Viral Hepatitis, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Sun, Lunquan] Cent S Univ, Ctr Mol Med, Key Lab Mol Radiat Oncol Hunan Prov, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Li, Ning] Cent S Univ, Dept Blood Transfus, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
RP Fan, XG (corresponding author), Cent S Univ, Dept Infect Dis, Hunan Key Lab Viral Hepatitis, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.; Li, N (corresponding author), Cent S Univ, Dept Blood Transfus, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
EM nxli@hotmail.com
RI Hu, Xingwang/ABG-6400-2021
OI Xiao, Yinzong/0000-0001-8360-5352; Hu, Xingwang/0000-0002-2320-3279
FU Special National International Technology Cooperation of China
   [2015DFA31490]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [81272253, 81670538];
   National Major Sciences Research Program of China (973 Program)National
   Basic Research Program of China [2013CB910502]
FX This study was supported by grants from the Special National
   International Technology Cooperation of China (2015DFA31490), the
   National Natural Science Foundation of China (No. 81272253) and the
   National Major Sciences Research Program of China (973 Program) (No.
   2013CB910502) received by XGF. XGF supervised the design of the study
   and critically revised the manuscript. This study was supported by a
   grant from the National Natural Science Foundation of China (No.
   81670538) received by NL; NL was involved in the study design and
   drafting the manuscript.
CR Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   Chen J, 2015, CANCER LETT, V367, P1, DOI 10.1016/j.canlet.2015.06.019
   Chen KF, 2011, J PHARMACOL EXP THER, V337, P155, DOI 10.1124/jpet.110.175786
   Chen RC, 2014, MOL CELL BIOCHEM, V390, P271, DOI 10.1007/s11010-014-1978-6
   Chen RC, 2013, MOL MED, V19, P357, DOI 10.2119/molmed.2013.00099
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Cheng P, 2014, BIOCHEM BIOPH RES CO, V443, P1162, DOI 10.1016/j.bbrc.2013.12.064
   Cui XS, 2008, MOL REPROD DEV, V75, P1290, DOI 10.1002/mrd.20694
   Feng XJ, 2016, TISSUE CELL, V48, P121, DOI 10.1016/j.tice.2015.12.007
   Gauthier A, 2013, HEPATOL RES, V43, P147, DOI 10.1111/j.1872-034X.2012.01113.x
   Gores GJ, 2014, NAT REV GASTRO HEPAT, V11, P645, DOI 10.1038/nrgastro.2014.157
   Guerin R, 2008, MOL BIOL CELL, V19, P4404, DOI 10.1091/mbc.E08-02-0188
   Huang J, 2016, CANCER SCI, V107, P242, DOI 10.1111/cas.12864
   Huang J, 2012, AUTOPHAGY, V8, P275, DOI 10.4161/auto.8.2.18940
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Jiang W, 2012, PATHOL ONCOL RES, V18, P293, DOI 10.1007/s12253-011-9442-3
   Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang R, 2014, MOL ASPECTS MED, V40, P1, DOI 10.1016/j.mam.2014.05.001
   Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495
   Kong Q, 2015, INT J ONCOL, V47, P161, DOI 10.3892/ijo.2015.2985
   Lee HJ, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI DOI 10.1371/J0URNAL.P0NE.0034318
   Li N, 2014, ANN SURG ONCOL, V2014, P1, DOI DOI 10.1111/JCMM.12331)
   Liu FR, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-135
   Liu L., 2010, INT J DIGITAL MULTIM, V2010, P1, DOI DOI 10.1016/I"PSYCHRES.2008.10.024
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]
   Meng QB, 2014, TUMOR BIOL, V35, P12265, DOI 10.1007/s13277-014-2535-3
   Narumi T, 2015, J MOL CELL CARDIOL, V82, P1, DOI 10.1016/j.yjmcc.2015.02.018
   Newell P, 2009, J HEPATOL, V51, P725, DOI 10.1016/j.jhep.2009.03.028
   Ouyang F, 2016, INT J MOL MED, V27, P237
   Pang XA, 2014, INT J MOL SCI, V15, P8699, DOI 10.3390/ijms15058699
   Personeni N, 2013, J CANCER RES CLIN, V139, P1179, DOI 10.1007/s00432-013-1429-x
   Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679
   Shi YH, 2011, AUTOPHAGY, V7, P1159, DOI 10.4161/auto.7.10.16818
   Shimizu S, 2012, INT J CANCER, V131, P548, DOI 10.1002/ijc.26374
   Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024
   Sieghart W, 2012, J HEPATOL, V57, P592, DOI 10.1016/j.jhep.2012.04.034
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Singal AG, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001624
   Soyoung C, 2016, NAT COMMUN, V7, P10384
   Stumbo AC, 2008, CELL BIOL INT, V32, P235, DOI 10.1016/j.cellbi.2007.08.031
   Sun XF, 2014, AUTOPHAGY, V10, P1873, DOI 10.4161/auto.32184
   Sun Y, 2016, ONCOL LETT, V11, P59, DOI 10.3892/ol.2015.3843
   Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008
   Tang DL, 2011, ANTIOXID REDOX SIGN, V15, P2185, DOI 10.1089/ars.2010.3666
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   van Malenstein H, 2013, CANCER LETT, V329, P74, DOI 10.1016/j.canlet.2012.10.021
   Wang Y, 2010, J HEPATOL, V53, P132, DOI 10.1016/j.jhep.2010.02.027
   Wu TY, 2016, ONCOTARGET, V7, P50417, DOI 10.18632/oncotarget.10413
   Xiao JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0090396, 10.1371/journal.pone.0095214]
   Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662
   Zheng H, 2016, DNA CELL BIOL, V35, P622, DOI 10.1089/dna.2016.3360
   Zhou JR, 2013, J NEUROIMMUNOL, V260, P55, DOI 10.1016/j.jneuroim.2013.04.005
NR 57
TC 9
Z9 9
U1 4
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 15
PY 2017
VL 17
AR 857
DI 10.1186/s12885-017-3868-2
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FQ0MU
UT WOS:000418052200004
PM 29246127
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Guan, YP
   Fu, YY
   Liu, Y
   Wang, SY
   Zhao, M
   Jin, ZM
   Jiang, FL
   Hong, L
   Huang, M
   Li, M
   Zhong, GP
AF Guan, Yanping
   Fu, Yuanyuan
   Liu, Yao
   Wang, Siyi
   Zhao, Man
   Jin, Zhongming
   Jiang, Fulin
   Hong, Liang
   Huang, Min
   Li, Min
   Zhong, Guoping
TI Quantitative bioanalytical LC-MS/MS assay for S130 in rat plasma -
   application to a pharmacokinetic study
SO BIOANALYSIS
LA English
DT Article
DE Atg4B inhibitor; bioavailability; LC-MS/MS; pharmacokinetics; PK; rat
   plasma; S130
ID COLORECTAL-CANCER; ATG4B; AUTOPHAGY
AB Aim: An innovative Atg4B inhibitor, S130, exhibited a negative influence on colorectal cancer cells in vitro and in vivo. To assist reliable toxicodynamic and pharmacokinetic evaluation, an LC-MS/MS assay of S130 in rat plasma must be necessary. Results: An LC-MS/MS assay for determination of S130 in rat plasma has been first developed and fully verifiedwhose valuesmet the admissible limits as per the US FDA guidelines. Chromatographic separation was achieved by using an isocratic elution after 3 min. MS was conducted under the ESI+ mode fitted with selected reaction monitoring. The calibration curve proved acceptable linearity over 0.50-800 ng/ml. Conclusion: The developed LC-MS/MS assay of S130 in rat plasma is easily applicable in pharmacokinetics study and the further toxicological evaluation.
C1 [Guan, Yanping; Liu, Yao; Wang, Siyi; Jin, Zhongming; Jiang, Fulin; Huang, Min; Zhong, Guoping] Sun Yat Sen Univ, Sch Pharmaceut Sci, Inst Clin Pharmacol, Guangzhou 510006, Guangdong, Peoples R China.
   [Guan, Yanping; Fu, Yuanyuan; Liu, Yao; Wang, Siyi; Zhao, Man; Jin, Zhongming; Jiang, Fulin; Hong, Liang; Huang, Min; Li, Min; Zhong, Guoping] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Guangdong, Peoples R China.
   [Guan, Yanping] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Pharm, Guangzhou 510120, Guangdong, Peoples R China.
   [Fu, Yuanyuan; Zhao, Man; Hong, Liang; Li, Min] Sun Yat Sen Univ, Sch Pharmaceut Sci, Natl & Local United Engn Lab Druggabil & New Drug, Guangzhou 510006, Guangdong, Peoples R China.
RP Zhong, GP (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Inst Clin Pharmacol, Guangzhou 510006, Guangdong, Peoples R China.; Zhong, GP (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Design & Evaluat, Guangzhou 510006, Guangdong, Peoples R China.
EM zhonggp@mail.sysu.edu.cn
RI 管, 宴萍/AAL-5308-2020
FU National Key Research and Development Program [2017YFC0909303,
   2016YFC0905001]; Guangdong Science and Technology Planning Project
   [2016A040403047]; National Natural Science Foundation of ChinaNational
   Natural Science Foundation of China (NSFC) [31671437]; National Science
   and Technology Major Project of the Ministry of Science and Technology
   of China [2018ZX09735010]; Natural Science Foundation of Guangdong
   Province, ChinaNational Natural Science Foundation of Guangdong Province
   [2016A030313335]; Guangdong Provincial Key Laboratory of Construction
   Foundation [2017B030314030]
FX The authors appreciate the financial support provided by The National
   Key Research and Development Program (no. 2017YFC0909303), The Guangdong
   Science and Technology Planning Project (no. 2016A040403047); the
   National Key Research and Development Program (no. 2016YFC0905001);
   National Natural Science Foundation of China (no. 31671437); The
   National Science and Technology Major Project of the Ministry of Science
   and Technology of China (no. 2018ZX09735010); The Natural Science
   Foundation of Guangdong Province, China (no. 2016A030313335), and
   Guangdong Provincial Key Laboratory of Construction Foundation (no.
   2017B030314030). The authors have no other relevant affiliations or
   financial involvement with any organization or entity with a financial
   interest in or financial conflict with the subject matter or materials
   discussed in the manuscript apart from those disclosed.
CR Akabane R, 2018, J VET PHARMACOL THER, V41, P457, DOI 10.1111/jvp.12487
   Akin D, 2014, AUTOPHAGY, V10, P2021, DOI 10.4161/auto.32229
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   CLSI, 2007, C50A CLSI
   European Medicines Agency, 2012, GUIDELINE BIOANALYTI
   Fu Y., 2018, AUTOPHAGY, P1
   Li M, 2017, METHOD ENZYMOL, V587, P207, DOI 10.1016/bs.mie.2016.10.024
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Marino G, 2003, J BIOL CHEM, V278, P3671, DOI 10.1074/jbc.M208247200
   Marmol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Mei SH, 2018, J CHROMATOGR B, V1072, P199, DOI 10.1016/j.jchromb.2017.11.024
   Panczyk M, 2014, WORLD J GASTROENTERO, V20, P9775, DOI 10.3748/wjg.v20.i29.9775
   Pang HX, 2016, CLIN DRUG INVEST, V36, P713, DOI 10.1007/s40261-016-0418-7
   Qiu ZX, 2016, ACS MED CHEM LETT, V7, P802, DOI 10.1021/acsmedchemlett.6b00208
   Rothe K, 2014, BLOOD, V123, P3622, DOI 10.1182/blood-2013-07-516807
   Shu CW, 2011, J BIOMOL SCREEN, V16, P174, DOI 10.1177/1087057110392996
   Smith BP, 2000, PHARMACEUT RES, V17, P1278, DOI 10.1023/A:1026451721686
   Sun JL, 2013, J ETHNOPHARMACOL, V148, P617, DOI 10.1016/j.jep.2013.05.013
   US FDA, 2018, GUID IND 2018 BIOAN
   US FDA, 2013, DRAFT GUID IND 2013
   Zhang L, 2016, CANCER LETT, V373, P19, DOI 10.1016/j.canlet.2016.01.022
NR 21
TC 4
Z9 4
U1 5
U2 21
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 1757-6180
EI 1757-6199
J9 BIOANALYSIS
JI Bioanalysis
PD AUG
PY 2019
VL 11
IS 16
BP 1469
EP 1481
DI 10.4155/bio-2019-0101
PG 13
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JF4JS
UT WOS:000491354600003
PM 31512492
DA 2022-04-25
ER

PT J
AU Liu, Z
   Wang, F
   Ma, H
   Xia, HC
   Tian, JH
   Sun, T
AF Liu, Zheng
   Wang, Feng
   Ma, Hui
   Xia, Hechun
   Tian, Jihui
   Sun, Tao
TI Amentoflavone induces cell cycle arrest, apoptosis, and autophagy in
   BV-2 cells
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Epilepsy; Amentoflavone; BV-2 cells; Apoptosis; Cell cycle arrest;
   Autophagy
ID COLORECTAL-CANCER; EPILEPSY; PATHWAY; GROWTH; PROLIFERATION;
   INFLAMMATION; GENES; PHASE; NEUROPROTECTION; SUPPRESSION
AB Previous studies have shown that amentoflavone (AF) elicits anti-inflammatory and neuroprotective effects. To further investigate the effects of AF on the microglia cell line BV-2, proteomic analysis was performed to screen potential key regulators. The top 5 canonical pathways associated with AF treatment were EIF2 signaling, regulation of eIF4 and p70s6k signaling, mTOR signaling, protein ubiquitination pathway and phagosome maturation. The top up-regulated genes were DOCK2, SEC23A, ME1, UGGT1 and STOM, while the most down-regulated molecules were IGF2R, ATP5O, DDX47, WBP11 and IKBIP. AF significantly decreased BV-2 cell proliferation. It induced cell cycle arrest at G2/M, increased CDK2, p27Kip1 and p53/p-p53, and decreased CDK1/CDC2 and cyclin B1. Cell apoptosis was induced, with increased levels of BAX, c-caspase-3 and ccaspase-9, and decreased levels of BCL-XL. Increased level of autophagosome induced by AF was observed, and increased Beclin-1 and decreased phosphorylation of PI3K and Erk1 were found as well. In conclusion, AF induces cell cycle arrest at G2/M, promotes apoptosis and autophagy in BV-2 cells, which may account for the anti-inflammatory effect of AF in epilepsy.
C1 [Liu, Zheng; Wang, Feng; Ma, Hui; Xia, Hechun; Tian, Jihui; Sun, Tao] Ningxia Med Univ, Dept Neurosurg, Gen Hosp, 804 South Shengli St, Yinchuan 750004, Ningxia, Peoples R China.
   [Liu, Zheng; Wang, Feng; Sun, Tao] Ningxia Med Univ, Incubat Base Natl Key Lab, Ningxia Key Lab Cerebrocranial Dis, Yinchuan 750004, Ningxia, Peoples R China.
RP Sun, T (corresponding author), Ningxia Med Univ, Dept Neurosurg, Gen Hosp, 804 South Shengli St, Yinchuan 750004, Ningxia, Peoples R China.
EM ssldeng@sina.com
OI Sun, Tao/0000-0001-8062-3432
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81460208]; Ningxia Brain Project-the Basic
   and Clinical Research on the Temporal-insular Network, Epilepsy and
   Cognitive Function [2016BZ07]; Key Research and Development Projects of
   Ningxia Hui Autonomous Region [2018BEG03023]
FX The authors appreciate the financial support from the National Natural
   Science Foundation of China (Grant No.: 81460208), Ningxia Brain
   Project-the Basic and Clinical Research on the Temporal-insular Network,
   Epilepsy and Cognitive Function (Grant No.: 2016BZ07) and the Key
   Research and Development Projects of Ningxia Hui Autonomous Region
   (Grant No.: 2018BEG03023).
CR Al-Dwairi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113058
   An JG, 2016, MOL CELL BIOCHEM, V413, P87, DOI 10.1007/s11010-015-2641-6
   Aronica E, 2011, EPILEPSIA, V52, P26, DOI 10.1111/j.1528-1167.2011.03033.x
   Bacevic K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12868-5
   Baude A, 2016, NUCLEIC ACIDS RES, V44, P2214, DOI 10.1093/nar/gkv1526
   Birt DF, 2009, PHARM BIOL, V47, P774, DOI 10.1080/13880200902988645
   Chen XQ, 2018, NEUROCHEM RES, V43, P1491, DOI 10.1007/s11064-018-2570-3
   Choi EJ, 2009, J NUTR BIOCHEM, V20, P285, DOI 10.1016/j.jnutbio.2008.03.005
   Dambach H, 2014, EPILEPSIA, V55, P184, DOI 10.1111/epi.12473
   Faustmann PM, 2003, GLIA, V42, P101, DOI 10.1002/glia.10141
   Gu L, 2013, EPILEPSY RES, V105, P195, DOI 10.1016/j.eplepsyres.2013.02.002
   Hansen RS, 2005, EUR J PHARMACOL, V519, P199, DOI 10.1016/j.ejphar.2005.06.036
   Hausenloy DJ, 2004, CARDIOVASC RES, V61, P448, DOI 10.1016/j.cardiores.2003.09.024
   Hofer-Warbinek R, 2004, CELL DEATH DIFFER, V11, P1317, DOI 10.1038/sj.cdd.4401502
   Hsu SC, 2008, J ETHNOPHARMACOL, V120, P394, DOI 10.1016/j.jep.2008.09.025
   Hwang IS, 2012, MYCOPATHOLOGIA, V173, P207, DOI 10.1007/s11046-011-9503-x
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Jeong EJ, 2014, FOOD CHEM TOXICOL, V64, P397, DOI 10.1016/j.fct.2013.12.003
   Jimenez-Marin Angeles, 2009, BMC Proc, V3 Suppl 4, pS6, DOI 10.1186/1753-6561-3-S4-S6
   Jung HJ, 2007, BIOL PHARM BULL, V30, P1969, DOI 10.1248/bpb.30.1969
   Kang SS, 2005, BIOORG MED CHEM LETT, V15, P3588, DOI 10.1016/j.bmcl.2005.05.078
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   Lee JH, 2005, BIOTECHNOL LETT, V27, P623, DOI 10.1007/s10529-005-3628-2
   Lee S, 2011, J MED FOOD, V14, P808, DOI 10.1089/jmf.2010.1428
   Lenne-Gouverneur AF, 1999, MOL MEMBR BIOL, V16, P157, DOI 10.1080/096876899294616
   Li CL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2628-z
   Li YC, 2014, CANCER LETT, V344, P239, DOI 10.1016/j.canlet.2013.11.001
   Liu H, 2016, STROKE VASC NEUROL, V1, P52, DOI 10.1136/svn-2016-000012
   Masuch A, 2016, GLIA, V64, P76, DOI 10.1002/glia.22904
   Michalec B, 2010, INT J BIOCHEM CELL B, V42, P736, DOI 10.1016/j.biocel.2010.01.011
   Nadimpalli R, 2000, J BIOL CHEM, V275, P29579, DOI 10.1074/jbc.M002339200
   Nunez L, 2009, UDP GLUCOSE GLYCOPRO
   Oh J, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/761506
   Ou JM, 2014, INT J ONCOL, V45, P1241, DOI 10.3892/ijo.2014.2512
   Pei JS, 2012, IN VIVO, V26, P963
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pluskal T, 2018, CHEM SOC REV, V47, P1592, DOI 10.1039/c7cs00411g
   Schimmel P, 2002, P NATL ACAD SCI USA, V99, P15518, DOI [10.1073/pnas.012602099, DOI 10.1073/PNAS.012602099]
   Shin DH, 2006, J NEUROCHEM, V96, P561, DOI 10.1111/j.1471-4159.2005.03582.x
   Singh A, 2016, NEUROL CLIN, V34, P837, DOI 10.1016/j.ncl.2016.06.015
   Siveen KS, 2011, J ENVIRON PATHOL TOX, V30, P301, DOI 10.1615/JEnvironPatholToxicolOncol.v30.i4.30
   Sun D, 2018, CURR MED SCI, V38, P70, DOI 10.1007/s11596-018-1848-7
   Szeliga M, 2014, TUMOR BIOL, V35, P1855, DOI 10.1007/s13277-013-1247-4
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Thomas MP, 2015, CELL REP, V11, P1079, DOI 10.1016/j.celrep.2015.04.026
   Thulasitha WS, 2016, COMP BIOCHEM PHYS C, V185, P29, DOI 10.1016/j.cbpc.2016.02.005
   van Riel B, 2012, MOL CELL BIOL, V32, P3814, DOI 10.1128/MCB.05938-11
   Vezzani A, 2005, EPILEPSIA, V46, P1724, DOI 10.1111/j.1528-1167.2005.00298.x
   Vezzani A, 2011, EPILEPSIA, V52, P1, DOI 10.1111/j.1528-1167.2011.03028.x
   Vezzani A, 2013, EXP NEUROL, V244, P11, DOI 10.1016/j.expneurol.2011.09.033
   Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069
   Wang L, 2010, BIOCHEM BIOPH RES CO, V395, P111, DOI 10.1016/j.bbrc.2010.03.148
   Wang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep44265
   Wang LN, 2019, ONCOGENE, V38, P3134, DOI 10.1038/s41388-018-0642-0
   Wondergem N, 2001, J PHYSIOL-LONDON, V532, P661, DOI 10.1111/j.1469-7793.2001.0661e.x
   [杨雨 Yang Yu], 2014, [南方医科大学学报, Journal of Southern Medical University], V34, P1035
   Yin MB, 1999, EXP CELL RES, V247, P189, DOI 10.1006/excr.1998.4346
   Yuan CX, 2015, DRUG DES DEV THER, V9, P1293, DOI 10.2147/DDDT.S74964
   Zhang JL, 2014, BURNS, V40, P922, DOI 10.1016/j.burns.2013.10.012
   Zhang YF, 2013, ONCOL LETT, V5, P749, DOI 10.3892/ol.2013.1116
   Zhang Z, 2015, NEURAL REGEN RES, V10, P1125, DOI 10.4103/1673-5374.160109
   Zhao Y, 2012, MAR DRUGS, V10, P1345, DOI 10.3390/md10061345
NR 63
TC 4
Z9 4
U1 3
U2 19
PU FRONTIERS IN BIOSCIENCE INC
PI IRVINE
PA 16471 SCIENTIFIC WAY, IRVINE, CA 92618 USA
SN 1093-9946
EI 1093-4715
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD JAN 1
PY 2020
VL 25
BP 798
EP 816
DI 10.2741/4835
PG 19
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA NG1TK
UT WOS:000563769400001
PM 31585918
DA 2022-04-25
ER

PT J
AU Lu, Y
   Shi, CM
   Qiu, SB
   Fan, Z
AF Lu, Yang
   Shi, Chunmei
   Qiu, Songbo
   Fan, Zhen
TI Identification and validation of COX-2 as a co-target for overcoming
   cetuximab resistance in colorectal cancer cells
SO ONCOTARGET
LA English
DT Article
DE EGFR; cetuximab; COX-2; COX-2 inhibitor; colorectal cancer
ID GROWTH-FACTOR-RECEPTOR; MONOCLONAL-ANTIBODY; K-RAS; ACQUIRED-RESISTANCE;
   MUTATION STATUS; EGF RECEPTOR; CYCLOOXYGENASE-2; INHIBITION; APOPTOSIS;
   CELECOXIB
AB Cetuximab, an epidermal growth factor receptor (EGFR)-blocking antibody, was approved for treatment of metastatic colorectal cancer over a decade ago; however, patients' responses to cetuximab vary substantially due to intrinsic and acquired resistance to cetuximab. Here, we report our findings using Affymetrix HG-U133A array to examine changes in global gene expression between DiFi, a human colorectal cancer cell line that is highly sensitive to cetuximab, and two other cell lines: DiFi5, a DiFi subline with acquired resistance to cetuximab, and DiFi-AG, a DiFi subline with acquired resistance to the EGFR tyrosine kinase inhibitor AG1478 but sensitivity to cetuximab. We identified prostaglandin-endoperoxide synthase 2 (PTGS2), which encodes cyclooxygenase-2 (COX-2), as the gene with the greatest difference between the cetuximab-resistant DiFi5 cells and the cetuximab-sensitive DiFi cells and DiFi-AG cells. Reverse transcription polymerase chain reaction and Western blotting validated upregulation of COX-2 in DiFi5 but not in DiFi or DiFi-AG cells. We developed COX-2 knockdown stable clones from DiFi5 cells and demonstrated that genetic knockdown of COX-2 partially re-sensitized DiFi5 cells to cetuximab. We further confirmed that cetuximab in combination with a COX-2 inhibitor led to cell death via apoptosis or autophagy not only in DiFi5 cells but also in another colorectal cancer cell line naturally resistant to cetuximab. Our findings support further evaluation of the strategy of combining cetuximab and a COX-2 inhibitor for treatment of metastatic colorectal cancer.
C1 [Lu, Yang; Shi, Chunmei; Qiu, Songbo; Fan, Zhen] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Shi, Chunmei] Fujian Med Univ, Union Hosp, Dept Oncol, Fuzhou 350001, Fujian, Peoples R China.
RP Fan, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA.
EM zfan@mdanderson.org
FU US National Institutes of Health (NIH)United States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USA [CA129036,
   CA179015]; NIH through MD Anderson's Cancer Center Support Grant
   [CA016672]; NATIONAL CANCER INSTITUTEUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R01CA179015, R01CA129036, P30CA016672] Funding
   Source: NIH RePORTER
FX This work was supported in part by US National Institutes of Health
   (NIH) R01 awards CA129036 and CA179015. The work was also supported in
   part by the NIH through MD Anderson's Cancer Center Support Grant,
   CA016672. We thank the staff of the Flow Cytometry and Cellular Imaging
   Core Facility for technical assistance and thank Stephanie Deming of the
   Department of Scientific Publications at The University of Texas MD
   Anderson Cancer Center for editorial assistance.
CR Asting AG, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-511
   Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107
   Chan Emily, 2011, Am J Clin Oncol, V34, P581, DOI 10.1097/COC.0b013e3181fe46a1
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Drey LL, 2013, BIOTECHNIQUES, V55, P28, DOI 10.2144/000114056
   Gavet O, 2010, DEV CELL, V18, P533, DOI 10.1016/j.devcel.2010.02.013
   Graham J, 2004, NAT REV DRUG DISCOV, V3, P549, DOI 10.1038/nrd1445
   Jalili A, 2008, J DTSCH DERMATOL GES, V6, P1066, DOI 10.1111/j.1610-0387.2008.06861.x
   Jensen EC, 2013, ANAT REC, V296, P378, DOI 10.1002/ar.22641
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Kim SH, 2014, INVEST NEW DRUG, V32, P1105, DOI 10.1007/s10637-014-0144-z
   Koehne CH, 2004, SEMIN ONCOL, V31, P12, DOI 10.1053/j.seminoncol.2004.03.041
   Li F, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-27
   Li XQ, 2008, MOL CANCER THER, V7, P1207, DOI 10.1158/1535-7163.MCT-07-2187
   Li XQ, 2015, ONCOTARGET, V6, P11507, DOI 10.18632/oncotarget.3432
   Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Liu B, 2000, BRIT J CANCER, V82, P1991
   Liu BL, 2001, ONCOGENE, V20, P3726, DOI 10.1038/sj.onc.1204490
   Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277
   Lu HY, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/124958
   Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589
   Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015823
   Lurje G, 2008, CLIN CANCER RES, V14, P7884, DOI 10.1158/1078-0432.CCR-07-5165
   Marnett LJ, 2002, ANNU REV PHARMACOL, V42, P55, DOI 10.1146/annurev.pharmtox.42.082301.164620
   McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401
   Midgley RS, 2010, J CLIN ONCOL, V28, P4575, DOI 10.1200/JCO.2010.29.6244
   Ng K, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju345
   Ninomiya I, 2012, ONCOL REP, V28, P777, DOI 10.3892/or.2012.1885
   Noda M, 2002, J GASTROENTEROL, V37, P896, DOI 10.1007/s005350200151
   Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1
   Pan CX, 2005, ONCOLOGY-BASEL, V69, P63, DOI 10.1159/000087302
   Roelofs HMJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-1
   Shin DM, 2013, CLIN CANCER RES, V19, P1244, DOI 10.1158/1078-0432.CCR-12-3149
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thierry AR, 2014, NAT MED, V20, P430, DOI 10.1038/nm.3511
   Vallbohmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/JCO.2005.09.100
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421
   Williams CS, 2000, CANCER RES, V60, P6045
   WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871
   Wu XP, 1996, ONCOGENE, V12, P1397
NR 44
TC 16
Z9 16
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 4
PY 2016
VL 7
IS 40
BP 64766
EP 64777
DI 10.18632/oncotarget.8649
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EB3QQ
UT WOS:000387281000018
PM 27074568
OA gold, Green Published, Green Submitted
DA 2022-04-25
ER

PT J
AU Tacar, O
   Indumathy, S
   Tan, ML
   Baindur-Hudson, S
   Friedhuber, AM
   Dass, CR
AF Tacar, Oktay
   Indumathy, Sivanjah
   Tan, Mei Lin
   Baindur-Hudson, Swati
   Friedhuber, Anna M.
   Dass, Crispin R.
TI Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin
   treatment: comparison with osteosarcoma cells
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE apoptosis; autophagy; Bax; Beclin-1; cardiotoxicity
ID DOWN-REGULATION; CANCER; CARDIOTOXICITY; MITOCHONDRIAL; CHEMOTHERAPY;
   ADRIAMYCIN; DELIVERY; THERAPY; STRESS; TARGET
AB ObjectiveDoxorubicin (Dox) is a frontline chemotherapeutic against osteosarcoma (OS) that is plagued by side effects, particularly in the heart. The specific objective of this article is to investigate whether low-dose Dox treatment had pro-autophagic effects in cardiomyocytes as well as osteosarcoma cells.
   MethodsThis study characterises apoptotic (Bax) and autophagic (Beclin-1) biomarker levels in human OS and cardiomyocyte cell lines as well as in various tissues when mice are exposed to low (1mg/kg, thrice weekly) and high (3mg/kg thrice weekly) dose Dox for a month.
   Key findingsThere was a decrease in Bax and increase in Beclin-1 in cardiac tissue in the high-dose group. Dox decreased Beclin-1 in the skin and liver, with no clear indication in the stomach, small intestine and testis. At low Dox doses of 10 and 100nm in cardiomyocytes and OS cells, there is a pro-apoptotic effect, with a quicker response in the 100-nm condition, and a slower but steady increase of a pro-apoptotic response at the lower 10-nm dose. However, electron microscopy images revealed changes to human OS cells that resembled autophagy. Human prostate, breast and colorectal cells treated with 10-nm Dox showed approximate to 40% reduction in cell viability after 24h.
   ConclusionIn culture, cells of both cardiomyocytes and OS revealed a predominant pro-apoptotic response at the expense of autophagy, although both seemed to be occurring in vivo.
C1 [Tacar, Oktay; Indumathy, Sivanjah; Baindur-Hudson, Swati] Victoria Univ, Coll Hlth & Biomed, Melbourne, Vic 8001, Australia.
   [Tan, Mei Lin] St Vincents Hlth, Dept Orthopaed, Melbourne, Vic, Australia.
   [Friedhuber, Anna M.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
   [Dass, Crispin R.] Curtin Univ, Curtin Biosci Res Precinct, Perth, WA 6845, Australia.
   [Dass, Crispin R.] Curtin Univ, Sch Pharm, Perth, WA 6102, Australia.
RP Dass, CR (corresponding author), Curtin Univ, Sch Pharm, Bldg 306,Brand Dr, Perth, WA 6102, Australia.
EM crispin.dass@curtin.edu.au
FU Academic50 grant
FX This study was supported by the Academic50 grant support to CRD.
CR Akiyama T, 2010, BIOCHEM BIOPH RES CO, V391, P789, DOI 10.1016/j.bbrc.2009.11.139
   Ashley N, 2009, BIOCHEM BIOPH RES CO, V378, P450, DOI 10.1016/j.bbrc.2008.11.059
   Auvinen PK, 2010, TUMORI J, V96, P271, DOI 10.1177/030089161009600214
   Balli E, 2004, HISTOL HISTOPATHOL, V19, P1101, DOI 10.14670/HH-19.1101
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Carvalho C, 2009, CURR MED CHEM, V16, P3267, DOI 10.2174/092986709788803312
   Chatterjee K, 2010, CARDIOLOGY, V115, P155, DOI 10.1159/000265166
   Clark JCM, 2011, CANCER-AM CANCER SOC, V117, P3517, DOI 10.1002/cncr.25757
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Dass CR, 2008, J PHARM PHARMACOL, V60, P405, DOI 10.1211/jpp.60.4.0001
   Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585-006-9046-6
   Dass CR, 2005, CLIN EXP METASTAS, V22, P643, DOI 10.1007/s10585-006-9004-3
   Dekaney CM, 2009, AM J PHYSIOL-GASTR L, V297, pG461, DOI 10.1152/ajpgi.90446.2008
   Devarajan E, 2002, ONCOGENE, V21, P8843, DOI 10.1038/sj.onc.1206044
   Djavaheri-Mergny M, 2010, ONCOGENE, V29, P1717, DOI 10.1038/onc.2009.519
   Drevs J, 2004, ANTICANCER RES, V24, P1759
   Ek ETH, 2007, J ORTHOP RES, V25, P1671, DOI 10.1002/jor.20434
   Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4
   Giuliani CM, 2014, J PHARM PHARMACOL, V66, P597, DOI 10.1111/jphp.12191
   Giuliani CM, 2013, J PHARM PHARMACOL, V65, P777, DOI 10.1111/jphp.12034
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kaushal V, 2004, J THROMB HAEMOST, V2, P327, DOI 10.1046/j.1538-7933.2003.00573.x
   Lennernas B, 2003, ACTA ONCOL, V42, P294, DOI 10.1080/02841860310001835
   McLoon LK, 1998, MUSCLE NERVE, V21, P1457, DOI 10.1002/(SICI)1097-4598(199811)21:11<1457::AID-MUS14>3.3.CO;2-U
   Nithipongvanitch R, 2007, ANTIOXID REDOX SIGN, V9, P1001, DOI 10.1089/ars.2007.1632
   RUSHING DA, 1994, CANCER, V74, P834, DOI 10.1002/1097-0142(19940801)74:3<834::AID-CNCR2820740308>3.0.CO;2-9
   RUSSELL LD, 1991, AM J ANAT, V192, P142, DOI 10.1002/aja.1001920205
   Sakr SA, 2012, TOXICOL IND HEALTH, V28, P876, DOI 10.1177/0748233711425076
   Shiozawa Y, 2013, PHARMACOL THERAPEUT, V138, P285, DOI 10.1016/j.pharmthera.2013.01.014
   Sishi BJN, 2012, EXP BIOL MED, V237, P219, DOI 10.1258/ebm.2011.011106
   Ta HT, 2009, BIOMATERIALS, V30, P3605, DOI 10.1016/j.biomaterials.2009.03.022
   Tacar O, 2013, J PHARM PHARMACOL, V65, P1577, DOI 10.1111/jphp.12144
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x
   Tan ML, 2010, BIOMATERIALS, V31, P541, DOI 10.1016/j.biomaterials.2009.09.069
   Tan ML, 2013, J PHARM PHARMACOL, V65, P35, DOI 10.1111/j.2042-7158.2012.01572.x
   Tan ML, 2009, CANCER BIOL THER, V8, P106, DOI 10.4161/cbt.8.2.7385
   The American Cancer Society, 2012, FACTS AND FIG
   Umlauf J, 2002, Exp Clin Cardiol, V7, P35
   Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664
   Wirawan E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.16
   Zhu WQ, 2009, CIRCULATION, V119, P99, DOI 10.1161/CIRCULATIONAHA.108.799700
NR 41
TC 9
Z9 11
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD FEB
PY 2015
VL 67
IS 2
BP 231
EP 243
DI 10.1111/jphp.12324
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AZ9BU
UT WOS:000348507100009
PM 25208656
DA 2022-04-25
ER

PT J
AU Rivas-Garcia, L
   Quiles, JL
   Varela-Lopez, A
   Giampieri, F
   Battino, M
   Bettmer, J
   Montes-Bayon, M
   Llopis, J
   Sanchez-Gonzalez, C
AF Rivas-Garcia, Lorenzo
   Quiles, Jose Luis
   Varela-Lopez, Alfonso
   Giampieri, Francesca
   Battino, Maurizio
   Bettmer, Jorg
   Montes-Bayon, Maria
   Llopis, Juan
   Sanchez-Gonzalez, Cristina
TI Ultra-Small Iron Nanoparticles Target Mitochondria Inducing Autophagy,
   Acting on Mitochondrial DNA and Reducing Respiration
SO PHARMACEUTICS
LA English
DT Article
DE nanotechnology; mitochondria; respiration; mtDNA deletions; copy number;
   metals
AB The application of metallic nanoparticles (materials with size at least in one dimension ranging from 1 to 100 nm) as a new therapeutic tool will improve the diagnosis and treatment of diseases. The mitochondria could be a therapeutic target to treat pathologies whose origin lies in mitochondrial dysfunctions or whose progression is dependent on mitochondrial function. We aimed to study the subcellular distribution of 2-4 nm iron nanoparticles and its effect on mitochondrial DNA (mtDNA), mitochondrial function, and autophagy in colorectal cell lines (HT-29). Results showed that when cells were exposed to ultra-small iron nanoparticles, their subcellular fate was mainly mitochondria, affecting its respiratory and glycolytic parameters, inducing the migration of the cellular state towards quiescence, and promoting and triggering the autophagic process. These effects support the potential use of nanoparticles as therapeutic agents using mitochondria as a target for cancer and other treatments for mitochondria-dependent pathologies.
C1 [Rivas-Garcia, Lorenzo; Quiles, Jose Luis; Varela-Lopez, Alfonso; Llopis, Juan; Sanchez-Gonzalez, Cristina] Univ Granada, Fac Pharm, Dept Physiol Inst Nutr & Food Technol, Biomed Res Ctr, Avda Conocimiento S-N, Armilla 18071, Spain.
   [Rivas-Garcia, Lorenzo; Llopis, Juan; Sanchez-Gonzalez, Cristina] Univ Granada, Sport & Hlth Res Ctr, C Menendez Pelayo 32, Armilla 18016, Spain.
   [Quiles, Jose Luis] Univ Europea Atlantico UEA, Ctr Nutr & Hlth, Santander 39011, Spain.
   [Giampieri, Francesca; Battino, Maurizio] Polytech Univ Marche, Dept Clin Specialist & Odontostomatol Sci DISCO S, Biochem, I-60131 Ancona, Italy.
   [Giampieri, Francesca] King Abdulaziz Univ, Dept Biochem, Fac Sci, Jeddah 21589, Saudi Arabia.
   [Battino, Maurizio] Jiangsu Univ, Int Res Ctr Food Nutr & Safety, Zhenjiang 212013, Jiangsu, Peoples R China.
   [Bettmer, Jorg; Montes-Bayon, Maria] Univ Oviedo, Dept Analyt Chem, Fac Chem, Oviedo 33007, Spain.
   [Bettmer, Jorg; Montes-Bayon, Maria] Univ Oviedo, Inst Invest Sanitaria Principado Asturias ISPA, Oviedo 33007, Spain.
RP Sanchez-Gonzalez, C (corresponding author), Univ Granada, Fac Pharm, Dept Physiol Inst Nutr & Food Technol, Biomed Res Ctr, Avda Conocimiento S-N, Armilla 18071, Spain.; Sanchez-Gonzalez, C (corresponding author), Univ Granada, Sport & Hlth Res Ctr, C Menendez Pelayo 32, Armilla 18016, Spain.
EM lorenrivas@ugr.es; jlquiles@ugr.es; alvarela@ugr.es;
   f.giampieri@staff.univpm.it; m.a.battino@staff.univpm.it;
   bettmerjorg@uniovi.es; montesmaria@uniovi.es; jllopis@ugr.es;
   crissg@ugr.es
RI Varela-López, Alfonso/F-8055-2016; García, Lorenzo Rivas/ABD-6217-2020;
   Battino, Maurizio/E-6103-2012; Giampieri, Francesca/I-1911-2015; Quiles,
   José L./C-6911-2013; Sanchez Gonzalez, Cristina/Q-6219-2017
OI Varela-López, Alfonso/0000-0002-0504-5086; Battino,
   Maurizio/0000-0002-7250-1782; Giampieri, Francesca/0000-0002-8151-9132;
   Quiles, José L./0000-0002-9048-9086; /0000-0002-0413-8432; Sanchez
   Gonzalez, Cristina/0000-0002-1044-4858
FU government of Asturias through the Science, Technology and Innovation
   Plan (PCTI) - FEDER funds [FC-GRUPIN-IDI/2018/000242]; Spanish Ministry
   of Economy, Industry and Competitiveness (MINECO) [CTQ2016-80069-C 2-1R,
   RTI2018-094605-B-I00]
FX Regional funding from the government of Asturias through the Science,
   Technology and Innovation Plan (PCTI) cofinanced by FEDER funds
   (FC-GRUPIN-IDI/2018/000242) and the funding from the Spanish Ministry of
   Economy, Industry and Competitiveness (MINECO) through projects
   CTQ2016-80069-C 2-1R and RTI2018-094605-B-I00.
CR Afrin S, 2018, FOOD FUNCT, V9, P2158, DOI [10.1039/c8fo00165k, 10.1039/C8FO00165K]
   Alphandery E, 2019, NANOTOXICOLOGY, V13, P573, DOI 10.1080/17435390.2019.1572809
   Amendoeira A, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.201900153
   Auffan M, 2009, ENVIRON POLLUT, V157, P1127, DOI 10.1016/j.envpol.2008.10.002
   Bressan E, 2013, INT J DENT, V2013, DOI 10.1155/2013/312747
   Cordani M, 2019, CELL MOL LIFE SCI, V76, P1215, DOI 10.1007/s00018-018-2973-y
   Feng QY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19628-z
   Foley S, 2002, BIOCHEM BIOPH RES CO, V294, P116, DOI 10.1016/S0006-291X(02)00445-X
   Foroozandeh P, 2018, NANOSCALE RES LETT, V13, DOI 10.1186/s11671-018-2728-6
   Garcia-Fernandez J, 2020, NANOTOXICOLOGY, V14, P388, DOI 10.1080/17435390.2019.1710613
   Giampieri F, 2019, ANTIOXID REDOX SIGN, V30, P577, DOI 10.1089/ars.2017.7234
   He CY, 2019, NANOMED-NANOTECHNOL, V15, P59, DOI 10.1016/j.nano.2018.09.003
   Khan MI, 2012, BIOMATERIALS, V33, P1477, DOI 10.1016/j.biomaterials.2011.10.080
   Kim YK, 2016, J DRUG TARGET, V24, P457, DOI 10.3109/1061186X.2015.1087527
   Lee HC, 2005, INT J BIOCHEM CELL B, V37, P822, DOI 10.1016/j.biocel.2004.09.010
   Lopez-Chaves C, 2018, NANOMED-NANOTECHNOL, V14, P1, DOI 10.1016/j.nano.2017.08.011
   Malik AN, 2013, MITOCHONDRION, V13, P481, DOI 10.1016/j.mito.2012.10.011
   Man N, 2010, AUTOPHAGY, V6, P310, DOI 10.4161/auto.6.2.11138
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Papackova Z, 2014, PHYSIOL RES, V63, P409, DOI 10.33549/physiolres.932684
   Paul BT, 2017, EXPERT REV HEMATOL, V10, P65, DOI 10.1080/17474086.2016.1268047
   Pavlovich E, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671-017-2264-9
   Pereira DIA, 2014, NANOMED-NANOTECHNOL, V10, P1877, DOI 10.1016/j.nano.2014.06.012
   Quiles JL, 2010, MECH AGEING DEV, V131, P38, DOI 10.1016/j.mad.2009.11.004
   Rambold AS, 2011, CELL CYCLE, V10, P4032, DOI 10.4161/cc.10.23.18384
   Raposo M, 2019, MOL NEUROBIOL, V56, P119, DOI 10.1007/s12035-018-1069-x
   Riley MK, 2017, NANOMATERIALS-BASEL, V7, DOI 10.3390/nano7050094
   Rivas-Garcia L, 2020, FOOD CHEM TOXICOL, V135, DOI 10.1016/j.fct.2019.110900
   Roma-Rodrigues C, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030233
   Suganya M, 2019, SAUDI J BIOL SCI, V26, P767, DOI 10.1016/j.sjbs.2019.03.007
   Sun L, 2011, TOXICOL IN VITRO, V25, P1619, DOI 10.1016/j.tiv.2011.06.012
   Wang WJ, 2019, BIOMATER SCI-UK, V7, P1052, DOI 10.1039/c8bm01414k
   Yamamoto H, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1735841
   Yoo SM, 2018, MOL CELLS, V41, P18, DOI 10.14348/molcells.2018.2277
   Zdrojewicz Z, 2015, POSTEP HIG MED DOSW, V69, P1196
   Zhang JH, 2015, REDOX BIOL, V4, P242, DOI 10.1016/j.redox.2015.01.003
   Zhang LZ, 2019, J BIOMED NANOTECHNOL, V15, P396, DOI 10.1166/jbn.2019.2689
   Zhang XD, 2016, MOL PHARMACEUT, V13, P2578, DOI 10.1021/acs.molpharmaceut.6b00405
NR 38
TC 2
Z9 2
U1 4
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD JAN
PY 2021
VL 13
IS 1
AR 90
DI 10.3390/pharmaceutics13010090
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PW5AE
UT WOS:000610680800001
PM 33445442
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bijnsdorp, IV
   Peters, GJ
AF Bijnsdorp, I. V.
   Peters, G. J.
TI DEOXYRIBOSE PROTECTS AGAINST RAPAMYCIN-INDUCED CYTOTOXICITY IN
   COLORECTAL CANCER CELLS IN VITRO
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article
DE Deoxyribose; thymidine phosphorylase; rapamycin
ID THYMIDINE PHOSPHORYLASE; DIHYDROPYRIMIDINE DEHYDROGENASE; SIGNALING
   PATHWAYS; ANGIOGENIC FACTORS; AUTOPHAGY; EXPRESSION; MIGRATION;
   SECRETION; MTOR
AB Thymidine phosphorylase (TPase) is also known as the platelet-derived endothelial cell growth factor (PD-ECGF) and plays a role in angiogenesis. Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin. Rapamycin is a specific mammalian target of the rapamycin (mTOR) inhibitor, a kinase that lies directly upstream of p70/S6k. This suggests a role for TPase in the mTOR/p70/S6k pathway. In order to study this in more detail, we exposed cells with and without TPase expression to dR and rapamycin and determined the effect on cell growth. We observed protection in cytotoxicity in Colo320 cells, but not Colo320 TP1 cells. This was in part mediated by activation of p70/S6k and inhibition of autophagy. Further studies are recommended to elucidate the mechanism behind the protective effect of dR.
C1 [Bijnsdorp, I. V.] Vrije Univ Amsterdam Med Ctr, Dept Urol, Amsterdam, Netherlands.
   [Bijnsdorp, I. V.; Peters, G. J.] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.
RP Peters, GJ (corresponding author), Boelelaan 1117,CCA 1-42, NL-1081 HV Amsterdam, Netherlands.
EM GJ.Peters@vumc.nl
RI Peters, Godefridus J/C-7562-2013
OI Peters, Godefridus J/0000-0002-5447-2877
CR Bijnsdorp IV, 2011, BRIT J CANCER, V104, P1185, DOI 10.1038/bjc.2011.74
   Bijnsdorp IV, 2010, BIOCHEM PHARMACOL, V80, P786, DOI 10.1016/j.bcp.2010.05.009
   Bronckaers A, 2009, MED RES REV, V29, P903, DOI 10.1002/med.20159
   Brown NS, 2000, CANCER RES, V60, P6298
   Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001
   Hayashi T, 2008, HEPATO-GASTROENTEROL, V55, P403
   Hotchkiss KA, 2003, J BIOL CHEM, V278, P19272, DOI 10.1074/jbc.M212670200
   Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200
   KEEPERS YP, 1991, EUR J CANCER, V27, P897, DOI 10.1016/0277-5379(91)90142-Z
   Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390
   Nakayama Y, 2005, ANTICANCER RES, V25, P3755
   Seeliger H, 2004, CLIN CANCER RES, V10, P1843, DOI 10.1158/1078-0432.CCR-1176-3
   Shigemitsu K, 1999, J BIOL CHEM, V274, P1058, DOI 10.1074/jbc.274.2.1058
   White E, 2009, CLIN CANCER RES, V15, P5308, DOI 10.1158/1078-0432.CCR-07-5023
NR 14
TC 4
Z9 5
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1525-7770
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PY 2011
VL 30
IS 12
BP 1197
EP 1202
DI 10.1080/15257770.2011.602657
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 871LB
UT WOS:000298738500027
PM 22132975
DA 2022-04-25
ER

PT J
AU Scott, TA
   Quintaneiro, LM
   Norvaisas, P
   Lui, PP
   Wilson, MP
   Leung, KY
   Herrera-Dominguez, L
   Sudiwala, S
   Pessia, A
   Clayton, PT
   Bryson, K
   Velagapudi, V
   Mills, PB
   Typas, A
   Greene, NDE
   Cabreiro, F
AF Scott, Timothy A.
   Quintaneiro, Leonor M.
   Norvaisas, Povilas
   Lui, Prudence P.
   Wilson, Matthew P.
   Leung, Kit-Yi
   Herrera-Dominguez, Lucia
   Sudiwala, Sonia
   Pessia, Alberto
   Clayton, Peter T.
   Bryson, Kevin
   Velagapudi, Vidya
   Mills, Philippa B.
   Typas, Athanasios
   Greene, Nicholas D. E.
   Cabreiro, Filipe
TI Host-Microbe Co-metabolism Dictates Cancer Drug Efficacy in C. elegans
SO CELL
LA English
DT Article
ID DNTP POOLS; 5-FLUOROURACIL; AUTOPHAGY; DEFECTS; THERAPY; GLYCINE; GENE
AB Fluoropyrimidines are the first-line treatment for colorectal cancer, but their efficacy is highly variable between patients. We queried whether gut microbes, a known source of inter-individual variability, impacted drug efficacy. Combining two tractable genetic models, the bacterium E. coli and the nematode C. elegans, we performed three-way high-throughput screens that unraveled the complexity underlying host-microbe-drug interactions. We report that microbes can bolster or suppress the effects of fluoropyrimidines through metabolic drug interconversion involving bacterial vitamin B-6, B-9, and ribonucleotide metabolism. Also, disturbances in bacterial deoxynucleotide pools amplify 5-FU-induced autophagy and cell death in host cells, an effect regulated by the nucleoside diphosphate kinase ndk-1. Our data suggest a two-way bacterial mediation of fluoropyrimidine effects on host metabolism, which contributes to drug efficacy. These findings highlight the potential therapeutic power of manipulating intestinal microbiota to ensure host metabolic health and treat disease.
C1 [Scott, Timothy A.; Quintaneiro, Leonor M.; Norvaisas, Povilas; Lui, Prudence P.; Cabreiro, Filipe] Univ Coll London & Birkbeck, Inst Struct & Mol Biol, London WC1E 6BT, England.
   [Quintaneiro, Leonor M.; Wilson, Matthew P.; Leung, Kit-Yi; Sudiwala, Sonia; Clayton, Peter T.; Mills, Philippa B.; Greene, Nicholas D. E.] UCL, Great Ormond St Inst Child Hlth, London WC1N 1EH, England.
   [Norvaisas, Povilas; Bryson, Kevin] UCL, Dept Comp Sci, London WC1E 6BT, England.
   [Herrera-Dominguez, Lucia; Typas, Athanasios] European Mol Biol Lab EMBL Heidelberg, Genome Biol, Meyerhofstr 1, D-69117 Heidelberg, Germany.
   [Pessia, Alberto; Velagapudi, Vidya] Univ Helsinki, Inst Mol Med Finland, Metabol Unit, FIN-00290 Helsinki, Finland.
RP Cabreiro, F (corresponding author), Univ Coll London & Birkbeck, Inst Struct & Mol Biol, London WC1E 6BT, England.
EM f.cabreiro@ucl.ac.uk
RI Wilson, Matthew/ABA-8602-2021; Bryson, Kevin/AAZ-8177-2020; Pessia,
   Alberto/N-3072-2014; Velagapudi, Vidya/L-7278-2015
OI Wilson, Matthew/0000-0003-2252-8730; Pessia,
   Alberto/0000-0001-8607-9191; Velagapudi, Vidya/0000-0002-8261-7164;
   Herrera-Dominguez, Lucia/0000-0001-8276-2241; Scott,
   Timothy/0000-0001-7042-8609; Lui, Prudence/0000-0003-2562-5261; Mills,
   Philippa/0000-0002-9704-1268; Cabreiro, Filipe/0000-0002-3696-4843;
   Greene, Nicholas/0000-0002-4170-5248; Typas,
   Athanasios/0000-0002-0797-9018; Norvaisas, Povilas/0000-0003-4790-9820;
   Clayton, Peter/0000-0001-7592-4302
FU Wellcome Trust/Royal Society (Sir Henry Dale Fellowship)
   [102532/Z/12/Z]; MRCUK Research & Innovation (UKRI)Medical Research
   Council UK (MRC) [MR/N003713/1]; Great Ormond Street Hospital Children's
   Charity; Medical Research CouncilUK Research & Innovation (UKRI)Medical
   Research Council UK (MRC)European Commission [MR/N003713/1, 1649908]
   Funding Source: researchfish; Wellcome TrustWellcome TrustEuropean
   Commission [102531/Z/13/Z] Funding Source: researchfish; Great Ormond
   Street Hospital Childrens Charity [V1273, V4115] Funding Source:
   researchfish
FX Worm strains were provided by the Caenorhabditis Genetics Center. F.C.
   acknowledges funding from the Wellcome Trust/Royal Society (Sir Henry
   Dale Fellowship-102532/Z/12/Z) and N.D.E.G. from the MRC (MR/N003713/1).
   N.D.E.G. is supported by Great Ormond Street Hospital Children's
   Charity. We thank Helena Cocheme, Andrew Osborne, and Jurg Bahler for
   critical reading of the manuscript.
CR Baba T, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100050
   Cabreiro F, 2016, CELL HOST MICROBE, V19, P1, DOI 10.1016/j.chom.2015.12.012
   Cabreiro F, 2013, CELL, V153, P228, DOI 10.1016/j.cell.2013.02.035
   Chen W, 2014, AUTOPHAGY, V10, P1272, DOI 10.4161/auto.28954
   Chi CW, 2016, GENE DEV, V30, P307, DOI 10.1101/gad.275107.115
   Degnan PH, 2014, CELL METAB, V20, P769, DOI 10.1016/j.cmet.2014.10.002
   Fitzpatrick TB, 2007, BIOCHEM J, V407, P1, DOI 10.1042/BJ20070765
   Footitt EJ, 2012, J INHERIT METAB DIS, V35, pS18, DOI 10.1007/s10545-012-9493-y
   Garcia-Gonzalez AP, 2017, CELL, V169, P431, DOI 10.1016/j.cell.2017.03.046
   Haiser HJ, 2013, SCIENCE, V341, P295, DOI 10.1126/science.1235872
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Kim S, 2008, MOL CELLS, V26, P344
   Koyama F, 2000, CANCER GENE THER, V7, P1015, DOI 10.1038/sj.cgt.7700189
   Kwon YK, 2008, NAT CHEM BIOL, V4, P602, DOI 10.1038/nchembio.108
   Laourdakis CD, 2014, J CHROMATOGR B, V967, P127, DOI 10.1016/j.jchromb.2014.07.012
   Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Maslowska KH, 2015, NUCLEIC ACIDS RES, V43, P4109, DOI 10.1093/nar/gkv217
   Merry A, 2014, BIOCHEM J, V458, P343, DOI 10.1042/BJ20131085
   Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X
   Nicholson JK, 2012, SCIENCE, V336, P1262, DOI 10.1126/science.1223813
   Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019
   O'Donnell PH, 2009, CLIN CANCER RES, V15, P4806, DOI 10.1158/1078-0432.CCR-09-0344
   Offer SM, 2016, J CLIN ONCOL, V34, P205, DOI 10.1200/JCO.2015.64.2546
   Pai YJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7388
   Peregrin-Alvarez JM, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r63
   Pinkston JM, 2006, SCIENCE, V313, P971, DOI 10.1126/science.1121908
   Rosenberg E, 2011, BIRTH DEFECTS RES C, V93, P56, DOI 10.1002/bdrc.20196
   SenGupta T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3674
   Ser Z, 2016, CELL REP, V15, P2367, DOI 10.1016/j.celrep.2016.05.035
   Spanogiannopoulos P, 2016, NAT REV MICROBIOL, V14, P273, DOI 10.1038/nrmicro.2016.17
   Watson E, 2014, CELL, V156, P759, DOI 10.1016/j.cell.2014.01.047
   Zeng XH, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00030
NR 33
TC 120
Z9 131
U1 11
U2 77
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD APR 20
PY 2017
VL 169
IS 3
BP 442
EP +
DI 10.1016/j.cell.2017.03.040
PG 33
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ES5EP
UT WOS:000399560600009
PM 28431245
OA Green Published, Green Accepted, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Koshkina, NV
   Briggs, K
   Palalon, F
   Curley, SA
AF Koshkina, Nadezhda V.
   Briggs, Katrina
   Palalon, Flavio
   Curley, Steven A.
TI Autophagy and Enhanced Chemosensitivity in Experimental Pancreatic
   Cancers Induced by Noninvasive Radiofrequency Field Treatment
SO CANCER
LA English
DT Article
DE noninvasive radiofrequency; pancreatic cancer; autophagy; gemcitabine;
   chemotherapy enhancer
ID COLORECTAL LIVER METASTASES; CELL-PROLIFERATION; COMBINED
   RESECTION/ABLATION; HEPATIC RESECTION; ABLATION; DEATH; GEMCITABINE;
   RECURRENCE; MODELS; GROWTH
AB BACKGROUNDPatients with pancreatic ductal adenocarcinoma (PDAC) have limited therapeutic options and poor response to the standard gemcitabine (GCB)-based chemotherapy. In the current study, the authors investigated the feasibility of noninvasive short-wave radiofrequency (RF) electric fields to improve the cytotoxic effect of GCB on PDAC cells and determined its mechanism of action.
   METHODSThe cytotoxicity of RF alone and in combination with GCB was studied in vitro on normal pancreatic human pancreatic ductal epithelial cells and different PDAC cell lines by flow cytometry, and in vivo on ectopic and orthotopic human PDAC xenograft models in mice. The mechanism of RF activity was studied by Western blot analysis and immunohistochemistry. Toxicity was determined by histopathology.
   RESULTSExposure of different PDAC cells to 13.56-megahertz radio waves resulted in a substantial cytotoxic effect, which was accompanied by the induction of autophagy but not apoptosis. These effects of RF were found to be absent in normal cells. Excessive numbers of autophagosomes in cancer cells persisted 24 to 48 hours after RF exposure and then declined. The addition of a subtoxic dose of GCB to RF treatment inhibited the recovery of cancer cells from the RF-induced autophagy and enhanced the cytotoxic effect of the latter on cancer cells. The treatment of PDAC in situ in mice with the combination of noninvasive RF and GCB was found to have a superior antitumor effect compared with the use of RF or GCB alone, yet there was no evidence of systemic toxicity.
   CONCLUSIONSNoninvasive RF treatment induced autophagy but not apoptosis in cancer cells and demonstrated potential as an enhancer of chemotherapy for treating patients with pancreatic cancer without toxicity to normal cells. Cancer 2014;120:480-491. (c) 2013 American Cancer Society.
C1 [Koshkina, Nadezhda V.; Briggs, Katrina; Palalon, Flavio; Curley, Steven A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   [Curley, Steven A.] Rice Univ, Dept Mech Engn & Mat Sci, Houston, TX 77251 USA.
RP Koshkina, NV (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM nvkoshki@mdanderson.org
FU National Institutes of HealthUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USA [U54CA143837];
   National Institutes of Health University of Texas MD Anderson Cancer
   Center Support Grant [CA016672]; Kanzius Cancer Research Foundation;
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [U54CA143837, P30CA016672] Funding Source: NIH RePORTER
FX Supported by the National Institutes of Health (grant U54CA143837),
   National Institutes of Health University of Texas MD Anderson Cancer
   Center Support Grant CA016672, and a research grant from the Kanzius
   Cancer Research Foundation (to Dr. Curley).
CR Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
   Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Adair ER, 2005, BIOELECTROMAGNETICS, V26, P448, DOI 10.1002/bem.20105
   Arumugam T, 2006, J NATL CANCER I, V98, P1806, DOI 10.1093/jnci/djj498
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   Glazer ES, 2010, CLIN CANCER RES, V16, P5712, DOI 10.1158/1078-0432.CCR-10-2055
   Goldberg SN, 1996, ACAD RADIOL, V3, P929
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kirson ED, 2007, P NATL ACAD SCI USA, V104, P10152, DOI 10.1073/pnas.0702916104
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Laane E, 2009, CELL DEATH DIFFER, V16, P1018, DOI 10.1038/cdd.2009.46
   Li M, 2006, CANCER-AM CANCER SOC, V106, P2284, DOI 10.1002/cncr.21862
   Marchionni I, 2006, BBA-BIOMEMBRANES, V1758, P597, DOI 10.1016/j.bbamem.2006.03.014
   Matsui Y, 2000, PANCREAS, V20, P14, DOI 10.1097/00006676-200001000-00002
   MCGAHAN JP, 1990, INVEST RADIOL, V25, P267, DOI 10.1097/00004424-199003000-00011
   Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600
   Philip PA, 2010, J CLIN ONCOL, V28, P3605, DOI 10.1200/JCO.2009.25.7550
   Renouf D, 2010, EXPERT REV ANTICANC, V10, P529, DOI [10.1586/era.10.21, 10.1586/ERA.10.21]
   Taghi M, 2012, RECENT PATENTS ENDOC, V6, P251, DOI 10.2174/187221412802481757
   Tang K, 2011, ONCOL REP, V25, P963, DOI 10.3892/or.2011.1139
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yu L, 2004, CELL CYCLE, V3, P1124
   Zimmerman JW, 2012, BRIT J CANCER, V106, P307, DOI 10.1038/bjc.2011.523
NR 23
TC 24
Z9 24
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD FEB 15
PY 2014
VL 120
IS 4
BP 480
EP 491
DI 10.1002/cncr.28453
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 301UO
UT WOS:000330557800008
PM 24496866
OA Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Liu, MP
   Liao, M
   Dai, C
   Chen, JF
   Yang, CJ
   Liu, M
   Chen, ZG
   Yao, MC
AF Liu, Meng-ping
   Liao, Min
   Dai, Cong
   Chen, Jie-feng
   Yang, Chun-juan
   Liu, Ming
   Chen, Zuan-guang
   Yao, Mei-cun
TI Sanguisorba officinalis L synergistically enhanced 5-fluorouracil
   cytotoxicity in colorectal cancer cells by promoting a reactive oxygen
   species-mediated, mitochondria-caspase-dependent apoptotic pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CYTOCHROME-C; PHASE-II; AUTOPHAGY; EXTRACT; GROWTH; ACID; 5-FU;
   COMBINATION; OXALIPLATIN; MECHANISMS
AB Sanguisorba officinalis L. radix is a widely used herb called DiYu (DY) in China and has an extensive range of bioactivities, including anti-cancer, anti-inflammatory, and anti-oxidative activities. However, there is little evidence to support its anti-cancer effects against colorectal cancer (CRC). The first-line chemotherapeutic agent 5-fluorouracil (5-FU) is used to treat CRC, but its efficiency is hampered by acquired drug resistance. This study found that a water extract of DY exerted anti-proliferative effects against two CRC cell lines (HCT-116 and RKO), and it sensitized CRC cells to 5-FU therapy by activating a reactive oxygen species (ROS)-mediated, mitochondria-caspase-dependent apoptotic pathway. Co-treatment of DY and 5-FU significantly elevated ROS levels, up-regulated Bax/Bcl-2 ratio and triggered mitochondrial dysfunction, followed by a release of cytochrome c and up-regulation of proteins such as cleaved-caspase-9/3 and cleaved-PARP. Additionally, the induction of autophagy may be involved in mediating synergism of DY in HCT-116 cells. Gallic acid (GA), catechinic acid (CA) and ellagic acid (EA) were identified as the potential chief constituents responsible for the synergistic effects of DY. In conclusion, co-treatment of DY, specifically GA, CA and EA, with 5-FU may be a potential alternative therapeutic strategy for CRC by enhancing an intrinsic apoptotic pathway.
C1 [Liu, Meng-ping; Liao, Min; Dai, Cong; Chen, Jie-feng; Liu, Ming; Chen, Zuan-guang; Yao, Mei-cun] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
   [Yang, Chun-juan] Harbin Med Univ, Coll Pharm, Harbin 150081, Peoples R China.
RP Yao, MC (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China.
EM yaomeicun@gmail.com
RI Liao, Min/L-7491-2018
OI Liao, Min/0000-0001-7050-0711
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81573551, 81573689]
FX We appreciate Kornberg lab (Sun Yat-sen University) to provide us
   experimental platform and National Natural Science Foundation of China
   (No. 81573551 and No. 81573689) to sponsor our study.
CR Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3
   Bleiberg H, 1998, SEMIN ONCOL, V25, P32
   Cerezo-Guisado MI, 2015, FOOD CHEM TOXICOL, V84, P125, DOI 10.1016/j.fct.2015.08.017
   Cheah KY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098921
   Chen JS, 2010, J BIOL CHEM, V285, P25458, DOI 10.1074/jbc.M110.139345
   Chinese Pharmacopoeia Commission, 2015, PHARM PEOPL REP CHIN, P126
   Choi ES, 2012, MOL MED REP, V6, P670, DOI 10.3892/mmr.2012.949
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   De Angelis PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-20
   Dinicola S, 2012, INT J MOL SCI, V13, P651, DOI 10.3390/ijms13010651
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Fishbein AB, 2009, ARCH PHARM RES, V32, P505, DOI 10.1007/s12272-009-1405-9
   Flynn JM, 2013, FREE RADICAL BIO MED, V62, P4, DOI 10.1016/j.freeradbiomed.2013.05.027
   Forester SC, 2014, MOL CARCINOGEN, V53, P432, DOI 10.1002/mc.21974
   Gariboldi MB, 2015, CANCER LETT, V364, P156, DOI 10.1016/j.canlet.2015.05.008
   Gonzalez-Sarrias A., 2015, MOL NUTR FOOD RES, V0, P1
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Jara-Palacios MJ, 2015, FOOD CHEM, V183, P78, DOI 10.1016/j.foodchem.2015.03.022
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Kinnally KW, 2007, APOPTOSIS, V12, P857, DOI 10.1007/s10495-007-0722-z
   KOIZUMI W, 1993, CANCER, V72, P658, DOI 10.1002/1097-0142(19930801)72:3<658::AID-CNCR2820720306>3.0.CO;2-K
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Li XL, 2009, ONCOL REP, V22, P943, DOI 10.3892/or_00000521
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Ma LX, 2015, SUPPORT CARE CANCER, V23, P561, DOI 10.1007/s00520-014-2469-8
   Mimaki Y, 2001, PHYTOCHEMISTRY, V57, P773, DOI 10.1016/S0031-9422(01)00083-8
   Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028
   Munakata K, 2014, INT J ONCOL, V44, P1521, DOI 10.3892/ijo.2014.2316
   Naus PJ, 2007, J HEPATOL, V46, P222, DOI 10.1016/j.jhep.2006.08.012
   Nguyen TTH, 2008, BIOL PHARM BULL, V31, P2028, DOI 10.1248/bpb.31.2028
   Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x
   Raisova M, 2001, J INVEST DERMATOL, V117, P333, DOI 10.1046/j.0022-202x.2001.01409.x
   Shin JA, 2012, ONCOL LETT, V4, P489, DOI 10.3892/ol.2012.748
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Solarova Z, 2015, INT J ONCOL, V46, P907, DOI 10.3892/ijo.2014.2791
   Sun W, 2012, MOLECULES, V17, P7629, DOI 10.3390/molecules17077629
   Tabernero J, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.13.2183
   Thant AA, 2008, ANTICANCER RES, V28, P3579
   Umesalma S, 2015, MOL CELL BIOCHEM, V399, P303, DOI 10.1007/s11010-014-2257-2
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Wang ZY, 2012, EXPERT OPIN THER TAR, V16, pS79, DOI 10.1517/14728222.2011.642371
   Wu XX, 2000, CANCER RES, V60, P2912
   Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129
   Yang SY, 2009, TRENDS MOL MED, V15, P225, DOI 10.1016/j.molmed.2009.03.003
   Yoshioka K, 2000, ONCOL REP, V7, P1221
   Zhang Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.200
   Zhang YJ, 2008, J AGR FOOD CHEM, V56, P670, DOI 10.1021/jf071989c
   Zhu X, 2013, INT J MOL SCI, V14, P18041, DOI 10.3390/ijms140918041
   Zhu YS, 2015, SCI REP-UK, V5, DOI 10.1038/srep17730
NR 49
TC 29
Z9 31
U1 2
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 27
PY 2016
VL 6
AR 34245
DI 10.1038/srep34245
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DX1NS
UT WOS:000384134700001
PM 27671231
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Chen, SG
   Wu, XZ
   Hu, JW
   Dai, GX
   Rong, AH
   Guo, G
AF Chen, Shengguang
   Wu, Xianzheng
   Hu, Jiawen
   Dai, Guoxing
   Rong, Aihong
   Guo, Gang
TI PM2.5 exposure decreases viability, migration and angiogenesis in human
   umbilical vein endothelial cells and human microvascular endothelial
   cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE particulate matter; human umbilical vein endothelial cells; human
   microvascular endothelial cells; migration; angiogenesis
ID AMBIENT PARTICULATE MATTER; EPITHELIAL A549 CELLS; OXIDATIVE STRESS;
   COLORECTAL-CANCER; TENASCIN-C; EXPRESSION; INFLAMMATION; ADHESION;
   ATHEROSCLEROSIS; AUTOPHAGY
AB Previous studies have confirmed that exposure to particulate matter with a diameter of <= 2.5 mu m (PM2.5) is associated with inflammation. PM2.5 decreases cardiac cell viability and increases apoptosis through overproduction of reactive oxygen species (ROS). In the present study, the role of PM2.5 in ECs was investigated in vitro. Human umbilical vein endothelial cells and human microvascular endothelial cells (ECs) were incubated with PM2.5 (100-800 mu g/ml) to investigate the effects of PM2.5 on EC viability, migration, tube formation and intracellular levels of ROS. Cell viability and cell apoptosis were determined by MTT assay and flow cytometry analysis. Cell migration was assessed using a Boyden chamber assay, and tube formation was determined by matrigel assay. Tumor necrosis factor-a and interleukin-8 levels were measured by ELISA, and ROS levels were assessed with 2', 7' -dichlorofluorescin diacetate. The results indicated that PM2.5 decreases EC viability and increases EC apoptosis in a concentration-dependent manner. PM2.5 also decreased EC tube formation in a dose-dependent manner. The results also demonstrated that PM2.5 suppresses adhesion to EC extracellular matrix proteins. Furthermore, PM2.5 exposure significantly induced ROS generation, indicative of oxidative stress. Finally, it was demonstrated that PM2.5 decreased angiogenesis in vivo. These results suggested that repeated exposure to PM2.5 induces vascular inflammation.
C1 [Chen, Shengguang; Wu, Xianzheng; Hu, Jiawen; Dai, Guoxing; Rong, Aihong; Guo, Gang] Tongji Univ, Tongji Hosp, Dept Emergency, 389 Xin Cun Rd, Shanghai 200333, Peoples R China.
RP Wu, XZ (corresponding author), Tongji Univ, Tongji Hosp, Dept Emergency, 389 Xin Cun Rd, Shanghai 200333, Peoples R China.
EM xianzhengwubio@sohu.com
CR Aaron CP, 2016, ENVIRON HEALTH PERSP, V124, P1166, DOI 10.1289/ehp.1409451
   Abdelrahim M, 2010, INT J ONCOL, V36, P5, DOI 10.3892/ijo_00000470
   Amatullah H, 2012, INHAL TOXICOL, V24, P161, DOI 10.3109/08958378.2011.650235
   Cui P, 2015, EUR J PUBLIC HEALTH, V25, P324, DOI 10.1093/eurpub/cku145
   Cui YQ, 2015, CELL PHYSIOL BIOCHEM, V35, P353, DOI 10.1159/000369701
   Deng XB, 2013, TOXICOL IN VITRO, V27, P1762, DOI 10.1016/j.tiv.2013.05.004
   Favreau AJ, 2014, CANCER MED-US, V3, P265, DOI 10.1002/cam4.203
   Fu JY, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009452
   Gimbrone MA, 2016, CIRC RES, V118, P620, DOI 10.1161/CIRCRESAHA.115.306301
   Hessel M, 2009, CELL PHYSIOL BIOCHEM, V24, P201, DOI 10.1159/000233246
   Hu H, 2013, BREAST CANCER RES TR, V139, P217, DOI 10.1007/s10549-013-2527-9
   Ide M, 2007, ONCOL REP, V18, P1451
   Li RJ, 2015, ENVIRON SCI POLLUT R, V22, P20167, DOI 10.1007/s11356-015-5222-z
   Lin CP, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/845037
   Madsen CD, 2007, J CELL BIOL, V177, P927, DOI 10.1083/jcb.200612058
   Montiel-Davalos A, 2007, INHAL TOXICOL, V19, P91, DOI 10.1080/08958370701495212
   Ostro B, 2014, ENVIRON RES, V132, P168, DOI 10.1016/j.envres.2014.03.042
   Potera C, 2014, ENVIRON HEALTH PERSP, V122, pA29, DOI 10.1289/ehp.122-A29
   Rui W, 2016, J APPL TOXICOL, V36, P48, DOI 10.1002/jat.3143
   Thurston G, 2015, SEMIN RESP CRIT CARE, V36, P422, DOI 10.1055/s-0035-1549455
   Tong GQ, 2015, ARCH ENVIRON CON TOX, V68, P31, DOI 10.1007/s00244-014-0077-8
   Wang FF, 2016, BIOMED ENVIRON SCI, V29, P107, DOI 10.3967/bes2016.012
   Wang YH, 2015, INT J CLIN EXP MED, V8, P58
   Yang GZ, 2015, MOLECULES, V20, P6626, DOI 10.3390/molecules20046626
   Yue HF, 2015, ENVIRON SCI TECHNOL, V49, P14484, DOI 10.1021/es506280c
   Zhu GW, 2016, CELL PHYSIOL BIOCHEM, V39, P1665, DOI 10.1159/000447868
NR 26
TC 16
Z9 18
U1 1
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2017
VL 16
IS 3
BP 2425
EP 2430
DI 10.3892/mmr.2017.6877
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FD3VX
UT WOS:000407461600009
PM 28677750
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Hobbs, GA
   Baker, NM
   Miermont, AM
   Thurman, RD
   Pierobon, M
   Tran, TH
   Anderson, AO
   Waters, AM
   Diehl, JN
   Papke, B
   Hodge, RG
   Klomp, JE
   Goodwin, CM
   DeLiberty, JM
   Wang, JN
   Ng, RWS
   Gautam, P
   Bryant, KL
   Esposito, D
   Campbell, SL
   Petricoin, EF
   Simanshu, DK
   Aguirre, AJ
   Wolpin, BM
   Wennerberg, K
   Rudloff, U
   Cox, AD
   Der, CJ
AF Hobbs, G. Aaron
   Baker, Nicole M.
   Miermont, Anne M.
   Thurman, Ryan D.
   Pierobon, Mariaelena
   Tran, Timothy H.
   Anderson, Andrew O.
   Waters, Andrew M.
   Diehl, J. Nathaniel
   Papke, Bjoern
   Hodge, Richard G.
   Klomp, Jennifer E.
   Goodwin, Craig M.
   DeLiberty, Jonathan M.
   Wang, Junning
   Ng, Raymond W. S.
   Gautam, Prson
   Bryant, Kirsten L.
   Esposito, Dominic
   Campbell, Sharon L.
   Petricoin, Emanuel F., III
   Simanshu, Dhirendra K.
   Aguirre, Andrew J.
   Wolpin, Brian M.
   Wennerberg, Krister
   Rudloff, Udo
   Cox, Adrienne D.
   Der, Channing J.
TI Atypical KRAS(G12R) Mutant Is Impaired in PI3K Signaling and
   Macropinocytosis in Pancreatic Cancer
SO CANCER DISCOVERY
LA English
DT Article
ID GUANINE-NUCLEOTIDE EXCHANGE; ONCOGENIC KRAS; RAS-BINDING; PROTEIN;
   ACTIVATION; TRANSFORMATION; KINASE; TUMORIGENESIS; DEGRADATION;
   P110-ALPHA
AB Allele-specific signaling by different KRAS alleles remains poorly understood. The KRAS(G12R) mutation displays uneven prevalence among cancers that harbor the highest occurrence of KRAS mutations: It is rare (similar to 1%) in lung and colorectal cancers, yet relatively common (similar to 20%) in pancreatic ductal adenocarcinoma (PDAC), suggesting context-specific properties. We evaluated whether KRAS(G12R) is functionally distinct from the more common KRAS(G12D)- or KRAS(G12V)-mutant proteins (KRASG(12D/V)). We found that KRAS(G12D/V) but not KRAS(G12R) drives macropinocytosis and that MYC is essential for macropinocytosis in KRAS(G12D/V)- but not KRAS(G12R)-mutant PDAC. Surprisingly, we found that KRAS(G12R) is defective for interaction with a key effector, p110 alpha PI3K (PI3K alpha), due to structural perturbations in switch II. Instead, upregulated KRAS-independent P13K gamma activity was able to support macropinocytosis in KRAS(G12R)-mutant PDAC. Finally, we determined that KRAS(G12R)-mutant PDAC displayed a distinct drug sensitivity profile compared with KRAS(G12 D)-mutant PDAC but is still responsive to the combined inhibition of ERK and autophagy.
   SIGNIFICANCE: We determined that KRAS(G12R) is impaired in activating a key effector, p110 alpha PI3K. As such, KRAS(G12R) is impaired in driving macropinocytosis. However, overexpression of PI3K gamma in PDAC compensates for this deficiency, providing one basis for the prevalence of this otherwise rare KRAS mutant in pancreatic cancer but not other cancers.
C1 [Hobbs, G. Aaron; Baker, Nicole M.; DeLiberty, Jonathan M.; Bryant, Kirsten L.; Cox, Adrienne D.; Der, Channing J.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27515 USA.
   [Miermont, Anne M.; Anderson, Andrew O.; Rudloff, Udo] NCI, Thorac & GI Oncol Branch, Bethesda, MD 20892 USA.
   [Thurman, Ryan D.; Campbell, Sharon L.] Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27515 USA.
   [Pierobon, Mariaelena; Petricoin, Emanuel F., III] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA USA.
   [Tran, Timothy H.; Esposito, Dominic; Simanshu, Dhirendra K.] NCI, RAS Initiat, Canc Res Technol Program, Frederick Natl Lab Canc Res,Leidos Biomed Res Inc, Frederick, MD 21701 USA.
   [Waters, Andrew M.; Papke, Bjoern; Hodge, Richard G.; Klomp, Jennifer E.; Goodwin, Craig M.; Campbell, Sharon L.; Cox, Adrienne D.; Der, Channing J.] Univ N Carolina, Lineberger Comprehens Canc Ctr, CB7295, Chapel Hill, NC 27599 USA.
   [Diehl, J. Nathaniel; Der, Channing J.] Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27515 USA.
   [Wang, Junning; Ng, Raymond W. S.; Aguirre, Andrew J.; Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Gautam, Prson; Wennerberg, Krister] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland.
   [Aguirre, Andrew J.] Broad Inst MIT & Harvard, Cambridge, MA USA.
   [Wennerberg, Krister] Univ Copenhagen, BRIC, Copenhagen, Denmark.
   [Rudloff, Udo] NCI, Rare Tumor Initiat, Pediat Oncol Branch, Bethesda, MD 20892 USA.
   [Cox, Adrienne D.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC USA.
RP Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, CB7295, Chapel Hill, NC 27599 USA.; Rudloff, U (corresponding author), NCI, Ctr Canc Res, Bldg 10,Hatfield CRC,Room 2B-34D, Bethesda, MD 20892 USA.
EM rudloffu@mail.nih.gov
RI Wennerberg, Krister/AAH-2919-2022; Ariel, Pablo/AGJ-4118-2022
OI Wennerberg, Krister/0000-0002-1352-4220; DeLiberty,
   Jonathan/0000-0001-6001-6678; Diehl, John/0000-0002-7309-0903; Waters,
   Andrew/0000-0002-6058-5878; Gautam, Prson/0000-0002-1154-8501; Hodge,
   Richard/0000-0002-1920-1385; campbell, sharon/0000-0003-0311-409X;
   Simanshu, Dhirendra/0000-0002-9717-4618; Klomp,
   Jennifer/0000-0003-1781-648X; Esposito, Dominic/0000-0002-9987-1687;
   Hobbs, Aaron/0000-0002-4751-9681; Papke, Bjoern/0000-0001-8156-7508; Ng,
   Raymond/0000-0003-2573-8207
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [R01CA42978, U01CA199235, P50CA196510, R35CA232113, P01CA203657,
   CA203657, K08CA218420-02, P50CA127003, U01CA224146, F32CA200313,
   T32CA009156, F31CA180628, F32CA221005, T32CA071341, HHSN261200800001E];
   Department of DefenseUnited States Department of Defense
   [W81XWH-15-1-0611]; Lustgarten Pancreatic Cancer Foundation [388222];
   2015 Pancreatic Cancer Action Network-AACR Research Acceleration Network
   Grant [15-90-25-DER]; Lustgarten Foundation; Dana-Farber Cancer
   Institute Hale Center for Pancreatic Cancer Research; Doris Duke
   Charitable FoundationDoris Duke Charitable Foundation (DDCF) [2017066];
   Pancreatic Cancer Action Network [18-35-AGUI]; DFCI Hale Family Center
   for Pancreatic Cancer Research; 2018 -Debbie's Dream Foundation-AACR
   Gastric Cancer Research Fellowship [18-40-41-HODG]; American Cancer
   SocietyAmerican Cancer Society [PF-18-061]; Slomo and Cindy Silvian
   Foundation; Intramural Research Program of the NIH, NCIUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Cancer Institute (NCI) [ZIA BC 011267]; Deutsche
   Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [PA
   3051/1-1]; Pancreatic Cancer Action Network/AACR Pathway to Leadership
   grant; Center for AIDS Research [5P30AI050410];  [P30CA016086]
FX C.J. Der and A.D. Cox were supported by grants from the NCI (R01CA42978,
   U01CA199235, P50CA196510, R35CA232113, and P01CA203657), the Department
   of Defense (W81XWH-15-1-0611), and the Lustgarten Pancreatic Cancer
   Foundation (388222). For C.J. Der and K. Wennerberg, research was
   supported by the 2015 Pancreatic Cancer Action Network-AACR Research
   Acceleration Network Grant, Grant Number 15-90-25-DER. K. Wennerberg was
   supported by NCI P01CA203657. S.L. Campbell and E.F. Petricoin III were
   supported by NCI CA203657. A.J. Aguirre was supported by the Lustgarten
   Foundation, the Dana-Farber Cancer Institute Hale Center for Pancreatic
   Cancer Research, the Doris Duke Charitable Foundation (2017066), the
   Pancreatic Cancer Action Network (18-35-AGUI), and NCI K08CA218420-02,
   P50CA127003, and U01CA224146. B.M. Wolpin was supported by the
   Lustgarten Foundation and DFCI Hale Family Center for Pancreatic Cancer
   Research. G.A. Hobbs was supported by NCI F32CA200313 and T32CA009156;
   N.M. Baker by NCI F31CA180628; R.D. Thurman, J.E. Klomp, and C.M.
   -Goodwin by NCI T32CA009156. C.M. Goodwin was supported by NCI
   F32CA221005. R.G. Hodge was supported by the 2018 -Debbie's Dream
   Foundation-AACR Gastric Cancer Research Fellowship, in memory of Sally
   Mandel, Grant Number 18-40-41-HODG. A.M. Waters was supported by a
   fellowship from the American Cancer Society (PF-18-061); J.N. Diehl by
   NCI T32CA071341 and a fellowship from the Slomo and Cindy Silvian
   Foundation. A.M. Miermont and U. Rudloff were supported by the
   Intramural Research Program of the NIH, NCI (ZIA BC 011267). B. Papke
   was supported by the Deutsche Forschungsgemeinschaft (DFG PA 3051/1-1).
   K.L. Bryant was supported by T32CA009156 and by a Pancreatic Cancer
   Action Network/AACR Pathway to Leadership grant. Support to T.H. Tran,
   D. Esposito, and D.K. Simanshu was provided by NCI under contract
   HHSN261200800001E. Structural work used Northeastern Collaborative
   Access Team beamline (GM103403) at the Advanced Photon Source
   (DE-AC02-06CH11357). The UNC Microscopy Services Laboratory and Flow
   Cytometry Core Facility were supported in part by P30CA016086. Research
   reported in this article was supported by the Center for AIDS Research
   award number 5P30AI050410. The content is solely the responsibility of
   the authors and does not necessarily represent the official views of the
   NIH.
CR Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925
   Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007
   Baer R, 2014, GENE DEV, V28, P2621, DOI 10.1101/gad.249409.114
   Baldelli E, 2017, METHODS MOL BIOL, V1606, P149, DOI 10.1007/978-1-4939-6990-6_11
   Baldelli E, 2015, ONCOTARGET, V6, P32368, DOI 10.18632/oncotarget.5941
   Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244
   Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021
   Bournet B, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2016.18
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004
   Bunney TD, 2006, MOL CELL, V21, P495, DOI 10.1016/j.molcel.2006.01.008
   Campbell PM, 2007, CANCER RES, V67, P2098, DOI 10.1158/0008-5472.CAN-06-3752
   Caruso C, 2019, CANCER DISCOV, V9, P988, DOI 10.1158/2159-8290.CD-NB2019-073
   Castellano E, 2013, CANCER CELL, V24, P617, DOI 10.1016/j.ccr.2013.09.012
   Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Federici G, 2013, MOL CANCER RES, V11, P676, DOI 10.1158/1541-7786.MCR-12-0690
   Fujii M, 2013, SCI REP-UK, V3, DOI 10.1038/srep02385
   Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051
   Haigis KM, 2017, TRENDS CANCER, V3, P686, DOI 10.1016/j.trecan.2017.08.006
   Hayes TK, 2016, CANCER CELL, V29, P75, DOI 10.1016/j.ccell.2015.11.011
   HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901
   Hoeller O, 2013, J CELL SCI, V126, P4296, DOI 10.1242/jcs.134015
   Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203
   Iwig JS, 2013, ELIFE, V2, DOI 10.7554/eLife.00813
   Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016
   Kabsch W, 2010, ACTA CRYSTALLOGR D, V66, P125, DOI 10.1107/S0907444909047337
   Kamphorst JJ, 2015, CANCER RES, V75, P544, DOI 10.1158/0008-5472.CAN-14-2211
   KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923
   KRENGEL U, 1990, CELL, V62, P539, DOI 10.1016/0092-8674(90)90018-A
   LENZEN C, 1995, METHOD ENZYMOL, V255, P95
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   McFall A, 2001, MOL CELL BIOL, V21, P5488, DOI 10.1128/MCB.21.16.5488-5499.2001
   Mott HR, 2015, CRIT REV BIOCHEM MOL, V50, P85, DOI 10.3109/10409238.2014.999191
   Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924
   Pacold ME, 2000, CELL, V103, P931, DOI 10.1016/S0092-8674(00)00196-3
   Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622
   Pemovska T, 2013, CANCER DISCOV, V3, P1416, DOI 10.1158/2159-8290.CD-13-0350
   Pin E, 2014, CURR PROTOC PROTEIN, V75
   Pin E, 2016, MOL ONCOL, V10, P1585, DOI 10.1016/j.molonc.2016.09.007
   Poulin EJ, 2019, CANCER DISCOV, V9, P738, DOI 10.1158/2159-8290.CD-18-1220
   RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3
   Ryan MB, 2015, TRENDS CANCER, V1, P183, DOI 10.1016/j.trecan.2015.10.001
   Scheich C, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm067
   Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004
   Signore M, 2012, METHODS MOL BIOL, V823, P139, DOI 10.1007/978-1-60327-216-2_10
   Smith MJ, 2014, NAT CHEM BIOL, V10, P223, DOI [10.1038/NCHEMBIO.1435, 10.1038/nchembio.1435]
   Smith MJ, 2013, P NATL ACAD SCI USA, V110, P4574, DOI 10.1073/pnas.1218173110
   Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Vaseva AV, 2018, CANCER CELL, V34, P807, DOI 10.1016/j.ccell.2018.10.001
   WAKIZAKA A, 1979, J CHROMATOGR, V162, P319, DOI 10.1016/S0378-4347(00)81518-2
   Waters AM, 2017, COLD SPRING HARB PER, V8
   Welch HCE, 2002, CELL, V108, P809, DOI 10.1016/S0092-8674(02)00663-3
   Welsch ME, 2017, CELL, V168, P878, DOI 10.1016/j.cell.2017.02.006
   WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3
   Winters IP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01519-y
   Yao WT, 2019, NATURE, V568, P410, DOI 10.1038/s41586-019-1062-1
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
NR 62
TC 50
Z9 50
U1 6
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD JAN
PY 2020
VL 10
IS 1
BP 104
EP 123
DI 10.1158/2159-8290.CD-19-1006
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KB9TZ
UT WOS:000506831600025
PM 31649109
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Novohradsky, V
   Markova, L
   Kostrhunova, H
   Kasparkova, J
   Hoeschele, J
   Brabec, V
AF Novohradsky, Vojtech
   Markova, Lenka
   Kostrhunova, Hana
   Kasparkova, Jana
   Hoeschele, James
   Brabec, Viktor
TI A [Pt(cis-1,3-diaminocycloalkane)Cl-2] analog exhibits hallmarks typical
   of immunogenic cell death inducers in model cancer cells
SO JOURNAL OF INORGANIC BIOCHEMISTRY
LA English
DT Article
DE Platinum; Cancer; Immunogenic cell death; Damage-associated molecular
   pattern; CT26 cell line
ID ANTICANCER THERAPY; AUTOPHAGY; DAMPS; CALRETICULIN; MECHANISMS;
   INDUCTION; PAMPS; DRUGS
AB The platinum drugs belong to prevailing chemotherapeutics used in the treatment of cancer. At present, however, the search for new anticancer metal-based drugs that operate by the mechanisms distinct from those of the conventional chemotherapeutics is very active. Furthermore, it has been demonstrated that cytotoxic chemotherapy and immunotherapy may exert a highly synergistic anticancer activity. Thus, the development of antitumor platinum and other metal-based drugs that exhibit cytostatic effects and concurrently elicit immunogenic cell death (ICD) has shown promise for cancer treatment. Notably, conventional platinum drug oxaliplatin ([Pt (1R,2R-DACH)(oxalate)], DACH = diaminocyclohexane) is a well-known agent that displays both cytostatic and immune responses. Moreover, it was also demonstrated that even minor derivatization of the unleaving cycloalkyl moiety in oxaliplatin might have a pronounced effect on its immunomodulatory activity. Here, we investigated how replacing the 1R,2R- diaminocyclohexane ring by 1,3-diaminocycloalkane (alkane = butane, pentane, or hexane) affects the ability to evoke secretion of damage-associated molecular patterns characteristic of ICD in model murine colorectal carcinoma cell line CT26. The results indicate that among the investigated [Pt (cis-1,3-diaminocycloalkane)Cl2] complexes, the complex containing the cyclobutyl moiety exhibits the hallmarks typical of ICD inducers. Thus, [Pt(cis-1,3-diaminocyclobutane)Cl2] may expand the spectrum of anticancer chemotherapeutics capable of inducing ICD in cancer cells and might be of interest for further (pre)clinical development.
C1 [Novohradsky, Vojtech; Markova, Lenka; Kostrhunova, Hana; Kasparkova, Jana; Brabec, Viktor] Czech Acad Sci, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
   [Hoeschele, James] Eastern Michigan Univ, Dept Chem, Ypsilanti, MI 48197 USA.
RP Brabec, V (corresponding author), Czech Acad Sci, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
EM brabec@ibp.cz
RI Kostrhunová, Hana/H-1934-2014
OI Kostrhunová, Hana/0000-0003-2706-6491
CR Ahmed A, 2020, MOL ONCOL, V14, P2994, DOI 10.1002/1878-0261.12851
   Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164
   Brabec V, 2017, COORDIN CHEM REV, V351, P2, DOI 10.1016/j.ccr.2017.04.013
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   dos Santos-Rodrigues A, 2014, NEUROCHEM INT, V73, P229, DOI 10.1016/j.neuint.2014.03.014
   Englinger B, 2019, CHEM REV, V119, P1519, DOI 10.1021/acs.chemrev.8b00396
   FANIZZI FP, 1987, INORG CHIM A-BIOINOR, V137, P45, DOI 10.1016/S0020-1693(00)87114-5
   Fucikova J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03221-2
   Galluzzi Lorenzo, 2020, J Immunother Cancer, V8, DOI 10.1136/jitc-2019-000337
   Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012
   Garg AD, 2016, CELL DEATH DIFFER, V23, P938, DOI 10.1038/cdd.2016.5
   Gou HF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085789
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hoeschele JD, 2020, J BIOL INORG CHEM, V25, P913, DOI 10.1007/s00775-020-01809-9
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   Johnstone TC, 2015, PHILOS T R SOC A, V373, DOI 10.1098/rsta.2014.0185
   Jungwirth U, 2012, MOL PHARMACOL, V81, P719, DOI 10.1124/mol.111.077321
   Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Liu P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14848-1
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847
   Novohradsky V, 2020, INORG CHEM FRONT, V7, P4150, DOI 10.1039/d0qi00991a
   Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024
   Pitt JM, 2017, ADV EXP MED BIOL, V1036, P65, DOI 10.1007/978-3-319-67577-0_5
   Rufo N, 2017, TRENDS CANCER, V3, P643, DOI 10.1016/j.trecan.2017.07.002
   Serrano-del Valle A, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00050
   Stojanovska V, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4650695
   Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008
   Tang DL, 2012, IMMUNOL REV, V249, P158, DOI 10.1111/j.1600-065X.2012.01146.x
   Terenzi A, 2016, J INORG BIOCHEM, V165, P71, DOI 10.1016/j.jinorgbio.2016.06.021
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Tesniere A, 2008, CURR OPIN IMMUNOL, V20, P504, DOI 10.1016/j.coi.2008.05.007
   Trautmann A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.256pe6
   Venereau E., 2012, J GEN PHYSIOL, V140, pI6
   Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5
   Wong DYQ, 2015, ANGEW CHEM INT EDIT, V54, P6483, DOI 10.1002/anie.201500934
   Zhao TS, 2015, ONCOTARGET, V6, P27816, DOI 10.18632/oncotarget.4816
   Zhong WY, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-019-6344-3
   Zhou JY, 2019, J CELL MOL MED, V23, P4854, DOI 10.1111/jcmm.14356
   Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891
NR 46
TC 1
Z9 1
U1 9
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0162-0134
EI 1873-3344
J9 J INORG BIOCHEM
JI J. Inorg. Biochem.
PD JAN
PY 2022
VL 226
AR 111628
DI 10.1016/j.jinorgbio.2021.111628
EA OCT 2021
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WN7NV
UT WOS:000711955100001
PM 34673378
DA 2022-04-25
ER

PT J
AU Li, SX
   Liu, FL
   Xu, L
   Li, C
   Yang, X
   Guo, B
   Gu, JX
   Wang, L
AF Li, Shuxuan
   Liu, Fenglin
   Xu, Ling
   Li, Can
   Yang, Xu
   Guo, Bao
   Gu, Jianxin
   Wang, Lan
TI Wnt/beta-Catenin Signaling Axis Is Required for TFEB-Mediated Gastric
   Cancer Metastasis and Epithelial-Mesenchymal Transition
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID TRANSCRIPTION FACTOR EB; ENDOLYSOSOMAL BIOGENESIS; COLORECTAL-CANCER;
   TGF-BETA; AUTOPHAGY; EXPRESSION; INHIBITOR; PHENOTYPE; LOX-1
AB Gastric cancer remains the third leading cause of cancer-related death, and tumor metastasis is the main risk factor for poor prognosis of patients with gastric cancer. Transcription factor EB (TFEB) is a MiT family member and has been found to drive tumorigenesis in a number of tissues, whereas few studies were focused on investigating its prometastasis role and mechanism in gastric cancer. Here, we found TFEB was upregulated in gastric cancer tissues compared with adjacent normal gastric epithelial tissues. IHC analysis from gastric cancer tissue microarray revealed that TFEB in gastric cancer was correlated with depth of tumor invasion, lymph node or distant metastasis, tumor tumor-nodemetastasis stage, and overall survival. Gastric cancer cells with TFEB overexpression presented an increased cell migration or invasion, and epithelial-mesenchymal transition (EMT). Furthermore, gene correlation analysis and gene set enrichment analysis enriched Wnt/beta-catenin signaling pathway members in TFEB high-expression group, and the TOP/FOPflash assay verified the effect of TFEB on beta-catenin transcription activity. Besides, we found that TFEB could trigger the aggregation of beta-catenin in nucleus and activate its transcription, as well as facilitate the expression of Wnt/beta-catenin target genes and EMT-related markers, which could be reversed by the Wnt/beta-catenin inhibitor XAV-939. Collectively, TFEB enhances gastric cancer metastatic potential by activating Wnt/ beta-catenin signaling pathway and may become a promising therapeutic target for gastric cancer metastasis.
C1 [Li, Shuxuan; Xu, Ling; Li, Can; Yang, Xu; Guo, Bao; Gu, Jianxin; Wang, Lan] Fudan Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, NHC Key Lab Glycoconjugate Res, Shanghai, Peoples R China.
   [Liu, Fenglin] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
RP Wang, L (corresponding author), Fudan Univ, Shanghai 200032, Peoples R China.
EM wanglan@fudan.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31870800, 31600648, 31842033]
FX This work was supported by the National Natural Science Foundation of
   China (31870800, 31600648, 31842033).
CR Amin MB., 2017, AJCC CANC STAGING MA, V8th ed.
   Attisano L, 2004, CANCER METAST REV, V23, P53, DOI 10.1023/A:1025811012690
   Audrey G, 2018, COMPOSITIONS METHODS
   Bahrami A, 2019, CELL ONCOL, V42, P405, DOI 10.1007/s13402-019-00442-2
   Calcagn A, 2016, MODELLING TFE RENAL, V5
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Ding ZF, 2014, CAN J PHYSIOL PHARM, V92, P524, DOI 10.1139/cjpp-2013-0420
   Fang LM, 2017, ACTA PHARMACOL SIN, V38, P1305, DOI 10.1038/aps.2017.25
   Giatromanolaki A, 2015, LUNG CANCER, V90, P98, DOI 10.1016/j.lungcan.2015.07.008
   Gonzalez-Chavarria I, 2018, CANCER LETT, V414, P34, DOI 10.1016/j.canlet.2017.10.035
   Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012
   Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jung HY, 2019, NAT CELL BIOL, V21, P359, DOI 10.1038/s41556-019-0291-8
   Klein K, 2016, INT J ONCOL, V49, P164, DOI 10.3892/ijo.2016.3505
   Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Li C, 2017, SCI REP-UK, V7, DOI 10.1038/srep45275
   Li F, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5380319
   Liang J, 2018, ONCOTARGETS THER, V11, P8089, DOI 10.2147/OTT.S180112
   Lianos GD, 2019, J GASTROINTEST CANC, V50, P201, DOI 10.1007/s12029-019-00217-w
   Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001
   Lyons K, 2019, EUR J CANCER PREV, V28, P397, DOI 10.1097/CEJ.0000000000000480
   McGonigle S, 2015, ONCOTARGET, V6, P41307, DOI 10.18632/oncotarget.5846
   Menear KA, 2008, J MED CHEM, V51, P6581, DOI 10.1021/jm8001263
   Napolitano G, 2016, J CELL SCI, V129, P2475, DOI 10.1242/jcs.146365
   OFlanagan CH, 2016, P 107 ANN M AM ASS C
   Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7
   Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3
   Ploper D, 2015, PHARMACOL RES, V99, P36, DOI 10.1016/j.phrs.2015.04.006
   Ploper D, 2015, P NATL ACAD SCI USA, V112, pE420, DOI 10.1073/pnas.1424576112
   Raben N, 2016, ANNU REV CELL DEV BI, V32, P255, DOI 10.1146/annurev-cellbio-111315-125407
   Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447
   Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592
   Sitarz R, 2018, CANCER MANAG RES, V10, P239, DOI 10.2147/CMAR.S149619
   Slade L, 2017, MOL CANCER RES, V15, P1637, DOI 10.1158/1541-7786.MCR-17-0320
   Stefanski CD, 2019, PREDICTIVE BIOMARKER
   Techasen A, 2014, TUMOR BIOL, V35, P8645, DOI 10.1007/s13277-014-2087-6
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   Wang FH, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0349-9
   Xi L, 2016, ONCOTARGET, V7, P33152
   Zhang J, 2018, CELL ONCOL, V41, P73, DOI 10.1007/s13402-017-0360-6
   Zhang J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0864-6
   Zhang XF, 2017, INT J ONCOL, V51, P18, DOI 10.3892/ijo.2017.4025
NR 45
TC 4
Z9 5
U1 1
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD NOV
PY 2020
VL 18
IS 11
BP 1650
EP 1659
DI 10.1158/1541-7786.MCR-20-0180
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA OQ4BC
UT WOS:000588729500004
PM 32753474
OA Bronze
DA 2022-04-25
ER

PT J
AU Feng, YQ
   Zou, W
   Hu, CH
   Li, GY
   Zhou, SH
   He, Y
   Ma, F
   Deng, C
   Sun, LL
AF Feng, Yeqian
   Zou, Wen
   Hu, Chunhong
   Li, Guiyuan
   Zhou, Shenghua
   He, Yan
   Ma, Fang
   Deng, Chao
   Sun, Lili
TI Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to
   cisplatin
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE CASC2; miR-21; PTEN; Cervical cancer; DDP; Chemoresistance
ID LONG NONCODING RNA; TUMOR-SUPPRESSOR GENE; CELL LUNG-CANCER; SIGNALING
   PATHWAY; MIR-21 PROMOTES; NEOADJUVANT CHEMOTHERAPY; INHIBITING
   AUTOPHAGY; COLORECTAL-CANCER; PTEN/AKT PATHWAY; CASC2 SUPPRESSES
AB Cisplatin (DDP)-based chemotherapy is a standard strategy for cervical cancer, while chemoresistance remains a challenge. Recent evidence highlights the crucial regulatory roles of long non-coding RNAs (IncRNA) in tumor biology. However, the roles and regulatory mechanisms of the novel IncRNA, cancer susceptibility candidate 2 (CASC2), in cervical cancer tumorigenesis and chemoresistance are poorly understood. In this study, CASC2 expression was down-regulated in cervical cancer tissues, and was related to a shorter survival time and poorer clinicopathologic features. Exogenous CACS2 alone was sufficient to inhibit cervical cancer cell proliferation and amplified DDP-induced repression of cell proliferation. A lower expression of CACS2 was observed in the DDP-resistant cervical cancer tissues, compared to DDP-sensitive cancer tissues; CACS2 overexpression could sensitize DDP-resistant cervical cancer cell (HeLa/DDP and CaSki/DDP) to DDP. Further functional experiments indicate that CASC2 upregulated PTEN expression by direct inhibiting miR-21 in the DDP-resistant cancer cells, leading to the down-regulation of p-AKT protein. In DDP-resistant cervical cancer tissues, miR-21 was up-regulated while PTEN was down-regulated. Taken together, these observations suggest CASC2 up-regulates PTEN as a ceRNA of miR-21 and plays an important role in cervical cancer sensitivity to DDP and may serve as a potential target for cancer diagnosis and treatment. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Feng, Yeqian; Zou, Wen; Hu, Chunhong; He, Yan; Ma, Fang; Deng, Chao] Cent S Univ, Dept Oncol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
   [Li, Guiyuan] Cent S Univ, Canc Res Inst, Changsha, Hunan, Peoples R China.
   [Zhou, Shenghua] Cent S Univ, Xiangya Hosp 2, Dept Cardiovascularol, Changsha 410011, Hunan, Peoples R China.
   [Sun, Lili] First Peoples Hosp YueYang, Dept Oncol, Yueyang, Hunan, Peoples R China.
RP Zou, W; Hu, CH (corresponding author), Cent S Univ, Dept Oncol, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.
EM 13507411313@139.com; huchunh@medmail.com.cn
FU Natural Science Fund Project of Hunan Province [2016JJ4096]
FX This study was supported by the Natural Science Fund Project of Hunan
   Province (project ID: 2016JJ4096).
CR Baez-Vega PM, 2016, ONCOTARGET, V7, P36321, DOI 10.18632/oncotarget.9216
   Bian ZH, 2016, SCI REP-UK, V6, DOI 10.1038/srep23892
   Cao YJ, 2016, MOL MED REP, V14, P1019, DOI 10.3892/mmr.2016.5337
   Chen QY, 2015, CELL PHYSIOL BIOCHEM, V36, P956, DOI 10.1159/000430270
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Eto K, 2014, ANN SURG ONCOL, V21, P343, DOI 10.1245/s10434-013-3325-7
   He CJ, 2015, ONCOTARGET, V6, P28867, DOI 10.18632/oncotarget.4814
   He XZ, 2016, TUMOR BIOL, V37, P9503, DOI 10.1007/s13277-016-4787-6
   Hu LT, 2016, TUMOR BIOL, V37, P2691, DOI 10.1007/s13277-015-4111-x
   Huang GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26524
   Joshi PK, 2015, NATURE, V523, P459, DOI 10.1038/nature14618
   Khachane AN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010316
   Li J, 2015, TUMOR BIOL, V36, P3611, DOI 10.1007/s13277-014-2998-2
   Li P, 2016, AM J TRANSL RES, V8, P3522
   Li XY, 2014, EUR REV MED PHARMACO, V18, P3491
   Liu SK, 2015, BIOCHEM BIOPH RES CO, V459, P679, DOI 10.1016/j.bbrc.2015.03.004
   Liu ZL, 2013, MOL CELL BIOCHEM, V372, P35, DOI 10.1007/s11010-012-1443-3
   Liu ZL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077293
   LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704
   Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003
   McClelland AD, 2015, CLIN SCI, V129, P1237, DOI 10.1042/CS20150427
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057
   OZOLS RF, 1989, CURR PROB CANCER, V13, P287
   Peralta-Zaragoza O, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2231-3
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Ren Y, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-27
   Shen H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103305
   Song LL, 2016, TUMOR BIOL, V37, P12161, DOI 10.1007/s13277-016-5073-3
   Umemura S, 2014, J THORAC ONCOL, V9, P1324, DOI 10.1097/JTO.0000000000000250
   Wang LJ, 2015, ONCOTARGET, V6, P5932, DOI 10.18632/oncotarget.3465
   Wang P, 2015, CELL SIGNAL, V27, P275, DOI 10.1016/j.cellsig.2014.11.011
   Wang YS, 2012, ASIAN PAC J CANCER P, V13, P255, DOI 10.7314/APJCP.2012.13.1.255
   Xiong Y, 2011, GYNECOL ONCOL, V123, P99, DOI 10.1016/j.ygyno.2011.06.011
   Xu HM, 2016, J PHYSIOL BIOCHEM, V72, P721, DOI 10.1007/s13105-016-0511-7
   Xu JJ, 2015, ONCOL REP, V33, P3108, DOI 10.3892/or.2015.3931
   Yan LX, 2016, INT J ONCOL, V48, P471, DOI 10.3892/ijo.2015.3287
   Yang SM, 2013, TOXICOLOGY, V306, P162, DOI 10.1016/j.tox.2013.02.014
   Yang ZJ, 2016, GYNECOL ONCOL, V141, P231, DOI 10.1016/j.ygyno.2015.06.027
   Zhang W, 2014, CLIN TRANSL ONCOL, V16, P708, DOI 10.1007/s12094-013-1135-9
   Zhou SG, 2014, J CANCER RES CLIN, V140, P1989, DOI 10.1007/s00432-014-1699-y
NR 41
TC 88
Z9 94
U1 0
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JUN 1
PY 2017
VL 623
BP 20
EP 30
DI 10.1016/j.abb.2017.05.001
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EY1OT
UT WOS:000403735900003
PM 28495512
DA 2022-04-25
ER

PT J
AU Stoetzer, OJ
   Wittwer, C
   Lehner, J
   Fahmueller, YN
   Kohles, N
   Fersching, DMI
   Leszinski, G
   Roessner, J
   Holdenrieder, S
AF Stoetzer, Oliver J.
   Wittwer, Christin
   Lehner, Julia
   Fahmueller, Yvonne N.
   Kohles, Nikolaus
   Fersching, Debora M. I.
   Leszinski, Gloria
   Roessner, Juliane
   Holdenrieder, Stefan
TI Circulating nucleosomes and biomarkers of immunogenic cell death as
   predictive and prognostic markers in cancer patients undergoing
   cytotoxic therapy
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE biomarkers; cancer; chemotherapy; DNAse; HMGB1; immunogenic cell death;
   nucleosomes; prediction; prognosis; RAGE; serum; SIRT; TACE
ID LUNG-CANCER; COLORECTAL-CANCER; IMMUNE-RESPONSES; TUMOR RESPONSE; CYFRA
   21-1; HMGB1; SERUM; CHEMOTHERAPY; DNA; AUTOPHAGY
AB Introduction: Immunogenic cell death markers are released from apoptotic and necrotic cells upon pathologic or therapeutic causes and stimulate the innate and adaptive immune system. Cell death products such as nucleosomes, damage-associated molecular pattern (DAMP) molecules such as the high-mobility group box 1 protein (HMGB1) and its receptor of advanced glycation end products (sRAGE) are supposed to play an essential role in driving this process. However, this immunogenic activation may have dual effects, either by sensitizing the immune system for more efficient tumor cell removal or by creating a favorable tumor microenvironment that facilitates tumor growth, proliferation and invasiveness.
   Areas covered: Here, we review recent findings on the relevance of serum nucleosomes, DNAse activity, HMGB1 and sRAGE as biomarkers for the diagnosis, prognosis and therapy prediction in cancer disease.
   Expert opinion: In comparison with healthy controls, cancer patients demonstrated elevated serum levels of nucleosomes and HMGB1 while sRAGE levels were decreased. During locoregional and systemic cytotoxic therapies, a high release of nucleosomes and HMGB1 as well as low release of sRAGE before and during the initial phase of the treatment was found to be associated with poor response to the therapy and patient survival. Therefore, immunogenic cell death markers are promising tools for the prognosis, therapy prediction and monitoring in cancer patients.
C1 [Holdenrieder, Stefan] Univ Hosp Bonn, Inst Clin Chem & Clin Pharmacol, D-53105 Bonn, Germany.
   [Wittwer, Christin; Lehner, Julia; Fahmueller, Yvonne N.; Kohles, Nikolaus; Fersching, Debora M. I.; Leszinski, Gloria; Roessner, Juliane; Holdenrieder, Stefan] Univ Hosp Munich, Inst Clin Chem, D-81366 Munich, Germany.
   [Stoetzer, Oliver J.] Outpatient Specialty Ctr, D-80638 Munich, Germany.
RP Holdenrieder, S (corresponding author), Univ Hosp Bonn, Inst Clin Chem & Clin Pharmacol, Sigmund Freud Str 25, D-53105 Bonn, Germany.
EM Stefan.Holdenrieder@uni-bonn.de
CR Apetoh L, 2008, CANCER RES, V68, P4026, DOI 10.1158/0008-5472.CAN-08-0427
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Beachy SH, 2008, CANCER IMMUNOL IMMUN, V57, P759, DOI 10.1007/s00262-007-0445-6
   Bianchi ME, 2009, J LEUKOCYTE BIOL, V86, P573, DOI 10.1189/jlb.1008585
   Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125-009-1458-9
   Cheng BQ, 2008, DIGEST LIVER DIS, V40, P446, DOI 10.1016/j.dld.2007.11.024
   Chung HW, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-38
   D'Ippolito G, 2011, Q J NUCL MED MOL IM, V55, P603
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fahmueller Y, 2012, INT J CANC IN PRESS
   Fahmueller YN, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-5
   Fehr Y, 2011, CIRCULATING NUCLEIC ACIDS IN PLASMA AND SERUM, P91
   Geiger S, 2006, CEREBROVASC DIS, V21, P32, DOI 10.1159/000089591
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Geroldi D, 2006, CURR MED CHEM, V13, P1971, DOI 10.2174/092986706777585013
   Goldstein RS, 2006, SHOCK, V25, P571, DOI 10.1097/01.shk.0000209540.99176.72
   Holdenrieder S, 2004, TUMOR BIOL, V25, P321, DOI 10.1159/000081401
   Holdenrieder S, 2004, CLIN CANCER RES, V10, P5981, DOI 10.1158/1078-0432.CCR-04-0625
   Holdenrieder S, 2008, ANN NY ACAD SCI, V1137, P180, DOI 10.1196/annals.1448.012
   Holdenrieder S, 2006, ANN NY ACAD SCI, V1075, P318, DOI 10.1196/annals.1368.043
   Holdenrieder S, 2006, ANN NY ACAD SCI, V1075, P244, DOI 10.1196/annals.1368.033
   Holdenrieder S, 2008, CLIN CANCER RES, V14, P7813, DOI 10.1158/1078-0432.CCR-08-0678
   Holdenrieder S, 2009, LUNG CANCER, V63, P128, DOI 10.1016/j.lungcan.2008.05.001
   Holdenrieder S, 2009, CRIT REV CL LAB SCI, V46, P1, DOI [10.1080/10408360802485875, 10.1080/10408360802485875 ]
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4
   Kohles N, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-202
   Koutouzov S, 2004, RHEUM DIS CLIN N AM, V30, P529, DOI 10.1016/j.rdc.2004.04.001
   Kremer A, 2005, TUMOR BIOL, V26, P44, DOI 10.1159/000084339
   Kremer A, 2006, TUMOR BIOL, V27, P235, DOI 10.1159/000094694
   Kulasingam V, 2008, NAT CLIN PRACT ONCOL, V5, P588, DOI 10.1038/ncponc1187
   Kumar S, 2010, CLIN LUNG CANCER, V11, P36, DOI 10.3816/CLC.2010.n.006
   Lehner J, 2012, ANTICANCER IN PRESS
   Li SP, 2012, J MAGN RESON IMAGING, V35, P745, DOI 10.1002/jmri.22838
   Liu RR, 2012, CANCER IMMUNOL IMMUN, V61, P855, DOI 10.1007/s00262-011-1146-8
   Lo YMD, 2000, CLIN CHEM, V46, P319
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Mueller S, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-143
   Naumnik W, 2009, FOLIA HISTOCHEM CYTO, V47, P703, DOI 10.2478/v10042-009-0025-z
   Sallai K, 2005, CLIN DIAGN LAB IMMUN, V12, P56, DOI 10.1128/CDLI.12.1.56-59.2005
   Shang GH, 2009, RESP MED, V103, P1949, DOI 10.1016/j.rmed.2009.05.019
   Sheng XG, 2009, CROAT MED J, V50, P455, DOI 10.3325/cmj.2009.50.455
   Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603
   Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17
   Stieber P, 2010, CANCER BIOMARK, V6, P221, DOI 10.3233/CBM-2009-0132
   Sturgeon CM, 2008, CLIN CHEM, V54, pE11, DOI 10.1373/clinchem.2008.105601
   Sunden-Cullberg J, 2005, CRIT CARE MED, V33, P564, DOI 10.1097/01.ccm.0000155991.88802.4D
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   Tesniere A, 2008, CELL DEATH DIFFER, V15, P3, DOI 10.1038/sj.cdd.4402269
   Urbonaviciute V, 2008, J EXP MED, V205, P3007, DOI 10.1084/jem.20081165
   Weiner LM, 2012, NEW ENGL J MED, V366, P1156, DOI 10.1056/NEJMcibr1114526
   Wittwer C, 2012, ANTICANCER IN PRESS
   Zeerleder S, 2003, CRIT CARE MED, V31, P1947, DOI 10.1097/01.CCM.0000074719.40109.95
   Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216
NR 56
TC 18
Z9 18
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD JUN
PY 2012
VL 12
SU 1
BP S217
EP S224
DI 10.1517/14712598.2012.689280
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 947CY
UT WOS:000304405600026
PM 22620489
DA 2022-04-25
ER

PT J
AU Chi, YY
   Xu, H
   Wang, F
   Chen, XL
   Shan, ZZ
   Sun, Y
   Fan, QX
AF Chi, Yanyan
   Xu, Han
   Wang, Feng
   Chen, Xiaoling
   Shan, Zhengzheng
   Sun, Yan
   Fan, Qingxia
TI ZKSCAN3 promotes breast cancer cell proliferation, migration and
   invasion
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE ZKSCAN3; Breast cancer; Tumor progression; Akt; mTOR
ID COLORECTAL-CANCER; PROGRESSION; REPRESSOR; AUTOPHAGY; LOCALIZATION;
   PROTEINS; SURFACE; GROWTH
AB ZKSCAN3, a zinc-finger transcription factor, which has been shown to be upregulated in several human cancer. However, the expression level, function and mechanism of ZKSCAN3 in breast cancer remains unknown. In the current study, immunohistochemistry, western blot and quantitative real time polymerase chain reaction (qRT-PCR) results showed that ZKSCAN3 was overexpressed in breast cancer tissue compared with normal breast tissue. Through analyzing the clinicopathological characteristics, we demonstrated that positive ZKSCAN3 expression predicted poor prognosis of patients with breast cancer. The expression level of ZKSCAN3 protein/mRNA in breast cancer cells (MCF-7 and MDA-MB-231) was higher than its expression in normal breast cells (HBL-100). Knocking down ZKSCAN3 via its short hairpin RNA (shRNA) in MCF-7 and MDA-MB-231 inhibited cell viability, migration and invasion. Western blot analysis showed that ZKSCAN3 silencing lead to significant decreases in the expression of Cyclin D1, B-cell lymphoma-2 (Bcl-2), and matrix metalloproteinase (MMP)-2/MMP-9, as well as increases in the expression of Bcl2 Associated X Protein (Bax) in breast cancer cells. Additionally, ZKSCAN3-shRNA expression markedly suppressed tumor growth in breast cancer xenograft mice. Finally, we demonstrated that silencing of ZKSCAN3 was able to inhibit Akt/mTOR signaling pathway by blocking p-Akt and p-mTOR protein expression in breast cancer cells. These results demonstrate that ZKSCAN3 plays a significant role in the progression of breast cancer. Therefore, ZKSCAN3 is a potential therapeutic target for breast cancer. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Chi, Yanyan; Wang, Feng; Shan, Zhengzheng; Sun, Yan; Fan, Qingxia] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou 450052, Henan, Peoples R China.
   [Xu, Han] Zhengzhou Univ, Affiliated Hosp 1, Dept Breast Dis Surg, Zhengzhou 450052, Henan, Peoples R China.
   [Chen, Xiaoling] Wenzhou Med Univ, Zhejiang Prov Key Lab Med Genet, Sch Life Sci, Wenzhou 325035, Peoples R China.
RP Sun, Y; Fan, QX (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou 450052, Henan, Peoples R China.
EM YanSun1221@126.com; fqx1221@126.com
CR Akcakanat A, 2008, CANCER-AM CANCER SOC, V112, P2352, DOI 10.1002/cncr.23456
   Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0
   Chauhan S, 2013, MOL CELL, V50, P16, DOI 10.1016/j.molcel.2013.01.024
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chua JP, 2014, HUM MOL GENET, V23, P1376, DOI 10.1093/hmg/ddt527
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Evans AJ, 2004, AM J PATHOL, V164, P285, DOI 10.1016/S0002-9440(10)63118-5
   Fullgrabe J, 2014, NAT REV MOL CELL BIO, V15, P65, DOI 10.1038/nrm3716
   Kawahara T, 2016, ONCOTARGET, V7, P53599, DOI 10.18632/oncotarget.10679
   Liu J. Y., 2018, SPAG5 PROMOTES PROLI
   Lupo A, 2013, CURR GENOMICS, V14, P268, DOI 10.2174/13892029113149990002
   McAuliffe PF, 2010, CLIN BREAST CANCER, V10, pS59, DOI 10.3816/CBC.2010.s.013
   Saftig P, 2016, NAT CELL BIOL, V18, P1025, DOI 10.1038/ncb3409
   Santos GC, 2007, J CLIN PATHOL, V60, P1, DOI 10.1136/jcp.2005.034389
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Takeha S, 1997, JPN J CANCER RES, V88, P72, DOI 10.1111/j.1349-7006.1997.tb00304.x
   Urrutia R, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-231
   Yang L, 2011, ONCOGENE, V30, P1329, DOI 10.1038/onc.2010.515
   Yang L, 2008, CANCER RES, V68, P4321, DOI 10.1158/0008-5472.CAN-08-0407
   Yang L, 2008, J BIOL CHEM, V283, P35295, DOI 10.1074/jbc.M806965200
   Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35
   Yu T, 2015, ONCOGENE, V34, P413, DOI 10.1038/onc.2013.574
   Zhang XD, 2012, INT J BIOCHEM CELL B, V44, P1166, DOI 10.1016/j.biocel.2012.04.005
NR 25
TC 13
Z9 13
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 18
PY 2018
VL 503
IS 4
BP 2583
EP 2589
DI 10.1016/j.bbrc.2018.07.019
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GT8MM
UT WOS:000444791600058
PM 30049438
DA 2022-04-25
ER

PT J
AU Czerwinska, P
   Shah, PK
   Tomczak, K
   Klimczak, M
   Mazurek, S
   Sozanska, B
   Biecek, P
   Korski, K
   Filas, V
   Mackiewicz, A
   Andersen, JN
   Wiznerowicz, M
AF Czerwinska, Patrycja
   Shah, Parantu K.
   Tomczak, Katarzyna
   Klimczak, Marta
   Mazurek, Sylwia
   Sozanska, Barbara
   Biecek, Przemyslaw
   Korski, Konstanty
   Filas, Violetta
   Mackiewicz, Andrzej
   Andersen, Jannik N.
   Wiznerowicz, Maciej
TI TRIM28 multi-domain protein regulates cancer stem cell population in
   breast tumor development
SO ONCOTARGET
LA English
DT Article
DE TRIM28; KAP1; breast cancer stem cells; pluripotency; epigenetics
ID EPITHELIAL-MESENCHYMAL TRANSITION; DIFFERENTIAL EXPRESSION ANALYSIS;
   MITOCHONDRIAL BIOGENESIS; COLORECTAL-CANCER; PANCREATIC-CANCER;
   MOLECULAR SUBTYPE; SELF-RENEWAL; KAP1; PHENOTYPE; AUTOPHAGY
AB The expression of Tripartite motif-containing protein 28 (TRIM28)/Kruppel-associated box (KRAB)-associated protein 1 (KAP1), is elevated in at least 14 tumor types, including solid and hematopoietic tumors. High level of TRIM28 is associated with triple-negative subtype of breast cancer (TNBC), which shows higher aggressiveness and lower survival rates. Interestingly, TRIM28 is essential for maintaining the pluripotent phenotype in embryonic stem cells. Following on that finding, we evaluated the role of TRIM28 protein in the regulation of breast cancer stem cells (CSC) populations and tumorigenesis in vitro and in vivo. Downregulation of TRIM28 expression in xenografts led to deceased expression of pluripotency and mesenchymal markers, as well as inhibition of signaling pathways involved in the complex mechanism of CSC maintenance. Moreover, TRIM28 depletion reduced the ability of cancer cells to induce tumor growth when subcutaneously injected in limiting dilutions. Our data demonstrate that the downregulation of TRIM28 gene expression reduced the ability of CSCs to self-renew that resulted in significant reduction of tumor growth. Loss of function of TRIM28 leads to dysregulation of cell cycle, cellular response to stress, cancer cell metabolism, and inhibition of oxidative phosphorylation. All these mechanisms directly regulate maintenance of CSC population. Our original results revealed the role of the TRIM28 in regulating the CSC population in breast cancer. These findings may pave the way to novel and more effective therapies targeting cancer stem cells in breast tumors.
C1 [Czerwinska, Patrycja; Tomczak, Katarzyna; Klimczak, Marta; Mazurek, Sylwia; Mackiewicz, Andrzej; Wiznerowicz, Maciej] Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Lab Gene Therapy, Poznan, Poland.
   [Czerwinska, Patrycja; Tomczak, Katarzyna; Mackiewicz, Andrzej; Wiznerowicz, Maciej] Poznan Univ Med Sci, Dept Canc Immunol, Chair Med Biotechnol, Poznan, Poland.
   [Czerwinska, Patrycja; Tomczak, Katarzyna; Klimczak, Marta; Mazurek, Sylwia] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.
   [Shah, Parantu K.; Andersen, Jannik N.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77058 USA.
   [Sozanska, Barbara; Biecek, Przemyslaw] Warsaw Univ Technol, Fac Math & Informat Sci, Warsaw, Poland.
   [Biecek, Przemyslaw] Univ Warsaw, Fac Math Informat & Mech, Warsaw, Poland.
   [Korski, Konstanty; Filas, Violetta] Greater Poland Canc Ctr, Dept Canc Pathol, Poznan, Poland.
RP Czerwinska, P; Wiznerowicz, M (corresponding author), Greater Poland Canc Ctr, Dept Diagnost & Canc Immunol, Lab Gene Therapy, Poznan, Poland.; Czerwinska, P; Wiznerowicz, M (corresponding author), Poznan Univ Med Sci, Dept Canc Immunol, Chair Med Biotechnol, Poznan, Poland.; Czerwinska, P (corresponding author), Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.
EM patrycja.czerwinska@wco.pl; maciej.wiznerowicz@wco.pl
RI Czerwinska, Patrycja/AAE-2419-2021
OI Czerwinska, Patrycja/0000-0003-2400-1174; Filas,
   Violetta/0000-0003-2028-877X; , Sylwia/0000-0002-5064-458X; Biecek,
   Przemyslaw/0000-0001-8423-1823
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [CA16672]; PL-Grid Infrastructure; National Science CenterNational
   Science Centre, Poland [3342/B/P01/2010/39]; Greater Poland Cancer
   Center; MD Anderson Cancer Center; NATIONAL CANCER INSTITUTEUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA016672]
   Funding Source: NIH RePORTER
FX MD Anderson Cancer Center RPPA Core Facility is funded by NCI #CA16672.
   The MD Anderson Cancer Center Cancer Genomics Core Laboratory is a part
   of the NCI-funded Cancer Center Support Grant. This research was
   supported in part by PL-Grid Infrastructure. The research was supported
   by the National Science Center grant No: 3342/B/P01/2010/39 and by
   Greater Poland Cancer Center and MD Anderson Cancer Center intramural
   grants.
CR Addison J, 2014, CANCER RES, V75, P344
   Al-Dhfyan A, 2013, SAUDI PHARM J, V21, P229, DOI 10.1016/j.jsps.2012.08.001
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Band V, 2011, J CARCINOG, V10, P38
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Britton KM, 2012, CANCER LETT, V323, P97, DOI 10.1016/j.canlet.2012.03.041
   Brooks MD, 2015, CANCER DISCOV, V5, P469, DOI 10.1158/2159-8290.CD-15-0327
   Callihan P, 2011, PHARMACOL THERAPEUT, V129, P290, DOI 10.1016/j.pharmthera.2010.10.007
   Cann KL, 2011, BIOCHEM CELL BIOL, V89, P45, DOI 10.1139/O10-113
   Chaube B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.404
   Cufi S, 2011, CELL CYCLE, V10, P3871, DOI 10.4161/cc.10.22.17976
   Czerwinska P, 2015, CONT ONCOL A, V1A, P7
   De Luca A, 2015, ONCOTARGET, V6, P14777, DOI 10.18632/oncotarget.4401
   de Sio FRS, 2012, BLOOD, V119, P4675, DOI 10.1182/blood-2011-12-401117
   Del Vecchio CA, 2012, CANCER RES, V72, P2657, DOI 10.1158/0008-5472.CAN-11-2656
   Descamps S, 2001, CANCER RES, V61, P4337
   Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4
   Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107
   Findlay VJ, 2014, CANCER GENE THER, V21, P181, DOI 10.1038/cgt.2014.15
   Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Gonzales KAU, 2015, CELL, V162, P564, DOI 10.1016/j.cell.2015.07.001
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hu G, 2009, GENE DEV, V23, P837, DOI 10.1101/gad.1769609
   Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008
   Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349
   Ito K, 2014, NAT REV MOL CELL BIO, V15, P243, DOI 10.1038/nrm3772
   Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260
   Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200
   Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338
   Li LH, 2006, CANCER RES, V66, P4553, DOI 10.1158/0008-5472.CAN-05-3986
   Li X, 2007, J BIOL CHEM, V282, P36177, DOI 10.1074/jbc.M706912200
   Li X, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000781
   Liu H, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-583
   Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789
   Milla LA, 2012, BIOL RES, V45, P223, DOI 10.4067/S0716-97602012000300004
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Munoz P, 2012, MOL ONCOL, V6, P620, DOI 10.1016/j.molonc.2012.10.006
   Neve RM, 2009, CANCER CELL, V10, P515, DOI DOI 10.1016/J.CCR.2006.10.008
   Okamoto K, 2006, BIOCHEM BIOPH RES CO, V351, P216, DOI 10.1016/j.bbrc.2006.10.022
   Pasto A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010
   Pineda CT, 2015, AUTOPHAGY, V11, P844, DOI 10.1080/15548627.2015.1034420
   Pond AC, 2013, STEM CELLS, V31, P178, DOI 10.1002/stem.1266
   Poyurovsky MV, 2003, MOL CELL, V12, P875, DOI 10.1016/S1097-2765(03)00400-3
   Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Samur MK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056228
   Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Seki Y, 2010, P NATL ACAD SCI USA, V107, P10926, DOI 10.1073/pnas.0907601107
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Singh AM, 2015, STEM CELL REP, V5, P323, DOI 10.1016/j.stemcr.2015.07.005
   Singh S, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-73
   Stickeler E, 2011, ONCOL REP, V26, P1037, DOI 10.3892/or.2011.1392
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tian C, 2009, NAT CELL BIOL, V11, P580, DOI 10.1038/ncb1864
   Venkov CD, 2007, J CLIN INVEST, V117, P482, DOI 10.1172/JCI29544
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Wang CG, 2007, J BIOL CHEM, V282, P29902, DOI 10.1074/jbc.M704757200
   Wang F, 2012, MOL MED, V18, P887, DOI 10.2119/molmed.2011.00444
   Yang YH, 2013, P NATL ACAD SCI USA, V110, P6841, DOI 10.1073/pnas.1217692110
   Yokoe T, 2010, ANN SURG ONCOL, V17, P821, DOI 10.1245/s10434-009-0795-8
   Yu C, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0025-5
   Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012
   Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446
NR 75
TC 29
Z9 31
U1 2
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 3
PY 2017
VL 8
IS 1
BP 863
EP 882
DI 10.18632/oncotarget.13273
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EH1DH
UT WOS:000391503300068
PM 27845900
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Pajuelo-Reguera, D
   Alan, L
   Olejar, T
   Jezek, P
AF Pajuelo-Reguera, David
   Alan, Lukas
   Olejar, Tomas
   Jezek, Petr
TI Dichloroacetate stimulates changes in the mitochondrial network
   morphology via partial mitophagy in human SH-SY5Y neuroblastoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE dichloroacetate; mitochondria; mitophagy; neuroblastoma SH-SY5Y cells;
   mitochondrial network
ID COLORECTAL-CANCER CELLS; IN-VITRO; MEDIATED AUTOPHAGY; PINK1; FUSION;
   METABOLISM; APOPTOSIS; FISSION; PROTEIN; PARKIN
AB Dichloroacetate (DCA) is beneficial in cancer therapy because it induces apoptosis and decreases cancer growth in vitro and in vivo without affecting non-cancer cells. DCA stimulates the activity of the enzyme pyruvate dehydrogenase by inhibiting pyruvate dehydrogenase kinase. Consequently, DCA promotes oxidative phosphorylation after glycolysis. Therefore, DCA produces changes in energy metabolism that could affect the mitochondrial network and mitophagy. This investigation determined the effects of DCA treatment on mitophagy in human neuroblastoma SH-SY5Y cells. SH-SY5Y cells were cultured and distributed into 3 groups: control, NH4Cl and chloroquine. Each group was treated with DCA at 0, 5, 30 and 60 mM for 16 h. Samples were analyzed for cell viability, mtDNA copy number, mitochondrial network morphology and expression of key proteins involved in mitochondrial dynamics, such as LC3b, FIS1, OPA1, PARKIN and PINK1. In all groups, DCA caused a decrease in cell viability, an induction of autophagy in a dose-dependent manner and a decrease in Tim23, FIS1 and PARKIN protein expression, leading to profound morphological changes in the mitochondrial network resulting in shorter and more fragmented filaments. However, TFAM protein levels remained unchanged. Similarly, the mitochondrial copy number was not significantly different among the treatment groups. In conclusion, DCA induces mitophagy and remodeling of the mitochondrial network. In this remodeling, DCA induces a decrease in the expression of key proteins involved in protein degradation and mitochondrial dynamics but does not significantly affect the mtDNA density. Blocking late phase autophagy increases the effects of DCA, suggesting that autophagy protects the cell, at least partially, against DCA.
C1 [Pajuelo-Reguera, David; Alan, Lukas; Olejar, Tomas; Jezek, Petr] Acad Sci Czech Republic, Inst Physiol, Dept Membrane Transport Biophys, Prague, Czech Republic.
RP Pajuelo-Reguera, D (corresponding author), Acad Sci Czech Republic, Inst Physiol, Dept Membrane Transport Biophys, Prague, Czech Republic.
EM d.pajuel@outlook.com
RI Olejar, Tomas/E-3760-2017; Reguera, David Pajuelo/G-3814-2014; Jezek,
   Petr/B-9264-2012; Alán, Lukáš/H-9063-2013
OI Olejar, Tomas/0000-0002-0786-5029; Reguera, David
   Pajuelo/0000-0002-7715-9402; Jezek, Petr/0000-0002-2720-9395; Alán,
   Lukáš/0000-0001-7417-2620; olejar, tomas/0000-0002-6469-6970
FU Centre of Biomedical Research [CZ.1.07/2.3.00/30.0025]; European Social
   FundEuropean Social Fund (ESF); state budget of the Czech Republic
FX This study was supported within the project The Centre of Biomedical
   Research (CZ.1.07/2.3.00/30.0025). This study was also co-funded by the
   European Social Fund and the state budget of the Czech Republic.
CR Alan L, 2011, TRANSPL P, V43, P3281, DOI 10.1016/j.transproceed.2011.09.055
   Astuti D, 2003, CLIN ENDOCRINOL, V59, P728, DOI 10.1046/j.1365-2265.2003.01914.x
   Ayyanathan K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039949
   Bertholet AM, 2013, BRAIN, V136, P1518, DOI 10.1093/brain/awt060
   BIEDLER JL, 1978, CANCER RES, V38, P3751
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   Cai QA, 2010, NEURON, V68, P73, DOI 10.1016/j.neuron.2010.09.022
   Cao WG, 2008, PROSTATE, V68, P1223, DOI 10.1002/pros.20788
   Castino R, 2011, TOXICOL SCI, V123, P523, DOI 10.1093/toxsci/kfr179
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Cheng P, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.17
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Exner N, 2007, J NEUROSCI, V27, P12413, DOI 10.1523/JNEUROSCI.0719-07.2007
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023
   Gandhi S, 2006, BRAIN, V129, P1720, DOI 10.1093/brain/awl114
   Gaude E, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-10
   Gong F, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.438
   Kankotia S, 2014, BBA-REV CANCER, V1846, P617, DOI 10.1016/j.bbcan.2014.08.005
   KARESS RE, 1979, P NATL ACAD SCI USA, V76, P3154, DOI 10.1073/pnas.76.7.3154
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kopek BG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077209
   Lin G, 2014, BRIT J CANCER, V111, P375, DOI 10.1038/bjc.2014.281
   Maclean KH, 2008, J CLIN INVEST, V118, P79, DOI 10.1172/JCI33700
   Madhok BM, 2010, BRIT J CANCER, V102, P1746, DOI 10.1038/sj.bjc.6605701
   Maes H, 2014, CANCER CELL, V26, P190, DOI 10.1016/j.ccr.2014.06.025
   Matthay K K, 1997, Oncology (Williston Park), V11, P1857
   MATTHAY KK, 1997, ONCOLOGY, V11, P1869
   MATTHAY KK, 1997, ONCOLOGY, V11, P1875
   Michiorri S, 2010, CELL DEATH DIFFER, V17, P962, DOI 10.1038/cdd.2009.200
   MORTON RE, 1992, ANAL BIOCHEM, V204, P332, DOI 10.1016/0003-2697(92)90248-6
   Nakahara K, 2014, J NEUROL SCI, V345, P276, DOI 10.1016/j.jns.2014.07.053
   PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X
   Raynaud FI, 2007, CANCER RES, V67, P5840, DOI 10.1158/0008-5472.CAN-06-4615
   Sanchez WY, 2013, BRIT J CANCER, V108, P1624, DOI 10.1038/bjc.2013.120
   Santin G, 2013, NEUROTOXICOLOGY, V34, P51, DOI 10.1016/j.neuro.2012.10.011
   Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0
   Scarffe LA, 2014, TRENDS NEUROSCI, V37, P315, DOI 10.1016/j.tins.2014.03.004
   Schaffer S, 2011, BIOGERONTOLOGY, V12, P195, DOI 10.1007/s10522-010-9310-7
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Singleterry J, 2014, MITOCHONDRION, V17, P50, DOI 10.1016/j.mito.2014.05.010
   Stacpoole PW, 2011, ENVIRON HEALTH PERSP, V119, P155, DOI 10.1289/ehp.1002554
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Stockwin LH, 2010, INT J CANCER, V127, P2510, DOI 10.1002/ijc.25499
   Sun RC, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-142
   Sun RC, 2010, BREAST CANCER RES TR, V120, P253, DOI 10.1007/s10549-009-0435-9
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Vella S, 2012, INT J CANCER, V130, P1484, DOI 10.1002/ijc.26173
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107
   Wong JYY, 2008, GYNECOL ONCOL, V109, P394, DOI 10.1016/j.ygyno.2008.01.038
   Youle RJ, 2011, NAT REV MOL CELL BIO, V12, P9, DOI 10.1038/nrm3028
   Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697
   Zorzano A, 2010, SEMIN CELL DEV BIOL, V21, P566, DOI 10.1016/j.semcdb.2010.01.002
NR 56
TC 9
Z9 9
U1 1
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUN
PY 2015
VL 46
IS 6
BP 2409
EP 2418
DI 10.3892/ijo.2015.2953
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI3QK
UT WOS:000354662300014
PM 25846762
OA Bronze
DA 2022-04-25
ER

PT J
AU Bachari, A
   Piva, TJ
   Salami, SA
   Jamshidi, N
   Mantri, N
AF Bachari, Ava
   Piva, Terrence J.
   Salami, Seyed Alireza
   Jamshidi, Negar
   Mantri, Nitin
TI Roles of Cannabinoids in Melanoma: Evidence from In Vivo Studies
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE medicinal herbs; apoptosis; THC; CBD; melanoma; cannabinoids
ID METASTATIC MELANOMA; CUTANEOUS MELANOMA; POTENTIAL ROLE; CANCER PAIN;
   CANNABIDIOL; VEMURAFENIB; RECEPTOR; THERAPY; GROWTH; CELLS
AB Melanoma is the fourth most common type of cancer diagnosed in Australians after breast, prostate, and colorectal cancers. While there has been substantial progress in the treatment of cancer in general, malignant melanoma, in particular, is resistant to existing medical therapies requiring an urgent need to develop effective treatments with lesser side effects. Several studies have shown that "cannabinoids", the major compounds of theCannabis sativaL.plant, can reduce cell proliferation and induce apoptosis in melanoma cells. Despite prohibited use ofCannabisin most parts of the world, in recent years there have been renewed interests in exploiting the beneficial health effects of theCannabisplant-derived compounds. Therefore, the aim of this study was in the first instance to review the evidence from in vivo studies on the effects of cannabinoids on melanoma. Systematic searches were carried out in PubMed, Embase, Scopus, and ProQuest Central databases for relevant articles published from inception. From a total of 622 potential studies, six in vivo studies assessing the use of cannabinoids for treatment of melanoma were deemed eligible for the final analysis. The findings revealed cannabinoids, individually or combined, reduced tumor growth and promoted apoptosis and autophagy in melanoma cells. Further preclinical and animal studies are required to determine the underlying mechanisms of cannabinoids-mediated inhibition of cancer-signaling pathways. Well-structured, randomized clinical studies on cannabinoid use in melanoma patients would also be required prior to cannabinoids becoming a viable and recognized therapeutic option for melanoma treatment in patients.
C1 [Bachari, Ava; Mantri, Nitin] RMIT Univ, Sch Sci, Melbourne, Vic 3083, Australia.
   [Piva, Terrence J.; Jamshidi, Negar] RMIT Univ, Sch Hlth & Biomed Sci, POB 71, Melbourne, Vic 3083, Australia.
   [Salami, Seyed Alireza] Univ Tehran, Fac Agr Sci & Engn, Karaj 31587, Iran.
RP Mantri, N (corresponding author), RMIT Univ, Sch Sci, Melbourne, Vic 3083, Australia.
EM Ava.Bachari@student.rmit.edu.au; terry.piva@rmit.edu.au;
   asalami@ut.ac.ir; negar.jamshidi@rmit.edu.au; nitin.mantri@rmit.edu.au
RI Salami, Seyed Alireza/AAC-7474-2022; Piva, Terrence/E-4129-2012
OI bachari, Ava/0000-0002-9864-2794; Piva, Terrence/0000-0003-0343-1781;
   Mantri, Nitin/0000-0002-7621-035X
FU MGC Pharmaceuticals Limited, Australia; RMIT University Scholarship
FX This research is funded by MGC Pharmaceuticals Limited, Australia. Ava
   Bachari is a Ph.D. student supported by an RMIT University Scholarship.
CR Armstrong JL, 2015, J INVEST DERMATOL, V135, P1629, DOI 10.1038/jid.2015.45
   Ball S, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19120
   Basu S, 2011, J IMMUNOL, V187, P5720, DOI 10.4049/jimmunol.1102195
   Blake A, 2017, ANN PALLIAT MED, V6, pS215, DOI 10.21037/apm.2017.08.05
   Blazquez C, 2004, CANCER RES, V64, P5617, DOI 10.1158/0008-5472.CAN-03-3927
   Blazquez C, 2006, FASEB J, V20, P2633, DOI 10.1096/fj.06-6638fje
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brown MRD, 2018, EUR J INTERN MED, V49, P30, DOI 10.1016/j.ejim.2018.01.020
   Daris B, 2019, BOSNIAN J BASIC MED, V19, P14, DOI 10.17305/bjbms.2018.3532
   Davey RJ, 2016, CRIT REV ONCOL HEMAT, V98, P242, DOI 10.1016/j.critrevonc.2015.11.011
   Gandhi S, 2017, CUAJ-CAN UROL ASSOC, V11, pE138, DOI 10.5489/cuaj.4371
   Gandini S, 2005, EUR J CANCER, V41, P2040, DOI 10.1016/j.ejca.2005.03.034
   Garbe C, 2016, EUR J CANCER, V63, P201, DOI 10.1016/j.ejca.2016.05.005
   Glodde N, 2015, LIFE SCI, V138, P35, DOI 10.1016/j.lfs.2015.04.003
   Griffin LL, 2016, CLIN MED, V16, P62, DOI 10.7861/clinmedicine.16-1-62
   Gudbjartsson DF, 2008, NAT GENET, V40, P886, DOI 10.1038/ng.161
   Guzman M, 2006, BRIT J CANCER, V95, P197, DOI 10.1038/sj.bjc.6603236
   Guzman M, 2003, NAT REV CANCER, V3, P745, DOI 10.1038/nrc1188
   Hanus LO, 2016, NAT PROD REP, V33, P1357, DOI 10.1039/c6np00074f
   Happyana N, 2016, PLANTA MED, V82, P1217, DOI 10.1055/s-0042-108058
   Hassan S., 2018, J PAIN MANAG MED, V4, P1, DOI DOI 10.35248/2684-1320.18.4.131
   Haustein M, 2014, BIOCHEM PHARMACOL, V92, P312, DOI 10.1016/j.bcp.2014.07.014
   Heakal Y, 2011, ANN PHARMACOTHER, V45, P1399, DOI 10.1345/aph.1Q363
   Hinz B, 2019, BRIT J PHARMACOL, V176, P1384, DOI 10.1111/bph.14426
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Izzo AA, 2009, PHARMACOL RES, V60, P117, DOI 10.1016/j.phrs.2009.03.008
   Johnson JR, 2010, J PAIN SYMPTOM MANAG, V39, P167, DOI 10.1016/j.jpainsymman.2009.06.008
   Kenessey I, 2012, PATHOL ONCOL RES, V18, P857, DOI 10.1007/s12253-012-9515-y
   Khan MI, 2016, CURR PHARM DESIGN, V22, P1756, DOI 10.2174/1381612822666151211094901
   Kirkwood JM, 2010, CLIN CANCER RES, V16, P1042, DOI 10.1158/1078-0432.CCR-09-2033
   Kuhathasan N, 2019, EXP CLIN PSYCHOPHARM, V27, P383, DOI 10.1037/pha0000285
   LADIN DA, 2016, FRONT PHARMACOL, V7, DOI DOI 10.3389/FPHAR.2016.00361
   Lafaye G, 2017, DIALOGUES CLIN NEURO, V19, P309
   Lasithiotakis K, 2008, CANCER, V112, P1795, DOI 10.1002/cncr.23359
   Lee CS, 2017, PHARMACOTHERAPY, V37, P319, DOI 10.1002/phar.1895
   Leweke FM, 2016, BIOL PSYCHIAT, V79, P604, DOI 10.1016/j.biopsych.2015.11.018
   Ligresti A, 2006, J PHARMACOL EXP THER, V318, P1375, DOI 10.1124/jpet.106.105247
   Lopez-Valero I, 2018, BIOCHEM PHARMACOL, V157, P266, DOI 10.1016/j.bcp.2018.09.007
   Luke JJ, 2012, CLIN CANCER RES, V18, P9, DOI 10.1158/1078-0432.CCR-11-2197
   Marcu JP, 2010, MOL CANCER THER, V9, P180, DOI 10.1158/1535-7163.MCT-09-0407
   Marks Dustin H., 2018, Skin Therapy Lett, V23, P1
   Maverakis E, 2015, ACTA DERM-VENEREOL, V95, P516, DOI 10.2340/00015555-2035
   McKallip RJ, 2005, J IMMUNOL, V174, P3281, DOI 10.4049/jimmunol.174.6.3281
   Merhavi-Shoham E, 2017, CANCER J, V23, P48, DOI 10.1097/PPO.0000000000000240
   Milando R, 2019, AM J CLIN DERMATOL, V20, P167, DOI 10.1007/s40257-018-0410-5
   Moher D., 2015, REV ESP NUTR HUM DIE, V4, P1, DOI [DOI 10.1186/2046-4053-4-1, 10.1186/2046-4053-4-1]
   Moshi MJ, 2013, ELSEV INSIGHT, P843, DOI 10.1016/B978-0-12-405927-6.00023-0
   Olsen CM, 2019, J INVEST DERMATOL, V139, P1392, DOI 10.1016/j.jid.2018.12.006
   Ramesh, 2008, AFR J PHARM PHARMACO, V2, P130
   Ribas Antoni, 2007, Update Cancer Ther, V2, P133, DOI 10.1016/j.uct.2007.09.001
   Serrone L, 2000, J EXP CLIN CANC RES, V19, P21
   Simmerman E, 2019, J SURG RES, V235, P210, DOI 10.1016/j.jss.2018.08.055
   Singh Y, 2013, CASE REP ONCOL, V6, P585, DOI 10.1159/000356446
   Soderstrom K, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00720
   Strouse T, 2016, J COMMUNITY SUPPORT, V14, P1, DOI 10.12788/jcso.0212
   Taha T, 2019, ONCOLOGIST, V24, P549, DOI 10.1634/theoncologist.2018-0383
   Tariq A. L., 2012, International Research Journal of Biotechnology, V3, P022
   Torres S, 2011, MOL CANCER THER, V10, P90, DOI 10.1158/1535-7163.MCT-10-0688
   Vainio H, 2000, INT J CANCER, V88, P838, DOI 10.1002/1097-0215(20001201)88:5<838::AID-IJC25>3.0.CO;2-X
   Velasco G, 2016, CURR ONCOL, V23, pS23, DOI 10.3747/co.23.3080
   Velasco G, 2015, HANDB EXP PHARMACOL, V231, P449, DOI 10.1007/978-3-319-20825-1_16
   Wang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2864384
NR 62
TC 6
Z9 6
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 17
AR 6040
DI 10.3390/ijms21176040
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NO6NK
UT WOS:000569606100001
PM 32839414
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, XY
   Liu, QK
   Wang, K
   Luo, WZ
   Liang, TS
   Yuan, SP
   Zhen, YW
   Yan, DM
AF Li, Xueyuan
   Liu, Qiankun
   Wang, Kang
   Luo, Wenzheng
   Liang, Tiansong
   Yuan, Shanpeng
   Zhen, Yingwei
   Yan, Dongming
TI RETRACTED: LncRNA SNHG5 regulates the cell viability and apoptosis of
   glioma cells by the miR-1297/KPNA2 axis (Retracted article. See vol. 11,
   pg. 6239, 2021)
SO RSC ADVANCES
LA English
DT Article; Retracted Publication
ID COLORECTAL-CANCER; MICRORNA-1297; PROLIFERATION; PROGNOSIS; PROMOTES;
   GROWTH; GLIOBLASTOMA; METASTASIS; MIGRATION; INVASION
AB Long non-coding RNA small nucleolar RNA host gene 5 (lncRNA SNHG5) has been reported to participate in the occurrence and development of glioma. However, the function and underlying molecular mechanisms of SNHG5 in glioma remain largely unknown. The expressions of SNHG5, microRNA-1297 (miR-1297) and karyopherin subunit alpha 2 (KPNA2) in glioma tissues and cells were evaluated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) or western blot. 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay and flow cytometry were used to detect cell viability and apoptosis, respectively. Western blot was also performed to detect the expressions of autophagy-associated proteins. The relationship among lncRNA SNHG5, miR-1297 and KPNA2 was verified by luciferase reporter assay and RNA immunoprecipitation (RIP) assay. SNHG5 and KPNA2 were over expressed, and the level of miR-1297 was down-regulated in glioma tissues and cell lines. Knockdown of SHNG5 promoted apoptosis, while suppressing cell viability and autophagy of A172 and LN340 cells. Meanwhile, SHNG5 harbored the binding sites with miR-1297, and a negative correlation between the expression of SNHG5 and miR-1297 in glioma tissues was also observed. Interestingly, silencing of miR-1297 undermined the SHNG5 depletion-mediated effect on cell viability, apoptosis, and autophagy. KPNA2 was a direct target of miR-1297, and negatively regulated by miR-1297. More importantly, gain of KPNA2 mitigated the effect of SHNG5l knockdown on glioma cells. Silencing of SNHG5 had an implication in inhibiting apoptosis and stimulating cell viability and autophagy by the miR-1297/KPNA2 axis in glioma.
C1 [Li, Xueyuan; Liu, Qiankun; Wang, Kang; Luo, Wenzheng; Yuan, Shanpeng; Zhen, Yingwei; Yan, Dongming] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Longhu Middle Ring Rd, Zhengzhou 450000, Henan, Peoples R China.
   [Liang, Tiansong] Zhengzhou Univ, Affiliated Hosp 1, Dept Radiotherapy, Zhengzhou, Henan, Peoples R China.
RP Yan, DM (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Neurosurg, 1 Longhu Middle Ring Rd, Zhengzhou 450000, Henan, Peoples R China.
EM mrdmyan@163.com
FU Henan Science and Technology Research Project [172102410015]; Henan
   Province Higher Education Research Project [18A320077]; Medical Science
   and Technology Project of Henan Province [2018020043]
FX This work was supported by Henan Science and Technology Research Project
   (No. 172102410015), Henan Province Higher Education Research Project
   (No. 18A320077) and Medical Science and Technology Project of Henan
   Province (No. 2018020043).
CR Aprea J, 2015, EMBO J, V34, P2865, DOI 10.15252/embj.201592655
   Bolha L, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7243968
   Bu WJ, 2017, DNA CELL BIOL, V36, P976, DOI 10.1089/dna.2017.3886
   Chen ZH, 2018, ARTIF CELL NANOMED B, V46, P1120, DOI 10.1080/21691401.2018.1479711
   Chen ZL, 2018, MOL CELL PROBE, V40, P19, DOI 10.1016/j.mcp.2018.06.003
   Damas ND, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13875
   Delgado-Lopez PD, 2016, CLIN TRANSL ONCOL, V18, P1062, DOI 10.1007/s12094-016-1497-x
   Guo XG, 2019, ACTA BIOCH BIOPH SIN, V51, P285, DOI 10.1093/abbs/gmz003
   Hu XH, 2019, J CANCER, V10, P1333, DOI 10.7150/jca.29517
   Huang L, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317706289
   Iwakawa HO, 2015, TRENDS CELL BIOL, V25, P651, DOI 10.1016/j.tcb.2015.07.011
   Jin JG, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.108968
   Ju C, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0641-9
   Kouri FM, 2015, CELL CYCLE, V14, P3794, DOI 10.1080/15384101.2015.1093711
   Lapointe S, 2018, LANCET, V392, P432, DOI 10.1016/S0140-6736(18)30990-5
   Li GX, 2019, J NEURO-ONCOL, V143, P525, DOI 10.1007/s11060-019-03185-0
   Li XJ, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190668
   Li YR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0882-5
   Lian Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0918-9
   Liang X, 2016, BIOCHEM BIOPH RES CO, V480, P208, DOI 10.1016/j.bbrc.2016.10.029
   Liu C, 2017, ONCOL REP, V38, P2435, DOI 10.3892/or.2017.5884
   Liu CY, 2016, ONCOL LETT, V12, P5177, DOI 10.3892/ol.2016.5326
   Liu L, 2018, J CELL PHYSIOL, V233, P6822, DOI 10.1002/jcp.26432
   Ma ZP, 2018, ONCOL LETT, V15, P1924, DOI 10.3892/ol.2017.7527
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Takada T, 2016, J SURG ONCOL, V113, P213, DOI 10.1002/jso.24114
   Taylor LP, 2010, NEUROLOGY, V75, pS28, DOI 10.1212/WNL.0b013e3181fb3661
   Wang HZ, 2015, ONCOTARGETS THER, V8, P3211, DOI 10.2147/OTT.S79282
   Wang JC, 2016, AM J TRANSL RES, V8, P2149
   Wang YA, 2017, DNA CELL BIOL, V36, P991, DOI 10.1089/dna.2017.3829
   Wang ZY, 2017, ONCOL REP, V38, P3121, DOI 10.3892/or.2017.5979
   Wu ZW, 2016, ONCOL REP, V35, P869, DOI 10.3892/or.2015.4418
   Young RM, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.05.10
   Zhang LN, 2019, J GENE MED, V21, DOI 10.1002/jgm.3074
   Zhang XQ, 2019, ANTI-CANCER DRUG, V30, P803, DOI 10.1097/CAD.0000000000000776
   Zhang ZH, 2019, J CANCER RES THER, V15, P927, DOI 10.4103/jcrt.JCRT_284_19
   Zhao LM, 2017, FASEB J, V31, P893, DOI 10.1096/fj.201600994R
   Zhou K, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0849-2
NR 38
TC 3
Z9 3
U1 0
U2 0
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD JAN 8
PY 2020
VL 10
IS 3
BP 1498
EP 1506
DI 10.1039/c9ra08693e
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA KC6PD
UT WOS:000507296300032
OA gold
DA 2022-04-25
ER

PT J
AU Rrapaj, E
   Trisolini, E
   Bertero, L
   Salvo, M
   Indellicato, R
   Andorno, S
   Garcia-Manteiga, JM
   Rena, O
   Boldorini, RL
AF Rrapaj, Eltjona
   Trisolini, Elena
   Bertero, Luca
   Salvo, Michela
   Indellicato, Rossella
   Andorno, Silvano
   Garcia-Manteiga, Jose M.
   Rena, Ottavio
   Boldorini, Renzo L.
TI Expression analysis of HMGB1 in histological samples of malignant
   pleural mesothelioma
SO HISTOPATHOLOGY
LA English
DT Article
DE biomarker; high mobility group box 1; histological samples; malignant
   pleural mesothelioma; prognosis
ID GROUP BOX 1; MOBILITY GROUP BOX-1; REGULATES AUTOPHAGY; ASBESTOS
   EXPOSURE; COLORECTAL-CANCER; CHROMATIN PROTEIN; GENE-EXPRESSION; CELL;
   CARCINOMA; CARCINOGENESIS
AB AimsHigh mobility group box 1 (HMGB1) is a chromatin structural protein, expressed ubiquitously in the nuclei of mammalian cells. When transported extracellularly, it acts as a tumour suppressor and oncogenic protein. In malignant pleural mesothelioma (MPM), high serum levels of HMGB1 have been related to a poor prognosis. Conversely, the significance of HMGB1 expression in MPM tissues is still unclear.
   Methods and resultsBiopsy samples from 170 patients with MPM were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) to evaluate HMGB1 protein and gene expression. The expression level of HMGB1 protein was scored using a semiquantitative system that sums the intensity (0-3) and the percentage (from 0 to 4) of positively stained cells in nuclei, cytoplasm and in both. The final score was considered as high (>3) or low (<3) expression. Gene expression levels were calculated using the C-t method. High expression levels of HMGB1 as total (P = 0.0011) and cytoplasmic score (P = 0.0462) were related to a worse disease-specific survival (DSS) in the entire cohort and in the clinicopathological subgroups. No significant correlation was found between HMGB1 gene expression and DSS.
   ConclusionsThese findings indicate that HMGB1 may be a useful prognostic biomarker in MPM when detected by immunohistochemistry. Conversely, as it is also expressed in normal and reactive mesothelial cells, HMGB1 cannot be considered a diagnostic biomarker in histological samples of mesothelioma.
C1 [Rrapaj, Eltjona; Trisolini, Elena; Salvo, Michela; Indellicato, Rossella; Andorno, Silvano; Boldorini, Renzo L.] Univ Piemonte Orientale, Dept Hlth Sci, Via Solaroli 17, I-28100 Novara, Italy.
   [Bertero, Luca] Univ Turin, Dept Med Sci, Div Pathol, Turin, Italy.
   [Garcia-Manteiga, Jose M.] IRCCS San Raffaele Hosp, Ctr Translat Genom & Bioinformat, Milan, Italy.
   [Rena, Ottavio] Maggiore della Carita Hosp, Unit Thorac Surg, Novara, Italy.
   [Boldorini, Renzo L.] Maggiore della Carita Hosp, Unit Pathol, Novara, Italy.
RP Boldorini, RL (corresponding author), Univ Piemonte Orientale, Dept Hlth Sci, Via Solaroli 17, I-28100 Novara, Italy.
EM renzo.boldorini@med.uniupo.it
RI Rrapaj, Eltjona/AAW-1390-2020; Rrapaj, Eltjona/AAO-1526-2020; Bertero,
   Luca/N-5357-2017; Manteiga, Jose Manuel Garcia/AAN-1954-2020; Trisolini,
   Elena/J-2698-2017; BOLDORINI, Renzo Luciano/J-5330-2016
OI Rrapaj, Eltjona/0000-0003-3601-4888; Bertero, Luca/0000-0001-9887-7668;
   Manteiga, Jose Manuel Garcia/0000-0002-5481-040X; Trisolini,
   Elena/0000-0003-0919-3630; Andorno, Silvano/0000-0002-4207-2227;
   BOLDORINI, Renzo Luciano/0000-0003-1183-2737; Indellicato,
   Rossella/0000-0003-2134-4665
FU Department of Health Sciences, University of Eastern Piedmont, Novara
   (Italy)
FX This work was supported in part by the funds of Department of Health
   Sciences, University of Eastern Piedmont, Novara (Italy). The authors
   thank Fjona Zeneli MSc from the University of Porto (Portugal), Faculty
   of Economics for her assistance performing in part the statistical
   analysis of data. The authors also thank Professor Marco E. Bianchi, San
   Raffaele Institute who provided general support for this work.
CR Akaike H, 2007, ANTICANCER RES, V27, P449
   Andersson U, 2014, J INTERN MED, V276, P420, DOI 10.1111/joim.12309
   Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030
   Brezniceanu ML, 2003, FASEB J, V17, P1295, DOI 10.1096/fj.02-0621fje
   Bridda Alessio, 2007, MedGenMed, V9, P32
   Brierley J., 2016, TNM CLASSIFICATION M, V8th ed
   Carbone M, 2012, J CELL PHYSIOL, V227, P44, DOI 10.1002/jcp.22724
   Curran D, 1998, J CLIN ONCOL, V16, P145, DOI 10.1200/JCO.1998.16.1.145
   Ellerman JE, 2007, CLIN CANCER RES, V13, P2836, DOI 10.1158/1078-0432.CCR-06-1953
   Fennell DA, 2008, NAT CLIN PRACT ONCOL, V5, P136, DOI 10.1038/ncponc1039
   Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198
   Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679
   Hollevoet K, 2012, J CLIN ONCOL, V30, P1541, DOI 10.1200/JCO.2011.39.6671
   Husain AN, 2013, ARCH PATHOL LAB MED, V137, P647, DOI 10.5858/arpa.2012-0214-OA
   Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481
   Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495
   Koo CL, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-25
   Kostova N, 2010, MOL CELL BIOCHEM, V337, P251, DOI 10.1007/s11010-009-0305-0
   Liu K, 2014, AUTOPHAGY, V10, P442, DOI 10.4161/auto.27418
   Liu Y, 2010, EUR J CANCER, V46, P3007, DOI 10.1016/j.ejca.2010.07.016
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594
   Mittal D, 2010, EMBO J, V29, P2242, DOI 10.1038/emboj.2010.94
   Moore AJ, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-34
   Muller S, 2004, J INTERN MED, V255, P332, DOI 10.1111/j.1365-2796.2003.01296.x
   Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337
   Napolitano A, 2016, CLIN CANCER RES, V22, P3087, DOI 10.1158/1078-0432.CCR-15-1130
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Pass HI, 2012, NEW ENGL J MED, V367, P1417, DOI 10.1056/NEJMoa1115050
   Pass HI, 2005, NEW ENGL J MED, V353, P1564, DOI 10.1056/NEJMoa051185
   Peto J, 1999, BRIT J CANCER, V79, P666, DOI 10.1038/sj.bjc.6690105
   Soumaoro LT, 2004, CLIN CANCER RES, V10, P8465, DOI 10.1158/1078-0432.CCR-04-0653
   Tabata C, 2013, J CLIN GASTROENTEROL, V47, P684, DOI 10.1097/MCG.0b013e318297fa65
   Tabata C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-205
   Tan C, 2005, J ROY SOC MED, V98, P455, DOI 10.1258/jrsm.98.10.455
   Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078
   Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014
   Testa JR, 2011, NAT GENET, V43, P1022, DOI 10.1038/ng.912
   Travis W., 2015, WHO CLASSIFICATION T
   Ueda M, 2014, ANTICANCER RES, V34, P5357
   Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136
   Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729
   WAGNER J C, 1960, Br J Ind Med, V17, P260
   Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391
   Wu TY, 2016, ONCOTARGET, V7, P50417, DOI 10.18632/oncotarget.10413
   Yang HN, 2010, P NATL ACAD SCI USA, V107, P12611, DOI 10.1073/pnas.1006542107
   Yang HN, 2008, CURR TREAT OPTION ON, V9, P147, DOI 10.1007/s11864-008-0067-z
   Zhang CL, 2013, ACTA BIOCH BIOPH SIN, V45, P1055, DOI 10.1093/abbs/gmt109
NR 48
TC 9
Z9 9
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0309-0167
EI 1365-2559
J9 HISTOPATHOLOGY
JI Histopathology
PD MAY
PY 2018
VL 72
IS 6
BP 1039
EP 1050
DI 10.1111/his.13470
PG 12
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA GC9GY
UT WOS:000430106700016
PM 29356044
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Honkala, AT
   Tailor, D
   Malhotra, SV
AF Honkala, Alexander T.
   Tailor, Dhanir
   Malhotra, Sanjay V.
TI Guanylate-Binding Protein 1: An Emerging Target in Inflammation and
   Cancer
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE guanylate-binding protein 1; cytokine-induced GTPase; inflammation;
   interferon alpha (IFN alpha); infection; cancer
ID IFN-GAMMA; NUCLEOTIDE-BINDING; ENDOTHELIAL-CELLS; ALPHA-INTERFERON;
   GTPASE-ACTIVITY; GENE; HGBP1; IDENTIFICATION; GROWTH; PROLIFERATION
AB Guanylate-binding protein 1 (GBP1) is a large GTPase of the dynamin superfamily involved in the regulation of membrane, cytoskeleton, and cell cycle progression dynamics. In many cell types, such as endothelial cells and monocytes, GBP1 expression is strongly provoked by interferon gamma (IFN gamma) and acts to restrain cellular proliferation in inflammatory contexts. In immunity, GBP1 activity is crucial for the maturation of autophagosomes infected by intracellular pathogens and the cellular response to pathogen-associated molecular patterns. In chronic inflammation, GBP1 activity inhibits endothelial cell proliferation even as it protects from IFN gamma-induced apoptosis. A similar inhibition of proliferation has also been found in some tumor models, such as colorectal or prostate carcinoma mouse models. However, this activity appears to be context-dependent, as in other cancers, such as oral squamous cell carcinoma and ovarian cancer, GBP1 activity appears to anchor a complex, taxane chemotherapy resistance profile where its expression levels correlate with worsened prognosis in patients. This discrepancy in GBP1 function may be resolved by GBP1's involvement in the induction of a cellular senescence phenotype, wherein anti-proliferative signals coincide with potent resistance to apoptosis and set the stage for dysregulated proliferative mechanisms present in growing cancers to hijack GBP1 as a pro- chemotherapy treatment resistance (TXR) and pro-survival factor even in the face of continued cytotoxic treatment. While the structure of GBP1 has been extensively characterized, its roles in inflammation, TXR, senescence, and other biological functions remain under-investigated, although initial findings suggest that GBP1 is a compelling target for therapeutic intervention in a variety of conditions ranging from chronic inflammatory disorders to cancer.
C1 [Honkala, Alexander T.; Tailor, Dhanir; Malhotra, Sanjay V.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
RP Malhotra, SV (corresponding author), Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA.
EM smalhotra@stanford.edu
OI Honkala, Alexander/0000-0002-7338-4039
CR Abdullah N, 2009, J MOL BIOL, V386, P690, DOI 10.1016/j.jmb.2008.12.060
   Al-Zeer MA, 2013, AUTOPHAGY, V9, P50, DOI 10.4161/auto.22482
   Ascierto ML, 2012, BREAST CANCER RES TR, V131, P871, DOI 10.1007/s10549-011-1470-x
   Bai S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19401-2
   Barz B, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007193
   Bleiziffer O, 2012, BMC BIOTECHNOL, V12, DOI 10.1186/1472-6750-12-94
   Britzen-Laurent N, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-4047
   Britzen-Laurent N, 2016, WORLD J GASTROENTERO, V22, P6434, DOI 10.3748/wjg.v22.i28.6434
   Britzen-Laurent N, 2013, CARCINOGENESIS, V34, P153, DOI 10.1093/carcin/bgs310
   Capaldo CT, 2012, MUCOSAL IMMUNOL, V5, P681, DOI 10.1038/mi.2012.41
   CHENG YSE, 1991, MOL CELL BIOL, V11, P4717, DOI 10.1128/MCB.11.9.4717
   De Donato M, 2012, J CELL PHYSIOL, V227, P1034, DOI 10.1002/jcp.22813
   DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x
   Duan ZF, 2006, CANCER CHEMOTH PHARM, V57, P25, DOI 10.1007/s00280-005-0026-3
   Fekete JT, 2019, INT J CANCER, V145, P3140, DOI 10.1002/ijc.32369
   Forster F, 2014, J IMMUNOL, V192, P771, DOI 10.4049/jimmunol.1300377
   Fukumoto M, 2014, CANCER SCI, V105, P1351, DOI 10.1111/cas.12489
   Ghosh A, 2006, NATURE, V440, P101, DOI 10.1038/nature04510
   Gomes MTR, 2019, J LEUKOCYTE BIOL, V106, P553, DOI 10.1002/JLB.4MR0119-013R
   Guenzi E, 2003, EMBO J, V22, P3772, DOI 10.1093/emboj/cdg382
   Guenzi E, 2001, EMBO J, V20, P5568, DOI 10.1093/emboj/20.20.5568
   Itsui Y, 2009, HEPATOLOGY, V50, P1727, DOI 10.1002/hep.23195
   Kim BH, 2011, SCIENCE, V332, P717, DOI 10.1126/science.1201711
   Kunzelmann S, 2005, METHOD ENZYMOL, V404, P512, DOI 10.1016/S0076-6879(05)04045-0
   Lan Q, 2016, ONCOTARGET, V7, P9680, DOI 10.18632/oncotarget.7109
   LEW DJ, 1989, MOL CELL BIOL, V9, P5404, DOI 10.1128/MCB.9.12.5404
   LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182
   Li L, 2015, DISCOV MED, V20, P369
   Lipnik K, 2010, MOL MED, V16, P177, DOI 10.2119/molmed.2009.00172
   Lorenz C, 2020, FEBS J, V287, P496, DOI 10.1111/febs.15015
   Lu XM, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-5144
   Lubeseder-Martellato C, 2002, AM J PATHOL, V161, P1749, DOI 10.1016/S0002-9440(10)64452-5
   Marigo I, 2010, IMMUNITY, V32, P790, DOI 10.1016/j.immuni.2010.05.010
   Modiano N, 2005, P NATL ACAD SCI USA, V102, P8680, DOI 10.1073/pnas.0503227102
   Mustafa DAM, 2018, ACTA NEUROPATHOL, V135, P581, DOI 10.1007/s00401-018-1806-2
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Naschberger E, 2005, ADV ENZYME REGUL, V45, P215, DOI 10.1016/j.advenzreg.2005.02.011
   Naschberger E, 2004, BIOCHEM J, V379, P409, DOI 10.1042/BJ20031873
   Naschberger E, 2008, INT J CANCER, V123, P2120, DOI 10.1002/ijc.23764
   Naschberger E, 2006, AM J PATHOL, V169, P1088, DOI 10.2353/ajpath.2006.060244
   Nawijn MC, 2011, NAT REV CANCER, V11, P23, DOI 10.1038/nrc2986
   Ostler N, 2014, MOL CELL BIOL, V34, P196, DOI 10.1128/MCB.00664-13
   Pammer J, 2006, LAB INVEST, V86, P997, DOI 10.1038/labinvest.3700461
   Pan W, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-292
   Pandita E, 2016, BIOCHEM J, V473, P1745, DOI 10.1042/BCJ20160220
   Persico M, 2015, EUR J MED CHEM, V91, P132, DOI 10.1016/j.ejmech.2014.07.093
   Pilla DM, 2014, P NATL ACAD SCI USA, V111, P6046, DOI 10.1073/pnas.1321700111
   Pilla-Moffett D, 2016, J MOL BIOL, V428, P3495, DOI 10.1016/j.jmb.2016.04.032
   Praefcke GJK, 1999, J MOL BIOL, V292, P321, DOI 10.1006/jmbi.1999.3062
   Prakash B, 2000, NATURE, V403, P567, DOI 10.1038/35000617
   Qiu XX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19828-7
   Schnoor M, 2009, MUCOSAL IMMUNOL, V2, P33, DOI 10.1038/mi.2008.62
   SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299
   Shenoy AR, 2007, IMMUNOBIOLOGY, V212, P771, DOI 10.1016/j.imbio.2007.09.018
   Shydlovskyi S, 2017, P NATL ACAD SCI USA, V114, pE5559, DOI 10.1073/pnas.1620959114
   Syguda A, 2012, FEBS J, V279, P2544, DOI 10.1111/j.1742-4658.2012.08637.x
   Tietzel I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006499
   Tipton AR, 2016, BIOCHEM BIOPH RES CO, V478, P1617, DOI 10.1016/j.bbrc.2016.08.169
   Vestal DJ, 2015, CYTOKINE, V76, P103, DOI 10.1016/j.cyto.2015.08.216
   Vopel T, 2010, J MOL BIOL, V400, P63, DOI 10.1016/j.jmb.2010.04.053
   Wadi Suzan, 2016, J Cancer Ther, V7, P994, DOI 10.4236/jct.2016.713097
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wang QQ, 2018, ONCOL LETT, V15, P7914, DOI 10.3892/ol.2018.8306
   Weinlander K, 2008, FASEB J, V22, P4168, DOI 10.1096/fj.08-107524
   Yamakita I, 2019, BIOCHEM BIOPH RES CO, V518, P266, DOI 10.1016/j.bbrc.2019.08.045
   Yu CJ, 2011, J PROTEOME RES, V10, P3778, DOI 10.1021/pr2004133
   Zhu ZX, 2013, BIOCHEM BIOPH RES CO, V436, P204, DOI 10.1016/j.bbrc.2013.05.074
   Zhu ZX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055920
NR 68
TC 25
Z9 25
U1 1
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 24
PY 2020
VL 10
AR 3139
DI 10.3389/fimmu.2019.03139
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA KJ2AV
UT WOS:000511861200001
PM 32117203
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ou, JJ
   Peng, Y
   Yang, WW
   Zhang, Y
   Hao, J
   Li, F
   Chen, YR
   Zhao, Y
   Xie, X
   Wu, S
   Zha, L
   Luo, X
   Xie, GF
   Wang, LT
   Sun, W
   Zhou, Q
   Li, JJ
   Liang, HJ
AF Ou, Juanjuan
   Peng, Yuan
   Yang, Weiwen
   Zhang, Yue
   Hao, Jie
   Li, Fu
   Chen, Yanrong
   Zhao, Yang
   Xie, Xiong
   Wu, Shuang
   Zha, Lin
   Luo, Xi
   Xie, Ganfeng
   Wang, Liting
   Sun, Wei
   Zhou, Qi
   Li, Jianjun
   Liang, Houjie
TI ABHD5 blunts the sensitivity of colorectal cancer to fluorouracil via
   promoting autophagic uracil yield
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DNA MISMATCH REPAIR; ADJUVANT THERAPY; LYSOSOME FUSION; RNA DEGRADATION;
   MECHANISMS; PROTEIN; CHEMOTHERAPY; STRATEGIES; RESISTANCE; TARGET
AB The efficacy of Fluorouracil (FU) in the treatment of colorectal cancer (CRC) is greatly limited by drug resistance. Autophagy has been implicated in chemoresistance, but the role of selective autophagic degradation in regulating chemoresistance remains unknown. In this study, we revealed a critical role of ABHD5 in charging CRC sensitivity to FU via regulating autophagic uracil yield. We demonstrated that ABHD5 localizes to lysosome and interacts with PDIA5 to prevent PDIA5 from interacting with RNASET2 and inactivating RNASET2. ABHD5 deficiency releases PDIA5 to directly interact with RNASET2 and leave RNASET2 in an inactivate state, which impairs RNASET2-mediated autophagic uracil yield and promotes CRC cells to uptake FU as an exogenous uracil, thus increasing their sensitivity to FU. Our findings for the first time reveal a novel role of ABHD5 in regulating lysosome function, highlighting the significance of ABHD5 as a compelling biomarker predicting the sensitivity of CRCs to FU-based chemotherapy.
C1 [Ou, Juanjuan; Peng, Yuan; Yang, Weiwen; Zhang, Yue; Hao, Jie; Li, Fu; Chen, Yanrong; Zhao, Yang; Xie, Xiong; Wu, Shuang; Zha, Lin; Luo, Xi; Xie, Ganfeng; Li, Jianjun; Liang, Houjie] Army Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.
   [Ou, Juanjuan; Peng, Yuan; Yang, Weiwen; Zhang, Yue; Hao, Jie; Li, Fu; Chen, Yanrong; Zhao, Yang; Xie, Xiong; Wu, Shuang; Zha, Lin; Luo, Xi; Xie, Ganfeng; Li, Jianjun; Liang, Houjie] Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
   [Wang, Liting; Sun, Wei] Army Med Univ, Biomed Anal Ctr, Chongqing 400038, Peoples R China.
   [Zhou, Qi] Fuling Cent Hosp, Dept Oncol, Chongqing 408099, Peoples R China.
RP Ou, JJ; Li, JJ; Liang, HJ (corresponding author), Army Med Univ, Southwest Hosp, Dept Oncol, Chongqing 400038, Peoples R China.; Ou, JJ; Li, JJ; Liang, HJ (corresponding author), Army Med Univ, Southwest Hosp, Southwest Canc Ctr, Chongqing 400038, Peoples R China.
EM ojj521000@sina.com; leejjun2007@163.com; lianghoujie@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81772647, 81672856, 81672384, 81602628,
   81602423]; Basic and Frontier Research Project of Chongqing
   [cstc2015jcyjB10001]; Social Science and Technology Innovation Project
   of Chongqing [cstc2015shmszx120058]; Health Bureau of Chongqing
   [2008-2-374];  [81370063]
FX This work was supported in part by grant numbers 81772647 (J.O.),
   81672856 (J.L.), 81672384 (H.L.), 81602628 (X.L.) and 81602423 (L.Z.)
   from the National Natural Science Foundation of China,
   cstc2015jcyjB10001 (J.O.) from Basic and Frontier Research Project of
   Chongqing, cstc2015shmszx120058 (H.L.) from Social Science and
   Technology Innovation Project of Chongqing and 2008-2-374 (Q.Z.) from
   The Health Bureau of Chongqing. We got a writing assistance from Nature
   Research Editing Service, which is supported by grant 81370063 (J.O.).
   We thank the assistance from Shanghai Biotree Biotech Co., Ltd.
CR Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   CHANARIN I, 1975, BRIT MED J, V1, P553, DOI 10.1136/bmj.1.5957.553
   Chen N, 2011, CANCER BIOL THER, V11, P157, DOI 10.4161/cbt.11.2.14622
   Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597
   Dewaele M, 2010, AUTOPHAGY, V6, P838, DOI 10.4161/auto.6.7.12113
   DORFMAN ML, 1974, ARCH DERMATOL, V110, P261, DOI 10.1001/archderm.110.2.261
   Fink D, 1998, CLIN CANCER RES, V4, P1
   Fu XM, 2011, BBA-PROTEINS PROTEOM, V1814, P487, DOI 10.1016/j.bbapap.2011.01.004
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Guo JYX, 2016, COLD SH Q B, V81, P73, DOI 10.1101/sqb.2016.81.030981
   Haud N, 2011, P NATL ACAD SCI USA, V108, P1099, DOI 10.1073/pnas.1009811107
   Havugimana PC, 2012, CELL, V150, P1068, DOI 10.1016/j.cell.2012.08.011
   Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017
   Irie M, 1999, PHARMACOL THERAPEUT, V81, P77, DOI 10.1016/S0163-7258(98)00035-7
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Katunuma Nobuhiko, 2010, J Signal Transduct, V2010, P375345, DOI 10.1155/2010/375345
   Kawai A, 2007, AUTOPHAGY, V3, P154, DOI 10.4161/auto.3634
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   LARDEUX BR, 1987, J BIOL CHEM, V262, P14507
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liu YT, 2015, INT J ONCOL, V46, P299, DOI 10.3892/ijo.2014.2714
   Miao HM, 2014, CELL REP, V7, P223, DOI 10.1016/j.celrep.2014.02.047
   MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602
   MORTIMORE GE, 1989, RBC-CELL BIOL REV, V20, P79
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Peng Y, 2016, AUTOPHAGY, V12, P2167, DOI 10.1080/15548627.2016.1217380
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rebecca VW, 2016, ONCOGENE, V35, P1, DOI 10.1038/onc.2015.99
   Reggiori Fulvio, 2012, Int J Cell Biol, V2012, P219625, DOI 10.1155/2012/219625
   Repnik U, 2012, BBA-PROTEINS PROTEOM, V1824, P22, DOI 10.1016/j.bbapap.2011.08.016
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Sahoo D, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r157
   Sahoo D, 2007, NUCLEIC ACIDS RES, V35, P3705, DOI 10.1093/nar/gkm284
   Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Shingu T, 2009, INT J CANCER, V124, P1060, DOI 10.1002/ijc.24030
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI 10.3322/caac.21220
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Thorn A, 2012, NUCLEIC ACIDS RES, V40, P8733, DOI 10.1093/nar/gks614
   Vinaik R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062021
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zeng XH, 2007, AUTOPHAGY, V3, P368, DOI 10.4161/auto.4205
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhao S, 2012, INT J MOL MED, V30, P939, DOI 10.3892/ijmm.2012.1066
   Zhou J, 2012, AUTOPHAGY, V8, P338, DOI 10.4161/auto.18721
NR 48
TC 24
Z9 26
U1 9
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAR 6
PY 2019
VL 10
AR 1078
DI 10.1038/s41467-019-08902-x
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HN7YS
UT WOS:000460410300003
PM 30842415
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Han, HG
   Moon, HW
   Jeon, YJ
AF Han, Hye Gyeong
   Moon, Hye Won
   Jeon, Young Joo
TI ISG15 in cancer: Beyond ubiquitin-like protein
SO CANCER LETTERS
LA English
DT Review
DE Autophagy; Cancer; Cancer therapies; Exosomes; ISG15; Ubiquitin
ID INTERFERON-STIMULATED GENE; COLORECTAL-CANCER; PROGNOSTIC VALUE;
   MESSENGER-RNA; CRUCIAL ROLE; T-CELLS; CONJUGATION; EXPRESSION;
   ISGYLATION; USP18
AB ISG15, the product of interferon (IFN)-stimulated gene 15, is the first identified ubiquitin-like protein (Ubl), playing roles not only as an unconjugated form but also as a covalently conjugated form onto a target protein. ISG15 is not present in lower eukaryotes such as yeast, nematode (Caenorhabditis), or insect (Drosophila), indicating that the functions of ISG15 and ISG15 conjugation (ISGylation) are restricted to higher eukaryotes and have evolved with IFN signaling. Despite the highlighted complexity of ISG15 and ISGylation, increasing evidences have been emerging that ISG15 and ISGylation are implicated in a variety of pivotal cellular processes, involving protein translation, autophagy, exosome secretion, DNA repair, and immune modulation, which emphasizes the necessity of re-evaluation of ISG15 and ISGylation. In this review, we highlight current knowledge in the molecular understanding and physiological relevance of ISG15 and ISGylation and discuss new insights into how ISG15 is implicated in the pathogenesis of cancer, which could contribute to therapeutic intervention in cancer.
C1 [Han, Hye Gyeong; Moon, Hye Won; Jeon, Young Joo] Chungnam Natl Univ, Coll Med, Dept Biochem, 266 Munhwa Ro, Daejeon 35015, South Korea.
   [Han, Hye Gyeong; Moon, Hye Won; Jeon, Young Joo] Chungnam Natl Univ, Coll Med, Dept Med Sci, 266 Munhwa Ro, Daejeon 35015, South Korea.
RP Jeon, YJ (corresponding author), Chungnam Natl Univ, Coll Med, Dept Biochem, 266 Munhwa Ro, Daejeon 35015, South Korea.; Jeon, YJ (corresponding author), Chungnam Natl Univ, Coll Med, Dept Med Sci, 266 Munhwa Ro, Daejeon 35015, South Korea.
EM yjjeon@cnu.ac.kr
RI Jeon, Young Joo/AAB-7040-2021
OI Jeon, Young Joo/0000-0003-1004-5336
FU National Research Foundation of KoreaNational Research Foundation of
   Korea [NRF-2016R1A2B4006566]; BK21 Plus fellowship
FX This work was supported by grant from the National Research Foundation
   of Korea (NRF-2016R1A2B4006566). H.G. Han and H.W. Moon were the
   recipients of the BK21 Plus fellowship.
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Andreola G, 2002, J EXP MED, V195, P1303, DOI 10.1084/jem.20011624
   Arimoto K, 2017, NAT STRUCT MOL BIOL, V24, P279, DOI 10.1038/nsmb.3378
   Balchin D, 2016, SCIENCE, V353, DOI 10.1126/science.aac4354
   Baldanta S, 2017, PLOS PATHOG, V13, DOI 10.1371/journal.ppat.1006651
   Bashar MM, 2013, J POLYM ENVIRON, V21, P181, DOI 10.1007/s10924-012-0476-8
   Basters A, 2017, NAT STRUCT MOL BIOL, V24, P270, DOI 10.1038/nsmb.3371
   Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117
   Blanchard N, 2002, J IMMUNOL, V168, P3235, DOI 10.4049/jimmunol.168.7.3235
   Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051
   Bogunovic D, 2012, SCIENCE, V337, P1684, DOI 10.1126/science.1224026
   Brown AR, 2015, CARCINOGENESIS, V36, P946, DOI 10.1093/carcin/bgv104
   Burkart C, 2013, EMBO MOL MED, V5, P1035, DOI 10.1002/emmm.201201864
   Burks J, 2014, ONCOGENE, V33, P794, DOI 10.1038/onc.2012.633
   Cappadocia L, 2018, CHEM REV, V118, P889, DOI 10.1021/acs.chemrev.6b00737
   Care M.A., 2016, J IMMUNOL
   Cerikan B, 2017, CELL CYCLE, V16, P304, DOI 10.1080/15384101.2016.1256153
   Chalmin F, 2010, J CLIN INVEST, V120, P457, DOI 10.1172/JCI40483
   Chen RH, 2016, ONCOTARGET, V7, P16910, DOI 10.18632/oncotarget.7626
   Cheon H, 2014, SEMIN ONCOL, V41, P156, DOI 10.1053/j.seminoncol.2014.02.002
   Choudhary C, 2014, NAT REV MOL CELL BIO, V15, P536, DOI 10.1038/nrm3841
   Chun JH, 2004, CANCER RES, V64, P4703, DOI 10.1158/0008-5472.CAN-04-1063
   Costantini E, 2011, EUR UROL, V59, P945, DOI 10.1016/j.eururo.2011.01.050
   Dastur A, 2006, J BIOL CHEM, V281, P4334, DOI 10.1074/jbc.M512830200
   DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211
   DCunha J, 1996, J IMMUNOL, V157, P4100
   Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623
   Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123
   Desai S, 2018, EXP BIOL MED, V243, P554, DOI 10.1177/1535370217752351
   Desai SD, 2008, MOL CANCER THER, V7, P1430, DOI 10.1158/1535-7163.MCT-07-2345
   Desai SD, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1052935
   Desai SD, 2013, J BIOL CHEM, V288, P2388, DOI 10.1074/jbc.M112.403832
   Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236
   dos Santos PF, 2017, J INTERF CYTOK RES, V37, P246, DOI 10.1089/jir.2016.0103
   Du Y, 2018, EMBO J, V37, P351, DOI 10.15252/embj.201796781
   Duex JE, 2011, J BIOL CHEM, V286, P25377, DOI 10.1074/jbc.M111.222760
   Durfee LA, 2010, MOL CELL, V38, P722, DOI 10.1016/j.molcel.2010.05.002
   Fan JB, 2015, P NATL ACAD SCI USA, V112, P14313, DOI 10.1073/pnas.1505690112
   Fan JB, 2015, SCI REP-UK, V5, DOI 10.1038/srep12704
   FARRELL PJ, 1979, NATURE, V279, P523, DOI 10.1038/279523a0
   Feng Q, 2008, MOL CANCER THER, V7, P3780, DOI 10.1158/1535-7163.MCT-08-0753
   Forys JT, 2014, CELL REP, V7, P514, DOI 10.1016/j.celrep.2014.03.026
   Francois-Newton V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022200
   Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396
   Fruhbeis C, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001604
   Giannakopoulos NV, 2005, BIOCHEM BIOPH RES CO, V336, P496, DOI 10.1016/j.bbrc.2005.08.132
   GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11
   Guilbaud G, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002322
   Guo YL, 2012, MOL CANCER THER, V11, P1968, DOI 10.1158/1535-7163.MCT-12-0248
   Guo YL, 2010, CANCER RES, V70, P9875, DOI 10.1158/0008-5472.CAN-10-1100
   HAAS AL, 1987, J BIOL CHEM, V262, P11315
   Hadjivasiliou A, 2012, EXPERT REV PROTEOMIC, V9, P7
   Hershko A., 1998, UBIQUITIN SYSTEM ANN
   Hipp MS, 2005, MOL CELL BIOL, V25, P3483, DOI 10.1128/MCB.25.9.3483-3491.2005
   Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643
   Hochstrasser M, 2009, NATURE, V458, P422, DOI 10.1038/nature07958
   Hollingsworth J, 2018, NEOPLASIA, V20, P697, DOI 10.1016/j.neo.2018.05.005
   Hong BX, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-132
   Honke N, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.326
   Ina S, 2010, PANCREAS, V39, P473, DOI 10.1097/MPA.0b013e3181c0decc
   Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2
   Jeon YJ, 2017, MOL CELLS, V40, P83, DOI 10.14348/molcells.2017.0027
   Jeon YJ, 2012, J CLIN INVEST, V122, P2622, DOI 10.1172/JCI61762
   Jeon YJ, 2010, BBA-MOL BASIS DIS, V1802, P485, DOI 10.1016/j.bbadis.2010.02.006
   Jeon YJ, 2009, EMBO REP, V10, P374, DOI 10.1038/embor.2009.23
   Jinawath N, 2004, ONCOGENE, V23, P6830, DOI 10.1038/sj.onc.1207886
   Johnson LN, 2009, BIOCHEM SOC T, V37, P627, DOI 10.1042/BST0370627
   Kang DC, 2001, GENE, V267, P233, DOI 10.1016/S0378-1119(01)00384-5
   Katzenell S, 2016, J VIROL, V90, P4706, DOI 10.1128/JVI.02908-15
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010
   Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100
   Kiessling A, 2009, ONCOGENE, V28, P2606, DOI 10.1038/onc.2009.115
   Kim KI, 2004, MOL CELL BIOL, V24, P9592, DOI 10.1128/MCB.24.21.9592-9600.2004
   Kim KI, 2003, BIOCHEM BIOPH RES CO, V307, P431, DOI 10.1016/S0006-291X(03)01216-6
   Kim KI, 2005, J IMMUNOL, V175, P847, DOI 10.4049/jimmunol.175.2.847
   Kim ST, 2014, CANCER GENOM PROTEOM, V11, P259
   Kim YH, 2014, J KOREAN MED SCI, V29, P351, DOI 10.3346/jkms.2014.29.3.351
   KNIGHT E, 1991, J IMMUNOL, V146, P2280
   KNIGHT E, 1988, J BIOL CHEM, V263, P4520
   Lai C, 2009, J VIROL, V83, P1147, DOI 10.1128/JVI.00105-08
   Lai CH, 2015, BEILSTEIN J ORG CHEM, V11, P617, DOI 10.3762/bjoc.11.69
   Lee GY, 2015, BMB REP, V48, P427, DOI 10.5483/BMBRep.2015.48.8.152
   Lee JH, 2010, GUT, V59, P907, DOI 10.1136/gut.2009.194068
   Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405
   Li C, 2014, ONCOTARGET, V5, P8429, DOI 10.18632/oncotarget.2316
   Li XL, 2000, J BIOL CHEM, V275, P8880, DOI 10.1074/jbc.275.12.8880
   Liu MJ, 2003, J BIOL CHEM, V278, P1594, DOI 10.1074/jbc.M208123200
   Lo PK, 2018, ELIFE, V7, DOI 10.7554/eLife.31334
   LOEB KR, 1992, J BIOL CHEM, V267, P7806
   MacParland SA, 2016, J VIROL, V90, P5549, DOI 10.1128/JVI.02557-15
   Malakhov MP, 2002, J BIOL CHEM, V277, P9976, DOI 10.1074/jbc.M109078200
   Malakhova O, 2002, J BIOL CHEM, V277, P14703, DOI 10.1074/jbc.M111527200
   Malakhova OA, 2008, J BIOL CHEM, V283, P8783, DOI 10.1074/jbc.C800030200
   Malakhova OA, 2006, EMBO J, V25, P2358, DOI 10.1038/sj.emboj.7601149
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Moremen KW, 2012, NAT REV MOL CELL BIO, V13, P448, DOI 10.1038/nrm3383
   Moreno-Gonzalo O, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00383
   Mustachio LM, 2017, MOL CANCER RES, V15, P905, DOI 10.1158/1541-7786.MCR-16-0369
   Mustachio LM, 2017, ONCOTARGET, V8, P3, DOI 10.18632/oncotarget.13914
   Nabhan JF, 2012, P NATL ACAD SCI USA, V109, P4146, DOI 10.1073/pnas.1200448109
   Nakashima H, 2015, J BIOL CHEM, V290, P1485, DOI 10.1074/jbc.M114.593871
   Narasimhan J, 2005, J BIOL CHEM, V280, P27356, DOI 10.1074/jbc.M502814200
   Hoan NX, 2016, ONCOTARGET, V7, P67777, DOI 10.18632/oncotarget.11955
   Nillegoda NB, 2018, TRENDS BIOCHEM SCI, V43, P285, DOI 10.1016/j.tibs.2018.02.003
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ochi K, 2004, INT J ONCOL, V24, P647
   Okumura A, 2008, P NATL ACAD SCI USA, V105, P3974, DOI 10.1073/pnas.0710629105
   Okumura F, 2007, GENE DEV, V21, P255, DOI 10.1101/gad.1521607
   Okumura F, 2013, J BIOL CHEM, V288, P2839, DOI 10.1074/jbc.M112.401851
   Owhashi M, 2003, BIOCHEM BIOPH RES CO, V309, P533, DOI 10.1016/j.bbrc.2003.08.038
   Padovan E, 2002, CANCER RES, V62, P3453
   Park JH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12513
   Park JM, 2014, MOL CELL, V54, P626, DOI 10.1016/j.molcel.2014.03.031
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Perng Y.-C., 2018, NAT REV MICROBIOL, P1
   Pitha-Rowe I, 2004, J BIOL CHEM, V279, P18178, DOI 10.1074/jbc.M309259200
   Potter JL, 1999, J BIOL CHEM, V274, P25061, DOI 10.1074/jbc.274.35.25061
   Putz U, 2008, J BIOL CHEM, V283, P32621, DOI 10.1074/jbc.M804120200
   Qiu KY, 2014, POLYM REV, V54, P598, DOI 10.1080/15583724.2014.896018
   Qiu XX, 2015, INT J CLIN EXP MED, V8, P17140
   Radoshevich L, 2015, ELIFE, V4, DOI 10.7554/eLife.06848
   Rahnefeld A, 2014, CIRCULATION, V130, P1589, DOI 10.1161/CIRCULATIONAHA.114.009847
   Rask-Andersen M, 2015, MOL GENET GENOMICS, V290, P1485, DOI 10.1007/s00438-015-1009-7
   RECHT M, 1991, J IMMUNOL, V147, P2617
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056
   Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354
   Sgorbissa A, 2011, APOPTOSIS, V16, P1229, DOI 10.1007/s10495-011-0639-4
   Shen J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-73
   Shi HX, 2010, MOL CELL BIOL, V30, P2424, DOI 10.1128/MCB.01466-09
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Son YJ, 2016, MICROB CELL FACT, V15, DOI 10.1186/s12934-015-0400-8
   Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898
   Speer SD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11496
   Sun L, 2016, ANTIVIR RES, V134, P167, DOI 10.1016/j.antiviral.2016.07.013
   Swaim CD, 2017, MOL CELL, V68, P581, DOI 10.1016/j.molcel.2017.10.003
   Tan NGS, 2003, FEBS LETT, V554, P501, DOI 10.1016/S0014-5793(03)01235-3
   Tanaka K, 2014, BBA-MOL CELL RES, V1843, P197, DOI 10.1016/j.bbamcr.2013.03.012
   Tao J, 2015, INT J CLIN EXP PATHO, V8, P10975
   Thery C, 2002, NAT IMMUNOL, V3, P1156, DOI 10.1038/ni854
   Tokarz S, 2004, J BIOL CHEM, V279, P46424, DOI 10.1074/jbc.M403189200
   van der Veen AG, 2012, ANNU REV BIOCHEM, V81, P323, DOI 10.1146/annurev-biochem-093010-153308
   van der Vlist EJ, 2012, J EXTRACELL VESICLES, V1, DOI 10.3402/jev.v1i0.18364
   Villarreal DO, 2015, MOL THER, V23, P1653, DOI 10.1038/mt.2015.120
   Villarroya-Beltri C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13588
   Villarroya-Beltri C, 2014, SEMIN CANCER BIOL, V28, P3, DOI 10.1016/j.semcancer.2014.04.009
   Villarroya-Beltri C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3980
   Wang Ren-Gang, 2012, Shengli Xuebao, V64, P577
   Weichselbaum RR, 2008, P NATL ACAD SCI USA, V105, P18490, DOI 10.1073/pnas.0809242105
   Wong E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a006734
   Wong JJY, 2006, P NATL ACAD SCI USA, V103, P10735, DOI 10.1073/pnas.0600397103
   Wood LM, 2012, CANCER IMMUNOL IMMUN, V61, P689, DOI 10.1007/s00262-011-1129-9
   Wood LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016422
   Xu DC, 2015, AUTOPHAGY, V11, P617, DOI 10.1080/15548627.2015.1023982
   Yan M, 2007, BLOOD, V110, P305, DOI 10.1182/blood-2006-07-033209
   Yan Wusheng, 2012, BMC Res Notes, V5, P73, DOI 10.1186/1756-0500-5-73
   Yang ZF, 2015, SCI REP-UK, V5, DOI 10.1038/srep12738
   Yeh YH, 2013, CLIN CANCER RES, V19, P5927, DOI 10.1158/1078-0432.CCR-13-0018
   Yoo L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0138-9
   Yoo Y.S., 2017, OXIDATIVE MED CELLUL, V2017
   Yuan WM, 2001, EMBO J, V20, P362, DOI 10.1093/emboj/20.3.362
   Zeng Z, 2007, CELL MOTIL CYTOSKEL, V64, P186, DOI 10.1002/cm.20175
   Zhang XQ, 2015, NATURE, V517, P89, DOI 10.1038/nature13801
   Zhao C, 2004, P NATL ACAD SCI USA, V101, P7578, DOI 10.1073/pnas.0402528101
   Zhao C, 2005, P NATL ACAD SCI USA, V102, P10200, DOI 10.1073/pnas.0504754102
   Zhao C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12754
   Zou WG, 2007, BIOCHEM BIOPH RES CO, V354, P321, DOI 10.1016/j.bbrc.2006.12.210
   Zou WG, 2006, J BIOL CHEM, V281, P3989, DOI 10.1074/jbc.M510787200
NR 171
TC 28
Z9 29
U1 3
U2 16
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PY 2018
VL 438
BP 52
EP 62
DI 10.1016/j.canlet.2018.09.007
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GZ1PG
UT WOS:000449139400007
PM 30213559
DA 2022-04-25
ER

PT J
AU Liang, JM
   Zeng, F
   Zhang, M
   Pan, ZZ
   Chen, YZ
   Zeng, YN
   Xu, Y
   Xu, Q
   Huang, YZ
AF Liang, Jianming
   Zeng, Feng
   Zhang, Meng
   Pan, Zhenzhen
   Chen, Yingzhi
   Zeng, Yuaner
   Xu, Yong
   Xu, Qin
   Huang, Yongzhuo
TI Green synthesis of hyaluronic acid-based silver nanoparticles and their
   enhanced delivery to CD44(+) cancer cells
SO RSC ADVANCES
LA English
DT Article
ID COLORECTAL-CANCER; IN-VIVO; APOPTOSIS; EXPRESSION; AUTOPHAGY;
   MONODANSYLCADAVERINE; PHOSPHATIDYLSERINE; INHIBITION; RESISTANCE;
   RELEASE
AB The potent antitumor activities of silver nanoparticles (AgNP) have attracted great attention. However, the application of AgNP is restricted by its non-specific delivery and poor cellular uptake. We developed a novel hyaluronic acid (HA)-based strategy for the green synthesis of AgNP, in which HA was used as the reducing agent and stabilizer. More importantly, HA is a ligand of CD44, and the HA-modified AgNP can target CD44 receptors that are overexpressed in many types of cancer cells. The CD44-dependent endocytosis can significantly increase the intracellular delivery of HA-AgNP, compared to the non-modified one. The antitumor efficacy was significantly improved by HA modification. Furthermore, we found that multiple mechanisms were involved for the enhanced anticancer activities of HA-AgNP, including the decline of mitochondrial membrane potential, cell-cycle arrest, apoptosis, and autophagy. The HA-based strategy for green synthesis and CD44-targeting delivery provided a promising solution for AgNP-mediated cancer treatment.
C1 [Liang, Jianming; Zeng, Feng; Zhang, Meng; Pan, Zhenzhen; Chen, Yingzhi; Huang, Yongzhuo] Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China.
   [Liang, Jianming; Zeng, Feng; Xu, Qin] Guangzhou Univ Chinese Med, Inst Trop Med, Guangzhou 501450, Guangdong, Peoples R China.
   [Pan, Zhenzhen; Zeng, Yuaner] Guangzhou Univ Chinese Med, Sch Chinese Mat Med, Guangzhou 501450, Guangdong, Peoples R China.
   [Xu, Yong] Hubei Biol Med Ind Technol Inst Co Ltd, Wuhan 430075, Peoples R China.
RP Huang, YZ (corresponding author), Chinese Acad Sci, Shanghai Inst Mat Med, 501 Hai Ke Rd, Shanghai 201203, Peoples R China.
EM xuqin@163.com; yzhuang@simm.ac.cn
RI Huang, Yongzhuo/A-4688-2013
OI Huang, Yongzhuo/0000-0001-7067-8915
FU 973 Program, ChinaNational Basic Research Program of China
   [2014CB931900, 2013CB932503]; NSFC, ChinaNational Natural Science
   Foundation of China (NSFC) [81172996, 81373357, 81422048]
FX This work was supported by 973 Program, China (2014CB931900,
   2013CB932503) and NSFC, China (81172996, 81373357, 81422048).
CR Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x
   Amendola V, 2010, PLASMONICS, V5, P85, DOI 10.1007/s11468-009-9120-4
   Anilanmert B, 2001, ANAL LETT, V34, P113, DOI 10.1081/AL-100002709
   AshaRani PV, 2009, ACS NANO, V3, P279, DOI 10.1021/nn800596w
   BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3
   Bressan E, 2013, INT J DENT, V2013, DOI 10.1155/2013/312747
   Cao XL, 2010, J MATER SCI-MATER M, V21, P2861, DOI 10.1007/s10856-010-4133-2
   Chopra I, 2007, J ANTIMICROB CHEMOTH, V59, P587, DOI 10.1093/jac/dkm006
   Contento AL, 2005, PLANT J, V42, P598, DOI 10.1111/j.1365-313X.2005.02396.x
   Coradini D, 2004, CLIN CANCER RES, V10, P4822, DOI 10.1158/1078-0432.CCR-04-0349
   Fang XJ, 2014, ONCOL REP, V31, P2735, DOI 10.3892/or.2014.3131
   Filippo E, 2010, J NON-CRYST SOLIDS, V356, P344, DOI 10.1016/j.jnoncrysol.2009.11.021
   Foldbjerg R, 2011, ARCH TOXICOL, V85, P743, DOI 10.1007/s00204-010-0545-5
   Ganesh S, 2013, BIOMATERIALS, V34, P3489, DOI 10.1016/j.biomaterials.2013.01.077
   Greulich C, 2011, ACTA BIOMATER, V7, P347, DOI 10.1016/j.actbio.2010.08.003
   Guo DW, 2013, BIOMATERIALS, V34, P7884, DOI 10.1016/j.biomaterials.2013.07.015
   Gurunathan S, 2009, BIOMATERIALS, V30, P6341, DOI 10.1016/j.biomaterials.2009.08.008
   Hackenberg S, 2011, TOXICOL LETT, V201, P27, DOI 10.1016/j.toxlet.2010.12.001
   Huang ZH, 2011, J NANOSCI NANOTECHNO, V11, P9395, DOI 10.1166/jnn.2011.5317
   Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885
   Kareem TA, 2011, ARAB J CHEM, V4, P325, DOI 10.1016/j.arabjc.2010.06.054
   Kim KD, 2004, CHEM ENG J, V104, P55, DOI 10.1016/j.cej.2004.08.003
   Kittler S, 2010, CHEM MATER, V22, P4548, DOI 10.1021/cm100023p
   Knudson W, 2002, MATRIX BIOL, V21, P15, DOI 10.1016/S0945-053X(01)00186-X
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Lin XZ, 2003, LANGMUIR, V19, P10081, DOI 10.1021/la035185c
   Liu JH, 2012, BIOMATERIALS, V33, P6155, DOI 10.1016/j.biomaterials.2012.05.035
   Liu YS, 2009, RADIAT PHYS CHEM, V78, P251, DOI 10.1016/j.radphyschem.2009.01.003
   MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545
   Nallathamby PD, 2010, NANOSCALE, V2, P942, DOI 10.1039/c0nr00080a
   Oh EJ, 2010, J CONTROL RELEASE, V141, P2, DOI 10.1016/j.jconrel.2009.09.010
   PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157
   Phuc PV, 2011, ONCOTARGETS THER, V4, P71, DOI 10.2147/OTT.S21431
   Rao GH, 2013, ACTA PHARMACOL SIN, V34, P793, DOI 10.1038/aps.2013.56
   Rao GH, 2013, CLIN CANCER RES, V19, P785, DOI 10.1158/1078-0432.CCR-12-2788
   Sanpui P, 2011, ACS APPL MATER INTER, V3, P218, DOI 10.1021/am100840c
   Soares J.P., 2004, ECLETICA QUIMICA, V29, P57, DOI [10.1590/S0100-46702004000200009, DOI 10.1590/S0100-46702004000200009]
   Sriram MI, 2010, INT J NANOMED, V5, P753, DOI 10.2147/IJN.S11727
   Surace C, 2009, MOL PHARMACEUT, V6, P1062, DOI 10.1021/mp800215d
   Syed Abdul Rahman S. N., 2013, J EVIDENCE BASED COM, DOI [10.1155/2013/257108, DOI 10.1155/2013/257108]
   Tan HP, 2009, BIOMATERIALS, V30, P6844, DOI 10.1016/j.biomaterials.2009.08.058
   Tyagi A, 2004, CARCINOGENESIS, V25, P1711, DOI 10.1093/carcin/bgh180
   Tzircotis G, 2005, J CELL SCI, V118, P5119, DOI 10.1242/jcs.02629
   Van Hyning DL, 1998, LANGMUIR, V14, P7034, DOI 10.1021/la980325h
   Verma NK, 2012, TOXICOL APPL PHARM, V264, P451, DOI 10.1016/j.taap.2012.08.023
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wang CX, 2012, ONCOL REP, V28, P1301, DOI 10.3892/or.2012.1951
   Yang WJ, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/8/085102
   Yasuda M, 2001, INT IMMUNOL, V13, P1309, DOI 10.1093/intimm/13.10.1309
NR 49
TC 23
Z9 23
U1 0
U2 33
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2046-2069
J9 RSC ADV
JI RSC Adv.
PY 2015
VL 5
IS 54
BP 43733
EP 43740
DI 10.1039/c5ra03083h
PG 8
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA CI7SJ
UT WOS:000354964600080
DA 2022-04-25
ER

PT J
AU Farzaei, MH
   El-Senduny, FF
   Momtaz, S
   Parvizi, F
   Iranpanah, A
   Tewari, D
   Naseri, R
   Abdolghaffari, AH
   Rezaei, N
AF Farzaei, Mohammad Hosein
   El-Senduny, Fardous F.
   Momtaz, Saeideh
   Parvizi, Fatemeh
   Iranpanah, Amin
   Tewari, Devesh
   Naseri, Rozita
   Abdolghaffari, Amir Hossein
   Rezaei, Nima
TI An update on dietary consideration in inflammatory bowel disease:
   anthocyanins and more
SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE Natural product; anthocyanins; IBD; cellular signaling pathways; natural
   dietary supplement; colorectal cancer
ID INTESTINAL ANTIINFLAMMATORY ACTIVITY; INDUCED ULCERATIVE-COLITIS;
   SODIUM-INDUCED COLITIS; TNBS-INDUCED COLITIS; COLORECTAL-CANCER;
   INHIBITS COLITIS; EPITHELIAL-CELLS; EXTRACT; L.; ACID
AB Introduction: Inflammatory bowel disease (IBD) is a chronic idiopathic inflammatory disorder. A wealth of data pointed out that various aspects of chronic inflammation may be affected by several specific dietary factors. This paper calls attention to anthocyanins enriched plant food and anthocyanin dietary supplements, whose role in the management of IBD and its associated oncogenesis deems crucial.
   Area covered: We updated the most relevant dietary anthocyanins with potential anti-colitis and preventive effect on inflammatory associated colorectal cancer based on the recent animal and human researches along with revealing the major cellular and molecular mechanisms of action. Mounting evidence reported that anthocyanins enriched plant foods perform their protective role on IBD and inflammatory-induced colorectal cancer via different cellular transduction signaling pathways, including inflammatory transcription factors, SAPK/JNK and p38 MAPK cascade, JAK/STAT signaling, NF-kB/pERK/MAPK, Wnt signaling pathway, Nrf2 cytoprotective pathway as well as AMPK pathway and autophagy.
   Expert commentary: Combination of anthocyanins enriched dietary supplements with existing medications can provide new therapeutic options for IBD patients. Further, well-designed randomized control trials (RCTs) are essential to evaluate the role of anthocyanins enriched medicinal foods as well as isolated anthocyanin components as promising preventive and therapeutic dietary agents for IBD and its associated oncogenesis.
C1 [Farzaei, Mohammad Hosein; Naseri, Rozita] Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, Iran.
   [El-Senduny, Fardous F.] Mansoura Univ, Biochem Div, Chem Dept, Mansoura, Egypt.
   [Momtaz, Saeideh; Abdolghaffari, Amir Hossein] Univ Tehran Med Sci, Fac Pharm & Pharmaceut Sci, Dept Toxicol & Pharmacol, Res Ctr, Tehran, Iran.
   [Momtaz, Saeideh; Abdolghaffari, Amir Hossein] Univ Tehran Med Sci, Fac Pharm & Pharmaceut Sci, Dept Toxicol & Pharmacol, Res Ctr, Tehran, Iran.
   [Parvizi, Fatemeh] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran.
   [Iranpanah, Amin] Kermanshah Univ Med Sci, Students Res Comm, Fac Pharm, Kermanshah, Iran.
   [Iranpanah, Amin] USERN, PhytoPharmacol Interest Grp PPIG, Kermanshah, Iran.
   [Tewari, Devesh] Kumaun Univ, Fac Technol, Dept Pharmaceut Sci, Bhimtal Campus, Naini Tal, Uttarakhand, India.
   [Abdolghaffari, Amir Hossein] Islamic Azad Univ, Pharmaceut Sci Branch, Dept Pharmacol, Tehran, Iran.
   [Abdolghaffari, Amir Hossein] USERN, GPIG, Tehran, Iran.
   [Rezaei, Nima] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran.
   [Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran.
   [Rezaei, Nima] USERN, NIIMA, Tehran, Iran.
RP Rezaei, N (corresponding author), Childrens Med Ctr Hosp, Dr Qarib St,Keshavarz Blvd,POB 14194, Tehran, Iran.; Abdolghaffari, AH (corresponding author), ACECR, Inst Med Plants, Jahade Daneshgahi Res Soc, Karaj Qazvin Freeway,Supa Blvd,POB 141554364, Alborz, Karaj, Iran.
EM amirhosein172@hotmail.com; rezaei_nima@tums.ac.ir
RI Abdolghaffari, Amir Hossein/AAQ-1161-2021; El-Senduny,
   Fardous/E-3512-2019; Farzaei, Mohammad Hosein/M-5779-2017; Tewari,
   Devesh/P-9954-2019; Rezaei, Nima/B-4245-2008
OI El-Senduny, Fardous/0000-0002-4572-2061; Farzaei, Mohammad
   Hosein/0000-0001-7081-6521; Tewari, Devesh/0000-0002-5125-3791; Rezaei,
   Nima/0000-0002-3836-1827; Iranpanah, Amin/0000-0001-8422-6151;
   Abdolghaffari, Amir Hossein/0000-0001-9961-9097
CR Almeida LD, 2017, WORLD J GASTROENTERO, V23, P4369, DOI 10.3748/wjg.v23.i24.4369
   Amin HP, 2015, MOL NUTR FOOD RES, V59, P1095, DOI 10.1002/mnfr.201400803
   Annese V, 2012, PPAR RES, V2012, DOI 10.1155/2012/620839
   Azer SA, 2013, EUR J GASTROEN HEPAT, V25, P271, DOI 10.1097/MEG.0b013e32835b5803
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Bibi S, 2018, J NUTR BIOCHEM, V51, P40, DOI 10.1016/j.jnutbio.2017.08.017
   Biedermann L, 2013, J CROHNS COLITIS, V7, P271, DOI 10.1016/j.crohns.2012.07.010
   Bitzer ZT, 2015, J NUTR BIOCHEM, V26, P827, DOI 10.1016/j.jnutbio.2015.02.007
   Boussenna A, 2016, J SCI FOOD AGR, V96, P1260, DOI 10.1002/jsfa.7214
   Branning C, 2012, PLOS ONE, V7
   Bucheli P, 2011, OPTOMETRY VISION SCI, V88, P257, DOI 10.1097/OPX.0b013e318205a18f
   Cassidy A, 2015, AM J CLIN NUTR, V102, P172, DOI 10.3945/ajcn.115.108555
   Castro J, 2015, J CROHNS COLITIS, V9, P1004, DOI 10.1093/ecco-jcc/jjv132
   Chen T, 2017, FOOD FUNCT, V8, P659, DOI [10.1039/c6fo01273f, 10.1039/C6FO01273F]
   Choo J, 2015, J BIOL CHEM, V290, P25609, DOI 10.1074/jbc.M115.673046
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Da Silva M, 2012, FREE RADICAL BIO MED, V52, P151, DOI 10.1016/j.freeradbiomed.2011.10.436
   David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820
   Dinu M, 2017, CRIT REV FOOD SCI, V57, P3640, DOI 10.1080/10408398.2016.1138447
   Direito R, 2017, J NUTR BIOCHEM, V46, P100, DOI 10.1016/j.jnutbio.2017.03.002
   Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526
   Edelblum KL, 2009, CURR OPIN PHARMACOL, V9, P715, DOI 10.1016/j.coph.2009.06.022
   Farzaei MH, 2015, CURR PHARM BIOTECHNO, V16, P196, DOI 10.2174/1389201016666150118131704
   Fernandes P, 2016, CLIN EXP IMMUNOL, V183, P358, DOI 10.1111/cei.12732
   Ferrari D, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3454023
   Ferrari D, 2016, TOXICOL LETT, V264, P51, DOI 10.1016/j.toxlet.2016.10.014
   Figuera-Losada M, 2014, J BIOMOL SCREEN, V19, P17, DOI 10.1177/1087057113499406
   Fontani F., 2017, J CLIN GASTROENTEROL, V3, P039, DOI [10.23937/2469-584X/1510039, DOI 10.23937/2469-584X/1510039]
   Geremia A, 2014, AUTOIMMUN REV, V13, P3, DOI 10.1016/j.autrev.2013.06.004
   Gomes-Santos AC, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/560817
   Hasona N, 2017, J INTERCULT ETHNOPHA, V6, P351, DOI 10.5455/jice.20170917062451
   He JA, 2010, ANNU REV FOOD SCI T, V1, P163, DOI 10.1146/annurev.food.080708.100754
   Hou DX, 2003, CURR MOL MED, V3, P149, DOI 10.2174/1566524033361555
   Hou JK, 2014, CLIN GASTROENTEROL H, V12, P1592, DOI 10.1016/j.cgh.2013.09.063
   Jang Se-Eun, 2016, Natural Product Sciences, V22, P282, DOI 10.20307/nps.2016.22.4.282
   Jansakova K, 2015, FOLIA BIOL-PRAGUE, V61, P104
   Ju SW, 2013, MOL THER, V21, P1345, DOI 10.1038/mt.2013.64
   Kakodkar S, 2017, GASTROENTEROL CLIN N, V46, P745, DOI 10.1016/j.gtc.2017.08.016
   Kamali M, 2015, COMPLEMENT THER CLIN, V21, P141, DOI 10.1016/j.ctcp.2015.03.001
   Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191
   Kang SH, 2017, J MED FOOD, V20, P667, DOI 10.1089/jmf.2016.3822
   Kang YF, 2017, J NUTR BIOCHEM, V40, P70, DOI 10.1016/j.jnutbio.2016.10.009
   Kaspar KL, 2011, J NUTR, V141, P108, DOI 10.3945/jn.110.128074
   Kim H, 2017, J NUTR BIOCHEM, V43, P107, DOI 10.1016/j.jnutbio.2017.02.005
   Kim H, 2016, MOL NUTR FOOD RES, V60, P1912, DOI 10.1002/mnfr.201501008
   Kim J, 2015, MOL IMMUNOL, V66, P189, DOI 10.1016/j.molimm.2015.03.003
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kuntz S, 2014, BRIT J NUTR, V112, P925, DOI 10.1017/S0007114514001482
   Kusmardi KD, 2017, PRIOSOERYANTO, V2017, P6
   Larussa T, 2017, WORLD J GASTROENTERO, V23, P2483, DOI 10.3748/wjg.v23.i14.2483
   Lee SJ, 2014, FOOD CHEM TOXICOL, V63, P53, DOI 10.1016/j.fct.2013.10.040
   Li L, 2014, SCI REP-UK, V4, DOI 10.1038/srep06234
   Li RQ, 2017, J AGR FOOD CHEM, V65, P769, DOI 10.1021/acs.jafc.6b03806
   Limketkai BN, 2018, GASTROENTEROL CLIN N, V47, P155, DOI 10.1016/j.gtc.2017.09.007
   Lin LZ, 2008, FOOD CHEM, V107, P399, DOI 10.1016/j.foodchem.2007.08.038
   Loddo I, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00551
   Lynch SV, 2016, NEW ENGL J MED, V375, P2369, DOI 10.1056/NEJMra1600266
   Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320
   Malekinejad H, 2013, J MED FOOD, V16, P593, DOI 10.1089/jmf.2012.2672
   Mann ER, 2014, WORLD J GASTROENTERO, V20, P9653, DOI 10.3748/wjg.v20.i29.9653
   Martin DA, 2018, J FUNCT FOODS, V44, P48, DOI 10.1016/j.jff.2018.02.025
   Mehta M, 2017, INNATE IMMUN-LONDON, V23, P497, DOI 10.1177/1753425917722206
   Micha R, 2017, JAMA-J AM MED ASSOC, V317, P912, DOI 10.1001/jama.2017.0947
   Monk JM, 2016, J NUTR BIOCHEM, V28, P129, DOI 10.1016/j.jnutbio.2015.10.014
   Monk JM, 2015, J NUTR BIOCHEM, V26, P752, DOI 10.1016/j.jnutbio.2015.02.003
   Montrose DC, 2011, CARCINOGENESIS, V32, P343, DOI 10.1093/carcin/bgq248
   Nasef NA, 2014, NUTRIENTS, V6, P5265, DOI 10.3390/nu6115265
   Nunes C, 2016, TOXICOL RES-UK, V5, P53, DOI [10.1039/c5tx00214a, 10.1039/C5TX00214A]
   Olejnik A, 2016, FOOD FUNCT, V7, P557, DOI [10.1039/c5fo00890e, 10.1039/C5FO00890E]
   Pan P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00997
   Pandurangan AK, 2015, BIOFACTORS, V41, P1, DOI 10.1002/biof.1195
   Peng Y, 2016, J FUNCT FOODS, V20, P139, DOI 10.1016/j.jff.2015.10.026
   Pereira SR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174116
   Perez-Berezo T, 2012, EXP BIOL MED, V237, P1181, DOI [10.1258/ebm.2012.012083, 10.1258/]
   Pervin M, 2016, J NUTR BIOCHEM, V28, P103, DOI 10.1016/j.jnutbio.2015.10.006
   Piper JT, 1998, INT J BIOCHEM CELL B, V30, P445, DOI 10.1016/S1357-2725(98)00015-6
   Pojer E, 2013, COMPR REV FOOD SCI F, V12, P483, DOI 10.1111/1541-4337.12024
   Pramod Chandrasenan, 2016, Journal of Applied Pharmaceutical Science, V6, P137
   Qian ZJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep17348
   Riaz A, 2017, PAK J PHARM SCI, V30, P155
   Paiotti APR, 2013, BRIT J NUTR, V110, P973, DOI 10.1017/S000711451300007X
   Rogler G, 2015, PHARMACOL RES, V100, P220, DOI 10.1016/j.phrs.2015.07.005
   Romagnolo Donato F, 2017, Nutr Today, V52, P208, DOI 10.1097/NT.0000000000000228
   Roth S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154817
   Roth S, 2014, DIGESTION, V90, P179, DOI 10.1159/000366055
   Rutz S, 2013, IMMUNOL REV, V252, P116, DOI 10.1111/imr.12027
   Saadatdoust Z, 2015, J NUTR BIOCHEM, V26, P1547, DOI 10.1016/j.jnutbio.2015.07.024
   Scarano A, 2018, FRONT NUTR, V4, DOI 10.3389/fnut.2017.00075
   Serra D, 2016, CHEM-BIOL INTERACT, V260, P102, DOI 10.1016/j.cbi.2016.11.003
   Serra D, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0073001, 10.1371/journal.pone.0063915]
   Shah TA, 2016, MOL CELL BIOCHEM, V419, P65, DOI 10.1007/s11010-016-2750-x
   Shi N, 2015, NUTRIENTS, V7, P1696, DOI 10.3390/nu7031696
   Shukla PK, 2003, HUM EXP TOXICOL, V22, P653, DOI 10.1191/0960327103ht411oa
   Sodagari HR, 2015, EXPERT REV GASTROENT, V9, P807, DOI 10.1586/17474124.2015.1002086
   Tadic VM, 2008, J AGR FOOD CHEM, V56, P7700, DOI 10.1021/jf801668c
   Taverniti V, 2014, J AGR FOOD CHEM, V62, P8346, DOI 10.1021/jf502180j
   Tomlinson ML, 2017, FRONT NUTR, V4, DOI 10.3389/fnut.2017.00061
   Turrini E, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/938475
   Valcheva-Kuzmanova S, 2018, FOOD CHEM TOXICOL, V113, P33, DOI 10.1016/j.fct.2018.01.011
   Vezza T, 2016, NUTRIENTS, V8, DOI 10.3390/nu8040211
   Wang H, 2013, MOL NUTR FOOD RES, V57, P2253, DOI 10.1002/mnfr.201300146
   Wang LS, 2013, CANCER PREV RES, V6, P1317, DOI 10.1158/1940-6207.CAPR-13-0077
   Wright EK, 2015, INFLAMM BOWEL DIS, V21, P1219, DOI 10.1097/MIB.0000000000000382
   Yang G, 2014, FOOD FUNCT, V5, P2558, DOI [10.1039/C4FO00451E, 10.1039/c4fo00451e]
   Yook JS, 2017, J MED FOOD, V20, P367, DOI 10.1089/jmf.2016.3821
   Zhao L, 2018, FOOD FUNCT
   Zhao R, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/412576
   Zielinska M, 2015, J FUNCT FOODS, V17, P587, DOI 10.1016/j.jff.2015.05.046
   Zorrilla P, 2014, J FUNCT FOODS, V11, P449, DOI 10.1016/j.jff.2014.10.022
NR 111
TC 22
Z9 22
U1 6
U2 32
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-4124
EI 1747-4132
J9 EXPERT REV GASTROENT
JI Expert Rev. Gastroenterol. Hepatol.
PY 2018
VL 12
IS 10
BP 1007
EP 1024
DI 10.1080/17474124.2018.1513322
PG 18
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA GW8AU
UT WOS:000447195700008
PM 30136591
DA 2022-04-25
ER

PT J
AU Koehler, BC
   Scherr, AL
   Lorenz, S
   Urbanik, T
   Kautz, N
   Elssner, C
   Welte, S
   Bermejo, JL
   Jager, D
   Schulze-Bergkamen, H
AF Koehler, Bruno Christian
   Scherr, Anna-Lena
   Lorenz, Stephan
   Urbanik, Toni
   Kautz, Nicole
   Elssner, Christin
   Welte, Stefan
   Bermejo, Justo Lorenzo
   Jaeger, Dirk
   Schulze-Bergkamen, Henning
TI Beyond Cell Death - Antiapoptotic Bcl-2 Proteins Regulate Migration and
   Invasion of Colorectal Cancer Cells In Vitro
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; APOPTOSIS RESISTANCE; OBATOCLAX MESYLATE; METASTASIS;
   FAMILY; AUTOPHAGY; LIFE; XL; OVEREXPRESSION; PROGRESSION
AB Migration and invasion of malignant cells are prerequisites for cancer progression and metastasis. The Bcl-2 family of proteins consists of about 25 members and has been extensively studied in the context of apoptosis. Despite the fact that small molecules targeting Bcl-2 proteins have already entered clinical trials, very few studies investigated a role of antiapoptotic Bcl-2 proteins beside cell death in the context of metastasis. The aim of this study was to dissect a potential role of the antiapoptotic Bcl-2 proteins Mcl-1, Bcl-2 and Bcl-xL on migration and invasion of colorectal cancer cells independent of their cell death control function. We used migration and invasion assays as well as three dimensional cell cultures to analyze colorectal cancer cell lines (HT29 and SW480) after siRNA mediated knockdown or overexpression of Mcl-1, Bcl-2 or Bcl-xL. We observed neither spontaneous cell death induction nor impaired proliferation of cells lacking Mcl-1, Bcl-2 or Bcl-xL. In contrast, knockdown of Mcl-1 led to increased proliferation. Strikingly, we demonstrate a profound impairment of both, migration and invasion, of colorectal cancer cells after Mcl-1, Bcl-2 or Bcl-xL knockdown. This phenotype was completely revised in cells overexpressing Mcl-1, Bcl-2 or Bcl-xL. The most pronounced effect among the investigated proteins was observed for Bcl-2. The data presented indicate a pivotal role of Mcl-1, Bcl-2 and Bcl-xL for migration and invasion of colorectal cancer cells independent of their known antiapoptotic effects. Thus, our study illustrates novel antitumoral mechanisms of Bcl-2 protein targeting.
C1 [Koehler, Bruno Christian; Scherr, Anna-Lena; Lorenz, Stephan; Urbanik, Toni; Kautz, Nicole; Elssner, Christin; Welte, Stefan; Jaeger, Dirk; Schulze-Bergkamen, Henning] Univ Heidelberg Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany.
   [Bermejo, Justo Lorenzo] Univ Heidelberg Hosp, Inst Med Biometry & Informat, Heidelberg, Germany.
RP Koehler, BC (corresponding author), Univ Heidelberg Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany.
EM bruno.koehler@nct-heidelberg.de
OI Lorenzo Bermejo, Justo/0000-0002-6568-5333
FU Medical Faculty of the University of Heidelberg, Germany; German
   Research Foundation (Deutsche Forschungsgemeinschaft)German Research
   Foundation (DFG) [DFG SCHU 1443/4-1]; Merck Serono GmbH (Darmstadt,
   Germany)
FX This study was supported by a Postdoctoral-Fellowship granted to BCK
   from the Medical Faculty of the University of Heidelberg, Germany
   (http://www.medizinische-fakultaet-hd.uni-heidelberg.de), and grants to
   HSB from the German Research Foundation (Deutsche
   Forschungsgemeinschaft, http://www.dfg.de/, DFG SCHU 1443/4-1) and from
   Merck Serono GmbH (Darmstadt, Germany). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ackermann M, 2011, INT J ONCOL, V38, P71, DOI 10.3892/ijo_00000825
   Alderton GK, 2013, NAT REV CANCER, V13, P3, DOI 10.1038/nrc3428
   Bokhari M, 2007, J ANAT, V211, P567, DOI 10.1111/j.1469-7580.2007.00778.x
   Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Cragg MS, 2009, NAT REV CANCER, V9, P321, DOI 10.1038/nrc2615
   DelBufalo D, 1997, FASEB J, V11, P947, DOI 10.1096/fasebj.11.12.9337147
   DEVRIES JE, 1995, BRIT J CANCER, V71, P271, DOI 10.1038/bjc.1995.55
   Dubois F, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2357174
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fernandez Y, 2002, INT J CANCER, V101, P317, DOI 10.1002/ijc.10628
   Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200
   Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1
   Goard CA, 2013, CORE EVID, V8, P15, DOI 10.2147/CE.S42568
   Gordy C, 2012, PROTEIN CELL, V3, P17, DOI 10.1007/s13238-011-1127-x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Henderson-Jackson EB, 2010, INT J CLIN EXP PATHO, V3, P768
   Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533
   Joudeh J, 2012, EXPERT OPIN INV DRUG, V21, P363, DOI 10.1517/13543784.2012.652302
   Koehler BC, 2009, WORLD J GASTROENTERO, V15, P5924, DOI 10.3748/wjg.15.5924
   KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516
   Krishna S, 2011, BIOCHEM J, V435, P545, DOI 10.1042/BJ20101996
   Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37
   Laulier C, 2012, MUTAT RES-REV MUTAT, V751, P247, DOI 10.1016/j.mrrev.2012.05.002
   LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0
   Liu YQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038000
   Low ICC, 2011, ANTIOXID REDOX SIGN, V15, P2975, DOI 10.1089/ars.2010.3851
   Martin SS, 2004, ONCOGENE, V23, P4641, DOI 10.1038/sj.onc.1207595
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Mitry E, 2002, BRIT J SURG, V89, P1557, DOI 10.1046/j.1365-2168.2002.02276.x
   Ni F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038802
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Olopade OI, 1997, CANCER J SCI AM, V3, P230
   Perciavalle RM, 2012, NAT CELL BIOL, V14, P575, DOI 10.1038/ncb2488
   Schulze-Bergkamen H, 2008, WORLD J GASTROENTERO, V14, P3829, DOI 10.3748/wjg.14.3829
   Schutte M, 2011, ASSAY DRUG DEV TECHN, V9, P475, DOI 10.1089/adt.2011.0371
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Tischner D, 2012, APOPTOSIS, V17, P1197, DOI 10.1007/s10495-012-0756-8
   Um JH, 2004, J PHARMACOL EXP THER, V311, P1062, DOI 10.1124/jpet.104.070938
   Wanebo HJ, 2012, CLIN EXP METASTAS, V29, P821, DOI 10.1007/s10585-012-9517-x
   Wick W, 2001, J NEURO-ONCOL, V53, P177, DOI 10.1023/A:1012209518843
   Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002
   Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002
   Yang JS, 2011, WORLD J SURG ONCOL, V9, DOI 10.1186/1477-7819-9-117
   Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x
   Zinkel SS, 2008, METHOD ENZYMOL, V442, P231, DOI 10.1016/S0076-6879(08)01412-2
NR 48
TC 68
Z9 70
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 3
PY 2013
VL 8
IS 10
AR e76446
DI 10.1371/journal.pone.0076446
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 232HM
UT WOS:000325483600053
PM 24098503
OA Green Submitted, Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, Q
   Wang, BL
   Sun, FR
   Li, JQ
   Cao, XP
   Tan, L
AF Li, Quan
   Wang, Bai-Ling
   Sun, Fu-Rong
   Li, Jie-Qiong
   Cao, Xi-Peng
   Tan, Lan
TI The role of UNC5C in Alzheimer's disease
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Alzheimer's disease (AD); apoptosis/autophagy; activating
   death-associated protein kinase 1 (activating DAPK1); tau; UNC5C
ID AMYLOID PRECURSOR PROTEIN; COLORECTAL-CANCER; RECEPTORS UNC5H; RARE
   MUTATION; CELL-DEATH; KINASE 1; NETRIN-1; APOPTOSIS; GENE; EXPRESSION
AB Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease in adults characterized by the deposition of extracellular plaques of beta-amyloid protein (A beta), intracellular neurofibrillary tangles (NFTs), synaptic loss and neuronal apoptosis. AD has a strong and complex genetic component that involving into multiple genes. With recent advances in whole-exome sequencing (WES) and whole-genome sequencing (WGS) technology, UNC5C was identified to have association with AD. Emerging studies on cell and animal models identified that aberrant UNC5C may contribute to AD by activating death-associated protein kinase 1 (DAPK1) which is a new component involved in AD pathogenesis with an extensive involvement in aberrant tau, A beta and neuronal apoptosis/autophagy. In this review, we briefly summarize the biochemical properties, genetics, epigenetics, and the speculative role of UNC5C in AD. We hope our review would bring comprehensive understandings of AD pathogenesis and provide new therapeutic targets for AD.
C1 [Li, Quan; Sun, Fu-Rong; Li, Jie-Qiong; Tan, Lan] Qingdao Univ, Qingdao Municipal Hosp, Dept Neurol, Qingdao 266071, Peoples R China.
   [Wang, Bai-Ling] Qingdao Mental Hlth Ctr, Dept Geriatr, Qingdao 266034, Peoples R China.
   [Cao, Xi-Peng] Qingdao Univ, Qingdao Municipal Hosp, Clin Res Ctr, Qingdao 266071, Peoples R China.
RP Tan, L (corresponding author), Qingdao Univ, Sch Med, Qingdao Municipal Hosp, Dept Neurol, 5 Donghai Middle Rd, Qingdao 266071, Peoples R China.
EM dr.tanlan@163.com
FU Shandong Taishan Scholar; Qingdao Key Health Discipline Development
   Fund; Shandong Provincial Collaborative Innovation Center for
   Neurodegenerative Disorders
FX This work was supported by grants from the Shandong Taishan Scholar,
   Qingdao Key Health Discipline Development Fund, and Shandong Provincial
   Collaborative Innovation Center for Neurodegenerative Disorders.
CR Ackerman SL, 1998, GENOMICS, V52, P205, DOI 10.1006/geno.1998.5425
   Athanasopoulos D, 2016, ADV NUTR, V7, P917, DOI 10.3945/an.116.012229
   Bell RAV, 2017, CELL DEATH DIFFER, V24, P1359, DOI 10.1038/cdd.2017.37
   Bordeaux MC, 2000, EMBO J, V19, P4056, DOI 10.1093/emboj/19.15.4056
   Del-Aguila JL, 2015, CURR OPIN GENET DEV, V33, P49, DOI 10.1016/j.gde.2015.07.008
   Driver JA, 2015, BBA-GEN SUBJECTS, V1850, P2069, DOI 10.1016/j.bbagen.2014.12.025
   Dyukov Ye V, 2015, Adv Gerontol, V28, P299
   Eisenberg-Lerner A, 2007, CELL DEATH DIFFER, V14, P1908, DOI 10.1038/sj.cdd.4402212
   Farrer LA, 2015, LANCET NEUROL, V14, P783, DOI 10.1016/S1474-4422(15)00146-5
   Francois A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0139-x
   Gaj P, 2012, J ALZHEIMERS DIS, V32, P157, DOI 10.3233/JAD-2012-120520
   Ganguly G, 2017, DRUG DES DEV THER, V11, P797, DOI 10.2147/DDDT.S130514
   Genin E, 2011, MOL PSYCHIATR, V16, P903, DOI 10.1038/mp.2011.52
   Goedert M, 2015, SCIENCE, V349, DOI 10.1126/science.1255555
   Gonzalez D, 2010, MOL CELL BIOCHEM, V333, P151, DOI 10.1007/s11010-009-0215-1
   Grimm MOW, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00063
   Hashimoto Y, 2005, MOL CELL BIOL, V25, P9304, DOI 10.1128/MCB.25.21.9304-9317.2005
   Hashimoto Y, 2016, J BIOL CHEM, V291, P12282, DOI 10.1074/jbc.M115.698092
   Hashimoto Y, 2014, J NEUROCHEM, V130, P291, DOI 10.1111/jnc.12717
   Hibi K, 2012, HEPATO-GASTROENTEROL, V59, P2573, DOI 10.5754/hge10616
   Iqbal K, 2016, NAT REV NEUROL, V12, DOI 10.1038/nrneurol.2015.225
   Jiao B, 2014, NEUROBIOL AGING, V35
   Johnson GVW, 2004, J CELL SCI, V117, P5721, DOI 10.1242/jcs.01558
   Kim BM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.216
   Kim D, 2011, J NEUROSCI, V31, P2167, DOI 10.1523/JNEUROSCI.5254-10.2011
   Kiriyama Y, 2015, INT J MOL SCI, V16, P26797, DOI 10.3390/ijms161125990
   Korvatska O, 2015, JAMA NEUROL, V72, P920, DOI 10.1001/jamaneurol.2015.0979
   Kury S, 2014, WORLD J GASTROENTERO, V20, P204, DOI 10.3748/wjg.v20.i1.204
   Lane-Donovan C, 2017, TRENDS ENDOCRIN MET, V28, P273, DOI 10.1016/j.tem.2016.12.001
   Lanoiselee HM, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002270
   Lauritzen I, 2016, ACTA NEUROPATHOL, V132, P257, DOI 10.1007/s00401-016-1577-6
   Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0
   Li YH, 2006, HUM MOL GENET, V15, P2560, DOI 10.1093/hmg/ddl178
   Liao YY, 2014, J MOL BIOL, V426, P3935, DOI 10.1016/j.jmb.2014.10.011
   Llambi F, 2001, EMBO J, V20, P2715, DOI 10.1093/emboj/20.11.2715
   Lourenco FC, 2009, CELL DEATH DIFFER, V16, P655, DOI 10.1038/cdd.2008.191
   Mandell JW, 1996, PERSPECT DEV NEUROBI, V4, P125
   Mehlen P, 2010, CURR OPIN ONCOL, V22, P46, DOI 10.1097/CCO.0b013e328333dcd1
   Mendez MF, 2017, NEUROL CLIN, V35, P263, DOI 10.1016/j.ncl.2017.01.005
   Muller UC, 2017, NAT REV NEUROSCI, V18, P281, DOI 10.1038/nrn.2017.29
   Mur P, 2016, SCI REP-UK, V6, DOI 10.1038/srep20697
   Ng SB, 2010, NAT GENET, V42, P30, DOI 10.1038/ng.499
   Nishimura YV, 2010, J BIOL CHEM, V285, P5878, DOI 10.1074/jbc.M109.033761
   O'Brien RJ, 2011, ANNU REV NEUROSCI, V34, P185, DOI 10.1146/annurev-neuro-061010-113613
   Poliak S, 2015, ELIFE, V4, DOI 10.7554/eLife.10841
   Rodrigues S, 2007, ONCOGENE, V26, P5615, DOI 10.1038/sj.onc.1210347
   Sanchez-Mut J, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00347
   Scheltens P, 2016, LANCET, V388, P505, DOI 10.1016/S0140-6736(15)01124-1
   Shanker S, 2008, INT J ANDROL, V31, P462, DOI 10.1111/j.1365-2605.2008.00904.x
   Shin SK, 2007, GASTROENTEROLOGY, V133, P1849, DOI 10.1053/j.gastro.2007.08.074
   Singh P, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00046
   Son TW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.94
   Spires-Jones TL, 2017, ACTA NEUROPATHOL, V134, P187, DOI 10.1007/s00401-017-1709-7
   SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031
   Sugimoto M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131283
   Sun JH, 2016, MOL NEUROBIOL, V53, P6759, DOI 10.1007/s12035-015-9589-0
   Tachi N, 2012, BIOCHEM J, V442, P413, DOI 10.1042/BJ20100993
   Takanishi R, 2017, PROMOTING THE EDUCATIONAL SUCCESS OF CHILDREN AND YOUTH LEARNING ENGLISH: PROMISING FUTURES, P1, DOI 10.1111/pin.12520
   Tang XL, 2008, NAT CELL BIOL, V10, P698, DOI 10.1038/ncb1732
   Thibert C, 2003, SCIENCE, V301, P843, DOI 10.1126/science.1085405
   Thiebault K, 2003, P NATL ACAD SCI USA, V100, P4173, DOI 10.1073/pnas.0738063100
   Wang XL, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/7067259
   Wetzel-Smith MK, 2014, NAT MED, V20, P1452, DOI 10.1038/nm.3736
   Williams ME, 2003, J BIOL CHEM, V278, P17483, DOI 10.1074/jbc.M300415200
   Wood Heather, 2014, Nat Rev Neurol, V10, P548, DOI 10.1038/nrneurol.2014.164
   Wu J, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697564
   Wu ZC, 2011, BRAIN RES, V1374, P129, DOI 10.1016/j.brainres.2010.12.036
   Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349
   Yang B, 2013, GENE EXPR PATTERNS, V13, P311, DOI 10.1016/j.gep.2013.06.001
   You MH, 2017, CELL DEATH DIFFER, V24, P238, DOI 10.1038/cdd.2016.114
   Yu JT, 2014, ANNU REV NEUROSCI, V37, P79, DOI 10.1146/annurev-neuro-071013-014300
   Yu NN, 2016, MOL NEUROBIOL, V53, P5692, DOI 10.1007/s12035-015-9459-9
   Zhang CC, 2016, MOL NEUROBIOL, V53, P4893, DOI 10.1007/s12035-015-9415-8
NR 73
TC 6
Z9 6
U1 3
U2 7
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD MAY
PY 2018
VL 6
IS 10
AR 178
DI 10.21037/atm.2018.04.43
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GH3SK
UT WOS:000433322300010
PM 29951500
OA Green Published
DA 2022-04-25
ER

PT J
AU Xavier, S
   Gilbert, V
   Rastaldi, MP
   Krick, S
   Kollins, D
   Reddy, A
   Bottinger, E
   Cohen, CD
   Schlondorff, D
AF Xavier, Sandhya
   Gilbert, Victoria
   Rastaldi, Maria Pia
   Krick, Stefanie
   Kollins, Dmitrij
   Reddy, Anand
   Bottinger, Erwin
   Cohen, Clemens D.
   Schlondorff, Detlef
TI BAMBI Is Expressed in Endothelial Cells and Is Regulated by
   Lysosomal/Autolysosomal Degradation
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-BETA; MEMBRANE-BOUND INHIBITOR; ISOLATED RAT HEPATOCYTES;
   TGF-BETA; GENE-EXPRESSION; PSEUDORECEPTOR BAMBI; PROTEIN-DEGRADATION;
   COLORECTAL-CANCER; MESANGIAL CELLS; AUTOPHAGY
AB Background: BAMBI (BMP and Activin Membrane Bound Inhibitor) is considered to influence TGF beta and Wnt signaling, and thereby fibrosis. Surprisingly data on cell type-specific expression of BAMBI are not available. We therefore examined the localization, gene regulation, and protein turnover of BAMBI in kidneys.
   Methodology/Principal Findings: By immunofluorescence microscopy and by mRNA expression, BAMBI is restricted to endothelial cells of the glomerular and some peritubular capillaries and of arteries and veins in both murine and human kidneys. TGF beta upregulated mRNA of BAMBI in murine glomerular endothelial cells (mGEC). LPS did not downregulate mRNA for BAMBI in mGEC or in HUVECs. BAMBI mRNA had a half-life of only 60 minutes and was stabilized by cycloheximide, indicating post-transcriptional regulation due to AU-rich elements, which we identified in the 3' untranslated sequence of both the human and murine BAMBI gene. BAMBI protein turnover was studied in HUVECs with BAMBI overexpression using a lentiviral system. Serum starvation as an inducer of autophagy caused marked BAMBI degradation, which could be totally prevented by inhibition of lysosomal and autolysosomal degradation with bafilomycin, and partially by inhibition of autophagy with 3-methyladenine, but not by proteasomal inhibitors. Rapamycin activates autophagy by inhibiting TOR, and resulted in BAMBI protein degradation. Both serum starvation and rapamycin increased the conversion of the autophagy marker LC3 from LC3-I to LC3-II and also enhanced co-staining for BAMBI and LC3 in autolysosomal vesicles.
   Conclusions/Significance: 1. BAMBI localizes to endothelial cells in the kidney and to HUVECs. 2. BAMBI mRNA is regulated by post-transcriptional mechanisms. 3. BAMBI protein is regulated by lysosomal and autolysosomal degradation. The endothelial localization and the quick turnover of BAMBI may indicate novel, yet to be defined functions of this modulator for TGF beta and Wnt protein actions in the renal vascular endothelium in health and disease.
C1 [Xavier, Sandhya; Gilbert, Victoria; Krick, Stefanie; Kollins, Dmitrij; Reddy, Anand; Bottinger, Erwin; Schlondorff, Detlef] Mt Sinai Sch Med, Dept Med, New York, NY USA.
   [Cohen, Clemens D.] Univ Hosp, Div Nephrol, Zurich, Switzerland.
   [Cohen, Clemens D.] Univ Hosp, Inst Physiol, Ctr Integrat Human Physiol, Zurich, Switzerland.
   [Cohen, Clemens D.] Univ Zurich, Zurich, Switzerland.
   [Rastaldi, Maria Pia] Fdn DAmico Ric Malattie Renali, Renal Immunopathol Lab, Milan, Italy.
RP Xavier, S (corresponding author), Mt Sinai Sch Med, Dept Med, New York, NY USA.
EM detlef.schlondorff@mssm.edu
FU National Institutes of Health (National Institute of Diabetes and
   Digestive and Kidney Diseases)United States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01-DK081420-01];
   Else Kroener-Fresenius Foundation [A62/04]; Swiss National Science
   FoundationSwiss National Science Foundation (SNSF)European Commission
   [32-122439/1]; Fondazione IRCCS Policlinico; NATIONAL INSTITUTE OF
   DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)
   [R01DK056077, R01DK081420, R01DK060043] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health ( National
   Institute of Diabetes and Digestive and Kidney Diseases R01-DK081420-01
   to D. S.) and in part by the Else Kroener-Fresenius Foundation (A62/04
   to C. D. C.) and the Swiss National Science Foundation (32-122439/1 to
   C. D. C.), and Progetto a concorso 2009/2010 Fondazione IRCCS
   Policlinico to M. P. R. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akis N, 2004, KIDNEY INT, V65, P2223, DOI 10.1111/j.1523-1755.2004.00634.x
   Barreau C, 2005, NUCLEIC ACIDS RES, V33, P7138, DOI 10.1093/nar/gki1012
   Bedford JJ, 2003, J AM SOC NEPHROL, V14, P2581, DOI 10.1097/01.ASN.0000089566.28106.F6
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Bottinger EP, 2007, SEMIN NEPHROL, V27, P309, DOI 10.1016/j.semnephrol.2007.02.009
   Chen JQ, 2007, GENESIS, V45, P482, DOI 10.1002/dvg.20320
   Cohen CD, 2002, KIDNEY INT, V61, P133, DOI 10.1046/j.1523-1755.2002.00113.x
   Demaison C, 2002, HUM GENE THER, V13, P803, DOI 10.1089/10430340252898984
   EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734
   El-Achkar TM, 2006, AM J PHYSIOL-RENAL, V290, pF1034, DOI 10.1152/ajprenal.00414.2005
   Finn PE, 2005, AUTOPHAGY, V1, P141, DOI 10.4161/auto.1.3.2000
   Fritzmann J, 2009, GASTROENTEROLOGY, V137, P165, DOI 10.1053/j.gastro.2009.03.041
   GAZIT D, 1993, MOL ENDOCRINOL, V7, P189, DOI 10.1210/me.7.2.189
   Grotewold L, 2001, MECH DEVELOP, V100, P327, DOI 10.1016/S0925-4773(00)00524-4
   Hao SL, 2009, NAT IMMUNOL, V10, P281, DOI 10.1038/ni.1699
   HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359
   Hayes S, 2002, J CELL BIOL, V158, P1239, DOI 10.1083/jcb.200204088
   Higashihori N, 2008, DEV DYNAM, V237, P1500, DOI 10.1002/dvdy.21529
   Hwang I, 2009, ARCH PHARM RES, V32, P1653, DOI 10.1007/s12272-009-2200-3
   Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9
   Klionsky DJ, 2008, AUTOPHAGY, V4, P849, DOI 10.4161/auto.6845
   Knight C, 2001, J DENT RES, V80, P1895, DOI 10.1177/00220345010800100701
   Lin CL, 2006, J AM SOC NEPHROL, V17, P2812, DOI 10.1681/ASN.2005121355
   Lin ZH, 2008, J BIOL CHEM, V283, P33053, DOI 10.1074/jbc.M804039200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loveland KL, 2003, ENDOCRINOLOGY, V144, P4180, DOI 10.1210/en.2002-0124
   Meng LH, 1999, P NATL ACAD SCI USA, V96, P10403, DOI 10.1073/pnas.96.18.10403
   Merkel CE, 2007, PEDIATR NEPHROL, V22, P1825, DOI 10.1007/s00467-007-0504-4
   Mizushima N, 2004, INT J BIOCHEM CELL B, V36, P2491, DOI 10.1016/j.biocel.2004.02.005
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739
   Neusser MA, 2010, AM J PATHOL, V176, P594, DOI 10.2353/ajpath.2010.090268
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   O'Connor MN, 2009, BLOOD, V113, P4754, DOI 10.1182/blood-2008-06-162693
   Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794
   Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898
   ROTE KV, 1983, J CELL PHYSIOL, V116, P103, DOI 10.1002/jcp.1041160116
   Satriano JA, 1997, J AM SOC NEPHROL, V8, P596
   Schlondorff D, 2009, J AM SOC NEPHROL, V20, P1179, DOI 10.1681/ASN.2008050549
   Schmid H, 2003, J AM SOC NEPHROL, V14, P2958, DOI 10.1097/01.ASN.0000090745.85482.06
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   SEGLEN PO, 1982, P NATL ACAD SCI-BIOL, V79, P1889, DOI 10.1073/pnas.79.6.1889
   Seki E, 2007, NAT MED, V13, P1324, DOI 10.1038/nm1663
   Sekiya T, 2004, BIOCHEM BIOPH RES CO, V320, P680, DOI 10.1016/j.bbrc.2004.06.017
   Sekiya T, 2004, J BIOL CHEM, V279, P6840, DOI 10.1074/jbc.M310876200
   Shi SL, 2008, J AM SOC NEPHROL, V19, P2159, DOI 10.1681/ASN.2008030312
   Togo N, 2008, WORLD J GASTROENTERO, V14, P4880, DOI 10.3748/wjg.14.4880
   Tsang M, 2000, GENESIS, V28, P47, DOI 10.1002/1526-968X(200010)28:2<47::AID-GENE20>3.0.CO;2-S
   WOLF G, 1993, J CLIN INVEST, V92, P1366, DOI 10.1172/JCI116710
   WOODWARD TL, 1995, J CELL PHYSIOL, V165, P339, DOI 10.1002/jcp.1041650215
   Xavier S, 2009, J AM SOC NEPHROL, V20, P2127, DOI 10.1681/ASN.2008070806
   Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373
   YAMAWAKI M, 1993, J HISTOCHEM CYTOCHEM, V41, P105, DOI 10.1177/41.1.8417105
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Zerlin M, 2008, ANGIOGENESIS, V11, P63, DOI 10.1007/s10456-008-9095-3
NR 55
TC 34
Z9 40
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2010
VL 5
IS 9
AR e12995
DI 10.1371/journal.pone.0012995
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 653UN
UT WOS:000282122600020
PM 20886049
OA Green Published, gold, Green Submitted, Green Accepted
DA 2022-04-25
ER

PT J
AU Lu, W
   Fu, DL
   Kong, XX
   Huang, ZH
   Hwang, M
   Zhu, YS
   Chen, LB
   Jiang, K
   Li, XL
   Wu, YH
   Li, J
   Yuan, Y
   Ding, KF
AF Lu, Wei
   Fu, Dongliang
   Kong, Xiangxing
   Huang, Zhiheng
   Hwang, Maxwell
   Zhu, Yingshuang
   Chen, Liubo
   Jiang, Kai
   Li, Xinlin
   Wu, Yihua
   Li, Jun
   Yuan, Ying
   Ding, Kefeng
TI FOLFOX treatment response prediction in metastatic or recurrent
   colorectal cancer patients via machine learning algorithms
SO CANCER MEDICINE
LA English
DT Article
DE colorectal cancer; FOLFOX; machine learning algorithm; microarray
   meta-analysis
ID POOR RESPONSE; R PACKAGE; OXALIPLATIN; MICROARRAY; FOLFIRI; EXPRESSION;
   SIGNATURE; THERAPY; FLUOROURACIL; CHEMOTHERAPY
AB Early identification of metastatic or recurrent colorectal cancer (CRC) patients who will be sensitive to FOLFOX (5-FU, leucovorin and oxaliplatin) therapy is very important. We performed microarray meta-analysis to identify differentially expressed genes (DEGs) between FOLFOX responders and nonresponders in metastatic or recurrent CRC patients, and found that the expression levels of WASHC4, HELZ, ERN1, RPS6KB1, and APPBP2 were downregulated, while the expression levels of IRF7, EML3, LYPLA2, DRAP1, RNH1, PKP3, TSPAN17, LSS, MLKL, PPP1R7, GCDH, C19ORF24, and CCDC124 were upregulated in FOLFOX responders compared with nonresponders. Subsequent functional annotation showed that DEGs were significantly enriched in autophagy, ErbB signaling pathway, mitophagy, endocytosis, FoxO signaling pathway, apoptosis, and antifolate resistance pathways. Based on those candidate genes, several machine learning algorithms were applied to the training set, then performances of models were assessed via the cross validation method. Candidate models with the best tuning parameters were applied to the test set and the final model showed satisfactory performance. In addition, we also reported that MLKL and CCDC124 gene expression were independent prognostic factors for metastatic CRC patients undergoing FOLFOX therapy.
C1 [Lu, Wei; Fu, Dongliang; Kong, Xiangxing; Huang, Zhiheng; Hwang, Maxwell; Zhu, Yingshuang; Chen, Liubo; Jiang, Kai; Li, Xinlin; Li, Jun; Ding, Kefeng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Colorectal Surg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
   [Lu, Wei; Fu, Dongliang; Kong, Xiangxing; Huang, Zhiheng; Hwang, Maxwell; Zhu, Yingshuang; Chen, Liubo; Jiang, Kai; Li, Xinlin; Li, Jun; Yuan, Ying; Ding, Kefeng] Zhejiang Univ, Affiliated Hosp 2, Key Lab Canc Prevent & Intervent China Natl Minis, Key Lab Mol Biol Med Sci,Sch Med,Canc Inst, Hangzhou, Zhejiang, Peoples R China.
   [Yuan, Ying] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Wu, Yihua] Zhejiang Univ, Sch Publ Hlth, Dept Toxicol, Hangzhou, Zhejiang, Peoples R China.
RP Ding, KF (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Colorectal Surg, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.; Ding, KF (corresponding author), Zhejiang Univ, Sch Med, China Natl Minist Educ, Key Lab Canc Prevent & Intervent, 88 Jiefang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM dingkefeng@zju.edu.cn
FU Key Technology Research and Development Program of Zhejiang Province
   [2017C03017]
FX This work was supported by the Key Technology Research and Development
   Program of Zhejiang Province (2017C03017).
CR Ahn SJ, 2016, EUR J RADIOL, V85, P1867, DOI 10.1016/j.ejrad.2016.08.014
   Arlot S, 2010, STAT SURV, V4, P40, DOI 10.1214/09-SS054
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergmeir C, 2012, J STAT SOFTW, V46, P1
   Carlson M., 2016, HGU133PLUS2 DB AFFYM
   Cassidy J, 2011, BRIT J CANCER, V105, P58, DOI 10.1038/bjc.2011.201
   Chang WJ, 2014, GUT, V63, P1457, DOI 10.1136/gutjnl-2013-305475
   Cho Eugene, 2018, Oncotarget, V9, P7902, DOI 10.18632/oncotarget.24083
   Choi JK, 2003, BIOINFORMATICS, V19, pi84, DOI 10.1093/bioinformatics/btg1010
   Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
   Ein-Dor L, 2005, BIOINFORMATICS, V21, P171, DOI 10.1093/bioinformatics/bth469
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Gentleman R, 2017, ANNOTATE ANNOTATION
   Gentleman R, 2017, GENEFILTER GENEFILTE
   Jensen NF, 2015, MOL ONCOL, V9, P1169, DOI 10.1016/j.molonc.2015.02.008
   Kang DD, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1071
   Kap EJ, 2016, INT J CANCER, V138, P2993, DOI 10.1002/ijc.30026
   Kornmann M, 2012, EUR J CANCER, V48, P1443, DOI 10.1016/j.ejca.2011.11.007
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Li PL, 2017, MOL CANCER THER, V16, P739, DOI 10.1158/1535-7163.MCT-16-0591
   Liaw A., 2002, R NEWS, V2, P18, DOI 10.1021/ci034160g
   Lin HH, 2017, ONCOTARGET, V8, P13805, DOI 10.18632/oncotarget.14638
   Meyer D., 2015, R PACKAGE VERSION, V1, P6
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Ntzani EE, 2003, LANCET, V362, P1439, DOI 10.1016/S0140-6736(03)14686-7
   Pepper SD, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-273
   Ramasamy A, 2008, PLOS MED, V5, P1320, DOI 10.1371/journal.pmed.0050184
   Rasmussen MH, 2013, MOL ONCOL, V7, P637, DOI 10.1016/j.molonc.2013.02.016
   Ridgeway G., 2006, R PACKAGE VERSION, V1, P55
   RIPLEY B, 2005, TREE CLASSIFICATION
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Statnikov A, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-319
   Sun D, 2018, J DRUG TARGET, V26, P45, DOI 10.1080/1061186X.2017.1339192
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002
   Tseng GC, 2012, NUCLEIC ACIDS RES, V40, P3785, DOI 10.1093/nar/gkr1265
   Tsuji S, 2012, BRIT J CANCER, V106, P126, DOI 10.1038/bjc.2011.505
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012
   Venerables W.N., 2002, MODERN APPL STAT S
   Wang XB, 2012, BIOINFORMATICS, V28, P2534, DOI 10.1093/bioinformatics/bts485
   Wang XB, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-52
   Watanabe T, 2011, CLIN TRANSL ONCOL, V13, P419, DOI 10.1007/s12094-011-0676-z
   Yan C, 2018, ANTICANCER RES, V38, P617, DOI 10.21873/anticanres.12266
   Yang HZ, 2015, CANCER LETT, V361, P128, DOI 10.1016/j.canlet.2015.02.045
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
NR 51
TC 5
Z9 5
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD FEB
PY 2020
VL 9
IS 4
BP 1419
EP 1429
DI 10.1002/cam4.2786
EA JAN 2020
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KK2ZX
UT WOS:000504965800001
PM 31893575
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bergamin, LS
   Figueiro, F
   Dietrich, F
   Manica, FD
   Filippi-Chiela, EC
   Mendes, FB
   Jandrey, EHF
   Lopes, DV
   Oliveira, FH
   Nascimento, IC
   Ulrich, H
   Battastini, AMO
AF Bergamin, Leticia Scussel
   Figueiro, Fabricio
   Dietrich, Fabricia
   Manica, Fabiana de Mattos
   Filippi-Chiela, Eduardo C.
   Mendes, Franciane Brackman
   Farias Jandrey, Elisa Helena
   Lopes, Daniela Vasconcelos
   Oliveira, Francine H.
   Nascimento, Isis C.
   Ulrich, Henning
   Oliveira Battastini, Ana Maria
TI Interference of ursolic acid treatment with glioma growth: An in vitro
   and in vivo study
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Ursolic acid; Glioma; Glioma cell death; In vivo glioma model
ID NF-KAPPA-B; PROSTATE-CANCER CELLS; GLIOBLASTOMA CELLS;
   COLORECTAL-CANCER; INDUCED APOPTOSIS; INDUCE APOPTOSIS; INHIBITS GROWTH;
   OLEANOLIC ACID; AUTOPHAGY; PATHWAYS
AB Glioblastoma multiforme is the most devastating tumor in the brain. Ursolic acid (UA) is found in a variety of plants, and exhibits several pharmacological activities. In this study, we investigated the effects of UA in vitro, clarifying the mechanisms that mediate its toxicity and the long-lasting actions of UA in C6 glioma cells. We also evaluated the antitumor activity of UA in an in vivo orthotopic glioma model. Cell numbers were assessed using the Trypan blue exclusion test, and the cell cycle was characterized by flow cytometry using propidium iodide staining. Apoptosis was analyzed using an Annexin V kit and by examining caspase-3. Akt immunocontent was verified by Western blot and the long-lasting actions of UA were measured by cumulative population doubling (CPD). In vivo experiments were performed in rats to measure the effects on tumor size, malignant features and toxicological parameters. In vitro results showed that UA decreased glioma cell numbers, increased the sub-G1 fraction and induced apoptotic death, accompanied by increased active caspase-3 protein levels. Akt phosphorylation/activation in cells was also diminished by UA. With regard to CPD, cell proliferation was almost completely restored upon single UA treatments, but when the UA was added again, the majority of cells died, demonstrating the importance of re-treatment cycles with chemotherapeutic agents for abolishing tumor growth. In vivo, ursolic acid slightly reduced glioma tumor size but did not decrease malignant features. Ursolic acid may be a potential candidate as an adjuvant for glioblastoma therapy.
C1 [Bergamin, Leticia Scussel; Figueiro, Fabricio; Dietrich, Fabricia; Mendes, Franciane Brackman; Oliveira Battastini, Ana Maria] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Biol Bioquim, Inst Ciencias Basicas Saude, Porto Alegre, RS, Brazil.
   [Bergamin, Leticia Scussel; Nascimento, Isis C.; Ulrich, Henning] Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, Brazil.
   [Manica, Fabiana de Mattos; Farias Jandrey, Elisa Helena; Lopes, Daniela Vasconcelos; Oliveira Battastini, Ana Maria] Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Bioquim, Rua Ramiro Barcelos 2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.
   [Filippi-Chiela, Eduardo C.] Univ Fed Rio Grande do Sul, Programa Posgrad Gastroenterol & Hepatol, Fac Med, Porto Alegre, RS, Brazil.
   [Oliveira, Francine H.] Univ Fed Rio Grande do Sul, Serv Patol, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil.
RP Battastini, AMO (corresponding author), Univ Fed Rio Grande do Sul, Inst Ciencias Basicas Saude, Dept Bioquim, Rua Ramiro Barcelos 2600 Anexo, BR-90035003 Porto Alegre, RS, Brazil.
EM abattastini@gmail.com
RI Nascimento, Isis C/A-2725-2017; Figueiró, Fabrício/M-3625-2016;
   Dietrich, Fabrícia/F-8658-2019; Filippi-Chiela, Eduardo/F-1959-2014;
   Battastini, Ana M/E-2809-2012; Jandrey, Elisa Helena
   Farias/ABA-8577-2020; Ulrich, Henning/C-5245-2013
OI Figueiró, Fabrício/0000-0003-0899-6407; Filippi-Chiela,
   Eduardo/0000-0001-8192-3779; Battastini, Ana M/0000-0001-6068-3278;
   Jandrey, Elisa Helena Farias/0000-0003-0750-7552; Ulrich,
   Henning/0000-0002-2114-3815; Nascimento, Isis/0000-0002-2633-8216;
   Dietrich, Fabricia/0000-0002-6458-2359
FU CNPq-BrazilConselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPQ) [303264/2013-4]; FAPERGS/PRONEXFundacao de Amparo a Ciencia e
   Tecnologia do Estado do Rio Grande do Sul (FAPERGS) [16/2551-0000473-0];
   Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo (FAPESP) [2012/50880-4, 2015/18730-0]; CNPqConselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)
   [157647/2013-7, 150410/2016-6]
FX This work was supported by CNPq-Brazil (Project No 303264/2013-4),
   FAPERGS/PRONEX (Project No: 16/2551-0000473-0); L.S.B. PhD fellowship
   supported by CNPq (Project No: 157647/2013-7) and postdoctoral
   fellowship supported by CNPq (Project No: 150410/2016-6). H.U.
   acknowledges grant support from the Sao Paulo Research Foundation
   (FAPESP project No. 2012/50880-4). I.C.N. is supported by a postdoctoral
   fellowship granted by FAPESP (project No. 2015/18730-0).
CR Bernardi A, 2009, CANCER LETT, V281, P53, DOI 10.1016/j.canlet.2009.02.018
   Cargnin ST, 2017, FOOD CHEM, V220, P477, DOI 10.1016/j.foodchem.2016.10.029
   Chekhonin VP, 2007, B EXP BIOL MED+, V143, P501, DOI 10.1007/s10517-007-0167-y
   Chen HJ, 2015, EUR J MED CHEM, V92, P648, DOI 10.1016/j.ejmech.2015.01.031
   Chen QH, 2011, ANAL BIOANAL CHEM, V399, P2877, DOI 10.1007/s00216-011-4651-x
   Christodoulou MI, 2014, ANTI-CANCER AGENT ME, V14, P375, DOI 10.2174/18715206113139990089
   Collins K, 1997, P NATL ACAD SCI USA, V94, P2776, DOI 10.1073/pnas.94.7.2776
   Figueiro F, 2015, J BIOMED NANOTECHNOL, V11, P1808, DOI 10.1166/jbn.2015.2125
   Filippi-Chiela EC, 2015, AUTOPHAGY, V11, P1099, DOI 10.1080/15548627.2015.1009795
   Gao N, 2012, BRIT J PHARMACOL, V165, P1813, DOI 10.1111/j.1476-5381.2011.01684.x
   Gao X, 2007, J NEURO-ONCOL, V84, P147, DOI 10.1007/s11060-007-9364-9
   Huang HC, 2009, MOL CARCINOGEN, V48, P517, DOI 10.1002/mc.20490
   Ikeda Y, 2008, MOL NUTR FOOD RES, V52, P26, DOI 10.1002/mnfr.200700389
   Jokinen E, 2015, THER ADV MED ONCOL, V7, P170, DOI 10.1177/1758834015571111
   Kashyap D, 2016, LIFE SCI, V146, P201, DOI 10.1016/j.lfs.2016.01.017
   Kim DK, 2000, INT J CANCER, V87, P629, DOI 10.1002/1097-0215(20000901)87:5<629::AID-IJC2>3.0.CO;2-P
   Kim ES, 2015, ONCOL LETT, V9, P897, DOI 10.3892/ol.2014.2735
   Kim KH, 2011, ARCH PHARM RES, V34, P1363, DOI 10.1007/s12272-011-0817-5
   Kowalczyk MC, 2009, CARCINOGENESIS, V30, P1008, DOI 10.1093/carcin/bgp069
   Li J, 2002, WORLD J GASTROENTERO, V8, P493, DOI 10.3748/wjg.v8.i3.493
   Li JJ, 2012, ONCOL REP, V28, P501, DOI 10.3892/or.2012.1827
   Li YL, 2010, INT J CANCER, V127, P462, DOI 10.1002/ijc.25044
   Limami Y, 2011, BIOCHIMIE, V93, P749, DOI 10.1016/j.biochi.2011.01.003
   Lu CC, 2014, MOL NUTR FOOD RES, V58, P2146, DOI 10.1002/mnfr.201400051
   Mazumder K, 2013, MOLECULES, V18, P8929, DOI 10.3390/molecules18088929
   Meng Y, 2015, AM J CHINESE MED, V43, P1471, DOI 10.1142/S0192415X15500834
   Morrone FB, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-226
   PETERSON GL, 1979, ANAL BIOCHEM, V100, P201, DOI 10.1016/0003-2697(79)90222-7
   Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805
   Prasad S, 2011, J BIOL CHEM, V286, P5546, DOI 10.1074/jbc.M110.183699
   Saraswati S, 2013, CHEM-BIOL INTERACT, V206, P153, DOI 10.1016/j.cbi.2013.09.004
   Shan JZ, 2011, CHIN J INTEGR MED, V17, P607, DOI 10.1007/s11655-011-0815-y
   Shanmugam MK, 2013, BIOCHEM PHARMACOL, V85, P1579, DOI 10.1016/j.bcp.2013.03.006
   Shanmugam MK, 2011, J MOL MED, V89, P713, DOI 10.1007/s00109-011-0746-2
   Shao JW, 2011, EUR J MED CHEM, V46, P2652, DOI 10.1016/j.ejmech.2011.03.050
   Shen SY, 2014, CHEM-BIOL INTERACT, V218, P28, DOI 10.1016/j.cbi.2014.04.017
   Shin SW, 2013, BBA-MOL CELL RES, V1833, P723, DOI 10.1016/j.bbamcr.2012.12.005
   Silva AO, 2016, TUMOR BIOL, V37, P13743, DOI 10.1007/s13277-016-5255-z
   Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296
   Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010
   Tu HY, 2009, BIOORGAN MED CHEM, V17, P7265, DOI 10.1016/j.bmc.2009.08.046
   Vlachostergios PJ, 2013, NEUROL RES, V35, P879, DOI 10.1179/1743132813Y.0000000191
   Wang J, 2012, BASIC CLIN PHARMACOL, V111, P106, DOI 10.1111/j.1742-7843.2012.00870.x
   Wang JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063872
   Wang XM, 2011, J BIOMED BIOTECHNOL, P1, DOI 10.1155/2011/419343
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Weng H, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0096-6
   Westphal M, 2015, NAT REV NEUROL, V11, P556, DOI 10.1038/nrneurol.2015.171
   WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Yie YY, 2015, MOL CELL BIOCHEM, V402, P63, DOI 10.1007/s11010-014-2314-x
   Zamin LL, 2014, FOOD CHEM TOXICOL, V63, P205, DOI 10.1016/j.fct.2013.11.002
   Zhang YX, 2010, MOL CARCINOGEN, V49, P374, DOI 10.1002/mc.20610
   Zhao C, 2013, AUTOPHAGY, V9, P196, DOI 10.4161/auto.22805
   Zheng QY, 2013, CELL SIGNAL, V25, P206, DOI 10.1016/j.cellsig.2012.09.012
   Zhu ZL, 2016, AM J TRANSL RES, V8, P3299
NR 56
TC 9
Z9 10
U1 1
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 15
PY 2017
VL 811
BP 268
EP 275
DI 10.1016/j.ejphar.2017.06.030
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FH1EF
UT WOS:000410881800032
PM 28663034
DA 2022-04-25
ER

PT J
AU Liu, W
   Phang, JM
AF Liu, Wei
   Phang, James M.
TI Proline dehydrogenase (oxidase) in cancer
SO BIOFACTORS
LA English
DT Review
DE proline dehydrogenase; oxidase; reactive oxygen species; tumor
   suppressor; oncogene; metabolic stress
ID INDUCED APOPTOSIS; PPAR-GAMMA; P53-INDUCED GENE-6; COLORECTAL-CANCER;
   TUMOR-SUPPRESSOR; METABOLISM; EXPRESSION; PATHWAY; STRESS; RISK
AB Proline dehydrogenase (oxidase, PRODH/POX), the first enzyme in the proline degradative pathway, plays a special role in tumorigenesis and tumor development. Proline metabolism catalyzed by PRODH/POX is closely linked with the tricarboxylic acid (TCA) cycle and urea cycle. The proline cycle formed by the interconversion of proline and ?1-pyrroline-5-carboxylate (P5C) between mitochondria and cytosol interlocks with pentose phosphate pathway. Importantly, by catalyzing proline to P5C, PRODH/POX donates electrons into the electron transport chain to generate ROS or ATP. In earlier studies, we found that PRODH/POX functions as a tumor suppressor to initiate apoptosis, inhibit tumor growth, and block the cell cycle, all by ROS signaling. It also suppresses hypoxia inducible factor signaling by increasing a-ketoglutarate. During tumor progression, PRODH/POX is under the control of various tumor-associated factors, such as tumor suppressor p53, inflammatory factor peroxisome proliferator-activated receptor gamma (PPAR?), onco-miRNA miR-23b*, and oncogenic transcription factor c-MYC. Recent studies revealed the two-sided features of PRODH/POX-mediated regulation. Under metabolic stress such as oxygen and glucose deprivation, PRODH/POX can be induced to serve as a tumor survival factor through ATP production or ROS-induced autophagy. The paradoxical roles of PRODH/POX can be understood considering the temporal and spatial context of the tumor. Further studies will provide additional insights into this protein and on its metabolic effects in tumors, which may lead to new therapeutic strategies.(C) 2012 International Union of Biochemistry and Molecular Biology, Inc.
C1 [Liu, Wei; Phang, James M.] NIH, Metab & Canc Susceptibil Sect, Basic Res Lab, Ctr Canc Res,Frederick Natl Lab Canc Res, Frederick, MD USA.
RP Phang, JM (corresponding author), Frederick Natl Lab, 1050 Boyles St,Bldg 538,Rm 144, Frederick, MD 21702 USA.
EM phangj@mail.nih.gov
RI liu, wei/E-7340-2012
FU Intramural Research Program of the NIH, National Cancer Institute,
   Center for Cancer ResearchUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI); National Cancer Institute, NIHUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [HHSN27612080001]; NATIONAL CANCER
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [ZIABC010744, ZIABC010743] Funding Source: NIH RePORTER
FX The work was supported by the Intramural Research Program of the NIH,
   National Cancer Institute, Center for Cancer Research. This project also
   has been funded in part with Federal funds from the National Cancer
   Institute, NIH, under contract no. HHSN27612080001. The content of this
   review does not necessarily reflect the views or policies of the
   Department of Health and Human Services, nor does mention of trade
   names, commercial products, or organizations imply endorsement by the U.
   S. government. The authors thank Dr. Ziqiang Zhu for his reading of the
   manuscript.
CR ADAMS E, 1980, ANNU REV BIOCHEM, V49, P1005, DOI 10.1146/annurev.bi.49.070180.005041
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bender HU, 2005, AM J HUM GENET, V76, P409, DOI 10.1086/428142
   Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278
   Cao Y, 2007, CELL RES, V17, P839, DOI 10.1038/cr.2007.78
   Catchpole G, 2011, J CELL MOL MED, V15, P109, DOI 10.1111/j.1582-4934.2009.00939.x
   Delimaris L, 2007, CLIN BIOCHEM, V40, P1129, DOI 10.1016/j.clinbiochem.2007.06.007
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   Donald SP, 2001, CANCER RES, V61, P1810
   GORDON G, 1995, ARCH BIOCHEM BIOPHYS, V318, P25, DOI 10.1006/abbi.1995.1199
   Govindarajan R, 2007, J CLIN ONCOL, V25, P1476, DOI 10.1200/JCO.2006.07.2777
   Hirayama A, 2009, CANCER RES, V69, P4918, DOI 10.1158/0008-5472.CAN-08-4806
   Kakkad SM, 2010, NEOPLASIA, V12, P608, DOI 10.1593/neo.10344
   Kim KY, 2007, MOL PHARMACOL, V72, P674, DOI 10.1124/mol.107.035584
   Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200
   Liu W, 2010, ONCOGENE, V29, P4914, DOI 10.1038/onc.2010.237
   Liu W., CANC RES, V72, P3677
   Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109
   Liu Y, 2008, ONCOGENE, V27, P6729, DOI 10.1038/onc.2008.322
   Liu Y, 2006, ONCOGENE, V25, P5640, DOI 10.1038/sj.onc.1209564
   Liu YM, 2005, CARCINOGENESIS, V26, P1335, DOI 10.1093/carcin/bgi083
   Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223
   Lu ML, 2005, J BIOL CHEM, V280, P6742, DOI 10.1074/jbc.M411519200
   Maxwell SA, 2003, J BIOL CHEM, V278, P9784, DOI 10.1074/jbc.M210012200
   Maxwell SA, 2008, BIOCHEM BIOPH RES CO, V369, P308, DOI 10.1016/j.bbrc.2008.01.171
   Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3
   Pandhare J, 2006, J BIOL CHEM, V281, P2044, DOI 10.1074/jbc.M507867200
   Pandhare J, 2009, J CELL BIOCHEM, V107, P759, DOI 10.1002/jcb.22174
   Peng Z, 1996, MOL GEN GENET, V253, P334, DOI 10.1007/s004380050329
   Phang JM, 2008, AMINO ACIDS, V35, P681, DOI 10.1007/s00726-008-0063-4
   Phang JM, 2012, FRONT BIOSCI-LANDMRK, V17, P1835, DOI 10.2741/4022
   Phang JM, 2010, ANNU REV NUTR, V30, P441, DOI 10.1146/annurev.nutr.012809.104638
   Phang JM, 2008, PPAR RES, V2008, DOI 10.1155/2008/542694
   Phang JM, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00060
   PHANG JM, 1982, J CELL PHYSIOL, V110, P255, DOI 10.1002/jcp.1041100306
   PHANG JM, 1980, BIOCHEM BIOPH RES CO, V93, P462, DOI 10.1016/0006-291X(80)91100-6
   PHANG JM, 1985, CURR TOP CELL REGUL, V25, P91
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889
   Rivera A, 2005, J BIOL CHEM, V280, P29346, DOI 10.1074/jbc.M504852200
   Robbins GT, 2012, FRONT BIOSCI-LANDMRK, V17, P1816, DOI 10.2741/4021
   SCHAFER IA, 1962, NEW ENGL J MED, V267, P51, DOI 10.1056/NEJM196207122670201
   Scriver C.R., 2001, METABOLIC MOL BASIS, P1821
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Suzuki K, 2004, CANCER EPIDEM BIOMAR, V13, P1781
   Talbert DR, 2008, BREAST CANCER RES TR, V108, P23, DOI 10.1007/s10549-007-9575-y
   Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5
   Verma A, 2006, CURR OPIN CLIN NUTR, V9, P366, DOI 10.1097/01.mco.0000232895.28674.79
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wang J, 2011, BIOMED ENVIRON SCI, V24, P391, DOI 10.3967/0895-3988.2011.04.010
   Willis A, 2008, AMINO ACIDS, V35, P673, DOI 10.1007/s00726-008-0111-0
   Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g
   XU HJ, 1994, JNCI-J NATL CANCER I, V86, P695, DOI 10.1093/jnci/86.9.695
   YEH GC, 1984, J BIOL CHEM, V259, P5454
   Zabirnyk O, 2010, CARCINOGENESIS, V31, P446, DOI 10.1093/carcin/bgp299
   Zarse K, 2012, CELL METAB, V15, P451, DOI 10.1016/j.cmet.2012.02.013
NR 56
TC 50
Z9 51
U1 1
U2 41
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0951-6433
EI 1872-8081
J9 BIOFACTORS
JI Biofactors
PD NOV-DEC
PY 2012
VL 38
IS 6
BP 398
EP 406
DI 10.1002/biof.1036
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 056YN
UT WOS:000312528300002
PM 22886911
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Wang, C
   Luo, J
   Chen, ZH
   Ye, ML
   Hong, YH
   Liu, JL
   Nie, JY
   Zhao, Q
   Chang, Y
AF Wang, Chun
   Luo, Jie
   Chen, Zhihang
   Ye, Mingliang
   Hong, Yinghui
   Liu, Jialiang
   Nie, Jiayan
   Zhao, Qiu
   Chang, Ying
TI MiR-375 Impairs the Invasive Capabilities of Hepatoma Cells by Targeting
   HIF1 alpha Under Hypoxia
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Article
DE HIF1 alpha; MiR-375; Hypoxia; Hepatocellular carcinoma
ID HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; LIVER-DISEASE; EXPRESSION;
   METASTASIS; LENVATINIB; MICRORNAS; AUTOPHAGY
AB Background and Aims Hypoxia represents one of the most pervasive microenvironmental stresses in HCC due to the overwhelming growth and inadequate blood supply. HIF1 alpha as an important transcription factor participates in the regulation of various biological behaviors of HCC cells under hypoxia. Our previous study indicated that miR-375 is a hypoxia-associated miRNA. However, the interaction between miR-375 and HIF1 alpha remains unclear. Methods Bioinformatic analysis was performed for miRNA screening. qRT-PCR, western blotting, and immunohistochemical staining were used to detect the expression of related molecules. Bioinformatic analysis and dual luciferase assay were used to predict and further confirm the target association. Transwell chamber assay and flow cytometry were, respectively, used to detect migration, invasion and apoptosis of hepatoma cells. Results MiR-375 presented an obviously differential expression in human HCCs versus background livers (BLs) and HCCs versus normal liver tissues (NLTs). In rat models, miR-375 was gradually declined during hepatocarcinogenesis. HIF1 alpha was remarkably upregulated at protein level rather than at mRNA level in human HCCs versus BLs, HCCs versus NLTs, BLs versus NLTs, and in rat fibrotic livers versus NLTs. HIF1 alpha was determined to be a target of miR-375. MiR-375 inhibitor induced the migration and invasive capabilities and attenuated apoptosis of hepatoma cells under hypoxia. Depriving HIF1 alpha by siRNA could partially reverse the function of miR-375 inhibitor under hypoxia. Conclusions MiR-375 impairs the invasive capabilities of HCC cells by targeting HIF1 alpha under hypoxia.
C1 [Wang, Chun; Luo, Jie; Ye, Mingliang; Hong, Yinghui; Liu, Jialiang; Nie, Jiayan; Zhao, Qiu; Chang, Ying] Wuhan Univ, Dept Gastroenterol, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Wang, Chun; Luo, Jie; Ye, Mingliang; Hong, Yinghui; Liu, Jialiang; Nie, Jiayan; Zhao, Qiu; Chang, Ying] Hubei Clin Ctr, Wuhan, Peoples R China.
   [Wang, Chun; Luo, Jie; Ye, Mingliang; Hong, Yinghui; Liu, Jialiang; Nie, Jiayan; Zhao, Qiu; Chang, Ying] Key Lab Intestinal & Colorectal Dis, Wuhan, Peoples R China.
   [Chen, Zhihang] Guangxi Med Univ, Affiliated Hosp 1, Dept Coloproctol Surg, Nanning, Peoples R China.
RP Chang, Y (corresponding author), Wuhan Univ, Dept Gastroenterol, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Chang, Y (corresponding author), Hubei Clin Ctr, Wuhan, Peoples R China.; Chang, Y (corresponding author), Key Lab Intestinal & Colorectal Dis, Wuhan, Peoples R China.
EM changying@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670554, 81302112, 81870390]; Natural
   Science Fund for Distinguished Young Scholar of Hubei Province
   [2017CFA068]; National Key R&D Program of China [2017YFC0112302];
   Ministry of Public Health in Hubei Province of China [XF2012-8]
FX This work was supported by research grants from the National Natural
   Science Foundation of China (Nos. 81670554, 81302112, 81870390); the
   Natural Science Fund for Distinguished Young Scholar of Hubei Province
   (No. 2017CFA068); the National Key R&D Program of China (No.
   2017YFC0112302); and the Ministry of Public Health in Hubei Province of
   China (No. XF2012-8).
CR Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Campbell EJ, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5503-x
   Cao D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-432
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Cui FY, 2016, ONCOL REP, V36, P487, DOI 10.3892/or.2016.4834
   Cummins EP, 2005, PFLUG ARCH EUR J PHY, V450, P363, DOI 10.1007/s00424-005-1413-7
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Guo J, 2018, ASIAN AUSTRAL J ANIM, V31, P1103, DOI 10.5713/ajas.17.0338
   He XX, 2012, ONCOGENE, V31, P3357, DOI 10.1038/onc.2011.500
   Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266
   KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511
   Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178
   Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
   Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036
   Liu XW, 2014, AUTOPHAGY, V10, P111, DOI 10.4161/auto.26838
   Lu XX, 2013, WORLD J GASTROENTERO, V19, P1912, DOI 10.3748/wjg.v19.i12.1912
   Osako Y, 2016, INT J ONCOL, V49, P2255, DOI 10.3892/ijo.2016.3745
   Pirola CJ, 2015, GUT, V64, P800, DOI 10.1136/gutjnl-2014-306996
   Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405
   Rapino F, 2018, NATURE, V558, P605, DOI 10.1038/s41586-018-0243-7
   Reig M, 2018, LANCET, V391, P1123, DOI 10.1016/S0140-6736(18)30208-3
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Tuomisto A, 2016, VIRCHOWS ARCH, V469, P395, DOI 10.1007/s00428-016-1988-8
   Wang WW, 2019, NANOSCALE, V11, P2211, DOI 10.1039/c8nr06452k
   Wen Y, 2015, INT J CANCER, V137, P1679, DOI 10.1002/ijc.29544
   Wilson GK, 2014, J HEPATOL, V61, P1397, DOI 10.1016/j.jhep.2014.08.025
   Zhao JF, 2018, MOL THER-NUCL ACIDS, V11, P538, DOI 10.1016/j.omtn.2018.04.007
NR 30
TC 6
Z9 6
U1 3
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
EI 1573-2568
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD FEB
PY 2021
VL 66
IS 2
BP 493
EP 502
DI 10.1007/s10620-020-06202-9
EA MAR 2020
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA QD1HR
UT WOS:000521791800001
PM 32215815
DA 2022-04-25
ER

PT J
AU Chen, HT
   Li, RR
   Zhang, F
   Yao, QH
   Guo, Y
AF Chen, Haitao
   Li, Rongrong
   Zhang, Fan
   Yao, Qinghua
   Guo, Yong
TI A Scientometric Visualization Analysis for Natural Products on Cancer
   Research from 2008 to 2020
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE natural product; cancer; bibliometric; citation analysis; molecular
   docking; gut microbiota; immune checkpoint
ID CHEMOTHERAPY; MODULATION; INDUCTION; APOPTOSIS; AUTOPHAGY; CELLS; ACID
AB Background: An increasing number of studies have shown that natural products have anti-tumor effects, and it has become a hotspot in cancer research. However, few bibliometric analyses have been examined in this field systematically. The current study aimed to explore the status and provide the developing trends in the natural products on cancer research. Methods: Publications on natural products in cancer research were extracted from the Web of Science core collection database. CiteSpace (5.6.R3) software and GraphPad prism 6 were used to analyze and plot the references. Results: On February 1, 2021, 34,611 records of natural products in cancer research published from 2008 to 2020 were collected. The United States was the driving force, with a strong academic reputation in this area. The top-contributing institution was the Chinese Academy of Sciences. Most publications were published in Molecules. Efferth Thomas was the most prolific author, while Newman DJ was the most cited and frequently co-cited author. Flavonoid, curcumin, and polyphenol were the most widely studied natural products. Oleanolic acid and rosmarinic acid have gradually become research hotspots recently. Breast cancer, prostate cancer, and colorectal cancer were the most common types of cancer in this field. "Natural killer cell" was the leading research hotspot. The keywords of "leaf extract," "molecular docking" and "gold nanoparticle" appeared most recently as research frontiers. Conclusion: Our results provided a general overview of the major research directions of natural products research in cancer. The mechanisms of natural products, especially those related to molecular docking, gold nanoparticle, gut microbiota, and immune checkpoints may soon become hotspots and should be closely monitored.
C1 [Chen, Haitao; Zhang, Fan] Zhejiang Chinese Med Univ, Clin Coll 1, Hangzhou, Peoples R China.
   [Li, Rongrong] Zhejiang Chinese Med Univ, Clin Coll 3, Hangzhou, Peoples R China.
   [Yao, Qinghua] Univ Chinese Acad Sci, Dept Integrated Tradit Chinese & Western Med, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China.
   [Guo, Yong] Zhejiang Chinese Med Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China.
RP Yao, QH (corresponding author), Univ Chinese Acad Sci, Dept Integrated Tradit Chinese & Western Med, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China.; Guo, Y (corresponding author), Zhejiang Chinese Med Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou, Peoples R China.
EM yaoqh@zjcc.org.cn; guoyong1047@zcmu.edu.cn
CR Al-Ani LA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216725
   Anwar A, 2018, MOL BIOL REP, V45, P1339, DOI 10.1007/s11033-018-4294-5
   Bian Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21020684
   Blagden SP, 2020, LANCET ONCOL, V21, P969, DOI 10.1016/S1470-2045(20)30218-7
   Boss A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080513
   Brandt CS, 2009, J EXP MED, V206, P1495, DOI 10.1084/jem.20090681
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen HT, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.588079
   Chen LX, 2016, INT IMMUNOPHARMACOL, V37, P65, DOI 10.1016/j.intimp.2016.02.005
   Chen YX, 2020, LANCET GASTROENTEROL, V5, P267, DOI 10.1016/S2468-1253(19)30409-1
   Cheung MK, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00744
   Cueva C, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030625
   Deng R, 2020, MINI-REV MED CHEM, V20, P161, DOI 10.2174/1389557519666191011154923
   Dobrzynska M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10091268
   Farhood B, 2019, J CELL PHYSIOL, V234, P5728, DOI 10.1002/jcp.27442
   Farkkila N., 2019, ACTA ONCOL, V58, P1062, DOI [10.1080/0284186X.2019.1592218, DOI 10.1080/0284186X.2019.1592218]
   Feng XL, 2020, EUR J CANCER PREV, V29, P493, DOI 10.1097/CEJ.0000000000000561
   Hallajzadeh J, 2020, MED ONCOL, V37, DOI 10.1007/s12032-020-01367-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hayakawa T, 2020, CANCER SCI, V111, P4326, DOI 10.1111/cas.14675
   Kim SY, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090938
   Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581
   Lin Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00764
   Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0
   Meng X, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101457
   Merigo JM, 2019, TOURISM GEOGR, V21, P881, DOI 10.1080/14616688.2019.1666913
   Moradi M, 2020, N-S ARCH PHARMACOL, V393, P2145, DOI 10.1007/s00210-020-01917-y
   Mulet-Forteza C, 2019, INT J CONTEMP HOSP M, V31, P4574, DOI 10.1108/IJCHM-10-2018-0828
   Najmuddin SUFS, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1290-y
   Narozna M, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14010032
   Naveed S, 2019, INDIAN J DERMATOL, V64, P122, DOI 10.4103/ijd.IJD_129_17
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Patel SA, 2018, IMMUNITY, V48, P417, DOI 10.1016/j.immuni.2018.03.007
   Perng DS, 2016, J DRUG TARGET, V24, P624, DOI 10.3109/1061186X.2015.1132221
   Qin JJ, 2017, CHIN J NAT MEDICINES, V15, P401, DOI 10.1016/S1875-5364(17)30062-6
   Rodriguez-Garcia C, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8050137
   Rodriguez-Luna A, 2019, MAR DRUGS, V17, DOI 10.3390/md17080451
   Rosado-Perez J, 2018, CURR PHARM DESIGN, V24, P4807, DOI 10.2174/1381612824666190114164758
   Schnipper LE, 2015, J CLIN ONCOL, V33, P2563, DOI 10.1200/JCO.2015.61.6706
   Shafabakhsh R., 2019, PHARMACOL RES, V147, P104353, DOI [10.1016/j.phrs.2019.104353, DOI 10.1016/j.phrs.2019.104353]
   Shahwar D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20082010
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sinha D, 2016, SEMIN CANCER BIOL, V40-41, P209, DOI 10.1016/j.semcancer.2015.11.001
   Song YL, 2017, CELL BIOL INT, V41, P1367, DOI 10.1002/cbin.10868
   Stout NL, 2018, JNCI-J NATL CANCER I, V110, P815, DOI 10.1093/jnci/djy108
   Tan HD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01504
   Troselj KG, 2020, MOLECULES, V25, DOI 10.3390/molecules25225240
   Wang YS, 2018, PROTEIN CELL, V9, P568, DOI 10.1007/s13238-018-0513-z
   Xu XL, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.010414
   Yamamoto S, 2017, BREAST CANCER-TOKYO, V24, P783, DOI 10.1007/s12282-017-0779-7
   Yang MM, 2021, J CANCER RES CLIN, V147, P1101, DOI 10.1007/s00432-021-03510-z
   Yeung Andy Wai Kan, 2018, Critical Reviews in Oncogenesis, V23, P347, DOI 10.1615/CritRevOncog.2018027566
   Zeng Y, 2019, CURR MED CHEM, V26, P1849, DOI 10.2174/0929867324666170523123655
   Zhang Y, 2018, J BUON, V23, P763
   Zhang YY, 2019, ONCOTARGETS THER, V12, P5457, DOI 10.2147/OTT.S200161
NR 56
TC 0
Z9 0
U1 9
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD AUG 6
PY 2021
VL 12
DI 10.3389/fphar.2021.650141
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UM6DE
UT WOS:000693420100001
PM 34421584
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Chekhonin, VP
   Shein, SA
   Korchagina, AA
   Gurina, OI
AF Chekhonin, Vladimir P.
   Shein, Sergey A.
   Korchagina, Anna A.
   Gurina, Olga I.
TI VEGF in Tumor Progression and Targeted Therapy
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Antiangiogenic therapy; bevacizumab; cell invasion; glioma; target
   therapy; tumor resistance; VEGF
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; BEVACIZUMAB
   PLUS IRINOTECAN; HIGH-GRADE GLIOMAS; CANCER STEM-CELLS; PHASE-II TRIAL;
   BREAST-CANCER; RECURRENT GLIOBLASTOMA; IN-VIVO; MONOCLONAL-ANTIBODIES
AB Progression of solid tumors depends on vascularization and angiogenesis in a malignant tissue. Among a whole range of proangiogenic factors, a vascular endothelial growth factor A (VEGF-A) plays a key role. Blockade of VEGF may lead to regression of vascular network and inhibition of a tumor growth. In the present time, bevacizumab has been introduced into wide clinical practice in therapy of breast cancer, colorectal cancer and recurrent high-grade gliomas (HGGs). Coadministration of antiangiogenic therapy with irinotecan may increase probability of the response to the treatment and prolong progression-free survival rate (PFS). Moreover, bevacizumab is well tolerated and significantly improves patient's quality of life. However, in the case of brain tumors, the efficiency of such an approach is controversial. The antiangiogenic therapy can slightly delay tumor growth and does not lead to complete recovery. In addition, it contributes to enhanced tumor cell invasion into the normal brain. The mechanisms of resistance include activation of alternative proangiogenic signaling pathways, of an invasive population of tumor cells, metabolic change toward glycolysis and recruitment of myeloid bone marrow-derived cells to tumors. Obviously, that anti-VEGF therapy as monotherapy was not effective against HGGs. To enhance the antitumor treatment efficacy, it is necessary to develop a multi-target strategy to inhibit critical processes in malignancy progression such as angiogenesis, invasion, autophagy, metastatic spread, recruitment of bone marrow-derived endothelial cells and tumor stem-like cells. In addition, anti-VEGF antibodies have shown a promising result as a tumor-targeting vector for delivery therapeutic and diagnostic drugs in brain tumors.
C1 [Chekhonin, Vladimir P.; Shein, Sergey A.; Korchagina, Anna A.] NI Pirogov Russian Natl Res Med Univ, Dept Med Nanobiotechnol, Moscow 117997, Russia.
   [Chekhonin, Vladimir P.; Shein, Sergey A.; Korchagina, Anna A.; Gurina, Olga I.] Serbsky Natl Res Ctr Social & Forens Psychiat, Dept Fundamental & Appl Neurobiol, Moscow 119991, Russia.
RP Shein, SA (corresponding author), Kropotkinsky Per 23, Moscow, Russia.
EM sheinsergey@gmail.com
RI Chekhonin, Vladimir VP/T-4511-2018; Gurina, Olga OI/H-2401-2013
OI Gurina, Olga OI/0000-0001-6942-5531; Chekhonin, Vladimir
   P./0000-0003-4386-7897; Anna, Korchagina/0000-0003-3633-2392
CR Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437
   Ali MM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008727
   Arico S, 2001, J BIOL CHEM, V276, P35243, DOI 10.1074/jbc.C100319200
   Asahara T, 1999, EMBO J, V18, P3964, DOI 10.1093/emboj/18.14.3964
   Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107
   Baluk P, 2005, CURR OPIN GENET DEV, V15, P102, DOI 10.1016/j.gde.2004.12.005
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Benbrook D. M., 2012, Experimental Oncology, V34, P286
   Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bertolini F, 2001, ANN ONCOL, V12, P987, DOI 10.1023/A:1011141009812
   Bikfalvi A, 2011, BIOCHEM SOC T, V39, P1560, DOI 10.1042/BST20110710
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Borgstrom P, 1999, ANTICANCER RES, V19, P4203
   Brasch R, 1997, JMRI-J MAGN RESON IM, V7, P68, DOI 10.1002/jmri.1880070110
   Brown JM, 2002, CANCER BIOL THER, V1, P453, DOI 10.4161/cbt.1.5.157
   BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1
   BROWN LF, 1997, EXS, V79, P233
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Caraglia M, 2012, CURR CANCER DRUG TAR, V12, P186, DOI 10.2174/156800912799277421
   Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Charalambous C, 2005, CANCER RES, V65, P10347, DOI 10.1158/0008-5472.CAN-05-0949
   Chaux P, 1996, LAB INVEST, V74, P975
   Chekhonin VP, 2012, NANOMED-NANOTECHNOL, V8, P63, DOI 10.1016/j.nano.2011.05.011
   Chi AS, 2009, NEUROTHERAPEUTICS, V6, P513, DOI 10.1016/j.nurt.2009.04.010
   Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055
   Cina C, 2009, J NEUROSCI, V29, P2009, DOI 10.1523/JNEUROSCI.5025-08.2009
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Cuervo AM, 2004, TRENDS CELL BIOL, V14, P70, DOI 10.1016/j.tcb.2003.12.002
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082
   Darland DC, 2003, DEV BIOL, V264, P275, DOI 10.1016/j.ydbio.2003.08.015
   di Tomaso E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005123
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Duda DG, 2011, CLIN CANCER RES, V17, P2074, DOI 10.1158/1078-0432.CCR-10-2636
   Duggan ST, 2011, DRUGS, V71, P2531, DOI 10.2165/11207510-000000000-00000
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287
   Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje
   Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829
   Fan F, 2011, BRIT J CANCER, V104, P1270, DOI 10.1038/bjc.2011.81
   Farhat FS, 2011, CLIN BREAST CANCER, V11, P384, DOI 10.1016/j.clbc.2011.08.005
   Feng B, 2010, BIOMATERIALS, V31, P4139, DOI 10.1016/j.biomaterials.2010.01.086
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Fischer I, 2008, NEURO-ONCOLOGY, V10, P700, DOI 10.1215/15228517-2008-042
   Folkins C, 2007, CANCER RES, V67, P3560, DOI 10.1158/0008-5472.CAN-06-4238
   Folkins C, 2009, CANCER RES, V69, P7243, DOI 10.1158/0008-5472.CAN-09-0167
   Folkman J, 2006, ANNU REV MED, V57, P1, DOI 10.1146/annurev.med.57.121304.131306
   Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539
   Gabrilovich D, 1998, BLOOD, V92, P4150, DOI 10.1182/blood.V92.11.4150.423k45_4150_4166
   Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096
   Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364
   Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Gomez-Manzano C, 2008, NEURO-ONCOLOGY, V10, P940, DOI 10.1215/15228517-2008-061
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Greenberg DA, 2005, NATURE, V438, P954, DOI 10.1038/nature04481
   Guiu S, 2008, REV NEUROL-FRANCE, V164, P588, DOI 10.1016/j.neurol.2008.04.003
   Hadjipanayis CG, 2009, TRENDS MOL MED, V15, P519, DOI 10.1016/j.molmed.2009.09.003
   Hamerlik P, 2012, J EXP MED, V209, P507, DOI 10.1084/jem.20111424
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200
   Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Hendriksen EM, 2009, MICROVASC RES, V77, P96, DOI 10.1016/j.mvr.2008.11.002
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P302, DOI 10.1073/pnas.1016917108
   Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Hu YL, 2012, CANCER RES, V72, P4294, DOI 10.1158/0008-5472.CAN-12-1076
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ignatova TN, 2002, GLIA, V39, P193, DOI 10.1002/glia.10094
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Iruela-Arispe ML, 2004, INT J BIOCHEM CELL B, V36, P1070, DOI 10.1016/j.biocel.2004.01.025
   Ito H, 2005, INT J ONCOL, V26, P1401
   Iwamoto FM, 2009, NEUROLOGY, V73, P1200, DOI 10.1212/WNL.0b013e3181bc0184
   Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175
   Jain RK, 2001, NAT MED, V7, P987, DOI 10.1038/nm0901-987
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jakobsen JN, 2011, EXPERT OPIN PHARMACO, V12, P825, DOI 10.1517/14656566.2011.566558
   Kabanov AV, 2009, ANGEW CHEM INT EDIT, V48, P5418, DOI 10.1002/anie.200900441
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   Kanzawa T, 2004, CELL DEATH DIFFER, V11, P448, DOI 10.1038/sj.cdd.4401359
   Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kirkegaard K, 2004, NAT REV MICROBIOL, V2, P301, DOI 10.1038/nrmicro865
   KISEN GO, 1993, CARCINOGENESIS, V14, P2501, DOI 10.1093/carcin/14.12.2501
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Komata T, 2004, J NEURO-ONCOL, V68, P101, DOI 10.1023/B:NEON.0000027739.33842.6c
   Komatsu Y, 2012, ACTA ONCOL, V51, P867, DOI 10.3109/0284186X.2012.682629
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Koren E, 2012, J CONTROL RELEASE, V160, P264, DOI 10.1016/j.jconrel.2011.12.002
   Kuczynski EA, 2011, ONCOLOGY-BASEL, V81, P126, DOI 10.1159/000332849
   Kuesters GM, 2010, NANOMEDICINE-UK, V5, P181, DOI 10.2217/NNM.09.105
   Kullberg M., 2012, MOL PHARM
   Kunkel P, 2001, CANCER RES, V61, P6624
   Lakka Sajani S, 2008, Expert Rev Neurother, V8, P1457, DOI 10.1586/14737175.8.10.1457
   Lamalice L, 2006, J BIOL CHEM, V281, P34009, DOI 10.1074/jbc.M603928200
   Lambrechts D, 2004, TRENDS MOL MED, V10, P275, DOI 10.1016/j.molmed.2004.04.004
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Lamszus K, 2003, ACT NEUR S, V88, P169
   Lee CG, 2000, CANCER RES, V60, P5565
   Lee H, 2007, J CONTROL RELEASE, V119, P245, DOI 10.1016/j.jconrel.2007.02.011
   Lee JC, 2000, EUR J CANCER, V36, P748, DOI 10.1016/S0959-8049(00)00003-4
   Lee SLC, 2009, P NATL ACAD SCI USA, V106, P19485, DOI 10.1073/pnas.0909228106
   Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200
   Lefranc F, 2005, J CLIN ONCOL, V23, P2411, DOI 10.1200/JCO.2005.03.089
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143
   Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lingappa M, 2010, CANCER RES, V70, P6815, DOI 10.1158/0008-5472.CAN-09-4548
   List AF, 2001, ONCOLOGIST, V6, P24, DOI 10.1634/theoncologist.6-suppl_5-24
   Liu WB, 2011, INT J ONCOL, V39, P1213, DOI 10.3892/ijo.2011.1138
   Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575
   Ma Y, 2012, SEMIN CANCER BIOL, V22, P298, DOI 10.1016/j.semcancer.2012.02.010
   Mackey JR, 2012, CANCER TREAT REV, V38, P673, DOI 10.1016/j.ctrv.2011.12.002
   Mamot C, 2012, J DRUG TARGET, V20, P422, DOI 10.3109/1061186X.2012.680960
   MANDRIOTA SJ, 1995, J BIOL CHEM, V270, P9709, DOI 10.1074/jbc.270.17.9709
   Martin M, 2012, ONCOLOGIST, V17, P469, DOI 10.1634/theoncologist.2011-0344
   Marx J, 2002, SCIENCE, V295, P1444
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200
   Mechtcheriakova D, 2001, FASEB J, V15, P230, DOI 10.1096/fj.00-0247com
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   Miletic H, 2009, EXPERT OPIN THER TAR, V13, P455, DOI [10.1517/14728220902806444 , 10.1517/14728220902806444]
   MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   Mok H, 2006, BIOCONJUGATE CHEM, V17, P1369, DOI 10.1021/bc060119i
   Moller S, 2012, ACTA ONCOL, V51, P797, DOI 10.3109/0284186X.2012.681063
   Nagpal Seema, 2011, Chemother Res Pract, V2011, P602812, DOI 10.1155/2011/602812
   Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z
   Narayana A, 2012, J NEUROSURG, V116, P341, DOI 10.3171/2011.9.JNS11656
   Narayana A, 2009, J NEUROSURG, V110, P173, DOI 10.3171/2008.4.17492
   Navajas A, 2012, CLIN TRANSL ONCOL, V14, P280, DOI 10.1007/s12094-012-0796-0
   Nayak TK, 2011, INT J CANCER, V128, P920, DOI 10.1002/ijc.25409
   Nghiemphu PL, 2009, NEUROLOGY, V72, P1217, DOI 10.1212/01.wnl.0000345668.03039.90
   Nishikawa K, 2012, J CONTROL RELEASE, V160, P274, DOI 10.1016/j.jconrel.2011.10.010
   Norden AD, 2008, NEUROLOGY, V70, P779, DOI 10.1212/01.wnl.0000304121.57857.38
   Norden AD, 2009, NAT REV NEUROL, V5, P610, DOI 10.1038/nrneurol.2009.159
   Nukolova NV, 2011, BIOMATERIALS, V32, P5417, DOI 10.1016/j.biomaterials.2011.04.006
   Nukolova NV, 2011, REACT FUNCT POLYM, V71, P315, DOI 10.1016/j.reactfunctpolym.2010.10.011
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Palucka K, 2012, NAT REV CANCER, V12, P265, DOI 10.1038/nrc3258
   Pegram MD, 2002, SEMIN ONCOL, V29, P29, DOI 10.1053/sonc.2002.34053
   PEKALA P, 1990, J BIOL CHEM, V265, P18051
   PEPPER MS, 1991, BIOCHEM BIOPH RES CO, V181, P902, DOI 10.1016/0006-291X(91)91276-I
   PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pham CD, 1998, CANCER INVEST, V16, P225, DOI 10.3109/07357909809039771
   Ping YF, 2011, J PATHOL, V224, P344, DOI 10.1002/path.2908
   Plate KH, 1999, J NEUROPATH EXP NEUR, V58, P313, DOI 10.1097/00005072-199904000-00001
   Poon RTP, 2001, J CLIN ONCOL, V19, P1207, DOI 10.1200/JCO.2001.19.4.1207
   Pope WB, 2006, NEUROLOGY, V66, P1258, DOI 10.1212/01.wnl.0000208958.29600.87
   Poulsen HS, 2009, ACTA ONCOL, V48, P52, DOI 10.1080/02841860802537924
   Pupa SM, 2002, J CELL PHYSIOL, V192, P259, DOI 10.1002/jcp.10142
   Rak J, 2000, J INVEST DERM SYMP P, V5, P24, DOI 10.1046/j.1087-0024.2000.00012.x
   Rapisarda A, 2009, MOL CANCER THER, V8, P1867, DOI 10.1158/1535-7163.MCT-09-0274
   Reiss Y, 2005, BRAIN PATHOL, V15, P311
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Rich JN, 2007, CANCER RES, V67, P8980, DOI 10.1158/0008-5472.CAN-07-0895
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Robey RB, 2009, SEMIN CANCER BIOL, V19, P25, DOI 10.1016/j.semcancer.2008.11.010
   Robinson CJ, 2001, J CELL SCI, V114, P853
   Rosen Lee S, 2002, Cancer Control, V9, P36
   Roy H, 2006, FEBS LETT, V580, P2879, DOI 10.1016/j.febslet.2006.03.087
   Rubin JB, 2003, P NATL ACAD SCI USA, V100, P13513, DOI 10.1073/pnas.2235846100
   Ryu JH, 2012, BIOMACROMOLECULES, V13, P1515, DOI 10.1021/bm300201x
   Saito H, 1998, BRIT J CANCER, V78, P1573, DOI 10.1038/bjc.1998.725
   Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103
   Salhia B, 2000, BRAIN RES, V883, P87, DOI 10.1016/S0006-8993(00)02825-0
   SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389
   SAMOTO K, 1995, CANCER RES, V55, P1189
   Scheer MGW, 2008, EUR J CANCER, V44, P1835, DOI 10.1016/j.ejca.2008.05.026
   Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3
   Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.0.CO;2-L
   Sciume G, 2010, J NEUROIMMUNOL, V224, P8, DOI 10.1016/j.jneuroim.2010.05.019
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shao M, 2012, J LIPOSOME RES, V22, P168, DOI 10.3109/08982104.2012.668552
   Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979
   Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25
   Shibuya Masaubmi, 2006, Angiogenesis, V9, P225, DOI 10.1007/s10456-006-9055-8
   Shih AH, 2006, CANCER LETT, V232, P139, DOI 10.1016/j.canlet.2005.02.002
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SHWEIKI D, 1993, J CLIN INVEST, V91, P2235, DOI 10.1172/JCI116450
   Simard P, 2010, MOL PHARMACEUT, V7, P1098, DOI 10.1021/mp900261m
   Singh SK, 2003, CANCER RES, V63, P5821
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289
   STEFANIK DF, 1991, CANCER RES, V51, P5760
   Stollman TH, 2009, CANCER BIOTHER RADIO, V24, P195, DOI 10.1089/cbr.2008.0574
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100
   Sun JZ, 2005, ONCOGENE, V24, P4701, DOI 10.1038/sj.onc.1208391
   Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527
   Takahashi T, 2001, EMBO J, V20, P2768, DOI 10.1093/emboj/20.11.2768
   Takeuchi H, 2005, CANCER RES, V65, P3336, DOI 10.1158/0008-5472.CAN-04-3640
   Taylor TE, 2012, CURR CANCER DRUG TAR, V12, P197
   Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998
   Toi M, 2001, LANCET ONCOL, V2, P667, DOI 10.1016/S1470-2045(01)00556-3
   Tokunaga T, 1998, BRIT J CANCER, V77, P998, DOI 10.1038/bjc.1998.164
   Tong RT, 2004, CANCER RES, V64, P3731, DOI 10.1158/0008-5472.CAN-04-0074
   Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
   TSAI JC, 1995, J NEUROSURG, V82, P864, DOI 10.3171/jns.1995.82.5.0864
   UNEMORI EN, 1992, J CELL PHYSIOL, V153, P557, DOI 10.1002/jcp.1041530317
   van den Bent MJ, 2006, J CLIN ONCOL, V24, P2715, DOI 10.1200/JCO.2005.04.6078
   Vauleon E, 2012, B CANCER, V99, P121, DOI 10.1684/bdc.2011.1528
   Verreault M, 2012, J CONTROL RELEASE, V158, P34, DOI 10.1016/j.jconrel.2011.09.095
   Verschraegen C. F., 2012, ANN ONCOL
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Vosseler S, 2005, CANCER RES, V65, P1294, DOI 10.1158/0008-5472.CAN-03-3986
   Vredenburgh JJ, 2007, J CLIN ONCOL, V25, P4722, DOI 10.1200/JCO.2007.12.2440
   Vredenburgh JJ, 2007, CLIN CANCER RES, V13, P1253, DOI 10.1158/1078-0432.CCR-06-2309
   Wachsberger PR, 2007, INT J RADIAT ONCOL, V67, P1526, DOI 10.1016/j.ijrobp.2006.11.011
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Wedam SB, 2006, J CLIN ONCOL, V24, P769, DOI 10.1200/JCO.2005.03.4645
   WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101
   Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126
   Wicki A, 2012, CLIN CANCER RES, V18, P454, DOI 10.1158/1078-0432.CCR-11-1102
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825
   Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378
   Yoncheva K, 2011, EXPERT OPIN DRUG DEL, V8, P1041, DOI 10.1517/17425247.2011.585155
   Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327
   Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316
   Yusubalieva GM, 2012, B EXP BIOL MED+, V153, P163, DOI 10.1007/s10517-012-1667-y
   Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375
   Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482
   Zhou QY, 2008, CLIN CANCER RES, V14, P1540, DOI 10.1158/1078-0432.CCR-07-4544
   ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E
   Zuniga RM, 2009, J NEURO-ONCOL, V91, P329, DOI 10.1007/s11060-008-9718-y
NR 255
TC 62
Z9 74
U1 3
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PD MAY
PY 2013
VL 13
IS 4
BP 423
EP 443
DI 10.2174/15680096113139990074
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 144XV
UT WOS:000318976500006
PM 23167597
DA 2022-04-25
ER

PT J
AU Guo, ZZ
   Meng, MJ
   Geng, SN
   Du, ZH
   Zheng, YQ
   Yao, JJ
   Li, ZB
   Han, G
   Lin, HH
   Du, GJ
AF Guo, Zhenzhen
   Meng, Mingjing
   Geng, Shengnan
   Du, Zhenhua
   Zheng, Yaqiu
   Yao, Jingjing
   Li, Zibo
   Han, Guang
   Lin, Haihong
   Du, Gangjun
TI The optimal dose of arsenic trioxide induced opposite efficacy in
   autophagy between K562 cells and their initiating cells to eradicate
   human myelogenous leukemia
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Arsenic trioxide; Chronic myelogenous leukemia (CML); Leukemiainitiating
   cells (LICs); Autophagy; Senescence
ID ACUTE PROMYELOCYTIC LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; DIFFERENTIATION;
   CANCER; DEGRADATION; CONTRIBUTES; INHIBITION; MUTATION; AS2O3; AGENT
AB Ethnopharmacological relevance: Arsenic trioxide (As2O3), a main component of arsenolite which is a common traditional Chinese medicine (TCM) wildly used as a therapeutic agent for more than 2400 years in china, has been accepted as a standard treatment for the patients with acute promyelocytic leukemia (APL) based on the principle in TCM of "using a poison to fight against other poisons or malignancy illnesses". However, it remains unknown that which mechanism is actually responsible for the therapeutic effects against these blood malignancies.
   Aim of the study: The purpose of this study was to explore the actual mechanism that ATO exerts its effects in K562 cells and their initiating cells (K562s).
   Materials and methods: K562s cells were separated and enriched for CD34+/CD38- cells using magnetic microbeads. Cell proliferation was determined by incorporation of BrdU. Cell apoptosis was evaluated by Annexin-V binding and PI uptake. Autophagy was estimated by acridine orange and immunofluorescence staining of LC3-B and p62. MC colonic formation was used to examine cell self-renew. ROS generation inside living cells was measured by DCFH-DA. Cell differentiation was assessed by the benzidine staining. The SA-beta-gal assay was used to detect cell senescence. Protein expression was examined by western blotting and immunohistochemical staining.
   Results: K562s cells were stronger in self-renew and resistance to ATO cytotoxicity and starvation-induced apoptosis than K562 cells. Unexpectedly, we found that ATO at a dose of 0.5 mu M which had no effect on cell proliferation resulted in maximum suppression on self-renew in both cells and maximum starvation-induced apoptosis in K562s cells but minimum starvation-induced apoptosis in K562 cells. Next, we found that ATO no more than 0.5 mu M selectively induced K562s cell differentiation indicated by benzidine staining, gamma-globin and CD235a expression. More importantly, we found that ATO no more than 0.5 mu M led to opposite efficacy in autophagy between K562 and K562s cells, and the opposite autophagy could induced late-phase senescence in both cells. Finally, we used the optimal dose of ATO to eradicate leukemia cells and obtained a satisfied therapeutic outcomes in vivo.
   Conclusions: Our results suggest that the used dose of ATO may determine the fate of cell differentiation senescence or malignant transformation, and the optimal dose of ATO induced opposite efficacy in autophagy between K562 cells and their initiating cells and ultimately leads both cells to late-phase senescence.
C1 [Guo, Zhenzhen; Meng, Mingjing; Geng, Shengnan; Du, Zhenhua; Zheng, Yaqiu; Yao, Jingjing; Li, Zibo; Han, Guang; Lin, Haihong; Du, Gangjun] Henan Univ, Inst Pharm, Coll Pharm, Kaifeng 475004, Henan Province, Peoples R China.
RP Lin, HH; Du, GJ (corresponding author), Henan Univ, Inst Pharm, Coll Pharm, Kaifeng 475004, Henan Province, Peoples R China.
EM 1070417690@qq.com; 2272352627@qq.com; 1017172540@qq.com;
   1256747886@qq.com; 2388756645@qq.com; yaojingjing123456@qq.com;
   963235757@qq.com; hang@henu.edu.cn; linhaihong369@126.com;
   724200@henu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81173094, 81373974]
FX This work was supported by National Natural Science Foundation of China
   (No. 81173094, 81373974).
CR Albano F, 2015, ONCOTARGET, V6, P13269, DOI 10.18632/oncotarget.3773
   Chen GQ, 1997, BLOOD, V89, P3345
   Chiarini F, 2012, ONCOTARGET, V3, P1615
   Coombs CC, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.25
   Gallipoli P, 2014, BLOOD, V124, P1492, DOI 10.1182/blood-2013-12-545640
   Griessinger E, 2014, STEM CELL TRANSL MED, V3, P520, DOI 10.5966/sctm.2013-0166
   Hua HQ, 2011, ASIAN PAC J CANCER P, V12, P61
   Huff J, 2000, TOXICOL SCI, V55, P17, DOI 10.1093/toxsci/55.1.17
   Isakson P, 2010, BLOOD, V116, P2324, DOI 10.1182/blood-2010-01-261040
   Kim SH, 2008, BRIT J PHARMACOL, V155, P814, DOI 10.1038/bjp.2008.319
   Kim SH, 2006, J BIOL CHEM, V281, P13117, DOI 10.1074/jbc.M510944200
   Kobayashi CI, 2014, BLOOD, V123, P2540, DOI 10.1182/blood-2013-07-517847
   Liang YH, 2012, CHINESE MED J-PEKING, V125, P4481, DOI 10.3760/cma.j.issn.0366-6999.2012.24.029
   Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694
   Nencioni A, 2013, HAEMATOLOGICA, V98, P1335, DOI 10.3324/haematol.2012.079061
   Randrianarison-Huetz V, 2010, BLOOD, V115, P2784, DOI 10.1182/blood-2009-09-241752
   Rang S. N., 2002, BRIT J PHARMACOL, V135, P1235
   Roche-Lestienne C, 2002, BLOOD, V100, P1014, DOI 10.1182/blood.V100.3.1014
   Shiotsu Y, 2000, BLOOD, V96, P2284, DOI 10.1182/blood.V96.6.2284
   Sinha N, 2013, ORAL ONCOL, V49, P854, DOI 10.1016/j.oraloncology.2013.06.010
   Smythies J, 2015, J CANCER, V6, P604, DOI 10.7150/jca.12372
   Soignet SL, 2001, J CLIN ONCOL, V19, P3852, DOI 10.1200/JCO.2001.19.18.3852
   Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901
   Soto AM, 2011, BIOESSAYS, V33, P332, DOI 10.1002/bies.201100025
   Steffen B, 2011, BLOOD, V117, P4328, DOI 10.1182/blood-2009-09-242545
   Wagner J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124366
   Wang QQ, 2015, ONCOTARGET, V6, P25646, DOI 10.18632/oncotarget.4662
   Watson AS, 2011, CELL CYCLE, V10, P1719, DOI 10.4161/cc.10.11.15673
   Wu JZ, 2011, J ETHNOPHARMACOL, V135, P595, DOI 10.1016/j.jep.2011.03.071
   Wurth R, 2013, CELL CYCLE, V12, P145, DOI 10.4161/cc.23050
   Yang LC, 2015, AM J CANCER RES, V5, P714
   Zhang SJ, 2008, P NATL ACAD SCI USA, V105, P2076, DOI 10.1073/pnas.0711824105
   Zhang TD, 2001, ONCOGENE, V20, P7146, DOI 10.1038/sj.onc.1204762
NR 33
TC 11
Z9 13
U1 3
U2 27
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-8741
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 20
PY 2017
VL 196
BP 29
EP 38
DI 10.1016/j.jep.2016.12.010
PG 10
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA EJ9ER
UT WOS:000393529900004
PM 27965050
DA 2022-04-25
ER

PT J
AU Jin, CL
   Yuan, P
AF Jin, Chunlai
   Yuan, Peng
TI Implications of lipid droplets in lung cancer: Associations with drug
   resistance
SO ONCOLOGY LETTERS
LA English
DT Review
DE lung cancer; non-small cell lung cancer; drug resistance; epidermal
   growth factor receptor; tyrosine kinase inhibitors; lipid droplet
ID FATTY-ACID OXIDATION; TYROSINE KINASE INHIBITORS; HORMONE-SENSITIVE
   LIPASE; GROWTH-FACTOR; COLORECTAL-CANCER; CELL-SURVIVAL;
   MITOCHONDRIAL-FUNCTION; ENDOPLASMIC-RETICULUM; INCREASED EXPRESSION;
   REGULATES AUTOPHAGY
AB Cancer cells usually show different metabolic patterns compared with healthy cells due to the reprogramming of metabolic processes. The process of lipid metabolism undergoes notable changes, leading to the accumulation of lipid droplets in cells. Additionally, this phenotype is considered an important marker of cancer cells. Lipid droplets are a highly dynamic type of organelle in the cell, which is composed of a neutral lipid core, a monolayer phospholipid membrane and lipid droplet-related proteins. Lipid droplets are involved in several biological processes, including cell proliferation, apoptosis, lipid metabolism, stress, immunity, signal transduction and protein trafficking. Epidermal growth factor receptor (EGFR)-activating mutations are currently the most effective therapeutic targets for non-small cell lung cancer. Several EGFR tyrosine kinase inhibitors (EGFR-TKIs) that target these mutations, including gefitinib, erlotinib, afatinib and osimertinib, have been widely used clinically. However, the development of acquired resistance has a major impact on the efficacy of these drugs. A number of previous studies have reported that the expression of lipid droplets in the tumor tissues of patients with lung cancer are elevated, whereas the association between elevated numbers of lipid droplets and drug resistance has received little attention. The present review describes the potential association between lipid droplets and drug resistance. Furthermore, the mechanisms and implications of lipid droplet accumulation in cancer cells are analyzed, as wells as the mechanism by which lipid droplets suppress endoplasmic reticulum stress and apoptosis, which are essential for the development and treatment of lung cancer.
C1 [Jin, Chunlai; Yuan, Peng] First Peoples Hosp Jinan, Dept Surg, 132 Ming Lake St, Jinan 250011, Shandong, Peoples R China.
RP Yuan, P (corresponding author), First Peoples Hosp Jinan, Dept Surg, 132 Ming Lake St, Jinan 250011, Shandong, Peoples R China.
EM pengyuan_dr@126.com
FU College of Animal Science, Huazhong Agricultural University
FX The authors of the present study would like to thank Dr Yi Jin, from the
   College of Animal Science, Huazhong Agricultural University (Wuhan,
   China) for his help in researching the progress of lipid droplets and
   oxidative stress.
CR ABOUMRAD M H, 1963, Cancer, V16, P521, DOI 10.1002/1097-0142(196304)16:4<521::AID-CNCR2820160414>3.0.CO;2-B
   Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Ali A, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708313
   Ali R, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-261
   Amri Jamal, 2019, Asian Pac J Cancer Prev, V20, P3361, DOI 10.31557/APJCP.2019.20.11.3361
   Aramburu J, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005326
   Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
   Bailey AP, 2015, CELL, V163, P340, DOI 10.1016/j.cell.2015.09.020
   Bartz R, 2007, J LIPID RES, V48, P837, DOI 10.1194/jlr.M600413-JLR200
   Bischof J, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.16
   Blas-Garcia A, 2010, HEPATOLOGY, V52, P115, DOI 10.1002/hep.23647
   Bollu LR, 2015, ONCOTARGET, V6, P34992, DOI 10.18632/oncotarget.5252
   Bozza PT, 2010, PROSTAG LEUKOTR ESS, V82, P243, DOI 10.1016/j.plefa.2010.02.005
   Cabodevilla AG, 2013, J BIOL CHEM, V288, P27777, DOI 10.1074/jbc.M113.466656
   Cai YY, 2016, CANCER CELL, V29, P751, DOI 10.1016/j.ccell.2016.04.003
   Chen C, 2020, CANCER LETT, V486, P58, DOI 10.1016/j.canlet.2020.05.009
   Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200
   Cohen S, 2018, CURR OPIN CELL BIOL, V53, P84, DOI 10.1016/j.ceb.2018.06.003
   Cotte AK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02732-5
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Covington JD, 2015, DIABETES, V64, pA11
   De Rosa V, 2015, CLIN CANCER RES, V21, P5110, DOI 10.1158/1078-0432.CCR-15-0375
   Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022
   Efeyan A, 2015, NATURE, V517, P302, DOI 10.1038/nature14190
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Fujimoto M, 2017, HISTOPATHOLOGY, V70, P232, DOI 10.1111/his.13048
   Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079
   Fujimoto T, 2008, HISTOCHEM CELL BIOL, V130, P263, DOI 10.1007/s00418-008-0449-0
   Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5
   Gao GG, 2017, BBA-MOL CELL BIOL L, V1862, P1197, DOI 10.1016/j.bbalip.2017.06.009
   Garcia D, 2017, MOL CELL, V66, P789, DOI 10.1016/j.molcel.2017.05.032
   Germann S, 2012, ONCOGENE, V31, P4536, DOI 10.1038/onc.2011.618
   Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1
   Grillitsch K, 2011, BBA-MOL CELL BIOL L, V1811, P1165, DOI 10.1016/j.bbalip.2011.07.015
   Guo K, 2015, BIOCHEM BIOPH RES CO, V465, P644, DOI 10.1016/j.bbrc.2015.08.078
   Hager MH, 2006, CURR OPIN CLIN NUTR, V9, P379, DOI 10.1097/01.mco.0000232896.66791.62
   Hambek M, 2007, HEAD NECK-J SCI SPEC, V29, P244, DOI 10.1002/hed.20503
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Hariri H, 2018, EMBO REP, V19, P57, DOI 10.15252/embr.201744815
   Heller S, 2016, AM J PHYSIOL-GASTR L, V310, pG844, DOI 10.1152/ajpgi.00407.2015
   Henne WM, 2018, EMBO J, V37, DOI 10.15252/embj.201898947
   Herms A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8176
   Herms A, 2013, CURR BIOL, V23, P1489, DOI 10.1016/j.cub.2013.06.032
   Heuer TS, 2017, EBIOMEDICINE, V16, P51, DOI 10.1016/j.ebiom.2016.12.012
   Hirsch HA, 2010, CANCER CELL, V17, P348, DOI 10.1016/j.ccr.2010.01.022
   HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405
   Huang QF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1120-4
   Huang WC, 2012, MOL CANCER RES, V10, P133, DOI 10.1158/1541-7786.MCR-11-0206
   Jafari N, 2019, MOL CANCER RES, V17, P140, DOI 10.1158/1541-7786.MCR-18-0199
   Jarc E, 2019, YALE J BIOL MED, V92, P435
   Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816
   Jaworski K, 2007, AM J PHYSIOL-GASTR L, V293, pG1, DOI 10.1152/ajpgi.00554.2006
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Juchum M, 2015, DRUG RESIST UPDATE, V20, P12, DOI 10.1016/j.drup.2015.05.002
   Kalinski P, 2012, J IMMUNOL, V188, P21, DOI 10.4049/jimmunol.1101029
   Karagiannis F, 2020, IMMUNITY, V52, P885, DOI 10.1016/j.immuni.2020.04.021
   Karlsson M, 1997, J BIOL CHEM, V272, P27218, DOI 10.1074/jbc.272.43.27218
   Kasahara K, 2010, CLIN CANCER RES, V16, P4616, DOI 10.1158/1078-0432.CCR-10-0383
   Kim DH, 2018, BIOCHEM BIOPH RES CO, V505, P748, DOI 10.1016/j.bbrc.2018.09.171
   Kim HY, 2017, ARCH TOXICOL, V91, P2353, DOI 10.1007/s00204-016-1889-2
   Krawczyk SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034904
   Kuper C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00293
   Lee CK, 2013, JNCI-J NATL CANCER I, V105, P595, DOI 10.1093/jnci/djt072
   Li Robert, 2016, React Oxyg Species (Apex), V1, P9, DOI 10.20455/ros.2016.803
   Liao Y, 2019, MOL BIOL CELL, V30, P2969, DOI 10.1091/mbc.E19-05-0284
   Lin Y, 2020, SCI REP-UK, V10, P4748, DOI 10.1038/s41598-020-61727-3
   Liu K, 2009, AM J PHYSIOL-ENDOC M, V297, pE1395, DOI 10.1152/ajpendo.00188.2009
   Liu L, 2015, CELL, V160, P177, DOI 10.1016/j.cell.2014.12.019
   Liu Y, 2006, PROSTATE CANCER P D, V9, P230, DOI 10.1038/sj.pcan.4500879
   Liu Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00467
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Makinoshima H, 2014, J BIOL CHEM, V289, P20813, DOI 10.1074/jbc.M114.575464
   Martinez-Lopez N, 2015, ANNU REV NUTR, V35, P215, DOI 10.1146/annurev-nutr-071813-105336
   MCLEMORE TL, 1988, CANCER RES, V48, P3140
   Melo RCN, 2016, EXP CELL RES, V340, P193, DOI 10.1016/j.yexcr.2015.10.028
   Meng XY, 2019, THORAC CANCER, V10, P1051, DOI 10.1111/1759-7714.13038
   Muller G, 2008, BRIT J PHARMACOL, V154, P901, DOI 10.1038/bjp.2008.146
   Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818
   Muoio DM, 1999, BIOCHEM J, V338, P783, DOI 10.1042/0264-6021:3380783
   Nguyen TB, 2017, DEV CELL, V42, P9, DOI 10.1016/j.devcel.2017.06.003
   Nielsen J, 2017, AM J PHYSIOL-ENDOC M, V313, pE721, DOI 10.1152/ajpendo.00062.2017
   Nieva C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046456
   Olzmann JA, 2019, NAT REV MOL CELL BIO, V20, P137, DOI 10.1038/s41580-018-0085-z
   Ou JJ, 2014, CELL REP, V9, P1798, DOI 10.1016/j.celrep.2014.11.016
   Owen JL, 2012, P NATL ACAD SCI USA, V109, P16184, DOI 10.1073/pnas.1213343109
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Patterson AD, 2011, CANCER RES, V71, P6590, DOI 10.1158/0008-5472.CAN-11-0885
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Penrose H, 2016, BIOCHEM BIOPH RES CO, V469, P370, DOI 10.1016/j.bbrc.2015.11.119
   Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276-020-0384-2
   Petan T, 2018, MOLECULES, V23, DOI 10.3390/molecules23081941
   Porstmann T, 2008, CELL METAB, V8, P224, DOI 10.1016/j.cmet.2008.07.007
   Prevost C, 2018, DEV CELL, V44, P73, DOI 10.1016/j.devcel.2017.12.011
   Qiu B, 2015, CANCER DISCOV, V5, P652, DOI 10.1158/2159-8290.CD-14-1507
   Rak S, 2014, ANALYST, V139, P3407, DOI 10.1039/c4an00412d
   Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029
   RAMOS CV, 1974, CANCER, V33, P812, DOI 10.1002/1097-0142(197403)33:3<812::AID-CNCR2820330328>3.0.CO;2-4
   Ramzan R, 2020, J MOL MED, V98, P651, DOI 10.1007/s00109-020-01905-y
   Reid BN, 2008, J BIOL CHEM, V283, P13087, DOI 10.1074/jbc.M800533200
   Remon J, 2014, CANCER TREAT REV, V40, P93, DOI 10.1016/j.ctrv.2013.06.002
   RIGAS B, 1993, J LAB CLIN MED, V122, P518
   Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89
   Romanauska A, 2018, CELL, V174, P700, DOI 10.1016/j.cell.2018.05.047
   Salo VT, 2019, CURR OPIN CELL BIOL, V57, P64, DOI 10.1016/j.ceb.2018.11.002
   Satapati S, 2015, J CLIN INVEST, V125, P4447, DOI 10.1172/JCI82204
   Schaffer JE, 2003, CURR OPIN LIPIDOL, V14, P281, DOI 10.1097/00041433-200306000-00008
   Schuldiner M, 2017, BBA-MOL CELL BIOL L, V1862, P1188, DOI 10.1016/j.bbalip.2017.06.005
   Schulze RJ, 2017, BBA-MOL CELL BIOL L, V1862, P1178, DOI 10.1016/j.bbalip.2017.06.008
   Sciacovelli M, 2017, FEBS J, V284, P3132, DOI 10.1111/febs.14090
   Sekiya M, 2008, BIOCHEM BIOPH RES CO, V375, P602, DOI 10.1016/j.bbrc.2008.08.068
   Seo AY, 2017, ELIFE, V6, DOI 10.7554/eLife.21690
   Settembre C, 2014, TRENDS CELL BIOL, V24, P743, DOI 10.1016/j.tcb.2014.06.006
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Soltysik K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09294-8
   Sturley SL, 2012, J LIPID RES, V53, P1800, DOI 10.1194/jlr.R028290
   Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032
   Thun MJ, 2012, NAT REV CLIN ONCOL, V9, P259, DOI 10.1038/nrclinonc.2011.199
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Tomin T, 2018, J PROTEOME RES, V17, P1415, DOI 10.1021/acs.jproteome.7b00782
   Tsai TH, 2017, AUTOPHAGY, V13, P1130, DOI 10.1080/15548627.2017.1319544
   Turro S, 2006, TRAFFIC, V7, P1254, DOI 10.1111/j.1600-0854.2006.00465.x
   Ueno M, 2013, J LIPID RES, V54, P734, DOI 10.1194/jlr.M033365
   Valm AM, 2017, NATURE, V546, P162, DOI 10.1038/nature22369
   Velazquez AR, 2016, J CELL BIOL, V212, P621, DOI 10.1083/jcb.201508102
   Vrablik TL, 2015, BBA-MOL CELL BIOL L, V1851, P1337, DOI 10.1016/j.bbalip.2015.06.004
   Walther TC, 2017, ANNU REV CELL DEV BI, V33, P491, DOI 10.1146/annurev-cellbio-100616-060608
   Wang DZ, 2004, SEMIN ONCOL, V31, P64, DOI 10.1053/j.seminoncol.2004.01.008
   Wang G, 2018, BIOCHEM BIOPH RES CO, V500, P873, DOI 10.1016/j.bbrc.2018.04.177
   Wang HY, 2016, CANCER MED-US, V5, P1599, DOI 10.1002/cam4.711
   Wang HJ, 2016, ELIFE, V5, DOI 10.7554/eLife.16582
   Wang TH, 2019, PHYTOMEDICINE, V64, DOI 10.1016/j.phymed.2019.152926
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Welte MA, 2017, BBA-MOL CELL BIOL L, V1862, P1260, DOI 10.1016/j.bbalip.2017.07.006
   Welte MA, 2015, CELL, V163, P269, DOI 10.1016/j.cell.2015.09.046
   Welte MA, 2015, CURR BIOL, V25, pR470, DOI 10.1016/j.cub.2015.04.004
   Wen CJ, 2020, J CANCER, V11, P3816, DOI 10.7150/jca.39783
   Wendel AA, 2009, BBA-MOL CELL BIOL L, V1791, P501, DOI 10.1016/j.bbalip.2008.10.010
   Wilfling F, 2014, CURR OPIN CELL BIOL, V29, P39, DOI 10.1016/j.ceb.2014.03.008
   Wilfling F, 2014, ELIFE, V3, DOI 10.7554/eLife.01607
   Wu JY, 2011, LUNG CANCER, V72, P205, DOI 10.1016/j.lungcan.2010.08.013
   Yan M, 2009, P NATL ACAD SCI USA, V106, P9409, DOI 10.1073/pnas.0902367106
   Yang SS, 2020, MOL CELL BIOCHEM, V467, P1, DOI 10.1007/s11010-019-03667-9
   Yecies JL, 2011, CELL METAB, V14, P280, DOI 10.1016/j.cmet.2011.07.004
   Young SG, 2013, GENE DEV, V27, P459, DOI 10.1101/gad.209296.112
   Yu WG, 1998, AM J PATHOL, V152, P759
   Yu WG, 2000, BLOOD, V95, P1078, DOI 10.1182/blood.V95.3.1078.003k16_1078_1085
   Zagani R, 2015, ONCOTARGET, V6, P28282, DOI 10.18632/oncotarget.5061
   Zaytseva YY, 2015, ONCOTARGET, V6, P18891, DOI 10.18632/oncotarget.3783
   Zechner R, 2017, NAT REV MOL CELL BIO, V18, P671, DOI 10.1038/nrm.2017.76
   Zechner R, 2012, CELL METAB, V15, P279, DOI 10.1016/j.cmet.2011.12.018
   Zhang CY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15979
   Zhang JQ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0704-x
   Zhang XD, 2014, INT J CLIN EXP MED, V7, P1190
   Zhang ZL, 2017, REDOX BIOL, V11, P322, DOI 10.1016/j.redox.2016.12.021
   Zhao YY, 2019, ANAL CHEM, V91, P4466, DOI 10.1021/acs.analchem.8b05122
   Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747
NR 160
TC 9
Z9 9
U1 2
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2020
VL 20
IS 3
BP 2091
EP 2104
DI 10.3892/ol.2020.11769
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NG4EX
UT WOS:000563938300004
PM 32782526
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Subramaniam, S
   Jeet, V
   Clements, JA
   Gunter, JH
   Batra, J
AF Subramaniam, Sugarniya
   Jeet, Varinder
   Clements, Judith A.
   Gunter, Jennifer H.
   Batra, Jyotsna
TI Emergence of MicroRNAs as Key Players in Cancer Cell Metabolism
SO CLINICAL CHEMISTRY
LA English
DT Review
ID INHIBITS TUMOR-GROWTH; PYRUVATE-DEHYDROGENASE; COLORECTAL-CANCER;
   PROSTATE-CANCER; LACTATE-DEHYDROGENASE; FATTY-ACID; AEROBIC GLYCOLYSIS;
   CERVICAL-CANCER; BLADDER-CANCER; PROLIFERATION
AB BACKGROUND: Metabolic reprogramming is a hallmark of cancer. MicroRNAs (miRNAs) have been found to regulate cancer metabolism by regulating genes involved in metabolic pathways. Understanding this layer of complexity could lead to the development of novel therapeutic approaches.
   CONTENT: miRNAs are noncoding RNAs that have been implicated as master regulators of gene expression. Studies have revealed the role of miRNAs in the metabolic reprogramming of tumor cells, with several miRNAs both positively and negatively regulating multiple metabolic genes. The tricarboxylic acid (TCA) cycle, aerobic glycolysis, de novo fatty acid synthesis, and altered autophagy allow tumor cells to survive under adverse conditions. In addition, major signaling molecules, hypoxiainducible factor, phosphatidylinositol-3 kinase/protein kinase B/mammalian target of rapamycin/phosphatase and tensin homolog, and insulin signaling pathways facilitate metabolic adaptation in tumor cells and are all regulated by miRNAs. Accumulating evidence suggests that miRNA mimics or inhibitors could be used to modulate the activity of miRNAs that drive tumor progression via altering their metabolism. Currently, several clinical trials investigating the role of miRNA-based therapy for cancer have been launched that may lead to novel therapeutic interventions in the future.
   SUMMARY: In this review, we summarize cancer-related metabolic pathways, including glycolysis, TCA cycle, pentose phosphate pathway, fatty acid metabolism, amino acid metabolism, and other metabolism-related oncogenic signaling pathways, and their regulation by miRNAs that arc known to lead to tumorigenesis. Fur- ther, we discuss the current state of miRNA therapeutics in the clinic and their future potential. (C) 2019 American Association for Clinical Chemistry
C1 [Subramaniam, Sugarniya; Jeet, Varinder; Clements, Judith A.; Gunter, Jennifer H.; Batra, Jyotsna] Queensland Univ Technol, Fac Hlth, Sch Biomed Sci, Inst Hlth & Biomed Innovat, Brisbane, Qld, Australia.
   [Subramaniam, Sugarniya; Jeet, Varinder; Clements, Judith A.; Gunter, Jennifer H.; Batra, Jyotsna] Queensland Univ Technol, APCRC Q, Translat Res Inst, Brisbane, Qld, Australia.
RP Batra, J (corresponding author), Translat Res Inst, 37 Kent St, Brisbane, Qld 4102, Australia.
EM jyotsna.batra@qut.edu.au
RI Gunter, Jennifer H/B-8960-2016
OI Gunter, Jennifer H/0000-0003-2447-5732; Jeet,
   Varinder/0000-0003-3765-5310
FU QUT Postgraduate Research Award (QUTPRA); QUT HDR Tuition Fee
   Sponsorship; Movember Foundation; Prostate Cancer Foundation of
   Australia; Queensland Government; Cancer Council AustraliaCancer Council
   Australia; Cure Cancer Australia; Cancer Australia; National Health and
   Medical Research Council (NHMRC)National Health and Medical Research
   Council (NHMRC) of Australia
FX S. Subramaniam, QUT Postgraduate Research Award (QUTPRA) and QUT HDR
   Tuition Fee Sponsorship; J. Gunter, the Movember Foundation, the
   Prostate Cancer Foundation of Australia, a Queensland Government Advance
   Queensland Fellowship; J. Batra, Cancer Council Australia and Cure
   Cancer and Cancer Australia Young Investigator award, National Health
   and Medical Research Council (NHMRC) Career Development Fellowship.
CR Beg MS, 2017, INVEST NEW DRUG, V35, P180, DOI 10.1007/s10637-016-0407-y
   Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031
   Chai J, 2015, IUBMB LIFE, V67, P191, DOI 10.1002/iub.1361
   Chang X, 2017, CLIN EXP DERMATOL, V42, P614, DOI 10.1111/ced.13119
   Chen B, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-443
   Cheng X, 2016, J ANIM SCI, V94, P65, DOI 10.2527/jas.2015-9456
   Choi J, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/9369358
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Dai DW, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-478
   Dong J, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.59
   Du JY, 2015, ONCOL REP, V33, P1890, DOI 10.3892/or.2015.3797
   Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006
   Fong MY, 2015, NAT CELL BIOL, V17, P183, DOI 10.1038/ncb3094
   Guo HB, 2016, TUMOR BIOL, V37, P13751, DOI 10.1007/s13277-016-5219-3
   Hatziapostolou M, 2013, TRENDS ENDOCRIN MET, V24, P361, DOI 10.1016/j.tem.2013.03.002
   Hu JW, 2014, CELL SIGNAL, V26, P2210, DOI 10.1016/j.cellsig.2014.04.015
   Huang SQ, 2017, DNA CELL BIOL, V36, P303, DOI 10.1089/dna.2016.3612
   Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301
   Izreig S, 2016, CELL REP, V16, P1915, DOI 10.1016/j.celrep.2016.07.036
   Ji WD, 2017, GENES-BASEL, V8, DOI 10.3390/genes8010021
   Kabir TD, 2016, AGING-US, V8, P1608, DOI 10.18632/aging.100987
   KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297
   Li G, 2017, ONCOGENE, V36, P989, DOI 10.1038/onc.2016.265
   Li P, 2017, CELL PHYSIOL BIOCHEM, V41, P921, DOI 10.1159/000460505
   Li XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070987
   Li XY, 2015, MOL MED REP, V11, P577, DOI 10.3892/mmr.2014.2726
   Li XG, 2016, MOL MED REP, V13, P3661, DOI 10.3892/mmr.2016.4974
   Li YJ, 2016, BIOMED PHARMACOTHER, V78, P177, DOI 10.1016/j.biopha.2016.01.022
   Liu G, 2016, ONCOL LETT, V11, P2903, DOI 10.3892/ol.2016.4316
   Liu PF, 2016, ONCOL LETT, V12, P3882, DOI 10.3892/ol.2016.5180
   Liu W, 2012, BIOFACTORS, V38, P398, DOI 10.1002/biof.1036
   Liu WP, 2018, ONCOTARGETS THER, V11, P1643, DOI 10.2147/OTT.S161586
   Liu YY, 2010, ANTICANCER RES, V30, P369
   Liu ZY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317691429
   Lu Lei, 2014, Zhonghua Nan Ke Xue, V20, P495
   Maddocks ODK, 2017, NATURE, V544, P372, DOI 10.1038/nature22056
   Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085
   Meng F, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00197
   Mersey BD, 2005, HUM MOL GENET, V14, P3371, DOI 10.1093/hmg/ddi368
   Nijhuis A, 2017, HUM MOL GENET, V26, P1552, DOI 10.1093/hmg/ddx059
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Petrovic N, 2018, MOL DIAGN THER, V22, P157, DOI 10.1007/s40291-017-0314-8
   Qiu ZP, 2015, GASTROENTEROLOGY, V149, P1587, DOI 10.1053/j.gastro.2015.07.050
   Qu W, 2016, FEBS OPEN BIO, V6, P735, DOI 10.1002/2211-5463.12086
   Ren P, 2016, TUMOR BIOL, V37, P3215, DOI 10.1007/s13277-015-4150-3
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Sanderson SJ, 1996, EUR J BIOCHEM, V236, P68, DOI 10.1111/j.1432-1033.1996.00068.x
   Sun Y, 2012, ONCOL REP, V28, P1346, DOI 10.3892/or.2012.1958
   Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254
   Ta T, 2017, ONCOL REP, V37, P1430, DOI 10.3892/or.2017.5430
   Tanaka H, 2013, J NEURO-ONCOL, V111, P273, DOI 10.1007/s11060-012-1027-9
   Tomasetti M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050754
   Wang J, 2015, ONCOTARGET, V6, P19456, DOI 10.18632/oncotarget.3318
   Wang N, 2018, CANCERS, V11
   Wang TZ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0402-5
   Wang XZ, 2017, ONCOL LETT, V13, P4825, DOI 10.3892/ol.2017.6053
   Wei SF, 2017, BIOMED PHARMACOTHER, V90, P278, DOI 10.1016/j.biopha.2017.03.068
   Wen YA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0330-6
   Wu HL, 2016, J AGR FOOD CHEM, V64, P9356, DOI 10.1021/acs.jafc.6b04549
   Wu SJ, 2016, TUMOR BIOL, V37, P5193, DOI 10.1007/s13277-015-4369-z
   Wu XL, 2018, J CELL BIOCHEM, V119, P2356, DOI 10.1002/jcb.26399
   Wu YH, 2016, FASEB J, V30
   Wu YY, 2017, CELL PHYSIOL BIOCHEM, V43, P945, DOI 10.1159/000481648
   Xiao HJ, 2018, PROSTATE, V78, P86, DOI 10.1002/pros.23448
   Xin M, 2016, ONCOTARGET, V7, P44252, DOI 10.18632/oncotarget.10020
   Xu Z, 2017, TUMOR BIOL, V39
   Yan S, 2015, CELL PHYSIOL BIOCHEM, V37, P375, DOI 10.1159/000430361
   Yang H, 2016, AM J CANCER RES, V6, P2690
   Yang J, 2016, AM J CANCER RES, V6, P473
   Zhang DX, 2015, CELL REP, V10, P1335, DOI 10.1016/j.celrep.2015.02.006
   Zhang HY, 2014, INT J ONCOL, V45, P2143, DOI 10.3892/ijo.2014.2596
   Zhang LF, 2017, CELL MOL LIFE SCI, V74, P2929, DOI 10.1007/s00018-017-2508-y
   Zhang W, 2017, J RECEPT SIG TRANSD, V37, P217, DOI 10.1080/10799893.2016.1212375
   Zhao G, 2016, ONCOL REP, V36, P1709, DOI 10.3892/or.2016.4952
   Zhao MT, 2016, CRIT REV EUKAR GENE, V26, P223, DOI 10.1615/CritRevEukaryotGeneExpr.2016016531
   Zhu WJ, 2017, MOL CARCINOGEN, V56, P1570, DOI 10.1002/mc.22612
   Zhu YZ, 2017, AM J CANCER RES, V7, P1136
NR 77
TC 36
Z9 38
U1 0
U2 7
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD SEP
PY 2019
VL 65
IS 9
BP 1090
EP 1101
DI 10.1373/clinchem.2018.299651
PG 12
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA IV6HS
UT WOS:000484370100008
PM 31101638
OA Green Submitted, Bronze
DA 2022-04-25
ER

PT J
AU Kosmidou, V
   Vlassi, M
   Anagiotos, K
   Raftopoulou, S
   Kalogerakou, E
   Skarmalioraki, S
   Aggeli, C
   Choreftaki, T
   Zografos, G
   Pintzas, A
AF Kosmidou, Vivian
   Vlassi, Margarita
   Anagiotos, Kyriakos
   Raftopoulou, Sofia
   Kalogerakou, Eirini
   Skarmalioraki, Salomi
   Aggeli, Chrysanthi
   Choreftaki, Theodosia
   Zografos, George
   Pintzas, Alexander
TI Noxaupregulation and 5-gene apoptotic biomarker panel in colorectal
   cancer
SO EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
DE apoptosis; CRC; novel 5-biomarker panel; Noxa early detection
ID TARGETING MCL-1; IAP PROTEINS; NOXA; INHIBITOR; EXPRESSION; ACTIVATION;
   AUTOPHAGY; PATHWAYS; MEK/ERK; MARKERS
AB Background NOXA and MCL1 are involved in the intrinsic pathway of apoptosis, where Noxa selectively binds to MCL1 and prevents it from inhibiting apoptosis. Both factors are considered as potential tumour biomarkers, while MCL1 has attracted interest as target in cancer. The purpose of this study was to investigate the expression of NOXA and MCL1 in 160 CRC tumour samples, to investigate their significance, also in combination with IAPs, DR5 expression andKRASgene mutations in CRC. Materials and methods Fresh frozen colorectal tissue was obtained from patients undergoing surgery for CRC. Real-time quantitative PCR was performed for the determination of mRNA expression levels. Protein expression was determined immunohistochemically. Differences in the mRNA expression profile were evaluated with the nonparametric Wilcoxon signed ranks test. Statistical analysis was performed with the use of Mann-WhitneyUtest and receiver-operating characteristic (ROC) curve. Results NOXAwas found to be overexpressed in CRC tumours (P < .0001), even from early stage. Moreover,NOXA/MCL1mRNA expression was significantly elevated in tumour samples compared to normal pairs (P < .0001). ROC curve analysis showed that bothNOXAexpression and its combination withMcl1expression have fair discriminatory value between CRC and normal colorectal tissue. Combinatorial ROC analysis revealed the most significant discriminatory value ofNOXA, MCL1withcIAP1andcIAP2(AUC = 0.834,P < .0001) as a 5-gene panel of markers. Conclusion Noxa, Mcl1, DR5,cIAP1andcIAP2mRNA expressions are significantly deregulated in CRC and could provide a panel of markers with significant discriminatory value between CRC and normal colorectal tissue.
C1 [Kosmidou, Vivian; Vlassi, Margarita; Anagiotos, Kyriakos; Raftopoulou, Sofia; Kalogerakou, Eirini; Skarmalioraki, Salomi; Pintzas, Alexander] Natl Hellen Res Fdn, Inst Chem Biol, Lab Signal Mediated Gene Express, Athens, Greece.
   [Aggeli, Chrysanthi; Zografos, George] Gen Hosp Athens G Gennimatas, Dept Surg 3, Athens, Greece.
   [Choreftaki, Theodosia] Gen Hosp Athens G Gennimatas, Dept Pathol, Athens, Greece.
RP Pintzas, A (corresponding author), Natl Hellen Res Fdn, Inst Chem Biol, Athens, Greece.
EM apint@eie.gr
FU General Secretariat for Research and TechnologyGreek Ministry of
   Development-GSRT [11SYN1-485]
FX General Secretariat for Research and Technology, Grant/Award Number:
   SYNERGASIA "THERACAN" 11SYN1-485
CR Abraha AM, 2016, WORLD J GASTRO ONCOL, V8, P583, DOI 10.4251/wjgo.v8.i8.583
   Bai YH, 2018, CELL PHYSIOL BIOCHEM, V48, P1755, DOI 10.1159/000492317
   Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030
   Conti A, 2015, ONCOTARGET, V6, P10994, DOI 10.18632/oncotarget.3552
   de Almagro M. C., 2012, Experimental Oncology, V34, P200
   Devetzi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36532
   Diallo JS, 2007, CLIN CANCER RES, V13, P7044, DOI 10.1158/1078-0432.CCR-07-1224
   Elgendy M, 2011, MOL CELL, V42, P23, DOI 10.1016/j.molcel.2011.02.009
   Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   Hauck P, 2009, MOL CANCER THER, V8, P883, DOI 10.1158/1535-7163.MCT-08-1118
   Horing E, 2017, BRIT J HAEMATOL, V177, P557, DOI 10.1111/bjh.14571
   Jansson AK, 2003, ONCOGENE, V22, P4675, DOI 10.1038/sj.onc.1206655
   Kawakami H, 2016, MOL CANCER THER, V15, P3015, DOI 10.1158/1535-7163.MCT-16-0017
   Liu YL, 2014, ONCOTARGET, V5, P11237
   Lopez H, 2010, J BIOL CHEM, V285, P15016, DOI 10.1074/jbc.M109.086231
   McCarthy N, 2011, NAT REV CANCER, V11, P313, DOI 10.1038/nrc3054
   McCubrey JA, 2012, ONCOTARGET, V3, P1505
   McLornan DP, 2010, CLIN CANCER RES, V16, P3442, DOI 10.1158/1078-0432.CCR-10-0052
   Miura K, 2011, SURG TODAY, V41, P175, DOI 10.1007/s00595-010-4390-1
   Montero J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12477-y
   Nangia V, 2018, CANCER DISCOV, V8, P1598, DOI 10.1158/2159-8290.CD-18-0277
   Ouchi K, 2016, J CELL PHYSIOL, V231, P1932, DOI 10.1002/jcp.25293
   Qin JZ, 2006, CANCER RES, V66, P9636, DOI 10.1158/0008-5472.CAN-06-0747
   Quinn BA, 2011, EXPERT OPIN INV DRUG, V20, P1397, DOI 10.1517/13543784.2011.609167
   Simera I, 2010, EUR J CLIN INVEST, V40, P35, DOI 10.1111/j.1365-2362.2009.02234.x
   Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202
   Thomas LW, 2010, FEBS LETT, V584, P2981, DOI 10.1016/j.febslet.2010.05.061
   Tong JS, 2017, CANCER RES, V77, P2512, DOI 10.1158/0008-5472.CAN-16-3242
   Torres-Adorno AM, 2017, CLIN CANCER RES, V23, P4780, DOI 10.1158/1078-0432.CCR-16-2622
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Wu JY, 2018, EJSO-EUR J SURG ONC, V44, P1254, DOI 10.1016/j.ejso.2018.05.005
   Wuilleme-Toumi S, 2005, LEUKEMIA, V19, P1248, DOI 10.1038/sj.leu.2403784
   Xiang GA, 2009, J SURG ONCOL, V100, P708, DOI 10.1002/jso.21408
   Zeestraten Eliane C M, 2013, Biomark Cancer, V5, P13, DOI 10.4137/BIC.S11475
   Zhang B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048748
   Zhang L, 2011, CELL DEATH DIFFER, V18, P864, DOI 10.1038/cdd.2010.152
   Zhou ZY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-159
NR 38
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2972
EI 1365-2362
J9 EUR J CLIN INVEST
JI Eur. J. Clin. Invest.
PD JAN
PY 2021
VL 51
IS 1
AR e13353
DI 10.1111/eci.13353
EA AUG 2020
PG 17
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA PH0JP
UT WOS:000558012900001
PM 32682341
DA 2022-04-25
ER

PT J
AU Helmy, MW
   Ghoneim, AI
   Katary, MA
   Elmahdy, RK
AF Helmy, Maged W.
   Ghoneim, Asser, I
   Katary, Mohamed A.
   Elmahdy, Rana K.
TI The synergistic anti-proliferative effect of the combination of diosmin
   and BEZ-235 (dactolisib) on the HCT-116 colorectal cancer cell line
   occurs through inhibition of the PI3K/Akt/mTOR/NF-kappa B axis
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Colorectal cancer; BEZ-235; Diosmin; PI3K; NF-kappa b
ID NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL
   3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; PATHWAY COMPONENTS;
   SIGNALING PATHWAYS; MAMMALIAN TARGET; DUAL INHIBITOR; PI3K PATHWAY;
   FACTOR-ALPHA
AB One of the most lethal malignancies worldwide is colorectal cancer (CRC). Alterations in various signalling pathways, including PI3K-mTOR and NF-kappa B, have been reported in CRC with subsequent dysregulation of proliferation, apoptosis, angiogenesis and, questionably, autophagy processes. BEZ-235 (dactolisib) is a dual PI3K-mTOR inhibitor with potent anti-tumour activity. However, the observed toxicity of BEZ-235 necessitated the termination of its clinical trials. Hence, we aimed to evaluate the potential long-lasting anti-carcinogenic effects of adding diosmin (DIO, a natural NF-kappa B inhibitor) to BEZ-235 in HCT-116 CRC cells. The median inhibitory concentrations (IC50s) of BEZ-235 and/or DIO were evaluated in the HCT-116 CRC cell line. Caspase-3 activity was assessed colorimetrically, and p-Akt, NF-kappa B, CD1, VEGF and LC3B levels were assessed by ELISA. Additionally, LC3-II and P62 gene expression were assessed using qRT-PCR. The observed CIs (combination indices) and DRIs (dose reduction indices) confirmed the synergistic effect of DIO and BEZ-235. Co-administration of both drugs either in combination-1 (1 mu M for BEZ-235, 250 mu M for DIO) or in combination-2 (0.51 mu M for BEZ-235 + 101.99 mu M for DIO) inhibited the PI3K/Akt/mTOR/NF-kappa B axis, leading to the induction of apoptosis (via active caspase-3), and the inhibition of proliferation marker (CD1), angiogenesis marker (VEGF), autophagy protein (LC3B) and altered effects on LC3-IIandP62 gene expression. Our results reveal the synergistic chemotherapeutic effects of DIO combined with BEZ-235 in the HCT-116 CRC cell line and encourage future preclinical and clinical studies of this combination with reduced BEZ-235 concentrations to avoid its reported toxicity.
   [GRAPHICS]
   .
C1 [Helmy, Maged W.; Ghoneim, Asser, I; Katary, Mohamed A.; Elmahdy, Rana K.] Damanhour Univ, Fac Pharm, Pharmacol & Toxicol, Damanhour 22514, Egypt.
RP Helmy, MW (corresponding author), Damanhour Univ, Fac Pharm, Pharmacol & Toxicol, Damanhour 22514, Egypt.
EM maged.helmy@pharm.dmu.edu.eg; asser.ghoneim@pharm.dmu.edu.eg;
   mohamedalaa_pharmacy@hotmail.com; rana.elmandy992@gmail.com
CR Abdallah FM, 2018, N-S ARCH PHARMACOL, V391, P1399, DOI 10.1007/s00210-018-1557-6
   Abdelmoneem MA, 2018, J CONTROL RELEASE, V287, P78, DOI 10.1016/j.jconrel.2018.08.026
   Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009
   Ahluwalia A, 2014, CURR PHARM DESIGN, V20, P1041, DOI 10.2174/1381612819999131218175905
   Alqurashi N, 2018, ONCOL REP, V40, P1083, DOI 10.3892/or.2018.6457
   Alvarez N, 2009, CANCER BIOTHER RADIO, V24, P347, DOI 10.1089/cbr.2008.0565
   Pena-Moran OA, 2016, MOLECULES, V21, DOI 10.3390/molecules21081013
   Awasthi N, 2012, J CELL BIOCHEM, V113, P784, DOI 10.1002/jcb.23405
   Awwad RA, 2003, CANCER RES, V63, P4731
   Bendardaf R, 2017, LIBYAN J MED, V12, DOI 10.1080/19932820.2017.1290741
   Berg M, 2012, DISCOV MED, V14, P207
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Brown L F, 1997, EXS, V79, P233
   BROWN LF, 1993, CANCER RES, V53, P4727
   Buddhan R, 2017, J CANCER RES THER, V13, P471, DOI 10.4103/0973-1482.183213
   Butler DE, 2017, ONCOTARGET, V8, P56698, DOI 10.18632/oncotarget.18082
   Calvani M, 2008, CANCER RES, V68, P285, DOI 10.1158/0008-5472.CAN-07-5564
   Cao YH, 2013, J MATER CHEM B, V1, P5602, DOI 10.1039/c3tb20764a
   Carlo MI, 2016, ONCOLOGIST, V21, P787, DOI 10.1634/theoncologist.2016-0145
   Chang ZX, 2013, INT J MOL MED, V31, P1449, DOI 10.3892/ijmm.2013.1351
   Chen JZ, 2015, CLIN EXP PHARMACOL P, V42, P1317, DOI 10.1111/1440-1681.12493
   Chiarini F, 2010, CANCER RES, V70, P8097, DOI 10.1158/0008-5472.CAN-10-1814
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Chowdhury S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060299
   Cudjoe E.K., 2019, TARGETING CELL SURVI, P259
   Dan HC, 2008, GENE DEV, V22, P1490, DOI 10.1101/gad.1662308
   Davoodi H, 2012, IRAN J ALLERGY ASTHM, V11, P121, DOI 011.02/ijaai.121132
   Dey N, 2016, AM J CANCER RES, V6, P714
   Diana G, 2001, ALTERN MED REV, V6, P212
   Ellis L M, 2000, Oncologist, V5 Suppl 1, P11
   Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890
   Farooqi AA, 2019, SEMIN CANCER BIOL, V58, P65, DOI 10.1016/j.semcancer.2019.01.001
   Fazio N, 2016, ANTICANCER RES, V36, P713
   Fortin J, 2016, CANCER CELL, V29, P429, DOI 10.1016/j.ccell.2016.03.020
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Guba M, 2004, INT J COLORECTAL DIS, V19, P510, DOI 10.1007/s00384-003-0576-y
   Hassanzadeh Parichehr, 2011, Gastroenterol Hepatol Bed Bench, V4, P127
   Herrera VA, 2011, ANTICANCER RES, V31, P849
   Hnatek Lukas, 2015, Vnitr Lek, V61, P807
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Kelsoe J., 2012, INT CLIN PSYCHOPHARM, V28, pe5, DOI [DOI 10.1097/01.YIC.0000423231.81230.9E, 10.1097/01.yic.0000423231.81230.9e]
   Kenific CM, 2015, TRENDS CELL BIOL, V25, P37, DOI 10.1016/j.tcb.2014.09.001
   Kojima M, 2004, ANTICANCER RES, V24, P675
   Kuntz S, 1999, EUR J NUTR, V38, P133, DOI 10.1007/s003940050054
   Lee JC, 2000, EUR J CANCER, V36, P748, DOI 10.1016/S0959-8049(00)00003-4
   Lewinska A, 2017, TOXICOL LETT, V265, P117, DOI 10.1016/j.toxlet.2016.11.018
   Lewinska A, 2015, TOXICOL IN VITRO, V29, P417, DOI 10.1016/j.tiv.2014.12.005
   Li HY, 2013, CELL BIOCHEM FUNCT, V31, P427, DOI 10.1002/cbf.2917
   Liu X, 2015, FUTURE ONCOL, V11, P2911, DOI 10.2217/fon.15.235
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Maksimovic Z V, 2008, Acta Chir Iugosl, V55, P53
   Martinez Conesa Cristina, 2005, J Agric Food Chem, V53, P6791, DOI 10.1021/jf058050g
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006
   Merga YJ, 2016, AM J PHYSIOL-GASTR L, V310, pG1081, DOI 10.1152/ajpgi.00026.2016
   Mirzoeva OK, 2011, J MOL MED, V89, P877, DOI 10.1007/s00109-011-0774-y
   Monograph D, 2004, ALTERN MED REV, V9, P308
   Motawi TK, 2018, LIFE SCI, V198, P71, DOI 10.1016/j.lfs.2018.02.019
   NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0
   O'Kennedy R., 2017, IMMUNOASSAYS DEV APP
   Oh Iljoong, 2016, Dev Reprod, V20, P1, DOI 10.12717/DR.2016.20.1.001
   Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271
   Pandurangan AK, 2018, WORLD J GASTRO ONCOL, V10, P244, DOI 10.4251/wjgo.v10.i9.244
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Qian HR, 2017, ONCOTARGET, V8, P62759, DOI 10.18632/oncotarget.18663
   Rajasekar M, 2016, BIOMED PHARMACOTHER, V83, P1064, DOI 10.1016/j.biopha.2016.08.019
   Romano MF, 2004, EUR J CANCER, V40, P2829, DOI 10.1016/j.ejca.2004.08.017
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201
   Russo R, 2018, MOLECULES, V23, DOI 10.3390/molecules23092174
   Rychahou PG, 2005, SURGERY, V138, P391, DOI 10.1016/j.surg.2005.05.012
   Rychahou PG, 2006, ANN SURG, V243, P833, DOI 10.1097/01.sla.0000220040.66012.a9
   Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Slattery ML, 2018, J CANCER RES CLIN, V144, P269, DOI 10.1007/s00432-017-2548-6
   Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025
   Suresh K, 2014, INT J PHARM BIOL ARC, V5, P82
   TABANA YM, 2016, RECENT ADV COLON CAN, V1, P1, DOI DOI 10.14302/ISSN.2471-7061.JCRC-14-579
   Tahir M, 2013, TOXICOL LETT, V220, P205, DOI 10.1016/j.toxlet.2013.04.004
   Tanaka T, 1997, CARCINOGENESIS, V18, P957, DOI 10.1093/carcin/18.5.957
   Tiwari A, 2018, WORLD J GASTROENTERO, V24, P4428, DOI 10.3748/wjg.v24.i39.4428
   Toda K, 2016, NEOPLASIA, V18, P654, DOI 10.1016/j.neo.2016.09.004
   Dung TD, 2012, FOOD CHEM TOXICOL, V50, P1802, DOI 10.1016/j.fct.2012.01.021
   Troiani T, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000088
   van Meerloo J, 2011, METHODS MOL BIOL, V731, P237, DOI 10.1007/978-1-61779-080-5_20
   Voboril R, 2006, NEOPLASMA, V53, P518
   Wang QD, 2002, CLIN CANCER RES, V8, P1940
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Xin PL, 2017, DRUG DES DEV THER, V11, P1115, DOI 10.2147/DDDT.S132092
   Yang F, 2017, ONCOTARGETS THER, V10, P4413, DOI 10.2147/OTT.S145601
   Yang F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059879
   Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047
   Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014
NR 100
TC 12
Z9 12
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAR
PY 2020
VL 47
IS 3
BP 2217
EP 2230
DI 10.1007/s11033-020-05327-4
EA FEB 2020
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA LG1EV
UT WOS:000516374900001
PM 32088816
DA 2022-04-25
ER

PT J
AU Guo, LL
   Ma, LL
   Liu, C
   Lei, Y
   Tang, N
   Huang, YX
   Huang, G
   Li, DZ
   Wang, Q
   Liu, GL
   Tang, MS
   Jing, ZL
   Deng, YJ
AF Guo, Lili
   Ma, Lili
   Liu, Chao
   Lei, Yan
   Tang, Na
   Huang, Yingxin
   Huang, Guan
   Li, Dazhou
   Wang, Qi
   Liu, Guanglong
   Tang, Minshan
   Jing, Zhiliang
   Deng, Yongjian
TI ERp29 counteracts the suppression of malignancy mediated by endoplasmic
   reticulum stress and promotes the metastasis of colorectal cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE endoplasmic reticulum protein 29; endoplasmic reticulum stress;
   colorectal cancer cells; CUL5; metastasis
ID UNFOLDED PROTEIN RESPONSE; ER-STRESS; UP-REGULATION; APOPTOSIS;
   EXPRESSION; CELLS; GENE; INFLAMMATION; ACTIVATION; AUTOPHAGY
AB Endoplasmic reticulum protein 29 (ERp29), an endoplasmic reticulum (ER) protein, participates in ER stress (ERS), but little is known about the association of ERp29 with ERS in the metastasis and prognosis of cancerous diseases. The present study revealed that ERp29 was important to ERS and interfered with the malignant behaviors of colorectal cancer (CRC). Experiments in in vitro and in animal models revealed that ERS inhibited the cell growth and suppressed the metastatic capacity of CRC cells, but ERp29 counteracted these effects. Furthermore, it was demonstrated that ERp29 recovered the migration and metastatic behaviors of CRC cells suppressed by ERS, mediated only when it combined with cullin5 (CUL5). ERp29 also relied on CUL5 to promote epithelial-mesenchymal transition. From the immunohistochemical examination of CRC tissues, the high expression of ERp29 was revealed to predict the poor prognosis of 457 CRC cases. The retrospective analysis of the clinicopathological data of patients with CRC was consistent with the results of the in vitro and in vivo experiments. Thus, ERp29 protected CRC cells from ERS-mediated reduction of malignancy to promote metastasis and may be a potential target of medical intervention for CRC therapy.
C1 [Guo, Lili; Ma, Lili; Lei, Yan; Huang, Yingxin; Huang, Guan; Li, Dazhou; Wang, Qi; Liu, Guanglong; Tang, Minshan; Jing, Zhiliang; Deng, Yongjian] Southern Med Univ, Nanfang Hosp, Dept Pathol, 1838 North Guangzhou Rd, Guangzhou 510515, Guangdong, Peoples R China.
   [Guo, Lili; Ma, Lili; Lei, Yan; Huang, Yingxin; Huang, Guan; Li, Dazhou; Wang, Qi; Liu, Guanglong; Tang, Minshan; Jing, Zhiliang; Deng, Yongjian] Southern Med Univ, Sch Basic Med Sci, 1838 North Guangzhou Rd, Guangzhou 510515, Guangdong, Peoples R China.
   [Guo, Lili; Ma, Lili; Lei, Yan; Huang, Yingxin; Huang, Guan; Li, Dazhou; Wang, Qi; Liu, Guanglong; Tang, Minshan; Jing, Zhiliang; Deng, Yongjian] Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.
   [Ma, Lili] Taishan City Peoples Hosp, Dept Cardiothorac Surg, Taishan 529200, Guangdong, Peoples R China.
   [Liu, Chao] Guangdong Gen Hosp, Dept Pathol & Lab Med, Guangzhou 510080, Guangdong, Peoples R China.
   [Liu, Chao] Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China.
   [Tang, Na] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Pathol, Shenzhen 518020, Guangdong, Peoples R China.
RP Deng, YJ (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, 1838 North Guangzhou Rd, Guangzhou 510515, Guangdong, Peoples R China.; Deng, YJ (corresponding author), Southern Med Univ, Sch Basic Med Sci, 1838 North Guangzhou Rd, Guangzhou 510515, Guangdong, Peoples R China.
EM dengyj@smu.edu.cn
FU National Key Research and Development Program of China [2016YFC1201801];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672453, 81372584, 81201970, 81702359];
   Guangdong Provincial Natural Science Foundation of ChinaNational Natural
   Science Foundation of Guangdong Province [2015A030313243,
   2015A030310089, C1051156]; China Postdoctoral Science FoundationChina
   Postdoctoral Science Foundation [2017M622736]; Guangdong Medical Science
   and Technology Research Foundation [A2017403]
FX The present study was supported by the National Key Research and
   Development Program of China (grant no. 2016YFC1201801), the National
   Natural Science Foundation of China (grant nos. 81672453, 81372584,
   81201970 and 81702359), the Guangdong Provincial Natural Science
   Foundation of China (grant nos. 2015A030313243, 2015A030310089 and
   C1051156), the China Postdoctoral Science Foundation (grant no.
   2017M622736) and the Guangdong Medical Science and Technology Research
   Foundation (grant no. A2017403).
CR Araki Kazutaka, 2012, Cold Spring Harb Perspect Biol, V4, pa015438, DOI 10.1101/cshperspect.a015438
   Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320
   Chen SH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14723
   Choi SI, 2016, BIOCHEM BIOPH RES CO, V477, P841, DOI 10.1016/j.bbrc.2016.06.146
   Dandekar A, 2015, METHODS MOL BIOL, V1292, P205, DOI 10.1007/978-1-4939-2522-3_15
   Demmer J, 1997, FEBS LETT, V402, P145, DOI 10.1016/S0014-5793(96)01513-X
   Deng YJ, 2014, CLIN CANCER RES, V20, P3809, DOI 10.1158/1078-0432.CCR-13-1887
   Eletto D, 2010, SEMIN CELL DEV BIOL, V21, P479, DOI 10.1016/j.semcdb.2010.03.004
   Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x
   Gan PP, 2017, CELL PHYSIOL BIOCHEM, V44, P133, DOI 10.1159/000484622
   Gao DM, 2012, LAB INVEST, V92, P200, DOI 10.1038/labinvest.2011.163
   Gao F, 2015, CELL PHYSIOL BIOCHEM, V37, P1547, DOI 10.1159/000438522
   Gao JL, 2016, MOL MED REP, V13, P398, DOI 10.3892/mmr.2015.4527
   Han J, 2013, NAT CELL BIOL, V15, P481, DOI 10.1038/ncb2738
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Hirsch I, 2014, APOPTOSIS, V19, P801, DOI 10.1007/s10495-013-0961-0
   Hotamisligil GS, 2005, DIABETES, V54, pS73, DOI 10.2337/diabetes.54.suppl_2.S73
   Hsiao JR, 2009, CANCER RES, V69, P4461, DOI 10.1158/0008-5472.CAN-09-0277
   Hubbard MJ, 2000, EUR J BIOCHEM, V267, P1945, DOI 10.1046/j.1432-1327.2000.01193.x
   Kim HJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep01142
   Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2
   Krajaejun T, 2018, INT J INFECT DIS, V77, P61, DOI 10.1016/j.ijid.2018.09.006
   Kunkler B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196760
   Lee DG, 2015, J HEPATOL, V63, P1429, DOI 10.1016/j.jhep.2015.08.007
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lubbers J, 2011, CELL BIOL TOXICOL, V27, P95, DOI 10.1007/s10565-010-9173-3
   Lugea A, 2017, GASTROENTEROLOGY, V153, P1674, DOI 10.1053/j.gastro.2017.08.036
   Morishima N, 2002, J BIOL CHEM, V277, P34287, DOI 10.1074/jbc.M204973200
   Nair S, 2007, TOXICOL LETT, V168, P21, DOI 10.1016/j.toxlet.2006.10.012
   Nakagawa H, 2014, CANCER CELL, V26, P331, DOI 10.1016/j.ccr.2014.07.001
   Navid F, 2017, NAT REV RHEUMATOL, V13, P25, DOI 10.1038/nrrheum.2016.192
   Northcott JM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00017
   Oakes SA, 2015, ANNU REV PATHOL-MECH, V10, P173, DOI 10.1146/annurev-pathol-012513-104649
   Preissler S, 2015, ELIFE, V4, DOI 10.7554/eLife.12621
   Qi L, 2012, MED ONCOL, V29, P721, DOI 10.1007/s12032-011-9929-5
   Reiling JH, 2011, P NATL ACAD SCI USA, V108, P11756, DOI 10.1073/pnas.1018098108
   Schaeffer C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175970
   Shnyder SD, 2002, J HISTOCHEM CYTOCHEM, V50, P557, DOI 10.1177/002215540205000413
   Thirunavukarasu P, 2015, JAMA SURG, V150, P747, DOI 10.1001/jamasurg.2015.0871
   Thivolet C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182027
   Wang MX, 2018, CRIT REV ONCOL HEMAT, V127, P66, DOI 10.1016/j.critrevonc.2018.05.003
   Xu XM, 2012, CANCER LETT, V322, P148, DOI 10.1016/j.canlet.2012.02.038
   Yam GHT, 2007, INVEST OPHTH VIS SCI, V48, P1683, DOI 10.1167/iovs.06-0943
   Ye W, 2015, ANTI-CANCER DRUG, V26, P612, DOI 10.1097/CAD.0000000000000225
   Yuan LW, 2013, HEPATOB PANCREAT DIS, V12, P189, DOI 10.1016/S1499-3872(13)60030-2
   Zelenka J, 2018, BIOTECHNOL ADV, V36, P583, DOI 10.1016/j.biotechadv.2018.01.007
   Zeng MC, 2017, TOXICOL LETT, V271, P26, DOI 10.1016/j.toxlet.2017.02.023
   Zhang B, 2008, J RADIAT RES, V49, P587, DOI 10.1269/jrr.08014
   Zhang DH, 2010, EXP CELL RES, V316, P3522, DOI 10.1016/j.yexcr.2010.08.014
   Zhang K, 2016, CLIN TRANSL ONCOL, V18, P352, DOI 10.1007/s12094-015-1331-x
   Zhang YH, 2015, MOL NEUROBIOL, V52, P522, DOI 10.1007/s12035-014-8840-4
   Zhao L, 2007, J CANCER RES CLIN, V133, P771, DOI 10.1007/s00432-007-0222-0
NR 52
TC 6
Z9 7
U1 6
U2 16
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2019
VL 41
IS 3
BP 1603
EP 1615
DI 10.3892/or.2018.6943
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HM5ZB
UT WOS:000459552700015
PM 30569094
OA Green Published, hybrid, Green Submitted
DA 2022-04-25
ER

PT J
AU Bodmer, WF
   Crouch, DJM
AF Bodmer, Walter F.
   Crouch, Daniel J. M.
TI Somatic selection of poorly differentiating variant stem cell clones
   could be a key to human ageing
SO JOURNAL OF THEORETICAL BIOLOGY
LA English
DT Article
DE Ageing; Tissue stem cells; Somatic mutation; Cellular differentiation;
   Natural selection
ID COLONIC CRYPT; CANCER; MUTATIONS; HEMATOPOIESIS; POPULATION; SENESCENCE;
   PRECURSORS; MECHANISM; EVOLUTION; AUTOPHAGY
AB Any replicating system in which heritable variants with differing replicative potentials can arise is subject to a Darwinian evolutionary process. The continually replicating adult tissue stem cells that control the integrity of many tissues of long-lived, multicellular, complex vertebrate organisms, including humans, constitute such a replicating system. Our suggestion is that somatic selection for mutations (or stable epigenetic changes) that cause an increased rate of adult tissue stem cell proliferation, and their long-term persistence, at the expense of normal differentiation, is a major key to the ageing process. Once an organism has passed the reproductive age, there is no longer any significant counterselection at the organismal level to this inevitable cellular level Darwinian process. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Bodmer, Walter F.] Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Dept Oncol,Canc & Immunogenet Lab, Oxford, England.
   [Crouch, Daniel J. M.] Univ Oxford, JDRF Wellcome Trust Diabet & Inflammat Lab, Wellcome Ctr Human Genet, Old Rd Campus, Oxford, England.
RP Bodmer, WF (corresponding author), Univ Oxford, Weatherall Inst Mol Med, John Radcliffe Hosp, Dept Oncol,Canc & Immunogenet Lab, Oxford, England.
EM walter.bodmer@hertford.ox.ac.uk; daniel.crouch@well.ox.ac.uk
FU JDRFJuvenile Diabetes Research Foundation [5-SRA-2015-130-A-N]; Wellcome
   TrustWellcome TrustEuropean Commission [107212/Z/15/Z, 203131/Z/16/Z]
FX This work was supported by JDRF Grant 5-SRA-2015-130-A-N and Wellcome
   Trust Grants 107212/Z/15/Z and 203131/Z/16/Z.
CR Beerman I, 2010, P NATL ACAD SCI USA, V107, P5465, DOI 10.1073/pnas.1000834107
   Benz C, 2012, CELL STEM CELL, V10, P273, DOI 10.1016/j.stem.2012.02.007
   Biteau B, 2008, CELL STEM CELL, V3, P442, DOI 10.1016/j.stem.2008.07.024
   Bodmer W, 1997, J ROY COLL PHYS LOND, V31, P82
   Bodmer W, 2008, CANCER RES, V68, P3558, DOI 10.1158/0008-5472.CAN-07-6544
   Boyette LB, 2014, J CLIN MED, V3, P88, DOI 10.3390/jcm3010088
   Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965
   Buscarlet M, 2017, BLOOD, V130, P753, DOI 10.1182/blood-2017-04-777029
   Cavalli-Sforza LL, 1971, SERIES BIOL BOOKS, p965 xvi
   Cavalli-Sforza LL, 1999, GENETICS HUMAN POPUL, p965 xvii
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591
   Cho RH, 2008, BLOOD, V111, P5553, DOI 10.1182/blood-2007-11-123547
   Fisher R. A., 1930, GENETICAL THEORY NAT, P272
   Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020
   Genovese G, 2014, NEW ENGL J MED, V371, P2477, DOI 10.1056/NEJMoa1409405
   Goodell MA, 2015, SCIENCE, V350, P1199, DOI 10.1126/science.aab3388
   HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]
   Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617
   JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0
   Johnston MD, 2007, P NATL ACAD SCI USA, V104, P4008, DOI 10.1073/pnas.0611179104
   Johnston MD, 2007, CELL CYCLE, V6, P2106, DOI 10.4161/cc.6.17.4649
   Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025
   Kirkwood TBL, 2005, CELL, V120, P437, DOI 10.1016/j.cell.2005.01.027
   Kwon Y, 2017, MOL CELLS, V40, P607, DOI 10.14348/molcells.2017.0151
   Lopez-Otin C, 2013, CELL, V153, P1194, DOI 10.1016/j.cell.2013.05.039
   Maher GJ, 2014, ANDROLOGY-US, V2, P304, DOI 10.1111/j.2047-2927.2013.00175.x
   Maher GJ, 2016, P NATL ACAD SCI USA, V113, P2454, DOI 10.1073/pnas.1521325113
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Martin K, 1998, EXP CELL RES, V241, P316, DOI 10.1006/excr.1998.4001
   Martin K, 1998, J CELL SCI, V111, P2297
   Martincorena I, 2016, SCIENCE, V353, P132
   Martincorena I, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0648-4
   Medawar P.B., 1951, LECT U COLL LOND 6 D
   Morrison SJ, 1996, NAT MED, V2, P1011, DOI 10.1038/nm0996-1011
   Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823
   Nicholson AM, 2018, CELL STEM CELL, V22, P909, DOI 10.1016/j.stem.2018.04.020
   Novelli MR, 1996, SCIENCE, V272, P1187, DOI 10.1126/science.272.5265.1187
   PIGNATELLI M, 1992, INT J CANCER, V50, P683, DOI 10.1002/ijc.2910500503
   Ren ZP, 1996, ONCOGENE, V12, P765
   Risques RA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007108
   Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036
   Roth S, 2011, CELL COMMUN ADHES, V18, P33, DOI 10.3109/15419061.2011.615422
   Signer RAJ, 2013, CELL STEM CELL, V12, P152, DOI 10.1016/j.stem.2013.01.001
   Slack C, 2016, CELL CYCLE, V15, P153, DOI 10.1080/15384101.2015.1118905
   Su TH, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040182
   Sun DQ, 2014, CELL STEM CELL, V14, P673, DOI 10.1016/j.stem.2014.03.002
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687
   TOMLINSON IPM, 1995, P NATL ACAD SCI USA, V92, P11130, DOI 10.1073/pnas.92.24.11130
   Weissman IL, 2015, P NATL ACAD SCI USA, V112, P8922, DOI 10.1073/pnas.1505464112
   WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x
   Wright NA, 2000, INT J EXP PATHOL, V81, P117, DOI 10.1046/j.1365-2613.2000.00146.x
   Xie MC, 2014, NAT MED, V20, P1472, DOI 10.1038/nm.3733
   Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109
NR 55
TC 0
Z9 0
U1 0
U2 9
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-5193
EI 1095-8541
J9 J THEOR BIOL
JI J. Theor. Biol.
PD MAR 21
PY 2020
VL 489
AR 110153
DI 10.1016/j.jtbi.2020.110153
PG 10
WC Biology; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Mathematical & Computational
   Biology
GA KL2ZB
UT WOS:000513296000007
PM 31935413
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Subasi, E
   Atalay, EB
   Erdogan, D
   Sen, B
   Pakyapan, B
   Kayali, HA
AF Subasi, Elif
   Atalay, Esra Bulut
   Erdogan, Duygu
   Sen, Betill
   Pakyapan, Bilge
   Kayali, Hulya Ayar
TI Synthesis and characterization of thiosemicarbazone-functionalized
   organoruthenium (II)-arene complexes: Investigation of antitumor
   characteristics in colorectal cancer cell lines
SO MATERIALS SCIENCE & ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS
LA English
DT Article
DE Organoruthenium (II)-arene complexes; Thiosemicarbazone; Antitumor
   activity; Colorectal cancer cell lines; Crystal structure
ID CRYSTAL-STRUCTURE; DNA-BINDING; RUTHENIUM; MEDICINE
AB In the current study, organoruthenium(II)-arene complexes (I-IV) have been prepared by the reaction of ({(eta(6)-pcym)RuCl}(2)(mu-Cl)(2)] with new thiosemicarbazones (TSC1-4).The isolate was analyzed using elemental analysis, FT-IR, H-1 and C-13 NMR spectroscopy and single-crystal XRD. Subsequently, the complexes and TSC ligands were assessed for anticancer properties in vitro against three different colorectal cancer stage's cell lines (Caco-2, DLD-1, and SW620) and a noncancerous cell line (CCD18Co). The complexes (I-IV) showed higher cytotoxicity with low IC50 values as 0.1-0.33 mu M in colorectal cell lines except for SW620 (47.4-84.20 mu M) than in a noncancerous cell. Complex I was 2.8 and 24.5-fold more active against Caco-2 and DLD-1 than CCD18Co, respectively. The complexes (I-IV) accumulated at a high concentration in the cell nuclei and caused cell cycle arrest by affecting the G0/G1 and/or G2/M phase and showed high binding affinity with CT-DNA (Kb = 10(4) M-1). The expression of Caspase-3 and Caspase-9 apoptosis-related protein levels was slightly upregulated and Atg5 autophagy-related protein level was clearly downregulated according to control and 5-FU-treated cells after complex I and II treatment. Furthermore, it was observed that cytotoxicity of the complexes is decreased while cancer progresses. Altogether, this study indicates that all organoruthenium (II)-arene complexes (particularly complex I) can be a promising alternative to platinum counterparts in cancer treatment.
C1 [Subasi, Elif] Dokuz Eylul Univ, Fac Sci, Dept Chem, TR-35160 Izmir, Turkey.
   [Atalay, Esra Bulut; Erdogan, Duygu] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst, TR-35340 Izmir, Turkey.
   [Sen, Betill] Dokuz Eylul Univ, Fac Sci, Dept Phys, TR-35160 Izmir, Turkey.
   [Pakyapan, Bilge] Ege Univ, Inst Sci & Technol, TR-35100 Izmir, Turkey.
   [Kayali, Hulya Ayar] Izmir Biomed & Genome Ctr, TR-35340 Izmir, Turkey.
   [Kayali, Hulya Ayar] Dokuz Eylul Univ, Fac Sci, Div Biochem, Dept Chem, TR-35160 Izmir, Turkey.
RP Subasi, E; Kayali, HA (corresponding author), Dokuz Eylul Univ, Fac Sci, Dept Chem, TR-35160 Izmir, Turkey.
EM elif.subasi@deu.edu.tr; hulya.ayarkayali@gmail.com
OI Erdogan, Duygu/0000-0002-4930-7017
FU TUBITAK (The Scientific and Technological Research Council of
   Turkey)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)
   [215Z663]; Dokuz Eylul UniversityDokuz Eylul University [2010.KB.FEN.13]
FX This study was financed by project number 215Z663 TUBITAK (The
   Scientific and Technological Research Council of Turkey). The authors
   acknowledge Dokuz Eylul University for the use of the Oxford Rigaku
   Xcalibur Eos Diffractometer (purchased under University Research Grant
   No: 2010.KB.FEN.13) and Izmir Biomedicine and Genome Center. We also
   gratefully thank Zehra Taysan for her help in vitro part.
CR Ali KA, 2013, INT J MED CHEM, V2013, DOI 10.1155/2013/256836
   Allardyce CS, 2001, PLATIN MET REV, V45, P62
   Allardyce CS, 2005, APPL ORGANOMET CHEM, V19, P1, DOI 10.1002/aoc.725
   [Anonymous], 2014, CRYSALISPRO SOFTW SY
   Armarego WLF., 2017, PURIFICATION LAB CHE, P1, DOI [10.1016/s0022-328x(00)82974-5, DOI 10.1016/S0022-328X(00)82974-5]
   Beraldo H, 2002, TRANSIT METAL CHEM, V27, P85, DOI 10.1023/A:1013441400773
   Bergamo A, 2012, J INORG BIOCHEM, V106, P90, DOI 10.1016/j.jinorgbio.2011.09.030
   BERNSTEIN J, 1995, ANGEW CHEM INT EDIT, V34, P1555, DOI 10.1002/anie.199515551
   Bohme U, 2007, CHEM PHYS LETT, V435, P342, DOI 10.1016/j.cplett.2006.12.068
   Brabec V, 2006, DRUG RESIST UPDATE, V9, P111, DOI 10.1016/j.drup.2006.05.002
   Carballo R, 2014, ACTA CRYSTALLOGR E, V70, pO970, DOI 10.1107/S1600536814017255
   Carethers John M, 2008, Therap Adv Gastroenterol, V1, P33, DOI 10.1177/1756283X08093607
   Dale SH, 2006, ACTA CRYSTALLOGR C, V62, pM166, DOI 10.1107/S0108270106007487
   de Carvalho NC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0104-6
   Dincer M, 2006, ACTA CRYSTALLOGR A, V62, pS293, DOI 10.1107/S0108767306094153
   Dolomanov OV, 2009, J APPL CRYSTALLOGR, V42, P339, DOI 10.1107/S0021889808042726
   Farrugia LJ, 2012, J APPL CRYSTALLOGR, V45, P849, DOI 10.1107/S0021889812029111
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Gatti A, 2018, ORGANOMETALLICS, V37, P891, DOI 10.1021/acs.organomet.7b00875
   Gaye PA, 2011, ACTA CRYSTALLOGR E, V67, pO1168, DOI 10.1107/S1600536811011986
   Gundogdu C, 2011, ACTA CRYSTALLOGR E, V67, pO1321, DOI 10.1107/S1600536811016151
   Haghdoost M.M., 2017, EUR J MED CHEM, DOI [10.1016/j.ejmech.2017.03, DOI 10.1016/J.EJMECH.2017.03]
   Hessler JA, 2005, LANGMUIR, V21, P9280, DOI 10.1021/la051837g
   Irace C, 2017, SCI REP-UK, V7, DOI 10.1038/srep45236
   Jayabalakrishnan C, 2002, TRANSIT METAL CHEM, V27, P790, DOI 10.1023/A:1020341703855
   Kathiravan A, 2009, J MOL STRUCT, V919, P210, DOI 10.1016/j.molstruc.2008.09.005
   Kimani SG, 2017, SCI REP-UK, V7, DOI 10.1038/srep43908
   Kumbhar A, 1997, J CHEM CRYSTALLOGR, V27, P533
   LAKOWICZ JR, 1991, REV SCI INSTRUM, V62, P1727, DOI 10.1063/1.1142413
   Latheef L, 2006, ACTA CRYSTALLOGR C, V62, pO16, DOI 10.1107/S010827010503564X
   Leijen S, 2015, INVEST NEW DRUG, V33, P201, DOI 10.1007/s10637-014-0179-1
   Lentz F, 2009, ANTI-CANCER DRUG, V20, P97, DOI 10.1097/CAD.0b013e328322fbc5
   Licona C, 2017, ONCOTARGET, V8, P2568, DOI 10.18632/oncotarget.13711
   Liu YC, 2013, EUR J MED CHEM, V69, P554, DOI 10.1016/j.ejmech.2013.08.033
   Morais T.S., 2012, J INORG BIOCHEM, DOI [10.1016/jjinorgbio.2012.04.014, DOI 10.1016/JJINORGBIO.2012.04.014]
   Oelkers B, 2011, ACTA CRYSTALLOGR E, V67, pM319, DOI 10.1107/S160053681100314X
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Prasath R, 2010, ACTA CRYSTALLOGR E, V66, pO2883, DOI 10.1107/S160053681004167X
   Reddy KL, 2009, NUCLEOS NUCLEOT NUCL, V28, P953, DOI 10.1080/15257770903307060
   Romero-Canelon I, 2013, J MED CHEM, V56, P1291, DOI 10.1021/jm3017442
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Sheldrick GM, 2015, ACTA CRYSTALLOGR C, V71, P3, DOI 10.1107/S2053229614024218
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Singh S, 2006, EUR J MED CHEM, V41, P592, DOI 10.1016/j.ejmech.2006.01.014
   Soleimannejad J, 2005, ACTA CRYSTALLOGR C, V61, pM125, DOI 10.1107/S0108270104033815
   Spek AL, 2003, J APPL CRYSTALLOGR, V36, P7, DOI 10.1107/S0021889802022112
   Spreckelmeyer S, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00377
   Su W, 2018, APPL ORGANOMET CHEM, V32, DOI 10.1002/aoc.4420
   Su W, 2015, J ORGANOMET CHEM, V783, P10, DOI 10.1016/j.jorganchem.2014.12.041
   Sultan S, 2014, ACTA CRYSTALLOGR E, V70, P0751, DOI 10.1107/S1600536814011568
   Sykora RE, 2011, ACTA CRYSTALLOGR E, V67, pM99, DOI 10.1107/S1600536810051962
   Tarafder MTH, 2008, ACTA CRYSTALLOGR E, V64, pO988, DOI 10.1107/S1600536808012671
   TARNOWSKI BI, 1991, BIOTECH HISTOCHEM, V66, P296, DOI 10.3109/10520299109109990
   Tavsan Z, 2018, J BIOL INORG CHEM, V23, P425, DOI 10.1007/s00775-018-1549-5
   Therrien B, 2009, COORDIN CHEM REV, V253, P493, DOI 10.1016/j.ccr.2008.04.014
   Thota S, 2015, CHINESE CHEM LETT, V26, P721, DOI 10.1016/j.cclet.2015.03.011
   TRINAJSTIC N, 1968, TETRAHEDRON LETT, P1529
   Weiss A, 2014, CHEM SCI, V5, P4742, DOI 10.1039/c4sc01255k
   West DX, 1999, POLYHEDRON, V18, P2919, DOI 10.1016/S0277-5387(99)00210-7
   WOLFE A, 1987, BIOCHEMISTRY-US, V26, P6392, DOI 10.1021/bi00394a013
   Yaman PK, 2017, J ORGANOMET CHEM, V832, P27, DOI 10.1016/j.jorganchem.2017.01.013
   Yan YK, 2005, CHEM COMMUN, P4764, DOI 10.1039/b508531b
   Yao WR, 2003, ACTA CRYSTALLOGR C, V59, pM156, DOI 10.1107/S0108270103005808
   Zheng CG, 2011, CHEM BIODIVERS, V8, P1486, DOI 10.1002/cbdv.201000336
NR 64
TC 7
Z9 7
U1 2
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-4931
EI 1873-0191
J9 MAT SCI ENG C-MATER
JI Mater. Sci. Eng. C-Mater. Biol. Appl.
PD JAN
PY 2020
VL 106
AR 110152
DI 10.1016/j.msec.2019.110152
PG 15
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA JU3ZA
UT WOS:000501616000021
PM 31753399
DA 2022-04-25
ER

PT J
AU Lu, M
   Sun, LHR
   Zhou, J
   Zhao, Y
   Deng, X
AF Lu, Min
   Sun, Luhaoran
   Zhou, Jin
   Zhao, Yan
   Deng, Xin
TI Dihydroartemisinin-Induced Apoptosis is Associated with Inhibition of
   Sarco/Endoplasmic Reticulum Calcium ATPase Activity in Colorectal Cancer
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Colorectal cancer; Dihydroartemisinin; Endoplasmic reticulum stress;
   Mitochondrial apoptosis pathway; Sarco/endoplasmic reticulum calcium
   ATPase
ID ENDOPLASMIC-RETICULUM; IN-VITRO; STRESS; CELLS; MITOCHONDRIA;
   EXPRESSION; AUTOPHAGY; CA2+
AB Dihydroartemisinin (DHA) is a promising anti-cancer compound capable of inhibiting proliferation and inducing apoptosis of various cancer cells, including colorectal cancer. However, the molecular mechanisms have not been well understood. This study aimed to explore the underlying mechanism of DHA-induced apoptosis in HCT-116 cells. Cell counting kit-8 assay and flow cytometry analysis confirmed that DHA inhibited proliferation, arrested cell cycle at G0/G1 phase, and enhanced apoptosis in HCT-116 cells. Fluo-3/AM-stained flow cytometry assay revealed that the intracellular Ca2+ concentration of HCT-116 cells was increased significantly after DHA treatment. Meanwhile, the activity of sarco/endoplasmic reticulum calcium ATPase (SERCA) was appeared to be reduced in a dose-dependent manner. We further detected the upregulated expression of CAAT/enhancer binding protein homologous protein (CHOP) in DHA-treated HCT-116 cells. Conversely, silencing CHOP resulted in a decrease of DHA-induced apoptosis. In addition, the expression of Bax in cytoplasm was elevated significantly along with the sharply decline of Bcl-2 expression in DHA-treated HCT-116 cells. Moreover, the distributions of Bid on mitochondria were increased, accompanied by the activation of caspase-3 in the presence of DHA. Overall, our data indicated that DHA triggered endoplasmic reticulum (ER) stress through inhibiting SERCA activity to release intracellular Ca2+ from ER, the upregulated expression of CHOP activated mitochondrial apoptosis pathway to induce apoptosis of HCT-116 cells. Therefore, our findings provide a theoretical foundation for DHA as a potential candidate in treatment of colorectal cancer.
C1 [Lu, Min; Zhou, Jin] China Med Univ, Affiliated Hosp 1, Dept Colorectal Surg, Shenyang 110001, Peoples R China.
   [Sun, Luhaoran] China Med Univ, Dept Clin Med, Year Syst 7, Shenyang 110001, Peoples R China.
   [Zhao, Yan] China Med Univ, Sch Pharm, Dept Pharmaceut, Shenyang 110013, Peoples R China.
   [Deng, Xin] China Med Univ, Coll Basic Med Sci, Expt Ctr Funct Subjects, Shenyang 110013, Peoples R China.
RP Lu, M (corresponding author), China Med Univ, Affiliated Hosp 1, Dept Colorectal Surg, 155 North Nanjing St, Shenyang 110001, Peoples R China.
EM minlu1@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81250020]
FX This study was supported by a Grant from the National Natural Science
   Foundation of China (Grant No.: 81250020).
CR Chen H, 2010, J CANCER RES CLIN, V136, P897, DOI 10.1007/s00432-009-0731-0
   Chen Hua, 2009, Zhonghua Wai Ke Za Zhi, V47, P1002
   Chen T, 2009, J CELL MOL MED, V13, P1358, DOI 10.1111/j.1582-4934.2008.00360.x
   Cross AJ, 2014, CANCER-AM CANCER SOC, V120, P3049, DOI 10.1002/cncr.28799
   Dolai S, 2011, J BIOL CHEM, V286, P13638, DOI 10.1074/jbc.M110.201889
   Du XX, 2013, BIOMED PHARMACOTHER, V67, P417, DOI 10.1016/j.biopha.2013.01.013
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao XL, 2011, TUMORI, V97, P771, DOI 10.1700/1018.11095
   Guerrero-Hernandez A, 2014, CELL CALCIUM, V56, P311, DOI 10.1016/j.ceca.2014.08.006
   Guerrero-Hernandez A, 2010, CELL CALCIUM, V48, P143, DOI 10.1016/j.ceca.2010.08.001
   Jiao Y, 2007, ACTA PHARMACOL SIN, V28, P1045, DOI 10.1111/j.1745-7254.2007.00612.x
   Ju YT, 2015, J CELL BIOCHEM, V116, P277, DOI 10.1002/jcb.24966
   Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Lan YT, 2014, AM J SURG, V207, P922, DOI 10.1016/j.amjsurg.2013.08.035
   Lu JJ, 2011, INVEST NEW DRUG, V29, P1276, DOI 10.1007/s10637-010-9481-8
   Lu M, 2014, TUMOR BIOL, V35, P5307, DOI 10.1007/s13277-014-1691-9
   Markan S, 2009, MOL CELL BIOCHEM, V324, P131, DOI 10.1007/s11010-008-9991-2
   McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001
   Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Ontikatze T, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00116
   Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683
   Paraskevas GP, 1997, ACTA NEUROL SCAND, V96, P88
   Quick QA, 2012, EXP THER MED, V3, P487, DOI 10.3892/etm.2011.422
   Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208
   Shi JM, 2013, BIOCHEM PHARMACOL, V85, P913, DOI 10.1016/j.bcp.2013.01.009
   Sun HJ, 2013, TUMOR BIOL, V34, P3791, DOI 10.1007/s13277-013-0963-0
   Sun SX, 2012, BIOSCIENCE REP, V32, P83, DOI 10.1042/BSR20110062
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Uhlemann AC, 2005, NAT STRUCT MOL BIOL, V12, P628, DOI 10.1038/nsmb947
   Wang GL, 2005, J BIOL CHEM, V280, P26508, DOI 10.1074/jbc.M503789200
   Woo KJ, 2007, BIOCHEM PHARMACOL, V73, P68, DOI 10.1016/j.bcp.2006.09.015
   Wu BC, 2012, ONCOL REP, V27, P101, DOI 10.3892/or.2011.1505
   Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761
   Zhang CZ, 2012, BIOCHEM PHARMACOL, V83, P1278, DOI 10.1016/j.bcp.2012.02.002
NR 36
TC 15
Z9 17
U1 3
U2 22
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
EI 1559-0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD SEP
PY 2015
VL 73
IS 1
BP 137
EP 145
DI 10.1007/s12013-015-0643-3
PG 9
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CP3WD
UT WOS:000359812500023
PM 25701954
DA 2022-04-25
ER

PT J
AU Ayan, IC
   Cetinkaya, S
   Dursun, HG
   Suntar, I
AF Ayan, Ilknur Cnar
   Cetinkaya, Sumeyra
   Dursun, Hatice Gul
   Suntar, Ipek
TI Bioactive Compounds of Rheum ribes L. and its Anticancerogenic Effect
   via Induction of Apoptosis and miR-200 Family Expression in Human
   Colorectal Cancer Cells
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID ANTIOXIDANT ACTIVITY; MICRORNA-200 FAMILY; IN-VITRO; PROLIFERATION;
   CYTOTOXICITY; COMBINATION; AUTOPHAGY; EXTRACTS; PROMOTES; TARGETS
AB Rheum ribes L. is a widespread plant species in the eastern part of our country and is consumed as a vegateble by the folk people. In our study, we investigated whether R. ribeshas anti-cancerogenic effect on colorectal cancer cell lines. Six different extracts were obtained from R. ribes. Total phenolic, flavonoid contents, antioxidant activities, and cytotoxic effects of all extracts on colorectal cancer cells were determined. Differences in expression levels of the miR-200 family and target genes were assessed by real-time qPCR in cells. Antiproliferative effect was determined by TUNEL, Annexin V, cell cycle, invasion analysis; and levels of BCL-2, ZEB1, GATA4 and FAS/CD95 proteins were determined by ELISA. According to the results of miRNA expression analysis, the only dose group with a significant increase (p < 0,05) in the expression level of all of miRNAs in both cell lines was RM (Root methanol) extract alone. Our results showed that, RM caused a significant increase in the expressions of miR-200a/b/c and miR-141, and it suppressed BCL-2, ZEB1, GATA4 expressions, with this way. Thus, it has been suggested that the treatment of RM alone, or combined treatment of RM with 5-FU result in a better response than cancer cells treated with 5-FU alone.
C1 [Ayan, Ilknur Cnar; Dursun, Hatice Gul] Necmettin Erbakan Univ, Med Fac, Dept Med Biol, Konya, Turkey.
   [Cetinkaya, Sumeyra] Minist Agr & Forestry, Biotechnol Res Ctr, Ankara, Turkey.
   [Suntar, Ipek] Gazi Univ, Dept Pharmacognosy, Fac Pharm, Ankara, Turkey.
RP Ayan, IC (corresponding author), Necmettin Erbakan Univ, Dept Med Biol, Med Fac, TR-42090 Meram, Konya, Turkey.
EM ilknurcinar@msn.com
RI cetinkaya, sumeyra/ABG-9815-2020
FU scientific research projects foundation of Necmettin Erbakan university
   [161418001]
FX This work was supported by scientific research projects foundation of
   Necmettin Erbakan university (Grant number: 161418001).
CR Abdulla K. K., 2014, Der Pharmacia Lettre, V6, P201
   Abu-Irmaileh BE, 2003, J ETHNOPHARMACOL, V89, P193, DOI 10.1016/S0378-8741(03)00283-6
   Ahmed M., 2013, OPEN ACCESS SCI REPO, V2, P00641, DOI DOI 10.2174/1381612826666200515132218
   Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   CHEN H, 2013, SCI WORLD J, V2013, DOI DOI 10.1155/2013/269165
   Chen Q, 2015, ONCOL REP, V33, P840, DOI 10.3892/or.2014.3626
   Chen Y, 2017, EXP THER MED, V14, P10, DOI 10.3892/etm.2017.4488
   Choi EJ, 2007, LIFE SCI, V80, P1403, DOI 10.1016/j.lfs.2006.12.031
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Esmaeilbeig M, 2015, IRAN J CANCER PREV, V8, DOI 10.17795/ijcp-4032
   Gao JH, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0595-y
   Han SE, 2019, IN VIVO, V33, P375, DOI 10.21873/invivo.11484
   Iscan M., 2014, J PLANT SCI, V2, P339, DOI DOI 10.11648/j.jps.20140206.22
   Jain D, 2011, INT J TOXICOL, V30, P225, DOI 10.1177/1091581810390527
   Keser S, 2020, NAT PROD RES, V34, P3353, DOI 10.1080/14786419.2018.1560294
   Kim DJ, 2017, CARCINOGENESIS, V38, P1136, DOI 10.1093/carcin/bgx082
   Lambert JD, 2005, AM J CLIN NUTR, V81, p284S, DOI 10.1093/ajcn/81.1.284S
   Lee JJ, 2016, CANCER CHEMOTH PHARM, V78, P447, DOI 10.1007/s00280-016-3054-2
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lu ZL, 2016, CURR CANCER DRUG TAR, V16, P455, DOI 10.2174/1568009616666151207105720
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   MERICLI A H, 1990, Fitoterapia, V61, P375
   Ozturk M, 2007, FOOD CHEM, V103, P623, DOI 10.1016/j.foodchem.2006.09.005
   Sardari S, 2009, TOXICOL IN VITRO, V23, P1412, DOI 10.1016/j.tiv.2009.07.011
   Saunders IT, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0820-3
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song WT, 2014, ACTA BIOMATER, V10, P1392, DOI 10.1016/j.actbio.2013.11.026
   Uhlmann S, 2010, ONCOGENE, V29, P4297, DOI 10.1038/onc.2010.201
   Wan L, 2017, MOL MED REP, V16, P5759, DOI 10.3892/mmr.2017.7379
   Wang HX, 2017, ONCOL REP, V38, P703, DOI 10.3892/or.2017.5767
   Weidner C, 2015, PHYTOMEDICINE, V22, P262, DOI 10.1016/j.phymed.2014.12.008
   Yang CJ, 2009, LUNG CANCER, V66, P162, DOI 10.1016/j.lungcan.2009.01.016
   Yao YY, 2019, ONCOL REP, V42, P131, DOI 10.3892/or.2019.7136
   Yildirim I., 2015, Pakistan Journal of Biological Sciences, V18, P232, DOI 10.3923/pjbs.2015.232.239
   Zhang RJ, 2019, ONCOTARGETS THER, V12, P4109, DOI 10.2147/OTT.S195615
   Zhu W, 2012, CANCER CHEMOTH PHARM, V69, P723, DOI 10.1007/s00280-011-1752-3
NR 37
TC 3
Z9 3
U1 3
U2 5
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PD JUN 10
PY 2021
VL 73
IS 7
BP 1228
EP 1243
DI 10.1080/01635581.2020.1792947
EA JUL 2020
PG 16
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA SO3SE
UT WOS:000550551300001
PM 32691634
DA 2022-04-25
ER

PT J
AU Akhtar, MF
   Saleem, A
   Rasul, A
   Baig, MMFA
   Bin-Jumah, M
   Daim, MMA
AF Akhtar, Muhammad Furqan
   Saleem, Ammara
   Rasul, Azhar
   Baig, Mirza Muhammad Faran Ashraf
   Bin-Jumah, May
   Daim, Mohamed M. Abdel
TI Anticancer natural medicines: An overview of cell signaling and other
   targets of anticancer phytochemicals
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Apoptosis; Autophagy; Cell cycle; mTOR pathway; Angiogenesis;
   Epigenetics
ID EPITHELIAL-MESENCHYMAL TRANSITION; IN-VITRO; CANCER-CELLS;
   COLORECTAL-CANCER; OXIDATIVE STRESS; DIHYDROFOLATE-REDUCTASE;
   ANTIMUTAGENIC ACTIVITY; INDUCED APOPTOSIS; DNA METHYLATION;
   GENE-EXPRESSION
AB Therapies of cancer are as diverse as multifaceted the cancer is. Anticancer drugs include, but not limited to synthetic, semisynthetic and natural drugs and monoclonal antibodies. A recent decline in new drug development has led to the rebirth of herbal therapeutics in the form of dietary supplements and botanical preparations. Medicinal plants comprise of complex phytochemicals due to vast biosynthetic capacity. A wide array of phytochemicals has been pharmacologically evaluated for their chemo-preventive and chemotherapeutic potential for several decades. These phytochemicals target cancer at diverse sites such as apoptotic pathways, genetic and epigenetic mutations, damage to deoxyribonucleic acid, production of reactive oxygen species, autophagy, invasion and metastasis of cancer cells, and modulation of cell signaling through Janus-activated kinase/Signal transducer and activator of transcription, Notch, mitogen-activated protein kinase/Extracellular signal-regulated kinase, phosphatidylinositol 3-kinase/Protein kinase B/mammalian target of rapamycin, Nuclear factor kappa B, Wingless-related integration site and Transforming growth factor beta pathways. This review focuses on the therapeutic targets of anticancer and chemo-preventive phytochemicals and their mode of action.
C1 [Akhtar, Muhammad Furqan] Riphah Int Univ, Riphah Inst Pharmaceut Sci, Lahore Campus, Lahore, Pakistan.
   [Saleem, Ammara] Govt Coll Univ Faisalabad, Fac Pharmaceut Sci, Dept Pharmacol, Faisalabad, Pakistan.
   [Rasul, Azhar] Govt Coll Univ Faisalabad, Dept Zool, Faisalabad, Pakistan.
   [Baig, Mirza Muhammad Faran Ashraf] Nanjing Univ, Sch Chem & Chem Engn, Nanjing, Peoples R China.
   [Bin-Jumah, May] Princess Nourah Bint Abdulrahman Univ, Coll Sci, Biol Dept, Riyadh, Saudi Arabia.
   [Daim, Mohamed M. Abdel] King Saud Univ, Coll Sci, Dept Zool, Riyadh 11451, Saudi Arabia.
   [Daim, Mohamed M. Abdel] Suez Canal Univ, Fac Vet Med, Pharmacol Dept, Ismailia 41522, Egypt.
RP Akhtar, MF (corresponding author), Riphah Int Univ, Riphah Inst Pharmaceut Sci, Lahore Campus, Lahore, Pakistan.
EM furqan.pharmacist@gmail.com
RI Saleem, Ammara/AAD-3227-2022; Bin-Jumah, May Nasser/I-1646-2018; Akhtar,
   Muhammad Furqan/O-8793-2019; Baig, Mirza Muhammad Faran
   Ashraf/N-8128-2014; Abdel-Daim, Mohamed M./B-2545-2013; Akhtar, Muhmmmad
   Furqan/T-8811-2017; Rasul, Azhar/AAF-5253-2021; Akhtar, Muhammad
   Furqan/ABI-7498-2020
OI Bin-Jumah, May Nasser/0000-0002-3017-9924; Akhtar, Muhammad
   Furqan/0000-0002-2407-1503; Baig, Mirza Muhammad Faran
   Ashraf/0000-0003-4791-9594; Abdel-Daim, Mohamed M./0000-0002-4341-2713;
   Akhtar, Muhmmmad Furqan/0000-0002-2407-1503; Rasul,
   Azhar/0000-0001-9669-7364; Akhtar, Muhammad Furqan/0000-0003-2270-6242
FU Deanship of Scientific Research at Princess Nourah bint Abdulrahman
   University through the Fast-track Research Funding Program
FX This research was funded by the Deanship of Scientific Research at
   Princess Nourah bint Abdulrahman University through the Fast-track
   Research Funding Program.
CR Abraham SK, 2007, MOL NUTR FOOD RES, V51, P880, DOI 10.1002/mnfr.200600214
   Ahmed K, 2019, ONCOL LETT, V18, P487, DOI 10.3892/ol.2019.10349
   Akhtar B., 2017, CRIT REV EUKAR GENE, V27, P1
   Amado NG, 2014, INT J MOL SCI, V15, P12094, DOI 10.3390/ijms150712094
   Ambasta RK, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0665-z
   An S, 2015, CRIT REV BIOCHEM MOL, V50, P520, DOI 10.3109/10409238.2015.1102858
   Anand J.R., 2013, BIOMED PREV NUTR, V3, P107, DOI DOI 10.1016/J.BIONUT.2012.11.004
   Angsutararux P, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/795602
   Aqil F, 2012, FOOD RES INT, V49, P345, DOI 10.1016/j.foodres.2012.07.059
   Aviello G, 2010, J CELL MOL MED, V14, P2006, DOI 10.1111/j.1582-4934.2009.00815.x
   Ayyad SEN, 2012, ENVIRON TOXICOL PHAR, V33, P245, DOI 10.1016/j.etap.2011.12.010
   Bauer D, 2017, PLOS ONE, V12, P1
   Bauer TM, 2015, PHARMACOL THERAPEUT, V146, P53, DOI 10.1016/j.pharmthera.2014.09.006
   Behbahani M., 2015, PLOS ONE, V9, P1
   Granado-Serrano AB, 2006, J NUTR, V136, P2715, DOI 10.1093/jn/136.11.2715
   Bennett RL, 2018, ANNU REV PHARMACOL, V58, P187, DOI 10.1146/annurev-pharmtox-010716-105106
   Birosova Lucia, 2005, Biomedical Papers (Olomouc), V149, P489
   Biswas S, 2017, PHARMACOL THERAPEUT, V173, P118, DOI 10.1016/j.pharmthera.2017.02.011
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Bridgeman BB, 2016, CELL SIGNAL, V28, P460, DOI 10.1016/j.cellsig.2016.02.008
   Bunz F., 2008, PRINCIPLES CANC GENE, P173, DOI DOI 10.1007/978-1-4020-6784-6_5
   Cai J, 2009, J CELL MOL MED, V13, P909, DOI 10.1111/j.1582-4934.2008.00620.x
   Chakraborty D, 2012, EUR J PHARMACOL, V694, P20, DOI 10.1016/j.ejphar.2012.08.001
   CHEN J, 2016, COLD SPRING HARB PER, V6, P1
   Chen JH, 2017, ONCOTARGET, V8, P9961, DOI 10.18632/oncotarget.14283
   Choi Eun Jeong, 2008, Nutr Res Pract, V2, P322, DOI 10.4162/nrp.2008.2.4.322
   Choudhari SK, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-118
   Chow JM, 2005, BIOCHEM PHARMACOL, V69, P1839, DOI 10.1016/j.bcp.2005.03.017
   Chu SC, 2014, MOL PHARMACOL, V86, P609, DOI 10.1124/mol.114.094037
   Damianaki A, 2000, J CELL BIOCHEM, V78, P429, DOI 10.1002/1097-4644(20000901)78:3<429::AID-JCB8>3.0.CO;2-M
   Dandawate PR, 2016, SEMIN CANCER BIOL, V40-41, P192, DOI 10.1016/j.semcancer.2016.09.001
   Della Pietra E, 2015, NITRIC OXIDE-BIOL CH, V45, P43, DOI 10.1016/j.niox.2015.02.005
   dos Santos PC, 2018, ASIAN PAC J TROP BIO, V8, P292, DOI 10.4103/2221-1691.235324
   Duraipandiyan V., 2012, ASIAN PAC J TROP DIS, V2, P517, DOI DOI 10.1016/S2222-1808(12)60213-8
   El-Shemy HA, 2010, CURR MED CHEM, V17, P129, DOI 10.2174/092986710790112620
   Ferrari S, 2015, EXPERT OPIN PHARMACO, V16, P2727, DOI 10.1517/14656566.2015.1102226
   Ghasemi F, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152556
   Gonzalez-Vallinas M, 2013, NUTR REV, V71, P585, DOI 10.1111/nure.12051
   Gossner G, 2007, GYNECOL ONCOL, V105, P23, DOI 10.1016/j.ygyno.2006.11.009
   Gupta C, 2010, PHYTOTHER RES, V24, P119, DOI 10.1002/ptr.2883
   Hao Y., 2019, AUTOPHAGY, V15, P1
   Hargraves KG, 2016, MOL CARCINOGEN, V55, P486, DOI 10.1002/mc.22296
   Hassan SB, 2010, ANTICANCER RES, V30, P1911
   Hirata H, 2014, BRIT J CANCER, V110, P1645, DOI 10.1038/bjc.2014.48
   Hisano Y, 2019, PHARMACOL THERAPEUT, V193, P91, DOI 10.1016/j.pharmthera.2018.07.006
   Hsieh SL, 2015, INT J ONCOL, V47, P2240, DOI 10.3892/ijo.2015.3206
   Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3
   HUANG MT, 1988, CANCER RES, V48, P5941
   Huynh HT, 2005, ANTICANCER RES, V25, P117
   Iqbal J, 2019, BIOMED PHARMACOTHER, V109, P1381, DOI 10.1016/j.biopha.2018.10.107
   Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670
   Jablonska-Trypuc A, 2016, J ENZYM INHIB MED CH, V31, P177, DOI 10.3109/14756366.2016.1161620
   Janicke B, 2011, NUTR CANCER, V63, P611, DOI 10.1080/01635581.2011.538486
   Jeong CH, 2009, CANCER RES, V69, P5584, DOI 10.1158/0008-5472.CAN-09-0491
   Kakarala M, 2010, BREAST CANCER RES TR, V122, P777, DOI 10.1007/s10549-009-0612-x
   KAMPA M, 2004, BREAST CANCER RES, V6, P63
   Kanda M, 2016, WORLD J GASTROENTERO, V22, P6829, DOI 10.3748/wjg.v22.i30.6829
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-89
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316
   Kaur P, 2009, TOXICOL IN VITRO, V23, P680, DOI 10.1016/j.tiv.2009.01.019
   Kensler TW, 2013, TOP CURR CHEM, V329, P163, DOI 10.1007/128_2012_339
   Khan M., 2012, Journal of Medicinal Plants Research, V6, P3754
   Khan M, 2010, MUTAT RES-FUND MOL M, V683, P123, DOI 10.1016/j.mrfmmm.2009.11.001
   Kim SH, 2007, J MED FOOD, V10, P232, DOI 10.1089/jmf.2006.1089
   Kobaek-Larsen M, 2005, J AGR FOOD CHEM, V53, P1823, DOI 10.1021/jf048519s
   Koff JL, 2015, INT J MOL SCI, V16, P2942, DOI 10.3390/ijms16022942
   Lamy S, 2008, CARCINOGENESIS, V29, P1033, DOI 10.1093/carcin/bgn070
   Lamy S, 2008, CANCER PREV RES, V1, P452, DOI 10.1158/1940-6207.CAPR-08-0072
   Lawrence KS, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005150
   Lee JH, 2013, PHARMACOL THERAPEUT, V137, P153, DOI 10.1016/j.pharmthera.2012.09.008
   Lee MC, 2014, BIOMARK GENOM MED, V6, P144, DOI 10.1016/j.bgm.2014.08.005
   Lee YH, 2013, BIOSCI BIOTECH BIOCH, V77, P375, DOI 10.1271/bbb.120465
   Lennon H, 2016, CURR ONCOL REP, V18, DOI 10.1007/s11912-016-0539-4
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Limanaqi F., 2019, INT J MOL SCI, V20, P1
   Liu JM, 2015, CHIN AUTOM CONGR, P2247, DOI 10.1109/CAC.2015.7382877
   Liu R, 2017, ONCOL LETT, V13, P1024, DOI 10.3892/ol.2016.5495
   Llado V, 2009, P NATL ACAD SCI USA, V106, P13754, DOI 10.1073/pnas.0907300106
   Loarca-Pina G, 2019, J FOOD SCI TECH MYS, V56, P3177, DOI 10.1007/s13197-019-03671-3
   Losso JN, 2004, J NUTR BIOCHEM, V15, P672, DOI 10.1016/j.jnutbio.2004.06.004
   Lu HT, 2007, CURR CANCER DRUG TAR, V7, P343, DOI 10.2174/156800907780809750
   Lu Y, 2010, EUR J PHARMACOL, V641, P102, DOI 10.1016/j.ejphar.2010.05.043
   Ma B, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00378
   Macedo F, 2017, J GASTRIC CANCER, V17, P1, DOI 10.5230/jgc.2017.17.e1
   Madunic IV, 2018, N-S ARCH PHARMACOL, V391, P537, DOI 10.1007/s00210-018-1486-4
   Mainz L, 2018, FEBS J, V285, P792, DOI 10.1111/febs.14274
   Mbaveng AT, 2018, PHYTOMEDICINE, V48, P112, DOI 10.1016/j.phymed.2017.12.016
   Mileo AM, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/6475624
   Miller TM, 1997, J CELL BIOL, V139, P205, DOI 10.1083/jcb.139.1.205
   Mills CC, 2018, CANCER RES, V78, P320, DOI 10.1158/0008-5472.CAN-17-2782
   Min JK, 2004, CANCER RES, V64, P644, DOI 10.1158/0008-5472.CAN-03-3250
   Min KJ, 2014, INTEGR MED RES, V3, P16, DOI 10.1016/j.imr.2013.12.001
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001
   Nibret E, 2011, PHYTOTHER RES, V25, P1883, DOI 10.1002/ptr.3651
   Nigam N, 2007, FOOD CHEM TOXICOL, V45, P2331, DOI 10.1016/j.fct.2007.06.002
   Nurgalieva Z, 2011, MED ONCOL, V28, P716, DOI 10.1007/s12032-010-9512-5
   Olsvik HL, 2019, AUTOPHAGY, V15, P182, DOI 10.1080/15548627.2018.1532265
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Owen H.C., 2017, INT REV NEUROBIOL, P249
   Pandey M, 2012, MOL CARCINOGEN, V51, P952, DOI 10.1002/mc.20866
   Paquette M, 2018, CANCERS, V10, DOI 10.3390/cancers10010018
   Paredes-Gonzalez X, 2014, AAPS J, V16, P727, DOI 10.1208/s12248-014-9613-8
   Park S, 2010, J CELL BIOCHEM, V110, P1376, DOI 10.1002/jcb.22654
   Parveen A, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030350
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Polivkova Z, 2010, J MED FOOD, V13, P1443, DOI 10.1089/jmf.2009.0277
   Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005
   Prakash J, 2002, NUTR CANCER, V42, P91, DOI 10.1207/S15327914NC421_12
   Qie S, 2016, J MOL MED, V94, P1313, DOI 10.1007/s00109-016-1475-3
   Qin S, 2016, MOL NUTR FOOD RES, V60, P1731, DOI 10.1002/mnfr.201501017
   Raju J, 2004, CANCER EPIDEM BIOMAR, V13, P1392
   Ranjan A, 2015, CHIN J NAT MEDICINES, V13, P730, DOI 10.1016/S1875-5364(15)30073-X
   Rao KN, 2000, TOXICOL IN VITRO, V14, P53, DOI 10.1016/S0887-2333(99)00092-2
   Roberto MM, 2016, TOXICOL IN VITRO, V33, P9, DOI 10.1016/j.tiv.2016.02.005
   Satyavarapu EM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0989-8
   Serra D, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0073001, 10.1371/journal.pone.0063915]
   Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098
   Shan YJ, 2013, J NUTR BIOCHEM, V24, P1062, DOI 10.1016/j.jnutbio.2012.08.004
   Shukla V, 2015, RSC ADV, V5, P56075, DOI 10.1039/c5ra06167a
   Shukla Y, 2002, MUTAT RES-GEN TOX EN, V515, P197, DOI 10.1016/S1383-5718(02)00016-5
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Singh R, 2016, FRONT PLANT SCI, V7, P1, DOI 10.3389/fpls.2016.01299
   Sinha S, 2013, INT J CANCER, V132, P1201, DOI 10.1002/ijc.27724
   Soltani M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020344
   Stan SD, 2008, NUTR CANCER, V60, P51, DOI 10.1080/01635580802381477
   Stefanson AL, 2014, NUTRIENTS, V6, P3777, DOI 10.3390/nu6093777
   Stirzaker C, 2017, ONCOGENE, V36, P1328, DOI 10.1038/onc.2016.297
   Sur S, 2017, NUTRITION, V43-44, P8, DOI 10.1016/j.nut.2017.06.006
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Tian XY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0702-y
   Tian YS, 2018, MOLECULES, V23, DOI 10.3390/molecules23123327
   Tsuruta F, 2002, J BIOL CHEM, V277, P14040, DOI 10.1074/jbc.M108975200
   Tung N.H., 2013, ANTI CANC DRUGS, V24, P1
   van Erk MJ, 2005, EUR J NUTR, V44, P143, DOI 10.1007/s00394-004-0503-1
   Phan VA, 2016, INT CONF KNOWL SYS, P85, DOI 10.1109/KSE.2016.7758034
   Viret C, 2018, J MOL BIOL, V430, P1696, DOI 10.1016/j.jmb.2018.04.018
   Wei R, 2018, FOOD FUNCT, V9, P5682, DOI 10.1039/c8fo01397g
   Weiss JF, 2003, TOXICOLOGY, V189, P1, DOI 10.1016/S0300-483X(03)00149-5
   Wu C., 2012, EUR J CANCER, V48, P84
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yamada J, 1996, BIOSCI BIOTECH BIOCH, V60, P328, DOI 10.1271/bbb.60.328
   Yang L, 2010, TRENDS IMMUNOL, V31, P220, DOI 10.1016/j.it.2010.04.002
   Yoshida GJ, 2016, CANCER SCI, V107, P5, DOI 10.1111/cas.12817
   Yoshimoto M, 2001, BIOSCI BIOTECH BIOCH, V65, P1652, DOI 10.1271/bbb.65.1652
   Zahin M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/467465
   Zaini RG, 2012, ANTI-CANCER AGENT ME, V12, P640
   Zhang L, 2014, BIOCHEM BIOPH RES CO, V450, P247, DOI 10.1016/j.bbrc.2014.05.101
   Zhang WP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08463-z
   Zhao YJ, 2015, ONCOLOGIST, V20, P660, DOI 10.1634/theoncologist.2014-0465
NR 152
TC 19
Z9 19
U1 6
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD DEC 5
PY 2020
VL 888
AR 173488
DI 10.1016/j.ejphar.2020.173488
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA OV7QD
UT WOS:000592398600007
PM 32805253
DA 2022-04-25
ER

PT J
AU Wang, R
   Liu, HW
   Shao, YY
   Wang, KL
   Yin, SS
   Qiu, YL
   Wu, HH
   Liu, EW
   Wang, T
   Gao, XM
   Yu, HY
AF Wang, Rui
   Liu, Hongwei
   Shao, Yingying
   Wang, Kailong
   Yin, Shuangshuang
   Qiu, Yuling
   Wu, Honghua
   Liu, Erwei
   Wang, Tao
   Gao, Xiumei
   Yu, Haiyang
TI Sophoridine Inhibits Human Colorectal Cancer Progression via Targeting
   MAPKAPK2
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID NATURAL-PRODUCTS; NETWORK PHARMACOLOGY; DRUG DISCOVERY; MATRINE; KINASE;
   OPPORTUNITIES; MECHANISMS
AB Radian Sophorae flavescentis is a traditional Chinese medicine commonly used to treat cancer in China. However, its active components and underlying mechanism remain ambiguous. In this study, we have screened the pharmacokinetic parameters of the main chemical constituents of Radian Sophorae flavescentis by Traditional Chinese Medicine Systems Pharmacology (TCMSP) Database and Analysis Platform and have found that Sophoridine is one of the best antitumor active ingredients. We have found that MAPKAPK2 is a potential target for Sophoridine by the PharmMapper and KEGG datab-Xase analysis. Moreover, we have found that Sophoridine selectively inactivates phospho-MAPKAPK2 (Thr222) and directly binds into the ATP site of MAPKAPK2 by molecular docking. Furthermore, we have found out a direct binding between MAPKAPK2 and Sophoridine by cellular thermal shift assay and drug affinity responsive targets stability assay. The inhibition effects are further confirmed by Western blot: Sophoridine significantly decreases phospho-MAPKAPK2 (Thr222) in a time-dependent manner, but there is no obvious change in its total expression in colorectal cancer cells. Clinical studies have shown that a higher level of MAPKAPK2 is associated with a poorer percent survival rate (prognosis). Furthermore, a higher level of MAPKAPK2 is positively associated with the enrichment of downregulation of apoptosis and autophagy by gene set enrichment analysis, as well as upregulation of proliferation and cell-cycle arrest. Taken together, our results suggest that the MAPKAPK2 plays a key role in Sophoridine-inhibited growth and invasion in colorectal cancers.
C1 [Wang, Rui; Liu, Hongwei; Shao, Yingying; Wang, Kailong; Yin, Shuangshuang; Wu, Honghua; Liu, Erwei; Wang, Tao; Gao, Xiumei; Yu, Haiyang] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China.
   [Qiu, Yuling] Tianjin Med Univ, Sch Pharm, Tianjin, Peoples R China.
RP Yu, HY (corresponding author), Tianjin Univ Tradit Chinese Med, 312 Anshan Rd, Tianjin 300193, Peoples R China.
EM hyyu@tjutcm.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81603253, 21711540293, 81873089, 81602614,
   81973570]; Important Drug Development Fund, Ministry of Science and
   Technology of China [2018ZX09735-002]; Natural Science Foundation of
   Tianjin CityNatural Science Foundation of Tianjin [15PTCYSY00030]
FX This work was supported by grants from National Natural Science
   Foundation of China (81603253, 21711540293, and 81873089 to H. Yu, and
   81602614 and 81973570 to Y. Qiu), Important Drug Development Fund,
   Ministry of Science and Technology of China (2018ZX09735-002 to T.
   Wang), and Natural Science Foundation of Tianjin City (No. 15PTCYSY00030
   to Z. Li).
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Atanasov AG, 2015, BIOTECHNOL ADV, V33, P1582, DOI 10.1016/j.biotechadv.2015.08.001
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brophy CM, 1998, J VASC SURG, V27, P963, DOI 10.1016/S0741-5214(98)70279-4
   Cai XH, 2018, MINI-REV MED CHEM, V18, P730, DOI 10.2174/1389557516666161104150334
   Cassidy S, 2017, NAT REV DRUG DISCOV, V16, P525, DOI 10.1038/nrd.2017.59
   Chang E, 2011, BLOOD, V117, P2527, DOI 10.1182/blood-2010-08-302281
   Clarke JM, 2014, CANCER TREAT REV, V40, P1065, DOI 10.1016/j.ctrv.2014.07.001
   David B, 2015, PHYTOCHEM REV, V14, P299, DOI 10.1007/s11101-014-9367-z
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Fotis C, 2018, DRUG DISCOV TODAY, V23, P626, DOI 10.1016/j.drudis.2017.12.001
   Gartner ZJ, 2017, NAT CHEM BIOL, V13, P564, DOI 10.1038/nchembio.2391
   Gharwan H, 2016, NAT REV CLIN ONCOL, V13, P209, DOI 10.1038/nrclinonc.2015.213
   Goldstein DA, 2015, J CLIN ONCOL, V33, P3727, DOI 10.1200/JCO.2015.61.9569
   Harvey AL, 2015, NAT REV DRUG DISCOV, V14, P111, DOI 10.1038/nrd4510
   He XR, 2015, J ETHNOPHARMACOL, V172, P10, DOI 10.1016/j.jep.2015.06.010
   Henriques A, 2018, P NATL ACAD SCI USA, V115, pE5546, DOI 10.1073/pnas.1805683115
   Herranz N, 2015, NAT CELL BIOL, V17, P1205, DOI 10.1038/ncb3225
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Hsin KY, 2016, NUCLEIC ACIDS RES, V44, pW507, DOI 10.1093/nar/gkw335
   Huang JL, 2016, CURR TOP MED CHEM, V16, P3365, DOI 10.2174/1568026616666160506131012
   Johansen C, 2009, CARCINOGENESIS, V30, P2100, DOI 10.1093/carcin/bgp238
   Kayyali US, 2002, J BIOL CHEM, V277, P42596, DOI 10.1074/jbc.M205863200
   Kibble M, 2015, NAT PROD REP, V32, P1249, DOI 10.1039/c5np00005j
   Korcsmaros T, 2017, INTEGR BIOL-UK, V9, P97, DOI 10.1039/c6ib00215c
   Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918
   Li YZ, 2018, CANCER LETT, V428, P45, DOI 10.1016/j.canlet.2018.04.030
   Moffat JG, 2017, NAT REV DRUG DISCOV, V16, P531, DOI 10.1038/nrd.2017.111
   Murali B, 2018, CANCER RES, V78, P5618, DOI 10.1158/0008-5472.CAN-18-0234
   Ni WJ, 2017, J AGR FOOD CHEM, V65, P2039, DOI 10.1021/acs.jafc.6b05474
   Rashid HU, 2019, EUR J MED CHEM, V161, P205, DOI 10.1016/j.ejmech.2018.10.037
   Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/NCHEM.2479, 10.1038/nchem.2479]
   Soni S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1167-2
   Soni S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1115-1
   Sun MY, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/373219
   Taniyama Y, 2004, AM J PHYSIOL-CELL PH, V287, pC494, DOI 10.1152/ajpcell.00439.2003
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Wang W, 2015, ACTA PHARMACOL SIN, V36, P676, DOI 10.1038/aps.2015.24
   Wright GD, 2017, NAT PROD REP, V34, P694, DOI 10.1039/c7np00019g
   Wu S, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00881
   Yin SS, 2019, INT J CANCER, V145, P3334, DOI 10.1002/ijc.32395
   Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4
   Yu HY, 2017, MOL CANCER THER, V16, P2711, DOI 10.1158/1535-7163.MCT-17-0498
   Zhao S, 2012, ANNU REV PHARMACOL, V52, P505, DOI 10.1146/annurev-pharmtox-010611-134520
   Zhou QJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4552
NR 45
TC 17
Z9 18
U1 6
U2 34
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD DEC
PY 2019
VL 17
IS 12
BP 2469
EP 2479
DI 10.1158/1541-7786.MCR-19-0553
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA JT4HH
UT WOS:000500951800011
PM 31575657
OA Bronze
DA 2022-04-25
ER

PT J
AU Novohradsky, V
   Pracharova, J
   Kasparkova, J
   Imberti, C
   Bridgewater, HE
   Sadler, PJ
   Brabec, V
AF Novohradsky, Vojtech
   Pracharova, Jitka
   Kasparkova, Jana
   Imberti, Cinzia
   Bridgewater, Hannah E.
   Sadler, Peter J.
   Brabec, Viktor
TI Induction of immunogenic cell death in cancer cells by a photoactivated
   platinum(iv) prodrug
SO INORGANIC CHEMISTRY FRONTIERS
LA English
DT Article
ID IMMUNE-SYSTEM; EXPOSURE; CHEMOTHERAPY; GENERATION; AUTOPHAGY; RESPONSES;
   THERAPY; AGENTS; DRUGS; DNA
AB The platinum(iv) prodrug trans,trans,trans-[Pt(N-3)(2)(OH)(2)(py)(2)] (1) is stable and non-toxic in the dark, but potently cytotoxic to cancer cells when irradiated by visible light, including cisplatin-resistant cells. On irradiation with visible light, it generates reactive Pt(ii) species which can attack DNA, and produces reactive oxygen species (ROS) and reactive nitrogen species (RNS) which exert unusual effects on biochemical pathways. We now show that its novel mechanism of action includes induction of immunogenic cell death (ICD). Treatment of cancer cells with 1 followed by photoirradiation with visible light induces calreticulin (CRT) expression at the surface of dying cancer cells. This is accompanied by release of high mobility group protein-1B (HMGB1) and the secretion of ATP. Autophagy appears to play a key role in this chemotherapeutically-stimulated ICD. The observed uneven distribution of ecto-CRT promotes phagocytosis, confirmed by the observation of engulfment of photoirradiated CT26 colorectal cancer cells treated with 1 by J774.A1 macrophages. The photoactivatable prodrug 1 has a unique mechanism of action which distinguishes it from other platinum drugs due to its immunomodulating properties, which may enhance its anticancer efficacy.
C1 [Novohradsky, Vojtech; Pracharova, Jitka; Kasparkova, Jana; Brabec, Viktor] Czech Acad Sci, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
   [Pracharova, Jitka] Palacky Univ, Ctr Reg Hana Biotechnol & Agr Res, Dept Biophys, Slechtitelu 27, Olomouc 78371, Czech Republic.
   [Imberti, Cinzia; Bridgewater, Hannah E.; Sadler, Peter J.] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
RP Brabec, V (corresponding author), Czech Acad Sci, Inst Biophys, Kralovopolska 135, CZ-61265 Brno, Czech Republic.
EM brabec@ibp.cz
RI Imberti, Cinzia/N-2717-2018; Brabec, Viktor/H-1946-2014
OI Imberti, Cinzia/0000-0003-1187-7951; Brabec, Viktor/0000-0002-8233-1393;
   Bridgewater, Hannah/0000-0003-1769-9025
FU Czech Science FoundationGrant Agency of the Czech Republic [18-09502S];
   Wellcome TrustWellcome TrustEuropean Commission [209173/Z/17/Z]; EPSRCUK
   Research & Innovation (UKRI)Engineering & Physical Sciences Research
   Council (EPSRC) [EP/F034210/1, EP/P030572/1]; MRCUK Research &
   Innovation (UKRI)Medical Research Council UK (MRC) [G0701062] Funding
   Source: UKRI
FX This work was supported by the Czech Science Foundation (Grant
   18-09502S), the Wellcome Trust (Grant 209173/Z/17/Z, Fellowship for C.
   I.), EPSRC (Grants EP/F034210/1 and EP/P030572/1) and Anglo American
   Platinum Mike and Enfys Bagguley (PhD Studentship for H. E. B).
CR Apetoh L, 2008, CANCER RES, V68, P4026, DOI 10.1158/0008-5472.CAN-08-0427
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Bednarski PJ, 2007, ANTI-CANCER AGENT ME, V7, P75, DOI 10.2174/187152007779314053
   Brabec V, 2017, COORDIN CHEM REV, V351, P2, DOI 10.1016/j.ccr.2017.04.013
   Du J, 2018, INORG CHEM, V57, P5575, DOI 10.1021/acs.inorgchem.8b00529
   Dudek AM, 2013, CYTOKINE GROWTH F R, V24, P319, DOI 10.1016/j.cytogfr.2013.01.005
   Englinger B, 2019, CHEM REV, V119, P1519, DOI 10.1021/acs.chemrev.8b00396
   Farrer N. J., 2010, ANGEW CHEM INT EDIT, V49, P1
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Garg A, 2015, J GERIATR ONCOL, V6, P29, DOI 10.1016/j.jgo.2014.09.182
   Garg AD, 2012, CANCER IMMUNOL IMMUN, V61, P215, DOI 10.1007/s00262-011-1184-2
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   Imberti C, 2020, ANGEW CHEM INT EDIT, V59, P61, DOI 10.1002/anie.201905171
   Johnstone TC, 2016, CHEM REV, V116, P3436, DOI 10.1021/acs.chemrev.5b00597
   Jung YW, 2007, CHEM REV, V107, P1387, DOI 10.1021/cr068207j
   Jungwirth U, 2012, MOL PHARMACOL, V81, P719, DOI 10.1124/mol.111.077321
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kepp O, 2013, CYTOKINE GROWTH F R, V24, P311, DOI 10.1016/j.cytogfr.2013.05.001
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Li W, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11269-8
   Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931
   Martins I, 2014, CELL DEATH DIFFER, V21, P79, DOI 10.1038/cdd.2013.75
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Menger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Monro S, 2019, CHEM REV, V119, P797, DOI 10.1021/acs.chemrev.8b00211
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Pizarro AM, 2014, CHEMMEDCHEM, V9, P1169, DOI 10.1002/cmdc.201402066
   Pol J, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008866
   Pracharova J, 2012, CHEM RES TOXICOL, V25, P1099, DOI 10.1021/tx300057y
   Rebe C, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010013
   Shi HY, 2019, INORG CHEM FRONT, V6, P1623, DOI 10.1039/c9qi00288j
   Terenzi A, 2016, J INORG BIOCHEM, V165, P71, DOI 10.1016/j.jinorgbio.2016.06.021
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691
   Wang YJ, 2018, GENES DIS, V5, P194, DOI 10.1016/j.gendis.2018.05.003
   Wong DYQ, 2015, ANGEW CHEM INT EDIT, V54, P6483, DOI 10.1002/anie.201500934
   Wootton CA, 2018, CHEM SCI, V9, P2733, DOI 10.1039/c7sc05135b
   Xiang YC, 2020, ACS APPL MATER INTER, V12, P1606, DOI 10.1021/acsami.9b19323
   Xu XJ, 2014, NAT IMMUNOL, V15, P1152, DOI 10.1038/ni.3025
   Zhao Y, 2013, ANGEW CHEM INT EDIT, V52, P13633, DOI 10.1002/anie.201307505
   Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891
NR 44
TC 10
Z9 10
U1 10
U2 35
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2052-1553
J9 INORG CHEM FRONT
JI Inorg. Chem. Front.
PD NOV 7
PY 2020
VL 7
IS 21
BP 4150
EP 4159
DI 10.1039/d0qi00991a
PG 10
WC Chemistry, Inorganic & Nuclear
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA OM1XY
UT WOS:000585823500011
PM 34540235
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Lim, EG
   Kim, GT
   Kim, BM
   Kim, EJ
   Kim, SY
   Kim, YM
AF Lim, Eun Gyeong
   Kim, Guen Tae
   Kim, Bo Min
   Kim, Eun Ji
   Kim, Sang-Yong
   Kim, Young Min
TI Ethanol extract from Cnidium monnieri (L.) Cusson induces cell cycle
   arrest and apoptosis via regulation of the p53-independent pathway in
   HepG2 and Hep3B hepatocellular carcinoma cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE apoptosis; Akt/GSK-3 beta signaling pathway; cell cycle arrest; CME;
   hepatocellular carcinoma cells; p53-independent pathway
ID COLORECTAL-CANCER CELLS; SIGNALING PATHWAY; A549 CELLS; IN-VITRO; P21;
   P53; MITOCHONDRIAL; EXPRESSION; COUMARINS; AUTOPHAGY
AB Cnidium monnieri (L.) Cusson is a frequently used traditional Chinese medicine that treats gynecological diseases and carbuncles. However, the mechanism of action of C. monnieri remains to be fully elucidated. The present study examined the cell cycle arrest and apoptotic effects resulting from ethanol extract of C. monnieri (CME) in HepG2 (wild-type p53) and Hep3B (p53-null) hepatocellular carcinoma cells. An MTT assay was used to confirm the anti-proliferative effect of CME. The cells were stained with Hoechst 33342 or propidium iodide. It was demonstrated that proliferation of HepG2 cells was suppressed by CME. Cell cycle arrest occurred in the G1 phase following treatment with CME and the number of apoptotic bodies was increased. The expression levels of cell cycle-associated proteins, including protein kinase B (Akt), glycogen synthase kinase-3 beta (GSK-3 beta), p53, cyclin E and cyclin-dependent kinase 2 (CDK2) were determined by western blot analysis. The protein levels of phosphorylated (p)-Akt, p-GSK-3 beta, p-MDM2 and cyclin E were decreased, whereas the protein levels of p53, p21 and p-CDK2 (Thr14/Tyr15) were increased following treatment with CME. Furthermore, treatment or co-treatment with LY294002 (phosphoinositide-3-kinase/Akt inhibitor) or Pifithrin-alpha (p53 inhibitor) with CME resulted in CME-induced G1 arrest which occurred through the p53-independent signaling pathway in hepatocellular carcinoma cells. In conclusion, CME induces G1 arrest and apoptosis via the Akt/GSK-3 beta signaling pathway which is regulated by MDM2-induced degradation of p21, rather than p53.
C1 [Lim, Eun Gyeong; Kim, Guen Tae; Kim, Bo Min; Kim, Eun Ji; Kim, Young Min] Hannam Univ, Coll Life Sci & Nanotechnol, Dept Biol Sci & Biotechnol, Yuseong Dero 1646, Daejeon 34054, South Korea.
   [Kim, Sang-Yong] Shinansan Univ, Dept Food Sci & Biotechnol, Ansan 425792, Gyeonggi Do, South Korea.
RP Kim, YM (corresponding author), Hannam Univ, Coll Life Sci & Nanotechnol, Dept Biol Sci & Biotechnol, Yuseong Dero 1646, Daejeon 34054, South Korea.
EM kym@hnu.kr
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Byambaragchaa M, 2013, ASIAN PAC J CANCER P, V14, P5397, DOI 10.7314/APJCP.2013.14.9.5397
   Chien SY, 2009, HUM EXP TOXICOL, V28, P493, DOI 10.1177/0960327109107002
   Choi EJ, 2013, CHINESE J CANCER RES, V25, P536, DOI 10.3978/j.issn.1000-9604.2013.10.02
   Esposti MD, 2003, BIOCHEM BIOPH RES CO, V304, P455, DOI 10.1016/S0006-291X(03)00617-X
   Gartel AL, 2002, MOL CANCER THER, V1, P639
   Grizzi F, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-3
   Hsu SC, 2007, ANTICANCER RES, V27, P2415
   Jiang GQ, 2016, J ETHNOPHARMACOL, V193, P368, DOI 10.1016/j.jep.2016.08.045
   Karimian A, 2016, DNA REPAIR, V42, P63, DOI 10.1016/j.dnarep.2016.04.008
   Kim Eun Ji, 2015, Korean Society for Biotechnology and Bioengineering Journal, V30, P175
   Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005
   Li HB, 2005, J SEP SCI, V28, P268, DOI 10.1002/jssc.200400002
   Meng J, 2012, ONCOL REP, V28, P384, DOI 10.3892/or.2012.1793
   Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6
   Park C, 2016, ASIAN PAC J TROP MED, V9, P336, DOI 10.1016/j.apjtm.2016.03.003
   Prakash O., 2013, J PHARMACOL SCI, V1, P104, DOI [10.12691/ajps-1-6-1, DOI 10.12691/AJPS-1-6-1]
   Romorini L, 2016, SCI REP-UK, V6, DOI 10.1038/srep35660
   Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200
   Shen GX, 2006, CANCER CHEMOTH PHARM, V57, P317, DOI 10.1007/s00280-005-0050-3
   Sun Y, 2016, ONCOTARGETS THER, V9, P2845, DOI 10.2147/OTT.S99770
   Sutherland C., 2011, INT J ALZHEIMERS DIS, V2011
   Tai Y, 2016, EXP THER MED, V12, P2681, DOI 10.3892/etm.2016.3630
   Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226
   Thotala DK, 2012, CELL DEATH DIFFER, V19, P387, DOI 10.1038/cdd.2011.94
   Wang R, 2016, SCI REP-UK, V6, DOI 10.1038/srep27071
   Wang Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2767-2
   Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200
   Yang LL, 2003, PLANTA MED, V69, P1091, DOI 10.1055/s-2003-45188
   이세희, 2012, [Journal of Cancer Prevention, 대한암예방학회지], V17, P244
   Yuan L, 2015, MOL MED REP, V11, P2459, DOI 10.3892/mmr.2014.3100
   Zhang RW, 2014, J BIOL CHEM, V289, P6394, DOI 10.1074/jbc.M113.513960
   Zhang Z, 2004, J BIOL CHEM, V279, P16000, DOI 10.1074/jbc.M312264200
   Zhao T, 2016, EXP THER MED, V12, P3301, DOI 10.3892/etm.2016.3765
   Zhu YP, 1998, CHINESE MAT MED CHEM, P624
NR 35
TC 7
Z9 7
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2018
VL 17
IS 2
BP 2572
EP 2580
DI 10.3892/mmr.2017.8183
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA FT5WP
UT WOS:000423224300061
PM 29207130
OA Bronze
DA 2022-04-25
ER

PT J
AU Jin, SG
   Li, XP
   Dai, Y
   Li, C
   Wang, DX
AF Jin, Shiguang
   Li, Xueping
   Dai, Yan
   Li, Cheng
   Wang, Daxin
TI NF-kappa B-mediated miR-650 plays oncogenic roles and activates
   AKT/ERK/NF-kappa B pathways by targeting RERG in glioma cells
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Glioma; miR-650; RERG; PHLPP2; NF-kappa B; AKT; ERK
ID COLORECTAL-CANCER; LUNG-CANCER; PROLIFERATION; PROMOTES; GLIOBLASTOMA;
   EXPRESSION; PROTEIN; PROGRESSION; MICRORNAS; INVASION
AB Purpose Glioma is the most common cancer in the central nervous system and has a high mortality rate. Despite advances that have been made in the treatment of glioma, its prognosis still remains poor. Dysregulation of miRNAs has been reported in many cancers, including glioma. Here, we set out to assess the role of miR-650 in glioma, including its diagnostic and therapeutic potential.
   Methods miR-650 and RAS-like estrogen-regulated growth inhibitor (RERG) expression levels were analyzed using qRT-PCR in primary glioma tissues and cell lines. Cell Counting Kit-8, 5-ethynyl-2 '-deoxyuridine, colony formation, Western blotting, scratch wound healing, Transwell, adhesion, autophagy, immunofluorescence, luciferase reporter, electrophoretic mobility shift, tumor xenograft and flow cytometry assays were employed to investigate the mechanisms underlying the effect of miR-650 and RERG on glioma development.
   Results miR-650 was found to be up-regulated in glioma tissues and cell lines compared to non-cancerous brain tissues and neural progenitor cells, respectively. We also found that miR-650 promoted cell proliferation, migration and invasion in glioma cells, and enhanced glioma tumor formation and growth in vivo. We identified and validated RERG as a direct target of miR-650. RERG was shown to act as a tumor suppressor in glioma cells, and its suppressor roles were rescued by miR-650. We found that nuclear factor (NF)-kappa B bound to the promoter of miR-650 and enhanced its expression. PH domain and leucine rich repeat protein phosphatase 2 (PHLPP2), as a co-factor of the RERG/PHLPP2 complex, mediated miR-650-induced activation of the protein kinase B/extracellular-signal-regulated kinase/NF-kappa B signaling pathways.
   Conclusions Our data revealed novel functional roles for miR-650 in glioma development and may provide new avenues for future clinical applications.
C1 [Jin, Shiguang; Dai, Yan; Li, Cheng; Wang, Daxin] Yangzhou Univ, Clin Med Coll, Yangzhou 225001, Jiangsu, Peoples R China.
   [Jin, Shiguang] Cent South Univ, Xiangya Hosp 2, Changsha 410008, Hunan, Peoples R China.
   [Li, Xueping] Nanjing Med Univ, Hosp Nanjing 1, Nanjing Hosp, Nanjing 210029, Jiangsu, Peoples R China.
RP Wang, DX (corresponding author), Yangzhou Univ, Clin Med Coll, Yangzhou 225001, Jiangsu, Peoples R China.
EM Daxinw2002@sina.com
FU Yangzhou Natural Science Foundation [YZ2016125]; Jiangsu Provincial "333
   Engineering" Project [BRA2015171]; Self-help Research Project of
   Postdoctor in Jiangsu
FX This work was supported partially by the Yangzhou Natural Science
   Foundation (YZ2016125), Jiangsu Provincial "333 Engineering" Project
   (BRA2015171) and The Self-help Research Project of Postdoctor in
   Jiangsu.
CR Agarwal NK, 2014, ONCOTARGET, V5, P815, DOI 10.18632/oncotarget.1774
   Ahir BK, 2017, CRIT REV ONCOL HEMAT, V120, P22, DOI 10.1016/j.critrevonc.2017.10.003
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Ames H, 2017, J NEUROPATH EXP NEUR, V76, P246, DOI 10.1093/jnen/nlx005
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bing ZT, 2016, IET SYST BIOL, V10, P244, DOI 10.1049/iet-syb.2016.0004
   Brognard J, 2008, TRENDS ENDOCRIN MET, V19, P223, DOI 10.1016/j.tem.2008.04.001
   Brognard J, 2009, J BIOL CHEM, V284, P15215, DOI 10.1074/jbc.M901468200
   Chen X, 2015, J CELL BIOCHEM, V116, P225, DOI 10.1002/jcb.24949
   Ding L, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0516-2
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Ho JY, 2017, ONCOTARGET, V8, P22443, DOI 10.18632/oncotarget.12338
   Kaur E, 2019, CELL ONCOL, V42, P107, DOI 10.1007/s13402-018-0411-7
   Key MD, 2006, METHOD ENZYMOL, V407, P513, DOI 10.1016/S0076-6879(05)07041-2
   Li CF, 2017, EUR J PHARMACOL, V807, P168, DOI 10.1016/j.ejphar.2017.04.023
   Liao WT, 2013, CLIN CANCER RES, V19, P4662, DOI 10.1158/1078-0432.CCR-13-0244
   Linz U, 2010, CANCER-AM CANCER SOC, V116, P1844, DOI 10.1002/cncr.24950
   Mei ZF, 2014, FEBS LETT, V588, P3055, DOI 10.1016/j.febslet.2014.06.020
   Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Stupp R, 2008, CLIN MED ONCOL, V2, P421
   Sun BQ, 2013, J NEURO-ONCOL, V115, P375, DOI 10.1007/s11060-013-1243-y
   Tian R, 2017, ONCOGENE, V36, P5861, DOI 10.1038/onc.2017.182
   Vicentic JM, 2019, CELL ONCOL, V42, P41, DOI 10.1007/s13402-018-0405-5
   Wang B, 2019, CELL ONCOL, V42, P783, DOI 10.1007/s13402-019-00461-z
   Yang J, 2017, INT J CANCER, V141, P2082, DOI 10.1002/ijc.30912
   Ye Y, 2017, EXP THER MED, V14, P867, DOI 10.3892/etm.2017.4538
   You Q, 2018, ONCOL LETT, V16, P2326, DOI 10.3892/ol.2018.8910
   Yun JH, 2015, ONCOL LETT, V10, P2603, DOI 10.3892/ol.2015.3581
   Zeng ZL, 2013, J SURG ONCOL, V107, P105, DOI 10.1002/jso.23210
   Zhao K, 2017, CANCER LETT, V406, P12, DOI 10.1016/j.canlet.2017.07.022
   Zhao WL, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0554-9
   Zhou KC, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00046
   Zuo ZH, 2015, AM J PATHOL, V185, P1991, DOI 10.1016/j.ajpath.2015.03.015
NR 36
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD DEC
PY 2020
VL 43
IS 6
BP 1035
EP 1048
DI 10.1007/s13402-020-00533-5
EA SEP 2020
PG 14
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA PA6VA
UT WOS:000573418300001
PM 32986146
DA 2022-04-25
ER

PT J
AU Khan, GJ
   Rizwan, M
   Abbas, M
   Naveed, M
   Yu, BY
   Naeem, MA
   Khan, S
   Yuan, ST
   Baig, MMFA
   Sun, L
AF Khan, Ghulam Jilany
   Rizwan, Mohsin
   Abbas, Muhammad
   Naveed, Muhammad
   Yu Boyang
   Naeem, Muhammad Ahsan
   Khan, Sara
   Yuan, Shengtao
   Baig, Mirza Muhammad Faran Ashraf
   Sun, Li
TI Pharmacological effects and potential therapeutic targets of DT-13
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE DT-13; Anti-cancer; Anti-metastasis; Cardio protective; Pharmacological
   effects
ID DWARF LILYTURF TUBER; RADIX-OPHIOPOGON-JAPONICUS; CANCER-CELL-MIGRATION;
   LIRIOPE-MUSCARI; SAPONIN MONOMER; AQUEOUS EXTRACT; STEROIDAL SAPONINS;
   CALCIUM CURRENTS; LUNG-CANCER; HYPOXIA
AB DT-13 is an isolated compound from Dwarf lillytruf tuber and currently among active research drugs by National Natural Science foundation of China for its several potential effects. The drug has been reported for its multiple pharmacological actions however no thorough review studies are available on it. Our present study is highlighting the pros and cons of DT-13 focusing on its potential pharmacological actions, therapeutic utilization and further exploration for novel targets. The drug possesses very low toxicity profile, quick onset and long duration of action with slow elimination that combinely makes it favorable for the clinical studies. In vivo and in vitro studies show that the drug regulates multiple cellular functions for its several pharmacological effects including, anti-adhesive effects via regulation of tissue factor and transforming growth factor; anti-migratory effects through indirect regulation of NM-IIA in the tumor microenvironment, Tissue factor, down-regulation of CCR5-CCL5 axis and MMP-2/9 inhibition; anti-metastatic effects via regulation of MMPs and tissue factor; proapoptotic effects by modulation of endocytosis of EGF receptor; anti-angiogenic effects via regulation of HIF1a, ERK, Akt signalling and autophagy inducing characteristics by regulating PI3K/Akt/mTOR signalling pathway. In addition to anti-tumor activities, DT-13 has significant anti-inflammatory, cardioprotective, hepatoprotective and immunomodulating effects. Pharmaceutical dosage form and targeted drug delivery system for DT-13 has not been established yet. Moreover, DT-13, has not been studied for its action on brain, colorectal, hepatic, pancreatic, prostate and blood cancers. Similarly the effects of drug on carbohydrate and glucose metabolism is another niche yet to be explored. In some traditional therapies, crude drug from the plant is used against diabetic and neurological disorders that are not reported in scientific literature, however due to profound
C1 [Khan, Ghulam Jilany; Sun, Li] China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Jiangsu, Peoples R China.
   [Khan, Ghulam Jilany] Univ Cent Punjab, Fac Pharm, Dept Pharmacol, Lahore, Pakistan.
   [Khan, Ghulam Jilany; Yuan, Shengtao] China Pharmaceut Univ, Jiangsu Ctr Pharmacodynam Res & Evaluat, Nanjing 210009, Jiangsu, Peoples R China.
   [Rizwan, Mohsin; Naeem, Muhammad Ahsan] Univ Engn & Technol, Dept Mechatron & Control Engn, Lahore, Pakistan.
   [Abbas, Muhammad; Naveed, Muhammad] China Pharmaceut Univ, Dept Clin Pharm, Sch Basic Med & Clin Pharm, Sch Pharm, Nanjing 211198, Jiangsu, Peoples R China.
   [Abbas, Muhammad] Affiliated Nanjing Med Univ, Dept Med Oncol, Jiangsu Canc Hosp, Nanjing 211198, Jiangsu, Peoples R China.
   [Abbas, Muhammad] Jiangsu Inst Canc & Res, Nanjing 211198, Jiangsu, Peoples R China.
   [Yu Boyang] China Pharmaceut Univ, Dept Complex Prescript Tradit Chinese Med, Sch Chinese Mat Med, Nanjing 210009, Jiangsu, Peoples R China.
   [Khan, Sara] Univ Punjab, Univ Coll Pharm, Dept Pharmaceut Chem, Lahore, Pakistan.
   [Baig, Mirza Muhammad Faran Ashraf] Nanjing Univ, State Key Lab Coordinat Chem, Sch Chem & Chem Engn, Nanjing 210023, Jiangsu, Peoples R China.
RP Sun, L (corresponding author), China Pharmaceut Univ, Jiangsu Key Lab Drug Screening, Nanjing 210009, Jiangsu, Peoples R China.; Yuan, ST (corresponding author), China Pharmaceut Univ, Jiangsu Ctr Pharmacodynam Res & Evaluat, Nanjing 210009, Jiangsu, Peoples R China.
EM U4574904@hotmail.com; U4574904@aol.com; tanoliabbass7@yahoo.com;
   navedO4@yahoo.com; boyangyu59@163.com; mahsan.naeem@gmail.com;
   Pharmacist_pu@hotmail.com; 13914798635@163.com; u4574904@gmail.com;
   Sunli@cpu.edu.cn
RI Khan, Ghulam Jilany/C-2135-2017; Baig, Mirza Muhammad Faran
   Ashraf/N-8128-2014; Abbas, Muhammad/AAY-1430-2020; Naveed,
   Muhammad/Y-3856-2018
OI Khan, Ghulam Jilany/0000-0002-2748-5314; Baig, Mirza Muhammad Faran
   Ashraf/0000-0003-4791-9594; Abbas, Muhammad/0000-0002-4453-0981; Naveed,
   Muhammad/0000-0002-2193-9266
FU National natural science foundation of chinaNational Natural Science
   Foundation of China (NSFC) [81573456, 81773766]
FX The work is supported by National natural science foundation of china
   (Grant No.< gn1 > 81573456 < /gn1 > and Grant no.< gn1 > 81773766 < /gn1
   >)
CR Abbas M, 2017, BIOMED PHARMACOTHER, V95, P1082, DOI 10.1016/j.biopha.2017.09.032
   [Anonymous], 2015, DT 13 PUBCHE7 COMP D
   Beach JR, 2011, P NATL ACAD SCI USA, V108, P17991, DOI 10.1073/pnas.1106499108
   Boyang Y., 1995, CHIN TRADIT HERB DRU, V4
   Chen Chao-yang, 2013, COMPLEMENTARY ALTERN, V2013, P14
   Chen LL, 2011, J PHARMACEUT BIOMED, V56, P650, DOI 10.1016/j.jpba.2011.07.003
   CHEN M, 1990, ACTA PHARM SINIC, V11, P161
   Conti MA, 2008, J CELL SCI, V121, P11, DOI 10.1242/jcs.007112
   Coukell AJ, 1999, PHARMACOECONOMICS, V15, P405, DOI 10.2165/00019053-199915040-00008
   Du HZ, 2016, ONCOL REP, V36, P721, DOI 10.3892/or.2016.4890
   Duan CL, 2010, HELV CHIM ACTA, V93, P227, DOI 10.1002/hlca.200900165
   FANG XC, 1990, J CHROMATOGR, V514, P287, DOI 10.1016/S0021-9673(01)89400-0
   Feng Y., 2014, APPL DWARF LILYTURF
   Guan T, 2013, EUR J PHARMACOL, V714, P303, DOI 10.1016/j.ejphar.2013.07.036
   Herben VMM, 1996, CLIN PHARMACOKINET, V31, P85, DOI 10.2165/00003088-199631020-00001
   Huang YL, 2008, J PHARMACOL SCI, V108, P198, DOI 10.1254/jphs.08083FP
   Ishibashi H, 2001, BRIT J PHARMACOL, V132, P461, DOI 10.1038/sj.bjp.0703818
   Jiang L, 2012, WORLD J GASTROENTERO, V18, P2035, DOI 10.3748/wjg.v18.i17.2035
   Jilany K. Ghulam, 2017, CURR CANCER DRUG TAR, V17, P1
   Jordan R. Beach, 2014, CURR BIOL, V24, P1160
   Kanard A, 2004, LUNG CANCER, V43, P345, DOI 10.1016/j.lungcan.2003.09.012
   Kefeng Z., 2015, THROMB HAEMOSTASIS, V114, P173
   Kohga K, 2010, J HEPATOL, V52, P872, DOI 10.1016/j.jhep.2009.12.030
   Kou JP, 2005, BIOL PHARM BULL, V28, P1234, DOI 10.1248/bpb.28.1234
   Kou J, 2006, BIOL PHARM BULL, V29, P1267, DOI 10.1248/bpb.29.1267
   Lan S, 2013, FITOTERAPIA, V85, P57, DOI 10.1016/j.fitote.2012.12.025
   Li F, 2015, ACTA PHARMACOL SIN, V36, P1337, DOI 10.1038/aps.2015.70
   Li H. H., 2017, PLANT CELL TISSUE OR, V2017, P1, DOI DOI 10.1016/J.EC0LM0DEL.2017.01.003
   Li HY, 2016, EUR J PHARMACOL, V781, P164, DOI 10.1016/j.ejphar.2016.04.016
   Liang HH, 2012, J APPL MATH, DOI 10.1155/2012/498073
   Lin SS, 2014, CHIN J NAT MEDICINES, V12, P833, DOI 10.1016/S1875-5364(14)60125-4
   Lv YN, 2013, J MOL MODEL, V19, P1801, DOI 10.1007/s00894-012-1750-3
   Ma ST, 2011, FOOD CHEM TOXICOL, V49, P2243, DOI 10.1016/j.fct.2011.06.022
   Mimaki Y, 1996, PHYTOCHEMISTRY, V42, P1609, DOI 10.1016/0031-9422(96)00107-0
   Mimaki Y, 2001, BIOL PHARM BULL, V24, P1286, DOI 10.1248/bpb.24.1286
   Mochitomi Yuji, 1998, Journal of Dermatology (Tokyo), V25, P662
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nikkaji, 2015, DT 13 NCBI PUBCHEM D
   Podolak I, 2010, PHYTOCHEM REV, V9, P425, DOI 10.1007/s11101-010-9183-z
   Qian JC, 2010, J ETHNOPHARMACOL, V128, P438, DOI 10.1016/j.jep.2010.01.031
   Qiu C, 2014, BIOCHEM BIOPH RES CO, V443, P74, DOI 10.1016/j.bbrc.2013.11.056
   Ribeiro J, 2015, BIOINFORMATICS, V31, P2751, DOI 10.1093/bioinformatics/btv203
   Saeed M, 2017, BIOMED PHARMACOTHER, V95, P1260, DOI 10.1016/j.biopha.2017.09.024
   Shutova MS, 2014, CURR BIOL, V24, P1958, DOI 10.1016/j.cub.2014.07.070
   Sun Li, 2010, Chinese Journal of Natural Medicines, V8, P466, DOI 10.3724/SP.J.1009.2010.00466
   Sun L, 2010, BIOL PHARM BULL, V33, P1192, DOI 10.1248/bpb.33.1192
   TADA A, 1973, CHEM PHARM BULL, V21, P308
   Tao J, 2005, LIFE SCI, V77, P3021, DOI 10.1016/j.lfs.2005.01.039
   Tao J, 2005, AM J CHINESE MED, V33, P797, DOI 10.1142/S0192415X05003417
   Tian You-Qing, 2011, Chinese Journal of Natural Medicines, V9, P222, DOI 10.3724/SP.J.1009.2011.00222
   Tian YQ, 2013, INDIAN J PHARMACOL, V45, P283, DOI 10.4103/0253-7613.111896
   Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786
   Wang ZH, 2017, THERMOCHIM ACTA, V651, P53, DOI 10.1016/j.tca.2017.02.018
   WATANABE Y, 1977, CHEM PHARM BULL, V25, P3049
   Wei XH, 2016, ONCOL REP, V36, P991, DOI 10.3892/or.2016.4879
   Weng X., 2017, CYTOKINE
   Wu FH, 2001, J PHARM PHARMACOL, V53, P681, DOI 10.1211/0022357011775802
   Wu Y, 2017, RSC ADV, V7, P13696, DOI 10.1039/c6ra26031d
   Xiao P., 2002, MODERN CHINESE MAT M
   Xiong S. L., 2012, J DAIRY RES, V25, P315
   Xiong SL, 2011, CARBOHYD POLYM, V86, P1273, DOI 10.1016/j.carbpol.2011.06.025
   Xu Q., 1993, CHIN J IMMUNOL, V9, P287
   XU Q, 1993, J CHIN PHARM U, V24, P98
   Xu TH, 2008, J ASIAN NAT PROD RES, V10, P415, DOI 10.1080/10286020801966567
   Xu XH, 2016, MOLECULES, V21, DOI 10.3390/molecules21101326
   Yang CR, 2006, ANTIMICROB AGENTS CH, V50, P1710, DOI 10.1128/AAC.50.5.1710-1714.2006
   Yu Bo-Yang, 2007, Chinese Journal of Natural Medicines, V5, P10
   YU BY, 1990, CHEM PHARM BULL, V38, P1931, DOI 10.1248/cpb.38.1931
   Yu J. Q. Boyang, 2011, CN102180932A
   Yu XW, 2016, ONCOTARGET, V7, P32990, DOI 10.18632/oncotarget.8843
   Zhai KF, 2017, BRIT J PHARMACOL, V174, P2818, DOI 10.1111/bph.13885
   Zhang M, 2017, FRONT IMMUNOL, V8, P1, DOI 10.3389/fimmu.2017.00942
   Zhang YY, 2012, CHIN J NAT MEDICINES, V10, P436, DOI [10.3724/SP.J.1009.2012.00436, 10.1016/S1875-5364(12)60084-3]
   Zhang YY, 2015, INT J BIOL SCI, V11, P970, DOI 10.7150/ijbs.11635
   Zhao RP, 2014, CHIN J NAT MEDICINES, V12, P24, DOI [10.3724/SP.J.1009.2014.00024, 10.1016/S1875-5364(14)60005-4]
   Zhao RP, 2013, ONCOL REP, V29, P1379, DOI 10.3892/or.2013.2272
NR 76
TC 25
Z9 25
U1 2
U2 26
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2018
VL 97
BP 255
EP 263
DI 10.1016/j.biopha.2017.10.101
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4NC
UT WOS:000419041300034
PM 29107216
DA 2022-04-25
ER

PT J
AU Polato, F
   Rusconi, P
   Zangrossi, S
   Morelli, F
   Boeri, M
   Musi, A
   Marchini, S
   Castiglioni, V
   Scanziani, E
   Torri, V
   Broggini, M
AF Polato, Federica
   Rusconi, Paolo
   Zangrossi, Stefano
   Morelli, Federica
   Boeri, Mattia
   Musi, Alberto
   Marchini, Sergio
   Castiglioni, Vittoria
   Scanziani, Eugenio
   Torri, Valter
   Broggini, Massimo
TI DRAGO (KIAA0247), a New DNA Damage-Responsive, p53-Inducible Gene That
   Cooperates With p53 as Oncosupprossor
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID COLORECTAL-CANCER; ACTIVATION; BINDING; PROTEIN; ACETYLATION;
   METHYLATION; SUPPRESSION; MEDIATOR; INNATE; FAMILY
AB Background p53 influences genomic stability, apoptosis, autophagy, response to stress, and DNA damage. New p53-target genes could elucidate mechanisms through which p53 controls cell integrity and response to damage.
   Methods DRAGO (drug-activated gene overexpressed, KIAA0247) was characterized by bioinformatics methods as well as by real-time polymerase chain reaction, chromatin immunoprecipitation and luciferase assays, time-lapse microscopy, and cell viability assays. Transgenic mice (94 p53(-/-) and 107 p53(+/-) mice on a C57BL/6J background) were used to assess DRAGO activity in vivo. Survival analyses were performed using Kaplan-Meier curves and the Mantel-Haenszel test. All statistical tests were two-sided.
   Results We identified DRAGO as a new p53-responsive gene induced upon treatment with DNA-damaging agents. DRAGO is highly conserved, and its ectopic overexpression resulted in growth suppression and cell death. DRAGO(-/-) mice are viable without macroscopic alterations. However, in p53(-/-) or p53(+/-) mice, the deletion of both DRAGO alleles statistically significantly accelerated tumor development and shortened lifespan compared with p53(-/-) or p53(+/-) mice bearing wild-type DRAGO alleles (p53(-/-), DRAGO(-/-) mice: hazard ratio [HR] = 3.25, 95% confidence interval [CI] = 1.7 to 6.1, P < .001; p53(+/-), DRAGO(-/-) mice: HR = 2.35, 95% CI = 1.3 to 4.0, P < .001; both groups compared with DRAGO(+/+) counterparts). DRAGO mRNA levels were statistically significantly reduced in advanced-stage, compared with early-stage, ovarian tumors, but no mutations were found in several human tumors. We show that DRAGO expression is regulated both at transcriptional-through p53 (and p73) and methylation-dependent control-and post-transcriptional levels by miRNAs.
   Conclusions DRAGO represents a new p53-dependent gene highly regulated in human cells and whose expression cooperates with p53 in tumor suppressor functions.
C1 [Polato, Federica; Rusconi, Paolo; Zangrossi, Stefano; Morelli, Federica; Boeri, Mattia; Musi, Alberto; Marchini, Sergio; Broggini, Massimo] IRCCS Ist Ric Farmacol Mario Negri, Mol Pharmacol Lab, Dept Oncol, I-20156 Milan, Italy.
   [Torri, Valter] IRCCS Ist Ric Farmacol Mario Negri, Lab Methodol Biomed Res, Dept Oncol, I-20156 Milan, Italy.
   [Castiglioni, Vittoria; Scanziani, Eugenio] Univ Milan, Dipartimento Patol Anim Igiene & Sanita Pubbl Vet, Milan, Italy.
   [Castiglioni, Vittoria; Scanziani, Eugenio] Fdn Filarete, Mouse & Anim Pathol Lab, Milan, Italy.
RP Broggini, M (corresponding author), IRCCS Ist Ric Farmacol Mario Negri, Via G La Masa 19, I-20156 Milan, Italy.
EM massimo.broggini@marionegri.it
RI Torri, Valter/H-7550-2015; Boeri, Mattia/L-4393-2013; Marchini,
   sergio/J-3968-2018; broggini, massimo/AAA-6460-2020; Polato,
   Federica/Q-1803-2018; Scanziani, Eugenio/G-8046-2017
OI Torri, Valter/0000-0001-9541-9354; Boeri, Mattia/0000-0001-7106-3138;
   Marchini, sergio/0000-0003-1783-7651; Scanziani,
   Eugenio/0000-0003-3996-5048; BROGGINI, MASSIMO/0000-0002-8138-9358
CR Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x
   Aylon Y, 2011, CURR OPIN GENET DEV, V21, P86, DOI 10.1016/j.gde.2010.10.002
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117
   DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X
   ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P
   Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019
   Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462
   Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8
   HARPER JW, 1993, CELL, V75, P805
   Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7
   Huang CJ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-82
   Kodach LL, 2010, CARCINOGENESIS, V31, P1567, DOI 10.1093/carcin/bgq147
   Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Li H, 2011, CELL CYCLE, V10, P3346, DOI 10.4161/cc.10.19.17630
   Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008
   Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101
   Marchini S, 2001, EXPERT OPIN INV DRUG, V10, P1703, DOI 10.1517/13543784.10.9.1703
   Menendez D, 2009, NAT REV CANCER, V9, P724, DOI 10.1038/nrc2730
   Munoz-Fontela C, 2011, J IMMUNOL, V187, P6428, DOI 10.4049/jimmunol.1101459
   Nagase T, 1996, DNA Res, V3, P321, DOI 10.1093/dnares/3.5.321
   Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3
   Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053
   Rigatti MJ, 2012, MOL CARCINOGEN, V51, P363, DOI 10.1002/mc.20795
   SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175
   Schwanzer-Pfeiffer D, 2010, CELL IMMUNOL, V263, P65, DOI 10.1016/j.cellimm.2010.02.017
   Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X
   SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781
   Staib F, 2005, CANCER RES, V65, P10255, DOI 10.1158/0008-5472.CAN-05-1714
   Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864
   Wang YM, 2007, CLIN CANCER RES, V13, P4111, DOI 10.1158/1078-0432.CCR-07-0408
   Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141
NR 35
TC 11
Z9 14
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD APR
PY 2014
VL 106
IS 4
AR dju053
DI 10.1093/jnci/dju053
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AF4OA
UT WOS:000334691500028
PM 24652652
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Abraham, D
   Jackson, N
   Gundara, JS
   Zhao, JT
   Gill, AJ
   Delbridge, L
   Robinson, BG
   Sidhu, SB
AF Abraham, Deepak
   Jackson, Nicole
   Gundara, Justin S.
   Zhao, JingTing
   Gill, Anthony J.
   Delbridge, Leigh
   Robinson, Bruce G.
   Sidhu, Stan B.
TI MicroRNA Profiling of Sporadic and Hereditary Medullary Thyroid Cancer
   Identifies Predictors of Nodal Metastasis, Prognosis, and Potential
   Therapeutic Targets
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID RET PROTOONCOGENE; COLORECTAL-CANCER; SOMATIC MUTATIONS; CARCINOMA;
   EXPRESSION; DISSECTION; ONCOGENE; CELLS
AB Purpose: While the molecular basis of hereditary medullary thyroid cancer (HMTC) has been well defined, little is known about the molecular pathogenesis of sporadic medullary thyroid cancer (SMTC). In addition, microRNAs (miRNAs) have been shown to be important diagnostic and prognostic markers in cancer but have not been defined in MTC. Our aim was to study the miRNA profile of MTC to identify prognostic biomarkers and potential therapeutic targets.
   Experimental Design: MiRNA microarray profiling was carried out in fresh frozen tissues from patients with SMTC (n = 12) and HMTC (n = 7). Differential expression of three miRNAs was confirmed in a validation cohort of SMTC and HMTC samples (n = 45) using quantitative reverse transcriptase-PCR and correlated with clinical outcomes. The functional role of a selected miRNA was investigated in vitro in the human medullary thyroid carcinoma cell line (TT cells) using cell proliferation assays and Western blotting analysis.
   Results: MiRs-183 and 375 were overexpressed (P = 0.001; 0.031) and miR-9* was under-expressed (P = 0.011) in SMTC versus HMTC. Overexpression of miRs-183 and 375 in MTC predicted lateral lymph node metastases (P < 0.001; P = 0.001) and was associated with residual disease (P = 0.001; 0.003), distant metastases (P = 0.003; 0.001), and mortality (P = 0.01; 0.011). Knock down of miR-183 expression in the TT cell line induced a significant decrease in the viable cell count and upregulation of the protein LC3B, which is associated with autophagy.
   Conclusions: Our data indicate that miRNAs play a pivotal role in the biology of MTC and represent an important class of prognostic biomarkers and therapeutic targets warranting further investigation. Clin Cancer Res; 17(14); 4772-81. (C)2011 AACR.
C1 [Abraham, Deepak; Jackson, Nicole; Gundara, Justin S.; Zhao, JingTing; Robinson, Bruce G.; Sidhu, Stan B.] Univ Sydney, Kolling Inst Med Res, Royal N Shore Hosp, Sydney, NSW 2006, Australia.
   [Abraham, Deepak; Gundara, Justin S.; Delbridge, Leigh; Sidhu, Stan B.] Univ Sydney, Royal N Shore Hosp, Dept Endocrine Surg Unit, Sydney, NSW 2006, Australia.
RP Sidhu, SB (corresponding author), Level 2,69 Christie St, St Leonards, NSW 2065, Australia.
EM stansidhu@nebsc.com.au
RI Sidhu, Stan/K-1555-2015; Gill, Anthony J/D-4215-2015; Gill, Anthony
   J./M-5015-2019
OI Gill, Anthony J/0000-0002-9447-1967; Delbridge,
   leigh/0000-0001-8281-8831
FU NSW Cancer Institute; Endeavour International Postgraduate Research
   ScholarshipAustralian Government
FX This work was supported by a NSW Cancer Institute Research Innovation
   Grant. D. Abraham is an Endeavour International Postgraduate Research
   Scholarship recipient. S. Sidhu is a NSW Cancer Institute Fellow.
CR ABRAHAM DT, 2010, ANN SURG ONCOL
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bastian BC, 1998, CANCER RES, V58, P2170
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Chen YT, 2008, MODERN PATHOL, V21, P1139, DOI 10.1038/modpathol.2008.105
   Clayman GL, 2003, OTOLARYNG CLIN N AM, V36, P91, DOI 10.1016/S0030-6665(02)00136-6
   desSouza Rocha Simonini P, 2010, CANC RE, V70, P9175
   Dvorakova S, 2008, MOL CELL ENDOCRINOL, V284, P21, DOI 10.1016/j.mce.2007.12.016
   Elisei R, 2008, J CLIN ENDOCR METAB, V93, P682, DOI 10.1210/jc.2007-1714
   Gimm O, 1997, J CLIN ENDOCR METAB, V82, P3902, DOI 10.1210/jc.82.11.3902
   HAZARD JB, 1959, J CLIN ENDOCR METAB, V19, P152, DOI 10.1210/jcem-19-1-152
   Hundahl SA, 1998, CANCER-AM CANCER SOC, V83, P2638, DOI 10.1002/(SICI)1097-0142(19981215)83:12<2638::AID-CNCR31>3.0.CO;2-1
   Jiang JM, 2005, NUCLEIC ACIDS RES, V33, P5394, DOI 10.1093/nar/gki863
   Kebebew E, 2000, CANCER-AM CANCER SOC, V88, P1139, DOI 10.1002/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z
   Kloos RT, 2009, THYROID, V19, P565, DOI 10.1089/thy.2008.0403
   Leboulleux S, 2004, CLIN ENDOCRINOL, V61, P299, DOI 10.1111/j.1365-2265.2004.02037.x
   Li JP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-354
   Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Machens A, 2008, BRIT J SURG, V95, P586, DOI 10.1002/bjs.6075
   Machens A, 2010, J CLIN ENDOCR METAB, V95, P2655, DOI 10.1210/jc.2009-2368
   Marsh DJ, 1996, CLIN ENDOCRINOL, V44, P249, DOI 10.1046/j.1365-2265.1996.681503.x
   Meyer-Rochow GY, 2010, ENDOCR-RELAT CANCER, V17, P835, DOI 10.1677/ERC-10-0142
   Motoyama K, 2009, INT J ONCOL, V34, P1069, DOI 10.3892/ijo_00000233
   Pelizzo MR, 2007, EJSO-EUR J SURG ONC, V33, P493, DOI 10.1016/j.ejso.2006.10.021
   Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074
   Scollo C, 2003, J CLIN ENDOCR METAB, V88, P2070, DOI 10.1210/jc.2002-021713
   Soon PSH, 2009, CLIN CANCER RES, V15, P7684, DOI 10.1158/1078-0432.CCR-09-1587
   Uchino S, 1998, JPN J CANCER RES, V89, P411, DOI 10.1111/j.1349-7006.1998.tb00579.x
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang GF, 2008, FEBS LETT, V582, P3663, DOI 10.1016/j.febslet.2008.09.051
   Weber T, 2001, SURGERY, V130, P1044, DOI 10.1067/msy.2001.118380a
NR 33
TC 109
Z9 119
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUL 15
PY 2011
VL 17
IS 14
BP 4772
EP 4781
DI 10.1158/1078-0432.CCR-11-0242
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 793JI
UT WOS:000292816900016
PM 21622722
DA 2022-04-25
ER

PT J
AU Wang, Y
   Wang, Y
   Wang, J
   Lei, W
   Li, K
   Wu, DC
   Wang, XJ
AF Wang, Ying
   Wang, Ya
   Wang, Ji
   Lei, Wan
   Li, Ke
   Wu, Daocheng
   Wang, Xiaojuan
TI Pharmacokinetics, biodistribution, and bioavailability of
   gossypol-loaded Pluronic (R) F127 nanoparticles
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Article
DE Gossypol; Pluronic (R) F127; Nanoparticle; Pharmacokinetics;
   Biodistribution
ID COLORECTAL-CARCINOMA CELLS; BLOCK-COPOLYMER MICELLES; PROSTATE-CANCER;
   DRUG-DELIVERY; INHIBITOR; (-)-GOSSYPOL; AUTOPHAGY; GROWTH; BCL-2;
   PROLIFERATION
AB To enhance the water solubility and improve the bioavailability of gossypol, gossypol-loaded Pluronic (R) F127 nanoparticles (GLPFNs) for intravenous (i.v.) administration were prepared through thin-film hydration. The morphological characteristics of the GLPFNs were determined by transmission electron microscopy and particle size analysis. Pharmacokinetic and biodistribution studies were performed using Kun Ming (KM) mice by measuring gossypol concentrations in plasma and tissue samples of the mice using ultra-high performance liquid chromatography-electrospray ionization-tandem mass spectrometry (UHPLC- ESI-MS/MS). The GLPFNs exhibited uniform spherical shapes with a dynamic size of 70 +/- 2.4 nm. The encapsulation and drug-loading efficiencies of the GLPFNs were 91.2% +/- 3.1% and 9.1% +/- 0.42%, respectively. The particles further exhibited sustained drug release for about 200 h. The UHPLC-ESI-MS/MS method used in this work for plasma and tissue sample analysis was fully validated. The pharmacokinetics of the GLPFNs was studied after intravenous (i.v.) and intragastric (i.g.) administration to KM mice, and tissue distribution studies of the GLPFNs were performed. The AUC (0-inf) of the GLPFNs exhibited five- and sixfold increases. The clearance of GLPFNs decreased up to 5.6-fold when the gossypol entrapped in GLPFNs was i.g. administered. The absolute bioavailability of GLPFNs, which was 44.32%, increased by threefold compared with that of gossypol alone. The relative bioavailability of the GLPFNs after intravenous (i.v.) and intragastric (i.g.) administration was 192.38% and 560.75%, respectively. The concentration of GLPFNs was higher than that of gossypol, especially in reticuloendothelial cell-containing organs. Thus, the GLPFNs improved the bioavailability of the lipophilic drug gossypol. The gossypol-loaded Pluronic (R) F127 nanoparticles exhibited high biocompatibility and tunable drug release characteristics for treating cancer.
C1 [Wang, Ying; Wang, Ji; Lei, Wan; Wang, Xiaojuan] Fourth Mil Med Univ, State Key Lab Mil Stomatol, Sch Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Ying; Wang, Ji; Lei, Wan; Wang, Xiaojuan] Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Sch Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Ying; Wang, Ji; Lei, Wan; Wang, Xiaojuan] Fourth Mil Med Univ, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, Dept Pharm, Xian 710032, Shaanxi, Peoples R China.
   [Wang, Ya; Li, Ke; Wu, Daocheng] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Educ Minist, Xian 710049, Shaanxi, Peoples R China.
RP Wang, XJ (corresponding author), Fourth Mil Med Univ, State Key Lab Mil Stomatol, Sch Stomatol, Xian 710032, Shaanxi, Peoples R China.; Wang, XJ (corresponding author), Fourth Mil Med Univ, Natl Clin Res Ctr Oral Dis, Sch Stomatol, Xian 710032, Shaanxi, Peoples R China.; Wang, XJ (corresponding author), Fourth Mil Med Univ, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Sch Stomatol, Dept Pharm, Xian 710032, Shaanxi, Peoples R China.; Wu, DC (corresponding author), Xi An Jiao Tong Univ, Sch Life Sci & Technol, Key Lab Biomed Informat Engn, Educ Minist, Xian 710049, Shaanxi, Peoples R China.
EM wudaocheng@mail.xjtu.edu.cn; wxjyh231@fmmu.edu.cn
OI Wu, Daocheng/0000-0002-6183-539X
FU Shan xi province science and technology and innovation project
   [2011KTCL03-07, 2011KTCL03-01]
FX This study was supported by the grants of Shan xi province science and
   technology and innovation project (Nos. 2011KTCL03-07 and
   2011KTCL03-01).
CR Ahn JH, 2013, J CELL PHYSIOL, V228, P1496, DOI 10.1002/jcp.24305
   Bauer JA, 2005, MOL CANCER THER, V4, P1096, DOI 10.1158/1535-7163.MCT-05-0081
   Chien CC, 2012, J CELL PHYSIOL, V227, P3128, DOI 10.1002/jcp.23067
   Cho H, 2013, J CONTROL RELEASE, V166, P1, DOI 10.1016/j.jconrel.2012.12.005
   Huang SJ, 2009, EUR J PHARM SCI, V38, P64, DOI 10.1016/j.ejps.2009.06.002
   Jia L, 2008, CANCER CHEMOTH PHARM, V61, P63, DOI 10.1007/s00280-007-0446-3
   Jiang JH, 2012, CLIN EXP METASTAS, V29, P165, DOI 10.1007/s10585-011-9439-z
   Kenar J.A., 2007, CHEMINFORM, V38, P269
   Ko CH, 2007, INT J CANCER, V121, P1670, DOI 10.1002/ijc.22910
   Kozlov MY, 2000, MACROMOLECULES, V33, P3305, DOI 10.1021/ma991634x
   Kwon SH, 2007, ARCH PHARM RES, V30, P1138, DOI 10.1007/BF02980249
   Li H, 2011, PHARM RES-DORDR, V28, P3256, DOI 10.1007/s11095-011-0498-2
   Li J, 2013, J AGR FOOD CHEM, V61, P1309, DOI 10.1021/jf3043055
   Li ZM, 2008, CANCER BIOL THER, V7, P51, DOI 10.4161/cbt.7.1.5128
   Lian J, 2011, CELL DEATH DIFFER, V18, P60, DOI 10.1038/cdd.2010.74
   Lian JQ, 2012, MOL CANCER THER, V11, P416, DOI 10.1158/1535-7163.MCT-11-0559
   [林圣森 Lin Shengsen], 2011, [日用化学工业, China Surfactant Detergent and Cosmetics], V41, P313
   Liu H, 2014, J MATER CHEM B, V2, P5238, DOI 10.1039/c4tb00539b
   Liu XM, 2004, BIOMATERIALS, V25, P2619, DOI 10.1016/j.biomaterials.2003.09.028
   Mao C, 2009, COLLOID SURFACE B, V74, P362, DOI 10.1016/j.colsurfb.2009.07.022
   Mohammad RM, 2005, PANCREAS, V31, P317, DOI 10.1097/01.mpa.0000179731.46210.01
   Mya KY, 2010, J PHYS CHEM B, V114, P9128, DOI 10.1021/jp102919t
   Ni ZH, 2013, LEUKEMIA LYMPHOMA, V54, P2263, DOI 10.3109/10428194.2013.775437
   Qian CY, 2014, DRUG DES DEV THER, V8, P485, DOI 10.2147/DDDT.S62963
   Sahu A, 2011, J BIOMATER APPL, V25, P619, DOI 10.1177/0885328209357110
   Wang X, 2008, J AGR FOOD CHEM, V56, P4393, DOI 10.1021/jf073297u
   Wang Y, 2012, ADV DRUG DELIVER REV, V64, P852, DOI 10.1016/j.addr.2012.03.011
   Wu Y, 2015, GENET MOL RES, V14, P13456, DOI 10.4238/2015.October.28.6
   Wulff-Perez M, 2012, INT J PHARMACEUT, V423, P161, DOI 10.1016/j.ijpharm.2011.12.025
   Yu L, 2013, SEMIN CANCER BIOL, V23, P553, DOI 10.1016/j.semcancer.2013.08.008
   Yuan Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.191
   Zhai GX, 2008, ANTICANCER RES, V28, P2801
   Zhang W, 2011, BIOMATERIALS, V32, P2894, DOI 10.1016/j.biomaterials.2010.12.039
   Zhang XQ, 2010, ASIAN J ANDROL, V12, P390, DOI 10.1038/aja.2009.87
   Zhong DF., 2011, DRUG EVAL RES, V34, P409
   Zhong S, 2013, ANTICANCER RES, V33, P949
NR 36
TC 15
Z9 15
U1 3
U2 27
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1773-2247
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD JUN
PY 2018
VL 45
BP 388
EP 396
DI 10.1016/j.jddst.2018.04.002
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GM8QQ
UT WOS:000438498100044
DA 2022-04-25
ER

PT J
AU Wang, ZG
   Chen, K
   Li, DC
   Chen, MD
   Li, AQ
   Wang, J
AF Wang, Zhengguang
   Chen, Ke
   Li, Dongchang
   Chen, Mengding
   Li, Angqing
   Wang, Jian
TI miR-140-3p is involved in the occurrence and metastasis of gastric
   cancer by regulating the stability of FAM83B
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Gastric cancer; miR-140-3p; SNHG12; RNA-binding protein HuR; FAM38B;
   Proliferation; Nuclear transportation; Metastasis; mRNA stability
ID NONCODING RNA SNHG12; GENE-EXPRESSION; COLORECTAL-CANCER; SIGNALING
   PATHWAY; PROLIFERATION; PROGRESSION; AUTOPHAGY
AB Background Gastric cancer (GC) is a malignant tumor and microRNAs (miRNAs) are closely connected to GC development. The purpose of this study is to investigate the effect of miR-140-3p on the occurrence and metastasis of GC. Methods We detected miR-140-3p expression in GC cells and tissues. The correlation between miR-140-3p and prognosis and clinicopathological features in GC was analyzed. The role of miR-140-3p in GC cell migration, invasion, and proliferation was analyzed. The model of tumor transplantation and metastasis in nude mice was established, and the effect of miR-140-3p on the development and metastasis of GC was assessed. The relation between miR-140-3p and SNHG12 and the relations among HuR, SNHG12, and FAM83B were analyzed. Results miR-140-3p was poorly expressed in GC. GC patients with low miR-140-3p expression had a poor prognosis and unfavorable clinicopathologic features. Overexpression of miR-140-3p inhibited GC cell migration, invasion, and proliferation, and inhibited the development and metastasis of GC. miR-140-3p directly bound to SNHG12 in GC tissues and downregulated SNHG12 expression. SNHG12 overexpression induced HuR nuclear transportation. HuR can bind to FAM83B and up-regulate the mRNA level of FAM83B. Overexpression of SNHG12 or FAM83B reduced the inhibition of overexpression of miR-140-3p on GC. Conclusion miR-140-3p directly bound to SNHG12 in GC and down-regulated the expression of SNHG12, reduced the binding of SNHG12 and HuR, thus inhibiting the nuclear transportation of HuR and the binding of HuR and FAM83B, and reducing the transcription of FAM83B, and finally inhibiting the growth and metastasis of GC.
C1 [Wang, Zhengguang; Chen, Ke] Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
   [Li, Dongchang; Chen, Mengding; Li, Angqing; Wang, Jian] Anhui Med Univ, Hefei 230001, Anhui, Peoples R China.
RP Wang, ZG (corresponding author), Anhui Med Univ, Dept Gen Surg, Affiliated Hosp 1, 218 Jixi Rd, Hefei 230022, Anhui, Peoples R China.
EM wangzhengguang0401@163.com
FU Anhui Provincial Natural Science FoundationNatural Science Foundation of
   Anhui Province [2008085MH294]
FX This work was supported by Anhui Provincial Natural Science Foundation
   [2008085MH294].
CR Allemani C, 2015, LANCET, V385, P977, DOI 10.1016/S0140-6736(14)62038-9
   [Anonymous], 2020, Onco Targets Ther, V13, P5589, DOI 10.2147/OTT.S266115
   [Anonymous], 2011, COMMITTEE UPDATE GUI
   Cai L, 2019, CANCERS, V11, DOI 10.3390/cancers11060886
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen JL, 2021, ONCOTARGETS THER, V14, P2879, DOI 10.2147/OTT.S299234
   Chen RS, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10201
   Cipriano R, 2012, J CLIN INVEST, V122, P3197, DOI 10.1172/JCI60517
   Fu CY, 2019, DISABIL REHABIL, V41, P2881, DOI 10.1080/09638288.2018.1481148
   Goodlad RA, 2017, WIRES DEV BIOL, V6, DOI 10.1002/wdev.274
   Guo WH, 2018, J CANCER, V9, P4363, DOI 10.7150/jca.27533
   He YM, 2020, MOL THER-ONCOLYTICS, V17, P83, DOI 10.1016/j.omto.2020.03.009
   Hu ML, 2019, NEOPLASMA, V66, P176, DOI 10.4149/neo_2018_180703N439
   Hu ML, 2019, ONCOL REP, V41, P1439, DOI 10.3892/or.2019.6962
   Jiang W, 2019, ONCOTARGETS THER, V12, P10275, DOI 10.2147/OTT.S226465
   Lei W, 2018, INT J ONCOL, V53, P1374, DOI 10.3892/ijo.2018.4478
   Li HY, 2019, ARTIF CELL NANOMED B, V47, P3163, DOI 10.1080/21691401.2019.1642903
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Lin QY, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108939
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Menyhart O, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.181006
   Montes M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7967
   Muppirala UK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-489
   Pan HW, 2013, CURR PHARM DESIGN, V19, P1273
   Park S, 2014, REV ENDOCR METAB DIS, V15, P45, DOI 10.1007/s11154-013-9275-3
   Shen XS, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0361-5
   Song ZY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714626
   Suravajhala P, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00255
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Wang J, 2015, ONCOTARGET, V6, P37852, DOI 10.18632/oncotarget.5635
   Xie MY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01208-3
   Xie M, 2019, CANCER LETT, V443, P67, DOI 10.1016/j.canlet.2018.11.032
   Yang BF, 2018, EUR REV MED PHARMACO, V22, P1297, DOI 10.26355/eurrev_201803_14471
   Yang F, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1094-z
   Yoon JH, 2012, MOL CELL, V47, P648, DOI 10.1016/j.molcel.2012.06.027
   Zhang HY, 2018, MOL MED REP, V17, P2743, DOI 10.3892/mmr.2017.8143
   Zhang LW, 2020, BIOCHEM BIOPH RES CO, V525, P841, DOI 10.1016/j.bbrc.2020.02.100
   Zhang R, 2019, AGING-US, V11, P10902, DOI 10.18632/aging.102493
   Zhang TQ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.645832
   Zhang TQ, 2021, INT J BIOL SCI, V17, P1629, DOI 10.7150/ijbs.58921
   Zhao GD, 2019, EXP THER MED, V18, P199, DOI 10.3892/etm.2019.7526
   Zhou Y, 2019, ONCOL LETT, V17, P3835, DOI 10.3892/ol.2019.10038
   Zou ZG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0758-8
NR 43
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD OCT 16
PY 2021
VL 21
IS 1
AR 537
DI 10.1186/s12935-021-02245-8
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WH5ED
UT WOS:000707699900001
PM 34656115
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Eloranta, K
   Cairo, S
   Liljestrom, E
   Soini, T
   Kyronlahti, A
   Judde, JG
   Wilson, DB
   Heikinheimo, M
   Pihlajoki, M
AF Eloranta, Katja
   Cairo, Stefano
   Liljestrom, Emmi
   Soini, Tea
   Kyronlahti, Antti
   Judde, Jean-Gabriel
   Wilson, David B.
   Heikinheimo, Markku
   Pihlajoki, Marjut
TI Chloroquine Triggers Cell Death and Inhibits PARPs in Cell Models of
   Aggressive Hepatoblastoma
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE liver cancer; hepatoblastoma; pediatric oncology; poly(ADP)-ribose
   polymerase; metabolomics; aspartate; NAD(+)
ID COLORECTAL-CANCER CELLS; BREAST-CANCER; STEM-CELLS; IN-VITRO; AUTOPHAGY;
   TUMOR; APOPTOSIS; GROWTH; HYDROXYCHLOROQUINE; POLY(ADP-RIBOSE)
AB Background:Hepatoblastoma (HB) is the most common pediatric liver malignancy. Despite advances in chemotherapeutic regimens and surgical techniques, the survival of patients with advanced HB remains poor, underscoring the need for new therapeutic approaches. Chloroquine (CQ), a drug used to treat malaria and rheumatologic diseases, has been shown to inhibit the growth and survival of various cancer types. We examined the antineoplastic activity of CQ in cell models of aggressive HB. Methods:Seven human HB cell models, all derived from chemoresistant tumors, were cultured as spheroids in the presence of relevant concentrations of CQ. Morphology, viability, and induction of apoptosis were assessed after 48 and 96 h of CQ treatment. Metabolomic analysis and RT-qPCR based Death Pathway Finder array were used to elucidate the molecular mechanisms underlying the CQ effect in a 2-dimensional cell culture format. Quantitative western blotting was performed to validate findings at the protein level. Results:CQ had a significant dose and time dependent effect on HB cell viability both in spheroids and in 2-dimensional cell cultures. Following CQ treatment HB spheroids exhibited increased caspase 3/7 activity indicating the induction of apoptotic cell death. Metabolomic profiling demonstrated significant decreases in the concentrations of NAD(+)and aspartate in CQ treated cells. In further investigations, oxidation of NAD(+)decreased as consequence of CQ treatment and NAD(+)/NADH balance shifted toward NADH. Aspartate supplementation rescued cells from CQ induced cell death. Additionally, downregulated expression of PARP1 and PARP2 was observed. Conclusions:CQ treatment inhibits cell survival in cell models of aggressive HB, presumably by perturbing NAD(+)levels, impairing aspartate bioavailability, and inhibiting PARP expression. CQ thus holds potential as a new agent in the management of HB.
C1 [Eloranta, Katja; Liljestrom, Emmi; Soini, Tea; Kyronlahti, Antti; Heikinheimo, Markku; Pihlajoki, Marjut] Univ Helsinki, Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland.
   [Cairo, Stefano; Judde, Jean-Gabriel] Xentech, Evry, France.
   [Soini, Tea] Karolinska Inst, Ctr Infect Med, Dept Med, Stockholm, Sweden.
   [Wilson, David B.; Heikinheimo, Markku] Washington Univ, Sch Med, Dept Pediat, St Louis Childrens Hosp, St Louis, MO 63110 USA.
   [Wilson, David B.] Washington Univ, Dept Dev Biol, Sch Med, St Louis, MO USA.
RP Pihlajoki, M (corresponding author), Univ Helsinki, Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland.
EM marjut.pihlajoki@helsinki.fi
RI Wilson, David/K-7433-2014
OI Wilson, David/0000-0002-1826-7745; Eloranta, Katja/0000-0002-0396-5137
FU Cancer Foundation Finland; Finska Lakaresallskapet; Helsinki University
   Central Hospital Research Grants; Paivikki, and Sakari Sohlberg
   Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation;
   Doctoral Program in Clinical Research at University of Helsinki Funds
FX This study was supported by the Cancer Foundation Finland, Finska
   Lakaresallskapet, Helsinki University Central Hospital Research Grants,
   Paivikki, and Sakari Sohlberg Foundation, Sigrid Juselius Foundation,
   and Doctoral Program in Clinical Research at University of Helsinki
   Funds.
CR Alam MM, 2016, APOPTOSIS, V21, P1191, DOI 10.1007/s10495-016-1277-7
   Balic A, 2014, MOL CANCER THER, V13, P1758, DOI 10.1158/1535-7163.MCT-13-0948
   Chang YX, 2011, FEBS J, V278, P4811, DOI 10.1111/j.1742-4658.2011.08381.x
   Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Chong J, 2018, NUCLEIC ACIDS RES, V46, pW486, DOI 10.1093/nar/gky310
   COATNEY GR, 1963, AM J TROP MED HYG, V12, P121, DOI 10.4269/ajtmh.1963.12.121
   Czauderna P, 2016, EUR J CANCER, V52, P92, DOI 10.1016/j.ejca.2015.09.023
   De Ioris M, 2008, EUR J CANCER, V44, P545, DOI 10.1016/j.ejca.2007.11.022
   Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6
   Dzieran J, 2008, CANCER SCI, V99, P1685, DOI 10.1111/j.1349-7006.2008.00868.x
   Egger ME, 2013, J SURG RES, V184, P274, DOI 10.1016/j.jss.2013.04.055
   Elliott IA, 2019, P NATL ACAD SCI USA, V116, P6842, DOI 10.1073/pnas.1812410116
   Finegold MJ, 2008, LIVER TRANSPLANT, V14, P1545, DOI 10.1002/lt.21654
   Fuchs J, 2002, EUR J PEDIATR SURG, V12, P255, DOI 10.1055/s-2002-34484
   Garcia-Bermudez J, 2018, NAT CELL BIOL, V20, P775, DOI 10.1038/s41556-018-0118-z
   Geng Y, 2010, NEURO-ONCOLOGY, V12, P473, DOI 10.1093/neuonc/nop048
   Gibson BA, 2012, NAT REV MOL CELL BIO, V13, P411, DOI 10.1038/nrm3376
   Goncalves RM, 2019, BIOCHEM PHARMACOL, V163, P440, DOI 10.1016/j.bcp.2019.03.015
   Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444
   Helmy SA, 2018, CHEM-BIOL INTERACT, V279, P84, DOI 10.1016/j.cbi.2017.11.009
   Hu T, 2016, ONCOL REP, V35, P43, DOI 10.3892/or.2015.4380
   HUGHES LJ, 1992, AM J MED GENET, V43, P1023, DOI 10.1002/ajmg.1320430621
   Jiang PD, 2008, CELL PHYSIOL BIOCHEM, V22, P431, DOI 10.1159/000185488
   Kats Dina, 2019, Oncotarget, V10, P6403, DOI 10.18632/oncotarget.27237
   Kim EL, 2010, NEURO-ONCOLOGY, V12, P389, DOI 10.1093/neuonc/nop046
   LaBarbera DV, 2012, EXPERT OPIN DRUG DIS, V7, P819, DOI 10.1517/17460441.2012.708334
   Lakhter AJ, 2013, J INVEST DERMATOL, V133, P2247, DOI 10.1038/jid.2013.56
   Lee SJ, 2011, NAT REV NEPHROL, V7, P718, DOI 10.1038/nrneph.2011.150
   Liang X, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-10
   Lin YC, 2017, KAOHSIUNG J MED SCI, V33, P215, DOI 10.1016/j.kjms.2017.01.004
   Liu XY, 2016, CELL MOL NEUROBIOL, V36, P1197, DOI 10.1007/s10571-015-0318-z
   Liu YY, 2019, AMB EXPRESS, V9, DOI 10.1186/s13568-019-0836-z
   Lopez-Terrada DH, 2014, DIAGN HISTOPATHOL, V20, P67, DOI [10.1016/j.mpdhp.2014.01.002, DOI 10.1016/J.MPDHP.2014.01.002]
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Maes H, 2014, AUTOPHAGY, V10, P2082, DOI 10.4161/auto.36259
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Molejon Maria Ines, 2018, Oncotarget, V9, P30837, DOI 10.18632/oncotarget.25745
   Monma H, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193990
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Pascolo S, 2016, EUR J PHARMACOL, V771, P139, DOI 10.1016/j.ejphar.2015.12.017
   Pritchard J, 2000, J CLIN ONCOL, V18, P3819, DOI 10.1200/JCO.2000.18.22.3819
   Qu XZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173712
   Quan M, 2015, J CELL BIOCHEM, V116, P1574, DOI 10.1002/jcb.25111
   Quenet D, 2009, INT J BIOCHEM CELL B, V41, P60, DOI 10.1016/j.biocel.2008.07.023
   Rainsford KD, 2015, INFLAMMOPHARMACOLOGY, V23, P231, DOI 10.1007/s10787-015-0239-y
   Raney B, 1997, J PEDIAT HEMATOL ONC, V19, P418, DOI 10.1097/00043426-199709000-00002
   Ren JG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012520
   Roman-Garcia P, 2014, J CLIN INVEST, V124, P2988, DOI 10.1172/JCI72606
   Roy LO, 2015, INVEST NEW DRUG, V33, P1020, DOI 10.1007/s10637-015-0275-x
   Rynes RI, 1997, BRIT J RHEUMATOL, V36, P799
   Samaras P, 2017, CANCER CHEMOTH PHARM, V80, P1005, DOI 10.1007/s00280-017-3446-y
   Schonewolf CA, 2014, WORLD J GASTRO ONCOL, V6, P74, DOI 10.4251/wjgo.v6.i3.74
   SOTELOAVILA C, 1980, J PEDIATR-US, V96, P47, DOI 10.1016/S0022-3476(80)80322-2
   Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017
   Tanimura M, 1998, CANCER RES, V58, P3032
   Valanejad L, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0077-8
   Volkova M, 2011, CURR CARDIOL REV, V7, P214, DOI 10.2174/157340311799960645
   Ye HX, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0700-6
   Yelamos J, 2011, AM J CANCER RES, V1, P328
   Zai WJ, 2020, CARCINOGENESIS, V41, P345, DOI 10.1093/carcin/bgz104
   Zhang YJ, 2017, INT IMMUNOPHARMACOL, V42, P100, DOI 10.1016/j.intimp.2016.11.027
   Zheng YZ, 2009, CANCER INVEST, V27, P286, DOI 10.1080/07357900802427927
   Zou YY, 2013, J THORAC ONCOL, V8, P693, DOI 10.1097/JTO.0b013e31828c7210
   Zsiros J, 2010, J CLIN ONCOL, V28, P2584, DOI 10.1200/JCO.2009.22.4857
NR 65
TC 4
Z9 5
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 17
PY 2020
VL 10
AR 1138
DI 10.3389/fonc.2020.01138
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NA8UD
UT WOS:000560093100001
PM 32766148
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Wei, B
   Wang, YY
   Wang, JW
   Cai, XM
   Xu, LY
   Wu, JJ
   Wang, Y
   Liu, W
   Gu, YH
   Guo, WJ
   Xu, Q
AF Wei, Bin
   Wang, Yuanyuan
   Wang, Jiawei
   Cai, Xiaomin
   Xu, Lingyan
   Wu, Jingjing
   Wang, Ying
   Liu, Wen
   Gu, Yanhong
   Guo, Wenjie
   Xu, Qiang
TI Apatinib suppresses tumor progression and enhances cisplatin sensitivity
   in esophageal cancer via the Akt/beta-catenin pathway
SO CANCER CELL INTERNATIONAL
LA English
DT Article
DE Apatinib; Esophageal cancer; Tumor progression; Cisplatin sensitivity;
   VEGFR2; Akt/beta-catenin pathway
ID COLORECTAL-CANCER; SIGNALING PATHWAY; EXPRESSION; SURVIVAL; EFFICACY;
   AUTOPHAGY; SAFETY
AB Background: Esophageal cancer is the sixth leading cause of cancer-related mortality worldwide, which is partially due to limited progress of therapy. Apatinib, an inhibitor of VEGFR2, has a promising antitumor effect on malignancies. However, the underlying mechanism of its antitumor effect on esophageal cancer remains poorly understood.
   Materials and methods: Eighteen pairs of frozen esophageal cancer and their para-cancer samples and 25 paraffin specimens from advanced esophageal cancer patients treated with cisplatin-based regimen were collected. The effects of apatinib on cell growth, cell apoptosis, cell cycle and invasion/migration of esophageal cancer cells were assessed. Bioinformatics, luciferase reporter, immunoprecipitation and immunofluorescence assays were conducted for mechanic investigation. Quantitative RT-PCR, western blotting and immunohistochemistry were used to measure the expression of functional genes. Xenograft tumor growth of mice was performed.
   Results: We found that VEGFR2 was highly expressed in esophageal cancer and associated with poor efficacy of cisplatin-based treatment. Apatinib displayed profound actions against tumor cell growth of human esophageal cancer via promoting cell apoptosis and cell cycle arrest. Also, apatinib displayed the inhibitory effects on cell migration and invasion. Moreover, apatinib strongly suppressed the growth of esophageal cancer xenografts in mice. The effects of apatinib on esophageal cancer were partially dependent on its block of the VEGFR2/Akt/beta-catenin pathway. Specifically, apatinib induced the degradation of beta-catenin and decreased its transcriptional activity through Akt/GSK-3 beta repression. Further in vitro and in vivo studies revealed that low dose apatinib had a synergistic antitumor effect with cisplatin on esophageal cancer.
   Conclusion: Our study indicates that apatinib suppresses tumor progression and enhances cisplatin sensitivity in esophageal cancer by deactivating the Akt/beta-catenin pathway. These findings provide a theoretical foundation for using apatinib as an effective therapeutic drug for esophageal cancer.
C1 [Wei, Bin; Wang, Yuanyuan; Wang, Jiawei; Cai, Xiaomin; Xu, Lingyan; Wang, Ying; Gu, Yanhong] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
   [Wei, Bin; Wu, Jingjing] Nanjing Med Univ, Dept Oncol, Affiliated Huaian Peoples Hosp 1, Huaian, Peoples R China.
   [Liu, Wen; Guo, Wenjie; Xu, Qiang] Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 22 Hankou Rd, Nanjing 210093, Peoples R China.
RP Gu, YH (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.; Guo, WJ; Xu, Q (corresponding author), Nanjing Univ, Sch Life Sci, State Key Lab Pharmaceut Biotechnol, 22 Hankou Rd, Nanjing 210093, Peoples R China.
EM guyhphd@163.com; guowj@nju.edu.cn; molpharm@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81871944, 81572389]; Jiangsu 333 project
   [BRA2016517]; Jiangsu province key medical talents [ZDRCA2016026];
   Science and Technology Development Foundation of Nanjing Medical
   University [NMUB2018151, NMUB2019346]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities [020814380114]
FX This study was supported by National Natural Science Foundation of China
   (81871944, 81572389), Jiangsu 333 project (BRA2016517), Jiangsu province
   key medical talents (ZDRCA2016026), Science and Technology Development
   Foundation of Nanjing Medical University (NMUB2018151, NMUB2019346) and
   Fundamental Research Funds for the Central Universities (020814380114).
CR Babyshkina N, 2018, MOL CELL BIOCHEM, V444, P197, DOI 10.1007/s11010-017-3244-1
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen XF, 2019, ONCOLOGIST, V24, P883, DOI 10.1634/theoncologist.2019-0164
   Dang YZ, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005772
   Deng FY, 2015, INT J CLIN EXP PATHO, V8, P3045
   Deng MM, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1421-y
   El-Sahli S, 2019, CANCERS, V11, DOI 10.3390/cancers11070904
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fitzmaurice C, 2015, JAMA ONCOL, V1, P505, DOI 10.1001/jamaoncol.2015.0735
   Gou MM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22302-z
   Hu XC, 2014, INT J CANCER, V135, P1961, DOI 10.1002/ijc.28829
   Huang MP, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0870-3
   Jiang Q, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016065
   Jin ZJ, 2017, CELL PHYSIOL BIOCHEM, V44, P1471, DOI 10.1159/000485583
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kanehisa M, 2002, NUCLEIC ACIDS RES, V30, P42, DOI 10.1093/nar/30.1.42
   Kumar R, 2017, J BIOSCIENCES, V42, P695, DOI 10.1007/s12038-017-9710-9
   Li JQ, 2017, ONCOTARGETS THER, V10, P3965, DOI 10.2147/OTT.S132756
   Li J, 2019, ONCOTARGETS THER, V12, P2577, DOI 10.2147/OTT.S191736
   Lian L, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5322-0
   Liu KS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.422
   Luo H, 2020, INVEST NEW DRUG, V38, P148, DOI 10.1007/s10637-019-00828-x
   Markar SR, 2012, ANN THORAC SURG, V94, P1652, DOI 10.1016/j.athoracsur.2012.06.067
   Nasir A, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0427-5
   Nobrega-Pereira S, 2018, CANCER RES, V78, P731, DOI 10.1158/0008-5472.CAN-17-1166
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Ohara T, 2010, CANCER LETT, V293, P207, DOI 10.1016/j.canlet.2010.01.017
   Pai VC, 2019, ONCOGENE, V38, P1340, DOI 10.1038/s41388-018-0497-4
   Pare-Brunet L, 2015, PHARMACOGENOMICS J, V15, P397, DOI 10.1038/tpj.2015.1
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6
   Roviello G, 2016, EXPERT REV GASTROENT, V10, P887, DOI 10.1080/17474124.2016.1209407
   Scott AJ, 2015, DRUG TODAY, V51, P223, DOI 10.1358/dot.2015.51.4.2320599
   Seebacher NA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1094-2
   Song ZB, 2017, ONCOTARGETS THER, V10, P1821, DOI 10.2147/OTT.S113435
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Wang G, 2006, CANCER LETT, V241, P102, DOI 10.1016/j.canlet.2005.10.050
   Wang WC, 2016, BIOCHEM PHARMACOL, V121, P8, DOI 10.1016/j.bcp.2016.09.024
   Wang ZN, 2019, J CLIN INVEST, V129, P4850, DOI 10.1172/JCI127471
   Wei B, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1364-0
   Wen S, 2019, PATHOL RES PRACT, V215, P816, DOI 10.1016/j.prp.2019.01.021
   Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263
   Zhang HZ, 2012, CHIN J CANCER, V31, P281, DOI 10.5732/cjc.011.10390
   Zhao DZ, 2018, ONCOTARGETS THER, V11, P4137, DOI 10.2147/OTT.S172305
   Zheng BX, 2018, BIOCHEM BIOPH RES CO, V495, P1695, DOI 10.1016/j.bbrc.2017.12.032
   Zhou T, 2019, J THORAC DIS, V11, P1831, DOI 10.21037/jtd.2019.05.33
NR 45
TC 9
Z9 9
U1 2
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD MAY 27
PY 2020
VL 20
IS 1
AR 198
DI 10.1186/s12935-020-01290-z
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LW0HW
UT WOS:000538828800001
PM 32514243
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Kuo, KK
   Hsiao, PJ
   Chang, WT
   Chuang, SC
   Yang, YH
   Wuputra, K
   Ku, CC
   Pan, JB
   Li, CP
   Kato, K
   Liu, CJ
   Wu, DC
   Yokoyama, KK
AF Kuo, Kung-Kai
   Hsiao, Pi-Jung
   Chang, Wen-Tsan
   Chuang, Shih-Chang
   Yang, Ya-Han
   Wuputra, Kenly
   Ku, Chia-Chen
   Pan, Jia-Bin
   Li, Chia-Pei
   Kato, Kohsuke
   Liu, Chung-Jung
   Wu, Deng-Chyang
   Yokoyama, Kazunari K.
TI Therapeutic Strategies Targeting Tumor Suppressor Genes in Pancreatic
   Cancer
SO CANCERS
LA English
DT Review
DE BRCA1; BRCA2; clinical trial; pancreatic cancer; p53; translational
   research; tumor suppressor gene
ID MUTANT P53 REACTIVATION; WILD-TYPE; DUCTAL ADENOCARCINOMA; GERMLINE
   MUTATIONS; SIGNALING PATHWAYS; INDUCE APOPTOSIS; BREAST-CANCER; IN-VIVO;
   PHASE-I; CELLS
AB Simple Summary Tumor suppressor genes are critical in the control of many biological functions. They can be classified based on their roles in proliferation, cell-cycle progression, DNA repair/damage, and crucial signaling functions, including apoptosis, autophagy, and necrosis. The absence of functional tumor suppressor genes entails a higher risk of dysfunction of cell growth, differentiation, cell death, and cancer development. Loss of function or mutations of such genes has been identified in many types of cancer, such as breast, bladder, colorectal, head and neck, lung, ovarian, uterine, and pancreatic cancers. Familial cancer syndromes, such as Li-Fraumeni syndrome, are associated with loss of TP53 function. Extensive studies have been carried out to clarify the roles of the products of these genes, as well as their mechanistic link to cancers, to identify novel targets for specific cancer types. Here, we introduce the roles of tumor suppressor gene products in pancreatic cancer development and its therapeutics for tumorigenesis prevention. The high mortality of pancreatic cancer is attributed to the insidious progression of this disease, which results in a delayed diagnosis and advanced disease stage at diagnosis. More than 35% of patients with pancreatic cancer are in stage III, whereas 50% are in stage IV at diagnosis. Thus, understanding the aggressive features of pancreatic cancer will contribute to the resolution of problems, such as its early recurrence, metastasis, and resistance to chemotherapy and radiotherapy. Therefore, new therapeutic strategies targeting tumor suppressor gene products may help prevent the progression of pancreatic cancer. In this review, we discuss several recent clinical trials of pancreatic cancer and recent studies reporting safe and effective treatment modalities for patients with advanced pancreatic cancer.
C1 [Kuo, Kung-Kai; Chang, Wen-Tsan; Chuang, Shih-Chang; Yang, Ya-Han] Kaohsiung Med Univ Hosp, Dept Surg, Div Gen & Digest Surg, Kaohsiung 80756, Taiwan.
   [Kuo, Kung-Kai; Yang, Ya-Han; Wuputra, Kenly; Ku, Chia-Chen; Pan, Jia-Bin; Li, Chia-Pei; Liu, Chung-Jung; Wu, Deng-Chyang; Yokoyama, Kazunari K.] Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80708, Taiwan.
   [Kuo, Kung-Kai; Chang, Wen-Tsan; Chuang, Shih-Chang; Yang, Ya-Han] Kaohsiung Med Univ, Coll Med, Dept Surg, Kaohsiung 80708, Taiwan.
   [Hsiao, Pi-Jung] I Shou Univ, Dept Internal Med, Div Endocrinol & Metab, EDA Hosp,Coll Med, Kaohsiung 82445, Taiwan.
   [Wuputra, Kenly; Ku, Chia-Chen; Pan, Jia-Bin; Li, Chia-Pei; Yokoyama, Kazunari K.] Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 80708, Taiwan.
   [Kato, Kohsuke] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Infect Biol, Tsukuba, Ibaraki 3058577, Japan.
   [Liu, Chung-Jung; Wu, Deng-Chyang] Kaohsiung Med Univ Hosp, Dept Internal Med, Div Gastroenterol, Kaohsiung 80756, Taiwan.
   [Liu, Chung-Jung; Wu, Deng-Chyang; Yokoyama, Kazunari K.] Kaohsiung Med Univ Hosp, Cell Therapy & Res Ctr, Kaohsiung 80756, Taiwan.
RP Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Regenerat Med & Cell Therapy Res Ctr, Kaohsiung 80708, Taiwan.; Yokoyama, KK (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Kaohsiung 80708, Taiwan.; Yokoyama, KK (corresponding author), Kaohsiung Med Univ Hosp, Cell Therapy & Res Ctr, Kaohsiung 80756, Taiwan.
EM kkkuo@kmu.edu.tw; ed112609@edah.org.tw; wtchang@kmu.edu.tw;
   chuangsc@kmu.edu.tw; R030126@kmu.edu.tw; r020017@kmu.edu.tw;
   r991046@gap.kmu.edu.tw; r060139@gap.kmu.edu.tw; 1100058@kmuh.org.tw;
   kkato@md.tsukuba.ac.jp; 1020590@ms.kmuh.org.tw; dechwu@kmu.edu.tw;
   Kazu@kmu.edu.tw
RI Ku, Chiachen/AAA-2868-2022; Liu, Chung-Jung/AAX-1889-2021
OI Ku, Chiachen/0000-0002-1496-3081; Liu, Chung-Jung/0000-0002-2657-565X;
   Chang, Wen-Tsan/0000-0001-5622-8299; Yokoyama,
   Kazunari/0000-0001-8508-7587
FU Ministry of Science and Technology [MOST 109-2314-B-037-119, MOST
   109-2320-B-037-033]; National Health Research InstitutesNational Health
   Research Institutes, Japan [NHRI-EX109-10720SI]; Kaohsiung Medical
   University Hospital [SA10803C]; Kaohsiung Medical University Research
   Center [KMU-TC109A02, KMU-TC109A02-0, KMU-TC109A02-3]
FX This work was supported by grants from the Ministry of Science and
   Technology (MOST 109-2314-B-037-119; MOST 109-2320-B-037-033), the
   National Health Research Institutes (NHRIEX109-10720SI), Kaohsiung
   Medical University Hospital (SA10803C), and Kaohsiung Medical University
   Research Center (KMU-TC109A02; KMU-TC109A02-0, KMU-TC109A02-3).
CR Aggarwal M, 2016, CELL DEATH DIFFER, V23, P1615, DOI 10.1038/cdd.2016.48
   Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430
   Alvarado-Ortiz E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607670
   Amelio I, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0251-x
   Amin S, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.15444
   Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169
   Axilbund JE, 2012, CANCER J, V18, P350, DOI 10.1097/PPO.0b013e3182624694
   Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Bardeesy N, 2006, P NATL ACAD SCI USA, V103, P5947, DOI 10.1073/pnas.0601273103
   Baugh EH, 2018, CELL DEATH DIFFER, V25, P154, DOI 10.1038/cdd.2017.180
   Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547
   BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933
   Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105
   Bromley D, 2016, PROTEIN ENG DES SEL, V29, P377, DOI 10.1093/protein/gzw035
   Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077
   Burmakin M, 2013, CLIN CANCER RES, V19, P5092, DOI 10.1158/1078-0432.CCR-12-2211
   Bykov VJN, 2014, FEBS LETT, V588, P2622, DOI 10.1016/j.febslet.2014.04.017
   Cao ZJ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf4148
   Capaci V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17596-5
   Chaffee KG, 2018, GENET MED, V20, P119, DOI 10.1038/gim.2017.85
   Chan-Seng-Yue M, 2020, NAT GENET, V52, P231, DOI 10.1038/s41588-019-0566-9
   Chen LP, 2004, NAT REV IMMUNOL, V4, P336, DOI 10.1038/nri1349
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344
   Cooks T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03224-w
   de Bono J, 2017, CANCER DISCOV, V7, P620, DOI 10.1158/2159-8290.CD-16-1250
   Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013
   Donehower LA, 2019, CELL REP, V28, P3010, DOI 10.1016/j.celrep.2019.08.061
   ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0
   Escoll M, 2017, ONCOGENE, V36, P3515, DOI 10.1038/onc.2016.518
   Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006
   Furukawa T, 2006, CANCER SCI, V97, P1, DOI 10.1111/j.1349-7006.2005.00134.x
   Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5
   Galvano A, 2020, CANCERS, V12, DOI 10.3390/cancers12030534
   Gamboa AC, 2020, J SURG ONCOL, V122, P457, DOI 10.1002/jso.25976
   Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387
   Grant RC, 2015, GASTROENTEROLOGY, V148, P556, DOI 10.1053/j.gastro.2014.11.042
   Habbe N, 2008, P NATL ACAD SCI USA, V105, P18913, DOI 10.1073/pnas.0810097105
   Hahn SA, 2003, JNCI-J NATL CANCER I, V95, P214, DOI 10.1093/jnci/95.3.214
   Hartman SJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.642328
   Hassan Z, 2021, PANCREATOLOGY, V21, P912, DOI 10.1016/j.pan.2021.03.012
   Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023
   Hiraki M, 2015, CHEM BIOL, V22, P1206, DOI 10.1016/j.chembiol.2015.07.016
   Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108
   JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0
   Jiang LR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2445-9
   Joerger AC, 2006, P NATL ACAD SCI USA, V103, P15056, DOI 10.1073/pnas.0607286103
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202
   Kessler J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-605
   Kim MP, 2021, CANCER DISCOV, V11, P2094, DOI 10.1158/2159-8290.CD-20-1228
   Klein AP, 2012, MOL CARCINOGEN, V51, P14, DOI 10.1002/mc.20855
   Kung AL, 2004, CANCER CELL, V6, P33, DOI 10.1016/j.ccr.2004.06.009
   Kuo KK, 2016, PANCREAS, V45, P71, DOI 10.1097/MPA.0000000000000388
   Lambert JMR, 2010, ONCOGENE, V29, P1329, DOI 10.1038/onc.2009.425
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Leijen S, 2016, J CLIN ONCOL, V34, P4354, DOI 10.1200/JCO.2016.67.5942
   Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534
   Lindemann A, 2019, CLIN CANCER RES, V25, P5650, DOI 10.1158/1078-0432.CCR-19-0096
   Liu XR, 2013, NUCLEIC ACIDS RES, V41, P6034, DOI 10.1093/nar/gkt305
   Liu Y, 2020, CYTOTHERAPY, V22, P573, DOI 10.1016/j.jcyt.2020.04.088
   Lugli E, 2019, J CLIN INVEST, V129, P949, DOI 10.1172/JCI126295
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Margalit O, 2012, INT J CANCER, V131, pE562, DOI 10.1002/ijc.26441
   Mello SS, 2013, CELL DEATH DIFFER, V20, P855, DOI 10.1038/cdd.2013.53
   Meng XB, 2018, CANCERS, V10, DOI 10.3390/cancers10050149
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Mueller S, 2018, NATURE, V554, P62, DOI 10.1038/nature25459
   Murphy KM, 2002, CANCER RES, V62, P3789
   Narayanan G, 2021, CANCERS, V13, DOI 10.3390/cancers13112511
   Nummer D, 2007, J NATL CANCER I, V99, P1188, DOI 10.1093/jnci/djm064
   PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0
   Pavlakis E, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020307
   Petersen GM, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.4108
   Pintus SS, 2013, J BIOMOL STRUCT DYN, V31, P78, DOI 10.1080/07391102.2012.691364
   Ponz-Sarvise M, 2015, HEMATOL ONCOL CLIN N, V29, P609, DOI 10.1016/j.hoc.2015.04.010
   Qiu ZJ, 2018, RADIOTHER ONCOL, V126, P450, DOI 10.1016/j.radonc.2017.09.043
   Rippin TM, 2002, ONCOGENE, V21, P2119, DOI 10.1038/sj.onc.1205362
   Russo A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100164
   Said Rabih, 2020, Oncotarget, V11, P188, DOI 10.18632/oncotarget.27418
   Shetzer Y, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026203
   Shi CJ, 2009, MOL CANCER RES, V7, P230, DOI 10.1158/1541-7786.MCR-08-0206
   Shroff RT, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.17.00316
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Singhi AD, 2019, GASTROENTEROLOGY, V156, P2242, DOI 10.1053/j.gastro.2019.02.037
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0
   Staab A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-213
   Synnott NC, 2017, INT J CANCER, V140, P234, DOI 10.1002/ijc.30425
   Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41
   Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102
   Tuli R, 2019, EBIOMEDICINE, V40, P375, DOI 10.1016/j.ebiom.2018.12.060
   Umut O, 2021, MEMO-MAG EUR MED ONC, V14, P143, DOI 10.1007/s12254-021-00703-7
   van Roessel S, 2020, JAMA ONCOL, V6, P1733, DOI 10.1001/jamaoncol.2020.3537
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Wei XL, 2020, P NATL ACAD SCI USA, V117, P28068, DOI 10.1073/pnas.2009899117
   Weinmann L, 2008, CELL DEATH DIFFER, V15, P718, DOI 10.1038/sj.cdd.4402301
   Weinstein IB, 2006, NAT CLIN PRACT ONCOL, V3, P448, DOI 10.1038/ncponc0558
   Win AK, 2012, J CLIN ONCOL, V30, P958, DOI 10.1200/JCO.2011.39.5590
   WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0
   Xiao G, 2020, CANCER RES, V80, P394, DOI 10.1158/0008-5472.CAN-19-1036
   Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042
   Zache N, 2008, MOL ONCOL, V2, P70, DOI 10.1016/j.molonc.2008.02.004
   Zhao ZJ, 2018, ACTA PHARM SIN B, V8, P539, DOI 10.1016/j.apsb.2018.03.001
   Zhen DB, 2015, GENET MED, V17, P569, DOI 10.1038/gim.2014.153
   Zhou X, 2019, J MOL CELL BIOL, V11, P293, DOI 10.1093/jmcb/mjy072
NR 107
TC 2
Z9 2
U1 7
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG
PY 2021
VL 13
IS 15
AR 3920
DI 10.3390/cancers13153920
PG 32
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TV7IK
UT WOS:000681892300001
PM 34359820
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Choy, YY
   Fraga, M
   Mackenzie, GG
   Waterhouse, AL
   Cremonini, E
   Oteiza, PI
AF Choy, Ying Yng
   Fraga, Magdalena
   Mackenzie, Gerardo G.
   Waterhouse, Andrew L.
   Cremonini, Eleonora
   Oteiza, Patricia I.
TI The PI3K/Akt pathway is involved in procyanidin-mediated suppression of
   human colorectal cancer cell growth
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE apoptosis; proanthocyanidin; autophagy; cell cycle arrest
ID GRAPE SEED EXTRACT; NF-KAPPA-B; IN-VITRO; APPLE PROCYANIDINS; OXIDANT
   PRODUCTION; DIETARY FIBER; AKT INHIBITOR; CACO-2 CELLS; RISK; ACTIVATION
AB Colorectal cancer (CRC) has the third highest incidence worldwide. Epidemiological studies showed that the consumption of fruit and vegetables containing procyanidins (PCA), polymers of flavan-3-ols, is associated with lower CRC risk. However, the molecular mechanisms supporting this positive association are unclear. This study investigated the capacity of PCA with different degrees of polymerization to reduce CRC cell growth, characterizing the underlying mechanisms. Compared to the monomer ((-)-epicatechin) and the trimer, the hexamer (Hex) was the most active at reducing CRC cell viability. Hex caused a concentration- (2.5-50M) and time- (24-72h) dependent decrease in the viability of six human CRC cell lines in culture. Hex caused CRC apoptotic Caco-2 cell death within 24h, as evidenced by caspase 3 and caspase 9 activation, DNA fragmentation, and changes in nuclear morphology/staining. Hex-induced apoptosis occurs through the mitochondrial pathway, as evidenced by an increased Bad mitochondrial translocation, and cytochrome c release from the mitochondria to the cytosol. Hex also arrested the Caco-2 cell cycle at G(2)/M phase and upregulated genes involved in autophagy. Mechanistically, in Caco-2 cells Hex inhibited the PI3K/Akt signaling pathway, causing the downstream downregulation of proteins involved in the regulation of cell survival (Bad, GSK-3). Accordingly, the Akt inhibitor MKK-2206 decreased Bad and GSK-3 phosphorylation. MKK-2206 decreased cell growth, having an additive effect with Hex. In conclusion, our results show that large PCA can inhibit CRC cell growth via the Akt kinase pathway, demonstrating a mechanism to explain the epidemiological evidence linking PCA-rich diets with lower CRC risk. (c) 2016 Wiley Periodicals, Inc.
C1 [Choy, Ying Yng; Waterhouse, Andrew L.] Univ Calif Davis, Dept Viticulture & Enol, Davis, CA 95616 USA.
   [Fraga, Magdalena; Cremonini, Eleonora; Oteiza, Patricia I.] Univ Calif Davis, Dept Nutr, One Shields Ave, Davis, CA 95616 USA.
   [Fraga, Magdalena; Cremonini, Eleonora; Oteiza, Patricia I.] Univ Calif Davis, Dept Environm Toxicol, One Shields Ave, Davis, CA 95616 USA.
   [Mackenzie, Gerardo G.] SUNY Stony Brook, Dept Prevent Med, Stony Brook Canc Ctr, Stony Brook, NY 11794 USA.
RP Oteiza, PI (corresponding author), Univ Calif Davis, Dept Nutr, One Shields Ave, Davis, CA 95616 USA.; Oteiza, PI (corresponding author), Univ Calif Davis, Dept Environm Toxicol, One Shields Ave, Davis, CA 95616 USA.
EM poteiza@ucdavis.edu
RI Mackenzie, Gerardo G/AAW-5114-2020; Waterhouse, Andrew/F-6719-2011
OI Waterhouse, Andrew/0000-0002-5088-7442
FU NIFA-USDAUnited States Department of Agriculture (USDA)
   [CA-D*-xxx-7244-H]; Stony Brook Cancer Center
FX Grant sponsor: NIFA-USDA; Grant number: CA-D*-xxx-7244-H; Grant sponsor:
   Stony Brook Cancer Center
CR Adamson GE, 1999, J AGR FOOD CHEM, V47, P4184, DOI 10.1021/jf990317m
   Agarwal E, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-145
   Aune D, 2011, GASTROENTEROLOGY, V141, P106, DOI 10.1053/j.gastro.2011.04.013
   Ben QW, 2014, GASTROENTEROLOGY, V146, P689, DOI 10.1053/j.gastro.2013.11.003
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865
   Carnesecchi S, 2002, CANCER LETT, V175, P147, DOI 10.1016/S0304-3835(01)00731-5
   Chan DSM, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0020456, 10.1371/journal.pone.0027218]
   Chappell WH, 2011, ONCOTARGET, V2, P135, DOI 10.18632/oncotarget.240
   Choy YY, 2014, FOOD FUNCT, V5, P2298, DOI [10.1039/c4fo00325j, 10.1039/C4FO00325J]
   Choy YY, 2013, J AGR FOOD CHEM, V61, P121, DOI 10.1021/jf301939e
   Da Silva M, 2012, FREE RADICAL BIO MED, V52, P151, DOI 10.1016/j.freeradbiomed.2011.10.436
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209
   Engelbrecht AM, 2007, CANCER LETT, V258, P144, DOI 10.1016/j.canlet.2007.08.020
   Erlejman AG, 2008, ARCH BIOCHEM BIOPHYS, V476, P186, DOI 10.1016/j.abb.2008.01.024
   Forester SC, 2010, J AGR FOOD CHEM, V58, P5320, DOI 10.1021/jf9040172
   Gosse F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074
   Hammerstone JF, 2000, J NUTR, V130, p2086S, DOI 10.1093/jn/130.8.2086S
   Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Jiang BH, 2008, BBA-PROTEINS PROTEOM, V1784, P150, DOI 10.1016/j.bbapap.2007.09.008
   Kaur M, 2006, CLIN CANCER RES, V12, P6194, DOI 10.1158/1078-0432.CCR-06-1465
   Kerr D, 2003, NAT REV CANCER, V3, P615, DOI 10.1038/nrc1147
   Lizarraga D, 2007, FEBS J, V274, P4802, DOI 10.1111/j.1742-4658.2007.06010.x
   Mackenzie GG, 2008, INT J CANCER, V123, P56, DOI 10.1002/ijc.23477
   Mai W, 2006, ONCOLOGY-BASEL, V71, P297, DOI 10.1159/000106429
   Maiti D, 2001, J BIOL CHEM, V276, P329, DOI 10.1074/jbc.M002650200
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Miura T, 2008, CARCINOGENESIS, V29, P585, DOI 10.1093/carcin/bgm198
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Noguchi M, 2014, BBA-REV CANCER, V1846, P342, DOI 10.1016/j.bbcan.2014.07.013
   Pierini R, 2008, MOL NUTR FOOD RES, V52, P1399, DOI 10.1002/mnfr.200700513
   Prasad R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043064
   Rossi M, 2010, CANCER CAUSE CONTROL, V21, P243, DOI 10.1007/s10552-009-9455-3
   Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Suman S, 2014, MOL CARCINOGEN, V53, pE151, DOI 10.1002/mc.22076
   Terry P, 2001, JNCI-J NATL CANCER I, V93, P525, DOI 10.1093/jnci/93.7.525
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Theodoratou E, 2007, CANCER EPIDEM BIOMAR, V16, P684, DOI 10.1158/1055-9965.EPI-06-0785
   Tsang C, 2005, BRIT J NUTR, V94, P170, DOI 10.1079/BJN20051480
   Verstraeten SV, 2013, BBA-BIOMEMBRANES, V1828, P2646, DOI 10.1016/j.bbamem.2013.07.023
   Verstraeten SV, 2003, FREE RADICAL BIO MED, V34, P84, DOI 10.1016/S0891-5849(02)01185-1
   Wang W. K., 2014, ENV TOXICOL
   Weng WH, 2015, INT J CANCER, V136, P493, DOI 10.1002/ijc.28722
   Young MR, 2003, TRENDS MOL MED, V9, P36, DOI 10.1016/S1471-4914(02)00009-6
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010
NR 49
TC 19
Z9 23
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD DEC
PY 2016
VL 55
IS 12
BP 2196
EP 2209
DI 10.1002/mc.22461
PG 14
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA EC1GY
UT WOS:000387854100025
PM 26774105
OA Green Published
DA 2022-04-25
ER

PT J
AU Choroba, K
   Machura, B
   Szlapa-Kula, A
   Malecki, JG
   Raposo, L
   Roma-Rodrigues, C
   Cordeiro, S
   Baptista, PV
   Fernandes, AR
AF Choroba, Katarzyna
   Machura, Barbara
   Szlapa-Kula, Agata
   Malecki, Jan G.
   Raposo, Luis
   Roma-Rodrigues, Catarina
   Cordeiro, Sandra
   Baptista, Pedro, V
   Fernandes, Alexandra R.
TI Square planar Au(III), Pt(II) and Cu(II) complexes with
   quinoline-substituted 2,2 ':6 ',2 ''-terpyridine ligands: From in vitro
   to in vivo biological properties
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Square planar metal complexes; Apoptosis; Autophagy induction;
   Mitochondrial membrane potential changes; Intracellular reactive oxygen
   species; Ex-ovo chorioallantoic membrane in vivo assay
ID LUMINESCENT PLATINUM(II) COMPLEXES; PI STACKING INTERACTIONS;
   DNA-BINDING PROPERTIES; TERPYRIDINE COMPLEXES; METAL-COMPLEXES;
   CRYSTAL-STRUCTURE; PHOTOPHYSICAL PROPERTIES; COPPER(II) COMPLEXES;
   GOLD(III) COMPLEXES; SOLUTION CHEMISTRY
AB Cancer is the second leading cause of death worldwide. Cisplatin has challenged cancer treatment; however, resistance and side effects hamper its use. New agents displaying improved activity and more reduced side effects relative to cisplatin are needed. In this work we present the synthesis, characterization and biological activities of three complexes with quinoline-substituted 2,2':6',2 ''-terpyridine ligand: [Pt(4'-(2-quin)-terpy)Cl](SO3CF3) (1), [Au(4 '-(2-quin)-terpy)Cl](PF6)(2)center dot CH3CN (2) and [Cu(4'-(2-quin)-terpy)Cl](PF6) (3). The three complexes displayed a high antiproliferative activity in ovarian carcinoma cell line (A2780) and even more noticeable in a colorectal carcinoma cell line (HCT116) following the order 3 > 2 > 1. The complexes IC50 are at least 20 x lower than the IC50 displayed by cisplatin (15.4 mu M) in HCT116 cell line while displaying at the same time, much reduced cytotoxicity in a normal dermal fibroblast culture. These cytotoxic activities seem to be correlated with the inclination angles of 2-quin unit to the central pyridine. Interestingly, all complexes can interact with calf-thymus DNA (CT-DNA) in vitro via different mechanisms, although intercalation seems to be the preferred mechanism at least for 2 and 3 at higher concentrations of DNA. Moreover, circular dichroism (CD) data seems to indicate that complex 3, more planar, induces a high destabilization of the DNA double helix (shift from B-form to Z-form). Higher the deviation from planar, the lower the cytotoxicity displayed by the complexes. Cellular uptake may be also responsible for the different cytotoxicity exhibited by complexes with 3 > 2 > 1. Complex 2 seems to enter cells more passively while complex 1 and 3 might enter cells via energy-dependent and -independent mechanisms. Complexes 1-3 were shown to induce ROS are associated with the increased apoptosis and autophagy. Moreover, all complexes dissipate the mitochondrial membrane potential leading to an increased BAX/BCL-2 ratio that triggered apoptosis. Complexes 2 and 3 were also shown to exhibit an anti-angiogenic effect by significantly reduce the number of newly formed blood vessel in a CAM model with no toxicity in this in vivo model.
   Our results seem to suggest that the increased cytotoxicity of complex 3 in HCT116 cells and its potential interest for further translation to pre-clinical mice xenografts might be associated with: 1) higher % of internalization of HCT116 cells via energy-dependent and -independent mechanisms; 2) ability to intercalate DNA and due to its planarity induced higher destabilization of DNA; 3) induce intracellular ROS that trigger apoptosis and autophagy; 4) low toxicity in an in vivo model of CAM; 5) potential anti-angiogenic effect. (c) 2021 The Author(s). Published by Elsevier Masson SAS. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Choroba, Katarzyna; Machura, Barbara; Szlapa-Kula, Agata; Malecki, Jan G.] Univ Silesia, Inst Chem, Szkolna 9, PL-40006 Katowice, Poland.
   [Raposo, Luis; Roma-Rodrigues, Catarina; Cordeiro, Sandra; Baptista, Pedro, V; Fernandes, Alexandra R.] NOVA Sch Sci & Technol, Dept Ciencias Vida, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.
RP Choroba, K (corresponding author), Univ Silesia, Inst Chem, Szkolna 9, PL-40006 Katowice, Poland.; Fernandes, AR (corresponding author), NOVA Sch Sci & Technol, Dept Ciencias Vida, UCIBIO, Campus Caparica, P-2829516 Caparica, Portugal.
EM katarzyna.choroba@us.edu.pl; ma.fernandes@fct.unl.pt
RI Raposo, Luís/AAX-1610-2021; Roma-Rodrigues, Catarina/S-6144-2016;
   Roma-Rodrigues, Catarina/AAT-5658-2021; Raposo, Luís R/T-3754-2017;
   Baptista, Pedro/A-1237-2009; Malecki, Jan Grzegorz/M-4022-2017;
   Fernandes, Alexandra/C-7465-2011
OI Raposo, Luís/0000-0002-8637-346X; Roma-Rodrigues,
   Catarina/0000-0002-8676-6562; Roma-Rodrigues,
   Catarina/0000-0002-8676-6562; Raposo, Luís R/0000-0002-8637-346X;
   Szlapa-Kula, Agata/0000-0001-6539-5419; Cordeiro,
   Sandra/0000-0002-3825-1695; Choroba, Katarzyna/0000-0003-0168-5753;
   Machura, Barbara/0000-0001-7688-6491; Baptista,
   Pedro/0000-0001-5255-7095; Malecki, Jan Grzegorz/0000-0001-5571-3196;
   Fernandes, Alexandra/0000-0003-2054-4438
FU Applied Molecular Biosciences Unit - UCIBIO - FCT [UIDP/04378/2020,
   UIDB/04378/2020, SFRH/BPD/124612/2016, PTDC/CVT-EPI/6685/2014]
FX This work was supported by the Applied Molecular Biosciences Unit -
   UCIBIO which is financed by national funds from FCT (UIDP/04378/2020,
   UIDB/04378/2020 and fellowships SFRH/BPD/124612/2016 (C.
   Roma-Rodrigues), and PTDC/CVT-EPI/6685/2014 (L R. Raposo)).
CR Abbate F, 2000, INORG CHIM ACTA, V311, P1, DOI 10.1016/S0020-1693(00)00299-1
   Alderden RA, 2006, J CHEM EDUC, V83, P728, DOI 10.1021/ed083p728
   Altmann S, 2019, J INORG BIOCHEM, V201, DOI 10.1016/j.jinorgbio.2019.110809
   ANNIBALE G, 1995, POLYHEDRON, V14, P451, DOI 10.1016/0277-5387(94)00408-7
   [Anonymous], 2011, PRO CRYALIS
   Barry NPE, 2013, CHEM COMMUN, V49, P5106, DOI 10.1039/c3cc41143e
   Beves JE, 2009, CRYSTENGCOMM, V11, P2406, DOI 10.1039/b909639f
   Bhowmik S, 2014, ORG BIOMOL CHEM, V12, P8836, DOI 10.1039/c4ob01867b
   BONDI A, 1964, J PHYS CHEM-US, V68, P441, DOI 10.1021/j100785a001
   Buchner R, 1999, J CHEM SOC DALTON, P711, DOI 10.1039/a807914e
   Buchner R, 1997, INORG CHEM, V36, P3952, DOI 10.1021/ic961068b
   Cao LY, 2007, INORG CHEM, V46, P1361, DOI 10.1021/ic061911y
   Casamento M, 1998, INORG CHIM ACTA, V276, P242
   Casini A, 2010, DALTON T, V39, P2239, DOI 10.1039/b921019a
   Chang YM, 2012, INT J MOL SCI, V13, P3394, DOI 10.3390/ijms13033394
   Cheng HK, 2017, ACS APPL MATER INTER, V9, P36220, DOI 10.1021/acsami.7b11807
   Cho EJ, 2010, CHEM COMMUN, V46, P6557, DOI 10.1039/c0cc00991a
   Choroba K, 2020, DALTON T, V49, P6596, DOI 10.1039/d0dt01017k
   Choroba K, 2019, DALTON T, V48, P13081, DOI 10.1039/c9dt02894c
   Choroba K, 2019, DALTON T, V48, P12656, DOI 10.1039/c9dt01922g
   Chu WH, 2013, BIOORG MED CHEM LETT, V23, P5187, DOI 10.1016/j.bmcl.2013.07.003
   Cinellu MA, 2009, ORGANOMETALLICS, V28, P7015, DOI 10.1021/om900841b
   Gimeno MC, 2015, INORG CHEM, V54, P10667, DOI 10.1021/acs.inorgchem.5b01477
   Crites DK, 1998, INORG CHIM ACTA, V273, P346, DOI 10.1016/S0020-1693(97)06082-9
   Czerwinska K, 2017, DALTON T, V46, DOI 10.1039/c6dt04584g
   Czerwinska K, 2017, DALTON T, V46, P9591, DOI 10.1039/c7dt01244f
   Deka B, 2017, DALTON T, V46, P396, DOI 10.1039/c6dt03660k
   Deo KM, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111818
   Doerrer LH, 2008, COMMENT INORG CHEM, V29, P93, DOI 10.1080/02603590802310760
   Doerrer LH, 2010, DALTON T, V39, P3543, DOI 10.1039/b920389c
   Dostani M, 2017, SPECTROCHIM ACTA A, V180, P144, DOI 10.1016/j.saa.2017.02.047
   Erkkila KE, 1999, CHEM REV, V99, P2777, DOI 10.1021/cr9804341
   Eryazici I, 2008, CHEM REV, V108, P1834, DOI 10.1021/cr0781059
   Fang WW, 2015, CHEM COMMUN, V51, P4267, DOI [10.1039/c5cc00196j, 10.1039/C5CC00196J]
   Fu HLK, 2016, CHEM-EUR J, V22, P11826, DOI 10.1002/chem.201601983
   Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608
   Galindo-Murillo R, 2015, NUCLEIC ACIDS RES, V43, P5364, DOI 10.1093/nar/gkv467
   Gao X, 2020, FOOD RES INT, V129, DOI 10.1016/j.foodres.2019.108854
   Garbett NC, 2007, NAT PROTOC, V2, P3166, DOI 10.1038/nprot.2007.475
   Gillard R.D., 1987, COMPREHENSIVE COORDI
   Glisic BD, 2018, POLYHEDRON, V139, P313, DOI 10.1016/j.poly.2017.11.008
   Gomez V, 2012, J CHEM CRYSTALLOGR, V42, P824, DOI 10.1007/s10870-012-0320-y
   Grau J, 2015, DALTON T, V44, P16061, DOI 10.1039/c5dt02211h
   Hajiana R, 2017, J PHARM ANAL, V7, P176, DOI 10.1016/j.jpha.2017.01.003
   HATHAWAY BJ, 1970, COORDIN CHEM REV, V5, P143, DOI 10.1016/S0010-8545(00)80135-6
   HEYNS AM, 1973, SPECTROCHIM ACTA A, VA 29, P1163, DOI 10.1016/0584-8539(73)80154-0
   Huang TH, 2013, INORG CHIM ACTA, V408, P91, DOI 10.1016/j.ica.2013.08.024
   Huo JQ, 2011, DALTON T, V40, P7534, DOI 10.1039/c1dt10465a
   Jin XH, 2010, INORG CHEM COMMUN, V13, P86, DOI 10.1016/j.inoche.2009.10.024
   Jungwirth U, 2011, ANTIOXID REDOX SIGN, V15, P1085, DOI 10.1089/ars.2010.3663
   Klemens T, 2016, DALTON T, V45, P1746, DOI 10.1039/c5dt04093k
   Lai SW, 1999, INORG CHEM, V38, P4262, DOI 10.1021/ic990446k
   LAWRANCE GA, 1986, CHEM REV, V86, P17, DOI 10.1021/cr00071a002
   Lenis-Rojas OA, 2016, DALTON T, V45, P19127, DOI 10.1039/c6dt03591d
   LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1
   Ma Z, 2014, DALTON T, V43, P4048, DOI 10.1039/c3dt53054j
   Macrae CF, 2008, J APPL CRYSTALLOGR, V41, P466, DOI 10.1107/S0021889807067908
   Mahendiran D, 2017, MAT SCI ENG C-MATER, V76, P601, DOI 10.1016/j.msec.2017.03.085
   Malarz K, 2021, EUR J MED CHEM, V212, DOI 10.1016/j.ejmech.2020.113032
   Mandegani Z, 2016, DALTON T, V45, P6592, DOI 10.1039/c5dt04788a
   Manikandamathavan VM, 2017, EUR J MED CHEM, V135, P434, DOI 10.1016/j.ejmech.2017.04.030
   Manikandamathavan VM, 2012, EUR J MED CHEM, V57, P449, DOI 10.1016/j.ejmech.2012.06.039
   Mansour AM, 2018, DALTON T, V47, P3459, DOI 10.1039/c7dt04347c
   Mansour MA, 1998, INORG CHEM, V37, P4625, DOI 10.1021/ic980032b
   Marcon G, 2002, J MED CHEM, V45, P1672, DOI 10.1021/jm010997w
   MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8
   Maron A, 2018, DALTON T, V47, P6444, DOI 10.1039/c8dt00558c
   Maron A, 2017, EUR J ORG CHEM, V2017, P2730, DOI 10.1002/ejoc.201700141
   Maron A, 2016, ORG BIOMOL CHEM, V14, P3793, DOI 10.1039/c6ob00038j
   Martin-Santos C, 2015, J INORG BIOCHEM, V153, P339, DOI 10.1016/j.jinorgbio.2015.09.012
   Mbugua SN, 2020, J CHEM-NY, V2020, DOI 10.1155/2020/3863269
   McGivern TJP, 2018, INORG CHIM ACTA, V472, P12, DOI 10.1016/j.ica.2017.08.043
   McMillin DR, 2002, COORDIN CHEM REV, V229, P113, DOI 10.1016/S0010-8545(02)00041-3
   Michalec JF, 2000, INORG CHEM, V39, P2708, DOI 10.1021/ic000304m
   Michalec JF, 2001, INORG CHEM, V40, P2193, DOI 10.1021/ic0013126
   Monim-ul-Mehboob M, 2013, POLYHEDRON, V61, P225, DOI 10.1016/j.poly.2013.05.054
   Ndagi U, 2017, DRUG DES DEV THER, V11, P599, DOI 10.2147/DDDT.S119488
   Novakova O, 2003, BIOCHEMISTRY-US, V42, P11544, DOI 10.1021/bi034933u
   Okuniewski A, 2015, POLYHEDRON, V90, P47, DOI 10.1016/j.poly.2015.01.035
   Olsen PM, 2014, J INORG BIOCHEM, V141, P121, DOI 10.1016/j.jinorgbio.2014.08.014
   Ott I, 2007, ARCH PHARM, V340, P117, DOI 10.1002/ardp.200600151
   Ott I, 2009, COORDIN CHEM REV, V253, P1670, DOI 10.1016/j.ccr.2009.02.019
   Pages BJ, 2015, DALTON T, V44, P3505, DOI 10.1039/c4dt02700k
   Perontsis S, 2020, J INORG BIOCHEM, V212, DOI 10.1016/j.jinorgbio.2020.111213
   Protogeraki C, 2014, EUR J MED CHEM, V86, P189, DOI 10.1016/j.ejmech.2014.08.043
   Qi YY, 2018, EUR J MED CHEM, V154, P220, DOI 10.1016/j.ejmech.2018.05.023
   Raposo LR, 2021, BIOORGAN MED CHEM, V30, DOI 10.1016/j.bmc.2020.115880
   RATILLA EMA, 1987, J AM CHEM SOC, V109, P4592, DOI 10.1021/ja00249a023
   Rehman SU, 2015, ARCH BIOCHEM BIOPHYS, V576, P49, DOI 10.1016/j.abb.2015.03.024
   REICHMANN ME, 1954, J AM CHEM SOC, V76, P3047, DOI 10.1021/ja01640a067
   Ribatti D, 2017, REPROD TOXICOL, V70, P97, DOI 10.1016/j.reprotox.2016.11.004
   ROJO T, 1987, J CHEM SOC DALTON, P285, DOI 10.1039/dt9870000285
   Roma-Rodrigues C, 2020, BIOORG CHEM, V99, DOI 10.1016/j.bioorg.2020.103849
   Roma-Rodrigues C, 2019, INT J NANOMED, V14, P6843, DOI 10.2147/IJN.S215711
   Roma-Rodrigues C, 2016, INT J NANOMED, V11, P2633, DOI 10.2147/IJN.S108661
   Ronconi L, 2006, J MED CHEM, V49, P1648, DOI 10.1021/jm0509288
   Sakthikumar K, 2019, RSC ADV, V9, P14220, DOI 10.1039/c8ra09218d
   Sarkar S, 2014, J PHOTOCH PHOTOBIO B, V130, P272, DOI 10.1016/j.jphotobiol.2013.11.021
   Sequeira D, 2021, DALTON T, V50, P1845, DOI 10.1039/d0dt03566a
   Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930
   Shi PF, 2009, J BIOCHEM MOL TOXIC, V23, P295, DOI 10.1002/jbt.20292
   Singh V, 2016, NEW J CHEM, V40, P5906, DOI 10.1039/c6nj00409a
   Sirajuddin M, 2013, J PHOTOCH PHOTOBIO B, V124, P1, DOI 10.1016/j.jphotobiol.2013.03.013
   Skyrianou KC, 2011, J INORG BIOCHEM, V105, P1273, DOI 10.1016/j.jinorgbio.2011.06.005
   Spackman M, 2012, CRYSTAL EXPLORER
   Spackman MA, 2002, CRYSTENGCOMM, V4, P378, DOI 10.1039/b203191b
   Spackman MA, 2009, CRYSTENGCOMM, V11, P19, DOI 10.1039/b818330a
   Suntharalingam K, 2011, ANNU REP PROG CHEM A, V107, P339, DOI 10.1039/c1ic90027g
   Suntharalingam K, 2010, INORG CHEM, V49, P8371, DOI 10.1021/ic100884p
   Ucar I, 2007, J PHYS CHEM SOLIDS, V68, P2271, DOI 10.1016/j.jpcs.2007.06.017
   Uma V, 2007, EUR J INORG CHEM, P3484, DOI 10.1002/ejic.200700053
   Valdes-Martinez J, 2002, ACTA CRYSTALLOGR E, V58, pM712, DOI 10.1107/S1600536802020470
   Wang SX, 2013, APPL ORGANOMET CHEM, V27, P373, DOI 10.1002/aoc.2988
   Wein AN, 2011, J INORG BIOCHEM, V105, P663, DOI 10.1016/j.jinorgbio.2011.01.006
   Wong VCH, 2018, J AM CHEM SOC, V140, P657, DOI 10.1021/jacs.7b09770
   Xia DC, 2012, Z KRIST-NEW CRYST ST, V227, P133, DOI 10.1524/ncrs.2012.0061
   YIP HK, 1993, J CHEM SOC DALTON, P2933, DOI 10.1039/dt9930002933
   Zeglis BM, 2007, CHEM COMMUN, P4565, DOI 10.1039/b710949k
   Zhang GQ, 2015, EUR J INORG CHEM, P939, DOI 10.1002/ejic.201403140
   Zou HH, 2016, EUR J MED CHEM, V108, P1, DOI 10.1016/j.ejmech.2015.11.005
   Zuazo-Gaztelu I, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00248
NR 121
TC 7
Z9 7
U1 8
U2 16
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JUN 5
PY 2021
VL 218
AR 113404
DI 10.1016/j.ejmech.2021.113404
EA APR 2021
PG 19
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RW0EA
UT WOS:000646195900027
PM 33823390
OA hybrid, Green Published
DA 2022-04-25
ER

PT J
AU Zheng, L
   Chen, JT
   Zhou, ZY
   He, ZK
AF Zheng, Li
   Chen, Jiangtao
   Zhou, Zhongyong
   He, Zhikuan
TI miR-195 enhances the radiosensitivity of colorectal cancer cells by
   suppressing CARM1
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE miR-195; CARM1; colorectal cancer; radiosensitivity
ID UP-REGULATION; RADIORESISTANCE; EXPRESSION; MICRORNAS; RADIATION;
   AUTOPHAGY; RESISTANCE
AB Background: microRNAs (miRNAs) can regulate the sensitivity of cancer cells to chemotherapy and radiotherapy. Aberrant expression of miR-195 has been found to be involved in colorectal cancer (CRC); however, its function and underlying mechanism in the radioresistance of CRC remains unclear.
   Methods: The levels of miR-195 and CARM1 were detected by quantitative reverse transcription-polymerase chain reaction and Western blot analysis in HCT-116 and HT-29 cells, respectively. Colony survival and apoptosis were determined by clonogenic assay and flow cytometry analysis, respectively. The apoptosis-related proteins Bax, Bcl-2, and gamma-H2AX were detected using Western blot. The targets of miR-195 were identified by bioinformatic prediction and luciferase reporter assays. CRC cells in vitro and in vivo were exposed to different doses of X-ray radiations.
   Results: miR-195 was downregulated, and CARM1 was upregulated in HCT-116 and HT-29 cells. miR-195 overexpression or CARM1 knockdown suppressed colony survival, induced apoptosis, promoted expression of Bax and gamma-H2AX, and inhibited Bcl-2 expression in CRC cells. CARM1 was identified and validated to be a functional target of miR-195. Moreover, restored expression of CARM1 reversed the enhanced radiosensitivity of CRC cells induced by miR-195. Furthermore, miR-195 increased the sensitivity of CRC cells to radiation in vivo.
   Conclusion: miR-195 enhances radiosensitivity of CRC cells through suppressing CARM1. Therefore, miR-195 acts as a potential regulator of radioresistance for CRC cells and as a promising therapeutic target for CRC patients.
C1 [Zheng, Li; Chen, Jiangtao; Zhou, Zhongyong; He, Zhikuan] Henan Univ, Huaihe Hosp, Dept Gen Surg, 8 Baobei Rd, Gulou Dist 475000, Kaifeng, Peoples R China.
RP Zheng, L (corresponding author), Henan Univ, Huaihe Hosp, Dept Gen Surg, 8 Baobei Rd, Gulou Dist 475000, Kaifeng, Peoples R China.
EM lizhengccn@163.com
CR Ahmed MAH, 2009, J CLIN PATHOL, V62, P1117, DOI 10.1136/jcp.2009.069310
   Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Beskow C, 2009, BRIT J CANCER, V101, P816, DOI 10.1038/sj.bjc.6605201
   Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002
   Chiu SJ, 2010, BIOCHEM BIOPH RES CO, V394, P774, DOI 10.1016/j.bbrc.2010.03.068
   Covic M, 2005, EMBO J, V24, P85, DOI 10.1038/sj.emboj.7600500
   Deng XB, 2013, J NEURO-ONCOL, V114, P263, DOI 10.1007/s11060-013-1179-2
   Duan WM, 2013, J RADIAT RES, V54, P611, DOI 10.1093/jrr/rrs136
   Dumont FJ, 2012, CURR CANCER DRUG TAR, V12, P899
   Francescone RA, 2011, J BIOL CHEM, V286, P15332, DOI 10.1074/jbc.M110.212514
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI 10.1146/annurev.med.59.053006.104707
   Hung PS, 2008, J PATHOL, V214, P368, DOI 10.1002/path.2280
   Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Lin J, 2013, J CELL BIOCHEM, V114, P606, DOI 10.1002/jcb.24398
   Liu L, 2010, BIOCHEM BIOPH RES CO, V400, P236, DOI 10.1016/j.bbrc.2010.08.046
   Liu YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062383
   Metheetrairut C, 2013, CURR OPIN GENET DEV, V23, P12, DOI 10.1016/j.gde.2013.01.002
   Moncharmont C, 2012, CANCER LETT, V322, P139, DOI 10.1016/j.canlet.2012.03.024
   Gutierrez JJP, 2011, COLORECTAL DIS, V13, pE145, DOI 10.1111/j.1463-1318.2011.02577.x
   Rundle AG, 2008, GASTROENTEROLOGY, V134, P1311, DOI 10.1053/j.gastro.2008.02.032
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Vu LP, 2010, BLOOD, V116, P1494, DOI 10.1182/blood.V116.21.3632.3632
   Wang L, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500463
   Wang L, 2014, CANCER CELL, V25, P21, DOI 10.1016/j.ccr.2013.12.007
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Wang XQ, 2012, MED ONCOL, V29, P919, DOI 10.1007/s12032-011-9880-5
   Xiao SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108810
   Xue Q, 2013, WORLD J GASTROENTERO, V19, P9307, DOI 10.3748/wjg.v19.i48.9307
   Yang XD, 2015, AM J CANCER RES, V5, P545
   Yaromina A, 2007, RADIOTHER ONCOL, V83, P304, DOI 10.1016/j.radonc.2007.04.020
   Zhang YH, 2015, CHIN J INTEGR MED, V10, P10, DOI DOI 10.1371/J0URNAL.P0NE.0131597
   Zhang Y, 2014, CELL BIOCHEM BIOPHYS, V69, P303, DOI 10.1007/s12013-013-9799-x
   Zhang Yin, 2014, EURASIP J ADV SIG PR, V2014, P1, DOI DOI 10.1016/J.ENGGE0.2014.08.024
   Zheng L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0592-z
   Zhu J, 2015, INT J CLIN EXP MED, V8, P9142
NR 39
TC 31
Z9 38
U1 1
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2017
VL 10
BP 1027
EP 1038
DI 10.2147/OTT.S125067
PG 12
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA EL3JH
UT WOS:000394514900001
PM 28255246
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Li, SY
   Chen, S
   Wang, BX
   Zhang, L
   Su, YN
   Zhang, XP
AF Li, Shuyuan
   Chen, Shuo
   Wang, Boxue
   Zhang, Lin
   Su, Yinan
   Zhang, Xipeng
TI A Robust 6-lncRNA Prognostic Signature for Predicting the Prognosis of
   Patients With Colorectal Cancer Metastasis
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE colorectal cancer; metastasis; prognosis; long non-coding RNAs;
   prognostic signature
ID NONCODING RNA SIGNATURE; EXPRESSION; SURVIVAL; CERNA; SET
AB Objective: Our study aimed to construct a robust long non-coding RNA (lncRNA) prognostic signature for colorectal cancer (CRC) metastasis.
   Methods: Differentially expressed lncRNAs were identified between metastatic CRC and non-metastatic CRC samples from The Cancer Genome Atlas Database (TCGA) using the edgeR package. The differentially expressed lncRNAs with prognosis of patients with CRC metastasis were identified by univariate Cox regression analysis, followed by a stepwise multivariate Cox regression model. The survminer package in R was used to identify the optimal cutoff point for high-risk and low-risk groups. The receiver operating characteristic (ROC) curves were plotted to assess this signature. To explore potential signaling pathways associated with these lncRNAs, Gene Set Enrichment Analysis (GSEA) was performed.
   Results: A 6-lncRNA signature was built based on the lncRNA expression profile for CRC metastasis. The optimal cutoff value was used to classify high-risk and low-risk groups using the survminer package. The high-risk groups could have poorer survival time than the low-risk groups. ROC curve result indicated that this lncRNA signature had high sensitivity and accuracy. GSEA analysis results showed that the six lncRNAs were significantly enriched in several CRC metastasis-related signaling pathways such as "cell cycle," "DNA replication," "mismatch repair," "oxidative phosphorylation," "regulation of autophagy," and "insulin signaling pathway."
   Conclusion: Our study constructed a 6-lncRNA model for predicting the survival outcomes of patients with CRC metastasis, which could become potential prognostic biomarkers, and therapeutic targets for CRC metastasis.
C1 [Li, Shuyuan; Chen, Shuo; Wang, Boxue; Zhang, Lin; Su, Yinan; Zhang, Xipeng] Tianjin Union Med Ctr, Dept Colorectal Surg, Tianjin, Peoples R China.
RP Zhang, XP (corresponding author), Tianjin Union Med Ctr, Dept Colorectal Surg, Tianjin, Peoples R China.
EM zhangxipeng2016@sina.com
FU Foundation of Tianjin Union Medical Center [2016RMNK002]
FX This work was funded by The Foundation of Tianjin Union Medical Center
   (2016RMNK002).
CR Chen DL, 2017, THERANOSTICS, V7, P4836, DOI 10.7150/thno.20942
   Fan QW, 2018, J CELL BIOCHEM, V119, P3574, DOI 10.1002/jcb.26548
   Gennaro VJ, 2018, P NATL ACAD SCI USA, V115, pE9298, DOI 10.1073/pnas.1807704115
   Gu JX, 2019, WORLD J GASTROENTERO, V25, P220, DOI 10.3748/wjg.v25.i2.220
   Guo WN, 2016, SCI REP-UK, V6, DOI 10.1038/srep27931
   Huang L, 2019, J CELL PHYSIOL, V234, P7032, DOI 10.1002/jcp.27456
   Jin ZH, 2018, ONCOLOGIST, V23, P1083, DOI 10.1634/theoncologist.2017-0289
   Liu XX, 2019, ONCOL RES, V27, P99, DOI 10.3727/096504018X15195193936573
   Liu YH, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01269
   Lorenzi L, 2019, GENE CHROMOSOME CANC, V58, P191, DOI 10.1002/gcc.22709
   Lu XY, 2018, ONCOL RES, V26, P473, DOI 10.3727/096504017X15105708598531
   Luo ZF, 2016, WORLD J GASTROENTERO, V22, P5254, DOI 10.3748/wjg.v22.i22.5254
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Pan SM, 2019, BBA-MOL CELL RES, V1866, P750, DOI 10.1016/j.bbamcr.2019.02.004
   Peng K, 2018, BIOMED PHARMACOTHER, V97, P1138, DOI 10.1016/j.biopha.2017.11.031
   Qi L, 2018, BIOCHEM BIOPH RES CO, V501, P113, DOI 10.1016/j.bbrc.2018.04.186
   Quo QH, 2014, ONCOL LETT, V8, P869, DOI 10.3892/ol.2014.2154
   REZANEJAD BH, 2018, EUR J CELL BIOL, V97, P279, DOI DOI 10.1016/j.ejcb.2018.04.004
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Salomaa V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010100
   Shen XG, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0136-5
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun XC, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0011-z
   Torres S, 2017, J PATHOL, V242, P39, DOI 10.1002/path.4874
   Wang XN, 2018, CANCER MANAG RES, V10, P5799, DOI 10.2147/CMAR.S178732
   Wang Y, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0082-5
   Wu D, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1707-x
   Xu J, 2019, CANCER RES, V79, P4882, DOI 10.1158/0008-5472.CAN-18-3880
   Yan JH, 2019, J CELL BIOCHEM, V120, P213, DOI 10.1002/jcb.27321
   Zhang L, 2019, J CELL BIOCHEM, V120, P5636, DOI 10.1002/jcb.27847
   Zhao L, 2019, ONCOGENE, V38, P935, DOI 10.1038/s41388-018-0493-8
   Zhao WH, 2018, MOL CARCINOGEN, V57, P193, DOI 10.1002/mc.22746
   Zhou M, 2018, MOL NEUROBIOL, V55, P3684, DOI 10.1007/s12035-017-0572-9
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
NR 36
TC 11
Z9 11
U1 1
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD MAR 6
PY 2020
VL 7
AR 56
DI 10.3389/fmed.2020.00056
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LC3MK
UT WOS:000525228800001
PM 32211413
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Yan, SY
   Li, QQ
   Zhang, DR
   Wang, XW
   Xu, Y
   Zhang, C
   Guo, DL
   Bao, YH
AF Yan, Siyuan
   Li, Qianqian
   Zhang, Deru
   Wang, Xiaowen
   Xu, Yang
   Zhang, Cong
   Guo, Dongli
   Bao, Yonghua
TI Necroptosis pathway blockage attenuates PFKFB3 inhibitor-induced cell
   viability loss and genome instability in colorectal cancer cells
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE PFKFB3; necroptosis; genome instability; colorectal cancer; cell
   viability
ID MIXED LINEAGE KINASE; MOLECULAR-MECHANISMS; RIP1 KINASE; DNA-REPAIR;
   DEATH; AUTOPHAGY; APOPTOSIS; CASPASE-8; GROWTH
AB Cancer cells prone to utilize aerobic glycolysis other than oxidative phosphorylation to sustain its continuous cell activity in the stress microenvironment. Meanwhile, cancer cells generally suffer from genome instability, and both radiotherapy and chemotherapy may arouse DNA strand break, a common phenotype of genome instability. Glycolytic enzyme PFKFB3 (6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase isoform 3), plays essential roles in variety physiology and pathology processes, and generally maintain high level in cancer cells. Although this protein has been reported to involve in genome instability, its role remains unclear and controversial. Here, we showed that PFK-15, a PFKFB3 inhibitor, obviously induced apoptosis, cell viability loss, and inhibited cell proliferation/migration. Besides, PFK-15 was also found to induce necroptosis, as it not only up-regulated the phosphorylated RIP1, RIP3 and MLKL, but also enhanced the interaction between RIP3 and RIP1/MLKL, all of which are characterization of necroptosis induction. Both genetically and pharmacologically deprivation of necroptosis attenuated the cytotoxic effect of PFK-15. Besides, PFK-15 increased the gamma-H2AX level and micronuclei formation, markers for genome instability, and inhibition of necroptosis attenuated these phenotypes. Collectively, the presented data demonstrated that PFK-15 induced genome instability and necroptosis, and deprivation of necroptosis attenuated cytotoxicity and genotoxicity of PFK-15 in colorectal cancer cells, thereby revealing a more intimate relationship among PFKFB3, necroptosis and genome instability.
C1 [Yan, Siyuan; Li, Qianqian; Zhang, Deru; Wang, Xiaowen; Xu, Yang; Zhang, Cong; Bao, Yonghua] Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining 272067, Peoples R China.
   [Guo, Dongli] Jining Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Jining 272000, Peoples R China.
RP Yan, SY (corresponding author), Jining Med Univ, Inst Precis Med, Key Lab Precis Oncol Shandong Higher Educ, Jining 272067, Peoples R China.
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31801169]; Faculty Startup Funds from Jining
   Medical University; Teacher Research Support Foundation in Jining
   medical university [JYFC2018KJ065]; Student Innovation Training Program
   in Jining Medical University [cx2019-010, 201702010332]
FX This work was supported by grants from the National Natural Science
   Foundation of China (31801169 to Yan S.) , The Faculty Startup Funds
   from Jining Medical University (to Yan S.) , the Teacher Research
   Support Foundation in Jining medical university (JYFC2018KJ065 to Yan
   S.) , and The Student Innovation Training Program in Jining Medical
   University (cx2019-010, 201702010332) .
CR Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322
   Andrabi SA, 2006, P NATL ACAD SCI USA, V103, P18308, DOI 10.1073/pnas.0606526103
   Balmus G, 2015, NAT PROTOC, V10, P205, DOI 10.1038/nprot.2015.010
   Bras M, 2007, MOL CELL BIOL, V27, P7073, DOI 10.1128/MCB.02116-06
   Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83
   Dillon CP, 2014, CELL, V157, P1189, DOI 10.1016/j.cell.2014.04.018
   Franklin DA, 2016, SCI REP-UK, V6, DOI 10.1038/srep38067
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Han QR, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1580-x
   Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467
   Jouan-Lanhouet S, 2014, SEMIN CELL DEV BIOL, V35, P2, DOI 10.1016/j.semcdb.2014.08.010
   Kisurina-Evgenieva OP, 2016, BIOCHEMISTRY-MOSCOW+, V81, P453, DOI 10.1134/S0006297916050035
   LaRocca TJ, 2016, J BIOL CHEM, V291, P13753, DOI 10.1074/jbc.M116.716027
   Li FL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02950-5
   Li JX, 2012, CELL, V150, P339, DOI 10.1016/j.cell.2012.06.019
   Lu Q, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.344
   Metzig MO, 2016, ONCOGENE, V35, P3399, DOI 10.1038/onc.2015.398
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   Murphy JM, 2013, IMMUNITY, V39, P443, DOI 10.1016/j.immuni.2013.06.018
   Ros S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-8
   Shi WK, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0435-y
   Su Z, 2016, CELL DEATH DIFFER, V23, P748, DOI 10.1038/cdd.2016.8
   Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031
   Sun YM, 2015, J BIOENERG BIOMEMBR, V47, P319, DOI 10.1007/s10863-015-9612-1
   Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036
   Yalcin A, 2009, J BIOL CHEM, V284, P24223, DOI 10.1074/jbc.M109.016816
   Yamamoto T, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4480
   Yan S, 2014, CANCER GENE THER, V21, P188, DOI 10.1038/cgt.2014.16
   Yan SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215415
   Yan SY, 2017, ONCOTARGET, V8, P80909, DOI 10.18632/oncotarget.20757
   Yan SY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.387
   Yang Z, 2013, J EXP MED, V210, P2119, DOI 10.1084/jem.20130252
   Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021
NR 37
TC 2
Z9 2
U1 2
U2 3
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2021
VL 11
IS 5
BP 2062
EP +
PG 27
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SI3FY
UT WOS:000654712200001
PM 34094669
DA 2022-04-25
ER

PT J
AU Jin, GY
   Liu, YH
   Zhang, J
   Bian, ZH
   Yao, SR
   Fei, BJ
   Zhou, LY
   Yin, Y
   Huang, ZH
AF Jin, Guoying
   Liu, Yuhang
   Zhang, Jia
   Bian, Zehua
   Yao, Surui
   Fei, Bojian
   Zhou, Leyuan
   Yin, Yuan
   Huang, Zhaohui
TI A panel of serum exosomal microRNAs as predictive markers for
   chemoresistance in advanced colorectal cancer
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE Colorectal cancer; Chemoresistance; Exosome; MicroRNAs
ID PROMOTES CELL-PROLIFERATION; DRUG-RESISTANCE; SENSITIVITY; STATISTICS;
   BIOMARKERS; DIAGNOSIS; INVASION; TARGETS; MIRNAS
AB BackgroundChemoresistance is a common problem for cancer treatment worldwide. Circulating exosomal microRNAs (miRNAs) have been considered as promising biomarkers of cancers. However, few studies have assessed the relationship between serum/plasma exosomal microRNAs and chemoresistance in colorectal cancer (CRC).MethodsBased on previous microarray analysis, we selected 30 miRNAs which are aberrantly expressed during CRC progression and then detected their expression levels in three pairs of oxaliplatin/5-fluorouracil-resistant CRC cell lines and the corresponding secreted exosomes. Six candidate exosomal miRNAs were identified for further evaluating potential value in predicting chemotherapeutic effect in advanced CRC patients. Finally, the molecular mechanisms of these miRNAs in drug resistance were explored by bioinformatics preliminarily.ResultsWe observed that the expression of 14 miRNAs was significantly higher in three drug-resistant CRC cells comparing with their parental cells. Among these miRNAs, miR-21-5p, miR-1246, miR-1229-5p, miR-135b, miR-425 and miR-96-5p are also up-regulated in exosomes from culture media of resistant cells. Clinical sample analysis confirmed that the expression levels of miR-21-5p, miR-1246, miR-1229-5p and miR-96-5p in serum exosomes were significantly higher in chemoresistant patients in contrast with chemosensitive controls. ROC curve showed that the combination of the four miRNAs had an area of under the curve (AUC) of 0.804 (P<0.05). In addition, GO analysis and KEGG pathway analysis revealed that these miRNAs were enriched in PI3K-Akt signaling pathway, FoxO signaling pathway and autophagy pathway.ConclusionsOur study demonstrates that a panel of serum exosomal miRNAs containing miR-21-5p, miR-1246, miR-1229-5p and miR-96-5p could significantly distinguish the chemotherapy-resistant group from advanced colorectal cancer patients. Targeting these miRNAs may promote chemosensitivity to oxaliplatin and 5-fluorouracil, and might be promising strategy for CRC treatment.
C1 [Jin, Guoying; Liu, Yuhang; Zhang, Jia; Bian, Zehua; Yao, Surui; Yin, Yuan; Huang, Zhaohui] Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, 200 Huihe Rd, Wuxi 214062, Jiangsu, Peoples R China.
   [Jin, Guoying; Liu, Yuhang; Zhang, Jia; Bian, Zehua; Yao, Surui; Yin, Yuan; Huang, Zhaohui] Jiangnan Univ, Wuxi Sch Med, Canc Epigenet Program, Wuxi 214122, Jiangsu, Peoples R China.
   [Fei, Bojian] Jiangnan Univ, Affiliated Hosp, Dept Surg Oncol, Wuxi 214062, Jiangsu, Peoples R China.
   [Zhou, Leyuan] Jiangnan Univ, Affiliated Hosp, Dept Radiat Oncol, Wuxi 214062, Jiangsu, Peoples R China.
RP Yin, Y; Huang, ZH (corresponding author), Jiangnan Univ, Affiliated Hosp, Wuxi Canc Inst, 200 Huihe Rd, Wuxi 214062, Jiangsu, Peoples R China.; Yin, Y; Huang, ZH (corresponding author), Jiangnan Univ, Wuxi Sch Med, Canc Epigenet Program, Wuxi 214122, Jiangsu, Peoples R China.
EM yinyuandiana@163.com; hzhwxsy@126.com
RI Yin, Yuan/AAG-1707-2020; Huang, Zhaohui/S-9410-2019
OI Huang, Zhaohui/0000-0002-0117-9976
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81672328, 81772636]; Fundamental Research
   Funds for the Central UniversitiesFundamental Research Funds for the
   Central Universities [NOJUSRP51619B, JUSRP51710A]; Medical Key
   Professionals Program of Jiangsu Province [AF052141]; Medical Youth
   Professionals Program of Jiangsu Province [QNRC2016162]; Medical
   Innovation Team Program of Wuxi [CXTP003]; National First-class
   Discipline Program of Food Science and Technology [JUFSTR20180101];
   Project of the Wuxi Health and Family Planning Commission [Z201806]
FX This study was partially supported by grants from the National Natural
   Science Foundation of China (81672328 and 81772636), Fundamental
   Research Funds for the Central Universities (NOJUSRP51619B and
   JUSRP51710A), Medical Key Professionals Program of Jiangsu Province
   (AF052141), Medical Youth Professionals Program of Jiangsu Province
   (QNRC2016162), Medical Innovation Team Program of Wuxi (CXTP003),
   National First-class Discipline Program of Food Science and Technology
   (JUFSTR20180101), Project of the Wuxi Health and Family Planning
   Commission (Z201806).
CR Becerra AZ, 2016, ANN SURG ONCOL, V23, P1554, DOI 10.1245/s10434-015-5014-1
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P1, DOI 10.3978/j.issn.1000-9604.2015.02.07
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Chu SH, 2017, ONCOL REP, V38, P2401, DOI 10.3892/or.2017.5859
   Eze N, 2019, ORAL ONCOL, V91, P69, DOI 10.1016/j.oraloncology.2019.02.026
   Gaudelot K, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317707372
   Gauthier SA, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0466-0
   Guo P, 2018, INT J ONCOL, V53, P1591, DOI 10.3892/ijo.2018.4498
   Hage C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.158
   Hamam R, 2016, SCI REP-UK, V6, DOI 10.1038/srep25997
   Hasegawa S, 2014, BRIT J CANCER, V111, P1572, DOI 10.1038/bjc.2014.454
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hoshino I, 2013, SURG TODAY, V43, P467, DOI 10.1007/s00595-012-0392-5
   Huang XX, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0969-3
   Huang ZH, 2011, CANCER RES, V71, P2582, DOI 10.1158/0008-5472.CAN-10-3032
   Koberle V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075184
   Krause M, 2017, ADV DRUG DELIVER REV, V109, P63, DOI 10.1016/j.addr.2016.02.002
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Li XJ, 2017, CELL PHYSIOL BIOCHEM, V44, P1741, DOI 10.1159/000485780
   Lin SS, 2018, CANCERS, V10, DOI 10.3390/cancers10080272
   Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710
   Liu G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190249
   Moon JH, 2019, BRIT J CANCER, V5, P6
   Ogata-Kawata H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092921
   Onoda N, 2015, MOL CLIN ONCOL, V3, P522, DOI 10.3892/mco.2015.496
   Panczyk M, 2014, WORLD J GASTROENTERO, V20, P9775, DOI 10.3748/wjg.v20.i29.9775
   Papa A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9040153
   Qin Y, 2018, CELL PHYSIOL BIOCHEM, V48, P1627, DOI 10.1159/000492284
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Shao LL, 2019, FASEB J, V33, P264, DOI 10.1096/fj.201701456RR
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Su WM, 2016, BIOMED PHARMACOTHER, V84, P123, DOI 10.1016/j.biopha.2016.09.027
   Tan ZY, 2016, ONCOTARGET, V7, P24076, DOI 10.18632/oncotarget.8119
   Uratani R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160722
   Vidal SJ, 2014, ONCOGENE, V33, P4451, DOI 10.1038/onc.2013.411
   Wang JJ, 2019, EUR REV MED PHARMACO, V23, P2497, DOI 10.26355/eurrev_201903_17397
   Xu M, 2019, MOL CARCINOGEN, V58, P577, DOI 10.1002/mc.22952
   Yin Y, 2016, GENE, V578, P177, DOI 10.1016/j.gene.2015.12.015
   Yin Y, 2014, CLIN CANCER RES, V20, P6187, DOI 10.1158/1078-0432.CCR-14-1030
   Zhang L, 2016, INT J LAB HEMATOL, V38, P589, DOI 10.1111/ijlh.12560
   Zhu MX, 2017, ONCOTARGET, V8, P17081, DOI 10.18632/oncotarget.15059
   Zhu WJ, 2017, ONCOTARGET, V8, P89631, DOI 10.18632/oncotarget.20099
NR 43
TC 53
Z9 54
U1 4
U2 21
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD AUG
PY 2019
VL 84
IS 2
BP 315
EP 325
DI 10.1007/s00280-019-03867-6
PG 11
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA IJ1VG
UT WOS:000475686400010
PM 31089750
DA 2022-04-25
ER

PT J
AU Deshpande, NP
   Wilkins, MR
   Castano-Rodriguez, N
   Bainbridge, E
   Sodhi, N
   Riordan, SM
   Mitchell, HM
   Kaakoush, NO
AF Deshpande, Nandan P.
   Wilkins, Marc R.
   Castano-Rodriguez, Natalia
   Bainbridge, Emily
   Sodhi, Nidhi
   Riordan, Stephen M.
   Mitchell, Hazel M.
   Kaakoush, Nadeem O.
TI Campylobacter concisus pathotypes induce distinct global responses in
   intestinal epithelial cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; COMPARATIVE GENOMICS; COLORECTAL-CANCER;
   INDUCED APOPTOSIS; TIGHT JUNCTIONS; VIBRIO-CHOLERAE; ASSOCIATION;
   MICROBIOTA; INFECTION; AUTOPHAGY
AB The epithelial response to the opportunistic pathogen Campylobacter concisus is poorly characterised. Here, we assessed the intestinal epithelial responses to two C. concisus strains with different virulence characteristics in Caco-2 cells using RNAseq, and validated a subset of the response using qPCR arrays. C. concisus strains induced distinct response patterns from intestinal epithelial cells, with the toxigenic strain inducing a significantly more amplified response. A range of cellular functions were significantly regulated in a strain-specific manner, including epithelial-to-mesenchymal transition (NOTCH and Hedgehog), cytoskeletal remodeling, tight junctions, inflammatory responses and autophagy. Pattern recognition receptors were regulated, including TLR3 and IFI16, suggesting that nucleic acid sensing was important for epithelial recognition of C. concisus. C. concisus zonula occludens toxin (ZOT) was expressed and purified, and the epithelial response to the toxin was analysed using RNAseq. ZOT upregulated PAR2 expression, as well as processes related to tight junctions and cytoskeletal remodeling. C. concisus ZOT also induced upregulation of TLR3, pro-inflammatory cytokines IL6, IL8 and chemokine CXCL16, as well as the executioner caspase CASP7. Here, we characterise distinct global epithelial responses to C. concisus strains, and the virulence factor ZOT, and provide novel information on mechanisms by which this bacterium may affect the host.
C1 [Deshpande, Nandan P.; Wilkins, Marc R.] UNSW Australia, Sch Biotechnol & Biomol Sci, Syst Biol Initiat, Sydney, NSW 2052, Australia.
   [Wilkins, Marc R.; Castano-Rodriguez, Natalia; Bainbridge, Emily; Sodhi, Nidhi; Mitchell, Hazel M.] UNSW Australia, Sch Biotechnol & Biomol Sci, Sydney, NSW 2052, Australia.
   [Wilkins, Marc R.] UNSW Australia, Ramaciotti Ctr Gene Funct Anal, Sydney, NSW 2052, Australia.
   [Riordan, Stephen M.] Prince Wales Hosp, Gastrointestinal & Liver Unit, Randwick, NSW 2031, Australia.
   [Kaakoush, Nadeem O.] UNSW Australia, Sch Med Sci, Sydney, NSW 2052, Australia.
RP Kaakoush, NO (corresponding author), UNSW Australia, Sch Med Sci, Sydney, NSW 2052, Australia.
EM n.kaakoush@unsw.edu.au
RI Kaakoush, Nadeem/ABG-9499-2020
OI Kaakoush, Nadeem Omar/0000-0003-4017-1077; Castano-Rodriguez,
   Natalia/0000-0001-8819-8872
FU Cancer Institute NSW Career Development Fellowship [15/CDF/1-11];
   Australian Federal Government NCRIS SchemeAustralian
   GovernmentDepartment of Industry, Innovation and Science; New South
   Wales State Government RAAP Scheme; University of New South Wales;
   Ministry of Higher Education, MalaysiaMinistry of Education, Malaysia
   [UM.C/625/HIR/MOHE/CHAN/13/1]
FX This work was supported by a Cancer Institute NSW Career Development
   Fellowship (15/CDF/1-11 to N.O.K.). M.R.W. and N.P.D. acknowledge
   funding from the Australian Federal Government NCRIS Scheme, the New
   South Wales State Government RAAP Scheme and the University of New South
   Wales. H.M.M. receives funding from the Ministry of Higher Education,
   Malaysia (UM.C/625/HIR/MOHE/CHAN/13/1).
CR Blackett KL, 2013, ALIMENT PHARM THER, V37, P1084, DOI 10.1111/apt.12317
   Boyd EF, 2000, INFECT IMMUN, V68, P1507, DOI 10.1128/IAI.68.3.1507-1513.2000
   Burgos-Portugal JA, 2014, FEBS OPEN BIO, V4, P301, DOI 10.1016/j.fob.2014.03.008
   Castano-Rodriguez N, 2017, GUT, V66, P235, DOI 10.1136/gutjnl-2015-310545
   Deshpande NP, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-585
   FASANO A, 1995, J CLIN INVEST, V96, P710, DOI 10.1172/JCI118114
   FASANO A, 1991, P NATL ACAD SCI USA, V88, P5242, DOI 10.1073/pnas.88.12.5242
   GABRIEL SE, 1994, SCIENCE, V266, P107, DOI 10.1126/science.7524148
   Goldblum SE, 2011, FASEB J, V25, P144, DOI 10.1096/fj.10-158972
   Hirata H, 1998, J EXP MED, V187, P587, DOI 10.1084/jem.187.4.587
   Ji S, 2009, INFECT IMMUN, V77, P1044, DOI 10.1128/IAI.00449-08
   Kaakoush NO, 2015, CLIN MICROBIOL REV, V28, P687, DOI 10.1128/CMR.00006-15
   Kaakoush NO, 2015, TRENDS MICROBIOL, V23, P455, DOI 10.1016/j.tim.2015.03.009
   Kaakoush NO, 2015, INFECT IMMUN, V83, P832, DOI 10.1128/IAI.03012-14
   Kaakoush NO, 2014, INFLAMM BOWEL DIS, V20, P2189, DOI 10.1097/MIB.0000000000000074
   Kaakoush NO, 2014, J MED MICROBIOL, V63, P99, DOI 10.1099/jmm.0.067231-0
   Kaakoush NO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029045
   Kaakoush NO, 2010, FEBS J, V277, P1606, DOI 10.1111/j.1742-4658.2010.07587.x
   Kaakoush NO, 2012, FRONT CELL INFECT MI, V2, DOI 10.3389/fcimb.2012.00004
   Kee JY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-949
   Kirk KF, 2016, GUT PATHOG, V8, DOI 10.1186/s13099-016-0111-7
   Koop A, 2011, EUR J IMMUNOL, V41, P224, DOI 10.1002/eji.201040814
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Man SM, 2010, J INFECT DIS, V202, P1855, DOI 10.1086/657316
   Nielsen HL, 2013, CLIN MICROBIOL INFEC, V19, P445, DOI 10.1111/j.1469-0691.2012.03852.x
   Nielsen HL, 2012, CLIN MICROBIOL INFEC, V18, pE459, DOI 10.1111/j.1469-0691.2012.03990.x
   Nielsen HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023858
   Ramirez-Valle F, 2008, J CELL BIOL, V181, P293, DOI 10.1083/jcb.200710215
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Walsh JG, 2008, P NATL ACAD SCI USA, V105, P12815, DOI 10.1073/pnas.0707715105
   Warren RL, 2013, MICROBIOME, V1, DOI 10.1186/2049-2618-1-16
   Wu N, 2013, MICROB ECOL, V66, P462, DOI 10.1007/s00248-013-0245-9
   Zhang L, 2014, WORLD J GASTROENTERO, V20, P1259, DOI 10.3748/wjg.v20.i5.1259
   Zhang L, 2010, J CLIN MICROBIOL, V48, P2965, DOI 10.1128/JCM.02391-09
NR 34
TC 15
Z9 15
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 28
PY 2016
VL 6
AR 34288
DI 10.1038/srep34288
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DX1GO
UT WOS:000384114600001
PM 27677841
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Friedhuber, AM
   Chandolu, V
   Manchun, S
   Donkor, O
   Sriamornsak, P
   Dass, CR
AF Friedhuber, Anna M.
   Chandolu, Vijay
   Manchun, Somkamon
   Donkor, Osaana
   Sriamornsak, Pornsak
   Dass, Crispin R.
TI Nucleotropic doxorubicin nanoparticles decrease cancer cell viability,
   destroy mitochondria, induce autophagy and enhance tumour necrosis
SO JOURNAL OF PHARMACY AND PHARMACOLOGY
LA English
DT Article
DE cancer; doxorubicin; efficacy; nanoparticle; nucleus
ID EPITHELIUM-DERIVED FACTOR; DELIVERY-SYSTEMS; CHITOSAN NANOPARTICLES;
   DRUG-RESISTANCE; GENE DELIVERY; MURINE MODEL; C-JUN; OSTEOSARCOMA;
   GROWTH; THERAPY
AB Objective Doxorubicin (Dox) is used clinically against various neoplasias, but suffers from serious side effects, and for the past three decades, this shortcoming has spurred research towards finding better drug delivery systems (DDSs) for this frontline drug.
   Methods A non-targeted nucleotropic Dox-loaded nanoparticle (DNP) DDS is described, which has a simple chemical design, is easy to formulate and administer, is inexpensive, non-biohazardous and may prove to be useful clinically.
   Key findings The DNP formulated via vortex-assisted complex coarcevation enhanced (300-fold) cell-inhibitory activity of the drug in a panel of human cancer cells (osteosarcoma, breast, prostate and colorectal cancer) and enhanced (10-fold) efficacy against osteosarcoma (OS) in vivo. The slow-release DNPs localised to the endoplasmic reticulum disrupted the mitochondria and entered the nucleus. Prominent cytosolic vacuolisation, budding off of portions of the cytoplasm, both suggestive of autophagy, were observed. Mice that were administered with DNPs intratumorally had the smallest tumours at the end of the study, with more necrotic hotspots.
   Conclusion This promising nucleotropic DDS enhances the cell delivery and activity of Dox against a variety of human cancer cell lines and in OS tumours in mice.
C1 [Friedhuber, Anna M.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
   [Chandolu, Vijay] Victoria Univ, Canc Res Lab, Melbourne, Vic 8001, Australia.
   [Donkor, Osaana] Victoria Univ, Coll Hlth & Biomed, Melbourne, Vic 8001, Australia.
   [Dass, Crispin R.] Curtin Univ, Sch Pharm, Perth, WA 6845, Australia.
   [Dass, Crispin R.] Curtin Univ, Perth, WA 6845, Australia.
   [Manchun, Somkamon; Sriamornsak, Pornsak] Silpakorn Univ, Dept Pharmaceut Technol, Nakhon Pathom, Thailand.
   [Sriamornsak, Pornsak] Silpakorn Univ, Pharmaceut Biopolymer Grp PBiG, Nakhon Pathom, Thailand.
RP Dass, CR (corresponding author), Curtin Univ, Sch Pharm, Bldg 306, Perth, WA 6102, Australia.
EM crispin.dass@curtin.edu.au
RI Sriamornsak, Pornsak/F-5850-2010
OI Sriamornsak, Pornsak/0000-0002-5525-1494
FU Curtin Academic50 scheme; Australia/New Zealand (ANZ) Bank grant;
   Thailand Research FundThailand Research Fund (TRF)
FX The authors acknowledge the support of a Curtin Academic50 scheme to
   CRD, an Australia/New Zealand (ANZ) Bank grant to CRD, and a Thailand
   Research Fund allowance to PS and SM.
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535-7163.MCT-08-0530
   Bacci G, 2006, CANCER-AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724
   Broadhead Matthew L., 2011, Sarcoma, V2011, P959248, DOI 10.1155/2011/959248
   Celikoglu F, 2008, LUNG CANCER, V61, P1, DOI 10.1016/j.lungcan.2008.03.009
   Dam DHM, 2012, ACS NANO, V6, P3318, DOI 10.1021/nn300296p
   Das UN, 2004, PROSTAG LEUKOTR ESS, V70, P539, DOI 10.1016/j.plefa.2003.12.001
   Dass CR, 2002, ANTISENSE NUCLEIC A, V12, P289, DOI 10.1089/108729002761381276
   Dass CR, 2002, DRUG DELIV, V9, P11, DOI 10.1080/107175402753413136
   Dass CR, 2000, DRUG DELIV, V7, P15, DOI 10.1080/107175400266740
   Dass CR, 2008, J MICROENCAPSUL, V25, P421, DOI 10.1080/02652040802033673
   Dass CR, 2008, MOL CANCER RES, V6, P1289, DOI 10.1158/1541-7786.MCR-08-0036
   Dass CR, 2007, BIOMATERIALS, V28, P3026, DOI 10.1016/j.biomaterials.2007.03.016
   del Carmen MG, 2012, GYNECOL ONCOL, V126, P369, DOI 10.1016/j.ygyno.2012.05.028
   Ek ETH, 2007, J ORTHOP RES, V25, P1671, DOI 10.1002/jor.20434
   Ek ETH, 2007, CLIN EXP METASTAS, V24, P93, DOI 10.1007/s10585-007-9062-1
   Fahmy RG, 2003, NAT MED, V9, P1026, DOI 10.1038/nm905
   Farr KP, 2011, CASE REP ONCOL, V4, P229, DOI 10.1159/000327767
   Gu YJ, 2009, TOXICOL APPL PHARM, V237, P196, DOI 10.1016/j.taap.2009.03.009
   Huhn D, 2013, ACS NANO, V7, P3253, DOI 10.1021/nn3059295
   ISHIOKA T, 1987, CRIT REV TOXICOL, V17, P215, DOI 10.3109/10408448709071209
   Kaushal V, 2004, J THROMB HAEMOST, V2, P327, DOI 10.1046/j.1538-7933.2003.00573.x
   Kiyomiya K, 1998, LIFE SCI, V62, P1853, DOI 10.1016/S0024-3205(98)00151-9
   Klotzsche-von Ameln A, 2011, CANCER RES, V71, P3306, DOI 10.1158/0008-5472.CAN-10-3838
   Lee JH, 2003, BIOCONJUGATE CHEM, V14, P1214, DOI 10.1021/bc034095g
   Ma P, 2013, NANO TODAY, V8, P313, DOI 10.1016/j.nantod.2013.04.006
   Maimon T, 2012, STRUCTURE, V20, P998, DOI 10.1016/j.str.2012.03.025
   Nemunaitis J, 2011, HEAD NECK-J SCI SPEC, V33, P131, DOI 10.1002/hed.21364
   Peetla C, 2010, MOL PHARMACEUT, V7, P2334, DOI 10.1021/mp100308n
   Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385
   Stylianopoulos T, 2013, CANCER RES, V73, P3833, DOI 10.1158/0008-5472.CAN-12-4521
   Ta HT, 2009, BIOMATERIALS, V30, P4815, DOI 10.1016/j.biomaterials.2009.05.035
   Ta HT, 2009, BIOMATERIALS, V30, P3605, DOI 10.1016/j.biomaterials.2009.03.022
   Tacar O, 2013, J PHARM PHARMACOL, V65, P1577, DOI 10.1111/jphp.12144
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x
   Tan ML, 2010, BIOMATERIALS, V31, P541, DOI 10.1016/j.biomaterials.2009.09.069
   Tan ML, 2013, J PHARM PHARMACOL, V65, P35, DOI 10.1111/j.2042-7158.2012.01572.x
   Tan ML, 2010, J CONTROL RELEASE, V144, P196, DOI 10.1016/j.jconrel.2010.01.011
   Tan ML, 2009, J PHARM PHARMACOL, V61, P3, DOI 10.1211/jpp/61.01.0002
   Tan ML, 2009, J PHARM PHARMACOL, V61, P131, DOI 10.1211/jpp/61.02.0001
   Tanemura A, 2013, CANCER GENE THER, V20, P599, DOI 10.1038/cgt.2013.61
   Xia WS, 2008, BIORESOURCE TECHNOL, V99, P6751, DOI 10.1016/j.biortech.2008.01.011
   Xu YL, 2009, ANTICANCER RES, V29, P5103
   Zhang GS, 2004, JNCI-J NATL CANCER I, V96, P683, DOI 10.1093/jnci/djh120
NR 43
TC 16
Z9 16
U1 2
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3573
EI 2042-7158
J9 J PHARM PHARMACOL
JI J. Pharm. Pharmacol.
PD JAN
PY 2015
VL 67
IS 1
BP 68
EP 77
DI 10.1111/jphp.12322
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AX5ZU
UT WOS:000347004100007
PM 25208603
DA 2022-04-25
ER

PT J
AU Pan, L
   Li, Y
   Jin, L
   Li, J
   Xu, AX
AF Pan, Li
   Li, Yi
   Jin, Li
   Li, Jing
   Xu, Aixiang
TI TRPM2-AS promotes cancer cell proliferation through control of TAF15
SO INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
LA English
DT Article
DE TRPM2-AS; TAF15; TRPM2; Colorectal cancer
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; APOPTOSIS;
   AUTOPHAGY; DOCETAXEL; PATHWAY; RNA
AB Background: Colorectal cancer (CRC) ranks the third among all common malignancy worldwide. Long noncoding RNAs (lncRNAs) have been demonstrated as implicated in CRC, but the roles of many lncRNAs in CRC remain unclear. Exploration of lncRNA TRMP2-AS and its nearby gene in CRC progress was the focus of current study.
   Methods: The expression of TRPM2-AS and its nearby mRNA TRPM2 was measured by using RT-qPCR. The protein levels of TRPM2 and TAF15 were determined using western blot. Cell proliferation was detected by using CCK-8, colony formation and EdU assays. The interaction between TAF15 and TRPM2-AS or TRPM2 was evaluated by RNA pull-down and RIP assays. The TRPM2 mRNA stability was probed using the transcriptional inhibitor Actinomycin D.
   Results: TRPM2-AS was significantly upregulated in CRC cells. Knock-down of TRPM2-AS inhibited CRC cell proliferation. Mechanically, TRPM2-AS directly interacted with RNA-binding protein (RBP) TAF15 and thus maintained the mRNA stability of TRPM2. TRPM2 was a prerequisite for TRPM2-AS to exert its promoting function in CRC cell proliferation.
   Conclusion: This research demonstrated that TRPM2-AS facilitated proliferation of CRC cells by enhancing TAF15-mediated mRNA stability of TRPM2, unmasking the role of TRPM2-AS in CRC.
C1 [Pan, Li; Jin, Li] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sch Med, Radiotherapy Dept, Chengdu, Peoples R China.
   [Li, Yi] Univ Elect Sci & Technol China, Acad Med Sci, Dept Gastroenterol & Hepatol, Affiliated Hosp, Chengdu 610000, Sichuan, Peoples R China.
   [Li, Yi] Univ Elect Sci & Technol China, Acad Med Sci, Sichuan Prov Peoples Hosp, Chengdu 610000, Sichuan, Peoples R China.
   [Li, Jing] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sch Med, Dept Gen Internal Med, Chengdu, Peoples R China.
   [Xu, Aixiang] Zaozhuang Tradit Chinese Med Hosp, Dept Outpatient, 2666 Taihang Mt Rd, Zaozhuang 277000, Shandong, Peoples R China.
RP Xu, AX (corresponding author), Zaozhuang Tradit Chinese Med Hosp, Dept Outpatient, 2666 Taihang Mt Rd, Zaozhuang 277000, Shandong, Peoples R China.; Li, J (corresponding author), Univ Elect Sci & Technol China, Dept Gen Internal Med, Sichuan Canc Hosp & Inst, 55,Sect 4,Renmin South Rd, Chengdu, Peoples R China.; Li, J (corresponding author), Univ Elect Sci & Technol China, Sch Med, 55,Sect 4,Renmin South Rd, Chengdu, Peoples R China.
EM ligu637279897@163.com; zai47077303962@163.com
CR Ballarino M, 2013, ONCOGENE, V32, P4646, DOI 10.1038/onc.2012.490
   Bertuzzi M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1058-7
   Bester AC, 2018, CELL, V173, P649, DOI 10.1016/j.cell.2018.03.052
   Chan THM, 2014, GUT, V63, P832, DOI 10.1136/gutjnl-2012-304037
   Cheng X, 2018, CANCER LETT, V431, P105, DOI 10.1016/j.canlet.2018.05.046
   Cubillos-Ruiz JR, 2017, CELL, V168, P692, DOI 10.1016/j.cell.2016.12.004
   Davila-Gonzalez D, 2018, CLIN CANCER RES, V24, P1152, DOI 10.1158/1078-0432.CCR-17-1437
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Frakes AE, 2017, MOL CELL, V66, P761, DOI 10.1016/j.molcel.2017.05.031
   Galluzzi L, 2017, NAT REV CLIN ONCOL, V14, P247, DOI 10.1038/nrclinonc.2016.183
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Heymach JV, 2014, ANN ONCOL, V25, P1941, DOI 10.1093/annonc/mdu269
   Ibrahim S, 2019, CANCERS, V11, DOI 10.3390/cancers11040561
   Igder S., 2019, KRAS MUTATION ABNORM
   Jiang DD, 2015, SEMIN CANCER BIOL, V33, P48, DOI 10.1016/j.semcancer.2015.04.010
   Lebedeva S, 2011, MOL CELL, V43, P340, DOI 10.1016/j.molcel.2011.06.008
   Loktionov A, 2019, EUR J GASTROEN HEPAT, V31, P1220, DOI 10.1097/MEG.0000000000001535
   Senft D, 2015, TRENDS BIOCHEM SCI, V40, P141, DOI 10.1016/j.tibs.2015.01.002
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang C, 2019, ONCOGENE, V38, P1611, DOI 10.1038/s41388-018-0548-x
   Wang JW, 2018, AUTOPHAGY, V14, P2007, DOI 10.1080/15548627.2018.1501133
   Wang YH, 2017, CANCER LETT, V393, P8, DOI 10.1016/j.canlet.2017.01.036
   Wu XC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1699-6
   Yarom N., 2019, CLIN COLORECTAL CANC, DOI [10.1016/j.cicc.2019.05.004, DOI 10.1016/J.CICC.2019.05.004]
   Zhang W, 2019, MOL ONCOL, V13, P2194, DOI 10.1002/1878-0261.12560
   Zhu XL, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.59
NR 26
TC 19
Z9 19
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1357-2725
EI 1878-5875
J9 INT J BIOCHEM CELL B
JI Int. J. Biochem. Cell Biol.
PD MAR
PY 2020
VL 120
AR 105683
DI 10.1016/j.biocel.2019.105683
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA KO0AR
UT WOS:000515208900006
PM 31887411
DA 2022-04-25
ER

PT J
AU Wu, XY
   Chen, J
   Cao, QH
   Dong, M
   Lin, Q
   Fan, XJ
   Xia, Q
   Chen, ZH
   Liu, QT
   Wan, XB
AF Wu, Xiang-Yuan
   Chen, Jie
   Cao, Qing-Hua
   Dong, Min
   Lin, Qu
   Fan, Xin-Juan
   Xia, Qing
   Chen, Zhan-Hong
   Liu, Quentin
   Wan, Xiang-Bo
TI Beclin 1 activation enhances chemosensitivity and predicts a favorable
   outcome for primary duodenal adenocarcinoma
SO TUMOR BIOLOGY
LA English
DT Article
DE Autophagy; Beclin 1; HIF-1 alpha; Prognostic biomarker; PDA
ID POOR-PROGNOSIS; MALIGNANT PHENOTYPE; COLORECTAL-CANCER; GASTRIC-CANCER;
   AUTOPHAGY; EXPRESSION; CELLS; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN
AB We and others had proven that hypoxia-induced autophagy was essential to regulate cancer cell destiny under anticancer therapeutic stress. Here, we addressed the clinicopathologic effect of HIF-1 alpha and autophagic Beclin 1 in primary duodenal adenocarcinoma (PDA). HIF-1 alpha and Beclin 1 expression level were semi-quantitatively evaluated using tissue microarrays and immunohistochemistry (IHC) staining in 141 PDA patients. Among these patients, 77 acted as training set to select HIF-1 alpha and Beclin 1 IHC cutoff score for patient outcome, and 64 cases were used as testing set to evaluate their prognostic effect. We found that Beclin 1 was cytoplasmic overexpressed, defined by training set fixed cutoff point, in 49.6 % PDA tissue, compared to 46.8 % patients had HIF-1 alpha high expression. In testing set, Beclin 1 overexpression predicted a superior 5-year overall survival (OS) in both univariate (P = 0.010) and multivariate (P = 0.017) analyses. However, we did not detect any correlation between HIF-1 alpha level and patient prognosis (P = 0.989). Significantly, among Beclin 1 overexpressed patients, radical surgery plus adjuvant chemotherapy had a 23.1-month OS improvement than given radical surgery alone (59.2 vs 36.1 months; P = 0.01). For Beclin 1 lowly expressed patients, radical surgery plus adjuvant chemotherapy and given radical surgery alone had the similar OS (P = 0.283). Contrary to previous studies, we failed to detect any correlation between Beclin 1 and HIF-1 alpha levels in PDA (correlation coefficient 0.217, P = 0.099). In conclusions, our results confirmed that Beclin 1 was a favorable prognostic biomarker for PDA, and might be used to identify particular patients for more selective therapy.
C1 [Wu, Xiang-Yuan; Chen, Jie; Dong, Min; Lin, Qu; Chen, Zhan-Hong; Wan, Xiang-Bo] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China.
   [Cao, Qing-Hua] Sun Yat Sen Univ, Dept Pathol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Fan, Xin-Juan] Sun Yat Sen Univ, Dept Pathol, Gastrointestinal Inst, Affiliated Hosp 6, Guangzhou 510655, Guangdong, Peoples R China.
   [Xia, Qing; Liu, Quentin] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510060, Guangdong, Peoples R China.
RP Wu, XY (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM wuxiangy@mail.sysu.edu.cn; wanxbo@mail.sysu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81000934]; Fundamental Research Funds for
   the Central UniversitiesFundamental Research Funds for the Central
   Universities; Science and Technology Foundation of Guangdong Province
   [2009B060700024, 2011B03180076]
FX This work was supported by National Natural Science Foundation of China
   (No. 81000934 to X. B. Wan), the Fundamental Research Funds for the
   Central Universities (to X. B. Wan), Science and Technology Foundation
   of Guangdong Province (2009B060700024 to X.Y. Wu and 2011B03180076 to Q.
   Lin).
CR Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039
   Ahn CH, 2007, APMIS, V115, P1344, DOI 10.1111/j.1600-0463.2007.00858.x
   Amaravadi RK, 2007, CLIN CANCER RES, V13, P7271, DOI 10.1158/1078-0432.CCR-07-1595
   Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Bang YJ, 2010, LANCET, V376, P1302
   Begnami MD, 2011, J CLIN ONCOL, V29, P3030, DOI 10.1200/JCO.2010.33.6313
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Boutin AT, 2008, CELL, V133, P223, DOI 10.1016/j.cell.2008.02.038
   Chen YS, 2009, PATHOL ONCOL RES, V15, P487, DOI 10.1007/s12253-008-9143-8
   Crazzolara R, 2009, AUTOPHAGY, V5, P727, DOI 10.4161/auto.5.5.8507
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Ding ZB, 2008, CANCER RES, V68, P9167, DOI 10.1158/0008-5472.CAN-08-1573
   Domart MC, 2009, J HEPATOL, V51, P881, DOI 10.1016/j.jhep.2009.06.028
   Dong LW, 2011, AUTOPHAGY, V7, P1222, DOI 10.4161/auto.7.10.16610
   Furuya D, 2005, EXP CELL RES, V307, P26, DOI 10.1016/j.yexcr.2005.02.023
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Goldstein NS, 2001, CANCER, V92, P1331, DOI 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
   Gravalos C, 2008, ANN ONCOL, V19, P1523, DOI 10.1093/annonc/mdn169
   Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844
   Koukourakis MI, 2010, BRIT J CANCER, V103, P1209, DOI 10.1038/sj.bjc.6605904
   Lamparska-Przybysz M, 2006, AUTOPHAGY, V2, P47, DOI 10.4161/auto.2149
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Li BX, 2009, AUTOPHAGY, V5, P303, DOI 10.4161/auto.5.3.7491
   Li Jun-Lin, 2011, Chin J Cancer, V30, P655, DOI 10.5732/cjc.011.10185
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liu B, 2013, CHIN J CANCER, V32, P113, DOI 10.5732/cjc.012.10010
   Mazure NM, 2010, CURR OPIN CELL BIOL, V22, P177, DOI 10.1016/j.ceb.2009.11.015
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2010, NAT CELL BIOL, V12, P823, DOI 10.1038/ncb0910-823
   Mylonis I, 2008, J BIOL CHEM, V283, P27620, DOI 10.1074/jbc.M803081200
   Pirtoli L, 2009, AUTOPHAGY, V5, P930, DOI 10.4161/auto.5.7.9227
   Shi YH, 2009, AUTOPHAGY, V5, P380, DOI 10.4161/auto.5.3.7658
   Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993
   Trotti A., 2010, AJCC CANC STAGING MA, V7th
   Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176
   Wan XB, 2010, AUTOPHAGY, V6, P395, DOI 10.4161/auto.6.3.11303
   Wang K, 2011, AUTOPHAGY, V7, P966, DOI 10.4161/auto.7.9.15863
   Xu J, 2010, J CLIN ONCOL, V28, P5202, DOI 10.1200/JCO.2009.25.6552
   Yang ZF, 2010, CURR OPIN CELL BIOL, V22, P124, DOI 10.1016/j.ceb.2009.11.014
   ZENKLUSEN HR, 1989, VIRCHOWS ARCH A, V414, P529, DOI 10.1007/BF00781711
   Zhou WH, 2012, AUTOPHAGY, V8, P389, DOI 10.4161/auto.18641
   Zhuang Wen-Zhuo, 2011, Chin J Cancer, V30, P712, DOI 10.5732/cjc.011.10234
NR 44
TC 20
Z9 20
U1 0
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD APR
PY 2013
VL 34
IS 2
BP 713
EP 722
DI 10.1007/s13277-012-0599-5
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 109JX
UT WOS:000316364500013
PM 23225331
DA 2022-04-25
ER

PT J
AU Cui, FC
   Chen, Y
   Wu, XY
   Hu, M
   Qin, WS
AF Cui, F. -C.
   Chen, Y.
   Wu, X. -Y.
   Hu, M.
   Qin, W. -S.
TI MicroRNA-493-5p suppresses colorectal cancer progression via the
   PI3K-Akt-FoxO3a signaling pathway
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE MiR-493-5p; Colorectal cancer; PI3K-Akt-FoxO3a signaling pathway;
   Migration; Progression
ID CELLS; PROMOTES; INVASION; METASTASIS; PROLIFERATION; GLYCOLYSIS;
   AUTOPHAGY; MIGRATION; GROWTH; PI3K
AB OBJECTIVE: MicroRNA493-5p (miR-493-5p) appears to have an essential role in the abnormal cell proliferation and migration observed in the development and progression of various cancers. However, the function and mechanism of action of miR-493-5p in colorectal cancer (CRC) is unclear.
   PATIENTS AND METHODS: MiR-493-5p expression was analyzed in CRC patient tissue samples and cell lines by fluorescence quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). SW480 and Caco-2 cells were transfected with miR-493-5p mimics or treated with the phosphoinositide 3-kinase (PI3K) agonist 740Y-P. Cell proliferation was determined by colony formation and cell proliferation assays and cell migration and invasion by transwell migration and wound-healing assays. The Luciferase reporter assay was used to verify the association between the expression of miR-493-5p and PI3K activity. Expression levels of PI3K, protein kinase B(Akt). and forkhead box O 3a (FoxO3a) proteins were measured by Western blot analysis and immunofluorescence assay.
   RESULTS: MiR-493-5p expression was significantly downregulated in CRC tissue samples and cell lines which was associated with progression of CRC. The proliferation, migration, and invasion of CRC cells were inhibited by miR-493-5p overexpression, The finding that miR-493-5p upregulation decreased PI3K. Akt, and FoxO3a protein expression revealed that it directly targets PI3K. Additionally, the miR-493-5p-mediated suppression of CRC cell proliferation, migration and invasion was counteracted by the PI3K agonist, indicating that miR-493-5p suppresses CRC progression by inhibiting the PI3K-Akt-FoxO3a signaling pathway.
   CONCLUSIONS: MiR-493-5p suppresses the proliferation, migration, invasion, and progression of CRC via the PI3K-Akt-FoxO3a signaling pathway.
C1 [Cui, F. -C.; Wu, X. -Y.; Hu, M.; Qin, W. -S.] Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Clin Lab, Peoples Hosp, Zhengzhou, Henan, Peoples R China.
   [Chen, Y.] Zhengzhou Univ, Dept Pathol, Affiliated Tumor Hosp, Zhengzhou, Henan, Peoples R China.
RP Cui, FC (corresponding author), Zhengzhou Univ, Henan Prov Peoples Hosp, Dept Clin Lab, Peoples Hosp, Zhengzhou, Henan, Peoples R China.
EM facaichn@163.com
CR Ain A, 2015, CANC LETT, V359, P47
   ar FM, 2016, CHIN CLIN ONCOL, V5, P76
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Challagundla KB, 2014, EXPERT REV MOL DIAGN, V14, P565, DOI 10.1586/14737159.2014.922879
   Cui ZH, 2019, ONCOTARGETS THER, V12, P11531, DOI 10.2147/OTT.S229104
   Deng FL, 2019, THERANOSTICS, V9, P1001, DOI 10.7150/thno.30056
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Dijkers PF, 2002, J CELL BIOL, V156, P531
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Garrido-Laguna I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038033
   Ji X, 2019, J CELL BIOCH
   Kopetz S, 2009, J CLIN ONCOL, V27, P3677, DOI 10.1200/JCO.2008.20.5278
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Li Z, 2013, MOL CELL BIOCHEM, V381, P233, DOI 10.1007/s11010-013-1707-6
   Liang CC, 2019, INT J CLIN EXP PATHO, V12, P4011
   Liang Z, 2017, ONCOTARGET, V8, P47389, DOI 10.18632/oncotarget.17650
   Liao RF, 2017, MOL NEUROBIOL, V54, P6931, DOI 10.1007/s12035-016-0211-x
   Luo H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.3
   Pan S, 2020, LIFE SCI, V244
   Sbarouni E, 2018, J THORAC DIS, V10, P1256, DOI 10.21037/jtd.2018.03.27
   Stacey DW, 2003, CURR OPIN CELL BIOL, V15, P158, DOI 10.1016/S0955-0674(03)00008-5
   Sun L, 2020, J CANCER, V11, P630, DOI 10.7150/jca.33022
   Syed DN, 2014, BIOCHEM PHARMACOL, V89, P349, DOI 10.1016/j.bcp.2014.03.007
   Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772
   Vannini I, 2018, CURR OPIN GENET DEV, V48, P128, DOI 10.1016/j.gde.2018.01.001
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   Vucicevic L, 2011, AUTOPHAGY, V7, P40, DOI 10.4161/auto.7.1.13883
   Wang GN, 2018, INT J MOL MED, V41, P1740, DOI 10.3892/ijmm.2018.3358
   Wang K, 2016, AUTOPHAGY, V12, P2498, DOI 10.1080/15548627.2016.1231494
   Wang S, 2017, ONCOTARGET, V8, P82303, DOI 10.18632/oncotarget.19398
   Wei QD, 2019, INT J CLIN EXP PATHO, V12, P1565
   Wu FL, 2018, INT J CLIN EXP PATHO, V11, P3943
   Yan S, 2019, MEDIATORS INFLAMM 20, V2019
   Yasukawa K, 2020, CANCER SCI, V111, P869, DOI 10.1111/cas.14292
   Zhang Y, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1053-1
   Zhang ZQ, 2019, J CELL PHYSIOL, V234, P13525, DOI 10.1002/jcp.28030
   Zhao LF, 2016, ONCOL REP, V36, P1007, DOI 10.3892/or.2016.4882
NR 37
TC 4
Z9 5
U1 0
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 8
BP 4212
EP 4223
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA LO7BQ
UT WOS:000533783000027
PM 32373957
DA 2022-04-25
ER

PT J
AU Hsu, YC
   Huang, TY
   Chen, MJ
AF Hsu, Y-C
   Huang, T-Y
   Chen, M-J
TI Therapeutic ROS targeting of GADD45 gamma in the induction of G2/M
   arrest in primary human colorectal cancer cell lines by cucurbitacin E
SO CELL DEATH & DISEASE
LA English
DT Article
DE Cucurbitacin E; Colorectal cancer (CRC); G2/M arrest; Growth arrest and
   DNA damage 45 (GADD45)
ID NF-KAPPA-B; CYCLE ARREST; APOPTOSIS; AUTOPHAGY; ACTIN; PHOSPHORYLATION;
   MITOSIS; STRESS; INHIBITORS; TRITERPENE
AB Cucurbitacin E (CuE) or alpha-elaterin is a natural compound previously shown to be an antifeedant as well as a potent chemopreventive agent against several types of cancer. The present study investigated the anticancer effects of CuE on colorectal cancer (CRC) using primary cell lines isolated from five CRC patients in Taiwan, Specifically, we explored the anti-proliferation and cell cycle G2/M arrest induced by CuE in CRC cells. MPM-2 flow cytometry tests show that CuE-treated cells accumulated in metaphase (CuE 2.5-7.5 mu M). Results further indicate that CuE produced G(2)/M arrest as well as the downregulation of CDC2 and cyclin B1 expression and dissociation. Both effects increased proportionally with the dose of CuE; however, the inhibition of proliferation, arrest of mitosis, production of reactive oxygen species (ROS), and loss of mitochondrial membrane potential (Delta Psi m) were found to be dependent on the quantity of CuE used to treat the cancer cells. In addition, cell cycle arrest in treated cells coincided with the activation of the gene GADD45(alpha, beta, gamma). Incubation with CuE resulted in the binding of GADD45 gamma to CDC2, which suggests that the delay in CuE-induced mitosis is regulated by the overexpression of GADD45 gamma. Our findings suggest that, in addition to the known effects on cancer prevention, CuE may have antitumor activities in established CRC.
C1 [Hsu, Y-C] Chang Jung Christian Univ, Grad Inst Med Sci, Coll Hlth Sci, Tainan 71101, Taiwan.
   [Hsu, Y-C] Chang Jung Christian Univ, Coll Hlth Sci, Innovat Res Ctr Med, Tainan 71101, Taiwan.
   [Huang, T-Y] Tainan Sin Lau Hosp, Dept Neurosurg, Tainan, Taiwan.
   [Chen, M-J] Chi Mei Med Ctr, Dept Surg, Div Traumatol, Tainan, Taiwan.
   [Chen, M-J] Chia Nan Univ Pharm & Sci, Coll Leisure & Recreat Management, Dept Sports Management, Tainan, Taiwan.
RP Hsu, YC (corresponding author), Chang Jung Christian Univ, Grad Inst Med Sci, 1 Changda Rd, Tainan 71101, Taiwan.
EM d8702008@tmu.edu.tw
RI Hsu, Yi-Chiang/AAX-5470-2021; Hsu, Yi-Chiang/AGZ-2083-2022
OI Hsu, Yi-Chiang/0000-0002-6256-9521; 
FU National Science Council (Taiwan)Ministry of Science and Technology,
   Taiwan [NSC100-2313-B-309-001, NSC101-2313-B-309-001]
FX The authors appreciate the funding support provided by the National
   Science Council (Taiwan) (grant NSC100-2313-B-309-001) and
   (NSC101-2313-B-309-001). The authors are also grateful to the technical
   assistance provided by Ms Ai-Jie Han of Innovative Research Center of
   Medicine.
CR Abdelwahab SI, 2011, FITOTERAPIA, V82, P1190, DOI 10.1016/j.fitote.2011.08.002
   Alghasham AA, 2013, INT J HEALTH SCI-IJH, V7, P77, DOI 10.12816/0006025
   Aribi A, 2013, INT J CANCER, V132, P2730, DOI 10.1002/ijc.27950
   Bincoletto C, 2013, CHEM-BIOL INTERACT, V206, P279, DOI 10.1016/j.cbi.2013.09.018
   Caratozzolo MF, 2012, CELL CYCLE, V11, P511, DOI 10.4161/cc.11.3.19008
   Chen MJ, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/415231
   Chen XP, 2012, ANTI-CANCER DRUG, V23, P777, DOI 10.1097/CAD.0b013e3283541384
   Coldwell MJ, 2013, CELL CYCLE, V12, P3615, DOI 10.4161/cc.26588
   Dong YM, 2010, CARCINOGENESIS, V31, P2097, DOI 10.1093/carcin/bgq167
   Duncan KLK, 1996, BIOCHEM PHARMACOL, V52, P1553, DOI 10.1016/S0006-2952(96)00557-6
   Escargueil AE, 2007, BIOCHEM J, V403, P235, DOI 10.1042/BJ20061460
   Gabrielsen M, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-58
   Geifman-Holtzman O, 2013, ADV EXP MED BIOL, V793, P121, DOI 10.1007/978-1-4614-8289-5_7
   Guo JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088140
   Habib L, 2013, INT J PHARMACEUT, V448, P313, DOI 10.1016/j.ijpharm.2013.03.027
   He J, 2013, INT IMMUNOPHARMACOL, V16, P27, DOI 10.1016/j.intimp.2013.03.013
   Hensley P, 2013, BIOL CHEM, V394, P831, DOI 10.1515/hsz-2013-0128
   Hsu YC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.22
   Hsu YC, 2007, J AGR FOOD CHEM, V55, P8213, DOI 10.1021/jf070684v
   Huang WW, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/952762
   Hung CM, 2013, INT J MOL SCI, V14, P17147, DOI 10.3390/ijms140817147
   Lang KL, 2013, J AGR FOOD CHEM, V61, P5534, DOI 10.1021/jf4002457
   Li YC, 2010, ANTI-CANCER DRUG, V21, P389, DOI 10.1097/CAD.0b013e328336b383
   Million K, 2006, INT J ONCOL, V29, P147
   MUSZA LL, 1994, J NAT PRODUCTS, V57, P1498, DOI 10.1021/np50113a004
   Notas G, 2012, J IMMUNOL, V189, P4748, DOI 10.4049/jimmunol.1102891
   Patlolla JMR, 2012, CURR PHARM BIOTECHNO, V13, P147
   Qiao J, 2013, INFLAMM RES, V62, P461, DOI 10.1007/s00011-013-0598-z
   Rios JL, 2012, CURR PHARM DESIGN, V18, P1663, DOI 10.2174/138161212799958549
   Salvador JM, 2013, ADV EXP MED BIOL, V793, P1, DOI 10.1007/978-1-4614-8289-5_1
   Schafer A, 2013, ADV EXP MED BIOL, V793, P35, DOI 10.1007/978-1-4614-8289-5_3
   Shan Xiao-Lei, 2010, Chin J Cancer, V29, P20
   Shih RSM, 2010, EXP BIOL MED, V235, P932, DOI 10.1258/ebm.2010.010076
   Sorensen PM, 2012, ACS CHEM BIOL, V7, P1502, DOI 10.1021/cb300254s
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140
   Yang Z, 2009, CURR CANCER DRUG TAR, V9, P915, DOI 10.2174/156800909790192383
   Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
   Zhu JS, 2012, PHARMACOLOGY, V89, P348, DOI 10.1159/000338757
   Zhu N, 2009, MOL BIOL REP, V36, P2075, DOI 10.1007/s11033-008-9419-9
NR 41
TC 28
Z9 29
U1 0
U2 23
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD APR
PY 2014
VL 5
AR e1198
DI 10.1038/cddis.2014.151
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AG5HP
UT WOS:000335450400044
PM 24763055
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Huang, WS
   Lin, CT
   Chen, CN
   Chang, SF
   Chang, HI
   Lee, KC
AF Huang, Wen-Shih
   Lin, Chien-Tsong
   Chen, Cheng-Nan
   Chang, Shun-Fu
   Chang, Hsin-I
   Lee, Ko-Chao
TI Metformin increases the cytotoxicity of oxaliplatin in human DLD-1
   colorectal cancer cells through down-regulating HMGB1 expression
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE colorectal cancer; HMGB1; metformin; NF-b; oxaliplatin
ID NF-KAPPA-B; BOX 1 HMGB1; DRUG-RESISTANCE; PATHWAY; APOPTOSIS; AUTOPHAGY;
   CHEMOTHERAPY; SENSITIVITY; METASTASIS; INHIBITION
AB Colorectal cancer (CRC) is the fourth most common cause of cancer death worldwide. Chemotherapy has been the major strategy for treating patients with advanced CRC. Oxaliplatin (OXA) is used as both an adjuvant and neoadjuvant anticancer agent available to treat advanced CRC. High-mobility group box 1 protein (HMGB1) is a critical regulator of cell death and survival. HMGB1 overexpression has been shown to be resistant to cytotoxic agents. In addition, Metformin, a widely used drug for diabetes, has emerged as a potential anticancer agent. In this study, we examined whether HMGB1 plays a role in the OXA- and/or metformin-induced cytotoxic effect on CRC cells. The results showed that treatment with OXA increased HMGB1 expression in the ERK1/2- and Akt-dependent manners in DLD-1 cells. HMGB1 gene knockdown enhanced the cytotoxicity and cell growth inhibition of OXA. Moreover, OXA-increased HMGB1 expression was by inducing NF-B-DNA-binding activity to in DLD-1 cells. Compared to a single agent, OXA combined with metformin administration resulted in cytotoxicity and cell growth inhibition synergistically, accompanied with reduced HMGB1 level. These findings may have implications for the rational design of future drug regimens incorporating OXA and metformin for the treatment of CRC.
   The results of this study suggest that decreasing HMGB1 expression may enhance the therapeutic effect of OXA in patients with CRC and the concept of metformin combined with OXA seems to present a therapeutic strategy for the treatment of CRC.
C1 [Huang, Wen-Shih] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan.
   [Huang, Wen-Shih] Chang Gung Mem Hosp, Div Colon & Rectal Surg, Dept Surg, Chiayi, Taiwan.
   [Lin, Chien-Tsong] Natl Formosa Univ, Ctr Gen Educ, Huwei Township, Yunlin, Taiwan.
   [Lin, Chien-Tsong] Natl Chiayi Univ, Dept Wood Based Mat & Design, Chiayi, Taiwan.
   [Chen, Cheng-Nan; Chang, Hsin-I] Natl Chiayi Univ, Dept Biochem Sci & Technol, Chiayi, Taiwan.
   [Chang, Shun-Fu] Chang Gung Mem Hosp, Dept Med Res & Dev, Chiayi Branch, Chiayi, Taiwan.
   [Lee, Ko-Chao] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Colorectal Surg, Kaohsiung, Taiwan.
RP Lee, KC (corresponding author), Chang Gung Mem Hosp, Dept Colorectal Surg, 123 Taipei Rd, Kaohsiung 833, Taiwan.
EM kmch4329@gmail.com
OI Chang, Shun-Fu/0000-0002-2276-7785
FU Ministry of Science and Technology, TaiwanMinistry of Science and
   Technology, Taiwan [MOST 105-2314-B-182A-132]; Chang Gung Memorial
   Hospital-Chiayi branch [CMRPG6E0332, CMRPG6G0301]
FX Ministry of Science and Technology, Taiwan, Grant number: MOST
   105-2314-B-182A-132; Chang Gung Memorial Hospital-Chiayi branch, Grant
   numbers: CMRPG6E0332, CMRPG6G0301
CR Al Bandar MH, 2017, ONCOL REP, V37, P2553, DOI 10.3892/or.2017.5531
   Banerjee S, 2009, CANCER RES, V69, P5575, DOI 10.1158/0008-5472.CAN-08-4235
   Boteanu RM, 2017, J PROTEOMICS, V153, P21, DOI 10.1016/j.jprot.2016.11.006
   Chen JL, 2017, CANCER CHEMOTH PHARM, V79, P369, DOI 10.1007/s00280-016-3225-1
   Cheng H, 2017, ONCOL LETT, V14, P159, DOI 10.3892/ol.2017.6116
   Choi YK, 2013, MOL CELLS, V36, P279, DOI 10.1007/s10059-013-0169-8
   Daugan M, 2016, PHARMACOL RES, V113, P675, DOI 10.1016/j.phrs.2016.10.006
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Hanna RK, 2012, GYNECOL ONCOL, V125, P458, DOI 10.1016/j.ygyno.2012.01.009
   He WL, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-161
   Hongo K, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/1477-7819-13-7
   Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876
   Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001
   Huang WS, 2015, INT J MOL SCI, V16, P29370, DOI 10.3390/ijms161226174
   Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495
   Kim HG, 2011, BRIT J PHARMACOL, V162, P1096, DOI 10.1111/j.1476-5381.2010.01101.x
   Lee Jaeryun, 2017, Dev Reprod, V21, P139, DOI 10.12717/DR.2017.21.2.139
   Li L, 2014, CLIN CANCER RES, V20, P2714, DOI 10.1158/1078-0432.CCR-13-2613
   Liu WJ, 2015, CANCER BIOL THER, V16, P511, DOI 10.1080/15384047.2015.1017691
   Luo QQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-517
   Mao L, 2017, ONCOL LETT, V14, P647, DOI 10.3892/ol.2017.6209
   Martinez-Balibrea E, 2015, MOL CANCER THER, V14, P1767, DOI 10.1158/1535-7163.MCT-14-0636
   McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436
   Meng FQ, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/5063239
   Mohammad RM, 2015, SEMIN CANCER BIOL, V35, pS78, DOI 10.1016/j.semcancer.2015.03.001
   Pancione M, 2017, CURR MED CHEM, V24, P1383, DOI 10.2174/0929867324666170227114356
   Peng M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28611
   Pires IM, 2010, BRIT J PHARMACOL, V159, P1326, DOI 10.1111/j.1476-5381.2009.00607.x
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   de Porras VR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24675
   Song J, 2016, ONCOTARGET, V7, P80803, DOI 10.18632/oncotarget.13096
   Stros M, 2010, BBA-GENE REGUL MECH, V1799, P101, DOI 10.1016/j.bbagrm.2009.09.008
   Sun Y, 2016, INT J ONCOL, V48, P225, DOI 10.3892/ijo.2015.3256
   Sun ZN, 2017, ONCOL LETT, V13, P2377, DOI 10.3892/ol.2017.5722
   Takada Y, 2005, J BIOL CHEM, V280, P17203, DOI 10.1074/jbc.M500077200
   Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261
   Tang DF, 2017, MED SCI MONIT BASIC, V23, P141, DOI 10.12659/MSMBR.903910
   Ueda M, 2014, ANTICANCER RES, V34, P5357
   Volp K, 2006, GUT, V55, P234, DOI 10.1136/gut.2004.062729
   Wang XB, 2015, INT J MOL SCI, V16, P22527, DOI 10.3390/ijms160922527
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Wegiel B, 2008, INT J CANCER, V122, P1521, DOI 10.1002/ijc.23261
   Wiegering A, 2017, NEOPLASIA, V19, P301, DOI 10.1016/j.neo.2017.01.007
   Wu TY, 2016, ONCOTARGET, V7, P50417, DOI 10.18632/oncotarget.10413
   Xia YF, 2014, CANCER IMMUNOL RES, V2, P823, DOI 10.1158/2326-6066.CIR-14-0112
   Yardley DA, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/137414
   Zahreddine H, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00028
   Zhang BH, 2016, ONCOL REP, V35, P1807, DOI 10.3892/or.2015.4479
   Zhang RG, 2015, TUMOR BIOL, V36, P8585, DOI 10.1007/s13277-015-3617-6
   Zhang XL, 2016, ONCOTARGETS THER, V9, P4901, DOI 10.2147/OTT.S105512
NR 50
TC 8
Z9 9
U1 1
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD AUG
PY 2018
VL 119
IS 8
BP 6943
EP 6952
DI 10.1002/jcb.26898
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GK9EG
UT WOS:000436542900061
PM 29737584
DA 2022-04-25
ER

PT J
AU Pourhanifeh, MH
   Mehrzadi, S
   Hosseinzadeh, A
AF Pourhanifeh, Mohammad Hossein
   Mehrzadi, Saeed
   Hosseinzadeh, Azam
TI Melatonin and regulation of miRNAs: novel targeted therapy for cancerous
   and noncancerous disease
SO EPIGENOMICS
LA English
DT Review
DE angiogenesis; apoptosis; cancer; chemotherapy; gene expression;
   inflammation; melatonin; metastasis; microRNA; oxidative stress
ID COLORECTAL-CANCER; OXIDATIVE STRESS; DRUG-RESISTANCE; GENE-EXPRESSION;
   NONCODING RNA; BREAST-CANCER; UP-REGULATION; ORAL-CANCER; CELL-LINES;
   AUTOPHAGY
AB miRNAs, small noncoding RNAs with crucial diagnostic and prognostic capabilities, play essential therapeutic roles in different human diseases. These biomarkers are involved in several biological mechanisms and are responsible for the regulation of multiple genes expressions in cells. miRNA-based therapy has shown a very bright future in the case of clinical interventions. Melatonin, the main product of the pineal gland, is a multifunctional neurohormone with numerous therapeutic potentials in human diseases. Melatonin is able to regulate miRNAs in different pathologies such as malignant and nonmalignant diseases, which can be considered as a novel kind of targeted therapy. Herein, this review discusses possible therapeutic utility of melatonin for the regulation of miRNAs in various pathological conditions.
C1 [Pourhanifeh, Mohammad Hossein; Mehrzadi, Saeed; Hosseinzadeh, Azam] Iran Univ Med Sci, Razi Drug Res Ctr, Tehran, Iran.
RP Hosseinzadeh, A (corresponding author), Iran Univ Med Sci, Razi Drug Res Ctr, Tehran, Iran.
EM hosseinzadeazam@gmail.com
RI Hosseinzadeh, Azam/AAN-6886-2021; Mehrzadi, Saeed/AAY-8389-2020
OI Hosseinzadeh, Azam/0000-0001-6379-5769; Mehrzadi,
   Saeed/0000-0001-6619-2330; Pourhanifeh, Mohammad
   Hossein/0000-0002-6752-2765
CR Ahmadloo N, 2013, J EGYPT NATL CANCER, V25, P21, DOI 10.1016/j.jnci.2012.11.001
   Alghamdi BS, 2018, J NEUROSCI RES, V96, P1136, DOI 10.1002/jnr.24220
   Ali T, 2019, ARCH BIOCHEM BIOPHYS, V661, P56, DOI 10.1016/j.abb.2018.11.007
   Alves AM, 2018, J ORAL PATHOL MED, V47, P460, DOI 10.1111/jop.12643
   Anderson G, 2019, BIOCHEM PHARMACOL, V168, P259, DOI 10.1016/j.bcp.2019.07.014
   Anderson G, 2019, INT J TRYPTOPHAN RES, V12, DOI 10.1177/1178646919855942
   Ang TL, 2014, SINGAP MED J, V55, P621, DOI 10.11622/smedj.2014174
   Asghari MH, 2018, LIFE SCI, V196, P143, DOI 10.1016/j.lfs.2018.01.024
   Bae H, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12670
   Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Bates DJ, 2009, BBA-GEN SUBJECTS, V1790, P970, DOI 10.1016/j.bbagen.2009.03.028
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Candia J, 2018, REV MED CHILE, V146, P487, DOI 10.4067/s0034-98872018000400487
   Capote-Moreno A, 2019, CANCERS, V11, DOI 10.3390/cancers11111712
   Carloni S, 2016, J PINEAL RES, V61, P370, DOI 10.1111/jpi.12354
   Carrillo-Vico A, 2005, ENDOCRINE, V27, P189, DOI 10.1385/ENDO:27:2:189
   Castaneda SA, 2017, SURG ONCOL CLIN N AM, V26, P371, DOI 10.1016/j.soc.2017.01.013
   Che H, 2020, FASEB J, V34, P14042, DOI 10.1096/fj.202001328R
   Che H, 2020, FASEB J, V34, P5282, DOI 10.1096/fj.201902692R
   Chen L, 2018, IN VITRO CELL DEV-AN, V54, P1, DOI 10.1007/s11626-017-0200-z
   Chen YY, 2020, NEUROSCIENCE, V446, P69, DOI 10.1016/j.neuroscience.2020.06.026
   Chok KC, 2019, HORM MOL BIOL CLIN I, V39, DOI 10.1515/hmbci-2019-0001
   Cotterill SJ, 2004, PEDIATR BLOOD CANCER, V42, P59, DOI 10.1002/pbc.10437
   Daryani A, 2018, BIOMED PHARMACOTHER, V97, P948, DOI 10.1016/j.biopha.2017.11.007
   Chuffa LGD, 2017, CARCINOGENESIS, V38, P945, DOI 10.1093/carcin/bgx054
   Dehdashtian E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3336
   Dehdashtian E, 2018, LIFE SCI, V193, P20, DOI 10.1016/j.lfs.2017.12.001
   DeMuro RL, 2000, J CLIN PHARMACOL, V40, P781, DOI 10.1177/00912700022009422
   Deng XN, 2017, INT J CLIN ONCOL, V22, P641, DOI 10.1007/s10147-017-1155-5
   Don SSL, 2019, CELL CYCLE, V18, P2447, DOI 10.1080/15384101.2019.1648957
   Ekmekcioglu C, 2006, BIOMED PHARMACOTHER, V60, P97, DOI 10.1016/j.biopha.2006.01.002
   El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Fang Z, 2018, CELL PHYSIOL BIOCHEM, V47, P1751, DOI 10.1159/000491058
   Farhood B, 2019, CLIN TRANSL ONCOL, V21, P268, DOI 10.1007/s12094-018-1934-0
   Fendler A, 2011, INT J ONCOL, V39, P1183, DOI 10.3892/ijo.2011.1128
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Ferreira LC, 2019, MELATONIN RES, V2, P86, DOI DOI 10.32794/MR11250023
   Ferreira LC, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228062
   Gonzalez A, 2017, ONCOL REP, V37, P2433, DOI 10.3892/or.2017.5446
   Gu JY, 2017, BIOMED PHARMACOTHER, V93, P969, DOI 10.1016/j.biopha.2017.07.010
   Guraya SY, 2019, CLIN COLORECTAL CANC, V18, pE223, DOI 10.1016/j.clcc.2019.01.003
   Hai B, 2019, CLIN INTERV AGING, V14, P621, DOI 10.2147/CIA.S193765
   Han YS, 2020, BIOCHEM BIOPH RES CO, V525, P354, DOI 10.1016/j.bbrc.2020.02.090
   Hardeland R., 2018, BIOCH MOL BIOL J, V4, P7, DOI DOI 10.21767/2471-8084.100056
   Hardeland R, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12377
   Hardeland R, 2014, INT J MOL SCI, V15, P18221, DOI 10.3390/ijms151018221
   Hemati K, 2020, COMPLEMENT THER CLIN, V38, DOI 10.1016/j.ctcp.2019.101072
   Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X
   Hosseinzadeh A, 2019, CURR DRUG TARGETS, V20, P1112, DOI 10.2174/1389450120666190319162147
   Hosseinzadeh A, 2018, EXPERT OPIN THER TAR, V22, P1049, DOI 10.1080/14728222.2018.1541318
   Hosseinzadeh A, 2018, LIFE SCI, V201, P17, DOI 10.1016/j.lfs.2018.03.032
   Hou Y, 2019, DRUG DES DEV THER, V13, P1135, DOI 10.2147/DDDT.S194182
   Hsieh MJ, 2020, MOL THER-NUCL ACIDS, V19, P877, DOI 10.1016/j.omtn.2019.12.022
   Huang CC, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12560
   Hunsaker M, 2019, DENT J-BASEL, V7, DOI 10.3390/dj7020048
   Iravani S, 2020, J GASTROINTEST CANC, V51, P748, DOI 10.1007/s12029-019-00336-4
   Iuvone PM, 2005, PROG RETIN EYE RES, V24, P433, DOI 10.1016/j.preteyeres.2005.01.003
   Jayaraj R, 2020, CANCERS, V12, DOI 10.3390/cancers12051199
   Jiang Y, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5179048
   Jin XW, 2003, MOL CELL BIOL, V23, P1054, DOI 10.1128/MCB.23.3.1054-1060.2003
   Jockers R, 2008, BRIT J PHARMACOL, V154, P1182, DOI 10.1038/bjp.2008.184
   Jung JH, 2019, CANCERS, V11, DOI 10.3390/cancers11111684
   Juybari KB, 2019, CURR PHARM DESIGN, V25, P3057, DOI 10.2174/1381612825666190829151314
   Karasek M, 2006, J PHYSIOL PHARMACOL, V57, P19
   Kartini D, 2020, J EGYPT NATL CANCER, V32, DOI 10.1186/s43046-020-0021-0
   Kim SJ, 2015, BIOCHEM BIOPH RES CO, V458, P462, DOI 10.1016/j.bbrc.2015.01.117
   Kim YD, 2017, J PINEAL RES, V62, DOI 10.1111/jpi.12386
   Klingenberg M, 2017, J HEPATOL, V67, P603, DOI 10.1016/j.jhep.2017.04.009
   Korkmaz A, 2012, GENE, V503, P1, DOI 10.1016/j.gene.2012.04.040
   Lacerda Jessica Zani, 2019, Microrna, V8, P237, DOI 10.2174/2211536608666190219095426
   Lan YT, 2014, AM J SURG, V207, P922, DOI 10.1016/j.amjsurg.2013.08.035
   Laothong U, 2015, ONCOL REP, V33, P1443, DOI 10.3892/or.2015.3738
   Lee HY, 2012, RNA, V18, P2012, DOI 10.1261/rna.035501.112
   Lee SE, 2011, J PINEAL RES, V51, P345, DOI 10.1111/j.1600-079X.2011.00896.x
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Li H Z, 2017, Zhonghua Wai Ke Za Zhi, V55, P59, DOI 10.3760/cma.j.issn.0529-5815.2017.01.015
   Li NN, 2020, J CELL MOL MED, V24, P5615, DOI 10.1111/jcmm.15221
   Li Y, 2019, J CELL MOL MED, V23, P6140, DOI 10.1111/jcmm.14490
   Li Z, 2019, J PINEAL RES, V66, DOI 10.1111/jpi.12558
   Liu F, 2018, KIDNEY BLOOD PRESS R, V43, P1425, DOI 10.1159/000493380
   Liu H, 2018, AM J TRANSL RES, V10, P2579
   Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742
   Liu VWS, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061130
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Lu KH, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12507
   Ma WY, 2021, ACTA PHARMACOL SIN, V42, P921, DOI 10.1038/s41401-020-0495-2
   Maestroni GJM, 2005, J NEUROIMMUNOL, V158, P106, DOI 10.1016/j.jneuroim.2004.08.015
   Maitra S, 2019, REV NEUROSCIENCE, V30, P527, DOI 10.1515/revneuro-2018-0041
   Markus RP, 2018, BRIT J PHARMACOL, V175, P3239, DOI 10.1111/bph.14083
   Marques JHM, 2018, LIFE SCI, V208, P131, DOI 10.1016/j.lfs.2018.07.012
   Mehrzadi S, 2020, EXPERT OPIN THER TAR, V24, P359, DOI 10.1080/14728222.2020.1737015
   Menendez-Menendez J, 2019, CANCERS, V11, DOI 10.3390/cancers11071011
   Meng XT, 2018, MOL MED REP, V17, P7202, DOI 10.3892/mmr.2018.8729
   Bonilla JAM, 2017, RADIOLOGIA-MADRID, V59, P368, DOI 10.1016/j.rx.2017.06.003
   Miller SC, 2006, INT J EXP PATHOL, V87, P81, DOI 10.1111/j.0959-9673.2006.00474.x
   Moretti E, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030599
   Mori F, 2016, ONCOTARGET, V7, P20532, DOI 10.18632/oncotarget.7978
   Mortezaee K, 2018, J CELL PHYSIOL, V233, P6486, DOI 10.1002/jcp.26586
   Murodumi H, 2020, MOL MED REP, V22, P3549, DOI 10.3892/mmr.2020.11401
   Muxel SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052010
   O'Brien J, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00402
   Pagan C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02152-x
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Peng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep20304
   Petrescu GED, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1180-5
   Pourhanifeh MH, 2020, DIABETOL METAB SYNDR, V12, DOI 10.1186/s13098-020-00537-z
   Pourhanifeh MH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0853-7
   Pourhanifeh MH, 2019, J CELL PHYSIOL, V234, P12142, DOI 10.1002/jcp.28129
   Rao Jiang-Yan, 2020, Zhongguo Zhong Yao Za Zhi, V45, P932, DOI 10.19540/j.cnki.cjcmm.20191112.402
   Rapado-Gonzalez O, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121653
   Rawla P, 2018, WSPOLCZESNA ONKOL, V22, P141, DOI 10.5114/wo.2018.78941
   Reiter RJ, 2005, J PINEAL RES, V39, P215, DOI 10.1111/j.1600-079X.2005.00261.x
   Reiter RJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040843
   Reiter RJ, 2010, ANN MED, V42, P276, DOI 10.3109/07853890903485748
   Fernandes JCR, 2019, FRONT CELL INFECT MI, V9, DOI 10.3389/fcimb.2019.00060
   Ribeiro Isabella Lima Arrais, 2015, Rev. bras. epidemiol., V18, P618, DOI 10.1590/1980-5497201500030008
   Safi AF, 2019, CLIN ORAL INVEST, V23, P3759, DOI 10.1007/s00784-019-02804-4
   Sakatani A, 2019, CARCINOGENESIS, V40, P422, DOI 10.1093/carcin/bgy186
   Scheer FAJL, 2004, HYPERTENSION, V43, P192, DOI 10.1161/01.HYP.0000113293.15186.3b
   Scott SE, 2005, ORAL ONCOL, V41, P396, DOI 10.1016/j.oraloncology.2004.10.010
   Shen YQ, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12461
   Shin VY, 2014, WORLD J GASTROENTERO, V20, P10432, DOI 10.3748/wjg.v20.i30.10432
   Sohn EJ, 2015, J CANCER, V6, P19, DOI 10.7150/jca.9591
   Srinivasan V, 2005, NEUROTOX RES, V7, P293, DOI 10.1007/BF03033887
   Stacchiotti A, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091053
   Tang Q, 2019, ARTIF CELL NANOMED B, V47, P2800, DOI 10.1080/21691401.2019.1638791
   Tang YL, 2019, CANCER LETT, V443, P167, DOI 10.1016/j.canlet.2018.11.037
   Treiber T, 2019, NAT REV MOL CELL BIO, V20, P5, DOI 10.1038/s41580-018-0059-1
   Tu YY, 2020, J CELL PHYSIOL, V235, P8724, DOI 10.1002/jcp.29716
   Vimalraj S, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.118011
   Wang TH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092687
   Wang X, 2009, CNS NEUROSCI THER, V15, P345, DOI 10.1111/j.1755-5949.2009.00105.x
   Wang X, 2013, MOL NEUROBIOL, V47, P373, DOI 10.1007/s12035-012-8355-9
   Wang YJ, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12666
   Wei X, 2019, J CELL BIOCHEM, V120, P9781, DOI 10.1002/jcb.28258
   Wen YC, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12668
   Wu X, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/4087298
   Wu ZZ, 2018, J PINEAL RES, V65, DOI 10.1111/jpi.12483
   Xia D-Y, 2020, PREPRINT
   Xu F, 2020, J PINEAL RES, V68, DOI 10.1111/jpi.12631
   Xu K, 2015, CELL PHYSIOL BIOCHEM, V35, P499, DOI 10.1159/000369715
   Yang B, 2020, DRUG DES DEV THER, V14, P3177, DOI 10.2147/DDDT.S262121
   Yang S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0155-8
   Yoon YM, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155323
   Zhang SJ, 2016, CLIN CHIM ACTA, V457, P27, DOI 10.1016/j.cca.2016.03.016
   Zhang XF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010046
   Zhang YJ, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9705929
   Zhao Y, 2018, BIOFACTORS, V44, P609, DOI 10.1002/biof.1411
   Zhdanova IV, 1997, SLEEP, V20, P899
   Zheng YS, 2019, ONCOTARGETS THER, V12, P10187, DOI 10.2147/OTT.S226140
   Zhou B, 2019, J CELL MOL MED, V23, P5246, DOI 10.1111/jcmm.14399
   Zhou N, 2019, BMC NEUROSCI, V20, DOI 10.1186/s12868-019-0545-1
   Zhu CY, 2018, DNA CELL BIOL, V37, P244, DOI 10.1089/dna.2017.4040
   Zhu LQ, 2004, J PINEAL RES, V37, P71, DOI 10.1111/j.1600-079X.2004.00136.x
   Zou ZW, 2018, REDOX BIOL, V16, P226, DOI 10.1016/j.redox.2018.02.025
NR 156
TC 7
Z9 7
U1 4
U2 8
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD JAN
PY 2021
VL 13
IS 1
BP 65
EP 81
DI 10.2217/epi-2020-0241
EA DEC 2020
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA PV0YF
UT WOS:000600903800001
PM 33350862
DA 2022-04-25
ER

PT J
AU Ryoo, IG
   Choi, BH
   Ku, SK
   Kwak, MK
AF Ryoo, In-geun
   Choi, Bo-hyun
   Ku, Sae-Kwang
   Kwak, Mi-Kyoung
TI High CD44 expression mediates p62-associated NFE2L2/NRF2 activation in
   breast cancer stem cell-like cells: Implications for cancer stem cell
   resistance
SO REDOX BIOLOGY
LA English
DT Article
DE CD44; Cancer stem cell (CSC); NFE2L2/NRF2; Reactive oxygen species
   (ROS); Stress resistance; p62
ID TRANSCRIPTION FACTOR NRF2; COLORECTAL-CANCER; OXIDATIVE STRESS;
   IDENTIFICATION; AUTOPHAGY; INHIBITION; SYSTEM; REDOX; KEAP1;
   CHEMORESISTANCE
AB Cluster of differentiation 44 (CD44) is the most common cancer stem cell (CSC) marker and high CD44 expression has been associated with anticancer drug resistance, tumor recurrence, and metastasis. In this study, we aimed to investigate the molecular mechanism by which CD44 and nuclear factor erythroid 2-like 2 (NFE2L2; NRF2), a key regulator of antioxidant genes, are linked to CSC resistance using CD44(high) breast CSC-like cells. NRF2 expression was higher in CD44(high) cell populations isolated from doxorubicin-resistant MCF7 (ADR), as well as MCF7, MDA-MB231, and A549 cells, than in corresponding CD44(low) cells. High NRF2 expression in the CD44(high)CD24(low) CSC population (ADR44P) established from ADR cells depended on standard isoform of CD44. Silencing of CD44 or overexpression of CD44 resulted in the reduction or elevation of NRF2, respectively, and treatment with hyaluronic acid, a CD44 ligand, augmented NRF2 activation. As functional implications, NRF2 silencing rendered ADR44P cells to retain higher levels of reactive oxygen species and to be sensitive to anticancer drug toxicity. Moreover, NRF2-silenced ADR44P cells displayed tumor growth retardation and reduced colony/sphere formation and invasion capacity. In line with these, CD44 significantly colocalized with NRF2 in breast tumor clinical samples. The molecular mechanism of CD44-mediated NRF2 activation was found to involve high p62 expression. CD44 elevation led to an increase in p62, and inhibition of p62 resulted in NRF2 suppression in ADR44P. Collectively, our results showed that high CD44 led to p62-associated NRF2 activation in CD44(high) breast CSC-like cells. NRF2 activation contributed to the aggressive phenotype, tumor growth, and anticancer drug resistance of CD44(high) CSCs. Therefore, the CD44-NRF2 axis might be a promising therapeutic target for the control of stress resistance and survival of CD44(high) CSC population within breast tumors.
C1 [Ryoo, In-geun; Kwak, Mi-Kyoung] Catholic Univ Korea, Integrated Res Inst Pharmaceut Sci, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
   [Choi, Bo-hyun; Kwak, Mi-Kyoung] Catholic Univ Korea, Dept Pharm, Grad Sch, Bucheon, Gyeonggi Do, South Korea.
   [Choi, Bo-hyun; Kwak, Mi-Kyoung] Catholic Univ Korea, PLUS Team Creat Leader Program Pharmac Based Futu, Grad Sch, Bucheon, Gyeonggi Do, South Korea.
   [Ku, Sae-Kwang] Daegu Haany Univ, Coll Korean Med, Gyongsan 712715, Gyeonsangbuk Do, South Korea.
   [Kwak, Mi-Kyoung] Catholic Univ Korea, Coll Pharm, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
RP Kwak, MK (corresponding author), Catholic Univ Korea, Coll Pharm, 43 Jibong Ro, Bucheon 14662, Gyeonggi Do, South Korea.
EM mkwak@catholic.ac.kr
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [NRF-2015R1A2A1A10054384]; BK21Plus grant of NRF - Korean government
   [22A20130012250]
FX This study was financially supported by a grant from the National
   Research Foundation of Korea (NRF) funded by the Korea government (MSIP)
   (NRF-2015R1A2A1A10054384). This study was also supported by the BK21Plus
   grant of NRF funded by Korean government (22A20130012250).
CR Achuthan S, 2011, J BIOL CHEM, V286, P37813, DOI 10.1074/jbc.M110.200675
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Borowicz S, 2014, JOVE-J VIS EXP, DOI 10.3791/51998
   Calkins MJ, 2009, ANTIOXID REDOX SIGN, V11, P497, DOI [10.1089/ars.2008.2242, 10.1089/ARS.2008.2242]
   Chang CW, 2014, CANCER RES, V74, P6291, DOI 10.1158/0008-5472.CAN-14-0626
   Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76
   Choi BH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107158
   Dayem Ahmed Abdal, 2010, Cancers (Basel), V2, P859, DOI 10.3390/cancers2020859
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Emmink BL, 2013, J PROTEOMICS, V91, P84, DOI 10.1016/j.jprot.2013.06.027
   Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283
   Gong C, 2013, ONCOGENE, V32, P2261, DOI 10.1038/onc.2012.252
   Guan JL, 2013, AUTOPHAGY, V9, P830, DOI 10.4161/auto.24132
   Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038
   Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388
   Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989
   Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jung KA, 2013, TOXICOL LETT, V218, P39, DOI 10.1016/j.toxlet.2012.12.026
   Justus CR, 2014, JOVE-J VIS EXP, DOI 10.3791/51046
   Kakehashi A, 2016, CANCER SCI, V107, P609, DOI 10.1111/cas.12908
   Karousou E, 2017, MATRIX BIOL, V59, P3, DOI 10.1016/j.matbio.2016.10.001
   Kim HJ, 2005, J IMMUNOL, V175, P2948, DOI 10.4049/jimmunol.175.5.2948
   Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007
   Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013
   Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10
   Li K, 2017, CHIN J CANCER, V36, P1, DOI 10.1186/s40880-017-0231-6
   Lin PL, 2016, FREE RADICAL BIO MED, V95, P121, DOI 10.1016/j.freeradbiomed.2016.03.014
   Luo Rong-Zhen, 2013, Onco Targets Ther, V6, P883, DOI 10.2147/OTT.S46222
   Manandhar S, 2012, FREE RADICAL BIO MED, V52, P1773, DOI 10.1016/j.freeradbiomed.2012.02.031
   Manandhar S, 2010, ARCH PHARM RES, V33, P717, DOI 10.1007/s12272-010-0511-z
   Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003
   Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327
   Ryoo I., 2015, ONCOTARGET
   Ryoo IG, 2016, BIOMOL THER, V24, P482, DOI 10.4062/biomolther.2016.145
   Singh A, 2010, MOL CANCER THER, V9, P2365, DOI 10.1158/1535-7163.MCT-10-0108
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Song N, 2015, PLOS ONE, V10, P1
   Taguchi K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00085
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Wu SB, 2013, BIOCHEM BIOPH RES CO, V434, P898, DOI 10.1016/j.bbrc.2013.04.053
   Wu TD, 2015, MOL CARCINOGEN, V54, P1494, DOI 10.1002/mc.22202
   Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048
   Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011
   Zhu JH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-380
   Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023
NR 54
TC 60
Z9 63
U1 3
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2213-2317
J9 REDOX BIOL
JI Redox Biol.
PD JUL
PY 2018
VL 17
BP 246
EP 258
DI 10.1016/j.redox.2018.04.015
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GW3JB
UT WOS:000446792900022
PM 29729523
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Patankar, JV
   Becker, C
AF Patankar, Jay V.
   Becker, Christoph
TI Cell death in the gut epithelium and implications for chronic
   inflammation
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID DOMAIN-LIKE PROTEIN; APOPTOTIC CELLS; BOWEL-DISEASE; ULCERATIVE-COLITIS;
   SMALL-INTESTINE; GASDERMIN-D; STEM-CELLS; IN-VITRO;
   ENDOPLASMIC-RETICULUM; ACTIVATED MACROPHAGES
AB The intestinal epithelium has one of the highest rates of cellular turnover in a process that is tightly regulated. As the transit-amplifying progenitors of the intestinal epithelium generate similar to 300 cells per crypt every day, regulated cell death and sloughing at the apical surface keeps the overall cell number in check. An aberrant increase in the rate of intestinal epithelial cell (IEC) death underlies instances of extensive epithelial erosion, which is characteristic of several intestinal diseases such as inflammatory bowel disease and infectious colitis. Emerging evidence points to a crucial role of necroptosis, autophagy and pyroptosis as important modes of programmed cell death in the intestine in addition to apoptosis. The mode of cell death affects tissue restitution responses and ultimately the long-term risks of intestinal fibrosis and colorectal cancer. A vicious cycle of intestinal barrier breach, misregulated cell death and subsequent inflammation is at the heart of chronic inflammatory and infectious gastrointestinal diseases. This Review discusses the underlying molecular and cellular underpinnings that control programmed cell death in IECs, which emerge during intestinal diseases. Translational aspects of cell death modulation for the development of novel therapeutic alternatives for inflammatory bowel diseases and colorectal cancer are also discussed.
C1 [Patankar, Jay V.; Becker, Christoph] Friedrich Alexander Univ, Dept Med 1, Erlangen, Germany.
RP Becker, C (corresponding author), Friedrich Alexander Univ, Dept Med 1, Erlangen, Germany.
EM christoph.becker@uk-erlangen.de
RI Becker, Christoph/L-2996-2016; Becker, Christoph/A-6694-2008
OI Becker, Christoph/0000-0002-1388-1041; Patankar, Jay/0000-0002-1884-7424
FU DFGGerman Research Foundation (DFG)European Commission [TRR241, SFB1181,
   FOR2438, BE3686/9]; Interdisciplinary Center for Clinical Research
   (IZKF) [J68, A76]
FX This work received funding from the DFG projects TRR241 (A03), SFB1181
   (C05) and FOR2438 (TP05) and individual grant BE3686/9, as well as the
   Interdisciplinary Center for Clinical Research (IZKF; J68, A76).
CR Abreu MT, 2010, NAT REV IMMUNOL, V10, P131, DOI 10.1038/nri2707
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Aglietti RA, 2016, P NATL ACAD SCI USA, V113, P7858, DOI 10.1073/pnas.1607769113
   Bao JQ, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99767
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Bast A, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1003986
   Baxt LA, 2015, GASTROENTEROLOGY, V149, P553, DOI 10.1053/j.gastro.2015.06.046
   Bertheloot D, 2017, CELL MOL IMMUNOL, V14, P43, DOI 10.1038/cmi.2016.34
   Bortner CD, 1998, BIOCHEM PHARMACOL, V56, P1549, DOI 10.1016/S0006-2952(98)00225-1
   Bosurgi L, 2017, IMMUNOL REV, V280, P8, DOI 10.1111/imr.12585
   Botto M, 2002, IMMUNOBIOLOGY, V205, P395, DOI 10.1078/0171-2985-00141
   BOUNOUS G, 1982, GASTROENTEROLOGY, V82, P1457
   BOUNOUS G, 1984, DIGEST DIS SCI, V29, P872, DOI 10.1007/BF01318436
   Boyapati RK, 2018, INFLAMM BOWEL DIS, V24, P2113, DOI 10.1093/ibd/izy095
   Brazil JC, 2016, IMMUNOL REV, V273, P94, DOI 10.1111/imr.12446
   Bullen TF, 2006, LAB INVEST, V86, P1052, DOI 10.1038/labinvest.3700464
   Cai ZY, 2014, NAT CELL BIOL, V16, P55, DOI 10.1038/ncb2883
   Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000
   Cario E, 2007, GASTROENTEROLOGY, V132, P1359, DOI 10.1053/j.gastro.2007.02.056
   Chan FKM, 2015, ANNU REV IMMUNOL, V33, P79, DOI 10.1146/annurev-immunol-032414-112248
   Chan FKM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008805
   Chen DS, 2018, P NATL ACAD SCI USA, V115, P3930, DOI 10.1073/pnas.1717190115
   Chen X, 2016, CELL RES, V26, P1007, DOI 10.1038/cr.2016.100
   Chen X, 2014, CELL RES, V24, P105, DOI 10.1038/cr.2013.171
   Christofferson DE, 2010, CURR OPIN CELL BIOL, V22, P263, DOI 10.1016/j.ceb.2009.12.003
   Cummings RJ, 2016, NATURE, V539, P565, DOI 10.1038/nature20138
   D'Angelo F, 2013, CLIN EXP IMMUNOL, V174, P60, DOI 10.1111/cei.12157
   Dannappel M, 2014, NATURE, V513, P90, DOI 10.1038/nature13608
   de Vasconcelos NM, 2019, CELL DEATH DIFFER, V26, P146, DOI 10.1038/s41418-018-0106-7
   Demers MJ, 2009, J CELL BIOCHEM, V107, P639, DOI 10.1002/jcb.22131
   Demon D, 2014, MUCOSAL IMMUNOL, V7, P1480, DOI 10.1038/mi.2014.36
   Di L, 2010, P NATL ACAD SCI USA, V107, P1541, DOI 10.1073/pnas.0910133107
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Dondelinger Y, 2015, MOL CELL, V60, P63, DOI 10.1016/j.molcel.2015.07.032
   Dondelinger Y, 2014, CELL REP, V7, P971, DOI 10.1016/j.celrep.2014.04.026
   Eisenhoffer GT, 2012, NATURE, V484, P546, DOI 10.1038/nature10999
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Farin HF, 2014, J EXP MED, V211, P1388, DOI 10.1084/jem.20130753
   Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326
   Fritsch M, 2019, NATURE, V575, P683, DOI 10.1038/s41586-019-1770-6
   Galluzzi L, 2014, CELL RES, V24, P139, DOI 10.1038/cr.2014.8
   Garcia-Carbonell R, 2018, P NATL ACAD SCI USA, V115, pE9192, DOI 10.1073/pnas.1810584115
   Geng JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00406-w
   Ginzberg HH, 2004, AM J PHYSIOL-GASTR L, V287, pG286, DOI 10.1152/ajpgi.00350.2003
   Gong YN, 2017, CELL, V169, P286, DOI 10.1016/j.cell.2017.03.020
   Gourbeyre P, 2015, PHYSIOL REP, V3, DOI 10.14814/phy2.12225
   Grauso M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47851-9
   Green DR, 2016, CELL DEATH DIFFER, V23, P915, DOI 10.1038/cdd.2015.172
   Greenow KR, 2009, ONCOGENE, V28, P1443, DOI 10.1038/onc.2008.482
   Grunert M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.154
   Gunther C, 2015, GUT, V64, P601, DOI 10.1136/gutjnl-2014-307226
   Gunther C, 2011, NATURE, V477, P335, DOI 10.1038/nature10400
   Gulbins E, 1997, BIOCHEM BIOPH RES CO, V236, P517, DOI 10.1006/bbrc.1997.6775
   Guo XY, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.294
   Gupta KH, 2017, DEV CELL, V41, P674, DOI 10.1016/j.devcel.2017.05.014
   Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489
   Hagiwara C, 2002, J GASTROEN HEPATOL, V17, P758, DOI 10.1046/j.1440-1746.2002.02791.x
   He SD, 2011, P NATL ACAD SCI USA, V108, P20054, DOI 10.1073/pnas.1116302108
   Hefele M, 2018, MUCOSAL IMMUNOL, V11, P1191, DOI 10.1038/s41385-018-0011-x
   Henry CM, 2017, MOL CELL, V65, P715, DOI 10.1016/j.molcel.2017.01.022
   Hill AA, 2018, IMMUNITY, V49, P389, DOI 10.1016/j.immuni.2018.08.027
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8
   Hugle B, 2017, PEDIATR RHEUMATOL, V15, DOI 10.1186/s12969-017-0147-3
   Hunter MM, 2010, GASTROENTEROLOGY, V138, P1395, DOI 10.1053/j.gastro.2009.12.041
   Hyoh Y, 2002, GUT, V50, P71, DOI 10.1136/gut.50.1.71
   Ingram JP, 2018, J IMMUNOL, V200, P3626, DOI 10.4049/jimmunol.1701386
   Iwakiri R, 2001, SCAND J GASTROENTERO, V36, P39, DOI 10.1080/00365520150218048
   Iwamoto M, 1996, J PATHOL, V180, P152
   Jiao HP, 2020, NATURE, V580, P391, DOI 10.1038/s41586-020-2129-8
   Jorgensen I, 2015, IMMUNOL REV, V265, P130, DOI 10.1111/imr.12287
   Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582
   Kaczmarek A, 2013, IMMUNITY, V38, P209, DOI 10.1016/j.immuni.2013.02.003
   Kajino-Sakamoto R, 2008, J IMMUNOL, V181, P1143, DOI 10.4049/jimmunol.181.2.1143
   Kang S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8515
   Kang TB, 2013, IMMUNITY, V38, P27, DOI 10.1016/j.immuni.2012.09.015
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kaser A, 2014, GUT, V63, P1038, DOI 10.1136/gutjnl-2013-306103
   Kattah MG, 2018, J EXP MED, V215, P1839, DOI 10.1084/jem.20180198
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kayagaki N, 2011, NATURE, V479, P117, DOI 10.1038/nature10558
   KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103
   Khoury MK, 2020, AM J PATHOL, V190, P272, DOI 10.1016/j.ajpath.2019.10.012
   Kim JM, 1998, J CLIN INVEST, V102, P1815, DOI 10.1172/JCI2466
   KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x
   Knodler LA, 2014, CELL HOST MICROBE, V16, P249, DOI 10.1016/j.chom.2014.07.002
   Koren E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06941-4
   Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001
   Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005
   Kunzelmann K, 2016, CELL MOL LIFE SCI, V73, P2387, DOI 10.1007/s00018-016-2208-z
   Kunzelmann K, 2012, EXP PHYSIOL, V97, P184, DOI 10.1113/expphysiol.2011.058206
   Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247
   Lawlor KE, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7282
   Lee CS, 2016, IMMUNITY, V44, P807, DOI 10.1016/j.immuni.2016.02.005
   Lee KZ, 2016, CELL HOST MICROBE, V20, P716, DOI 10.1016/j.chom.2016.10.010
   Lehle AS, 2019, GASTROENTEROLOGY, V156, P275, DOI 10.1053/j.gastro.2018.09.041
   Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634
   Lim CH, 2007, METHOD ENZYMOL, V428, P325, DOI 10.1016/S0076-6879(07)28019-x
   Liu JZ, 2015, NAT GENET, V47, P979, DOI 10.1038/ng.3359
   Liu L, 2017, J CROHNS COLITIS, V11, P737, DOI 10.1093/ecco-jcc/jjw219
   Liu X, 2016, NATURE, V535, P153, DOI 10.1038/nature18629
   Liu ZP, 2012, J BIOL CHEM, V287, P16955, DOI 10.1074/jbc.M112.358705
   Loetscher Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034812
   Loo D, 2007, MOL CANCER THER, V6, P856, DOI 10.1158/1535-7163.MCT-06-0581
   Lopetuso LR, 2018, P NATL ACAD SCI USA, V115, pE9362, DOI 10.1073/pnas.1803613115
   Lucas M, 2003, J IMMUNOL, V171, P2610, DOI 10.4049/jimmunol.171.5.2610
   MADARA JL, 1990, J MEMBRANE BIOL, V116, P177, DOI 10.1007/BF01868675
   Mahapatro M, 2016, CELL REP, V15, P1743, DOI 10.1016/j.celrep.2016.04.049
   Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105
   Manda P, 2018, IMMUNITY, V49, P42, DOI 10.1016/j.immuni.2018.06.011
   Marchiando AM, 2011, GASTROENTEROLOGY, V140, P1208, DOI 10.1053/j.gastro.2011.01.004
   Hernandez AM, 2011, J IMMUNOL, V186, P3735, DOI 10.4049/jimmunol.1000609
   Martin SJ, 2013, METHODS, V61, P87, DOI 10.1016/j.ymeth.2013.06.001
   Middendorp S, 2014, STEM CELLS, V32, P1083, DOI 10.1002/stem.1655
   Miguel JC, 2017, J CELL SCI, V130, P90, DOI 10.1242/jcs.182584
   Mitsuhashi S, 2016, INFLAMM BOWEL DIS, V22, P1587, DOI 10.1097/MIB.0000000000000840
   Moller P, 1996, AM J PATHOL, V149, P9
   Moriwaki K, 2014, IMMUNITY, V41, P567, DOI 10.1016/j.immuni.2014.09.016
   Moss SF, 1996, GUT, V39, P811, DOI 10.1136/gut.39.6.811
   Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698
   Newton K, 2019, NATURE, V575, P679, DOI 10.1038/s41586-019-1752-8
   Nowarski R, 2015, CELL, V163, P1444, DOI 10.1016/j.cell.2015.10.072
   Odze R, 2003, MODERN PATHOL, V16, P347, DOI 10.1097/01.MP.0000064746.82024.D1
   Okumura R, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.20
   Olivan-Viguera A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190307
   Orlov SN, 2013, AM J PHYSIOL-CELL PH, V305, pC361, DOI 10.1152/ajpcell.00040.2013
   Ousingsawat J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7245
   Parker A, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1275-5
   Pastorelli L, 2010, P NATL ACAD SCI USA, V107, P8017, DOI 10.1073/pnas.0912678107
   Paul WE, 2015, FUNDAMENTAL IMMUNOLO
   Pentecost M, 2006, PLOS PATHOG, V2, pe3
   Perera AP, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26775-w
   Perez-Lopez AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153209
   Peters AA, 2017, ONCOGENE, V36, P6490, DOI 10.1038/onc.2017.234
   Petersen SL, 2007, CANCER CELL, V12, P445, DOI 10.1016/j.ccr.2007.08.029
   Pierdomenico M, 2014, AM J GASTROENTEROL, V109, P279, DOI 10.1038/ajg.2013.403
   Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607
   Price AE, 2018, IMMUNITY, V49, P560, DOI 10.1016/j.immuni.2018.07.016
   Progatzky F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6864
   Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102
   Rauch I, 2017, IMMUNITY, V46, P649, DOI 10.1016/j.immuni.2017.03.016
   Rebsamen M, 2009, EMBO REP, V10, P916, DOI 10.1038/embor.2009.109
   Reed KR, 2016, ONCOTARGET, V7, P51665, DOI 10.18632/oncotarget.10076
   Rogers C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14128
   Ruder B, 2018, MUCOSAL IMMUNOL, V11, P1621, DOI 10.1038/s41385-018-0068-6
   Ruemmele FM, 1999, CELL DEATH DIFFER, V6, P729, DOI 10.1038/sj.cdd.4400545
   Saavedra PHV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07386-5
   Sachet M, 2017, APOPTOSIS, V22, P1189, DOI 10.1007/s10495-017-1413-z
   Said H.M., 2018, PHYSL GASTROINTESTIN
   Sangiuliano B, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/821043
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858
   Scarpa M, 2015, AM J PATHOL, V185, P1624, DOI 10.1016/j.ajpath.2015.02.018
   Schreiber R, 2010, J BIOL CHEM, V285, P7838, DOI 10.1074/jbc.M109.065367
   Schroeder ME, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01836-8
   Sellin ME, 2014, CELL HOST MICROBE, V16, P237, DOI 10.1016/j.chom.2014.07.001
   Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714
   Shi JJ, 2017, TRENDS BIOCHEM SCI, V42, P245, DOI 10.1016/j.tibs.2016.10.004
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   SHIBAHARA T, 1995, ARCH HISTOL CYTOL, V58, P205, DOI 10.1679/aohc.58.205
   Shindo R, 2019, ISCIENCE, V15, P536, DOI 10.1016/j.isci.2019.05.011
   Sidi S, 2008, CELL, V133, P864, DOI 10.1016/j.cell.2008.03.037
   Silva MT, 2010, FEBS LETT, V584, P4491, DOI 10.1016/j.febslet.2010.10.046
   Simmons AN, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.98
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Song HL, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-70
   Soucy G, 2012, MODERN PATHOL, V25, P295, DOI 10.1038/modpathol.2011.120
   Souza HSP, 2005, INT J COLORECTAL DIS, V20, P277, DOI 10.1007/s00384-004-0639-8
   Spit M, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180120
   Strater J, 1997, GASTROENTEROLOGY, V113, P160, DOI 10.1016/S0016-5085(97)70091-X
   Strater J, 2000, ANN NY ACAD SCI, V915, P162
   Sun GP, 2017, J CELL BIOL, V216, P3355, DOI 10.1083/jcb.201706134
   Sun YX, 2018, BIOMED PHARMACOTHER, V102, P699, DOI 10.1016/j.biopha.2018.03.132
   Suzanne M, 2013, CELL DEATH DIFFER, V20, P669, DOI 10.1038/cdd.2013.11
   Talmon G, 2017, AM J CLIN PATHOL, V148, P538, DOI [10.1093/ajcp/aqx100, 10.1093/AJCP/AQX100]
   Tanaka H, 2015, GUT, V64, P1529, DOI 10.1136/gutjnl-2014-308419
   TANAKA M, 1990, HEPATO-GASTROENTEROL, V37, P18
   Tang DL, 2019, CELL RES, V29, P347, DOI 10.1038/s41422-019-0164-5
   Tang HL, 2015, JOVE-J VIS EXP, DOI 10.3791/51964
   Tang HL, 2015, SCI REP-UK, V5, DOI 10.1038/srep09015
   Tang HL, 2012, MOL BIOL CELL, V23, P2240, DOI 10.1091/mbc.E11-11-0926
   Tang HM, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.181629
   Tang HM, 2018, JOVE-J VIS EXP, DOI 10.3791/54107
   Tang Ho Man, 2017, F1000Res, V6, P43, DOI 10.12688/f1000research.10568.2
   Tessner TG, 2004, J CLIN INVEST, V114, P1676, DOI 10.1172/JCI200422218
   Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0
   Totzke J, 2017, CELL CHEM BIOL, V24, P1029, DOI 10.1016/j.chembiol.2017.07.011
   Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116
   van der Wijk T, 2000, CELL PHYSIOL BIOCHEM, V10, P289, DOI 10.1159/000016359
   Van Opdenbosch N, 2017, CELL REP, V21, P3427, DOI 10.1016/j.celrep.2017.11.088
   Vlantis K, 2016, IMMUNITY, V44, P553, DOI 10.1016/j.immuni.2016.02.020
   Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022
   Wang HY, 2014, MOL CELL, V54, P133, DOI 10.1016/j.molcel.2014.03.003
   Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036
   Wang RC, 2020, NATURE, V580, P386, DOI 10.1038/s41586-020-2127-x
   Wang RP, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90632
   Wang SY, 1998, CELL, V92, P501, DOI 10.1016/S0092-8674(00)80943-5
   Watari A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145631
   Weisser SB, 2011, J LEUKOCYTE BIOL, V90, P483, DOI 10.1189/jlb.0311124
   Welz PS, 2011, NATURE, V477, P330, DOI 10.1038/nature10273
   Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989
   Wittkopf N, 2013, GASTROENTEROLOGY, V145, P1369, DOI 10.1053/j.gastro.2013.08.059
   Wulff H, 2019, NAT REV DRUG DISCOV, V18, P339, DOI 10.1038/s41573-019-0013-8
   Xia BQ, 2016, CELL RES, V26, P517, DOI 10.1038/cr.2016.26
   Yang ZP, 2018, P NATL ACAD SCI USA, V115, P11054, DOI 10.1073/pnas.1804094115
   Ye P, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007697
   Zaidi D, 2018, CLIN EXP GASTROENTER, V11, P217, DOI 10.2147/CEG.S148217
   Zargarian S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2002711
   Zarnegar BJ, 2008, NAT IMMUNOL, V9, P1371, DOI 10.1038/ni.1676
   Zhang HS, 2015, J BIOL CHEM, V290, P15327, DOI 10.1074/jbc.M114.633560
   Zhang YY, 2018, CELL RES, V28, P9, DOI 10.1038/cr.2017.133
   Zhao XL, 2017, J PATHOL, V243, P376, DOI 10.1002/path.4958
   Zushi S, 1997, INT J CANCER, V73, P917, DOI 10.1002/(SICI)1097-0215(19971210)73:6<917::AID-IJC26>3.0.CO;2-#
NR 212
TC 39
Z9 42
U1 16
U2 62
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
EI 1759-5053
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD SEP
PY 2020
VL 17
IS 9
BP 543
EP 556
DI 10.1038/s41575-020-0326-4
EA JUL 2020
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA NF2RW
UT WOS:000547227600001
PM 32651553
DA 2022-04-25
ER

PT J
AU Mogavero, A
   Maiorana, MV
   Zanutto, S
   Varinelli, L
   Bozzi, F
   Belfiore, A
   Volpi, CC
   Gloghini, A
   Pierotti, MA
   Gariboldi, M
AF Mogavero, Angela
   Maiorana, Maria Valeria
   Zanutto, Susanna
   Varinelli, Luca
   Bozzi, Fabio
   Belfiore, Antonino
   Volpi, Chiara C.
   Gloghini, Annunziata
   Pierotti, Marco A.
   Gariboldi, Manuela
TI Metformin transiently inhibits colorectal cancer cell proliferation as a
   result of either AMPK activation or increased ROS production
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CYCLE ARREST; STEM-CELLS; MATRIX METALLOPROTEINASES; IN-VITRO; GROWTH;
   SURVIVAL; ROLES; DRUG; PHOSPHORYLATION; MECHANISMS
AB Metformin is a widely used and well-tolerated anti-diabetic drug that can reduce cancer risk and improve the prognosis of certain malignancies. However, the mechanism underlying its anti-cancer effect is still unclear. We studied the anti-cancer activity of metformin on colorectal cancer (CRC) by using the drug to treat HT29, HCT116 and HCT116 p53-/- CRC cells. Metformin reduced cell proliferation and migration by inducing cell cycle arrest in the G0/G1 phase. This was accompanied by a sharp decrease in the expression of c-Myc and down-regulation of IGF1R. The anti-proliferative action of metformin was mediated by two different mechanisms: AMPK activation and increase in the production of reactive oxygen species, which suppressed the mTOR pathway and its downstream targets S6 and 4EBP1. A reduction in CD44 and LGR5 expression suggested that the drug had an effect on tumour cells with stem characteristics. However, a colony formation assay showed that metformin slowed the cells' ability to form colonies without arresting cell growth, as confirmed by absence of apoptosis, autophagy or senescence. Our finding that metformin only transiently arrests CRC cell growth suggests that efforts should be made to identify compounds that combined with the biguanide can act synergistically to induce cell death.
C1 [Mogavero, Angela; Maiorana, Maria Valeria; Zanutto, Susanna; Varinelli, Luca; Gariboldi, Manuela] Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Via G Amadeo 42, I-20133 Milan, Italy.
   [Mogavero, Angela; Maiorana, Maria Valeria; Zanutto, Susanna; Varinelli, Luca; Pierotti, Marco A.; Gariboldi, Manuela] Fdn Ist FIRC Oncol Mol, Mol Genet Canc, Via Adamello 16, I-20139 Milan, Italy.
   [Bozzi, Fabio; Belfiore, Antonino; Volpi, Chiara C.; Gloghini, Annunziata] Fdn IRCCS Ist Nazl Tumori, Dept Diagnost Pathol & Lab Med, Via G Venezian 1, I-20133 Milan, Italy.
RP Gariboldi, M (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Expt Oncol & Mol Med, Via G Amadeo 42, I-20133 Milan, Italy.; Gariboldi, M (corresponding author), Fdn Ist FIRC Oncol Mol, Mol Genet Canc, Via Adamello 16, I-20139 Milan, Italy.
EM manuela.gariboldi@istitutotumori.mi.it
RI zanutto, susanna/K-3431-2018; Gloghini, Annunziata/AAB-4809-2019;
   Zanutto, Susanna/AAC-7693-2022; Belfiore, Antonino AB/K-7657-2016;
   Gloghini, Annunziata/C-1992-2017; Pierotti, Marco
   Alessandro/AAC-4728-2022; Volpi, Chiara Costanza/C-2002-2017; Belfiore,
   Antonino/AAC-1284-2019; Gariboldi, Manuela/K-4744-2016; Bozzi,
   Fabio/H-6091-2017
OI zanutto, susanna/0000-0001-6115-8424; Gloghini,
   Annunziata/0000-0002-7226-1942; Zanutto, Susanna/0000-0001-6115-8424;
   Belfiore, Antonino AB/0000-0002-8011-6382; Gloghini,
   Annunziata/0000-0002-7226-1942; Pierotti, Marco
   Alessandro/0000-0002-7431-8332; Volpi, Chiara
   Costanza/0000-0002-8306-6851; Belfiore, Antonino/0000-0002-8011-6382;
   Varinelli, Luca/0000-0002-0273-5807; Gariboldi,
   Manuela/0000-0001-8406-165X; Bozzi, Fabio/0000-0003-0729-1288
FU AIRC (Associazione Italiana Ricerca Cancro)Fondazione AIRC per la
   ricerca sul cancro [14487]; Italian Ministry of Public HealthMinistry of
   Health, Italy
FX This research was supported in part by a grant [No. 14487] to MA
   Pierotti from AIRC (Associazione Italiana Ricerca Cancro), by the
   Italian Ministry of Public Health and by funds obtained through an
   Italian law that allows taxpayers to allocate 0.5 per cent share of
   their income tax contribution to a research institution. We thank the
   staff of the IFOM Imaging Facility and the staff of the IFOM Cell
   Culture Facility.
CR Al-Kharusi MRA, 2013, CARCINOGENESIS, V34, P1150, DOI 10.1093/carcin/bgt020
   Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252
   Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933
   Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-12
   Bae S, 2015, J CANCER EPIDEMIOL, V2015, DOI 10.1155/2015/189132
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Bednar F, 2012, CANCER PREV RES, V5, P351, DOI 10.1158/1940-6207.CAPR-12-0026
   Ben Sahra I, 2008, ONCOGENE, V27, P3576, DOI 10.1038/sj.onc.1211024
   Ben Sahra I, 2011, CANCER RES, V71, P4366, DOI 10.1158/0008-5472.CAN-10-1769
   Biswas S, 2006, BIOCHEM PHARMACOL, V71, P551, DOI 10.1016/j.bcp.2005.10.044
   Bozzi F, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0475-z
   Bridges HR, 2014, BIOCHEM J, V462, P475, DOI 10.1042/BJ20140620
   Buzzai M, 2007, CANCER RES, V67, P6745, DOI 10.1158/0008-5472.CAN-06-4447
   Cantrell LA, 2010, GYNECOL ONCOL, V116, P92, DOI 10.1016/j.ygyno.2009.09.024
   Chan DK, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-19
   Dowling RJO, 2007, CANCER RES, V67, P10804, DOI 10.1158/0008-5472.CAN-07-2310
   Dowling RJO, 2016, CELL METAB, V23, P567, DOI 10.1016/j.cmet.2016.03.006
   Faller WJ, 2015, NATURE, V517, P497, DOI 10.1038/nature13896
   Foretz M, 2014, CELL METAB, V20, P953, DOI 10.1016/j.cmet.2014.09.018
   Garrett CR, 2012, BRIT J CANCER, V106, P1374, DOI 10.1038/bjc.2012.71
   Gotlieb WH, 2008, GYNECOL ONCOL, V110, P246, DOI 10.1016/j.ygyno.2008.04.008
   Green AS, 2010, BLOOD, V116, P4262, DOI 10.1182/blood-2010-02-269837
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hwang YP, 2010, BRIT J PHARMACOL, V160, P1195, DOI 10.1111/j.1476-5381.2010.00762.x
   Isakovic A, 2007, CELL MOL LIFE SCI, V64, P1290, DOI 10.1007/s00018-007-7080-4
   Kalender A, 2010, CELL METAB, V11, P390, DOI 10.1016/j.cmet.2010.03.014
   Kato H, 2015, BIOCHEM BIOPH RES CO, V461, P115, DOI 10.1016/j.bbrc.2015.03.178
   Lee JH, 2012, INT J CANCER, V131, P752, DOI 10.1002/ijc.26421
   Li L, 2016, ONCOTARGET, V7, P34442, DOI 10.18632/oncotarget.9120
   Mackenzie RM, 2013, CLIN SCI, V124, P403, DOI 10.1042/CS20120239
   Marchi Saverio, 2012, J Signal Transduct, V2012, P329635, DOI 10.1155/2012/329635
   Marshall DC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127063
   Memmott RM, 2010, CANCER PREV RES, V3, P1066, DOI 10.1158/1940-6207.CAPR-10-0055
   Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750
   Moss LAS, 2012, AM J PATHOL, V181, P1895, DOI 10.1016/j.ajpath.2012.08.044
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264-6021:3480607
   Pedersen G, 2009, CLIN EXP IMMUNOL, V155, P257, DOI 10.1111/j.1365-2249.2008.03836.x
   Pernicova I, 2014, NAT REV ENDOCRINOL, V10, P143, DOI 10.1038/nrendo.2013.256
   Pierotti MA, 2013, ONCOGENE, V32, P1475, DOI 10.1038/onc.2012.181
   Sachdev D, 2007, MOL CANCER THER, V6, P1, DOI 10.1158/1535-7163.MCT-06-0080
   Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621
   Salani B, 2013, SCI REP-UK, V3, DOI 10.1038/srep02070
   Silvestri A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136250
   Singh PP, 2016, ONCOLOGIST, V21, P1509, DOI 10.1634/theoncologist.2016-0153
   Sokolova V, 2015, J CELL PHYSIOL, V230, P3105, DOI 10.1002/jcp.25051
   Spillane S, 2013, CANCER EPIDEM BIOMAR, V22, P1364, DOI 10.1158/1055-9965.EPI-13-0347
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tsilidis KK, 2014, DIABETES CARE, V37, P2522, DOI 10.2337/dc14-0584
   Viale A, 2015, CANCER RES, V75, P3687, DOI 10.1158/0008-5472.CAN-15-0491
   Vizioli MG, 2014, ONCOTARGET, V5, P8270, DOI 10.18632/oncotarget.2013
   Weber MM, 2002, CANCER-AM CANCER SOC, V95, P2086, DOI 10.1002/cncr.10945
   Zakikhani M, 2008, CANCER PREV RES, V1, P369, DOI 10.1158/1940-6207.CAPR-08-0081
   Zhang SZ, 2006, CANCER RES, V66, P8847, DOI 10.1158/0008-5472.CAN-06-0769
   Zhang YF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081264
   Zhang YM, 2014, ONCOTARGET, V5, P12936, DOI 10.18632/oncotarget.2683
NR 55
TC 70
Z9 72
U1 0
U2 13
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 22
PY 2017
VL 7
AR 15992
DI 10.1038/s41598-017-16149-z
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FN6IT
UT WOS:000416118300016
PM 29167573
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bouhidel, JO
   Wang, P
   Siu, KL
   Li, H
   Youn, JY
   Cai, H
AF Bouhidel, Jalaleddinne Omar
   Wang, Ping
   Siu, Kin Lung
   Li, Hong
   Youn, Ji Youn
   Cai, Hua
TI Netrin-1 improves post-injury cardiac function in vivo via
   DCC/NO-dependent preservation of mitochondrial integrity, while
   attenuating autophagy
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Netrin-1; Nitric oxide (NO); Ischemia reperfusion (I/R) injury; NADPH
   oxidase isoforms 4 (NOX4); Myocardial infarction (MI); Autophagy
ID NITRIC-OXIDE SYNTHASE; MYOCARDIAL-ISCHEMIA; PERMEABILITY TRANSITION;
   REPERFUSION INJURY; CA-2+-DEPENDENT PORE; HEART; INHIBITION;
   CARDIOPROTECTION; ANGIOGENESIS; DYSFUNCTION
AB Reperfusion injury of the heart is a severe complication of angioplasty treatment of acute myocardial ischemia, for which no therapeutics are currently available. The present study aimed to identify whether and how a novel protein, netrin-1, induces cardioprotection in vivo during ischemia/reperfusion (I/R) injury. Wild type (WT) C57BL6/j mice were subjected to a 30 min coronary occlusion followed by a 24 h reperfusion with vehicle (normal saline), netrin-1, UO126 (MEK1/2 inhibitor), PTIO (nitric oxide/NO scavenger), netrin-1/UO126 or netrin-l/PTIO intraventricularly. Some were injected of netrin-1 via tail vein. Netrin-1 at 5 mu g/kg induced a substantial reduction in infarct size (19.7 +/- 5.0% from 41.3 +/- 1.8% in the controls), and markedly improved cardiac function as measured by ejection fraction and fractional shortening from echocardiography. Experiments with mice deficient in netrin-1 receptor DCC (deleted in colorectal cancer, DCC+/-), or reperfusion with netrin-1/UO126 or netrin-1/PTIO, attenuated the protective effects of netrin-1, implicating intermediate roles of DCC, ERK1/2 and NO. Netrin-1 induced phosphorylation of ERK1/2 and eNOS was abolished in DCC+/- mice. Electron spin resonance (ESR) determination of NO production from isolated left ventricles demonstrated that netrin-1 improves NO bioavailability, which was attenuated by UO126 or in DCC+/- mice, suggesting upstream roles of DCC and ERK1/2 in NO production. Netrin-1 further reduced mitochondrial swelling and mitochondria] superoxide production, which was absent when co-treated with PTIO or UO126, or in DCC +/- mice, indicating critical roles of DCC, ERK1/2 and NO in preserving mitochondrial integrity. In a permanent coronary ligation model of myocardial infarction (MI) to assess post-MI remodeling, netrin-1 abolished the marked increase in autophagy. In summary, our data demonstrate robust cardioprotective effect of netrin-1 in vivo, as shown by reduced infarct size and improved cardiac function. Mechanistically, this protection is mediated by netrin-1 receptor DCC, and NO dependent preservation of mitochondria. This work clearly establishes a therapeutic potential of netrin-1 for acute treatment of MI, perhaps also for chronic post-MI remodeling. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Bouhidel, Jalaleddinne Omar; Wang, Ping; Siu, Kin Lung; Li, Hong; Youn, Ji Youn; Cai, Hua] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol & Med, Div Mol Med & Cardiol,Cardiovasc Res Labs, Los Angeles, CA 90095 USA.
RP Cai, H (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol & Med, Div Mol Med & Cardiol,Cardiovasc Res Labs, 650 Charles E Young Dr, Los Angeles, CA 90095 USA.
EM hcai@mednet.ucla.edu
FU National Institute of Health National Heart, Lung and Blood Institute
   (NHLBI)United States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [HL077440, HL088975, HL108701, HL119968]; American
   Heart Association Established Investigator Award (EIA)American Heart
   Association [12EIA8990025]; NATIONAL HEART, LUNG, AND BLOOD
   INSTITUTEUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Heart Lung & Blood
   Institute (NHLBI) [R01HL108701, R01HL077440, R01HL119968, R01HL088975]
   Funding Source: NIH RePORTER
FX This study was supported by National Institute of Health National Heart,
   Lung and Blood Institute (NHLBI) Grants HL077440 (HC), HL088975 (HC),
   HL108701 (HC, DGH), HL119968 (HC), and an American Heart Association
   Established Investigator Award (EIA) 12EIA8990025 (HC).
CR Baines C.P., 2009, PEDIAT CARDIOL, V32, P258
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   Bhandarkar SS, 2009, J CLIN INVEST, V119, P2359, DOI 10.1172/JCI33877
   Bilodeau MT, 2009, CURR TOP MED CHEM, V9, P436, DOI 10.2174/156802609788340832
   BOLLI R, 1989, P NATL ACAD SCI USA, V86, P4695, DOI 10.1073/pnas.86.12.4695
   Bouvree K, 2008, DEV BIOL, V318, P172, DOI 10.1016/j.ydbio.2008.03.023
   Bryan NS, 2007, P NATL ACAD SCI USA, V104, P19144, DOI 10.1073/pnas.0706579104
   Choi BM, 2002, J BIOCHEM MOL BIOL, V35, P116
   Cirulli V, 2007, NAT REV MOL CELL BIO, V8, P296, DOI 10.1038/nrm2142
   CROMPTON M, 1987, BIOCHEM J, V245, P915, DOI 10.1042/bj2450915
   CROMPTON M, 1988, BIOCHEM J, V255, P357
   Di Napoli P, 2001, CARDIOVASC RES, V51, P283, DOI 10.1016/S0008-6363(01)00306-6
   Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493
   Elrod JW, 2007, AM J PHYSIOL-HEART C, V292, pH342, DOI 10.1152/ajpheart.00306.2006
   Fraser H, 2000, CARDIOVASC RES, V46, P111, DOI 10.1016/S0008-6363(99)00424-1
   Go AS, 2014, CIRCULATION, V129, pE28, DOI 10.1161/01.cir.0000441139.02102.80
   Gustafsson AB, 2009, CIRC RES, V104, P150, DOI 10.1161/CIRCRESAHA.108.187427
   Halestrap AP, 1998, BBA-BIOENERGETICS, V1366, P79, DOI 10.1016/S0005-2728(98)00122-4
   Huber AB, 2003, ANNU REV NEUROSCI, V26, P509, DOI 10.1146/annurev.neuro.26.010302.081139
   Jones SP, 2006, J MOL CELL CARDIOL, V40, P16, DOI 10.1016/j.yjmcc.2005.09.011
   Jones SP, 1999, AM J PHYSIOL-HEART C, V276, pH1567, DOI 10.1152/ajpheart.1999.276.5.H1567
   Kanamori H, 2011, CARDIOVASC RES, V91, P330, DOI 10.1093/cvr/cvr073
   KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9
   Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1
   Larrivee B, 2007, GENE DEV, V21, P2433, DOI 10.1101/gad.437807
   Liu XS, 2007, J AM COLL CARDIOL, V50, P808, DOI 10.1016/j.jacc.2007.04.069
   Massoudy P, 2000, J THORAC CARDIOV SUR, V119, P566, DOI 10.1016/S0022-5223(00)70138-3
   MASSOUDY P, 1995, J CARDIOVASC PHARM, V25, P440, DOI 10.1097/00005344-199503000-00014
   Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265
   NAZARETH W, 1991, J MOL CELL CARDIOL, V23, P1351, DOI 10.1016/0022-2828(91)90181-K
   Nguyen A, 2006, P NATL ACAD SCI USA, V103, P6530, DOI 10.1073/pnas.0511011103
   Nikolopoulos SN, 2005, CELL CYCLE, V4, P429, DOI 10.4161/cc.4.3.1547
   Oak JH, 2007, DIABETES, V56, P118, DOI 10.2337/db06-0288
   Pabla R, 1996, CIRC RES, V78, P65, DOI 10.1161/01.RES.78.1.65
   Scherz-Shouval R, 2019, EMBO J, V38, DOI 10.15252/embj.2019101812
   Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X
   SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0
   SIEGFRIED MR, 1992, AM J PHYSIOL, V263, pH771, DOI 10.1152/ajpheart.1992.263.3.H771
   Siu K, NETRIN 1 ABROGATES I
   Toledo-Pereyra Luis H, 2004, Exp Clin Transplant, V2, P174
   West MB, 2008, CIRCULATION, V118, P1970, DOI 10.1161/CIRCULATIONAHA.108.791533
   Yan L, 2005, P NATL ACAD SCI USA, V102, P13807, DOI 10.1073/pnas.0506843102
   Yebra M, 2003, DEV CELL, V5, P695, DOI 10.1016/S1534-5807(03)00330-7
   Youn JY, 2009, CIRC RES, V104, P50, DOI 10.1161/CIRCRESAHA.108.178467
   Zhai PY, 2012, AUTOPHAGY, V8, P138, DOI 10.4161/auto.8.1.18314
   Zhang J, 2010, J MOL CELL CARDIOL, V48, P1060, DOI 10.1016/j.yjmcc.2009.11.020
   Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001
NR 47
TC 19
Z9 19
U1 0
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD FEB
PY 2015
VL 1852
IS 2
SI SI
BP 277
EP 289
DI 10.1016/j.bbadis.2014.06.005
PG 13
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CA5QR
UT WOS:000348963400012
PM 24928309
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Otto, C
   Hahlbrock, T
   Eich, K
   Karaaslan, F
   Jurgens, C
   Germer, CT
   Wiegering, A
   Kammerer, U
AF Otto, Christoph
   Hahlbrock, Theresa
   Eich, Kilian
   Karaaslan, Ferdi
   Juergens, Constantin
   Germer, Christoph-Thomas
   Wiegering, Armin
   Kaemmerer, Ulrike
TI Antiproliferative and antimetabolic effects behind the anticancer
   property of fermented wheat germ extract
SO BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
DE FWGE; Benzoquinone; Cancer cells; Reactive oxygen species; Autophagy;
   Cytotoxicity; Cytostatic
ID POLY(ADP-RIBOSE) POLYMERASE ACTIVATION; CANCER CELL-LINES; REACTIVE
   OXYGEN; COLORECTAL-CANCER; VITAMIN-C; APOPTOSIS; AVEMAR; GLYCOLYSIS;
   METABOLISM; REDUCTASE
AB Background: Fermented wheat germ extract (FWGE) sold under the trade name Avemar exhibits anticancer activity in vitro and in vivo. Its mechanisms of action are divided into antiproliferative and antimetabolic effects. Its influcence on cancer cell metabolism needs further investigation. One objective of this study, therefore, was to further elucidate the antimetabolic action of FWGE. The anticancer compound 2,6-dimethoxy-1,4-benzoquinone (DMBQ) is the major bioactive compound in FWGE and is probably responsible for its anticancer activity. The second objective of this study was to compare the antiproliferative properties in vitro of FWGE and the DMBQ compound.
   Methods: The IC50 values of FWGE were determined for nine human cancer cell lines after 24 h of culture. The DMBQ compound was used at a concentration of 24 mu mol/l, which is equal to the molar concentration of DMBQ in FWGE. Cell viability, cell cycle, cellular redox state, glucose consumption, lactic acid production, cellular ATP levels, and the NADH/NAD(+) ratio were measured.
   Results: The mean IC50 value of FWGE for the nine human cancer cell lines tested was 10 mg/ml. Both FWGE (10 mg/ml) and the DMBQ compound (24 mu mol/l) induced massive cell damage within 24 h after starting treatment, with changes in the cellular redox state secondary to formation of intracellular reactive oxygen species. Unlike the DMBQ compound, which was only cytotoxic, FWGE exhibited cytostatic and growth delay effects in addition to cytotoxicity. Both cytostatic and growth delay effects were linked to impaired glucose utilization which influenced the cell cycle, cellular ATP levels, and the NADH/NAD(+) ratio. The growth delay effect in response to FWGE treatment led to induction of autophagy.
   Conclusions: FWGE and the DMBQ compound both induced oxidative stress-promoted cytotoxicity. In addition, FWGE exhibited cytostatic and growth delay effects associated with impaired glucose utilization which led to autophagy, a possible previously unknown mechanism behind the influence of FWGE on cancer cell metabolism.
C1 [Otto, Christoph; Hahlbrock, Theresa; Eich, Kilian; Karaaslan, Ferdi; Juergens, Constantin] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.
   [Hahlbrock, Theresa] Spital Bulach, Med Klin, Spitalstr 24, D-8180 Bulach, Germany.
   [Eich, Kilian] Missionsarztl Klin, Fachabteilung Urol, Salvatorstr 7, D-97074 Wurzburg, Germany.
   [Karaaslan, Ferdi] Krankenhaus Leopoldina Stadt Schweinfurt, Klin Allgemein Viszeral Gefass & Thoraxchirurg, Gustav Adolf Str 8, D-97422 Schweinfurt, Germany.
   [Otto, Christoph; Germer, Christoph-Thomas; Wiegering, Armin] Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.
   [Wiegering, Armin] Univ Wurzburg, Dept Biochem & Mol Biol, Theodor Boveri Inst, Bioctr, D-97070 Wurzburg, Germany.
   [Kaemmerer, Ulrike] Univ Wurzburg, Dept Obstet & Gynaecol, Josef Schneider Str 4, D-97070 Wurzburg, Germany.
RP Otto, C (corresponding author), Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Expt Surg, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.; Otto, C (corresponding author), Univ Hosp Wurzburg, Dept Gen Visceral Vasc & Pediat Surg, Oberdurrbacher Str 6, D-97080 Wurzburg, Germany.
EM Otto_c@ukw.de
FU Interdisciplinary Centre for Clinical Research (IZKF) of the University
   of Wurzburg [B-186, D-150]; University of Wurzburg
FX The study was supported by funds from the Interdisciplinary Centre for
   Clinical Research (IZKF) of the University of Wurzburg (B-186 to AW, and
   D-150 to CO). The publication was funded by the University of Wurzburg
   through the funding program "Open Access Publishing".
CR BACHUR NR, 1978, CANCER RES, V38, P1745
   Boros LG, 2001, PANCREAS, V23, P141, DOI 10.1097/00006676-200108000-00004
   BUTLER J, 1987, British Journal of Cancer, V55, P53
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
   Circu ML, 2012, BBA-MOL CELL RES, V1823, P1767, DOI 10.1016/j.bbamcr.2012.06.019
   Comin-Anduix B, 2002, J BIOL CHEM, V277, P46408, DOI 10.1074/jbc.M206150200
   Deer EL, 2010, PANCREAS, V39, P425, DOI 10.1097/MPA.0b013e3181c15963
   Demidov LV, 2008, CANCER BIOTHER RADIO, V23, P477, DOI 10.1089/cbr.2008.0486
   FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Heimbach JT, 2007, INT J TOXICOL, V26, P253, DOI 10.1080/10915810701369709
   Hidvegi M, 1998, ANTICANCER RES, V18, P2353
   Hidvegi M, 1999, CANCER BIOTHER RADIO, V14, P277, DOI 10.1089/cbr.1999.14.277
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   HUBER W, 1993, ACTA TROP, V55, P257, DOI 10.1016/0001-706X(93)90083-N
   Illmer C, 2005, EXP BIOL MED, V230, P144
   Jakab F, 2003, BRIT J CANCER, V89, P465, DOI 10.1038/sj.bjc.6601153
   Kammerer U, 2015, BMC CANCER, V15, DOI 10.1186/1471-2407-15-2
   Kalyanaraman B, 2012, FREE RADICAL BIO MED, V52, P1, DOI 10.1016/j.freeradbiomed.2011.09.030
   Klingelhoeffer C, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-61
   LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7
   Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773
   PETHIG R, 1983, P NATL ACAD SCI-BIOL, V80, P129, DOI 10.1073/pnas.80.1.129
   Piccart-Gebhart MJ, 2006, NEW ENGL J MED, V354, P2177, DOI 10.1056/NEJMe068065
   POWIS G, 1987, PHARMACOL THERAPEUT, V35, P57, DOI 10.1016/0163-7258(87)90105-7
   Saiko P, 2007, CANCER LETT, V250, P323, DOI 10.1016/j.canlet.2006.10.018
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   TOMPKINS WA, 1974, J NATL CANCER I, V52, P1101, DOI 10.1093/jnci/52.4.1101
   TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561
   Verrax J, 2007, INT J CANCER, V120, P1192, DOI 10.1002/ijc.22439
   VOLLMERS HP, 1993, VIRCHOWS ARCH B, V63, P335, DOI 10.1007/BF02899281
   Wiegering A, 2014, NEOPLASIA, V16, P972, DOI 10.1016/j.neo.2014.09.008
   Wilson JX, 2005, ANNU REV NUTR, V25, P105, DOI 10.1146/annurev.nutr.25.050304.092647
   Winterbourn CC, 2008, NAT CHEM BIOL, V4, P278, DOI 10.1038/nchembio.85
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105
NR 38
TC 19
Z9 19
U1 1
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6882
J9 BMC COMPLEM ALTERN M
JI BMC Complement. Altern. Med.
PD JUN 1
PY 2016
VL 16
AR 160
DI 10.1186/s12906-016-1138-5
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA DN4ZB
UT WOS:000377074600003
PM 27245162
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Lu, CC
   Huang, BR
   Liao, PJ
   Yen, GC
AF Lu, Chi-Cheng
   Huang, Bo-Ru
   Liao, Pei-Jyuan
   Yen, Gow-Chin
TI Ursolic acid triggers nonprogrammed death (necrosis) in human
   glioblastoma multiforme DBTRG-05MG cells through MPT pore opening and
   ATP decline
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE ATP depletion; Glioblastoma DBTRG-05MG cells; MPT pore opening;
   Necrosis; Ursolic acid
ID MITOCHONDRIAL PERMEABILITY TRANSITION; COLORECTAL-CANCER; INDUCE
   APOPTOSIS; DRUG-RESISTANCE; INHIBITS GROWTH; IN-VITRO; AUTOPHAGY;
   PATHWAY; ROS; TARGET
AB Scope: Ursolic acid, a natural pentacyclic triterpenic acid, possesses anticancer potential and diverse biological effects, but its correlation with glioblastoma multiforme cells and different modes of cell death is unclear. We studied the cellular actions of human glioblastoma multiforme DBTRG-05MG cells after ursolic acid treatment and explored cell-selective killing effect of necrotic death as a cell fate.
   Methods and results: Ursolic acid effectively reversed temozolomide resistance and reduced DBTRG-05MG cell viability. Surprisingly, ursolic acid failed to stimulate the apoptosis- and autophagy-related signaling networks. The necrotic death was characterized by annexin V/propidium iodide double-positive detection and release of high-mobility group protein B1 and lactate dehydrogenase. These ursolic acid elicited responses were accompanied by reactive oxygen species generation and glutathione depletion. Rapid mitochondrial dysfunction was paralleled by the preferential induction of necrosis, rather than apoptotic death. Mitochondrial permeability transition (MPT) is a phenomenon to provide the onset of mitochondrial depolarization during cellular necrosis. The opening of MPT pores that were mechanistically regulated by cyclophilin D, and adenosine triphosphate decline occurred in treated necrotic DBTRG-05MG cells. Cyclosporine A (an MPT pore inhibitor) prevented ursolic acid-provoked necrotic death and the acid-involved key regulators.
   Conclusion: Our study is the first to report that ursolic acid-modified mitochondrial function triggers defective death by necrosis in DBTRG-05MG cells rather than augmenting programmed death.
C1 [Lu, Chi-Cheng; Huang, Bo-Ru; Liao, Pei-Jyuan; Yen, Gow-Chin] Natl Chung Hsing Univ, Dept Food Sci & Biotechnol, Taichung 40227, Taiwan.
   [Yen, Gow-Chin] Natl Chung Hsing Univ, Agr Biotechnol Ctr, Taichung 40227, Taiwan.
RP Yen, GC (corresponding author), Natl Chung Hsing Univ, Dept Food Sci & Biotechnol, 250 Kuokuang Rd, Taichung 40227, Taiwan.
EM gcyen@nchu.edu.tw
RI Yen, Gow-Chin/B-7886-2009; Lu, Chi-Cheng/N-7770-2013
OI Lu, Chi-Cheng/0000-0003-3149-0914; Yen, Gow-Chin/0000-0001-9538-4219
FU National Science Council, TaiwanMinistry of Science and Technology,
   Taiwan [NSC99-2313-B-005-002-MY3]; Ministry of Education, Taiwan, under
   ATU planMinistry of Education, Taiwan
FX This research work was supported in part by the National Science
   Council, NSC99-2313-B-005-002-MY3, Taiwan, and by the Ministry of
   Education, Taiwan, under the ATU plan.
CR Baritaud M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.120
   Biasoli D, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.283
   Chan Francis Ka-Ming, 2013, Methods Mol Biol, V979, P65, DOI 10.1007/978-1-62703-290-2_7
   Chen Z, 2008, MOL CANCER THER, V7, P698, DOI 10.1158/1535-7163.MCT-07-2312
   Cheng YT, 2013, J NUTR BIOCHEM, V24, P475, DOI 10.1016/j.jnutbio.2012.01.010
   Chiang JH, 2013, TOXICOL APPL PHARM, V269, P150, DOI 10.1016/j.taap.2013.03.007
   Chipuk JE, 2006, CELL DEATH DIFFER, V13, P1396, DOI 10.1038/sj.cdd.4401963
   Clark AJ, 2012, NEUROSURGERY, V70, P361, DOI 10.1227/NEU.0b013e3182314f9d
   Eich M, 2013, MOL CANCER THER, V12, P2529, DOI 10.1158/1535-7163.MCT-13-0136
   Fan CH, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.388
   Festjens N, 2006, CELL DEATH DIFFER, V13, P166, DOI 10.1038/sj.cdd.4401746
   Fontanini A, 2009, J BIOL CHEM, V284, P8369, DOI 10.1074/jbc.M806113200
   Gao N, 2012, BRIT J PHARMACOL, V165, P1813, DOI 10.1111/j.1476-5381.2011.01684.x
   Golstein P, 2007, TRENDS BIOCHEM SCI, V32, P37, DOI 10.1016/j.tibs.2006.11.001
   Gonzalez-Vallinas M, 2013, NUTR REV, V71, P585, DOI 10.1111/nure.12051
   Halestrap A, 2005, NATURE, V434, P578, DOI 10.1038/434578a
   Ho CY, 2012, J AGR FOOD CHEM, V60, P100, DOI 10.1021/jf203800d
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Ikeda Y, 2008, MOL NUTR FOOD RES, V52, P26, DOI 10.1002/mnfr.200700389
   Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84
   Jhaveri N, 2011, CANCER LETT, V312, P245, DOI 10.1016/j.canlet.2011.08.015
   Kao TC, 2009, J AGR FOOD CHEM, V57, P754, DOI 10.1021/jf802864k
   Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373
   Kim CH, 2007, J CELL PHYSIOL, V211, P371, DOI 10.1002/jcp.20941
   Kim J, 2010, J NEUROCHEM, V112, P1415, DOI 10.1111/j.1471-4159.2009.06562.x
   Kuo YF, 2010, FREE RADICAL BIO MED, V49, P214, DOI 10.1016/j.freeradbiomed.2010.04.005
   Li JJ, 2012, ONCOL REP, V28, P501, DOI 10.3892/or.2012.1827
   Li L, 2007, CANCER RES, V67, P4894, DOI 10.1158/0008-5472.CAN-06-3818
   Li YH, 2014, J PHARMACOL SCI, V125, P202, DOI 10.1254/jphs.14017FP
   Liu GT, 2005, ONCOGENE, V24, P5226, DOI 10.1038/sj.onc.1208519
   Lu CC, 2014, BBA-GEN SUBJECTS, V1840, P2310, DOI 10.1016/j.bbagen.2014.02.022
   Lu CC, 2010, MOL NUTR FOOD RES, V54, P967, DOI 10.1002/mnfr.200900265
   Ma H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.412
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   Nomura M, 2014, CANCER RES, V74, P1056, DOI 10.1158/0008-5472.CAN-13-1283
   Piao L, 2009, CANCER RES, V69, P3397, DOI 10.1158/0008-5472.CAN-08-3235
   Pozsgai E, 2013, NUTR CANCER, V65, P1059, DOI 10.1080/01635581.2013.810291
   Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805
   Rasola A, 2011, CELL CALCIUM, V50, P222, DOI 10.1016/j.ceca.2011.04.007
   Sadava D, 2013, CANCER LETT, V339, P102, DOI 10.1016/j.canlet.2013.07.017
   Shanmugam MK, 2013, BIOCHEM PHARMACOL, V85, P1579, DOI 10.1016/j.bcp.2013.03.006
   Shen J, 2013, BRIT J CANCER, V109, P164, DOI 10.1038/bjc.2013.306
   Shen SY, 2014, CHEM-BIOL INTERACT, V218, P28, DOI 10.1016/j.cbi.2014.04.017
   Shyu MH, 2010, J AGR FOOD CHEM, V58, P6110, DOI 10.1021/jf100574j
   Suh DH, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00041
   Tang XH, 2005, BIOCHEM BIOPH RES CO, V337, P320, DOI 10.1016/j.bbrc.2005.09.062
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Vanden Berghe T, 2014, NAT REV MOL CELL BIO, V15, P134, DOI 10.1038/nrm3737
   Wang J, 2012, BASIC CLIN PHARMACOL, V111, P106, DOI 10.1111/j.1742-7843.2012.00870.x
   Wang JS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063872
   Wilkinson K, 2011, J BIOL CHEM, V286, P34914, DOI 10.1074/jbc.M111.232116
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Xie Q, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-77
   Yang L, 2010, CANCER LETT, V298, P128, DOI 10.1016/j.canlet.2010.06.010
   Yeh CT, 2010, MOL NUTR FOOD RES, V54, P1285, DOI 10.1002/mnfr.200900414
   Zheng QY, 2013, CELL SIGNAL, V25, P206, DOI 10.1016/j.cellsig.2012.09.012
NR 56
TC 31
Z9 31
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD NOV
PY 2014
VL 58
IS 11
BP 2146
EP 2156
DI 10.1002/mnfr.201400051
PG 11
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA AT8XK
UT WOS:000345212200005
PM 25131308
DA 2022-04-25
ER

PT J
AU Patel, KR
   Andreadi, C
   Britton, RG
   Horner-Glister, E
   Karmokar, A
   Sale, S
   Brown, VA
   Brenner, DE
   Singh, R
   Steward, WP
   Gescher, AJ
   Brown, K
AF Patel, Ketan R.
   Andreadi, Catherine
   Britton, Robert G.
   Horner-Glister, Emma
   Karmokar, Ankur
   Sale, Stewart
   Brown, Victoria A.
   Brenner, Dean E.
   Singh, Rajinder
   Steward, William P.
   Gescher, Andreas J.
   Brown, Karen
TI Sulfate Metabolites Provide an Intracellular Pool for Resveratrol
   Generation and Induce Autophagy with Senescence
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HEALTHY-VOLUNTEERS; IN-VIVO; CANCER; MECHANISMS; RESTRICTION;
   PHARMACOKINETICS; EXPRESSION; RESISTANCE; DISEASE
AB The phytochemical resveratrol has been shown to exert numerous health benefits in preclinical studies, but its rapid metabolism and resulting poor bioavailability may limit translation of these effects to humans. Resveratrol metabolites might contribute to in vivo activity through regeneration of the parent compound. We present quantitation of sulfate and glucuronide conjugates of resveratrol in human plasma and tissue after repeated ingestion of resveratrol by volunteers and cancer patients, respectively. Subsequent pharmacokinetic characterization of a mixture of resveratrol-3-O-sulfate and resveratrol-4'-O-sulfate in mice showed that these metabolites are absorbed orally but have low bioavailabilities of similar to 14 and 3%, respectively. Sulfate hydrolysis in vivo liberated free resveratrol, which accounted for similar to 2% of the total resveratrol species present in mouse plasma. Monosulfate metabolites were also converted to the parent in human colorectal cells. The extent of cellular uptake was dependent on specific membrane transporters and dictated antiproliferative activity. Sulfate metabolites induced autophagy and senescence in human cancer cells; these effects were abrogated by inclusion of a sulfatase inhibitor, which reduced intracellular resveratrol. Together, our findings suggest that resveratrol is delivered to target tissues in a stable sulfate-conjugated form and that the parent compound is gradually regenerated in selected cells and may give rise to the beneficial effects in vivo. At doses considered to be safe in humans, resveratrol generated via this route may be of greater importance than the unmetabolized form.
C1 [Patel, Ketan R.; Andreadi, Catherine; Britton, Robert G.; Horner-Glister, Emma; Karmokar, Ankur; Sale, Stewart; Brown, Victoria A.; Singh, Rajinder; Steward, William P.; Gescher, Andreas J.; Brown, Karen] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE2 7LX, Leics, England.
   [Brenner, Dean E.] Univ Michigan, Sch Med, Dept Internal Med & Pharmacol, Ann Arbor, MI 48109 USA.
   [Brenner, Dean E.] Vet Affairs Med Ctr, Ann Arbor, MI 48109 USA.
RP Brown, K (corresponding author), Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE2 7LX, Leics, England.
EM kb20@le.ac.uk
RI Singh, Raj/A-5398-2011
OI Brown, Karen/0000-0002-5217-1501
FU Cancer Research UK programmeCancer Research UK [C325/A6691]; Cancer
   Research UK/UK Department of HealthCancer Research UK; U.S. National
   Cancer InstituteUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [NCI-N01-CN-25025]; MRCUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC) [MC_G0802524] Funding Source:
   UKRI; DIVISION OF CANCER PREVENTION AND CONTROLUnited States Department
   of Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [N01CN025025] Funding Source: NIH
   RePORTER; Cancer Research UKCancer Research UK [13101] Funding Source:
   researchfish; Medical Research CouncilUK Research & Innovation
   (UKRI)Medical Research Council UK (MRC)European Commission [MC_G0802524]
   Funding Source: researchfish
FX Supported by a Cancer Research UK programme (C325/A6691) with assistance
   from the Leicester Experimental Cancer Medicine Centre (C325/A15575,
   funded by Cancer Research UK/UK Department of Health) and U.S. National
   Cancer Institute (NCI-N01-CN-25025).
CR Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Boocock DJ, 2007, CANCER EPIDEM BIOMAR, V16, P1246, DOI 10.1158/1055-9965.EPI-07-0022
   Boocock DJ, 2007, J CHROMATOGR B, V848, P182, DOI 10.1016/j.jchromb.2006.10.017
   Brown VA, 2010, CANCER RES, V70, P9003, DOI 10.1158/0008-5472.CAN-10-2364
   Calamini B, 2010, BIOCHEM J, V429, P273, DOI 10.1042/BJ20091857
   Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)82148-6
   Dutta D, 2012, CIRC RES, V110, P1125, DOI 10.1161/CIRCRESAHA.111.246108
   Eskelinen EL, 2008, AUTOPHAGY, V4, P257, DOI 10.4161/auto.5179
   Gescher AJ, 2003, CANCER EPIDEM BIOMAR, V12, P953
   Gui Chunshan, 2010, Curr Chem Genomics, V4, P1, DOI 10.2174/1875397301004010001
   Harper CE, 2009, PROSTATE, V69, P1668, DOI 10.1002/pros.21017
   Heiss EH, 2007, J BIOL CHEM, V282, P26759, DOI 10.1074/jbc.M703229200
   Hoare M, 2011, SEMIN CANCER BIOL, V21, P397, DOI 10.1016/j.semcancer.2011.09.004
   Hoshino J, 2010, J MED CHEM, V53, P5033, DOI 10.1021/jm100274c
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Jeong JK, 2012, NEUROSCI RES, V73, P99, DOI 10.1016/j.neures.2012.03.005
   Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599
   Kenealey JD, 2011, J AGR FOOD CHEM, V59, P4979, DOI 10.1021/jf104901g
   Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013
   Lancon A, 2004, BIOCHEM BIOPH RES CO, V316, P1132, DOI 10.1016/j.bbrc.2004.02.164
   Lee W, 2008, CANCER RES, V68, P10315, DOI 10.1158/0008-5472.CAN-08-1984
   Lin CJ, 2012, FREE RADICAL BIO MED, V52, P377, DOI 10.1016/j.freeradbiomed.2011.10.487
   Lucas R, 2009, CARBOHYD RES, V344, P1340, DOI 10.1016/j.carres.2009.05.016
   Miksits M, 2010, CANCER LETT, V289, P237, DOI 10.1016/j.canlet.2009.08.020
   Miksits M, 2009, PLANTA MED, V75, P1227, DOI 10.1055/s-0029-1185533
   Morselli E, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.8
   Obaidat A, 2012, ANNU REV PHARMACOL, V52, P135, DOI 10.1146/annurev-pharmtox-010510-100556
   Patel KR, 2011, ANN NY ACAD SCI, V1215, P161, DOI 10.1111/j.1749-6632.2010.05853.x
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Pearson KJ, 2008, CELL METAB, V8, P157, DOI 10.1016/j.cmet.2008.06.011
   Pezzuto JM, 2008, PHARM BIOL, V46, P443, DOI 10.1080/13880200802116610
   Puissant A, 2010, CANCER RES, V70, P1042, DOI 10.1158/0008-5472.CAN-09-3537
   Qin FZ, 2012, CIRCULATION, V125, P1757, DOI 10.1161/CIRCULATIONAHA.111.067801
   Roth M, 2012, BRIT J PHARMACOL, V165, P1260, DOI 10.1111/j.1476-5381.2011.01724.x
   Roy SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025166
   Shankar S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016530
   Subramanian L, 2010, CLIN CANCER RES, V16, P5942, DOI 10.1158/1078-0432.CCR-10-1486
   Sun AY, 2010, MOL NEUROBIOL, V41, P375, DOI 10.1007/s12035-010-8111-y
   Timmers S, 2011, CELL METAB, V14, P612, DOI 10.1016/j.cmet.2011.10.002
   van de Wetering K, 2009, MOL PHARMACOL, V75, P876, DOI 10.1124/mol.108.052019
   Vang O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019881
   Vingtdeux V, 2010, J BIOL CHEM, V285, P9100, DOI 10.1074/jbc.M109.060061
   Wang LX, 2004, J PHARM SCI-US, V93, P2448, DOI 10.1002/jps.20156
   Woo LWL, 2007, J MED CHEM, V50, P3540, DOI 10.1021/jm061462b
   Wu YC, 2011, NEUROSIGNALS, V19, P163, DOI 10.1159/000328516
   Young ARJ, 2010, CURR OPIN CELL BIOL, V22, P234, DOI 10.1016/j.ceb.2009.12.005
   Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709
   Yu C, 2003, RAPID COMMUN MASS SP, V17, P307, DOI 10.1002/rcm.918
NR 49
TC 138
Z9 141
U1 1
U2 28
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD OCT 2
PY 2013
VL 5
IS 205
AR 205ra133
DI 10.1126/scitranslmed.3005870
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA 229MV
UT WOS:000325271300003
PM 24089405
OA Green Submitted
DA 2022-04-25
ER

PT J
AU Li, YZ
   Ke, JZ
   Peng, C
   Wu, FG
   Song, YK
AF Li, Yexuzi
   Ke, Junzhong
   Peng, Chen
   Wu, Fugen
   Song, Yukang
TI microRNA-300/NAMPT regulates inflammatory responses through activation
   of AMPK/mTOR signaling pathway in neonatal sepsis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Neonatal sepsis (NS); microRNA-300 (miR-300); Inflammation; Nicotinamide
   phosphoribosyltransferase (NAMPT); AMPK; Signaling
ID COLORECTAL-CANCER; NAMPT; CELLS; OVEREXPRESSION; SUPPRESSION;
   RESISTANCE; VISFATIN
AB Aim: Rapid and accurate diagnosis of neonatal sepsis (NS) is highly warranted because of high associated morbidity and mortality. The study aims to evaluate the effects of miR-300 on inflammatory responses in a septic neonate mouse model.
   Methods: A septic mouse model was established by intraperitoneal (i.p.) cecal slurry (CS) injection in order to validate the effect of miR-300 on the inflammatory response in endothelial cells. Bioinformatics tools and luciferase activity were employed to detect the target of miR-300. Serum inflammatory factors were determined by ELISA assay. RT-qPCR and western blot analysis were used to determine the gene expressions. Flow cytometry was employed to evaluate cell apoptosis.
   Results: Gain-and loss-of-function studies revealed that miR-300 overexpression augmented autophagy, inhibited cell apoptosis, enhanced cell cycle entry in endothelial cells, and decreased inflammatory response through the regulation of pro-and anti-apoptotic factors in endothelial cells. The effect of miR-300 on endothelial cells was upregulated after nicotinamide phosphoribosyltransferase (NAMPT) silencing and AMPK/mTOR signaling pathway activation, indicating that miR-300 influences sepsis via suppressing NAMPT and triggering the AMPK/mTOR signaling pathway.
   Conclusions: Our study provides evidence indicating that overexpressed miR-300 enhances autophagy by targeting NAMPT through activation of the AMPK/mTOR signaling pathway in septic mouse models, indicating it may serve as a potential therapeutic target for sepsis.
C1 [Li, Yexuzi; Ke, Junzhong; Peng, Chen; Song, Yukang] First Peoples Hosp Wenling, Dept Med Intens Care Unit, Wenling 317500, Zhejiang, Peoples R China.
   [Wu, Fugen] First Peoples Hosp Wenling, Dept Neonatal Intens Care Unit, Wenling 317500, Zhejiang, Peoples R China.
RP Wu, FG; Song, YK (corresponding author), 333 Chuanan Nan St, Taizhou 317500, Zhejiang, Peoples R China.
EM yexuzili@163.com; kejunzhongdoc@sina.com; linling_jiang@163.com;
   wufu_gen@163.com; garysongyk@163.com
FU Foundation of Zhejiang Provincial Medical and Health Science and
   Technology Project, Zhejiang Province, China [2017KY169]; Scientific
   Research Foundation of Taizhou Science and Technology Bureau, Taizhou,
   Zhejiang Province, China [1601KY45]; Scientific Research Foundation of
   Wenling Science and Technology Bureau, Wenling, Zhejiang Province, China
   [2012C31087]
FX This work was supported by the Foundation of Zhejiang Provincial Medical
   and Health Science and Technology Project, Zhejiang Province, China (No.
   2017KY169), the Scientific Research Foundation of Taizhou Science and
   Technology Bureau, Taizhou, Zhejiang Province, China (1601KY45) and the
   Scientific Research Foundation of Wenling Science and Technology Bureau,
   Wenling, Zhejiang Province, China (No. 2012C31087).
CR Bi TQ, 2011, ONCOL REP, V26, P1251, DOI 10.3892/or.2011.1378
   Burnham JP, 2015, CRIT CARE MED, V43, P1580, DOI 10.1097/CCM.0000000000001013
   Chen H, 2016, EXPERT REV ANTICANC, V16, P827, DOI 10.1080/14737140.2016.1190649
   Dalamaga M, 2012, MED HYPOTHESES, V79, P617, DOI 10.1016/j.mehy.2012.07.036
   Daniel P, 2010, PANCREATOLOGY, V10, P477, DOI 10.1159/000276986
   Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gopurappilly R, 2013, J CELL BIOCHEM, V114, P2240, DOI 10.1002/jcb.24572
   Hermans G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0993-7
   Hu BL, 2016, CELL PHYSIOL BIOCHEM, V40, P155, DOI 10.1159/000452533
   Hufton SE, 1999, FEBS LETT, V463, P77, DOI 10.1016/S0014-5793(99)01578-1
   Mondanizadeh M, 2015, J CELL BIOCHEM, V116, P943, DOI 10.1002/jcb.25045
   Muller MC, 2014, CRIT CARE, V18, DOI 10.1186/cc13721
   Nakajima TE, 2010, CANCER SCI, V101, P1286, DOI 10.1111/j.1349-7006.2010.01518.x
   Nowell M, 2012, FUTURE MED CHEM, V4, P751, DOI [10.4155/fmc.12.34, 10.4155/FMC.12.34]
   Pavlakou P, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6193694
   Roulston A, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1052180
   Salminen A, 2012, AGEING RES REV, V11, P230, DOI 10.1016/j.arr.2011.12.005
   SepNet Critical Care Trials Grp, 2016, INTENS CARE MED, V42, P1980, DOI 10.1007/s00134-016-4504-3
   Shane AL, 2014, J INFECTION, V68, pS24, DOI 10.1016/j.jinf.2013.09.011
   Srivastava Mousami, 2012, BMC Res Notes, V5, P617, DOI 10.1186/1756-0500-5-617
   Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468
   Wu X, 2014, CELL PHYSIOL BIOCHEM, V34, P506, DOI 10.1159/000363018
   Wynn JL, 2007, SHOCK, V28, P675, DOI 10.1097/shk.0b013e3180556d09
NR 24
TC 28
Z9 28
U1 1
U2 11
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2018
VL 108
BP 271
EP 279
DI 10.1016/j.biopha.2018.08.064
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA HA2UZ
UT WOS:000450101800033
PM 30223098
OA hybrid
DA 2022-04-25
ER

PT J
AU Scuto, M
   Salinaro, AT
   Caligiuri, I
   Ontario, ML
   Greco, V
   Sciuto, N
   Crea, R
   Calabrese, EJ
   Rizzolio, F
   Canzonieri, V
   Calabrese, V
AF Scuto, Maria
   Salinaro, Angela Trovato
   Caligiuri, Isabella
   Ontario, Maria Laura
   Greco, Valentina
   Sciuto, Nello
   Crea, Roberto
   Calabrese, Edward J.
   Rizzolio, Flavio
   Canzonieri, Vincenzo
   Calabrese, Vittorio
TI Redox modulation of vitagenes via plant polyphenols and vitamin D: Novel
   insights for chemoprevention and therapeutic interventions based on
   organoid technology
SO MECHANISMS OF AGEING AND DEVELOPMENT
LA English
DT Article
DE Cancer; Plant polyphenols; Chemoprevention; Vitamin D; Vitagenes;
   Autophagy process; Organoids; Personalized therapy
ID HEME OXYGENASE-1 INDUCTION; MORINGA-OLEIFERA LEAVES; ABERRANT CRYPT
   FOCI; S-TRANSFERASE-PI; COLORECTAL-CANCER; OVARIAN-CANCER; OLIVE OIL;
   OXIDATIVE STRESS; SIGNALING PATHWAY; PROSTATE-CANCER
AB Polyphenols are chemopreventive through the induction of nuclear factor erythroid 2 related factor 2 (Nrf2)mediated proteins and anti-inflammatory pathways. These pathways, encoding cytoprotective vitagenes, include heat shock proteins, such as heat shock protein 70 (Hsp70) and heme oxygenase-1 (HO-1), as well as glutathione redox system to protect against cancer initiation and progression. Phytochemicals exhibit biphasic dose responses on cancer cells, activating at low dose, signaling pathways resulting in upregulation of vitagenes, as in the case of the Nrf2 pathway upregulated by hydroxytyrosol (HT) or curcumin and NAD/NADH-sirtuin-1 activated by resveratrol. Here, the importance of vitagenes in redox stress response and autophagy mechanisms, as well as the potential use of dietary antioxidants in the prevention and treatment of multiple types of cancer are discussed. We also discuss the possible relationship between SARS-CoV-2, inflammation and cancer, exploiting innovative therapeutic approaches with HT-rich aqueous olive pulp extract (Hidrox (R)), a natural polyphenolic formulation, as well as the rationale of Vitamin D supplementation. Finally, we describe innovative approaches with organoids technology to study human carcinogenesis in preclinical models from basic cancer research to clinical practice, suggesting patient-derived organoids as an innovative tool to test drug toxicity and drive personalized therapy.
C1 [Scuto, Maria; Salinaro, Angela Trovato; Ontario, Maria Laura; Greco, Valentina; Sciuto, Nello; Calabrese, Vittorio] Univ Catania, Dept Biomed & Biotechnol Sci, I-95124 Catania, Italy.
   [Scuto, Maria; Caligiuri, Isabella; Rizzolio, Flavio; Canzonieri, Vincenzo] IRCCS, Ctr Riferimento Oncol Aviano CRO, Pathol Unit, I-33081 Aviano, Italy.
   [Crea, Roberto] Oliphenol LLC, 26225 Eden Landing Rd,Suite C, Hayward, CA 94545 USA.
   [Calabrese, Edward J.] Univ Massachusetts, Dept Environm Hlth Sci, Morrill I,N344, Amherst, MA 01003 USA.
   [Rizzolio, Flavio] Ca Foscari Univ Venice, Dept Mol Sci & Nanosyst, I-30123 Venice, Italy.
   [Canzonieri, Vincenzo] Univ Trieste, Dept Med Surg & Hlth Sci, I-34127 Trieste, Italy.
RP Calabrese, V (corresponding author), Univ Catania, Dept Biomed & Biotechnol Sci, I-95124 Catania, Italy.; Canzonieri, V (corresponding author), IRCCS, Ctr Riferimento Oncol Aviano CRO, Pathol Unit, I-33081 Aviano, Italy.; Canzonieri, V (corresponding author), Univ Trieste, Dept Med Surg & Hlth Sci, I-34127 Trieste, Italy.
EM mariaconcetta.scuto@unict.it; trovato@unict.it;
   Isabella.caligiuri@cro.it; Marialaura.ontario@ontariosrl.it;
   vgreco@unict.it; ssciuto@unict.it; robertocrea@oliphenol.com;
   edwardc@schoolph.umass.edu; Flavio.rizzolio@unive.it;
   vcanzonieri@cro.it; calabres@unict.it
RI Caligiuri, Isabella/J-9956-2016; Ontario, Maria Laura/AAC-7849-2022;
   Trovato Salinaro, Angela/AAC-1326-2022; Rizzolio, Flavio/K-2690-2018
OI Caligiuri, Isabella/0000-0002-4355-5597; Rizzolio,
   Flavio/0000-0002-3400-4363; TROVATO SALINARO,
   Angela/0000-0003-2377-858X; Greco, Valentina/0000-0002-6694-2151; Scuto,
   Maria/0000-0003-1019-5158
FU "Piano di incentivi per la Ricerca, Linea Intervento 2 PIACERI,
   2020-2022", University of Cata-nia, Italy
FX This study was supported by grants from "Piano di incentivi per la
   Ricerca, Linea Intervento 2 PIACERI, 2020-2022", University of Cata-nia,
   Italy. We acknowledge helpful discussions with Sergio Modafferi, Thomas
   Hartung and Lena Smirnova, JHU) .
CR A J, 2019, MOLECULES, V24, P4335, DOI DOI 10.3390/MOLECULES24234335
   Abou-Hashem MMM, 2019, J INTEGR MED-JIM, V17, P410, DOI 10.1016/j.joim.2019.09.004
   Afzal S, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6330
   Ahn M, 2019, NAT MICROBIOL, V4, P789, DOI 10.1038/s41564-019-0371-3
   Alistar A, 2017, LANCET ONCOL, V18, P770, DOI 10.1016/S1470-2045(17)30314-5
   Alkhalaf M, 2007, PHARMACOLOGY, V80, P134, DOI 10.1159/000103253
   Allam L, 2020, BIOINFORM BIOL INSIG, V14, DOI 10.1177/1177932220965505
   Amani A, 2019, J DRUG DELIV SCI TEC, V49, P534, DOI 10.1016/j.jddst.2018.12.034
   Amara I, 2020, CELL STRESS CHAPERON, V25, P919, DOI 10.1007/s12192-020-01127-8
   Amara I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062138
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   An BS, 2010, MOL CELL BIOL, V30, P4890, DOI 10.1128/MCB.00180-10
   Anderson WA, 2021, IN VITRO CELL DEV-AN, V57, P191, DOI 10.1007/s11626-020-00532-8
   Avila-Galvez MA, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801239
   Annweiler C, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04928-5
   Assi M, 2017, AM J PHYSIOL-REG I, V313, pR646, DOI 10.1152/ajpregu.00247.2017
   Atwell LL, 2015, CANCER PREV RES, V8, P1184, DOI 10.1158/1940-6207.CAPR-15-0119
   Austin R.C., 2018, CELL SURFACE GRP78 N, P63
   Azmi AS., 2020, FUNCTIONAL FOODS CAN, P221, DOI DOI 10.1016/B978-0-12-816151-7.00012-0
   Bagherniya M, 2018, AGEING RES REV, V47, P183, DOI 10.1016/j.arr.2018.08.004
   Bai T, 2020, J CELL PHYSIOL, V235, P5637, DOI 10.1002/jcp.29496
   Bao BY, 2008, INT J CANCER, V122, P2699, DOI 10.1002/ijc.23460
   Bao RY, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001020
   Basit F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.133
   Bauckman KA, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.87
   Bauckman K, 2015, BIOCHEM J, V466, P401, DOI 10.1042/BJ20140878
   Bayat Mokhtari Reza, 2018, J Cell Commun Signal, V12, P91, DOI 10.1007/s12079-017-0401-y
   Bayat S, 2019, J CELL BIOCHEM, V120, P9172, DOI 10.1002/jcb.28193
   Benlloch M, 2005, J BIOL CHEM, V280, P6950, DOI 10.1074/jbc.M408531200
   Benvenuto M, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050275
   Bernini R, 2017, J AGR FOOD CHEM, V65, P6506, DOI 10.1021/acs.jafc.6b05457
   Bhasin N, 2018, GASTROENTEROLOGY, V155, P1192, DOI 10.1053/j.gastro.2018.06.049
   Bider CM, 2007, NUTR RES, V27, P470, DOI 10.1016/j.nutres.2007.06.003
   Bitler, 2007, US Patent. Appl., Patent No. 20070020350
   Bitler CM, 2005, J NUTR, V135, P1475, DOI 10.1093/jn/135.6.1475
   Bourgonje AR, 2021, ANTIOXID REDOX SIGN, V35, P1207, DOI 10.1089/ars.2020.8247
   Brancaccio M, 2019, J BIOL CHEM, V294, P14603, DOI 10.1074/jbc.RA119.009304
   Broutier L, 2017, NAT MED, V23, P1424, DOI 10.1038/nm.4438
   Brune B, 2013, ANTIOXID REDOX SIGN, V19, P595, DOI 10.1089/ars.2012.4785
   Brunelli D, 2010, BIOCHEM PHARMACOL, V79, P1141, DOI 10.1016/j.bcp.2009.12.008
   Brunetti G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072588
   Buchser WJ, 2012, CANCER RES, V72, P2970, DOI 10.1158/0008-5472.CAN-11-3396
   Bullen CK, 2020, ALTEX-ALTERN ANIM EX, V37, P665, DOI 10.14573/altex.2006111
   Busch C, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0095-z
   Calabrese V, 2014, J CELL COMMUN SIGNAL, V8, P369, DOI 10.1007/s12079-014-0253-7
   Calabrese V, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9121303
   Calabrese V, 2010, ANTIOXID REDOX SIGN, V13, P1763, DOI 10.1089/ars.2009.3074
   Calahorra J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63417-6
   Campbell MJ, 2017, ENDOCRIN METAB CLIN, V46, P1009, DOI 10.1016/j.ecl.2017.07.007
   Cao JY, 2016, CELL MOL LIFE SCI, V73, P2195, DOI 10.1007/s00018-016-2194-1
   Cao XY, 2019, TUMORI J, V105, P456, DOI 10.1177/0300891619868007
   Castejon-Vega B, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144829
   Chang LC, 2018, CANCER LETT, V416, P124, DOI 10.1016/j.canlet.2017.12.025
   Chen MM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-71071-1
   Chen YJ, 2014, BIOINFORMATICS, V30, P2386, DOI 10.1093/bioinformatics/btu301
   Chen YB, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1413-7
   Chian S, 2014, BIOCHEM BIOPH RES CO, V447, P602, DOI 10.1016/j.bbrc.2014.04.039
   Chiou YS, 2011, J AGR FOOD CHEM, V59, P2725, DOI 10.1021/jf2000103
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Choi BH, 2017, ONCOTARGET, V8, P107188, DOI 10.18632/oncotarget.22513
   Choupani J, 2019, J CELL PHYSIOL, V234, P9093, DOI 10.1002/jcp.27586
   Christian MS, 2004, DRUG CHEM TOXICOL, V27, P309, DOI 10.1081/DCT-200039714
   Chun LF, 2020, DRUG DELIV, V27, P1018, DOI 10.1080/10717544.2020.1785583
   Chung Seyung S, 2018, Oncotarget, V9, P32943, DOI 10.18632/oncotarget.25993
   Cirmi S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081930
   Cordaro M, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9080660
   Cornelius C, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00120
   Costales-Carrera A, 2020, CANCERS, V12, DOI 10.3390/cancers12082302
   Crea, 2002, United States Patent, Patent No. [6,416,808, 6416808]
   Crespo M, 2017, NAT MED, V23, P878, DOI 10.1038/nm.4355
   Cruz-Lozano M, 2019, EUR J NUTR, V58, P3207, DOI 10.1007/s00394-018-1864-1
   Cuadrado A, 2020, TRENDS PHARMACOL SCI, V41, P598, DOI 10.1016/j.tips.2020.07.003
   Cuellar-Nunez ML, 2018, FOOD RES INT, V105, P159, DOI 10.1016/j.foodres.2017.11.004
   Cuperlovic-Culf M, 2016, INT J CANCER, V138, P2439, DOI 10.1002/ijc.29947
   D'Avolio A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12051359
   de Figueiredo SM, 2013, RECENT PATENTS ENDOC, V7, P213, DOI 10.2174/18722148113079990011
   de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   de Sa PL, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2467940
   DeDiego ML, 2014, J VIROL, V88, P913, DOI 10.1128/JVI.02576-13
   Di Rosa G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113893
   Diaz GD, 2000, CANCER RES, V60, P2304
   DiMarco-Crook C, 2020, J FOOD SCI, V85, P1292, DOI 10.1111/1750-3841.15073
   Dimitrakopoulou VI, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4761
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dong SC, 2018, DRUG DES DEV THER, V12, P3535, DOI 10.2147/DDDT.S169833
   Dou RX, 2016, BRIT J NUTR, V115, P1643, DOI 10.1017/S0007114516000696
   Drozd E, 2016, POSTEP HIG MED DOSW, V70, P319, DOI 10.5604/17322693.1199712
   El-Sharkawy A, 2020, MOLECULES, V25, DOI 10.3390/molecules25143219
   Elamin MH, 2019, ALTERN THER HEALTH M, V25, P17
   Elbadawy M, 2020, CANCERS, V12, DOI 10.3390/cancers12040777
   Elfiky AA, 2020, LIFE SCI, V260, DOI 10.1016/j.lfs.2020.118317
   Elfiky AA, 2021, J BIOMOL STRUCT DYN, V39, P3194, DOI 10.1080/07391102.2020.1761881
   Elfiky AA, 2020, J MED VIROL, V92, P3759, DOI 10.1002/jmv.25737
   Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113
   Enkhbat T, 2018, ANTICANCER RES, V38, P6247, DOI 10.21873/anticanres.12980
   Entrenas Castillo Marta, 2020, J Steroid Biochem Mol Biol, V203, P105751, DOI 10.1016/j.jsbmb.2020.105751
   Erazo T, 2016, CLIN CANCER RES, V22, P2508, DOI 10.1158/1078-0432.CCR-15-1808
   Ershaid N, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12370-8
   Fahey JW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26058-4
   Fajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131
   Fan Z, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.65
   Fang CY, 2019, J PHOTOCH PHOTOBIO B, V190, P72, DOI 10.1016/j.jphotobiol.2018.11.011
   Faul J L, 2020, Ir Med J, V113, P84
   Federico A, 2007, INT J CANCER, V121, P2381, DOI 10.1002/ijc.23192
   Fedirko V, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081954
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Fernandez-Barral A, 2020, FEBS J, V287, P53, DOI 10.1111/febs.14998
   Fernando W, 2019, CANCER LETT, V452, P168, DOI 10.1016/j.canlet.2019.03.022
   Fini L, 2008, CARCINOGENESIS, V29, P139, DOI 10.1093/carcin/bgm255
   Firczuk M, 2020, CANCER LETT, V471, P1, DOI 10.1016/j.canlet.2019.11.037
   Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003
   Fujiki H, 2018, MOL CELLS, V41, P73, DOI 10.14348/molcells.2018.2227
   Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835
   Furfaro AL, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1958174
   Fusco R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194845
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Gallazzi M, 2020, NUTRIENTS, V12, DOI 10.3390/nu12040903
   Galluzzi L, 2014, CELL, V159, P1263, DOI 10.1016/j.cell.2014.11.006
   Gao AM, 2017, ONCOTARGET, V8, P82085, DOI 10.18632/oncotarget.18294
   Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016
   Gao M, 2019, BIOMATERIALS, V223, DOI 10.1016/j.biomaterials.2019.119486
   Gao Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208762
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Giammanco M, 2015, PHARM BIOL, V53, P1399, DOI 10.3109/13880209.2014.988274
   Gifford JB, 2018, CURR DRUG TARGETS, V19, P701, DOI 10.2174/1389450118666170615100918
   Giner E, 2016, MOL NUTR FOOD RES, V60, P242, DOI 10.1002/mnfr.201500605
   Giordano A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102376
   Glinsky GV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050129
   GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070
   Goldsmith CD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071937
   Goldsmith CD, 2015, MOLECULES, V20, P12992, DOI 10.3390/molecules200712992
   Gong TT, 2020, EXP CELL RES, V393, DOI 10.1016/j.yexcr.2020.112061
   Gonzales S, 2002, DEV NEUROSCI-BASEL, V24, P161, DOI 10.1159/000065686
   Gonzalez-Donquiles C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177549
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Gowder S, 2017, CRITICAL EVALUATION
   Graczyk-Jarzynka A, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.020
   Granchi C, 2021, EUR J MED CHEM, V209, DOI 10.1016/j.ejmech.2020.112857
   Grant WB, 2019, CURR NUTR REP, V8, P203, DOI 10.1007/s13668-019-0262-5
   Greenshields AL, 2017, MOL CARCINOGEN, V56, P75, DOI 10.1002/mc.22474
   Guo JP, 2018, CANCER RES TREAT, V50, P445, DOI 10.4143/crt.2016.572
   Gupta N, 2020, MOLECULES, V25, DOI 10.3390/molecules25225390
   Han Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040925
   Hao Q, 2020, ONCOL REP, V43, P1067, DOI 10.3892/or.2020.7495
   Harvie M., 2014, AM SOC CLIN ONCOL ED, V34, DOI [10.14694/EdBook_AM.2014.34.e478e478-e486, DOI 10.14694/EDBOOK_AM.2014.34.E478E478-E486]
   Hassannia B, 2018, J CLIN INVEST, V128, P3341, DOI 10.1172/JCI99032
   He F, 2020, CARCINOGENESIS, V41, P405, DOI 10.1093/carcin/bgaa039
   Hendrickson WK, 2011, J CLIN ONCOL, V29, P2378, DOI 10.1200/JCO.2010.30.9880
   Hill SJ, 2018, CANCER DISCOV, V8, P1404, DOI 10.1158/2159-8290.CD-18-0474
   Hochwald SN, 1997, ANN SURG ONCOL, V4, P303, DOI 10.1007/BF02303579
   Holkem AT, 2021, NUTR CANCER, V73, P671, DOI 10.1080/01635581.2020.1761986
   Horowitz RI, 2020, RESPIR MED CASE REP, V30, DOI 10.1016/j.rmcr.2020.101063
   Horvath HC, 2010, J HISTOCHEM CYTOCHEM, V58, P277, DOI 10.1369/jhc.2009.954339
   Howells LM, 2019, J NUTR, V149, P1133, DOI 10.1093/jn/nxz029
   Howells LM, 2011, CANCER PREV RES, V4, P1419, DOI 10.1158/1940-6207.CAPR-11-0148
   Hu KJ, 2018, INTEGR CANCER THER, V17, P217, DOI 10.1177/1534735417712007
   Huang JW, 2013, MOL CANCER RES, V11, P1564, DOI 10.1158/1541-7786.MCR-13-0292
   Hummel DM, 2014, J STEROID BIOCHEM, V144, P91, DOI 10.1016/j.jsbmb.2013.09.017
   Ibrahim H, 2020, CLIN IMMUNOL, V219, DOI 10.1016/j.clim.2020.108544
   Ibrahim IM, 2020, J INFECTION, V80, P554, DOI 10.1016/j.jinf.2020.02.026
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Imran M, 2018, J FOOD SCI, V83, P1781, DOI 10.1111/1750-3841.14198
   Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031
   Irving GRB, 2013, CANCER PREV RES, V6, P119, DOI 10.1158/1940-6207.CAPR-12-0281
   Jabs J, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20177697
   Jaramillo MC, 2013, GENE DEV, V27, P2179, DOI 10.1101/gad.225680.113
   Jennis M, 2016, GENE DEV, V30, P918, DOI 10.1101/gad.275891.115
   Jeon D, 2018, BIOCHEM BIOPH RES CO, V495, P212, DOI 10.1016/j.bbrc.2017.11.018
   Jeon SM, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0038-9
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Ji T, 2014, ASIAN PAC J CANCER P, V15, P1739, DOI 10.7314/APJCP.2014.15.4.1739
   Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344
   Jiang T, 2015, FREE RADICAL BIO MED, V88, P199, DOI 10.1016/j.freeradbiomed.2015.06.014
   Jin XX, 2019, CANCER MED-US, V8, P1246, DOI 10.1002/cam4.1993
   Kan SF, 2018, INT J MOL MED, V42, P2447, DOI 10.3892/ijmm.2018.3860
   Kaufman HW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239252
   Kennedy L, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101429
   Kenny TC, 2019, CELL REP, V27, P2292, DOI 10.1016/j.celrep.2019.04.095
   Kiffin R, 2006, ANTIOXID REDOX SIGN, V8, P152, DOI 10.1089/ars.2006.8.152
   Killeen MJ, 2014, DRUG DISCOV TODAY, V19, P373, DOI 10.1016/j.drudis.2013.11.002
   Kimura Y, 2009, J NUTR, V139, P2079, DOI 10.3945/jn.109.104992
   King SM, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-12
   Kittiratphatthana N, 2016, J PHARM PHARMACOL, V68, P1184, DOI 10.1111/jphp.12586
   Ko JH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122589
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kong J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19313-8
   Koren R, 2001, CANCER RES, V61, P1439
   Koval A, 2018, CANCER LETT, V435, P110, DOI 10.1016/j.canlet.2018.08.003
   Krajka-Kuzniak V, 2017, PHARMACOL REP, V69, P393, DOI 10.1016/j.pharep.2016.12.011
   Kugel S, 2016, CELL, V165, P1401, DOI 10.1016/j.cell.2016.04.033
   Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162
   Suraweera TL, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9100973
   Lambert JR, 2006, J CELL PHYSIOL, V208, P566, DOI 10.1002/jcp.20692
   Lamy S, 2016, J NUTR BIOCHEM, V27, P136, DOI 10.1016/j.jnutbio.2015.08.026
   Lan AX, 2016, ONCOTARGET, V7, P53502, DOI 10.18632/oncotarget.10609
   Lanceta L, 2013, BIOCHEM J, V449, P189, DOI 10.1042/BJ20120936
   Lang XT, 2019, CANCER DISCOV, V9, P1673, DOI 10.1158/2159-8290.CD-19-0338
   Laskar P, 2019, NANOSCALE, V11, P20058, DOI 10.1039/c9nr07254c
   Leak RK, 2018, DOSE-RESPONSE, V16, DOI 10.1177/1559325818784501
   Lee JE, 2011, CANCER PREV RES, V4, P735, DOI 10.1158/1940-6207.CAPR-10-0289
   Lee SH, 2015, CANCER LETT, V367, P34, DOI 10.1016/j.canlet.2015.06.024
   Lee YH, 2018, CANCER LETT, V431, P219, DOI 10.1016/j.canlet.2018.05.036
   Leon-Gonzalez AJ, 2015, BIOCHEM PHARMACOL, V98, P371, DOI 10.1016/j.bcp.2015.07.017
   Contreras ML, 2019, STRUCT CHEM, V30, P369, DOI 10.1007/s11224-018-1210-5
   Leri M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041250
   Lermant A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8080315
   Levine M, 2011, ADV NUTR, V2, P78, DOI 10.3945/an.110.000109
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   LEWIS AD, 1988, CARCINOGENESIS, V9, P1283, DOI 10.1093/carcin/9.7.1283
   Li I, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0975-5
   Li L, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2018.11.034
   Li S, 2014, ONCOL REP, V31, P145, DOI 10.3892/or.2013.2853
   Li TT, 2019, ACTA BIOMATER, V89, P1, DOI 10.1016/j.actbio.2019.02.031
   Liang YC, 1999, CARCINOGENESIS, V20, P1945, DOI 10.1093/carcin/20.10.1945
   Lim WF, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102993
   Liu DS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14844
   Liu GK, 2016, CANCER LETT, V383, P171, DOI 10.1016/j.canlet.2016.09.033
   Liu K, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10148-6
   Liu LD, 2019, ARCH GYNECOL OBSTET, V299, P1627, DOI 10.1007/s00404-019-05058-3
   Liu P, 2019, FOOD CHEM TOXICOL, V128, P129, DOI 10.1016/j.fct.2019.03.050
   Liu XY, 2016, CELL MOL NEUROBIOL, V36, P1197, DOI 10.1007/s10571-015-0318-z
   Liu YW, 2019, BIOMED PHARMACOTHER, V109, P2145, DOI 10.1016/j.biopha.2018.11.066
   Liu Y, 2018, J CELL BIOCHEM, V119, P6162, DOI 10.1002/jcb.26822
   Liu ZT, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00479
   Lu HY, 2021, NUTR CANCER, V73, P350, DOI 10.1080/01635581.2020.1750661
   Lu R, 2019, FASEB J, V33, P11845, DOI 10.1096/fj.201900727R
   Lu RJ, 2020, LANCET, V395, P565, DOI 10.1016/S0140-6736(20)30251-8
   Luborsky J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227081
   Lucas C, 2020, NATURE, V584, P463, DOI 10.1038/s41586-020-2588-y
   Luetragoon T, 2020, MOLECULES, V25, DOI 10.3390/molecules25163563
   Luo C, 2013, CURR CANCER DRUG TAR, V13, P625, DOI 10.2174/15680096113139990035
   Luo MY, 2018, CELL DEATH DIFFER, V25, P1457, DOI 10.1038/s41418-017-0053-8
   Luo W, 2013, J STEROID BIOCHEM, V136, P252, DOI 10.1016/j.jsbmb.2012.09.031
   Lurie G, 2007, CANCER EPIDEM BIOMAR, V16, P2566, DOI 10.1158/1055-9965.EPI-07-0753
   Lushchak Volodymyr I, 2012, J Amino Acids, V2012, P736837, DOI 10.1155/2012/736837
   Ma LL, 2021, NEOPLASMA, V68, P165, DOI 10.4149/neo_2020_200707N705
   Madeddu C, 2018, HAEMATOLOGICA, V103, pE388, DOI 10.3324/haematol.2018.191551
   Maenhoudt N, 2020, STEM CELL REP, V14, P717, DOI 10.1016/j.stemcr.2020.03.004
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mailloux RJ, 2020, REDOX BIOL, V32, DOI 10.1016/j.redox.2020.101472
   Manna P, 2017, ARCH BIOCHEM BIOPHYS, V615, P22, DOI 10.1016/j.abb.2017.01.002
   Mantovani G, 2002, J CELL MOL MED, V6, P570, DOI 10.1111/j.1582-4934.2002.tb00455.x
   Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454
   Marinella MA, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13535
   Marinkovic M, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8023821
   Martinez N, 2019, CLIN TRANSL ONCOL, V21, P489, DOI 10.1007/s12094-018-1950-0
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Maya-Cano DA, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06297
   McCarty MF, 2021, NUTRIENTS, V13, DOI 10.3390/nu13010047
   McCord Joe M, 2020, bioRxiv, DOI 10.1101/2020.05.16.099788
   McCullough ML, 2019, JNCI-J NATL CANCER I, V111, P158, DOI 10.1093/jnci/djy087
   Meltzer David O, 2020, medRxiv, DOI 10.1101/2020.05.08.20095893
   Menendez JA, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-80
   Michl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157430
   Mieyal JJ, 2008, ANTIOXID REDOX SIGN, V10, P1941, DOI 10.1089/ars.2008.2089
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Modafferi S, 2021, ENVIRON HEALTH PERSP, V129, DOI 10.1289/EHP8580
   Moltgen S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061322
   Montero AJ, 2012, BREAST CANCER RES TR, V132, P215, DOI 10.1007/s10549-011-1889-0
   MULCAHY RT, 1994, MOL PHARMACOL, V46, P909
   Musaogullari A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218113
   Nachliely M, 2019, J STEROID BIOCHEM, V188, P8, DOI 10.1016/j.jsbmb.2018.11.017
   Nain M, 2017, J VIROL, V91, DOI [10.1128/JVI.02274-16, 10.1128/jvi.02274-16]
   Narayanankutty A, 2019, CURR PROTEIN PEPT SC, V20, P907, DOI 10.2174/1389203720666190206130003
   Nediani C, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8120578
   Neetha Mellekatte C, 2020, J Contemp Dent Pract, V21, P521
   Ni HM, 2012, TOXICOL SCI, V127, P438, DOI 10.1093/toxsci/kfs133
   Notarnicola M, 2011, GENES NUTR, V6, P63, DOI 10.1007/s12263-010-0177-7
   O AM, J OVARIAN RES, V14, P28, DOI DOI 10.1186/S13048-021-00772-6
   Olagnier D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18764-3
   Ong JS, 2016, INT J EPIDEMIOL, V45, P1619, DOI 10.1093/ije/dyw207
   Ooft SN, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aay2574
   Panagiotou G, 2020, CLIN ENDOCRINOL, V93, P508, DOI 10.1111/cen.14276
   Pandey P, 2021, NATL ACAD SCI LETT, V44, P225, DOI 10.1007/s40009-020-00978-0
   Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105
   Papanikolaou G, 2005, TOXICOL APPL PHARM, V202, P199, DOI 10.1016/j.taap.2004.06.021
   Paredes-Gonzalez X, 2015, BIOPHARM DRUG DISPOS, V36, P440, DOI 10.1002/bdd.1956
   Park YH, 2017, INT J ONCOL, V51, P573, DOI 10.3892/ijo.2017.4039
   Patel KR, 2010, CANCER RES, V70, P7392, DOI 10.1158/0008-5472.CAN-10-2027
   Pauli C, 2017, CANCER DISCOV, V7, P462, DOI 10.1158/2159-8290.CD-16-1154
   Penson, 2008, J CLIN ONCOL, V26
   Phannasil P, 2020, ONCOL LETT, V20, P1792, DOI 10.3892/ol.2020.11730
   Pineda-Moncusi M, 2018, MATURITAS, V116, P83, DOI 10.1016/j.maturitas.2018.07.015
   Poli G, 2019, J ENZYM INHIB MED CH, V34, P589, DOI 10.1080/14756366.2019.1571271
   Puca L, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04495-z
   Rajagopal C, 2018, PHARMACOL RES, V130, P273, DOI 10.1016/j.phrs.2017.12.034
   Ramdani LH, 2020, ACTA VIROL, V64, P276, DOI 10.4149/av_2020_309
   Ramnath N, 2014, J THORAC ONCOL, V9, P473, DOI 10.1097/JTO.0000000000000114
   Rangwala R, 2014, AUTOPHAGY, V10, P1369, DOI 10.4161/auto.29118
   Rasgon, 2017, 135350 BIORXIV
   Ravindranathan P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32267-8
   Ren YL, 2017, CANCER LETT, V390, P126, DOI 10.1016/j.canlet.2017.01.009
   Ricca C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061672
   Richard N, 2011, PLANTA MED, V77, P1890, DOI 10.1055/s-0031-1280022
   Richter K, 2010, MOL CELL, V40, P253, DOI 10.1016/j.molcel.2010.10.006
   Rietjens SJ, 2007, J AGR FOOD CHEM, V55, P7609, DOI 10.1021/jf0706934
   Rigacci S, 2015, ONCOTARGET, V6, P35344, DOI 10.18632/oncotarget.6119
   Ristow M, 2014, NAT MED, V20, P709, DOI 10.1038/nm.3624
   Ristow M, 2014, DOSE-RESPONSE, V12, P288, DOI 10.2203/dose-response.13-035.Ristow
   Rizvi A, 2016, APOPTOSIS, V21, P997, DOI 10.1007/s10495-016-1261-2
   Rodrigues TS, 2021, J EXP MED, V218, DOI 10.1084/jem.20201707
   Rodriguez-Enriquez S, 2019, TOXICOL APPL PHARM, V370, P65, DOI 10.1016/j.taap.2019.03.008
   Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010
   Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836
   Ruzzolini J, 2020, CANCERS, V12, DOI 10.3390/cancers12020317
   Rychahou P, 2018, J CONTROL RELEASE, V275, P85, DOI 10.1016/j.jconrel.2018.02.008
   Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010
   Sajadimajd S, 2018, CURR CANCER DRUG TAR, V18, P538, DOI 10.2174/1568009617666171002144228
   Sale S, 2005, INT J CANCER, V115, P194, DOI 10.1002/ijc.20884
   Samara P, 2017, EUR J MED CHEM, V137, P11, DOI 10.1016/j.ejmech.2017.05.029
   Sampaziotis F, 2017, NAT MED, V23, P954, DOI 10.1038/nm.4360
   Santos I, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102523
   Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499
   Savoie MB, 2019, J GASTROINTEST CANC, V50, P769, DOI 10.1007/s12029-018-0147-7
   Scattolin T, 2020, CHEM-EUR J, V26, P11868, DOI 10.1002/chem.202002199
   Schneider Y, 2001, NUTR CANCER, V39, P102, DOI 10.1207/S15327914nc391_14
   Schutte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262
   Schuster I, 2003, RECENT RESULTS CANC, V164, P169
   Scire A, 2019, BIOFACTORS, V45, P152, DOI 10.1002/biof.1476
   Scoditti E, 2014, VASC PHARMACOL, V63, P127, DOI 10.1016/j.vph.2014.07.001
   Scuto M, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8060177
   Scuto M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010284
   Scuto MC, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102417
   Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Seino T, 2018, CELL STEM CELL, V22, P454, DOI 10.1016/j.stem.2017.12.009
   Sengottuvelan M, 2006, CARCINOGENESIS, V27, P1038, DOI 10.1093/carcin/bgi286
   Sengottuvelan M, 2006, BRIT J NUTR, V96, P145, DOI 10.1079/BJN20061789
   Seo M, 2014, J MOL BIOL, V426, P830, DOI 10.1016/j.jmb.2013.11.021
   Shang JL, 2020, THERANOSTICS, V10, P5845, DOI 10.7150/thno.44043
   Sharif T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032526
   Shen T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0638-9
   SHI M, 1993, FREE RADICAL BIO MED, V15, P57, DOI 10.1016/0891-5849(93)90125-E
   Shi YC, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12023
   Shin D, 2018, FREE RADICAL BIO MED, V129, P454, DOI 10.1016/j.freeradbiomed.2018.10.426
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Silva S, 2015, J NUTR BIOCHEM, V26, P360, DOI 10.1016/j.jnutbio.2014.11.011
   Singh B, 2014, CARCINOGENESIS, V35, P1872, DOI 10.1093/carcin/bgu120
   Singh BN, 2017, CRIT REV FOOD SCI, V57, P1394, DOI 10.1080/10408398.2014.994700
   Siracusa R, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090824
   Sirianni R, 2010, MOL NUTR FOOD RES, V54, P833, DOI 10.1002/mnfr.200900111
   Sirota R, 2015, REDOX BIOL, V4, P48, DOI 10.1016/j.redox.2014.11.012
   Song Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0511-7
   Soni MG, 2006, FOOD CHEM TOXICOL, V44, P903, DOI 10.1016/j.fct.2006.01.008
   Soragni A, 2016, CANCER CELL, V29, P90, DOI 10.1016/j.ccell.2015.12.002
   Soy M, 2020, CLIN RHEUMATOL, V39, P2085, DOI 10.1007/s10067-020-05190-5
   Sridhar S, 2012, J PATHOL, V226, P255, DOI 10.1002/path.3025
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371
   Sun CL, 2018, INT J BIOL MACROMOL, V112, P65, DOI 10.1016/j.ijbiomac.2018.01.136
   Sun HZ, 2020, THERANOSTICS, V10, P6928, DOI 10.7150/thno.43811
   Sun JK, 2020, AGING-US, V12, P11287, DOI 10.18632/aging.103526
   Sun X, 2015, ONCOGENE, V34, P5617, DOI 10.1038/onc.2015.32
   Sun XF, 2016, HEPATOLOGY, V63, P173, DOI 10.1002/hep.28251
   Tahata S, 2018, CANCER PREV RES, V11, P429, DOI 10.1158/1940-6207.CAPR-17-0268
   Takeda Y, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13020232
   Tan QX, 2015, CANCER SCI, V106, P1023, DOI 10.1111/cas.12712
   Tang R, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-2554a
   Tannour-Louet M, 2014, FASEB J, V28, P364, DOI 10.1096/fj.13-236109
   Tao SS, 2019, ENVIRON TOXICOL, V34, P594, DOI 10.1002/tox.22726
   Tarangelo A, 2018, CELL REP, V22, P569, DOI 10.1016/j.celrep.2017.12.077
   Tasselli L, 2017, TRENDS ENDOCRIN MET, V28, P168, DOI 10.1016/j.tem.2016.10.002
   Tew KD, 2011, FREE RADICAL BIO MED, V51, P299, DOI 10.1016/j.freeradbiomed.2011.04.013
   Thomas RG, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.610533
   Tian M, 2019, J CELL PHYSIOL, V234, P21126, DOI 10.1002/jcp.28715
   Townsend DM, 2009, BIOMED PHARMACOTHER, V63, P75, DOI 10.1016/j.biopha.2008.08.019
   Townsend DM, 2009, J BIOL CHEM, V284, P436, DOI 10.1074/jbc.M805586200
   Traverso N, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/972913
   Trovato A, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0078-8
   Trovato A, 2016, NEUROTOXICOLOGY, V53, P350, DOI 10.1016/j.neuro.2015.09.012
   Trovato Salinaro Angela, 2018, Immun Ageing, V15, P8, DOI 10.1186/s12979-017-0108-1
   Trump Donald L, 2018, Bone Rep, V9, P110, DOI 10.1016/j.bonr.2018.06.002
   Truong VL, 2018, BIOFACTORS, V44, P36, DOI 10.1002/biof.1399
   Tuveson D, 2019, SCIENCE, V364, P952, DOI 10.1126/science.aaw6985
   Ullah MF, 2011, CANCER CHEMOTH PHARM, V67, P103, DOI 10.1007/s00280-010-1290-4
   Uruena C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76619-9
   Vabret N, 2020, IMMUNITY, V52, P910, DOI 10.1016/j.immuni.2020.05.002
   Valizadeh H, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107088
   van Die MD, 2017, PROSTATE, V77, P765, DOI 10.1002/pros.23317
   Vaughan-Shaw PG, 2017, BRIT J CANCER, V116, P1092, DOI 10.1038/bjc.2017.44
   Vernier M, 2020, GENE DEV, V34, P544, DOI 10.1101/gad.330746.119
   Visioli F, 1998, BIOCHEM BIOPH RES CO, V247, P60, DOI 10.1006/bbrc.1998.8735
   Visioli F, 2009, J AGR FOOD CHEM, V57, P1793, DOI 10.1021/jf8034429
   Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774
   Wagener FADTG, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060540
   Wang HM, 2017, AGING DIS, V8, P346, DOI 10.14336/AD.2016.1021
   Wang J, 2018, DRUG DES DEV THER, V12, P721, DOI 10.2147/DDDT.S160020
   Wang K, 2019, DRUG DES DEV THER, V13, P2135, DOI 10.2147/DDDT.S199459
   Wang QS, 2014, J BIOL CHEM, V289, P11681, DOI 10.1074/jbc.M113.517581
   Wang R, 2021, CONTEMP CLIN TRIALS, V100, DOI 10.1016/j.cct.2020.106176
   Wang SJ, 2016, CELL REP, V17, P366, DOI 10.1016/j.celrep.2016.09.022
   Wang YB, 2018, BIOCHEM BIOPH RES CO, V495, P1418, DOI 10.1016/j.bbrc.2017.11.156
   Watanabe Reiko, 2015, Clin Calcium, V25, P373, DOI CliCa1503373380
   Weeber F, 2015, P NATL ACAD SCI USA, V112, P13308, DOI 10.1073/pnas.1516689112
   Weir EK, 2020, CLIN MED, V20, pE107, DOI 10.7861/clinmed.2020-0301
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994
   Wu X, 2019, ACTA PHARM SIN B, V9, P203, DOI 10.1016/j.apsb.2018.09.002
   Xian ZY, 2020, NEOPLASMA, V67, P1063, DOI 10.4149/neo_2020_191024N1084
   Xie DD, 2017, ONCOTARGET, V8, P22076, DOI 10.18632/oncotarget.16195
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Xie YC, 2016, BIOCHEM BIOPH RES CO, V473, P775, DOI 10.1016/j.bbrc.2016.03.052
   Xing YB, 2017, FOOD FUNCT, V8, P2857, DOI 10.1039/c7fo00552k
   Xiong L, 2017, ONCOTARGET, V8, P6419, DOI 10.18632/oncotarget.14117
   Xu HX, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0662-9
   Xu R, 2021, PHARMACOL THERAPEUT, V218, DOI 10.1016/j.pharmthera.2020.107668
   Xu S, 2017, P 2017 4 INT C BIOM
   Xu T, 2019, J CELL MOL MED, V23, P4900, DOI 10.1111/jcmm.14511
   Xue YS, 2019, TRENDS IMMUNOL, V40, P1035, DOI 10.1016/j.it.2019.09.005
   Yan ZL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1226-8
   Yang Chung S, 2014, Enzymes, V36, P195, DOI 10.1016/B978-0-12-802215-3.00010-0
   Yang F, 2020, J MED VIROL, V92, P2067, DOI 10.1002/jmv.25972
   Yang J, 2020, J BIOL CHEM, V295, P8302, DOI 10.1074/jbc.RA119.012372
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yap JKY, 2020, J IMMUNOL, V205, P307, DOI 10.4049/jimmunol.2000513
   Ye ZW, 2017, ANTIOXID REDOX SIGN, V26, P248, DOI 10.1089/ars.2015.6486
   Yin L, 2011, GYNECOL ONCOL, V121, P369, DOI 10.1016/j.ygyno.2011.01.023
   Ying SY, 2018, METHODS MOL BIOL, V1733, P1, DOI 10.1007/978-1-4939-7601-0_1
   Yu MY, 2019, CANCER SCI, V110, P3173, DOI 10.1111/cas.14181
   Zhang C, 2018, MOL MED REP, V18, P5409, DOI 10.3892/mmr.2018.9589
   Zhang G, 2015, EUR J GYNAECOL ONCOL, V36, P629
   Zhang HB, 2020, CHIN J INTEGR MED, V26, P510, DOI 10.1007/s11655-020-3183-7
   Zhang J, 2020, FREE RADICAL BIO MED, V160, P755, DOI 10.1016/j.freeradbiomed.2020.09.013
   Zhang LL, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50288-9
   Zhang PF, 2018, ADV MATER, V30, DOI 10.1002/adma.201705350
   Zhang XF, 2016, INT J NANOMED, V11, P3655, DOI 10.2147/IJN.S111279
   Zhang XM, 2009, N-S ARCH PHARMACOL, V379, P581, DOI 10.1007/s00210-009-0399-7
   Zhang X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0935-5
   Zhang YG, 2020, CELL MOL GASTROENTER, V10, P729, DOI 10.1016/j.jcmgh.2020.05.010
   Zhang ZZ, 2020, NUTR CANCER, V72, P74, DOI 10.1080/01635581.2019.1619783
   Zhao BL, 2014, CANCER LETT, V347, P79, DOI 10.1016/j.canlet.2014.01.028
   Zhao Z, 2016, AM J CANCER RES, V6, P2162
   Zhou XY, 2018, BIOCHEM PHARMACOL, V155, P252, DOI 10.1016/j.bcp.2018.07.006
   Zhu S, 2017, CANCER RES, V77, P2064, DOI 10.1158/0008-5472.CAN-16-1979
   Zhu WZ, 2012, NUTR CANCER, V64, P393, DOI 10.1080/01635581.2012.654926
   Zubair H, 2017, NUTR CANCER, V69, P932, DOI 10.1080/01635581.2017.1339818
NR 438
TC 3
Z9 3
U1 3
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0047-6374
EI 1872-6216
J9 MECH AGEING DEV
JI Mech. Ageing Dev.
PD OCT
PY 2021
VL 199
AR 111551
DI 10.1016/j.mad.2021.111551
EA AUG 2021
PG 25
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA WC8TX
UT WOS:000704526000001
PM 34358533
DA 2022-04-25
ER

PT J
AU Han, D
   Zhang, XJ
   Zhang, JTT
   Guo, XZ
   Zheng, Y
   Sui, SH
   Zheng, JP
AF Han, Di
   Zhang, Xuejuan
   Zhang, Jietao
   Guo, Xiaozi
   Zheng, Yu
   Sui, Shihua
   Zheng, Jiaping
TI Oleanolic acid suppresses vascular smooth muscle cell proliferation by
   increasing lincRNA-p21 expression
SO ONCOLOGY LETTERS
LA English
DT Article
DE oleanolic acid; long non-coding RNA; vascular smooth muscle cell
ID INTERGENIC NONCODING RNA-P21; CANCER-CELLS; COLORECTAL-CANCER; PATHWAY;
   APOPTOSIS; AUTOPHAGY; KINASE
AB Arteriosclerosis poses a significant risk to human health and involves the thickening and hardening of the walls of arteries. Accumulated evidence demonstrates that aberrant proliferation of vascular smooth muscle cells (VSMCs) accounts for the onset and progression of arteriosclerosis. Suppression of their proliferation has been demonstrated to be an effective anti-arteriosclerosis strategy. Long non-coding RNAs (lncRNAs) have recently been observed to be implicated in the proliferation of VSMCs and arteriosclerosis. In this study, we observed that oleanolic acid (OA), a natural compound from plants, inhibited the proliferation of VSMCs. The expression of lincRNA-p21, an arteriosclerosis-associated lncRNA, was demonstrated to be elevated by OA treatment. Suppression of lincRNA-p21 rescued the effect of OA on the proliferation of VSMCs. Collectively, targeting lncRNA is a promising strategy for arteriosclerosis prevention and treatment, and OA ameliorates arteriosclerosis by increasing lncRNA levels.
C1 [Han, Di; Zhang, Xuejuan; Zhang, Jietao; Guo, Xiaozi; Zheng, Yu] Qingdao Univ, Dept Gen Med, Affiliated Hosp, Qingdao 266031, Shandong, Peoples R China.
   [Sui, Shihua; Zheng, Jiaping] Peoples Hosp Rizhao, Dept Neurol, 126 Taian Rd, Rizhao 276800, Shandong, Peoples R China.
RP Zheng, JP (corresponding author), Peoples Hosp Rizhao, Dept Neurol, 126 Taian Rd, Rizhao 276800, Shandong, Peoples R China.
EM jiapingzhengrz@126.com
CR Chaabane C, 2014, CURR OPIN LIPIDOL, V25, P374, DOI 10.1097/MOL.0000000000000113
   Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025
   Feng J, 2011, J CELL BIOCHEM, V112, P1524, DOI 10.1002/jcb.23065
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Hong D, 2014, PHARMAZIE, V69, P698, DOI 10.1691/ph.2014.4556
   Liu J, 2014, J NUTR BIOCHEM, V25, P1154, DOI 10.1016/j.jnutbio.2014.06.006
   Liu J, 2014, J AGR FOOD CHEM, V62, P5528, DOI 10.1021/jf500622p
   Liu J, 2014, ASIAN PAC J CANCER P, V15, P4519, DOI 10.7314/APJCP.2014.15.11.4519
   Liu J, 2014, ONCOL REP, V32, P567, DOI 10.3892/or.2014.3239
   Liu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091606
   Qin XF, 2014, MOL CELL BIOCHEM, V390, P61, DOI 10.1007/s11010-013-1956-4
   Rudijanto Achmad, 2007, Acta Med Indones, V39, P86
   Spurlock CF, 2014, ARTHRITIS RHEUMATOL, V66, P2947, DOI 10.1002/art.38805
   SUN AS, 1989, MUTAT RES, V219, P295, DOI 10.1016/0921-8734(89)90031-3
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wu GZ, 2014, CIRCULATION, V130, P1452, DOI 10.1161/CIRCULATIONAHA.114.011675
   Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004
   Yu LF, 2015, MOL MED REP, V12, P705, DOI 10.3892/mmr.2015.3383
   Zhai HY, 2013, CLIN COLORECTAL CANC, V12, P261, DOI 10.1016/j.clcc.2013.06.003
NR 19
TC 7
Z9 8
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD NOV
PY 2016
VL 12
IS 5
BP 3519
EP 3522
DI 10.3892/ol.2016.5096
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED4RR
UT WOS:000388838900072
PM 27900030
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Bertrand, K
AF Bertrand, Kaeffer
TI Survival of Exfoliated Epithelial Cells: A Delicate Balance between
   Anoikis and Apoptosis
SO JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
LA English
DT Review
ID GENE-EXPRESSION PROFILES; MOLECULAR-MECHANISMS; COLORECTAL-CANCER;
   CIRCADIAN-RHYTHM; BUCCAL MUCOSA; AUTOPHAGY; CLOCK; COLONOCYTES; TISSUE;
   STOOL
AB The recovery of exfoliated cells from biological fluids is a noninvasive technology which is in high demand in the field of translational research. Exfoliated epithelial cells can be isolated from several body fluids (i.e., breast milk, urines, and digestives fluids) as a cellular mixture (senescent, apoptotic, proliferative, or quiescent cells). The most intriguing are quiescent cells which can be used to derive primary cultures indicating that some phenotypes retain clonogenic potentials. Such exfoliated cells are believed to enter rapidly in anoikis after exfoliation. Anoikis can be considered as an autophagic state promoting epithelial cell survival after a timely loss of contact with extracellular matrix and cell neighbors. This paper presents current understanding of exfoliation along with the influence of methodology on the type of gastrointestinal epithelial cells isolated and, finally, speculates on the balance between anoikis and apoptosis to explain the survival of gastrointestinal epithelial cells in the environment.
C1 UMR Phan 1280, F-44000 Nantes, France.
RP Bertrand, K (corresponding author), UMR Phan 1280, Pl Alexis Ricordeau, F-44000 Nantes, France.
EM bertrand.kaeffer@univ-nantes.fr
OI Kaeffer, Bertrand/0000-0003-2459-5072
FU Departement Alimentation Humaine (Inra, France); Region Pays de la
   Loire, FranceRegion Pays de la Loire
FX The author is grateful for 2 financial supports: ANSSD-2008 from
   Departement Alimentation Humaine (Inra, France); PremaCol-2008 (Region
   Pays de la Loire, France).
CR ALBAUGH GP, 1992, INT J CANCER, V52, P347, DOI 10.1002/ijc.2910520303
   Alenghat T, 2008, NATURE, V456, P997, DOI 10.1038/nature07541
   Altieri DC, 2008, ONCOGENE, V27, P6276, DOI 10.1038/onc.2008.303
   Aoyama F, 2008, HISTOCHEM CELL BIOL, V129, P785, DOI 10.1007/s00418-008-0403-1
   Bandaletova T, 2002, APMIS, V110, P239, DOI 10.1034/j.1600-0463.2002.100306.x
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Brown SA, 2005, PLOS BIOL, V3, P1813, DOI 10.1371/journal.pbio.0030338
   BUCHI KN, 1991, GASTROENTEROLOGY, V101, P410, DOI 10.1016/0016-5085(91)90019-H
   Burscha W, 2008, TOXICOLOGY, V254, P147, DOI 10.1016/j.tox.2008.07.048
   Cecconi F, 2008, DEV CELL, V15, P344, DOI 10.1016/j.devcel.2008.08.012
   Chandel DS, 2011, PEDIATR RES, V70, P153, DOI 10.1203/PDR.0b013e3182225ac9
   Chapkin RS, 2010, AM J PHYSIOL-GASTR L, V298, pG582, DOI 10.1152/ajpgi.00004.2010
   Chen A, 2010, J MATERN-FETAL NEO M, V23, P1172, DOI 10.3109/14767051003677947
   Chiou SK, 2011, BIOCHEM PHARMACOL, V81, P1317, DOI 10.1016/j.bcp.2011.03.019
   Davidson LA, 2003, BIOMARKERS, V8, P51, DOI 10.1080/1354750021000042268
   Davis CD, 2003, J NUTR, V133, P1769, DOI 10.1093/jn/133.6.1769
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Felix J S, 1980, Birth Defects Orig Artic Ser, V16, P231
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375
   Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092
   Gallego M, 2007, NAT REV MOL CELL BIO, V8, P139, DOI 10.1038/nrm2106
   Gan BY, 2006, J BIOL CHEM, V281, P37321, DOI 10.1074/jbc.M605241200
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Godlewski MM, 2007, J PHYSIOL PHARMACOL, V58, P97
   Gomes JR, 2005, CELL PROLIFERAT, V38, P147, DOI 10.1111/j.1365-2184.2005.00339.x
   Guo HG, 2006, J NEUROSCI, V26, P6406, DOI 10.1523/JNEUROSCI.4676-05.2006
   HAUS E, 1984, Chronobiology International, V1, P185, DOI 10.3109/07420528409063895
   Hausmann M, 2011, J BIOL CHEM, V286, P26533, DOI 10.1074/jbc.M111.265322
   Holland N, 2007, PEDIATR RES, V61, P209, DOI 10.1203/pdr.0b013e31802d77c7
   Iwakiri R, 2001, SCAND J GASTROENTERO, V36, P39, DOI 10.1080/00365520150218048
   Kaeffer B, 2005, IN VITRO CELL DEV-AN, V41, P311
   Kaeffer B, 2002, IN VITRO CELL DEV-AN, V38, P123
   KAEFFER B, 2009, P 11 C EUR BIOL RHYT
   KAEFFER B, 2010, Patent No. 1054245
   Kaeffer B, 2007, PEDIATR RES, V62, P564, DOI 10.1203/PDR.0b013e318155a402
   Kalhan SC, 2007, CURR OPIN CLIN NUTR, V10, P69, DOI 10.1097/MCO.0b013e328011924d
   Kamra A, 2005, J NUTR, V135, P2719, DOI 10.1093/jn/135.11.2719
   KARAM SM, 1999, FRONT BIOSCI, V4, P286
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kitazawa H, 2004, J BIOL CHEM, V279, P42867, DOI 10.1074/jbc.M408047200
   Klein P, 2001, Breast J, V7, P378, DOI 10.1046/j.1524-4741.2001.07601.x
   Klionsky DJ, 2005, CURR BIOL, V15, pR282, DOI 10.1016/j.cub.2005.04.013
   Kotoulas OB, 2006, PATHOL RES PRACT, V202, P631, DOI 10.1016/j.prp.2006.04.001
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Liu Z, 2006, ONCOGENE, V25, P7680, DOI 10.1038/sj.onc.1209753
   Loboda A, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-7
   Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002
   LOKTIONOV A, 2006, Patent No. 2006003447
   Loktionov A, 2007, INT J CANCER, V120, P2281, DOI 10.1002/ijc.22647
   MARRA G, 1994, GASTROENTEROLOGY, V106, P982, DOI 10.1016/0016-5085(94)90757-9
   Martinet W, 2006, AUTOPHAGY, V2, P55, DOI 10.4161/auto.2217
   Massey AC, 2006, AUTOPHAGY, V2, P325, DOI 10.4161/auto.3090
   Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271
   Mizushima N, 2004, MOL BIOL CELL, V15, P1101, DOI 10.1091/mbc.E03-09-0704
   Mojica WD, 2005, CANCER CYTOPATHOL, V105, P483, DOI 10.1002/cncr.21347
   Mojica WD, 2007, BMC CLIN PATHOL, V7, DOI 10.1186/1472-6890-7-7
   MOLDENHAUER G, 1987, BRIT J CANCER, V56, P714, DOI 10.1038/bjc.1987.276
   MUNOZ N, 1987, J NATL CANCER I, V79, P687
   Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/S0092-8674(04)01054-2
   Nair P, 2003, J CLIN GASTROENTEROL, V36, pS84, DOI 10.1097/00004836-200305001-00015
   Orozco-Solis R, 2011, INT J OBESITY, V35, P990, DOI 10.1038/ijo.2010.223
   Osborn NK, 2005, GASTROENTEROLOGY, V128, P192, DOI 10.1053/j.gastro.2004.10.041
   Polidarova L, 2009, CHRONOBIOL INT, V26, P607, DOI 10.1080/07420520902924889
   POTTEN CS, 1990, DEVELOPMENT, V110, P1001
   QIU JM, 1994, EPITHELIAL CELL BIOL, V3, P137
   Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699
   ROBINE N, 1988, BIOL NEONATE, V54, P93
   Roca H, 2008, AUTOPHAGY, V4, P969, DOI 10.4161/auto.6822
   Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698
   Sachdeva UM, 2008, AUTOPHAGY, V4, P581, DOI 10.4161/auto.6141
   SHEIBANI K, 1991, AM J SURG PATHOL, V15, P779, DOI 10.1097/00000478-199108000-00008
   Steinau M, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-64
   STICH HF, 1984, INT J CANCER, V34, P745, DOI 10.1002/ijc.2910340602
   Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490
   Sumova A, 2006, FEBS LETT, V580, P2836, DOI 10.1016/j.febslet.2006.03.023
   Thompson PA, 1998, CANCER EPIDEM BIOMAR, V7, P37
   Van Lieshout EMM, 2004, SCAND J GASTROENTERO, V39, P852, DOI 10.1080/00365520410006891
   Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705
   Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542
   Yan SR, 2005, ONCOGENE, V24, P6482, DOI 10.1038/sj.onc.1208810
NR 82
TC 16
Z9 16
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1110-7243
EI 1110-7251
J9 J BIOMED BIOTECHNOL
JI J. Biomed. Biotechnol.
PY 2011
AR 534139
DI 10.1155/2011/534139
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 868EW
UT WOS:000298507500001
PM 22131811
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Su, M
   Zhang, Z
   Zhou, L
   Han, C
   Huang, CH
   Nice, EC
AF Su, Miao
   Zhang, Zhe
   Zhou, Li
   Han, Chao
   Huang, Canhua
   Nice, Edouard C.
TI Proteomics, Personalized Medicine and Cancer
SO CANCERS
LA English
DT Review
DE personalized; precision medicine; proteomics; cancer; biomarkers;
   microbiome; HUPO
ID SINGLE-CELL DATA; INTEGRATED PROTEOGENOMIC CHARACTERIZATION;
   COLORECTAL-CANCER; LUNG-CANCER; MASS-SPECTROMETRY; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; FUSOBACTERIUM-NUCLEATUM; PANCREATIC-CANCER;
   HELICOBACTER-PYLORI
AB Simple Summary
   Cancer, a major public health issue worldwide, is the second most common cause of death. Initiatives such as the Human Genome Project (HGP) and Human Proteome Project (HPP) have greatly advanced the understanding of human health and disease, including cancer, and are supporting the current trend towards personalized/precision medicine. In this review, we will overview recent technological achievements, the key hallmarks of cancer, and unmet clinical needs. We will specifically detail the importance of cancer biomarkers in diagnosis and treatment, the role of the microbiome in health and disease, the potential of emerging omics technologies and the goals of personalized/precision medicine. Finally, we will discuss future perspectives, both from the standpoint of perceived advances in treatment, but also from the hurdles that have to be overcome.
   As of 2020 the human genome and proteome are both at >90% completion based on high stringency analyses. This has been largely achieved by major technological advances over the last 20 years and has enlarged our understanding of human health and disease, including cancer, and is supporting the current trend towards personalized/precision medicine. This is due to improved screening, novel therapeutic approaches and an increased understanding of underlying cancer biology. However, cancer is a complex, heterogeneous disease modulated by genetic, molecular, cellular, tissue, population, environmental and socioeconomic factors, which evolve with time. In spite of recent advances in treatment that have resulted in improved patient outcomes, prognosis is still poor for many patients with certain cancers (e.g., mesothelioma, pancreatic and brain cancer) with a high death rate associated with late diagnosis. In this review we overview key hallmarks of cancer (e.g., autophagy, the role of redox signaling), current unmet clinical needs, the requirement for sensitive and specific biomarkers for early detection, surveillance, prognosis and drug monitoring, the role of the microbiome and the goals of personalized/precision medicine, discussing how emerging omics technologies can further inform on these areas. Exemplars from recent onco-proteogenomic-related publications will be given. Finally, we will address future perspectives, not only from the standpoint of perceived advances in treatment, but also from the hurdles that have to be overcome.
C1 [Su, Miao; Zhang, Zhe; Zhou, Li; Han, Chao; Huang, Canhua] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Su, Miao; Zhang, Zhe; Zhou, Li; Han, Chao; Huang, Canhua] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Peoples R China.
   [Su, Miao; Zhang, Zhe; Zhou, Li; Han, Chao; Huang, Canhua] Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China.
   [Su, Miao; Zhang, Zhe; Zhou, Li; Han, Chao; Huang, Canhua] Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.
   [Nice, Edouard C.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
RP Huang, CH (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Chengdu 610041, Peoples R China.; Huang, CH (corresponding author), Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Chengdu 610041, Peoples R China.; Huang, CH (corresponding author), Collaborat Innovat Ctr Biotherapy, Chengdu 610041, Peoples R China.; Nice, EC (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
EM 2019224065144@stu.scu.edu.cn; scuzz@stu.scu.edu.cn;
   2015224060079@stu.scu.edu.cn; 2017141494205@stu.scu.edu.cn;
   hcanhua@scu.edu.cn; ed.nice@monash.edu
OI Nice, Edouard/0000-0001-5480-4715; Zhang, Zhe/0000-0001-7509-6965
FU Chinese NSFCNational Natural Science Foundation of China (NSFC)
   [81821002, 81790251]; National Key Research and Development Project of
   China [2020YFA0509400, 2020YFC2002705]; Guangdong Basic and Applied
   Basic Research Foundation [2019B030302012]; Sichuan Applied Basic
   Research Project [2020YJ0107]
FX This researchwas funded by the Chinese NSFC, grant number 81821002, and
   81790251; National Key Research and Development Project of China, grant
   number 2020YFA0509400, and 2020YFC2002705; Guangdong Basic and Applied
   Basic Research Foundation, grant number 2019B030302012, and Sichuan
   Applied Basic Research Project, grant number (2020YJ0107).
CR Abe Y, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29837-1
   Adhikari S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19045-9
   Agus DB, 2021, LANCET ONCOL, V22, P164, DOI 10.1016/S1470-2045(21)00003-6
   Ahn SB, 2019, CLIN PROTEOM, V16, DOI 10.1186/s12014-019-9255-z
   Ahn SB, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201900026
   Aikawa A, 2019, CANCER SCI, V110, P2667, DOI 10.1111/cas.14093
   Al-wajeeh AS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227404
   Alanazi B, 2020, LEUKEMIA, V34, P427, DOI 10.1038/s41375-019-0596-4
   Ali HR, 2020, NAT CANCER, V1, P163, DOI 10.1038/s43018-020-0026-6
   Ali MRK, 2016, J AM CHEM SOC, V138, P15434, DOI 10.1021/jacs.6b08787
   Alshamsan A, 2017, SAUDI PHARM J, V25, P1151, DOI 10.1016/j.jsps.2017.05.007
   Martins BAA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01284
   Ambartsumian Noona, 2019, Methods Mol Biol, V1929, P339, DOI 10.1007/978-1-4939-9030-6_22
   Amir ED, 2013, NAT BIOTECHNOL, V31, P545, DOI 10.1038/nbt.2594
   Anand S, 2017, METHODS MOL BIOL, V1549, P31, DOI 10.1007/978-1-4939-6740-7_4
   Ang CS, 2011, ELECTROPHORESIS, V32, P1926, DOI 10.1002/elps.201000502
   [Anonymous], 2017, CANCER CELL, V32, P185, DOI DOI 10.1016/J.CCELL.2017.07.007
   [Anonymous], 2021, FINANC TIMES, P14
   Anttalainen O, 2020, INT J ION MOBIL SPEC, V23, P1, DOI 10.1007/s12127-019-00251-1
   Aranda F, 2015, ONCOGENE, V34, P3053, DOI 10.1038/onc.2014.234
   Arora A, 2019, BIOESSAYS, V41, DOI 10.1002/bies.201800042
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Babu HKRR, 2018, BIOSENS BIOELECTRON, V122, P290, DOI 10.1016/j.bios.2018.09.051
   Bachi A, 2013, CHEM REV, V113, P596, DOI 10.1021/cr300073p
   Baharlou H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02657
   Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920
   Bauer M, 2014, J PROTEOME RES, V13, P5973, DOI 10.1021/pr500860c
   Bereta M, 2007, VACCINE, V25, P4183, DOI 10.1016/j.vaccine.2007.03.008
   Bergmann KR, 2013, AM J PATHOL, V182, P1595, DOI 10.1016/j.ajpath.2013.01.013
   Biot C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003586
   Bjorling E, 2008, MOL CELL PROTEOMICS, V7, P2028, DOI 10.1074/mcp.M800264-MCP200
   Boehm JS, 2021, NATURE, V589, P514, DOI 10.1038/d41586-021-00182-0
   Bolhassani A, 2017, EXPERT OPIN BIOL TH, V17, P1389, DOI 10.1080/14712598.2017.1366446
   Borras E, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201700180
   Bosch LJW, 2017, ANN INTERN MED, V167, P855, DOI 10.7326/M17-1068
   Bourmaud A, 2016, PROTEOMICS, V16, P2146, DOI 10.1002/pmic.201500543
   Brown KA, 2020, EXPERT REV PROTEOMIC, V17, P719, DOI 10.1080/14789450.2020.1855982
   Bruning U, 2018, CELL METAB, V28, P866, DOI 10.1016/j.cmet.2018.07.019
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Burckhardt I, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01744
   Cai YD, 2021, BBA-PROTEINS PROTEOM, V1869, DOI 10.1016/j.bbapap.2020.140560
   Califf RM, 2018, EXP BIOL MED, V243, P213, DOI 10.1177/1535370217750088
   Callaway E, 2020, NATURE, V588, P203, DOI 10.1038/d41586-020-03348-4
   Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764
   Cantor DI, 2015, EXPERT REV PROTEOMIC, V12, P279, DOI 10.1586/14789450.2015.1040770
   Capello M, 2016, ONCOTARGET, V7, P5598, DOI 10.18632/oncotarget.6798
   Chen DF, 2019, INT J CANCER, V145, P2021, DOI 10.1002/ijc.32003
   Chen JZ, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051026
   Chen XL, 2015, PROTEOMICS, V15, P3175, DOI 10.1002/pmic.201500108
   Cheng SS, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00137-18
   Chew V, 2017, P NATL ACAD SCI USA, V114, pE5900, DOI 10.1073/pnas.1706559114
   Chumduri C, 2013, CELL HOST MICROBE, V13, P746, DOI 10.1016/j.chom.2013.05.010
   Cifani P, 2017, MOL CELL PROTEOMICS, V16, P2006, DOI 10.1074/mcp.RA117.000023
   Collins BC, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00249-5
   Coscia F, 2018, CELL, V175, P159, DOI 10.1016/j.cell.2018.08.065
   Cristobal A, 2017, CELL REP, V18, P263, DOI 10.1016/j.celrep.2016.12.016
   Cuomo A, 2011, AMINO ACIDS, V41, P387, DOI 10.1007/s00726-010-0668-2
   Da ZJ, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01212-z
   Dai LP, 2017, ONCOTARGET, V8, P36664, DOI 10.18632/oncotarget.17067
   Dapito DH, 2012, CANCER CELL, V21, P504, DOI 10.1016/j.ccr.2012.02.007
   Das T, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.578345
   Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363
   Chantada-Vazquez MD, 2020, J PROTEOMICS, V212, DOI 10.1016/j.jprot.2019.103581
   Diaz P, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00005
   Dietrich S, 2018, J CLIN INVEST, V128, P427, DOI 10.1172/JCI93801
   Do M, 2020, CLIN CHEM, V66, P1339, DOI 10.1093/clinchem/hvaa178
   Doerr A, 2015, NAT METHODS, V12, P35, DOI 10.1038/nmeth.3234
   Droller MJ, 2017, J UROLOGY, V197, pS146, DOI 10.1016/j.juro.2016.10.083
   Dunn J, 2019, EBIOMEDICINE, V40, P77, DOI 10.1016/j.ebiom.2018.12.048
   Duong VA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041524
   Eckert MA, 2019, NATURE, V569, P723, DOI 10.1038/s41586-019-1173-8
   Edwards NJ, 2015, J PROTEOME RES, V14, P2707, DOI 10.1021/pr501254j
   Ewaschuk JB, 2008, AM J PHYSIOL-GASTR L, V295, pG1025, DOI 10.1152/ajpgi.90227.2008
   Fang HM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8941340
   Felfoul O, 2016, NAT NANOTECHNOL, V11, P941, DOI [10.1038/nnano.2016.137, 10.1038/NNANO.2016.137]
   Felgner Sebastian, 2016, Int J Microbiol, V2016, P8451728, DOI 10.1155/2016/8451728
   Flickinger JC, 2018, VACCINES-BASEL, V6, DOI 10.3390/vaccines6030048
   Gallien S, 2014, J PROTEOMICS, V100, P147, DOI 10.1016/j.jprot.2013.10.029
   Garralda E, 2019, MOL ONCOL, V13, P549, DOI 10.1002/1878-0261.12465
   Gessulat S, 2019, NAT METHODS, V16, P509, DOI 10.1038/s41592-019-0426-7
   Ghahremanifard P, 2020, CANCERS, V12, DOI 10.3390/cancers12123650
   Gillet LC, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016717
   Gillette MA, 2020, CELL, V182, P200, DOI 10.1016/j.cell.2020.06.013
   Giulietti M, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11020206
   Graham DY, 2015, GASTROENTEROLOGY, V148, P719, DOI 10.1053/j.gastro.2015.01.040
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   Guo SH, 2021, GUT, V70, P1507, DOI 10.1136/gutjnl-2020-321187
   Guo TN, 2015, NAT MED, V21, P407, DOI 10.1038/nm.3807
   Gur C, 2015, IMMUNITY, V42, P344, DOI 10.1016/j.immuni.2015.01.010
   Hallal S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134754
   Han DJ, 2013, YONSEI MED J, V54, P1186, DOI 10.3349/ymj.2013.54.5.1186
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He L, 2019, J BIOL ENG, V13, DOI 10.1186/s13036-019-0189-9
   He YJ, 2019, CLIN CHIM ACTA, V495, P611, DOI 10.1016/j.cca.2019.06.006
   Helfinger V, 2018, MOL ASPECTS MED, V63, P88, DOI 10.1016/j.mam.2018.02.003
   Herr HW, 2008, J UROLOGY, V179, P53, DOI 10.1016/j.juro.2007.08.122
   Ho M.-W., 2013, J AUSTRALAS COLL NUT, V32, P12
   Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Honda K, 2015, SCI REP-UK, V5, DOI 10.1038/srep15921
   Honda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046908
   Ibrahim S, 2020, ANAL CHEM, V92, P12407, DOI 10.1021/acs.analchem.0c02157
   Ijiri M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317711311
   Jafri MA, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0324-x
   JAIN M, 1989, AM J EPIDEMIOL, V129, P422, DOI 10.1093/oxfordjournals.aje.a115146
   Jia MT, 2020, NAT IMMUNOL, V21, P727, DOI 10.1038/s41590-020-0699-0
   Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040
   Kalev P, 2021, CANCER CELL, V39, P209, DOI 10.1016/j.ccell.2020.12.010
   Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8
   Karagiannis GS, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan0026
   Kaur G, 2021, J PROTEOME RES, V20, P1261, DOI 10.1021/acs.jproteome.0c00670
   Kita A, 2020, INT J ONCOL, V57, P721, DOI 10.3892/ijo.2020.5096
   Kolch W, 2005, CLIN SCI, V108, P369, DOI 10.1042/CS20050006
   Konishi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12365
   Kono M, 2017, J ORAL MAXIL SURG, V75, P336, DOI 10.1016/j.joms.2016.08.013
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kota U, 2016, ADV EXP MED BIOL, V919, P83, DOI 10.1007/978-3-319-41448-5_5
   Krug K, 2020, CELL, V183, P1436, DOI 10.1016/j.cell.2020.10.036
   Kumar V, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.543997
   Kusebauch U, 2016, CELL, V166, P766, DOI 10.1016/j.cell.2016.06.041
   Labib M, 2020, NAT REV CHEM, V4, P143, DOI 10.1038/s41570-020-0162-7
   Lahnemann D, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-1926-6
   Lagier JC, 2012, CLIN MICROBIOL INFEC, V18, P1185, DOI 10.1111/1469-0691.12023
   Lai ZW, 2012, ACS NANO, V6, P10438, DOI 10.1021/nn3052499
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014
   Lee Jung-Woo, 2004, J Vet Sci, V5, P41
   Lee SH, 2016, LUNG CANCER, V102, P89, DOI 10.1016/j.lungcan.2016.10.016
   Li AL, 2020, CANCER-AM CANCER SOC, V126, P4838, DOI 10.1002/cncr.33205
   Li B, 2018, TRANSL PSYCHIAT, V8, DOI 10.1038/s41398-017-0078-2
   Li BW, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100720
   Li JW, 2015, SCI REP-UK, V5, DOI 10.1038/srep17903
   Li J, 2017, CANCER CELL, V31, P225, DOI 10.1016/j.ccell.2017.01.005
   Lim ZF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0818-2
   Lin HF, 2019, EXPERT REV PROTEOMIC, V16, P501, DOI 10.1080/14789450.2018.1523724
   Lin P, 2019, J PROTEOMICS, V204, DOI 10.1016/j.jprot.2019.103414
   Lindhorst PH, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.604492
   Liu S, 2014, ONCOL LETT, V8, P2359, DOI 10.3892/ol.2014.2525
   Liu TZ, 2017, THERANOSTICS, V7, P3138, DOI 10.7150/thno.19506
   Long SP, 2020, NPJ BIOFILMS MICROME, V6, DOI 10.1038/s41522-020-0123-4
   Ludwig C, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20178126
   Madhusoodanan J, 2020, NATURE, V585, pS13, DOI 10.1038/d41586-020-02678-7
   Martel S, 2017, THER DELIV, V8, P301, DOI 10.4155/tde-2016-0088
   Meyerson M, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.abc4218
   Middleton JD, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113333
   Midha MK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18901-y
   Ming H, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188519
   Mitra R, 2014, CANCER INFORM, V13, P79, DOI 10.4137/CIN.S13984
   Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992
   Moldogazieva NT, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020159
   Monroe AA, 2020, MOL ECOL RESOUR, V20, P1647, DOI 10.1111/1755-0998.13229
   Mori K, 2017, ONCOTARGET, V8, P106935, DOI 10.18632/oncotarget.22149
   Nejman D, 2020, SCIENCE, V368, P973, DOI 10.1126/science.aay9189
   Nesvizhskii AI, 2014, NAT METHODS, V11, P1114, DOI [10.1038/nmeth.3144, 10.1038/NMETH.3144]
   Nice EC, 2007, J CHROMATOGR A, V1168, P190, DOI 10.1016/j.chroma.2007.06.015
   Nice EC, 2021, BIOMED CHROMATOGR, V35, DOI 10.1002/bmc.4995
   Nice Edouard C, 2022, Anal Biochem, V644, P113840, DOI 10.1016/j.ab.2020.113840
   Nunez EV, 2017, METHODS MOL BIOL, V1546, P267, DOI 10.1007/978-1-4939-6730-8_23
   Ohayon S, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1007067
   Ohta N, 2010, LARYNGOSCOPE, V120, P2193, DOI 10.1002/lary.21141
   Ohta N, 2010, ACTA OTO-LARYNGOL, V130, P1287, DOI 10.3109/00016489.2010.483480
   Olivieri C, 2016, PEDIATR NEONATOL, V57, P240, DOI 10.1016/j.pedneo.2013.06.011
   Omenn GS, 2020, J PROTEOME RES, V19, P4735, DOI 10.1021/acs.jproteome.0c00485
   Pagliara V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197186
   Parhi L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16967-2
   Parker WB, 1997, HUM GENE THER, V8, P1637, DOI 10.1089/hum.1997.8.14-1637
   Patel VJ, 2009, J PROTEOME RES, V8, P3752, DOI 10.1021/pr900080y
   Patil S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01515
   Paton AW, 2012, TRENDS MOL MED, V18, P417, DOI 10.1016/j.molmed.2012.05.006
   Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703
   Pellegrino M, 2019, CANCERS, V11, DOI 10.3390/cancers11121858
   Petralia F, 2020, CELL, V183, P1962, DOI 10.1016/j.cell.2020.10.044
   Picardo SL, 2019, CRIT REV ONCOL HEMAT, V141, P1, DOI 10.1016/j.critrevonc.2019.06.004
   Ponomarenko EA, 2016, INT J ANAL CHEM, V2016, DOI 10.1155/2016/7436849
   Poulos RC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17641-3
   Powell Bradford S, 2012, Methods Mol Biol, V881, P27, DOI 10.1007/978-1-61779-827-6_2
   Prudova A, 2016, CELL REP, V16, P1762, DOI 10.1016/j.celrep.2016.06.086
   Qian XL, 2017, ONCOTARGET, V8, P47691, DOI 10.18632/oncotarget.17868
   Qiu Q, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.612202
   Rawla P, 2019, WORLD J ONCOL, V10, P10, DOI 10.14740/wjon1166
   Ren Y, 2015, CANCER LETT, V362, P174, DOI 10.1016/j.canlet.2015.03.038
   Reuben A, 2017, CANCER DISCOV, V7, P1088, DOI 10.1158/2159-8290.CD-17-0256
   Riley NM, 2016, CELL SYST, V2, P142, DOI 10.1016/j.cels.2016.03.002
   Rinke C, 2013, NATURE, V499, P431, DOI 10.1038/nature12352
   Rodrigues G, 2019, NAT CELL BIOL, V21, P1403, DOI 10.1038/s41556-019-0404-4
   Rodriguez H, 2018, CELL, V173, P533, DOI 10.1016/j.cell.2018.04.008
   Ronsein GE, 2015, J PROTEOMICS, V113, P388, DOI 10.1016/j.jprot.2014.10.017
   Rubinstein MR, 2019, EMBO REP, V20, DOI 10.15252/embr.201847638
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Russo P, 2017, METHODS MOL BIOL, V1606, P313, DOI 10.1007/978-1-4939-6990-6_20
   Sahni S, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2020.129682
   Sauer U, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17020256
   Schmitz-Winnenthal FH, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1303584
   Seng P, 2009, CLIN INFECT DIS, V49, P543, DOI 10.1086/600885
   Serada S, 2010, ANN RHEUM DIS, V69, P770, DOI 10.1136/ard.2009.118919
   Shen JJ, 2004, CANCER RES, V64, P9018, DOI 10.1158/0008-5472.CAN-04-3262
   Shenoy A, 2015, EXPERT REV PROTEOMIC, V12, P13, DOI 10.1586/14789450.2015.982538
   Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Specht H, 2018, J PROTEOME RES, V17, P2565, DOI 10.1021/acs.jproteome.8b00257
   Staedtke V, 2016, GENES DIS, V3, P144, DOI 10.1016/j.gendis.2016.01.003
   Stehling O, 2012, SCIENCE, V337, P195, DOI 10.1126/science.1219723
   Sung HJ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103213
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Swaminathan J, 2018, NAT BIOTECHNOL, V36, P1076, DOI 10.1038/nbt.4278
   Talevi A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00205
   Tan HY, 2021, HEPATOLOGY, V73, P2326, DOI 10.1002/hep.31600
   Tangney M, 2010, CURR GENE THER, V10, P46, DOI 10.2174/156652310790945539
   Thul PJ, 2017, SCIENCE, V356, DOI 10.1126/science.aal3321
   Timp W, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax8978
   Tunali I, 2021, CSH PERSPECT MED, V11, DOI 10.1101/cshperspect.a039537
   Tyanova S, 2018, METHODS MOL BIOL, V1711, P133, DOI 10.1007/978-1-4939-7493-1_7
   Uccello M, 2012, BMC SURG, V12, DOI 10.1186/1471-2482-12-S1-S35
   Ueno T, 2017, NAT REV GASTRO HEPAT, V14, P170, DOI 10.1038/nrgastro.2016.185
   Uhlen M, 2016, NAT METHODS, V13, P823, DOI [10.1038/nmeth.3995, 10.1038/NMETH.3995]
   van Ginkel J, 2018, P NATL ACAD SCI USA, V115, P3338, DOI 10.1073/pnas.1707207115
   Vasaikar SV, 2018, NUCLEIC ACIDS RES, V46, pD956, DOI 10.1093/nar/gkx1090
   Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040
   Verberkmoes NC, 2009, ISME J, V3, P179, DOI 10.1038/ismej.2008.108
   WASINGER VC, 1995, ELECTROPHORESIS, V16, P1090, DOI 10.1002/elps.11501601185
   Wei W, 2016, LEUKEMIA LYMPHOMA, V57, P2401, DOI 10.3109/10428194.2016.1144879
   Whiteaker JR, 2015, MOL CELL PROTEOMICS, V14, P2261, DOI 10.1074/mcp.O115.050351
   Whitman JD, 2019, CLIN CHEM, V65, P862, DOI 10.1373/clinchem.2018.300756
   Winter DL, 2019, TRENDS BIOTECHNOL, V37, P198, DOI 10.1016/j.tibtech.2018.07.018
   Wu PJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641469
   Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015
   Xiao HP, 2020, CELL, V180, P968, DOI 10.1016/j.cell.2020.02.012
   Xu JY, 2020, CELL, V182, P245, DOI 10.1016/j.cell.2020.05.043
   Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347
   Yu JK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14539-x
   Yu L, 2014, CLIN LUNG CANCER, V15, P372, DOI 10.1016/j.cllc.2014.05.003
   Yuan HM, 2019, ANAL CHEM, V91, P264, DOI 10.1021/acs.analchem.8b04894
   Yuan K, 2016, CELL DEATH DIFFER, V23, P616, DOI 10.1038/cdd.2015.129
   Zeng L, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6016-3
   Zhang B, 2019, NAT REV CLIN ONCOL, V16, P256, DOI 10.1038/s41571-018-0135-7
   Zhang FF, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.201900276
   Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069
   Zhang JH, 2020, PROSTATE, V80, P588, DOI 10.1002/pros.23972
   Zhang Q, 2018, ONCOTARGETS THER, V11, P2745, DOI 10.2147/OTT.S153375
   Zhang SW, 2021, CHEM COMMUN, V57, P737, DOI 10.1039/d0cc06493a
   Zhang Z, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.11.005
   Zhao W, 2020, CANCER CELL, V38, P829, DOI 10.1016/j.ccell.2020.10.008
   Zhao YH, 2020, J PROTEOMICS, V225, DOI 10.1016/j.jprot.2020.103780
   Zheng H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00068
   Zitvogel L, 2016, CELL, V165, P276, DOI 10.1016/j.cell.2016.03.001
NR 246
TC 5
Z9 5
U1 10
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUN
PY 2021
VL 13
IS 11
AR 2512
DI 10.3390/cancers13112512
PG 31
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SP3LJ
UT WOS:000659573500001
PM 34063807
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zupa, A
   Improta, G
   Silvestri, A
   Pin, E
   Deng, JH
   Aieta, M
   Musto, P
   Nitti, D
   Mammano, E
   Liotta, L
   Belluco, C
   Wulfkuhle, J
   Petricoin, E
AF Zupa, Angela
   Improta, Giuseppina
   Silvestri, Alessandra
   Pin, Elisa
   Deng, Jianghong
   Aieta, Michele
   Musto, Pellegrino
   Nitti, Donato
   Mammano, Enzo
   Liotta, Lance
   Belluco, Claudio
   Wulfkuhle, Julia
   Petricoin, Emanuel, III
TI A Pilot Characterization of Human Lung NSCLC by Protein Pathway
   Activation Mapping
SO JOURNAL OF THORACIC ONCOLOGY
LA English
DT Article
DE Cell signaling; Protein pathway activation mapping; Reverse-phase
   protein microarrays; Non-small-cell lung cancer
ID GROWTH-FACTOR RECEPTOR; SMALL-CELL-LUNG; LASER-CAPTURE MICRODISSECTION;
   TYROSINE KINASE INHIBITORS; EXPRESSION PROFILES; SIGNALING ANALYSIS;
   COLORECTAL-CANCER; POOR-PROGNOSIS; MESSENGER-RNA; EGFR MUTATION
AB Background: An understanding of the activated protein signaling architecture in non-small-cell lung cancer (NSCLC) is of critical importance to the development of new therapeutic approaches and identification of predictive and prognostic biomarkers for patient stratification.
   Methods: We used reverse-phase protein microarrays to map the activated protein signaling networks of 47 NSCLC tumors, 28 of which were node negative, which were subjected to tumor cellular enrichment using laser capture microdissection. The phosphorylation/cleavage levels of 111 key signaling proteins and total levels of 17 proteins were measured for broadscale signaling analysis.
   Results: Pathway activation mapping of NSCLC revealed distinct subgroups composed of epidermal growth factor receptor (ERBB1), v-erb-b2 erythroblastic leukemia viral oncogene homolog 2 (ERBB2), v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3), v-erb-a erythroblastic leukemia viral oncogene homolog 4 (ERBB4), v-akt murine thymoma viral oncogene homolog 1-mammalian target of rapamycin (AKT-mTOR), protein kinase, AMP-activated, alpha 2 catalytic subunit (AMPK), and autophagy-related signaling, along with transforming growth factor-beta-signaling protein 1 (SMAD), insulin-line growth factor receptor (IGFR), rearranged during transfection proto-oncogene (RET), and activated CDC42-associated kinase (ACK) activation. Investigation of epidermal growth factor receptor (EGFR)-driven signaling identified a unique cohort of tumors with low EGFR protein expression yet high relative levels of phosphorylated EGFR and high EGFR total protein with low relative levels of phosphorylation. Last, mapping analysis of patients with NSCLC with N0 disease revealed a pilot pathway activation signature composed of linked epidermal growth factor receptor family (HER)-AMPK-AKT-mTOR signaling network along with focal adhesion kinase-LIM domain kinase-1 (FAK-LIMK) and janus kinase (JAK)-signal transducers and activators of transcription (STAT) pathways that correlated with short-term survival and aggressive disease.
   Conclusions: Functional protein pathway activation mapping of NSCLC reveals distinct activation subgroups that are underpinned by important therapeutic targets and that patients with early-stage node negative disease and poor prognosis may be identified by activation of defined, biochemically linked protein signaling events. Such findings, if confirmed in larger study sets, could help select and stratify patients for personalized targeted therapies.
C1 [Deng, Jianghong; Wulfkuhle, Julia; Petricoin, Emanuel, III] George Mason Univ, Ctr Appl Prote & Mol Med, Manassas, VA 20110 USA.
   [Silvestri, Alessandra; Pin, Elisa; Liotta, Lance; Belluco, Claudio] Natl Canc Inst, CRO IRCCS, Aviano, Italy.
   [Nitti, Donato; Mammano, Enzo] Univ Padua, Clin Chirurg 2, Padua, Italy.
RP Petricoin, E (corresponding author), George Mason Univ, Ctr Appl Prote & Mol Med, 10900 Univ Blvd,MS 4E3, Manassas, VA 20110 USA.
EM epetrico@gmu.edu
RI aieta, michele/AAC-1978-2019; belluco, claudio/J-1339-2018
OI aieta, michele/0000-0001-9487-6238; PIN, ELISA/0000-0002-2158-2674;
   Silvestri, Alessandra/0000-0003-4891-1826; belluco,
   claudio/0000-0001-5972-9574; Musto, Pellegrino/0000-0003-3277-6594
FU U.S. law and George Mason University policy; Italian Istituto Superiore
   di Sanita; NATIONAL CANCER INSTITUTEUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USANIH National
   Cancer Institute (NCI) [R33CA157403] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Allergy & Infectious Diseases (NIAID)
   [R21AI099851, R21AI117425] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal
   & Skin Diseases (NIAMS) [R01AR068436] Funding Source: NIH RePORTER
FX J.W., L. L. and E. P. are inventors on U. S. government and/or
   University assigned patents and patent applications that cover aspects
   of the technologies discussed. As inventors, they are entitled to
   receive royalties as provided by U.S. law and George Mason University
   policy. J.W., L. L., and E. P. are consultants and shareholders of
   Theranostics Health, Inc. The authors declare no conflicts of interest.;
   The authors appreciate the generous support of Dr. Vikas Chandhoke and
   the College of Life Sciences at George Mason University. This work was
   partly supported by the Italian Istituto Superiore di Sanita within the
   framework Italy/USA cooperation agreement between the U.S. Department of
   Health and Human Services, George Mason University, and the Italian
   Ministry of Public Health.
CR Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333
   Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733
   Boyle P, 2005, ANN ONCOL, V16, P481, DOI 10.1093/annonc/mdi098
   Brambilla E, 2001, EUR RESPIR J, V18, P1059, DOI 10.1183/09031936.01.00275301
   Bryant CM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011712
   Carey KD, 2006, CANCER RES, V66, P8163, DOI 10.1158/0008-5472.CAN-06-0453
   Cohen MH, 2003, ONCOLOGIST, V8, P303, DOI 10.1634/theoncologist.8-4-303
   Dahabreh IJ, 2010, CLIN CANCER RES, V16, P291, DOI 10.1158/1078-0432.CCR-09-1660
   Dhillon T, 2010, J THORAC ONCOL, V5, P314, DOI 10.1097/JTO.0b013e3181ce6604
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Engelman JA, 2006, CLIN CANCER RES, V12, p4372S, DOI 10.1158/1078-0432.CCR-06-0795
   Espina V, 2006, NAT PROTOC, V1, P586, DOI 10.1038/nprot.2006.85
   Franceschi S, 1999, ANN ONCOL, V10, P3, DOI 10.1023/A:1008379532307
   Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a
   Gordon GJ, 2003, CANCER EPIDEM BIOMAR, V12, P905
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Havaleshko DM, 2009, NEOPLASIA, V11, P1185, DOI 10.1593/neo.09898
   Hayes DN, 2006, J CLIN ONCOL, V24, P5079, DOI 10.1200/JCO.2005.05.1748
   Janku F, 2010, NAT REV CLIN ONCOL, V7, P401, DOI 10.1038/nrclinonc.2010.64
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jeon HS, 2010, J THORAC ONCOL, V5, P417, DOI 10.1097/JTO.0b013e3181ce3afd
   Kadara H, 2011, CLIN CANCER RES, V17, P1490, DOI 10.1158/1078-0432.CCR-10-2703
   Kurie JM, 1996, CLIN CANCER RES, V2, P1787
   Larsen JE, 2007, CLIN CANCER RES, V13, P2946, DOI 10.1158/1078-0432.CCR-06-2525
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Machida K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013470
   Maione P, 2006, ONCOLOGIST, V11, P274, DOI 10.1634/theoncologist.11-3-274
   McMillen E, 2010, EXP LUNG RES, V36, P531, DOI 10.3109/01902148.2010.482176
   Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003
   Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082
   Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992
   Nanjundan M, 2010, J THORAC ONCOL, V5, P1894, DOI 10.1097/JTO.0b013e3181f2a266
   Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3
   Ohsaki Y, 2000, ONCOL REP, V7, P603
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Patnaik SK, 2010, CANCER RES, V70, P36, DOI 10.1158/0008-5472.CAN-09-3153
   Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265
   Pierobon M, 2009, CLIN COLORECTAL CANC, V8, P110, DOI 10.3816/CCC.2009.n.018
   Piyathilake CJ, 2002, CLIN CANCER RES, V8, P734
   Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846
   Rosell R, 2010, CURR OPIN ONCOL, V22, P112, DOI 10.1097/CCO.0b013e32833500d2
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Scagliotti GV, 2004, CLIN CANCER RES, V10, p4227S, DOI 10.1158/1078-0432.CCR-040007
   Shankavaram UT, 2007, MOL CANCER THER, V6, P820, DOI 10.1158/1535-7163.MCT-06-0650
   Silvestri A, 2010, LAB INVEST, V90, P787, DOI 10.1038/labinvest.2010.47
   Tang JM, 2006, LUNG CANCER, V51, P181, DOI 10.1016/j.lungcan.2005.10.003
   TRAVIS WD, 1995, CANCER-AM CANCER SOC, V75, P191, DOI 10.1002/1097-0142(19950101)75:1+<191::AID-CNCR2820751307>3.0.CO;2-Y
   VanMeter AJ, 2008, MOL CELL PROTEOMICS, V7, P1902, DOI 10.1074/mcp.M800204-MCP200
   Wang YT, 2010, J PROTEOME RES, V9, P5582, DOI 10.1021/pr100394u
   Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358
   Wulfkuhle JD, 2008, J PROTEOME RES, V7, P1508, DOI 10.1021/pr7008127
   Yang DK, 2009, HUM PATHOL, V40, P464, DOI 10.1016/j.humpath.2008.10.001
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yoshizawa A, 2010, CLIN CANCER RES, V16, P240, DOI 10.1158/1078-0432.CCR-09-0986
   Yu GC, 2011, MOL BIOSYST, V7, P472, DOI 10.1039/c0mb00055h
   Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017
   Zhang GL, 2011, J PROTEOME RES, V10, P305, DOI 10.1021/pr1006203
NR 63
TC 23
Z9 23
U1 1
U2 12
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1556-0864
J9 J THORAC ONCOL
JI J. Thorac. Oncol.
PD DEC
PY 2012
VL 7
IS 12
BP 1755
EP 1766
DI 10.1097/JTO.0b013e3182725fc7
PG 12
WC Oncology; Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Respiratory System
GA 041GM
UT WOS:000311387700013
PM 23154546
OA Green Accepted, Bronze
DA 2022-04-25
ER

PT J
AU Sugito, N
   Heishima, K
   Ito, Y
   Akao, Y
AF Sugito, Nobuhiko
   Heishima, Kazuki
   Ito, Yuko
   Akao, Yukihiro
TI Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by
   Interrupting RAS Pathways Including PAX3-FOXO1
SO CANCERS
LA English
DT Article
DE RMS; PAX3-FOXO1; MIR143-3p; KRAS; NRAS
ID MUSCLE-SPECIFIC MICRORNA; BLADDER-CANCER; OSTEOSARCOMA CELLS;
   TUMOR-SUPPRESSOR; IN-VITRO; FUSION; EXPRESSION; PAX3-FKHR; APOPTOSIS;
   MIR-143
AB Simple Summary
   Rhabdomyosarcoma (RMS) is a soft tissue sarcoma with embryonal (ERMS) and alveoral (ARMS) features, most frequently found in children. ARMS has the worse prognosis due to the formation of the chimeric PAX3-FOXO1 gene. New therapies are needed for the treatment of ARMS. The aim of this study is to evaluate the anticancer effect of chemically-modified MIR143-3p#12 (CM-MIR143#12) on RMS. The ectopic expression of CM-MIR143#12 induced a cell growth suppression by silencing not only KRAS, AKT, and ERK but also the PAX3-FOXO1 chimeric gene, and KRAS networks could control the expression of chimeric PAX3-FOXO1 in ARMS cells. Moreover, CM-MIR143#12 also silenced NRAS mutant in ERMS RD cells. CM-MIR143#12 can be a new nucleic acid medicine for the treatment of RMS by impairing the RAS networks including PAX3-FOXO1.
   Rhabdomyosarcoma (RMS) is a soft tissue sarcoma most frequently found in children. In RMS, there are two major subtypes, embryonal RMS (ERMS) and alveolar RMS (ARMS). ARMS has the worse prognosis of the two owing to the formation of the chimeric PAX3-FOXO1 gene. A novel therapeutic method is required for treating ARMS. In our previous study, we found that the ectopic expression of chemically modified MIR143-3p#12 (CM-MIR143#12), which is RNase-resistant and shows the highest anti-proliferation activity among the synthesized MIR143 derivatives that were tested, induces significant cell growth suppression by targeting KRAS, AKT, and ERK in colorectal cancer cells. The expression of MIR143-3p in RMS was dramatically downregulated compared with that of normal tissue. Ectopic expression of CM-MIR143#12 in RMS cells resulted in a significant growth inhibitory effect through the induction of apoptosis and autophagy. Interestingly, we found that CM-MIR143#12 also silenced the expression of chimeric PAX3-FOXO1 directly and, using siR-KRAS or siR-AKT, that KRAS networks regulated the expression of PAX3-FOXO1 in ARMS cells. In ERMS harboring NRAS mutation, CM-MIR143#12 silenced mutated NRAS. These findings indicate that CM-MIR143#12 efficiently perturbed the RAS signaling pathway, including the ARMS-specific KRAS/PAX3-FOXO1 networks.
C1 [Sugito, Nobuhiko; Heishima, Kazuki; Akao, Yukihiro] Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagido, Gifu 5011194, Japan.
   [Ito, Yuko] Osaka Med Coll, Div Life Sci, Dept Anat & Cell Biol, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.
RP Akao, Y (corresponding author), Gifu Univ, United Grad Sch Drug Discovery & Med Informat Sci, 1-1 Yanagido, Gifu 5011194, Japan.
EM nsugito@gifu-u.ac.jp; heishima@gifu-u.ac.jp; an1006@osaka-med.ac.jp;
   yakao@gifu-u.ac.jp
RI Heishima, Kazuki/J-6233-2019
OI Heishima, Kazuki/0000-0002-4629-8661; Sugito,
   Nobuhiko/0000-0003-1892-9005
FU Project for Cancer Research and Therapeutic Evolution (P-CREATE) from
   the Japan Agency for Medical Research and Development (AMED)Japan Agency
   for Medical Research and Development (AMED) [16cm0106202 h0001]
FX This work was supported by the Project for Cancer Research and
   Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical
   Research and Development (AMED; 16cm0106202 h0001 to Y.A.).
CR Ahmad I, 2013, BRIT J CANCER, V108, P149, DOI 10.1038/bjc.2012.510
   Akao Y, 2007, CANCER SCI, V98, P1914, DOI 10.1111/j.1349-7006.2007.00618.x
   Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Akao Y, 2018, CANCER SCI, V109, P1455, DOI 10.1111/cas.13559
   Akao Y, 2009, LEUKEMIA RES, V33, P1530, DOI 10.1016/j.leukres.2009.04.019
   Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8
   Anderson MJ, 2001, P NATL ACAD SCI USA, V98, P1589, DOI 10.1073/pnas.98.4.1589
   Arnold MA, 2017, EXPERT REV MOL DIAGN, V17, P189, DOI 10.1080/14737159.2017.1275965
   Chen C, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01458
   Cheng TL, 2014, INT J ONCOL, V45, P1977, DOI 10.3892/ijo.2014.2623
   Choo KB, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0095-x
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Crose LES, 2012, CLIN CANCER RES, V18, P3780, DOI 10.1158/1078-0432.CCR-10-3063
   Dolgikh N, 2018, CANCER RES, V78, P2000, DOI 10.1158/0008-5472.CAN-17-1737
   FELIX CA, 1992, CANCER RES, V52, P2243
   FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522
   GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230
   Gary DJ, 2007, J CONTROL RELEASE, V121, P64, DOI 10.1016/j.jconrel.2007.05.021
   Gokita K, 2020, MOL THER-NUCL ACIDS, V19, P330, DOI 10.1016/j.omtn.2019.10.045
   Hanna JA, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.159
   Hosoi H, 2016, PEDIATR INT, V58, P81, DOI 10.1111/ped.12867
   Hou Y, 2019, ARTIF CELL NANOMED B, V47, P2065, DOI 10.1080/21691401.2019.1620252
   Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Li WH, 2016, BIOMED PHARMACOTHER, V80, P8, DOI 10.1016/j.biopha.2016.03.001
   Lin XT, 2018, INFLAMM BOWEL DIS, V24, P781, DOI 10.1093/ibd/izx075
   Liu H, 2015, INT J CLIN EXP PATHO, V8, P14241
   Liu XY, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.172376
   Marshall AD, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-25
   Meza JL, 2006, J CLIN ONCOL, V24, P3844, DOI 10.1200/JCO.2005.05.3801
   Minami K, 2017, ONCOTARGET, V8, P33064, DOI 10.18632/oncotarget.16524
   Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591
   Miyachi M, 2010, BIOCHEM BIOPH RES CO, V400, P89, DOI 10.1016/j.bbrc.2010.08.015
   Nakagawa N, 2019, BIOCHEM BIOPH RES CO, V512, P524, DOI 10.1016/j.bbrc.2019.03.038
   Noguchi S, 2013, MOL THER, V21, P1204, DOI 10.1038/mt.2013.70
   Noguchi S, 2013, CANCER LETT, V328, P353, DOI 10.1016/j.canlet.2012.10.017
   Noguchi S, 2011, CANCER LETT, V307, P211, DOI 10.1016/j.canlet.2011.04.005
   Seki M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8557
   Shen JZ, 2014, ONCOL REP, V31, P2035, DOI 10.3892/or.2014.3078
   Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639
   Sugito N, 2017, NUCLEIC ACID THER, V27, P365, DOI 10.1089/nat.2017.0673
   Sun XR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18739-3
   Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199
   Suzuki Y, 2016, INT J PHARMACEUT, V510, P350, DOI 10.1016/j.ijpharm.2016.06.124
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Taniguchi K, 2015, CANCER LETT, V363, P17, DOI 10.1016/j.canlet.2015.03.026
   Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075
   Tokumaru Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071697
   Tsujino T, 2019, CANCER SCI, V110, P2189, DOI 10.1111/cas.14035
   Watanabe S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09856-w
   Yoshikawa Y, 2019, MOL THER-METH CLIN D, V13, P290, DOI 10.1016/j.omtm.2019.02.005
   Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160
   Zhou JH, 2015, EXP BIOL MED, V240, P867, DOI 10.1177/1535370214563893
NR 53
TC 1
Z9 1
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD NOV
PY 2020
VL 12
IS 11
AR 3312
DI 10.3390/cancers12113312
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OX4MQ
UT WOS:000593541100001
PM 33182548
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Liu, CZ
   Mottinelli, M
   Nicholson, HE
   McVeigh, BM
   Wong, NK
   McCurdy, CR
   Bowen, WD
AF Liu, Cheri Z.
   Mottinelli, Marco
   Nicholson, Hilary E.
   McVeigh, Bridget M.
   Wong, Neelum K.
   McCurdy, Christopher R.
   Bowen, Wayne D.
TI Identification and characterization of MAM03055A: A novel bivalent
   sigma-2 receptor/TMEM97 ligand with cytotoxic activity
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE TMEM97; Sigma-2 receptor; Progesterone receptor membrane component 1;
   Neuroblastoma; Cancer metabolism; Apoptosis
ID TUMOR-CELL DEATH; BINDING; DRUGS; AGONISTS; SN79
AB Sigma-2 receptor/transmembrane protein 97 (TMEM97) is upregulated in cancer cells compared to normal cells. Traditional sigma-2 receptor agonists induce apoptosis and autophagy, making them of interest in cancer therapy. Recently, we reported a novel metabolically stimulative function of the sigma-2 receptor, showing increased 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction and stimulation of glycolytic hallmarks. 6-Substituted analogs of the canonical sigma-2 receptor antagonist, 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), produce both metabolically stimulative and cytotoxic effects. Here, we compare the activities of two related compounds: 6-amino-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (CM571), the 6-amino derivative of SN79, which binds with high affinity to both sigma-1 and sigma-2 receptors, and 1,3-bis(3-(4-(4-(4-fluorophenyl)piperazin-1-yl) butyl)-2-oxo-2,3-dihydrobenzo[d]oxazol-6-yl)thiourea (MAM03055A), a homo-bivalent dimer of CM571. MAM03055A resulted from the degradation of 3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)-6-isothiocyanatobenzo[d]oxazol-2(3H)-one (CM572), the cytotoxic 6-isothiocyanato SN79 derivative. MAM03055A exhibited high affinity and strong preference for sigma-2 receptors (sigma-1 K-i = 3371 nM; sigma-2 receptor K-i = 55.9 nM). Functionally, MAM03055A treatment potently induced cell death in SK-N-SH neuroblastoma, MDA-MB-231 breast, and both SW48 and SW480 colorectal cancer cell lines, causing proapoptotic BH3 interacting-domain death agonist (BID) cleavage in SK-N-SH cells. Conversely, CM571 induced metabolic stimulation. CM571 bound reversibly to both receptors, while MAM03055A bound pseudo-irreversibly to sigma 2 receptors and caused residual cytotoxic activity after acute exposure and removal of the compound from the media. Interestingly, MAM03055A induced a time-dependent loss of sigma-2 receptor/TMEM97 protein from cells, whereas monomer CM571 had no effect on receptor levels. These results suggest that monovalent and bivalent sigma-2 receptor ligands in this series interact differently with the receptor, thus resulting in divergent effects.
C1 [Liu, Cheri Z.; Nicholson, Hilary E.; McVeigh, Bridget M.; Wong, Neelum K.; Bowen, Wayne D.] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02912 USA.
   [Mottinelli, Marco; McCurdy, Christopher R.] Univ Florida, Coll Pharm, Dept Med Chem, Gainesville, FL USA.
RP Bowen, WD (corresponding author), 171 Meeting St,Box G-B389, Providence, RI USA.
EM wayne_bowen@brown.edu
OI Liu, Cheri/0000-0002-2394-750X; Nicholson, Hilary/0000-0002-3393-3013;
   Mottinelli, Marco/0000-0001-5725-0439; Mcveigh,
   Bridget/0000-0003-4200-6016; McCurdy, Christopher
   Robert/0000-0001-8695-2915
FU NIH NIGMSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of General
   Medical Sciences (NIGMS) [5T32GM077995]; Brown University Pharmacia
   Pre-doctoral Fellowship in Pharmacology; University of Florida College
   of Pharmacy start-up funds; State of Florida; Upjohn Professorship in
   Pharmacology, Brown University
FX This work was supported by NIH NIGMS 5T32GM077995 (CZL); Brown
   University Pharmacia Pre-doctoral Fellowship in Pharmacology (CZL);
   University of Florida College of Pharmacy start-up funds and the State
   of Florida (MM and CRM); and the Upjohn Professorship in Pharmacology,
   Brown University (WDB).
CR Crawford KW, 2002, EUR J PHARMACOL, V443, P207, DOI 10.1016/S0014-2999(02)01581-9
   Crawford KW, 2002, CANCER RES, V62, P313
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492
   Grundman M, 2019, ALZH DEMENT-TRCI, V5, P20, DOI 10.1016/j.trci.2018.11.001
   Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036
   HELLEWELL SB, 1990, BRAIN RES, V527, P244, DOI 10.1016/0006-8993(90)91143-5
   HELLEWELL SB, 1994, EUR J PHARM-MOLEC PH, V268, P9, DOI 10.1016/0922-4106(94)90115-5
   Intagliata S, 2020, AAPS J, V22, DOI 10.1208/s12248-020-00472-x
   Intagliata S, 2019, EUR J MED CHEM, V165, P250, DOI 10.1016/j.ejmech.2019.01.019
   Izzo NJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111899
   Kaushal N, 2011, AAPS J, V13, P336, DOI 10.1208/s12248-011-9274-9
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Limegrover CS, 2021, J NEUROSCI RES, V99, P1161, DOI 10.1002/jnr.24782
   Mach RH, 2013, J MED CHEM, V56, P7137, DOI 10.1021/jm301545c
   MARTIN WR, 1976, J PHARMACOL EXP THER, V197, P517
   MARTIN WR, 1983, PHARMACOL REV, V35, P283
   Menendez AG, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e14068
   Nicholson H, 2016, J PHARMACOL EXP THER, V356, P232, DOI 10.1124/jpet.115.228387
   Nicholson H, 2015, J PHARMACOL EXP THER, V354, P203, DOI 10.1124/jpet.115.224105
   Nicholson HE, 2019, J PHARMACOL EXP THER, V368, P272, DOI 10.1124/jpet.118.253484
   Ostenfeld MS, 2005, CANCER RES, V65, P8975, DOI 10.1158/0008-5472.CAN-05-0269
   Quadir SG, 2021, NEUROPHARMACOLOGY, V184, DOI 10.1016/j.neuropharm.2020.108409
   Riad A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35430-3
   Romeo G, 2019, EUR J MED CHEM, V174, P226, DOI 10.1016/j.ejmech.2019.04.056
   Rousseaux CG, 2016, J RECEPT SIG TRANSD, V36, P327, DOI 10.3109/10799893.2015.1015737
   Sahn JJ, 2017, ACS MED CHEM LETT, V8, P455, DOI 10.1021/acsmedchemlett.7b00066
   SU TP, 1982, J PHARMACOL EXP THER, V223, P284
   TAM SW, 1984, P NATL ACAD SCI-BIOL, V81, P5618, DOI 10.1073/pnas.81.17.5618
   Vazquez-Rosa E, 2019, ACS CHEM NEUROSCI, V10, P1595, DOI 10.1021/acschemneuro.8b00543
   VILNER BJ, 1995, J NEUROSCI, V15, P117
   VILNER BJ, 1995, CANCER RES, V55, P408
   Wang X., 2006, NEUR M PLANN
   Xie XY, 2021, EUR J MED CHEM, V209, DOI 10.1016/j.ejmech.2020.112906
   Zampieri D, 2020, ACS MED CHEM LETT, V11, P651, DOI 10.1021/acsmedchemlett.9b00524
   Zeng C, 2012, BRIT J CANCER, V106, P693, DOI 10.1038/bjc.2011.602
   Zeng C, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0141-2
   Zeng CB, 2014, ANAL BIOCHEM, V448, P68, DOI 10.1016/j.ab.2013.12.008
NR 38
TC 0
Z9 0
U1 3
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2021
VL 906
AR 174263
DI 10.1016/j.ejphar.2021.174263
EA JUL 2021
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UJ8TH
UT WOS:000691551500006
PM 34144027
DA 2022-04-25
ER

PT J
AU Stenmark, H
AF Stenmark, Harald
TI How a lipid mediates tumour suppression. Delivered on 29 June 2010 at
   the 35th FEBS Congress in Gothenburg, Sweden
SO FEBS JOURNAL
LA English
DT Article
DE autophagy; cancer; cell division; cytokinesis; endocytosis; PI 3-kinase;
   tumour suppressor
ID PHOSPHATIDYLINOSITOL 3-KINASE COMPLEXES; MULTIVESICULAR-BODY; ESCRT-II;
   ENDOPLASMIC-RETICULUM; RAB5 EFFECTOR; SACCHAROMYCES-CEREVISIAE;
   AUTOPHAGOSOME FORMATION; COLORECTAL CANCERS; STRUCTURAL BASIS;
   MEMBRANE-FUSION
AB Phosphorylated derivatives of the membrane lipid phosphatidylinositol (PtdIns), known as phosphoinositides (PIs), regulate membrane-proximal cellular processes by recruiting specific protein effectors involved in cell signalling, membrane trafficking and cytoskeletal dynamics. Two PIs that are generated through the activities of distinct PI 3-kinases (PI3Ks) are of special interest in cancer research. PtdIns(3,4,5)P-3, generated by class I PI3Ks, functions as tumour promotor by recruiting effectors involved in cell survival, proliferation, growth and motility. Conversely, there is evidence that PtdIns3P, generated by class III PI3K, functions in tumour suppression. Three subunits of the class III PI3K complex (Beclin 1, UVRAG and BIF-1) have been independently identified as tumour suppressors in mice and humans, and their mechanism of action in this context has been proposed to entail activation of autophagy, a catabolic pathway that is considered to mediate tumour suppression by scavenging damaged organelles that would otherwise cause DNA instability through the production of reactive oxygen species. Recent studies have revealed two additional functions of PtdIns3P that might contribute to its tumour suppressor activity. The first involves endosomal sorting and lysosomal downregulation of mitogenic receptors. The second involves regulation of cytokinesis, which is the final stage of cell division. Further elucidation of the mechanisms of tumour suppression mediated by class III PI3K and PtdIns3P will identify novel Achilles' heels of the cell's defence against tumourigenesis and will be useful in the search for prognostic and diagnostic biomarkers in cancer.
C1 [Stenmark, Harald] Oslo Univ Hosp, Norwegian Radium Hosp, Inst Canc Res, Montebello, Norway.
   [Stenmark, Harald] Univ Oslo, Ctr Canc Biomed, Fac Med, N-0316 Oslo, Norway.
RP Stenmark, H (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.
EM stenmark@ulrik.uio.no
RI Stenmark, Harald/B-8868-2008
FU Norwegian Cancer SocietyNorwegian Cancer Society; Research Council of
   NorwayResearch Council of Norway; South-Eastern Norway Regional Health
   Authority; European Research FoundationEuropean Science Foundation
   (ESF); European Research CouncilEuropean Research Council (ERC)European
   Commission
FX I thank my mentors Sjur Olsnes and Marino Zerial, and my excellent
   co-workers at the Institute for Cancer Research. Research in my
   laboratory is generously sponsored by the Norwegian Cancer Society, the
   Research Council of Norway, the South-Eastern Norway Regional Health
   Authority, the European Research Foundation, and by an Advanced Grant
   from the European Research Council.
CR Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137
   Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292
   Birkeland HCG, 2004, CURR TOP MICROBIOL, V282, P89
   Bonifacino JS, 2008, CURR OPIN CELL BIOL, V20, P427, DOI 10.1016/j.ceb.2008.03.009
   Brech A, 2009, MOL ONCOL, V3, P366, DOI 10.1016/j.molonc.2009.05.007
   Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2
   Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089
   Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539
   Cao CH, 2008, MOL BIOL CELL, V19, P3334, DOI 10.1091/mbc.E08-04-0367
   Cao C, 2007, TRAFFIC, V8, P1052, DOI 10.1111/j.1600-0854.2007.00586.x
   Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422
   Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000
   Christoforidis S, 1999, NAT CELL BIOL, V1, P249, DOI 10.1038/12075
   Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185
   Dove SK, 2004, EMBO J, V23, P1922, DOI 10.1038/sj.emboj.7600203
   Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076
   Fernandez-Borja M, 1999, CURR BIOL, V9, P55, DOI 10.1016/S0960-9822(99)80048-7
   Furuya T, 2010, MOL CELL, V38, P500, DOI 10.1016/j.molcel.2010.05.009
   Futter CE, 2001, J CELL BIOL, V155, P1251, DOI 10.1083/jcb.200108152
   Gallop JL, 2005, BIOCHEM SOC SYMP, V72, P223, DOI 10.1042/bss0720223
   Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767
   Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577
   Hailey DW, 2010, CELL, V141, P656, DOI 10.1016/j.cell.2010.04.009
   Hayakawa A, 2004, J BIOL CHEM, V279, P5958, DOI 10.1074/jbc.M310503200
   Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   HERMAN PK, 1991, CELL, V64, P425, DOI 10.1016/0092-8674(91)90650-N
   Hirano S, 2006, NAT STRUCT MOL BIOL, V13, P1031, DOI 10.1038/nsmb1163
   Itakura E, 2008, MOL BIOL CELL, V19, P5360, DOI 10.1091/mbc.E08-01-0080
   Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070
   Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973
   Kihara A, 2001, J CELL BIOL, V152, P519, DOI 10.1083/jcb.152.3.519
   Knaevelsrud H, 2010, AUTOPHAGY, V6, P863, DOI 10.4161/auto.6.7.13033
   Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328
   Li L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593
   Liang CY, 2008, NAT CELL BIOL, V10, P776, DOI 10.1038/ncb1740
   Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Lorenowicz MJ, 2009, EXP CELL RES, V315, P2683, DOI 10.1016/j.yexcr.2009.06.015
   Maffucci T, 2005, J CELL BIOL, V169, P789, DOI 10.1083/jcb.200408005
   Maffucci T, 2003, EMBO J, V22, P4178, DOI 10.1093/emboj/cdg402
   Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200
   Mathew R, 2007, GENE DEV, V21, P1367, DOI 10.1101/gad.1545107
   Matsunaga K, 2010, J CELL BIOL, V190, P511, DOI 10.1083/jcb.200911141
   Matsunaga K, 2009, NAT CELL BIOL, V11, P385, DOI 10.1038/ncb1846
   McBride HM, 1999, CELL, V98, P377, DOI 10.1016/S0092-8674(00)81966-2
   McCrea HJ, 2009, PHYSIOLOGY, V24, P8, DOI 10.1152/physiol.00035.2008
   Miller S, 2010, SCIENCE, V327, P1638, DOI 10.1126/science.1184429
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Moberg KH, 2005, DEV CELL, V9, P699, DOI 10.1016/j.devcel.2005.09.018
   Morita E, 2007, EMBO J, V26, P4215, DOI 10.1038/sj.emboj.7601850
   Morrison HA, 2008, MOL BIOL CELL, V19, P4167, DOI 10.1091/mbc.E08-07-0716
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   Mottola G, 2010, DEVELOPMENT, V137, P2353, DOI 10.1242/dev.048413
   Murray JT, 2002, TRAFFIC, V3, P416, DOI 10.1034/j.1600-0854.2002.30605.x
   Nair U, 2010, J BIOL CHEM, V285, P11476, DOI 10.1074/jbc.M109.080374
   Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601
   Obara K, 2008, J BIOL CHEM, V283, P23972, DOI 10.1074/jbc.M803180200
   Obara K, 2008, GENES CELLS, V13, P537, DOI 10.1111/j.1365-2443.2008.01188.x
   Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9
   Ohya T, 2009, NATURE, V459, P1091, DOI 10.1038/nature08107
   Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771
   Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326
   Polson HEJ, 2010, AUTOPHAGY, V6, P506, DOI 10.4161/auto.6.4.11863
   Proikas-Cezanne T, 2004, ONCOGENE, V23, P9314, DOI 10.1038/sj.onc.1208331
   Raiborg C, 2001, J CELL SCI, V114, P2255
   Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961
   Sagona AP, 2010, FEBS LETT, V584, P2652, DOI 10.1016/j.febslet.2010.03.044
   Sagona AP, 2010, NAT CELL BIOL, V12, P362, DOI 10.1038/ncb2036
   SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367
   Scott CC, 2002, J BIOL CHEM, V277, P12770, DOI 10.1074/jbc.M110399200
   Siddhanta U, 1998, J CELL BIOL, V143, P1647, DOI 10.1083/jcb.143.6.1647
   Simonsen A, 1999, J BIOL CHEM, V274, P28857, DOI 10.1074/jbc.274.41.28857
   Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879
   Simonsen A, 2009, J CELL BIOL, V186, P773, DOI 10.1083/jcb.200907014
   Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Slagsvold T, 2005, J BIOL CHEM, V280, P19600, DOI 10.1074/jbc.M501510200
   STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321
   Stein MP, 2003, TRAFFIC, V4, P754, DOI 10.1034/j.1600-0854.2003.00133.x
   Stenmark H, 2001, SEMIN CELL DEV BIOL, V12, P193, DOI 10.1006/scdb.2000.0236
   Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048
   Sun QM, 2008, P NATL ACAD SCI USA, V105, P19211, DOI 10.1073/pnas.0810452105
   Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634
   Tall GG, 1999, MOL BIOL CELL, V10, P1873, DOI 10.1091/mbc.10.6.1873
   Teis D, 2008, DEV CELL, V15, P578, DOI 10.1016/j.devcel.2008.08.013
   Teo HL, 2006, CELL, V125, P99, DOI 10.1016/j.cell.2006.01.047
   Thompson BJ, 2005, DEV CELL, V9, P711, DOI 10.1016/j.devcel.2005.09.020
   Thoresen SB, 2010, EXP CELL RES, V316, P3368, DOI 10.1016/j.yexcr.2010.07.008
   Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8
   Vaccari T, 2005, DEV CELL, V9, P687, DOI 10.1016/j.devcel.2005.09.019
   Vaccari T, 2009, J CELL SCI, V122, P2413, DOI 10.1242/jcs.046391
   Vanhaesebroeck B, 2010, NAT REV MOL CELL BIO, V11, P329, DOI 10.1038/nrm2882
   Wang YM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-8
   Williams RL, 2007, NAT REV MOL CELL BIO, V8, P355, DOI 10.1038/nrm2162
   Wollert T, 2010, NATURE, V464, P864, DOI 10.1038/nature08849
   Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051
   Zhong Y, 2009, NAT CELL BIOL, V11, P468, DOI 10.1038/ncb1854
NR 99
TC 8
Z9 8
U1 0
U2 5
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1742-464X
J9 FEBS J
JI FEBS J.
PD DEC
PY 2010
VL 277
IS 23
BP 4837
EP 4848
DI 10.1111/j.1742-4658.2010.07900.x
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 681NA
UT WOS:000284321400005
PM 20977678
OA Green Published
DA 2022-04-25
ER

PT J
AU Xu, JQ
   Tang, N
   Zhang, LF
   Tan, C
   Su, Y
   George, DM
   He, GX
   Huang, TL
AF Xu, Jia-Qi
   Tang, Ning
   Zhang, Ling-Feng
   Tan, Chen
   Su, Yang
   George, Daniel M.
   He, Guang-Xu
   Huang, Tian-Long
TI A bibliometric analysis of Wnt signaling pathway: from the top-100 cited
   articles to emerging trends
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Bibliometric analysis; top-100 articles; cell signaling;
   Wnt-beta-catenin; embryo development; cancer
ID CANONICAL WNT; COLORECTAL-CANCER; CELL APOPTOSIS; STEM-CELLS; CATENIN;
   AUTOPHAGY; DIFFERENTIATION; MECHANISMS; SURGERY; GROWTH
AB Background: Wnt signaling pathway plays a vital role in the regulation of development. An increasing number of articles about Wnt pathway components have been published. By analyzing these studies' characteristics and qualities, we aim to reveal the current research focus and emerging trends in Wnt signaling.
   Methods: The databases of Web of Science Core Collection, BIOSIS Citation Index, MEDLINE, etc. were utilized to identify articles on May 23rd, 2020. Wnt signaling pathway-related articles were identified, the 100 most cited articles and articles in the last decade were selected and calculated for citations without self-citation. The subsequent analysis included citation density (citations/article age), time-related flux, authorship, institution, journal, geographic distribution, and theme.
   Results: These articles were published mainly from 2000 to 2009 (62%). Citations per article ranged from 599 to 3,780 with a median number of 880 times. Most studies (66%) came from the United States. Nusse Roel and Clevers Hans (15 and 13 papers) have contributed significantly to the field. The most highlighted study themes were cancer (15%), embryo development (14%), and cytoplasm signal transduction (11%). From 2011 to 2020, interest in emerging subtopics, including osteogenesis, immune, apoptosis, autophagy, microRNA, and cancer stem cell, are rising.
   Conclusions: Cancer, embryo development, stem cell, and signal transduction process still play a major role in the field. With multiple emerging subtopics and investigation on an integrated view of the Wnt signal network, the association of Wnt with diseases was further revealed.
C1 [Xu, Jia-Qi; Tang, Ning; Su, Yang; He, Guang-Xu; Huang, Tian-Long] Cent South Univ, Orthopaed Dept, Xiangya Hosp 2, Changsha, Peoples R China.
   [Xu, Jia-Qi; Zhang, Ling-Feng; Tan, Chen] Royal Adelaide Hosp, Adelaide, SA, Australia.
   [George, Daniel M.] Cent South Univ, Xiangya Sch Med, 139 Middle Renmin Rd, Changsha 410011, Peoples R China.
RP Huang, TL (corresponding author), Cent South Univ, Xiangya Sch Med, 139 Middle Renmin Rd, Changsha 410011, Peoples R China.
EM tianlong.huang@csu.edu.cn
OI Zhang, Lingfeng/0000-0002-2216-5207
FU Hunan Provincial Innovation Foundation for Postgraduate [2020zzts885];
   Innovation and Entrepreneurship Training Program for College Student
   [S2020105330605]; Hunan province Funds for Distinguished Young youth
   [2018JJ1046]; Youth program of national natural science foundation of
   China [81802207]
FX This work was supported by Hunan Provincial Innovation Foundation for
   Postgraduate (No.2020zzts885), the Innovation and Entrepreneurship
   Training Program for College Student (No. S2020105330605), Hunan
   province Funds for Distinguished Young youth: (grant number 2018JJ1046),
   and Youth program of national natural science foundation of China (grant
   number 81802207).
CR Ahmad SS, 2015, OBES SURG, V25, P900, DOI 10.1007/s11695-014-1542-1
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Cisternas P, 2019, J NEUROCHEM, V149, P54, DOI 10.1111/jnc.14608
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Melo FDE, 2016, CANCERS, V8, DOI 10.3390/cancers8070060
   Ding HD, 2018, INT J SURG, V53, P230, DOI 10.1016/j.ijsu.2018.03.076
   Eyre R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12807-0
   Gao K, 2016, J NEUROCHEM, V138, P139, DOI 10.1111/jnc.13382
   Hu S, 2019, LIFE SCI, V228, P242, DOI 10.1016/j.lfs.2019.05.011
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306
   Jiang GY, 2019, PEERJ, V7, DOI 10.7717/peerj.7073
   Jiang Q, 2016, TUMOR BIOL, V37, P5001, DOI 10.1007/s13277-015-4342-x
   Kim HJ, 2016, NEUROIMAGE, V139, P149, DOI 10.1016/j.neuroimage.2016.06.029
   Kong LY, 2017, ONCOTARGET, V8, P15507, DOI 10.18632/oncotarget.14662
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/S0168-9525(00)02028-X
   Kulkarni AV, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000403
   Kwak B, 2018, INT J ONCOL, V53, P1800, DOI 10.3892/ijo.2018.4505
   Li N, 2019, ONCOL LETT, V17, P2631, DOI 10.3892/ol.2019.9923
   Li XG, 2018, BIOCHEM BIOPH RES CO, V496, P443, DOI 10.1016/j.bbrc.2018.01.052
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Liang J, 2017, J ORAL PATHOL MED, V46, P98, DOI 10.1111/jop.12466
   Liang TS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1023-4
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lum ZC, 2020, J ORTHOP, V19, P132, DOI 10.1016/j.jor.2019.11.039
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Maeda K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225525
   Martyn I, 2018, NATURE, V558, P132, DOI 10.1038/s41586-018-0150-y
   Moed HF, 2009, ARCH IMMUNOL THER EX, V57, P13, DOI 10.1007/s00005-009-0001-5
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439
   Paunkov A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090353
   Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606
   Peng Y, 2017, ONCOTARGET, V8, P52960, DOI 10.18632/oncotarget.17674
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Shi ZY, 2017, INT J MOL MED, V40, P1699, DOI 10.3892/ijmm.2017.3158
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Su N, 2016, ONCOL LETT, V12, P4623, DOI 10.3892/ol.2016.5289
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Tao TZ, 2012, CRIT CARE, V16, DOI 10.1186/cc11401
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   van Amerongen R, 2009, DEVELOPMENT, V136, P3205, DOI 10.1242/dev.033910
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1
   Veltri A, 2018, STEM CELLS, V36, P22, DOI 10.1002/stem.2723
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Wang YY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03899-z
   Xia L, 2018, BIOCHEM BIOPH RES CO, V503, P385, DOI 10.1016/j.bbrc.2018.06.045
   Yamaguchi TP, 1999, DEVELOPMENT, V126, P1211
   Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313
   Yu FJ, 2016, ONCOTARGET, V7, P81, DOI 10.18632/oncotarget.6447
   Zhang J, 2017, BIOCHEM BIOPH RES CO, V491, P469, DOI 10.1016/j.bbrc.2017.07.041
   Zhang J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0864-6
   Zhang WC, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018-019-1476-3
   Zhang YG, 2019, ARTIF CELL NANOMED B, V47, P2282, DOI 10.1080/21691401.2019.1623234
   Zheng RZ, 2017, MED SCI MONITOR, V23, P163, DOI 10.12659/MSM.902711
NR 64
TC 0
Z9 0
U1 7
U2 13
PU AME PUBL CO
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUL
PY 2021
VL 9
IS 13
AR 174
DI 10.21037/atm-21-174
PG 18
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA UN4WW
UT WOS:000694018300026
PM 34422977
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Romano, S
   Di Giacinto, F
   Primiano, A
   Mazzini, A
   Panzetta, C
   Papi, M
   Di Gaspare, A
   Ortolani, M
   Gervasoni, J
   De Spirito, M
   Nocca, G
   Ciasca, G
AF Romano, Sabrina
   Di Giacinto, Flavio
   Primiano, Aniello
   Mazzini, Alberto
   Panzetta, Claudia
   Papi, Massimiliano
   Di Gaspare, Alessandra
   Ortolani, Michele
   Gervasoni, Jacopo
   De Spirito, Marco
   Nocca, Giuseppina
   Ciasca, Gabriele
TI Fourier Transform Infrared Spectroscopy as a useful tool for the
   automated classification of cancer cell-derived exosomes obtained under
   different culture conditions
SO ANALYTICA CHIMICA ACTA
LA English
DT Article
DE Exosomes; Cancer cells; Infrared; Liquid biopsy; Personalized medicine
ID EXTRACELLULAR VESICLES; FTIR SPECTROSCOPY; HUMAN-SALIVA; TOLERANCE;
   SIGNATURE; AUTOPHAGY
AB Exosomes possess great potential as cancer biomarkers in personalized medicine due to their easy accessibility and capability of representing their parental cells. To boost the translational process of exosomes in diagnostics, the development of novel and effective strategies for their label-free and automated characterization is highly desirable. In this context, Fourier Transform Infrared Spectroscopy (FTIR) has great potential as it provides direct access to specific biomolecular bands that give compositional information on exosomes in terms of their protein, lipid and genetic content. Here, we used FTIR spectroscopy in the mid-Infrared (mid-IR) range to study exosomes released from human colorectal adenocarcinoma HT-29 cancer cells cultured in different media. To this purpose, cells were studied in well-fed condition of growth, with 10% of exosome-depleted FBS (EVd-FBS), and under serum starvation with 0.5% EVd-FBS. Our data show the presence of statistically significant differences in the shape of the Amide I and II bands in the two conditions. Based on these differences, we showed the possibility to automatically classify cancer cell-derived exosomes using Principal Component Analysis combined with Linear Discriminant Analysis (PCA-LDA); we tested the effectiveness of the classifier with a crossvalidation approach, obtaining very high accuracy, precision, and recall. Aside from classification purposes, our FTIR data provide hints on the underlying cellular mechanisms responsible for the compositional differences in exosomes, suggesting a possible role of starvation-induced autophagy. (C) 2020 Elsevier B.V. All rights reserved.
C1 [Romano, Sabrina; Di Giacinto, Flavio; Mazzini, Alberto; Panzetta, Claudia; Papi, Massimiliano; De Spirito, Marco; Ciasca, Gabriele] Univ Cattolica Sacro Cuore, Sez Fis, Dipartimento Neurosci, Rome, Italy.
   [Romano, Sabrina; Di Giacinto, Flavio; Primiano, Aniello; Papi, Massimiliano; Di Gaspare, Alessandra; Gervasoni, Jacopo; De Spirito, Marco; Ciasca, Gabriele] Fdn Policlin Univ A Gemelli IRCCS, Rome, Italy.
   [Primiano, Aniello; Gervasoni, Jacopo; Nocca, Giuseppina] Univ Cattolica Sacro Cuore, Dipartimento Sci Biotecnol Base Clin Intens & Per, Rome, Italy.
   [Di Gaspare, Alessandra] CNR, NEST, Ist Nanosci, Piazza San Silvestro 12, I-56127 Pisa, Italy.
   [Di Gaspare, Alessandra] Scuola Normale Super Pisa, Piazza San Silvestro 12, I-56127 Pisa, Italy.
   [Ortolani, Michele] Sapienza Univ Rome, Dipartimento Fis, Piazzale Aldo Moro 5, I-00185 Rome, Italy.
   [Ortolani, Michele] Ist Italiano Tecnol, Ctr Life Nanosci, Viale Regina Elena 291, I-00161 Rome, Italy.
RP De Spirito, M; Ciasca, G (corresponding author), Univ Cattolica Sacro Cuore, Sez Fis, Dipartimento Neurosci, Rome, Italy.
EM marco.despirito@unicatt.it; gabriele.ciasca@unicatt.it
RI Ciasca, Gabriele/D-2447-2013; Primiano, Aniello/AAC-3548-2022; Papi,
   Massimiliano/AAC-3657-2022; Gervasoni, Jacopo/K-7251-2016; nocca,
   giuseppina/L-1659-2018
OI Papi, Massimiliano/0000-0002-0029-1309; Primiano,
   Aniello/0000-0001-9415-9175; Gervasoni, Jacopo/0000-0002-3600-392X;
   nocca, giuseppina/0000-0002-2799-4557; Di Giacinto,
   Flavio/0000-0002-6726-7768; Ciasca, Gabriele/0000-0002-3694-8229
FU Italian Ministry of HealthMinistry of Health, Italy [GR-2016-02363310]
FX The Italian Ministry of Health ("Progetto Giovani Ricercatori
   2014e2015", Grant No. GR-2016-02363310) is gratefully acknowledged.
CR [Anonymous], 1996, J BIOL CHEM, DOI [10.1096/ fj.201601272R., DOI 10.1074/JBC.721.45.28593]
   Arganda-Carreras I, 2017, BIOINFORMATICS, V33, P2424, DOI 10.1093/bioinformatics/btx180
   Baddela VS, 2016, APPL BIOCHEM BIOTECH, V178, P544, DOI 10.1007/s12010-015-1893-7
   Caetano Júnior Paulo Cesar, 2015, Res. Biomed. Eng., V31, P116, DOI 10.1590/2446-4740.0664
   Ciasca G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220571
   Ciasca G, 2016, NANOSCALE, V8, P19629, DOI 10.1039/c6nr06840e
   Ciasca G, 2016, WORLD J GASTROENTERO, V22, P7203, DOI 10.3748/wjg.v22.i32.7203
   De Ninno A, 2015, PHYS CHEM CHEM PHYS, V17, P21337, DOI 10.1039/c4cp05023a
   De-Giorgio F, 2019, INT J LEGAL MED, V133, P1133, DOI 10.1007/s00414-019-02034-z
   Esumi H, 2002, J BIOL CHEM, V277, P32791, DOI 10.1074/jbc.M112270200
   Faix J, 2006, CURR OPIN CELL BIOL, V18, P18, DOI 10.1016/j.ceb.2005.11.002
   Hanson BA, 2015, CHEMOSPEC R PACKAGE
   Izuishi K., 2000, CANC RES
   Krafft C, 2017, NANOMED-NANOTECHNOL, V13, P835, DOI 10.1016/j.nano.2016.11.016
   Krasnowska EK, 2008, FREE RADICAL BIO MED, V45, P1566, DOI 10.1016/j.freeradbiomed.2008.09.012
   Lee J, 2017, FASEB J, V31, P2817, DOI 10.1096/fj.201601272R
   Lotvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807
   Mihaly J, 2017, BBA-BIOMEMBRANES, V1859, P459, DOI 10.1016/j.bbamem.2016.12.005
   Movasaghi Z, 2008, APPL SPECTROSC REV, V43, P134, DOI 10.1080/05704920701829043
   Necas D, 2012, CENT EUR J PHYS, V10, P181, DOI 10.2478/s11534-011-0096-2
   Nocca G, 2015, EUR J ORAL SCI, V123, P208, DOI 10.1111/eos.12178
   Ogier-Denis E, 2003, BBA-REV CANCER, V1603, P113, DOI 10.1016/S0304-419X(03)00004-0
   OgierDenis E, 1996, J BIOL CHEM, V271, P28593, DOI 10.1074/jbc.271.45.28593
   Palanisamy V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008577
   Palmieri V, 2015, SOFT MATTER, V11, P5719, DOI 10.1039/c5sm01089f
   Palmieri V, 2014, APPL PHYS LETT, V105, DOI 10.1063/1.4896161
   Perini G, 2019, INT J BIOL MACROMOL, V141, P278, DOI 10.1016/j.ijbiomac.2019.08.220
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Sharma S, 2011, LANGMUIR, V27, P14394, DOI 10.1021/la2038763
   Sharma S, 2010, ACS NANO, V4, P1921, DOI 10.1021/nn901824n
   Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111
   Talari ACS, 2017, APPL SPECTROSC REV, V52, P456, DOI 10.1080/05704928.2016.1230863
   Woo JungReem, 2016, J Circ Biomark, V5, P11, DOI 10.5772/64148
   Xu J, 2018, J CELL SCI, V131, DOI 10.1242/jcs.215210
   Zhang X, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0181-x
   Zlotogorski-Hurvitz A, 2019, J CANCER RES CLIN, V145, P685, DOI 10.1007/s00432-018-02827-6
   Zlotogorski-Hurvitz A, 2016, J CANCER RES CLIN, V142, P101, DOI 10.1007/s00432-015-2005-3
NR 39
TC 7
Z9 7
U1 1
U2 14
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0003-2670
EI 1873-4324
J9 ANAL CHIM ACTA
JI Anal. Chim. Acta
PD DEC 15
PY 2020
VL 1140
BP 219
EP 227
DI 10.1016/j.aca.2020.09.037
PG 9
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA OZ0YD
UT WOS:000594661300005
PM 33218484
DA 2022-04-25
ER

PT J
AU Hsieh, YY
   Huang, TC
   Lo, HL
   Jhan, JY
   Chen, ST
   Yang, PM
AF Hsieh, Yao-Yu
   Huang, Tsui-Chin
   Lo, Hsiang-Ling
   Jhan, Jyun-Yan
   Chen, Shui-Tein
   Yang, Pei-Ming
TI Systematic discovery of drug action mechanisms by an integrated chemical
   genomics approach: identification of functional disparities between
   azacytidine and decitabine
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; DNMT inhibitor; drug repurposing; polypharmacology;
   systems pharmacology
ID ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION SIGNATURES; CELL-CYCLE ARREST;
   RIBONUCLEOTIDE REDUCTASE; INHIBITORS AZACITIDINE; KINASE INHIBITOR; DNA
   METHYLATION; AURORA KINASE; 5-AZACYTIDINE; APOPTOSIS
AB Polypharmacology (the ability of a drug to affect more than one molecular target) is considered a basic property of many therapeutic small molecules. Herein, we used a chemical genomics approach to systematically analyze polypharmacology by integrating several analytical tools, including the LINCS (Library of Integrated Cellular Signatures), STITCH (Search Tool for Interactions of Chemicals), and WebGestalt (WEB-based GEne SeT AnaLysis Toolkit). We applied this approach to identify functional disparities between two cytidine nucleoside analogs: azacytidine (AZA) and decitabine (DAC). AZA and DAC are structurally and mechanistically similar DNA-hypomethylating agents. However, their metabolism and destinations in cells are distinct. Due to their differential incorporation into RNA or DNA, functional disparities between AZA and DAC are expected. Indeed, different cytotoxicities of AZA and DAC toward human colorectal cancer cell lines were observed, in which cells were more sensitive to AZA. Based on a polypharmacological analysis, we found that AZA transiently blocked protein synthesis and induced an acute apoptotic response that was antagonized by concurrently induced cytoprotective autophagy. In contrast, DAC caused cell cycle arrest at the G(2)/M phase associated with p53 induction. Therefore, our study discriminated functional disparities between AZA and DAC, and also demonstrated the value of this chemical genomics approach that can be applied to discover novel drug action mechanisms.
C1 [Hsieh, Yao-Yu; Huang, Tsui-Chin; Lo, Hsiang-Ling; Jhan, Jyun-Yan; Chen, Shui-Tein; Yang, Pei-Ming] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei, Taiwan.
   [Hsieh, Yao-Yu; Huang, Tsui-Chin; Lo, Hsiang-Ling; Jhan, Jyun-Yan; Chen, Shui-Tein; Yang, Pei-Ming] Acad Sinica, Taipei 115, Taiwan.
   [Hsieh, Yao-Yu] Taipei Med Univ, Shuang Ho Hosp, Div Hematol & Oncol, Taipei, Taiwan.
   [Huang, Tsui-Chin; Lo, Hsiang-Ling; Jhan, Jyun-Yan; Yang, Pei-Ming] Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan.
   [Chen, Shui-Tein] Acad Sinica, Inst Biol Chem, Taipei, Taiwan.
RP Yang, PM (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei, Taiwan.; Yang, PM (corresponding author), Acad Sinica, Taipei 115, Taiwan.; Yang, PM (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, Grad Inst Canc Biol & Drug Discovery, Taipei, Taiwan.
EM yangpm@tmu.edu.tw
RI Yang, Pei-Ming/G-3763-2014
OI Yang, Pei-Ming/0000-0002-4004-2518
FU Taiwan's Ministry of Science and Technology [MOST103-2632-B-038-001,
   MOST104-2320-B-038-005]; Taipei Medical University-Shuang Ho Hospital
   [102TMU-SHH-04, 104TMU-SHH-03]; Research Team of Prevention and Therapy
   of Colorectal Cancer at Taipei Medical University [TMU-T104-01];
   Ministry of Health and WelfareMinistry of Health, Labour and Welfare,
   Japan [MOHW103-TDU-B-212-113001, MOHW103-TDU-212-114006]; Comprehensive
   Cancer Center of Taipei Medical University - Health and welfare
   surcharge of tobacco products [MOHW103-TD-B-111-01,
   MOHW104-TDU-B-212-124-001, MOHW105-TDU-B-212-134001]
FX This work was supported by research grants from Taiwan's Ministry of
   Science and Technology (MOST103-2632-B-038-001 and
   MOST104-2320-B-038-005), Taipei Medical University-Shuang Ho Hospital
   (102TMU-SHH-04 and 104TMU-SHH-03), Research Team of Prevention and
   Therapy of Colorectal Cancer at Taipei Medical University (TMU-T104-01),
   Ministry of Health and Welfare (MOHW103-TDU-B-212-113001 and
   MOHW103-TDU-212-114006), and Comprehensive Cancer Center of Taipei
   Medical University (MOHW103-TD-B-111-01, MOHW104-TDU-B-212-124-001, and
   MOHW105-TDU-B-212-134001) funded by the Health and welfare surcharge of
   tobacco products. The authors would like to thank the Office of Research
   and Development (Taipei Medicial University, Taipei, Taiwan) for the
   help in English editing.
CR ADAMS RLP, 1982, BIOCHIM BIOPHYS ACTA, V697, P286, DOI 10.1016/0167-4781(82)90091-4
   Aimiuwu J, 2012, BLOOD, V119, P5229, DOI 10.1182/blood-2011-11-382226
   Barrett T, 2007, NUCLEIC ACIDS RES, V35, pD760, DOI 10.1093/nar/gkl887
   Buchi F, 2012, LEUKEMIA RES, V36, P607, DOI 10.1016/j.leukres.2011.11.024
   Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245
   Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001
   Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174
   David A, 2012, J CELL BIOL, V197, P45, DOI 10.1083/jcb.201112145
   Duan QN, 2014, NUCLEIC ACIDS RES, V42, pW449, DOI 10.1093/nar/gku476
   Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33
   Fancelli D, 2006, J MED CHEM, V49, P7247, DOI 10.1021/jm060897w
   Flotho C, 2009, LEUKEMIA, V23, P1019, DOI 10.1038/leu.2008.397
   Goll MG, 2006, SCIENCE, V311, P395, DOI 10.1126/science.1120976
   Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000
   Hollenbach PW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009001
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Khoddami V, 2013, NAT BIOTECHNOL, V31, P458, DOI 10.1038/nbt.2566
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kuhn M, 2014, NUCLEIC ACIDS RES, V42, pD401, DOI 10.1093/nar/gkt1207
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lee KH, 2014, SCI REP-UK, V4, DOI 10.1038/srep06394
   LI LH, 1970, CANCER RES, V30, P2760
   Ma'ayan A, 2014, TRENDS PHARMACOL SCI, V35, P450, DOI 10.1016/j.tips.2014.07.001
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mei YD, 2010, MOL CELL, V37, P668, DOI 10.1016/j.molcel.2010.01.023
   Meijer AJ, 2004, BIOCHEM BIOPH RES CO, V313, P397, DOI 10.1016/j.bbrc.2003.07.012
   Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228
   Peck D, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r61
   Pellegata NS, 1996, P NATL ACAD SCI USA, V93, P15209, DOI 10.1073/pnas.93.26.15209
   PESTKA S, 1971, ANNU REV MICROBIOL, V25, P487, DOI 10.1146/annurev.mi.25.100171.002415
   Pleyer L, 2015, DRUG METAB REV, V47, P252, DOI 10.3109/03602532.2014.995379
   Qiu X, 2010, PLOS ONE, V5
   Reddy AS, 2013, EXPERT REV CLIN PHAR, V6, P41, DOI [10.1586/ECP.12.74, 10.1586/ecp.12.74]
   Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153
   Schaefer M, 2009, CANCER RES, V69, P8127, DOI 10.1158/0008-5472.CAN-09-0458
   SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tuorto F, 2012, NAT STRUCT MOL BIOL, V19, P900, DOI 10.1038/nsmb.2357
   Venturelli S, 2013, MOL CANCER THER, V12, P2226, DOI 10.1158/1535-7163.MCT-13-0137
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Yuan CX, 2015, DRUG DES DEV THER, V9, P1293, DOI 10.2147/DDDT.S74964
NR 42
TC 8
Z9 9
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAY 10
PY 2016
VL 7
IS 19
BP 27363
EP 27378
DI 10.18632/oncotarget.8455
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DO4HF
UT WOS:000377741700035
PM 27036028
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Yang, Y
   Gu, JJ
   Li, XC
   Xue, CL
   Ba, L
   Gao, Y
   Zhou, JF
   Bai, CM
   Sun, Z
   Zhao, RC
AF Yang, Ying
   Gu, Junjie
   Li, Xuechun
   Xue, Chunling
   Ba, Li
   Gao, Yang
   Zhou, Jianfeng
   Bai, Chunmei
   Sun, Zhao
   Zhao, Robert Chunhua
TI HIF-1 alpha promotes the migration and invasion of cancer-associated
   fibroblasts by miR-210
SO AGING AND DISEASE
LA English
DT Article
DE cancer-associated fibroblasts; migration; invasion; colorectal cancer;
   HIF-1 alpha
ID MESENCHYMAL STEM-CELLS; DOWN-REGULATION; HYPOXIA; METASTASIS; AUTOPHAGY;
   PROLIFERATION
AB Metastasis is the major cause of death in colorectal cancer (CRC) patients. Inhibition of metastasis will prolong the survival of patients with CRC. Cancer cells bring their own soil, cancer-associated fibroblasts (CAFs), to metastasize together, promoting the survival and colonization of circulating cancer cells. However, the mechanism by which CAFs metastasize remains unclear. In this study, CAFs were derived from adipose mesenchymal stem cells (MSCs) after co-culture with CRC cell lines. Transwell assays showed that CAFs have stronger migration and invasion abilities than MSCs. In a nude mouse subcutaneous xenograft model, CAFs metastasized from the primary tumour to the lung and promoted the formation of CRC metastases. The expression of HIF-1 alpha was upregulated when MSCs differentiated into CAFs. Inhibition of HIF-1 alpha expression inhibited the migration and invasion of CAFs. Western blot and ChIP assays were used to identify the genes regulated by HIF-1 alpha. HIF-1 alpha regulated the migration and invasion of CAFs by upregulating miR-210 transcription. Bioinformatics analysis and luciferase reporter assays revealed that miR-210 specifically targeted the 3'UTR of VMP1 and regulated its expression. Downregulation of VMP1 enhanced the migration and invasion of CAFs. In vivo, inhibition of miR-210 expression in CAFs reduced the metastasis of CAFs and tumour cells. Therefore, the HIF-1 alpha/miR-210/VMP1 pathway might regulate the migration and invasion of CAFs in CRC. Inhibition of CAF metastasis might reduce CRC metastasis.
C1 [Yang, Ying; Gu, Junjie; Gao, Yang; Zhou, Jianfeng; Bai, Chunmei; Sun, Zhao] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Med Oncol, Beijing 100730, Peoples R China.
   [Li, Xuechun; Xue, Chunling; Ba, Li; Zhao, Robert Chunhua] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Ctr Excellence Tissue Engn,Beijing Key Lab BZO381, Inst Basic Med Sci,Sch Basic Med,Peking Union Med, Beijing 100005, Peoples R China.
RP Zhou, JF; Bai, CM; Sun, Z; Zhao, RC (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Beijing, Peoples R China.
EM ZhouJF@pumch.cn; baichunmei1964@163.com; jessiesz@126.com;
   zhaochunhua@vip.163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [61435001]; CAMS Innovation Fund for Medical
   Sciences [2016-I2M-1-001]
FX We thank all the members involved in this study. This work was supported
   by grants from the National Natural Science Foundation of China (No.
   61435001) and the CAMS Innovation Fund for Medical Sciences (No.
   2016-I2M-1-001).
CR Annabi B, 2003, STEM CELLS, V21, P337, DOI 10.1634/stemcells.21-3-337
   Ao Z, 2015, CANCER RES, V75, P4681, DOI 10.1158/0008-5472.CAN-15-1633
   Barcellos-de-Souza P, 2016, STEM CELLS, V34, P2536, DOI 10.1002/stem.2412
   Borriello L, 2017, CANCER RES, V77, P5142, DOI 10.1158/0008-5472.CAN-16-2586
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756
   Bennett JC, 2018, CURR MOL MED, V18, P199, DOI 10.2174/1566524018666180926163218
   Cazet AS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05220-6
   Chiavarina B, 2010, CELL CYCLE, V9, P3534, DOI 10.4161/cc.9.17.12908
   Cui XR, 2019, ONCOL REP, V41, P2148, DOI 10.3892/or.2019.7007
   Duda DG, 2010, P NATL ACAD SCI USA, V107, P21677, DOI 10.1073/pnas.1016234107
   Ejtehadifar M, 2015, ADV PHARM BULL, V5, P141, DOI 10.15171/apb.2015.021
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0
   Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Glentis A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00985-8
   Grotenhuis N, 2016, TISSUE ENG PT A, V22, P1098, DOI [10.1089/ten.tea.2016.0162, 10.1089/ten.TEA.2016.0162]
   Guo L, 2012, CANCER SCI, V103, P2110, DOI 10.1111/cas.12025
   Guo XZ, 2015, ONCOL REP, V34, P2557, DOI 10.3892/or.2015.4240
   Haasters F, 2014, BIOCHEM BIOPH RES CO, V452, P118, DOI 10.1016/j.bbrc.2014.08.055
   Jones ML, 2013, PROSTATE, V73, P176, DOI 10.1002/pros.22553
   Kai AKL, 2016, HEPATOLOGY, V64, P473, DOI 10.1002/hep.28577
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478
   Li HL, 2018, AGING DIS, V9, P1058, DOI 10.14336/AD.2018.0214
   Li J, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0707-8
   Li SK, 2019, J CANCER, V10, P1879, DOI 10.7150/jca.30477
   Liu J, 2016, CANCER LETT, V379, P49, DOI 10.1016/j.canlet.2016.05.022
   Liu T, 2014, INT J MOL MED, V33, P1236, DOI 10.3892/ijmm.2014.1661
   Liu ZJ, 2015, J ZHEJIANG UNIV-SC B, V16, P32, DOI 10.1631/jzus.B1400221
   Luo F, 2019, FEBS OPEN BIO, V9, P901, DOI 10.1002/2211-5463.12623
   Malekshah Abbasali Karimpour, 2006, Indian Journal of Experimental Biology, V44, P189
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Mikula-Pietrasik J, 2018, CELL MOL LIFE SCI, V75, P509, DOI 10.1007/s00018-017-2663-1
   O'Connell JT, 2011, P NATL ACAD SCI USA, V108, P16002, DOI 10.1073/pnas.1109493108
   Okuyama H, 2006, J BIOL CHEM, V281, P15554, DOI 10.1074/jbc.M602003200
   Paolillo M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194947
   Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200
   Qu AL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090952
   Radhakrishnan R, 2019, CANCER LETT, V442, P464, DOI 10.1016/j.canlet.2018.11.023
   Rankin EB, 2016, SCIENCE, V352, P175, DOI 10.1126/science.aaf4405
   Rizwani W, 2015, CANCERS, V7, P1785, DOI 10.3390/cancers7030861
   Sabry D, 2019, MOL CELL BIOCHEM, V454, P177, DOI 10.1007/s11010-018-3462-1
   Shen YM, 2019, STEM CELLS DEV, V28, P464, DOI 10.1089/scd.2018.0125
   Sun Y, 2015, INT J ONCOL, V46, P750, DOI 10.3892/ijo.2014.2745
   Sun Z, 2013, MOL ONCOL, V7, P884, DOI 10.1016/j.molonc.2013.04.007
   Tang TT, 2018, FASEB J, V32, P6965, DOI 10.1096/fj.201801013R
   Ullmann P, 2016, ONCOTARGET, V7, P65454, DOI 10.18632/oncotarget.11772
   Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410
   Wen SY, 2019, CANCER LETT, V442, P320, DOI 10.1016/j.canlet.2018.10.015
   Xue CL, 2018, STEM CELLS DEV, V27, P456, DOI 10.1089/scd.2017.0296
   Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614
   Zhang Y, 2017, CANCER BIOTHER RADIO, V32, P297, DOI 10.1089/cbr.2017.2270
   Zhou BJ, 2020, STEM CELL REV REP, V16, P702, DOI 10.1007/s12015-019-09947-7
   Zhu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.263
NR 55
TC 0
Z9 0
U1 9
U2 9
PU INT SOC AGING & DISEASE
PI FORT WORTH
PA EDITORIAL OFF, 3400 CAMP BOWIE BLVD, FORT WORTH, TX 76106 USA
SN 2152-5250
J9 AGING DIS
JI Aging Dis.
PD OCT
PY 2021
VL 12
IS 7
BP 1794
EP 1807
DI 10.14336/AD.2021.0315
PG 14
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA WE3XT
UT WOS:000705563500020
PM 34631221
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Schulte, ML
   Fu, A
   Zhao, P
   Li, J
   Geng, L
   Smith, ST
   Kondo, J
   Coffey, RJ
   Johnson, MO
   Rathmell, JC
   Sharick, JT
   Skala, MC
   Smith, JA
   Berlin, J
   Washington, MK
   Nickels, ML
   Manning, HC
AF Schulte, Michael L.
   Fu, Allie
   Zhao, Ping
   Li, Jun
   Geng, Ling
   Smith, Shannon T.
   Kondo, Jumpei
   Coffey, Robert J.
   Johnson, Marc O.
   Rathmell, Jeffrey C.
   Sharick, Joe T.
   Skala, Melissa C.
   Smith, Jarrod A.
   Berlin, Jordan
   Washington, M. Kay
   Nickels, Michael L.
   Manning, H. Charles
TI Pharmacological blockade of ASCT2-dependent glutamine transport leads to
   antitumor efficacy in preclinical models
SO NATURE MEDICINE
LA English
DT Article
ID BREAST-CANCER; SIGNALING PATHWAYS; COLORECTAL-CANCER; LUNG-CANCER;
   CELL-GROWTH; IN-VIVO; METABOLISM; INHIBITION; EXPRESSION; AUTOPHAGY
AB The unique metabolic demands of cancer cells underscore potentially fruitful opportunities for drug discovery in the era of precision medicine. However, therapeutic targeting of cancer metabolism has led to surprisingly few new drugs to date. The neutral amino acid glutamine serves as a key intermediate in numerous metabolic processes leveraged by cancer cells, including biosynthesis, cell signaling, and oxidative protection. Herein we report the preclinical development of V-9302, a competitive small molecule antagonist of transmembrane glutamine flux that selectively and potently targets the amino acid transporter ASCT2. Pharmacological blockade of ASCT2 with V-9302 resulted in attenuated cancer cell growth and proliferation, increased cell death, and increased oxidative stress, which collectively contributed to antitumor responses in vitro and in vivo. This is the first study, to our knowledge, to demonstrate the utility of a pharmacological inhibitor of glutamine transport in oncology, representing a new class of targeted therapy and laying a framework for paradigm-shifting therapies targeting cancer cell metabolism.
C1 [Schulte, Michael L.; Fu, Allie; Zhao, Ping; Li, Jun; Geng, Ling; Smith, Shannon T.; Nickels, Michael L.; Manning, H. Charles] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Mol Probes, Nashville, TN 37235 USA.
   [Schulte, Michael L.; Nickels, Michael L.; Manning, H. Charles] Vanderbilt Univ, Med Ctr, Inst Imaging Sci, Nashville, TN 37235 USA.
   [Schulte, Michael L.; Nickels, Michael L.; Manning, H. Charles] Vanderbilt Univ, Med Ctr, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA.
   [Kondo, Jumpei; Coffey, Robert J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA.
   [Coffey, Robert J.; Berlin, Jordan; Washington, M. Kay; Manning, H. Charles] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA.
   [Coffey, Robert J.] Tennessee Valley Healthcare Syst, Vet Hlth Adm, Nashville, TN USA.
   [Johnson, Marc O.; Rathmell, Jeffrey C.; Washington, M. Kay] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN 37235 USA.
   [Sharick, Joe T.; Skala, Melissa C.; Manning, H. Charles] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.
   [Smith, Jarrod A.] Vanderbilt Univ, Vanderbilt Ctr Struct Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Smith, Jarrod A.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.
   [Manning, H. Charles] Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN 37235 USA.
   [Manning, H. Charles] Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA.
   [Skala, Melissa C.] Univ Wisconsin, Dept Biomed Engn, Morgridge Inst Res, Madison, WI USA.
RP Manning, HC (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Mol Probes, Nashville, TN 37235 USA.; Manning, HC (corresponding author), Vanderbilt Univ, Med Ctr, Inst Imaging Sci, Nashville, TN 37235 USA.; Manning, HC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA.; Manning, HC (corresponding author), Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA.; Manning, HC (corresponding author), Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA.; Manning, HC (corresponding author), Vanderbilt Univ, Med Ctr, Dept Neurosurg, Nashville, TN 37235 USA.; Manning, HC (corresponding author), Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA.
EM henry.c.manning@vanderbilt.edu
RI Kondo, Jumpei/AAC-4336-2020
OI Coffey, Robert/0000-0002-2180-3844; Kondo, Jumpei/0000-0002-1350-0480
FU Vanderbilt Ingram Cancer Center (National Institutes of Health (NIH)
   National Cancer Institute (NCI)) [P30CA068485]; Center for Small Animal
   Imaging; Kleberg Foundation; Vanderbilt Trans-Institutional Program
   (TIPS) Award; Vanderbilt Specialized Program of Research Excellence
   (SPORE) in Gastrointestinal Cancer [NIH NCI P50CA095103]; NCIUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USANIH National Cancer Institute (NCI) [R35CA197570];
   Vanderbilt Digestive Disease Research Center (NIH National Institute of
   Diabetes and Digestive and Kidney Diseases (NIDDK)) [P30DK058404];
   NATIONAL CANCER INSTITUTEUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Cancer
   Institute (NCI) [R35CA197570, R01CA205101, R01CA185747, P50CA095103,
   R01CA046413, R01CA217987, P30CA068485, R01CA211082] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL136664]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of Diabetes & Digestive & Kidney Diseases (NIDDK) [P30DK058404,
   R01DK105550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL
   MEDICAL SCIENCESUnited States Department of Health & Human
   ServicesNational Institutes of Health (NIH) - USANIH National Institute
   of General Medical Sciences (NIGMS) [T32GM007105] Funding Source: NIH
   RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited
   States Department of Health & Human ServicesNational Institutes of
   Health (NIH) - USA [S10OD019963] Funding Source: NIH RePORTER
FX The authors acknowledge M. Tantawy for assistance with PET imaging, F.
   Revetta for histology expertise, and A. Rosenberg and A. Cohen for
   helpful discussions and editorial assistance. The authors wish to
   acknowledge research support from the Vanderbilt Ingram Cancer Center
   Support Grant (National Institutes of Health (NIH) National Cancer
   Institute (NCI) P30CA068485, H.C.M.), which supports the
   Vanderbilt-Ingram Cancer Center (VICC) Chemical Synthesis Core,
   Vanderbilt University Medical Center (VUMC) Radiochemistry Core, and
   Center for Small Animal Imaging; the Kleberg Foundation (H.C.M.); a
   Vanderbilt Trans-Institutional Program (TIPS) Award to the Vanderbilt
   Center for Molecular Probes (H.C.M.); the Vanderbilt Specialized Program
   of Research Excellence (SPORE) in Gastrointestinal Cancer (NIH NCI
   P50CA095103, R.J.C. and H.C.M.); an Outstanding Investigator Award from
   the NCI (R35CA197570, R.J.C.); and the Vanderbilt Digestive Disease
   Research Center (NIH National Institute of Diabetes and Digestive and
   Kidney Diseases (NIDDK) P30DK058404, H.C.M.).
CR Canul-Tec JC, 2017, NATURE, V544, P446, DOI 10.1038/nature22064
   Chiu M, 2017, AMINO ACIDS, V49, P1365, DOI 10.1007/s00726-017-2436-z
   Dall'Armi C, 2013, CURR BIOL, V23, pR33, DOI 10.1016/j.cub.2012.10.041
   DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003
   Esslinger CS, 2005, BIOORGAN MED CHEM, V13, P1111, DOI 10.1016/j.bmc.2004.11.028
   Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005
   Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823
   Gross MI, 2014, MOL CANCER THER, V13, P890, DOI 10.1158/1535-7163.MCT-13-0870
   Hanover JA, 2010, BBA-GEN SUBJECTS, V1800, P80, DOI 10.1016/j.bbagen.2009.07.017
   HARDING JJ, 2015, J CLIN ONCOL S, V33
   Hassanein M, 2013, CLIN CANCER RES, V19, P560, DOI 10.1158/1078-0432.CCR-12-2334
   Huang F, 2014, INT J CLIN EXP PATHO, V7, P1093
   Jin L, 2016, ONCOGENE, V35, P3619, DOI 10.1038/onc.2015.447
   Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   McKinley ET, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108193
   McKinley ET, 2011, CLIN CANCER RES, V17, P3332, DOI 10.1158/1078-0432.CCR-10-2274
   Meiler J, 2006, PROTEINS, V65, P538, DOI 10.1002/prot.21086
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305
   Pochini L, 2014, FRONT CHEM, V2, DOI 10.3389/fchem.2014.00061
   Rathmell JC, 2011, IMMUNITY, V35, P845, DOI 10.1016/j.immuni.2011.12.001
   Rhoads JM, 2000, GASTROENTEROLOGY, V118, P90, DOI 10.1016/S0016-5085(00)70417-3
   Rhoads JM, 1997, AM J PHYSIOL-GASTR L, V272, pG943, DOI 10.1152/ajpgi.1997.272.5.G943
   Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407
   Santio NM, 2016, EXP CELL RES, V342, P113, DOI 10.1016/j.yexcr.2016.02.018
   Schulte ML, 2017, MOL IMAGING BIOL, V19, P421, DOI 10.1007/s11307-016-1008-z
   Schulte ML, 2016, BIOORG MED CHEM LETT, V26, P1044, DOI 10.1016/j.bmcl.2015.12.031
   Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666
   Sentelle RD, 2012, NAT CHEM BIOL, V8, P831, DOI 10.1038/NCHEMBIO.1059
   Shatz O, 2016, TRENDS BIOCHEM SCI, V41, P907, DOI 10.1016/j.tibs.2016.08.001
   Shukla K, 2012, J MED CHEM, V55, P10551, DOI 10.1021/jm301191p
   Skala M, 2010, METHODS MOL BIOL, V594, P155, DOI 10.1007/978-1-60761-411-1_11
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Tresse E, 2008, AUTOPHAGY, V4, P680, DOI 10.4161/auto.6084
   van Geldermalsen M, 2016, ONCOGENE, V35, P3201, DOI 10.1038/onc.2015.381
   Vichai V, 2006, NAT PROTOC, V1, P1112, DOI 10.1038/nprot.2006.179
   Walsh AJ, 2014, CANCER RES, V74, P5184, DOI 10.1158/0008-5472.CAN-14-0663
   Watanabe T, 2011, EUR J CANCER, V47, P1946, DOI 10.1016/j.ejca.2011.03.029
   Willems L, 2013, BLOOD, V122, P3521, DOI 10.1182/blood-2013-03-493163
   Wiza C, 2012, AM J PHYSIOL-ENDOC M, V302, pE1453, DOI 10.1152/ajpendo.00660.2011
   Xiang Y, 2015, J CLIN INVEST, V125, P2293, DOI 10.1172/JCI75836
NR 42
TC 163
Z9 166
U1 25
U2 96
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1078-8956
EI 1546-170X
J9 NAT MED
JI Nat. Med.
PD FEB
PY 2018
VL 24
IS 2
BP 194
EP +
DI 10.1038/nm.4464
PG 13
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA FV1MQ
UT WOS:000424327200016
PM 29334372
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Jin, YZ
   Sun, HN
   Liu, Y
   Lee, DH
   Kim, JS
   Kim, SU
   Jiao, BY
   Han, YH
   Jin, MH
   Shen, GN
   Lee, DS
   Kwon, T
   Xu, DY
   Jin, Y
AF Jin, Yong-Zhe
   Sun, Hu-Nan
   Liu, Yue
   Lee, Dong-Ho
   Kim, Ji-Su
   Kim, Sun-Uk
   Jiao, Bing-Yang
   Han, Ying-Hao
   Jin, Mei-Hua
   Shen, Gui-Nan
   Lee, Dong-Seok
   Kwon, Taeho
   Xu, Dong-Yuan
   Jin, Yu
TI Peroxiredoxin V Inhibits Emodin-induced Gastric Cancer Cell Apoptosis
   via the ROS/Bcl2 Pathway
SO IN VIVO
LA English
DT Article
DE Peroxiredoxin V; apoptosis; emodin; gastric cancer; ROS
ID EPITHELIAL-MESENCHYMAL TRANSITION; COLORECTAL-CANCER; OXIDATIVE STRESS;
   PATHOGENESIS; ANTIOXIDANT; PEROXIDASE; AUTOPHAGY; PROMOTES; BIOLOGY;
   BCL-2
AB Background/Aim: Peroxiredoxin (Prx) protein family is aberrantly expressed in various cancers including gastric cancer. Among the six family members, Prx V has been known as an antioxidant enzyme which scavenges intracellular reactive oxygen species (ROS) and modulates cellular apoptosis. This study aimed at investigating the role of Prx V in apoptosis of gastric cancer cells. Materials and Methods: Stably constructed Prx V knockdown, over-expression and mock AGS cells (a human gastric adenocarcinoma cell line) were used to study the effect of Prx V on emodin-induced apoptosis by western blotting, cell viability, apoptosis and ROS detection assays. Results: Overexpression of Prx V significantly decreased emodin-induced cellular apoptosis and ROS levels compared to Mock and Prx V knockdown AGS cells. Also, overexpression of Prx V down-regulated the expression of proapoptotic proteins, Bad and cleaved PARP, and increased the expression of anti-apoptotic protein, Bcl2. Conclusion: Prx V suppresses AGS cell apoptosis via scavenging intracellular ROS and modulating apoptosis-related markers.
C1 [Jin, Yong-Zhe; Xu, Dong-Yuan; Jin, Yu] Yanbian Univ, Sch Nursing, Yanji, Peoples R China.
   [Jin, Yong-Zhe; Xu, Dong-Yuan; Jin, Yu] Yanbian Univ, Coll Med, Gongyuan Rd 977, Yanji 133000, Peoples R China.
   [Sun, Hu-Nan; Liu, Yue; Jiao, Bing-Yang; Han, Ying-Hao; Jin, Mei-Hua; Shen, Gui-Nan] Heilongjiang Bayi Agr Univ, Coll Life Sci & Technol, Daqing, Peoples R China.
   [Lee, Dong-Ho; Kim, Ji-Su; Kwon, Taeho] KRIBB, Primate Resources Ctr, 351-33 Neongme Gil, Jeongeup Si 56216, Jeonbuk, South Korea.
   [Kim, Sun-Uk] Korea Res Inst Biosci & Biotechnol, Futurist Anim Resource & Res Ctr, Chungcheongbuk Do, South Korea.
   [Lee, Dong-Seok] Kyungpook Natl Univ, KNU Creat BioRes Grp Plus Project BK21, Sch Life Sci, Daegu, South Korea.
RP Xu, DY; Jin, Y (corresponding author), Yanbian Univ, Coll Med, Gongyuan Rd 977, Yanji 133000, Peoples R China.; Kwon, T (corresponding author), KRIBB, Primate Resources Ctr, 351-33 Neongme Gil, Jeongeup Si 56216, Jeonbuk, South Korea.
EM kwon@kribb.re.kr; dyxu@ybu.edu.cn; jinyu@ybu.edu.cn
FU Innovative Research projects for postgraduates of Heilongjiang Bayi
   Agricultural University [YJSCX2018-Y60]; University Nursing Program for
   Young Scholars with Creative Talents in Heilongjiang Province
   [CXRC2017016]; National Research Foundation of Korea (NRF) - Ministry of
   Education [2017R1D1A1B03028188]; KRIBB Research Initiative Program
   [KGM5161914, KGM4251913];  [KRIBB-OGM5201922]
FX This research was supported by the Innovative Research projects for
   postgraduates of Heilongjiang Bayi Agricultural University (No:
   YJSCX2018-Y60) and University Nursing Program for Young Scholars with
   Creative Talents in Heilongjiang Province (CXRC2017016). This research
   was supported by Basic Science Research Program through the National
   Research Foundation of Korea (NRF) funded by the Ministry of Education
   (2017R1D1A1B03028188), KRIBB-OGM5201922. This study was supported by
   grants from the KRIBB Research Initiative Program (KGM5161914 and
   KGM4251913).
CR Abbas K, 2009, FREE RADICAL BIO MED, V47, P794, DOI 10.1016/j.freeradbiomed.2009.06.018
   Ahn HM, 2017, BIOCHEM BIOPH RES CO, V487, P580, DOI 10.1016/j.bbrc.2017.04.094
   Athreya K, 2017, NUTR CANCER, V69, P1099, DOI 10.1080/01635581.2017.1362445
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   Burlaka AP, 2016, CANCER MICROENVIRON, V9, P27, DOI 10.1007/s12307-016-0182-5
   Cha MK, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-93
   Chen X, 2018, EUR REV MED PHARMACO, V22, P7289, DOI 10.26355/eurrev_201811_16265
   Cheng CS, 2018, MED SCI MONITOR, V24, P6331, DOI 10.12659/MSM.908400
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687
   Hall A, 2011, ANTIOXID REDOX SIGN, V15, P795, DOI 10.1089/ars.2010.3624
   Jang JY, 2019, MOLECULES, V24, DOI 10.3390/molecules24010096
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Jiao L, 2016, TUMOR BIOL, V37, P8413, DOI 10.1007/s13277-015-4736-9
   Kamangar F, 2012, INT J PREVENTIVE MED, V3, P221
   Kim B, 2017, INT J ONCOL, V51, P298, DOI 10.3892/ijo.2017.4013
   Kim B, 2016, FREE RADICAL BIO MED, V90, P184, DOI 10.1016/j.freeradbiomed.2015.11.015
   Knoops B, 2011, ANTIOXID REDOX SIGN, V15, P817, DOI 10.1089/ars.2010.3584
   Kropotov A, 2006, EXP CELL RES, V312, P2806, DOI 10.1016/j.yexcr.2006.05.006
   Lee DG, 2018, NEUROTOXICOLOGY, V68, P133, DOI 10.1016/j.neuro.2018.07.011
   Li H, 2011, CANCER RES, V71, P3625, DOI 10.1158/0008-5472.CAN-10-4475
   Li LQ, 2013, FEBS OPEN BIO, V3, P51, DOI 10.1016/j.fob.2012.12.002
   Li N, 2018, MOL MED REP, V18, P3366, DOI 10.3892/mmr.2018.9304
   Lu WD, 2014, MOL CELL BIOCHEM, V387, P261, DOI 10.1007/s11010-013-1891-4
   Murphy KM, 2000, CELL DEATH DIFFER, V7, P102, DOI 10.1038/sj.cdd.4400597
   Ow SH, 2017, EXP BIOL MED, V242, P140, DOI 10.1177/1535370216669834
   Poli G, 2004, CURR MED CHEM, V11, P1163, DOI 10.2174/0929867043365323
   Rubinstein AD, 2012, J CELL SCI, V125, P5259, DOI 10.1242/jcs.115865
   Seo MJ, 2012, INT J ONCOL, V40, P655, DOI 10.3892/ijo.2011.1236
   Shen GN, 2018, MOL MED REP, V17, P7827, DOI 10.3892/mmr.2018.8826
   Song ZY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714626
   Sun HN, 2010, J NEUROCHEM, V114, P39, DOI 10.1111/j.1471-4159.2010.06691.x
   Sun XC, 2018, CANCER MANAG RES, V10, P5019, DOI 10.2147/CMAR.S177243
   Taylor PR, 2005, J CLIN ONCOL, V23, P333, DOI 10.1200/JCO.2005.06.190
   THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464
   Thyagarajan A, 2018, INTEGR CANCER THER, V17, P210, DOI 10.1177/1534735416681639
   Vaux DL, 1996, P NATL ACAD SCI USA, V93, P2239, DOI 10.1073/pnas.93.6.2239
   Walbrecq G, 2015, FREE RADICAL BIO MED, V84, P215, DOI 10.1016/j.freeradbiomed.2015.02.032
   YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5
   Yu JQ, 2013, PHYTOTHER RES, V27, P251, DOI 10.1002/ptr.4703
   Zhou Y, 2000, BIOCHEM BIOPH RES CO, V268, P921, DOI 10.1006/bbrc.2000.2231
   Zu C, 2015, ONCOL LETT, V10, P2919, DOI 10.3892/ol.2015.3646
NR 42
TC 7
Z9 8
U1 1
U2 5
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD JUL-AUG
PY 2019
VL 33
IS 4
BP 1183
EP 1192
DI 10.21873/invivo.11589
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA II0PB
UT WOS:000474906500022
PM 31280208
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Pol, J
   Vacchelli, E
   Aranda, F
   Castoldi, F
   Eggermont, A
   Cremer, I
   Sautes-Fridman, C
   Fucikova, J
   Galon, J
   Spisek, R
   Tartour, E
   Zitvogel, L
   Kroemer, G
   Galluzzi, L
AF Pol, Jonathan
   Vacchelli, Erika
   Aranda, Fernando
   Castoldi, Francesca
   Eggermont, Alexander
   Cremer, Isabelle
   Sautes-Fridman, Catherine
   Fucikova, Jitka
   Galon, Jerome
   Spisek, Radek
   Tartour, Eric
   Zitvogel, Laurence
   Kroemer, Guido
   Galluzzi, Lorenzo
TI Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy
SO ONCOIMMUNOLOGY
LA English
DT Review
DE antigen-presenting cell; autophagy; damage-associated molecular pattern;
   dendritic cell; endoplasmic reticulum stress; type I interferon
ID METASTATIC COLORECTAL-CANCER; PHASE-II TRIAL; FIND-ME SIGNAL;
   CALRETICULIN EXPOSURE; PANCREATIC-CANCER; DENDRITIC CELL;
   MULTIPLE-MYELOMA; OVARIAN-CANCER; IMMUNE-SYSTEM; BREAST-CANCER
AB The term "immunogenic cell death" (ICD) is now employed to indicate a functionally peculiar form of apoptosis that is sufficient for immunocompetent hosts to mount an adaptive immune response against dead cell-associated antigens. Several drugs have been ascribed with the ability to provoke ICD when employed as standalone therapeutic interventions. These include various chemotherapeutics routinely employed in the clinic (e.g., doxorubicin, epirubicin, idarubicin, mitoxantrone, bleomycin, bortezomib, cyclophosphamide and oxaliplatin) as well as some anticancer agents that are still under preclinical or clinical development (e.g., some microtubular inhibitors of the epothilone family). In addition, a few drugs are able to convert otherwise non-immunogenic instances of cell death into bona fide ICD, and may therefore be employed as chemotherapeutic adjuvants within combinatorial regimens. This is the case of cardiac glycosides, like digoxin and digitoxin, and zoledronic acid. Here, we discuss recent developments on anticancer chemotherapy based on ICD inducers.
C1 [Pol, Jonathan; Vacchelli, Erika; Castoldi, Francesca; Eggermont, Alexander; Zitvogel, Laurence; Galluzzi, Lorenzo] Gustave Roussy Canc Campus, Villejuif, France.
   [Pol, Jonathan; Vacchelli, Erika; Castoldi, Francesca; Cremer, Isabelle; Sautes-Fridman, Catherine; Galon, Jerome; Kroemer, Guido; Galluzzi, Lorenzo] INSERM, U1138, Paris, France.
   [Pol, Jonathan; Vacchelli, Erika; Castoldi, Francesca; Kroemer, Guido; Galluzzi, Lorenzo] Ctr Rech Cordeliers, Equipe Labellisee Ligue Natl Canc 11, Paris, France.
   [Aranda, Fernando] Inst Invest Biomed August Pi i Sunyer IDIBAPS, Grp Immune Receptors Innate & Adapt Syst, Barcelona, Spain.
   [Castoldi, Francesca] Univ Paris 11, Fac Med, Le Kremlin Bicetre, France.
   [Castoldi, Francesca; Fucikova, Jitka; Spisek, Radek] Sotio Ac, Prague, Czech Republic.
   [Cremer, Isabelle; Sautes-Fridman, Catherine] Ctr Rech Cordeliers, Equipe 13, Paris, France.
   [Cremer, Isabelle; Sautes-Fridman, Catherine; Fucikova, Jitka] Univ Paris 06, Paris, France.
   [Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Fac Med 2, Dept Immunol, Prague, Czech Republic.
   [Fucikova, Jitka; Spisek, Radek] Charles Univ Prague, Univ Hosp Motol, Prague, Czech Republic.
   [Galon, Jerome] Ctr Rech Cordeliers, Lab Integrat Canc Immunol, Paris, France.
   [Tartour, Eric; Kroemer, Guido; Galluzzi, Lorenzo] Univ Paris 05, Sorbonne Paris Cite, Paris, France.
   [Tartour, Eric] INSERM, U970, Paris, France.
   [Tartour, Eric] Paris Cardiovasc Res Ctr PARCC, Paris, France.
   [Tartour, Eric] HEGP, AP HP, Serv Immunol Biol, Paris, France.
   [Zitvogel, Laurence] INSERM, U1015, CICBT507, Villejuif, France.
   [Kroemer, Guido] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
   [Kroemer, Guido] Gustave Roussy Canc Campus, Metab & Cell Biol Platforms, Villejuif, France.
RP Kroemer, G (corresponding author), INSERM, U1138, Paris, France.
EM kroemer@orange.fr; deadoc@vodafone.it
RI Pol, Jonathan/R-6507-2016; Cremer, Isabelle/D-4278-2017; Galluzzi,
   Lorenzo/AAG-6432-2019; Aranda, Fernando/N-2112-2014; Galluzzi,
   Lorenzo/AAG-6294-2019; Kroemer, Guido/AAY-9859-2020; Vacchelli,
   Erika/E-5212-2018; KROEMER, Guido/B-4263-2013; Aranda,
   Fernando/N-9649-2019; Galluzzi, Lorenzo/AAH-3286-2021; Galon,
   Jerome/G-9838-2019; tartour, eric/O-7957-2017
OI Pol, Jonathan/0000-0002-8355-7562; Cremer, Isabelle/0000-0002-0963-1031;
   Aranda, Fernando/0000-0002-9364-474X; Vacchelli,
   Erika/0000-0001-8010-0594; KROEMER, Guido/0000-0002-9334-4405; Aranda,
   Fernando/0000-0002-9364-474X; Galon, Jerome/0000-0001-9635-1339;
   tartour, eric/0000-0002-7323-468X; sautes-fridman,
   catherine/0000-0003-1735-8722
FU Ligue contre le Cancer (equipe labelisee)Ligue nationale contre le
   cancer; Agence National de la Recherche (ANR)French National Research
   Agency (ANR); Association pour la recherche sur le cancer (ARC)Fondation
   ARC pour la Recherche sur le Cancer; Canceropole Ile-de-FranceRegion
   Ile-de-France; AXA Chair for Longevity Research; Institut National du
   Cancer (INCa)Institut National du Cancer (INCA) France; Fondation
   Bettencourt-Schueller; Fondation de FranceFondation de France; Fondation
   pour la Recherche Medicale (FRM)Fondation pour la Recherche Medicale;
   European Commission (ArtForce)European CommissionEuropean Commission
   Joint Research Centre; European Research Council (ERC)European Research
   Council (ERC)European Commission; LabEx Immuno-Oncology; SIRIC
   Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
   (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM);
   Paris Alliance of Cancer Research Institutes (PACRI)
FX Authors are supported by the Ligue contre le Cancer (equipe labelisee);
   Agence National de la Recherche (ANR); Association pour la recherche sur
   le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity
   Research; Institut National du Cancer (INCa); Fondation
   Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche
   Medicale (FRM); the European Commission (ArtForce); the European
   Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified
   Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the
   SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris
   Alliance of Cancer Research Institutes (PACRI).
CR Affara NI, 2007, CELL, V129, P25, DOI 10.1016/j.cell.2007.03.029
   [Anonymous], 2014, Cancer Discov, V4, pOF8, DOI 10.1158/2159-8290.CD-RW2014-051
   Antonarakis ES, 2010, EXPERT OPIN INV DRUG, V19, P311, DOI 10.1517/13543780903530678
   Apetoh L, 2007, IMMUNOL REV, V220, P47, DOI 10.1111/j.1600-065X.2007.00573.x
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Aranda F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28344
   Aranda F, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27297
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Ashida H, 2012, NAT CHEM BIOL, V8, P36, DOI 10.1038/nchembio.741
   Bazzola L, 2014, BRIT J CANCER, V112, P52, DOI DOI 10.1038/HJR
   Besser MJ, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26098
   Bloy N, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.954929
   Boulin M, 2011, ANTI-CANCER DRUG, V22, P741, DOI 10.1097/CAD.0b013e328346a0c5
   Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67
   Brenner C, 2013, J HEPATOL, V59, P583, DOI 10.1016/j.jhep.2013.03.033
   Brown EM, 2013, NAT IMMUNOL, V14, P660, DOI 10.1038/ni.2611
   Bugaut H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065181
   Bultman SJ, 2014, CARCINOGENESIS, V35, P249, DOI 10.1093/carcin/bgt392
   Butts C, 2014, LANCET ONCOL, V15, P59, DOI 10.1016/S1470-2045(13)70510-2
   Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915
   Chekeni FB, 2010, NATURE, V467, P863, DOI 10.1038/nature09413
   Cirone M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26198
   Cirone M, 2012, ONCOIMMUNOLOGY, V1, P1218, DOI 10.4161/onci.20428
   Cirone M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031732
   Conroy T, 2014, LANCET ONCOL, V15, P305, DOI 10.1016/S1470-2045(14)70028-2
   Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923
   Cottini F, 2014, NAT MED, V20, P599, DOI 10.1038/nm.3562
   Creelan B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23428
   Croucher DR, 2008, NAT REV CANCER, V8, P535, DOI 10.1038/nrc2400
   Delfino C, 2012, GIORN ITAL DERMAT V, V147, P573
   Demaria S, 2005, J LEUKOCYTE BIOL, V77, P361, DOI 10.1189/jlb.0804478
   Dudek AM, 2013, CYTOKINE GROWTH F R, V24, P319, DOI 10.1016/j.cytogfr.2013.01.005
   Elliott MR, 2009, NATURE, V461, P282, DOI 10.1038/nature08296
   Formenti SC, 2012, INT J RADIAT ONCOL, V84, P879, DOI 10.1016/j.ijrobp.2012.06.020
   Fucikova J, 2014, INT J CANCER, V135, P1165, DOI 10.1002/ijc.28766
   Fucikova J, 2011, CANCER RES, V71, P4821, DOI 10.1158/0008-5472.CAN-11-0950
   Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Galluzzi L, 2014, ONCOTARGET, V5, P12472, DOI 10.18632/oncotarget.2998
   Galluzzi L, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.967147
   Galluzzi L, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26536
   Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145
   Galluzzi L, 2012, ONCOIMMUNOLOGY, V1, P699, DOI 10.4161/onci.20696
   Galluzzi L, 2012, NAT REV MOL CELL BIO, V13, P780, DOI 10.1038/nrm3479
   Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946
   Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017
   Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626
   Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112
   Garg AD, 2014, CELL DEATH DIFFER, V21, P26, DOI 10.1038/cdd.2013.48
   Garg AD, 2011, PHOTOCH PHOTOBIO SCI, V10, P670, DOI 10.1039/c0pp00294a
   Garg AD, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26260
   Garg AD, 2013, AUTOPHAGY, V9, P1292, DOI 10.4161/auto.25399
   Garg AD, 2013, BIOFACTORS, V39, P355, DOI 10.1002/biof.1125
   Garg AD, 2012, ONCOIMMUNOLOGY, V1, P786, DOI 10.4161/onci.19750
   Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497
   Garg AD, 2010, BBA-REV CANCER, V1805, P53, DOI 10.1016/j.bbcan.2009.08.003
   Garrido G, 2011, J IMMUNOL, V187, P4954, DOI 10.4049/jimmunol.1003477
   Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331
   Ghiringhelli F, 2009, NAT MED, V15, P1170, DOI 10.1038/nm.2028
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Golden EB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28518
   Golubovskaya VM, 2014, FRONT BIOSCI-LANDMRK, V19, P687, DOI 10.2741/4236
   Gourgou-Bourgade S, 2013, J CLIN ONCOL, V31, P23, DOI 10.1200/JCO.2012.44.4869
   Gujar SA, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27622
   Hashimoto D, 2011, IMMUNITY, V35, P323, DOI 10.1016/j.immuni.2011.09.007
   Hoehler T, 2013, BRIT J CANCER, V109, P1408, DOI 10.1038/bjc.2013.409
   Hoffmann J, 2008, CANCER RES, V68, P5301, DOI 10.1158/0008-5472.CAN-08-0237
   Hong YS, 2014, LANCET ONCOL, V15, P1245, DOI 10.1016/S1470-2045(14)70377-8
   HOPKINS PCR, 1994, SCIENCE, V265, P1893
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Ichikawa Y, 2014, J CLIN INVEST, V124, P617, DOI 10.1172/JCI72931
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kepp O, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.955691
   Kepp O, 2013, CYTOKINE GROWTH F R, V24, P311, DOI 10.1016/j.cytogfr.2013.05.001
   Kepp O, 2012, ONCOIMMUNOLOGY, V1, P1640, DOI 10.4161/onci.21684
   Kepp O, 2011, CANCER METAST REV, V30, P61, DOI 10.1007/s10555-011-9273-4
   Kharaziha P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.1
   Kharaziha P, 2012, CANCER RES, V72, P5348, DOI 10.1158/0008-5472.CAN-12-0658
   Knol AC, 2010, EXP DERMATOL, V19, pE299, DOI 10.1111/j.1600-0625.2009.00995.x
   Knol AC, 2010, EXP DERMATOL, V19, pE95, DOI 10.1111/j.1600-0625.2009.00993.x
   Ko A, 2014, CELL DEATH DIFFER, V21, P92, DOI 10.1038/cdd.2013.124
   Koomoa DLT, 2008, CANCER RES, V68, P9825, DOI 10.1158/0008-5472.CAN-08-1865
   Korbelik M, 2005, CANCER RES, V65, P1018
   Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Ladoire S, 2014, ANTIOXID REDOX SIGN, V20, P1098, DOI 10.1089/ars.2012.5133
   Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019
   Lee AF, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22889
   Lerret NM, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22731
   Liu Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010189
   Lu JY, 2013, J SURG ONCOL, V108, P213, DOI 10.1002/jso.23394
   Luk JM, 2014, NAT MED, V20, P587, DOI 10.1038/nm.3593
   Lunardi S, 2014, CANCER LETT, V343, P147, DOI 10.1016/j.canlet.2013.09.039
   Lutz ER, 2014, CANCER IMMUNOL RES, V2, P616, DOI 10.1158/2326-6066.CIR-14-0027
   Ma Y, 2013, CANCER RES, V74, P436
   Ma YT, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27663
   Ma YT, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24568
   Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003
   Ma YT, 2011, J EXP MED, V208, P491, DOI 10.1084/jem.20100269
   Marks E, 2014, J PANCREAS, V15, P99, DOI 10.6092/1590-8577/2279
   Martins I, 2011, ONCOGENE, V30, P1147, DOI 10.1038/onc.2010.500
   Menger L, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23082
   Menger L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003807
   Michaud M, 2012, ONCOIMMUNOLOGY, V1, P392, DOI 10.4161/onci.19070
   Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347
   Miller K, 2007, NEW ENGL J MED, V357, P2666, DOI 10.1056/NEJMoa072113
   Morton SW, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005261
   Necchi A, 2015, ANN ONCOL, V26, P167, DOI 10.1093/annonc/mdu485
   Njiaju UO, 2013, CANCER CHEMOTH PHARM, V71, P613, DOI 10.1007/s00280-012-2044-2
   Noh SH, 2014, LANCET ONCOL, V15, P1389, DOI 10.1016/S1470-2045(14)70473-5
   O'Reilly EM, 2014, ANN SURG, V260, P142, DOI 10.1097/SLA.0000000000000251
   Obeid M, 2007, CELL DEATH DIFFER, V14, P1848, DOI 10.1038/sj.cdd.4402201
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Oettle H, 2014, J CLIN ONCOL, V32, P2423, DOI 10.1200/JCO.2013.53.6995
   Okines AFC, 2010, J CLIN ONCOL, V28, P3945, DOI 10.1200/JCO.2010.29.2847
   Pallasch CP, 2014, CELL, V156, P590, DOI 10.1016/j.cell.2013.12.041
   Panaretakis T, 2009, EMBO J, V28, P578, DOI 10.1038/emboj.2009.1
   Panzarini E, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/482160
   Pellicciotta I, 2011, GYNECOL ONCOL, V122, P625, DOI 10.1016/j.ygyno.2011.05.007
   Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913
   Pol J, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28694
   Riganti C, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25770
   Riganti C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060975
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2
   Robert L, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.29244
   Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538
   Roulstone V, 2015, CLIN CANC RES
   Rounbehler RJ, 2009, CANCER RES, V69, P547, DOI 10.1158/0008-5472.CAN-08-2968
   Schadt CR, 2013, DERMATOL THER, V26, P400, DOI 10.1111/dth.12087
   Schiavoni G, 2011, CANCER RES, V71, P768, DOI 10.1158/0008-5472.CAN-10-2788
   Schroeder A, 2012, NAT REV CANCER, V12, P39, DOI 10.1038/nrc3180
   Semeraro M, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28386
   Semeraro M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26494
   Senovilla L, 2014, CURR OPIN IMMUNOL, V30, P24, DOI 10.1016/j.coi.2014.05.009
   Senovilla L, 2012, ONCOIMMUNOLOGY, V1, P1323, DOI 10.4161/onci.22009
   Senovilla L, 2012, SCIENCE, V337, P1678, DOI 10.1126/science.1224922
   Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708
   Spisek R, 2007, BLOOD, V109, P4839, DOI 10.1182/blood-2006-10-054221
   Springett GM, 2014, CANCER CONTROL, V21, P242, DOI 10.1177/107327481402100311
   Straus DJ, 2014, ANN ONCOL, V25, P206, DOI 10.1093/annonc/mdt480
   Sukkurwala AQ, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28473
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Tavora B, 2014, NATURE, V514, P112, DOI 10.1038/nature13541
   Tesniere A, 2010, ONCOGENE, V29, P482, DOI 10.1038/onc.2009.356
   Thomas ES, 2007, J CLIN ONCOL, V25, P5210, DOI 10.1200/JCO.2007.12.6557
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tomlinson V, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.7
   Triulzi T, 2014, INT J CANCER, V134, P2789, DOI 10.1002/ijc.28608
   Urner-Bloch U, 2014, ANN ONCOL, V25, P1437, DOI 10.1093/annonc/mdu169
   Vacchelli E, 2013, ONCOIMMUNOLOGY, V2, DOI DOI 10.4161/0NCI.24238
   Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.957994
   Vacchelli E, 2014, ONCOIMMUNOLOGY, V3, DOI [10.4161/onci.27878, 10.4161/onci.27048]
   Vacchelli E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24238
   Vacchelli E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.25396
   Vacchelli E, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22789
   Viaud S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27574
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Vici P, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-49
   Yamada Y, 2015, ANN ONCOL, V26, P141, DOI 10.1093/annonc/mdu472
   Yang JL, 2014, CANCER CHEMOTH PHARM, V74, P637, DOI 10.1007/s00280-014-2523-8
   Zheng L, 2014, ANN SURG ONCOL, V21, P3931, DOI 10.1245/s10434-014-3844-x
   Zitvogel L, 2013, IMMUNITY, V39, P74, DOI 10.1016/j.immuni.2013.06.014
   Zitvogel L, 2011, NAT REV CLIN ONCOL, V8, P151, DOI 10.1038/nrclinonc.2010.223
   Zitvogel L, 2010, CELL, V140, P798, DOI 10.1016/j.cell.2010.02.015
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 170
TC 166
Z9 171
U1 5
U2 74
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PY 2015
VL 4
IS 4
AR e1008866
DI 10.1080/2162402X.2015.1008866
PG 13
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA CH7NS
UT WOS:000354224400025
PM 26137404
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, KS
   Jin, HT
   Guo, YM
   Liu, Y
   Wan, Y
   Zhao, P
   Zhou, ZF
   Wang, JH
   Wang, ML
   Zou, C
   Wu, WQ
   Cheng, ZQ
   Dai, Y
AF Liu, Kaisheng
   Jin, Hongtao
   Guo, Yaomin
   Liu, Ying
   Wan, Yong
   Zhao, Pan
   Zhou, Zhifan
   Wang, Jianhong
   Wang, Maolin
   Zou, Chang
   Wu, Weiqing
   Cheng, Zhiqiang
   Dai, Yong
TI CFTR interacts with Hsp90 and regulates the phosphorylation of AKT and
   ERK1/2 in colorectal cancer cells
SO FEBS OPEN BIO
LA English
DT Article
DE AKT; cystic fibrosis transmembrane conductance regulator; extracellular
   signal-regulated kinase 1; 2; heat-shock protein 90; mitochondria
ID TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; CYCLE ARREST;
   APOPTOSIS; INHIBITOR; PROLIFERATION; DEGRADATION; EXPRESSION; AUTOPHAGY;
   SNX-2112
AB Cystic fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. CF cells and tissues exhibit various mitochondrial abnormalities. However, the underlying molecular mechanisms remain elusive. Here, we examined the mechanisms through which CFTR regulates Bcl-2 family proteins, which in turn regulate permeabilization of the mitochondrial outer membrane. Notably, inhibition of CFTR activated Bax and Bad, but inhibited Bcl-2. Moreover, degradation of phosphorylated extracellular signal-regulated kinase 1/2 (ERK1/2) and AKT increased significantly in CFTR-knockdown cells. Dysfunction of CFTR decreased heat-shock protein 90 (Hsp90) mRNA levels, and CFTR was found to interact with Hsp90. Inhibition of Hsp90 by SNX-2112 induced the degradation of phosphorylated AKT and ERK1/2 in Caco2 and HRT18 cells. These findings may help provide insights into the physiological role of CFTR in CF-related diseases.
C1 [Liu, Kaisheng; Jin, Hongtao; Guo, Yaomin; Liu, Ying; Wan, Yong; Zhao, Pan; Zhou, Zhifan; Wang, Jianhong; Zou, Chang; Wu, Weiqing; Cheng, Zhiqiang; Dai, Yong] Jinan Univ, Clin Med Coll 2, Southern Univ Sci & Technol, Affiliated Hosp 1,Shenzhen Peoples Hosp, Shenzhen, Peoples R China.
   [Liu, Kaisheng] Chinese Univ Hong Kong, Sch Biomed Sci, Fac Med, Hong Kong, Peoples R China.
   [Wang, Maolin] Shenzhen Univ, Hlth Sci Ctr, Sch Med, Shenzhen, Peoples R China.
RP Wu, WQ; Cheng, ZQ; Dai, Y (corresponding author), Jinan Univ, Affiliated Hosp 1, Southern Univ Sci & Technol, Clin Med Coll 2,Shenzhen Peoples Hosp, Shenzhen 518020, Guangdong, Peoples R China.
EM wweiqing007@sina.com; chengzhiqiang2004@aliyun.com; daiyong22@aliyun.com
RI Zou, Chang/AAS-3356-2021
OI Zou, Chang/0000-0002-2003-7834; Liu, Kaisheng/0000-0002-4755-0523; Dai,
   Yong/0000-0002-6840-9158
FU Science and Technology Foundation of Shenzhen [JCYJ20180301170047864];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81802749]; Shenzhen Public Service Platform
   on Tumor Precision Medicine and Molecular Diagnosis
FX This work was supported by grants from the Science and Technology
   Foundation of Shenzhen (JCYJ20180301170047864) and the National Natural
   Science Foundation of China (No. 81802749). This work was also supported
   by the Shenzhen Public Service Platform on Tumor Precision Medicine and
   Molecular Diagnosis.
CR Aitken M L, 1995, Curr Opin Pulm Med, V1, P425, DOI 10.1097/00063198-199511000-00001
   Antigny F, 2009, MITOCHONDRION, V9, P232, DOI 10.1016/j.mito.2009.02.003
   Asnaghi L, 2004, ONCOGENE, V23, P5781, DOI 10.1038/sj.onc.1207698
   Chan HC, 2006, MOL CELL ENDOCRINOL, V250, P106, DOI 10.1016/j.mce.2005.12.032
   Couzin-Frankel J, 2009, SCIENCE, V324, P1504, DOI 10.1126/science.324_1504
   FEIGAL RJ, 1979, NATURE, V278, P276, DOI 10.1038/278276a0
   Valdivieso AG, 2013, REDOX BIOL, V1, P190, DOI 10.1016/j.redox.2012.11.007
   Gottlieb RA, 1996, P NATL ACAD SCI USA, V93, P3587, DOI 10.1073/pnas.93.8.3587
   Grund K, 2008, CANCER BIOL THER, V7, P1982, DOI 10.4161/cbt.7.12.6966
   Hayakawa J, 2000, CANCER RES, V60, P5988
   Homma K, 2010, BBA-BIOMEMBRANES, V1798, P1029, DOI 10.1016/j.bbamem.2010.02.001
   Ju HQ, 2011, EUR J PHARMACOL, V666, P26, DOI 10.1016/j.ejphar.2011.05.020
   Kelly-Aubert M, 2011, HUM MOL GENET, V20, P2745, DOI 10.1093/hmg/ddr173
   Kleme ML, 2018, NUTRIENTS, V10, DOI 10.3390/nu10070836
   Kogan I, 2003, EMBO J, V22, P1981, DOI 10.1093/emboj/cdg194
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   l'Hoste S, 2010, AM J PHYSIOL-RENAL, V298, pF435, DOI 10.1152/ajprenal.00286.2009
   LEIGH MW, 1995, AM J RESP CELL MOL, V12, P605, DOI 10.1165/ajrcmb.12.6.7766425
   Liu KS, 2012, INT J ONCOL, V41, P2276, DOI 10.3892/ijo.2012.1670
   Liu KS, 2012, CANCER LETT, V318, P180, DOI 10.1016/j.canlet.2011.12.015
   Liu KS, 2016, ONCOTARGET, V7, P64030, DOI 10.18632/oncotarget.11747
   Liu ZQ, 2017, CELL DEATH DIFFER, V24, P98, DOI 10.1038/cdd.2016.118
   Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879
   Luciani A, 2010, NAT CELL BIOL, V12, P863, DOI 10.1038/ncb2090
   Mabuchi S, 2002, J BIOL CHEM, V277, P33490, DOI 10.1074/jbc.M204042200
   Maiuri L, 1997, FEBS LETT, V408, P225, DOI 10.1016/S0014-5793(97)00347-5
   Mehta A, 2005, PEDIATR PULM, V39, P292, DOI 10.1002/ppul.20147
   Merkwirth C, 2008, GENE DEV, V22, P476, DOI 10.1101/gad.460708
   Pearson H, 2009, NATURE, V460, P164, DOI 10.1038/460164a
   PICCI L, 1991, ADV EXP MED BIOL, V290, P379
   Pugazhenthi S, 2000, J BIOL CHEM, V275, P10761, DOI 10.1074/jbc.275.15.10761
   RIORDAN JR, 1989, SCIENCE, V245, P1066
   Rowe SM, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a009761
   Ruan YC, 2014, J CELL SCI, V127, P4396, DOI 10.1242/jcs.148098
   SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405
   Sikic M, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000278
   Spielberg DR, 2016, ANNU REV GENOM HUM G, V17, P155, DOI 10.1146/annurev-genom-090314-050024
   Than BLN, 2016, ONCOGENE, V35, P4191, DOI 10.1038/onc.2015.483
   Valdivieso AG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048059
   Wang RN, 2013, ELECTRON J QUAL THEO, P1
   Wang SX, 2011, BIOSCI BIOTECH BIOCH, V75, P1540, DOI 10.1271/bbb.110225
   Wang X, 2014, BIOCHEM BIOPH RES CO, V446, P160, DOI 10.1016/j.bbrc.2014.02.081
   Xie C, 2013, ONCOGENE, V32, P2282, DOI 10.1038/onc.2012.251
   Xu J, 2015, ONCOL REP, V33, P2227, DOI 10.3892/or.2015.3829
   Zhai QQ, 2011, BIOMED PHARMACOTHER, V65, P132, DOI 10.1016/j.biopha.2010.12.009
   Zhang JT, 2013, BBA-MOL CELL RES, V1833, P2961, DOI 10.1016/j.bbamcr.2013.07.021
   Zhang XY, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0326-7
NR 47
TC 5
Z9 7
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2211-5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD JUN
PY 2019
VL 9
IS 6
BP 1119
EP 1127
DI 10.1002/2211-5463.12641
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA IP9TU
UT WOS:000480394000005
PM 30985981
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Li, WH
   Zhang, L
   Wu, YH
AF Li, W-H
   Zhang, L.
   Wu, Y-H
TI CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE CDKN3; TIPE1; Colorectal cancer (CRC); Cisplatin resistance
ID BIOMARKERS; AUTOPHAGY
AB OBJECTIVE: The aim of this study was to investigate the level of cyclin-dependent kinase inhibitor 3 (CDKN3) in colorectal cancer (CRC), to explore the underlying mechanism of CDKN3 in modulating cisplatin resistance and promoting the malignant progression of CRC.
   PATIENTS AND METHODS: 43 pairs of CRC tissues and para-cancerous tissues were collected from CRC patients. CDKN3 expression was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The relationship between CDKN3 expression and the prognosis of CRC patients was analyzed. Meanwhile, qRT-PCR was performed to verify CDKN3 level in CRC cell lines. Next, CDKN3 knockdown model was constructed in CRC cisplatin-resistant cell lines. The influence of CDKN3 on the biological function of CRC cells was analyzed by Cell Counting Kit-8 (CCK-8) and plate cloning assays. Furthermore, the mechanism of its regulation of TIPE1 affecting cisplatin resistance to CRC was explored.
   RESULTS: QRT-PCR results showed that CDKN3 level in CRC tissues was remarkably higher than that of the adjacent tissues (p<0.05). Compared with patients with low expression of CDKN3, the prognosis of patients with high expression of CDKN3 was significantly worse (p<0.05). Similarly, the proliferation and colony formation ability of cells in CDKN3 knockdown group remarkably decreased when compared with the sh-NC group (p<0.05). In addition, CDKN3 level was remarkably elevated in CRC patients with cisplatin resistance. In cisplatin-resistant cell lines (including HT28 and HCT-116), the knockdown of CDKN3 remarkably reduced cell viability (p<0.05). Furthermore, TIPE1 expression was remarkably downregulated in CRC tissues (p<0.05). A negative correlation was observed between the expressions of TIPE1 and CDKN3. Cell reverse experiment demonstrated that TIPE1 could reverse the promoting effect of CDKN3 on the malignant progression of CRC. All these findings suggested that there might exist a mutual regulation between CDKN3 and TIPE1.
   CONCLUSIONS: CDKN3 was highly expressed in CRC, which might be closely correlated with poor prognosis of CRC patients. In addition, CDKN3 regulated cisplatin resistance to CRC by modulating TIPE1, thereby promoting the proliferation of CRC.
C1 [Li, W-H] North China Univ Sci & Technol, Dept Pharm, Affiliated Hosp, Tangshan, Peoples R China.
   [Zhang, L.] North China Univ Sci & Technol, Dept Neurol, Affiliated Hosp, Tangshan, Peoples R China.
   [Wu, Y-H] Kailuan Gen Hosp, Dept Pharm, Tangshan, Peoples R China.
RP Li, WH (corresponding author), North China Univ Sci & Technol, Dept Pharm, Affiliated Hosp, Tangshan, Peoples R China.
EM Lwh_1919@163.com
CR Berumen J, 2014, EXPERT OPIN THER TAR, V18, P1149, DOI 10.1517/14728222.2014.941808
   Chen P, 2019, CLIN TRANSL ONCOL, V21, P334, DOI 10.1007/s12094-018-1927-z
   Chen QR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105393
   Cress WD, 2017, INT J BIOCHEM CELL B, V91, P98, DOI 10.1016/j.biocel.2017.05.013
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   Duan JC, 2018, J BUON, V23, P1402
   Espina M, 2017, METALLOMICS, V9, P564, DOI 10.1039/c7mt00014f
   HU WS, 2019, INTERN EMERG MED, V9, P1
   Kostakis Ioannis, 2018, J BUON, V23, P84
   Liao JK, 2018, BIOMED PHARMACOTHER, V97, P1341, DOI 10.1016/j.biopha.2017.11.024
   Liu DF, 2018, INT J CANCER, V142, P1392, DOI 10.1002/ijc.31173
   Liu TB, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0827-9
   Luan YY, 2019, J INFECT DIS, V220, P699, DOI 10.1093/infdis/jiz158
   Luo H, 2016, DRUG DES DEV THER, V10, P1885
   Mankaney G, 2019, CLEV CLIN J MED, V86, P385, DOI 10.3949/ccjm.86a.17125
   Mastrokostas A, 2018, J BUON, V23, pS67
   Pardieck IN, 2016, EXPERT REV GASTROENT, V10, P465, DOI 10.1586/17474124.2016.1122522
   Rashtchizadeh N, 2019, BIOCHEM PHARMACOL, V163, P94, DOI 10.1016/j.bcp.2019.02.006
   Sun CY, 2019, BIOMED PHARMACOTHER, V110, P518, DOI 10.1016/j.biopha.2018.12.010
   Weinberg BA, 2017, ONCOLOGY-NY, V31, P381
   Wu SX, 2019, ONCOL LETT, V17, P4667, DOI 10.3892/ol.2019.10076
   Ye T, 2020, CARCINOGENESIS, V41, P25, DOI 10.1093/carcin/bgz079
   Yiu AJ, 2016, ANTICANCER RES, V36, P1093
   Yu Z, 2018, EUR REV MED PHARMACO, V22, P5867, DOI 10.26355/eurrev_201809_15913
   Zhang F, 2017, ONCOTARGET, V8, P35460, DOI 10.18632/oncotarget.16727
NR 25
TC 2
Z9 2
U1 2
U2 7
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD APR
PY 2020
VL 24
IS 7
BP 3614
EP 3623
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA LH4XH
UT WOS:000528789200028
PM 32329836
DA 2022-04-25
ER

PT J
AU Sain, A
   Kandasamy, T
   Naskar, D
AF Sain, Arindam
   Kandasamy, Thirukumaran
   Naskar, Debdut
TI In silico approach to target PI3K/Akt/mTOR axis by selected Olea
   europaea phenols in PIK3CA mutant colorectal cancer
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article; Early Access
DE Olive phenolic compounds; apigenin; pinoresinol; molecular docking;
   molecular dynamics simulation
ID OLIVE OIL; PROLIFERATION; OLEUROPEIN; APOPTOSIS; AUTOPHAGY; PATHWAY;
   INHIBITION; INVASION; COLITIS; CELLS
AB Worldwide disease burden of colorectal cancer (CRC) increasing alarmingly, but a suitable therapeutic strategy is not available yet. Abnormal activation of the PI3K/Akt/mTOR signalling because of mutation in the PIK3CA gene is a driving force behind CRC development. Therefore, this study aimed to comprehensively characterise the potential of phenolic compounds from Olea europaea against the PI3K/Akt/mTOR axis by using in silico methodologies. Molecular docking was utilised to study key interactions between phenolic compounds of O. europaea and target proteins PI3K, Akt, mTOR with reference to known inhibitor of target. Drug likeness and ADME/T properties of selected phenols were explored by online tools. Dynamic properties and binding free energy of target-ligand interactions were studied by molecular dynamic simulation and MM-PBSA method respectively. Molecular docking revealed apigenin, luteolin, pinoresinol, oleuropein, and oleuropein aglycone as the top five phenolic compounds which showed comparable/better binding affinity than the known inhibitor of the respective target protein. Drug likeness and ADME/T properties were employed to select the top three phenols namely, apigenin, luteolin, and pinoresinol which shown to bind stably to the catalytic cleft of target proteins as confirmed by molecular dynamics simulations. Therefore, Apigenin, luteolin, and pinoresinol have the potential to be used as the non-toxic alternative to synthetic chemical inhibitors generally used in CRC treatment as they can target PI3K/Akt/mTOR axis. Particularly, pinoresinol showed great potential as dual PI3K/mTOR inhibitor. However, this study needs to be complemented with future in vitro and in vivo studies to provide an alternative way of CRC treatment. Communicated by Ramaswamy H. Sarma
C1 [Sain, Arindam; Naskar, Debdut] Maulana Abul Kalam Azad Univ Technol, Dept Biotechnol, Nadia 741249, W Bengal, India.
   [Kandasamy, Thirukumaran] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Gauhati, Assam, India.
RP Naskar, D (corresponding author), Maulana Abul Kalam Azad Univ Technol, Dept Biotechnol, Nadia 741249, W Bengal, India.
EM debdut1984@gmail.com
RI Naskar, Debdut/AAY-8486-2021
OI , Thirukumaran/0000-0002-4533-9337; Naskar, Debdut/0000-0001-8243-2066
FU Department of Science and Technology, Govt. of India (DST)-Inspire
   faculty research grant [DST/INSPIRE/04/2017/000675]; Maulana Abul Kalam
   Azad University of Technology, West Bengal (MAKAUT); Council of
   Scientific and Industrial Research (CSIR), Govt. of IndiaCouncil of
   Scientific & Industrial Research (CSIR) - India
FX This work was supported by Department of Science and Technology, Govt.
   of India (DST)-Inspire faculty research grant
   (DST/INSPIRE/04/2017/000675) and Maulana Abul Kalam Azad University of
   Technology, West Bengal (MAKAUT, WB) research seed grant to D.N. A.S was
   supported by fellowship from Council of Scientific and Industrial
   Research (CSIR), Govt. of India.
CR Afrin S, 2020, BIOTECHNOL ADV, V38, DOI 10.1016/j.biotechadv.2018.11.011
   Bahrami A, 2018, J CELL BIOCHEM, V119, P2460, DOI 10.1002/jcb.25950
   Banavath HN, 2014, SCI REP-UK, V4, DOI 10.1038/srep06948
   Bonvino N.P., 2018, DATABASE-OXFORD, V2018, pBAY016, DOI [https://doi.org/10.1093/database/bay016, DOI 10.1093/database/bay016]
   Borzi AM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010032
   Castejon ML, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9020149
   Chen Y, 2018, ANTICANCER RES, V38, P1445, DOI 10.21873/anticanres.12369
   Dannenberg JJ, 1998, J AM CHEM SOC, V120, P5604, DOI [10.1021/ja9756331, DOI 10.1021/JA9756331, DOI 10.1021/ja9756331]
   Drott J, 2018, ONCOL NURS FORUM, V45, P690, DOI 10.1188/18.ONF.690-697
   Erbas A, 2018, PHYS REV E, V97, DOI 10.1103/PhysRevE.97.022405
   Foley TM, 2017, MOL CANCER RES, V15, P317, DOI [10.1158/1541-7786.MCR-16-0256-T, 10.1158/1541-7786.MCR-16-0256]
   Giner E, 2016, MOL NUTR FOOD RES, V60, P242, DOI 10.1002/mnfr.201500605
   Hamada T, 2017, ONCOTARGET, V8, P22305, DOI [10.18632/oncotarget.15278, 10.18632/oncotarget.15724]
   Hashmi MA, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/541591
   Heerding DA, 2008, J MED CHEM, V51, P5663, DOI 10.1021/jm8004527
   Je IG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129829
   Kim S, 2019, NUCLEIC ACIDS RES, V47, pD1102, DOI 10.1093/nar/gky1033
   Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   Lemkul J., 2019, LIVECOMS, V1, P5068, DOI [10.33011/livecoms.1.1.5068, DOI 10.33011/LIVECOMS.1.1.5068, 10.33011/ livecoms.1.1.5068.]
   Li CH, 2013, J NUTR BIOCHEM, V24, P1766, DOI 10.1016/j.jnutbio.2013.03.006
   Liu M, 2016, ONCOL REP, V36, P2009, DOI 10.3892/or.2016.4978
   Lynch T, 2007, AM FAM PHYSICIAN, V76, P391
   Morris G.M., 2009, J COMPUT CHEM, V30, P2785, DOI [https://doi.org/10.1002/jcc.21256, DOI 10.1002/jcc.21256]
   Nagappan A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174591
   Narayanankutty A, 2019, CURR DRUG TARGETS, V20, P1217, DOI 10.2174/1389450120666190618123846
   Nitulescu GM, 2018, INT J ONCOL, V53, P2319, DOI 10.3892/ijo.2018.4597
   Park YL, 2019, INT J CANCER, V144, P389, DOI 10.1002/ijc.31662
   Pei Y-h., 2016, MEDIAT INFLAMM, V2016, P1232103, DOI [https://doi.org/10.1155/2016/1232103, DOI 10.1155/2016/1232103]
   Pires DEV, 2015, J MED CHEM, V58, P4066, DOI 10.1021/acs.jmedchem.5b00104
   Poini B, 2018, TOXICOL IN VITRO, V52, P243, DOI 10.1016/j.tiv.2018.06.021
   Rigacci S, 2015, ONCOTARGET, V6, P35344, DOI 10.18632/oncotarget.6119
   Sabri Mohamad Zulkeflee, 2019, Advances in Bioinformatics, V2019, P6912914, DOI 10.1155/2019/6912914
   Sanchez-Fidalgo S, 2015, J NUTR BIOCHEM, V26, P513, DOI 10.1016/j.jnutbio.2014.12.001
   Sanguinetti MC, 2014, CURR OPIN PHARMACOL, V15, P22, DOI 10.1016/j.coph.2013.11.006
   Scotece M, 2013, CURR MED CHEM, V20, P2467, DOI 10.2174/0929867311320190006
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Stoneham M, 2000, J EPIDEMIOL COMMUN H, V54, P756, DOI 10.1136/jech.54.10.756
   Stuttfeld E, 2018, ELIFE, V7, DOI [10.7554/elife.33101, 10.7554/eLife.33101]
   Veber DF, 2002, J MED CHEM, V45, P2615, DOI 10.1021/jm020017n
   Wang CH, 2018, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00087
   Xavier CPR, 2009, CANCER LETT, V281, P162, DOI 10.1016/j.canlet.2009.02.041
   Xing CG, 2008, ACTA BIOCH BIOPH SIN, V40, P194, DOI 10.1111/j.1745-7270.2008.00393.x
   Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00416-0
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yang T, 2019, INT J CANCER, V145, P2315, DOI 10.1002/ijc.32057
   Yao X, 2019, FOOD FUNCT, V10, P703, DOI 10.1039/c8fo02013b
   Yu J, 2019, FOOD CHEM TOXICOL, V125, P376, DOI 10.1016/j.fct.2019.01.017
NR 48
TC 3
Z9 3
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
DI 10.1080/07391102.2021.1953603
EA JUL 2021
PG 16
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA TN2AC
UT WOS:000676042400001
PM 34296655
DA 2022-04-25
ER

PT J
AU Nazeri, M
   Mirzaie-asl, A
   Saidijam, M
   Moradi, M
AF Nazeri, Mehri
   Mirzaie-asl, Asghar
   Saidijam, Massoud
   Moradi, Mohammadreza
TI Methanolic extract of Artemisia absinthium prompts apoptosis, enhancing
   expression of Bax/Bcl-2 ratio, cell cycle arrest, caspase-3 activation
   and mitochondrial membrane potential destruction in human colorectal
   cancer HCT-116 cells
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Artemisia absinthium; bcl-2-Associated X Protein; Caspase3 protein; Flow
   Cytometry; HCT116 cells
ID GENE-EXPRESSION; IN-VITRO; ASTERACEAE; INDUCTION; AUTOPHAGY; ANTITUMOR;
   ROOT; L.
AB The Artemisia absinthium (AA), belongs to the Asteraceae family, is used as a therapeutic agent in traditional medicine in Iran. It is a rich source of biology-active compounds. However, the molecular mechanism of AA contributing to cell proliferation and apoptosis is still unknown. This study aims to assess the anticancer activity of the methanolic extract of A. absinthium (MEAA) against human colorectal cancer HCT-116 cell line. The cytotoxic effects of MEAA on HCT-116 cells was evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) assay. The expression levels of BAX and BCL-2 in HCT-116 cell line were examined by qRT-PCR. Annexin V/PI-flow cytometry technique was used to detect the cell cycle and apoptosis. MMP was predicted by Rhodamine 123 staining, and caspase 3 activity was analyzed by ELISA. Western blot method was performed to detect the expression level of BAX, Bcl-2 and Caspase-3 proteins. The MTT test revealed MEAA reduced the viability of HCT-116 cells. The mRNA and protein levels of BAX increased, but those of BCL-2 decreased in MEAA-treated cells. MEAA also prompted cell cycle arrest and induced apoptosis. After adding MEAA, the protein level and activity of caspase 3 and MMP destruction significantly increased. MEAA predominantly prompted apoptosis in HCT-116 cells by activating the mitochondrial pathway.
C1 [Nazeri, Mehri; Mirzaie-asl, Asghar] Bu Ali Sina Univ, Fac Agr, Dept Biotechnol, Hamadan, Hamadan, Iran.
   [Saidijam, Massoud; Moradi, Mohammadreza] Hamadan Univ Med Sci, Res Ctr Mol Med, Hamadan, Iran.
RP Mirzaie-asl, A (corresponding author), Bu Ali Sina Univ, Fac Agr, Dept Biotechnol, Hamadan, Hamadan, Iran.
EM a.mirzaie@basu.ac.ir
FU Bu-Ali Sina University, Hamedan, Iran
FX This original paper was supported by grants from Bu-Ali Sina University,
   Hamedan, Iran.
CR Abdulridha MK, 2020, J GASTROINTEST CANC, V51, P439, DOI 10.1007/s12029-019-00299-6
   Baghbani-Arani F, 2017, J PHOTOCH PHOTOBIO B, V173, P640, DOI 10.1016/j.jphotobiol.2017.07.003
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Canadanovic-Brunet JM, 2005, J SCI FOOD AGR, V85, P265, DOI 10.1002/jsfa.1950
   Craciunescu O, 2012, CHEM CENT J, V6, DOI 10.1186/1752-153X-6-97
   Dane Y, 2016, ARAB J SCI ENG, V41, P2147, DOI 10.1007/s13369-015-1977-2
   Diao Shu-Ling, 2016, Med Sci Monit, V22, P1497
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gordanian B, 2014, RES PHARM SCI, V9, P91
   Hamilton W., 2007, CANC DIAGNOSIS PRIMA
   Huang M, 2007, CLIN CANCER RES, V13, P1298, DOI 10.1158/1078-0432.CCR-06-1277
   Huang XM, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109142
   Jo EH, 2005, CANCER LETT, V230, P239, DOI 10.1016/j.canlet.2004.12.038
   Abad MJ, 2012, MOLECULES, V17, P2542, DOI 10.3390/molecules17032542
   Karimi DF, 2017, J CELL BIOCHEM, V118, P1547, DOI DOI 10.1002/jcb.25816
   Li L, 2008, CANCER LETT, V272, P61, DOI 10.1016/j.canlet.2008.06.033
   Lian GH, 2018, J BUON, V23, P73
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Martinez-Diaz RA, 2015, MEM I OSWALDO CRUZ, V110, P693, DOI 10.1590/0074-02760140129
   Moac E.-A., 2019, PHYSICOCHEMICAL NUTR, V24, P3087, DOI DOI 10.3390/molecules24173087
   Mubashir Hussain, 2017, Asian Pacific Journal of Tropical Disease, V7, P185, DOI 10.12980/apjtd.7.2017D6-385
   Mudd AM, 2020, CANCER PREV RES, V13, P41, DOI 10.1158/1940-6207.CAPR-19-0362
   Roshanravan N, 2018, ADV PHARM BULL, V8, P667, DOI 10.15171/apb.2018.075
   Shafi G, 2012, MOL BIOL REP, V39, P7373, DOI 10.1007/s11033-012-1569-0
   Shamas-Din A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008714
   Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053
   Tayarani-Najaran Z, 2017, IRAN J BASIC MED SCI, V20, P166, DOI 10.22038/ijbms.2017.8242
   Umezawa S, 2019, CANCER SCI, V110, P3018, DOI 10.1111/cas.14149
   Vahed SZ, 2017, BIOMED PHARMACOTHER, V94, P1094, DOI 10.1016/j.biopha.2017.08.033
   van der Stok EP, 2017, NAT REV CLIN ONCOL, V14, P297, DOI 10.1038/nrclinonc.2016.199
   Wang W, 2019, SEMIN CANCER BIOL, V55, P37, DOI 10.1016/j.semcancer.2018.05.002
   Wang Y, 2018, CURR DRUG METAB, V19, P739, DOI 10.2174/1389200219666180511154722
   Willcox M, 2009, J ALTERN COMPLEM MED, V15, P101, DOI 10.1089/acm.2008.0327
   Xie YZ, 2017, MOL MED REP, V15, P2633, DOI 10.3892/mmr.2017.6300
   Zeng YT, 2015, MOL MED REP, V11, P2234, DOI 10.3892/mmr.2014.3012
NR 36
TC 4
Z9 4
U1 1
U2 12
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD NOV
PY 2020
VL 47
IS 11
BP 8831
EP 8840
DI 10.1007/s11033-020-05933-2
EA NOV 2020
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA PB8WL
UT WOS:000585000700001
PM 33141288
DA 2022-04-25
ER

PT J
AU Gines, A
   Bystrup, S
   de Porras, VR
   Guardia, C
   Musulen, E
   Martinez-Cardus, A
   Manzano, JL
   Layos, L
   Abad, A
   Martinez-Balibrea, E
AF Gines, Alba
   Bystrup, Sara
   Ruiz de Porras, Vicenc
   Guardia, Cristina
   Musulen, Eva
   Martinez-Cardus, Anna
   Luis Manzano, Jose
   Layos, Laura
   Abad, Albert
   Martinez-Balibrea, Eva
TI PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance
   Acquisition in HT29 Human Colorectal Cancer Cell Lines
SO PLOS ONE
LA English
DT Article
ID PYRUVATE-KINASE M2; NUCLEAR TRANSLOCATION; MOLECULAR-MECHANISMS;
   GENE-TRANSCRIPTION; DEATH; IDENTIFICATION; METABOLISM; AUTOPHAGY; P53;
   DETERMINANTS
AB Chemoresistance is the main cause of treatment failure in advanced colorectal cancer (CRC). However, molecular mechanisms underlying this phenomenon remain to be elucidated. In a previous work we identified low levels of PKM2 as a putative oxaliplatin-resistance marker in HT29 CRC cell lines and also in patients. In order to assess how PKM2 influences oxaliplatin response in CRC cells, we silenced PKM2 using specific siRNAs in HT29, SW480 and HCT116 cells. MTT test demonstrated that PKM2 silencing induced resistance in HT29 and SW480 cells and sensitivity in HCT116 cells. Same experiments in isogenic HCT116 p53 null cells and double silencing of p53 and PKM2 in HT29 cells failed to show an influence of p53. By using trypan blue stain and FITC-Annexin V/PI tests we detected that PKM2 knockdown was associated with an increase in cell viability but not with a decrease in apoptosis activation in HT29 cells. Fluorescence microscopy revealed PKM2 nuclear translocation in response to oxaliplatin in HCT116 and HT29 cells but not in OXA-resistant HTOXAR3 cells. Finally, by using a qPCR Array we demonstrated that oxaliplatin and PKM2 silencing altered cell death gene expression patterns including those of BMF, which was significantly increased in HT29 cells in response to oxaliplatin, in a dose and time-dependent manner, but not in siPKM2-HT29 and HTOXAR3 cells. BMF gene silencing in HT29 cells lead to a decrease in oxaliplatin-induced cell death. In conclusion, our data report new non-glycolytic roles of PKM2 in response to genotoxic damage and proposes BMF as a possible target gene of PKM2 to be involved in oxaliplatin response and resistance in CRC cells.
C1 [Gines, Alba; Bystrup, Sara; Ruiz de Porras, Vicenc; Guardia, Cristina; Musulen, Eva; Martinez-Cardus, Anna; Luis Manzano, Jose; Layos, Laura; Abad, Albert; Martinez-Balibrea, Eva] Germans Trias I Pujol Fdn IGTP, Hlth Sci Res Inst, Lab Mol Canc Biol, Translat Res Digest Tumours Grp, Badalona, Spain.
   [Musulen, Eva] Univ Hosp Germans Trias I Pujol, Human Pathol Dept, Badalona, Spain.
   [Luis Manzano, Jose; Layos, Laura; Abad, Albert; Martinez-Balibrea, Eva] Univ Hosp Germans Trias I Pujol, Catalan Inst Oncol ICO, Med Oncol Serv, Badalona, Spain.
RP Martinez-Balibrea, E (corresponding author), Germans Trias I Pujol Fdn IGTP, Hlth Sci Res Inst, Lab Mol Canc Biol, Translat Res Digest Tumours Grp, Badalona, Spain.
EM embalibrea@iconcologia.net
RI Martinez, Anna/AAA-4939-2020; Musulen, Eva/AAI-9169-2020
OI Musulen, Eva/0000-0002-9667-6464; Martinez-Balibrea,
   Eva/0000-0002-4501-7100; Ruiz de Porras, Vicenc/0000-0002-4352-1784;
   Martinez Cardus, Anna/0000-0002-3937-8794; Guardia Valenzuela,
   Cristina/0000-0001-5176-1924; Bystrup, Sara/0000-0001-9029-1734
FU beca bianual de la Fundacion Olga Torres
FX This work was funded by beca bianual de la Fundacion Olga Torres
   2008-2009 (http://www.fundacioolgatorres.org/beques_d-investigacio/) to
   EMB AGM AA AMC EM JLM.
CR ALLEY MC, 1988, CANCER RES, V48, P589
   Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485
   Arango D, 2004, BRIT J CANCER, V91, P1931, DOI 10.1038/sj.bjc.6602215
   Arnould S, 2003, EUR J CANCER, V39, P112, DOI 10.1016/S0959-8049(02)00411-2
   Bose D, 2011, BRIT J CANCER, V105, P1759, DOI 10.1038/bjc.2011.449
   Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497
   Cheung EC, 2010, CURR OPIN CELL BIOL, V22, P186, DOI 10.1016/j.ceb.2009.12.006
   Choi YE, 2009, J BIOL CHEM, V284, P12772, DOI 10.1074/jbc.M807550200
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667
   Contreras AU, 2013, J CELL BIOL, V201, P427, DOI 10.1083/jcb.201205064
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Du HL, 2012, ONCOL REP, V27, P143, DOI 10.3892/or.2011.1464
   Elkholi Rana, 2011, Genes Cancer, V2, P523, DOI 10.1177/1947601911417177
   Galluzzi L, 2007, CELL DEATH DIFFER, V14, P1237, DOI 10.1038/sj.cdd.4402148
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Hata T, 2005, MOL CANCER THER, V4, P1585, DOI 10.1158/1535-7163.MCT-05-0011
   Heiden MGV, 2010, SCIENCE, V329, P1492, DOI 10.1126/science.1188015
   Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044
   Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431
   Hoshino A, 2007, J BIOL CHEM, V282, P17706, DOI 10.1074/jbc.M700094200
   Kang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.422
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Lee JW, 2008, INT J BIOCHEM CELL B, V40, P1043, DOI 10.1016/j.biocel.2007.11.009
   Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025
   Martinez-Balibrea E, 2009, MOL CANCER THER, V8, P771, DOI 10.1158/1535-7163.MCT-08-0882
   Martinez-Cardus A, 2009, MOL CANCER THER, V8, P194, DOI 10.1158/1535-7163.MCT-08-0659
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Plasencia C, 2006, INT J ONCOL, V29, P225
   Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006
   Rakitina TV, 2007, BIOCHEM PHARMACOL, V73, P1715, DOI 10.1016/j.bcp.2007.01.037
   Sakai A, 2012, J PROTEOMICS, V75, P806, DOI 10.1016/j.jprot.2011.09.023
   Spoden GA, 2009, J CELL BIOCHEM, V107, P293, DOI 10.1002/jcb.22125
   Stetak A, 2007, CANCER RES, V67, P1602, DOI 10.1158/0008-5472.CAN-06-2870
   Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024
   Tischner D, 2012, APOPTOSIS, V17, P1197, DOI 10.1007/s10495-012-0756-8
   Toscano F, 2007, BIOCHEM PHARMACOL, V74, P392, DOI 10.1016/j.bcp.2007.05.001
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(05)17706-X
   William-Faltaos S, 2007, FUND CLIN PHARMACOL, V21, P165, DOI 10.1111/j.1472-8206.2007.00462.x
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598
   Yoo BC, 2004, INT J CANCER, V108, P532, DOI 10.1002/ijc.11604
   Zhang DW, 2009, SCIENCE, V325, P332, DOI 10.1126/science.1172308
   Zhou R, 2002, CANCER RES, V62, P3515
NR 44
TC 27
Z9 30
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 8
PY 2015
VL 10
IS 5
AR e0123830
DI 10.1371/journal.pone.0123830
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CL2IX
UT WOS:000356768100021
PM 25955657
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Pantelic, ND
   Bozic, B
   Zmejkovski, BB
   Banjac, NR
   Dojcinovic, B
   Wessjohann, LA
   Kaluderovic, GN
AF Pantelic, Nebojsa D.
   Bozic, Bojan
   Zmejkovski, Bojana B.
   Banjac, Nebojsa R.
   Dojcinovic, Biljana
   Wessjohann, Ludger A.
   Kaluderovic, Goran N.
TI In Vitro Evaluation of Antiproliferative Properties of Novel
   Organotin(IV) Carboxylate Compounds with Propanoic Acid Derivatives on a
   Panel of Human Cancer Cell Lines
SO MOLECULES
LA English
DT Article
DE triphenyltin(IV); breast cancer; cytotoxicity; apoptosis; ICP-MS
ID ANTITUMOR-ACTIVITY; METAL-COMPLEXES; GOLD(III) COMPLEXES; APOPTOSIS;
   AUTOPHAGY; CASPASE-3
AB The synthesis of novel triphenyltin(IV) compounds, Ph(3)SnLn (n = 1-3), with oxaprozin (3-(4,5-diphenyloxazol-2-yl)propanoic acid), HL1, and the new propanoic acid derivatives 3-(4,5-bis(4-methoxylphenyl)oxazol-2-yl)propanoic acid, HL2, and 3-(2,5-dioxo-4,4-diphenylimidazolidin-1-yl)propanoic acid, HL3, has been performed. The ligands represent commercial drugs or their derivatives and the tin complexes have been characterized by standard analytical methods. The in vitro antiproliferative activity of both ligands and organotin(IV) compounds has been evaluated on the following tumour cell lines: human prostate cancer (PC-3), human colorectal adenocarcinoma (HT-29), breast cancer (MCF-7), and hepatocellular cancer (HepG2), as well as on normal mouse embryonic fibroblast cells (NIH3T3) with the aid of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-12 diphenyltetrazolium bromide) and CV (crystal violet) assays. Contrary to the inactive ligand precursors, all organotin(IV) carboxylates showed very good activity with IC50 values ranging from 0.100 to 0.758 mu M. According to the CV assay (IC50 = 0.218 +/- 0.025 mu M), complex Ph(3)SnL1 demonstrated the highest cytotoxicity against the caspase 3 deficient MCF-7 cell line. Inductively coupled plasma mass spectrometry (ICP-MS) analysis indicated a two-fold lower concentration of tin in MCF-7 cells in comparison to platinum. To investigate the mechanism of action of the compound Ph(3)SnL1 on MCF-7 cells, morphological, autophagy and cell cycle analysis, as well as the activation of caspase and ROS/RNS and NO production, has been performed. Results suggest that Ph(3)SnL1 induces caspase-independent apoptosis in MCF-7 cells.
C1 [Pantelic, Nebojsa D.; Kaluderovic, Goran N.] Univ Appl Sci Merseburg, Dept Engn & Nat Sci, Eberhard Leibnitz Str 2, DE-06217 Merseburg, Germany.
   [Pantelic, Nebojsa D.; Banjac, Nebojsa R.] Univ Belgrade, Fac Agr, Dept Chem & Biochem, Nemanjina 6, Belgrade 11080, Serbia.
   [Pantelic, Nebojsa D.; Wessjohann, Ludger A.; Kaluderovic, Goran N.] Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Saale, Germany.
   [Bozic, Bojan] Univ Belgrade, Inst Physiol & Biochem Ivan Djaja, Fac Biol, Studentski Trg 16, Belgrade 11000, Serbia.
   [Zmejkovski, Bojana B.; Dojcinovic, Biljana] Univ Belgrade, Inst Chem Technol & Met, Dept Chem, Studentski Trg 14, Belgrade 11000, Serbia.
RP Pantelic, ND; Kaluderovic, GN (corresponding author), Univ Appl Sci Merseburg, Dept Engn & Nat Sci, Eberhard Leibnitz Str 2, DE-06217 Merseburg, Germany.; Pantelic, ND (corresponding author), Univ Belgrade, Fac Agr, Dept Chem & Biochem, Nemanjina 6, Belgrade 11080, Serbia.; Pantelic, ND; Kaluderovic, GN (corresponding author), Leibniz Inst Plant Biochem, Dept Bioorgan Chem, Weinberg 3, D-06120 Halle, Saale, Germany.
EM pantelic@agrif.bg.ac.rs; bbozic@bio.bg.ac.rs;
   bojana.zmejkovski@ihtm.bg.ac.rs; nbanjac@agrif.bg.ac.rs;
   bmatic@chem.bg.ac.rs; nbanjac@agrif.bg.ac.rs;
   goran.kaluderovic@hs-merseburg.de
RI Wessjohann, Ludger/AAZ-3838-2021; Kaluderovic, Goran/E-6310-2013
OI Kaluderovic, Goran/0000-0001-5168-1000; Pantelic, Nebojsa
   D./0000-0003-1843-9890; Bozic, Bojan/0000-0001-9910-2741
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia [451-03-9/2021-14/200026, 451-03-9/202114/200116,
   451-03-9/2021-14/200178]; German Academic Exchange Service
   (DAAD)Deutscher Akademischer Austausch Dienst (DAAD) [57448219];
   National Scholarship for Postdoctoral Studies of the Republic of Serbia
FX This work was supported by the Ministry of Education, Science and
   Technological Development of the Republic of Serbia, Contract numbers:
   451-03-9/2021-14/200026, 451-03-9/202114/200116 and
   451-03-9/2021-14/200178; National Scholarship for Postdoctoral Studies
   of the Republic of Serbia (N. D. Panteli ' c); German Academic Exchange
   Service (DAAD) Grant number 57448219.
CR Adam MAA, 2017, ONCOL REP, V37, P1321, DOI 10.3892/or.2017.5424
   Alama A, 2009, DRUG DISCOV TODAY, V14, P500, DOI 10.1016/j.drudis.2009.02.002
   Banada N.K., 1996, APOPTOSIS, V1, P49, DOI DOI 10.1007/bf00142078
   Banti CN, 2019, J INORG BIOCHEM, V194, P114, DOI 10.1016/j.jinorgbio.2019.02.003
   Bozic B, 2017, ARAB J CHEM, V10, pS2637, DOI 10.1016/j.arabjc.2013.10.002
   Bozic BDJ, 2012, CHEM PHARM BULL, V60, P865
   Bulatovic MZ, 2014, ANGEW CHEM INT EDIT, V53, P5982, DOI 10.1002/anie.201400763
   Chernyavskiy P, 2017, BRIT J CANCER, V117, P41, DOI 10.1038/bjc.2017.141
   Dalby KN, 2010, AUTOPHAGY, V6, P322, DOI 10.4161/auto.6.3.11625
   Davies MJ, 2005, BBA-PROTEINS PROTEOM, V1703, P93, DOI 10.1016/j.bbapap.2004.08.007
   DEACON GB, 1980, COORDIN CHEM REV, V33, P227, DOI 10.1016/S0010-8545(00)80455-5
   Esmail SAA, 2019, APPL ORGANOMET CHEM, V33, DOI 10.1002/aoc.4651
   Gomez-Ruiz S, 2008, J INORG BIOCHEM, V102, P2087, DOI 10.1016/j.jinorgbio.2008.07.009
   Hadjikakou SK, 2009, COORDIN CHEM REV, V253, P235, DOI 10.1016/j.ccr.2007.12.026
   Hara K, 2011, J PHARMACOL EXP THER, V337, P838, DOI 10.1124/jpet.111.179473
   Kagawa S, 2001, CLIN CANCER RES, V7, P1474
   Kaluderovic GN, 2015, J INORG BIOCHEM, V153, P315, DOI 10.1016/j.jinorgbio.2015.09.006
   Kaluderovic GN, 2010, J ORGANOMET CHEM, V695, P1883, DOI 10.1016/j.jorganchem.2010.04.029
   Kaluderovic GN, 2010, METALLOMICS, V2, P419, DOI 10.1039/c0mt00007h
   Kang BW, 2014, WORLD J GASTROENTERO, V20, P5396, DOI 10.3748/wjg.v20.i18.5396
   Kntayya SB, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060718
   Krajnovic T, 2016, PHARMACOL RES, V105, P62, DOI 10.1016/j.phrs.2016.01.011
   Kritchenkov AS, 2019, PHARM CHEM J+, V53, P6, DOI 10.1007/s11094-019-01947-8
   Ksouri R, 2019, FOOD QUAL SAF-OXFORD, V3, P227, DOI 10.1093/fqsafe/fyz021
   Lennicke C, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964-015-0118-6
   Li Y, 2015, BIOMATERIALS, V39, P95, DOI 10.1016/j.biomaterials.2014.10.070
   Liao John B, 2006, Yale J Biol Med, V79, P115
   Lushchak VI, 2014, CHEM-BIOL INTERACT, V224, P164, DOI 10.1016/j.cbi.2014.10.016
   Moldogazieva NT, 2018, FREE RADICAL RES, V52, P507, DOI 10.1080/10715762.2018.1457217
   Mucha P, 2019, RSC ADV, V9, P31943, DOI 10.1039/c9ra05971g
   Ott I, 2007, ARCH PHARM, V340, P117, DOI 10.1002/ardp.200600151
   Pantelic N, 2017, J INORG BIOCHEM, V172, P55, DOI 10.1016/j.jinorgbio.2017.04.001
   Pantelic N, 2015, EUR J MED CHEM, V90, P766, DOI 10.1016/j.ejmech.2014.12.019
   Pantelic ND, 2020, J INORG BIOCHEM, V211, DOI 10.1016/j.jinorgbio.2020.111207
   Pantelic ND, 2019, J SERB CHEM SOC, V84, P1119, DOI 10.2298/JSC190322032P
   Pantelic ND, 2019, J CHEM-NY, V2019, DOI 10.1155/2019/2905840
   Phaniendra A, 2015, INDIAN J CLIN BIOCHE, V30, P11, DOI 10.1007/s12291-014-0446-0
   Qin JL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46056
   Sies H, 2017, ANNU REV BIOCHEM, V86, P715, DOI 10.1146/annurev-biochem-061516-045037
   SLADOWSKI D, 1993, J IMMUNOL METHODS, V157, P203, DOI 10.1016/0022-1759(93)90088-O
   Sliwka L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155772
   Yang XH, 2001, CANCER RES, V61, P348
   Zhang XJ, 2012, ONCOL REP, V27, P1128, DOI 10.3892/or.2011.1599
NR 43
TC 0
Z9 0
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD JUN
PY 2021
VL 26
IS 11
AR 3199
DI 10.3390/molecules26113199
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SQ5CQ
UT WOS:000660374300001
PM 34071809
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Deng, YD
   Zhang, XD
   Yang, XS
   Huang, ZL
   Wei, X
   Yang, XF
   Liao, WZ
AF Deng, Yu-Di
   Zhang, Xu-Dong
   Yang, Xu-Shan
   Huang, Zhen-Lie
   Wei, Xi
   Yang, Xing-Fen
   Liao, Wen-Zhen
TI Subacute toxicity of mesoporous silica nanoparticles to the intestinal
   tract and the underlying mechanism
SO JOURNAL OF HAZARDOUS MATERIALS
LA English
DT Article
DE Mesoporous silica nanoparticles; Oral exposure; Subacute Toxicity;
   Intestinal flora; Metabolomics
ID COMMENSAL BACTERIA; OXIDATIVE STRESS; GUT MICROBIOTA; IN-VITRO;
   INFLAMMATION; GLUTAMINE; NANOTHERANOSTICS; PROLIFERATION; MITOCHONDRIA;
   HOMEOSTASIS
AB The biological safety of mesoporous silica nanoparticles (MSNs) has gradually attracted attention. However, few studies of their toxicity to the intestine and mechanism are available. In this study, their primary structures were characterized, and their subacute toxicity to mice was investigated. After 2 weeks of intragastric administration of MSNs, they significantly enhanced serum ALP, ALT, AST and TNF-alpha levels and caused infiltration of inflammatory cells in the spleen and intestines. MSNs induced intestinal oxidative stress and colonic epithelial cell apoptosis in mice. Intestinal epithelial cells exhibited mitochondrial ridge rupture and membrane potential decrease after MSN treatment. Additionally, MSNs increased ROS and NLRP3 levels and inhibited expression of the autophagy proteins LC3-II and Beclin1. MSNs significantly changed the intestinal flora diversity in mice, especially for harmful bacteria, leading to intestinal microecology imbalance. Meanwhile, MSNs influenced the expression of metabolites, which were involved in a range of metabolic pathways, including pyrimidine metabolism, central carbon metabolism in cancer, protein digestion and absorption, mineral absorption, ABC transport and purine metabolism. These results indicated that the subacute toxicity of mesoporous silicon was mainly caused by intestinal damage. Thus, our research provides additional evidence about the safe dosage of MSNs in the clinical and food industries.
C1 [Deng, Yu-Di; Zhang, Xu-Dong; Yang, Xu-Shan; Wei, Xi; Liao, Wen-Zhen] Southern Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China.
   [Huang, Zhen-Lie] Southern Med Univ, Sch Publ Hlth, Dept Toxicol, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China.
   [Yang, Xing-Fen] Southern Med Univ, Sch Publ Hlth, Food Safety & Hlth Res Ctr, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China.
RP Liao, WZ (corresponding author), Southern Med Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China.; Yang, XF (corresponding author), Southern Med Univ, Sch Publ Hlth, Food Safety & Hlth Res Ctr, Guangdong Prov Key Lab Trop Dis Res, Guangzhou 510515, Peoples R China.
EM xfyang@vip.163.com; wenzhenliao@163.com
FU Guangdong Key RD Program [2019B020210002]; National Natural Science
   Foundation of ChinaNational Natural Science Foundation of China (NSFC)
   [81973013]; Natural Science Foundation of Guangdong ProvinceNational
   Natural Science Foundation of Guangdong Province [2018030310301,
   2020A1515010594]; Guangdong Regular Institutions of Higher Learning
   Characteristic Innovation Projects [2018KTSCX030]
FX This research is partially supported by grants from Guangdong Key R&D
   Program (No. 2019B020210002), National Natural Science Foundation of
   China (No. 81973013), Natural Science Foundation of Guangdong Province
   (No. 2018030310301, 2020A1515010594), Guangdong Regular Institutions of
   Higher Learning Characteristic Innovation Projects (No. 2018KTSCX030).
CR AbouAitah Khaled, 2018, Oncotarget, V9, P26466, DOI 10.18632/oncotarget.25470
   Akira S, 2003, SCAND J INFECT DIS, V35, P555, DOI 10.1080/00365540310015683
   [Anonymous], 2021, J HAZARD MATER, V409
   Apostolova N, 2015, ANTIOXID REDOX SIGN, V22, P686, DOI 10.1089/ars.2014.5952
   Auffan M, 2009, NAT NANOTECHNOL, V4, P634, DOI 10.1038/nnano.2009.242
   Banoth B, 2015, ELIFE, V4, DOI 10.7554/eLife.05648
   Biodistribution, 2015, NANOMED-NANOTECHNOL, V11
   Chen HQ, 2017, NANOIMPACT, V8, P80, DOI 10.1016/j.impact.2017.07.005
   Chi L, 2017, TOXICOL APPL PHARM, V331, P142, DOI 10.1016/j.taap.2017.06.008
   CHRISTOPHER T, 2013, J CLIN INVEST, V123, P3678
   Cilla A, 2018, FOOD RES INT, V103, P335, DOI 10.1016/j.foodres.2017.10.066
   Costa PM, 2016, TOXICOL APPL PHARM, V299, P101, DOI 10.1016/j.taap.2015.12.014
   Deretic V, 2009, DIGEST DIS, V27, P246, DOI 10.1159/000228557
   Dunn JD, 2015, REDOX BIOL, V6, P472, DOI 10.1016/j.redox.2015.09.005
   Engur S, 2017, ACTA CLIN BELG, V72, P391, DOI 10.1080/17843286.2017.1302623
   Farhadi A, 2003, J GASTROEN HEPATOL, V18, P479, DOI 10.1046/j.1440-1746.2003.03032.x
   Fu CH, 2012, CHINESE SCI BULL, V57, P2525, DOI 10.1007/s11434-012-5187-y
   Fu LL, 2013, INT J BIOCHEM CELL B, V45, P921, DOI 10.1016/j.biocel.2013.02.007
   Gioacchino M.D., 2012, ICOH
   Guo CX, 2015, INT J NANOMED, V10, P1463, DOI 10.2147/IJN.S76114
   Hammer AM, 2016, SHOCK, V45, P73, DOI 10.1097/SHK.0000000000000483
   Haspel JA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5753
   Hassankhani R, 2015, ENVIRON SCI POLLUT R, V22, P1127, DOI 10.1007/s11356-014-3413-7
   He QJ, 2012, BIOMATERIALS, V33, P4392, DOI 10.1016/j.biomaterials.2012.02.056
   Heischmann S, 2016, SCI REP-UK, V6, DOI 10.1038/srep31424
   Hernandez JB, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms8216, 10.1038/ncomms8489]
   Hills RD, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071613
   Hozayen WG, 2019, BIOMED PHARMACOTHER, V109, P2527, DOI 10.1016/j.biopha.2018.11.093
   Huang WJ, 2013, CELL RES, V23, P724, DOI 10.1038/cr.2013.15
   Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25
   Junying Zhu, 2016, LWT -- Food Science and Technology, V74, P211, DOI 10.1016/j.lwt.2016.07.016
   Kamei Y, 2020, NUTRIENTS, V12, DOI 10.3390/nu12010261
   Karu N, 2018, ANAL CHIM ACTA, V1030, P1, DOI 10.1016/j.aca.2018.05.031
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Kissova I, 2004, J BIOL CHEM, V279, P39068, DOI 10.1074/jbc.M406960200
   Klein J, 2007, P NATL ACAD SCI USA, V104, P2029, DOI 10.1073/pnas.0611610104
   Larsen JM, 2015, IMMUNOLOGY, V144, P333, DOI 10.1111/imm.12376
   Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009
   Li B, 2013, WATER RES, V47, P4207, DOI 10.1016/j.watres.2013.04.021
   Li LB, 2009, LASER MED SCI, V24, P597, DOI 10.1007/s10103-008-0620-9
   Li RS, 2015, ENVIRON HEALTH PERSP, V123, P34, DOI 10.1289/ehp.1307036
   Li XL, 2015, SHOCK, V43, P540, DOI 10.1097/SHK.0000000000000353
   Linder MC, 2003, BIOMETALS, V16, P145, DOI 10.1023/A:1020729831696
   Lu YY, 2016, SCI REP-UK, V6, DOI 10.1038/srep26337
   Lundberg DS, 2013, NAT METHODS, V10, P999, DOI 10.1038/nmeth.2634
   Ma SP, 2011, J POROUS MAT, V18, P233, DOI 10.1007/s10934-010-9375-3
   Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735
   Martinez JO, 2013, SMALL, V9, P1722, DOI 10.1002/smll.201201939
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Min-Hyun Kim, 2017, International Journal of Molecular Sciences, V18, DOI 10.3390/ijms18051051
   MINCHIN PR, 1987, VEGETATIO, V69, P89, DOI 10.1007/BF00038690
   Morishige T, 2012, ARCH TOXICOL, V86, P1297, DOI 10.1007/s00204-012-0823-5
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P735, DOI 10.1038/nrd.2016.223
   Murshid A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122529
   Png CW, 2010, AM J GASTROENTEROL, V105, P2420, DOI 10.1038/ajg.2010.281
   RASMUSON T, 1987, ACTA ONCOL, V26, P261, DOI 10.3109/02841868709089972
   Rasmussen K, 2018, REGUL TOXICOL PHARM, V92, P8, DOI 10.1016/j.yrtph.2017.10.019
   Ren GM, 2019, EMBO J, V38, DOI 10.15252/embj.2018100376
   Renato M, 2014, PLOS ONE, V9
   Samuelson DR, 2015, FRONT MICROBIOL, V6, DOI [10.5389/fmicb.2015.01085, 10.3389/fmicb.2015.01085]
   Schroder K, 2010, SCIENCE, V327, P296, DOI 10.1126/science.1184003
   Shen DK, 2014, NANO LETT, V14, P923, DOI 10.1021/nl404316v
   Sheng YH, 2011, GUT, V60, P1661, DOI 10.1136/gut.2011.239194
   Shi CS, 2012, NAT IMMUNOL, V13, P255, DOI 10.1038/ni.2215
   Shimizu K, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2167-x
   Shimizu K, 2011, DIGEST DIS SCI, V56, P1171, DOI 10.1007/s10620-010-1418-8
   Shirkey TW, 2006, EXP BIOL MED, V231, P1333, DOI 10.1177/153537020623100807
   Singh R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-07859-7
   Singh RK, 2017, ACS APPL MATER INTER, V9, P10309, DOI 10.1021/acsami.6b16505
   SMITH RJ, 1990, JPEN-PARENTER ENTER, V14, pS94, DOI 10.1177/014860719001400412
   Sun JG, 2019, INT J NANOMED, V14, P1489, DOI 10.2147/IJN.S195504
   Sun WF, 2014, PHYS CHEM CHEM PHYS, V16, P5846, DOI 10.1039/c3cp55082f
   Tan HWS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00369-y
   Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552
   van der Zande M, 2014, PART FIBRE TOXICOL, V11, DOI 10.1186/1743-8977-11-8
   Waluyo I, 2011, J CHEM PHYS, V134, DOI 10.1063/1.3533958
   Wang J, 2014, J EXP MED, V211, P2397, DOI 10.1084/jem.20140625
   Willing BP, 2007, J ANIM SCI, V85, P3256, DOI 10.2527/jas.2007-0320
   Wilschefski Scott C, 2019, Clin Biochem Rev, V40, P115, DOI 10.33176/AACB-19-00024
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Wu GY, 1998, J NUTR, V128, P1249, DOI 10.1093/jn/128.8.1249
   Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k
   Yiu HHP, 2001, PHYS CHEM CHEM PHYS, V3, P2983, DOI 10.1039/b104729a
   Yu HM, 2017, ANNU REV PHYSIOL, V79, P291, DOI 10.1146/annurev-physiol-021115-105211
   Zinkernagel RM, 2000, SEMIN IMMUNOL, V12, P163, DOI 10.1006/smim.2000.0253
NR 85
TC 8
Z9 8
U1 24
U2 101
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-3894
EI 1873-3336
J9 J HAZARD MATER
JI J. Hazard. Mater.
PD MAY 5
PY 2021
VL 409
AR 124502
DI 10.1016/j.jhazmat.2020.124502
EA FEB 2021
PG 22
WC Engineering, Environmental; Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Environmental Sciences & Ecology
GA QM3GJ
UT WOS:000621669800006
PM 33229260
DA 2022-04-25
ER

PT J
AU Tato, I
   Bartrons, R
   Ventura, F
   Rosa, JL
AF Tato, Irantzu
   Bartrons, Ramon
   Ventura, Francesc
   Luis Rosa, Jose
TI Amino Acids Activate Mammalian Target of Rapamycin Complex 2 (mTORC2)
   via PI3K/Akt Signaling
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID P70 S6 KINASE; MUSCLE PROTEIN-SYNTHESIS; FOXO TRANSCRIPTION FACTORS;
   ISOLATED RAT HEPATOCYTES; CELL-SURVIVAL; LIFE-SPAN; PHOSPHOINOSITIDE
   3-KINASE; INSULIN-RESISTANCE; COLORECTAL-CANCER; IN-VIVO
AB The activity of mammalian target of rapamycin (mTOR) complexes regulates essential cellular processes, such as growth, proliferation, or survival. Nutrients such as amino acids are important regulators of mTOR complex 1 (mTORC1) activation, thus affecting cell growth, protein synthesis, and autophagy. Here, we show that amino acids may also activate mTOR complex 2 (mTORC2). This activation is mediated by the activity of class I PI3K and of Akt. Amino acids induced a rapid phosphorylation of Akt at Thr-308 and Ser-473. Whereas both phosphorylations were dependent on the presence of mTOR, only Akt phosphorylation at Ser-473 was dependent on the presence of rictor, a specific component of mTORC2. Kinase assays confirmed mTORC2 activation by amino acids. This signaling was functional, as demonstrated by the phosphorylation of Akt substrate FOXO3a. Interestingly, using different starvation conditions, amino acids can selectively activate mTORC1 or mTORC2. These findings identify a new signaling pathway used by amino acids underscoring the crucial importance of these nutrients in cell metabolism and offering new mechanistic insights.
C1 [Tato, Irantzu; Bartrons, Ramon; Ventura, Francesc; Luis Rosa, Jose] Univ Barcelona, Inst Invest Biomed Bellvitge IDIBELL, Dept Ciencies Fisiol 2, E-08907 Barcelona, Spain.
RP Rosa, JL (corresponding author), Univ Barcelona, Inst Invest Biomed Bellvitge IDIBELL, Dept Ciencies Fisiol 2, Campus Bellvitge, E-08907 Barcelona, Spain.
EM joseluisrosa@ub.edu
RI Ventura, Francesc/K-9700-2014; Rosa, Jose Luis/K-6685-2014; Ventura,
   Francesc/ABG-2285-2020
OI Ventura, Francesc/0000-0001-9673-9405; Rosa, Jose
   Luis/0000-0002-6161-5688; Ventura, Francesc/0000-0001-9673-9405;
   Bartrons, Ramon/0000-0001-9349-5847
FU Ministerio de Educacion y Ciencia (MEC)Spanish GovernmentEuropean
   Commission [BFU2008-02084/BMC]; Instituto de Salud Carlos III Redes
   Tematicas de Investigacion Cooperativa en SaludInstituto de Salud Carlos
   III [RD06/0020]; Generalitat de CatalunyaGeneralitat de CatalunyaGeneral
   Electric [2009SGR1059]; Juan de la Cierva Program
FX This work was supported in part by Ministerio de Educacion y Ciencia
   (MEC) Grant BFU2008-02084/BMC, Instituto de Salud Carlos III Redes
   Tematicas de Investigacion Cooperativa en Salud Grant RD06/0020 and
   Generalitat de Catalunya Grant 2009SGR1059.; Supported by the Juan de la
   Cierva Program.
CR Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27
   Avruch J, 2006, ONCOGENE, V25, P6361, DOI 10.1038/sj.onc.1209882
   Beugnet A, 2003, J BIOL CHEM, V278, P40717, DOI 10.1074/jbc.M308573200
   Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020
   Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963
   Billottet C, 2006, ONCOGENE, V25, P6648, DOI 10.1038/sj.onc.1209670
   Birkenkamp KU, 2003, BIOCHEM SOC T, V31, P292, DOI 10.1042/bst0310292
   Bjedov I, 2010, CELL METAB, V11, P35, DOI 10.1016/j.cmet.2009.11.010
   BLOMMAART EFC, 1995, J BIOL CHEM, V270, P2320, DOI 10.1074/jbc.270.5.2320
   Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4
   Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Campbell LE, 1999, BIOCHEM J, V344, P433, DOI 10.1042/0264-6021:3440433
   Carlson CJ, 2004, BIOCHEM BIOPH RES CO, V316, P533, DOI 10.1016/j.bbrc.2004.02.082
   Casas-Terradellas E, 2006, ELECTROPHORESIS, V27, P3935, DOI 10.1002/elps.200600141
   Casas-Terradellas E, 2008, BBA-MOL CELL RES, V1783, P2241, DOI 10.1016/j.bbamcr.2008.08.011
   Chaussade C, 2007, BIOCHEM J, V404, P449, DOI 10.1042/BJ20070003
   Cully M, 2010, MOL CELL BIOL, V30, P481, DOI 10.1128/MCB.00688-09
   D'Antona G, 2010, CELL METAB, V12, P362, DOI 10.1016/j.cmet.2010.08.016
   Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002
   DeFeo-Jones D, 2005, MOL CANCER THER, V4, P271
   Dennis PB, 1996, MOL CELL BIOL, V16, P6242
   Drummond MJ, 2009, J APPL PHYSIOL, V106, P1374, DOI 10.1152/japplphysiol.91397.2008
   Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Essaghir A, 2009, J BIOL CHEM, V284, P10334, DOI 10.1074/jbc.M808848200
   Findlay GM, 2007, BIOCHEM J, V403, P13, DOI 10.1042/BJ20061881
   Foster KG, 2010, J BIOL CHEM, V285, P80, DOI 10.1074/jbc.M109.029637
   Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8
   Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24
   Fujita S, 2007, J PHYSIOL-LONDON, V582, P813, DOI 10.1113/jphysiol.2007.134593
   Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668
   Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007
   Gulati P, 2008, CELL METAB, V7, P456, DOI 10.1016/j.cmet.2008.03.002
   Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484
   Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069
   Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221
   Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783
   Hsieh AC, 2004, NUCLEIC ACIDS RES, V32, P893, DOI 10.1093/nar/gkh238
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08
   Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033
   Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782
   Kanazawa T, 2004, J BIOL CHEM, V279, P8452, DOI 10.1074/jbc.M306337200
   KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0
   Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5
   Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245
   Krebs M, 2005, EUR J CLIN INVEST, V35, P351, DOI 10.1111/j.1365-2362.2005.01506.x
   Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13
   Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011
   Meijer AJ, 2004, INT J BIOCHEM CELL B, V36, P2445, DOI 10.1016/j.biocel.2004.02.002
   MORTIMORE GE, 1977, NATURE, V270, P174, DOI 10.1038/270174a0
   Mrkonjic M, 2009, BRIT J CANCER, V100, P1966, DOI 10.1038/sj.bjc.6605097
   Newgard CB, 2009, CELL METAB, V9, P311, DOI 10.1016/j.cmet.2009.02.002
   Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044
   Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102
   Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200
   Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20
   Panowski SH, 2007, NATURE, V447, P550, DOI 10.1038/nature05837
   Pearce LR, 2007, BIOCHEM J, V405, P513, DOI 10.1042/BJ20070540
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Ruckle T, 2004, J MED CHEM, V47, P6921, DOI 10.1021/jm031112e
   Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105
   Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161
   Sadhu C, 2003, BIOCHEM BIOPH RES CO, V308, P764, DOI 10.1016/S0006-291X(03)01480-3
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054
   Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221
   Takano T, 2001, MOL CELL BIOL, V21, P5050, DOI 10.1128/MCB.21.15.5050-5062.2001
   Thompson HJ, 2003, J MAMMARY GLAND BIOL, V8, P133, DOI 10.1023/A:1025743607445
   Toden S, 2007, CARCINOGENESIS, V28, P2355, DOI 10.1093/carcin/bgm216
   Toschi A, 2009, MOL CELL BIOL, V29, P1411, DOI 10.1128/MCB.00782-08
   Um SH, 2006, CELL METAB, V3, P393, DOI 10.1016/j.cmet.2006.05.003
   Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005
   Wang XM, 2008, J BIOL CHEM, V283, P30482, DOI 10.1074/jbc.M803348200
   Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Xiao L, 2010, CELL DEATH DIFFER, V17, P1448, DOI 10.1038/cdd.2010.16
   Yamaoka I, 2009, BIOCHEM BIOPH RES CO, V386, P252, DOI 10.1016/j.bbrc.2009.06.031
   Yoshizawa F, 2004, BIOCHEM BIOPH RES CO, V313, P417, DOI 10.1016/j.bbrc.2003.07.013
   Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345
NR 87
TC 123
Z9 127
U1 2
U2 24
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD FEB 25
PY 2011
VL 286
IS 8
BP 6128
EP 6142
DI 10.1074/jbc.M110.166991
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 723AB
UT WOS:000287476400022
PM 21131356
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Bakke, D
   Sun, J
AF Bakke, Danika
   Sun, Jun
TI Ancient Nuclear Receptor VDR With New Functions: Microbiome and
   Inflammation
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Review
DE immunity; infection; myeloid; nuclear receptor; Salmonella
ID VITAMIN-D-RECEPTOR; GENOME-WIDE ASSOCIATION; KAPPA-B ACTIVITY;
   CROHNS-DISEASE; GENE POLYMORPHISMS; COLORECTAL-CANCER; EPITHELIAL-CELLS;
   DENDRITIC CELLS; GUT MICROBIOME; KNOCKOUT MICE
AB The biological functions of 1 alpha,25-dihydroxyvitamin D-3 are regulated by nuclear receptor vitamin D receptor (VDR). The expression level of VDR is high in intestine. VDR is an essential regulator of intestinal cell proliferation, barrier function, and immunity. Vitamin D/VDR plays a protective role in inflammatory bowel diseases (IBDs), both ulcerative colitis and Crohn's disease. Emerging evidence demonstrates low VDR expression and dysfunction of vitamin D/VDR signaling in patients with IBD. Here, we summarize the progress made in vitamin D/VDR signaling in genetic regulation, immunity, and the microbiome in IBD. We cover the mechanisms of intestinal VDR in regulating inflammation through inhibiting the NF-kappa B pathway and activating autophagy. Recent studies suggest that the association of VDR single nucleotide polymorphisms with immune and intestinal pathology may be sex dependent. We emphasize the tissue specificity of VDR and its sex-and time-dependent effects. Furthermore, we discuss potential clinical application and future direction of vitamin D/VDR in preventing and treating IBD.
C1 [Bakke, Danika; Sun, Jun] Univ Illinois, Dept Med, Div Gastroenterol & Hepatol, 840 S Wood St,Room 704 CSB,MC716, Chicago, IL 60612 USA.
RP Sun, J (corresponding author), Univ Illinois, Dept Med, Div Gastroenterol & Hepatol, 840 S Wood St,Room 704 CSB,MC716, Chicago, IL 60612 USA.
EM junsun7@uic.edu
FU National Institute of Diabetes and Digestive and Kidney
   Diseases/National Institutes of HealthUnited States Department of Health
   & Human ServicesNational Institutes of Health (NIH) - USANIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01
   DK105118]; Department of DefenseUnited States Department of Defense
   [BC160450P1]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASESUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Diabetes &
   Digestive & Kidney Diseases (NIDDK) [R01DK114126, R01DK105118] Funding
   Source: NIH RePORTER
FX Supported by: We would like to acknowledge the National Institute of
   Diabetes and Digestive and Kidney Diseases/National Institutes of Health
   grant R01 DK105118 and Department of Defense BC160450P1 to Jun Sun.
CR Abreu MT, 2004, GUT, V53, P1129, DOI 10.1136/gut.2003.036657
   Ardesia M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/470805
   Azad AK, 2012, INFECT IMMUN, V80, P3343, DOI 10.1128/IAI.00443-12
   Bakdash G, 2014, VACCINE, V32, P6294, DOI 10.1016/j.vaccine.2014.08.075
   Barbachano A, 2017, MOL CELL ENDOCRINOL, V453, P79, DOI 10.1016/j.mce.2016.11.028
   Barengolts E, 2013, ENDOCR PRACT, V19, P497, DOI 10.4158/EP12263.RA
   Barragan M, 2015, NUTRIENTS, V7, P8127, DOI 10.3390/nu7095383
   Bashir M, 2016, EUR J NUTR, V55, P1479, DOI 10.1007/s00394-015-0966-2
   Beckett EL, 2016, NUTR CANCER, V68, P193, DOI 10.1080/01635581.2016.1142584
   Ben-Selma W, 2015, INT J IMMUNOGENET, V42, P174, DOI 10.1111/iji.12197
   Bentley RW, 2012, NEW ZEAL MED J, V125, P47
   Bikle DD, 2014, CHEM BIOL, V21, P319, DOI 10.1016/j.chembiol.2013.12.016
   Chen Y, 2015, CHEM ENG SCI, V132, P1, DOI 10.1016/j.ces.2015.04.006
   Chen YZ, 2014, INFLAMM BOWEL DIS, V20, P1910, DOI 10.1097/MIB.0000000000000158
   Chen Y, 2013, J BIOL CHEM, V288, P19450, DOI 10.1074/jbc.M113.467670
   Clark A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00627
   Colombini A, 2015, INT J MOL SCI, V16, P3722, DOI 10.3390/ijms16023722
   Corridoni D, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00317
   Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196
   DeSmet ML, 2017, J STEROID BIOCHEM, V173, P194, DOI 10.1016/j.jsbmb.2017.01.008
   Devkota S, 2012, NATURE, V487, P104, DOI 10.1038/nature11225
   Du J, 2015, INFLAMM BOWEL DIS, V21, P2495, DOI 10.1097/MIB.0000000000000526
   Everard A, 2013, P NATL ACAD SCI USA, V110, P9066, DOI 10.1073/pnas.1219451110
   Fawaz L, 2016, CLIN IMMUNOL, V166, P59, DOI 10.1016/j.clim.2016.02.011
   Fox JG, 2011, MUCOSAL IMMUNOL, V4, P22, DOI 10.1038/mi.2010.61
   Frank DN, 2011, INFLAMM BOWEL DIS, V17, P179, DOI 10.1002/ibd.21339
   Froicu M, 2006, IMMUNOLOGY, V117, P310, DOI 10.1111/j.1365-2567.2005.02290.x
   Glenn AJ, 2014, NUTRIENTS, V6, P3847, DOI 10.3390/nu6093847
   Golan MA, 2015, DIGEST DIS SCI, V60, P1941, DOI 10.1007/s10620-015-3634-8
   Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com
   Gubatan J, 2017, CLIN GASTROENTEROL H, V15, P240, DOI 10.1016/j.cgh.2016.05.035
   Gyorffy B, 2002, EUR J ENDOCRINOL, V147, P803, DOI 10.1530/eje.0.1470803
   Hakansson A, 2015, CLIN EXP MED, V15, P107, DOI 10.1007/s10238-013-0270-5
   Jin DP, 2017, J STEROID BIOCHEM, V165, P430, DOI 10.1016/j.jsbmb.2016.09.002
   Jin DP, 2015, CLIN THER, V37, P996, DOI 10.1016/j.clinthera.2015.04.004
   Kabat AM, 2016, ELIFE, V5, DOI 10.7554/eLife.12444
   Kaplan GG, 2017, GASTROENTEROLOGY, V152, P313, DOI 10.1053/j.gastro.2016.10.020
   Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007
   Korf H, 2012, IMMUNOBIOLOGY, V217, P1292, DOI 10.1016/j.imbio.2012.07.018
   Kuhne H, 2016, NUTR RES, V36, P184, DOI 10.1016/j.nutres.2015.10.005
   Lee YH, 2012, DNA CELL BIOL, V31, P1549, DOI 10.1089/dna.2012.1605
   Leyssens C, 2017, ENDOCRINOLOGY, V158, P2354, DOI 10.1210/en.2017-00139
   Lim WC, 2005, NAT CLIN PRACT GASTR, V2, P308, DOI 10.1038/ncpgasthep0215
   Liu WC, 2013, J CLIN INVEST, V123, P3983, DOI 10.1172/JCI65842
   Ma D, 2017, BIOCHEM BIOPH RES CO, V482, P366, DOI 10.1016/j.bbrc.2016.11.069
   Mathur J, 2017, PEERJ, V5, DOI 10.7717/peerj.3654
   Narula N, 2017, DIGEST DIS SCI, V62, P448, DOI 10.1007/s10620-016-4396-7
   Newmark H, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00062
   Ooi JH, 2013, J NUTR, V143, P1679, DOI 10.3945/jn.113.180794
   Ottman N, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173004
   Pols TWH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176715
   Sadabad MS, 2015, GUT, V64, P1546, DOI 10.1136/gutjnl-2014-307289
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Sentongo TA, 2002, AM J CLIN NUTR, V76, P1077, DOI 10.1093/ajcn/76.5.1077
   Shi YY, 2016, MOL MED REP, V13, P1186, DOI 10.3892/mmr.2015.4685
   Simmons JD, 2000, GUT, V47, P211, DOI 10.1136/gut.47.2.211
   Singh PK, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3481-4
   Su DM, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00498
   Sun J, 2006, AM J PHYSIOL-ENDOC M, V291, pE315, DOI 10.1152/ajpendo.00590.2005
   Touvier M, 2011, CANCER EPIDEM BIOMAR, V20, P1003, DOI 10.1158/1055-9965.EPI-10-1141
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Wang J, 2016, NAT GENET, V48, P1396, DOI 10.1038/ng.3695
   Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225
   Wu SP, 2015, AM J PHYSIOL-GASTR L, V309, pG341, DOI 10.1152/ajpgi.00105.2015
   Wu SP, 2015, GUT, V64, P1082, DOI 10.1136/gutjnl-2014-307436
   Wu SP, 2010, AM J PATHOL, V177, P686, DOI 10.2353/ajpath.2010.090998
   Young VB, 2011, FRONT MICROBIOL, V2, DOI 10.3389/fmicb.2011.00144
   Zhang H, 2017, IMMUNOBIOLOGY, V222, P831, DOI 10.1016/j.imbio.2017.03.002
   Zhang H, 2017, J IMMUNOL, V198, P2133, DOI 10.4049/jimmunol.1601293
   Zhang YG, 2015, SCI REP-UK, V5, DOI 10.1038/srep10642
NR 70
TC 51
Z9 55
U1 2
U2 20
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2018
VL 24
IS 6
BP 1149
EP 1154
DI 10.1093/ibd/izy092
PG 6
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA GG4WO
UT WOS:000432697200005
PM 29718408
OA Green Published, Bronze, Green Accepted
DA 2022-04-25
ER

PT J
AU Wen, PB
   Xia, JF
   Cao, XB
   Chen, B
   Tao, YP
   Wu, LJ
   Xu, A
   Zhao, GP
AF Wen, Pengbo
   Xia, Junfeng
   Cao, Xianbin
   Chen, Bin
   Tao, Yinping
   Wu, Lijun
   Xu, An
   Zhao, Guoping
TI dbCRSR: a manually curated database for regulation of cancer
   radiosensitivity
SO DATABASE-THE JOURNAL OF BIOLOGICAL DATABASES AND CURATION
LA English
DT Article
ID COLORECTAL-CANCER; RADIOTHERAPY; CELLS; INHIBITOR; RADIORESISTANCE;
   STRATEGIES; AUTOPHAGY
AB Radiotherapy is used to treat approximately 50% of all cancer patients, with varying prognoses. Intrinsic radiosensitivity is an important factor underlying the radiotherapeutic efficacy of this precise treatment. During the past decades, great efforts have been made to improve radiotherapy treatment through multiple strategies. However, invaluable data remains buried in the extensive radiotherapy literature, making it difficult to obtain an overall view of the detailed mechanisms leading to radiosensitivity, thus limiting advances in radiotherapy. To address this issue, we collected data from the relevant literature contained in the PubMed database and developed a literature-based database that we term the cancer radiosensitivity regulation factors database (dbCRSR). dbCRSR is a manually curated catalogue of radiosensitivity, containing multiple radiosensitivity regulation factors (395 coding genes, 119 non-coding RNAs and 306 chemical compounds) with appropriate annotation. To illustrate the value of the data we collected, data mining was performed including functional annotation and network analysis. In summary, dbCRSR is the first literature-based database to focus on radiosensitivity and provides a resource to better understand the detailed mechanisms of radiosensitivity. We anticipate dbCRSR will be a useful resource to enrich our knowledge and to promote further study of radiosensitivity.
C1 [Wen, Pengbo; Cao, Xianbin; Chen, Bin; Tao, Yinping; Wu, Lijun; Xu, An; Zhao, Guoping] Chinese Acad Sci, Anhui Prov Key Lab Environm Toxicol & Pollut Cont, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei, Anhui, Peoples R China.
   [Wen, Pengbo] Univ Sci & Technol China, Hefei, Anhui, Peoples R China.
   [Xia, Junfeng] Anhui Univ, Inst Phys Sci & Informat Technol, Sch Comp Sci & Technol, Hefei, Anhui, Peoples R China.
RP Xia, JF (corresponding author), Anhui Univ, Inst Phys Sci & Informat Technol, Sch Comp Sci & Technol, Hefei, Anhui, Peoples R China.
EM jfxia@ahu.edu.cn; gpz@ipp.ac.cn
RI Xia, Junfeng/S-2456-2019
OI Xia, Junfeng/0000-0003-3024-1705
FU CAS Pioneer Hundred Talents Program; National Natural Science Foundation
   of ChinaNational Natural Science Foundation of China (NSFC) [31601124,
   61672037, 31470829]; Anhui Provincial Natural Science FoundationNatural
   Science Foundation of Anhui Province [1708085MC66]; Anhui Provincial
   Outstanding Young Talent Support Plan [gxyqZD2017005]; Young Wanjiang
   Scholar Program of Anhui Province, China
FX This work was supported by CAS Pioneer Hundred Talents Program (GZ),
   National Natural Science Foundation of China (31601124, 61672037 and
   31470829), the Anhui Provincial Natural Science Foundation
   (1708085MC66), the Anhui Provincial Outstanding Young Talent Support
   Plan (gxyqZD2017005) and the Young Wanjiang Scholar Program of Anhui
   Province, China.
CR Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007
   Bernier J, 2017, CRIT REV ONCOL HEMAT, V113, P79, DOI 10.1016/j.critrevonc.2017.03.015
   Chakradeo S, 2015, MOL PHARMACOL, V87, P803, DOI 10.1124/mol.114.095273
   Chen HHW, 2017, ONCOTARGET, V8, P62742, DOI 10.18632/oncotarget.18409
   Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377
   Forker LJ, 2015, CLIN ONCOL-UK, V27, P561, DOI 10.1016/j.clon.2015.06.002
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Gerweck LE, 2016, CANCER RES, V76, P994, DOI 10.1158/0008-5472.CAN-15-2455
   Goto Y, 2017, MUTAT RES-FUND MOL M, V803, P76, DOI 10.1016/j.mrfmmm.2017.07.007
   Guo Q, 2017, ONCOL LETT, V13, P949, DOI 10.3892/ol.2016.5515
   He SQ, 2014, INVEST NEW DRUG, V32, P577, DOI 10.1007/s10637-014-0095-4
   He XL, 2006, PLOS GENET, V2, P826, DOI 10.1371/journal.pgen.0020088
   Ji XQ, 2017, FUTURE ONCOL, V13, P1537, DOI 10.2217/fon-2017-0054
   Li G, 2017, BIOMED PHARMACOTHER, V94, P974, DOI 10.1016/j.biopha.2017.07.148
   Ma H., 2017, TUMOR BIOL, V39
   Ma H., 2017, TUMOUR BIOL J INT SO, V39, DOI [10.1177/1010428317706224, DOI 10.1177/1010428317706224]
   Ma H, 2015, ONCOL REP, V33, P1161, DOI 10.3892/or.2014.3699
   Ni J, 2017, THERANOSTICS, V7, P3243, DOI 10.7150/thno.19934
   Pavlopoulou A, 2017, CANCER LETT, V403, P37, DOI 10.1016/j.canlet.2017.05.023
   Walker F, 2009, HUM PATHOL, V40, P1517, DOI 10.1016/j.humpath.2009.05.010
   Xin Y, 2017, J CANCER RES CLIN, V143, P2147, DOI 10.1007/s00432-017-2487-2
   Yong Y, 2017, ACS NANO, V11, P7164, DOI 10.1021/acsnano.7b03037
   Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278
   Zhang TT, 2015, INT J RADIAT BIOL, V91, P368, DOI 10.3109/09553002.2015.1001531
   Zhang Y., 2015, SCI TRANSL MED, V7, P290
   Zhou Y, 2017, ONCOL LETT, V13, P1143, DOI 10.3892/ol.2017.5587
NR 28
TC 2
Z9 2
U1 6
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1758-0463
J9 DATABASE-OXFORD
JI Database
PD MAY 30
PY 2018
AR bay049
DI 10.1093/database/bay049
PG 8
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA GI4PY
UT WOS:000434354900001
PM 29860480
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhu, HH
   Zhang, LJ
   Xu, JM
   Zhu, CH
   Zhao, H
   Zhu, YK
   Lv, GQ
AF Zhu, Huanhuan
   Zhang, Linjie
   Xu, Jianmin
   Zhu, Chunhua
   Zhao, Hui
   Zhu, Yongkang
   Lv, Guoqiang
TI AntogomiR-451 protects human gastric epithelial cells from ethanol via
   activating AMPK signaling
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE AntogomiR-451; AMPK; Gastric epithelial cells; Ethanol; Oxidative stress
ID HELICOBACTER-PYLORI; COLORECTAL-CANCER; INDUCED APOPTOSIS; OXIDATIVE
   STRESS; PEPTIC-ULCER; KINASE AMPK; COMPOUND 13; GROWTH; AUTOPHAGY;
   PATHWAY
AB The prevention and treatment efficiency of ethanol-induced gastric epithelial injury are not satisfied. We have previously shown that AMP-activated protein kinase (AMPK) activation exerts a pro-survival function in human gastric epithelial cells (GECs). miroRNA-451 ("miR-451")'s inhibitor, antagomiR-451, can activate AMPK signaling. In the present study, we show that forced-expression of antagomiR-451 via a lentiviral vector depleted miR-451, leading to AMPK activation in established GES-1 cells and primary human GECs. AntagomiR-451 efficiently protected GES-1 cells and primary human GECs from ethanol-induced viability reduction and apoptosis. AMPK activation is required for antagomiR-451-induced GEC protection. AMPK alpha l knockdown (by targeted-shRNAs) or knockout (by CRISPR-Cas-9 KO plasmid) blocked antagomiR-451-induced AMPK activation, and GEC protection against ethanol. Further experimental results show that antagomiR-451 significantly attenuated ethanol-induced reactive oxygen species (ROS) production, lipid peroxidation and DNA damage. Collectively, antagomiR-451 protects human GECs from ethanol via activating AMPK signaling. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Zhu, Huanhuan; Zhang, Linjie; Xu, Jianmin; Zhu, Chunhua; Zhao, Hui; Lv, Guoqiang] Nantong Univ, Wuxi Peoples Hosp 3, Dept Gastroenterol, 585 North Xingyuan Rd, Wuxi 214041, Jiangsu, Peoples R China.
   [Zhu, Yongkang] Nanjing Univ, TCM, Affiliated Hosp, Dept Gen Surg, 155 Hanzhong Rd, Nanjing 210000, Jiangsu, Peoples R China.
RP Lv, GQ (corresponding author), Nantong Univ, Wuxi Peoples Hosp 3, Dept Gastroenterol, 585 North Xingyuan Rd, Wuxi 214041, Jiangsu, Peoples R China.; Zhu, YK (corresponding author), Nanjing Univ, TCM, Affiliated Hosp, Dept Gen Surg, 155 Hanzhong Rd, Nanjing 210000, Jiangsu, Peoples R China.
EM zhuykwuxiys@163.com; Ivguoqiangwuxivip@163.com
FU Wuxi Young Medical Talents of the program for developing health care
   through science and education
FX The authors thank the laboratory members. This study is supported by the
   Wuxi Young Medical Talents of the program for developing health care
   through science and education.
CR Carling D, 2012, BIOCHEM J, V445, P11, DOI 10.1042/BJ20120546
   Chen MB, 2014, CELL SIGNAL, V26, P102, DOI 10.1016/j.cellsig.2013.07.017
   Cohen H, 2000, GASTROENTEROL CLIN N, V29, P775, DOI 10.1016/S0889-8553(05)70146-1
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300-483X(00)00181-5
   Dai CP, 2017, ONCOTARGET, V8, P95810, DOI 10.18632/oncotarget.21336
   Du H, 2008, NAT MED, V14, P1097, DOI 10.1038/nm.1868
   El-Assal O, 2004, CELL MOL IMMUNOL, V1, P205
   Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138
   Godlewski J, 2010, MOL CELL, V37, P620, DOI 10.1016/j.molcel.2010.02.018
   Gong YQ, 2016, ONCOTARGET, V7, P60123, DOI 10.18632/oncotarget.11164
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V471, P545, DOI 10.1016/j.bbrc.2016.02.036
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6
   Huo HZ, 2013, MOL CELL BIOCHEM, V378, P171, DOI 10.1007/s11010-013-1608-8
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Ji F, 2015, BIOCHEM BIOPH RES CO, V458, P568, DOI 10.1016/j.bbrc.2015.02.007
   Jonas S, 2015, NAT REV GENET, V16, P421, DOI 10.1038/nrg3965
   Joo MS, 2016, MOL CELL BIOL, V36, P1931, DOI 10.1128/MCB.00118-16
   Kim IY, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00175
   Konturek SJ, 2006, J PHYSIOL PHARMACOL, V57, P29
   Kuwabara Y, 2015, CIRC RES, V116, P279, DOI 10.1161/CIRCRESAHA.116.304707
   Lanas A, 2017, LANCET, V390, P613, DOI 10.1016/S0140-6736(16)32404-7
   Li Z. W., 2016, ONCOTARGET IN PRESS
   Liu WD, 2017, ONCOTARGET, V8, P10543, DOI 10.18632/oncotarget.14454
   Lv GQ, 2014, BIOCHEM BIOPH RES CO, V453, P13, DOI 10.1016/j.bbrc.2014.09.028
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Peng Y, 2005, NEUROPHARMACOLOGY, V48, P426, DOI 10.1016/j.neuropharm.2004.10.018
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   She C, 2014, CELL SIGNAL, V26, P1, DOI 10.1016/j.cellsig.2013.08.046
   Song L, 2014, J CELL MOL MED, V18, P2266, DOI 10.1111/jcmm.12380
   Sujobert P, 2015, CELL REP, V11, P1446, DOI 10.1016/j.celrep.2015.04.063
   Szuster-Ciesielska A, 2011, TOXICOLOGY, V280, P152, DOI 10.1016/j.tox.2010.12.006
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wang X, 2014, BIOCHEM PHARMACOL, V88, P334, DOI 10.1016/j.bcp.2014.01.040
   Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3
   Yang X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175507
   Zhang JL, 2014, INT J MOL SCI, V15, P12119, DOI 10.3390/ijms150712119
   Zhao HY, 2015, BIOCHEM BIOPH RES CO, V463, P510, DOI 10.1016/j.bbrc.2015.05.059
   Zheng KL, 2016, BIOCHEM BIOPH RES CO, V469, P753, DOI 10.1016/j.bbrc.2015.12.014
   Zhu YL, 2014, INT J MOL SCI, V15, P11190, DOI 10.3390/ijms150611190
   Zimmermann K, 2015, FREE RADICAL BIO MED, V88, P417, DOI 10.1016/j.freeradbiomed.2015.03.030
NR 45
TC 4
Z9 4
U1 1
U2 13
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 26
PY 2018
VL 497
IS 1
BP 339
EP 346
DI 10.1016/j.bbrc.2018.02.082
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GB5CI
UT WOS:000429079600051
PM 29432731
DA 2022-04-25
ER

PT J
AU Weng, YF
   Lin, JX
   Liu, H
   Wu, H
   Yan, ZM
   Zhao, J
AF Weng, Yingfeng
   Lin, Jixian
   Liu, Hui
   Wu, Hui
   Yan, Zhimin
   Zhao, Jing
TI AMPK activation by Tanshinone IIA protects neuronal cells from
   oxygen-glucose deprivation
SO ONCOTARGET
LA English
DT Article
DE OGDR; neuroprotection; Tanshinone IIA; AMP-activated protein kinase
   (AMPK); Ppm1e
ID IN-VITRO; OXIDATIVE STRESS; NEUROBLASTOMA-CELLS; ENERGY HOMEOSTASIS;
   COLORECTAL-CANCER; SIGNALING PATHWAY; KINASE; DEATH; AUTOPHAGY;
   APOPTOSIS
AB The current study tested the potential neuroprotective function of Tanshinone IIA (ThIIA) in neuronal cells with oxygen-glucose deprivation (ODG) and re-oxygenation (OGDR). In SH-SY5Y neuronal cells and primary murine cortical neurons, ThIIA pretreatment attenuated OGDR-induced viability reduction and apoptosis. Further, OGDR-induced mitochondrial depolarization, reactive oxygen species production, lipid peroxidation and DNA damages in neuronal cells were significantly attenuated by ThIIA. ThIIA activated AMP-activated protein kinase (AMPK) signaling, which was essential for neuroprotection against OGDR. AMPK alpha 1 knockdown or complete knockout in SH-SY5Y cells abolished ThIIA-induced AMPK activation and neuroprotection against OGDR. Further studies found that ThIIA up-regulated microRNA-135b to downregulate the AMPK phosphatase Ppm1e. Notably, knockdown of Ppm1e by targeted shRNA or forced microRNA-135b expression also activated AMPK and protected SH-SY5Y cells from OGDR. Together, AMPK activation by ThIIA protects neuronal cells from OGDR. microRNA-135b-mediated silence of Ppm1e could be the key mechanism of AMPK activation by ThIIA.
C1 [Weng, Yingfeng; Lin, Jixian; Liu, Hui; Wu, Hui; Yan, Zhimin; Zhao, Jing] Fudan Univ, Zhongshan Hosp, Minhang Branch, Dept Neurol, Shanghai, Peoples R China.
RP Yan, ZM; Zhao, J (corresponding author), Fudan Univ, Zhongshan Hosp, Minhang Branch, Dept Neurol, Shanghai, Peoples R China.
EM yanzhiminmh@163.com; zhaojinmhyy7@163.com
RI lin, jixian/Y-9573-2018
OI lin, jixian/0000-0002-8640-9995
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81572232]; Central Hospital of Shanghai
   Minxing District young student research foundation [2016 MHLC04,
   2017MHLC10]
FX This study was supported by the National Natural Science Foundation of
   China (81572232) and by the Central Hospital of Shanghai Minxing
   District young student research foundation (2016 MHLC04, 2017MHLC10).
CR Allen CL, 2009, INT J STROKE, V4, P461, DOI 10.1111/j.1747-4949.2009.00387.x
   Almeida A, 2002, J NEUROCHEM, V81, P207, DOI 10.1046/j.1471-4159.2002.00827.x
   Chen MB, 2016, ONCOTARGET, V7, P17047, DOI 10.18632/oncotarget.7742
   Chen MB, 2015, CARCINOGENESIS, V36, P1061, DOI 10.1093/carcin/bgv094
   Chen MB, 2015, BIOCHEM BIOPH RES CO, V463, P954, DOI 10.1016/j.bbrc.2015.06.041
   Chen MB, 2014, CELL SIGNAL, V26, P102, DOI 10.1016/j.cellsig.2013.07.017
   Chen Z., 2014, EVID-BASED COMPL ALT, V2014, DOI DOI 10.1155/2014/267976
   Chen ZY, 2013, MOL CELL BIOCHEM, V377, P35, DOI 10.1007/s11010-013-1568-z
   Cortizo AM, 2000, TOXICOLOGY, V147, P89, DOI 10.1016/S0300-483X(00)00181-5
   Domise M, 2016, EXPERIENTIA SUPPL, V107, P153, DOI 10.1007/978-3-319-43589-3_7
   Ewald B, 2007, MOL CANCER THER, V6, P1239, DOI 10.1158/1535-7163.MCT-06-0633
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138
   Gu DM, 2015, BIOCHEM BIOPH RES CO, V457, P391, DOI 10.1016/j.bbrc.2015.01.002
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   Guo SG, 2016, BIOCHEM BIOPH RES CO, V471, P545, DOI 10.1016/j.bbrc.2016.02.036
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Herrero-Martin G, 2009, EMBO J, V28, P677, DOI 10.1038/emboj.2009.8
   Hwang SL, 2013, BIOCHEM BIOPH RES CO, V430, P1246, DOI 10.1016/j.bbrc.2012.12.066
   Jensen TE, 2007, AM J PHYSIOL-ENDOC M, V292, pE1308, DOI 10.1152/ajpendo.00456.2006
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Joo MS, 2016, MOL CELL BIOL, V36, P1931, DOI 10.1128/MCB.00118-16
   Kwon MY, 2015, ONCOTARGET, V6, P24393, DOI 10.18632/oncotarget.5162
   Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li P, 2016, ONCOTARGET, V7, P77978, DOI 10.18632/oncotarget.12866
   Li ZW, 2017, ONCOTARGET, V8, P26424, DOI 10.18632/oncotarget.15477
   Lin CY, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.65
   Lin JJ, 2015, NEUROCHEM INT, V89, P92, DOI 10.1016/j.neuint.2015.07.022
   Liu WD, 2017, ONCOTARGET, V8, P10543, DOI 10.18632/oncotarget.14454
   Liu YJ, 2015, J NEUROGENET, V29, P50, DOI 10.3109/01677063.2015.1067203
   Lu PH, 2016, ONCOTARGET, V7, P45889, DOI 10.18632/oncotarget.9969
   Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329
   Ming Y, 2014, BIOCHEM BIOPH RES CO, V454, P42, DOI 10.1016/j.bbrc.2014.10.033
   Pimentel GD, 2013, METABOLISM, V62, P171, DOI 10.1016/j.metabol.2012.07.001
   Pineda-Ramirez N., 2017, NUTR NEUROSCI, V14, P1
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Tian XH, 2013, EXPERT OPIN THER PAT, V23, P19, DOI 10.1517/13543776.2013.736494
   Varshney R, 2017, MOL CELL ENDOCRINOL, V448, P1, DOI 10.1016/j.mce.2017.02.033
   Verklan MT, 2009, J PERINAT NEONAT NUR, V23, P59, DOI 10.1097/01.JPN.0000346221.48202.7e
   Voss M, 2011, CELL SIGNAL, V23, P114, DOI 10.1016/j.cellsig.2010.08.010
   Wang K, 2014, FOLIA NEUROPATHOL, V52, P121, DOI 10.5114/fn.2014.43783
   Wang SB, 2012, CLIN SCI, V122, P555, DOI 10.1042/CS20110625
   Wu WF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094697
   Wu Y, 2007, J BIOL CHEM, V282, P9777, DOI 10.1074/jbc.M608310200
   Xu YM, 2016, EXP THER MED, V12, P2741, DOI 10.3892/etm.2016.3674
   Yu T, 2010, CANCER CHEMOTH PHARM, V66, P999, DOI 10.1007/s00280-010-1374-1
   Zhang D, 2007, EUR J PHARMACOL, V561, P1, DOI 10.1016/j.ejphar.2006.11.015
   Zhang L, 2007, EUR J PHARMACOL, V564, P18, DOI 10.1016/j.ejphar.2007.01.089
   Zhao HL, 2016, ONCOTARGET, V7, P25640, DOI 10.18632/oncotarget.8241
   Zhao LP, 2013, NEUROCHEM RES, V38, P705, DOI 10.1007/s11064-013-0968-5
   Zheng KL, 2016, BIOCHEM BIOPH RES CO, V469, P753, DOI 10.1016/j.bbrc.2015.12.014
   Zheng KL, 2014, BIOCHEM BIOPH RES CO, V451, P79, DOI 10.1016/j.bbrc.2014.07.072
   Zimmermann K, 2015, FREE RADICAL BIO MED, V88, P417, DOI 10.1016/j.freeradbiomed.2015.03.030
   Zou Y, 2017, BIOCHEM BIOPH RES CO, V490, P385, DOI 10.1016/j.bbrc.2017.06.052
NR 55
TC 11
Z9 12
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 12
PY 2018
VL 9
IS 4
BP 4511
EP 4521
DI 10.18632/oncotarget.23391
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS8HP
UT WOS:000422651700020
PM 29435120
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Liu, XL
   Ardizzone, A
   Sui, BL
   Anzola, M
   Ventosa, N
   Liu, TH
   Veciana, J
   Belfield, KD
AF Liu, Xinglei
   Ardizzone, Antonio
   Sui, Binglin
   Anzola, Mattia
   Ventosa, Nora
   Liu, Taihong
   Veciana, Jaume
   Belfield, Kevin D.
TI Fluorenyl-Loaded Quatsome Nanostructured Fluorescent Probes
SO ACS OMEGA
LA English
DT Article
ID TURN-ON SENSOR; 2-PHOTON ABSORPTION; IN-VIVO; DERIVATIVES; AUTOPHAGY;
   NANOPARTICLES
AB Delivery of hydrophobic materials in biological systems, for example, contrast agents or drugs, is an obdurate challenge, severely restricting the use of materials with otherwise advantageous properties. The synthesis and characterization of a highly stable and water-soluble nanovesicle, referred to as a quatsome (QS, vesicle prepared from cholesterol and amphiphilic quaternary amines), that allowed the nanostructuration of a nonwater soluble fluorene-based probe are reported. Photophysical properties of fluorenyl-quatsome nanovesicles were investigated via ultraviolet-visible absorption and fluorescence spectroscopy in various solvents. Colloidal stability and morphology of the nanostructured fluorescent probes were studied via cryogenic transmission electronic microscopy, revealing a "patchy" quatsome vascular morphology. As an example of the utility of these fluorescent nanoprobes, examination of cellular distribution was evaluated in HCT 116 (an epithelial colorectal carcinoma cell line) and COS-7 (an African green monkey kidney cell line) cell lines, demonstrating the selective localization of C-QS and M-QS vesicles in lysosomes with high Pearson's colocalization coefficient, where C-QS and M-QS refer to quatsomes prepared with hexadecyltrimethylammonium bromide or tetradecyldimethylbenzylammonium chloride, respectively. Further experiments demonstrated their use in time-dependent lysosomal tracking.
C1 [Liu, Xinglei; Sui, Binglin; Liu, Taihong; Belfield, Kevin D.] New Jersey Inst Technol, Dept Chem & Environm Sci, Coll Sci & Liberal Arts, 323 Martin Luther King,Jr Blvd, Newark, NJ 07102 USA.
   [Ardizzone, Antonio; Anzola, Mattia; Ventosa, Nora; Veciana, Jaume] Inst Ciencia Mat Barcelona CSIC CIBER BBN, Campus Univ Bellaterra, Cerdanyola Del Valles 08193, Spain.
RP Belfield, KD (corresponding author), New Jersey Inst Technol, Dept Chem & Environm Sci, Coll Sci & Liberal Arts, 323 Martin Luther King,Jr Blvd, Newark, NJ 07102 USA.; Ventosa, N; Veciana, J (corresponding author), Inst Ciencia Mat Barcelona CSIC CIBER BBN, Campus Univ Bellaterra, Cerdanyola Del Valles 08193, Spain.
EM ventosa@icmab.es; vecianaj@icmab.es; belfield@njit.edu
RI Ventosa, Nora/C-2170-2015; Belfield, Kevin D/D-4765-2009; Veciana,
   Jaume/A-2147-2008; Liu, Xinglei/AAS-9515-2021; Liu, Taihong/Y-9421-2019
OI Ventosa, Nora/0000-0002-8008-4974; Belfield, Kevin
   D/0000-0002-7339-2813; Veciana, Jaume/0000-0003-1023-9923; Liu,
   Taihong/0000-0002-9600-1045
FU DGI, Spain [BE-WELL CTQ2013-40480-R, Mother MAT 2016-80826-R]; AGAUR,
   Generalitat de CatalunyaAgencia de Gestio D'Ajuts Universitaris de
   Recerca Agaur (AGAUR)Generalitat de Catalunya [2014-SGR-17]; Networking
   Research Center on Bioengineering, Biomaterials, and Nanomedicine
   (CIBER-BBN); Spanish Ministry of Economy and Competitiveness, through
   the "Severo Ochoa" Programme for Centres of Excellence in R&D through
   FIP Flowers project [SEV-2015-0496]; People Programme (Marie Curie
   Actions) of the European Union's Seventh Framework Programme FP7 under
   REA grant [607721]; National Science FoundationNational Science
   Foundation (NSF) [CBET-1517273]
FX This work was supported by the DGI, Spain, "Grants BE-WELL
   CTQ2013-40480-R" and "Mother MAT 2016-80826-R", by AGAUR, Generalitat de
   Catalunya, "Grant 2014-SGR-17", the Networking Research Center on
   Bioengineering, Biomaterials, and Nanomedicine (CIBER-BBN), and the
   Spanish Ministry of Economy and Competitiveness, through the "Severo
   Ochoa" Programme for Centres of Excellence in R&D (SEV-2015-0496)
   through FIP Flowers project. Characterizations of nanovesicles were made
   at the ICTS "NANBIOSIS", more specifically by the U6 unit of CIBER-BBN.
   The research leading to these results received funding from the People
   Programme (Marie Curie Actions) of the European Union's Seventh
   Framework Programme FP7/2007-2013 under REA grant agreement no. 607721
   (Nano2-Fun) A.A. is enrolled in the Materials Science Ph.D. program of
   UAB. K.D.B. and X.L. acknowledge support from the National Science
   Foundation (CBET-1517273).
CR Andrade CD, 2011, J FLUORESC, V21, P1223, DOI 10.1007/s10895-010-0801-3
   Belfield KD, 2004, CHEM MATER, V16, P4634, DOI 10.1021/cm049872g
   Belfield KD, 2012, CHEMPHYSCHEM, V13, P3481, DOI 10.1002/cphc.201200405
   Cabrera I, 2013, NANO LETT, V13, P3766, DOI 10.1021/nl4017072
   Chen X, 2015, SCI REP, V5
   Cheng L, 2013, ADV FUNCT MATER, V23, P5893, DOI 10.1002/adfm.201301045
   Cooper G., 2013, CELL MOL APPROACH, P412
   Elizondo E, 2012, J AM CHEM SOC, V134, P1918, DOI 10.1021/ja2086678
   Fadhel AA, 2016, INT J NANOMED, V11, P6161, DOI 10.2147/IJN.S113292
   Ferrer-Tasies L, 2013, LANGMUIR, V29, P6519, DOI 10.1021/la4003803
   Ha-Thi MH, 2008, CHEM-EUR J, V14, P5941, DOI 10.1002/chem.200800084
   Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910
   He X, 2013, THER DELIV, V4, P1499, DOI [10.4155/TDE.13.120, 10.4155/tde.13.120]
   Hughes AL, 2012, NATURE, V492, P261, DOI 10.1038/nature11654
   Kalbacova M, 2014, COLLOID SURFACE A, V460, P204, DOI 10.1016/j.colsurfa.2013.12.048
   Khaokeaw C, 2016, J FLUORESC, V26, P745, DOI 10.1007/s10895-016-1766-7
   Kim SE, 2013, SEMIN CANCER BIOL, V23, P329, DOI 10.1016/j.semcancer.2013.05.004
   Kurhuzenkau SA, 2016, PHYS CHEM CHEM PHYS, V18, P12839, DOI 10.1039/c6cp01393g
   Liu XG, 2014, J PHYS CHEM A, V118, P10318, DOI 10.1021/jp500397g
   Maeda H, 2008, TETRAHEDRON, V64, P5268, DOI 10.1016/j.tet.2008.03.031
   Maes H, 2014, MITOCHONDRION, V19, P58, DOI 10.1016/j.mito.2014.07.003
   Peterson JJ, 2009, MACROMOLECULES, V42, P8594, DOI 10.1021/ma901703r
   Sui BL, 2016, CHEM-EUR J, V22, P10351, DOI 10.1002/chem.201602162
   Thorburn A, 2014, MOL PHARMACOL, V85, P830, DOI 10.1124/mol.114.091850
   Vlachy N, 2009, COLLOID SURFACE B, V70, P278, DOI 10.1016/j.colsurfb.2008.12.038
   Wang XH, 2011, BIOCONJUGATE CHEM, V22, P1438, DOI 10.1021/bc2002506
   Wang XH, 2010, J AM CHEM SOC, V132, P12237, DOI 10.1021/ja1057423
   Yamada A, 2015, BIOMACROMOLECULES, V16, P2356, DOI 10.1021/acs.biomac.5b00591
   Yanez CO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067559
   Yao S, 2007, ORG LETT, V9, P5645, DOI 10.1021/ol7026366
   Yao S, 2010, J ORG CHEM, V75, P3965, DOI 10.1021/jo100554j
   Yapici NB, 2015, SCI REP-UK, V5, DOI 10.1038/srep08576
   Yue XL, 2015, ORG BIOMOL CHEM, V13, P10716, DOI 10.1039/c5ob01536g
   Yue XL, 2013, J AM CHEM SOC, V135, P2112, DOI 10.1021/ja3122312
   Zhang M, 2007, J AM CHEM SOC, V129, P10322, DOI 10.1021/ja073140i
   Zhang YW, 2013, ACS APPL MATER INTER, V5, P8710, DOI 10.1021/am402361w
NR 36
TC 11
Z9 11
U1 2
U2 18
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470-1343
J9 ACS OMEGA
JI ACS Omega
PD AUG
PY 2017
VL 2
IS 8
BP 4112
EP 4122
DI 10.1021/acsomega.7b00779
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA FG2JL
UT WOS:000409924000006
PM 30023713
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, D
   Yan, PG
   Han, TT
   Cheng, XY
   Li, JN
AF Zhang, Di
   Yan, Pengguang
   Han, Taotao
   Cheng, Xiaoyun
   Li, Jingnan
TI Identification of key genes and biological processes contributing to
   colitis associated dysplasia in ulcerative colitis
SO PEERJ
LA English
DT Article
DE Ulcerative colitis; Colitis associated dysplasia; Ulcerative colitis
   associated colorectal cancer; Weighted gene co-expression network
   analysis
ID INFLAMMATORY-BOWEL-DISEASE; BREAST-CANCER CELLS; COLORECTAL-CANCER;
   EXPRESSION; PROTEIN; PROLIFERATION; SUPPRESSES; ACTIVATION; APOPTOSIS;
   AUTOPHAGY
AB Background. Ulcerative colitis-associated colorectal cancer (UC-CRC) is a life-threatening complication of ulcerative colitis (UC). The mechanisms underlying UC-CRC remain to be elucidated. The purpose of this study was to explore the key genes and biological processes contributing to colitis-associated dysplasia (CAD) or carcinogenesis in UC via database mining, thus offering opportunities for early prediction and intervention of UC-CRC.
   Methods. Microarray datasets (GSE47908 and GSE87466) were downloaded from Gene Expression Omnibus (GEO). Differentially expressed genes (DEGs) between groups of GSE47908 were identified using the "limma'' R package. Weighted gene co-expression network analysis (WGCNA) based on DEGs between the CAD and control groups was conducted subsequently. Functional enrichment analysis was performed, and hub genes of selected modules were identified using the "clusterProfiler'' R package. Single-gene gene set enrichment analysis (GSEA) was conducted to predict significant biological processes and pathways associated with the specified gene.
   Results. Six functional modules were identified based on 4929 DEGs. Green and blue modules were selected because of their consistent correlation with UC and CAD, and the highest correlation coefficient with the progress of UC-associated carcinogenesis. Functional enrichment analysis revealed that genes of these two modules were significantly enriched in biological processes, including mitochondrial dysfunction, cell-cell junction, and immune responses. However, GSEA based on differential expression analysis between sporadic colorectal cancer (CRC) and normal controls from The Cancer Genome Atlas (TCGA) indicated that mitochondrial dysfunction may not be the major carcinogenic mechanism underlying sporadic CRC. Thirteen hub genes (SLC25A3, ACO2, AIFM1, ATP5A1, DLD, TFE3, UQCRC1, ADIPOR2, SLC35D1, TOR1AIP1, PRR5L, ATOX1, and DTX3) were identified. Their expression trends were validated in UC patients of GSE87466, and their potential carcinogenic effects in UC were supported by their known functions and other relevant studies reported in the literature. Single-gene GSEA indicated that biological processes and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to angiogenesis and immune response were positively correlated with the upregulation of TFE3, whereas those related to mitochondrial function and energy metabolism were negatively correlated with the upregulation of TFE3.
   Conclusions. Using WGCNA, this study found two gene modules that were significantly correlated with CAD, of which 13 hub genes were identified as the potential key genes. The critical biological processes in which the genes of these two modules were significantly enriched include mitochondrial dysfunction, cell-cell junction, and immune responses. TFE3, a transcription factor related to mitochondrial function and cancers, may play a central role in UC-associated carcinogenesis.
C1 [Zhang, Di; Yan, Pengguang; Han, Taotao; Cheng, Xiaoyun; Li, Jingnan] Chinese Acad Med Sci, Dept Gastroenterol, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing, Peoples R China.
   [Zhang, Di; Yan, Pengguang; Han, Taotao; Cheng, Xiaoyun; Li, Jingnan] Chinese Acad Med Sci, Key Lab Gut Microbiota Translat Med Res, Beijing, Peoples R China.
RP Li, JN (corresponding author), Chinese Acad Med Sci, Dept Gastroenterol, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing, Peoples R China.; Li, JN (corresponding author), Chinese Acad Med Sci, Key Lab Gut Microbiota Translat Med Res, Beijing, Peoples R China.
EM puincjnl@126.com
FU Chinese Academy of Medical Sciences (CAMS) Initiative for Innovative
   Medicine [CAMS-2016-I2M-1-007]
FX This work was supported by the Chinese Academy of Medical Sciences
   (CAMS) Initiative for Innovative Medicine (CAMS-2016-I2M-1-007). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167
   Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   Bjerrum JT, 2014, INFLAMM BOWEL DIS, V20, P2340, DOI 10.1097/MIB.0000000000000235
   Bopanna S, 2017, LANCET GASTROENTEROL, V2, P269, DOI 10.1016/S2468-1253(17)30004-3
   Bruggemann M, 2017, TRANSL ONCOL, V10, P661, DOI 10.1016/j.tranon.2017.06.002
   Chung SJ, 2017, AUTOPHAGY, V13, P1386, DOI 10.1080/15548627.2017.1332565
   Ciccarone F, 2020, BRIT J CANCER, V122, P182, DOI 10.1038/s41416-019-0641-0
   Ding XY, 2020, CANCER SCI, V111, P489, DOI 10.1111/cas.14288
   Feigin ME, 2009, CURR OPIN CELL BIOL, V21, P694, DOI 10.1016/j.ceb.2009.07.003
   Garcia MA, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a029181
   Itzkowitz SH, 2004, AM J PHYSIOL-GASTR L, V287, pG7, DOI 10.1152/ajpgi.00079.2004
   Itzkowitz SH, 2006, GASTROENTEROL CLIN N, V35, P553, DOI 10.1016/j.gtc.2006.07.002
   Jana A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227916
   Ju ZL, 2020, CANCERS, V12, DOI 10.3390/cancers12030722
   Karaman R, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028753
   Karginova O, 2019, MOL CANCER THER, V18, P873, DOI 10.1158/1535-7163.MCT-18-0667
   Khalil AA, 2007, CANCER SCI, V98, P201, DOI 10.1111/j.1349-7006.2007.00374.x
   Kim YJ, 2019, METALLOMICS, V11, P1430, DOI 10.1039/c9mt00042a
   LAIHO P, 2003, J MED GENET, V40
   Laine L, 2015, GASTROENTEROLOGY, V148, P639, DOI 10.1053/j.gastro.2015.01.031
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Lee HC, 2005, ANN NY ACAD SCI, V1042, P109, DOI 10.1196/annals.1338.011
   Li K, 2018, J PEDIATR GASTR NUTR, V67, P45, DOI 10.1097/MPG.0000000000001898
   Li WH, 2019, EJSO-EUR J SURG ONC, V45, P1005, DOI 10.1016/j.ejso.2019.02.025
   Linehan WM, 2019, CANCER DISCOV, V9, P1006, DOI 10.1158/2159-8290.CD-18-1354
   Liu DJ, 2018, BIOCHEM BIOPH RES CO, V498, P453, DOI 10.1016/j.bbrc.2018.02.203
   Millan A, 2009, J SURG RES, V151, P163, DOI 10.1016/j.jss.2007.05.020
   Nowicki S, 2015, FEBS J, V282, P2796, DOI 10.1111/febs.13295
   Oehler VG, 2009, BLOOD, V114, P3292, DOI 10.1182/blood-2009-03-212969
   Perera R, 2015, NATURE, V524, P361, DOI 10.1038/nature14587
   Rao S, 2019, CELL RES, V29, P579, DOI 10.1038/s41422-019-0181-4
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rubin DT, 2019, AM J GASTROENTEROL, V114, P384, DOI 10.14309/ajg.0000000000000152
   Sajnani K, 2017, BIOCHIMIE, V135, P164, DOI 10.1016/j.biochi.2017.02.008
   Seth R, 2009, J CLIN PATHOL, V62, P598, DOI 10.1136/jcp.2009.064436
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang AL, 2012, CARCINOGENESIS, V33, P1375, DOI 10.1093/carcin/bgs183
   Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217
   Viola M, 2017, GLYCOCONJUGATE J, V34, P411, DOI 10.1007/s10719-016-9735-6
   Wang P, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0552-5
   Wang Q, 2020, THERANOSTICS, V10, P2141, DOI 10.7150/thno.38704
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Willett R, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01871-z
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhang YJ, 2020, J PATHOL, V251, P135, DOI 10.1002/path.5434
   Zou DH, 2019, AGING-US, V11, P11673, DOI 10.18632/aging.102571
NR 47
TC 1
Z9 1
U1 2
U2 3
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD APR 27
PY 2021
VL 9
AR e11321
DI 10.7717/peerj.11321
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RU5ZG
UT WOS:000645225700010
PM 33987007
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Liu, JH
   Li, JJ
   Chen, G
   Cai, XY
   Huang, YB
   Li, CJ
   Gan, XN
   Wei, DM
   Dang, YW
   Luo, DZ
AF Liu, Jianghua
   Li, Jianjun
   Chen, Gang
   Cai, Xiaoyong
   Huang, Yubin
   Li, Chunjun
   Gan, Xiaoning
   Wei, Danming
   Dang, Yiwu
   Luo, Dianzhong
TI Association of microRNA-23b-3p down-regulation with progression and
   survival in pancreatic duct adenocarcinoma and its prospective function
   via bioinformatics analysis
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Pancreatic duct adenocarcinoma (PDAC); MiR-23b-3p; disease specific
   survival (DSS); prognosis; real time RT-qPCR
ID PROGNOSTIC-SIGNIFICANCE; COLORECTAL-CANCER; CELLS; EXPRESSION;
   STATISTICS; AUTOPHAGY; THERAPY; TARGETS; MIR-23B; GROWTH
AB Background: MicroRNAs (miRNAs) have been reported in various human malignancies, which play important roles in tumorigenesis and progression, acting as oncogenes or tumor suppressors. However, the role of miR-23b-3p in pancreatic duct adenocarcinoma (PDAC) is to be elucidated. The goal of this study was to explore the association of miR-23b-3p expression with clinic features in PDAC formalin-fixed, paraffin embedded (FFPE) tissues and survival in PDAC patients and to investigate the prospective function of miR-23b-3p via bioinformatics analysis. Methods: The expression of miR-23b-3p was detected in 57 PDAC and 25 adjacent normal pancreatic tissues (ANT), also in five PDAC cell lines and an immortal pancreatic epithelium cell line HPDE6c-7 by qRT-PCR. The relationship between miR-23b-3p level and clinicopathological parameters including survival of PDAC patients was analyzed with Spearman correlation, Kaplan-Meier method and Cox proportional hazards mode, respectively. In addition, the validated target genes of miR-23b-3p gathered from DIANA-TarBase v7.0 and miRTarBase 6.0 were assessed with Gene Ontology (GO) and KEGG pathway enrichment analyses. Results: The relative level of miR-23b3p was significantly lower in PDAC compared to ANT (P=0.0053). Remarkably lesser expression of miR-23b-3p was also found in capan-1, aspc1 and panc-1 PDAC cells, compared with HPDE6c-7 cell line, respectively (all P<0.05). Furthermore, miR-23b-3p expression level was significantly correlated with tumor size (r=0.341, P=0.001), depth of invasion (r=0.264 P=0.048) and tumor stage (r=0.281, P=0.034). Kaplan-Meier analysis displayed that patients with lower miR-23b-3p expression presented a poorer disease specific survival (DSS) (P=0.036). Additionally, multivariate analysis revealed that down-expression of miR-23b-3p, as well as the histological grade and tumor stage, was an independent predictor of DSS of PDAC. A total of 173 validated targets were collected and they had enriched GO terms in different pathways. KEGG enrichment analysis revealed that the validated targets of miR-23b3p were significantly enriched in some well-known oncogenic pathways of malignancies, including the pathway of "Pancreatic cancer" with the genes of E2F1, RAF1, JAK1, RB1, BCL2L1, CHUK and RAD51. Conclusion: MiR-23b-3p might become as a potential indicator related to progress and prognosis via targeting various key pathways in PDAC.
C1 [Liu, Jianghua; Chen, Gang; Li, Chunjun; Gan, Xiaoning; Wei, Danming; Dang, Yiwu; Luo, Dianzhong] Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Liu, Jianghua] Guangxi Med Univ, Affiliated Hosp 1, Dept Emergency, Nanning, Guangxi Zhuang, Peoples R China.
   [Li, Jianjun; Cai, Xiaoyong; Huang, Yubin] Guangxi Med Univ, Affiliated Hosp 1, Dept Gen Surg, Western Branch, Nanning, Guangxi Zhuang, Peoples R China.
RP Dang, YW; Luo, DZ (corresponding author), Guangxi Med Univ, Affiliated Hosp 1, Dept Pathol, 6 Shuangyong Rd, Nanning 530021, Guangxi Zhuang, Peoples R China.
EM dangyiwu@126.com; 13878802796@163.com
FU Fund of Guangxi National Science Foundation [2014GXNS-FBA118167];
   Natural Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [NSFC 81560448]
FX The study was supported by the Fund of Guangxi National Science
   Foundation (2014GXNS-FBA118167) and Natural Science Foundation of China
   (NSFC 81560448). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Brunetti O, 2015, ONCOTARGET, V6, P23323, DOI 10.18632/oncotarget.4492
   Cekaite L, 2016, ONCOTARGET, V7, P6476, DOI 10.18632/oncotarget.6390
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258
   Conroy T, 2016, EUR J CANCER, V57, P10, DOI 10.1016/j.ejca.2015.12.026
   Frixa T, 2015, CANCERS, V7, P2466, DOI 10.3390/cancers7040904
   Gharibi A, 2016, ACTA HISTOCHEM, V118, P305, DOI 10.1016/j.acthis.2016.01.009
   Ibrahim AM, 2016, WORLD J GASTROENTERO, V22, P748, DOI 10.3748/wjg.v22.i2.748
   Ishteiwy RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052106
   Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162
   Kimura Hitomi, 2004, Nucleic Acids Symp Ser (Oxf), P213
   Kowalewska M, 2013, TUMOR BIOL, V34, P2153, DOI 10.1007/s13277-013-0748-5
   Krska Zdenek, 2015, Prague Med Rep, V116, P253, DOI 10.14712/23362936.2015.65
   Le TD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145386
   Lee YJ, 2015, DRUG DEVELOP RES, V76, P389, DOI 10.1002/ddr.21278
   Li BL, 2013, CELL PHYSIOL BIOCHEM, V32, P1729, DOI 10.1159/000356607
   Liu JH, 2014, ASIAN PAC J CANCER P, V15, P2971, DOI 10.7314/APJCP.2014.15.7.2971
   Majid S, 2012, CANCER RES, V72, P6435, DOI 10.1158/0008-5472.CAN-12-2181
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Ostenfeld MS, 2014, CANCER RES, V74, P5758, DOI 10.1158/0008-5472.CAN-13-3512
   Qu JJ, 2015, INT J CLIN EXP MED, V8, P17110
   Qureshi A, 2011, ASIAN PAC J CANCER P, V12, P953
   Salvi A, 2009, FEBS J, V276, P2966, DOI 10.1111/j.1742-4658.2009.07014.x
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Slaby O, 2013, NUTR CANCER, V65, P247, DOI 10.1080/01635581.2013.756530
   Sun LH, 2015, J GENET GENOMICS, V42, P563, DOI 10.1016/j.jgg.2015.07.003
   Tian L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075885
   Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pD153, DOI 10.1093/nar/gku1215
   Wang KC, 2010, P NATL ACAD SCI USA, V107, P3234, DOI 10.1073/pnas.0914825107
   Wang P, 2013, AUTOPHAGY, V9, P2171, DOI 10.4161/auto.26463
   Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048
   Yuan B, 2011, FEBS LETT, V585, P927, DOI 10.1016/j.febslet.2011.02.031
   Zaman MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050203
   Zhang HS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1555
   Zheng J, 2012, ALLERGY, V67, P362, DOI 10.1111/j.1398-9995.2011.02776.x
NR 35
TC 0
Z9 0
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 7
BP 6645
EP 6658
PG 14
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DT8GY
UT WOS:000381729200004
DA 2022-04-25
ER

PT J
AU Chern, YJ
   Wong, JCT
   Cheng, GSW
   Yu, A
   Yin, YL
   Schaeffer, DF
   Kennecke, HF
   Morin, G
   Tai, IT
AF Chern, Yi-Jye
   Wong, John C. T.
   Cheng, Grace S. W.
   Yu, Angel
   Yin, Yaling
   Schaeffer, David F.
   Kennecke, Hagen F.
   Morin, Gregg
   Tai, Isabella T.
TI The interaction between SPARC and GRP78 interferes with ER stress
   signaling and potentiates apoptosis via PERK/eIF2 alpha and IRE1
   alpha/XBP-1 in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; EXPRESSION; CELLS; RICH; SENSITIVITY;
   METABOLISM; RESISTANCE; AUTOPHAGY; MIGRATION; TARGET
AB Therapy-refractory disease is one of the main contributors of treatment failure in cancer. In colorectal cancer (CRC), SPARC can function as a sensitizer to conventional chemotherapy by enhancing apoptosis by interfering with the activity of Bcl-2. Here, we examine a novel mechanism by which SPARC further potentiates apoptosis via its modulation of the unfolded protein response (UPR). Using mass spectrometry to identify SPARC-associated proteins, GRP78 was identified as a protein partner for SPARC in CRC. In vitro studies conducted to assess the signaling events resulting from this interaction, included induction of ER stress with tunicamycin, 5-fluorouracil (5-FU), and irinotecan (CPT-11). We found that the interaction between GRP78 and SPARC increased during exposure to 5-FU, CPT-11, and tunicamycin, resulting in an attenuation of GRP78's inhibition of apoptosis. In addition, we also show that SPARC can sensitize CRC cells to PERK/eIF2 alpha and IRE1 alpha/XBP-1 UPR signaling by interfering with ER stress following binding to GRP78, which leads to ER stress-associated cell death in CRC cells. In line with these findings, a lower expression of GRP78 relative to SPARC in CRC is associated with a lower IC50 for 5-FU in either sensitive or therapy-refractory CRC cells. Interestingly, this observation correlates with tissue microarray analysis of 143 human CRC, where low GRP78 to SPARC expression level was prognostic of higher survival rate (P= 0.01) in individuals with CRC. This study demonstrates that modulation of UPR signaling by SPARC promotes ER stress-associated death and potentiates apoptosis. This may be an effective strategy that can be combined with current treatment options to improve therapeutic efficacy in CRC.
C1 [Chern, Yi-Jye; Wong, John C. T.; Yu, Angel; Tai, Isabella T.] Univ British Columbia, Dept Med, Div Gastroenterol, Vancouver, BC, Canada.
   [Chern, Yi-Jye; Wong, John C. T.; Cheng, Grace S. W.; Yu, Angel; Morin, Gregg; Tai, Isabella T.] British Columbia Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC, Canada.
   [Cheng, Grace S. W.; Morin, Gregg] British Columbia Canc Agcy, Dept Med Genet, Vancouver, BC, Canada.
   [Yin, Yaling] British Columbia Canc Agcy, Canc Surveillance & Outcomes, Vancouver, BC, Canada.
   [Yin, Yaling; Kennecke, Hagen F.] British Columbia Canc Agcy, Dept Med Oncol, Vancouver, BC, Canada.
   [Schaeffer, David F.] Univ British Columbia, Dept Pathol, Vancouver, BC, Canada.
RP Tai, IT (corresponding author), Univ British Columbia, Dept Med, Div Gastroenterol, Vancouver, BC, Canada.; Tai, IT (corresponding author), British Columbia Canc Agcy, Michael Smith Genome Sci Ctr, Vancouver, BC, Canada.
EM itai@bcgsc.ca
RI Morin, Gregg B/E-9123-2012; Chern, Yi-Jye/AAE-9283-2022; Tai, Isabella
   T/E-8035-2012
OI Morin, Gregg B/0000-0001-8949-4374; Chern, Yi-Jye/0000-0003-3533-5735
FU Canadian Institutes of Health Research (CIHR)Canadian Institutes of
   Health Research (CIHR) [MOP-82881]; CIHRCanadian Institutes of Health
   Research (CIHR) [MSH-95344]
FX This work was supported by Canadian Institutes of Health Research (CIHR)
   research grant#MOP-82881; CIHR New Investigator salary award to Isabella
   T. Tai (MSH-95344). The authors would like to thank Dr. Hla Win Piazza
   for her technical assistance in this study.
CR ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Bolte S, 2006, J MICROSC-OXFORD, V224, P213, DOI 10.1111/j.1365-2818.2006.01706.x
   Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013
   Chew A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022047
   Dejeans N, 2012, J CELL SCI, V125, P4278, DOI 10.1242/jcs.099291
   DiMartino JF, 2006, LEUKEMIA, V20, P426, DOI 10.1038/sj.leu.2404102
   Fan X, 2016, TUMOR BIOL, V37, P2267, DOI 10.1007/s13277-015-4044-4
   Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135
   Gopal U, 2016, J BIOL CHEM, V291, P10904, DOI 10.1074/jbc.M115.708131
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Hollien J, 2006, SCIENCE, V313, P104, DOI 10.1126/science.1129631
   Hua HW, 2015, TUMOR BIOL, V36, P303, DOI 10.1007/s13277-014-2633-2
   Kang BR, 2016, SCI REP-UK, V6, DOI 10.1038/srep34922
   Kim KW, 2010, ONCOGENE, V29, P3241, DOI 10.1038/onc.2010.74
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   Liu B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.422
   Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130
   Luo DH, 2008, J BIOL CHEM, V283, P11905, DOI 10.1074/jbc.M710557200
   Mead CLR, 2010, J NEUROCHEM, V113, P1491, DOI 10.1111/j.1471-4159.2010.06690.x
   Mhaidat NM, 2015, CANCER BIOMARK, V15, P197, DOI 10.3233/CBM-140454
   Notaro A, 2016, INT J ONCOL, V48, P1039, DOI 10.3892/ijo.2015.3307
   Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133
   Rahman MM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028065
   Rasche L, 2016, CLIN CANCER RES, V22, P4341, DOI 10.1158/1078-0432.CCR-15-3111
   Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387
   Rutkowski DT, 2006, PLOS BIOL, V4, P2024, DOI 10.1371/journal.pbio.0040374
   Said N, 2005, AM J PATHOL, V167, P1739, DOI 10.1016/S0002-9440(10)61255-2
   Said N, 2013, J CLIN INVEST, V123, P751, DOI 10.1172/JCI64782
   Sailaja GS, 2013, INT J ONCOL, V42, P188, DOI 10.3892/ijo.2012.1678
   Samali A, 2010, INT J CELL BIOL, V2010, DOI [10.1155/2010/830307, DOI 10.1155/2010/830307]
   Schleicher SM, 2010, DRUG RESIST UPDATE, V13, P79, DOI 10.1016/j.drup.2010.04.002
   Tai IT, 2005, J CLIN INVEST, V115, P1492, DOI 10.1172/JCI23002
   Tan SS, 2011, J PATHOL, V223, P81, DOI 10.1002/path.2795
   Tang MJ, 2007, J BIOL CHEM, V282, P34457, DOI 10.1074/jbc.M704459200
   Thornton M, 2013, INT J CANCER, V133, P1408, DOI 10.1002/ijc.28137
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Uckun FM, 2011, BRIT J HAEMATOL, V153, P741, DOI 10.1111/j.1365-2141.2011.08671.x
   Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060
   Wang N, 2014, CARCINOGENESIS, V35, P2544, DOI 10.1093/carcin/bgu187
   Wu J, 2006, CELL DEATH DIFFER, V13, P374, DOI 10.1038/sj.cdd.4401840
   Xing XM, 2006, CLIN CHIM ACTA, V364, P308, DOI 10.1016/j.cca.2005.07.016
   Yin YC, 2017, CELL SIGNAL, V35, P154, DOI 10.1016/j.cellsig.2017.04.003
   Zhang YJ, 2013, ENGINEERING, V5, P4, DOI DOI 10.1371/J0URNAL.P0NE.0080071
   Zoni E, 2017, ONCOGENE, V36, P4739, DOI 10.1038/onc.2017.87
NR 46
TC 37
Z9 39
U1 1
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN 26
PY 2019
VL 10
AR 504
DI 10.1038/s41419-019-1687-x
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IF2YV
UT WOS:000472947600003
PM 31243264
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Li, MY
   Zhang, SH
   Qiu, Y
   He, Y
   Chen, BL
   Mao, R
   Cui, Y
   Zeng, ZR
   Chen, MH
AF Li, Manying
   Zhang, Shenghong
   Qiu, Yun
   He, Yao
   Chen, Baili
   Mao, Ren
   Cui, Yi
   Zeng, Zhirong
   Chen, Minhu
TI Upregulation of miR-665 promotes apoptosis and colitis in inflammatory
   bowel disease by repressing the endoplasmic reticulum stress components
   XBP1 and ORMDL3
SO CELL DEATH & DISEASE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; ER STRESS; HEPATOCELLULAR-CARCINOMA;
   ULCERATIVE-COLITIS; EXPRESSION; CANCER; AUTOPHAGY; IMMUNITY; CELLS; RISK
AB MicroRNAs are critical post-transcriptional regulators of gene expression and key mediators of pathophysiology of inflammatory bowel disease (IBD). This study is aimed to study the role of miR-665 in the progression of IBD. Real-time PCR analysis was used to determine miR-665 expression in 89 freshly isolated IBD samples and dextran sulfate sodium (DSS)-induced colonic mucosal tissues. The role of miR-665 in inducing apoptosis and colitis were examined by Annexin V, TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining, colony formation in vitro and DSS-induced colitis mice model in vivo. Moreover, luciferase reporter assay, western blot analysis and microribonucleoprotein immunoprecipitation were performed to determine that miR-665 directly repressed XBP1 (X-box-binding protein-1) and ORMDL3 expression. Herein, our results revealed that miR-665 was markedly upregulated in active colitis. Gain-of-function and loss-of-function studies showed that ectopic expression of miR-665 promoted apoptosis under different inflammatory stimuli. Importantly, delivery of miR-665 mimic promoted, while injection of antagomiR-665 markedly impaired DSS-induced colitis in vivo. Mechanistically, we demonstrated that miR-665 induced apoptosis by inhibiting XBP1 and ORMDL3. Taken together, our findings reveal a new regulatory mechanism for ER stress signaling and suggest that miR-665 might be a potential target in IBD therapy.
C1 [Li, Manying; Zhang, Shenghong; Qiu, Yun; He, Yao; Chen, Baili; Mao, Ren; Cui, Yi; Zeng, Zhirong; Chen, Minhu] Sun Yat Sen Univ, First Affiliated Hosp, Div Gastroenterol, 58,Zhongshan Rd 2, Guangzhou 510080, Peoples R China.
RP Zhang, SH (corresponding author), Sun Yat Sen Univ, First Affiliated Hosp, Div Gastroenterol, 58,Zhongshan Rd 2, Guangzhou 510080, Peoples R China.
EM shenghongzhang@163.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81670498, 81470821, 81630018]; Pearl River
   S&T Nova Program of Guangzhou [201610010126]; Guangdong Science and
   Technology [2014A020212128, 2016A020214006]; Fundamental Research Funds
   for Sun Yat-sen University [15ykpy12]
FX This project was supported by grants from the National Natural Science
   Foundation of China (nos 81670498, 81470821 and 81630018), the Pearl
   River S&T Nova Program of Guangzhou (no. 201610010126), Guangdong
   Science and Technology (nos 2014A020212128 and 2016A020214006) and the
   Fundamental Research Funds for Sun Yat-sen University (no. 15ykpy12).
CR Adolph TE, 2012, DIGEST DIS, V30, P341, DOI 10.1159/000338121
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bettigole SE, 2015, ANNU REV IMMUNOL, V33, P107, DOI 10.1146/annurev-immunol-032414-112116
   Cao SS, 2016, INFLAMM BOWEL DIS, V22, P984, DOI 10.1097/MIB.0000000000000660
   Cao SS, 2015, INFLAMM BOWEL DIS, V21, P636, DOI 10.1097/MIB.0000000000000238
   Cao SS, 2014, INFLAMM BOWEL DIS, V20, P712, DOI 10.1097/MIB.0000000000000010
   Chen J, 2015, ONCOL REP, V33, P2963, DOI 10.3892/or.2015.3935
   Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490
   Chhabra R, 2011, RNA BIOL, V8, P648, DOI 10.4161/rna.8.4.15583
   Dalmasso G, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023806, 10.1371/journal.pone.0019293]
   Francescone R, 2015, INFLAMM BOWEL DIS, V21, P409, DOI 10.1097/MIB.0000000000000236
   Fritz T, 2011, GUT, V60, P1580, DOI 10.1136/gut.2009.206466
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Hoefkens E, 2013, AUTOPHAGY, V9, P2046, DOI 10.4161/auto.26337
   Hsu KJ, 2013, ALLERGY ASTHMA CL IM, V9, DOI 10.1186/1710-1492-9-4
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kaser A, 2011, GASTROENTEROLOGY, V140, P1738, DOI 10.1053/j.gastro.2011.02.048
   Kaser A, 2011, GASTROENTEROLOGY, V140, P393, DOI 10.1053/j.gastro.2010.12.015
   Kaser A, 2010, CURR OPIN GASTROEN, V26, P318, DOI 10.1097/MOG.0b013e32833a9ff1
   Kotanko P, 2006, NEPHROL DIAL TRANSPL, V21, P2057, DOI 10.1093/ndt/gfl281
   Pedersen J, 2014, TRENDS MOL MED, V20, P652, DOI 10.1016/j.molmed.2014.09.006
   Polytarchou C, 2015, GASTROENTEROLOGY, V149, P981, DOI 10.1053/j.gastro.2015.05.057
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Sano R, 2013, BBA-MOL CELL RES, V1833, P3460, DOI 10.1016/j.bbamcr.2013.06.028
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Van der Goten J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116117
   Wang HL, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0901-8
   Yang F, 2011, NEOPLASIA, V13, P590, DOI 10.1593/neo.11422
   Yang Y, 2015, ONCOTARGET, V6, P16227, DOI 10.18632/oncotarget.3970
   Yu Q, 2016, J CROHNS COLITIS, V10, P713, DOI 10.1093/ecco-jcc/jjw023
NR 30
TC 58
Z9 60
U1 2
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAR
PY 2017
VL 8
AR e2699
DI 10.1038/cddis.2017.76
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EP5VM
UT WOS:000397447100023
PM 28333149
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Qian, XL
   Pan, YH
   Huang, QY
   Shi, YB
   Huang, QY
   Hu, ZZ
   Xiong, LX
AF Qian, Xian-Ling
   Pan, Yi-Hang
   Huang, Qi-Yuan
   Shi, Yu-Bo
   Huang, Qing-Yun
   Hu, Zhen-Zhen
   Xiong, Li-Xia
TI Caveolin-1: a multifaceted driver of breast cancer progression and its
   application in clinical treatment
SO ONCOTARGETS AND THERAPY
LA English
DT Review
DE breast cancer; caveolin-1; migration; metastasis; prognosis; invasion
ID ANTIBODY-DRUG CONJUGATE; STEM-CELLS; MESENCHYMAL TRANSITION;
   COLORECTAL-CANCER; DOWN-REGULATION; LIPID RAFTS; TRANSCRIPTIONAL
   REGULATION; PROGNOSTIC BIOMARKER; DOCOSAHEXAENOIC ACID;
   ANTITUMOR-ACTIVITY
AB Human breast cancer is one of the most frequent cancer diseases and causes of death among female population worldwide. It appears at a high incidence and has a high malignancy, mortality, recurrence rate and poor prognosis. Caveolin-1 (Cav1) is the main component of caveolae and participates in various biological events. More and more experimental studies have shown that Cav1 plays a critical role in the progression of breast cancer including cell proliferation, apoptosis, autophagy, invasion, migration and breast cancer metastasis. Besides, Cav1 has been found to be involved in chemotherapeutics and radiotherapy resistance, which are still the principal problems encountered in clinical breast cancer treatment. In addition, stromal Cav1 may be a potential indicator for breast cancer patients' prognosis. In the current review, we cover the state-of-the-art study, development and progress on Cav1 and breast cancer, altogether describing the role of Cav1 in breast cancer progression and application in clinical treatment, in the hope of providing a basis for further research and promoting CAV1 gene as a potential target to diagnose and treat aggressive breast cancers.
C1 [Qian, Xian-Ling; Pan, Yi-Hang; Huang, Qi-Yuan; Shi, Yu-Bo; Huang, Qing-Yun; Hu, Zhen-Zhen; Xiong, Li-Xia] Nanchang Univ, Dept Pathophysiol, Basic Med Coll, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.
   [Qian, Xian-Ling; Pan, Yi-Hang] Nanchang Univ, Clin Med Coll 1, Nanchang 330006, Jiangxi, Peoples R China.
   [Huang, Qi-Yuan] Nanchang Univ, Clin Med Coll 2, Nanchang 330006, Jiangxi, Peoples R China.
   [Hu, Zhen-Zhen; Xiong, Li-Xia] Jiangxi Prov Key Lab Tumor Pathogenesis & Mol Pat, Nanchang, Jiangxi, Peoples R China.
RP Hu, ZZ; Xiong, LX (corresponding author), Nanchang Univ, Dept Pathophysiol, Basic Med Coll, 461 Bayi Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM huzhenzhen@ncu.edu.cn; xionglixia@ncu.edu.cn
RI Qian, Xianling/V-6981-2019
OI Qian, Xianling/0000-0001-5366-4976; Xiong, Lixia/0000-0003-3769-2496
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [31860317]
FX LXX received a grant from the National Natural Science Foundation of
   China (No 31860317). The authors report no other conflicts of interest
   in this work.
CR Al-Ansari MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090907
   Alawin OA, 2016, J NUTR BIOCHEM, V27, P266, DOI 10.1016/j.jnutbio.2015.09.018
   Albanito L, 2015, ENVIRON HEALTH PERSP, V123, P493, DOI 10.1289/ehp.1408586
   Alevizos L, 2014, CLIN EXP METASTAS, V31, P511, DOI 10.1007/s10585-014-9645-6
   Anwar Sumadi Lukman, 2015, Asian Pac J Cancer Prev, V16, P6803
   Aysola K, 2013, HEREDITARY GENET S2, V2013
   Badana A, 2016, J BREAST CANCER, V19, P372, DOI 10.4048/jbc.2016.19.4.372
   Badana AK, 2018, BIOMED PHARMACOTHER, V97, P359, DOI 10.1016/j.biopha.2017.10.045
   Bailey KM, 2008, J BIOL CHEM, V283, P13714, DOI 10.1074/jbc.M709329200
   Braun AC, 2015, CELL SIGNAL, V27, P1643, DOI 10.1016/j.cellsig.2015.04.003
   Sanchez RC, 2016, CHEM RES TOXICOL, V29, P285, DOI 10.1021/acs.chemrestox.5b00457
   Celus W, 2017, CELL REP, V21, P2842, DOI 10.1016/j.celrep.2017.11.034
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chamberlain LH, 2004, FEBS LETT, V559, P1, DOI 10.1016/S0014-5793(04)00050-X
   Chantome A, 2013, CANCER RES, V73, P4852, DOI 10.1158/0008-5472.CAN-12-4572
   Chanvorachote P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057466
   Chen DL, 2014, ONCOL LETT, V8, P1409, DOI 10.3892/ol.2014.2385
   Chen SS, 2016, ATHEROSCLEROSIS, V246, P148, DOI 10.1016/j.atherosclerosis.2016.01.008
   Chen YH, 2008, EXPERT REV ANTICANC, V8, P1689, DOI 10.1586/14737140.8.10.1689
   Cheng CL, 2015, BREAST CANCER RES TR, V151, P99, DOI 10.1007/s10549-015-3371-x
   Cheng JPX, 2016, TRENDS CELL BIOL, V26, P177, DOI 10.1016/j.tcb.2015.10.010
   Chung YC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22250-8
   Chung YC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133072
   Cole Greg M, 2005, Neurobiol Aging, V26 Suppl 1, P133, DOI 10.1016/j.neurobiolaging.2005.09.005
   Collignon J, 2016, BREAST CANCER-TARGET, V8, P93, DOI 10.2147/BCTT.S69488
   Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9
   Daskalaki I, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00104
   Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9
   Deb M, 2014, TUMOR BIOL, V35, P12031, DOI 10.1007/s13277-014-2502-z
   Demirci NS, 2017, SAUDI J GASTROENTERO, V23, P183, DOI 10.4103/sjg.SJG_483_16
   DeSantis CE, 2017, CA-CANCER J CLIN, V67, P439, DOI 10.3322/caac.21412
   Diaz J, 2014, J CELL SCI, V127, P2401, DOI 10.1242/jcs.141689
   Donnenberg VS, 2009, METHODS MOL BIOL, V568, P261, DOI 10.1007/978-1-59745-280-9_17
   Drews-Elger K, 2014, BREAST CANCER RES TR, V148, P41, DOI 10.1007/s10549-014-3122-4
   Du C, 2014, INT J MOL SCI, V15, P20706, DOI 10.3390/ijms151120706
   Duhon D, 2010, MOL CARCINOGEN, V49, P739, DOI 10.1002/mc.20649
   Ebisawa M, 2015, VET J, V206, P191, DOI 10.1016/j.tvjl.2015.07.020
   Echarri A, 2012, CURR BIOL, V22, pR114, DOI 10.1016/j.cub.2011.11.049
   Eliyatkin N, 2018, PATHOL ONCOL RES, V24, P59, DOI 10.1007/s12253-017-0212-8
   Elsheikh SE, 2008, BRIT J CANCER, V99, P327, DOI 10.1038/sj.bjc.6604463
   Ettlin J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18051101
   Fard ZT, 2018, CLIN BREAST CANCER, V18, pE893, DOI 10.1016/j.clbc.2018.01.005
   Fu P, 2017, ONCOTARGETS THER, V10, P819, DOI 10.2147/OTT.S123912
   Gai XH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084551
   Gajate C, 2007, BLOOD, V109, P711, DOI 10.1182/blood-2006-04-016824
   Gallardo M, 2016, INT J ONCOL, V48, P2534, DOI 10.3892/ijo.2016.3477
   Garcia-Rivas G, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0440-5
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Girerd B, 2017, CURR OPIN PULM MED, V23, P386, DOI 10.1097/MCP.0000000000000414
   Gleissman H, 2011, INT J CANCER, V128, P1703, DOI 10.1002/ijc.25473
   Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9
   Gupta R, 2014, BIOCHIMIE, V107, P188, DOI 10.1016/j.biochi.2014.09.010
   Han B, 2016, TRAFFIC, V17, P1297, DOI 10.1111/tra.12452
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]
   Hehlgans S, 2011, AM J CANCER RES, V1, P521
   Herzog M, 2011, N-S ARCH PHARMACOL, V383, P1, DOI 10.1007/s00210-010-0568-8
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hu ZY, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120344
   Huang H, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18103249
   Jensen DH, 2015, J ORAL PATHOL MED, V44, P714, DOI 10.1111/jop.12297
   Jhan JR, 2017, PHARMACOGENOMICS, V18, P1595, DOI 10.2217/pgs-2017-0117
   Joglekar M, 2015, J CELL BIOCHEM, V116, P923, DOI 10.1002/jcb.25025
   Kandpal RP, 2006, CURR PROTEIN PEPT SC, V7, P355
   Kang J, 2016, CANCER RES TREAT, V48, P715, DOI 10.4143/crt.2015.227
   Kim EG, 2015, BIOMOL THER, V23, P493, DOI 10.4062/biomolther.2015.116
   Kim Yu-Kyoung, 2012, ISRN Microbiol, V2012, P650563, DOI 10.5402/2012/650563
   Kobayashi H, 2018, PULM CIRC, V8, DOI 10.1177/2045894018778155
   Kovtun O, 2015, J CELL SCI, V128, P1269, DOI 10.1242/jcs.167866
   Kowalska K, 2016, ACTA BIOCHIM POL, V63, P493, DOI 10.18388/abp.2015_1016
   Kozyulina PY, 2015, MOL CANCER RES, V13, P423, DOI 10.1158/1541-7786.MCR-14-0353
   Kuczynski EA, 2013, NAT REV CLIN ONCOL, V10, P571, DOI 10.1038/nrclinonc.2013.158
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee EJ, 2014, BBA-MOL CELL BIOL L, V1841, P190, DOI 10.1016/j.bbalip.2013.10.006
   Li S, 2019, J CELL PHYSIOL, V234, P3730, DOI 10.1002/jcp.27149
   Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026
   Li XY, 2017, WIEN KLIN WOCHENSCHR, V129, P558, DOI 10.1007/s00508-017-1173-3
   Li Z, 2015, THORAC CANCER, V6, P695, DOI 10.1111/1759-7714.12239
   Liang X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0608-8
   Liang YN, 2018, ONCOL LETT, V15, P9271, DOI 10.3892/ol.2018.8533
   Liu J, 2015, J APPL TOXICOL, V35, P1309, DOI 10.1002/jat.3112
   LoRusso PM, 2011, CLIN CANCER RES, V17, P6437, DOI 10.1158/1078-0432.CCR-11-0762
   Lv W, 2016, CANCER LETT, V375, P245, DOI 10.1016/j.canlet.2016.02.005
   Ma XL, 2013, BREAST, V22, P462, DOI 10.1016/j.breast.2013.03.005
   Magbanua MJM, 2018, NPJ BREAST CANCER, V4, DOI 10.1038/s41523-018-0083-5
   Malik Babar, 2012, Front Biosci (Elite Ed), V4, P2142
   Mallini P, 2014, CANCER TREAT REV, V40, P341, DOI 10.1016/j.ctrv.2013.09.008
   Mandy MM, 2016, J CLIN TRANSL HEPATO, V4, P293, DOI 10.14218/JCTH.2016.00046
   Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019
   Martinez-Outschoorn UE, 2015, NAT REV CANCER, V15, P225, DOI 10.1038/nrc3915
   Martins D, 2013, CELL CYCLE, V12, P2684, DOI 10.4161/cc.25794
   Maugeri-Sacca M, 2011, CLIN CANCER RES, V17, P4942, DOI 10.1158/1078-0432.CCR-10-2538
   Mercier I, 2012, ADV EXP MED BIOL, V729, P83, DOI 10.1007/978-1-4614-1222-9_6
   Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Mollinedo F, 2010, CLIN CANCER RES, V16, P2046, DOI 10.1158/1078-0432.CCR-09-2456
   Monti D, 2017, SEMIN ONCOL, V44, P226, DOI 10.1053/j.seminoncol.2017.10.001
   Moreno-Bueno G, 2008, ONCOGENE, V27, P6958, DOI 10.1038/onc.2008.346
   Na HK, 2008, ASIA PAC J CLIN NUTR, V17, P204
   Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509
   Nimri L, 2013, MOL CARCINOGEN, V52, P859, DOI 10.1002/mc.21927
   Obeidat FN, 2018, ANN SAUDI MED, V38, P326, DOI 10.5144/0256-4947.2018.326
   Omidvari S, 2013, IRAN J CANCER PREV, V6, P113
   Pal S, 2013, CELL COMMUN ADHES, V20, P105, DOI 10.3109/15419061.2013.833193
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Parat MO, 2012, NEURO-ONCOLOGY, V14, P679, DOI 10.1093/neuonc/nos079
   Patani N, 2012, BREAST CANCER RES TR, V131, P1, DOI 10.1007/s10549-011-1751-4
   Peng L, 2015, BIOCONJUGATE CHEM, V26, P2169, DOI 10.1021/acs.bioconjchem.5b00515
   Perona R, 2011, CLIN TRANSL ONCOL, V13, P289, DOI 10.1007/s12094-011-0656-3
   Peter ME, 2015, CELL DEATH DIFFER, V22, P549, DOI 10.1038/cdd.2015.3
   Pfeffer CM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020448
   Pike LJ, 2005, BBA-MOL CELL RES, V1746, P260, DOI 10.1016/j.bbamcr.2005.05.005
   Ponce-Cusi R, 2015, INT J ONCOL, V46, P2663, DOI 10.3892/ijo.2015.2955
   Pucci M, 2015, CANCER GENOM PROTEOM, V12, P143
   Qian N, 2011, CANCER SCI, V102, P1590, DOI 10.1111/j.1349-7006.2011.01985.x
   Quest AFG, 2013, CURR MOL MED, V13, P266
   Ren MJ, 2014, VIRCHOWS ARCH, V465, P291, DOI 10.1007/s00428-014-1614-6
   Salis O, 2014, EUR REV MED PHARMACO, V18, P1602
   Salis O, 2014, CANCER BIOTHER RADIO, V29, P368, DOI 10.1089/cbr.2013.1593
   Sekhar SC, 2013, J CANCER, V4, P391, DOI 10.7150/jca.6470
   Selvi V, 2018, BIOMED RES INT, V2018, P1
   SEMENZA GL, 2015, BIOCHIM BIOPHYS ACTA, V1863, P382, DOI DOI 10.1016/J.BBAMCR.2015.05.036
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Shi XY, 2016, MOL MED REP, V13, P744, DOI 10.3892/mmr.2015.4610
   Shi Y, 2015, AUTOPHAGY, V11, P769, DOI 10.1080/15548627.2015.1034411
   Shinoda H, 2014, J VET DIAGN INVEST, V26, P390, DOI 10.1177/1040638714527289
   Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029
   Somrit M, 2016, VIRUS RES, V223, P1, DOI 10.1016/j.virusres.2016.06.012
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856
   Sung M, 2018, MOL CANCER THER, V17, P243, DOI 10.1158/1535-7163.MCT-17-0403
   Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Takeda M, 2018, CANCER SCI, V109, P2401, DOI 10.1111/cas.13659
   Tasdemir N, 2018, CANCER RES, V78, P6209, DOI 10.1158/0008-5472.CAN-18-1416
   Thompson MA, 2014, EXPERT REV RESP MED, V8, P111, DOI 10.1586/17476348.2014.855610
   Torella D, 2018, DIABETES, V67, P2554, DOI 10.2337/db17-1434
   Totta P, 2016, J CELL PHYSIOL, V231, P1219, DOI 10.1002/jcp.25218
   Trumpp A, 2008, NAT CLIN PRACT ONCOL, V5, P337, DOI 10.1038/ncponc1110
   Truong A, 2016, FEBS J, V283, P704, DOI 10.1111/febs.13625
   Tsao SM, 2016, SCI REP-UK, V6, DOI 10.1038/srep36563
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   von der Heyde S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117818
   Vranic S, 2015, HUM PATHOL, V46, P1350, DOI 10.1016/j.humpath.2015.05.017
   Wachter DL, 2019, ARCH PATHOL LAB MED, V143, P206, DOI 10.5858/arpa.2017-0578-OA
   Wang CL, 2018, ONCOL LETT, V15, P213, DOI 10.3892/ol.2017.7351
   Wang H., 2013, J NANOMATER MOL NANO, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0070192
   Wang K, 2018, ARCH BIOCHEM BIOPHYS, V646, P10, DOI 10.1016/j.abb.2018.03.029
   Wang R, 2014, INT J MOL MED, V34, P822, DOI 10.3892/ijmm.2014.1836
   Wang R, 2014, MOL MED REP, V9, P1723, DOI 10.3892/mmr.2014.2018
   Wang SM, 2017, DESTECH TRANS SOC, P1, DOI 10.1155/2017/8608032
   Wang Y, 2018, ONCOL REP, V40, P1287, DOI 10.3892/or.2018.6550
   Wang ZY, 2016, CURR DRUG TARGETS, V17, P853, DOI 10.2174/1389450116666150316223655
   Wang ZY, 2014, CARCINOGENESIS, V35, P2346, DOI 10.1093/carcin/bgu155
   Ward EM, 2015, CA-CANCER J CLIN, V65, P481, DOI 10.3322/caac.21321
   Witkiewicz AK, 2009, CANCER BIOL THER, V8, P1071, DOI 10.4161/cbt.8.11.8874
   Wu Jie, 2018, Asian Pac J Cancer Prev, V19, P401
   Xiang SN, 2018, SMALL, V14, DOI 10.1002/smll.201704245
   Xiong NY, 2017, BBA-MOL CELL RES, V1864, P12, DOI 10.1016/j.bbamcr.2016.10.013
   Xu FY, 2017, ENVIRON POLLUT, V231, P1609, DOI 10.1016/j.envpol.2017.09.069
   Yang BW, 2017, IN VITRO CELL DEV-AN, V53, P354, DOI 10.1007/s11626-016-0123-0
   Yao Q, 2018, TRENDS PHARMACOL SCI, V39, P766, DOI 10.1016/j.tips.2018.06.003
   Yeong J, 2018, J CLIN PATHOL, V71, P161, DOI 10.1136/jclinpath-2017-204495
   Yongsanguanchai N, 2015, AM J PHYSIOL-CELL PH, V308, pC89, DOI 10.1152/ajpcell.00187.2014
   Yu C, 2018, CANCER MED-US, V7, P471, DOI 10.1002/cam4.1287
   Yuan G, 2013, ONCOGENE, V32, P375, DOI 10.1038/onc.2012.40
   Yue Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149661
   Zhang L, 2010, NATURE, V464, P1058, DOI 10.1038/nature08871
   Zhang T, 2017, MOL MED REP, V15, P3566, DOI 10.3892/mmr.2017.6480
   Zhao Z, 2015, WORLD J GASTROENTERO, V21, P1140, DOI 10.3748/wjg.v21.i4.1140
   Zheng WL, 2018, LIFE SCI, V192, P270, DOI 10.1016/j.lfs.2017.11.011
   Zheng YF, 2019, J CELL PHYSIOL, V234, P4277, DOI 10.1002/jcp.27196
   Zhou WD, 2018, EXP THER MED, V16, P2811, DOI 10.3892/etm.2018.6537
   Zielinska HA, 2018, CANCER LETT, V419, P187, DOI 10.1016/j.canlet.2018.01.028
   Zou M, 2017, CELL PHYSIOL BIOCHEM, V44, P778, DOI 10.1159/000485291
NR 172
TC 25
Z9 25
U1 7
U2 11
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2019
VL 12
BP 1539
EP 1552
DI 10.2147/OTT.S191317
PG 14
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA HN3GI
UT WOS:000460071400001
PM 30881011
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Zhang, LP
   Zhang, Q
   Lv, LX
   Zhu, JH
   Ting, C
   Wu, YT
AF Zhang, Liping
   Zhang, Qiang
   Lv, Lingxia
   Zhu, Jianhua
   Ting, Chen
   Wu, Yutao
TI LncRNA SNHG1 regulates vascular endothelial cell proliferation and
   angiogenesis via miR-196a
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE Atherosclerosis; SNHG1; Inflammatory cytokines; HUVECs
ID INFLAMMATORY CYTOKINES; COLORECTAL-CANCER; NONCODING RNAS;
   ATHEROSCLEROSIS; APOPTOSIS; MIGRATION; DISEASE; MAPK; INHIBITION;
   INVASION
AB Inflammatory cytokines are important protagonists in the formation of atherosclerotic plaques, triggering effects throughout the atherosclerotic vessels due to the destruction in proliferation, migration and angiogenesis of endothelial cells. In this study, we found SNHG1 is upregulated in TNF-alpha-treated HUVECs. We silenced SNHG1 and found it inhibited vascular endothelial cell proliferation and angiogenesis. In the other hand, exogenetic overexpression of SNHG1 promotes proliferation, migration and angiogenesis. Then we demonstrated that SNHG1 may interact directly with miR-196a to act as a miR-196a sponge. Further, MAPK6 were predicted to be the target of miR-196a. So we blocked miR-196a, which increased expression level of MAPK6, enhanced cell proliferation, migration and angiogenesis. These data indicated that SNHG1/miR-196a/MAPK6 axis may take a part in autophagy regulation in TNF-alpha-treated HUVECs. The subsequent rescue experiments come to the results ascertained the specificity of SNHG1/miR-196a/MAPK6 axis in regulating MAPK6. Overall, our findings demonstrate a novel mechanism by which SNHG1 overexpression protects the function of HUVECs, which may delay the progression of AS. SNHG1/miR-196a/MAPK6 axis may be of therapeutic significance in AS.
C1 [Zhang, Liping; Zhang, Qiang; Lv, Lingxia; Zhu, Jianhua; Ting, Chen; Wu, Yutao] Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
RP Wu, YT (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Cardiol, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM vfdgijgjn@sina.com
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81700238, 81670397, 91539103]; Zhejiang
   Medical Science and Technology Project [2019KY376, 2018KY071]
FX This work was supported by the National Natural Science Foundation of
   China Grants (81700238, 81670397, 91539103), and the Zhejiang Medical
   Science and Technology Project (2019KY376, 2018KY071).
CR Beermann J, 2016, PHYSIOL REV, V96, P1297, DOI 10.1152/physrev.00041.2015
   Chen J, 2019, EUR REV MED PHARMACO, V23, P5366, DOI 10.26355/eurrev_201906_18205
   Dong LY, 2013, AM J CHINESE MED, V41, P1251, DOI 10.1142/S0192415X13500845
   Faxon DP, 2004, CIRCULATION, V109, P2595, DOI 10.1161/01.CIR.0000128517.52533.DB
   Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Hu CM, 2019, ONCOL LETT, V17, P5201, DOI 10.3892/ol.2019.10186
   Hu CX, 2018, EXP THER MED, V15, P2755, DOI 10.3892/etm.2018.5735
   Huang DL, 2019, GENE, V714, DOI 10.1016/j.gene.2019.143994
   Kim JA, 2006, CIRCULATION, V113, P1888, DOI 10.1161/CIRCULATIONAHA.105.563213
   Lei JL, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191523
   Li SQ, 2018, BIOMED PHARMACOTHER, V104, P451, DOI 10.1016/j.biopha.2018.05.056
   Liao JQ, 2016, GENE, V578, P158, DOI 10.1016/j.gene.2015.12.032
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Liu Y, 2018, BIOCHEM CELL BIOL, V96, P38, DOI 10.1139/bcb-2017-0188
   Munzel T, 2018, EUR HEART J, V39, P3543, DOI 10.1093/eurheartj/ehy481
   Pan JX, 2017, EUR REV MED PHARMACO, V21, P322
   Pin AL, 2012, J BIOL CHEM, V287, P30541, DOI 10.1074/jbc.M112.393561
   Qi H, 2017, PHARMAZIE, V72, P395, DOI 10.1691/ph.2017.7463
   Sacks FM, 2017, CIRCULATION, V136, pE1, DOI 10.1161/CIR.0000000000000510
   Shirwany NA, 2010, ACTA PHARMACOL SIN, V31, P1075, DOI 10.1038/aps.2010.139
   Tak H, 2007, CELL SIGNAL, V19, P2379, DOI 10.1016/j.cellsig.2007.07.016
   Tan JJ, 2017, SCI REP-UK, V7, DOI 10.1038/srep46602
   Tanaki K, 2001, J AM COLL CARDIOL, V37, P676, DOI 10.1016/S0735-1097(00)01123-2
   Thin KZ, 2019, CLIN CHIM ACTA, V494, P38, DOI 10.1016/j.cca.2019.03.002
   Tousoulis D, 2016, EUR HEART J, V37, P1723, DOI 10.1093/eurheartj/ehv759
   Wang JD, 2018, INT J ONCOL, V52, P77, DOI 10.3892/ijo.2017.4187
   Yang H, 2018, ONCOL REP, V40, P261, DOI 10.3892/or.2018.6412
   Yang K, 2019, J CELL BIOCHEM, V120, P17811, DOI 10.1002/jcb.29047
   Zhang SX, 2019, DNA CELL BIOL, V38, P41, DOI 10.1089/dna.2018.4387
   Zhang ZY, 2018, J AM COLL CARDIOL, V72, P2380, DOI 10.1016/j.jacc.2018.08.2161
   Zhao Y, 2018, EUR REV MED PHARMACO, V22, P976, DOI 10.26355/eurrev_201802_14379
   Zhong XM, 2018, BIOMED PHARMACOTHER, V97, P1078, DOI 10.1016/j.biopha.2017.11.052
   Zhou SS, 2018, ACTA PHARMACOL SIN, V39, P1073, DOI 10.1038/aps.2018.30
NR 34
TC 5
Z9 5
U1 1
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567-2379
EI 1567-2387
J9 J MOL HISTOL
JI J. Mol. Histol.
PD APR
PY 2020
VL 51
IS 2
BP 117
EP 124
DI 10.1007/s10735-020-09862-z
EA APR 2020
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA LE2JF
UT WOS:000526249700001
PM 32297149
DA 2022-04-25
ER

PT J
AU Maiese, K
AF Maiese, Kenneth
TI FoxO Proteins in the Nervous System
SO ANALYTICAL CELLULAR PATHOLOGY
LA English
DT Review
ID FORKHEAD TRANSCRIPTION FACTORS; COLORECTAL-CANCER CELLS;
   OXIDATIVE-STRESS; BETA-CATENIN; SIGNALING PATHWAY; STEM-CELLS;
   ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; CEREBRAL-ISCHEMIA; AMYLOID
   TOXICITY
AB Acute as well as chronic disorders of the nervous system lead to significant morbidity and mortality for millions of individuals globally. Given the ability to govern stem cell proliferation and differentiated cell survival, mammalian forkhead transcription factors of the forkhead box class O (FoxO) are increasingly being identified as potential targets for disorders of the nervous system, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and auditory neuronal disease. FoxO proteins are present throughout the body, but they are selectively expressed in the nervous system and have diverse biological functions. The forkhead O class transcription factors interface with an array of signal transduction pathways that include protein kinase B (Akt), serum-and glucocorticoid-inducible protein kinase (SgK), I kappa B kinase (IKK), silentmating type information regulation 2 homolog 1 (S. cerevisiae) (SIRT1), growth factors, and Wnt signaling that can determine the activity and integrity of FoxO proteins. Ultimately, there exists a complex interplay between FoxO proteins and their signal transduction pathways that can significantly impact programmed cell death pathways of apoptosis and autophagy as well as the development of clinical strategies for the treatment of neurodegenerative disorders.
C1 Cellular & Mol Signaling, Newark, NJ 07101 USA.
RP Maiese, K (corresponding author), Cellular & Mol Signaling, Newark, NJ 07101 USA.
EM wntin75@yahoo.com
FU American Diabetes AssociationAmerican Diabetes Association; American
   Heart AssociationAmerican Heart Association; NIH NIEHSUnited States
   Department of Health & Human ServicesNational Institutes of Health (NIH)
   - USANIH National Institute of Environmental Health Sciences (NIEHS);
   NIH NIAUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute on Aging (NIA);
   NIH NINDSUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Institute of Neurological
   Disorders & Stroke (NINDS); NIH ARRAUnited States Department of Health &
   Human ServicesNational Institutes of Health (NIH) - USA
FX This research was supported by the following grants to Kenneth Maiese:
   American Diabetes Association, American Heart Association, NIH NIEHS,
   NIH NIA, NIH NINDS, and NIH ARRA.
CR Akasaki Y, 2014, ARTHRITIS RHEUMATOL, V66, P3349, DOI 10.1002/art.38868
   Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Anitha M, 2006, J CLIN INVEST, V116, P344, DOI 10.1172/JCI26295
   Arimoto-Ishida E, 2004, ENDOCRINOLOGY, V145, P2014, DOI 10.1210/en.2003-1199
   Arunachalam G, 2014, BRIT J PHARMACOL, V171, P523, DOI 10.1111/bph.12496
   Bahia PK, 2012, J NEUROCHEM, V123, P182, DOI 10.1111/j.1471-4159.2012.07877.x
   Bakker WJ, 2007, MOL CELL BIOL, V27, P3839, DOI 10.1128/MCB.01662-06
   Balduini W, 2012, J MATERN-FETAL NEO M, V25, P119, DOI 10.3109/14767058.2012.663232
   Bayod S, 2014, BRAIN RES, V1543, P38, DOI 10.1016/j.brainres.2013.10.048
   Berwick DC, 2014, J MOL CELL BIOL, V6, P3, DOI 10.1093/jmcb/mjt037
   Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002
   Bing LL, 2015, NEUROCHEM RES, V40, P41, DOI 10.1007/s11064-014-1463-3
   Busch S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102013
   Cai Zhiyou, 2013, J Biochem Pharmacol Res, V1, P84
   Carbajo-Pescador S, 2014, CURR MED CHEM, V21, P1231, DOI 10.2174/0929867321666131228205703
   Case N, 2010, J ORTHOP RES, V28, P1531, DOI 10.1002/jor.21156
   Castaneda-Arellano R, 2014, FRONT BIOSCI-LANDMRK, V19, P1445, DOI 10.2741/4295
   Castrillon DH, 2003, SCIENCE, V301, P215, DOI 10.1126/science.1086336
   Chae HD, 2011, STEM CELLS DEV, V20, P1277, DOI 10.1089/scd.2010.0465
   Chang ZY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055291
   Charvet C, 2003, ONCOGENE, V22, P4557, DOI 10.1038/sj.onc.1206778
   Chen CJ, 2014, MOL CELL BIOCHEM, V386, P167, DOI 10.1007/s11010-013-1855-8
   Chen WQ, 2014, NEURAL REGEN RES, V9, P1210, DOI 10.4103/1673-5374.135329
   Chen Y, 2014, CELL PROLIFERAT, V47, P105, DOI 10.1111/cpr.12095
   Cheng ZY, 2011, ANTIOXID REDOX SIGN, V14, P649, DOI 10.1089/ars.2010.3370
   Chong ZZ, 2007, BRIT J PHARMACOL, V150, P839, DOI 10.1038/sj.bjp.0707161
   Chong ZZ, 2007, CELL SIGNAL, V19, P1150, DOI 10.1016/j.cellsig.2006.12.009
   Chong ZZ, 2006, CURR NEUROVASC RES, V3, P107, DOI 10.2174/156720206776875830
   Chong ZZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045456
   Chong ZZ, 2012, EXPERT OPIN THER TAR, V16, P167, DOI 10.1517/14728222.2012.648926
   Chong ZZ, 2012, FUTUR CARDIOL, V8, P89, DOI [10.2217/fca.11.76, 10.2217/FCA.11.76]
   Chong ZZ, 2011, CURR NEUROVASC RES, V8, P103
   Chong ZZ, 2010, OXID MED CELL LONGEV, V3, P153, DOI 10.4161/oxim.3.2.11758
   Chong ZZ, 2005, BRAIN RES REV, V49, P1, DOI 10.1016/j.brainresrev.2004.11.005
   Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004
   Chong ZZ, 2005, HISTOL HISTOPATHOL, V20, P299, DOI 10.14670/HH-20.299
   Chong ZZ, 2004, J CEREBR BLOOD F MET, V24, P728, DOI 10.1097/01.WCB.0000122746.72175.0E
   Chong ZZ, 2003, BRIT J PHARMACOL, V138, P1107, DOI 10.1038/sj.bjp.0705161
   Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528
   Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F
   Chonga ZZ, 2004, EXP CELL RES, V296, P196, DOI 10.1016/j.yexcr.2004.01.021
   CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0
   Dentice M, 2010, J CLIN INVEST, V120, P4021, DOI 10.1172/JCI43670
   Domanskyi A, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00275
   Dong LQ, 2013, J MOL NEUROSCI, V50, P469, DOI 10.1007/s12031-013-9964-0
   Eddy SF, 2007, CANCER RES, V67, P9018, DOI 10.1158/0008-5472.CAN-07-1691
   Estevez AO, 2014, NEUROTOXICOLOGY, V41, P28, DOI 10.1016/j.neuro.2013.12.012
   Chamorro ME, 2013, BBA-MOL CELL RES, V1833, P1960, DOI 10.1016/j.bbamcr.2013.04.006
   Exil V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094753
   Favaloro B, 2012, AGING-US, V4, P330, DOI 10.18632/aging.100459
   Ferrara N, 2008, REJUV RES, V11, P139, DOI 10.1089/rej.2007.0576
   Filley CM, 2007, COGN BEHAV NEUROL, V20, P149, DOI 10.1097/WNN.0b013e318145a8c8
   Folch J, 2012, NEUROTOX RES, V22, P195, DOI 10.1007/s12640-011-9277-4
   Fong Y, 2014, SCI WORLD J, DOI 10.1155/2014/937051
   Fox JH, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-26
   Gao F, 2015, MOL MED REP, V11, P1200, DOI 10.3892/mmr.2014.2854
   Genin EC, 2014, STEM CELLS, V32, P1398, DOI 10.1002/stem.1673
   Gezginci-Oktayoglu S, 2014, ACTA HISTOCHEM, V116, P32, DOI 10.1016/j.acthis.2013.04.016
   Gilels F, 2013, J NEUROSCI, V33, P18409, DOI 10.1523/JNEUROSCI.2529-13.2013
   Gonzalez-Fernandez C, 2014, J NEUROTRAUM, V31, P565, DOI 10.1089/neu.2013.3067
   Gubern C, 2014, NEUROSCIENCE, V268, P48, DOI 10.1016/j.neuroscience.2014.02.051
   Guo XJ, 2013, J MOL NEUROSCI, V50, P453, DOI 10.1007/s12031-013-9955-1
   Hariharan N, 2010, CIRC RES, V107, P1470, DOI 10.1161/CIRCRESAHA.110.227371
   Harish G., 2015, J NEUROCHEMISTRY
   He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511
   He CY, 2013, DIABETES, V62, P1270, DOI 10.2337/db12-0533
   Heo J, 2013, BIOCHEM BIOPH RES CO, V434, P235, DOI 10.1016/j.bbrc.2013.02.109
   Hoekman MFM, 2006, GENE EXPR PATTERNS, V6, P134, DOI 10.1016/j.modgep.2005.07.003
   Hong YK, 2012, BIOCHEM BIOPH RES CO, V419, P49, DOI 10.1016/j.bbrc.2012.01.122
   Hong Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096212
   Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200
   Hosaka T, 2004, P NATL ACAD SCI USA, V101, P2975, DOI 10.1073/pnas.0400093101
   Hou JL, 2011, CURR NEUROVASC RES, V8, P220, DOI 10.2174/156720211796558069
   Hou JL, 2010, MOL CELL ENDOCRINOL, V321, P194, DOI 10.1016/j.mce.2010.02.037
   Hou JL, 2010, CURR NEUROVASC RES, V7, P95, DOI 10.2174/156720210791184899
   Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2
   Huang CY, 2013, J NUTR BIOCHEM, V24, P1596, DOI 10.1016/j.jnutbio.2013.01.010
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Iyer S, 2014, J BIOL CHEM, V289, P24069, DOI 10.1074/jbc.M114.561803
   Jagani Z, 2008, BBA-REV CANCER, V1785, P63, DOI 10.1016/j.bbcan.2007.10.003
   Jalsrai A, 2014, AM J CHINESE MED, V42, P119, DOI 10.1142/S0192415X14500086
   Jenwitheesuk A, 2014, INT J MOL SCI, V15, P16848, DOI 10.3390/ijms150916848
   Jiang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102342
   Jin CW, 1998, BIOCHEMISTRY-US, V37, P6179, DOI 10.1021/bi980031v
   Jung DW, 2014, ACS CHEM BIOL, V9, P80, DOI 10.1021/cb400754f
   Kaestner KH, 2000, GENE DEV, V14, P142
   Kafka A, 2014, CROAT MED J, V55, P459, DOI 10.3325/cmj.2014.55.459
   Kajihara T, 2006, MOL ENDOCRINOL, V20, P2444, DOI 10.1210/me.2006-0118
   Kamarudin MNA, 2014, DRUG DES DEV THER, V8, P1765, DOI 10.2147/DDDT.S67980
   Kamei Y, 2004, J BIOL CHEM, V279, P41114, DOI 10.1074/jbc.M400674200
   Kaushal N, 2011, ANTIOXID REDOX SIGN, V14, P1403, DOI 10.1089/ars.2010.3323
   Kelly KR, 2012, INT J CANCER, V131, P2693, DOI 10.1002/ijc.27579
   Kibbe C, 2013, J BIOL CHEM, V288, P23194, DOI 10.1074/jbc.M113.473082
   Kim KA, 2014, BIOL PHARM BULL, V37, P1248, DOI 10.1248/bpb.b14-00172
   Kim S, 2014, DIABETES, V63, pA32
   Kimura R, 2013, NEUROENDOCRINOLOGY, V97, P300, DOI 10.1159/000345529
   Klinke DJ, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003409
   Knoblich K, 2014, CELL MOL LIFE SCI, V71, P1305, DOI 10.1007/s00018-013-1444-8
   Kobayashi Y, 2005, INT J MOL MED, V16, P237
   Kwon MS, 2014, NEUROL RES, V36, P215, DOI 10.1179/1743132813Y.0000000284
   Kwon SH, 2015, FOOD CHEM TOXICOL, V80, P41, DOI 10.1016/j.fct.2015.02.014
   L'Episcopo F, 2011, NEUROBIOL DIS, V41, P508, DOI 10.1016/j.nbd.2010.10.023
   L'Episcopo F, 2012, J NEUROSCI, V32, P2062, DOI 10.1523/JNEUROSCI.5259-11.2012
   L'Episcopo F, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-49
   Larson ET, 2007, VIROLOGY, V368, P249, DOI 10.1016/j.virol.2007.06.040
   Lee SJ, 2014, GLIA, V62, P639, DOI 10.1002/glia.22631
   Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046
   Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200
   Li F, 2006, HISTOL HISTOPATHOL, V21, P103, DOI 10.14670/HH-21.103
   Li MY, 2006, J BIOL CHEM, V281, P40429, DOI 10.1074/jbc.M606596200
   Li RP, 2012, PHYTOMEDICINE, V19, P677, DOI 10.1016/j.phymed.2012.03.002
   Li YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093639
   Lim YM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5934
   Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319
   Liu H, 2015, CELL SIGNAL, V27, P510, DOI 10.1016/j.cellsig.2015.01.001
   Liu L, 2007, DEVELOPMENT, V134, P199, DOI 10.1242/dev.02667
   Liu Y, 2013, AGE, V35, P1531, DOI 10.1007/s11357-012-9456-0
   Lough D, 2013, PLAST RECONSTR SURG, V132, P1159, DOI 10.1097/PRS.0b013e3182a48af6
   Maeda A, 2015, J BIOL CHEM, V290, P14004, DOI 10.1074/jbc.M114.628818
   Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006
   Maiese K, 2011, ROM J MORPHOL EMBRYO, V52, P1173
   Maiese K, 2005, JAMA-J AM MED ASSOC, V293, P90, DOI 10.1001/jama.293.1.90
   Maiese K, 2008, EXPERT OPIN THER TAR, V12, P905, DOI 10.1517/14728222.12.7.905 
   Maiese K, 2008, TRENDS MOL MED, V14, P219, DOI 10.1016/j.molmed.2008.03.002
   Maiese K, 2008, PHARMACOL THERAPEUT, V118, P58, DOI 10.1016/j.pharmthera.2008.01.004
   Maiese K, 2007, CURR NEUROVASC RES, V4, P295, DOI 10.2174/156720207782446306
   Maiese K, 2008, CYTOKINE GROWTH F R, V19, P145, DOI 10.1016/j.cytogfr.2008.01.004
   Maiese K, 2007, CURR MED CHEM, V14, P1729
   Maiese K, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/875961
   Maiese K, 2015, NEURAL REGEN RES, V10, P518, DOI 10.4103/1673-5374.155427
   Maiese K, 2015, CURR NEUROVASC RES, V12, P173, DOI 10.2174/1567202612666150305110929
   Maiese K, 2015, WORLD J STEM CELLS, V7, P235, DOI 10.4252/wjsc.v7.i2.235
   Maiese K, 2015, WORLD J DIABETES, V6, P217, DOI 10.4239/wjd.v6.i2.217
   Maiese K, 2014, ANN MED, V46, P587, DOI 10.3109/07853890.2014.941921
   Maiese K, 2014, CURR NEUROVASC RES, V11, P378, DOI 10.2174/1567202611666140912115107
   Maiese K, 2014, NEURAL REGEN RES, V9, P1413, DOI 10.4103/1673-5374.139453
   Maiese K, 2014, CURR NEUROVASC RES, V11, P177, DOI 10.2174/1567202611666140408104831
   Maiese K, 2013, EXPERT OPIN DRUG DIS, V8, P35, DOI 10.1517/17460441.2013.736485
   Maiese K, 2012, INT J MOL SCI, V13, P13830, DOI 10.3390/ijms131113830
   Maiese K, 2012, EXPERT OPIN THER TAR, V16, P1203, DOI 10.1517/14728222.2012.719499
   Maiese K, 2012, INT J MOL SCI, V13, P11102, DOI 10.3390/ijms130911102
   Maiese K, 2011, J CLIN PHARMACOL, V51, P128, DOI 10.1177/0091270010362904
   Maiese K, 2010, EXP GERONTOL, V45, P217, DOI 10.1016/j.exger.2010.01.004
   Maiese K, 2009, THESCIENTIFICWORLDJO, V9, P1072, DOI 10.1100/tsw.2009.121
   Maiese K, 2009, ADV EXP MED BIOL, V665, P242
   Maiese K, 2009, OXID MED CELL LONGEV, V2, P119, DOI 10.4161/oxim.2.3.8916
   Maiese K, 2009, MOLECULES, V14, P3446, DOI 10.3390/molecules14093446
   Maiese K, 2009, CLIN SCI, V116, P191, DOI 10.1042/CS20080113
   Maiese K, 2008, CELL CYCLE, V7, P3829, DOI 10.4161/cc.7.24.7231
   Mao XY, 2014, INT J MOL SCI, V15, P7667, DOI 10.3390/ijms15057667
   Marchetti B, 2013, EUR J NEUROSCI, V37, P1550, DOI 10.1111/ejn.12166
   Marchetti B, 2013, TRENDS MOL MED, V19, P144, DOI 10.1016/j.molmed.2012.12.001
   Uranga RM, 2013, J BIOL CHEM, V288, P19773, DOI 10.1074/jbc.M113.457622
   Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100
   Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102
   Maurice T, 2013, J PSYCHOPHARMACOL, V27, P1044, DOI 10.1177/0269881113494939
   Merkely B, 2015, STEM CELLS DEV, V24, P869, DOI 10.1089/scd.2014.0247
   Messier AM, 2014, CURR OPIN PEDIATR, V26, P139, DOI 10.1097/MOP.0000000000000077
   Mhillaj E, 2015, CURR PHARM DESIGN, V21, P1396, DOI 10.2174/1381612821666150105122422
   Miret JA, 2014, AMINO ACIDS, V46, P809, DOI 10.1007/s00726-013-1653-3
   Miyamoto K, 2007, CELL STEM CELL, V1, P101, DOI 10.1016/j.stem.2007.02.001
   Miyauchi H, 2004, EMBO J, V23, P212, DOI 10.1038/sj.emboj.7600045
   Moghaddasi M, 2014, J PHYSIOL SCI, V64, P325, DOI 10.1007/s12576-014-0322-y
   Muley MM, 2012, PHARMACOL BIOCHEM BE, V102, P286, DOI 10.1016/j.pbb.2012.05.004
   Murahovschi V, 2015, DIABETES, V64, P856, DOI 10.2337/db14-0444
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Nakamura T, 2008, MOL CELL ENDOCRINOL, V281, P47, DOI 10.1016/j.mce.2007.10.007
   Nakazawa Y, 2013, J NEPHROL, V26, P527, DOI 10.5301/jn.5000178
   Nakka V. P., 2014, MOL NEUROBIOLOGY
   Nguyen AQ, 2014, EXP BIOL MED, V239, P1461, DOI 10.1177/1535370214523703
   Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017
   Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194
   Palazuelos J, 2014, J NEUROSCI, V34, P7917, DOI 10.1523/JNEUROSCI.0363-14.2014
   Palazzuoli A, 2014, THER CLIN RISK MANAG, V10, P641, DOI 10.2147/TCRM.S61551
   Palma HE, 2014, MOL CELL BIOCHEM, V386, P199, DOI 10.1007/s11010-013-1858-5
   Pan LL, 2013, BBA-GEN SUBJECTS, V1830, P2861, DOI 10.1016/j.bbagen.2013.01.008
   Pandey S, 2013, MOL BIOL REP, V40, P6011, DOI 10.1007/s11033-013-2710-4
   Paraiso A, 2013, MOL NEUROBIOL, V48, P681, DOI 10.1007/s12035-013-8459-x
   Park HY, 2014, CHEMBIOCHEM, V15, P872, DOI 10.1002/cbic.201300786
   Park J, 2014, GASTRIC CANCER, V17, P423, DOI 10.1007/s10120-013-0314-2
   Peng SY, 2015, J NEUROSCI, V35, P1250, DOI 10.1523/JNEUROSCI.2444-14.2015
   Pergola PE, 2014, AM J HYPERTENS, V27, P1052, DOI 10.1093/ajh/hpu027
   Pineda D, 2012, GLIA, V60, P526, DOI 10.1002/glia.22284
   Pino E, 2014, HUM MOL GENET, V23, P1435, DOI 10.1093/hmg/ddt530
   Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200
   Puthanveetil P, 2013, CARDIOVASC RES, V97, P393, DOI 10.1093/cvr/cvs426
   Qi XF, 2013, EXP MOL PATHOL, V95, P242, DOI 10.1016/j.yexmp.2013.08.003
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rjiba-Touati K., 2015, HUMAN EXPT TOXICOLOG
   Rong Z, 2013, NEUROSCIENCE, V255, P292, DOI 10.1016/j.neuroscience.2013.09.030
   Russo E, 2014, BRAIN BEHAV IMMUN, V42, P157, DOI 10.1016/j.bbi.2014.06.016
   Salih DAM, 2012, GENE DEV, V26, P2780, DOI 10.1101/gad.208926.112
   Schips TG, 2011, CARDIOVASC RES, V91, P587, DOI 10.1093/cvr/cvr144
   Schutters K, 2010, APOPTOSIS, V15, P1072, DOI 10.1007/s10495-010-0503-y
   Bilbao PS, 2013, BBA-GEN SUBJECTS, V1830, P4456, DOI 10.1016/j.bbagen.2013.05.034
   Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565
   Shang YC, 2013, CURR NEUROVASC RES, V10, P29
   Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440
   Shang YC, 2010, CELL SIGNAL, V22, P1317, DOI 10.1016/j.cellsig.2010.04.009
   Shang YC, 2009, CURR NEUROVASC RES, V6, P223, DOI 10.2174/156720209789630302
   Shang YC, 2009, CURR NEUROVASC RES, V6, P20, DOI 10.2174/156720209787466064
   Shao SY, 2013, DNA CELL BIOL, V32, P41, DOI 10.1089/dna.2012.1874
   Shi J, 2012, ACTA PHARMACOL SIN, V33, P888, DOI 10.1038/aps.2012.73
   Song JJ, 2008, CELL SIGNAL, V20, P892, DOI 10.1016/j.cellsig.2008.01.001
   Sowers LP, 2013, MOL PSYCHIATR, V18, P1077, DOI 10.1038/mp.2013.71
   Srinivasan S, 2005, MOL CELL NEUROSCI, V29, P107, DOI 10.1016/j.mcn.2005.02.005
   Srivastava A, 2014, NUTR NEUROSCI, V17, P164, DOI 10.1179/1476830513Y.0000000075
   Sun TJ, 2014, EUR REV MED PHARMACO, V18, P2460
   Sunayama J, 2005, J CELL BIOL, V170, P295, DOI 10.1083/jcb.200409117
   Tan C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119210
   Tanaka T, 2014, FEBS J, V281, P1068, DOI 10.1111/febs.12669
   Tang Z, 2014, J PROTEOME RES, V13, P2433, DOI 10.1021/pr500192g
   Tang Z, 2013, J BIOL CHEM, V288, P15556, DOI 10.1074/jbc.M112.435123
   Tao GZ, 2013, J BIOL CHEM, V288, P17214, DOI 10.1074/jbc.M112.445965
   Tazangi PE, 2015, PHARMACOL BIOCHEM BE, V130, P15, DOI 10.1016/j.pbb.2014.12.011
   Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003
   Tsai KL, 2007, NUCLEIC ACIDS RES, V35, P6984, DOI 10.1093/nar/gkm703
   Turkcu UO, 2014, GENE, V536, P129, DOI 10.1016/j.gene.2013.11.055
   Uhlenhaut NH, 2011, REPRODUCTION, V142, P489, DOI 10.1530/REP-11-0092
   Valcifahmetoglu-Norberg H, 2015, J CLIN INVEST, V125, P5, DOI 10.1172/JCI73937
   Van der Heide LP, 2005, BIOCHEM J, V391, P623, DOI 10.1042/BJ20050525
   van der Heide LP, 2004, BIOCHEM J, V380, P297, DOI 10.1042/BJ20040167
   van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190
   Vidal RL, 2012, HUM MOL GENET, V21, P2245, DOI 10.1093/hmg/dds040
   Vishwas DK, 2013, EXP GERONTOL, V48, P168, DOI 10.1016/j.exger.2012.11.012
   Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347
   Wang GB, 2014, MOL CELL BIOCHEM, V385, P125, DOI 10.1007/s11010-013-1821-5
   Wang JG, 2014, INT J MOL MED, V33, P441, DOI 10.3892/ijmm.2013.1587
   Wang L, 2014, INT J BIOL SCI, V10, P921, DOI 10.7150/ijbs.9518
   Wang SH, 2013, CURR NEUROVASC RES, V10, P54, DOI 10.2174/156720213804805945
   Wang T, 2013, ONCOL LETT, V6, P600, DOI 10.3892/ol.2013.1400
   Wang WR, 2013, APOPTOSIS, V18, P689, DOI 10.1007/s10495-013-0833-7
   Watkins WJ, 2006, FERTIL STERIL, V86, P1518, DOI 10.1016/j.fertnstert.2006.03.054
   Wei L, 2013, J MOL NEUROSCI, V49, P105, DOI 10.1007/s12031-012-9900-8
   WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5
   WHO, 2006, NEUR DIS PUBL HLTH C
   Wilk A, 2011, J NEUROSCI RES, V89, P183, DOI 10.1002/jnr.22542
   Won CK, 2006, NEUROSCI LETT, V398, P39, DOI 10.1016/j.neulet.2005.12.060
   Wong CP, 2014, J NAT MED-TOKYO, V68, P22, DOI 10.1007/s11418-013-0755-2
   Xing YX, 2012, BRAIN RES, V1482, P71, DOI 10.1016/j.brainres.2012.08.057
   Xiong SQ, 2011, J BIOL CHEM, V286, P5289, DOI 10.1074/jbc.M110.163667
   Xiong XX, 2014, NEUROBIOL DIS, V66, P43, DOI 10.1016/j.nbd.2014.02.006
   Xu DW, 2014, J MOL NEUROSCI, V52, P410, DOI 10.1007/s12031-013-0191-5
   Xu GF, 2014, TOXICOL LETT, V226, P294, DOI 10.1016/j.toxlet.2014.02.019
   Xu YJ, 2014, HEART FAIL REV, V19, P113, DOI 10.1007/s10741-013-9379-6
   Yang CS, 2011, STEM CELLS, V29, P1528, DOI 10.1002/stem.717
   Yang YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/351895
   Yang YL, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0054736, 10.1371/journal.pone.0067755, 10.1371/journal.pone.0055384]
   Yang ZH, 2014, CANCER GENE THER, V21, P74, DOI 10.1038/cgt.2013.86
   Yoo KY, 2012, NEUROCHEM RES, V37, P588, DOI 10.1007/s11064-011-0648-2
   Yousef JM, 2015, PAK J PHARM SCI, V28, P175
   Yu T, 2015, NEUROCHEM RES, V40, P698, DOI 10.1007/s11064-015-1516-2
   Zara S, 2013, GERONTOLOGY, V59, P250, DOI 10.1159/000346445
   Zeldich E, 2014, J BIOL CHEM, V289, P24700, DOI 10.1074/jbc.M114.567321
   Zhang H, 2015, MOL NEUROBIOL, V51, P89, DOI 10.1007/s12035-014-8787-5
   Zhao Y., 2014, PLOS ONE, V9
   Zheng WH, 2002, J NEUROCHEM, V80, P1049, DOI 10.1046/j.0022-3042.2002.00783.x
   Zhou Q, 2015, TOXICOL SCI, V143, P81, DOI 10.1093/toxsci/kfu211
   Zhu WW, 2004, MOL BRAIN RES, V126, P45, DOI 10.1016/j.molbrainres.2004.03.019
   Zhu Y, 2014, INT J CLIN EXP MED, V7, P2585
   Zhu ZY, 2013, J NEUROSCI, V33, P13138, DOI 10.1523/JNEUROSCI.4790-12.2013
   Zolotukhin P, 2013, MOL BIOSYST, V9, P2085, DOI 10.1039/c3mb70096h
NR 263
TC 58
Z9 60
U1 0
U2 17
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2210-7177
EI 2210-7185
J9 ANAL CELL PATHOL
JI Anal. Cell. Pathol.
PY 2015
VL 2015
AR 569392
DI 10.1155/2015/569392
PG 15
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA CL2MQ
UT WOS:000356778700001
PM 26171319
OA gold, Green Submitted, Green Published
DA 2022-04-25
ER

PT J
AU Velloso, FJ
   Trombetta-Lima, M
   Anschau, V
   Sogayar, MC
   Correa, RG
AF Velloso, Fernando J.
   Trombetta-Lima, Marina
   Anschau, Valesca
   Sogayar, Mari C.
   Correa, Ricardo G.
TI NOD-like receptors: major players (and targets) in the interface between
   innate immunity and cancer
SO BIOSCIENCE REPORTS
LA English
DT Review
ID NF-KAPPA-B; APOPTOSIS INHIBITORY PROTEIN; CENTRAL-NERVOUS-SYSTEM; NLRP3
   INFLAMMASOME; PROSTATE-CANCER; COLORECTAL-CANCER; NUCLEOTIDE-BINDING;
   HOST-DEFENSE; BACTERIAL PEPTIDOGLYCAN; PATHOGEN-RECOGNITION
AB Innate immunity comprises several inflammation-related modulatory pathways which receive signals from an array of membrane-bound and cytoplasmic pattern recognition receptors (PRRs). The NLRs (NACHT (NAIP (neuronal apoptosis inhibitor protein), C2TA (MHC class 2 transcription activator), HET-E (incompatibility locus protein from Podospora anserina) and TP1 (telomerase-associated protein) and Leucine-Rich Repeat (LRR) domain containing proteins) relate to a large family of cytosolic innate receptors, involved in detection of intracellular pathogens and endogenous byproducts of tissue injury. These receptors may recognize pathogen-associated molecular patterns (PAMPs) and/or danger-associated molecular patterns (DAMPs), activating host responses against pathogen infection and cellular stress. NLR-driven downstream signals trigger a number of signaling circuitries, which may either initiate the formation of inflammasomes and/or activate nuclear factor kappa B (NF-kappa B), stress kinases, interferon response factors (IRFs), inflammatory caspases and autophagy. Disruption of those signals may lead to a number of pro-inflammatory conditions, eventually promoting the onset of human malignancies. In this review, we describe the structures and functions of the most well-defined NLR proteins and highlight their association and biological impact on a diverse number of cancers.
C1 [Velloso, Fernando J.] Rutgers New Jersey Med Sch Newark, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA.
   [Velloso, Fernando J.; Trombetta-Lima, Marina; Sogayar, Mari C.] Univ Sao Paulo, Cell & Mol Therapy Ctr NUCEL, Sch Med, Internal Med Dept, Sao Paulo, SP, Brazil.
   [Anschau, Valesca] Univ Valencia, Inst Integrat Syst Biol I2SysBio, CSIC, Valencia 46980, Spain.
   [Sogayar, Mari C.] Univ Sao Paulo, Chem Inst, Biochem Dept, Sao Paulo, Brazil.
   [Correa, Ricardo G.] Sanford Burnham Prebys Med Discovery Inst, NCI Designated Canc Ctr, La Jolla, CA 92037 USA.
RP Velloso, FJ (corresponding author), Rutgers New Jersey Med Sch Newark, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA.; Velloso, FJ (corresponding author), Univ Sao Paulo, Cell & Mol Therapy Ctr NUCEL, Sch Med, Internal Med Dept, Sao Paulo, SP, Brazil.; Correa, RG (corresponding author), Sanford Burnham Prebys Med Discovery Inst, NCI Designated Canc Ctr, La Jolla, CA 92037 USA.
EM fernando.velloso@rutgers.edu; rcorrea@sbpdiscovery.org
RI Correa, Ricardo G/G-7613-2012; Anschau, Valesca/Z-6231-2019; Velloso,
   Fernando/AAA-5262-2020; Anschau, Ph. D, Valesca/ABH-3426-2021; Lima,
   Marina Trombetta/P-1757-2015
OI Correa, Ricardo G/0000-0001-6940-7034; Anschau,
   Valesca/0000-0002-9681-7204; Velloso, Fernando/0000-0002-5582-2912;
   Lima, Marina Trombetta/0000-0002-3687-6210
FU CAPES (Federal Agency for Superior Education and Training) research
   funding agency [88887.091759/2015-00]; FAPESP (Sao Paulo State
   Foundation for Research)Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo (FAPESP) [2016/05311-2]; CNPq (National Research Council)Conselho
   Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)
   [148684/2013-0, 457201/2013-2]; BNDES (Brazilian National Bank for
   Economic and Social Development) [09.2.1066.1]; FINEP (Project Financing
   Agency) [01.06.0664.00, 01.08.0622.00]; MCTI (Science, Technology and
   Innovation Ministry); MS-DECIT (Science and Technology Department of the
   Health Ministry); 'Science without Borders' Program (CAPES, Brazil)
   [88887.091759/2015-00]
FX This work was supported by CAPES (Federal Agency for Superior Education
   and Training) research funding agency [grant number 88887.091759/2015-00
   (to F.J.V.)]; FAPESP (Sao Paulo State Foundation for Research) [grant
   number 2016/05311-2 (to M.C.S.)]; CNPq (National Research Council)
   [grant number 148684/2013-0; 457201/2013-2 (to M.C.S.)]; BNDES
   (Brazilian National Bank for Economic and Social Development) [grant
   number 09.2.1066.1 (to M.C.S.)]; FINEP (Project Financing Agency) [grant
   number 01.06.0664.00; 01.08.0622.00 (to M.C.S.)]; MCTI (Science,
   Technology and Innovation Ministry) (to M.C.S.); MS-DECIT (Science and
   Technology Department of the Health Ministry) (to M.C.S.); and a Special
   Visiting Researcher (PVE) grant from the 'Science without Borders'
   Program (CAPES, Brazil) [grant number 88887.091759/2015-00 (to R.G.C.)].
CR Abadia-Molina F, 2017, SCI REP-UK, V7, DOI 10.1038/srep39981
   Afonina IS, 2017, NAT IMMUNOL, V18, P861, DOI 10.1038/ni.3772
   Ahmad I, 2013, TOXICOL APPL PHARM, V270, P70, DOI 10.1016/j.taap.2013.03.027
   Akincilar SC, 2016, CANCER DISCOV, V6, P1276, DOI 10.1158/2159-8290.CD-16-0177
   Akincilar SC, 2015, FEBS LETT, V589, P974, DOI 10.1016/j.febslet.2015.02.035
   Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015
   Allam R, 2015, J EXP MED, V212, P369, DOI 10.1084/jem.20140474
   Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012
   Amarante-Mendes GP, 2015, PHARMACOL THERAPEUT, V155, P117, DOI 10.1016/j.pharmthera.2015.09.001
   Ansa BE, 2018, J CLIN MED, V7, DOI 10.3390/jcm7020022
   Apps JR, 2018, ACTA NEUROPATHOL, V135, P757, DOI 10.1007/s00401-018-1830-2
   Asano N, 2016, CANCER RES, V76, P1135, DOI 10.1158/0008-5472.CAN-15-2272
   Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008
   Bauernfeind F, 2013, EMBO MOL MED, V5, P814, DOI 10.1002/emmm.201201771
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070
   Bernales S, 2006, PLOS BIOL, V4, P2311, DOI 10.1371/journal.pbio.0040423
   Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724
   Bushdid PB, 1998, NATURE, V392, P615, DOI 10.1038/33435
   Carneiro LAM, 2008, J PATHOL, V214, P136, DOI 10.1002/path.2271
   Caruso R, 2014, IMMUNITY, V41, P898, DOI 10.1016/j.immuni.2014.12.010
   Castano-Rodriguez N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098899
   Catalano C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192385
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
   Chereau D, 2005, BIOCHEMISTRY-US, V44, P4971, DOI 10.1021/bi047360+
   Chiu HHL, 2010, CANCER LETT, V292, P176, DOI 10.1016/j.canlet.2009.11.023
   Choi J, 2007, J KOREAN MED SCI, V22, pS17, DOI 10.3346/jkms.2007.22.S.S17
   Cinar B, 2004, BIOCHEM J, V379, P421, DOI 10.1042/BJ20031661
   Cookson BT, 2001, TRENDS MICROBIOL, V9, P113, DOI 10.1016/S0966-842X(00)01936-3
   Cooney R, 2010, NAT MED, V16, P90, DOI 10.1038/nm.2069
   Correa RG, 2005, CURR BIOL, V15, P1291, DOI 10.1016/j.cub.2005.06.023
   Correa RG, 2004, MOL CELL BIOL, V24, P5257, DOI 10.1128/MCB.24.12.5257-5268.2004
   Correa RG, 2014, ONCOTARGET, V5, P1666, DOI 10.18632/oncotarget.1850
   Correa RG, 2012, BIOSCIENCE REP, V32, P597, DOI 10.1042/BSR20120055
   Correia JD, 2007, CELL DEATH DIFFER, V14, P830, DOI 10.1038/sj.cdd.4402070
   Correia JD, 2006, P NATL ACAD SCI USA, V103, P1840, DOI 10.1073/pnas.0509228103
   Couturier-Maillard A, 2013, J CLIN INVEST, V123, P700, DOI 10.1172/JCI62236
   Craven RR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007446
   Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003
   da Silva HB, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/920612
   Dantonio PM, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180511
   Davis BK, 2011, ANNU REV IMMUNOL, V29, P707, DOI 10.1146/annurev-immunol-031210-101405
   Davoodi J, 2010, INT J BIOCHEM CELL B, V42, P958, DOI 10.1016/j.biocel.2010.02.008
   de Castro-Sobrinho JM, 2016, DIAGN CYTOPATHOL, V44, P80, DOI 10.1002/dc.23388
   de Miguel D, 2016, CELL DEATH DIFFER, V23, P733, DOI 10.1038/cdd.2015.174
   Deng QT, 2019, CANCER LETT, V442, P21, DOI 10.1016/j.canlet.2018.10.030
   Dey A, 2008, CELL CYCLE, V7, P3759, DOI 10.4161/cc.7.23.7213
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Ding QP, 2018, PATHOL RES PRACT, V214, P1330, DOI 10.1016/j.prp.2018.05.012
   Ding WX, 2007, J BIOL CHEM, V282, P4702, DOI 10.1074/jbc.M609267200
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Du QM, 2016, BIOCHEM PHARMACOL, V105, P42, DOI 10.1016/j.bcp.2016.02.017
   Dunleavy K, 2015, BLOOD, V125, P33, DOI 10.1182/blood-2014-05-575092
   Dupaul-Chicoine J, 2015, IMMUNITY, V43, P751, DOI 10.1016/j.immuni.2015.08.013
   Endo T, 2004, CANCER IMMUNOL IMMUN, V53, P770, DOI 10.1007/s00262-004-0534-8
   Ewald SE, 2014, INFECT IMMUN, V82, P460, DOI 10.1128/IAI.01170-13
   Fenini G, 2018, J INVEST DERMATOL, V138, P2644, DOI 10.1016/j.jid.2018.07.016
   Franchi L, 2006, NAT IMMUNOL, V7, P576, DOI 10.1038/ni1346
   Fujita K, 2011, INT J CANCER, V129, P424, DOI 10.1002/ijc.25705
   Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Gross O, 2009, NATURE, V459, P433, DOI 10.1038/nature07965
   Grossmann M, 1999, P NATL ACAD SCI USA, V96, P11848, DOI 10.1073/pnas.96.21.11848
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Harton JA, 2002, J IMMUNOL, V169, P4088, DOI 10.4049/jimmunol.169.8.4088
   Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962
   Hasegawa T, 2016, BIOCHEM BIOPH RES CO, V477, P329, DOI 10.1016/j.bbrc.2016.06.106
   He AQ, 2017, ONCOTARGET, V8, P33214, DOI 10.18632/oncotarget.16596
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Homer CR, 2012, J BIOL CHEM, V287, P25565, DOI 10.1074/jbc.M111.326835
   Hoque R, 2015, AM J PHYSIOL-GASTR L, V308, pG643, DOI 10.1152/ajpgi.00388.2014
   Hsu YMS, 2007, NAT IMMUNOL, V8, P198, DOI 10.1038/ni1426
   Hu B, 2010, P NATL ACAD SCI USA, V107, P21635, DOI 10.1073/pnas.1016814108
   Huang XP, 2016, FASEB J, V30, P3069, DOI 10.1096/fj.201600331R
   Huber S, 2012, NATURE, V491, P259, DOI 10.1038/nature11535
   Huhn S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199350
   Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347
   Irving AT, 2014, CELL HOST MICROBE, V15, P623, DOI 10.1016/j.chom.2014.04.001
   Ishaq Sauid, 2015, Gastroenterol Hepatol Bed Bench, V8, pS6
   Janssen LME, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0283-9
   Jin Y, 2007, NEW ENGL J MED, V356, P1216, DOI 10.1056/NEJMoa061592
   Jochems C, 2011, EXP BIOL MED, V236, P567, DOI 10.1258/ebm.2011.011007
   Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002
   Kanneganti TD, 2015, CELL METAB, V21, P793, DOI 10.1016/j.cmet.2015.05.019
   Kaparakis M, 2010, CELL MICROBIOL, V12, P372, DOI 10.1111/j.1462-5822.2009.01404.x
   Karki R, 2017, CELL CYCLE, V16, P1243, DOI 10.1080/15384101.2017.1317414
   Kashyap M, 2015, J INFLAMM-LOND, V12, DOI 10.1186/s12950-015-0082-3
   Keestra-Gounder AM, 2017, TRENDS IMMUNOL, V38, P758, DOI 10.1016/j.it.2017.07.004
   Keestra-Gounder AM, 2016, NATURE, V532, P394, DOI 10.1038/nature17631
   Keita M, 2010, J OVARIAN RES, V3, DOI 10.1186/1757-2215-3-3
   Kerur N, 2011, CELL HOST MICROBE, V9, P363, DOI 10.1016/j.chom.2011.04.008
   Khattar E, 2016, J CLIN INVEST, V126, P4045, DOI 10.1172/JCI86042
   Kim JY, 2008, J BIOL CHEM, V283, P137, DOI 10.1074/jbc.M704746200
   Kim JY, 2018, ONCOTARGET, V9, P1705, DOI 10.18632/oncotarget.23083
   Kim YK, 2016, YONSEI MED J, V57, P5, DOI 10.3349/ymj.2016.57.1.5
   Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Kolb R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13007
   Kufer TA, 2008, CELL MICROBIOL, V10, P477, DOI 10.1111/j.1462-5822.2007.01062.x
   Kufer TA, 2006, ANN NY ACAD SCI, V1072, P19, DOI 10.1196/annals.1326.020
   Kutikhin AG, 2011, HUM IMMUNOL, V72, P955, DOI 10.1016/j.humimm.2011.06.003
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lee J, 2009, J BIOL CHEM, V284, P23818, DOI 10.1074/jbc.M109.033670
   Lee WS, 2015, CURR MOL MED, V15, P735, DOI 10.2174/1566524015666150921105453
   Legrand-Poels S, 2007, J CELL SCI, V120, P1299, DOI 10.1242/jcs.03424
   Levi I, 2015, ONCOTARGET, V6, P1, DOI 10.18632/oncotarget.3453
   Li L, 2015, J OCEAN WIND ENERGY, V2, P1, DOI DOI 10.1371/J0URNAL.P0NE.0133813
   Li LL, 2015, AM J CANCER RES, V5, P442
   Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321
   Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113
   Li YM, 2018, OPEN MED-WARSAW, V13, P443, DOI 10.1515/med-2018-0066
   Lilienbaum Alain, 2013, Int J Biochem Mol Biol, V4, P1
   Linares MA, 2015, PRIMARY CARE, V42, P645, DOI 10.1016/j.pop.2015.07.006
   [刘京 Liu Jing], 2018, [生命科学研究, Life Science Research], V22, P3
   Liu JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089340
   Liu L, 2018, FOOD FUNCT, V9, P5588, DOI [10.1039/C8FO01143E, 10.1039/c8fo01143e]
   Liu RR, 2015, ONCOTARGET, V6, P33456, DOI 10.18632/oncotarget.5587
   Liu Y, 1999, J BIOL CHEM, V274, P24819, DOI 10.1074/jbc.274.35.24819
   Lortet-Tieulent J, 2018, JNCI-J NATL CANCER I, V110, P354, DOI 10.1093/jnci/djx214
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Maier JKX, 2002, J NEUROSCI, V22, P2035, DOI 10.1523/JNEUROSCI.22-06-02035.2002
   Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515
   Marinis JM, 2011, J BIOL CHEM, V286, P1938, DOI 10.1074/jbc.M110.189308
   Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038
   Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Masters SL, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1471
   McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968
   Miao EA, 2010, P NATL ACAD SCI USA, V107, P3076, DOI 10.1073/pnas.0913087107
   Miranda-Filho A, 2017, NEURO-ONCOLOGY, V19, P270, DOI 10.1093/neuonc/now166
   Moossavi M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0900-3
   Moreira DM, 2015, PROSTATE, V75, P1492, DOI 10.1002/pros.23041
   Morgan JE, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150091
   Motta V, 2015, PHYSIOL REV, V95, P149, DOI 10.1152/physrev.00009.2014
   Mottok A, 2015, CELL REP, V13, P1418, DOI 10.1016/j.celrep.2015.10.008
   Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098
   Murray PJ, 2005, CURR OPIN IMMUNOL, V17, P352, DOI 10.1016/j.coi.2005.05.006
   Muruve DA, 2008, NATURE, V452, P103, DOI 10.1038/nature06664
   Naik E, 2010, J CLIN IMMUNOL, V30, P485, DOI 10.1007/s10875-010-9383-8
   Nakamura N, 2014, NATURE, V509, P240, DOI 10.1038/nature13133
   Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108
   Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06
   Ohno S, 2008, ANTICANCER RES, V28, P2493
   Okamoto M, 2010, J BIOL CHEM, V285, P6477, DOI 10.1074/jbc.M109.064907
   Ozcan M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445453
   Parker H, 2010, INFECT IMMUN, V78, P5054, DOI 10.1128/IAI.00299-10
   Philpott DJ, 2014, NAT REV IMMUNOL, V14, P9, DOI 10.1038/nri3565
   Pontillo A, 2016, J MED VIROL, V88, P1646, DOI 10.1002/jmv.24514
   Poon CC, 2017, BRAIN, V140, P1548, DOI 10.1093/brain/aww355
   Proell M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002119
   Radian AD, 2013, MICROBES INFECT, V15, P630, DOI 10.1016/j.micinf.2013.04.001
   Ramachandran RA, 2018, ADV MICROB PHYSIOL, V72, P65, DOI 10.1016/bs.ampbs.2018.01.004
   Raval A, 2001, MOL CELL, V7, P105, DOI 10.1016/S1097-2765(01)00159-9
   Ribeiro AA, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0011-3
   Rose DP, 2009, EXPERT REV ANTICANC, V9, P1091, DOI [10.1586/era.09.71, 10.1586/ERA.09.71]
   Sagulenko V, 2013, CELL DEATH DIFFER, V20, P1149, DOI 10.1038/cdd.2013.37
   Sasawatari S, 2011, GASTROENTEROLOGY, V140, P1513, DOI 10.1053/j.gastro.2011.01.041
   Sastalla I, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-188
   Schwartzbaum JA, 2006, NAT CLIN PRACT NEURO, V2, P494, DOI 10.1038/ncpneuro0289
   Shang S, 2018, CELL MOL NEUROBIOL, V38, P1479, DOI 10.1007/s10571-018-0617-2
   Sharma D, 2016, J CELL BIOL, V213, P617, DOI 10.1083/jcb.201602089
   Shenoy A., 2011, HUMANITIES, V333, P481
   Shenoy AR, 2012, SCIENCE, V336, P481, DOI 10.1126/science.1217141
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Sirisinha S, 2011, ASIAN PAC J ALLERGY, V29, P1
   Sitarz R, 2018, CANCER MANAG RES, V10, P239, DOI 10.2147/CMAR.S149619
   Sollberger G, 2015, J INVEST DERMATOL, V135, P1395, DOI 10.1038/jid.2014.551
   Sorosky JI, 2012, OBSTET GYNECOL, V120, P383, DOI 10.1097/AOG.0b013e3182605bf1
   Steidl C, 2011, NATURE, V471, P377, DOI 10.1038/nature09754
   Stein C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r251
   Stockmann C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00069
   Stutz A, 2009, J CLIN INVEST, V119, P3502, DOI 10.1172/JCI40599
   Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291
   Symons LK, 2018, TRENDS MOL MED, V24, P748, DOI 10.1016/j.molmed.2018.07.004
   Szabo G, 2012, J HEPATOL, V57, P642, DOI 10.1016/j.jhep.2012.03.035
   Tafani M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3907147
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432
   Tarassishin L, 2014, J PROTEOMICS, V99, P152, DOI 10.1016/j.jprot.2014.01.024
   Tattoli I, 2007, SEMIN IMMUNOPATHOL, V29, P289, DOI 10.1007/s00281-007-0083-2
   Tian X, 2009, BMC EVOL BIOL, V9, DOI 10.1186/1471-2148-9-202
   Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005
   Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6
   Travassos LH, 2010, AUTOPHAGY, V6, P409, DOI 10.4161/auto.6.3.11305
   Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823
   Trinchieri G, 2012, ANNU REV IMMUNOL, V30, P677, DOI 10.1146/annurev-immunol-020711-075008
   Udden SMN, 2017, CELL REP, V19, P2756, DOI 10.1016/j.celrep.2017.05.084
   Vanaja SK, 2015, TRENDS CELL BIOL, V25, P308, DOI 10.1016/j.tcb.2014.12.009
   Velloso FJ, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-5523-6
   Velloso Fernando J, 2018, BMC Res Notes, V11, P222, DOI 10.1186/s13104-018-3335-4
   Velloso FJ, 2017, ONCOTARGETS THER, V10, P5491, DOI 10.2147/OTT.S142154
   Verma D, 2012, PIGM CELL MELANOMA R, V25, P506, DOI 10.1111/j.1755-148X.2012.01008.x
   Wang HB, 2017, ONCOTARGET, V8, P111597, DOI 10.18632/oncotarget.22876
   Wang H, 2016, EXP CELL RES, V342, P184, DOI 10.1016/j.yexcr.2016.03.009
   Wong MCS, 2016, EUR UROL, V70, P862, DOI 10.1016/j.eururo.2016.05.043
   Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866
   Yin X, 2016, CHINESE MED J-PEKING, V129, P1047, DOI 10.4103/0366-6999.180528
   Yin XF, 2018, INT J ONCOL, V53, P973, DOI 10.3892/ijo.2018.4480
   Yoshihama S, 2016, P NATL ACAD SCI USA, V113, P5999, DOI 10.1073/pnas.1602069113
   Yun BH, 2015, INT UROL NEPHROL, V47, P1251, DOI 10.1007/s11255-015-1029-6
   Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022
   Zaki MH, 2011, TRENDS IMMUNOL, V32, P171, DOI 10.1016/j.it.2011.02.002
   Zaki MH, 2010, J IMMUNOL, V185, P4912, DOI 10.4049/jimmunol.1002046
   Zambirinis CP, 2014, CANCER J, V20, P195, DOI 10.1097/PPO.0000000000000045
   Zhai Z, 2017, ONCOGENE, V36, P3820, DOI 10.1038/onc.2017.26
   Zhan Y, 2016, J IMMUNOL, V196, P5121, DOI 10.4049/jimmunol.1501822
   Zhao Y, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1375640
   Zhong FL, 2016, CELL, V167, P187, DOI 10.1016/j.cell.2016.09.001
   Zhong Y, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00333
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2
   2017, J IMMUNOL, V199, P263, DOI DOI 10.4049/JIMMUNOL.1600409
   2018, INT IMMUNOPHARMACOL, V54, P385, DOI DOI 10.1016/J.INTIMP.2017.11.036
   2016, EXP HEMATOL, V44, P519, DOI DOI 10.1016/J.EXPHEM.2016.03.010
   2009, J IMMUNOL, V182, P4321, DOI DOI 10.4049/JIMMUNOL.0802197
   2015, IMMUNOL REV, V265, P22, DOI DOI 10.1111/IMR.12283
   2007, CURR OPIN IMMUNOL, V19, P615, DOI DOI 10.1016/J.COI.2007.09.002
   2016, METHOD MOL BIOL, V1417, P1, DOI DOI 10.1007/978-1-4939-3566-6.1
   2009, J BIOL CHEM, V284, P1276, DOI DOI 10.1074/JBC.M806084200
NR 219
TC 50
Z9 53
U1 2
U2 17
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD APR 30
PY 2019
VL 39
AR BSR20181709
DI 10.1042/BSR20181709
PN 4
PG 21
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA HW3RC
UT WOS:000466609400022
PM 30837326
OA Green Submitted, gold, Green Published
DA 2022-04-25
ER

PT J
AU Jung, O
   Lee, J
   Lee, YJ
   Yun, JM
   Son, YJ
   Cho, JY
   Ryou, C
   Lee, SY
AF Jung, Okkeun
   Lee, Jongsung
   Lee, Yu Jin
   Yun, Jung-Mi
   Son, Young-Jin
   Cho, Jae Youl
   Ryou, Chongsuk
   Lee, Sang Yeol
TI Timosaponin AIII inhibits migration and invasion of A549 human
   non-small-cell lung cancer cells via attenuations of MMP-2 and MMP-9 by
   inhibitions of ERK1/2, Src/FAK and beta-catenin signaling pathways
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Timosaponin AIII; ERK1/2; Src; FAK; Metastasis; Matrix
   metalloproteinases; Human non-small-cell lung cancer
ID ANEMARRHENA-ASPHODELOIDES; SUPPRESSES MIGRATION; METASTASIS; APOPTOSIS;
   MEMORY; BUNGE; MYC
AB Timosaponin AIII (TAIII) is a type of steroidal saponins isolated from Anemarrhena asphodeloides. It was known to improve learning and memory deficits through anti-inflammatory effects. TAIII was also reported to induce autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells and inhibit the growth of human colorectal cancer cells, thus regarded as a potential candidate for anti-cancer agent. In this study, we verified apoptosis-inducing and cell-cycle-arresting effects of TAIII in A549 human non-small-cell lung cancer (NSCLC) cells. Then, we report that TAIII suppresses migration and invasion of A549 human NSCLC cells. We propose that two matrix metalloproteinases (MMPs), MMP-2 and MMP-9, which are well known to be involved in cancer-metastasis, are attenuated by the treatment of TAIII. TAIII exerts its suppressive effects on MMP-2 and MMP-9 via inhibitions of ERK1/2, Src/FAK and beta-catenin signalings which are closely related with the regulations of MMP-2 and MMP-9. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Jung, Okkeun; Lee, Yu Jin; Lee, Sang Yeol] Gachon Univ, Dept Life Sci, San 65, Songnam 461701, Gyeonggi, South Korea.
   [Lee, Jongsung; Cho, Jae Youl] Sungkyunkwan Univ, Dept Genet Engn, Suwon 440746, Gyeonggi, South Korea.
   [Yun, Jung-Mi] Chonnam Natl Univ, Dept Food & Nutr, Gwangju, South Korea.
   [Son, Young-Jin] Sunchon Natl Univ, Dept Pharm, Sunchon 530742, Jeonnam, South Korea.
   [Ryou, Chongsuk] Hanyang Univ, Coll Pharm, Dept Pharm, Ansan 426791, Gyeonggi Do, South Korea.
   [Ryou, Chongsuk] Hanyang Univ, Inst Pharmaceut Sci & Technol, Ansan 426791, Gyeonggi Do, South Korea.
RP Lee, SY (corresponding author), Gachon Univ, Dept Life Sci, San 65, Songnam 461701, Gyeonggi, South Korea.
EM leesaye@gachon.ac.kr
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2015R1D1A1A09058494]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education (NRF-2015R1D1A1A09058494).
CR Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Dufour A, 2008, J CELL PHYSIOL, V217, P643, DOI 10.1002/jcp.21535
   HAMAGUCHI M, 1995, ONCOGENE, V10, P1037
   Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481
   Ji X., 2010, CHIN TRADIT HERB DRU, V41, P12
   Kang YJ, 2011, J NAT PROD, V74, P701, DOI 10.1021/np1007735
   Kim JH, 2015, CHEM-BIOL INTERACT, V242, P25, DOI 10.1016/j.cbi.2015.08.014
   King FW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007283
   Ku MJ, 2013, BIOORG MED CHEM LETT, V23, P5609, DOI 10.1016/j.bmcl.2013.08.043
   Ku MJ, 2015, MOL CELL BIOCHEM, V402, P243, DOI 10.1007/s11010-015-2331-4
   Lee B, 2009, PHARMACOL BIOCHEM BE, V93, P121, DOI 10.1016/j.pbb.2009.04.021
   [李素燕 LI SuYan], 2006, [军事医学科学院院刊, Bulletin of the Academy of Military Medical Sciences], V30, P340
   Li TJ, 2007, NEUROSCI LETT, V421, P147, DOI 10.1016/j.neulet.2007.04.082
   Matsuzaki S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061690
   NIWA A, 1988, YAKUGAKU ZASSHI, V108, P555, DOI 10.1248/yakushi1947.108.6_555
   Ryu BJ, 2014, MOL CELL BIOCHEM, V389, P69, DOI 10.1007/s11010-013-1928-8
   Sy LK, 2008, CANCER RES, V68, P10229, DOI 10.1158/0008-5472.CAN-08-1983
   Takeda Y, 2001, J GASTROENTEROL, V36, P79, DOI 10.1007/s005350170135
   Wang N, 2013, BBA-MOL CELL RES, V1833, P2890, DOI 10.1016/j.bbamcr.2013.07.018
   Wang YL, 2014, J ETHNOPHARMACOL, V153, P42, DOI 10.1016/j.jep.2014.02.013
   Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781
   Wolfer A, 2011, CANCER RES, V71, P2034, DOI 10.1158/0008-5472.CAN-10-3776
NR 22
TC 44
Z9 51
U1 3
U2 22
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
EI 1464-3405
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD AUG 15
PY 2016
VL 26
IS 16
BP 3963
EP 3967
DI 10.1016/j.bmcl.2016.07.004
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA DS2FB
UT WOS:000380574400024
PM 27422337
DA 2022-04-25
ER

PT J
AU Nagasawa, I
   Kunimasa, K
   Tsukahara, S
   Tomida, A
AF Nagasawa, Ikuko
   Kunimasa, Kazuhiro
   Tsukahara, Satomi
   Tomida, Akihiro
TI BRAF-mutated cells activate GCN2-mediated integrated stress response as
   a cytoprotective mechanism in response to vemurafenib
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Vemurafenib; BRAF; Integrated stress response; GCN2; ATF4
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; MELANOMA-CELLS;
   BRAF(V600E) INHIBITION; GENE-EXPRESSION; KINASE; RESISTANCE; AUTOPHAGY;
   CANCER; GCN2
AB In BRAF-mutated melanoma cells, the BRAF inhibitor, vemurafenib, induces phosphorylation of eukaryotic initiation factor 2 alpha (eIF2 alpha) and subsequent induction of activating transcription factor 4 (ATF4), the central regulation node of the integrated stress response (ISR). While the ISR supports cellular adaptation to various stresses, the role of vemurafenib-triggered ISR has not been fully characterized. Here, we showed that in response to vemurafenib, BRAF-mutated melanoma and colorectal cancer cells rapidly induced the ISR as a cytoprotective mechanism through activation of general control non-derepressible 2 (GCN2), an eIF2 alpha kinase sensing amino acid levels. The vemurafenib-triggered ISR, an event independent of downstream MEK inhibition, was specifically prevented by silencing GCN2, but not other eIF2 alpha kinases, including protein kinase-like endoplasmic reticulum kinase, which transmits endoplasmic reticulum (ER) stress. Consistently, the ER stress gatekeeper, GRP78, was not induced by vemurafenib. Interestingly, ATF4 silencing by siRNA rendered BRAF-mutated melanoma cells sensitive to vemurafenib. Thus, the GCN2-mediated ISR can promote cellular adaptation to vemurafenib-induced stress, providing an insight into the development of drug resistance. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Nagasawa, Ikuko; Kunimasa, Kazuhiro; Tsukahara, Satomi; Tomida, Akihiro] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.
   [Nagasawa, Ikuko; Tomida, Akihiro] Meiji Pharmaceut Univ, 2-522-1 Noshio, Tokyo 2048588, Japan.
RP Tomida, A (corresponding author), Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.
EM akihiro.tomida@jfcr.or.jp
FU JSPS KAKENHIMinistry of Education, Culture, Sports, Science and
   Technology, Japan (MEXT)Japan Society for the Promotion of
   ScienceGrants-in-Aid for Scientific Research (KAKENHI) [25290061,
   16H04717]
FX This work was supported in part by JSPS KAKENHI Grant Numbers 25290061
   and 16H04717. The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR B'chir W, 2013, NUCLEIC ACIDS RES, V41, P7683, DOI 10.1093/nar/gkt563
   Baenke F, 2016, MOL ONCOL, V10, P73, DOI 10.1016/j.molonc.2015.08.003
   Beck D, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003057
   Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x
   Chen JJ, 2007, BLOOD, V109, P2693, DOI 10.1182/blood-2006-08-041830
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Flaherty KT, 2012, NAT REV CANCER, V12, P349, DOI 10.1038/nrc3218
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003
   Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   Hernandez-Davies JE, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0581-2
   Hetz C, 2013, NAT REV DRUG DISCOV, V12, P703, DOI 10.1038/nrd3976
   Kawaguchi K, 2016, ONCOTARGET, V7, P71737, DOI 10.18632/oncotarget.12328
   Kilberg MS, 2009, TRENDS ENDOCRIN MET, V20, P436, DOI 10.1016/j.tem.2009.05.008
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   Lu PD, 2004, J CELL BIOL, V167, P27, DOI 10.1083/jcb.200408003
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Nakamura T, 2010, CELL, V140, P338, DOI 10.1016/j.cell.2010.01.001
   Padyana AK, 2005, J BIOL CHEM, V280, P29289, DOI 10.1074/jbc.M504096200
   Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282
   Rzymski T, 2010, ONCOGENE, V29, P4424, DOI 10.1038/onc.2010.191
   Saito S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045845
   Saito S, 2009, CANCER RES, V69, P4225, DOI 10.1158/0008-5472.CAN-08-2689
   Sueda T, 2016, SCI REP-UK, V6, DOI 10.1038/srep18949
   Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Tsukumo Y, 2015, BIOCHEM BIOPH RES CO, V462, P383, DOI 10.1016/j.bbrc.2015.04.144
   Vattem KM, 2004, P NATL ACAD SCI USA, V101, P11269, DOI 10.1073/pnas.0400541101
   Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81
NR 32
TC 11
Z9 11
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 22
PY 2017
VL 482
IS 4
BP 1491
EP 1497
DI 10.1016/j.bbrc.2016.12.062
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA EK1XB
UT WOS:000393720000149
PM 27965097
DA 2022-04-25
ER

PT J
AU Bitorina, AV
   Oligschlaeger, Y
   Ding, LL
   Yadati, T
   Westheim, A
   Houben, T
   Vaes, RDW
   Damink, SWMO
   Theys, J
   Shiri-Sverdlov, R
AF Bitorina, Albert V.
   Oligschlaeger, Yvonne
   Ding, Lingling
   Yadati, Tulasi
   Westheim, Annemarie
   Houben, Tom
   Vaes, Rianne D. W.
   Damink, Steven W. M. Olde
   Theys, Jan
   Shiri-Sverdlov, Ronit
TI OxLDL as an Inducer of a Metabolic Shift in Cancer Cells
SO JOURNAL OF CANCER
LA English
DT Article
DE Pancreatic cancer cells; oxLDL; metabolic switch; HIF-1 alpha; autophagy
ID LOW-DENSITY-LIPOPROTEIN; OXIDIZED LDL; NONALCOHOLIC STEATOHEPATITIS;
   CARDIOVASCULAR-DISEASE; COLORECTAL-CANCER; OXIDATIVE STRESS; RISK;
   AUTOPHAGY; HYPOXIA; PROLIFERATION
AB Recent evidence established a link between disturbed lipid metabolism and increased risk for cancer. One of the most prominent features related to disturbed lipid metabolism is an increased production of oxidized low-density-lipoproteins (oxLDL), which results from elevated oxidative stress. OxLDL is known to have detrimental effects on healthy cells and plays a primary role in diseases related to the metabolic syndrome. Nevertheless, so far, the exact role of oxLDL in cancer cell metabolism is not yet known. To examine changes in metabolic profile induced by oxLDL, pancreatic KLM-1 cells were treated with oxLDL in a concentration- (25 or 50 mu g/ml) and/or time-dependent (4 hr or 8 hr) manner and the impact of oxLDL on oxygen consumption rates (OCR) as well as extracellular acidification rates (ECAR) was analyzed using Seahorse technology. Subsequently, to establish the link between oxLDL and glycolysis, stabilization of the master regulator hypoxia-inducible factor 1-alpha (HIF-1 alpha) was measured by means of Western blot. Furthermore, autophagic responses were assessed by measuring protein levels of the autophagosomal marker LC3B-II. Finally, the therapeutic potential of natural anti-oxLDL IgM antibodies in reversing these effects was tested. Incubation of KLM-1 cells with oxLDL shifted the energy balance towards a more glycolytic phenotype, which is an important hallmark of cancer cells. These data were supported by measurement of increased oxLDL-mediated HIF-1 alpha stabilization. In line, oxLDL incubation also increased the levels of LC3B-II, suggesting an elevated autophagic response. Importantly, antibodies against oxLDL were able to reverse these oxLDL-mediated metabolic effects. Our data provides a novel proof-of-concept that oxLDL induces a shift in energy balance. These data not only support a role for oxLDL in the progression of cancer but also suggest the possibility of targeting oxLDL as a therapeutic option in cancer.
C1 [Bitorina, Albert V.; Oligschlaeger, Yvonne; Yadati, Tulasi; Houben, Tom; Shiri-Sverdlov, Ronit] Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Dept Mol Genet, Maastricht, Netherlands.
   [Vaes, Rianne D. W.; Damink, Steven W. M. Olde] Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Dept Surg, Maastricht, Netherlands.
   [Westheim, Annemarie; Theys, Jan] Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Precis Med, Med Ctr, Maastricht, Netherlands.
RP Shiri-Sverdlov, R (corresponding author), Maastricht Univ, Sch Nutr & Translat Res Metab NUTRIM, Dept Mol Genet, Maastricht, Netherlands.; Theys, J (corresponding author), Maastricht Univ, Sch Oncol & Dev Biol GROW, Dept Precis Med, Med Ctr, Maastricht, Netherlands.
EM jan.theys@maastrichtuniversity.nl; r.sverdlov@maastrichtuniversity.nl
RI Theys, Jan/AAI-9211-2021; Houben, Tom/T-1083-2017; Shiri-Sverdlov,
   Ronit/E-5571-2017
OI Theys, Jan/0000-0002-9718-8251; Houben, Tom/0000-0002-0441-3166;
   Shiri-Sverdlov, Ronit/0000-0002-6736-7814; Olde Damink,
   Steven/0000-0002-5202-9345
FU CVON IN-CONTROL grant [CVON2012-03]; Dutch Organisation for Scientific
   Research (NWO)Netherlands Organization for Scientific Research (NWO)
   [016.126.327]; ASPASIA [015.008.043]; TKI-LSH [40-41200-98-9306]; Dutch
   Cancer Society (KWF)KWF Kankerbestrijding [10820]; VCK [Swu16.0057-VT]
FX This research was supported by the CVON IN-CONTROL grant (CVON2012-03),
   the Dutch Organisation for Scientific Research (NWO; Vidi grant no.
   016.126.327), ASPASIA (grant no. 015.008.043), TKI-LSH (grant no.
   40-41200-98-9306), Dutch Cancer Society (KWF grant no. 10820) and VCK
   (grant no. Swu16.0057-VT). The funding bodies had no role in the
   preparation of this manuscript or the decision to publish.
CR Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
   Baron JA, 2000, ANNU REV MED, V51, P511, DOI 10.1146/annurev.med.51.1.511
   Bieghs V, 2013, LIVER INT, V33, P1056, DOI 10.1111/liv.12170
   Bieghs V, 2012, HEPATOLOGY, V56, P894, DOI 10.1002/hep.25660
   Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876
   Borgquist S, 2018, J INTERN MED, V284, P346, DOI 10.1111/joim.12806
   Boushehri SN, 2012, IRAN J BASIC MED SCI, V15, P958
   Brahmkhatri VP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/538019
   Capper CP, 2016, HORM CANCER-US, V7, P149, DOI 10.1007/s12672-016-0259-0
   Chen KC, 2015, ONCOTARGET, V6, P24105, DOI 10.18632/oncotarget.4152
   Chen Y, 2012, EUR J CANCER, V48, P2137, DOI 10.1016/j.ejca.2012.02.063
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Delimaris L, 2007, CLIN BIOCHEM, V40, P1129, DOI 10.1016/j.clinbiochem.2007.06.007
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Di Pietro N, 2016, VASC PHARMACOL, V84, P1, DOI 10.1016/j.vph.2016.05.013
   Doerstling SS, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00216
   Esposito K, 2012, DIABETES CARE, V35, P2402, DOI 10.2337/dc12-0336
   Faubert B, 2017, CELL, V171, P358, DOI 10.1016/j.cell.2017.09.019
   Feinberg T, 2017, J BREATH RES, V11, DOI 10.1088/1752-7163/aa51d6
   Friedrich MJ, 2017, JAMA-J AM MED ASSOC, V318, P603, DOI 10.1001/jama.2017.10693
   Galle J, 2006, ATHEROSCLEROSIS, V185, P219, DOI 10.1016/j.atherosclerosis.2005.10.005
   Genkinger JM, 2011, INT J CANCER, V129, P1708, DOI 10.1002/ijc.25794
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HARRIS WS, 1992, CLIN CARDIOL, V15, P636, DOI 10.1002/clc.4960150904
   Hendrikx T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078792
   Iommarini L, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00286
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kwanten WJ, 2016, AM J PHYSIOL-GASTR L, V311, pG599, DOI 10.1152/ajpgi.00418.2015
   Landskron G, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/149185
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Lian X, 2018, BIOCHEM BIOPH RES CO, V496, P70, DOI 10.1016/j.bbrc.2017.12.168
   Lin L, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.985913
   Liu J, 2014, INT J MOL MED, V33, P1341, DOI 10.3892/ijmm.2014.1681
   Maan M, 2018, BIOCHEM BIOPH RES CO, V504, P582, DOI 10.1016/j.bbrc.2018.02.097
   Micucci C, 2016, ONCOTARGET, V7, P38959, DOI 10.18632/oncotarget.8341
   Multhoff G, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00098
   Nicholls David G, 2010, J Vis Exp, DOI 10.3791/2511
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Poitz DM, 2011, BASIC RES CARDIOL, V106, P761, DOI 10.1007/s00395-011-0186-8
   Poteet E, 2013, J BIOL CHEM, V288, P9153, DOI 10.1074/jbc.M112.440354
   Prentice RL, 2007, JNCI-J NATL CANCER I, V99, P1534, DOI 10.1093/jnci/djm159
   Redmann M, 2017, REDOX BIOL, V11, P73, DOI 10.1016/j.redox.2016.11.004
   Rodriguez LAG, 2001, EPIDEMIOLOGY, V12, P88, DOI 10.1097/00001648-200101000-00015
   Rosenson RS, 2007, DIABETES CARE, V30, P1945, DOI 10.2337/dc07-0015
   Saunier E, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07006-0
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Seibold S, 2004, J AM SOC NEPHROL, V15, P3026, DOI 10.1097/01.ASN.0000146425.58046.6A
   Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678
   Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607
   Shatrov VA, 2003, BLOOD, V101, P4847, DOI 10.1182/blood-2002-09-2711
   Shern-Brewer R, 1998, ARTERIOSCL THROM VAS, V18, P1181, DOI 10.1161/01.ATV.18.7.1181
   Silaste ML, 2004, ARTERIOSCL THROM VAS, V24, P498, DOI 10.1161/01.ATV.0000118012.64932.f4
   Singh R, 2009, NATURE, V458, P1131, DOI 10.1038/nature07976
   Singh U, 2008, AM J CARDIOL, V102, P321, DOI 10.1016/j.amjcard.2008.03.057
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Suzuki K, 2004, CANCER EPIDEM BIOMAR, V13, P1781
   Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30
   Takashima A, 2014, CIRC J, V78, P2682, DOI 10.1253/circj.CJ-14-0532
   Tanida Isei, 2008, V445, P77, DOI 10.1007/978-1-59745-157-4_4
   Thyagarajan A, 2018, INTEGR CANCER THER, V17, P210, DOI 10.1177/1534735416681639
   Walenbergh SMA, 2013, J HEPATOL, V58, P801, DOI 10.1016/j.jhep.2012.11.014
   Xie XP, 2010, ACTA BIOCHIM POL, V57, P393
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Zabirnyk O, 2010, CARCINOGENESIS, V31, P446, DOI 10.1093/carcin/bgp299
   Zettler ME, 2003, AM J PHYSIOL-HEART C, V284, pH644, DOI 10.1152/ajpheart.00494.2001
   Zhang Y, 2013, CANCER BIOL THER, V14, P81, DOI 10.4161/cbt.22958
   Zhou JL, 2018, BIOL REPROD, V99, P308, DOI 10.1093/biolre/ioy061
   Zitvogel L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010473
NR 70
TC 1
Z9 1
U1 0
U2 2
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2021
VL 12
IS 19
BP 5817
EP 5824
DI 10.7150/jca.56307
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UE2KC
UT WOS:000687721900012
PM 34475995
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Nkwe, DO
   Lotshwao, B
   Rantong, G
   Matshwele, J
   Kwape, TE
   Masisi, K
   Gaobotse, G
   Hefferon, K
   Makhzoum, A
AF Nkwe, David O.
   Lotshwao, Bonolo
   Rantong, Gaolathe
   Matshwele, James
   Kwape, Tebogo E.
   Masisi, Kabo
   Gaobotse, Goabaone
   Hefferon, Kathleen
   Makhzoum, Abdullah
TI Anticancer Mechanisms of Bioactive Compounds from Solanaceae: An Update
SO CANCERS
LA English
DT Review
DE Solanaceae; cancer; anticancer/antitumour; apoptosis; cell cycle;
   transcription; autophagy; signalling
ID CELL-CYCLE ARREST; C-MYB; METABOLITES INHIBIT; MAD2-CDC20 COMPLEX;
   COLORECTAL-CANCER; VEGF-A; APOPTOSIS; BREAST; GROWTH; EXPRESSION
AB Simple Summary
   The Solanaceae plant family has been a good source of natural compounds that can treat several diseases, including cancer. However, the site and mechanism of action of these compounds in cells has not been entirely clear. With ongoing developments in biological science research, it has become possible to study and identify some of the cellular targets. In this review, we assess publications from the last five years and identify research articles that explain how some of these compounds may work against cancer. These studies show that a number of different components or pathways in cells are targeted by these compounds to inhibit cell proliferation. Interestingly, some compounds have multiple targets and may be effective against different types of cancer. This knowledge may allow scientists to design new and more effective anticancer drugs.
   Plants continue to provide unlimited pharmacologically active compounds that can treat various illnesses, including cancer. The Solanaceae family, besides providing economically important food plants, such as potatoes and tomatoes, has been exploited extensively in folk medicine, as it provides an array of bioactive compounds. Many studies have demonstrated the anticancer potency of some of the compounds, but the corresponding molecular targets are not well defined. However, advances in molecular cell biology and in silico modelling have made it possible to dissect some of the underlying mechanisms. By reviewing the literature over the last five years, we provide an update on anticancer mechanisms associated with phytochemicals isolated from species in the Solanaceae plant family. These mechanisms are conveniently grouped into cell cycle arrest, transcription regulation, modulation of autophagy, inhibition of signalling pathways, suppression of metabolic enzymes, and membrane disruption. The majority of the bioactive compounds exert their antiproliferative effects by inhibiting diverse signalling pathways, as well as arresting the cell cycle. Furthermore, some of the phytochemicals are effective against more than one cancer type. Therefore, understanding these mechanisms provides paths for future formulation of novel anticancer drugs, as well as highlighting potential areas of research.
C1 [Nkwe, David O.; Lotshwao, Bonolo; Rantong, Gaolathe; Kwape, Tebogo E.; Masisi, Kabo; Gaobotse, Goabaone; Makhzoum, Abdullah] Botswana Int Univ Sci & Technol, Dept Biol Sci & Biotechnol, Palapye, Botswana.
   [Matshwele, James] Botswana Int Univ Sci & Technol, Dept Chem & Forens Sci, Palapye, Botswana.
   [Matshwele, James] Botho Univ, Dept Appl Sci, Gaborone, Botswana.
   [Hefferon, Kathleen] Univ Toronto, Dept Cell & Syst Biol, Virol Lab, Toronto, ON M5S 3B2, Canada.
RP Nkwe, DO; Makhzoum, A (corresponding author), Botswana Int Univ Sci & Technol, Dept Biol Sci & Biotechnol, Palapye, Botswana.
EM nkwed@biust.ac.bw; bonolo.lotshwao@studentmail.biust.ac.bw;
   rantongg@biust.ac.bw; james.matshwele@studentmail.biust.ac.bw;
   kwapet@biust.ac.bw; masisik@biust.ac.bw; gaobotseg@biust.ac.bw;
   kathleen.hefferon@alumni.utoronto.ca; makhzouma@biust.ac.bw
OI Nkwe, David/0000-0001-6673-5980; Hefferon, Kathleen/0000-0003-3550-0366;
   Gaobotse, Goabaone/0000-0003-2174-2823
CR Akhtar N, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090333
   ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534
   Badadani M., 2012, ISRN CELL BIOL, DOI [10.5402/2012/927064, DOI 10.5402/2012/927064]
   Baxter AA, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.102
   Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1
   Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169
   Burger T, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2208-7
   Carbajo-Pescador S, 2013, BRIT J CANCER, V108, P442, DOI 10.1038/bjc.2012.563
   Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3
   Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200
   Chen Z, 2008, MED RES REV, V28, P185, DOI 10.1002/med.20101
   Das T, 2014, BIOCHEM PHARMACOL, V91, P31, DOI 10.1016/j.bcp.2014.06.022
   Dodd KM, 2015, ONCOGENE, V34, P2239, DOI 10.1038/onc.2014.164
   Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104
   El-Sayed MA, 2009, Z NATURFORSCH C, V64, P644
   Falkenberg KD, 2017, BBA-MOL CELL RES, V1864, P1349, DOI 10.1016/j.bbamcr.2017.05.003
   Fan YQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123175
   Fekry MI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36089-6
   Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999
   Fridlender M, 2015, FRONT PLANT SCI, V6, DOI 10.3389/fpls.2015.00799
   Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959
   Gao W, 2015, ANN RHEUM DIS, V74, P1275, DOI 10.1136/annrheumdis-2013-204105
   Gebhardt C, 2016, THEOR APPL GENET, V129, P2281, DOI 10.1007/s00122-016-2804-1
   Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199
   Gong GP, 2020, INT J BIOL MACROMOL, V149, P639, DOI 10.1016/j.ijbiomac.2020.01.251
   Guo JY, 2013, CELL, V155, P1216, DOI 10.1016/j.cell.2013.11.019
   Gurushankar K, 2021, J MOL STRUCT, V1230, DOI 10.1016/j.molstruc.2021.129925
   Guzman-Rodriguez JJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/735087
   Hail N, 2006, APOPTOSIS, V11, P889, DOI 10.1007/s10495-006-6712-8
   Jafari A, 2020, CANCER INVEST, V38, P310, DOI 10.1080/07357907.2020.1752227
   Johnson PF, 2005, J CELL SCI, V118, P2545, DOI 10.1242/jcs.02459
   Kuruppu AI, 2019, SAUDI PHARM J, V27, P565, DOI 10.1016/j.jsps.2019.02.004
   Lambert M, 2018, MOLECULES, V23, DOI 10.3390/molecules23061479
   Lay F.T., 2003, STRUCTURE FUNCTION F
   Lay FT, 2019, FASEB J, V33, P6470, DOI 10.1096/fj.201802540R
   Lazarevic T, 2017, EUR J MED CHEM, V142, P8, DOI 10.1016/j.ejmech.2017.04.007
   Lee EF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1568-3
   Lee IC, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030290
   Lee KR, 2004, J AGR FOOD CHEM, V52, P2832, DOI 10.1021/jf030526d
   Li J, 2008, FITOTERAPIA, V79, P548, DOI 10.1016/j.fitote.2008.06.010
   Li N, 2016, CHIN HERB MED, V8, P164, DOI 10.1016/S1674-6384(16)60026-6
   Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001
   Lim J, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.590344
   Lin H, 2018, PHYTOMEDICINE, V42, P190, DOI 10.1016/j.phymed.2018.03.046
   Liu G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166823
   Ma T, 2017, BIOCHEM PHARMACOL, V143, P90, DOI 10.1016/j.bcp.2017.07.018
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Makovec T, 2019, RADIOL ONCOL, V53, P148, DOI 10.2478/raon-2019-0018
   Malojirao VH, 2018, LIFE SCI, V199, P139, DOI 10.1016/j.lfs.2018.03.015
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Metibemu DS, 2019, EGYPTIAN J MED HUMAN, V20, DOI 10.1186/s43042-019-0035-0
   Mitra P, 2012, NUCLEIC ACIDS RES, V40, P5988, DOI 10.1093/nar/gks286
   Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725
   Mondal G, 2006, BIOCHEM J, V396, P243, DOI 10.1042/BJ20051914
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106
   Pottier C, 2020, CANCERS, V12, DOI 10.3390/cancers12030731
   Pucci B, 2000, NEOPLASIA, V2, P291, DOI 10.1038/sj.neo.7900101
   Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235
   Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439
   Regad T, 2015, CANCERS, V7, P1758, DOI 10.3390/cancers7030860
   Riedl S, 2011, BBA-BIOMEMBRANES, V1808, P2638, DOI 10.1016/j.bbamem.2011.07.026
   SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585
   Seca AML, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010263
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Sengupta P, 2018, REPROD BIOMED ONLINE, V36, P311, DOI 10.1016/j.rbmo.2017.11.007
   Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504
   Shi Y, 2014, CELL DEATH DIFFER, V21, P612, DOI 10.1038/cdd.2013.186
   SHOHAT B., 1967, CANCER CHEMOTHER REP, V51, P271
   Singh Bhuminder, 2016, F1000Res, V5, DOI 10.12688/f1000research.9025.1
   Sung HH, 2022, CLIN EXP HYPERTENS, V44, P146, DOI 10.1080/10641963.2021.2007943
   Tabana YM, 2016, MICROVASC RES, V107, P17, DOI 10.1016/j.mvr.2016.04.009
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tolomeo M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124308
   Trepel J, 2010, NAT REV CANCER, V10, P537, DOI 10.1038/nrc2887
   Wang HC, 2010, J AGR FOOD CHEM, V58, P11913, DOI 10.1021/jf1022065
   Wang HC, 2019, PHYTOMEDICINE, V53, P213, DOI 10.1016/j.phymed.2018.09.017
   Wen ZD, 2016, EUR J PHARMACOL, V771, P93, DOI 10.1016/j.ejphar.2015.12.020
   Xie MF, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200004
   Xu JA, 2017, REDOX BIOL, V12, P198, DOI 10.1016/j.redox.2017.02.017
   Yang KY, 2019, BIOORG CHEM, V92, DOI 10.1016/j.bioorg.2019.103186
   Ye ZN, 2019, MOLECULES, V24, DOI 10.3390/molecules24061146
   Zarubin T, 2005, CELL RES, V15, P11, DOI 10.1038/sj.cr.7290257
   Zhang LW, 2017, ONCOL REP, V37, P2994, DOI 10.3892/or.2017.5529
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 88
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD OCT
PY 2021
VL 13
IS 19
AR 4989
DI 10.3390/cancers13194989
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WH1XW
UT WOS:000707480800001
PM 34638473
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhang, H
   Hu, CAA
   Kovacs-Nolan, J
   Mine, Y
AF Zhang, Hua
   Hu, Chien-An A.
   Kovacs-Nolan, Jennifer
   Mine, Yoshinori
TI Bioactive dietary peptides and amino acids in inflammatory bowel disease
SO AMINO ACIDS
LA English
DT Article
DE Apoptosis; Autophagy; Dietary peptides; Amino acids; Inflammatory bowel
   disease; CasR
ID NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; EGG-YOLK PHOSVITIN; OXIDATIVE STRESS;
   CROHNS-DISEASE; EXTRACELLULAR CALCIUM; ANTIOXIDATIVE PROPERTIES;
   CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; GENE-EXPRESSION
AB Inflammatory bowel disease (IBD), most commonly ulcerative colitis (UC) and Crohn's disease (CD), is a chronic inflammation of the gastrointestinal tract. Patients affected with IBD experience symptoms including abdominal pain, persistent diarrhea, rectal bleeding, and weight loss. There is no cure for IBD; thus treatments typically focus on preventing complications, inducing and maintaining remission, and improving quality of life. During IBD, dysregulation of the intestinal immune system leads to increased production of pro-inflammatory cytokines, such as TNF-alpha and IL-6, and recruitment of activated immune cells to the intestine, causing tissue damage and perpetuating the inflammatory response. Recent biological therapies targeting specific inflammatory cytokines or pathways, in particular TNF-alpha, have shown promise, but not all patients respond to treatment, and some individuals become intolerant to treatment over time. Dietary peptides and amino acids (AAs) have been shown to modulate intestinal immune functions and influence inflammatory responses, and may be useful as alternative or ancillary treatments in IBD. This review focuses on dietary interventions for IBD treatment, in particular the role of dietary peptides and AAs in reducing inflammation, oxidative stress, and apoptosis in the gut, as well as recent advances in the cellular mechanisms responsible for their anti-inflammatory activity.
C1 [Zhang, Hua; Kovacs-Nolan, Jennifer; Mine, Yoshinori] Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada.
   [Hu, Chien-An A.] Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA.
RP Mine, Y (corresponding author), Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada.
EM ymine@uoguelph.ca
RI Zhang, hua/AAF-9354-2019
CR Adibi SA, 1997, GASTROENTEROLOGY, V113, P332, DOI 10.1016/S0016-5085(97)70112-4
   Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184
   Ajibade AA, 2012, IMMUNITY, V36, P43, DOI 10.1016/j.immuni.2011.12.010
   Bailey M, 2006, VET RES, V37, P443, DOI 10.1051/vetres:2006013
   Bassaganya-Riera J, 2006, CLIN NUTR, V25, P454, DOI 10.1016/j.clnu.2005.12.008
   Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5
   Baumgart DC, 2007, LANCET, V369, P1641, DOI 10.1016/S0140-6736(07)60751-X
   Beutheu S, 2013, CLIN NUTR, V32, P863, DOI 10.1016/j.clnu.2013.01.014
   Borm M, 2004, DRUG DISCOV TODAY, V1, P437
   Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086
   Brandtzaeg P, 2006, ADV EXP MED BIOL, V579, P149
   BREESE EJ, 1994, GASTROENTEROLOGY, V106, P1455, DOI 10.1016/0016-5085(94)90398-0
   Bresalier R S, 1999, Gastroenterology, V116, P1261, DOI 10.1016/S0016-5085(99)70033-8
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Casteel SW, 1996, ADVANCES IN SWINE IN BIOMEDICAL RESEARCH, VOLS 1 AND 2, P637
   Chakrabarty S, 2003, CANCER RES, V63, P67
   Chapkin RS, 2007, J NUTR, V137, p200S, DOI 10.1093/jn/137.1.200S
   Charerntantanakul Wasin, 2006, Animal Health Research Reviews, V7, P81, DOI 10.1017/S1466252307001235
   CHEN HM, 1995, J AGR FOOD CHEM, V43, P574, DOI 10.1021/jf00051a004
   Chen HM, 1998, J AGR FOOD CHEM, V46, P49, DOI 10.1021/jf970649w
   Cho JH, 2006, CAN J GASTROENTEROL, V20, P641, DOI 10.1155/2006/561643
   Conigrave AD, 2006, AM J PHYSIOL-GASTR L, V291, pG753, DOI 10.1152/ajpgi.00189.2006
   Daniel H, 2004, PFLUG ARCH EUR J PHY, V447, P610, DOI 10.1007/s00424-003-1101-4
   de Silva S, 2010, NAT REV GASTRO HEPAT, V7, P93, DOI 10.1038/nrgastro.2009.221
   DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749
   Disilvestro R.A., 2001, HDB NUTRACEUTICALS F, P127
   Elias RJ, 2008, CRIT REV FOOD SCI, V48, P430, DOI 10.1080/10408390701425615
   Fan HK, 2007, MOL IMMUNOL, V44, P3092, DOI 10.1016/j.molimm.2007.02.009
   Faure M, 2006, J NUTR, V136, P1558, DOI 10.1093/jn/136.6.1558
   Fillmann H, 2007, TOXICOLOGY, V236, P217, DOI 10.1016/j.tox.2007.04.012
   Fossum C, 1998, DOMEST ANIM ENDOCRIN, V15, P439, DOI 10.1016/S0739-7240(98)80001-5
   Fuss IJ, 1996, J IMMUNOL, V157, P1261
   Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3
   Gill HS, 2000, BRIT J NUTR, V84, pS111
   Grell M, 1996, J INFLAMM, V47, P8
   Hebert SC, 2004, CELL CALCIUM, V35, P239, DOI 10.1016/j.ceca.2003.10.015
   Hofer AM, 2003, NAT REV MOL CELL BIO, V4, P530, DOI 10.1038/nrm1154
   Hommes D, 2006, GASTROENTEROLOGY, V130, pA108
   Hou YC, 2013, EUR J NUTR, V52, P1089, DOI 10.1007/s00394-012-0416-3
   Inokuchi S, 2010, P NATL ACAD SCI USA, V107, P844, DOI 10.1073/pnas.0909781107
   Iskandar MM, 2013, BR J NUTR, V3, P1
   Itakura E, 2012, CELL, V151, P1256, DOI 10.1016/j.cell.2012.11.001
   Jobin C, 1999, J IMMUNOL, V162, P4447
   Johnson IT, 2001, P NUTR SOC, V60, P481, DOI 10.1079/PNS2001106
   Jurjus Abdo R., 2004, Journal of Pharmacological and Toxicological Methods, V50, P81, DOI 10.1016/j.vascn.2003.12.002
   Kajino-Sakamoto R, 2008, J IMMUNOL, V181, P1143, DOI 10.4049/jimmunol.181.2.1143
   Kanayama A, 2002, J BIOL CHEM, V277, P24049, DOI 10.1074/jbc.M110832200
   Katayama S, 2006, J AGR FOOD CHEM, V54, P773, DOI 10.1021/jf052280d
   Katayama S, 2007, J AGR FOOD CHEM, V55, P8458, DOI 10.1021/jf070866p
   Katayama S, 2007, J AGR FOOD CHEM, V55, P2829, DOI 10.1021/jf0628936
   Kim CJ, 2009, BBA-GEN SUBJECTS, V1790, P1161, DOI 10.1016/j.bbagen.2009.05.018
   Kim CJ, 2010, J NUTR BIOCHEM, V21, P468, DOI 10.1016/j.jnutbio.2009.01.019
   Kim JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004561
   Kovacs-Nolan J, 2014, J AGR FOOD CHEM, V62, P9499, DOI 10.1021/jf503257w
   Kovacs-Nolan J, 2012, BBA-GEN SUBJECTS, V1820, P1753, DOI 10.1016/j.bbagen.2012.07.007
   Kretzmann NA, 2008, INFLAMM BOWEL DIS, V14, P1504, DOI 10.1002/ibd.20543
   Li YW, 2013, J THEOR BIOL, V318, P29, DOI 10.1016/j.jtbi.2012.10.029
   LihBrody L, 1996, DIGEST DIS SCI, V41, P2078, DOI 10.1007/BF02093613
   Liu QH, 2009, NAT CELL BIOL, V11, P154, DOI 10.1038/ncb1823
   Lowenberg M, 2006, DRUGS, V66, P1431
   Macarthur M, 2004, AM J PHYSIOL-GASTR L, V286, pG515, DOI 10.1152/ajpgi.00475.2003
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Mizoguchi A, 2012, PROG MOL BIOL TRANSL, V105, P263, DOI 10.1016/B978-0-12-394596-9.00009-3
   Moffett JR, 2003, IMMUNOL CELL BIOL, V81, P247, DOI 10.1046/j.1440-1711.2003.t01-1-01177.x
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Ockenga J, 2005, EUR J CLIN NUTR, V59, P1302, DOI 10.1038/sj.ejcn.1602243
   Ohsu T, 2010, J BIOL CHEM, V285, P1016, DOI 10.1074/jbc.M109.029165
   Omori E, 2006, J BIOL CHEM, V281, P19610, DOI 10.1074/jbc.M603384200
   Othman M, 2008, CURR OPIN GASTROEN, V24, P11, DOI 10.1097/MOG.0b013e3282f2b0d7
   Oz HS, 2005, J NUTR BIOCHEM, V16, P297, DOI 10.1016/j.jnutbio.2004.09.007
   Pache I, 2009, SWISS MED WKLY, V139, P278, DOI smw-12549
   Pacheco II, 2008, AM J PHYSIOL-GASTR L, V295, pG748, DOI 10.1152/ajpgi.00560.2007
   Pan MH, 2010, FOOD FUNCT, V1, P15, DOI 10.1039/c0fo00103a
   Papa A, 2009, EUR REV MED PHARMACO, V13, P33
   Pena-Ramos EA, 2001, J DAIRY SCI, V84, P2577, DOI 10.3168/jds.S0022-0302(01)74711-X
   Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577
   Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315
   Reeds P, 1996, ADVANCES IN SWINE IN BIOMEDICAL RESEARCH, VOLS 1 AND 2, P709
   Ronchi VP, 2010, J PHYSIOL BIOCHEM, V66, P93, DOI 10.1007/s13105-010-0014-x
   ROYALL D, 1994, GUT, V35, P783, DOI 10.1136/gut.35.6.783
   Saito K, 2003, J AGR FOOD CHEM, V51, P3668, DOI 10.1021/jf021191n
   Sakiyama T, 2009, GASTROENTEROLOGY, V136, P924, DOI 10.1053/j.gastro.2008.12.002
   Sartor R B., 2007, IMMUNE MECH INFLAMMA, P35
   Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528
   Shimizu M, 2004, BIOFACTORS, V21, P43, DOI 10.1002/biof.552210109
   Sipos W, 2004, VET IMMUNOL IMMUNOP, V99, P63, DOI 10.1016/j.vetimm.2004.01.001
   Son DO, 2005, FEBS LETT, V579, P4671, DOI 10.1016/j.febslet.2005.07.038
   Son DO, 2008, CYTOKINE, V42, P265, DOI 10.1016/j.cyto.2008.02.011
   Son M, 1998, ADV EXP MED BIOL, V442, P291
   Suchner U, 2000, P NUTR SOC, V59, P553, DOI 10.1017/S0029665100000793
   Suetsuna K, 2000, J NUTR BIOCHEM, V11, P128, DOI 10.1016/S0955-2863(99)00083-2
   Sundaram U, 2007, AM J PHYSIOL-GASTR L, V292, pG467, DOI 10.1152/ajpgi.00503.2005
   TEAHON K, 1991, GASTROENTEROLOGY, V101, P84, DOI 10.1016/0016-5085(91)90463-U
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   van Deventer SJH, 1999, ANN RHEUM DIS, V58, P114
   VanDeventer SJH, 1997, GUT, V40, P443, DOI 10.1136/gut.40.4.443
   VANDULLEMEN HM, 1995, GASTROENTEROLOGY, V109, P129, DOI 10.1016/0016-5085(95)90277-5
   Velde AAT, 2006, INFLAMM BOWEL DIS, V12, P995, DOI 10.1097/01.mib.0000227817.54969.5e
   Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597
   Wang MH, 2006, J BIOL CHEM, V281, P8864, DOI 10.1074/jbc.M512865200
   Wang Y, 2011, AM J PHYSIOL-GASTR L, V300, pG528, DOI 10.1152/ajpgi.00387.2010
   Wang YY, 2006, NAT IMMUNOL, V7, P139, DOI 10.1038/ni1294
   Witherow DS, 2004, P NATL ACAD SCI USA, V101, P8603, DOI 10.1073/pnas.0402851101
   Wolf AM, 2004, CLIN IMMUNOL, V113, P47, DOI 10.1016/j.clim.2004.05.004
   Yamamoto T, 2013, CURR OPIN GASTROEN, V29, P216, DOI 10.1097/MOG.0b013e32835b9a40
   Young D, 2012, J NUTR, V142, P363, DOI 10.3945/jn.111.149104
NR 107
TC 48
Z9 48
U1 4
U2 51
PU SPRINGER WIEN
PI WIEN
PA SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA
SN 0939-4451
EI 1438-2199
J9 AMINO ACIDS
JI Amino Acids
PD OCT
PY 2015
VL 47
IS 10
BP 2127
EP 2141
DI 10.1007/s00726-014-1886-9
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CS1AA
UT WOS:000361792600007
PM 25501277
DA 2022-04-25
ER

PT J
AU Yang, X
   Zhao, HJ
   Wang, Y
   Liu, JJ
   Guo, MH
   Fei, DX
   Mu, MY
   Xing, MW
AF Yang, Xin
   Zhao, Hongjing
   Wang, Yu
   Liu, Juanjuan
   Guo, Menghao
   Fei, Dongxue
   Mu, Mengyao
   Xing, Mingwei
TI The Activation of Heat-Shock Protein After Copper(II) and/or
   Arsenic(III)-Induced Imbalance of Homeostasis, Inflammatory Response in
   Chicken Rectum
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Arsenic; Copper; Rectum; Elemental disorder; Oxidative stress;
   Heat-shock proteins
ID NF-KAPPA-B; INDUCED OXIDATIVE STRESS; ARSENIC EXPOSURE; NITRIC-OXIDE;
   APOPTOSIS; AUTOPHAGY; CADMIUM; TISSUES; ACCUMULATION; INDUCTION
AB Arsenic and copper, two toxic pollutants, are powerful inducers of oxidative stress. Exposure to copper and arsenic can cause intestinal injury in cockerel. This study was carried out to investigate the effects of these two pollutants on the gastrointestinal tract of cockerels. Experimental results showed that the activity of antioxidant enzymes (catalase and glutathione peroxidase) was inhibited and the ionic balance was destroyed after exposure to copper sulfate (300 mg/kg) and/or arsenic trioxide (30 mg/kg). However, the expression of pro-inflammatory cytokines (nuclear factor kappa-B, cyclooxygenase-2, tumor necrosis factor-alpha, and prostaglandin E2 synthases) increased markedly. Damages to the biofilm structure and inflammatory cell infiltration were simultaneously observed during histological examination. Heat-shock proteins were also expressed in large quantities after exposure to the poisons. Collectively, exposure to arsenite and/or Cu2+ can cause rectal damage in cockerels, inducing inflammation and an imbalance in immune system responses. Sometimes, exposure to both pollutants can produce even more toxic effects. Heat-shock proteins can protect the tissue from the exotoxins but the specific mechanisms require exploration. After oral ingestion of toxins, the rectum can still be damaged, necessitating attention to the safety of poultry breeding, human food safety, and environmental protection.
C1 [Yang, Xin; Zhao, Hongjing; Wang, Yu; Liu, Juanjuan; Guo, Menghao; Fei, Dongxue; Mu, Mengyao; Xing, Mingwei] Northeast Forestry Univ, Coll Wildlife & Protected Area, Harbin 150040, Heilongjiang, Peoples R China.
RP Xing, MW (corresponding author), Northeast Forestry Univ, Coll Wildlife & Protected Area, Harbin 150040, Heilongjiang, Peoples R China.
EM xingmingwei@nefu.edu.cn
OI Xing, Mingwei/0000-0003-1636-897X
CR Ahmad S, 2000, ARCH BIOCHEM BIOPHYS, V382, P195, DOI 10.1006/abbi.2000.2023
   Al-Waeli A, 2012, BRIT POULTRY SCI, V53, P817, DOI 10.1080/00071668.2012.751523
   Bisceglie F, 2016, METALLOMICS, V8, P1255, DOI 10.1039/c6mt00170j
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Brahman KD, 2014, CHEMOSPHERE, V100, P182, DOI 10.1016/j.chemosphere.2013.11.035
   Pereira TCB, 2016, J APPL TOXICOL, V36, P876, DOI 10.1002/jat.3303
   Burger J, 2013, ENVIRON RES, V122, P11, DOI 10.1016/j.envres.2013.01.003
   Cakic M, 2013, EXPERT OPIN DRUG DIS, V8, P1253, DOI 10.1517/17460441.2013.825245
   CERVANTES C, 1994, FEMS MICROBIOL REV, V15, P355, DOI 10.1111/j.1574-6976.1994.tb00145.x
   Chu BX, 2018, J INORG BIOCHEM, V182, P184, DOI 10.1016/j.jinorgbio.2018.02.015
   Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8
   Da SM, 2018, MEDIAT INFLAMM, V2018, P3421897
   Fage SW, 2014, CONTACT DERMATITIS, V71, P191, DOI 10.1111/cod.12273
   Garza-Lombo C, 2018, ANTIOXID REDOX SIGN, V28, P1669, DOI 10.1089/ars.2017.7272
   Georgopoulos PG, 2001, J TOXICOL ENV HEAL B, V4, P341, DOI 10.1080/109374001753146207
   Ghiselli A, 2000, FREE RADICAL BIO MED, V29, P1106, DOI 10.1016/S0891-5849(00)00394-4
   Gomez G, 2004, ARCH ENVIRON CON TOX, V47, P521, DOI 10.1007/s00244-004-0189-z
   Gong ZG, 2019, J INORG BIOCHEM, V192, P62, DOI 10.1016/j.jinorgbio.2018.12.008
   Guo Y, 2016, BIOL TRACE ELEM RES, V169, P134, DOI 10.1007/s12011-015-0389-1
   Gupta SC, 2010, LIFE SCI, V86, P377, DOI 10.1016/j.lfs.2009.12.015
   Ken CF, 2005, J AGR FOOD CHEM, V53, P1470, DOI 10.1021/jf048269f
   Kraemer LD, 2005, ENVIRON POLLUT, V138, P324, DOI 10.1016/j.envpol.2005.03.006
   Li SW, 2018, ECOTOX ENVIRON SAFE, V148, P125, DOI 10.1016/j.ecoenv.2017.10.018
   Lin CC, 2014, J TRACE ELEM MED BIO, V28, P18, DOI 10.1016/j.jtemb.2013.11.001
   Lin J, 2016, ONCOTARGET, V7, P83880, DOI 10.18632/oncotarget.13794
   Liu F, 2017, TOXICOLOGY, V383, P13, DOI 10.1016/j.tox.2017.03.016
   Liu LL, 2016, FOOD FUNCT, V7, P1329, DOI [10.1039/c5fo01338k, 10.1039/C5FO01338K]
   Liu Y, 2008, AQUAT TOXICOL, V89, P242, DOI 10.1016/j.aquatox.2008.07.009
   Livingstone DR, 2001, MAR POLLUT BULL, V42, P656, DOI 10.1016/S0025-326X(01)00060-1
   Lo JC, 2016, ENVIRON SCI TECHNOL, V50, P13299, DOI 10.1021/acs.est.6b03602
   Lund H, 2019, MOL IMMUNOL, V106, P99, DOI 10.1016/j.molimm.2018.12.018
   Ma JG, 2015, ENVIRON TOXICOL, V30, P422, DOI 10.1002/tox.21918
   Nagy G, 2007, IMMUNOL LETT, V111, P1, DOI 10.1016/j.imlet.2007.04.013
   Naujokas MF, 2013, ENVIRON HEALTH PERSP, V121, P295, DOI 10.1289/ehp.1205875
   Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724
   Olsen RE, 2005, AQUACULTURE, V250, P480, DOI 10.1016/j.aquaculture.2005.03.014
   Pardee AB, 1966, J LEYDEN WEBB AM SCI, VII & III
   PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8
   Rao SVR, 2013, TROP ANIM HEALTH PRO, V45, P1447, DOI 10.1007/s11250-013-0384-5
   ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6
   Shao YZ, 2018, ENVIRON SCI POLLUT R, V25, P7719, DOI 10.1007/s11356-017-1042-7
   Sun L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038845
   Sun X, 2018, J INORG BIOCHEM, V178, P54, DOI 10.1016/j.jinorgbio.2017.10.006
   Sun ZP, 2018, METALLOMICS, V10, P759, DOI 10.1039/c8mt00039e
   Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X
   Torres MA, 2008, ECOTOX ENVIRON SAFE, V71, P1, DOI 10.1016/j.ecoenv.2008.05.009
   Upadhyay MK, 2019, FOOD CHEM, V276, P608, DOI 10.1016/j.foodchem.2018.10.069
   Wang F, 2016, INT J BIOL MACROMOL, V86, P764, DOI 10.1016/j.ijbiomac.2016.02.013
   Wang YW, 2017, ENVIRON SCI POLLUT R, V24, P9036, DOI 10.1007/s11356-015-5907-3
   Wang YR, 2018, METALLOMICS, V10, DOI 10.1039/c8mt00269j
   Wang Y, 2018, CHEMOSPHERE, V206, P597, DOI 10.1016/j.chemosphere.2018.05.013
   Wang Y, 2018, INT IMMUNOPHARMACOL, V60, P64, DOI 10.1016/j.intimp.2018.04.038
   Yavuz Y, 1999, RES EXP MED, V199, P101, DOI 10.1007/s004330050137
   Yin Y, 2018, CLIN EXP DERMATOL
   Yokozeki H, 2003, CLIN EXP IMMUNOL, V132, P385, DOI 10.1046/j.1365-2249.2003.02164.x
   YOUNG RA, 1990, ANNU REV IMMUNOL, V8, P401, DOI 10.1146/annurev.iy.08.040190.002153
   Zhang ZW, 2017, AQUAT TOXICOL, V192, P171, DOI 10.1016/j.aquatox.2017.09.022
   Zhao G, 2018, NANOMATERIALS BASEL, V9
   Zhao H, 2019, ECOTOX ENV SAFE
   Zhao HJ, 2018, CHEMOSPHERE, V210, P76, DOI 10.1016/j.chemosphere.2018.06.165
   Zhao HJ, 2017, ONCOTARGET, V8, P40327, DOI 10.18632/oncotarget.16960
   Zhao PP, 2016, BIOL TRACE ELEM RES, V170, P224, DOI 10.1007/s12011-015-0462-9
NR 62
TC 4
Z9 4
U1 2
U2 14
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0163-4984
EI 1559-0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD JUN
PY 2020
VL 195
IS 2
BP 613
EP 623
DI 10.1007/s12011-019-01871-8
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA LG2QR
UT WOS:000527952400026
PM 31473897
DA 2022-04-25
ER

PT J
AU Abbruzzese, C
   Matteoni, S
   Persico, M
   Ascione, B
   Schenone, S
   Musumeci, F
   Amato, R
   Perrotti, N
   Matarrese, P
   Paggi, MG
AF Abbruzzese, Claudia
   Matteoni, Silvia
   Persico, Michele
   Ascione, Barbara
   Schenone, Silvia
   Musumeci, Francesca
   Amato, Rosario
   Perrotti, Nicola
   Matarrese, Paola
   Paggi, Marco G.
TI The small molecule SI113 hinders epithelial-to-mesenchymal transition
   and subverts cytoskeletal organization in human cancer cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE activity-based protein profiling (ABPP); cytoskeleton;
   epithelial-to-mesenchymal transition; kinase inhibitors; SI113
ID IN-VITRO; SGK1; ACTIVATION; DISCOVERY; PROTEINS; GROWTH; FAK
AB The small molecule SI113 is an inhibitor of the kinase activity of SGK1, a key biological regulator acting on the PI3K/mTOR signal transduction pathway. Several studies demonstrate that this compound is able to strongly restrain cancer growth in vitro and in vivo, alone or in associative antineoplastic treatments, being able to elicit an autophagic response, either cytotoxic or cytoprotective. To elucidate more exhaustively the molecular mechanisms targeted by SI113, we performed activity-based protein profiling (ABPP) proteomic analysis using a kinase enrichment procedure. This technique allowed the identification via mass spectrometry of novel targets of this compound, most of them involved in functions concerning cell motility and cytoskeletal architecture. Using a glioblastoma multiforme, hepatocarcinoma and colorectal carcinoma cell line, we recognized an inhibitory effect of SI113 on cell migration, invading, and epithelial-to-mesenchymal transition. In addition, these cancer cells, when exposed to this compound, showed a remarkable subversion of the cytoskeletal architecture characterized by F-actin destabilization, phospho-FAK delocalization, and tubulin depolimerization. These results were definitely concordant in attributing to SI113 a key role in hindering cancer cell malignancy and, due to its negligible in vivo toxicity, can sustain performing a Phase I clinical trial to employ this drug in associative cancer therapy.
C1 [Abbruzzese, Claudia; Matteoni, Silvia; Persico, Michele; Paggi, Marco G.] IRCCS Regina Elena Natl Canc Inst, Prote Unit, Div Cellular Networks & Mol Therapeut Targets, Rome, Italy.
   [Ascione, Barbara; Matarrese, Paola] Ist Super Sanita, Oncol Unit, Ctr Gender Specif Med, Viale Regina Elena 299, I-00162 Rome, Italy.
   [Schenone, Silvia; Musumeci, Francesca] Univ Genoa, Dept Pharm, Genoa, Italy.
   [Amato, Rosario; Perrotti, Nicola] Magna Graecia Univ Catanzaro, Dept Sci Salute, Catanzaro, Italy.
RP Matarrese, P (corresponding author), Ist Super Sanita, Oncol Unit, Ctr Gender Specif Med, Viale Regina Elena 299, I-00162 Rome, Italy.; Paggi, MG (corresponding author), IRCCS Regina Elena Natl Canc Inst, Via Elio Chianesi 53, I-00144 Rome, Italy.
EM paola.matarrese@iss.it; marco.paggi@ifo.gov.it
RI Matteoni, Silvia/U-7578-2017; Abbruzzese, Claudia/U-7576-2017
OI Matteoni, Silvia/0000-0001-6926-6593; Abbruzzese,
   Claudia/0000-0003-3301-9421; Persico, Michele/0000-0001-9030-3707;
   MUSUMECI, Francesca Michela/0000-0002-7228-0086; matarrese,
   paola/0000-0001-5477-3752
FU Associazione Italiana per la Ricerca sul CancroFondazione AIRC per la
   ricerca sul cancro [IG 16971, IG 18526]; Peretti Foundation; Arcobaleno
   ONLUS; Italian Association for Cancer ResearchFondazione AIRC per la
   ricerca sul cancro; Ricerca Corrente IRE
FX Associazione Italiana per la Ricerca sul Cancro, Grant/Award Numbers: IG
   16971, IG 18526; Peretti Foundation; Arcobaleno ONLUS; Ricerca Corrente
   IRE; The Italian Association for Cancer Research
CR Abbruzzese C, 2017, ONCOTARGET, V8, P110743, DOI 10.18632/oncotarget.22500
   Abbruzzese C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-4
   Amato R, 2013, ONCOGENE, V32, P4572, DOI 10.1038/onc.2012.470
   Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5
   Andres-Mateos E, 2013, EMBO MOL MED, V5, P80, DOI 10.1002/emmm.201201443
   Barglow KT, 2007, NAT METHODS, V4, P822, DOI 10.1038/NMETH1092
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   BRATTAIN MG, 1981, CANCER RES, V41, P1751
   Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004
   Conza D, 2017, J CELL PHYSIOL, V232, P3735, DOI 10.1002/jcp.25850
   D'Antona L, 2015, CELL PHYSIOL BIOCHEM, V35, P2006, DOI 10.1159/000374008
   Dattilo V, 2017, SCI REP-UK, V7, DOI 10.1038/srep45361
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   Dogterom M, 2019, NAT REV MOL CELL BIO, V20, P38, DOI 10.1038/s41580-018-0067-1
   KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960
   Kuo JC, 2013, J CELL MOL MED, V17, P704, DOI 10.1111/jcmm.12054
   Lang F, 2013, EXPERT OPIN INV DRUG, V22, P701, DOI 10.1517/13543784.2013.778971
   Leonetti C, 2008, CLIN CANCER RES, V14, P7284, DOI 10.1158/1078-0432.CCR-08-0941
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liu WW, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0743-1
   Liu YZ, 2014, PROTEOMICS, V14, P399, DOI 10.1002/pmic.201300261
   MALORNI W, 1994, CELL BIOL TOXICOL, V10, P207, DOI 10.1007/BF00756761
   Matarrese P, 2016, ONCOTARGET, V7, P50972, DOI 10.18632/oncotarget.8646
   Matarrese P, 2014, AUTOPHAGY, V10, P750, DOI 10.4161/auto.27959
   Matarrese P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-207
   Matteoni S, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1212-1
   Nagano Makoto, 2012, Int J Cell Biol, V2012, P310616, DOI 10.1155/2012/310616
   Ortuso F, 2014, J CHEM INF MODEL, V54, P1828, DOI 10.1021/ci500235f
   Riemann D, 2005, BIOCHEM BIOPH RES CO, V331, P1408, DOI 10.1016/j.bbrc.2005.04.061
   Roberts DJ, 2015, CELL DEATH DIFFER, V22, P248, DOI 10.1038/cdd.2014.173
   Schaller MD, 2010, J CELL SCI, V123, P1007, DOI 10.1242/jcs.045112
   Spagnuolo R, 2018, INFLAMM BOWEL DIS, V24, P1967, DOI 10.1093/ibd/izy158
   Stehbens SJ, 2014, NAT CELL BIOL, V16, P558, DOI 10.1038/ncb2975
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   Talarico C, 2016, ONCOTARGET, V7, DOI 10.18632/oncotarget.7520
   Talarico C, 2015, ONCOTARGET, V6, P37520, DOI 10.18632/oncotarget.5527
   Xiao YS, 2013, ANAL CHEM, V85, P3198, DOI 10.1021/ac303383c
NR 37
TC 7
Z9 7
U1 0
U2 34
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2019
VL 234
IS 12
BP 22529
EP 22542
DI 10.1002/jcp.28816
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA IV6KF
UT WOS:000484376600093
PM 31099037
DA 2022-04-25
ER

PT J
AU Yao, QH
   Zhang, XC
   Fu, T
   Gu, JZ
   Wang, L
   Wang, Y
   Lai, YB
   Wang, YQ
   Guo, Y
AF Yao, Qing-Hua
   Zhang, Xiao-Chen
   Fu, Ting
   Gu, Jian-Zhong
   Wang, Lu
   Wang, Yun
   Lai, Yue-Biao
   Wang, Yu-Qi
   Guo, Yong
TI .-3 polyunsaturated fatty acids inhibit the proliferation of the lung
   adenocarcinoma cell line A549 in vitro
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE -3 polyunsaturated fatty acids; eicosapentaenoic acid; docosahexaenoic
   acid; lung cancer
ID NORMAL COLONIC-MUCOSA; BREAST-CANCER CELLS; FISH-OIL; INCREASES
   APOPTOSIS; PROSTATE-CANCER; OMEGA-3; OMEGA-3-FATTY-ACIDS; MICE;
   CONSUMPTION; GROWTH
AB -3 polyunsaturated fatty acids (n-3 PUFA), in particular the marine-derived forms eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been demonstrated to affect cancer cell replication, the cell cycle and cell death. Epidemiological studies have also suggested diets rich in n-3 PUFA were inversely correlated with the development of cancer. In the present study, we explored the effects of DHA and EPA on the proliferation activity and apoptosis of the human lung adenocarcinoma cell line A549. A methyl thiazolyl tetrazolium (MTT) assay was used to detect cell proliferation, apoptosis was detected by flow cytometry and morphological analysis was determined by fluorescence microscopy and transmission electron microscopy. A549 cells were treated with different doses of DHA (40, 45, 50 and 55 g/ml) or EPA (45, 50, 55 and 60 g/ml) for 24, 48 and 72 h. The results demonstrated that DHA and EPA significantly suppressed the proliferation of A549 cells and induced apoptosis of A549 cells in a dose- and time-dependent manner. The apoptotic phenomenon was also confirmed by fluorescence microscopy and transmission electron microscopy. Furthermore, compared with the control, the formation of autophagosomes was clearly enhanced in DHA- or EPA-treated cells. In conclusion, DHA and EPA inhibited the proliferation of A549 cells and induced cell apoptosis and autophagy, which may provide new safe and effective options for the treatment of lung cancer in the future.
C1 [Yao, Qing-Hua; Gu, Jian-Zhong; Guo, Yong] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Oncol, Hangzhou 310006, Zhejiang, Peoples R China.
   [Zhang, Xiao-Chen] Zhejiang Univ, Dept Oncol, Affiliated Hosp 1, Hangzhou 310003, Zhejiang, Peoples R China.
   [Fu, Ting; Wang, Lu; Wang, Yun; Lai, Yue-Biao; Wang, Yu-Qi] Zhejiang Chinese Med Univ, Dept Tradit Chinese Med, Hangzhou 310053, Zhejiang, Peoples R China.
RP Guo, Y (corresponding author), Zhejiang Chinese Med Univ, Affiliated Hosp 1, Dept Oncol, 54 Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM guoyong1047@163.com
FU Zhejiang Provincial Natural Science Foundation of ChinaNatural Science
   Foundation of Zhejiang Province [64212006]
FX This study was supported by a grant from the Zhejiang Provincial Natural
   Science Foundation of China (Grant no. 64212006). We would like to thank
   the Zhejiang Provincial Key Laboratory of Gastroenterology for providing
   the experimental facilities, instruments and guidance.
CR Akinsete JA, 2012, CARCINOGENESIS, V33, P140, DOI 10.1093/carcin/bgr238
   Algamas-Dimantov A, 2012, J LIPID RES, V53, P1056, DOI 10.1194/jlr.M021949
   Andrews J, 2011, CANCER J, V17, P104, DOI 10.1097/PPO.0b013e318213f3cf
   Apte SA, 2013, NUTR CANCER, V65, P556, DOI 10.1080/01635581.2013.775316
   Bathen TF, 2008, ANTICANCER RES, V28, P3717
   Blanckaert V, 2010, INT J ONCOL, V36, P737, DOI 10.3892/ijo_00000549
   Calviello G, 1999, LIPIDS, V34, P599, DOI 10.1007/s11745-999-0404-6
   Cao W, 2012, PLOS ONE, V7
   Cerchietti LCA, 2007, NUTR CANCER, V59, P14, DOI 10.1080/01635580701365068
   Chatterjee S, 2012, BIOINFORMATION, V8, P1249, DOI 10.6026/97320630081249
   Courtney ED, 2007, INT J COLORECTAL DIS, V22, P765, DOI 10.1007/s00384-006-0240-4
   Fukui M, 2013, J CELL BIOCHEM, V114, P192, DOI 10.1002/jcb.24354
   Gravaghi C, 2011, J NUTR BIOCHEM, V22, P360, DOI 10.1016/j.jnutbio.2010.03.003
   Gu ZN, 2013, CARCINOGENESIS, V34, P1968, DOI 10.1093/carcin/bgt147
   Hawcroft G, 2012, BRIT J PHARMACOL, V166, P1724, DOI 10.1111/j.1476-5381.2012.01882.x
   Hull MA, 2011, BEST PRACT RES CL GA, V25, P547, DOI 10.1016/j.bpg.2011.08.001
   Jude S, 2007, BRIT J NUTR, V98, P1143, DOI 10.1017/S0007114507798914
   Karapanagiotidis IT, 2007, LIPIDS, V42, P547, DOI 10.1007/s11745-007-3057-1
   Kroenke CH, 2013, JNCI-J NATL CANCER I, V105, P616, DOI 10.1093/jnci/djt027
   Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198
   Mannini A, 2009, BRIT J NUTR, V101, P688, DOI 10.1017/S0007114508043791
   Mernitz H, 2009, NUTR CANCER, V61, P663, DOI 10.1080/01635580902825589
   Murphy RA, 2012, CURR OPIN CLIN NUTR, V15, P246, DOI 10.1097/MCO.0b013e328351c32f
   Rovito D, 2013, J CELL PHYSIOL, V228, P1314, DOI 10.1002/jcp.24288
   Serini S, 2011, CURR MED CHEM, V18, P4065, DOI 10.2174/092986711796957310
   Serini S, 2012, CARCINOGENESIS, V33, P164, DOI 10.1093/carcin/bgr240
   Shen XJ, 2012, BRIT J NUTR, V108, P1550, DOI 10.1017/S0007114512003546
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Signori C, 2011, CANCER RES, V71, P6091, DOI 10.1158/0008-5472.CAN-11-0977
   Siriwardhana N, 2012, J NUTR BIOCHEM, V23, P1661, DOI 10.1016/j.jnutbio.2011.11.009
   Sun HG, 2011, CARCINOGENESIS, V32, P1518, DOI 10.1093/carcin/bgr132
   Takezaki T, 2001, BRIT J CANCER, V84, P1199, DOI 10.1054/bjoc.2001.1722
   Veierod MB, 1997, EUR J CANCER PREV, V6, P540, DOI 10.1097/00008469-199712000-00009
   Wang L., 2011, PLOS ONE, V6
   Yam D, 2001, CANCER CHEMOTH PHARM, V47, P34, DOI 10.1007/s002800000205
   Yee LD, 2005, J NUTR, V135, P983, DOI 10.1093/jn/135.5.983
   Zajdel A, 2013, ACTA POL PHARM, V70, P365
   Zhang JJ, 2000, INT J EPIDEMIOL, V29, P615, DOI 10.1093/ije/29.4.615
NR 38
TC 39
Z9 47
U1 1
U2 15
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD FEB
PY 2014
VL 9
IS 2
BP 401
EP 406
DI 10.3892/mmr.2013.1829
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AC7FU
UT WOS:000332694100003
PM 24276408
OA Bronze
DA 2022-04-25
ER

PT J
AU Zhao, LL
   Wang, XB
   Yu, Y
   Deng, L
   Chen, L
   Peng, XP
   Jiao, CC
   Gao, GL
   Tan, X
   Pan, WJ
   Ge, X
   Wang, P
AF Zhao, Linlin
   Wang, Xinbo
   Yu, Yue
   Deng, Lu
   Chen, Lei
   Peng, Xiaoping
   Jiao, Chenchen
   Gao, Guoli
   Tan, Xiao
   Pan, Weijuan
   Ge, Xin
   Wang, Ping
TI OTUB1 protein suppresses mTOR complex 1 (mTORC1) activity by
   deubiquitinating the mTORC1 inhibitor DEPTOR
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BETA-TRCP; CELL-PROLIFERATION; SIGNALING PATHWAYS; COLORECTAL-CANCER;
   UBIQUITIN CODE; POOR-PROGNOSIS; ER-ALPHA; ENZYMES; DEGRADATION; GROWTH
AB Mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) integrates various environmental signals to regulate cell growth and metabolism. DEPTOR, also termed DEPDC6, is an endogenous inhibitor of mTORC1 and mTORC2 activities. The abundance of DEPTOR centrally orchestrates the mTOR signaling network. However, the mechanisms by which DEPTOR stability is regulated are still elusive. Here, we report that OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) specifically deubiquitinates DEPTOR in a deubiquitination assay. We found that OTUB1 directly interacted with DEPTOR via its N-terminal domain, deubiquitinated DEPTOR, and there by stabilized DEPTOR in a Cys-91-independent but Asp-88-dependent manner, suggesting that OTUB1 targets DEPTOR for deubiquitination via a deubiquitinase activity-independent non-canonical mechanism. The interaction between OTUB1 and DEPTOR was enhanced when the cells were treated with amino acids. Moreover, OTUB1 suppressed amino acid-induced activation of mTORC1 in a DEPTOR-dependent manner and thereby ultimately controlled cellular autophagy, cell proliferation, and size. Our findings reveal a mechanism that stabilizes the mTORC1 inhibitor DEPTOR via OTUB1's deubiquitinase activity. Our insights may inform research into various mTOR activity-related diseases, such as cancer, and may contribute to the identification of new diagnostic markers and therapeutic strategies for cancer treatments.
C1 [Zhao, Linlin; Wang, Xinbo; Yu, Yue; Pan, Weijuan] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
   [Zhao, Linlin; Wang, Xinbo; Yu, Yue; Pan, Weijuan] East China Normal Univ, Sch Life Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
   [Deng, Lu; Chen, Lei; Peng, Xiaoping; Jiao, Chenchen; Tan, Xiao; Wang, Ping] Tongji Univ, Sch Life Sci & Technol, Sch Med, Dept Cent Lab,Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
   [Ge, Xin] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China.
   [Gao, Guoli] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China.
RP Wang, P (corresponding author), Tongji Univ, Sch Life Sci & Technol, Sch Med, Dept Cent Lab,Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.; Ge, X (corresponding author), Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Clin Lab Med, Shanghai 200072, Peoples R China.
EM xin.ge@tongji.edu.cn; wangp@tongji.edu.cn
FU National Key Research and Development Program of China [2016YFC0902102];
   National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81625019, 91440104, 91519322, 81402417];
   Science Technology Commission of Shanghai MunicipalityScience &
   Technology Commission of Shanghai Municipality (STCSM) [16JC1404500];
   Fundamental Research Funds for the Central UniversitiesFundamental
   Research Funds for the Central Universities [1501219106, 1500219121,
   1500219133]
FX This work was supported by National Key Research and Development Program
   of China Grant 2016YFC0902102; National Natural Science Foundation of
   China Grants 81625019, 91440104, 91519322, and 81402417; Science
   Technology Commission of Shanghai Municipality Grant 16JC1404500; and
   Fundamental Research Funds for the Central Universities Grants
   1501219106, 1500219121, and 1500219133. The authors declare that they
   have no conflicts of interest with the contents of this article.
CR Chen L, 2016, ONCOL REP, V35, P1049, DOI 10.3892/or.2015.4442
   Deng L, 2015, MOL CELL, V58, P804, DOI 10.1016/j.molcel.2015.03.033
   Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809
   Dibble CC, 2013, NAT CELL BIOL, V15, P555, DOI 10.1038/ncb2763
   Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009
   Duan SS, 2011, MOL CELL, V44, P317, DOI 10.1016/j.molcel.2011.09.005
   Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030
   Goncharov T, 2013, EMBO J, V32, P1103, DOI 10.1038/emboj.2013.62
   Herhaus L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3519
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Iglesias-Gato D, 2015, MOL CANCER, V14, DOI 10.1186/s12943-014-0280-2
   Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jin GX, 2015, MOL CELL, V58, P989, DOI 10.1016/j.molcel.2015.05.010
   Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200
   Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107
   Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328
   Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731
   Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017
   Li S, 2010, J BIOL CHEM, V285, P4291, DOI 10.1074/jbc.M109.074971
   Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007
   Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440
   Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47
   Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024
   Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297
   Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007
   Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849
   Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046
   Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009
   Rajalingam K, 2016, CELL, V164, DOI 10.1016/j.cell.2016.02.019
   Ramanathan HN, 2012, CRIT REV BIOCHEM MOL, V47, P17, DOI 10.3109/10409238.2011.620943
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Schulman BA, 2009, NAT REV MOL CELL BIO, V10, P319, DOI 10.1038/nrm2673
   Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026
   Soares L, 2004, NAT IMMUNOL, V5, P45, DOI 10.1038/ni1017
   Song WJ, 2018, GYNECOL OBSTET INVES, V83, P124, DOI 10.1159/000464351
   Stanisic V, 2009, J BIOL CHEM, V284, P16135, DOI 10.1074/jbc.M109.007484
   Sun XX, 2012, EMBO J, V31, P576, DOI 10.1038/emboj.2011.434
   Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798
   Wang T, 2009, J MOL BIOL, V386, P1011, DOI 10.1016/j.jmb.2008.12.085
   Wang YQ, 2016, ONCOTARGET, V7, P36681, DOI 10.18632/oncotarget.9160
   Wiener R, 2013, NAT STRUCT MOL BIOL, V20, P1033, DOI 10.1038/nsmb.2655
   Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8
   Xue JF, 2014, J CLIN INVEST, V124, P564, DOI 10.1172/JCI71104
   Yang Z, 2012, OBES REV, V13, P58, DOI 10.1111/j.1467-789X.2012.01038.x
   Yuan L, 2017, AM J CANCER RES, V7, P159
   Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029
   Zhou Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-258
NR 49
TC 33
Z9 36
U1 6
U2 19
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 30
PY 2018
VL 293
IS 13
BP 4883
EP 4892
DI 10.1074/jbc.M117.809533
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA GB1YT
UT WOS:000428848300027
PM 29382726
OA Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Zhang, M
   Wang, R
   Tian, J
   Song, MQ
   Zhao, R
   Liu, KD
   Zhu, F
   Shim, JH
   Dong, ZG
   Lee, MH
AF Zhang, Man
   Wang, Rui
   Tian, Jie
   Song, Mengqiu
   Zhao, Ran
   Liu, Kangdong
   Zhu, Feng
   Shim, Jung-Hyun
   Dong, Zigang
   Lee, Mee-Hyun
TI Targeting LIMK1 with luteolin inhibits the growth of lung cancer in
   vitro and in vivo
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE LIMK1; luteolin; non&#8208; small cell lung cancer
ID COLORECTAL-CANCER; SIGNALING PATHWAYS; CELL-MIGRATION; APOPTOSIS;
   KINASE; MODELS; XENOGRAFTS; ACTIVATION
AB Lung cancer is the leading cause of cancer-related deaths. LIM domain kinase (LIMK) 1 is a member of serine/threonine kinase family and highly expressed in various cancers. Luteolin, a polyphenolic plant flavonoid, has been reported to suppress tumour proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. However, the mechanism of luteolin on suppressing lung cancer growth is still unclear. We found that luteolin targeted LIMK1 from the in silico screening and significantly inhibited the LIMK1 kinase activity, which was confirmed with pull-down binding assay and computational docking models. Treatment with luteolin inhibited lung cancer cells anchorage-independent colony growth and induced apoptosis and cell cycle arrest at G1 phase. Luteolin also decreased the expression of cyclin D1 and increased the levels of cleaved caspase-3 by down-regulating LIMK1 signalling related targets, including p-LIMK and p-cofilin. Furthermore, luteolin suppressed the lung cancer patient-derived xenograft tumour growth by decreasing Ki-67, p-LIMK and p-cofilin expression in vivo. Taken together, these results provide insight into the mechanism that underlies the anticancer effects of luteolin on lung cancer, which involved in down-regulation of LIMK1 and its interaction with cofilin. It also provides valuable evidence for translation towards lung cancer clinical trials with luteolin.
C1 [Zhang, Man; Wang, Rui; Tian, Jie; Song, Mengqiu; Zhao, Ran; Liu, Kangdong; Dong, Zigang; Lee, Mee-Hyun] China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.
   [Song, Mengqiu; Zhao, Ran; Liu, Kangdong; Dong, Zigang; Lee, Mee-Hyun] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.
   [Zhu, Feng] Guilin Med Univ, Canc Res Inst, Affiliated Hosp, Guilin, Peoples R China.
   [Shim, Jung-Hyun] Mokpo Natl Univ, Dept Pharm, Coll Pharm, Muan, South Korea.
   [Lee, Mee-Hyun] Dongshin Univ, Coll Korean Med, Naju, South Korea.
   [Zhang, Man] Zhengzhou Univ, Henan Prov Key Lab Childrens Genet & Metab Dis, Childrens Hosp, Zhengzhou 450018, Henan, Peoples R China.
RP Lee, MH (corresponding author), China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.; Dong, ZG (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.
EM zgdong@hci-cn.org; mhyun_lee@hanmail.net
OI Lee, Mee-Hyun/0000-0002-1216-0218
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [NSFC81972839]
FX This work was supported by grant funding from the National Natural
   Science Foundation of China NSFC81972839, China.
CR Ahmed S, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2019.152883
   Aneknan P, 2014, ASIAN PAC J CANCER P, V15, P5071, DOI 10.7314/APJCP.2014.15.12.5071
   Byun S, 2010, CANCER RES, V70, P2415, DOI 10.1158/0008-5472.CAN-09-4093
   Charles MD, 2015, J MED CHEM, V58, P8309, DOI 10.1021/acs.jmedchem.5b01242
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Ham S, 2014, ONCOL REP, V31, P2683, DOI 10.3892/or.2014.3157
   Imran M, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108612
   Jiang ZQ, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020447
   Kang KA, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0238-y
   Krifa M, 2014, NUTR CANCER, V66, P1220, DOI 10.1080/01635581.2014.951729
   Kwon Y, 2017, EXP GERONTOL, V95, P39, DOI 10.1016/j.exger.2017.05.014
   Lee MH, 2019, ARCH PHARM RES, V42, P481, DOI 10.1007/s12272-019-01153-w
   Li R, 2013, CLIN EXP METASTAS, V30, P483, DOI 10.1007/s10585-012-9553-6
   Ma L, 2015, MOL MED REP, V12, P4196, DOI 10.3892/mmr.2015.3956
   Mardilovich K, 2015, ONCOTARGET, V6, P38469, DOI 10.18632/oncotarget.6288
   Mardilovich K, 2015, MOL CANCER THER, V14, P246, DOI 10.1158/1535-7163.MCT-14-0447
   Nabavi SF, 2015, BRAIN RES BULL, V119, P1, DOI 10.1016/j.brainresbull.2015.09.002
   Nunes M, 2015, CANCER RES, V75, P1560, DOI 10.1158/0008-5472.CAN-14-1590
   Ohashi K, 2014, MOL BIOL CELL, V25, P828, DOI 10.1091/mbc.E13-09-0540
   Pandurangan AK, 2014, ASIAN PAC J CANCER P, V15, P5501, DOI 10.7314/APJCP.2014.15.14.5501
   Prunier C, 2016, CANCER RES, V76, P3541, DOI 10.1158/0008-5472.CAN-15-1864
   Qi L, 2020, CANCER LETT, V493, P197, DOI 10.1016/j.canlet.2020.08.035
   Sari-Hassoun M, 2016, BIOCHEM PHARMACOL, V102, P45, DOI 10.1016/j.bcp.2015.12.013
   Schr?dinger, 2016, SCHROD SUIT 2016
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song Huapei, 2018, Front Physiol, V9, P1090, DOI 10.3389/fphys.2018.01090
   Tentler JJ, 2012, NAT REV CLIN ONCOL, V9, P338, DOI 10.1038/nrclinonc.2012.61
   van Rheenen J, 2009, J CELL SCI, V122, P305, DOI 10.1242/jcs.031146
   Wu H, 2015, TECHNOL CANCER RES T, V14, P747, DOI 10.7785/tcrt.2012.500434
   Yang MY, 2014, CHEM-BIOL INTERACT, V213, P60, DOI 10.1016/j.cbi.2014.02.002
   Yao X, 2019, FOOD FUNCT, V10, P703, DOI 10.1039/c8fo02013b
   You YJ, 2019, ONCOTARGETS THER, V12, P2383, DOI 10.2147/OTT.S191158
   Zho YJ, 2013, ONCOL REP, V29, P605, DOI 10.3892/or.2012.2168
   Zhu X, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01044
   Zuo Q, 2018, J CELL BIOCHEM, V119, P9573, DOI 10.1002/jcb.27275
NR 35
TC 2
Z9 2
U1 6
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JUN
PY 2021
VL 25
IS 12
BP 5560
EP 5571
DI 10.1111/jcmm.16568
EA MAY 2021
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA SN7XS
UT WOS:000649700700001
PM 33982869
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Hu, XJ
   Li, XJ
   Yin, M
   Li, P
   Huang, P
   Wang, LH
   Jiang, YG
   Wang, H
   Chen, N
   Fan, CH
   Song, HY
AF Hu, Xingjie
   Li, Xiaojiao
   Yin, Min
   Li, Ping
   Huang, Ping
   Wang, Lihua
   Jiang, Yiguo
   Wang, Hui
   Chen, Nan
   Fan, Chunhai
   Song, Haiyun
TI Nanodiamonds Mediate Oral Delivery of Proteins for Stem Cell Activation
   and Intestinal Remodeling in Drosophila
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE nanodiamonds; protein delivery; oral delivery; stem cells
   microenvironment; intestinal remodeling
ID WALLED CARBON NANOTUBES; FLUORESCENT NANODIAMONDS; DNA NANOSTRUCTURES;
   DRUG-DELIVERY; NANOPARTICLES; CANCER; PATHWAY; AUTOPHAGY; OXIDE;
   BIOCOMPATIBILITY
AB Introduction of exogenous biomacromolecules into living systems is of great interest in genome editing, cancer immunotherapy, and stem cell reprogramming. Whereas current strategies generally depend on nucleic acids transfection, direct delivery of functional proteins that provides enhanced specificity, increased safety, and fast and temporal regulation is highly desirable. Nevertheless, intracellular delivery of intact and bioactive proteins, especially in vivo, remains poorly explored. In this study, we developed a nanodiamonds (NDs)-based protein delivery system in cultured cells and in Drosophila that showed high adsorption, high efficiency, and effective cytosolic release of fully functional proteins. Through live-cell imaging, we observed a novel phenomenon wherein a substantial amount of internalized NDsprotein complex rejected fusion with the early endosome, thereby evading protein degradation in the lysosome. More significantly, we demonstrated that dietary NDsRNase induced apoptosis in enterocytes, stimulating regenerative divisions in intestinal stem cells and increasing the number of stem cells and precursor cells in Drosophila intestine. As stem cells are poorly accessible by exogenous agents in vivo, NDs-mediated oral delivery of proteins provides a new approach to modulate the stem cell microenvironment for intestinal remodeling, which has important implications for colorectal cancer therapy and regenerative medicine.
C1 [Hu, Xingjie; Yin, Min; Wang, Lihua; Chen, Nan; Fan, Chunhai] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Appl Phys, Div Phys Biol, Shanghai 201800, Peoples R China.
   [Hu, Xingjie; Yin, Min; Wang, Lihua; Chen, Nan; Fan, Chunhai] Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Appl Phys,CAS Key Lab Interfacial P, Bioimaging Ctr,Shanghai Synchrotron Radiat Facil, Shanghai 201800, Peoples R China.
   [Li, Xiaojiao; Li, Ping; Huang, Ping; Wang, Hui; Song, Haiyun] Univ Chinese Acad Sci, Chinese Acad Sci, Key Lab Food Safety Res, Inst Nutr Sci,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.
   [Li, Xiaojiao; Li, Ping; Huang, Ping; Wang, Hui; Song, Haiyun] Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing 100021, Peoples R China.
   [Jiang, Yiguo] Guangzhou Med Univ, Sch Publ Hlth, Guangzhou 511436, Guangdong, Peoples R China.
RP Chen, N; Fan, CH (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Appl Phys, Div Phys Biol, Shanghai 201800, Peoples R China.; Chen, N; Fan, CH (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Appl Phys,CAS Key Lab Interfacial P, Bioimaging Ctr,Shanghai Synchrotron Radiat Facil, Shanghai 201800, Peoples R China.; Song, HY (corresponding author), Univ Chinese Acad Sci, Chinese Acad Sci, Key Lab Food Safety Res, Inst Nutr Sci,Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.; Song, HY (corresponding author), Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing 100021, Peoples R China.
EM chennan@sinap.ac.cn; fchh@sinap.ac.cn; hysong@sibs.ac.cn
RI Fan, Chunhai/A-7569-2011
OI Fan, Chunhai/0000-0002-7171-7338; Song, Haiyun/0000-0001-8146-5552; Li,
   Xiaojiao/0000-0002-0662-2850
FU National Basic Research Program of ChinaNational Basic Research Program
   of China [2016YFA0201200]; National Natural Science Foundation of
   ChinaNational Natural Science Foundation of China (NSFC) [31371493,
   31571498, 31470970, 31322039, U1332119]; Youth Innovation Promotion
   Association from Chinese Academy of Sciences [2015211]; Key Research
   Program of Frontier Sciences, CAS [QYZDJ-SSW-SLH019]
FX We would like to dedicate this article to Prof. Qing Huang. This study
   was supported by the National Basic Research Program of China
   (2016YFA0201200), National Natural Science Foundation of China
   (31371493, 31571498, 31470970, 31322039 and U1332119), the Youth
   Innovation Promotion Association from Chinese Academy of Sciences
   (2015211), and the Key Research Program of Frontier Sciences, CAS
   (QYZDJ-SSW-SLH019).
CR Alhaddad A, 2011, SMALL, V7, P3087, DOI 10.1002/smll.201101193
   Antonucci A, 2017, ACS APPL MATER INTER, V9, P11321, DOI 10.1021/acsami.7b00810
   Bale SS, 2010, ACS NANO, V4, P1493, DOI 10.1021/nn901586e
   Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495
   Boyer PD, 2016, ACS APPL MATER INTER, V8, P3524, DOI 10.1021/acsami.5b12602
   BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W
   Chow EK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001713
   Das P, 2016, ACS APPL MATER INTER, V8, P8710, DOI 10.1021/acsami.6b01667
   Estes ML, 2016, SCIENCE, V353, P772, DOI 10.1126/science.aag3194
   Faklaris O, 2008, SMALL, V4, P2236, DOI 10.1002/smll.200800655
   Ghosh S, 2016, ACS APPL MATER INTER, V8, P30824, DOI 10.1021/acsami.6b11798
   Gu Z, 2011, CHEM SOC REV, V40, P3638, DOI 10.1039/c0cs00227e
   Han L, 2017, ACS APPL MATER INTER, V9, P6941, DOI 10.1021/acsami.7b00246
   Huang DS, 2016, J MOL CELL BIOL, V8, P328, DOI 10.1093/jmcb/mjw036
   Jiang HQ, 2011, CELL STEM CELL, V8, P84, DOI 10.1016/j.stem.2010.11.026
   Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014
   Jurs PC, 2000, CHEM REV, V100, P2649, DOI 10.1021/cr9800964
   Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389
   Khodabandehlou K, 2015, ACS APPL MATER INTER, V7, P5756, DOI 10.1021/am508520z
   Kolesnikova TA, 2017, ACS APPL MATER INTER, V9, P11506, DOI 10.1021/acsami.7b01313
   Lee DS, 2016, CHEM SOC REV, V45, P4199, DOI 10.1039/c5cs00700c
   Leland PA, 2001, CHEM BIOL, V8, P405, DOI 10.1016/S1074-5521(01)00030-8
   Mahmoudi S, 2016, CELL, V167, P1672, DOI 10.1016/j.cell.2016.11.050
   Malathi K, 2004, CANCER RES, V64, P9144, DOI 10.1158/0008-5472.CAN-04-2226
   Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a
   Medema JP, 2011, NATURE, V474, P318, DOI 10.1038/nature10212
   Minardi S, 2015, ACS APPL MATER INTER, V7, P16364, DOI 10.1021/acsami.5b03464
   Mochalin VN, 2012, NAT NANOTECHNOL, V7, P11, DOI [10.1038/nnano.2011.209, 10.1038/NNANO.2011.209]
   Mohan N, 2010, NANO LETT, V10, P3692, DOI 10.1021/nl1021909
   Moscat J, 2016, CELL, V167, P606, DOI 10.1016/j.cell.2016.09.030
   Pulakkat S, 2016, ACS APPL MATER INTER, V8, P23437, DOI 10.1021/acsami.6b04179
   Qian H, 2017, CHEM SCI, V8, P1062, DOI 10.1039/c6sc01829g
   ROBEY E, 1990, CELL, V60, P697, DOI 10.1016/0092-8674(90)90082-P
   Rodriguez-Enriquez S, 2006, AUTOPHAGY, V2, P39, DOI 10.4161/auto.2229
   Schertel C, 2013, DEV CELL, V25, P207, DOI 10.1016/j.devcel.2013.02.019
   Setyawati MI, 2016, ACS NANO, V10, P1170, DOI 10.1021/acsnano.5b06487
   Setyawati MI, 2015, SMALL, V11, P3458, DOI 10.1002/smll.201403232
   Shimkunas RA, 2009, BIOMATERIALS, V30, P5720, DOI 10.1016/j.biomaterials.2009.07.004
   Song HY, 2009, EMBO REP, V10, P1140, DOI 10.1038/embor.2009.157
   Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186
   Tay CY, 2015, ACS NANO, V9, P5609, DOI 10.1021/acsnano.5b01954
   Vaijayanthimala V, 2012, BIOMATERIALS, V33, P7794, DOI 10.1016/j.biomaterials.2012.06.084
   Varkouhi AK, 2011, J CONTROL RELEASE, V151, P220, DOI 10.1016/j.jconrel.2010.11.004
   Wang F, 2013, NANOSCALE, V5, P12375, DOI 10.1039/c3nr04143c
   Wang M, 2016, P NATL ACAD SCI USA, V113, P2868, DOI 10.1073/pnas.1520244113
   Wang M, 2014, ANGEW CHEM INT EDIT, V53, P2893, DOI 10.1002/anie.201311245
   Wang X, 2014, ACS NANO, V8, P12151, DOI 10.1021/nn503491e
   Wu TJ, 2013, NAT NANOTECHNOL, V8, P682, DOI [10.1038/NNANO.2013.147, 10.1038/nnano.2013.147]
   YAMASHIRO DJ, 1983, J CELL BIOL, V97, P929, DOI 10.1083/jcb.97.3.929
   Yi HY, 2016, THERANOSTICS, V6, P1810, DOI 10.7150/thno.16127
   Zhang Y, 2016, ADV MATER, V28, P1387, DOI 10.1002/adma.201503893
   Zhang Y, 2016, ADV MATER, V28, P2699, DOI 10.1002/adma.201506232
   Zhu Y, 2012, THERANOSTICS, V2, P302, DOI 10.7150/thno.3627
   Zuris JA, 2015, NAT BIOTECHNOL, V33, P73, DOI 10.1038/nbt.3081
NR 54
TC 15
Z9 16
U1 6
U2 75
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944-8244
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD JUN 7
PY 2017
VL 9
IS 22
BP 18575
EP 18583
DI 10.1021/acsami.7b04788
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science
GA EX3MO
UT WOS:000403136400022
PM 28509532
DA 2022-04-25
ER

PT J
AU Kalas, W
   Swiderek, E
   Rapak, A
   Kopij, M
   Rak, J
   Strzadala, L
AF Kalas, Wojciech
   Swiderek, Ewelna
   Rapak, Andrzej
   Kopij, Magdalena
   Rak, Janusz
   Strzadala, Leon
TI H-ras Up-regulates Expression of BNIP3
SO ANTICANCER RESEARCH
LA English
DT Article
DE Ras; BNIP3; CD47; cancer; programmed cell death; 4N1K
ID PROTEIN-KINASE-A; DEATH GENE BNIP3; CELL-DEATH; VENTRICULAR MYOCYTES;
   CANCER-CELLS; COLORECTAL-CANCER; PANCREATIC-CANCER; INDUCED APOPTOSIS;
   IN-SITU; KAPPA-B
AB Background: Bcl-2/adenovirus E1B 19-kDa protein-interacting protein 3 (BNIP3) is a key regulator of cell death/autophagy and can act as an effector of a necrosis-like, atypical death program. It was implicated in execution of cell death induced by cluster of differentiation 47 (CD47). Despite the postulated role of BNIP3 in the regulation of survival of cancer cells, the influence of oncogenic transformation on BNIP3 expression is unclear. Materials and Methods: The influence of oncogenic transformation on expression of BNIP3 was studied using H-ras-transformed cells. The consequences of BNIP3 expression for sensitivity to CD47-mediated cell death were assessed using tetrazolium salt-based assay. Results: Here, the enforced and endogenous expression of Ras coincided with the up-regulation of BNIP3 across a wide spectrum of cancer cells, providing the first experimental evidence that BNIP3 is a regulatory target of H-Ras. This indicated that merely the introduction of a single oncogene may result in the up-regulation of BNIP3. The consequences of CD47 ligation strongly depended on the BNIP3 presence, which in turn correlated with Ras expression. Interestingly, the indirect effect of that phenomenon was the selective sensitivity of Ras-transformed cells to CD47-mediated cell death.
C1 [Kalas, Wojciech] Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Oncol, PL-53114 Wroclaw, Poland.
   [Rak, Janusz] McGill Univ, Montreal Childrens Hosp, Res Inst, Montreal, PQ H3H 1P3, Canada.
RP Kalas, W (corresponding author), Polish Acad Sci, Ludwik Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Oncol, PL-53114 Wroclaw, Poland.
EM kalas@iitd.pan.wroc.pl
RI Kałas, Wojciech/AAB-4469-2019; Rapak, Andrzej/ABE-6262-2021
OI Kałas, Wojciech/0000-0003-2656-5192; Rapak, Andrzej/0000-0003-4897-0287;
   Strzadala, Leon/0000-0002-7323-2254
FU Polish State Committee for Scientific ResearchPolish State Committee for
   Scientific Research [N301 104 31/3087, 1243/B/P01/2007/33]; Canadian
   Cancer Society Research InstituteCanadian Cancer Society (CCS)
FX This work was supported by grant no. N301 104 31/3087 and
   1243/B/P01/2007/33 from the Polish State Committee for Scientific
   Research and a grant from the Canadian Cancer Society Research Institute
   to JR, who also holds the Jack Cole Chair in Pediatric
   Hematology/Oncology.
CR Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1
   Armant M, 1999, J EXP MED, V190, P1175, DOI 10.1084/jem.190.8.1175
   Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278
   Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761
   Baetz D, 2005, CIRCULATION, V112, P3777, DOI 10.1161/CIRCULATIONAHA.105.573899
   Brown LF, 1999, CLIN CANCER RES, V5, P1041
   Burton TR, 2009, J NEUROSCI, V29, P4189, DOI 10.1523/JNEUROSCI.5747-08.2009
   Chin L, 1999, ONCOGENE, V18, P5304, DOI 10.1038/sj.onc.1203106
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Filleur S, 2001, GENE DEV, V15, P1373, DOI 10.1101/gad.193501
   Giatromanolaki A, 2004, CLIN CANCER RES, V10, P5566, DOI 10.1158/1078-0432.CCR-04-0076
   Graf R, 2003, APOPTOSIS, V8, P531, DOI 10.1023/A:1025598609965
   Hamacher-Brady A, 2007, CELL DEATH DIFFER, V14, P146, DOI 10.1038/sj.cdd.4401936
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Isenberg JS, 2008, AM J PATHOL, V173, P1100, DOI 10.2353/ajpath.2008.080237
   Johansson U, 2004, SCAND J IMMUNOL, V59, P40, DOI 10.1111/j.0300-9475.2004.01355.x
   Kalas W, 2005, CANCER RES, V65, P8878, DOI 10.1158/0008-5472.CAN-05-1479
   Koukourakis MI, 2006, CANCER SCI, V97, P582, DOI 10.1111/j.1349-7006.2006.00220.x
   Lamy L, 2003, J BIOL CHEM, V278, P23915, DOI 10.1074/jbc.M301869200
   Lamy L, 2007, J IMMUNOL, V178, P5930, DOI 10.4049/jimmunol.178.9.5930
   Lee H, 2006, MOL CELLS, V21, P1
   Leo C, 2006, INT J GYNECOL CANCER, V16, P1314, DOI 10.1111/j.1525-1438.2006.00394.x
   Lim MJ, 2006, MOL THER, V13, P899, DOI 10.1016/j.ymthe.2005.11.023
   Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887
   Manna PP, 2004, CANCER RES, V64, P1026, DOI 10.1158/0008-5472.CAN-03-1708
   Manna PP, 2003, J IMMUNOL, V170, P3544, DOI 10.4049/jimmunol.170.7.3544
   Mateo W, 2002, BLOOD, V100, P2882, DOI 10.1182/blood-2001-12-0217
   McCormick F, 2009, CANCER J SCI AM, V5, P139
   Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0
   Murai M, 2005, BRIT J CANCER, V92, P1165, DOI 10.1038/sj.bjc.6602422
   Murai M, 2005, CLIN CANCER RES, V11, P1021
   Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089
   RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001
   Rath GM, 2006, BBA-MOL CELL RES, V1763, P1125, DOI 10.1016/j.bbamcr.2006.08.001
   Rath GM, 2006, INT J BIOCHEM CELL B, V38, P2219, DOI 10.1016/j.biocel.2006.07.004
   Saumet A, 2005, BLOOD, V106, P658, DOI 10.1182/blood-2004-09-3585
   Shaw J, 2006, CIRC RES, V99, P1347, DOI 10.1161/01.RES.0000251744.06138.50
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Sington J, 2007, HISTOPATHOLOGY, V50, P555, DOI 10.1111/j.1365-2559.2007.02657.x
   Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466
   Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06
   Vande Velde C, 2000, MOL CELL BIOL, V20, P5454, DOI 10.1128/MCB.20.15.5454-5468.2000
   Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293
   Yamauchi Y, 2002, MATRIX BIOL, V21, P441, DOI 10.1016/S0945-053X(02)00036-7
   Yurkova N, 2008, CIRC RES, V102, P472, DOI 10.1161/CIRCRESAHA.107.164731
   Zamora R, 2001, J BIOL CHEM, V276, P46887, DOI 10.1074/jbc.M101865200
   Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16
NR 47
TC 19
Z9 19
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD SEP
PY 2011
VL 31
IS 9
BP 2869
EP 2875
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 800KG
UT WOS:000293357700024
PM 21868531
DA 2022-04-25
ER

PT J
AU Cao, P
   Chen, YY
   Chen, Y
   Su, WH
   Zhan, N
   Dong, WG
AF Cao, Pan
   Chen, Yongyu
   Chen, Yan
   Su, Wenhao
   Zhan, Na
   Dong, Weiguo
TI Fusobacterium nucleatum Activates Endoplasmic Reticulum Stress to
   Promote Crohn's Disease Development via the Upregulation of CARD3
   Expression
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Fusobacterium nucleatum; intestinal mucosal barrier; endoplasmic
   reticulum stress; Crohn's disease; gene regulation
ID COLORECTAL-CANCER; CARCINOGENESIS; MICROBIOTA; AUTOPHAGY; CELLS
AB There is increasing evidence that members of the gut microbiota, especially Fusobacterium nucleatum (F. nucleatum), are associated with Crohn's disease (CD), but the specific mechanism by which F. nucleatum promotes CD development is unclear. Here, we first examined the abundance of F. nucleatum and its effects on CD disease activity and explored whether F. nucleatum aggravated intestinal inflammation and promoted intestinal mucosal barrier damage in vitro and in vivo. Our data showed that F. nucleatum was enriched in 41.21% of CD tissues from patients and was correlated with the clinical course, clinical activity, and refractory behavior of CD (P < 0.05). In addition, we found that F. nucleatum infection is involved in activating the endoplasmic reticulum stress (ERS) pathway during CD development to promote intestinal mucosal barrier destruction. Mechanistically, F. nucleatum targeted caspase activation and recruitment domain 3 (CARD3) to activate the ERS pathway and promote F. nucleatum-mediated mucosal barrier damage in vivo and in vitro. Thus, F. nucleatum coordinates a molecular network involving CARD3 and ERS to control the CD process. Measuring and targeting F. nucleatum and its associated pathways will provide valuable insight into the prevention and treatment of CD.
C1 [Cao, Pan; Chen, Yongyu; Chen, Yan; Su, Wenhao; Zhan, Na; Dong, Weiguo] Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan, Peoples R China.
   [Cao, Pan; Chen, Yongyu; Chen, Yan; Su, Wenhao; Zhan, Na; Dong, Weiguo] Wuhan Univ, Key Lab Hubei Prov Digest Syst Dis, Renmin Hosp, Wuhan, Peoples R China.
   [Su, Wenhao; Zhan, Na] Wuhan Univ, Cent Lab, Renmin Hosp, Wuhan, Peoples R China.
RP Dong, WG (corresponding author), Wuhan Univ, Dept Gastroenterol, Renmin Hosp, Wuhan, Peoples R China.; Dong, WG (corresponding author), Wuhan Univ, Key Lab Hubei Prov Digest Syst Dis, Renmin Hosp, Wuhan, Peoples R China.
EM dongweiguo@whu.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81870392, 81372551, 81572426]; Guiding
   Foundation of Renmin Hospital of Wuhan University [RMYD2018Z01]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81870392, No. 81372551, and No. 81572426) and
   the Guiding Foundation of Renmin Hospital of Wuhan University (No.
   RMYD2018Z01).
CR Actis Giovanni C, 2014, World J Gastrointest Pharmacol Ther, V5, P169, DOI 10.4292/wjgpt.v5.i3.169
   Allen-Vercoe E, 2014, IMMUNOL LETT, V162, P54, DOI 10.1016/j.imlet.2014.05.014
   Allen-Vercoe E, 2011, GUT MICROBES, V2, P294, DOI 10.4161/gmic.2.5.18603
   Chen WY, 2017, AM J PATHOL, V187, P2686, DOI 10.1016/j.ajpath.2017.08.015
   Chen YY, 2020, J PATHOL, V250, P170, DOI 10.1002/path.5358
   Cheung WY, 2007, CAN FAM PHYSICIAN, V53, P1451
   Danese S, 2007, GUT, V56, P855, DOI 10.1136/gut.2006.114314
   Dinakaran V, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03220
   Feng YY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215088
   Ge CX, 2019, FREE RADICAL BIO MED, V141, P67, DOI 10.1016/j.freeradbiomed.2019.05.031
   Gursoy UK, 2010, J PERIODONTOL, V81, P1084, DOI 10.1902/jop.2010.090664
   Han YPW, 2010, OBSTET GYNECOL, V115, P442, DOI 10.1097/AOG.0b013e3181cb9955
   He C, 2019, WORLD J GASTROENTERO, V25, P2204, DOI 10.3748/wjg.v25.i18.2204
   Huang YL, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00606
   Irving AT, 2014, CELL HOST MICROBE, V15, P623, DOI 10.1016/j.chom.2014.04.001
   Kaakoush NO, 2012, J CLIN MICROBIOL, V50, P3258, DOI 10.1128/JCM.01396-12
   Keestra-Gounder AM, 2016, NATURE, V532, P394, DOI 10.1038/nature17631
   Kolb PS, 2015, INT J BIOCHEM CELL B, V61, P45, DOI 10.1016/j.biocel.2015.01.015
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Krisanaprakornkit S, 2000, INFECT IMMUN, V68, P2907, DOI 10.1128/IAI.68.5.2907-2915.2000
   Kumar A, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0700-0
   Li B, 2016, J PEDIATR SURG, V51, P1001, DOI 10.1016/j.jpedsurg.2016.02.073
   Li LP, 2015, BASIC RES CARDIOL, V110, DOI 10.1007/s00395-015-0515-4
   Li P, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.05.050
   Ma AG, 2019, KAOHSIUNG J MED SCI, V35, P591, DOI 10.1002/kjm2.12093
   Malluta EF, 2019, CLINICS, V74, DOI 10.6061/clinics/2019/e853
   McCoy AN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053653
   Nishikawa J, 2009, SCAND J GASTROENTERO, V44, P180, DOI 10.1080/00365520802433231
   Odenwald MA, 2017, NAT REV GASTRO HEPAT, V14, P9, DOI 10.1038/nrgastro.2016.169
   Panda S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07016-0
   Purcell RV, 2018, INT J MICROBIOL, V2018, DOI 10.1155/2018/9203908
   Repass J, 2018, ELIFE, V7, DOI 10.7554/eLife.25801
   Strauss J, 2011, INFLAMM BOWEL DIS, V17, P1971, DOI 10.1002/ibd.21606
   Swidsinski A, 2011, GUT, V60, P34, DOI 10.1136/gut.2009.191320
   Tigno-Aranjuez JT, 2014, J BIOL CHEM, V289, P29651, DOI 10.1074/jbc.M114.591388
   Wang XA, 2013, ENDOCRINOLOGY, V154, P685, DOI 10.1210/en.2012-1911
   Wu J, 2019, TRANSL ONCOL, V12, P846, DOI 10.1016/j.tranon.2019.03.003
   Wu YQ, 2018, ONCOTARGETS THER, V11, P5621, DOI 10.2147/OTT.S176744
   Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018
   Yu JH, 2016, INT J CANCER, V139, P1318, DOI 10.1002/ijc.30168
   Yu SJ, 2015, INFLAMM BOWEL DIS, V21, P862, DOI 10.1097/MIB.0000000000000322
   Zhang ZF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010031
   Zhou YL, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005019
NR 43
TC 10
Z9 11
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 21
PY 2020
VL 11
AR 106
DI 10.3389/fphar.2020.00106
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KZ7QY
UT WOS:000523455200001
PM 32153411
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Koehler, BC
   Scherr, AL
   Lorenz, S
   Elssner, C
   Kautz, N
   Welte, S
   Jaeger, D
   Urbanik, T
   Schulze-Bergkamen, H
AF Koehler, Bruno Christian
   Scherr, Anna-Lena
   Lorenz, Stephan
   Elssner, Christin
   Kautz, Nicole
   Welte, Stefan
   Jaeger, Dirk
   Urbanik, Toni
   Schulze-Bergkamen, Henning
TI Pan-Bcl-2 Inhibitor Obatoclax Delays Cell Cycle Progression and Blocks
   Migration of Colorectal Cancer Cells
SO PLOS ONE
LA English
DT Article
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; BH3 MIMETICS; E-CADHERIN; PHASE-I;
   APOPTOSIS; AUTOPHAGY; GX15-070; EXPRESSION; MCL-1; RESISTANCE
AB Despite the fact that new treatment regimes have improved overall survival of patients challenged by colorectal cancer (CRC), prognosis in the metastatic situation is still restricted. The Bcl-2 family of proteins has been identified as promising anti cancer drug target. Even though small molecules targeting Bcl-2 proteins are in clinical trials, little is known regarding their effects on CRC. The aim of this study was to preclinically investigate the value of ABT-737 and Obatoclax as anticancer drugs for CRC treatment. The effects of the BH3-mimetics ABT-737 and Obatoclax on CRC cells were assessed using viability and apoptosis assays. Wound healing migration and boyden chamber invasion assays were applied. 3-dimensional cell cultures were used for long term assessment of invasion and proliferation. Clinically relevant concentrations of pan-Bcl-2 inhibitor Obatoclax did not induce cell death. In contrast, the BH3-mimetic ABT-737 induced apoptosis in a dose dependent manner. Obatoclax caused a cell line specific slowdown of CRC cell growth. Furthermore, Obatoclax, but not ABT-737, recovered E-Cadherin expression and led to impaired migration and invasion of CRC cells. The proliferative capacity and invasiveness of CRC cells was strikingly inhibited by low dose Obatoclax in long term 3-dimensional cell cultures. Obatoclax, but not ABT-737, caused a G1-phase arrest accompanied by a downregulation of Cyclin D1 and upregulation of p27 and p21. Overexpression of Mcl-1, Bcl-xL or Bcl-2 reversed the inhibitory effect of Obatoclax on migration but failed to restore the proliferative capacity of Obatoclax-treated CRC cells. The data presented indicate broad and multifaceted antitumor effects of the pan-Bcl-2 inhibitor Obatoclax on CRC cells. In contrast to ABT-737, Obatoclax inhibited migration, invasion and proliferation in sublethal doses. In summary, this study recommends pan-Bcl-2 inhibition as a promising approach for clinical trials in CRC.
C1 [Koehler, Bruno Christian; Scherr, Anna-Lena; Lorenz, Stephan; Elssner, Christin; Kautz, Nicole; Welte, Stefan; Jaeger, Dirk; Urbanik, Toni; Schulze-Bergkamen, Henning] Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany.
RP Koehler, BC (corresponding author), Univ Heidelberg Hosp, Natl Ctr Tumor Dis, Dept Med Oncol, Heidelberg, Germany.
EM Bruno.koehler@nct-heidelberg.de
FU Medical Faculty of the University of Heidelberg, Germany; German
   Research Foundation (Deutsche Forschungsgemeinschaft)German Research
   Foundation (DFG) [DFG SCHU 1443/4-1]
FX This study was supported by a Postdoctoral-Fellowship granted to BCK
   from the Medical Faculty of the University of Heidelberg, Germany
   (http://www.medizinische-fakultaet-hd.uni-heidelberg.de), and grants to
   HSB from the German Research Foundation (Deutsche
   Forschungsgemeinschaft, http://www.dfg.de/, DFG SCHU 1443/4-1). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Azmi AS, 2011, EXPERT OPIN EMERG DR, V16, P59, DOI 10.1517/14728214.2010.515210
   Backus HHJ, 2001, ANN ONCOL, V12, P779, DOI 10.1023/A:1011112227044
   Bodur C, 2012, CURR MED CHEM, V19, P1804, DOI 10.2174/092986712800099839
   Crawford N, 2011, APOPTOSIS, V16, P311, DOI 10.1007/s10495-010-0561-1
   Espona-Fiedler M, 2012, BIOCHEM PHARMACOL, V83, P489, DOI 10.1016/j.bcp.2011.11.027
   Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200
   Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263
   Harrison LRE, 2011, J CLIN INVEST, V121, P1075, DOI 10.1172/JCI43505
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   Heidari N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.53
   Hermiston ML, 1996, GENE DEV, V10, P985, DOI 10.1101/gad.10.8.985
   Huang SB, 2010, AUTOPHAGY, V6, P256, DOI 10.4161/auto.6.2.11124
   Hwang JJ, 2010, CLIN CANCER RES, V16, P4038, DOI 10.1158/1078-0432.CCR-10-0822
   Jain HV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081582
   Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533
   Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791
   Koehler BC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076446
   Labi V, 2008, CELL DEATH DIFFER, V15, P977, DOI 10.1038/cdd.2008.37
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Martinez-Paniagua MA, 2011, CELL CYCLE, V10, P2792, DOI 10.4161/cc.10.16.16952
   Mazumder S, 2012, CANCER RES, V72, P3069, DOI 10.1158/0008-5472.CAN-11-4106
   McCoy F, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.86
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Paik PK, 2010, CANCER CHEMOTH PHARM, V66, P1079, DOI 10.1007/s00280-010-1265-5
   Pan JX, 2010, CANCER LETT, V293, P167, DOI 10.1016/j.canlet.2010.01.006
   Raats DAE, 2011, CELL ONCOL, V34, P307, DOI 10.1007/s13402-011-0026-8
   Schneider MR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014325
   Schoenwaelder SM, 2011, BLOOD, V118, P1663, DOI 10.1182/blood-2011-04-347849
   Schulze-Bergkamen H, 2008, WORLD J GASTROENTERO, V14, P3829, DOI 10.3748/wjg.14.3829
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Sieghart W, 2006, J HEPATOL, V44, P151, DOI 10.1016/j.jhep.2005.09.010
   Urbanik T, 2012, J HEPATOL, V57, P995, DOI 10.1016/j.jhep.2012.06.017
   Urtishak KA, 2013, BLOOD, V121, P2689, DOI 10.1182/blood-2012-04-425033
   Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x
   Vick B, 2009, HEPATOLOGY, V49, P627, DOI 10.1002/hep.22664
   Wanebo HJ, 2012, CLIN EXP METASTAS, V29, P821, DOI 10.1007/s10585-012-9517-x
   Wei Y, 2010, CLIN CANCER RES, V16, P3923, DOI 10.1158/1078-0432.CCR-10-0032
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Wroblewski D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084073
   Yamaguchi H, 2005, CURR OPIN CELL BIOL, V17, P559, DOI 10.1016/j.ceb.2005.08.002
   Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002
   Zhai D, 2006, CELL DEATH DIFFER, V13, P1419, DOI 10.1038/sj.cdd.4401937
   Zhang YL, 2008, WORLD J GASTROENTERO, V14, P3069, DOI 10.3748/wjg.14.3069
   Zinkel SS, 2008, METHOD ENZYMOL, V442, P231, DOI 10.1016/S0076-6879(08)01412-2
NR 47
TC 24
Z9 24
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 5
PY 2014
VL 9
IS 9
AR e106571
DI 10.1371/journal.pone.0106571
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AZ1IR
UT WOS:000347993600039
PM 25192188
OA Green Published, Green Submitted, gold
DA 2022-04-25
ER

PT J
AU Wu, YN
   Wu, PC
   Yang, LX
   Ratinac, KR
   Thordarson, P
   Jahn, KA
   Chen, DH
   Shieh, DB
   Braet, F
AF Wu, Ya-Na
   Wu, Ping-Ching
   Yang, Li-Xing
   Ratinac, Kyle R.
   Thordarson, Pall
   Jahn, Kristina A.
   Chen, Dong-Hwang
   Shieh, Dar-Bin
   Braet, Filip
TI The anticancer properties of iron core-gold shell nanoparticles in
   colorectal cancer cells
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE cancer therapy; Fe; gold-coated iron; nanoparticles; differential
   cytotoxicity
ID FE-AT-AU; OXIDE NANOPARTICLES; MAGNETITE NANOPARTICLES; BIOMEDICAL
   APPLICATIONS; CARBON NANOTUBES; ORAL-CANCER; IN-VIVO; APOPTOSIS;
   TRICHLOROETHYLENE; HYPERTHERMIA
AB Previously, iron core-gold shell nanoparticles (Fe@Au) have been shown to possess cancer-preferential cytotoxicity in oral and colorectal cancer (CRC) cells. However, CRC cell lines are less sensitive to Fe@Au treatment when compared with oral cancer cell lines. In this research, Fe@Au are found to decrease the cell viability of CRC cell lines, including Caco-2, HT-29, and SW480, through growth inhibition rather than the induction of cell death. The cytotoxicity induced by Fe@Au in CRC cells uses different subcellular pathways to the mitochondria-mediated autophagy found in Fe@Au-treated oral cancer cells, OECM1. Interestingly, the Caco-2 cell line shows a similar response to OECM1 cells and is thus more sensitive to Fe@Au treatment than the other CRC cell lines studied. We have investigated the underlying cell resistance mechanisms of Fe@Au-treated CRC cells. The resistance of CRC cells to Fe@Au does not result from the total amount of Fe@Au internalized. Instead, the different amounts of Fe and Au internalized appear to determine the different response to treatment with Fe-only nanoparticles in Fe@Au-resistant CRC cells compared with the Fe@Au-sensitive OECM1 cells. The only moderately cytotoxic effect of Fe@Au nanoparticles on CRC cells, when compared to the highly sensitive OECM1 cells, appears to arise from the CRC cells' relative insensitivity to Fe, as is demonstrated by our Fe-only treatments. This is a surprising outcome, given that Fe has thus far been considered to be the "active" component of Fe@Au nanoparticles. Instead, we have found that the Au coatings, previously considered only as a passivating coating to protect the Fe cores from oxidation, significantly enhance the cytotoxicity of Fe@Au in certain CRC cells. Therefore, we conclude that both the Fe and Au in these core-shell nanoparticles are essential for the anticancer properties observed in CRC cells.
C1 [Wu, Ya-Na; Wu, Ping-Ching; Yang, Li-Xing; Shieh, Dar-Bin] Natl Cheng Kung Univ Hosp, Coll Med, Inst Oral Med, Tainan 701, Taiwan.
   [Wu, Ya-Na; Wu, Ping-Ching; Yang, Li-Xing; Shieh, Dar-Bin] Natl Cheng Kung Univ Hosp, Coll Med, Dept Stomatol, Tainan 701, Taiwan.
   [Ratinac, Kyle R.; Jahn, Kristina A.; Braet, Filip] Univ Sydney, Australian Ctr Microscopy & Microanal, Sydney, NSW 2006, Australia.
   [Chen, Dong-Hwang] Natl Cheng Kung Univ, Dept Chem Engn, Tainan, Taiwan.
   [Thordarson, Pall] Univ New S Wales, Sch Chem, Sydney, NSW, Australia.
   [Shieh, Dar-Bin] Natl Cheng Kung Univ, Ctr Micro Nano Sci & Technol, Tainan 70101, Taiwan.
   [Shieh, Dar-Bin] Natl Cheng Kung Univ, Adv Optoelect Technol Ctr, Tainan 70101, Taiwan.
   [Braet, Filip] Univ Sydney, Sch Med Sci, Discipline Anat & Histol, Bosch Inst, Sydney, NSW 2006, Australia.
RP Wu, YN (corresponding author), Natl Cheng Kung Univ Hosp, Coll Med, Inst Oral Med, Tainan 701, Taiwan.
EM yana.wu@gmail.com
RI Braet, F/AAB-3660-2022; Thordarson, Pall/A-2138-2015; Wu,
   Ya-Na/AGX-5385-2022; Chen, Dong-Hwang/B-7299-2011; Braet, F/V-7003-2019
OI Thordarson, Pall/0000-0002-1200-8814; Braet, F/0000-0002-5222-0895;
   Ratinac, Kyle/0000-0001-6492-9490; Yang, Li-Xing/0000-0002-3723-4391
FU Taiwan National Science CouncilMinistry of Science and Technology,
   Taiwan [101-2120-M-006-008-, 101-2314-B-006-048-MY3,
   101-2320-B-006-004]; Taiwan Department of Health
   [DOH101-TD-PB-111-NSC004, DOH102-TD-PB-111-TM017]; Australian Research
   CouncilAustralian Research Council [DP0985059]; Cancer Institute NSW
   [08/RFG/1-29]
FX DBS is indebted to Taiwan National Science Council (grant number
   101-2120-M-006-008-, 101-2314-B-006-048-MY3) and the Taiwan Department
   of Health (grant number DOH101-TD-PB-111-NSC004,
   DOH102-TD-PB-111-TM017). PCW thanks Taiwan National Science Council for
   grant support (101-2320-B-006-004). We also thank the Australian
   Research Council for a Discovery Project Grant (DP0985059) to PT and FB,
   as well as the Cancer Institute NSW (08/RFG/1-29) for supporting our
   work. We acknowledge the facilities as well as scientific and technical
   assistance from staff at the Australian Microscopy and Microanalysis
   Research Facility at the Australian Centre for Microscopy and
   Microanalysis, the University of Sydney. All animal studies and human
   primary cell cultures were performed in accordance with the University
   of Cheng-Kung Internal Review Board for Ethics and Human Research
   (ethical approval No 97218).
CR Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200
   Allen RT, 1997, J PHARMACOL TOX MET, V37, P215, DOI 10.1016/S1056-8719(97)00033-6
   Carpenter EE, 1999, IEEE T MAGN, V35, P3496, DOI 10.1109/20.800568
   Carpenter EE, 1999, ABSTR PAP AM CHEM S, V218, pU441
   Chen B, 2011, CURR CANCER DRUG TAR, V11, P184, DOI 10.2174/156800911794328475
   Chen M, 2003, J APPL PHYS, V93, P7551, DOI 10.1063/1.1555312
   Cho SJ, 2006, NANOTECHNOLOGY, V17, P640, DOI 10.1088/0957-4484/17/3/004
   Chou SW, 2010, J AM CHEM SOC, V132, P13270, DOI 10.1021/ja1035013
   Gupta AK, 2005, BIOMATERIALS, V26, P3995, DOI 10.1016/j.biomaterials.2004.10.012
   Ito A, 2006, CANCER IMMUNOL IMMUN, V55, P320, DOI 10.1007/s00262-005-0049-y
   Jain TK, 2008, MOL PHARMACEUT, V5, P316, DOI 10.1021/mp7001285
   Jiang LQ, 2013, INT J NANOMED, V8, P1825, DOI 10.2147/IJN.S44342
   Karlsson HL, 2008, CHEM RES TOXICOL, V21, P1726, DOI 10.1021/tx800064j
   Kayal S, 2010, J NANOSCI NANOTECHNO, V10, P5527, DOI 10.1166/jnn.2010.2461
   Kim DH, 2009, IEEE T MAGN, V45, P4821, DOI 10.1109/TMAG.2009.2024000
   Li F, 2003, COLLOID SURFACE A, V223, P103, DOI 10.1016/S0927-7757(03)00187-0
   Lin J, 2001, J SOLID STATE CHEM, V159, P26, DOI 10.1006/jssc.2001.9117
   Park HY, 2007, LANGMUIR, V23, P9050, DOI 10.1021/la701305f
   Peng YC, 2006, BIOORGAN MED CHEM, V14, P263, DOI 10.1016/j.bmc.2005.08.027
   Ravel B, 2002, J APPL PHYS, V91, P8195, DOI 10.1063/1.1453941
   Reimer P, 2003, EUR RADIOL, V13, P1266, DOI 10.1007/s00330-002-1721-7
   Schroterova L, 2009, TOXICOL IN VITRO, V23, P1406, DOI 10.1016/j.tiv.2009.07.013
   Shieh DB, 2005, BIOMATERIALS, V26, P7183, DOI 10.1016/j.biomaterials.2005.05.020
   Singh N, 2010, NANO REV EXP, V1, DOI 10.3402/nano.v1i0.5358
   Summers HD, 2010, CYTOM PART A, V77A, P933, DOI 10.1002/cyto.a.20932
   Tang W, 2012, INVEST OPHTH VIS SCI, V53, P4874, DOI 10.1167/iovs.11-8968
   Thurber A, 2012, NANOTOXICOLOGY, V6, P440, DOI 10.3109/17435390.2011.587031
   Tshikhudo TR, 2004, MATER SCI TECH-LOND, V20, P980, DOI 10.1179/026708304225019849
   Uboldi C, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-18
   Vangestel C, 2011, MOL IMAGING, V10, P340, DOI 10.2310/7290.2010.00058
   Vyoral D, 2005, INT J BIOCHEM CELL B, V37, P1768, DOI 10.1016/j.biocel.2005.02.023
   Worle-Knirsch JM, 2006, NANO LETT, V6, P1261, DOI 10.1021/nl060177c
   Wu L, 2005, J NANOPART RES, V7, P469, DOI 10.1007/s11051-005-4271-5
   Wu PC, 2007, CHEM-EUR J, V13, P3878, DOI 10.1002/chem.200601372
   Wu YN, 2011, BIOMATERIALS, V32, P4565, DOI 10.1016/j.biomaterials.2011.03.006
   Wu YN, 2011, NANOMED-NANOTECHNOL, V7, P420, DOI 10.1016/j.nano.2011.01.002
   Zhou WL, 2001, EUR PHYS J D, V16, P289, DOI 10.1007/s100530170112
NR 37
TC 21
Z9 22
U1 2
U2 55
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2013
VL 8
BP 3321
EP 3331
DI 10.2147/IJN.S47742
PG 11
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA 209DK
UT WOS:000323734200001
PM 24039416
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Olejniczak-Keder, A
   Szarynska, M
   Wronska, A
   Siedlecka-Kroplewska, K
   Kmiec, Z
AF Olejniczak-Keder, Agata
   Szarynska, Magdalena
   Wronska, Agata
   Siedlecka-Kroplewska, Kamila
   Kmiec, Zbigniew
TI Effects of 5-FU and anti-EGFR antibody in combination with ASA on the
   spherical culture system of HCT116 and HT29 colorectal cancer cell lines
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE colorectal cancer cell lines; spherical cultures; cancer stem like
   cells; 5-fluorouracil; anti-epidermal growth factor receptor antibody;
   aspirin
ID GROWTH-FACTOR-RECEPTOR; STEM-CELLS; CYCLOOXYGENASE-2 EXPRESSION;
   BREAST-CANCER; ASPIRIN; RESISTANCE; CETUXIMAB; CD95; CHEMOTHERAPY;
   RECURRENCE
AB The aim of this study was to examine the effects of 5-fluorouracil (5-FU), anti-epidermal growth factor receptor (EGFR) antibody and aspirin (ASA) on the characteristics of two CRC cell lines, HCT116 and HT29, maintained in a spherical culture system. We observed that the morphology of both the HCT116 and HT29 cell-derived spheres was significantly impaired and the size of the colonospheres was markedly reduced following treatment with the aforementioned three drugs. In contrast to adherent cultures, the spherical cultures were more resistant to the tested drugs, as was reflected by their capacity to re-create the colonospheres when sustained in serum-free medium. Flow cytometric analysis of the drug-treated HCT116 cell-derived spheres revealed changes in the fraction of cells expressing markers of cancer stem cells (CSCs), whereas the CSC phenotype of HT29 cell-derived colonospheres was affected to a lesser extent. All reagents enhanced the percentage of non-viable cells in the colonospheres despite the diminished fraction of active caspase-3-positive cells following treatment of the HT29 cell-derived spheres with anti-EGFR antibody. Increased autophagy, assessed by acridine orange staining, was noted following the incubation of the HT29-colonospheres with ASA and 5-FU in comparison to the control. Notably, the percentage of cyclooxygenase (COX)-2-positive cells was not affected by ASA, although its activity was markedly elevated in the colonospheres incubated with anti-EGFR antibody. On the whole, the findings of this study indicate that all the tested drugs were involved in different cellular processes, which suggests that they should be considered for the combined therapeutic treatment of CRC, particularly for targeting the population of CSC-like cells. Thus, cancer cell-derived spheres may be used as a preferable model for in vitro anticancer drug testing.
C1 [Olejniczak-Keder, Agata; Szarynska, Magdalena; Wronska, Agata; Siedlecka-Kroplewska, Kamila; Kmiec, Zbigniew] Med Univ Gdansk, Dept Histol, 1 Debinki St, PL-80211 Gdansk, Poland.
RP Olejniczak-Keder, A (corresponding author), Med Univ Gdansk, Dept Histol, 1 Debinki St, PL-80211 Gdansk, Poland.
EM agata.olejniczak-keder@gumed.edu.pl
RI Olejniczak-Kęder, Agata/AAO-7667-2020; Szarynska, Magdalena/N-5871-2018
OI Olejniczak-Kęder, Agata/0000-0001-5201-9254; Siedlecka-Kroplewska,
   Kamila/0000-0002-6313-0799; Szarynska, Magdalena/0000-0002-9976-5833
FU Polish Ministry of Science and Higher EducationMinistry of Science and
   Higher Education, Poland [MN 01-0232/08/280]
FX This study was supported by the grant from the Polish Ministry of
   Science and Higher Education no. MN 01-0232/08/280.
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Alfonso L, 2014, BRIT J CANCER, V111, P61, DOI 10.1038/bjc.2014.271
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Butler SJ, 2017, BIOCHEM BIOPH RES CO, V490, P29, DOI 10.1016/j.bbrc.2017.05.176
   Cao SQ, 2011, INT J ONCOL, V39, P383, DOI 10.3892/ijo.2011.1053
   Celia-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116
   Ceppi P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6238
   Chan AT, 2007, ARCH INTERN MED, V167, P562, DOI 10.1001/archinte.167.6.562
   Chen L, 2010, NATURE, V465, P492, DOI 10.1038/nature09075
   Chen XW, 2017, ONCOTARGET, V8, P17301, DOI 10.18632/oncotarget.14230
   Choe MS, 2005, MOL CANCER THER, V4, P1448, DOI 10.1158/1535-7163.MCT-04-0251
   Costa EC, 2016, BIOTECHNOL ADV, V34, P1427, DOI 10.1016/j.biotechadv.2016.11.002
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Din FVN, 2012, GASTROENTEROLOGY, V142, P1504, DOI 10.1053/j.gastro.2012.02.050
   Drew DA, 2016, NAT REV CANCER, V16, P173, DOI 10.1038/nrc.2016.4
   Elder DJE, 2000, INT J CANCER, V86, P553, DOI 10.1002/(SICI)1097-0215(20000515)86:4<553::AID-IJC18>3.0.CO;2-9
   Flanagan L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.7
   Fujita J, 2008, CELL STEM CELL, V2, P595, DOI 10.1016/j.stem.2008.04.001
   Gajate P, 2012, CLIN COLORECTAL CANC, V11, P291, DOI 10.1016/j.clcc.2012.02.003
   Gao XL, 2017, ONCOTARGETS THER, V10, P5219, DOI 10.2147/OTT.S140854
   Goel A, 2003, CLIN CANCER RES, V9, P383
   Guren TK, 2017, BRIT J CANCER, V116, P1271, DOI 10.1038/bjc.2017.93
   Heerdt BG, 2003, CANCER RES, V63, P6311
   Heerdt BG, 2005, CANCER RES, V65, P9861, DOI 10.1158/0008-5472.CAN-05-2444
   Heerdt BG, 2006, CANCER RES, V66, P1591, DOI 10.1158/0008-5472.CAN-05-2717
   Hu H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00288-4
   Huang CY, 2015, WORLD J GASTROENTERO, V21, P11777, DOI 10.3748/wjg.v21.i41.11777
   Huang Q, 2011, NAT MED, V17, P860, DOI 10.1038/nm.2385
   Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2011.34, 10.1038/nrclinonc.2010.204]
   Islam F, 2015, EXP CELL RES, V335, P135, DOI 10.1016/j.yexcr.2015.04.018
   Janzen V, 2008, CELL STEM CELL, V2, P584, DOI 10.1016/j.stem.2008.03.012
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Karlsson H, 2012, EXP CELL RES, V318, P1577, DOI 10.1016/j.yexcr.2012.03.026
   Kastrati I, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1868-7
   Kaur J, 2010, TUMOR BIOL, V31, P623, DOI 10.1007/s13277-010-0078-9
   Kim SY, 2016, J CELL BIOCHEM, V117, P2289, DOI 10.1002/jcb.25527
   Kim YM, 2009, MOL CANCER RES, V7, P1367, DOI 10.1158/1541-7786.MCR-09-0004
   Kleber S, 2008, CANCER CELL, V13, P235, DOI 10.1016/j.ccr.2008.02.003
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Li F, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000634
   Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815
   Lin PC, 2013, ONCOL LETT, V6, P733, DOI 10.3892/ol.2013.1426
   Lippman SM, 2005, CLIN CANCER RES, V11, P6097, DOI 10.1158/1078-0432.CCR-05-1217
   Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027
   Manhas J, 2016, TUMOR BIOL, V37, P14069, DOI 10.1007/s13277-016-5232-6
   Martin-Villalba A, 2013, TRENDS MOL MED, V19, P329, DOI 10.1016/j.molmed.2013.03.002
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Mhaidat NM, 2014, ONCOL LETT, V8, P699, DOI 10.3892/ol.2014.2211
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Miyamoto Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040752
   Moon CM, 2014, INT J CANCER, V134, P519, DOI 10.1002/ijc.28381
   Morselli E, 2009, BBA-MOL CELL RES, V1793, P1524, DOI 10.1016/j.bbamcr.2009.01.006
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Olejniczak A, 2018, INT J ONCOL, V52, P599, DOI 10.3892/ijo.2017.4206
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   Pasto A, 2014, ONCOTARGET, V5, P4305, DOI 10.18632/oncotarget.2010
   Peter ME, 2015, CELL DEATH DIFFER, V22, P885, DOI 10.1038/cdd.2015.25
   Pietila M, 2010, TISSUE ENG PART C-ME, V16, P435, DOI 10.1089/ten.tec.2009.0247
   Qureshi-Baig K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146052
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Roelofs HMJ, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-1
   Saha S, 2016, CANCER RES, V76, P2000, DOI 10.1158/0008-5472.CAN-15-1360
   Sant Shilpa, 2017, Drug Discov Today Technol, V23, P27, DOI 10.1016/j.ddtec.2017.03.002
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Sun T, 2017, ONCOTARGET, V8, P74781, DOI 10.18632/oncotarget.20367
   Szarynska M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30525-3
   Szarynska M, 2017, ONCOL LETT, V14, P7653, DOI 10.3892/ol.2017.7261
   Szarynska M, 2017, INT J ONCOL, V51, P975, DOI 10.3892/ijo.2017.4083
   Takeishi S, 2016, CANCER SCI, V107, P875, DOI 10.1111/cas.12958
   Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592
   Thorat MA, 2013, CURR ONCOL REP, V15, P533, DOI 10.1007/s11912-013-0351-3
   Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031
   Valverde A, 2017, ONCOTARGET, V8, P21754, DOI 10.18632/oncotarget.15567
   Van Emburgh BO, 2014, MOL ONCOL, V8, P1084, DOI 10.1016/j.molonc.2014.05.003
   Virgone-Carlotta A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188100
   Wang HF, 2017, CELL PHYSIOL BIOCHEM, V44, P1051, DOI 10.1159/000485405
   Wang SS, 2015, ONCOTARGETS THER, V8, P2973, DOI 10.2147/OTT.S91863
   Wang ZM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/364207
   Weiswald LB, 2015, NEOPLASIA, V17, P1, DOI 10.1016/j.neo.2014.12.004
   Xu F, 2017, ONCOTARGET, V8, P6003, DOI 10.18632/oncotarget.13990
   Xu XT, 2017, AM J TRANSL RES, V9, P1088
   Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109
   Ye XQ, 2011, INT J CANCER, V129, P820, DOI 10.1002/ijc.25944
NR 89
TC 8
Z9 8
U1 0
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD JUL
PY 2019
VL 55
IS 1
BP 223
EP 242
DI 10.3892/ijo.2019.4809
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IK4LE
UT WOS:000476557600019
PM 31180528
OA Bronze
DA 2022-04-25
ER

PT J
AU Narsale, AA
   Carson, JA
AF Narsale, Aditi A.
   Carson, James A.
TI Role of interleukin-6 in cachexia: therapeutic implications
SO CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE
LA English
DT Review
DE cancer cachexia; gut; IL-6 therapies; liver; skeletal muscle
ID SKELETAL-MUSCLE; CANCER CACHEXIA; COLORECTAL-CANCER; IL-6; TOCILIZUMAB;
   PATHWAY; SUPPRESSION; TURNOVER; ANTIBODY; SYSTEM
AB Purpose of review
   Interleukin-6 (IL-6) has emerged as a cytokine involved in cachexia progression with some cancers. This review will present the recent breakthroughs in animal models and humans related to targeting IL-6 as a cancer cachexia therapy.
   Recent findings
   IL-6 can target adipose, skeletal muscle, gut, and liver tissue, which can all affect cachectic patient recovery. IL-6 trans-signaling through the soluble IL-6R has the potential to amplify IL-6 signaling in the cachectic patient. In the skeletal muscle, chronic IL-6 exposure induces proteasome and autophagy protein degradation pathways that lead to wasting. IL-6 is also indirectly associated with AMP-activated kinase (AMPK) and nuclear factor kappa B (NF-kappa B) activation. Several mouse cancer models have clearly demonstrated that blocking IL-6 and associated signaling can attenuate cachexia progression. Additionally, pharmaceuticals targeting IL-6 and associated signaling can relieve some cachectic symptoms in cancer patients. Research with cachectic mice has demonstrated that exercise and nutraceutical administration can interact with chronic IL-6 signaling during cachexia progression.
   Summary
   IL-6 remains a promising therapeutic strategy for attenuating cachexia progression with many types of cancer. However, improvement of this treatment will require a better understanding of the indirect and direct effects of IL-6 as well as its tissue-specific actions in the cancer patient.
C1 [Narsale, Aditi A.; Carson, James A.] Univ S Carolina, Dept Exercise Sci, Integrat Muscle Biol Lab, Columbia, SC 29208 USA.
   [Narsale, Aditi A.; Carson, James A.] Univ S Carolina, Dept Exercise Sci, Div Appl Physiol, Columbia, SC 29208 USA.
   [Carson, James A.] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA.
RP Carson, JA (corresponding author), Univ S Carolina, Publ Hlth Res Ctr, Dept Exercise Sci, Room 405,921 Assembly St, Columbia, SC 29208 USA.
EM carsonj@mailbox.sc.edu
RI Carson, James/Q-5693-2019; Narsale, Aditi/U-4643-2019
OI Carson, James/0000-0003-3733-8796; Narsale, Aditi/0000-0002-1421-5104
FU NCIUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)
   [RO1CA121249]; NATIONAL CANCER INSTITUTEUnited States Department of
   Health & Human ServicesNational Institutes of Health (NIH) - USANIH
   National Cancer Institute (NCI) [R01CA121249] Funding Source: NIH
   RePORTER
FX J.A.C. is currently being funded by the NCI grant RO1CA121249.
CR Amitani M, 2013, INT J BIOCHEM CELL B, V45, P2179, DOI 10.1016/j.biocel.2013.07.016
   Ando K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102436
   Ando K, 2013, J CLIN ONCOL, V31, pE69, DOI 10.1200/JCO.2012.44.2020
   Bayliss TJ, 2011, EXPERT OPIN BIOL TH, V11, P1663, DOI 10.1517/14712598.2011.627850
   Begue G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057141
   Berti A, 2013, J CLIN ONCOL, V31, P2970, DOI 10.1200/JCO.2012.48.4147
   Bindels LB, 2013, INT J BIOCHEM CELL B, V45, P2186, DOI 10.1016/j.biocel.2013.06.021
   Bindels LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037971
   Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012
   Bonetto A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022538
   Carow B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00058
   Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379
   Egerman MA, 2014, CRIT REV BIOCHEM MOL, V49, P59, DOI 10.3109/10409238.2013.857291
   Fearon K, 2013, NAT REV CLIN ONCOL, V10, P90, DOI 10.1038/nrclinonc.2012.209
   Fearon KCH, 2012, CELL METAB, V16, P153, DOI 10.1016/j.cmet.2012.06.011
   Gallagher IJ, 2012, CLIN CANCER RES, V18, P2817, DOI 10.1158/1078-0432.CCR-11-2133
   Gordon BS, 2013, INT J BIOCHEM CELL B, V45, P2147, DOI 10.1016/j.biocel.2013.05.039
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Hirata H, 2013, J PAIN SYMPTOM MANAG, V46, pE9, DOI 10.1016/j.jpainsymman.2013.01.009
   Johns N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083618
   Jones A, 2013, EMBO MOL MED, V5, P294, DOI 10.1002/emmm.201201869
   Laine A, 2013, MOL CANCER RES, V11, P967, DOI 10.1158/1541-7786.MCR-13-0189
   Mi L, 2012, HEPATO-GASTROENTEROL, V59, P2348, DOI 10.5754/hge11810
   Morley JE, 2014, J CACHEXIA SARCOPENI, V5, P83, DOI 10.1007/s13539-014-0149-7
   Onesti JK, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/168407
   Penna F, 2013, MECH BASED THERAPEUT
   Petruzzelli M, 2014, CELL METAB, V20, P433, DOI 10.1016/j.cmet.2014.06.011
   Puppa M.J., 2012, BIOCHIM BIOPHYS ACTA, V1812, P1601
   Puppa MJ, 2014, J APPL PHYSIOL, V116, P1078, DOI 10.1152/japplphysiol.01270.2013
   Puppa MJ, 2014, FASEB J, V28, P998, DOI 10.1096/fj.13-240580
   Puppa MJ, 2012, J CACHEXIA SARCOPENI, V3, P117, DOI 10.1007/s13539-011-0047-1
   Ruzzo A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-357
   Scheller J, 2014, SEMIN IMMUNOL, V26, P2, DOI 10.1016/j.smim.2013.11.002
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Sommer J, 2014, INT J MOL MED, V34, P651, DOI 10.3892/ijmm.2014.1825
   Srivastava DS, 2013, AM J CANC BIOL, V1, P8
   Stephens NA, 2010, GENOME MED, V2, DOI 10.1186/gm122
   Suh SY, 2013, SUPPORT CARE CANCER, V21, P3071, DOI 10.1007/s00520-013-1878-4
   Sumpter TL, 2012, J IMMUNOL, V189, P3848, DOI 10.4049/jimmunol.1200819
   Suzuki H, 2013, J GASTROENTEROL, V48, P574, DOI 10.1007/s00535-013-0787-0
   Tachibana S, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-6
   Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001
   Tardif N, 2013, AM J CLIN NUTR, V98, P1485, DOI 10.3945/ajcn.113.063859
   Tuca A, 2013, CRIT REV ONCOL HEMAT, V88, P625, DOI 10.1016/j.critrevonc.2013.07.015
   Ulrich CM, 2012, BIOL PATHWAYS IMPACT, P59
   Velazquez KT, 2014, J NUTR, V144, P868, DOI 10.3945/jn.113.188367
   Wang KP, 2013, ANN RHEUM DIS, V72, P100, DOI 10.1136/annrheumdis-2012-202201
   Wen HS, 2012, CHEMOTHERAPY, V58, P461, DOI 10.1159/000346446
   White JP, 2013, BIOL OPEN, V2, P1346, DOI 10.1242/bio.20136544
   White JP, 2013, AM J PHYSIOL-ENDOC M, V304, pE1042, DOI 10.1152/ajpendo.00410.2012
   White JP, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-14
   White JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024650
   White UA, 2011, CURR PHARM DESIGN, V17, P340
   Williams JP, 2012, AM J CLIN NUTR, V96, P1064, DOI 10.3945/ajcn.112.045708
   Winter A, 2012, CLIN NUTR, V31, P765, DOI 10.1016/j.clnu.2012.05.003
   Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024
   Yang YQ, 2008, ENDOCRINE, V33, P261, DOI 10.1007/s12020-008-9085-7
NR 57
TC 105
Z9 107
U1 0
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1751-4258
EI 1751-4266
J9 CURR OPIN SUPPORT PA
JI Curr. Opin Support Palliat. Car.
PD DEC
PY 2014
VL 8
IS 4
BP 321
EP 327
DI 10.1097/SPC.0000000000000091
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA AT2CA
UT WOS:000344737500002
PM 25319274
OA Green Accepted
DA 2022-04-25
ER

PT J
AU Lin, Z
   Hegarty, JP
   Cappel, JA
   Yu, W
   Chen, X
   Faber, P
   Wang, Y
   Kelly, AA
   Poritz, LS
   Peterson, BZ
   Schreiber, S
   Fan, JB
   Koltun, WA
AF Lin, Z.
   Hegarty, J. P.
   Cappel, J. A.
   Yu, W.
   Chen, X.
   Faber, P.
   Wang, Y.
   Kelly, A. A.
   Poritz, L. S.
   Peterson, B. Z.
   Schreiber, S.
   Fan, J-B
   Koltun, W. A.
TI Identification of disease-associated DNA methylation in intestinal
   tissues from patients with inflammatory bowel disease
SO CLINICAL GENETICS
LA English
DT Article
DE Crohn's disease; DNA methylation; inflammatory bowel disease; intestinal
   tissue; ulcerative colitis
ID GENOME-WIDE ASSOCIATION; ULCERATIVE-COLITIS; SUSCEPTIBILITY LOCI;
   COLORECTAL-CANCER; CROHN-DISEASE; GENE; HYPERMETHYLATION; EPIGENETICS;
   AUTOPHAGY; DEFINES
AB Overwhelming evidence supports the theory that inflammatory bowel disease (IBD) is caused by a complex interplay between genetic predispositions of multiple genes, combined with an abnormal interaction with environmental factors. It is becoming apparent that epigenetic factors can have a significant contribution in the pathogenesis of disease. Changes in the methylation state of IBD-associated genes could significantly alter levels of gene expression, potentially contributing to disease onset and progression. We have explored the role of DNA methylation in IBD pathogenesis. DNA methylation profiles (1505 CpG sites of 807 genes) of matched diseased (n = 26) and non-diseased (n = 26) intestinal tissues from 26 patients with IBD [Crohn's disease (CD) n = 9, ulcerative colitis (UC) n = 17] were profiled using the GoldenGate (TM) methylation assay. After an initial identification of a panel of 50 differentially methylated CpG sites from a training set (14 non-diseased and 14 diseased tissues) and subsequent validation with a testing set (12 non-diseased and 12 diseased tissues), we identified seven CpG sites that are differentially methylated in intestinal tissues of IBD patients. We have also identified changes in DNA methylation associated with the two major IBD subtypes, CD and UC. This study reports IBD-associated changes in DNA methylation in intestinal tissue, which may be disease subtype-specific.
C1 [Lin, Z.; Hegarty, J. P.; Cappel, J. A.; Yu, W.; Wang, Y.; Kelly, A. A.; Poritz, L. S.; Koltun, W. A.] Penn State Univ, Dept Surg, Coll Med, Hershey, PA 17033 USA.
   [Chen, X.] Vanderbilt Univ, Dept Biostat, Nashville, TN USA.
   [Faber, P.] Cleveland Clin, Inst Mol Med, Cleveland, OH 44106 USA.
   [Poritz, L. S.; Peterson, B. Z.] Penn State Univ, Dept Cell & Mol Physiol, Coll Med, Hershey, PA 17033 USA.
   [Schreiber, S.] Univ Kiel, Inst Clin Mol Biol, Kiel, Germany.
   [Fan, J-B] Illumina Inc, San Diego, CA USA.
RP Lin, Z (corresponding author), Penn State Univ, Dept Surg, Coll Med, 500 Univ Dr,H 137, Hershey, PA 17033 USA.
EM zlin@hmc.psu.edu; wkoltun@hmc.psu.edu
RI yu, wei/B-5859-2011
FU Philadelphia Health Care Trust, Philadelphia, PA; Department of Surgery,
   The Pennsylvania State University College of Medicine, Hershey, PA
FX This study was supported by a grant from the Philadelphia Health Care
   Trust, Philadelphia, PA (W. A. K.) and a feasibility research grant from
   the Department of Surgery, The Pennsylvania State University College of
   Medicine, Hershey, PA (Z. L.).
CR Ahmed FE, 2007, J ENVIRON SCI HEAL C, V25, P101, DOI 10.1080/10590500701399184
   Anderson CA, 2009, GASTROENTEROLOGY, V136, P523, DOI 10.1053/j.gastro.2008.10.032
   Azarschab P, 2002, GENE CHROMOSOME CANC, V35, P121, DOI 10.1002/gcc.10101
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245
   Fisher SA, 2008, NAT GENET, V40, P710, DOI 10.1038/ng.145
   Fujii S, 2005, GUT, V54, P1287, DOI 10.1136/gut.2004.062059
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Issa JPJ, 2001, CANCER RES, V61, P3573
   Lin ZW, 2007, INT J ONCOL, V31, P181
   Maeda O., 2006, Inflammopharmacology, V14, P204, DOI 10.1007/s10787-006-1540-6
   Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038
   Parkes M, 2007, NAT GENET, V39, P830, DOI 10.1038/ng2061
   Petronis A, 2000, GUT, V47, P302, DOI 10.1136/gut.47.2.302
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Sato F, 2002, CANCER RES, V62, P1148
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Shames DS, 2007, CURR MOL MED, V7, P85, DOI 10.2174/156652407779940413
   Tahara T, 2009, INT J MOL MED, V23, P521, DOI 10.3892/ijmm_00000160
   Toyota M, 2002, J GASTROENTEROL, V37, P97, DOI 10.1007/BF03326425
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   Vamadevan AS, 2010, INNATE IMMUN-LONDON, V16, P93, DOI 10.1177/1753425909339231
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wong JJL, 2007, GUT, V56, P140, DOI 10.1136/gut.2005.088799
   Xavier RJ, 2008, NAT REV IMMUNOL, V8, P631, DOI 10.1038/nri2361
   Yamazaki K, 2005, HUM MOL GENET, V14, P3499, DOI 10.1093/hmg/ddi379
NR 30
TC 56
Z9 58
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD JUL
PY 2011
VL 80
IS 1
BP 59
EP 67
DI 10.1111/j.1399-0004.2010.01546.x
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 774QW
UT WOS:000291402200009
PM 20950376
DA 2022-04-25
ER

PT J
AU Bernatsky, S
   Ramsey-Goldman, R
   Urowitz, MB
   Hanly, JG
   Gordon, C
   Petri, MA
   Ginzler, EM
   Wallace, DJ
   Bae, SC
   Romero-Diaz, J
   Dooley, MA
   Peschken, CA
   Isenberg, DA
   Rahman, A
   Manzi, S
   Jacobsen, S
   Lim, SS
   van Vollenhoven, R
   Nived, O
   Kamen, DL
   Aranow, C
   Ruiz-Irastorza, G
   Sanchez-Guerrero, J
   Gladman, DD
   Fortin, PR
   Alarcon, GS
   Merrill, JT
   Kalunian, KC
   Ramos-Casals, M
   Steinsson, K
   Zoma, A
   Askanase, A
   Khamashta, MA
   Bruce, I
   Inanc, M
   Clarke, AE
AF Bernatsky, Sasha
   Ramsey-Goldman, Rosalind
   Urowitz, Murray B.
   Hanly, John G.
   Gordon, Caroline
   Petri, Michelle A.
   Ginzler, Ellen M.
   Wallace, Daniel J.
   Bae, Sang-Cheol
   Romero-Diaz, Juanita
   Dooley, Mary Anne
   Peschken, Christine A.
   Isenberg, David A.
   Rahman, Anisur
   Manzi, Susan
   Jacobsen, Soren
   Lim, S. Sam
   van Vollenhoven, Ronald
   Nived, Ola
   Kamen, Diane L.
   Aranow, Cynthia
   Ruiz-Irastorza, Guillermo
   Sanchez-Guerrero, Jorge
   Gladman, Dafna D.
   Fortin, Paul R.
   Alarcon, Graciela S.
   Merrill, Joan T.
   Kalunian, Kenneth C.
   Ramos-Casals, Manuel
   Steinsson, Kristjan
   Zoma, Asad
   Askanase, Anca
   Khamashta, Munther A.
   Bruce, Ian
   Inanc, Murat
   Clarke, Ann E.
TI Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort:
   Effects of Demographic Characteristics, Smoking, and Medications
SO ARTHRITIS CARE & RESEARCH
LA English
DT Article
ID DISEASE-ACTIVITY; MALIGNANCY; HYDROXYCHLOROQUINE; AUTOPHAGY
AB Objective To assess cancer risk factors in incident systemic lupus erythematosus (SLE). Methods Clinical variables and cancer outcomes were assessed annually among incident SLE patients. Multivariate hazard regression models (overall risk and most common cancers) included demographic characteristics and time-dependent medications (corticosteroids, antimalarial drugs, immunosuppressants), smoking, and the adjusted mean Systemic Lupus Erythematosus Disease Activity Index 2000 score. Results Among 1,668 patients (average 9 years follow-up), 65 cancers occurred: 15 breast, 10 nonmelanoma skin, 7 lung, 6 hematologic, 6 prostate, 5 melanoma, 3 cervical, 3 renal, 2 each gastric, head and neck, and thyroid, and 1 each rectal, sarcoma, thymoma, and uterine cancers. Half of the cancers (including all lung cancers) occurred in past/current smokers, versus one-third of patients without cancer. Multivariate analyses indicated that overall cancer risk was related primarily to male sex and older age at SLE diagnosis. In addition, smoking was associated with lung cancer. For breast cancer risk, age was positively associated and antimalarial drugs were negatively associated. Antimalarial drugs and higher disease activity were also negatively associated with nonmelanoma skin cancer risk, whereas age and cyclophosphamide were positively associated. Disease activity was associated positively with hematologic and negatively with nonmelanoma skin cancer risk. Conclusion Smoking is a key modifiable risk factor, especially for lung cancer, in SLE. Immunosuppressive medications were not clearly associated with higher risk except for cyclophosphamide and nonmelanoma skin cancer. Antimalarials were negatively associated with breast cancer and nonmelanoma skin cancer risk. SLE activity was associated positively with hematologic cancer and negatively with nonmelanoma skin cancer. Since the absolute number of cancers was small, additional follow-up will help consolidate these findings.
C1 [Bernatsky, Sasha] McGill Univ, Montreal, PQ, Canada.
   [Ramsey-Goldman, Rosalind] Northwestern Univ, Chicago, IL 60611 USA.
   [Ramsey-Goldman, Rosalind] Feinberg Sch Med, Chicago, IL 60611 USA.
   [Urowitz, Murray B.; Sanchez-Guerrero, Jorge; Gladman, Dafna D.] Toronto Western Hosp, Toronto, ON, Canada.
   [Urowitz, Murray B.; Sanchez-Guerrero, Jorge; Gladman, Dafna D.] Univ Toronto, Toronto, ON, Canada.
   [Hanly, John G.] Queen Elizabeth II Hlth Sci, Halifax, NS, Canada.
   [Hanly, John G.] Dalhousie Univ, Halifax, NS, Canada.
   [Gordon, Caroline] Univ Birmingham, Coll Med & Dent Sci, Birmingham, W Midlands, England.
   [Petri, Michelle A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Ginzler, Ellen M.] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA.
   [Wallace, Daniel J.] Univ Calif Los Angeles, David Geffen Sch Med, Cedars Sinai, Los Angeles, CA 90095 USA.
   [Bae, Sang-Cheol] Hanyang Univ, Hosp Rheumat Dis, Seoul, South Korea.
   [Romero-Diaz, Juanita] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.
   [Dooley, Mary Anne] Univ N Carolina, Chapel Hill, NC 27515 USA.
   [Peschken, Christine A.] Univ Manitoba, Winnipeg, MB, Canada.
   [Isenberg, David A.] UCL, London, England.
   [Manzi, Susan] Allegheny Hlth Network, Pittsburgh, PA USA.
   [Jacobsen, Soren] Copenhagen Univ Hosp, Rigshosp, Copenhagen, Denmark.
   [Lim, S. Sam] Emory Univ, Atlanta, GA 30322 USA.
   [van Vollenhoven, Ronald] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
   [Nived, Ola] Lund Univ, Lund, Sweden.
   [Kamen, Diane L.] Med Univ South Carolina, Charleston, SC 29425 USA.
   [Aranow, Cynthia] Feinstein Inst Med Res, Manhasset, NY USA.
   [Ruiz-Irastorza, Guillermo] Univ Basque Country, Hosp Univ Cruces, Baracaldo, Spain.
   [Fortin, Paul R.] Univ Laval, CHU Quebec, Quebec City, PQ, Canada.
   [Alarcon, Graciela S.] Univ Alabama Birmingham, Birmingham, AL USA.
   [Merrill, Joan T.] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.
   [Kalunian, Kenneth C.] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA.
   [Ramos-Casals, Manuel] Hosp Clin Barcelona, Barcelona, Spain.
   [Steinsson, Kristjan] Fossvogur Landspitali Univ Hosp, Reykjavik, Iceland.
   [Zoma, Asad] Hairmyres Hosp, E Kilbride, Lanark, Scotland.
   [Askanase, Anca] Columbia Univ, Coll Phys & Surg, New York, NY USA.
   [Khamashta, Munther A.] Kings Coll London, St Thomas Hosp, Sch Med, London, England.
   [Bruce, Ian] Univ Manchester, Manchester, Lancs, England.
   [Bruce, Ian] Manchester Univ NHS Fdn Trust, NIHR Manchester Musculoskeletal Biomed Res Ctr, Manchester, Lancs, England.
   [Bruce, Ian] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Inanc, Murat] Istanbul Univ, Istanbul Fac Med, Istanbul, Turkey.
   [Clarke, Ann E.] Univ Calgary, Cumming Sch Med, Calgary, AB, Canada.
RP Bernatsky, S (corresponding author), Div Clin Epidemiol, 5252 Boul Maisonneuve Ouest,3F-51, Montreal, PQ H4A 3S5, Canada.
EM Sasha.bernatsky@mcgill.ca
RI van Vollenhoven, Ronald/ABE-1244-2021
OI Gordon, Caroline/0000-0002-1244-6443; Bernatsky,
   Sasha/0000-0002-9515-2802; Kalunian, Kenneth/0000-0003-0261-3102;
   Urowitz, Murray B./0000-0001-7506-9166; Jacobsen,
   Soren/0000-0002-5654-4993
FU Montreal General Hospital Lupus Clinic; Singer Family Fund for Lupus
   Research; NIHUnited States Department of Health & Human ServicesNational
   Institutes of Health (NIH) - USA [5UL1-TR-001422-02, 8UL1-TR-000150,
   UL-1RR-025741, K24-AR-02318, P60-AR-064464, P60-AR-48098, RR-00046];
   Lupus UK; West Birmingham Hospitals NHS Trust; National Institute for
   Health Research/Wellcome Trust Birmingham Clinical Research Facility
   [AR-69572]; Republic of Korea [NRF-2017M3A9B4050335]; National Institute
   for Health Research University College London Hospitals Biomedical
   Research CentreGeneral Electric; Danish Rheumatism Association [A3865];
   Novo Nordisk FoundationNovo Nordisk FoundationNovocure Limited [A05990];
   Centers for Disease Control and PreventionUnited States Department of
   Health & Human ServicesCenters for Disease Control & Prevention - USA
   [U01DP005119]; Department of Education, Universities, and Research of
   the Basque Government; Arthritis Research UKVersus Arthritis; NIHR
   Manchester Biomedical Centre; NIHR/Wellcome Trust Manchester Clinical
   Research Facility; Arthritis Society Chair in Rheumatic Diseases at the
   University of Calgary
FX Dr. Bernatsky's work was supported by the Montreal General Hospital
   Lupus Clinic, which is supported by the Singer Family Fund for Lupus
   Research. Dr. Ramsey-Goldman's work was supported by the NIH
   (5UL1-TR-001422-02, formerly 8UL1-TR-000150 and UL-1RR-025741,
   K24-AR-02318, and P60-AR-064464, formerly P60-AR-48098). Dr. Gordon's
   work was supported by Lupus UK, Sandwell, and West Birmingham Hospitals
   NHS Trust and the National Institute for Health Research/Wellcome Trust
   Birmingham Clinical Research Facility. Dr. Petri's work was supported by
   the Hopkins Lupus Cohort (NIH AR-69572). Dr. Bae's work was supported by
   the Republic of Korea (NRF-2017M3A9B4050335). Dr. Dooley's work was
   supported by the NIH (RR-00046). Dr. Isenberg's and Dr. Rahman's work
   was supported by the National Institute for Health Research University
   College London Hospitals Biomedical Research Centre. Dr. Jacobsen's work
   was supported by the Danish Rheumatism Association (A3865) and the Novo
   Nordisk Foundation (A05990). Dr. Lim's work was supported by the Centers
   for Disease Control and Prevention (U01DP005119). Dr. Ruiz-Irastorza's
   work was supported by the Department of Education, Universities, and
   Research of the Basque Government. Dr. Fortin holds a Tier 1 Canada
   Research Chair on Systemic Autoimmune Rheumatic Diseases at Universite
   Laval. Dr. Bruce is a National Institute for Health Research (NIHR)
   Senior Investigator and is supported by Arthritis Research UK, the NIHR
   Manchester Biomedical Centre and the NIHR/Wellcome Trust Manchester
   Clinical Research Facility. Dr. Clarke holds The Arthritis Society Chair
   in Rheumatic Diseases at the University of Calgary.
CR Akinyemiju T, 2018, ANN EPIDEMIOL, V28, P33, DOI 10.1016/j.annepidem.2017.11.003
   Baez CF, 2019, EUR J CLIN MICROBIOL, V38, P1129, DOI 10.1007/s10096-019-03508-z
   Bernatsky S, 2008, ANN RHEUM DIS, V67, P277, DOI 10.1136/ard.2007.075705
   Bernatsky S, 2008, ANN RHEUM DIS, V67, P74, DOI 10.1136/ard.2006.069039
   Bernatsky S, 2005, ARTHRIT RHEUM-ARTHR, V53, P781, DOI 10.1002/art.21458
   Bernatsky S, 2018, J RHEUMATOL, V45, P393, DOI 10.3899/jrheum.170652
   Bernatsky S, 2014, ANN RHEUM DIS, V73, P138, DOI 10.1136/annrheumdis-2012-202099
   Bernatsky S, 2013, J AUTOIMMUN, V42, P130, DOI 10.1016/j.jaut.2012.12.009
   Chung EYM, 2019, TRANSPLANTATION, V103, P1206, DOI 10.1097/TP.0000000000002641
   Clouser MC, 2006, CANCER EPIDEM BIOMAR, V15, P2292, DOI 10.1158/1055-9965.EPI-06-0405
   Cook KL, 2014, CLIN CANCER RES, V20, P3222, DOI 10.1158/1078-0432.CCR-13-3227
   Dey D, 2013, LUPUS, V22, P919, DOI 10.1177/0961203313497118
   Dreyer L, 2011, ARTHRITIS RHEUM-US, V63, P3032, DOI 10.1002/art.30483
   Eder L, 2013, LUPUS, V22, P1225, DOI 10.1177/0961203313492872
   Egiziano G, 2016, BEST PRACT RES CL RH, V30, P53, DOI 10.1016/j.berh.2016.03.001
   Faurschou M, 2008, J RHEUMATOL, V35, P100
   Goldberg SB, 2012, J THORAC ONCOL, V7, P1602, DOI 10.1097/JTO.0b013e318262de4a
   Hochberg MC, 1997, ARTHRITIS RHEUM, V40, P1725, DOI 10.1002/art.1780400928
   Ibanez D, 2003, J RHEUMATOL, V30, P1977
   Kidane D, 2014, CRIT REV BIOCHEM MOL, V49, P116, DOI 10.3109/10409238.2013.875514
   King Catherine, 2017, Curr Treatm Opt Rheumatol, V3, P230, DOI 10.1007/s40674-017-0082-y
   Li Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0938-5
   O'Keeffe LM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021611
   Parikh-Patel A, 2008, CANCER CAUSE CONTROL, V19, P887, DOI 10.1007/s10552-008-9151-8
   Ramsey-Goldman R, 1998, J INVEST MED, V46, P217
   Ruiz-Irastorza G, 2007, ANN RHEUM DIS, V66, P815, DOI 10.1136/ard.2006.067777
   Urowitz Murray B, 2008, Curr Rheumatol Rep, V10, P281, DOI 10.1007/s11926-008-0045-2
   van den Brand JAJG, 2014, CLIN J AM SOC NEPHRO, V9, P1066, DOI 10.2215/CJN.08880813
   Yang W, 2018, FASEB J, V32, P1222, DOI 10.1096/fj.201700477R
   Zaalberg A, 2019, J INVEST DERMATOL, V139, P62, DOI 10.1016/j.jid.2018.06.185
NR 30
TC 1
Z9 1
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2151-464X
EI 2151-4658
J9 ARTHRIT CARE RES
JI Arthritis Care Res.
PD DEC
PY 2021
VL 73
IS 12
BP 1789
EP 1795
DI 10.1002/acr.24425
EA OCT 2021
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA XM4RL
UT WOS:000706551200001
PM 32813314
DA 2022-04-25
ER

PT J
AU Kulka, LAM
   Fangmann, PV
   Panfilova, D
   Olzscha, H
AF Kulka, Linda Anna Michelle
   Fangmann, Pia-Victoria
   Panfilova, Diana
   Olzscha, Heidi
TI Impact of HDAC Inhibitors on Protein Quality Control Systems:
   Consequences for Precision Medicine in Malignant Disease
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE autophagy; bromodomain-containing protein; epigenetic drug; histone
   deacetylase inhibitor; molecular chaperone; precision medicine; protein
   quality control; ubiquitin proteasome system
ID HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; CELL
   LUNG-CANCER; SYNERGISTIC ANTITUMOR-ACTIVITY; ORAL PANOBINOSTAT LBH589;
   MESSENGER-RNA EXPRESSION; HUMAN COLORECTAL-CANCER; HIGH-DOSE
   DEXAMETHASONE; PHASE-I TRIAL; MULTIPLE-MYELOMA
AB Lysine acetylation is one of the major posttranslational modifications (PTM) in human cells and thus needs to be tightly regulated by the writers of this process, the histone acetyl transferases (HAT), and the erasers, the histone deacetylases (HDAC). Acetylation plays a crucial role in cell signaling, cell cycle control and in epigenetic regulation of gene expression. Bromodomain (BRD)-containing proteins are readers of the acetylation mark, enabling them to transduce the modification signal. HDAC inhibitors (HDACi) have been proven to be efficient in hematologic malignancies with four of them being approved by the FDA. However, the mechanisms by which HDACi exert their cytotoxicity are only partly resolved. It is likely that HDACi alter the acetylation pattern of cytoplasmic proteins, contributing to their anti-cancer potential. Recently, it has been demonstrated that various protein quality control (PQC) systems are involved in recognizing the altered acetylation pattern upon HDACi treatment. In particular, molecular chaperones, the ubiquitin proteasome system (UPS) and autophagy are able to sense the structurally changed proteins, providing additional targets. Recent clinical studies of novel HDACi have proven that proteins of the UPS may serve as biomarkers for stratifying patient groups under HDACi regimes. In addition, members of the PQC systems have been shown to modify the epigenetic readout of HDACi treated cells and alter proteostasis in the nucleus, thus contributing to changing gene expression profiles. Bromodomain (BRD)-containing proteins seem to play a potent role in transducing the signaling process initiating apoptosis, and many clinical trials are under way to test BRD inhibitors. Finally, it has been demonstrated that HDACi treatment leads to protein misfolding and aggregation, which may explain the effect of panobinostat, the latest FDA approved HDACi, in combination with the proteasome inhibitor bortezomib in multiple myeloma. Therefore, proteins of these PQC systems provide valuable targets for precision medicine in cancer. In this review, we give an overview of the impact of HDACi treatment on PQC systems and their implications for malignant disease. We exemplify the development of novel HDACi and how affected proteins belonging to PQC can be used to determine molecular signatures and utilized in precision medicine.
C1 [Kulka, Linda Anna Michelle; Fangmann, Pia-Victoria; Panfilova, Diana; Olzscha, Heidi] Martin Luther Univ Halle Wittenberg, Inst Physiol Chem, Fac Med, Halle, Saale, Germany.
RP Olzscha, H (corresponding author), Martin Luther Univ Halle Wittenberg, Inst Physiol Chem, Fac Med, Halle, Saale, Germany.
EM Heidi.Olzscha@medizin.uni-halle.de
RI Olzscha, Heidi/AAU-1296-2020
OI Olzscha, Heidi/0000-0002-1929-1384
FU DFGGerman Research Foundation (DFG)European Commission [RTK 2155, FKZ
   PK28]
FX LK and HO were supported by the DFG, RTK 2155 (ProMoAge) and P-VF by
   theWilhelm Roux Program HaPKoM (FKZ PK28).
CR Abaza MSI, 2010, EXP THER MED, V1, P675, DOI 10.3892/etm_00000106
   Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361
   Aldana-Masangkay GI, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/875824
   Alqahtani A, 2019, FUTUR SCI OA, V5, DOI 10.4155/fsoa-2018-0115
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Amemiya S, 2017, BIOORGAN MED CHEM, V25, P3677, DOI 10.1016/j.bmc.2017.04.043
   An B, 1998, CELL DEATH DIFFER, V5, P1062, DOI 10.1038/sj.cdd.4400436
   Annunziato AT, 2000, GENE EXPRESSION, V9, P37
   Arora SP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3551
   Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Atkinson AJ, 2001, CLIN PHARMACOL THER, V69, P89, DOI 10.1067/mcp.2000.113989
   Atkinson SJ, 2014, MEDCHEMCOMM, V5, P342, DOI 10.1039/c3md00285c
   Badros A, 2009, CLIN CANCER RES, V15, P5250, DOI 10.1158/1078-0432.CCR-08-2850
   Ban HS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194758
   Banerji U, 2009, CLIN CANCER RES, V15, P9, DOI 10.1158/1078-0432.CCR-08-0132
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Berdeja JG, 2015, HAEMATOLOGICA, V100, P670, DOI 10.3324/haematol.2014.119735
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bhutia SK, 2013, ADV CANCER RES, V118, P61, DOI 10.1016/B978-0-12-407173-5.00003-0
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Booth L, 2017, ONCOTARGET, V8, P16367, DOI 10.18632/oncotarget.14829
   Borbely G, 2015, ONCOTARGET, V6, P33623, DOI 10.18632/oncotarget.5601
   Boutouja F, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122541
   Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614
   Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407
   Braiteh F, 2008, CLIN CANCER RES, V14, P6296, DOI 10.1158/1078-0432.CCR-08-1247
   Buglio D, 2010, BRIT J HAEMATOL, V151, P387, DOI 10.1111/j.1365-2141.2010.08342.x
   Cagney DN, 2018, NEURO-ONCOLOGY, V20, P1162, DOI 10.1093/neuonc/nox242
   Califf RM, 2018, EXP BIOL MED, V243, P213, DOI 10.1177/1535370217750088
   Campbell RA, 2010, EUR J HAEMATOL, V84, P201, DOI 10.1111/j.1600-0609.2009.01384.x
   Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345
   Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311
   Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260
   Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
   Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x
   Caron C, 2005, BIOESSAYS, V27, P408, DOI 10.1002/bies.20210
   Cashen A, 2012, ANN HEMATOL, V91, P33, DOI 10.1007/s00277-011-1240-1
   Catley L, 2003, BLOOD, V102, P2615, DOI 10.1182/blood-2003-01-0233
   Catley L, 2006, BLOOD, V108, P3441, DOI 10.1182/blood-2006-04-016055
   Chaidos A, 2014, BLOOD, V123, P697, DOI 10.1182/blood-2013-01-478420
   Chen B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004374
   Chen T, 2002, ARCH BIOCHEM BIOPHYS, V408, P171, DOI 10.1016/S0003-9861(02)00564-7
   Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066
   Chiu HW, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0531-5
   Choi JH, 2001, JPN J CANCER RES, V92, P1300, DOI 10.1111/j.1349-7006.2001.tb02153.x
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Chun Y, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7120278
   Cloutier P, 2013, BBA-GENE REGUL MECH, V1829, P443, DOI 10.1016/j.bbagrm.2013.02.010
   Cohen TJ, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1255
   Coiffier B, 2012, J CLIN ONCOL, V30, P631, DOI 10.1200/JCO.2011.37.4223
   Condelli V, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060532
   Conery AR, 2016, ELIFE, V5, DOI [10.7554/eLife.10483, 10.7554/eLife.19432]
   Cosenza M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082337
   Coyle KM, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9620870
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   de Lera AR, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0271-9
   Dejligbjerg M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-70
   Deshpande A, 2005, ONCOGENE, V24, P2909, DOI 10.1038/sj.onc.1208618
   Dias SD, 2005, CANCER RES, V65, P10686, DOI 10.1158/0008-5472.CAN-05-2632
   Diaz T, 2017, HAEMATOLOGICA, V102, P1776, DOI 10.3324/haematol.2017.164632
   Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594
   Dimopoulos M, 2013, LANCET ONCOL, V14, P1129, DOI 10.1016/S1470-2045(13)70398-X
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Dong LH, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-53
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   Duan H, 2005, MOL CELL BIOL, V25, P1608, DOI 10.1128/MCB.25.5.1608-1619.2005
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Ellis L, 2008, CLIN CANCER RES, V14, P4500, DOI 10.1158/1078-0432.CCR-07-4262
   Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919
   Eyre TA, 2019, CANCER-AM CANCER SOC, V125, P99, DOI 10.1002/cncr.31791
   Eyupoglu IY, 2005, J NEUROCHEM, V93, P992, DOI 10.1111/j.1471-4159.2005.03098.x
   FDA, 2015, DRUG TRIALS SNAPSH F
   Feng YC, 2014, CELL RES, V24, P24, DOI 10.1038/cr.2013.168
   Fernald K, 2013, TRENDS CELL BIOL, V23, P620, DOI 10.1016/j.tcb.2013.07.006
   Field-Smith Antonia, 2006, Ther Clin Risk Manag, V2, P271, DOI 10.2147/tcrm.2006.2.3.271
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fotheringham S, 2009, CANCER CELL, V15, P57, DOI 10.1016/j.ccr.2008.12.001
   Fournel M, 2008, MOL CANCER THER, V7, P759, DOI 10.1158/1535-7163.MCT-07-2026
   Friday BB, 2012, NEURO-ONCOLOGY, V14, P215, DOI 10.1093/neuonc/nor198
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Fukutomi A, 2012, INVEST NEW DRUG, V30, P1096, DOI 10.1007/s10637-011-9666-9
   Gao L, 2002, J BIOL CHEM, V277, P25748, DOI 10.1074/jbc.M111871200
   Garcia-Manero G, 2007, J CLIN ONCOL, V25
   Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Goldberg AL, 2007, BIOCHEM SOC T, V35, P12, DOI 10.1042/BST0350012
   Gozzetti Alessandro, 2014, Central Nervous System Agents in Medicinal Chemistry, V14, P23
   Groen K, 2019, CANCER MANAG RES, V11, P2663, DOI 10.2147/CMAR.S150653
   Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Grunstein E, 2019, ARCH PHARM, V352, DOI 10.1002/ardp.201900026
   Grunstein E., 2018, THESIS
   Gu YY, 2014, BLOOD, V123, P3269, DOI 10.1182/blood-2013-08-521914
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Gump JM, 2011, TRENDS CELL BIOL, V21, P387, DOI 10.1016/j.tcb.2011.03.007
   Gunst JD, 2019, J VIRUS ERAD, V5, P133
   Hakami NY, 2016, J CELL MOL MED, V20, P1932, DOI 10.1111/jcmm.12885
   Halkidou K, 2004, PROSTATE, V59, P177, DOI 10.1002/pros.20022
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839
   Harris GF, 2008, ARCH OTOLARYNGOL, V134, P157, DOI 10.1001/archoto.2007.37
   Hartl FU, 2009, NAT STRUCT MOL BIOL, V16, P574, DOI 10.1038/nsmb.1591
   Hay DA, 2014, J AM CHEM SOC, V136, P9308, DOI 10.1021/ja412434f
   Heider U, 2008, EUR J HAEMATOL, V80, P133, DOI 10.1111/j.1600-0609.2007.00995.x
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Hoang T, 2014, INVEST NEW DRUG, V32, P195, DOI 10.1007/s10637-013-9980-5
   Holkova B, 2016, LEUKEMIA LYMPHOMA, V57, P635, DOI 10.3109/10428194.2015.1075019
   Holkova B, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.1794.1794
   Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567
   Huang FI, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00249
   Huang WJ, 2014, CANCER LETT, V346, P84, DOI 10.1016/j.canlet.2013.12.016
   Hug BA, 2004, ONCOGENE, V23, P4270, DOI 10.1038/sj.onc.1207674
   Hyun SY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32196-6
   Issa JP, 2015, CANCER-AM CANCER SOC, V121, P556, DOI 10.1002/cncr.29085
   Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71
   Jarosz D, 2016, ADV CANCER RES, V129, P225, DOI 10.1016/bs.acr.2015.11.001
   Jeng Wilson, 2015, F1000Res, V4, DOI 10.12688/f1000research.7214.1
   Jin X, 2017, ONCOL LETT, V13, P4619, DOI 10.3892/ol.2017.6032
   John RM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00130
   Johnson DE, 2015, ENDOCR-RELAT CANCER, V22, pT1, DOI 10.1530/ERC-14-0005
   Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772
   Jones DR, 2012, J THORAC ONCOL, V7, P1683, DOI 10.1097/JTO.0b013e318267928d
   Kahali S, 2010, NEOPLASIA, V12, P80, DOI 10.1593/neo.91422
   Kaliszczak M, 2018, BRIT J CANCER, V119, P1278, DOI 10.1038/s41416-018-0232-5
   Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913
   Kaufman JL, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-018-0154-8
   Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107
   Khan SB, 2004, BRIT J HAEMATOL, V125, P156, DOI 10.1111/j.1365-2141.2004.04882.x
   Khurana N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00100
   Kirschbaum MH, 2014, LEUKEMIA LYMPHOMA, V55, P2301, DOI 10.3109/10428194.2013.877134
   Kirschbaum MH, 2012, LEUKEMIA LYMPHOMA, V53, P259, DOI 10.3109/10428194.2011.608448
   Koprinarova M, 2016, CURR TOP MED CHEM, V16, P732, DOI 10.2174/1568026615666150825140822
   Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176
   Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021
   Kumar SK, 2017, LEUKEMIA, V31, P2443, DOI 10.1038/leu.2017.138
   Kung CP, 2011, CRIT REV EUKAR GENE, V21, P71, DOI 10.1615/CritRevEukarGeneExpr.v21.i1.50
   Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672
   LeBlanc R, 2002, CANCER RES, V62, P4996
   Lee AH, 2003, P NATL ACAD SCI USA, V100, P9946, DOI 10.1073/pnas.1334037100
   Leyk J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.415
   Leyk J, 2015, J MOL NEUROSCI, V55, P1031, DOI 10.1007/s12031-014-0460-y
   Li T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0654-9
   Li WW, 2012, CELL MOL LIFE SCI, V69, P1125, DOI 10.1007/s00018-011-0865-5
   Liu L, 1999, MOL CELL BIOL, V19, P1202
   Liu YL, 2010, AUTOPHAGY, V6, P1057, DOI 10.4161/auto.6.8.13365
   Llinas-Arias P, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170152
   Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109
   Long J, 2014, J BIOL CHEM, V289, P35494, DOI 10.1074/jbc.M114.595348
   Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Marquard L, 2008, HISTOPATHOLOGY, V53, P267, DOI [10.1111/j.1365-2559.2008.03109.x, 10.1111/j.0309-0167.2008.03109.x]
   Masdehors P, 2000, BLOOD, V96, P269, DOI 10.1182/blood.V96.1.269.013k10_269_274
   Mathew R, 2007, NAT REV CANCER, V7, P961, DOI 10.1038/nrc2254
   Mathieson T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03106-1
   Mayer MP, 2005, CELL MOL LIFE SCI, V62, P670, DOI 10.1007/s00018-004-4464-6
   McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265
   Meccariello R, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/561426
   Mehta-Shah N, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.2991.2991
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Millward M, 2012, INVEST NEW DRUG, V30, P2303, DOI 10.1007/s10637-011-9766-6
   Mithraprabhu S, 2014, EPIGENETICS-US, V9, P1511, DOI 10.4161/15592294.2014.983367
   Miyanaga A, 2008, MOL CANCER THER, V7, P1923, DOI 10.1158/1535-7163.MCT-07-2140
   Mogk A, 2006, MICROB CELL FACT, V5, pS8, DOI [10.1186/1475-2859-5-S1-S8, DOI 10.1186/1475-2859-5-S1-S8]
   Moros A, 2014, LEUKEMIA, V28, P2049, DOI 10.1038/leu.2014.106
   Mottamal M, 2015, MOLECULES, V20, P3898, DOI 10.3390/molecules20033898
   Mrakovcic M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123952
   Mrakovcic M, 2018, BIOMOLECULES, V8, DOI 10.3390/biom8020014
   Mrakovcic M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091883
   Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961
   Nepali K, 2014, EUR J MED CHEM, V77, P422, DOI 10.1016/j.ejmech.2014.03.018
   New M, 2013, CELL DEATH DIFFER, V20, P1306, DOI 10.1038/cdd.2013.47
   New M, 2012, MOL ONCOL, V6, P637, DOI 10.1016/j.molonc.2012.09.003
   Niesvizky R, 2011, CANCER-AM CANCER SOC, V117, P336, DOI 10.1002/cncr.25584
   Nihira NT, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aai8026
   Noack K, 2017, ARCH TOXICOL, V91, P2191, DOI 10.1007/s00204-016-1878-5
   Noack M, 2014, GLIA, V62, P535, DOI 10.1002/glia.22624
   Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531
   Ocio EM, 2010, HAEMATOL-HEMATOL J, V95, P794, DOI 10.3324/haematol.2009.015495
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Olzscha H, 2019, BIOL CHEM, V400, P895, DOI 10.1515/hsz-2018-0458
   Olzscha H, 2017, CELL CHEM BIOL, V24, P9, DOI 10.1016/j.chembiol.2016.11.009
   Olzscha Heidi, 2015, Critical Reviews in Oncogenesis, V20, P1
   Orlowski RZ, 1998, CANCER RES, V58, P4342
   Ouyang H, 2012, J BIOL CHEM, V287, P2317, DOI 10.1074/jbc.M111.273730
   Patel S, 2008, EXPERT OPIN INV DRUG, V17, P1865, DOI [10.1517/13543780802493366, 10.1517/13543780802493366 ]
   Patel S, 2016, ONCOTARGET, V7, P59087, DOI 10.18632/oncotarget.10824
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Pei XY, 2004, CLIN CANCER RES, V10, P3839, DOI 10.1158/1078-0432.CCR-03-0561
   Perez-Salvia M, 2017, EPIGENETICS-US, V12, P323, DOI 10.1080/15592294.2016.1265710
   PERRIN P, 1994, GASTROENTEROLOGY, V107, P1697, DOI 10.1016/0016-5085(94)90810-9
   Picaud S, 2015, CANCER RES, V75, P5106, DOI 10.1158/0008-5472.CAN-15-0236
   Platzbecker U, 2014, LEUKEMIA, V28, P696, DOI 10.1038/leu.2013.325
   Plumb JA, 2003, MOL CANCER THER, V2, P721
   Porcu M, 2005, TRENDS PHARMACOL SCI, V26, P94, DOI 10.1016/j.tips.2004.12.009
   Powers MV, 2006, ENDOCR-RELAT CANCER, V13, pS125, DOI 10.1677/erc.1.01324
   Qiu TZ, 2013, FUTURE ONCOL, V9, P255, DOI [10.2217/fon.12.173, 10.2217/FON.12.173]
   Rahmani M, 2003, CANCER RES, V63, P8420
   Rajkumar SV, 2008, J CLIN ONCOL, V26, P2171, DOI 10.1200/JCO.2007.14.1853
   Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468
   Richardson P, 2005, BLOOD, V106, p715A
   Richardson P, 2008, LEUKEMIA LYMPHOMA, V49, P502, DOI 10.1080/10428190701817258
   Richardson PG, 2013, BLOOD, V122, P2331, DOI 10.1182/blood-2013-01-481325
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Ruegsegger C, 2016, BRAIN RES, V1648, P571, DOI 10.1016/j.brainres.2016.03.032
   Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831
   Saldanha SN, 2014, EXP CELL RES, V324, P40, DOI 10.1016/j.yexcr.2014.01.024
   Salimi V, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0593-4
   San-Miguel JF, 2014, LANCET ONCOL, V15, P1195, DOI 10.1016/S1470-2045(14)70440-1
   San-Miguel JF, 2013, J CLIN ONCOL, V31, P3696, DOI 10.1200/JCO.2012.46.7068
   Sanchez E, 2011, LEUKEMIA RES, V35, P373, DOI 10.1016/j.leukres.2010.06.026
   SANMIGUEL JF, 2011, J CLIN ONCOL S, V29
   Santos AL, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5716409
   Sarkar D, 2015, EPIGENETICS-US, V10, P103, DOI 10.1080/15592294.2014.1003746
   Sasaki H, 2004, LUNG CANCER, V46, P171, DOI 10.1016/j.lungcan.2004.03.021
   Schrader EK, 2009, NAT CHEM BIOL, V5, P815, DOI 10.1038/nchembio.250
   Scognamiglio A, 2008, BBA-MOL CELL RES, V1783, P2030, DOI 10.1016/j.bbamcr.2008.07.007
   Scroggins BT, 2007, MOL CELL, V25, P151, DOI 10.1016/j.molcel.2006.12.008
   Sellmer A, 2018, J MED CHEM, V61, P3454, DOI 10.1021/acs.jmedchem.7b01593
   Sengupta N, 2004, J CELL BIOCHEM, V93, P57, DOI 10.1002/jcb.20179
   Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Shimamura T, 2005, CANCER RES, V65, P6401, DOI 10.1158/0008-5472.CAN-05-0933
   Shimamura T, 2008, J THORAC ONCOL, V3, pS152, DOI 10.1097/JTO.0b013e318174ea3a
   Sigalotti L, 2007, J CELL PHYSIOL, V212, P330, DOI 10.1002/jcp.21066
   Singh AK, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060731
   Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x
   Soodgupta D, 2015, MOL CANCER THER, V14, P1286, DOI 10.1158/1535-7163.MCT-14-0774-T
   Stankov MV, 2014, LEUKEMIA, V28, P577, DOI 10.1038/leu.2013.264
   Steele NL, 2008, CLIN CANCER RES, V14, P804, DOI 10.1158/1078-0432.CCR-07-1786
   Strait KA, 2002, MOL CANCER THER, V1, P1181
   Subramanian S, 2010, PHARMACEUTICALS, V3, P2751, DOI 10.3390/ph3092751
   Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X
   Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092
   Tan D, 2015, LANCET HAEMATOL, V2, pE326, DOI 10.1016/S2352-3026(15)00097-6
   Theodoulou NH, 2016, CHEMMEDCHEM, V11, P477, DOI 10.1002/cmdc.201500540
   Tsankova N, 2007, NAT REV NEUROSCI, V8, P355, DOI 10.1038/nrn2132
   Ugur HC, 2007, J NEURO-ONCOL, V83, P267, DOI 10.1007/s11060-007-9337-z
   Venza I, 2013, PIGM CELL MELANOMA R, V26, P761, DOI [10.1111/pcmr.12146, 10.1111/pcmr.12049]
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Vogl DT, 2017, CLIN CANCER RES, V23, P3307, DOI 10.1158/1078-0432.CCR-16-2526
   Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693
   Wang Zhi-min, 2002, Ai Zheng, V21, P1100
   Wang ZF, 2016, SCI REP-UK, V6, DOI 10.1038/srep19626
   Warri A, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0105-y
   Wegiel B, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00284
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   WELCH WJ, 1982, J BIOL CHEM, V257, P4949
   Wesselborg S, 2015, CELL MOL LIFE SCI, V72, P4721, DOI 10.1007/s00018-015-2034-8
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200/JCO.2010.28.9066
   WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0
   Wilson AJ, 2006, J BIOL CHEM, V281, P13548, DOI 10.1074/jbc.M510023200
   Yan G, 2013, MOL CARCINOGEN, V52, P404, DOI 10.1002/mc.21875
   Yan MM, 2015, ONCOL LETT, V10, P1959, DOI 10.3892/ol.2015.3508
   Yang YT, 2009, NEOPLASIA, V11, P552, DOI 10.1593/neo.09204
   Yang YH, 2008, CANCER RES, V68, P4833, DOI 10.1158/0008-5472.CAN-08-0644
   Yin D, 2007, CLIN CANCER RES, V13, P1045, DOI 10.1158/1078-0432.CCR-06-1261
   Yoon Somy, 2016, Chonnam Med J, V52, P1, DOI 10.4068/cmj.2016.52.1.1
   YOSHIDA M, 1990, J BIOL CHEM, V265, P17174
   Younes A, 2012, J CLIN ONCOL, V30, P2197, DOI 10.1200/JCO.2011.38.1350
   Younes A, 2011, LANCET ONCOL, V12, P1222, DOI 10.1016/S1470-2045(11)70265-0
   Yu L, 2017, J CANCER, V8, P3430, DOI 10.7150/jca.21125
   Zhang JB, 2015, AUTOPHAGY, V11, P629, DOI 10.1080/15548627.2015.1023981
   Zhang ZH, 2005, BREAST CANCER RES TR, V94, P11, DOI 10.1007/s10549-005-6001-1
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhou L, 2016, BLOOD, V127, P2219, DOI 10.1182/blood-2015-06-653717
   Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X
   Zismanov V, 2014, ANTI-CANCER DRUG, V25, P998, DOI 10.1097/CAD.0000000000000140
   Zucconi BE, 2016, BIOCHEMISTRY-US, V55, P3727, DOI 10.1021/acs.biochem.6b00480
NR 277
TC 13
Z9 14
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 3
PY 2020
VL 8
AR 425
DI 10.3389/fcell.2020.00425
PG 28
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA MC3JI
UT WOS:000543187200001
PM 32582706
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Hofer, SJ
   Davinelli, S
   Bergmann, M
   Scapagnini, G
   Madeo, F
AF Hofer, Sebastian J.
   Davinelli, Sergio
   Bergmann, Martina
   Scapagnini, Giovanni
   Madeo, Frank
TI Caloric Restriction Mimetics in Nutrition and Clinical Trials
SO FRONTIERS IN NUTRITION
LA English
DT Review
DE caloric restriction mimetics; nutrition; spermidine; clinical trials;
   polyphenols; polyamines; healthy diet
ID FOOD-FREQUENCY QUESTIONNAIRE; CAMBOGIA HYDROXYCITRIC ACID;
   CARDIOVASCULAR RISK-FACTORS; TYPE-2 DIABETES-MELLITUS; DIETARY POLYAMINE
   INTAKE; COLORECTAL-CANCER RISK; C-REACTIVE PROTEIN; ELEGANS LIFE-SPAN;
   GARCINIA-CAMBOGIA; RESVERATROL SUPPLEMENTATION
AB The human diet and dietary patterns are closely linked to the health status. High-calorie Western-style diets have increasingly come under scrutiny as their caloric load and composition contribute to the development of non-communicable diseases, such as diabetes, cancer, obesity, and cardiovascular disorders. On the other hand, calorie-reduced and health-promoting diets have shown promising results in maintaining health and reducing disease burden throughout aging. More recently, pharmacological Caloric Restriction Mimetics (CRMs) have gained interest of the public and scientific community as promising candidates that mimic some of the myriad of effects induced by caloric restriction. Importantly, many of the CRM candidates activate autophagy, prolong life- and healthspan in model organisms and ameliorate diverse disease symptoms without the need to cut calories. Among others, glycolytic inhibitors (e.g., D-allulose, D-glucosamine), hydroxycitric acid, NAD(+) precursors, polyamines (e.g., spermidine), polyphenols (e.g., resveratrol, dimethoxychalcones, curcumin, EGCG, quercetin) and salicylic acid qualify as CRM candidates, which are naturally available via foods and beverages. However, it is yet unclear how these bioactive substances contribute to the benefits of healthy diets. In this review, we thus discuss dietary sources, availability and intake levels of dietary CRMs. Finally, since translational research on CRMs has entered the clinical stage, we provide a summary of their effects in clinical trials.
C1 [Hofer, Sebastian J.; Bergmann, Martina; Madeo, Frank] Karl Franzens Univ Graz, Inst Mol Biosci, NAWI Graz, Graz, Austria.
   [Hofer, Sebastian J.; Madeo, Frank] BioTechMed Graz, Graz, Austria.
   [Hofer, Sebastian J.; Madeo, Frank] Karl Franzens Univ Graz, Field Excellence BioHlth, Graz, Austria.
   [Davinelli, Sergio; Scapagnini, Giovanni] Univ Molise, Dept Med & Hlth Sci V Tiberio, Campobasso, Italy.
RP Hofer, SJ (corresponding author), Karl Franzens Univ Graz, Inst Mol Biosci, NAWI Graz, Graz, Austria.; Hofer, SJ (corresponding author), BioTechMed Graz, Graz, Austria.; Hofer, SJ (corresponding author), Karl Franzens Univ Graz, Field Excellence BioHlth, Graz, Austria.
EM sebastian.hofer@uni-graz.at
RI Davinelli, Sergio/U-1545-2017
OI Davinelli, Sergio/0000-0003-2578-7199; Madeo, Frank/0000-0002-5070-1329;
   Hofer, Sebastian/0000-0002-0756-0014
FU Austrian Science Fund FWFAustrian Science Fund (FWF) [F3007, F3012,
   W1226, P29203, P29262, P27893, P31727]; Austrian Federal Ministry of
   Education, Science and Research; University of Graz; flysleep(BMWFW)
   [80.109/0001-WF/V/3b/2015]; Field of Excellence BioHealth; NAWI Graz;
   BioTechMed-Graz flagship project EPIAge
FX FM was grateful to the Austrian Science Fund FWF (SFB LIPOTOX F3007 and
   F3012, DK-MCD W1226, as well as Grant Nos. P29203, P29262, P27893, and
   P31727) and the Austrian Federal Ministry of Education, Science and
   Research, as well as the University of Graz for grants Unkonventionelle
   Forschung-InterFast and Fast4Health, as well as flysleep(BMWFW-80.109/
   0001-WF/V/3b/2015). We acknowledge the support of the Field of
   Excellence BioHealth, of NAWI Graz and the BioTechMed-Graz flagship
   project EPIAge.
CR Abdellatif M, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abd7064
   Abdellatif M, 2020, PROG MOL BIOL TRANSL, V172, P87, DOI 10.1016/bs.pmbts.2020.04.022
   Abdellatif M, 2018, CIRC RES, V123, P803, DOI 10.1161/CIRCRESAHA.118.312208
   Airhart SE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186459
   Akbari M, 2020, LIPIDS HEALTH DIS, V19, DOI 10.1186/s12944-020-1198-x
   Akbari M, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00649
   ALI B, 1983, J PHARMACOL EXP THER, V226, P589
   Ali MA, 2011, FOOD NUTR RES, V55, DOI [10.3402/fnr.v55i0.5455, 10.3402/fnr.v55i0.5572]
   Alisky JM, 2005, NUTR NEUROSCI, V8, P327, DOI 10.1080/10284150500484638
   Amalraj Augustine, 2017, J Tradit Complement Med, V7, P205, DOI 10.1016/j.jtcme.2016.05.005
   Anandhi R, 2013, J PHYSIOL BIOCHEM, V69, P313, DOI 10.1007/s13105-012-0215-6
   [Anonymous], 1969, Nutr Rev, V27, P206
   Asgary S, 2019, REV ENDOCR METAB DIS, V20, P173, DOI 10.1007/s11154-019-09494-z
   Bai W, 2014, INT J FOOD SCI NUTR, V65, P9, DOI 10.3109/09637486.2013.832170
   Barrientos C, 2010, NUTR RES, V30, P791, DOI 10.1016/j.nutres.2010.10.008
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   BECHGAARD H, 1977, J PHARM SCI, V66, P871, DOI 10.1002/jps.2600660635
   Bell GA, 2012, EUR J EPIDEMIOL, V27, P593, DOI 10.1007/s10654-012-9714-6
   Bhagwat S, 2016, USDA DATABASE FLAVON
   Bhagwat S, 2013, PROC FOOD SCI, V2, P81, DOI 10.1016/j.profoo.2013.04.013
   Blacklock CJ, 2001, J CLIN PATHOL, V54, P553, DOI 10.1136/jcp.54.7.553
   Bogan KL, 2008, ANNU REV NUTR, V28, P115, DOI 10.1146/annurev.nutr.28.061807.155443
   Bonkowski MS, 2016, NAT REV MOL CELL BIO, V17, P679, DOI 10.1038/nrm.2016.93
   Braunstein CR, 2018, NUTRIENTS, V10, DOI 10.3390/nu10060750
   Buyukuslu N, 2014, FOODS, V3, P541, DOI 10.3390/foods3040541
   Carames B, 2012, OSTEOARTHR CARTILAGE, V20, pS117, DOI 10.1016/j.joca.2012.02.143
   Carmona-Gutierrez D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08555-w
   Barbosa MC, 2019, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00790
   CARPENTER KJ, 1985, J NUTR, V115, P543, DOI 10.1093/jn/115.5.543
   Cena H, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020334
   Chachay VS, 2011, BRIT J CLIN PHARMACO, V72, P27, DOI 10.1111/j.1365-2125.2011.03966.x
   CHEEMADHS, 1973, EUR J BIOCHEM, V38, P98, DOI DOI 10.1111/J.1432-1033.1973.TB03038.X
   Chen G, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910469
   Chi YL, 2013, CURR OPIN CLIN NUTR, V16, P657, DOI 10.1097/MCO.0b013e32836510c0
   Chuengsamarn S, 2012, DIABETES CARE, V35, P2121, DOI 10.2337/dc12-0116
   Clouatre DL, 2013, WORLD J GASTROENTERO, V19, P8160, DOI 10.3748/wjg.v19.i44.8160
   Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
   Conze D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46120-z
   Corley DA, 2003, GASTROENTEROLOGY, V124, P47, DOI 10.1053/gast.2003.50008
   COSTELLO PB, 1984, ARTHRITIS RHEUM, V27, P422, DOI 10.1002/art.1780270409
   Covarrubias AJ, 2021, NAT REV MOL CELL BIO, V22, P119, DOI 10.1038/s41580-020-00313-x
   Cryer B, 1999, GASTROENTEROLOGY, V117, P17, DOI 10.1016/S0016-5085(99)70545-7
   Custodero C, 2018, AGEING RES REV, V46, P42, DOI 10.1016/j.arr.2018.05.004
   Cuzick J, 2015, ANN ONCOL, V26, P47, DOI 10.1093/annonc/mdu225
   Cuzick J, 2009, LANCET ONCOL, V10, P501, DOI 10.1016/S1470-2045(09)70035-X
   Da-Costa-Rocha I, 2014, FOOD CHEM, V165, P424, DOI 10.1016/j.foodchem.2014.05.002
   Dai WQ, 2015, ONCOTARGET, V6, P13703, DOI 10.18632/oncotarget.3800
   Das A, 2018, CELL, V173, P74, DOI 10.1016/j.cell.2018.02.008
   Davinelli S, 2020, TRENDS ENDOCRIN MET, V31, P536, DOI 10.1016/j.tem.2020.02.011
   Davis C, 2015, NUTRIENTS, V7, P9139, DOI 10.3390/nu7115459
   de Cabo R, 2019, NEW ENGL J MED, V381, P2541, DOI 10.1056/NEJMra1905136
   de Ridder D, 2017, PSYCHOL HEALTH, V32, P907, DOI 10.1080/08870446.2017.1316849
   Dellinger RW, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0016-9
   Demarest TG, 2019, ANNU REV CANC BIOL, V3, P105, DOI 10.1146/annurev-cancerbio-030518-055905
   Di Francesco A, 2018, SCIENCE, V362, P770, DOI 10.1126/science.aau2095
   Ding M, 2016, EUR J CLIN NUTR, V70, P1381, DOI 10.1038/ejcn.2016.117
   Dollerup OL, 2019, J CLIN ENDOCR METAB, V104, P5703, DOI 10.1210/jc.2019-01081
   Duthie GG, 2011, FOOD FUNCT, V2, P515, DOI 10.1039/c1fo10128e
   Egbuna C, 2021, CURR TOP MED CHEM, V21, P1067, DOI 10.2174/1568026621666210509161059
   Ehala S, 2005, J AGR FOOD CHEM, V53, P6484, DOI 10.1021/jf050397w
   Eisenberg T, 2016, NAT MED, V22, P1428, DOI 10.1038/nm.4222
   Eisenberg T, 2014, CELL METAB, V19, P431, DOI 10.1016/j.cmet.2014.02.010
   Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975
   Elgebaly A, 2017, J GASTROINTEST LIVER, V26, P59, DOI 10.15403/jgld.2014.1121.261.ely
   Elhassan YS, 2019, CELL REP, V28, P1717, DOI 10.1016/j.celrep.2019.07.043
   Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9
   Eriau E, 2021, CANCERS, V13, DOI 10.3390/cancers13061260
   Fang EF, 2017, TRENDS MOL MED, V23, P899, DOI 10.1016/j.molmed.2017.08.001
   Ferguson JJA, 2021, NUTR REV, V79, P1043, DOI 10.1093/nutrit/nuaa114
   Ferrucci L, 2018, NAT REV CARDIOL, V15, P505, DOI 10.1038/s41569-018-0064-2
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574-018-0059-4
   Franchi F, 2021, BMJ OPEN DIAB RES CA, V9, DOI 10.1136/bmjdrc-2020-001939
   Fulop T, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01960
   Furuse M, 2003, J OLEO SCI, V52, P499, DOI [10.5650/jos.52.499, DOI 10.5650/J0S.52.499]]
   Garg A, 2017, AM J MED, V130, P173, DOI 10.1016/j.amjmed.2016.07.038
   Ghosh A, 2009, FASEB J, V23
   Gilsing AMJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep13484
   Goh KP, 2014, INT J SPORT NUTR EXE, V24, P2, DOI 10.1123/ijsnem.2013-0045
   Goldberger J, 1914, PUBLIC HEALTH REP, V29, P1683, DOI 10.2307/4570920
   Grosso G, 2014, NUTRITION, V30, P1398, DOI 10.1016/j.nut.2014.04.012
   Guo WF, 2019, CURR PHARM DESIGN, V25, P3087, DOI 10.2174/1381612825666190829153552
   Guo XF, 2018, CRIT REV FOOD SCI, V58, P3016, DOI 10.1080/10408398.2017.1349076
   Haber SL, 2018, AM J HEALTH-SYST PH, V75, P17, DOI 10.2146/ajhp160915
   Haghighatdoost F, 2019, PHYTOTHER RES, V33, P2274, DOI 10.1002/ptr.6432
   Haghighatdoost F, 2019, EUR J CLIN NUTR, V73, P345, DOI 10.1038/s41430-018-0253-4
   Haghighatdoost F, 2018, PHARMACOL RES, V129, P141, DOI [10.1016/j.phrs.2017.12.033, 10.1016/j.phrs.2017.11033]
   Han YJ, 2018, NUTRIENTS, V10, DOI 10.3390/nu10122010
   Han Y, 2018, NUTRIENTS, V10, DOI 10.3390/nu10020160
   Hariri M, 2018, J AM COLL NUTR, V37, P215, DOI 10.1080/07315724.2017.1392263
   Hausenblas HA, 2015, MOL NUTR FOOD RES, V59, P147, DOI 10.1002/mnfr.201400173
   Hayamizu K, 2003, CURR THER RES CLIN E, V64, P551, DOI 10.1016/j.curtheres.2003.08.006
   Hayamizu K, 2008, FITOTERAPIA, V79, P255, DOI 10.1016/j.fitote.2007.12.003
   Hayashi N, 2010, BIOSCI BIOTECH BIOCH, V74, P510, DOI 10.1271/bbb.90707
   Haytowitz D.B., 2018, USDA DATABASE FLAVON
   Heimler D, 2017, EUR FOOD RES TECHNOL, V243, P1107, DOI 10.1007/s00217-016-2826-6
   Hellenbrand W, 1996, NEUROLOGY, V47, P644, DOI 10.1212/WNL.47.3.644
   Hemati N, 2020, FOOD RES INT, V128, DOI 10.1016/j.foodres.2019.108764
   Heymsfield SB, 1998, JAMA-J AM MED ASSOC, V280, P1596, DOI 10.1001/jama.280.18.1596
   Hollman PCH, 1999, FOOD CHEM TOXICOL, V37, P937, DOI 10.1016/S0278-6915(99)00079-4
   Hossain A, 2015, PHARMACOL THERAPEUT, V155, P49, DOI 10.1016/j.pharmthera.2015.08.004
   Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569
   Huang HH, 2020, NUTR REV, V78, P615, DOI 10.1093/nutrit/nuz071
   Huang HH, 2019, DIABETES METAB SYNDR, V12, P553, DOI 10.2147/DMSO.S199830
   Hursel R, 2009, INT J OBESITY, V33, P956, DOI 10.1038/ijo.2009.135
   Igarashi M, 2019, AGING CELL, V18, DOI 10.1111/acel.12935
   Iida T, 2008, J NUTR SCI VITAMINOL, V54, P511, DOI 10.3177/jnsv.54.511
   Iida T, 2010, METABOLISM, V59, P206, DOI 10.1016/j.metabol.2009.07.018
   Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x
   Ingram DK, 2021, GEROSCIENCE, V43, P1159, DOI 10.1007/s11357-020-00298-7
   Ingram DK, 2015, AGEING RES REV, V20, P46, DOI 10.1016/j.arr.2014.11.005
   Ingram DK, 2011, EXP GERONTOL, V46, P148, DOI 10.1016/j.exger.2010.12.001
   Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate Other B Vitamins and Choline, 1998, DIET REF INT THIAM R, P6
   Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate Other B Vitamins and Choline, 1998, DIET REF INT THIAM R
   Janssen PLTMK, 1997, CANCER LETT, V114, P163, DOI 10.1016/S0304-3835(97)04650-8
   Janssen PLTMK, 1996, AM J CLIN NUTR, V64, P743, DOI 10.1093/ajcn/64.5.743
   Jayaprakasha GK, 2002, J AGR FOOD CHEM, V50, P3668, DOI 10.1021/jf025506a
   Kahkeshani N, 2019, IRAN J BASIC MED SCI, V22, P225, DOI 10.22038/ijbms.2019.32806.7897
   Kalogeropoulos N, 2013, FOOD CHEM TOXICOL, V55, P378, DOI 10.1016/j.fct.2013.01.010
   Kantor ED, 2012, AM J EPIDEMIOL, V176, P1002, DOI 10.1093/aje/kws186
   Kapoor MP, 2017, J NUTR BIOCHEM, V43, P1, DOI 10.1016/j.jnutbio.2016.10.013
   Katsyuba E, 2020, NAT METAB, V2, P9, DOI 10.1038/s42255-019-0161-5
   Kiechl S, 2019, GERONTOLOGY, V65, P9, DOI 10.1159/000492329
   Kiechl S, 2018, AM J CLIN NUTR, V108, P371, DOI 10.1093/ajcn/nqy102
   Kimura T, 2017, NUTRITION, V43-44, P16, DOI 10.1016/j.nut.2017.06.007
   King DE, 2020, J AM BOARD FAM MED, V33, P842, DOI 10.3122/jabfm.2020.06.200110
   Kirkwood KL, 2018, IMMUNOL INVEST, V47, P770, DOI 10.1080/08820139.2018.1552392
   Koushki M, 2018, CLIN THER, V40, P1180, DOI 10.1016/j.clinthera.2018.05.015
   Kuhnle GGC, 2018, MOL ASPECTS MED, V61, P2, DOI 10.1016/j.mam.2017.10.003
   Kwon HJ, 2012, J CHROMATOGR A, V1232, P212, DOI 10.1016/j.chroma.2011.12.035
   Kwon SH, 2007, INT J PHARMACEUT, V337, P148, DOI 10.1016/j.ijpharm.2006.12.046
   Lamikanra O, 1996, J AGR FOOD CHEM, V44, P1111, DOI 10.1021/jf950274j
   Lane MA, 1998, J ANTI-AGING MED, V1, P327, DOI [10.1089/rej.1.1998.1.327, DOI 10.1089/REJ.1.1998.1.327]
   Lanou Amy Joy, 2010, Cancer Manag Res, V3, P1, DOI 10.2147/CMR.S6910
   Lawrence JR, 2003, J CLIN PATHOL, V56, P651, DOI 10.1136/jcp.56.9.651
   Lee C, 2016, F1000Research, V5, DOI 10.12688/f1000research.7136.1
   Lee SH, 2013, BMB REP, V46, P181, DOI 10.5483/BMBRep.2013.46.4.033
   Lee SY, 2014, FOOD CHEM, V165, P157, DOI 10.1016/j.foodchem.2014.05.089
   Li ZH, 2020, ANN RHEUM DIS, V79, P829, DOI 10.1136/annrheumdis-2020-217176
   Liu K, 2014, AM J CLIN NUTR, V99, P1510, DOI 10.3945/ajcn.113.082024
   Loe YCC, 2001, ANAL BIOCHEM, V292, P148, DOI 10.1006/abio.2001.5046
   Longo VD, 2015, AGING CELL, V14, P497, DOI 10.1111/acel.12338
   Lopes Junior Osmar Valadao, 2013, Rev. bras. ortop., V48, P300, DOI [10.1016/j.rboe.2012.12.001, 10.1016/j.rbo.2012.09.007]
   Lopez-Otin C, 2021, CELL, V184, P33, DOI 10.1016/j.cell.2020.11.034
   Louter-van de Haar Johanna, 2005, Nutr Metab (Lond), V2, P23, DOI 10.1186/1743-7075-2-23
   Madeo F, 2020, ANNU REV NUTR, V40, P135, DOI 10.1146/annurev-nutr-120419-015419
   Madeo F, 2019, CELL METAB, V29, P592, DOI 10.1016/j.cmet.2019.01.018
   Madeo F, 2018, SCIENCE, V359, P410, DOI 10.1126/science.aan2788
   Madeo F, 2015, J CLIN INVEST, V125, P85, DOI 10.1172/JCI73946
   Madeo F, 2014, NAT REV DRUG DISCOV, V13, P727, DOI 10.1038/nrd4391
   Maglione M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56133-3
   Mah S. H., 2019, HDB DIETARY PHYTOCHE, P1, DOI [10.1007/978-981-13-1745-3_10-1, DOI 10.1007/978-981-13-1745-3_10-1]
   Mani R, 2018, PHYTOCHEMISTRY, V145, P187, DOI 10.1016/j.phytochem.2017.09.016
   Marino G, 2014, AUTOPHAGY, V10, P1879, DOI 10.4161/auto.36413
   Marino G, 2014, MOL CELL, V53, P710, DOI 10.1016/j.molcel.2014.01.016
   Marquez F, 2012, CRIT REV FOOD SCI, V52, P585, DOI 10.1080/10408398.2010.500551
   Martel J, 2021, AGEING RES REV, V66, DOI 10.1016/j.arr.2020.101240
   Martens CR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03421-7
   Matsumoto M, 2019, NUTRIENTS, V11, DOI 10.3390/nu11051188
   McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469
   McKnight LL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143324
   McNeil JJ, 2021, JNCI-J NATL CANCER I, V113, P258, DOI 10.1093/jnci/djaa114
   Messina M, 2006, NUTR CANCER, V55, P1, DOI 10.1207/s15327914nc5501_1
   Micha R, 2017, JAMA-J AM MED ASSOC, V317, P912, DOI 10.1001/jama.2017.0947
   Mills KF, 2016, CELL METAB, V24, P795, DOI 10.1016/j.cmet.2016.09.013
   Minor RK, 2010, TOXICOL APPL PHARM, V243, P332, DOI 10.1016/j.taap.2009.11.025
   Mohammadi M, 2012, J AGR FOOD CHEM, V60, P10511, DOI 10.1021/jf303488w
   Mohammadi V, 2016, J RES MED SCI, V21, DOI 10.4103/1735-1995.196605
   Molina-Montes E, 2020, NUTRIENTS, V12, DOI 10.3390/nu12072010
   Most J, 2017, AGEING RES REV, V39, P36, DOI 10.1016/j.arr.2016.08.005
   Motlekar N, 2006, J APPL POLYM SCI, V101, P2070, DOI 10.1002/app.23827
   Mousavi SM, 2019, OBES REV, V20, P487, DOI 10.1111/obr.12775
   Mu WM, 2012, APPL MICROBIOL BIOT, V94, P1461, DOI 10.1007/s00253-012-4093-1
   Munhoz ACM, 2018, CURR DIABETES REV, V14, P36, DOI 10.2174/1573399813666170505120621
   Munoz-Esparza NC, 2021, FOODS, V10, DOI 10.3390/foods10081752
   Munoz-Esparza NC, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00108
   Na LX, 2013, MOL NUTR FOOD RES, V57, P1569, DOI 10.1002/mnfr.201200131
   Nabavi SF, 2015, NEUROCHEM INT, V90, P224, DOI 10.1016/j.neuint.2015.09.006
   Navarro SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117534
   Naz S, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116797
   Neveu V, 2010, DATABASE-OXFORD, DOI 10.1093/database/bap024
   Nishimura K, 2006, J BIOCHEM, V139, P81, DOI 10.1093/jb/mvj003
   Noronha JC, 2018, DIABETES OBES METAB, V20, P2361, DOI 10.1111/dom.13374
   Ohsumi Y, 2014, CELL RES, V24, P9, DOI 10.1038/cr.2013.169
   Onakpoya I, 2011, J OBES, V2011, DOI 10.1155/2011/509038
   Oshima H, 2006, FOOD SCI TECHNOL RES, V12, P137, DOI 10.3136/fstr.12.137
   Ostadmohammadi V, 2019, PHYTOTHER RES, V33, P1330, DOI 10.1002/ptr.6334
   Ou QW, 2020, INT J FOOD SCI NUTR, V71, P152, DOI 10.1080/09637486.2019.1627515
   Park H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093369
   Paterson JR, 2006, J AGR FOOD CHEM, V54, P2891, DOI 10.1021/jf058158w
   Paterson JR, 2001, QJM-MON J ASSOC PHYS, V94, P445, DOI 10.1093/qjmed/94.8.445
   Patrignani P, 2016, J AM COLL CARDIOL, V68, P967, DOI 10.1016/j.jacc.2016.05.083
   Pegg AE, 2009, IUBMB LIFE, V61, P880, DOI 10.1002/iub.230
   Pekar T, 2021, WIEN KLIN WOCHENSCHR, V133, P484, DOI 10.1007/s00508-020-01758-y
   Perez-Jimenez J, 2010, J AGR FOOD CHEM, V58, P4959, DOI 10.1021/jf100128b
   Phan NTB, 2011, NUTR DIET SUPPL, V3, P1, DOI 10.2147/NDS.S15349
   Phan Nguyen Thanh Binh, 2010, Health, V2, P1390, DOI 10.4236/health.2010.212206
   Phan Nguyen Thanh Binh, 2010, Health, V2, P1327, DOI 10.4236/health.2010.211198
   Phelan MJ, 2017, J GERIATR MED GERONT, V3, P2469, DOI 10.23937/2469-5858/1510021
   Phung OJ, 2010, AM J CLIN NUTR, V91, P73, DOI 10.3945/ajcn.2009.28157
   Pichichero E, 2010, INT J ONCOL, V37, P973, DOI 10.3892/ijo_00000748
   Pietrocola F, 2018, CELL REP, V22, P2395, DOI 10.1016/j.celrep.2018.02.024
   Pietrocola F, 2016, CANCER CELL, V30, P147, DOI 10.1016/j.ccell.2016.05.016
   Pirinen E, 2020, CELL METAB, V31, P1078, DOI 10.1016/j.cmet.2020.04.008
   Pocobelli G, 2010, AM J CLIN NUTR, V91, P1791, DOI 10.3945/ajcn.2009.28639
   Poljsak B, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/8819627
   Polkowski K, 2000, Acta Pol Pharm, V57, P135
   Pounis G, 2018, NUTRITION, V48, P87, DOI 10.1016/j.nut.2017.11.012
   Preuss H G, 2004, J Med, V35, P33
   Qato DM, 2008, JAMA-J AM MED ASSOC, V300, P2867, DOI 10.1001/jama.2008.892
   Qin S, 2017, NUTR J, V16, DOI 10.1186/s12937-017-0293-y
   Quinhone A, 2015, FOOD CHEM, V166, P173, DOI 10.1016/j.foodchem.2014.06.012
   Rabassa M, 2015, J AM GERIATR SOC, V63, P938, DOI 10.1111/jgs.13379
   Radtke J, 1998, Z ERNAHRUNGSWISS, V37, P190, DOI 10.1007/s003940050016
   Rajman L, 2018, CELL METAB, V27, P529, DOI 10.1016/j.cmet.2018.02.011
   Raju N, 2016, AM J MED, V129, pE35, DOI 10.1016/j.amjmed.2015.10.046
   Raju N, 2011, AM J MED, V124, P621, DOI 10.1016/j.amjmed.2011.01.018
   Raman G, 2019, AM J CLIN NUTR, V110, P1067, DOI 10.1093/ajcn/nqz178
   Ramirez-Garza SL, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121892
   Ramos-Molina B, 2019, FRONT NUTR, V6, DOI 10.3389/fnut.2019.00024
   Ramot Y, 2010, EXP DERMATOL, V19, P784, DOI 10.1111/j.1600-0625.2010.01111.x
   Ranka S, 2008, EUR J CLIN NUTR, V62, P1131, DOI 10.1038/sj.ejcn.1602827
   Reedy J, 2014, J NUTR, V144, P881, DOI 10.3945/jn.113.189407
   Riaz A, 2018, ADV PHARMACOL SCI, V2018, DOI 10.1155/2018/9794625
   Richy F, 2003, ARCH INTERN MED, V163, P1514, DOI 10.1001/archinte.163.13.1514
   Rienks J, 2018, AM J CLIN NUTR, V108, P49, DOI 10.1093/ajcn/nqy083
   Rienks J, 2017, NUTR REV, V75, P616, DOI 10.1093/nutrit/nux021
   Rinaldi Fabio, 2017, Dermatol Pract Concept, V7, P17, DOI 10.5826/dpc.0704a05
   Roongpisuthipong C, 2007, ASIA PAC J CLIN NUTR, V16, P25
   Rothwell JA, 2013, DATABASE-OXFORD, DOI 10.1093/database/bat070
   Ryu D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf5504
   Sahebkar A, 2017, CRIT REV FOOD SCI, V57, P666, DOI 10.1080/10408398.2014.948609
   Sahebkar A, 2015, INT J CARDIOL, V189, P47, DOI 10.1016/j.ijcard.2015.04.008
   Sakaguchi, 2002, J OLEO SCI, V51, P365, DOI [DOI 10.5650/J0S.51.365], 10.5650/jos.51.365]
   Sansai K, 2020, OSTEOPOROSIS INT, V31, P1853, DOI 10.1007/s00198-020-05476-z
   Satia JA, 2009, CANCER EPIDEM BIOMAR, V18, P1419, DOI 10.1158/1055-9965.EPI-09-0038
   Scalbert A, 2000, J NUTR, V130, p2073S, DOI 10.1093/jn/130.8.2073S
   Schroeder S, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.108985
   Schultz MB, 2016, CELL METAB, V23, P965, DOI 10.1016/j.cmet.2016.05.022
   Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011
   Schwarz C, 2018, AGING-US, V10, P19, DOI 10.18632/aging.101354
   Semwal RB, 2015, FITOTERAPIA, V102, P134, DOI 10.1016/j.fitote.2015.02.012
   Serban MC, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002713
   Shintani H, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121821
   Shintani T, 2018, J APPL GLYOSCI, V65, P37, DOI 10.5458/jag.jag.JAG-2018_002
   Shintani T, 2017, BIOCHEM BIOPH RES CO, V493, P1528, DOI 10.1016/j.bbrc.2017.09.147
   Shintani T, 2010, BIOCHEM BIOPH RES CO, V391, P1775, DOI 10.1016/j.bbrc.2009.12.154
   Simental-Mendia M, 2018, RHEUMATOL INT, V38, P1413, DOI 10.1007/s00296-018-4077-2
   Singh JA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005614.pub2
   Soda Kuniyasu, 2021, Med Sci (Basel), V9, DOI 10.3390/medsci9020022
   Soda Kuniyasu, 2012, Glob J Health Sci, V4, P170, DOI 10.5539/gjhs.v4n6p170
   Spagnuolo C, 2015, ADV NUTR, V6, P408, DOI 10.3945/an.114.008052
   Stekovic S, 2019, CELL METAB, V30, P462, DOI 10.1016/j.cmet.2019.07.016
   Stompor-Goracy M, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062038
   Strong R, 2008, AGING CELL, V7, P641, DOI 10.1111/j.1474-9726.2008.00414.x
   Suresh D, 2007, J FOOD COMPOS ANAL, V20, P346, DOI 10.1016/j.jfca.2006.10.002
   Tabrizi R, 2020, CRIT REV FOOD SCI, V60, P375, DOI 10.1080/10408398.2018.1529654
   Tabrizi R, 2020, CRIT REV FOOD SCI, V60, P1855, DOI 10.1080/10408398.2019.1604491
   Tabrizi R, 2018, FOOD FUNCT, V9, P6117, DOI 10.1039/c8fo01259h
   Takahashi Y, 2004, KIDNEY INT, V65, P1099, DOI 10.1111/j.1523-1755.2004.00482.x
   Tayyem RR, 2006, NUTR CANCER, V55, P126, DOI 10.1207/s15327914nc5502_2
   Teng H, 2019, CRIT REV FOOD SCI, V59, P2040, DOI 10.1080/10408398.2018.1437023
   Tian HP, 2016, J ETHNOPHARMACOL, V191, P206, DOI 10.1016/j.jep.2016.05.062
   Tjandrawinata RR, 2016, NUTR DIET SUPPL, V8, P85, DOI 10.2147/NDS.S116151
   Tobin PJ, 2006, CANCER CHEMOTH PHARM, V57, P309, DOI 10.1007/s00280-005-0053-0
   Tomi H., 2003, J OLEO SCI, V52, P663, DOI [10.5650/jos.52.663, DOI 10.5650/J0S.52.663]]
   Trammell SAJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12948
   Tresserra-Rimbau A, 2013, NUTR METAB CARDIOVAS, V23, P953, DOI 10.1016/j.numecd.2012.10.008
   Trichopoulou A, 2000, BRIT J NUTR, V84, pS205, DOI 10.1079/096582197388554
   Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231
   Tuli HS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01336
   van Erp-Baart MAJ, 2003, BRIT J NUTR, V89, pS25, DOI 10.1079/BJN2002793
   Vargas AJ, 2015, AM J CLIN NUTR, V102, P411, DOI 10.3945/ajcn.114.103895
   Vargas AJ, 2012, AM J CLIN NUTR, V96, P133, DOI 10.3945/ajcn.111.030353
   Vellai T, 2009, TRENDS CELL BIOL, V19, P487, DOI 10.1016/j.tcb.2009.07.007
   de Melo ISV, 2018, PHARMACOL RES, V128, P137, DOI 10.1016/j.phrs.2017.09.010
   Vogiatzoglou A, 2014, EUR J NUTR, V53, P635, DOI 10.1007/s00394-013-0572-0
   Vogt T, 2010, MOL PLANT, V3, P2, DOI 10.1093/mp/ssp106
   Wakade C, 2015, CLIN CASE REP, V3, P635, DOI 10.1002/ccr3.232
   Walle T, 2001, BRIT J CLIN PHARMACO, V51, P143, DOI 10.1111/j.1365-2125.2001.01317.x
   Wan RQ, 2003, FASEB J, V17, P1133, DOI 10.1096/fj.02-0996fje
   Weimer S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4563
   Wirth A, 2021, GEROSCIENCE, V43, P673, DOI 10.1007/s11357-020-00310-0
   Wirth M, 2018, CORTEX, V109, P181, DOI 10.1016/j.cortex.2018.09.014
   Wood A, 2011, MOL NUTR FOOD RES, V55, pS7, DOI 10.1002/mnfr.201000408
   Wu QY, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2326-2
   Xing DQ, 2008, AM J PHYSIOL-HEART C, V295, pH335, DOI 10.1152/ajpheart.01259.2007
   Xu D, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0514-4
   Yamada T, 2007, APPL MICROBIOL BIOT, V75, P977, DOI 10.1007/s00253-007-0962-4
   Yao ZX, 2019, EUR J NUTR, V58, P819, DOI 10.1007/s00394-018-1713-2
   Yen WL, 2008, PHYSIOLOGY, V23, P248, DOI 10.1152/physiol.00013.2008
   Yeomans ND, 2005, ALIMENT PHARM THER, V22, P795, DOI 10.1111/j.1365-2036.2005.02649.x
   Yin ZY, 2016, MICROB CELL, V3, P457, DOI 10.15698/mic2016.12.546
   Yoshino J, 2012, CELL METAB, V16, P658, DOI 10.1016/j.cmet.2012.09.015
   Zamora-Ros R, 2008, BRIT J NUTR, V100, P188, DOI 10.1017/S0007114507882997
   Zhang CY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161792
   Zhang HB, 2016, SCIENCE, V352, P1436, DOI 10.1126/science.aaf2693
   Zhang PC, 2020, G3-GENES GENOM GENET, V10, P849, DOI 10.1534/g3.119.400618
   Zhang WL, 2021, ADV SCI, V8, DOI 10.1002/advs.202004555
   Zhao H, 2019, OBESITY, V27, P94, DOI 10.1002/oby.22348
   Zhu XY, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018-018-0871-5
   Zhu ZJ, 2005, CANCER RES, V65, P7023, DOI 10.1158/0008-5472.CAN-05-0453
   Zimmermann A, 2019, AUTOPHAGY, V15, P1662, DOI 10.1080/15548627.2019.1632623
   Zoumas-Morse C, 2007, J AM DIET ASSOC, V107, P1024, DOI 10.1016/j.jada.2007.03.012
NR 303
TC 6
Z9 6
U1 6
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-861X
J9 FRONT NUTR
JI Front. Nutr.
PD SEP 6
PY 2021
VL 8
AR 717343
DI 10.3389/fnut.2021.717343
PG 20
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA UT2LJ
UT WOS:000697952300001
PM 34552954
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Luo, H
   Vong, CT
   Chen, HB
   Gao, Y
   Lyu, P
   Qiu, L
   Zhao, MM
   Liu, Q
   Cheng, ZH
   Zou, J
   Yao, PF
   Gao, CF
   Wei, JC
   Ung, COL
   Wang, SP
   Zhong, ZF
   Wang, YT
AF Luo, Hua
   Vong, Chi Teng
   Chen, Hanbin
   Gao, Yan
   Lyu, Peng
   Qiu, Ling
   Zhao, Mingming
   Liu, Qiao
   Cheng, Zehua
   Zou, Jian
   Yao, Peifen
   Gao, Caifang
   Wei, Jinchao
   Ung, Carolina Oi Lam
   Wang, Shengpeng
   Zhong, Zhangfeng
   Wang, Yitao
TI Naturally occurring anti-cancer compounds: shining from Chinese herbal
   medicine
SO CHINESE MEDICINE
LA English
DT Review
DE Cancer; Chinese herbal medicine; Natural products; Bioactive compounds;
   Traditional Chinese medicine
ID CELL-CYCLE ARREST; NF-KAPPA-B; BREAST-CANCER CELLS;
   ENDOPLASMIC-RETICULUM STRESS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN
   COLORECTAL-CANCER; HUMAN BLADDER-CANCER; ORIDONIN-INDUCED APOPTOSIS;
   HUMAN PANCREATIC-CANCER; MULTIPLE-MYELOMA CELLS
AB Numerous natural products originated from Chinese herbal medicine exhibit anti-cancer activities, including anti-proliferative, pro-apoptotic, anti-metastatic, anti-angiogenic effects, as well as regulate autophagy, reverse multidrug resistance, balance immunity, and enhance chemotherapy in vitro and in vivo. To provide new insights into the critical path ahead, we systemically reviewed the most recent advances (reported since 2011) on the key compounds with anti-cancer effects derived from Chinese herbal medicine (curcumin, epigallocatechin gallate, berberine, artemisinin, ginsenoside Rg3, ursolic acid, silibinin, emodin, triptolide, cucurbitacin B, tanshinone I, oridonin, shikonin, gambogic acid, artesunate, wogonin, beta-elemene, and cepharanthine) in scientific databases (PubMed, Web of Science, Medline, Scopus, and Clinical Trials). With a broader perspective, we focused on their recently discovered and/or investigated pharmacological effects, novel mechanism of action, relevant clinical studies, and their innovative applications in combined therapy and immunomodulation. In addition, the present review has extended to describe other promising compounds including dihydroartemisinin, ginsenoside Rh2, compound K, cucurbitacins D, E, I, tanshinone IIA and cryptotanshinone in view of their potentials in cancer therapy. Up to now, the evidence about the immunomodulatory effects and clinical trials of natural anti-cancer compounds from Chinese herbal medicine is very limited, and further research is needed to monitor their immunoregulatory effects and explore their mechanisms of action as modulators of immune checkpoints.
C1 [Luo, Hua; Vong, Chi Teng; Chen, Hanbin; Gao, Yan; Lyu, Peng; Qiu, Ling; Zhao, Mingming; Liu, Qiao; Cheng, Zehua; Zou, Jian; Yao, Peifen; Gao, Caifang; Wei, Jinchao; Ung, Carolina Oi Lam; Wang, Shengpeng; Zhong, Zhangfeng; Wang, Yitao] Univ Macau, State Key Lab Qual Res Chinese Med, Inst Chinese Med Sci, Macau, Peoples R China.
RP Zhong, ZF; Wang, YT (corresponding author), Univ Macau, State Key Lab Qual Res Chinese Med, Inst Chinese Med Sci, Macau, Peoples R China.
EM zfzhong@aliyun.com; ytwang@um.edu.mo
RI Huan, Zhao/AAU-8477-2021; Ung, Carolina Oi Lam/AAR-2672-2020
OI Jinchao, Wei/0000-0002-9777-4867; Ung, Carolina Oi
   Lam/0000-0003-1915-5099; Vong, Chi Teng/0000-0002-4032-657X
FU Macao Science and Technology Development Fund [FDCT 071/2017/A2];
   Research Committee of the University of Macau [CPG2019-00006-ICMS]
FX This work was financially supported by the Macao Science and Technology
   Development Fund (FDCT 071/2017/A2), and the Research Committee of the
   University of Macau (CPG2019-00006-ICMS).
CR Akhtar R, 2014, NUTR HOSP, V29, P388, DOI 10.3305/nh.2014.29.2.7080
   Al-Ani LA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216725
   Alamzeb M, 2015, NAT PROD RES, V29, P692, DOI 10.1080/14786419.2014.981187
   Alisi A, 2012, INT J MOL SCI, V13, P2276, DOI 10.3390/ijms13022276
   Amin ARMR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124218
   Amirsaadat S, 2017, ARTIF CELL NANOMED B, V45, P1649, DOI 10.1080/21691401.2016.1276922
   Anirudhan TS, 2017, CARBOHYD POLYM, V173, P131, DOI 10.1016/j.carbpol.2017.05.045
   Aribi A, 2013, INT J CANCER, V132, P2730, DOI 10.1002/ijc.27950
   Augustin Y., 2015, ECANCERMEDICALSCIENC, V9, P50, DOI DOI 10.3332/ecancer.2015.ed50
   Aziz F, 2016, TOXICOL IN VITRO, V31, P158, DOI 10.1016/j.tiv.2015.09.025
   Bai DF, 2017, NEUROCHEM RES, V42, P3439, DOI 10.1007/s11064-017-2389-3
   Bai S, 2016, ANAT REC, V299, P256, DOI 10.1002/ar.23293
   Bai YQ, 2016, EXP THER MED, V11, P1085, DOI 10.3892/etm.2016.2984
   Bai ZL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/6165192
   Barzegar E, 2015, IRAN J BASIC MED SCI, V18, P334
   Beccafico S, 2015, CARCINOGENESIS, V36, P1071, DOI 10.1093/carcin/bgv098
   Bimonte S, 2015, INFECT AGENTS CANCER, V10, DOI 10.1186/s13027-015-0016-y
   Biswas S, 2019, DRUG DEV IND PHARM, V45, P946, DOI 10.1080/03639045.2019.1583755
   Borutinskaite V, 2018, LEUKEMIA LYMPHOMA, V59, P469, DOI 10.1080/10428194.2017.1339881
   Brandon-Warner E, 2012, CANCER LETT, V326, P88, DOI 10.1016/j.canlet.2012.07.028
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Brincks EL, 2015, FEBS J, V282, P4747, DOI 10.1111/febs.13532
   Cai B, 2018, ONCOL LETT, V16, P6019, DOI 10.3892/ol.2018.9401
   Cai DT, 2013, MOL CELL BIOCHEM, V379, P161, DOI 10.1007/s11010-013-1638-2
   Cai F, 2016, ONCOL REP, V36, P1180, DOI 10.3892/or.2016.4892
   Cai YY, 2013, ASIAN PAC J CANCER P, V14, P4267, DOI 10.7314/APJCP.2013.14.7.4267
   Cao SJ, 2019, APOPTOSIS, V24, P33, DOI 10.1007/s10495-018-1497-0
   Cao Y, 2019, INT IMMUNOPHARMACOL, V70, P110, DOI 10.1016/j.intimp.2019.01.041
   Cascao R, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/195327
   Cha TL, 2015, MOL CARCINOGEN, V54, P167, DOI 10.1002/mc.22084
   Chakrabarti M, 2015, BRAIN RES, V1629, P85, DOI 10.1016/j.brainres.2015.10.010
   Chan SF, 2017, ENVIRON TOXICOL, V32, P550, DOI 10.1002/tox.22259
   Chen CM, 2013, EUR J PHARM SCI, V49, P18, DOI 10.1016/j.ejps.2013.02.003
   Chen CH, 2012, ANN SURG ONCOL, V19, P3097, DOI 10.1245/s10434-012-2324-4
   Chen CY, 2017, AM J TRANSL RES, V9, P5507
   Chen FH, 2017, BIOCHEM PHARMACOL, V135, P50, DOI 10.1016/j.bcp.2017.03.004
   Chen GY, 2016, AM J CHINESE MED, V44, P1187, DOI 10.1142/S0192415X1650066X
   Chen GL, 2015, INT J OPHTHALMOL-CHI, V8, P665, DOI 10.3980/j.issn.2222-3959.2015.04.04
   Chen GL, 2015, INT J CLIN EXP MED, V8, P12382
   Chen GQ, 2016, ONCOTARGET, V7, P50302, DOI 10.18632/oncotarget.10367
   Chen H, 2010, INT J HEMATOL, V92, P587, DOI 10.1007/s12185-010-0697-3
   Chen HM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-42
   Chen H, 2011, ONCOL REP, V25, P1253, DOI 10.3892/or.2011.1174
   Chen J, 2011, ONCOGENE, V30, P4297, DOI 10.1038/onc.2011.137
   Chen JJ, 2018, SAUDI J BIOL SCI, V25, P1488, DOI 10.1016/j.sjbs.2018.04.003
   Chen J, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/4751260
   Chen J, 2012, ONCOL REP, V27, P523, DOI 10.3892/or.2011.1524
   Chen JX, 2017, THERANOSTICS, V7, P2250, DOI 10.7150/thno.18816
   Chen K, 2014, ANTI-CANCER DRUG, V25, P652, DOI 10.1097/CAD.0000000000000089
   Chen L, 2011, CANCER CHEMOTH PHARM, V68, P17, DOI 10.1007/s00280-010-1440-8
   Chen PN, 2011, J AGR FOOD CHEM, V59, P3836, DOI 10.1021/jf1049408
   Chen P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1234-8
   Chen QY, 2014, J NUTR BIOCHEM, V25, P177, DOI 10.1016/j.jnutbio.2013.10.004
   Chen RY, 2014, WORLD J GASTROENTERO, V20, P14895, DOI 10.3748/wjg.v20.i40.14895
   Chen W, 2016, ONCOTARGET, V7, P56842, DOI 10.18632/oncotarget.10863
   Chen W, 2011, AAPS PHARMSCITECH, V12, P705, DOI 10.1208/s12249-011-9632-z
   Chen WX, 2011, CANCER CHEMOTH PHARM, V67, P799, DOI 10.1007/s00280-010-1378-x
   Chen X, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.019
   Chen X, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414-431X20197992, 10.1590/1414-431x20197992]
   Chen X, 2017, MOLECULES, V22, DOI 10.3390/molecules22081272
   Chen XP, 2011, INT J CLIN ONCOL, V16, P519, DOI 10.1007/s10147-011-0222-6
   Chen XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079201
   Chen YQ, 2014, INT IMMUNOPHARMACOL, V21, P447, DOI 10.1016/j.intimp.2014.05.026
   Chen Y, 2018, CELL PHYSIOL BIOCHEM, V47, P981, DOI 10.1159/000490142
   Cheng TS, 2013, CANCER PREV RES, V6, P495, DOI 10.1158/1940-6207.CAPR-12-0293-T
   Cheng WE, 2015, EUR J PHARMACOL, V757, P1, DOI 10.1016/j.ejphar.2015.03.013
   Cheng XL, 2016, MOL MED REP, V13, P3257, DOI 10.3892/mmr.2016.4931
   Chi YHBL, 2013, CHINESE MED J-PEKING, V126, P1642, DOI 10.3760/cma.j.issn.0366-6999.20122582
   Chihara Takeshi, 2015, Asian Pac J Cancer Prev, V16, P3887
   Cho J, 2015, CANCER PREV RES, V8, P817, DOI 10.1158/1940-6207.CAPR-15-0098
   Choi ES, 2017, CELL ONCOL, V40, P235, DOI 10.1007/s13402-017-0318-8
   Choi YJ, 2013, ONCOL REP, V30, P1362, DOI 10.3892/or.2013.2555
   Choudhury D, 2013, BIOCHIMIE, V95, P1297, DOI 10.1016/j.biochi.2013.02.010
   Chow SE, 2012, J CELL BIOCHEM, V113, P3476, DOI 10.1002/jcb.24224
   Chu SC, 2014, MOL PHARMACOL, V86, P609, DOI 10.1124/mol.114.094037
   Chuang TY, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0429-3
   Ciolac OA, 2017, ROM BIOTECH LETT, V22, P13068
   Cui C, 2015, INT IMMUNOPHARMACOL, V27, P110, DOI 10.1016/j.intimp.2015.05.004
   Dai GL, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172525
   Dakeng S, 2012, J CELL BIOCHEM, V113, P49, DOI 10.1002/jcb.23326
   De Amicis F, 2013, MOL NUTR FOOD RES, V57, P840, DOI 10.1002/mnfr.201200560
   Lopes SCD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/467147
   Deeken JF, 2018, CANCER CHEMOTH PHARM, V81, P587, DOI 10.1007/s00280-018-3533-8
   Deep G, 2017, MOL CARCINOGEN, V56, P833, DOI 10.1002/mc.22537
   Deng C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.13
   Deng G, 2015, MOL MED REP, V12, P4427, DOI 10.3892/mmr.2015.3923
   Deng XR, 2013, J HUAZHONG U SCI-MED, V33, P862, DOI 10.1007/s11596-013-1212-x
   Deng YT, 2011, J AGR FOOD CHEM, V59, P13318, DOI 10.1021/jf204149c
   Desgrouas C, 2014, MALARIA J, V13, DOI 10.1186/1475-2875-13-327
   Dettlaff K, 2017, INT J MOL MED, V40, P329, DOI 10.3892/ijmm.2017.3024
   Ding LJ, 2017, PHARMACOLOGY, V99, P188, DOI 10.1159/000452340
   Ding LJ, 2016, ENVIRON TOXICOL PHAR, V46, P264, DOI 10.1016/j.etap.2016.07.021
   Ding LX, 2018, MOL MED REP, V17, P1022, DOI 10.3892/mmr.2017.7965
   Ding XF, 2013, ONCOL LETT, V5, P1554, DOI 10.3892/ol.2013.1213
   Ding XL, 2015, MOL MED REP, V12, P4508, DOI 10.3892/mmr.2015.3960
   Ding Y, 2016, EUR J MED CHEM, V122, P102, DOI 10.1016/j.ejmech.2016.06.015
   Huynh DL, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1788-y
   Dong FY, 2015, INT J MOL MED, V35, P1381, DOI 10.3892/ijmm.2015.2140
   Dong FY, 2014, CANCER BIOL THER, V15, P1479, DOI 10.4161/15384047.2014.955728
   Dong HY, 2014, CHINESE J CANCER RES, V26, P200, DOI 10.3978/j.issn.1000-9604.2014.04.07
   Dong XX, 2018, ONCOL REP, V40, P1985, DOI 10.3892/or.2018.6620
   Drenberg CD, 2016, CANCER CHEMOTH PHARM, V77, P1231, DOI 10.1007/s00280-016-3038-2
   Du WZ, 2013, CNS NEUROSCI THER, V19, P926, DOI 10.1111/cns.12163
   Duan WJ, 2011, J ASIAN NAT PROD RES, V13, P27, DOI 10.1080/10286020.2010.540757
   Duangmano S, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-185
   Dudas J, 2013, EXP CELL RES, V319, P800, DOI 10.1016/j.yexcr.2012.12.001
   Durr C, 2018, HAEMATOLOGICA, V103, P688, DOI 10.3324/haematol.2017.177808
   Durchschein C, 2018, MOLECULES, V23, DOI 10.3390/molecules23112820
   Efferth T, 2004, BIOCHEM PHARMACOL, V67, P1689, DOI 10.1016/j.bcp.2003.12.035
   Efferth T, 2017, SEMIN CANCER BIOL, V46, P65, DOI 10.1016/j.semcancer.2017.02.009
   Efferth T, 2015, PHYTOMEDICINE, V22, pA1, DOI 10.1016/j.phymed.2015.10.003
   El-Senduny FF, 2016, TUMOR BIOL, V37, P685, DOI 10.1007/s13277-015-3773-8
   Eling Nils, 2015, Oncoscience, V2, P517
   Eloy JD, 2012, AAPS PHARMSCITECH, V13, P1436, DOI 10.1208/s12249-012-9868-2
   Ericsson T, 2014, EUR J CLIN PHARMACOL, V70, P1453, DOI 10.1007/s00228-014-1754-2
   Eyol E, 2016, CLIN EXP PHARMACOL P, V6, P1000219
   Fang YY, 2018, FITOTERAPIA, V124, P92, DOI 10.1016/j.fitote.2017.10.015
   Faridnia Roghiyeh, 2018, Annals of Parasitology, V64, P29, DOI 10.17420/ap6401.129
   Feng Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01356
   Feng X, 2014, BIOCHEM BIOPH RES CO, V444, P376, DOI 10.1016/j.bbrc.2014.01.053
   Fernandes V, 2018, INT J NEUROSCI, V128, P935, DOI 10.1080/00207454.2018.1443926
   Flores-Perez A, 2016, PROTEOM CLIN APPL, V10, P172, DOI 10.1002/prca.201500008
   Forghani P, 2014, CANCER MED-US, V3, P215, DOI 10.1002/cam4.186
   Fu HB, 2018, J CELL PHYSIOL, V233, P4634, DOI 10.1002/jcp.26190
   Fu R, 2016, ONCOTARGET, V7, P5715, DOI 10.18632/oncotarget.6796
   Gaikwad D, 2017, INT J BIOL MACROMOL, V104, P656, DOI 10.1016/j.ijbiomac.2017.05.170
   Gandara L, 2014, J PHOTOCH PHOTOBIO B, V133, P55, DOI 10.1016/j.jphotobiol.2014.03.006
   Ganguli A, 2014, BIOCHIMIE, V107, P338, DOI 10.1016/j.biochi.2014.10.001
   Gao FH, 2012, INT J MOL MED, V29, P649, DOI 10.3892/ijmm.2012.895
   Gao GY, 2018, EXP THER MED, V16, P1758, DOI 10.3892/etm.2018.6421
   Gao H, 2018, EXP THER MED, V15, P3413, DOI 10.3892/etm.2018.5830
   Gao N, 2012, BRIT J PHARMACOL, V165, P1813, DOI 10.1111/j.1476-5381.2011.01684.x
   Gao R, 2019, ONCOTARGETS THER, V12, P3713, DOI 10.2147/OTT.S182405
   Gao SM, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-27
   Gao SY, 2014, ASIAN PAC J CANCER P, V15, P6437, DOI 10.7314/APJCP.2014.15.15.6437
   Gao SY, 2016, INT J ONCOL, V48, P2453, DOI 10.3892/ijo.2016.3479
   Gao SM, 2017, CELL PHYSIOL BIOCHEM, V41, P1633, DOI 10.1159/000471234
   Gao WJ, 2013, APOPTOSIS, V18, P1201, DOI 10.1007/s10495-013-0857-z
   Gao X, 2015, J BIOMED NANOTECHNOL, V11, P578, DOI 10.1166/jbn.2015.1964
   Gao YJ, 2014, CANCER LETT, V349, P15, DOI 10.1016/j.canlet.2014.03.015
   Garg S, 2020, J GERONTOL A-BIOL, V75, P1031, DOI 10.1093/gerona/glz077
   Ge GQ, 2017, BIOL PHARM BULL, V40, P2117, DOI 10.1248/bpb.b17-00463
   Ge WZ, 2018, MOLECULES, V23, DOI 10.3390/molecules23123345
   Ge WL, 2015, J MOL NEUROSCI, V56, P652, DOI 10.1007/s12031-015-0530-9
   Ge XL, 2014, J INT MED RES, V42, P628, DOI 10.1177/0300060513505491
   Ge YK, 2011, INT J MOL SCI, V12, P4861, DOI 10.3390/ijms12084861
   Go JH, 2018, INT J MOL MED, V42, P1899, DOI 10.3892/ijmm.2018.3776
   Gohulkumar M, 2014, MAT SCI ENG C-MATER, V41, P274, DOI 10.1016/j.msec.2014.04.056
   Gong K, 2014, EUR J PHARMACOL, V738, P142, DOI 10.1016/j.ejphar.2014.05.034
   Gong Y, 2011, INT J CANCER, V129, P1042, DOI 10.1002/ijc.25678
   Greeno E, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT207
   Greenshields AL, 2019, EXP MOL PATHOL, V107, P10, DOI 10.1016/j.yexmp.2019.01.006
   Greenshields AL, 2017, MOL CARCINOGEN, V56, P75, DOI 10.1002/mc.22474
   Greil R, 2018, CANCER CHEMOTH PHARM, V82, P695, DOI 10.1007/s00280-018-3654-0
   Gu ZM, 2015, BIOCHEM BIOPH RES CO, V457, P187, DOI 10.1016/j.bbrc.2014.12.086
   Guan CY, 2014, INT J CLIN EXP PATHO, V7, P3948
   Guan F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146553
   Guerram M, 2015, ONCOTARGET, V6, P21865, DOI 10.18632/oncotarget.4156
   Guo JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088140
   Guo JL, 2013, MOL CELL BIOCHEM, V382, P103, DOI 10.1007/s11010-013-1723-6
   Guo JL, 2019, J OBSTET GYNAECOL RE, V45, P877, DOI 10.1111/jog.13919
   Guo JQ, 2014, INT J ONCOL, V45, P1065, DOI 10.3892/ijo.2014.2500
   Gupta P, 2014, ONCOTARGET, V5, P1812, DOI 10.18632/oncotarget.1743
   Hagelgans A, 2014, ANTICANCER RES, V34, P1723
   Hajigholami S, 2018, IRAN J PHARM RES, V17, P1
   Han L, 2014, BIOMED RES INT, V2014, P6
   Han X, 2019, BIOMOL THER, V27, P41, DOI 10.4062/biomolther.2018.047
   Hao ZF, 2015, ONCOL LETT, V9, P629, DOI 10.3892/ol.2014.2771
   Haque A, 2015, APOPTOSIS, V20, P986, DOI 10.1007/s10495-015-1126-0
   Haque E, 2018, INT J BIOCHEM CELL B, V96, P90, DOI 10.1016/j.biocel.2018.01.014
   Harada T, 2012, INT J ONCOL, V41, P565, DOI 10.3892/ijo.2012.1501
   Harati K, 2017, MOL MED REP, V15, P103, DOI 10.3892/mmr.2016.5969
   Hashemi-Niasari F, 2018, BIOMED PHARMACOTHER, V106, P858, DOI 10.1016/j.biopha.2018.07.019
   Hassan L, 2016, EXP CELL RES, V345, P60, DOI 10.1016/j.yexcr.2016.05.023
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   He F, 2012, ONCOL REP, V28, P601, DOI 10.3892/or.2012.1841
   He GD, 2016, BIOCHEM BIOPH RES CO, V469, P1075, DOI 10.1016/j.bbrc.2015.12.100
   He LC, 2013, TOXICOLOGY, V312, P36, DOI 10.1016/j.tox.2013.07.013
   He NW, 2012, J MED FOOD, V15, P350, DOI 10.1089/jmf.2011.1801
   He W, 2012, J PHARMACOL SCI, V119, P341, DOI 10.1254/jphs.12052FP
   Hira SK, 2015, CYTOTHERAPY, V17, P647, DOI 10.1016/j.jcyt.2015.01.006
   Ho JN, 2015, J UROLOGY, V193, P1016, DOI 10.1016/j.juro.2014.09.007
   Ho WE, 2014, PHARMACOL THERAPEUT, V142, P126, DOI 10.1016/j.pharmthera.2013.12.001
   Hong M, 2018, MOLECULES, V23, DOI 10.3390/molecules23020384
   Hong ZP, 2018, PHYTOMEDICINE, V39, P168, DOI 10.1016/j.phymed.2017.12.019
   Hou D, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.471
   Houh YK, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071600
   Hsiao YT, 2018, AM J CHINESE MED, V46, P1145, DOI 10.1142/S0192415X1850060X
   Hsieh YS, 2017, J CELL BIOCHEM, V118, P4639, DOI 10.1002/jcb.26128
   Hsu PC, 2019, ONCOL REP, V42, P697, DOI 10.3892/or.2019.7207
   Hsu YC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.151
   Hu B, 2015, BIOCHEM BIOPH RES CO, V468, P525, DOI 10.1016/j.bbrc.2015.10.031
   Hu CJ, 2011, DRUG DEV IND PHARM, V37, P765, DOI 10.3109/03639045.2010.541261
   Hu CJ, 2015, ONCOL REP, V33, P3146, DOI 10.3892/or.2015.3896
   Hu CX, 2019, PHYTOMEDICINE, V58, DOI 10.1016/j.phymed.2018.11.001
   Hu CJ, 2014, CANCER BIOL THER, V15, P279, DOI 10.4161/cbt.27223
   Hu F, 2015, J PHARMACOL SCI, V128, P27, DOI 10.1016/j.jphs.2015.04.003
   Hu H, 2018, ONCOL REP, V39, P1191, DOI 10.3892/or.2017.6158
   Hu P, 2019, DIGEST LIVER DIS, V51, P120, DOI 10.1016/j.dld.2018.06.012
   Hu Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01150
   Hu Q, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0390-0
   Hu TL, 2018, BIOMED PHARMACOTHER, V106, P1557, DOI 10.1016/j.biopha.2018.07.124
   Hu W, 2014, CANCER LETT, V343, P239, DOI 10.1016/j.canlet.2013.09.035
   Hua PY, 2015, BIOCHEM BIOPH RES CO, V460, P136, DOI 10.1016/j.bbrc.2015.02.131
   Huang B, 2016, J NANOSCI NANOTECHNO, V16, P2499, DOI 10.1166/jnn.2016.10792
   Huang CY, 2017, ONCOL LETT, V14, P3623, DOI 10.3892/ol.2017.6641
   Huang CZ, 2017, ONCOL REP, V38, P2558, DOI 10.3892/or.2017.5879
   Huang CY, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903783
   Huang CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066326
   Huang CY, 2011, TOXICOL IN VITRO, V25, P1274, DOI 10.1016/j.tiv.2011.04.014
   Huang HR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144293
   Huang HL, 2012, MOL CANCER THER, V11, P1155, DOI 10.1158/1535-7163.MCT-12-0066
   Huang J, 2017, ONCOL LETT, V13, P37, DOI 10.3892/ol.2016.5435
   Huang ST, 2017, SCI REP-UK, V7, DOI 10.1038/srep40382
   Huang SY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081616
   Huang WW, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/952762
   Huang Y, 2018, ONCOTARGETS THER, V11, P769, DOI 10.2147/OTT.S149788
   Huang YF, 2017, ONCOTARGET, V8, P40264, DOI 10.18632/oncotarget.16828
   Hung CM, 2013, INT J MOL SCI, V14, P17147, DOI 10.3390/ijms140817147
   Hwang YS, 2013, EUR J PHARMACOL, V715, P286, DOI 10.1016/j.ejphar.2013.05.008
   Ilamathi M, 2016, CURR TOP MED CHEM, V16, P2453, DOI 10.2174/1568026616666160212122820
   Im E, 2018, LIFE SCI, V192, P286, DOI 10.1016/j.lfs.2017.11.008
   Irimie AI, 2015, ONCOTARGETS THER, V8, P461, DOI 10.2147/OTT.S78358
   Ishaq M, 2014, BBA-GEN SUBJECTS, V1840, P3374, DOI 10.1016/j.bbagen.2014.08.019
   Iwanowycz S, 2016, MOL CANCER THER, V15, P1931, DOI 10.1158/1535-7163.MCT-15-0987
   Iwanowycz S, 2016, J BIOL CHEM, V291, P11491, DOI 10.1074/jbc.M115.702092
   Jahanafrooz Zohreh, 2016, Asian Pac J Cancer Prev, V17, P2661
   Jamal M, 2015, INT IMMUNOPHARMACOL, V29, P361, DOI 10.1016/j.intimp.2015.10.029
   Jang JH, 2016, INT J ONCOL, V48, P376, DOI 10.3892/ijo.2015.3249
   Jang JY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-421
   Jang SY, 2015, BIOCHEM BIOPH RES CO, V465, P71, DOI 10.1016/j.bbrc.2015.07.131
   Jang SY, 2014, ONCOL REP, V31, P2827, DOI 10.3892/or.2014.3159
   Jansen FH, 2011, ANTICANCER RES, V31, P4417
   Jao HY, 2016, ENVIRON TOXICOL, V31, P1974, DOI 10.1002/tox.22198
   Jeong DE, 2015, ONCOTARGET, V6, P33046, DOI 10.18632/oncotarget.5422
   Jeong Y, 2018, J BREAST CANCER, V21, P21, DOI 10.4048/jbc.2018.21.1.21
   Jeung YJ, 2016, BBA-MOL CELL RES, V1863, P2584, DOI 10.1016/j.bbamcr.2016.07.005
   Ji J, 2014, ASIAN PAC J CANCER P, V15, P7747, DOI 10.7314/APJCP.2014.15.18.7747
   Ji Z, 2011, ONCOL LETT, V2, P1303, DOI 10.3892/ol.2011.408
   Jia JG, 2016, MOL MED REP, V13, P4461, DOI 10.3892/mmr.2016.5073
   Jiang CH, 2016, ONCOTARGETS THER, V9, P6609, DOI 10.2147/OTT.S107101
   Jiang CM, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317697556
   Jiang F, 2018, INT J MOL MED, V42, P1295, DOI 10.3892/ijmm.2018.3712
   Jiang J, 2018, ONCOL RES, V26, P1235, DOI 10.3727/096504018X15179661552702
   Jiang JW, 2011, WORLD J GASTROENTERO, V17, P3605, DOI 10.3748/wjg.v17.i31.3605
   Jiang J, 2016, ONCOTARGET, V7, P87271, DOI 10.18632/oncotarget.13536
   Jiang J, 2017, BIOMED PHARMACOTHER, V96, P619, DOI 10.1016/j.biopha.2017.10.043
   Jiang JH, 2019, J CELL BIOCHEM, V120, P3736, DOI 10.1002/jcb.27654
   Jiang K, 2015, ONCOL REP, V33, P2711, DOI 10.3892/or.2015.3915
   Jiang RB, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9381513
   Jiang SX, 2017, WORLD J GASTROENTERO, V23, P2511, DOI 10.3748/wjg.v23.i14.2511
   Jiang ZS, 2017, BIOMED PHARMACOTHER, V96, P378, DOI 10.1016/j.biopha.2017.09.129
   Jin F, 2019, PHARM BIOL, V56, P665, DOI 10.1080/13880209.2018.1548627
   Jin HY, 2011, J GASTROEN HEPATOL, V26, P706, DOI 10.1111/j.1440-1746.2010.06500.x
   Jing XP, 2016, CANCER CHEMOTH PHARM, V77, P1171, DOI 10.1007/s00280-016-3034-6
   Joo EJ, 2015, CHEM-BIOL INTERACT, V233, P25, DOI 10.1016/j.cbi.2015.03.016
   Jose A, 2017, J DRUG TARGET, V25, P330, DOI 10.1080/1061186X.2016.1258567
   Jung JH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/805639
   Jwa M, 2012, NAT CELL BIOL, V14, P1223, DOI 10.1038/ncb2593
   Kaewthawee N, 2013, EXCLI J, V12, P102
   Kanai M, 2013, CANCER CHEMOTH PHARM, V71, P1521, DOI 10.1007/s00280-013-2151-8
   Kang N, 2015, INT J ONCOL, V47, P2045, DOI 10.3892/ijo.2015.3186
   Kang S, 2018, ANTICANCER RES, V38, P787, DOI 10.21873/anticanres.12285
   Kashyap D, 2016, RECENT PATENTS INFLA, V10, P21, DOI 10.2174/1872213X10666160711143904
   Kauntz H, 2012, INT J ONCOL, V41, P849, DOI 10.3892/ijo.2012.1526
   Kausar H, 2013, CANCER LETT, V332, P35, DOI 10.1016/j.canlet.2013.01.008
   Ke R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23780-x
   Khan MA, 2016, INT J BIOL MACROMOL, V93, P242, DOI 10.1016/j.ijbiomac.2016.08.050
   Khan MN, 2018, CURR DRUG DELIV, V15, P286, DOI 10.2174/1567201814666171019104002
   Khan N, 2014, CARCINOGENESIS, V35, P415, DOI 10.1093/carcin/bgt321
   Khan S, 2016, MOL CELL ENDOCRINOL, V428, P101, DOI 10.1016/j.mce.2016.03.025
   Kharat M, 2017, J AGR FOOD CHEM, V65, P1525, DOI 10.1021/acs.jafc.6b04815
   Kim AD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.273
   Kim BR, 2013, INFLAMM RES, V62, P941, DOI 10.1007/s00011-013-0640-1
   Kim Bo-Min, 2014, J Cancer Prev, V19, P23
   Kim DG, 2014, ONCOTARGET, V5, P4438, DOI 10.18632/oncotarget.2034
   Kim EH, 2016, APOPTOSIS, V21, P1265, DOI 10.1007/s10495-016-1284-8
   Kim EO, 2016, INT J ONCOL, V48, P2205, DOI 10.3892/ijo.2016.3441
   Kim HJ, 2015, ARCH PHARM RES, V38, P290, DOI 10.1007/s12272-014-0386-5
   Kim HJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1223-7
   Kim JS, 2015, ONCOL REP, V33, P1775, DOI 10.3892/or.2015.3768
   Kim JH, 2016, MOL CELL TOXICOL, V12, P53, DOI 10.1007/s13273-016-0008-z
   Kim KH, 2011, ARCH PHARM RES, V34, P1363, DOI 10.1007/s12272-011-0817-5
   Kim KC, 2014, KOREAN J PHYSIOL PHA, V18, P61, DOI 10.4196/kjpp.2014.18.1.61
   Kim SA, 2018, INT J MOL SCI, V19, DOI [10.3390/ijms19092739, 10.15818/ihss.2018.19.1.1]
   Kim SH, 2015, BIOCHEM BIOPH RES CO, V468, P151, DOI 10.1016/j.bbrc.2015.10.143
   Kim S, 2018, PHYTOMEDICINE, V50, P43, DOI 10.1016/j.phymed.2018.08.004
   Kim S, 2014, ONCOL REP, V32, P2230, DOI 10.3892/or.2014.3450
   Kim S, 2012, J SURG RES, V176, pE21, DOI 10.1016/j.jss.2011.11.1041
   Kim YJ, 2014, TOXICOLOGY, V322, P23, DOI 10.1016/j.tox.2014.04.002
   Klippstein R, 2016, INT J PHARMACEUT, V514, P169, DOI 10.1016/j.ijpharm.2016.08.003
   Kondo A, 2013, INT J CLIN ONCOL, V18, P380, DOI 10.1007/s10147-012-0387-7
   Kong JM, 2018, TOXICOL APPL PHARM, V342, P1, DOI 10.1016/j.taap.2018.01.011
   Kong YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103760
   Kostin SF, 2012, J SURG RES, V177, P255, DOI 10.1016/j.jss.2012.04.023
   Kou Y, 2016, BIOCHEM BIOPH RES CO, V479, P290, DOI 10.1016/j.bbrc.2016.09.061
   Krishna S, 2015, EBIOMEDICINE, V2, P82, DOI 10.1016/j.ebiom.2014.11.010
   Krosch TCK, 2013, AM J SURG, V205, P387, DOI 10.1016/j.amjsurg.2013.01.008
   Krusche B, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/454783
   Ku JM, 2015, MOL CELL BIOCHEM, V409, P33, DOI 10.1007/s11010-015-2509-9
   Kumar A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160783
   Kumar S, 2014, ONCOTARGET, V5, P4972, DOI 10.18632/oncotarget.2068
   Kumari K, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3863-7
   Kumazoe M, 2015, BRIT J HAEMATOL, V168, P610, DOI 10.1111/bjh.13135
   Kuo HP, 2015, J FUNCT FOODS, V17, P600, DOI 10.1016/j.jff.2015.06.006
   Kuo HP, 2011, J AGR FOOD CHEM, V59, P8216, DOI 10.1021/jf2012584
   Kwan HY, 2013, J GASTROENTEROL, V48, P182, DOI 10.1007/s00535-012-0612-1
   Kwon HY, 2013, INDIAN J BIOCHEM BIO, V50, P485
   Kwon HY, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/172548
   La XQ, 2017, ONCOTARGET, V8, P20909, DOI 10.18632/oncotarget.14959
   Lan T, 2013, INT J CLIN EXP PATHO, V6, P1799
   Lan WJ, 2014, CELL BIOCHEM BIOPHYS, V70, P1459, DOI 10.1007/s12013-014-0083-5
   Larasati YA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20179-6
   Law BYK, 2014, SCI REP-UK, V4, DOI 10.1038/srep05510
   Lee DH, 2011, CANCER LETT, V306, P161, DOI 10.1016/j.canlet.2011.03.001
   Lee HP, 2017, ONCOTARGET, V8, P109217, DOI 10.18632/oncotarget.22649
   Lee HM, 2016, PHYTOMEDICINE, V23, P1535, DOI 10.1016/j.phymed.2016.09.005
   Lee IS, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/7521601
   Lee J, 2017, ONCOTARGET, V8, P25032, DOI 10.18632/oncotarget.15336
   Lee JY, 2015, TOX RESEARCH, V31, P11, DOI 10.5487/TR.2015.31.1.011
   Lee PNH, 2013, ONCOL REP, V29, P1744, DOI 10.3892/or.2013.2291
   Lee SH, 2013, EUR J CANCER, V49, P3210, DOI 10.1016/j.ejca.2013.06.025
   Lee S, 2017, PHYTOMEDICINE, V24, P49, DOI 10.1016/j.phymed.2016.11.007
   Leem DG, 2018, ONCOL LETT, V15, P6043, DOI 10.3892/ol.2018.8057
   Leng SL, 2013, INT J CANCER, V133, P2781, DOI 10.1002/ijc.28301
   Lewinska A, 2017, APOPTOSIS, V22, P800, DOI 10.1007/s10495-017-1353-7
   Li BH, 2011, CANCER LETT, V301, P185, DOI 10.1016/j.canlet.2010.11.015
   Li BN, 2018, ACTA BIOCH BIOPH SIN, V50, P1227, DOI 10.1093/abbs/gmy125
   Li C, 2019, BIOCHEM CELL BIOL, V97, P406, DOI 10.1139/bcb-2018-0226
   Li CL, 2012, BIOCHEM CELL BIOL, V90, P718, DOI [10.1139/O2012-030, 10.1139/o2012-030]
   Li CF, 2016, MAR GEOPHYS RES, V37, P1, DOI 10.1007/s11001-016-9265-4
   Li CY, 2018, ONCOL LETT, V15, P1362, DOI 10.3892/ol.2017.7421
   Li CY, 2018, ONCOL LETT, V16, P2289, DOI 10.3892/ol.2018.8943
   Li DX, 2015, GENET MOL RES, V14, P10553, DOI 10.4238/2015.September.8.17
   Li D, 2015, CHIN J NAT MEDICINES, V13, P41, DOI 10.1016/S1875-5364(15)60005-X
   Li G, 2017, BIOMED PHARMACOTHER, V94, P974, DOI 10.1016/j.biopha.2017.07.148
   Li H, 2018, J CELL BIOCH
   Li H, 2015, ACTA PHARMACOL SIN, V36, P606, DOI 10.1038/aps.2014.162
   Li J, 2019, J CELL PHYSIOL, V234, P12663, DOI 10.1002/jcp.27875
   Li J, 2018, ONCOL LETT, V15, P7409, DOI 10.3892/ol.2018.8249
   Li J, 2015, INT J ONCOL, V46, P775, DOI 10.3892/ijo.2014.2767
   Li Jin, 2011, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V36, P754, DOI 10.3969/j.issn.1672-7347.2011.08.010
   Li J, 2015, MOL MED REP, V12, P4572, DOI 10.3892/mmr.2015.3926
   Li J, 2011, MOL CANCER THER, V10, P1346, DOI 10.1158/1535-7163.MCT-10-0985
   Li JJ, 2012, ONCOL REP, V28, P501, DOI 10.3892/or.2012.1827
   Li K, 2019, PHYTOTHER RES, V33, P1658, DOI 10.1002/ptr.6353
   Li LW, 2011, EUR J PHARMACOL, V670, P13, DOI 10.1016/j.ejphar.2011.08.054
   Li LW, 2011, EUR J PHARM SCI, V43, P393, DOI 10.1016/j.ejps.2011.06.001
   Li M, 2016, ONCOL REP, V35, P2339, DOI 10.3892/or.2016.4587
   Li N, 2018, MOL MED REP, V18, P3366, DOI 10.3892/mmr.2018.9304
   Li PC, 2014, J CANCER RES CLIN, V140, P2065, DOI 10.1007/s00432-014-1771-7
   Li PH, 2017, MED SCI MONITOR, V23, P809, DOI 10.12659/MSM.903197
   Li QQ, 2013, ANTICANCER RES, V33, P1421
   Li QQ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0488-9
   Li Q, 2017, EUR J PHARMACOL, V815, P173, DOI 10.1016/j.ejphar.2017.09.023
   Li Q, 2016, ASIAN PAC J TROP MED, V9, P1062, DOI 10.1016/j.apjtm.2016.09.003
   Li QH, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2353-z
   Li Q, 2018, MOLECULES, V23, DOI 10.3390/molecules23051101
   Li SJ, 2016, ONCOL LETT, V12, P5059, DOI 10.3892/ol.2016.5367
   Li SY, 2018, THERANOSTICS, V8, P1361, DOI 10.7150/thno.18299
   Li T, 2017, EUR J PHARM SCI, V96, P456, DOI 10.1016/j.ejps.2016.10.019
   Li W, 2018, MEDICINA-LITHUANIA, V54, DOI 10.3390/medicina54030039
   Li WJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094079
   Li X, 2012, INT J BIOL SCI, V8, P901, DOI 10.7150/ijbs.4554
   Li XN, 2017, ONCOTARGET, V8, P65022, DOI 10.18632/oncotarget.17531
   Li XL, 2012, BIOMACROMOLECULES, V13, P873, DOI 10.1021/bm2017959
   Li XG, 2017, CELL DISCOV, V3, DOI 10.1038/celldisc.2017.42
   Li XJ, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3329-y
   Li XX, 2013, STEM CELLS DEV, V22, P554, DOI 10.1089/scd.2011.0709
   Li XX, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2640-3
   Li XY, 2018, ENVIRON TOXICOL PHAR, V57, P86, DOI 10.1016/j.etap.2017.12.004
   Li XG, 2018, BIOCHEM BIOPH RES CO, V496, P443, DOI 10.1016/j.bbrc.2018.01.052
   Li Y, 2017, IMMUNOPHARM IMMUNOT, V39, P124, DOI 10.1080/08923973.2017.1299174
   Li Y, 2016, ONCOTARGET, V7, P70535, DOI 10.18632/oncotarget.12059
   Li Y, 2016, MOL MED REP, V14, P2222, DOI 10.3892/mmr.2016.5475
   Li YJ, 2014, CELL PHYSIOL BIOCHEM, V33, P1527, DOI 10.1159/000358716
   Li YJ, 2018, CELL PHYSIOL BIOCHEM, V48, P2035, DOI 10.1159/000492541
   Li YP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5130-y
   Li Y, 2015, IRAN J KIDNEY DIS, V9, P202
   Li Y, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0365-1
   Li Z, 2018, ARTIF CELL NANOMED B, V46, pS578, DOI 10.1080/21691401.2018.1431651
   Li Z, 2019, J CELL BIOCHEM, V120, P11462, DOI 10.1002/jcb.28424
   Li ZM, 2018, ACTA PHARMACOL SIN, V39, P802, DOI 10.1038/aps.2017.193
   Liang D, 2012, J CANCER RES CLIN, V138, P1865, DOI 10.1007/s00432-012-1256-5
   Liang J, 2014, FOOD SCI BIOTECHNOL, V23, P569, DOI 10.1007/s10068-014-0078-4
   Liang J, 2019, PHYTOTHER RES, V33, P618, DOI 10.1002/ptr.6250
   Liang L, 2012, ONCOL REP, V28, P999, DOI 10.3892/or.2012.1874
   Liang LL, 2016, CELL PHYSIOL BIOCHEM, V38, P1618, DOI 10.1159/000443102
   Liang WQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38267
   Liao BW, 2016, INT J PHARMACEUT, V512, P22, DOI 10.1016/j.ijpharm.2016.08.038
   Liao F, 2018, ARCH ORAL BIOL, V92, P32, DOI 10.1016/j.archoralbio.2018.04.015
   Liao HH, 2015, INT J CLIN EXP MED, V8, P8948
   Liao W, 2017, BIOMED PHARMACOTHER, V95, P1177, DOI 10.1016/j.biopha.2017.09.026
   Lim TG, 2014, CANCER PREV RES, V7, P466, DOI 10.1158/1940-6207.CAPR-13-0387
   Lin CW, 2019, ENVIRON TOXICOL, V34, P983, DOI 10.1002/tox.22769
   Lin CH, 2014, INT J CLIN EXP PATHO, V7, P2372
   Lin CC, 2011, INT J ONCOL, V39, P217, DOI 10.3892/ijo.2011.1027
   Lin CC, 2011, J AGR FOOD CHEM, V59, P755, DOI 10.1021/jf103904b
   Lin CC, 2018, DRUG DELIV, V25, P256, DOI 10.1080/10717544.2018.1425777
   Lin L, 2018, ONCOL LETT, V16, P3380, DOI 10.3892/ol.2018.8980
   Lin RY, 2016, CANCER LETT, V381, P165, DOI 10.1016/j.canlet.2016.07.033
   Lin S, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031201, 10.1371/journal.pone.0042146]
   Lin SZ, 2015, MOL MED REP, V12, P5865, DOI 10.3892/mmr.2015.4158
   Lin YS, 2019, J CELL BIOCHEM, V120, P13531, DOI 10.1002/jcb.28628
   Link A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057709
   Liu A, 2011, ONCOL REP, V26, P81, DOI 10.3892/or.2011.1257
   Liu A, 2011, MOL MED REP, V4, P221, DOI 10.3892/mmr.2011.414
   Liu D, 2016, INT IMMUNOPHARMACOL, V39, P265, DOI 10.1016/j.intimp.2016.07.035
   Liu FL, 2019, BIOMATER SCI-UK, V7, P1028, DOI 10.1039/c8bm01154k
   Liu FR, 2018, ONCOL REP, V39, P1523, DOI 10.3892/or.2018.6188
   Liu FR, 2017, ONCOL LETT, V14, P2775, DOI 10.3892/ol.2017.6565
   Liu GJ, 2015, ONCOL REP, V34, P2002, DOI 10.3892/or.2015.4193
   Liu GY, 2016, EUR J MED CHEM, V112, P157, DOI 10.1016/j.ejmech.2016.02.019
   Liu H, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2595801
   Liu HT, 2018, EXP THER MED, V16, P830, DOI 10.3892/etm.2018.6200
   Liu J, 2013, CELL PHYSIOL BIOCHEM, V32, P1213, DOI 10.1159/000354520
   Liu J, 2015, BIOCHEM BIOPH RES CO, V466, P103, DOI 10.1016/j.bbrc.2015.08.115
   Liu J, 2012, J PHARM PHARMACOL, V64, P146, DOI 10.1111/j.2042-7158.2011.01371.x
   Liu J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-183
   Liu JY, 2018, J BUON, V23, P124
   Liu JB, 2014, J INT MED RES, V42, P984, DOI 10.1177/0300060513507389
   Liu JS, 2015, WORLD J GASTROENTERO, V21, P9945, DOI 10.3748/wjg.v21.i34.9945
   Liu JS, 2014, ONCOL REP, V32, P2635, DOI 10.3892/or.2014.3490
   Liu L, 2018, J BIOMED NANOTECHNOL, V14, P1761, DOI 10.1166/jbn.2018.2633
   Liu L, 2016, BIOMED PHARMACOTHER, V83, P79, DOI 10.1016/j.biopha.2016.06.001
   Liu L, 2019, BIOL RES, V52, DOI 10.1186/s40659-019-0243-6
   Liu L, 2015, MOL MED REP, V12, P1465, DOI 10.3892/mmr.2015.3517
   Liu LC, 2012, J AGR FOOD CHEM, V60, P9863, DOI 10.1021/jf303690x
   Liu M, 2017, BIOMED PHARMACOTHER, V95, P1789, DOI 10.1016/j.biopha.2017.08.092
   Liu M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0644-y
   Liu Q, 2015, MOL CANCER THER, V14, P355, DOI 10.1158/1535-7163.MCT-14-0634
   Liu RX, 2018, INT J ONCOL, V53, P2091, DOI 10.3892/ijo.2018.4527
   Liu S, 2016, TROP J PHARM RES, V15, P1853, DOI 10.4314/tjpr.v15i9.6
   Liu S, 2019, CANCER IMMUNOL IMMUN, V68, P1059, DOI 10.1007/s00262-019-02326-8
   Liu TG, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1580427
   Liu TC, 2019, ONCOTARGETS THER, V12, P2605, DOI 10.2147/OTT.S200740
   Liu TS, 2017, INT J ONCOL, V51, P555, DOI 10.3892/ijo.2017.4035
   Liu T, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317692225
   Liu WW, 2013, J PHOTOCH PHOTOBIO B, V123, P23, DOI 10.1016/j.jphotobiol.2013.03.014
   Liu WW, 2013, BIOCHEM BIOPH RES CO, V432, P314, DOI 10.1016/j.bbrc.2013.01.109
   Liu XD, 2016, INT J MOL MED, V38, P1250, DOI 10.3892/ijmm.2016.2700
   Liu XN, 2018, ONCOL LETT, V15, P2881, DOI 10.3892/ol.2017.7665
   Liu XF, 2015, RSC ADV, V5, P34572, DOI 10.1039/c4ra17009a
   Liu X, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123478
   Liu XC, 2017, ONCOL LETT, V14, P4270, DOI 10.3892/ol.2017.6702
   Liu YN, 2018, FOOD FUNCT, V9, DOI 10.1039/c8fo01122b
   Liu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0959-0
   Liu Y, 2017, BIOMED PHARMACOTHER, V93, P490, DOI 10.1016/j.biopha.2017.06.073
   Liu Y, 2013, J PHARM PHARMACOL, V65, P1622, DOI 10.1111/jphp.12140
   Liu YS, 2014, DNA CELL BIOL, V33, P418, DOI 10.1089/dna.2014.2356
   Liu YK, 2019, ARTIF CELL NANOMED B, V47, P626, DOI 10.1080/21691401.2019.1575229
   Lopez-Haber C, 2013, MOL PHARMACOL, V83, P1141, DOI 10.1124/mol.112.084293
   Lu B, 2018, CANCER LETT, V425, P31, DOI 10.1016/j.canlet.2018.03.046
   Lu B, 2017, ACTA PHARMACOL SIN, V38, P1543, DOI 10.1038/aps.2017.112
   Lu JL, 2017, ONCOL LETT, V13, P2838, DOI 10.3892/ol.2017.5751
   Lu JJ, 2017, ONCOTARGETS THER, V10, P3579, DOI 10.2147/OTT.S138217
   Lu L, 2012, ACTA PHARMACOL SIN, V33, P531, DOI 10.1038/aps.2011.180
   Lu L, 2011, EUR J PHARMACOL, V658, P242, DOI 10.1016/j.ejphar.2011.02.043
   Lu M, 2014, TUMOR BIOL, V35, P5307, DOI 10.1007/s13277-014-1691-9
   Lu MX, 2018, BIOMED PHARMACOTHER, V97, P1282, DOI 10.1016/j.biopha.2017.11.006
   Lu N, 2013, EUR J PHARM SCI, V49, P220, DOI 10.1016/j.ejps.2013.02.018
   Lu P, 2012, CANCER BIOTHER RADIO, V27, P495, DOI 10.1089/cbr.2012.1219
   Lu SM, 2017, ONCOL LETT, V14, P7577, DOI 10.3892/ol.2017.7080
   Lu Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0031-6
   Lu ZY, 2018, EXP THER MED, V15, P1277, DOI 10.3892/etm.2017.5594
   Luo FF, 2011, INT IMMUNOPHARMACOL, V11, P1234, DOI 10.1016/j.intimp.2011.04.002
   Luo J, 2017, EXP THER MED, V14, P3623, DOI 10.3892/etm.2017.4965
   Luo KW, 2017, J NUTR BIOCHEM, V41, P56, DOI 10.1016/j.jnutbio.2016.12.004
   Luo XC, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-82
   Luo Y, 2015, MOL MED REP, V12, P3557, DOI 10.3892/mmr.2015.3802
   Lyu JF, 2017, CANCER LETT, V409, P91, DOI 10.1016/j.canlet.2017.09.009
   Lyu L, 2018, DRUG DES DEV THER, V12, P743, DOI 10.2147/DDDT.S161821
   Ma GX, 2016, CHEM-BIOL INTERACT, V253, P1, DOI 10.1016/j.cbi.2016.04.028
   Ma JX, 2012, ONCOL RES, V20, P359, DOI 10.3727/096504013X13657689382932
   Ma JJ, 2018, IRAN J BASIC MED SCI, V21, P717, DOI 10.22038/IJBMS.2018.23897.5995
   Ma J, 2014, EUR J PHARMACOL, V723, P46, DOI 10.1016/j.ejphar.2013.12.005
   Ma LS, 2017, BIOMED PHARMACOTHER, V90, P615, DOI 10.1016/j.biopha.2017.03.088
   Ma YC, 2019, EUR J PHARMACOL, V851, P43, DOI 10.1016/j.ejphar.2019.02.030
   Ma YS, 2012, FOOD CHEM TOXICOL, V50, P1271, DOI 10.1016/j.fct.2012.01.033
   Ma ZK, 2015, ONCOL REP, V34, P2461, DOI 10.3892/or.2015.4224
   Magoulas GE, 2017, BIOORGAN MED CHEM, V25, P3756, DOI 10.1016/j.bmc.2017.05.018
   Mahammedi H, 2016, ONCOLOGY-BASEL, V90, P69, DOI 10.1159/000441148
   Manimaran Asokan, 2017, Afr J Tradit Complement Altern Med, V14, P83, DOI 10.21010/ajtcam.v14i2.10
   Manjegowda MC, 2015, GENOM DATA, V5, P210, DOI 10.1016/j.gdata.2015.05.040
   Manjili HK, 2018, ARTIF CELL NANOMED B, V46, P926, DOI 10.1080/21691401.2017.1347880
   Manu KA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057015
   Mao D, 2019, NEOPLASMA, V66, P593, DOI 10.4149/neo_2018_180929N729
   Mao XL, 2018, MOL MED REP, V18, P3041, DOI 10.3892/mmr.2018.9263
   Marquardt JU, 2015, J HEPATOL, V63, P661, DOI 10.1016/j.jhep.2015.04.018
   Martinotti S, 2018, J CELL PHYSIOL, V233, P7082, DOI 10.1002/jcp.26631
   Marverti G, 2013, INT J ONCOL, V43, P1269, DOI 10.3892/ijo.2013.2045
   Matsuda K, 2014, BIOORG MED CHEM LETT, V24, P2115, DOI 10.1016/j.bmcl.2014.03.041
   Mayr C, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0721-5
   Meng GM, 2015, INT J ONCOL, V46, P1007, DOI 10.3892/ijo.2015.2814
   Meng Y, 2015, AM J CHINESE MED, V43, P1471, DOI 10.1142/S0192415X15500834
   Milano F, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00137
   Min NY, 2012, BIOCHEM BIOPH RES CO, V421, P91, DOI 10.1016/j.bbrc.2012.03.120
   Mineva ND, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073464
   Pi J, 2017, PHARMACOL RES, V119, P479, DOI 10.1016/j.phrs.2016.11.036
   Zhang WN, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0071511, 10.1371/journal.pone.0107941]
   Tran BN, 2017, DRUG DEV IND PHARM, V43, P1952, DOI 10.1080/03639045.2017.1357729
   Vue B, 2016, EUR J MED CHEM, V109, P36, DOI 10.1016/j.ejmech.2015.12.041
   Ming M, 2016, ASIAN PAC J TROP MED, V9, P182, DOI 10.1016/j.apjtm.2016.01.007
   Modi S, 2016, J GASTROINTEST SURG, V20, P13, DOI 10.1007/s11605-015-3000-3
   Mohamadabadi MA, 2013, IRAN J IMMUNOL, V10, P139, DOI IJIv10i3A2
   Montazeri M, 2017, ANTI-CANCER AGENT ME, V17, P662, DOI 10.2174/1871520616666160815124537
   Moses MA, 2015, CANCER PREV RES, V8, P249, DOI 10.1158/1940-6207.CAPR-14-0224
   Mu L, 2016, INT J ONCOL, V49, P1427, DOI 10.3892/ijo.2016.3626
   Murray-Stewart T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202677
   Murthy KNC, 2012, EUR J PHARMACOL, V688, P14, DOI 10.1016/j.ejphar.2012.05.004
   Nafees S, 2018, ARCH MED RES, V49, P226, DOI 10.1016/j.arcmed.2018.09.008
   Nakazato T, 2014, INT J ONCOL, V44, P1131, DOI 10.3892/ijo.2014.2280
   Nam H, 2013, FOOD CHEM TOXICOL, V62, P579, DOI 10.1016/j.fct.2013.09.024
   Nambiar D, 2013, CANCER LETT, V334, P109, DOI 10.1016/j.canlet.2012.09.004
   Nardi I, 2018, INT J CANCER, V143, P2470, DOI 10.1002/ijc.31756
   Nasiri M, 2013, ASIAN PAC J CANCER P, V14, P3449, DOI 10.7314/APJCP.2013.14.6.3449
   Naveen CR, 2016, PHYTOMEDICINE, V23, P736, DOI 10.1016/j.phymed.2016.03.013
   Ni F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21570-z
   Ni Jing, 2015, Asian Pac J Cancer Prev, V16, P4571
   Ni J, 2018, MOLECULES, V23, DOI 10.3390/molecules23040788
   Nicolin Vanessa, 2014, Italian Journal of Anatomy and Embryology, V119, P38
   Noel P, 2019, TRENDS PHARMACOL SCI, V40, P327, DOI 10.1016/j.tips.2019.03.002
   Noori S, 2014, CHIN J INTEGR MED, V20, P618, DOI 10.1007/s11655-013-1454-2
   Odaka Y, 2014, CARCINOGENESIS, V35, P192, DOI 10.1093/carcin/bgt277
   Ogawa K, 2012, ONCOL LETT, V4, P546, DOI 10.3892/ol.2012.761
   Oh SJ, 2013, ONCOL REP, V29, P1343, DOI 10.3892/or.2013.2252
   Onoda C, 2011, INT J ONCOL, V38, P1403, DOI 10.3892/ijo.2011.951
   Onoue S, 2011, INT J PHARMACEUT, V410, P111, DOI 10.1016/j.ijpharm.2011.03.020
   Ooko E, 2015, PHYTOMEDICINE, V22, P1045, DOI 10.1016/j.phymed.2015.08.002
   Osaki T, 2017, MOLECULES, V22, DOI 10.3390/molecules22040533
   Paccez JD, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0122-6
   Palmieri A, 2018, J BIOL REG HOMEOS AG, V32, P167
   Pan H, 2018, CHIN J INTEGR MED, V24, P109, DOI 10.1007/s11655-017-2410-3
   Pan H, 2017, ONCOTARGET, V8, P77181, DOI 10.18632/oncotarget.20424
   Pan XH, 2016, J PHARMACOL SCI, V130, P85, DOI 10.1016/j.jphs.2015.12.003
   Pan XY, 2012, EUR J PHARMACOL, V683, P27, DOI 10.1016/j.ejphar.2012.02.040
   Pandey MK, 2014, EXP HEMATOL, V42, P883, DOI 10.1016/j.exphem.2014.07.261
   Pandey P, 2019, NUTR CANCER, V71, P676, DOI 10.1080/01635581.2018.1508732
   Pang J, 2016, INT J CARDIOL, V202, P967, DOI 10.1016/j.ijcard.2014.12.176
   Park GB, 2016, INT J ONCOL, V49, P411, DOI 10.3892/ijo.2016.3502
   Park IJ, 2012, APOPTOSIS, V17, P248, DOI 10.1007/s10495-011-0680-3
   Park JH, 2013, PHARMACOL REP, V65, P1366, DOI 10.1016/S1734-1140(13)71495-6
   Park JJ, 2012, BIOCHEM BIOPH RES CO, V426, P461, DOI 10.1016/j.bbrc.2012.08.091
   Park KS, 2012, J OBSTET GYNAECOL RE, V38, P535, DOI 10.1111/j.1447-0756.2011.01743.x
   Park KS, 2012, YONSEI MED J, V53, P346, DOI 10.3349/ymj.2012.53.2.346
   Park SH, 2015, BRAZ J MED BIOL RES, V48, P111, DOI 10.1590/1414-431X20144293
   Park SH, 2014, MOL CELL BIOCHEM, V394, P209, DOI 10.1007/s11010-014-2096-1
   Park SY, 2016, NEUROCHEM RES, V41, P2981, DOI 10.1007/s11064-016-2018-6
   Parsons HA, 2016, ONCOTARGET, V7, P20293, DOI 10.18632/oncotarget.7773
   Pashaei-Asl F, 2018, ARTIF CELL NANOMED B, V46, P1483, DOI 10.1080/21691401.2017.1374281
   Paudel KR, 2016, TOXICOL IN VITRO, V34, P16, DOI 10.1016/j.tiv.2016.03.010
   Payon V, 2019, PLANTA MED, V85, P41, DOI 10.1055/a-0706-7503
   Pazhang Y, 2011, MED ONCOL, V28, P1577, DOI 10.1007/s12032-010-9586-0
   Piao XM, 2018, INT J MOL MED, V42, P1018, DOI 10.3892/ijmm.2018.3647
   Pooja D, 2014, INT J BIOL MACROMOL, V69, P267, DOI 10.1016/j.ijbiomac.2014.05.035
   Prasad S, 2012, CLIN CANCER RES, V18, P4942, DOI 10.1158/1078-0432.CCR-11-2805
   Promkan M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055732
   Puthdee N, 2017, BIOL PHARM BULL, V40, P751, DOI 10.1248/bpb.b16-00428
   Qi HW, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-22
   Qi Q, 2015, MOL CARCINOGEN, V54, pE13, DOI 10.1002/mc.22138
   Qi XM, 2016, TOXICOL RES-UK, V5, P594, DOI 10.1039/c5tx00409h
   Qian HR, 2011, EUR J PHARM SCI, V43, P125, DOI 10.1016/j.ejps.2011.04.002
   Qian P, 2018, IMMUNOPHARM IMMUNOT, V40, P107, DOI 10.1080/08923973.2017.1386212
   Qian ZZ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/809714
   Qiao ZX, 2016, ONCOL LETT, V11, P3527, DOI 10.3892/ol.2016.4379
   Qin GY, 2018, ONCOL LETT, V16, P3929, DOI 10.3892/ol.2018.9074
   Qin GQ, 2015, APOPTOSIS, V20, P1072, DOI 10.1007/s10495-015-1132-2
   Qin JH, 2018, BIOMED PHARMACOTHER, V105, P758, DOI 10.1016/j.biopha.2018.06.028
   Qin XD, 2017, BIOORGAN MED CHEM, V25, P2507, DOI 10.1016/j.bmc.2017.03.007
   Qiu SH, 2016, BIOORG MED CHEM LETT, V26, P2503, DOI 10.1016/j.bmcl.2016.03.097
   Qiu Y, 2018, CANCER MED-US, V7, P397, DOI 10.1002/cam4.1281
   Qu D, 2015, EXP THER MED, V9, P1265, DOI 10.3892/etm.2015.2283
   Qu W, 2015, INT J CLIN EXP MED, V8, P15054
   Radhakrishnan R, 2016, CHEM PHYS LIPIDS, V198, P51, DOI 10.1016/j.chemphyslip.2016.05.006
   Raghav D, 2017, BIOCHEMISTRY-US, V56, P2594, DOI 10.1021/acs.biochem.7b00101
   Raina K, 2013, MOL CARCINOGEN, V52, P195, DOI 10.1002/mc.21843
   Rattanawong A, 2018, ONCOL REP, V39, P227, DOI 10.3892/or.2017.6084
   Ravindranathan P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32267-8
   Rawangkan A, 2018, MOLECULES, V23, DOI 10.3390/molecules23082071
   Raza A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08058-y
   Ren CM, 2016, ONCOL REP, V35, P2691, DOI 10.3892/or.2016.4654
   Reno TA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2487-7
   Reno TA, 2015, ANN THORAC SURG, V100, P1817, DOI 10.1016/j.athoracsur.2015.05.074
   Rocha TGR, 2016, INTEGR CANCER THER, V15, P512, DOI 10.1177/1534735416628273
   Roberts JL, 2017, ONCOTARGET, V8, P99451, DOI 10.18632/oncotarget.19807
   Rogosnitzky M, 2011, PHARMACOL REP, V63, P337, DOI 10.1016/S1734-1140(11)70500-X
   Roh JL, 2017, REDOX BIOL, V11, P254, DOI 10.1016/j.redox.2016.12.010
   Rong LW, 2017, ONCOL LETT, V13, P5028, DOI 10.3892/ol.2017.6059
   Rouholamini SEY, 2018, ARTIF CELL NANOMED B, V46, P524, DOI 10.1080/21691401.2017.1326928
   Sakamoto Y, 2013, BIOSCI BIOTECH BIOCH, V77, P1799, DOI 10.1271/bbb.120882
   Samarghandian S, 2017, BIOMED PHARMACOTHER, V87, P223, DOI 10.1016/j.biopha.2016.12.105
   Sang W, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0193-x
   Sangwan V, 2015, PANCREAS, V44, P583, DOI 10.1097/MPA.0000000000000317
   Saraswati S, 2013, CHEM-BIOL INTERACT, V206, P153, DOI 10.1016/j.cbi.2013.09.004
   Satoh M, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-19
   Saunders IT, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0820-3
   Saxena S, 2018, TOXICOL APPL PHARM, V347, P92, DOI 10.1016/j.taap.2018.03.033
   Schwertheim S, 2017, J CANCER RES CLIN, V143, P1143, DOI 10.1007/s00432-017-2380-z
   Seo BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095588
   Seo SU, 2018, ONCOGENE, V37, P5205, DOI 10.1038/s41388-018-0345-6
   Seo YS, 2015, ONCOL REP, V34, P3025, DOI 10.3892/or.2015.4312
   Seong RK, 2018, ACTA VIROL, V62, P78, DOI 10.4149/av_2018_109
   Shahriyar SA, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103280
   Shan JZ, 2011, CHIN J INTEGR MED, V17, P607, DOI 10.1007/s11655-011-0815-y
   Shan X, 2015, INT J ONCOL, V46, P1667, DOI 10.3892/ijo.2015.2886
   Shan X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115401
   Shan ZL, 2017, MOL MED REP, V16, P3055, DOI 10.3892/mmr.2017.6965
   Shanmugam MK, 2011, J MOL MED, V89, P713, DOI 10.1007/s00109-011-0746-2
   Shao S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8148510
   Sharma C, 2012, ASIAN PAC J CANCER P, V13, P4815, DOI 10.7314/APJCP.2012.13.9.4815
   Sharma R, 2014, INT J RADIAT BIOL, V90, P275, DOI 10.3109/09553002.2014.884292
   Shi F, 2013, INT J NANOMED, V8, P2533, DOI 10.2147/IJN.S46578
   Shi GL, 2017, ACTA BIOCH BIOPH SIN, V49, P302, DOI 10.1093/abbs/gmx006
   Shi GH, 2018, MOL MED REP, V18, P5191, DOI 10.3892/mmr.2018.9510
   Shi MY, 2016, INT J ONCOL, V48, P734, DOI 10.3892/ijo.2015.3294
   Shi SQ, 2014, ONCOL LETT, V8, P1087, DOI 10.3892/ol.2014.2293
   Shi XP, 2014, CLIN CANCER RES, V20, P151, DOI 10.1158/1078-0432.CCR-13-1063
   Shi XL, 2017, ONCOTARGET, V8, P45981, DOI 10.18632/oncotarget.17520
   Shimada K, 2018, CANCER CHEMOTH PHARM, V82, P265, DOI 10.1007/s00280-018-3616-6
   Shin CM, 2018, CLIN NUTR, V37, P452, DOI 10.1016/j.clnu.2017.01.014
   Shin DM, 2012, EUR J CANCER, V48, pS286, DOI 10.1016/S0959-8049(12)71781-1
   Shin EA, 2014, ONCOTARGET, V5, P5624, DOI 10.18632/oncotarget.2152
   Shin SW, 2013, BBA-MOL CELL RES, V1833, P723, DOI 10.1016/j.bbamcr.2012.12.005
   Shin SW, 2012, BBA-MOL CELL RES, V1823, P451, DOI 10.1016/j.bbamcr.2011.10.014
   Shin YS, 2016, PHYTOMEDICINE, V23, P1344, DOI 10.1016/j.phymed.2016.07.005
   Shukla R, 2012, P NATL ACAD SCI USA, V109, P12426, DOI 10.1073/pnas.1121174109
   Shukla S, 2016, SCI REP-UK, V6, DOI 10.1038/srep21860
   Shukla S, 2014, FREE RADICAL BIO MED, V76, P185, DOI 10.1016/j.freeradbiomed.2014.07.039
   Si LL, 2019, ARCH BIOCHEM BIOPHYS, V671, P42, DOI 10.1016/j.abb.2019.05.009
   Siddiqui FA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25524-3
   Siddiqui RA, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-418
   Sidhar H, 2017, SCI REP-UK, V7, DOI 10.1038/srep41420
   Silva G, 2018, MOLECULES, V23, DOI 10.3390/molecules23020279
   Sin S, 2012, INT J ONCOL, V41, P1669, DOI 10.3892/ijo.2012.1604
   Singh T, 2013, TOXICOL APPL PHARM, V273, P418, DOI 10.1016/j.taap.2013.09.021
   Sinha S, 2016, INT J BIOCHEM CELL B, V77, P41, DOI 10.1016/j.biocel.2016.05.014
   Sivanantham B, 2016, ACS COMB SCI, V18, P22, DOI 10.1021/acscombsci.5b00043
   Song JM, 2015, ONCOL REP, V33, P1867, DOI 10.3892/or.2015.3749
   Song XY, 2018, INT J MOL MED, V42, P579, DOI 10.3892/ijmm.2018.3638
   Song XM, 2013, TOXICOL APPL PHARM, V271, P144, DOI 10.1016/j.taap.2013.04.031
   Song YH, 2012, BIOL PHARM BULL, V35, P1022, DOI 10.1248/bpb.b110660
   Spear SA, 2013, OTOL NEUROTOL, V34, P1519, DOI 10.1097/MAO.0b013e3182956169
   Starok M, 2015, BIOMACROMOLECULES, V16, P1634, DOI 10.1021/acs.biomac.5b00229
   Steinmann J, 2013, BRIT J PHARMACOL, V168, P1059, DOI 10.1111/bph.12009
   Su J, 2017, ONCOL REP, V37, P1565, DOI 10.3892/or.2017.5428
   Suberu JO, 2014, CHEMMEDCHEM, V9, P2791, DOI 10.1002/cmdc.201402285
   Subramaniam A, 2013, BRIT J PHARMACOL, V170, P807, DOI 10.1111/bph.12302
   Sui H, 2017, CANCER LETT, V403, P86, DOI 10.1016/j.canlet.2017.05.013
   Sui JQ, 2014, ASIAN PAC J CANCER P, V15, P6247, DOI 10.7314/APJCP.2014.15.15.6247
   Sun CX, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0274-y
   Sun HP, 2016, ACTA PHARMACOL SIN, V37, P941, DOI 10.1038/aps.2016.20
   Sun HY, 2016, ANTICANCER RES, V36, P4647, DOI 10.21873/anticanres.11015
   Sun MX, 2018, EUR REV MED PHARMACO, V22, P5033, DOI 10.26355/eurrev_201808_15646
   Sun Y, 2018, CHEM-BIOL INTERACT, V296, P57, DOI 10.1016/j.cbi.2018.09.013
   Sun Y, 2015, ONCOL REP, V33, P338, DOI 10.3892/or.2014.3585
   Sun YQ, 2015, EUR J PHARMACOL, V768, P28, DOI 10.1016/j.ejphar.2015.10.003
   Sundram V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035368
   Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126
   Tamgue Ousman, 2017, Asian Pac J Cancer Prev, V18, P2519, DOI 10.22034/APJCP.2017.18.9.2519
   Tan BJ, 2013, INT J ONCOL, V42, P1605, DOI 10.3892/ijo.2013.1843
   Tan WF, 2011, PHYTOMEDICINE, V18, P158, DOI 10.1016/j.phymed.2010.07.003
   Tang HS, 2017, ONCOTARGET, V8, P82842, DOI 10.18632/oncotarget.20666
   Tang JC, 2018, J CANCER, V9, P32, DOI 10.7150/jca.21224
   Tang L, 2018, DRUG DELIV, V25, P862, DOI 10.1080/10717544.2018.1425773
   Tang QS, 2017, ONCOL LETT, V13, P384, DOI 10.3892/ol.2016.5433
   Tang YC, 2018, INT J ONCOL, V52, P127, DOI 10.3892/ijo.2017.4183
   Tang ZH, 2018, CANCER LETT, V412, P1, DOI 10.1016/j.canlet.2017.10.001
   Thacker PC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120045
   Thida M, 2016, BIOORG MED CHEM LETT, V26, P1097, DOI 10.1016/j.bmcl.2015.11.043
   Thongchot S, 2018, MOL CARCINOGEN, V57, P1735, DOI 10.1002/mc.22893
   Tian JL, 2014, DRUG DELIV, V21, P553, DOI 10.3109/10717544.2013.853850
   Tian L, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1706-3
   Tian R, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150002
   Tilaoui M, 2014, NAT PRODUCT BIOPROSP, V4, P189, DOI 10.1007/s13659-014-0024-4
   Tin AS, 2012, ANTI-CANCER DRUG, V23, P370, DOI 10.1097/CAD.0b013e32834f6ea8
   Ting H, 2016, CARCINOGENESIS, V37, P589, DOI 10.1093/carcin/bgw039
   Tiwari P, 2011, CANCER INVEST, V29, P12, DOI 10.3109/07357907.2010.535053
   Tiwari RV, 2015, MOL CELL BIOCHEM, V408, P123, DOI 10.1007/s11010-015-2488-x
   Tong WH, 2016, ONCOL LETT, V12, P4139, DOI 10.3892/ol.2016.5148
   Tong YL, 2016, ONCOTARGET, V7, P31413, DOI 10.18632/oncotarget.8920
   Tran KQ, 2014, ANTI-CANCER DRUG, V25, P270, DOI 10.1097/CAD.0000000000000054
   Tremmel L, 2019, MOL CARCINOGEN, V58, P185, DOI 10.1002/mc.22918
   Tsai CF, 2012, INT J MOL SCI, V13, P9877, DOI 10.3390/ijms13089877
   Tsai CY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010016
   Tseng LM, 2012, J PHARMACOL EXP THER, V341, P410, DOI 10.1124/jpet.111.188730
   Tudoran O, 2012, J CELL MOL MED, V16, P520, DOI 10.1111/j.1582-4934.2011.01346.x
   Uthaisar K, 2012, ASIAN PAC J CANCER P, V13, P149, DOI 10.7314/APJCP.2012.13.KKSuppl.149
   Uto T, 2011, INT IMMUNOPHARMACOL, V11, P1932, DOI 10.1016/j.intimp.2011.08.003
   Van Aller GS, 2011, BIOCHEM BIOPH RES CO, V406, P194, DOI 10.1016/j.bbrc.2011.02.010
   Vatsveen TK, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0561-0
   Verma S, 2017, CHEM-BIOL INTERACT, V278, P84, DOI 10.1016/j.cbi.2017.10.011
   Villeneuve NF, 2009, CELL CYCLE, V8, P3255, DOI 10.4161/cc.8.20.9565
   Vimalraj S, 2018, COLLOID SURFACE B, V167, P134, DOI 10.1016/j.colsurfb.2018.04.007
   von Hagens C, 2019, PHYTOMEDICINE, V54, P140, DOI 10.1016/j.phymed.2018.09.178
   von Hagens C, 2017, BREAST CANCER RES TR, V164, P359, DOI 10.1007/s10549-017-4261-1
   Wan L, 2019, PHYTOTHER RES, V33, P1579, DOI 10.1002/ptr.6350
   Wang BL, 2015, CANCER BIOL THER, V16, P1548, DOI 10.1080/15384047.2015.1071738
   Wang C, 2017, ONCOL REP, V37, P2109, DOI 10.3892/or.2017.5489
   Wang CM, 2017, MOLECULES, V22, DOI 10.3390/molecules22122119
   Wang G, 2015, BIOMARK RES, V3, DOI 10.1186/s40364-015-0043-2
   Wang HJ, 2016, MED SCI MONITOR, V22, P1827, DOI 10.12659/MSM.898801
   Wang H, 2017, EUR J PHARMACOL, V815, P282, DOI 10.1016/j.ejphar.2017.09.021
   Wang HY, 2013, TOXICOLOGY, V308, P104, DOI 10.1016/j.tox.2013.03.015
   Wang HC, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-018-0705-x
   Wang H, 2018, EXP THER MED, V15, P1484, DOI 10.3892/etm.2017.5591
   Wang H, 2011, INTEGR CANCER THER, V10, P160, DOI 10.1177/1534735410383171
   Wang JX, 2013, CELL BIOCHEM BIOPHYS, V67, P199, DOI 10.1007/s12013-013-9534-7
   Wang JZ, 2018, CANCER LETT, V412, P10, DOI 10.1016/j.canlet.2017.09.054
   Wang J, 2014, TUMOR BIOL, V35, P4859, DOI 10.1007/s13277-014-1637-2
   Wang JS, 2012, MED ONCOL, V29, P10, DOI 10.1007/s12032-010-9777-8
   Wang JW, 2016, ONCOTARGET, V7, P66944, DOI 10.18632/oncotarget.11396
   Wang J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1596-z
   Wang JJ, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.34
   Wang J, 2017, ONCOL REP, V37, P2425, DOI 10.3892/or.2017.5499
   Wang JX, 2016, ONCOTARGET, V7, P76076, DOI 10.18632/oncotarget.12589
   Wang K, 2017, DRUG METAB REV, V49, P139, DOI 10.1080/03602532.2017.1306544
   Wang L, 2017, ARCH MED RES, V48, P623, DOI 10.1016/j.arcmed.2018.03.004
   Wang L, 2015, MOL MED REP, V12, P609, DOI 10.3892/mmr.2015.3397
   Wang L, 2012, CANCER LETT, V324, P75, DOI 10.1016/j.canlet.2012.05.004
   Wang L, 2019, PHYTOMEDICINE, V52, P147, DOI 10.1016/j.phymed.2018.09.221
   Wang L, 2015, MOL MED REP, V11, P931, DOI 10.3892/mmr.2014.2819
   Wang LH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036418
   Wang LH, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0513-5
   Wang LK, 2014, INT J MOL SCI, V15, P16226, DOI 10.3390/ijms150916226
   Wang LF, 2018, MOL MED REP, V17, P4299, DOI 10.3892/mmr.2018.8455
   Wang ML, 2017, MAT SCI ENG C-MATER, V71, P1231, DOI 10.1016/j.msec.2016.11.014
   Wang M, 2017, ONCOL LETT, V13, P681, DOI 10.3892/ol.2016.5490
   Wang N, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111899
   Wang N, 2015, J ETHNOPHARMACOL, V176, P35, DOI 10.1016/j.jep.2015.10.028
   Wang Q, 2018, ONCOL LETT, V16, P2366, DOI 10.3892/ol.2018.8916
   Wang SQ, 2017, J PHARM PHARMACOL, V69, P213, DOI 10.1111/jphp.12678
   Wang SS, 2017, ONCOTARGET, V8, P10650, DOI 10.18632/oncotarget.12890
   Wang SP, 2018, FOOD CHEM TOXICOL, V119, P334, DOI 10.1016/j.fct.2018.02.037
   Wang SP, 2017, DRUG DELIV, V24, P1791, DOI 10.1080/10717544.2017.1406558
   Wang SP, 2015, CHEM-BIOL INTERACT, V235, P76, DOI 10.1016/j.cbi.2015.03.017
   Wang SP, 2014, AM J CHINESE MED, V42, P1279, DOI 10.1142/S0192415X14500803
   Wang SP, 2012, J ETHNOPHARMACOL, V140, P33, DOI 10.1016/j.jep.2011.12.041
   Wang TT, 2013, CHINESE J CANCER RES, V25, P505, DOI 10.3978/j.issn.1000-9604.2013.08.14
   Wang WC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0689-3
   Wang W, 2018, TRANSL CANCER RES, V7, P142, DOI 10.21037/tcr.2018.01.17
   Wang X, 2017, CELL PHYSIOL BIOCHEM, V44, P1337, DOI 10.1159/000485495
   Wang XH, 2013, EXPERT OPIN DRUG MET, V9, P117, DOI 10.1517/17425255.2013.738667
   Wang XJ, 2019, EUR J PHARMACOL, V850, P141, DOI 10.1016/j.ejphar.2019.02.023
   Wang X, 2017, ONCOTARGET, V8, P45874, DOI 10.18632/oncotarget.17437
   Wang X, 2012, ANTI-CANCER AGENT ME, V12, P994, DOI 10.2174/187152012802650066
   Wang XD, 2017, EUR J PHARMACOL, V798, P49, DOI 10.1016/j.ejphar.2016.12.027
   Wang XT, 2018, BIOMED PHARMACOTHER, V97, P1461, DOI 10.1016/j.biopha.2017.11.032
   Wang XM, 2016, BMC GENET, V17, DOI 10.1186/s12863-015-0309-6
   Wang XM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125402
   Wang Y, 2015, ONCOTARGET, V6, P16031, DOI 10.18632/oncotarget.3648
   Wang YX, 2018, EUR J MED CHEM, V143, P1858, DOI 10.1016/j.ejmech.2017.10.078
   Wang YY, 2014, ANTI-CANCER DRUG, V25, P1192, DOI 10.1097/CAD.0000000000000154
   Wang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089751
   Wang Y, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160165
   Wang Y, 2016, INT J PHARMACEUT, V502, P47, DOI 10.1016/j.ijpharm.2016.02.025
   Wang YW, 2014, BIOCHEM PHARMACOL, V88, P322, DOI 10.1016/j.bcp.2014.01.041
   Wang Y, 2018, ACTA PHARMACOL SIN, V39, P311, DOI 10.1038/aps.2017.95
   Wang Y, 2012, MUTAT RES-FUND MOL M, V734, P20, DOI 10.1016/j.mrfmmm.2012.04.005
   Wang YS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12572-4
   Wang YY, 2018, ONCOL RES, V26, P889, DOI 10.3727/096504017X15009419625178
   Wang Z, 2012, FEBS OPEN BIO, V2, P103, DOI 10.1016/j.fob.2012.05.002
   Wang ZH, 2011, INT J ONCOL, V39, P1123, DOI 10.3892/ijo.2011.1115
   Wang Z, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0231-3
   Wang ZZ, 2018, ONCOL LETT, V16, P2143, DOI 10.3892/ol.2018.8909
   Wei JC, 2017, EXP THER MED, V13, P662, DOI 10.3892/etm.2017.4021
   Wen CY, 2015, INT J ONCOL, V47, P1663, DOI 10.3892/ijo.2015.3166
   Wen CJ, 2013, ASIAN PAC J CANCER P, V14, P6089, DOI 10.7314/APJCP.2013.14.10.6089
   Wen CJ, 2016, MOL MED REP, V14, P2250, DOI 10.3892/mmr.2016.5490
   Wen L, 2012, ACTA PHARMACOL SIN, V33, P109, DOI 10.1038/aps.2011.145
   Wen XC, 2018, MOLECULES, V23, DOI 10.3390/molecules23020268
   Weng HY, 2014, CANCER RES, V74, P4409, DOI 10.1158/0008-5472.CAN-13-1748
   Wiench B, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/726025
   Woo SM, 2014, CHEM-BIOL INTERACT, V211, P36, DOI 10.1016/j.cbi.2014.01.004
   Wu B, 2012, ARCH PHARM RES, V35, P543, DOI 10.1007/s12272-012-0318-1
   Wu CC, 2016, MOLECULES, V21, DOI 10.3390/molecules21121640
   Wu CC, 2016, J AGR FOOD CHEM, V64, P4220, DOI 10.1021/acs.jafc.6b00542
   Wu GQ, 2016, ONCOTARGET, V7, P26535, DOI 10.18632/oncotarget.8532
   Wu HL, 2015, FERTIL STERIL, V103, P1098, DOI 10.1016/j.fertnstert.2015.01.010
   Wu KR, 2015, BIOCHEM BIOPH RES CO, V466, P369, DOI 10.1016/j.bbrc.2015.09.030
   Wu M, 2017, J FUNCT FOODS, V39, P257, DOI 10.1016/j.jff.2017.10.038
   Wu PP, 2011, ONCOL REP, V25, P551, DOI 10.3892/or.2010.1080
   Wu Q, 2018, BIOCHEM PHARMACOL, V148, P64, DOI 10.1016/j.bcp.2017.12.004
   Wu QJ, 2018, RES VET SCI, V119, P262, DOI 10.1016/j.rvsc.2018.07.008
   Wu QX, 2016, ONCOL REP, V35, P3341, DOI 10.3892/or.2016.4735
   Wu RH, 2014, J FOOD SCI, V79, pH1430, DOI 10.1111/1750-3841.12518
   Wu SS, 2013, J AGR FOOD CHEM, V61, P7268, DOI 10.1021/jf4000083
   Wu X, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3145-4
   Wu ZB, 2017, EXP THER MED, V13, P3153, DOI 10.3892/etm.2017.4350
   Xavier CPR, 2013, J NUTR BIOCHEM, V24, P706, DOI 10.1016/j.jnutbio.2012.04.004
   Xia GG, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0579-0
   Xia SX, 2017, SAUDI PHARM J, V25, P638, DOI 10.1016/j.jsps.2017.04.037
   Xia T, 2017, MOL MED REP, V15, P3591, DOI 10.3892/mmr.2017.6459
   Xiao FL, 2012, APOPTOSIS, V17, P600, DOI 10.1007/s10495-012-0706-5
   Xiao WM, 2015, J IMMUNOTHER, V38, P167, DOI 10.1097/CJI.0000000000000080
   Xie CQ, 2016, ONCOL LETT, V12, P3586, DOI 10.3892/ol.2016.5099
   Xie J, 2015, TUMOR BIOL, V36, P1279, DOI 10.1007/s13277-014-2754-7
   Xie QP, 2017, BIOMED PHARMACOTHER, V85, P16, DOI 10.1016/j.biopha.2016.11.096
   Xie YL, 2016, EXP THER MED, V12, P2709, DOI 10.3892/etm.2016.3670
   Xiong YX, 2015, ONCOTARGET, V6, P35625, DOI 10.18632/oncotarget.5521
   Xu B, 2015, ACTA BIOCH BIOPH SIN, V47, P164, DOI 10.1093/abbs/gmu134
   Xu LN, 2012, BIOCELL, V36, P113
   Xu L, 2018, CELL BIOL INT, V42, P1377, DOI 10.1002/cbin.11023
   Xu N, 2015, INT J MED SCI, V12, P524, DOI 10.7150/ijms.11352
   Xu PP, 2018, CHINESE MED J-PEKING, V131, P495, DOI 10.4103/0366-6999.225064
   Xu PL, 2018, EXP THER MED, V16, P4070, DOI 10.3892/etm.2018.6671
   Xu SW, 2011, ARCH BIOCHEM BIOPHYS, V515, P72, DOI 10.1016/j.abb.2011.08.006
   Xu WC, 2019, CHEM-BIOL INTERACT, V310, DOI 10.1016/j.cbi.2019.108726
   Xu XM, 2017, MICROVASC RES, V111, P25, DOI 10.1016/j.mvr.2016.12.011
   Xu XF, 2017, SCI REP-UK, V7, DOI 10.1038/srep39950
   Xu Y, 2016, ONCOTARGET, V7, P72503, DOI 10.18632/oncotarget.12700
   Yan JJ, 2011, J VISION, V11, DOI 10.1167/11.12.7
   Yan MY, 2012, INT J MOL MED, V29, P855, DOI 10.3892/ijmm.2012.908
   Yan XM, 2015, MOL MED REP, V11, P791, DOI 10.3892/mmr.2014.2814
   Yang CY, 2017, CLIN ORAL INVEST, V21, P419, DOI 10.1007/s00784-016-1808-1
   Yang CG, 2016, INT J FOOD SCI NUTR, V67, P818, DOI 10.1080/09637486.2016.1198892
   Yang H, 2014, ONCOTARGET, V5, P8188, DOI 10.18632/oncotarget.2340
   Yang IH, 2017, EUR J ORAL SCI, V125, P438, DOI 10.1111/eos.12387
   Yang JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094180
   Yang JJ, 2016, J GINSENG RES, V40, P400, DOI 10.1016/j.jgr.2016.03.007
   Yang J, 2018, BIOMED PHARMACOTHER, V100, P226, DOI 10.1016/j.biopha.2018.02.011
   Yang L, 2013, APOPTOSIS, V18, P618, DOI 10.1007/s10495-013-0808-8
   Yang LH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1015-9
   Yang Q, 2013, J CLIN ENDOCR METAB, V98, pE1909, DOI 10.1210/jc.2013-2583
   Yang Q, 2017, MOL MED REP, V16, P1347, DOI 10.3892/mmr.2017.6729
   Yang R, 2017, INT J BIOL MACROMOL, V105, P252, DOI 10.1016/j.ijbiomac.2017.07.040
   Yang X, 2013, CANCER BIOL THER, V14, P1068, DOI 10.4161/cbt.26426
   Yang Y, 2014, INT J PHARMACEUT, V467, P113, DOI 10.1016/j.ijpharm.2014.03.044
   Yang YY, 2016, CHEM BIOL DRUG DES, V87, P895, DOI 10.1111/cbdd.12722
   Yang Y, 2018, BIOMED PHARMACOTHER, V106, P1307, DOI 10.1016/j.biopha.2018.07.083
   Yang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050811
   Yang ZQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep19383
   Yao CC, 2014, ONCOL REP, V31, P2131, DOI 10.3892/or.2014.3083
   Yao WY, 2015, MOL MED REP, V11, P1416, DOI 10.3892/mmr.2014.2789
   Yao YY, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0574-5
   Yao ZH, 2018, ONCOL REP, V40, P3603, DOI 10.3892/or.2018.6757
   Yao Z, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.35
   Ye LH, 2012, ANAT REC, V295, P417, DOI 10.1002/ar.21528
   Ye LJ, 2018, J CANCER RES THER, V14, pS942, DOI 10.4103/0973-1482.206866
   Yen JH, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1016-9
   Yi TT, 2015, NUTR CANCER, V67, P523, DOI 10.1080/01635581.2015.1004733
   Yin SY, 2016, ONCOTARGET, V7, P43629, DOI 10.18632/oncotarget.9660
   Yin X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0038381, 10.1371/journal.pone.0051853]
   Ying JH, 2015, INT J CLIN EXP PATHO, V8, P12837
   Yip NKY, 2013, ONCOL REP, V30, P1107, DOI 10.3892/or.2013.2543
   Yoshida K, 2017, CARCINOGENESIS, V38, P1036, DOI 10.1093/carcin/bgx065
   You LT, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00813
   Youns M, 2018, N-S ARCH PHARMACOL, V391, P551, DOI 10.1007/s00210-018-1485-5
   Yousefi M, 2014, ARCH IRAN MED, V17, P366, DOI 0141705/AIM.0011
   Yousefi M, 2012, NEUROCHEM RES, V37, P2053, DOI 10.1007/s11064-012-0827-9
   Yu HH, 2016, J BUON, V21, P125
   Yu J, 2017, ONCOL REP, V37, P1394, DOI 10.3892/or.2017.5408
   Yu R, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-49
   Yu XM, 2017, BIOCHEM BIOPH RES CO, V490, P514, DOI 10.1016/j.bbrc.2017.06.071
   Yu Y, 2013, EXP THER MED, V5, P761, DOI 10.3892/etm.2012.873
   Yu Y, 2012, BIOL PHARM BULL, V35, P2148, DOI 10.1248/bpb.b12-00405
   Yu Y, 2012, FREE RADICAL RES, V46, P1393, DOI 10.3109/10715762.2012.720017
   Yu ZY, 2014, ACTA PHARM SIN B, V4, P424, DOI 10.1016/j.apsb.2014.10.001
   Yuan G, 2014, J BIOL CHEM, V289, P10607, DOI 10.1074/jbc.M113.528760
   Yuan SQ, 2016, BIOMED PHARMACOTHER, V84, P1776, DOI 10.1016/j.biopha.2016.10.104
   Yuan ZX, 2015, EUR J PHARM BIOPHARM, V94, P363, DOI 10.1016/j.ejpb.2015.06.012
   Yuan ZG, 2017, BIOMED PHARMACOTHER, V89, P227, DOI 10.1016/j.biopha.2017.02.038
   Yun DG, 2017, IUBMB LIFE, V69, P631, DOI 10.1002/iub.1647
   Yun SM, 2014, PHYTOTHER RES, V28, P458, DOI 10.1002/ptr.5015
   Zeng DF, 2014, INT J CLIN EXP PATHO, V7, P2172
   Zeng J, 2011, MOL CANCER THER, V10, P104, DOI 10.1158/1535-7163.MCT-10-0577
   Zeng L, 2017, SCI REP-UK, V7, DOI 10.1038/srep45521
   Zeng R, 2012, ACTA PHARMACOL SIN, V33, P91, DOI 10.1038/aps.2011.143
   Zeng YY, 2019, MOLECULES, V24, DOI 10.3390/molecules24091697
   Zha QB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124355
   Zhai TY, 2017, ONCOL REP, V38, P3473, DOI 10.3892/or.2017.6038
   Zhan W, 2016, RSC ADV, V6, P96918, DOI 10.1039/c6ra20750b
   Zhang CK, 2018, INT J ONCOL, V53, P2531, DOI 10.3892/ijo.2018.4569
   Zhang CJ, 2016, ANGEW CHEM INT EDIT, V55, P13770, DOI 10.1002/anie.201607303
   Zhang CZ, 2012, BIOCHEM PHARMACOL, V83, P1278, DOI 10.1016/j.bcp.2012.02.002
   Zhang CL, 2012, MOL MED REP, V5, P1295, DOI 10.3892/mmr.2012.808
   Zhang F, 2015, DRUG DES DEV THER, V9, P3969, DOI 10.2147/DDDT.S84527
   Zhang HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096418
   Zhang JB, 2018, REDOX BIOL, V19, P263, DOI 10.1016/j.redox.2018.07.025
   Zhang JL, 2016, ONCOTARGET, V7, P79543, DOI 10.18632/oncotarget.12836
   Zhang JW, 2012, BRIT J PHARMACOL, V165, P120, DOI 10.1111/j.1476-5381.2011.01505.x
   Zhang JM, 2014, INT J PHARMACEUT, V476, P185, DOI 10.1016/j.ijpharm.2014.09.017
   Zhang J, 2015, CELL PHYSIOL BIOCHEM, V36, P2274, DOI 10.1159/000430191
   Zhang J, 2014, CELL PHYSIOL BIOCHEM, V34, P2027, DOI 10.1159/000366398
   Zhang KJ, 2016, BLOOD CELL MOL DIS, V56, P46, DOI 10.1016/j.bcmd.2015.10.007
   Zhang LD, 2016, INT J ONCOL, V49, P657, DOI 10.3892/ijo.2016.3557
   Zhang LX, 2014, CELL BIOL INT, V38, P639, DOI 10.1002/cbin.10244
   Zhang LH, 2018, INT J ONCOL, V53, P515, DOI 10.3892/ijo.2018.4423
   Zhang L, 2018, INT IMMUNOPHARMACOL, V65, P429, DOI 10.1016/j.intimp.2018.10.035
   Zhang L, 2017, BIOMED PHARMACOTHER, V90, P222, DOI 10.1016/j.biopha.2017.03.046
   Zhang LX, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164838
   Zhang M, 2014, MOL MED REP, V10, P2905, DOI 10.3892/mmr.2014.2581
   Zhang P, 2015, ONCOTARGETS THER, V8, P845, DOI 10.2147/OTT.S81041
   Zhang RW, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15039008
   Zhang T, 2013, WSPOLCZESNA ONKOL, V17, P38, DOI 10.5114/wo.2013.33772
   Zhang T, 2012, AUTOPHAGY, V8, P559, DOI 10.4161/auto.18867
   Zhang W, 2012, INT J MOL MED, V29, P159, DOI 10.3892/ijmm.2011.820
   Zhang WY, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122139
   Zhang WD, 2016, ONCOTARGETS THER, V9, P3359, DOI 10.2147/OTT.S100936
   Zhang X, 2015, AFR HEALTH SCI, V15, P97, DOI 10.4314/ahs.v15i1.13
   Zhang X, 2013, ONCOL REP, V30, P745, DOI 10.3892/or.2013.2519
   Zhang XB, 2017, FREE RADICAL BIO MED, V112, P49, DOI 10.1016/j.freeradbiomed.2017.07.011
   Zhang XB, 2012, J CANCER RES CLIN, V138, P2051, DOI 10.1007/s00432-012-1276-1
   Zhang XK, 2018, ONCOL LETT, V15, P9868, DOI 10.3892/ol.2018.8541
   Zhang XZ, 2014, J MED FOOD, V17, P955, DOI 10.1089/jmf.2013.2967
   Zhang X, 2015, AAPS PHARMSCITECH, V16, P259, DOI 10.1208/s12249-014-0217-5
   Zhang XD, 2016, EXP BIOL MED, V241, P501, DOI 10.1177/1535370215616195
   Zhang Y, 2012, CELL BIOCHEM FUNCT, V30, P243, DOI 10.1002/cbf.1842
   Zhang YH, 2011, ACTA PHARMACOL SIN, V32, P1266, DOI 10.1038/aps.2011.92
   Zhang Y, 2017, THORAC CANCER, V8, P296, DOI 10.1111/1759-7714.12441
   Zhang YZ, 2018, ONCOL REP, V39, P2595, DOI 10.3892/or.2018.6361
   Zhang Y, 2018, CANCER SCI, V109, P94, DOI 10.1111/cas.13425
   Zhang Y, 2017, MOL MED REP, V16, P794, DOI 10.3892/mmr.2017.6638
   Zhang Y, 2015, J NEURO-ONCOL, V121, P41, DOI 10.1007/s11060-014-1604-1
   Zhang Y, 2017, SAUDI J BIOL SCI, V24, P678, DOI 10.1016/j.sjbs.2017.01.042
   Zhang YX, 2013, PHYTOTHER RES, V27, P397, DOI 10.1002/ptr.4733
   Zhang Y, 2016, ASIAN PAC J TROP MED, V9, P178, DOI 10.1016/j.apjtm.2016.01.010
   Zhang ZY, 2018, MOL MED REP, V17, P7142, DOI 10.3892/mmr.2018.8767
   Zhang ZY, 2013, INT J MOL SCI, V14, P2980, DOI 10.3390/ijms14022980
   Zhao CB, 2014, APOPTOSIS, V19, P668, DOI 10.1007/s10495-013-0953-0
   Zhao F, 2016, ONCOTARGET, V7, P5366, DOI 10.18632/oncotarget.6783
   Zhao GJ, 2012, INT IMMUNOPHARMACOL, V14, P99, DOI 10.1016/j.intimp.2012.06.016
   Zhao GM, 2016, ONCOL REP, V35, P1065, DOI 10.3892/or.2015.4413
   Zhao HX, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20150665
   Zhao HX, 2015, RADIOTHER ONCOL, V114, P351, DOI 10.1016/j.radonc.2015.02.014
   Zhao HX, 2012, EXP MOL MED, V44, P633, DOI 10.3858/emm.2012.44.11.072
   Zhao J, 2017, MOL MED REP, V15, P1807, DOI 10.3892/mmr.2017.6213
   Zhao JJ, 2012, J HUAZHONG U SCI-MED, V32, P883, DOI 10.1007/s11596-012-1052-0
   Zhao K, 2017, ONCOTARGET, V8, P27120, DOI 10.18632/oncotarget.15449
   Zhao K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106458
   Zhao K, 2014, EUR J PHARMACOL, V737, P57, DOI 10.1016/j.ejphar.2014.05.011
   Zhao L, 2010, FOOD IND, V5, P11, DOI DOI 10.3892/etm.2016.3164
   Zhao L, 2016, MOL CARCINOGEN, V55, P778, DOI 10.1002/mc.22321
   Zhao QL, 2015, ONCOTARGET, V6, P38934, DOI 10.18632/oncotarget.5380
   Zhao SY, 2015, J CELL MOL MED, V19, P630, DOI 10.1111/jcmm.12476
   Zhao TT, 2015, MAT SCI ENG C-MATER, V53, P196, DOI 10.1016/j.msec.2015.04.022
   Zhao XW, 2016, ONCOL REP, V36, P1499, DOI 10.3892/or.2016.4957
   Zhao XY, 2017, EXP THER MED, V14, P4083, DOI 10.3892/etm.2017.5063
   Zhao Y, 2015, MOL CARCINOGEN, V54, pE81, DOI 10.1002/mc.22182
   Zhao YW, 2017, BIOMED PHARMACOTHER, V95, P18, DOI 10.1016/j.biopha.2017.08.045
   Zhaol K, 2017, EXP CELL RES, V356, P8, DOI 10.1016/j.yexcr.2017.03.063
   Zhen YZ, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/842091
   Zheng F, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0146-6
   Zheng L, 2018, CURR CANCER DRUG TAR, V18, P988, DOI 10.2174/1568009618666180425142653
   Zheng MX, 2017, MOL MED REP, V15, P375, DOI 10.3892/mmr.2016.6008
   Zheng N, 2017, ACTA PHARMACOL SIN, V38, P277, DOI 10.1038/aps.2016.117
   Zheng Q, 2014, MOL MED REP, V10, P89, DOI 10.3892/mmr.2014.2175
   Zheng QY, 2013, CELL SIGNAL, V25, P206, DOI 10.1016/j.cellsig.2012.09.012
   Zheng QY, 2012, BIOCHEM BIOPH RES CO, V419, P741, DOI 10.1016/j.bbrc.2012.02.093
   Zheng X, 2017, BIOMED PHARMACOTHER, V85, P620, DOI 10.1016/j.biopha.2016.11.072
   Zheng ZZ, 2014, ONCOL REP, V32, P325, DOI 10.3892/or.2014.3171
   Zhong Y, 2012, J FUNCT FOODS, V4, P323, DOI 10.1016/j.jff.2011.12.011
   Zhong Y, 2011, J AGR FOOD CHEM, V59, P6526, DOI 10.1021/jf201050j
   Zhong ZF, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0260-y
   Zhong ZF, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0203-z
   Zhou B, 2016, RADIOLOGY, V280, P630, DOI 10.1148/radiol.2016150719
   Zhou DH, 2013, INT J MOL SCI, V14, P12023, DOI 10.3390/ijms140612023
   Zhou GM, 2017, INT J ONCOL, V50, P933, DOI 10.3892/ijo.2017.3853
   Zhou JC, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.121
   Zhou J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6723807
   Zhou Kun, 2017, Oncol Res, DOI 10.3727/096504017X14954936991990
   Zhou M, 2014, VASC PHARMACOL, V60, P110, DOI 10.1016/j.vph.2014.01.010
   Zhou PJ, 2017, ONCOTARGET, V8, P111144, DOI 10.18632/oncotarget.22676
   Zhou XX, 2016, ONCOTARGET, V7, P79062, DOI 10.18632/oncotarget.12596
   Zhou XY, 2012, HEPATOL RES, V42, P401, DOI 10.1111/j.1872-034X.2011.00933.x
   Zhou Y, 2017, ONCOTARGET, V8, P18260, DOI 10.18632/oncotarget.15353
   Zhou YY, 2018, CELL PHYSIOL BIOCHEM, V45, P2548, DOI 10.1159/000488273
   Zhou ZH, 2013, INT IMMUNOPHARMACOL, V17, P850, DOI 10.1016/j.intimp.2013.09.015
   Zhou ZJ, 2017, CANCER LETT, V390, P77, DOI 10.1016/j.canlet.2017.01.004
   Zhu BH, 2011, WORLD J GASTROENTERO, V17, P2315, DOI 10.3748/wjg.v17.i18.2315
   Zhu C, 2018, BIOMED PHARMACOTHER, V97, P168, DOI 10.1016/j.biopha.2017.10.013
   Zhu GH, 2016, PHARM BIOL, V54, P1303, DOI 10.3109/13880209.2015.1060508
   Zhu JX, 2013, DRUG DEV IND PHARM, V39, P499, DOI 10.3109/03639045.2012.683875
   Zhu JY, 2018, TOXICOL APPL PHARM, V358, P1, DOI 10.1016/j.taap.2018.09.004
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
   Zhu LF, 2017, ACTA PHARMACOL SIN B, V7, P80, DOI 10.1016/j.apsb.2016.09.006
   Zhu M, 2013, ONCOL LETT, V6, P1502, DOI 10.3892/ol.2013.1541
   Zhu MH, 2019, MED SCI MONITOR, V25, P3983, DOI 10.12659/MSM.916835
   Zhu MH, 2018, MED SCI MONITOR, V24, P7146, DOI 10.12659/MSM.912563
   Zhu Q, 2017, ONCOL LETT, V13, P3760, DOI 10.3892/ol.2017.5945
   Zhu SQ, 2014, ONCOL REP, V32, P1094, DOI 10.3892/or.2014.3323
   Zhu TZ, 2011, INT J ONCOL, V38, P419, DOI 10.3892/ijo.2010.855
   Zhu XF, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2391820
   Zhu ZL, 2013, INT J NANOMED, V8, P129, DOI 10.2147/IJN.S38271
   Zong L, 2019, J PHARMACEUT BIOMED, V165, P268, DOI 10.1016/j.jpba.2018.11.057
   Zou P, 2015, ONCOTARGET, V6, P5860, DOI 10.18632/oncotarget.3333
   Zou ZY, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-58
   Zuo AR, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0206-9
   Zuo W, 2014, INT J MOL SCI, V15, P14298, DOI 10.3390/ijms150814298
NR 988
TC 127
Z9 131
U1 99
U2 206
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749-8546
J9 CHIN MED-UK
JI Chin. Med.
PD NOV 6
PY 2019
VL 14
IS 1
AR 48
DI 10.1186/s13020-019-0270-9
PG 58
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA JL6FK
UT WOS:000495625600001
PM 31719837
OA Green Published, gold
HC Y
HP N
DA 2022-04-25
ER

PT J
AU Yamaguchi, N
   Suzuki, Y
   Mahbub, MH
   Takahashi, H
   Hase, R
   Ishimaru, Y
   Sunagawa, H
   Watanabe, R
   Eishi, Y
   Tanabe, T
AF Yamaguchi, Natsu
   Suzuki, Yoshimi
   Mahbub, M. H.
   Takahashi, Hidekazu
   Hase, Ryosuke
   Ishimaru, Yasutaka
   Sunagawa, Hiroshi
   Watanabe, Rie
   Eishi, Yoshinobu
   Tanabe, Tsuyoshi
TI The different roles of innate immune receptors in inflammation and
   carcinogenesis between races
SO ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE
LA English
DT Review
DE TLR; NOD; Crohn's disease; Sarcoidosis
ID JAPANESE PATIENTS; CROHNS-DISEASE; NOD2/CARD15 VARIANTS; 3020INSC
   MUTATION; HOST RECOGNITION; CARD15 MUTATIONS; GENE; NOD1;
   TRANSPLANTATION; POLYMORPHISMS
AB Innate immune factors exert widespread effects on cytokine secretion, cell survival, autophagy, and apoptosis. Nucleotide-binding and oligomerization domain-like receptors (NLRs) are members of the innate immune system in the cytosol that sense pathogens, endogenous danger molecules such as uric acid, and pollutants. Nucleotidebinding oligomerization domain-containing protein 1 and 2 (NOD1 and NOD2) are components of NLR family, and ligands of these factors are gamma-D-glutamyl-meso-diaminopimelic acid (iE-DAP) and muramyl dipeptide (MDP), respectively. Upon recognition of ligands, NOD1 and NOD2 induce the production of inflammatory cytokines and transcription factors including interleukin-6 (IL-6) and nuclear factor-kappa B (NF-kappa B). We examined the function of NOD1 and NOD2 in innate immunity, with a focus on their differing roles in disease pathogenesis between Japanese and Caucasian populations. Susceptibility to several immune-related diseases, including Crohn's disease, colorectal and breast cancers, and graft-versus-host-disease (GVHD) showed a correlation with genetic variants of NOD2 in Caucasian, but not in Japanese, populations. This difference may be primarily due to the fact that three major NOD2 SNPs (R702W, G908R, L1007insC) prevalent in Caucasians are rare or absent in Japanese populations. Because NLR has diverse effects on immune function, it is possible that many as yet uncharacterized immune-related diseases will also show different susceptibilities between races due to the different ratio of genetic variants in innate immune genes.
C1 [Yamaguchi, Natsu; Mahbub, M. H.; Takahashi, Hidekazu; Hase, Ryosuke; Ishimaru, Yasutaka; Sunagawa, Hiroshi; Watanabe, Rie; Tanabe, Tsuyoshi] Yamaguchi Univ, Grad Sch Med, Depnt Publ Hlth & Prevent Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.
   [Suzuki, Yoshimi; Eishi, Yoshinobu] Tokyo Med & Dent Univ, Grad Sch, Dept Human Pathol, Tokyo, Japan.
   [Suzuki, Yoshimi; Eishi, Yoshinobu] Tokyo Med & Dent Univ, Fac Med, Tokyo, Japan.
RP Tanabe, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Depnt Publ Hlth & Prevent Med, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan.
EM tanabe@yamaguchi-u.ac.jp
CR Akahoshi M, 2008, TISSUE ANTIGENS, V71, P564, DOI 10.1111/j.1399-0039.2008.01043.x
   Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019
   Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945
   Croucher PJP, 2003, EUR J HUM GENET, V11, P6, DOI 10.1038/sj.ejhg.5200897
   Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995
   Granell M, 2006, HAEMATOLOGICA, V91, P1372
   Holler E, 2006, BLOOD, V107, P4189, DOI 10.1182/blood-2005-09-3741
   Holler E, 2004, BLOOD, V104, P889, DOI 10.1182/blood-2003-10-3543
   Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200
   Inohara N, 2000, J BIOL CHEM, V275, P27823
   Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347
   Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200
   Ishige I, 1999, LANCET, V354, P120, DOI 10.1016/S0140-6736(98)12310-3
   JABS DA, 1985, AM J MED, V78, P801, DOI 10.1016/0002-9343(85)90286-4
   Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016
   Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Kurzawski G, 2004, CANCER RES, V64, P1604, DOI 10.1158/0008-5472.CAN-03-3791
   Lener MR, 2006, BREAST CANCER RES TR, V95, P141, DOI 10.1007/s10549-005-9057-z
   Leong RWL, 2003, ALIMENT PHARM THER, V17, P1465, DOI 10.1046/j.1365-2036.2003.01607.x
   Masumoto J, 2006, J EXP MED, V203, P203, DOI 10.1084/jem.20051229
   Miceli-Richard C, 2001, NAT GENET, V29, P19, DOI 10.1038/ng720
   Ogino K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092710
   Oh H, 2005, BLOOD, V105, P1408, DOI 10.1182/blood-2004-06-2385
   Okafuji I, 2009, ARTHRITIS RHEUM-US, V60, P242, DOI 10.1002/art.24134
   Rosenstiel P, 2006, CELL MICROBIOL, V8, P1188, DOI 10.1111/j.1462-5822.2006.00701.x
   Schurmann M, 2003, EUR RESPIR J, V22, P748, DOI 10.1183/09031936.03.00040602
   Sioud M, 2009, J LEUKOCYTE BIOL, V85, P939, DOI 10.1189/jlb.1008650
   Sugimura M, 2003, CLIN GENET, V63, P160, DOI 10.1046/j.0009-9163.2002.00174.x
   Tanabe T, 2004, EMBO J, V23, P1587, DOI 10.1038/sj.emboj.7600175
   Tanabe T, 2006, BBA-MOL BASIS DIS, V1762, P794, DOI 10.1016/j.bbadis.2006.07.006
   Tanabe T, 2011, INT J HEMATOL, V93, P771, DOI 10.1007/s12185-011-0860-5
   van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013
   Yamazaki K, 2002, J HUM GENET, V47, P469, DOI 10.1007/s100380200067
NR 34
TC 7
Z9 7
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1342-078X
EI 1347-4715
J9 ENVIRON HEALTH PREV
JI Environ. Health Prev.
PY 2017
VL 22
IS 1
AR 70
DI 10.1186/s12199-017-0678-8
PG 5
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA FL5QA
UT WOS:000414299400005
PM 29165176
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Ray, M
   Rai, N
   Jana, K
   Ghatak, S
   Basu, A
   Mustafi, SB
   Raha, S
AF Ray, Mahan
   Rai, Neha
   Jana, Kuladip
   Ghatak, Supratim
   Basu, Arnab
   Mustafi, Soumyajit Banerjee
   Raha, Sanghamitra
TI Beta catenin is degraded by both caspase-3 and proteasomal activity
   during resveratrol-induced apoptosis in He. La cells in a GSK3
   beta-independent manner
SO INDIAN JOURNAL OF BIOCHEMISTRY & BIOPHYSICS
LA English
DT Article
DE Resveratrol; HeLa; Apoptosis; beta-Catenin; Caspase-3; GSK3 beta;
   Proteasomal degradation
ID COLORECTAL-CANCER CELLS; DEPENDENT DEGRADATION; PROTEIN; INHIBITION;
   GSK-3-BETA; AUTOPHAGY; PATHWAY; AKT
AB Increased activity of beta-catenin, an important transcriptional activator for survival and proliferation-associated genes has been linked with many cancers. We examined whether beta-catenin is a target of resveratrol and whether its degradation contributes to the pro-apoptotic effects of resveratrol. HeLa cells were exposed to 60 mu M resveratrol for 48 h. Apoptosis was confirmed by measurement of annexin V externalization, caspase-3 activation and DNA fragmentation. Induction of apoptosis was observed as early as 12 h, when both caspase-3 activation and PARP (poly ADP ribose polymerase) cleavage occurred. Nuclear beta-catenin levels remained unchanged for 48 h during resveratrol exposure. However, extranuclear cell lysate beta-catenin underwent a decrease at a late stage of apoptosis namely at 36-48 h. Alterations in the phosphorylation status of Akt/GSK3 beta were not observed during resveratrol-induced apoptosis. Furthermore, inhibition of GSK3 beta activity which is largely responsible for beta-catenin degradation failed to influence beta-catenin stability. However, inhibition of caspase-3 activity prevented the decline in beta-catenin levels at 36-48 h of resveratrol exposure. Lactacystin, a proteosomal inhibitor also prevented the degradation of beta-catenin by resveratrol. In conclusion, resveratrol induced apoptosis in He La cells in an Akt/GSK3 beta-independent manner and down-regulated beta-catenin levels during apoptosis through action of caspase-3 and proteasomal degradation, independent of GSK3 beta-mediated phosphorylation.
C1 [Ray, Mahan; Rai, Neha; Jana, Kuladip; Ghatak, Supratim; Mustafi, Soumyajit Banerjee; Raha, Sanghamitra] Saha Inst Nucl Phys, Crystallog & Mol Biol Div, Kolkata 700064, India.
   [Basu, Arnab] Saha Inst Nucl Phys, Div Chem Sci, Kolkata 700064, India.
   [Raha, Sanghamitra] VisvaBharati, Integrated Sci Educ & Res Ctr, Santini Ketan 731235, W Bengal, India.
   [Raha, Sanghamitra] VisvaBharati, Dept Biotechnol, Santini Ketan 731235, W Bengal, India.
RP Raha, S (corresponding author), Saha Inst Nucl Phys, Crystallog & Mol Biol Div, 1-AF Bidhannagar, Kolkata 700064, India.
EM sanghamitra.raha@visva-bharati.ac.in
FU CBAUNP project of Saha Institute of Nuclear Physics
FX We thank Mr. Sushanta Debnath for his excellent support with microscopy.
   We also thank Ms. Fatema Calcuttawala, who did a project in the lab, for
   her help during the initial period of the project. This study was funded
   by the CBAUNP project of Saha Institute of Nuclear Physics and the
   experimental work was done in the Crystallography & Molecular Biology
   Division of Saha Institute of Nuclear Physics.
CR Calviello G, 2007, CARCINOGENESIS, V28, P1202, DOI 10.1093/carcin/bgl254
   Chakraborty PK, 2008, CANCER SCI, V99, P1109, DOI 10.1111/j.1349-7006.2008.00809.x
   Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87
   Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94
   Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001
   Hsu KF, 2009, AUTOPHAGY, V5, P451, DOI 10.4161/auto.5.4.7666
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Luo H, 2012, CANCER LETT, V315, P78, DOI 10.1016/j.canlet.2011.10.014
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mustafi SB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008719
   Nair VD, 2008, J BIOL CHEM, V283, P15469, DOI 10.1074/jbc.M707238200
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Omori E, 2011, ONCOGENE, V30, P3336, DOI 10.1038/onc.2011.49
   Paul S, 2010, CARCINOGENESIS, V31, P1272, DOI 10.1093/carcin/bgq004
   Pervaiz S, 2009, ANTIOXID REDOX SIGN, V11, P2851, DOI [10.1089/ars.2008.2412, 10.1089/ARS.2008.2412]
   Rice PL, 2003, MOL CANCER THER, V2, P885
   Saifo MS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-310
   Sarkar F H, 2010, CANC METASTAS REV, V29, P383
   Senthivinayagam S, 2009, J BIOL CHEM, V284, P13577, DOI 10.1074/jbc.M900248200
   Stoica BA, 2003, MOL CELL NEUROSCI, V22, P365, DOI 10.1016/S1044-7431(02)00028-3
   Sun XL, 2010, BBA-GEN SUBJECTS, V1800, P912, DOI 10.1016/j.bbagen.2010.04.015
   Vanamala J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-238
   Wang YS, 2012, AM J TRANSL RES, V4, P44
   Yeste-Velasco M, 2008, EUR J PHARMACOL, V588, P239, DOI 10.1016/j.ejphar.2008.04.019
   Zhang HF, 2008, NEUROREPORT, V19, P821, DOI 10.1097/WNR.0b013e3282ffda72
NR 26
TC 6
Z9 8
U1 0
U2 3
PU NATL INST SCIENCE COMMUNICATION-NISCAIR
PI NEW DELHI
PA DR K S KRISHNAN MARG, PUSA CAMPUS, NEW DELHI 110 012, INDIA
SN 0301-1208
EI 0975-0959
J9 INDIAN J BIOCHEM BIO
JI Indian J. Biochem. Biophys.
PD FEB
PY 2015
VL 52
IS 1
BP 7
EP 13
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CI5WH
UT WOS:000354830000001
PM 26040106
DA 2022-04-25
ER

PT J
AU Iuchi, K
   Ema, M
   Suzuki, M
   Yokoyama, C
   Hisatomi, H
AF Iuchi, Katsuya
   Ema, Mika
   Suzuki, Moe
   Yokoyama, Chikako
   Hisatomi, Hisashi
TI Oxidized unsaturated fatty acids induce apoptotic cell death in cultured
   cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE polyunsaturated fatty acids; non-enzymatic oxidation; cell death;
   apoptosis; lipotoxicity
ID OMEGA-3-FATTY-ACID OXIDATION-PRODUCTS; BREAST-CANCER;
   LIPID-PEROXIDATION; PPAR-GAMMA; GENERATION; EXPRESSION; AUTOPHAGY;
   FAMILY
AB Polyunsaturated fatty acids are oxidized by non-enzymatic or enzymatic reactions. The oxidized products are multifunctional. In this study, we investigated how oxidized fatty acids inhibit cell proliferation in cultured cells. We used polyunsaturated and saturated fatty acids, docosahexaenoic acid (DHA; 22:6), eicosapentaenoic acid (EPA; 20:5), linoleic acid (LA; 18:2), and palmitic acid (16:0). Oxidized fatty acids were produced by autoxidation of fatty acids for 2 days in the presence of a gas mixture (20% O-2 and 80% N-2). We found that oxidized polyunsaturated fatty acids (OxDHA, OxEPA and OxLA) inhibited cell proliferation much more effectively compared with un-oxidized fatty acids (DHA, EPA and LA, respectively) in THP-1 (a human monocytic leukemia cell line) and DLD-1 (a human colorectal cancer cell line) cells. In particular, OxDHA markedly inhibited cell proliferation. DHA has the largest number of double bonds and is most susceptible to oxidation among the fatty acids. OxDHA has the largest number of highly active oxidized products. Therefore, the oxidative levels of fatty acids are associated with the anti-proliferative activity. Moreover, caspase-3/7 was activated in the cells treated with OxDHA, but not in those treated with DHA. A pan-caspase inhibitor (zVAD-fmk) reduced the cell death induced by OxDHA. These results indicated that oxidized products from polyunsaturated fatty acids induced apoptosis in cultured cells. Collectively, the switch between cell survival and cell death may be regulated by the activity and/or number of oxidized products from polyunsaturated fatty acids.
C1 [Iuchi, Katsuya; Ema, Mika; Suzuki, Moe; Hisatomi, Hisashi] Seikei Univ, Dept Mat & Life Sci, Fac Sci & Technol, 3-3-1 Kichijojikitamachi, Tokyo 1808633, Japan.
   [Yokoyama, Chikako] Yamagata Univ, Dept Biochem Engn, Grad Sch Sci & Engn, Yonezawa, Yamagata 9928510, Japan.
RP Iuchi, K (corresponding author), Seikei Univ, Dept Mat & Life Sci, Fac Sci & Technol, 3-3-1 Kichijojikitamachi, Tokyo 1808633, Japan.
EM iuchi@st.seikei.ac.jp
RI Iuchi, Katsuya/F-3317-2015
OI Iuchi, Katsuya/0000-0003-0625-6018
FU Seikei University (Tokyo, Japan); Japan Society for the Promotion of
   ScienceMinistry of Education, Culture, Sports, Science and Technology,
   Japan (MEXT)Japan Society for the Promotion of Science [15K16524,
   18K11001]
FX Financial support for this research was provided by Grants-in-Aid for
   Scientific Research of Seikei University (Tokyo, Japan; grant no. 2017)
   and Scientific Research from the Japan Society for the Promotion of
   Science (grant nos. 15K16524 and 18K11001 to KI).
CR Abdelmagid SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116195
   Bochkov VN, 2010, ANTIOXID REDOX SIGN, V12, P1009, DOI 10.1089/ars.2009.2597
   Calder PC, 2005, BIOCHEM SOC T, V33, P423, DOI 10.1042/BST0330423
   Chen R, 2007, J BIOL CHEM, V282, P24842, DOI 10.1074/jbc.M702865200
   Clay CE, 2002, J LIPID RES, V43, P1818, DOI 10.1194/jlr.M200224-JLR200
   D'Eliseo D, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020015
   Dwarakanath RS, 2004, J MOL CELL CARDIOL, V36, P585, DOI 10.1016/j.yjmcc.2004.02.007
   Eguchi Y, 1997, CANCER RES, V57, P1835
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Gao B, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.144
   Haeiwa H, 2014, MOL CELL BIOCHEM, V386, P73, DOI 10.1007/s11010-013-1846-9
   Hill BG, 2008, BIOCHEM J, V410, P525, DOI 10.1042/BJ20071063
   Iuchi K, 2016, SCI REP-UK, V6, DOI 10.1038/srep18971
   Kang KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010296
   Lim SY, 2004, J BIOL CHEM, V279, P46263, DOI 10.1074/jbc.M406555200
   Liu XB, 2008, J CLIN BIOCHEM NUTR, V43, P26, DOI 10.3164/jcbn.2008040
   Majkova Z, 2011, TOXICOL APPL PHARM, V251, P41, DOI 10.1016/j.taap.2010.11.013
   Mansara PP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136542
   Martinez B, 2005, J LIPID RES, V46, P736, DOI 10.1194/jlr.M400392-JLR200
   Meilhac O, 2000, J LIPID RES, V41, P1205
   Miller YI, 2017, TRENDS ENDOCRIN MET, V28, P143, DOI 10.1016/j.tem.2016.11.002
   Milne GL, 2011, CHEM REV, V111, P5973, DOI 10.1021/cr200160h
   Mu YM, 2001, ENDOCRINOLOGY, V142, P3590, DOI 10.1210/en.142.8.3590
   Murray M, 2014, BRIT J PHARMACOL, V171, P2051, DOI 10.1111/bph.12417
   Niki E, 2014, BBA-GEN SUBJECTS, V1840, P809, DOI 10.1016/j.bbagen.2013.03.020
   Notarnicola M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030485
   Notarnicola M, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-10
   Nourooz-Zadeh J, 1998, BIOCHEM BIOPH RES CO, V242, P338, DOI 10.1006/bbrc.1997.7883
   Parisi LR, 2018, ACS CHEM BIOL, V13, P506, DOI 10.1021/acschembio.7b01082
   Perluigi M, 2012, ANTIOXID REDOX SIGN, V17, P1590, DOI 10.1089/ars.2011.4406
   Pizato N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20422-0
   Schley PD, 2005, BREAST CANCER RES TR, V92, P187, DOI 10.1007/s10549-005-2415-z
   Shimizu S, 2000, P NATL ACAD SCI USA, V97, P577, DOI 10.1073/pnas.97.2.577
   Timucin AC, 2017, FREE RADICAL BIO MED, V111, P209, DOI 10.1016/j.freeradbiomed.2016.11.010
   Tsujimoto Y, 2003, J CELL PHYSIOL, V195, P158, DOI 10.1002/jcp.10254
   Usatyuk PV, 2012, MICROVASC RES, V83, P45, DOI 10.1016/j.mvr.2011.04.012
   Wang LM, 2009, J LIPID RES, V50, P204, DOI 10.1194/jlr.M700505-JLR200
   Wang WC, 2014, PROSTAG OTH LIPID M, V113, P13, DOI 10.1016/j.prostaglandins.2014.07.002
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Yadav UCS, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/690545
   Yee LD, 2005, J NUTR, V135, P983, DOI 10.1093/jn/135.5.983
   Yeh A, 2015, TOXICOL IN VITRO, V29, P672, DOI 10.1016/j.tiv.2015.01.015
   Yin YQ, 2017, LIPIDS HEALTH DIS, V16, DOI 10.1186/s12944-017-0474-x
   Yotsumoto S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15668-z
   Yun EJ, 2016, ONCOTARGET, V7, P49961, DOI 10.18632/oncotarget.10266
   Zajdel A, 2013, ACTA POL PHARM, V70, P365
   Zhang Y, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-1
NR 47
TC 14
Z9 14
U1 1
U2 5
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2019
VL 19
IS 4
BP 2767
EP 2773
DI 10.3892/mmr.2019.9940
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HQ7YD
UT WOS:000462639100033
PM 30720142
OA Green Submitted, Green Published, hybrid
DA 2022-04-25
ER

PT J
AU Phosri, S
   Jangpromma, N
   Chang, LC
   Tan, GT
   Wongwiwatthananukit, S
   Maijaroen, S
   Anwised, P
   Payoungkiattikun, W
   Klaynongsruang, S
AF Phosri, Santi
   Jangpromma, Nisachon
   Chang, Leng Chee
   Tan, Ghee T.
   Wongwiwatthananukit, Supakit
   Maijaroen, Surachai
   Anwised, Preeyanan
   Payoungkiattikun, Wisarut
   Klaynongsruang, Sompong
TI Siamese Crocodile White Blood Cell Extract Inhibits Cell Proliferation
   and Promotes Autophagy in Multiple Cancer Cell Lines
SO JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY
LA English
DT Article
DE Antitumor; breast cancer; colorectal cancer; Crocodylus siamensis; lung
   cancer; prostate cancer
ID ANTIBACTERIAL ACTIVITY; ANTICANCER ACTIVITY; ANTIMICROBIAL PEPTIDES;
   CYCLE ARREST; IN-VITRO; APOPTOSIS; ANTIOXIDANT; EXPRESSION; MIGRATION;
   TOXICITY
AB Cancer represents one of the most significant threats to human health on a global scale. Hence, the development of effective cancer prevention strategies, as well as the discovery of novel therapeutic agents against cancer, is urgently required. In light of this challenge, this research aimed to evaluate the effects of several potent bioactive peptides and proteins contained in crocodile white blood cell extract (cWBC) against LU-1, LNCaP, PC-3, MCF-7, and CaCo-2 cancer cell lines. The results demonstrate that 25, 50, 100, and 200 mu g/ml cWBC exhibits a strong cytotoxic effect against all investigated cell lines (IC50 70.34-101.0 mu g/ml), while showing no signs of cytotoxicity towards noncancerous Vero and HaCaT cells. Specifically, cWBC treatment caused a significant reduction in the cancerous cells' colony forming ability. A remarkable suppression of cancerous cell migration was observed after treatment with cWBC, indicating potent antimetastatic properties. The mechanism involved in the cancer cell cytotoxicity of cWBC may be related to apoptosis induction, as evidenced by typical apoptotic morphology features. Moreover, certain cWBC concentrations induced significant overproduction of ROS and significantly inhibited the S-G(2)/M transition in the cancer cell. The molecular mechanisms of cWBC in apoptosis induction were to decrease Bcl-2 and XIAP expression levels and increase the expression levels of caspase-3, caspase-8, and p53. These led to a decrease in the expression level of the cell cycle-associated gene cyclin-B1 and the arrest of cell population growth. Consequently, these findings demonstrate the prospect of the use of cWBC for cancer therapy.
C1 [Phosri, Santi] Burapha Univ, Off Educ, Fac Engn, Chon Buri 20131, Thailand.
   [Phosri, Santi; Jangpromma, Nisachon; Maijaroen, Surachai; Anwised, Preeyanan; Payoungkiattikun, Wisarut; Klaynongsruang, Sompong] Khon Kaen Univ, Prot & Prote Res Ctr Commercial & Ind Purposes Pr, Fac Sci, Khon Kaen 40002, Thailand.
   [Jangpromma, Nisachon] Khon Kaen Univ, Fac Sci, Off Dean, Khon Kaen 40002, Thailand.
   [Chang, Leng Chee; Tan, Ghee T.] Univ Hawaii, Coll Pharm, Dept Pharmaceut Sci, Hilo, HI 96720 USA.
   [Wongwiwatthananukit, Supakit] Univ Hawaii, Dept Pharm Practice, Coll Pharm, Hilo, HI 96720 USA.
   [Maijaroen, Surachai; Klaynongsruang, Sompong] Khon Kaen Univ, Dept Biochem, Fac Sci, Khon Kaen 40002, Thailand.
RP Klaynongsruang, S (corresponding author), Khon Kaen Univ, Prot & Prote Res Ctr Commercial & Ind Purposes Pr, Fac Sci, Khon Kaen 40002, Thailand.; Klaynongsruang, S (corresponding author), Khon Kaen Univ, Dept Biochem, Fac Sci, Khon Kaen 40002, Thailand.
EM somkly@kku.ac.th
RI Jangpromma, Nisachon/AFR-0011-2022
OI Jangpromma, Nisachon/0000-0002-2071-2406; Klaynongsruang,
   Sompong/0000-0003-2872-1291
FU Protein and Proteomics Research Center for Commercial and Industrial
   Purposes (ProCCI), Faculty of Science, Khon Kaen University
FX This present research was supported by the Protein and Proteomics
   Research Center for Commercial and Industrial Purposes (ProCCI), Faculty
   of Science, Khon Kaen University. We would like to thank the Department
   of Pharmaceutical Sciences, College of Pharmacy, University of Hawaii at
   Hilo, USA, for providing laboratory facilities and equipment to perform
   the anticancer assays. Our special thanks to Sriracha Moda Co. Ltd.,
   Chonburi, Thailand, for providing the crocodile blood samples, as well
   as the Research Instrument Center, Khon Kaen University, for granting
   access to and support on the flow cytometer.
CR Ameziane-El-Hassani R., 2013, BIO-PROTOCOL, V3, pe313, DOI [10.21769/BioProtoc.313, DOI 10.21769/BIOPROTOC.313, 10.21769/bioprotoc.313]
   Anunthawan T, 2015, BBA-BIOMEMBRANES, V1848, P1352, DOI 10.1016/j.bbamem.2015.02.021
   Arouri A, 2009, BBA-BIOMEMBRANES, V1788, P650, DOI 10.1016/j.bbamem.2008.11.022
   Barksdale SM, 2017, DEV COMP IMMUNOL, V70, P135, DOI 10.1016/j.dci.2017.01.011
   Boohaker RJ, 2012, CURR MED CHEM, V19, P3794
   Brandenburg LO, 2012, POLYMERS-BASEL, V4, P539, DOI 10.3390/polym4010539
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   Chen JH, 2015, MED SCI MONITOR, V21, P1604, DOI 10.12659/MSM.893004
   Chen R, 2014, ASIAN J UROL, V1, P15, DOI 10.1016/j.ajur.2014.08.007
   Collins K, 1997, P NATL ACAD SCI USA, V94, P2776, DOI 10.1073/pnas.94.7.2776
   Dia VP, 2016, SCI REP-UK, V6, DOI 10.1038/srep33532
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Flatt PM, 2000, DRUG METAB REV, V32, P283, DOI 10.1081/DMR-100102335
   Gaspar D, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00294
   Hacker G, 2000, CELL TISSUE RES, V301, P5, DOI 10.1007/s004410000193
   Hao J, 2012, COMP BIOCHEM PHYS B, V163, P309, DOI 10.1016/j.cbpb.2012.08.002
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Hsu SC, 2007, ANTICANCER RES, V27, P2377
   Iwasaki T, 2009, PEPTIDES, V30, P660, DOI 10.1016/j.peptides.2008.12.019
   Jangpromma N, 2016, J MICROBIOL BIOTECHN, V26, P1140, DOI 10.4014/jmb.1601.01054
   Jeyamogan S, 2017, CANCER CHEMOTH PHARM, V80, P919, DOI 10.1007/s00280-017-3410-x
   Kommanee J, 2012, ANN CLIN MICROB ANTI, V11, DOI 10.1186/1476-0711-11-22
   Lee JH, 2015, J MICROBIOL BIOTECHN, V25, P1275, DOI 10.4014/jmb.1503.03091
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Liu EL, 2013, FOOD CHEM TOXICOL, V60, P302, DOI 10.1016/j.fct.2013.07.072
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mancinelli L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-55
   Mehta Rajendra G, 2002, Curr Oncol Rep, V4, P478, DOI 10.1007/s11912-002-0059-2
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Omrani, 2014, CLIN OVAR OTHER GYNE, V7, P18, DOI [10.1016/j, DOI 10.1016/J.COGC.2014.12.004, 10.1016/j.cogc.2014.12.004]
   Pandey S, 2017, BIOMED PHARMACOTHER, V89, P515, DOI 10.1016/j.biopha.2017.02.050
   Pata S, 2011, DEV COMP IMMUNOL, V35, P545, DOI 10.1016/j.dci.2010.12.011
   Patathananone S, 2016, ENVIRON TOXICOL, V31, P1329, DOI 10.1002/tox.22138
   Patathananone S, 2016, ENVIRON TOXICOL, V31, P986, DOI 10.1002/tox.22108
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Phosri S, 2017, INFLAMMATION, V40, P205, DOI 10.1007/s10753-016-0471-7
   Phosri S, 2014, PROTEIN J, V33, P484, DOI 10.1007/s10930-014-9581-y
   Preecharram S, 2008, AFR J BIOTECHNOL, V7, P3121
   Riedl S, 2011, CHEM PHYS LIPIDS, V164, P766, DOI 10.1016/j.chemphyslip.2011.09.004
   Risso A, 2000, J LEUKOCYTE BIOL, V68, P785
   Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3
   Shrestha LB, 2000, HEALTH AFFAIR, V19, P204, DOI 10.1377/hlthaff.19.3.204
   Singh A, 2015, EUR J PHARM SCI, V76, P57, DOI 10.1016/j.ejps.2015.04.020
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Syed Abdul Rahman SN, 2013, ALTERNAT MED, V2013
   Theansungnoen T, 2014, PROTEIN J, V33, P24, DOI 10.1007/s10930-013-9536-8
   Umayaparvathi S., 2014, Biomedicine & Preventive Nutrition, V4, P343
   Wan QH, 2013, CELL RES, V23, P1091, DOI 10.1038/cr.2013.104
   Wijesinghe WAJP, 2013, FOOD CHEM, V139, P326, DOI 10.1016/j.foodchem.2013.01.058
   Woo CC, 2011, BIOCHEM PHARMACOL, V82, P464, DOI 10.1016/j.bcp.2011.05.030
   Xiao JX, 2007, TOXICOL IN VITRO, V21, P820, DOI 10.1016/j.tiv.2007.01.025
   Xuan HZ, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/280120
   Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616
   Yaraksa N, 2014, J ANTIBIOT, V67, P205, DOI 10.1038/ja.2013.114
   Yong WK, 2015, PHARMACOGN MAG, V11, pS275, DOI 10.4103/0973-1296.166069
   Zhang L, 2014, INT J MOL MED, V33, P1613, DOI 10.3892/ijmm.2014.1718
NR 56
TC 4
Z9 4
U1 1
U2 9
PU KOREAN SOC MICROBIOLOGY & BIOTECHNOLOGY
PI SEOUL
PA KOREA SCI TECHNOL CENTER #507,  635-4 YEOGSAM-DONG, KANGNAM-GU, SEOUL
   135-703, SOUTH KOREA
SN 1017-7825
EI 1738-8872
J9 J MICROBIOL BIOTECHN
JI J. Microbiol. Biotechnol.
PD JUN
PY 2018
VL 28
IS 6
BP 1007
EP 1021
DI 10.4014/jmb.1712.12002
PG 15
WC Biotechnology & Applied Microbiology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Microbiology
GA GL3AC
UT WOS:000436997500018
PM 29847866
OA Bronze
DA 2022-04-25
ER

PT J
AU Okuda, Y
   Shimura, T
   Iwasaki, H
   Katano, T
   Kitagawa, M
   Nishigaki, R
   Fukusada, S
   Natsume, M
   Tanaka, M
   Nishie, H
   Ozeki, K
   Yamada, T
   Kataoka, H
AF Okuda, Yusuke
   Shimura, Takaya
   Iwasaki, Hiroyasu
   Katano, Takahito
   Kitagawa, Mika
   Nishigaki, Ruriko
   Fukusada, Shigeki
   Natsume, Makoto
   Tanaka, Mamoru
   Nishie, Hirotada
   Ozeki, Keiji
   Yamada, Tamaki
   Kataoka, Hiromi
TI Serum Exosomal Dicer Is a Useful Biomarker for Early Detection of
   Differentiated Gastric Adenocarcinoma
SO DIGESTION
LA English
DT Article
DE Biomarker; Dicer; Exosome; Gastric cancer; Serum
ID FECAL OCCULT BLOOD; MICRORNA BIOGENESIS; CANCER EXOSOMES; PROLIFERATION;
   AUTOPHAGY
AB Background and Aim: A recent basic study identified that Dicer is contained in exosomes derived from cancer cells and plays crucial roles in microRNA maturation and cancer development. Based on this novel basic concept, we analyzed the usefulness of serum exosomal Dicer as a diagnostic biomarker for gastrointestinal cancers. Methods: Enrolled participants (691) were categorized into 3 groups: gastric cancer (GC) cohort, 183 patients (90 healthy controls (HCs) and 93 GC patients); esophageal cancer (EC) cohort, 115 patients (90 HCs and 25 EC patients); and colorectal cancer (CRC) cohort, 188 patients (92 HCs and 96 CRC patients) after age- and sex matching using the propensity score. The quality of isolated serum exosomes was validated with an electron microscope, particle size analyzer, and exosome marker, CD63. Results: Serum exosomal Dicer was significantly higher in the GC group than in the HC group (p = 0.004), whereas no significant differences were found in both EC and CRC cohorts. Serum exosomal Dicer was significantly higher in only differentiated gastric adenocarcinoma and not in the undifferentiated type. Moreover, serum exosomal Dicer showed no significant differences regardless of Helicobacter pylori (H. pylori) status. The biomarker panel combining serum exosomal Dicer with H. pylori status distinguished between HC and differentiated GC patients with an area under the curve (AUC) of 0.762. As for early-stage diagnosis, this combination distinguished between HC and stage I differentiated GC with an AUC = 0.758. Conclusions: Serum exosomal Dicer is a potential noninvasive diagnostic biomarker for early detection of differentiated gastric adenocarcinoma.
C1 [Okuda, Yusuke; Shimura, Takaya; Iwasaki, Hiroyasu; Katano, Takahito; Kitagawa, Mika; Nishigaki, Ruriko; Fukusada, Shigeki; Natsume, Makoto; Tanaka, Mamoru; Nishie, Hirotada; Ozeki, Keiji; Kataoka, Hiromi] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan.
   [Yamada, Tamaki] Okazaki Publ Hlth Ctr, Okazaki, Aichi, Japan.
RP Shimura, T (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Mizuho Ku, 1 Kawasumi, Nagoya, Aichi 4678601, Japan.
EM tshimura@med.nagoya-cu.ac.jp
OI Okuda, Yusuke/0000-0003-1390-0609; Shimura, Takaya/0000-0002-6048-0021
FU Suzuken Memorial Foundation
FX This study was supported, in part, by Suzuken Memorial Foundation (to
   T.S.).
CR Ando Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023385
   Asadi M, 2019, J GASTROINTEST CANC, V50, P855, DOI 10.1007/s12029-018-0154-8
   Avery-Kiejda KA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-253
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Chen X, 2017, CARCINOGENESIS, V38, P873, DOI 10.1093/carcin/bgx059
   Chiosea S, 2007, CANCER RES, V67, P2345, DOI 10.1158/0008-5472.CAN-06-3533
   Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480
   Cole C, 2009, RNA, V15, P2147, DOI 10.1261/rna.1738409
   Collins JF, 2005, ANN INTERN MED, V142, P81, DOI 10.7326/0003-4819-142-2-200501180-00006
   Faber C, 2011, EUR J CANCER, V47, P1414, DOI 10.1016/j.ejca.2011.01.006
   Faggad A, 2012, HISTOPATHOLOGY, V61, P552, DOI 10.1111/j.1365-2559.2011.04110.x
   Fu M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1001-7
   Gibbings D, 2012, NAT CELL BIOL, V14, P1314, DOI 10.1038/ncb2611
   Hannafon BN, 2013, INT J MOL SCI, V14, P14240, DOI 10.3390/ijms140714240
   Hong CC, 2014, CANCER RES, V74, P6280, DOI 10.1158/0008-5472.CAN-14-0524
   Hunt RH, 2015, GUT, V64, P1650, DOI 10.1136/gutjnl-2014-307595
   Iwasaki H, 2019, J GASTROENTEROL, V54, P1061, DOI 10.1007/s00535-019-01601-w
   Kahlert C, 2013, J MOL MED, V91, P431, DOI 10.1007/s00109-013-1020-6
   Kahroba H, 2019, CELL MOL LIFE SCI, V76, P1747, DOI 10.1007/s00018-019-03035-2
   Kim S, 2017, ONCOL LETT, V14, P4379, DOI 10.3892/ol.2017.6674
   Kovaleva V, 2012, CANCER RES, V72, P1763, DOI 10.1158/0008-5472.CAN-11-3671
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Maute RL, 2013, P NATL ACAD SCI USA, V110, P1404, DOI 10.1073/pnas.1206761110
   McShane LM, 2005, J CLIN ONCOL, V23, P9067, DOI 10.1200/JCO.2004.01.0454
   Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
   Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005
   Morikawa T, 2005, GASTROENTEROLOGY, V129, P422, DOI 10.1053/j.gastro.2005.05.056
   Rybak-Wolf A, 2014, CELL, V159, P1153, DOI 10.1016/j.cell.2014.10.040
   Saito H, 2000, ONCOL REP, V7, P815
   Shimura T, 2019, TRANSL ONCOL, V12, P539, DOI 10.1016/j.tranon.2018.12.006
   Shimura T, 2017, ONCOTARGET, V8, P29247, DOI 10.18632/oncotarget.16453
   Shimura T, 2015, CANCER PREV RES, V8, P240, DOI 10.1158/1940-6207.CAPR-14-0229
   Sturgeon CM, 2010, CLIN CHEM, V56, pE1, DOI 10.1373/clinchem.2009.133124
   Sugito N, 2006, CLIN CANCER RES, V12, P7322, DOI 10.1158/1078-0432.CCR-06-0515
   Sun LC, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-288
   Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0897-7
   Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511
   Wang JH, 2014, BLOOD, V124, P555, DOI 10.1182/blood-2014-03-562439
   Wang WN, 2013, TUMOR BIOL, V34, P1865, DOI 10.1007/s13277-013-0728-9
   Wittekind, 2009, TNM CLASSIFICATION M
   Yang ZY, 2018, CANCER LETT, V415, P20, DOI 10.1016/j.canlet.2017.11.026
   Zhang J, 2014, INT J CLIN EXP PATHO, V7, P1702
   Zheng X, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-490
NR 44
TC 1
Z9 1
U1 4
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0012-2823
EI 1421-9867
J9 DIGESTION
JI Digestion
PD JUN
PY 2021
VL 102
IS 4
BP 640
EP 649
DI 10.1159/000510993
PG 10
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA TC4UW
UT WOS:000668636500017
PM 33049740
DA 2022-04-25
ER

PT J
AU Shao, M
   Chang, C
   Liu, ZH
   Chen, K
   Zhou, YM
   Zheng, GH
   Huang, ZJ
   Xu, HX
   Xu, PH
   Lu, B
AF Shao, Mei
   Chang, Cong
   Liu, Zuhao
   Chen, Kai
   Zhou, Yimin
   Zheng, Guohua
   Huang, Zhijun
   Xu, Haixing
   Xu, Peihu
   Lu, Bo
TI Polydopamine coated hollow mesoporous silica nanoparticles as
   pH-sensitive nanocarriers for overcoming multidrug resistance
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Polydopamine; Hollow mesoporous silica nanoparticles; Multidrug
   resistance; Stimuli response; Drug delivery system
ID DRUG-DELIVERY SYSTEM; CO-DELIVERY; INSPIRED POLYDOPAMINE; PHOTOTHERMAL
   THERAPY; IN-VITRO; QUERCETIN; RELEASE; DOXORUBICIN; AUTOPHAGY; PLATFORM
AB A nanocarrier system of methoxypolyethylene glycol amine (mPEG-NH2) functionalized polydopamine (PDA) coated hollow mesoporous silica nanoparticles (HMSNs-PDA-PEG) was developed with pH-responsive, which combined doxorubicin hydrochloride (DOX) and quercetin (QUR) to reverse multidrug resistance (MDR) and improved anticancer effects on taxol (TAX) and DOX double resistant human colorectal cancer cell line HCT-8 (HCT-8/TAX cells). Well-dispersed nanoparticles (HMSNs-PDA-PEG) were prepared with a dimension of around 170 nm. The surface morphology and chemical properties of HMSNs-PDA-PEG were also successfully characterized by transmission electron microscopy (TEM), X-ray photoelectron spectroscopy (XPS), thermal gravimetric analysis (TGA), X-ray diffraction (XRD), Brunauer-Emmett-Teller (BET) method, Fourier transform infrared spectroscopy (FT-IR) and dynamic light scattering (DLS). Drug release experiments results indicated that DOX and QUR (QD) loaded nanoparticles (HMSNs-PDA-PEG@QD) had similar release kinetic profiles of each drug, which all exhibited highly sensitive to pH value due to the surface PDA coating. Additionally, the HCT-8 cells or HCT-8/TAX cells were employed to assess the cellular uptake and cytotoxicity of various drug-free or drug-loaded HMSNs samples. Meanwhile, a series of biological evaluations demonstrated that the HMSNs-PDA-PEG@QD exhibited remarkable ability to overcome MDR compared with free DOX and HMSNs-PDA-PEG@DOX. Taken together, these results revealed that HMSNs-PDA-PEG@QD was suitable as a prospective and efficient drug delivery nanosystem for overcoming multidrug resistance.
C1 [Shao, Mei; Chen, Kai; Zhou, Yimin; Huang, Zhijun; Xu, Haixing; Xu, Peihu; Lu, Bo] Wuhan Univ Technol, Sch Chem Chem Engn & Life Sci, Wuhan 430070, Hubei, Peoples R China.
   [Chang, Cong; Liu, Zuhao; Zheng, Guohua] Hubei Univ Chinese Med, Coll Pharm, Wuhan, Hubei, Peoples R China.
RP Lu, B (corresponding author), Wuhan Univ Technol, Sch Chem Chem Engn & Life Sci, Wuhan 430070, Hubei, Peoples R China.
EM lvb@whut.edu.cn
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [51773162, 21204071]; Open Fund Project of
   Hubei TCM Standardization Engineering and Technology Center
   [ZDSYS201802]
FX This work was financially supported by the National Natural Science
   Foundation of China (51773162, 21204071) and the Open Fund Project of
   Hubei TCM Standardization Engineering and Technology Center
   (ZDSYS201802).
CR Agardan NBM, 2018, CHEM COMMUN, V54, P6368, DOI 10.1039/c8cc01376d
   Bian YC, 2017, IEEE DATA MINING, P21, DOI 10.1109/ICDM.2017.11
   Caddeo C, 2016, J COLLOID INTERF SCI, V461, P69, DOI 10.1016/j.jcis.2015.09.013
   Chen H, 2018, J MATER SCI, V53, P10653, DOI 10.1007/s10853-018-2363-8
   Cheng W, 2017, SMALL, V13, DOI 10.1002/smll.201700623
   Cote B, 2015, J CONTROL RELEASE, V213, P128, DOI 10.1016/j.jconrel.2015.06.040
   Duo YH, 2017, RSC ADV, V7, P39641, DOI 10.1039/c7ra05135b
   Fang XL, 2011, NANOSCALE, V3, P1632, DOI 10.1039/c0nr00893a
   Han N, 2015, ACS APPL MATER INTER, V7, P3342, DOI 10.1021/am5082793
   Huang GM, 2018, SCI CHINA CHEM, V61, P806, DOI 10.1007/s11426-017-9217-4
   Huang L, 2018, J MATER CHEM B, V6, P4618, DOI 10.1039/c8tb00989a
   Jambhrunkar S, 2014, J COLLOID INTERF SCI, V434, P218, DOI 10.1016/j.jcis.2014.08.019
   Ji F, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10030326
   Jia X, 2018, ACS APPL NANO MATER, V1, P3486, DOI 10.1021/acsanm.8b00657
   Kong N, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00125
   Lan RC, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201900013
   Lee J, 2014, J AM CHEM SOC, V136, P12880, DOI 10.1021/ja507767h
   Li J, 2017, INT J NANOMED, V12, P8043, DOI 10.2147/IJN.S148273
   Li QL, 2015, ACS APPL MATER INTER, V7, P28656, DOI 10.1021/acsami.5b10534
   Li XR, 2018, COLLOID SURFACE A, V548, P61, DOI 10.1016/j.colsurfa.2018.03.047
   Liu EL, 2015, J NANOMATER, V2015, DOI 10.1155/2015/390358
   Liu JJ, 2016, BIOMATERIALS, V83, P51, DOI 10.1016/j.biomaterials.2016.01.008
   Liu Q, 2013, J AM CHEM SOC, V135, P17679, DOI 10.1021/ja4080562
   Liu R, 2013, ACS APPL MATER INTER, V5, P9167, DOI 10.1021/am402585y
   Maeda H, 2013, CANCER SCI, V104, P779, DOI 10.1111/cas.12152
   Oh Y, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/aa5d7d
   Peng HP, 2015, SENSOR ACTUAT B-CHEM, V207, P269, DOI 10.1016/j.snb.2014.10.059
   Peng YM, 2018, BIOMATER SCI-UK, V6, P1084, DOI 10.1039/c7bm01206c
   Primikyri A, 2014, ACS CHEM BIOL, V9, P2737, DOI 10.1021/cb500259e
   Qian M, 2018, ACS APPL MATER INTER, V10, P4031, DOI 10.1021/acsami.7b19716
   Qiao L, 2016, NANOSCALE, V8, P17241, DOI 10.1039/c6nr05943k
   Rahoui N, 2018, COLLOID SURFACE B, V171, P176, DOI 10.1016/j.colsurfb.2018.07.015
   Riganti C, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00105
   Sharom FJ, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00041
   Summerlin N, 2016, COLLOID SURFACE B, V144, P1, DOI 10.1016/j.colsurfb.2016.03.076
   Sun X, 2017, RSC ADV, V7, P16401, DOI 10.1039/c7ra01128h
   Vyas VS, 2016, ADV MATER, V28, P8749, DOI 10.1002/adma.201603006
   Wang LC, 2018, MOL PHARMACEUT, V15, P2503, DOI 10.1021/acs.molpharmaceut.7b01096
   Wei Y, 2017, DRUG DELIV, V24, P681, DOI 10.1080/10717544.2017.1309475
   Yu MH, 2013, NANOSCALE, V5, P178, DOI 10.1039/c2nr32145a
   Zhang L, 2016, ACS NANO, V10, P10404, DOI 10.1021/acsnano.6b06267
   Zhang W, 2016, ACS APPL MATER INTER, V8, P13332, DOI 10.1021/acsami.6b03881
   Zhang Y, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.170986
   Zhang ZP, 2018, J COLLOID INTERF SCI, V509, P47, DOI 10.1016/j.jcis.2017.08.097
   Zhao QF, 2017, MAT SCI ENG C-MATER, V78, P475, DOI 10.1016/j.msec.2017.04.059
   Zheng QS, 2014, INT J PHARMACEUT, V463, P22, DOI 10.1016/j.ijpharm.2013.12.045
   Zhou ZJ, 2017, BIOMATERIALS, V141, P116, DOI 10.1016/j.biomaterials.2017.06.030
NR 47
TC 28
Z9 28
U1 10
U2 150
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD NOV 1
PY 2019
VL 183
AR 110427
DI 10.1016/j.colsurfb.2019.110427
PG 8
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA JJ3GD
UT WOS:000494048600032
PM 31408782
DA 2022-04-25
ER

PT J
AU Elgenaidi, IS
   Spiers, JP
AF Elgenaidi, Ismail Suliman
   Spiers, James Paul
TI Hypoxia modulates protein phosphatase 2A through HIF-1 alpha dependent
   and independent mechanisms in human aortic smooth muscle cells and
   ventricular cardiomyocytes
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID SERINE/THREONINE PHOSPHATASES; REGULATORY SUBUNITS; COLORECTAL-CANCER;
   CATALYTIC SUBUNIT; CONCISE GUIDE; PP2A; EXPRESSION; INHIBITION;
   PHOSPHORYLATION; AUTOPHAGY
AB Background and Purpose Although protein phosphatases regulate multiple cellular functions, their modulation under hypoxia remains unclear. We investigated expression of the protein phosphatase system under normoxic/hypoxic conditions and the mechanism by which hypoxia alters protein phosphatase 2A (PP2A) activity. Experimental Approach Human cardiovascular cells were cultured in cell type specific media under normoxic or hypoxic conditions (1% O-2). Effects on mRNA expression, phosphatase activity, post-translational modification, and involvement of hypoxia inducible factor 1 alpha (HIF-1 alpha) were assessed using RT-PCR, immunoblotting, an activity assay, and siRNA silencing. Key Results All components of the protein phosphatase system studied were expressed in each cell line. Hypoxia attenuated mRNA expression of the transcripts in a cell line- and time-dependent manner. In human aortic smooth muscle cells (HASMC) and AC16 cells, hypoxia decreased PP2Ac activity and mRNA expression without altering PP2Ac abundance. Hypoxia increased demethylated PP2Ac (DPP2Ac) and phosphatase methylesterase 1 (PME-1) abundance but decreased leucine carboxyl methyltransferase 1 (LCMT-1) abundance. HIF-1 alpha siRNA prevented the hypoxia-mediated decrease in phosphatase activity and expression of the catalytic subunit of protein phosphatase 2A (PPP2CA), independently of altering pPP2Ac, DPP2Ac, LCMT-1, or PME-1 abundance. Conclusion and Implications Cardiovascular cells express multiple components of the PP2A system. In HASMC and AC16 cells, hypoxia inhibits PP2A activity through HIF-1 alpha-dependent and -independent mechanisms, with the latter being consistent with altered PP2A holoenzyme assembly. This indicates a complex inhibitory effect of hypoxia on the PP2A system, and highlights PP2A as a therapeutic target for diseases associated with dysregulated protein phosphorylation.
C1 [Elgenaidi, Ismail Suliman; Spiers, James Paul] Trinity Coll Dublin, Dept Pharmacol & Therapeut, Dublin, Ireland.
RP Spiers, JP (corresponding author), Trinity Coll Dublin, Dept Pharmacol & Therapeut, St Jamess Hosp, Trinity Ctr Hlth Sci, Dublin DO8 W9RT 8, Ireland.
EM paul.spiers@tcd.ie
RI Spiers, Paul/E-6831-2015
OI Spiers, Paul/0000-0003-2635-5056
FU Ministry of Higher Education and Scientific Research/Libya [469/2009]
FX Ministry of Higher Education and Scientific Research/Libya, Grant/Award
   Number: 469/2009
CR Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS272, DOI 10.1111/bph.13877
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS17, DOI 10.1111/bph.13878
   Baharians Z, 1998, J BIOL CHEM, V273, P19019, DOI 10.1074/jbc.273.30.19019
   Bryant JC, 1999, BIOCHEM J, V339, P241, DOI 10.1042/0264-6021:3390241
   CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671
   Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047
   Cho US, 2007, NATURE, V445, P53, DOI 10.1038/nature05351
   Choi H, 2016, AUTOPHAGY, V12, P1631, DOI 10.1080/15548627.2016.1192753
   Cohen PTW, 2002, J CELL SCI, V115, P241
   Cristobal I, 2014, MOL CANCER THER, V13, P938, DOI 10.1158/1535-7163.MCT-13-0150
   Davidson MM, 2005, J MOL CELL CARDIOL, V39, P133, DOI 10.1016/j.yjmcc.2005.03.003
   de la Vega CM, 2002, J NEUROSCI RES, V69, P540, DOI 10.1002/jnr.10306
   DeGrande ST, 2013, J BIOL CHEM, V288, P1032, DOI 10.1074/jbc.M112.426957
   Di Conza G, 2017, CELL REP, V18, P2836, DOI 10.1016/j.celrep.2017.02.081
   Di Conza G, 2017, CELL REP, V18, P1699, DOI 10.1016/j.celrep.2017.01.051
   Everett AD, 1999, J AM SOC NEPHROL, V10, P1737
   Gomes LR, 2017, AUTOPHAGY, V13, P928, DOI 10.1080/15548627.2017.1293767
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Heijman J, 2017, J MOL CELL CARDIOL, V103, P110, DOI 10.1016/j.yjmcc.2016.12.009
   Heijman J, 2013, J MOL CELL CARDIOL, V64, P90, DOI 10.1016/j.yjmcc.2013.09.006
   Herzig S, 2000, PHYSIOL REV, V80, P173, DOI 10.1152/physrev.2000.80.1.173
   Hofstetter CP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030059
   Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026
   Hwang J, 2016, J BIOL CHEM, V291, P21008, DOI 10.1074/jbc.M116.739920
   Jackson TC, 2013, J PHARMACOL EXP THER, V347, P516, DOI 10.1124/jpet.113.206888
   Kirchhefer U, 2014, J BIOL CHEM, V289, P33862, DOI 10.1074/jbc.M114.598938
   Koh MY, 2011, CANCER RES, V71, P4015, DOI 10.1158/0008-5472.CAN-10-4142
   Koh PO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054217
   Krtolica A, 1998, ONCOGENE, V17, P2295, DOI 10.1038/sj.onc.1202159
   Kucera J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4386947
   Larsen KO, 2008, CARDIOVASC RES, V80, P47, DOI 10.1093/cvr/cvn180
   Lee J, 2013, RHEUMATOL INT, V33, P2241, DOI 10.1007/s00296-013-2711-6
   Lee WH, 2018, INT J MOL MED, V42, P2489, DOI 10.3892/ijmm.2018.3851
   Leulliot N, 2004, J BIOL CHEM, V279, P8351, DOI 10.1074/jbc.M311484200
   Little SC, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa5876
   Liu CD, 2016, NEUROBIOL AGING, V45, P76, DOI 10.1016/j.neurobiolaging.2016.05.010
   Longin S, 2007, J BIOL CHEM, V282, P26971, DOI 10.1074/jbc.M704059200
   Lubbers ER, 2016, J MOL CELL CARDIOL, V101, P127, DOI 10.1016/j.yjmcc.2016.11.003
   Luss H, 2000, J MOL CELL CARDIOL, V32, P2349, DOI 10.1006/jmcc.2000.1265
   Matoulkova E, 2012, RNA BIOL, V9, P563, DOI 10.4161/rna.20231
   Mohindra V, 2013, GENE, V530, P127, DOI 10.1016/j.gene.2013.07.042
   Morioka M, 1999, BRAIN RES, V828, P135, DOI 10.1016/S0006-8993(99)01349-9
   Nicolaou P, 2009, J MOL CELL CARDIOL, V47, P365, DOI 10.1016/j.yjmcc.2009.05.010
   Ogris E, 1999, J BIOL CHEM, V274, P14382, DOI 10.1074/jbc.274.20.14382
   Price NE, 2000, BIOCHEMISTRY-US, V39, P11312, DOI 10.1021/bi0008478
   Sangodkar J, 2016, FEBS J, V283, P1004, DOI 10.1111/febs.13573
   Santos CXC, 2016, EMBO J, V35, P319, DOI 10.15252/embj.201592394
   Shen GM, 2010, FEBS LETT, V584, P4366, DOI 10.1016/j.febslet.2010.09.040
   Shi YG, 2009, CELL, V139, P468, DOI 10.1016/j.cell.2009.10.006
   Takai M, 2015, CANCER BIOL THER, V16, P325, DOI 10.1080/15384047.2014.1002362
   Tian HP, 2009, BRAIN INJURY, V23, P1073, DOI 10.3109/02699050903379388
   Truttmann AC, 2004, NEUROSCIENCE, V127, P355, DOI 10.1016/j.neuroscience.2004.05.033
   Tsao CC, 2007, CELL CYCLE, V6, P2377, DOI 10.4161/cc.6.19.4737
   Varadkar P, 2014, DEV DYNAM, V243, P778, DOI 10.1002/dvdy.24111
   Wan X, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184213
   Westermarck J, 2018, FEBS J, V285, P4139, DOI 10.1111/febs.14617
   Wijnker PJM, 2011, J MUSCLE RES CELL M, V32, P221, DOI 10.1007/s10974-011-9261-x
   Wlodarchak N, 2016, CRIT REV BIOCHEM MOL, V51, P162, DOI 10.3109/10409238.2016.1143913
   Wong TY, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110410
   Xing Y, 2006, CELL, V127, P341, DOI 10.1016/j.cell.2006.09.025
   Yao XQ, 2011, BIOCHEM J, V437, P335, DOI 10.1042/BJ20110347
   Zhou Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099665
   Zhu MM, 2015, VASC PHARMACOL, V73, P149, DOI 10.1016/j.vph.2015.06.002
NR 63
TC 5
Z9 5
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD JUN
PY 2019
VL 176
IS 11
BP 1745
EP 1763
DI 10.1111/bph.14648
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HY1FZ
UT WOS:000467862800010
PM 30825189
OA Green Published, Bronze
DA 2022-04-25
ER

PT J
AU Singh, D
   Khan, MA
   Siddique, HR
AF Singh, Deepti
   Khan, Mohammad A.
   Siddique, Hifzur R.
TI Apigenin, A Plant Flavone Playing Noble Roles in Cancer Prevention Via
   Modulation of Key Cell Signaling Networks
SO RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
LA English
DT Review
DE Apigenin; bioavailability; cancer; cell signaling; chemoresistance;
   patents; prevention; therapy
ID HUMAN PROSTATE-CANCER; CYCLE ARREST; COLORECTAL-CANCER; INDUCED
   APOPTOSIS; IN-VITRO; INHIBITS PROLIFERATION; ANTITUMOR-ACTIVITY;
   MOLECULAR TARGETS; AUTOPHAGY; MIGRATION
AB Background: Cancer is a global health problem and the continuous rise in incidence and mortality due to cancer carries a real economic burden to all countries. Accumulation of genetic mutation, exposure of environmental carcinogens and food habits due to change in lifestyles arc the key reasons for cancer. Targeting cancer cells, we need a multitargeting molecule with low/no toxicity.
   Objective: To review the current update of the research status of chemopreventive/therapeutic molecule, Apigenin.
   Methods: Compare the results of the published articles and granted patents on this compound. We also discuss the pros and cons of the present research and future direction.
   Results: Cancer cells have characteristic alterations and dysregulation of various cell signaling pathways that control cell homeostasis, proliferation, motility, and survival in normal cells. Natural tlavonoids are the compounds well known for their anti-inflammatory, anti-oxidant, and anti-cancerous properties. Apigenin, along with several other physiological effects, has a very low intrinsic toxicity and striking effects on the proliferation of cancer cells. Interestingly, this multitargeting molecule is getting wide acceptance among researchers. It is evident from the recent patents filed in this compound. At present, three patents have been granted only on the anticancer properties of apigenin.
   Conclusion: This mini-review will explain the present research status of apigenin and will further shine some light on how apigenin performs its anti-cancerous actions by interfering with the key cell-signaling pathways.
C1 [Singh, Deepti; Khan, Mohammad A.; Siddique, Hifzur R.] Aligarh Muslim Univ, Sect Genet, Mol Canc Genet & Translat Res Lab, Dept Zool, Aligarh 202002, Uttar Pradesh, India.
RP Siddique, HR (corresponding author), Aligarh Muslim Univ, Sect Genet, Mol Canc Genet & Translat Res Lab, Dept Zool, Aligarh 202002, Uttar Pradesh, India.
EM hifzur.zo@amu.ac.in
RI Khan, Anish/X-6117-2019; Khan, Anish/H-6033-2012; Siddique, Hifzur
   R/H-4049-2019
OI Khan, Anish/0000-0002-3806-5956; Khan, Anish/0000-0002-3806-5956;
   Siddique, Hifzur R/0000-0001-8736-0487; KHAN, MOHAMMAD
   AFSAR/0000-0002-6326-1000; SINGH, DEEPTI/0000-0002-4271-2351
FU University Grant Commissions, India [F.30377/2017]; DST-SERB, India
   [EMR/2017/001758]
FX University Grant Commissions, India: Grant no. F.30377/2017(BSR)
   DST-SERB, India: Grant no. EMR/2017/001758.
CR Abrahamsson AE, 2009, P NATL ACAD SCI USA, V106, P3925, DOI 10.1073/pnas.0900189106
   Abu-Yousif AO, 2008, CANCER RES, V68, P3057, DOI 10.1158/0008-5472.CAN-07-2763
   Arjmand F, 2019, COORDIN CHEM REV, V387, P47, DOI 10.1016/j.ccr.2019.02.015
   Baddani M, 2012, ISRN CELL BIOL BASEL, V2012, DOI 10.5402/2012/927064
   Baek B.E., 2016, Method for Improving Anti- cancer Effect of Apigenin by Irradiation and Pharmaceutical Composition for Treating or Preventing Cancer Comprising Irradiated Apigenin, Patent No. [KR20160132185, 20160132185]
   Batra P, 2013, 3 BIOTECH, V3, P439, DOI 10.1007/s13205-013-0117-5
   Bjorklund P, 2007, PLOS MED, V4, P1829, DOI 10.1371/journal.pmed.0040328
   Blackadar CB, 2016, WORLD J CLIN ONCOL, V7, P54, DOI 10.5306/wjco.v7.i1.54
   Budhraja A, 2012, MOL CANCER THER, V11, P132, DOI 10.1158/1535-7163.MCT-11-0343
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Cao HH, 2016, SCI REP-UK, V6, DOI 10.1038/srep21731
   Cao XC, 2013, CHINESE J CANCER RES, V25, P212, DOI 10.3978/j.issn.1000-9604.2013.04.01
   Chen MH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35468
   Cheol-woo K., 2017, Pharmaceutical Compositions for Preventing or Treating Lung Cancer Comprising Apigenin, Curcumin, and Honokiol as Active Ingredients, Patent No. [KR101803000B1, 101803000]
   Cheung M, 2013, CURR CANCER DRUG TAR, V13, P234, DOI 10.2174/1568009611313030002
   Cochran DB, 2016, J BIOMED MATER RES B, V104, P1438, DOI 10.1002/jbm.b.33486
   Coelho PLC, 2016, ANTI-CANCER DRUG, V27, P960, DOI 10.1097/CAD.0000000000000413
   Cohen I., 2010, Patent No. [AU2009289644, 2009289644]
   Constantinescu SN, 2008, TRENDS BIOCHEM SCI, V33, P122, DOI 10.1016/j.tibs.2007.12.002
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Dai J, 2016, TOXICOL APPL PHARM, V311, P106, DOI 10.1016/j.taap.2016.09.016
   De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Ding BY, 2013, J NANOSCI NANOTECHNO, V13, P6546, DOI 10.1166/jnn.2013.7763
   Fulda S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00128
   Gaballah HH, 2017, TOXICOL APPL PHARM, V316, P27, DOI 10.1016/j.taap.2016.12.012
   Galy Olivier, 2011, Hepat Res Treat, V2011, P697162, DOI 10.1155/2011/697162
   Gradolatto A, 2005, DRUG METAB DISPOS, V33, P49, DOI 10.1124/dmd.104.000893
   Gupta S, 2002, ONCOGENE, V21, P3727, DOI 10.1038/sj.onc.1205474
   Gupta S, 2001, BIOCHEM BIOPH RES CO, V287, P914, DOI 10.1006/bbrc.2001.5672
   Gutierrez-Uribe J.A, 2010, Patent No. [US7763292, 7763292]
   Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hasnat MA, 2015, MOLECULES, V20, P21157, DOI 10.3390/molecules201219752
   He B, 2009, Patent No. [US20090304695, 20090304695]
   Hollman PCH, 1999, FREE RADICAL RES, V31, pS75, DOI 10.1080/10715769900301351
   Hu XW, 2008, CARCINOGENESIS, V29, P2369, DOI 10.1093/carcin/bgn244
   Pham H, 2012, PANCREAS, V41, P1306, DOI 10.1097/MPA.0b013e31824d64d9
   Hwa-Jeong C, 2013, Patent No. [KR101334348, 101334348]
   Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2
   Jiang B.H., 2013, Apigenin for chemoprevention, and chemotherapy combined with therapeutic reagents, Patent No. [US8377918, 8377918]
   Kaur P, 2008, CARCINOGENESIS, V29, P2210, DOI 10.1093/carcin/bgn201
   Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1
   Kim EY, 2012, BIOMOL THER, V20, P62, DOI 10.4062/biomolther.2012.20.1.062
   Kim J.W, 2007, Patent No. [WO2007061254, 2007061254]
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Lammi L, 2004, AM J HUM GENET, V74, P1043, DOI 10.1086/386293
   Lee Y, 2014, INT J ONCOL, V44, P1599, DOI 10.3892/ijo.2014.2339
   Lei Z, 2014, Patent No. [CN102441167, 102441167]
   Leopoldini M, 2004, J PHYS CHEM A, V108, P92, DOI 10.1021/jp035901j
   LI C, 2017, ASIA COMMUN PHOTON
   Li CH, 2013, J NUTR BIOCHEM, V24, P1766, DOI 10.1016/j.jnutbio.2013.03.006
   Lim W, 2016, J CELL PHYSIOL, V231, P2690, DOI 10.1002/jcp.25372
   Lin CM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00409-z
   Liu Y, 2004, US Patent, Patent No. [US20040072790A1, 20040072790]
   Liu Y., 2019, Patent No. [CN109824642, 109824642]
   Maggioni D, 2013, INT J ONCOL, V43, P1675, DOI 10.3892/ijo.2013.2072
   Masuelli L, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00373
   Middleton E, 2000, PHARMACOL REV, V52, P673
   Mishra AP, 2018, MOL DIAGN THER, V22, P281, DOI 10.1007/s40291-018-0329-9
   Morales JK, 2010, GENES IMMUN, V11, P599, DOI 10.1038/gene.2010.35
   Mukhtar H, 2010, Patent No. [US20100010078, 20100010078]
   Nakajima N, 2012, Patent No. [JP2012025724, 2012025724]
   Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015
   Oikonomou E, 2005, J NEURO-ONCOL, V73, P205, DOI 10.1007/s11060-004-5232-z
   Rajendran I, 2015, RSC ADV, V5, P51055, DOI 10.1039/c5ra04303d
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Ruela-de-Sousa RR, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.18
   Salehi B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061305
   Sankaranarayanan R, 2014, BMC MED, V12, DOI 10.1186/1741-7015-12-3
   Schwaller J, 2012, HAEMATOL-HEMATOL J, V97, P1783, DOI 10.3324/haematol.2012.080754
   Seo HS, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150165
   Seo HS, 2015, MOL MED REP, V12, P2977, DOI 10.3892/mmr.2015.3698
   Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098
   Shao HJ, 2013, MOL CANCER THER, V12, P2640, DOI 10.1158/1535-7163.MCT-13-0066
   Shukla S, 2006, MOL CANCER THER, V5, P843, DOI 10.1158/1535-7163.MCT-05-0370
   Shukla S, 2007, CANCER RES, V67, P6925, DOI 10.1158/0008-5472.CAN-07-0717
   Shukla S, 2007, CELL CYCLE, V6, P1102, DOI 10.4161/cc.6.9.4146
   Shukla S, 2014, APOPTOSIS, V19, P883, DOI 10.1007/s10495-014-0971-6
   Shukla S, 2014, CARCINOGENESIS, V35, P452, DOI 10.1093/carcin/bgt316
   Shukla S, 2012, PHARM RES-DORDR, V29, P1506, DOI 10.1007/s11095-011-0625-0
   Siddique HR, 2015, HEPATOLOGY, V62, P1466, DOI 10.1002/hep.27987
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Silvan S, 2011, INT J PHARM SCI RES, V2, P1753, DOI 10.13040/IJPSR.0975-8232.2(7).1753-58
   Singh PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031666
   Song K.H., 2018, Patent No. [KR20180132212, 20180132212]
   Suh YA, 2015, INT J ONCOL, V46, P1405, DOI 10.3892/ijo.2014.2808
   Tatsuta M, 2001, CLIN EXP METASTAS, V18, P657
   Tong X, 2013, ANTI-CANCER AGENT ME, V13, P971, DOI 10.2174/18715206113139990119
   Tong X, 2012, MOL CARCINOGEN, V51, P268, DOI 10.1002/mc.20793
   UCKUN FM, 1999, Patent No. 5911995
   Villarino AV, 2015, J IMMUNOL, V194, P21, DOI 10.4049/jimmunol.1401867
   Vorsa N., 2007, U.S. Patent, Patent No. [7,270,837, 7270837]
   Walle T, 2001, A Method of Treating Colon Cancer by Administering Apigenin, Luteolin, Diosmetin and Crysin, Patent No. [WO2001058410, 2001058410]
   Walle UK, 2002, DRUG METAB DISPOS, V30, P564, DOI 10.1124/dmd.30.5.564
   Wang IK, 1999, EUR J CANCER, V35, P1517, DOI 10.1016/S0959-8049(99)00168-9
   Wang Q, 2015, INT IMMUNOPHARMACOL, V27, P24, DOI 10.1016/j.intimp.2015.04.018
   Warsch W, 2013, BLOOD, V122, P2167, DOI 10.1182/blood-2013-02-485573
   Wenzhe M.A, 2017, Patent No. [US9808477, 9808477]
   Willems L, 2012, CURR ONCOL REP, V14, P129, DOI 10.1007/s11912-012-0227-y
   Xu M, 2016, ONCOL LETT, V11, P3075, DOI 10.3892/ol.2016.4331
   Yan XH, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0179-x
   Yang JL, 2018, BIOMED PHARMACOTHER, V103, P699, DOI 10.1016/j.biopha.2018.04.072
   Yang SF, 2017, ONCOL LETT, V13, P1041, DOI 10.3892/ol.2017.5557
   Young C., 2004, U.S. Patent, Patent No. [6,680,342, 6680342]
   Young S.S., 2010, Patent No. [KR20100134966, 20100134966]
   Yuan J., 2012, Patent No. [CN102218052, 102218052]
   Yuen K, 2005, Patent No. [WO2005044291, 2005044291]
   Zakaryan H, 2017, ARCH VIROL, V162, P2539, DOI 10.1007/s00705-017-3417-y
   Zeng X, 2008, DEVELOPMENT, V135, P367, DOI 10.1242/dev.013540
   Zhang L, 2015, FOOD FUNCT, V6, P3464, DOI [10.1039/c5fo00671f, 10.1039/C5FO00671F]
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhao GM, 2017, ONCOL REP, V37, P2277, DOI 10.3892/or.2017.5450
   Zhong Y, 2010, EUR J CANCER, V46, P3365, DOI 10.1016/j.ejca.2010.07.007
   Zhu JL, 2018, ONCOL REP, V40, P1927, DOI 10.3892/or.2018.6599
   Zhu Y, 2015, MOL MED REP, V11, P1004, DOI 10.3892/mmr.2014.2801
   [No title captured]
NR 118
TC 11
Z9 12
U1 4
U2 9
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-8928
EI 2212-3970
J9 RECENT PAT ANTI-CANC
JI Recent Patents Anti-Canc. Drug Discov.
PY 2019
VL 14
IS 4
BP 298
EP 311
DI 10.2174/1574892814666191026095728
PG 14
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA KA1YR
UT WOS:000505595500002
PM 31746310
DA 2022-04-25
ER

PT J
AU Wu, YD
   Liu, F
   Luo, SY
   Yin, XH
   He, DQ
   Liu, JG
   Yue, ZH
   Song, JK
AF Wu, Yadong
   Liu, Feng
   Luo, Siyang
   Yin, Xinhai
   He, Dengqi
   Liu, Jianguo
   Yue, Zhaohui
   Song, Jukun
TI Co-expression of key gene modules and pathways of human breast cancer
   cell lines
SO BIOSCIENCE REPORTS
LA English
DT Article
ID REDUCTASE 3 CBR3; PROGNOSTIC MARKERS; EXPRESSION; REGULATOR; SDR21C2
AB Breast cancer (BC) is the most common leading cause of cancer-related death in women worldwide. Gene expression profiling analysis for human BCs has been studied previously. However, co-expression analysis for BC cell lines is still devoid to date. The aim of the study was to identify key pathways and hub genes that may serve as a biomarker for BC and uncover potential molecular mechanism using weighted correlation network analysis. We analyzed microarray data of BC cell lines (GSE 48213) listed in the Gene Expression Omnibus database. Gene co-expression networks were used to construct and explore the biological function in hub modules using the weighted correlation network analysis algorithm method. Meanwhile, Gene ontology and KEGG pathway analysis were performed using Cytoscape plug-in ClueGo. The network of the key module was also constructed using Cytoscape. A total of 5000 genes were selected, 28 modules of co-expressed genes were identified from the gene co-expression network, one of which was found to be significantly associated with a subtype of BC lines. Functional enrichment analysis revealed that the brown module was mainly involved in the pathway of the autophagy, spliceosome, and mitophagy, the black module was mainly enriched in the pathway of colorectal cancer and pancreatic cancer, and genes in midnightblue module played critical roles in ribosome and regulation of lipolysis in adipocytes pathway. Three hub genes CBR3, SF3B6, and RHPN1 may play an important role in the development and malignancy of the disease. The findings of the present study could improve our understanding of the molecular pathogenesis of breast cancer.
C1 [Wu, Yadong; Luo, Siyang; Yin, Xinhai; Yue, Zhaohui; Song, Jukun] Guizhou Prov Peoples Hosp, Dept Oral & Maxillofacial Surg, Guiyang, Guizhou, Peoples R China.
   [Liu, Feng] Guizhou Prov Peoples Hosp, Dept Ultrason, Guiyang, Guizhou, Peoples R China.
   [He, Dengqi] Lanzphou Univ, Hosp 1, Dept Stomatol, Lanzhou, Gansu, Peoples R China.
   [Liu, Jianguo] Zunyi Med Univ, Stomatol Hosp, Special Key Lab Oral Dis Res, Zunyi, Guizhou, Peoples R China.
RP Yue, ZH; Song, JK (corresponding author), Guizhou Prov Peoples Hosp, Dept Oral & Maxillofacial Surg, Guiyang, Guizhou, Peoples R China.
EM 458085768@qq.com; songjukun@163.com
OI jukun, song/0000-0003-2542-9340
FU Guizhou Science and Technology Cooperation Project [Qiankehe LH
   character [2017] 1110]
FX The work was supported by the Guizhou Science and Technology Cooperation
   Project (Qiankehe LH character [2017] 1110).
CR Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bindea G, 2009, BIOINFORMATICS, V25, P1091, DOI 10.1093/bioinformatics/btp101
   Chang YC, 2012, J MOL MED, V90, P847, DOI 10.1007/s00109-012-0898-8
   Daemen A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r110
   Ebert B, 2010, BIOCHEMISTRY-US, V49, P8499, DOI 10.1021/bi100814d
   Guo YH, 2016, LIFE SCI, V151, P339, DOI 10.1016/j.lfs.2016.02.074
   Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Hertz DL, 2016, PHARMACOGENOMICS, V17, P231, DOI 10.2217/pgs.15.162
   Horvath S, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000117
   Huang H, 2017, J CANCER RES CLIN, V143, P2571, DOI 10.1007/s00432-017-2497-0
   Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]
   Lal MA, 2015, J AM SOC NEPHROL, V26, P647, DOI 10.1681/ASN.2013111195
   Lal S, 2008, CANCER SCI, V99, P2045, DOI 10.1111/j.1349-7006.2008.00903.x
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Langfelder P, 2012, J STAT SOFTW, V46, P1
   Levine AJ, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-4
   Liu XH, 2018, MOL MED REP, V17, P6985, DOI 10.3892/mmr.2018.8756
   Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015
   Malatkova P, 2012, BIOCHEM BIOPH RES CO, V420, P368, DOI 10.1016/j.bbrc.2012.03.002
   Marusyk Andriy, 2010, Biochim Biophys Acta, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002
   McGuire S, 2014, ADV NUTR, V5, P456, DOI 10.3945/an.114.006171
   Miller JA, 2010, P NATL ACAD SCI USA, V107, P12698, DOI 10.1073/pnas.0914257107
   Ohkura-Hada S, 2008, OPEN DENT J, V2, P78, DOI 10.2174/1874210600802010078
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Siebring-van Olst E, 2017, MOL ONCOL, V11, P534, DOI 10.1002/1878-0261.12052
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Tang Y, 2018, J CELL BIOCHEM, V119, P2102, DOI 10.1002/jcb.26372
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   Wan Q, 2018, EXP EYE RES, V166, P13, DOI 10.1016/j.exer.2017.10.007
   Wang XC, 2014, IET SYST BIOL, V8, P47, DOI 10.1049/iet-syb.2013.0041
   Yao DJ, 2017, EUR REV MED PHARMACO, V21, P47
   Yepes S, 2016, GENOMICS, V108, P93, DOI 10.1016/j.ygeno.2016.07.002
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
NR 35
TC 7
Z9 7
U1 3
U2 8
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUL 19
PY 2019
VL 39
AR BSR20181925
DI 10.1042/BSR20181925
PN 7
PG 18
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IK3FK
UT WOS:000476474700001
PM 31285391
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Zimmermann, L
   Moldzio, R
   Vazdar, K
   Krewenka, C
   Pohl, EE
AF Zimmermann, Lars
   Moldzio, Rudolf
   Vazdar, Katarina
   Krewenka, Christopher
   Pohl, Elena E.
TI Nutrient deprivation in neuroblastoma cells alters
   4-hydroxynonenal-induced stress response
SO ONCOTARGET
LA English
DT Article
DE cancer cell metabolism; mitochondrial membrane potential; starvation;
   oxononenal; beta-oxidation
ID LIPID-PEROXIDATION PRODUCT; SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS;
   CANCER-CELLS; MITOCHONDRIAL DYSFUNCTION; COLORECTAL-CANCER; APOPTOSIS;
   METABOLISM; GLUTAMINE; AUTOPHAGY
AB 4-hydroxy-2-nonenal (HNE), a toxic lipid peroxidation product, is associated with oxidative damage in cells and involved in various diseases including the initiation and progression of cancer. Cancer cells have a high, adaptable metabolism with a shift from oxidative phosphorylation to glycolysis and rely on high levels of glucose and glutamine as essential nutrients for cell growth. Here we investigated whether the toxic effects of HNE on the mitochondrial membrane potential (MMP) of cancer cells depends on their metabolic state by deprivation of glucose and/or glutamine. The addition of 16 mu M HNE to N18TG2 neuroblastoma cells incubated in glucose medium led to a severe reduction of MMP, which was similar to the MMP of cells fed with both glucose and glutamine. In contrast, HNE addition to cells starved in glutamine medium increased their MMP slightly for a prolonged time period and this was accompanied by increased cellular survival. We found that beta-oxidation of HNE did not cause the increased MMP, since the aldehyde dehydrogenase was distinctly more active in cells with glucose medium. However, after blocking fatty acid beta-oxidation in cells starved in glutamine medium with etomoxir, which inhibits carnitine palmitoyltransferase 1, HNE addition induced a strong reduction of MMP similar to cells in glucose medium. Surprisingly, the effect of more toxic 4-oxo-2-nonenal was less pronounced. Our results suggest that in contrast to cells fed with glucose, glutamine-fed cancer cells are capable of beta-oxidizing fatty acids to maintain their MMP to combat the toxic effects of HNE.
C1 [Zimmermann, Lars; Pohl, Elena E.] Univ Vet Med, Dept Biomed Sci, Inst Physiol Pathophysiol & Biophys, Vienna, Austria.
   [Moldzio, Rudolf; Krewenka, Christopher] Univ Vet Med, Inst Med Biochem, Dept Biomed Sci, Vienna, Austria.
   [Vazdar, Katarina] Rudjer Boskovic Inst, Div Organ Chem & Biochem, Zagreb, Croatia.
RP Zimmermann, L; Pohl, EE (corresponding author), Univ Vet Med, Dept Biomed Sci, Inst Physiol Pathophysiol & Biophys, Vienna, Austria.
EM lars.zimmermann@vetmeduni.ac.at; elena.pohl@vetmeduni.ac.at
RI Pohl, Elena E./A-4025-2009
OI Pohl, Elena E./0000-0002-0604-5950
FU Austrian Research Fund (FWF)Austrian Science Fund (FWF) [P25123];
   Croatian Science Foundation [UIP-2014-09-6090]; Austrian Science Fund
   (FWF)Austrian Science Fund (FWF) [P 25123] Funding Source: researchfish
FX This work was supported by the Austrian Research Fund (FWF, P25123 to
   E.P.) and Croatian Science Foundation (UIP-2014-09-6090 to KV).
CR Abarikwu SO, 2012, BASIC CLIN PHARMACOL, V110, P441, DOI 10.1111/j.1742-7843.2011.00834.x
   Angelova PR, FREE RADICAL BIOL ME
   Bauer G, 2015, FREE RADICAL BIO MED, V81, P128, DOI 10.1016/j.freeradbiomed.2015.01.010
   Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362
   Boland ML, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00292
   Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8
   Catala A, 2009, CHEM PHYS LIPIDS, V157, P1, DOI 10.1016/j.chemphyslip.2008.09.004
   Chapple SJ, 2013, REDOX BIOL, V1, P319, DOI 10.1016/j.redox.2013.04.001
   Csala M, 2015, BBA-MOL BASIS DIS, V1852, P826, DOI 10.1016/j.bbadis.2015.01.015
   Dalleau S, 2013, CELL DEATH DIFFER, V20, P1615, DOI 10.1038/cdd.2013.138
   Dodson M, 2013, AUTOPHAGY, V9, P1996, DOI 10.4161/auto.26094
   Doorn JA, 2003, CHEM-BIOL INTERACT, V143, P93, DOI 10.1016/S0009-2797(02)00178-3
   Doorn JA, 2002, CHEM RES TOXICOL, V15, P1445, DOI 10.1021/tx025590o
   ESTERBAUER H, 1986, BIOCHEM J, V239, P405, DOI 10.1042/bj2390405
   Faccenda D, 2012, INT J CELL BIOL, V2012
   Fan J, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.65
   Graham NA, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.20
   Grune Tilman, 2003, Molecular Aspects of Medicine, V24, P195, DOI 10.1016/S0098-2997(03)00014-1
   Guichardant M, 1998, FREE RADICAL BIO MED, V25, P1049, DOI 10.1016/S0891-5849(98)00149-X
   Hensley CT, 2013, J CLIN INVEST, V123, P3678, DOI 10.1172/JCI69600
   Hill BG, 2008, BIOCHEM J, V410, P525, DOI 10.1042/BJ20071063
   Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Hu WW, 2002, CARCINOGENESIS, V23, P1781, DOI 10.1093/carcin/23.11.1781
   Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45
   Isono T, 2016, SCI REP-UK, V6, DOI 10.1038/srep25669
   Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012
   Jovanovic O, 2015, FREE RADICAL BIO MED, V89, P1067, DOI 10.1016/j.freeradbiomed.2015.10.422
   Juric-Sekhar G, 2009, TUMORI J, V95, P762
   Kim HK, 2007, AM J PHYSIOL-CELL PH, V293, pC761, DOI 10.1152/ajpcell.00043.2007
   Li L, 2013, CELL SIGNAL, V25, P50, DOI 10.1016/j.cellsig.2012.09.020
   Lin D, 2005, CHEM RES TOXICOL, V18, P1219, DOI 10.1021/tx050080q
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Lushchak Volodymyr I, 2012, J Amino Acids, V2012, P736837, DOI 10.1155/2012/736837
   Malingriaux EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077786
   Martinez-Useros J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0772-5
   Merrill CL, 2002, TOXICOL SCI, V68, P93, DOI 10.1093/toxsci/68.1.93
   Milkovic L, 2015, FREE RADICAL RES, V49, P850, DOI 10.3109/10715762.2014.999056
   Minn I, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4662
   Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9
   Murawaki Y, 2008, CANCER LETT, V259, P218, DOI 10.1016/j.canlet.2007.10.019
   Pfeiffer A, 2014, BRIT J PHARMACOL, V171, P2147, DOI 10.1111/bph.12549
   Picklo MJ, 1999, J NEUROCHEM, V72, P1617, DOI 10.1046/j.1471-4159.1999.721617.x
   Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022
   Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029
   Sayre LM, 2006, DRUG METAB REV, V38, P651, DOI 10.1080/03602530600959508
   Schneider L, 2011, FREE RADICAL BIO MED, V51, P2007, DOI 10.1016/j.freeradbiomed.2011.08.030
   Shanware NP, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5900
   Siems WG, 1997, J LIPID RES, V38, P612
   Simons AL, 2009, J CANCER RES THER, V5, P2, DOI 10.4103/0973-1482.55133
   Singh SP, 2010, J GERONTOL A-BIOL, V65, P14, DOI 10.1093/gerona/glp165
   Skrzydlewska E, 2001, J TOXICOL ENV HEAL A, V64, P213, DOI 10.1080/15287390152543690
   Smathers RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038459
   Soulere L, 2007, CHEM PHYS LIPIDS, V150, P239, DOI 10.1016/j.chemphyslip.2007.07.003
   Srivastava S, 2001, ATHEROSCLEROSIS, V158, P339, DOI 10.1016/S0021-9150(01)00454-3
   Srivastava S, 2001, CHEM-BIOL INTERACT, V130, P563, DOI 10.1016/S0009-2797(00)00299-4
   STROHMAIER H, 1995, J LIPID MEDIAT CELL, V11, P51, DOI 10.1016/0929-7855(94)00027-A
   Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Whitaker-Menezes D, 2011, CELL CYCLE, V10, P4047, DOI 10.4161/cc.10.23.18151
   Xu GZ, 1999, J ORG CHEM, V64, P5732, DOI 10.1021/jo982523j
   Yin HY, 2012, FREE RADICAL RES, V46, P959, DOI 10.3109/10715762.2012.676642
   Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099
NR 62
TC 9
Z9 9
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 31
PY 2017
VL 8
IS 5
BP 8173
EP 8188
DI 10.18632/oncotarget.14132
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EJ5YP
UT WOS:000393295500085
PM 28030790
OA Green Published, gold, Green Submitted
DA 2022-04-25
ER

PT J
AU Gong, XL
   Sun, RB
   Gao, ZW
   Han, WL
   Liu, YW
   Zhao, L
   Jing, LL
   Yao, XQ
   Sun, XG
AF Gong, Xianling
   Sun, Ruibo
   Gao, Zhuowei
   Han, Weili
   Liu, Yawei
   Zhao, Liang
   Jing, Linlin
   Yao, Xueqing
   Sun, Xuegang
TI Tubeimoside 1 Acts as a Chemotherapeutic Synergist via Stimulating
   Macropinocytosis
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE tubeimoside 1; chemotherapeutic synergist; macropinocytosis; methuosis;
   endocytosis
ID NONAPOPTOTIC-CELL-DEATH; CANCER-CELLS; PROGRAMMED NECROSIS; AUTOPHAGY;
   MIGRATION; COMPLEX; HYPERSTIMULATION; PHOSPHORYLATION; INFLAMMATION;
   INHIBITION
AB Macropinocytosis is a highly conserved endocytic process which characterizes the engulfment of extracellular fluid and its contents into cells via large, heterogeneous vacuoles known as macropinosomes. Tubeimoside-1 (TBM1) is a low toxic triterpenoid saponin extracted from a traditional Chinese herb Bolbostemma paniculatum (Maxim.). TBM1 stimulates a quick accumulation of numerous phase-lucent cytoplasmic vacuoles in multiple colorectal cancer (CRC) cell lines. These vacuoles can be termed as macropinosomes that efficiently engulf lucifer yellow. These vesicles are not overlaps with endocytic organelle tracers, such as ERTracker, LysoTracker and mitoTracker. These vacuoles induced by TBM1 partially incorporate into lysosomes. Transmission electron microscope indicates membrane ruffling to form lamellipodia. Protrusions collapse onto and then fuse back with the plasma membrane to generate these large endocytic vacuoles. Notably, TBM1 efficiently trafficks dextrans into heterotopic xenografts in vivo, thus provide consolidated evidence that the vacuolization can be mainly defined as macropinocytosis. TBM1 downregulates cell viability and increases PI-positive, but not highlighted Hoechst 33342-positive cells. TBM1 induced cell death can be ascribed as methuosis by hyperstimulation of macropinocytosis which can be compromised by amiloride derivative 5-(Nethyl-N-isopropyl). Light chain 3 II is recruited to these vesicles to stimulate macropinocytosis. The cell death and vacuoles can be significantly neutralized by chloroquine, but can not be the inhibited by 3-methyladenine. TBM1 can coordinate with 5-FU to exert toxicity reducing and efficacy enhancing effects in vivo by increasing the uptake of the latter without hepatic injury. In conclusion, TBM1 effectively induces in vitro and in vivo macropinocytosis which can traffick small molecules into CRC cells. It is an attractive drug transporter and can be harnessed as a chemotherapeutic synergist with translational potential.
C1 [Gong, Xianling; Sun, Ruibo; Gao, Zhuowei; Yao, Xueqing; Sun, Xuegang] Southern Med Univ, Sch Tradit Chinese Med, State Adm Tradit Chinese Med, Key Lab Mol Biol, Guangzhou, Guangdong, Peoples R China.
   [Gong, Xianling] Guangdong Med Univ, Sch Pharm, Dongguan, Peoples R China.
   [Gao, Zhuowei] Southern Med Univ, Shunde Hosp, Foshan, Peoples R China.
   [Han, Weili] Sch Publ Hlth, Guangzhou, Guangdong, Peoples R China.
   [Liu, Yawei] Southern Med Univ, Nanfang Hosp, Guangzhou, Guangdong, Peoples R China.
   [Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.
   [Jing, Linlin] Southern Med Univ, Tradit Chinese Med Integrated Hosp, Guangzhou, Guangdong, Peoples R China.
RP Sun, XG (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, State Adm Tradit Chinese Med, Key Lab Mol Biol, Guangzhou, Guangdong, Peoples R China.
EM sxg_smu@126.com
RI Zhao, Liang/T-9147-2019
FU National Science Foundation of ChinaNational Natural Science Foundation
   of China (NSFC) [81573848, 81774172]; Guangdong Natural Science
   FoundationNational Natural Science Foundation of Guangdong Province
   [2014A030313323, 2017A030313903]; Combined Science Technology Project of
   Guangdong Provincial Department of Science and Technology
   [2014A020221011]; Guangdong Provincial Academy of Traditional Chinese
   Medicine [2014A020221011]; Planned Science Technology Project of
   Guangzhou [201607010146]; Guangdong Province Bureau of Traditional
   Chinese Medicine Scientific Research Project [20151024, 20161161]
FX This work was supported by the National Science Foundation of China
   (81573848 and 81774172), Guangdong Natural Science Foundation
   (2014A030313323 and 2017A030313903), Combined Science Technology Project
   of Guangdong Provincial Department of Science and Technology and
   Guangdong Provincial Academy of Traditional Chinese Medicine
   (2014A020221011), Planned Science Technology Project of Guangzhou
   (201607010146), and Guangdong Province Bureau of Traditional Chinese
   Medicine Scientific Research Project (Nos. 20151024 and 20161161).
CR Cai Hongbing, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P1844
   Cho Y, 2009, CELL, V137, P1112, DOI 10.1016/j.cell.2009.05.037
   Cingolani F, 2017, J LIPID RES, V58, P1500, DOI 10.1194/jlr.M072611
   Commisso C, 2014, NAT PROTOC, V9, P182, DOI 10.1038/nprot.2014.004
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711
   Diederich M, 2016, SEMIN CANCER BIOL, V40-41, P4, DOI 10.1016/j.semcancer.2016.06.001
   Dolat L, 2016, J CELL BIOL, V214, P517, DOI 10.1083/jcb.201603030
   Florey O, 2011, NAT CELL BIOL, V13, P1335, DOI 10.1038/ncb2363
   Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96
   Galluzzi L, 2008, CELL, V135, P1161, DOI 10.1016/j.cell.2008.12.004
   Henson PM, 2005, CURR BIOL, V15, pR29, DOI 10.1016/j.cub.2004.12.017
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   Li CH, 2013, J NUTR BIOCHEM, V24, P1766, DOI 10.1016/j.jnutbio.2013.03.006
   Lin XC, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-105
   Maltese WA, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00038
   Maltese WA, 2014, AM J PATHOL, V184, P1630, DOI 10.1016/j.ajpath.2014.02.028
   Manara MC, 2016, ONCOTARGET, V7, P79925, DOI 10.18632/oncotarget.13160
   Marques PE, 2017, CELL, V169, P766, DOI 10.1016/j.cell.2017.04.031
   Overmeyer JH, 2008, MOL CANCER RES, V6, P965, DOI 10.1158/1541-7786.MCR-07-2036
   Park JM, 2016, AUTOPHAGY, V12, P547, DOI 10.1080/15548627.2016.1140293
   Qian YR, 2014, CANCER LETT, V351, P242, DOI 10.1016/j.canlet.2014.06.008
   Redelman-Sidi G, 2013, CANCER RES, V73, P1156, DOI 10.1158/0008-5472.CAN-12-1882
   Reyes-Reyes EM, 2010, CANCER RES, V70, P8617, DOI 10.1158/0008-5472.CAN-10-0920
   Seo JW, 2016, SCI REP-UK, V6, DOI 10.1038/srep37594
   Sun L, 2017, J MED CHEM, V60, P6638, DOI 10.1021/acs.jmedchem.7b00592
   Valdivia A, 2017, MOL BIOL CELL, V28, P1768, DOI 10.1091/mbc.E16-06-0412
   Wang Q, 2015, INT IMMUNOPHARMACOL, V27, P24, DOI 10.1016/j.intimp.2015.04.018
   White E, 2013, GENE DEV, V27, P2065, DOI 10.1101/gad.228122.113
   Xu WJ, 2015, ONCOTARGET, V6, P30017, DOI 10.18632/oncotarget.5013
   YU LJ, 1994, PLANTA MED, V60, P204, DOI 10.1055/s-2006-959459
NR 32
TC 10
Z9 11
U1 2
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD SEP 26
PY 2018
VL 9
AR 1044
DI 10.3389/fphar.2018.01044
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GU9EB
UT WOS:000445646400001
PM 30319403
OA gold, Green Published
DA 2022-04-25
ER

PT J
AU Zhu, XH
   Li, SQ
   Huang, C
   Huang, GC
   Xu, J
AF Zhu, Xiaohua
   Li, Shuiqi
   Huang, Chen
   Huang, Gongcheng
   Xu, Jing
TI LncRNA CRNDE inhibits cardiomyocytes apoptosis by YAP1 in myocardial
   ischaemia/reperfusion injury
SO AUTOIMMUNITY
LA English
DT Article
DE Myocardial ischaemia; reperfusion injury; lncRNA CRNDE; YAP1;
   cardiomyocytes apoptosis
ID NONCODING RNA CRNDE; HIPPO PATHWAY; PROLIFERATION; PROTECTS; EXPRESSION;
   AUTOPHAGY; CANCER; CELLS; HEART
AB Background Cardiomyocytes apoptosis is the basic pathological process of myocardial ischaemia/reperfusion (MI/R) injury, so inhibiting apoptosis of cardiomyocytes can effectively improve MI/R injury. Long non-coding RNA colorectal neoplasia differentially expressed (lncRNA CRNDE) can inhibit cell apoptosis, but its specific role in MI/R injury has not been studied. The aim of this study is to explore the specific effect of lncRNA CRNDE on cardiomyocytes apoptosis. Methods MI/R model in vivo and hypoxia/re-oxygenation (H/R) model in vitro were constructed. Apoptotic levels were assessed by TUNEL staining assay. QRT-PCR was used to validate lncRNA CRNDE level in myocardial tissues and HL-1 cells. The protein expressions of YAP1, Bcl-2 and cleaved caspase-3 were detected by western blot analysis. Flow cytometry was used to determine the apoptosis rate of cardiomyocytes. RIP assay was used to detect the interaction between lncRNA CRNDE and YAP1. Results The extent of cardiomyocytes apoptosis was significantly increased, and the levels of lncRNA CRNDE, YAP1 and Bcl-2 were down-regulated, while cleaved caspase-3 expression was up-regulated in MI/R mice and H/R-treated HL-1 cells. The expressions of YAP1 and Bcl-2 were decreased, while the expression of cleaved caspase-3 was increased after the knockdown of lncRNA CRNDE. Furthermore, lncRNA CRNDE could bind to YAP1 and regulated the protein level of YAP1 by ubiquitination and proteasomal degradation pathway. After transfection of Si-YAP1 in the H/R-treated HL-1 cells transfected with pc-DNA CRNDE, the protein level of Bcl-2 was decreased, while cleaved caspase-3 expression and the apoptosis rate were increased. Conclusion Our study suggested that lncRNA CRNDE could regulate YAP1 level by ubiquitination and proteasomal degradation pathway, thus inhibiting cardiomyocytes apoptosis in MI/R injury.
C1 [Zhu, Xiaohua; Huang, Chen; Huang, Gongcheng; Xu, Jing] Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 East Jianshe Rd, Zhengzhou 450052, Peoples R China.
   [Li, Shuiqi] Zhengzhou Univ, Dept Dermatol, Affiliated Hosp 1, Zhengzhou, Peoples R China.
RP Xu, J (corresponding author), Zhengzhou Univ, Dept Cardiovasc Surg, Affiliated Hosp 1, 1 East Jianshe Rd, Zhengzhou 450052, Peoples R China.
EM xujing00111@sina.com
CR Ding J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.328
   Ebadollahi SH, 2021, CELL J, V22, P532, DOI 10.22074/cellj.2021.6902
   Ellis BC, 2014, BBA-MOL CELL RES, V1843, P372, DOI 10.1016/j.bbamcr.2013.10.016
   Ellis Blake C., 2012, Frontiers in Genetics, V3, P270, DOI 10.3389/fgene.2012.00270
   Fan YF, 2019, MED SCI MONITOR, V25, P2745, DOI 10.12659/MSM.913420
   Fu V, 2017, CURR OPIN CELL BIOL, V49, P99, DOI 10.1016/j.ceb.2017.12.012
   Fujita T, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-87
   Gao D, 2017, J CELL BIOCHEM, V118, P3341, DOI 10.1002/jcb.25987
   Graham Lloyd D, 2011, Genes Cancer, V2, P829, DOI 10.1177/1947601911431081
   Hausenloy DJ, 2017, EUR HEART J, V38, P935, DOI 10.1093/eurheartj/ehw145
   Heallen T, 2011, SCIENCE, V332, P458, DOI 10.1126/science.1199010
   Huang JM, 2013, ONCOGENE, V32, P2220, DOI 10.1038/onc.2012.231
   Jiang BM, 2013, CARDIOVASC RES, V99, P92, DOI 10.1093/cvr/cvt085
   Jing XZ, 2018, INT J MOL MED, V42, P1526, DOI 10.3892/ijmm.2018.3734
   Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746
   Khan K, 2019, EXP BIOL MED, V244, P802, DOI 10.1177/1535370219851243
   Liu PD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168767
   Meng YB, 2017, ONCOL RES, V25, P1207, DOI 10.3727/096504017X14886679715637
   Miskinyte S, 2011, AM J HUM GENET, V88, P718, DOI 10.1016/j.ajhg.2011.04.017
   Peng G., 2018, CELL PROLIFERAT, V51
   Quan CJ, 2018, J CELL COMMUN SIGNAL, V12, P549, DOI 10.1007/s12079-017-0406-6
   Roman Madeline G, 2020, Aging Pathobiol Ther, V2, P20, DOI 10.31491/apt.2020.03.009
   Ruan XF, 2017, EXP THER MED, V14, P3523, DOI 10.3892/etm.2017.4964
   Setsuie R, 2007, NEUROCHEM INT, V51, P105, DOI 10.1016/j.neuint.2007.05.007
   Song HX, 2017, BBA-MOL BASIS DIS, V1863, P1893, DOI 10.1016/j.bbadis.2016.11.015
   Wang J, 2017, J DENT RES, V96, P1229, DOI 10.1177/0022034517719886
   Wang JS, 2006, CELL MOL IMMUNOL, V3, P255
   Wang J, 2018, NAT REV CARDIOL, V15, P672, DOI 10.1038/s41569-018-0063-3
   Xiao Yang, 2016, Curr Treat Options Cardiovasc Med, V18, P38, DOI 10.1007/s11936-016-0461-y
   Xue JY, 2019, BASIC RES CARDIOL, V114, DOI 10.1007/s00395-019-0748-8
   Yang F, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.029
   Yang J, 2021, J CELL PHYSIOL, V236, P157, DOI 10.1002/jcp.29831
   Yingchun H., 2016, W CHINA MED J, V31, P06
   Zhai ME, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12419
   Zheng JY, 2019, LIFE SCI, V219, P129, DOI 10.1016/j.lfs.2019.01.014
   Zhu Y, 2020, LIFE SCI, V255, DOI 10.1016/j.lfs.2020.117849
NR 36
TC 0
Z9 0
U1 2
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0891-6934
EI 1607-842X
J9 AUTOIMMUNITY
JI Autoimmunity
PD MAY 19
PY 2021
VL 54
IS 4
BP 204
EP 212
DI 10.1080/08916934.2021.1913580
EA MAY 2021
PG 9
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA SO3QK
UT WOS:000650632500001
PM 33988471
DA 2022-04-25
ER

PT J
AU Slaihim, MM
   Al-Suede, FSR
   Khairuddean, M
   Ahamed, MBK
   Majid, AMSA
AF Slaihim, Mukhlif Mohsin
   Al-Suede, Fouad Saleih R.
   Khairuddean, Melati
   Ahamed, Mohamed B. Khadeer
   Majid, Amin Malik Shah Abdul
TI Synthesis, characterisation of new derivatives with mono ring system of
   1,2,4-triazole scaffold and their anticancer activities
SO JOURNAL OF MOLECULAR STRUCTURE
LA English
DT Article
DE Pyridinium salt; Piperidinium salt; Anticancer activity; MTT assay;
   Anti-proliferation; 1,2,4-Triazole
AB In the present study, two important starting materials and 18 new 1,2,4-triazole compounds with mono ring system have been synthesized and characterized. The mono system showed 16 compounds of a Schiff base moiety attached to the triazole ring which was prepared from the corresponding starting material 5(A-B) or piperidinium salt system 6(A-B). All these compounds were characterized using Fourier Transform Infrared (FT-IR) and Nuclear Magnetic Resonance (NMR) spectroscopy and carbon hydrogen nitrogen (CHN) elemental analysis. The compounds were selected for in vitro anticancer study to test the therapeutic cytotoxic potential against cancer cells. The MIT test was conducted against human breast (MCF-7) and colorectal (HCT-116) cancer cells. Among all the compounds tested, 7A-i demonstrated more pronounced in vitro anticancer effect against MCF-7 and HCT-116 cells with IC50 of 38 and 19.2 mu M, respectively, comparable to that of the standard reference drugs, tamoxifen and 5-fluorouracil, respectively. Compound 7A-vi showed a considerable cytotoxic effect with IC50 53 and 41.2 mu M against MCF-7 and HCT-116 cells, respectively. Compounds 7A-ii, 7A-iii and 7A-v exhibited moderate cytotoxicity with IC50 68, 91 and 85 mu M, respectively against MCF-7 cells and also 59.3, 81.7 and 137.1 mu M against HCT-116 cells, respectively. However, all other compounds tested in this study showed poor cytotoxicity against both the cell lines. Cellular morphological analysis revealed that the cytotoxicity induced by the compounds could probably due to autophagy. It can be concluded that 1,2,4-triazole derivatives can be promising therapeutic agents. Further studies will be done to investigate the antitumor efficacy of the 1,2,4-triazole derivatives using suitable preclinical models. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Slaihim, Mukhlif Mohsin] Samarra Univ, Appl Sci Fac, Samarra, Iraq.
   [Al-Suede, Fouad Saleih R.; Ahamed, Mohamed B. Khadeer] EMAN Biodiscoveries Sdn Bhd, A1-4,Lot 5,Persiaran 2-1,Kedah Halal Pk, Sungai Petani 08000, Kedah, Malaysia.
   [Khairuddean, Melati] Univ Sains Malaysia, Sch Chem Sci, George Town 11800, Malaysia.
   [Majid, Amin Malik Shah Abdul] Univ Sains Malaysia, Sch Pharmaceut Sci, George Town 11800, Malaysia.
   [Majid, Amin Malik Shah Abdul] Australian Natl Univ, John Curtin Sch Med Res, ACRF Dept Canc Biol & Therapeut, Acton, Australia.
   [Majid, Amin Malik Shah Abdul] Eman Res Ltd, Acton, Australia.
RP Khairuddean, M (corresponding author), Univ Sains Malaysia, Sch Chem Sci, George Town 11800, Malaysia.
EM melati@usm.my
RI Alsuede, Fouad Saleih Resq/AAE-6203-2021; Basheer, Mohamed Khadeer
   Ahamed/P-1681-2014; Khairuddean, Melati/B-2622-2018
OI Basheer, Mohamed Khadeer Ahamed/0000-0001-9616-1770; M. Slaihim,
   Mukhlif/0000-0002-6801-4148; Khairuddean, Melati/0000-0001-7280-302X;
   Al-Suede, fouad/0000-0003-1816-6722
FU  [1001/PKIMIA/811332]
FX The authors would like to thank the Universiti Sains Malaysia in
   providing the lab facilities and the finical support under a research
   grant (1001/PKIMIA/811332).
CR Abdel-Rahman R. M., 2011, International Journal of ChemTech Research, V3, P423
   Adan A, 2016, CURR PHARM BIOTECHNO, V17, P1213, DOI 10.2174/1389201017666160808160513
   Al-Suede FSR, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/396016
   Aouad MR, 2017, CHEM CENT J, V11, DOI 10.1186/s13065-017-0347-4
   Arafath MA, 2017, J MOL STRUCT, V1149, P216, DOI 10.1016/j.molstruc.2017.07.092
   Arul K, 2014, EXPERIMENT, V21, P1439
   Asif M., 2014, GLOB J RES REV, V1, P51
   Baumann M, 2011, BEILSTEIN J ORG CHEM, V7, P442, DOI 10.3762/bjoc.7.57
   Bele D.S., 2011, ASIAN J BIOCH PHARM, V1, P38
   Bhat KS, 2009, EUR J MED CHEM, V44, P5066, DOI 10.1016/j.ejmech.2009.09.010
   Bonandi E, 2017, DRUG DISCOV TODAY, V22, P1572, DOI 10.1016/j.drudis.2017.05.014
   CLAXTON GP, 1988, ORG SYNTH, V50-9, P968
   Demirbas N, 2004, TURK J CHEM, V28, P559
   Gupta D, 2015, J ADV PHARM TECHNOL, V6, P141, DOI 10.4103/2231-4040.161515
   Gupta D, 2015, COMPUT THERM SCI, V7, P1, DOI 10.1615/ComputThermalScien.2014011545
   HEINDEL ND, 1980, J HETEROCYCLIC CHEM, V17, P1087, DOI 10.1002/jhet.5570170547
   HIROTA T, 1991, J HETEROCYCLIC CHEM, V28, P257, DOI 10.1002/jhet.5570280209
   Holla BS, 2003, EUR J MED CHEM, V38, P759, DOI 10.1016/S0223-5234(03)00128-4
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Kamel MM, 2014, EUR J MED CHEM, V86, P75, DOI 10.1016/j.ejmech.2014.08.047
   Kaplancikli ZA, 2005, J ENZYM INHIB MED CH, V20, P179, DOI 10.1080/14756360500043471
   Kaur P., 2017, INT RES J PHARM, V8, P10, DOI DOI 10.7897/2230-8407.087112
   Krishna Prasad PullaguraM., 2016, INT J PHARM PHARM SC, V8, P22, DOI DOI 10.22159/IJPPS.2016V8I12.14949
   Martins P, 2015, MOLECULES, V20, P16852, DOI 10.3390/molecules200916852
   Memon AH, 2015, MOLECULES, V20, P14212, DOI 10.3390/molecules200814212
   Muhammad Radzi A. H., 2016, EPIDEMIOLOGY HLTH, V38
   Rajesh K.S., 2012, J CANC RES UPDATES, V1, P129
   Riss T., 2003, CELL NOTES, P6, DOI [10.1200/JCO.2011.36.1360, DOI 10.1200/JCO.2011.36.1360]
   Siddiqui N, 2011, J PHARM BIOALLIED SC, V3, P194, DOI 10.4103/0975-7406.80765
   Skrzydlewska E, 2005, WORLD J GASTROENTERO, V11, P403, DOI 10.3748/wjg.v11.i3.403
   Sliwka L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155772
   Song MX, 2018, J ENZYM INHIB MED CH, V33, P453, DOI 10.1080/14756366.2017.1423068
   Swamy D. K., 2010, J CHEM CHEM PHARM RE, V2, P411
   Sztanke K, 2008, EUR J MED CHEM, V43, P404, DOI 10.1016/j.ejmech.2007.03.033
   Unver Y, 2016, J ENZYM INHIB MED CH, V31, P89, DOI 10.1080/14756366.2016.1206088
NR 35
TC 11
Z9 11
U1 2
U2 11
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-2860
EI 1872-8014
J9 J MOL STRUCT
JI J. Mol. Struct.
PD NOV 15
PY 2019
VL 1196
BP 78
EP 87
DI 10.1016/j.molstruc.2019.06.066
PG 10
WC Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA JA6DB
UT WOS:000487930600008
DA 2022-04-25
ER

PT J
AU Si, LL
   Fu, JN
   Liu, WW
   Hayashi, T
   Nie, YH
   Mizuno, K
   Hattori, S
   Fujisaki, H
   Onodera, S
   Ikejima, T
AF Si, Lingling
   Fu, Jianing
   Liu, Weiwei
   Hayashi, Toshihiko
   Nie, Yuheng
   Mizuno, Kazunori
   Hattori, Shunji
   Fujisaki, Hitomi
   Onodera, Satoshi
   Ikejima, Takashi
TI Silibinin inhibits migration and invasion of breast cancer MDA-MB-231
   cells through induction of mitochondrial fusion
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Silibinin; Mitochondrial fusion; ROS; Migration and invasion;
   Inflammation; MDA-MB-231 cells
ID EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; COLORECTAL-CANCER; ROS;
   APOPTOSIS; FISSION; LPS; DNA; MICROENVIRONMENT; PROLIFERATION
AB Human triple negative breast cancer cells, MDA-MB-231, show typical epithelial to mesenchymal transition associated with cancer progression. Mitochondria play a major role in cancer progression, including metastasis. Changes in mitochondrial architecture affect cellular migration, autophagy and apoptosis. Silibinin is reported to have anti-breast cancer effect. We here report that silibinin at lower concentrations (30-90 mu M) inhibits epithelial to mesenchymal transition (EMT) of MDA-MB-231, by increasing the expression of epithelial marker, E-cadherin, and decreasing the expression of mesenchymal markers, N-cadherin and vimentin. Besides, silibinin inhibition of cell migration is associated with reduction in the protein expression of matrix metalloproteinases 2 and 9 (MMP2 and MMP9) and paxillin. In addition, silibinin treatment increases mitochondrial fusion through down-regulating the expression of mitochondrial fission-associated protein dynamin-related protein 1 (DRP1) and up-regulating the expression of mitochondrial fusion-associated proteins, optic atrophy 1, mitofusin 1 and mitofusin 2. Silibinin perturbed mitochondrial biogenesis via down-regulating the levels of mitochondrial biogenesis regulators including mitochondrial transcription factor A (TFAM), peroxisome proliferator-activated receptor gamma coactivator (PGC1) and nuclear respiratory factor (NRF2). Moreover, DRP1 knockdown or silibinin inhibited cell migration, and MFN1&2 knockdown restored it. Mitochondrial fusion contributes to silibinin's negative effect on cell migration. Silibinin decreased reactive oxygen species (ROS) generation, leading to inhibition of the NLRP3 inflammasome activation. In addition, knockdown of mitofusin 1&2 (MFN 1&2) relieved silibinin-induced inhibition of NLRP3 inflammasome activation. Repression of ROS contributes to the inhibition of the expression of NLRP3, caspase-1 and IL-beta proteins as well as of cell migration. Taken together, our study provides evidence that silibinin impairs mitochondrial dynamics and biogenesis, resulting in reduced migration and invasion of the MDA-MB-231 breast cancer cells.
C1 [Si, Lingling; Fu, Jianing; Liu, Weiwei; Hayashi, Toshihiko; Nie, Yuheng; Ikejima, Takashi] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang 110016, Liaoning, Peoples R China.
   [Hayashi, Toshihiko] Kogakuin Univ, Sch Adv Engn, Dept Chem & Life Sci, 2665-1 Nakanomachi, Hachioji, Tokyo 1920015, Japan.
   [Mizuno, Kazunori; Hattori, Shunji; Fujisaki, Hitomi] Nippi Res Inst Biomatrix, Toride, Ibaraki 3020017, Japan.
   [Onodera, Satoshi] Med Res Inst Curing Mibyo, 1-6-28 Narusedai, Machida, Tokyo 1940042, Japan.
   [Ikejima, Takashi] Shenyang Pharmaceut Univ, Key Lab Computat Chem Based Nat Antitumor Drug Re, Shenyang 110016, Liaoning, Peoples R China.
RP Ikejima, T (corresponding author), Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang 110016, Liaoning, Peoples R China.; Ikejima, T (corresponding author), Shenyang Pharmaceut Univ, Key Lab Computat Chem Based Nat Antitumor Drug Re, Shenyang 110016, Liaoning, Peoples R China.
EM ikejimat@vip.sina.com
RI Mizuno, Kazunori/AAY-7613-2021
OI Mizuno, Kazunori/0000-0003-3354-6264; Ikejima,
   Takashi/0000-0001-8202-9429
FU National Natural Science Foundation of ChinaNational Natural Science
   Foundation of China (NSFC) [81703528]
FX This research was supported by National Natural Science Foundation of
   China (No. 81703528).
CR Arumugam A, 2016, TUMOR BIOL, V37, P6527, DOI 10.1007/s13277-015-4468-x
   Bahat A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07519-w
   Bordon Y, 2018, NAT REV IMMUNOL, V18, P539, DOI 10.1038/s41577-018-0049-8
   Byun HJ, 2017, ONCOL REP, V37, P3270, DOI 10.3892/or.2017.5588
   Caino MC, 2015, P NATL ACAD SCI USA, V112, P8638, DOI 10.1073/pnas.1500722112
   Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877
   Chio IIC, 2017, TRENDS MOL MED, V23, P411, DOI 10.1016/j.molmed.2017.03.004
   Cohen EN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132710
   Dong X, 2017, NEUROSCI LETT, V636, P127, DOI 10.1016/j.neulet.2016.10.054
   El Hasasna H, 2016, SCI REP-UK, V6, DOI 10.1038/srep21144
   Fonseca TB, 2019, NATURE, V570, pE34, DOI 10.1038/s41586-019-1296-y
   Gao Q, 2012, CANCER RES, V72, P3546, DOI 10.1158/0008-5472.CAN-11-4032
   Ham J, 2018, J CELL PHYSIOL, V233, P1638, DOI 10.1002/jcp.26069
   Han XJ, 2015, INT J ONCOL, V46, P691, DOI 10.3892/ijo.2014.2781
   Jiang K, 2015, ONCOL REP, V33, P2711, DOI 10.3892/or.2015.3915
   Jin X, 2019, CLIN TRANSL ONCOL, V21, P1207, DOI 10.1007/s12094-019-02042-w
   Kalemci S, 2015, EXP THER MED, V10, P503, DOI 10.3892/etm.2015.2542
   Kim KW, 2009, NEUROCHEM RES, V34, P1479, DOI 10.1007/s11064-009-9935-6
   Kim TH, 2014, J PHARMACOL EXP THER, V349, P268, DOI 10.1124/jpet.113.207563
   Kolgiri V, 2017, BRAZ J INFECT DIS, V21, P35, DOI 10.1016/j.bjid.2016.09.007
   Lee H, 2016, BIOCHEM SOC T, V44, P1725, DOI 10.1042/BST20160129
   Lee JY, 2014, J CELL SCI, V127, P4954, DOI 10.1242/jcs.157321
   Li HJ, 2017, CELL PHYSIOL BIOCHEM, V44, P2073, DOI 10.1159/000485946
   Li H, 2018, EXCLI J, V17, P302, DOI 10.17179/excli2017-1018
   Li X, 2019, MED SCI MONITOR, V25, P711, DOI 10.12659/MSM.912218
   Liu BB, 2011, FREE RADICAL RES, V45, P835, DOI 10.3109/10715762.2011.580343
   Liu XX, 2017, BIOMED PHARMACOTHER, V92, P429, DOI 10.1016/j.biopha.2017.05.102
   Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027
   Lugus JJ, 2011, J MOL CELL CARDIOL, V51, P885, DOI 10.1016/j.yjmcc.2011.07.023
   Mao WJ, 2016, LASER MED SCI, V31, P1697, DOI 10.1007/s10103-016-2040-6
   Masso-Welch P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010085
   Qiu Y, 2018, ONCOL REP, V39, P138, DOI 10.3892/or.2017.6081
   Seol MA, 2017, ONCOTARGET, V8, P40190, DOI 10.18632/oncotarget.15360
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Si LL, 2019, ARCH BIOCHEM BIOPHYS, V671, P42, DOI 10.1016/j.abb.2019.05.009
   Song XY, 2016, NEUROCHEM RES, V41, P1662, DOI 10.1007/s11064-016-1881-5
   Wang ZW, 2010, CURR STEM CELL RES T, V5, P74, DOI 10.2174/157488810790442813
   West AP, 2017, NAT REV IMMUNOL, V17, P363, DOI 10.1038/nri.2017.21
   Wu YZ, 2014, CANCER LETT, V345, P164, DOI 10.1016/j.canlet.2013.08.014
   Ye K, 2018, J CELL BIOCHEM, V119, P1922, DOI 10.1002/jcb.26353
   Zhang HL, 2017, CARDIOVASC RES, V113, P160, DOI 10.1093/cvr/cvw212
   Zhang JS, 2019, ONCOL REP, V41, P3292, DOI 10.3892/or.2019.7131
   Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494
   Zhong ZY, 2018, NATURE, V560, P198, DOI 10.1038/s41586-018-0372-z
   Zhou Q, 2015, VASC PHARMACOL, V72, P163, DOI 10.1016/j.vph.2015.05.007
NR 45
TC 21
Z9 21
U1 3
U2 14
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JAN
PY 2020
VL 463
IS 1-2
BP 189
EP 201
DI 10.1007/s11010-019-03640-6
EA OCT 2019
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KI4DF
UT WOS:000489917600001
PM 31612353
DA 2022-04-25
ER

PT J
AU Wang, JQ
   Zhang, YB
   Liu, X
   Wang, JZ
   Li, B
   Liu, YK
   Wang, JS
AF Wang, Jiquan
   Zhang, Yingbing
   Liu, Xu
   Wang, Jizhao
   Li, Bin
   Liu, Yongkang
   Wang, Jiansheng
TI Alantolactone enhances gemcitabine sensitivity of lung cancer cells
   through the reactive oxygen species-mediated endoplasmic reticulum
   stress and Akt/GSK3 beta pathway
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE lung cancer cells; apoptosis; cell cycle arrest; endoplasmic reticulum
   stress; Akt; glycogen synthase kinase 3 beta; alantolactone; gemcitabine
   resistance
ID ER STRESS; DEPENDENT APOPTOSIS; GALLBLADDER CANCER; ANTITUMOR-ACTIVITY;
   SIGNALING PATHWAY; BREAST-CANCER; ROS; INDUCTION; AUTOPHAGY; CURCUMIN
AB Lung cancer is one of the leading causes of cancer-associated mortality in China and globally. Gemcitabine (GEM), as a first-line therapeutic drug, has been used to treat lung cancer, but GEM resistance poses a major limitation on the efficacy of GEM chemotherapy. Alantolactone (ALT), a sesquiterpene lactone compound isolated from Inula helenium, has been identified to exert anticancer activity in various types of cancer, including breast, pancreatic, lung squamous and colorectal cancer. However, the underlying mechanisms of the anticancer activity of ALT in lung cancer remain to be fully elucidated. The present study aimed to determine whether ALT enhances the anticancer efficacy of GEM in lung cancer cells and investigated the underlying mechanisms. The cell viability was assessed with a Cell Counting Kit-8 assay. The cell cycle, apoptosis and the level of reactive oxygen species (ROS) were assessed by flow cytometry, and the expression of cell cycle-associated and apoptosis-associated proteins were determined by western blot analysis. The results demonstrated that ALT inhibited cell growth and induced S-phase arrest and cell apoptosis in A549 and NCI-H520 cells. Furthermore, ALT increased the level of ROS, inhibited the Akt/glycogen synthase kinase (GSK)3 beta pathway and induced endoplasmic reticulum (ER) stress in A549 and NCI-H520 cells. Additionally, ALT treatment sensitized lung cancer cells to GEM. Analysis of the molecular mechanisms further revealed that ALT enhanced the anticancer effects of GEM via ROS-mediated activation of the Akt/GSK3 beta and ER stress pathways. In conclusion, combined treatment with ALT and GEM may have potential as a clinical strategy for lung cancer treatment.
C1 [Wang, Jiquan; Zhang, Yingbing] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Radiat Oncol, Xian 710061, Shaanxi, Peoples R China.
   [Liu, Xu; Wang, Jizhao; Wang, Jiansheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Thorac Surg, 277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
   [Li, Bin; Liu, Yongkang] Northwest Univ, Key Lab Resource Biol & Biotechnol Western China, Xian 710069, Shaanxi, Peoples R China.
RP Wang, JS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Thorac Surg, 277 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM wangjsh@mail.xjtu.edu.cn
FU Shaanxi Provincial Education Department [16JK1761]; National Key
   Research and Development Program [2016YFC0905001]; National Natural
   Science Foundation of ChinaNational Natural Science Foundation of China
   (NSFC) [81471710]
FX This study was supported by grants from the Scientific Research Program
   Funded by Shaanxi Provincial Education Department (program no.
   16JK1761), the National Key Research and Development Program (grant. no.
   2016YFC0905001) and the National Natural Science Foundation of China
   (grant. no. 81471710).
CR Abd Razak N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37796-w
   Ahn KI, 2017, BIOSCI TRENDS, V11, P565, DOI 10.5582/bst.2017.01218
   Albuquerque Kamylla Rafaella Sena, 2018, Mediators Inflamm, V2018, P6797924, DOI 10.1155/2018/6797924
   Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157
   Broecker-Preuss M, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0303-8
   Carvajal-Hausdorf D, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0540-1
   Chen W, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0987-9
   Cheng L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/9482018
   Chipurupalli S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030749
   Cui L, 2018, ARCH PHARM RES, V41, P299, DOI 10.1007/s12272-017-0990-2
   Demain AL, 2011, MICROB BIOTECHNOL, V4, P687, DOI 10.1111/j.1751-7915.2010.00221.x
   Ding YS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040558
   FELDMAN MW, 1975, THEOR POPUL BIOL, V7, P197, DOI 10.1016/0040-5809(75)90014-3
   Ge GQ, 2017, BIOL PHARM BULL, V40, P2117, DOI 10.1248/bpb.b17-00463
   Gebregiworgis T, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1452-7
   Geng YD, 2020, NAT PROD RES, V34, P2616, DOI 10.1080/14786419.2018.1544976
   Gregoraszczuk EL, 2015, IRAN J PHARM RES, V14, P1153
   Guo CL, 2018, MAR DRUGS, V16, DOI 10.3390/md16020043
   Hong SW, 2014, APOPTOSIS, V19, P895, DOI 10.1007/s10495-014-0973-4
   Huang H, 2018, CELL PHYSIOL BIOCHEM, V45, P267, DOI 10.1159/000486773
   Huang YF, 2017, ONCOTARGET, V8, P40264, DOI 10.18632/oncotarget.16828
   Ji L, 2017, ONCOTARGET, V8, P112498, DOI 10.18632/oncotarget.22274
   Jia YF, 2015, GENES DIS, V2, P299, DOI 10.1016/j.gendis.2015.07.003
   Jiang Y, 2016, ONCOL LETT, V11, P4203, DOI 10.3892/ol.2016.4511
   Kim C, 2018, NUTRIENTS, V10, DOI 10.3390/nu10081021
   Lai ZQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00936
   Lee SH, 2018, TUBERC RESP DIS SEOU
   Li J, 2013, ONCOL LETT, V5, P440, DOI 10.3892/ol.2012.1017
   Li Y, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/960458
   Li Y, 2014, CELL BIOCHEM BIOPHYS, V70, P1337, DOI 10.1007/s12013-014-0061-y
   Lin CL, 2018, CELL PHYSIOL BIOCHEM, V46, P322, DOI 10.1159/000488433
   Liu FR, 2018, ONCOL REP, V39, P1523, DOI 10.3892/or.2018.6188
   Liu M, 2014, INT J MOL MED, V33, P1451, DOI 10.3892/ijmm.2014.1713
   Liu YK, 2019, ARTIF CELL NANOMED B, V47, P626, DOI 10.1080/21691401.2019.1575229
   Logothetis C, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat3975
   Ma GX, 2016, CHEM-BIOL INTERACT, V253, P1, DOI 10.1016/j.cbi.2016.04.028
   Madhunapantula SV, 2011, CANCER BIOL THER, V12, P1032, DOI 10.4161/cbt.12.12.18442
   Maryam A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06535-y
   Meng LQ, 2018, MED SCI MONITOR, V24, P3710, DOI 10.12659/MSM.907163
   Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584
   Qin JJ, 2018, GENES DIS, V5, P204, DOI 10.1016/j.gendis.2018.07.002
   Seervi M, 2018, BIOMED PHARMACOTHER, V106, P200, DOI 10.1016/j.biopha.2018.06.123
   Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442
   Song XL, 2017, INT J BIOL SCI, V13, P782, DOI 10.7150/ijbs.18732
   Tang Y, 2013, MOL MED REP, V8, P221, DOI 10.3892/mmr.2013.1495
   Teng JP, 2018, EUR REV MED PHARMACO, V22, P3819, DOI 10.26355/eurrev_201806_15266
   Torre LA, 2016, ADV EXP MED BIOL, V893, P1, DOI 10.1007/978-3-319-24223-1_1
   Tuya N, 2017, EXP THER MED, V14, P5767, DOI 10.3892/etm.2017.5286
   Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800
   Wang S, 2016, WSPOLCZESNA ONKOL, V20, P33, DOI 10.5114/wo.2016.58499
   Wang YF, 2018, CHEM-BIOL INTERACT, V290, P44, DOI 10.1016/j.cbi.2018.05.007
   Wang YM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-8
   Wu SJ, 2018, ONCOTARGETS THER, V11, P2593, DOI 10.2147/OTT.S157707
   Xu B, 2015, ONCOL RES, V22, P213, DOI 10.3727/096504015X14386062091398
   Xu Y, 2018, ONCOL LETT, V15, P9117, DOI 10.3892/ol.2018.8522
   Xue ML, 2017, BIOMED PHARMACOTHER, V94, P898, DOI 10.1016/j.biopha.2017.08.013
   Yadav Raj Kumar, 2014, J Cancer Prev, V19, P75, DOI 10.15430/JCP.2014.19.2.75
   Yang QH, 2018, EUR J PHARMACOL, V822, P85, DOI 10.1016/j.ejphar.2018.01.011
   Yang XH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37553-z
   Yao Y, 2015, APOPTOSIS, V20, P1122, DOI 10.1007/s10495-015-1140-2
   Zhang YB, 2019, INT J MOL MED, V43, P1382, DOI 10.3892/ijmm.2019.4057
   Zhao P, 2015, J BIOCHEM MOL TOXIC, V29, P199, DOI 10.1002/jbt.21685
   Zhou GZ, 2018, BIOMED PHARMACOTHER, V103, P391, DOI 10.1016/j.biopha.2018.04.086
NR 63
TC 9
Z9 11
U1 4
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD SEP
PY 2019
VL 44
IS 3
BP 1026
EP 1038
DI 10.3892/ijmm.2019.4268
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA IN5ZZ
UT WOS:000478757000023
PM 31524219
OA Green Published, Green Submitted, hybrid
DA 2022-04-25
ER

PT J
AU Alnuqaydan, AM
   Rah, B
AF Alnuqaydan, Abdullah M.
   Rah, Bilal
TI Comparative assessment of biological activities of different parts of
   halophytic plant Tamarix articulata (T. articulata) growing in Saudi
   Arabia
SO SAUDI JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Tamarix articulata; Antioxidant activity; Antimicrobial activity;
   Antiproliferative activity; Cancer cell
ID ANTIMICROBIAL ACTIVITIES; MEDICINAL-PLANTS; ANTIOXIDANT; EXTRACTS; L.;
   WITHAFERIN; APOPTOSIS; AUTOPHAGY
AB Owing to extremely high salinity and harsh environmental conditions, T. articulata is one of the most abundant wild plants growing in the deserts of Saudi Arabia. Such plants may contain novel compounds to display promising biological activities. Here, in this study, we evaluate the biological activities of methanolic extracts of fresh leaves, dry leaves, stem, and roots of T. articulata. The antioxidant activity was determined by 2, 2-diphenyl-1-picrylhydrazyl (DPPH) and total phenolic and flavonoid content were determined using standard colorimetric methods. Whereas antimicrobial and ant-proliferative activities were determined by standard well-diffusion and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) methods, respectively. Our results demonstrate that all methanolic extracts of T. articulata showed antioxidant activity, however, the methanolic extract of dry leaves exhibits promising antioxidant effect with IC50 value 49.08 +/- 1.98, which was strongly supported by total phenolic (409.92 +/- 6.03 mg GAE/g DW) and flavonoid (177.71 mg QE/g DW) content. Although, antimicrobial activity was also exhibited by all the methanolic extracts, however, methanolic extract of dry leaves exhibits promising antimicrobial activity in Gram-positive bacteria Staphylococcus epidemidis. Furthermore, MTT assay revealed that all methanolic extracts exhibit antiproliferative activity in MCF-7 (breast cancer) and RKO (colorectal cancer) cells with IC50 values ranges from 219 +/- 5.112 mg/ml to 253 +/- 5.231 mg/ml and 220 +/- 4.330 mu g/ml to 325 +/- 6.213 mu g/ml, respectively. However, the most promising antiproliferative effect was displayed by methanolic extract of dry leaves with IC50 values 219 +/- 5.112 mu g/ml and 220 +/- 4.330 mu g/ml, respectively. In summary, these findings provide evidence that T. articulata has promising biological activities and can be used for many pharmaceutical activities in the future. (C) 2020 Published by Elsevier B.V. on behalf of King Saud University.
C1 [Alnuqaydan, Abdullah M.; Rah, Bilal] Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, GPO POB 6666, Buraydah 51452, Saudi Arabia.
RP Alnuqaydan, AM; Rah, B (corresponding author), Qassim Univ, Coll Appl Med Sci, Dept Med Biotechnol, GPO POB 6666, Buraydah 51452, Saudi Arabia.
EM ami.alnuqaydan@qu.edu.sa; b.rah@qu.edu.sa
CR Ahmad I, 2001, J ETHNOPHARMACOL, V74, P113, DOI 10.1016/S0378-8741(00)00335-4
   Alara OR, 2019, J KING SAUD UNIV SCI, V31, P495, DOI 10.1016/j.jksus.2017.05.018
   Alnuqaydan AM, 2020, AM J CANCER RES, V10, P799
   Alnuqaydan AM, 2019, CURR PHARM BIOTECHNO, V20, P285, DOI 10.2174/1389201020666190318120103
   Bag A, 2012, MICROBIOL RES, V167, P352, DOI 10.1016/j.micres.2012.02.005
   BRAND-WILLIAMS W, 1995, FOOD SCI TECHNOL-LEB, V28, P25
   Chanda D, 2012, EUR J PHARM SCI, V47, P988, DOI 10.1016/j.ejps.2012.08.013
   de Fatima Angelo, 2014, Recent Pat Biotechnol, V8, P76, DOI 10.2174/1872208307666131220163108
   de Oliveira AC, 2009, FOOD CHEM, V115, P469, DOI 10.1016/j.foodchem.2008.12.045
   Eberle L., 2018, TRENDS PHYTOCHEM RES, V2, P37
   Ghasemzadeh A, 2011, J MED PLANTS RES, V5, P6697, DOI 10.5897/JMPR11.1404
   Hebi Morad, 2019, Cardiovascular & Hematological Agents in Medicinal Chemistry, V16, P94, DOI 10.2174/1871525717666181211143858
   Hebi M, 2017, J INTEGR MED-JIM, V15, P476, DOI 10.1016/S2095-4964(17)60361-3
   Hebi M, 2017, BIOMED PHARMACOTHER, V87, P230, DOI 10.1016/j.biopha.2016.12.111
   Hogberg LD, 2010, TRENDS PHARMACOL SCI, V31, P509, DOI 10.1016/j.tips.2010.08.002
   Iwara I., 2014, PHARM PHARM, V2014
   Jeong JH, 2010, J KOREAN SOC APPL BI, V53, P33, DOI 10.3839/jksabc.2010.006
   Kasote DM, 2015, INT J BIOL SCI, V11, P982, DOI 10.7150/ijbs.12096
   Ksouri R, 2009, FOOD CHEM TOXICOL, V47, P2083, DOI 10.1016/j.fct.2009.05.040
   Kumar MSY, 2013, FOOD CHEM, V141, P3443, DOI 10.1016/j.foodchem.2013.06.057
   Kumaran A, 2006, FOOD CHEM, V97, P109, DOI 10.1016/j.foodchem.2005.03.032
   Menshawi El., 2013, INT J PHARM PHARM SC, V5, P178
   Mubashir K, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1593-7
   Nascimento GGF, 2000, BRAZ J MICROBIOL, V31, P247
   Patridge E, 2016, DRUG DISCOV TODAY, V21, P204, DOI 10.1016/j.drudis.2015.01.009
   Patwardhan B, 2005, J ETHNOPHARMACOL, V100, P50, DOI 10.1016/j.jep.2005.06.006
   Rah B, 2015, AUTOPHAGY, V11, P314, DOI 10.1080/15548627.2015.1017182
   Rah B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044039
   Rahmani AH, 2014, INT J CLIN EXP MED, V7, P483
   Ramesh N, 2002, J ETHNOPHARMACOL, V79, P129, DOI 10.1016/S0378-8741(01)00352-X
   Samy RP, 1999, J ETHNOPHARMACOL, V66, P235, DOI 10.1016/S0378-8741(99)00038-0
   Shakeel-u-Rehman, 2015, J MED CHEM, V58, P3432, DOI 10.1021/jm501942m
   Sher H, 2010, J MED PLANTS RES, V4, P1853
   Tabet A., 2018, J ADV PHARM ED RES, V8
   Tatsimo Simplice Joel Ndendoung, 2012, BMC Res Notes, V5, P158, DOI 10.1186/1756-0500-5-158
   Wannes WA, 2010, FOOD CHEM TOXICOL, V48, P1362, DOI 10.1016/j.fct.2010.03.002
   Zilla MK, 2014, CHEM-BIOL INTERACT, V224, P100, DOI 10.1016/j.cbi.2014.09.022
NR 37
TC 3
Z9 3
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1319-562X
EI 2213-7106
J9 SAUDI J BIOL SCI
JI Saudi J. Biol. Sci.
PD OCT
PY 2020
VL 27
IS 10
BP 2586
EP 2592
DI 10.1016/j.sjbs.2020.05.028
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA NQ4UB
UT WOS:000570858800013
PM 32994715
OA Green Published, gold
DA 2022-04-25
ER

PT J
AU Juszczak, GR
   Stankiewicz, AM
AF Juszczak, Grzegorz R.
   Stankiewicz, Adrian M.
TI Glucocorticoids, genes and brain function
SO PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Gene; Brain; Glucocorticoids; Cortisol; Corticosterone; Dexamethasone
ID EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; CELL-CYCLE PROGRESSION;
   PYRUVATE-DEHYDROGENASE KINASE; CEREBRAL GLUCOSE-UTILIZATION; CHAIN
   AMINOTRANSFERASE PROTEINS; COLORECTAL-CANCER PROLIFERATION;
   STRESS-INDUCED GLUCOCORTICOIDS; MONO-ADP-RIBOSYLTRANSFERASE; AKT/MTOR
   SIGNALING PATHWAY
AB The identification of key genes in transcriptomic data constitutes a huge challenge. Our review of microarray reports revealed 88 genes whose transcription is consistently regulated by glucocorticoids (GCs), such as cortisol, corticosterone and dexamethasone, in the brain. Replicable transcriptomic data were combined with biochemical and physiological data to create an integrated view of the effects induced by GCs. The most frequently reported genes were Errfi1 and Ddit4. Their up-regulation was associated with the altered transcription of genes regulating growth factor and mTORC1 signaling (Gab1, Tsc22d3, Dusp1, Ndrg2, Ppp5c and Sesn1) and progression of the cell cycle (Ccnd1, Cdkn1a and Cables1). The GC-induced reprogramming of cell function involves changes in the mRNA level of genes responsible for the regulation of transcription (Klf9, Bcl6, Klf15, Tle3, Cxxc5, Litaf, Tle4, Jun, Sox4, Sox2, Sox9, Irf1, Sall2, Nfkbia and Id1) and the selective degradation of mRNA (Tob2). Other genes are involved in the regulation of metabolism (Gpd1, Aldoc and Pdk4), actin cytoskeleton (Myh2, Nedd9, Mical2, Rhou, Arl4d, Osbpl3, Arhgef3, Sdc4, Rdx, Wipf3, Chst1 and Hepacam), autophagy (Eva1a and Plekhf1), vesicular transport (Rhob, Ehd3, Vps37b and Scamp2), gap junctions (Gjb6), immune response (Tiparp, Mertk, Lyve1 and Il6r), signaling mediated by thyroid hormones (Thra and Sult1a1), calcium (Calm2), adrenaline/noradrenaline (Adcy9 and Adra1d), neuropeptide Y (Npy1r) and histamine (Hdc). GCs also affected genes involved in the synthesis of polyamines (Azin1) and taurine (Cdo1). The actions of GCs are restrained by feedback mechanisms depending on the transcription of Sgk1, Fkbp5 and Nr3c1. A side effect induced by GCs is increased production of reactive oxygen species. Available data show that the brain's response to GCs is part of an emergency mode characterized by inactivation of non-core activities, restrained inflammation, restriction of investments (growth), improved efficiency of energy production and the removal of unnecessary or malfunctioning cellular components to conserve energy and maintain nutrient supply during the stress response.
C1 [Juszczak, Grzegorz R.] Inst Genet & Anim Breeding, Dept Anim Behav, Ul Postepu 36A, PL-05552 Jastrzebiec, Magdalenka, Poland.
   [Stankiewicz, Adrian M.] Inst Genet & Anim Breeding, Dept Mol Biol, Ul Postepu 36A, PL-05552 Jastrzebiec, Magdalenka, Poland.
RP Juszczak, GR (corresponding author), Inst Genet & Anim Breeding, Dept Anim Behav, Ul Postepu 36A, PL-05552 Jastrzebiec, Magdalenka, Poland.
EM g.juszczak@ighz.pl
RI Stankiewicz, Adrian/AAD-1363-2021; Juszczak, Grzegorz R/A-1339-2008
OI Stankiewicz, Adrian/0000-0002-2719-6205; Juszczak,
   Grzegorz/0000-0002-0976-6905
FU Polish Ministry of Science and Higher EducationMinistry of Science and
   Higher Education, Poland [N N311 604938]; KNOW (Leading National
   Research Centre) Scientific Consortium "Healthy Animal - Safe Food"
   (decision of Ministry of Science and Higher Education) [05-1/KNOW2/2015]
FX The authors declare no conflicts of interest. This work was supported by
   the Polish Ministry of Science and Higher Education (grant number N N311
   604938) and KNOW (Leading National Research Centre) Scientific
   Consortium "Healthy Animal - Safe Food" (decision of Ministry of Science
   and Higher Education No. 05-1/KNOW2/2015"). The editorial assistance of
   Ewa Pajak is highly appreciated. All authors have approved the final
   article.
CR Aasrum M, 2013, BBA-MOL CELL RES, V1833, P3286, DOI 10.1016/j.bbamcr.2013.10.004
   Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abraham G, 2004, PHARMACOLOGY, V72, P196, DOI 10.1159/000080105
   Abraham I, 1996, BRAIN RES, V733, P56
   Abraham SM, 2006, BIOCHEM SOC T, V34, P1018, DOI 10.1042/BST0341018
   Abramovici H, 2009, MOL BIOL CELL, V20, P2049, DOI 10.1091/mbc.E07-12-1248
   Adachi N, 2015, SCI REP-UK, V5, DOI 10.1038/srep12684
   ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617
   Adeva-Andany MM, 2016, BBA CLIN, V5, P85, DOI 10.1016/j.bbacli.2016.02.001
   Adini I, 2003, GENE DEV, V17, P2721, DOI 10.1101/gad.1134603
   AGIUS L, 1986, BIOCHEM J, V239, P593, DOI 10.1042/bj2390593
   Ahmad S, 2013, BIOCHEMISTRY-US, V52, P1755, DOI 10.1021/bi3014104
   Ahmed S, 2015, J BIOL CHEM, V290, P16824, DOI 10.1074/jbc.M115.660100
   Ahn S, 2014, MOL CELLS, V37, P257, DOI 10.14348/molcells.2014.2384
   Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34
   AKOMPONG T, 1993, ENDOCRINOLOGY, V133, P1963, DOI 10.1210/en.133.5.1963
   Aksoy I, 2007, STEM CELLS, V25, P2996, DOI 10.1634/stemcells.2007-0066
   Aksoy MO, 2002, J ALLERGY CLIN IMMUN, V109, P491, DOI 10.1067/mai.2002.122154
   Alfonso J, 2004, J NEUROSCI RES, V78, P702, DOI 10.1002/jnr.20328
   Allaman I, 2004, J NEUROCHEM, V88, P900, DOI 10.1046/j.1471-4159.2003.02235.x
   Allen D, 2011, J CEREBR BLOOD F MET, V31, P2302, DOI 10.1038/jcbfm.2011.90
   Alm K, 2009, ESSAYS BIOCHEM, V46, P63, DOI [10.1042/BSE0460005, 10.1042/bse0460005]
   Altonsy MO, 2014, J BIOL CHEM, V289, P8231, DOI 10.1074/jbc.M113.545178
   Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5
   Amessou M, 2016, ONCOTARGET, V7, P79189, DOI 10.18632/oncotarget.13008
   Anacker C, 2013, P NATL ACAD SCI USA, V110, P8708, DOI 10.1073/pnas.1300886110
   Anacker C, 2013, NEUROPSYCHOPHARMACOL, V38, P872, DOI 10.1038/npp.2012.253
   Anderson RM, 2016, J COMP NEUROL, V524, P3729, DOI 10.1002/cne.24027
   Andres-Barquin PJ, 2000, HISTOL HISTOPATHOL, V15, P603, DOI 10.14670/HH-15.603
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   Antoni FA, 1998, J NEUROSCI, V18, P9650
   Ard R, 2012, MOL BIOL CELL, V23, P4008, DOI 10.1091/mbc.E12-01-0026
   Arthur WT, 2002, J BIOL CHEM, V277, P42964, DOI 10.1074/jbc.M207401200
   AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286
   Aviello G, 2017, BRIT J PHARMACOL, V174, P1704, DOI 10.1111/bph.13428
   Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002
   Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724
   Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09-134684
   Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200
   Bagamasbad P, 2012, ENDOCRINOLOGY, V153, P5334, DOI 10.1210/en.2012-1303
   Bagamasbad PD, 2015, MOL ENDOCRINOL, V29, P856, DOI 10.1210/me.2014-1349
   Bai D, 2009, INT J CANCER, V125, P2863, DOI 10.1002/ijc.24748
   Bailey D, 2015, PHARMACOL BIOCHEM BE, V133, P57, DOI 10.1016/j.pbb.2015.03.014
   Ball K L, 1997, Prog Cell Cycle Res, V3, P125
   Bargon SD, 2005, BBA-MOL CELL RES, V1746, P143, DOI 10.1016/j.bbamcr.2005.10.008
   Barish GD, 2012, CELL METAB, V15, P554, DOI 10.1016/j.cmet.2012.02.012
   Barnett AC, 2004, J BIOL CHEM, V279, P18799, DOI 10.1074/jbc.M312253200
   Bass MD, 2002, BIOCHEM J, V368, P1, DOI 10.1042/BJ20021228
   Bayeva M, 2012, CELL METAB, V16, P645, DOI 10.1016/j.cmet.2012.10.001
   Beaulieu E, 2011, NAT REV RHEUMATOL, V7, P340, DOI 10.1038/nrrheum.2011.59
   Beazley KE, 2015, ARTERIOSCL THROM VAS, V35, P573, DOI 10.1161/ATVBAHA.114.304393
   Beitner R, 1998, MOL GENET METAB, V64, P161, DOI 10.1006/mgme.1998.2691
   Bellavance MA, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00136
   Ben-Efraim I, 2004, BIOCHEMISTRY-US, V43, P3518, DOI 10.1021/bi0356911
   Berchtold MW, 2014, BBA-MOL CELL RES, V1843, P398, DOI 10.1016/j.bbamcr.2013.10.021
   Berger P, 2011, J CELL MOL MED, V15, P307, DOI 10.1111/j.1582-4934.2009.00967.x
   Bertolo C, 2013, BRIT J HAEMATOL, V162, P621, DOI 10.1111/bjh.12440
   Binder EB, 2009, PSYCHONEUROENDOCRINO, V34, P99, DOI [10.1016/j.psyneuen.2008.08.018, 10.1016/j.psyneuen.2009.05.021]
   Binet R, 2009, CANCER RES, V69, P9183, DOI 10.1158/0008-5472.CAN-09-1016
   Birben E, 2012, WORLD ALLERGY ORGAN, V5, P9, DOI 10.1097/WOX.0b013e3182439613
   Bixel MG, 1997, J HISTOCHEM CYTOCHEM, V45, P685, DOI 10.1177/002215549704500506
   Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131
   Blecharz KG, 2008, J CEREBR BLOOD F MET, V28, P1139, DOI 10.1038/jcbfm.2008.2
   Bobulescu IA, 2005, AM J PHYSIOL-RENAL, V289, pF685, DOI 10.1152/ajprenal.00447.2004
   Bohrer C, 2015, EMBO J, V34, P2804, DOI 10.15252/embj.201591118
   Boku S, 2009, NEUROPSYCHOPHARMACOL, V34, P805, DOI 10.1038/npp.2008.198
   Bose R, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.159
   Bose R, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.60
   Bradbury P, 2014, J BIOL CHEM, V289, P24792, DOI 10.1074/jbc.M113.544106
   Britto FA, 2014, AM J PHYSIOL-ENDOC M, V307, pE983, DOI 10.1152/ajpendo.00234.2014
   Brown AM, 2007, GLIA, V55, P1263, DOI 10.1002/glia.20557
   Brown AM, 2015, METAB BRAIN DIS, V30, P233, DOI 10.1007/s11011-014-9588-2
   Budanou AV, 2010, EMBO MOL MED, V2, P388, DOI 10.1002/emmm.201000097
   Budanov AV, 2011, ANTIOXID REDOX SIGN, V15, P1679, DOI 10.1089/ars.2010.3530
   Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569
   BUGAJSKI J, 1981, AGENTS ACTIONS, V11, P147, DOI 10.1007/BF01991485
   Bushell KN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025849
   Cai BS, 2016, P NATL ACAD SCI USA, V113, P6526, DOI 10.1073/pnas.1524292113
   Campbell EL, 2014, IMMUNITY, V40, P66, DOI 10.1016/j.immuni.2013.11.020
   Campeau S, 2010, BRAIN RES, V1323, P109, DOI 10.1016/j.brainres.2010.01.084
   Cao CH, 2008, MOL BIOL CELL, V19, P3334, DOI 10.1091/mbc.E08-04-0367
   Carloto A, 2006, BBA-GEN SUBJECTS, V1760, P1545, DOI 10.1016/j.bbagen.2006.06.003
   Carter BS, 2012, PHYSIOL GENOMICS, V44, P1188, DOI 10.1152/physiolgenomics.00097.2012
   Castro-Vale I, 2016, NEUROSCI BIOBEHAV R, V63, P143, DOI 10.1016/j.neubiorev.2016.02.005
   Cattaneo A, 2016, J STEROID BIOCHEM, V160, P169, DOI 10.1016/j.jsbmb.2015.07.021
   Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Ceccarelli M, 2015, DEV BIOL, V408, P109, DOI 10.1016/j.ydbio.2015.10.007
   Cha HH, 1998, J BIOL CHEM, V273, P1998, DOI 10.1074/jbc.273.4.1998
   Chabaud M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8526
   Chakravarthy B, 2008, BIOCHEM BIOPH RES CO, V371, P679, DOI 10.1016/j.bbrc.2008.04.119
   Champeil-Potokar G, 2016, J NEUROCHEM, V136, P1155, DOI 10.1111/jnc.13510
   Chantong B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-260
   Chatterjee S, 2013, GLIA, V61, P2050, DOI 10.1002/glia.22576
   Chen JC, 2016, PHYSIOL REV, V96, P1025, DOI 10.1152/physrev.00030.2015
   Chen KC, 2013, ENDOCRINOLOGY, V154, P2807, DOI 10.1210/en.2013-1139
   Chen S, 2011, NEUROREPORT, V22, P660, DOI 10.1097/WNR.0b013e32834a282a
   Chen WQ, 2013, AM J PHYSIOL-ENDOC M, V304, pE770, DOI 10.1152/ajpendo.00523.2012
   Chen YX, 2006, J STEROID BIOCHEM, V101, P179, DOI 10.1016/j.jsbmb.2006.06.030
   Chen YF, 2015, BIOCHEM BIOPH RES CO, V462, P208, DOI 10.1016/j.bbrc.2015.04.117
   Chetty S, 2014, MOL PSYCHIATR, V19, P1275, DOI 10.1038/mp.2013.190
   Childs AC, 2003, CELL MOL LIFE SCI, V60, P1394, DOI 10.1007/s00018-003-2332-4
   Choi YJ, 2016, ONCOTARGET, V7, P52685, DOI 10.18632/oncotarget.10943
   Chuang YY, 2007, J CELL SCI, V120, P1927, DOI 10.1242/jcs.03456
   Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776
   Ciani L, 2011, P NATL ACAD SCI USA, V108, P10732, DOI 10.1073/pnas.1018132108
   Claessens SEF, 2012, BRAIN RES, V1482, P1, DOI 10.1016/j.brainres.2012.08.017
   Clark AR, 2003, J ENDOCRINOL, V178, P5, DOI 10.1677/joe.0.1780005
   Colvin ES, 2013, ENDOCRINOLOGY, V154, P1039, DOI 10.1210/en.2012-1923
   Connaughton S, 2010, MOL CELL ENDOCRINOL, V315, P159, DOI 10.1016/j.mce.2009.08.011
   Cook I, 2015, BIOCHEMISTRY-US, V54, P6114, DOI 10.1021/acs.biochem.5b00406
   CORDER R, 1988, LIFE SCI, V43, P1879, DOI 10.1016/S0024-3205(88)80005-5
   COSI C, 1993, NEUROREPORT, V4, P527, DOI 10.1097/00001756-199305000-00016
   Costello LC, 2004, J INORG BIOCHEM, V98, P664, DOI 10.1016/j.jinorgbio.2004.02.005
   Crossin KL, 1997, P NATL ACAD SCI USA, V94, P2687, DOI 10.1073/pnas.94.6.2687
   Crudo A, 2013, ENDOCRINOLOGY, V154, P1168, DOI 10.1210/en.2012-1980
   Cruz F, 1999, NMR BIOMED, V12, P451, DOI 10.1002/(SICI)1099-1492(199911)12:7<451::AID-NBM571>3.0.CO;2-E
   Curran J, 2014, CIRC RES, V115, P68, DOI 10.1161/CIRCRESAHA.115.304149
   Dadke D, 2006, MOL BIOL CELL, V17, P1204, DOI 10.1091/mbc.E05-03-0237
   Dahl E, 1996, J BIOL CHEM, V271, P17903, DOI 10.1074/jbc.271.30.17903
   Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185
   Dance M, 2006, J BIOL CHEM, V281, P23285, DOI 10.1074/jbc.M600987200
   Dantzer R, 2001, BRAIN BEHAV IMMUN, V15, P7, DOI 10.1006/brbi.2000.0613
   Datson NA, 2011, ENDOCRINOLOGY, V152, P3749, DOI 10.1210/en.2011-0287
   Datson NA, 2001, EUR J NEUROSCI, V14, P675, DOI 10.1046/j.0953-816x.2001.01685.x
   Datson NA, 2013, ENDOCRINOLOGY, V154, P3261, DOI 10.1210/en.2012-2233
   Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200
   Day HEW, 2008, BRAIN RES, V1218, P132, DOI 10.1016/j.brainres.2008.04.067
   De Bosscher K, 2003, ENDOCR REV, V24, P488, DOI 10.1210/er.2002-0006
   de Kloet ER, 2013, EUR J PHARMACOL, V719, P53, DOI 10.1016/j.ejphar.2013.04.053
   de Quervain D, 2017, NAT REV NEUROSCI, V18, P7, DOI 10.1038/nrn.2016.155
   deLeon MJ, 1997, J CLIN ENDOCR METAB, V82, P3251, DOI 10.1210/jcem.82.10.4305
   Dell'Accio F, 2008, ARTHRITIS RHEUM-US, V58, P1410, DOI 10.1002/art.23444
   Dennis MD, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005103
   Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006
   Di Meco A, 2016, MOL PSYCHIATR, V21, P403, DOI 10.1038/mp.2015.78
   Di Noia MA, 2014, J BIOL CHEM, V289, P33137, DOI 10.1074/jbc.M114.610808
   Dolga AM, 2013, J BIOL CHEM, V288, P10792, DOI 10.1074/jbc.M113.453522
   Dong XP, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1037
   DOYLE P, 1994, BRAIN RES, V645, P225, DOI 10.1016/0006-8993(94)91655-1
   Dransfield I, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.18
   Du HF, 2015, CANCER BIOL THER, V16, P1502, DOI 10.1080/15384047.2015.1071732
   Du J, 2009, P NATL ACAD SCI USA, V106, P3543, DOI 10.1073/pnas.0812671106
   Duan B, 2011, J NEUROSCI, V31, P2101, DOI 10.1523/JNEUROSCI.4351-10.2011
   Dugas JC, 2012, MOL CELL NEUROSCI, V50, P45, DOI 10.1016/j.mcn.2012.03.007
   Duque ED, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00078
   Dwivedi Y, 2000, J PHARMACOL EXP THER, V295, P244
   Eastman SW, 2005, J BIOL CHEM, V280, P628, DOI 10.1074/jbc.M410384200
   Elfenbein A, 2013, J CELL SCI, V126, P3799, DOI 10.1242/jcs.124636
   Elhamdani A, 2000, J NEUROSCI, V20, P2495
   Escobar D, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.165
   Essenfelder GM, 2005, GENE, V350, P33, DOI 10.1016/j.gene.2004.12.048
   Estrada C, 2006, CONT NEUROS, P265, DOI 10.1007/978-1-59745-021-8_20
   Eva C, 2006, FRONT NEUROENDOCRIN, V27, P308, DOI 10.1016/j.yfrne.2006.07.002
   Evangelisti C, 2010, CELL CYCLE, V9, P384, DOI 10.4161/cc.9.2.10469
   Evangelisti C, 2009, CELL SIGNAL, V21, P801, DOI 10.1016/j.cellsig.2009.01.027
   Ezzeddine N, 2012, MOL CELL BIOL, V32, P1089, DOI 10.1128/MCB.06370-11
   Fagerli UM, 2011, ONCOGENE, V30, P3198, DOI 10.1038/onc.2011.79
   Favre C, 2010, ONCOGENE, V29, P3964, DOI 10.1038/onc.2010.146
   Feldman JD, 1998, J BIOL CHEM, V273, P16535, DOI 10.1074/jbc.273.26.16535
   Feng M, 2011, ONCOGENE, V30, P2242, DOI 10.1038/onc.2010.602
   Fernandez-Borja M, 2005, J CELL SCI, V118, P2661, DOI 10.1242/jcs.02384
   Filippakopoulos P, 2010, J MOL BIOL, V401, P389, DOI 10.1016/j.jmb.2010.06.017
   Fiorini M, 2002, ONCOGENE, V21, P6530, DOI 10.1038/sj.onc.1205823
   Fjorback AW, 2011, BIOCHEM BIOPH RES CO, V406, P165, DOI 10.1016/j.bbrc.2011.01.069
   Fletcher DA, 2010, NATURE, V463, P485, DOI 10.1038/nature08908
   Flugge G, 2014, CELL TISSUE RES, V357, P31, DOI 10.1007/s00441-014-1837-5
   Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179
   Frank MG, 2007, PSYCHONEUROENDOCRINO, V32, P376, DOI 10.1016/j.psyneuen.2007.02.001
   Frank MG, 2013, BRAIN BEHAV IMMUN, V33, P1, DOI 10.1016/j.bbi.2013.02.004
   Frosi Y, 2010, J CELL BIOL, V189, P557, DOI 10.1083/jcb.201002032
   Fujisawa S, 2005, ANTICANCER RES, V25, P965
   Fukumoto K, 2009, MOL PSYCHIATR, V14, P1119, DOI 10.1038/mp.2009.60
   Galloway A, 2016, SCIENCE, V352, P453, DOI 10.1126/science.aad5978
   Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9
   GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205
   Gao YZ, 2011, J APPL GENET, V52, P451, DOI 10.1007/s13353-011-0050-4
   Garabuczi E, 2015, BBA-MOL CELL RES, V1853, P573, DOI 10.1016/j.bbamcr.2014.12.014
   Garcia-Sainz JA, 2004, EUR J PHARMACOL, V500, P113, DOI 10.1016/j.ejphar.2004.07.016
   Garza JC, 2012, MOL PSYCHIATR, V17, P790, DOI 10.1038/mp.2011.161
   Gauer S, 2007, NEPHROL DIAL TRANSPL, V22, P3154, DOI 10.1093/ndt/gfm410
   Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024
   Gil-Ibanez P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091692
   GILAD GM, 1994, BRAIN RES, V636, P187, DOI 10.1016/0006-8993(94)91016-2
   Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249
   Giridharan SSP, 2012, J CELL SCI, V125, P614, DOI 10.1242/jcs.089367
   Gosejacob D, 2011, GLIA, V59, P511, DOI 10.1002/glia.21120
   GOULD E, 1990, NEUROSCIENCE, V37, P367, DOI 10.1016/0306-4522(90)90407-U
   Gray JD, 2014, MOL PSYCHIATR, V19, P1171, DOI 10.1038/mp.2013.175
   Guan P, 2014, NUTRITION, V30, P968, DOI 10.1016/j.nut.2013.12.016
   Guimaraes S, 2001, PHARMACOL REV, V53, P319
   Haas HL, 2008, PHYSIOL REV, V88, P1183, DOI 10.1152/physrev.00043.2007
   Hacker BM, 1998, GENOMICS, V50, P97, DOI 10.1006/geno.1998.5293
   Hacker C, 2010, GROWTH FACTORS, V28, P178, DOI 10.3109/08977190903578660
   Hagimoto S, 2013, NEUROSCI LETT, V553, P165, DOI 10.1016/j.neulet.2013.08.040
   Halim ND, 2010, GLIA, V58, P1168, DOI 10.1002/glia.20996
   HALL TR, 1993, J BIOL CHEM, V268, P3092
   Hamon L, 2016, BIOESSAYS, V38, P498, DOI 10.1002/bies.201500195
   Han W, 2012, CANCER LETT, V318, P124, DOI 10.1016/j.canlet.2012.01.011
   HART BL, 1988, NEUROSCI BIOBEHAV R, V12, P123, DOI 10.1016/S0149-7634(88)80004-6
   HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015
   Hausrat TJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7872
   Helene R, 2016, INT J BIOCHEM CELL B, V71, P102, DOI 10.1016/j.biocel.2015.12.014
   Henmi Y, 2016, EXP CELL RES, V342, P1, DOI 10.1016/j.yexcr.2016.02.011
   HERMANGNJIDIC Z, 1994, AM J OBSTET GYNECOL, V171, P1651, DOI 10.1016/0002-9378(94)90417-0
   Hertel M, 2000, EUR J NEUROSCI, V12, P376, DOI 10.1046/j.1460-9568.2000.00930.x
   Higgins SC, 2010, ANTICANCER RES, V30, P391
   Hinkerohe D, 2011, J NEURO-ONCOL, V103, P479, DOI 10.1007/s11060-010-0456-6
   Ho HYH, 2001, P NATL ACAD SCI USA, V98, P11306, DOI 10.1073/pnas.211420498
   Ho LJ, 2015, BIOCHEM PHARMACOL, V97, P16, DOI 10.1016/j.bcp.2015.06.009
   Hoeflich KP, 2004, INT J BIOCHEM CELL B, V36, P2131, DOI 10.1016/j.biocel.2003.11.018
   Hong NH, 2015, J CELL BIOL, V210, P753, DOI 10.1083/jcb.201412127
   Hoppstadter J, 2015, ONCOTARGET, V6, P38446, DOI 10.18632/oncotarget.6197
   HORNER HC, 1990, NEUROENDOCRINOLOGY, V52, P57
   Hoshino H, 2014, J HISTOCHEM CYTOCHEM, V62, P145, DOI 10.1369/0022155413511619
   Howell KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020198
   Hu JY, 2016, AUTEX RES J, V16, P7, DOI 10.1515/aut-2015-0048
   Hu S, 2015, AM J CANCER RES, V5, P651
   Hu W, 2016, ONCOTARGET, V7, P209, DOI 10.18632/oncotarget.6228
   Huang BL, 2002, DIABETES, V51, P276, DOI 10.2337/diabetes.51.2.276
   Huang CX, 2013, NAT IMMUNOL, V14, P380, DOI 10.1038/ni.2543
   Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001
   Huang SY, 2015, CANCER LETT, V356, P547, DOI 10.1016/j.canlet.2014.10.007
   Hubler TR, 2004, CELL STRESS CHAPERON, V9, P243, DOI 10.1379/CSC-32R.1
   Hull J, 2015, J NEUROSCI RES, V93, P987, DOI 10.1002/jnr.23558
   Hull J, 2012, J NEUROCHEM, V123, P997, DOI 10.1111/jnc.12044
   Hunt MC, 2002, PROG LIPID RES, V41, P99, DOI 10.1016/S0163-7827(01)00017-0
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Hunter RG, 2016, P NATL ACAD SCI USA, V113, P9099, DOI 10.1073/pnas.1602185113
   Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215
   Iacomino G, 2012, BBA-MOL CELL RES, V1823, P1745, DOI 10.1016/j.bbamcr.2012.05.033
   Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719
   IENTILE R, 1988, J NEUROCHEM, V51, P677, DOI 10.1111/j.1471-4159.1988.tb01797.x
   IIZUKA H, 1983, J INVEST DERMATOL, V80, P524, DOI 10.1111/1523-1747.ep12535121
   Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018
   Ing NH, 2014, J STEROID BIOCHEM, V143, P451, DOI 10.1016/j.jsbmb.2014.07.003
   Ioannidis JPA, 2005, LANCET, V365, P454, DOI 10.1016/S0140-6736(05)17878-7
   Ishisaka M, 2014, J PHARMACOL SCI, V124, P336, DOI 10.1254/jphs.13R07CR
   Ismail F. S., 2016, J NEUROONCOL
   Iuchi T, 2003, CIRC RES, V92, P81, DOI 10.1161/01.RES.0000050588.35034.3C
   Iwakura Y, 2011, J NEUROCHEM, V118, P57, DOI 10.1111/j.1471-4159.2011.07295.x
   Janne J, 2006, J BIOCHEM, V139, P155, DOI 10.1093/jb/mvj035
   Janne J, 2004, EUR J BIOCHEM, V271, P877, DOI 10.1111/j.1432-1033.2004.04009.x
   JAZAYERI A, 1988, HYPERTENSION, V12, P393, DOI 10.1161/01.HYP.12.4.393
   Jenkins SI, 2014, ACS CHEM NEUROSCI, V5, P51, DOI 10.1021/cn400167n
   Jiang Z, 2014, J CELL PHYSIOL, V229, P384, DOI 10.1002/jcp.24460
   Joels M, 2012, PHARMACOL REV, V64, P901, DOI 10.1124/pr.112.005892
   Joha S, 2012, ONCOGENE, V31, P1419, DOI 10.1038/onc.2011.328
   Jorgensen EA, 2007, NEUROENDOCRINOLOGY, V86, P210, DOI 10.1159/000108341
   Jurkowska H, 2015, AMINO ACIDS, V47, P1215, DOI 10.1007/s00726-015-1948-7
   Juszczak GR, 2008, BRAIN BEHAV IMMUN, V22, P74, DOI 10.1016/j.bbi.2007.06.007
   Juszczak GR, 2013, GAP JUNCTIONS IN THE BRAIN: PHYSIOLOGICAL AND PATHOLOGICAL ROLES, P261, DOI 10.1016/B978-0-12-415901-3.00016-5
   Juszczak GR, 2009, PROG NEURO-PSYCHOPH, V33, P181, DOI 10.1016/j.pnpbp.2008.12.014
   KADEKARO M, 1988, NEUROENDOCRINOLOGY, V47, P329, DOI 10.1159/000124933
   Kahl CR, 2003, ENDOCR REV, V24, P719, DOI 10.1210/er.2003-0008
   Kalafatakis K, 2016, NEUROSCI BIOBEHAV R, V61, P12, DOI 10.1016/j.neubiorev.2015.11.009
   Karst H, 2000, NAT NEUROSCI, V3, P977, DOI 10.1038/79910
   Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045
   Kelner MJ, 2000, J BIOL CHEM, V275, P13000, DOI 10.1074/jbc.275.17.13000
   Khurana S, 2008, FEBS LETT, V582, P2128, DOI 10.1016/j.febslet.2008.02.040
   Kim A, 2009, CARCINOGENESIS, V30, P927, DOI 10.1093/carcin/bgp072
   Kim J, 2016, BIOSCI BIOTECH BIOCH, V80, P2093, DOI 10.1080/09168451.2016.1210502
   Kim K, 2009, EMBO J, V28, P1170, DOI 10.1038/emboj.2009.44
   Kim YJ, 2009, INT J CANCER, V124, P7, DOI 10.1002/ijc.23945
   Kimura M, 2011, BIOL PHARM BULL, V34, P682, DOI 10.1248/bpb.34.682
   Kinker GS, 2016, SCI REP-UK, V6, DOI 10.1038/srep24160
   Kiyatkin A, 2006, J BIOL CHEM, V281, P19925, DOI 10.1074/jbc.M600482200
   Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131
   Klement JF, 1996, MOL CELL BIOL, V16, P2341
   Klengel T, 2013, NAT NEUROSCI, V16, P33, DOI 10.1038/nn.3275
   KLEPAC R, 1985, EXP CLIN ENDOCRINOL, V86, P305, DOI 10.1055/s-0029-1210502
   Knoedler JR, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-3640-7
   Knutson DC, 2016, BRAIN RES, V1632, P141, DOI 10.1016/j.brainres.2015.12.005
   Kolben T, 2012, BIOL CHEM, V393, P1433, DOI 10.1515/hsz-2012-0186
   Komatsuzaki Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034124
   Kominsky DJ, 2010, J IMMUNOL, V184, P4062, DOI 10.4049/jimmunol.0903002
   Koukouritaki SB, 1999, MOL MED, V5, P731, DOI 10.1007/BF03402097
   Kozaki T, 2017, P NATL ACAD SCI USA, V114, P2681, DOI 10.1073/pnas.1621508114
   Kozyreva VK, 2014, MOL CANCER RES, V12, P681, DOI 10.1158/1541-7786.MCR-13-0654
   Kubota S, 2015, CLIN SCI, V128, P181, DOI 10.1042/CS20140264
   Kuhn HG, 1997, J NEUROSCI, V17, P5820
   Kumamaru E, 2011, FEBS LETT, V585, P3224, DOI 10.1016/j.febslet.2011.09.010
   Kunzelmann P, 1999, GLIA, V25, P111, DOI 10.1002/(SICI)1098-1136(19990115)25:2<111::AID-GLIA2>3.0.CO;2-I
   Kuo T, 2015, ADV EXP MED BIOL, V872, P99, DOI 10.1007/978-1-4939-2895-8_5
   Kurosu T, 2003, ONCOGENE, V22, P4459, DOI 10.1038/sj.onc.1206755
   Kwon HS, 2004, DIABETES, V53, P899, DOI 10.2337/diabetes.53.4.899
   Kye MJ, 2007, MOL CELL BIOCHEM, V300, P9, DOI 10.1007/s11010-006-9320-6
   LaCroix-Fralish ML, 2011, PAIN, V152, P1888, DOI 10.1016/j.pain.2011.04.014
   Laforet P, 2016, REV NEUROL-FRANCE, V172, P541, DOI 10.1016/j.neurol.2016.08.001
   LANDGRAF R, 1978, ENDOCRINOL EXP, V12, P119
   Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058
   Lauriola M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6073
   Lawrance W, 2016, J BIOL CHEM, V291, P8014, DOI 10.1074/jbc.M115.708305
   Lebrun C, 2013, MOL CELL NEUROSCI, V54, P9, DOI 10.1016/j.mcn.2012.11.010
   Lee AK, 2011, ONCOL REP, V25, P559, DOI 10.3892/or.2010.1091
   Lee B, 2005, J MOL BIOL, V345, P1083, DOI 10.1016/j.jmb.2004.11.027
   Lee BC, 2013, MOL CELL, V51, P397, DOI 10.1016/j.molcel.2013.06.019
   Lee D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088417
   Lee HW, 2010, J NEUROSCI, V30, P5508, DOI 10.1523/JNEUROSCI.4283-09.2010
   Lee RS, 2010, ENDOCRINOLOGY, V151, P4332, DOI 10.1210/en.2010-0225
   Lee SH, 2015, J EXP MED, V212, P1061, DOI 10.1084/jem.20141601
   LEERS J, 1994, MOL ENDOCRINOL, V8, P440, DOI 10.1210/me.8.4.440
   LEHMANMCKEEMAN LD, 1988, BIOCHEM J, V249, P429, DOI 10.1042/bj2490429
   Lehto M, 2008, J CELL SCI, V121, P695, DOI 10.1242/jcs.016964
   Lei YL, 2015, MED RES REV, V35, P306, DOI 10.1002/med.21330
   Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200
   Leroux P, 2010, NEUROSCIENCE, V167, P716, DOI 10.1016/j.neuroscience.2010.02.042
   Leroy V, 2009, J AM SOC NEPHROL, V20, P131, DOI 10.1681/ASN.2008020232
   Li BG, 2004, DEV NEUROSCI-BASEL, V26, P197, DOI 10.1159/000082137
   Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149
   Li XF, 2002, J BIOL CHEM, V277, P48410, DOI 10.1074/jbc.M210011200
   Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003
   Liebmann M, 2013, NEUROSCI LETT, V545, P40, DOI 10.1016/j.neulet.2013.04.013
   Lin WJ, 2012, BIOCHEM BIOPH RES CO, V417, P35, DOI 10.1016/j.bbrc.2011.11.043
   Lindsey S, 2015, INT REV CEL MOL BIO, V314, P1, DOI 10.1016/bs.ircmb.2014.10.001
   Ling F, 2014, CURR TOP DEV BIOL, V110, P189, DOI 10.1016/B978-0-12-405943-6.00005-1
   Liston C, 2013, NAT NEUROSCI, V16, P698, DOI 10.1038/nn.3387
   Liston C, 2011, P NATL ACAD SCI USA, V108, P16074, DOI 10.1073/pnas.1110444108
   Liu D, 2009, INT J BIOCHEM CELL B, V41, P2315, DOI 10.1016/j.biocel.2009.05.021
   Liu LX, 2005, MOL BIOL CELL, V16, P4463, DOI 10.1091/mbc.E05-03-0231
   Liu RJ, 2008, P NATL ACAD SCI USA, V105, P359, DOI 10.1073/pnas.0706679105
   Liu S, 2015, J BIOL CHEM, V290, P17894, DOI 10.1074/jbc.M114.607184
   Louveau A, 2015, NATURE, V523, P337, DOI 10.1038/nature14432
   Lu B, 2007, BBA-MOL CELL BIOL L, V1771, P1177, DOI 10.1016/j.bbalip.2007.05.002
   Lu Y, 2013, J CLIN INVEST, V123, P4232, DOI 10.1172/JCI68552
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Luo JC, 2007, J PHARMACOL EXP THER, V320, P687, DOI 10.1124/jpet.106.113035
   Lyssand JS, 2008, J BIOL CHEM, V283, P18792, DOI 10.1074/jbc.M801860200
   Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927
   MacPherson L, 2013, NUCLEIC ACIDS RES, V41, P1604, DOI 10.1093/nar/gks1337
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Magomedova L, 2016, HANDB EXP PHARMACOL, V233, P73, DOI 10.1007/164_2015_1
   Malik AR, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00237
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Manders PM, 2005, P NATL ACAD SCI USA, V102, P7418, DOI 10.1073/pnas.0501585102
   Marcelo KL, 2016, TRENDS ENDOCRIN MET, V27, P706, DOI 10.1016/j.tem.2016.06.001
   Mardones MD, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0209-3
   Martinho A, 2013, MOL CELL BIOCHEM, V376, P41, DOI 10.1007/s11010-012-1547-9
   Masana M, 2014, PSYCHONEUROENDOCRINO, V48, P98, DOI 10.1016/j.psyneuen.2014.06.009
   Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   Masters JN, 1996, NEUROENDOCRINOLOGY, V63, P28, DOI 10.1159/000126932
   Masuno K, 2011, AM J RESP CELL MOL, V45, P642, DOI 10.1165/rcmb.2010-0369OC
   MATSUDA T, 1978, BIOCHEM PHARMACOL, V27, P2973, DOI 10.1016/0006-2952(78)90222-8
   Mazalouskas MD, 2014, J BIOL CHEM, V289, P4219, DOI 10.1074/jbc.M113.518514
   McAvoy KM, 2016, NEURON, V91, P1356, DOI 10.1016/j.neuron.2016.08.009
   McCartney AJ, 2014, BIOESSAYS, V36, P52, DOI 10.1002/bies.201300012
   McEwen BS, 2015, NAT NEUROSCI, V18, P1353, DOI 10.1038/nn.4086
   McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154
   Meng SS, 2005, BIOCHEM J, V391, P143, DOI 10.1042/BJ20050229
   Merrill JC, 2011, P NATL ACAD SCI USA, V108, P21247, DOI 10.1073/pnas.1111492108
   MEYER RD, 1983, J CELL PHYSIOL, V114, P203, DOI 10.1002/jcp.1041140209
   Mikosz CA, 2001, J BIOL CHEM, V276, P16649, DOI 10.1074/jbc.M010842200
   Miller L, 2011, PHYSIOL BEHAV, V104, P312, DOI 10.1016/j.physbeh.2011.03.026
   MILLER SC, 1982, J CELL BIOCHEM, V18, P423, DOI 10.1002/jcb.1982.240180404
   Miller-Fleming L, 2015, J MOL BIOL, V427, P3389, DOI 10.1016/j.jmb.2015.06.020
   Miner JJ, 2015, NAT MED, V21, P1464, DOI 10.1038/nm.3974
   Mitra R, 2008, P NATL ACAD SCI USA, V105, P5573, DOI 10.1073/pnas.0705615105
   Miyata S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019859
   Mocchetti I, 1996, J NEUROSCI, V16, P2141
   Moh MC, 2009, J CELL PHYSIOL, V219, P382, DOI 10.1002/jcp.21685
   Molitoris JK, 2011, J BIOL CHEM, V286, P30181, DOI 10.1074/jbc.M111.245423
   Molteni R, 2001, BRAIN RES REV, V37, P249, DOI 10.1016/S0165-0173(01)00128-X
   Montesinos MM, 2012, STEROIDS, V77, P67, DOI 10.1016/j.steroids.2011.10.006
   Moore-Smith L, 2011, J MAMMARY GLAND BIOL, V16, P89, DOI 10.1007/s10911-011-9216-2
   Morishita D, 2008, CANCER RES, V68, P5076, DOI 10.1158/0008-5472.CAN-08-0634
   Morsink MC, 2006, J NEUROCHEM, V99, P1282, DOI 10.1111/j.1471-4159.2006.04187.x
   Morsink MC, 2006, J NEUROENDOCRINOL, V18, P239, DOI 10.1111/j.1365-2826.2006.01413.x
   Mracek T, 2013, BBA-BIOENERGETICS, V1827, P401, DOI 10.1016/j.bbabio.2012.11.014
   Muller C, 2006, J STEROID BIOCHEM, V100, P95, DOI 10.1016/j.jsbmb.2006.03.001
   Muller HK, 2006, J BIOL CHEM, V281, P28901, DOI 10.1074/jbc.M602848200
   MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25
   Munhoz CD, 2010, J NEUROSCI, V30, P13690, DOI 10.1523/JNEUROSCI.0303-09.2010
   Nadella M, 2005, P NATL ACAD SCI USA, V102, P16830, DOI 10.1073/pnas.0504838102
   Nagy JI, 1999, NEUROSCIENCE, V88, P447, DOI 10.1016/S0306-4522(98)00191-2
   Naito M, 2015, HISTOCHEM CELL BIOL, V144, P261, DOI 10.1007/s00418-015-1334-2
   Nakahata S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4393
   Nam HS, 2009, CELL STEM CELL, V5, P515, DOI 10.1016/j.stem.2009.08.017
   Nanjundan M, 2003, J BIOL CHEM, V278, P37413, DOI 10.1074/jbc.M306182200
   Neel NF, 2007, J CELL SCI, V120, P1559, DOI 10.1242/jcs.03437
   Newton AC, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a005926
   Newton R, 2014, EUR J PHARMACOL, V724, P231, DOI 10.1016/j.ejphar.2013.05.035
   Ngo-Anh TJ, 2005, NAT NEUROSCI, V8, P642, DOI 10.1038/nn1449
   Nichols NR, 2003, ANN NY ACAD SCI, V1007, P349, DOI 10.1196/annals.1286.034
   NICHOLS NR, 1990, BRAIN RES BULL, V24, P659, DOI 10.1016/0361-9230(90)90004-J
   Nicot AS, 2008, TRAFFIC, V9, P1240, DOI 10.1111/j.1600-0854.2008.00754.x
   Nilsson J, 2000, BIOCHEM J, V346, P699, DOI 10.1042/0264-6021:3460699
   Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x
   Nishiya T, 2011, J BIOL CHEM, V286, P9009, DOI 10.1074/jbc.M110.190678
   Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953
   Niu HR, 1997, MOL BRAIN RES, V51, P97, DOI 10.1016/S0169-328X(97)00221-0
   Numakawa T, 2013, NEUROSCIENCE, V239, P157, DOI 10.1016/j.neuroscience.2012.09.073
   Nunes JA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00080
   Nygren MK, 2009, EXP HEMATOL, V37, P225, DOI 10.1016/j.exphem.2008.10.007
   O'Connor BP, 2008, P NATL ACAD SCI USA, V105, P13015, DOI 10.1073/pnas.0803386105
   O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x
   Odaka H, 2016, NEUROSCI RES, V113, P28, DOI 10.1016/j.neures.2016.07.002
   Oexle H, 1999, BBA-BIOENERGETICS, V1413, P99, DOI 10.1016/S0005-2728(99)00088-2
   OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F
   OHKAWARA A, 1985, ARCH DERMATOL RES, V277, P88, DOI 10.1007/BF00414103
   Okada M, 2012, CELL SIGNAL, V24, P1573, DOI 10.1016/j.cellsig.2012.03.021
   Okumura M, 2013, BIOSCI BIOTECH BIOCH, V77, P1715, DOI 10.1271/bbb.130280
   Oppelt SA, 2017, BRAIN RES, V1657, P312, DOI 10.1016/j.brainres.2016.12.022
   Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176
   Ory S, 2007, BIOL CELL, V99, P701, DOI 10.1042/BC20070058
   Ory S, 2013, J NEUROSCI, V33, P3545, DOI 10.1523/JNEUROSCI.3654-12.2013
   Otaki JM, 2010, DEV NEUROBIOL, V70, P424, DOI 10.1002/dneu.20786
   Ou XJ, 2006, J MOL BIOL, V357, P858, DOI 10.1016/j.jmb.2005.12.074
   Paakinaho V, 2010, MOL ENDOCRINOL, V24, P511, DOI 10.1210/me.2009-0443
   Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009
   Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443
   Pandya JD, 2007, INT J DEV NEUROSCI, V25, P309, DOI 10.1016/j.ijdevneu.2007.05.001
   Pannasch U, 2014, NAT NEUROSCI, V17, P549, DOI 10.1038/nn.3662
   Pante G, 2005, J CELL BIOL, V171, P337, DOI 10.1083/jcb.200502013
   Park E, 2015, NAT STRUCT MOL BIOL, V22, P703, DOI 10.1038/nsmb.3074
   Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32
   Patnode ML, 2013, GLYCOBIOLOGY, V23, P381, DOI 10.1093/glycob/cws166
   Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722
   Peffer ME, 2014, MOL CELL BIOL, V34, P2611, DOI 10.1128/MCB.01121-13
   Pegg AE, 2008, AM J PHYSIOL-ENDOC M, V294, pE995, DOI 10.1152/ajpendo.90217.2008
   Pegg AE, 2016, J BIOL CHEM, V291, P14904, DOI 10.1074/jbc.R116.731661
   Pegg AE, 2014, IUBMB LIFE, V66, P8, DOI 10.1002/iub.1237
   Pegg AE, 2013, CHEM RES TOXICOL, V26, P1782, DOI 10.1021/tx400316s
   Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016
   Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001
   Perraud AL, 2003, J BIOL CHEM, V278, P1794, DOI 10.1074/jbc.M205601200
   Persson AI, 2006, EUR J NEUROSCI, V23, P2277, DOI 10.1111/j.1460-9568.2006.04764.x
   Persson A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00161
   Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245
   Piemonti L, 1999, INT IMMUNOL, V11, P1519, DOI 10.1093/intimm/11.9.1519
   Pincheira R, 2009, EMBO J, V28, P261, DOI 10.1038/emboj.2008.274
   Polman JAE, 2013, ENDOCRINOLOGY, V154, P1832, DOI 10.1210/en.2012-2187
   Polman JAE, 2012, BMC NEUROSCI, V13, DOI 10.1186/1471-2202-13-118
   Polman JAE, 2012, ENDOCRINOLOGY, V153, P4317, DOI 10.1210/en.2012-1255
   Poplawski MM, 2010, ENDOCRINOLOGY, V151, P5206, DOI 10.1210/en.2010-0702
   Poppelreuther M, 2012, J LIPID RES, V53, P888, DOI 10.1194/jlr.M024562
   Powell JD, 2010, IMMUNITY, V33, P301, DOI 10.1016/j.immuni.2010.09.002
   Previtali Stefano C., 2007, Expert Reviews in Molecular Medicine, V9, DOI 10.1017/S1462399407000439
   Psarra AMG, 2011, BBA-MOL CELL RES, V1813, P1814, DOI 10.1016/j.bbamcr.2011.05.014
   Qiao F, 2016, MOL CARCINOGEN, V55, P280, DOI 10.1002/mc.22277
   Qu QH, 2013, MOL CELL BIOL, V33, P2551, DOI 10.1128/MCB.00325-13
   Rahman MH, 2016, J BIOL CHEM, V291, P6011, DOI 10.1074/jbc.M115.699215
   Ramalingam A, 1997, MOL ENDOCRINOL, V11, P577, DOI 10.1210/me.11.5.577
   Ranuncolo SA, 2008, BLOOD CELL MOL DIS, V41, P95, DOI 10.1016/j.bcmd.2008.02.003
   Rao RP, 2012, BIOL PSYCHIAT, V72, P466, DOI 10.1016/j.biopsych.2012.04.008
   Ratman D, 2013, MOL CELL ENDOCRINOL, V380, P41, DOI 10.1016/j.mce.2012.12.014
   Reichmann F, 2016, NEUROPEPTIDES, V55, P99, DOI 10.1016/j.npep.2015.09.008
   Reinecke F, 2006, BIOCHEM J, V395, P405, DOI 10.1042/BJ20051253
   Riches Z, 2007, BIOCHEM PHARMACOL, V74, P352, DOI 10.1016/j.bcp.2007.04.006
   Richter M, 2016, CELL DEATH DIFFER, V23, P814, DOI 10.1038/cdd.2015.146
   Roberts R, 2013, ESSAYS BIOCHEM, V55, P17, DOI [10.1042/BSE0550017, 10.1042/bse0550017]
   Rothlin CV, 2007, CELL, V131, P1124, DOI 10.1016/j.cell.2007.10.034
   ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x
   Roussel-Gervais A, 2016, J CLIN ENDOCR METAB, V101, P513, DOI 10.1210/jc.2015-3324
   Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x
   Roy M, 2003, NEUROENDOCRINOLOGY, V77, P24, DOI 10.1159/000068337
   Ruksee N, 2014, J STEROID BIOCHEM, V143, P72, DOI 10.1016/j.jsbmb.2014.02.011
   Sadowska GB, 2014, NEUROSCIENCE, V275, P248, DOI 10.1016/j.neuroscience.2014.05.066
   Saegusa M, 2012, LAB INVEST, V92, P511, DOI 10.1038/labinvest.2011.196
   Saito M, 2007, CANCER CELL, V12, P280, DOI 10.1016/j.ccr.2007.08.011
   SAKAKI T, 1995, NEUROSCI RES, V23, P289, DOI 10.1016/0168-0102(95)00954-X
   Salaria S, 2006, NEUROBIOL DIS, V23, P630, DOI 10.1016/j.nbd.2006.05.003
   Salehzadeh F, 2009, DIABETES-METAB RES, V25, P250, DOI 10.1002/dmrr.944
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Saras J, 2004, EXP CELL RES, V299, P356, DOI 10.1016/j.yexcr.2004.05.029
   Sarlak G, 2016, MOL NEUROBIOL, V53, P1679, DOI 10.1007/s12035-015-9123-4
   Sasaki T, 2005, STROKE, V36, P2457, DOI 10.1161/01.STR.0000185672.10390.30
   Sasse SK, 2015, J BIOL CHEM, V290, P19756, DOI 10.1074/jbc.M115.668558
   Sasse SK, 2013, MOL CELL BIOL, V33, P2104, DOI 10.1128/MCB.01474-12
   Sato H, 2008, J NEUROCHEM, V106, P805, DOI 10.1111/j.1471-4159.2008.05489.x
   Sato T, 2015, BIOCHEM BIOPH RES CO, V457, P653, DOI 10.1016/j.bbrc.2015.01.043
   Scharf SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016883
   Schmidt PJ, 2015, J BIOL CHEM, V290, P18975, DOI 10.1074/jbc.R115.650150
   Schneider EH, 2014, NEUROSCI BIOBEHAV R, V47, P101, DOI 10.1016/j.neubiorev.2014.07.020
   Schonfeld P, 2013, J CEREBR BLOOD F MET, V33, P1493, DOI 10.1038/jcbfm.2013.128
   Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930
   Schwabe L, 2012, NEUROSCI BIOBEHAV R, V36, P1740, DOI 10.1016/j.neubiorev.2011.07.002
   Schwartze JT, 2014, J BIOL CHEM, V289, P3262, DOI 10.1074/jbc.M113.541052
   Scobie KN, 2009, J NEUROSCI, V29, P9875, DOI 10.1523/JNEUROSCI.2260-09.2009
   Scott CE, 2010, NAT NEUROSCI, V13, P1181, DOI 10.1038/nn.2646
   Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603
   SECO AJ, 1995, LUNG, V173, P321
   Sefton C, 2016, ENDOCRINOLOGY, V157, P4257, DOI 10.1210/en.2016-1571
   Seifuddin F., 2017, EPIGENETICS
   SHAH M, 1995, J CELL SCI, V108, P985
   Sharma D, 2013, MOL ENDOCRINOL, V27, P1142, DOI 10.1210/me.2013-1079
   Shen C, 2016, CALCIFIED TISSUE INT, V99, P88, DOI 10.1007/s00223-016-0121-y
   Shen PL, 2014, PROSTATE, V74, P946, DOI 10.1002/pros.22812
   Shi-Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002
   Shimizu H, 2008, ENDOCRINOLOGY, V149, P4544, DOI 10.1210/en.2008-0229
   Shimizu H, 2010, PEPTIDES, V31, P145, DOI 10.1016/j.peptides.2009.09.036
   Shostak K, 2015, TRENDS MOL MED, V21, P385, DOI 10.1016/j.molmed.2015.04.001
   Sima N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074594
   Simard M, 1999, GLIA, V28, P1, DOI 10.1002/(SICI)1098-1136(199910)28:1<1::AID-GLIA1>3.0.CO;2-4
   Skupio U, 2015, NEUROSCIENCE, V286, P141, DOI 10.1016/j.neuroscience.2014.11.035
   Slezak M, 2013, GLIA, V61, P623, DOI 10.1002/glia.22460
   SMITH MA, 1995, J NEUROSCI, V15, P1768, DOI 10.1523/JNEUROSCI.15-03-01768.1995
   SNYERS L, 1990, P NATL ACAD SCI USA, V87, P2838, DOI 10.1073/pnas.87.7.2838
   Sominsky Luba, 2014, Front Psychol, V5, P434, DOI 10.3389/fpsyg.2014.00434
   Son GH, 2005, BIOCHEM BIOPH RES CO, V338, P1751, DOI 10.1016/j.bbrc.2005.10.152
   Speksnijder N, 2012, J MOL NEUROSCI, V48, P209, DOI 10.1007/s12031-012-9809-2
   Sporl F, 2012, P NATL ACAD SCI USA, V109, P10903, DOI 10.1073/pnas.1118641109
   Srinivasan M., 2016, MOL NEUROBIOL
   Srinivasan M, 2011, J BIOL CHEM, V286, P44799, DOI 10.1074/jbc.M111.279257
   Stankiewicz AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142195
   Stankiewicz AM, 2014, BMC NEUROSCI, V15, DOI 10.1186/s12868-014-0130-6
   Stankovic RK, 2007, INT J BIOCHEM CELL B, V39, P484, DOI 10.1016/j.biocel.2006.09.010
   Stavreva DA, 2015, GENOME RES, V25, P845, DOI 10.1101/gr.184168.114
   Stechschulte LA, 2014, MOL ENDOCRINOL, V28, P1254, DOI 10.1210/me.2014-1023
   Stenmark H, 1999, J CELL SCI, V112, P4175
   Stephan AB, 2012, NAT NEUROSCI, V15, P131, DOI 10.1038/nn.2943
   Sun D, 2010, J NEUROTRAUM, V27, P923, DOI 10.1089/neu.2009.1209
   SUPKO DE, 1994, EUR J PHARM-ENVIRON, V270, P105, DOI 10.1016/0926-6917(94)90086-8
   Suri D, 2013, NEUROSCIENCE, V239, P196, DOI 10.1016/j.neuroscience.2012.08.065
   Suwanjang W, 2013, CELL CALCIUM, V53, P256, DOI 10.1016/j.ceca.2012.12.006
   Tai DJC, 2009, J BIOL CHEM, V284, P4073, DOI 10.1074/jbc.M805055200
   Takahashi K, 2012, J NEUROSCI RES, V90, P160, DOI 10.1002/jnr.22727
   Takayama S, 2006, J BIOL CHEM, V281, P17856, DOI 10.1074/jbc.M602290200
   Takeichi T, 2011, NEUROCHEM INT, V59, P21, DOI 10.1016/j.neuint.2011.03.019
   Takeuchi Y, 2016, CELL REP, V16, P2373, DOI 10.1016/j.celrep.2016.07.069
   Takizawa N, 2006, J CELL BIOL, V174, P447, DOI 10.1083/jcb.200512051
   Takubo K, 2013, CELL STEM CELL, V12, P49, DOI 10.1016/j.stem.2012.10.011
   Tan B, 2014, MOL CELL BIOCHEM, V391, P95, DOI 10.1007/s11010-014-1991-9
   Tang WJ, 2008, J STEROID BIOCHEM, V112, P63, DOI 10.1016/j.jsbmb.2008.08.004
   Tao WK, 2001, GENE DEV, V15, P1796, DOI 10.1101/gad.894301
   Teh MT, 2007, J CELL SCI, V120, P330, DOI 10.1242/jcs.03329
   Terada K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093223
   Terada Y, 2012, CLIN EXP NEPHROL, V16, P81, DOI 10.1007/s10157-011-0498-x
   Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Thakkar MM, 2011, SLEEP MED REV, V15, P65, DOI 10.1016/j.smrv.2010.06.004
   Thompson MD, 2000, ANESTHESIOLOGY, V93, P1279, DOI 10.1097/00000542-200011000-00022
   Tiberi L, 2012, NAT NEUROSCI, V15, P1627, DOI 10.1038/nn.3264
   TOMBAUGH GC, 1992, J NEUROCHEM, V59, P137, DOI 10.1111/j.1471-4159.1992.tb08884.x
   Troncoso R, 2014, CELL CYCLE, V13, P2281, DOI 10.4161/cc.29272
   Tuor UI, 1997, J NEUROCHEM, V69, P1954
   Tureyen K, 2005, NEUROSURGERY, V57, P1254, DOI 10.1227/01.NEU.0000186040.96929.8A
   Unsicker K, 2000, EUR J BIOCHEM, V267, P6972, DOI 10.1046/j.1432-1327.2000.01824.x
   Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140
   van Amerongen R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007914
   van der Kooij MA, 2016, NEUROSCI BIOBEHAV R, V62, P69, DOI 10.1016/j.neubiorev.2015.12.001
   van Galen JC, 2010, BLOOD, V115, P4810, DOI 10.1182/blood-2009-05-223081
   van Maanen MH, 1999, BBA-GENE STRUCT EXPR, V1447, P284, DOI 10.1016/S0167-4781(99)00159-1
   Varela-Nallar L, 2009, NEURAL DEV, V4, DOI 10.1186/1749-8104-4-41
   Viales RR, 2015, STEM CELLS, V33, P892, DOI 10.1002/stem.1883
   Viaud J, 2014, BIOESSAYS, V36, P260, DOI 10.1002/bies.201300132
   Vicinanza M, 2015, MOL CELL, V57, P219, DOI 10.1016/j.molcel.2014.12.007
   Villanueva CJ, 2011, CELL METAB, V13, P413, DOI 10.1016/j.cmet.2011.02.014
   VIRGIN CE, 1991, J NEUROCHEM, V57, P1422, DOI 10.1111/j.1471-4159.1991.tb08309.x
   Visser F, 2007, J BIOL CHEM, V282, P4453, DOI 10.1074/jbc.M610582200
   Vitali T, 2016, ARCH BIOCHEM BIOPHYS, V593, P24, DOI 10.1016/j.abb.2016.01.016
   Viti J, 2003, J NEUROSCI, V23, P5919
   Voelkl J, 2013, CELL PHYSIOL BIOCHEM, V32, P25, DOI 10.1159/000350120
   Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720
   Wancket LM, 2012, LIFE SCI, V90, P237, DOI 10.1016/j.lfs.2011.11.017
   Wang HM, 2006, J BIOL CHEM, V281, P39128, DOI 10.1074/jbc.M610023200
   Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303
   Wang L, 2010, BIOL TRACE ELEM RES, V137, P88, DOI 10.1007/s12011-009-8565-9
   Wang QJ, 2013, J UROLOGY, V190, P1912, DOI 10.1016/j.juro.2013.05.013
   Wang SY, 2016, ONCOTARGET, V7, P2878, DOI 10.18632/oncotarget.6694
   Wang Y, 2008, INT J BIOCHEM CELL B, V40, P909, DOI 10.1016/j.biocel.2007.10.028
   Wang ZJ, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/475389
   Wang ZS, 2005, MOL CELL BIOL, V25, P5022, DOI 10.1128/MCB.25.12.5022-5030.2005
   Wayman GA, 2008, NEURON, V59, P914, DOI 10.1016/j.neuron.2008.08.021
   Webster JI, 2004, J ENDOCRINOL, V181, P207, DOI 10.1677/joe.0.1810207
   Weichhart T, 2012, METHODS MOL BIOL, V821, P1, DOI 10.1007/978-1-61779-430-8_1
   Weina K, 2016, PIGM CELL MELANOMA R, V29, P453, DOI 10.1111/pcmr.12483
   Wender R, 2000, J NEUROSCI, V20, P6804, DOI 10.1523/JNEUROSCI.20-18-06804.2000
   Wheat JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105557
   Wianny F, 1998, DEV DYNAM, V212, P49, DOI 10.1002/(SICI)1097-0177(199805)212:1<49::AID-AJA5>3.0.CO;2-2
   Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188
   Wochnik GM, 2005, J BIOL CHEM, V280, P4609, DOI 10.1074/jbc.M407498200
   Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200
   Woodbury ME, 2014, J NEUROIMMUNE PHARM, V9, P92, DOI 10.1007/s11481-013-9501-5
   Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4
   WOOLLEY CS, 1990, BRAIN RES, V531, P225, DOI 10.1016/0006-8993(90)90778-A
   Wu CL, 2001, CANCER RES, V61, P7325
   Wu PF, 2000, ARCH BIOCHEM BIOPHYS, V381, P1, DOI 10.1006/abbi.2000.1946
   Wu SY, 2005, THYROID, V15, P943, DOI 10.1089/thy.2005.15.943
   Wulfkuhle JD, 1999, J CELL SCI, V112, P2125
   Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016
   Wylie SR, 2003, MOL BIOL CELL, V14, P4654, DOI 10.1091/mbc.E03-03-0187
   Wyss MT, 2011, J NEUROSCI, V31, P7477, DOI 10.1523/JNEUROSCI.0415-11.2011
   Xia ZG, 2005, NAT REV NEUROSCI, V6, P267, DOI 10.1038/nrn1647
   Xu DZ, 2005, J BIOL CHEM, V280, P2924, DOI 10.1074/jbc.M408907200
   Xue WL, 2009, TOXICOL LETT, V188, P70, DOI 10.1016/j.toxlet.2009.03.007
   Xydous M, 2014, BBA-GENE REGUL MECH, V1839, P866, DOI 10.1016/j.bbagrm.2014.07.011
   Yakubchyk Y, 2005, MOL CELL BIOL, V25, P7289, DOI 10.1128/MCB.25.16.7289-7302.2005
   Yamada T, 2016, NAT IMMUNOL, V17, P687, DOI 10.1038/ni.3422
   Yamaguchi S, 1999, J MOL ENDOCRINOL, V22, P81, DOI 10.1677/jme.0.0220081
   Yang HD, 2011, MOL CELLS, V32, P235, DOI 10.1007/s10059-011-1026-z
   Yang RW, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0426-8
   YANG SY, 1987, J BIOL CHEM, V262, P13027
   Yang YC, 2006, MOL CELL BIOL, V26, P8357, DOI 10.1128/MCB.01017-06
   Ying HQ, 2010, P NATL ACAD SCI USA, V107, P6912, DOI 10.1073/pnas.0914930107
   Yoo JY, 2015, BIOCHEM BIOPH RES CO, V462, P409, DOI 10.1016/j.bbrc.2015.04.146
   You JM, 2009, CAN J PHYSIOL PHARM, V87, P440, DOI [10.1139/Y09-027, 10.1139/y09-027]
   Yu RYL, 2005, BLOOD, V105, P1777, DOI 10.1182/blood-2004-08-3171
   Yu S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022419
   Yuan SY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159513
   Yuan Y, 2013, INVEST OPHTH VIS SCI, V54, P6502, DOI 10.1167/iovs.13-12447
   Yuen EY, 2011, MOL PSYCHIATR, V16, P156, DOI 10.1038/mp.2010.50
   Zahuczky G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021349
   Zawalich WS, 2006, METABOLISM, V55, P35, DOI 10.1016/j.metabol.2005.06.023
   Zechel S, 2010, NEUROSCIENTIST, V16, P357, DOI 10.1177/1073858410371513
   Zeng JW, 2013, NEUROCHEM RES, V38, P382, DOI 10.1007/s11064-012-0929-4
   Zentner GE, 2013, NAT STRUCT MOL BIOL, V20, P259, DOI 10.1038/nsmb.2470
   Zhang P, 2009, J CELL PHYSIOL, V220, P82, DOI 10.1002/jcp.21733
   Zhang Y, 2005, P NATL ACAD SCI USA, V102, P14883, DOI 10.1073/pnas.0505164102
   Zhang YF, 2003, AM J PHYSIOL-HEART C, V284, pH2078, DOI 10.1152/ajpheart.00942.2001
   Zhong W, 2014, CELL SIGNAL, V26, P2765, DOI 10.1016/j.cellsig.2014.08.002
   Zhou YP, 2011, MOL CELL BIOL, V31, P3603, DOI 10.1128/MCB.01389-10
   Zucchini D, 2011, ARCH BIOCHEM BIOPHYS, V515, P1, DOI 10.1016/j.abb.2011.08.004
   Zucker SN, 2014, MOL CELL, V53, P916, DOI 10.1016/j.molcel.2014.01.033
NR 613
TC 51
Z9 51
U1 4
U2 46
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0278-5846
EI 1878-4216
J9 PROG NEURO-PSYCHOPH
JI Prog. Neuro-Psychopharmacol. Biol. Psychiatry
PD MAR 2
PY 2018
VL 82
BP 136
EP 168
DI 10.1016/j.pnpbp.2017.11.020
PG 33
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA FV6OT
UT WOS:000424701600014
PM 29180230
DA 2022-04-25
ER

PT J
AU Salla, M
   Aguayo-Ortiz, R
   Danmaliki, GI
   Zare, A
   Said, A
   Moore, J
   Pandya, V
   Manaloor, R
   Fong, S
   Blankstein, AR
   Gibson, SB
   Garcia, LR
   Meier, P
   Bhullar, KS
   Hubbard, BP
   Fiteh, Y
   Vliagoftis, H
   Goping, IS
   Brocks, D
   Hwang, P
   Velazquez-Martinez, CA
   Baksh, S
AF Salla, Mohamed
   Aguayo-Ortiz, Rodrigo
   Danmaliki, Gaddafi I.
   Zare, Alaa
   Said, Ahmed
   Moore, Jack
   Pandya, Vrajeshkumar
   Manaloor, Robin
   Fong, Sunny
   Blankstein, Anna R.
   Gibson, Spencer B.
   Garcia, Laura Ramos
   Meier, Pascal
   Bhullar, Khushwant S.
   Hubbard, Basil P.
   Fiteh, Yahya
   Vliagoftis, Harissios
   Goping, Ing Swie
   Brocks, Dion
   Hwang, Peter
   Velazquez-Martinez, Carlos A.
   Baksh, Shairaz
TI Identification and Characterization of Novel Receptor-Interacting
   Serine/Threonine-Protein Kinase 2 Inhibitors Using Structural Similarity
   Analysis
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; NF-KAPPA-B; COLORECTAL-CANCER; DISCOVERY;
   COLITIS; DESIGN; SYSTEM; POTENT; CELLS
AB Receptor-interacting protein kinase 2 (RIP2 or RICK, herein referred to as RIPK2) is linked to the pathogen pathway that activates nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) and autophagic activation. Using molecular modeling (docking) and chemoinformatics analyses, we used the RIPK2/ponatinib crystal structure and searched in chemical databases for small molecules exerting binding interactions similar to those exerted by ponatinib. The identified RIPK2 inhibitors potently inhibited the proliferation of cancer cells by. > 70% and also inhibited NFkB activity. More importantly, in vivo inhibition of intestinal and lung inflammation rodent models suggests effectiveness to resolve inflammation with low toxicity to the animals. Thus, our identified RIPK2 inhibitor may offer possible therapeutic control of inflammation in diseases such as inflammatory bowel disease, asthma, cystic fibrosis, primary sclerosing cholangitis, and pancreatitis.
C1 [Salla, Mohamed; Danmaliki, Gaddafi I.; Said, Ahmed; Moore, Jack; Pandya, Vrajeshkumar; Goping, Ing Swie; Hwang, Peter; Baksh, Shairaz] Univ Alberta, Dept Biochem, Edmonton, AB, Canada.
   [Zare, Alaa; Manaloor, Robin; Fong, Sunny; Baksh, Shairaz] Univ Alberta, Dept Pediat, Edmonton, AB, Canada.
   [Bhullar, Khushwant S.; Hubbard, Basil P.] Univ Alberta, Dept Pharmacol, Edmonton, AB, Canada.
   [Baksh, Shairaz] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
   [Fiteh, Yahya; Vliagoftis, Harissios; Hwang, Peter] Univ Alberta, Dept Med, Edmonton, AB, Canada.
   [Aguayo-Ortiz, Rodrigo; Brocks, Dion; Velazquez-Martinez, Carlos A.] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB, Canada.
   [Aguayo-Ortiz, Rodrigo] Univ Nacl Autonoma Mexico, Fac Quim, Dept Farm, Mexico City, DF, Mexico.
   [Blankstein, Anna R.; Gibson, Spencer B.] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB, Canada.
   [Blankstein, Anna R.; Gibson, Spencer B.] Univ Manitoba, Dept Immunol, Winnipeg, MB, Canada.
   [Garcia, Laura Ramos; Meier, Pascal] Chester Beatty Labs, Breakthrough Breast Canc Res Ctr, London, England.
   [Baksh, Shairaz] Canc Res Inst Northern Alberta, Edmonton, AB, Canada.
   [Baksh, Shairaz] Women & Childrens Hlth Res Inst, Edmonton, AB, Canada.
RP Baksh, S (corresponding author), Univ Alberta, Div Hematol Oncol, Fac Med & Dent, Dept Pediat,Ctr Pharm & Hlth Res,Katz Grp 020E 3, 113 St 87 Ave, Edmonton, AB T6G 2E1, Canada.
EM sbaksh@ualberta.ca
RI Velazquez-Martinez, Carlos A/G-3595-2012; Salla, Mohamed/ABA-5843-2021
OI Gaddafi Ibrahim, Danmaliki/0000-0003-1688-0711; Meier,
   Pascal/0000-0003-2760-6523; Hubbard, Basil/0000-0003-4353-9674; Salla,
   Mohamed/0000-0003-4744-0954; Aguayo-Ortiz, Rodrigo/0000-0001-9455-5397
FU Alberta Innovates - Health Solutions CRIO; Alberta Heritage Foundation
   for Medical ResearchAlberta Heritage Foundation for Medical
   ResearchGeneral Electric; Department of Pediatrics/Stollery Children's
   Hospital-WCHRI Hair Massacure Donation Fund; CONACyT (Mexico)Consejo
   Nacional de Ciencia y Tecnologia (CONACyT) [510728/288862]; division of
   Hematology/Oncology/Palliative Care/Epidemiology; Alberta Innovates
   [201600099] Funding Source: researchfish
FX The research in this study was supported by grants from Alberta
   Innovates - Health Solutions CRIO, Alberta Heritage Foundation for
   Medical Research, from the division of Hematology/Oncology/Palliative
   Care/Epidemiology under Dr. David Eisenstat for funds to partially
   support this project and from the Department of Pediatrics/Stollery
   Children's Hospital-WCHRI Hair Massacure Donation Fund. Aguayo-Ortiz is
   very grateful to CONACyT (Mexico) for the fellowship granted (No.
   510728/288862).
CR BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3
   Borisa AC, 2017, EUR J MED CHEM, V140, P1, DOI 10.1016/j.ejmech.2017.08.045
   Branquinho D, 2016, WORLD J GASTRO SURG, V8, P284, DOI 10.4240/wjgs.v8.i4.284
   Canning P, 2015, CHEM BIOL, V22, P1174, DOI 10.1016/j.chembiol.2015.07.017
   Cao Y, 2008, BIOINFORMATICS, V24, P1733, DOI 10.1093/bioinformatics/btn307
   Chirieleison SM, 2016, J IMMUNOL, V196, P4291, DOI 10.4049/jimmunol.1502631
   Dai H, 2016, METHOD ENZYMOL, V574, P213, DOI 10.1016/bs.mie.2016.01.012
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Dieleman LA, 1998, CLIN EXP IMMUNOL, V114, P385
   Dyson JK, 2012, WORLD J GASTROENTERO, V18, P3839, DOI 10.3748/wjg.v18.i29.3839
   Ermann J, 2014, P NATL ACAD SCI USA, V111, pE2559, DOI 10.1073/pnas.1408540111
   Goncalves P, 2015, INFLAMM BOWEL DIS, V21, P453, DOI 10.1097/MIB.0000000000000209
   Gordon M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075483
   Haile PA, 2016, J MED CHEM, V59, P4867, DOI 10.1021/acs.jmedchem.6b00211
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   He XH, 2017, ACS MED CHEM LETT, V8, P1048, DOI 10.1021/acsmedchemlett.7b00258
   Jun JC, 2013, J LEUKOCYTE BIOL, V94, P927, DOI 10.1189/jlb.0213109
   Kim S, 2016, NUCLEIC ACIDS RES, V44, pD1202, DOI 10.1093/nar/gkv951
   Kitzenberg D, 2016, CLIN TRANSL MED, V5, DOI 10.1186/s40169-016-0114-5
   Koes DR, 2012, BIOINFORMATICS, V28, P784, DOI 10.1093/bioinformatics/btr717
   KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P
   Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561
   Lagorce D, 2015, NUCLEIC ACIDS RES, V43, pW200, DOI 10.1093/nar/gkv353
   Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Lupfer C, 2013, NAT IMMUNOL, V14, P480, DOI 10.1038/ni.2563
   Lupfer CR, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004410
   Madrid Lee V, 2003, Methods Mol Biol, V223, P523
   Madsen K, 2001, GASTROENTEROLOGY, V121, P580, DOI 10.1053/gast.2001.27224
   Moriwaki K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.16
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Murgueitio MS, 2017, TRENDS PHARMACOL SCI, V38, P155, DOI 10.1016/j.tips.2016.10.007
   Nachbur U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7442
   Nakashima Kazuko, 2006, Allergol Int, V55, P77, DOI 10.2332/allergolint.55.77
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758-2946-3-33
   Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4
   Ostojic SM, 2017, RES SPORTS MED, V25, P91, DOI 10.1080/15438627.2016.1258646
   Owens BMJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00307
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Sterling T, 2015, J CHEM INF MODEL, V55, P2324, DOI 10.1021/acs.jcim.5b00559
   Suman S, 2016, BIOCHEM BIOPH RES CO, V472, P401, DOI 10.1016/j.bbrc.2015.10.133
   Tang BL, 2016, MOL CELLS, V39, P87, DOI 10.14348/molcells.2016.2318
   Tigno-Aranjuez JT, 2014, J BIOL CHEM, V289, P29651, DOI 10.1074/jbc.M114.591388
   Tigno-Aranjuez JT, 2010, GENE DEV, V24, P2666, DOI 10.1101/gad.1964410
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vanden Berghe T, 2016, CELL MOL LIFE SCI, V73, P2137, DOI 10.1007/s00018-016-2189-y
   Vieira SM, 2012, J IMMUNOL, V188, P5116, DOI 10.4049/jimmunol.1004190
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Williamson KD, 2015, BRIT MED BULL, V114, P53, DOI 10.1093/bmb/ldv019
   Wu S, 2012, ANTICANCER RES, V32, P3775
NR 50
TC 10
Z9 10
U1 0
U2 21
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAY 1
PY 2018
VL 365
IS 2
BP 354
EP 367
DI 10.1124/jpet.117.247163
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GC1OY
UT WOS:000429552700016
PM 29555876
OA hybrid
DA 2022-04-25
ER

PT J
AU Malik, P
   Chaudhry, N
   Mittal, R
   Mukherjee, TK
AF Malik, Parth
   Chaudhry, Narender
   Mittal, Rashmi
   Mukherjee, Tapan K.
TI Role of receptor for advanced glycation end products in the complication
   and progression of various types of cancers
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS
LA English
DT Review
DE RAGE; Cancer; Ligands; Inflammation; Cancer therapy
ID CELL-SURFACE RECEPTOR; DIABETIC-RETINOPATHY; COLORECTAL-CANCER;
   NITRIC-OXIDE; IN-VITRO; RAGE; EXPRESSION; AMINOGUANIDINE; LYSOZYME;
   PROLIFERATION
AB Background: Receptor for advanced glycation end-products popularly known as RAGE is a cell surface immunoglobulin class of molecule, binds with multiple ligands and therefore considered as a multi-ligand receptor. Use of RAGE deficient mice (RAGE(-/-)) as well as established mouse models pertaining to inflammation-associated carcinogenesis such as that of chemically induced carcinogenesis and colitis associated cancer provides a direct genetic evidence for a likelihood novel role of RAGE in cancer, with respect to its ability to lead cancer cell proliferation and survival. Besides inflammation, interaction of RAGE with its various ligands enhances oxidative stress both in cancerous and noncancerous cells which further complicates the progression of cancers.
   Scope of review: Till date, no single review article has discussed the mechanism of RAGE dependent complication of cancers, particularly the role of RAGE in cancer cell proliferation, angiogenesis, survival and anti-apoptosis needs to be discussed.
   Major conclusion: RAGE enhances the number of cancer cells by activating the cell cycle proteins (e.g., cyclin D1), anti-apoptotic proteins (e.g., BCl2), prosurvival (AKT) and autophagic proteins. Role of RAGE has also been detected in formation of new blood vessels (angiogenesis) in the cancer cells and activation of myeloid derived suppressor cells (MDSCs).
   General significance: This review article describes the role of RAGE in the complication of various types of cancers and the possible usefulness of RAGE dependent therapy to confront cancers in a stronger magnitude. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Malik, Parth; Chaudhry, Narender; Mittal, Rashmi; Mukherjee, Tapan K.] Cent Univ Gujarat, Ctr Nano Sci, Gandhinagar 382030, India.
RP Mukherjee, TK (corresponding author), Cent Univ Gujarat, Ctr Nano Sci, Gandhinagar 382030, India.
EM tapanmu@yahoo.com
OI Mukherjee, Tapan/0000-0001-6737-8321; Malik, Parth/0000-0003-1839-5701;
   Mittal, Rashmi/0000-0002-9487-2082
CR Alexiou P, 2010, CURR MED CHEM, V17, P2232, DOI 10.2174/092986710791331086
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Bartling B, 2006, AM J RESP CELL MOL, V34, P83, DOI 10.1165/rcmb.2005-0194OC
   Bartling B, 2005, CARCINOGENESIS, V26, P293, DOI 10.1093/carcin/bgh333
   Bhawal UK, 2005, ONCOLOGY-BASEL, V69, P246, DOI 10.1159/000087910
   BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117
   BUCALA R, 1991, J CLIN INVEST, V87, P432, DOI 10.1172/JCI115014
   Chavakis T, 2004, MICROBES INFECT, V6, P1219, DOI 10.1016/j.micinf.2004.08.004
   Cheng CM, 2005, MODERN PATHOL, V18, P1385, DOI 10.1038/modpathol.3800450
   Chipuk JE, 2005, NAT REV MOL CELL BIO, V6, P268, DOI [10.1038/nrm1573, 10.1038/nrm2239]
   Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734
   Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175
   Cocchietto M, 2008, DIABETES METAB, V34, P587, DOI 10.1016/j.diabet.2008.05.009
   Corman B, 1998, P NATL ACAD SCI USA, V95, P1301, DOI 10.1073/pnas.95.3.1301
   Demling N, 2006, CELL TISSUE RES, V323, P475, DOI 10.1007/s00441-005-0069-0
   Donato R, 2007, CURR MOL MED, V7, P711, DOI 10.2174/156652407783220688
   Forbes JM, 2004, DIABETES, V53, P1813, DOI 10.2337/diabetes.53.7.1813
   Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679
   Ghavami S, 2008, J LEUKOCYTE BIOL, V83, P1484, DOI 10.1189/jlb.0607397
   Gnanasekar M, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/157103
   HAMMES HP, 1994, DIABETOLOGIA, V37, P32
   HAMMES HP, 1995, DIABETOLOGIA, V38, P656, DOI 10.1007/BF00401835
   Heijmans J, 2013, ONCOGENE, V32, P1202, DOI 10.1038/onc.2012.119
   Hiwatashi K, 2008, ANN SURG ONCOL, V15, P923, DOI 10.1245/s10434-007-9698-8
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6
   Hou XW, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-78
   Huttunen HJ, 2002, CANCER RES, V62, P4805
   Ibrahim ZA, 2013, MOL IMMUNOL, V56, P739, DOI 10.1016/j.molimm.2013.07.008
   Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394
   Ishiguro H, 2005, PROSTATE, V64, P92, DOI 10.1002/pros.20219
   Kang R, 2014, ONCOGENE, V33, P567, DOI 10.1038/onc.2012.631
   Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149
   Kang R., 2011, J LANDES BIOSCIENCE, V7, P442
   Kang R., 2012, P NATL ACAD SCI, V1, P109
   Kang R, 2011, ANTIOXID REDOX SIGN, V15, P2175, DOI 10.1089/ars.2010.3378
   Kristen M., 2012, MOL CELLULAR PATHOBI, DOI 10.1158. 0008-5472
   Kuhla A, 2013, BRIT J SURG, V100, P1229, DOI 10.1002/bjs.9188
   Kuniyasu H, 2002, J PATHOL, V196, P163, DOI 10.1002/path.1031
   Lata K, 2014, BBA-GEN SUBJECTS, V1840, P1083, DOI 10.1016/j.bbagen.2013.11.014
   Leclerc E, 2009, BBA-MOL CELL RES, V1793, P993, DOI 10.1016/j.bbamcr.2008.11.016
   LI YM, 1995, NAT MED, V1, P1057, DOI 10.1038/nm1095-1057
   Liang HS, 2011, CANCER LETT, V313, P91, DOI 10.1016/j.canlet.2011.08.028
   Lin L, 2006, CELL MOL IMMUNOL, V3, P351
   Logsdon CD, 2007, CURR MOL MED, V7, P777, DOI 10.2174/156652407783220697
   Marinakis E, 2014, CLIN CHEM LAB MED, V52, P189, DOI 10.1515/cclm-2013-0578
   Meghnani V, 2014, BBA-MOL BASIS DIS, V1842, P1017, DOI 10.1016/j.bbadis.2014.02.013
   Mitsuhashi T, 1997, J CLIN INVEST, V100, P847, DOI 10.1172/JCI119600
   Mukherjee TK, 2008, RESP PHYSIOL NEUROBI, V162, P210, DOI 10.1016/j.resp.2008.07.001
   Mukherjee TK, 2005, BBA-MOL CELL RES, V1745, P300, DOI 10.1016/j.bbamcr.2005.03.012
   Mukherjee TK, 2005, BBA-MOL CELL RES, V1744, P213, DOI 10.1016/j.bbamcr.2005.03.007
   Nasser M.W., 2011, S100A7 ENHANCES MAMM
   Nasser MW, 2015, CANCER RES, V75, P974, DOI 10.1158/0008-5472.CAN-14-2161
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Norata GD, 2009, NUTR METAB CARDIOVAS, V19, P129, DOI 10.1016/j.numecd.2008.03.004
   Onyeagucha BC, 2013, EXP CELL RES, V319, P2081, DOI 10.1016/j.yexcr.2013.05.009
   Otero K, 2001, BIOCHEM J, V359, P567, DOI 10.1042/0264-6021:3590567
   Pan HM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04355
   Park IH, 2004, MOL IMMUNOL, V40, P1203, DOI 10.1016/j.molimm.2003.11.027
   Radia AM, 2013, INT J MOL SCI, V14, P7959, DOI 10.3390/ijms14047959
   Rojas A, 2004, LIFE SCI, V76, P715, DOI 10.1016/j.lfs.2004.09.011
   Schraml P, 1997, CANCER RES, V57, P3669
   Shimomoto T, 2012, J GASTROENTEROL, V47, P1073, DOI 10.1007/s00535-012-0572-5
   Sinha P, 2008, J IMMUNOL, V181, P4666, DOI 10.4049/jimmunol.181.7.4666
   Soulis T, 1997, DIABETOLOGIA, V40, P1141, DOI 10.1007/s001250050799
   SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328
   SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517
   Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626
   Tsuji A, 2008, CLIN CANCER RES, V14, P5368, DOI 10.1158/1078-0432.CCR-08-0198
   Wautier MP, 2001, AM J PHYSIOL-ENDOC M, V280, pE685, DOI 10.1152/ajpendo.2001.280.5.E685
   Wilkinson-Berka JL, 2002, DIABETES, V51, P3283, DOI 10.2337/diabetes.51.11.3283
   Wu XJ, 2013, MOL CELL BIOCHEM, V380, P249, DOI 10.1007/s11010-013-1680-0
   Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723
   Yamagishi S, 2005, MED HYPOTHESES, V64, P1208, DOI 10.1016/j.mehy.2005.01.015
   Yamamoto Y, 2007, ARTERIOSCL THROM VAS, V27, pE33, DOI 10.1161/ATVBAHA.107.144337
   Yan SF, 2008, NAT CLIN PRACT ENDOC, V4, P285, DOI 10.1038/ncpendmet0786
   Yan SS, 2003, NAT MED, V9, P287, DOI 10.1038/nm831
   Zheng F, 2001, MOL MED, V7, P737, DOI 10.1007/BF03401963
NR 78
TC 47
Z9 50
U1 0
U2 20
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-4165
EI 1872-8006
J9 BBA-GEN SUBJECTS
JI Biochim. Biophys. Acta-Gen. Subj.
PD SEP
PY 2015
VL 1850
IS 9
BP 1898
EP 1904
DI 10.1016/j.bbagen.2015.05.020
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CO5BF
UT WOS:000359173900028
PM 26028296
DA 2022-04-25
ER

EF